# BugSigDB 2024-08-27_16:58_UTC, License: Creative Commons Attribution 4.0 International, URL: https://bugsigdb.org
BSDB ID,Study,Study design,PMID,DOI,URL,Authors list,Title,Journal,Year,Keywords,Experiment,Location of subjects,Host species,Body site,UBERON ID,Condition,EFO ID,Group 0 name,Group 1 name,Group 1 definition,Group 0 sample size,Group 1 sample size,Antibiotics exclusion,Sequencing type,16S variable region,Sequencing platform,Statistical test,Significance threshold,MHT correction,LDA Score above,Matched on,Confounders controlled for,Pielou,Shannon,Chao1,Simpson,Inverse Simpson,Richness,Signature page name,Source,Curated date,Curator,Revision editor,Description,Abundance in Group 1,MetaPhlAn taxon names,NCBI Taxonomy IDs,State,Reviewer
bsdb:1/1/2,Study 1,case-control,28038683,10.1186/s40168-016-0218-6,NA,"Peters BA, Dominianni C, Shapiro JA, Church TR, Wu J, Miller G, Yuen E, Freiman H, Lustbader I, Salik J, Friedlander C, Hayes RB , Ahn J",The gut microbiota in conventional and serrated precursors of colorectal cancer,Microbiome,2016,"Adenoma, Cancer, Colorectal, Microbiome, Microbiota, Polyp, Serrated",Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Colorectal adenoma,EFO:0005406,controls,conventional adenoma cases,"conventional adenoma cases; those with at least one tubular or tubulovillous adenoma and no other polyps of hyperplastic, SSA, or unclassified histology. HP cases; having at least one HP, with no other polyps of tubular, tubulovillous, SSA, or unclassified histology. SSA cases; having at least one SSA, with or without HP(s), and with no other polyps of tubular, tubulovillous, or unclassified histology. Proximal polyps; polyps located in the cecum, ascending colon, hepatic flexure, transverse colon, or splenic flexure. Distal polyps; polyps located in the descending colon, sigmoid colon, or rectum.",323,144,NYU included who had not been on long-term antibiotic treatment,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,"age,body mass index,sex",NA,decreased,NA,NA,NA,decreased,Signature 2,Table 2 + Supplemental Table S5 + S3+ S4,10 January 2021,Levi Waldron,WikiWorks,"Differential abundance was detected by the “DESeq” function in the DESeq2 package. All classes and genera with an FDR-adjusted q < 0.10 are included in the table. Models were adjusted for sex, age, study, and categorical BMI. See Additional file 1: Table S5 for comparisons at the phylum, order, and family level",decreased,"k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Coprobacillaceae|g__Coprobacillus,k__Bacteria|p__Cyanobacteriota",2|1239|526524|526525|2810280|100883;2|1117,Complete,Shaimaa Elsafoury
bsdb:1/2/1,Study 1,case-control,28038683,10.1186/s40168-016-0218-6,NA,"Peters BA, Dominianni C, Shapiro JA, Church TR, Wu J, Miller G, Yuen E, Freiman H, Lustbader I, Salik J, Friedlander C, Hayes RB , Ahn J",The gut microbiota in conventional and serrated precursors of colorectal cancer,Microbiome,2016,"Adenoma, Cancer, Colorectal, Microbiome, Microbiota, Polyp, Serrated",Experiment 2,United States of America,Homo sapiens,Feces,UBERON:0001988,Hyperplastic Polyp,EFO:1000299,controls,hyperplastic polyp cases,"conventional adenoma cases; those with at least one tubular or tubulovillous adenoma and no other polyps of hyperplastic, SSA, or unclassified histology. HP cases; having at least one HP, with no other polyps of tubular, tubulovillous, SSA, or unclassified histology. SSA cases; having at least one SSA, with or without HP(s), and with no other polyps of tubular, tubulovillous, or unclassified histology. Proximal polyps; polyps located in the cecum, ascending colon, hepatic flexure, transverse colon, or splenic flexure. Distal polyps; polyps located in the descending colon, sigmoid colon, or rectum.",323,40,NYU included who had not been on long-term antibiotic treatment,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,"age,body mass index,sex",NA,unchanged,NA,NA,NA,unchanged,Signature 1,Table 2 + Supplemental Table S5 + S3+ S4,10 January 2021,Levi Waldron,WikiWorks,"Differential abundance was detected by the “DESeq” function in the DESeq2 package. All classes and genera with an FDR-adjusted q < 0.10 are included in the table. Models were adjusted for sex, age, study, and categorical BMI. See Additional file 1: Table S5 for comparisons at the phylum, order, and family level",increased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Anaerostipes,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lacticaseibacillus|s__Lacticaseibacillus zeae",2|1239|186801|3085636|186803|207244;2|1239|91061|186826|33958|2759736|57037,Complete,Shaimaa Elsafoury
bsdb:1/2/2,Study 1,case-control,28038683,10.1186/s40168-016-0218-6,NA,"Peters BA, Dominianni C, Shapiro JA, Church TR, Wu J, Miller G, Yuen E, Freiman H, Lustbader I, Salik J, Friedlander C, Hayes RB , Ahn J",The gut microbiota in conventional and serrated precursors of colorectal cancer,Microbiome,2016,"Adenoma, Cancer, Colorectal, Microbiome, Microbiota, Polyp, Serrated",Experiment 2,United States of America,Homo sapiens,Feces,UBERON:0001988,Hyperplastic Polyp,EFO:1000299,controls,hyperplastic polyp cases,"conventional adenoma cases; those with at least one tubular or tubulovillous adenoma and no other polyps of hyperplastic, SSA, or unclassified histology. HP cases; having at least one HP, with no other polyps of tubular, tubulovillous, SSA, or unclassified histology. SSA cases; having at least one SSA, with or without HP(s), and with no other polyps of tubular, tubulovillous, or unclassified histology. Proximal polyps; polyps located in the cecum, ascending colon, hepatic flexure, transverse colon, or splenic flexure. Distal polyps; polyps located in the descending colon, sigmoid colon, or rectum.",323,40,NYU included who had not been on long-term antibiotic treatment,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,"age,body mass index,sex",NA,unchanged,NA,NA,NA,unchanged,Signature 2,Table 2 + Supplemental Table S5 + S3+ S4,10 January 2021,Levi Waldron,WikiWorks,"Differential abundance was detected by the “DESeq” function in the DESeq2 package. All classes and genera with an FDR-adjusted q < 0.10 are included in the table. Models were adjusted for sex, age, study, and categorical BMI. See Additional file 1: Table S5 for comparisons at the phylum, order, and family level",decreased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Coprobacillaceae|g__Coprobacillus,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales",2|1224|1236;2|1239|526524|526525|2810280|100883;2|1224|1236|91347,Complete,Shaimaa Elsafoury
bsdb:1/3/1,Study 1,case-control,28038683,10.1186/s40168-016-0218-6,NA,"Peters BA, Dominianni C, Shapiro JA, Church TR, Wu J, Miller G, Yuen E, Freiman H, Lustbader I, Salik J, Friedlander C, Hayes RB , Ahn J",The gut microbiota in conventional and serrated precursors of colorectal cancer,Microbiome,2016,"Adenoma, Cancer, Colorectal, Microbiome, Microbiota, Polyp, Serrated",Experiment 3,United States of America,Homo sapiens,Feces,UBERON:0001988,Colon Sessile Serrated Adenoma/Polyp,EFO:1000189,controls,Sessile serrated adenoma cases,"conventional adenoma cases; those with at least one tubular or tubulovillous adenoma and no other polyps of hyperplastic, SSA, or unclassified histology. HP cases; having at least one HP, with no other polyps of tubular, tubulovillous, SSA, or unclassified histology. SSA cases; having at least one SSA, with or without HP(s), and with no other polyps of tubular, tubulovillous, or unclassified histology. Proximal polyps; polyps located in the cecum, ascending colon, hepatic flexure, transverse colon, or splenic flexure. Distal polyps; polyps located in the descending colon, sigmoid colon, or rectum.",323,33,NYU included who had not been on long-term antibiotic treatment,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,"age,body mass index,sex",NA,unchanged,NA,NA,NA,unchanged,Signature 1,Table 2 + Supplemental Table S5 + S3+ S4,10 January 2021,Levi Waldron,WikiWorks,"Differential abundance was detected by the “DESeq” function in the DESeq2 package. All classes and genera with an FDR-adjusted q < 0.10 are included in the table. Models were adjusted for sex, age, study, and categorical BMI. See Additional file 1: Table S5 for comparisons at the phylum, order, and family level",decreased,"k__Bacteria|p__Bacillota|c__Erysipelotrichia,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria",2|1239|526524;2|1224|1236,Complete,Shaimaa Elsafoury
bsdb:1/4/1,Study 1,case-control,28038683,10.1186/s40168-016-0218-6,NA,"Peters BA, Dominianni C, Shapiro JA, Church TR, Wu J, Miller G, Yuen E, Freiman H, Lustbader I, Salik J, Friedlander C, Hayes RB , Ahn J",The gut microbiota in conventional and serrated precursors of colorectal cancer,Microbiome,2016,"Adenoma, Cancer, Colorectal, Microbiome, Microbiota, Polyp, Serrated",Experiment 4,United States of America,Homo sapiens,Feces,UBERON:0001988,Colorectal adenoma,EFO:0005406,controls,Proximal conventional adenoma cases,"conventional adenoma cases; those with at least one tubular or tubulovillous adenoma and no other polyps of hyperplastic, SSA, or unclassified histology. HP cases; having at least one HP, with no other polyps of tubular, tubulovillous, SSA, or unclassified histology. SSA cases; having at least one SSA, with or without HP(s), and with no other polyps of tubular, tubulovillous, or unclassified histology. Proximal polyps; polyps located in the cecum, ascending colon, hepatic flexure, transverse colon, or splenic flexure. Distal polyps; polyps located in the descending colon, sigmoid colon, or rectum.",323,87,NYU included who had not been on long-term antibiotic treatment,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,"age,body mass index,sex",NA,unchanged,NA,NA,NA,unchanged,Signature 1,Supplemental Table S6 + S3,10 January 2021,Marianthi Thomatos,WikiWorks,"Differentially abundant taxa (phylum‐OTU level) between controls and proximal or distal conventional adenoma cases, as detected by the DESeq function in the DESeq2 package. Models were adjusted for age, sex, categorical BMI, and study. All taxa with an FDR‐adjusted q<0.10 are included in the table.",increased,"k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales|f__Actinomycetaceae,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales|f__Actinomycetaceae|g__Actinomyces,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Mycobacteriales|f__Corynebacteriaceae,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Mycobacteriales|f__Corynebacteriaceae|g__Corynebacterium,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Clostridium,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae|g__Porphyromonas,k__Bacteria|p__Bacillota|c__Bacilli,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales,k__Bacteria|p__Bacillota|c__Tissierellia|o__Tissierellales|f__Peptoniphilaceae|g__Peptoniphilus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus,k__Bacteria|p__Bacillota|c__Tissierellia|o__Tissierellales|f__Tissierellaceae,k__Bacteria|p__Bacillota|c__Tissierellia|o__Tissierellales|f__Peptoniphilaceae|g__Anaerococcus,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Odoribacteraceae|g__Odoribacter,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Anaerostipes,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Dorea,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Sutterellaceae|g__Sutterella,k__Bacteria|p__Bacillota|c__Negativicutes|o__Acidaminococcales|f__Acidaminococcaceae|g__Phascolarctobacterium,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Alcaligenaceae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Odoribacteraceae",2|201174|1760|2037;2|201174|1760|2037|2049;2|201174|1760|2037|2049|1654;2|201174|1760|85007|1653;2|201174|1760|85007|1653|1716;2|1239|91061|186826|1300;2|1239|186801|186802|31979|1485;2|976|200643|171549|171551|836;2|1239|91061;2|1239|91061|186826;2|1239|1737404|1737405|1570339|162289;2|1239|91061|186826|1300|1301;2|1239|1737404|1737405|1737406;2|1239|1737404|1737405|1570339|165779;2|976|200643|171549|1853231|283168;2|1239|909932|1843489|31977;2|1239|186801|3085636|186803|207244;2|1239|186801|3085636|186803|189330;2|1224|28216|80840|995019|40544;2|1239|909932|1843488|909930|33024;2|1224|28216|80840|506;2|1224|1236|91347;2|1224|1236;2|976|200643|171549|1853231,Complete,Shaimaa Elsafoury
bsdb:1/4/2,Study 1,case-control,28038683,10.1186/s40168-016-0218-6,NA,"Peters BA, Dominianni C, Shapiro JA, Church TR, Wu J, Miller G, Yuen E, Freiman H, Lustbader I, Salik J, Friedlander C, Hayes RB , Ahn J",The gut microbiota in conventional and serrated precursors of colorectal cancer,Microbiome,2016,"Adenoma, Cancer, Colorectal, Microbiome, Microbiota, Polyp, Serrated",Experiment 4,United States of America,Homo sapiens,Feces,UBERON:0001988,Colorectal adenoma,EFO:0005406,controls,Proximal conventional adenoma cases,"conventional adenoma cases; those with at least one tubular or tubulovillous adenoma and no other polyps of hyperplastic, SSA, or unclassified histology. HP cases; having at least one HP, with no other polyps of tubular, tubulovillous, SSA, or unclassified histology. SSA cases; having at least one SSA, with or without HP(s), and with no other polyps of tubular, tubulovillous, or unclassified histology. Proximal polyps; polyps located in the cecum, ascending colon, hepatic flexure, transverse colon, or splenic flexure. Distal polyps; polyps located in the descending colon, sigmoid colon, or rectum.",323,87,NYU included who had not been on long-term antibiotic treatment,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,"age,body mass index,sex",NA,unchanged,NA,NA,NA,unchanged,Signature 2,Supplemental Table S6 + S3,10 January 2021,Marianthi Thomatos,WikiWorks,"Differentially abundant taxa (phylum‐OTU level) between controls and proximal or distal conventional adenoma cases, as detected by the DESeq function in the DESeq2 package. Models were adjusted for age, sex, categorical BMI, and study. All taxa with an FDR‐adjusted q<0.10 are included in the table.",decreased,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Coprobacillaceae|g__Coprobacillus,2|1239|526524|526525|2810280|100883,Complete,Shaimaa Elsafoury
bsdb:1/5/1,Study 1,case-control,28038683,10.1186/s40168-016-0218-6,NA,"Peters BA, Dominianni C, Shapiro JA, Church TR, Wu J, Miller G, Yuen E, Freiman H, Lustbader I, Salik J, Friedlander C, Hayes RB , Ahn J",The gut microbiota in conventional and serrated precursors of colorectal cancer,Microbiome,2016,"Adenoma, Cancer, Colorectal, Microbiome, Microbiota, Polyp, Serrated",Experiment 5,United States of America,Homo sapiens,Feces,UBERON:0001988,Colorectal adenoma,EFO:0005406,controls,Distal conventional adenoma cases,"conventional adenoma cases; those with at least one tubular or tubulovillous adenoma and no other polyps of hyperplastic, SSA, or unclassified histology. HP cases; having at least one HP, with no other polyps of tubular, tubulovillous, SSA, or unclassified histology. SSA cases; having at least one SSA, with or without HP(s), and with no other polyps of tubular, tubulovillous, or unclassified histology. Proximal polyps; polyps located in the cecum, ascending colon, hepatic flexure, transverse colon, or splenic flexure. Distal polyps; polyps located in the descending colon, sigmoid colon, or rectum.",323,55,NYU included who had not been on long-term antibiotic treatment,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,"age,body mass index,sex",NA,unchanged,NA,NA,NA,unchanged,Signature 1,Supplemental Table S6 + S3,10 January 2021,Marianthi Thomatos,"Fatima,Merit,WikiWorks,Lwaldron,Davvve","Differentially abundant taxa (phylum‐OTU level) between controls and proximal or distal conventional adenoma cases, as detected by the DESeq function in the DESeq2 package. Models were adjusted for age, sex, categorical BMI, and study. All taxa with an FDR‐adjusted q<0.10, are included in the table.",decreased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Christensenellales|f__Christensenellaceae,k__Bacteria|p__Bacillota|c__Clostridia,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Clostridium,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Enterococcaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Enterococcaceae|g__Enterococcus,k__Bacteria|p__Mycoplasmatota|c__Mollicutes,k__Bacteria|p__Synergistota,k__Bacteria|p__Synergistota",2|1239|186801|3082768|990719;2|1239|186801;2|1239|186801|186802|31979;2|1239|186801|186802|31979|1485;2|1239|91061|186826|81852;2|1239|91061|186826|81852|1350;2|544448|31969;2|508458;2|508458,Complete,Fatima
bsdb:1/6/1,Study 1,case-control,28038683,10.1186/s40168-016-0218-6,NA,"Peters BA, Dominianni C, Shapiro JA, Church TR, Wu J, Miller G, Yuen E, Freiman H, Lustbader I, Salik J, Friedlander C, Hayes RB , Ahn J",The gut microbiota in conventional and serrated precursors of colorectal cancer,Microbiome,2016,"Adenoma, Cancer, Colorectal, Microbiome, Microbiota, Polyp, Serrated",Experiment 6,United States of America,Homo sapiens,Feces,UBERON:0001988,Colorectal adenoma,EFO:0005406,controls,Non-advanced conventional adenoma cases,"conventional adenoma cases; those with at least one tubular or tubulovillous adenoma and no other polyps of hyperplastic, SSA, or unclassified histology. HP cases; having at least one HP, with no other polyps of tubular, tubulovillous, SSA, or unclassified histology. SSA cases; having at least one SSA, with or without HP(s), and with no other polyps of tubular, tubulovillous, or unclassified histology. Proximal polyps; polyps located in the cecum, ascending colon, hepatic flexure, transverse colon, or splenic flexure. Distal polyps; polyps located in the descending colon, sigmoid colon, or rectum.",323,121,NYU included who had not been on long-term antibiotic treatment,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,"age,body mass index,sex",NA,unchanged,NA,NA,NA,unchanged,Signature 1,Supplemental Table S6 + S3,10 January 2021,Marianthi Thomatos,WikiWorks,"Differentially abundant taxa (phylum‐OTU level) between controls and non‐advanced or advanced conventional adenoma cases, as detected by the DESeq function in the DESeq2 package. Models were adjusted for age, sex, categorical BMI, and study. All taxa with an FDR‐adjusted q<0.10 are included in the table.",increased,"k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales|f__Actinomycetaceae|g__Actinomyces,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Odoribacteraceae|g__Odoribacter,k__Bacteria|p__Bacillota|c__Bacilli,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lacticaseibacillus|s__Lacticaseibacillus zeae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Dorea,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Sutterellaceae|g__Sutterella,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Alcaligenaceae,k__Bacteria|p__Bacillota|c__Negativicutes|o__Acidaminococcales|f__Acidaminococcaceae|g__Phascolarctobacterium",2|201174|1760|2037|2049|1654;2|976|200643|171549|1853231|283168;2|1239|91061;2|1239|91061|186826;2|1239|91061|186826|33958|2759736|57037;2|1239|91061|186826|1300;2|1239|91061|186826|1300|1301;2|1239|186801|3085636|186803|189330;2|1239|909932|1843489|31977;2|1224|28216|80840|995019|40544;2|1224|28216|80840|506;2|1239|909932|1843488|909930|33024,Complete,Shaimaa Elsafoury
bsdb:1/7/1,Study 1,case-control,28038683,10.1186/s40168-016-0218-6,NA,"Peters BA, Dominianni C, Shapiro JA, Church TR, Wu J, Miller G, Yuen E, Freiman H, Lustbader I, Salik J, Friedlander C, Hayes RB , Ahn J",The gut microbiota in conventional and serrated precursors of colorectal cancer,Microbiome,2016,"Adenoma, Cancer, Colorectal, Microbiome, Microbiota, Polyp, Serrated",Experiment 7,United States of America,Homo sapiens,Feces,UBERON:0001988,Colorectal adenoma,EFO:0005406,controls,advanced conventional adenoma cases,"conventional adenoma cases; those with at least one tubular or tubulovillous adenoma and no other polyps of hyperplastic, SSA, or unclassified histology. HP cases; having at least one HP, with no other polyps of tubular, tubulovillous, SSA, or unclassified histology. SSA cases; having at least one SSA, with or without HP(s), and with no other polyps of tubular, tubulovillous, or unclassified histology. Proximal polyps; polyps located in the cecum, ascending colon, hepatic flexure, transverse colon, or splenic flexure. Distal polyps; polyps located in the descending colon, sigmoid colon, or rectum.",323,22,NYU included who had not been on long-term antibiotic treatment,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,"age,body mass index,sex",NA,decreased,NA,NA,NA,decreased,Signature 1,Supplemental Table S7 + S3,10 January 2021,Marianthi Thomatos,WikiWorks,"Differentially abundant taxa (phylum‐OTU level) between controls and non‐advanced or advanced conventional adenoma cases, as detected by the DESeq function in the DESeq2 package. Models were adjusted for age, sex, categorical BMI, and study. All taxa with an FDR‐adjusted q<0.10 are included in the table.",increased,"k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales|f__Actinomycetaceae,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales|f__Actinomycetaceae|g__Actinomyces,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Mycobacteriales|f__Corynebacteriaceae|g__Corynebacterium,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae|g__Porphyromonas,k__Bacteria|p__Bacillota|c__Tissierellia|o__Tissierellales|f__Tissierellaceae,k__Bacteria|p__Bacillota|c__Tissierellia|o__Tissierellales|f__Peptoniphilaceae|g__Anaerococcus,k__Bacteria|p__Bacillota|c__Tissierellia|o__Tissierellales|f__Peptoniphilaceae|g__Finegoldia,k__Bacteria|p__Bacillota|c__Tissierellia|o__Tissierellales|f__Peptoniphilaceae|g__Peptoniphilus,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Haemophilus,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Mycobacteriales|f__Corynebacteriaceae",2|201174|1760|2037;2|201174|1760|2037|2049;2|201174|1760|2037|2049|1654;2|201174|1760|85007|1653|1716;2|976|200643|171549|171551|836;2|1239|1737404|1737405|1737406;2|1239|1737404|1737405|1570339|165779;2|1239|1737404|1737405|1570339|150022;2|1239|1737404|1737405|1570339|162289;2|1224|1236|135625;2|1224|1236|135625|712;2|1224|1236|135625|712|724;2|201174|1760|85007|1653,Complete,Shaimaa Elsafoury
bsdb:1/7/2,Study 1,case-control,28038683,10.1186/s40168-016-0218-6,NA,"Peters BA, Dominianni C, Shapiro JA, Church TR, Wu J, Miller G, Yuen E, Freiman H, Lustbader I, Salik J, Friedlander C, Hayes RB , Ahn J",The gut microbiota in conventional and serrated precursors of colorectal cancer,Microbiome,2016,"Adenoma, Cancer, Colorectal, Microbiome, Microbiota, Polyp, Serrated",Experiment 7,United States of America,Homo sapiens,Feces,UBERON:0001988,Colorectal adenoma,EFO:0005406,controls,advanced conventional adenoma cases,"conventional adenoma cases; those with at least one tubular or tubulovillous adenoma and no other polyps of hyperplastic, SSA, or unclassified histology. HP cases; having at least one HP, with no other polyps of tubular, tubulovillous, SSA, or unclassified histology. SSA cases; having at least one SSA, with or without HP(s), and with no other polyps of tubular, tubulovillous, or unclassified histology. Proximal polyps; polyps located in the cecum, ascending colon, hepatic flexure, transverse colon, or splenic flexure. Distal polyps; polyps located in the descending colon, sigmoid colon, or rectum.",323,22,NYU included who had not been on long-term antibiotic treatment,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,"age,body mass index,sex",NA,decreased,NA,NA,NA,decreased,Signature 2,Supplemental Table S7 + S3,10 January 2021,Marianthi Thomatos,WikiWorks,"Differentially abundant taxa (phylum‐OTU level) between controls and non‐advanced or advanced conventional adenoma cases, as detected by the DESeq function in the DESeq2 package. Models were adjusted for age, sex, categorical BMI, and study. All taxa with an FDR‐adjusted q<0.10 are included in the table.",decreased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Barnesiellaceae,k__Bacteria|p__Cyanobacteriota,k__Bacteria|p__Bacillota|c__Clostridia|o__Christensenellales|f__Christensenellaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Lachnobacterium,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Lachnospira,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria",2|976|200643|171549|2005519;2|1117;2|1239|186801|3082768|990719;2|1239|186801|3085636|186803|140625;2|1239|186801|3085636|186803|28050;2|1224|28211,Complete,Shaimaa Elsafoury
bsdb:2/1/1,Study 2,case-control,28173873,10.1186/s13073-017-0405-5,NA,"Wang H, Funchain P, Bebek G, Altemus J, Zhang H, Niazi F, Peterson C, Lee WT, Burkey BB , Eng C",Microbiomic differences in tumor and paired-normal tissue in head and neck squamous cell carcinomas,Genome medicine,2017,"Bacteria, Head and neck squamous cell carcinoma (HNSCC), Microbiome",Experiment 1,United States of America,Homo sapiens,Oral cavity,UBERON:0000167,Head and neck squamous cell carcinoma,EFO:0000181,normal adjacent tissues,squamous cell carcinoma tissues,tissues with evidence of squamous cell carcinoma,121,121,NA,16S,1234,Sanger,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,Signature 1,Figure 3 +text,10 January 2021,Nidhi Saini,WikiWorks,Significant taxa by Wilcoxon signed-rank in paired tumor and normal tissue. Box plots representing relative abundances of taxa observed to be significantly different between tumor (orange) and adjacent normal (blue) samples by paired Wilcoxon signed-rank testing after correction for FDR.,increased,"k__Bacteria|p__Bacillota|c__Tissierellia|o__Tissierellales|f__Tissierellaceae,k__Bacteria|p__Bacillota|c__Tissierellia|o__Tissierellales|f__Peptoniphilaceae|g__Parvimonas",2|1239|1737404|1737405|1737406;2|1239|1737404|1737405|1570339|543311,Complete,Shaimaa Elsafoury
bsdb:2/1/2,Study 2,case-control,28173873,10.1186/s13073-017-0405-5,NA,"Wang H, Funchain P, Bebek G, Altemus J, Zhang H, Niazi F, Peterson C, Lee WT, Burkey BB , Eng C",Microbiomic differences in tumor and paired-normal tissue in head and neck squamous cell carcinomas,Genome medicine,2017,"Bacteria, Head and neck squamous cell carcinoma (HNSCC), Microbiome",Experiment 1,United States of America,Homo sapiens,Oral cavity,UBERON:0000167,Head and neck squamous cell carcinoma,EFO:0000181,normal adjacent tissues,squamous cell carcinoma tissues,tissues with evidence of squamous cell carcinoma,121,121,NA,16S,1234,Sanger,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,Signature 2,Figure 3 +text,10 January 2021,Shaimaa Elsafoury,WikiWorks,Significant taxa by Wilcoxon signed-rank in paired tumor and normal tissue. Box plots representing relative abundances of taxa observed to be significantly different between tumor (orange) and adjacent normal (blue) samples by paired Wilcoxon signed-rank testing after correction for FDR.,decreased,"k__Bacteria|p__Actinomycetota,k__Bacteria|p__Actinomycetota|c__Actinomycetes,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales|f__Actinomycetaceae,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales|f__Actinomycetaceae|g__Actinomyces",2|201174;2|201174|1760;2|201174|1760|2037;2|201174|1760|2037|2049;2|201174|1760|2037|2049|1654,Complete,Shaimaa Elsafoury
bsdb:2/2/1,Study 2,case-control,28173873,10.1186/s13073-017-0405-5,NA,"Wang H, Funchain P, Bebek G, Altemus J, Zhang H, Niazi F, Peterson C, Lee WT, Burkey BB , Eng C",Microbiomic differences in tumor and paired-normal tissue in head and neck squamous cell carcinomas,Genome medicine,2017,"Bacteria, Head and neck squamous cell carcinoma (HNSCC), Microbiome",Experiment 2,United States of America,Homo sapiens,Oral cavity,UBERON:0000167,Head and neck squamous cell carcinoma,EFO:0000181,T0-T2 low tumor stages patients,T3-T4 high tumor stages patients,Not stated,NA,NA,NA,16S,1234,Sanger,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Figure 4 +text,10 January 2021,Shaimaa Elsafoury,WikiWorks,"Relative abundances of differentially represented taxa stratified by T-stage. Box plots representing relative abundances of phylum Actinobacteria (top), genus Actinomyces (middle), and genus Parvimonas (bottom) stratified by T-stage.",increased,k__Bacteria|p__Bacillota|c__Tissierellia|o__Tissierellales|f__Peptoniphilaceae|g__Parvimonas,2|1239|1737404|1737405|1570339|543311,Complete,Shaimaa Elsafoury
bsdb:2/2/2,Study 2,case-control,28173873,10.1186/s13073-017-0405-5,NA,"Wang H, Funchain P, Bebek G, Altemus J, Zhang H, Niazi F, Peterson C, Lee WT, Burkey BB , Eng C",Microbiomic differences in tumor and paired-normal tissue in head and neck squamous cell carcinomas,Genome medicine,2017,"Bacteria, Head and neck squamous cell carcinoma (HNSCC), Microbiome",Experiment 2,United States of America,Homo sapiens,Oral cavity,UBERON:0000167,Head and neck squamous cell carcinoma,EFO:0000181,T0-T2 low tumor stages patients,T3-T4 high tumor stages patients,Not stated,NA,NA,NA,16S,1234,Sanger,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 2,Figure 4 +text,10 January 2021,Shaimaa Elsafoury,WikiWorks,"Relative abundances of differentially represented taxa stratified by T-stage. Box plots representing relative abundances of phylum Actinobacteria (top), genus Actinomyces (middle), and genus Parvimonas (bottom) stratified by T-stage.",decreased,"k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales|f__Actinomycetaceae|g__Actinomyces,k__Bacteria|p__Actinomycetota",2|201174|1760|2037|2049|1654;2|201174,Complete,Shaimaa Elsafoury
bsdb:3/1/1,Study 3,case-control,27015276,10.1371/journal.pone.0152126,NA,"Sinha R, Ahn J, Sampson JN, Shi J, Yu G, Xiong X, Hayes RB , Goedert JJ","Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations",PloS one,2016,NA,Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,controls,adenocarcinoma of colon and rectum patients,Not stated,89,42,NA,16S,34,Roche454,Logistic Regression,0.05,FALSE,NA,"body mass index,sex","age,body mass index,sex",NA,NA,NA,NA,NA,NA,Signature 1,Table 2,10 January 2021,Shaimaa Elsafoury,WikiWorks,Fecal microbes independently associated with colorectal cancer,increased,"k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae|g__Fusobacterium,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae|g__Porphyromonas",2|32066|203490|203491|203492|848;2|976|200643|171549|171551|836,Complete,Shaimaa Elsafoury
bsdb:3/1/2,Study 3,case-control,27015276,10.1371/journal.pone.0152126,NA,"Sinha R, Ahn J, Sampson JN, Shi J, Yu G, Xiong X, Hayes RB , Goedert JJ","Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations",PloS one,2016,NA,Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,controls,adenocarcinoma of colon and rectum patients,Not stated,89,42,NA,16S,34,Roche454,Logistic Regression,0.05,FALSE,NA,"body mass index,sex","age,body mass index,sex",NA,NA,NA,NA,NA,NA,Signature 2,Table 2,10 January 2021,Nidhi Saini,WikiWorks,Fecal microbes independently associated with colorectal cancer,decreased,"k__Bacteria|p__Bacillota|c__Clostridia,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae",2|1239|186801;2|1239|186801|3085636|186803,Complete,Shaimaa Elsafoury
bsdb:4/1/1,Study 4,case-control,27625705,10.1186/s13099-016-0124-2,NA,"Aly AM, Adel A, El-Gendy AO, Essam TM , Aziz RK",Gut microbiome alterations in patients with stage 4 hepatitis C,Gut pathogens,2016,"Gastro-intestinal tract, High-throughput sequencing, Infectious diseases, Liver disease, Microbiome, Next-generation sequencing, Virology",Experiment 1,Egypt,Homo sapiens,Feces,UBERON:0001988,Hepatitis,HP:0012115,male healthy controls,HCV stage 4 male patients,Not stated,8,6,3 months,16S,4,Illumina,LEfSe,0.1,FALSE,2,NA,NA,NA,decreased,decreased,decreased,NA,NA,Signature 1,Table 2 and Fig 5,10 January 2021,Shaimaa Elsafoury,WikiWorks,Genera that are statistically signifcantly diferent between the two groups hcv patients and healthy participants  (non-parametric t test). All participants were male.,increased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Moraxellales|f__Moraxellaceae|g__Acinetobacter,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Veillonella,k__Bacteria|p__Bacillota|c__Negativicutes|o__Acidaminococcales|f__Acidaminococcaceae|g__Phascolarctobacterium,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pseudomonadales,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Moraxellales|f__Moraxellaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales,k__Bacteria|p__Bacteroidota|c__Bacteroidia,k__Bacteria|p__Bacteroidota",2|1224|1236|2887326|468|469;2|976|200643|171549|171552|838;2|1239|909932|1843489|31977|29465;2|1239|909932|1843488|909930|33024;2|1224|1236|72274;2|1224|1236|2887326|468;2|976|200643|171549;2|976|200643;2|976,Complete,Shaimaa Elsafoury
bsdb:4/1/2,Study 4,case-control,27625705,10.1186/s13099-016-0124-2,NA,"Aly AM, Adel A, El-Gendy AO, Essam TM , Aziz RK",Gut microbiome alterations in patients with stage 4 hepatitis C,Gut pathogens,2016,"Gastro-intestinal tract, High-throughput sequencing, Infectious diseases, Liver disease, Microbiome, Next-generation sequencing, Virology",Experiment 1,Egypt,Homo sapiens,Feces,UBERON:0001988,Hepatitis,HP:0012115,male healthy controls,HCV stage 4 male patients,Not stated,8,6,3 months,16S,4,Illumina,LEfSe,0.1,FALSE,2,NA,NA,NA,decreased,decreased,decreased,NA,NA,Signature 2,Table 2 and Fig 5,10 January 2021,Shaimaa Elsafoury,WikiWorks,Genera that are statistically signifcantly diferent between the two groups hcv patients and healthy participants  (non-parametric t test). All participants were male.,decreased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Tannerellaceae|g__Parabacteroides,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Ruminococcus,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Odoribacteraceae|g__Butyricimonas,k__Bacteria|p__Actinomycetota,k__Bacteria|p__Actinomycetota|c__Actinomycetes,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae,k__Bacteria|p__Mycoplasmatota|c__Mollicutes,k__Bacteria|p__Mycoplasmatota,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Alteromonadales|f__Pseudoalteromonadaceae|g__Pseudoalteromonas,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Alteromonadales|f__Pseudoalteromonadaceae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Vibrionales,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Dialister,f__Victivallaceae,f__Victivallaceae,k__Bacteria|p__Lentisphaerota",2|976|200643|171549|2005525|375288;2|1239|186801|186802|216572|1263;2|976|200643|171549|1853231|574697;2|201174;2|201174|1760;2|201174|1760|85004|31953|1678;2|201174|1760|85004;2|201174|1760|85004|31953;2|976|200643|171549|171551;2|544448|31969;2|544448;2|1224|1236|135622|267888|53246;2|1224|1236|135622|267888;2|1224|1236|135623;2|1239|909932|1843489|31977|39948;255528;255528;2|256845,Complete,Shaimaa Elsafoury
bsdb:5/1/1,Study 5,case-control,23071781,10.1371/journal.pone.0047305,NA,"Pragman AA, Kim HB, Reilly CS, Wendt C , Isaacson RE",The lung microbiome in moderate and severe chronic obstructive pulmonary disease,PloS one,2012,NA,Experiment 1,United States of America,Homo sapiens,Lung,UBERON:0002048,Chronic obstructive pulmonary disease,EFO:0000341,controls,Chronic obstructive pulmonary disease,Patients who have Chronic obstructive pulmonary disease,10,22,2 months,16S,3,Roche454,Mann-Whitney (Wilcoxon),0.1,TRUE,NA,NA,age,NA,unchanged,NA,unchanged,NA,NA,Signature 1,Table 2,10 January 2021,Fatima Zohra,"Lwaldron,Fatima,WikiWorks",Metastats Analysis of Differential Abundance of moderate and severe COPD Lung microbiome compared to controls,increased,"k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Aerococcaceae|g__Abiotrophia,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales|f__Actinomycetaceae|g__Actinomyces,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales|f__Actinomycetaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Aerococcaceae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Aeromonadales|f__Aeromonadaceae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Aeromonadales,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Aeromonadales|f__Aeromonadaceae|g__Aeromonas,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Anaerosporobacter,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales|f__Atopobiaceae|g__Atopobium,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae|g__Bulleidia,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Butyrivibrio,k__Bacteria|p__Campylobacterota|c__Epsilonproteobacteria|o__Campylobacterales|f__Campylobacteraceae|g__Campylobacter,k__Bacteria|p__Campylobacterota|c__Epsilonproteobacteria|o__Campylobacterales|f__Campylobacteraceae,k__Bacteria|p__Campylobacterota|c__Epsilonproteobacteria|o__Campylobacterales,k__Bacteria|p__Bacteroidota|c__Flavobacteriia|o__Flavobacteriales|f__Flavobacteriaceae|g__Capnocytophaga,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Catonella,k__Bacteria|p__Bacillota|c__Negativicutes|o__Selenomonadales|f__Selenomonadaceae|g__Centipeda,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales|f__Coriobacteriaceae,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Eggerthellales|f__Eggerthellaceae|g__Cryptobacterium,k__Bacteria|p__Thermodesulfobacteriota|c__Desulfobacteria|o__Desulfobacterales|f__Desulfobacteraceae,k__Bacteria|p__Thermodesulfobacteriota|c__Desulfobacteria|o__Desulfobacterales,k__Bacteria|p__Thermodesulfobacteriota|c__Desulfobulbia|o__Desulfobulbales|f__Desulfobulbaceae|g__Desulfobulbus,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Dialister,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Dysgonomonadaceae|g__Dysgonomonas,k__Bacteria|p__Campylobacterota,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Eubacteriaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Eubacteriaceae|g__Eubacterium,k__Bacteria|p__Fusobacteriota,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae|g__Fusobacterium,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Hallella,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Leptotrichiaceae|g__Leptotrichia,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Leptotrichiaceae,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micrococcales|f__Micrococcaceae,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Hyphomicrobiales|f__Methylobacteriaceae|g__Microvirga,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Neisseriaceae,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Propionibacteriales|f__Nocardioidaceae|g__Nocardioides,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales|f__Atopobiaceae|g__Olsenella,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Oribacterium,k__Bacteria|p__Bacillota|c__Tissierellia|o__Tissierellales|f__Peptoniphilaceae|g__Parvimonas,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Peptostreptococcaceae|g__Peptostreptococcus,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Rhodospirillales,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micrococcales|f__Micrococcaceae|g__Rothia,k__Bacteria|p__Bacillota|c__Negativicutes|o__Selenomonadales|f__Selenomonadaceae|g__Selenomonas,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Yersiniaceae|g__Serratia,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae|g__Solobacterium,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Tannerellaceae|g__Tannerella,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Veillonella,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales",2|1239|91061|186826|186827|46123;2|201174|1760|2037|2049|1654;2|201174|1760|2037|2049;2|1239|91061|186826|186827;2|1224|1236|135624|84642;2|1224|1236|135624;2|1224|1236|135624|84642|642;2|1239|186801|3085636|186803|653683;2|201174|84998|84999|1643824|1380;2|201174|1760|85004|31953|1678;2|1239|526524|526525|128827|118747;2|1239|186801|3085636|186803|830;2|29547|3031852|213849|72294|194;2|29547|3031852|213849|72294;2|29547|3031852|213849;2|976|117743|200644|49546|1016;2|1239|186801|3085636|186803|43996;2|1239|909932|909929|1843491|82202;2|201174|84998|84999|84107;2|201174|84998|1643822|1643826|84162;2|200940|3024418|213118|213119;2|200940|3024418|213118;2|200940|3031451|3024411|213121|893;2|1239|909932|1843489|31977|39948;2|976|200643|171549|2005520|156973;2|29547;2|1239|526524|526525|128827;2|1239|526524|526525;2|1239|186801|186802|186806;2|1239|186801|186802|186806|1730;2|32066;2|32066|203490|203491|203492;2|32066|203490|203491;2|32066|203490;2|32066|203490|203491|203492|848;2|976|200643|171549|171552|52228;2|1239|186801|3085636|186803;2|1239|91061|186826;2|32066|203490|203491|1129771|32067;2|32066|203490|203491|1129771;2|201174|1760|85006|1268;2|1224|28211|356|119045|186650;2|1224|28216|206351|481;2|1224|28216|206351;2|201174|1760|85009|85015|1839;2|201174|84998|84999|1643824|133925;2|1239|186801|3085636|186803|265975;2|1239|1737404|1737405|1570339|543311;2|1239|186801|3082720|186804|1257;2|976|200643|171549|171552|838;2|1224|28211|204441;2|201174|1760|85006|1268|32207;2|1239|909932|909929|1843491|970;2|1224|1236|91347|1903411|613;2|1239|526524|526525|128827|123375;2|1239|91061|186826|1300;2|1239|91061|186826|1300|1301;2|976|200643|171549|2005525|195950;2|1239|909932|1843489|31977|29465;2|1239|909932|1843489|31977;2|201174|84998|84999,Complete,Fatima
bsdb:5/1/2,Study 5,case-control,23071781,10.1371/journal.pone.0047305,NA,"Pragman AA, Kim HB, Reilly CS, Wendt C , Isaacson RE",The lung microbiome in moderate and severe chronic obstructive pulmonary disease,PloS one,2012,NA,Experiment 1,United States of America,Homo sapiens,Lung,UBERON:0002048,Chronic obstructive pulmonary disease,EFO:0000341,controls,Chronic obstructive pulmonary disease,Patients who have Chronic obstructive pulmonary disease,10,22,2 months,16S,3,Roche454,Mann-Whitney (Wilcoxon),0.1,TRUE,NA,NA,age,NA,unchanged,NA,unchanged,NA,NA,Signature 2,Table 2,10 January 2021,Fatima Zohra,WikiWorks,Metastats Analysis of Differential Abundance of moderate and severe COPD Lung microbiome compared to controls,decreased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Clostridium,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Geodermatophilales|f__Geodermatophilaceae|g__Blastococcus|s__Candidatus Blastococcus massiliensis,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Geodermatophilales|f__Geodermatophilaceae|g__Modestobacter,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Nakamurellales|f__Nakamurellaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Thermoactinomycetaceae|g__Thermoactinomyces,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Thermoactinomycetaceae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Citrobacter,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micrococcales|f__Micrococcaceae|g__Arthrobacter",2|1239|186801|186802|31979|1485;2|201174|1760|1643682|85030|38501|1470358;2|201174|1760|1643682|85030|88138;2|201174|1760|1643684|85031;2|1239|91061|1385|186824|2023;2|1239|91061|1385|186824;2|1224|1236|91347|543|544;2|201174|1760|85006|1268|1663,Complete,Shaimaa Elsafoury
bsdb:5/2/1,Study 5,case-control,23071781,10.1371/journal.pone.0047305,NA,"Pragman AA, Kim HB, Reilly CS, Wendt C , Isaacson RE",The lung microbiome in moderate and severe chronic obstructive pulmonary disease,PloS one,2012,NA,Experiment 2,United States of America,Homo sapiens,Lung,UBERON:0002048,Chronic obstructive pulmonary disease,EFO:0000341,moderate Chronic obstructive pulmonary disease,Severe,Patients who have severe Chronic obstructive pulmonary disease,8,14,2 months,16S,3,Roche454,Mann-Whitney (Wilcoxon),0.1,TRUE,NA,NA,age,NA,unchanged,NA,unchanged,NA,NA,Signature 1,Table 2,10 January 2021,Shaimaa Elsafoury,WikiWorks,Metastats Analysis of Differential Abundance of moderate and severe COPD Lung microbiome compared to controls,increased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Aeromonadales,k__Bacteria|p__Thermodesulfobacteriota|c__Desulfobacteria|o__Desulfobacterales,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Aeromonadales|f__Aeromonadaceae,k__Bacteria|p__Thermodesulfobacteriota|c__Desulfobulbia|o__Desulfobulbales|f__Desulfobulbaceae,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Propionibacteriales|f__Nocardioidaceae|g__Nocardioides,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Bacillaceae|g__Pontibacillus,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Clostridium,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Hyphomicrobiales|f__Methylobacteriaceae|g__Microvirga,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Aeromonadales|f__Aeromonadaceae|g__Aeromonas",2|1224|1236|135624;2|200940|3024418|213118;2|1224|1236|135624|84642;2|200940|3031451|3024411|213121;2|201174|1760|85009|85015|1839;2|1239|91061|1385|186817|289201;2|1239|186801|186802|31979|1485;2|1224|28211|356|119045|186650;2|1224|1236|135624|84642|642,Complete,Shaimaa Elsafoury
bsdb:6/1/1,Study 6,prospective cohort,28467925,10.1016/j.cmet.2017.04.001,NA,"Loomba R, Seguritan V, Li W, Long T, Klitgord N, Bhatt A, Dulai PS, Caussy C, Bettencourt R, Highlander SK, Jones MB, Sirlin CB, Schnabl B, Brinkac L, Schork N, Chen CH, Brenner DA, Biggs W, Yooseph S, Venter JC , Nelson KE",Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease,Cell metabolism,2017,"NASH, biomarker, cirrhosis, fatty liver, fibrosis, hepatic steatosis, hepatitis, liver disease, microbiome, non-invasive",Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Non-alcoholic fatty liver disease,EFO:0003095,mild/moderate fibrosis,advanced fibrosis,"Based on clinical, magnetic resonance, histology assessment; Mild/Moderate NAFLD: fibrosis 0-2. Advanced NAFLD: fibrosis 3-4",72,14,NA,WMS,NA,Illumina,Random Forest Analysis,0.05,TRUE,NA,NA,"age,body mass index",NA,NA,NA,NA,NA,NA,Signature 1,Table 3,10 January 2021,Shaimaa Elsafoury,"Lwaldron,WikiWorks",relative abundances of top 4 phyla found in all samples and representative species from the first 3 phyla.,decreased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Blautia|s__Blautia obeum,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Agathobacter|s__Agathobacter rectalis",2|1239|186801|3085636|186803|572511|40520;2|1239|186801|3085636|186803|1766253|39491,Complete,Fatima
bsdb:7/1/1,Study 7,case-control,20603222,10.1016/j.anaerobe.2010.06.008,NA,"Finegold SM, Dowd SE, Gontcharova V, Liu C, Henley KE, Wolcott RD, Youn E, Summanen PH, Granpeesheh D, Dixon D, Liu M, Molitoris DR , Green JA",Pyrosequencing study of fecal microflora of autistic and control children,Anaerobe,2010,NA,Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Autism,EFO:0003758,non-sibling control,severely autistic,"Cases were diagnosed with autistic spectrum disorder. Moreover, they were evaluated for autism and their diagnoses were validated based on impairment in social skills, impairment in language skills and verbal communication, sensory disturbances, repetitive stereotypical behaviors, and gastrointestinal disturbances.",8,11,within preceding month,16S,NA,Roche454,T-Test,0.05,FALSE,NA,NA,NA,NA,NA,increased,NA,NA,increased,Signature 1,Table 2 + Table 3 +  Table 5 + Table 6 + Table 8,10 January 2021,Marianthi Thomatos,WikiWorks,Significant fecal microflora of autistic and control children,increased,"k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Turicibacteraceae|g__Turicibacter,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Marinilabiliales|f__Marinilabiliaceae|g__Alkaliflexus,k__Bacteria|p__Thermodesulfobacteriota|c__Desulfovibrionia|o__Desulfovibrionales|f__Desulfovibrionaceae|g__Desulfovibrio,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Acetanaerobacterium,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Tannerellaceae|g__Parabacteroides,k__Bacteria|p__Thermodesulfobacteriota|c__Desulfovibrionia|o__Desulfovibrionales|f__Desulfovibrionaceae|g__Desulfovibrio|s__Desulfovibrio piger,k__Bacteria|p__Thermodesulfobacteriota|c__Desulfovibrionia|o__Desulfovibrionales|f__Desulfovibrionaceae|g__Desulfovibrio|s__Desulfovibrio desulfuricans,k__Bacteria|p__Thermodesulfobacteriota|c__Desulfovibrionia|o__Desulfovibrionales|f__Desulfovibrionaceae|g__Desulfovibrio|s__Desulfovibrio intestinalis,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Phocaeicola|s__Phocaeicola vulgatus,k__Bacteria|p__Bacteroidota,k__Bacteria|p__Pseudomonadota",2|1239|526524|526525|2810281|191303;2|976|200643|171549|815|816;2|976|200643|1970189|558415|286729;2|200940|3031449|213115|194924|872;2|1239|186801|186802|216572|258514;2|976|200643|171549|2005525|375288;2|200940|3031449|213115|194924|872|901;2|200940|3031449|213115|194924|872|876;2|200940|3031449|213115|194924|872|58621;2|976|200643|171549|815|909656|821;2|976;2|1224,Complete,Shaimaa Elsafoury
bsdb:7/1/2,Study 7,case-control,20603222,10.1016/j.anaerobe.2010.06.008,NA,"Finegold SM, Dowd SE, Gontcharova V, Liu C, Henley KE, Wolcott RD, Youn E, Summanen PH, Granpeesheh D, Dixon D, Liu M, Molitoris DR , Green JA",Pyrosequencing study of fecal microflora of autistic and control children,Anaerobe,2010,NA,Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Autism,EFO:0003758,non-sibling control,severely autistic,"Cases were diagnosed with autistic spectrum disorder. Moreover, they were evaluated for autism and their diagnoses were validated based on impairment in social skills, impairment in language skills and verbal communication, sensory disturbances, repetitive stereotypical behaviors, and gastrointestinal disturbances.",8,11,within preceding month,16S,NA,Roche454,T-Test,0.05,FALSE,NA,NA,NA,NA,NA,increased,NA,NA,increased,Signature 2,Table 2 + Table 3 +  Table 5 + Table 6 + Table 8,10 January 2021,Marianthi Thomatos,"Lwaldron,WikiWorks",Significant fecal microflora of autistic and control children,decreased,"k__Bacteria|p__Actinomycetota,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Natronincolaceae|g__Alkaliphilus,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Anaerofilum,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Anaerovoracaceae|g__Anaerovorax,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium|s__Bifidobacterium angulatum,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium|s__Bifidobacterium longum|s__Bifidobacterium longum subsp. longum,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Clostridium,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales|f__Coriobacteriaceae|g__Collinsella,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Dialister,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Dialister|s__Dialister invisus,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Ethanoligenens,k__Bacteria|p__Bacillota,k__Bacteria|p__Bacillota|c__Tissierellia|o__Tissierellales|f__Peptoniphilaceae|g__Helcococcus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Leuconostoc,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Eubacteriaceae|g__Pseudoramibacter,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Ruminococcus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Weissella,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|s__[Clostridium] leptum",2|201174;2|1239|186801|3082720|3118656|114627;2|1239|186801|186802|216572|52784;2|1239|186801|3082720|3030910|109326;2|201174|1760|85004|31953|1678;2|201174|1760|85004|31953|1678|1683;2|201174|1760|85004|31953|1678|216816|1679;2|1239|186801|186802|31979|1485;2|201174|84998|84999|84107|102106;2|1239|909932|1843489|31977|39948;2|1239|909932|1843489|31977|39948|218538;2|1239|186801|186802|216572|253238;2|1239;2|1239|1737404|1737405|1570339|31983;2|1239|91061|186826|33958|1578;2|1239|91061|186826|33958|1243;2|1239|186801|186802|186806|113286;2|1239|186801|186802|216572|1263;2|1239|91061|186826|1300|1301;2|1239|91061|186826|33958|46255;2|1239|186801|186802|216572|1535,Complete,Fatima
bsdb:8/1/1,Study 8,case-control,20140211,10.1371/journal.pone.0009085,NA,"Larsen N, Vogensen FK, van den Berg FW, Nielsen DS, Andreasen AS, Pedersen BK, Al-Soud WA, Sørensen SJ, Hansen LH , Jakobsen M",Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults,PloS one,2010,NA,Experiment 1,Denmark,Homo sapiens,Feces,UBERON:0001988,Type II diabetes mellitus,MONDO:0005148,Control,Diabetes Type 2,The diabetic group had elevated concentration of plasma glucose as determined by a fasting oral glucose tolerance test (OGTT),10,10,NA,16S,4,Roche454,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,Signature 1,Figure 2 + Text,10 January 2021,Phyu Han,WikiWorks,Relative abundances (%) of bacteria were determined in feces from human adults with type 2 diabetes and non-diabetic adult (all are males),increased,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria,2|1224|28216,Complete,Shaimaa Elsafoury
bsdb:8/1/2,Study 8,case-control,20140211,10.1371/journal.pone.0009085,NA,"Larsen N, Vogensen FK, van den Berg FW, Nielsen DS, Andreasen AS, Pedersen BK, Al-Soud WA, Sørensen SJ, Hansen LH , Jakobsen M",Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults,PloS one,2010,NA,Experiment 1,Denmark,Homo sapiens,Feces,UBERON:0001988,Type II diabetes mellitus,MONDO:0005148,Control,Diabetes Type 2,The diabetic group had elevated concentration of plasma glucose as determined by a fasting oral glucose tolerance test (OGTT),10,10,NA,16S,4,Roche454,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,Signature 2,Figure 2 + Text,10 January 2021,Phyu Han,WikiWorks,Relative abundances (%) of bacteria were determined in feces from human adults with type 2 diabetes and non-diabetic adult (all are males),decreased,"k__Bacteria|p__Bacillota,k__Bacteria|p__Bacillota|c__Clostridia",2|1239;2|1239|186801,Complete,Shaimaa Elsafoury
bsdb:9/1/1,Study 9,case-control,29190829,10.1371/journal.pone.0188873,NA,"Thompson KJ, Ingle JN, Tang X, Chia N, Jeraldo PR, Walther-Antonio MR, Kandimalla KK, Johnson S, Yao JZ, Harrington SC, Suman VJ, Wang L, Weinshilboum RL, Boughey JC, Kocher JP, Nelson H, Goetz MP , Kalari KR",A comprehensive analysis of breast cancer microbiota and host gene expression,PloS one,2017,NA,Experiment 1,United States of America,Homo sapiens,Breast,UBERON:0000310,Breast carcinoma,EFO:0000305,Control,Breast Cancer,Patients with breast cancer,668,72,NA,16S,345,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Figure 3 +text,10 January 2021,Phyu Han,"Lwaldron,WikiWorks",Species compositions of the Breast Caner and Non-cancerous Adjacent tissues,increased,"k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Bacillaceae|g__Alkalihalobacillus|s__Alkalihalobacillus alcalophilus,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micrococcales|f__Dermabacteraceae|g__Brachybacterium|s__Brachybacterium muris,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Furfurilactobacillus|s__Furfurilactobacillus rossiae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Salmonella|s__Salmonella enterica,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Mycobacteriales|f__Mycobacteriaceae|g__Mycolicibacterium|s__Mycolicibacterium phlei,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Mycobacteriales|f__Mycobacteriaceae|g__Mycolicibacterium|s__Mycolicibacterium fortuitum",2|1239|91061|1385|186817|2675234|1445;2|201174|1760|85006|85020|43668|219301;2|1239|91061|186826|33958|2767882|231049;2|1224|1236|91347|543|590|28901;2|201174|1760|85007|1762|1866885|1771;2|201174|1760|85007|1762|1866885|1766,Complete,Fatima
bsdb:9/1/2,Study 9,case-control,29190829,10.1371/journal.pone.0188873,NA,"Thompson KJ, Ingle JN, Tang X, Chia N, Jeraldo PR, Walther-Antonio MR, Kandimalla KK, Johnson S, Yao JZ, Harrington SC, Suman VJ, Wang L, Weinshilboum RL, Boughey JC, Kocher JP, Nelson H, Goetz MP , Kalari KR",A comprehensive analysis of breast cancer microbiota and host gene expression,PloS one,2017,NA,Experiment 1,United States of America,Homo sapiens,Breast,UBERON:0000310,Breast carcinoma,EFO:0000305,Control,Breast Cancer,Patients with breast cancer,668,72,NA,16S,345,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 2,Figure 3 +text,10 January 2021,Phyu Han,"Lwaldron,WikiWorks",Species compositions of the Breast Caner and Non-cancerous Adjacent tissues,decreased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Moraxellales|f__Moraxellaceae|g__Acinetobacter|s__Acinetobacter radioresistens,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Escherichia|s__Escherichia coli,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Burkholderiaceae|g__Ralstonia|s__Ralstonia pickettii,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micrococcales|f__Microbacteriaceae|g__Microbacterium|s__Microbacterium barkeri",2|1224|1236|2887326|468|469|40216;2|1224|1236|91347|543|561|562;2|1224|28216|80840|119060|48736|329;2|201174|1760|85006|85023|33882|33917,Complete,Fatima
bsdb:10/1/1,Study 10,case-control,29234019,10.1038/s41598-017-17351-9,NA,"Curty G, Costa RL, Siqueira JD, Meyrelles AI, Machado ES, Soares EA , Soares MA",Analysis of the cervical microbiome and potential biomarkers from postpartum HIV-positive women displaying cervical intraepithelial lesions,Scientific reports,2017,NA,Experiment 1,Brazil,Homo sapiens,Uterus,UBERON:0000995,Cervical glandular intraepithelial neoplasia,EFO:1000165,Normal tissue HIV patients,Cervical Intraepithelial Lesion HIV patients,Cases were identified by HIV rapid or ELISA test and subsequent Western blot following recommendations for HIV diagnosis by the Brazilian Ministry of Health. this were also patients with cervical intraepithelial lesions,42,38,NA,16S,3456,Illumina,LEfSe,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Figure 3,10 January 2021,Phyu Han,WikiWorks,Bacteria that presented higher relative abundance in cervical lesions using LEfse,increased,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Moryella,2|1239|186801|3085636|186803|437755,Complete,Shaimaa Elsafoury
bsdb:10/2/1,Study 10,case-control,29234019,10.1038/s41598-017-17351-9,NA,"Curty G, Costa RL, Siqueira JD, Meyrelles AI, Machado ES, Soares EA , Soares MA",Analysis of the cervical microbiome and potential biomarkers from postpartum HIV-positive women displaying cervical intraepithelial lesions,Scientific reports,2017,NA,Experiment 2,Brazil,Homo sapiens,Uterus,UBERON:0000995,Cervical glandular intraepithelial neoplasia,EFO:1000165,Normal tissue HIV patients,Cervical Intraepithelial Lesion HIV patients,Cases were identified by HIV rapid or ELISA test and subsequent Western blot following recommendations for HIV diagnosis by the Brazilian Ministry of Health.,42,38,NA,16S,3456,Illumina,LEfSe,0.1,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Figure 3,10 January 2021,Shaimaa Elsafoury,"WikiWorks,Davvve",Bacteria that presented higher relative abundance in cervical lesions using LEfse protocol,increased,"k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Aerococcaceae|g__Aerococcus,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium|s__Bifidobacterium bifidum,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Sphaerotilaceae|g__Caldimonas|s__Caldimonas thermodepolymerans,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Gardnerella|s__Gardnerella vaginalis",2|1239|91061|186826|186827|1375;2|201174|1760|85004|31953|1678|1681;2|1224|28216|80840|2975441|196013|215580;2|201174|1760|85004|31953|2701|2702,Complete,Shaimaa Elsafoury
bsdb:11/1/1,Study 11,time series / longitudinal observational,29234019,10.1038/s41598-017-17351-9,NA,"Curty G, Costa RL, Siqueira JD, Meyrelles AI, Machado ES, Soares EA , Soares MA",Analysis of the cervical microbiome and potential biomarkers from postpartum HIV-positive women displaying cervical intraepithelial lesions,Scientific reports,2017,NA,Experiment 1,Brazil,Homo sapiens,Uterus,UBERON:0000995,Cervical glandular intraepithelial neoplasia,EFO:1000165,HIV pateints with normal tissue at 6 months,HIV patients with lesion at 12 months,Cases were identified by HIV rapid or ELISA test and subsequent Western blot following recommendations for HIV diagnosis by the Brazilian Ministry of Health.,5,5,NA,16S,3456,Illumina,Mann-Whitney (Wilcoxon),0.1,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Figure 4,10 January 2021,Shaimaa Elsafoury,WikiWorks,Gardnerella vaginalis abundance longitudinal analysis at six and twelve months postpartum in paired samples,decreased,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Gardnerella|s__Gardnerella vaginalis,2|201174|1760|85004|31953|2701|2702,Complete,Shaimaa Elsafoury
bsdb:12/1/1,Study 12,time series / longitudinal observational,30341386,10.1038/s41598-018-33750-y,NA,"Arokiyaraj S, Seo SS, Kwon M, Lee JK , Kim MK","Association of cervical microbial community with persistence, clearance and negativity of Human Papillomavirus in Korean women: a longitudinal study",Scientific reports,2018,NA,Experiment 1,South Korea,Homo sapiens,Uterus,UBERON:0000995,Human papilloma virus infection,EFO:0001668,HPV clearance,HPV persistent,"HPV DNA was detected using the Digene HC2 high-risk DNA test (Qiagen, Gaithersburg, MD, USA) with signal amplification and chemiluminescence for 13 types of HR-HPV scored in RLU/PC. A positive result indicated a concentration of 1 pg/ml or higher than the RLU/cutoff ratio (RLU of the specimen/mean RLU of 2 positive controls).",15,16,NA,16S,NA,Roche454,LEfSe,0.05,FALSE,2,NA,"age,contraception,menopause,smoking behavior",NA,unchanged,unchanged,NA,NA,NA,Signature 1,Table 2,10 January 2021,Phyu Han,WikiWorks,Mulivariate odd ratios of species according to different types of HPV,increased,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Tannerellaceae|g__Parabacteroides|s__Parabacteroides johnsonii,2|976|200643|171549|2005525|375288|387661,Complete,Shaimaa Elsafoury
bsdb:12/2/1,Study 12,time series / longitudinal observational,30341386,10.1038/s41598-018-33750-y,NA,"Arokiyaraj S, Seo SS, Kwon M, Lee JK , Kim MK","Association of cervical microbial community with persistence, clearance and negativity of Human Papillomavirus in Korean women: a longitudinal study",Scientific reports,2018,NA,Experiment 2,South Korea,Homo sapiens,Uterus,UBERON:0000995,Human papilloma virus infection,EFO:0001668,HPV negative,HPV clearance,"HPV DNA was detected using the Digene HC2 high-risk DNA test (Qiagen, Gaithersburg, MD, USA) with signal amplification and chemiluminescence for 13 types of HR-HPV scored in RLU/PC. A positive result indicated a concentration of 1 pg/ml or higher than the RLU/cutoff ratio (RLU of the specimen/mean RLU of 2 positive controls).",10,15,NA,16S,NA,Roche454,LEfSe,0.05,FALSE,2,NA,"age,contraception,menopause,smoking behavior",NA,unchanged,unchanged,NA,NA,NA,Signature 1,Table 2,10 January 2021,Phyu Han,WikiWorks,Mulivariate odd ratios of species according to different types of HPV,increased,"k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Gardnerella|s__Gardnerella vaginalis,k__Bacteria|p__Mycoplasmatota|o__Mycoplasmoidales|f__Mycoplasmoidaceae|g__Ureaplasma|s__Ureaplasma urealyticum",2|201174|1760|85004|31953|2701|2702;2|544448|2790996|2790998|2129|2130,Complete,Shaimaa Elsafoury
bsdb:12/3/1,Study 12,time series / longitudinal observational,30341386,10.1038/s41598-018-33750-y,NA,"Arokiyaraj S, Seo SS, Kwon M, Lee JK , Kim MK","Association of cervical microbial community with persistence, clearance and negativity of Human Papillomavirus in Korean women: a longitudinal study",Scientific reports,2018,NA,Experiment 3,South Korea,Homo sapiens,Uterus,UBERON:0000995,Human papilloma virus infection,EFO:0001668,HPV presistent and clearance,HPV negative,"HPV DNA was detected using the Digene HC2 high-risk DNA test (Qiagen, Gaithersburg, MD, USA) with signal amplification and chemiluminescence for 13 types of HR-HPV scored in RLU/PC. A positive result indicated a concentration of 1 pg/ml or higher than the RLU/cutoff ratio (RLU of the specimen/mean RLU of 2 positive controls).",31,10,NA,16S,NA,Roche454,LEfSe,0.05,FALSE,2,NA,"age,contraception,menopause,smoking behavior",NA,unchanged,unchanged,NA,NA,NA,Signature 1,Table 2,10 January 2021,Phyu Han,WikiWorks,Mulivariate odd ratios of species according to different types of HPV,increased,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus|s__Lactobacillus crispatus,2|1239|91061|186826|33958|1578|47770,Complete,Shaimaa Elsafoury
bsdb:12/4/1,Study 12,time series / longitudinal observational,30341386,10.1038/s41598-018-33750-y,NA,"Arokiyaraj S, Seo SS, Kwon M, Lee JK , Kim MK","Association of cervical microbial community with persistence, clearance and negativity of Human Papillomavirus in Korean women: a longitudinal study",Scientific reports,2018,NA,Experiment 4,South Korea,Homo sapiens,Uterus,UBERON:0000995,Human papilloma virus infection,EFO:0001668,HPV presistent and negative,HPV clearance,"HPV DNA was detected using the Digene HC2 high-risk DNA test (Qiagen, Gaithersburg, MD, USA) with signal amplification and chemiluminescence for 13 types of HR-HPV scored in RLU/PC. A positive result indicated a concentration of 1 pg/ml or higher than the RLU/cutoff ratio (RLU of the specimen/mean RLU of 2 positive controls).",26,15,NA,16S,NA,Roche454,LEfSe,0.05,FALSE,2,NA,"age,contraception,menopause,smoking behavior",NA,unchanged,unchanged,NA,NA,NA,Signature 1,Table 2,10 January 2021,Shaimaa Elsafoury,WikiWorks,Mulivariate odd ratios of species according to different types of HPV,increased,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Lachnospira|s__Lachnospira eligens,2|1239|186801|3085636|186803|28050|39485,Complete,Shaimaa Elsafoury
bsdb:13/1/1,Study 13,"cross-sectional observational, not case-control",29608253,10.1002/cam4.1471,NA,"Zhang C, Liu Y, Gao W, Pan Y, Gao Y, Shen J , Xiong H",The direct and indirect association of cervical microbiota with the risk of cervical intraepithelial neoplasia,Cancer medicine,2018,"16sRNA, HPV, cervical intraepithelial neoplasia, cervical microbiota, next-generation sequencing",Experiment 1,China,Homo sapiens,Uterus,UBERON:0000995,Cervical glandular intraepithelial neoplasia,EFO:1000165,Cervical Intraepithelial Neoplasis -1,Cervical Intraepithelial Neoplasis +2,NA,126,40,NA,16S,34,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,NA,Signature 1,Figure 4,10 January 2021,Phyu Han,WikiWorks,LEfSe showing the differences in the 18 most abundant species according to Cervical Intraepithelial Neoplasia (CIN) status,increased,"k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus|s__Lactobacillus crispatus,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides|s__Bacteroides fragilis,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus|s__Streptococcus agalactiae,k__Bacteria|p__Campylobacterota|c__Epsilonproteobacteria|o__Campylobacterales|f__Campylobacteraceae|g__Campylobacter|s__Campylobacter ureolyticus",2|1239|91061|186826|33958|1578|47770;2|976|200643|171549|815|816|817;2|1239|91061|186826|1300|1301|1311;2|29547|3031852|213849|72294|194|827,Complete,Shaimaa Elsafoury
bsdb:13/1/2,Study 13,"cross-sectional observational, not case-control",29608253,10.1002/cam4.1471,NA,"Zhang C, Liu Y, Gao W, Pan Y, Gao Y, Shen J , Xiong H",The direct and indirect association of cervical microbiota with the risk of cervical intraepithelial neoplasia,Cancer medicine,2018,"16sRNA, HPV, cervical intraepithelial neoplasia, cervical microbiota, next-generation sequencing",Experiment 1,China,Homo sapiens,Uterus,UBERON:0000995,Cervical glandular intraepithelial neoplasia,EFO:1000165,Cervical Intraepithelial Neoplasis -1,Cervical Intraepithelial Neoplasis +2,NA,126,40,NA,16S,34,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,NA,Signature 2,Figure 4,10 January 2021,Phyu Han,WikiWorks,LEfSe showing the differences in the 18 most abundant species according to Cervical Intraepithelial Neoplasia (CIN) status,decreased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Vibrionales|f__Vibrionaceae|g__Photobacterium|s__Photobacterium damselae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus|s__Lactobacillus jensenii,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales|f__Atopobiaceae|g__Fannyhessea|s__Fannyhessea vaginae",2|1224|1236|135623|641|657|38293;2|1239|91061|186826|33958|1578|109790;2|201174|84998|84999|1643824|2767327|82135,Complete,Shaimaa Elsafoury
bsdb:13/2/1,Study 13,"cross-sectional observational, not case-control",29608253,10.1002/cam4.1471,NA,"Zhang C, Liu Y, Gao W, Pan Y, Gao Y, Shen J , Xiong H",The direct and indirect association of cervical microbiota with the risk of cervical intraepithelial neoplasia,Cancer medicine,2018,"16sRNA, HPV, cervical intraepithelial neoplasia, cervical microbiota, next-generation sequencing",Experiment 2,China,Homo sapiens,Uterus,UBERON:0000995,Cervical glandular intraepithelial neoplasia,EFO:1000165,HPV -ve among pateints with Cervical Intraepithelial Neoplasia different severity status,HPV +ve,NA,130,36,NA,16S,34,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Figure 4,10 January 2021,Shaimaa Elsafoury,WikiWorks,LEfSe showing the differences in the 18 most abundant species according to HPV infection,increased,"k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus|s__Streptococcus agalactiae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides|s__Bacteroides fragilis,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pseudomonadales|f__Pseudomonadaceae|g__Stutzerimonas|s__Stutzerimonas stutzeri,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Peptostreptococcaceae|g__Peptostreptococcus|s__Peptostreptococcus anaerobius",2|1239|91061|186826|1300|1301|1311;2|976|200643|171549|815|816|817;2|1224|1236|72274|135621|2901164|316;2|1239|186801|3082720|186804|1257|1261,Complete,Shaimaa Elsafoury
bsdb:13/2/2,Study 13,"cross-sectional observational, not case-control",29608253,10.1002/cam4.1471,NA,"Zhang C, Liu Y, Gao W, Pan Y, Gao Y, Shen J , Xiong H",The direct and indirect association of cervical microbiota with the risk of cervical intraepithelial neoplasia,Cancer medicine,2018,"16sRNA, HPV, cervical intraepithelial neoplasia, cervical microbiota, next-generation sequencing",Experiment 2,China,Homo sapiens,Uterus,UBERON:0000995,Cervical glandular intraepithelial neoplasia,EFO:1000165,HPV -ve among pateints with Cervical Intraepithelial Neoplasia different severity status,HPV +ve,NA,130,36,NA,16S,34,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,NA,NA,NA,NA,NA,Signature 2,Figure 4,10 January 2021,Shaimaa Elsafoury,WikiWorks,LEfSe showing the differences in the 18 most abundant species according to HPV infection,decreased,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus|s__Lactobacillus delbrueckii,2|1239|91061|186826|33958|1578|1584,Complete,Shaimaa Elsafoury
bsdb:14/1/1,Study 14,case-control,28875948,10.1088/1752-7163/aa7c24,NA,"Seerangaiyan K, van Winkelhoff AJ, Harmsen HJM, Rossen JWA , Winkel EG",The tongue microbiome in healthy subjects and patients with intra-oral halitosis,Journal of breath research,2017,NA,Experiment 1,Netherlands,Homo sapiens,Superior surface of tongue,UBERON:0007371,Halitosis,HP:0100812,Control,Oral Halitosis,"IOH patient group was selected based on an organoleptic score of >= 2 from the mouth and nose =< 1, having a VSC level > 160 ppb, and H2S > 4 nmol/ L (96 ppb) and CH3SH > 0.5 nmol/L (12 ppb) and a DPSI of =< 2",5,10,3 months,16S,34,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,NA,NA,NA,Signature 1,Figure 4,10 January 2021,Phyu Han,WikiWorks,Significant differentially abundant OTU of intr-aoral halitosis and Control,increased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Aggregatibacter|s__Aggregatibacter segnis,k__Bacteria|p__Campylobacterota|c__Epsilonproteobacteria|o__Campylobacterales|f__Campylobacteraceae|g__Campylobacter,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Tannerellaceae|g__Tannerella,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Dialister,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Peptostreptococcaceae|g__Peptostreptococcus,k__Bacteria|p__Bacillota|c__Negativicutes|o__Selenomonadales|f__Selenomonadaceae|g__Selenomonas,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Leptotrichiaceae|g__Leptotrichia,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Peptococcaceae|g__Peptococcus,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales,k__Bacteria|p__Bacillota|c__Tissierellia|o__Tissierellales|f__Peptoniphilaceae|g__Parvimonas,k__Bacteria|p__Spirochaetota|c__Spirochaetia|o__Spirochaetales|f__Treponemataceae|g__Treponema,k__Bacteria|p__Bacteroidota|c__Flavobacteriia|o__Flavobacteriales|f__Flavobacteriaceae|g__Capnocytophaga,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Aggregatibacter,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella",2|1224|1236|135625|712|416916|739;2|29547|3031852|213849|72294|194;2|976|200643|171549|2005525|195950;2|1239|909932|1843489|31977|39948;2|1239|186801|3082720|186804|1257;2|1239|909932|909929|1843491|970;2|32066|203490|203491|1129771|32067;2|1239|186801|186802|186807|2740;2|1239|186801|186802;2|1239|1737404|1737405|1570339|543311;2|203691|203692|136|2845253|157;2|976|117743|200644|49546|1016;2|1224|1236|135625|712|416916;2|976|200643|171549|171552|838,Complete,Shaimaa Elsafoury
bsdb:14/1/2,Study 14,case-control,28875948,10.1088/1752-7163/aa7c24,NA,"Seerangaiyan K, van Winkelhoff AJ, Harmsen HJM, Rossen JWA , Winkel EG",The tongue microbiome in healthy subjects and patients with intra-oral halitosis,Journal of breath research,2017,NA,Experiment 1,Netherlands,Homo sapiens,Superior surface of tongue,UBERON:0007371,Halitosis,HP:0100812,Control,Oral Halitosis,"IOH patient group was selected based on an organoleptic score of >= 2 from the mouth and nose =< 1, having a VSC level > 160 ppb, and H2S > 4 nmol/ L (96 ppb) and CH3SH > 0.5 nmol/L (12 ppb) and a DPSI of =< 2",5,10,3 months,16S,34,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,NA,NA,NA,Signature 2,Figure 4,10 January 2021,Phyu Han,"Merit,WikiWorks",Significant differentially abundant OTU of intra-oral halitosis and Control,decreased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Aggregatibacter,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Haemophilus,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Haemophilus|s__Haemophilus parainfluenzae,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Moryella,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Oribacterium,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micrococcales|f__Micrococcaceae|g__Rothia|s__Rothia dentocariosa,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Peptococcaceae|g__Peptococcus,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Leptotrichiaceae|g__Leptotrichia",2|1224|1236|135625|712|416916;2|1224|1236|135625|712|724;2|1224|1236|135625|712|724|729;2|1239|186801|3085636|186803|437755;2|1239|186801|3085636|186803|265975;2|976|200643|171549|171552|838;2|201174|1760|85006|1268|32207|2047;2|1239|91061|186826|1300|1301;2|1239|186801|186802|186807|2740;2|32066|203490|203491|1129771|32067,Complete,Shaimaa Elsafoury
bsdb:15/1/1,Study 15,"cross-sectional observational, not case-control",28932201,10.3389/fphys.2017.00675,NA,"Zheng J, Xiao X, Zhang Q, Mao L, Yu M, Xu J , Wang T",The Placental Microbiota Is Altered among Subjects with Gestational Diabetes Mellitus: A Pilot Study,Frontiers in physiology,2017,"16S rRNA gene, clinical characteristics, gestational diabetes mellitus, microbiota, placenta",Experiment 1,China,Homo sapiens,Uterus,UBERON:0000995,Gestational diabetes,EFO:0004593,controls,Gestational diabetes mellitus,"GDM was diagnosed when the fasting plasma glucose ≥5.1 mmol/L or 1 h post-OGTT glycemia ≥10.0 mmol/L or 2 h post-OGTT glycemia ≥8.5 mmol/L, according to the criteria set by International Association of Diabetes and Pregnancy Study Groups (IADPSG)",10,10,9 months,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,"age,body mass index",NA,NA,unchanged,NA,NA,NA,unchanged,Signature 1,Table 2+ Figure 4+ Supplemental Table S2,10 January 2021,Fatima Zohra,WikiWorks,Phlotypes in placental microbiota significantly different between GDM and NDM groups,increased,"k__Bacteria|p__Pseudomonadota,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Rhodocyclales|f__Zoogloeaceae|g__Thauera,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Hyphomicrobiales,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Alcaligenaceae",2|1224;2|1224|28216|206389|2008794|33057;2|1224|28216|80840;2|1224|28211|356;2|1224|28216|80840|506,Complete,Shaimaa Elsafoury
bsdb:15/1/2,Study 15,"cross-sectional observational, not case-control",28932201,10.3389/fphys.2017.00675,NA,"Zheng J, Xiao X, Zhang Q, Mao L, Yu M, Xu J , Wang T",The Placental Microbiota Is Altered among Subjects with Gestational Diabetes Mellitus: A Pilot Study,Frontiers in physiology,2017,"16S rRNA gene, clinical characteristics, gestational diabetes mellitus, microbiota, placenta",Experiment 1,China,Homo sapiens,Uterus,UBERON:0000995,Gestational diabetes,EFO:0004593,controls,Gestational diabetes mellitus,"GDM was diagnosed when the fasting plasma glucose ≥5.1 mmol/L or 1 h post-OGTT glycemia ≥10.0 mmol/L or 2 h post-OGTT glycemia ≥8.5 mmol/L, according to the criteria set by International Association of Diabetes and Pregnancy Study Groups (IADPSG)",10,10,9 months,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,"age,body mass index",NA,NA,unchanged,NA,NA,NA,unchanged,Signature 2,Table 2+ Figure 4+ Supplemental Table S2,10 January 2021,Fatima Zohra,WikiWorks,Phlotypes in placental microbiota significantly different between GDM and NDM groups,decreased,"k__Bacteria|p__Bacteroidota,k__Bacteria|p__Armatimonadota,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Paenibacillaceae|g__Brevibacillus,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Nitrosomonadales|f__Sulfuricellaceae|g__Sulfuricella,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Lysobacterales|f__Rhodanobacteraceae|g__Dyella,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales,k__Bacteria|p__Acidobacteriota|c__Holophagae|o__Holophagales,k__Bacteria|p__Pseudomonadota|c__Hydrogenophilia|o__Hydrogenophilales,k__Bacteria|p__Ignavibacteriota|c__Ignavibacteria|o__Ignavibacteriales,k__Bacteria|p__Chlorobiota,k__Bacteria|p__Bacteroidota|c__Bacteroidia,k__Bacteria|p__Acidobacteriota|c__Holophagae|o__Holophagales|f__Holophagaceae|g__Geothrix,k__Bacteria|p__Ignavibacteriota|c__Ignavibacteria,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae,k__Bacteria|p__Pseudomonadota|c__Hydrogenophilia|o__Hydrogenophilales|f__Hydrogenophilaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Paenibacillaceae",2|976;2|67819;2|1239|91061|1385|186822|55080;2|1224|28216|32003|2772226|935200;2|1239|91061|186826|33958|1578;2|1224|1236|135614|1775411|231454;2|976|200643|171549;2|1239|526524|526525;2|57723|533205|574975;2|1224|2008785|119069;2|1134404|795747|795748;2|1090;2|976|200643;2|57723|533205|574975|574976|44675;2|1134404|795747;2|1239|91061|186826|33958;2|1224|2008785|119069|206349;2|1239|91061|1385|186822,Complete,Shaimaa Elsafoury
bsdb:16/1/1,Study 16,"case-control,laboratory experiment",28199741,10.1111/jpi.12399,NA,"Xu P, Wang J, Hong F, Wang S, Jin X, Xue T, Jia L , Zhai Y",Melatonin prevents obesity through modulation of gut microbiota in mice,Journal of pineal research,2017,"gut microbiota, inflammation, insulin resistance, liver steatosis, melatonin, obesity",Experiment 1,United States of America,Mus musculus,Feces,UBERON:0001988,Obesity,EFO:0001073,normal chow diet,high fat diet,Obesity is (BMI ≥ 30kg/m2),5,5,NA,16S,34,Illumina,LEfSe,0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,Signature 1,Figure 6B + Data S1,10 January 2021,Marianthi Thomatos,WikiWorks,Differential abundant taxa in gut microbiota in response to melatonin treatment,increased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Acetitomaculum,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Ruminococcus,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Marvinbryantia,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Rikenellaceae|g__Alistipes,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Blautia",2|1239|186801|3085636|186803|31980;2|976|200643|171549|171552;2|1239|186801|186802|216572|1263;2|1239|186801|3085636|186803|248744;2|976|200643|171549|171550|239759;2|1239|186801|3085636|186803|572511,Complete,Shaimaa Elsafoury
bsdb:16/1/2,Study 16,"case-control,laboratory experiment",28199741,10.1111/jpi.12399,NA,"Xu P, Wang J, Hong F, Wang S, Jin X, Xue T, Jia L , Zhai Y",Melatonin prevents obesity through modulation of gut microbiota in mice,Journal of pineal research,2017,"gut microbiota, inflammation, insulin resistance, liver steatosis, melatonin, obesity",Experiment 1,United States of America,Mus musculus,Feces,UBERON:0001988,Obesity,EFO:0001073,normal chow diet,high fat diet,Obesity is (BMI ≥ 30kg/m2),5,5,NA,16S,34,Illumina,LEfSe,0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,Signature 2,Figure 6B + Data S1,10 January 2021,Marianthi Thomatos,WikiWorks,Differential abundant taxa in gut microbiota in response to melatonin treatment,decreased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Odoribacteraceae|g__Odoribacter,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Anaerovoracaceae|g__Anaerovorax,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Odoribacteraceae|g__Butyricimonas,k__Bacteria|p__Bacillota|c__Clostridia|o__Christensenellales|f__Christensenellaceae,k__Bacteria|p__Campylobacterota|c__Epsilonproteobacteria|o__Campylobacterales|f__Helicobacteraceae|g__Helicobacter,k__Bacteria|p__Bacillota|c__Clostridia|o__Christensenellales|f__Christensenellaceae|g__Christensenella,k__Bacteria|p__Thermodesulfobacteriota|c__Desulfovibrionia|o__Desulfovibrionales|f__Desulfovibrionaceae|g__Bilophila,k__Bacteria|p__Mycoplasmatota,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Oscillibacter",2|976|200643|171549|815|816;2|976|200643|171549|1853231|283168;2|1239|186801|3082720|3030910|109326;2|976|200643|171549|1853231|574697;2|1239|186801|3082768|990719;2|29547|3031852|213849|72293|209;2|1239|186801|3082768|990719|990721;2|200940|3031449|213115|194924|35832;2|544448;2|1239|186801|186802|216572|459786,Complete,Shaimaa Elsafoury
bsdb:16/2/1,Study 16,"case-control,laboratory experiment",28199741,10.1111/jpi.12399,NA,"Xu P, Wang J, Hong F, Wang S, Jin X, Xue T, Jia L , Zhai Y",Melatonin prevents obesity through modulation of gut microbiota in mice,Journal of pineal research,2017,"gut microbiota, inflammation, insulin resistance, liver steatosis, melatonin, obesity",Experiment 2,United States of America,Mus musculus,Feces,UBERON:0001988,Obesity,EFO:0001073,high fat diet,high fat diet + melatonin,Obesity is (BMI ≥ 30kg/m2),5,5,NA,16S,34,Illumina,LEfSe,0.05,TRUE,NA,NA,NA,NA,decreased,decreased,increased,NA,NA,Signature 1,Figure 6B + Data S1,10 January 2021,Marianthi Thomatos,WikiWorks,Differential abundant taxa in gut microbiota in response to melatonin treatment,increased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Morganellaceae|g__Proteus,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Odoribacteraceae|g__Odoribacter,k__Bacteria|p__Campylobacterota|c__Epsilonproteobacteria|o__Campylobacterales|f__Helicobacteraceae|g__Helicobacter,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Anaerovoracaceae|g__Anaerovorax,k__Bacteria|p__Thermodesulfobacteriota|c__Desulfovibrionia|o__Desulfovibrionales|f__Desulfovibrionaceae|g__Desulfovibrio,k__Bacteria|p__Thermodesulfobacteriota|c__Desulfovibrionia|o__Desulfovibrionales|f__Desulfovibrionaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Odoribacteraceae|g__Butyricimonas,k__Bacteria|p__Verrucomicrobiota|c__Verrucomicrobiia|o__Verrucomicrobiales|f__Akkermansiaceae|g__Akkermansia,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Geodermatophilales|f__Antricoccaceae|g__Antricoccus",2|1224|1236|91347|1903414|583;2|976|200643|171549|1853231|283168;2|29547|3031852|213849|72293|209;2|1239|186801|3082720|3030910|109326;2|200940|3031449|213115|194924|872;2|200940|3031449|213115|194924;2|976|200643|171549|1853231|574697;2|74201|203494|48461|1647988|239934;2|201174|1760|1643682|2805401|1920251,Complete,Shaimaa Elsafoury
bsdb:16/2/2,Study 16,"case-control,laboratory experiment",28199741,10.1111/jpi.12399,NA,"Xu P, Wang J, Hong F, Wang S, Jin X, Xue T, Jia L , Zhai Y",Melatonin prevents obesity through modulation of gut microbiota in mice,Journal of pineal research,2017,"gut microbiota, inflammation, insulin resistance, liver steatosis, melatonin, obesity",Experiment 2,United States of America,Mus musculus,Feces,UBERON:0001988,Obesity,EFO:0001073,high fat diet,high fat diet + melatonin,Obesity is (BMI ≥ 30kg/m2),5,5,NA,16S,34,Illumina,LEfSe,0.05,TRUE,NA,NA,NA,NA,decreased,decreased,increased,NA,NA,Signature 2,Figure 6B + Data S1 + Figure 7,10 January 2021,Marianthi Thomatos,WikiWorks,Differential abundant taxa in gut microbiota in response to melatonin treatment,decreased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Rikenellaceae|g__Alistipes,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Anaerotruncus,k__Bacteria|p__Campylobacterota|c__Epsilonproteobacteria|o__Campylobacterales|f__Helicobacteraceae|g__Helicobacter|s__Helicobacter marmotae",2|976|200643|171549|171550|239759;2|1239|186801|186802|216572|244127;2|29547|3031852|213849|72293|209|152490,Complete,Shaimaa Elsafoury
bsdb:17/1/1,Study 17,"cross-sectional observational, not case-control",30029052,10.1016/j.jpsychires.2018.07.007,NA,"Jiang HY, Zhang X, Yu ZH, Zhang Z, Deng M, Zhao JH , Ruan B",Altered gut microbiota profile in patients with generalized anxiety disorder,Journal of psychiatric research,2018,NA,Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Anxiety disorder,EFO:0006788,healthy controls,treatment active Generalized Anxiety disorder,The active state of GAD was defined as a baseline Hamilton Anxiety Rating Scale HAMA score ≥14 upon admission to the hospital. The remissive state was defined as a HAMA score < 7 after 3 months of treatment.,36,40,2 months,16S,34,Illumina,LEfSe,0.05,TRUE,2,"age,body mass index,sex",NA,NA,unchanged,NA,unchanged,NA,decreased,Signature 1,Figure 1,10 January 2021,Fatima Zohra,WikiWorks,Comparison of relative abundance at the bacterial phylum and genus levels between healthy controls and generalized anxiety disorder groups,increased,"k__Bacteria|p__Fusobacteriota,k__Bacteria|p__Bacteroidota,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae|g__Fusobacterium,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Mediterraneibacter|s__Mediterraneibacter gnavus,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Flavonifractor,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Eisenbergiella,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Coprobacillaceae|g__Thomasclavelia,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae|s__[Clostridium] innocuum,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales,k__Bacteria|p__Bacteroidota|c__Bacteroidia",2|32066;2|976;2|32066|203490|203491|203492|848;2|1239|186801|3085636|186803|2316020|33038;2|976|200643|171549|815|816;2|1239|186801|186802|216572|946234;2|32066|203490;2|32066|203490|203491|203492;2|32066|203490|203491;2|1239|186801|3085636|186803|1432051;2|1239|526524|526525|2810280|1505663;2|1239|526524|526525|128827|1522;2|976|200643|171549|815;2|976|200643|171549;2|976|200643,Complete,Shaimaa Elsafoury
bsdb:17/1/2,Study 17,"cross-sectional observational, not case-control",30029052,10.1016/j.jpsychires.2018.07.007,NA,"Jiang HY, Zhang X, Yu ZH, Zhang Z, Deng M, Zhao JH , Ruan B",Altered gut microbiota profile in patients with generalized anxiety disorder,Journal of psychiatric research,2018,NA,Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Anxiety disorder,EFO:0006788,healthy controls,treatment active Generalized Anxiety disorder,The active state of GAD was defined as a baseline Hamilton Anxiety Rating Scale HAMA score ≥14 upon admission to the hospital. The remissive state was defined as a HAMA score < 7 after 3 months of treatment.,36,40,2 months,16S,34,Illumina,LEfSe,0.05,TRUE,2,"age,body mass index,sex",NA,NA,unchanged,NA,unchanged,NA,decreased,Signature 2,Figure 1,10 January 2021,Fatima Zohra,"Lwaldron,WikiWorks",Comparison of relative abundance at the bacterial phylum and genus levels between healthy controls and generalized anxiety disorder groups,decreased,"k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Alcaligenaceae,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria,k__Bacteria|p__Thermodesulfobacteriota|c__Desulfovibrionia|o__Desulfovibrionales|f__Desulfovibrionaceae|g__Bilophila,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Butyricicoccaceae|g__Butyricicoccus,k__Bacteria|p__Bacillota|c__Clostridia|o__Christensenellales|f__Christensenellaceae,k__Bacteria|p__Bacillota|c__Clostridia,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales|f__Coriobacteriaceae,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales,k__Bacteria|c__Deltaproteobacteria,k__Bacteria|p__Thermodesulfobacteriota|c__Desulfovibrionia|o__Desulfovibrionales|f__Desulfovibrionaceae,k__Bacteria|p__Thermodesulfobacteriota|c__Desulfovibrionia|o__Desulfovibrionales,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Dialister,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Faecalibacterium,k__Bacteria|p__Bacillota,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Lachnospira,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Lachnospira|s__Lachnospira eligens,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Peptococcaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Pseudobutyrivibrio,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Roseburia,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Ruminococcus|s__Ruminococcus gauvreauii,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Subdoligranulum,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Sutterellaceae|g__Sutterella,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Agathobacter|s__Agathobacter rectalis",2|1224|28216|80840|506;2|1224|28216;2|200940|3031449|213115|194924|35832;2|1224|28216|80840;2|1239|186801|186802|3085642|580596;2|1239|186801|3082768|990719;2|1239|186801;2|201174|84998|84999|84107;2|201174|84998|84999;2|28221;2|200940|3031449|213115|194924;2|200940|3031449|213115;2|1239|909932|1843489|31977|39948;2|1239|186801|186802;2|1239|186801|186802|216572|216851;2|1239;2|1239|186801|3085636|186803|28050;2|1239|186801|3085636|186803|28050|39485;2|1239|186801|3085636|186803;2|1239|186801|186802|541000;2|1239|186801|186802|186807;2|1239|186801|3085636|186803|46205;2|1239|186801|3085636|186803|841;2|1239|186801|186802|216572|1263|438033;2|1239|186801|186802|216572|292632;2|1224|28216|80840|995019|40544;2|1239|186801|3085636|186803|1766253|39491,Complete,Fatima
bsdb:17/2/1,Study 17,"cross-sectional observational, not case-control",30029052,10.1016/j.jpsychires.2018.07.007,NA,"Jiang HY, Zhang X, Yu ZH, Zhang Z, Deng M, Zhao JH , Ruan B",Altered gut microbiota profile in patients with generalized anxiety disorder,Journal of psychiatric research,2018,NA,Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Anxiety disorder,EFO:0006788,healthy controls,treatment naiive Generalized Anxiety disorder,The active state of GAD was defined as a baseline Hamilton Anxiety Rating Scale HAMA score ≥14 upon admission to the hospital. The remissive state was defined as a HAMA score < 7 after 3 months of treatment.,17,12,2 months,16S,34,Illumina,LEfSe,0.05,TRUE,2,"age,body mass index,sex",NA,NA,decreased,decreased,NA,NA,decreased,Signature 1,Figure 2,10 January 2021,Shaimaa Elsafoury,WikiWorks,Comparison of relative abundance at the bacterial phylum and genus levels between healthy controls and treatment naiive generalized anxiety disorder groups,increased,"k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae|g__Fusobacterium,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Mediterraneibacter|s__Mediterraneibacter gnavus,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Escherichia,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Shigella,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales,k__Bacteria|p__Bacteroidota|c__Bacteroidia,k__Bacteria|p__Bacteroidota,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Tannerellaceae|g__Parabacteroides,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Coprobacillaceae|g__Thomasclavelia,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Mediterraneibacter|s__[Ruminococcus] torques,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae|s__[Clostridium] innocuum,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Flavonifractor,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia,k__Bacteria|p__Fusobacteriota",2|1239|91061|186826|33958|1578;2|32066|203490|203491|203492|848;2|1239|186801|3085636|186803|2316020|33038;2|976|200643|171549|815|816;2|1224|1236|91347|543|561;2|1224|1236|91347|543|620;2|976|200643|171549|815;2|976|200643|171549;2|976|200643;2|976;2|1224|1236|91347|543;2|1224|1236|91347;2|976|200643|171549|2005525|375288;2|1239|91061|186826|33958;2|1239|526524|526525|2810280|1505663;2|1239|186801|3085636|186803|2316020|33039;2|1239|526524|526525|128827|1522;2|1239|186801|186802|216572|946234;2|32066|203490|203491|203492;2|32066|203490|203491;2|32066|203490;2|32066,Complete,Shaimaa Elsafoury
bsdb:17/2/2,Study 17,"cross-sectional observational, not case-control",30029052,10.1016/j.jpsychires.2018.07.007,NA,"Jiang HY, Zhang X, Yu ZH, Zhang Z, Deng M, Zhao JH , Ruan B",Altered gut microbiota profile in patients with generalized anxiety disorder,Journal of psychiatric research,2018,NA,Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Anxiety disorder,EFO:0006788,healthy controls,treatment naiive Generalized Anxiety disorder,The active state of GAD was defined as a baseline Hamilton Anxiety Rating Scale HAMA score ≥14 upon admission to the hospital. The remissive state was defined as a HAMA score < 7 after 3 months of treatment.,17,12,2 months,16S,34,Illumina,LEfSe,0.05,TRUE,2,"age,body mass index,sex",NA,NA,decreased,decreased,NA,NA,decreased,Signature 2,Figure 2,10 January 2021,Shaimaa Elsafoury,"Fatima,WikiWorks",Comparison of relative abundance at the bacterial phylum and genus levels between healthy controls and treatment naiive generalized anxiety disorder groups,decreased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Anaerotruncus,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Barnesiellaceae|g__Barnesiella,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Butyricicoccaceae|g__Butyricicoccus,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Odoribacteraceae|g__Butyricimonas,k__Bacteria|p__Bacillota|c__Clostridia|o__Christensenellales|f__Christensenellaceae,k__Bacteria|p__Bacillota|c__Clostridia,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales|f__Coriobacteriaceae|g__Collinsella,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales|f__Coriobacteriaceae,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Eubacteriaceae|g__Eubacterium|s__Eubacterium coprostanoligenes,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Eubacteriaceae|g__Eubacterium|s__Eubacterium ruminantium,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Eubacteriaceae|g__Eubacterium|s__Eubacterium xylanophilum,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Faecalibacterium,k__Bacteria|p__Bacillota,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Fusicatenibacter,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Lachnospira,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Lachnospira|s__Lachnospira eligens,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Moryella,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Oxalobacteraceae|g__Oxalobacter,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Oxalobacteraceae,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Sutterellaceae|g__Parasutterella,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Peptococcaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Peptococcaceae|g__Peptococcus,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Roseburia,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Ruminococcus|s__Ruminococcus gauvreauii,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Subdoligranulum,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Agathobacter|s__Agathobacter rectalis",2|1239|186801|186802|216572|244127;2|976|200643|171549|2005519|397864;2|1239|186801|186802|3085642|580596;2|976|200643|171549|1853231|574697;2|1239|186801|3082768|990719;2|1239|186801;2|201174|84998|84999|84107|102106;2|201174|84998|84999|84107;2|201174|84998|84999;2|1239|186801|186802;2|1239|186801|186802|186806|1730|290054;2|1239|186801|186802|186806|1730|42322;2|1239|186801|186802|186806|1730|39497;2|1239|186801|186802|216572|216851;2|1239;2|1239|186801|3085636|186803|1407607;2|1239|186801|3085636|186803|28050;2|1239|186801|3085636|186803|28050|39485;2|1239|186801|3085636|186803;2|1239|186801|3085636|186803|437755;2|1239|186801|186802|541000;2|1224|28216|80840|75682|846;2|1224|28216|80840|75682;2|1224|28216|80840|995019|577310;2|1239|186801|186802|186807;2|1239|186801|186802|186807|2740;2|976|200643|171549|171552;2|1239|186801|3085636|186803|841;2|1239|186801|186802|216572|1263|438033;2|1239|186801|186802|216572|292632;2|1239|186801|3085636|186803|1766253|39491,Complete,Fatima
bsdb:18/1/1,Study 18,laboratory experiment,28390422,10.1186/s40168-017-0258-6,NA,"Xiao L, Sonne SB, Feng Q, Chen N, Xia Z, Li X, Fang Z, Zhang D, Fjære E, Midtbø LK, Derrien M, Hugenholtz F, Tang L, Li J, Zhang J, Liu C, Hao Q, Vogel UB, Mortensen A, Kleerebezem M, Licht TR, Yang H, Wang J, Li Y, Arumugam M, Wang J, Madsen L , Kristiansen K",High-fat feeding rather than obesity drives taxonomical and functional changes in the gut microbiota in mice,Microbiome,2017,"129S6/Sv mice, C57BL/6J mice, High-fat feeding, Indomethacin, Microbiome, Microbiota, Obesity",Experiment 1,Denmark,Mus musculus,Feces,UBERON:0001988,Obesity,EFO:0001073,BL6- Low Fat,Sv129- Low Fat,"(BL6): C57BL/6JBomTac mouse strain, (Sv129):  the obesity-resistant mouse strain 129S6/SvEvTac . LF:  (LF)low-fat diet, (HF) high fat diet without indomethacin,  (HFI) high fat diet supplemented with indomethacin.",10,7,NA,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,increased,NA,NA,NA,NA,Signature 1,"Data S4,S7,S8,S9,S10,S11,S13,S14",10 January 2021,Shaimaa Elsafoury,"Lwaldron,WikiWorks","Relative abundance at the bacterial phylum, genus and species levesl between two strain mices fed low fat diet, fed high fat diet and high fat diet + indomethacin",increased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Anaerotruncus,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Blautia,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Butyrivibrio,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Butyrivibrio|s__Butyrivibrio proteoclasticus,k__Bacteria|p__Chloroflexota,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Clostridium,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Hungatella|s__Hungatella hathewayi,k__Bacteria|p__Cyanobacteriota,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Dorea,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Enterococcaceae|g__Enterococcus|s__Enterococcus faecalis,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Eubacteriaceae|g__Eubacterium,k__Archaea|p__Euryarchaeota,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Faecalibacterium,k__Bacteria|p__Bacillota,k__Bacteria|p__Fusobacteriota,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|s__Lachnospiraceae bacterium 7_1_58FAA,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Ligilactobacillus|s__Ligilactobacillus animalis,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Marvinbryantia|s__Marvinbryantia formatexigens,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Oscillibacter,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Oscillibacter|s__Oscillibacter valericigenes,k__Bacteria|p__Planctomycetota,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Pseudoflavonifractor,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Pseudoflavonifractor|s__Pseudoflavonifractor capillosus,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Roseburia,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Roseburia|s__Roseburia intestinalis,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Roseburia|s__Roseburia inulinivorans,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Ruminococcus,k__Bacteria|p__Spirochaetota,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Subdoligranulum,k__Bacteria|p__Synergistota,k__Bacteria|p__Thermotogota,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Lachnoclostridium|s__[Clostridium] hylemonae,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Lachnoclostridium|s__[Clostridium] scindens,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Candidatus Arthromitus|s__Candidatus Arthromitus sp. SFB-mouse",2|1239|186801|186802|216572|244127;2|976|200643|171549|815|816;2|1239|186801|3085636|186803|572511;2|1239|186801|3085636|186803|830;2|1239|186801|3085636|186803|830|43305;2|200795;2|1239|186801|186802|31979|1485;2|1239|186801|186802|31979|1649459|154046;2|1117;2|1239|186801|3085636|186803|189330;2|1239|91061|186826|81852|1350|1351;2|1239|186801|186802|186806|1730;2157|28890;2|1239|186801|186802|216572|216851;2|1239;2|32066;2|1239|186801|3085636|186803|658087;2|1239|91061|186826|33958|1578;2|1239|91061|186826|33958|2767887|1605;2|1239|186801|3085636|186803|248744|168384;2|1239|186801|186802|216572|459786;2|1239|186801|186802|216572|459786|351091;2|203682;2|1239|186801|186802|216572|1017280;2|1239|186801|186802|216572|1017280|106588;2|1239|186801|3085636|186803|841;2|1239|186801|3085636|186803|841|166486;2|1239|186801|3085636|186803|841|360807;2|1239|186801|186802|216572|1263;2|203691;2|1239|186801|186802|216572|292632;2|508458;2|200918;2|1239|186801|3085636|186803|1506553|89153;2|1239|186801|3085636|186803|1506553|29347;2|1239|186801|186802|31979|49082|49118,Complete,Chloe
bsdb:18/1/2,Study 18,laboratory experiment,28390422,10.1186/s40168-017-0258-6,NA,"Xiao L, Sonne SB, Feng Q, Chen N, Xia Z, Li X, Fang Z, Zhang D, Fjære E, Midtbø LK, Derrien M, Hugenholtz F, Tang L, Li J, Zhang J, Liu C, Hao Q, Vogel UB, Mortensen A, Kleerebezem M, Licht TR, Yang H, Wang J, Li Y, Arumugam M, Wang J, Madsen L , Kristiansen K",High-fat feeding rather than obesity drives taxonomical and functional changes in the gut microbiota in mice,Microbiome,2017,"129S6/Sv mice, C57BL/6J mice, High-fat feeding, Indomethacin, Microbiome, Microbiota, Obesity",Experiment 1,Denmark,Mus musculus,Feces,UBERON:0001988,Obesity,EFO:0001073,BL6- Low Fat,Sv129- Low Fat,"(BL6): C57BL/6JBomTac mouse strain, (Sv129):  the obesity-resistant mouse strain 129S6/SvEvTac . LF:  (LF)low-fat diet, (HF) high fat diet without indomethacin,  (HFI) high fat diet supplemented with indomethacin.",10,7,NA,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,increased,NA,NA,NA,NA,Signature 2,"Data S4,S7,S8,S9,S10,S11,S13,S14",10 January 2021,Shaimaa Elsafoury,"Fatima,WikiWorks","Relative abundance at the bacterial phylum, genus and species levesl between two strain mices fed low fat diet, fed high fat diet and high fat diet + indomethacin",decreased,"k__Bacteria|p__Actinomycetota,k__Bacteria|p__Verrucomicrobiota|c__Verrucomicrobiia|o__Verrucomicrobiales|f__Akkermansiaceae|g__Akkermansia,k__Bacteria|p__Verrucomicrobiota|c__Verrucomicrobiia|o__Verrucomicrobiales|f__Akkermansiaceae|g__Akkermansia|s__Akkermansia muciniphila,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Rikenellaceae|g__Alistipes,k__Bacteria|p__Chlorobiota,k__Bacteria|p__Fibrobacterota,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Odoribacteraceae|g__Odoribacter,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Tannerellaceae|g__Parabacteroides,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Tannerellaceae|g__Tannerella,k__Bacteria|p__Verrucomicrobiota,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae|g__Holdemanella|s__Holdemanella biformis",2|201174;2|74201|203494|48461|1647988|239934;2|74201|203494|48461|1647988|239934|239935;2|976|200643|171549|171550|239759;2|1090;2|65842;2|976|200643|171549|1853231|283168;2|976|200643|171549|2005525|375288;2|976|200643|171549|171552|838;2|976|200643|171549|2005525|195950;2|74201;2|1239|526524|526525|128827|1573535|1735,Complete,Chloe
bsdb:18/2/1,Study 18,laboratory experiment,28390422,10.1186/s40168-017-0258-6,NA,"Xiao L, Sonne SB, Feng Q, Chen N, Xia Z, Li X, Fang Z, Zhang D, Fjære E, Midtbø LK, Derrien M, Hugenholtz F, Tang L, Li J, Zhang J, Liu C, Hao Q, Vogel UB, Mortensen A, Kleerebezem M, Licht TR, Yang H, Wang J, Li Y, Arumugam M, Wang J, Madsen L , Kristiansen K",High-fat feeding rather than obesity drives taxonomical and functional changes in the gut microbiota in mice,Microbiome,2017,"129S6/Sv mice, C57BL/6J mice, High-fat feeding, Indomethacin, Microbiome, Microbiota, Obesity",Experiment 2,Denmark,Mus musculus,Feces,UBERON:0001988,Obesity,EFO:0001073,BL6-High Fat without enomithacin,Sv129-High Fat without enomithacin,"(BL6): C57BL/6JBomTac mouse strain, (Sv129):  the obesity-resistant mouse strain 129S6/SvEvTac . LF:  (LF)low-fat diet, (HF) high fat diet without indomethacin,  (HFI) high fat diet supplemented with indomethacin.",10,8,NA,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,Signature 1,"Data S4,S7,S8,S9,S10,S11,S13,S14",10 January 2021,Shaimaa Elsafoury,"Fatima,WikiWorks","Relative abundance at the bacterial phylum, genus and species levesl between two strain mices fed low fat diet, fed high fat diet and high fat diet + indomethacin",increased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Clostridium,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Hungatella|s__Hungatella hathewayi,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Enterococcaceae|g__Enterococcus|s__Enterococcus faecalis,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Enterococcaceae|g__Enterococcus|s__Enterococcus faecium,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Ligilactobacillus|s__Ligilactobacillus animalis,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Marvinbryantia|s__Marvinbryantia formatexigens,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Roseburia,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Roseburia|s__Roseburia intestinalis,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Roseburia|s__Roseburia inulinivorans,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Lachnoclostridium|s__[Clostridium] scindens,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Candidatus Arthromitus|s__Candidatus Arthromitus sp. SFB-mouse",2|1239|186801|186802|31979|1485;2|1239|186801|186802|31979|1649459|154046;2|1239|91061|186826|81852|1350|1351;2|1239|91061|186826|81852|1350|1352;2|1239|91061|186826|33958|2767887|1605;2|1239|186801|3085636|186803|248744|168384;2|1239|186801|3085636|186803|841;2|1239|186801|3085636|186803|841|166486;2|1239|186801|3085636|186803|841|360807;2|1239|186801|3085636|186803|1506553|29347;2|1239|186801|186802|31979|49082|49118,Complete,Fatima
bsdb:18/2/2,Study 18,laboratory experiment,28390422,10.1186/s40168-017-0258-6,NA,"Xiao L, Sonne SB, Feng Q, Chen N, Xia Z, Li X, Fang Z, Zhang D, Fjære E, Midtbø LK, Derrien M, Hugenholtz F, Tang L, Li J, Zhang J, Liu C, Hao Q, Vogel UB, Mortensen A, Kleerebezem M, Licht TR, Yang H, Wang J, Li Y, Arumugam M, Wang J, Madsen L , Kristiansen K",High-fat feeding rather than obesity drives taxonomical and functional changes in the gut microbiota in mice,Microbiome,2017,"129S6/Sv mice, C57BL/6J mice, High-fat feeding, Indomethacin, Microbiome, Microbiota, Obesity",Experiment 2,Denmark,Mus musculus,Feces,UBERON:0001988,Obesity,EFO:0001073,BL6-High Fat without enomithacin,Sv129-High Fat without enomithacin,"(BL6): C57BL/6JBomTac mouse strain, (Sv129):  the obesity-resistant mouse strain 129S6/SvEvTac . LF:  (LF)low-fat diet, (HF) high fat diet without indomethacin,  (HFI) high fat diet supplemented with indomethacin.",10,8,NA,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,Signature 2,"Data S4,S7,S8,S9,S10,S11,S13,S14",10 January 2021,Shaimaa Elsafoury,"Fatima,WikiWorks","Relative abundance at the bacterial phylum, genus and species levesl between two strain mices fed low fat diet, fed high fat diet and high fat diet + indomethacin",decreased,"k__Bacteria|p__Verrucomicrobiota|c__Verrucomicrobiia|o__Verrucomicrobiales|f__Akkermansiaceae|g__Akkermansia,k__Bacteria|p__Verrucomicrobiota|c__Verrucomicrobiia|o__Verrucomicrobiales|f__Akkermansiaceae|g__Akkermansia|s__Akkermansia muciniphila,k__Bacteria|p__Planctomycetota,k__Bacteria|p__Verrucomicrobiota,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae|g__Holdemanella|s__Holdemanella biformis",2|74201|203494|48461|1647988|239934;2|74201|203494|48461|1647988|239934|239935;2|203682;2|74201;2|1239|526524|526525|128827|1573535|1735,Complete,Fatima
bsdb:18/3/1,Study 18,laboratory experiment,28390422,10.1186/s40168-017-0258-6,NA,"Xiao L, Sonne SB, Feng Q, Chen N, Xia Z, Li X, Fang Z, Zhang D, Fjære E, Midtbø LK, Derrien M, Hugenholtz F, Tang L, Li J, Zhang J, Liu C, Hao Q, Vogel UB, Mortensen A, Kleerebezem M, Licht TR, Yang H, Wang J, Li Y, Arumugam M, Wang J, Madsen L , Kristiansen K",High-fat feeding rather than obesity drives taxonomical and functional changes in the gut microbiota in mice,Microbiome,2017,"129S6/Sv mice, C57BL/6J mice, High-fat feeding, Indomethacin, Microbiome, Microbiota, Obesity",Experiment 3,Denmark,Mus musculus,Feces,UBERON:0001988,Obesity,EFO:0001073,BL6-High Fat with enomithacin,Sv129-High Fat with enomithacin,"(BL6): C57BL/6JBomTac mouse strain, (Sv129):  the obesity-resistant mouse strain 129S6/SvEvTac . LF:  (LF)low-fat diet, (HF) high fat diet without indomethacin,  (HFI) high fat diet supplemented with indomethacin.",10,9,NA,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,Signature 1,"Data S4,S7,S8,S9,S10,S11,S13,S14",10 January 2021,Shaimaa Elsafoury,WikiWorks,"Relative abundance at the bacterial phylum, genus and species levesl between two strain mices fed low fat diet, fed high fat diet and high fat diet + indomethacin",increased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides,k__Bacteria|p__Bacteroidota,k__Bacteria|p__Cyanobacteriota,k__Bacteria|p__Chlorobiota,k__Bacteria|p__Fibrobacterota",2|976|200643|171549|815|816;2|976;2|1117;2|1090;2|65842,Complete,Shaimaa Elsafoury
bsdb:18/3/2,Study 18,laboratory experiment,28390422,10.1186/s40168-017-0258-6,NA,"Xiao L, Sonne SB, Feng Q, Chen N, Xia Z, Li X, Fang Z, Zhang D, Fjære E, Midtbø LK, Derrien M, Hugenholtz F, Tang L, Li J, Zhang J, Liu C, Hao Q, Vogel UB, Mortensen A, Kleerebezem M, Licht TR, Yang H, Wang J, Li Y, Arumugam M, Wang J, Madsen L , Kristiansen K",High-fat feeding rather than obesity drives taxonomical and functional changes in the gut microbiota in mice,Microbiome,2017,"129S6/Sv mice, C57BL/6J mice, High-fat feeding, Indomethacin, Microbiome, Microbiota, Obesity",Experiment 3,Denmark,Mus musculus,Feces,UBERON:0001988,Obesity,EFO:0001073,BL6-High Fat with enomithacin,Sv129-High Fat with enomithacin,"(BL6): C57BL/6JBomTac mouse strain, (Sv129):  the obesity-resistant mouse strain 129S6/SvEvTac . LF:  (LF)low-fat diet, (HF) high fat diet without indomethacin,  (HFI) high fat diet supplemented with indomethacin.",10,9,NA,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,Signature 2,"Data S4,S7,S8,S9,S10,S11,S13,S14",10 January 2021,Shaimaa Elsafoury,"Fatima,Kwekuamoo,WikiWorks","Relative abundance at the bacterial phylum, genus and species levesl between two strain mices fed low fat diet, fed high fat diet and high fat diet + indomethacin",decreased,"k__Bacteria|p__Actinomycetota,k__Bacteria|p__Verrucomicrobiota|c__Verrucomicrobiia|o__Verrucomicrobiales|f__Akkermansiaceae|g__Akkermansia,k__Bacteria|p__Verrucomicrobiota|c__Verrucomicrobiia|o__Verrucomicrobiales|f__Akkermansiaceae|g__Akkermansia|s__Akkermansia muciniphila,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Anaerotruncus,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|s__[Clostridium] leptum,k__Bacteria|p__Fusobacteriota,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae|g__Holdemanella|s__Holdemanella biformis,k__Bacteria|p__Planctomycetota,k__Bacteria|p__Verrucomicrobiota,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Peptostreptococcaceae|g__Peptacetobacter|s__Peptacetobacter hiranonis",2|201174;2|74201|203494|48461|1647988|239934;2|74201|203494|48461|1647988|239934|239935;2|1239|186801|186802|216572|244127;2|1239|186801|186802|216572|1535;2|32066;2|1239|526524|526525|128827|1573535|1735;2|203682;2|74201;2|1239|186801|3082720|186804|2743582|89152,Complete,Fatima
bsdb:19/1/1,Study 19,"cross-sectional observational, not case-control",29352709,10.1016/j.schres.2018.01.002,NA,"Shen Y, Xu J, Li Z, Huang Y, Yuan Y, Wang J, Zhang M, Hu S , Liang Y",Analysis of gut microbiota diversity and auxiliary diagnosis as a biomarker in patients with schizophrenia: A cross-sectional study,Schizophrenia research,2018,"16S rRNA sequencing, Biomarker, Brain-gut axis, Gut microbiota, Schizophrenia",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Schizophrenia,MONDO:0005090,Healthy controls,Schizophrenia,The patients were examined and diagnosed according to the ICD-10 by two trained psychiatric physicians.,53,64,6 months,16S,34,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,Signature 1,"Figure 4, S3",10 January 2021,Fatima Zohra,WikiWorks,"Microbial composition at phylum, genus and species level in healthy and schizophrenia cohorts",increased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria,k__Bacteria|p__Pseudomonadota,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Aeromonadales,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Aeromonadales|f__Succinivibrionaceae|g__Succinivibrio,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Aeromonadales|f__Succinivibrionaceae,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia,k__Bacteria|p__Fusobacteriota,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae|g__Fusobacterium,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Megasphaera,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Citrobacter,k__Bacteria|p__Bacillota|c__Negativicutes|o__Acidaminococcales|f__Acidaminococcaceae|g__Phascolarctobacterium,k__Bacteria|p__Bacillota|c__Negativicutes|o__Acidaminococcales|f__Acidaminococcaceae|g__Acidaminococcus,k__Bacteria|p__Thermodesulfobacteriota|c__Desulfovibrionia|o__Desulfovibrionales|f__Desulfovibrionaceae|g__Desulfovibrio",2|976|200643|171549|171552;2|976|200643|171549|171552|838;2|1224|1236;2|1224;2|1224|1236|135624;2|1224|1236|135624|83763|83770;2|1224|1236|91347|543;2|1224|1236|91347;2|1224|1236|135624|83763;2|32066|203490;2|32066;2|32066|203490|203491|203492;2|32066|203490|203491|203492|848;2|32066|203490|203491;2|1239|909932|1843489|31977;2|1239|909932|1843489|31977|906;2|1239|91061|186826|33958|1578;2|1239|91061|186826|33958;2|1224|1236|91347|543|544;2|1239|909932|1843488|909930|33024;2|1239|909932|1843488|909930|904;2|200940|3031449|213115|194924|872,Complete,Shaimaa Elsafoury
bsdb:19/1/2,Study 19,"cross-sectional observational, not case-control",29352709,10.1016/j.schres.2018.01.002,NA,"Shen Y, Xu J, Li Z, Huang Y, Yuan Y, Wang J, Zhang M, Hu S , Liang Y",Analysis of gut microbiota diversity and auxiliary diagnosis as a biomarker in patients with schizophrenia: A cross-sectional study,Schizophrenia research,2018,"16S rRNA sequencing, Biomarker, Brain-gut axis, Gut microbiota, Schizophrenia",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Schizophrenia,MONDO:0005090,Healthy controls,Schizophrenia,The patients were examined and diagnosed according to the ICD-10 by two trained psychiatric physicians.,53,64,6 months,16S,34,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,Signature 2,"Figure 4, S3",10 January 2021,Fatima Zohra,WikiWorks,"Microbial composition at phylum, genus and species level in healthy and schizophrenia cohorts",decreased,"k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Coprococcus,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Roseburia,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Blautia,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Alcaligenaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales,k__Bacteria|p__Bacillota|c__Clostridia,k__Bacteria|p__Bacillota,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae",2|1239|91061|186826|1300;2|1239|91061|186826|1300|1301;2|1239|186801|3085636|186803|33042;2|1239|186801|3085636|186803|841;2|1239|186801|3085636|186803|572511;2|1224|28216|80840|506;2|1239|186801|186802;2|1239|186801;2|1239;2|1239|186801|3085636|186803,Complete,Shaimaa Elsafoury
bsdb:20/1/1,Study 20,case-control,26600078,10.1002/hep.28356,NA,"Boursier J, Mueller O, Barret M, Machado M, Fizanne L, Araujo-Perez F, Guy CD, Seed PC, Rawls JF, David LA, Hunault G, Oberti F, Calès P , Diehl AM",The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota,"Hepatology (Baltimore, Md.)",2016,NA,Experiment 1,France,Homo sapiens,Feces,UBERON:0001988,Non-alcoholic fatty liver disease,EFO:0003095,Non-NASH,NASH,"NAFLD was defined as liver steatosis on liver biopsy after exclusion of concomitant steatosis-inducing drugs, excessive alcohol consumption (>210 g/week in men or >140 g/week in women), chronic hepatitis B or C infection, and histological evidence of other concomitant chronic liver disease. NASH was defined as the presence of each of the three following conditions: steatosis grade 1; lobular inflammation grade 1; and ballooning grade 1. “Significant fibrosis” was defined as fibrosis stage F2.",22,35,2 months,16S,4,Illumina,Logistic Regression,0.1,FALSE,NA,NA,"HDL cholesterol change measurement,blood pressure,body mass index,diabetes mellitus,hypertriglyceridemia,metabolic syndrome",NA,NA,NA,NA,NA,NA,Signature 1,Table 2 + text,10 January 2021,Shaimaa Elsafoury,WikiWorks,Relative significant Abundance of Gut Microbiome Taxa in Patients With NASH and Without NASH,increased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides",2|976|200643|171549|815;2|976|200643|171549|815|816,Complete,Shaimaa Elsafoury
bsdb:20/1/2,Study 20,case-control,26600078,10.1002/hep.28356,NA,"Boursier J, Mueller O, Barret M, Machado M, Fizanne L, Araujo-Perez F, Guy CD, Seed PC, Rawls JF, David LA, Hunault G, Oberti F, Calès P , Diehl AM",The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota,"Hepatology (Baltimore, Md.)",2016,NA,Experiment 1,France,Homo sapiens,Feces,UBERON:0001988,Non-alcoholic fatty liver disease,EFO:0003095,Non-NASH,NASH,"NAFLD was defined as liver steatosis on liver biopsy after exclusion of concomitant steatosis-inducing drugs, excessive alcohol consumption (>210 g/week in men or >140 g/week in women), chronic hepatitis B or C infection, and histological evidence of other concomitant chronic liver disease. NASH was defined as the presence of each of the three following conditions: steatosis grade 1; lobular inflammation grade 1; and ballooning grade 1. “Significant fibrosis” was defined as fibrosis stage F2.",22,35,2 months,16S,4,Illumina,Logistic Regression,0.1,FALSE,NA,NA,"HDL cholesterol change measurement,blood pressure,body mass index,diabetes mellitus,hypertriglyceridemia,metabolic syndrome",NA,NA,NA,NA,NA,NA,Signature 2,Table 2 + text,10 January 2021,Shaimaa Elsafoury,WikiWorks,Relative significant Abundance of Gut Microbiome Taxa in Patients With NASH and Without NASH,decreased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae",2|976|200643|171549|171552|838;2|976|200643|171549|171552,Complete,Shaimaa Elsafoury
bsdb:20/2/1,Study 20,case-control,26600078,10.1002/hep.28356,NA,"Boursier J, Mueller O, Barret M, Machado M, Fizanne L, Araujo-Perez F, Guy CD, Seed PC, Rawls JF, David LA, Hunault G, Oberti F, Calès P , Diehl AM",The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota,"Hepatology (Baltimore, Md.)",2016,NA,Experiment 2,France,Homo sapiens,Feces,UBERON:0001988,Non-alcoholic fatty liver disease,EFO:0003095,mild fibrosis (F 0-1),significant fibrosis (F>2),"NAFLD was defined as liver steatosis on liver biopsy after exclusion of concomitant steatosis-inducing drugs, excessive alcohol consumption (>210 g/week in men or >140 g/week in women), chronic hepatitis B or C infection, and histological evidence of other concomitant chronic liver disease. NASH was defined as the presence of each of the three following conditions: steatosis grade 1; lobular nflammation grade 1; and ballooning grade 1. “Significant fibrosis” was defined as fibrosis stage F2.",30,27,2 months,16S,4,Illumina,Logistic Regression,0.05,FALSE,NA,NA,"HDL cholesterol change measurement,blood pressure,body mass index,diabetes mellitus,hypertriglyceridemia,metabolic syndrome",NA,NA,NA,NA,NA,NA,Signature 1,Table 3,10 January 2021,Shaimaa Elsafoury,WikiWorks,Relative significant Abundance of Gut Microbiome Taxa in Patients With Significant F 2 Fibrosis and No/Mild Fibrosis (F0/F1 Stage),increased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Ruminococcus,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides",2|1239|186801|186802|216572|1263;2|976|200643|171549|815;2|976|200643|171549|815|816,Complete,Shaimaa Elsafoury
bsdb:20/2/2,Study 20,case-control,26600078,10.1002/hep.28356,NA,"Boursier J, Mueller O, Barret M, Machado M, Fizanne L, Araujo-Perez F, Guy CD, Seed PC, Rawls JF, David LA, Hunault G, Oberti F, Calès P , Diehl AM",The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota,"Hepatology (Baltimore, Md.)",2016,NA,Experiment 2,France,Homo sapiens,Feces,UBERON:0001988,Non-alcoholic fatty liver disease,EFO:0003095,mild fibrosis (F 0-1),significant fibrosis (F>2),"NAFLD was defined as liver steatosis on liver biopsy after exclusion of concomitant steatosis-inducing drugs, excessive alcohol consumption (>210 g/week in men or >140 g/week in women), chronic hepatitis B or C infection, and histological evidence of other concomitant chronic liver disease. NASH was defined as the presence of each of the three following conditions: steatosis grade 1; lobular nflammation grade 1; and ballooning grade 1. “Significant fibrosis” was defined as fibrosis stage F2.",30,27,2 months,16S,4,Illumina,Logistic Regression,0.05,FALSE,NA,NA,"HDL cholesterol change measurement,blood pressure,body mass index,diabetes mellitus,hypertriglyceridemia,metabolic syndrome",NA,NA,NA,NA,NA,NA,Signature 2,Table 3,10 January 2021,Shaimaa Elsafoury,WikiWorks,Relative significant  Abundance of Gut Microbiome Taxa in Patients With Significant F 2 Fibrosis and No/Mild Fibrosis (F0/F1 Stage),decreased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae",2|976|200643|171549|171552;2|976|200643|171549|171552|838;2|1239|526524|526525|128827,Complete,Shaimaa Elsafoury
bsdb:21/1/1,Study 21,"cross-sectional observational, not case-control",25763184,10.1186/s40168-015-0072-y,NA,"Ross MC, Muzny DM, McCormick JB, Gibbs RA, Fisher-Hoch SP , Petrosino JF",16S gut community of the Cameron County Hispanic Cohort,Microbiome,2015,NA,Experiment 1,United States-Mexico Border,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,Human Microbiome Project samples,Cameron County Hispanic Cohort samples,NA,213,63,NA,16S,123,Roche454,Mann-Whitney (Wilcoxon),0.02,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Table 1,10 January 2021,Marianthi Thomatos,WikiWorks,Relative abundance comparision between Cameron County Hispanic Cohort (CCHC) and Human microbiome project (HMP) subject stool samples,increased,"k__Bacteria|p__Bacillota,k__Bacteria|p__Actinomycetota,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales|f__Coriobacteriaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales|f__Coriobacteriaceae|g__Collinsella,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Roseburia,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Dialister",2|1239;2|201174;2|1239|186801|3085636|186803;2|1239|909932|1843489|31977;2|201174|84998|84999|84107;2|1239|186801|186802|541000;2|976|200643|171549|171552;2|976|200643|171549|171552|838;2|201174|84998|84999|84107|102106;2|1239|186801|3085636|186803|841;2|1239|91061|186826|1300|1301;2|1239|909932|1843489|31977|39948,Complete,Shaimaa Elsafoury
bsdb:21/1/2,Study 21,"cross-sectional observational, not case-control",25763184,10.1186/s40168-015-0072-y,NA,"Ross MC, Muzny DM, McCormick JB, Gibbs RA, Fisher-Hoch SP , Petrosino JF",16S gut community of the Cameron County Hispanic Cohort,Microbiome,2015,NA,Experiment 1,United States-Mexico Border,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,Human Microbiome Project samples,Cameron County Hispanic Cohort samples,NA,213,63,NA,16S,123,Roche454,Mann-Whitney (Wilcoxon),0.02,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 2,Table 1,10 January 2021,Marianthi Thomatos,WikiWorks,Relative abundance comparision between Cameron County Hispanic Cohort (CCHC) and Human microbiome project (HMP) subject stool samples,decreased,"k__Bacteria|p__Bacteroidota,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Rikenellaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Tannerellaceae|g__Parabacteroides,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Rikenellaceae|g__Alistipes",2|976;2|976|200643|171549|815;2|976|200643|171549|171550;2|976|200643|171549|815|816;2|976|200643|171549|2005525|375288;2|976|200643|171549|171550|239759,Complete,Shaimaa Elsafoury
bsdb:22/1/1,Study 22,"cross-sectional observational, not case-control",28429209,10.1007/s10517-017-3700-7,NA,"Petrov VA, Saltykova IV, Zhukova IA, Alifirova VM, Zhukova NG, Dorofeeva YB, Tyakht AV, Kovarsky BA, Alekseev DG, Kostryukova ES, Mironova YS, Izhboldina OP, Nikitina MA, Perevozchikova TV, Fait EA, Babenko VV, Vakhitova MT, Govorun VM , Sazonov AE",Analysis of Gut Microbiota in Patients with Parkinson's Disease,Bulletin of experimental biology and medicine,2017,"16S rRNA sequencing, Parkinson’s disease, gut microbiota",Experiment 1,Russian Federation,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Healthy controls,Parkinson's,NA,66,89,NA,16S,34,Illumina,T-Test,0.05,TRUE,NA,NA,NA,NA,NA,decreased,NA,NA,NA,Signature 1,Figure 3,10 January 2021,Fatima Zohra,WikiWorks,Differences in the content of bacterial taxa in PD patients and control subjects at the genus and species level,increased,"k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus,k__Bacteria|p__Bacillota|c__Clostridia|o__Christensenellales|f__Christensenellaceae|g__Christensenella,k__Bacteria|p__Bacillota|c__Clostridia|o__Christensenellales|f__Christensenellaceae|g__Christensenella,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Oscillospira,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium,k__Bacteria|p__Bacillota|c__Clostridia|o__Christensenellales|f__Christensenellaceae|g__Christensenella|s__Christensenella minuta,k__Bacteria|p__Bacillota|c__Clostridia|o__Christensenellales|f__Christensenellaceae|g__Christensenella|s__Christensenella hongkongensis,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Limosilactobacillus|s__Limosilactobacillus mucosae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Ruminococcus|s__Ruminococcus bromii,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Papillibacter|s__Papillibacter cinnamivorans",2|1239|91061|186826|33958|1578;2|1239|186801|3082768|990719|990721;2|1239|186801|3082768|990719|270497;2|1239|186801|186802|216572|119852;2|201174|1760|85004|31953|1678;2|1239|186801|3082768|990719|990721|626937;2|1239|186801|3082768|990719|990721|270498;2|1239|91061|186826|33958|2742598|97478;2|1239|186801|186802|216572|1263|40518;2|1239|186801|186802|216572|100175|100176,Complete,Shaimaa Elsafoury
bsdb:22/1/2,Study 22,"cross-sectional observational, not case-control",28429209,10.1007/s10517-017-3700-7,NA,"Petrov VA, Saltykova IV, Zhukova IA, Alifirova VM, Zhukova NG, Dorofeeva YB, Tyakht AV, Kovarsky BA, Alekseev DG, Kostryukova ES, Mironova YS, Izhboldina OP, Nikitina MA, Perevozchikova TV, Fait EA, Babenko VV, Vakhitova MT, Govorun VM , Sazonov AE",Analysis of Gut Microbiota in Patients with Parkinson's Disease,Bulletin of experimental biology and medicine,2017,"16S rRNA sequencing, Parkinson’s disease, gut microbiota",Experiment 1,Russian Federation,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Healthy controls,Parkinson's,NA,66,89,NA,16S,34,Illumina,T-Test,0.05,TRUE,NA,NA,NA,NA,NA,decreased,NA,NA,NA,Signature 2,Figure 3,10 January 2021,Fatima Zohra,WikiWorks,Differences in the content of bacterial taxa in PD patients and control subjects at the genus and species level,decreased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Dorea,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Faecalibacterium,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Phocaeicola|s__Phocaeicola massiliensis,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Blautia|s__Blautia glucerasea,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae|g__Candidatus Stoquefichus|s__Candidatus Stoquefichus massiliensis,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Phocaeicola|s__Phocaeicola coprocola,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Ruminococcus|s__Ruminococcus callidus,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Dorea|s__Dorea longicatena,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Phocaeicola|s__Phocaeicola dorei,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Segatella|s__Segatella copri,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Phocaeicola|s__Phocaeicola plebeius,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Coprococcus|s__Coprococcus eutactus",2|1239|186801|3085636|186803|189330;2|976|200643|171549|815|816;2|976|200643|171549|171552|838;2|1239|186801|186802|216572|216851;2|976|200643|171549|815|909656|204516;2|1239|186801|3085636|186803|572511|536633;2|1239|526524|526525|128827|1470349|1470350;2|976|200643|171549|815|909656|310298;2|1239|186801|186802|216572|1263|40519;2|1239|186801|3085636|186803|189330|88431;2|976|200643|171549|815|909656|357276;2|976|200643|171549|171552|2974251|165179;2|976|200643|171549|815|909656|310297;2|1239|186801|3085636|186803|33042|33043,Complete,Shaimaa Elsafoury
bsdb:23/1/1,Study 23,case-control,29051531,10.1038/s41598-017-13601-y,NA,"Vogt NM, Kerby RL, Dill-McFarland KA, Harding SJ, Merluzzi AP, Johnson SC, Carlsson CM, Asthana S, Zetterberg H, Blennow K, Bendlin BB , Rey FE",Gut microbiome alterations in Alzheimer's disease,Scientific reports,2017,NA,Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Alzheimer's disease,MONDO:0004975,Healhty controls,Alzheimer's,NA,25,25,6 months,16S,4,Illumina,DESeq2,0.05,TRUE,NA,"age,sex",NA,NA,decreased,decreased,unchanged,unchanged,NA,Signature 1,Figure 2+figure 1,10 January 2021,Fatima Zohra,"Kwekuamoo,Merit,WikiWorks",Bacterias differentially represented in faeces from AD participants compared to controls,increased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Rikenellaceae|g__Alistipes,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Blautia,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Gemellaceae|g__Gemella,k__Bacteria|p__Bacillota|c__Negativicutes|o__Acidaminococcales|f__Acidaminococcaceae|g__Phascolarctobacterium,k__Bacteria|p__Thermodesulfobacteriota|c__Desulfovibrionia|o__Desulfovibrionales|f__Desulfovibrionaceae|g__Bilophila,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Rikenellaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales",2|976|200643|171549|171550|239759;2|976|200643|171549|815;2|976|200643|171549|815|816;2|1239|186801|3085636|186803|572511;2|1239|91061|1385|539738|1378;2|1239|909932|1843488|909930|33024;2|200940|3031449|213115|194924|35832;2|976|200643|171549|171550;2|976|200643|171549,Complete,Shaimaa Elsafoury
bsdb:23/1/2,Study 23,case-control,29051531,10.1038/s41598-017-13601-y,NA,"Vogt NM, Kerby RL, Dill-McFarland KA, Harding SJ, Merluzzi AP, Johnson SC, Carlsson CM, Asthana S, Zetterberg H, Blennow K, Bendlin BB , Rey FE",Gut microbiome alterations in Alzheimer's disease,Scientific reports,2017,NA,Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Alzheimer's disease,MONDO:0004975,Healhty controls,Alzheimer's,NA,25,25,6 months,16S,4,Illumina,DESeq2,0.05,TRUE,NA,"age,sex",NA,NA,decreased,decreased,unchanged,unchanged,NA,Signature 2,Figure 2+figure 1,10 January 2021,Fatima Zohra,"Fatima,Kwekuamoo,WikiWorks",Bacterias differentially represented in faeces from AD participants compared to controls,decreased,"k__Bacteria|p__Actinomycetota,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Eggerthellales|f__Eggerthellaceae|g__Adlercreutzia,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Clostridium,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Dialister,k__Bacteria|p__Bacillota,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Peptostreptococcaceae,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Turicibacteraceae,k__Bacteria|p__Bacillota|c__Clostridia,k__Bacteria,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Anaerovoracaceae|g__Mogibacterium",2|201174;2|201174|84998|1643822|1643826|447020;2|201174|1760|85004|31953;2|201174|1760|85004|31953|1678;2|1239|186801|186802|31979;2|1239|186801|186802|31979|1485;2|1239|909932|1843489|31977|39948;2|1239;2|1239|186801|186802|541000;2|1239|186801|3082720|186804;2|1239|526524|526525|2810281;2|1239|186801;2;2|1239|186801|3082720|3030910|86331,Complete,Fatima
bsdb:24/1/1,Study 24,case-control,30204780,10.1371/journal.pone.0203503,NA,"Wang T, Yu L, Xu C, Pan K, Mo M, Duan M, Zhang Y , Xiong H",Chronic fatigue syndrome patients have alterations in their oral microbiome composition and function,PloS one,2018,NA,Experiment 1,China,Homo sapiens,Saliva,UBERON:0001836,Chronic fatigue syndrome,EFO:0004540,Healthy controls,Chronic Fatigue patients,NA,45,46,2 months for healthy control only,16S,34,Illumina,LEfSe,0.05,FALSE,3,"age,body mass index,sex",NA,NA,unchanged,NA,unchanged,NA,NA,Signature 1,Figure 3b,10 January 2021,Shaimaa Elsafoury,"Fatima,WikiWorks",LEfSe analysis identified the most differentially abundant taxa between healthy controls and CFS patients.Only taxa with LDA > 3 are shown.,increased,"k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Bacillaceae|g__Alkalibacillus,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides,k__Bacteria|p__Campylobacterota|c__Epsilonproteobacteria|o__Campylobacterales|f__Campylobacteraceae|g__Campylobacter,k__Bacteria|p__Campylobacterota|c__Epsilonproteobacteria|o__Campylobacterales|f__Campylobacteraceae,k__Bacteria|p__Campylobacterota|c__Epsilonproteobacteria|o__Campylobacterales,k__Bacteria|p__Campylobacterota,k__Bacteria|p__Fusobacteriota,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae|g__Fusobacterium,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Gemellaceae|g__Gemella",2|1239|91061|1385|186817|331654;2|976|200643|171549|815;2|976|200643|171549|815|816;2|29547|3031852|213849|72294|194;2|29547|3031852|213849|72294;2|29547|3031852|213849;2|29547;2|32066;2|32066|203490|203491|203492;2|32066|203490|203491;2|32066|203490;2|32066|203490|203491|203492|848;2|1239|91061|1385|539738|1378,Complete,Fatima
bsdb:24/1/2,Study 24,case-control,30204780,10.1371/journal.pone.0203503,NA,"Wang T, Yu L, Xu C, Pan K, Mo M, Duan M, Zhang Y , Xiong H",Chronic fatigue syndrome patients have alterations in their oral microbiome composition and function,PloS one,2018,NA,Experiment 1,China,Homo sapiens,Saliva,UBERON:0001836,Chronic fatigue syndrome,EFO:0004540,Healthy controls,Chronic Fatigue patients,NA,45,46,2 months for healthy control only,16S,34,Illumina,LEfSe,0.05,FALSE,3,"age,body mass index,sex",NA,NA,unchanged,NA,unchanged,NA,NA,Signature 2,Figure 3b,10 January 2021,Shaimaa Elsafoury,WikiWorks,LEfSe analysis identified the most differentially abundant taxa between healthy controls and CFS patients.Only taxa with LDA > 3 are shown.,decreased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae,k__Bacteria|p__Bacillota|c__Negativicutes,k__Bacteria|p__Bacillota|c__Negativicutes|o__Selenomonadales,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Veillonella,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Haemophilus,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae|g__Porphyromonas,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Moraxellales|f__Moraxellaceae|g__Moraxella,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pseudomonadales|f__Pseudomonadaceae|s__Azotobacter group,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pseudomonadales|f__Pseudomonadaceae|g__Pseudomonas",2|1224|1236;2|1239|909932|1843489|31977;2|1239|909932;2|1239|909932|909929;2|1239|909932|1843489|31977|29465;2|1224|1236|135625|712|724;2|1224|1236|135625|712;2|1224|1236|135625;2|976|200643|171549|171551;2|976|200643|171549|171551|836;2|1224|1236|2887326|468|475;2|1224|1236|72274|135621|351;2|1224|1236|72274|135621|286,Complete,Shaimaa Elsafoury
bsdb:25/1/1,Study 25,prospective cohort,23153041,10.1186/gb-2012-13-11-r101,NA,"Zeeuwen PL, Boekhorst J, van den Bogaard EH, de Koning HD, van de Kerkhof PM, Saulnier DM, van Swam II, van Hijum SA, Kleerebezem M, Schalkwijk J , Timmerman HM",Microbiome dynamics of human epidermis following skin barrier disruption,Genome biology,2012,NA,Experiment 1,United States of America,Homo sapiens,Skin of body,UBERON:0002097,Psoriasis,EFO:0000676,Female,Psoriasis Male,"tape stripping method involves the repeated application of adhesive tape to the skin surface, thereby removing stratum corneum layers, it creates a superficial wound showing slight skin irritation (erythema) and loss of barrier function (transepidermal water loss)",6,6,NA,16S,34,Roche454,Mann-Whitney (Wilcoxon),0.1,FALSE,NA,NA,NA,NA,increased,increased,NA,NA,NA,Signature 1,Figure 4,10 January 2021,WikiWorks,WikiWorks,Difference in microbial community composition of upper buttok skin between males and females,increased,"k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Aerococcaceae,k__Bacteria|p__Bacillota|c__Clostridia,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae,k__Bacteria|p__Bacillota|c__Tissierellia|o__Tissierellales|f__Peptoniphilaceae|g__Finegoldia,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Peptostreptococcaceae,k__Bacteria|p__Bacillota|c__Tissierellia|o__Tissierellales|f__Peptoniphilaceae|g__Anaerococcus,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Veillonella,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Tepidibacteraceae|g__Sporacetigenium,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Mycobacteriales|f__Corynebacteriaceae,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Mycobacteriales|f__Corynebacteriaceae|g__Corynebacterium,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micrococcales|f__Dermabacteraceae,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micrococcales|f__Dermabacteraceae|g__Brachybacterium,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micrococcales|f__Micrococcaceae|g__Rothia,k__Bacteria|p__Actinomycetota,k__Bacteria|p__Actinomycetota|c__Actinomycetes,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micrococcales|f__Microbacteriaceae,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micrococcales|f__Microbacteriaceae|g__Microbacterium,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micrococcales|f__Dermacoccaceae|g__Dermacoccus,k__Bacteria|p__Bacteroidota|c__Flavobacteriia,k__Bacteria|p__Bacteroidota|c__Flavobacteriia|o__Flavobacteriales,k__Bacteria|p__Bacteroidota|c__Flavobacteriia|o__Flavobacteriales|f__Flavobacteriaceae,k__Bacteria|p__Bacteroidota|c__Flavobacteriia|o__Flavobacteriales|f__Flavobacteriaceae|g__Capnocytophaga,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Moraxellales|f__Moraxellaceae|g__Acinetobacter,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micrococcales|f__Dermabacteraceae|g__Dermabacter,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Aerococcaceae|g__Eremococcus",2|1239|91061|186826|1300;2|1239|91061|186826|1300|1301;2|1239|91061|186826|186827;2|1239|186801;2|1239|186801|186802;2|1239|186801|186802|31979;2|1239|1737404|1737405|1570339|150022;2|1239|186801|3082720|186804;2|1239|1737404|1737405|1570339|165779;2|1239|909932|1843489|31977;2|1239|909932|1843489|31977|29465;2|1239|186801|3082720|3120162|360541;2|201174|1760|85007|1653;2|201174|1760|85007|1653|1716;2|201174|1760|2037;2|201174|1760|85006|85020;2|201174|1760|85006|85020|43668;2|201174|1760|85006|1268|32207;2|201174;2|201174|1760;2|201174|1760|85006|85023;2|201174|1760|85006|85023|33882;2|201174|1760|85006|145357|57495;2|976|117743;2|976|117743|200644;2|976|117743|200644|49546;2|976|117743|200644|49546|1016;2|1224|1236|2887326|468|469;2|201174|1760|85006|85020|36739;2|1239|91061|186826|186827|171412,Complete,Shaimaa Elsafoury
bsdb:25/1/2,Study 25,prospective cohort,23153041,10.1186/gb-2012-13-11-r101,NA,"Zeeuwen PL, Boekhorst J, van den Bogaard EH, de Koning HD, van de Kerkhof PM, Saulnier DM, van Swam II, van Hijum SA, Kleerebezem M, Schalkwijk J , Timmerman HM",Microbiome dynamics of human epidermis following skin barrier disruption,Genome biology,2012,NA,Experiment 1,United States of America,Homo sapiens,Skin of body,UBERON:0002097,Psoriasis,EFO:0000676,Female,Psoriasis Male,"tape stripping method involves the repeated application of adhesive tape to the skin surface, thereby removing stratum corneum layers, it creates a superficial wound showing slight skin irritation (erythema) and loss of barrier function (transepidermal water loss)",6,6,NA,16S,34,Roche454,Mann-Whitney (Wilcoxon),0.1,FALSE,NA,NA,NA,NA,increased,increased,NA,NA,NA,Signature 2,Figure 4,10 January 2021,WikiWorks,WikiWorks,Difference in microbial community composition of upper buttok skin between males and females,decreased,"k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Propionibacteriales|f__Propionibacteriaceae,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Propionibacteriales|f__Propionibacteriaceae|g__Propionibacterium,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Gardnerella,k__Bacteria|p__Pseudomonadota,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pseudomonadales,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Moraxellales|f__Moraxellaceae,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Hyphomicrobiales|g__Enhydrobacter,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micrococcales|f__Brevibacteriaceae,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micrococcales|f__Brevibacteriaceae|g__Brevibacterium",2|1239|91061|186826|33958;2|1239|91061|186826|33958|1578;2|201174|1760|85009|31957;2|201174|1760|85009|31957|1743;2|201174|1760|85004;2|201174|1760|85004|31953;2|201174|1760|85004|31953|2701;2|1224;2|1224|1236;2|1224|1236|72274;2|1224|1236|2887326|468;2|1224|28211|356|212791;2|201174|1760|85006|85019;2|201174|1760|85006|85019|1696,Complete,Shaimaa Elsafoury
bsdb:26/1/1,Study 26,"cross-sectional observational, not case-control",27228093,10.1371/journal.pone.0154090,NA,"Haro C, Rangel-Zúñiga OA, Alcalá-Díaz JF, Gómez-Delgado F, Pérez-Martínez P, Delgado-Lista J, Quintana-Navarro GM, Landa BB, Navas-Cortés JA, Tena-Sempere M, Clemente JC, López-Miranda J, Pérez-Jiménez F , Camargo A",Intestinal Microbiota Is Influenced by Gender and Body Mass Index,PloS one,2016,NA,Experiment 1,Spain,Homo sapiens,Feces,UBERON:0001988,Sex design,EFO:0001752,male,female,three groups according to the BMI: BMI < 30; BMI between 30- 33; and BMI > 33.,39,36,NA,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,age,NA,NA,NA,NA,NA,NA,NA,Signature 1,Text + Table 2,10 January 2021,Marianthi Thomatos,WikiWorks,Intestinal Microbiota Is Influenced by Gender and Body Mass Index,increased,"k__Bacteria|p__Thermodesulfobacteriota|c__Desulfovibrionia|o__Desulfovibrionales|f__Desulfovibrionaceae|g__Bilophila,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides|s__Bacteroides caccae",2|200940|3031449|213115|194924|35832;2|976|200643|171549|815|816|47678,Complete,Shaimaa Elsafoury
bsdb:26/1/2,Study 26,"cross-sectional observational, not case-control",27228093,10.1371/journal.pone.0154090,NA,"Haro C, Rangel-Zúñiga OA, Alcalá-Díaz JF, Gómez-Delgado F, Pérez-Martínez P, Delgado-Lista J, Quintana-Navarro GM, Landa BB, Navas-Cortés JA, Tena-Sempere M, Clemente JC, López-Miranda J, Pérez-Jiménez F , Camargo A",Intestinal Microbiota Is Influenced by Gender and Body Mass Index,PloS one,2016,NA,Experiment 1,Spain,Homo sapiens,Feces,UBERON:0001988,Sex design,EFO:0001752,male,female,three groups according to the BMI: BMI < 30; BMI between 30- 33; and BMI > 33.,39,36,NA,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,age,NA,NA,NA,NA,NA,NA,NA,Signature 2,Text + Table 2,10 January 2021,Marianthi Thomatos,WikiWorks,Intestinal Microbiota Is Influenced by Gender and Body Mass Index,decreased,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Phocaeicola|s__Phocaeicola plebeius,2|976|200643|171549|815|909656|310297,Complete,Shaimaa Elsafoury
bsdb:26/2/1,Study 26,"cross-sectional observational, not case-control",27228093,10.1371/journal.pone.0154090,NA,"Haro C, Rangel-Zúñiga OA, Alcalá-Díaz JF, Gómez-Delgado F, Pérez-Martínez P, Delgado-Lista J, Quintana-Navarro GM, Landa BB, Navas-Cortés JA, Tena-Sempere M, Clemente JC, López-Miranda J, Pérez-Jiménez F , Camargo A",Intestinal Microbiota Is Influenced by Gender and Body Mass Index,PloS one,2016,NA,Experiment 2,Spain,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,male,BMI >33 female,three groups according to the BMI: BMI < 30; BMI between 30- 33; and BMI > 33.,13,13,NA,16S,4,Illumina,Kruskall-Wallis,0.05,TRUE,NA,age,NA,NA,NA,NA,NA,NA,NA,Signature 1,Text + Figure 2 +Table 2,10 January 2021,Marianthi Thomatos,WikiWorks,Intestinal Microbiota Is Influenced by Gender and Body Mass Index,increased,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides,2|976|200643|171549|815|816,Complete,Shaimaa Elsafoury
bsdb:26/2/2,Study 26,"cross-sectional observational, not case-control",27228093,10.1371/journal.pone.0154090,NA,"Haro C, Rangel-Zúñiga OA, Alcalá-Díaz JF, Gómez-Delgado F, Pérez-Martínez P, Delgado-Lista J, Quintana-Navarro GM, Landa BB, Navas-Cortés JA, Tena-Sempere M, Clemente JC, López-Miranda J, Pérez-Jiménez F , Camargo A",Intestinal Microbiota Is Influenced by Gender and Body Mass Index,PloS one,2016,NA,Experiment 2,Spain,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,male,BMI >33 female,three groups according to the BMI: BMI < 30; BMI between 30- 33; and BMI > 33.,13,13,NA,16S,4,Illumina,Kruskall-Wallis,0.05,TRUE,NA,age,NA,NA,NA,NA,NA,NA,NA,Signature 2,Text + Figure2 + Table 2,10 January 2021,Marianthi Thomatos,WikiWorks,Intestinal Microbiota Is Influenced by Gender and Body Mass Index,decreased,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Phocaeicola|s__Phocaeicola plebeius,2|976|200643|171549|815|909656|310297,Complete,Shaimaa Elsafoury
bsdb:27/1/1,Study 27,laboratory experiment,29793531,10.1186/s40168-018-0476-6,NA,"Robertson RC, Kaliannan K, Strain CR, Ross RP, Stanton C , Kang JX",Maternal omega-3 fatty acids regulate offspring obesity through persistent modulation of gut microbiota,Microbiome,2018,"Maternal diet, Microbiome, Microbiota, Obesity, n-3 PUFA",Experiment 1,United States of America,Mus musculus,Feces,UBERON:0001988,Obesity,EFO:0001073,foster mother fat1 pre HFD,foster mother wild-type pre HFD,fat-1 mice: with a balanced tissue n-6/n-3 ratio (~ 1:1) and wild-type (WT) mice: with a high n-6/ n-3 ratio similar to the Western diet (> 10:1).,15,9,NA,16S,34,Illumina,LEfSe,0.05,TRUE,2.4,age,NA,NA,NA,NA,NA,NA,NA,Signature 1,"Text, Figure S4",10 January 2021,Marianthi Thomatos,WikiWorks,"Pre-High fat diet (HFD) and Post-HF diet differential abundance in offspring according to foster mother genotype at lactation, wild type (WT) or fat-1 (balanced tissue n-6/n-3)",increased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Clostridium,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Turicibacteraceae|g__Turicibacter,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Peptococcaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Peptococcaceae|g__Peptococcus,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Flavonifractor,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales,k__Bacteria|p__Bacillota|c__Erysipelotrichia,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Odoribacteraceae|g__Butyricimonas,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Butyricicoccaceae|g__Butyricicoccus,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Tannerellaceae|g__Parabacteroides,k__Bacteria|p__Bacillota,k__Bacteria|p__Bacillota|c__Clostridia,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales",2|1239|186801|186802|31979|1485;2|1239|186801|186802|31979;2|1239|526524|526525|2810281|191303;2|1239|526524|526525|128827;2|1239|186801|186802|186807;2|1239|186801|186802|186807|2740;2|1239|186801|186802|216572|946234;2|1239|526524|526525;2|1239|526524;2|976|200643|171549|1853231|574697;2|1239|186801|186802|541000;2|1239|186801|186802|3085642|580596;2|976|200643|171549|2005525|375288;2|1239;2|1239|186801;2|1239|186801|186802,Complete,Shaimaa Elsafoury
bsdb:27/1/2,Study 27,laboratory experiment,29793531,10.1186/s40168-018-0476-6,NA,"Robertson RC, Kaliannan K, Strain CR, Ross RP, Stanton C , Kang JX",Maternal omega-3 fatty acids regulate offspring obesity through persistent modulation of gut microbiota,Microbiome,2018,"Maternal diet, Microbiome, Microbiota, Obesity, n-3 PUFA",Experiment 1,United States of America,Mus musculus,Feces,UBERON:0001988,Obesity,EFO:0001073,foster mother fat1 pre HFD,foster mother wild-type pre HFD,fat-1 mice: with a balanced tissue n-6/n-3 ratio (~ 1:1) and wild-type (WT) mice: with a high n-6/ n-3 ratio similar to the Western diet (> 10:1).,15,9,NA,16S,34,Illumina,LEfSe,0.05,TRUE,2.4,age,NA,NA,NA,NA,NA,NA,NA,Signature 2,"Text, Figure S4",10 January 2021,Marianthi Thomatos,WikiWorks,"Pre-High fat diet (HFD) and Post-HF diet differential abundance in offspring according to foster mother genotype at lactation, wild type (WT) or fat-1 (balanced tissue n-6/n-3)",decreased,"k__Bacteria|p__Bacteroidota,k__Bacteria|p__Bacteroidota|c__Bacteroidia,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales,k__Bacteria|p__Campylobacterota|c__Epsilonproteobacteria|o__Campylobacterales,k__Bacteria|p__Campylobacterota,k__Bacteria|p__Pseudomonadota,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides,k__Bacteria|c__Deltaproteobacteria,k__Bacteria|p__Thermodesulfobacteriota|c__Desulfovibrionia|o__Desulfovibrionales,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Rikenellaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Rikenellaceae|g__Alistipes,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Barnesiellaceae|g__Barnesiella,k__Bacteria|p__Campylobacterota|c__Epsilonproteobacteria|o__Campylobacterales|f__Helicobacteraceae,k__Bacteria|p__Campylobacterota|c__Epsilonproteobacteria|o__Campylobacterales|f__Helicobacteraceae|g__Helicobacter,k__Bacteria|p__Thermodesulfobacteriota|c__Desulfovibrionia|o__Desulfovibrionales|f__Desulfovibrionaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Odoribacteraceae|g__Odoribacter,k__Bacteria|p__Thermodesulfobacteriota|c__Desulfovibrionia|o__Desulfovibrionales|f__Desulfovibrionaceae|g__Desulfovibrio,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae|g__Allobaculum,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Rikenellaceae|g__Rikenella,k__Bacteria|p__Candidatus Saccharibacteria|c__Candidatus Saccharimonadia|o__Candidatus Saccharimonadales|f__Candidatus Saccharimonadaceae|g__Candidatus Saccharimonas",2|976;2|976|200643;2|976|200643|171549;2|29547|3031852|213849;2|29547;2|1224;2|976|200643|171549|815;2|976|200643|171549|815|816;2|28221;2|200940|3031449|213115;2|976|200643|171549|171550;2|976|200643|171549|171550|239759;2|976|200643|171549|2005519|397864;2|29547|3031852|213849|72293;2|29547|3031852|213849|72293|209;2|200940|3031449|213115|194924;2|976|200643|171549|1853231|283168;2|200940|3031449|213115|194924|872;2|1239|526524|526525|128827|174708;2|976|200643|171549|171550|28138;2|95818|2093818|2093825|2171986|1331051,Complete,Shaimaa Elsafoury
bsdb:27/2/1,Study 27,laboratory experiment,29793531,10.1186/s40168-018-0476-6,NA,"Robertson RC, Kaliannan K, Strain CR, Ross RP, Stanton C , Kang JX",Maternal omega-3 fatty acids regulate offspring obesity through persistent modulation of gut microbiota,Microbiome,2018,"Maternal diet, Microbiome, Microbiota, Obesity, n-3 PUFA",Experiment 2,United States of America,Mus musculus,Feces,UBERON:0001988,Obesity,EFO:0001073,foster mother fat1 post HFD,foster mother wild-type post HFD,fat-1 mice: with a balanced tissue n-6/n-3 ratio (~ 1:1) and wild-type (WT) mice: with a high n-6/ n-3 ratio similar to the Western diet (> 10:1).,15,9,NA,16S,34,Illumina,LEfSe,0.05,TRUE,2.4,age,NA,NA,NA,NA,NA,NA,NA,Signature 1,"Text, Figure S4",10 January 2021,Marianthi Thomatos,WikiWorks,"Pre-High fat diet (HFD) and Post-HF diet differential abundance in offspring according to foster mother genotype at lactation, wild type (WT) or fat-1 (balanced tissue n-6/n-3)",increased,"f__Victivallaceae|g__Victivallis,k__Bacteria|p__Lentisphaerota|c__Lentisphaeria|o__Lentisphaerales|f__Lentisphaeraceae|g__Lentisphaera,f__Victivallaceae,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Clostridium,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales,k__Bacteria|p__Bacillota|c__Erysipelotrichia,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Rikenellaceae|g__Rikenella,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Anaerotruncus,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Oscillibacter,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Flavonifractor,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Peptococcaceae|g__Peptococcus,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Peptococcaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales,k__Bacteria|p__Bacillota|c__Bacilli,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Odoribacteraceae|g__Butyricimonas,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Tannerellaceae|g__Parabacteroides,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae,k__Bacteria|p__Bacillota,k__Bacteria|p__Bacillota|c__Clostridia,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales,k__Bacteria|p__Lentisphaerota|c__Lentisphaeria",255528|172900;2|256845|1313211|278081|566277|256846;255528;2|1239|526524|526525|128827;2|1239|526524|526525|128827;2|1239|186801|186802|31979|1485;2|1239|526524|526525;2|1239|526524;2|976|200643|171549|171550|28138;2|1239|186801|186802|216572|244127;2|1239|186801|186802|216572|459786;2|1239|186801|186802|216572|946234;2|1239|91061|186826|33958;2|1239|91061|186826|33958|1578;2|1239|186801|186802|186807|2740;2|1239|186801|186802|186807;2|1239|91061|186826;2|1239|91061;2|976|200643|171549|1853231|574697;2|1239|186801|186802|541000;2|1239|186801|3085636|186803;2|976|200643|171549|2005525|375288;2|976|200643|171549|171551;2|1239;2|1239|186801;2|1239|186801|186802;2|256845|1313211,Complete,Shaimaa Elsafoury
bsdb:27/2/2,Study 27,laboratory experiment,29793531,10.1186/s40168-018-0476-6,NA,"Robertson RC, Kaliannan K, Strain CR, Ross RP, Stanton C , Kang JX",Maternal omega-3 fatty acids regulate offspring obesity through persistent modulation of gut microbiota,Microbiome,2018,"Maternal diet, Microbiome, Microbiota, Obesity, n-3 PUFA",Experiment 2,United States of America,Mus musculus,Feces,UBERON:0001988,Obesity,EFO:0001073,foster mother fat1 post HFD,foster mother wild-type post HFD,fat-1 mice: with a balanced tissue n-6/n-3 ratio (~ 1:1) and wild-type (WT) mice: with a high n-6/ n-3 ratio similar to the Western diet (> 10:1).,15,9,NA,16S,34,Illumina,LEfSe,0.05,TRUE,2.4,age,NA,NA,NA,NA,NA,NA,NA,Signature 2,"Text, Figure S4",10 January 2021,Marianthi Thomatos,WikiWorks,"Pre-High fat diet (HFD) and Post-HF diet differential abundance in offspring according to foster mother genotype at lactation, wild type (WT) or fat-1 (balanced tissue n-6/n-3)",decreased,"k__Bacteria|p__Campylobacterota,k__Bacteria|p__Campylobacterota|c__Epsilonproteobacteria|o__Campylobacterales,k__Bacteria|p__Pseudomonadota,k__Bacteria|c__Deltaproteobacteria,k__Bacteria|p__Thermodesulfobacteriota|c__Desulfovibrionia|o__Desulfovibrionales,k__Bacteria|p__Campylobacterota|c__Epsilonproteobacteria|o__Campylobacterales|f__Helicobacteraceae,k__Bacteria|p__Campylobacterota|c__Epsilonproteobacteria|o__Campylobacterales|f__Helicobacteraceae|g__Helicobacter,k__Bacteria|p__Thermodesulfobacteriota|c__Desulfovibrionia|o__Desulfovibrionales|f__Desulfovibrionaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Odoribacteraceae|g__Odoribacter,k__Bacteria|p__Candidatus Saccharibacteria|c__Candidatus Saccharimonadia|o__Candidatus Saccharimonadales|f__Candidatus Saccharimonadaceae|g__Candidatus Saccharimonas",2|29547;2|29547|3031852|213849;2|1224;2|28221;2|200940|3031449|213115;2|29547|3031852|213849|72293;2|29547|3031852|213849|72293|209;2|200940|3031449|213115|194924;2|976|200643|171549|815;2|976|200643|171549|815|816;2|976|200643|171549|1853231|283168;2|95818|2093818|2093825|2171986|1331051,Complete,Shaimaa Elsafoury
bsdb:28/1/1,Study 28,case-control,27338587,10.1186/s40168-016-0171-4,NA,"Giloteaux L, Goodrich JK, Walters WA, Levine SM, Ley RE , Hanson MR",Reduced diversity and altered composition of the gut microbiome in individuals with myalgic encephalomyelitis/chronic fatigue syndrome,Microbiome,2016,"Beta-diversity, Chronic fatigue syndrome, Inflammation, Lipopolysaccharides, Microbial translocation, Microbiome, Myalgic encephalomyelitis",Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Chronic fatigue syndrome,EFO:0004540,Healthy controls,CFS cases,"Subjects with ME/CFS were established patients of a ME/ CFS specialist, Susan Levine, M.D. and fit the Fukuda diag- nostic criteria",39,48,NA,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,decreased,decreased,NA,NA,NA,Signature 1,figure 5,10 January 2021,Shaimaa Elsafoury,WikiWorks,taxonomy of differentially abundant microbiota between  ME/CFS and healthy individuals,increased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Oscillospira,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Eggerthellales|f__Eggerthellaceae|g__Eggerthella,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Lactococcus,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Anaerotruncus,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Coprobacillaceae|g__Coprobacillus",2|1239|186801|186802|216572|119852;2|201174|84998|1643822|1643826|84111;2|1239|91061|186826|1300|1357;2|1239|186801|186802|216572|244127;2|1239|526524|526525|2810280|100883,Complete,Shaimaa Elsafoury
bsdb:28/1/2,Study 28,case-control,27338587,10.1186/s40168-016-0171-4,NA,"Giloteaux L, Goodrich JK, Walters WA, Levine SM, Ley RE , Hanson MR",Reduced diversity and altered composition of the gut microbiome in individuals with myalgic encephalomyelitis/chronic fatigue syndrome,Microbiome,2016,"Beta-diversity, Chronic fatigue syndrome, Inflammation, Lipopolysaccharides, Microbial translocation, Microbiome, Myalgic encephalomyelitis",Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Chronic fatigue syndrome,EFO:0004540,Healthy controls,CFS cases,"Subjects with ME/CFS were established patients of a ME/ CFS specialist, Susan Levine, M.D. and fit the Fukuda diag- nostic criteria",39,48,NA,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,decreased,decreased,NA,NA,NA,Signature 2,figure 5,10 January 2021,Shaimaa Elsafoury,WikiWorks,taxonomy of differentially abundant microbiota between  ME/CFS and healthy individuals,decreased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Peptococcaceae|g__Peptococcus,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Haemophilus,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales|f__Atopobiaceae|g__Atopobium,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Clostridium,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Faecalibacterium,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Ruminococcus,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Aggregatibacter,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales|f__Coriobacteriaceae|g__Collinsella,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Sutterellaceae|g__Sutterella",2|1239|186801|186802|186807|2740;2|1224|1236|135625|712|724;2|201174|84998|84999|1643824|1380;2|1239|186801|186802|31979|1485;2|1239|186801|186802|216572|216851;2|1239|186801|186802|216572|1263;2|1224|1236|135625|712|416916;2|201174|1760|85004|31953|1678;2|201174|84998|84999|84107|102106;2|1224|28216|80840|995019|40544,Complete,Shaimaa Elsafoury
bsdb:29/1/1,Study 29,case-control,25882912,10.1016/j.bbi.2015.03.016,NA,"Jiang H, Ling Z, Zhang Y, Mao H, Ma Z, Yin Y, Wang W, Tang W, Tan Z, Shi J, Li L , Ruan B",Altered fecal microbiota composition in patients with major depressive disorder,"Brain, behavior, and immunity",2015,"Antidepressant, Depression, Gut bacteria, Gut–brain, Inflammation",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Unipolar depression,EFO:0003761,Healthy Controls,Active Major Depressive Disorder,The A-MDD group was defined as having an HAMDS score P20. The patients in the R-MDD group were defined as those with a baseline HAMDS scores P20 upon admission to the hospi- tal.,30,29,1 month,16S,123,Roche454,LEfSe,0.05,FALSE,2,NA,NA,NA,increased,NA,unchanged,NA,unchanged,Signature 1,Figure 2,10 January 2021,Fatima Zohra,WikiWorks,Taxonomic differences of fecal microbiota between Healthy Controls and Active Major Depressive Disorder groups,increased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Flavonifractor,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Odoribacteraceae|g__Butyricimonas,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Tannerellaceae|g__Parabacteroides,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Rikenellaceae|g__Alistipes,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Rikenellaceae",2|1239|186801|186802|216572|946234;2|976|200643|171549|1853231|574697;2|1224|1236|91347;2|1224|1236|91347|543;2|976|200643|171549|2005525|375288;2|976|200643|171549|171551;2|976|200643|171549|171550|239759;2|976|200643|171549|171550,Complete,Shaimaa Elsafoury
bsdb:29/1/2,Study 29,case-control,25882912,10.1016/j.bbi.2015.03.016,NA,"Jiang H, Ling Z, Zhang Y, Mao H, Ma Z, Yin Y, Wang W, Tang W, Tan Z, Shi J, Li L , Ruan B",Altered fecal microbiota composition in patients with major depressive disorder,"Brain, behavior, and immunity",2015,"Antidepressant, Depression, Gut bacteria, Gut–brain, Inflammation",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Unipolar depression,EFO:0003761,Healthy Controls,Active Major Depressive Disorder,The A-MDD group was defined as having an HAMDS score P20. The patients in the R-MDD group were defined as those with a baseline HAMDS scores P20 upon admission to the hospi- tal.,30,29,1 month,16S,123,Roche454,LEfSe,0.05,FALSE,2,NA,NA,NA,increased,NA,unchanged,NA,unchanged,Signature 2,Figure 2,10 January 2021,Fatima Zohra,WikiWorks,Taxonomic differences of fecal microbiota between Healthy Controls and Active Major Depressive Disorder groups,decreased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Faecalibacterium,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Dialister,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Ruminococcus,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Haemophilus,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Peptostreptococcaceae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Escherichia,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Shigella",2|1239|186801|186802|541000;2|1239|186801|186802|216572|216851;2|1239|909932|1843489|31977|39948;2|1224|1236|135625|712;2|1224|1236|135625;2|1239|186801|186802|216572|1263;2|1224|1236|135625|712|724;2|1239|186801|3082720|186804;2|1224|1236|91347|543|561;2|1224|1236|91347|543|620,Complete,Shaimaa Elsafoury
bsdb:29/2/1,Study 29,case-control,25882912,10.1016/j.bbi.2015.03.016,NA,"Jiang H, Ling Z, Zhang Y, Mao H, Ma Z, Yin Y, Wang W, Tang W, Tan Z, Shi J, Li L , Ruan B",Altered fecal microbiota composition in patients with major depressive disorder,"Brain, behavior, and immunity",2015,"Antidepressant, Depression, Gut bacteria, Gut–brain, Inflammation",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Unipolar depression,EFO:0003761,Healthy Controls,Responded Major Depressive Disorder,The A-MDD group was defined as having an HAMDS score P20. The patients in the R-MDD group were defined as those with a baseline HAMDS scores P20 upon admission to the hospi- tal.,30,17,1 month,16S,123,Roche454,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,NA,unchanged,NA,unchanged,Signature 1,Figure 3,10 January 2021,Fatima Zohra,WikiWorks,Taxonomic differences of fecal microbiota between Healthy Controls and Responded Major Depressive Disorder groups,increased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Odoribacteraceae|g__Butyricimonas,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae",2|976|200643|171549|1853231|574697;2|976|200643|171549|171551,Complete,Shaimaa Elsafoury
bsdb:29/2/2,Study 29,case-control,25882912,10.1016/j.bbi.2015.03.016,NA,"Jiang H, Ling Z, Zhang Y, Mao H, Ma Z, Yin Y, Wang W, Tang W, Tan Z, Shi J, Li L , Ruan B",Altered fecal microbiota composition in patients with major depressive disorder,"Brain, behavior, and immunity",2015,"Antidepressant, Depression, Gut bacteria, Gut–brain, Inflammation",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Unipolar depression,EFO:0003761,Healthy Controls,Responded Major Depressive Disorder,The A-MDD group was defined as having an HAMDS score P20. The patients in the R-MDD group were defined as those with a baseline HAMDS scores P20 upon admission to the hospi- tal.,30,17,1 month,16S,123,Roche454,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,NA,unchanged,NA,unchanged,Signature 2,Figure 3,10 January 2021,Fatima Zohra,WikiWorks,Taxonomic differences of fecal microbiota between Healthy Controls and Responded Major Depressive Disorder groups,decreased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Ruminococcus,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Haemophilus,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Clostridium,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae",2|1239|186801|186802|216572|1263;2|1224|1236|135625|712;2|1224|1236|135625;2|1224|1236|135625|712|724;2|1239|186801|186802|31979|1485;2|1239|186801|186802|31979,Complete,Shaimaa Elsafoury
bsdb:30/1/1,Study 30,case-control,23791918,10.1016/j.anaerobe.2013.06.002,NA,"Frémont M, Coomans D, Massart S , De Meirleir K",High-throughput 16S rRNA gene sequencing reveals alterations of intestinal microbiota in myalgic encephalomyelitis/chronic fatigue syndrome patients,Anaerobe,2013,"Chronic fatigue syndrome, High-throughput sequencing, Intestinal microbiota, Myalgic encephalomyelitis",Experiment 1,Belgium,Homo sapiens,Feces,UBERON:0001988,Chronic fatigue syndrome,EFO:0004540,Belgian controls,Norweigan controls,Patients were diagnosed for CFS according to the clinical criteria of Fukuda et al,19,17,4 weeks,16S,56,Roche454,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,Signature 1,table 1,10 January 2021,Shaimaa Elsafoury,WikiWorks,Differentiately abundant mictobiota between Norwegian controls and Belgian controls.,increased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Roseburia,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae|g__Holdemania",2|1239|186801|3085636|186803|841;2|1239|526524|526525|128827|61170,Complete,Shaimaa Elsafoury
bsdb:30/1/2,Study 30,case-control,23791918,10.1016/j.anaerobe.2013.06.002,NA,"Frémont M, Coomans D, Massart S , De Meirleir K",High-throughput 16S rRNA gene sequencing reveals alterations of intestinal microbiota in myalgic encephalomyelitis/chronic fatigue syndrome patients,Anaerobe,2013,"Chronic fatigue syndrome, High-throughput sequencing, Intestinal microbiota, Myalgic encephalomyelitis",Experiment 1,Belgium,Homo sapiens,Feces,UBERON:0001988,Chronic fatigue syndrome,EFO:0004540,Belgian controls,Norweigan controls,Patients were diagnosed for CFS according to the clinical criteria of Fukuda et al,19,17,4 weeks,16S,56,Roche454,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,Signature 2,table 1,10 January 2021,Shaimaa Elsafoury,WikiWorks,Differentiately abundant mictobiota between Norwegian controls and Belgian controls,decreased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Rikenellaceae|g__Alistipes,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Barnesiellaceae|g__Barnesiella,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Tannerellaceae|g__Parabacteroides",2|976|200643|171549|815|816;2|976|200643|171549|171550|239759;2|976|200643|171549|2005519|397864;2|976|200643|171549|171552|838;2|976|200643|171549|2005525|375288,Complete,Shaimaa Elsafoury
bsdb:30/2/1,Study 30,case-control,23791918,10.1016/j.anaerobe.2013.06.002,NA,"Frémont M, Coomans D, Massart S , De Meirleir K",High-throughput 16S rRNA gene sequencing reveals alterations of intestinal microbiota in myalgic encephalomyelitis/chronic fatigue syndrome patients,Anaerobe,2013,"Chronic fatigue syndrome, High-throughput sequencing, Intestinal microbiota, Myalgic encephalomyelitis",Experiment 2,Belgium,Homo sapiens,Feces,UBERON:0001988,Chronic fatigue syndrome,EFO:0004540,Norweigan controls,Norweigan CFS/ME patients,Patients were diagnosed for CFS according to the clinical criteria of Fukuda et al,17,25,4 weeks,16S,56,Roche454,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,Signature 1,table 2,10 January 2021,Shaimaa Elsafoury,WikiWorks,Differentiately abundant mictobiota between Norwegian CFS patients and Norwegian controls,increased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Rikenellaceae|g__Alistipes,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Lactonifactor",2|976|200643|171549|171550|239759;2|1239|186801|186802|31979|420345,Complete,Shaimaa Elsafoury
bsdb:30/2/2,Study 30,case-control,23791918,10.1016/j.anaerobe.2013.06.002,NA,"Frémont M, Coomans D, Massart S , De Meirleir K",High-throughput 16S rRNA gene sequencing reveals alterations of intestinal microbiota in myalgic encephalomyelitis/chronic fatigue syndrome patients,Anaerobe,2013,"Chronic fatigue syndrome, High-throughput sequencing, Intestinal microbiota, Myalgic encephalomyelitis",Experiment 2,Belgium,Homo sapiens,Feces,UBERON:0001988,Chronic fatigue syndrome,EFO:0004540,Norweigan controls,Norweigan CFS/ME patients,Patients were diagnosed for CFS according to the clinical criteria of Fukuda et al,17,25,4 weeks,16S,56,Roche454,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,Signature 2,table 2,10 January 2021,Shaimaa Elsafoury,WikiWorks,Differentiately abundant mictobiota between Norwegian CFS patients and Norwegian controls,decreased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Roseburia,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae|g__Holdemania,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Dialister,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Syntrophococcus",2|1239|186801|3085636|186803|841;2|1239|526524|526525|128827|61170;2|1239|909932|1843489|31977|39948;2|1239|186801|3085636|186803|84036,Complete,Shaimaa Elsafoury
bsdb:30/3/1,Study 30,case-control,23791918,10.1016/j.anaerobe.2013.06.002,NA,"Frémont M, Coomans D, Massart S , De Meirleir K",High-throughput 16S rRNA gene sequencing reveals alterations of intestinal microbiota in myalgic encephalomyelitis/chronic fatigue syndrome patients,Anaerobe,2013,"Chronic fatigue syndrome, High-throughput sequencing, Intestinal microbiota, Myalgic encephalomyelitis",Experiment 3,Belgium,Homo sapiens,Feces,UBERON:0001988,Chronic fatigue syndrome,EFO:0004540,Belgian controls,Belgian CFS/ME patients,Patients were diagnosed for CFS according to the clinical criteria of Fukuda et al,19,18,4 weeks,16S,56,Roche454,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,Signature 1,table 3,10 January 2021,Shaimaa Elsafoury,WikiWorks,Differentiately abundant mictobiota between Belgian CFS patients and Belgian controls,increased,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Lactonifactor,2|1239|186801|186802|31979|420345,Complete,Shaimaa Elsafoury
bsdb:30/3/2,Study 30,case-control,23791918,10.1016/j.anaerobe.2013.06.002,NA,"Frémont M, Coomans D, Massart S , De Meirleir K",High-throughput 16S rRNA gene sequencing reveals alterations of intestinal microbiota in myalgic encephalomyelitis/chronic fatigue syndrome patients,Anaerobe,2013,"Chronic fatigue syndrome, High-throughput sequencing, Intestinal microbiota, Myalgic encephalomyelitis",Experiment 3,Belgium,Homo sapiens,Feces,UBERON:0001988,Chronic fatigue syndrome,EFO:0004540,Belgian controls,Belgian CFS/ME patients,Patients were diagnosed for CFS according to the clinical criteria of Fukuda et al,19,18,4 weeks,16S,56,Roche454,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,Signature 2,table 3,10 January 2021,Shaimaa Elsafoury,WikiWorks,Differentiately abundant mictobiota between Belgian CFS patients and Belgian controls,decreased,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Eggerthellales|f__Eggerthellaceae|g__Asaccharobacter,2|201174|84998|1643822|1643826|553372,Complete,Shaimaa Elsafoury
bsdb:31/1/1,Study 31,case-control,28441964,10.1186/s40168-017-0261-y,NA,"Nagy-Szakal D, Williams BL, Mishra N, Che X, Lee B, Bateman L, Klimas NG, Komaroff AL, Levine S, Montoya JG, Peterson DL, Ramanan D, Jain K, Eddy ML, Hornig M , Lipkin WI",Fecal metagenomic profiles in subgroups of patients with myalgic encephalomyelitis/chronic fatigue syndrome,Microbiome,2017,"Chronic fatigue syndrome, Irritable bowel syndrome, Metabolic pathway, Metagenomic, Microbiota-gut-brain axis, Myalgic encephalomyelitis, Topological data analysis",Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Chronic fatigue syndrome,EFO:0004540,controls,CFS/ME patients,Cases met the 1994 CDC Fukuda and the 2003 Canadian consensus criteria for ME/CFS,50,50,3 months for controls only,WMS,NA,Illumina,LEfSe,0.2,TRUE,2,"age,ethnic group,geographic area,sex",NA,NA,NA,NA,NA,NA,NA,Signature 1,Figure 3a,10 January 2021,Shaimaa Elsafoury,"Fatima,WikiWorks",Differentiately abundant mictobiota between CFS/ME and healthy controls,increased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Anaerostipes,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Anaerostipes|s__Anaerostipes caccae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Clostridium,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Coprobacillaceae|g__Coprobacillus,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Enterocloster|s__Enterocloster asparagiformis,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Pseudoflavonifractor,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Pseudoflavonifractor|s__Pseudoflavonifractor capillosus,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Lachnoclostridium|s__[Clostridium] scindens,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Lachnoclostridium|s__[Clostridium] symbiosum,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Mediterraneibacter|s__Mediterraneibacter gnavus,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Coprobacillaceae|g__Coprobacillus|s__Coprobacillus cateniformis",2|1239|186801|3085636|186803|207244;2|1239|186801|3085636|186803|207244|105841;2|1239|186801|186802|31979;2|1239|186801|186802|31979|1485;2|1239|526524|526525|2810280|100883;2|1239|186801|3085636|186803|2719313|333367;2|1239|186801|186802|216572|1017280;2|1239|186801|186802|216572|1017280|106588;2|1239|186801|3085636|186803|1506553|29347;2|1239|186801|3085636|186803|1506553|1512;2|1239|186801|3085636|186803|2316020|33038;2|1239|526524|526525|2810280|100883|100884,Complete,Fatima
bsdb:31/1/2,Study 31,case-control,28441964,10.1186/s40168-017-0261-y,NA,"Nagy-Szakal D, Williams BL, Mishra N, Che X, Lee B, Bateman L, Klimas NG, Komaroff AL, Levine S, Montoya JG, Peterson DL, Ramanan D, Jain K, Eddy ML, Hornig M , Lipkin WI",Fecal metagenomic profiles in subgroups of patients with myalgic encephalomyelitis/chronic fatigue syndrome,Microbiome,2017,"Chronic fatigue syndrome, Irritable bowel syndrome, Metabolic pathway, Metagenomic, Microbiota-gut-brain axis, Myalgic encephalomyelitis, Topological data analysis",Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Chronic fatigue syndrome,EFO:0004540,controls,CFS/ME patients,Cases met the 1994 CDC Fukuda and the 2003 Canadian consensus criteria for ME/CFS,50,50,3 months for controls only,WMS,NA,Illumina,LEfSe,0.2,TRUE,2,"age,ethnic group,geographic area,sex",NA,NA,NA,NA,NA,NA,NA,Signature 2,Figure 3a,10 January 2021,Shaimaa Elsafoury,"Fatima,Lwaldron,WikiWorks",Differentiately abundant mictobiota between CFS/ME and healthy controls,decreased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Rikenellaceae|g__Alistipes|s__Alistipes putredinis,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Anaerobutyricum|s__Anaerobutyricum hallii,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Blautia|s__Blautia obeum,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Coprococcus,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Coprococcus|s__Coprococcus catus,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Dorea,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Dorea|s__Dorea formicigenerans,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Dorea|s__Dorea longicatena,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Eubacteriaceae|g__Eubacterium|s__Eubacterium ventriosum,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Faecalibacterium,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Faecalibacterium|s__Faecalibacterium prausnitzii,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Gemellaceae|g__Gemella,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Haemophilus,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Haemophilus|s__Haemophilus parainfluenzae,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Tannerellaceae|g__Parabacteroides|s__Parabacteroides distasonis,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Roseburia,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Roseburia|s__Roseburia inulinivorans,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Faecalibacterium|s__Faecalibacterium sp.",2|976|200643|171549|171550|239759|28117;2|1239|186801|3085636|186803|2569097|39488;2|1239|186801|3085636|186803|572511|40520;2|1239|186801|3085636|186803|33042;2|1239|186801|3085636|186803|33042|116085;2|1239|186801|3085636|186803|189330;2|1239|186801|3085636|186803|189330|39486;2|1239|186801|3085636|186803|189330|88431;2|1239|186801|186802|186806|1730|39496;2|1239|186801|186802|216572|216851;2|1239|186801|186802|216572|216851|853;2|1239|91061|1385|539738|1378;2|1224|1236|135625|712|724;2|1224|1236|135625|712|724|729;2|1239|186801|3085636|186803;2|976|200643|171549|2005525|375288|823;2|1224|1236|135625|712;2|1224|1236|135625;2|1239|186801|3085636|186803|841;2|1239|186801|3085636|186803|841|360807;2|1239|186801|186802|216572|216851|1971605,Complete,Fatima
bsdb:31/2/1,Study 31,case-control,28441964,10.1186/s40168-017-0261-y,NA,"Nagy-Szakal D, Williams BL, Mishra N, Che X, Lee B, Bateman L, Klimas NG, Komaroff AL, Levine S, Montoya JG, Peterson DL, Ramanan D, Jain K, Eddy ML, Hornig M , Lipkin WI",Fecal metagenomic profiles in subgroups of patients with myalgic encephalomyelitis/chronic fatigue syndrome,Microbiome,2017,"Chronic fatigue syndrome, Irritable bowel syndrome, Metabolic pathway, Metagenomic, Microbiota-gut-brain axis, Myalgic encephalomyelitis, Topological data analysis",Experiment 2,United States of America,Homo sapiens,Feces,UBERON:0001988,Chronic fatigue syndrome,EFO:0004540,controls,CFS/ME patients with IBS,Cases met the 1994 CDC Fukuda and the 2003 Canadian consensus criteria for ME/CFS,50,21,3 months for controls only,WMS,NA,Illumina,LEfSe,0.2,TRUE,2,"age,ethnic group,geographic area,sex",NA,NA,NA,NA,NA,NA,NA,Signature 1,Figure 3b,10 January 2021,Shaimaa Elsafoury,WikiWorks,Differentiately abundant mictobiota between CFS/ME with IBS and healthy controls,increased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Anaerostipes|s__Anaerostipes caccae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Clostridium,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Enterocloster|s__Enterocloster bolteae,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Anaerostipes",2|1239|186801|3085636|186803|207244|105841;2|1239|186801|186802|31979|1485;2|1239|186801|186802|31979;2|1239|186801|3085636|186803|2719313|208479;2|1239|186801|3085636|186803|207244,Complete,Shaimaa Elsafoury
bsdb:31/2/2,Study 31,case-control,28441964,10.1186/s40168-017-0261-y,NA,"Nagy-Szakal D, Williams BL, Mishra N, Che X, Lee B, Bateman L, Klimas NG, Komaroff AL, Levine S, Montoya JG, Peterson DL, Ramanan D, Jain K, Eddy ML, Hornig M , Lipkin WI",Fecal metagenomic profiles in subgroups of patients with myalgic encephalomyelitis/chronic fatigue syndrome,Microbiome,2017,"Chronic fatigue syndrome, Irritable bowel syndrome, Metabolic pathway, Metagenomic, Microbiota-gut-brain axis, Myalgic encephalomyelitis, Topological data analysis",Experiment 2,United States of America,Homo sapiens,Feces,UBERON:0001988,Chronic fatigue syndrome,EFO:0004540,controls,CFS/ME patients with IBS,Cases met the 1994 CDC Fukuda and the 2003 Canadian consensus criteria for ME/CFS,50,21,3 months for controls only,WMS,NA,Illumina,LEfSe,0.2,TRUE,2,"age,ethnic group,geographic area,sex",NA,NA,NA,NA,NA,NA,NA,Signature 2,Figure 3b,10 January 2021,Shaimaa Elsafoury,"Lwaldron,WikiWorks",Differentiately abundant mictobiota between CFS/ME with IBS and healthy controls,decreased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Anaerobutyricum|s__Anaerobutyricum hallii,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Coprococcus,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Coprococcus|s__Coprococcus catus,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Coprococcus|s__Coprococcus comes,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Dorea,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Dorea|s__Dorea formicigenerans,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Dorea|s__Dorea longicatena,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Faecalibacterium,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Faecalibacterium|s__Faecalibacterium prausnitzii,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Roseburia,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Roseburia|s__Roseburia inulinivorans,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Faecalibacterium|s__Faecalibacterium sp.,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Blautia|s__Blautia obeum",2|1239|186801|3085636|186803|2569097|39488;2|1239|186801|3085636|186803|33042;2|1239|186801|3085636|186803|33042|116085;2|1239|186801|3085636|186803|33042|410072;2|1239|186801|3085636|186803|189330;2|1239|186801|3085636|186803|189330|39486;2|1239|186801|3085636|186803|189330|88431;2|1239|186801|186802|216572|216851;2|1239|186801|186802|216572|216851|853;2|1239|186801|3085636|186803;2|1239|186801|3085636|186803|841;2|1239|186801|3085636|186803|841|360807;2|1239|186801|186802|216572|216851|1971605;2|1239|186801|3085636|186803|572511|40520,Complete,Shaimaa Elsafoury
bsdb:31/3/1,Study 31,case-control,28441964,10.1186/s40168-017-0261-y,NA,"Nagy-Szakal D, Williams BL, Mishra N, Che X, Lee B, Bateman L, Klimas NG, Komaroff AL, Levine S, Montoya JG, Peterson DL, Ramanan D, Jain K, Eddy ML, Hornig M , Lipkin WI",Fecal metagenomic profiles in subgroups of patients with myalgic encephalomyelitis/chronic fatigue syndrome,Microbiome,2017,"Chronic fatigue syndrome, Irritable bowel syndrome, Metabolic pathway, Metagenomic, Microbiota-gut-brain axis, Myalgic encephalomyelitis, Topological data analysis",Experiment 3,United States of America,Homo sapiens,Feces,UBERON:0001988,Chronic fatigue syndrome,EFO:0004540,controls,CFS/ME patients without IBS,Cases met the 1994 CDC Fukuda and the 2003 Canadian consensus criteria for ME/CFS,50,29,3 months for controls only,WMS,NA,Illumina,LEfSe,0.2,TRUE,2,"age,ethnic group,geographic area,sex",NA,NA,NA,NA,NA,NA,NA,Signature 1,Figure 3c,10 January 2021,Shaimaa Elsafoury,"Fatima,Lwaldron,WikiWorks",Differentiately abundant mictobiota between CFS/ME without IBS and healthy controls,increased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pseudomonadales|f__Pseudomonadaceae|s__Azotobacter group,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Clostridium,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Coprobacillaceae|g__Coprobacillus,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Coprobacillaceae|g__Coprobacillus|s__Coprobacillus cateniformis,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Dorea|s__Dorea longicatena,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Eggerthellales|f__Eggerthellaceae|g__Eggerthella,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Eggerthellales|f__Eggerthellaceae|g__Eggerthella|s__Eggerthella lenta,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Pseudoflavonifractor,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Pseudoflavonifractor|s__Pseudoflavonifractor capillosus,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pseudomonadales,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pseudomonadales|f__Pseudomonadaceae|g__Pseudomonas,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Lachnoclostridium|s__[Clostridium] scindens,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Lachnoclostridium|s__[Clostridium] symbiosum,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Mediterraneibacter|s__Mediterraneibacter gnavus,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Clostridium|s__Clostridium sp.",2|1224|1236|72274|135621|351;2|1239|186801|186802|31979;2|1239|186801|186802|31979|1485;2|1239|526524|526525|2810280|100883;2|1239|526524|526525|2810280|100883|100884;2|1239|186801|3085636|186803|189330|88431;2|201174|84998|1643822|1643826|84111;2|201174|84998|1643822|1643826|84111|84112;2|1239|186801|186802|216572|1017280;2|1239|186801|186802|216572|1017280|106588;2|1224|1236|72274;2|1224|1236|72274|135621|286;2|1239|186801|3085636|186803|1506553|29347;2|1239|186801|3085636|186803|1506553|1512;2|1239|186801|3085636|186803|2316020|33038;2|1239|186801|186802|31979|1485|1506,Complete,Fatima
bsdb:31/3/2,Study 31,case-control,28441964,10.1186/s40168-017-0261-y,NA,"Nagy-Szakal D, Williams BL, Mishra N, Che X, Lee B, Bateman L, Klimas NG, Komaroff AL, Levine S, Montoya JG, Peterson DL, Ramanan D, Jain K, Eddy ML, Hornig M , Lipkin WI",Fecal metagenomic profiles in subgroups of patients with myalgic encephalomyelitis/chronic fatigue syndrome,Microbiome,2017,"Chronic fatigue syndrome, Irritable bowel syndrome, Metabolic pathway, Metagenomic, Microbiota-gut-brain axis, Myalgic encephalomyelitis, Topological data analysis",Experiment 3,United States of America,Homo sapiens,Feces,UBERON:0001988,Chronic fatigue syndrome,EFO:0004540,controls,CFS/ME patients without IBS,Cases met the 1994 CDC Fukuda and the 2003 Canadian consensus criteria for ME/CFS,50,29,3 months for controls only,WMS,NA,Illumina,LEfSe,0.2,TRUE,2,"age,ethnic group,geographic area,sex",NA,NA,NA,NA,NA,NA,NA,Signature 2,Figure 3c,10 January 2021,Shaimaa Elsafoury,WikiWorks,Differentiately abundant mictobiota between CFS/ME without IBS and healthy controls,decreased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Coprococcus|s__Coprococcus catus,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Tannerellaceae|g__Parabacteroides|s__Parabacteroides distasonis,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Dorea|s__Dorea formicigenerans,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Dorea",2|1239|186801|3085636|186803|33042|116085;2|976|200643|171549|2005525|375288|823;2|1239|186801|3085636|186803|189330|39486;2|1239|186801|3085636|186803|189330,Complete,Shaimaa Elsafoury
bsdb:32/1/1,Study 32,prospective cohort,28636668,10.1371/journal.pone.0179739,NA,"Borgo F, Riva A, Benetti A, Casiraghi MC, Bertelli S, Garbossa S, Anselmetti S, Scarone S, Pontiroli AE, Morace G , Borghi E","Microbiota in anorexia nervosa: The triangle between bacterial species, metabolites and psychological tests",PloS one,2017,NA,Experiment 1,Italy,Homo sapiens,Feces,UBERON:0001988,Anorexia nervosa,EFO:0004215,Controls,Aonerxia Nervosa patients,"The severity of eating disorder and psychopathology tests were assessed by means of the Symptom Checklist 90 (general psychopathology), Eating Disorder Inventory 2 (eating disorder), State Trait Anxiety Inventory (anxiety disorder) and Beck Depression Inventory (depressive symptoms). Psychologists and psychiatrists (all extensively trained in the use of the instruments) conducted clinical evaluations.",15,15,1 month,16S,NA,Illumina,T-Test,0.05,TRUE,NA,"age,sex",NA,NA,NA,NA,NA,NA,NA,Signature 1,Table 3 +text,10 January 2021,Fatima Zohra,WikiWorks,Significant differential abundance in anorexia nervosa vs controls,increased,"k__Bacteria|p__Pseudomonadota,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae,k__Archaea|p__Euryarchaeota|c__Methanobacteria|o__Methanobacteriales|f__Methanobacteriaceae|g__Methanobrevibacter|s__Methanobrevibacter smithii",2|1224;2|1224|1236|91347|543;2157|28890|183925|2158|2159|2172|2173,Complete,Shaimaa Elsafoury
bsdb:32/1/2,Study 32,prospective cohort,28636668,10.1371/journal.pone.0179739,NA,"Borgo F, Riva A, Benetti A, Casiraghi MC, Bertelli S, Garbossa S, Anselmetti S, Scarone S, Pontiroli AE, Morace G , Borghi E","Microbiota in anorexia nervosa: The triangle between bacterial species, metabolites and psychological tests",PloS one,2017,NA,Experiment 1,Italy,Homo sapiens,Feces,UBERON:0001988,Anorexia nervosa,EFO:0004215,Controls,Aonerxia Nervosa patients,"The severity of eating disorder and psychopathology tests were assessed by means of the Symptom Checklist 90 (general psychopathology), Eating Disorder Inventory 2 (eating disorder), State Trait Anxiety Inventory (anxiety disorder) and Beck Depression Inventory (depressive symptoms). Psychologists and psychiatrists (all extensively trained in the use of the instruments) conducted clinical evaluations.",15,15,1 month,16S,NA,Illumina,T-Test,0.05,TRUE,NA,"age,sex",NA,NA,NA,NA,NA,NA,NA,Signature 2,Table 3 +text,10 January 2021,Fatima Zohra,WikiWorks,Significant differential abundance in anorexia nervosa vs controls,decreased,"k__Bacteria|p__Bacillota,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Ruminococcus,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Roseburia,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Clostridium",2|1239;2|1239|186801|186802|541000;2|1239|186801|186802|216572|1263;2|1239|186801|3085636|186803|841;2|1239|186801|186802|31979|1485,Complete,Shaimaa Elsafoury
bsdb:33/1/1,Study 33,"cross-sectional observational, not case-control",26261039,10.1186/s12876-015-0330-2,NA,"Kasai C, Sugimoto K, Moritani I, Tanaka J, Oya Y, Inoue H, Tameda M, Shiraki K, Ito M, Takei Y , Takase K","Comparison of the gut microbiota composition between obese and non-obese individuals in a Japanese population, as analyzed by terminal restriction fragment length polymorphism and next-generation sequencing",BMC gastroenterology,2015,NA,Experiment 1,Japan,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,controls,obese,BMI ≥25 kg/m2,4,6,current use,16S,34,Illumina,Welch's T-Test,0.05,FALSE,NA,NA,NA,NA,increased,NA,NA,NA,NA,Signature 1,"Table 2, Table 4 & Table 5",10 January 2021,Marianthi Thomatos,"Fatima,WikiWorks","Comparison of the gut microbiota composition between obese and non-obese individuals in a Japanese population, using  Next generation sequencing",increased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Blautia|s__Blautia hydrogenotrophica,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Coprococcus|s__Coprococcus catus,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Eubacteriaceae|g__Eubacterium|s__Eubacterium ventriosum,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Ruminococcus|s__Ruminococcus bromii,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Blautia|s__Blautia obeum",2|1239|186801|3085636|186803|572511|53443;2|1239|186801|3085636|186803|33042|116085;2|1239|186801|186802|186806|1730|39496;2|1239|186801|186802|216572|1263|40518;2|1239|186801|3085636|186803|572511|40520,Complete,Fatima
bsdb:33/1/2,Study 33,"cross-sectional observational, not case-control",26261039,10.1186/s12876-015-0330-2,NA,"Kasai C, Sugimoto K, Moritani I, Tanaka J, Oya Y, Inoue H, Tameda M, Shiraki K, Ito M, Takei Y , Takase K","Comparison of the gut microbiota composition between obese and non-obese individuals in a Japanese population, as analyzed by terminal restriction fragment length polymorphism and next-generation sequencing",BMC gastroenterology,2015,NA,Experiment 1,Japan,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,controls,obese,BMI ≥25 kg/m2,4,6,current use,16S,34,Illumina,Welch's T-Test,0.05,FALSE,NA,NA,NA,NA,increased,NA,NA,NA,NA,Signature 2,"Table 2, Table 4 & Table 5",10 January 2021,Marianthi Thomatos,WikiWorks,"Comparison of the gut microbiota composition between obese and non-obese individuals in a Japanese population, using  Next generation sequencing",decreased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Flavonifractor|s__Flavonifractor plautii,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides|s__Bacteroides faecichinchillae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides|s__Bacteroides thetaiotaomicron,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Blautia|s__Blautia wexlerae,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Enterocloster|s__Enterocloster bolteae,k__Bacteria|p__Bacteroidota",2|1239|186801|186802|216572|946234|292800;2|976|200643|171549|815|816|871325;2|976|200643|171549|815|816|818;2|1239|186801|3085636|186803|572511|418240;2|1239|186801|3085636|186803|2719313|208479;2|976,Complete,Shaimaa Elsafoury
bsdb:34/1/1,Study 34,"cross-sectional observational, not case-control",30051546,10.1111/bdi.12682,NA,"Painold A, Mörkl S, Kashofer K, Halwachs B, Dalkner N, Bengesser S, Birner A, Fellendorf F, Platzer M, Queissner R, Schütze G, Schwarz MJ, Moll N, Holzer P, Holl AK, Kapfhammer HP, Gorkiewicz G , Reininghaus EZ",A step ahead: Exploring the gut microbiota in inpatients with bipolar disorder during a depressive episode,Bipolar disorders,2019,"16S rRNA gene, bipolar disorder, diversity, gut microbiota, gut-brain axis, illness duration, inflammation, metabolic syndrome, oxidative stress, tryptophan",Experiment 1,Austria,Homo sapiens,Feces,UBERON:0001988,Bipolar disorder,MONDO:0004985,Controls,Bipolar disorder,cases followed the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)21 diagnosis of bipolar I disorder,10,32,1 month,16S,12,Ion Torrent,LEfSe,0.05,FALSE,3,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,Signature 1,Table 3,10 January 2021,Fatima Zohra,WikiWorks,Differentially abundant features of Bipolar disorder individuals in comparison to HC,increased,"k__Bacteria|p__Actinomycetota,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales|f__Coriobacteriaceae,k__Bacteria|p__Actinomycetota|c__Coriobacteriia",2|201174;2|201174|84998|84999;2|201174|84998|84999|84107;2|201174|84998,Complete,Shaimaa Elsafoury
bsdb:34/1/2,Study 34,"cross-sectional observational, not case-control",30051546,10.1111/bdi.12682,NA,"Painold A, Mörkl S, Kashofer K, Halwachs B, Dalkner N, Bengesser S, Birner A, Fellendorf F, Platzer M, Queissner R, Schütze G, Schwarz MJ, Moll N, Holzer P, Holl AK, Kapfhammer HP, Gorkiewicz G , Reininghaus EZ",A step ahead: Exploring the gut microbiota in inpatients with bipolar disorder during a depressive episode,Bipolar disorders,2019,"16S rRNA gene, bipolar disorder, diversity, gut microbiota, gut-brain axis, illness duration, inflammation, metabolic syndrome, oxidative stress, tryptophan",Experiment 1,Austria,Homo sapiens,Feces,UBERON:0001988,Bipolar disorder,MONDO:0004985,Controls,Bipolar disorder,cases followed the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)21 diagnosis of bipolar I disorder,10,32,1 month,16S,12,Ion Torrent,LEfSe,0.05,FALSE,3,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,Signature 2,Table 3,10 January 2021,Fatima Zohra,WikiWorks,Differentially abundant features of Bipolar disorder individuals in comparison to HC,decreased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Faecalibacterium",2|1239|186801|186802|541000;2|1239|186801|186802|216572|216851,Complete,Shaimaa Elsafoury
bsdb:34/2/1,Study 34,"cross-sectional observational, not case-control",30051546,10.1111/bdi.12682,NA,"Painold A, Mörkl S, Kashofer K, Halwachs B, Dalkner N, Bengesser S, Birner A, Fellendorf F, Platzer M, Queissner R, Schütze G, Schwarz MJ, Moll N, Holzer P, Holl AK, Kapfhammer HP, Gorkiewicz G , Reininghaus EZ",A step ahead: Exploring the gut microbiota in inpatients with bipolar disorder during a depressive episode,Bipolar disorders,2019,"16S rRNA gene, bipolar disorder, diversity, gut microbiota, gut-brain axis, illness duration, inflammation, metabolic syndrome, oxidative stress, tryptophan",Experiment 2,Austria,Homo sapiens,Feces,UBERON:0001988,Bipolar disorder,MONDO:0004985,low IL-6,Bipolar patients with high IL-6,cases followed the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)21 diagnosis of bipolar I disorder,NA,NA,1 month,16S,12,Ion Torrent,LEfSe,0.05,FALSE,3,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,text (results),10 January 2021,Fatima Zohra,WikiWorks,Microbiota composition in relation to inflammatory markers among bipolar patients,increased,"k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus",2|1239|91061|186826;2|1239|91061|186826|33958;2|1239|91061|186826|33958|1578;2|1239|91061|186826|1300;2|1239|91061|186826|1300|1301,Complete,Shaimaa Elsafoury
bsdb:34/3/1,Study 34,"cross-sectional observational, not case-control",30051546,10.1111/bdi.12682,NA,"Painold A, Mörkl S, Kashofer K, Halwachs B, Dalkner N, Bengesser S, Birner A, Fellendorf F, Platzer M, Queissner R, Schütze G, Schwarz MJ, Moll N, Holzer P, Holl AK, Kapfhammer HP, Gorkiewicz G , Reininghaus EZ",A step ahead: Exploring the gut microbiota in inpatients with bipolar disorder during a depressive episode,Bipolar disorders,2019,"16S rRNA gene, bipolar disorder, diversity, gut microbiota, gut-brain axis, illness duration, inflammation, metabolic syndrome, oxidative stress, tryptophan",Experiment 3,Austria,Homo sapiens,Feces,UBERON:0001988,Bipolar disorder,MONDO:0004985,low total cholesterol,Bipolar patients with high total cholesterol,cases followed the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)21 diagnosis of bipolar I disorder,NA,NA,1 month,16S,12,Ion Torrent,LEfSe,0.05,FALSE,3,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,text (results),10 January 2021,Fatima Zohra,WikiWorks,Microbiota composition in relation to lipid levels among bipolar patients,increased,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae,2|1239|186801|186802|31979,Complete,Shaimaa Elsafoury
bsdb:34/4/1,Study 34,"cross-sectional observational, not case-control",30051546,10.1111/bdi.12682,NA,"Painold A, Mörkl S, Kashofer K, Halwachs B, Dalkner N, Bengesser S, Birner A, Fellendorf F, Platzer M, Queissner R, Schütze G, Schwarz MJ, Moll N, Holzer P, Holl AK, Kapfhammer HP, Gorkiewicz G , Reininghaus EZ",A step ahead: Exploring the gut microbiota in inpatients with bipolar disorder during a depressive episode,Bipolar disorders,2019,"16S rRNA gene, bipolar disorder, diversity, gut microbiota, gut-brain axis, illness duration, inflammation, metabolic syndrome, oxidative stress, tryptophan",Experiment 4,Austria,Homo sapiens,Feces,UBERON:0001988,Bipolar disorder,MONDO:0004985,low LDL,Bipolar patients with high LDL,cases followed the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)21 diagnosis of bipolar I disorder,NA,NA,1 month,16S,12,Ion Torrent,LEfSe,0.05,FALSE,3,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,text (results),10 January 2021,Shaimaa Elsafoury,WikiWorks,Microbiota composition in relation to lipid levels among bipolar patients,decreased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella",2|976|200643|171549|171552;2|976|200643|171549|171552|838,Complete,Shaimaa Elsafoury
bsdb:34/5/1,Study 34,"cross-sectional observational, not case-control",30051546,10.1111/bdi.12682,NA,"Painold A, Mörkl S, Kashofer K, Halwachs B, Dalkner N, Bengesser S, Birner A, Fellendorf F, Platzer M, Queissner R, Schütze G, Schwarz MJ, Moll N, Holzer P, Holl AK, Kapfhammer HP, Gorkiewicz G , Reininghaus EZ",A step ahead: Exploring the gut microbiota in inpatients with bipolar disorder during a depressive episode,Bipolar disorders,2019,"16S rRNA gene, bipolar disorder, diversity, gut microbiota, gut-brain axis, illness duration, inflammation, metabolic syndrome, oxidative stress, tryptophan",Experiment 5,Austria,Homo sapiens,Feces,UBERON:0001988,Bipolar disorder,MONDO:0004985,low TRP,Bipolar patients with high TRP,cases followed the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)21 diagnosis of bipolar I disorder,NA,NA,1 month,16S,12,Ion Torrent,LEfSe,0.05,FALSE,3,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,text (results),10 January 2021,Fatima Zohra,WikiWorks,Microbiota composition in relation to tryptophan metabolites among bipolar patients,increased,"k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales|f__Coriobacteriaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae",2|1239|91061|186826|33958|1578;2|1239|91061|186826|33958;2|201174|84998|84999|84107;2|1239|186801|186802|31979,Complete,Shaimaa Elsafoury
bsdb:34/6/1,Study 34,"cross-sectional observational, not case-control",30051546,10.1111/bdi.12682,NA,"Painold A, Mörkl S, Kashofer K, Halwachs B, Dalkner N, Bengesser S, Birner A, Fellendorf F, Platzer M, Queissner R, Schütze G, Schwarz MJ, Moll N, Holzer P, Holl AK, Kapfhammer HP, Gorkiewicz G , Reininghaus EZ",A step ahead: Exploring the gut microbiota in inpatients with bipolar disorder during a depressive episode,Bipolar disorders,2019,"16S rRNA gene, bipolar disorder, diversity, gut microbiota, gut-brain axis, illness duration, inflammation, metabolic syndrome, oxidative stress, tryptophan",Experiment 6,Austria,Homo sapiens,Feces,UBERON:0001988,Bipolar disorder,MONDO:0004985,low TBARS level,Bipolar patients with high TBARS level,cases followed the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)21 diagnosis of bipolar I disorder,NA,NA,1 month,16S,12,Ion Torrent,LEfSe,0.05,FALSE,2,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,text (results),10 January 2021,Fatima Zohra,WikiWorks,Microbiota composition in relation to markers of oxidative stress among bipolar patients,increased,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Eubacteriaceae|g__Eubacterium,2|1239|186801|186802|186806|1730,Complete,Shaimaa Elsafoury
bsdb:34/7/1,Study 34,"cross-sectional observational, not case-control",30051546,10.1111/bdi.12682,NA,"Painold A, Mörkl S, Kashofer K, Halwachs B, Dalkner N, Bengesser S, Birner A, Fellendorf F, Platzer M, Queissner R, Schütze G, Schwarz MJ, Moll N, Holzer P, Holl AK, Kapfhammer HP, Gorkiewicz G , Reininghaus EZ",A step ahead: Exploring the gut microbiota in inpatients with bipolar disorder during a depressive episode,Bipolar disorders,2019,"16S rRNA gene, bipolar disorder, diversity, gut microbiota, gut-brain axis, illness duration, inflammation, metabolic syndrome, oxidative stress, tryptophan",Experiment 7,Austria,Homo sapiens,Feces,UBERON:0001988,Bipolar disorder,MONDO:0004985,low MDA level,Bipolar patients with high MDA level,cases followed the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)21 diagnosis of bipolar I disorder,NA,NA,1 month,16S,12,Ion Torrent,LEfSe,0.05,FALSE,3,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,text (results),10 January 2021,Fatima Zohra,WikiWorks,Microbiota composition in relation to markers of oxidative stress among bipolar patients,decreased,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Faecalibacterium,2|1239|186801|186802|216572|216851,Complete,Shaimaa Elsafoury
bsdb:34/8/1,Study 34,"cross-sectional observational, not case-control",30051546,10.1111/bdi.12682,NA,"Painold A, Mörkl S, Kashofer K, Halwachs B, Dalkner N, Bengesser S, Birner A, Fellendorf F, Platzer M, Queissner R, Schütze G, Schwarz MJ, Moll N, Holzer P, Holl AK, Kapfhammer HP, Gorkiewicz G , Reininghaus EZ",A step ahead: Exploring the gut microbiota in inpatients with bipolar disorder during a depressive episode,Bipolar disorders,2019,"16S rRNA gene, bipolar disorder, diversity, gut microbiota, gut-brain axis, illness duration, inflammation, metabolic syndrome, oxidative stress, tryptophan",Experiment 8,Austria,Homo sapiens,Feces,UBERON:0001988,Bipolar disorder,MONDO:0004985,low BMI,Bipolar patients with high BMI,cases followed the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)21 diagnosis of bipolar I disorder,NA,NA,1 month,16S,12,Ion Torrent,LEfSe,0.05,FALSE,3,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,text (results),10 January 2021,Fatima Zohra,WikiWorks,Microbiota composition in relation to BMI among bipolar patients,increased,"k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae,k__Bacteria|p__Bacillota|c__Bacilli",2|1239|91061|186826|33958|1578;2|1239|91061|186826|33958;2|1239|91061,Complete,Shaimaa Elsafoury
bsdb:34/9/1,Study 34,"cross-sectional observational, not case-control",30051546,10.1111/bdi.12682,NA,"Painold A, Mörkl S, Kashofer K, Halwachs B, Dalkner N, Bengesser S, Birner A, Fellendorf F, Platzer M, Queissner R, Schütze G, Schwarz MJ, Moll N, Holzer P, Holl AK, Kapfhammer HP, Gorkiewicz G , Reininghaus EZ",A step ahead: Exploring the gut microbiota in inpatients with bipolar disorder during a depressive episode,Bipolar disorders,2019,"16S rRNA gene, bipolar disorder, diversity, gut microbiota, gut-brain axis, illness duration, inflammation, metabolic syndrome, oxidative stress, tryptophan",Experiment 9,Austria,Homo sapiens,Feces,UBERON:0001988,Bipolar disorder,MONDO:0004985,no metabolic syndrome,Bipolar patients with metabolic syndrome,cases followed the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)21 diagnosis of bipolar I disorder,NA,NA,1 month,16S,12,Ion Torrent,LEfSe,0.05,FALSE,3,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,text (results),10 January 2021,Fatima Zohra,WikiWorks,Microbiota composition in relation to metabolic syndrome among bipolar patients,increased,"k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales|f__Coriobacteriaceae",2|1239|91061|186826|33958;2|1239|91061|186826|33958|1578;2|201174|84998|84999|84107,Complete,Shaimaa Elsafoury
bsdb:34/10/1,Study 34,"cross-sectional observational, not case-control",30051546,10.1111/bdi.12682,NA,"Painold A, Mörkl S, Kashofer K, Halwachs B, Dalkner N, Bengesser S, Birner A, Fellendorf F, Platzer M, Queissner R, Schütze G, Schwarz MJ, Moll N, Holzer P, Holl AK, Kapfhammer HP, Gorkiewicz G , Reininghaus EZ",A step ahead: Exploring the gut microbiota in inpatients with bipolar disorder during a depressive episode,Bipolar disorders,2019,"16S rRNA gene, bipolar disorder, diversity, gut microbiota, gut-brain axis, illness duration, inflammation, metabolic syndrome, oxidative stress, tryptophan",Experiment 10,Austria,Homo sapiens,Feces,UBERON:0001988,Bipolar disorder,MONDO:0004985,healthier bipolar patients,Bipolar patients with depressive syndrome,cases followed the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)21 diagnosis of bipolar I disorder,NA,NA,1 month,16S,12,Ion Torrent,LEfSe,0.05,FALSE,3,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,text (results),10 January 2021,Fatima Zohra,WikiWorks,Microbiota composition in relation to depressive syndrome among bipolar patients,increased,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae,2|1224|1236|91347|543,Complete,Shaimaa Elsafoury
bsdb:34/10/2,Study 34,"cross-sectional observational, not case-control",30051546,10.1111/bdi.12682,NA,"Painold A, Mörkl S, Kashofer K, Halwachs B, Dalkner N, Bengesser S, Birner A, Fellendorf F, Platzer M, Queissner R, Schütze G, Schwarz MJ, Moll N, Holzer P, Holl AK, Kapfhammer HP, Gorkiewicz G , Reininghaus EZ",A step ahead: Exploring the gut microbiota in inpatients with bipolar disorder during a depressive episode,Bipolar disorders,2019,"16S rRNA gene, bipolar disorder, diversity, gut microbiota, gut-brain axis, illness duration, inflammation, metabolic syndrome, oxidative stress, tryptophan",Experiment 10,Austria,Homo sapiens,Feces,UBERON:0001988,Bipolar disorder,MONDO:0004985,healthier bipolar patients,Bipolar patients with depressive syndrome,cases followed the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)21 diagnosis of bipolar I disorder,NA,NA,1 month,16S,12,Ion Torrent,LEfSe,0.05,FALSE,3,NA,NA,NA,NA,NA,NA,NA,NA,Signature 2,text (results),10 January 2021,Fatima Zohra,WikiWorks,Microbiota composition in relation to depressive syndrome among bipolar patients,decreased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Roseburia",2|1239|186801|186802|31979;2|1239|186801|3085636|186803|841,Complete,Shaimaa Elsafoury
bsdb:34/11/1,Study 34,"cross-sectional observational, not case-control",30051546,10.1111/bdi.12682,NA,"Painold A, Mörkl S, Kashofer K, Halwachs B, Dalkner N, Bengesser S, Birner A, Fellendorf F, Platzer M, Queissner R, Schütze G, Schwarz MJ, Moll N, Holzer P, Holl AK, Kapfhammer HP, Gorkiewicz G , Reininghaus EZ",A step ahead: Exploring the gut microbiota in inpatients with bipolar disorder during a depressive episode,Bipolar disorders,2019,"16S rRNA gene, bipolar disorder, diversity, gut microbiota, gut-brain axis, illness duration, inflammation, metabolic syndrome, oxidative stress, tryptophan",Experiment 11,Austria,Homo sapiens,Feces,UBERON:0001988,Bipolar disorder,MONDO:0004985,Controls,Bipolar disorder,cases followed the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)21 diagnosis of bipolar I disorder,10,27,1 month,16S,12,Ion Torrent,LEfSe,0.05,FALSE,3,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Supplementary Table 1,10 January 2021,Fatima Zohra,WikiWorks,Differentially abundant features of Bipolar disorder individuals in comparison to HC after exclusion obese and diabetic patients,increased,"k__Bacteria|p__Actinomycetota,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales|f__Coriobacteriaceae,k__Bacteria|p__Actinomycetota|c__Coriobacteriia",2|201174;2|201174|84998|84999;2|201174|84998|84999|84107;2|201174|84998,Complete,Shaimaa Elsafoury
bsdb:34/11/2,Study 34,"cross-sectional observational, not case-control",30051546,10.1111/bdi.12682,NA,"Painold A, Mörkl S, Kashofer K, Halwachs B, Dalkner N, Bengesser S, Birner A, Fellendorf F, Platzer M, Queissner R, Schütze G, Schwarz MJ, Moll N, Holzer P, Holl AK, Kapfhammer HP, Gorkiewicz G , Reininghaus EZ",A step ahead: Exploring the gut microbiota in inpatients with bipolar disorder during a depressive episode,Bipolar disorders,2019,"16S rRNA gene, bipolar disorder, diversity, gut microbiota, gut-brain axis, illness duration, inflammation, metabolic syndrome, oxidative stress, tryptophan",Experiment 11,Austria,Homo sapiens,Feces,UBERON:0001988,Bipolar disorder,MONDO:0004985,Controls,Bipolar disorder,cases followed the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)21 diagnosis of bipolar I disorder,10,27,1 month,16S,12,Ion Torrent,LEfSe,0.05,FALSE,3,NA,NA,NA,NA,NA,NA,NA,NA,Signature 2,Supplementary Table 1,10 January 2021,Fatima Zohra,WikiWorks,Differentially abundant features of Bipolar disorder individuals in comparison to HC after exclusion obese and diabetic patients,decreased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Faecalibacterium",2|1239|186801|186802|541000;2|1239|186801|186802|216572|216851,Complete,Shaimaa Elsafoury
bsdb:35/1/1,Study 35,case-control,30280027,10.7717/peerj.5649,NA,"Zhou Z, Ling G, Ding N, Xun Z, Zhu C, Hua H , Chen X",Molecular analysis of oral microflora in patients with primary Sjögren's syndrome by using high-throughput sequencing,PeerJ,2018,"Core microbiome, Dental caries, High-throughput sequencing, Oral microflora, Primary Sjögren’s syndrome",Experiment 1,China,Homo sapiens,Saliva,UBERON:0001836,Sjogren syndrome,EFO:0000699,Controls,PSS,Patients with Sjogren syndrome,23,22,NA,16S,34,Illumina,LEfSe,0.05,FALSE,4,"age,sex",NA,decreased,decreased,unchanged,NA,decreased,NA,Signature 1,Figure 3,10 January 2021,Rimsha Azhar,WikiWorks,Comparison of microbiota using LDA score by LEfSe analysis between primary sjogres patients(PSS) and healthy controls,increased,"k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Veillonella,k__Bacteria|p__Bacillota|c__Negativicutes|o__Selenomonadales,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria,k__Bacteria|p__Pseudomonadota",2|1239|909932|1843489|31977|29465;2|1239|909932|909929;2|1239|909932|1843489|31977;2|1224|1236;2|1224,Complete,Shaimaa Elsafoury
bsdb:35/1/2,Study 35,case-control,30280027,10.7717/peerj.5649,NA,"Zhou Z, Ling G, Ding N, Xun Z, Zhu C, Hua H , Chen X",Molecular analysis of oral microflora in patients with primary Sjögren's syndrome by using high-throughput sequencing,PeerJ,2018,"Core microbiome, Dental caries, High-throughput sequencing, Oral microflora, Primary Sjögren’s syndrome",Experiment 1,China,Homo sapiens,Saliva,UBERON:0001836,Sjogren syndrome,EFO:0000699,Controls,PSS,Patients with Sjogren syndrome,23,22,NA,16S,34,Illumina,LEfSe,0.05,FALSE,4,"age,sex",NA,decreased,decreased,unchanged,NA,decreased,NA,Signature 2,Figure 3,10 January 2021,Rimsha Azhar,WikiWorks,Comparison of microbiota using LDA score by LEfSe analysis between primary sjogres patients(PSS) and healthy controls,decreased,"k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales|f__Actinomycetaceae|g__Actinomyces,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Haemophilus,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Neisseriaceae|g__Neisseria,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micrococcales|f__Micrococcaceae|g__Rothia,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae|g__Porphyromonas,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Peptostreptococcaceae|g__Peptostreptococcus,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales|f__Actinomycetaceae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Neisseriaceae,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micrococcales|f__Micrococcaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia,k__Bacteria|p__Fusobacteriota,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales,k__Bacteria|p__Bacillota|c__Clostridia,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales,k__Bacteria|p__Actinomycetota",2|201174|1760|2037|2049|1654;2|1224|1236|135625|712|724;2|1224|28216|206351|481|482;2|201174|1760|85006|1268|32207;2|976|200643|171549|171551|836;2|1239|186801|3082720|186804|1257;2|1224|28216;2|201174|1760|2037|2049;2|1224|1236|135625|712;2|1224|28216|206351|481;2|1224|28216|206351;2|201174|1760|85006|1268;2|976|200643|171549|171551;2|201174|1760|2037;2|32066|203490;2|32066;2|32066|203490|203491;2|1239|186801;2|1239|186801|186802;2|1224|1236|135625;2|201174,Complete,Shaimaa Elsafoury
bsdb:36/1/1,Study 36,case-control,29922272,10.3389/fmicb.2018.01210,NA,"Del Chierico F, Abbatini F, Russo A, Quagliariello A, Reddel S, Capoccia D, Caccamo R, Ginanni Corradini S, Nobili V, De Peppo F, Dallapiccola B, Leonetti F, Silecchia G , Putignani L",Gut Microbiota Markers in Obese Adolescent and Adult Patients: Age-Dependent Differential Patterns,Frontiers in microbiology,2018,"bacterial markers, dysbiosis, gut microbiota, metabolic pathways, obesity",Experiment 1,Italy,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,control adult,obese adolescent,Adolescents who are obese,25,12,2 months,16S,123,Roche454,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,age,NA,NA,unchanged,decreased,NA,NA,NA,Signature 1,Table 2,10 January 2021,Marianthi Thomatos,"WikiWorks,ChiomaBlessing",Gut microbiota markers in Obese adolescents compared to the Adult control group.,increased,"k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales|f__Actinomycetaceae|g__Actinomyces,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales|f__Coriobacteriaceae|g__Collinsella|s__Collinsella aerofaciens,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Propionibacteriales|f__Propionibacteriaceae|g__Cutibacterium|s__Cutibacterium acnes,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Faecalibacterium|s__Faecalibacterium prausnitzii",2|201174|1760|2037|2049|1654;2|1239|186801|186802|31979;2|201174|84998|84999|84107|102106|74426;2|201174|1760|85009|31957|1912216|1747;2|1239|186801|186802|216572|216851|853,Complete,Shaimaa Elsafoury
bsdb:36/1/2,Study 36,case-control,29922272,10.3389/fmicb.2018.01210,NA,"Del Chierico F, Abbatini F, Russo A, Quagliariello A, Reddel S, Capoccia D, Caccamo R, Ginanni Corradini S, Nobili V, De Peppo F, Dallapiccola B, Leonetti F, Silecchia G , Putignani L",Gut Microbiota Markers in Obese Adolescent and Adult Patients: Age-Dependent Differential Patterns,Frontiers in microbiology,2018,"bacterial markers, dysbiosis, gut microbiota, metabolic pathways, obesity",Experiment 1,Italy,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,control adult,obese adolescent,Adolescents who are obese,25,12,2 months,16S,123,Roche454,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,age,NA,NA,unchanged,decreased,NA,NA,NA,Signature 2,Table 2,10 January 2021,Marianthi Thomatos,"WikiWorks,ChiomaBlessing",Gut microbiota markers in Obese adolescents compared to the Adult control group.,decreased,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Oscillospira,2|1239|186801|186802|216572|119852,Complete,Shaimaa Elsafoury
bsdb:36/2/1,Study 36,case-control,29922272,10.3389/fmicb.2018.01210,NA,"Del Chierico F, Abbatini F, Russo A, Quagliariello A, Reddel S, Capoccia D, Caccamo R, Ginanni Corradini S, Nobili V, De Peppo F, Dallapiccola B, Leonetti F, Silecchia G , Putignani L",Gut Microbiota Markers in Obese Adolescent and Adult Patients: Age-Dependent Differential Patterns,Frontiers in microbiology,2018,"bacterial markers, dysbiosis, gut microbiota, metabolic pathways, obesity",Experiment 2,Italy,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,control adolescent,obese adult,Adults who are obese,20,12,2 months,16S,123,Roche454,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,age,NA,NA,unchanged,decreased,NA,NA,NA,Signature 1,Table 2,10 January 2021,Marianthi Thomatos,"WikiWorks,ChiomaBlessing",Gut microbiota markers in Obese adults compared to the Adolescents control group.,increased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Propionibacteriales|f__Propionibacteriaceae|g__Cutibacterium|s__Cutibacterium acnes,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Faecalibacterium|s__Faecalibacterium prausnitzii,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus",2|1239|186801|186802|31979;2|201174|1760|85009|31957|1912216|1747;2|1239|186801|186802|216572|216851|853;2|1239|186801|3085636|186803;2|1239|91061|186826|1300|1301,Complete,Shaimaa Elsafoury
bsdb:36/2/2,Study 36,case-control,29922272,10.3389/fmicb.2018.01210,NA,"Del Chierico F, Abbatini F, Russo A, Quagliariello A, Reddel S, Capoccia D, Caccamo R, Ginanni Corradini S, Nobili V, De Peppo F, Dallapiccola B, Leonetti F, Silecchia G , Putignani L",Gut Microbiota Markers in Obese Adolescent and Adult Patients: Age-Dependent Differential Patterns,Frontiers in microbiology,2018,"bacterial markers, dysbiosis, gut microbiota, metabolic pathways, obesity",Experiment 2,Italy,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,control adolescent,obese adult,Adults who are obese,20,12,2 months,16S,123,Roche454,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,age,NA,NA,unchanged,decreased,NA,NA,NA,Signature 2,Table 2,10 January 2021,Marianthi Thomatos,"WikiWorks,ChiomaBlessing",Gut microbiota markers in Obese adults compared to the Adolescents control group.,decreased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides|s__Bacteroides caccae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Barnesiellaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Oscillospira",2|976|200643|171549|815|816|47678;2|976|200643|171549|2005519;2|1239|186801|186802|216572|119852,Complete,Shaimaa Elsafoury
bsdb:36/3/1,Study 36,case-control,29922272,10.3389/fmicb.2018.01210,NA,"Del Chierico F, Abbatini F, Russo A, Quagliariello A, Reddel S, Capoccia D, Caccamo R, Ginanni Corradini S, Nobili V, De Peppo F, Dallapiccola B, Leonetti F, Silecchia G , Putignani L",Gut Microbiota Markers in Obese Adolescent and Adult Patients: Age-Dependent Differential Patterns,Frontiers in microbiology,2018,"bacterial markers, dysbiosis, gut microbiota, metabolic pathways, obesity",Experiment 3,Italy,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,control adult,control adolescent,NA,12,12,2 months,16S,123,Roche454,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,age,NA,NA,unchanged,increased,NA,NA,NA,Signature 1,Table 2,10 January 2021,Marianthi Thomatos,WikiWorks,Gut microbiota markers in obese adolescent and adult patterns: age-dependent differential patterns,increased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Oscillospira,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides|s__Bacteroides caccae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Barnesiellaceae",2|1239|186801|186802|216572|119852;2|976|200643|171549|815|816|47678;2|976|200643|171549|2005519,Complete,Shaimaa Elsafoury
bsdb:36/3/2,Study 36,case-control,29922272,10.3389/fmicb.2018.01210,NA,"Del Chierico F, Abbatini F, Russo A, Quagliariello A, Reddel S, Capoccia D, Caccamo R, Ginanni Corradini S, Nobili V, De Peppo F, Dallapiccola B, Leonetti F, Silecchia G , Putignani L",Gut Microbiota Markers in Obese Adolescent and Adult Patients: Age-Dependent Differential Patterns,Frontiers in microbiology,2018,"bacterial markers, dysbiosis, gut microbiota, metabolic pathways, obesity",Experiment 3,Italy,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,control adult,control adolescent,NA,12,12,2 months,16S,123,Roche454,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,age,NA,NA,unchanged,increased,NA,NA,NA,Signature 2,Table 2,10 January 2021,Marianthi Thomatos,WikiWorks,Gut microbiota markers in obese adolescent and adult patterns: age-dependent differential patterns,decreased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus",2|1239|186801|3085636|186803;2|1239|91061|186826|1300|1301,Complete,Shaimaa Elsafoury
bsdb:36/4/1,Study 36,case-control,29922272,10.3389/fmicb.2018.01210,NA,"Del Chierico F, Abbatini F, Russo A, Quagliariello A, Reddel S, Capoccia D, Caccamo R, Ginanni Corradini S, Nobili V, De Peppo F, Dallapiccola B, Leonetti F, Silecchia G , Putignani L",Gut Microbiota Markers in Obese Adolescent and Adult Patients: Age-Dependent Differential Patterns,Frontiers in microbiology,2018,"bacterial markers, dysbiosis, gut microbiota, metabolic pathways, obesity",Experiment 4,Italy,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,obese adult,obese adolescent,Adolescents who are obese,20,25,2 months,16S,123,Roche454,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,age,NA,NA,unchanged,unchanged,NA,NA,NA,Signature 1,Table S4,10 January 2021,Shaimaa Elsafoury,"WikiWorks,ChiomaBlessing",Gut microbiota markers in Obese adolescents compared to the Obese adult group.,increased,"k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales|f__Actinomycetaceae|g__Actinomyces,k__Bacteria|p__Actinomycetota,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Eggerthellales|f__Eggerthellaceae|g__Adlercreutzia,k__Bacteria|p__Bacillota,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales|f__Coriobacteriaceae|g__Collinsella|s__Collinsella aerofaciens,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Faecalibacterium|s__Faecalibacterium prausnitzii",2|201174|1760|2037|2049|1654;2|201174;2|201174|84998|1643822|1643826|447020;2|1239;2|201174|84998|84999|84107|102106|74426;2|1239|186801|186802|216572|216851|853,Complete,Shaimaa Elsafoury
bsdb:36/5/1,Study 36,case-control,29922272,10.3389/fmicb.2018.01210,NA,"Del Chierico F, Abbatini F, Russo A, Quagliariello A, Reddel S, Capoccia D, Caccamo R, Ginanni Corradini S, Nobili V, De Peppo F, Dallapiccola B, Leonetti F, Silecchia G , Putignani L",Gut Microbiota Markers in Obese Adolescent and Adult Patients: Age-Dependent Differential Patterns,Frontiers in microbiology,2018,"bacterial markers, dysbiosis, gut microbiota, metabolic pathways, obesity",Experiment 5,Italy,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,control adolescent,obese adolescent,Adolescents who are obese,12,25,2 months,16S,123,Roche454,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,age,NA,NA,unchanged,decreased,NA,NA,NA,Signature 1,Table S4,10 January 2021,Shaimaa Elsafoury,"WikiWorks,ChiomaBlessing",Gut microbiota markers in Obese adolescents compared to the Adolescents control group.,increased,"k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales|f__Actinomycetaceae|g__Actinomyces,k__Bacteria|p__Actinomycetota,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Eggerthellales|f__Eggerthellaceae|g__Adlercreutzia,k__Bacteria|p__Bacillota,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales|f__Coriobacteriaceae|g__Collinsella|s__Collinsella aerofaciens,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Propionibacteriales|f__Propionibacteriaceae|g__Cutibacterium|s__Cutibacterium acnes,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Faecalibacterium|s__Faecalibacterium prausnitzii,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Veillonella|s__Veillonella parvula",2|201174|1760|2037|2049|1654;2|201174;2|201174|84998|1643822|1643826|447020;2|1239;2|1239|186801|186802|31979;2|201174|84998|84999|84107|102106|74426;2|201174|1760|85009|31957|1912216|1747;2|1239|186801|186802|216572|216851|853;2|1239|186801|3085636|186803;2|1239|91061|186826|1300|1301;2|1239|909932|1843489|31977|29465|29466,Complete,Shaimaa Elsafoury
bsdb:36/5/2,Study 36,case-control,29922272,10.3389/fmicb.2018.01210,NA,"Del Chierico F, Abbatini F, Russo A, Quagliariello A, Reddel S, Capoccia D, Caccamo R, Ginanni Corradini S, Nobili V, De Peppo F, Dallapiccola B, Leonetti F, Silecchia G , Putignani L",Gut Microbiota Markers in Obese Adolescent and Adult Patients: Age-Dependent Differential Patterns,Frontiers in microbiology,2018,"bacterial markers, dysbiosis, gut microbiota, metabolic pathways, obesity",Experiment 5,Italy,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,control adolescent,obese adolescent,Adolescents who are obese,12,25,2 months,16S,123,Roche454,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,age,NA,NA,unchanged,decreased,NA,NA,NA,Signature 2,Table S4,10 January 2021,Shaimaa Elsafoury,"WikiWorks,ChiomaBlessing",Gut microbiota markers in Obese adolescents compared to the Adolescents control group.,decreased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides|s__Bacteroides caccae,k__Bacteria|p__Bacteroidota,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Barnesiellaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Oscillospira",2|976|200643|171549|815|816|47678;2|976;2|976|200643|171549|2005519;2|1239|186801|186802|216572|119852,Complete,Shaimaa Elsafoury
bsdb:36/6/1,Study 36,case-control,29922272,10.3389/fmicb.2018.01210,NA,"Del Chierico F, Abbatini F, Russo A, Quagliariello A, Reddel S, Capoccia D, Caccamo R, Ginanni Corradini S, Nobili V, De Peppo F, Dallapiccola B, Leonetti F, Silecchia G , Putignani L",Gut Microbiota Markers in Obese Adolescent and Adult Patients: Age-Dependent Differential Patterns,Frontiers in microbiology,2018,"bacterial markers, dysbiosis, gut microbiota, metabolic pathways, obesity",Experiment 6,Italy,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,control adult,obese adult,Adults who are obese,12,20,2 months,16S,123,Roche454,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,age,NA,NA,unchanged,unchanged,NA,NA,NA,Signature 1,Table S4,10 January 2021,Shaimaa Elsafoury,"WikiWorks,ChiomaBlessing",Gut microbiota markers in Obese adults compared to the Adults control group.,increased,"k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Propionibacteriales|f__Propionibacteriaceae|g__Cutibacterium|s__Cutibacterium acnes,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Faecalibacterium|s__Faecalibacterium prausnitzii",2|201174|1760|85009|31957|1912216|1747;2|1239|186801|186802|216572|216851|853,Complete,Shaimaa Elsafoury
bsdb:37/1/1,Study 37,case-control,23733170,10.1007/s00248-013-0245-9,NA,"Wu N, Yang X, Zhang R, Li J, Xiao X, Hu Y, Chen Y, Yang F, Lu N, Wang Z, Luan C, Liu Y, Wang B, Xiang C, Wang Y, Zhao F, Gao GF, Wang S, Li L, Zhang H , Zhu B",Dysbiosis signature of fecal microbiota in colorectal cancer patients,Microbial ecology,2013,NA,Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,Healthy controls,CRC patients,NA,20,19,3 months,16S,3,Roche454,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,"age,body mass index,sex",NA,NA,unchanged,unchanged,NA,NA,NA,Signature 1,Figure 3,10 January 2021,Shaimaa Elsafoury,"Fatima,WikiWorks",Cladogram of Colorectal cancer and healthy microbiota,increased,"k__Bacteria|p__Bacillota|c__Tissierellia|o__Tissierellales|f__Peptoniphilaceae|g__Anaerococcus,k__Bacteria|p__Campylobacterota|c__Epsilonproteobacteria|o__Campylobacterales|f__Campylobacteraceae|g__Campylobacter,k__Bacteria|p__Campylobacterota|c__Epsilonproteobacteria|o__Campylobacterales|f__Campylobacteraceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Eubacteriaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Eubacteriaceae|g__Eubacterium,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Fastidiosipila,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae|g__Fusobacterium,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Gemellaceae|g__Gemella,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae|g__Holdemania,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Neisseriaceae|g__Kingella,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Leptotrichiaceae|g__Leptotrichia,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Odoribacteraceae|g__Odoribacter,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Oscillibacter,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Tannerellaceae|g__Parabacteroides,k__Bacteria|p__Bacillota|c__Tissierellia|o__Tissierellales|f__Peptoniphilaceae|g__Parvimonas,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Peptostreptococcaceae|g__Peptostreptococcus,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae|g__Porphyromonas,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae|g__Solobacterium,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Staphylococcaceae,k__Bacteria|p__Bacillota|c__Tissierellia",2|1239|1737404|1737405|1570339|165779;2|29547|3031852|213849|72294|194;2|29547|3031852|213849|72294;2|1239|186801|186802|186806;2|1239|186801|186802|186806|1730;2|1239|186801|186802|216572|236752;2|32066|203490|203491|203492;2|32066|203490;2|32066|203490|203491|203492|848;2|1239|91061|1385|539738|1378;2|1239|526524|526525|128827|61170;2|1224|28216|206351|481|32257;2|32066|203490|203491|1129771|32067;2|976|200643|171549|1853231|283168;2|1239|186801|186802|216572|459786;2|976|200643|171549|2005525|375288;2|1239|1737404|1737405|1570339|543311;2|1239|186801|3082720|186804|1257;2|976|200643|171549|171551;2|976|200643|171549|171551|836;2|1239|526524|526525|128827|123375;2|1239|91061|1385|90964;2|1239|1737404,Complete,Fatima
bsdb:37/1/2,Study 37,case-control,23733170,10.1007/s00248-013-0245-9,NA,"Wu N, Yang X, Zhang R, Li J, Xiao X, Hu Y, Chen Y, Yang F, Lu N, Wang Z, Luan C, Liu Y, Wang B, Xiang C, Wang Y, Zhao F, Gao GF, Wang S, Li L, Zhang H , Zhu B",Dysbiosis signature of fecal microbiota in colorectal cancer patients,Microbial ecology,2013,NA,Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,Healthy controls,CRC patients,NA,20,19,3 months,16S,3,Roche454,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,"age,body mass index,sex",NA,NA,unchanged,unchanged,NA,NA,NA,Signature 2,Figure 3,10 January 2021,Shaimaa Elsafoury,WikiWorks,Cladogram of Colorectal cancer and healthy microbiota,decreased,"k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Leuconostoc,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus",2|1239|91061|186826|33958|1243;2|1239|91061|186826|1300|1301,Complete,Shaimaa Elsafoury
bsdb:38/1/1,Study 38,"cross-sectional observational, not case-control",30497517,10.1186/s40168-018-0588-z,NA,"Lam TH, Verzotto D, Brahma P, Ng AHQ, Hu P, Schnell D, Tiesman J, Kong R, Ton TMU, Li J, Ong M, Lu Y, Swaile D, Liu P, Liu J , Nagarajan N",Understanding the microbial basis of body odor in pre-pubescent children and teenagers,Microbiome,2018,NA,Experiment 1,Philippines,Homo sapiens,Skin of body,UBERON:0002097,Body odor measurement,EFO:0008386,head of child,head of teenager,Malodor is a phenotype that is well known to arise from specific interactions between host-derived odor precursors and the microbial metabolism that they support,15,15,NA,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,"Figure S3, S4",10 January 2021,Rimsha Azhar,"WikiWorks,Davvve,ChiomaBlessing",Significant microbial genera and species associated with teen head VS child head,increased,"k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Propionibacteriales|f__Propionibacteriaceae|g__Cutibacterium,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Propionibacteriales|f__Propionibacteriaceae|g__Cutibacterium|s__Cutibacterium acnes",2|201174|1760|85009|31957|1912216;2|201174|1760|85009|31957|1912216|1747,Complete,Shaimaa Elsafoury
bsdb:38/1/2,Study 38,"cross-sectional observational, not case-control",30497517,10.1186/s40168-018-0588-z,NA,"Lam TH, Verzotto D, Brahma P, Ng AHQ, Hu P, Schnell D, Tiesman J, Kong R, Ton TMU, Li J, Ong M, Lu Y, Swaile D, Liu P, Liu J , Nagarajan N",Understanding the microbial basis of body odor in pre-pubescent children and teenagers,Microbiome,2018,NA,Experiment 1,Philippines,Homo sapiens,Skin of body,UBERON:0002097,Body odor measurement,EFO:0008386,head of child,head of teenager,Malodor is a phenotype that is well known to arise from specific interactions between host-derived odor precursors and the microbial metabolism that they support,15,15,NA,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 2,"Figure S3, S4",10 January 2021,Rimsha Azhar,"WikiWorks,Davvve,ChiomaBlessing",Significant microbial genera and species associated with teen head VS child head,decreased,"k__Eukaryota|k__Fungi|p__Basidiomycota|c__Malasseziomycetes|o__Malasseziales|f__Malasseziaceae|g__Malassezia,k__Eukaryota|k__Fungi|p__Basidiomycota|c__Malasseziomycetes|o__Malasseziales|f__Malasseziaceae|g__Malassezia|s__Malassezia globosa,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Staphylococcaceae|g__Staphylococcus,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Staphylococcaceae|g__Staphylococcus|s__Staphylococcus epidermidis,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Staphylococcaceae|g__Staphylococcus|s__Staphylococcus hominis",2759|4751|5204|1538075|162474|742845|55193;2759|4751|5204|1538075|162474|742845|55193|76773;2|1239|91061|1385|90964|1279;2|1239|91061|1385|90964|1279|1282;2|1239|91061|1385|90964|1279|1290,Complete,Shaimaa Elsafoury
bsdb:38/2/1,Study 38,"cross-sectional observational, not case-control",30497517,10.1186/s40168-018-0588-z,NA,"Lam TH, Verzotto D, Brahma P, Ng AHQ, Hu P, Schnell D, Tiesman J, Kong R, Ton TMU, Li J, Ong M, Lu Y, Swaile D, Liu P, Liu J , Nagarajan N",Understanding the microbial basis of body odor in pre-pubescent children and teenagers,Microbiome,2018,NA,Experiment 2,Philippines,Homo sapiens,Skin of body,UBERON:0002097,Body odor measurement,EFO:0008386,child neck,teen neck,Malodor is a phenotype that is well known to arise from specific interactions between host-derived odor precursors and the microbial metabolism that they support,15,15,NA,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,"Figure S3, S4",10 January 2021,Rimsha Azhar,"WikiWorks,ChiomaBlessing",Significant microbial genera and species associated with teen neck VS child neck,increased,"k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Propionibacteriales|f__Propionibacteriaceae|g__Cutibacterium,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Propionibacteriales|f__Propionibacteriaceae|g__Cutibacterium|s__Cutibacterium acnes,k__Eukaryota|k__Fungi|p__Basidiomycota|c__Malasseziomycetes|o__Malasseziales|f__Malasseziaceae|g__Malassezia,k__Eukaryota|k__Fungi|p__Basidiomycota|c__Malasseziomycetes|o__Malasseziales|f__Malasseziaceae|g__Malassezia|s__Malassezia globosa",2|201174|1760|85009|31957|1912216;2|201174|1760|85009|31957|1912216|1747;2759|4751|5204|1538075|162474|742845|55193;2759|4751|5204|1538075|162474|742845|55193|76773,Complete,Shaimaa Elsafoury
bsdb:38/2/2,Study 38,"cross-sectional observational, not case-control",30497517,10.1186/s40168-018-0588-z,NA,"Lam TH, Verzotto D, Brahma P, Ng AHQ, Hu P, Schnell D, Tiesman J, Kong R, Ton TMU, Li J, Ong M, Lu Y, Swaile D, Liu P, Liu J , Nagarajan N",Understanding the microbial basis of body odor in pre-pubescent children and teenagers,Microbiome,2018,NA,Experiment 2,Philippines,Homo sapiens,Skin of body,UBERON:0002097,Body odor measurement,EFO:0008386,child neck,teen neck,Malodor is a phenotype that is well known to arise from specific interactions between host-derived odor precursors and the microbial metabolism that they support,15,15,NA,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 2,"Figure S3, S4",10 January 2021,Rimsha Azhar,"WikiWorks,ChiomaBlessing",Significant microbial genera and species associated with teen neck VS child neck,decreased,"k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Staphylococcaceae|g__Staphylococcus,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Staphylococcaceae|g__Staphylococcus|s__Staphylococcus hominis",2|1239|91061|1385|90964|1279;2|1239|91061|1385|90964|1279|1290,Complete,Shaimaa Elsafoury
bsdb:38/3/1,Study 38,"cross-sectional observational, not case-control",30497517,10.1186/s40168-018-0588-z,NA,"Lam TH, Verzotto D, Brahma P, Ng AHQ, Hu P, Schnell D, Tiesman J, Kong R, Ton TMU, Li J, Ong M, Lu Y, Swaile D, Liu P, Liu J , Nagarajan N",Understanding the microbial basis of body odor in pre-pubescent children and teenagers,Microbiome,2018,NA,Experiment 3,Philippines,Homo sapiens,Skin of body,UBERON:0002097,Body odor measurement,EFO:0008386,child underarm,teen underarm,Malodor is a phenotype that is well known to arise from specific interactions between host-derived odor precursors and the microbial metabolism that they support,15,15,NA,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,"Figure S3, S4",10 January 2021,Rimsha Azhar,"WikiWorks,ChiomaBlessing",Significant microbial genera and species associated with teen underarm VS child underarm,increased,"k__Eukaryota|k__Fungi|p__Basidiomycota|c__Malasseziomycetes|o__Malasseziales|f__Malasseziaceae|g__Malassezia|s__Malassezia globosa,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Staphylococcaceae|g__Staphylococcus|s__Staphylococcus epidermidis",2759|4751|5204|1538075|162474|742845|55193|76773;2|1239|91061|1385|90964|1279|1282,Complete,Shaimaa Elsafoury
bsdb:38/3/2,Study 38,"cross-sectional observational, not case-control",30497517,10.1186/s40168-018-0588-z,NA,"Lam TH, Verzotto D, Brahma P, Ng AHQ, Hu P, Schnell D, Tiesman J, Kong R, Ton TMU, Li J, Ong M, Lu Y, Swaile D, Liu P, Liu J , Nagarajan N",Understanding the microbial basis of body odor in pre-pubescent children and teenagers,Microbiome,2018,NA,Experiment 3,Philippines,Homo sapiens,Skin of body,UBERON:0002097,Body odor measurement,EFO:0008386,child underarm,teen underarm,Malodor is a phenotype that is well known to arise from specific interactions between host-derived odor precursors and the microbial metabolism that they support,15,15,NA,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 2,"Figure S3, S4",10 January 2021,Rimsha Azhar,"WikiWorks,ChiomaBlessing",Significant microbial genera and species associated with teen underarm VS child underarm,decreased,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Staphylococcaceae|g__Staphylococcus|s__Staphylococcus hominis,2|1239|91061|1385|90964|1279|1290,Complete,Shaimaa Elsafoury
bsdb:39/1/1,Study 39,time series / longitudinal observational,30497517,10.1186/s40168-018-0588-z,NA,"Lam TH, Verzotto D, Brahma P, Ng AHQ, Hu P, Schnell D, Tiesman J, Kong R, Ton TMU, Li J, Ong M, Lu Y, Swaile D, Liu P, Liu J , Nagarajan N",Understanding the microbial basis of body odor in pre-pubescent children and teenagers,Microbiome,2018,NA,Experiment 1,Philippines,Homo sapiens,Skin of body,UBERON:0002097,Body odor measurement,EFO:0008386,youth underarm before,youth underarm after exercise,Malodor is a phenotype that is well known to arise from specific interactions between host-derived odor precursors and the microbial metabolism that they support,30,30,NA,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.01,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Table 1& S3,10 January 2021,Shaimaa Elsafoury,WikiWorks,List of microbes at the genus level that show significant correlation with odor intensity in at least one age group,increased,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Staphylococcaceae|g__Staphylococcus|s__Staphylococcus epidermidis,2|1239|91061|1385|90964|1279|1282,Complete,Shaimaa Elsafoury
bsdb:39/1/2,Study 39,time series / longitudinal observational,30497517,10.1186/s40168-018-0588-z,NA,"Lam TH, Verzotto D, Brahma P, Ng AHQ, Hu P, Schnell D, Tiesman J, Kong R, Ton TMU, Li J, Ong M, Lu Y, Swaile D, Liu P, Liu J , Nagarajan N",Understanding the microbial basis of body odor in pre-pubescent children and teenagers,Microbiome,2018,NA,Experiment 1,Philippines,Homo sapiens,Skin of body,UBERON:0002097,Body odor measurement,EFO:0008386,youth underarm before,youth underarm after exercise,Malodor is a phenotype that is well known to arise from specific interactions between host-derived odor precursors and the microbial metabolism that they support,30,30,NA,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.01,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 2,Table 1& S3,10 January 2021,Shaimaa Elsafoury,WikiWorks,List of microbes at the genus level that show significant correlation with odor intensity in at least one age group,decreased,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Rhodobacterales|f__Paracoccaceae|g__Paracoccus,2|1224|28211|204455|31989|265,Complete,Shaimaa Elsafoury
bsdb:39/2/1,Study 39,time series / longitudinal observational,30497517,10.1186/s40168-018-0588-z,NA,"Lam TH, Verzotto D, Brahma P, Ng AHQ, Hu P, Schnell D, Tiesman J, Kong R, Ton TMU, Li J, Ong M, Lu Y, Swaile D, Liu P, Liu J , Nagarajan N",Understanding the microbial basis of body odor in pre-pubescent children and teenagers,Microbiome,2018,NA,Experiment 2,Philippines,Homo sapiens,Skin of body,UBERON:0002097,Body odor measurement,EFO:0008386,after excercise,youth Neck before,Malodor is a phenotype that is well known to arise from specific interactions between host-derived odor precursors and the microbial metabolism that they support,30,30,NA,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.01,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Table 1& S3,10 January 2021,Shaimaa Elsafoury,WikiWorks,List of microbes at the genus level that show significant correlation with odor intensity in at least one age group,decreased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Moraxellales|f__Moraxellaceae|g__Acinetobacter,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Propionibacteriales|f__Propionibacteriaceae|g__Cutibacterium|s__Cutibacterium granulosum,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Moraxellales|f__Moraxellaceae|g__Acinetobacter|s__Acinetobacter schindleri",2|1224|1236|2887326|468|469;2|201174|1760|85009|31957|1912216|33011;2|1224|1236|2887326|468|469|108981,Complete,Shaimaa Elsafoury
bsdb:39/3/1,Study 39,time series / longitudinal observational,30497517,10.1186/s40168-018-0588-z,NA,"Lam TH, Verzotto D, Brahma P, Ng AHQ, Hu P, Schnell D, Tiesman J, Kong R, Ton TMU, Li J, Ong M, Lu Y, Swaile D, Liu P, Liu J , Nagarajan N",Understanding the microbial basis of body odor in pre-pubescent children and teenagers,Microbiome,2018,NA,Experiment 3,Philippines,Homo sapiens,Skin of body,UBERON:0002097,Body odor measurement,EFO:0008386,after excercise,Children underarm before,Malodor is a phenotype that is well known to arise from specific interactions between host-derived odor precursors and the microbial metabolism that they support,15,15,NA,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.01,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Table 1& S3,10 January 2021,Shaimaa Elsafoury,WikiWorks,List of microbes at the genus level that show significant correlation with odor intensity in at least one age group,decreased,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Rhodobacterales|f__Paracoccaceae|g__Paracoccus,2|1224|28211|204455|31989|265,Complete,Shaimaa Elsafoury
bsdb:39/4/1,Study 39,time series / longitudinal observational,30497517,10.1186/s40168-018-0588-z,NA,"Lam TH, Verzotto D, Brahma P, Ng AHQ, Hu P, Schnell D, Tiesman J, Kong R, Ton TMU, Li J, Ong M, Lu Y, Swaile D, Liu P, Liu J , Nagarajan N",Understanding the microbial basis of body odor in pre-pubescent children and teenagers,Microbiome,2018,NA,Experiment 4,Philippines,Homo sapiens,Skin of body,UBERON:0002097,Body odor measurement,EFO:0008386,after excercise,Children Neck before,Malodor is a phenotype that is well known to arise from specific interactions between host-derived odor precursors and the microbial metabolism that they support,15,15,NA,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.01,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Table 1& S3,10 January 2021,Shaimaa Elsafoury,WikiWorks,List of microbes at the genus level that show significant correlation with odor intensity in at least one age group,increased,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Staphylococcaceae|g__Staphylococcus,2|1239|91061|1385|90964|1279,Complete,Shaimaa Elsafoury
bsdb:39/4/2,Study 39,time series / longitudinal observational,30497517,10.1186/s40168-018-0588-z,NA,"Lam TH, Verzotto D, Brahma P, Ng AHQ, Hu P, Schnell D, Tiesman J, Kong R, Ton TMU, Li J, Ong M, Lu Y, Swaile D, Liu P, Liu J , Nagarajan N",Understanding the microbial basis of body odor in pre-pubescent children and teenagers,Microbiome,2018,NA,Experiment 4,Philippines,Homo sapiens,Skin of body,UBERON:0002097,Body odor measurement,EFO:0008386,after excercise,Children Neck before,Malodor is a phenotype that is well known to arise from specific interactions between host-derived odor precursors and the microbial metabolism that they support,15,15,NA,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.01,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 2,Table 1& S3,10 January 2021,Shaimaa Elsafoury,WikiWorks,List of microbes at the genus level that show significant correlation with odor intensity in at least one age group,decreased,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Propionibacteriales|f__Propionibacteriaceae|g__Cutibacterium,2|201174|1760|85009|31957|1912216,Complete,Shaimaa Elsafoury
bsdb:39/5/1,Study 39,time series / longitudinal observational,30497517,10.1186/s40168-018-0588-z,NA,"Lam TH, Verzotto D, Brahma P, Ng AHQ, Hu P, Schnell D, Tiesman J, Kong R, Ton TMU, Li J, Ong M, Lu Y, Swaile D, Liu P, Liu J , Nagarajan N",Understanding the microbial basis of body odor in pre-pubescent children and teenagers,Microbiome,2018,NA,Experiment 5,Philippines,Homo sapiens,Skin of body,UBERON:0002097,Body odor measurement,EFO:0008386,after excercise,teen underarm before,Malodor is a phenotype that is well known to arise from specific interactions between host-derived odor precursors and the microbial metabolism that they support,15,15,NA,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.01,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Table 1& S3,10 January 2021,Shaimaa Elsafoury,WikiWorks,List of microbes at the genus level that show significant correlation with odor intensity in at least one age group,decreased,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Rhodobacterales|f__Paracoccaceae|g__Paracoccus,2|1224|28211|204455|31989|265,Complete,Shaimaa Elsafoury
bsdb:39/6/1,Study 39,time series / longitudinal observational,30497517,10.1186/s40168-018-0588-z,NA,"Lam TH, Verzotto D, Brahma P, Ng AHQ, Hu P, Schnell D, Tiesman J, Kong R, Ton TMU, Li J, Ong M, Lu Y, Swaile D, Liu P, Liu J , Nagarajan N",Understanding the microbial basis of body odor in pre-pubescent children and teenagers,Microbiome,2018,NA,Experiment 6,Philippines,Homo sapiens,Skin of body,UBERON:0002097,Body odor measurement,EFO:0008386,after excercise,teen Neck before,Malodor is a phenotype that is well known to arise from specific interactions between host-derived odor precursors and the microbial metabolism that they support,15,15,NA,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.01,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Table 1& S3,10 January 2021,Shaimaa Elsafoury,WikiWorks,List of microbes at the genus level that show significant correlation with odor intensity in at least one age group,decreased,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Moraxellales|f__Moraxellaceae|g__Acinetobacter,2|1224|1236|2887326|468|469,Complete,Shaimaa Elsafoury
bsdb:40/1/1,Study 40,case-control,28863139,10.1371/journal.pone.0183509,NA,"Aarts E, Ederveen THA, Naaijen J, Zwiers MP, Boekhorst J, Timmerman HM, Smeekens SP, Netea MG, Buitelaar JK, Franke B, van Hijum SAFT , Arias Vasquez A",Gut microbiome in ADHD and its relation to neural reward anticipation,PloS one,2017,NA,Experiment 1,Netherlands,Homo sapiens,Feces,UBERON:0001988,Attention deficit hyperactivity disorder,EFO:0003888,Controls,ADHD,cases were diagnosed based on DSM-IV symptoms using the Schedule for Affective Disorders and Schizophrenia for School-Age Children,77,19,NA,16S,34,Roche454,Mann-Whitney (Wilcoxon),0.1,FALSE,NA,NA,NA,NA,unchanged,unchanged,NA,NA,NA,Signature 1,Figure 3,10 January 2021,Fatima Zohra,WikiWorks,Differential abundance of microbial taxa for ADHD cases versus healthy controls,increased,"k__Bacteria|p__Actinomycetota,k__Bacteria|p__Actinomycetota|c__Actinomycetes,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Eggerthellales|f__Eggerthellaceae|g__Eggerthella,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium|s__Bifidobacterium pseudocatenulatum,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium|s__Bifidobacterium longum|s__Bifidobacterium longum subsp. longum,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium|s__Bifidobacterium adolescentis,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Odoribacteraceae|g__Odoribacter,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Rikenellaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Tannerellaceae|g__Parabacteroides,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Rikenellaceae|g__Alistipes,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Phocaeicola|s__Phocaeicola vulgatus,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides|s__Bacteroides ovatus,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides|s__Bacteroides uniformis,k__Bacteria|c__Deltaproteobacteria,k__Bacteria|p__Thermodesulfobacteriota|c__Desulfovibrionia|o__Desulfovibrionales",2|201174;2|201174|1760;2|201174|1760|85004;2|201174|1760|85004|31953;2|201174|1760|85004|31953|1678;2|201174|84998|1643822|1643826|84111;2|201174|1760|85004|31953|1678|28026;2|201174|1760|85004|31953|1678|216816|1679;2|201174|1760|85004|31953|1678|1680;2|976|200643|171549|1853231|283168;2|976|200643|171549|171551;2|976|200643|171549|171550;2|976|200643|171549|2005525|375288;2|976|200643|171549|171550|239759;2|976|200643|171549|815|909656|821;2|976|200643|171549|815|816|28116;2|976|200643|171549|815|816|820;2|28221;2|200940|3031449|213115,Complete,Shaimaa Elsafoury
bsdb:40/1/2,Study 40,case-control,28863139,10.1371/journal.pone.0183509,NA,"Aarts E, Ederveen THA, Naaijen J, Zwiers MP, Boekhorst J, Timmerman HM, Smeekens SP, Netea MG, Buitelaar JK, Franke B, van Hijum SAFT , Arias Vasquez A",Gut microbiome in ADHD and its relation to neural reward anticipation,PloS one,2017,NA,Experiment 1,Netherlands,Homo sapiens,Feces,UBERON:0001988,Attention deficit hyperactivity disorder,EFO:0003888,Controls,ADHD,cases were diagnosed based on DSM-IV symptoms using the Schedule for Affective Disorders and Schizophrenia for School-Age Children,77,19,NA,16S,34,Roche454,Mann-Whitney (Wilcoxon),0.1,FALSE,NA,NA,NA,NA,unchanged,unchanged,NA,NA,NA,Signature 2,Figure 3,10 January 2021,Fatima Zohra,WikiWorks,Differential abundance of microbial taxa for ADHD cases versus healthy controls,decreased,"k__Bacteria|p__Bacillota,k__Bacteria|p__Bacillota|c__Clostridia,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Coprococcus|s__Coprococcus eutactus,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Subdoligranulum,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Ruminococcus,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Acetivibrio,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Coprococcus",2|1239;2|1239|186801;2|1239|186801|186802;2|1239|186801|3085636|186803|33042|33043;2|1239|186801|186802|216572|292632;2|1239|186801|186802|216572|1263;2|1239|186801|186802|216572|35829;2|1239|186801|3085636|186803|33042,Complete,Shaimaa Elsafoury
bsdb:41/1/1,Study 41,case-control,28442250,10.1016/j.schres.2017.04.017,NA,"Schwarz E, Maukonen J, Hyytiäinen T, Kieseppä T, Orešič M, Sabunciyan S, Mantere O, Saarela M, Yolken R , Suvisaari J",Analysis of microbiota in first episode psychosis identifies preliminary associations with symptom severity and treatment response,Schizophrenia research,2018,"Microbiome, Psychosis, Response, Schizophrenia",Experiment 1,Finland,Homo sapiens,Feces,UBERON:0001988,Psychosis,EFO:0005407,Controls,FIrst episode Psychosis,NA,16,28,3 months,16S,NA,Illumina,LEfSe,0.05,FALSE,2,"age,region of residence,sex",NA,NA,NA,NA,NA,NA,NA,Signature 1,Figure 2,10 January 2021,Fatima Zohra,WikiWorks,Taxonomic differences of fecal microbiota between first episode psychosis patients and healthy controls,increased,"k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Hyphomicrobiales|f__Brucellaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Chromatiales|f__Halothiobacillaceae,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micrococcales|f__Tropherymataceae|g__Tropheryma,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Hyphomicrobiales|f__Brucellaceae|g__Ochrobactrum,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Cellvibrionales|f__Cellvibrionaceae|g__Saccharophagus,k__Archaea|p__Euryarchaeota|c__Halobacteria|o__Halobacteriales|f__Haloferacaceae|g__Halorubrum,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus,k__Bacteria|p__Deferribacterota|c__Deferribacteres|o__Deferribacterales|f__Deferribacteraceae|g__Deferribacter,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Chromatiales|f__Halothiobacillaceae|g__Halothiobacillus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus|s__Lactobacillus acidophilus,k__Bacteria|p__Deferribacterota|c__Deferribacteres|o__Deferribacterales|f__Deferribacteraceae|g__Deferribacter|s__Deferribacter desulfuricans,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Burkholderiaceae|g__Burkholderia|s__Burkholderia cenocepacia,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Desulfitobacteriaceae|g__Desulfosporosinus|s__Desulfosporosinus acidiphilus,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Chromatiales|f__Halothiobacillaceae|g__Halothiobacillus|s__Halothiobacillus neapolitanus,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Cellvibrionales|f__Cellvibrionaceae|g__Saccharophagus|s__Saccharophagus degradans,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Thiotrichales|f__Francisellaceae|g__Francisella|s__Francisella hispaniensis,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micrococcales|f__Tropherymataceae|g__Tropheryma|s__Tropheryma whipplei,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Hyphomicrobiales|f__Brucellaceae|g__Brucella|s__Brucella canis,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus|s__Lactobacillus johnsonii,k__Archaea|p__Euryarchaeota|c__Halobacteria|o__Halobacteriales|f__Haloferacaceae|g__Halorubrum|s__Halorubrum lacusprofundi,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Limosilactobacillus|s__Limosilactobacillus reuteri,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Chromatiales|f__Chromatiaceae|g__Nitrosococcus|s__Nitrosococcus halophilus,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Hyphomicrobiales|f__Bartonellaceae|g__Bartonella|s__Bartonella clarridgeiae,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Hyphomicrobiales|f__Brucellaceae|g__Brucella|s__Brucella anthropi,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Hyphomicrobiales,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Limosilactobacillus|s__Limosilactobacillus fermentum,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Ligilactobacillus|s__Ligilactobacillus salivarius,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus|s__Lactobacillus gasseri,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium|s__Bifidobacterium dentium",2|1224|28211|356|118882;2|1239|91061|186826|33958;2|1224|1236|135613|255526;2|201174|1760|85006|2805591|2038;2|1224|28211|356|118882|528;2|1224|1236|1706369|1706371|316625;2157|28890|183963|2235|1644056|56688;2|1239|91061|186826|33958|1578;2|200930|68337|191393|191394|53572;2|1224|1236|135613|255526|109262;2|1239|91061|186826|33958|1578|1579;2|200930|68337|191393|191394|53572|197162;2|1224|28216|80840|119060|32008|95486;2|1239|186801|186802|2937909|79206|885581;2|1224|1236|135613|255526|109262|927;2|1224|1236|1706369|1706371|316625|86304;2|1224|1236|72273|34064|262|622488;2|201174|1760|85006|2805591|2038|2039;2|1224|28211|356|118882|234|36855;2|1239|91061|186826|33958|1578|33959;2157|28890|183963|2235|1644056|56688|2247;2|1239|91061|186826|33958|2742598|1598;2|1224|1236|135613|1046|1227|133539;2|1224|28211|356|772|773|56426;2|1224|28211|356|118882|234|529;2|1239|91061|1385;2|1224|28211|356;2|1239|91061|186826|33958|2742598|1613;2|1239|91061|186826|33958|2767887|1624;2|1239|91061|186826|33958|1578|1596;2|201174|1760|85004|31953|1678|1689,Complete,Shaimaa Elsafoury
bsdb:41/1/2,Study 41,case-control,28442250,10.1016/j.schres.2017.04.017,NA,"Schwarz E, Maukonen J, Hyytiäinen T, Kieseppä T, Orešič M, Sabunciyan S, Mantere O, Saarela M, Yolken R , Suvisaari J",Analysis of microbiota in first episode psychosis identifies preliminary associations with symptom severity and treatment response,Schizophrenia research,2018,"Microbiome, Psychosis, Response, Schizophrenia",Experiment 1,Finland,Homo sapiens,Feces,UBERON:0001988,Psychosis,EFO:0005407,Controls,FIrst episode Psychosis,NA,16,28,3 months,16S,NA,Illumina,LEfSe,0.05,FALSE,2,"age,region of residence,sex",NA,NA,NA,NA,NA,NA,NA,Signature 2,Figure 2,10 January 2021,Fatima Zohra,"Lwaldron,WikiWorks",Taxonomic differences of fecal microbiota between first episode psychosis patients and healthy controls,decreased,"k__Bacteria|p__Cyanobacteriota|c__Cyanophyceae|o__Nostocales|f__Nostocaceae|g__Anabaena,k__Bacteria|p__Chlorobiota|c__Chlorobiia|o__Chlorobiales|f__Chlorobiaceae|g__Chlorobium|s__Chlorobium chlorochromatii,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Nitrosomonadales|f__Gallionellaceae|g__Gallionella,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Nitrosomonadales|f__Gallionellaceae|g__Gallionella|s__Gallionella capsiferriformans,k__Bacteria|p__Bacillota|c__Negativicutes,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Nitrosomonadales|f__Nitrosomonadaceae|g__Nitrosomonas|s__Nitrosomonas sp.,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Nitrosomonadales|f__Nitrosomonadaceae|g__Nitrosospira,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Nitrosomonadales|f__Nitrosomonadaceae|g__Nitrosospira|s__Nitrosospira multiformis,k__Bacteria|p__Bacillota|c__Negativicutes|o__Selenomonadales,k__Archaea|p__Euryarchaeota|c__Thermococci|o__Thermococcales|f__Thermococcaceae|g__Thermococcus|s__Thermococcus gammatolerans,k__Bacteria|p__Cyanobacteriota|c__Cyanophyceae|o__Nostocales|f__Nostocaceae|g__Trichormus|s__Trichormus variabilis,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Morganellaceae|g__Xenorhabdus|s__Xenorhabdus nematophila,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Leuconostoc|s__Leuconostoc gasicomitatum",2|1117|3028117|1161|1162|1163;2|1090|191410|191411|191412|1091|337090;2|1224|28216|32003|90627|96;2|1224|28216|32003|90627|96|370405;2|1239|909932;2|1224|28216|32003|206379|914|42353;2|1224|28216|32003|206379|35798;2|1224|28216|32003|206379|35798|1231;2|1239|909932|909929;2157|28890|183968|2258|2259|2263|187878;2|1117|3028117|1161|1162|264688|264691;2|1239|909932|1843489|31977;2|1224|1236|91347|1903414|626|628;2|1239|91061|186826|33958|1243|115778,Complete,Shaimaa Elsafoury
bsdb:41/2/1,Study 41,case-control,28442250,10.1016/j.schres.2017.04.017,NA,"Schwarz E, Maukonen J, Hyytiäinen T, Kieseppä T, Orešič M, Sabunciyan S, Mantere O, Saarela M, Yolken R , Suvisaari J",Analysis of microbiota in first episode psychosis identifies preliminary associations with symptom severity and treatment response,Schizophrenia research,2018,"Microbiome, Psychosis, Response, Schizophrenia",Experiment 2,Finland,Homo sapiens,Feces,UBERON:0001988,Psychosis,EFO:0005407,Controls,FIrst episode Psychosis (physically active),NA,16,15,3 months,16S,NA,Illumina,LEfSe,0.05,FALSE,2,"age,region of residence,sex",NA,NA,NA,NA,NA,NA,NA,Signature 1,Supplemental Table 1+results (text),10 January 2021,Fatima Zohra,WikiWorks,Taxonomic differences of fecal microbiota between physically active psychosis patients and healthy controls,increased,"k__Archaea|p__Thermoproteota|c__Thermoprotei|o__Thermoproteales|f__Thermoproteaceae,k__Archaea|p__Thermoproteota|c__Thermoprotei|o__Thermoproteales,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae",2157|28889|183924|2266|2267;2157|28889|183924|2266;2|1239|91061|186826|33958,Complete,NA
bsdb:41/2/2,Study 41,case-control,28442250,10.1016/j.schres.2017.04.017,NA,"Schwarz E, Maukonen J, Hyytiäinen T, Kieseppä T, Orešič M, Sabunciyan S, Mantere O, Saarela M, Yolken R , Suvisaari J",Analysis of microbiota in first episode psychosis identifies preliminary associations with symptom severity and treatment response,Schizophrenia research,2018,"Microbiome, Psychosis, Response, Schizophrenia",Experiment 2,Finland,Homo sapiens,Feces,UBERON:0001988,Psychosis,EFO:0005407,Controls,FIrst episode Psychosis (physically active),NA,16,15,3 months,16S,NA,Illumina,LEfSe,0.05,FALSE,2,"age,region of residence,sex",NA,NA,NA,NA,NA,NA,NA,Signature 2,Supplemental Table 1+results (text),10 January 2021,Fatima Zohra,WikiWorks,Taxonomic differences of fecal microbiota between physically active psychosis patients and healthy controls,decreased,"k__Bacteria|p__Bacillota|c__Negativicutes,k__Bacteria|p__Bacillota|c__Negativicutes|o__Selenomonadales,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae",2|1239|909932;2|1239|909932|909929;2|1239|909932|1843489|31977,Complete,NA
bsdb:42/1/1,Study 42,case-control,30483228,10.3389/fmicb.2018.02682,NA,"Guo C, Li Y, Wang P, Li Y, Qiu C, Li M, Wang D, Zhao R, Li D, Wang Y, Li S, Dai W , Zhang L",Alterations of Gut Microbiota in Cholestatic Infants and Their Correlation With Hepatic Function,Frontiers in microbiology,2018,"16S rRNA, bacterial biomarkers, co-abundance network, hepatic function, infantile cholestasis",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Extrahepatic cholestasis,EFO:1000933,healthy infants,cholestasis infants,NA,37,43,4 weeks,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,decreased,NA,NA,NA,NA,Signature 1,Figure 2+ text,10 January 2021,Christina Brown,WikiWorks,Differentially abundundant gut microbiota in cholestatic infants vs healthy infants,increased,"k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Enterococcaceae|g__Enterococcus,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Staphylococcaceae|g__Staphylococcus,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Megasphaera,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Hyphomicrobiales|f__Phyllobacteriaceae|g__Phyllobacterium,k__Bacteria|p__Bacillota|c__Negativicutes|o__Selenomonadales|f__Selenomonadaceae|g__Megamonas",2|1239|91061|186826|1300|1301;2|1239|91061|186826|81852|1350;2|1239|91061|1385|90964|1279;2|1239|909932|1843489|31977|906;2|1224|28211|356|69277|28100;2|1239|909932|909929|1843491|158846,Complete,Shaimaa Elsafoury
bsdb:42/1/2,Study 42,case-control,30483228,10.3389/fmicb.2018.02682,NA,"Guo C, Li Y, Wang P, Li Y, Qiu C, Li M, Wang D, Zhao R, Li D, Wang Y, Li S, Dai W , Zhang L",Alterations of Gut Microbiota in Cholestatic Infants and Their Correlation With Hepatic Function,Frontiers in microbiology,2018,"16S rRNA, bacterial biomarkers, co-abundance network, hepatic function, infantile cholestasis",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Extrahepatic cholestasis,EFO:1000933,healthy infants,cholestasis infants,NA,37,43,4 weeks,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,decreased,NA,NA,NA,NA,Signature 2,Figure 2 + text,10 January 2021,Christina Brown,WikiWorks,Differentially abundundant gut microbiota in cholestatic infants vs healthy infants,decreased,"k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Blautia,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Faecalibacterium,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Roseburia,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Anaerostipes,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales|f__Coriobacteriaceae|g__Collinsella",2|201174|1760|85004|31953|1678;2|976|200643|171549|815|816;2|1239|186801|3085636|186803|572511;2|1239|186801|186802|216572|216851;2|1239|186801|3085636|186803|841;2|1239|186801|3085636|186803|207244;2|201174|84998|84999|84107|102106,Complete,Shaimaa Elsafoury
bsdb:43/1/1,Study 43,case-control,27283393,10.1016/j.clim.2016.06.002,NA,"Coit P, Mumcu G, Ture-Ozdemir F, Unal AU, Alpar U, Bostanci N, Ergun T, Direskeneli H , Sawalha AH",Sequencing of 16S rRNA reveals a distinct salivary microbiome signature in Behçet's disease,"Clinical immunology (Orlando, Fla.)",2016,"16s rRNA, Behçet's disease, Genetics, Microbiome, Oral microbial diversity, Sequencing",Experiment 1,Turkey,Homo sapiens,Saliva,UBERON:0001836,Behcet's syndrome,EFO:0003780,controls,behcet's disease,Patients with Behcet's disease,15,31,6 months,16S,4,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,decreased,NA,Signature 1,Table 4,10 January 2021,Rimsha Azhar,"WikiWorks,ChiomaBlessing",Differential abundant taxa in patients with Behcet's disease VS controls,increased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Alloprevotella,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Haemophilus|s__Haemophilus parainfluenzae",2|976|200643|171549|171552|1283313;2|1224|1236|135625|712|724|729,Complete,Shaimaa Elsafoury
bsdb:43/1/2,Study 43,case-control,27283393,10.1016/j.clim.2016.06.002,NA,"Coit P, Mumcu G, Ture-Ozdemir F, Unal AU, Alpar U, Bostanci N, Ergun T, Direskeneli H , Sawalha AH",Sequencing of 16S rRNA reveals a distinct salivary microbiome signature in Behçet's disease,"Clinical immunology (Orlando, Fla.)",2016,"16s rRNA, Behçet's disease, Genetics, Microbiome, Oral microbial diversity, Sequencing",Experiment 1,Turkey,Homo sapiens,Saliva,UBERON:0001836,Behcet's syndrome,EFO:0003780,controls,behcet's disease,Patients with Behcet's disease,15,31,6 months,16S,4,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,decreased,NA,Signature 2,Table 4,10 January 2021,Rimsha Azhar,"WikiWorks,ChiomaBlessing",Differential abundant taxa in patients with Behcet's disease VS controls,decreased,"k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales|f__Actinomycetaceae|g__Actinomyces|s__Actinomyces graevenitzii,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Alloprevotella|s__Alloprevotella rava,k__Bacteria|p__Bacteroidota,k__Bacteria|p__Campylobacterota|c__Epsilonproteobacteria|o__Campylobacterales|f__Campylobacteraceae|g__Campylobacter|s__Campylobacter concisus,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Hoylesella|s__Hoylesella enoeca,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Lachnoanaerobaculum|s__Lachnoanaerobaculum orale,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales|f__Atopobiaceae|g__Lancefieldella|s__Lancefieldella parvula,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Leptotrichiaceae|g__Leptotrichia|s__Leptotrichia sp.,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella|s__Prevotella pallens,k__Bacteria|p__Bacillota|c__Negativicutes|o__Selenomonadales|f__Selenomonadaceae|g__Selenomonas|s__Selenomonas sp.,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae|g__Solobacterium|s__Solobacterium moorei,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Veillonella|s__Veillonella sp.",2|201174|1760|2037|2049|1654|55565;2|976|200643|171549|171552|1283313|671218;2|976;2|29547|3031852|213849|72294|194|199;2|1239|186801|186802;2|976|200643|171549|171552|2974257|76123;2|1239|186801|3085636|186803|1164882|979627;2|1239|186801|3085636|186803;2|201174|84998|84999|1643824|2767353|1382;2|32066|203490|203491|1129771|32067|104608;2|976|200643|171549|171552|838|60133;2|1239|909932|909929|1843491|970|2053611;2|1239|526524|526525|128827|123375|102148;2|1239|909932|1843489|31977|29465|1926307,Complete,Shaimaa Elsafoury
bsdb:43/2/1,Study 43,case-control,27283393,10.1016/j.clim.2016.06.002,NA,"Coit P, Mumcu G, Ture-Ozdemir F, Unal AU, Alpar U, Bostanci N, Ergun T, Direskeneli H , Sawalha AH",Sequencing of 16S rRNA reveals a distinct salivary microbiome signature in Behçet's disease,"Clinical immunology (Orlando, Fla.)",2016,"16s rRNA, Behçet's disease, Genetics, Microbiome, Oral microbial diversity, Sequencing",Experiment 2,Turkey,Homo sapiens,Saliva,UBERON:0001836,Behcet's syndrome,EFO:0003780,non-immunosuppressent users among behcet's patients,immunosuppressant users,NA,19,12,6 months,16S,4,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,text,10 January 2021,Shaimaa Elsafoury,WikiWorks,the association between the use of immunosuppressants in BD patients with gut microbiota,increased,"k__Bacteria|p__Bacteroidota|c__Flavobacteriia|o__Flavobacteriales|f__Weeksellaceae|g__Bergeyella,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae|g__Porphyromonas|s__Porphyromonas catoniae",2|976|117743|200644|2762318|59735;2|976|200643|171549|171552|838;2|976|200643|171549|171551|836|41976,Complete,Shaimaa Elsafoury
bsdb:43/2/2,Study 43,case-control,27283393,10.1016/j.clim.2016.06.002,NA,"Coit P, Mumcu G, Ture-Ozdemir F, Unal AU, Alpar U, Bostanci N, Ergun T, Direskeneli H , Sawalha AH",Sequencing of 16S rRNA reveals a distinct salivary microbiome signature in Behçet's disease,"Clinical immunology (Orlando, Fla.)",2016,"16s rRNA, Behçet's disease, Genetics, Microbiome, Oral microbial diversity, Sequencing",Experiment 2,Turkey,Homo sapiens,Saliva,UBERON:0001836,Behcet's syndrome,EFO:0003780,non-immunosuppressent users among behcet's patients,immunosuppressant users,NA,19,12,6 months,16S,4,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 2,text,10 January 2021,Shaimaa Elsafoury,WikiWorks,the association between the use of immunosuppressants in BD patients with gut microbiota,decreased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Segatella|s__Segatella baroniae,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Oribacterium|s__Oribacterium sp.",2|976|200643|171549|171552|2974251|305719;2|1239|186801|3085636|186803|265975|1969407,Complete,Shaimaa Elsafoury
bsdb:44/1/1,Study 44,case-control,27450202,10.1111/1462-2920.13463,NA,"Riva A, Borgo F, Lassandro C, Verduci E, Morace G, Borghi E , Berry D",Pediatric obesity is associated with an altered gut microbiota and discordant shifts in Firmicutes populations,Environmental microbiology,2017,NA,Experiment 1,Italy,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,controls,pediatric obese,NA,36,42,6 months,16S,NA,Illumina,Linear Regression,0.05,TRUE,NA,NA,"age,sex",NA,unchanged,unchanged,NA,unchanged,unchanged,Signature 1,Table 1 & Supplementary Table 5,10 January 2021,Marianthi Thomatos,WikiWorks,Differential abundance in pediatric obesity  versus normal weight  controls,increased,"k__Bacteria|p__Bacillota,k__Bacteria|p__Bacillota|c__Clostridia,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Faecalibacterium|s__Faecalibacterium prausnitzii",2|1239;2|1239|186801;2|1239|186801|186802;2|1239|186801|186802|541000;2|1239|186801|186802|216572|216851|853,Complete,Shaimaa Elsafoury
bsdb:44/1/2,Study 44,case-control,27450202,10.1111/1462-2920.13463,NA,"Riva A, Borgo F, Lassandro C, Verduci E, Morace G, Borghi E , Berry D",Pediatric obesity is associated with an altered gut microbiota and discordant shifts in Firmicutes populations,Environmental microbiology,2017,NA,Experiment 1,Italy,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,controls,pediatric obese,NA,36,42,6 months,16S,NA,Illumina,Linear Regression,0.05,TRUE,NA,NA,"age,sex",NA,unchanged,unchanged,NA,unchanged,unchanged,Signature 2,Table 1 & Supplementary Table 5,10 January 2021,Marianthi Thomatos,WikiWorks,Differential abundance in pediatric obesity  versus normal weight  controls,decreased,"k__Bacteria|p__Bacteroidota,k__Bacteria|p__Bacteroidota|c__Bacteroidia,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Phocaeicola|s__Phocaeicola vulgatus,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides|s__Bacteroides stercoris",2|976;2|976|200643;2|976|200643|171549;2|976|200643|171549|815;2|976|200643|171549|815|816;2|976|200643|171549|815|909656|821;2|976|200643|171549|815|816|46506,Complete,Shaimaa Elsafoury
bsdb:45/1/1,Study 45,laboratory experiment,30466372,10.1080/1028415X.2018.1537169,NA,"Reichelt AC, Loughman A, Bernard A, Raipuria M, Abbott KN, Dachtler J, Van TTH , Moore RJ","An intermittent hypercaloric diet alters gut microbiota, prefrontal cortical gene expression and social behaviours in rats",Nutritional neuroscience,2018,"Adolescence, Diet, Memory, Microbiota, Obesity, Social interaction",Experiment 1,Australia,Rattus norvegicus,Feces,UBERON:0001988,Obesity,EFO:0001073,control rats,Rats fed  HFHS,NA,8,8,NA,16S,34,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,Signature 1,Figure 3a & 3b,10 January 2021,Marianthi Thomatos,WikiWorks,Relative abundance of rats fed high fat and high surgar diet (HFHS) VS. Controls,increased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Blautia,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium,k__Bacteria|p__Bacillota|c__Negativicutes|o__Acidaminococcales|f__Acidaminococcaceae|g__Phascolarctobacterium,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae|g__Allobaculum",2|1239|186801|3085636|186803|572511;2|201174|1760|85004|31953|1678;2|1239|909932|1843488|909930|33024;2|1239|526524|526525|128827|174708,Complete,Shaimaa Elsafoury
bsdb:46/1/1,Study 46,case-control,27007700,10.1089/chi.2015.0194,NA,"Borgo F, Verduci E, Riva A, Lassandro C, Riva E, Morace G , Borghi E",Relative Abundance in Bacterial and Fungal Gut Microbes in Obese Children: A Case Control Study,Childhood obesity (Print),2017,NA,Experiment 1,Italy,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,controls,pediatric obese,NA,33,28,previous month,16S,23,RT-qPCR,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,"age,sex",NA,NA,NA,NA,NA,NA,NA,Signature 1,"Text, figure 2",10 January 2021,Marianthi Thomatos,"Fatima,WikiWorks",Relative abundance of bacterial and fungal gut microbes in obese children vs. controls,decreased,"k__Bacteria|p__Verrucomicrobiota|c__Verrucomicrobiia|o__Verrucomicrobiales|f__Akkermansiaceae|g__Akkermansia|s__Akkermansia muciniphila,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Faecalibacterium|s__Faecalibacterium prausnitzii,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Eukaryota|k__Fungi|p__Ascomycota|c__Saccharomycetes|o__Saccharomycetales|f__Saccharomycetaceae|g__Saccharomyces|s__Saccharomyces sp.,k__Eukaryota|k__Fungi|p__Ascomycota|c__Saccharomycetes|o__Saccharomycetales|s__[Candida] sp. (uncertain placement)",2|74201|203494|48461|1647988|239934|239935;2|976|200643|171549|815|816;2|1239|186801|186802|216572|216851|853;2|976|200643|171549|171552|838;2759|4751|4890|4891|4892|4893|4930|4935;2759|4751|4890|4891|4892|1853550,Complete,Fatima
bsdb:46/1/2,Study 46,case-control,27007700,10.1089/chi.2015.0194,NA,"Borgo F, Verduci E, Riva A, Lassandro C, Riva E, Morace G , Borghi E",Relative Abundance in Bacterial and Fungal Gut Microbes in Obese Children: A Case Control Study,Childhood obesity (Print),2017,NA,Experiment 1,Italy,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,controls,pediatric obese,NA,33,28,previous month,16S,23,RT-qPCR,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,"age,sex",NA,NA,NA,NA,NA,NA,NA,Signature 2,"Text, Figure 2",17 October 2023,Uchechukwu,"Uchechukwu,Davvve,MyleeeA",Difference in relative proportions of gut microbial communities in obese versus normal-weight children,decreased,"k__Bacteria|p__Verrucomicrobiota|c__Verrucomicrobiia|o__Verrucomicrobiales|f__Akkermansiaceae|g__Akkermansia|s__Akkermansia muciniphila,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Faecalibacterium|s__Faecalibacterium prausnitzii,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Eukaryota|k__Fungi|p__Ascomycota|c__Saccharomycetes|o__Saccharomycetales|f__Saccharomycetaceae|g__Saccharomyces|s__Saccharomyces sp.,k__Bacteria|p__Candidatus Saccharibacteria|c__Candidatus Saccharimonadia|o__Candidatus Saccharimonadales|f__Candidatus Saccharimonadaceae|g__Candidatus Saccharimonas|s__uncultured Candidatus Saccharimonas sp.,k__Eukaryota|k__Fungi|p__Ascomycota|c__Saccharomycetes|o__Saccharomycetales|s__[Candida] sp. (uncertain placement)",2|74201|203494|48461|1647988|239934|239935;2|1239|186801|186802|216572|216851|853;2|976|200643|171549|171552|838;2759|4751|4890|4891|4892|4893|4930|4935;2|95818|2093818|2093825|2171986|1331051|1983405;2759|4751|4890|4891|4892|1853550,Complete,NA
bsdb:46/2/1,Study 46,case-control,27007700,10.1089/chi.2015.0194,NA,"Borgo F, Verduci E, Riva A, Lassandro C, Riva E, Morace G , Borghi E",Relative Abundance in Bacterial and Fungal Gut Microbes in Obese Children: A Case Control Study,Childhood obesity (Print),2017,NA,Experiment 2,Italy,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,controls,pediatric obese,Obese children,33,28,previous month,16S,23,RT-qPCR,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,"age,sex",NA,NA,NA,NA,NA,NA,decreased,Signature 1,"Text, Figure 2",17 October 2023,Uchechukwu,"Uchechukwu,Davvve",Differences in relative proportions of gut microbial communities in obese versus normal-weight,increased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Agathobacter|s__Agathobacter rectalis,k__Eukaryota|k__Fungi|p__Ascomycota|c__Saccharomycetes|o__Saccharomycetales|f__Debaryomycetaceae|g__Candida|s__Candida albicans,k__Eukaryota|k__Fungi|p__Ascomycota|c__Saccharomycetes|o__Saccharomycetales|f__Saccharomycetaceae|g__Saccharomyces|s__Saccharomyces cerevisiae",2|1239|186801|3085636|186803|1766253|39491;2759|4751|4890|4891|4892|766764|5475|5476;2759|4751|4890|4891|4892|4893|4930|4932,Complete,NA
bsdb:47/1/1,Study 47,"cross-sectional observational, not case-control",30541450,10.1186/s12866-018-1362-x,NA,"Whisner CM, Maldonado J, Dente B, Krajmalnik-Brown R , Bruening M","Diet, physical activity and screen time but not body mass index are associated with the gut microbiome of a diverse cohort of college students living in university housing: a cross-sectional study",BMC microbiology,2018,"Adolescence, Diet, Lifestyle behaviors, Microbiome, Microbiota, Obesity, Pediatric, Physical activity",Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,high dietary fiber,low,BMI ≥ 30.0 kg/m2 was considered obese,68,68,2-3 months,16S,4,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,NA,unchanged,NA,NA,unchanged,Signature 1,Text and figure 4,10 January 2021,Marianthi Thomatos,WikiWorks,Relative abundance of fiber intake in a cohort of diverse cohort of first year college students living in university housing,increased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Barnesiellaceae,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Ruminococcus",2|976|200643|171549|2005519;2|1224|28211;2|1239|186801|186802|216572|1263,Complete,Shaimaa Elsafoury
bsdb:47/1/2,Study 47,"cross-sectional observational, not case-control",30541450,10.1186/s12866-018-1362-x,NA,"Whisner CM, Maldonado J, Dente B, Krajmalnik-Brown R , Bruening M","Diet, physical activity and screen time but not body mass index are associated with the gut microbiome of a diverse cohort of college students living in university housing: a cross-sectional study",BMC microbiology,2018,"Adolescence, Diet, Lifestyle behaviors, Microbiome, Microbiota, Obesity, Pediatric, Physical activity",Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,high dietary fiber,low,BMI ≥ 30.0 kg/m2 was considered obese,68,68,2-3 months,16S,4,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,NA,unchanged,NA,NA,unchanged,Signature 2,Text and figure 4,10 January 2021,Marianthi Thomatos,WikiWorks,Relative abundance of fiber intake in a cohort of diverse cohort of first year college students living in university housing,decreased,k__Bacteria|p__Mycoplasmatota,2|544448,Complete,Shaimaa Elsafoury
bsdb:47/2/1,Study 47,"cross-sectional observational, not case-control",30541450,10.1186/s12866-018-1362-x,NA,"Whisner CM, Maldonado J, Dente B, Krajmalnik-Brown R , Bruening M","Diet, physical activity and screen time but not body mass index are associated with the gut microbiome of a diverse cohort of college students living in university housing: a cross-sectional study",BMC microbiology,2018,"Adolescence, Diet, Lifestyle behaviors, Microbiome, Microbiota, Obesity, Pediatric, Physical activity",Experiment 2,United States of America,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,hight moderate to vigrous physical activity,low,BMI ≥ 30.0 kg/m2 was considered obese,68,68,2-3 months,16S,4,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Text and figure 4,10 January 2021,Shaimaa Elsafoury,WikiWorks,Relative abundance of fiber intake in a cohort of diverse cohort of first year college students living in university housing,increased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales",2|1224|1236|91347|543;2|1224|1236|91347,Complete,Shaimaa Elsafoury
bsdb:47/2/2,Study 47,"cross-sectional observational, not case-control",30541450,10.1186/s12866-018-1362-x,NA,"Whisner CM, Maldonado J, Dente B, Krajmalnik-Brown R , Bruening M","Diet, physical activity and screen time but not body mass index are associated with the gut microbiome of a diverse cohort of college students living in university housing: a cross-sectional study",BMC microbiology,2018,"Adolescence, Diet, Lifestyle behaviors, Microbiome, Microbiota, Obesity, Pediatric, Physical activity",Experiment 2,United States of America,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,hight moderate to vigrous physical activity,low,BMI ≥ 30.0 kg/m2 was considered obese,68,68,2-3 months,16S,4,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 2,Text and figure 4,10 January 2021,Shaimaa Elsafoury,"Merit,WikiWorks,Lwaldron,Iram jamshed,Folakunmi",Relative abundance of fiber intake in a cohort of diverse cohort of first year college students living in university housing,decreased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Dorea,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Lachnospira,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Paraprevotella",2|1239|186801|3085636|186803|189330;2|1239|186801|3085636|186803|28050;2|1239|186801|3085636|186803;2|976|200643|171549|171552|577309,Complete,Shaimaa Elsafoury
bsdb:48/1/1,Study 48,case-control,26230509,10.1371/journal.pone.0134333,NA,"Hu HJ, Park SG, Jang HB, Choi MK, Choi MG, Park KH, Kang JH, Park SI, Lee HJ , Cho SH",Obesity Alters the Microbial Community Profile in Korean Adolescents,PloS one,2015,NA,Experiment 1,South Korea,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,control adolescent,obese adolescent,"body mass index BMI >= 30 kg/m2, or >= 99th BMI percentile",67,67,1 month,16S,123,Roche454,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,"age,sex",NA,unchanged,NA,NA,NA,unchanged,Signature 1,Table 2 and Table 3,10 January 2021,Marianthi Thomatos,WikiWorks,Relative microbial abundance in obese Korean adolescents (13-16 year old),increased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Sutterellaceae,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella",2|976|200643|171549|171552;2|1224|28216|80840|995019;2|1239|909932|1843489|31977;2|976|200643|171549|171552|838,Complete,Shaimaa Elsafoury
bsdb:48/1/2,Study 48,case-control,26230509,10.1371/journal.pone.0134333,NA,"Hu HJ, Park SG, Jang HB, Choi MK, Choi MG, Park KH, Kang JH, Park SI, Lee HJ , Cho SH",Obesity Alters the Microbial Community Profile in Korean Adolescents,PloS one,2015,NA,Experiment 1,South Korea,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,control adolescent,obese adolescent,"body mass index BMI >= 30 kg/m2, or >= 99th BMI percentile",67,67,1 month,16S,123,Roche454,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,"age,sex",NA,unchanged,NA,NA,NA,unchanged,Signature 2,Table 2 and Table 3,10 January 2021,Marianthi Thomatos,WikiWorks,Relative microbial abundance in obese Korean adolescents (13-16 year old),decreased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Rikenellaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Rikenellaceae|g__Alistipes,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Faecalibacterium,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Oscillibacter",2|976|200643|171549|815;2|976|200643|171549|171550;2|1239|186801|186802|541000;2|976|200643|171549|815|816;2|976|200643|171549|171550|239759;2|1239|186801|186802|216572|216851;2|1239|186801|186802|216572|459786,Complete,Shaimaa Elsafoury
bsdb:48/2/1,Study 48,case-control,26230509,10.1371/journal.pone.0134333,NA,"Hu HJ, Park SG, Jang HB, Choi MK, Choi MG, Park KH, Kang JH, Park SI, Lee HJ , Cho SH",Obesity Alters the Microbial Community Profile in Korean Adolescents,PloS one,2015,NA,Experiment 2,South Korea,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,low BMI zscores,high BMI zscore,"body mass index BMI >= 30 kg/m2, or >= 99th BMI percentile",67,67,1 month,16S,123,Roche454,Spearman Correlation,0.05,FALSE,NA,NA,"age,sex",NA,NA,NA,NA,NA,NA,Signature 1,Table 4,10 January 2021,Marianthi Thomatos,WikiWorks,Relative microbial abundance in obese Korean adolescents (13-16 year old),increased,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,2|976|200643|171549|171552|838,Complete,Shaimaa Elsafoury
bsdb:48/2/2,Study 48,case-control,26230509,10.1371/journal.pone.0134333,NA,"Hu HJ, Park SG, Jang HB, Choi MK, Choi MG, Park KH, Kang JH, Park SI, Lee HJ , Cho SH",Obesity Alters the Microbial Community Profile in Korean Adolescents,PloS one,2015,NA,Experiment 2,South Korea,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,low BMI zscores,high BMI zscore,"body mass index BMI >= 30 kg/m2, or >= 99th BMI percentile",67,67,1 month,16S,123,Roche454,Spearman Correlation,0.05,FALSE,NA,NA,"age,sex",NA,NA,NA,NA,NA,NA,Signature 2,Table 4,10 January 2021,Marianthi Thomatos,WikiWorks,Relative microbial abundance in obese Korean adolescents (13-16 year old),decreased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Rikenellaceae|g__Alistipes",2|976|200643|171549|815|816;2|976|200643|171549|171550|239759,Complete,Shaimaa Elsafoury
bsdb:48/3/1,Study 48,case-control,26230509,10.1371/journal.pone.0134333,NA,"Hu HJ, Park SG, Jang HB, Choi MK, Choi MG, Park KH, Kang JH, Park SI, Lee HJ , Cho SH",Obesity Alters the Microbial Community Profile in Korean Adolescents,PloS one,2015,NA,Experiment 3,South Korea,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,low triglycerides,high triglycerides,"body mass index BMI >= 30 kg/m2, or >= 99th BMI percentile",67,67,1 month,16S,123,Roche454,Spearman Correlation,0.05,FALSE,NA,NA,"age,sex",NA,NA,NA,NA,NA,NA,Signature 1,Table 4,10 January 2021,Shaimaa Elsafoury,WikiWorks,Relative microbial abundance in obese Korean adolescents (13-16 year old),increased,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,2|976|200643|171549|171552|838,Complete,Shaimaa Elsafoury
bsdb:48/3/2,Study 48,case-control,26230509,10.1371/journal.pone.0134333,NA,"Hu HJ, Park SG, Jang HB, Choi MK, Choi MG, Park KH, Kang JH, Park SI, Lee HJ , Cho SH",Obesity Alters the Microbial Community Profile in Korean Adolescents,PloS one,2015,NA,Experiment 3,South Korea,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,low triglycerides,high triglycerides,"body mass index BMI >= 30 kg/m2, or >= 99th BMI percentile",67,67,1 month,16S,123,Roche454,Spearman Correlation,0.05,FALSE,NA,NA,"age,sex",NA,NA,NA,NA,NA,NA,Signature 2,Table 4,10 January 2021,Shaimaa Elsafoury,WikiWorks,Relative microbial abundance in obese Korean adolescents (13-16 year old),decreased,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides,2|976|200643|171549|815|816,Complete,Shaimaa Elsafoury
bsdb:48/4/1,Study 48,case-control,26230509,10.1371/journal.pone.0134333,NA,"Hu HJ, Park SG, Jang HB, Choi MK, Choi MG, Park KH, Kang JH, Park SI, Lee HJ , Cho SH",Obesity Alters the Microbial Community Profile in Korean Adolescents,PloS one,2015,NA,Experiment 4,South Korea,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,low total cholesterol,high total cholesterol,"body mass index BMI >= 30 kg/m2, or >= 99th BMI percentile",67,67,1 month,16S,123,Roche454,Spearman Correlation,0.05,FALSE,NA,NA,"age,sex",NA,NA,NA,NA,NA,NA,Signature 1,Table 4,10 January 2021,Shaimaa Elsafoury,WikiWorks,Relative microbial abundance in obese Korean adolescents (13-16 year old),decreased,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides,2|976|200643|171549|815|816,Complete,Shaimaa Elsafoury
bsdb:48/5/1,Study 48,case-control,26230509,10.1371/journal.pone.0134333,NA,"Hu HJ, Park SG, Jang HB, Choi MK, Choi MG, Park KH, Kang JH, Park SI, Lee HJ , Cho SH",Obesity Alters the Microbial Community Profile in Korean Adolescents,PloS one,2015,NA,Experiment 5,South Korea,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,low HDL-C,high HDL-C,"body mass index BMI >= 30 kg/m2, or >= 99th BMI percentile",67,67,1 month,16S,123,Roche454,Spearman Correlation,0.05,FALSE,NA,NA,"age,sex",NA,NA,NA,NA,NA,NA,Signature 1,Table 4,10 January 2021,Shaimaa Elsafoury,WikiWorks,Relative microbial abundance in obese Korean adolescents (13-16 year old),increased,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides,2|976|200643|171549|815|816,Complete,Shaimaa Elsafoury
bsdb:48/6/1,Study 48,case-control,26230509,10.1371/journal.pone.0134333,NA,"Hu HJ, Park SG, Jang HB, Choi MK, Choi MG, Park KH, Kang JH, Park SI, Lee HJ , Cho SH",Obesity Alters the Microbial Community Profile in Korean Adolescents,PloS one,2015,NA,Experiment 6,South Korea,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,low sensetive C reactive protein,high senstive C reactive protein,"body mass index BMI >= 30 kg/m2, or >= 99th BMI percentile",67,67,1 month,16S,123,Roche454,Spearman Correlation,0.05,FALSE,NA,NA,"age,sex",NA,NA,NA,NA,NA,NA,Signature 1,Table 4,10 January 2021,Shaimaa Elsafoury,WikiWorks,Relative microbial abundance in obese Korean adolescents (13-16 year old),increased,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,2|976|200643|171549|171552|838,Complete,Shaimaa Elsafoury
bsdb:48/6/2,Study 48,case-control,26230509,10.1371/journal.pone.0134333,NA,"Hu HJ, Park SG, Jang HB, Choi MK, Choi MG, Park KH, Kang JH, Park SI, Lee HJ , Cho SH",Obesity Alters the Microbial Community Profile in Korean Adolescents,PloS one,2015,NA,Experiment 6,South Korea,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,low sensetive C reactive protein,high senstive C reactive protein,"body mass index BMI >= 30 kg/m2, or >= 99th BMI percentile",67,67,1 month,16S,123,Roche454,Spearman Correlation,0.05,FALSE,NA,NA,"age,sex",NA,NA,NA,NA,NA,NA,Signature 2,Table 4,10 January 2021,Shaimaa Elsafoury,WikiWorks,Relative microbial abundance in obese Korean adolescents (13-16 year old),decreased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Oscillibacter",2|976|200643|171549|815|816;2|1239|186801|186802|216572|459786,Complete,Shaimaa Elsafoury
bsdb:49/1/1,Study 49,case-control,29576948,10.7717/peerj.4458,NA,"Wu Y, Chi X, Zhang Q, Chen F , Deng X",Characterization of the salivary microbiome in people with obesity,PeerJ,2018,"Body-Mass Index, High-throughput nucleotide sequencing, Microbiome, Obesity, Oral microbiome",Experiment 1,China,Homo sapiens,Saliva,UBERON:0001836,Obesity,EFO:0001073,controls,Obesity group,obesity group (BMI ≥30),29,33,3 months,16S,34,Illumina,Kruskall-Wallis,0.05,TRUE,NA,NA,NA,NA,decreased,decreased,NA,NA,decreased,Signature 1,Figure 2,10 January 2021,Rimsha Azhar,"Lwaldron,WikiWorks",Differentially abundant taxa between people with obesity and normal weight control,increased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales,k__Bacteria|p__Bacteroidota|c__Bacteroidia,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Cardiobacteriales|f__Cardiobacteriaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Carnobacteriaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Catonella,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Comamonadaceae,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales,k__Bacteria|p__Bacillota|c__Erysipelotrichia,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Carnobacteriaceae|g__Granulicatella,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Anaerovoracaceae|g__Mogibacterium,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Peptococcaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Peptostreptococcaceae|g__Peptostreptococcus,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae|g__Solobacterium,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Hyphomicrobiales|f__Xanthobacteraceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Peptostreptococcaceae",2|976|200643|171549;2|976|200643;2|1224|1236|135615|868;2|1239|91061|186826|186828;2|1239|186801|3085636|186803|43996;2|1224|28216|80840|80864;2|1239|526524|526525|128827;2|1239|526524|526525;2|1239|526524;2|1239|91061|186826|186828|117563;2|1239|186801|3082720|3030910|86331;2|1239|186801|186802|186807;2|1239|186801|3082720|186804|1257;2|976|200643|171549|171552|838;2|976|200643|171549|171552;2|1239|526524|526525|128827|123375;2|1224|28211|356|335928;2|1239|186801|3082720|186804,Complete,Shaimaa Elsafoury
bsdb:49/1/2,Study 49,case-control,29576948,10.7717/peerj.4458,NA,"Wu Y, Chi X, Zhang Q, Chen F , Deng X",Characterization of the salivary microbiome in people with obesity,PeerJ,2018,"Body-Mass Index, High-throughput nucleotide sequencing, Microbiome, Obesity, Oral microbiome",Experiment 1,China,Homo sapiens,Saliva,UBERON:0001836,Obesity,EFO:0001073,controls,Obesity group,obesity group (BMI ≥30),29,33,3 months,16S,34,Illumina,Kruskall-Wallis,0.05,TRUE,NA,NA,NA,NA,decreased,decreased,NA,NA,decreased,Signature 2,Figure 2,10 January 2021,Rimsha Azhar,WikiWorks,Differentially abundant taxa between people with obesity and normal weight control,decreased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria,k__Bacteria|p__Bacteroidota|c__Flavobacteriia,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales,k__Bacteria|p__Bacteroidota|c__Flavobacteriia|o__Flavobacteriales,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Mycobacteriales,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Cardiobacteriales,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Lysobacterales,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Burkholderiaceae,k__Bacteria|p__Bacteroidota|c__Flavobacteriia|o__Flavobacteriales|f__Flavobacteriaceae,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Mycobacteriales|f__Corynebacteriaceae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Haemophilus,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Cardiobacteriales|f__Cardiobacteriaceae|g__Cardiobacterium,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Staphylococcaceae,k__Bacteria|p__Bacteroidota|c__Flavobacteriia|o__Flavobacteriales|f__Flavobacteriaceae|g__Capnocytophaga,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Burkholderiaceae|g__Lautropia,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Mycobacteriales|f__Corynebacteriaceae|g__Corynebacterium,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Staphylococcaceae|g__Staphylococcus,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Lysobacterales|f__Lysobacteraceae|g__Stenotrophomonas",2|1224|1236;2|976|117743;2|1224|1236|135625;2|1224|28216|80840;2|976|117743|200644;2|201174|1760|85007;2|1224|1236|135615;2|1224|1236|135614;2|1224|1236|135625|712;2|1224|28216|80840|119060;2|976|117743|200644|49546;2|201174|1760|85007|1653;2|1224|1236|135625|712|724;2|1224|1236|135615|868|2717;2|1239|91061|1385|90964;2|976|117743|200644|49546|1016;2|1224|28216|80840|119060|47670;2|201174|1760|85007|1653|1716;2|1239|91061|1385|90964|1279;2|1224|1236|135614|32033|40323,Complete,Shaimaa Elsafoury
bsdb:50/1/1,Study 50,case-control,21850056,10.1038/ismej.2011.109,NA,"Wang T, Cai G, Qiu Y, Fei N, Zhang M, Pang X, Jia W, Cai S , Zhao L",Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers,The ISME journal,2012,NA,Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,healthy controls,Colrectal cancer patients,All patients were categorized according to histopathological features by TNM classification of malignant tumors after surgery,56,46,3 months,16S,3,Roche454,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,unchanged,NA,unchanged,NA,NA,Signature 1,table 2,10 January 2021,Shaimaa Elsafoury,WikiWorks,List of genera that were significantly different between Healthy controls and Colorectal cancer patients,increased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae|g__Porphyromonas,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Escherichia,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Shigella,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Enterococcaceae|g__Enterococcus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Peptostreptococcaceae|g__Peptostreptococcus",2|976|200643|171549|171551|836;2|1224|1236|91347|543|561;2|1224|1236|91347|543|620;2|1239|91061|186826|81852|1350;2|1239|91061|186826|1300|1301;2|1239|186801|3082720|186804|1257,Complete,Shaimaa Elsafoury
bsdb:50/1/2,Study 50,case-control,21850056,10.1038/ismej.2011.109,NA,"Wang T, Cai G, Qiu Y, Fei N, Zhang M, Pang X, Jia W, Cai S , Zhao L",Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers,The ISME journal,2012,NA,Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,healthy controls,Colrectal cancer patients,All patients were categorized according to histopathological features by TNM classification of malignant tumors after surgery,56,46,3 months,16S,3,Roche454,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,unchanged,NA,unchanged,NA,NA,Signature 2,table 2,10 January 2021,Shaimaa Elsafoury,WikiWorks,List of genera that were significantly different between Healthy controls and Colorectal cancer patients,decreased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Roseburia,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Rikenellaceae|g__Alistipes,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Eubacteriaceae|g__Eubacterium,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Sutterellaceae|g__Parasutterella",2|976|200643|171549|815|816;2|1239|186801|3085636|186803|841;2|976|200643|171549|171550|239759;2|1239|186801|186802|186806|1730;2|1224|28216|80840|995019|577310,Complete,Shaimaa Elsafoury
bsdb:51/1/1,Study 51,case-control,30548192,10.1111/1462-2920.14498,NA,"Jin Y, Liu Y, Zhao L, Zhao F, Feng J, Li S, Chen H, Sun J, Zhu B, Geng R , Wei Y",Gut microbiota in patients after surgical treatment for colorectal cancer,Environmental microbiology,2019,NA,Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,postoperation patients,Carcinoma patients,The adenoma and carcinoma patients were diagnosed by colonoscopic examination and histopathological review of biopsies. Postoperative patients were classified as having NDA or CIT by follow-up surveillance colonoscopy and biopsies,47,15,3 months,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.1,TRUE,NA,"age,body mass index,sex",NA,NA,NA,NA,NA,NA,unchanged,Signature 1,Supplemental Figure 5 and Table S2,10 January 2021,Rimsha Azhar,WikiWorks,The relative abundance of genus in carcinoma and postoperative patients,increased,"k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Bacillota|c__Tissierellia|o__Tissierellales|f__Peptoniphilaceae|g__Finegoldia,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Burkholderiaceae|g__Ralstonia,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales|f__Atopobiaceae|g__Atopobium,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|g__Howardella,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Alloprevotella,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Mycobacteriales|f__Corynebacteriaceae|g__Corynebacterium,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Coprobacillaceae|g__Catenibacterium,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae|g__Holdemanella,k__Bacteria|p__Bacillota|c__Tissierellia|o__Tissierellales|f__Peptoniphilaceae|g__Parvimonas,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pseudomonadales|f__Pseudomonadaceae|g__Pseudomonas,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Gemellaceae|g__Gemella,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Peptostreptococcaceae|g__Peptostreptococcus,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae|g__Porphyromonas,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Weissella,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Carnobacteriaceae|g__Granulicatella,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales|f__Actinomycetaceae|g__Actinomyces",2|1239|91061|186826|33958|1578;2|976|200643|171549|171552|838;2|1239|1737404|1737405|1570339|150022;2|1224|28216|80840|119060|48736;2|201174|84998|84999|1643824|1380;2|1239|186801|186802|404402;2|976|200643|171549|171552|1283313;2|201174|1760|85007|1653|1716;2|1239|526524|526525|2810280|135858;2|1239|526524|526525|128827|1573535;2|1239|1737404|1737405|1570339|543311;2|1224|1236|72274|135621|286;2|1239|91061|1385|539738|1378;2|1239|186801|3082720|186804|1257;2|976|200643|171549|171551|836;2|1239|91061|186826|33958|46255;2|1239|91061|186826|186828|117563;2|201174|1760|2037|2049|1654,Complete,Shaimaa Elsafoury
bsdb:51/1/2,Study 51,case-control,30548192,10.1111/1462-2920.14498,NA,"Jin Y, Liu Y, Zhao L, Zhao F, Feng J, Li S, Chen H, Sun J, Zhu B, Geng R , Wei Y",Gut microbiota in patients after surgical treatment for colorectal cancer,Environmental microbiology,2019,NA,Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,postoperation patients,Carcinoma patients,The adenoma and carcinoma patients were diagnosed by colonoscopic examination and histopathological review of biopsies. Postoperative patients were classified as having NDA or CIT by follow-up surveillance colonoscopy and biopsies,47,15,3 months,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.1,TRUE,NA,"age,body mass index,sex",NA,NA,NA,NA,NA,NA,unchanged,Signature 2,Supplemental Figure 5 and Table S2,10 January 2021,Rimsha Azhar,WikiWorks,The relative abundance of genus in carcinoma and postoperative patients,decreased,"k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Leptotrichiaceae|g__Leptotrichia,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Parascardovia,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micrococcales|f__Microbacteriaceae|g__Microbacterium,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Mycobacteriales|f__Lawsonellaceae|g__Lawsonella,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae|g__Faecalitalea,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Sutterellaceae|g__Sutterella,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Lachnospira,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Tyzzerella,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Klebsiella,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Mediterraneibacter|s__Mediterraneibacter gnavus",2|32066|203490|203491|1129771|32067;2|201174|1760|85004|31953|196082;2|201174|1760|85004|31953|1678;2|201174|1760|85006|85023|33882;2|201174|1760|85007|2805586|1847725;2|1239|526524|526525|128827|1573534;2|1224|28216|80840|995019|40544;2|1239|186801|3085636|186803|28050;2|1239|186801|3085636|186803|1506577;2|1224|1236|91347|543|570;2|1239|186801|3085636|186803|2316020|33038,Complete,Shaimaa Elsafoury
bsdb:51/2/1,Study 51,case-control,30548192,10.1111/1462-2920.14498,NA,"Jin Y, Liu Y, Zhao L, Zhao F, Feng J, Li S, Chen H, Sun J, Zhu B, Geng R , Wei Y",Gut microbiota in patients after surgical treatment for colorectal cancer,Environmental microbiology,2019,NA,Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,CIT(cleain intestine),NDA(new dev. adenoma),The adenoma and carcinoma patients were diagnosed by colonoscopic examination and histopathological review of biopsies. Postoperative patients were classified as having NDA or CIT by follow-up surveillance colonoscopy and biopsies,26,21,3 months,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,2.5,"age,body mass index,sex",NA,NA,NA,NA,NA,NA,decreased,Signature 1,Figure 4 and Table B,10 January 2021,Rimsha Azhar,WikiWorks,LEfSe identified differene in abundace between NDA and CIT,increased,"k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Aerococcaceae|g__Abiotrophia,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales|f__Atopobiaceae|g__Atopobium,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Morganellaceae|g__Morganella,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae|g__Solobacterium",2|1239|91061|186826|186827|46123;2|201174|84998|84999|1643824|1380;2|1224|1236|91347|1903414|581;2|976|200643|171549|171552|838;2|1239|526524|526525|128827|123375,Complete,Shaimaa Elsafoury
bsdb:51/2/2,Study 51,case-control,30548192,10.1111/1462-2920.14498,NA,"Jin Y, Liu Y, Zhao L, Zhao F, Feng J, Li S, Chen H, Sun J, Zhu B, Geng R , Wei Y",Gut microbiota in patients after surgical treatment for colorectal cancer,Environmental microbiology,2019,NA,Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,CIT(cleain intestine),NDA(new dev. adenoma),The adenoma and carcinoma patients were diagnosed by colonoscopic examination and histopathological review of biopsies. Postoperative patients were classified as having NDA or CIT by follow-up surveillance colonoscopy and biopsies,26,21,3 months,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,2.5,"age,body mass index,sex",NA,NA,NA,NA,NA,NA,decreased,Signature 2,Figure 4 and Table B,10 January 2021,Rimsha Azhar,WikiWorks,LEfSe identified differene in abundace between NDA and CIT,decreased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Odoribacteraceae|g__Butyricimonas,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Ruminococcus,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Clostridium,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Coprococcus,k__Bacteria|p__Bacillota|c__Tissierellia|o__Tissierellales|f__Peptoniphilaceae|g__Finegoldia,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Eubacteriaceae|g__Eubacterium|s__Eubacterium coprostanoligenes,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Moryella,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Oscillibacter,k__Bacteria|p__Thermodesulfobacteriota|c__Desulfovibrionia|o__Desulfovibrionales|f__Desulfovibrionaceae|g__Desulfovibrio,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Anaerotruncus",2|976|200643|171549|1853231|574697;2|1239|186801|186802|216572|1263;2|1239|186801|186802|31979|1485;2|1239|186801|3085636|186803|33042;2|1239|1737404|1737405|1570339|150022;2|1239|186801|186802|186806|1730|290054;2|1239|186801|3085636|186803|437755;2|1239|186801|186802|216572|459786;2|200940|3031449|213115|194924|872;2|1239|186801|186802|216572|244127,Complete,Shaimaa Elsafoury
bsdb:52/1/1,Study 52,case-control,28620208,10.1038/s41598-017-03706-9,NA,"Xu Y, Xie Z, Wang H, Shen Z, Guo Y, Gao Y, Chen X, Wu Q, Li X , Wang K",Bacterial Diversity of Intestinal Microbiota in Patients with Substance Use Disorders Revealed by 16S rRNA Gene Deep Sequencing,Scientific reports,2017,NA,Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Substance-related disorder,MONDO:0002494,Healthy controls,Substance use disorder patients,NA,45,48,3 months,16S,34,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,NA,unchanged,NA,NA,increased,Signature 1,Figure 4,10 January 2021,Fatima Zohra,WikiWorks,Differential abundance in community compositions between SUD and healthy controls,increased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Rhodobacterales|f__Paracoccaceae,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Rhodocyclales|f__Rhodocyclaceae,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Rhodobacterales|f__Paracoccaceae|g__Paracoccus,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Clostridium,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Rhodocyclales|f__Zoogloeaceae|g__Thauera",2|976|200643|171549|171552;2|1224|28211|204455|31989;2|1224|28216|206389|75787;2|1224|28211;2|976|200643|171549|171552|838;2|1224|28211|204455|31989|265;2|1239|186801|186802|31979|1485;2|1224|28216|206389|2008794|33057,Complete,Shaimaa Elsafoury
bsdb:52/1/2,Study 52,case-control,28620208,10.1038/s41598-017-03706-9,NA,"Xu Y, Xie Z, Wang H, Shen Z, Guo Y, Gao Y, Chen X, Wu Q, Li X , Wang K",Bacterial Diversity of Intestinal Microbiota in Patients with Substance Use Disorders Revealed by 16S rRNA Gene Deep Sequencing,Scientific reports,2017,NA,Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Substance-related disorder,MONDO:0002494,Healthy controls,Substance use disorder patients,NA,45,48,3 months,16S,34,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,NA,unchanged,NA,NA,increased,Signature 2,Figure 4,10 January 2021,Fatima Zohra,WikiWorks,Differential abundance in community compositions between SUD and healthy controls,decreased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Rikenellaceae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae,k__Bacteria|p__Thermodesulfobacteriota|c__Desulfovibrionia|o__Desulfovibrionales|f__Desulfovibrionaceae,k__Bacteria|p__Bacillota|c__Bacilli,k__Bacteria|p__Bacillota|c__Erysipelotrichia,k__Bacteria|c__Deltaproteobacteria,k__Bacteria|p__Thermodesulfobacteriota|c__Desulfovibrionia|o__Desulfovibrionales|f__Desulfovibrionaceae|g__Bilophila,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Dorea,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Tannerellaceae|g__Parabacteroides,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Anaerostipes,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Megasphaera,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Fusicatenibacter,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Rikenellaceae|g__Alistipes,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|g__Gemmiger,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Ruminococcus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae",2|976|200643|171549|815;2|976|200643|171549|171550;2|1224|1236|91347|543;2|1239|526524|526525|128827;2|200940|3031449|213115|194924;2|1239|91061;2|1239|526524;2|28221;2|200940|3031449|213115|194924|35832;2|1239|186801|3085636|186803|189330;2|976|200643|171549|2005525|375288;2|1239|91061|186826|1300|1301;2|1239|186801|3085636|186803|207244;2|1239|909932|1843489|31977|906;2|1239|186801|3085636|186803|1407607;2|976|200643|171549|171550|239759;2|1239|186801|186802|204475;2|976|200643|171549|815|816;2|1239|526524|526525;2|1239|91061|186826;2|1239|186801|186802|216572|1263;2|1239|91061|186826|1300,Complete,Shaimaa Elsafoury
bsdb:52/2/1,Study 52,case-control,28620208,10.1038/s41598-017-03706-9,NA,"Xu Y, Xie Z, Wang H, Shen Z, Guo Y, Gao Y, Chen X, Wu Q, Li X , Wang K",Bacterial Diversity of Intestinal Microbiota in Patients with Substance Use Disorders Revealed by 16S rRNA Gene Deep Sequencing,Scientific reports,2017,NA,Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Substance-related disorder,MONDO:0002494,adjusted Healthy controls,Substance use disorder patients,NA,28,29,3 months,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,age,NA,NA,NA,unchanged,NA,NA,NA,Signature 1,Figure 5B,10 January 2021,Fatima Zohra,WikiWorks,Significantly different microbial composition between SUD and age matched healthy controls,increased,"k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Rhodocyclales|f__Zoogloeaceae|g__Thauera,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Rhodobacterales|f__Paracoccaceae|g__Paracoccus,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella",2|1224|28216|206389|2008794|33057;2|1224|28211|204455|31989|265;2|976|200643|171549|171552|838,Complete,Shaimaa Elsafoury
bsdb:52/2/2,Study 52,case-control,28620208,10.1038/s41598-017-03706-9,NA,"Xu Y, Xie Z, Wang H, Shen Z, Guo Y, Gao Y, Chen X, Wu Q, Li X , Wang K",Bacterial Diversity of Intestinal Microbiota in Patients with Substance Use Disorders Revealed by 16S rRNA Gene Deep Sequencing,Scientific reports,2017,NA,Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Substance-related disorder,MONDO:0002494,adjusted Healthy controls,Substance use disorder patients,NA,28,29,3 months,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,age,NA,NA,NA,unchanged,NA,NA,NA,Signature 2,Figure 5B,10 January 2021,Fatima Zohra,WikiWorks,Significantly different microbial composition between SUD and age matched healthy controls,decreased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Anaerostipes,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Tannerellaceae|g__Parabacteroides,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|g__Gemmiger,k__Bacteria|p__Thermodesulfobacteriota|c__Desulfovibrionia|o__Desulfovibrionales|f__Desulfovibrionaceae|g__Bilophila,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Megasphaera,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Fusicatenibacter",2|1239|186801|3085636|186803|207244;2|976|200643|171549|2005525|375288;2|1239|186801|186802|204475;2|200940|3031449|213115|194924|35832;2|1239|91061|186826|1300|1301;2|1239|909932|1843489|31977|906;2|1239|186801|3085636|186803|1407607,Complete,Shaimaa Elsafoury
bsdb:53/1/1,Study 53,case-control,26683192,10.1371/journal.pone.0145453,NA,"Shukla SK, Cook D, Meyer J, Vernon SD, Le T, Clevidence D, Robertson CE, Schrodi SJ, Yale S , Frank DN",Changes in Gut and Plasma Microbiome following Exercise Challenge in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS),PloS one,2015,NA,Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Chronic fatigue syndrome,EFO:0004540,healthy controls,chronic fatigue syndrome patients,patients met the ME/CFS case definition criteria established by Fukuda et al in 1994,10,10,current use,16S,NA,Roche454,Kolmogorov-Smirnov Test,0.05,FALSE,NA,"age,body mass index,sex",NA,NA,NA,NA,NA,NA,NA,Signature 1,Table 4,10 January 2021,Shaimaa Elsafoury,WikiWorks,Relative Abundance of Bacterial Phyla in Blood and Stool Samples from ME/CFS Patients and Health Controls.,decreased,k__Bacteria|p__Acidobacteriota,2|57723,Complete,Shaimaa Elsafoury
bsdb:54/1/1,Study 54,time series / longitudinal observational,27001291,10.1038/srep23129,NA,"Collado MC, Rautava S, Aakko J, Isolauri E , Salminen S",Human gut colonisation may be initiated in utero by distinct microbial communities in the placenta and amniotic fluid,Scientific reports,2016,NA,Experiment 1,Finland,Homo sapiens,Meconium,UBERON:0007109,Cesarean section,EFO:0009636,placenta,meconium,meconium samples,15,15,prior to or during c-section,16S,123,Roche454,LEfSe,0.05,TRUE,3,NA,NA,NA,increased,decreased,NA,NA,unchanged,Signature 1,Figure 4B,10 January 2021,Rimsha Azhar,"WikiWorks,ChiomaBlessing",Differentially abundant bacteria in meconium sample compared to placenta sample from LEfSe analysis,increased,"k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Bacillaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae",2|1239|91061|1385|186817;2|1239|91061|186826|1300,Complete,Shaimaa Elsafoury
bsdb:54/1/2,Study 54,time series / longitudinal observational,27001291,10.1038/srep23129,NA,"Collado MC, Rautava S, Aakko J, Isolauri E , Salminen S",Human gut colonisation may be initiated in utero by distinct microbial communities in the placenta and amniotic fluid,Scientific reports,2016,NA,Experiment 1,Finland,Homo sapiens,Meconium,UBERON:0007109,Cesarean section,EFO:0009636,placenta,meconium,meconium samples,15,15,prior to or during c-section,16S,123,Roche454,LEfSe,0.05,TRUE,3,NA,NA,NA,increased,decreased,NA,NA,unchanged,Signature 2,Figure 4B,10 January 2021,Rimsha Azhar,"WikiWorks,ChiomaBlessing",Differentially abundant bacteria in meconium sample compared to placenta sample from LEfSe analysis,decreased,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae,2|1224|1236|91347|543,Complete,Shaimaa Elsafoury
bsdb:54/2/1,Study 54,time series / longitudinal observational,27001291,10.1038/srep23129,NA,"Collado MC, Rautava S, Aakko J, Isolauri E , Salminen S",Human gut colonisation may be initiated in utero by distinct microbial communities in the placenta and amniotic fluid,Scientific reports,2016,NA,Experiment 2,Finland,Homo sapiens,Meconium,UBERON:0007109,Cesarean section,EFO:0009636,placenta,colostrum,maternal colostrum samples,15,15,prior to or during c-section,16S,123,Roche454,LEfSe,0.05,TRUE,3,NA,NA,NA,increased,unchanged,NA,NA,unchanged,Signature 1,Figure 4D,10 January 2021,Rimsha Azhar,"Merit,WikiWorks,ChiomaBlessing",Differentially abundant bacteria in colostrum samples compared to placenta samples from LEfSe analysis,increased,"k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Bacillaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae",2|1239|91061|1385|186817;2|1239|91061|186826|1300,Complete,Shaimaa Elsafoury
bsdb:54/2/2,Study 54,time series / longitudinal observational,27001291,10.1038/srep23129,NA,"Collado MC, Rautava S, Aakko J, Isolauri E , Salminen S",Human gut colonisation may be initiated in utero by distinct microbial communities in the placenta and amniotic fluid,Scientific reports,2016,NA,Experiment 2,Finland,Homo sapiens,Meconium,UBERON:0007109,Cesarean section,EFO:0009636,placenta,colostrum,maternal colostrum samples,15,15,prior to or during c-section,16S,123,Roche454,LEfSe,0.05,TRUE,3,NA,NA,NA,increased,unchanged,NA,NA,unchanged,Signature 2,Figure 4D,10 January 2021,Rimsha Azhar,"WikiWorks,ChiomaBlessing",Differentially abundant bacteria in colostrum samples compared to placenta samples from LEfSe analysis,decreased,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae,2|1224|1236|91347|543,Complete,Shaimaa Elsafoury
bsdb:55/1/1,Study 55,laboratory experiment,23056268,10.1371/journal.pone.0046231,NA,"Bangsgaard Bendtsen KM, Krych L, Sørensen DB, Pang W, Nielsen DS, Josefsen K, Hansen LH, Sørensen SJ , Hansen AK",Gut microbiota composition is correlated to grid floor induced stress and behavior in the BALB/c mouse,PloS one,2012,NA,Experiment 1,Denmark,Mus musculus,Caecum,UBERON:0001153,Stimulus or stress design,EFO:0001762,control,grid floor induced stress,cases were exposed to a stress factor which is a grid floor exposure for two weeks. this implies that the use of grid floor is a sufficient stressor for inducing a depression-like behavioral state in the TST.,14,14,NA,16S,4,Roche454,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Table 2,10 January 2021,Fatima Zohra,WikiWorks,Significantly different taxa between control mice and grid floor housed mice,increased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Odoribacteraceae|g__Odoribacter,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Rikenellaceae|g__Alistipes",2|976|200643|171549|1853231|283168;2|976|200643|171549|171550|239759,Complete,Shaimaa Elsafoury
bsdb:56/1/1,Study 56,"cross-sectional observational, not case-control",24223144,10.1371/journal.pone.0078257,NA,"Hu J, Nomura Y, Bashir A, Fernandez-Hernandez H, Itzkowitz S, Pei Z, Stone J, Loudon H , Peter I",Diversified microbiota of meconium is affected by maternal diabetes status,PloS one,2013,NA,Experiment 1,United States of America,Homo sapiens,Meconium,UBERON:0007109,Type II diabetes mellitus,MONDO:0005148,adult stool,Healthy baby meconium,NA,9,13,9 months,16S,34,PacBio RS,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Text + Figure 2,10 January 2021,Rimsha Azhar,WikiWorks,Bacterial Composition of the Meconium and Comparison to the healthy Adult and healthy Infant Microbiome,increased,"k__Bacteria|p__Pseudomonadota,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Comamonadaceae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Comamonadaceae|g__Comamonas,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Escherichia,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Klebsiella,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Morganellaceae|g__Proteus,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Shigella",2|1224;2|1224|28216|80840|80864;2|1224|1236|91347|543;2|1224|28216|80840|80864|283;2|1224|1236|91347|543|561;2|1224|1236|91347|543|570;2|1224|1236|91347|1903414|583;2|1224|1236|91347|543|620,Complete,Shaimaa Elsafoury
bsdb:56/1/2,Study 56,"cross-sectional observational, not case-control",24223144,10.1371/journal.pone.0078257,NA,"Hu J, Nomura Y, Bashir A, Fernandez-Hernandez H, Itzkowitz S, Pei Z, Stone J, Loudon H , Peter I",Diversified microbiota of meconium is affected by maternal diabetes status,PloS one,2013,NA,Experiment 1,United States of America,Homo sapiens,Meconium,UBERON:0007109,Type II diabetes mellitus,MONDO:0005148,adult stool,Healthy baby meconium,NA,9,13,9 months,16S,34,PacBio RS,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 2,Text + Figure 2,10 January 2021,Rimsha Azhar,WikiWorks,Bacterial Composition of the Meconium and Comparison to the healthy Adult and healthy Infant Microbiome,decreased,"k__Bacteria|p__Bacteroidota,k__Bacteria|p__Bacillota,k__Bacteria|p__Verrucomicrobiota,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae",2|976;2|1239;2|74201;2|976|200643|171549|815;2|1239|186801|3085636|186803;2|1239|186801|186802|541000;2|1239|909932|1843489|31977,Complete,Shaimaa Elsafoury
bsdb:56/2/1,Study 56,"cross-sectional observational, not case-control",24223144,10.1371/journal.pone.0078257,NA,"Hu J, Nomura Y, Bashir A, Fernandez-Hernandez H, Itzkowitz S, Pei Z, Stone J, Loudon H , Peter I",Diversified microbiota of meconium is affected by maternal diabetes status,PloS one,2013,NA,Experiment 2,United States of America,Homo sapiens,Meconium,UBERON:0007109,Gestational diabetes,EFO:0004593,Healthy baby meconium,Baby meconium with GDM mothers,NA,13,5,9 months,16S,34,PacBio RS,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Text + Figure 4,10 January 2021,Rimsha Azhar,WikiWorks,Significant difference between neonates from mothers with different diabetes states,decreased,"k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Hyphomicrobiales|f__Brucellaceae,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Alcaligenaceae,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Comamonadaceae,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Hyphomicrobiales|f__Xanthobacteraceae,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Alcaligenaceae|g__Alcaligenes,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Burkholderiaceae|g__Cupriavidus,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Comamonadaceae|g__Comamonas,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Comamonadaceae|g__Delftia,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Lysobacterales|f__Lysobacteraceae|g__Stenotrophomonas",2|1224|28216;2|1224|28211|356|118882;2|1224|28216|80840|506;2|1224|28216|80840|80864;2|1224|28211|356|335928;2|1224|28216|80840|506|507;2|1224|28216|80840|119060|106589;2|1224|28216|80840|80864|283;2|1224|28216|80840|80864|80865;2|1224|1236|135614|32033|40323,Complete,Shaimaa Elsafoury
bsdb:56/3/1,Study 56,"cross-sectional observational, not case-control",24223144,10.1371/journal.pone.0078257,NA,"Hu J, Nomura Y, Bashir A, Fernandez-Hernandez H, Itzkowitz S, Pei Z, Stone J, Loudon H , Peter I",Diversified microbiota of meconium is affected by maternal diabetes status,PloS one,2013,NA,Experiment 3,United States of America,Homo sapiens,Meconium,UBERON:0007109,Type II diabetes mellitus,MONDO:0005148,Healthy baby meconium,Baby meconium with DM mothers,NA,13,5,9 months,16S,34,PacBio RS,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Text + Figure 4,10 January 2021,Rimsha Azhar,"Lwaldron,WikiWorks",Significant difference between neonates from mothers with different diabetes states,increased,"k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Rhodospirillales|f__Acetobacteraceae,k__Bacteria|p__Bacillota|c__Negativicutes|o__Acidaminococcales|f__Acidaminococcaceae|g__Acidaminococcus,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micrococcales|f__Intrasporangiaceae|g__Arsenicicoccus,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales|f__Atopobiaceae|g__Atopobium,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae,k__Bacteria|p__Bacteroidota,k__Bacteria|p__Bacteroidota|c__Bacteroidia,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Odoribacteraceae|g__Butyricimonas,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Coprobacillaceae|g__Catenibacterium,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales|f__Coriobacteriaceae|g__Collinsella,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Coprococcus,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales|f__Coriobacteriaceae,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micrococcales|f__Dermabacteraceae,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Dialister,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Dorea,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Dysgonomonadaceae|g__Dysgonomonas,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae,k__Bacteria|p__Bacillota|c__Erysipelotrichia,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Eubacteriaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Eubacteriaceae|g__Eubacterium,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Gemellaceae|g__Gemella,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Mycobacteriales|f__Gordoniaceae|g__Gordonia,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae|g__Holdemania,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micrococcales|f__Micrococcaceae|g__Kocuria,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micrococcales|f__Microbacteriaceae|g__Microbacterium,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Geodermatophilales|f__Geodermatophilaceae|g__Modestobacter,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Oscillibacter,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Tannerellaceae|g__Parabacteroides,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Hyphomicrobiales|f__Phyllobacteriaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Planococcaceae|g__Planomicrobium,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae|g__Porphyromonas,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Roseburia,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Rhodospirillales|f__Acetobacteraceae|g__Roseomonas,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Ruminococcus,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Turicibacteraceae|g__Turicibacter,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae",2|1224|28211|204441|433;2|1239|909932|1843488|909930|904;2|201174|1760|85006|85021|267408;2|201174|84998|84999|1643824|1380;2|976|200643|171549|815;2|976;2|976|200643;2|201174|1760|85004|31953;2|201174|1760|85004|31953|1678;2|976|200643|171549|1853231|574697;2|1239|526524|526525|2810280|135858;2|201174|84998|84999|84107|102106;2|1239|186801|3085636|186803|33042;2|201174|84998|84999|84107;2|201174|1760|85006|85020;2|1239|909932|1843489|31977|39948;2|1239|186801|3085636|186803|189330;2|976|200643|171549|2005520|156973;2|1239|526524|526525|128827;2|1239|526524;2|1239|186801|186802|186806;2|1239|186801|186802|186806|1730;2|1239|91061|1385|539738|1378;2|201174|1760|85007|85026|2053;2|1239|526524|526525|128827|61170;2|201174|1760|85006|1268|57493;2|1239|186801|3085636|186803;2|201174|1760|85006|85023|33882;2|201174|1760|1643682|85030|88138;2|1239|186801|186802|216572|459786;2|976|200643|171549|2005525|375288;2|1224|28211|356|69277;2|1239|91061|1385|186818|162291;2|976|200643|171549|171551;2|976|200643|171549|171551|836;2|976|200643|171549|171552|838;2|1239|186801|3085636|186803|841;2|1224|28211|204441|433|125216;2|1239|186801|186802|216572|1263;2|1239|526524|526525|2810281|191303;2|1239|909932|1843489|31977,Complete,Fatima
bsdb:57/1/1,Study 57,case-control,26963804,10.1080/19490976.2016.1162363,NA,"Fourie NH, Wang D, Abey SK, Sherwin LB, Joseph PV, Rahim-Williams B, Ferguson EG , Henderson WA",The microbiome of the oral mucosa in irritable bowel syndrome,Gut microbes,2016,"irritable bowel syndrome, microbiome, mucosa, oral, overweight, visceral pain",Experiment 1,United States of America,Homo sapiens,Buccal mucosa,UBERON:0006956,Irritable bowel syndrome,EFO:0000555,control,irritable bowel syndrome,IBS are who suffered from chronic visceral pain and altered bowel habits for more than 6 months for which no organic cause had been identified,20,9,NA,16S,NA,PhyloChip,Welch's T-Test,0.05,FALSE,NA,"age,body weight,race,sex",NA,NA,NA,NA,NA,NA,NA,Signature 1,Figure 6,10 January 2021,Rimsha Azhar,WikiWorks,OTUs showed significant differential abundance between healthy controls and IBS participants,increased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Clostridium,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Desulfitobacteriaceae|g__Desulfosporosinus,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Peptostreptococcaceae|g__Peptostreptococcus,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Alcaligenaceae|g__Alcaligenes,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Burkholderiaceae|g__Burkholderia,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Neisseriaceae|g__Neisseria",2|976|200643|171549|171552|838;2|1239|186801|186802|31979|1485;2|1239|186801|186802|2937909|79206;2|1239|186801|3082720|186804|1257;2|1224|28216|80840|506|507;2|1224|28216|80840|119060|32008;2|1224|28216|206351|481|482,Complete,Shaimaa Elsafoury
bsdb:57/1/2,Study 57,case-control,26963804,10.1080/19490976.2016.1162363,NA,"Fourie NH, Wang D, Abey SK, Sherwin LB, Joseph PV, Rahim-Williams B, Ferguson EG , Henderson WA",The microbiome of the oral mucosa in irritable bowel syndrome,Gut microbes,2016,"irritable bowel syndrome, microbiome, mucosa, oral, overweight, visceral pain",Experiment 1,United States of America,Homo sapiens,Buccal mucosa,UBERON:0006956,Irritable bowel syndrome,EFO:0000555,control,irritable bowel syndrome,IBS are who suffered from chronic visceral pain and altered bowel habits for more than 6 months for which no organic cause had been identified,20,9,NA,16S,NA,PhyloChip,Welch's T-Test,0.05,FALSE,NA,"age,body weight,race,sex",NA,NA,NA,NA,NA,NA,NA,Signature 2,Figure 6,10 January 2021,Rimsha Azhar,WikiWorks,OTUs showed significant differential abundance between healthy controls and IBS participants,decreased,"k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Mycobacteriales|f__Corynebacteriaceae|g__Corynebacterium,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Propionibacteriales|f__Propionibacteriaceae|g__Propionibacterium,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Sphingomonadales|f__Sphingomonadaceae|g__Sphingomonas,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pseudomonadales|f__Pseudomonadaceae|g__Pseudomonas",2|201174|1760|85007|1653|1716;2|201174|1760|85009|31957|1743;2|1239|91061|186826|1300|1301;2|1224|28211|204457|41297|13687;2|1224|1236|72274|135621|286,Complete,Shaimaa Elsafoury
bsdb:57/2/1,Study 57,case-control,26963804,10.1080/19490976.2016.1162363,NA,"Fourie NH, Wang D, Abey SK, Sherwin LB, Joseph PV, Rahim-Williams B, Ferguson EG , Henderson WA",The microbiome of the oral mucosa in irritable bowel syndrome,Gut microbes,2016,"irritable bowel syndrome, microbiome, mucosa, oral, overweight, visceral pain",Experiment 2,United States of America,Homo sapiens,Buccal mucosa,UBERON:0006956,Irritable bowel syndrome,EFO:0000555,control,overweight irritable bowel syndrome,IBS are who suffered from chronic visceral pain and altered bowel habits for more than 6 months for which no organic cause had been identified,20,11,NA,16S,NA,PhyloChip,Welch's T-Test,0.05,FALSE,NA,"age,body weight,race,sex",NA,NA,NA,NA,NA,NA,NA,Signature 1,Figure 6,10 January 2021,Rimsha Azhar,WikiWorks,OTUs showed significant differential abundance between healthy controls and IBS participants,increased,"k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Mycobacteriales|f__Corynebacteriaceae|g__Corynebacterium,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales|f__Atopobiaceae|g__Atopobium,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales|f__Atopobiaceae|g__Olsenella,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Bacillaceae|g__Bacillus,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Planococcaceae|g__Planomicrobium,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Eubacteriaceae|g__Pseudoramibacter,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Oribacterium,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Shuttleworthella,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Dialister,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Megasphaera,k__Bacteria|p__Bacillota|c__Negativicutes|o__Selenomonadales|f__Selenomonadaceae|g__Selenomonas,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|g__Aquabacterium,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Comamonadaceae|g__Delftia,k__Bacteria|p__Campylobacterota|c__Epsilonproteobacteria|o__Campylobacterales|f__Campylobacteraceae|g__Campylobacter,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pseudomonadales|f__Pseudomonadaceae|g__Pseudomonas,k__Bacteria|p__Spirochaetota|c__Spirochaetia|o__Spirochaetales|f__Treponemataceae|g__Treponema,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Staphylococcaceae|g__Staphylococcus",2|201174|1760|85007|1653|1716;2|201174|1760|85004|31953|1678;2|201174|84998|84999|1643824|1380;2|201174|84998|84999|1643824|133925;2|1239|91061|1385|186817|1386;2|1239|91061|1385|186818|162291;2|1239|91061|186826|33958|1578;2|1239|186801|186802|186806|113286;2|1239|186801|3085636|186803|265975;2|1239|186801|3085636|186803|177971;2|1239|909932|1843489|31977|39948;2|1239|909932|1843489|31977|906;2|1239|909932|909929|1843491|970;2|1224|28216|80840|92793;2|1224|28216|80840|80864|80865;2|29547|3031852|213849|72294|194;2|1224|1236|72274|135621|286;2|203691|203692|136|2845253|157;2|976|200643|171549|171552|838;2|1239|91061|1385|90964|1279,Complete,Shaimaa Elsafoury
bsdb:57/2/2,Study 57,case-control,26963804,10.1080/19490976.2016.1162363,NA,"Fourie NH, Wang D, Abey SK, Sherwin LB, Joseph PV, Rahim-Williams B, Ferguson EG , Henderson WA",The microbiome of the oral mucosa in irritable bowel syndrome,Gut microbes,2016,"irritable bowel syndrome, microbiome, mucosa, oral, overweight, visceral pain",Experiment 2,United States of America,Homo sapiens,Buccal mucosa,UBERON:0006956,Irritable bowel syndrome,EFO:0000555,control,overweight irritable bowel syndrome,IBS are who suffered from chronic visceral pain and altered bowel habits for more than 6 months for which no organic cause had been identified,20,11,NA,16S,NA,PhyloChip,Welch's T-Test,0.05,FALSE,NA,"age,body weight,race,sex",NA,NA,NA,NA,NA,NA,NA,Signature 2,Figure 6,10 January 2021,Rimsha Azhar,WikiWorks,OTUs showed significant differential abundance between healthy controls and IBS participants,decreased,"k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Propionibacteriales|f__Propionibacteriaceae|g__Aestuariimicrobium,k__Bacteria|p__Bacteroidota|c__Flavobacteriia|o__Flavobacteriales|f__Weeksellaceae|g__Chryseobacterium,k__Bacteria|p__Bacteroidota|c__Flavobacteriia|o__Flavobacteriales|f__Flavobacteriaceae|g__Haloanella,k__Bacteria|p__Chloroflexota|c__Dehalococcoidia|o__Dehalococcoidales|f__Dehalococcoidaceae|g__Dehalogenimonas,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Gemellaceae|g__Gemella,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Neisseriaceae|g__Neisseria,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Haemophilus,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Staphylococcaceae|g__Staphylococcus",2|201174|1760|85009|31957|396388;2|976|117743|200644|2762318|59732;2|976|117743|200644|49546|109244;2|200795|301297|1202465|1202464|670486;2|1239|91061|1385|539738|1378;2|1239|91061|186826|1300|1301;2|1224|28216|206351|481|482;2|1224|1236|135625|712|724;2|976|200643|171549|171552|838;2|1239|91061|1385|90964|1279,Complete,Shaimaa Elsafoury
bsdb:58/1/1,Study 58,prospective cohort,27503374,10.1186/s13073-016-0330-z,NA,"Chu DM, Antony KM, Ma J, Prince AL, Showalter L, Moller M , Aagaard KM",The early infant gut microbiome varies in association with a maternal high-fat diet,Genome medicine,2016,"High-fat diet, Maternal gestational diet, Microbiome, Neonatal microbiome development",Experiment 1,United States of America,Homo sapiens,Meconium,UBERON:0007109,High fat diet,EFO:0002757,nebowrns of maternal control,newborns of maternal high-fat diet,"To determine maternal dietary intake during pregnancy, each mother was asked by trained personnel at each sample collection time point to answer the Dietary Screener Questionnaire (DSQ), which was developed and validated by the National Health and Examination Survey (NHANES) program (2009–2010)",13,13,NA,16S,345,Roche454,LEfSe,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Figure 4,10 January 2021,Rimsha Azhar,WikiWorks,Neonaatal meconium identified by  LEfSe betwen maternal high-fat or maternal control diet during pregnancy,increased,"k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Lactococcus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Carnobacteriaceae|g__Granulicatella,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Enterococcaceae|g__Enterococcus",2|1239|91061|186826|1300|1357;2|1239|91061|186826|186828|117563;2|1239|91061|186826|81852|1350,Complete,Shaimaa Elsafoury
bsdb:58/1/2,Study 58,prospective cohort,27503374,10.1186/s13073-016-0330-z,NA,"Chu DM, Antony KM, Ma J, Prince AL, Showalter L, Moller M , Aagaard KM",The early infant gut microbiome varies in association with a maternal high-fat diet,Genome medicine,2016,"High-fat diet, Maternal gestational diet, Microbiome, Neonatal microbiome development",Experiment 1,United States of America,Homo sapiens,Meconium,UBERON:0007109,High fat diet,EFO:0002757,nebowrns of maternal control,newborns of maternal high-fat diet,"To determine maternal dietary intake during pregnancy, each mother was asked by trained personnel at each sample collection time point to answer the Dietary Screener Questionnaire (DSQ), which was developed and validated by the National Health and Examination Survey (NHANES) program (2009–2010)",13,13,NA,16S,345,Roche454,LEfSe,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 2,Figure 4,10 January 2021,Rimsha Azhar,WikiWorks,Neonaatal meconium identified by  LEfSe betwen maternal high-fat or maternal control diet during pregnancy,decreased,"k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Sutterellaceae|g__Sutterella,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Tannerellaceae|g__Parabacteroides,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Comamonadaceae|g__Comamonas",2|1224|28216|80840|995019|40544;2|976|200643|171549|2005525|375288;2|976|200643|171549|815|816;2|1224|28216|80840|80864|283,Complete,Shaimaa Elsafoury
bsdb:58/2/1,Study 58,prospective cohort,27503374,10.1186/s13073-016-0330-z,NA,"Chu DM, Antony KM, Ma J, Prince AL, Showalter L, Moller M , Aagaard KM",The early infant gut microbiome varies in association with a maternal high-fat diet,Genome medicine,2016,"High-fat diet, Maternal gestational diet, Microbiome, Neonatal microbiome development",Experiment 2,United States of America,Homo sapiens,Feces,UBERON:0001988,High fat diet,EFO:0002757,6 months babies control,6 months babies of maternal high-fat diet,"To determine maternal dietary intake during pregnancy, each mother was asked by trained personnel at each sample collection time point to answer the Dietary Screener Questionnaire (DSQ), which was developed and validated by the National Health and Examination Survey (NHANES) program (2009–2010)",75,75,NA,16S,345,Roche454,LEfSe,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Figure 5 + Supplemental Figure 3,10 January 2021,Rimsha Azhar,WikiWorks,The impact of maternal gestational diet persists to 6 weeks of age,increased,"k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Escherichia",2|1239|91061|186826|1300|1301;2|1224|1236|91347|543|561,Complete,Shaimaa Elsafoury
bsdb:58/2/2,Study 58,prospective cohort,27503374,10.1186/s13073-016-0330-z,NA,"Chu DM, Antony KM, Ma J, Prince AL, Showalter L, Moller M , Aagaard KM",The early infant gut microbiome varies in association with a maternal high-fat diet,Genome medicine,2016,"High-fat diet, Maternal gestational diet, Microbiome, Neonatal microbiome development",Experiment 2,United States of America,Homo sapiens,Feces,UBERON:0001988,High fat diet,EFO:0002757,6 months babies control,6 months babies of maternal high-fat diet,"To determine maternal dietary intake during pregnancy, each mother was asked by trained personnel at each sample collection time point to answer the Dietary Screener Questionnaire (DSQ), which was developed and validated by the National Health and Examination Survey (NHANES) program (2009–2010)",75,75,NA,16S,345,Roche454,LEfSe,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 2,Figure 5 + Supplemental Figure 3,10 January 2021,Rimsha Azhar,WikiWorks,The impact of maternal gestational diet persists to 6 weeks of age,decreased,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides,2|976|200643|171549|815|816,Complete,Shaimaa Elsafoury
bsdb:59/1/1,Study 59,time series / longitudinal observational,30656437,10.1186/s11671-018-2834-5,NA,"Mao Z, Li Y, Dong T, Zhang L, Zhang Y, Li S, Hu H, Sun C , Xia Y",Exposure to Titanium Dioxide Nanoparticles During Pregnancy Changed Maternal Gut Microbiota and Increased Blood Glucose of Rat,Nanoscale research letters,2019,"Gut microbiota, Increased fasting blood glucose, Pregnancy exposure, TiO2 NPs",Experiment 1,China,Rattus norvegicus,Feces,UBERON:0001988,Titanium dioxide nanoparticle,CHEBI:51050,control pregnant rats at gestational day 10,pregnant rats exposed to titanium dioxide nanoparticles,The female rats were daily gavage administrated with 5 mg/kg bw/day of TiO2 NPs from the 5th to 18th day after pregnancy.,4,4,NA,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,Signature 1,Figure 4,10 January 2021,Yaseen Javaid,WikiWorks,Exposure to Titanium Dioxide Nanoparticles During Pregnancy Changed Maternal Gut Microbiota of preganat rats,increased,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales,2|1239|186801|186802,Complete,Shaimaa Elsafoury
bsdb:59/1/2,Study 59,time series / longitudinal observational,30656437,10.1186/s11671-018-2834-5,NA,"Mao Z, Li Y, Dong T, Zhang L, Zhang Y, Li S, Hu H, Sun C , Xia Y",Exposure to Titanium Dioxide Nanoparticles During Pregnancy Changed Maternal Gut Microbiota and Increased Blood Glucose of Rat,Nanoscale research letters,2019,"Gut microbiota, Increased fasting blood glucose, Pregnancy exposure, TiO2 NPs",Experiment 1,China,Rattus norvegicus,Feces,UBERON:0001988,Titanium dioxide nanoparticle,CHEBI:51050,control pregnant rats at gestational day 10,pregnant rats exposed to titanium dioxide nanoparticles,The female rats were daily gavage administrated with 5 mg/kg bw/day of TiO2 NPs from the 5th to 18th day after pregnancy.,4,4,NA,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,Signature 2,Figure 4,10 January 2021,Yaseen Javaid,"Fatima,WikiWorks",Exposure to Titanium Dioxide Nanoparticles During Pregnancy Changed Maternal Gut Microbiota of preganat rats,decreased,k__Bacteria|p__Acidobacteriota|c__Terriglobia|o__Terriglobales|f__Acidobacteriaceae|s__bacterium Ellin6075,2|57723|204432|204433|204434|234266,Complete,Fatima
bsdb:60/1/1,Study 60,case-control,30714640,10.1002/jcla.22842,NA,"Qiu J, Zhou H, Jing Y , Dong C",Association between blood microbiome and type 2 diabetes mellitus: A nested case-control study,Journal of clinical laboratory analysis,2019,"16S ribosomal RNA, blood microbiome, nested case-control study, type 2 diabetes mellitus",Experiment 1,China,Homo sapiens,Blood,UBERON:0000178,Type II diabetes mellitus,MONDO:0005148,controls,Type-2 DM cases,NA,100,50,2 months,16S,56,Illumina,T-Test,0.05,FALSE,NA,"age,sex","alcohol drinking,blood pressure,body mass index,smoking behavior,total cholesterol measurement,triglycerides",NA,unchanged,unchanged,unchanged,NA,NA,Signature 1,Table 5,10 January 2021,Yaseen Javaid,WikiWorks,Association between blood microbiome and type 2 diabetes mellitus: A nested case-control study. (all the bacteria either have zero mean or not detectable in both groups except Aquabacterium),increased,"k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micrococcales|f__Cellulomonadaceae|g__Actinotalea,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Alteromonadales|f__Alteromonadaceae|g__Alishewanella,k__Bacteria|p__Bacteroidota|c__Chitinophagia|o__Chitinophagales|f__Chitinophagaceae|g__Sediminibacterium,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micrococcales|f__Microbacteriaceae|g__Pseudoclavibacter",2|201174|1760|85006|85016|458839;2|1224|1236|135622|72275|111142;2|976|1853228|1853229|563835|504481;2|201174|1760|85006|85023|255204,Complete,Shaimaa Elsafoury
bsdb:60/1/2,Study 60,case-control,30714640,10.1002/jcla.22842,NA,"Qiu J, Zhou H, Jing Y , Dong C",Association between blood microbiome and type 2 diabetes mellitus: A nested case-control study,Journal of clinical laboratory analysis,2019,"16S ribosomal RNA, blood microbiome, nested case-control study, type 2 diabetes mellitus",Experiment 1,China,Homo sapiens,Blood,UBERON:0000178,Type II diabetes mellitus,MONDO:0005148,controls,Type-2 DM cases,NA,100,50,2 months,16S,56,Illumina,T-Test,0.05,FALSE,NA,"age,sex","alcohol drinking,blood pressure,body mass index,smoking behavior,total cholesterol measurement,triglycerides",NA,unchanged,unchanged,unchanged,NA,NA,Signature 2,Table 5,10 January 2021,Yaseen Javaid,WikiWorks,Association between blood microbiome and type 2 diabetes mellitus: A nested case-control study. (all the bacteria either have zero mean or not detectable in both groups except Aquabacterium),decreased,"k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|g__Aquabacterium,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Lysobacterales|f__Lysobacteraceae|g__Xanthomonas,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Pseudonocardiales|f__Pseudonocardiaceae|g__Pseudonocardia",2|1224|28216|80840|92793;2|1224|1236|135614|32033|338;2|201174|1760|85010|2070|1847,Complete,Shaimaa Elsafoury
bsdb:60/2/1,Study 60,case-control,30714640,10.1002/jcla.22842,NA,"Qiu J, Zhou H, Jing Y , Dong C",Association between blood microbiome and type 2 diabetes mellitus: A nested case-control study,Journal of clinical laboratory analysis,2019,"16S ribosomal RNA, blood microbiome, nested case-control study, type 2 diabetes mellitus",Experiment 2,China,Homo sapiens,Blood,UBERON:0000178,Type II diabetes mellitus,MONDO:0005148,carier of pathogens controls,Type-2 DM cariers of pathogens,The non-carrier meant that the individual did not have sequence read for the specific pathogen.,NA,NA,2 months,16S,56,Illumina,T-Test,0.05,FALSE,NA,"age,sex","alcohol drinking,blood pressure,body mass index,smoking behavior,total cholesterol measurement,triglycerides",NA,NA,NA,NA,NA,NA,Signature 1,Table 6,10 January 2021,Shaimaa Elsafoury,WikiWorks,Associations between blood microbiome and the subsequent risk of Type-2 diabetes mellitus,increased,k__Bacteria|p__Bacteroidota|c__Chitinophagia|o__Chitinophagales|f__Chitinophagaceae|g__Sediminibacterium,2|976|1853228|1853229|563835|504481,Complete,Shaimaa Elsafoury
bsdb:60/2/2,Study 60,case-control,30714640,10.1002/jcla.22842,NA,"Qiu J, Zhou H, Jing Y , Dong C",Association between blood microbiome and type 2 diabetes mellitus: A nested case-control study,Journal of clinical laboratory analysis,2019,"16S ribosomal RNA, blood microbiome, nested case-control study, type 2 diabetes mellitus",Experiment 2,China,Homo sapiens,Blood,UBERON:0000178,Type II diabetes mellitus,MONDO:0005148,carier of pathogens controls,Type-2 DM cariers of pathogens,The non-carrier meant that the individual did not have sequence read for the specific pathogen.,NA,NA,2 months,16S,56,Illumina,T-Test,0.05,FALSE,NA,"age,sex","alcohol drinking,blood pressure,body mass index,smoking behavior,total cholesterol measurement,triglycerides",NA,NA,NA,NA,NA,NA,Signature 2,Table 6,10 January 2021,Shaimaa Elsafoury,WikiWorks,Associations between blood microbiome and the subsequent risk of Type-2 diabetes mellitus,decreased,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides,2|976|200643|171549|815|816,Complete,Shaimaa Elsafoury
bsdb:61/1/1,Study 61,time series / longitudinal observational,20844065,10.3945/ajcn.2010.29877,NA,"Collado MC, Isolauri E, Laitinen K , Salminen S","Effect of mother's weight on infant's microbiota acquisition, composition, and activity during early infancy: a prospective follow-up study initiated in early pregnancy",The American journal of clinical nutrition,2010,NA,Experiment 1,Finland,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,infants of normal weight mother at age 1 month,infants of overweight mothers,mothers whose prepregnancy body mass index (BMI; in kg/m2) was >25,26,16,NA,16S,NA,RT-qPCR,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Table 2 & Tale 4,10 January 2021,Rimsha Azhar,WikiWorks,Mirobial groups in feacal samples at 1 and 6 months of age according to maternal weight gain during pregnancy and BMI,decreased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella",2|976|200643|171549|815|816;2|976|200643|171549|171552|838,Complete,Shaimaa Elsafoury
bsdb:61/2/1,Study 61,time series / longitudinal observational,20844065,10.3945/ajcn.2010.29877,NA,"Collado MC, Isolauri E, Laitinen K , Salminen S","Effect of mother's weight on infant's microbiota acquisition, composition, and activity during early infancy: a prospective follow-up study initiated in early pregnancy",The American journal of clinical nutrition,2010,NA,Experiment 2,Finland,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,infants of normal weight mother at age 6 month,infants of overweight mothers,mothers whose prepregnancy body mass index (BMI; in kg/m2) was >25,26,16,NA,16S,NA,RT-qPCR,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Table 2 & Tale 4,10 January 2021,Shaimaa Elsafoury,WikiWorks,Mirobial groups in feacal samples at 1 and 6 months of age according to maternal weight gain during pregnancy and BMI,increased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Hathewaya|s__Hathewaya histolytica,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium|s__Bifidobacterium catenulatum",2|1239|186801|186802|31979|1769729|1498;2|201174|1760|85004|31953|1678|1686,Complete,Shaimaa Elsafoury
bsdb:61/3/1,Study 61,time series / longitudinal observational,20844065,10.3945/ajcn.2010.29877,NA,"Collado MC, Isolauri E, Laitinen K , Salminen S","Effect of mother's weight on infant's microbiota acquisition, composition, and activity during early infancy: a prospective follow-up study initiated in early pregnancy",The American journal of clinical nutrition,2010,NA,Experiment 3,Finland,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,infants of normal maternal weight gain mothers at age 1 month,infants of excessive maternal weight gain mothers,Weight gain >16.0 kg in women with BMI (in kg/m2) <25 and >11.5 kg in women with BMI >25 was considered excessive,20,22,NA,16S,NA,RT-qPCR,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Table 3,10 January 2021,Shaimaa Elsafoury,WikiWorks,Bacterial counts in infant fecal samples at 1 and 6 months of age according to maternal weight gain during pregnancy,decreased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella",2|976|200643|171549|815|816;2|976|200643|171549|171552|838,Complete,Shaimaa Elsafoury
bsdb:61/4/1,Study 61,time series / longitudinal observational,20844065,10.3945/ajcn.2010.29877,NA,"Collado MC, Isolauri E, Laitinen K , Salminen S","Effect of mother's weight on infant's microbiota acquisition, composition, and activity during early infancy: a prospective follow-up study initiated in early pregnancy",The American journal of clinical nutrition,2010,NA,Experiment 4,Finland,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,infants of normal maternal weight gain mothers at age 6 months,infants of excessive maternal weight gain mothers,Weight gain >16.0 kg in women with BMI (in kg/m2) <25 and >11.5 kg in women with BMI >25 was considered excessive,20,22,NA,16S,NA,RT-qPCR,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Table 3,10 January 2021,Shaimaa Elsafoury,WikiWorks,Bacterial counts in infant fecal samples at 1 and 6 months of age according to maternal weight gain during pregnancy,increased,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Hathewaya|s__Hathewaya histolytica,2|1239|186801|186802|31979|1769729|1498,Complete,Shaimaa Elsafoury
bsdb:62/1/1,Study 62,case-control,38582855,10.1038/s41531-024-00687-1,https://www.nature.com/articles/s41531-024-00687-1,"Aho VTE, Klee M, Landoulsi Z, Heintz-Buschart A, Pavelka L, Leist AK, Krüger R, May P , Wilmes P",Gut microbiome is not associated with mild cognitive impairment in Parkinson's disease,NPJ Parkinson's disease,2024,NA,Experiment 1,Luxembourg,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Control Subjects,Cognitively Unimpaired PD (PD-NC),Parkinson’s disease (PD) patients without cognitive impairment (NC).,90,60,N/A,16S,34,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,NA,unchanged,NA,unchanged,NA,Signature 1,Supplementary Figure 1d,16 July 2024,Aleru Divine,Aleru Divine,Heatmap summarizing differentially abundant taxa.,increased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Anaerotruncus,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|s__Clostridiales bacterium DTU089,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|s__Escherichia/Shigella sp.,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Eubacteriaceae|g__Eubacterium|s__Eubacterium coprostanoligenes,k__Archaea|p__Euryarchaeota,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Faecalibacterium|s__Faecalibacterium sp. UBA1819,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Hungatella,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Hungatella|s__Hungatella sp.,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Hydrogenoanaerobacterium,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Klebsiella|s__Klebsiella pneumoniae,k__Archaea|p__Euryarchaeota|c__Methanobacteria|o__Methanobacteriales|f__Methanobacteriaceae|g__Methanobrevibacter,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Phocaeicola|s__Phocaeicola dorei,k__Bacteria|p__Bacillota|c__Negativicutes|o__Selenomonadales|s__Selenomonadales bacterium Marseille-P2399",2|1239|186801|186802|216572|244127;2|201174|1760|85004|31953|1678;2|1239|186801|186802|1671661;2|1224|1236|91347;2|1224|1236|91347|543;2|1224|1236|91347|543|1940338;2|1239|186801|186802|186806|1730|290054;2157|28890;2|1239|186801|186802|216572|216851|1946507;2|1239|186801|3085636|186803|1649459;2|1239|186801|3085636|186803|1649459|2613924;2|1239|186801|186802|216572|596767;2|1224|1236|91347|543|570|573;2157|28890|183925|2158|2159|2172;2|976|200643|171549|815|909656|357276;2|1239|909932|909929|1806836,Complete,Shaimaa Elsafoury
bsdb:62/1/2,Study 62,case-control,38582855,10.1038/s41531-024-00687-1,https://www.nature.com/articles/s41531-024-00687-1,"Aho VTE, Klee M, Landoulsi Z, Heintz-Buschart A, Pavelka L, Leist AK, Krüger R, May P , Wilmes P",Gut microbiome is not associated with mild cognitive impairment in Parkinson's disease,NPJ Parkinson's disease,2024,NA,Experiment 1,Luxembourg,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Control Subjects,Cognitively Unimpaired PD (PD-NC),Parkinson’s disease (PD) patients without cognitive impairment (NC).,90,60,N/A,16S,34,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,NA,unchanged,NA,unchanged,NA,Signature 2,Supplementary Figure 1d,20 June 2024,Aleru Divine,Aleru Divine,Heatmap summarizing differentially abundant taxa.,decreased,"k__Bacteria|p__Bacillota,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Butyricicoccaceae,k__Bacteria|p__Bacillota|c__Clostridia,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Clostridium,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|s__Lachnospiraceae bacterium 10-1,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Peptostreptococcaceae|g__Romboutsia,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Roseburia,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|s__Ruminococcaceae bacterium UCG-005",2|1239;2|1239|186801|186802|3085642;2|1239|186801;2|1239|186801|186802|31979;2|1239|186801|186802|31979|1485;2|1239|186801|186802;2|1239|186801|3085636|186803;2|1239|186801|3085636|186803|1235800;2|1239|186801|186802|216572;2|976|200643|171549|171552|838;2|1239|186801|3082720|186804|1501226;2|1239|186801|3085636|186803|841;2|1239|186801|186802|216572|3068309,Complete,NA
bsdb:62/2/1,Study 62,case-control,38582855,10.1038/s41531-024-00687-1,https://www.nature.com/articles/s41531-024-00687-1,"Aho VTE, Klee M, Landoulsi Z, Heintz-Buschart A, Pavelka L, Leist AK, Krüger R, May P , Wilmes P",Gut microbiome is not associated with mild cognitive impairment in Parkinson's disease,NPJ Parkinson's disease,2024,NA,Experiment 2,Luxembourg,Homo sapiens,Feces,UBERON:0001988,Cognitive impairment,HP:0100543,Cognitively Unimpaired-PD (PD-NC),Mild Cognitive Impairment-PD,Parkinson’s disease (PD) patients with mild cognitive impairment (MCI).,60,58,N/A,16S,34,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,NA,unchanged,NA,unchanged,NA,Signature 1,Supplementary Figure 1d and table 3c,20 June 2024,Aleru Divine,Aleru Divine,Heatmap summarizing differentially abundant taxa.,increased,"k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus",2|1239|91061|186826;2|1239|91061|186826|1300;2|1239|91061|186826|1300|1301,Complete,NA
bsdb:62/2/2,Study 62,case-control,38582855,10.1038/s41531-024-00687-1,https://www.nature.com/articles/s41531-024-00687-1,"Aho VTE, Klee M, Landoulsi Z, Heintz-Buschart A, Pavelka L, Leist AK, Krüger R, May P , Wilmes P",Gut microbiome is not associated with mild cognitive impairment in Parkinson's disease,NPJ Parkinson's disease,2024,NA,Experiment 2,Luxembourg,Homo sapiens,Feces,UBERON:0001988,Cognitive impairment,HP:0100543,Cognitively Unimpaired-PD (PD-NC),Mild Cognitive Impairment-PD,Parkinson’s disease (PD) patients with mild cognitive impairment (MCI).,60,58,N/A,16S,34,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,NA,unchanged,NA,unchanged,NA,Signature 2,Supplementary Figure 1d and table 3c,20 June 2024,Aleru Divine,Aleru Divine,Heatmap summarizing differentially abundant taxa.,decreased,"k__Bacteria|p__Verrucomicrobiota|c__Verrucomicrobiia|o__Verrucomicrobiales|f__Akkermansiaceae|g__Akkermansia|s__Akkermansia muciniphila,k__Bacteria|p__Mycoplasmatota|c__Mollicutes|o__Anaeroplasmatales|f__Anaeroplasmataceae|g__Asteroleplasma",2|74201|203494|48461|1647988|239934|239935;2|544448|31969|186332|186333|2152,Complete,NA
bsdb:62/3/1,Study 62,case-control,38582855,10.1038/s41531-024-00687-1,https://www.nature.com/articles/s41531-024-00687-1,"Aho VTE, Klee M, Landoulsi Z, Heintz-Buschart A, Pavelka L, Leist AK, Krüger R, May P , Wilmes P",Gut microbiome is not associated with mild cognitive impairment in Parkinson's disease,NPJ Parkinson's disease,2024,NA,Experiment 3,Luxembourg,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Control Subjects,Mild Cognitive Impairment -PD (PD-MCI),Parkinson’s disease (PD) patients with Mild Cognitive Impairment (MCI).,90,58,N/A,16S,34,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,NA,unchanged,NA,unchanged,NA,Signature 1,Supplementary Figure 1d,20 June 2024,Aleru Divine,Aleru Divine,Heatmap summarizing differentially abundant taxa.,increased,"k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|s__Clostridiales bacterium DTU089,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|s__Escherichia/Shigella sp.,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Eubacteriaceae|g__Eubacterium|s__Eubacterium coprostanoligenes,k__Archaea|p__Euryarchaeota,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Faecalibacterium|s__Faecalibacterium sp. UBA1819,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Hungatella,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Hungatella|s__Hungatella sp.,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Hydrogenoanaerobacterium,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Klebsiella|s__Klebsiella pneumoniae,k__Archaea|p__Euryarchaeota|c__Methanobacteria|o__Methanobacteriales|f__Methanobacteriaceae|g__Methanobrevibacter,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Phocaeicola|s__Phocaeicola dorei,k__Bacteria|p__Bacillota|c__Negativicutes|o__Selenomonadales|s__Selenomonadales bacterium Marseille-P2399",2|201174|1760|85004|31953|1678;2|1239|186801|186802|1671661;2|1224|1236|91347;2|1224|1236|91347|543;2|1224|1236|91347|543|1940338;2|1239|186801|186802|186806|1730|290054;2157|28890;2|1239|186801|186802|216572|216851|1946507;2|1239|186801|3085636|186803|1649459;2|1239|186801|3085636|186803|1649459|2613924;2|1239|186801|186802|216572|596767;2|1224|1236|91347|543|570|573;2157|28890|183925|2158|2159|2172;2|976|200643|171549|815|909656|357276;2|1239|909932|909929|1806836,Complete,NA
bsdb:62/3/2,Study 62,case-control,38582855,10.1038/s41531-024-00687-1,https://www.nature.com/articles/s41531-024-00687-1,"Aho VTE, Klee M, Landoulsi Z, Heintz-Buschart A, Pavelka L, Leist AK, Krüger R, May P , Wilmes P",Gut microbiome is not associated with mild cognitive impairment in Parkinson's disease,NPJ Parkinson's disease,2024,NA,Experiment 3,Luxembourg,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Control Subjects,Mild Cognitive Impairment -PD (PD-MCI),Parkinson’s disease (PD) patients with Mild Cognitive Impairment (MCI).,90,58,N/A,16S,34,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,NA,unchanged,NA,unchanged,NA,Signature 2,Supplementary Figure 1d,16 July 2024,Aleru Divine,Aleru Divine,Heatmap summarizing differentially abundant taxa.,decreased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Butyricicoccaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Clostridium,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|s__Lachnospiraceae bacterium 10-1,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Peptostreptococcaceae|g__Romboutsia,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|s__Ruminococcaceae bacterium UCG-005",2|1239|186801|186802|3085642;2|1239|186801|186802|31979;2|1239|186801|186802|31979|1485;2|1239|186801|186802;2|1239|186801|3085636|186803;2|1239|186801|3085636|186803|1235800;2|976|200643|171549|171552|838;2|1239|186801|3082720|186804|1501226;2|1239|186801|186802|216572|3068309,Complete,NA
bsdb:62/4/1,Study 62,case-control,38582855,10.1038/s41531-024-00687-1,https://www.nature.com/articles/s41531-024-00687-1,"Aho VTE, Klee M, Landoulsi Z, Heintz-Buschart A, Pavelka L, Leist AK, Krüger R, May P , Wilmes P",Gut microbiome is not associated with mild cognitive impairment in Parkinson's disease,NPJ Parkinson's disease,2024,NA,Experiment 4,Luxembourg,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Control Subjects,Cognitively Unimpaired PD (PD-NC),Parkinson’s disease (PD) patients without cognitive impairment (NC).,90,60,N/A,16S,34,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,NA,unchanged,NA,unchanged,NA,Signature 1,Supplementary Figure 1d,17 July 2024,Aleru Divine,Aleru Divine,Heatmap summarizing differentially abundant taxa.,increased,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|s__Clostridiales bacterium DTU089,2|1239|186801|186802|1671661,Complete,NA
bsdb:62/4/2,Study 62,case-control,38582855,10.1038/s41531-024-00687-1,https://www.nature.com/articles/s41531-024-00687-1,"Aho VTE, Klee M, Landoulsi Z, Heintz-Buschart A, Pavelka L, Leist AK, Krüger R, May P , Wilmes P",Gut microbiome is not associated with mild cognitive impairment in Parkinson's disease,NPJ Parkinson's disease,2024,NA,Experiment 4,Luxembourg,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Control Subjects,Cognitively Unimpaired PD (PD-NC),Parkinson’s disease (PD) patients without cognitive impairment (NC).,90,60,N/A,16S,34,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,NA,unchanged,NA,unchanged,NA,Signature 2,Supplementary Figure 1d,17 July 2024,Aleru Divine,Aleru Divine,Heatmap summarizing differentially abundant taxa.,decreased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Agathobacter,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|s__Ruminococcaceae bacterium UCG-005,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|s__Lachnospiraceae bacterium 10-1",2|1239|186801|3085636|186803|1766253;2|1239|186801|3085636|186803;2|1239|186801|186802|216572|3068309;2|1239|186801|3085636|186803|1235800,Complete,NA
bsdb:62/5/1,Study 62,case-control,38582855,10.1038/s41531-024-00687-1,https://www.nature.com/articles/s41531-024-00687-1,"Aho VTE, Klee M, Landoulsi Z, Heintz-Buschart A, Pavelka L, Leist AK, Krüger R, May P , Wilmes P",Gut microbiome is not associated with mild cognitive impairment in Parkinson's disease,NPJ Parkinson's disease,2024,NA,Experiment 5,Luxembourg,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Control Subjects,Mild Cognitive Impairment PD (PD-MCI),Parkinson’s disease (PD) patients with Mild Cognitive Impairment (NC).,90,58,N/A,16S,34,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,NA,unchanged,NA,unchanged,NA,Signature 1,Supplementary Figure 1d,17 July 2024,Aleru Divine,Aleru Divine,Heatmap summarizing differentially abundant taxa.,decreased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Butyricicoccaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae",2|1239|186801|186802|3085642;2|1239|186801|3085636|186803,Complete,NA
bsdb:62/6/1,Study 62,case-control,38582855,10.1038/s41531-024-00687-1,https://www.nature.com/articles/s41531-024-00687-1,"Aho VTE, Klee M, Landoulsi Z, Heintz-Buschart A, Pavelka L, Leist AK, Krüger R, May P , Wilmes P",Gut microbiome is not associated with mild cognitive impairment in Parkinson's disease,NPJ Parkinson's disease,2024,NA,Experiment 6,Luxembourg,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Control Subjects,Cognitively Unimpaired PD (PD-NC),Parkinson’s disease (PD) patients without cognitive impairment (NC).,90,60,N/A,16S,34,Illumina,Linear Regression,0.05,TRUE,NA,NA,NA,NA,NA,unchanged,NA,unchanged,NA,Signature 1,Supplementary Figure 1d,17 July 2024,Aleru Divine,Aleru Divine,Heatmap summarizing differentially abundant taxa.,increased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Hydrogenoanaerobacterium,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Faecalibacterium|s__Faecalibacterium sp. UBA1819,k__Bacteria|p__Bacillota|c__Negativicutes|o__Selenomonadales|s__Selenomonadales bacterium Marseille-P2399,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|s__Clostridiales bacterium DTU089,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Hungatella,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Eubacteriaceae|g__Eubacterium|s__Eubacterium coprostanoligenes,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Anaerotruncus",2|1239|186801|186802|216572|596767;2|1239|186801|186802|216572|216851|1946507;2|1239|909932|909929|1806836;2|1239|186801|186802|1671661;2|1239|186801|3085636|186803|1649459;2|1239|186801|186802|186806|1730|290054;2|1239|186801|186802|216572|244127,Complete,NA
bsdb:62/6/2,Study 62,case-control,38582855,10.1038/s41531-024-00687-1,https://www.nature.com/articles/s41531-024-00687-1,"Aho VTE, Klee M, Landoulsi Z, Heintz-Buschart A, Pavelka L, Leist AK, Krüger R, May P , Wilmes P",Gut microbiome is not associated with mild cognitive impairment in Parkinson's disease,NPJ Parkinson's disease,2024,NA,Experiment 6,Luxembourg,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Control Subjects,Cognitively Unimpaired PD (PD-NC),Parkinson’s disease (PD) patients without cognitive impairment (NC).,90,60,N/A,16S,34,Illumina,Linear Regression,0.05,TRUE,NA,NA,NA,NA,NA,unchanged,NA,unchanged,NA,Signature 2,Supplementary Figure 1d,17 July 2024,Aleru Divine,Aleru Divine,Heatmap summarizing differentially abundant taxa.,decreased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Agathobacter,k__Bacteria|p__Bacillota,k__Bacteria|p__Bacillota|c__Clostridia,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Clostridium,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Roseburia,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|s__Ruminococcaceae bacterium UCG-005,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|s__Lachnospiraceae bacterium 10-1",2|1239|186801|3085636|186803|1766253;2|1239;2|1239|186801;2|1239|186801|186802|31979;2|1239|186801|186802|31979|1485;2|1239|186801|186802;2|1239|186801|3085636|186803;2|1239|186801|186802|216572;2|1239|186801|3085636|186803|841;2|1239|186801|186802|216572|3068309;2|1239|186801|3085636|186803|1235800,Complete,NA
bsdb:62/7/1,Study 62,case-control,38582855,10.1038/s41531-024-00687-1,https://www.nature.com/articles/s41531-024-00687-1,"Aho VTE, Klee M, Landoulsi Z, Heintz-Buschart A, Pavelka L, Leist AK, Krüger R, May P , Wilmes P",Gut microbiome is not associated with mild cognitive impairment in Parkinson's disease,NPJ Parkinson's disease,2024,NA,Experiment 7,Luxembourg,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Control Subjects,Mild Cognitive Impairment PD (PD-MCI),Parkinson’s disease (PD) patients with Mild Cognitive Impairment (NC).,90,58,N/A,16S,34,Illumina,Linear Regression,0.05,TRUE,NA,NA,NA,NA,NA,unchanged,NA,unchanged,NA,Signature 1,Supplementary Figure 1d,17 July 2024,Aleru Divine,Aleru Divine,Heatmap summarizing differentially abundant taxa.,decreased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Butyricicoccaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae",2|1239|186801|186802|3085642;2|1239|186801|3085636|186803,Complete,NA
bsdb:63/1/1,Study 63,time series / longitudinal observational,28018325,10.3389/fmicb.2016.01997,NA,"Nagpal R, Tsuji H, Takahashi T, Kawashima K, Nagata S, Nomoto K , Yamashiro Y",Sensitive Quantitative Analysis of the Meconium Bacterial Microbiota in Healthy Term Infants Born Vaginally or by Cesarean Section,Frontiers in microbiology,2016,"C-section, Lactobacillus, RT-qPCR, dysbiosis, gut bacteria, intestinal microbiota, meconium",Experiment 1,Japan,Homo sapiens,Feces,UBERON:0001988,Cesarean section,EFO:0009636,vaginal delivery after 7 days of delivery,C-section delivery,NA,134,17,No information about pre-delivey duration. 3 Vaginally-delivered infants have been exposed to antibiotics (birth to sampling),16S,NA,RT-qPCR,T-Test,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Figure 2,10 January 2021,Shaimaa Elsafoury,WikiWorks,"Differences in the detection rate of Lactobacillus genus, subgroups and species between vaginally- and cesarean-born babies at different time-points during the first 3 years of life.",decreased,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus|s__Lactobacillus gasseri,2|1239|91061|186826|33958|1578|1596,Complete,Shaimaa Elsafoury
bsdb:63/2/1,Study 63,time series / longitudinal observational,28018325,10.3389/fmicb.2016.01997,NA,"Nagpal R, Tsuji H, Takahashi T, Kawashima K, Nagata S, Nomoto K , Yamashiro Y",Sensitive Quantitative Analysis of the Meconium Bacterial Microbiota in Healthy Term Infants Born Vaginally or by Cesarean Section,Frontiers in microbiology,2016,"C-section, Lactobacillus, RT-qPCR, dysbiosis, gut bacteria, intestinal microbiota, meconium",Experiment 2,Japan,Homo sapiens,Feces,UBERON:0001988,Cesarean section,EFO:0009636,vaginal delivery after 3 months of delivery,C-section delivery,NA,134,17,No information about pre-delivey duration. 3 Vaginally-delivered infants have been exposed to antibiotics (birth to sampling),16S,NA,RT-qPCR,T-Test,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Figure 2,10 January 2021,Shaimaa Elsafoury,WikiWorks,"Differences in the detection rate of Lactobacillus genus, subgroups and species between vaginally- and cesarean-born babies at different time-points during the first 3 years of life.",decreased,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus,2|1239|91061|186826|33958|1578,Complete,Shaimaa Elsafoury
bsdb:63/3/1,Study 63,time series / longitudinal observational,28018325,10.3389/fmicb.2016.01997,NA,"Nagpal R, Tsuji H, Takahashi T, Kawashima K, Nagata S, Nomoto K , Yamashiro Y",Sensitive Quantitative Analysis of the Meconium Bacterial Microbiota in Healthy Term Infants Born Vaginally or by Cesarean Section,Frontiers in microbiology,2016,"C-section, Lactobacillus, RT-qPCR, dysbiosis, gut bacteria, intestinal microbiota, meconium",Experiment 3,Japan,Homo sapiens,Feces,UBERON:0001988,Cesarean section,EFO:0009636,vaginal delivery after 6 months of delivery,C-section delivery,NA,134,17,No information about pre-delivey duration. 3 Vaginally-delivered infants have been exposed to antibiotics (birth to sampling),16S,NA,RT-qPCR,T-Test,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Figure 2,10 January 2021,Shaimaa Elsafoury,WikiWorks,"Differences in the detection rate of Lactobacillus genus, subgroups and species between vaginally- and cesarean-born babies at different time-points during the first 3 years of life.",decreased,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Limosilactobacillus|s__Limosilactobacillus reuteri,2|1239|91061|186826|33958|2742598|1598,Complete,Shaimaa Elsafoury
bsdb:64/1/1,Study 64,case-control,23613868,10.1371/journal.pone.0061516,NA,"Zhou M, Rong R, Munro D, Zhu C, Gao X, Zhang Q , Dong Q",Investigation of the effect of type 2 diabetes mellitus on subgingival plaque microbiota by high-throughput 16S rDNA pyrosequencing,PloS one,2013,NA,Experiment 1,China,Homo sapiens,Subgingival dental plaque,UBERON:0016484,Periodontitis,EFO:0000649,No Periodontitis within negative diabetic background only,periodontitis,"Periodontitis was defined by the following criteria: at least 30% of sites with probing depth and attachment loss, and more than four with probing depth >=4 mm and clinical attachment loss >=2 mm. Subjects with type 2 diabetes had been diagnosed for at least one year with HbA1c >= 6.5%, fasting plasma glucose test >=7.0 mmol/L, or OGTT 2 hour glucose test >=11.1 mmol/L",5,6,3 months,16S,123,Roche454,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Table 1,10 January 2021,Yaseen Javaid,"WikiWorks,ChiomaBlessing",Significant differential abundant bacteria in periodontitis group VS healthy group within the diabetes-negative group,increased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae,k__Bacteria|p__Bacillota|c__Negativicutes|o__Selenomonadales|f__Selenomonadaceae|g__Selenomonas|s__Selenomonas sputigena,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus|s__Streptococcus gordonii",2|976|200643|171549|171552;2|1239|909932|909929|1843491|970|69823;2|1239|91061|186826|1300|1301|1302,Complete,Shaimaa Elsafoury
bsdb:64/1/2,Study 64,case-control,23613868,10.1371/journal.pone.0061516,NA,"Zhou M, Rong R, Munro D, Zhu C, Gao X, Zhang Q , Dong Q",Investigation of the effect of type 2 diabetes mellitus on subgingival plaque microbiota by high-throughput 16S rDNA pyrosequencing,PloS one,2013,NA,Experiment 1,China,Homo sapiens,Subgingival dental plaque,UBERON:0016484,Periodontitis,EFO:0000649,No Periodontitis within negative diabetic background only,periodontitis,"Periodontitis was defined by the following criteria: at least 30% of sites with probing depth and attachment loss, and more than four with probing depth >=4 mm and clinical attachment loss >=2 mm. Subjects with type 2 diabetes had been diagnosed for at least one year with HbA1c >= 6.5%, fasting plasma glucose test >=7.0 mmol/L, or OGTT 2 hour glucose test >=11.1 mmol/L",5,6,3 months,16S,123,Roche454,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 2,Table 1,10 January 2021,Yaseen Javaid,"Fatima,WikiWorks,ChiomaBlessing",Significant differential abundant bacteria in periodontitis group VS healthy group within the diabetes-negative group,decreased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Aggregatibacter,k__Bacteria|p__Bacteroidota|c__Flavobacteriia|o__Flavobacteriales|f__Flavobacteriaceae|g__Capnocytophaga|s__Capnocytophaga sputigena,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Cardiobacteriales|f__Cardiobacteriaceae|g__Cardiobacterium|s__Cardiobacterium hominis,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Cardiobacteriales|f__Cardiobacteriaceae|g__Cardiobacterium|s__Cardiobacterium valvarum,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Mycobacteriales|f__Corynebacteriaceae|g__Corynebacterium|s__Corynebacterium matruchotii,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Hoylesella|s__Hoylesella loescheii,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Leptotrichiaceae|g__Leptotrichia,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Leptotrichiaceae,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Neisseriaceae|g__Neisseria|s__Neisseria flavescens,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae|g__Porphyromonas|s__Porphyromonas sp.,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Propionibacteriales|f__Propionibacteriaceae,k__Bacteria|p__Bacillota|c__Negativicutes|o__Selenomonadales|f__Selenomonadaceae|g__Selenomonas|s__Selenomonas noxia",2|1224|1236|135625|712|416916;2|976|117743|200644|49546|1016|1019;2|1224|1236|135615|868|2717|2718;2|1224|1236|135615|868|2717|194702;2|201174|1760|85007|1653|1716|43768;2|976|200643|171549|171552|2974257|840;2|32066|203490|203491|1129771|32067;2|32066|203490|203491|1129771;2|1224|28216|206351|481|482|484;2|976|200643|171549|171551|836|1924944;2|201174|1760|85009|31957;2|1239|909932|909929|1843491|970|135083,Complete,Fatima
bsdb:64/2/1,Study 64,case-control,23613868,10.1371/journal.pone.0061516,NA,"Zhou M, Rong R, Munro D, Zhu C, Gao X, Zhang Q , Dong Q",Investigation of the effect of type 2 diabetes mellitus on subgingival plaque microbiota by high-throughput 16S rDNA pyrosequencing,PloS one,2013,NA,Experiment 2,China,Homo sapiens,Subgingival dental plaque,UBERON:0016484,Type II diabetes mellitus,MONDO:0005148,Non-diabetic within negative periodontitis,Diabetic,"Periodontitis was defined by the following criteria: at least 30% of sites with probing depth and attachment loss, and more than four with probing depth >=4 mm and clinical attachment loss >=2 mm. Subjects with type 2 diabetes had been diagnosed for at least one year with HbA1c >= 6.5%, fasting plasma glucose test >=7.0 mmol/L, or OGTT 2 hour glucose test >=11.1 mmol/L",5,8,3 months,16S,123,Roche454,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Table 2,10 January 2021,Yaseen Javaid,"WikiWorks,ChiomaBlessing",Significant differential abundant bacteria in diabetic VS non-diabetic group within periodontitis-negative samples,increased,"k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Tannerellaceae|g__Tannerella|s__Tannerella forsythia",2|201174|1760|2037;2|1224|28216|80840;2|1224|28216|206351;2|976|200643|171549|2005525|195950|28112,Complete,Shaimaa Elsafoury
bsdb:64/2/2,Study 64,case-control,23613868,10.1371/journal.pone.0061516,NA,"Zhou M, Rong R, Munro D, Zhu C, Gao X, Zhang Q , Dong Q",Investigation of the effect of type 2 diabetes mellitus on subgingival plaque microbiota by high-throughput 16S rDNA pyrosequencing,PloS one,2013,NA,Experiment 2,China,Homo sapiens,Subgingival dental plaque,UBERON:0016484,Type II diabetes mellitus,MONDO:0005148,Non-diabetic within negative periodontitis,Diabetic,"Periodontitis was defined by the following criteria: at least 30% of sites with probing depth and attachment loss, and more than four with probing depth >=4 mm and clinical attachment loss >=2 mm. Subjects with type 2 diabetes had been diagnosed for at least one year with HbA1c >= 6.5%, fasting plasma glucose test >=7.0 mmol/L, or OGTT 2 hour glucose test >=11.1 mmol/L",5,8,3 months,16S,123,Roche454,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 2,Table 2,10 January 2021,Yaseen Javaid,"WikiWorks,ChiomaBlessing",Significant differential abundant bacteria in diabetic VS non-diabetic group within periodontitis-negative samples,decreased,"k__Bacteria|p__Bacteroidota|c__Flavobacteriia|o__Flavobacteriales|f__Flavobacteriaceae|g__Capnocytophaga|s__Capnocytophaga ochracea,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Cardiobacteriales|f__Cardiobacteriaceae|g__Cardiobacterium|s__Cardiobacterium valvarum,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Mycobacteriales|f__Corynebacteriaceae|g__Corynebacterium|s__Corynebacterium matruchotii,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Hoylesella|s__Hoylesella loescheii,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Neisseriaceae|g__Neisseria|s__Neisseria flavescens",2|976|117743|200644|49546|1016|1018;2|1224|1236|135615|868|2717|194702;2|201174|1760|85007|1653|1716|43768;2|976|200643|171549|171552|2974257|840;2|1224|28216|206351|481|482|484,Complete,Shaimaa Elsafoury
bsdb:64/3/1,Study 64,case-control,23613868,10.1371/journal.pone.0061516,NA,"Zhou M, Rong R, Munro D, Zhu C, Gao X, Zhang Q , Dong Q",Investigation of the effect of type 2 diabetes mellitus on subgingival plaque microbiota by high-throughput 16S rDNA pyrosequencing,PloS one,2013,NA,Experiment 3,China,Homo sapiens,Subgingival dental plaque,UBERON:0016484,Type II diabetes mellitus,MONDO:0005148,Non-diabetic within positive periodontitis,Diabetic,"Periodontitis was defined by the following criteria: at least 30% of sites with probing depth and attachment loss, and more than four with probing depth >=4 mm and clinical attachment loss >=2 mm. Subjects with type 2 diabetes had been diagnosed for at least one year with HbA1c >= 6.5%, fasting plasma glucose test >=7.0 mmol/L, or OGTT 2 hour glucose test >=11.1 mmol/L",6,12,3 months,16S,123,Roche454,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Table 2,10 January 2021,Shaimaa Elsafoury,"WikiWorks,ChiomaBlessing",Significant differential abundant bacteria in diabetic VS non-diabetic group within periodontitis-positive samples,increased,"k__Bacteria|p__Bacteroidota|c__Flavobacteriia|o__Flavobacteriales|f__Flavobacteriaceae|g__Capnocytophaga|s__Capnocytophaga sputigena,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Propionibacteriales|f__Propionibacteriaceae",2|976|117743|200644|49546|1016|1019;2|201174|1760|85009|31957,Complete,Shaimaa Elsafoury
bsdb:64/4/1,Study 64,case-control,23613868,10.1371/journal.pone.0061516,NA,"Zhou M, Rong R, Munro D, Zhu C, Gao X, Zhang Q , Dong Q",Investigation of the effect of type 2 diabetes mellitus on subgingival plaque microbiota by high-throughput 16S rDNA pyrosequencing,PloS one,2013,NA,Experiment 4,China,Homo sapiens,Subgingival dental plaque,UBERON:0016484,Periodontitis,EFO:0000649,No Periodontitis within positive diabetic background only,periodontitis,"Periodontitis was defined by the following criteria: at least 30% of sites with probing depth and attachment loss, and more than four with probing depth >=4 mm and clinical attachment loss >=2 mm. Subjects with type 2 diabetes had been diagnosed for at least one year with HbA1c >= 6.5%, fasting plasma glucose test >=7.0 mmol/L, or OGTT 2 hour glucose test >=11.1 mmol/L",8,12,3 months,16S,123,Roche454,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Table 1,10 January 2021,Shaimaa Elsafoury,"WikiWorks,ChiomaBlessing",Significant differential abundant bacteria in periodontitis group VS healthy group within the diabetes-positive background,increased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Filifactoraceae|g__Filifactor|s__Filifactor alocis,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Leptotrichiaceae|g__Leptotrichia,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae|g__Porphyromonas|s__Porphyromonas endodontalis,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae|g__Porphyromonas|s__Porphyromonas gingivalis,k__Bacteria|p__Synergistota|c__Synergistia|o__Synergistales|f__Synergistaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Tannerellaceae|g__Tannerella|s__Tannerella forsythia,k__Bacteria|p__Spirochaetota|c__Spirochaetia|o__Spirochaetales|f__Treponemataceae|g__Treponema|s__Treponema medium",2|976|200643|171549;2|1239|186801|3082720|3118655|44259|143361;2|32066|203490|203491|1129771|32067;2|976|200643|171549|171551|836|28124;2|976|200643|171549|171551|836|837;2|508458|649775|649776|649777;2|976|200643|171549|2005525|195950|28112;2|203691|203692|136|2845253|157|58231,Complete,Shaimaa Elsafoury
bsdb:64/4/2,Study 64,case-control,23613868,10.1371/journal.pone.0061516,NA,"Zhou M, Rong R, Munro D, Zhu C, Gao X, Zhang Q , Dong Q",Investigation of the effect of type 2 diabetes mellitus on subgingival plaque microbiota by high-throughput 16S rDNA pyrosequencing,PloS one,2013,NA,Experiment 4,China,Homo sapiens,Subgingival dental plaque,UBERON:0016484,Periodontitis,EFO:0000649,No Periodontitis within positive diabetic background only,periodontitis,"Periodontitis was defined by the following criteria: at least 30% of sites with probing depth and attachment loss, and more than four with probing depth >=4 mm and clinical attachment loss >=2 mm. Subjects with type 2 diabetes had been diagnosed for at least one year with HbA1c >= 6.5%, fasting plasma glucose test >=7.0 mmol/L, or OGTT 2 hour glucose test >=11.1 mmol/L",8,12,3 months,16S,123,Roche454,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 2,Table 1,10 January 2021,Shaimaa Elsafoury,"WikiWorks,ChiomaBlessing",Significant differential abundant bacteria in periodontitis group VS healthy group within the diabetes-positive background,decreased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Haemophilus|s__Haemophilus parainfluenzae,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Neisseriaceae|g__Neisseria,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Neisseriaceae|g__Neisseria|s__Neisseria elongata,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micrococcales|f__Micrococcaceae|g__Rothia|s__Rothia dentocariosa,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Veillonella",2|1224|1236|135625|712|724|729;2|1224|28216|206351|481|482;2|1224|28216|206351|481|482|495;2|201174|1760|85006|1268|32207|2047;2|1239|909932|1843489|31977|29465,Complete,Shaimaa Elsafoury
bsdb:64/5/1,Study 64,case-control,23613868,10.1371/journal.pone.0061516,NA,"Zhou M, Rong R, Munro D, Zhu C, Gao X, Zhang Q , Dong Q",Investigation of the effect of type 2 diabetes mellitus on subgingival plaque microbiota by high-throughput 16S rDNA pyrosequencing,PloS one,2013,NA,Experiment 5,China,Homo sapiens,Subgingival dental plaque,UBERON:0016484,Periodontitis,EFO:0000649,No Periodontitis within both positive and negative diabetic background,periodontitis,"Periodontitis was defined by the following criteria: at least 30% of sites with probing depth and attachment loss, and more than four with probing depth >=4 mm and clinical attachment loss >=2 mm. Subjects with type 2 diabetes had been diagnosed for at least one year with HbA1c >= 6.5%, fasting plasma glucose test >=7.0 mmol/L, or OGTT 2 hour glucose test >=11.1 mmol/L",13,18,3 months,16S,123,Roche454,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Table 1,10 January 2021,Shaimaa Elsafoury,"WikiWorks,ChiomaBlessing",Significant differential abundant bacteria in periodontitis group VS healthy group within both the diabetes-positive and diabetes-negative background,increased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella|s__Prevotella intermedia,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae,k__Bacteria|p__Spirochaetota|c__Spirochaetia|o__Spirochaetales|f__Treponemataceae|g__Treponema|s__Treponema denticola",2|976|200643|171549|171552|838|28131;2|976|200643|171549|171552;2|203691|203692|136|2845253|157|158,Complete,Shaimaa Elsafoury
bsdb:64/5/2,Study 64,case-control,23613868,10.1371/journal.pone.0061516,NA,"Zhou M, Rong R, Munro D, Zhu C, Gao X, Zhang Q , Dong Q",Investigation of the effect of type 2 diabetes mellitus on subgingival plaque microbiota by high-throughput 16S rDNA pyrosequencing,PloS one,2013,NA,Experiment 5,China,Homo sapiens,Subgingival dental plaque,UBERON:0016484,Periodontitis,EFO:0000649,No Periodontitis within both positive and negative diabetic background,periodontitis,"Periodontitis was defined by the following criteria: at least 30% of sites with probing depth and attachment loss, and more than four with probing depth >=4 mm and clinical attachment loss >=2 mm. Subjects with type 2 diabetes had been diagnosed for at least one year with HbA1c >= 6.5%, fasting plasma glucose test >=7.0 mmol/L, or OGTT 2 hour glucose test >=11.1 mmol/L",13,18,3 months,16S,123,Roche454,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 2,Table 1,10 January 2021,Shaimaa Elsafoury,"WikiWorks,ChiomaBlessing",Significant differential abundant bacteria in periodontitis group VS healthy group within both the diabetes-positive and diabetes-negative background,decreased,"k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales|f__Actinomycetaceae|g__Actinomyces|s__Actinomyces naeslundii,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus|s__Streptococcus gordonii,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus|s__Streptococcus infantis",2|201174|1760|2037|2049|1654|1655;2|1239|91061|186826|1300|1301|1302;2|1239|91061|186826|1300|1301|68892,Complete,Shaimaa Elsafoury
bsdb:65/1/1,Study 65,case-control,22762355,10.1111/j.1600-0765.2012.01498.x,NA,"Casarin RC, Barbagallo A, Meulman T, Santos VR, Sallum EA, Nociti FH, Duarte PM, Casati MZ , Gonçalves RB",Subgingival biodiversity in subjects with uncontrolled type-2 diabetes and chronic periodontitis,Journal of periodontal research,2013,NA,Experiment 1,Brazil,Homo sapiens,Subgingival dental plaque,UBERON:0016484,Type II diabetes mellitus,MONDO:0005148,Non-diabetic,Diabetic,"chronic periodontitis, according to the criteria of the 1999 International Classification; the presence of at least 15 teeth; >= 30% of the sites and at least nine teeth pre-senting a probing pocket depth of >= 5 mm with bleeding on probing (with two or more of these teeth having a probing pocket depth of >= 7 mm); uncontrolled type-2 DM, determined by a glycated hemoglobin (HbA1c) concentration of > 8%",11,12,3 months,16S,NA,Illumina,T-Test,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Table 2 & Table 3 & text,10 January 2021,Yaseen Javaid,WikiWorks,Subgingival biodiversity in subjects with uncontrolled type-2 diabetes and chronic periodontitis.,increased,"k__Bacteria|p__Actinomycetota,k__Bacteria|p__Deferribacterota,k__Bacteria|p__Bacillota,k__Bacteria|p__Fusobacteriota,k__Bacteria|p__Pseudomonadota,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus|s__Streptococcus mitis,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae|g__Fusobacterium|s__Fusobacterium nucleatum,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Veillonella|s__Veillonella parvula,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Veillonella|s__Veillonella dispar,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Neisseriaceae|g__Eikenella|s__Eikenella corrodens,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Aggregatibacter,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Neisseriaceae|g__Neisseria,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Gemellaceae|g__Gemella,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Neisseriaceae|g__Eikenella,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales|f__Actinomycetaceae|g__Actinomyces,k__Bacteria|p__Bacteroidota|c__Flavobacteriia|o__Flavobacteriales|f__Flavobacteriaceae|g__Capnocytophaga,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae|g__Fusobacterium,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Veillonella,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus,k__Bacteria|p__Bacillota|c__Negativicutes|o__Selenomonadales|f__Selenomonadaceae|g__Selenomonas",2|201174;2|200930;2|1239;2|32066;2|1224;2|1239|91061|186826|1300|1301|28037;2|32066|203490|203491|203492|848|851;2|1239|909932|1843489|31977|29465|29466;2|1239|909932|1843489|31977|29465|39778;2|1224|28216|206351|481|538|539;2|1224|1236|135625|712|416916;2|1224|28216|206351|481|482;2|1239|91061|1385|539738|1378;2|1224|28216|206351|481|538;2|201174|1760|2037|2049|1654;2|976|117743|200644|49546|1016;2|32066|203490|203491|203492|848;2|1239|909932|1843489|31977|29465;2|1239|91061|186826|1300|1301;2|1239|909932|909929|1843491|970,Complete,Shaimaa Elsafoury
bsdb:65/1/2,Study 65,case-control,22762355,10.1111/j.1600-0765.2012.01498.x,NA,"Casarin RC, Barbagallo A, Meulman T, Santos VR, Sallum EA, Nociti FH, Duarte PM, Casati MZ , Gonçalves RB",Subgingival biodiversity in subjects with uncontrolled type-2 diabetes and chronic periodontitis,Journal of periodontal research,2013,NA,Experiment 1,Brazil,Homo sapiens,Subgingival dental plaque,UBERON:0016484,Type II diabetes mellitus,MONDO:0005148,Non-diabetic,Diabetic,"chronic periodontitis, according to the criteria of the 1999 International Classification; the presence of at least 15 teeth; >= 30% of the sites and at least nine teeth pre-senting a probing pocket depth of >= 5 mm with bleeding on probing (with two or more of these teeth having a probing pocket depth of >= 7 mm); uncontrolled type-2 DM, determined by a glycated hemoglobin (HbA1c) concentration of > 8%",11,12,3 months,16S,NA,Illumina,T-Test,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 2,Table 2 & Table 3 & text,10 January 2021,Yaseen Javaid,WikiWorks,Subgingival biodiversity in subjects with uncontrolled type-2 diabetes and chronic periodontitis.,decreased,"k__Bacteria|p__Bacteroidota,k__Bacteria|p__Spirochaetota,k__Bacteria|p__Synergistota,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Filifactoraceae|g__Filifactor|s__Filifactor alocis,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae|g__Porphyromonas|s__Porphyromonas gingivalis,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Eubacteriaceae|g__Eubacterium,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Filifactoraceae|g__Filifactor,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae|g__Porphyromonas,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Peptostreptococcaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Tannerellaceae|g__Tannerella|s__Tannerella forsythia,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Tannerellaceae|g__Tannerella,k__Bacteria|p__Spirochaetota|c__Spirochaetia|o__Spirochaetales|f__Treponemataceae|g__Treponema",2|976;2|203691;2|508458;2|1239|186801|3082720|3118655|44259|143361;2|976|200643|171549|171551|836|837;2|1239|186801|186802|186806|1730;2|1239|186801|3082720|3118655|44259;2|976|200643|171549|171551|836;2|1239|186801|3082720|186804;2|976|200643|171549|2005525|195950|28112;2|976|200643|171549|2005525|195950;2|203691|203692|136|2845253|157,Complete,Shaimaa Elsafoury
bsdb:66/1/1,Study 66,case-control,30237489,10.1038/s41424-018-0048-x,NA,"Dong T, Chen T, White RA, Wang X, Hu W, Liang Y, Zhang Y, Lu C, Chen M, Aase H , Xia Y",Meconium microbiome associates with the development of neonatal jaundice,Clinical and translational gastroenterology,2018,NA,Experiment 1,China,Homo sapiens,Meconium,UBERON:0007109,Neonatal jaundice,EFO:1000739,control,cesarean infants with jaundice,cesarean infants with jaundice,160,141,"among all the participants,11 mothers used antibiotics during pregnancy and 4 infants used antibiotics after birth.",16S,3,Illumina,LEfSe,0.05,FALSE,2.5,NA,"alcohol drinking,birth weight,gestational age,gestational diabetes,maternal age,preterm premature rupture of the membranes,sex,smoking behavior",NA,unchanged,NA,NA,NA,NA,Signature 1,Figure 3,10 January 2021,Rimsha Azhar,WikiWorks,LDA Score (log10) between control and case groups in cesarean infants with jaundice,increased,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Burkholderiaceae|g__Cupriavidus,2|1224|28216|80840|119060|106589,Complete,Shaimaa Elsafoury
bsdb:66/1/2,Study 66,case-control,30237489,10.1038/s41424-018-0048-x,NA,"Dong T, Chen T, White RA, Wang X, Hu W, Liang Y, Zhang Y, Lu C, Chen M, Aase H , Xia Y",Meconium microbiome associates with the development of neonatal jaundice,Clinical and translational gastroenterology,2018,NA,Experiment 1,China,Homo sapiens,Meconium,UBERON:0007109,Neonatal jaundice,EFO:1000739,control,cesarean infants with jaundice,cesarean infants with jaundice,160,141,"among all the participants,11 mothers used antibiotics during pregnancy and 4 infants used antibiotics after birth.",16S,3,Illumina,LEfSe,0.05,FALSE,2.5,NA,"alcohol drinking,birth weight,gestational age,gestational diabetes,maternal age,preterm premature rupture of the membranes,sex,smoking behavior",NA,unchanged,NA,NA,NA,NA,Signature 2,Figure 3,10 January 2021,Rimsha Azhar,WikiWorks,LDA Score (log10) between control and case groups in cesarean infants with jaundice,decreased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium|s__Bifidobacterium pseudolongum|s__Bifidobacterium pseudolongum subsp. globosum,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales",2|1239|186801|186802|31979;2|1224|1236|135625|712;2|201174|1760|85004|31953|1678|1694|1690;2|1224|1236|135625,Complete,Shaimaa Elsafoury
bsdb:66/2/1,Study 66,case-control,30237489,10.1038/s41424-018-0048-x,NA,"Dong T, Chen T, White RA, Wang X, Hu W, Liang Y, Zhang Y, Lu C, Chen M, Aase H , Xia Y",Meconium microbiome associates with the development of neonatal jaundice,Clinical and translational gastroenterology,2018,NA,Experiment 2,China,Homo sapiens,Meconium,UBERON:0007109,Neonatal jaundice,EFO:1000739,control,infants with jaundice,infants with jaundice,160,141,"among all the participants,11 mothers used antibiotics during pregnancy and 4 infants used antibiotics after birth.",16S,3,Illumina,LEfSe,0.05,FALSE,2.5,NA,"alcohol drinking,birth weight,feeding practices,gestational age,gestational diabetes,maternal age,mode of birth,preterm premature rupture of the membranes,sex,smoking behavior",NA,unchanged,NA,NA,NA,NA,Signature 1,Supplementary Figure 2,10 January 2021,Rimsha Azhar,WikiWorks,LDA Score (log10) between control and case groups in all infants,increased,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Clostridium|s__Clostridium perfringens,2|1239|186801|186802|31979|1485|1502,Complete,Shaimaa Elsafoury
bsdb:66/2/2,Study 66,case-control,30237489,10.1038/s41424-018-0048-x,NA,"Dong T, Chen T, White RA, Wang X, Hu W, Liang Y, Zhang Y, Lu C, Chen M, Aase H , Xia Y",Meconium microbiome associates with the development of neonatal jaundice,Clinical and translational gastroenterology,2018,NA,Experiment 2,China,Homo sapiens,Meconium,UBERON:0007109,Neonatal jaundice,EFO:1000739,control,infants with jaundice,infants with jaundice,160,141,"among all the participants,11 mothers used antibiotics during pregnancy and 4 infants used antibiotics after birth.",16S,3,Illumina,LEfSe,0.05,FALSE,2.5,NA,"alcohol drinking,birth weight,feeding practices,gestational age,gestational diabetes,maternal age,mode of birth,preterm premature rupture of the membranes,sex,smoking behavior",NA,unchanged,NA,NA,NA,NA,Signature 2,Supplementary Figure 2,10 January 2021,Rimsha Azhar,WikiWorks,LDA Score (log10) between control and case groups in all infants,decreased,"k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micrococcales|f__Micrococcaceae|g__Rothia|s__Rothia mucilaginosa,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus",2|201174|1760|85006|1268|32207|43675;2|1239|91061|186826|1300|1301,Complete,Shaimaa Elsafoury
bsdb:67/1/1,Study 67,case-control,28222761,10.1186/s40168-017-0242-1,NA,"Strati F, Cavalieri D, Albanese D, De Felice C, Donati C, Hayek J, Jousson O, Leoncini S, Renzi D, Calabrò A , De Filippo C",New evidences on the altered gut microbiota in autism spectrum disorders,Microbiome,2017,"Autism spectrum disorders, Constipation, Gut microbiota, Metataxonomy, Mycobiota",Experiment 1,Italy,Homo sapiens,Feces,UBERON:0001988,Autism,EFO:0003758,neurotypical,autistic,"cases were diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition.",40,40,3 months,16S,345,Roche454,Welch's T-Test,0.05,TRUE,NA,NA,"age,sex",NA,NA,NA,NA,NA,NA,Signature 1,Figure 2,10 January 2021,Fatima Zohra,WikiWorks,Mean relative abundance in autistic (AD) and neurotypical (NT) subjects,decreased,k__Bacteria|p__Bacteroidota,2|976,Complete,Shaimaa Elsafoury
bsdb:67/2/1,Study 67,case-control,28222761,10.1186/s40168-017-0242-1,NA,"Strati F, Cavalieri D, Albanese D, De Felice C, Donati C, Hayek J, Jousson O, Leoncini S, Renzi D, Calabrò A , De Filippo C",New evidences on the altered gut microbiota in autism spectrum disorders,Microbiome,2017,"Autism spectrum disorders, Constipation, Gut microbiota, Metataxonomy, Mycobiota",Experiment 2,Italy,Homo sapiens,Feces,UBERON:0001988,Autism,EFO:0003758,neurotypical,autistic,"cases were diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition.",40,40,3 months,16S,345,Roche454,LEfSe,0.01,FALSE,2,NA,"age,sex",NA,NA,NA,NA,NA,NA,Signature 1,Figure 3,10 January 2021,Fatima Zohra,WikiWorks,Differences in the bacterial taxa between autistic (AD) and neurotypical (NT) subjects,increased,"k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales|f__Coriobacteriaceae|g__Collinsella,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Mycobacteriales|f__Corynebacteriaceae|g__Corynebacterium,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Mycobacteriales|f__Corynebacteriaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Dorea,k__Bacteria|p__Bacteroidota|c__Bacteroidia",2|1239|91061|186826|33958|1578;2|201174|84998|84999|84107|102106;2|201174|1760|85007|1653|1716;2|201174|1760|85007|1653;2|1239|186801|3085636|186803|189330;2|976|200643,Complete,Shaimaa Elsafoury
bsdb:67/2/2,Study 67,case-control,28222761,10.1186/s40168-017-0242-1,NA,"Strati F, Cavalieri D, Albanese D, De Felice C, Donati C, Hayek J, Jousson O, Leoncini S, Renzi D, Calabrò A , De Filippo C",New evidences on the altered gut microbiota in autism spectrum disorders,Microbiome,2017,"Autism spectrum disorders, Constipation, Gut microbiota, Metataxonomy, Mycobiota",Experiment 2,Italy,Homo sapiens,Feces,UBERON:0001988,Autism,EFO:0003758,neurotypical,autistic,"cases were diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition.",40,40,3 months,16S,345,Roche454,LEfSe,0.01,FALSE,2,NA,"age,sex",NA,NA,NA,NA,NA,NA,Signature 2,Figure 3,10 January 2021,Fatima Zohra,WikiWorks,Differences in the bacterial taxa between autistic (AD) and neurotypical (NT) subjects,decreased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Rikenellaceae|g__Alistipes,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae,k__Bacteria|p__Bacillota|c__Negativicutes|o__Selenomonadales,k__Bacteria|p__Bacillota|c__Negativicutes,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Dialister,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Tannerellaceae|g__Parabacteroides,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Veillonella,k__Bacteria|p__Thermodesulfobacteriota|c__Desulfovibrionia|o__Desulfovibrionales|f__Desulfovibrionaceae|g__Bilophila,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales",2|976|200643|171549|171550|239759;2|1239|909932|1843489|31977;2|1239|909932|909929;2|1239|909932;2|1239|909932|1843489|31977|39948;2|976|200643|171549|2005525|375288;2|1239|909932|1843489|31977|29465;2|200940|3031449|213115|194924|35832;2|976|200643|171549,Complete,Shaimaa Elsafoury
bsdb:67/3/1,Study 67,case-control,28222761,10.1186/s40168-017-0242-1,NA,"Strati F, Cavalieri D, Albanese D, De Felice C, Donati C, Hayek J, Jousson O, Leoncini S, Renzi D, Calabrò A , De Filippo C",New evidences on the altered gut microbiota in autism spectrum disorders,Microbiome,2017,"Autism spectrum disorders, Constipation, Gut microbiota, Metataxonomy, Mycobiota",Experiment 3,Italy,Homo sapiens,Feces,UBERON:0001988,Autism,EFO:0003758,non constipated autistic,constipated autistic,"cases were diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition.",29,5,3 months,16S,345,Roche454,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,"age,sex",NA,NA,NA,NA,NA,NA,Signature 1,Figure 4,10 January 2021,Shaimaa Elsafoury,WikiWorks,Differences in the bacterial taxa between constipated and non-constipated autistic (AD) patients,increased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Escherichia,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Shigella,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Clostridium",2|1224|1236|91347|543|561;2|1224|1236|91347|543|620;2|1239|186801|186802|31979|1485,Complete,Shaimaa Elsafoury
bsdb:67/4/1,Study 67,case-control,28222761,10.1186/s40168-017-0242-1,NA,"Strati F, Cavalieri D, Albanese D, De Felice C, Donati C, Hayek J, Jousson O, Leoncini S, Renzi D, Calabrò A , De Filippo C",New evidences on the altered gut microbiota in autism spectrum disorders,Microbiome,2017,"Autism spectrum disorders, Constipation, Gut microbiota, Metataxonomy, Mycobiota",Experiment 4,Italy,Homo sapiens,Feces,UBERON:0001988,Autism,EFO:0003758,non constipated neurotypical,constipated neurotypical,"cases were diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition.",29,11,3 months,16S,345,Roche454,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,"age,sex",NA,NA,NA,NA,NA,NA,Signature 1,Figure 4,10 January 2021,Shaimaa Elsafoury,WikiWorks,Differences in the bacterial taxa between constipated and non-constipated neurotypical (NT) subjects,decreased,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|g__Gemmiger,2|1239|186801|186802|204475,Complete,Shaimaa Elsafoury
bsdb:68/1/1,Study 68,"cross-sectional observational, not case-control",29950689,10.1038/s41598-018-28126-1,NA,"Peters BA, Shapiro JA, Church TR, Miller G, Trinh-Shevrin C, Yuen E, Friedlander C, Hayes RB , Ahn J",A taxonomic signature of obesity in a large study of American adults,Scientific reports,2018,NA,Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,normal weight,obese,"Healthy-weight was defined as BMI ≥ 18.5 and <25 kg/m2, overweight as BMI ≥ 25 and <30 kg/m2, and obese as BMI ≥ 30 kg/m2",211,142,long term use in NYU study. NA for CDC study,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,"age,polyp,sex",NA,unchanged,NA,NA,NA,decreased,Signature 1,Supplemental Table 4,10 January 2021,Marianthi Thomatos,"Merit,WikiWorks",Taxonomic sginature of obesity in a large study of American adults,increased,"k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales|f__Actinomycetaceae,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae|g__Amedibacillus|s__Amedibacillus dolichus,k__Bacteria|p__Bacillota|c__Bacilli,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides|s__Bacteroides ovatus,k__Bacteria|p__Thermodesulfobacteriota|c__Desulfovibrionia|o__Desulfovibrionales|f__Desulfovibrionaceae|g__Bilophila,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Blautia,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Clostridium,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Coprococcus,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Lachnobacterium,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae,k__Bacteria|p__Pseudomonadota,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Ruminococcus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae",2|201174|1760|2037|2049;2|201174|1760|2037;2|1239|526524|526525|128827|2749846|31971;2|1239|91061;2|976|200643|171549|815|816|28116;2|200940|3031449|213115|194924|35832;2|1239|186801|3085636|186803|572511;2|1239|186801|186802|31979|1485;2|1239|186801|3085636|186803|33042;2|1224|1236|91347;2|1224|1236|91347|543;2|1239|186801|186802;2|1224|1236;2|1239|186801|3085636|186803|140625;2|1239|186801|3085636|186803;2|1239|91061|186826|33958;2|1239|91061|186826;2|1239|91061|186826|33958|1578;2|1239|186801|186802|541000;2|1224;2|1239|186801|186802|216572|1263;2|1239|91061|186826|1300;2|1239|91061|186826|1300|1301;2|1239|909932|1843489|31977,Complete,Shaimaa Elsafoury
bsdb:68/1/2,Study 68,"cross-sectional observational, not case-control",29950689,10.1038/s41598-018-28126-1,NA,"Peters BA, Shapiro JA, Church TR, Miller G, Trinh-Shevrin C, Yuen E, Friedlander C, Hayes RB , Ahn J",A taxonomic signature of obesity in a large study of American adults,Scientific reports,2018,NA,Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,normal weight,obese,"Healthy-weight was defined as BMI ≥ 18.5 and <25 kg/m2, overweight as BMI ≥ 25 and <30 kg/m2, and obese as BMI ≥ 30 kg/m2",211,142,long term use in NYU study. NA for CDC study,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,"age,polyp,sex",NA,unchanged,NA,NA,NA,decreased,Signature 2,Supplemental Table 4,10 January 2021,Marianthi Thomatos,"Merit,WikiWorks",Taxonomic sginature of obesity in a large study of American adults,decreased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Christensenellales|f__Christensenellaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Clostridium,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Coprococcus,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Peptococcaceae|g__Dehalobacterium,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Dorea,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Faecalibacterium|s__Faecalibacterium prausnitzii,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Oscillospira,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Tannerellaceae|g__Parabacteroides,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Rikenellaceae",2|1239|186801|3082768|990719;2|1239|186801|186802|31979;2|1239|186801|186802|31979|1485;2|1239|186801|3085636|186803|33042;2|1239|186801|186802|186807|51514;2|1239|186801|3085636|186803|189330;2|1239|526524|526525|128827;2|1239|186801|186802;2|1239|186801|186802|216572|216851|853;2|1239|186801|3085636|186803;2|1239|186801|186802|216572|119852;2|1239|186801|186802|541000;2|976|200643|171549|2005525|375288;2|1224|1236|135625|712;2|1224|1236|135625;2|976|200643|171549|171550,Complete,Shaimaa Elsafoury
bsdb:68/2/1,Study 68,"cross-sectional observational, not case-control",29950689,10.1038/s41598-018-28126-1,NA,"Peters BA, Shapiro JA, Church TR, Miller G, Trinh-Shevrin C, Yuen E, Friedlander C, Hayes RB , Ahn J",A taxonomic signature of obesity in a large study of American adults,Scientific reports,2018,NA,Experiment 2,United States of America,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,normal weight,overweight,"Healthy-weight was defined as BMI ≥ 18.5 and <25 kg/m2, overweight as BMI ≥ 25 and <30 kg/m2, and obese as BMI ≥ 30 kg/m2",211,246,long term use in NYU study. NA for CDC study,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,"age,polyp,sex",NA,unchanged,NA,NA,NA,unchanged,Signature 1,Supplemental Table 4,10 January 2021,Shaimaa Elsafoury,WikiWorks,Taxonomic sginature of obesity in a large study of American adults,increased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides,k__Bacteria|p__Bacillota|c__Bacilli,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Clostridium,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Blautia,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Lachnobacterium,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Faecalibacterium|s__Faecalibacterium prausnitzii,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Ruminococcus,k__Bacteria|p__Thermodesulfobacteriota|c__Desulfovibrionia|o__Desulfovibrionales|f__Desulfovibrionaceae|g__Bilophila",2|976|200643|171549|815|816;2|1239|91061;2|1239|91061|186826;2|1239|91061|186826|33958;2|1239|91061|186826|33958|1578;2|1239|91061|186826|1300;2|1239|91061|186826|1300|1301;2|1239|186801|186802;2|1239|186801|186802|31979|1485;2|1239|186801|3085636|186803;2|1239|186801|3085636|186803|572511;2|1239|186801|3085636|186803|140625;2|1239|186801|186802|541000;2|1239|186801|186802|216572|216851|853;2|1239|186801|186802|216572|1263;2|200940|3031449|213115|194924|35832,Complete,Shaimaa Elsafoury
bsdb:68/2/2,Study 68,"cross-sectional observational, not case-control",29950689,10.1038/s41598-018-28126-1,NA,"Peters BA, Shapiro JA, Church TR, Miller G, Trinh-Shevrin C, Yuen E, Friedlander C, Hayes RB , Ahn J",A taxonomic signature of obesity in a large study of American adults,Scientific reports,2018,NA,Experiment 2,United States of America,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,normal weight,overweight,"Healthy-weight was defined as BMI ≥ 18.5 and <25 kg/m2, overweight as BMI ≥ 25 and <30 kg/m2, and obese as BMI ≥ 30 kg/m2",211,246,long term use in NYU study. NA for CDC study,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,"age,polyp,sex",NA,unchanged,NA,NA,NA,unchanged,Signature 2,Supplemental Table 4,10 January 2021,Shaimaa Elsafoury,"Merit,WikiWorks",Taxonomic sginature of obesity in a large study of American adults,decreased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Christensenellales|f__Christensenellaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Peptococcaceae|g__Dehalobacterium,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Oscillospira,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Tannerellaceae|g__Parabacteroides",2|1239|186801|3082768|990719;2|1239|186801|186802|31979;2|1239|186801|186802|186807|51514;2|1239|526524|526525|128827;2|1239|186801|186802;2|1239|186801|186802|216572|119852;2|1239|186801|186802|541000;2|976|200643|171549|2005525|375288,Complete,Shaimaa Elsafoury
bsdb:68/3/1,Study 68,"cross-sectional observational, not case-control",29950689,10.1038/s41598-018-28126-1,NA,"Peters BA, Shapiro JA, Church TR, Miller G, Trinh-Shevrin C, Yuen E, Friedlander C, Hayes RB , Ahn J",A taxonomic signature of obesity in a large study of American adults,Scientific reports,2018,NA,Experiment 3,United States of America,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,normal weight men,obese men,"Healthy-weight was defined as BMI ≥ 18.5 and <25 kg/m2, overweight as BMI ≥ 25 and <30 kg/m2, and obese as BMI ≥ 30 kg/m2",80,70,long term use in NYU study. NA for CDC study,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,"age,polyp,sex",NA,NA,NA,NA,NA,NA,Signature 1,Supplemental Table 5,10 January 2021,Marianthi Thomatos,WikiWorks,Taxonomic sginature of obesity in a large study of American adults,increased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Tannerellaceae|g__Parabacteroides|s__Parabacteroides distasonis,k__Bacteria|p__Bacillota|c__Bacilli,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Blautia,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae,k__Bacteria|p__Pseudomonadota,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria",2|976|200643|171549|2005525|375288|823;2|1239|91061;2|1239|91061|186826;2|1239|91061|186826|33958;2|1239|91061|186826|33958|1578;2|1239|91061|186826|1300|1301;2|1239|186801|3085636|186803|572511;2|1239|186801|186802|541000;2|1239|909932|1843489|31977;2|1224;2|1224|1236,Complete,Shaimaa Elsafoury
bsdb:68/3/2,Study 68,"cross-sectional observational, not case-control",29950689,10.1038/s41598-018-28126-1,NA,"Peters BA, Shapiro JA, Church TR, Miller G, Trinh-Shevrin C, Yuen E, Friedlander C, Hayes RB , Ahn J",A taxonomic signature of obesity in a large study of American adults,Scientific reports,2018,NA,Experiment 3,United States of America,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,normal weight men,obese men,"Healthy-weight was defined as BMI ≥ 18.5 and <25 kg/m2, overweight as BMI ≥ 25 and <30 kg/m2, and obese as BMI ≥ 30 kg/m2",80,70,long term use in NYU study. NA for CDC study,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,"age,polyp,sex",NA,NA,NA,NA,NA,NA,Signature 2,Supplemental Table 5,10 January 2021,Marianthi Thomatos,"Merit,WikiWorks",Taxonomic sginature of obesity in a large study of American adults,decreased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Mycobacteriales|f__Corynebacteriaceae,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Mycobacteriales|f__Corynebacteriaceae|g__Corynebacterium,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Peptococcaceae|g__Dehalobacterium,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Ruminococcus,k__Bacteria|p__Bacillota|c__Tissierellia|o__Tissierellales|f__Tissierellaceae",2|1239|186801|186802|31979;2|201174|1760|85007|1653;2|201174|1760|85007|1653|1716;2|1239|186801|186802|186807|51514;2|1239|186801|186802|216572|1263;2|1239|1737404|1737405|1737406,Complete,Shaimaa Elsafoury
bsdb:68/4/1,Study 68,"cross-sectional observational, not case-control",29950689,10.1038/s41598-018-28126-1,NA,"Peters BA, Shapiro JA, Church TR, Miller G, Trinh-Shevrin C, Yuen E, Friedlander C, Hayes RB , Ahn J",A taxonomic signature of obesity in a large study of American adults,Scientific reports,2018,NA,Experiment 4,United States of America,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,normal weight men,overweight men,"Healthy-weight was defined as BMI ≥ 18.5 and <25 kg/m2, overweight as BMI ≥ 25 and <30 kg/m2, and obese as BMI ≥ 30 kg/m3",80,171,long term use in NYU study. NA for CDC study,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,"age,polyp,sex",NA,NA,NA,NA,NA,NA,Signature 1,Supplemental Table 5,10 January 2021,Shaimaa Elsafoury,WikiWorks,Taxonomic sginature of obesity in a large study of American adults,increased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides,k__Bacteria|p__Bacillota|c__Bacilli,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Blautia,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Coprococcus,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Lachnobacterium",2|976|200643|171549|815|816;2|1239|91061;2|1239|91061|186826;2|1239|91061|186826|33958;2|1239|91061|186826|33958|1578;2|1239|91061|186826|1300|1301;2|1239|186801|3085636|186803|572511;2|1239|186801|3085636|186803|33042;2|1239|186801|3085636|186803|140625,Complete,Shaimaa Elsafoury
bsdb:68/4/2,Study 68,"cross-sectional observational, not case-control",29950689,10.1038/s41598-018-28126-1,NA,"Peters BA, Shapiro JA, Church TR, Miller G, Trinh-Shevrin C, Yuen E, Friedlander C, Hayes RB , Ahn J",A taxonomic signature of obesity in a large study of American adults,Scientific reports,2018,NA,Experiment 4,United States of America,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,normal weight men,overweight men,"Healthy-weight was defined as BMI ≥ 18.5 and <25 kg/m2, overweight as BMI ≥ 25 and <30 kg/m2, and obese as BMI ≥ 30 kg/m3",80,171,long term use in NYU study. NA for CDC study,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,"age,polyp,sex",NA,NA,NA,NA,NA,NA,Signature 2,Supplemental Table 5,10 January 2021,Shaimaa Elsafoury,"Merit,WikiWorks",Taxonomic sginature of obesity in a large study of American adults,decreased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Christensenellales|f__Christensenellaceae,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Mycobacteriales|f__Corynebacteriaceae,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Mycobacteriales|f__Corynebacteriaceae|g__Corynebacterium,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Peptococcaceae|g__Dehalobacterium,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae,k__Bacteria|p__Bacillota|c__Tissierellia|o__Tissierellales|f__Peptoniphilaceae|g__Finegoldia,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Megasphaera,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Ruminococcus,k__Bacteria|p__Synergistota|c__Synergistia,k__Bacteria|p__Bacillota|c__Tissierellia|o__Tissierellales|f__Tissierellaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Mediterraneibacter|s__Mediterraneibacter gnavus",2|1239|186801|3082768|990719;2|1224|28216|80840;2|1239|186801|186802|31979;2|201174|1760|85007|1653;2|201174|1760|85007|1653|1716;2|1239|186801|186802|186807|51514;2|1224|1236|91347;2|1224|1236|91347|543;2|1239|1737404|1737405|1570339|150022;2|1239|909932|1843489|31977|906;2|1239|186801|186802|216572|1263;2|508458|649775;2|1239|1737404|1737405|1737406;2|1239|186801|3085636|186803|2316020|33038,Complete,Shaimaa Elsafoury
bsdb:68/5/1,Study 68,"cross-sectional observational, not case-control",29950689,10.1038/s41598-018-28126-1,NA,"Peters BA, Shapiro JA, Church TR, Miller G, Trinh-Shevrin C, Yuen E, Friedlander C, Hayes RB , Ahn J",A taxonomic signature of obesity in a large study of American adults,Scientific reports,2018,NA,Experiment 5,United States of America,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,normal weight women,obese women,"Healthy-weight was defined as BMI ≥ 18.5 and <25 kg/m2, overweight as BMI ≥ 25 and <30 kg/m2, and obese as BMI ≥ 30 kg/m5",131,72,long term use in NYU study. NA for CDC study,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,"age,polyp,sex",NA,NA,NA,NA,NA,NA,Signature 1,Supplemental Table 5,10 January 2021,Marianthi Thomatos,WikiWorks,Taxonomic sginature of obesity in a large study of American adults,increased,"k__Bacteria|p__Bacillota|c__Bacilli,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Mediterraneibacter|s__Mediterraneibacter gnavus,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Lachnobacterium,k__Bacteria|p__Pseudomonadota,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae,k__Bacteria|p__Bacillota|c__Tissierellia|o__Tissierellales|f__Tissierellaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Ruminococcus",2|1239|91061;2|1239|91061|186826;2|1239|91061|186826|1300;2|1239|91061|186826|1300|1301;2|1239|186801|3085636|186803|2316020|33038;2|1239|186801|3085636|186803|140625;2|1224;2|1224|28216|80840;2|1224|1236;2|1224|1236|91347;2|1224|1236|91347|543;2|1239|1737404|1737405|1737406;2|1239|186801|186802|216572|1263,Complete,Shaimaa Elsafoury
bsdb:68/5/2,Study 68,"cross-sectional observational, not case-control",29950689,10.1038/s41598-018-28126-1,NA,"Peters BA, Shapiro JA, Church TR, Miller G, Trinh-Shevrin C, Yuen E, Friedlander C, Hayes RB , Ahn J",A taxonomic signature of obesity in a large study of American adults,Scientific reports,2018,NA,Experiment 5,United States of America,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,normal weight women,obese women,"Healthy-weight was defined as BMI ≥ 18.5 and <25 kg/m2, overweight as BMI ≥ 25 and <30 kg/m2, and obese as BMI ≥ 30 kg/m5",131,72,long term use in NYU study. NA for CDC study,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,"age,polyp,sex",NA,NA,NA,NA,NA,NA,Signature 2,Supplemental Table 5,10 January 2021,Marianthi Thomatos,"Merit,WikiWorks",Taxonomic sginature of obesity in a large study of American adults,decreased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Christensenellales|f__Christensenellaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Peptococcaceae|g__Dehalobacterium,k__Bacteria|p__Bacillota|c__Clostridia,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|s__Clostridiales bacterium",2|1239|186801|3082768|990719;2|1239|186801|186802|31979;2|1239|186801|186802|186807|51514;2|1239|186801;2|1239|186801|186802|1898207,Complete,Shaimaa Elsafoury
bsdb:68/6/1,Study 68,"cross-sectional observational, not case-control",29950689,10.1038/s41598-018-28126-1,NA,"Peters BA, Shapiro JA, Church TR, Miller G, Trinh-Shevrin C, Yuen E, Friedlander C, Hayes RB , Ahn J",A taxonomic signature of obesity in a large study of American adults,Scientific reports,2018,NA,Experiment 6,United States of America,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,normal weight women,overweight women,"Healthy-weight was defined as BMI ≥ 18.5 and <25 kg/m2, overweight as BMI ≥ 25 and <30 kg/m2, and obese as BMI ≥ 30 kg/m7",131,75,long term use in NYU study. NA for CDC study,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,"age,polyp,sex",NA,NA,NA,NA,NA,NA,Signature 1,Supplemental Table 5,10 January 2021,Shaimaa Elsafoury,WikiWorks,Taxonomic sginature of obesity in a large study of American adults,increased,"k__Bacteria|p__Bacillota|c__Bacilli,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Mediterraneibacter|s__Mediterraneibacter gnavus,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Ruminococcus,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Lachnobacterium,k__Bacteria|p__Pseudomonadota,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae",2|1239|91061;2|1239|91061|186826;2|1239|91061|186826|1300;2|1239|91061|186826|1300|1301;2|1239|186801|3085636|186803|2316020|33038;2|1239|186801|186802|216572|1263;2|1239|186801|3085636|186803|140625;2|1224;2|1224|28216|80840;2|1224|1236;2|1224|1236|91347;2|1224|1236|91347|543,Complete,Shaimaa Elsafoury
bsdb:68/6/2,Study 68,"cross-sectional observational, not case-control",29950689,10.1038/s41598-018-28126-1,NA,"Peters BA, Shapiro JA, Church TR, Miller G, Trinh-Shevrin C, Yuen E, Friedlander C, Hayes RB , Ahn J",A taxonomic signature of obesity in a large study of American adults,Scientific reports,2018,NA,Experiment 6,United States of America,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,normal weight women,overweight women,"Healthy-weight was defined as BMI ≥ 18.5 and <25 kg/m2, overweight as BMI ≥ 25 and <30 kg/m2, and obese as BMI ≥ 30 kg/m7",131,75,long term use in NYU study. NA for CDC study,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,"age,polyp,sex",NA,NA,NA,NA,NA,NA,Signature 2,Supplemental Table 5,10 January 2021,Shaimaa Elsafoury,"Merit,WikiWorks",Taxonomic sginature of obesity in a large study of American adults,decreased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae,k__Bacteria|p__Bacillota|c__Clostridia",2|1239|186801|186802|31979;2|1239|186801,Complete,Shaimaa Elsafoury
bsdb:69/1/1,Study 69,"cross-sectional observational, not case-control",29988340,10.3389/fmicb.2018.01250,NA,"Gao X, Zhang M, Xue J, Huang J, Zhuang R, Zhou X, Zhang H, Fu Q , Hao Y",Body Mass Index Differences in the Gut Microbiota Are Gender Specific,Frontiers in microbiology,2018,"16S rRNA, Chinese, gender, gut microbiota, obesity",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Sex design,EFO:0001752,male,female,NA,259,292,2 months,16S,34,Illumina,DESeq2,0.05,TRUE,NA,NA,age,NA,increased,NA,unchanged,unchanged,increased,Signature 1,supplementry figure S2,10 January 2021,Marianthi Thomatos,WikiWorks,Differences in body mass index  and gut microbiota by Gender,increased,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Ruminococcus,2|1239|186801|186802|216572|1263,Complete,Shaimaa Elsafoury
bsdb:69/2/1,Study 69,"cross-sectional observational, not case-control",29988340,10.3389/fmicb.2018.01250,NA,"Gao X, Zhang M, Xue J, Huang J, Zhuang R, Zhou X, Zhang H, Fu Q , Hao Y",Body Mass Index Differences in the Gut Microbiota Are Gender Specific,Frontiers in microbiology,2018,"16S rRNA, Chinese, gender, gut microbiota, obesity",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,female normal weight,female obese,NA,168,20,2 months,16S,34,Illumina,DESeq2,0.05,TRUE,NA,NA,age,NA,unchanged,NA,unchanged,unchanged,increased,Signature 1,Text + fig 2B,10 January 2021,Marianthi Thomatos,WikiWorks,Differences in body mass index and gut microbiota by Gender,decreased,k__Bacteria|p__Bacillota|c__Negativicutes|o__Acidaminococcales|f__Acidaminococcaceae|g__Phascolarctobacterium,2|1239|909932|1843488|909930|33024,Complete,Shaimaa Elsafoury
bsdb:69/3/1,Study 69,"cross-sectional observational, not case-control",29988340,10.3389/fmicb.2018.01250,NA,"Gao X, Zhang M, Xue J, Huang J, Zhuang R, Zhou X, Zhang H, Fu Q , Hao Y",Body Mass Index Differences in the Gut Microbiota Are Gender Specific,Frontiers in microbiology,2018,"16S rRNA, Chinese, gender, gut microbiota, obesity",Experiment 3,China,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,male normal weight,male obese,NA,93,38,2 months,16S,34,Illumina,DESeq2,0.05,TRUE,NA,NA,age,NA,unchanged,NA,unchanged,unchanged,unchanged,Signature 1,Text + fig 2B,10 January 2021,Marianthi Thomatos,WikiWorks,Differences in body mass index and gut microbiota by Gender,increased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Odoribacteraceae|g__Butyricimonas,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae|g__Fusobacterium",2|976|200643|171549|1853231|574697;2|32066|203490|203491|203492|848,Complete,Shaimaa Elsafoury
bsdb:69/4/1,Study 69,"cross-sectional observational, not case-control",29988340,10.3389/fmicb.2018.01250,NA,"Gao X, Zhang M, Xue J, Huang J, Zhuang R, Zhou X, Zhang H, Fu Q , Hao Y",Body Mass Index Differences in the Gut Microbiota Are Gender Specific,Frontiers in microbiology,2018,"16S rRNA, Chinese, gender, gut microbiota, obesity",Experiment 4,China,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,normal weight,obese,NA,261,58,2 months,16S,34,Illumina,DESeq2,0.05,TRUE,NA,NA,age,NA,unchanged,NA,unchanged,unchanged,unchanged,Signature 1,Text + fig 2B,10 January 2021,Marianthi Thomatos,WikiWorks,Differences in body mass index and gut microbiota by Gender,increased,"k__Bacteria|p__Fusobacteriota,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae|g__Fusobacterium",2|32066;2|32066|203490|203491|203492|848,Complete,Shaimaa Elsafoury
bsdb:70/1/1,Study 70,case-control,29388394,10.1111/ijpo.12262,NA,"López-Contreras BE, Morán-Ramos S, Villarruel-Vázquez R, Macías-Kauffer L, Villamil-Ramírez H, León-Mimila P, Vega-Badillo J, Sánchez-Muñoz F, Llanos-Moreno LE, Canizalez-Román A, Del Río-Navarro B, Ibarra-González I, Vela-Amieva M, Villarreal-Molina T, Ochoa-Leyva A, Aguilar-Salinas CA , Canizales-Quinteros S",Composition of gut microbiota in obese and normal-weight Mexican school-age children and its association with metabolic traits,Pediatric obesity,2018,"Amino acids, Mexican children, gut microbiota, obesity",Experiment 1,Mexico,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,pediatric normal weight,pediatric obese,"Obesity was defined as body mass index (BMI) ≥95th percentile, whereas NW was de- fined as BMI between the 15th and 75th percentiles for age and gender based on Centers for Disease Control and Prevention (CDC) reference data",67,71,3 months,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,Signature 1,Table S6,10 January 2021,Marianthi Thomatos,WikiWorks,Composition of gut microbiota in obese and normal-weight mexican school-age children,increased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides|s__Bacteroides eggerthii,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides|s__Bacteroides acidifaciens,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides|s__Bacteroides ovatus,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Dialister,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Segatella|s__Segatella copri,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae",2|976|200643|171549|815|816|28111;2|976|200643|171549|815|816|85831;2|976|200643|171549|815|816|28116;2|1239|909932|1843489|31977|39948;2|976|200643|171549|815|816;2|976|200643|171549|171552|838;2|976|200643|171549|171552|2974251|165179;2|1239|186801|3085636|186803,Complete,Shaimaa Elsafoury
bsdb:70/1/2,Study 70,case-control,29388394,10.1111/ijpo.12262,NA,"López-Contreras BE, Morán-Ramos S, Villarruel-Vázquez R, Macías-Kauffer L, Villamil-Ramírez H, León-Mimila P, Vega-Badillo J, Sánchez-Muñoz F, Llanos-Moreno LE, Canizalez-Román A, Del Río-Navarro B, Ibarra-González I, Vela-Amieva M, Villarreal-Molina T, Ochoa-Leyva A, Aguilar-Salinas CA , Canizales-Quinteros S",Composition of gut microbiota in obese and normal-weight Mexican school-age children and its association with metabolic traits,Pediatric obesity,2018,"Amino acids, Mexican children, gut microbiota, obesity",Experiment 1,Mexico,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,pediatric normal weight,pediatric obese,"Obesity was defined as body mass index (BMI) ≥95th percentile, whereas NW was de- fined as BMI between the 15th and 75th percentiles for age and gender based on Centers for Disease Control and Prevention (CDC) reference data",67,71,3 months,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,Signature 2,Table S6,10 January 2021,Marianthi Thomatos,WikiWorks,Composition of gut microbiota in obese and normal-weight mexican school-age children,decreased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Christensenellales|f__Christensenellaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Phocaeicola|s__Phocaeicola plebeius,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Rikenellaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Anaerostipes,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Leyella|s__Leyella stercorea,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Segatella|s__Segatella copri,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Sutterellaceae|g__Sutterella,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides",2|1239|186801|3082768|990719;2|976|200643|171549|815|909656|310297;2|1224|1236|91347|543;2|976|200643|171549|171550;2|1239|186801|3085636|186803|207244;2|1239|186801|3085636|186803;2|976|200643|171549|171552|2974265|363265;2|976|200643|171549|171552|2974251|165179;2|1224|28216|80840|995019|40544;2|976|200643|171549|815|816,Complete,Shaimaa Elsafoury
bsdb:70/2/1,Study 70,case-control,29388394,10.1111/ijpo.12262,NA,"López-Contreras BE, Morán-Ramos S, Villarruel-Vázquez R, Macías-Kauffer L, Villamil-Ramírez H, León-Mimila P, Vega-Badillo J, Sánchez-Muñoz F, Llanos-Moreno LE, Canizalez-Román A, Del Río-Navarro B, Ibarra-González I, Vela-Amieva M, Villarreal-Molina T, Ochoa-Leyva A, Aguilar-Salinas CA , Canizales-Quinteros S",Composition of gut microbiota in obese and normal-weight Mexican school-age children and its association with metabolic traits,Pediatric obesity,2018,"Amino acids, Mexican children, gut microbiota, obesity",Experiment 2,Mexico,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,female pediatric normal weight,female pediatric obese,"Obesity was defined as body mass index (BMI) ≥95th percentile, whereas NW was de- fined as BMI between the 15th and 75th percentiles for age and gender based on Centers for Disease Control and Prevention (CDC) reference data",29,29,3 months,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Text,10 January 2021,Marianthi Thomatos,WikiWorks,Gut microbiota in obese and normal weight mexican school-age children,increased,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides|s__Bacteroides eggerthii,2|976|200643|171549|815|816|28111,Complete,Shaimaa Elsafoury
bsdb:70/2/2,Study 70,case-control,29388394,10.1111/ijpo.12262,NA,"López-Contreras BE, Morán-Ramos S, Villarruel-Vázquez R, Macías-Kauffer L, Villamil-Ramírez H, León-Mimila P, Vega-Badillo J, Sánchez-Muñoz F, Llanos-Moreno LE, Canizalez-Román A, Del Río-Navarro B, Ibarra-González I, Vela-Amieva M, Villarreal-Molina T, Ochoa-Leyva A, Aguilar-Salinas CA , Canizales-Quinteros S",Composition of gut microbiota in obese and normal-weight Mexican school-age children and its association with metabolic traits,Pediatric obesity,2018,"Amino acids, Mexican children, gut microbiota, obesity",Experiment 2,Mexico,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,female pediatric normal weight,female pediatric obese,"Obesity was defined as body mass index (BMI) ≥95th percentile, whereas NW was de- fined as BMI between the 15th and 75th percentiles for age and gender based on Centers for Disease Control and Prevention (CDC) reference data",29,29,3 months,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 2,Text,10 January 2021,Marianthi Thomatos,WikiWorks,Gut microbiota in obese and normal weight mexican school-age children,decreased,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Odoribacteraceae|g__Odoribacter,2|976|200643|171549|1853231|283168,Complete,Shaimaa Elsafoury
bsdb:70/3/1,Study 70,case-control,29388394,10.1111/ijpo.12262,NA,"López-Contreras BE, Morán-Ramos S, Villarruel-Vázquez R, Macías-Kauffer L, Villamil-Ramírez H, León-Mimila P, Vega-Badillo J, Sánchez-Muñoz F, Llanos-Moreno LE, Canizalez-Román A, Del Río-Navarro B, Ibarra-González I, Vela-Amieva M, Villarreal-Molina T, Ochoa-Leyva A, Aguilar-Salinas CA , Canizales-Quinteros S",Composition of gut microbiota in obese and normal-weight Mexican school-age children and its association with metabolic traits,Pediatric obesity,2018,"Amino acids, Mexican children, gut microbiota, obesity",Experiment 3,Mexico,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,male pediatric normal weight,male pediatric obese,"Obesity was defined as body mass index (BMI) ≥95th percentile, whereas NW was de- fined as BMI between the 15th and 75th percentiles for age and gender based on Centers for Disease Control and Prevention (CDC) reference data",38,42,3 months,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Text,10 January 2021,Marianthi Thomatos,WikiWorks,Gut microbiota in obese and normal weight mexican school-age children,increased,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides|s__Bacteroides eggerthii,2|976|200643|171549|815|816|28111,Complete,Shaimaa Elsafoury
bsdb:70/3/2,Study 70,case-control,29388394,10.1111/ijpo.12262,NA,"López-Contreras BE, Morán-Ramos S, Villarruel-Vázquez R, Macías-Kauffer L, Villamil-Ramírez H, León-Mimila P, Vega-Badillo J, Sánchez-Muñoz F, Llanos-Moreno LE, Canizalez-Román A, Del Río-Navarro B, Ibarra-González I, Vela-Amieva M, Villarreal-Molina T, Ochoa-Leyva A, Aguilar-Salinas CA , Canizales-Quinteros S",Composition of gut microbiota in obese and normal-weight Mexican school-age children and its association with metabolic traits,Pediatric obesity,2018,"Amino acids, Mexican children, gut microbiota, obesity",Experiment 3,Mexico,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,male pediatric normal weight,male pediatric obese,"Obesity was defined as body mass index (BMI) ≥95th percentile, whereas NW was de- fined as BMI between the 15th and 75th percentiles for age and gender based on Centers for Disease Control and Prevention (CDC) reference data",38,42,3 months,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 2,Text,10 January 2021,Marianthi Thomatos,WikiWorks,Gut microbiota in obese and normal weight mexican school-age children,decreased,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Phocaeicola|s__Phocaeicola plebeius,2|976|200643|171549|815|909656|310297,Complete,Shaimaa Elsafoury
bsdb:71/1/1,Study 71,"cross-sectional observational, not case-control",24614698,10.1371/journal.pone.0090784,NA,"Ardissone AN, de la Cruz DM, Davis-Richardson AG, Rechcigl KT, Li N, Drew JC, Murgas-Torrazza R, Sharma R, Hudak ML, Triplett EW , Neu J",Meconium microbiome analysis identifies bacteria correlated with premature birth,PloS one,2014,NA,Experiment 1,United States of America,Homo sapiens,Meconium,UBERON:0007109,Cesarean section,EFO:0009636,vaginal delivery,C-section,the study groups are devided into two groups acc to the gestational age. 1) gestational age < 33 weeks. 2) gestational age >/= 33 weeks,19,33,NA,16S,4,Ion Torrent,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,"birth weight,chorioamnionitis,feeding practices,sex",NA,increased,increased,NA,NA,NA,Signature 1,Table S6 in File S1,10 January 2021,Rimsha Azhar,WikiWorks,Meconium microbiome related to mode of delivery in premature infants,increased,"k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Leuconostoc,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Negativicoccus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Enterococcaceae|g__Vagococcus,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Butyrivibrio",2|1239|91061|186826|33958|1243;2|1239|909932|1843489|31977|909928;2|1239|91061|186826|81852|2737;2|1239|186801|3085636|186803|830,Complete,Shaimaa Elsafoury
bsdb:71/2/1,Study 71,"cross-sectional observational, not case-control",24614698,10.1371/journal.pone.0090784,NA,"Ardissone AN, de la Cruz DM, Davis-Richardson AG, Rechcigl KT, Li N, Drew JC, Murgas-Torrazza R, Sharma R, Hudak ML, Triplett EW , Neu J",Meconium microbiome analysis identifies bacteria correlated with premature birth,PloS one,2014,NA,Experiment 2,United States of America,Homo sapiens,Meconium,UBERON:0007109,Premature birth,EFO:0003917,>/=33 weeks,infants <33 weeks gestational age,the study groups are devided into two groups acc to the gestational age. 1) gestational age < 33 weeks. 2) gestational age >/= 33 weeks,17,35,NA,16S,4,Ion Torrent,Spearman Correlation,0.05,FALSE,NA,NA,"birth weight,chorioamnionitis,feeding practices,sex",NA,unchanged,unchanged,NA,NA,unchanged,Signature 1,Table 1,10 January 2021,Rimsha Azhar,WikiWorks,"Phyla, family, and genera taxonomy significantly correlated with gestational age",increased,"k__Bacteria|p__Bacillota,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Bacillaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Staphylococcaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Enterococcaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Peptostreptococcaceae,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Bacillaceae|g__Bacillus,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Staphylococcaceae|g__Staphylococcus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Enterococcaceae|g__Enterococcus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Enterococcaceae|g__Vagococcus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Leuconostoc,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Clostridium,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Veillonella,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Negativicoccus,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Enterobacter,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Citrobacter,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Erwiniaceae|g__Erwinia,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Klebsiella,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Raoultella,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Erwiniaceae|g__Pantoea,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Morganellaceae|g__Photorhabdus,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Tannerellaceae|g__Tannerella,k__Bacteria|p__Actinomycetota",2|1239;2|1239|91061|1385|186817;2|1239|91061|1385|90964;2|1239|91061|186826|81852;2|1239|91061|186826|33958;2|1239|91061|186826|81850;2|1239|186801|186802|31979;2|1239|186801|3082720|186804;2|1239|909932|1843489|31977;2|1239|526524|526525|128827;2|201174|1760|85004|31953;2|1224|1236|91347|543;2|1239|91061|1385|186817|1386;2|1239|91061|1385|90964|1279;2|1239|91061|186826|81852|1350;2|1239|91061|186826|81852|2737;2|1239|91061|186826|33958|1578;2|1239|91061|186826|33958|1243;2|1239|186801|186802|31979|1485;2|1239|909932|1843489|31977|29465;2|1239|909932|1843489|31977|909928;2|201174|1760|85004|31953|1678;2|1224|1236|91347|543|547;2|1224|1236|91347|543|544;2|1224|1236|91347|1903409|551;2|1224|1236|91347|543|570;2|1224|1236|91347|543|160674;2|1224|1236|91347|1903409|53335;2|1224|1236|91347|1903414|29487;2|976|200643|171549|2005525|195950;2|201174,Complete,Shaimaa Elsafoury
bsdb:71/2/2,Study 71,"cross-sectional observational, not case-control",24614698,10.1371/journal.pone.0090784,NA,"Ardissone AN, de la Cruz DM, Davis-Richardson AG, Rechcigl KT, Li N, Drew JC, Murgas-Torrazza R, Sharma R, Hudak ML, Triplett EW , Neu J",Meconium microbiome analysis identifies bacteria correlated with premature birth,PloS one,2014,NA,Experiment 2,United States of America,Homo sapiens,Meconium,UBERON:0007109,Premature birth,EFO:0003917,>/=33 weeks,infants <33 weeks gestational age,the study groups are devided into two groups acc to the gestational age. 1) gestational age < 33 weeks. 2) gestational age >/= 33 weeks,17,35,NA,16S,4,Ion Torrent,Spearman Correlation,0.05,FALSE,NA,NA,"birth weight,chorioamnionitis,feeding practices,sex",NA,unchanged,unchanged,NA,NA,unchanged,Signature 2,Table 1,10 January 2021,Rimsha Azhar,WikiWorks,"Phyla, family, and genera taxonomy significantly correlated with gestational age",decreased,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Oxalobacteraceae|g__Oxalicibacterium,2|1224|28216|80840|75682|223927,Complete,Shaimaa Elsafoury
bsdb:72/1/1,Study 72,case-control,30228282,10.1038/s41598-018-32219-2,NA,"Zhang M, Ma W, Zhang J, He Y , Wang J",Analysis of gut microbiota profiles and microbe-disease associations in children with autism spectrum disorders in China,Scientific reports,2018,NA,Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Autism,EFO:0003758,typically developing controls,autism,diagnosed with autistic spectrum disorder according to DSM-5 (Diagnostic and Statistical Manual of Mental Disorders-5th Edition),6,35,1 month,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,Signature 1,Table 2,10 January 2021,Fatima Zohra,WikiWorks,The bacterial abundance at the level of phylum and genus in autistic and typically developing children with significant difference,increased,k__Bacteria|p__Bacteroidota,2|976,Complete,Shaimaa Elsafoury
bsdb:72/1/2,Study 72,case-control,30228282,10.1038/s41598-018-32219-2,NA,"Zhang M, Ma W, Zhang J, He Y , Wang J",Analysis of gut microbiota profiles and microbe-disease associations in children with autism spectrum disorders in China,Scientific reports,2018,NA,Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Autism,EFO:0003758,typically developing controls,autism,diagnosed with autistic spectrum disorder according to DSM-5 (Diagnostic and Statistical Manual of Mental Disorders-5th Edition),6,35,1 month,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,Signature 2,Table 2,10 January 2021,Fatima Zohra,WikiWorks,The bacterial abundance at the level of phylum and genus in autistic and typically developing children with significant difference,decreased,"k__Bacteria|p__Bacillota,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Veillonella,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Escherichia,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales|f__Actinomycetaceae|g__Actinomyces,k__Bacteria|p__Bacillota|c__Tissierellia|o__Tissierellales|f__Peptoniphilaceae|g__Parvimonas,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae|g__Bulleidia,k__Bacteria|p__Bacillota|c__Tissierellia|o__Tissierellales|f__Peptoniphilaceae|g__Peptoniphilus",2|1239;2|1239|91061|186826|1300|1301;2|1239|909932|1843489|31977|29465;2|1224|1236|91347|543|561;2|201174|1760|2037|2049|1654;2|1239|1737404|1737405|1570339|543311;2|1239|526524|526525|128827|118747;2|1239|1737404|1737405|1570339|162289,Complete,Shaimaa Elsafoury
bsdb:73/1/1,Study 73,"cross-sectional observational, not case-control",30669548,10.3390/ijms20020438,NA,"Chávez-Carbajal A, Nirmalkar K, Pérez-Lizaur A, Hernández-Quiroz F, Ramírez-Del-Alto S, García-Mena J , Hernández-Guerrero C",Gut Microbiota and Predicted Metabolic Pathways in a Sample of Mexican Women Affected by Obesity and Obesity Plus Metabolic Syndrome,International journal of molecular sciences,2019,"16S rDNA, Mexican women, gut microbiota, high-throughput DNA sequencing, ion torrent, metabolic syndrome, obesity",Experiment 1,Mexico,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,normal weight,obese,"the guidelines from the American Heart Association was used to diagnose metabolic syndrome, which must adhere to at least three of the five following parameters; 1. Elevated waist circumference: waist circumference of ≥80, 2. Elevated Triglycerides ≥150 mg/dL, 3. Reduced HDL- Cholesterol <50 mg/dL, 4. Elevated Blood pressure; systolic ≥130 mm Hg and/or diastolic ≥85 mm Hg and 5. Elevated Fasting blood glucose ≥100 mg/dL. On the other hand, the women with just OB were identified using body mass index (BMI) as follows: normal rank was considered 18.5–24.99 kg/m2, the rank for obese class I was 30–34.99 kg/m2, obese class II 35–39.99 kg/m2, and obese class III greater than or equal to 40 kg/m2.",25,17,3 months,16S,3,Ion Torrent,Kruskall-Wallis,0.05,TRUE,NA,NA,NA,NA,unchanged,increased,unchanged,NA,unchanged,Signature 1,Text + figure 1 + Table S1 + Table S2  Table S7,10 January 2021,Marianthi Thomatos,WikiWorks,Gut microbiota in a sample of Mexican Women Affected by Obesity and Obesity Plus Metabolic Syndrome,increased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Faecalibacterium,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Roseburia,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Lachnospira,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Coprococcus",2|1239|186801|186802|216572|216851;2|1239|186801|3085636|186803|841;2|1239|186801|3085636|186803|28050;2|1239|186801|3085636|186803|33042,Complete,Shaimaa Elsafoury
bsdb:73/1/2,Study 73,"cross-sectional observational, not case-control",30669548,10.3390/ijms20020438,NA,"Chávez-Carbajal A, Nirmalkar K, Pérez-Lizaur A, Hernández-Quiroz F, Ramírez-Del-Alto S, García-Mena J , Hernández-Guerrero C",Gut Microbiota and Predicted Metabolic Pathways in a Sample of Mexican Women Affected by Obesity and Obesity Plus Metabolic Syndrome,International journal of molecular sciences,2019,"16S rDNA, Mexican women, gut microbiota, high-throughput DNA sequencing, ion torrent, metabolic syndrome, obesity",Experiment 1,Mexico,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,normal weight,obese,"the guidelines from the American Heart Association was used to diagnose metabolic syndrome, which must adhere to at least three of the five following parameters; 1. Elevated waist circumference: waist circumference of ≥80, 2. Elevated Triglycerides ≥150 mg/dL, 3. Reduced HDL- Cholesterol <50 mg/dL, 4. Elevated Blood pressure; systolic ≥130 mm Hg and/or diastolic ≥85 mm Hg and 5. Elevated Fasting blood glucose ≥100 mg/dL. On the other hand, the women with just OB were identified using body mass index (BMI) as follows: normal rank was considered 18.5–24.99 kg/m2, the rank for obese class I was 30–34.99 kg/m2, obese class II 35–39.99 kg/m2, and obese class III greater than or equal to 40 kg/m2.",25,17,3 months,16S,3,Ion Torrent,Kruskall-Wallis,0.05,TRUE,NA,NA,NA,NA,unchanged,increased,unchanged,NA,unchanged,Signature 2,Text + figure 1 + Table S1 + Table S2  Table S7,10 January 2021,Marianthi Thomatos,WikiWorks,Gut microbiota in a sample of Mexican Women Affected by Obesity and Obesity Plus Metabolic Syndrome,decreased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae",2|976|200643|171549|815|816;2|1239|526524|526525|128827,Complete,Shaimaa Elsafoury
bsdb:73/2/1,Study 73,"cross-sectional observational, not case-control",30669548,10.3390/ijms20020438,NA,"Chávez-Carbajal A, Nirmalkar K, Pérez-Lizaur A, Hernández-Quiroz F, Ramírez-Del-Alto S, García-Mena J , Hernández-Guerrero C",Gut Microbiota and Predicted Metabolic Pathways in a Sample of Mexican Women Affected by Obesity and Obesity Plus Metabolic Syndrome,International journal of molecular sciences,2019,"16S rDNA, Mexican women, gut microbiota, high-throughput DNA sequencing, ion torrent, metabolic syndrome, obesity",Experiment 2,Mexico,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,normal weight,obese + metabolic syndrome,"the guidelines from the American Heart Association was used to diagnose metabolic syndrome, which must adhere to at least three of the five following parameters; 1. Elevated waist circumference: waist circumference of ≥80, 2. Elevated Triglycerides ≥150 mg/dL, 3. Reduced HDL- Cholesterol <50 mg/dL, 4. Elevated Blood pressure; systolic ≥130 mm Hg and/or diastolic ≥85 mm Hg and 5. Elevated Fasting blood glucose ≥100 mg/dL. On the other hand, the women with just OB were identified using body mass index (BMI) as follows: normal rank was considered 18.5–24.99 kg/m2, the rank for obese class I was 30–34.99 kg/m2, obese class II 35–39.99 kg/m2, and obese class III greater than or equal to 40 kg/m2.",25,25,3 months,16S,3,Ion Torrent,Kruskall-Wallis,0.05,TRUE,NA,NA,NA,NA,unchanged,increased,unchanged,NA,unchanged,Signature 1,Text + figure 1 + Table S1 + Table S2  Table S7,10 January 2021,Marianthi Thomatos,WikiWorks,Gut microbiota in a sample of Mexican Women Affected by Obesity and Obesity Plus Metabolic Syndrome,increased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Faecalibacterium,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Roseburia,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Lachnospira,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Coprococcus",2|1239|186801|186802|216572|216851;2|1239|186801|3085636|186803|841;2|1239|186801|3085636|186803|28050;2|1239|186801|3085636|186803|33042,Complete,Shaimaa Elsafoury
bsdb:73/2/2,Study 73,"cross-sectional observational, not case-control",30669548,10.3390/ijms20020438,NA,"Chávez-Carbajal A, Nirmalkar K, Pérez-Lizaur A, Hernández-Quiroz F, Ramírez-Del-Alto S, García-Mena J , Hernández-Guerrero C",Gut Microbiota and Predicted Metabolic Pathways in a Sample of Mexican Women Affected by Obesity and Obesity Plus Metabolic Syndrome,International journal of molecular sciences,2019,"16S rDNA, Mexican women, gut microbiota, high-throughput DNA sequencing, ion torrent, metabolic syndrome, obesity",Experiment 2,Mexico,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,normal weight,obese + metabolic syndrome,"the guidelines from the American Heart Association was used to diagnose metabolic syndrome, which must adhere to at least three of the five following parameters; 1. Elevated waist circumference: waist circumference of ≥80, 2. Elevated Triglycerides ≥150 mg/dL, 3. Reduced HDL- Cholesterol <50 mg/dL, 4. Elevated Blood pressure; systolic ≥130 mm Hg and/or diastolic ≥85 mm Hg and 5. Elevated Fasting blood glucose ≥100 mg/dL. On the other hand, the women with just OB were identified using body mass index (BMI) as follows: normal rank was considered 18.5–24.99 kg/m2, the rank for obese class I was 30–34.99 kg/m2, obese class II 35–39.99 kg/m2, and obese class III greater than or equal to 40 kg/m2.",25,25,3 months,16S,3,Ion Torrent,Kruskall-Wallis,0.05,TRUE,NA,NA,NA,NA,unchanged,increased,unchanged,NA,unchanged,Signature 2,Text + figure 1 + Table S1 + Table S2  Table S7,10 January 2021,Marianthi Thomatos,WikiWorks,Gut microbiota in a sample of Mexican Women Affected by Obesity and Obesity Plus Metabolic Syndrome,decreased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae",2|976|200643|171549|815|816;2|1239|526524|526525|128827,Complete,Shaimaa Elsafoury
bsdb:74/1/1,Study 74,case-control,23526699,10.1002/oby.20466,NA,"Verdam FJ, Fuentes S, de Jonge C, Zoetendal EG, Erbil R, Greve JW, Buurman WA, de Vos WM , Rensen SS",Human intestinal microbiota composition is associated with local and systemic inflammation in obesity,"Obesity (Silver Spring, Md.)",2013,NA,Experiment 1,Netherlands,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,non-obese,obese,obesity: BMI 30.5-60.3 kg/m2,13,15,6 months,16S,NA,Human Intestinal Tract Chip,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Table 2,10 January 2021,Marianthi Thomatos,"WikiWorks,ChiomaBlessing",Differential microbial abundance between obese and non-obese individuals,increased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Dorea|s__Dorea formicigenerans,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Papillibacter|s__Papillibacter cinnamivorans,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Lachnoclostridium|s__[Clostridium] symbiosum",2|1239|186801|3085636|186803|189330|39486;2|1239|186801|186802|216572|100175|100176;2|1239|186801|3085636|186803|1506553|1512,Complete,Shaimaa Elsafoury
bsdb:74/1/2,Study 74,case-control,23526699,10.1002/oby.20466,NA,"Verdam FJ, Fuentes S, de Jonge C, Zoetendal EG, Erbil R, Greve JW, Buurman WA, de Vos WM , Rensen SS",Human intestinal microbiota composition is associated with local and systemic inflammation in obesity,"Obesity (Silver Spring, Md.)",2013,NA,Experiment 1,Netherlands,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,non-obese,obese,obesity: BMI 30.5-60.3 kg/m2,13,15,6 months,16S,NA,Human Intestinal Tract Chip,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 2,Table 2,10 January 2021,Marianthi Thomatos,"WikiWorks,ChiomaBlessing",Differential microbial abundance between obese and non-obese individuals,decreased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Rikenellaceae|g__Alistipes,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Alloprevotella|s__Alloprevotella tannerae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides|s__Bacteroides fragilis,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides|s__Bacteroides intestinalis,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides|s__Bacteroides ovatus,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides|s__Bacteroides stercoris,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides|s__Bacteroides uniformis,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Hoylesella|s__Hoylesella oralis,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Odoribacteraceae|g__Odoribacter|s__Odoribacter splanchnicus,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Tannerellaceae|g__Parabacteroides|s__Parabacteroides distasonis,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Phocaeicola|s__Phocaeicola plebeius,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Tannerellaceae|g__Tannerella,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Xylanibacter|s__Xylanibacter ruminicola",2|976|200643|171549|171550|239759;2|976|200643|171549|171552|1283313|76122;2|976|200643|171549|815|816|817;2|976|200643|171549|815|816|329854;2|976|200643|171549|815|816|28116;2|976|200643|171549|815|816|46506;2|976|200643|171549|815|816|820;2|976|200643|171549|171552|2974257|28134;2|976|200643|171549|1853231|283168|28118;2|976|200643|171549|2005525|375288|823;2|976|200643|171549|815|909656|310297;2|976|200643|171549|2005525|195950;2|976|200643|171549|171552|558436|839,Complete,Shaimaa Elsafoury
bsdb:74/2/1,Study 74,case-control,23526699,10.1002/oby.20466,NA,"Verdam FJ, Fuentes S, de Jonge C, Zoetendal EG, Erbil R, Greve JW, Buurman WA, de Vos WM , Rensen SS",Human intestinal microbiota composition is associated with local and systemic inflammation in obesity,"Obesity (Silver Spring, Md.)",2013,NA,Experiment 2,Netherlands,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,Nonobese microbiota cluster,obese,obesity: BMI 30.5-60.3 kg/m3,13,15,6 months,16S,NA,Human Intestinal Tract Chip,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,decreased,NA,Signature 1,Table 2,10 January 2021,Shaimaa Elsafoury,WikiWorks,Association of intestinal microbiota with local and systemic inflammation in obesity,increased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Lachnoclostridium|s__[Clostridium] symbiosum,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Tyzzerella|s__[Clostridium] colinum,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Anaerobutyricum|s__Anaerobutyricum hallii",2|1239|186801|3085636|186803|1506553|1512;2|1239|186801|3085636|186803|1506577|36835;2|1239|186801|3085636|186803|2569097|39488,Complete,Shaimaa Elsafoury
bsdb:74/2/2,Study 74,case-control,23526699,10.1002/oby.20466,NA,"Verdam FJ, Fuentes S, de Jonge C, Zoetendal EG, Erbil R, Greve JW, Buurman WA, de Vos WM , Rensen SS",Human intestinal microbiota composition is associated with local and systemic inflammation in obesity,"Obesity (Silver Spring, Md.)",2013,NA,Experiment 2,Netherlands,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,Nonobese microbiota cluster,obese,obesity: BMI 30.5-60.3 kg/m3,13,15,6 months,16S,NA,Human Intestinal Tract Chip,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,decreased,NA,Signature 2,Table 2,10 January 2021,Shaimaa Elsafoury,WikiWorks,Association of intestinal microbiota with local and systemic inflammation in obesity,decreased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Rikenellaceae|g__Alistipes,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides|s__Bacteroides fragilis,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides|s__Bacteroides intestinalis,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Odoribacteraceae|g__Odoribacter|s__Odoribacter splanchnicus,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Oscillospira|s__Oscillospira guilliermondii",2|976|200643|171549|171550|239759;2|976|200643|171549|815|816|817;2|976|200643|171549|815|816|329854;2|976|200643|171549|1853231|283168|28118;2|1239|186801|186802|216572|119852|119853,Complete,Shaimaa Elsafoury
bsdb:74/3/1,Study 74,case-control,23526699,10.1002/oby.20466,NA,"Verdam FJ, Fuentes S, de Jonge C, Zoetendal EG, Erbil R, Greve JW, Buurman WA, de Vos WM , Rensen SS",Human intestinal microbiota composition is associated with local and systemic inflammation in obesity,"Obesity (Silver Spring, Md.)",2013,NA,Experiment 3,Netherlands,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,low BMI,high BMI,obesity: BMI 30.5-60.3 kg/m4,13,15,6 months,16S,NA,Human Intestinal Tract Chip,Spearman Correlation,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Table 3,10 January 2021,Marianthi Thomatos,"WikiWorks,ChiomaBlessing",Differential microbial abundance between high-BMI and low-BMI individuals,increased,"k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Paenibacillaceae|g__Aneurinibacillus,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Dorea|s__Dorea formicigenerans,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Eubacteriaceae|g__Eubacterium|s__Eubacterium limosum,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Klebsiella|s__Klebsiella aerogenes,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Klebsiella|s__Klebsiella pneumoniae,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Mediterraneibacter|s__Mediterraneibacter gnavus,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Papillibacter|s__Papillibacter cinnamivorans,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Roseburia|s__Roseburia intestinalis,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Vibrionales|f__Vibrionaceae|g__Vibrio,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Yersiniaceae|g__Yersinia,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Tyzzerella|s__[Clostridium] colinum",2|1239|91061|1385|186822|55079;2|201174|1760|85004|31953|1678;2|1239|186801|3085636|186803|189330|39486;2|1239|186801|186802|186806|1730|1736;2|1224|1236|91347|543|570|548;2|1224|1236|91347|543|570|573;2|1239|186801|3085636|186803|2316020|33038;2|1239|186801|186802|216572|100175|100176;2|1239|186801|3085636|186803|841|166486;2|1224|1236|135623|641|662;2|1224|1236|91347|1903411|629;2|1239|186801|3085636|186803|1506577|36835,Complete,Shaimaa Elsafoury
bsdb:74/3/2,Study 74,case-control,23526699,10.1002/oby.20466,NA,"Verdam FJ, Fuentes S, de Jonge C, Zoetendal EG, Erbil R, Greve JW, Buurman WA, de Vos WM , Rensen SS",Human intestinal microbiota composition is associated with local and systemic inflammation in obesity,"Obesity (Silver Spring, Md.)",2013,NA,Experiment 3,Netherlands,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,low BMI,high BMI,obesity: BMI 30.5-60.3 kg/m4,13,15,6 months,16S,NA,Human Intestinal Tract Chip,Spearman Correlation,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 2,Table 3,10 January 2021,Marianthi Thomatos,"WikiWorks,ChiomaBlessing",Differential microbial abundance between high-BMI and low-BMI individuals,decreased,"k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Alcaligenaceae|g__Alcaligenes|s__Alcaligenes faecalis,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Rikenellaceae|g__Alistipes,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides|s__Bacteroides fragilis,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides|s__Bacteroides intestinalis,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides|s__Bacteroides uniformis,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Coprobacillaceae|g__Coprobacillus|s__Coprobacillus cateniformis,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Faecalibacterium|s__Faecalibacterium prausnitzii,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Hoylesella|s__Hoylesella oralis,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Odoribacteraceae|g__Odoribacter|s__Odoribacter splanchnicus,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Tannerellaceae|g__Parabacteroides|s__Parabacteroides distasonis,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Phocaeicola|s__Phocaeicola plebeius,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Phocaeicola|s__Phocaeicola vulgatus,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Tannerellaceae|g__Tannerella,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Xylanibacter|s__Xylanibacter ruminicola",2|1224|28216|80840|506|507|511;2|976|200643|171549|171550|239759;2|976|200643|171549|815|816|817;2|976|200643|171549|815|816|329854;2|976|200643|171549|815|816|820;2|1239|526524|526525|2810280|100883|100884;2|1239|186801|186802|216572|216851|853;2|976|200643|171549|171552|2974257|28134;2|976|200643|171549|1853231|283168|28118;2|976|200643|171549|2005525|375288|823;2|976|200643|171549|815|909656|310297;2|976|200643|171549|815|909656|821;2|976|200643|171549|2005525|195950;2|976|200643|171549|171552|558436|839,Complete,Shaimaa Elsafoury
bsdb:74/4/1,Study 74,case-control,23526699,10.1002/oby.20466,NA,"Verdam FJ, Fuentes S, de Jonge C, Zoetendal EG, Erbil R, Greve JW, Buurman WA, de Vos WM , Rensen SS",Human intestinal microbiota composition is associated with local and systemic inflammation in obesity,"Obesity (Silver Spring, Md.)",2013,NA,Experiment 4,Netherlands,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,low C-Reactive Protein,high C-Reactive Protein,obesity: BMI 30.5-60.3 kg/m5,13,15,6 months,16S,NA,Human Intestinal Tract Chip,Spearman Correlation,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Table 3,10 January 2021,Shaimaa Elsafoury,"WikiWorks,ChiomaBlessing",Differential microbial abundance between high C-reactive protein group and low C-reactive protein group,increased,"k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Paenibacillaceae|g__Aneurinibacillus,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Lacrimispora|s__Lacrimispora sphenoides,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Papillibacter|s__Papillibacter cinnamivorans,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Roseburia|s__Roseburia intestinalis,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Subdoligranulum|s__Subdoligranulum variabile",2|1239|91061|1385|186822|55079;2|1239|186801|3085636|186803|2719231|29370;2|1239|186801|186802|216572|100175|100176;2|1239|186801|3085636|186803|841|166486;2|1239|186801|186802|216572|292632|214851,Complete,Shaimaa Elsafoury
bsdb:74/4/2,Study 74,case-control,23526699,10.1002/oby.20466,NA,"Verdam FJ, Fuentes S, de Jonge C, Zoetendal EG, Erbil R, Greve JW, Buurman WA, de Vos WM , Rensen SS",Human intestinal microbiota composition is associated with local and systemic inflammation in obesity,"Obesity (Silver Spring, Md.)",2013,NA,Experiment 4,Netherlands,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,low C-Reactive Protein,high C-Reactive Protein,obesity: BMI 30.5-60.3 kg/m5,13,15,6 months,16S,NA,Human Intestinal Tract Chip,Spearman Correlation,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 2,Table 3,10 January 2021,Shaimaa Elsafoury,"WikiWorks,ChiomaBlessing",Differential microbial abundance between high C-reactive protein group and low C-reactive protein group,decreased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Rikenellaceae|g__Alistipes,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides|s__Bacteroides intestinalis,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Odoribacteraceae|g__Odoribacter|s__Odoribacter splanchnicus,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Tannerellaceae|g__Parabacteroides|s__Parabacteroides distasonis,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Phocaeicola|s__Phocaeicola plebeius,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Phocaeicola|s__Phocaeicola vulgatus,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Tannerellaceae|g__Tannerella",2|976|200643|171549|171550|239759;2|976|200643|171549|815|816|329854;2|976|200643|171549|1853231|283168|28118;2|976|200643|171549|2005525|375288|823;2|976|200643|171549|815|909656|310297;2|976|200643|171549|815|909656|821;2|976|200643|171549|2005525|195950,Complete,Shaimaa Elsafoury
bsdb:75/1/1,Study 75,case-control,21188149,10.1371/journal.pone.0015216,NA,"Charlson ES, Chen J, Custers-Allen R, Bittinger K, Li H, Sinha R, Hwang J, Bushman FD , Collman RG",Disordered microbial communities in the upper respiratory tract of cigarette smokers,PloS one,2010,NA,Experiment 1,United States of America,Homo sapiens,Oropharynx,UBERON:0001729,Smoking behavior,EFO:0004318,right oropharynx of nonsmokers,right oropharynx of smokers,"Smokers were defined as current smoking of .2 cigarettes daily for more than 6 months, and nonsmokers were defined as less than 100 cigarettes lifetime.",33,29,3 months,16S,12,Roche454,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Table3 + Table S3,10 January 2021,Rimsha Azhar,WikiWorks,Bacterial taxa that distinguish airway microbial communities of smokers from nonsmokers,increased,"k__Bacteria|p__Bacteroidota|c__Flavobacteriia|o__Flavobacteriales|f__Flavobacteriaceae|g__Capnocytophaga,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Peptostreptococcaceae|g__Peptostreptococcus,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae|g__Fusobacterium,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Comamonadaceae|g__Acidovorax,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Haemophilus,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Neisseriaceae|g__Neisseria",2|976|117743|200644|49546|1016;2|1239|186801|3082720|186804|1257;2|32066|203490|203491|203492|848;2|1224|28216|80840|80864|12916;2|1224|1236|135625|712|724;2|1224|28216|206351|481|482,Complete,Shaimaa Elsafoury
bsdb:75/1/2,Study 75,case-control,21188149,10.1371/journal.pone.0015216,NA,"Charlson ES, Chen J, Custers-Allen R, Bittinger K, Li H, Sinha R, Hwang J, Bushman FD , Collman RG",Disordered microbial communities in the upper respiratory tract of cigarette smokers,PloS one,2010,NA,Experiment 1,United States of America,Homo sapiens,Oropharynx,UBERON:0001729,Smoking behavior,EFO:0004318,right oropharynx of nonsmokers,right oropharynx of smokers,"Smokers were defined as current smoking of .2 cigarettes daily for more than 6 months, and nonsmokers were defined as less than 100 cigarettes lifetime.",33,29,3 months,16S,12,Roche454,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 2,Table3 + Table S4,10 January 2021,Shaimaa Elsafoury,WikiWorks,Bacterial taxa that distinguish airway microbial communities of smokers from nonsmokers,decreased,"k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Megasphaera,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Veillonella,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Hallella,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae",2|1239|909932|1843489|31977|906;2|1239|909932|1843489|31977|29465;2|976|200643|171549|171552|52228;2|1239|91061|186826|1300|1301;2|1239|186801|186802|541000,Complete,Shaimaa Elsafoury
bsdb:75/2/1,Study 75,case-control,21188149,10.1371/journal.pone.0015216,NA,"Charlson ES, Chen J, Custers-Allen R, Bittinger K, Li H, Sinha R, Hwang J, Bushman FD , Collman RG",Disordered microbial communities in the upper respiratory tract of cigarette smokers,PloS one,2010,NA,Experiment 2,United States of America,Homo sapiens,Oropharynx,UBERON:0001729,Smoking behavior,EFO:0004318,left oropharynx of nonsmokers,left oropharynx of smokers,"Smokers were defined as current smoking of .2 cigarettes daily for more than 6 months, and nonsmokers were defined as less than 100 cigarettes lifetime.",33,29,3 months,16S,12,Roche454,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Table3 + Table S5,10 January 2021,Rimsha Azhar,WikiWorks,Bacterial taxa that distinguish airway microbial communities of smokers from nonsmokers,increased,"k__Bacteria|p__Bacteroidota|c__Flavobacteriia|o__Flavobacteriales|f__Flavobacteriaceae|g__Capnocytophaga,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae|g__Fusobacterium,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Neisseriaceae|g__Neisseria,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Aggregatibacter",2|976|117743|200644|49546|1016;2|32066|203490|203491|203492|848;2|1224|28216|206351|481|482;2|1224|1236|135625|712|416916,Complete,Shaimaa Elsafoury
bsdb:75/2/2,Study 75,case-control,21188149,10.1371/journal.pone.0015216,NA,"Charlson ES, Chen J, Custers-Allen R, Bittinger K, Li H, Sinha R, Hwang J, Bushman FD , Collman RG",Disordered microbial communities in the upper respiratory tract of cigarette smokers,PloS one,2010,NA,Experiment 2,United States of America,Homo sapiens,Oropharynx,UBERON:0001729,Smoking behavior,EFO:0004318,left oropharynx of nonsmokers,left oropharynx of smokers,"Smokers were defined as current smoking of .2 cigarettes daily for more than 6 months, and nonsmokers were defined as less than 100 cigarettes lifetime.",33,29,3 months,16S,12,Roche454,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 2,Table3 + Table S6,10 January 2021,Shaimaa Elsafoury,WikiWorks,Bacterial taxa that distinguish airway microbial communities of smokers from nonsmokers,decreased,"k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales|f__Actinomycetaceae|g__Actinomyces,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Eggerthellales|f__Eggerthellaceae|g__Eggerthella,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Megasphaera,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Veillonella,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Leptotrichiaceae|g__Streptobacillus",2|201174|1760|2037|2049|1654;2|201174|84998|1643822|1643826|84111;2|1239|909932|1843489|31977|906;2|1239|909932|1843489|31977|29465;2|32066|203490|203491|1129771|34104,Complete,Shaimaa Elsafoury
bsdb:75/3/1,Study 75,case-control,21188149,10.1371/journal.pone.0015216,NA,"Charlson ES, Chen J, Custers-Allen R, Bittinger K, Li H, Sinha R, Hwang J, Bushman FD , Collman RG",Disordered microbial communities in the upper respiratory tract of cigarette smokers,PloS one,2010,NA,Experiment 3,United States of America,Homo sapiens,Nasopharynx,UBERON:0001728,Smoking behavior,EFO:0004318,right nasopharynx of nonsmokers,right nasopharynx of smokers,"Smokers were defined as current smoking of .2 cigarettes daily for more than 6 months, and nonsmokers were defined as less than 100 cigarettes lifetime.",33,29,3 months,16S,12,Roche454,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Table3 + Table S7,10 January 2021,Rimsha Azhar,WikiWorks,Bacterial taxa that distinguish airway microbial communities of smokers from nonsmokers,increased,"k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales|f__Actinomycetaceae|g__Actinomyces,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Leuconostoc,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Moraxellales|f__Moraxellaceae|g__Acinetobacter,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Chromobacteriaceae|g__Aquitalea,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Shigella,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Rhodocyclales|f__Zoogloeaceae|g__Zoogloea",2|201174|1760|2037|2049|1654;2|1239|91061|186826|33958|1243;2|1224|1236|2887326|468|469;2|1224|28216|206351|1499392|407217;2|1224|1236|91347|543|620;2|1224|28216|206389|2008794|349,Complete,Shaimaa Elsafoury
bsdb:75/3/2,Study 75,case-control,21188149,10.1371/journal.pone.0015216,NA,"Charlson ES, Chen J, Custers-Allen R, Bittinger K, Li H, Sinha R, Hwang J, Bushman FD , Collman RG",Disordered microbial communities in the upper respiratory tract of cigarette smokers,PloS one,2010,NA,Experiment 3,United States of America,Homo sapiens,Nasopharynx,UBERON:0001728,Smoking behavior,EFO:0004318,right nasopharynx of nonsmokers,right nasopharynx of smokers,"Smokers were defined as current smoking of .2 cigarettes daily for more than 6 months, and nonsmokers were defined as less than 100 cigarettes lifetime.",33,29,3 months,16S,12,Roche454,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 2,Table3 + Table S8,10 January 2021,Rimsha Azhar,WikiWorks,Bacterial taxa that distinguish airway microbial communities of smokers from nonsmokers,decreased,"k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Eggerthellales|f__Eggerthellaceae|g__Eggerthella,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Dorea,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Eubacteriaceae|g__Eubacterium,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Aerococcaceae|g__Abiotrophia,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae|g__Allobaculum,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Anaerovoracaceae|g__Anaerovorax,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Coprococcus,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae,k__Bacteria|p__Bacillota|c__Tissierellia|o__Tissierellales|f__Peptoniphilaceae|g__Finegoldia,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Gemellaceae|g__Gemella,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Peptostreptococcaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Syntrophococcus,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Anaerofilum",2|201174|84998|1643822|1643826|84111;2|1239|186801|3085636|186803|189330;2|1239|186801|186802|186806|1730;2|1239|91061|186826|186827|46123;2|1239|526524|526525|128827|174708;2|1239|186801|3082720|3030910|109326;2|1239|186801|3085636|186803|33042;2|1239|526524|526525|128827;2|1239|1737404|1737405|1570339|150022;2|1239|91061|1385|539738|1378;2|1239|186801|3085636|186803;2|1239|186801|3082720|186804;2|1239|186801|186802|541000;2|1239|186801|3085636|186803|84036;2|1239|186801|186802|216572|52784,Complete,Shaimaa Elsafoury
bsdb:75/4/1,Study 75,case-control,21188149,10.1371/journal.pone.0015216,NA,"Charlson ES, Chen J, Custers-Allen R, Bittinger K, Li H, Sinha R, Hwang J, Bushman FD , Collman RG",Disordered microbial communities in the upper respiratory tract of cigarette smokers,PloS one,2010,NA,Experiment 4,United States of America,Homo sapiens,Nasopharynx,UBERON:0001728,Smoking behavior,EFO:0004318,left nasopharynx of nonsmokers,left nasopharynx of smokers,"Smokers were defined as current smoking of .2 cigarettes daily for more than 6 months, and nonsmokers were defined as less than 100 cigarettes lifetime.",33,29,3 months,16S,12,Roche454,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Table3 + Table S9,10 January 2021,Shaimaa Elsafoury,WikiWorks,Bacterial taxa that distinguish airway microbial communities of smokers from nonsmokers,increased,"k__Bacteria|p__Bacteroidota|c__Flavobacteriia|o__Flavobacteriales|f__Flavobacteriaceae|g__Flavobacterium,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae|g__Erysipelothrix,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Gemellaceae|g__Gemella,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Shigella,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Sutterellaceae|g__Sutterella",2|976|117743|200644|49546|237;2|1239|526524|526525|128827|1647;2|1239|91061|1385|539738|1378;2|1224|1236|91347|543|620;2|1224|28216|80840|995019|40544,Complete,Shaimaa Elsafoury
bsdb:75/4/2,Study 75,case-control,21188149,10.1371/journal.pone.0015216,NA,"Charlson ES, Chen J, Custers-Allen R, Bittinger K, Li H, Sinha R, Hwang J, Bushman FD , Collman RG",Disordered microbial communities in the upper respiratory tract of cigarette smokers,PloS one,2010,NA,Experiment 4,United States of America,Homo sapiens,Nasopharynx,UBERON:0001728,Smoking behavior,EFO:0004318,left nasopharynx of nonsmokers,left nasopharynx of smokers,"Smokers were defined as current smoking of .2 cigarettes daily for more than 6 months, and nonsmokers were defined as less than 100 cigarettes lifetime.",33,29,3 months,16S,12,Roche454,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 2,Table3 + Table S10,10 January 2021,Shaimaa Elsafoury,WikiWorks,Bacterial taxa that distinguish airway microbial communities of smokers from nonsmokers,decreased,"k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Eggerthellales|f__Eggerthellaceae|g__Eggerthella,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae|g__Porphyromonas,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Aerococcaceae|g__Abiotrophia,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Anaerofilum,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Anaerovoracaceae|g__Anaerovorax,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Dorea,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Eubacteriaceae|g__Eubacterium,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Roseburia,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Syntrophococcus,k__Bacteria|p__Campylobacterota|c__Epsilonproteobacteria|o__Campylobacterales|f__Campylobacteraceae|g__Campylobacter,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Haemophilus,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Lysobacterales|f__Lysobacteraceae|g__Stenotrophomonas",2|201174|84998|1643822|1643826|84111;2|976|200643|171549|171551|836;2|1239|91061|186826|186827|46123;2|1239|186801|186802|216572|52784;2|1239|186801|3082720|3030910|109326;2|1239|186801|3085636|186803|189330;2|1239|526524|526525|128827;2|1239|186801|186802|186806|1730;2|1239|186801|3085636|186803;2|1239|186801|3085636|186803|841;2|1239|186801|186802|541000;2|1239|186801|3085636|186803|84036;2|29547|3031852|213849|72294|194;2|1224|1236|135625|712|724;2|1224|1236|135614|32033|40323,Complete,Shaimaa Elsafoury
bsdb:76/1/1,Study 76,case-control,27231166,10.4103/0366-6999.182841,NA,"Qi CJ, Zhang Q, Yu M, Xu JP, Zheng J, Wang T , Xiao XH",Imbalance of Fecal Microbiota at Newly Diagnosed Type 1 Diabetes in Chinese Children,Chinese medical journal,2016,NA,Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Type I diabetes mellitus,MONDO:0005147,controls,type I diabetes mellitus children,type 1 diabetes mellitus,15,15,3 months,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,"age,breastfeeding duration,delivery procedure,race,sex",NA,NA,unchanged,decreased,NA,NA,decreased,Signature 1,Table 3 +  Figure 3,10 January 2021,Yaseen Javaid,WikiWorks,Imbalance of Fecal Microbiota at Newly Diagnosed Type 1 Diabetes in Chinese Children,increased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Blautia,k__Bacteria|p__Bacillota|c__Negativicutes|o__Acidaminococcales|f__Acidaminococcaceae|g__Acidaminococcus",2|1239|186801|3085636|186803|572511;2|1239|909932|1843488|909930|904,Complete,Rimsha Azhar
bsdb:76/1/2,Study 76,case-control,27231166,10.4103/0366-6999.182841,NA,"Qi CJ, Zhang Q, Yu M, Xu JP, Zheng J, Wang T , Xiao XH",Imbalance of Fecal Microbiota at Newly Diagnosed Type 1 Diabetes in Chinese Children,Chinese medical journal,2016,NA,Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Type I diabetes mellitus,MONDO:0005147,controls,type I diabetes mellitus children,type 1 diabetes mellitus,15,15,3 months,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,"age,breastfeeding duration,delivery procedure,race,sex",NA,NA,unchanged,decreased,NA,NA,decreased,Signature 2,Table 3 +  Figure 3,10 January 2021,Yaseen Javaid,WikiWorks,Imbalance of Fecal Microbiota at Newly Diagnosed Type 1 Diabetes in Chinese Children,decreased,"k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Dialister,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Haemophilus,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Defluviitaleaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Eubacteriales Family XIII. Incertae Sedis,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micrococcales,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Caulobacterales,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|g__Intestinimonas",2|1239|909932|1843489|31977|39948;2|1224|1236|135625;2|1224|1236|135625|712;2|1239|186801|3085636|186803;2|1224|1236|135625|712|724;2|1239|186801|3085636|1185407;2|1239|186801|186802|543314;2|201174|1760|85006;2|1224|28211|204458;2|1239|186801|186802|1392389,Complete,Rimsha Azhar
bsdb:77/1/1,Study 77,"cross-sectional observational, not case-control",28035686,10.1002/phar.1890,NA,"Flowers SA, Evans SJ, Ward KM, McInnis MG , Ellingrod VL",Interaction Between Atypical Antipsychotics and the Gut Microbiome in a Bipolar Disease Cohort,Pharmacotherapy,2017,"atypical antipsychotics, metabolic disease, microbiome",Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Bipolar disorder,MONDO:0004985,non users,atypical antipsychotic users,Medication group was defined by the use of an Atypical Antipsychotics at the time of fecal sample collection,68,49,NA,16S,4,Illumina,LEfSe,0.05,FALSE,NA,NA,"age,body mass index,sex",NA,NA,NA,NA,decreased,NA,Signature 1,Figure3,10 January 2021,Fatima Zohra,WikiWorks,Differentially abundant members of gut microbiota in bipolar disorder (BD) patients treated with atypical antipsychotics (AAP),increased,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae,2|1239|186801|3085636|186803,Complete,Shaimaa Elsafoury
bsdb:77/1/2,Study 77,"cross-sectional observational, not case-control",28035686,10.1002/phar.1890,NA,"Flowers SA, Evans SJ, Ward KM, McInnis MG , Ellingrod VL",Interaction Between Atypical Antipsychotics and the Gut Microbiome in a Bipolar Disease Cohort,Pharmacotherapy,2017,"atypical antipsychotics, metabolic disease, microbiome",Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Bipolar disorder,MONDO:0004985,non users,atypical antipsychotic users,Medication group was defined by the use of an Atypical Antipsychotics at the time of fecal sample collection,68,49,NA,16S,4,Illumina,LEfSe,0.05,FALSE,NA,NA,"age,body mass index,sex",NA,NA,NA,NA,decreased,NA,Signature 2,Figure3,10 January 2021,Fatima Zohra,WikiWorks,Differentially abundant members of gut microbiota in bipolar disorder (BD) patients treated with atypical antipsychotics (AAP),decreased,k__Bacteria|p__Verrucomicrobiota|c__Verrucomicrobiia|o__Verrucomicrobiales|f__Akkermansiaceae|g__Akkermansia,2|74201|203494|48461|1647988|239934,Complete,Shaimaa Elsafoury
bsdb:78/1/1,Study 78,laboratory experiment,27829577,10.5056/jnm16105,NA,"Moussaoui N, Jacobs JP, Larauche M, Biraud M, Million M, Mayer E , Taché Y","Chronic Early-life Stress in Rat Pups Alters Basal Corticosterone, Intestinal Permeability, and Fecal Microbiota at Weaning: Influence of Sex",Journal of neurogastroenterology and motility,2017,"Corticosterone, Microbiota, Permeability, Stress, psychological, Weaning",Experiment 1,United States of America,Rattus norvegicus,Feces,UBERON:0001988,Stimulus or stress design,EFO:0001762,controls,limited nesting stress,pups exposed to limited nesting stress,23,23,NA,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,sex,NA,decreased,decreased,NA,NA,NA,Signature 1,Fig3C + text,10 January 2021,Fatima Zohra,WikiWorks,Genera with differentially abundance in the LNS ( limited nesting stress) group compared to control,increased,"k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Enterococcaceae|g__Enterococcus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Peptococcaceae|g__Peptococcus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Aerococcaceae|g__Aerococcus,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Staphylococcaceae|g__Jeotgalicoccus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Aerococcaceae|g__Facklamia,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Clostridium,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Mycobacteriales|f__Corynebacteriaceae|g__Corynebacterium,k__Bacteria|p__Thermodesulfobacteriota|c__Desulfovibrionia|o__Desulfovibrionales|f__Desulfovibrionaceae|g__Desulfovibrio,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Carnobacteriaceae|g__Granulicatella,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micrococcales|f__Micrococcaceae|g__Rothia,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Morganellaceae|g__Proteus,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Coprobacillaceae|g__Coprobacillus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Lactococcus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Enterococcaceae,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Turicibacteraceae|g__Turicibacter,k__Archaea|p__Euryarchaeota|c__Methanobacteria|o__Methanobacteriales|f__Methanobacteriaceae|g__Methanosphaera",2|1239|91061|186826|81852|1350;2|1239|91061|186826|1300|1301;2|1239|186801|186802|186807|2740;2|1239|91061|186826|186827|1375;2|1239|91061|1385|90964|227979;2|1239|91061|186826|186827|66831;2|1239|186801|186802|31979|1485;2|201174|1760|85007|1653|1716;2|200940|3031449|213115|194924|872;2|1239|91061|186826|186828|117563;2|201174|1760|85006|1268|32207;2|1224|1236|91347|1903414|583;2|1239|186801|186802|31979;2|1239|526524|526525|2810280|100883;2|1239|91061|186826|1300|1357;2|1239|91061|186826|1300;2|1239|91061|186826|81852;2|1239|526524|526525|2810281|191303;2157|28890|183925|2158|2159|2316,Complete,Claregrieve1
bsdb:78/1/2,Study 78,laboratory experiment,27829577,10.5056/jnm16105,NA,"Moussaoui N, Jacobs JP, Larauche M, Biraud M, Million M, Mayer E , Taché Y","Chronic Early-life Stress in Rat Pups Alters Basal Corticosterone, Intestinal Permeability, and Fecal Microbiota at Weaning: Influence of Sex",Journal of neurogastroenterology and motility,2017,"Corticosterone, Microbiota, Permeability, Stress, psychological, Weaning",Experiment 1,United States of America,Rattus norvegicus,Feces,UBERON:0001988,Stimulus or stress design,EFO:0001762,controls,limited nesting stress,pups exposed to limited nesting stress,23,23,NA,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,sex,NA,decreased,decreased,NA,NA,NA,Signature 2,Fig3C + text,10 January 2021,Fatima Zohra,WikiWorks,Genera with differentially abundance in the LNS ( limited nesting stress) group compared to control,decreased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Ruminococcus,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Roseburia,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Coprococcus,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae|g__Amedibacillus|s__Amedibacillus dolichus,k__Bacteria|p__Verrucomicrobiota|c__Verrucomicrobiia|o__Verrucomicrobiales|f__Akkermansiaceae|g__Akkermansia|s__Akkermansia muciniphila,k__Bacteria|p__Deferribacterota|c__Deferribacteres|o__Deferribacterales|f__Mucispirillaceae|g__Mucispirillum|s__Mucispirillum schaedleri,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae|g__Holdemanella,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Barnesiellaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Staphylococcaceae|g__Staphylococcus,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Tannerellaceae|g__Parabacteroides,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Peptococcaceae,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Lachnospira,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Anaerotruncus,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Haemophilus,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Odoribacteraceae|g__Odoribacter",2|1239|186801|186802|216572|1263;2|1239|186801|3085636|186803|841;2|1239|186801|3085636|186803|33042;2|1239|526524|526525|128827|2749846|31971;2|74201|203494|48461|1647988|239934|239935;2|200930|68337|191393|2945020|248038|248039;2|1239|526524|526525|128827|1573535;2|1239|186801|186802|541000;2|976|200643|171549|2005519;2|1239|91061|1385|90964|1279;2|976|200643|171549|2005525|375288;2|1239|186801|186802|186807;2|1239|526524|526525|128827;2|1239|186801|186802;2|1239|186801|3085636|186803|28050;2|1239|186801|186802|216572|244127;2|1224|1236|135625|712|724;2|976|200643|171549|1853231|283168,Complete,Claregrieve1
bsdb:79/1/1,Study 79,time series / longitudinal observational,25710027,10.1155/2015/806248,NA,"Damms-Machado A, Mitra S, Schollenberger AE, Kramer KM, Meile T, Königsrainer A, Huson DH , Bischoff SC",Effects of surgical and dietary weight loss therapy for obesity on gut microbiota composition and nutrient absorption,BioMed research international,2015,NA,Experiment 1,Germany,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,Laparoscopic sleeve gastrectomy after 3 months and 6 Months combined,Laparoscopic sleeve gastrectomy baseline,NA,3,3,3 months,WMS,NA,Roche454,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Table S1A,10 January 2021,Marianthi Thomatos,WikiWorks,Effects of laparoscopic sleeve gastrectomy (LSG) and very low calorie diet (VLCD) for obesity on gut microbiota composition,increased,"k__Bacteria|p__Bacillota|c__Clostridia,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Coprococcus,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Dorea,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Ruminococcus,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides|s__Bacteroides sp. 3_1_40A,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Clostridium|s__Clostridium sp. L2-50,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Blautia|s__Blautia obeum,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Dorea|s__Dorea longicatena",2|1239|186801;2|1239|186801|186802;2|1239|186801|186802|541000;2|1239|186801|3085636|186803|33042;2|1239|186801|3085636|186803|189330;2|1239|186801|186802|216572|1263;2|976|200643|171549|815|816|469593;2|1239|186801|186802|31979|1485|411489;2|1239|186801|3085636|186803|572511|40520;2|1239|186801|3085636|186803|189330|88431,Complete,Shaimaa Elsafoury
bsdb:79/2/1,Study 79,time series / longitudinal observational,25710027,10.1155/2015/806248,NA,"Damms-Machado A, Mitra S, Schollenberger AE, Kramer KM, Meile T, Königsrainer A, Huson DH , Bischoff SC",Effects of surgical and dietary weight loss therapy for obesity on gut microbiota composition and nutrient absorption,BioMed research international,2015,NA,Experiment 2,Germany,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,very low calorie diet after 3 months and 6 months,Very low calorie diet baseline,NA,3,3,3 months,WMS,NA,Roche454,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Table S1B,10 January 2021,Marianthi Thomatos,"Fatima,WikiWorks",Effects of laparoscopic sleeve gastrectomy (LSG) and very low calorie diet (VLCD) for obesity on gut microbiota composition,decreased,"k__Bacteria|p__Bacillota|c__Bacilli,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Blautia|s__Blautia hydrogenotrophica,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Clostridium|s__Clostridium sp. D5,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Clostridium|s__Clostridium sp. M62/1,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Coprobacillaceae|g__Coprobacillus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Enterococcaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Enterococcaceae|g__Enterococcus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Enterococcaceae|g__Enterococcus|s__Enterococcus faecium,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Eubacteriaceae|g__Eubacterium|s__Eubacterium limosum,k__Bacteria|p__Fusobacteriota,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae|g__Holdemania,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Lacrimispora|s__Lacrimispora saccharolytica,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Oribacterium,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Peptostreptococcaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Ruminococcus,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Lachnoclostridium|s__[Clostridium] symbiosum,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Coprobacillaceae|g__Coprobacillus|s__Coprobacillus cateniformis",2|1239|91061;2|1239|186801|3085636|186803|572511|53443;2|1239|186801|186802|31979|1485|556261;2|1239|186801|186802|31979|1485|411486;2|1239|526524|526525|2810280|100883;2|1239|91061|186826|81852;2|1239|91061|186826|81852|1350;2|1239|91061|186826|81852|1350|1352;2|1239|186801|186802|186806|1730|1736;2|32066;2|32066|203490|203491|203492;2|32066|203490|203491;2|1239|526524|526525|128827|61170;2|1239|186801|3085636|186803|2719231|84030;2|1239|91061|186826;2|1239|91061|186826|33958|1578;2|1239|186801|3085636|186803|265975;2|1239|186801|186802|541000;2|1239|186801|3082720|186804;2|1239|186801|186802|216572|1263;2|1239|186801|3085636|186803|1506553|1512;2|1239|526524|526525|2810280|100883|100884,Complete,Fatima
bsdb:80/1/1,Study 80,"cross-sectional observational, not case-control",24448554,10.1038/srep03814,NA,"Mejía-León ME, Petrosino JF, Ajami NJ, Domínguez-Bello MG , de la Barca AM",Fecal microbiota imbalance in Mexican children with type 1 diabetes,Scientific reports,2014,NA,Experiment 1,Mexico,Homo sapiens,Feces,UBERON:0001988,Type I diabetes mellitus,MONDO:0005147,controls,Type I diabetic children at onset,"T1D diagnose as established according to the American Diabetes Association criteria1, a positive anti-GAD and/or anti-IA-2 auto- antibodies result, HbA1C levels , 8%",8,8,3 months,16S,4,Roche454,ANOVA,0.05,FALSE,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,Signature 1,text,10 January 2021,Yaseen Javaid,WikiWorks,Fecal microbiota imbalance in Mexican children with type 1 diabetes,increased,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides,2|976|200643|171549|815|816,Complete,Shaimaa Elsafoury
bsdb:80/1/2,Study 80,"cross-sectional observational, not case-control",24448554,10.1038/srep03814,NA,"Mejía-León ME, Petrosino JF, Ajami NJ, Domínguez-Bello MG , de la Barca AM",Fecal microbiota imbalance in Mexican children with type 1 diabetes,Scientific reports,2014,NA,Experiment 1,Mexico,Homo sapiens,Feces,UBERON:0001988,Type I diabetes mellitus,MONDO:0005147,controls,Type I diabetic children at onset,"T1D diagnose as established according to the American Diabetes Association criteria1, a positive anti-GAD and/or anti-IA-2 auto- antibodies result, HbA1C levels , 8%",8,8,3 months,16S,4,Roche454,ANOVA,0.05,FALSE,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,Signature 2,text,10 January 2021,Yaseen Javaid,WikiWorks,Fecal microbiota imbalance in Mexican children with type 1 diabetes,decreased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Bacillota|c__Negativicutes|o__Acidaminococcales|f__Acidaminococcaceae|g__Acidaminococcus,k__Bacteria|p__Bacillota|c__Negativicutes|o__Selenomonadales|f__Selenomonadaceae|g__Megamonas",2|976|200643|171549|171552|838;2|1239|909932|1843488|909930|904;2|1239|909932|909929|1843491|158846,Complete,Shaimaa Elsafoury
bsdb:81/1/1,Study 81,time series / longitudinal observational,27306058,10.1186/s13073-016-0312-1,NA,"Palleja A, Kashani A, Allin KH, Nielsen T, Zhang C, Li Y, Brach T, Liang S, Feng Q, Jørgensen NB, Bojsen-Møller KN, Dirksen C, Burgdorf KS, Holst JJ, Madsbad S, Wang J, Pedersen O, Hansen T , Arumugam M",Roux-en-Y gastric bypass surgery of morbidly obese patients induces swift and persistent changes of the individual gut microbiota,Genome medicine,2016,NA,Experiment 1,Denmark,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,baseline,3 Months after Roux-en-Y gastric bypass surgery,NA,13,12,NA,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,increased,Signature 1,Figure 3 & Table S3,10 January 2021,Marianthi Thomatos,WikiWorks,Roux-en-Y gastric bypass surgery and changes of gut microbiota in morbidly obese,increased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Escherichia|s__Escherichia coli,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Klebsiella|s__Klebsiella pneumoniae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus|s__Streptococcus salivarius,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Veillonella|s__Veillonella atypica,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Veillonella|s__Veillonella parvula,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus|s__Streptococcus vestibularis,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus|s__Streptococcus parasanguinis,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Veillonella|s__Veillonella dispar,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus|s__Streptococcus pneumoniae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus|s__Streptococcus thermophilus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus|s__Streptococcus australis,k__Bacteria|p__Verrucomicrobiota|c__Verrucomicrobiia|o__Verrucomicrobiales|f__Akkermansiaceae|g__Akkermansia|s__Akkermansia muciniphila,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Clostridium|s__Clostridium perfringens,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus|s__Streptococcus infantis,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus|s__Streptococcus gordonii,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus|s__Streptococcus anginosus,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Mediterraneibacter|s__[Ruminococcus] lactaris,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Rikenellaceae|g__Alistipes|s__Alistipes shahii,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Odoribacteraceae|g__Odoribacter|s__Odoribacter splanchnicus,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium|s__Bifidobacterium dentium,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Enterococcaceae|g__Enterococcus|s__Enterococcus faecalis,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Megasphaera|s__Megasphaera micronuciformis,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Anaerotruncus|s__Anaerotruncus colihominis,k__Bacteria|p__Fusobacteriota,k__Bacteria|p__Pseudomonadota",2|1224|1236|91347|543|561|562;2|1224|1236|91347|543|570|573;2|1239|91061|186826|1300|1301|1304;2|1239|909932|1843489|31977|29465|39777;2|1239|909932|1843489|31977|29465|29466;2|1239|91061|186826|1300|1301|1343;2|1239|91061|186826|1300|1301|1318;2|1239|909932|1843489|31977|29465|39778;2|1239|91061|186826|1300|1301|1313;2|1239|91061|186826|1300|1301|1308;2|1239|91061|186826|1300|1301|113107;2|74201|203494|48461|1647988|239934|239935;2|1239|186801|186802|31979|1485|1502;2|1239|91061|186826|1300|1301|68892;2|1239|91061|186826|1300|1301|1302;2|1239|91061|186826|1300|1301|1328;2|1239|186801|3085636|186803|2316020|46228;2|976|200643|171549|171550|239759|328814;2|976|200643|171549|1853231|283168|28118;2|201174|1760|85004|31953|1678|1689;2|1239|91061|186826|81852|1350|1351;2|1239|909932|1843489|31977|906|187326;2|1239|186801|186802|216572|244127|169435;2|32066;2|1224,Complete,Shaimaa Elsafoury
bsdb:81/1/2,Study 81,time series / longitudinal observational,27306058,10.1186/s13073-016-0312-1,NA,"Palleja A, Kashani A, Allin KH, Nielsen T, Zhang C, Li Y, Brach T, Liang S, Feng Q, Jørgensen NB, Bojsen-Møller KN, Dirksen C, Burgdorf KS, Holst JJ, Madsbad S, Wang J, Pedersen O, Hansen T , Arumugam M",Roux-en-Y gastric bypass surgery of morbidly obese patients induces swift and persistent changes of the individual gut microbiota,Genome medicine,2016,NA,Experiment 1,Denmark,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,baseline,3 Months after Roux-en-Y gastric bypass surgery,NA,13,12,NA,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,increased,Signature 2,Figure 3 & Table S3,10 January 2021,Marianthi Thomatos,WikiWorks,Roux-en-Y gastric bypass surgery and changes of gut microbiota in morbidly obese,decreased,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Faecalibacterium|s__Faecalibacterium prausnitzii,2|1239|186801|186802|216572|216851|853,Complete,Shaimaa Elsafoury
bsdb:81/2/1,Study 81,time series / longitudinal observational,27306058,10.1186/s13073-016-0312-1,NA,"Palleja A, Kashani A, Allin KH, Nielsen T, Zhang C, Li Y, Brach T, Liang S, Feng Q, Jørgensen NB, Bojsen-Møller KN, Dirksen C, Burgdorf KS, Holst JJ, Madsbad S, Wang J, Pedersen O, Hansen T , Arumugam M",Roux-en-Y gastric bypass surgery of morbidly obese patients induces swift and persistent changes of the individual gut microbiota,Genome medicine,2016,NA,Experiment 2,Denmark,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,baseline,one year after Roux-en-Y gastric bypass surgery,NA,13,8,NA,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,increased,Signature 1,Figure 3 & Table S3,10 January 2021,Shaimaa Elsafoury,WikiWorks,Roux-en-Y gastric bypass surgery and changes of gut microbiota in morbidly obese,increased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Klebsiella|s__Klebsiella pneumoniae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Escherichia|s__Escherichia coli,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus|s__Streptococcus salivarius,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Veillonella|s__Veillonella atypica,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Veillonella|s__Veillonella parvula,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus|s__Streptococcus vestibularis,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus|s__Streptococcus parasanguinis,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Veillonella|s__Veillonella dispar,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus|s__Streptococcus thermophilus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus|s__Streptococcus australis,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus|s__Streptococcus infantis,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Rikenellaceae|g__Alistipes|s__Alistipes shahii,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Carnobacteriaceae|g__Granulicatella|s__Granulicatella adiacens,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales|f__Actinomycetaceae|g__Schaalia|s__Schaalia odontolytica,k__Bacteria|p__Pseudomonadota,k__Bacteria|p__Fusobacteriota",2|1224|1236|91347|543|570|573;2|1224|1236|91347|543|561|562;2|1239|91061|186826|1300|1301|1304;2|1239|909932|1843489|31977|29465|39777;2|1239|909932|1843489|31977|29465|29466;2|1239|91061|186826|1300|1301|1343;2|1239|91061|186826|1300|1301|1318;2|1239|909932|1843489|31977|29465|39778;2|1239|91061|186826|1300|1301|1308;2|1239|91061|186826|1300|1301|113107;2|1239|91061|186826|1300|1301|68892;2|976|200643|171549|171550|239759|328814;2|1239|91061|186826|186828|117563|46124;2|201174|1760|2037|2049|2529408|1660;2|1224;2|32066,Complete,Shaimaa Elsafoury
bsdb:82/1/1,Study 82,case-control,23032991,10.1038/tpj.2012.43,NA,"Graessler J, Qin Y, Zhong H, Zhang J, Licinio J, Wong ML, Xu A, Chavakis T, Bornstein AB, Ehrhart-Bornstein M, Lamounier-Zepter V, Lohmann T, Wolf T , Bornstein SR",Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: correlation with inflammatory and metabolic parameters,The pharmacogenomics journal,2013,NA,Experiment 1,Germany,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,lean controls,before surgery,Roux-en-Y gastric-bypass operation were recruited according to the S3 guidelines of the German Society for Obesity,6,NA,3 weeks,WMS,NA,Illumina,ANOVA,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Table 2,10 January 2021,Marianthi Thomatos,WikiWorks,gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes,increased,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Faecalibacterium|s__Faecalibacterium prausnitzii,2|1239|186801|186802|216572|216851|853,Complete,Shaimaa Elsafoury
bsdb:82/1/2,Study 82,case-control,23032991,10.1038/tpj.2012.43,NA,"Graessler J, Qin Y, Zhong H, Zhang J, Licinio J, Wong ML, Xu A, Chavakis T, Bornstein AB, Ehrhart-Bornstein M, Lamounier-Zepter V, Lohmann T, Wolf T , Bornstein SR",Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: correlation with inflammatory and metabolic parameters,The pharmacogenomics journal,2013,NA,Experiment 1,Germany,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,lean controls,before surgery,Roux-en-Y gastric-bypass operation were recruited according to the S3 guidelines of the German Society for Obesity,6,NA,3 weeks,WMS,NA,Illumina,ANOVA,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 2,Table 2,10 January 2021,Marianthi Thomatos,WikiWorks,gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes,decreased,"k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Coprobacillaceae|g__Thomasclavelia|s__Thomasclavelia spiroformis,k__Bacteria|p__Spirochaetota|c__Spirochaetia|o__Brachyspirales|f__Brachyspiraceae|g__Brachyspira|s__Brachyspira hyodysenteriae,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae|g__Fusobacterium|s__Fusobacterium periodonticum",2|1239|526524|526525|2810280|3025755|29348;2|203691|203692|1643686|143786|29521|159;2|32066|203490|203491|203492|848|860,Complete,Shaimaa Elsafoury
bsdb:83/1/1,Study 83,time series / longitudinal observational,23032991,10.1038/tpj.2012.43,NA,"Graessler J, Qin Y, Zhong H, Zhang J, Licinio J, Wong ML, Xu A, Chavakis T, Bornstein AB, Ehrhart-Bornstein M, Lamounier-Zepter V, Lohmann T, Wolf T , Bornstein SR",Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: correlation with inflammatory and metabolic parameters,The pharmacogenomics journal,2013,NA,Experiment 1,Germany,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,after surgery,before surgery,Roux-en-Y gastric-bypass operation were recruited according to the S3 guidelines of the German Society for Obesity,6,6,3 weeks,WMS,NA,Illumina,ANOVA,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Table 2 &Table 3,10 January 2021,Marianthi Thomatos,"Fatima,WikiWorks",gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes,increased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Moraxellales|f__Moraxellaceae|g__Acinetobacter|s__Acinetobacter johnsonii,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Anaerostipes,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Anaerostipes|s__Anaerostipes caccae,k__Bacteria|p__Spirochaetota|c__Spirochaetia|o__Brachyspirales|f__Brachyspiraceae|g__Brachyspira|s__Brachyspira hyodysenteriae,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Coprococcus,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Coprococcus|s__Coprococcus comes,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Faecalibacterium,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Faecalibacterium|s__Faecalibacterium prausnitzii,k__Bacteria|p__Fibrobacterota|c__Fibrobacteria|o__Fibrobacterales|f__Fibrobacteraceae|g__Fibrobacter|s__Fibrobacter succinogenes,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae|g__Fusobacterium|s__Fusobacterium periodonticum,k__Bacteria|p__Campylobacterota|c__Epsilonproteobacteria|o__Campylobacterales|f__Helicobacteraceae|g__Helicobacter,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus|s__Lactobacillus acidophilus,k__Bacteria|p__Spirochaetota|c__Spirochaetia|o__Leptospirales|f__Leptospiraceae|g__Leptospira|s__Leptospira interrogans,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Limosilactobacillus|s__Limosilactobacillus reuteri,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Mycobacteriales|f__Mycobacteriaceae|g__Mycobacterium|s__Mycobacterium kansasii,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Nakamurellales|f__Nakamurellaceae|g__Nakamurella|s__Nakamurella multipartita,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pseudomonadales|f__Pseudomonadaceae|g__Pseudomonas|s__Pseudomonas mendocina,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Staphylococcaceae|g__Staphylococcus|s__Staphylococcus epidermidis,k__Bacteria|p__Thermomicrobiota|c__Thermomicrobia|o__Thermomicrobiales|f__Thermomicrobiaceae|g__Thermomicrobium|s__Thermomicrobium roseum,k__Bacteria|p__Spirochaetota|c__Spirochaetia|o__Spirochaetales|f__Treponemataceae|g__Treponema|s__Treponema pallidum,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Coprobacillaceae|g__Thomasclavelia|s__Thomasclavelia spiroformis,k__Eukaryota|p__Evosea|c__Eumycetozoa|o__Dictyosteliales|f__Dictyosteliaceae|g__Dictyostelium,k__Eukaryota|p__Ciliophora|c__Litostomatea|o__Entodiniomorphida|f__Ophryoscolecidae|g__Epidinium",2|1224|1236|2887326|468|469|40214;2|1239|186801|3085636|186803|207244;2|1239|186801|3085636|186803|207244|105841;2|203691|203692|1643686|143786|29521|159;2|1239|186801|3085636|186803|33042;2|1239|186801|3085636|186803|33042|410072;2|1239|186801|186802|216572|216851;2|1239|186801|186802|216572|216851|853;2|65842|204430|218872|204431|832|833;2|32066|203490|203491|203492|848|860;2|29547|3031852|213849|72293|209;2|1239|91061|186826|33958|1578|1579;2|203691|203692|1643688|170|171|173;2|1239|91061|186826|33958|2742598|1598;2|201174|1760|85007|1762|1763|1768;2|201174|1760|1643684|85031|53460|53461;2|1224|1236|72274|135621|286|300;2|1239|91061|1385|90964|1279|1282;2|3027942|189775|189776|189777|499|500;2|203691|203692|136|2845253|157|160;2|1239|526524|526525|2810280|3025755|29348;2759|2605435|142796|2058949|2058185|5782;2759|5878|5988|40634|47890|40637,Complete,Fatima
bsdb:83/1/2,Study 83,time series / longitudinal observational,23032991,10.1038/tpj.2012.43,NA,"Graessler J, Qin Y, Zhong H, Zhang J, Licinio J, Wong ML, Xu A, Chavakis T, Bornstein AB, Ehrhart-Bornstein M, Lamounier-Zepter V, Lohmann T, Wolf T , Bornstein SR",Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: correlation with inflammatory and metabolic parameters,The pharmacogenomics journal,2013,NA,Experiment 1,Germany,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,after surgery,before surgery,Roux-en-Y gastric-bypass operation were recruited according to the S3 guidelines of the German Society for Obesity,6,6,3 weeks,WMS,NA,Illumina,ANOVA,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 2,Table 2 &Table 3,10 January 2021,Marianthi Thomatos,"Fatima,WikiWorks",gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes,decreased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Citrobacter,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Enterobacter,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Enterobacter|s__Enterobacter cancerogenus,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Salmonella,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Salmonella|s__Salmonella enterica,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Shigella|s__Shigella boydii,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Veillonella,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Veillonella|s__Veillonella dispar,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Veillonella|s__Veillonella parvula,k__Eukaryota|k__Fungi|p__Ascomycota|c__Sordariomycetes|o__Sordariales|f__Sordariaceae|g__Neurospora",2|1224|1236|91347|543|544;2|1224|1236|91347|543|547;2|1224|1236|91347|543|547|69218;2|1224|1236|91347|543|590;2|1224|1236|91347|543|590|28901;2|1224|1236|91347|543|620|621;2|1239|909932|1843489|31977|29465;2|1239|909932|1843489|31977|29465|39778;2|1239|909932|1843489|31977|29465|29466;2759|4751|4890|147550|5139|5148|5140,Complete,Fatima
bsdb:84/1/1,Study 84,case-control,23032991,10.1038/tpj.2012.43,NA,"Graessler J, Qin Y, Zhong H, Zhang J, Licinio J, Wong ML, Xu A, Chavakis T, Bornstein AB, Ehrhart-Bornstein M, Lamounier-Zepter V, Lohmann T, Wolf T , Bornstein SR",Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: correlation with inflammatory and metabolic parameters,The pharmacogenomics journal,2013,NA,Experiment 1,Germany,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,lean controls,after surgery,Roux-en-Y gastric-bypass operation were recruited according to the S3 guidelines of the German Society for Obesity,6,NA,3 weeks,WMS,NA,Illumina,ANOVA,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Table 2,10 January 2021,Shaimaa Elsafoury,WikiWorks,gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes,increased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Enterobacter|s__Enterobacter cancerogenus,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Veillonella|s__Veillonella parvula,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Shigella|s__Shigella boydii",2|1224|1236|91347|543|547|69218;2|1239|909932|1843489|31977|29465|29466;2|1224|1236|91347|543|620|621,Complete,Shaimaa Elsafoury
bsdb:84/1/2,Study 84,case-control,23032991,10.1038/tpj.2012.43,NA,"Graessler J, Qin Y, Zhong H, Zhang J, Licinio J, Wong ML, Xu A, Chavakis T, Bornstein AB, Ehrhart-Bornstein M, Lamounier-Zepter V, Lohmann T, Wolf T , Bornstein SR",Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: correlation with inflammatory and metabolic parameters,The pharmacogenomics journal,2013,NA,Experiment 1,Germany,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,lean controls,after surgery,Roux-en-Y gastric-bypass operation were recruited according to the S3 guidelines of the German Society for Obesity,6,NA,3 weeks,WMS,NA,Illumina,ANOVA,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 2,Table 2,10 January 2021,Shaimaa Elsafoury,WikiWorks,gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes,decreased,"k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Coprobacillaceae|g__Thomasclavelia|s__Thomasclavelia spiroformis,k__Bacteria|p__Spirochaetota|c__Spirochaetia|o__Brachyspirales|f__Brachyspiraceae|g__Brachyspira|s__Brachyspira hyodysenteriae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Limosilactobacillus|s__Limosilactobacillus reuteri,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Anaerostipes|s__Anaerostipes caccae,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae|g__Fusobacterium|s__Fusobacterium periodonticum,k__Bacteria|p__Thermomicrobiota|c__Thermomicrobia|o__Thermomicrobiales|f__Thermomicrobiaceae|g__Thermomicrobium|s__Thermomicrobium roseum,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Staphylococcaceae|g__Staphylococcus|s__Staphylococcus epidermidis,k__Bacteria|p__Fibrobacterota|c__Fibrobacteria|o__Fibrobacterales|f__Fibrobacteraceae|g__Fibrobacter|s__Fibrobacter succinogenes",2|1239|526524|526525|2810280|3025755|29348;2|203691|203692|1643686|143786|29521|159;2|1239|91061|186826|33958|2742598|1598;2|1239|186801|3085636|186803|207244|105841;2|32066|203490|203491|203492|848|860;2|3027942|189775|189776|189777|499|500;2|1239|91061|1385|90964|1279|1282;2|65842|204430|218872|204431|832|833,Complete,Shaimaa Elsafoury
bsdb:85/1/1,Study 85,"cross-sectional observational, not case-control",28968427,10.1371/journal.pone.0185569,NA,"Brazier L, Elguero E, Koumavor CK, Renaud N, Prugnolle F, Thomas F, Ategbo S, Engoba M, Obengui EM, Leroy P, Durand F, Renaud P , Becquart",Evolution in fecal bacterial/viral composition in infants of two central African countries (Gabon and Republic of the Congo) during their first month of life,PloS one,2017,NA,Experiment 1,Gabon,Homo sapiens,Meconium,UBERON:0007109,Cesarean section,EFO:0009636,vaginal delivery,two-day aged babies c-section,NA,7,8,NA,16S,3,Roche454,Linear Regression,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,Signature 1,figure 4 &text,10 January 2021,Shaimaa Elsafoury,WikiWorks,"Signatures include bacterial genera with a read frequency higher than 5% in at least one child. Viruses were tested and not found in meconium samples. preterm, normal and postterm included",increased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Klebsiella,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Sarcina",2|1224|1236|91347|543|570;2|1239|186801|186802|31979|1266,Complete,Shaimaa Elsafoury
bsdb:85/2/1,Study 85,"cross-sectional observational, not case-control",28968427,10.1371/journal.pone.0185569,NA,"Brazier L, Elguero E, Koumavor CK, Renaud N, Prugnolle F, Thomas F, Ategbo S, Engoba M, Obengui EM, Leroy P, Durand F, Renaud P , Becquart",Evolution in fecal bacterial/viral composition in infants of two central African countries (Gabon and Republic of the Congo) during their first month of life,PloS one,2017,NA,Experiment 2,Congo,Homo sapiens,Meconium,UBERON:0007109,Cesarean section,EFO:0009636,vaginal delivery,two-day aged babies c-section,NA,7,8,NA,16S,3,Roche454,Linear Regression,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,Signature 1,figure 4 &text,10 January 2021,Shaimaa Elsafoury,WikiWorks,"Signatures include bacterial genera with a read frequency higher than 5% in at least one child. Viruses were tested and not found in meconium samples. preterm, normal and postterm included",decreased,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides,2|976|200643|171549|815|816,Complete,Shaimaa Elsafoury
bsdb:85/3/1,Study 85,"cross-sectional observational, not case-control",28968427,10.1371/journal.pone.0185569,NA,"Brazier L, Elguero E, Koumavor CK, Renaud N, Prugnolle F, Thomas F, Ategbo S, Engoba M, Obengui EM, Leroy P, Durand F, Renaud P , Becquart",Evolution in fecal bacterial/viral composition in infants of two central African countries (Gabon and Republic of the Congo) during their first month of life,PloS one,2017,NA,Experiment 3,Gabon,Homo sapiens,Feces,UBERON:0001988,Cesarean section,EFO:0009636,vaginal delivery,seven-day aged babies c-section,NA,7,8,NA,16S,3,Roche454,Linear Regression,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,Signature 1,figure 4 &text,10 January 2021,Shaimaa Elsafoury,WikiWorks,"Signatures include bacterial genera with a read frequency higher than 5% in at least one child. Viruses were tested and not found in meconium samples. preterm, normal and postterm included",increased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Klebsiella,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Sarcina",2|1224|1236|91347|543|570;2|1239|186801|186802|31979|1266,Complete,Shaimaa Elsafoury
bsdb:85/4/1,Study 85,"cross-sectional observational, not case-control",28968427,10.1371/journal.pone.0185569,NA,"Brazier L, Elguero E, Koumavor CK, Renaud N, Prugnolle F, Thomas F, Ategbo S, Engoba M, Obengui EM, Leroy P, Durand F, Renaud P , Becquart",Evolution in fecal bacterial/viral composition in infants of two central African countries (Gabon and Republic of the Congo) during their first month of life,PloS one,2017,NA,Experiment 4,Congo,Homo sapiens,Feces,UBERON:0001988,Cesarean section,EFO:0009636,vaginal delivery,seven-day aged babies c-section,NA,7,8,NA,16S,3,Roche454,Linear Regression,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,Signature 1,figure 4 &text,10 January 2021,Shaimaa Elsafoury,WikiWorks,"Signatures include bacterial genera with a read frequency higher than 5% in at least one child. Viruses were tested and not found in meconium samples. preterm, normal and postterm included",decreased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales|f__Coriobacteriaceae|g__Collinsella",2|976|200643|171549|815|816;2|201174|84998|84999|84107|102106,Complete,Shaimaa Elsafoury
bsdb:86/1/1,Study 86,time series / longitudinal observational,28512451,10.3389/fmicb.2017.00738,NA,"Wampach L, Heintz-Buschart A, Hogan A, Muller EEL, Narayanasamy S, Laczny CC, Hugerth LW, Bindl L, Bottu J, Andersson AF, de Beaufort C , Wilmes P","Colonization and Succession within the Human Gut Microbiome by Archaea, Bacteria, and Microeukaryotes during the First Year of Life",Frontiers in microbiology,2017,"amplicon sequencing, delivery mode, fungi, infant gut microbiome, microbial colonization, quantitative real-time PCR, succession",Experiment 1,Luxembourg,Homo sapiens,Feces,UBERON:0001988,Cesarean section,EFO:0009636,vaginal delivery at day 3,c-section,meconium samples were collected at day 1 after delivery,6,3,11 mothers (6 contols and 5 cases) used antibiotices 12 hours before and after delivery.,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,unchanged,unchanged,increased,NA,NA,increased,Signature 1,Figure 7 and Fig. S4,10 January 2021,Shaimaa Elsafoury,WikiWorks,qPCR validation of 16S rRNA gene sequencing data based differences according to delivery mode.,increased,"k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Staphylococcaceae|g__Staphylococcus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus",2|1239|91061|1385|90964|1279;2|1239|91061|186826|33958|1578,Complete,Shaimaa Elsafoury
bsdb:86/2/1,Study 86,time series / longitudinal observational,28512451,10.3389/fmicb.2017.00738,NA,"Wampach L, Heintz-Buschart A, Hogan A, Muller EEL, Narayanasamy S, Laczny CC, Hugerth LW, Bindl L, Bottu J, Andersson AF, de Beaufort C , Wilmes P","Colonization and Succession within the Human Gut Microbiome by Archaea, Bacteria, and Microeukaryotes during the First Year of Life",Frontiers in microbiology,2017,"amplicon sequencing, delivery mode, fungi, infant gut microbiome, microbial colonization, quantitative real-time PCR, succession",Experiment 2,Luxembourg,Homo sapiens,Feces,UBERON:0001988,Cesarean section,EFO:0009636,vaginal delivery at day 5,c-section,meconium samples were collected at day 1 after delivery,7,5,11 mothers (6 contols and 5 cases) used antibiotices 12 hours before and after delivery.,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.01,TRUE,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,unchanged,Signature 1,Figure 6S,10 January 2021,Shaimaa Elsafoury,WikiWorks,qPCR validation of 16S rRNA gene sequencing data based differences according to delivery mode.,increased,k__Bacteria|p__Bacillota,2|1239,Complete,Shaimaa Elsafoury
bsdb:86/2/2,Study 86,time series / longitudinal observational,28512451,10.3389/fmicb.2017.00738,NA,"Wampach L, Heintz-Buschart A, Hogan A, Muller EEL, Narayanasamy S, Laczny CC, Hugerth LW, Bindl L, Bottu J, Andersson AF, de Beaufort C , Wilmes P","Colonization and Succession within the Human Gut Microbiome by Archaea, Bacteria, and Microeukaryotes during the First Year of Life",Frontiers in microbiology,2017,"amplicon sequencing, delivery mode, fungi, infant gut microbiome, microbial colonization, quantitative real-time PCR, succession",Experiment 2,Luxembourg,Homo sapiens,Feces,UBERON:0001988,Cesarean section,EFO:0009636,vaginal delivery at day 5,c-section,meconium samples were collected at day 1 after delivery,7,5,11 mothers (6 contols and 5 cases) used antibiotices 12 hours before and after delivery.,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.01,TRUE,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,unchanged,Signature 2,Figure 6S,10 January 2021,Shaimaa Elsafoury,WikiWorks,qPCR validation of 16S rRNA gene sequencing data based differences according to delivery mode.,decreased,k__Bacteria|p__Bacteroidota,2|976,Complete,Shaimaa Elsafoury
bsdb:86/3/1,Study 86,time series / longitudinal observational,28512451,10.3389/fmicb.2017.00738,NA,"Wampach L, Heintz-Buschart A, Hogan A, Muller EEL, Narayanasamy S, Laczny CC, Hugerth LW, Bindl L, Bottu J, Andersson AF, de Beaufort C , Wilmes P","Colonization and Succession within the Human Gut Microbiome by Archaea, Bacteria, and Microeukaryotes during the First Year of Life",Frontiers in microbiology,2017,"amplicon sequencing, delivery mode, fungi, infant gut microbiome, microbial colonization, quantitative real-time PCR, succession",Experiment 3,Luxembourg,Homo sapiens,Feces,UBERON:0001988,Cesarean section,EFO:0009636,vaginal delivery at day 28,c-section,meconium samples were collected at day 1 after delivery,7,6,11 mothers (6 contols and 5 cases) used antibiotices 12 hours before and after delivery.,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,unchanged,unchanged,decreased,NA,NA,unchanged,Signature 1,Figure 6S and Fig. S4,10 January 2021,Shaimaa Elsafoury,WikiWorks,qPCR validation of 16S rRNA gene sequencing data based differences according to delivery mode.,decreased,"k__Bacteria|p__Bacteroidota,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides",2|976;2|976|200643|171549|815|816,Complete,Shaimaa Elsafoury
bsdb:86/4/1,Study 86,time series / longitudinal observational,28512451,10.3389/fmicb.2017.00738,NA,"Wampach L, Heintz-Buschart A, Hogan A, Muller EEL, Narayanasamy S, Laczny CC, Hugerth LW, Bindl L, Bottu J, Andersson AF, de Beaufort C , Wilmes P","Colonization and Succession within the Human Gut Microbiome by Archaea, Bacteria, and Microeukaryotes during the First Year of Life",Frontiers in microbiology,2017,"amplicon sequencing, delivery mode, fungi, infant gut microbiome, microbial colonization, quantitative real-time PCR, succession",Experiment 4,Luxembourg,Homo sapiens,Feces,UBERON:0001988,Cesarean section,EFO:0009636,vaginal delivery at day 150,c-section,meconium samples were collected at day 1 after delivery,6,4,11 mothers (6 contols and 5 cases) used antibiotices 12 hours before and after delivery.,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,unchanged,Signature 1,Figure 6S,10 January 2021,Shaimaa Elsafoury,WikiWorks,qPCR validation of 16S rRNA gene sequencing data based differences according to delivery mode.,decreased,"k__Bacteria|p__Bacteroidota,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides",2|976;2|976|200643|171549|815|816,Complete,Shaimaa Elsafoury
bsdb:86/5/1,Study 86,time series / longitudinal observational,28512451,10.3389/fmicb.2017.00738,NA,"Wampach L, Heintz-Buschart A, Hogan A, Muller EEL, Narayanasamy S, Laczny CC, Hugerth LW, Bindl L, Bottu J, Andersson AF, de Beaufort C , Wilmes P","Colonization and Succession within the Human Gut Microbiome by Archaea, Bacteria, and Microeukaryotes during the First Year of Life",Frontiers in microbiology,2017,"amplicon sequencing, delivery mode, fungi, infant gut microbiome, microbial colonization, quantitative real-time PCR, succession",Experiment 5,Luxembourg,Homo sapiens,Feces,UBERON:0001988,Cesarean section,EFO:0009636,vaginal delivery at day 365,c-section,meconium samples were collected at day 1 after delivery,5,5,11 mothers (6 contols and 5 cases) used antibiotices 12 hours before and after delivery.,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,unchanged,Signature 1,Figure 6S,10 January 2021,Shaimaa Elsafoury,WikiWorks,qPCR validation of 16S rRNA gene sequencing data based differences according to delivery mode.,decreased,k__Bacteria|p__Bacteroidota,2|976,Complete,Shaimaa Elsafoury
bsdb:86/6/1,Study 86,time series / longitudinal observational,28512451,10.3389/fmicb.2017.00738,NA,"Wampach L, Heintz-Buschart A, Hogan A, Muller EEL, Narayanasamy S, Laczny CC, Hugerth LW, Bindl L, Bottu J, Andersson AF, de Beaufort C , Wilmes P","Colonization and Succession within the Human Gut Microbiome by Archaea, Bacteria, and Microeukaryotes during the First Year of Life",Frontiers in microbiology,2017,"amplicon sequencing, delivery mode, fungi, infant gut microbiome, microbial colonization, quantitative real-time PCR, succession",Experiment 6,Luxembourg,Homo sapiens,Feces,UBERON:0001988,Premature birth,EFO:0003917,full-term delivery >39 weeks at day 3,late preterm 34-36 weeks,meconium samples were collected at day 1 after delivery,4,5,11 mothers (6 contols and 5 cases) used antibiotices 12 hours before and after delivery.,16S,4,Illumina,Kruskall-Wallis,0.01,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,text pg11 and figure 7s,10 January 2021,Shaimaa Elsafoury,WikiWorks,qPCR validation of 16S rRNA gene sequencing data based differences according to delivery mode.,decreased,k__Bacteria|p__Bacteroidota,2|976,Complete,Shaimaa Elsafoury
bsdb:86/7/1,Study 86,time series / longitudinal observational,28512451,10.3389/fmicb.2017.00738,NA,"Wampach L, Heintz-Buschart A, Hogan A, Muller EEL, Narayanasamy S, Laczny CC, Hugerth LW, Bindl L, Bottu J, Andersson AF, de Beaufort C , Wilmes P","Colonization and Succession within the Human Gut Microbiome by Archaea, Bacteria, and Microeukaryotes during the First Year of Life",Frontiers in microbiology,2017,"amplicon sequencing, delivery mode, fungi, infant gut microbiome, microbial colonization, quantitative real-time PCR, succession",Experiment 7,Luxembourg,Homo sapiens,Feces,UBERON:0001988,Cesarean section,EFO:0009636,vaginal delivery,overall time point infants samples of c-section,meconium samples were collected at day 1 after delivery,8,7,11 mothers (6 contols and 5 cases) used antibiotices 12 hours before and after delivery.,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,supplemantry file 9,10 January 2021,Shaimaa Elsafoury,"Fatima,WikiWorks",qPCR validation of 16S rRNA gene sequencing data based differences according to delivery mode.,increased,"k__Bacteria|p__Verrucomicrobiota|c__Verrucomicrobiia|o__Verrucomicrobiales|f__Akkermansiaceae|g__Akkermansia,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Anaerostipes,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Clostridium,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Dialister,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Enterobacter,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Enterococcaceae|g__Enterococcus,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Flavonifractor,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Gemellaceae|g__Gemella,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Haemophilus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Propionibacteriales|f__Propionibacteriaceae|g__Propionibacterium,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micrococcales|f__Micrococcaceae|g__Rothia,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Staphylococcaceae|g__Staphylococcus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae",2|74201|203494|48461|1647988|239934;2|1239|186801|3085636|186803|207244;2|1239|186801|186802|31979|1485;2|1239|909932|1843489|31977|39948;2|1224|1236|91347|543|547;2|1239|91061|186826|81852|1350;2|1239|186801|186802|216572|946234;2|1239|91061|1385|539738|1378;2|1224|1236|135625|712|724;2|1239|91061|186826|33958|1578;2|201174|1760|85009|31957|1743;2|201174|1760|85006|1268|32207;2|1239|91061|1385|90964|1279;2|1239|91061|186826|1300|1301;2|1239|186801|3085636|186803,Complete,Fatima
bsdb:86/7/2,Study 86,time series / longitudinal observational,28512451,10.3389/fmicb.2017.00738,NA,"Wampach L, Heintz-Buschart A, Hogan A, Muller EEL, Narayanasamy S, Laczny CC, Hugerth LW, Bindl L, Bottu J, Andersson AF, de Beaufort C , Wilmes P","Colonization and Succession within the Human Gut Microbiome by Archaea, Bacteria, and Microeukaryotes during the First Year of Life",Frontiers in microbiology,2017,"amplicon sequencing, delivery mode, fungi, infant gut microbiome, microbial colonization, quantitative real-time PCR, succession",Experiment 7,Luxembourg,Homo sapiens,Feces,UBERON:0001988,Cesarean section,EFO:0009636,vaginal delivery,overall time point infants samples of c-section,meconium samples were collected at day 1 after delivery,8,7,11 mothers (6 contols and 5 cases) used antibiotices 12 hours before and after delivery.,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 2,supplemantry file 9,10 January 2021,Shaimaa Elsafoury,WikiWorks,qPCR validation of 16S rRNA gene sequencing data based differences according to delivery mode.,decreased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Tannerellaceae|g__Parabacteroides,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Rikenellaceae|g__Alistipes",2|976|200643|171549|2005525|375288;2|976|200643|171549|815|816;2|976|200643|171549|171550|239759,Complete,Shaimaa Elsafoury
bsdb:86/8/NA,Study 86,time series / longitudinal observational,28512451,10.3389/fmicb.2017.00738,NA,"Wampach L, Heintz-Buschart A, Hogan A, Muller EEL, Narayanasamy S, Laczny CC, Hugerth LW, Bindl L, Bottu J, Andersson AF, de Beaufort C , Wilmes P","Colonization and Succession within the Human Gut Microbiome by Archaea, Bacteria, and Microeukaryotes during the First Year of Life",Frontiers in microbiology,2017,"amplicon sequencing, delivery mode, fungi, infant gut microbiome, microbial colonization, quantitative real-time PCR, succession",Experiment 8,Luxembourg,Homo sapiens,Meconium,UBERON:0007109,Cesarean section,EFO:0009636,vaginal delivery,C-section,NA,4,6,"11 mothers (6 controls and 5 cases) used antibiotics 12 hours before and after delivery, 3 VD mothers were positive group B Streptococcus screening.",16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,unchanged,unchanged,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:87/1/1,Study 87,case-control,30224347,10.2337/dc18-0253,NA,"Leiva-Gea I, Sánchez-Alcoholado L, Martín-Tejedor B, Castellano-Castillo D, Moreno-Indias I, Urda-Cardona A, Tinahones FJ, Fernández-García JC , Queipo-Ortuño MI",Gut Microbiota Differs in Composition and Functionality Between Children With Type 1 Diabetes and MODY2 and Healthy Control Subjects: A Case-Control Study,Diabetes care,2018,NA,Experiment 1,Spain,Homo sapiens,Feces,UBERON:0001988,Type I diabetes mellitus,MONDO:0005147,maturity-onset diabetes of the young 2 (MODY2) and healthy Controls,Type I Diabetics,"type 1 diabetes was diagnosed according to the criteria of the American Diabetes Association and the positivity of at least two persistent, confirmed anti-islet autoantibodies (anti-insulin autoantibodies, GAD autoantibodies, or tyrosine phosphatase autoantibodies). MODY2 children were diagnosed by suggestive clinical history, negative anti-islet autoantibodies, and positive genetic testing. Healthy control subjects were children with negative anti-islet autoantibodies,",28,15,3 months,16S,23,Roche454,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,"age,body mass index,breastfeeding duration,delivery procedure,race,sex",NA,NA,NA,NA,NA,NA,NA,Signature 1,Text,10 January 2021,Yaseen Javaid,WikiWorks,"differentially abundant taxa of the fecal microbiota in type 1 diabetes, MODY2, and healthy controls",increased,"k__Bacteria|p__Bacteroidota,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Rikenellaceae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Blautia,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Veillonella,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Ruminococcus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Enterobacter,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Sutterellaceae|g__Sutterella",2|976;2|976|200643|171549|815;2|976|200643|171549|171550;2|1224|1236|91347|543;2|1239|186801|3085636|186803|572511;2|1239|186801|186802|541000;2|1239|909932|1843489|31977;2|1239|91061|186826|1300;2|976|200643|171549|815|816;2|1239|909932|1843489|31977|29465;2|1239|186801|186802|216572|1263;2|1239|91061|186826|1300|1301;2|1224|1236|91347|543|547;2|1224|28216|80840|995019|40544,Complete,Shaimaa Elsafoury
bsdb:87/1/2,Study 87,case-control,30224347,10.2337/dc18-0253,NA,"Leiva-Gea I, Sánchez-Alcoholado L, Martín-Tejedor B, Castellano-Castillo D, Moreno-Indias I, Urda-Cardona A, Tinahones FJ, Fernández-García JC , Queipo-Ortuño MI",Gut Microbiota Differs in Composition and Functionality Between Children With Type 1 Diabetes and MODY2 and Healthy Control Subjects: A Case-Control Study,Diabetes care,2018,NA,Experiment 1,Spain,Homo sapiens,Feces,UBERON:0001988,Type I diabetes mellitus,MONDO:0005147,maturity-onset diabetes of the young 2 (MODY2) and healthy Controls,Type I Diabetics,"type 1 diabetes was diagnosed according to the criteria of the American Diabetes Association and the positivity of at least two persistent, confirmed anti-islet autoantibodies (anti-insulin autoantibodies, GAD autoantibodies, or tyrosine phosphatase autoantibodies). MODY2 children were diagnosed by suggestive clinical history, negative anti-islet autoantibodies, and positive genetic testing. Healthy control subjects were children with negative anti-islet autoantibodies,",28,15,3 months,16S,23,Roche454,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,"age,body mass index,breastfeeding duration,delivery procedure,race,sex",NA,NA,NA,NA,NA,NA,NA,Signature 2,Text,10 January 2021,Yaseen Javaid,WikiWorks,"differentially abundant taxa of the fecal microbiota in type 1 diabetes, MODY2, and healthy controls",decreased,"k__Bacteria|p__Bacillota,k__Bacteria|p__Actinomycetota",2|1239;2|201174,Complete,Shaimaa Elsafoury
bsdb:87/2/1,Study 87,case-control,30224347,10.2337/dc18-0253,NA,"Leiva-Gea I, Sánchez-Alcoholado L, Martín-Tejedor B, Castellano-Castillo D, Moreno-Indias I, Urda-Cardona A, Tinahones FJ, Fernández-García JC , Queipo-Ortuño MI",Gut Microbiota Differs in Composition and Functionality Between Children With Type 1 Diabetes and MODY2 and Healthy Control Subjects: A Case-Control Study,Diabetes care,2018,NA,Experiment 2,Spain,Homo sapiens,Feces,UBERON:0001988,Type I diabetes mellitus,MONDO:0005147,healthy Controls,Type I Diabetics and maturity-onset diabetes of the young 2 (MODY2),"type 1 diabetes was diagnosed according to the criteria of the American Diabetes Association and the positivity of at least two persistent, confirmed anti-islet autoantibodies (anti-insulin autoantibodies, GAD autoantibodies, or tyrosine phosphatase autoantibodies). MODY2 children were diagnosed by suggestive clinical history, negative anti-islet autoantibodies, and positive genetic testing. Healthy control subjects were children with negative anti-islet autoantibodies,",13,30,3 months,16S,23,Roche454,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,"age,body mass index,breastfeeding duration,delivery procedure,race,sex",NA,NA,decreased,NA,NA,NA,NA,Signature 1,Text,10 January 2021,Shaimaa Elsafoury,WikiWorks,"differentially abundant taxa of the fecal microbiota in type 1 diabetes, MODY2, and healthy controls",decreased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Lachnospira,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Roseburia,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Anaerostipes,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Faecalibacterium",2|1239|186801|3085636|186803|28050;2|1239|186801|3085636|186803;2|1239|186801|3085636|186803|841;2|1239|186801|3085636|186803|207244;2|1239|186801|186802|216572|216851,Complete,Shaimaa Elsafoury
bsdb:88/1/1,Study 88,"cross-sectional observational, not case-control",30268819,10.1016/j.schres.2018.09.014,NA,"Nguyen TT, Kosciolek T, Maldonado Y, Daly RE, Martin AS, McDonald D, Knight R , Jeste DV",Differences in gut microbiome composition between persons with chronic schizophrenia and healthy comparison subjects,Schizophrenia research,2019,"Bacteria, Gut-brain axis, Microbes, Phylum, Probiotics, Psychosis",Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Schizophrenia,MONDO:0005090,non-psychiatric controls,schizophrenia,outpatients with schizophrenia or schizoaffective disorder,25,25,NA,16S,4,Illumina,Kruskall-Wallis,0.01,TRUE,NA,demographics,"age,antimicrobial agent,body mass index,race,sex",NA,unchanged,NA,NA,NA,NA,Signature 1,Figure 2+ Supplemental Table S2,10 January 2021,Fatima Zohra,WikiWorks,Differentially abundant genera in schizophrenia and non-psychiatric controls,increased,"k__Bacteria|p__Bacillota|c__Tissierellia|o__Tissierellales|f__Peptoniphilaceae|g__Anaerococcus,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Megasphaera,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Blautia",2|1239|1737404|1737405|1570339|165779;2|1239|909932|1843489|31977|906;2|1239|186801|186802;2|1239|186801|3085636|186803|572511,Complete,Atrayees
bsdb:88/1/2,Study 88,"cross-sectional observational, not case-control",30268819,10.1016/j.schres.2018.09.014,NA,"Nguyen TT, Kosciolek T, Maldonado Y, Daly RE, Martin AS, McDonald D, Knight R , Jeste DV",Differences in gut microbiome composition between persons with chronic schizophrenia and healthy comparison subjects,Schizophrenia research,2019,"Bacteria, Gut-brain axis, Microbes, Phylum, Probiotics, Psychosis",Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Schizophrenia,MONDO:0005090,non-psychiatric controls,schizophrenia,outpatients with schizophrenia or schizoaffective disorder,25,25,NA,16S,4,Illumina,Kruskall-Wallis,0.01,TRUE,NA,demographics,"age,antimicrobial agent,body mass index,race,sex",NA,unchanged,NA,NA,NA,NA,Signature 2,Figure 2+ Supplemental Table S2,10 January 2021,Fatima Zohra,WikiWorks,Differentially abundant genera in schizophrenia and non-psychiatric controls,decreased,"k__Bacteria|p__Pseudomonadota,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Haemophilus,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Sutterellaceae|g__Sutterella,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Clostridium,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Haemophilus|s__Haemophilus parainfluenzae",2|1224;2|1224|1236|135625|712|724;2|1224|28216|80840|995019|40544;2|1239|186801|186802|31979|1485;2|1224|1236|135625|712|724|729,Complete,Atrayees
bsdb:89/1/1,Study 89,case-control,26789999,https://doi.org/10.1159/000441768,https://pubmed.ncbi.nlm.nih.gov/26789999/,"Takahashi K, Nishida A, Fujimoto T, Fujii M, Shioya M, Imaeda H, Inatomi O, Bamba S, Sugimoto M , Andoh A",Reduced Abundance of Butyrate-Producing Bacteria Species in the Fecal Microbial Community in Crohn's Disease,Digestion,2016,NA,Experiment 1,Japan,Homo sapiens,Feces,UBERON:0001988,Crohn's disease,EFO:0000384,Healthy controls,CD patients,Patients with Crohn's disease,46,68,NA,16S,34,Illumina,T-Test,0.05,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,"Table 2, Figure 2",9 June 2023,Atrayees,Atrayees,Relative abundance of bacteria between control and CD,increased,"k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales|f__Actinomycetaceae|g__Actinomyces,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium",2|201174|1760|2037|2049|1654;2|201174|1760|85004|31953|1678,Complete,Shaimaa Elsafoury
bsdb:89/1/2,Study 89,case-control,26789999,https://doi.org/10.1159/000441768,https://pubmed.ncbi.nlm.nih.gov/26789999/,"Takahashi K, Nishida A, Fujimoto T, Fujii M, Shioya M, Imaeda H, Inatomi O, Bamba S, Sugimoto M , Andoh A",Reduced Abundance of Butyrate-Producing Bacteria Species in the Fecal Microbial Community in Crohn's Disease,Digestion,2016,NA,Experiment 1,Japan,Homo sapiens,Feces,UBERON:0001988,Crohn's disease,EFO:0000384,Healthy controls,CD patients,Patients with Crohn's disease,46,68,NA,16S,34,Illumina,T-Test,0.05,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 2,"Figure 2, Table 2",9 June 2023,Atrayees,Atrayees,Relative abundance of bacteria between control and CD,decreased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Cellulosilyticaceae|g__Cellulosilyticum,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Eubacteriaceae|g__Eubacterium,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae|g__Holdemania,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Tannerellaceae|g__Parabacteroides,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Roseburia,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Pseudoflavonifractor,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Subdoligranulum,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Blautia|s__Blautia faecis,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Roseburia|s__Roseburia intestinalis,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Mediterraneibacter|s__[Ruminococcus] torques,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Enterocloster|s__Enterocloster lavalensis",2|1239|186801|3085636|3018741|698776;2|1239|186801|186802|186806|1730;2|1239|526524|526525|128827|61170;2|976|200643|171549|2005525|375288;2|1239|186801|3085636|186803|841;2|1239|186801|186802|216572|1017280;2|1239|186801|186802|216572|292632;2|1239|186801|3085636|186803|572511|871665;2|1239|186801|3085636|186803|841|166486;2|1239|186801|3085636|186803|2316020|33039;2|1239|186801|3085636|186803|2719313|460384,Complete,NA
bsdb:90/1/1,Study 90,time series / longitudinal observational,29207565,10.3390/genes8120364,NA,"Mueller NT, Shin H, Pizoni A, Werlang IC, Matte U, Goldani MZ, Goldani HAS , Dominguez-Bello MG","Delivery Mode and the Transition of Pioneering Gut-Microbiota Structure, Composition and Predicted Metabolic Function",Genes,2017,"cesarean section, microbial community, microbiome, microbiota, obesity",Experiment 1,Brazil,Homo sapiens,Meconium,UBERON:0007109,Cesarean section,EFO:0009636,mecomium in vaginal delivery,transitional stool,cases are delivery or an elective C-section delivery between 38 and 42 weeks of gestation (confirmed by an ultrasound taken before the 20th week of pregnancy).,10,10,oral antibiotics in the third trimester of pregnancy,16S,4,Illumina,LEfSe,NA,FALSE,3,NA,NA,NA,NA,NA,NA,NA,decreased,Signature 1,Figure S2,10 January 2021,Shaimaa Elsafoury,WikiWorks,Bacterial taxa comparisons in meconium and transitional stool by delivery mode.,increased,k__Bacteria|p__Campylobacterota|c__Epsilonproteobacteria|o__Campylobacterales|f__Helicobacteraceae|g__Helicobacter,2|29547|3031852|213849|72293|209,Complete,Shaimaa Elsafoury
bsdb:90/1/2,Study 90,time series / longitudinal observational,29207565,10.3390/genes8120364,NA,"Mueller NT, Shin H, Pizoni A, Werlang IC, Matte U, Goldani MZ, Goldani HAS , Dominguez-Bello MG","Delivery Mode and the Transition of Pioneering Gut-Microbiota Structure, Composition and Predicted Metabolic Function",Genes,2017,"cesarean section, microbial community, microbiome, microbiota, obesity",Experiment 1,Brazil,Homo sapiens,Meconium,UBERON:0007109,Cesarean section,EFO:0009636,mecomium in vaginal delivery,transitional stool,cases are delivery or an elective C-section delivery between 38 and 42 weeks of gestation (confirmed by an ultrasound taken before the 20th week of pregnancy).,10,10,oral antibiotics in the third trimester of pregnancy,16S,4,Illumina,LEfSe,NA,FALSE,3,NA,NA,NA,NA,NA,NA,NA,decreased,Signature 2,Figure S2,10 January 2021,Shaimaa Elsafoury,WikiWorks,Bacterial taxa comparisons in meconium and transitional stool by delivery mode.,decreased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Moraxellales|f__Moraxellaceae|g__Acinetobacter,k__Bacteria|p__Pseudomonadota|c__Hydrogenophilia|o__Hydrogenophilales|f__Hydrogenophilaceae|g__Hydrogenophilus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Sphingomonadales|f__Sphingomonadaceae|g__Sphingomonas,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Mycobacteriales|f__Corynebacteriaceae|g__Corynebacterium,k__Bacteria|p__Actinomycetota|c__Rubrobacteria|o__Rubrobacterales|f__Rubrobacteraceae|g__Rubrobacter,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Sphingomonadales|f__Sphingomonadaceae|g__Sphingobium,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Bacillaceae|g__Geobacillus,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Neisseriaceae|g__Neisseria,k__Bacteria|p__Bacillota|c__Tissierellia|o__Tissierellales|f__Peptoniphilaceae|g__Anaerococcus,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Hyphomicrobiales|f__Methylobacteriaceae|g__Methylobacterium,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Veillonella,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micrococcales|f__Micrococcaceae|g__Micrococcus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Lactococcus,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Hyphomicrobiales|f__Rhizobiaceae|g__Agrobacterium,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Hyphomicrobiales|g__Enhydrobacter,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Oxalobacteraceae|g__Janthinobacterium,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Comamonadaceae|g__Delftia",2|1224|1236|2887326|468|469;2|1224|2008785|119069|206349|70774;2|1239|91061|186826|1300|1301;2|1224|28211|204457|41297|13687;2|201174|1760|85007|1653|1716;2|201174|84995|84996|84997|42255;2|1224|28211|204457|41297|165695;2|1239|91061|1385|186817|129337;2|1224|28216|206351|481|482;2|1239|1737404|1737405|1570339|165779;2|1224|28211|356|119045|407;2|1239|909932|1843489|31977|29465;2|201174|1760|85006|1268|1269;2|1239|91061|186826|1300|1357;2|1224|28211|356|82115|357;2|1224|28211|356|212791;2|1224|28216|80840|75682|29580;2|1224|28216|80840|80864|80865,Complete,Shaimaa Elsafoury
bsdb:90/2/1,Study 90,time series / longitudinal observational,29207565,10.3390/genes8120364,NA,"Mueller NT, Shin H, Pizoni A, Werlang IC, Matte U, Goldani MZ, Goldani HAS , Dominguez-Bello MG","Delivery Mode and the Transition of Pioneering Gut-Microbiota Structure, Composition and Predicted Metabolic Function",Genes,2017,"cesarean section, microbial community, microbiome, microbiota, obesity",Experiment 2,Brazil,Homo sapiens,Meconium,UBERON:0007109,Cesarean section,EFO:0009636,mecomium in C-section delivery,transitional stool,cases are delivery or an elective C-section delivery between 38 and 42 weeks of gestation (confirmed by an ultrasound taken before the 20th week of pregnancy).,40,40,oral antibiotics in the third trimester of pregnancy,16S,4,Illumina,LEfSe,NA,FALSE,3,NA,NA,NA,NA,NA,NA,NA,decreased,Signature 1,Figure S2,10 January 2021,Shaimaa Elsafoury,WikiWorks,Bacterial taxa comparisons in meconium and transitional stool by delivery mode.,increased,"k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Veillonella,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Enterococcaceae|g__Enterococcus",2|1239|909932|1843489|31977|29465;2|1239|91061|186826|81852|1350,Complete,Shaimaa Elsafoury
bsdb:90/2/2,Study 90,time series / longitudinal observational,29207565,10.3390/genes8120364,NA,"Mueller NT, Shin H, Pizoni A, Werlang IC, Matte U, Goldani MZ, Goldani HAS , Dominguez-Bello MG","Delivery Mode and the Transition of Pioneering Gut-Microbiota Structure, Composition and Predicted Metabolic Function",Genes,2017,"cesarean section, microbial community, microbiome, microbiota, obesity",Experiment 2,Brazil,Homo sapiens,Meconium,UBERON:0007109,Cesarean section,EFO:0009636,mecomium in C-section delivery,transitional stool,cases are delivery or an elective C-section delivery between 38 and 42 weeks of gestation (confirmed by an ultrasound taken before the 20th week of pregnancy).,40,40,oral antibiotics in the third trimester of pregnancy,16S,4,Illumina,LEfSe,NA,FALSE,3,NA,NA,NA,NA,NA,NA,NA,decreased,Signature 2,Figure S2,10 January 2021,Shaimaa Elsafoury,WikiWorks,Bacterial taxa comparisons in meconium and transitional stool by delivery mode.,decreased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pseudomonadales|f__Pseudomonadaceae|g__Pseudomonas,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Bacillaceae|g__Lysinibacillus,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Mycobacteriales|f__Corynebacteriaceae|g__Corynebacterium,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Burkholderiaceae|g__Cupriavidus,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Leptotrichiaceae|g__Leptotrichia,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales|f__Actinomycetaceae|g__Actinomyces,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae|g__Fusobacterium,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Sphingomonadales|f__Sphingomonadaceae|g__Sphingomonas,k__Bacteria|p__Actinomycetota|c__Rubrobacteria|o__Rubrobacterales|f__Rubrobacteraceae|g__Rubrobacter,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Oceanospirillales|f__Halomonadaceae|g__Halomonas,k__Bacteria|p__Spirochaetota|c__Spirochaetia|o__Spirochaetales|f__Treponemataceae|g__Treponema,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Haemophilus,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Caulobacterales|f__Caulobacteraceae|g__Brevundimonas,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Cardiobacteriales|f__Cardiobacteriaceae|g__Cardiobacterium,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Sphingomonadales|f__Sphingomonadaceae|g__Sphingobium",2|1224|1236|72274|135621|286;2|1239|91061|1385|186817|400634;2|201174|1760|85007|1653|1716;2|1239|91061|186826|1300|1301;2|1224|28216|80840|119060|106589;2|32066|203490|203491|1129771|32067;2|201174|1760|2037|2049|1654;2|32066|203490|203491|203492|848;2|1224|28211|204457|41297|13687;2|201174|84995|84996|84997|42255;2|1224|1236|135619|28256|2745;2|203691|203692|136|2845253|157;2|1224|1236|135625|712|724;2|1224|28211|204458|76892|41275;2|1224|1236|135615|868|2717;2|1224|28211|204457|41297|165695,Complete,Shaimaa Elsafoury
bsdb:91/1/1,Study 91,"cross-sectional observational, not case-control",29459704,10.1038/s41598-018-21657-7,NA,"Shi YC, Guo H, Chen J, Sun G, Ren RR, Guo MZ, Peng LH , Yang YS",Initial meconium microbiome in Chinese neonates delivered naturally or by cesarean section,Scientific reports,2018,NA,Experiment 1,China,Homo sapiens,Meconium,UBERON:0007109,Cesarean section,EFO:0009636,vaginal delivery,C-section,the first-pass meconium stools from within 24 h of delivery,8,10,None of VD mothers received antibiotics during delivery. CSD mothers recieved prophylactic antibiotics after delivery.,WMS,NA,Illumina,LEfSe,0.05,FALSE,3.5,NA,NA,NA,unchanged,NA,unchanged,NA,NA,Signature 1,Figure 1,10 January 2021,Shaimaa Elsafoury,"Fatima,WikiWorks",Comparison of the microbiome of vaginally delivered and C-section-delivered newborns,increased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Aeromonadales|f__Aeromonadaceae|g__Aeromonas|s__Aeromonas veronii,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Bacillaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales,k__Bacteria|p__Bacillota|c__Bacilli,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Bacillaceae|g__Bacillus,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Bacillaceae|g__Bacillus|s__Bacillus amyloliquefaciens,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Bacillaceae|g__Bacillus|s__Bacillus licheniformis,k__Bacteria|p__Deinococcota|c__Deinococci|o__Deinococcales|f__Deinococcaceae,k__Bacteria|p__Deinococcota|c__Deinococci|o__Deinococcales,k__Bacteria|p__Deinococcota|c__Deinococci,k__Bacteria|p__Deinococcota|c__Deinococci|o__Deinococcales|f__Deinococcaceae|g__Deinococcus,k__Bacteria|p__Deinococcota,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Eubacteriaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Eubacteriaceae|g__Eubacterium,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Faecalibacterium,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Faecalibacterium|s__Faecalibacterium prausnitzii,k__Bacteria|p__Bacillota,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Phocaeicola|s__Phocaeicola vulgatus,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Lysobacterales|f__Lysobacteraceae|g__Stenotrophomonas,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Lysobacterales|f__Lysobacteraceae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Lysobacterales,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Agathobacter|s__Agathobacter rectalis",2|1224|1236|135624|84642|642|654;2|1224|28211;2|1239|91061|1385|186817;2|1239|91061|1385;2|1239|91061;2|1239|91061|1385|186817|1386;2|1239|91061|1385|186817|1386|1390;2|1239|91061|1385|186817|1386|1402;2|1297|188787|118964|183710;2|1297|188787|118964;2|1297|188787;2|1297|188787|118964|183710|1298;2|1297;2|1239|186801|186802|186806;2|1239|186801|186802|186806|1730;2|1239|186801|186802|216572|216851;2|1239|186801|186802|216572|216851|853;2|1239;2|976|200643|171549|815|909656|821;2|1224|1236|135614|32033|40323;2|1224|1236|135614|32033;2|1224|1236|135614;2|1239|186801|3085636|186803|1766253|39491,Complete,Fatima
bsdb:91/1/2,Study 91,"cross-sectional observational, not case-control",29459704,10.1038/s41598-018-21657-7,NA,"Shi YC, Guo H, Chen J, Sun G, Ren RR, Guo MZ, Peng LH , Yang YS",Initial meconium microbiome in Chinese neonates delivered naturally or by cesarean section,Scientific reports,2018,NA,Experiment 1,China,Homo sapiens,Meconium,UBERON:0007109,Cesarean section,EFO:0009636,vaginal delivery,C-section,the first-pass meconium stools from within 24 h of delivery,8,10,None of VD mothers received antibiotics during delivery. CSD mothers recieved prophylactic antibiotics after delivery.,WMS,NA,Illumina,LEfSe,0.05,FALSE,3.5,NA,NA,NA,unchanged,NA,unchanged,NA,NA,Signature 2,Figure 1,10 January 2021,Shaimaa Elsafoury,WikiWorks,ComparisonofthemicrobiomesofvaginallydeliveredandC-section-deliverednewborns,decreased,"k__Bacteria|p__Actinomycetota|c__Actinomycetes,k__Bacteria|p__Actinomycetota,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Propionibacteriales|f__Propionibacteriaceae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Propionibacteriales|f__Propionibacteriaceae|g__Cutibacterium|s__Cutibacterium acnes,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Propionibacteriales|f__Propionibacteriaceae|g__Propionibacterium,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pseudomonadales,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Pseudonocardiales|f__Pseudonocardiaceae,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Comamonadaceae|g__Comamonas,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Comamonadaceae,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Comamonadaceae|g__Comamonas|s__Comamonas testosteroni,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pseudomonadales|f__Pseudomonadaceae|g__Pseudomonas",2|201174|1760;2|201174;2|201174|1760|2037;2|201174|1760|85009|31957;2|1224|1236;2|201174|1760|85009|31957|1912216|1747;2|201174|1760|85009|31957|1743;2|1224|1236|72274;2|201174|1760|85010|2070;2|1224|28216|80840;2|1224|28216;2|1224|28216|80840|80864|283;2|1224|28216|80840|80864;2|1224|28216|80840|80864|283|285;2|1224|1236|72274|135621|286,Complete,Shaimaa Elsafoury
bsdb:92/1/1,Study 92,case-control,25764541,10.1093/femsec/fiu002,NA,"Michail S, Lin M, Frey MR, Fanter R, Paliy O, Hilbush B , Reo NV",Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease,FEMS microbiology ecology,2015,"NASH, carbohydrate, energy metabolism, gut microbiome, obesity",Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,healthy controls,obese without non-alcoholic fatty liver disease,clinical diagnosis of NAFLD based on ultrasound findings and elevated transaminases.  BMI for obese children with and without clinical NAFLD were greater than the 95% for age,26,11,6 months,16S,NA,Ion Torrent,ANOVA,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Table 2,10 January 2021,Marianthi Thomatos,WikiWorks,Altered gut microbial energy and metabolism in children withi non-alcoholic fatty liver disease,increased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria,k__Bacteria|p__Actinomycetota",2|1224|1236;2|201174,Complete,Shaimaa Elsafoury
bsdb:92/1/2,Study 92,case-control,25764541,10.1093/femsec/fiu002,NA,"Michail S, Lin M, Frey MR, Fanter R, Paliy O, Hilbush B , Reo NV",Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease,FEMS microbiology ecology,2015,"NASH, carbohydrate, energy metabolism, gut microbiome, obesity",Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,healthy controls,obese without non-alcoholic fatty liver disease,clinical diagnosis of NAFLD based on ultrasound findings and elevated transaminases.  BMI for obese children with and without clinical NAFLD were greater than the 95% for age,26,11,6 months,16S,NA,Ion Torrent,ANOVA,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 2,Table 2,10 January 2021,Marianthi Thomatos,WikiWorks,Altered gut microbial energy and metabolism in children withi non-alcoholic fatty liver disease,decreased,k__Bacteria|p__Bacillota|c__Clostridia,2|1239|186801,Complete,Shaimaa Elsafoury
bsdb:92/2/1,Study 92,case-control,25764541,10.1093/femsec/fiu002,NA,"Michail S, Lin M, Frey MR, Fanter R, Paliy O, Hilbush B , Reo NV",Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease,FEMS microbiology ecology,2015,"NASH, carbohydrate, energy metabolism, gut microbiome, obesity",Experiment 2,United States of America,Homo sapiens,Feces,UBERON:0001988,Non-alcoholic fatty liver disease,EFO:0003095,healthy controls,non-alcoholic fatty liver disease patients,clinical diagnosis of NAFLD based on ultrasound findings and elevated transaminases.  BMI for obese children with and without clinical NAFLD were greater than the 95% for age,26,13,6 months,16S,NA,Ion Torrent,ANOVA,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Table 2,10 January 2021,Marianthi Thomatos,WikiWorks,Altered gut microbial energy and metabolism in children withi non-alcoholic fatty liver disease (NAFLD),increased,"k__Bacteria|p__Actinomycetota|c__Actinomycetes,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia,k__Bacteria|p__Campylobacterota,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria",2|201174|1760;2|976|200643|171549|171552|838;2|32066|203490;2|29547;2|1224|1236,Complete,Shaimaa Elsafoury
bsdb:92/2/2,Study 92,case-control,25764541,10.1093/femsec/fiu002,NA,"Michail S, Lin M, Frey MR, Fanter R, Paliy O, Hilbush B , Reo NV",Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease,FEMS microbiology ecology,2015,"NASH, carbohydrate, energy metabolism, gut microbiome, obesity",Experiment 2,United States of America,Homo sapiens,Feces,UBERON:0001988,Non-alcoholic fatty liver disease,EFO:0003095,healthy controls,non-alcoholic fatty liver disease patients,clinical diagnosis of NAFLD based on ultrasound findings and elevated transaminases.  BMI for obese children with and without clinical NAFLD were greater than the 95% for age,26,13,6 months,16S,NA,Ion Torrent,ANOVA,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 2,Table 2,10 January 2021,Marianthi Thomatos,WikiWorks,Altered gut microbial energy and metabolism in children withi non-alcoholic fatty liver disease (NAFLD),decreased,"k__Bacteria|p__Bacillota|c__Erysipelotrichia,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria",2|1239|526524;2|1224|28211,Complete,Shaimaa Elsafoury
bsdb:92/3/1,Study 92,case-control,25764541,10.1093/femsec/fiu002,NA,"Michail S, Lin M, Frey MR, Fanter R, Paliy O, Hilbush B , Reo NV",Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease,FEMS microbiology ecology,2015,"NASH, carbohydrate, energy metabolism, gut microbiome, obesity",Experiment 3,United States of America,Homo sapiens,Feces,UBERON:0001988,Non-alcoholic fatty liver disease,EFO:0003095,obese without non-alcoholic fatty liver disease,non-alcoholic fatty liver disease patients,clinical diagnosis of NAFLD based on ultrasound findings and elevated transaminases.  BMI for obese children with and without clinical NAFLD were greater than the 95% for age,11,13,6 months,16S,NA,Ion Torrent,ANOVA,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Table 2,10 January 2021,Shaimaa Elsafoury,WikiWorks,Altered gut microbial energy and metabolism in children withi non-alcoholic fatty liver disease (NAFLD),increased,"k__Bacteria|p__Actinomycetota|c__Actinomycetes,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia,k__Bacteria|p__Campylobacterota",2|201174|1760;2|976|200643|171549|171552|838;2|32066|203490;2|29547,Complete,Shaimaa Elsafoury
bsdb:92/3/2,Study 92,case-control,25764541,10.1093/femsec/fiu002,NA,"Michail S, Lin M, Frey MR, Fanter R, Paliy O, Hilbush B , Reo NV",Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease,FEMS microbiology ecology,2015,"NASH, carbohydrate, energy metabolism, gut microbiome, obesity",Experiment 3,United States of America,Homo sapiens,Feces,UBERON:0001988,Non-alcoholic fatty liver disease,EFO:0003095,obese without non-alcoholic fatty liver disease,non-alcoholic fatty liver disease patients,clinical diagnosis of NAFLD based on ultrasound findings and elevated transaminases.  BMI for obese children with and without clinical NAFLD were greater than the 95% for age,11,13,6 months,16S,NA,Ion Torrent,ANOVA,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 2,Table 2,10 January 2021,Shaimaa Elsafoury,WikiWorks,Altered gut microbial energy and metabolism in children withi non-alcoholic fatty liver disease (NAFLD),decreased,"k__Bacteria|p__Bacillota|c__Erysipelotrichia,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria",2|1239|526524;2|1224|28211;2|1224|1236,Complete,Shaimaa Elsafoury
bsdb:93/1/1,Study 93,"cross-sectional observational, not case-control",29538354,10.1038/pr.2018.29,NA,"Tapiainen T, Paalanne N, Tejesvi MV, Koivusaari P, Korpela K, Pokka T, Salo J, Kaukola T, Pirttilä AM, Uhari M , Renko M",Maternal influence on the fetal microbiome in a population-based study of the first-pass meconium,Pediatric research,2018,NA,Experiment 1,Finland,Homo sapiens,Meconium,UBERON:0007109,Cesarean section,EFO:0009636,vaginal delivery,C-section,Delivery via cesarean section,172,40,None,16S,45,Ion Torrent,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,Signature 1,Table 3,10 January 2021,Shaimaa Elsafoury,"WikiWorks,ChiomaBlessing",Effect of delivery mode on the microbiome in the CS group compared to the vaginal delivery group,decreased,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Staphylococcaceae|g__Staphylococcus,2|1239|91061|1385|90964|1279,Complete,Shaimaa Elsafoury
bsdb:93/2/1,Study 93,"cross-sectional observational, not case-control",29538354,10.1038/pr.2018.29,NA,"Tapiainen T, Paalanne N, Tejesvi MV, Koivusaari P, Korpela K, Pokka T, Salo J, Kaukola T, Pirttilä AM, Uhari M , Renko M",Maternal influence on the fetal microbiome in a population-based study of the first-pass meconium,Pediatric research,2018,NA,Experiment 2,Finland,Homo sapiens,Meconium,UBERON:0007109,Cesarean section,EFO:0009636,Antimicrobials use during delivery (no),Antimicrobials use during delivery (yes),"Mothers who used antimicrobials during delivery (Cefuroxime (n= 31), penicillin (n= 28), piperacillin-tazobactam (n=2))",151,61,None.,16S,45,Ion Torrent,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,Signature 1,Table 3,10 January 2021,Shaimaa Elsafoury,"WikiWorks,ChiomaBlessing",Effect of antimicrobial use on the microbiome of the first stool in the group who received antimicrobials (YES) compared to those did not (NO),increased,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium,2|201174|1760|85004|31953|1678,Complete,Shaimaa Elsafoury
bsdb:93/3/1,Study 93,"cross-sectional observational, not case-control",29538354,10.1038/pr.2018.29,NA,"Tapiainen T, Paalanne N, Tejesvi MV, Koivusaari P, Korpela K, Pokka T, Salo J, Kaukola T, Pirttilä AM, Uhari M , Renko M",Maternal influence on the fetal microbiome in a population-based study of the first-pass meconium,Pediatric research,2018,NA,Experiment 3,Finland,Homo sapiens,Meconium,UBERON:0007109,Cesarean section,EFO:0009636,Maternal consumption of probiotics (NO),Maternal consumption of probiotics (YES),Mothers who consumed probiotics (lactobacilli) during pregnancy,151,61,None.,16S,45,Ion Torrent,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,Signature 1,Table 3,10 January 2021,Shaimaa Elsafoury,"WikiWorks,ChiomaBlessing",Effect of probiotics on the microbiome in the group who consumed lactobacilli (YES) compared to the group who did not (NO),increased,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus,2|1239|91061|186826|33958|1578,Complete,Shaimaa Elsafoury
bsdb:93/4/1,Study 93,"cross-sectional observational, not case-control",29538354,10.1038/pr.2018.29,NA,"Tapiainen T, Paalanne N, Tejesvi MV, Koivusaari P, Korpela K, Pokka T, Salo J, Kaukola T, Pirttilä AM, Uhari M , Renko M",Maternal influence on the fetal microbiome in a population-based study of the first-pass meconium,Pediatric research,2018,NA,Experiment 4,Finland,Homo sapiens,Meconium,UBERON:0007109,Cesarean section,EFO:0009636,Furry pets at home (NO),Furry pets at home (YES),Mothers who have furry pets at home during pregnancy,108,104,None.,16S,45,Ion Torrent,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,"antimicrobial agent during labor,delivery procedure,probiotics during pregnancy",NA,increased,NA,NA,NA,increased,Signature 1,Table 4,10 January 2021,Shaimaa Elsafoury,"WikiWorks,ChiomaBlessing",Effect of furry pets at home on the microbiome in the group who have furry pets at home (YES) compared to the group who don't have (NO),increased,"k__Bacteria|p__Bacteroidota,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Faecalibacterium",2|976;2|1239|186801|186802|216572|216851,Complete,Shaimaa Elsafoury
bsdb:93/4/2,Study 93,"cross-sectional observational, not case-control",29538354,10.1038/pr.2018.29,NA,"Tapiainen T, Paalanne N, Tejesvi MV, Koivusaari P, Korpela K, Pokka T, Salo J, Kaukola T, Pirttilä AM, Uhari M , Renko M",Maternal influence on the fetal microbiome in a population-based study of the first-pass meconium,Pediatric research,2018,NA,Experiment 4,Finland,Homo sapiens,Meconium,UBERON:0007109,Cesarean section,EFO:0009636,Furry pets at home (NO),Furry pets at home (YES),Mothers who have furry pets at home during pregnancy,108,104,None.,16S,45,Ion Torrent,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,"antimicrobial agent during labor,delivery procedure,probiotics during pregnancy",NA,increased,NA,NA,NA,increased,Signature 2,Table 4,10 January 2021,Shaimaa Elsafoury,"WikiWorks,ChiomaBlessing",Effect of furry pets at home on the microbiome in the group who have furry pets at home (YES) compared to the group who don't have (NO),decreased,"k__Bacteria|p__Bacillota,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Staphylococcaceae|g__Staphylococcus",2|1239;2|1239|91061|1385|90964|1279,Complete,Shaimaa Elsafoury
bsdb:94/1/1,Study 94,time series / longitudinal observational,26919743,10.1371/journal.pone.0149564,NA,"Louis S, Tappu RM, Damms-Machado A, Huson DH , Bischoff SC",Characterization of the Gut Microbial Community of Obese Patients Following a Weight-Loss Intervention Using Whole Metagenome Shotgun Sequencing,PloS one,2016,NA,Experiment 1,Germany,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,baseline participants,3 months,A threshold of 10% weight loss and maintenance of it over one year has been proposed as definition for successful weight loss maintenance,16,16,3 months,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,Signature 1,Figure 3,10 January 2021,Marianthi Thomatos,"Fatima,WikiWorks",Gut microbial community of obese patients following weight-loss intervention,increased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Aeromonadales|f__Succinivibrionaceae|g__Anaerobiospirillum|s__Anaerobiospirillum succiniciproducens,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales|f__Coriobacteriaceae|g__Collinsella|s__Collinsella aerofaciens,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Sutterellaceae|g__Parasutterella|s__Parasutterella excrementihominis,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Roseburia|s__Roseburia intestinalis,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Roseburia|s__Roseburia inulinivorans,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Subdoligranulum|s__Subdoligranulum variabile,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|s__Burkholderiales bacterium 1_1_47",2|1224|1236|135624|83763|13334|13335;2|201174|84998|84999|84107|102106|74426;2|1224|28216|80840|995019|577310|487175;2|1239|186801|3085636|186803|841|166486;2|1239|186801|3085636|186803|841|360807;2|1239|186801|186802|216572|292632|214851;2|1224|28216|80840|469610,Complete,Fatima
bsdb:94/1/2,Study 94,time series / longitudinal observational,26919743,10.1371/journal.pone.0149564,NA,"Louis S, Tappu RM, Damms-Machado A, Huson DH , Bischoff SC",Characterization of the Gut Microbial Community of Obese Patients Following a Weight-Loss Intervention Using Whole Metagenome Shotgun Sequencing,PloS one,2016,NA,Experiment 1,Germany,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,baseline participants,3 months,A threshold of 10% weight loss and maintenance of it over one year has been proposed as definition for successful weight loss maintenance,16,16,3 months,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,Signature 2,Figure 3,10 January 2021,Marianthi Thomatos,WikiWorks,Gut microbial community of obese patients following weight-loss intervention,decreased,"k__Bacteria|p__Spirochaetota|c__Spirochaetia|o__Spirochaetales|f__Treponemataceae|g__Treponema|s__Treponema brennaborense,k__Bacteria|p__Bacteroidota|c__Sphingobacteriia|o__Sphingobacteriales|f__Sphingobacteriaceae|g__Pedobacter|s__Pedobacter heparinus,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Rikenellaceae|g__Alistipes|s__Alistipes finegoldii,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Dysgonomonadaceae|g__Dysgonomonas|s__Dysgonomonas gadei,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Desulfitobacteriaceae|g__Desulfitobacterium|s__Desulfitobacterium hafniense,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Peptococcaceae|g__Desulforamulus|s__Desulforamulus ruminis,k__Bacteria|p__Bacillota|c__Negativicutes|o__Selenomonadales|f__Selenomonadaceae|g__Selenomonas|s__Selenomonas sputigena,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Anaerotruncus|s__Anaerotruncus colihominis,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Ethanoligenens|s__Ethanoligenens harbinense,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Oscillibacter|s__Oscillibacter valericigenes,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Pseudoflavonifractor|s__Pseudoflavonifractor capillosus,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae|g__Holdemania|s__Holdemania filiformis,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Bacillaceae|g__Heyndrickxia|s__Heyndrickxia coagulans,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Enterococcaceae|g__Enterococcus|s__Enterococcus faecalis,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Enterococcaceae|g__Enterococcus|s__Enterococcus faecium,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Paenibacillaceae|g__Paenibacillus|s__Paenibacillus mucilaginosus,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Peptostreptococcaceae|g__Clostridioides|s__Clostridioides difficile,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Enterocloster|s__Enterocloster asparagiformis,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Marvinbryantia|s__Marvinbryantia formatexigens,k__Bacteria|p__Thermodesulfobacteriota|c__Desulfuromonadia|o__Geobacterales|f__Geobacteraceae|g__Geobacter|s__Geobacter sp. M18,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Escherichia|s__Escherichia coli,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pseudomonadales|f__Pseudomonadaceae|g__Stutzerimonas|s__Stutzerimonas stutzeri,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Kitasatosporales|f__Streptomycetaceae|g__Streptomyces|s__Streptomyces coelicolor,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Eggerthellales|f__Eggerthellaceae|g__Slackia|s__Slackia heliotrinireducens,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Eggerthellales|f__Eggerthellaceae|g__Eggerthella|s__Eggerthella lenta,k__Bacteria|p__Verrucomicrobiota|c__Verrucomicrobiia|o__Verrucomicrobiales|f__Akkermansiaceae|g__Akkermansia|s__Akkermansia muciniphila,k__Bacteria|p__Synergistota|c__Synergistia|o__Synergistales|f__Synergistaceae|g__Thermanaerovibrio|s__Thermanaerovibrio acidaminovorans,k__Bacteria|p__Synergistota|c__Synergistia|o__Synergistales|f__Aminobacteriaceae|g__Fretibacterium|s__Fretibacterium fastidiosum",2|203691|203692|136|2845253|157|81028;2|976|117747|200666|84566|84567|984;2|976|200643|171549|171550|239759|214856;2|976|200643|171549|2005520|156973|156974;2|1239|186801|186802|2937909|36853|49338;2|1239|186801|186802|186807|2916693|1564;2|1239|909932|909929|1843491|970|69823;2|1239|186801|186802|216572|244127|169435;2|1239|186801|186802|216572|253238|253239;2|1239|186801|186802|216572|459786|351091;2|1239|186801|186802|216572|1017280|106588;2|1239|526524|526525|128827|61170|61171;2|1239|91061|1385|186817|2837504|1398;2|1239|91061|186826|81852|1350|1351;2|1239|91061|186826|81852|1350|1352;2|1239|91061|1385|186822|44249|61624;2|1239|186801|3082720|186804|1870884|1496;2|1239|186801|3085636|186803|2719313|333367;2|1239|186801|3085636|186803|248744|168384;2|200940|3031651|3031668|213422|28231|443143;2|1224|1236|91347|543|561|562;2|1224|1236|72274|135621|2901164|316;2|201174|1760|85011|2062|1883|1902;2|201174|84998|1643822|1643826|84108|84110;2|201174|84998|1643822|1643826|84111|84112;2|74201|203494|48461|1647988|239934|239935;2|508458|649775|649776|649777|81461|81462;2|508458|649775|649776|3029087|1434006|651822,Complete,Shaimaa Elsafoury
bsdb:94/2/1,Study 94,time series / longitudinal observational,26919743,10.1371/journal.pone.0149564,NA,"Louis S, Tappu RM, Damms-Machado A, Huson DH , Bischoff SC",Characterization of the Gut Microbial Community of Obese Patients Following a Weight-Loss Intervention Using Whole Metagenome Shotgun Sequencing,PloS one,2016,NA,Experiment 2,Germany,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,3 months participants,6 months,A threshold of 10% weight loss and maintenance of it over one year has been proposed as definition for successful weight loss maintenance,16,16,3 months,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,Signature 1,Figure 3,10 January 2021,Marianthi Thomatos,WikiWorks,Gut microbial community of obese patients following weight-loss intervention,increased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Rikenellaceae|g__Alistipes|s__Alistipes finegoldii,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Dysgonomonadaceae|g__Dysgonomonas|s__Dysgonomonas gadei,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Enterocloster|s__Enterocloster asparagiformis,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Lacrimispora|s__Lacrimispora saccharolytica,k__Bacteria|p__Thermodesulfobacteriota|c__Desulfovibrionia|o__Desulfovibrionales|f__Desulfovibrionaceae|g__Desulfovibrio|s__Desulfovibrio desulfuricans,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Escherichia|s__Escherichia coli,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Eggerthellales|f__Eggerthellaceae|g__Eggerthella|s__Eggerthella lenta,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Eggerthellales|f__Eggerthellaceae|g__Gordonibacter|s__Gordonibacter pamelaeae,k__Bacteria|p__Synergistota|c__Synergistia|o__Synergistales|f__Synergistaceae|g__Thermanaerovibrio|s__Thermanaerovibrio acidaminovorans",2|976|200643|171549|171550|239759|214856;2|976|200643|171549|2005520|156973|156974;2|1239|186801|3085636|186803|2719313|333367;2|1239|186801|3085636|186803|2719231|84030;2|200940|3031449|213115|194924|872|876;2|1224|1236|91347|543|561|562;2|201174|84998|1643822|1643826|84111|84112;2|201174|84998|1643822|1643826|644652|471189;2|508458|649775|649776|649777|81461|81462,Complete,Shaimaa Elsafoury
bsdb:94/2/2,Study 94,time series / longitudinal observational,26919743,10.1371/journal.pone.0149564,NA,"Louis S, Tappu RM, Damms-Machado A, Huson DH , Bischoff SC",Characterization of the Gut Microbial Community of Obese Patients Following a Weight-Loss Intervention Using Whole Metagenome Shotgun Sequencing,PloS one,2016,NA,Experiment 2,Germany,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,3 months participants,6 months,A threshold of 10% weight loss and maintenance of it over one year has been proposed as definition for successful weight loss maintenance,16,16,3 months,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,Signature 2,Figure 3,10 January 2021,Marianthi Thomatos,"Fatima,WikiWorks",Gut microbial community of obese patients following weight-loss intervention,decreased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Aeromonadales|f__Succinivibrionaceae|g__Anaerobiospirillum|s__Anaerobiospirillum succiniciproducens,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Lactococcus|s__Lactococcus lactis,k__Bacteria|p__Bdellovibrionota|c__Bdellovibrionia|o__Bdellovibrionales|f__Pseudobdellovibrionaceae|g__Micavibrio|s__Micavibrio aeruginosavorus,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Sutterellaceae|g__Parasutterella|s__Parasutterella excrementihominis,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Roseburia|s__Roseburia inulinivorans,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus|s__Streptococcus thermophilus,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Veillonella|s__Veillonella parvula,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|s__Burkholderiales bacterium 1_1_47",2|1224|1236|135624|83763|13334|13335;2|1239|91061|186826|1300|1357|1358;2|3018035|3031418|213481|213483|213485|349221;2|1224|28216|80840|995019|577310|487175;2|1239|186801|3085636|186803|841|360807;2|1239|91061|186826|1300|1301|1308;2|1239|909932|1843489|31977|29465|29466;2|1224|28216|80840|469610,Complete,Fatima
bsdb:94/3/1,Study 94,time series / longitudinal observational,26919743,10.1371/journal.pone.0149564,NA,"Louis S, Tappu RM, Damms-Machado A, Huson DH , Bischoff SC",Characterization of the Gut Microbial Community of Obese Patients Following a Weight-Loss Intervention Using Whole Metagenome Shotgun Sequencing,PloS one,2016,NA,Experiment 3,Germany,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,6 months participants,24 months,A threshold of 10% weight loss and maintenance of it over one year has been proposed as definition for successful weight loss maintenance,16,16,3 months,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,Signature 1,Figure 3,10 January 2021,Marianthi Thomatos,WikiWorks,Gut microbial community of obese patients following weight-loss intervention,increased,k__Bacteria|p__Bacteroidota|c__Sphingobacteriia|o__Sphingobacteriales|f__Sphingobacteriaceae|g__Pedobacter|s__Pedobacter heparinus,2|976|117747|200666|84566|84567|984,Complete,Shaimaa Elsafoury
bsdb:94/3/2,Study 94,time series / longitudinal observational,26919743,10.1371/journal.pone.0149564,NA,"Louis S, Tappu RM, Damms-Machado A, Huson DH , Bischoff SC",Characterization of the Gut Microbial Community of Obese Patients Following a Weight-Loss Intervention Using Whole Metagenome Shotgun Sequencing,PloS one,2016,NA,Experiment 3,Germany,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,6 months participants,24 months,A threshold of 10% weight loss and maintenance of it over one year has been proposed as definition for successful weight loss maintenance,16,16,3 months,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,Signature 2,Figure 3,10 January 2021,Marianthi Thomatos,WikiWorks,Gut microbial community of obese patients following weight-loss intervention,decreased,"k__Bacteria|p__Verrucomicrobiota|c__Verrucomicrobiia|o__Verrucomicrobiales|f__Akkermansiaceae|g__Akkermansia|s__Akkermansia muciniphila,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Escherichia|s__Escherichia coli,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales|f__Coriobacteriaceae|g__Collinsella|s__Collinsella aerofaciens",2|74201|203494|48461|1647988|239934|239935;2|1224|1236|91347|543|561|562;2|201174|84998|84999|84107|102106|74426,Complete,Shaimaa Elsafoury
bsdb:95/1/1,Study 95,"cross-sectional observational, not case-control",30568265,10.1038/s41366-018-0290-z,https://pubmed.ncbi.nlm.nih.gov/30568265/,"Karvonen AM, Sordillo JE, Gold DR, Bacharier LB, O'Connor GT, Zeiger RS, Beigelman A, Weiss ST , Litonjua AA",Gut microbiota and overweight in 3-year old children,International journal of obesity (2005),2019,NA,Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,control babies at the age of 3,overweight/obese babies,NA,356,146,7 days,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,"age,education level",NA,unchanged,NA,NA,NA,NA,Signature 1,Table 3 & 4,10 January 2021,Marianthi Thomatos,WikiWorks,Gut microbiota in overweight 3 year old children,increased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Dorea,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Roseburia",2|1239|186801|3085636|186803|189330;2|1239|186801|3085636|186803|841,Complete,Shaimaa Elsafoury
bsdb:95/1/2,Study 95,"cross-sectional observational, not case-control",30568265,10.1038/s41366-018-0290-z,https://pubmed.ncbi.nlm.nih.gov/30568265/,"Karvonen AM, Sordillo JE, Gold DR, Bacharier LB, O'Connor GT, Zeiger RS, Beigelman A, Weiss ST , Litonjua AA",Gut microbiota and overweight in 3-year old children,International journal of obesity (2005),2019,NA,Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,control babies at the age of 3,overweight/obese babies,NA,356,146,7 days,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,"age,education level",NA,unchanged,NA,NA,NA,NA,Signature 2,Table 3 & 4,10 January 2021,Marianthi Thomatos,WikiWorks,Gut microbiota in overweight 3 year old children,decreased,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Tannerellaceae|g__Parabacteroides,2|976|200643|171549|2005525|375288,Complete,Shaimaa Elsafoury
bsdb:96/1/1,Study 96,case-control,27499582,10.3164/jcbn.15-152,NA,"Andoh A, Nishida A, Takahashi K, Inatomi O, Imaeda H, Bamba S, Kito K, Sugimoto M , Kobayashi T",Comparison of the gut microbial community between obese and lean peoples using 16S gene sequencing in a Japanese population,Journal of clinical biochemistry and nutrition,2016,"16S sequence, Bacteroides, Firmicutes, SCFA, datamining",Experiment 1,Japan,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,controls,obese,NA,10,10,NA,16S,34,Illumina,T-Test,0.05,FALSE,NA,NA,NA,NA,decreased,NA,NA,NA,NA,Signature 1,"Table 2, 3, 4",10 January 2021,Marianthi Thomatos,"Fatima,WikiWorks",Gut microbial community comparison between obese and lean Japanese population,increased,"k__Bacteria|p__Bacillota|c__Negativicutes|o__Acidaminococcales|f__Acidaminococcaceae|g__Acidaminococcus|s__Acidaminococcus intestini,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Rikenellaceae|g__Alistipes,k__Bacteria|p__Bacillota|c__Tissierellia|o__Tissierellales|f__Peptoniphilaceae|g__Anaerococcus,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Coprococcus,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae|g__Fusobacterium,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Gemellaceae|g__Gemella|s__Gemella haemolysans,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Carnobacteriaceae|g__Granulicatella|s__Granulicatella adiacens,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Klebsiella|s__Klebsiella pneumoniae,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales|f__Atopobiaceae|g__Lancefieldella|s__Lancefieldella parvula,k__Bacteria|p__Bacillota|c__Tissierellia|o__Tissierellales|f__Peptoniphilaceae|g__Parvimonas,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Peptostreptococcaceae|g__Peptostreptococcus|s__Peptostreptococcus stomatis,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Phocaeicola|s__Phocaeicola vulgatus,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Roseburia|s__Roseburia faecis,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micrococcales|f__Micrococcaceae|g__Rothia|s__Rothia mucilaginosa,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales|f__Actinomycetaceae|g__Schaalia|s__Schaalia meyeri,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Anaerostipes|s__Anaerostipes hadrus",2|1239|909932|1843488|909930|904|187327;2|976|200643|171549|171550|239759;2|1239|1737404|1737405|1570339|165779;2|1239|186801|3085636|186803|33042;2|32066|203490|203491|203492|848;2|1239|91061|1385|539738|1378|1379;2|1239|91061|186826|186828|117563|46124;2|1224|1236|91347|543|570|573;2|201174|84998|84999|1643824|2767353|1382;2|1239|1737404|1737405|1570339|543311;2|1239|186801|3082720|186804|1257|341694;2|976|200643|171549|815|909656|821;2|1239|186801|3085636|186803|841|301302;2|201174|1760|85006|1268|32207|43675;2|201174|1760|2037|2049|2529408|52773;2|1239|186801|3085636|186803|207244|649756,Complete,Fatima
bsdb:96/1/2,Study 96,case-control,27499582,10.3164/jcbn.15-152,NA,"Andoh A, Nishida A, Takahashi K, Inatomi O, Imaeda H, Bamba S, Kito K, Sugimoto M , Kobayashi T",Comparison of the gut microbial community between obese and lean peoples using 16S gene sequencing in a Japanese population,Journal of clinical biochemistry and nutrition,2016,"16S sequence, Bacteroides, Firmicutes, SCFA, datamining",Experiment 1,Japan,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,controls,obese,NA,10,10,NA,16S,34,Illumina,T-Test,0.05,FALSE,NA,NA,NA,NA,decreased,NA,NA,NA,NA,Signature 2,"Table 2, 3, 4",10 January 2021,Marianthi Thomatos,"Fatima,WikiWorks",Gut microbial community comparison between obese and lean Japanese population,decreased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides,k__Bacteria|p__Thermodesulfobacteriota|c__Desulfovibrionia|o__Desulfovibrionales|f__Desulfovibrionaceae|g__Desulfovibrio,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Enterocloster|s__Enterocloster citroniae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Faecalibacterium,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Faecalibacterium|s__Faecalibacterium prausnitzii,k__Bacteria|p__Bacillota|c__Tissierellia|o__Tissierellales|f__Peptoniphilaceae|g__Finegoldia,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae|g__Holdemania|s__Holdemania filiformis,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Lachnoanaerobaculum,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales|f__Atopobiaceae|g__Olsenella,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Subdoligranulum,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Coprobacillaceae|g__Thomasclavelia|s__Thomasclavelia ramosa,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Butyricicoccaceae|g__Agathobaculum|s__Agathobaculum desmolans,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Faecalicatena|s__Faecalicatena fissicatena",2|976|200643|171549|815|816;2|200940|3031449|213115|194924|872;2|1239|186801|3085636|186803|2719313|358743;2|1239|186801|186802|216572|216851;2|1239|186801|186802|216572|216851|853;2|1239|1737404|1737405|1570339|150022;2|1239|526524|526525|128827|61170|61171;2|1239|186801|3085636|186803|1164882;2|201174|84998|84999|1643824|133925;2|1239|186801|186802|216572|292632;2|1239|526524|526525|2810280|3025755|1547;2|1239|186801|186802|3085642|2048137|39484;2|1239|186801|3085636|186803|2005359|290055,Complete,Fatima
bsdb:97/1/1,Study 97,case-control,30867711,10.3892/etm.2019.7200,NA,"Wang FG, Bai RX, Yan WM, Yan M, Dong LY , Song MM","Differential composition of gut microbiota among healthy volunteers, morbidly obese patients and post-bariatric surgery patients",Experimental and therapeutic medicine,2019,"Roux-en-Y gastric bypass, bariatric surgery, gut microbiota, morbid obesity, sleeve gastrectomy, type 2 diabetes mellitus",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,healthy controls,obese patients prior to Sleeve gastrectomy SG0,obese patients had a body mass index (BMI) of >28 kg/m2.,20,19,3 months,16S,4,Ion Torrent,Kruskall-Wallis,0.05,FALSE,4,"age,sex",NA,NA,unchanged,unchanged,NA,NA,unchanged,Signature 1,Table 3,10 January 2021,Marianthi Thomatos,WikiWorks,Differential composition of gut microbiota among healthy volunteers and morbidly obese patients before recieving sleeve gastrectomy,increased,"k__Bacteria|p__Bacillota|c__Clostridia,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae|g__Fusobacterium|s__Fusobacterium mortiferum,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Peptostreptococcaceae",2|1239|186801;2|1239|186801|186802;2|1239|186801|186802|541000;2|32066|203490|203491|203492|848|850;2|1239|186801|3082720|186804,Complete,Shaimaa Elsafoury
bsdb:97/2/1,Study 97,case-control,30867711,10.3892/etm.2019.7200,NA,"Wang FG, Bai RX, Yan WM, Yan M, Dong LY , Song MM","Differential composition of gut microbiota among healthy volunteers, morbidly obese patients and post-bariatric surgery patients",Experimental and therapeutic medicine,2019,"Roux-en-Y gastric bypass, bariatric surgery, gut microbiota, morbid obesity, sleeve gastrectomy, type 2 diabetes mellitus",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,healthy controls,Roux-en-Y gastric bypass (RYGB),obese patients had a body mass index (BMI) of >28 kg/m2.,20,7,3 months,16S,4,Ion Torrent,Kruskall-Wallis,0.05,FALSE,4,"age,sex",NA,NA,unchanged,unchanged,NA,NA,unchanged,Signature 1,Table 3,10 January 2021,Shaimaa Elsafoury,WikiWorks,Differential composition of gut microbiota among healthy volunteers and morbidly obese patients before recieving Roux-en-Y gastric bypass,increased,"k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Peptostreptococcaceae,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Megasphaera",2|201174|1760|85004;2|201174|1760|85004|31953;2|201174|1760|85004|31953|1678;2|1239|186801|3082720|186804;2|1239|909932|1843489|31977|906,Complete,Shaimaa Elsafoury
bsdb:97/3/1,Study 97,case-control,30867711,10.3892/etm.2019.7200,NA,"Wang FG, Bai RX, Yan WM, Yan M, Dong LY , Song MM","Differential composition of gut microbiota among healthy volunteers, morbidly obese patients and post-bariatric surgery patients",Experimental and therapeutic medicine,2019,"Roux-en-Y gastric bypass, bariatric surgery, gut microbiota, morbid obesity, sleeve gastrectomy, type 2 diabetes mellitus",Experiment 3,China,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,obese patients prior to Sleeve gastrectomy SG0,obese patients three months after Sleeve gastrectomy SG3,obese patients had a body mass index (BMI) of >28 kg/m2.,19,8,3 months,16S,4,Ion Torrent,Kruskall-Wallis,0.05,FALSE,4,"age,sex",NA,NA,increased,increased,NA,NA,increased,Signature 1,Table 3,10 January 2021,Shaimaa Elsafoury,WikiWorks,Differential composition of gut microbiota among healthy volunteers and morbidly obese patients before recieving sleeve gastrectomy,decreased,"k__Bacteria|p__Bacillota|c__Bacilli,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Rikenellaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Rikenellaceae|g__Alistipes,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus|s__Streptococcus thermophilus,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Rikenellaceae|g__Alistipes|s__Alistipes finegoldii",2|1239|91061;2|1239|91061|186826;2|1239|91061|186826|1300;2|976|200643|171549|171550;2|976|200643|171549|171550|239759;2|1239|91061|186826|1300|1301;2|1239|91061|186826|1300|1301|1308;2|976|200643|171549|171551;2|976|200643|171549|171550|239759|214856,Complete,Shaimaa Elsafoury
bsdb:97/4/1,Study 97,case-control,30867711,10.3892/etm.2019.7200,NA,"Wang FG, Bai RX, Yan WM, Yan M, Dong LY , Song MM","Differential composition of gut microbiota among healthy volunteers, morbidly obese patients and post-bariatric surgery patients",Experimental and therapeutic medicine,2019,"Roux-en-Y gastric bypass, bariatric surgery, gut microbiota, morbid obesity, sleeve gastrectomy, type 2 diabetes mellitus",Experiment 4,China,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,patients prior to Roux-en-Y gastric bypass RYGB0,obese patients 3 moths after Roux-en-Y gastric bypass RYGB3,obese patients had a body mass index (BMI) of >28 kg/m2.,7,3,3 months,16S,4,Ion Torrent,Kruskall-Wallis,0.05,FALSE,4,"age,sex",NA,NA,unchanged,unchanged,NA,NA,unchanged,Signature 1,Table 3,10 January 2021,Shaimaa Elsafoury,WikiWorks,Differential composition of gut microbiota among healthy volunteers and morbidly obese patients before recieving Roux-en-Y gastric bypass,increased,"k__Bacteria|p__Bacillota|c__Negativicutes,k__Bacteria|p__Bacillota|c__Negativicutes|o__Selenomonadales,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Faecalibacterium",2|1239|909932;2|1239|909932|909929;2|1239|186801|186802|216572|216851,Complete,Shaimaa Elsafoury
bsdb:97/4/2,Study 97,case-control,30867711,10.3892/etm.2019.7200,NA,"Wang FG, Bai RX, Yan WM, Yan M, Dong LY , Song MM","Differential composition of gut microbiota among healthy volunteers, morbidly obese patients and post-bariatric surgery patients",Experimental and therapeutic medicine,2019,"Roux-en-Y gastric bypass, bariatric surgery, gut microbiota, morbid obesity, sleeve gastrectomy, type 2 diabetes mellitus",Experiment 4,China,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,patients prior to Roux-en-Y gastric bypass RYGB0,obese patients 3 moths after Roux-en-Y gastric bypass RYGB3,obese patients had a body mass index (BMI) of >28 kg/m2.,7,3,3 months,16S,4,Ion Torrent,Kruskall-Wallis,0.05,FALSE,4,"age,sex",NA,NA,unchanged,unchanged,NA,NA,unchanged,Signature 2,Table 3,10 January 2021,Shaimaa Elsafoury,WikiWorks,Differential composition of gut microbiota among healthy volunteers and morbidly obese patients before recieving Roux-en-Y gastric bypass,decreased,"k__Bacteria|p__Bacillota|c__Bacilli,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus|s__Streptococcus thermophilus",2|1239|91061;2|1239|91061|186826;2|1239|91061|186826|1300;2|1239|91061|186826|1300|1301;2|1239|91061|186826|1300|1301|1308,Complete,Shaimaa Elsafoury
bsdb:98/1/1,Study 98,"cross-sectional observational, not case-control",30962186,10.2215/CJN.12161018,NA,"Shah NB, Allegretti AS, Nigwekar SU, Kalim S, Zhao S, Lelouvier B, Servant F, Serena G, Thadhani RI, Raj DS , Fasano A",Blood Microbiome Profile in CKD : A Pilot Study,Clinical journal of the American Society of Nephrology : CJASN,2019,"Blood microbiome, Cross-Sectional Studies, DNA, Bacterial, Ribosomal, Dysbiosis, Endotoxemia, Enterobacteriaceae, Metagenomics, Microbiota, Permeability, Pilot Projects, Polymerase Chain Reaction, Proteobacteria, Pseudomonadaceae, Renal Insufficiency, Chronic, Sequence Analysis, chronic kidney disease, glomerular filtration rate",Experiment 1,United States of America,Homo sapiens,Blood,UBERON:0000178,Chronic kidney disease,EFO:0003884,controls,CKD,NA,20,20,current use,16S,34,Illumina,LEfSe,0.05,TRUE,NA,age,"age,body mass index,hyperlipidemia,hypertension,immunosuppressant use measurement,leukocyte",NA,NA,decreased,NA,NA,NA,Signature 1,Figure 3 and Table 2,10 January 2021,Rimsha Azhar,"Lwaldron,WikiWorks",Linear discriminant analysis Effect Size (LEfSe) showing microbiome differences between groups at various taxonomic levels.,increased,"k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Rhodospirillales|f__Acetobacteraceae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Moraxellales|f__Moraxellaceae|g__Acinetobacter,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pseudomonadales|f__Pseudomonadaceae|s__Azotobacter group,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Bacillaceae|g__Bacillus,k__Bacteria|p__Bacteroidota|c__Chitinophagia|o__Chitinophagales|f__Chitinophagaceae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Hyphomicrobiales|f__Hyphomicrobiaceae,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Hyphomicrobiales|f__Hyphomicrobiaceae|g__Hyphomicrobium,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Legionellales|f__Legionellaceae|g__Legionella,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Legionellales|f__Legionellaceae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Legionellales,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Lysobacterales|f__Lysobacteraceae|g__Lysobacter,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Peptostreptococcaceae,k__Bacteria|p__Pseudomonadota,k__Bacteria|p__Bacteroidota|c__Cytophagia|o__Cytophagales|f__Flectobacillaceae|g__Pseudarcicella,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pseudomonadales|f__Pseudomonadaceae|g__Pseudomonas,k__Bacteria|p__Bacteroidota|c__Chitinophagia|o__Chitinophagales|f__Chitinophagaceae|g__Sediminibacterium,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Yersiniaceae|g__Serratia,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Yersiniaceae|g__Yersinia,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Yersiniaceae|g__Yersinia|s__Yersinia intermedia,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Rhodospirillales",2|1224|28211|204441|433;2|1224|1236|2887326|468|469;2|1224|1236|72274|135621|351;2|1239|91061|1385|186817|1386;2|976|1853228|1853229|563835;2|1224|1236|91347;2|1224|1236|91347|543;2|1224|1236;2|1224|28211|356|45401;2|1224|28211|356|45401|81;2|1224|1236|118969|444|445;2|1224|1236|118969|444;2|1224|1236|118969;2|1224|1236|135614|32033|68;2|1239|186801|3082720|186804;2|1224;2|976|768503|768507|3141701|1664383;2|1224|1236|72274|135621|286;2|976|1853228|1853229|563835|504481;2|1224|1236|91347|1903411|613;2|1224|1236|91347|1903411|629;2|1224|1236|91347|1903411|629|631;2|1224|28211|204441,Complete,Shaimaa Elsafoury
bsdb:98/1/2,Study 98,"cross-sectional observational, not case-control",30962186,10.2215/CJN.12161018,NA,"Shah NB, Allegretti AS, Nigwekar SU, Kalim S, Zhao S, Lelouvier B, Servant F, Serena G, Thadhani RI, Raj DS , Fasano A",Blood Microbiome Profile in CKD : A Pilot Study,Clinical journal of the American Society of Nephrology : CJASN,2019,"Blood microbiome, Cross-Sectional Studies, DNA, Bacterial, Ribosomal, Dysbiosis, Endotoxemia, Enterobacteriaceae, Metagenomics, Microbiota, Permeability, Pilot Projects, Polymerase Chain Reaction, Proteobacteria, Pseudomonadaceae, Renal Insufficiency, Chronic, Sequence Analysis, chronic kidney disease, glomerular filtration rate",Experiment 1,United States of America,Homo sapiens,Blood,UBERON:0000178,Chronic kidney disease,EFO:0003884,controls,CKD,NA,20,20,current use,16S,34,Illumina,LEfSe,0.05,TRUE,NA,age,"age,body mass index,hyperlipidemia,hypertension,immunosuppressant use measurement,leukocyte",NA,NA,decreased,NA,NA,NA,Signature 2,Figure 3 and Table 2,10 January 2021,Rimsha Azhar,"Fatima,Lwaldron,WikiWorks",Linear discriminant analysis Effect Size (LEfSe) showing microbiome differences between groups at various taxonomic levels.,decreased,"k__Bacteria|p__Actinomycetota|c__Acidimicrobiia|o__Acidimicrobiales|f__Acidimicrobiaceae,k__Bacteria|p__Actinomycetota|c__Acidimicrobiia|o__Acidimicrobiales,k__Bacteria|p__Acidobacteriota|c__Terriglobia,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micrococcales|f__Microbacteriaceae|g__Aurantimicrobium,k__Bacteria|p__Acidobacteriota|c__Terriglobia|o__Bryobacterales|f__Bryobacteraceae|g__Bryobacter,k__Bacteria|p__Acidobacteriota|c__Terriglobia|o__Bryobacterales,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Mycobacteriales|f__Corynebacteriaceae|g__Corynebacterium,k__Bacteria|p__Thermodesulfobacteriota|c__Desulfobulbia|o__Desulfobulbales|f__Desulfobulbaceae,k__Eukaryota|k__Metazoa|p__Arthropoda|c__Insecta|o__Grylloblattodea|f__Grylloblattidae|g__Galloisiana|s__Galloisiana yuasai,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae,k__Bacteria|p__Bacteroidota|c__Cytophagia|o__Cytophagales|f__Microscillaceae,k__Bacteria|p__Bacteroidota|c__Cytophagia|o__Cytophagales|f__Fulvivirgaceae|g__Ohtaekwangia,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Rhodobacterales|f__Paracoccaceae|g__Paracoccus,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Sphingomonadales|f__Sphingomonadaceae|g__Sphingomonas,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Lysobacterales|f__Lysobacteraceae|g__Stenotrophomonas,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Tyzzerella",2|201174|84992|84993|84994;2|201174|84992|84993;2|57723|204432;2|201174|1760|85006|85023|1705353;2|57723|204432|332160|1962910|911113;2|57723|204432|332160;2|201174|1760|85007|1653|1716;2|200940|3031451|3024411|213121;2759|33208|6656|50557|58557|244939|73579|378494;2|1239|186801|3085636|186803;2|976|768503|768507|1937962;2|976|768503|768507|2762286|1210119;2|1224|28211|204455|31989|265;2|1224|28211|204457|41297|13687;2|1224|1236|135614|32033|40323;2|1239|186801|3085636|186803|1506577,Complete,Shaimaa Elsafoury
bsdb:99/1/1,Study 99,case-control,28628112,10.1038/nm.4358,NA,"Liu R, Hong J, Xu X, Feng Q, Zhang D, Gu Y, Shi J, Zhao S, Liu W, Wang X, Xia H, Liu Z, Cui B, Liang P, Xi L, Jin J, Ying X, Wang X, Zhao X, Li W, Jia H, Lan Z, Li F, Wang R, Sun Y, Yang M, Shen Y, Jie Z, Li J, Chen X, Zhong H, Xie H, Zhang Y, Gu W, Deng X, Shen B, Xu X, Yang H, Xu G, Bi Y, Lai S, Wang J, Qi L, Madsen L, Wang J, Ning G, Kristiansen K , Wang W",Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention,Nature medicine,2017,NA,Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,controls,obese,NA,79,72,1 month,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,"age,sex",NA,NA,decreased,NA,NA,NA,NA,Signature 1,Figure 1,10 January 2021,Marianthi Thomatos,"Fatima,WikiWorks",Gut microbiome alterations in obesity among cohort of lean vs obese Chinese,increased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Blautia|s__Blautia obeum,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales|f__Coriobacteriaceae|g__Collinsella|s__Collinsella aerofaciens,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Coprococcus|s__Coprococcus comes,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Dorea|s__Dorea formicigenerans,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Dorea|s__Dorea longicatena,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae|g__Fusobacterium|s__Fusobacterium ulcerans,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae|g__Fusobacterium|s__Fusobacterium varium,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Megasphaera|s__Megasphaera elsdenii,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Mediterraneibacter|s__Mediterraneibacter gnavus,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Mediterraneibacter|s__[Ruminococcus] torques,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Anaerobutyricum|s__Anaerobutyricum hallii",2|1239|186801|3085636|186803|572511|40520;2|201174|84998|84999|84107|102106|74426;2|1239|186801|3085636|186803|33042|410072;2|1239|186801|3085636|186803|189330|39486;2|1239|186801|3085636|186803|189330|88431;2|32066|203490|203491|203492|848|861;2|32066|203490|203491|203492|848|856;2|1239|186801|3085636|186803;2|1239|909932|1843489|31977|906|907;2|1239|186801|3085636|186803|2316020|33038;2|1239|186801|3085636|186803|2316020|33039;2|1239|186801|3085636|186803|2569097|39488,Complete,Fatima
bsdb:99/1/2,Study 99,case-control,28628112,10.1038/nm.4358,NA,"Liu R, Hong J, Xu X, Feng Q, Zhang D, Gu Y, Shi J, Zhao S, Liu W, Wang X, Xia H, Liu Z, Cui B, Liang P, Xi L, Jin J, Ying X, Wang X, Zhao X, Li W, Jia H, Lan Z, Li F, Wang R, Sun Y, Yang M, Shen Y, Jie Z, Li J, Chen X, Zhong H, Xie H, Zhang Y, Gu W, Deng X, Shen B, Xu X, Yang H, Xu G, Bi Y, Lai S, Wang J, Qi L, Madsen L, Wang J, Ning G, Kristiansen K , Wang W",Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention,Nature medicine,2017,NA,Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,controls,obese,NA,79,72,1 month,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,"age,sex",NA,NA,decreased,NA,NA,NA,NA,Signature 2,Figure 1,10 January 2021,Marianthi Thomatos,WikiWorks,Gut microbiome alterations in obesity among cohort of lean vs obese Chinese,decreased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides|s__Bacteroides ovatus,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides|s__Bacteroides xylanisolvens,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides|s__Bacteroides uniformis,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides|s__Bacteroides thetaiotaomicron,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides|s__Bacteroides intestinalis,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Rikenellaceae|g__Alistipes|s__Alistipes shahii,k__Bacteria|p__Verrucomicrobiota|c__Verrucomicrobiia|o__Verrucomicrobiales|f__Akkermansiaceae|g__Akkermansia|s__Akkermansia muciniphila,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Rikenellaceae|g__Alistipes|s__Alistipes putredinis,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Odoribacteraceae|g__Odoribacter|s__Odoribacter splanchnicus,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides|s__Bacteroides eggerthii,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Klebsiella|s__Klebsiella pneumoniae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Klebsiella|s__Klebsiella oxytoca,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Haemophilus|s__Haemophilus parainfluenzae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Faecalibacterium|s__Faecalibacterium prausnitzii,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Rikenellaceae|g__Alistipes",2|976|200643|171549|815|816|28116;2|976|200643|171549|815|816|371601;2|976|200643|171549|815|816|820;2|976|200643|171549|815|816|818;2|976|200643|171549|815|816|329854;2|976|200643|171549|171550|239759|328814;2|74201|203494|48461|1647988|239934|239935;2|976|200643|171549|171550|239759|28117;2|976|200643|171549|1853231|283168|28118;2|976|200643|171549|815|816|28111;2|1224|1236|91347|543|570|573;2|1224|1236|91347|543|570|571;2|1224|1236|135625|712|724|729;2|1239|186801|186802|216572|216851|853;2|976|200643|171549|815|816;2|976|200643|171549|171550|239759,Complete,ChiomaBlessing
bsdb:100/1/1,Study 100,"cross-sectional observational, not case-control",30257444,10.3390/microorganisms6040098,NA,"Kashtanova DA, Tkacheva ON, Doudinskaya EN, Strazhesko ID, Kotovskaya YV, Popenko AS, Tyakht AV , Alexeev DG",Gut Microbiota in Patients with Different Metabolic Statuses: Moscow Study,Microorganisms,2018,"cardiovascular risk factors, diet, glucose metabolism, gut microbiota, metabolic status",Experiment 1,Russian Federation,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,low BMI,High BMI,NA,69,23,3 months,16S,34,Illumina,Linear Regression,0.05,TRUE,NA,NA,"age,sex",NA,NA,NA,NA,NA,NA,Signature 1,Table 2,10 January 2021,Marianthi Thomatos,WikiWorks,Gut microbiota in patients with obesity,increased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Yersiniaceae|g__Serratia,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella",2|1224|1236|91347|1903411|613;2|976|200643|171549|171552|838,Complete,Shaimaa Elsafoury
bsdb:100/2/1,Study 100,"cross-sectional observational, not case-control",30257444,10.3390/microorganisms6040098,NA,"Kashtanova DA, Tkacheva ON, Doudinskaya EN, Strazhesko ID, Kotovskaya YV, Popenko AS, Tyakht AV , Alexeev DG",Gut Microbiota in Patients with Different Metabolic Statuses: Moscow Study,Microorganisms,2018,"cardiovascular risk factors, diet, glucose metabolism, gut microbiota, metabolic status",Experiment 2,Russian Federation,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,non-abdominal obesity,Abdominal obesity,NA,39,53,3 months,16S,34,Illumina,Linear Regression,0.05,TRUE,NA,NA,"age,sex",NA,NA,NA,NA,NA,NA,Signature 1,Table 2,10 January 2021,Marianthi Thomatos,WikiWorks,Gut microbiota in patients with obesity,increased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Yersiniaceae|g__Serratia,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella",2|1224|1236|91347|1903411|613;2|976|200643|171549|171552|838,Complete,Shaimaa Elsafoury
bsdb:100/2/2,Study 100,"cross-sectional observational, not case-control",30257444,10.3390/microorganisms6040098,NA,"Kashtanova DA, Tkacheva ON, Doudinskaya EN, Strazhesko ID, Kotovskaya YV, Popenko AS, Tyakht AV , Alexeev DG",Gut Microbiota in Patients with Different Metabolic Statuses: Moscow Study,Microorganisms,2018,"cardiovascular risk factors, diet, glucose metabolism, gut microbiota, metabolic status",Experiment 2,Russian Federation,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,non-abdominal obesity,Abdominal obesity,NA,39,53,3 months,16S,34,Illumina,Linear Regression,0.05,TRUE,NA,NA,"age,sex",NA,NA,NA,NA,NA,NA,Signature 2,Table 2,10 January 2021,Marianthi Thomatos,WikiWorks,Gut microbiota in patients with obesity,decreased,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Oscillospira,2|1239|186801|186802|216572|119852,Complete,Shaimaa Elsafoury
bsdb:101/1/1,Study 101,case-control,21829158,10.1038/ijo.2011.153,NA,"Million M, Maraninchi M, Henry M, Armougom F, Richet H, Carrieri P, Valero R, Raccah D, Vialettes B , Raoult D",Obesity-associated gut microbiota is enriched in Lactobacillus reuteri and depleted in Bifidobacterium animalis and Methanobrevibacter smithii,International journal of obesity (2005),2012,NA,Experiment 1,France,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,lean controls,obese,"Obese patients, as defined by a BMI>=30 kg/m2",47,68,less than one month before stool collection,16S,NA,RT-qPCR,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,age,NA,NA,NA,NA,NA,NA,Signature 1,"Text & Tables 2, 3, 4 & 5",10 January 2021,Marianthi Thomatos,WikiWorks,Gut alterations of Lactobacillus or bifidobacterium species between obese and controls,increased,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus,2|1239|91061|186826|33958|1578,Complete,Shaimaa Elsafoury
bsdb:101/1/2,Study 101,case-control,21829158,10.1038/ijo.2011.153,NA,"Million M, Maraninchi M, Henry M, Armougom F, Richet H, Carrieri P, Valero R, Raccah D, Vialettes B , Raoult D",Obesity-associated gut microbiota is enriched in Lactobacillus reuteri and depleted in Bifidobacterium animalis and Methanobrevibacter smithii,International journal of obesity (2005),2012,NA,Experiment 1,France,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,lean controls,obese,"Obese patients, as defined by a BMI>=30 kg/m2",47,68,less than one month before stool collection,16S,NA,RT-qPCR,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,age,NA,NA,NA,NA,NA,NA,Signature 2,"Text & Tables 2, 3, 4 & 5",10 January 2021,Marianthi Thomatos,WikiWorks,Gut alterations of Lactobacillus or bifidobacterium species between obese and controls,decreased,"k__Archaea|p__Euryarchaeota|c__Methanobacteria|o__Methanobacteriales|f__Methanobacteriaceae|g__Methanobrevibacter|s__Methanobrevibacter smithii,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium|s__Bifidobacterium animalis,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lacticaseibacillus|s__Lacticaseibacillus paracasei,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactiplantibacillus|s__Lactiplantibacillus plantarum",2157|28890|183925|2158|2159|2172|2173;2|201174|1760|85004|31953|1678|28025;2|1239|91061|186826|33958|2759736|1597;2|1239|91061|186826|33958|2767842|1590,Complete,Shaimaa Elsafoury
bsdb:102/1/1,Study 102,"cross-sectional observational, not case-control",26279179,10.1038/srep13212,NA,"Fugmann M, Breier M, Rottenkolber M, Banning F, Ferrari U, Sacco V, Grallert H, Parhofer KG, Seissler J, Clavel T , Lechner A","The stool microbiota of insulin resistant women with recent gestational diabetes, a high risk group for type 2 diabetes",Scientific reports,2015,NA,Experiment 1,Germany,Homo sapiens,Feces,UBERON:0001988,Type II diabetes mellitus,MONDO:0005148,normoglycemic controls,Women with gestational DM,Gestational Diabetes Mellitus  was diagnosed by a standardized oral glucose tolerance test (OGTT) after the 23rd week of the preceding pregnecy,35,42,14 days,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,Signature 1,Text and Figure 2,10 January 2021,Yaseen Javaid,WikiWorks,Comparison of relative sequence abundances at the different bacterial taxonomic ranks between pGDM and controls.,increased,"k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Ruminococcus",2|1239|909932|1843489|31977;2|976|200643|171549|171552|838;2|1239|186801|186802|216572|1263,Complete,Shaimaa Elsafoury
bsdb:102/1/2,Study 102,"cross-sectional observational, not case-control",26279179,10.1038/srep13212,NA,"Fugmann M, Breier M, Rottenkolber M, Banning F, Ferrari U, Sacco V, Grallert H, Parhofer KG, Seissler J, Clavel T , Lechner A","The stool microbiota of insulin resistant women with recent gestational diabetes, a high risk group for type 2 diabetes",Scientific reports,2015,NA,Experiment 1,Germany,Homo sapiens,Feces,UBERON:0001988,Type II diabetes mellitus,MONDO:0005148,normoglycemic controls,Women with gestational DM,Gestational Diabetes Mellitus  was diagnosed by a standardized oral glucose tolerance test (OGTT) after the 23rd week of the preceding pregnecy,35,42,14 days,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,Signature 2,Text and Figure 2,10 January 2021,Yaseen Javaid,WikiWorks,Comparison of relative sequence abundances at the different bacterial taxonomic ranks between pGDM and controls.,decreased,"k__Bacteria|p__Bacillota,k__Bacteria|p__Bacillota|c__Clostridia,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Rikenellaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Blautia,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Rikenellaceae|g__Alistipes",2|1239;2|1239|186801;2|1239|186801|186802;2|976|200643|171549|171550;2|1239|186801|3085636|186803|572511;2|976|200643|171549|171550|239759,Complete,Shaimaa Elsafoury
bsdb:103/1/1,Study 103,case-control,29520144,10.2147/NDT.S159322,NA,"Chen JJ, Zheng P, Liu YY, Zhong XG, Wang HY, Guo YJ , Xie P",Sex differences in gut microbiota in patients with major depressive disorder,Neuropsychiatric disease and treatment,2018,"MDD, biomarker, gut microbiota, major depressive disorder",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Unipolar depression,EFO:0003761,Healthy Controls,depressed female,NA,24,24,yes,16S,345,Roche454,LEfSe,0.05,FALSE,NA,demographics,NA,NA,NA,NA,NA,NA,NA,Signature 1,Figure 5,10 January 2021,Fatima Zohra,WikiWorks,Sex differences in gut microbiota in female patients with major depressive disorder,increased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Blautia,k__Bacteria|p__Actinomycetota,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales|f__Actinomycetaceae|g__Actinomyces,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Eggerthellales|f__Eggerthellaceae|g__Asaccharobacter,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales|f__Atopobiaceae|g__Atopobium,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Eggerthellales|f__Eggerthellaceae|g__Eggerthella,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Eggerthellales|f__Eggerthellaceae|g__Gordonibacter,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales|f__Atopobiaceae|g__Olsenella,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Eubacteriaceae|g__Eubacterium,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Anaerostipes,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Roseburia,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Faecalibacterium,k__Bacteria|p__Thermodesulfobacteriota|c__Desulfovibrionia|o__Desulfovibrionales|f__Desulfovibrionaceae|g__Desulfovibrio,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Eubacteriaceae,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales|f__Coriobacteriaceae",2|1239|186801|3085636|186803|572511;2|201174;2|201174|1760|2037|2049|1654;2|201174|1760|85004|31953|1678;2|201174|84998|1643822|1643826|553372;2|201174|84998|84999|1643824|1380;2|201174|84998|1643822|1643826|84111;2|201174|84998|1643822|1643826|644652;2|201174|84998|84999|1643824|133925;2|1239|186801|186802|186806|1730;2|1239|186801|3085636|186803|207244;2|1239|186801|3085636|186803|841;2|1239|186801|186802|216572|216851;2|200940|3031449|213115|194924|872;2|201174|84998|84999;2|1239|186801|3085636|186803;2|201174|1760|85004|31953;2|201174|1760|85004;2|1224|1236|135625;2|1224|1236|135625|712;2|1239|186801|186802|186806;2|201174|84998|84999|84107,Complete,Shaimaa Elsafoury
bsdb:103/1/2,Study 103,case-control,29520144,10.2147/NDT.S159322,NA,"Chen JJ, Zheng P, Liu YY, Zhong XG, Wang HY, Guo YJ , Xie P",Sex differences in gut microbiota in patients with major depressive disorder,Neuropsychiatric disease and treatment,2018,"MDD, biomarker, gut microbiota, major depressive disorder",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Unipolar depression,EFO:0003761,Healthy Controls,depressed female,NA,24,24,yes,16S,345,Roche454,LEfSe,0.05,FALSE,NA,demographics,NA,NA,NA,NA,NA,NA,NA,Signature 2,Figure 5,10 January 2021,Fatima Zohra,WikiWorks,Sex differences in gut microbiota in female patients with major depressive disorder,decreased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|g__Howardella,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Sutterellaceae|g__Sutterella,k__Bacteria|p__Synergistota|c__Synergistia|o__Synergistales|f__Dethiosulfovibrionaceae|g__Pyramidobacter",2|1239|186801|186802|404402;2|1224|28216|80840|995019|40544;2|508458|649775|649776|3029088|638847,Complete,Shaimaa Elsafoury
bsdb:103/2/1,Study 103,case-control,29520144,10.2147/NDT.S159322,NA,"Chen JJ, Zheng P, Liu YY, Zhong XG, Wang HY, Guo YJ , Xie P",Sex differences in gut microbiota in patients with major depressive disorder,Neuropsychiatric disease and treatment,2018,"MDD, biomarker, gut microbiota, major depressive disorder",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Unipolar depression,EFO:0003761,Healthy Controls,depressed male,NA,20,20,yes,16S,345,Roche454,LEfSe,0.05,FALSE,NA,demographics,NA,NA,NA,NA,NA,NA,NA,Signature 1,Figure 6,10 January 2021,Fatima Zohra,"Fatima,WikiWorks",Sex differences in gut microbiota in male patients with major depressive disorder,increased,"k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales|f__Atopobiaceae|g__Atopobium,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides,k__Bacteria|p__Bacteroidota|c__Bacteroidia,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Veillonella,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae",2|201174|84998|84999|1643824|1380;2|976|200643|171549|815;2|976|200643|171549|815|816;2|976|200643;2|1239|909932|1843489|31977|29465;2|1239|526524|526525|128827,Complete,Fatima
bsdb:103/2/2,Study 103,case-control,29520144,10.2147/NDT.S159322,NA,"Chen JJ, Zheng P, Liu YY, Zhong XG, Wang HY, Guo YJ , Xie P",Sex differences in gut microbiota in patients with major depressive disorder,Neuropsychiatric disease and treatment,2018,"MDD, biomarker, gut microbiota, major depressive disorder",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Unipolar depression,EFO:0003761,Healthy Controls,depressed male,NA,20,20,yes,16S,345,Roche454,LEfSe,0.05,FALSE,NA,demographics,NA,NA,NA,NA,NA,NA,NA,Signature 2,Figure 6,10 January 2021,Fatima Zohra,WikiWorks,Sex differences in gut microbiota in male patients with major depressive disorder,decreased,"k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales|f__Coriobacteriaceae,k__Bacteria|p__Bacillota|c__Clostridia,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Eggerthellales|f__Eggerthellaceae|g__Gordonibacter,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Anaerovoracaceae|g__Anaerovorax,k__Bacteria|p__Synergistota|c__Synergistia|o__Synergistales|f__Dethiosulfovibrionaceae|g__Pyramidobacter",2|201174|84998|84999|84107;2|1239|186801;2|201174|84998|1643822|1643826|644652;2|1239|186801|3082720|3030910|109326;2|508458|649775|649776|3029088|638847,Complete,Shaimaa Elsafoury
bsdb:104/1/1,Study 104,case-control,27741466,10.1016/j.jad.2016.09.051,NA,"Lin P, Ding B, Feng C, Yin S, Zhang T, Qi X, Lv H, Guo X, Dong K, Zhu Y , Li Q",Prevotella and Klebsiella proportions in fecal microbial communities are potential characteristic parameters for patients with major depressive disorder,Journal of affective disorders,2017,"Fecal microbial communities, Klebsiella, Major depressive disorder, Prevotella",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Unipolar depression,EFO:0003761,healthy controls,major depressive disorder (visit 1),"The patients were assessed with the major depressive disorder criteria in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV- TR) and 17-items HAM-D scales ≥23.Three visits occurred on day 1, day 15 and day 29.",10,10,1 month,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.01,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,table 2 and table 3,10 January 2021,Fatima Zohra,WikiWorks,Major bacterial organism in subjects of MDD and control groups,increased,"k__Bacteria|p__Bacillota,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Klebsiella,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus",2|1239;2|976|200643|171549|171552|838;2|1224|1236|91347|543|570;2|1239|91061|186826|1300|1301,Complete,Shaimaa Elsafoury
bsdb:104/1/2,Study 104,case-control,27741466,10.1016/j.jad.2016.09.051,NA,"Lin P, Ding B, Feng C, Yin S, Zhang T, Qi X, Lv H, Guo X, Dong K, Zhu Y , Li Q",Prevotella and Klebsiella proportions in fecal microbial communities are potential characteristic parameters for patients with major depressive disorder,Journal of affective disorders,2017,"Fecal microbial communities, Klebsiella, Major depressive disorder, Prevotella",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Unipolar depression,EFO:0003761,healthy controls,major depressive disorder (visit 1),"The patients were assessed with the major depressive disorder criteria in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV- TR) and 17-items HAM-D scales ≥23.Three visits occurred on day 1, day 15 and day 29.",10,10,1 month,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.01,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 2,table 2 and table 3,10 January 2021,Fatima Zohra,WikiWorks,Major bacterial organism in subjects of MDD and control groups,decreased,k__Bacteria|p__Bacteroidota,2|976,Complete,Shaimaa Elsafoury
bsdb:104/2/1,Study 104,case-control,27741466,10.1016/j.jad.2016.09.051,NA,"Lin P, Ding B, Feng C, Yin S, Zhang T, Qi X, Lv H, Guo X, Dong K, Zhu Y , Li Q",Prevotella and Klebsiella proportions in fecal microbial communities are potential characteristic parameters for patients with major depressive disorder,Journal of affective disorders,2017,"Fecal microbial communities, Klebsiella, Major depressive disorder, Prevotella",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Unipolar depression,EFO:0003761,healthy controls,major depressive disorder (visit 2),"The patients were assessed with the major depressive disorder criteria in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV- TR) and 17-items HAM-D scales ≥23.Three visits occurred on day 1, day 15 and day 29.",10,10,1 month,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.01,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,table 2 and table 3,10 January 2021,Shaimaa Elsafoury,WikiWorks,Major bacterial organism in subjects of MDD and control groups,increased,"k__Bacteria|p__Bacillota,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus",2|1239;2|976|200643|171549|171552|838;2|1239|91061|186826|1300|1301,Complete,Shaimaa Elsafoury
bsdb:104/2/2,Study 104,case-control,27741466,10.1016/j.jad.2016.09.051,NA,"Lin P, Ding B, Feng C, Yin S, Zhang T, Qi X, Lv H, Guo X, Dong K, Zhu Y , Li Q",Prevotella and Klebsiella proportions in fecal microbial communities are potential characteristic parameters for patients with major depressive disorder,Journal of affective disorders,2017,"Fecal microbial communities, Klebsiella, Major depressive disorder, Prevotella",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Unipolar depression,EFO:0003761,healthy controls,major depressive disorder (visit 2),"The patients were assessed with the major depressive disorder criteria in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV- TR) and 17-items HAM-D scales ≥23.Three visits occurred on day 1, day 15 and day 29.",10,10,1 month,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.01,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 2,table 2 and table 3,10 January 2021,Shaimaa Elsafoury,WikiWorks,Major bacterial organism in subjects of MDD and control groups,decreased,k__Bacteria|p__Bacteroidota,2|976,Complete,Shaimaa Elsafoury
bsdb:104/3/1,Study 104,case-control,27741466,10.1016/j.jad.2016.09.051,NA,"Lin P, Ding B, Feng C, Yin S, Zhang T, Qi X, Lv H, Guo X, Dong K, Zhu Y , Li Q",Prevotella and Klebsiella proportions in fecal microbial communities are potential characteristic parameters for patients with major depressive disorder,Journal of affective disorders,2017,"Fecal microbial communities, Klebsiella, Major depressive disorder, Prevotella",Experiment 3,China,Homo sapiens,Feces,UBERON:0001988,Unipolar depression,EFO:0003761,healthy controls,major depressive disorder (visit 3),"The patients were assessed with the major depressive disorder criteria in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV- TR) and 17-items HAM-D scales ≥23.Three visits occurred on day 1, day 15 and day 29.",10,10,1 month,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.01,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,table 2 and table 3,10 January 2021,Shaimaa Elsafoury,"Fatima,WikiWorks",Major bacterial organism in subjects of MDD and control groups,increased,"k__Bacteria|p__Bacillota,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Peptostreptococcaceae",2|1239;2|1239|186801|3082720|186804,Complete,Fatima
bsdb:104/3/2,Study 104,case-control,27741466,10.1016/j.jad.2016.09.051,NA,"Lin P, Ding B, Feng C, Yin S, Zhang T, Qi X, Lv H, Guo X, Dong K, Zhu Y , Li Q",Prevotella and Klebsiella proportions in fecal microbial communities are potential characteristic parameters for patients with major depressive disorder,Journal of affective disorders,2017,"Fecal microbial communities, Klebsiella, Major depressive disorder, Prevotella",Experiment 3,China,Homo sapiens,Feces,UBERON:0001988,Unipolar depression,EFO:0003761,healthy controls,major depressive disorder (visit 3),"The patients were assessed with the major depressive disorder criteria in the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV- TR) and 17-items HAM-D scales ≥23.Three visits occurred on day 1, day 15 and day 29.",10,10,1 month,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.01,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 2,table 2 and table 3,10 January 2021,Shaimaa Elsafoury,WikiWorks,Major bacterial organism in subjects of MDD and control groups,decreased,k__Bacteria|p__Bacteroidota,2|976,Complete,Shaimaa Elsafoury
bsdb:105/1/1,Study 105,case-control,27988330,10.1016/j.jpsychires.2016.12.007,NA,"Evans SJ, Bassis CM, Hein R, Assari S, Flowers SA, Kelly MB, Young VB, Ellingrod VE , McInnis MG",The gut microbiome composition associates with bipolar disorder and illness severity,Journal of psychiatric research,2017,"Bipolar disorder, Faecalibacterium, Generalized Anxiety Disorder scale, Microbiome, Patient Health Questionnaire, Pittsburg Sleep Quality Index",Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Bipolar disorder,MONDO:0004985,Healthy controls,Bipolar,Individuals with bipolar disorder,64,115,NIL,16S,4,Illumina,Logistic Regression,0.05,TRUE,NA,NA,"age,body mass index,sex",NA,NA,NA,NA,NA,NA,Signature 1,Table 2b,10 January 2021,Fatima Zohra,"WikiWorks,Peace Sandy","Table 2b gives the mean and (SD) values for OTU fractional representations (percent of total) for all OTUs greater than 1% total in either group. P-values derive from logistical regressions with diagnosis (1,0) as the outcome measure and OTU as the predictor, adjusting for age, gender and BMI. Values in bold remained significant following FDR correction at the p<0.05 level.t",decreased,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Faecalibacterium,2|1239|186801|186802|216572|216851,Complete,Peace Sandy
bsdb:106/1/1,Study 106,"cross-sectional observational, not case-control",30261302,10.1016/j.bbi.2018.09.026,NA,"Coello K, Hansen TH, Sørensen N, Munkholm K, Kessing LV, Pedersen O , Vinberg M",Gut microbiota composition in patients with newly diagnosed bipolar disorder and their unaffected first-degree relatives,"Brain, behavior, and immunity",2019,"Bipolar disorder, Gut microbiota, Microbiota, Newly diagnosed, Unaffected relatives",Experiment 1,Denmark,Homo sapiens,Feces,UBERON:0001988,Bipolar disorder,MONDO:0004985,healthy controls,bipolar disorder patients,NA,77,113,NA,16S,34,Illumina,Fisher's Exact Test,0.05,TRUE,NA,NA,"age,physical activity,sex,smoking behavior,waist circumference",NA,unchanged,NA,NA,NA,unchanged,Signature 1,"table 2, figure3",10 January 2021,Fatima Zohra,"WikiWorks,Folakunmi",gut microbiota composition in patients with newly diagnosed bipolar and healthy controls,increased,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Flavonifractor,2|1239|186801|186802|216572|946234,Complete,Folakunmi
bsdb:106/2/1,Study 106,"cross-sectional observational, not case-control",30261302,10.1016/j.bbi.2018.09.026,NA,"Coello K, Hansen TH, Sørensen N, Munkholm K, Kessing LV, Pedersen O , Vinberg M",Gut microbiota composition in patients with newly diagnosed bipolar disorder and their unaffected first-degree relatives,"Brain, behavior, and immunity",2019,"Bipolar disorder, Gut microbiota, Microbiota, Newly diagnosed, Unaffected relatives",Experiment 2,Denmark,Homo sapiens,Feces,UBERON:0001988,Bipolar disorder,MONDO:0004985,unaffected relatives,bipolar disorder patients,Healthy first degree relatives of bipolar disorder patients,39,113,NA,16S,34,Illumina,Fisher's Exact Test,0.05,TRUE,NA,NA,"age,physical activity,sex,smoking behavior,waist circumference",NA,unchanged,NA,NA,NA,unchanged,Signature 1,"table 2, figure3",21 February 2024,Folakunmi,Folakunmi,Gut microbiota composition in patients with newly diagnosed bipolar and their unaffected first degree relatives,increased,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Flavonifractor,2|1239|186801|186802|216572|946234,Complete,Folakunmi
bsdb:107/1/1,Study 107,case-control,26428446,10.1097/PSY.0000000000000247,NA,"Kleiman SC, Watson HJ, Bulik-Sullivan EC, Huh EY, Tarantino LM, Bulik CM , Carroll IM","The Intestinal Microbiota in Acute Anorexia Nervosa and During Renourishment: Relationship to Depression, Anxiety, and Eating Disorder Psychopathology",Psychosomatic medicine,2015,NA,Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Anorexia nervosa,EFO:0004215,Healthy comparison group (HCG),Anorexia patients at T1,Patients with anorexia at hospital admission (T1),12,16,2 months,16S,123,Roche454,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,"age,sex",NA,NA,NA,decreased,NA,NA,decreased,Signature 1,Table 2,10 January 2021,Fatima Zohra,"WikiWorks,ChiomaBlessing",Differences in microbial taxa among anorexia patients at hospital admission (T1) VS healthy comparison group (HCG),increased,"k__Bacteria|p__Bacillota|c__Bacilli,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales",2|1239|91061;2|201174|84998|84999,Complete,ChiomaBlessing
bsdb:107/1/2,Study 107,case-control,26428446,10.1097/PSY.0000000000000247,NA,"Kleiman SC, Watson HJ, Bulik-Sullivan EC, Huh EY, Tarantino LM, Bulik CM , Carroll IM","The Intestinal Microbiota in Acute Anorexia Nervosa and During Renourishment: Relationship to Depression, Anxiety, and Eating Disorder Psychopathology",Psychosomatic medicine,2015,NA,Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Anorexia nervosa,EFO:0004215,Healthy comparison group (HCG),Anorexia patients at T1,Patients with anorexia at hospital admission (T1),12,16,2 months,16S,123,Roche454,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,"age,sex",NA,NA,NA,decreased,NA,NA,decreased,Signature 2,Table 2,10 January 2021,Fatima Zohra,"WikiWorks,ChiomaBlessing",Differences in microbial taxa among anorexia patients at hospital admission (T1) VS healthy comparison group (HCG),decreased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Anaerostipes,k__Bacteria|p__Bacillota|c__Clostridia,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Faecalibacterium",2|1239|186801|3085636|186803|207244;2|1239|186801;2|1239|186801|186802;2|1239|186801|186802|216572|216851,Complete,ChiomaBlessing
bsdb:107/2/1,Study 107,case-control,26428446,10.1097/PSY.0000000000000247,NA,"Kleiman SC, Watson HJ, Bulik-Sullivan EC, Huh EY, Tarantino LM, Bulik CM , Carroll IM","The Intestinal Microbiota in Acute Anorexia Nervosa and During Renourishment: Relationship to Depression, Anxiety, and Eating Disorder Psychopathology",Psychosomatic medicine,2015,NA,Experiment 2,United States of America,Homo sapiens,Feces,UBERON:0001988,Anorexia nervosa,EFO:0004215,Healthy comparison group (HCG),Anorexia patients at T2,Patients with anorexia at hospital discharge (T2),12,10,2 months,16S,123,Roche454,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,"age,sex",NA,NA,NA,decreased,NA,NA,decreased,Signature 1,Table 3,10 January 2021,Fatima Zohra,"WikiWorks,ChiomaBlessing",Differences in microbial taxa among anorexia patients at hospital discharge (T2) VS healthy comparison group (HCG),increased,"k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Tannerellaceae|g__Parabacteroides",2|201174|84998|84999;2|976|200643|171549|2005525|375288,Complete,ChiomaBlessing
bsdb:107/2/2,Study 107,case-control,26428446,10.1097/PSY.0000000000000247,NA,"Kleiman SC, Watson HJ, Bulik-Sullivan EC, Huh EY, Tarantino LM, Bulik CM , Carroll IM","The Intestinal Microbiota in Acute Anorexia Nervosa and During Renourishment: Relationship to Depression, Anxiety, and Eating Disorder Psychopathology",Psychosomatic medicine,2015,NA,Experiment 2,United States of America,Homo sapiens,Feces,UBERON:0001988,Anorexia nervosa,EFO:0004215,Healthy comparison group (HCG),Anorexia patients at T2,Patients with anorexia at hospital discharge (T2),12,10,2 months,16S,123,Roche454,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,"age,sex",NA,NA,NA,decreased,NA,NA,decreased,Signature 2,Table 3,10 February 2024,ChiomaBlessing,ChiomaBlessing,Differences in microbial taxa among anorexia patients at hospital discharge (T2) VS healthy comparison group (HCG),decreased,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae,2|1239|186801|186802|541000,Complete,ChiomaBlessing
bsdb:108/1/1,Study 108,case-control,26682545,10.1371/journal.pone.0145274,NA,"Morita C, Tsuji H, Hata T, Gondo M, Takakura S, Kawai K, Yoshihara K, Ogata K, Nomoto K, Miyazaki K , Sudo N",Gut Dysbiosis in Patients with Anorexia Nervosa,PloS one,2015,NA,Experiment 1,Japan,Homo sapiens,Feces,UBERON:0001988,Anorexia nervosa,EFO:0004215,healthy controls,anorexia nervosa patients,female patients with anorexia nervosa,21,25,3 months,16S,NA,RT-qPCR,Mann-Whitney (Wilcoxon),0.002,TRUE,NA,age,NA,NA,NA,NA,NA,NA,NA,Signature 1,"table 3, table 5",10 January 2021,Fatima Zohra,"Claregrieve1,WikiWorks",gut microbiome dysbiosis in patients with anorexia nervosa versus healthy controls,decreased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides|s__Bacteroides fragilis,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactiplantibacillus|s__Lactiplantibacillus plantarum,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Blautia|s__Blautia coccoides,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|s__[Clostridium] leptum",2|976|200643|171549|815|816|817;2|1239|91061|186826|33958|2767842|1590;2|1239|91061|186826|1300|1301;2|1239|186801|3085636|186803|572511|1532;2|1239|186801|186802|216572|1535,Complete,Claregrieve1
bsdb:109/1/1,Study 109,case-control,27229737,10.1038/srep26752,NA,"Mack I, Cuntz U, Grämer C, Niedermaier S, Pohl C, Schwiertz A, Zimmermann K, Zipfel S, Enck P , Penders J","Weight gain in anorexia nervosa does not ameliorate the faecal microbiota, branched chain fatty acid profiles, and gastrointestinal complaints",Scientific reports,2016,NA,Experiment 1,Germany,Homo sapiens,Feces,UBERON:0001988,Anorexia nervosa,EFO:0004215,normal weight participants,anorexia patients before weight gain,NA,55,55,8 weeks,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.15,TRUE,NA,NA,"age,sex",NA,unchanged,unchanged,NA,NA,NA,Signature 1,figure 3,10 January 2021,Fatima Zohra,"Lwaldron,WikiWorks",gut microbiota of anorexia patients before and after weight gain compared to healthy controls,increased,"k__Bacteria|p__Actinomycetota,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Anaerostipes,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Anaerotruncus,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium,k__Bacteria|p__Verrucomicrobiota,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Clostridium",2|201174;2|1239|186801|3085636|186803|207244;2|1239|186801|186802|216572|244127;2|201174|1760|85004|31953|1678;2|74201;2|1239|186801|186802|31979|1485,Complete,Lwaldron
bsdb:109/1/2,Study 109,case-control,27229737,10.1038/srep26752,NA,"Mack I, Cuntz U, Grämer C, Niedermaier S, Pohl C, Schwiertz A, Zimmermann K, Zipfel S, Enck P , Penders J","Weight gain in anorexia nervosa does not ameliorate the faecal microbiota, branched chain fatty acid profiles, and gastrointestinal complaints",Scientific reports,2016,NA,Experiment 1,Germany,Homo sapiens,Feces,UBERON:0001988,Anorexia nervosa,EFO:0004215,normal weight participants,anorexia patients before weight gain,NA,55,55,8 weeks,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.15,TRUE,NA,NA,"age,sex",NA,unchanged,unchanged,NA,NA,NA,Signature 2,figure 3,10 January 2021,Fatima Zohra,WikiWorks,gut microbiota of anorexia patients before and after weight gain compared to healthy controls,decreased,"k__Bacteria|p__Bacteroidota,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|g__Gemmiger,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Roseburia",2|976;2|1239|186801|186802|204475;2|1239|186801|3085636|186803|841,Complete,Lwaldron
bsdb:109/2/1,Study 109,case-control,27229737,10.1038/srep26752,NA,"Mack I, Cuntz U, Grämer C, Niedermaier S, Pohl C, Schwiertz A, Zimmermann K, Zipfel S, Enck P , Penders J","Weight gain in anorexia nervosa does not ameliorate the faecal microbiota, branched chain fatty acid profiles, and gastrointestinal complaints",Scientific reports,2016,NA,Experiment 2,Germany,Homo sapiens,Feces,UBERON:0001988,Anorexia nervosa,EFO:0004215,HC,anorexia patients after weight gain,NA,55,44,8 weeks,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.15,TRUE,NA,NA,"age,sex",NA,increased,unchanged,NA,NA,NA,Signature 1,figure 3,10 January 2021,Fatima Zohra,"Lwaldron,WikiWorks",gut microbiota of anorexia patients before and after weight gain compared to healthy controls,increased,"k__Bacteria|p__Actinomycetota,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Anaerostipes,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium,k__Bacteria|p__Bacillota,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Lactococcus,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Pseudoflavonifractor,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Ruminococcus,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Sporobacter,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Clostridium",2|201174;2|1239|186801|3085636|186803|207244;2|201174|1760|85004|31953|1678;2|1239;2|1239|91061|186826|33958|1578;2|1239|91061|186826|1300|1357;2|1239|186801|186802|216572|1017280;2|1239|186801|186802|216572|1263;2|1239|186801|186802|216572|44748;2|1239|186801|186802|31979|1485,Complete,Lwaldron
bsdb:109/2/2,Study 109,case-control,27229737,10.1038/srep26752,NA,"Mack I, Cuntz U, Grämer C, Niedermaier S, Pohl C, Schwiertz A, Zimmermann K, Zipfel S, Enck P , Penders J","Weight gain in anorexia nervosa does not ameliorate the faecal microbiota, branched chain fatty acid profiles, and gastrointestinal complaints",Scientific reports,2016,NA,Experiment 2,Germany,Homo sapiens,Feces,UBERON:0001988,Anorexia nervosa,EFO:0004215,HC,anorexia patients after weight gain,NA,55,44,8 weeks,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.15,TRUE,NA,NA,"age,sex",NA,increased,unchanged,NA,NA,NA,Signature 2,figure 3,10 January 2021,Fatima Zohra,"Lwaldron,WikiWorks",gut microbiota of anorexia patients before and after weight gain compared to healthy controls,decreased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides,k__Bacteria|p__Bacteroidota,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Clostridium",2|976|200643|171549|815|816;2|976;2|1239|186801|186802|31979|1485,Complete,Lwaldron
bsdb:110/1/1,Study 110,time series / longitudinal observational,29859859,10.1016/j.schres.2018.05.017,NA,"Yuan X, Zhang P, Wang Y, Liu Y, Li X, Kumar BU, Hei G, Lv L, Huang XF, Fan X , Song X","Changes in metabolism and microbiota after 24-week risperidone treatment in drug naïve, normal weight patients with first episode schizophrenia",Schizophrenia research,2018,"Metabolism, Microbiota, Schizophrenia",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Schizophrenia,MONDO:0005090,healthy controls,schizophrenia,Drug-naive first-episode schizophrenia patients,41,41,1 month,16S,NA,RT-qPCR,T-Test,0.05,FALSE,NA,NA,"age,sex,smoking status",NA,NA,NA,NA,NA,NA,Signature 1,table 2,10 January 2021,Fatima Zohra,WikiWorks,comparison of fecal bacteria between schizophrenic patients and controls,decreased,"k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Escherichia|s__Escherichia coli,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus",2|201174|1760|85004|31953|1678;2|1224|1236|91347|543|561|562;2|1239|91061|186826|33958|1578,Complete,Atrayees
bsdb:110/1/2,Study 110,time series / longitudinal observational,29859859,10.1016/j.schres.2018.05.017,NA,"Yuan X, Zhang P, Wang Y, Liu Y, Li X, Kumar BU, Hei G, Lv L, Huang XF, Fan X , Song X","Changes in metabolism and microbiota after 24-week risperidone treatment in drug naïve, normal weight patients with first episode schizophrenia",Schizophrenia research,2018,"Metabolism, Microbiota, Schizophrenia",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Schizophrenia,MONDO:0005090,healthy controls,schizophrenia,Drug-naive first-episode schizophrenia patients,41,41,1 month,16S,NA,RT-qPCR,T-Test,0.05,FALSE,NA,NA,"age,sex,smoking status",NA,NA,NA,NA,NA,NA,Signature 2,table 2,27 June 2023,Atrayees,Atrayees,comparison of fecal bacteria between schizophrenic patients and controls,decreased,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Blautia|s__Blautia coccoides,2|1239|186801|3085636|186803|572511|1532,Complete,Atrayees
bsdb:111/1/1,Study 111,"cross-sectional observational, not case-control",29580894,10.1016/j.bbr.2018.03.036,NA,"Jiang HY, Zhou YY, Zhou GL, Li YC, Yuan J, Li XH , Ruan B",Gut microbiota profiles in treatment-naïve children with attention deficit hyperactivity disorder,Behavioural brain research,2018,"Gut-brain axis, Hyperactivity, Inattention, Microbiome",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Attention deficit hyperactivity disorder,EFO:0003888,healthy control,ADHD,Treatment-Naive Children diagnosed with ADHD,32,51,2 months,16S,34,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,Signature 1,"Figure 1d , Figure S8",10 January 2021,Fatima Zohra,"WikiWorks,Peace Sandy","(d) LEfSe identified the most differentially abundant taxons between HC and ADHD groups at genus level. Taxonomic cladogram obtained from LEfSe analysis of 16S sequences (relative
abundance > 0.5%). HC-enriched taxa are indicated with a positive LDA score (green), and taxa enriched in ADHD have a negative score (red). Only taxa meeting an
LDA significant threshold > 2 are shown 

LEfSe identified the most differentially abundant taxons between HC and ADHD groups at family level. Taxonomic cladogram obtained from LEfSe analysis of 16S sequences (relative abundance >0.5%). (Red) ADHD taxa; (Green) taxa enriched in HCs. HC-enriched taxa are indicated with a positive LDA score (green), and taxa enriched in ADHD have a negative score (red). Only taxa meeting an LDA significant threshold >2 are shown.",increased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Moraxellales|f__Moraxellaceae|g__Acinetobacter,k__Bacteria|p__Bacillota|c__Clostridia|o__Christensenellales|f__Christensenellaceae|g__Christensenella,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Coprobacillaceae|g__Coprobacillus,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae|g__Faecalitalea,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Peptococcaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Peptostreptococcaceae,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales|f__Coriobacteriaceae|g__Senegalimassilia,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Lysobacterales|f__Lysobacteraceae|g__Stenotrophomonas,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Peptostreptococcaceae|g__Terrisporobacter,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Moraxellales|f__Moraxellaceae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Lysobacterales|f__Lysobacteraceae",2|1224|1236|2887326|468|469;2|1239|186801|3082768|990719|990721;2|1239|526524|526525|2810280|100883;2|1239|526524|526525|128827|1573534;2|1239|186801|186802|186807;2|1239|186801|3082720|186804;2|201174|84998|84999|84107|1473205;2|1224|1236|135614|32033|40323;2|1239|186801|3082720|186804|1505652;2|1224|1236|2887326|468;2|1224|1236|135614|32033,Complete,Peace Sandy
bsdb:111/1/2,Study 111,"cross-sectional observational, not case-control",29580894,10.1016/j.bbr.2018.03.036,NA,"Jiang HY, Zhou YY, Zhou GL, Li YC, Yuan J, Li XH , Ruan B",Gut microbiota profiles in treatment-naïve children with attention deficit hyperactivity disorder,Behavioural brain research,2018,"Gut-brain axis, Hyperactivity, Inattention, Microbiome",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Attention deficit hyperactivity disorder,EFO:0003888,healthy control,ADHD,Treatment-Naive Children diagnosed with ADHD,32,51,2 months,16S,34,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,Signature 2,"Figure1, Figure S8",10 January 2021,Fatima Zohra,"WikiWorks,Peace Sandy","d) LEfSe identified the most differentially abundant taxons between HC and ADHD groups at genus level. Taxonomic cladogram obtained from LEfSe analysis of 16S sequences (relative abundance > 0.5%). HC-enriched taxa are indicated with a positive LDA score (green), and taxa enriched in ADHD have a negative score (red). Only taxa meeting an LDA significant threshold > 2 are shown

LEfSe identified the most differentially abundant taxons between HC and ADHD groups at family level. Taxonomic cladogram obtained from LEfSe analysis of 16S sequences (relative abundance >0.5%). (Red) ADHD taxa; (Green) taxa enriched in HCs. HC-enriched taxa are indicated with a positive LDA score (green), and taxa enriched in ADHD have a negative score (red). Only taxa meeting an LDA significant threshold >2 are shown.",decreased,"k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Alcaligenaceae,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Dialister,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Lachnoclostridium,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Faecalibacterium,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Lachnospira|s__Lachnospira eligens,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Sutterellaceae|g__Sutterella,k__Bacteria|p__Bacillota|c__Negativicutes|o__Acidaminococcales|f__Acidaminococcaceae|g__Acidaminococcus,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Ruminiclostridium,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Tyzzerella",2|1224|28216|80840|506;2|1239|909932|1843489|31977|39948;2|1239|186801|3085636|186803|1506553;2|1239|186801|186802|216572|216851;2|1239|186801|3085636|186803|28050|39485;2|1224|28216|80840|995019|40544;2|1239|909932|1843488|909930|904;2|1239|186801|186802|216572|1508657;2|1239|186801|3085636|186803|1506577,Complete,Peace Sandy
bsdb:112/1/1,Study 112,case-control,30001426,10.1371/journal.pone.0200728,NA,"Prehn-Kristensen A, Zimmermann A, Tittmann L, Lieb W, Schreiber S, Baving L , Fischer A",Reduced microbiome alpha diversity in young patients with ADHD,PloS one,2018,NA,Experiment 1,Germany,Homo sapiens,Feces,UBERON:0001988,Attention deficit hyperactivity disorder,EFO:0003888,controls,ADHD males,NA,17,14,NA,16S,12,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,decreased,unchanged,NA,NA,NA,Signature 1,figure 3,10 January 2021,Fatima Zohra,WikiWorks,Differential abundance of taxa in male ADHD and healthy controls,increased,"k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Neisseriaceae,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Neisseriaceae|g__Neisseria,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides",2|1224|28216|206351|481;2|1224|28216|206351|481|482;2|976|200643|171549|815|816,Complete,NA
bsdb:112/1/2,Study 112,case-control,30001426,10.1371/journal.pone.0200728,NA,"Prehn-Kristensen A, Zimmermann A, Tittmann L, Lieb W, Schreiber S, Baving L , Fischer A",Reduced microbiome alpha diversity in young patients with ADHD,PloS one,2018,NA,Experiment 1,Germany,Homo sapiens,Feces,UBERON:0001988,Attention deficit hyperactivity disorder,EFO:0003888,controls,ADHD males,NA,17,14,NA,16S,12,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,decreased,unchanged,NA,NA,NA,Signature 2,figure 3,10 January 2021,Fatima Zohra,WikiWorks,Differential abundance of taxa in male ADHD and healthy controls,decreased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Christensenellales|f__Christensenellaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Tannerellaceae|g__Parabacteroides",2|976|200643|171549|171552;2|1239|186801|3082768|424536;2|976|200643|171549|171551;2|976|200643|171549|171552|838;2|976|200643|171549|2005525|375288,Complete,NA
bsdb:113/1/1,Study 113,"cross-sectional observational, not case-control",27288567,10.1016/j.jad.2016.05.038,NA,"Aizawa E, Tsuji H, Asahara T, Takahashi T, Teraishi T, Yoshida S, Ota M, Koga N, Hattori K , Kunugi H",Possible association of Bifidobacterium and Lactobacillus in the gut microbiota of patients with major depressive disorder,Journal of affective disorders,2016,"Bifidobacterium, Distress, Gut microbiota, Irritable bowel syndrome, Lactobacillus, Major depressive disorder",Experiment 1,Japan,Homo sapiens,Feces,UBERON:0001988,Unipolar depression,EFO:0003761,controls,MDD,NA,57,43,NA,16S,NA,RT-qPCR,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Figure 1,10 January 2021,Fatima Zohra,WikiWorks,Differential abundance of gut microbiota of patients with major depressive disorder,decreased,"k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Amylolactobacillus|s__Amylolactobacillus amylophilus",2|201174|1760|85004|31953|1678;2|1239|91061|186826|33958|2767876|1603,Complete,NA
bsdb:114/1/1,Study 114,case-control,30584306,10.2147/NDT.S188340,NA,"Huang Y, Shi X, Li Z, Shen Y, Shi X, Wang L, Li G, Yuan Y, Wang J, Zhang Y, Zhao L, Zhang M, Kang Y , Liang Y",Possible association of Firmicutes in the gut microbiota of patients with major depressive disorder,Neuropsychiatric disease and treatment,2018,"Firmicutes, brain–gut axis, depression, gut microbiota, short-chain fatty acids",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Unipolar depression,EFO:0003761,controls,MDD,NA,27,27,6 months,16S,34,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,decreased,decreased,NA,NA,NA,Signature 1,"Fig 1, fig 3b, figure 4",10 January 2021,Fatima Zohra,WikiWorks,Differential abundance of firmicutes in patients with major depressive disorder,increased,"k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Oxalobacteraceae|g__Oxalobacter,k__Bacteria|p__Bacillota|c__Tissierellia|o__Tissierellales|f__Peptoniphilaceae|g__Parvimonas,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae|g__Bulleidia,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pseudomonadales|f__Pseudomonadaceae|g__Pseudomonas,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Peptostreptococcaceae|g__Peptostreptococcus,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Gemellaceae|g__Gemella",2|1224|28216|80840|75682|846;2|1239|1737404|1737405|1570339|543311;2|1239|526524|526525|128827|118747;2|1224|1236|72274|135621|286;2|1239|186801|3082720|186804|1257;2|1239|91061|1385|539738|1378,Complete,Atrayees
bsdb:114/1/2,Study 114,case-control,30584306,10.2147/NDT.S188340,NA,"Huang Y, Shi X, Li Z, Shen Y, Shi X, Wang L, Li G, Yuan Y, Wang J, Zhang Y, Zhao L, Zhang M, Kang Y , Liang Y",Possible association of Firmicutes in the gut microbiota of patients with major depressive disorder,Neuropsychiatric disease and treatment,2018,"Firmicutes, brain–gut axis, depression, gut microbiota, short-chain fatty acids",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Unipolar depression,EFO:0003761,controls,MDD,NA,27,27,6 months,16S,34,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,decreased,decreased,NA,NA,NA,Signature 2,"Fig 1, fig 3b, figure 4",10 January 2021,Fatima Zohra,WikiWorks,Differential abundance of firmicutes in patients with major depressive disorder,decreased,"k__Bacteria|p__Bacillota,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Faecalibacterium,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Coprococcus,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Blautia,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Dorea",2|1239;2|1239|186801|3085636|186803;2|1239|186801|186802|216572|216851;2|1239|186801|186802|541000;2|1239|186801|3085636|186803|33042;2|1239|186801|3085636|186803|572511;2|1239|186801|186802|31979;2|1239|186801|3085636|186803|189330,Complete,Atrayees
bsdb:115/1/1,Study 115,case-control,30927646,10.1016/j.jpsychires.2019.03.017,NA,"Rong H, Xie XH, Zhao J, Lai WT, Wang MB, Xu D, Liu YH, Guo YY, Xu SX, Deng WF, Yang QF, Xiao L, Zhang YL, He FS, Wang S , Liu TB","Similarly in depression, nuances of gut microbiota: Evidences from a shotgun metagenomics sequencing study on major depressive disorder versus bipolar disorder with current major depressive episode patients",Journal of psychiatric research,2019,"Bipolar disorder, Diversity, G(m) coefficient, Gut microbiota, Major depressive disorder, Shotgun metagenomics sequencing",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Unipolar depression,EFO:0003761,controls,MDD,NA,30,31,1 month,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,decreased,NA,unchanged,NA,Signature 1,"Figure 1, Table 2, figure 3",10 January 2021,Fatima Zohra,WikiWorks,Comparison of bacterial abundance of major depressive disorder and healthy controls,increased,"k__Bacteria|p__Bacillota,k__Bacteria|p__Actinomycetota,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Clostridium,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Oscillibacter,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus,k__Bacteria|p__Bacillota|c__Negativicutes|o__Selenomonadales|f__Selenomonadaceae|g__Selenomonas,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Megasphaera,k__Bacteria|p__Bacillota|c__Negativicutes|o__Acidaminococcales|f__Acidaminococcaceae|g__Acidaminococcus,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Escherichia|s__Escherichia coli,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Megasphaera|s__Megasphaera elsdenii,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Oscillibacter|s__Oscillibacter valericigenes,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium|s__Bifidobacterium adolescentis,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella|s__Prevotella melaninogenica,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium|s__Bifidobacterium dentium",2|1239;2|201174;2|1239|186801|186802|31979|1485;2|201174|1760|85004|31953|1678;2|1239|186801|186802|216572|459786;2|1239|91061|186826|1300|1301;2|1239|909932|909929|1843491|970;2|1239|909932|1843489|31977|906;2|1239|909932|1843488|909930|904;2|1224|1236|91347|543;2|976|200643|171549|171552|838;2|1224|1236|91347|543|561|562;2|1239|909932|1843489|31977|906|907;2|1239|186801|186802|216572|459786|351091;2|201174|1760|85004|31953|1678|1680;2|976|200643|171549|171552|838|28132;2|201174|1760|85004|31953|1678|1689,Complete,NA
bsdb:115/1/2,Study 115,case-control,30927646,10.1016/j.jpsychires.2019.03.017,NA,"Rong H, Xie XH, Zhao J, Lai WT, Wang MB, Xu D, Liu YH, Guo YY, Xu SX, Deng WF, Yang QF, Xiao L, Zhang YL, He FS, Wang S , Liu TB","Similarly in depression, nuances of gut microbiota: Evidences from a shotgun metagenomics sequencing study on major depressive disorder versus bipolar disorder with current major depressive episode patients",Journal of psychiatric research,2019,"Bipolar disorder, Diversity, G(m) coefficient, Gut microbiota, Major depressive disorder, Shotgun metagenomics sequencing",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Unipolar depression,EFO:0003761,controls,MDD,NA,30,31,1 month,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,decreased,NA,unchanged,NA,Signature 2,"Figure 1, Table 2, figure 3",10 January 2021,Fatima Zohra,WikiWorks,Comparison of bacterial abundance of major depressive disorder and healthy controls,decreased,"k__Bacteria|p__Bacteroidota,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Odoribacteraceae|g__Odoribacter,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Tannerellaceae|g__Tannerella,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Haemophilus|s__Haemophilus parainfluenzae",2|976;2|976|200643|171549|815|816;2|976|200643|171549|1853231|283168;2|976|200643|171549|2005525|195950;2|1224|1236|135625|712|724|729,Complete,NA
bsdb:115/2/1,Study 115,case-control,30927646,10.1016/j.jpsychires.2019.03.017,NA,"Rong H, Xie XH, Zhao J, Lai WT, Wang MB, Xu D, Liu YH, Guo YY, Xu SX, Deng WF, Yang QF, Xiao L, Zhang YL, He FS, Wang S , Liu TB","Similarly in depression, nuances of gut microbiota: Evidences from a shotgun metagenomics sequencing study on major depressive disorder versus bipolar disorder with current major depressive episode patients",Journal of psychiatric research,2019,"Bipolar disorder, Diversity, G(m) coefficient, Gut microbiota, Major depressive disorder, Shotgun metagenomics sequencing",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Bipolar disorder,MONDO:0004985,healthy controls,bipolar,NA,30,30,1 month,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,NA,unchanged,NA,Signature 1,"Figure 1, Table 2, figure 3",10 January 2021,Fatima Zohra,WikiWorks,Comparison of bacterial abundance of bipolar disorder with major depressive disorder and healthy controls,decreased,"k__Bacteria|p__Bacteroidota,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Odoribacteraceae|g__Odoribacter,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Tannerellaceae|g__Tannerella,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides|s__Bacteroides helcogenes",2|976;2|976|200643|171549|815|816;2|976|200643|171549|1853231|283168;2|976|200643|171549|2005525|195950;2|976|200643|171549|815|816|290053,Complete,NA
bsdb:116/1/1,Study 116,case-control,23433344,10.1186/1741-7015-11-46,NA,"Murri M, Leiva I, Gomez-Zumaquero JM, Tinahones FJ, Cardona F, Soriguer F , Queipo-Ortuño MI",Gut microbiota in children with type 1 diabetes differs from that in healthy children: a case-control study,BMC medicine,2013,NA,Experiment 1,Spain,Homo sapiens,Feces,UBERON:0001988,Type I diabetes mellitus,MONDO:0005147,healthy controls,children with type 1 diabetes,"Type 1 diabetes was diagnosed following the criteria of the American Diabetes Association and the appearance of at least two persistent, confirmed anti-islet autoantibodies (insulin autoantibodies, glutamic acid decarboxylase autoantibodies or tyrosine phosphatase autoantibodies)",16,16,3 months,16S,23,RT-qPCR,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,"age,breastfeeding duration,delivery procedure,race,sex",NA,NA,NA,NA,NA,NA,NA,Signature 1,Table 5 &6,10 January 2021,Yaseen Javaid,WikiWorks,Gut microbiota in children with type 1 diabetes differs from that in healthy children: a case-control study.,increased,"k__Bacteria|p__Bacteroidota,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Clostridium,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Veillonella",2|976;2|1239|186801|186802|31979|1485;2|976|200643|171549|815|816;2|1239|909932|1843489|31977|29465,Complete,Shaimaa Elsafoury
bsdb:116/1/2,Study 116,case-control,23433344,10.1186/1741-7015-11-46,NA,"Murri M, Leiva I, Gomez-Zumaquero JM, Tinahones FJ, Cardona F, Soriguer F , Queipo-Ortuño MI",Gut microbiota in children with type 1 diabetes differs from that in healthy children: a case-control study,BMC medicine,2013,NA,Experiment 1,Spain,Homo sapiens,Feces,UBERON:0001988,Type I diabetes mellitus,MONDO:0005147,healthy controls,children with type 1 diabetes,"Type 1 diabetes was diagnosed following the criteria of the American Diabetes Association and the appearance of at least two persistent, confirmed anti-islet autoantibodies (insulin autoantibodies, glutamic acid decarboxylase autoantibodies or tyrosine phosphatase autoantibodies)",16,16,3 months,16S,23,RT-qPCR,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,"age,breastfeeding duration,delivery procedure,race,sex",NA,NA,NA,NA,NA,NA,NA,Signature 2,Table 5 &6,10 January 2021,Yaseen Javaid,WikiWorks,Gut microbiota in children with type 1 diabetes differs from that in healthy children: a case-control study.,decreased,"k__Bacteria|p__Actinomycetota,k__Bacteria|p__Bacillota,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Blautia|s__Blautia coccoides,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Agathobacter|s__Agathobacter rectalis,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus",2|201174;2|1239;2|976|200643|171549|171552|838;2|1239|186801|3085636|186803|572511|1532;2|1239|186801|3085636|186803|1766253|39491;2|201174|1760|85004|31953|1678;2|1239|91061|186826|33958|1578,Complete,Shaimaa Elsafoury
bsdb:117/1/1,Study 117,case-control,26151645,10.1038/ismej.2015.99,NA,"de Steenhuijsen Piters WA, Huijskens EG, Wyllie AL, Biesbroek G, van den Bergh MR, Veenhoven RH, Wang X, Trzciński K, Bonten MJ, Rossen JW, Sanders EA , Bogaert D",Dysbiosis of upper respiratory tract microbiota in elderly pneumonia patients,The ISME journal,2016,NA,Experiment 1,Netherlands,Homo sapiens,Mucosa of oropharynx,UBERON:0005023,Pneumonia,EFO:0003106,elderly controls,elderly pneumonia patients,patients >= 60 years of age with pneumonia,91,100,3 months,16S,567,Roche454,T-Test,0.05,TRUE,NA,NA,"age,comorbidity,smoking behavior",NA,increased,NA,NA,NA,decreased,Signature 1,Figure 2,10 January 2021,Rimsha Azhar,"Claregrieve1,WikiWorks",Differential microbial abundance between elderly controls and elderly pneumonia patients,increased,"k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micrococcales|f__Micrococcaceae|g__Rothia,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus|s__Streptococcus pseudopneumoniae",2|1239|91061|186826|33958|1578;2|201174|1760|85006|1268|32207;2|1239|91061|186826|1300|1301|257758,Complete,Claregrieve1
bsdb:117/1/2,Study 117,case-control,26151645,10.1038/ismej.2015.99,NA,"de Steenhuijsen Piters WA, Huijskens EG, Wyllie AL, Biesbroek G, van den Bergh MR, Veenhoven RH, Wang X, Trzciński K, Bonten MJ, Rossen JW, Sanders EA , Bogaert D",Dysbiosis of upper respiratory tract microbiota in elderly pneumonia patients,The ISME journal,2016,NA,Experiment 1,Netherlands,Homo sapiens,Mucosa of oropharynx,UBERON:0005023,Pneumonia,EFO:0003106,elderly controls,elderly pneumonia patients,patients >= 60 years of age with pneumonia,91,100,3 months,16S,567,Roche454,T-Test,0.05,TRUE,NA,NA,"age,comorbidity,smoking behavior",NA,increased,NA,NA,NA,decreased,Signature 2,Figure 2,10 January 2021,Rimsha Azhar,"Claregrieve1,Merit,WikiWorks",Differential microbial abundance between elderly controls and elderly pneumonia patients,decreased,"k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Leptotrichiaceae|g__Leptotrichia,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Parascardovia,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella|s__Prevotella melaninogenica,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Veillonella|s__Veillonella dispar",2|32066|203490|203491|1129771|32067;2|201174|1760|85004|31953|196082;2|976|200643|171549|171552|838|28132;2|1239|909932|1843489|31977|29465|39778,Complete,Claregrieve1
bsdb:117/2/1,Study 117,case-control,26151645,10.1038/ismej.2015.99,NA,"de Steenhuijsen Piters WA, Huijskens EG, Wyllie AL, Biesbroek G, van den Bergh MR, Veenhoven RH, Wang X, Trzciński K, Bonten MJ, Rossen JW, Sanders EA , Bogaert D",Dysbiosis of upper respiratory tract microbiota in elderly pneumonia patients,The ISME journal,2016,NA,Experiment 2,Netherlands,Homo sapiens,Mucosa of oropharynx,UBERON:0005023,Pneumonia,EFO:0003106,adult controls,adult pneumonia patients,patients <60 years of age with pneumonia,187,27,3 months,16S,567,Roche454,T-Test,0.05,TRUE,NA,NA,"age,comorbidity,smoking behavior",NA,unchanged,NA,NA,NA,NA,Signature 1,Figure 2,10 January 2021,Rimsha Azhar,"Claregrieve1,WikiWorks",Differential microbial abundance between healthy adult controls and pneumonia patients,increased,"k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micrococcales|f__Micrococcaceae|g__Rothia,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus|s__Streptococcus pseudopneumoniae",2|1239|91061|186826|33958|1578;2|201174|1760|85006|1268|32207;2|1239|91061|186826|1300|1301|257758,Complete,Claregrieve1
bsdb:117/2/2,Study 117,case-control,26151645,10.1038/ismej.2015.99,NA,"de Steenhuijsen Piters WA, Huijskens EG, Wyllie AL, Biesbroek G, van den Bergh MR, Veenhoven RH, Wang X, Trzciński K, Bonten MJ, Rossen JW, Sanders EA , Bogaert D",Dysbiosis of upper respiratory tract microbiota in elderly pneumonia patients,The ISME journal,2016,NA,Experiment 2,Netherlands,Homo sapiens,Mucosa of oropharynx,UBERON:0005023,Pneumonia,EFO:0003106,adult controls,adult pneumonia patients,patients <60 years of age with pneumonia,187,27,3 months,16S,567,Roche454,T-Test,0.05,TRUE,NA,NA,"age,comorbidity,smoking behavior",NA,unchanged,NA,NA,NA,NA,Signature 2,Figure 2,10 January 2021,Rimsha Azhar,"Claregrieve1,WikiWorks",Differential microbial abundance between healthy adult controls and pneumonia patients,decreased,"k__Bacteria|p__Bacillota|c__Bacilli,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Haemophilus,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Leptotrichiaceae|g__Leptotrichia,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Neisseriaceae|g__Neisseria,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella|s__Prevotella melaninogenica,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Veillonella|s__Veillonella dispar",2|1239|91061;2|1224|1236|135625|712|724;2|32066|203490|203491|1129771|32067;2|1224|28216|206351|481|482;2|976|200643|171549|171552|838|28132;2|1239|909932|1843489|31977|29465|39778,Complete,Claregrieve1
bsdb:118/1/1,Study 118,"cross-sectional observational, not case-control",30972048,10.3389/fmicb.2019.00598,NA,"Liu Y, Qin S, Song Y, Feng Y, Lv N, Xue Y, Liu F, Wang S, Zhu B, Ma J , Yang H",The Perturbation of Infant Gut Microbiota Caused by Cesarean Delivery Is Partially Restored by Exclusive Breastfeeding,Frontiers in microbiology,2019,"breastfeeding, delivery mode, early life, gut microbiome, infant, postnatal antibiotic exposure",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Cesarean section,EFO:0009636,vaginal born children,cesarean born,cesarean delivery,60,34,NA,16S,34,Illumina,LEfSe,0.05,FALSE,3,NA,NA,NA,unchanged,NA,NA,NA,NA,Signature 1,Figure 1C and Text,10 January 2021,Yaseen Javaid,"Merit,WikiWorks",The Perturbation of Infant Gut Microbiota Caused by Cesarean Delivery Is Partially Restored by Exclusive Breastfeeding,increased,"k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Amylolactobacillus|s__Amylolactobacillus amylophilus,k__Bacteria|p__Bacillota,k__Bacteria|p__Bacillota|c__Clostridia,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|s__Clostridiales bacterium,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus,k__Bacteria|p__Bacillota|c__Negativicutes,k__Bacteria|p__Bacillota|c__Negativicutes|o__Selenomonadales,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales",2|1239|91061|186826|33958|2767876|1603;2|1239;2|1239|186801;2|1239|186801|186802|31979;2|1239|186801|186802|1898207;2|1239|186801|186802;2|1239|91061|186826|33958;2|1239|91061|186826|33958|1578;2|1239|909932;2|1239|909932|909929;2|1239|909932|1843489,Complete,Rimsha Azhar
bsdb:118/1/2,Study 118,"cross-sectional observational, not case-control",30972048,10.3389/fmicb.2019.00598,NA,"Liu Y, Qin S, Song Y, Feng Y, Lv N, Xue Y, Liu F, Wang S, Zhu B, Ma J , Yang H",The Perturbation of Infant Gut Microbiota Caused by Cesarean Delivery Is Partially Restored by Exclusive Breastfeeding,Frontiers in microbiology,2019,"breastfeeding, delivery mode, early life, gut microbiome, infant, postnatal antibiotic exposure",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Cesarean section,EFO:0009636,vaginal born children,cesarean born,cesarean delivery,60,34,NA,16S,34,Illumina,LEfSe,0.05,FALSE,3,NA,NA,NA,unchanged,NA,NA,NA,NA,Signature 2,Figure 1C and Text,10 January 2021,Yaseen Javaid,WikiWorks,The Perturbation of Infant Gut Microbiota Caused by Cesarean Delivery Is Partially Restored by Exclusive Breastfeeding,decreased,"k__Bacteria|p__Actinomycetota,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium",2|201174;2|201174|1760|85004;2|201174|1760|85004|31953;2|201174|1760|85004|31953|1678,Complete,Rimsha Azhar
bsdb:118/2/1,Study 118,"cross-sectional observational, not case-control",30972048,10.3389/fmicb.2019.00598,NA,"Liu Y, Qin S, Song Y, Feng Y, Lv N, Xue Y, Liu F, Wang S, Zhu B, Ma J , Yang H",The Perturbation of Infant Gut Microbiota Caused by Cesarean Delivery Is Partially Restored by Exclusive Breastfeeding,Frontiers in microbiology,2019,"breastfeeding, delivery mode, early life, gut microbiome, infant, postnatal antibiotic exposure",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Cesarean section,EFO:0009636,cesarean born and breastfed,cesarean born and mixed-fed,cesarean delivery and mixed-fed,24,10,NA,16S,34,Illumina,LEfSe,0.05,FALSE,3,NA,NA,NA,unchanged,NA,NA,NA,NA,Signature 1,Figure 3d and Text,10 January 2021,Rimsha Azhar,WikiWorks,Enriched taxa of different level from cesarean born breastfed infants and from cesarean born mixed-fed infants,increased,"k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Veillonella,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae,k__Bacteria|p__Bacillota|c__Negativicutes,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Enterococcaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Enterococcaceae|g__Enterococcus",2|1239|909932|1843489|31977|29465;2|1239|909932|1843489|31977;2|1239|909932;2|1239|91061|186826|81852;2|1239|91061|186826|81852|1350,Complete,Rimsha Azhar
bsdb:118/2/2,Study 118,"cross-sectional observational, not case-control",30972048,10.3389/fmicb.2019.00598,NA,"Liu Y, Qin S, Song Y, Feng Y, Lv N, Xue Y, Liu F, Wang S, Zhu B, Ma J , Yang H",The Perturbation of Infant Gut Microbiota Caused by Cesarean Delivery Is Partially Restored by Exclusive Breastfeeding,Frontiers in microbiology,2019,"breastfeeding, delivery mode, early life, gut microbiome, infant, postnatal antibiotic exposure",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Cesarean section,EFO:0009636,cesarean born and breastfed,cesarean born and mixed-fed,cesarean delivery and mixed-fed,24,10,NA,16S,34,Illumina,LEfSe,0.05,FALSE,3,NA,NA,NA,unchanged,NA,NA,NA,NA,Signature 2,Figure 3d and Text,10 January 2021,Rimsha Azhar,WikiWorks,Enriched taxa of different level from cesarean born breastfed infants and from cesarean born mixed-fed infants,decreased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Tyzzerella,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Faecalibacterium,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae",2|1239|186801|3085636|186803|1506577;2|976|200643|171549|171552|838;2|1239|186801|186802|216572|216851;2|976|200643|171549|171552,Complete,Rimsha Azhar
bsdb:119/1/1,Study 119,"cross-sectional observational, not case-control",29596446,10.1371/journal.pone.0194171,NA,"Barengolts E, Green SJ, Eisenberg Y, Akbar A, Reddivari B, Layden BT, Dugas L , Chlipala G","Gut microbiota varies by opioid use, circulating leptin and oxytocin in African American men with diabetes and high burden of chronic disease",PloS one,2018,NA,Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Type II diabetes mellitus,MONDO:0005148,Metaformin negative among Opoid negative,Metaformin positive,"Opioid use was defined as “Yes” if during review of medical record two parameters were present: 1) the participant was under care of psychiatric care professional, and 2) psychiatric care professional established the diagnosis of opioid use disorder as official diagnosis in medical record",34,21,NA,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Table 4,10 January 2021,Yaseen Javaid,WikiWorks,the interactive influence of metformin and opioids on gut microbiota in the subgroup with diabetes.,increased,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium,2|201174|1760|85004|31953|1678,Complete,Shaimaa Elsafoury
bsdb:119/1/2,Study 119,"cross-sectional observational, not case-control",29596446,10.1371/journal.pone.0194171,NA,"Barengolts E, Green SJ, Eisenberg Y, Akbar A, Reddivari B, Layden BT, Dugas L , Chlipala G","Gut microbiota varies by opioid use, circulating leptin and oxytocin in African American men with diabetes and high burden of chronic disease",PloS one,2018,NA,Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Type II diabetes mellitus,MONDO:0005148,Metaformin negative among Opoid negative,Metaformin positive,"Opioid use was defined as “Yes” if during review of medical record two parameters were present: 1) the participant was under care of psychiatric care professional, and 2) psychiatric care professional established the diagnosis of opioid use disorder as official diagnosis in medical record",34,21,NA,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 2,Table 4,10 January 2021,Yaseen Javaid,WikiWorks,the interactive influence of metformin and opioids on gut microbiota in the subgroup with diabetes.,decreased,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides|s__Bacteroides caccae,2|976|200643|171549|815|816|47678,Complete,Shaimaa Elsafoury
bsdb:119/2/1,Study 119,"cross-sectional observational, not case-control",29596446,10.1371/journal.pone.0194171,NA,"Barengolts E, Green SJ, Eisenberg Y, Akbar A, Reddivari B, Layden BT, Dugas L , Chlipala G","Gut microbiota varies by opioid use, circulating leptin and oxytocin in African American men with diabetes and high burden of chronic disease",PloS one,2018,NA,Experiment 2,United States of America,Homo sapiens,Feces,UBERON:0001988,Type II diabetes mellitus,MONDO:0005148,Metaformin negative among Opoid positive,Metaformin positive,"Opioid use was defined as “Yes” if during review of medical record two parameters were present: 1) the participant was under care of psychiatric care professional, and 2) psychiatric care professional established the diagnosis of opioid use disorder as official diagnosis in medical record",35,9,NA,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Table 4,10 January 2021,Shaimaa Elsafoury,WikiWorks,the interactive influence of metformin and opioids on gut microbiota in the subgroup with diabetes.,increased,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,2|976|200643|171549|171552|838,Complete,Shaimaa Elsafoury
bsdb:119/2/2,Study 119,"cross-sectional observational, not case-control",29596446,10.1371/journal.pone.0194171,NA,"Barengolts E, Green SJ, Eisenberg Y, Akbar A, Reddivari B, Layden BT, Dugas L , Chlipala G","Gut microbiota varies by opioid use, circulating leptin and oxytocin in African American men with diabetes and high burden of chronic disease",PloS one,2018,NA,Experiment 2,United States of America,Homo sapiens,Feces,UBERON:0001988,Type II diabetes mellitus,MONDO:0005148,Metaformin negative among Opoid positive,Metaformin positive,"Opioid use was defined as “Yes” if during review of medical record two parameters were present: 1) the participant was under care of psychiatric care professional, and 2) psychiatric care professional established the diagnosis of opioid use disorder as official diagnosis in medical record",35,9,NA,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 2,Table 4,10 January 2021,Shaimaa Elsafoury,WikiWorks,the interactive influence of metformin and opioids on gut microbiota in the subgroup with diabetes.,decreased,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium,2|201174|1760|85004|31953|1678,Complete,Shaimaa Elsafoury
bsdb:119/3/1,Study 119,"cross-sectional observational, not case-control",29596446,10.1371/journal.pone.0194171,NA,"Barengolts E, Green SJ, Eisenberg Y, Akbar A, Reddivari B, Layden BT, Dugas L , Chlipala G","Gut microbiota varies by opioid use, circulating leptin and oxytocin in African American men with diabetes and high burden of chronic disease",PloS one,2018,NA,Experiment 3,United States of America,Homo sapiens,Feces,UBERON:0001988,Type II diabetes mellitus,MONDO:0005148,opoid negative among Metaformin negative,Opoid positive,"Opioid use was defined as “Yes” if during review of medical record two parameters were present: 1) the participant was under care of psychiatric care professional, and 2) psychiatric care professional established the diagnosis of opioid use disorder as official diagnosis in medical record",34,35,NA,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Table 4,10 January 2021,Shaimaa Elsafoury,WikiWorks,the interactive influence of metformin and opioids on gut microbiota in the subgroup with diabetes.,increased,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium,2|201174|1760|85004|31953|1678,Complete,Shaimaa Elsafoury
bsdb:119/3/2,Study 119,"cross-sectional observational, not case-control",29596446,10.1371/journal.pone.0194171,NA,"Barengolts E, Green SJ, Eisenberg Y, Akbar A, Reddivari B, Layden BT, Dugas L , Chlipala G","Gut microbiota varies by opioid use, circulating leptin and oxytocin in African American men with diabetes and high burden of chronic disease",PloS one,2018,NA,Experiment 3,United States of America,Homo sapiens,Feces,UBERON:0001988,Type II diabetes mellitus,MONDO:0005148,opoid negative among Metaformin negative,Opoid positive,"Opioid use was defined as “Yes” if during review of medical record two parameters were present: 1) the participant was under care of psychiatric care professional, and 2) psychiatric care professional established the diagnosis of opioid use disorder as official diagnosis in medical record",34,35,NA,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 2,Table 4,10 January 2021,Shaimaa Elsafoury,WikiWorks,the interactive influence of metformin and opioids on gut microbiota in the subgroup with diabetes.,decreased,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,2|976|200643|171549|171552|838,Complete,Shaimaa Elsafoury
bsdb:120/1/1,Study 120,laboratory experiment,23724144,10.1371/journal.pone.0065465,NA,"Queipo-Ortuño MI, Seoane LM, Murri M, Pardo M, Gomez-Zumaquero JM, Cardona F, Casanueva F , Tinahones FJ",Gut microbiota composition in male rat models under different nutritional status and physical activity and its association with serum leptin and ghrelin levels,PloS one,2013,NA,Experiment 1,Spain,Rattus norvegicus,Feces,UBERON:0001988,Physical activity,EFO:0003940,exercise group,Activity Based Anorexia group,"(a) Activity based anorexia (ABA) group: rats starved by restricting food access to 23 hours per day and confined to running wheels except during a 60 min meal per day, (b) Control ABA group: rats submitted to the same food restriction schedule as ABA with no wheel access exercise, (c) Exercise group: rats feed ad libitum with free access to the activity wheel and (d) Ad libitum group: rats feed ad libitum but without access to the activity wheel.",10,10,NA,16S,23,RT-qPCR,Kruskall-Wallis,0.05,TRUE,NA,body weight,NA,NA,NA,NA,NA,NA,NA,Signature 1,Table 3 and Text,10 January 2021,Yaseen Javaid,WikiWorks,Gut microbiota composition in male rat models under different nutritional status and physical activity and its association with serum leptin and ghrelin levels,increased,"k__Bacteria|p__Pseudomonadota,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Archaea|p__Euryarchaeota,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Clostridium,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Enterococcaceae|g__Enterococcus,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides",2|1224;2|976|200643|171549|171552|838;2157|28890;2|1239|186801|186802|31979|1485;2|1239|91061|186826|81852|1350;2|976|200643|171549|815|816,Complete,Shaimaa Elsafoury
bsdb:120/1/2,Study 120,laboratory experiment,23724144,10.1371/journal.pone.0065465,NA,"Queipo-Ortuño MI, Seoane LM, Murri M, Pardo M, Gomez-Zumaquero JM, Cardona F, Casanueva F , Tinahones FJ",Gut microbiota composition in male rat models under different nutritional status and physical activity and its association with serum leptin and ghrelin levels,PloS one,2013,NA,Experiment 1,Spain,Rattus norvegicus,Feces,UBERON:0001988,Physical activity,EFO:0003940,exercise group,Activity Based Anorexia group,"(a) Activity based anorexia (ABA) group: rats starved by restricting food access to 23 hours per day and confined to running wheels except during a 60 min meal per day, (b) Control ABA group: rats submitted to the same food restriction schedule as ABA with no wheel access exercise, (c) Exercise group: rats feed ad libitum with free access to the activity wheel and (d) Ad libitum group: rats feed ad libitum but without access to the activity wheel.",10,10,NA,16S,23,RT-qPCR,Kruskall-Wallis,0.05,TRUE,NA,body weight,NA,NA,NA,NA,NA,NA,NA,Signature 2,Table 3 and Text,10 January 2021,Yaseen Javaid,"Fatima,WikiWorks",Gut microbiota composition in male rat models under different nutritional status and physical activity and its association with serum leptin and ghrelin levels,decreased,"k__Bacteria|p__Actinomycetota,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides,k__Bacteria|p__Bacteroidota,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium,k__Bacteria|p__Bacillota,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Agathobacter|s__Agathobacter rectalis",2|201174;2|976|200643|171549|815|816;2|976;2|201174|1760|85004|31953|1678;2|1239;2|1239|91061|186826|33958|1578;2|1239|186801|3085636|186803|1766253|39491,Complete,Fatima
bsdb:120/2/1,Study 120,laboratory experiment,23724144,10.1371/journal.pone.0065465,NA,"Queipo-Ortuño MI, Seoane LM, Murri M, Pardo M, Gomez-Zumaquero JM, Cardona F, Casanueva F , Tinahones FJ",Gut microbiota composition in male rat models under different nutritional status and physical activity and its association with serum leptin and ghrelin levels,PloS one,2013,NA,Experiment 2,Spain,Rattus norvegicus,Feces,UBERON:0001988,Physical activity,EFO:0003940,exercise group,Ad libitum group,"(a) Activity based anorexia (ABA) group: rats starved by restricting food access to 23 hours per day and confined to running wheels except during a 60 min meal per day, (b) Control ABA group: rats submitted to the same food restriction schedule as ABA with no wheel access exercise, (c) Exercise group: rats feed ad libitum with free access to the activity wheel and (d) Ad libitum group: rats feed ad libitum but without access to the activity wheel.",10,10,NA,16S,23,RT-qPCR,Kruskall-Wallis,0.05,TRUE,NA,body weight,NA,NA,NA,NA,NA,NA,NA,Signature 1,Table 3 and Text,10 January 2021,Yaseen Javaid,WikiWorks,Gut microbiota composition in male rat models under different nutritional status and physical activity and its association with serum leptin and ghrelin levels,increased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Bacillota,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Enterococcaceae|g__Enterococcus,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Clostridium",2|976|200643|171549|815|816;2|976|200643|171549|171552|838;2|1239;2|1239|91061|186826|81852|1350;2|1239|186801|186802|31979|1485,Complete,Shaimaa Elsafoury
bsdb:120/2/2,Study 120,laboratory experiment,23724144,10.1371/journal.pone.0065465,NA,"Queipo-Ortuño MI, Seoane LM, Murri M, Pardo M, Gomez-Zumaquero JM, Cardona F, Casanueva F , Tinahones FJ",Gut microbiota composition in male rat models under different nutritional status and physical activity and its association with serum leptin and ghrelin levels,PloS one,2013,NA,Experiment 2,Spain,Rattus norvegicus,Feces,UBERON:0001988,Physical activity,EFO:0003940,exercise group,Ad libitum group,"(a) Activity based anorexia (ABA) group: rats starved by restricting food access to 23 hours per day and confined to running wheels except during a 60 min meal per day, (b) Control ABA group: rats submitted to the same food restriction schedule as ABA with no wheel access exercise, (c) Exercise group: rats feed ad libitum with free access to the activity wheel and (d) Ad libitum group: rats feed ad libitum but without access to the activity wheel.",10,10,NA,16S,23,RT-qPCR,Kruskall-Wallis,0.05,TRUE,NA,body weight,NA,NA,NA,NA,NA,NA,NA,Signature 2,Table 3 and Text,10 January 2021,Yaseen Javaid,"Fatima,WikiWorks",Gut microbiota composition in male rat models under different nutritional status and physical activity and its association with serum leptin and ghrelin levels,decreased,"k__Bacteria|p__Actinomycetota,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Agathobacter|s__Agathobacter rectalis",2|201174;2|201174|1760|85004|31953|1678;2|1239|91061|186826|33958|1578;2|1239|186801|3085636|186803|1766253|39491,Complete,Fatima
bsdb:121/1/1,Study 121,case-control,28808698,10.3290/j.cjdr.a38769,NA,"Deng K, Ouyang XY, Chu Y , Zhang Q",Subgingival Microbiome of Gingivitis in Chinese Undergraduates,The Chinese journal of dental research : the official journal of the Scientific Section of the Chinese Stomatological Association (CSA),2017,NA,Experiment 1,China,Homo sapiens,Subgingival dental plaque,UBERON:0016484,Gingivitis,MONDO:0002508,healthy controls,gingivitis,Patients with gingivitis,12,54,3 months,16S,34,Illumina,ANOSIM,0.05,FALSE,NA,NA,NA,NA,increased,increased,NA,NA,increased,Signature 1,figure 3 and text,10 January 2021,Marianthi Thomatos,"Lwaldron,WikiWorks,ChiomaBlessing",Subgingival Microbiome of Gingivitis in Chinese undergraduates VS healthy controls,increased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|s__Bacteroidales genomosp. P1,k__Bacteria|p__Bacteroidota,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae|g__Porphyromonas,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae|g__Porphyromonas|s__Porphyromonas endodontalis,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae|g__Porphyromonas|s__Porphyromonas gingivalis,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella|s__Prevotella intermedia,k__Bacteria|p__Spirochaetota,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Tannerellaceae|g__Tannerella,k__Bacteria|p__Spirochaetota|c__Spirochaetia|o__Spirochaetales|f__Treponemataceae|g__Treponema",2|976|200643|171549|241556;2|976;2|976|200643|171549|171551|836;2|976|200643|171549|171551|836|28124;2|976|200643|171549|171551|836|837;2|976|200643|171549|171552|838|28131;2|203691;2|976|200643|171549|2005525|195950;2|203691|203692|136|2845253|157,Complete,Shaimaa Elsafoury
bsdb:121/1/2,Study 121,case-control,28808698,10.3290/j.cjdr.a38769,NA,"Deng K, Ouyang XY, Chu Y , Zhang Q",Subgingival Microbiome of Gingivitis in Chinese Undergraduates,The Chinese journal of dental research : the official journal of the Scientific Section of the Chinese Stomatological Association (CSA),2017,NA,Experiment 1,China,Homo sapiens,Subgingival dental plaque,UBERON:0016484,Gingivitis,MONDO:0002508,healthy controls,gingivitis,Patients with gingivitis,12,54,3 months,16S,34,Illumina,ANOSIM,0.05,FALSE,NA,NA,NA,NA,increased,increased,NA,NA,increased,Signature 2,figure 3 and text,10 January 2021,Marianthi Thomatos,"WikiWorks,ChiomaBlessing",Subgingival Microbiome of Gingivitis in Chinese undergraduates VS healthy controls,decreased,k__Bacteria|p__Bacteroidota|c__Flavobacteriia|o__Flavobacteriales|f__Flavobacteriaceae|g__Capnocytophaga,2|976|117743|200644|49546|1016,Complete,Shaimaa Elsafoury
bsdb:122/1/1,Study 122,case-control,24421902,10.1371/journal.pone.0083744,NA,"Xuan C, Shamonki JM, Chung A, Dinome ML, Chung M, Sieling PA , Lee DJ",Microbial dysbiosis is associated with human breast cancer,PloS one,2014,NA,Experiment 1,United States of America,Homo sapiens,Breast,UBERON:0000310,Breast carcinoma,EFO:0000305,normal tissue,tumor tissue,NA,20,20,NA,16S,4,Illumina,T-Test,0.05,FALSE,NA,NA,age,NA,NA,NA,NA,NA,unchanged,Signature 1,Table S2 and Figure 1d,10 January 2021,Rimsha Azhar,"WikiWorks,Atrayees",OTUs enriched in paired normal or tumor tissue,increased,"k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Hyphomicrobiales|f__Methylobacteriaceae|g__Methylobacterium|s__Methylobacterium radiotolerans,k__Bacteria|p__Bacteroidota|c__Flavobacteriia|o__Flavobacteriales|f__Flavobacteriaceae|g__Flavobacterium,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Hyphomicrobiales|f__Methylobacteriaceae|g__Methylobacterium,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Hyphomicrobiales|f__Methylobacteriaceae",2|1224|28211|356|119045|407|31998;2|976|117743|200644|49546|237;2|1224|28211|356|119045|407;2|1224|28211|356|119045,Complete,Atrayees
bsdb:122/1/2,Study 122,case-control,24421902,10.1371/journal.pone.0083744,NA,"Xuan C, Shamonki JM, Chung A, Dinome ML, Chung M, Sieling PA , Lee DJ",Microbial dysbiosis is associated with human breast cancer,PloS one,2014,NA,Experiment 1,United States of America,Homo sapiens,Breast,UBERON:0000310,Breast carcinoma,EFO:0000305,normal tissue,tumor tissue,NA,20,20,NA,16S,4,Illumina,T-Test,0.05,FALSE,NA,NA,age,NA,NA,NA,NA,NA,unchanged,Signature 2,Table S2 and Figure 1d,10 January 2021,Rimsha Azhar,"WikiWorks,Atrayees",OTUs enriched in paired normal or tumor tissue,decreased,"k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Sphingomonadales|f__Sphingomonadaceae|g__Sphingobium|s__Sphingobium yanoikuyae,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Sphingomonadales|f__Sphingomonadaceae|g__Sphingomonas,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Nitrosomonadales|f__Nitrosomonadaceae|g__Nitrosomonas,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Sphingomonadales|f__Sphingomonadaceae|g__Novosphingobium|s__Novosphingobium aromaticivorans,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Hyphomicrobiales|f__Nitrobacteraceae|g__Bradyrhizobium,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus|s__Streptococcus pseudopneumoniae,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Sphingomonadales|f__Sphingomonadaceae",2|1224|28211|204457|41297|165695|13690;2|1224|28211|204457|41297|13687;2|1224|28216|32003|206379|914;2|1224|28211|204457|41297|165696|48935;2|1224|28211|356|41294|374;2|1239|91061|186826|1300|1301|257758;2|1224|28211|204457|41297,Complete,Atrayees
bsdb:123/1/1,Study 123,laboratory experiment,31141574,10.1371/journal.pone.0217553,NA,"Deshpande NG, Saxena J, Pesaresi TG, Carrell CD, Ashby GB, Liao MK , Freeman LR",High fat diet alters gut microbiota but not spatial working memory in early middle-aged Sprague Dawley rats,PloS one,2019,NA,Experiment 1,United States of America,Rattus norvegicus,Feces,UBERON:0001988,Diet,EFO:0002755,low fat diet,high fat diet,"High fat diet rats were fed (20% protein, 35% carbohydrate, 45% fat by calories).  Controls or low fat diet were fed (20% protein, 70% carbohydrate, 10% fat by calories) for eight weeks.",6,6,NA,16S,NA,Roche454,ANOVA,0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,Signature 1,Table 1,10 January 2021,Lora Kasselman,WikiWorks,Mean relative abundances for gut genera and p-value for differences between high-fat and control animals are listed. Class and phylum are indicated as well,increased,"k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Lactococcus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Carnobacteriaceae|g__Granulicatella,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Anaerobacterium,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Anaerovoracaceae|g__Anaerovorax,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Clostridium,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Coprococcus,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Eubacteriaceae|g__Eubacterium,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Faecalibacterium,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Flavonifractor,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Oscillospira,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Papillibacter,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Pseudoflavonifractor,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Sporobacter,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Tyzzerella,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Coprobacillaceae|g__Thomasclavelia,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae|g__Holdemania,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micrococcales|f__Micrococcaceae|g__Rothia,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Eggerthellales|f__Eggerthellaceae|g__Adlercreutzia,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales|f__Coriobacteriaceae|g__Collinsella",2|1239|91061|186826|1300|1357;2|1239|91061|186826|186828|117563;2|1239|186801|186802|216572|1486725;2|1239|186801|3082720|3030910|109326;2|1239|186801|186802|31979|1485;2|1239|186801|3085636|186803|33042;2|1239|186801|186802|186806|1730;2|1239|186801|186802|216572|216851;2|1239|186801|186802|216572|946234;2|1239|186801|186802|216572|119852;2|1239|186801|186802|216572|100175;2|1239|186801|186802|216572|1017280;2|1239|186801|186802|216572|44748;2|1239|186801|3085636|186803|1506577;2|1239|526524|526525|2810280|1505663;2|1239|526524|526525|128827|61170;2|201174|1760|85006|1268|32207;2|201174|84998|1643822|1643826|447020;2|201174|84998|84999|84107|102106,Complete,Shaimaa Elsafoury
bsdb:123/1/2,Study 123,laboratory experiment,31141574,10.1371/journal.pone.0217553,NA,"Deshpande NG, Saxena J, Pesaresi TG, Carrell CD, Ashby GB, Liao MK , Freeman LR",High fat diet alters gut microbiota but not spatial working memory in early middle-aged Sprague Dawley rats,PloS one,2019,NA,Experiment 1,United States of America,Rattus norvegicus,Feces,UBERON:0001988,Diet,EFO:0002755,low fat diet,high fat diet,"High fat diet rats were fed (20% protein, 35% carbohydrate, 45% fat by calories).  Controls or low fat diet were fed (20% protein, 70% carbohydrate, 10% fat by calories) for eight weeks.",6,6,NA,16S,NA,Roche454,ANOVA,0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,Signature 2,Table 1,10 January 2021,Lora Kasselman,WikiWorks,Mean relative abundances for gut genera and p-value for differences between high-fat and control animals are listed. Class and phylum are indicated as well,decreased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Citrobacter,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Barnesiellaceae|g__Barnesiella,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Robinsoniella",2|1224|1236|91347|543|544;2|976|200643|171549|2005519|397864;2|976|200643|171549|815|816;2|1239|186801|3085636|186803|588605,Complete,Shaimaa Elsafoury
bsdb:124/1/1,Study 124,"cross-sectional observational, not case-control",31053143,10.1186/s12970-019-0290-y,NA,"Jang LG, Choi G, Kim SW, Kim BY, Lee S , Park H",The combination of sport and sport-specific diet is associated with characteristics of gut microbiota: an observational study,Journal of the International Society of Sports Nutrition,2019,"Body builder, Dietary fiber, Distance runner, Gut microbiota",Experiment 1,South Korea,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,distance runners (high carb),body builders (high protein),NA,15,15,6 months,16S,34,Illumina,Kruskall-Wallis,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Table 3 and Text,10 January 2021,Lora Kasselman,WikiWorks,The combination of sport and sport-specific diet is associated with characteristics of gut microbiota: an observational study,increased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Blautia|s__Blautia wexlerae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Enterobacter|s__Enterobacter cloacae",2|1239|186801|3085636|186803|572511|418240;2|1224|1236|91347|543|547|550,Complete,Shaimaa Elsafoury
bsdb:124/1/2,Study 124,"cross-sectional observational, not case-control",31053143,10.1186/s12970-019-0290-y,NA,"Jang LG, Choi G, Kim SW, Kim BY, Lee S , Park H",The combination of sport and sport-specific diet is associated with characteristics of gut microbiota: an observational study,Journal of the International Society of Sports Nutrition,2019,"Body builder, Dietary fiber, Distance runner, Gut microbiota",Experiment 1,South Korea,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,distance runners (high carb),body builders (high protein),NA,15,15,6 months,16S,34,Illumina,Kruskall-Wallis,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 2,Table 3 and Text,10 January 2021,Lora Kasselman,WikiWorks,The combination of sport and sport-specific diet is associated with characteristics of gut microbiota: an observational study,decreased,"k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium|s__Bifidobacterium adolescentis,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Ruminococcus|s__Ruminococcus callidus,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides|s__Bacteroides caccae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Escherichia|s__Escherichia coli,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Escherichia,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Lactococcus",2|201174|1760|85004|31953|1678|1680;2|1239|186801|186802|216572|1263|40519;2|976|200643|171549|815|816|47678;2|1224|1236|91347|543|561|562;2|201174|1760|85004|31953|1678;2|1224|1236|91347|543|561;2|1239|91061|186826|1300|1357,Complete,Shaimaa Elsafoury
bsdb:124/2/1,Study 124,"cross-sectional observational, not case-control",31053143,10.1186/s12970-019-0290-y,NA,"Jang LG, Choi G, Kim SW, Kim BY, Lee S , Park H",The combination of sport and sport-specific diet is associated with characteristics of gut microbiota: an observational study,Journal of the International Society of Sports Nutrition,2019,"Body builder, Dietary fiber, Distance runner, Gut microbiota",Experiment 2,South Korea,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,control,body builders (high protein),NA,15,15,6 months,16S,34,Illumina,Kruskall-Wallis,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Table 3 and Text,10 January 2021,Lora Kasselman,WikiWorks,The combination of sport and sport-specific diet is associated with characteristics of gut microbiota: an observational study,increased,"k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Sutterellaceae|g__Sutterella,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Faecalibacterium,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Clostridium,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Haemophilus,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Eisenbergiella",2|1224|28216|80840|995019|40544;2|1239|186801|186802|216572|216851;2|1239|186801|186802|31979|1485;2|1224|1236|135625|712|724;2|1239|186801|3085636|186803|1432051,Complete,Shaimaa Elsafoury
bsdb:124/2/2,Study 124,"cross-sectional observational, not case-control",31053143,10.1186/s12970-019-0290-y,NA,"Jang LG, Choi G, Kim SW, Kim BY, Lee S , Park H",The combination of sport and sport-specific diet is associated with characteristics of gut microbiota: an observational study,Journal of the International Society of Sports Nutrition,2019,"Body builder, Dietary fiber, Distance runner, Gut microbiota",Experiment 2,South Korea,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,control,body builders (high protein),NA,15,15,6 months,16S,34,Illumina,Kruskall-Wallis,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 2,Table 3 and Text,10 January 2021,Lora Kasselman,WikiWorks,The combination of sport and sport-specific diet is associated with characteristics of gut microbiota: an observational study,decreased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Blautia|s__Blautia wexlerae,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Anaerobutyricum|s__Anaerobutyricum hallii,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides|s__Bacteroides stercoris,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Ruminococcus|s__Ruminococcus callidus,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium|s__Bifidobacterium longum|s__Bifidobacterium longum subsp. longum,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Escherichia|s__Escherichia coli,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Latilactobacillus|s__Latilactobacillus sakei,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Sutterellaceae|g__Parasutterella,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Leuconostoc",2|1239|186801|3085636|186803|572511|418240;2|1239|186801|3085636|186803|2569097|39488;2|976|200643|171549|815|816|46506;2|1239|186801|186802|216572|1263|40519;2|201174|1760|85004|31953|1678|216816|1679;2|1224|1236|91347|543|561|562;2|201174|1760|85004|31953|1678;2|1239|91061|186826|33958|2767885|1599;2|1224|28216|80840|995019|577310;2|1239|91061|186826|33958|1243,Complete,Shaimaa Elsafoury
bsdb:124/3/1,Study 124,"cross-sectional observational, not case-control",31053143,10.1186/s12970-019-0290-y,NA,"Jang LG, Choi G, Kim SW, Kim BY, Lee S , Park H",The combination of sport and sport-specific diet is associated with characteristics of gut microbiota: an observational study,Journal of the International Society of Sports Nutrition,2019,"Body builder, Dietary fiber, Distance runner, Gut microbiota",Experiment 3,South Korea,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,control,distance runners (high carb),NA,15,15,6 months,16S,34,Illumina,Kruskall-Wallis,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Table 3 and Text,10 January 2021,Lora Kasselman,WikiWorks,The combination of sport and sport-specific diet is associated with characteristics of gut microbiota: an observational study,increased,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Sutterellaceae|g__Sutterella,2|1224|28216|80840|995019|40544,Complete,Shaimaa Elsafoury
bsdb:124/3/2,Study 124,"cross-sectional observational, not case-control",31053143,10.1186/s12970-019-0290-y,NA,"Jang LG, Choi G, Kim SW, Kim BY, Lee S , Park H",The combination of sport and sport-specific diet is associated with characteristics of gut microbiota: an observational study,Journal of the International Society of Sports Nutrition,2019,"Body builder, Dietary fiber, Distance runner, Gut microbiota",Experiment 3,South Korea,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,control,distance runners (high carb),NA,15,15,6 months,16S,34,Illumina,Kruskall-Wallis,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 2,Table 3 and Text,10 January 2021,Lora Kasselman,WikiWorks,The combination of sport and sport-specific diet is associated with characteristics of gut microbiota: an observational study,decreased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Enterobacter|s__Enterobacter cloacae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Weissella|s__Weissella confusa,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae|s__[Clostridium] innocuum,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides|s__Bacteroides caccae,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Anaerobutyricum|s__Anaerobutyricum hallii,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Blautia|s__Blautia wexlerae,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Blautia,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Enterobacter,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Weissella,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Leuconostoc",2|1224|1236|91347|543|547|550;2|1239|91061|186826|33958|46255|1583;2|1239|526524|526525|128827|1522;2|976|200643|171549|815|816|47678;2|1239|186801|3085636|186803|2569097|39488;2|1239|186801|3085636|186803|572511|418240;2|1239|186801|3085636|186803|572511;2|1224|1236|91347|543|547;2|1239|91061|186826|33958|46255;2|1239|91061|186826|33958|1243,Complete,Shaimaa Elsafoury
bsdb:125/1/1,Study 125,case-control,31109865,10.1016/j.job.2019.03.003,NA,"Takahashi Y, Park J, Hosomi K, Yamada T, Kobayashi A, Yamaguchi Y, Iketani S, Kunisawa J, Mizuguchi K, Maeda N , Ohshima T",Analysis of oral microbiota in Japanese oral cancer patients using 16S rRNA sequencing,Journal of oral biosciences,2019,"Bacteria, Epidemiology, Metagenomics, Microbiota, Mouth neoplasms",Experiment 1,Japan,Homo sapiens,Saliva,UBERON:0001836,Squamous cell carcinoma,EFO:0000707,noncancer individuals,Oral Squamous Cell Cancer patients,All diagnoses of oral squamous cell carcinoma were confirmed by biopsy and pathological findings.The control group was defined as individuals without any diagnosed mucosal diseases and other cancers and these individuals were over the age of 40.,80,60,28 days,16S,34,Illumina,T-Test,0.05,FALSE,NA,NA,NA,NA,unchanged,increased,unchanged,NA,increased,Signature 1,"Fig 1,3 and Text",10 January 2021,Utsav Patel,WikiWorks,Oral microbiota in japanese oral cancer patients vs. noncancer individuals: a case-control study,increased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Peptostreptococcaceae|g__Peptostreptococcus,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae|g__Fusobacterium,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Alloprevotella,k__Bacteria|p__Bacteroidota|c__Flavobacteriia|o__Flavobacteriales|f__Flavobacteriaceae|g__Capnocytophaga",2|1239|186801|3082720|186804|1257;2|32066|203490|203491|203492|848;2|976|200643|171549|171552|1283313;2|976|117743|200644|49546|1016,Complete,Shaimaa Elsafoury
bsdb:125/1/2,Study 125,case-control,31109865,10.1016/j.job.2019.03.003,NA,"Takahashi Y, Park J, Hosomi K, Yamada T, Kobayashi A, Yamaguchi Y, Iketani S, Kunisawa J, Mizuguchi K, Maeda N , Ohshima T",Analysis of oral microbiota in Japanese oral cancer patients using 16S rRNA sequencing,Journal of oral biosciences,2019,"Bacteria, Epidemiology, Metagenomics, Microbiota, Mouth neoplasms",Experiment 1,Japan,Homo sapiens,Saliva,UBERON:0001836,Squamous cell carcinoma,EFO:0000707,noncancer individuals,Oral Squamous Cell Cancer patients,All diagnoses of oral squamous cell carcinoma were confirmed by biopsy and pathological findings.The control group was defined as individuals without any diagnosed mucosal diseases and other cancers and these individuals were over the age of 40.,80,60,28 days,16S,34,Illumina,T-Test,0.05,FALSE,NA,NA,NA,NA,unchanged,increased,unchanged,NA,increased,Signature 2,"Fig 1,3 and Text",10 January 2021,Utsav Patel,WikiWorks,Oral microbiota in japanese oral cancer patients vs. noncancer individuals: a case-control study,decreased,"k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micrococcales|f__Micrococcaceae|g__Rothia,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Haemophilus",2|201174|1760|85006|1268|32207;2|1224|1236|135625|712|724,Complete,Shaimaa Elsafoury
bsdb:126/1/1,Study 126,case-control,27026576,10.1016/j.oraloncology.2016.03.007,NA,"Xiaosheng Hu, Feng Chen, Qian Zhang, Hong",Changes in the salivary microbiota of oral leukoplakia and oral cancer,Oral oncology,2016,NA,Experiment 1,China,Homo sapiens,Saliva,UBERON:0001836,Oral leukoplakia,HP:0002745,healthy controls,Oral leukoplakia,Oral leukoplakia patients,19,10,NA,16S,NA,Illumina,Kruskall-Wallis,0.05,FALSE,NA,NA,NA,NA,unchanged,increased,unchanged,NA,NA,Signature 1,Fig 1 & 2,10 January 2021,Utsav Patel,WikiWorks,Changes in oral microbiota in oral leukoplakia vs. healthy control: a case-control study,increased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Haemophilus,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Bacillaceae|g__Bacillus",2|1224|1236|135625|712|724;2|1239|91061|1385|186817|1386,Complete,Shaimaa Elsafoury
bsdb:126/1/2,Study 126,case-control,27026576,10.1016/j.oraloncology.2016.03.007,NA,"Xiaosheng Hu, Feng Chen, Qian Zhang, Hong",Changes in the salivary microbiota of oral leukoplakia and oral cancer,Oral oncology,2016,NA,Experiment 1,China,Homo sapiens,Saliva,UBERON:0001836,Oral leukoplakia,HP:0002745,healthy controls,Oral leukoplakia,Oral leukoplakia patients,19,10,NA,16S,NA,Illumina,Kruskall-Wallis,0.05,FALSE,NA,NA,NA,NA,unchanged,increased,unchanged,NA,NA,Signature 2,Fig 1 & 2,10 January 2021,Utsav Patel,WikiWorks,Changes in oral microbiota in oral leukoplakia vs. healthy control: a case-control study,decreased,"k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Aerococcaceae|g__Abiotrophia",2|1239|91061|186826|1300|1301;2|1239|91061|186826|186827|46123,Complete,Shaimaa Elsafoury
bsdb:126/2/1,Study 126,case-control,27026576,10.1016/j.oraloncology.2016.03.007,NA,"Xiaosheng Hu, Feng Chen, Qian Zhang, Hong",Changes in the salivary microbiota of oral leukoplakia and oral cancer,Oral oncology,2016,NA,Experiment 2,China,Homo sapiens,Saliva,UBERON:0001836,Oral squamous cell carcinoma,EFO:0000199,healthy controls,Oral Squamous Cell Cancer patients,Oral Squamous Cell Cancer patients,19,16,NA,16S,NA,Illumina,Kruskall-Wallis,0.05,FALSE,NA,NA,NA,NA,increased,unchanged,increased,NA,NA,Signature 1,Fig 1 & 2,10 January 2021,Utsav Patel,WikiWorks,Changes in oral microbiota in OSCC vs. healthy control: a case-control study,increased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Haemophilus,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Bacillaceae|g__Bacillus",2|1224|1236|135625|712|724;2|1239|91061|1385|186817|1386,Complete,Shaimaa Elsafoury
bsdb:126/2/2,Study 126,case-control,27026576,10.1016/j.oraloncology.2016.03.007,NA,"Xiaosheng Hu, Feng Chen, Qian Zhang, Hong",Changes in the salivary microbiota of oral leukoplakia and oral cancer,Oral oncology,2016,NA,Experiment 2,China,Homo sapiens,Saliva,UBERON:0001836,Oral squamous cell carcinoma,EFO:0000199,healthy controls,Oral Squamous Cell Cancer patients,Oral Squamous Cell Cancer patients,19,16,NA,16S,NA,Illumina,Kruskall-Wallis,0.05,FALSE,NA,NA,NA,NA,increased,unchanged,increased,NA,NA,Signature 2,Fig 1 & 2,10 January 2021,Utsav Patel,WikiWorks,Changes in oral microbiota in OSCC vs. healthy control: a case-control study,decreased,"k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Aerococcaceae|g__Abiotrophia",2|1239|91061|186826|1300|1301;2|1239|91061|186826|186827|46123,Complete,Shaimaa Elsafoury
bsdb:126/3/1,Study 126,case-control,27026576,10.1016/j.oraloncology.2016.03.007,NA,"Xiaosheng Hu, Feng Chen, Qian Zhang, Hong",Changes in the salivary microbiota of oral leukoplakia and oral cancer,Oral oncology,2016,NA,Experiment 3,China,Homo sapiens,Saliva,UBERON:0001836,Oral leukoplakia,HP:0002745,Oral Squamous Cell Cancer patients,Oral leukoplakia,Oral leukoplakia patients,16,10,NA,16S,NA,Illumina,Kruskall-Wallis,0.05,FALSE,NA,NA,NA,NA,unchanged,unchanged,increased,NA,NA,Signature 1,Fig 1 & 2,10 January 2021,Utsav Patel,WikiWorks,Changes in oral microbiota in oral leukoplakia vs. OSCC: a case-control study,increased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Haemophilus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus",2|1224|1236|135625|712|724;2|1239|91061|186826|1300|1301,Complete,Shaimaa Elsafoury
bsdb:126/3/2,Study 126,case-control,27026576,10.1016/j.oraloncology.2016.03.007,NA,"Xiaosheng Hu, Feng Chen, Qian Zhang, Hong",Changes in the salivary microbiota of oral leukoplakia and oral cancer,Oral oncology,2016,NA,Experiment 3,China,Homo sapiens,Saliva,UBERON:0001836,Oral leukoplakia,HP:0002745,Oral Squamous Cell Cancer patients,Oral leukoplakia,Oral leukoplakia patients,16,10,NA,16S,NA,Illumina,Kruskall-Wallis,0.05,FALSE,NA,NA,NA,NA,unchanged,unchanged,increased,NA,NA,Signature 2,Fig 1 & 2,10 January 2021,Utsav Patel,WikiWorks,Changes in oral microbiota in oral leukoplakia vs. OSCC: a case-control study,decreased,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Bacillaceae|g__Bacillus,2|1239|91061|1385|186817|1386,Complete,Shaimaa Elsafoury
bsdb:127/1/1,Study 127,"cross-sectional observational, not case-control",30894059,10.1080/19490976.2019.1580097,NA,"Bjørkhaug ST, Aanes H, Neupane SP, Bramness JG, Malvik S, Henriksen C, Skar V, Medhus AW , Valeur J",Characterization of gut microbiota composition and functions in patients with chronic alcohol overconsumption,Gut microbes,2019,"Clostridium, Faecalibacterium, Holdemania, Nutritional screening, PICRUSt, Proteobacteria, Sutterella, short-chain fatty acids",Experiment 1,Norway,Homo sapiens,Feces,UBERON:0001988,Alcohol drinking,EFO:0004329,controls,alcohol overconsumers,subjects with ongoing or recent history of alcohol overconsumption of more than 20 or 40 g of alcohol per day,18,24,4 weeks,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,Signature 1,"Figure 2, 3",10 January 2021,Fatima Zohra,"Claregrieve1,WikiWorks",Differential abundance of microbiota between patients with alcohol overconsumption and controls,increased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Clostridium,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae|g__Holdemania,k__Bacteria|p__Pseudomonadota,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Sutterellaceae|g__Sutterella",2|1239|186801|186802|31979|1485;2|1239|526524|526525|128827|61170;2|1224;2|1224|28216|80840|995019|40544,Complete,Claregrieve1
bsdb:127/1/2,Study 127,"cross-sectional observational, not case-control",30894059,10.1080/19490976.2019.1580097,NA,"Bjørkhaug ST, Aanes H, Neupane SP, Bramness JG, Malvik S, Henriksen C, Skar V, Medhus AW , Valeur J",Characterization of gut microbiota composition and functions in patients with chronic alcohol overconsumption,Gut microbes,2019,"Clostridium, Faecalibacterium, Holdemania, Nutritional screening, PICRUSt, Proteobacteria, Sutterella, short-chain fatty acids",Experiment 1,Norway,Homo sapiens,Feces,UBERON:0001988,Alcohol drinking,EFO:0004329,controls,alcohol overconsumers,subjects with ongoing or recent history of alcohol overconsumption of more than 20 or 40 g of alcohol per day,18,24,4 weeks,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,Signature 2,"Figure 2, 3",10 January 2021,Fatima Zohra,"Claregrieve1,WikiWorks",Differential abundance of microbiota between patients with alcohol overconsumption and controls,decreased,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Faecalibacterium,2|1239|186801|186802|216572|216851,Complete,Claregrieve1
bsdb:127/2/1,Study 127,"cross-sectional observational, not case-control",30894059,10.1080/19490976.2019.1580097,NA,"Bjørkhaug ST, Aanes H, Neupane SP, Bramness JG, Malvik S, Henriksen C, Skar V, Medhus AW , Valeur J",Characterization of gut microbiota composition and functions in patients with chronic alcohol overconsumption,Gut microbes,2019,"Clostridium, Faecalibacterium, Holdemania, Nutritional screening, PICRUSt, Proteobacteria, Sutterella, short-chain fatty acids",Experiment 2,Norway,Homo sapiens,Feces,UBERON:0001988,Alcohol drinking,EFO:0004329,controls,alcohol overconsumers,NA,18,24,4 weeks,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,NA,NA,NA,NA,Signature 1,Figure 4a,10 January 2021,Fatima Zohra,"Claregrieve1,WikiWorks",Differentially abundant taxa between alcohol overconsumers and controls,increased,"k__Bacteria|p__Bacillota|c__Negativicutes|o__Acidaminococcales|f__Acidaminococcaceae|g__Acidaminococcus,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Alcaligenaceae,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae|g__Bulleidia,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Clostridium,k__Bacteria|p__Thermodesulfobacteriota|c__Desulfovibrionia|o__Desulfovibrionales,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Candidatus Epulonipiscium,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Escherichia,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae|g__Holdemania,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Klebsiella,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae,k__Bacteria|p__Bacillota|c__Negativicutes|o__Selenomonadales|f__Selenomonadaceae|g__Megamonas,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micrococcales|f__Micrococcaceae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Morganellaceae|g__Morganella,k__Bacteria|p__Pseudomonadota,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micrococcales|f__Micrococcaceae|g__Rothia,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Sutterellaceae|g__Sutterella,k__Bacteria|p__Bacillota|c__Tissierellia|o__Tissierellales|f__Tissierellaceae",2|1239|909932|1843488|909930|904;2|201174|1760|2037;2|1224|28216|80840|506;2|1239|526524|526525|128827|118747;2|1239|186801|186802|31979|1485;2|200940|3031449|213115;2|1224|1236|91347;2|1224|1236|91347|543;2|1239|186801|3085636|186803|2383;2|1224|1236|91347|543|561;2|1239|526524|526525|128827|61170;2|1224|1236|91347|543|570;2|1239|186801|3085636|186803;2|1239|909932|909929|1843491|158846;2|201174|1760|85006|1268;2|1224|1236|91347|1903414|581;2|1224;2|201174|1760|85006|1268|32207;2|1224|28216|80840|995019|40544;2|1239|1737404|1737405|1737406,Complete,Claregrieve1
bsdb:127/2/2,Study 127,"cross-sectional observational, not case-control",30894059,10.1080/19490976.2019.1580097,NA,"Bjørkhaug ST, Aanes H, Neupane SP, Bramness JG, Malvik S, Henriksen C, Skar V, Medhus AW , Valeur J",Characterization of gut microbiota composition and functions in patients with chronic alcohol overconsumption,Gut microbes,2019,"Clostridium, Faecalibacterium, Holdemania, Nutritional screening, PICRUSt, Proteobacteria, Sutterella, short-chain fatty acids",Experiment 2,Norway,Homo sapiens,Feces,UBERON:0001988,Alcohol drinking,EFO:0004329,controls,alcohol overconsumers,NA,18,24,4 weeks,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,NA,NA,NA,NA,Signature 2,Figure 4a,10 January 2021,Fatima Zohra,"Claregrieve1,WikiWorks",Differentially abundant taxa between alcohol overconsumers and controls,decreased,"k__Bacteria|p__Actinomycetota,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Eggerthellales|f__Eggerthellaceae|g__Adlercreutzia,k__Bacteria|p__Bacillota|c__Clostridia,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales|f__Coriobacteriaceae|g__Collinsella,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales|f__Coriobacteriaceae,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales,k__Bacteria|p__Actinomycetota|c__Coriobacteriia,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Faecalibacterium,k__Bacteria|p__Bacillota|c__Negativicutes|o__Selenomonadales|f__Selenomonadaceae|g__Mitsuokella,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Odoribacteraceae|g__Odoribacter,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Oribacterium,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Staphylococcaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Staphylococcaceae|g__Staphylococcus,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Aeromonadales|f__Succinivibrionaceae|g__Succinatimonas",2|201174;2|201174|84998|1643822|1643826|447020;2|1239|186801;2|201174|84998|84999|84107|102106;2|201174|84998|84999|84107;2|201174|84998|84999;2|201174|84998;2|1239|186801|186802|216572|216851;2|1239|909932|909929|1843491|52225;2|976|200643|171549|1853231|283168;2|1239|186801|3085636|186803|265975;2|976|200643|171549|171552|838;2|976|200643|171549|171552;2|1239|91061|1385|90964;2|1239|91061|1385|90964|1279;2|1224|1236|135624|83763|674963,Complete,Claregrieve1
bsdb:128/1/1,Study 128,"cross-sectional observational, not case-control",28765474,10.1136/gutjnl-2017-314281,NA,"Coker OO, Dai Z, Nie Y, Zhao G, Cao L, Nakatsu G, Wu WK, Wong SH, Chen Z, Sung JJY , Yu J",Mucosal microbiome dysbiosis in gastric carcinogenesis,Gut,2018,"Gastric cancer, mucosal microbiome dysbiosis, oral bacteria",Experiment 1,China,Homo sapiens,Stomach,UBERON:0000945,Gastric cancer,MONDO:0001056,intestinal metaplasia,gastric cancer,NA,37,17,2 months,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,"Helicobacter pylori,age,sex",NA,NA,decreased,NA,NA,decreased,Signature 1,Supplementary Figure 1,10 January 2021,Rimsha Azhar,"Fatima,Merit,WikiWorks",The abundance of gastric cancer -enriched and -depleted operational taxonomic units across stages of gastric cancer,increased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Alloprevotella,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Catonella,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Dialister,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Eubacteriaceae,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae|g__Fusobacterium,k__Bacteria|p__Bacillota|c__Tissierellia|o__Tissierellales|f__Peptoniphilaceae|g__Parvimonas,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Moryella,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Peptococcaceae|g__Peptococcus,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Peptostreptococcaceae|g__Peptostreptococcus,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Eggerthellales|f__Eggerthellaceae|g__Slackia,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales",2|976|200643|171549|171552|1283313;2|1239|186801|3085636|186803|43996;2|1239|909932|1843489|31977|39948;2|1239|186801|186802|186806;2|32066|203490|203491|203492|848;2|1239|1737404|1737405|1570339|543311;2|1239|91061|186826|33958|1578;2|1239|186801|3085636|186803|437755;2|1239|186801|186802|186807|2740;2|1239|186801|3082720|186804|1257;2|976|200643|171549|171552|838;2|201174|84998|1643822|1643826|84108;2|1239|91061|186826|1300|1301;2|1239|91061|186826,Complete,Atrayees
bsdb:128/1/2,Study 128,"cross-sectional observational, not case-control",28765474,10.1136/gutjnl-2017-314281,NA,"Coker OO, Dai Z, Nie Y, Zhao G, Cao L, Nakatsu G, Wu WK, Wong SH, Chen Z, Sung JJY , Yu J",Mucosal microbiome dysbiosis in gastric carcinogenesis,Gut,2018,"Gastric cancer, mucosal microbiome dysbiosis, oral bacteria",Experiment 1,China,Homo sapiens,Stomach,UBERON:0000945,Gastric cancer,MONDO:0001056,intestinal metaplasia,gastric cancer,NA,37,17,2 months,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,"Helicobacter pylori,age,sex",NA,NA,decreased,NA,NA,decreased,Signature 2,Supplementary Figure 1,10 January 2021,Rimsha Azhar,WikiWorks,The abundance of gastric cancer -enriched and -depleted operational taxonomic units across stages of gastric cancer,decreased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Moraxellales|f__Moraxellaceae|g__Acinetobacter,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Chromobacteriaceae|g__Vogesella,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Nitrosomonadales|f__Sterolibacteriaceae|g__Methyloversatilis,k__Bacteria|p__Thermodesulfobacteriota|c__Syntrophobacteria|o__Syntrophobacterales|f__Syntrophobacteraceae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Oceanospirillales|f__Halomonadaceae|g__Candidatus Portiera",2|1224|1236|2887326|468|469;2|1224|28216|206351|1499392|57739;2|1224|28216|32003|2008793|378210;2|200940|3024408|213462|213465;2|1224|1236|135619|28256|235572,Complete,Atrayees
bsdb:128/2/1,Study 128,"cross-sectional observational, not case-control",28765474,10.1136/gutjnl-2017-314281,NA,"Coker OO, Dai Z, Nie Y, Zhao G, Cao L, Nakatsu G, Wu WK, Wong SH, Chen Z, Sung JJY , Yu J",Mucosal microbiome dysbiosis in gastric carcinogenesis,Gut,2018,"Gastric cancer, mucosal microbiome dysbiosis, oral bacteria",Experiment 2,China,Homo sapiens,Stomach,UBERON:0000945,Gastric cancer,MONDO:0001056,atrophic gastric,gastric cancer,NA,37,74,2 months,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,"Helicobacter pylori,age,sex",NA,NA,unchanged,NA,NA,unchanged,Signature 1,Supplementary Figure 1,10 January 2021,Rimsha Azhar,WikiWorks,The abundance of gastric cancer -enriched and -depleted operational taxonomic units across stages of gastric cancer,increased,"k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Peptostreptococcaceae|g__Peptostreptococcus,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Gemellaceae|g__Gemella,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae|g__Fusobacterium,k__Bacteria|p__Bacillota|c__Tissierellia|o__Tissierellales|f__Peptoniphilaceae|g__Parvimonas,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Eubacteriaceae|g__Eubacterium,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Alloprevotella,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Dialister,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Eggerthellales|f__Eggerthellaceae|g__Slackia,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Eubacteriaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Peptococcaceae|g__Peptococcus,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Catonella,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Moryella",2|1239|91061|186826|1300|1301;2|1239|186801|3082720|186804|1257;2|1239|91061|1385|539738|1378;2|32066|203490|203491|203492|848;2|1239|1737404|1737405|1570339|543311;2|1239|91061|186826|33958|1578;2|1239|186801|186802|186806|1730;2|976|200643|171549|171552|1283313;2|976|200643|171549|171552|838;2|1239|909932|1843489|31977|39948;2|201174|84998|1643822|1643826|84108;2|1239|186801|186802|186806;2|1239|186801|186802|186807|2740;2|1239|186801|3085636|186803|43996;2|1239|186801|3085636|186803|437755,Complete,Atrayees
bsdb:128/2/2,Study 128,"cross-sectional observational, not case-control",28765474,10.1136/gutjnl-2017-314281,NA,"Coker OO, Dai Z, Nie Y, Zhao G, Cao L, Nakatsu G, Wu WK, Wong SH, Chen Z, Sung JJY , Yu J",Mucosal microbiome dysbiosis in gastric carcinogenesis,Gut,2018,"Gastric cancer, mucosal microbiome dysbiosis, oral bacteria",Experiment 2,China,Homo sapiens,Stomach,UBERON:0000945,Gastric cancer,MONDO:0001056,atrophic gastric,gastric cancer,NA,37,74,2 months,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,"Helicobacter pylori,age,sex",NA,NA,unchanged,NA,NA,unchanged,Signature 2,Supplementary Figure 1,10 January 2021,Rimsha Azhar,WikiWorks,The abundance of gastric cancer -enriched and -depleted operational taxonomic units across stages of gastric cancer,decreased,"k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Chromobacteriaceae|g__Vogesella,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Oceanospirillales|f__Halomonadaceae|g__Candidatus Portiera",2|1224|28216|206351|1499392|57739;2|1224|1236|135619|28256|235572,Complete,Atrayees
bsdb:128/3/1,Study 128,"cross-sectional observational, not case-control",28765474,10.1136/gutjnl-2017-314281,NA,"Coker OO, Dai Z, Nie Y, Zhao G, Cao L, Nakatsu G, Wu WK, Wong SH, Chen Z, Sung JJY , Yu J",Mucosal microbiome dysbiosis in gastric carcinogenesis,Gut,2018,"Gastric cancer, mucosal microbiome dysbiosis, oral bacteria",Experiment 3,China,Homo sapiens,Stomach,UBERON:0000945,Gastric cancer,MONDO:0001056,superficial gastric,gastric cancer,NA,37,77,2 months,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,"Helicobacter pylori,age,sex",NA,NA,decreased,NA,NA,decreased,Signature 1,Supplementary Figure 1,10 January 2021,Rimsha Azhar,"Merit,WikiWorks",The abundance of gastric cancer -enriched and -depleted operational taxonomic units across stages of gastric cancer,increased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Alloprevotella,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Catonella,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Dialister,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Eubacteriaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Eubacteriaceae|g__Eubacterium,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae|g__Fusobacterium,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Gemellaceae|g__Gemella,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Moryella,k__Bacteria|p__Bacillota|c__Tissierellia|o__Tissierellales|f__Peptoniphilaceae|g__Parvimonas,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Peptococcaceae|g__Peptococcus,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Peptostreptococcaceae|g__Peptostreptococcus,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Eggerthellales|f__Eggerthellaceae|g__Slackia,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus",2|976|200643|171549|171552|1283313;2|1239|186801|3085636|186803|43996;2|1239|909932|1843489|31977|39948;2|1239|186801|186802|186806;2|1239|186801|186802|186806|1730;2|32066|203490|203491|203492|848;2|1239|91061|1385|539738|1378;2|1239|91061|186826|33958|1578;2|1239|186801|3085636|186803|437755;2|1239|1737404|1737405|1570339|543311;2|1239|186801|186802|186807|2740;2|1239|186801|3082720|186804|1257;2|976|200643|171549|171552|838;2|201174|84998|1643822|1643826|84108;2|1239|91061|186826|1300|1301,Complete,Atrayees
bsdb:128/3/2,Study 128,"cross-sectional observational, not case-control",28765474,10.1136/gutjnl-2017-314281,NA,"Coker OO, Dai Z, Nie Y, Zhao G, Cao L, Nakatsu G, Wu WK, Wong SH, Chen Z, Sung JJY , Yu J",Mucosal microbiome dysbiosis in gastric carcinogenesis,Gut,2018,"Gastric cancer, mucosal microbiome dysbiosis, oral bacteria",Experiment 3,China,Homo sapiens,Stomach,UBERON:0000945,Gastric cancer,MONDO:0001056,superficial gastric,gastric cancer,NA,37,77,2 months,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,"Helicobacter pylori,age,sex",NA,NA,decreased,NA,NA,decreased,Signature 2,Supplementary Figure 1,10 January 2021,Rimsha Azhar,WikiWorks,The abundance of gastric cancer -enriched and -depleted operational taxonomic units across stages of gastric cancer,decreased,"k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Comamonadaceae,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Comamonadaceae|g__Hydrogenophaga,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Moraxellales|f__Moraxellaceae|g__Acinetobacter,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Chromobacteriaceae|g__Vogesella,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Nitrosomonadales|f__Sterolibacteriaceae|g__Methyloversatilis,k__Bacteria|p__Thermodesulfobacteriota|c__Syntrophobacteria|o__Syntrophobacterales|f__Syntrophobacteraceae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Oceanospirillales|f__Halomonadaceae|g__Candidatus Portiera",2|1224|28216|80840|80864;2|1224|28216|80840|80864|47420;2|1224|1236|2887326|468|469;2|1224|28216|206351|1499392|57739;2|1224|28216|32003|2008793|378210;2|200940|3024408|213462|213465;2|1224|1236|135619|28256|235572,Complete,Atrayees
bsdb:129/1/1,Study 129,case-control,27346372,10.1038/srep28484,NA,"Chen J, Chia N, Kalari KR, Yao JZ, Novotna M, Paz Soldan MM, Luckey DH, Marietta EV, Jeraldo PR, Chen X, Weinshenker BG, Rodriguez M, Kantarci OH, Nelson H, Murray JA , Mangalam AK",Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls,Scientific reports,2016,NA,Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Multiple sclerosis,MONDO:0005301,Healthy controls,Multiple sclerosis,Relapsing remitting MS (RRMS),36,31,Currently taking antibiotics,16S,345,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,"age,sex",NA,NA,unchanged,NA,NA,NA,NA,Signature 1,"Figure 3, Table 2",10 January 2021,Fatima Zohra,"WikiWorks,Peace Sandy","Microbial signatures of the gut microbiota of MS patients.
(A) Barplots comparing the abundances of differentially abundant taxa between MS and control. These “signature” taxa are selected by Wilcoxon rank-sum tests and a false discovery rate of 5%. Error bars represent standard errors. Phylum, family and genus-level taxa are plotted.

Differentially abundant taxa between MS and control samples at phylum, family and genus-level.",increased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pseudomonadales|f__Pseudomonadaceae|s__Azotobacter group,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Blautia,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Caulobacterales|f__Caulobacteraceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Dorea,k__Bacteria|p__Bacteroidota|c__Flavobacteriia|o__Flavobacteriales|f__Flavobacteriaceae,k__Bacteria|p__Bacteroidota|c__Flavobacteriia|o__Flavobacteriales|f__Flavobacteriaceae|g__Flavobacterium,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Hyphomicrobiales|f__Rhizobiaceae|g__Mycoplana,k__Bacteria|p__Bacteroidota|c__Sphingobacteriia|o__Sphingobacteriales|f__Sphingobacteriaceae|g__Pedobacter,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pseudomonadales|f__Pseudomonadaceae|g__Pseudomonas,k__Bacteria|p__Bacteroidota|c__Sphingobacteriia|o__Sphingobacteriales|f__Sphingobacteriaceae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pseudomonadales|f__Pseudomonadaceae,k__Bacteria|p__Pseudomonadota",2|1224|1236|72274|135621|351;2|1239|186801|3085636|186803|572511;2|1224|28211|204458|76892;2|1239|186801|3085636|186803|189330;2|976|117743|200644|49546;2|976|117743|200644|49546|237;2|1239|186801|3085636|186803;2|1224|28211|356|82115|13159;2|976|117747|200666|84566|84567;2|1224|1236|72274|135621|286;2|976|117747|200666|84566;2|1224|1236|72274|135621;2|1224,Complete,Peace Sandy
bsdb:129/1/2,Study 129,case-control,27346372,10.1038/srep28484,NA,"Chen J, Chia N, Kalari KR, Yao JZ, Novotna M, Paz Soldan MM, Luckey DH, Marietta EV, Jeraldo PR, Chen X, Weinshenker BG, Rodriguez M, Kantarci OH, Nelson H, Murray JA , Mangalam AK",Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls,Scientific reports,2016,NA,Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Multiple sclerosis,MONDO:0005301,Healthy controls,Multiple sclerosis,Relapsing remitting MS (RRMS),36,31,Currently taking antibiotics,16S,345,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,"age,sex",NA,NA,unchanged,NA,NA,NA,NA,Signature 2,"Figure 3, Table 2",10 January 2021,Fatima Zohra,"WikiWorks,Peace Sandy","Microbial signatures of the gut microbiota of MS patients. (A) Barplots comparing the abundances of differentially abundant taxa between MS and control. These “signature” taxa are selected by Wilcoxon rank-sum tests and a false discovery rate of 5%. Error bars represent standard errors. Phylum, family and genus-level taxa are plotted.

Differentially abundant taxa between MS and control samples at phylum, family and genus-level.",decreased,"k__Bacteria|p__Actinomycetota,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Eggerthellales|f__Eggerthellaceae|g__Adlercreutzia,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Blautia,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales|f__Coriobacteriaceae|g__Collinsella,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Coprobacillaceae|g__Coprobacillus,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales|f__Coriobacteriaceae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Haemophilus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus,k__Bacteria|p__Mycoplasmatota|c__Mollicutes|o__Mycoplasmatales|f__Mycoplasmataceae|g__Mycoplasma,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Tannerellaceae|g__Parabacteroides,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae,k__Bacteria|p__Pseudomonadota,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae",2|201174;2|201174|84998|1643822|1643826|447020;2|1239|186801|3085636|186803|572511;2|201174|84998|84999|84107|102106;2|1239|526524|526525|2810280|100883;2|201174|84998|84999|84107;2|1224|1236|91347|543;2|1239|526524|526525|128827;2|1224|1236|135625|712|724;2|1239|91061|186826|33958;2|1239|91061|186826|33958|1578;2|544448|31969|2085|2092|2093;2|976|200643|171549|2005525|375288;2|1224|1236|135625|712;2|976|200643|171549|171551;2|1224;2|1239|909932|1843489|31977,Complete,Peace Sandy
bsdb:130/1/1,Study 130,"cross-sectional observational, not case-control",28624933,10.1007/s13105-017-0570-4,NA,"Castro-Penalonga M, Roca-Saavedra P, Miranda JM, Porto-Arias JJ, Nebot C, Cardelle-Cobas A, Franco CM , Cepeda A",Influence of food consumption patterns and Galician lifestyle on human gut microbiota,Journal of physiology and biochemistry,2018,"Actinobacteria, Atlantic Diet, Bifidobacterium, Gut microbiota, Lactobacillus, Southern European Atlantic Diet",Experiment 1,Spain,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,low Southern European Atlantic Diet,high Southern European Atlantic Diet,"SEAD: Southern European Atlantic Diet. SEAD adherence was measured using an index of nine food components (fresh fish, cod, red meat and pork products, dairy products, legumes and vegetables, vegetable soup, po- tatoes, wholegrain bread and wine) that ranged from 0 (lowest adherence) to 9 (highest adherence).",3,7,6 months,16S,NA,RT-qPCR,ANOVA,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Table 5,10 January 2021,Lora Kasselman,WikiWorks,"Bacterial groups quantified in human fecal samples in subjects with low, intermediate, and high adherence to Southern European Atlantic Diet (SEAD)",increased,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium,2|201174|1760|85004|31953|1678,Complete,Shaimaa Elsafoury
bsdb:130/2/1,Study 130,"cross-sectional observational, not case-control",28624933,10.1007/s13105-017-0570-4,NA,"Castro-Penalonga M, Roca-Saavedra P, Miranda JM, Porto-Arias JJ, Nebot C, Cardelle-Cobas A, Franco CM , Cepeda A",Influence of food consumption patterns and Galician lifestyle on human gut microbiota,Journal of physiology and biochemistry,2018,"Actinobacteria, Atlantic Diet, Bifidobacterium, Gut microbiota, Lactobacillus, Southern European Atlantic Diet",Experiment 2,Spain,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,low Southern European Atlantic Diet,intermediate Southern European Atlantic Diet,"SEAD: Southern European Atlantic Diet. SEAD adherence was measured using an index of nine food components (fresh fish, cod, red meat and pork products, dairy products, legumes and vegetables, vegetable soup, po- tatoes, wholegrain bread and wine) that ranged from 0 (lowest adherence) to 9 (highest adherence).",3,21,6 months,16S,NA,RT-qPCR,ANOVA,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Table 5,10 January 2021,Lora Kasselman,WikiWorks,"Bacterial groups quantified in human fecal samples in subjects with low, intermediate, and high adherence to Southern European Atlantic Diet (SEAD)",increased,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium,2|201174|1760|85004|31953|1678,Complete,Shaimaa Elsafoury
bsdb:130/3/1,Study 130,"cross-sectional observational, not case-control",28624933,10.1007/s13105-017-0570-4,NA,"Castro-Penalonga M, Roca-Saavedra P, Miranda JM, Porto-Arias JJ, Nebot C, Cardelle-Cobas A, Franco CM , Cepeda A",Influence of food consumption patterns and Galician lifestyle on human gut microbiota,Journal of physiology and biochemistry,2018,"Actinobacteria, Atlantic Diet, Bifidobacterium, Gut microbiota, Lactobacillus, Southern European Atlantic Diet",Experiment 3,Spain,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,<20 years participants,> 30 years participants,"SEAD: Southern European Atlantic Diet. SEAD adherence was measured using an index of nine food components (fresh fish, cod, red meat and pork products, dairy products, legumes and vegetables, vegetable soup, po- tatoes, wholegrain bread and wine) that ranged from 0 (lowest adherence) to 9 (highest adherence).",5,11,6 months,16S,NA,RT-qPCR,ANOVA,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Table 4,10 January 2021,Lora Kasselman,WikiWorks,Gut microbiota composition in subjects of different age,increased,k__Bacteria|p__Pseudomonadota,2|1224,Complete,Shaimaa Elsafoury
bsdb:130/4/1,Study 130,"cross-sectional observational, not case-control",28624933,10.1007/s13105-017-0570-4,NA,"Castro-Penalonga M, Roca-Saavedra P, Miranda JM, Porto-Arias JJ, Nebot C, Cardelle-Cobas A, Franco CM , Cepeda A",Influence of food consumption patterns and Galician lifestyle on human gut microbiota,Journal of physiology and biochemistry,2018,"Actinobacteria, Atlantic Diet, Bifidobacterium, Gut microbiota, Lactobacillus, Southern European Atlantic Diet",Experiment 4,Spain,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,>20 years participants,20-30 years participants,"SEAD: Southern European Atlantic Diet. SEAD adherence was measured using an index of nine food components (fresh fish, cod, red meat and pork products, dairy products, legumes and vegetables, vegetable soup, po- tatoes, wholegrain bread and wine) that ranged from 0 (lowest adherence) to 9 (highest adherence).",5,15,6 months,16S,NA,RT-qPCR,ANOVA,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Table 4,10 January 2021,Shaimaa Elsafoury,WikiWorks,Gut microbiota composition in subjects of different age,increased,k__Bacteria|p__Pseudomonadota,2|1224,Complete,Shaimaa Elsafoury
bsdb:130/5/1,Study 130,"cross-sectional observational, not case-control",28624933,10.1007/s13105-017-0570-4,NA,"Castro-Penalonga M, Roca-Saavedra P, Miranda JM, Porto-Arias JJ, Nebot C, Cardelle-Cobas A, Franco CM , Cepeda A",Influence of food consumption patterns and Galician lifestyle on human gut microbiota,Journal of physiology and biochemistry,2018,"Actinobacteria, Atlantic Diet, Bifidobacterium, Gut microbiota, Lactobacillus, Southern European Atlantic Diet",Experiment 5,Spain,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,20-30 years participants,> 30 years participants,"SEAD: Southern European Atlantic Diet. SEAD adherence was measured using an index of nine food components (fresh fish, cod, red meat and pork products, dairy products, legumes and vegetables, vegetable soup, po- tatoes, wholegrain bread and wine) that ranged from 0 (lowest adherence) to 9 (highest adherence).",15,11,6 months,16S,NA,RT-qPCR,ANOVA,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Table 4,10 January 2021,Shaimaa Elsafoury,WikiWorks,Gut microbiota composition in subjects of different age,increased,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus,2|1239|91061|186826|33958|1578,Complete,Shaimaa Elsafoury
bsdb:130/6/1,Study 130,"cross-sectional observational, not case-control",28624933,10.1007/s13105-017-0570-4,NA,"Castro-Penalonga M, Roca-Saavedra P, Miranda JM, Porto-Arias JJ, Nebot C, Cardelle-Cobas A, Franco CM , Cepeda A",Influence of food consumption patterns and Galician lifestyle on human gut microbiota,Journal of physiology and biochemistry,2018,"Actinobacteria, Atlantic Diet, Bifidobacterium, Gut microbiota, Lactobacillus, Southern European Atlantic Diet",Experiment 6,Spain,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,BMI < 20,BMI >25,"SEAD: Southern European Atlantic Diet. SEAD adherence was measured using an index of nine food components (fresh fish, cod, red meat and pork products, dairy products, legumes and vegetables, vegetable soup, po- tatoes, wholegrain bread and wine) that ranged from 0 (lowest adherence) to 9 (highest adherence).",5,11,6 months,16S,NA,RT-qPCR,ANOVA,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Table 3,10 January 2021,Shaimaa Elsafoury,WikiWorks,Bacterial groups quantified in human fecal samples in subjects with different body mass index (BMI),increased,"k__Bacteria|p__Actinomycetota,k__Bacteria|p__Bacteroidota",2|201174;2|976,Complete,Shaimaa Elsafoury
bsdb:130/6/2,Study 130,"cross-sectional observational, not case-control",28624933,10.1007/s13105-017-0570-4,NA,"Castro-Penalonga M, Roca-Saavedra P, Miranda JM, Porto-Arias JJ, Nebot C, Cardelle-Cobas A, Franco CM , Cepeda A",Influence of food consumption patterns and Galician lifestyle on human gut microbiota,Journal of physiology and biochemistry,2018,"Actinobacteria, Atlantic Diet, Bifidobacterium, Gut microbiota, Lactobacillus, Southern European Atlantic Diet",Experiment 6,Spain,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,BMI < 20,BMI >25,"SEAD: Southern European Atlantic Diet. SEAD adherence was measured using an index of nine food components (fresh fish, cod, red meat and pork products, dairy products, legumes and vegetables, vegetable soup, po- tatoes, wholegrain bread and wine) that ranged from 0 (lowest adherence) to 9 (highest adherence).",5,11,6 months,16S,NA,RT-qPCR,ANOVA,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 2,Table 3,10 January 2021,Shaimaa Elsafoury,WikiWorks,Bacterial groups quantified in human fecal samples in subjects with different body mass index (BMI),decreased,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium,2|201174|1760|85004|31953|1678,Complete,Shaimaa Elsafoury
bsdb:130/7/1,Study 130,"cross-sectional observational, not case-control",28624933,10.1007/s13105-017-0570-4,NA,"Castro-Penalonga M, Roca-Saavedra P, Miranda JM, Porto-Arias JJ, Nebot C, Cardelle-Cobas A, Franco CM , Cepeda A",Influence of food consumption patterns and Galician lifestyle on human gut microbiota,Journal of physiology and biochemistry,2018,"Actinobacteria, Atlantic Diet, Bifidobacterium, Gut microbiota, Lactobacillus, Southern European Atlantic Diet",Experiment 7,Spain,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,BMI <20,BMI 20-25,"SEAD: Southern European Atlantic Diet. SEAD adherence was measured using an index of nine food components (fresh fish, cod, red meat and pork products, dairy products, legumes and vegetables, vegetable soup, po- tatoes, wholegrain bread and wine) that ranged from 0 (lowest adherence) to 9 (highest adherence).",5,15,6 months,16S,NA,RT-qPCR,ANOVA,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Table 3,10 January 2021,Shaimaa Elsafoury,WikiWorks,Bacterial groups quantified in human fecal samples in subjects with different body mass index (BMI),decreased,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium,2|201174|1760|85004|31953|1678,Complete,Shaimaa Elsafoury
bsdb:130/8/1,Study 130,"cross-sectional observational, not case-control",28624933,10.1007/s13105-017-0570-4,NA,"Castro-Penalonga M, Roca-Saavedra P, Miranda JM, Porto-Arias JJ, Nebot C, Cardelle-Cobas A, Franco CM , Cepeda A",Influence of food consumption patterns and Galician lifestyle on human gut microbiota,Journal of physiology and biochemistry,2018,"Actinobacteria, Atlantic Diet, Bifidobacterium, Gut microbiota, Lactobacillus, Southern European Atlantic Diet",Experiment 8,Spain,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,BMI 20-25,BMI >25,"SEAD: Southern European Atlantic Diet. SEAD adherence was measured using an index of nine food components (fresh fish, cod, red meat and pork products, dairy products, legumes and vegetables, vegetable soup, po- tatoes, wholegrain bread and wine) that ranged from 0 (lowest adherence) to 9 (highest adherence).",15,11,6 months,16S,NA,RT-qPCR,ANOVA,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Table 3,10 January 2021,Shaimaa Elsafoury,WikiWorks,Bacterial groups quantified in human fecal samples in subjects with different body mass index (BMI),increased,k__Bacteria|p__Actinomycetota,2|201174,Complete,Shaimaa Elsafoury
bsdb:131/1/1,Study 131,randomized controlled trial,30644740,10.1021/acs.jafc.8b05408,NA,"Brasili E, Hassimotto NMA, Del Chierico F, Marini F, Quagliariello A, Sciubba F, Miccheli A, Putignani L , Lajolo F",Daily Consumption of Orange Juice from Citrus sinensis L. Osbeck cv. Cara Cara and cv. Bahia Differently Affects Gut Microbiota Profiling as Unveiled by an Integrated Meta-Omics Approach,Journal of agricultural and food chemistry,2019,"1H NMR-based metabolomics, Clostridia, gut microbiota, pyrosequencing, “Bahia” orange juice, “Cara Cara” orange juice",Experiment 1,Brazil,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,Time 0 days controls,Time 7 days,NA,21,21,current,16S,123,Roche454,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,decreased,unchanged,NA,NA,unchanged,Signature 1,"Table 1, Table 2, Table S2",10 January 2021,Lora Kasselman,WikiWorks,"Relative Abundance of Significant Gut Microbiota OTUs at T7 in Cara Cara (Brazilian orange juice), Bahia (Brazilian orange juice) and CTRLs groups",decreased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Oscillospira,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae",2|1239|186801|186802|216572|119852;2|976|200643|171549|171551,Complete,Shaimaa Elsafoury
bsdb:131/2/1,Study 131,randomized controlled trial,30644740,10.1021/acs.jafc.8b05408,NA,"Brasili E, Hassimotto NMA, Del Chierico F, Marini F, Quagliariello A, Sciubba F, Miccheli A, Putignani L , Lajolo F",Daily Consumption of Orange Juice from Citrus sinensis L. Osbeck cv. Cara Cara and cv. Bahia Differently Affects Gut Microbiota Profiling as Unveiled by an Integrated Meta-Omics Approach,Journal of agricultural and food chemistry,2019,"1H NMR-based metabolomics, Clostridia, gut microbiota, pyrosequencing, “Bahia” orange juice, “Cara Cara” orange juice",Experiment 2,Brazil,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,Time 0 days Cara Cara,Time 7 days,NA,21,21,current,16S,123,Roche454,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,NA,NA,unchanged,Signature 1,"Table 1, Table 2, Table S3",10 January 2021,Lora Kasselman,"Aiyshaaaa,WikiWorks,Merit","Relative Abundance of Significant Gut Microbiota OTUs at T7 in Cara Cara (Brazilian orange juice), Bahia (Brazilian orange juice) and CTRLs groups",increased,"k__Bacteria|p__Bacillota|c__Tissierellia|o__Tissierellales|f__Tissierellaceae,k__Bacteria|p__Bacillota|c__Clostridia,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Odoribacteraceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae",2|1239|1737404|1737405|1737406;2|1239|186801;2|1239|909932|1843489|31977;2|976|200643|171549|1853231;2|1239|186801|186802|31979,Complete,Shaimaa Elsafoury
bsdb:131/2/2,Study 131,randomized controlled trial,30644740,10.1021/acs.jafc.8b05408,NA,"Brasili E, Hassimotto NMA, Del Chierico F, Marini F, Quagliariello A, Sciubba F, Miccheli A, Putignani L , Lajolo F",Daily Consumption of Orange Juice from Citrus sinensis L. Osbeck cv. Cara Cara and cv. Bahia Differently Affects Gut Microbiota Profiling as Unveiled by an Integrated Meta-Omics Approach,Journal of agricultural and food chemistry,2019,"1H NMR-based metabolomics, Clostridia, gut microbiota, pyrosequencing, “Bahia” orange juice, “Cara Cara” orange juice",Experiment 2,Brazil,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,Time 0 days Cara Cara,Time 7 days,NA,21,21,current,16S,123,Roche454,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,NA,NA,unchanged,Signature 2,"Table 1, Table 2, Table S4",10 January 2021,Lora Kasselman,WikiWorks,"Relative Abundance of Significant Gut Microbiota OTUs at T7 in Cara Cara (Brazilian orange juice), Bahia (Brazilian orange juice) and CTRLs groups",decreased,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Odoribacteraceae|g__Odoribacter,2|976|200643|171549|1853231|283168,Complete,Shaimaa Elsafoury
bsdb:131/3/1,Study 131,randomized controlled trial,30644740,10.1021/acs.jafc.8b05408,NA,"Brasili E, Hassimotto NMA, Del Chierico F, Marini F, Quagliariello A, Sciubba F, Miccheli A, Putignani L , Lajolo F",Daily Consumption of Orange Juice from Citrus sinensis L. Osbeck cv. Cara Cara and cv. Bahia Differently Affects Gut Microbiota Profiling as Unveiled by an Integrated Meta-Omics Approach,Journal of agricultural and food chemistry,2019,"1H NMR-based metabolomics, Clostridia, gut microbiota, pyrosequencing, “Bahia” orange juice, “Cara Cara” orange juice",Experiment 3,Brazil,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,Time 0 days Bahia,Time 7 days,NA,21,21,current,16S,123,Roche454,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,NA,NA,unchanged,Signature 1,"Table 1, Table 2, Table S5",10 January 2021,Lora Kasselman,"WikiWorks,Merit","Relative Abundance of Significant Gut Microbiota OTUs at T7 in Cara Cara (Brazilian orange juice), Bahia (Brazilian orange juice) and CTRLs groups",increased,"k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae,k__Bacteria|p__Bacillota|c__Clostridia,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae,k__Bacteria|p__Bacillota|c__Tissierellia|o__Tissierellales|f__Tissierellaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Odoribacteraceae",2|1239|909932|1843489|31977;2|1239|186801;2|1239|186801|186802|31979;2|1239|1737404|1737405|1737406;2|976|200643|171549|1853231,Complete,Shaimaa Elsafoury
bsdb:131/4/1,Study 131,randomized controlled trial,30644740,10.1021/acs.jafc.8b05408,NA,"Brasili E, Hassimotto NMA, Del Chierico F, Marini F, Quagliariello A, Sciubba F, Miccheli A, Putignani L , Lajolo F",Daily Consumption of Orange Juice from Citrus sinensis L. Osbeck cv. Cara Cara and cv. Bahia Differently Affects Gut Microbiota Profiling as Unveiled by an Integrated Meta-Omics Approach,Journal of agricultural and food chemistry,2019,"1H NMR-based metabolomics, Clostridia, gut microbiota, pyrosequencing, “Bahia” orange juice, “Cara Cara” orange juice",Experiment 4,Brazil,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,controls at time 7,Cara Cara,NA,21,21,current,16S,123,Roche454,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,"Table 1, Table 2, Table S7",10 January 2021,Lora Kasselman,WikiWorks,"Relative Abundance of Significant Gut Microbiota OTUs at T7 in Cara Cara (Brazilian orange juice), Bahia (Brazilian orange juice) and CTRLs groups",increased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Tannerellaceae|g__Parabacteroides,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Barnesiellaceae,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae|g__Amedibacillus|s__Amedibacillus dolichus,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Dorea,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Anaerotruncus,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Odoribacteraceae|g__Butyricimonas",2|976|200643|171549|2005525|375288;2|976|200643|171549|2005519;2|1239|526524|526525|128827|2749846|31971;2|1239|186801|186802|31979;2|1239|186801|3085636|186803|189330;2|1239|186801|186802|541000;2|1239|186801|186802|216572|244127;2|1224|1236|91347|543;2|976|200643|171549|1853231|574697,Complete,Shaimaa Elsafoury
bsdb:131/4/2,Study 131,randomized controlled trial,30644740,10.1021/acs.jafc.8b05408,NA,"Brasili E, Hassimotto NMA, Del Chierico F, Marini F, Quagliariello A, Sciubba F, Miccheli A, Putignani L , Lajolo F",Daily Consumption of Orange Juice from Citrus sinensis L. Osbeck cv. Cara Cara and cv. Bahia Differently Affects Gut Microbiota Profiling as Unveiled by an Integrated Meta-Omics Approach,Journal of agricultural and food chemistry,2019,"1H NMR-based metabolomics, Clostridia, gut microbiota, pyrosequencing, “Bahia” orange juice, “Cara Cara” orange juice",Experiment 4,Brazil,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,controls at time 7,Cara Cara,NA,21,21,current,16S,123,Roche454,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 2,"Table 1, Table 2, Table S8",10 January 2021,Lora Kasselman,WikiWorks,"Relative Abundance of Significant Gut Microbiota OTUs at T7 in Cara Cara (Brazilian orange juice), Bahia (Brazilian orange juice) and CTRLs groups",decreased,k__Bacteria|p__Bacillota|c__Clostridia|o__Christensenellales|f__Christensenellaceae,2|1239|186801|3082768|990719,Complete,Shaimaa Elsafoury
bsdb:131/5/1,Study 131,randomized controlled trial,30644740,10.1021/acs.jafc.8b05408,NA,"Brasili E, Hassimotto NMA, Del Chierico F, Marini F, Quagliariello A, Sciubba F, Miccheli A, Putignani L , Lajolo F",Daily Consumption of Orange Juice from Citrus sinensis L. Osbeck cv. Cara Cara and cv. Bahia Differently Affects Gut Microbiota Profiling as Unveiled by an Integrated Meta-Omics Approach,Journal of agricultural and food chemistry,2019,"1H NMR-based metabolomics, Clostridia, gut microbiota, pyrosequencing, “Bahia” orange juice, “Cara Cara” orange juice",Experiment 5,Brazil,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,controls at time 7,Bahia,NA,21,21,current,16S,123,Roche454,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,"Table 1, Table 2, Table S9",10 January 2021,Lora Kasselman,WikiWorks,"Relative Abundance of Significant Gut Microbiota OTUs at T7 in Cara Cara (Brazilian orange juice), Bahia (Brazilian orange juice) and CTRLs groups",increased,"k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Eggerthellales|f__Eggerthellaceae|g__Adlercreutzia,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Enterococcaceae|g__Enterococcus,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Clostridium,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Anaerotruncus",2|201174|84998|1643822|1643826|447020;2|1239|91061|186826|81852|1350;2|1239|186801|186802|31979;2|1239|186801|186802|31979|1485;2|1239|186801|186802|541000;2|1239|186801|186802|216572|244127,Complete,Shaimaa Elsafoury
bsdb:131/6/1,Study 131,randomized controlled trial,30644740,10.1021/acs.jafc.8b05408,NA,"Brasili E, Hassimotto NMA, Del Chierico F, Marini F, Quagliariello A, Sciubba F, Miccheli A, Putignani L , Lajolo F",Daily Consumption of Orange Juice from Citrus sinensis L. Osbeck cv. Cara Cara and cv. Bahia Differently Affects Gut Microbiota Profiling as Unveiled by an Integrated Meta-Omics Approach,Journal of agricultural and food chemistry,2019,"1H NMR-based metabolomics, Clostridia, gut microbiota, pyrosequencing, “Bahia” orange juice, “Cara Cara” orange juice",Experiment 6,Brazil,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,Bahia at time 7,Cara Cara,NA,21,21,current,16S,123,Roche454,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,"Table 1, Table 2, Table S11",10 January 2021,Lora Kasselman,WikiWorks,"Relative Abundance of Significant Gut Microbiota OTUs at T7 in Cara Cara (Brazilian orange juice), Bahia (Brazilian orange juice) and CTRLs groups",increased,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae|g__Amedibacillus|s__Amedibacillus dolichus,2|1239|526524|526525|128827|2749846|31971,Complete,Shaimaa Elsafoury
bsdb:132/1/1,Study 132,randomized controlled trial,30279332,10.3390/nu10101402,NA,"Hess J, Wang Q, Gould T , Slavin J",Impact of Agaricus bisporus Mushroom Consumption on Gut Health Markers in Healthy Adults,Nutrients,2018,"fiber, gut health, laxation, microbiota, mushrooms, prebiotic",Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,mushroom,Meat,NA,16,16,3 months,16S,123,Illumina,Linear Regression,0.004,TRUE,NA,NA,"age,body mass index,sex",NA,NA,NA,NA,NA,NA,Signature 1,Table 9 and text,10 January 2021,Lora Kasselman,WikiWorks,Percent abundance across 5 days of fecal collection for identified abundant bacterial taxa (mushroom diet vs meat diet),increased,"k__Bacteria|p__Bacillota,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Dorea",2|1239;2|1239|186801|3085636|186803|189330,Complete,Shaimaa Elsafoury
bsdb:132/1/2,Study 132,randomized controlled trial,30279332,10.3390/nu10101402,NA,"Hess J, Wang Q, Gould T , Slavin J",Impact of Agaricus bisporus Mushroom Consumption on Gut Health Markers in Healthy Adults,Nutrients,2018,"fiber, gut health, laxation, microbiota, mushrooms, prebiotic",Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,mushroom,Meat,NA,16,16,3 months,16S,123,Illumina,Linear Regression,0.004,TRUE,NA,NA,"age,body mass index,sex",NA,NA,NA,NA,NA,NA,Signature 2,Table 9 and text,10 January 2021,Lora Kasselman,WikiWorks,Percent abundance across 5 days of fecal collection for identified abundant bacterial taxa (mushroom diet vs meat diet),decreased,"k__Bacteria|p__Bacteroidota,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Tannerellaceae|g__Parabacteroides,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Coprococcus,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Anaerostipes,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Sutterellaceae|g__Sutterella",2|976;2|976|200643|171549|815|816;2|976|200643|171549|2005525|375288;2|1239|186801|3085636|186803|33042;2|1239|186801|3085636|186803|207244;2|1224|28216|80840|995019|40544,Complete,Shaimaa Elsafoury
bsdb:133/1/1,Study 133,"cross-sectional observational, not case-control",30188331,10.1097/GME.0000000000001202,NA,"Yoshikata R, Myint KZ, Ohta H , Ishigaki Y","Inter-relationship between diet, lifestyle habits, gut microflora, and the equol-producer phenotype: baseline findings from a placebo-controlled intervention trial","Menopause (New York, N.Y.)",2019,NA,Experiment 1,Japan,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,"Equol producer (""healhtier"" diet)","Equol NON producer (""unhealthier"" diet)",cross sectional,45,13,NA,16S,3,Illumina,Linear Regression,0.05,FALSE,NA,NA,NA,NA,decreased,NA,NA,NA,NA,Signature 1,"Table 2, Table 3, and text",10 January 2021,Lora Kasselman,WikiWorks,TABLE 2. Comparisons of microbial results between equol producers and nonproducers,increased,k__Bacteria|p__Pseudomonadota,2|1224,Complete,NA
bsdb:133/2/1,Study 133,"cross-sectional observational, not case-control",30188331,10.1097/GME.0000000000001202,NA,"Yoshikata R, Myint KZ, Ohta H , Ishigaki Y","Inter-relationship between diet, lifestyle habits, gut microflora, and the equol-producer phenotype: baseline findings from a placebo-controlled intervention trial","Menopause (New York, N.Y.)",2019,NA,Experiment 2,Japan,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,"Equol producer (""healhtier"" diet)","Equol NON producer (""unhealthier"" diet)",cross sectional,45,13,NA,16S,3,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,decreased,NA,NA,NA,NA,Signature 1,"Table 2, Table 3, and text",10 January 2021,Lora Kasselman,WikiWorks,TABLE 2. Comparisons of microbial results between equol producers and nonproducers,decreased,k__Bacteria|p__Bacillota,2|1239,Complete,NA
bsdb:134/1/1,Study 134,randomized controlled trial,24296500,10.1128/AEM.03549-13,NA,"Roager HM, Licht TR, Poulsen SK, Larsen TM , Bahl MI","Microbial enterotypes, inferred by the prevotella-to-bacteroides ratio, remained stable during a 6-month randomized controlled diet intervention with the new nordic diet",Applied and environmental microbiology,2014,NA,Experiment 1,Denmark,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,before Average Danish Diet,6 months after Average Danish Diet,"the dietary intervention study of the NND compared to the ADD was performed as a 6-month, nonblinded, parallel, randomized, controlled, ad libitum dietary intervention trial and was carried out between October 2010 and July 2011.",26,26,NA,16S,NA,RT-qPCR,T-Test,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Figure S3,10 January 2021,Lora Kasselman,WikiWorks,"Changes in bacterial groups following the diet intervention within A) Firmicutes, B) Bacteroidetes, C) Actinobacteria, and D) γ-proteobacteria and other bacterial groups for the two diet groups ADD (n = 26, white bars) and NND (n = 36, black bars). Columns show means of log2 transformed data and error bars represent standard errors of the means. Asterisks indicate a significant difference (q < 0.05) compared to baseline. BCoAT: Butyryl-CoA:acetate CoAtransferase, NND: New Nordic Diet, ADD: Average Danish",increased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Anaerobutyricum|s__Anaerobutyricum hallii,k__Bacteria|p__Actinomycetota,k__Bacteria|p__Thermodesulfobacteriota|c__Desulfovibrionia|o__Desulfovibrionales|f__Desulfovibrionaceae|g__Desulfovibrio",2|1239|186801|3085636|186803|2569097|39488;2|201174;2|200940|3031449|213115|194924|872,Complete,Shaimaa Elsafoury
bsdb:134/2/1,Study 134,randomized controlled trial,24296500,10.1128/AEM.03549-13,NA,"Roager HM, Licht TR, Poulsen SK, Larsen TM , Bahl MI","Microbial enterotypes, inferred by the prevotella-to-bacteroides ratio, remained stable during a 6-month randomized controlled diet intervention with the new nordic diet",Applied and environmental microbiology,2014,NA,Experiment 2,Denmark,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,before  New Nordic Diet,6 months after  New Nordic Diet,"the dietary intervention study of the NND compared to the ADD was performed as a 6-month, nonblinded, parallel, randomized, controlled, ad libitum dietary intervention trial and was carried out between October 2010 and July 2011.",36,36,NA,16S,NA,RT-qPCR,T-Test,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Figure S3,10 January 2021,Shaimaa Elsafoury,WikiWorks,"Changes in bacterial groups following the diet intervention within A) Firmicutes, B) Bacteroidetes, C) Actinobacteria, and D) γ-proteobacteria and other bacterial groups for the two diet groups ADD (n = 26, white bars) and NND (n = 36, black bars). Columns show means of log2 transformed data and error bars represent standard errors of the means. Asterisks indicate a significant difference (q < 0.05) compared to baseline. BCoAT: Butyryl-CoA:acetate CoAtransferase, NND: New Nordic Diet, ADD: Average Danish",increased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Clostridium,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Anaerobutyricum|s__Anaerobutyricum hallii,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus|s__Lactobacillus acidophilus,k__Bacteria|p__Actinomycetota,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Escherichia|s__Escherichia coli,k__Bacteria|p__Thermodesulfobacteriota|c__Desulfovibrionia|o__Desulfovibrionales|f__Desulfovibrionaceae|g__Desulfovibrio",2|1239|186801|186802|31979|1485;2|1239|186801|3085636|186803|2569097|39488;2|1239|91061|186826|33958|1578|1579;2|201174;2|1224|1236|91347|543|561|562;2|200940|3031449|213115|194924|872,Complete,Shaimaa Elsafoury
bsdb:134/2/2,Study 134,randomized controlled trial,24296500,10.1128/AEM.03549-13,NA,"Roager HM, Licht TR, Poulsen SK, Larsen TM , Bahl MI","Microbial enterotypes, inferred by the prevotella-to-bacteroides ratio, remained stable during a 6-month randomized controlled diet intervention with the new nordic diet",Applied and environmental microbiology,2014,NA,Experiment 2,Denmark,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,before  New Nordic Diet,6 months after  New Nordic Diet,"the dietary intervention study of the NND compared to the ADD was performed as a 6-month, nonblinded, parallel, randomized, controlled, ad libitum dietary intervention trial and was carried out between October 2010 and July 2011.",36,36,NA,16S,NA,RT-qPCR,T-Test,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 2,Figure S3,10 January 2021,Shaimaa Elsafoury,WikiWorks,"Changes in bacterial groups following the diet intervention within A) Firmicutes, B) Bacteroidetes, C) Actinobacteria, and D) γ-proteobacteria and other bacterial groups for the two diet groups ADD (n = 26, white bars) and NND (n = 36, black bars). Columns show means of log2 transformed data and error bars represent standard errors of the means. Asterisks indicate a significant difference (q < 0.05) compared to baseline. BCoAT: Butyryl-CoA:acetate CoAtransferase, NND: New Nordic Diet, ADD: Average Danish",decreased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Rikenellaceae|g__Alistipes,k__Archaea|p__Euryarchaeota|c__Methanobacteria|o__Methanobacteriales|f__Methanobacteriaceae|g__Methanobrevibacter|s__Methanobrevibacter smithii",2|976|200643|171549|171550|239759;2157|28890|183925|2158|2159|2172|2173,Complete,Shaimaa Elsafoury
bsdb:135/1/1,Study 135,"cross-sectional observational, not case-control",21885731,10.1126/science.1208344,NA,"Wu GD, Chen J, Hoffmann C, Bittinger K, Chen YY, Keilbaugh SA, Bewtra M, Knights D, Walters WA, Knight R, Sinha R, Gilroy E, Gupta K, Baldassano R, Nessel L, Li H, Bushman FD , Lewis JD",Linking long-term dietary patterns with gut microbial enterotypes,"Science (New York, N.Y.)",2011,NA,Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,low animal protein,High animal protein,high protein / low fiber,98,98,6 months,16S,12,Roche454,ANOVA,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Figure 2C and text,10 January 2021,Lora Kasselman,WikiWorks,"The association of dietary components with each enterotype. The strength and direction of each association, as measured by the means of the standardized nutrient measurements, is shown by the color key at the lower right. Enterotype is shown at the right. Red indicates greater amounts, blue lesser amounts of each nutrient in each enterotype (complete lists of nutrients are in table S2). Columns were clustered by Euclidean distance.",increased,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides,2|976|200643|171549|815|816,Complete,NA
bsdb:135/1/2,Study 135,"cross-sectional observational, not case-control",21885731,10.1126/science.1208344,NA,"Wu GD, Chen J, Hoffmann C, Bittinger K, Chen YY, Keilbaugh SA, Bewtra M, Knights D, Walters WA, Knight R, Sinha R, Gilroy E, Gupta K, Baldassano R, Nessel L, Li H, Bushman FD , Lewis JD",Linking long-term dietary patterns with gut microbial enterotypes,"Science (New York, N.Y.)",2011,NA,Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,low animal protein,High animal protein,high protein / low fiber,98,98,6 months,16S,12,Roche454,ANOVA,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 2,Figure 2C and text,10 January 2021,Lora Kasselman,WikiWorks,"The association of dietary components with each enterotype. The strength and direction of each association, as measured by the means of the standardized nutrient measurements, is shown by the color key at the lower right. Enterotype is shown at the right. Red indicates greater amounts, blue lesser amounts of each nutrient in each enterotype (complete lists of nutrients are in table S2). Columns were clustered by Euclidean distance.",decreased,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae,2|976|200643|171549|171552,Complete,NA
bsdb:135/2/1,Study 135,"cross-sectional observational, not case-control",21885731,10.1126/science.1208344,NA,"Wu GD, Chen J, Hoffmann C, Bittinger K, Chen YY, Keilbaugh SA, Bewtra M, Knights D, Walters WA, Knight R, Sinha R, Gilroy E, Gupta K, Baldassano R, Nessel L, Li H, Bushman FD , Lewis JD",Linking long-term dietary patterns with gut microbial enterotypes,"Science (New York, N.Y.)",2011,NA,Experiment 2,United States of America,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,high fiber,Low fiber,high protein / low fiber,98,98,6 months,16S,12,Roche454,ANOVA,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Figure 2C and text,10 January 2021,Lora Kasselman,WikiWorks,"The association of dietary components with each enterotype. The strength and direction of each association, as measured by the means of the standardized nutrient measurements, is shown by the color key at the lower right. Enterotype is shown at the right. Red indicates greater amounts, blue lesser amounts of each nutrient in each enterotype (complete lists of nutrients are in table S2). Columns were clustered by Euclidean distance.",increased,"k__Bacteria|p__Bacteroidota,k__Bacteria|p__Actinomycetota",2|976;2|201174,Complete,NA
bsdb:135/2/2,Study 135,"cross-sectional observational, not case-control",21885731,10.1126/science.1208344,NA,"Wu GD, Chen J, Hoffmann C, Bittinger K, Chen YY, Keilbaugh SA, Bewtra M, Knights D, Walters WA, Knight R, Sinha R, Gilroy E, Gupta K, Baldassano R, Nessel L, Li H, Bushman FD , Lewis JD",Linking long-term dietary patterns with gut microbial enterotypes,"Science (New York, N.Y.)",2011,NA,Experiment 2,United States of America,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,high fiber,Low fiber,high protein / low fiber,98,98,6 months,16S,12,Roche454,ANOVA,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 2,Figure 2C and text,10 January 2021,Lora Kasselman,WikiWorks,"The association of dietary components with each enterotype. The strength and direction of each association, as measured by the means of the standardized nutrient measurements, is shown by the color key at the lower right. Enterotype is shown at the right. Red indicates greater amounts, blue lesser amounts of each nutrient in each enterotype (complete lists of nutrients are in table S2). Columns were clustered by Euclidean distance.",decreased,k__Bacteria|p__Actinomycetota,2|201174,Complete,NA
bsdb:136/1/1,Study 136,time series / longitudinal observational,29738477,10.3390/nu10050576,NA,"Klimenko NS, Tyakht AV, Popenko AS, Vasiliev AS, Altukhov IA, Ischenko DS, Shashkova TI, Efimova DA, Nikogosov DA, Osipenko DA, Musienko SV, Selezneva KS, Baranova A, Kurilshikov AM, Toshchakov SM, Korzhenkov AA, Samarov NI, Shevchenko MA, Tepliuk AV , Alexeev DG",Microbiome Responses to an Uncontrolled Short-Term Diet Intervention in the Frame of the Citizen Science Project,Nutrients,2018,"16S rRNA metagenomics, citizen science, gut microbiota, intervention, microbiome stability, personalized diet, responders",Experiment 1,Russian Federation,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,"high vegetable, fruit, grain","Low vegetable, fruit, grains,",low fiber,215,215,NA,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Figure 1 and Figure 2,10 January 2021,Lora Kasselman,WikiWorks,"Figure 1. Associations of the microbial taxa with long-term dietary habits and other factors from the questionnaire (n = 207 subjects). Analysis was performed for the baseline samples at taxonomic levels from species to phyla. Rows are sorted in alphabetic order. Cell color denotes the value of the linear model coefficient from the MaAsLin analysis. All significant associations (FDR adjusted p < 0.1) are marked with one of the symbols (&, #, @): “&”. Figure 2. Major changes in the gut community structure of the volunteers after following the dietary
recommendations. Red branches of the cladogram denote the taxa that were increased in abundance,
while the blue ones—decreased. Significance criterion: p < 0.05 in metagenomeSeq model and log10 of
the effect size >2 in LEfSe method (n = 430 paired samples).",increased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Rikenellaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae,k__Bacteria|p__Bacillota|c__Negativicutes|o__Acidaminococcales|f__Acidaminococcaceae,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Sutterellaceae,k__Bacteria|p__Thermodesulfobacteriota|c__Desulfovibrionia|o__Desulfovibrionales|f__Desulfovibrionaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae",2|976|200643|171549|815;2|976|200643|171549|171551;2|976|200643|171549|171552;2|976|200643|171549|171550;2|1239|186801|186802|216572;2|1239|909932|1843488|909930;2|1239|909932|1843489|31977;2|1224|28216|80840|995019;2|200940|3031449|213115|194924;2|1239|91061|186826|33958,Complete,NA
bsdb:136/1/2,Study 136,time series / longitudinal observational,29738477,10.3390/nu10050576,NA,"Klimenko NS, Tyakht AV, Popenko AS, Vasiliev AS, Altukhov IA, Ischenko DS, Shashkova TI, Efimova DA, Nikogosov DA, Osipenko DA, Musienko SV, Selezneva KS, Baranova A, Kurilshikov AM, Toshchakov SM, Korzhenkov AA, Samarov NI, Shevchenko MA, Tepliuk AV , Alexeev DG",Microbiome Responses to an Uncontrolled Short-Term Diet Intervention in the Frame of the Citizen Science Project,Nutrients,2018,"16S rRNA metagenomics, citizen science, gut microbiota, intervention, microbiome stability, personalized diet, responders",Experiment 1,Russian Federation,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,"high vegetable, fruit, grain","Low vegetable, fruit, grains,",low fiber,215,215,NA,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,NA,NA,NA,NA,NA,Signature 2,Figure 1 and Figure 2,10 January 2021,Lora Kasselman,WikiWorks,"Figure 1. Associations of the microbial taxa with long-term dietary habits and other factors from the questionnaire (n = 207 subjects). Analysis was performed for the baseline samples at taxonomic levels from species to phyla. Rows are sorted in alphabetic order. Cell color denotes the value of the linear model coefficient from the MaAsLin analysis. All significant associations (FDR adjusted p < 0.1) are marked with one of the symbols (&, #, @): “&”. Figure 2. Major changes in the gut community structure of the volunteers after following the dietary
recommendations. Red branches of the cladogram denote the taxa that were increased in abundance,
while the blue ones—decreased. Significance criterion: p < 0.05 in metagenomeSeq model and log10 of
the effect size >2 in LEfSe method (n = 430 paired samples).",decreased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Clostridium,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Eubacteriaceae|g__Eubacterium,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Oscillibacter,k__Archaea|p__Euryarchaeota|c__Methanobacteria|o__Methanobacteriales|f__Methanobacteriaceae,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales|f__Coriobacteriaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Staphylococcaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Enterococcaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Christensenellales|f__Christensenellaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae,k__Bacteria|p__Bacillota,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Sphingomonadales|f__Sphingomonadaceae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae,k__Bacteria|p__Verrucomicrobiota|c__Verrucomicrobiia|o__Verrucomicrobiales|f__Verrucomicrobiaceae",2|1239|186801|186802|31979|1485;2|1239|186801|186802|186806|1730;2|1239|186801|3085636|186803;2|1239|186801|186802|216572|459786;2157|28890|183925|2158|2159;2|201174|1760|85004|31953;2|201174|84998|84999|84107;2|1239|91061|1385|90964;2|1239|91061|186826|81852;2|1239|91061|186826|1300;2|1239|186801|3082768|424536;2|1239|186801|186802|31979;2|1239|526524|526525|128827;2|1239;2|1224|28211|204457|41297;2|1224|1236|91347|543;2|74201|203494|48461|203557,Complete,NA
bsdb:136/2/1,Study 136,time series / longitudinal observational,29738477,10.3390/nu10050576,NA,"Klimenko NS, Tyakht AV, Popenko AS, Vasiliev AS, Altukhov IA, Ischenko DS, Shashkova TI, Efimova DA, Nikogosov DA, Osipenko DA, Musienko SV, Selezneva KS, Baranova A, Kurilshikov AM, Toshchakov SM, Korzhenkov AA, Samarov NI, Shevchenko MA, Tepliuk AV , Alexeev DG",Microbiome Responses to an Uncontrolled Short-Term Diet Intervention in the Frame of the Citizen Science Project,Nutrients,2018,"16S rRNA metagenomics, citizen science, gut microbiota, intervention, microbiome stability, personalized diet, responders",Experiment 2,Russian Federation,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,before dietary intervention,two weeks after a dietry intervention,NA,215,215,NA,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Figure S8,10 January 2021,Shaimaa Elsafoury,WikiWorks,"Сhanges in relative abundance of microbial taxa after dietary intervention. The analysis was performed using metagenomeSeq. For each taxon, the columns “Beta” and “Eff. size” contain the values of linear model coefficient and effect size calculated using LEfSe.",increased,"k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Eggerthellales|f__Eggerthellaceae|g__Eggerthella|s__Eggerthella lenta,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|g__Howardella|s__Howardella ureilytica,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Eggerthellales|f__Eggerthellaceae|g__Eggerthella,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Lactococcus|s__Lactococcus lactis,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium|s__Bifidobacterium longum|s__Bifidobacterium longum subsp. longum,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Lactococcus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus,k__Bacteria|p__Verrucomicrobiota|c__Verrucomicrobiia|o__Verrucomicrobiales|f__Verrucomicrobiaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Enterococcaceae|g__Enterococcus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Enterococcaceae,k__Bacteria|p__Verrucomicrobiota|c__Verrucomicrobiia,k__Bacteria|p__Verrucomicrobiota|c__Verrucomicrobiia|o__Verrucomicrobiales,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Dorea|s__Dorea longicatena,k__Bacteria|p__Verrucomicrobiota,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Eubacteriaceae|g__Eubacterium,k__Bacteria|p__Bacillota|c__Bacilli,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium|s__Bifidobacterium adolescentis,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales|f__Coriobacteriaceae|g__Collinsella|s__Collinsella aerofaciens,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales|f__Coriobacteriaceae|g__Collinsella,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Clostridium,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales,k__Bacteria|p__Bacillota|c__Clostridia,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Blautia",2|201174|84998|1643822|1643826|84111|84112;2|1239|186801|186802|404402|404403;2|201174|84998|1643822|1643826|84111;2|1239|91061|186826|1300|1357|1358;2|201174|1760|85004|31953|1678|216816|1679;2|1239|91061|186826|1300|1357;2|1239|91061|186826|1300|1301;2|74201|203494|48461|203557;2|1239|91061|186826|81852|1350;2|1239|91061|186826|1300;2|1239|91061|186826|81852;2|74201|203494;2|74201|203494|48461;2|1239|186801|3085636|186803|189330|88431;2|74201;2|1224|28211;2|1239|186801|186802|186806|1730;2|1239|91061;2|201174|1760|85004|31953|1678|1680;2|201174|84998|84999|84107|102106|74426;2|201174|84998|84999|84107|102106;2|1239|186801|186802|31979|1485;2|1239|186801|186802|31979;2|1239|186801|186802;2|1239|186801;2|201174|1760|85004|31953|1678;2|201174|1760|85004|31953;2|1239|186801|3085636|186803|572511,Complete,Shaimaa Elsafoury
bsdb:136/2/2,Study 136,time series / longitudinal observational,29738477,10.3390/nu10050576,NA,"Klimenko NS, Tyakht AV, Popenko AS, Vasiliev AS, Altukhov IA, Ischenko DS, Shashkova TI, Efimova DA, Nikogosov DA, Osipenko DA, Musienko SV, Selezneva KS, Baranova A, Kurilshikov AM, Toshchakov SM, Korzhenkov AA, Samarov NI, Shevchenko MA, Tepliuk AV , Alexeev DG",Microbiome Responses to an Uncontrolled Short-Term Diet Intervention in the Frame of the Citizen Science Project,Nutrients,2018,"16S rRNA metagenomics, citizen science, gut microbiota, intervention, microbiome stability, personalized diet, responders",Experiment 2,Russian Federation,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,before dietary intervention,two weeks after a dietry intervention,NA,215,215,NA,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,NA,NA,NA,NA,NA,Signature 2,Figure S8,10 January 2021,Shaimaa Elsafoury,"Fatima,WikiWorks","Сhanges in relative abundance of microbial taxa after dietary intervention. The analysis was performed using metagenomeSeq. For each taxon, the columns “Beta” and “Eff. size” contain the values of linear model coefficient and effect size calculated using LEfSe.",decreased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides|s__Bacteroides clarus,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides|s__Bacteroides eggerthii,k__Bacteria|c__Deltaproteobacteria,k__Bacteria|p__Thermodesulfobacteriota|c__Desulfovibrionia|o__Desulfovibrionales|f__Desulfovibrionaceae|g__Desulfovibrio,k__Bacteria|p__Thermodesulfobacteriota|c__Desulfovibrionia|o__Desulfovibrionales,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Dialister,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Faecalibacterium,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Lachnospira|s__Lachnospira eligens,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae,k__Bacteria|p__Bacillota|c__Negativicutes|o__Acidaminococcales|f__Acidaminococcaceae|g__Phascolarctobacterium|s__Phascolarctobacterium succinatutens,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Phocaeicola|s__Phocaeicola plebeius,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Roseburia|s__Roseburia hominis,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Ruminococcus,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Eggerthellales|f__Eggerthellaceae|g__Slackia,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Eggerthellales|f__Eggerthellaceae|g__Slackia|s__Slackia isoflavoniconvertens,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Veillonella,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Mediterraneibacter|s__[Ruminococcus] lactaris,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|s__[Eubacterium] siraeum",2|976|200643|171549|815|816|626929;2|976|200643|171549|815|816|28111;2|28221;2|200940|3031449|213115|194924|872;2|200940|3031449|213115;2|1239|909932|1843489|31977|39948;2|1239|186801|186802|216572|216851;2|1239|186801|3085636|186803|28050|39485;2|1239|91061|186826|33958;2|1239|909932|1843488|909930|33024|626940;2|976|200643|171549|815|909656|310297;2|1239|186801|3085636|186803|841|301301;2|1239|186801|186802|216572|1263;2|201174|84998|1643822|1643826|84108;2|201174|84998|1643822|1643826|84108|572010;2|1239|909932|1843489|31977|29465;2|1239|909932|1843489|31977;2|1239|186801|3085636|186803|2316020|46228;2|1239|186801|186802|216572|39492,Complete,Fatima
bsdb:137/1/1,Study 137,case-control,31358825,10.1038/s41598-019-45588-z,NA,"Yang TW, Lee WH, Tu SJ, Huang WC, Chen HM, Sun TH, Tsai MC, Wang CC, Chen HY, Huang CC, Shiu BH, Yang TL, Huang HT, Chou YP, Chou CH, Huang YR, Sun YR, Liang C, Lin FM, Ho SY, Chen WL, Yang SF, Ueng KC, Huang HD, Huang CN, Jong YJ , Lin CC",Enterotype-based Analysis of Gut Microbiota along the Conventional Adenoma-Carcinoma Colorectal Cancer Pathway,Scientific reports,2019,NA,Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,controls,CRC,CRC positive during colonoscopy,104,62,2 months,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.01,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,increased,Signature 1,"Figure 4A, Text",10 January 2021,Lora Kasselman,"Claregrieve1,WikiWorks",Differential microbial abundance between controls and colorectal cancer patients,increased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Aeromonadales|f__Aeromonadaceae|g__Aeromonas,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae|g__Fusobacterium",2|1224|1236|135624|84642|642;2|32066|203490|203491|203492|848,Complete,Claregrieve1
bsdb:137/1/2,Study 137,case-control,31358825,10.1038/s41598-019-45588-z,NA,"Yang TW, Lee WH, Tu SJ, Huang WC, Chen HM, Sun TH, Tsai MC, Wang CC, Chen HY, Huang CC, Shiu BH, Yang TL, Huang HT, Chou YP, Chou CH, Huang YR, Sun YR, Liang C, Lin FM, Ho SY, Chen WL, Yang SF, Ueng KC, Huang HD, Huang CN, Jong YJ , Lin CC",Enterotype-based Analysis of Gut Microbiota along the Conventional Adenoma-Carcinoma Colorectal Cancer Pathway,Scientific reports,2019,NA,Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,controls,CRC,CRC positive during colonoscopy,104,62,2 months,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.01,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,increased,Signature 2,"Figure 4A, Text",10 January 2021,Lora Kasselman,"Claregrieve1,WikiWorks",Differential microbial abundance between controls and colorectal cancer patients,decreased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides,k__Bacteria|p__Thermodesulfobacteriota|c__Desulfovibrionia|o__Desulfovibrionales|f__Desulfovibrionaceae|g__Bilophila,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Citrobacter,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Cronobacter,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Dorea,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Eubacteriaceae|g__Eubacterium,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Roseburia",2|976|200643|171549|815|816;2|200940|3031449|213115|194924|35832;2|1224|1236|91347|543|544;2|1224|1236|91347|543|413496;2|1239|186801|3085636|186803|189330;2|1239|186801|186802|186806|1730;2|1239|186801|3085636|186803|841,Complete,NA
bsdb:138/1/1,Study 138,case-control,31065547,10.3389/fcimb.2019.00112,NA,"Zhuang H, Cheng L, Wang Y, Zhang YK, Zhao MF, Liang GD, Zhang MC, Li YG, Zhao JB, Gao YN, Zhou YJ , Liu SL",Dysbiosis of the Gut Microbiome in Lung Cancer,Frontiers in cellular and infection microbiology,2019,"16S rRNA, biomarkers, gut microbiota, lung cancer, microbial diversity, next generation sequencing",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Lung cancer,MONDO:0008903,controls,lung cancer,lung cancer patients,30,30,3 months,16S,34,Illumina,LEfSe,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,Signature 1,"Figure 3, Supplementary Figure S3",10 January 2021,Rimsha Azhar,"Claregrieve1,WikiWorks",Differential microbial abundance between lung cancer patients and healthy controls by LefSe,increased,"k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales|f__Actinomycetaceae|g__Actinomyces,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales|f__Actinomycetaceae,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales|f__Atopobiaceae|g__Atopobium,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Enterococcaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Enterococcaceae|g__Enterococcus,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Coprobacillaceae|g__Thomasclavelia,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae|g__Holdemanella,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|g__Intestinimonas,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Staphylococcaceae|g__Macrococcus,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Raoultella,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Staphylococcaceae",2|201174|1760|2037|2049|1654;2|201174|1760|2037|2049;2|201174|1760|2037;2|201174|84998|84999|1643824|1380;2|1239|91061|186826|81852;2|1239|91061|186826|81852|1350;2|1239|526524|526525|2810280|1505663;2|1239|526524|526525|128827|1573535;2|1239|186801|186802|1392389;2|1239|91061|1385|90964|69965;2|1224|1236|91347|543|160674;2|1239|91061|1385|90964,Complete,Claregrieve1
bsdb:138/1/2,Study 138,case-control,31065547,10.3389/fcimb.2019.00112,NA,"Zhuang H, Cheng L, Wang Y, Zhang YK, Zhao MF, Liang GD, Zhang MC, Li YG, Zhao JB, Gao YN, Zhou YJ , Liu SL",Dysbiosis of the Gut Microbiome in Lung Cancer,Frontiers in cellular and infection microbiology,2019,"16S rRNA, biomarkers, gut microbiota, lung cancer, microbial diversity, next generation sequencing",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Lung cancer,MONDO:0008903,controls,lung cancer,lung cancer patients,30,30,3 months,16S,34,Illumina,LEfSe,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,Signature 2,"Figure 3, Supplementary Figure S3",10 January 2021,Rimsha Azhar,"Claregrieve1,WikiWorks",Differential microbial abundance between lung cancer patients and healthy controls by LefSe,decreased,"k__Bacteria|p__Actinomycetota|c__Actinomycetes,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Eggerthellales|f__Eggerthellaceae|g__Adlercreutzia,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Alteromonadales|f__Alteromonadaceae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Alteromonadales,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Alteromonadales|f__Alteromonadaceae|g__Alteromonas,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales|f__Coriobacteriaceae|g__Collinsella,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Barnesiellaceae|g__Coprobacter,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales|f__Coriobacteriaceae,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Dorea,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Lachnospira,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Bacillaceae|g__Lentibacillus,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Moryella,k__Bacteria|p__Bacillota|c__Tissierellia|o__Tissierellales|f__Peptoniphilaceae|g__Peptoniphilus,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Peptostreptococcaceae|g__Peptostreptococcus,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Pseudobutyrivibrio,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Ruminiclostridium,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Sutterellaceae|g__Sutterella",2|201174|1760;2|201174|84998|1643822|1643826|447020;2|1224|1236|135622|72275;2|1224|1236|135622;2|1224|1236|135622|72275|226;2|201174|1760|85004|31953;2|201174|1760|85004;2|201174|1760|85004|31953|1678;2|1239|186801|186802|31979;2|201174|84998|84999|84107|102106;2|976|200643|171549|2005519|1348911;2|201174|84998|84999|84107;2|201174|84998|84999;2|1239|186801|3085636|186803|189330;2|1239|186801|3085636|186803|28050;2|1239|91061|1385|186817|175304;2|1239|186801|3085636|186803|437755;2|1239|1737404|1737405|1570339|162289;2|1239|186801|3082720|186804|1257;2|1239|186801|3085636|186803|46205;2|1239|186801|186802|216572|1508657;2|1224|28216|80840|995019|40544,Complete,Claregrieve1
bsdb:139/1/1,Study 139,case-control,29327043,10.1001/jamaoncol.2017.4777,NA,"Hayes RB, Ahn J, Fan X, Peters BA, Ma Y, Yang L, Agalliu I, Burk RD, Ganly I, Purdue MP, Freedman ND, Gapstur SM , Pei Z",Association of Oral Microbiome With Risk for Incident Head and Neck Squamous Cell Cancer,JAMA oncology,2018,NA,Experiment 1,United States of America,Homo sapiens,Saliva,UBERON:0001836,Head and neck squamous cell carcinoma,EFO:0000181,controls,HNSCC,"histologically confirmed incident HNSCC including oral cavity, pharynx and larynx. (excluding salivary glands & nasopharynx)",254,129,NA,16S,34,Roche454,DESeq2,0.1,TRUE,NA,"age,date,ethnic group,sex","age,alcohol drinking,sex,smoking behavior",NA,NA,NA,NA,unchanged,unchanged,Signature 1,Table 2,10 January 2021,Utsav Patel,"Claregrieve1,WikiWorks",Differential microbial abundance between controls and HNSCC patients,increased,k__Bacteria|p__Actinomycetota,2|201174,Complete,Fatima Zohra
bsdb:139/1/2,Study 139,case-control,29327043,10.1001/jamaoncol.2017.4777,NA,"Hayes RB, Ahn J, Fan X, Peters BA, Ma Y, Yang L, Agalliu I, Burk RD, Ganly I, Purdue MP, Freedman ND, Gapstur SM , Pei Z",Association of Oral Microbiome With Risk for Incident Head and Neck Squamous Cell Cancer,JAMA oncology,2018,NA,Experiment 1,United States of America,Homo sapiens,Saliva,UBERON:0001836,Head and neck squamous cell carcinoma,EFO:0000181,controls,HNSCC,"histologically confirmed incident HNSCC including oral cavity, pharynx and larynx. (excluding salivary glands & nasopharynx)",254,129,NA,16S,34,Roche454,DESeq2,0.1,TRUE,NA,"age,date,ethnic group,sex","age,alcohol drinking,sex,smoking behavior",NA,NA,NA,NA,unchanged,unchanged,Signature 2,Table 2,10 January 2021,Utsav Patel,"Claregrieve1,WikiWorks",Differential microbial abundance between controls and HNSCC patients,decreased,"k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria,k__Bacteria|p__Bacteroidota|c__Flavobacteriia|o__Flavobacteriales|f__Flavobacteriaceae|g__Capnocytophaga|s__Capnocytophaga leadbetteri,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Mycobacteriales|f__Corynebacteriaceae|g__Corynebacterium,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Neisseriaceae|g__Kingella,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Hoylesella|s__Hoylesella nanceiensis,k__Bacteria|p__Bacillota|c__Negativicutes|o__Selenomonadales|f__Selenomonadaceae|g__Selenomonas|s__Selenomonas sputigena",2|1224|28216;2|976|117743|200644|49546|1016|327575;2|201174|1760|85007|1653|1716;2|1224|28216|206351|481|32257;2|976|200643|171549|171552|2974257|425941;2|1239|909932|909929|1843491|970|69823,Complete,Fatima Zohra
bsdb:139/2/1,Study 139,case-control,29327043,10.1001/jamaoncol.2017.4777,NA,"Hayes RB, Ahn J, Fan X, Peters BA, Ma Y, Yang L, Agalliu I, Burk RD, Ganly I, Purdue MP, Freedman ND, Gapstur SM , Pei Z",Association of Oral Microbiome With Risk for Incident Head and Neck Squamous Cell Cancer,JAMA oncology,2018,NA,Experiment 2,United States of America,Homo sapiens,Saliva,UBERON:0001836,Squamous cell carcinoma,EFO:0000707,controls,Larynx cancer cases,histologically confirmed incident HNSCC involving the larynx,254,58,NA,16S,34,Roche454,DESeq2,0.1,TRUE,NA,"age,date,ethnic group,sex","age,alcohol drinking,sex,smoking status",NA,NA,NA,NA,NA,NA,Signature 1,"Table 2, Supplementary Table 6, Text",10 January 2021,Utsav Patel,"Claregrieve1,WikiWorks",Differential microbial abundance between controls and larynx cancer patients,decreased,"k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Aerococcaceae|g__Abiotrophia,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria,k__Bacteria|p__Bacteroidota|c__Flavobacteriia|o__Flavobacteriales|f__Flavobacteriaceae|g__Capnocytophaga,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Mycobacteriales|f__Corynebacteriaceae|g__Corynebacterium,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Neisseriaceae|g__Kingella,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Neisseriaceae|g__Kingella|s__Kingella denitrificans,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Neisseriaceae|g__Neisseria,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus|s__Streptococcus sanguinis",2|1239|91061|186826|186827|46123;2|1224|28216;2|976|117743|200644|49546|1016;2|201174|1760|85007|1653|1716;2|1224|28216|206351|481|32257;2|1224|28216|206351|481|32257|502;2|1224|28216|206351|481|482;2|1224|28216|206351;2|1239|91061|186826|1300|1301|1305,Complete,Fatima Zohra
bsdb:139/3/1,Study 139,case-control,29327043,10.1001/jamaoncol.2017.4777,NA,"Hayes RB, Ahn J, Fan X, Peters BA, Ma Y, Yang L, Agalliu I, Burk RD, Ganly I, Purdue MP, Freedman ND, Gapstur SM , Pei Z",Association of Oral Microbiome With Risk for Incident Head and Neck Squamous Cell Cancer,JAMA oncology,2018,NA,Experiment 3,United States of America,Homo sapiens,Saliva,UBERON:0001836,Squamous cell carcinoma,EFO:0000707,controls,Pharynx cancer cases,histologically confirmed incident HNSCC involving the pharynx,254,30,NA,16S,34,Roche454,DESeq2,0.1,TRUE,NA,"age,date,ethnic group,sex","age,alcohol drinking,sex,smoking status",NA,NA,NA,NA,NA,NA,Signature 1,"Table 2, Supplementary Table 6, Text",10 January 2021,Utsav Patel,"Claregrieve1,WikiWorks",Differential microbial abundance between controls and pharynx cancer patients,decreased,"k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales|f__Actinomycetaceae|g__Actinomyces|s__Actinomyces oris,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Mycobacteriales|f__Corynebacteriaceae|g__Corynebacterium,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Neisseriaceae|g__Kingella,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Veillonella|s__Veillonella denticariosi",2|201174|1760|2037|2049|1654|544580;2|1224|28216;2|201174|1760|85007|1653|1716;2|1224|28216|206351|481|32257;2|1224|28216|206351;2|1239|909932|1843489|31977|29465|419208,Complete,Fatima Zohra
bsdb:139/4/1,Study 139,case-control,29327043,10.1001/jamaoncol.2017.4777,NA,"Hayes RB, Ahn J, Fan X, Peters BA, Ma Y, Yang L, Agalliu I, Burk RD, Ganly I, Purdue MP, Freedman ND, Gapstur SM , Pei Z",Association of Oral Microbiome With Risk for Incident Head and Neck Squamous Cell Cancer,JAMA oncology,2018,NA,Experiment 4,United States of America,Homo sapiens,Saliva,UBERON:0001836,Squamous cell carcinoma,EFO:0000707,controls,Oral cavity cancer cases,histologically confirmed incident HNSCC involving the oral cavity,254,41,NA,16S,34,Roche454,DESeq2,0.1,TRUE,NA,"age,date,ethnic group,sex","age,alcohol drinking,sex,smoking status",NA,NA,NA,NA,NA,NA,Signature 1,"Table 2, Supplementary Table 6, Text",10 January 2021,Utsav Patel,"Claregrieve1,WikiWorks",Differential microbial abundance between controls and oral cavity cancer patients,increased,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales|f__Actinomycetaceae|g__Actinomyces,2|201174|1760|2037|2049|1654,Complete,Fatima Zohra
bsdb:139/4/2,Study 139,case-control,29327043,10.1001/jamaoncol.2017.4777,NA,"Hayes RB, Ahn J, Fan X, Peters BA, Ma Y, Yang L, Agalliu I, Burk RD, Ganly I, Purdue MP, Freedman ND, Gapstur SM , Pei Z",Association of Oral Microbiome With Risk for Incident Head and Neck Squamous Cell Cancer,JAMA oncology,2018,NA,Experiment 4,United States of America,Homo sapiens,Saliva,UBERON:0001836,Squamous cell carcinoma,EFO:0000707,controls,Oral cavity cancer cases,histologically confirmed incident HNSCC involving the oral cavity,254,41,NA,16S,34,Roche454,DESeq2,0.1,TRUE,NA,"age,date,ethnic group,sex","age,alcohol drinking,sex,smoking status",NA,NA,NA,NA,NA,NA,Signature 2,"Table 2, Supplementary Table 6, Text",10 January 2021,Utsav Patel,"Claregrieve1,WikiWorks",Differential microbial abundance between controls and oral cavity cancer patients,decreased,"k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Neisseriaceae|g__Neisseria|s__Neisseria sicca,k__Bacteria|p__Bacillota|c__Tissierellia|o__Tissierellales|f__Peptoniphilaceae|g__Parvimonas|s__Parvimonas micra",2|1224|28216|206351|481|482|490;2|1239|1737404|1737405|1570339|543311|33033,Complete,Fatima Zohra
bsdb:140/1/1,Study 140,case-control,27352007,10.1038/ncomms12015,NA,"Jangi S, Gandhi R, Cox LM, Li N, von Glehn F, Yan R, Patel B, Mazzola MA, Liu S, Glanz BL, Cook S, Tankou S, Stuart F, Melo K, Nejad P, Smith K, Topçuolu BD, Holden J, Kivisäkk P, Chitnis T, De Jager PL, Quintana FJ, Gerber GK, Bry L , Weiner HL",Alterations of the human gut microbiome in multiple sclerosis,Nature communications,2016,NA,Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Multiple sclerosis,MONDO:0005301,healthy controls,multiple sclerosis,multiple sclerosis patients,43,60,6 months,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,Signature 1,"Figure 2a, 2c, Table 2",10 January 2021,Rimsha Azhar,WikiWorks,Compositional differences in fecal microbiota between patients of MS compared to healthy controls using Illumina MiSeq,increased,"k__Archaea|p__Euryarchaeota|c__Methanobacteria|o__Methanobacteriales|f__Methanobacteriaceae|g__Methanobrevibacter,k__Bacteria|p__Verrucomicrobiota|c__Verrucomicrobiia|o__Verrucomicrobiales|f__Akkermansiaceae|g__Akkermansia,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micromonosporales|f__Micromonosporaceae|g__Micromonospora,k__Archaea|p__Euryarchaeota",2157|28890|183925|2158|2159|2172;2|74201|203494|48461|1647988|239934;2|201174|1760|85008|28056|84593;2157|28890,Complete,Claregrieve1
bsdb:140/1/2,Study 140,case-control,27352007,10.1038/ncomms12015,NA,"Jangi S, Gandhi R, Cox LM, Li N, von Glehn F, Yan R, Patel B, Mazzola MA, Liu S, Glanz BL, Cook S, Tankou S, Stuart F, Melo K, Nejad P, Smith K, Topçuolu BD, Holden J, Kivisäkk P, Chitnis T, De Jager PL, Quintana FJ, Gerber GK, Bry L , Weiner HL",Alterations of the human gut microbiome in multiple sclerosis,Nature communications,2016,NA,Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Multiple sclerosis,MONDO:0005301,healthy controls,multiple sclerosis,multiple sclerosis patients,43,60,6 months,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,Signature 2,"Figure 2a, 2c, Table 2",10 January 2021,Rimsha Azhar,WikiWorks,Compositional differences in fecal microbiota between patients of MS compared to healthy controls using Illumina MiSeq,decreased,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Odoribacteraceae|g__Butyricimonas,2|976|200643|171549|1853231|574697,Complete,Claregrieve1
bsdb:140/2/1,Study 140,case-control,27352007,10.1038/ncomms12015,NA,"Jangi S, Gandhi R, Cox LM, Li N, von Glehn F, Yan R, Patel B, Mazzola MA, Liu S, Glanz BL, Cook S, Tankou S, Stuart F, Melo K, Nejad P, Smith K, Topçuolu BD, Holden J, Kivisäkk P, Chitnis T, De Jager PL, Quintana FJ, Gerber GK, Bry L , Weiner HL",Alterations of the human gut microbiome in multiple sclerosis,Nature communications,2016,NA,Experiment 2,United States of America,Homo sapiens,Feces,UBERON:0001988,Multiple sclerosis,MONDO:0005301,controls,multiple sclerosis patients,patients with multiple sclerosis,43,60,6 months,16S,345,Roche454,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,Signature 1,"Figure 2a, 2c, Table 2",10 January 2021,Rimsha Azhar,WikiWorks,Compositional differences in fecal microbiota between patients of MS compared to healthy controls using Roche 454,increased,"k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micromonosporales|f__Micromonosporaceae|g__Micromonospora,k__Archaea|p__Euryarchaeota|c__Methanobacteria|o__Methanobacteriales|f__Methanobacteriaceae|g__Methanobrevibacter,k__Bacteria|p__Verrucomicrobiota|c__Verrucomicrobiia|o__Verrucomicrobiales|f__Akkermansiaceae|g__Akkermansia,k__Archaea|p__Euryarchaeota",2|201174|1760|85008|28056|84593;2157|28890|183925|2158|2159|2172;2|74201|203494|48461|1647988|239934;2157|28890,Complete,Claregrieve1
bsdb:140/2/2,Study 140,case-control,27352007,10.1038/ncomms12015,NA,"Jangi S, Gandhi R, Cox LM, Li N, von Glehn F, Yan R, Patel B, Mazzola MA, Liu S, Glanz BL, Cook S, Tankou S, Stuart F, Melo K, Nejad P, Smith K, Topçuolu BD, Holden J, Kivisäkk P, Chitnis T, De Jager PL, Quintana FJ, Gerber GK, Bry L , Weiner HL",Alterations of the human gut microbiome in multiple sclerosis,Nature communications,2016,NA,Experiment 2,United States of America,Homo sapiens,Feces,UBERON:0001988,Multiple sclerosis,MONDO:0005301,controls,multiple sclerosis patients,patients with multiple sclerosis,43,60,6 months,16S,345,Roche454,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,Signature 2,"Figure 2a, 2c, Table 2",10 January 2021,Rimsha Azhar,WikiWorks,Compositional differences in fecal microbiota between patients of MS compared to healthy controls using Roche 454,decreased,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Odoribacteraceae|g__Butyricimonas,2|976|200643|171549|1853231|574697,Complete,Claregrieve1
bsdb:140/3/1,Study 140,case-control,27352007,10.1038/ncomms12015,NA,"Jangi S, Gandhi R, Cox LM, Li N, von Glehn F, Yan R, Patel B, Mazzola MA, Liu S, Glanz BL, Cook S, Tankou S, Stuart F, Melo K, Nejad P, Smith K, Topçuolu BD, Holden J, Kivisäkk P, Chitnis T, De Jager PL, Quintana FJ, Gerber GK, Bry L , Weiner HL",Alterations of the human gut microbiome in multiple sclerosis,Nature communications,2016,NA,Experiment 3,United States of America,Homo sapiens,Feces,UBERON:0001988,Multiple sclerosis,MONDO:0005301,controls,untreated multiple sclerosis,untreated multiple sclerosis,43,28,6 months,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,Signature 1,"Figure 2a, 2c, Table 2",10 January 2021,Rimsha Azhar,"Claregrieve1,WikiWorks",Compositional differences in fecal microbiota between untreated patients of MS compared to healthy controls using Illumina MiSeq,increased,"k__Bacteria|p__Verrucomicrobiota|c__Verrucomicrobiia|o__Verrucomicrobiales|f__Akkermansiaceae|g__Akkermansia,k__Bacteria|p__Verrucomicrobiota|c__Verrucomicrobiia|o__Verrucomicrobiales|f__Verrucomicrobiaceae|g__Verrucomicrobium",2|74201|203494|48461|1647988|239934;2|74201|203494|48461|203557|2735,Complete,Claregrieve1
bsdb:140/3/2,Study 140,case-control,27352007,10.1038/ncomms12015,NA,"Jangi S, Gandhi R, Cox LM, Li N, von Glehn F, Yan R, Patel B, Mazzola MA, Liu S, Glanz BL, Cook S, Tankou S, Stuart F, Melo K, Nejad P, Smith K, Topçuolu BD, Holden J, Kivisäkk P, Chitnis T, De Jager PL, Quintana FJ, Gerber GK, Bry L , Weiner HL",Alterations of the human gut microbiome in multiple sclerosis,Nature communications,2016,NA,Experiment 3,United States of America,Homo sapiens,Feces,UBERON:0001988,Multiple sclerosis,MONDO:0005301,controls,untreated multiple sclerosis,untreated multiple sclerosis,43,28,6 months,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,Signature 2,"Figure 2a, 2c, Table 2",10 January 2021,Rimsha Azhar,"Claregrieve1,WikiWorks",Compositional differences in fecal microbiota between untreated patients of MS compared to healthy controls using Illumina MiSeq,decreased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Odoribacteraceae|g__Butyricimonas,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Sutterellaceae|g__Sutterella",2|976|200643|171549|1853231|574697;2|976|200643|171549|171552|838;2|1224|28216|80840|995019|40544,Complete,Claregrieve1
bsdb:140/4/1,Study 140,case-control,27352007,10.1038/ncomms12015,NA,"Jangi S, Gandhi R, Cox LM, Li N, von Glehn F, Yan R, Patel B, Mazzola MA, Liu S, Glanz BL, Cook S, Tankou S, Stuart F, Melo K, Nejad P, Smith K, Topçuolu BD, Holden J, Kivisäkk P, Chitnis T, De Jager PL, Quintana FJ, Gerber GK, Bry L , Weiner HL",Alterations of the human gut microbiome in multiple sclerosis,Nature communications,2016,NA,Experiment 4,United States of America,Homo sapiens,Feces,UBERON:0001988,Multiple sclerosis,MONDO:0005301,controls,untreated multiple sclerosis,untreated multiple sclerosis,43,28,6 months,16S,345,Roche454,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,Signature 1,"Figure 2a, 2c, Table 2",10 January 2021,Rimsha Azhar,"Claregrieve1,WikiWorks",compositional differences in fecal microbiota between untreated patients of MS compared to healthy controls using Roche 454,increased,"k__Bacteria|p__Verrucomicrobiota|c__Verrucomicrobiia|o__Verrucomicrobiales|f__Akkermansiaceae|g__Akkermansia,k__Archaea|p__Euryarchaeota,k__Archaea|p__Euryarchaeota|c__Methanobacteria|o__Methanobacteriales|f__Methanobacteriaceae|g__Methanobrevibacter,k__Bacteria|p__Verrucomicrobiota|c__Verrucomicrobiia|o__Verrucomicrobiales|f__Verrucomicrobiaceae|g__Verrucomicrobium",2|74201|203494|48461|1647988|239934;2157|28890;2157|28890|183925|2158|2159|2172;2|74201|203494|48461|203557|2735,Complete,Claregrieve1
bsdb:140/4/2,Study 140,case-control,27352007,10.1038/ncomms12015,NA,"Jangi S, Gandhi R, Cox LM, Li N, von Glehn F, Yan R, Patel B, Mazzola MA, Liu S, Glanz BL, Cook S, Tankou S, Stuart F, Melo K, Nejad P, Smith K, Topçuolu BD, Holden J, Kivisäkk P, Chitnis T, De Jager PL, Quintana FJ, Gerber GK, Bry L , Weiner HL",Alterations of the human gut microbiome in multiple sclerosis,Nature communications,2016,NA,Experiment 4,United States of America,Homo sapiens,Feces,UBERON:0001988,Multiple sclerosis,MONDO:0005301,controls,untreated multiple sclerosis,untreated multiple sclerosis,43,28,6 months,16S,345,Roche454,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,Signature 2,"Figure 2a, 2c, Table 2",10 January 2021,Rimsha Azhar,"Claregrieve1,WikiWorks",compositional differences in fecal microbiota between untreated patients of MS compared to healthy controls using Roche 454,decreased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Odoribacteraceae|g__Butyricimonas,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Sutterellaceae|g__Sutterella",2|976|200643|171549|1853231|574697;2|976|200643|171549|171552|838;2|1224|28216|80840|995019|40544,Complete,Claregrieve1
bsdb:140/5/1,Study 140,case-control,27352007,10.1038/ncomms12015,NA,"Jangi S, Gandhi R, Cox LM, Li N, von Glehn F, Yan R, Patel B, Mazzola MA, Liu S, Glanz BL, Cook S, Tankou S, Stuart F, Melo K, Nejad P, Smith K, Topçuolu BD, Holden J, Kivisäkk P, Chitnis T, De Jager PL, Quintana FJ, Gerber GK, Bry L , Weiner HL",Alterations of the human gut microbiome in multiple sclerosis,Nature communications,2016,NA,Experiment 5,United States of America,Homo sapiens,Feces,UBERON:0001988,Multiple sclerosis,MONDO:0005301,untreated multiple sclerosis,treated multiple sclerosis,treated multiple sclerosis,28,32,6 months,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,Signature 1,"Figure 2c, Table 2",10 January 2021,Rimsha Azhar,WikiWorks,Compositional differences in fecal microbiota between treated patients of MS compared to untreated patients using Illumina MiSeq,increased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Sutterellaceae|g__Sutterella",2|976|200643|171549|171552|838;2|1224|28216|80840|995019|40544,Complete,Claregrieve1
bsdb:140/5/2,Study 140,case-control,27352007,10.1038/ncomms12015,NA,"Jangi S, Gandhi R, Cox LM, Li N, von Glehn F, Yan R, Patel B, Mazzola MA, Liu S, Glanz BL, Cook S, Tankou S, Stuart F, Melo K, Nejad P, Smith K, Topçuolu BD, Holden J, Kivisäkk P, Chitnis T, De Jager PL, Quintana FJ, Gerber GK, Bry L , Weiner HL",Alterations of the human gut microbiome in multiple sclerosis,Nature communications,2016,NA,Experiment 5,United States of America,Homo sapiens,Feces,UBERON:0001988,Multiple sclerosis,MONDO:0005301,untreated multiple sclerosis,treated multiple sclerosis,treated multiple sclerosis,28,32,6 months,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,Signature 2,"Figure 2c, Table 2",10 January 2021,Rimsha Azhar,WikiWorks,Compositional differences in fecal microbiota between treated patients of MS compared to untreated patients using Illumina MiSeq,decreased,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Sarcina,2|1239|186801|186802|31979|1266,Complete,Claregrieve1
bsdb:140/6/1,Study 140,case-control,27352007,10.1038/ncomms12015,NA,"Jangi S, Gandhi R, Cox LM, Li N, von Glehn F, Yan R, Patel B, Mazzola MA, Liu S, Glanz BL, Cook S, Tankou S, Stuart F, Melo K, Nejad P, Smith K, Topçuolu BD, Holden J, Kivisäkk P, Chitnis T, De Jager PL, Quintana FJ, Gerber GK, Bry L , Weiner HL",Alterations of the human gut microbiome in multiple sclerosis,Nature communications,2016,NA,Experiment 6,United States of America,Homo sapiens,Feces,UBERON:0001988,Multiple sclerosis,MONDO:0005301,untreated multiple sclerosis,treated multiple sclerosis,treated multiple sclerosis patients,28,32,6 months,16S,345,Roche454,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,Signature 1,"Figure 2c, Table 2",10 January 2021,Rimsha Azhar,WikiWorks,Compositional differences in fecal microbiota between treated patients of MS compared to untreated patients using Roche 454,increased,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,2|976|200643|171549|171552|838,Complete,Claregrieve1
bsdb:140/6/2,Study 140,case-control,27352007,10.1038/ncomms12015,NA,"Jangi S, Gandhi R, Cox LM, Li N, von Glehn F, Yan R, Patel B, Mazzola MA, Liu S, Glanz BL, Cook S, Tankou S, Stuart F, Melo K, Nejad P, Smith K, Topçuolu BD, Holden J, Kivisäkk P, Chitnis T, De Jager PL, Quintana FJ, Gerber GK, Bry L , Weiner HL",Alterations of the human gut microbiome in multiple sclerosis,Nature communications,2016,NA,Experiment 6,United States of America,Homo sapiens,Feces,UBERON:0001988,Multiple sclerosis,MONDO:0005301,untreated multiple sclerosis,treated multiple sclerosis,treated multiple sclerosis patients,28,32,6 months,16S,345,Roche454,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,Signature 2,"Figure 2c, Table 2",10 January 2021,Rimsha Azhar,WikiWorks,Compositional differences in fecal microbiota between treated patients of MS compared to untreated patients using Roche 454,decreased,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Sarcina,2|1239|186801|186802|31979|1266,Complete,Claregrieve1
bsdb:141/1/1,Study 141,prospective cohort,30633889,10.1016/j.trsl.2018.12.005,NA,"Brown RG, Al-Memar M, Marchesi JR, Lee YS, Smith A, Chan D, Lewis H, Kindinger L, Terzidou V, Bourne T, Bennett PR , MacIntyre DA",Establishment of vaginal microbiota composition in early pregnancy and its association with subsequent preterm prelabor rupture of the fetal membranes,Translational research : the journal of laboratory and clinical medicine,2019,NA,Experiment 1,United Kingdom,Homo sapiens,Vagina,UBERON:0000996,Preterm premature rupture of the membranes,MONDO:0012511,controls,PPROM,(PPROM) preterm premature rupture of the membranes,36,60,9 months,16S,12,Illumina,LEfSe,0.05,FALSE,NA,"body mass index,ethnic group,gestational age,maternal age",NA,NA,NA,NA,NA,unchanged,NA,Signature 1,Figure 3,10 January 2021,Rimsha Azhar,WikiWorks,The effect size for each of the differentially abundant species was estimated using LDA,increased,"k__Bacteria|p__Bacillota|c__Tissierellia|o__Tissierellales|f__Peptoniphilaceae|g__Anaerococcus,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales|f__Actinomycetaceae,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Dialister|s__Dialister micraerophilus,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Dialister,k__Bacteria|p__Bacillota|c__Tissierellia|o__Tissierellales|f__Peptoniphilaceae|g__Peptoniphilus,k__Bacteria|p__Bacillota|c__Tissierellia|o__Tissierellales|f__Peptoniphilaceae|g__Anaerococcus|s__Anaerococcus tetradius,k__Bacteria|p__Bacillota|c__Tissierellia|o__Tissierellales|f__Peptoniphilaceae,k__Bacteria|p__Bacillota|c__Tissierellia|o__Tissierellales|f__Peptoniphilaceae|g__Parvimonas,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella|s__Prevotella bivia,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Hoylesella|s__Hoylesella timonensis,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae,k__Bacteria|p__Bacillota|c__Negativicutes,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales,k__Bacteria|p__Fusobacteriota,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Catonella,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales,k__Bacteria|p__Bacteroidota,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Bacteroidota|c__Bacteroidia,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales,k__Bacteria|p__Bacillota|c__Clostridia,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae",2|1239|1737404|1737405|1570339|165779;2|201174|1760|2037|2049;2|1239|909932|1843489|31977|39948|309120;2|1239|909932|1843489|31977|39948;2|1239|1737404|1737405|1570339|162289;2|1239|1737404|1737405|1570339|165779|33036;2|1239|1737404|1737405|1570339;2|1239|1737404|1737405|1570339|543311;2|976|200643|171549|171552|838|28125;2|976|200643|171549|171552|2974257|386414;2|1239|909932|1843489|31977;2|1239|909932;2|32066|203490|203491;2|32066;2|1239|186801|3085636|186803|43996;2|1239|186801|3085636|186803;2|976|200643|171549|171552;2|976|200643|171549;2|976;2|976|200643|171549|171552|838;2|976|200643;2|1239|91061|186826|1300|1301;2|1239|186801|186802;2|1239|186801;2|1239|91061|186826|1300,Complete,Atrayees
bsdb:141/1/2,Study 141,prospective cohort,30633889,10.1016/j.trsl.2018.12.005,NA,"Brown RG, Al-Memar M, Marchesi JR, Lee YS, Smith A, Chan D, Lewis H, Kindinger L, Terzidou V, Bourne T, Bennett PR , MacIntyre DA",Establishment of vaginal microbiota composition in early pregnancy and its association with subsequent preterm prelabor rupture of the fetal membranes,Translational research : the journal of laboratory and clinical medicine,2019,NA,Experiment 1,United Kingdom,Homo sapiens,Vagina,UBERON:0000996,Preterm premature rupture of the membranes,MONDO:0012511,controls,PPROM,(PPROM) preterm premature rupture of the membranes,36,60,9 months,16S,12,Illumina,LEfSe,0.05,FALSE,NA,"body mass index,ethnic group,gestational age,maternal age",NA,NA,NA,NA,NA,unchanged,NA,Signature 2,Figure 3,10 January 2021,Rimsha Azhar,WikiWorks,The effect size for each of the differentially abundant species was estimated using LDA,decreased,"k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Limosilactobacillus|s__Limosilactobacillus vaginalis,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales,k__Bacteria|p__Bacillota|c__Bacilli,k__Bacteria|p__Bacillota",2|1239|91061|186826|33958|2742598|1633;2|1239|91061|186826|33958|1578;2|1239|91061|186826|33958;2|1239|91061|186826;2|1239|91061;2|1239,Complete,Atrayees
bsdb:142/1/1,Study 142,case-control,27259999,10.18632/oncotarget.9710,NA,"Guerrero-Preston R, Godoy-Vitorino F, Jedlicka A, Rodríguez-Hilario A, González H, Bondy J, Lawson F, Folawiyo O, Michailidi C, Dziedzic A, Thangavel R, Hadar T, Noordhuis MG, Westra W, Koch W , Sidransky D","16S rRNA amplicon sequencing identifies microbiota associated with oral cancer, human papilloma virus infection and surgical treatment",Oncotarget,2016,"16s rRNA, human papilloma virus (HPV), microbiome, oral cancer, oropharyngeal cancer",Experiment 1,United States of America,Homo sapiens,Saliva,UBERON:0001836,Oral squamous cell carcinoma,EFO:0000199,Controls,HNSCC,histopathologically confirmed HNSCC (Head & Neck Squamous Cell Cancer) patients with at least one post-treatment salivary sample,25,17,NA,16S,345,Roche454,LEfSe,0.05,FALSE,NA,NA,NA,NA,NA,decreased,NA,NA,decreased,Signature 1,"Figure 6, Sup Fig1",10 January 2021,Utsav Patel,"WikiWorks,Aiyshaaaa",Relative abundance of oral microbiome in HNSCC patients and controls,increased,"k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus,k__Bacteria|p__Bacillota|c__Tissierellia|o__Tissierellales|f__Peptoniphilaceae|g__Parvimonas,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Peptostreptococcaceae|g__Peptostreptococcus,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Staphylococcaceae|g__Staphylococcus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Tannerellaceae|g__Tannerella,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Veillonella",2|1239|91061|186826|33958|1578;2|1239|1737404|1737405|1570339|543311;2|1239|186801|3082720|186804|1257;2|1239|91061|1385|90964|1279;2|1239|91061|186826|1300|1301;2|976|200643|171549|2005525|195950;2|1239|909932|1843489|31977|29465,Complete,Rimsha Azhar
bsdb:142/1/2,Study 142,case-control,27259999,10.18632/oncotarget.9710,NA,"Guerrero-Preston R, Godoy-Vitorino F, Jedlicka A, Rodríguez-Hilario A, González H, Bondy J, Lawson F, Folawiyo O, Michailidi C, Dziedzic A, Thangavel R, Hadar T, Noordhuis MG, Westra W, Koch W , Sidransky D","16S rRNA amplicon sequencing identifies microbiota associated with oral cancer, human papilloma virus infection and surgical treatment",Oncotarget,2016,"16s rRNA, human papilloma virus (HPV), microbiome, oral cancer, oropharyngeal cancer",Experiment 1,United States of America,Homo sapiens,Saliva,UBERON:0001836,Oral squamous cell carcinoma,EFO:0000199,Controls,HNSCC,histopathologically confirmed HNSCC (Head & Neck Squamous Cell Cancer) patients with at least one post-treatment salivary sample,25,17,NA,16S,345,Roche454,LEfSe,0.05,FALSE,NA,NA,NA,NA,NA,decreased,NA,NA,decreased,Signature 2,"Figure 6, Sup Fig1",10 January 2021,Utsav Patel,WikiWorks,Relative abundance of oral microbiome in HNSCC patients and controls,decreased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Aggregatibacter,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Burkholderiaceae|g__Lautropia,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Haemophilus,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Neisseriaceae|g__Neisseria,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Leptotrichiaceae|g__Leptotrichia",2|1224|1236|135625|712|416916;2|1224|28216|80840|119060|47670;2|1224|1236|135625|712|724;2|1224|28216|206351|481|482;2|32066|203490|203491|1129771|32067,Complete,Rimsha Azhar
bsdb:142/2/1,Study 142,case-control,27259999,10.18632/oncotarget.9710,NA,"Guerrero-Preston R, Godoy-Vitorino F, Jedlicka A, Rodríguez-Hilario A, González H, Bondy J, Lawson F, Folawiyo O, Michailidi C, Dziedzic A, Thangavel R, Hadar T, Noordhuis MG, Westra W, Koch W , Sidransky D","16S rRNA amplicon sequencing identifies microbiota associated with oral cancer, human papilloma virus infection and surgical treatment",Oncotarget,2016,"16s rRNA, human papilloma virus (HPV), microbiome, oral cancer, oropharyngeal cancer",Experiment 2,United States of America,Homo sapiens,Saliva,UBERON:0001836,Oral squamous cell carcinoma,EFO:0000199,HPV -,HPV +,histopathologically confirmed HNSCC (Head & Neck Squamous Cell Cancer) patients with at least one post-treatment salivary sample who are HPV+,4,7,NA,16S,345,Roche454,LEfSe,0.05,FALSE,NA,NA,NA,NA,NA,decreased,NA,NA,decreased,Signature 1,"Figure 6, Text",10 January 2021,Utsav Patel,WikiWorks,Relative abundance of oral microbiome in HNSCC HPV + and HPV -,increased,"k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus,k__Bacteria|p__Bacteroidota|c__Flavobacteriia|o__Flavobacteriales|f__Weeksellaceae|g__Weeksella",2|1239|91061|186826|33958|1578;2|976|117743|200644|2762318|1013,Complete,Rimsha Azhar
bsdb:142/2/2,Study 142,case-control,27259999,10.18632/oncotarget.9710,NA,"Guerrero-Preston R, Godoy-Vitorino F, Jedlicka A, Rodríguez-Hilario A, González H, Bondy J, Lawson F, Folawiyo O, Michailidi C, Dziedzic A, Thangavel R, Hadar T, Noordhuis MG, Westra W, Koch W , Sidransky D","16S rRNA amplicon sequencing identifies microbiota associated with oral cancer, human papilloma virus infection and surgical treatment",Oncotarget,2016,"16s rRNA, human papilloma virus (HPV), microbiome, oral cancer, oropharyngeal cancer",Experiment 2,United States of America,Homo sapiens,Saliva,UBERON:0001836,Oral squamous cell carcinoma,EFO:0000199,HPV -,HPV +,histopathologically confirmed HNSCC (Head & Neck Squamous Cell Cancer) patients with at least one post-treatment salivary sample who are HPV+,4,7,NA,16S,345,Roche454,LEfSe,0.05,FALSE,NA,NA,NA,NA,NA,decreased,NA,NA,decreased,Signature 2,"Figure 6, Text",10 January 2021,Utsav Patel,WikiWorks,Relative abundance of oral microbiome in HNSCC HPV + and HPV -,decreased,"k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Neisseriaceae|g__Eikenella,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Neisseriaceae|g__Neisseria,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Leptotrichiaceae|g__Leptotrichia",2|1224|28216|206351|481|538;2|1224|28216|206351|481|482;2|32066|203490|203491|1129771|32067,Complete,Rimsha Azhar
bsdb:142/3/1,Study 142,case-control,27259999,10.18632/oncotarget.9710,NA,"Guerrero-Preston R, Godoy-Vitorino F, Jedlicka A, Rodríguez-Hilario A, González H, Bondy J, Lawson F, Folawiyo O, Michailidi C, Dziedzic A, Thangavel R, Hadar T, Noordhuis MG, Westra W, Koch W , Sidransky D","16S rRNA amplicon sequencing identifies microbiota associated with oral cancer, human papilloma virus infection and surgical treatment",Oncotarget,2016,"16s rRNA, human papilloma virus (HPV), microbiome, oral cancer, oropharyngeal cancer",Experiment 3,United States of America,Homo sapiens,Saliva,UBERON:0001836,Oral squamous cell carcinoma,EFO:0000199,surgery,chemotherapy-radiation and surgery,histopathologically confirmed HNSCC (Head & Neck Squamous Cell Cancer) patients with at least one post-treatment salivary sample who received chemo/radiation and surgery,5,13,NA,16S,345,Roche454,LEfSe,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,"Figure 6, Text",10 January 2021,Utsav Patel,WikiWorks,Relative abundance of oral microbiome in chemo-radiation therapy/radiation and surgery,increased,"k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus",2|1239|91061|186826|33958;2|1239|91061|186826|33958|1578,Complete,Rimsha Azhar
bsdb:142/3/2,Study 142,case-control,27259999,10.18632/oncotarget.9710,NA,"Guerrero-Preston R, Godoy-Vitorino F, Jedlicka A, Rodríguez-Hilario A, González H, Bondy J, Lawson F, Folawiyo O, Michailidi C, Dziedzic A, Thangavel R, Hadar T, Noordhuis MG, Westra W, Koch W , Sidransky D","16S rRNA amplicon sequencing identifies microbiota associated with oral cancer, human papilloma virus infection and surgical treatment",Oncotarget,2016,"16s rRNA, human papilloma virus (HPV), microbiome, oral cancer, oropharyngeal cancer",Experiment 3,United States of America,Homo sapiens,Saliva,UBERON:0001836,Oral squamous cell carcinoma,EFO:0000199,surgery,chemotherapy-radiation and surgery,histopathologically confirmed HNSCC (Head & Neck Squamous Cell Cancer) patients with at least one post-treatment salivary sample who received chemo/radiation and surgery,5,13,NA,16S,345,Roche454,LEfSe,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 2,"Figure 6, text",19 December 2022,Claregrieve1,Claregrieve1,Relative abundance of oral microbiome in chemo-radiation therapy/radiation and surgery,decreased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Haemophilus,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Aggregatibacter,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Leptotrichiaceae|g__Leptotrichia",2|1224|1236|135625|712|724;2|1224|1236|135625|712|416916;2|32066|203490|203491|1129771|32067,Complete,Claregrieve1
bsdb:143/1/1,Study 143,"cross-sectional observational, not case-control",30239655,10.1093/ecco-jcc/jjy136,NA,"Kiernan MG, Coffey JC, McDermott K, Cotter PD, Cabrera-Rubio R, Kiely PA , Dunne CP",The Human Mesenteric Lymph Node Microbiome Differentiates Between Crohn's Disease and Ulcerative Colitis,Journal of Crohn's & colitis,2019,NA,Experiment 1,Ireland,Homo sapiens,Mesenteric lymph node,UBERON:0002509,Inflammatory bowel disease,EFO:0003767,Ulcerative colitis,Crohn's disease,histopathologivally diagnosed ulcerative colitis and crohn's disease,8,5,NA,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,decreased,increased,NA,NA,increased,Signature 1,Figure 3B,10 January 2021,Fatima Zohra,WikiWorks,Abundance of phyla in MLN of crohn's disease (CD) and ulcerative colitis (UC) patients,increased,k__Bacteria|p__Pseudomonadota,2|1224,Complete,Rimsha Azhar
bsdb:143/2/1,Study 143,"cross-sectional observational, not case-control",30239655,10.1093/ecco-jcc/jjy136,NA,"Kiernan MG, Coffey JC, McDermott K, Cotter PD, Cabrera-Rubio R, Kiely PA , Dunne CP",The Human Mesenteric Lymph Node Microbiome Differentiates Between Crohn's Disease and Ulcerative Colitis,Journal of Crohn's & colitis,2019,NA,Experiment 2,Ireland,Homo sapiens,Mesenteric lymph node,UBERON:0002509,Inflammatory bowel disease,EFO:0003767,Ulcerative colitis,Crohn's disease,histopathologivally diagnosed ulcerative colitis and crohn's disease,8,5,NA,16S,34,Illumina,T-Test,0.05,FALSE,NA,NA,NA,NA,decreased,increased,NA,NA,increased,Signature 1,Figure 3B,10 January 2021,Fatima Zohra,WikiWorks,Abundance of phyla in MLN of crohn's disease (CD) and ulcerative colitis (UC) patients,decreased,k__Bacteria|p__Bacillota,2|1239,Complete,Rimsha Azhar
bsdb:144/1/1,Study 144,"cross-sectional observational, not case-control",31126003,10.1016/j.envpol.2018.12.083,NA,"Li X, Sun Y, An Y, Wang R, Lin H, Liu M, Li S, Ma M , Xiao C",Air pollution during the winter period and respiratory tract microbial imbalance in a healthy young population in Northeastern China,"Environmental pollution (Barking, Essex : 1987)",2019,"Air pollution, Airborne particulate matter, Coal burning, Oropharyngeal microbiota, Respiratory tract diseases",Experiment 1,China,Homo sapiens,Throat,UBERON:0000341,Air pollution,ENVO:02500037,lightly poluuted region (A),moderately polluted region (B),"paticipants lived in any of those regions for more than 2 years. region A: (lightly polluted region of PM 2.5), region B: (moderately polluted region of PM 2.5) and region C: (heavily polluted region of PM 2.5)",35,40,3 months,16S,3,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,"age,body height,body weight,sex,vital capacity",NA,NA,NA,NA,NA,NA,Signature 1,"Figure 3, 4, 5, 6",10 January 2021,Rimsha Azhar,WikiWorks,"Abundance analysis of the dominant bacterial taxa of A (lightly polluted region of PM 2.5), B (moderately polluted region of PM 2.5) and C (heavily polluted region of PM 2.5)",increased,"k__Bacteria|p__Bacillota,k__Bacteria|p__Actinomycetota,k__Bacteria|p__Bacillota|c__Clostridia,k__Bacteria|p__Actinomycetota|c__Actinomycetes,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micrococcales|f__Micrococcaceae,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales|f__Actinomycetaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micrococcales|f__Micrococcaceae|g__Rothia,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Oribacterium,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Neisseriaceae|g__Neisseria,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales|f__Actinomycetaceae|g__Actinomyces",2|1239;2|201174;2|1239|186801;2|201174|1760;2|1239|186801|186802;2|201174|1760|2037;2|1239|186801|3085636|186803;2|201174|1760|85006|1268;2|201174|1760|2037|2049;2|1239|186801|186802|541000;2|201174|1760|85006|1268|32207;2|1239|186801|3085636|186803|265975;2|1224|28216|206351|481|482;2|201174|1760|2037|2049|1654,Complete,Shaimaa Elsafoury
bsdb:144/1/2,Study 144,"cross-sectional observational, not case-control",31126003,10.1016/j.envpol.2018.12.083,NA,"Li X, Sun Y, An Y, Wang R, Lin H, Liu M, Li S, Ma M , Xiao C",Air pollution during the winter period and respiratory tract microbial imbalance in a healthy young population in Northeastern China,"Environmental pollution (Barking, Essex : 1987)",2019,"Air pollution, Airborne particulate matter, Coal burning, Oropharyngeal microbiota, Respiratory tract diseases",Experiment 1,China,Homo sapiens,Throat,UBERON:0000341,Air pollution,ENVO:02500037,lightly poluuted region (A),moderately polluted region (B),"paticipants lived in any of those regions for more than 2 years. region A: (lightly polluted region of PM 2.5), region B: (moderately polluted region of PM 2.5) and region C: (heavily polluted region of PM 2.5)",35,40,3 months,16S,3,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,"age,body height,body weight,sex,vital capacity",NA,NA,NA,NA,NA,NA,Signature 2,"Figure 3, 4, 5, 6",10 January 2021,Rimsha Azhar,"Merit,WikiWorks","Abundance analysis of the dominant bacterial taxa of A (lightly polluted region of PM 2.5), B (moderately polluted region of PM 2.5) and C (heavily polluted region of PM 2.5)",decreased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales,k__Bacteria|p__Bacteroidota|c__Bacteroidia,k__Bacteria|p__Bacteroidota,k__Bacteria|p__Bacteroidota|c__Flavobacteriia|o__Flavobacteriales,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia,k__Bacteria|p__Fusobacteriota,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae|g__Fusobacterium,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Moraxellales|f__Moraxellaceae|g__Moraxella,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Moraxellales|f__Moraxellaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Peptostreptococcaceae|g__Peptostreptococcus,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae|g__Porphyromonas,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pseudomonadales,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Veillonella,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae",2|976|200643|171549;2|976|200643;2|976;2|976|117743|200644;2|32066|203490|203491|203492;2|32066|203490|203491;2|32066|203490;2|32066;2|32066|203490|203491|203492|848;2|1224|1236|2887326|468|475;2|1224|1236|2887326|468;2|1239|186801|3082720|186804|1257;2|976|200643|171549|171551;2|976|200643|171549|171551|836;2|976|200643|171549|171552|838;2|976|200643|171549|171552;2|1224|1236|72274;2|1239|909932|1843489|31977|29465;2|1239|909932|1843489|31977,Complete,Shaimaa Elsafoury
bsdb:144/2/1,Study 144,"cross-sectional observational, not case-control",31126003,10.1016/j.envpol.2018.12.083,NA,"Li X, Sun Y, An Y, Wang R, Lin H, Liu M, Li S, Ma M , Xiao C",Air pollution during the winter period and respiratory tract microbial imbalance in a healthy young population in Northeastern China,"Environmental pollution (Barking, Essex : 1987)",2019,"Air pollution, Airborne particulate matter, Coal burning, Oropharyngeal microbiota, Respiratory tract diseases",Experiment 2,China,Homo sapiens,Throat,UBERON:0000341,Air pollution,ENVO:02500037,lightly poluuted region (A),heavily polluted region (C),"paticipants lived in any of those regions for more than 2 years. region A: (lightly polluted region of PM 2.5), region B: (moderately polluted region of PM 2.5) and region C: (heavily polluted region of PM 2.5)",35,39,3 months,16S,3,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,"age,body height,body weight,sex,vital capacity",NA,NA,NA,NA,NA,NA,Signature 1,"Figure 3, 4, 5, 6",10 January 2021,Rimsha Azhar,WikiWorks,"Abundance analysis of the dominant bacterial taxa of A (lightly polluted region of PM 2.5), B (moderately polluted region of PM 2.5) and C (heavily polluted region of PM 2.5)",increased,"k__Bacteria|p__Bacillota,k__Bacteria|p__Pseudomonadota,k__Bacteria|p__Actinomycetota,k__Bacteria|p__Bacillota|c__Clostridia,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae",2|1239;2|1224;2|201174;2|1239|186801;2|1239|186801|186802|541000;2|1224|1236;2|1224|28211;2|1239|186801|186802;2|1239|186801|3085636|186803,Complete,Shaimaa Elsafoury
bsdb:144/2/2,Study 144,"cross-sectional observational, not case-control",31126003,10.1016/j.envpol.2018.12.083,NA,"Li X, Sun Y, An Y, Wang R, Lin H, Liu M, Li S, Ma M , Xiao C",Air pollution during the winter period and respiratory tract microbial imbalance in a healthy young population in Northeastern China,"Environmental pollution (Barking, Essex : 1987)",2019,"Air pollution, Airborne particulate matter, Coal burning, Oropharyngeal microbiota, Respiratory tract diseases",Experiment 2,China,Homo sapiens,Throat,UBERON:0000341,Air pollution,ENVO:02500037,lightly poluuted region (A),heavily polluted region (C),"paticipants lived in any of those regions for more than 2 years. region A: (lightly polluted region of PM 2.5), region B: (moderately polluted region of PM 2.5) and region C: (heavily polluted region of PM 2.5)",35,39,3 months,16S,3,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,"age,body height,body weight,sex,vital capacity",NA,NA,NA,NA,NA,NA,Signature 2,"Figure 3, 4, 5, 6",10 January 2021,Rimsha Azhar,"Merit,WikiWorks","Abundance analysis of the dominant bacterial taxa of A (lightly polluted region of PM 2.5), B (moderately polluted region of PM 2.5) and C (heavily polluted region of PM 2.5)",decreased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales,k__Bacteria|p__Bacteroidota|c__Bacteroidia,k__Bacteria|p__Bacteroidota,k__Bacteria|p__Campylobacterota|c__Epsilonproteobacteria|o__Campylobacterales|f__Campylobacteraceae|g__Campylobacter,k__Bacteria|p__Campylobacterota|c__Epsilonproteobacteria|o__Campylobacterales,k__Bacteria|p__Bacteroidota|c__Flavobacteriia|o__Flavobacteriales|f__Flavobacteriaceae|g__Capnocytophaga,k__Bacteria|p__Bacteroidota|c__Flavobacteriia|o__Flavobacteriales|f__Flavobacteriaceae,k__Bacteria|p__Bacteroidota|c__Flavobacteriia|o__Flavobacteriales,k__Bacteria|p__Bacteroidota|c__Flavobacteriia,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia,k__Bacteria|p__Fusobacteriota,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae|g__Fusobacterium,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Moraxellales|f__Moraxellaceae|g__Moraxella,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Moraxellales|f__Moraxellaceae,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Peptostreptococcaceae|g__Peptostreptococcus,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae|g__Porphyromonas,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Veillonella,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae",2|976|200643|171549;2|976|200643;2|976;2|29547|3031852|213849|72294|194;2|29547|3031852|213849;2|976|117743|200644|49546|1016;2|976|117743|200644|49546;2|976|117743|200644;2|976|117743;2|32066|203490|203491|203492;2|32066|203490|203491;2|32066|203490;2|32066;2|32066|203490|203491|203492|848;2|1224|1236|2887326|468|475;2|1224|1236|2887326|468;2|1224|28216|206351;2|1239|186801|3082720|186804|1257;2|976|200643|171549|171551;2|976|200643|171549|171551|836;2|976|200643|171549|171552|838;2|976|200643|171549|171552;2|1239|909932|1843489|31977|29465;2|1239|909932|1843489|31977,Complete,Shaimaa Elsafoury
bsdb:144/3/1,Study 144,"cross-sectional observational, not case-control",31126003,10.1016/j.envpol.2018.12.083,NA,"Li X, Sun Y, An Y, Wang R, Lin H, Liu M, Li S, Ma M , Xiao C",Air pollution during the winter period and respiratory tract microbial imbalance in a healthy young population in Northeastern China,"Environmental pollution (Barking, Essex : 1987)",2019,"Air pollution, Airborne particulate matter, Coal burning, Oropharyngeal microbiota, Respiratory tract diseases",Experiment 3,China,Homo sapiens,Throat,UBERON:0000341,Air pollution,ENVO:02500037,moderately poluuted region (B),heavily polluted region (C),"paticipants lived in any of those regions for more than 2 years. region A: (lightly polluted region of PM 2.5), region B: (moderately polluted region of PM 2.5) and region C: (heavily polluted region of PM 2.5)",40,39,3 months,16S,3,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,"age,body height,body weight,sex,vital capacity",NA,NA,NA,NA,NA,NA,Signature 1,"Figure 3, 4, 5, 6",10 January 2021,Rimsha Azhar,WikiWorks,"Abundance analysis of the dominant bacterial taxa of A (lightly polluted region of PM 2.5), B (moderately polluted region of PM 2.5) and C (heavily polluted region of PM 2.5)",increased,"k__Bacteria|p__Pseudomonadota,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pseudomonadales",2|1224;2|1224|1236;2|1224|28211;2|1224|1236|72274,Complete,Shaimaa Elsafoury
bsdb:144/3/2,Study 144,"cross-sectional observational, not case-control",31126003,10.1016/j.envpol.2018.12.083,NA,"Li X, Sun Y, An Y, Wang R, Lin H, Liu M, Li S, Ma M , Xiao C",Air pollution during the winter period and respiratory tract microbial imbalance in a healthy young population in Northeastern China,"Environmental pollution (Barking, Essex : 1987)",2019,"Air pollution, Airborne particulate matter, Coal burning, Oropharyngeal microbiota, Respiratory tract diseases",Experiment 3,China,Homo sapiens,Throat,UBERON:0000341,Air pollution,ENVO:02500037,moderately poluuted region (B),heavily polluted region (C),"paticipants lived in any of those regions for more than 2 years. region A: (lightly polluted region of PM 2.5), region B: (moderately polluted region of PM 2.5) and region C: (heavily polluted region of PM 2.5)",40,39,3 months,16S,3,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,"age,body height,body weight,sex,vital capacity",NA,NA,NA,NA,NA,NA,Signature 2,"Figure 3, 4, 5, 6",10 January 2021,Rimsha Azhar,WikiWorks,"Abundance analysis of the dominant bacterial taxa of A (lightly polluted region of PM 2.5), B (moderately polluted region of PM 2.5) and C (heavily polluted region of PM 2.5)",decreased,"k__Bacteria|p__Fusobacteriota,k__Bacteria|p__Actinomycetota|c__Actinomycetes,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales,k__Bacteria|p__Campylobacterota|c__Epsilonproteobacteria|o__Campylobacterales,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micrococcales|f__Micrococcaceae,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Neisseriaceae,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Leptotrichiaceae,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales|f__Actinomycetaceae,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micrococcales|f__Micrococcaceae|g__Rothia,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae|g__Fusobacterium,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Oribacterium,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales|f__Actinomycetaceae|g__Actinomyces,k__Bacteria|p__Campylobacterota|c__Epsilonproteobacteria|o__Campylobacterales|f__Campylobacteraceae|g__Campylobacter,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Neisseriaceae|g__Neisseria",2|32066;2|201174|1760;2|32066|203490;2|201174|1760|2037;2|32066|203490|203491;2|1224|28216|206351;2|29547|3031852|213849;2|201174|1760|85006|1268;2|32066|203490|203491|203492;2|1224|28216|206351|481;2|32066|203490|203491|1129771;2|201174|1760|2037|2049;2|201174|1760|85006|1268|32207;2|32066|203490|203491|203492|848;2|1239|186801|3085636|186803|265975;2|201174|1760|2037|2049|1654;2|29547|3031852|213849|72294|194;2|1224|28216|206351|481|482,Complete,Shaimaa Elsafoury
bsdb:145/1/1,Study 145,case-control,15987522,10.1186/1479-5876-3-27,NA,"Mager DL, Haffajee AD, Devlin PM, Norris CM, Posner MR , Goodson JM","The salivary microbiota as a diagnostic indicator of oral cancer: a descriptive, non-randomized study of cancer-free and oral squamous cell carcinoma subjects",Journal of translational medicine,2005,NA,Experiment 1,United States of America,Homo sapiens,Saliva,UBERON:0001836,Oral squamous cell carcinoma,EFO:0000199,Controls,oral squamous cell carcinoma (OSCC),"disgnosed oral squamous cell carcinoma via biopsy, age 18 years or older and immunocompetent",229,45,3 months,NA,NA,DNA-DNA Hybridization,Mann-Whitney (Wilcoxon),0.001,TRUE,NA,"age,sex,smoking behavior",NA,NA,NA,NA,NA,NA,NA,Signature 1,"Figure 1 , Text",10 January 2021,Utsav Patel,WikiWorks,Relative abundance of oral microbiome in oral squamous cell carcinoma patients and controls,increased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella|s__Prevotella melaninogenica,k__Bacteria|p__Bacteroidota|c__Flavobacteriia|o__Flavobacteriales|f__Flavobacteriaceae|g__Capnocytophaga|s__Capnocytophaga gingivalis,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus|s__Streptococcus mitis,k__Bacteria|p__Bacteroidota|c__Flavobacteriia|o__Flavobacteriales|f__Flavobacteriaceae|g__Capnocytophaga|s__Capnocytophaga ochracea",2|976|200643|171549|171552|838|28132;2|976|117743|200644|49546|1016|1017;2|1239|91061|186826|1300|1301|28037;2|976|117743|200644|49546|1016|1018,Complete,Rimsha Azhar
bsdb:145/1/2,Study 145,case-control,15987522,10.1186/1479-5876-3-27,NA,"Mager DL, Haffajee AD, Devlin PM, Norris CM, Posner MR , Goodson JM","The salivary microbiota as a diagnostic indicator of oral cancer: a descriptive, non-randomized study of cancer-free and oral squamous cell carcinoma subjects",Journal of translational medicine,2005,NA,Experiment 1,United States of America,Homo sapiens,Saliva,UBERON:0001836,Oral squamous cell carcinoma,EFO:0000199,Controls,oral squamous cell carcinoma (OSCC),"disgnosed oral squamous cell carcinoma via biopsy, age 18 years or older and immunocompetent",229,45,3 months,NA,NA,DNA-DNA Hybridization,Mann-Whitney (Wilcoxon),0.001,TRUE,NA,"age,sex,smoking behavior",NA,NA,NA,NA,NA,NA,NA,Signature 2,"Figure 1 , Text",10 January 2021,Utsav Patel,WikiWorks,Relative abundance of oral microbiome in oral squamous cell carcinoma patients and controls,decreased,"k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Leptotrichiaceae|g__Leptotrichia|s__Leptotrichia buccalis,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Lachnoanaerobaculum|s__Lachnoanaerobaculum saburreum",2|32066|203490|203491|1129771|32067|40542;2|1239|186801|3085636|186803|1164882|467210,Complete,Rimsha Azhar
bsdb:146/1/1,Study 146,case-control,28924229,10.1038/s41598-017-11779-9,NA,"Zhao H, Chu M, Huang Z, Yang X, Ran S, Hu B, Zhang C , Liang J",Variations in oral microbiota associated with oral cancer,Scientific reports,2017,NA,Experiment 1,China,Homo sapiens,Saliva,UBERON:0001836,Oral squamous cell carcinoma,EFO:0000199,Controls,oral squamous cell carcinoma (OSCC),"subjects with oral squamous cell carcinoma and did not have detectable periodontal inflammation, visible carious lesions, oral mucosa disease or any sever systemic disorders such as diabetes, immune compromise or genetic diseases",40,40,2 weeks,16S,45,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,increased,unchanged,unchanged,NA,NA,Signature 1,"Figure 1c, Figure 3b, 3c, Text",10 January 2021,Utsav Patel,WikiWorks,Variations in oral microbiota associated with oral cancer,increased,"k__Bacteria|p__Mycoplasmatota|c__Mollicutes|o__Mycoplasmatales|f__Mycoplasmataceae|g__Mycoplasma,k__Bacteria|p__Spirochaetota|c__Spirochaetia|o__Spirochaetales|f__Treponemataceae|g__Treponema,k__Bacteria|p__Campylobacterota|c__Epsilonproteobacteria|o__Campylobacterales|f__Campylobacteraceae|g__Campylobacter,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Neisseriaceae|g__Eikenella,k__Bacteria|p__Bacillota|c__Negativicutes|o__Selenomonadales|f__Selenomonadaceae|g__Centipeda,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Alloprevotella,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae|g__Fusobacterium,k__Bacteria|p__Bacillota|c__Negativicutes|o__Selenomonadales|f__Selenomonadaceae|g__Selenomonas,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Dialister,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Peptostreptococcaceae|g__Peptostreptococcus,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Filifactoraceae|g__Filifactor,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Peptococcaceae|g__Peptococcus,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Catonella,k__Bacteria|p__Bacillota|c__Tissierellia|o__Tissierellales|f__Peptoniphilaceae|g__Parvimonas,k__Bacteria|p__Bacteroidota|c__Flavobacteriia|o__Flavobacteriales|f__Flavobacteriaceae|g__Capnocytophaga,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Peptostreptococcaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae,k__Bacteria|p__Bacteroidota,k__Bacteria|p__Fusobacteriota,k__Bacteria|p__Spirochaetota",2|544448|31969|2085|2092|2093;2|203691|203692|136|2845253|157;2|29547|3031852|213849|72294|194;2|1224|28216|206351|481|538;2|1239|909932|909929|1843491|82202;2|976|200643|171549|171552|1283313;2|32066|203490|203491|203492|848;2|1239|909932|909929|1843491|970;2|1239|909932|1843489|31977|39948;2|1239|186801|3082720|186804|1257;2|1239|186801|3082720|3118655|44259;2|1239|186801|186802|186807|2740;2|1239|186801|3085636|186803|43996;2|1239|1737404|1737405|1570339|543311;2|976|117743|200644|49546|1016;2|1239|186801|3082720|186804;2|1239|186801|3085636|186803;2|976;2|32066;2|203691,Complete,Rimsha Azhar
bsdb:146/1/2,Study 146,case-control,28924229,10.1038/s41598-017-11779-9,NA,"Zhao H, Chu M, Huang Z, Yang X, Ran S, Hu B, Zhang C , Liang J",Variations in oral microbiota associated with oral cancer,Scientific reports,2017,NA,Experiment 1,China,Homo sapiens,Saliva,UBERON:0001836,Oral squamous cell carcinoma,EFO:0000199,Controls,oral squamous cell carcinoma (OSCC),"subjects with oral squamous cell carcinoma and did not have detectable periodontal inflammation, visible carious lesions, oral mucosa disease or any sever systemic disorders such as diabetes, immune compromise or genetic diseases",40,40,2 weeks,16S,45,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,increased,unchanged,unchanged,NA,NA,Signature 2,"Figure 1c, Figure 3b, 3c, Text",10 January 2021,Utsav Patel,WikiWorks,Variations in oral microbiota associated with oral cancer,decreased,"k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Megasphaera,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Stomatobaculum,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Carnobacteriaceae|g__Granulicatella,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Burkholderiaceae|g__Lautropia,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Veillonella,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Scardovia,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micrococcales|f__Micrococcaceae|g__Rothia,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales|f__Actinomycetaceae|g__Actinomyces,k__Bacteria|p__Actinomycetota,k__Bacteria|p__Bacillota",2|1239|909932|1843489|31977|906;2|1239|186801|3085636|186803|1213720;2|1239|91061|186826|186828|117563;2|1224|28216|80840|119060|47670;2|1239|909932|1843489|31977|29465;2|1239|91061|186826|1300|1301;2|201174|1760|85004|31953|196081;2|201174|1760|85006|1268|32207;2|201174|1760|2037|2049|1654;2|201174;2|1239,Complete,Rimsha Azhar
bsdb:147/1/1,Study 147,case-control,25239901,10.1128/AEM.02329-14,NA,"Gong H, Shi Y, Zhou X, Wu C, Cao P, Xu C, Hou D, Wang Y , Zhou L",Microbiota in the Throat and Risk Factors for Laryngeal Carcinoma,Applied and environmental microbiology,2014,NA,Experiment 1,China,Homo sapiens,Throat,UBERON:0000341,Squamous cell carcinoma,EFO:0000707,controls,laryngeal squamous cell carcinoma (LSCC),histopathological confirmation of Laryngeal squamous cell carcinoma and underwent total laryngectomy,28,27,3 months,16S,12,Roche454,T-Test,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,"Table 2, Text, Supplementary Table S2",10 January 2021,Utsav Patel,WikiWorks,Differences in bacterial communities in the throats of LSCC patients and control subjects,increased,"k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae|g__Fusobacterium,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Bacillota|c__Tissierellia|o__Tissierellales|f__Peptoniphilaceae|g__Parvimonas,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Peptostreptococcaceae|g__Peptostreptococcus,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Dialister,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Catonella,k__Bacteria|p__Bacillota|c__Negativicutes|o__Selenomonadales|f__Selenomonadaceae|g__Selenomonas,k__Bacteria|p__Spirochaetota|c__Spirochaetia|o__Spirochaetales|f__Treponemataceae|g__Treponema,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Burkholderiaceae|g__Burkholderia,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Peptostreptococcaceae",2|32066|203490|203491|203492|848;2|976|200643|171549|171552|838;2|1239|1737404|1737405|1570339|543311;2|1239|186801|3082720|186804|1257;2|1239|909932|1843489|31977|39948;2|1239|186801|3085636|186803|43996;2|1239|909932|909929|1843491|970;2|203691|203692|136|2845253|157;2|1224|28216|80840|119060|32008;2|1239|186801|3082720|186804,Complete,Rimsha Azhar
bsdb:147/1/2,Study 147,case-control,25239901,10.1128/AEM.02329-14,NA,"Gong H, Shi Y, Zhou X, Wu C, Cao P, Xu C, Hou D, Wang Y , Zhou L",Microbiota in the Throat and Risk Factors for Laryngeal Carcinoma,Applied and environmental microbiology,2014,NA,Experiment 1,China,Homo sapiens,Throat,UBERON:0000341,Squamous cell carcinoma,EFO:0000707,controls,laryngeal squamous cell carcinoma (LSCC),histopathological confirmation of Laryngeal squamous cell carcinoma and underwent total laryngectomy,28,27,3 months,16S,12,Roche454,T-Test,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 2,"Table 2, Text, Supplementary Table S2",10 January 2021,Utsav Patel,WikiWorks,Differences in bacterial communities in the throats of LSCC patients and control subjects,decreased,"k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micrococcales|f__Micrococcaceae|g__Rothia",2|1239|91061|186826|1300|1301;2|201174|1760|85006|1268|32207,Complete,Rimsha Azhar
bsdb:147/2/1,Study 147,case-control,25239901,10.1128/AEM.02329-14,NA,"Gong H, Shi Y, Zhou X, Wu C, Cao P, Xu C, Hou D, Wang Y , Zhou L",Microbiota in the Throat and Risk Factors for Laryngeal Carcinoma,Applied and environmental microbiology,2014,NA,Experiment 2,China,Homo sapiens,Saliva,UBERON:0001836,Squamous cell carcinoma,EFO:0000707,Site 2 (site below the epiglottis in the throat),Site 1 (upper portion of throat near the epiglottis),histopathological confirmation of Laryngeal squamous cell carcinoma and underwent total laryngectomy,28,27,3 months,16S,12,Roche454,T-Test,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,"Table 2, Text, Supplementary Table S2",10 January 2021,Utsav Patel,WikiWorks,Differences in bacterial communities in the throats of LSCC patients and control subjects,increased,"k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Veillonella,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Leptotrichiaceae|g__Leptotrichia,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales|f__Actinomycetaceae|g__Actinomyces,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micrococcales|f__Micrococcaceae|g__Rothia,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Carnobacteriaceae|g__Granulicatella,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Megasphaera,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Oribacterium,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales|f__Atopobiaceae|g__Atopobium,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Moryella,k__Bacteria|p__Candidatus Saccharibacteria",2|1239|909932|1843489|31977|29465;2|32066|203490|203491|1129771|32067;2|201174|1760|2037|2049|1654;2|201174|1760|85006|1268|32207;2|1239|91061|186826|186828|117563;2|1239|909932|1843489|31977|906;2|1239|186801|3085636|186803|265975;2|201174|84998|84999|1643824|1380;2|1239|186801|3085636|186803|437755;2|95818,Complete,Rimsha Azhar
bsdb:147/2/2,Study 147,case-control,25239901,10.1128/AEM.02329-14,NA,"Gong H, Shi Y, Zhou X, Wu C, Cao P, Xu C, Hou D, Wang Y , Zhou L",Microbiota in the Throat and Risk Factors for Laryngeal Carcinoma,Applied and environmental microbiology,2014,NA,Experiment 2,China,Homo sapiens,Saliva,UBERON:0001836,Squamous cell carcinoma,EFO:0000707,Site 2 (site below the epiglottis in the throat),Site 1 (upper portion of throat near the epiglottis),histopathological confirmation of Laryngeal squamous cell carcinoma and underwent total laryngectomy,28,27,3 months,16S,12,Roche454,T-Test,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,Signature 2,"Table 2, Text, Supplementary Table S2",10 January 2021,Utsav Patel,WikiWorks,Differences in bacterial communities in the throats of LSCC patients and control subjects,decreased,"k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae|g__Fusobacterium,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Bacillota|c__Tissierellia|o__Tissierellales|f__Peptoniphilaceae|g__Parvimonas,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Peptostreptococcaceae|g__Peptostreptococcus,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae|g__Porphyromonas,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Dialister,k__Bacteria|p__Mycoplasmatota|c__Mollicutes|o__Mycoplasmatales|f__Mycoplasmataceae|g__Mycoplasma,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Filifactoraceae|g__Filifactor,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Catonella,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Neisseriaceae|g__Eikenella,k__Bacteria|p__Spirochaetota|c__Spirochaetia|o__Spirochaetales|f__Treponemataceae|g__Treponema,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Aggregatibacter,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Peptostreptococcaceae",2|32066|203490|203491|203492|848;2|976|200643|171549|171552|838;2|1239|1737404|1737405|1570339|543311;2|1239|186801|3082720|186804|1257;2|976|200643|171549|171551|836;2|1239|909932|1843489|31977|39948;2|544448|31969|2085|2092|2093;2|1239|186801|3082720|3118655|44259;2|1239|186801|3085636|186803|43996;2|1224|28216|206351|481|538;2|203691|203692|136|2845253|157;2|1224|1236|135625|712|416916;2|1239|186801|3082720|186804,Complete,Rimsha Azhar
bsdb:148/1/1,Study 148,case-control,30292647,10.1016/j.resmic.2018.09.002,NA,"Zeng B, Lai Z, Sun L, Zhang Z, Yang J, Li Z, Lin J , Zhang Z",Structural and functional profiles of the gut microbial community in polycystic ovary syndrome with insulin resistance (IR-PCOS): a pilot study,Research in microbiology,2019,"Gut microbial community, Insulin resistance, Polycystic ovary syndrome",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Polycystic ovary syndrome,EFO:0000660,HC - Healthy Controls,NIR-PCOS - NIR(Non-Insulin Resistance),NIR-PCOS - PCOS without insulin resistance,8,8,Administration of antibiotics,16S,34,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,decreased,NA,NA,NA,NA,Signature 1,Figure 3,10 January 2021,Fatima Zohra,"WikiWorks,Peace Sandy","Identification of the bacterial taxa with statistically significant difference between groups using LEfSe software. LEfSe was performed in pairwise manner for HC vs. NIR-PCOS (A), HC vs. IR-PCOS (B) and NIR-PCOS vs. IR-PCOS (C). Cladograms show the taxonomic hierarchical structure and the circles from the inside to the outside indicate kingdom, phyla, class, order, family, genus. Taxa enriched in HC, NIR-PCOS and IR-PCOS group are colored by green, blue and red respectively (LDA > 2.0 and P < 0.05), relative abundance of these biomarkers are showed in the histogram (mean and standard deviation values are plotted) under the corresponding cladogram.",increased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Lachnospira,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae",2|976|200643|171549|815;2|976|200643|171549|815|816;2|1239|186801|3085636|186803|28050;2|1239|186801|3085636|186803,Complete,Peace Sandy
bsdb:148/1/2,Study 148,case-control,30292647,10.1016/j.resmic.2018.09.002,NA,"Zeng B, Lai Z, Sun L, Zhang Z, Yang J, Li Z, Lin J , Zhang Z",Structural and functional profiles of the gut microbial community in polycystic ovary syndrome with insulin resistance (IR-PCOS): a pilot study,Research in microbiology,2019,"Gut microbial community, Insulin resistance, Polycystic ovary syndrome",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Polycystic ovary syndrome,EFO:0000660,HC - Healthy Controls,NIR-PCOS - NIR(Non-Insulin Resistance),NIR-PCOS - PCOS without insulin resistance,8,8,Administration of antibiotics,16S,34,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,decreased,NA,NA,NA,NA,Signature 2,Figure 3,10 January 2021,Fatima Zohra,"WikiWorks,Peace Sandy","Identification of the bacterial taxa with statistically significant difference between groups using LEfSe software. LEfSe was performed in pairwise manner for HC vs. NIR-PCOS (A), HC vs. IR-PCOS (B) and NIR-PCOS vs. IR-PCOS (C). Cladograms show the taxonomic hierarchical structure and the circles from the inside to the outside indicate kingdom, phyla, class, order, family, genus. Taxa enriched in HC, NIR-PCOS and IR-PCOS group are colored by green, blue and red respectively (LDA > 2.0 and P < 0.05), relative abundance of these biomarkers are showed in the histogram (mean and standard deviation values are plotted) under the corresponding cladogram.",decreased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae",2|976|200643|171549|171552|838;2|976|200643|171549|171552,Complete,Peace Sandy
bsdb:148/2/1,Study 148,case-control,30292647,10.1016/j.resmic.2018.09.002,NA,"Zeng B, Lai Z, Sun L, Zhang Z, Yang J, Li Z, Lin J , Zhang Z",Structural and functional profiles of the gut microbial community in polycystic ovary syndrome with insulin resistance (IR-PCOS): a pilot study,Research in microbiology,2019,"Gut microbial community, Insulin resistance, Polycystic ovary syndrome",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Polycystic ovary syndrome,EFO:0000660,HC - Healthy Controls,IR-PCOS IR-(Insulin Resistance),PCOS with Insulin resistance,8,9,Administration of antibiotics,16S,34,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,decreased,NA,NA,NA,NA,Signature 1,Figure 3,10 January 2021,Fatima Zohra,"WikiWorks,Peace Sandy","Identification of the bacterial taxa with statistically significant difference between groups using LEfSe software. LEfSe was performed in pairwise manner for HC vs. NIR-PCOS (A), HC vs. IR-PCOS (B) and NIR-PCOS vs. IR-PCOS (C). Cladograms show the taxonomic hierarchical structure and the circles from the inside to the outside indicate kingdom, phyla, class, order, family, genus. Taxa enriched in HC, NIR-PCOS and IR-PCOS group are colored by green, blue and red respectively (LDA > 2.0 and P < 0.05), relative abundance of these biomarkers are showed in the histogram (mean and standard deviation values are plotted) under the corresponding cladogram.",increased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Lachnospira",2|976|200643|171549|815;2|976|200643|171549|815|816;2|1239|186801|3085636|186803|28050,Complete,Peace Sandy
bsdb:148/2/2,Study 148,case-control,30292647,10.1016/j.resmic.2018.09.002,NA,"Zeng B, Lai Z, Sun L, Zhang Z, Yang J, Li Z, Lin J , Zhang Z",Structural and functional profiles of the gut microbial community in polycystic ovary syndrome with insulin resistance (IR-PCOS): a pilot study,Research in microbiology,2019,"Gut microbial community, Insulin resistance, Polycystic ovary syndrome",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Polycystic ovary syndrome,EFO:0000660,HC - Healthy Controls,IR-PCOS IR-(Insulin Resistance),PCOS with Insulin resistance,8,9,Administration of antibiotics,16S,34,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,decreased,NA,NA,NA,NA,Signature 2,Figure 3,10 January 2021,Fatima Zohra,"WikiWorks,Peace Sandy","Identification of the bacterial taxa with statistically significant difference between groups using LEfSe software. LEfSe was performed in pairwise manner for HC vs. NIR-PCOS (A), HC vs. IR-PCOS (B) and NIR-PCOS vs. IR-PCOS (C). Cladograms show the taxonomic hierarchical structure and the circles from the inside to the outside indicate kingdom, phyla, class, order, family, genus. Taxa enriched in HC, NIR-PCOS and IR-PCOS group are colored by green, blue and red respectively (LDA > 2.0 and P < 0.05), relative abundance of these biomarkers are showed in the histogram (mean and standard deviation values are plotted) under the corresponding cladogram.",decreased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae",2|976|200643|171549|171552|838;2|976|200643|171549|171552,Complete,Peace Sandy
bsdb:148/3/1,Study 148,case-control,30292647,10.1016/j.resmic.2018.09.002,NA,"Zeng B, Lai Z, Sun L, Zhang Z, Yang J, Li Z, Lin J , Zhang Z",Structural and functional profiles of the gut microbial community in polycystic ovary syndrome with insulin resistance (IR-PCOS): a pilot study,Research in microbiology,2019,"Gut microbial community, Insulin resistance, Polycystic ovary syndrome",Experiment 3,China,Homo sapiens,Feces,UBERON:0001988,Polycystic ovary syndrome,EFO:0000660,NIR-PCOS - NIR(Non-Insulin Resistance),IR-PCOS IR-(Insulin Resistance),PCOS with Insulin Resistance,8,9,Administration of antibiotics,16S,34,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,decreased,NA,NA,NA,NA,Signature 1,Figure 3,10 January 2021,Fatima Zohra,"WikiWorks,Peace Sandy","Identification of the bacterial taxa with statistically significant difference between groups using LEfSe software. LEfSe was performed in pairwise manner for HC vs. NIR-PCOS (A), HC vs. IR-PCOS (B) and NIR-PCOS vs. IR-PCOS (C). Cladograms show the taxonomic hierarchical structure and the circles from the inside to the outside indicate kingdom, phyla, class, order, family, genus. Taxa enriched in HC, NIR-PCOS and IR-PCOS group are colored by green, blue and red respectively (LDA > 2.0 and P < 0.05), relative abundance of these biomarkers are showed in the histogram (mean and standard deviation values are plotted) under the corresponding cladogram.",increased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides,k__Bacteria|p__Bacteroidota|c__Bacteroidia",2|976|200643|171549|815;2|976|200643|171549;2|976|200643|171549|815|816;2|976|200643,Complete,Peace Sandy
bsdb:148/3/2,Study 148,case-control,30292647,10.1016/j.resmic.2018.09.002,NA,"Zeng B, Lai Z, Sun L, Zhang Z, Yang J, Li Z, Lin J , Zhang Z",Structural and functional profiles of the gut microbial community in polycystic ovary syndrome with insulin resistance (IR-PCOS): a pilot study,Research in microbiology,2019,"Gut microbial community, Insulin resistance, Polycystic ovary syndrome",Experiment 3,China,Homo sapiens,Feces,UBERON:0001988,Polycystic ovary syndrome,EFO:0000660,NIR-PCOS - NIR(Non-Insulin Resistance),IR-PCOS IR-(Insulin Resistance),PCOS with Insulin Resistance,8,9,Administration of antibiotics,16S,34,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,decreased,NA,NA,NA,NA,Signature 2,Figure 3,10 January 2021,Fatima Zohra,"WikiWorks,Peace Sandy","Identification of the bacterial taxa with statistically significant difference between groups using LEfSe software. LEfSe was performed in pairwise manner for HC vs. NIR-PCOS (A), HC vs. IR-PCOS (B) and NIR-PCOS vs. IR-PCOS (C). Cladograms show the taxonomic hierarchical structure and the circles from the inside to the outside indicate kingdom, phyla, class, order, family, genus. Taxa enriched in HC, NIR-PCOS and IR-PCOS group are colored by green, blue and red respectively (LDA > 2.0 and P < 0.05), relative abundance of these biomarkers are showed in the histogram (mean and standard deviation values are plotted) under the corresponding cladogram.",decreased,"k__Bacteria|p__Bacillota|c__Clostridia,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Faecalibacterium,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae,k__Bacteria|p__Bacillota",2|1239|186801;2|1239|186801|186802;2|1239|186801|186802|216572|216851;2|1239|186801|3085636|186803;2|1239,Complete,Peace Sandy
bsdb:149/1/1,Study 149,case-control,30366118,10.1016/j.anaerobe.2018.10.009,NA,"Maya-Lucas O, Murugesan S, Nirmalkar K, Alcaraz LD, Hoyo-Vadillo C, Pizano-Zárate ML , García-Mena J",The gut microbiome of Mexican children affected by obesity,Anaerobe,2019,"Cholesterol, Gut microbiome, High-throughput sequencing, Mexican children, Obesity, Triglycerides",Experiment 1,Mexico,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,Normal weight children,Obese children,Obese children aged between 9 and 11 years-old,10,10,None.,WMS,NA,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,Signature 1,Figure 4A,10 January 2021,Rimsha Azhar,"WikiWorks,ChiomaBlessing","Differentially abundant bacterial genera, families, or species in obese children compared to normal weight children.",increased,"k__Bacteria|p__Bacillota|c__Negativicutes|o__Selenomonadales|f__Selenomonadaceae|g__Megamonas,k__Bacteria|p__Bacillota|c__Negativicutes|o__Selenomonadales|f__Selenomonadaceae|g__Megamonas",2|1239|909932|909929|1843491|158846;2|1239|909932|909929|1843491|158846,Complete,ChiomaBlessing
bsdb:149/1/2,Study 149,case-control,30366118,10.1016/j.anaerobe.2018.10.009,NA,"Maya-Lucas O, Murugesan S, Nirmalkar K, Alcaraz LD, Hoyo-Vadillo C, Pizano-Zárate ML , García-Mena J",The gut microbiome of Mexican children affected by obesity,Anaerobe,2019,"Cholesterol, Gut microbiome, High-throughput sequencing, Mexican children, Obesity, Triglycerides",Experiment 1,Mexico,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,Normal weight children,Obese children,Obese children aged between 9 and 11 years-old,10,10,None.,WMS,NA,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,Signature 2,Figure 4A,10 January 2021,Rimsha Azhar,"WikiWorks,ChiomaBlessing","Differentially abundant bacterial genera, families, or species in obese children compared to normal weight children.",decreased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Anaerostipes,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Anaerostipes|s__Anaerostipes hadrus,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides|s__Bacteroides faecis,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides|s__Bacteroides ovatus,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides|s__Bacteroides salyersiae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides|s__Bacteroides xylanisolvens,k__Bacteria|p__Thermodesulfobacteriota|c__Desulfovibrionia|o__Desulfovibrionales|f__Desulfovibrionaceae|g__Bilophila|s__Bilophila wadsworthia,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Coprococcus|s__Coprococcus comes,k__Bacteria|c__Deltaproteobacteria,k__Bacteria|p__Thermodesulfobacteriota|c__Desulfobacteria|o__Desulfobacterales,k__Archaea|p__Thermoproteota|c__Thermoprotei|o__Desulfurococcales|f__Desulfurococcaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Dorea|s__Dorea formicigenerans,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Enterocloster|s__Enterocloster citroniae,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae|g__Holdemania,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Oscillibacter,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus|s__Streptococcus thermophilus,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Veillonella|s__Veillonella parvula,k__Bacteria|p__Thermodesulfobacteriota|c__Desulfovibrionia|o__Desulfovibrionales|f__Desulfovibrionaceae,k__Bacteria|p__Thermodesulfobacteriota|c__Desulfovibrionia|o__Desulfovibrionales,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|s__Lachnospiraceae bacterium 7_1_58FAA,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Oscillibacter,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Ruminococcus|s__Ruminococcus sp. 5_1_39BFAA",2|1239|186801|3085636|186803|207244;2|1239|186801|3085636|186803|207244|649756;2|976|200643|171549|815;2|976|200643|171549|815|816|674529;2|976|200643|171549|815|816|28116;2|976|200643|171549|815|816|291644;2|976|200643|171549|815|816|371601;2|200940|3031449|213115|194924|35832|35833;2|1239|186801|3085636|186803|33042|410072;2|28221;2|200940|3024418|213118;2157|28889|183924|114380|2272;2|1239|186801|3085636|186803|189330|39486;2|1239|186801|3085636|186803|2719313|358743;2|1239|526524|526525|128827|61170;2|1239|186801|186802|216572|459786;2|1239|186801|186802|216572;2|1239|91061|186826|1300|1301|1308;2|1239|909932|1843489|31977|29465|29466;2|200940|3031449|213115|194924;2|200940|3031449|213115;2|1239|186801|3085636|186803|658087;2|1239|186801|186802|216572|459786;2|1239|186801|186802|216572|1263|457412,Complete,ChiomaBlessing
bsdb:150/1/1,Study 150,case-control,31334130,10.3389/fcimb.2019.00205,NA,"Wang L, Yin G, Guo Y, Zhao Y, Zhao M, Lai Y, Sui P, Shi T, Guo W , Huang Z",Variations in Oral Microbiota Composition Are Associated With a Risk of Throat Cancer,Frontiers in cellular and infection microbiology,2019,"16S rRNA gene, early diagnosis, microbiome, next-generation sequencing, oral health, throat cancer",Experiment 1,China,Homo sapiens,Saliva,UBERON:0001836,Head and neck carcinoma,MONDO:0002038,Healthy controls,Throat cancer,"throat cancer including cancer of oropharynx, hypopharynx, nasopharynx and larynx",29,32,6 months,16S,3,Illumina,LEfSe,0.05,FALSE,4,NA,NA,NA,decreased,decreased,decreased,NA,NA,Signature 1,"Figure 2, Figure 3, Text",10 January 2021,Utsav Patel,WikiWorks,Variations in oral microbiota composition associated with a risk of Throat Cancer,increased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pseudomonadales|f__Pseudomonadaceae|g__Pseudomonas,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Aggregatibacter,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Faecalibacterium,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Ruminiclostridium,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Burkholderiaceae|g__Lautropia,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Phocaeicola,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pseudomonadales|f__Pseudomonadaceae|s__Azotobacter group,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Burkholderiaceae,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Rickettsiales",2|1224|1236|72274|135621|286;2|1224|1236|135625|712|416916;2|1239|186801|186802|216572|216851;2|1239|186801|186802|216572|1508657;2|1224|28216|80840|119060|47670;2|976|200643|171549|815|909656;2|976|200643|171549|815|816;2|976|200643|171549|171552;2|1224|1236|72274|135621|351;2|976|200643|171549|815;2|1224|28216|80840|119060;2|1224|28216|80840;2|1224|28211;2|1224|28211|766,Complete,Fatima Zohra
bsdb:150/1/2,Study 150,case-control,31334130,10.3389/fcimb.2019.00205,NA,"Wang L, Yin G, Guo Y, Zhao Y, Zhao M, Lai Y, Sui P, Shi T, Guo W , Huang Z",Variations in Oral Microbiota Composition Are Associated With a Risk of Throat Cancer,Frontiers in cellular and infection microbiology,2019,"16S rRNA gene, early diagnosis, microbiome, next-generation sequencing, oral health, throat cancer",Experiment 1,China,Homo sapiens,Saliva,UBERON:0001836,Head and neck carcinoma,MONDO:0002038,Healthy controls,Throat cancer,"throat cancer including cancer of oropharynx, hypopharynx, nasopharynx and larynx",29,32,6 months,16S,3,Illumina,LEfSe,0.05,FALSE,4,NA,NA,NA,decreased,decreased,decreased,NA,NA,Signature 2,"Figure 2, Figure 3, Text",10 January 2021,Utsav Patel,"Lwaldron,WikiWorks",Variations in oral microbiota composition associated with a risk of Throat Cancer,decreased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Actinobacillus,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Anaerovoracaceae|g__Anaerovorax,k__Bacteria|p__Bacteroidota|c__Flavobacteriia|o__Flavobacteriales|f__Weeksellaceae|g__Bergeyella,k__Bacteria|p__Campylobacterota|c__Epsilonproteobacteria|o__Campylobacterales|f__Campylobacteraceae|g__Campylobacter,k__Bacteria|p__Campylobacterota|c__Epsilonproteobacteria|o__Campylobacterales|f__Campylobacteraceae,k__Bacteria|p__Campylobacterota|c__Epsilonproteobacteria|o__Campylobacterales,k__Bacteria|p__Candidatus Gracilibacteria,k__Bacteria|p__Candidatus Saccharibacteria,k__Bacteria|p__Bacillota|c__Clostridia,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Mycobacteriales|f__Corynebacteriaceae,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Mycobacteriales,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Mycobacteriales|f__Corynebacteriaceae|g__Corynebacterium,k__Bacteria|p__Campylobacterota,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Eubacteriaceae|g__Eubacterium,k__Bacteria|p__Fusobacteriota,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae|g__Fusobacterium,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Haemophilus,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Lachnoclostridium,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Leptotrichiaceae|g__Leptotrichia,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Leptotrichiaceae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Moraxellales|f__Moraxellaceae|g__Moraxella,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Moraxellales|f__Moraxellaceae,k__Bacteria|p__Bacillota|c__Negativicutes,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Neisseriaceae|g__Neisseria,k__Bacteria|p__Bacillota|c__Tissierellia|o__Tissierellales|f__Peptoniphilaceae|g__Parvimonas,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Peptostreptococcaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Peptostreptococcaceae|g__Peptostreptococcus,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae|g__Porphyromonas,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Roseburia,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micrococcales|f__Micrococcaceae|g__Rothia,k__Bacteria|p__Bacillota|c__Negativicutes|o__Selenomonadales,k__Bacteria|p__Bacillota|c__Negativicutes|o__Selenomonadales|f__Selenomonadaceae|g__Selenomonas,k__Bacteria|p__Spirochaetota|c__Spirochaetia|o__Spirochaetales|f__Spirochaetaceae,k__Bacteria|p__Spirochaetota|c__Spirochaetia|o__Spirochaetales,k__Bacteria|p__Spirochaetota|c__Spirochaetia,k__Bacteria|p__Spirochaetota|c__Spirochaetia|o__Spirochaetales|f__Treponemataceae|g__Treponema,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Veillonella,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae",2|1224|1236|135625|712|713;2|1239|186801|3082720|3030910|109326;2|976|117743|200644|2762318|59735;2|29547|3031852|213849|72294|194;2|29547|3031852|213849|72294;2|29547|3031852|213849;2|363464;2|95818;2|1239|186801;2|201174|1760|85007|1653;2|201174|1760|85007;2|201174|1760|85007|1653|1716;2|29547;2|1239|186801|186802;2|1239|186801|186802|186806|1730;2|32066;2|32066|203490|203491|203492;2|32066|203490|203491;2|32066|203490;2|32066|203490|203491|203492|848;2|1224|1236|135625|712|724;2|1239|186801|3085636|186803|1506553;2|32066|203490|203491|1129771|32067;2|32066|203490|203491|1129771;2|1224|1236|2887326|468|475;2|1224|1236|2887326|468;2|1239|909932;2|1224|28216|206351|481|482;2|1239|1737404|1737405|1570339|543311;2|1239|186801|3082720|186804;2|1239|186801|3082720|186804|1257;2|976|200643|171549|171551|836;2|976|200643|171549|171552|838;2|1239|186801|3085636|186803|841;2|201174|1760|85006|1268|32207;2|1239|909932|909929;2|1239|909932|909929|1843491|970;2|203691|203692|136|137;2|203691|203692|136;2|203691|203692;2|203691|203692|136|2845253|157;2|1239|909932|1843489|31977|29465;2|1239|909932|1843489|31977,Complete,Fatima
bsdb:150/2/1,Study 150,case-control,31334130,10.3389/fcimb.2019.00205,NA,"Wang L, Yin G, Guo Y, Zhao Y, Zhao M, Lai Y, Sui P, Shi T, Guo W , Huang Z",Variations in Oral Microbiota Composition Are Associated With a Risk of Throat Cancer,Frontiers in cellular and infection microbiology,2019,"16S rRNA gene, early diagnosis, microbiome, next-generation sequencing, oral health, throat cancer",Experiment 2,China,Homo sapiens,Saliva,UBERON:0001836,Head and neck carcinoma,MONDO:0002038,Vocal cord polyp,Cancer,"throat cancer including cancer of oropharynx, hypopharynx, nasopharynx and larynx",9,32,6 months,16S,3,Illumina,LEfSe,0.05,FALSE,4,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,Signature 1,"Figure 2, Figure 3, Text",10 January 2021,Utsav Patel,WikiWorks,Variations in oral microbiota composition associated with a risk of Throat Cancer,increased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Enterobacter,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Aggregatibacter,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pseudomonadales|f__Pseudomonadaceae|g__Pseudomonas,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pseudomonadales|f__Pseudomonadaceae|s__Azotobacter group",2|1224|1236|91347|543|547;2|1224|1236|135625|712|416916;2|1224|1236|72274|135621|286;2|1224|1236|72274|135621|351,Complete,Fatima Zohra
bsdb:150/2/2,Study 150,case-control,31334130,10.3389/fcimb.2019.00205,NA,"Wang L, Yin G, Guo Y, Zhao Y, Zhao M, Lai Y, Sui P, Shi T, Guo W , Huang Z",Variations in Oral Microbiota Composition Are Associated With a Risk of Throat Cancer,Frontiers in cellular and infection microbiology,2019,"16S rRNA gene, early diagnosis, microbiome, next-generation sequencing, oral health, throat cancer",Experiment 2,China,Homo sapiens,Saliva,UBERON:0001836,Head and neck carcinoma,MONDO:0002038,Vocal cord polyp,Cancer,"throat cancer including cancer of oropharynx, hypopharynx, nasopharynx and larynx",9,32,6 months,16S,3,Illumina,LEfSe,0.05,FALSE,4,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,Signature 2,"Figure 2, Figure 3, Text",10 January 2021,Utsav Patel,WikiWorks,Variations in oral microbiota composition associated with a risk of Throat Cancer,decreased,"k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae|g__Fusobacterium,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Filifactoraceae|g__Filifactor,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Actinobacillus,k__Bacteria|p__Campylobacterota|c__Epsilonproteobacteria|o__Campylobacterales|f__Helicobacteraceae|g__Helicobacter,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Rikenellaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Eubacteriaceae|g__Eubacterium,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Roseburia,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Anaerovoracaceae|g__Anaerovorax,k__Bacteria|p__Thermodesulfobacteriota|c__Desulfovibrionia|o__Desulfovibrionales|f__Desulfovibrionaceae|g__Desulfovibrio,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Johnsonella,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia,k__Bacteria|p__Fusobacteriota,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Leptotrichiaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Peptostreptococcaceae,k__Bacteria|p__Candidatus Saccharibacteria,k__Bacteria|p__Bacteroidota|c__Sphingobacteriia|o__Sphingobacteriales,k__Bacteria|p__Bacteroidota|c__Sphingobacteriia,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Lentimicrobiaceae,k__Bacteria|p__Campylobacterota|c__Epsilonproteobacteria|o__Campylobacterales|f__Helicobacteraceae,k__Bacteria|p__Candidatus Gracilibacteria,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Caulobacterales|f__Caulobacteraceae,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Caulobacterales,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Defluviitaleaceae,k__Bacteria|p__Thermodesulfobacteriota|c__Desulfovibrionia|o__Desulfovibrionales|f__Desulfovibrionaceae,k__Bacteria|p__Thermodesulfobacteriota|c__Desulfovibrionia|o__Desulfovibrionales",2|32066|203490|203491|203492|848;2|976|200643|171549|171552|838;2|1239|186801|3082720|3118655|44259;2|1224|1236|135625|712|713;2|29547|3031852|213849|72293|209;2|976|200643|171549|171550;2|1239|186801|186802|186806|1730;2|1239|186801|3085636|186803|841;2|1239|186801|3082720|3030910|109326;2|200940|3031449|213115|194924|872;2|1239|186801|3085636|186803|43994;2|32066|203490;2|32066;2|32066|203490|203491;2|32066|203490|203491|203492;2|32066|203490|203491|1129771;2|1239|186801|3082720|186804;2|95818;2|976|117747|200666;2|976|117747;2|976|200643|171549|1840213;2|29547|3031852|213849|72293;2|363464;2|1224|28211|204458|76892;2|1224|28211|204458;2|1239|186801|3085636|1185407;2|200940|3031449|213115|194924;2|200940|3031449|213115,Complete,Fatima Zohra
bsdb:151/1/1,Study 151,case-control,30081953,10.1186/s40168-018-0515-3,NA,"Zhu J, Liao M, Yao Z, Liang W, Li Q, Liu J, Yang H, Ji Y, Wei W, Tan A, Liang S, Chen Y, Lin H, Zhu X, Huang S, Tian J, Tang R, Wang Q , Mo Z",Breast cancer in postmenopausal women is associated with an altered gut metagenome,Microbiome,2018,"Breast cancer, Gut microbiota, Immunity, Metabolism, Metagenomic analyses",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Breast cancer,MONDO:0007254,controls,Postmenopausal breast cancer patients,Postmenopausal breast cancer patients,46,44,3 months,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,increased,NA,NA,unchanged,Signature 1,Table 2 and Supplementary Table S4,10 January 2021,Rimsha Azhar,WikiWorks,Relative abundance of the different species between postmenopausal breast cancer patients and postmenopausal healthy controls,increased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Escherichia|s__Escherichia coli,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Shigella|s__Shigella sonnei,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Morganellaceae|g__Proteus|s__Proteus mirabilis,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Shigella|s__Shigella boydii,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Vibrionales|f__Vibrionaceae|g__Vibrio|s__Vibrio cholerae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Escherichia|s__Escherichia fergusonii,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Shigella|s__Shigella flexneri,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Moraxellales|f__Moraxellaceae|g__Acinetobacter|s__Acinetobacter baumannii,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Moraxellales|f__Moraxellaceae|g__Acinetobacter|s__Acinetobacter johnsonii,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Morganellaceae|g__Providencia|s__Providencia rettgeri,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Limosilactobacillus|s__Limosilactobacillus mucosae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae|g__Porphyromonas|s__Porphyromonas uenonis,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae|g__Fusobacterium|s__Fusobacterium nucleatum,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Citrobacter|s__Citrobacter koseri,k__Bacteria|p__Thermodesulfobacteriota|c__Desulfovibrionia|o__Desulfovibrionales|f__Desulfovibrionaceae|g__Desulfovibrio|s__Desulfovibrio piger,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Enterococcaceae|g__Enterococcus|s__Enterococcus gallinarum,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Salmonella|s__Salmonella enterica,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Erwiniaceae|g__Erwinia|s__Erwinia amylovora,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Bruguierivoracaceae|g__Sodalis|s__Sodalis glossinidius,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Moraxellales|f__Moraxellaceae|g__Acinetobacter|s__Acinetobacter radioresistens,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae|g__Fusobacterium|s__Fusobacterium varium,k__Bacteria|p__Bacillota|c__Negativicutes|o__Acidaminococcales|f__Acidaminococcaceae|g__Acidaminococcus|s__Acidaminococcus intestini,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella|s__Prevotella amnii,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Yersiniaceae|g__Yersinia|s__Yersinia enterocolitica,k__Bacteria|p__Bacillota|c__Tissierellia|o__Tissierellales|f__Peptoniphilaceae|g__Anaerococcus|s__Anaerococcus vaginalis,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Alteromonadales|f__Shewanellaceae|g__Shewanella|s__Shewanella putrefaciens",2|1224|1236|91347|543|561|562;2|1224|1236|91347|543|620|624;2|1224|1236|91347|1903414|583|584;2|1224|1236|91347|543|620|621;2|1224|1236|135623|641|662|666;2|1224|1236|91347|543|561|564;2|1224|1236|91347|543|620|623;2|1224|1236|2887326|468|469|470;2|1224|1236|2887326|468|469|40214;2|1224|1236|91347|1903414|586|587;2|1239|91061|186826|33958|2742598|97478;2|976|200643|171549|171551|836|281920;2|32066|203490|203491|203492|848|851;2|1224|1236|91347|543|544|545;2|200940|3031449|213115|194924|872|901;2|1239|91061|186826|81852|1350|1353;2|1224|1236|91347|543|590|28901;2|1224|1236|91347|1903409|551|552;2|1224|1236|91347|2812006|84565|63612;2|1224|1236|2887326|468|469|40216;2|32066|203490|203491|203492|848|856;2|1239|909932|1843488|909930|904|187327;2|976|200643|171549|171552|838|419005;2|1224|1236|91347|1903411|629|630;2|1239|1737404|1737405|1570339|165779|33037;2|1224|1236|135622|267890|22|24,Complete,Fatima Zohra
bsdb:151/1/2,Study 151,case-control,30081953,10.1186/s40168-018-0515-3,NA,"Zhu J, Liao M, Yao Z, Liang W, Li Q, Liu J, Yang H, Ji Y, Wei W, Tan A, Liang S, Chen Y, Lin H, Zhu X, Huang S, Tian J, Tang R, Wang Q , Mo Z",Breast cancer in postmenopausal women is associated with an altered gut metagenome,Microbiome,2018,"Breast cancer, Gut microbiota, Immunity, Metabolism, Metagenomic analyses",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Breast cancer,MONDO:0007254,controls,Postmenopausal breast cancer patients,Postmenopausal breast cancer patients,46,44,3 months,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,increased,NA,NA,unchanged,Signature 2,Table 2 and Supplementary Table S4,10 January 2021,Rimsha Azhar,WikiWorks,Relative abundance of the different species between postmenopausal breast cancer patients and postmenopausal healthy controls,decreased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Lachnospira|s__Lachnospira eligens,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Escherichia|s__Escherichia albertii,k__Bacteria|p__Campylobacterota|c__Epsilonproteobacteria|o__Campylobacterales|f__Campylobacteraceae|g__Campylobacter|s__Campylobacter concisus,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Roseburia|s__Roseburia inulinivorans,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Hyphomicrobiales|f__Brucellaceae|g__Brucella|s__Brucella melitensis,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Limosilactobacillus|s__Limosilactobacillus vaginalis",2|1239|186801|3085636|186803|28050|39485;2|1224|1236|91347|543|561|208962;2|29547|3031852|213849|72294|194|199;2|1239|186801|3085636|186803|841|360807;2|1224|28211|356|118882|234|29459;2|1239|91061|186826|33958|2742598|1633,Complete,Fatima Zohra
bsdb:152/1/1,Study 152,case-control,30904962,10.1186/s13568-019-0763-z,NA,"Wang Z, Wang Q, Zhao J, Gong L, Zhang Y, Wang X , Yuan Z",Altered diversity and composition of the gut microbiome in patients with cervical cancer,AMB Express,2019,"16S rRNA, Cervical cancer, Deep sequencing, Gut microbiota",Experiment 1,Finland,Homo sapiens,Feces,UBERON:0001988,Cervical cancer,MONDO:0002974,healthy controls,cervical cancer,pathology confirmed cervical cancer patients,5,8,2 months,16S,4,Illumina,T-Test,0.05,FALSE,NA,age,NA,NA,unchanged,unchanged,NA,NA,unchanged,Signature 1,Table 3,10 January 2021,Fatima Zohra,"Claregrieve1,WikiWorks",Differential microbial abundance between patients with cervical cancer and healthy controls,increased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Dorea,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Morganellaceae|g__Morganella,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Morganellaceae|g__Proteus,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Ruminococcus,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Alteromonadales|f__Shewanellaceae|g__Shewanella,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Aeromonadales|f__Succinivibrionaceae|g__Succinivibrio",2|1239|186801|3085636|186803|189330;2|1224|1236|91347|1903414|581;2|1224|1236|91347|1903414|583;2|1239|186801|186802|216572|1263;2|1224|1236|135622|267890|22;2|1224|1236|135624|83763|83770,Complete,Claregrieve1
bsdb:152/1/2,Study 152,case-control,30904962,10.1186/s13568-019-0763-z,NA,"Wang Z, Wang Q, Zhao J, Gong L, Zhang Y, Wang X , Yuan Z",Altered diversity and composition of the gut microbiome in patients with cervical cancer,AMB Express,2019,"16S rRNA, Cervical cancer, Deep sequencing, Gut microbiota",Experiment 1,Finland,Homo sapiens,Feces,UBERON:0001988,Cervical cancer,MONDO:0002974,healthy controls,cervical cancer,pathology confirmed cervical cancer patients,5,8,2 months,16S,4,Illumina,T-Test,0.05,FALSE,NA,age,NA,NA,unchanged,unchanged,NA,NA,unchanged,Signature 2,Table 3,10 January 2021,Fatima Zohra,"Claregrieve1,WikiWorks",Differential microbial abundance between patients with cervical cancer and healthy controls,decreased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Oceanospirillales|f__Halomonadaceae|g__Halomonas,k__Bacteria|p__Bacillota|c__Negativicutes|o__Acidaminococcales|f__Acidaminococcaceae|g__Phascolarctobacterium",2|1224|1236|135619|28256|2745;2|1239|909932|1843488|909930|33024,Complete,Claregrieve1
bsdb:152/2/1,Study 152,case-control,30904962,10.1186/s13568-019-0763-z,NA,"Wang Z, Wang Q, Zhao J, Gong L, Zhang Y, Wang X , Yuan Z",Altered diversity and composition of the gut microbiome in patients with cervical cancer,AMB Express,2019,"16S rRNA, Cervical cancer, Deep sequencing, Gut microbiota",Experiment 2,Finland,Homo sapiens,Feces,UBERON:0001988,Cervical cancer,MONDO:0002974,healthy controls,cervical cancer patients,pathology confirmed cervical cancer patients,5,8,2 months,16S,4,Illumina,LEfSe,0.05,FALSE,4,age,NA,NA,unchanged,unchanged,NA,NA,unchanged,Signature 1,"Figure 4, Table 3, Figure 5",10 January 2021,Fatima Zohra,"Claregrieve1,WikiWorks",Differential microbial abundance between patients with cervical cancer and healthy controls,increased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides|s__Bacteroides stercoris,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Escherichia|s__Escherichia coli,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Tannerellaceae|g__Parabacteroides,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Tannerellaceae|g__Parabacteroides|s__Parabacteroides distasonis,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Phocaeicola|s__Phocaeicola plebeius,k__Bacteria|p__Pseudomonadota,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Roseburia,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Roseburia|s__Roseburia inulinivorans",2|976|200643|171549|815|816|46506;2|1224|1236|91347;2|1224|1236|91347|543;2|1224|1236|91347|543|561|562;2|1224|1236;2|976|200643|171549|2005525|375288;2|976|200643|171549|2005525|375288|823;2|976|200643|171549|815|909656|310297;2|1224;2|1239|186801|3085636|186803|841;2|1239|186801|3085636|186803|841|360807,Complete,Claregrieve1
bsdb:152/2/2,Study 152,case-control,30904962,10.1186/s13568-019-0763-z,NA,"Wang Z, Wang Q, Zhao J, Gong L, Zhang Y, Wang X , Yuan Z",Altered diversity and composition of the gut microbiome in patients with cervical cancer,AMB Express,2019,"16S rRNA, Cervical cancer, Deep sequencing, Gut microbiota",Experiment 2,Finland,Homo sapiens,Feces,UBERON:0001988,Cervical cancer,MONDO:0002974,healthy controls,cervical cancer patients,pathology confirmed cervical cancer patients,5,8,2 months,16S,4,Illumina,LEfSe,0.05,FALSE,4,age,NA,NA,unchanged,unchanged,NA,NA,unchanged,Signature 2,"Figure 4, Table 3, Figure 5",10 January 2021,Fatima Zohra,"Claregrieve1,WikiWorks",Differential microbial abundance between patients with cervical cancer and healthy controls,decreased,"k__Bacteria|p__Bacillota|c__Negativicutes|o__Acidaminococcales|f__Acidaminococcaceae,k__Bacteria|p__Bacillota|c__Negativicutes,k__Bacteria|p__Bacillota|c__Negativicutes|o__Acidaminococcales|f__Acidaminococcaceae|g__Phascolarctobacterium,k__Bacteria|p__Bacillota|c__Negativicutes|o__Selenomonadales",2|1239|909932|1843488|909930;2|1239|909932;2|1239|909932|1843488|909930|33024;2|1239|909932|909929,Complete,Claregrieve1
bsdb:153/1/1,Study 153,"cross-sectional observational, not case-control",31379800,10.3389/fmicb.2019.01664,NA,"Ma X, Chi C, Fan L, Dong B, Shao X, Xie S, Li M , Xue W",The Microbiome of Prostate Fluid Is Associated With Prostate Cancer,Frontiers in microbiology,2019,"cancer, microbiome, prostate, prostate cancer, prostatic fluid",Experiment 1,China,Homo sapiens,Prostate gland secretion,UBERON:0004796,Prostate cancer,MONDO:0008315,non-prostate cancer,prostate cancer,Prostate cancer  commonest male malignant tumors determined by pathology of prostate biopsy,27,32,4 weeks,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,decreased,NA,increased,NA,unchanged,Signature 1,Figure 5,10 January 2021,Rimsha Azhar,"WikiWorks,Peace Sandy",Analysis of the specific microbial species differences. (A) The differences in microbial species between the two groups were explored.,increased,"k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Carnobacteriaceae|g__Carnobacterium,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Bacillaceae|g__Geobacillus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Lactococcus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus",2|1239|91061|186826|186828|2747;2|1239|91061|1385|186817|129337;2|1239|91061|186826|1300|1357;2|1239|91061|186826|1300|1301,Complete,Peace Sandy
bsdb:153/1/2,Study 153,"cross-sectional observational, not case-control",31379800,10.3389/fmicb.2019.01664,NA,"Ma X, Chi C, Fan L, Dong B, Shao X, Xie S, Li M , Xue W",The Microbiome of Prostate Fluid Is Associated With Prostate Cancer,Frontiers in microbiology,2019,"cancer, microbiome, prostate, prostate cancer, prostatic fluid",Experiment 1,China,Homo sapiens,Prostate gland secretion,UBERON:0004796,Prostate cancer,MONDO:0008315,non-prostate cancer,prostate cancer,Prostate cancer  commonest male malignant tumors determined by pathology of prostate biopsy,27,32,4 weeks,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,decreased,NA,increased,NA,unchanged,Signature 2,Figure 5,10 January 2021,Rimsha Azhar,"WikiWorks,Peace Sandy",Analysis of the specific microbial species differences. (A) The differences in microbial species between the two groups were explored.,decreased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Natronincolaceae|g__Alkaliphilus,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Cronobacter,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Enterococcaceae|g__Enterococcus,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Paenibacillaceae|g__Paenibacillus",2|1239|186801|3082720|3118656|114627;2|1224|1236|91347|543|413496;2|1239|91061|186826|81852|1350;2|1239|91061|1385|186822|44249,Complete,Peace Sandy
bsdb:154/1/1,Study 154,case-control,31250341,10.1007/s11684-019-0695-7,NA,"Zhang H, Chang Y, Zheng Q, Zhang R, Hu C , Jia W",Altered intestinal microbiota associated with colorectal cancer,Frontiers of medicine,2019,"Devosia, Eubacterium, colorectal cancer (CRC), gut microbiota, intestinal",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,healthy controls,colorectal cancer,diagnosed only with colorectal cancer with endoscopy,14,9,30 days,16S,6,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,decreased,unchanged,NA,NA,NA,Signature 1,"Figure 3, Supplementary table 2, table 2",10 January 2021,Fatima Zohra,WikiWorks,Altered intestinal microbiota associated with colorectal cancer,increased,"k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Hyphomicrobiales|f__Hyphomicrobiaceae,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Hyphomicrobiales|f__Devosiaceae|g__Devosia,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Hyphomicrobiales,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Paenibacillaceae|g__Paenibacillus,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Paenibacillaceae,k__Bacteria|p__Bacteroidota|c__Flavobacteriia|o__Flavobacteriales|f__Weeksellaceae|g__Chryseobacterium",2|1224|28211|356|45401;2|1224|28211|356|2831106|46913;2|1224|28211|356;2|1224|28211;2|1239|91061|1385|186822|44249;2|1239|91061|1385|186822;2|976|117743|200644|2762318|59732,Complete,Atrayees
bsdb:154/1/2,Study 154,case-control,31250341,10.1007/s11684-019-0695-7,NA,"Zhang H, Chang Y, Zheng Q, Zhang R, Hu C , Jia W",Altered intestinal microbiota associated with colorectal cancer,Frontiers of medicine,2019,"Devosia, Eubacterium, colorectal cancer (CRC), gut microbiota, intestinal",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,healthy controls,colorectal cancer,diagnosed only with colorectal cancer with endoscopy,14,9,30 days,16S,6,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,decreased,unchanged,NA,NA,NA,Signature 2,"Figure 3, Supplementary table 2, table 2",10 January 2021,Fatima Zohra,WikiWorks,Altered intestinal microbiota associated with colorectal cancer,decreased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae,k__Bacteria|c__Deltaproteobacteria,k__Bacteria|p__Thermodesulfobacteriota|c__Desulfovibrionia|o__Desulfovibrionales,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Eubacteriaceae|g__Eubacterium,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Klebsiella,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Leptotrichiaceae|g__Leptotrichia,k__Bacteria|p__Bacillota|c__Negativicutes|o__Acidaminococcales|f__Acidaminococcaceae|g__Phascolarctobacterium,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Anaerovoracaceae|g__Mogibacterium,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Yersiniaceae|g__Serratia",2|976|200643|171549|171552;2|976|200643|171549|171552|838;2|1239|186801|186802|31979;2|28221;2|200940|3031449|213115;2|1239|186801|186802|186806|1730;2|1224|1236|91347|543|570;2|32066|203490|203491|1129771|32067;2|1239|909932|1843488|909930|33024;2|1239|186801|3082720|3030910|86331;2|1224|1236|91347|1903411|613,Complete,Atrayees
bsdb:155/1/1,Study 155,case-control,29196415,10.1158/0008-5472.CAN-17-1296,NA,"Peters BA, Wu J, Pei Z, Yang L, Purdue MP, Freedman ND, Jacobs EJ, Gapstur SM, Hayes RB , Ahn J",Oral Microbiome Composition Reflects Prospective Risk for Esophageal Cancers,Cancer research,2017,NA,Experiment 1,United States of America,Homo sapiens,Mouth,UBERON:0000165,Esophageal cancer,MONDO:0007576,controls,Esophageal Adenocarcinoma (EAC),diagnosed with easophageal cancer anytime after oral wash sample collection,160,81,NA,16S,4,Illumina,Logistic Regression,0.05,FALSE,NA,"age,race,sex","alcohol drinking,body mass index,smoking behavior",NA,unchanged,NA,NA,NA,unchanged,Signature 1,"Figure 1, Text",10 January 2021,Utsav Patel,WikiWorks,"Oral Microbiome composition and prospective risk for esophageal cancer, no significance for q-value",increased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Tannerellaceae|g__Tannerella|s__Tannerella forsythia,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales|f__Actinomycetaceae|g__Schaalia|s__Schaalia cardiffensis,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Veillonella,k__Bacteria|p__Bacillota|c__Negativicutes|o__Selenomonadales|f__Selenomonadaceae|g__Selenomonas",2|976|200643|171549|2005525|195950|28112;2|201174|1760|2037|2049|2529408|181487;2|1239|909932|1843489|31977|29465;2|1239|909932|909929|1843491|970,Complete,Fatima Zohra
bsdb:155/1/2,Study 155,case-control,29196415,10.1158/0008-5472.CAN-17-1296,NA,"Peters BA, Wu J, Pei Z, Yang L, Purdue MP, Freedman ND, Jacobs EJ, Gapstur SM, Hayes RB , Ahn J",Oral Microbiome Composition Reflects Prospective Risk for Esophageal Cancers,Cancer research,2017,NA,Experiment 1,United States of America,Homo sapiens,Mouth,UBERON:0000165,Esophageal cancer,MONDO:0007576,controls,Esophageal Adenocarcinoma (EAC),diagnosed with easophageal cancer anytime after oral wash sample collection,160,81,NA,16S,4,Illumina,Logistic Regression,0.05,FALSE,NA,"age,race,sex","alcohol drinking,body mass index,smoking behavior",NA,unchanged,NA,NA,NA,unchanged,Signature 2,"Figure 1, Text",10 January 2021,Utsav Patel,WikiWorks,"Oral Microbiome composition and prospective risk for esophageal cancer, no significance for q-value",decreased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Alloprevotella,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Oribacterium,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae|g__Solobacterium,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Neisseriaceae|g__Neisseria,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Mycobacteriales|f__Corynebacteriaceae|g__Corynebacterium|s__Corynebacterium durum,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Hoylesella|s__Hoylesella nanceiensis,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus|s__Streptococcus pneumoniae,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Lachnoanaerobaculum|s__Lachnoanaerobaculum umeaense,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Oribacterium|s__Oribacterium parvum,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae|g__Solobacterium|s__Solobacterium moorei,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Neisseriaceae|g__Neisseria|s__Neisseria flavescens,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Neisseriaceae|g__Neisseria|s__Neisseria sicca,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Haemophilus",2|976|200643|171549|171552|1283313;2|1239|186801|3085636|186803|265975;2|1239|526524|526525|128827|123375;2|1224|28216|206351|481|482;2|201174|1760|85007|1653|1716|61592;2|976|200643|171549|171552|2974257|425941;2|1239|91061|186826|1300|1301|1313;2|1239|186801|3085636|186803|1164882|617123;2|1239|186801|3085636|186803|265975|1501329;2|1239|526524|526525|128827|123375|102148;2|1224|28216|206351|481|482|484;2|1224|28216|206351|481|482|490;2|1224|1236|135625|712|724,Complete,Fatima Zohra
bsdb:155/2/1,Study 155,case-control,29196415,10.1158/0008-5472.CAN-17-1296,NA,"Peters BA, Wu J, Pei Z, Yang L, Purdue MP, Freedman ND, Jacobs EJ, Gapstur SM, Hayes RB , Ahn J",Oral Microbiome Composition Reflects Prospective Risk for Esophageal Cancers,Cancer research,2017,NA,Experiment 2,United States of America,Homo sapiens,Mouth,UBERON:0000165,Esophageal cancer,MONDO:0007576,controls,Esophageal Squamous cell carcinoma (ESCC),diagnosed with easophageal cancer anytime after oral wash sample collection,50,25,NA,16S,4,Illumina,Logistic Regression,0.05,FALSE,NA,"age,race,sex","alcohol drinking,body mass index,smoking behavior",NA,unchanged,NA,NA,NA,unchanged,Signature 1,"Figure 1, Text",10 January 2021,Utsav Patel,WikiWorks,"Oral Microbiome composition and prospective risk for esophageal cancer, no significance for q-value",increased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Hoylesella|s__Hoylesella nanceiensis,k__Bacteria|p__Bacteroidota|c__Flavobacteriia|o__Flavobacteriales|f__Weeksellaceae|g__Bergeyella,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Neisseriaceae|g__Neisseria|s__Neisseria weaveri,k__Bacteria|p__Spirochaetota|c__Spirochaetia|o__Spirochaetales|f__Treponemataceae|g__Treponema|s__Treponema vincentii",2|976|200643|171549|171552|2974257|425941;2|976|117743|200644|2762318|59735;2|1224|28216|206351|481|482|28091;2|203691|203692|136|2845253|157|69710,Complete,Fatima Zohra
bsdb:155/2/2,Study 155,case-control,29196415,10.1158/0008-5472.CAN-17-1296,NA,"Peters BA, Wu J, Pei Z, Yang L, Purdue MP, Freedman ND, Jacobs EJ, Gapstur SM, Hayes RB , Ahn J",Oral Microbiome Composition Reflects Prospective Risk for Esophageal Cancers,Cancer research,2017,NA,Experiment 2,United States of America,Homo sapiens,Mouth,UBERON:0000165,Esophageal cancer,MONDO:0007576,controls,Esophageal Squamous cell carcinoma (ESCC),diagnosed with easophageal cancer anytime after oral wash sample collection,50,25,NA,16S,4,Illumina,Logistic Regression,0.05,FALSE,NA,"age,race,sex","alcohol drinking,body mass index,smoking behavior",NA,unchanged,NA,NA,NA,unchanged,Signature 2,"Figure 1, Text",10 January 2021,Utsav Patel,WikiWorks,"Oral Microbiome composition and prospective risk for esophageal cancer, no significance for q-value",decreased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Aggregatibacter|s__Aggregatibacter aphrophilus",2|1239|186801|3085636|186803;2|976|200643|171549|171552|838;2|1224|1236|135625|712|416916|732,Complete,Fatima Zohra
bsdb:156/1/1,Study 156,case-control,30535886,10.1007/s10620-018-5411-y,NA,"Qi YF, Sun JN, Ren LF, Cao XL, Dong JH, Tao K, Guan XM, Cui YN , Su W","Intestinal Microbiota Is Altered in Patients with Gastric Cancer from Shanxi Province, China",Digestive diseases and sciences,2019,"Cellular immunity, Gastric cancer, Intestinal microbiota, Shanxi Province",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Gastric adenocarcinoma,EFO:0000503,healthy controls,Gastric cancer,gastric carcinoma confirmed by pathological examination,88,116,1 month,16S,34,Illumina,LEfSe,0.05,FALSE,3.5,NA,NA,NA,unchanged,NA,NA,NA,NA,Signature 1,Figure 4,10 January 2021,Fatima Zohra,WikiWorks,Most differentially abundant taxa between healthy controls and gastric cancer patients,increased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae,k__Bacteria|p__Pseudomonadota,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Escherichia,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Shigella,k__Bacteria|p__Bacillota|c__Bacilli,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Klebsiella,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Rikenellaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Rikenellaceae|g__Alistipes,k__Bacteria|p__Actinomycetota|c__Actinomycetes,k__Bacteria|p__Actinomycetota,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Veillonella,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium,k__Bacteria|p__Bacillota|c__Clostridia|o__Christensenellales|f__Christensenellaceae|g__Christensenella,k__Bacteria|p__Bacillota|c__Clostridia|o__Christensenellales|f__Christensenellaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Tannerellaceae|g__Parabacteroides",2|1224|1236;2|1224|1236|91347;2|1224|1236|91347|543;2|1224;2|976|200643|171549|171552;2|976|200643|171549|171552|838;2|1224|1236|91347|543|561;2|1224|1236|91347|543|620;2|1239|91061;2|1239|91061|186826;2|1224|1236|91347|543|570;2|1239|91061|186826|33958;2|1239|91061|186826|33958|1578;2|976|200643|171549|171551;2|1239|91061|186826|1300;2|1239|91061|186826|1300|1301;2|976|200643|171549|171550;2|976|200643|171549|171550|239759;2|201174|1760;2|201174;2|1239|909932|1843489|31977|29465;2|201174|1760|85004;2|201174|1760|85004|31953;2|201174|1760|85004|31953|1678;2|1239|186801|3082768|990719|990721;2|1239|186801|3082768|990719;2|976|200643|171549|2005525|375288,Complete,Shaimaa Elsafoury
bsdb:156/1/2,Study 156,case-control,30535886,10.1007/s10620-018-5411-y,NA,"Qi YF, Sun JN, Ren LF, Cao XL, Dong JH, Tao K, Guan XM, Cui YN , Su W","Intestinal Microbiota Is Altered in Patients with Gastric Cancer from Shanxi Province, China",Digestive diseases and sciences,2019,"Cellular immunity, Gastric cancer, Intestinal microbiota, Shanxi Province",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Gastric adenocarcinoma,EFO:0000503,healthy controls,Gastric cancer,gastric carcinoma confirmed by pathological examination,88,116,1 month,16S,34,Illumina,LEfSe,0.05,FALSE,3.5,NA,NA,NA,unchanged,NA,NA,NA,NA,Signature 2,Figure 4,10 January 2021,Fatima Zohra,WikiWorks,Most differentially abundant taxa between healthy controls and gastric cancer patients,decreased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales,k__Bacteria|p__Bacillota|c__Clostridia,k__Bacteria|p__Bacillota,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Faecalibacterium,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Agathobacter|s__Agathobacter rectalis,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Roseburia,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Lachnospira,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Lachnoclostridium",2|1239|186801|186802;2|1239|186801;2|1239;2|1239|186801|3085636|186803;2|1239|186801|186802|216572|216851;2|1239|186801|3085636|186803|1766253|39491;2|1239|186801|186802|541000;2|1239|186801|3085636|186803|841;2|1239|186801|3085636|186803|28050;2|1239|186801|3085636|186803|1506553,Complete,Shaimaa Elsafoury
bsdb:156/2/1,Study 156,case-control,30535886,10.1007/s10620-018-5411-y,NA,"Qi YF, Sun JN, Ren LF, Cao XL, Dong JH, Tao K, Guan XM, Cui YN , Su W","Intestinal Microbiota Is Altered in Patients with Gastric Cancer from Shanxi Province, China",Digestive diseases and sciences,2019,"Cellular immunity, Gastric cancer, Intestinal microbiota, Shanxi Province",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Gastric adenocarcinoma,EFO:0000503,healthy controls,Gastric cancer,gastric carcinoma confirmed by pathological examination,48,48,1 month,16S,34,Illumina,LEfSe,0.05,FALSE,3.5,"age,sex",NA,NA,unchanged,NA,NA,NA,NA,Signature 1,Supplementary figure 3,10 January 2021,Fatima Zohra,WikiWorks,Most differentially abundant taxa between healthy controls and gastric cancer patients who are age and sex matched,increased,"k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae|g__Faecalibaculum,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Escherichia,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Shigella,k__Bacteria|p__Bacillota|c__Bacilli,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Klebsiella,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus,k__Bacteria|p__Actinomycetota|c__Actinomycetes,k__Bacteria|p__Actinomycetota,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Rikenellaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Rikenellaceae|g__Alistipes,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Veillonella,k__Bacteria|p__Bacillota|c__Clostridia|o__Christensenellales|f__Christensenellaceae",2|1239|526524|526525|128827|1729679;2|1224|1236|91347;2|1224|1236|91347|543;2|1224|1236;2|976|200643|171549|171552;2|976|200643|171549|171552|838;2|1224|1236|91347|543|561;2|1224|1236|91347|543|620;2|1239|91061;2|1239|91061|186826;2|1224|1236|91347|543|570;2|1239|91061|186826|1300;2|1239|91061|186826|1300|1301;2|201174|1760;2|201174;2|1239|91061|186826|33958|1578;2|1239|91061|186826|33958;2|976|200643|171549|171550;2|976|200643|171549|171550|239759;2|201174|1760|85004;2|201174|1760|85004|31953;2|201174|1760|85004|31953|1678;2|1239|909932|1843489|31977|29465;2|1239|186801|3082768|990719,Complete,Shaimaa Elsafoury
bsdb:156/2/2,Study 156,case-control,30535886,10.1007/s10620-018-5411-y,NA,"Qi YF, Sun JN, Ren LF, Cao XL, Dong JH, Tao K, Guan XM, Cui YN , Su W","Intestinal Microbiota Is Altered in Patients with Gastric Cancer from Shanxi Province, China",Digestive diseases and sciences,2019,"Cellular immunity, Gastric cancer, Intestinal microbiota, Shanxi Province",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Gastric adenocarcinoma,EFO:0000503,healthy controls,Gastric cancer,gastric carcinoma confirmed by pathological examination,48,48,1 month,16S,34,Illumina,LEfSe,0.05,FALSE,3.5,"age,sex",NA,NA,unchanged,NA,NA,NA,NA,Signature 2,Supplementary figure 3,10 January 2021,Fatima Zohra,WikiWorks,Most differentially abundant taxa between healthy controls and gastric cancer patients who are age and sex matched,decreased,"k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria,k__Bacteria|p__Bacillota|c__Clostridia,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Agathobacter|s__Agathobacter rectalis,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Roseburia,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Lachnospira,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Lachnoclostridium",2|1224|28216|80840;2|1224|28216;2|1239|186801;2|1239|186801|186802;2|1239|186801|3085636|186803;2|1239|186801|3085636|186803|1766253|39491;2|1239|186801|3085636|186803|841;2|1239|186801|3085636|186803|28050;2|1239|186801|3085636|186803|1506553,Complete,Shaimaa Elsafoury
bsdb:157/1/1,Study 157,case-control,26641451,10.1371/journal.pone.0143603,NA,"Chen X, Winckler B, Lu M, Cheng H, Yuan Z, Yang Y, Jin L , Ye W",Oral Microbiota and Risk for Esophageal Squamous Cell Carcinoma in a High-Risk Area of China,PloS one,2015,NA,Experiment 1,China,Homo sapiens,Saliva,UBERON:0001836,Esophageal cancer,MONDO:0007576,Dysplasia,Esophageal Squamous cell carcinoma (ESCC),Subjects who were suspected to have esophageal cancer under endoscopy,63,87,1 month,16S,34,Roche454,Metastats,0.05,TRUE,NA,"age,sex","age,alcohol drinking,diet,education level,family history of cancer,number of teeth measurement,oral hygiene,sex,smoking status",NA,decreased,unchanged,NA,NA,NA,Signature 1,Table 3,10 January 2021,Utsav Patel,"WikiWorks,ChiomaBlessing",Relative abundance of significant microbiota in the ESCC group compared to the Dysplasia group,increased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Filifactoraceae|g__Filifactor,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae|g__Porphyromonas,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Aerococcaceae|g__Abiotrophia",2|1239|186801|3082720|3118655|44259;2|1239|91061|186826|33958|1578;2|976|200643|171549|171551|836;2|976|200643|171549|171552|838;2|1239|91061|186826|1300|1301;2|1239|91061|186826|186827|46123,Complete,ChiomaBlessing
bsdb:157/1/2,Study 157,case-control,26641451,10.1371/journal.pone.0143603,NA,"Chen X, Winckler B, Lu M, Cheng H, Yuan Z, Yang Y, Jin L , Ye W",Oral Microbiota and Risk for Esophageal Squamous Cell Carcinoma in a High-Risk Area of China,PloS one,2015,NA,Experiment 1,China,Homo sapiens,Saliva,UBERON:0001836,Esophageal cancer,MONDO:0007576,Dysplasia,Esophageal Squamous cell carcinoma (ESCC),Subjects who were suspected to have esophageal cancer under endoscopy,63,87,1 month,16S,34,Roche454,Metastats,0.05,TRUE,NA,"age,sex","age,alcohol drinking,diet,education level,family history of cancer,number of teeth measurement,oral hygiene,sex,smoking status",NA,decreased,unchanged,NA,NA,NA,Signature 2,Table 3,10 January 2021,Utsav Patel,"WikiWorks,ChiomaBlessing",Relative abundance of significant microbiota in the ESCC group compared to the Dysplasia group,decreased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Aggregatibacter,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales|f__Atopobiaceae|g__Atopobium,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae|g__Bulleidia,k__Bacteria|p__Campylobacterota|c__Epsilonproteobacteria|o__Campylobacterales|f__Campylobacteraceae|g__Campylobacter,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Catonella,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Mycobacteriales|f__Corynebacteriaceae|g__Corynebacterium,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Filifactoraceae|g__Filifactor,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae|g__Fusobacterium,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Haemophilus,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Oxalobacteraceae|g__Herbaspirillum,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Burkholderiaceae|g__Lautropia,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Leptotrichiaceae|g__Leptotrichia,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Neisseriaceae|g__Neisseria,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Oribacterium,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Peptococcaceae|g__Peptococcus,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micrococcales|f__Micrococcaceae|g__Rothia,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Veillonella,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Cardiobacteriales|f__Cardiobacteriaceae|g__Cardiobacterium",2|1224|1236|135625|712|416916;2|201174|84998|84999|1643824|1380;2|1239|526524|526525|128827|118747;2|29547|3031852|213849|72294|194;2|1239|186801|3085636|186803|43996;2|201174|1760|85007|1653|1716;2|1239|186801|3082720|3118655|44259;2|32066|203490|203491|203492|848;2|1224|1236|135625|712|724;2|1224|28216|80840|75682|963;2|1224|28216|80840|119060|47670;2|32066|203490|203491|1129771|32067;2|1224|28216|206351|481|482;2|1239|186801|3085636|186803|265975;2|1239|186801|186802|186807|2740;2|201174|1760|85006|1268|32207;2|1239|909932|1843489|31977|29465;2|1224|1236|135615|868|2717,Complete,ChiomaBlessing
bsdb:157/2/1,Study 157,case-control,26641451,10.1371/journal.pone.0143603,NA,"Chen X, Winckler B, Lu M, Cheng H, Yuan Z, Yang Y, Jin L , Ye W",Oral Microbiota and Risk for Esophageal Squamous Cell Carcinoma in a High-Risk Area of China,PloS one,2015,NA,Experiment 2,China,Homo sapiens,Saliva,UBERON:0001836,Esophageal cancer,MONDO:0007576,Healthy controls,Esophageal Squamous cell carcinoma (ESCC),Subjects who were suspected to have esophageal cancer under endoscopy,85,87,1 month,16S,34,Roche454,Metastats,0.05,TRUE,NA,"age,sex","age,alcohol drinking,diet,education level,family history of cancer,oral hygiene,sex,smoking status",NA,decreased,decreased,NA,NA,NA,Signature 1,Table 3,10 January 2021,Utsav Patel,"WikiWorks,ChiomaBlessing",Relative abundance of significant microbiota in the ESCC group compared to the Healthy control group,increased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides,k__Bacteria|p__Bacteroidota|c__Flavobacteriia|o__Flavobacteriales|f__Flavobacteriaceae|g__Capnocytophaga,k__Bacteria|p__Bacteroidota|c__Flavobacteriia|o__Flavobacteriales|f__Weeksellaceae|g__Elizabethkingia,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae|g__Porphyromonas,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Butyrivibrio",2|976|200643|171549|815|816;2|976|117743|200644|49546|1016;2|976|117743|200644|2762318|308865;2|976|200643|171549|171551|836;2|976|200643|171549|171552|838;2|1239|91061|186826|1300|1301;2|1239|186801|3085636|186803|830,Complete,ChiomaBlessing
bsdb:157/2/2,Study 157,case-control,26641451,10.1371/journal.pone.0143603,NA,"Chen X, Winckler B, Lu M, Cheng H, Yuan Z, Yang Y, Jin L , Ye W",Oral Microbiota and Risk for Esophageal Squamous Cell Carcinoma in a High-Risk Area of China,PloS one,2015,NA,Experiment 2,China,Homo sapiens,Saliva,UBERON:0001836,Esophageal cancer,MONDO:0007576,Healthy controls,Esophageal Squamous cell carcinoma (ESCC),Subjects who were suspected to have esophageal cancer under endoscopy,85,87,1 month,16S,34,Roche454,Metastats,0.05,TRUE,NA,"age,sex","age,alcohol drinking,diet,education level,family history of cancer,oral hygiene,sex,smoking status",NA,decreased,decreased,NA,NA,NA,Signature 2,Table 3,10 January 2021,Utsav Patel,"WikiWorks,ChiomaBlessing",Relative abundance of significant microbiota in the ESCC group compared to the Healthy control group,decreased,"k__Bacteria|p__Mycoplasmatota|c__Mollicutes|o__Acholeplasmatales|f__Acholeplasmataceae|g__Acholeplasma,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales|f__Actinomycetaceae|g__Actinomyces,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Aggregatibacter,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales|f__Atopobiaceae|g__Atopobium,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae|g__Bulleidia,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Butyrivibrio,k__Bacteria|p__Campylobacterota|c__Epsilonproteobacteria|o__Campylobacterales|f__Campylobacteraceae|g__Campylobacter,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Cardiobacteriales|f__Cardiobacteriaceae|g__Cardiobacterium,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Catonella,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Mycobacteriales|f__Corynebacteriaceae|g__Corynebacterium,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Dialister,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Filifactoraceae|g__Filifactor,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Haemophilus,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Burkholderiaceae|g__Lautropia,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Megasphaera,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Neisseriaceae|g__Neisseria,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Oribacterium,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Peptococcaceae|g__Peptococcus,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Peptostreptococcaceae|g__Peptostreptococcus,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micrococcales|f__Micrococcaceae|g__Rothia,k__Bacteria|p__Bacillota|c__Negativicutes|o__Selenomonadales|f__Selenomonadaceae|g__Selenomonas,k__Bacteria|p__Spirochaetota|c__Spirochaetia|o__Spirochaetales|f__Treponemataceae|g__Treponema,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Veillonella,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Leptotrichiaceae|g__Leptotrichia",2|544448|31969|186329|2146|2147;2|201174|1760|2037|2049|1654;2|1224|1236|135625|712|416916;2|201174|84998|84999|1643824|1380;2|1239|526524|526525|128827|118747;2|1239|186801|3085636|186803|830;2|29547|3031852|213849|72294|194;2|1224|1236|135615|868|2717;2|1239|186801|3085636|186803|43996;2|201174|1760|85007|1653|1716;2|1239|909932|1843489|31977|39948;2|1239|186801|3082720|3118655|44259;2|1224|1236|135625|712|724;2|1224|28216|80840|119060|47670;2|1239|909932|1843489|31977|906;2|1224|28216|206351|481|482;2|1239|186801|3085636|186803|265975;2|1239|186801|186802|186807|2740;2|1239|186801|3082720|186804|1257;2|201174|1760|85006|1268|32207;2|1239|909932|909929|1843491|970;2|203691|203692|136|2845253|157;2|1239|909932|1843489|31977|29465;2|32066|203490|203491|1129771|32067,Complete,ChiomaBlessing
bsdb:158/1/1,Study 158,case-control,30416659,NA,NA,"Zhang WQ, Zhao SK, Luo JW, Dong XP, Hao YT, Li H, Shan L, Zhou Y, Shi HB, Zhang ZY, Peng CL , Zhao XG",Alterations of fecal bacterial communities in patients with lung cancer,American journal of translational research,2018,"16S rRNA gene sequencing, Lung cancer, carcinogenesis, gut bacteria, microbial dysbiosis",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Lung cancer,MONDO:0008903,healthy volunteers,lung cancer patients,lung cancer patients with a definite postoperative pathological diagnosis,41,41,12 months,16S,12,Illumina,Metastats,0.05,TRUE,NA,"age,body mass index,sex",NA,NA,unchanged,unchanged,unchanged,NA,NA,Signature 1,Figure 4,10 January 2021,Fatima Zohra,WikiWorks,Significant differences of the predominant taxa from lung cancer patients and healthy volunteers,increased,"k__Bacteria|p__Bacteroidota,k__Bacteria|p__Fusobacteriota,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Veillonella,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae|g__Fusobacterium,k__Bacteria|p__Bacillota|c__Negativicutes|o__Acidaminococcales|f__Acidaminococcaceae|g__Phascolarctobacterium",2|976;2|32066;2|976|200643|171549|815|816;2|1239|909932|1843489|31977|29465;2|32066|203490|203491|203492|848;2|1239|909932|1843488|909930|33024,Complete,Claregrieve1
bsdb:158/1/2,Study 158,case-control,30416659,NA,NA,"Zhang WQ, Zhao SK, Luo JW, Dong XP, Hao YT, Li H, Shan L, Zhou Y, Shi HB, Zhang ZY, Peng CL , Zhao XG",Alterations of fecal bacterial communities in patients with lung cancer,American journal of translational research,2018,"16S rRNA gene sequencing, Lung cancer, carcinogenesis, gut bacteria, microbial dysbiosis",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Lung cancer,MONDO:0008903,healthy volunteers,lung cancer patients,lung cancer patients with a definite postoperative pathological diagnosis,41,41,12 months,16S,12,Illumina,Metastats,0.05,TRUE,NA,"age,body mass index,sex",NA,NA,unchanged,unchanged,unchanged,NA,NA,Signature 2,Figure 4,10 January 2021,Fatima Zohra,WikiWorks,Significant differences of the predominant taxa from lung cancer patients and healthy volunteers,decreased,"k__Bacteria|p__Bacillota,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Kluyvera,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Faecalibacterium,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Enterobacter,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Dialister,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Escherichia,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Shigella",2|1239;2|1224|1236|91347|543|579;2|1239|186801|186802|216572|216851;2|1224|1236|91347|543|547;2|1239|909932|1843489|31977|39948;2|1224|1236|91347|543|561;2|1224|1236|91347|543|620,Complete,Claregrieve1
bsdb:158/2/1,Study 158,case-control,30416659,NA,NA,"Zhang WQ, Zhao SK, Luo JW, Dong XP, Hao YT, Li H, Shan L, Zhou Y, Shi HB, Zhang ZY, Peng CL , Zhao XG",Alterations of fecal bacterial communities in patients with lung cancer,American journal of translational research,2018,"16S rRNA gene sequencing, Lung cancer, carcinogenesis, gut bacteria, microbial dysbiosis",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Lung cancer,MONDO:0008903,healthy volunteers,lung cancer patients,lung cancer patients with a definite postoperative pathological diagnosis,41,41,12 months,16S,12,Illumina,LEfSe,0.05,TRUE,4,"age,body mass index,sex",NA,NA,unchanged,unchanged,unchanged,NA,NA,Signature 1,Figure 5,10 January 2021,Fatima Zohra,"Claregrieve1,WikiWorks",Differential abundance of fecal microbiota from patients with lung cancer and healthy volunteers,increased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales,k__Bacteria|p__Bacteroidota,k__Bacteria|p__Bacteroidota|c__Bacteroidia,k__Bacteria|p__Fusobacteriota,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae|g__Fusobacterium,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Klebsiella,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Phocaeicola|s__Phocaeicola plebeius,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Phocaeicola|s__Phocaeicola vulgatus,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides",2|976|200643|171549;2|976;2|976|200643;2|32066;2|32066|203490|203491|203492;2|32066|203490|203491;2|32066|203490;2|32066|203490|203491|203492|848;2|1224|1236|91347|543|570;2|976|200643|171549|815|909656|310297;2|976|200643|171549|815|909656|821;2|976|200643|171549|171552;2|976|200643|171549|815;2|976|200643|171549|815|816,Complete,Claregrieve1
bsdb:158/2/2,Study 158,case-control,30416659,NA,NA,"Zhang WQ, Zhao SK, Luo JW, Dong XP, Hao YT, Li H, Shan L, Zhou Y, Shi HB, Zhang ZY, Peng CL , Zhao XG",Alterations of fecal bacterial communities in patients with lung cancer,American journal of translational research,2018,"16S rRNA gene sequencing, Lung cancer, carcinogenesis, gut bacteria, microbial dysbiosis",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Lung cancer,MONDO:0008903,healthy volunteers,lung cancer patients,lung cancer patients with a definite postoperative pathological diagnosis,41,41,12 months,16S,12,Illumina,LEfSe,0.05,TRUE,4,"age,body mass index,sex",NA,NA,unchanged,unchanged,unchanged,NA,NA,Signature 2,Figure 5,10 January 2021,Fatima Zohra,"Claregrieve1,WikiWorks",Differential abundance of fecal microbiota from patients with lung cancer and healthy volunteers,decreased,"k__Bacteria|p__Bacillota|c__Clostridia,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Dialister,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Enterobacter,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Escherichia,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Faecalibacterium,k__Bacteria|p__Bacillota,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae,k__Bacteria|p__Pseudomonadota,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Shigella,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|s__Clostridiales bacterium",2|1239|186801;2|1239|909932|1843489|31977|39948;2|1224|1236|91347|543|547;2|1224|1236|91347;2|1224|1236|91347|543;2|1224|1236|91347|543|561;2|1239|186801|186802;2|1239|186801|186802|216572|216851;2|1239;2|1224|1236;2|1239|186801|3085636|186803;2|1239|186801|186802|541000;2|1224;2|1224|1236|91347|543|620;2|1239|186801|186802|1898207,Complete,Claregrieve1
bsdb:159/1/1,Study 159,time series / longitudinal observational,30542916,10.1007/s00284-018-1610-1,NA,"Guo R, Liu H, Li X, Yang Q, Jia L, Zheng Y , Li W",Subgingival Microbial Changes During the First 3 Months of Fixed Appliance Treatment in Female Adult Patients,Current microbiology,2019,NA,Experiment 1,China,Homo sapiens,Dental plaque,UBERON:0016482,Gingival disease,EFO:0009670,before,1 month after the placement of the brackets,subgingial microbial changes during fixed appliance treatment,10,10,1 month,16S,34,Illumina,Metastats,0.05,FALSE,NA,NA,NA,NA,unchanged,unchanged,unchanged,unchanged,unchanged,Signature 1,Figure 5,10 January 2021,Rimsha Azhar,WikiWorks,Relative abundance of microbiota that showed statistically significant differences among three different time points,increased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Actinobacillus,k__Bacteria|p__Bacteroidota|c__Flavobacteriia|o__Flavobacteriales|f__Flavobacteriaceae|g__Capnocytophaga",2|1224|1236|135625|712|713;2|976|117743|200644|49546|1016,Complete,NA
bsdb:159/2/1,Study 159,time series / longitudinal observational,30542916,10.1007/s00284-018-1610-1,NA,"Guo R, Liu H, Li X, Yang Q, Jia L, Zheng Y , Li W",Subgingival Microbial Changes During the First 3 Months of Fixed Appliance Treatment in Female Adult Patients,Current microbiology,2019,NA,Experiment 2,China,Homo sapiens,Dental plaque,UBERON:0016482,Gingival disease,EFO:0009670,before,3 months after the placement of the brackets,subgingial microbial changes during fixed appliance treatment,10,10,1 month,16S,34,Illumina,Metastats,0.05,FALSE,NA,NA,NA,NA,unchanged,unchanged,unchanged,unchanged,unchanged,Signature 1,Figure 5,10 January 2021,Rimsha Azhar,WikiWorks,Relative abundance of microbiota that showed statistically significant differences among three different time points,increased,k__Bacteria|p__Bacteroidota|c__Flavobacteriia|o__Flavobacteriales|f__Flavobacteriaceae|g__Capnocytophaga,2|976|117743|200644|49546|1016,Complete,NA
bsdb:159/2/2,Study 159,time series / longitudinal observational,30542916,10.1007/s00284-018-1610-1,NA,"Guo R, Liu H, Li X, Yang Q, Jia L, Zheng Y , Li W",Subgingival Microbial Changes During the First 3 Months of Fixed Appliance Treatment in Female Adult Patients,Current microbiology,2019,NA,Experiment 2,China,Homo sapiens,Dental plaque,UBERON:0016482,Gingival disease,EFO:0009670,before,3 months after the placement of the brackets,subgingial microbial changes during fixed appliance treatment,10,10,1 month,16S,34,Illumina,Metastats,0.05,FALSE,NA,NA,NA,NA,unchanged,unchanged,unchanged,unchanged,unchanged,Signature 2,Figure 5,10 January 2021,Rimsha Azhar,"Fatima,WikiWorks",Relative abundance of microbiota that showed statistically significant differences among three different time points,decreased,"k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Carnobacteriaceae|g__Granulicatella,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus|s__Streptococcus oralis|s__Streptococcus oralis subsp. tigurinus",2|1239|91061|186826|186828|117563;2|1239|91061|186826|1300|1301|1303|1077464,Complete,NA
bsdb:160/1/1,Study 160,case-control,30123780,10.3389/fcimb.2018.00267,NA,"Lim Y, Fukuma N, Totsika M, Kenny L, Morrison M , Punyadeera C",The Performance of an Oral Microbiome Biomarker Panel in Predicting Oral Cavity and Oropharyngeal Cancers,Frontiers in cellular and infection microbiology,2018,"biomarker, oral cancer, oral microbiome, oral rinse, saliva",Experiment 1,Australia,Homo sapiens,Mouth,UBERON:0000165,Head and neck carcinoma,MONDO:0002038,High-risk individuals,OCC & OPC,Newly diagnosed OCC(Oral Cavity Cancer) and OPC (Oropharyngeal Cancer),11,32,NA,16S,678,Illumina,Kruskall-Wallis,0.05,FALSE,NA,NA,NA,NA,decreased,NA,NA,NA,NA,Signature 1,"Figure 1B, Supp. Table 2, Text",10 January 2021,Utsav Patel,WikiWorks,The Performance of an Oral Microbiome in Predicting Oral Cavity and Oropharyngeal Cancers,decreased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Paludibacteraceae|g__Paludibacter,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Mycobacteriales|f__Corynebacteriaceae|g__Corynebacterium,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae|g__Porphyromonas,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales|f__Actinomycetaceae|g__Actinomyces,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Actinobacillus,k__Bacteria|p__Bacteroidota|c__Flavobacteriia|o__Flavobacteriales|f__Flavobacteriaceae|g__Capnocytophaga,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae|g__Fusobacterium,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Aggregatibacter,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Burkholderiaceae|g__Lautropia",2|976|200643|171549|2005523|346096;2|201174|1760|85007|1653|1716;2|976|200643|171549|171551|836;2|201174|1760|2037|2049|1654;2|1224|1236|135625|712|713;2|976|117743|200644|49546|1016;2|32066|203490|203491|203492|848;2|1224|1236|135625|712|416916;2|1224|28216|80840|119060|47670,Complete,Atrayees
bsdb:160/2/1,Study 160,case-control,30123780,10.3389/fcimb.2018.00267,NA,"Lim Y, Fukuma N, Totsika M, Kenny L, Morrison M , Punyadeera C",The Performance of an Oral Microbiome Biomarker Panel in Predicting Oral Cavity and Oropharyngeal Cancers,Frontiers in cellular and infection microbiology,2018,"biomarker, oral cancer, oral microbiome, oral rinse, saliva",Experiment 2,Australia,Homo sapiens,Mouth,UBERON:0000165,Head and neck carcinoma,MONDO:0002038,Normal Healthy Controls,OCC & OPC,Newly diagnosed OCC(Oral Cavity Cancer) and OPC (Oropharyngeal Cancer),20,31,NA,16S,678,Illumina,Kruskall-Wallis,0.05,FALSE,NA,NA,NA,NA,decreased,NA,NA,NA,NA,Signature 1,"Supp. Table 2, Text",10 January 2021,Utsav Patel,"WikiWorks,Atrayees",The Performance of an Oral Microbiome in Predicting Oral Cavity and Oropharyngeal Cancers,increased,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Oribacterium,2|1239|186801|3085636|186803|265975,Complete,Atrayees
bsdb:160/2/2,Study 160,case-control,30123780,10.3389/fcimb.2018.00267,NA,"Lim Y, Fukuma N, Totsika M, Kenny L, Morrison M , Punyadeera C",The Performance of an Oral Microbiome Biomarker Panel in Predicting Oral Cavity and Oropharyngeal Cancers,Frontiers in cellular and infection microbiology,2018,"biomarker, oral cancer, oral microbiome, oral rinse, saliva",Experiment 2,Australia,Homo sapiens,Mouth,UBERON:0000165,Head and neck carcinoma,MONDO:0002038,Normal Healthy Controls,OCC & OPC,Newly diagnosed OCC(Oral Cavity Cancer) and OPC (Oropharyngeal Cancer),20,31,NA,16S,678,Illumina,Kruskall-Wallis,0.05,FALSE,NA,NA,NA,NA,decreased,NA,NA,NA,NA,Signature 2,"Figure 1B, Supp. Table 2, Text",10 January 2021,Utsav Patel,WikiWorks,The Performance of an Oral Microbiome in Predicting Oral Cavity and Oropharyngeal Cancers,decreased,"k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micrococcales|f__Micrococcaceae|g__Rothia,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Haemophilus,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Mycobacteriales|f__Corynebacteriaceae|g__Corynebacterium,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Paludibacteraceae|g__Paludibacter,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae|g__Porphyromonas,k__Bacteria|p__Bacteroidota|c__Flavobacteriia|o__Flavobacteriales|f__Flavobacteriaceae|g__Capnocytophaga",2|201174|1760|85006|1268|32207;2|1224|1236|135625|712|724;2|201174|1760|85007|1653|1716;2|976|200643|171549|2005523|346096;2|976|200643|171549|171551|836;2|976|117743|200644|49546|1016,Complete,Atrayees
bsdb:161/1/1,Study 161,case-control,31205521,10.7150/jca.28077,NA,"Zhang W, Luo J, Dong X, Zhao S, Hao Y, Peng C, Shi H, Zhou Y, Shan L, Sun Q, Li Y , Zhao X",Salivary Microbial Dysbiosis is Associated with Systemic Inflammatory Markers and Predicted Oral Metabolites in Non-Small Cell Lung Cancer Patients,Journal of Cancer,2019,NA,Experiment 1,China,Homo sapiens,Saliva,UBERON:0001836,Lung cancer,MONDO:0008903,Healthy controls,NSCLC,Newly diagnosed NSCLC (non-small cell lung cancer) patients,20,39,6 months,16S,12,Illumina,LEfSe,0.05,FALSE,4,"age,body mass index,sex",NA,NA,increased,unchanged,increased,NA,unchanged,Signature 1,Figure 3 (B),10 January 2021,Fatima Zohra,"WikiWorks,Peace Sandy","(b) Histogram of the linear discriminant analysis (LDA) scores for differentially abundant bacterial
taxa between non-small cell lung cancer patients and healthy controls. Only taxa meeting an LDA significant threshold > 4.0 are shown. Red (HC) indicates the healthy controls, and green (NSCLC), non-small cell lung cancer group",increased,"k__Bacteria|p__Pseudomonadota,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales,k__Bacteria|p__Bacillota|c__Bacilli,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Burkholderiaceae,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Burkholderiaceae|g__Lautropia",2|1224;2|1224|28216;2|1224|28216|80840;2|1239|91061;2|1239|91061|186826|1300;2|1239|91061|186826|1300|1301;2|1239|91061|186826;2|1224|28216|80840|119060;2|1224|28216|80840|119060|47670,Complete,Peace Sandy
bsdb:161/1/2,Study 161,case-control,31205521,10.7150/jca.28077,NA,"Zhang W, Luo J, Dong X, Zhao S, Hao Y, Peng C, Shi H, Zhou Y, Shan L, Sun Q, Li Y , Zhao X",Salivary Microbial Dysbiosis is Associated with Systemic Inflammatory Markers and Predicted Oral Metabolites in Non-Small Cell Lung Cancer Patients,Journal of Cancer,2019,NA,Experiment 1,China,Homo sapiens,Saliva,UBERON:0001836,Lung cancer,MONDO:0008903,Healthy controls,NSCLC,Newly diagnosed NSCLC (non-small cell lung cancer) patients,20,39,6 months,16S,12,Illumina,LEfSe,0.05,FALSE,4,"age,body mass index,sex",NA,NA,increased,unchanged,increased,NA,unchanged,Signature 2,Figure 3 (B),10 January 2021,Fatima Zohra,"WikiWorks,Peace Sandy","(b) Histogram of the linear discriminant analysis (LDA) scores for differentially abundant bacterial taxa between non-small cell lung cancer patients and healthy controls. Only taxa meeting an LDA significant threshold > 4.0 are shown. Red (HC) indicates the healthy controls, and green (NSCLC), non-small cell lung cancer group",decreased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella|s__Prevotella melaninogenica,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae,k__Bacteria|p__Bacteroidota,k__Bacteria|p__Bacteroidota|c__Bacteroidia,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales",2|976|200643|171549|171551;2|976|200643|171549|171552|838;2|976|200643|171549|171552|838|28132;2|976|200643|171549|171552;2|976;2|976|200643;2|976|200643|171549,Complete,Peace Sandy
bsdb:162/1/1,Study 162,case-control,31595156,10.7150/ijbs.35980,NA,"Liu F, Li J, Guan Y, Lou Y, Chen H, Xu M, Deng D, Chen J, Ni B, Zhao L, Li H, Sang H , Cai X",Dysbiosis of the Gut Microbiome is associated with Tumor Biomarkers in Lung Cancer,International journal of biological sciences,2019,"16SrRNAsequencing, Carcinoembryonic antigen, Cytokeratin 19 fragment, Fecal, Gut microbiome, Lung cancer, Neuron specific enolase",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Lung cancer,MONDO:0008903,healthy control,lung cancer group,newly diagnosed lung cancer patients by histopathology and computed tomography,16,30,1 month,16S,4,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,decreased,unchanged,decreased,NA,unchanged,Signature 1,Figure 3B,10 January 2021,Fatima Zohra,WikiWorks,Comparison of relative abundant microbiome at family level between cancer groups and healthy controls,decreased,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae,2|1239|186801|3085636|186803,Complete,Claregrieve1
bsdb:162/2/1,Study 162,case-control,31595156,10.7150/ijbs.35980,NA,"Liu F, Li J, Guan Y, Lou Y, Chen H, Xu M, Deng D, Chen J, Ni B, Zhao L, Li H, Sang H , Cai X",Dysbiosis of the Gut Microbiome is associated with Tumor Biomarkers in Lung Cancer,International journal of biological sciences,2019,"16SrRNAsequencing, Carcinoembryonic antigen, Cytokeratin 19 fragment, Fecal, Gut microbiome, Lung cancer, Neuron specific enolase",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Lung cancer,MONDO:0008903,controls + other lung cancer groups,CEA group,newly diagnosed lung cancer patients who are CEA-positive,35,11,1 month,16S,4,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,decreased,unchanged,decreased,NA,unchanged,Signature 1,Figure 3B,10 January 2021,Fatima Zohra,"Claregrieve1,WikiWorks",Comparison of relatively abundant microbiota between CEA group and other study groups,increased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae",2|976|200643|171549|815;2|1239|91061|186826|1300,Complete,Claregrieve1
bsdb:162/3/1,Study 162,case-control,31595156,10.7150/ijbs.35980,NA,"Liu F, Li J, Guan Y, Lou Y, Chen H, Xu M, Deng D, Chen J, Ni B, Zhao L, Li H, Sang H , Cai X",Dysbiosis of the Gut Microbiome is associated with Tumor Biomarkers in Lung Cancer,International journal of biological sciences,2019,"16SrRNAsequencing, Carcinoembryonic antigen, Cytokeratin 19 fragment, Fecal, Gut microbiome, Lung cancer, Neuron specific enolase",Experiment 3,China,Homo sapiens,Feces,UBERON:0001988,Lung cancer,MONDO:0008903,controls + other lung cancer groups,NSE group,newly diagnosed lung cancer patients who are NSE positive,37,9,1 month,16S,4,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,decreased,unchanged,decreased,NA,unchanged,Signature 1,Figure 3B,10 January 2021,Fatima Zohra,"Claregrieve1,WikiWorks",Differentially abundant microbiota between NSE group and the other study groups,increased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae,k__Bacteria|p__Verrucomicrobiota|c__Verrucomicrobiia|o__Verrucomicrobiales|f__Verrucomicrobiaceae",2|1224|1236|91347|543;2|32066|203490|203491|203492;2|74201|203494|48461|203557,Complete,Claregrieve1
bsdb:162/4/1,Study 162,case-control,31595156,10.7150/ijbs.35980,NA,"Liu F, Li J, Guan Y, Lou Y, Chen H, Xu M, Deng D, Chen J, Ni B, Zhao L, Li H, Sang H , Cai X",Dysbiosis of the Gut Microbiome is associated with Tumor Biomarkers in Lung Cancer,International journal of biological sciences,2019,"16SrRNAsequencing, Carcinoembryonic antigen, Cytokeratin 19 fragment, Fecal, Gut microbiome, Lung cancer, Neuron specific enolase",Experiment 4,China,Homo sapiens,Feces,UBERON:0001988,Lung cancer,MONDO:0008903,healthy controls,CYF group,newly diagnosed lung cancer patients who are CYFRA positive,16,10,1 month,16S,4,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,decreased,unchanged,decreased,NA,unchanged,Signature 1,Figure 3B,10 January 2021,Fatima Zohra,"Claregrieve1,WikiWorks",Relative microbial abundance between CYF group and healthy controls,increased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae,k__Bacteria|p__Verrucomicrobiota|c__Verrucomicrobiia|o__Verrucomicrobiales|f__Verrucomicrobiaceae",2|1224|1236|91347|543;2|32066|203490|203491|203492;2|74201|203494|48461|203557,Complete,Claregrieve1
bsdb:162/5/1,Study 162,case-control,31595156,10.7150/ijbs.35980,NA,"Liu F, Li J, Guan Y, Lou Y, Chen H, Xu M, Deng D, Chen J, Ni B, Zhao L, Li H, Sang H , Cai X",Dysbiosis of the Gut Microbiome is associated with Tumor Biomarkers in Lung Cancer,International journal of biological sciences,2019,"16SrRNAsequencing, Carcinoembryonic antigen, Cytokeratin 19 fragment, Fecal, Gut microbiome, Lung cancer, Neuron specific enolase",Experiment 5,China,Homo sapiens,Feces,UBERON:0001988,Lung cancer,MONDO:0008903,healthy controls + other lung cancer groups,CYF group,newly diagnosed lung cancer patients who are CYFRA positive,36,10,1 month,16S,4,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,decreased,unchanged,decreased,NA,unchanged,Signature 1,Figure 3B,11 November 2022,Claregrieve1,Claregrieve1,Relative microbial abundance between CYF group and other study groups,increased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae",2|976|200643|171549|171552;2|1239|909932|1843489|31977,Complete,Claregrieve1
bsdb:163/1/1,Study 163,case-control,28725009,10.1038/s41598-017-06361-2,NA,"Wolf A, Moissl-Eichinger C, Perras A, Koskinen K, Tomazic PV , Thurnher D",The salivary microbiome as an indicator of carcinogenesis in patients with oropharyngeal squamous cell carcinoma: A pilot study,Scientific reports,2017,NA,Experiment 1,Austria,Homo sapiens,Saliva,UBERON:0001836,Squamous cell carcinoma,EFO:0000707,Healthy Controls,Oropharyngeal Squamous Cell Carcinoma,diagnosed with OSCC and SCC of the oral cavity,11,11,1 month,16S,4,Illumina,DESeq2,0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,unchanged,NA,Signature 1,"Figure 3, Text",10 January 2021,Utsav Patel,"WikiWorks,ChiomaBlessing",Significant taxa in patients with oropharyngeal squamous cell carcinoma VS controls,increased,"k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales|f__Actinomycetaceae|g__Actinomyces,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium,k__Bacteria|p__Thermodesulfobacteriota|c__Desulfovibrionia|o__Desulfovibrionales|f__Desulfovibrionaceae|g__Desulfovibrio,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Leptotrichiaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Moryella,k__Bacteria|p__Bacillota|c__Negativicutes|o__Selenomonadales|f__Selenomonadaceae|g__Schwartzia,k__Bacteria|p__Bacillota|c__Negativicutes|o__Selenomonadales|f__Selenomonadaceae|g__Selenomonas,k__Bacteria|p__Spirochaetota|c__Spirochaetia|o__Spirochaetales|f__Treponemataceae|g__Treponema",2|201174|1760|2037|2049|1654;2|201174|1760|85004|31953|1678;2|200940|3031449|213115|194924|872;2|32066|203490|203491|1129771;2|1239|186801|3085636|186803|437755;2|1239|909932|909929|1843491|55506;2|1239|909932|909929|1843491|970;2|203691|203692|136|2845253|157,Complete,Atrayees
bsdb:163/1/2,Study 163,case-control,28725009,10.1038/s41598-017-06361-2,NA,"Wolf A, Moissl-Eichinger C, Perras A, Koskinen K, Tomazic PV , Thurnher D",The salivary microbiome as an indicator of carcinogenesis in patients with oropharyngeal squamous cell carcinoma: A pilot study,Scientific reports,2017,NA,Experiment 1,Austria,Homo sapiens,Saliva,UBERON:0001836,Squamous cell carcinoma,EFO:0000707,Healthy Controls,Oropharyngeal Squamous Cell Carcinoma,diagnosed with OSCC and SCC of the oral cavity,11,11,1 month,16S,4,Illumina,DESeq2,0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,unchanged,NA,Signature 2,"Figure 3, Text",10 January 2021,Utsav Patel,"WikiWorks,ChiomaBlessing",Significant taxa in patients with oropharyngeal squamous cell carcinoma VS controls,decreased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Catonella,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Haemophilus,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Neisseriaceae|g__Neisseria,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Veillonella",2|1239|186801|3085636|186803|43996;2|1224|1236|135625|712|724;2|1224|28216|206351|481|482;2|1224|1236|135625|712;2|976|200643|171549|171552|838;2|976|200643|171549|171552;2|1239|91061|186826|1300|1301;2|1239|909932|1843489|31977|29465,Complete,Atrayees
bsdb:163/2/1,Study 163,case-control,28725009,10.1038/s41598-017-06361-2,NA,"Wolf A, Moissl-Eichinger C, Perras A, Koskinen K, Tomazic PV , Thurnher D",The salivary microbiome as an indicator of carcinogenesis in patients with oropharyngeal squamous cell carcinoma: A pilot study,Scientific reports,2017,NA,Experiment 2,Austria,Homo sapiens,Saliva,UBERON:0001836,Squamous cell carcinoma,EFO:0000707,Healthy Controls,Oropharyngeal Squamous Cell Carcinoma,diagnosed with OSCC and SCC of the oral cavity,11,11,1 month,16S,4,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,unchanged,NA,Signature 1,Supplementary Figure S4,10 January 2021,Utsav Patel,"WikiWorks,ChiomaBlessing",Significant taxa in patients with oropharyngeal squamous cell carcinoma VS controls,increased,"k__Bacteria|p__Actinomycetota,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Aeromonadales,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales,k__Bacteria|p__Bacteroidota|c__Bacteroidia,k__Bacteria|p__Bacteroidota,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Mycobacteriales|f__Corynebacteriaceae,k__Bacteria|c__Deltaproteobacteria,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales,k__Bacteria|p__Bacillota|c__Erysipelotrichia,k__Bacteria|p__Bacteroidota|c__Flavobacteriia|o__Flavobacteriales|f__Flavobacteriaceae,k__Bacteria|p__Bacteroidota|c__Flavobacteriia|o__Flavobacteriales,k__Bacteria|p__Bacteroidota|c__Flavobacteriia,k__Bacteria|p__Bacillota|c__Negativicutes,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae,k__Bacteria|p__Pseudomonadota,k__Bacteria|p__Bacillota|c__Negativicutes|o__Selenomonadales,k__Bacteria|p__Bacteroidota|c__Sphingobacteriia|o__Sphingobacteriales,k__Bacteria|p__Bacteroidota|c__Sphingobacteriia,k__Bacteria|p__Spirochaetota|c__Spirochaetia|o__Spirochaetales|f__Spirochaetaceae|g__Spirochaeta,k__Bacteria|p__Spirochaetota|c__Spirochaetia|o__Spirochaetales|f__Spirochaetaceae,k__Bacteria|p__Spirochaetota|c__Spirochaetia|o__Spirochaetales,k__Bacteria|p__Spirochaetota,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Aeromonadales|f__Succinivibrionaceae,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Veillonella,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae",2|201174;2|1224|1236|135624;2|1224|28211;2|976|200643|171549;2|976|200643;2|976;2|201174|1760|85004;2|201174|1760|85007|1653;2|28221;2|1239|526524|526525;2|1239|526524;2|976|117743|200644|49546;2|976|117743|200644;2|976|117743;2|1239|909932;2|1224|1236|135625|712;2|976|200643|171549|171552;2|1224;2|1239|909932|909929;2|976|117747|200666;2|976|117747;2|203691|203692|136|137|146;2|203691|203692|136|137;2|203691|203692|136;2|203691;2|1224|1236|135624|83763;2|1239|909932|1843489|31977|29465;2|1239|909932|1843489|31977,Complete,Atrayees
bsdb:163/2/2,Study 163,case-control,28725009,10.1038/s41598-017-06361-2,NA,"Wolf A, Moissl-Eichinger C, Perras A, Koskinen K, Tomazic PV , Thurnher D",The salivary microbiome as an indicator of carcinogenesis in patients with oropharyngeal squamous cell carcinoma: A pilot study,Scientific reports,2017,NA,Experiment 2,Austria,Homo sapiens,Saliva,UBERON:0001836,Squamous cell carcinoma,EFO:0000707,Healthy Controls,Oropharyngeal Squamous Cell Carcinoma,diagnosed with OSCC and SCC of the oral cavity,11,11,1 month,16S,4,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,unchanged,NA,Signature 2,Supplementary Figure S4,10 January 2021,Utsav Patel,"WikiWorks,ChiomaBlessing",Significant taxa in patients with oropharyngeal squamous cell carcinoma VS controls,decreased,"k__Bacteria|p__Bacillota|c__Bacilli,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Peptostreptococcaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Stomatobaculum",2|1239|91061;2|1224|1236;2|1239|186801|3082720|186804;2|1239|186801|3085636|186803|1213720,Complete,Atrayees
bsdb:164/1/1,Study 164,case-control,26457297,10.1155/2015/173729,NA,"Hu J, Han S, Chen Y , Ji Z",Variations of Tongue Coating Microbiota in Patients with Gastric Cancer,BioMed research international,2015,NA,Experiment 1,China,Homo sapiens,Tongue,UBERON:0001723,Gastric cancer,MONDO:0001056,controls,gastric cancer,gastric cancer,16,34,2 months,16S,234,Illumina,T-Test,0.05,FALSE,NA,NA,NA,NA,decreased,decreased,NA,NA,NA,Signature 1,"Table 4, text",10 January 2021,Rimsha Azhar,WikiWorks,Relative abundances of selected tongue coating microbial taxa in 34 gastric cancer subjects and 16 control subjects.,increased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Veillonella,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales|f__Actinomycetaceae|g__Actinomyces,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Leptotrichiaceae|g__Leptotrichia,k__Bacteria|p__Actinomycetota",2|976|200643|171549|171552|838;2|1239|91061|186826|1300|1301;2|1239|909932|1843489|31977|29465;2|201174|1760|2037|2049|1654;2|32066|203490|203491|1129771|32067;2|201174,Complete,Atrayees
bsdb:164/1/2,Study 164,case-control,26457297,10.1155/2015/173729,NA,"Hu J, Han S, Chen Y , Ji Z",Variations of Tongue Coating Microbiota in Patients with Gastric Cancer,BioMed research international,2015,NA,Experiment 1,China,Homo sapiens,Tongue,UBERON:0001723,Gastric cancer,MONDO:0001056,controls,gastric cancer,gastric cancer,16,34,2 months,16S,234,Illumina,T-Test,0.05,FALSE,NA,NA,NA,NA,decreased,decreased,NA,NA,NA,Signature 2,"Table 4, text",10 January 2021,Rimsha Azhar,"WikiWorks,Atrayees",Relative abundances of selected tongue coating microbial taxa in 34 gastric cancer subjects and 16 control subjects.,decreased,"k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Neisseriaceae|g__Neisseria,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae|g__Fusobacterium,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Haemophilus,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae|g__Porphyromonas,k__Bacteria|p__Pseudomonadota,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus",2|1224|28216|206351|481|482;2|32066|203490|203491|203492|848;2|1224|1236|135625|712|724;2|976|200643|171549|171551|836;2|1224;2|1239|91061|186826|1300|1301,Complete,Atrayees
bsdb:165/1/1,Study 165,case-control,31245306,10.3389/fcimb.2019.00206,NA,"Li F, Wang M, Wang J, Li R , Zhang Y",Alterations to the Gut Microbiota and Their Correlation With Inflammatory Factors in Chronic Kidney Disease,Frontiers in cellular and infection microbiology,2019,"16S rDNA deep sequencing, Akkermansia, chronic kidney disease, gut microbiota, inflammatory factors",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Chronic kidney disease,EFO:0003884,healthy controls,chronic kidney disease patients,individuals diagnosed with chronic kidney disease because they exhibited an effective glomerular filtration rate of <60mL/min for a 3 month period,22,50,3 months,16S,34,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,unchanged,NA,NA,Signature 1,Figure 2a,10 January 2021,Fatima Zohra,"Claregrieve1,WikiWorks",Taxonomic differences in fecal microbiota exhibited by patients with chronic kidney disease compared with healthy controls,increased,"k__Bacteria|p__Actinomycetota,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales,k__Bacteria|p__Actinomycetota|c__Actinomycetes,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Alloprevotella,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Clostridium,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales|f__Coriobacteriaceae,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales,k__Bacteria|p__Thermodesulfobacteriota|c__Desulfovibrionia|o__Desulfovibrionales|f__Desulfovibrionaceae|g__Desulfovibrio,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Hyphomicrobiales|f__Methylobacteriaceae,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Hyphomicrobiales|f__Methylobacteriaceae|g__Methylobacterium,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Paraprevotella",2|201174;2|201174|1760|2037;2|201174|1760;2|976|200643|171549|171552|1283313;2|1239|186801|186802|31979;2|1239|186801|186802|31979|1485;2|201174|84998|84999|84107;2|201174|84998|84999;2|200940|3031449|213115|194924|872;2|1224|28211|356|119045;2|1224|28211|356|119045|407;2|976|200643|171549|171552|577309,Complete,Claregrieve1
bsdb:165/1/2,Study 165,case-control,31245306,10.3389/fcimb.2019.00206,NA,"Li F, Wang M, Wang J, Li R , Zhang Y",Alterations to the Gut Microbiota and Their Correlation With Inflammatory Factors in Chronic Kidney Disease,Frontiers in cellular and infection microbiology,2019,"16S rDNA deep sequencing, Akkermansia, chronic kidney disease, gut microbiota, inflammatory factors",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Chronic kidney disease,EFO:0003884,healthy controls,chronic kidney disease patients,individuals diagnosed with chronic kidney disease because they exhibited an effective glomerular filtration rate of <60mL/min for a 3 month period,22,50,3 months,16S,34,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,unchanged,NA,NA,Signature 2,Figure 2a,10 January 2021,Fatima Zohra,"Lwaldron,Claregrieve1,WikiWorks",Taxonomic differences in fecal microbiota exhibited by patients with chronic kidney disease compared with healthy controls,decreased,"k__Bacteria|p__Verrucomicrobiota|c__Verrucomicrobiia|o__Verrucomicrobiales|f__Akkermansiaceae|g__Akkermansia,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae|g__Allobaculum,k__Bacteria|p__Bacillota|c__Bacilli,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales,k__Bacteria|p__Campylobacterota|c__Epsilonproteobacteria|o__Campylobacterales,k__Bacteria|p__Deferribacterota|c__Deferribacteres|o__Deferribacterales|f__Deferribacteraceae,k__Bacteria|p__Deferribacterota|c__Deferribacteres|o__Deferribacterales,k__Bacteria|p__Deferribacterota|c__Deferribacteres,k__Bacteria|p__Deferribacterota,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Eggerthellales|f__Eggerthellaceae|g__Enterorhabdus,k__Bacteria|p__Campylobacterota,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Eubacteriaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Eubacteriaceae|g__Eubacterium,k__Bacteria|p__Campylobacterota|c__Epsilonproteobacteria|o__Campylobacterales|f__Helicobacteraceae|g__Helicobacter,k__Bacteria|p__Campylobacterota|c__Epsilonproteobacteria|o__Campylobacterales|f__Helicobacteraceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Lactococcus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Leuconostoc,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micrococcales|f__Micrococcaceae,k__Bacteria|p__Deferribacterota|c__Deferribacteres|o__Deferribacterales|f__Mucispirillaceae|g__Mucispirillum,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales|f__Atopobiaceae|g__Olsenella,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Oribacterium,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Sutterellaceae|g__Parasutterella,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales|f__Coriobacteriaceae|g__Parvibacter,k__Bacteria|p__Synergistota|c__Synergistia|o__Synergistales|f__Dethiosulfovibrionaceae|g__Pyramidobacter,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micrococcales|f__Micrococcaceae|g__Rothia,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Sutterellaceae,k__Bacteria|p__Synergistota|c__Synergistia|o__Synergistales|f__Synergistaceae,k__Bacteria|p__Synergistota|c__Synergistia|o__Synergistales,k__Bacteria|p__Synergistota|c__Synergistia|o__Synergistales|f__Synergistaceae|g__Synergistes,k__Bacteria|p__Synergistota,k__Bacteria|p__Synergistota|c__Synergistia,k__Bacteria|p__Verrucomicrobiota,k__Bacteria|p__Verrucomicrobiota|c__Verrucomicrobiia|o__Verrucomicrobiales|f__Verrucomicrobiaceae,k__Bacteria|p__Verrucomicrobiota|c__Verrucomicrobiia,k__Bacteria|p__Verrucomicrobiota|c__Verrucomicrobiia|o__Verrucomicrobiales",2|74201|203494|48461|1647988|239934;2|1239|526524|526525|128827|174708;2|1239|91061;2|1224|28216;2|1224|28216|80840;2|29547|3031852|213849;2|200930|68337|191393|191394;2|200930|68337|191393;2|200930|68337;2|200930;2|201174|84998|1643822|1643826|580024;2|29547;2|1239|186801|186802|186806;2|1239|186801|186802|186806|1730;2|29547|3031852|213849|72293|209;2|29547|3031852|213849|72293;2|1239|91061|186826|33958;2|1239|91061|186826;2|1239|91061|186826|33958|1578;2|1239|91061|186826|1300|1357;2|1239|91061|186826|33958|1243;2|201174|1760|85006|1268;2|200930|68337|191393|2945020|248038;2|201174|84998|84999|1643824|133925;2|1239|186801|3085636|186803|265975;2|1224|28216|80840|995019|577310;2|201174|84998|84999|84107|1427376;2|508458|649775|649776|3029088|638847;2|201174|1760|85006|1268|32207;2|1224|28216|80840|995019;2|508458|649775|649776|649777;2|508458|649775|649776;2|508458|649775|649776|649777|2753;2|508458;2|508458|649775;2|74201;2|74201|203494|48461|203557;2|74201|203494;2|74201|203494|48461,Complete,Claregrieve1
bsdb:166/1/1,Study 166,case-control,30088332,10.1002/mbo3.678,NA,"Lun H, Yang W, Zhao S, Jiang M, Xu M, Liu F , Wang Y",Altered gut microbiota and microbial biomarkers associated with chronic kidney disease,MicrobiologyOpen,2019,"chronic kidney disease, gut microbiota, hemodialysis, intestinal dysbiosis, microbial biomarker",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Chronic kidney disease,EFO:0003884,healthy controls,chronic kidney disease,patients with chronic kidney disease,24,49,3 months,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,NA,NA,NA,NA,NA,Signature 1,Figure 3b,10 January 2021,Fatima Zohra,"Claregrieve1,WikiWorks",Comparison of gut bacteria between the HC and chronic kidney disease groups,increased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides,k__Bacteria|p__Bacteroidota,k__Bacteria|p__Bacteroidota|c__Bacteroidia,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Eggerthellales|f__Eggerthellaceae|g__Eggerthella,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Coprobacillaceae|g__Thomasclavelia,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Escherichia,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Flavonifractor,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Tannerellaceae|g__Parabacteroides,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Ruminiclostridium,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Sellimonas,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Shigella,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Weissella,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Mediterraneibacter|s__Mediterraneibacter gnavus,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Mediterraneibacter|s__[Ruminococcus] torques,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae|s__[Clostridium] innocuum",2|976|200643|171549|815;2|976|200643|171549;2|976|200643|171549|815|816;2|976;2|976|200643;2|201174|84998|1643822|1643826|84111;2|1224|1236|91347;2|1224|1236|91347|543;2|1239|526524|526525|2810280|1505663;2|1224|1236|91347|543|561;2|1239|186801|186802|216572|946234;2|1224|1236;2|1239|91061|186826|81850;2|976|200643|171549|2005525|375288;2|976|200643|171549|171551;2|1239|186801|186802|216572|1508657;2|1239|186801|3085636|186803|1769710;2|1224|1236|91347|543|620;2|1239|91061|186826|33958|46255;2|1239|186801|3085636|186803|2316020|33038;2|1239|186801|3085636|186803|2316020|33039;2|1239|526524|526525|128827|1522,Complete,Claregrieve1
bsdb:166/1/2,Study 166,case-control,30088332,10.1002/mbo3.678,NA,"Lun H, Yang W, Zhao S, Jiang M, Xu M, Liu F , Wang Y",Altered gut microbiota and microbial biomarkers associated with chronic kidney disease,MicrobiologyOpen,2019,"chronic kidney disease, gut microbiota, hemodialysis, intestinal dysbiosis, microbial biomarker",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Chronic kidney disease,EFO:0003884,healthy controls,chronic kidney disease,patients with chronic kidney disease,24,49,3 months,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,NA,NA,NA,NA,NA,Signature 2,Figure 3b,10 January 2021,Fatima Zohra,WikiWorks,Comparison of gut bacteria between the HC and chronic kidney disease groups,decreased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Tyzzerella,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Anaerobutyricum|s__Anaerobutyricum hallii,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Coriobacteriales|f__Coriobacteriaceae|g__Collinsella,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Butyricicoccaceae|g__Butyricicoccus,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Peptostreptococcaceae|g__Romboutsia,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Ruminococcus,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Peptostreptococcaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Roseburia,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Coprococcus,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Eubacteriaceae|g__Eubacterium|s__Eubacterium coprostanoligenes,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Subdoligranulum,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Lachnospira,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Carnobacteriaceae|g__Carnobacterium,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Agathobacter|s__Agathobacter rectalis,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Dialister,k__Bacteria|p__Bacillota|c__Negativicutes|o__Selenomonadales,k__Bacteria|p__Bacillota|c__Negativicutes,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae,k__Bacteria|p__Bacillota|c__Clostridia,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales,k__Bacteria|p__Bacillota",2|1239|186801|3085636|186803;2|1239|186801|3085636|186803|1506577;2|1239|186801|3085636|186803|2569097|39488;2|1239|186801|186802|541000;2|201174|84998|84999|84107|102106;2|1239|186801|186802|3085642|580596;2|1239|186801|3082720|186804|1501226;2|1239|186801|186802|216572|1263;2|1239|186801|3082720|186804;2|1239|186801|3085636|186803|841;2|1239|186801|3085636|186803|33042;2|1239|186801|186802|186806|1730|290054;2|1239|186801|186802|216572|292632;2|1239|186801|3085636|186803|28050;2|1239|91061|186826|186828|2747;2|1239|186801|3085636|186803|1766253|39491;2|976|200643|171549|171552;2|1239|909932|1843489|31977|39948;2|1239|909932|909929;2|1239|909932;2|1239|909932|1843489|31977;2|1239|186801;2|1239|186801|186802;2|1239,Complete,Claregrieve1
bsdb:167/1/1,Study 167,case-control,29774014,10.3389/fmicb.2018.00862,NA,"Yang CY, Yeh YM, Yu HY, Chin CY, Hsu CW, Liu H, Huang PJ, Hu SN, Liao CT, Chang KP , Chang YL",Oral Microbiota Community Dynamics Associated With Oral Squamous Cell Carcinoma Staging,Frontiers in microbiology,2018,"16S rRNA sequencing, cancer progression, community dysbiosis, complexity, oral microbiome",Experiment 1,Taiwan,Homo sapiens,Mouth,UBERON:0000165,Squamous cell carcinoma,EFO:0000707,healthy controls,Stage 4,OSCC  confirmed by biopsy and pathological findings,51,90,No antibiotics treatment at the time of sample collection.,16S,34,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,increased,unchanged,NA,NA,unchanged,Signature 1,Figure 5,10 January 2021,Utsav Patel,"WikiWorks,Atrayees,ChiomaBlessing",Oral Microbiota Community Dynamics Associated With Oral Squamous Cell Carcinoma Staging in Stage 4 group compared to healthy control group,increased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Aggregatibacter|s__Aggregatibacter segnis,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Alloprevotella|s__Alloprevotella sp.,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Alloscardovia|s__Alloscardovia omnicolens,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Anaeroglobus|s__Anaeroglobus geminatus,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides|s__Bacteroides heparinolyticus,k__Bacteria|p__Campylobacterota|c__Epsilonproteobacteria|o__Campylobacterales|f__Campylobacteraceae|g__Campylobacter|s__Campylobacter gracilis,k__Bacteria|p__Campylobacterota|c__Epsilonproteobacteria|o__Campylobacterales|f__Campylobacteraceae|g__Campylobacter|s__Campylobacter sp.,k__Bacteria|p__Bacillota|c__Negativicutes|o__Selenomonadales|f__Selenomonadaceae|g__Centipeda,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Dialister|s__Dialister pneumosintes,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Neisseriaceae|g__Eikenella|s__Eikenella corrodens,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Escherichia|s__Escherichia coli,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Filifactoraceae|g__Filifactor|s__Filifactor alocis,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae|g__Fusobacterium|s__Fusobacterium periodonticum,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Carnobacteriaceae|g__Granulicatella|s__Granulicatella elegans,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Haemophilus|s__Haemophilus influenzae,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Leptotrichiaceae|g__Leptotrichia|s__Leptotrichia sp.,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Neisseriaceae|g__Neisseria|s__Neisseria elongata,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Neisseriaceae|g__Neisseria|s__Neisseria oralis,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Oribacterium|s__Oribacterium sp.,k__Bacteria|p__Bacillota|c__Tissierellia|o__Tissierellales|f__Peptoniphilaceae|g__Parvimonas|s__Parvimonas micra,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Peptostreptococcaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae|g__Porphyromonas|s__Porphyromonas sp.,k__Bacteria|p__Bacillota|c__Negativicutes|o__Selenomonadales|f__Selenomonadaceae|g__Selenomonas|s__Selenomonas sp.,k__Bacteria|p__Bacillota|c__Negativicutes|o__Selenomonadales|f__Selenomonadaceae|g__Selenomonas|s__Selenomonas sputigena,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus|s__Streptococcus constellatus",2|1224|1236|135625|712|416916|739;2|976|200643|171549|171552|1283313|1872471;2|201174|1760|85004|31953|419014|419015;2|1239|909932|1843489|31977|156454|156456;2|976|200643|171549|815|816|28113;2|29547|3031852|213849|72294|194|824;2|29547|3031852|213849|72294|194|205;2|1239|909932|909929|1843491|82202;2|1239|909932|1843489|31977|39948|39950;2|1224|28216|206351|481|538|539;2|1224|1236|91347|543|561|562;2|1239|186801|3082720|3118655|44259|143361;2|32066|203490|203491|203492|848|860;2|1239|91061|186826|186828|117563|137732;2|1224|1236|135625|712|724|727;2|32066|203490|203491|1129771|32067|104608;2|1224|28216|206351|481|482|495;2|1224|28216|206351|481|482|1107316;2|1239|186801|3085636|186803|265975|1969407;2|1239|1737404|1737405|1570339|543311|33033;2|1239|186801|3082720|186804;2|976|200643|171549|171551|836|1924944;2|1239|909932|909929|1843491|970|2053611;2|1239|909932|909929|1843491|970|69823;2|1239|91061|186826|1300|1301|76860,Complete,Atrayees
bsdb:167/1/2,Study 167,case-control,29774014,10.3389/fmicb.2018.00862,NA,"Yang CY, Yeh YM, Yu HY, Chin CY, Hsu CW, Liu H, Huang PJ, Hu SN, Liao CT, Chang KP , Chang YL",Oral Microbiota Community Dynamics Associated With Oral Squamous Cell Carcinoma Staging,Frontiers in microbiology,2018,"16S rRNA sequencing, cancer progression, community dysbiosis, complexity, oral microbiome",Experiment 1,Taiwan,Homo sapiens,Mouth,UBERON:0000165,Squamous cell carcinoma,EFO:0000707,healthy controls,Stage 4,OSCC  confirmed by biopsy and pathological findings,51,90,No antibiotics treatment at the time of sample collection.,16S,34,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,increased,unchanged,NA,NA,unchanged,Signature 2,Figure 5,10 January 2021,Utsav Patel,"WikiWorks,Atrayees,ChiomaBlessing",Oral Microbiota Community Dynamics Associated With Oral Squamous Cell Carcinoma Staging in Stage 4 group compared to healthy control group,decreased,"k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales|f__Actinomycetaceae|g__Actinomyces|s__Actinomyces gerencseriae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Carnobacteriaceae|g__Granulicatella|s__Granulicatella adiacens,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Hoylesella|s__Hoylesella nanceiensis,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella|s__Prevotella melaninogenica,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Leptotrichiaceae|g__Pseudoleptotrichia|s__Pseudoleptotrichia goodfellowii,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales|f__Actinomycetaceae|g__Schaalia|s__Schaalia georgiae",2|201174|1760|2037|2049|1654|52769;2|1239|91061|186826|186828|117563|46124;2|976|200643|171549|171552|2974257|425941;2|976|200643|171549|171552|838|28132;2|32066|203490|203491|1129771|2755140|157692;2|201174|1760|2037|2049|2529408|52768,Complete,Atrayees
bsdb:167/2/1,Study 167,case-control,29774014,10.3389/fmicb.2018.00862,NA,"Yang CY, Yeh YM, Yu HY, Chin CY, Hsu CW, Liu H, Huang PJ, Hu SN, Liao CT, Chang KP , Chang YL",Oral Microbiota Community Dynamics Associated With Oral Squamous Cell Carcinoma Staging,Frontiers in microbiology,2018,"16S rRNA sequencing, cancer progression, community dysbiosis, complexity, oral microbiome",Experiment 2,Taiwan,Homo sapiens,Mouth,UBERON:0000165,Squamous cell carcinoma,EFO:0000707,healthy controls,Stage 1,OSCC  confirmed by biopsy and pathological findings,51,41,No antibiotics treatment at the time of sample collection.,16S,34,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,unchanged,unchanged,NA,NA,increased,Signature 1,Supplementary Figure 5A,10 January 2021,Utsav Patel,"WikiWorks,ChiomaBlessing",Oral Microbiota Community Dynamics Associated With Oral Squamous Cell Carcinoma Staging  in Stage 1 group compared to healthy control group,increased,"k__Bacteria|p__Campylobacterota|c__Epsilonproteobacteria|o__Campylobacterales|f__Campylobacteraceae|g__Campylobacter|s__Campylobacter sp.,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Filifactoraceae|g__Filifactor|s__Filifactor alocis,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae|g__Fusobacterium|s__Fusobacterium periodonticum,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Carnobacteriaceae|g__Granulicatella|s__Granulicatella elegans,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Haemophilus|s__Haemophilus influenzae,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Neisseriaceae|g__Neisseria|s__Neisseria oralis,k__Bacteria|p__Bacillota|c__Tissierellia|o__Tissierellales|f__Peptoniphilaceae|g__Parvimonas|s__Parvimonas micra,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae|g__Porphyromonas|s__Porphyromonas sp.,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus|s__Streptococcus constellatus",2|29547|3031852|213849|72294|194|205;2|1239|186801|3082720|3118655|44259|143361;2|32066|203490|203491|203492|848|860;2|1239|91061|186826|186828|117563|137732;2|1224|1236|135625|712|724|727;2|1224|28216|206351|481|482|1107316;2|1239|1737404|1737405|1570339|543311|33033;2|976|200643|171549|171551|836|1924944;2|1239|91061|186826|1300|1301|76860,Complete,ChiomaBlessing
bsdb:167/2/2,Study 167,case-control,29774014,10.3389/fmicb.2018.00862,NA,"Yang CY, Yeh YM, Yu HY, Chin CY, Hsu CW, Liu H, Huang PJ, Hu SN, Liao CT, Chang KP , Chang YL",Oral Microbiota Community Dynamics Associated With Oral Squamous Cell Carcinoma Staging,Frontiers in microbiology,2018,"16S rRNA sequencing, cancer progression, community dysbiosis, complexity, oral microbiome",Experiment 2,Taiwan,Homo sapiens,Mouth,UBERON:0000165,Squamous cell carcinoma,EFO:0000707,healthy controls,Stage 1,OSCC  confirmed by biopsy and pathological findings,51,41,No antibiotics treatment at the time of sample collection.,16S,34,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,unchanged,unchanged,NA,NA,increased,Signature 2,Supplementary Figure 5A,10 January 2021,Utsav Patel,"WikiWorks,ChiomaBlessing",Oral Microbiota Community Dynamics Associated With Oral Squamous Cell Carcinoma Staging in Stage 1 group compared to healthy control group,decreased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Haemophilus|s__Haemophilus parainfluenzae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae|g__Porphyromonas|s__Porphyromonas pasteri,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella|s__Prevotella melaninogenica,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales|f__Actinomycetaceae|g__Schaalia|s__Schaalia odontolytica,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Veillonella|s__Veillonella parvula",2|1224|1236|135625|712|724|729;2|976|200643|171549|171551|836|1583331;2|976|200643|171549|171552|838|28132;2|201174|1760|2037|2049|2529408|1660;2|1239|909932|1843489|31977|29465|29466,Complete,ChiomaBlessing
bsdb:167/3/1,Study 167,case-control,29774014,10.3389/fmicb.2018.00862,NA,"Yang CY, Yeh YM, Yu HY, Chin CY, Hsu CW, Liu H, Huang PJ, Hu SN, Liao CT, Chang KP , Chang YL",Oral Microbiota Community Dynamics Associated With Oral Squamous Cell Carcinoma Staging,Frontiers in microbiology,2018,"16S rRNA sequencing, cancer progression, community dysbiosis, complexity, oral microbiome",Experiment 3,Taiwan,Homo sapiens,Mouth,UBERON:0000165,Squamous cell carcinoma,EFO:0000707,healthy controls,Stage 2 & 3,OSCC  confirmed by biopsy and pathological findings,51,66,No antibiotics treatment at the time of sample collection.,16S,34,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,increased,unchanged,NA,NA,increased,Signature 1,Supplementary Figure 5B,10 January 2021,Utsav Patel,"WikiWorks,ChiomaBlessing",Oral Microbiota Community Dynamics Associated With Oral Squamous Cell Carcinoma Staging in Stages 2 & 3 group compared to healthy control group,increased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Aggregatibacter|s__Aggregatibacter segnis,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Anaeroglobus|s__Anaeroglobus geminatus,k__Bacteria|p__Campylobacterota|c__Epsilonproteobacteria|o__Campylobacterales|f__Campylobacteraceae|g__Campylobacter|s__Campylobacter gracilis,k__Bacteria|p__Campylobacterota|c__Epsilonproteobacteria|o__Campylobacterales|f__Campylobacteraceae|g__Campylobacter|s__Campylobacter sp.,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Eubacteriaceae|g__Eubacterium,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Filifactoraceae|g__Filifactor|s__Filifactor alocis,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae|g__Fusobacterium|s__Fusobacterium periodonticum,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Carnobacteriaceae|g__Granulicatella|s__Granulicatella elegans,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Haemophilus|s__Haemophilus influenzae,k__Bacteria|p__Bacillota|c__Tissierellia|o__Tissierellales|f__Peptoniphilaceae|g__Parvimonas|s__Parvimonas micra,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae|g__Porphyromonas|s__Porphyromonas sp.,k__Bacteria|p__Bacillota|c__Negativicutes|o__Selenomonadales|f__Selenomonadaceae|g__Selenomonas|s__Selenomonas sputigena,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus|s__Streptococcus constellatus",2|1224|1236|135625|712|416916|739;2|1239|909932|1843489|31977|156454|156456;2|29547|3031852|213849|72294|194|824;2|29547|3031852|213849|72294|194|205;2|1239|186801|186802|186806|1730;2|1239|186801|3082720|3118655|44259|143361;2|32066|203490|203491|203492|848|860;2|1239|91061|186826|186828|117563|137732;2|1224|1236|135625|712|724|727;2|1239|1737404|1737405|1570339|543311|33033;2|976|200643|171549|171551|836|1924944;2|1239|909932|909929|1843491|970|69823;2|1239|91061|186826|1300|1301|76860,Complete,ChiomaBlessing
bsdb:167/3/2,Study 167,case-control,29774014,10.3389/fmicb.2018.00862,NA,"Yang CY, Yeh YM, Yu HY, Chin CY, Hsu CW, Liu H, Huang PJ, Hu SN, Liao CT, Chang KP , Chang YL",Oral Microbiota Community Dynamics Associated With Oral Squamous Cell Carcinoma Staging,Frontiers in microbiology,2018,"16S rRNA sequencing, cancer progression, community dysbiosis, complexity, oral microbiome",Experiment 3,Taiwan,Homo sapiens,Mouth,UBERON:0000165,Squamous cell carcinoma,EFO:0000707,healthy controls,Stage 2 & 3,OSCC  confirmed by biopsy and pathological findings,51,66,No antibiotics treatment at the time of sample collection.,16S,34,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,increased,unchanged,NA,NA,increased,Signature 2,Supplementary Figure 5B,10 January 2021,Utsav Patel,"WikiWorks,ChiomaBlessing",Oral Microbiota Community Dynamics Associated With Oral Squamous Cell Carcinoma Staging in Stages 2 & 3 group compared to healthy control group,decreased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Haemophilus|s__Haemophilus parainfluenzae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae|g__Porphyromonas|s__Porphyromonas pasteri,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella|s__Prevotella melaninogenica,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales|f__Actinomycetaceae|g__Schaalia|s__Schaalia odontolytica,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus|s__Streptococcus mitis,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Veillonella|s__Veillonella parvula,k__Bacteria|p__Candidatus Absconditabacteria|s__SR1 bacterium oral taxon 875",2|1224|1236|135625|712|724|729;2|976|200643|171549|171551|836|1583331;2|976|200643|171549|171552|838|28132;2|201174|1760|2037|2049|2529408|1660;2|1239|91061|186826|1300|1301|28037;2|1239|909932|1843489|31977|29465|29466;2|221235|1226342,Complete,ChiomaBlessing
bsdb:168/1/1,Study 168,case-control,30122883,10.3748/wjg.v24.i30.3448,NA,"Zhao Y, Mao YF, Tang YS, Ni MZ, Liu QH, Wang Y, Feng Q, Peng JH , Hu YY",Altered oral microbiota in chronic hepatitis B patients with different tongue coatings,World journal of gastroenterology,2018,"16S rRNA gene sequencing, Chronic hepatitis B, Metabolomics, Microbiota, Tongue diagnosis",Experiment 1,China,Homo sapiens,Tongue,UBERON:0001723,Chronic hepatitis B virus infection,EFO:0004239,healthy controls,chronic hepatitis B yellow tongue coating patients,"patients diagnosed with chronic hepatitis B per ""The Guidelines for the Prevention and Treatment of Chronic Hepatitis B (2010 version)"" with a yellow tongue coating",22,28,3 months,16S,3,Ion Torrent,Metastats,0.05,FALSE,NA,"age,sex",NA,NA,unchanged,unchanged,NA,NA,NA,Signature 1,"Figure 2B, Figure 3A",10 January 2021,Rimsha Azhar,"Claregrieve1,WikiWorks",Differentially abundant taxa between chronic hepatitis B yellow tongue coating patients and healthy controls,increased,"k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Burkholderiaceae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Cardiobacteriales|f__Cardiobacteriaceae,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Comamonadaceae,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Comamonadaceae|g__Comamonas,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Burkholderiaceae|g__Lautropia,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Neisseriaceae|g__Neisseria,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Neisseriaceae,k__Bacteria|p__Pseudomonadota",2|1224|28216|80840|119060;2|1224|1236|135615|868;2|1224|28216|80840|80864;2|1224|28216|80840|80864|283;2|1224|28216|80840|119060|47670;2|1224|28216|206351|481|482;2|1224|28216|206351|481;2|1224,Complete,Claregrieve1
bsdb:168/1/2,Study 168,case-control,30122883,10.3748/wjg.v24.i30.3448,NA,"Zhao Y, Mao YF, Tang YS, Ni MZ, Liu QH, Wang Y, Feng Q, Peng JH , Hu YY",Altered oral microbiota in chronic hepatitis B patients with different tongue coatings,World journal of gastroenterology,2018,"16S rRNA gene sequencing, Chronic hepatitis B, Metabolomics, Microbiota, Tongue diagnosis",Experiment 1,China,Homo sapiens,Tongue,UBERON:0001723,Chronic hepatitis B virus infection,EFO:0004239,healthy controls,chronic hepatitis B yellow tongue coating patients,"patients diagnosed with chronic hepatitis B per ""The Guidelines for the Prevention and Treatment of Chronic Hepatitis B (2010 version)"" with a yellow tongue coating",22,28,3 months,16S,3,Ion Torrent,Metastats,0.05,FALSE,NA,"age,sex",NA,NA,unchanged,unchanged,NA,NA,NA,Signature 2,"Figure 2B, Figure 3A",10 January 2021,Rimsha Azhar,"Claregrieve1,WikiWorks",Differentially abundant taxa between chronic hepatitis B yellow tongue coating patients and healthy controls,decreased,"k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae,k__Bacteria|p__Campylobacterota|c__Epsilonproteobacteria|o__Campylobacterales|f__Campylobacteraceae|g__Campylobacter,k__Bacteria|p__Campylobacterota|c__Epsilonproteobacteria|o__Campylobacterales|f__Campylobacteraceae,k__Bacteria|p__Candidatus Saccharibacteria|c__Candidatus Saccharimonadia|o__Candidatus Saccharimonadales|f__Candidatus Saccharimonadaceae|g__Candidatus Saccharimonas,k__Bacteria|p__Bacillota|c__Tissierellia|o__Tissierellales|f__Peptoniphilaceae|g__Parvimonas,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Peptoclostridiaceae|g__Peptoclostridium,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Scardovia",2|201174|1760|85004|31953;2|29547|3031852|213849|72294|194;2|29547|3031852|213849|72294;2|95818|2093818|2093825|2171986|1331051;2|1239|1737404|1737405|1570339|543311;2|1239|186801|3082720|3120161|1481960;2|201174|1760|85004|31953|196081,Complete,Claregrieve1
bsdb:168/2/1,Study 168,case-control,30122883,10.3748/wjg.v24.i30.3448,NA,"Zhao Y, Mao YF, Tang YS, Ni MZ, Liu QH, Wang Y, Feng Q, Peng JH , Hu YY",Altered oral microbiota in chronic hepatitis B patients with different tongue coatings,World journal of gastroenterology,2018,"16S rRNA gene sequencing, Chronic hepatitis B, Metabolomics, Microbiota, Tongue diagnosis",Experiment 2,China,Homo sapiens,Tongue,UBERON:0001723,Chronic hepatitis B virus infection,EFO:0004239,chronic hepatitis B white tongue coating patients,chronic hepatitis B yellow tongue coating patients,"patients diagnosed with chronic hepatitis B per ""The Guidelines for the Prevention and Treatment of Chronic Hepatitis B (2010 version)"" with a yellow tongue coating",25,28,3 months,16S,3,Ion Torrent,Metastats,0.05,FALSE,NA,"age,sex",NA,NA,unchanged,unchanged,NA,NA,NA,Signature 1,"Figure 2B, Figure 3A",10 January 2021,Rimsha Azhar,"Fatima,Claregrieve1,WikiWorks",Differentially abundant taxa between chronic hepatitis B yellow and white tongue coating patients,increased,"k__Bacteria|p__Candidatus Gracilibacteria,k__Bacteria|p__Mycoplasmatota|c__Mollicutes|o__Mycoplasmatales|f__Mycoplasmataceae|g__Mycoplasma,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Neisseriaceae|g__Neisseria,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Neisseriaceae,k__Bacteria|p__Pseudomonadota",2|363464;2|544448|31969|2085|2092|2093;2|1224|28216|206351|481|482;2|1224|28216|206351|481;2|1224,Complete,Claregrieve1
bsdb:168/2/2,Study 168,case-control,30122883,10.3748/wjg.v24.i30.3448,NA,"Zhao Y, Mao YF, Tang YS, Ni MZ, Liu QH, Wang Y, Feng Q, Peng JH , Hu YY",Altered oral microbiota in chronic hepatitis B patients with different tongue coatings,World journal of gastroenterology,2018,"16S rRNA gene sequencing, Chronic hepatitis B, Metabolomics, Microbiota, Tongue diagnosis",Experiment 2,China,Homo sapiens,Tongue,UBERON:0001723,Chronic hepatitis B virus infection,EFO:0004239,chronic hepatitis B white tongue coating patients,chronic hepatitis B yellow tongue coating patients,"patients diagnosed with chronic hepatitis B per ""The Guidelines for the Prevention and Treatment of Chronic Hepatitis B (2010 version)"" with a yellow tongue coating",25,28,3 months,16S,3,Ion Torrent,Metastats,0.05,FALSE,NA,"age,sex",NA,NA,unchanged,unchanged,NA,NA,NA,Signature 2,"Figure 2B, Figure 3A",10 January 2021,Rimsha Azhar,"Claregrieve1,WikiWorks",Differentially abundant taxa between chronic hepatitis B yellow and white tongue coating patients,decreased,"k__Bacteria|p__Bacteroidota,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Catonella,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella",2|976;2|1239|186801|3085636|186803|43996;2|976|200643|171549|171552|838,Complete,Claregrieve1
bsdb:168/3/1,Study 168,case-control,30122883,10.3748/wjg.v24.i30.3448,NA,"Zhao Y, Mao YF, Tang YS, Ni MZ, Liu QH, Wang Y, Feng Q, Peng JH , Hu YY",Altered oral microbiota in chronic hepatitis B patients with different tongue coatings,World journal of gastroenterology,2018,"16S rRNA gene sequencing, Chronic hepatitis B, Metabolomics, Microbiota, Tongue diagnosis",Experiment 3,China,Homo sapiens,Tongue,UBERON:0001723,Chronic hepatitis B virus infection,EFO:0004239,healthy controls,chronic hepatitis B white tongue coating patients,"patients diagnosed with chronic hepatitis B per ""The Guidelines for the Prevention and Treatment of Chronic Hepatitis B (2010 version)"" with a white tongue coating",22,25,3 months,16S,3,Ion Torrent,Metastats,0.05,FALSE,NA,"age,sex",NA,NA,unchanged,unchanged,NA,NA,NA,Signature 1,"Figure 2B, Figure 3A",10 January 2021,Rimsha Azhar,"Claregrieve1,WikiWorks",Differentially abundant taxa between healthy controls and chronic hepatitis B white tongue coating patients,increased,"k__Bacteria|p__Bacteroidota|c__Flavobacteriia|o__Flavobacteriales|f__Weeksellaceae|g__Bergeyella,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae|g__Bulleidia,k__Bacteria|p__Bacillota|c__Negativicutes|o__Selenomonadales|f__Selenomonadaceae|g__Centipeda,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae|g__Porphyromonas",2|976|117743|200644|2762318|59735;2|1239|526524|526525|128827|118747;2|1239|909932|909929|1843491|82202;2|976|200643|171549|171551;2|976|200643|171549|171551|836,Complete,Claregrieve1
bsdb:168/3/2,Study 168,case-control,30122883,10.3748/wjg.v24.i30.3448,NA,"Zhao Y, Mao YF, Tang YS, Ni MZ, Liu QH, Wang Y, Feng Q, Peng JH , Hu YY",Altered oral microbiota in chronic hepatitis B patients with different tongue coatings,World journal of gastroenterology,2018,"16S rRNA gene sequencing, Chronic hepatitis B, Metabolomics, Microbiota, Tongue diagnosis",Experiment 3,China,Homo sapiens,Tongue,UBERON:0001723,Chronic hepatitis B virus infection,EFO:0004239,healthy controls,chronic hepatitis B white tongue coating patients,"patients diagnosed with chronic hepatitis B per ""The Guidelines for the Prevention and Treatment of Chronic Hepatitis B (2010 version)"" with a white tongue coating",22,25,3 months,16S,3,Ion Torrent,Metastats,0.05,FALSE,NA,"age,sex",NA,NA,unchanged,unchanged,NA,NA,NA,Signature 2,"Figure 2B, Figure 3A",10 January 2021,Rimsha Azhar,"Claregrieve1,WikiWorks",Differentially abundant taxa between healthy controls and chronic hepatitis B white tongue coating patients,decreased,"k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales|f__Actinomycetaceae|g__Actinomyces,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales|f__Actinomycetaceae,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Neisseriaceae|g__Alysiella,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Cardiobacteriales|f__Cardiobacteriaceae,k__Bacteria|p__Mycoplasmatota|c__Mollicutes|o__Mycoplasmatales|f__Mycoplasmataceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Eubacteriaceae|g__Pseudoramibacter,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Scardovia",2|201174|1760|2037|2049|1654;2|201174|1760|2037|2049;2|1224|28216|206351|481|194195;2|1224|1236|135615|868;2|544448|31969|2085|2092;2|1239|186801|186802|186806|113286;2|201174|1760|85004|31953|196081,Complete,Claregrieve1
bsdb:169/1/1,Study 169,case-control,30508628,10.1016/j.micpath.2018.11.051,NA,"Xu J, Xiang C, Zhang C, Xu B, Wu J, Wang R, Yang Y, Shi L, Zhang J , Zhan Z",Microbial biomarkers of common tongue coatings in patients with gastric cancer,Microbial pathogenesis,2019,"Gastric cancer, Microbiome, Tongue coating",Experiment 1,China,Homo sapiens,Tongue,UBERON:0001723,Gastric cancer,MONDO:0001056,other coatings,white-thin tongue coating GC patient,gastric cancer with different tongue coatings,90,25,4 weeks,16S,345,RT-qPCR,LEfSe,0.05,FALSE,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,Signature 1,Table 1,10 January 2021,Rimsha Azhar,"WikiWorks,Atrayees",LEfSe analysis of microbial taxa from tongue coating in GC patients,increased,"k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Burkholderiaceae|g__Lautropia,k__Bacteria|p__Bacteroidota|c__Flavobacteriia|o__Flavobacteriales|f__Flavobacteriaceae|g__Capnocytophaga|s__Capnocytophaga leadbetteri,k__Eukaryota|k__Fungi|p__Ascomycota|c__Dothideomycetes|o__Pleosporales|f__Leptosphaeriaceae|g__Ampelomyces",2|1224|28216|80840|119060|47670;2|976|117743|200644|49546|1016|327575;2759|4751|4890|147541|92860|34374|50729,Complete,Atrayees
bsdb:169/1/2,Study 169,case-control,30508628,10.1016/j.micpath.2018.11.051,NA,"Xu J, Xiang C, Zhang C, Xu B, Wu J, Wang R, Yang Y, Shi L, Zhang J , Zhan Z",Microbial biomarkers of common tongue coatings in patients with gastric cancer,Microbial pathogenesis,2019,"Gastric cancer, Microbiome, Tongue coating",Experiment 1,China,Homo sapiens,Tongue,UBERON:0001723,Gastric cancer,MONDO:0001056,other coatings,white-thin tongue coating GC patient,gastric cancer with different tongue coatings,90,25,4 weeks,16S,345,RT-qPCR,LEfSe,0.05,FALSE,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,Signature 2,Table 1,10 January 2021,Rimsha Azhar,"WikiWorks,Atrayees",LEfSe analysis of microbial taxa from tongue coating in GC patients,decreased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Stomatobaculum,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Megasphaera|s__Megasphaera micronuciformis,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Eubacteriaceae|g__Eubacterium|s__Eubacterium sp.,k__Eukaryota|k__Fungi|p__Basidiomycota|c__Microbotryomycetes|o__Sporidiobolales,k__Eukaryota|k__Fungi|p__Ascomycota|c__Sordariomycetes|o__Hypocreales|f__Nectriaceae|g__Fusarium|s__Fusarium equiseti",2|1239|186801|3085636|186803|1213720;2|1239|909932|1843489|31977|906|187326;2|1239|186801|186802|186806|1730|142586;2759|4751|5204|162481|231213;2759|4751|4890|147550|5125|110618|5506|61235,Complete,Atrayees
bsdb:169/2/1,Study 169,case-control,30508628,10.1016/j.micpath.2018.11.051,NA,"Xu J, Xiang C, Zhang C, Xu B, Wu J, Wang R, Yang Y, Shi L, Zhang J , Zhan Z",Microbial biomarkers of common tongue coatings in patients with gastric cancer,Microbial pathogenesis,2019,"Gastric cancer, Microbiome, Tongue coating",Experiment 2,China,Homo sapiens,Tongue,UBERON:0001723,Gastric cancer,MONDO:0001056,other coatings,white-thick tongue coating GC patient,gastric cancer with different tongue coatings,72,43,4 weeks,16S,345,RT-qPCR,LEfSe,0.05,FALSE,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,Signature 1,Table 2,10 January 2021,Rimsha Azhar,"WikiWorks,Atrayees",LEfSe analysis of microbial taxa from tongue coating in GC patients,increased,"k__Bacteria|p__Candidatus Saccharibacteria,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Megasphaera|s__Megasphaera micronuciformis,k__Bacteria|p__Bacillota|c__Negativicutes|o__Selenomonadales|f__Selenomonadaceae|g__Selenomonas|s__Selenomonas sputigena,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Segatella|s__Segatella maculosa,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Eubacteriales Family XIII. Incertae Sedis|s__[Eubacterium] nodatum",2|95818;2|1239|186801|186802|541000;2|1239|909932|1843489|31977|906|187326;2|1239|909932|909929|1843491|970|69823;2|976|200643|171549|171552|2974251|439703;2|1239|186801|186802|543314|35518,Complete,Atrayees
bsdb:169/2/2,Study 169,case-control,30508628,10.1016/j.micpath.2018.11.051,NA,"Xu J, Xiang C, Zhang C, Xu B, Wu J, Wang R, Yang Y, Shi L, Zhang J , Zhan Z",Microbial biomarkers of common tongue coatings in patients with gastric cancer,Microbial pathogenesis,2019,"Gastric cancer, Microbiome, Tongue coating",Experiment 2,China,Homo sapiens,Tongue,UBERON:0001723,Gastric cancer,MONDO:0001056,other coatings,white-thick tongue coating GC patient,gastric cancer with different tongue coatings,72,43,4 weeks,16S,345,RT-qPCR,LEfSe,0.05,FALSE,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,Signature 2,Table 2,10 January 2021,Rimsha Azhar,"WikiWorks,Atrayees",LEfSe analysis of microbial taxa from tongue coating in GC patients,decreased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Moraxellales|f__Moraxellaceae|g__Acinetobacter|s__Acinetobacter ursingii,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Ligilactobacillus|s__Ligilactobacillus salivarius,k__Eukaryota|k__Fungi|p__Ascomycota|c__Sordariomycetes|o__Hypocreales",2|1224|1236|2887326|468|469|108980;2|1239|91061|186826|33958|2767887|1624;2759|4751|4890|147550|5125,Complete,Atrayees
bsdb:169/3/1,Study 169,case-control,30508628,10.1016/j.micpath.2018.11.051,NA,"Xu J, Xiang C, Zhang C, Xu B, Wu J, Wang R, Yang Y, Shi L, Zhang J , Zhan Z",Microbial biomarkers of common tongue coatings in patients with gastric cancer,Microbial pathogenesis,2019,"Gastric cancer, Microbiome, Tongue coating",Experiment 3,China,Homo sapiens,Tongue,UBERON:0001723,Gastric cancer,MONDO:0001056,other coatings,yellow-thick tongue coating GC patient,gastric cancer with different tongue coatings,95,20,4 weeks,16S,345,RT-qPCR,LEfSe,0.05,FALSE,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,Signature 1,Table 4,10 January 2021,Rimsha Azhar,"WikiWorks,Atrayees",LEfSe analysis of microbial taxa from tongue coating in GC patients,decreased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Burkholderiaceae|g__Lautropia,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Neisseriaceae|g__Neisseria,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Peptostreptococcaceae|g__Peptostreptococcus,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Gemellaceae|g__Gemella|s__Gemella sanguinis,k__Bacteria|p__Bacteroidota|c__Flavobacteriia|o__Flavobacteriales|f__Flavobacteriaceae|g__Capnocytophaga|s__Capnocytophaga sputigena,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Haemophilus|s__Haemophilus parainfluenzae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pseudomonadales|f__Marinobacteraceae|g__Marinobacter|s__Marinobacter sp. NP39,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Burkholderiaceae",2|1239|186801|186802|541000;2|1224|28216|80840|119060|47670;2|1224|28216|206351|481|482;2|1239|186801|3082720|186804|1257;2|1239|91061|1385|539738|1378|84135;2|976|117743|200644|49546|1016|1019;2|1224|1236|135625|712|724|729;2|1224|1236|72274|2887365|2742|479370;2|1224|28216|80840|119060,Complete,Atrayees
bsdb:169/4/1,Study 169,case-control,30508628,10.1016/j.micpath.2018.11.051,NA,"Xu J, Xiang C, Zhang C, Xu B, Wu J, Wang R, Yang Y, Shi L, Zhang J , Zhan Z",Microbial biomarkers of common tongue coatings in patients with gastric cancer,Microbial pathogenesis,2019,"Gastric cancer, Microbiome, Tongue coating",Experiment 4,China,Homo sapiens,Tongue,UBERON:0001723,Gastric cancer,MONDO:0001056,other coatings,yellow-thin coating GC patient,gastric cancer with yellow thin coating,88,27,4 weeks,16S,345,RT-qPCR,LEfSe,0.05,FALSE,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,Signature 1,Table 3,18 August 2023,Atrayees,Atrayees,LEfSe analysis of microbial taxa from tongue coating in GC patients,decreased,"k__Eukaryota|k__Fungi|p__Ascomycota|c__Dothideomycetes|o__Cladosporiales|f__Cladosporiaceae|g__Cladosporium|s__Cladosporium halotolerans,k__Eukaryota|k__Fungi|p__Ascomycota|c__Sordariomycetes|o__Hypocreales|f__Hypocreaceae|g__Trichoderma",2759|4751|4890|147541|2726946|452563|5498|1052096;2759|4751|4890|147550|5125|5129|5543,Complete,Atrayees
bsdb:170/1/1,Study 170,case-control,29023689,10.1002/ijc.31098,NA,"Liu HX, Tao LL, Zhang J, Zhu YG, Zheng Y, Liu D, Zhou M, Ke H, Shi MM , Qu JM",Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects,International journal of cancer,2018,"16S rRNA, bacteria, lower airway, lung cancer, microbiota",Experiment 1,China,Homo sapiens,Lung,UBERON:0002048,Lung cancer,MONDO:0008903,controls,cancerous site,diagnosis of lung cancer established by histological confirmation,18,24,none,16S,34,Illumina,LEfSe,0.05,FALSE,3.5,NA,NA,NA,decreased,NA,increased,NA,NA,Signature 1,Figure 3,10 January 2021,Fatima Zohra,"Claregrieve1,WikiWorks",Differentially abundant taxa between T (patients in cancerous site) and N (normal) groups,increased,"k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Mycobacteriales,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus",2|201174|1760|85007;2|1239|91061|186826|1300;2|1239|91061|186826|1300|1301,Complete,Claregrieve1
bsdb:170/1/2,Study 170,case-control,29023689,10.1002/ijc.31098,NA,"Liu HX, Tao LL, Zhang J, Zhu YG, Zheng Y, Liu D, Zhou M, Ke H, Shi MM , Qu JM",Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects,International journal of cancer,2018,"16S rRNA, bacteria, lower airway, lung cancer, microbiota",Experiment 1,China,Homo sapiens,Lung,UBERON:0002048,Lung cancer,MONDO:0008903,controls,cancerous site,diagnosis of lung cancer established by histological confirmation,18,24,none,16S,34,Illumina,LEfSe,0.05,FALSE,3.5,NA,NA,NA,decreased,NA,increased,NA,NA,Signature 2,Figure 3,10 January 2021,Fatima Zohra,"Claregrieve1,WikiWorks",Differentially abundant taxa between T (patients in cancerous site) and N (normal) groups,decreased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Moraxellales|f__Moraxellaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Staphylococcaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Staphylococcaceae|g__Staphylococcus",2|1224|1236|2887326|468;2|1239|91061|1385|90964;2|1239|91061|1385|90964|1279,Complete,Claregrieve1
bsdb:170/2/1,Study 170,case-control,29023689,10.1002/ijc.31098,NA,"Liu HX, Tao LL, Zhang J, Zhu YG, Zheng Y, Liu D, Zhou M, Ke H, Shi MM , Qu JM",Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects,International journal of cancer,2018,"16S rRNA, bacteria, lower airway, lung cancer, microbiota",Experiment 2,China,Homo sapiens,Lung,UBERON:0002048,Lung cancer,MONDO:0008903,controls,paired contralateral non-cancerous site in lung cancer patients,paired contralateral non-cancerous site samples from patients with diagnosis of lung cancer established by histological confirmation,18,24,none,16S,34,Illumina,LEfSe,0.05,FALSE,3.5,NA,NA,NA,unchanged,NA,unchanged,NA,NA,Signature 1,Figure 3,10 January 2021,Fatima Zohra,"Claregrieve1,WikiWorks",Differentially abundant taxa between TN (contralateral non-cancerous site) and N (normal) groups,increased,"k__Bacteria|p__Bacteroidota|c__Flavobacteriia|o__Flavobacteriales|f__Flavobacteriaceae|g__Capnocytophaga,k__Bacteria|p__Bacteroidota|c__Flavobacteriia|o__Flavobacteriales|f__Flavobacteriaceae,k__Bacteria|p__Bacteroidota|c__Flavobacteriia|o__Flavobacteriales,k__Bacteria|p__Bacteroidota|c__Flavobacteriia|o__Flavobacteriales|f__Flavobacteriaceae|g__Flavobacterium,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Haemophilus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Leptotrichiaceae|g__Leptotrichia,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Leptotrichiaceae,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Neisseriaceae|g__Neisseria,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Neisseriaceae,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales,k__Bacteria|p__Bacillota|c__Negativicutes|o__Selenomonadales|f__Selenomonadaceae|g__Selenomonas,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus",2|976|117743|200644|49546|1016;2|976|117743|200644|49546;2|976|117743|200644;2|976|117743|200644|49546|237;2|1224|1236|135625|712|724;2|1239|91061|186826;2|32066|203490|203491|1129771|32067;2|32066|203490|203491|1129771;2|1224|28216|206351|481|482;2|1224|28216|206351|481;2|1224|28216|206351;2|1224|1236|135625|712;2|1224|1236|135625;2|1239|909932|909929|1843491|970;2|1239|91061|186826|1300;2|1239|91061|186826|1300|1301,Complete,Claregrieve1
bsdb:170/2/2,Study 170,case-control,29023689,10.1002/ijc.31098,NA,"Liu HX, Tao LL, Zhang J, Zhu YG, Zheng Y, Liu D, Zhou M, Ke H, Shi MM , Qu JM",Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects,International journal of cancer,2018,"16S rRNA, bacteria, lower airway, lung cancer, microbiota",Experiment 2,China,Homo sapiens,Lung,UBERON:0002048,Lung cancer,MONDO:0008903,controls,paired contralateral non-cancerous site in lung cancer patients,paired contralateral non-cancerous site samples from patients with diagnosis of lung cancer established by histological confirmation,18,24,none,16S,34,Illumina,LEfSe,0.05,FALSE,3.5,NA,NA,NA,unchanged,NA,unchanged,NA,NA,Signature 2,Figure 3,10 January 2021,Fatima Zohra,"Claregrieve1,WikiWorks",Differentially abundant taxa between TN (contralateral non-cancerous site) and N (normal) groups,decreased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Moraxellales|f__Moraxellaceae|g__Acinetobacter,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Moraxellales|f__Moraxellaceae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pseudomonadales",2|1224|1236|2887326|468|469;2|1239|186801|3085636|186803;2|1224|1236|2887326|468;2|1224|1236|72274,Complete,Claregrieve1
bsdb:170/3/1,Study 170,case-control,29023689,10.1002/ijc.31098,NA,"Liu HX, Tao LL, Zhang J, Zhu YG, Zheng Y, Liu D, Zhou M, Ke H, Shi MM , Qu JM",Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects,International journal of cancer,2018,"16S rRNA, bacteria, lower airway, lung cancer, microbiota",Experiment 3,China,Homo sapiens,Lung,UBERON:0002048,Sampling site,EFO:0000688,paired contralateral non-cancerous site (TN),cancerous site (T),patients with diagnosis of lung cancer established by histological confirmation,24,24,none,16S,34,Illumina,LEfSe,0.05,FALSE,3.5,NA,NA,NA,unchanged,NA,unchanged,NA,NA,Signature 1,Figure 3,10 January 2021,Fatima Zohra,"WikiWorks,Folakunmi",Differentially abundant taxa between T (patients in cancerous site) and TN (contralateral non-cancerous site) groups,increased,"k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales,k__Bacteria|p__Candidatus Saccharibacteria,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Dialister",2|1239|91061|1385;2|95818;2|1239|909932|1843489|31977|39948,Complete,Folakunmi
bsdb:170/4/1,Study 170,case-control,29023689,10.1002/ijc.31098,NA,"Liu HX, Tao LL, Zhang J, Zhu YG, Zheng Y, Liu D, Zhou M, Ke H, Shi MM , Qu JM",Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects,International journal of cancer,2018,"16S rRNA, bacteria, lower airway, lung cancer, microbiota",Experiment 4,China,Homo sapiens,Lung,UBERON:0002048,Lung cancer,MONDO:0008903,control group with no antibiotics,cancerous site with no antibiotics,patients who have diagnosis of lung cancer established by histological confirmation,8,13,3 months,16S,34,Illumina,LEfSe,0.05,FALSE,3.5,NA,NA,NA,decreased,NA,increased,NA,NA,Signature 1,Supplemental Figure S1,10 January 2021,Fatima Zohra,"Claregrieve1,WikiWorks",Significant bacterial difference between To (samples from cancerous site who received no antibiotics prior to 3 months) and No (normal samples who received no antibiotics),increased,k__Bacteria|p__Bacteroidota|c__Flavobacteriia|o__Flavobacteriales|f__Flavobacteriaceae|g__Capnocytophaga,2|976|117743|200644|49546|1016,Complete,Folakunmi
bsdb:170/4/2,Study 170,case-control,29023689,10.1002/ijc.31098,NA,"Liu HX, Tao LL, Zhang J, Zhu YG, Zheng Y, Liu D, Zhou M, Ke H, Shi MM , Qu JM",Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects,International journal of cancer,2018,"16S rRNA, bacteria, lower airway, lung cancer, microbiota",Experiment 4,China,Homo sapiens,Lung,UBERON:0002048,Lung cancer,MONDO:0008903,control group with no antibiotics,cancerous site with no antibiotics,patients who have diagnosis of lung cancer established by histological confirmation,8,13,3 months,16S,34,Illumina,LEfSe,0.05,FALSE,3.5,NA,NA,NA,decreased,NA,increased,NA,NA,Signature 2,Supplemental Figure S1,10 January 2021,Fatima Zohra,"Claregrieve1,WikiWorks",Significant bacterial difference between To (samples from cancerous site who received no antibiotics prior to 3 months) and No (normal samples who received no antibiotics),decreased,"k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Comamonadaceae,k__Bacteria|c__Deltaproteobacteria,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Moraxellales|f__Moraxellaceae,k__Bacteria|p__Myxococcota|c__Myxococcia|o__Myxococcales,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Rhodobacterales|f__Paracoccaceae|g__Paracoccus,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Rhodobacterales|f__Paracoccaceae,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Rhodobacterales,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Staphylococcaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Staphylococcaceae|g__Staphylococcus,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pseudomonadales,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria,k__Bacteria|p__Bacteroidota|c__Chitinophagia|o__Chitinophagales|f__Chitinophagaceae,k__Bacteria|p__Bacillota|c__Clostridia,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|s__Clostridiales bacterium,k__Bacteria|p__Bacteroidota,k__Bacteria|p__Bacteroidota|c__Chitinophagia|o__Chitinophagales|f__Chitinophagaceae|g__Hydrotalea",2|1224|28216|80840|80864;2|28221;2|1224|1236|2887326|468;2|2818505|32015|29;2|1224|28211|204455|31989|265;2|1224|28211|204455|31989;2|1224|28211|204455;2|1239|91061|1385|90964;2|1239|91061|1385|90964|1279;2|1224|1236|72274;2|1224|28216|80840;2|1224|28211;2|976|1853228|1853229|563835;2|1239|186801;2|1239|186801|186802|1898207;2|976;2|976|1853228|1853229|563835|1004300,Complete,Folakunmi
bsdb:170/5/1,Study 170,case-control,29023689,10.1002/ijc.31098,NA,"Liu HX, Tao LL, Zhang J, Zhu YG, Zheng Y, Liu D, Zhou M, Ke H, Shi MM , Qu JM",Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects,International journal of cancer,2018,"16S rRNA, bacteria, lower airway, lung cancer, microbiota",Experiment 5,China,Homo sapiens,Lung,UBERON:0002048,Lung cancer,MONDO:0008903,control group with no antibiotics (No),contralateral non-cancerous site with no antibiotics (TNo),contralateral non-cancerous site samples from lung cancer patients who received no antibiotics in  the prior three months,8,13,3 months,16S,34,Illumina,LEfSe,0.05,FALSE,3.5,NA,NA,NA,increased,NA,unchanged,NA,NA,Signature 1,supplementary figure 1,3 February 2024,Folakunmi,Folakunmi,Differentially abundant taxa between TNo (samples from the contralateral noncancerous site of lung cancer patients who received no antibiotics prior to 3 months) and No (control samples who received no antibiotics),increased,"k__Bacteria|p__Bacillota|c__Bacilli,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Neisseriaceae|g__Neisseria,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Neisseriaceae,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Staphylococcaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Staphylococcaceae|g__Staphylococcus",2|1239|91061;2|1239|91061|186826;2|1224|28216|206351|481|482;2|1224|28216|206351|481;2|1224|28216|206351;2|1239|91061|1385|90964;2|1239|91061|1385|90964|1279,Complete,Folakunmi
bsdb:170/5/2,Study 170,case-control,29023689,10.1002/ijc.31098,NA,"Liu HX, Tao LL, Zhang J, Zhu YG, Zheng Y, Liu D, Zhou M, Ke H, Shi MM , Qu JM",Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects,International journal of cancer,2018,"16S rRNA, bacteria, lower airway, lung cancer, microbiota",Experiment 5,China,Homo sapiens,Lung,UBERON:0002048,Lung cancer,MONDO:0008903,control group with no antibiotics (No),contralateral non-cancerous site with no antibiotics (TNo),contralateral non-cancerous site samples from lung cancer patients who received no antibiotics in  the prior three months,8,13,3 months,16S,34,Illumina,LEfSe,0.05,FALSE,3.5,NA,NA,NA,increased,NA,unchanged,NA,NA,Signature 2,supplementary figure 1,3 February 2024,Folakunmi,Folakunmi,Differentially abundant taxa between TNo (samples from the contralateral noncancerous site of lung cancer patients who received no antibiotics prior to 3 months) and No (control samples who received no antibiotics),decreased,"k__Bacteria|s__uncultured bacterium,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Coprococcus,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Moraxellales|f__Moraxellaceae|g__Acinetobacter,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Caulobacterales|f__Caulobacteraceae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Moraxellales|f__Moraxellaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pseudomonadales,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria,k__Bacteria|p__Bacteroidota|c__Chitinophagia|o__Chitinophagales|f__Chitinophagaceae|g__Hydrotalea,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae,k__Bacteria|p__Bacillota|c__Clostridia,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|s__Clostridiales bacterium",2|77133;2|1239|186801|3085636|186803|33042;2|1224|1236|2887326|468|469;2|1224|28211|204458|76892;2|1224|1236|2887326|468;2|976|200643|171549|815;2|976|200643|171549|815|816;2|1224|28216|80840;2|1224|1236|72274;2|1224|28211;2|976|1853228|1853229|563835|1004300;2|1239|186801|3085636|186803;2|1239|186801;2|1239|186801|186802|1898207,Complete,Folakunmi
bsdb:170/6/1,Study 170,case-control,29023689,10.1002/ijc.31098,NA,"Liu HX, Tao LL, Zhang J, Zhu YG, Zheng Y, Liu D, Zhou M, Ke H, Shi MM , Qu JM",Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects,International journal of cancer,2018,"16S rRNA, bacteria, lower airway, lung cancer, microbiota",Experiment 6,China,Homo sapiens,Lung,UBERON:0002048,Sampling site,EFO:0000688,contralateral non-cancerous site with no antibiotics (TNo),Cancerous site with no antibiotics (To),cancerous site samples from lung cancer patients who received no antibiotics in  the prior three months,13,13,3 months,16S,34,Illumina,LEfSe,0.05,FALSE,3.5,NA,NA,NA,decreased,NA,unchanged,NA,NA,Signature 1,supplementary figure 1,4 February 2024,Folakunmi,Folakunmi,Differentially abundant taxa between TNo (samples from the contralateral noncancerous site of lung cancer patients who received no antibiotics prior to 3 months) and To (cancerous site samples of lung cancer patients who received no antibiotics prior to 3 months),increased,"k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Mycobacteriales|f__Corynebacteriaceae,k__Bacteria|p__Bacillota|c__Negativicutes|o__Acidaminococcales|f__Acidaminococcaceae,k__Bacteria|p__Bacillota|c__Negativicutes|o__Acidaminococcales|f__Acidaminococcaceae|g__Phascolarctobacterium",2|201174|1760|85007|1653;2|1239|909932|1843488|909930;2|1239|909932|1843488|909930|33024,Complete,Folakunmi
bsdb:171/1/1,Study 171,case-control,31428073,10.3389/fmicb.2019.01780,NA,"Kageyama S, Takeshita T, Takeuchi K, Asakawa M, Matsumi R, Furuta M, Shibata Y, Nagai K, Ikebe M, Morita M, Masuda M, Toh Y, Kiyohara Y, Ninomiya T , Yamashita Y",Characteristics of the Salivary Microbiota in Patients With Various Digestive Tract Cancers,Frontiers in microbiology,2019,"colorectal cancer, digestive tract cancer, esophageal cancer, gastric cancer, oral microbiota, pharyngeal cancer, saliva, tongue cancer",Experiment 1,Japan,Homo sapiens,Saliva,UBERON:0001836,Digestive system cancer,MONDO:0002516,controls,digestive tract cancer patients,"patients with digestive tract cancers (tongue/pharynx, esophagus, stomach and/or large intestine)",118,59,1 month,16S,12,Ion Torrent,LEfSe,0.05,FALSE,3,"age,sex",NA,NA,increased,increased,unchanged,NA,NA,Signature 1,"Figure 3, Figure S1",10 January 2021,Rimsha Azhar,"Claregrieve1,WikiWorks",Bacterial species corresponding to the differentially abundant OTUs between digestive tract cancer patients and control subjects,increased,"k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Mycobacteriales|f__Corynebacteriaceae|g__Corynebacterium,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae|g__Fusobacterium,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Neisseriaceae|g__Neisseria,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Neisseriaceae|g__Neisseria|s__Neisseria elongata,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae|g__Porphyromonas|s__Porphyromonas gingivalis,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales|f__Actinomycetaceae|g__Schaalia|s__Schaalia odontolytica,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus|s__Streptococcus parasanguinis,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus|s__Streptococcus sanguinis,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus|s__Streptococcus sp.,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Veillonella",2|201174|1760|85007|1653|1716;2|32066|203490|203491|203492|848;2|1224|28216|206351|481|482;2|1224|28216|206351|481|482|495;2|976|200643|171549|171551|836|837;2|201174|1760|2037|2049|2529408|1660;2|1239|91061|186826|1300|1301|1318;2|1239|91061|186826|1300|1301|1305;2|1239|91061|186826|1300|1301|1306;2|1239|909932|1843489|31977|29465,Complete,Claregrieve1
bsdb:171/1/2,Study 171,case-control,31428073,10.3389/fmicb.2019.01780,NA,"Kageyama S, Takeshita T, Takeuchi K, Asakawa M, Matsumi R, Furuta M, Shibata Y, Nagai K, Ikebe M, Morita M, Masuda M, Toh Y, Kiyohara Y, Ninomiya T , Yamashita Y",Characteristics of the Salivary Microbiota in Patients With Various Digestive Tract Cancers,Frontiers in microbiology,2019,"colorectal cancer, digestive tract cancer, esophageal cancer, gastric cancer, oral microbiota, pharyngeal cancer, saliva, tongue cancer",Experiment 1,Japan,Homo sapiens,Saliva,UBERON:0001836,Digestive system cancer,MONDO:0002516,controls,digestive tract cancer patients,"patients with digestive tract cancers (tongue/pharynx, esophagus, stomach and/or large intestine)",118,59,1 month,16S,12,Ion Torrent,LEfSe,0.05,FALSE,3,"age,sex",NA,NA,increased,increased,unchanged,NA,NA,Signature 2,"Figure 3, Figure S1",10 January 2021,Rimsha Azhar,"Claregrieve1,WikiWorks",Bacterial species corresponding to the differentially abundant OTUs between digestive tract cancer patients and control subjects,decreased,"k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales|f__Actinomycetaceae|g__Actinomyces|s__Actinomyces graevenitzii,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae|g__Porphyromonas,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae|g__Porphyromonas|s__Porphyromonas pasteri,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae|g__Porphyromonas|s__Porphyromonas sp.,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella|s__Prevotella melaninogenica,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micrococcales|f__Micrococcaceae|g__Rothia,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micrococcales|f__Micrococcaceae|g__Rothia|s__Rothia dentocariosa,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae|g__Solobacterium|s__Solobacterium moorei",2|201174|1760|2037|2049|1654|55565;2|976|200643|171549|171551|836;2|976|200643|171549|171551|836|1583331;2|976|200643|171549|171551|836|1924944;2|976|200643|171549|171552|838;2|976|200643|171549|171552|838|28132;2|201174|1760|85006|1268|32207;2|201174|1760|85006|1268|32207|2047;2|1239|526524|526525|128827|123375|102148,Complete,Claregrieve1
bsdb:171/2/1,Study 171,case-control,31428073,10.3389/fmicb.2019.01780,NA,"Kageyama S, Takeshita T, Takeuchi K, Asakawa M, Matsumi R, Furuta M, Shibata Y, Nagai K, Ikebe M, Morita M, Masuda M, Toh Y, Kiyohara Y, Ninomiya T , Yamashita Y",Characteristics of the Salivary Microbiota in Patients With Various Digestive Tract Cancers,Frontiers in microbiology,2019,"colorectal cancer, digestive tract cancer, esophageal cancer, gastric cancer, oral microbiota, pharyngeal cancer, saliva, tongue cancer",Experiment 2,China,Homo sapiens,Saliva,UBERON:0001836,Tongue neoplasm,EFO:0003871,controls,tongue/pharyngeal cancer patients,patients with tongue/pharyngeal cancer,26,13,1 month,16S,12,Ion Torrent,LEfSe,0.05,FALSE,3,"age,sex",NA,NA,increased,increased,unchanged,NA,NA,Signature 1,"Figure S3, Figure 5",10 January 2021,Rimsha Azhar,"Claregrieve1,WikiWorks",Bacterial species corresponding to the differentially abundant OTUs between tongue/pharyngeal cancer patients and control subjects,increased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Aggregatibacter|s__Aggregatibacter segnis,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Mycobacteriales|f__Corynebacteriaceae|g__Corynebacterium,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Leptotrichiaceae|g__Leptotrichia,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Neisseriaceae|g__Neisseria,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae|g__Porphyromonas|s__Porphyromonas gingivalis,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus|s__Streptococcus parasanguinis,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus|s__Streptococcus sanguinis",2|1224|1236|135625|712|416916|739;2|201174|1760|85007|1653|1716;2|32066|203490|203491|1129771|32067;2|1224|28216|206351|481|482;2|976|200643|171549|171551|836|837;2|976|200643|171549|171552|838;2|1239|91061|186826|1300|1301|1318;2|1239|91061|186826|1300|1301|1305,Complete,Claregrieve1
bsdb:171/2/2,Study 171,case-control,31428073,10.3389/fmicb.2019.01780,NA,"Kageyama S, Takeshita T, Takeuchi K, Asakawa M, Matsumi R, Furuta M, Shibata Y, Nagai K, Ikebe M, Morita M, Masuda M, Toh Y, Kiyohara Y, Ninomiya T , Yamashita Y",Characteristics of the Salivary Microbiota in Patients With Various Digestive Tract Cancers,Frontiers in microbiology,2019,"colorectal cancer, digestive tract cancer, esophageal cancer, gastric cancer, oral microbiota, pharyngeal cancer, saliva, tongue cancer",Experiment 2,China,Homo sapiens,Saliva,UBERON:0001836,Tongue neoplasm,EFO:0003871,controls,tongue/pharyngeal cancer patients,patients with tongue/pharyngeal cancer,26,13,1 month,16S,12,Ion Torrent,LEfSe,0.05,FALSE,3,"age,sex",NA,NA,increased,increased,unchanged,NA,NA,Signature 2,"Figure S3, Figure 5",10 January 2021,Rimsha Azhar,"Claregrieve1,WikiWorks",Bacterial species corresponding to the differentially abundant OTUs between tongue/pharyngeal cancer patients and control subjects,decreased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella|s__Prevotella melaninogenica,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micrococcales|f__Micrococcaceae|g__Rothia|s__Rothia dentocariosa,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus|s__Streptococcus australis",2|976|200643|171549|171552|838|28132;2|201174|1760|85006|1268|32207|2047;2|1239|91061|186826|1300|1301;2|1239|91061|186826|1300|1301|113107,Complete,Claregrieve1
bsdb:171/3/1,Study 171,case-control,31428073,10.3389/fmicb.2019.01780,NA,"Kageyama S, Takeshita T, Takeuchi K, Asakawa M, Matsumi R, Furuta M, Shibata Y, Nagai K, Ikebe M, Morita M, Masuda M, Toh Y, Kiyohara Y, Ninomiya T , Yamashita Y",Characteristics of the Salivary Microbiota in Patients With Various Digestive Tract Cancers,Frontiers in microbiology,2019,"colorectal cancer, digestive tract cancer, esophageal cancer, gastric cancer, oral microbiota, pharyngeal cancer, saliva, tongue cancer",Experiment 3,China,Homo sapiens,Saliva,UBERON:0001836,Esophageal cancer,MONDO:0007576,controls,esophageal cancer patients,patients with esophageal cancer,24,12,1 month,16S,12,Ion Torrent,LEfSe,0.05,FALSE,3,"age,sex",NA,NA,increased,increased,increased,NA,NA,Signature 1,"Figure S3, Figure 5",10 January 2021,WikiWorks,"Claregrieve1,WikiWorks",Bacterial species corresponding to the differentially abundant OTUs between esophageal cancer patients and control subjects,increased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Aggregatibacter|s__Aggregatibacter segnis,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Mycobacteriales|f__Corynebacteriaceae|g__Corynebacterium,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Leptotrichiaceae|g__Leptotrichia|s__Leptotrichia hofstadii,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Leptotrichiaceae|g__Leptotrichia|s__Leptotrichia sp.,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Megasphaera|s__Megasphaera micronuciformis,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae|g__Porphyromonas|s__Porphyromonas gingivalis,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus|s__Streptococcus sp.",2|1224|1236|135625|712|416916|739;2|201174|1760|85007|1653|1716;2|32066|203490|203491|1129771|32067|157688;2|32066|203490|203491|1129771|32067|104608;2|1239|909932|1843489|31977|906|187326;2|976|200643|171549|171551|836|837;2|1239|91061|186826|1300|1301|1306,Complete,Claregrieve1
bsdb:171/3/2,Study 171,case-control,31428073,10.3389/fmicb.2019.01780,NA,"Kageyama S, Takeshita T, Takeuchi K, Asakawa M, Matsumi R, Furuta M, Shibata Y, Nagai K, Ikebe M, Morita M, Masuda M, Toh Y, Kiyohara Y, Ninomiya T , Yamashita Y",Characteristics of the Salivary Microbiota in Patients With Various Digestive Tract Cancers,Frontiers in microbiology,2019,"colorectal cancer, digestive tract cancer, esophageal cancer, gastric cancer, oral microbiota, pharyngeal cancer, saliva, tongue cancer",Experiment 3,China,Homo sapiens,Saliva,UBERON:0001836,Esophageal cancer,MONDO:0007576,controls,esophageal cancer patients,patients with esophageal cancer,24,12,1 month,16S,12,Ion Torrent,LEfSe,0.05,FALSE,3,"age,sex",NA,NA,increased,increased,increased,NA,NA,Signature 2,"Figure S3, Figure 5",10 January 2021,Rimsha Azhar,"Claregrieve1,WikiWorks",Bacterial species corresponding to the differentially abundant OTUs between esophageal cancer patients and control subjects,decreased,"k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales|f__Actinomycetaceae|g__Actinomyces,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella|s__Prevotella melaninogenica,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micrococcales|f__Micrococcaceae|g__Rothia|s__Rothia dentocariosa,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Neisseriaceae|g__Neisseria,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus|s__Streptococcus australis",2|201174|1760|2037|2049|1654;2|976|200643|171549|171552|838|28132;2|201174|1760|85006|1268|32207|2047;2|1239|91061|186826|1300|1301;2|1224|28216|206351|481|482;2|1239|91061|186826|1300|1301|113107,Complete,Claregrieve1
bsdb:171/4/1,Study 171,case-control,31428073,10.3389/fmicb.2019.01780,NA,"Kageyama S, Takeshita T, Takeuchi K, Asakawa M, Matsumi R, Furuta M, Shibata Y, Nagai K, Ikebe M, Morita M, Masuda M, Toh Y, Kiyohara Y, Ninomiya T , Yamashita Y",Characteristics of the Salivary Microbiota in Patients With Various Digestive Tract Cancers,Frontiers in microbiology,2019,"colorectal cancer, digestive tract cancer, esophageal cancer, gastric cancer, oral microbiota, pharyngeal cancer, saliva, tongue cancer",Experiment 4,China,Homo sapiens,Saliva,UBERON:0001836,Colorectal cancer,EFO:0005842,controls,colorectal cancer patients,patients with colorectal cancer,48,24,1 month,16S,12,Ion Torrent,LEfSe,0.05,FALSE,3,"age,sex",NA,NA,unchanged,unchanged,unchanged,NA,NA,Signature 1,"Figure S3, Figure 5",10 January 2021,Rimsha Azhar,"Claregrieve1,WikiWorks",Bacterial species corresponding to the differentially abundant OTUs between colorectal cancer patients and control subjects,increased,"k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Mycobacteriales|f__Corynebacteriaceae|g__Corynebacterium,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Megasphaera|s__Megasphaera micronuciformis,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Neisseriaceae|g__Neisseria,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Oribacterium|s__Oribacterium sinus,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae|g__Porphyromonas|s__Porphyromonas gingivalis,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella|s__Prevotella sp.,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales|f__Actinomycetaceae|g__Schaalia|s__Schaalia odontolytica,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Kitasatosporales|f__Streptomycetaceae|g__Streptomyces|s__Streptomyces paraguayensis,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus|s__Streptococcus parasanguinis",2|201174|1760|85007|1653|1716;2|1239|909932|1843489|31977|906|187326;2|1224|28216|206351|481|482;2|1239|186801|3085636|186803|265975|237576;2|976|200643|171549|171551|836|837;2|976|200643|171549|171552|838|59823;2|201174|1760|2037|2049|2529408|1660;2|201174|1760|85011|2062|1883|68251;2|1239|91061|186826|1300|1301|1318,Complete,Claregrieve1
bsdb:171/4/2,Study 171,case-control,31428073,10.3389/fmicb.2019.01780,NA,"Kageyama S, Takeshita T, Takeuchi K, Asakawa M, Matsumi R, Furuta M, Shibata Y, Nagai K, Ikebe M, Morita M, Masuda M, Toh Y, Kiyohara Y, Ninomiya T , Yamashita Y",Characteristics of the Salivary Microbiota in Patients With Various Digestive Tract Cancers,Frontiers in microbiology,2019,"colorectal cancer, digestive tract cancer, esophageal cancer, gastric cancer, oral microbiota, pharyngeal cancer, saliva, tongue cancer",Experiment 4,China,Homo sapiens,Saliva,UBERON:0001836,Colorectal cancer,EFO:0005842,controls,colorectal cancer patients,patients with colorectal cancer,48,24,1 month,16S,12,Ion Torrent,LEfSe,0.05,FALSE,3,"age,sex",NA,NA,unchanged,unchanged,unchanged,NA,NA,Signature 2,"Figure S3, Figure 5",10 January 2021,Rimsha Azhar,"Claregrieve1,WikiWorks",Bacterial species corresponding to the differentially abundant OTUs between colorectal cancer patients and control subjects,decreased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae|g__Porphyromonas|s__Porphyromonas pasteri,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella|s__Prevotella melaninogenica,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella|s__Prevotella sp.,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus",2|976|200643|171549|171551|836|1583331;2|976|200643|171549|171552|838;2|976|200643|171549|171552|838|28132;2|976|200643|171549|171552|838|59823;2|1239|91061|186826|1300|1301,Complete,Claregrieve1
bsdb:171/5/1,Study 171,case-control,31428073,10.3389/fmicb.2019.01780,NA,"Kageyama S, Takeshita T, Takeuchi K, Asakawa M, Matsumi R, Furuta M, Shibata Y, Nagai K, Ikebe M, Morita M, Masuda M, Toh Y, Kiyohara Y, Ninomiya T , Yamashita Y",Characteristics of the Salivary Microbiota in Patients With Various Digestive Tract Cancers,Frontiers in microbiology,2019,"colorectal cancer, digestive tract cancer, esophageal cancer, gastric cancer, oral microbiota, pharyngeal cancer, saliva, tongue cancer",Experiment 5,China,Homo sapiens,Saliva,UBERON:0001836,Gastric cancer,MONDO:0001056,controls,gastric cancer patients,patients with gastric cancer,20,10,1 month,16S,12,Ion Torrent,LEfSe,0.05,FALSE,3,"age,sex",NA,NA,unchanged,unchanged,unchanged,NA,NA,Signature 1,"Figure S3, Figure 5",10 January 2021,Rimsha Azhar,"Claregrieve1,WikiWorks",Bacterial species corresponding to the differentially abundant OTUs between gastric cancer patients and control subjects,increased,"k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae|g__Fusobacterium|s__Fusobacterium periodonticum,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Gemellaceae|g__Gemella|s__Gemella sanguinis,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Haemophilus|s__Haemophilus parainfluenzae,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Neisseriales|f__Neisseriaceae|g__Neisseria,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae|g__Porphyromonas|s__Porphyromonas gingivalis,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus",2|32066|203490|203491|203492|848|860;2|1239|91061|1385|539738|1378|84135;2|1224|1236|135625|712|724|729;2|1224|28216|206351|481|482;2|976|200643|171549|171551|836|837;2|1239|91061|186826|1300|1301,Complete,Claregrieve1
bsdb:171/5/2,Study 171,case-control,31428073,10.3389/fmicb.2019.01780,NA,"Kageyama S, Takeshita T, Takeuchi K, Asakawa M, Matsumi R, Furuta M, Shibata Y, Nagai K, Ikebe M, Morita M, Masuda M, Toh Y, Kiyohara Y, Ninomiya T , Yamashita Y",Characteristics of the Salivary Microbiota in Patients With Various Digestive Tract Cancers,Frontiers in microbiology,2019,"colorectal cancer, digestive tract cancer, esophageal cancer, gastric cancer, oral microbiota, pharyngeal cancer, saliva, tongue cancer",Experiment 5,China,Homo sapiens,Saliva,UBERON:0001836,Gastric cancer,MONDO:0001056,controls,gastric cancer patients,patients with gastric cancer,20,10,1 month,16S,12,Ion Torrent,LEfSe,0.05,FALSE,3,"age,sex",NA,NA,unchanged,unchanged,unchanged,NA,NA,Signature 2,"Figure S3, Figure 5",10 January 2021,WikiWorks,"Claregrieve1,WikiWorks",Bacterial species corresponding to the differentially abundant OTUs between gastric cancer patients and control subjects,decreased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae|g__Porphyromonas|s__Porphyromonas sp.,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micrococcales|f__Micrococcaceae|g__Rothia,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus",2|1239|186801|3085636|186803;2|976|200643|171549|171551|836|1924944;2|976|200643|171549|171552|838;2|201174|1760|85006|1268|32207;2|1239|91061|186826|1300|1301,Complete,Claregrieve1
bsdb:172/1/1,Study 172,case-control,31481657,10.1038/s41598-019-48768-z,NA,"Newman TM, Krishnan LP, Lee J , Adami GR",Microbiomic differences at cancer-prone oral mucosa sites with marijuana usage,Scientific reports,2019,NA,Experiment 1,United States of America,Homo sapiens,Saliva,UBERON:0001836,Cannabis use,EFO:0007585,controls (lateral border of tongue),marijuana usage group,"using marijuana on 20 or more days in the past month associated with a distinct oral microbiota at the most common sites of HNSCC, the lateral border of the tongue",19,20,1 month,16S,123,Illumina,LEfSe,NA,FALSE,NA,"age,sex",NA,unchanged,unchanged,NA,NA,NA,unchanged,Signature 1,Figure 3,10 January 2021,Utsav Patel,"WikiWorks,Atrayees,ChiomaBlessing",Abundant taxa at the lateral border of the tongue in the marijuana usage group VS controls,increased,"k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales|f__Actinomycetaceae|g__Actinomyces|s__Actinomyces graevenitzii,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Hyphomicrobiales|f__Boseaceae|g__Bosea,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Hyphomicrobiales|f__Boseaceae|g__Bosea|s__Bosea vestrisii,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Comamonadaceae,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Comamonadaceae|g__Delftia,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Comamonadaceae|g__Delftia|s__Delftia acidovorans,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Sphaerotilaceae|g__Leptothrix,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micrococcales|f__Micrococcaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Anaerovoracaceae|g__Mogibacterium,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micrococcales|f__Micrococcaceae|g__Rothia,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micrococcales|f__Micrococcaceae|g__Rothia|s__Rothia mucilaginosa,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Veillonella|s__Veillonella atypica",2|201174|1760|2037|2049|1654|55565;2|1224|28211|356|2831100|85413;2|1224|28211|356|2831100|85413|151416;2|1224|28216|80840|80864;2|1224|28216|80840|80864|80865;2|1224|28216|80840|80864|80865|80866;2|1224|28216|80840|2975441|88;2|201174|1760|85006|1268;2|1239|186801|3082720|3030910|86331;2|201174|1760|85006|1268|32207;2|201174|1760|85006|1268|32207|43675;2|1239|909932|1843489|31977|29465|39777,Complete,Atrayees
bsdb:172/1/2,Study 172,case-control,31481657,10.1038/s41598-019-48768-z,NA,"Newman TM, Krishnan LP, Lee J , Adami GR",Microbiomic differences at cancer-prone oral mucosa sites with marijuana usage,Scientific reports,2019,NA,Experiment 1,United States of America,Homo sapiens,Saliva,UBERON:0001836,Cannabis use,EFO:0007585,controls (lateral border of tongue),marijuana usage group,"using marijuana on 20 or more days in the past month associated with a distinct oral microbiota at the most common sites of HNSCC, the lateral border of the tongue",19,20,1 month,16S,123,Illumina,LEfSe,NA,FALSE,NA,"age,sex",NA,unchanged,unchanged,NA,NA,NA,unchanged,Signature 2,Figure 3,10 January 2021,Utsav Patel,"WikiWorks,Atrayees,ChiomaBlessing",Abundant taxa at the lateral border of the tongue in the marijuana usage group VS controls,decreased,"k__Bacteria|p__Bacteroidota,k__Bacteria|p__Bacteroidota|c__Flavobacteriia|o__Flavobacteriales|f__Weeksellaceae|g__Bergeyella,k__Bacteria|p__Bacteroidota|c__Flavobacteriia|o__Flavobacteriales|f__Weeksellaceae|g__Bergeyella|s__Bergeyella sp.,k__Bacteria|p__Bacteroidota|c__Flavobacteriia|o__Flavobacteriales|f__Flavobacteriaceae|g__Capnocytophaga,k__Bacteria|p__Bacteroidota|c__Flavobacteriia|o__Flavobacteriales|f__Flavobacteriaceae,k__Bacteria|p__Bacteroidota|c__Flavobacteriia|o__Flavobacteriales,k__Bacteria|p__Bacteroidota|c__Flavobacteriia,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia,k__Bacteria|p__Fusobacteriota,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae|g__Fusobacterium,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Hoylesella|s__Hoylesella nanceiensis,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Porphyromonadaceae|g__Porphyromonas",2|976;2|976|117743|200644|2762318|59735;2|976|117743|200644|2762318|59735|1962306;2|976|117743|200644|49546|1016;2|976|117743|200644|49546;2|976|117743|200644;2|976|117743;2|32066|203490|203491|203492;2|32066|203490|203491;2|32066|203490;2|32066;2|32066|203490|203491|203492|848;2|976|200643|171549|171552|2974257|425941;2|976|200643|171549|171551;2|976|200643|171549|171551|836,Complete,Atrayees
bsdb:172/2/1,Study 172,case-control,31481657,10.1038/s41598-019-48768-z,NA,"Newman TM, Krishnan LP, Lee J , Adami GR",Microbiomic differences at cancer-prone oral mucosa sites with marijuana usage,Scientific reports,2019,NA,Experiment 2,United States of America,Homo sapiens,Pharynx,UBERON:0006562,Cannabis use,EFO:0007585,controls (oral pharynx),marijuana usage group,"using marijuana on 20 or more days in the past month associated with a distinct oral microbiota at the most common sites of HNSCC, the oral pharynx.",19,20,1 month,16S,123,Illumina,LEfSe,NA,FALSE,NA,"age,sex",NA,unchanged,unchanged,NA,NA,NA,unchanged,Signature 1,Figure 3,10 January 2021,Utsav Patel,"WikiWorks,Atrayees,ChiomaBlessing",Abundant taxa at the oral pharynx in the marijuana usage group VS controls,increased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Anaerovoracaceae|g__Mogibacterium,k__Bacteria|p__Bacillota|c__Negativicutes,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae,k__Bacteria|p__Bacillota|c__Negativicutes|o__Selenomonadales|f__Selenomonadaceae,k__Bacteria|p__Bacillota|c__Negativicutes|o__Selenomonadales,k__Bacteria|p__Bacillota|c__Negativicutes|o__Selenomonadales|f__Selenomonadaceae|g__Selenomonas,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Veillonella,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales",2|1239|186801|3082720|3030910|86331;2|1239|909932;2|1239|186801|186802|541000;2|1239|909932|909929|1843491;2|1239|909932|909929;2|1239|909932|909929|1843491|970;2|1239|909932|1843489|31977|29465;2|1239|909932|1843489|31977;2|1239|909932|1843489,Complete,Atrayees
bsdb:172/2/2,Study 172,case-control,31481657,10.1038/s41598-019-48768-z,NA,"Newman TM, Krishnan LP, Lee J , Adami GR",Microbiomic differences at cancer-prone oral mucosa sites with marijuana usage,Scientific reports,2019,NA,Experiment 2,United States of America,Homo sapiens,Pharynx,UBERON:0006562,Cannabis use,EFO:0007585,controls (oral pharynx),marijuana usage group,"using marijuana on 20 or more days in the past month associated with a distinct oral microbiota at the most common sites of HNSCC, the oral pharynx.",19,20,1 month,16S,123,Illumina,LEfSe,NA,FALSE,NA,"age,sex",NA,unchanged,unchanged,NA,NA,NA,unchanged,Signature 2,Figure 3,10 January 2021,Utsav Patel,"WikiWorks,Atrayees,ChiomaBlessing",Abundant taxa at the oral pharynx in the marijuana usage group VS controls,decreased,"k__Bacteria|p__Bacteroidota|c__Flavobacteriia|o__Flavobacteriales|f__Weeksellaceae|g__Bergeyella,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus",2|976|117743|200644|2762318|59735;2|1239|91061|186826;2|1239|91061|186826|1300;2|1239|91061|186826|1300|1301,Complete,Atrayees
bsdb:172/3/1,Study 172,case-control,31481657,10.1038/s41598-019-48768-z,NA,"Newman TM, Krishnan LP, Lee J , Adami GR",Microbiomic differences at cancer-prone oral mucosa sites with marijuana usage,Scientific reports,2019,NA,Experiment 3,United States of America,Homo sapiens,Saliva,UBERON:0001836,Cannabis use,EFO:0007585,controls (lateral border of tongue),marijuana usage group,"using marijuana on 20 or more days in the past month associated with a distinct oral microbiota at the most common sites of HNSCC, the lateral border of the tongue",19,20,1 month,16S,123,Illumina,DESeq2,NA,TRUE,NA,"age,sex",NA,unchanged,unchanged,NA,NA,NA,unchanged,Signature 1,table 1,10 January 2021,Utsav Patel,"WikiWorks,Atrayees,ChiomaBlessing",DESeq2 differentiation of taxa on the genus level at the lateral border of tongue in the marijuana usage group VS controls,increased,"k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Hyphomicrobiales|f__Boseaceae|g__Bosea,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Comamonadaceae|g__Delftia,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Burkholderiaceae|g__Lautropia,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Sphaerotilaceae|g__Leptothrix,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pseudomonadales|f__Pseudomonadaceae|g__Pseudomonas,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micrococcales|f__Micrococcaceae|g__Rothia",2|1224|28211|356|2831100|85413;2|1224|28216|80840|80864|80865;2|1224|28216|80840|119060|47670;2|1224|28216|80840|2975441|88;2|1224|1236|72274|135621|286;2|201174|1760|85006|1268|32207,Complete,Atrayees
bsdb:172/3/2,Study 172,case-control,31481657,10.1038/s41598-019-48768-z,NA,"Newman TM, Krishnan LP, Lee J , Adami GR",Microbiomic differences at cancer-prone oral mucosa sites with marijuana usage,Scientific reports,2019,NA,Experiment 3,United States of America,Homo sapiens,Saliva,UBERON:0001836,Cannabis use,EFO:0007585,controls (lateral border of tongue),marijuana usage group,"using marijuana on 20 or more days in the past month associated with a distinct oral microbiota at the most common sites of HNSCC, the lateral border of the tongue",19,20,1 month,16S,123,Illumina,DESeq2,NA,TRUE,NA,"age,sex",NA,unchanged,unchanged,NA,NA,NA,unchanged,Signature 2,Table 1,10 January 2021,Utsav Patel,"WikiWorks,Atrayees,ChiomaBlessing",DESeq2 differentiation of taxa on the genus level at the lateral border of tongue in the marijuana usage group VS controls,decreased,k__Bacteria|p__Bacteroidota|c__Flavobacteriia|o__Flavobacteriales|f__Weeksellaceae|g__Bergeyella,2|976|117743|200644|2762318|59735,Complete,Atrayees
bsdb:172/4/1,Study 172,case-control,31481657,10.1038/s41598-019-48768-z,NA,"Newman TM, Krishnan LP, Lee J , Adami GR",Microbiomic differences at cancer-prone oral mucosa sites with marijuana usage,Scientific reports,2019,NA,Experiment 4,United States of America,Homo sapiens,Pharynx,UBERON:0006562,Cannabis use,EFO:0007585,controls (oral pharynx),marijuana usage group,"using marijuana on 20 or more days in the past month associated with a distinct oral microbiota at the most common sites of HNSCC, the oral pharynx.",19,20,1 month,16S,123,Illumina,DESeq2,0.05,TRUE,NA,"age,sex",NA,unchanged,unchanged,NA,NA,NA,unchanged,Signature 1,Table 1,24 July 2023,Atrayees,"Atrayees,ChiomaBlessing",DESeq2 differentiation of taxa on the genus level at the oral pharynx in the marijuana usage group VS controls,increased,"k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Anaerovoracaceae|g__Mogibacterium,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Veillonella",2|1239|186801|3082720|3030910|86331;2|1239|186801|186802|216572;2|976|200643|171549|171552|838;2|1239|909932|1843489|31977|29465,Complete,Atrayees
bsdb:172/4/2,Study 172,case-control,31481657,10.1038/s41598-019-48768-z,NA,"Newman TM, Krishnan LP, Lee J , Adami GR",Microbiomic differences at cancer-prone oral mucosa sites with marijuana usage,Scientific reports,2019,NA,Experiment 4,United States of America,Homo sapiens,Pharynx,UBERON:0006562,Cannabis use,EFO:0007585,controls (oral pharynx),marijuana usage group,"using marijuana on 20 or more days in the past month associated with a distinct oral microbiota at the most common sites of HNSCC, the oral pharynx.",19,20,1 month,16S,123,Illumina,DESeq2,0.05,TRUE,NA,"age,sex",NA,unchanged,unchanged,NA,NA,NA,unchanged,Signature 2,Table 1,24 July 2023,Atrayees,"Atrayees,ChiomaBlessing",DESeq2 differentiation of taxa on the genus level at the oral pharynx in the marijuana usage group VS controls,decreased,"k__Bacteria|p__Bacteroidota|c__Flavobacteriia|o__Flavobacteriales|f__Weeksellaceae|g__Bergeyella,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Bacillaceae|g__Lysinibacillus",2|976|117743|200644|2762318|59735;2|1239|91061|1385|186817|400634,Complete,Atrayees
bsdb:173/1/1,Study 173,case-control,29221120,10.18632/oncotarget.18820,NA,"Ren Z, Jiang J, Xie H, Li A, Lu H, Xu S, Zhou L, Zhang H, Cui G, Chen X, Liu Y, Wu L, Qin N, Sun R, Wang W, Li L, Wang W , Zheng S",Gut microbial profile analysis by MiSeq sequencing of pancreatic carcinoma patients in China,Oncotarget,2017,"MiSeq sequencing, alpha diversity, biomarkers, gut microbiota, pancreatic carcinoma",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Pancreatic carcinoma,EFO:0002618,healthy controls,pancreatic cancer,patients with pancreatic cancer diagnosed according to international guidelines by comprehensive consideration of clinical symptoms,57,85,8 weeks,16S,345,Illumina,LEfSe,0.05,FALSE,NA,"age,body mass index,sex",NA,NA,decreased,decreased,decreased,NA,NA,Signature 1,Figure 4,10 January 2021,Fatima Zohra,"Claregrieve1,WikiWorks",Differential abundance of fecal microbial communities between PC patients and healthy controls,increased,"k__Bacteria|p__Bacillota|c__Negativicutes|o__Acidaminococcales|f__Acidaminococcaceae|g__Acidaminococcus,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Aggregatibacter,k__Bacteria|p__Campylobacterota|c__Epsilonproteobacteria|o__Campylobacterales|f__Campylobacteraceae|g__Campylobacter,k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Coprobacillaceae|g__Catenibacterium,k__Bacteria|p__Bacillota|c__Negativicutes|o__Selenomonadales|f__Selenomonadaceae|g__Centipeda,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Cronobacter,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Enterobacter,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Hallella,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Klebsiella,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Leptotrichiaceae|g__Leptotrichia,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Bacillaceae|g__Paraliobacillus,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Bacillota|c__Negativicutes|o__Selenomonadales|f__Selenomonadaceae|g__Selenomonas,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Veillonella",2|1239|909932|1843488|909930|904;2|1224|1236|135625|712|416916;2|29547|3031852|213849|72294|194;2|1239|526524|526525|2810280|135858;2|1239|909932|909929|1843491|82202;2|1224|1236|91347|543|413496;2|1224|1236|91347|543|547;2|976|200643|171549|171552|52228;2|1224|1236|91347|543|570;2|1239|91061|186826|33958|1578;2|32066|203490|203491|1129771|32067;2|1239|91061|1385|186817|200903;2|976|200643|171549|171552|838;2|1239|909932|909929|1843491|970;2|1239|909932|1843489|31977|29465,Complete,Claregrieve1
bsdb:173/1/2,Study 173,case-control,29221120,10.18632/oncotarget.18820,NA,"Ren Z, Jiang J, Xie H, Li A, Lu H, Xu S, Zhou L, Zhang H, Cui G, Chen X, Liu Y, Wu L, Qin N, Sun R, Wang W, Li L, Wang W , Zheng S",Gut microbial profile analysis by MiSeq sequencing of pancreatic carcinoma patients in China,Oncotarget,2017,"MiSeq sequencing, alpha diversity, biomarkers, gut microbiota, pancreatic carcinoma",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Pancreatic carcinoma,EFO:0002618,healthy controls,pancreatic cancer,patients with pancreatic cancer diagnosed according to international guidelines by comprehensive consideration of clinical symptoms,57,85,8 weeks,16S,345,Illumina,LEfSe,0.05,FALSE,NA,"age,body mass index,sex",NA,NA,decreased,decreased,decreased,NA,NA,Signature 2,Figure 4,10 January 2021,Fatima Zohra,"Claregrieve1,WikiWorks",Differential abundance of fecal microbial communities between PC patients and healthy controls,decreased,"k__Bacteria|p__Verrucomicrobiota|c__Verrucomicrobiia|o__Verrucomicrobiales|f__Akkermansiaceae|g__Akkermansia,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Rikenellaceae|g__Alistipes,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Anaerostipes,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Anaerotruncus,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Bifidobacteriales|f__Bifidobacteriaceae|g__Bifidobacterium,k__Bacteria|p__Thermodesulfobacteriota|c__Desulfovibrionia|o__Desulfovibrionales|f__Desulfovibrionaceae|g__Bilophila,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Blautia,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Caulobacterales|f__Caulobacteraceae|g__Brevundimonas,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Butyricicoccaceae|g__Butyricicoccus,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Clostridiaceae|g__Clostridium,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Coprococcus,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Dorea,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Eggerthellales|f__Eggerthellaceae|g__Eggerthella,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Flavonifractor,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|g__Gemmiger,k__Bacteria|p__Bacillota|c__Negativicutes|o__Selenomonadales|f__Selenomonadaceae|g__Megamonas,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae|g__Megasphaera,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Anaerovoracaceae|g__Mogibacterium,k__Bacteria|p__Actinomycetota|c__Coriobacteriia|o__Eggerthellales|f__Eggerthellaceae|g__Paraeggerthella,k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Sutterellaceae|g__Parasutterella,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Morganellaceae|g__Proteus,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Hyphomicrobiales|f__Rhizobiaceae|g__Rhizobium,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Sporobacter",2|74201|203494|48461|1647988|239934;2|976|200643|171549|171550|239759;2|1239|186801|3085636|186803|207244;2|1239|186801|186802|216572|244127;2|201174|1760|85004|31953|1678;2|200940|3031449|213115|194924|35832;2|1239|186801|3085636|186803|572511;2|1224|28211|204458|76892|41275;2|1239|186801|186802|3085642|580596;2|1239|186801|186802|31979|1485;2|1239|186801|3085636|186803|33042;2|1239|186801|3085636|186803|189330;2|201174|84998|1643822|1643826|84111;2|1239|186801|186802|216572|946234;2|1239|186801|186802|204475;2|1239|909932|909929|1843491|158846;2|1239|909932|1843489|31977|906;2|1239|186801|3082720|3030910|86331;2|201174|84998|1643822|1643826|651554;2|1224|28216|80840|995019|577310;2|1224|1236|91347|1903414|583;2|1224|28211|356|82115|379;2|1239|186801|186802|216572|44748,Complete,Claregrieve1
bsdb:173/2/1,Study 173,case-control,29221120,10.18632/oncotarget.18820,NA,"Ren Z, Jiang J, Xie H, Li A, Lu H, Xu S, Zhou L, Zhang H, Cui G, Chen X, Liu Y, Wu L, Qin N, Sun R, Wang W, Li L, Wang W , Zheng S",Gut microbial profile analysis by MiSeq sequencing of pancreatic carcinoma patients in China,Oncotarget,2017,"MiSeq sequencing, alpha diversity, biomarkers, gut microbiota, pancreatic carcinoma",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Pancreatic carcinoma,EFO:0002618,pancreatic head cancer without obstruction,pancreatic head cancer with obstruction,pancreatic head cancer with obstruction of common bile duct,32,22,8 weeks,16S,345,Illumina,LEfSe,0.05,FALSE,NA,"age,body mass index,sex",NA,NA,unchanged,unchanged,unchanged,NA,NA,Signature 1,Figure 5,10 January 2021,Fatima Zohra,"Claregrieve1,WikiWorks",Differential microbial abundance between pancreatic cancer patients with bile obstruction vs without obstruction,increased,"k__Bacteria|p__Pseudomonadota|c__Betaproteobacteria|o__Burkholderiales|f__Comamonadaceae|g__Comamonas,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Carnobacteriaceae|g__Granulicatella,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Lachnobacterium,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Leptotrichiaceae|g__Leptotrichia,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Parasporobacterium,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Pseudobutyrivibrio,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales|f__Oscillospiraceae|g__Saccharofermentans,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus",2|1224|28216|80840|80864|283;2|1239|91061|186826|186828|117563;2|1239|186801|3085636|186803|140625;2|32066|203490|203491|1129771|32067;2|1239|186801|3085636|186803|115543;2|1239|186801|3085636|186803|46205;2|1239|186801|186802|216572|1200657;2|1239|91061|186826|1300|1301,Complete,Claregrieve1
bsdb:173/2/2,Study 173,case-control,29221120,10.18632/oncotarget.18820,NA,"Ren Z, Jiang J, Xie H, Li A, Lu H, Xu S, Zhou L, Zhang H, Cui G, Chen X, Liu Y, Wu L, Qin N, Sun R, Wang W, Li L, Wang W , Zheng S",Gut microbial profile analysis by MiSeq sequencing of pancreatic carcinoma patients in China,Oncotarget,2017,"MiSeq sequencing, alpha diversity, biomarkers, gut microbiota, pancreatic carcinoma",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Pancreatic carcinoma,EFO:0002618,pancreatic head cancer without obstruction,pancreatic head cancer with obstruction,pancreatic head cancer with obstruction of common bile duct,32,22,8 weeks,16S,345,Illumina,LEfSe,0.05,FALSE,NA,"age,body mass index,sex",NA,NA,unchanged,unchanged,unchanged,NA,NA,Signature 2,Figure 5,10 January 2021,Fatima Zohra,"Claregrieve1,WikiWorks",Differential microbial abundance between pancreatic cancer patients with bile obstruction vs without obstruction,decreased,"k__Bacteria|p__Bacillota|c__Erysipelotrichia|o__Erysipelotrichales|f__Erysipelotrichaceae|g__Anaerorhabdus,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Escherichia,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae|g__Shigella",2|1239|526524|526525|128827|118966;2|1224|1236|91347|543|561;2|1224|1236|91347|543|620,Complete,Claregrieve1
bsdb:174/1/1,Study 174,case-control,31231345,10.3389/fmicb.2019.01261,NA,"Chen XH, Wang A, Chu AN, Gong YH , Yuan Y",Mucosa-Associated Microbiota in Gastric Cancer Tissues Compared With Non-cancer Tissues,Frontiers in microbiology,2019,"16S rDNA, cancer microenvironment, gastric cancer, microbiota, risk",Experiment 1,China,Homo sapiens,Stomach,UBERON:0000945,Gastric cancer,MONDO:0001056,adjacent normal tissue,cancer tissue,gastric cancer patients who underwent subtotal gastrectomy,62,62,1 month,16S,45,Illumina,LEfSe,0.05,TRUE,3,NA,NA,NA,increased,increased,NA,NA,increased,Signature 1,Figure 3,10 January 2021,Valentina Pineda,WikiWorks,Differential bacteria between non-cancerous tissues and cancerous tissues in Gastric Cancer Patients by LEfSe analysis,increased,"k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Hyphomicrobiales,k__Bacteria|p__Actinomycetota|c__Thermoleophilia,k__Bacteria|p__Acidobacteriota,k__Bacteria|p__Bacillota|c__Negativicutes|o__Selenomonadales|f__Selenomonadaceae|g__Selenomonas,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Segatella|s__Segatella oris,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae|g__Lachnoanaerobaculum,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus,k__Bacteria|p__Bacillota|c__Negativicutes|o__Selenomonadales,k__Bacteria|p__Bacillota|c__Negativicutes,k__Bacteria|p__Bacillota|c__Negativicutes|o__Veillonellales|f__Veillonellaceae,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Peptostreptococcaceae|g__Peptostreptococcus,k__Bacteria|p__Bacillota|c__Clostridia|o__Lachnospirales|f__Lachnospiraceae,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Sphingomonadales|f__Sphingomonadaceae|g__Sphingomonas,k__Bacteria|p__Actinomycetota,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Peptostreptococcaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella|s__Prevotella denticola,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Moraxellales|f__Moraxellaceae|g__Acinetobacter,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Moraxellales|f__Moraxellaceae,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Moraxellales|f__Moraxellaceae|g__Acinetobacter|s__Acinetobacter baumannii,k__Bacteria|p__Bacillota|c__Clostridia|o__Eubacteriales,k__Bacteria|p__Bacillota|c__Clostridia,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Bacillaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Bacillaceae|g__Bacillus,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales,k__Bacteria|p__Bacteroidota|c__Bacteroidia,k__Bacteria|p__Bacillota|c__Bacilli,k__Bacteria|p__Bacteroidota,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pseudomonadales|f__Pseudomonadaceae|g__Pseudomonas|s__Pseudomonas aeruginosa,k__Bacteria|p__Bacillota",2|1224|28211|356;2|201174|1497346;2|57723;2|1239|909932|909929|1843491|970;2|976|200643|171549|171552|838;2|976|200643|171549|171552|2974251|28135;2|1239|186801|3085636|186803|1164882;2|1239|91061|186826|1300|1301;2|1239|909932|909929;2|1239|909932;2|1239|909932|1843489|31977;2|1239|186801|3082720|186804|1257;2|1239|186801|3085636|186803;2|1224|28211|204457|41297|13687;2|201174;2|1239|186801|3082720|186804;2|976|200643|171549|171552|838|28129;2|1224|1236|2887326|468|469;2|1224|1236|2887326|468;2|976|200643|171549|171552;2|1224|1236|2887326|468|469|470;2|1239|186801|186802;2|1239|186801;2|1239|91061|1385|186817;2|1239|91061|1385|186817|1386;2|976|200643|171549;2|976|200643;2|1239|91061;2|976;2|1239|91061|1385;2|1224|1236|72274|135621|286|287;2|1239,Complete,Folakunmi
bsdb:174/1/2,Study 174,case-control,31231345,10.3389/fmicb.2019.01261,NA,"Chen XH, Wang A, Chu AN, Gong YH , Yuan Y",Mucosa-Associated Microbiota in Gastric Cancer Tissues Compared With Non-cancer Tissues,Frontiers in microbiology,2019,"16S rDNA, cancer microenvironment, gastric cancer, microbiota, risk",Experiment 1,China,Homo sapiens,Stomach,UBERON:0000945,Gastric cancer,MONDO:0001056,adjacent normal tissue,cancer tissue,gastric cancer patients who underwent subtotal gastrectomy,62,62,1 month,16S,45,Illumina,LEfSe,0.05,TRUE,3,NA,NA,NA,increased,increased,NA,NA,increased,Signature 2,Figure3,10 January 2021,Valentina Pineda,WikiWorks,Differential bacteria between non-cancerous tissues and cancerous tissues in Gastric Cancer Patients by LEfSe analysis,decreased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Yersiniaceae|g__Serratia,k__Bacteria|p__Campylobacterota|c__Epsilonproteobacteria|o__Campylobacterales|f__Helicobacteraceae|g__Helicobacter|s__Helicobacter pylori,k__Bacteria|p__Campylobacterota|c__Epsilonproteobacteria|o__Campylobacterales|f__Helicobacteraceae,k__Bacteria|p__Campylobacterota|c__Epsilonproteobacteria|o__Campylobacterales|f__Helicobacteraceae|g__Helicobacter,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Yersiniaceae|g__Serratia|s__Serratia marcescens,k__Bacteria|p__Campylobacterota|c__Epsilonproteobacteria|o__Campylobacterales,k__Bacteria|p__Campylobacterota,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Rhodospirillales|f__Azospirillaceae|g__Niveispirillum,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Rhodospirillales|f__Rhodospirillaceae,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Rhodospirillales,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Levilactobacillus|s__Levilactobacillus brevis,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Lactococcus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Lactococcus|s__Lactococcus lactis,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Lysobacterales",2|1224|1236|91347|543;2|1224|1236|91347;2|1224|1236|91347|1903411|613;2|29547|3031852|213849|72293|209|210;2|29547|3031852|213849|72293;2|29547|3031852|213849|72293|209;2|1224|1236|91347|1903411|613|615;2|29547|3031852|213849;2|29547;2|1224|28211|204441|2829815|1543704;2|1224|28211|204441|41295;2|1224|28211|204441;2|1239|91061|186826|33958|2767886|1580;2|1239|91061|186826|1300|1357;2|1239|91061|186826|1300|1357|1358;2|1224|1236|135614,Complete,Folakunmi
bsdb:174/2/1,Study 174,case-control,31231345,10.3389/fmicb.2019.01261,NA,"Chen XH, Wang A, Chu AN, Gong YH , Yuan Y",Mucosa-Associated Microbiota in Gastric Cancer Tissues Compared With Non-cancer Tissues,Frontiers in microbiology,2019,"16S rDNA, cancer microenvironment, gastric cancer, microbiota, risk",Experiment 2,China,Homo sapiens,Stomach,UBERON:0000945,Gastric cancer,MONDO:0001056,H-pylori sequencing negative,H-pylori sequencing positive,H-pylori sequencing positive non-cancerous samples while studying the correlation between non-cancerous tissue microbiota and gastric cancer risk factors,44,18,1 month,16S,45,Illumina,LEfSe,0.05,TRUE,3,NA,NA,NA,increased,increased,NA,NA,increased,Signature 1,supplementary figure 2,29 February 2024,Folakunmi,Folakunmi,Differential bacteria between H.pylori-sequencing positive and H.pylori-sequencing negative non-cancer samples by LEfSe analysis,increased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Yersiniaceae|g__Serratia,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Yersiniaceae|g__Serratia|s__Serratia marcescens,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales|f__Enterobacteriaceae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Enterobacterales,k__Bacteria|p__Campylobacterota|c__Epsilonproteobacteria|o__Campylobacterales,k__Bacteria|p__Campylobacterota|c__Epsilonproteobacteria,k__Bacteria|p__Campylobacterota|c__Epsilonproteobacteria|o__Campylobacterales|f__Helicobacteraceae,k__Bacteria|p__Campylobacterota|c__Epsilonproteobacteria|o__Campylobacterales|f__Helicobacteraceae|g__Helicobacter,k__Bacteria|p__Campylobacterota|c__Epsilonproteobacteria|o__Campylobacterales|f__Helicobacteraceae|g__Helicobacter|s__Helicobacter pylori,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Hoylesella|s__Hoylesella nanceiensis,k__Bacteria|p__Bacillota|c__Bacilli,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Alteromonadales|f__Alteromonadaceae,k__Bacteria|p__Bacillota,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Holosporales|f__Candidatus Hepatincolaceae|g__Candidatus Hepatincola,k__Bacteria|p__Myxococcota|o__Polyangiales|f__Polyangiaceae|g__Sorangium|s__Sorangium cellulosum,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Staphylococcaceae|g__Macrococcus,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Alteromonadales|f__Alteromonadaceae|g__Alishewanella,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales|f__Actinomycetaceae|g__Actinomyces|s__Actinomyces graevenitzii,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Carnobacteriaceae|g__Atopostipes,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Methylococcales,k__Bacteria|p__Mycoplasmatota|c__Mollicutes|o__Mycoplasmatales|f__Mycoplasmataceae|g__Mycoplasma,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus,k__Bacteria|p__Actinomycetota|c__Thermoleophilia|o__Solirubrobacterales|f__Solirubrobacteraceae|g__Solirubrobacter,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Micrococcales|f__Microbacteriaceae|g__Leifsonia,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Geodermatophilales|f__Geodermatophilaceae|g__Geodermatophilus,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pasteurellales|f__Pasteurellaceae|g__Aggregatibacter,k__Bacteria|p__Candidatus Melainabacteria,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus,k__Bacteria|p__Actinomycetota|c__Actinomycetes|o__Actinomycetales|f__Actinomycetaceae|g__Actinomyces|s__Actinomyces naeslundii",2|1224|1236|91347|1903411|613;2|1224|1236|91347|1903411|613|615;2|1224|1236|91347|543;2|1224|1236|91347;2|29547|3031852|213849;2|29547|3031852;2|29547|3031852|213849|72293;2|29547|3031852|213849|72293|209;2|29547|3031852|213849|72293|209|210;2|976|200643|171549|171552|2974257|425941;2|1239|91061;2|1239|91061|186826;2|1224|1236|135622|72275;2|1239;2|1224|28211|1921002|1921003|263960;2|2818505|3031712|49|39643|56;2|1239|91061|1385|90964|69965;2|1224|1236|135622|72275|111142;2|201174|1760|2037|2049|1654|55565;2|1239|91061|186826|186828|292480;2|1224|1236|135618;2|544448|31969|2085|2092|2093;2|1239|91061|186826|81850;2|1239|91061|186826|33958|1578;2|201174|1497346|588673|320599|207599;2|201174|1760|85006|85023|110932;2|201174|1760|1643682|85030|1860;2|1224|1236|135625|712|416916;2|1798710;2|1239|91061|186826|1300|1301;2|201174|1760|2037|2049|1654|1655,Complete,Folakunmi
bsdb:174/2/2,Study 174,case-control,31231345,10.3389/fmicb.2019.01261,NA,"Chen XH, Wang A, Chu AN, Gong YH , Yuan Y",Mucosa-Associated Microbiota in Gastric Cancer Tissues Compared With Non-cancer Tissues,Frontiers in microbiology,2019,"16S rDNA, cancer microenvironment, gastric cancer, microbiota, risk",Experiment 2,China,Homo sapiens,Stomach,UBERON:0000945,Gastric cancer,MONDO:0001056,H-pylori sequencing negative,H-pylori sequencing positive,H-pylori sequencing positive non-cancerous samples while studying the correlation between non-cancerous tissue microbiota and gastric cancer risk factors,44,18,1 month,16S,45,Illumina,LEfSe,0.05,TRUE,3,NA,NA,NA,increased,increased,NA,NA,increased,Signature 2,supplementary figure 2,29 February 2024,Folakunmi,Folakunmi,Differential bacteria between H.pylori-sequencing positive and H.pylori-sequencing negative non-cancer samples by LEfSe analysis,decreased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella|s__Prevotella intermedia,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pseudomonadales|f__Pseudomonadaceae|g__Pseudomonas|s__Pseudomonas aeruginosa,k__Bacteria|p__Pseudomonadota,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pseudomonadales|f__Pseudomonadaceae|g__Pseudomonas,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pseudomonadales|f__Pseudomonadaceae,k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Pseudomonadales",2|976|200643|171549|171552|838|28131;2|976|200643|171549|171552;2|1224|1236|72274|135621|286|287;2|1224;2|1224|1236;2|1224|1236|72274|135621|286;2|1224|1236|72274|135621;2|1224|1236|72274,Complete,Folakunmi
bsdb:174/3/1,Study 174,case-control,31231345,10.3389/fmicb.2019.01261,NA,"Chen XH, Wang A, Chu AN, Gong YH , Yuan Y",Mucosa-Associated Microbiota in Gastric Cancer Tissues Compared With Non-cancer Tissues,Frontiers in microbiology,2019,"16S rDNA, cancer microenvironment, gastric cancer, microbiota, risk",Experiment 3,China,Homo sapiens,Stomach,UBERON:0000945,Gastric cancer,MONDO:0001056,adjacent normal tissue,cancer tissue,gastric cancer patients who underwent subtotal gastrectomy,62,62,1 month,16S,45,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,increased,increased,NA,NA,increased,Signature 1,supplementary table S5,29 February 2024,Folakunmi,Folakunmi,Significantly differential bacteria identified among the top 20 abundant genera of the cancer  and non-cancer groups,increased,"k__Bacteria|p__Pseudomonadota|c__Gammaproteobacteria|o__Moraxellales|f__Moraxellaceae|g__Acinetobacter,k__Bacteria|p__Bacillota|c__Bacilli|o__Bacillales|f__Bacillaceae|g__Bacillus,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Bacteroidaceae|g__Bacteroides,k__Bacteria|p__Pseudomonadota|c__Alphaproteobacteria|o__Sphingomonadales|f__Sphingomonadaceae|g__Sphingomonas,k__Bacteria|p__Bacillota|c__Clostridia|o__Peptostreptococcales|f__Peptostreptococcaceae|g__Peptostreptococcus,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Streptococcaceae|g__Streptococcus,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Fusobacteriaceae|g__Fusobacterium,k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Prevotella|s__Prevotella sp.",2|1224|1236|2887326|468|469;2|1239|91061|1385|186817|1386;2|976|200643|171549|815|816;2|1224|28211|204457|41297|13687;2|1239|186801|3082720|186804|1257;2|1239|91061|186826|1300|1301;2|32066|203490|203491|203492|848;2|976|200643|171549|171552|838|59823,Complete,Folakunmi
bsdb:174/3/2,Study 174,case-control,31231345,10.3389/fmicb.2019.01261,NA,"Chen XH, Wang A, Chu AN, Gong YH , Yuan Y",Mucosa-Associated Microbiota in Gastric Cancer Tissues Compared With Non-cancer Tissues,Frontiers in microbiology,2019,"16S rDNA, cancer microenvironment, gastric cancer, microbiota, risk",Experiment 3,China,Homo sapiens,Stomach,UBERON:0000945,Gastric cancer,MONDO:0001056,adjacent normal tissue,cancer tissue,gastric cancer patients who underwent subtotal gastrectomy,62,62,1 month,16S,45,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,increased,increased,NA,NA,increased,Signature 2,supplementary table S5,29 February 2024,Folakunmi,Folakunmi,Significantly differential bacteria identified among the top 20 abundant genera of the cancer and non-cancer groups,decreased,"k__Bacteria|p__Campylobacterota|c__Epsilonproteobacteria|o__Campylobacterales|f__Helicobacteraceae|g__Helicobacter,k__Bacteria|p__Bacillota|c__Bacilli|o__Lactobacillales|f__Lactobacillaceae|g__Lactobacillus",2|29547|3031852|213849|72293|209;2|1239|91061|186826|33958|1578,Complete,Folakunmi
bsdb:175/1/1,Study 175,case-control,27742762,10.1136/gutjnl-2016-312580,NA,"Fan X, Alekseyenko AV, Wu J, Peters BA, Jacobs EJ, Gapstur SM, Purdue MP, Abnet CC, Stolzenberg-Solomon R, Miller G, Ravel J, Hayes RB , Ahn J",Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study,Gut,2018,PANCREAS,Experiment 1,United States of America,Homo sapiens,Saliva,UBERON:0001836,Pancreatic carcinoma,EFO:0002618,controls,pancreatic cancer cases,subjects from the two cohorts with incident primary pancreatic adenocarcinoma,371,361,NA,16S,34,Roche454,Logistic Regression,0.05,FALSE,NA,"age,date,race,sex","age,alcohol drinking,body mass index,diabetes mellitus,race,sex,smoking status",NA,NA,NA,NA,NA,NA,Signature 1,Table 3,10 January 2021,Fatima Zohra,"Claregrieve1,WikiWorks",Differential microbial abundance between controls and pancreatic cancer cases,increased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Alloprevotella,k__Bacteria|p__Bacteroidota",2|976|200643|171549|171552|1283313;2|976,Complete,Claregrieve1
bsdb:175/1/2,Study 175,case-control,27742762,10.1136/gutjnl-2016-312580,NA,"Fan X, Alekseyenko AV, Wu J, Peters BA, Jacobs EJ, Gapstur SM, Purdue MP, Abnet CC, Stolzenberg-Solomon R, Miller G, Ravel J, Hayes RB , Ahn J",Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study,Gut,2018,PANCREAS,Experiment 1,United States of America,Homo sapiens,Saliva,UBERON:0001836,Pancreatic carcinoma,EFO:0002618,controls,pancreatic cancer cases,subjects from the two cohorts with incident primary pancreatic adenocarcinoma,371,361,NA,16S,34,Roche454,Logistic Regression,0.05,FALSE,NA,"age,date,race,sex","age,alcohol drinking,body mass index,diabetes mellitus,race,sex,smoking status",NA,NA,NA,NA,NA,NA,Signature 2,Table 3,10 January 2021,Fatima Zohra,"Claregrieve1,WikiWorks",Differential microbial abundance between controls and pancreatic cancer cases,decreased,"k__Bacteria|p__Fusobacteriota,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Leptotrichiaceae|g__Leptotrichia,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Leptotrichiaceae",2|32066;2|32066|203490|203491;2|32066|203490;2|32066|203490|203491|1129771|32067;2|32066|203490|203491|1129771,Complete,Claregrieve1
bsdb:175/2/1,Study 175,case-control,27742762,10.1136/gutjnl-2016-312580,NA,"Fan X, Alekseyenko AV, Wu J, Peters BA, Jacobs EJ, Gapstur SM, Purdue MP, Abnet CC, Stolzenberg-Solomon R, Miller G, Ravel J, Hayes RB , Ahn J",Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study,Gut,2018,PANCREAS,Experiment 2,United States of America,Homo sapiens,Saliva,UBERON:0001836,Pancreatic carcinoma,EFO:0002618,controls,pancreatic cancer cases,subjects from the CPSII cohorts with incident primary pancreatic adenocarcinoma,170,170,NA,16S,34,Roche454,Logistic Regression,0.05,FALSE,NA,"age,date,race,sex","age,alcohol drinking,body mass index,diabetes mellitus,race,sex,smoking status",NA,NA,NA,NA,NA,NA,Signature 1,Supplementary Table 3a,10 January 2021,Fatima Zohra,"Claregrieve1,WikiWorks",Median relative abundance of selected oral microbiota in pancreatic cancer cases and controls in the Cancer Prevention Study(CPS) cohort,decreased,"k__Bacteria|p__Bacteroidota|c__Bacteroidia|o__Bacteroidales|f__Prevotellaceae|g__Alloprevotella,k__Bacteria|p__Fusobacteriota,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Leptotrichiaceae|g__Leptotrichia,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Leptotrichiaceae",2|976|200643|171549|171552|1283313;2|32066;2|32066|203490|203491;2|32066|203490;2|32066|203490|203491|1129771|32067;2|32066|203490|203491|1129771,Complete,Claregrieve1
bsdb:175/3/1,Study 175,case-control,27742762,10.1136/gutjnl-2016-312580,NA,"Fan X, Alekseyenko AV, Wu J, Peters BA, Jacobs EJ, Gapstur SM, Purdue MP, Abnet CC, Stolzenberg-Solomon R, Miller G, Ravel J, Hayes RB , Ahn J",Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study,Gut,2018,PANCREAS,Experiment 3,United States of America,Homo sapiens,Saliva,UBERON:0001836,Pancreatic carcinoma,EFO:0002618,controls,pancreatic cancer cases,subjects from the PLCO cohorts with incident primary pancreatic adenocarcinoma,201,191,NA,16S,34,Roche454,Logistic Regression,0.05,FALSE,NA,"age,date,race,sex","age,alcohol drinking,body mass index,diabetes mellitus,race,sex,smoking status",NA,NA,NA,NA,NA,NA,Signature 1,Supplementary Table 3b,10 January 2021,Fatima Zohra,"Claregrieve1,WikiWorks",Median relative abundance of selected oral microbiota in pancreatic cancer cases and controls in the Cancer Prevention Study(CPS) cohort,decreased,"k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Leptotrichiaceae|g__Leptotrichia,k__Bacteria|p__Fusobacteriota|c__Fusobacteriia|o__Fusobacteriales|f__Leptotrichiaceae",2|32066|203490|203491|1129771|32067;2|32066|203490|203491|1129771,Complete,ChiomaBlessing
bsdb:176/1/NA,Study 176,case-control,28320465,10.1186/s40168-017-0250-1,NA,"Chua LL, Rajasuriar R, Azanan MS, Abdullah NK, Tang MS, Lee SC, Woo YL, Lim YA, Ariffin H , Loke P",Reduced microbial diversity in adult survivors of childhood acute lymphoblastic leukemia and microbial associations with increased immune activation,Microbiome,2017,"Acute lymphoblastic leukemia, Adult survivors of childhood cancer, Alpha diversity, Immune activation, Inflammation, Microbiome, Microbiota dysbiosis",Experiment 1,Malaysia,Homo sapiens,Caecum,UBERON:0001153,Leukemia,EFO:0000565,controls,survivors of acute lymphoblastic leukemia,adult surviors of childhood leukemia,61,73,NA,16S,4,Illumina,LEfSe,0.05,TRUE,4,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:177/1/NA,Study 177,case-control,28944067,10.1136/bmjgast-2017-000145,NA,"Hibberd AA, Lyra A, Ouwehand AC, Rolny P, Lindegren H, Cedgård L , Wettergren Y",Intestinal microbiota is altered in patients with colon cancer and modified by probiotic intervention,BMJ open gastroenterology,2017,"COLORECTAL CANCER, INTESTINAL MICROBIOLOGY, PROBIOTICS, TUMOUR MARKERS",Experiment 1,Sweden,Homo sapiens,Mucosa of ascending colon,UBERON:0004990,Colorectal cancer,EFO:0005842,control group,colon cancer patients,patients diagnosed with stage I-III colon cancer,14,12,recent,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:177/2/NA,Study 177,case-control,28944067,10.1136/bmjgast-2017-000145,NA,"Hibberd AA, Lyra A, Ouwehand AC, Rolny P, Lindegren H, Cedgård L , Wettergren Y",Intestinal microbiota is altered in patients with colon cancer and modified by probiotic intervention,BMJ open gastroenterology,2017,"COLORECTAL CANCER, INTESTINAL MICROBIOLOGY, PROBIOTICS, TUMOUR MARKERS",Experiment 2,Sweden,Homo sapiens,Colon,UBERON:0001155,Colorectal cancer,EFO:0005842,control group,colon cancer patients (tumor samples),patients diagnosed with stage I-III colon cancer,14,12,recent,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:177/3/NA,Study 177,case-control,28944067,10.1136/bmjgast-2017-000145,NA,"Hibberd AA, Lyra A, Ouwehand AC, Rolny P, Lindegren H, Cedgård L , Wettergren Y",Intestinal microbiota is altered in patients with colon cancer and modified by probiotic intervention,BMJ open gastroenterology,2017,"COLORECTAL CANCER, INTESTINAL MICROBIOLOGY, PROBIOTICS, TUMOUR MARKERS",Experiment 3,Sweden,Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,control group,colon cancer patients (fecal samples),patients diagnosed with stage I-III colon cancer,21,14,recent,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:178/1/NA,Study 178,case-control,30936882,10.3389/fimmu.2019.00533,NA,"Ling Z, Shao L, Liu X, Cheng Y, Yan C, Mei Y, Ji F , Liu X",Regulatory T Cells and Plasmacytoid Dendritic Cells Within the Tumor Microenvironment in Gastric Cancer Are Correlated With Gastric Microbiota Dysbiosis: A Preliminary Study,Frontiers in immunology,2019,"Tregs (Regulatory T cells), gastric cancer, microbiota (microorganism), pDCs, tumor microenvironment",Experiment 1,China,Homo sapiens,Stomach,UBERON:0000945,Gastric cancer,MONDO:0001056,normal,gastric cancer peritumor group,gastric cancer,60,61,1 month,16S,34,Illumina,LEfSe,2,TRUE,2,NA,NA,NA,decreased,NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:178/2/NA,Study 178,case-control,30936882,10.3389/fimmu.2019.00533,NA,"Ling Z, Shao L, Liu X, Cheng Y, Yan C, Mei Y, Ji F , Liu X",Regulatory T Cells and Plasmacytoid Dendritic Cells Within the Tumor Microenvironment in Gastric Cancer Are Correlated With Gastric Microbiota Dysbiosis: A Preliminary Study,Frontiers in immunology,2019,"Tregs (Regulatory T cells), gastric cancer, microbiota (microorganism), pDCs, tumor microenvironment",Experiment 2,China,Homo sapiens,Stomach,UBERON:0000945,Gastric cancer,MONDO:0001056,peritumor,gastric cancer tumor group,gastric cancer,61,59,1 month,16S,34,Illumina,LEfSe,2,TRUE,2,NA,NA,NA,increased,NA,increased,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:178/3/NA,Study 178,case-control,30936882,10.3389/fimmu.2019.00533,NA,"Ling Z, Shao L, Liu X, Cheng Y, Yan C, Mei Y, Ji F , Liu X",Regulatory T Cells and Plasmacytoid Dendritic Cells Within the Tumor Microenvironment in Gastric Cancer Are Correlated With Gastric Microbiota Dysbiosis: A Preliminary Study,Frontiers in immunology,2019,"Tregs (Regulatory T cells), gastric cancer, microbiota (microorganism), pDCs, tumor microenvironment",Experiment 3,China,Homo sapiens,Stomach,UBERON:0000945,Gastric cancer,MONDO:0001056,normal,gastric cancer tumor group,gastric cancer,60,59,1 month,16S,34,Illumina,LEfSe,2,TRUE,2,NA,NA,NA,unchanged,NA,unchanged,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:179/1/NA,Study 179,case-control,31836795,10.1038/s41598-019-55667-w,NA,"Wang Q, Rao Y, Guo X, Liu N, Liu S, Wen P, Li S , Li Y",Oral Microbiome in Patients with Oesophageal Squamous Cell Carcinoma,Scientific reports,2019,NA,Experiment 1,China,Homo sapiens,Saliva,UBERON:0001836,Esophageal squamous cell carcinoma,EFO:0005922,Healthy controls,Oesophageal cancer,"patients with oesophageal cancer diagnosed by electronic gastroscopy and histopathology, with no related surgery, radiotherapy or chemotherapy for oesophageal cancer before sampling",21,20,1 month,16S,34,Illumina,Metastats,0.05,FALSE,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:179/2/NA,Study 179,case-control,31836795,10.1038/s41598-019-55667-w,NA,"Wang Q, Rao Y, Guo X, Liu N, Liu S, Wen P, Li S , Li Y",Oral Microbiome in Patients with Oesophageal Squamous Cell Carcinoma,Scientific reports,2019,NA,Experiment 2,China,Homo sapiens,Saliva,UBERON:0001836,Esophageal squamous cell carcinoma,EFO:0005922,Healthy controls,Oesophageal cancer,"patients with oesophageal cancer diagnosed by electronic gastroscopy and histopathology, with no related surgery, radiotherapy or chemotherapy for oesophageal cancer before sampling",21,20,1 month,16S,34,Illumina,LEfSe,0.05,FALSE,3,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:180/1/NA,Study 180,"cross-sectional observational, not case-control",29102920,10.1136/gutjnl-2017-314205,NA,"Ferreira RM, Pereira-Marques J, Pinto-Ribeiro I, Costa JL, Carneiro F, Machado JC , Figueiredo C",Gastric microbial community profiling reveals a dysbiotic cancer-associated microbiota,Gut,2018,"Helicobacter pylori, bacterial infection, gastric carcinoma, gastritis",Experiment 1,Portugal,Homo sapiens,Stomach,UBERON:0000945,Gastric carcinoma,EFO:0000178,chronic gastritis,gastric carcinoma,gastric carcinoma,81,54,NA,16S,56,Ion Torrent,LEfSe,0.05,TRUE,4,age,NA,NA,decreased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:181/1/NA,Study 181,"cross-sectional observational, not case-control",33429936,https://doi.org/10.3390/jpm11010035,NA,"Barandouzi ZA, Lee J, Maas K, Starkweather AR , Cong XS",Altered Gut Microbiota in Irritable Bowel Syndrome and Its Association with Food Components,Journal of personalized medicine,2021,"food components, irritable bowel syndrome, microbiome, microbiota, nutrients",Experiment 1,Canada,Homo sapiens,Feces,UBERON:0001988,Irritable bowel syndrome,EFO:0000555,Healthy control,IBS,The patient's who have been diagnosed from irritable bowel syndrome(IBS).,21,80,current,16S,4,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,increased,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:182/1/NA,Study 182,"cross-sectional observational, not case-control",31215600,10.1590/1678-7757-2018-0635,NA,"Yokoi A, Ekuni D, Hata H, Yamane-Takeuchi M, Maruyama T, Yamanaka R , Morita M",Relationship between acetaldehyde concentration in mouth air and characteristics of microbiota of tongue dorsum in Japanese healthy adults: a cross-sectional study,Journal of applied oral science : revista FOB,2019,NA,Experiment 1,Japan,Homo sapiens,Mouth,UBERON:0000165,Acetaldehyde,CHEBI:15343,low acetaldehyde concentration group,high acetaldehyde concentration group,"The Sensor Gas Chromatograph SGEA-P2 (FIS Inc., Itami, Japan) was used to measure acetaldehyde concentrations in mouth air.",6,6,current use,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:183/1/NA,Study 183,case-control,31764438,10.1097/MPG.0000000000002461,NA,"Kansal S, Catto-Smith AG, Boniface K, Thomas S, Cameron DJ, Oliver M, Alex G, Kirkwood CD , Wagner J",Variation of Gut Mucosal Microbiome With Anti-Saccharomyces cerevisiae Antibody Status in Pediatric Crohn Disease,Journal of pediatric gastroenterology and nutrition,2019,NA,Experiment 1,Australia,Homo sapiens,Ileum,UBERON:0002116,Crohn's disease,EFO:0000384,crohn disease ASCA negative patients,crohn disease ASCA positive patients,Crohn disease anti-Saccharomyces cerevisiae antibody status,39,38,3 months,16S,2,Non-quantitative PCR,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:184/1/NA,Study 184,"cross-sectional observational, not case-control,prospective cohort",30117171,10.1002/pros.23713,NA,"Alanee S, El-Zawahry A, Dynda D, Dabaja A, McVary K, Karr M , Braundmeier-Fleming A",A prospective study to examine the association of the urinary and fecal microbiota with prostate cancer diagnosis after transrectal biopsy of the prostate using 16sRNA gene analysis,The Prostate,2019,"benign prostate, microbiota, prostate cancer",Experiment 1,United States of America,Homo sapiens,Urine,UBERON:0001088,Prostate cancer,MONDO:0008315,controls,prostate cancer patients,the association of urinary and fecal microbiota with prostate cancer diagnosis,16,14,28 days,16S,345,Illumina,Kruskall-Wallis,0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:185/1/NA,Study 185,case-control,31464899,10.1097/MD.0000000000016626,NA,"Liang W, Yang Y, Wang H, Wang H, Yu X, Lu Y, Shen S , Teng L",Gut microbiota shifts in patients with gastric cancer in perioperative period,Medicine,2019,NA,Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Gastric cancer,MONDO:0001056,controls,gastric cancer,gastric cancer patients,22,20,1 month,16S,NA,Illumina,T-Test,0.05,FALSE,NA,NA,NA,NA,decreased,increased,unchanged,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:185/2/NA,Study 185,case-control,31464899,10.1097/MD.0000000000016626,NA,"Liang W, Yang Y, Wang H, Wang H, Yu X, Lu Y, Shen S , Teng L",Gut microbiota shifts in patients with gastric cancer in perioperative period,Medicine,2019,NA,Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Gastric cancer,MONDO:0001056,healthy gastric cancer (post surgery),gastric cancer,gastric cancer patients,6,20,1 month,16S,NA,Illumina,LEfSe,0.05,FALSE,3.5,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:186/2/NA,Study 186,laboratory experiment,35387878,http://dx.doi.org/10.1136/gutjnl-2021-325021,https://gut.bmj.com/content/71/12/2439,"Bai X, Wei H, Liu W, Coker OO, Gou H, Liu C, Zhao L, Li C, Zhou Y, Wang G, Kang W, Ng EK , Yu J",Cigarette smoke promotes colorectal cancer through modulation of gut microbiota and related metabolites,Gut,2022,"BACTERIAL PATHOGENESIS, BILE ACID METABOLISM, COLORECTAL CANCER",Experiment 2,China,Mus musculus,Feces,UBERON:0001988,Smoking behavior,EFO:0004318,Smoke-free control group intraperitoneally injected with carcinogen azoxymethane (AOM) (10 mg/kg),"Smoke-exposed group intraperitoneally injected with carcinogen, AOM (AOM + Smoking)",Mice exposed to cigarette smoke directly (4% of 2000 mL/ min airflow) 2 hours per day for 28 weeks (at end time point),15,15,NA,WMS,NA,Illumina,MaAsLin2,0.05,TRUE,NA,NA,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:187/1/NA,Study 187,time series / longitudinal observational,30866773,10.1080/22221751.2018.1563458,NA,"Yang L, Hao Y, Hu J, Kelly D, Li H, Brown S, Tasker C, Roche NE, Chang TL , Pei Z",Differential effects of depot medroxyprogesterone acetate administration on vaginal microbiome in Hispanic White and Black women,Emerging microbes & infections,2019,"HIV acquisition, Vaginal microbiome, bacterial vaginosis-associated bacteria, depot medroxyprogesterone acetate, network",Experiment 1,United States of America,Homo sapiens,Vagina,UBERON:0000996,Medroxyprogesterone acetate,CHEBI:6716,depot medroxyprogesterone acetate vaginal microbiome (visit 2) among black participants,naive black participants (baseline visit),participants who had not yet been given the medroxyprogesterone acetate treatment at baseline,16,16,before sample collection,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.2,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:187/2/NA,Study 187,time series / longitudinal observational,30866773,10.1080/22221751.2018.1563458,NA,"Yang L, Hao Y, Hu J, Kelly D, Li H, Brown S, Tasker C, Roche NE, Chang TL , Pei Z",Differential effects of depot medroxyprogesterone acetate administration on vaginal microbiome in Hispanic White and Black women,Emerging microbes & infections,2019,"HIV acquisition, Vaginal microbiome, bacterial vaginosis-associated bacteria, depot medroxyprogesterone acetate, network",Experiment 2,United States of America,Homo sapiens,Vagina,UBERON:0000996,Medroxyprogesterone acetate,CHEBI:6716,black naive vaginal microbiome (baseline visit ),white naiive vaginal microbiome (baseline),white participants at baseline,16,9,before sample collection,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.2,TRUE,NA,NA,NA,NA,unchanged,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:187/3/NA,Study 187,time series / longitudinal observational,30866773,10.1080/22221751.2018.1563458,NA,"Yang L, Hao Y, Hu J, Kelly D, Li H, Brown S, Tasker C, Roche NE, Chang TL , Pei Z",Differential effects of depot medroxyprogesterone acetate administration on vaginal microbiome in Hispanic White and Black women,Emerging microbes & infections,2019,"HIV acquisition, Vaginal microbiome, bacterial vaginosis-associated bacteria, depot medroxyprogesterone acetate, network",Experiment 3,United States of America,Homo sapiens,Vagina,UBERON:0000996,Medroxyprogesterone acetate,CHEBI:6716,black participants after using depot medroxyprogesterone (visit 2),white participants after using depot medroxyprogesterone (visit 2),white participants at visit 2,16,9,before sample collection,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.2,TRUE,NA,NA,NA,NA,decreased,unchanged,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:187/4/NA,Study 187,time series / longitudinal observational,30866773,10.1080/22221751.2018.1563458,NA,"Yang L, Hao Y, Hu J, Kelly D, Li H, Brown S, Tasker C, Roche NE, Chang TL , Pei Z",Differential effects of depot medroxyprogesterone acetate administration on vaginal microbiome in Hispanic White and Black women,Emerging microbes & infections,2019,"HIV acquisition, Vaginal microbiome, bacterial vaginosis-associated bacteria, depot medroxyprogesterone acetate, network",Experiment 4,United States of America,Homo sapiens,Vagina,UBERON:0000996,Medroxyprogesterone acetate,CHEBI:6716,black participants after using depot medroxyprogesterone (visit 3),white participants after using depot medroxyprogesterone (visit 3),white participants at visit 3,16,9,before sample collection,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.2,TRUE,NA,NA,NA,NA,decreased,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:188/1/NA,Study 188,case-control,30854760,10.1111/1471-0528.15600,NA,"Brown RG, Chan D, Terzidou V, Lee YS, Smith A, Marchesi JR, MacIntyre DA , Bennett PR",Prospective observational study of vaginal microbiota pre- and post-rescue cervical cerclage,BJOG : an international journal of obstetrics and gynaecology,2019,"Infection, preterm birth, rescue cerclage, vaginal microbiome",Experiment 1,United Kingdom,Homo sapiens,Vagina,UBERON:0000996,Cervical cerclage,NCIT:C102763,Vaginal microbiome of asymptomatic women prior to cerclage,Vaginal microbiome of symptomatic women prior ro cerclage,NA,13,7,NA,16S,12,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:189/1/NA,Study 189,case-control,29180991,10.3389/fmicb.2017.02222,NA,"Wang J, Wang Y, Zhang X, Liu J, Zhang Q, Zhao Y, Peng J, Feng Q, Dai J, Sun S, Zhao Y, Zhao L, Zhang Y, Hu Y , Zhang M",Gut Microbial Dysbiosis Is Associated with Altered Hepatic Functions and Serum Metabolites in Chronic Hepatitis B Patients,Frontiers in microbiology,2017,"16S rRNA gene sequencing, aromatic amino acids, chronic hepatitis B, gut sysbiosis, serum metabolomics",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Chronic hepatitis B virus infection,EFO:0004239,healthy controls,chronic hepatitis B patients,Chronic hepatitis B patients,22,85,1 month,16S,34,Illumina,LEfSe,0.05,FALSE,2,"age,body mass index,sex",NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:190/1/NA,Study 190,prospective cohort,30813950,10.1186/s40168-019-0645-2,NA,"Iszatt N, Janssen S, Lenters V, Dahl C, Stigum H, Knight R, Mandal S, Peddada S, González A, Midtvedt T , Eggesbø M",Environmental toxicants in breast milk of Norwegian mothers and gut bacteria composition and metabolites in their infants at 1 month,Microbiome,2019,"Birth cohort, Breast milk, Infant gut microbiome, Short-chain fatty acids, Toxicants",Experiment 1,Norway,Homo sapiens,Feces,UBERON:0001988,Environmental exposure measurement,EFO:0008360,one-month age infants exposed to low chemical breast milk (<20th percentile),one-month age infants exposed to high chemical breast milk,infants with high chemical exposure (≥ 80th percentile breast milk toxicant exposure),45,45,2 weeks,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,gestational age,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:191/1/NA,Study 191,"cross-sectional observational, not case-control",30791484,10.3390/nu11020433,NA,"Iino C, Shimoyama T, Iino K, Yokoyama Y, Chinda D, Sakuraba H, Fukuda S , Nakaji S",Daidzein Intake Is Associated with Equol Producing Status through an Increase in the Intestinal Bacteria Responsible for Equol Production,Nutrients,2019,"Asaccharobacter celatus, Slackia isoflavoniconvertens, daidzein, equol, gut microbiota",Experiment 1,Japan,Homo sapiens,Feces,UBERON:0001988,Equol,CHEBI:34741,equol non-producers,equol producers,The equol production status was defined by a urinary log 10 - transformed equol/daidzein ratio of −1.75 or more as described previously,586,458,NA,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:192/1/NA,Study 192,case-control,22339879,10.1111/j.1365-2982.2012.01891.x,NA,"Carroll IM, Ringel-Kulka T, Siddle JP , Ringel Y",Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome,Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society,2012,NA,Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Irritable bowel syndrome,EFO:0000555,healthy controls,diarrhea-predominant irritable bowel syndrome,Diarrhea-Predominant irritable bowel syndrome,23,23,2 months,16S,123,Roche454,T-Test,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:192/2/NA,Study 192,case-control,22339879,10.1111/j.1365-2982.2012.01891.x,NA,"Carroll IM, Ringel-Kulka T, Siddle JP , Ringel Y",Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome,Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society,2012,NA,Experiment 2,United States of America,Homo sapiens,Feces,UBERON:0001988,Irritable bowel syndrome,EFO:0000555,healthy controls,diarrhea-predominant irritable bowel syndrome,Diarrhea-Predominant irritable bowel syndrome,23,23,2 months,16S,6,Roche454,T-Test,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:193/1/NA,Study 193,prospective cohort,25052961,10.1111/hel.12145,NA,"Eun CS, Kim BK, Han DS, Kim SY, Kim KM, Choi BY, Song KS, Kim YS , Kim JF","Differences in gastric mucosal microbiota profiling in patients with chronic gastritis, intestinal metaplasia, and gastric cancer using pyrosequencing methods",Helicobacter,2014,"16S ribosomal RNA, H. pylori, carcinogenesis, gastric cancer",Experiment 1,South Korea,Homo sapiens,Mucosa of stomach,UBERON:0001199,Gastric cancer,MONDO:0001056,chronic gastritis and intestinal metaplasia,gastric cancer,noncardia gastric cancer patients whose diagnosis were confirmed by histopathology,20,11,6 months,16S,5,Roche454,NA,0.05,FALSE,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:193/2/NA,Study 193,prospective cohort,25052961,10.1111/hel.12145,NA,"Eun CS, Kim BK, Han DS, Kim SY, Kim KM, Choi BY, Song KS, Kim YS , Kim JF","Differences in gastric mucosal microbiota profiling in patients with chronic gastritis, intestinal metaplasia, and gastric cancer using pyrosequencing methods",Helicobacter,2014,"16S ribosomal RNA, H. pylori, carcinogenesis, gastric cancer",Experiment 2,South Korea,Homo sapiens,Mucosa of stomach,UBERON:0001199,Gastric cancer,MONDO:0001056,H. pylori negative chronic gastritis,H. pylori positive chronic gastritis,H. pylori positive chronic gastritis patients who were diagnosed by conventional laboratory method including rapid urease test and histopathology,0,7,6 months,16S,5,Roche454,NA,0.05,FALSE,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:194/1/NA,Study 194,case-control,30737418,10.1038/s41598-018-38031-2,NA,"Zhou B, Sun C, Huang J, Xia M, Guo E, Li N, Lu H, Shan W, Wu Y, Li Y, Xu X, Weng D, Meng L, Hu J, Gao Q, Ma D , Chen G",The biodiversity Composition of Microbiome in Ovarian Carcinoma Patients,Scientific reports,2019,NA,Experiment 1,China,Homo sapiens,Uterus,UBERON:0000995,Ovarian cancer,MONDO:0008170,normal tissue,ovarian cancer,women diagnosed with high grade ovarian cancer,25,25,3 months,16S,34,Illumina,LEfSe,0.05,FALSE,3.5,NA,NA,NA,decreased,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:195/1/NA,Study 195,case-control,26606973,10.1038/srep17098,NA,"Ling Z, Liu X, Cheng Y, Jiang X, Jiang H, Wang Y , Li L",Decreased Diversity of the Oral Microbiota of Patients with Hepatitis B Virus-Induced Chronic Liver Disease: A Pilot Project,Scientific reports,2015,NA,Experiment 1,China,Homo sapiens,Dental plaque,UBERON:0016482,Chronic hepatitis B virus infection,EFO:0004239,healthy controls,chronic hepatitis B,chronic hepatitis B,10,10,1 month,16S,123,Roche454,LEfSe,0.05,FALSE,2,NA,NA,NA,decreased,NA,increased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:195/2/NA,Study 195,case-control,26606973,10.1038/srep17098,NA,"Ling Z, Liu X, Cheng Y, Jiang X, Jiang H, Wang Y , Li L",Decreased Diversity of the Oral Microbiota of Patients with Hepatitis B Virus-Induced Chronic Liver Disease: A Pilot Project,Scientific reports,2015,NA,Experiment 2,China,Homo sapiens,Dental plaque,UBERON:0016482,Chronic hepatitis B virus infection,EFO:0004239,liver cirrhosis,chronic hepatitis B,chronic hepatitis B,10,10,1 month,16S,123,Roche454,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:196/1/NA,Study 196,case-control,29525681,10.1016/j.intimp.2018.03.003,NA,"Wang X, Zhang L, Wang Y, Liu X, Zhang H, Liu Y, Shen N, Yang J , Gai Z",Gut microbiota dysbiosis is associated with Henoch-Schönlein Purpura in children,International immunopharmacology,2018,"Dysbiosis, Henoch-Schönlein Purpura, IgA, Microbiota",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Henoch-Schoenlein purpura,EFO:1000965,controls,Henoch-Schönlein Purpura,Henoch-Schönlein Purpura in children,70,85,NA,16S,12,Illumina,LEfSe,0.05,FALSE,3,"age,sex",NA,NA,decreased,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:197/1/NA,Study 197,case-control,29031597,10.1016/j.jaci.2017.09.018,NA,"Goldman DL, Chen Z, Shankar V, Tyberg M, Vicencio A , Burk R",Lower airway microbiota and mycobiota in children with severe asthma,The Journal of allergy and clinical immunology,2018,NA,Experiment 1,United States of America,Homo sapiens,Right lung middle lobe bronchiole,UBERON:0012068,Asthma,MONDO:0004979,non-asthma,severe asthma,severe asthma,11,15,NA,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:198/1/NA,Study 198,case-control,30342346,10.1016/j.intimp.2018.10.017,NA,"Chen B, Wang J, Wang Y, Zhang J, Zhao C, Shen N, Yang J, Gai Z , Zhang L",Oral microbiota dysbiosis and its association with Henoch-Schönlein Purpura in children,International immunopharmacology,2018,"Dysbiosis, Henoch-Schönlein Purpura, Immunoglobulin, Oral microbiota",Experiment 1,China,Homo sapiens,Mouth,UBERON:0000165,Henoch-Schoenlein purpura,EFO:1000965,controls,Henoch-Schönlein Purpura,Henoch-Schönlein Purpura in children,66,98,4 weeks,16S,12,Illumina,LEfSe,0.05,FALSE,3.5,"age,sex",NA,NA,increased,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:199/1/NA,Study 199,case-control,31954395,10.1186/s13048-019-0603-4,NA,"Wang Q, Zhao L, Han L, Fu G, Tuo X, Ma S, Li Q, Wang Y, Liang D, Tang M, Sun C, Wang Q, Song Q , Li Q",The differential distribution of bacteria between cancerous and noncancerous ovarian tissues in situ,Journal of ovarian research,2020,"16S rRNA sequencing, Bacteria, KEGG, Lipopolysaccharide, Ovarian cancer",Experiment 1,China,Homo sapiens,Uterus,UBERON:0000995,Ovarian cancer,MONDO:0008170,controls,ovarian cancer,preliminary diagnosis of suspected ovarian cancer and undergoing laparotomy,10,6,2 months,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:200/1/NA,Study 200,"cross-sectional observational, not case-control",31844128,10.1038/s41598-019-55720-8,NA,"Walsh DM, Hokenstad AN, Chen J, Sung J, Jenkins GD, Chia N, Nelson H, Mariani A , Walther-Antonio MRS",Postmenopause as a key factor in the composition of the Endometrial Cancer Microbiome (ECbiome),Scientific reports,2019,NA,Experiment 1,United States of America,Homo sapiens,Lower part of vagina,UBERON:0015243,Postmenopausal,EFO:0002721,Pre-menopausal patients,Post-menopausal patients,Post-menopausal patients without Endometrial cancer,49,14,2 weeks,16S,345,Illumina,Wald Test,0.1,TRUE,NA,NA,"obesity,vaginal pH",NA,increased,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:200/2/NA,Study 200,"cross-sectional observational, not case-control",31844128,10.1038/s41598-019-55720-8,NA,"Walsh DM, Hokenstad AN, Chen J, Sung J, Jenkins GD, Chia N, Nelson H, Mariani A , Walther-Antonio MRS",Postmenopause as a key factor in the composition of the Endometrial Cancer Microbiome (ECbiome),Scientific reports,2019,NA,Experiment 2,United States of America,Homo sapiens,Lower part of vagina,UBERON:0015243,Endometrial cancer,MONDO:0011962,Benign,Endometrial cancer,Patients undergoing hysterectomy for endometrial cancer,67,57,2 weeks,16S,345,Illumina,Wald Test,0.1,TRUE,NA,NA,"body mass index,menopause,vaginal pH",NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:201/1/NA,Study 201,time series / longitudinal observational,30988420,10.1038/s41598-019-42652-6,NA,"Rashidi A, Kaiser T, Shields-Cutler R, Graiziger C, Holtan SG, Rehman TU, Wasko J, Weisdorf DJ, Dunny G, Khoruts A , Staley C",Dysbiosis patterns during re-induction/salvage versus induction chemotherapy for acute leukemia,Scientific reports,2019,NA,Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Leukemia,EFO:0000565,repeat therapy,induction,acute leukemia patients undergoing chemotherapy,7,13,NA,16S,4,Illumina,LEfSe,0.01,TRUE,4,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:202/1/NA,Study 202,case-control,30764497,10.3390/nu11020337,NA,"Plaza-Díaz J, Gómez-Fernández A, Chueca N, Torre-Aguilar MJ, Gil Á, Perez-Navero JL, Flores-Rojas K, Martín-Borreguero P, Solis-Urra P, Ruiz-Ojeda FJ, Garcia F , Gil-Campos M",Autism Spectrum Disorder (ASD) with and without Mental Regression is Associated with Changes in the Fecal Microbiota,Nutrients,2019,"autism spectrum disorder, children, intestinal microbiota, nutrients",Experiment 1,Spain,Homo sapiens,Feces,UBERON:0001988,Autism,EFO:0003758,children with autism non-mental regression (ANMR),children with autism mental regression (AMR),Children between 2-6 years old with an agreed clinical diagnosis of autism per the ICD 10th Edition for ASD and DSM-5 who had development regression during the first two years of life.,30,18,NA,16S,34,Illumina,Kruskall-Wallis,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:202/2/NA,Study 202,case-control,30764497,10.3390/nu11020337,NA,"Plaza-Díaz J, Gómez-Fernández A, Chueca N, Torre-Aguilar MJ, Gil Á, Perez-Navero JL, Flores-Rojas K, Martín-Borreguero P, Solis-Urra P, Ruiz-Ojeda FJ, Garcia F , Gil-Campos M",Autism Spectrum Disorder (ASD) with and without Mental Regression is Associated with Changes in the Fecal Microbiota,Nutrients,2019,"autism spectrum disorder, children, intestinal microbiota, nutrients",Experiment 2,Spain,Homo sapiens,Feces,UBERON:0001988,Autism,EFO:0003758,healthy controls,children with autism non-mental regression (ANMR),Children between 2-6 years old with an agreed clinical diagnosis of autism per the ICD 10th Edition for ASD and DSM-5 who did not have development regression during the first two years of life.,57,30,NA,16S,34,Illumina,Kruskall-Wallis,0.05,TRUE,NA,"age,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:202/3/NA,Study 202,case-control,30764497,10.3390/nu11020337,NA,"Plaza-Díaz J, Gómez-Fernández A, Chueca N, Torre-Aguilar MJ, Gil Á, Perez-Navero JL, Flores-Rojas K, Martín-Borreguero P, Solis-Urra P, Ruiz-Ojeda FJ, Garcia F , Gil-Campos M",Autism Spectrum Disorder (ASD) with and without Mental Regression is Associated with Changes in the Fecal Microbiota,Nutrients,2019,"autism spectrum disorder, children, intestinal microbiota, nutrients",Experiment 3,Spain,Homo sapiens,Feces,UBERON:0001988,Autism,EFO:0003758,healthy controls,children with autism mental regression (AMR),Children between 2-6 years old with an agreed clinical diagnosis of autism per the ICD 10th Edition for ASD and DSM-5 who had development regression during the first two years of life.,57,18,NA,16S,34,Illumina,Kruskall-Wallis,0.05,TRUE,NA,"age,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:202/4/NA,Study 202,case-control,30764497,10.3390/nu11020337,NA,"Plaza-Díaz J, Gómez-Fernández A, Chueca N, Torre-Aguilar MJ, Gil Á, Perez-Navero JL, Flores-Rojas K, Martín-Borreguero P, Solis-Urra P, Ruiz-Ojeda FJ, Garcia F , Gil-Campos M",Autism Spectrum Disorder (ASD) with and without Mental Regression is Associated with Changes in the Fecal Microbiota,Nutrients,2019,"autism spectrum disorder, children, intestinal microbiota, nutrients",Experiment 4,Spain,Homo sapiens,Feces,UBERON:0001988,Autism,EFO:0003758,healthy controls,children with autism spectrum disorders (ASD),Children between 2-6 years old with an agreed clinical diagnosis of autism per the ICD 10th Edition for ASD and DSM-5,57,48,NA,16S,34,Illumina,Kruskall-Wallis,0.05,TRUE,NA,"age,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:203/1/NA,Study 203,case-control,30707176,10.1097/CM9.0000000000000086,NA,"Bai W, Chen S, Tang CS, Qi JG, Cui QH, Xu M, Du JB , Jin HF",Gut microbiota analysis and its significance in vasovagal syncope in children,Chinese medical journal,2019,NA,Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Syncope,HP:0001279,healthy children,children with vasovagal syncope,children ages 5-18 who meet diagnostic criteria for vasovagal syncope,20,20,8 weeks,16S,4,Illumina,LEfSe,0.05,FALSE,4,"age,sex",NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:204/1/NA,Study 204,case-control,29791775,10.1111/1471-0528.15299,NA,"Tabatabaei N, Eren AM, Barreiro LB, Yotova V, Dumaine A, Allard C , Fraser WD",Vaginal microbiome in early pregnancy and subsequent risk of spontaneous preterm birth: a case-control study,BJOG : an international journal of obstetrics and gynaecology,2019,"16S rRNA, Lactobacillus, bacterial vaginosis, preterm birth, vaginal microbiome",Experiment 1,Canada,Homo sapiens,Vagina,UBERON:0000996,Premature birth,EFO:0003917,mothers whose newborns were delivered at ≥37 getastional weeks,mothers whose newborns were delivered at <34 gestational week,NA,365,17,NA,16S,4,Illumina,NLMIXED,0.05,TRUE,NA,NA,"body mass index,ethnic group,maternal age,parity,smoking behavior",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:205/1/NA,Study 205,"cross-sectional observational, not case-control",23758857,10.1186/1471-2334-13-271,NA,"Gao W, Weng J, Gao Y , Chen X",Comparison of the vaginal microbiota diversity of women with and without human papillomavirus infection: a cross-sectional study,BMC infectious diseases,2013,NA,Experiment 1,China,Homo sapiens,Vagina,UBERON:0000996,Human papilloma virus infection,EFO:0001668,HPV negative women,HPV positive women,women positive for HPV infection,38,32,1 month,16S,23,NA,Chi-Square,0.05,FALSE,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:206/1/NA,Study 206,"cross-sectional observational, not case-control",29317709,10.1038/s41598-017-18596-0,NA,"Hsieh YY, Tung SY, Pan HY, Yen CW, Xu HW, Lin YJ, Deng YF, Hsu WT, Wu CS , Li C",Increased Abundance of Clostridium and Fusobacterium in Gastric Microbiota of Patients with Gastric Cancer in Taiwan,Scientific reports,2018,NA,Experiment 1,China,Homo sapiens,Stomach,UBERON:0000945,Gastric cancer,MONDO:0001056,patients diagnosed with gastritis,patients diagnosed with gastric cancer,Patients with gastric cancer,16,11,NA,16S,34,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:207/1/NA,Study 207,case-control,24265786,10.1371/journal.pone.0079812,NA,"Liu MB, Xu SR, He Y, Deng GH, Sheng HF, Huang XM, Ouyang CY , Zhou HW",Diverse vaginal microbiomes in reproductive-age women with vulvovaginal candidiasis,PloS one,2013,NA,Experiment 1,China,Homo sapiens,Vagina,UBERON:0000996,Vulvovaginitis,EFO:1001240,Normal controls,Women with BV,BV assessment with a gram-stain score => 7,30,10,1 month,16S,6,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:207/2/NA,Study 207,case-control,24265786,10.1371/journal.pone.0079812,NA,"Liu MB, Xu SR, He Y, Deng GH, Sheng HF, Huang XM, Ouyang CY , Zhou HW",Diverse vaginal microbiomes in reproductive-age women with vulvovaginal candidiasis,PloS one,2013,NA,Experiment 2,China,Homo sapiens,Vagina,UBERON:0000996,Vulvovaginitis,EFO:1001240,Normal controls,Women with BV and VVC,Women infected with both BV and VVC,30,16,1 month,16S,6,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:208/1/NA,Study 208,case-control,24532064,10.1128/AEM.00003-14,NA,"Ling Z, Li Z, Liu X, Cheng Y, Luo Y, Tong X, Yuan L, Wang Y, Sun J, Li L , Xiang C",Altered fecal microbiota composition associated with food allergy in infants,Applied and environmental microbiology,2014,NA,Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Food allergy,EFO:1001890,healthy controls,infants with food allergies,infant with food allergy,45,34,1 month,16S,123,Roche454,Metastats,0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:208/2/NA,Study 208,case-control,24532064,10.1128/AEM.00003-14,NA,"Ling Z, Li Z, Liu X, Cheng Y, Luo Y, Tong X, Yuan L, Wang Y, Sun J, Li L , Xiang C",Altered fecal microbiota composition associated with food allergy in infants,Applied and environmental microbiology,2014,NA,Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Food allergy,EFO:1001890,healthy controls,infants with food allergies,infant with food allergy,45,34,1 month,16S,123,Roche454,LEfSe,2,FALSE,2,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:208/3/NA,Study 208,case-control,24532064,10.1128/AEM.00003-14,NA,"Ling Z, Li Z, Liu X, Cheng Y, Luo Y, Tong X, Yuan L, Wang Y, Sun J, Li L , Xiang C",Altered fecal microbiota composition associated with food allergy in infants,Applied and environmental microbiology,2014,NA,Experiment 3,China,Homo sapiens,Feces,UBERON:0001988,Food allergy,EFO:1001890,infants non-IgE mediated,infants IgE mediated,infant IgE mediated,17,17,1 month,16S,123,Roche454,LEfSe,2,FALSE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:208/4/NA,Study 208,case-control,24532064,10.1128/AEM.00003-14,NA,"Ling Z, Li Z, Liu X, Cheng Y, Luo Y, Tong X, Yuan L, Wang Y, Sun J, Li L , Xiang C",Altered fecal microbiota composition associated with food allergy in infants,Applied and environmental microbiology,2014,NA,Experiment 4,China,Homo sapiens,Feces,UBERON:0001988,Food allergy,EFO:1001890,infants non-IgE mediated,infants IgE mediated,infant IgE mediated,17,17,1 month,16S,123,Roche454,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:209/1/NA,Study 209,prospective cohort,32012716,10.3390/microorganisms8020179,NA,"Wong WSW, Sabu P, Deopujari V, Levy S, Shah AA, Clemency N, Provenzano M, Saadoon R, Munagala A, Baker R, Baveja R, Mueller NT, Dominguez-Bello MG, Huddleston K, Niederhuber JE , Hourigan SK",Prenatal and Peripartum Exposure to Antibiotics and Cesarean Section Delivery Are Associated with Differences in Diversity and Composition of the Infant Meconium Microbiome,Microorganisms,2020,"antibiotics, delivery mode, infant, microbiome, neonate, pediatrics",Experiment 1,United States of America,Homo sapiens,Meconium,UBERON:0007109,Cesarean section,EFO:0009636,vaginal delivery,C-section,"meconium defined as the first stool passed, other than meconium staining of amniotic fluid.",62,43,"Mothers of infants born by CS received significantly more peripartum antibiotics than those born by VD (43/43 (100%) in CS vs. 19/62 (31%) in VD, p < 0.001).",16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,increased,NA,increased,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:210/1/NA,Study 210,case-control,26663491,10.1111/pai.12522,NA,"Chen CC, Chen KJ, Kong MS, Chang HJ , Huang JL",Alterations in the gut microbiotas of children with food sensitization in early life,Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology,2016,"454 pyrosequencing, food sensitization, linear discriminant analysis, microbiota",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Food allergy,EFO:1001890,healthy controls,children with food sensitization,child with food sensitization,22,23,1 week,16S,345,Roche454,T-Test,0.01,FALSE,NA,age,NA,NA,decreased,decreased,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:210/2/NA,Study 210,case-control,26663491,10.1111/pai.12522,NA,"Chen CC, Chen KJ, Kong MS, Chang HJ , Huang JL",Alterations in the gut microbiotas of children with food sensitization in early life,Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology,2016,"454 pyrosequencing, food sensitization, linear discriminant analysis, microbiota",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Food allergy,EFO:1001890,healthy controls,children with food sensitization,child with food sensitization,22,23,1 week,16S,345,Roche454,LEfSe,0.05,FALSE,2,age,NA,NA,decreased,decreased,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:211/1/NA,Study 211,case-control,33718259,10.3389/fcimb.2021.549678,NA,"Long Y, Liang F, Guo R, Zhu C, Zhao X, Wang X, Liu F, Jiang M, Liang Q, Zeng S, Han M, Qin J, Li S, Li S , Yang H",Gut Microbiota Signatures in Gestational Anemia,Frontiers in cellular and infection microbiology,2021,"16S rRNA gene sequencing, gestational anemia, gut microbiota, microbial dysbiosis, pregnant women",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Anemia,MONDO:0002280,healthy controls(HC1 group),gestational anemia (GA1 group),Gestational diseases are associated with altered intestinal microbiota in pregnant women in the first trimester.,54,24,4 weeks,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,NA,NA,"age,body mass index,gestational age,sex",NA,unchanged,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:211/2/NA,Study 211,case-control,33718259,10.3389/fcimb.2021.549678,NA,"Long Y, Liang F, Guo R, Zhu C, Zhao X, Wang X, Liu F, Jiang M, Liang Q, Zeng S, Han M, Qin J, Li S, Li S , Yang H",Gut Microbiota Signatures in Gestational Anemia,Frontiers in cellular and infection microbiology,2021,"16S rRNA gene sequencing, gestational anemia, gut microbiota, microbial dysbiosis, pregnant women",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Anemia,MONDO:0002280,healthy controls (HC3 group),gestational anemia (GA3 group),Gestational diseases are associated with altered intestinal microbiota in pregnant women in the third trimester.,56,30,4 weeks,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,NA,NA,"age,body mass index,gestational age,sex",NA,unchanged,decreased,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:212/1/NA,Study 212,"cross-sectional observational, not case-control",30355393,10.1017/S0007114518002465,NA,"Lin D, Peters BA, Friedlander C, Freiman HJ, Goedert JJ, Sinha R, Miller G, Bernstein MA, Hayes RB , Ahn J",Association of dietary fibre intake and gut microbiota in adults,The British journal of nutrition,2018,"FC fold change, NCI National Cancer Institute, NYU New York University, Cross-sectional studies, Dietary fibre intake, Epidemiology, Gut microbiome",Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,low quartile of TOTAL fiber intake,Higher quartile of TOTAL fiber intake,Subjects who had a higher total fiber intake,76,75,"no ""long term"" antibiotics use",16S,34,"Illumina,Roche454",DESeq2,0.05,TRUE,NA,NA,"age,body mass index,sex,smoking status",NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:212/2/NA,Study 212,"cross-sectional observational, not case-control",30355393,10.1017/S0007114518002465,NA,"Lin D, Peters BA, Friedlander C, Freiman HJ, Goedert JJ, Sinha R, Miller G, Bernstein MA, Hayes RB , Ahn J",Association of dietary fibre intake and gut microbiota in adults,The British journal of nutrition,2018,"FC fold change, NCI National Cancer Institute, NYU New York University, Cross-sectional studies, Dietary fibre intake, Epidemiology, Gut microbiome",Experiment 2,United States of America,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,low fiber intake from FRUITS/ VEGETABLES,Higher fiber intake from FRUITS/ VEGETABLES,Subjects who had a higher fiber intake from FRUITS/ VEGETABLES,76,75,"no ""long term"" antibiotics use",16S,34,"Illumina,Roche454",DESeq2,0.05,TRUE,NA,NA,"age,body mass index,sex,smoking status",NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:212/3/NA,Study 212,"cross-sectional observational, not case-control",30355393,10.1017/S0007114518002465,NA,"Lin D, Peters BA, Friedlander C, Freiman HJ, Goedert JJ, Sinha R, Miller G, Bernstein MA, Hayes RB , Ahn J",Association of dietary fibre intake and gut microbiota in adults,The British journal of nutrition,2018,"FC fold change, NCI National Cancer Institute, NYU New York University, Cross-sectional studies, Dietary fibre intake, Epidemiology, Gut microbiome",Experiment 3,United States of America,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,low fiber intake from BEANS,Higher fiber intake from BEANS,Subjects who had a higher fiber intake from BEANS,76,75,"no ""long term"" antibiotics use",16S,34,"Illumina,Roche454",DESeq2,0.05,TRUE,NA,NA,"age,body mass index,sex,smoking status",NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:212/4/NA,Study 212,"cross-sectional observational, not case-control",30355393,10.1017/S0007114518002465,NA,"Lin D, Peters BA, Friedlander C, Freiman HJ, Goedert JJ, Sinha R, Miller G, Bernstein MA, Hayes RB , Ahn J",Association of dietary fibre intake and gut microbiota in adults,The British journal of nutrition,2018,"FC fold change, NCI National Cancer Institute, NYU New York University, Cross-sectional studies, Dietary fibre intake, Epidemiology, Gut microbiome",Experiment 4,United States of America,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,low fiber intake from GRAINS,Higher fiber intake from GRAINS,Subjects who had a higher fiber intake from GRAINS,76,75,"no ""long term"" antibiotics use",16S,34,"Illumina,Roche454",DESeq2,0.05,TRUE,NA,NA,"age,body mass index,sex,smoking status",NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:213/4/NA,Study 213,"cross-sectional observational, not case-control",27827448,10.1038/srep36666,NA,"Kuang YS, Li SH, Guo Y, Lu JH, He JR, Luo BJ, Jiang FJ, Shen H, Papasian CJ, Pang H, Xia HM, Deng HW , Qiu X",Composition of gut microbiota in infants in China and global comparison,Scientific reports,2016,NA,Experiment 4,China,Homo sapiens,Feces,UBERON:0001988,Gut microbiome measurement,EFO:0007874,Neonates,2-month-old infants,Samples from 2-month-old infants,15,14,NA,16S,345,Roche454,T-Test,0.05,FALSE,NA,NA,NA,NA,increased,increased,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:213/5/NA,Study 213,"cross-sectional observational, not case-control",27827448,10.1038/srep36666,NA,"Kuang YS, Li SH, Guo Y, Lu JH, He JR, Luo BJ, Jiang FJ, Shen H, Papasian CJ, Pang H, Xia HM, Deng HW , Qiu X",Composition of gut microbiota in infants in China and global comparison,Scientific reports,2016,NA,Experiment 5,China,Homo sapiens,Feces,UBERON:0001988,Delivery method,EFO:0000395,Cesarean delivered neonates,Vaginally delivered neonates,samples from neonates delivered by Vagina,9,6,NA,16S,345,Roche454,T-Test,0.05,FALSE,NA,NA,NA,NA,decreased,decreased,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:213/6/NA,Study 213,"cross-sectional observational, not case-control",27827448,10.1038/srep36666,NA,"Kuang YS, Li SH, Guo Y, Lu JH, He JR, Luo BJ, Jiang FJ, Shen H, Papasian CJ, Pang H, Xia HM, Deng HW , Qiu X",Composition of gut microbiota in infants in China and global comparison,Scientific reports,2016,NA,Experiment 6,China,Homo sapiens,Feces,UBERON:0001988,Delivery method,EFO:0000395,Cesarean delivered 2-month-olds,Vaginally delivered 2-month-olds,Two months infants that were delivered vaginally,7,7,NA,16S,345,Roche454,T-Test,0.05,FALSE,NA,NA,NA,NA,increased,increased,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:214/1/NA,Study 214,time series / longitudinal observational,27292825,10.1016/j.jaci.2016.03.041,NA,"Bunyavanich S, Shen N, Grishin A, Wood R, Burks W, Dawson P, Jones SM, Leung DYM, Sampson H, Sicherer S , Clemente JC",Early-life gut microbiome composition and milk allergy resolution,The Journal of allergy and clinical immunology,2016,"16s rRNA sequencing, Bacteroidetes, Clostridia, Cow's milk allergy, Firmicutes, fatty acid, food allergy, metagenome, microbiome, microbiota",Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Milk allergic reaction,EFO:0007369,milk allergy resolution,children with milk allergy persistence,child with persistent milk allergy at age 8,128,98,NA,16S,4,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:215/1/NA,Study 215,case-control,27812181,10.1371/journal.pone.0166026,NA,"Zheng H, Liang H, Wang Y, Miao M, Shi T, Yang F, Liu E, Yuan W, Ji ZS , Li DK",Altered Gut Microbiota Composition Associated with Eczema in Infants,PloS one,2016,NA,Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Eczema,HP:0000964,healthy control infants,infants with eczema,infants with eczema,51,50,NA,16S,34,Roche454,Metastats,1e-5,TRUE,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:216/1/NA,Study 216,"cross-sectional observational, not case-control",27362264,10.1371/journal.pone.0158498,NA,"Martin R, Makino H, Cetinyurek Yavuz A, Ben-Amor K, Roelofs M, Ishikawa E, Kubota H, Swinkels S, Sakai T, Oishi K, Kushiro A , Knol J","Early-Life Events, Including Mode of Delivery and Type of Feeding, Siblings and Gender, Shape the Developing Gut Microbiota",PloS one,2016,NA,Experiment 1,Netherlands,Homo sapiens,Meconium,UBERON:0007109,Cesarean section,EFO:0009636,vaginal delivery,C-section,babies that were delivered by c-section,80,28,"use of antibiotics between 2 weeks prior to delivery and 2 weeks after delivery, for any reason except for prophylactic use (e.g. cesarean section).",16S,NA,RT-qPCR,Mixed-Effects Regression,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:217/1/NA,Study 217,prospective cohort,23339708,10.1186/1471-2180-13-12,NA,"Nylund L, Satokari R, Nikkilä J, Rajilić-Stojanović M, Kalliomäki M, Isolauri E, Salminen S , de Vos WM",Microarray analysis reveals marked intestinal microbiota aberrancy in infants having eczema compared to healthy children in at-risk for atopic disease,BMC microbiology,2013,NA,Experiment 1,Finland,Homo sapiens,Feces,UBERON:0001988,Eczema,HP:0000964,healthy control,child with eczema,child with eczema,19,15,NA,16S,NA,Human Intestinal Tract Chip,ANOVA,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:217/2/NA,Study 217,prospective cohort,23339708,10.1186/1471-2180-13-12,NA,"Nylund L, Satokari R, Nikkilä J, Rajilić-Stojanović M, Kalliomäki M, Isolauri E, Salminen S , de Vos WM",Microarray analysis reveals marked intestinal microbiota aberrancy in infants having eczema compared to healthy children in at-risk for atopic disease,BMC microbiology,2013,NA,Experiment 2,Finland,Homo sapiens,Feces,UBERON:0001988,Age,EFO:0000246,infant at 6 months,infant at 18 months,infant 18 months of age,34,34,NA,16S,NA,Human Intestinal Tract Chip,ANOVA,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:217/3/NA,Study 217,prospective cohort,23339708,10.1186/1471-2180-13-12,NA,"Nylund L, Satokari R, Nikkilä J, Rajilić-Stojanović M, Kalliomäki M, Isolauri E, Salminen S , de Vos WM",Microarray analysis reveals marked intestinal microbiota aberrancy in infants having eczema compared to healthy children in at-risk for atopic disease,BMC microbiology,2013,NA,Experiment 3,Finland,Homo sapiens,Feces,UBERON:0001988,Age,EFO:0000246,infant at 6 months,infant at 18 months,infant 18 months of age,34,34,NA,16S,NA,Human Intestinal Tract Chip,ANOVA,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:217/4/NA,Study 217,prospective cohort,23339708,10.1186/1471-2180-13-12,NA,"Nylund L, Satokari R, Nikkilä J, Rajilić-Stojanović M, Kalliomäki M, Isolauri E, Salminen S , de Vos WM",Microarray analysis reveals marked intestinal microbiota aberrancy in infants having eczema compared to healthy children in at-risk for atopic disease,BMC microbiology,2013,NA,Experiment 4,Finland,Homo sapiens,Feces,UBERON:0001988,Lactobacillus rhamnosus GG,NCBITAXON:568703,placebo group at 18 months,children supplemented with LGG at 18 months,children who have been supplemented with L. rhamnosus GG at the age of 18 months i.e. a year after the cessation of the probiotic supplementation,15,19,NA,16S,NA,Human Intestinal Tract Chip,ANOVA,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:218/1/NA,Study 218,"cross-sectional observational, not case-control",30675188,10.1186/s13099-018-0281-6,NA,"Liu Q, Li F, Zhuang Y, Xu J, Wang J, Mao X, Zhang Y , Liu X",Alteration in gut microbiota associated with hepatitis B and non-hepatitis virus related hepatocellular carcinoma,Gut pathogens,2019,"Dysbiosis, Gut microbiome, HBV, Hepatocellular carcinoma, Liver cancer",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Hepatocellular carcinoma,EFO:0000182,healthy controls,non-HBV non-HCV related HCC,HCC patients whose disease is not related to hepatitis B/hepatitis virus,33,22,NA,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,increased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:218/2/NA,Study 218,"cross-sectional observational, not case-control",30675188,10.1186/s13099-018-0281-6,NA,"Liu Q, Li F, Zhuang Y, Xu J, Wang J, Mao X, Zhang Y , Liu X",Alteration in gut microbiota associated with hepatitis B and non-hepatitis virus related hepatocellular carcinoma,Gut pathogens,2019,"Dysbiosis, Gut microbiome, HBV, Hepatocellular carcinoma, Liver cancer",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Hepatocellular carcinoma,EFO:0000182,healthy controls,HBV-related HCC patients,HBV-related HCC patients,33,35,NA,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:218/3/NA,Study 218,"cross-sectional observational, not case-control",30675188,10.1186/s13099-018-0281-6,NA,"Liu Q, Li F, Zhuang Y, Xu J, Wang J, Mao X, Zhang Y , Liu X",Alteration in gut microbiota associated with hepatitis B and non-hepatitis virus related hepatocellular carcinoma,Gut pathogens,2019,"Dysbiosis, Gut microbiome, HBV, Hepatocellular carcinoma, Liver cancer",Experiment 3,China,Homo sapiens,Feces,UBERON:0001988,Hepatocellular carcinoma,EFO:0000182,HBV related HCC patients,non-HBV non-HCV patients,HCC patients whose disease is not related to hepatitis B/hepatitis virus,35,22,NA,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:219/1/NA,Study 219,randomized controlled trial,31528836,10.1093/cdn/nzz079,NA,"Dhillon J, Li Z , Ortiz RM",Almond Snacking for 8 wk Increases Alpha-Diversity of the Gastrointestinal Microbiome and Decreases <i>Bacteroides fragilis</i> Abundance Compared with an Isocaloric Snack in College Freshmen,Current developments in nutrition,2019,"ANCOM, adolescence, amplicon sequence variants, cardiovascular, functional foods, gut, metabolism, minority, nutrients, nuts",Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,higher fiber (almonds) - at baseline,"lower fiber (cracker), at baseline",students eating crackers,38,35,NA,16S,45,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,decreased,decreased,unchanged,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:219/2/NA,Study 219,randomized controlled trial,31528836,10.1093/cdn/nzz079,NA,"Dhillon J, Li Z , Ortiz RM",Almond Snacking for 8 wk Increases Alpha-Diversity of the Gastrointestinal Microbiome and Decreases <i>Bacteroides fragilis</i> Abundance Compared with an Isocaloric Snack in College Freshmen,Current developments in nutrition,2019,"ANCOM, adolescence, amplicon sequence variants, cardiovascular, functional foods, gut, metabolism, minority, nutrients, nuts",Experiment 2,United States of America,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,higher fiber (almonds) - 8 wk after intervention,lower fiber (cracker) - 8 wk after intervention,students eating crackers,38,35,NA,16S,45,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,decreased,decreased,unchanged,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:219/3/NA,Study 219,randomized controlled trial,31528836,10.1093/cdn/nzz079,NA,"Dhillon J, Li Z , Ortiz RM",Almond Snacking for 8 wk Increases Alpha-Diversity of the Gastrointestinal Microbiome and Decreases <i>Bacteroides fragilis</i> Abundance Compared with an Isocaloric Snack in College Freshmen,Current developments in nutrition,2019,"ANCOM, adolescence, amplicon sequence variants, cardiovascular, functional foods, gut, metabolism, minority, nutrients, nuts",Experiment 3,United States of America,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,higher fiber (almonds),lower fiber (cracker),students eating crackers,35,38,NA,16S,45,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:220/1/NA,Study 220,case-control,29791788,10.1111/jam.13929,NA,"Jugé R, Rouaud-Tinguely P, Breugnot J, Servaes K, Grimaldi C, Roth MP, Coppin H , Closs B",Shift in skin microbiota of Western European women across aging,Journal of applied microbiology,2018,"16S rRNA gene sequencing, Western European women, age-related changes, alpha diversity, beta diversity, microbiota, skin",Experiment 1,France,Homo sapiens,Skin of body,UBERON:0002097,Age,EFO:0000246,younger age,older age European women,aging,17,17,1 month,16S,34,Illumina,LEfSe,0.05,FALSE,3,NA,NA,NA,increased,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:221/1/NA,Study 221,case-control,30006660,10.1007/s10096-018-3322-7,NA,"Paalanne N, Husso A, Salo J, Pieviläinen O, Tejesvi MV, Koivusaari P, Pirttilä AM, Pokka T, Mattila S, Jyrkäs J, Turpeinen A, Uhari M, Renko M , Tapiainen T",Intestinal microbiome as a risk factor for urinary tract infections in children,European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,2018,NA,Experiment 1,Finland,Homo sapiens,Feces,UBERON:0001988,Urinary tract infection,EFO:0003103,healthy controls,urinary tract infection,urinary tract infection,69,37,NA,16S,45,Ion Torrent,LEfSe,3,FALSE,3,"age,sex",NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:222/1/NA,Study 222,"cross-sectional observational, not case-control",26729566,10.1038/srep18594,NA,"Yang I, Woltemate S, Piazuelo MB, Bravo LE, Yepez MC, Romero-Gallo J, Delgado AG, Wilson KT, Peek RM, Correa P, Josenhans C, Fox JG , Suerbaum S",Different gastric microbiota compositions in two human populations with high and low gastric cancer risk in Colombia,Scientific reports,2016,NA,Experiment 1,Colombia,Homo sapiens,Stomach,UBERON:0000945,Gastric cancer,MONDO:0001056,low gastric cancer risk patients (Tumaco residents),high gastric cancer risk patients (Tuquerres residents),individuals from Tuquerres with high gastric cancer risk,20,20,30 days,16S,NA,Illumina,Metastats,0.05,TRUE,NA,"age,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:223/1/NA,Study 223,"cross-sectional observational, not case-control",29411528,10.1111/jcmm.13508,NA,"Zhou Y, Ou Z, Tang X, Zhou Y, Xu H, Wang X, Li K, He J, Du Y, Wang H, Chen Y , Nie Y",Alterations in the gut microbiota of patients with acquired immune deficiency syndrome,Journal of cellular and molecular medicine,2018,"acquired immune deficiency syndrome, dysbiosis, highly active antiretroviral therapy, human immunodeficiency virus, microbiota, transmission route",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,HIV infection,EFO:0000764,healthy controls,HIV infected patients,patients infected with HIV,35,33,4 weeks,16S,4,Illumina,LEfSe,0.05,FALSE,3,"age,sex",NA,NA,decreased,NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:223/2/NA,Study 223,"cross-sectional observational, not case-control",29411528,10.1111/jcmm.13508,NA,"Zhou Y, Ou Z, Tang X, Zhou Y, Xu H, Wang X, Li K, He J, Du Y, Wang H, Chen Y , Nie Y",Alterations in the gut microbiota of patients with acquired immune deficiency syndrome,Journal of cellular and molecular medicine,2018,"acquired immune deficiency syndrome, dysbiosis, highly active antiretroviral therapy, human immunodeficiency virus, microbiota, transmission route",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,HIV infection,EFO:0000764,healthy controls,HIV infected patients who are homosexual,homosexual patients infected with HIV,35,4,4 weeks,16S,4,Illumina,LEfSe,0.05,FALSE,3,"age,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:223/3/NA,Study 223,"cross-sectional observational, not case-control",29411528,10.1111/jcmm.13508,NA,"Zhou Y, Ou Z, Tang X, Zhou Y, Xu H, Wang X, Li K, He J, Du Y, Wang H, Chen Y , Nie Y",Alterations in the gut microbiota of patients with acquired immune deficiency syndrome,Journal of cellular and molecular medicine,2018,"acquired immune deficiency syndrome, dysbiosis, highly active antiretroviral therapy, human immunodeficiency virus, microbiota, transmission route",Experiment 3,China,Homo sapiens,Feces,UBERON:0001988,HIV infection,EFO:0000764,healthy controls,Intravenous drug abuse HIV patients,Intravenous drug abuse patients infected with HIV,35,3,4 weeks,16S,4,Illumina,LEfSe,0.05,FALSE,3,"age,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:223/4/NA,Study 223,"cross-sectional observational, not case-control",29411528,10.1111/jcmm.13508,NA,"Zhou Y, Ou Z, Tang X, Zhou Y, Xu H, Wang X, Li K, He J, Du Y, Wang H, Chen Y , Nie Y",Alterations in the gut microbiota of patients with acquired immune deficiency syndrome,Journal of cellular and molecular medicine,2018,"acquired immune deficiency syndrome, dysbiosis, highly active antiretroviral therapy, human immunodeficiency virus, microbiota, transmission route",Experiment 4,China,Homo sapiens,Feces,UBERON:0001988,HIV infection,EFO:0000764,heterosexual subjects with HIV,homosexual subjects with HIV,homosexual patients infected with HIV,26,4,4 weeks,16S,4,Illumina,Metastats,0.05,FALSE,3,"age,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:223/5/NA,Study 223,"cross-sectional observational, not case-control",29411528,10.1111/jcmm.13508,NA,"Zhou Y, Ou Z, Tang X, Zhou Y, Xu H, Wang X, Li K, He J, Du Y, Wang H, Chen Y , Nie Y",Alterations in the gut microbiota of patients with acquired immune deficiency syndrome,Journal of cellular and molecular medicine,2018,"acquired immune deficiency syndrome, dysbiosis, highly active antiretroviral therapy, human immunodeficiency virus, microbiota, transmission route",Experiment 5,China,Homo sapiens,Feces,UBERON:0001988,HIV infection,EFO:0000764,healthy control,HAART-treated HIV+ patients,HIV infected patients treated with highly active antiretroviral therapy (HAART),35,14,4 weeks,16S,4,Illumina,LEfSe,0.05,FALSE,3,"age,sex",NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:223/6/NA,Study 223,"cross-sectional observational, not case-control",29411528,10.1111/jcmm.13508,NA,"Zhou Y, Ou Z, Tang X, Zhou Y, Xu H, Wang X, Li K, He J, Du Y, Wang H, Chen Y , Nie Y",Alterations in the gut microbiota of patients with acquired immune deficiency syndrome,Journal of cellular and molecular medicine,2018,"acquired immune deficiency syndrome, dysbiosis, highly active antiretroviral therapy, human immunodeficiency virus, microbiota, transmission route",Experiment 6,China,Homo sapiens,Feces,UBERON:0001988,HIV infection,EFO:0000764,healthy control,HAART untreated,HIV infected patients not treated with HAART,35,19,4 weeks,16S,4,Illumina,LEfSe,0.05,FALSE,3,"age,sex",NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:224/1/NA,Study 224,randomized controlled trial,23038174,10.1038/ismej.2012.104,NA,"Martínez I, Lattimer JM, Hubach KL, Case JA, Yang J, Weber CG, Louk JA, Rose DJ, Kyureghian G, Peterson DA, Haub MD , Walter J",Gut microbiome composition is linked to whole grain-induced immunological improvements,The ISME journal,2013,NA,Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,baseline,barley (WGB),subjects who took a daily 60g dose of barley,28,28,3 months,16S,123,Roche454,ANOVA,0.05,FALSE,NA,NA,NA,NA,increased,unchanged,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:224/2/NA,Study 224,randomized controlled trial,23038174,10.1038/ismej.2012.104,NA,"Martínez I, Lattimer JM, Hubach KL, Case JA, Yang J, Weber CG, Louk JA, Rose DJ, Kyureghian G, Peterson DA, Haub MD , Walter J",Gut microbiome composition is linked to whole grain-induced immunological improvements,The ISME journal,2013,NA,Experiment 2,United States of America,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,baseline,brown rice (BR),subjects who took a daily 60g dose of brown rice fiber,28,28,3 months,16S,123,Roche454,ANOVA,0.05,FALSE,NA,NA,NA,NA,increased,unchanged,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:224/3/NA,Study 224,randomized controlled trial,23038174,10.1038/ismej.2012.104,NA,"Martínez I, Lattimer JM, Hubach KL, Case JA, Yang J, Weber CG, Louk JA, Rose DJ, Kyureghian G, Peterson DA, Haub MD , Walter J",Gut microbiome composition is linked to whole grain-induced immunological improvements,The ISME journal,2013,NA,Experiment 3,United States of America,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,baseline,brown rice + barley (BR + WGB),subjects who took a daily dose of 30g barley + 30g brown rice,28,28,3 months,16S,123,Roche454,ANOVA,0.05,FALSE,NA,NA,NA,NA,increased,unchanged,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:225/1/NA,Study 225,prospective cohort,22153774,10.1016/j.jaci.2011.10.025,NA,"Abrahamsson TR, Jakobsson HE, Andersson AF, Björkstén B, Engstrand L , Jenmalm MC",Low diversity of the gut microbiota in infants with atopic eczema,The Journal of allergy and clinical immunology,2012,NA,Experiment 1,Sweden,Homo sapiens,Feces,UBERON:0001988,Atopic eczema,EFO:0000274,healthy infant,infant with atopic eczema,infant with atopic eczema- at 12 months,20,20,None,16S,34,Roche454,edgeR,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:225/2/NA,Study 225,prospective cohort,22153774,10.1016/j.jaci.2011.10.025,NA,"Abrahamsson TR, Jakobsson HE, Andersson AF, Björkstén B, Engstrand L , Jenmalm MC",Low diversity of the gut microbiota in infants with atopic eczema,The Journal of allergy and clinical immunology,2012,NA,Experiment 2,Sweden,Homo sapiens,Feces,UBERON:0001988,Atopic eczema,EFO:0000274,healthy infant,infant with atopic eczema,infant with atopic eczema- at 1 month,20,20,None,16S,34,Roche454,edgeR,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:226/1/NA,Study 226,case-control,27477587,10.1038/srep30673,NA,"Ling Z, Jin C, Xie T, Cheng Y, Li L , Wu N",Alterations in the Fecal Microbiota of Patients with HIV-1 Infection: An Observational Study in A Chinese Population,Scientific reports,2016,NA,Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,HIV infection,EFO:0000764,healthy controls,HIV-1 infected patients,HIV-1 diagnosed patients,16,67,1 month,16S,123,Roche454,LEfSe,0.05,TRUE,2,"age,body mass index,sex",NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:226/2/NA,Study 226,case-control,27477587,10.1038/srep30673,NA,"Ling Z, Jin C, Xie T, Cheng Y, Li L , Wu N",Alterations in the Fecal Microbiota of Patients with HIV-1 Infection: An Observational Study in A Chinese Population,Scientific reports,2016,NA,Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,HIV infection,EFO:0000764,HAART-naive HIV-1 patients,HAART-treated HIV-1 patients,HIV-1 diagnosed patients,35,32,1 month,16S,123,Roche454,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:227/1/NA,Study 227,case-control,32009325,10.4168/aair.2020.12.2.322,NA,"Park YM, Lee SY, Kang MJ, Kim BS, Lee MJ, Jung SS, Yoon JS, Cho HJ, Lee E, Yang SI, Seo JH, Kim HB, Suh DI, Shin YH, Kim KW, Ahn K , Hong SJ","Imbalance of Gut <i>Streptococcus</i>, <i>Clostridium</i>, and <i>Akkermansia</i> Determines the Natural Course of Atopic Dermatitis in Infant","Allergy, asthma & immunology research",2020,"Dermatitis, atopic, gastrointestinal microbiome, infant, metabolomics, metagenome",Experiment 1,South Korea,Homo sapiens,Feces,UBERON:0001988,Atopic eczema,EFO:0000274,healthy control,infant with transient atopic dermatitis,infant with transient atopic dermatitis,84,22,before sample collection,16S,123,Roche454,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:227/2/NA,Study 227,case-control,32009325,10.4168/aair.2020.12.2.322,NA,"Park YM, Lee SY, Kang MJ, Kim BS, Lee MJ, Jung SS, Yoon JS, Cho HJ, Lee E, Yang SI, Seo JH, Kim HB, Suh DI, Shin YH, Kim KW, Ahn K , Hong SJ","Imbalance of Gut <i>Streptococcus</i>, <i>Clostridium</i>, and <i>Akkermansia</i> Determines the Natural Course of Atopic Dermatitis in Infant","Allergy, asthma & immunology research",2020,"Dermatitis, atopic, gastrointestinal microbiome, infant, metabolomics, metagenome",Experiment 2,South Korea,Homo sapiens,Feces,UBERON:0001988,Atopic eczema,EFO:0000274,healthy controls,infants with persistent atopic dermatitis,infant with persistent atopic dermatitis,84,26,before sample collection,16S,123,Roche454,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:227/3/NA,Study 227,case-control,32009325,10.4168/aair.2020.12.2.322,NA,"Park YM, Lee SY, Kang MJ, Kim BS, Lee MJ, Jung SS, Yoon JS, Cho HJ, Lee E, Yang SI, Seo JH, Kim HB, Suh DI, Shin YH, Kim KW, Ahn K , Hong SJ","Imbalance of Gut <i>Streptococcus</i>, <i>Clostridium</i>, and <i>Akkermansia</i> Determines the Natural Course of Atopic Dermatitis in Infant","Allergy, asthma & immunology research",2020,"Dermatitis, atopic, gastrointestinal microbiome, infant, metabolomics, metagenome",Experiment 3,South Korea,Homo sapiens,Feces,UBERON:0001988,Atopic eczema,EFO:0000274,transient atopic dermatitis,infants with persistent atopic dermatitis,infant with persistent atopic dermatitis,22,26,before sample collection,16S,123,Roche454,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:227/4/NA,Study 227,case-control,32009325,10.4168/aair.2020.12.2.322,NA,"Park YM, Lee SY, Kang MJ, Kim BS, Lee MJ, Jung SS, Yoon JS, Cho HJ, Lee E, Yang SI, Seo JH, Kim HB, Suh DI, Shin YH, Kim KW, Ahn K , Hong SJ","Imbalance of Gut <i>Streptococcus</i>, <i>Clostridium</i>, and <i>Akkermansia</i> Determines the Natural Course of Atopic Dermatitis in Infant","Allergy, asthma & immunology research",2020,"Dermatitis, atopic, gastrointestinal microbiome, infant, metabolomics, metagenome",Experiment 4,South Korea,Homo sapiens,Feces,UBERON:0001988,Atopic eczema,EFO:0000274,healthy controls,infants with persistent atopic dermatitis,infant with persistent atopic dermatitis,84,26,before sample collection,16S,123,Roche454,LEfSe,0.05,FALSE,4,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:227/5/NA,Study 227,case-control,32009325,10.4168/aair.2020.12.2.322,NA,"Park YM, Lee SY, Kang MJ, Kim BS, Lee MJ, Jung SS, Yoon JS, Cho HJ, Lee E, Yang SI, Seo JH, Kim HB, Suh DI, Shin YH, Kim KW, Ahn K , Hong SJ","Imbalance of Gut <i>Streptococcus</i>, <i>Clostridium</i>, and <i>Akkermansia</i> Determines the Natural Course of Atopic Dermatitis in Infant","Allergy, asthma & immunology research",2020,"Dermatitis, atopic, gastrointestinal microbiome, infant, metabolomics, metagenome",Experiment 5,South Korea,Homo sapiens,Feces,UBERON:0001988,Atopic eczema,EFO:0000274,transient atopic dermatitis,infants with persistent atopic dermatitis,infant with persistent atopic dermatitis,22,26,before sample collection,16S,123,Roche454,LEfSe,0.05,FALSE,4,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:227/6/NA,Study 227,case-control,32009325,10.4168/aair.2020.12.2.322,NA,"Park YM, Lee SY, Kang MJ, Kim BS, Lee MJ, Jung SS, Yoon JS, Cho HJ, Lee E, Yang SI, Seo JH, Kim HB, Suh DI, Shin YH, Kim KW, Ahn K , Hong SJ","Imbalance of Gut <i>Streptococcus</i>, <i>Clostridium</i>, and <i>Akkermansia</i> Determines the Natural Course of Atopic Dermatitis in Infant","Allergy, asthma & immunology research",2020,"Dermatitis, atopic, gastrointestinal microbiome, infant, metabolomics, metagenome",Experiment 6,South Korea,Homo sapiens,Feces,UBERON:0001988,Atopic eczema,EFO:0000274,healthy control,infant with transient atopic dermatitis,infant with transient atopic dermatitis,84,22,before sample collection,16S,123,Roche454,LEfSe,0.05,FALSE,4,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:228/1/NA,Study 228,randomized controlled trial,30139999,10.1038/s41598-018-30783-1,NA,"Gurry T, Gibbons SM, Nguyen LTT, Kearney SM, Ananthakrishnan A, Jiang X, Duvallet C, Kassam Z , Alm EJ",Predictability and persistence of prebiotic dietary supplementation in a healthy human cohort,Scientific reports,2018,NA,Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,day 6 of PECTIN spike-in,day 3 of PECTIN spike-in,before pectin spike-in,9,9,6 months,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,"age,body mass index",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:228/2/NA,Study 228,randomized controlled trial,30139999,10.1038/s41598-018-30783-1,NA,"Gurry T, Gibbons SM, Nguyen LTT, Kearney SM, Ananthakrishnan A, Jiang X, Duvallet C, Kassam Z , Alm EJ",Predictability and persistence of prebiotic dietary supplementation in a healthy human cohort,Scientific reports,2018,NA,Experiment 2,United States of America,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,day 6 of INULIN spike-in,day 3 of INULIN spike-in,before pectin spike-in,9,9,6 months,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,"age,body mass index",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:229/1/NA,Study 229,time series / longitudinal observational,29909506,10.1186/s13568-018-0629-9,NA,"Bang SJ, Kim G, Lim MY, Song EJ, Jung DH, Kum JS, Nam YD, Park CS , Seo DH",The influence of in vitro pectin fermentation on the human fecal microbiome,AMB Express,2018,"Fecal microbiota, Fermentation, Pectin, Prebiotic, Short chain fatty acids",Experiment 1,South Korea,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,late pectin incubation time,early pectin incubation time,before/early pectin incubation,3,3,6 months,16S,12,Ion Torrent,Linear Regression,0.1,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:230/1/NA,Study 230,prospective cohort,28903469,10.1093/femsec/fix099,NA,"Tanaka M, Korenori Y, Washio M, Kobayashi T, Momoda R, Kiyohara C, Kuroda A, Saito Y, Sonomoto K , Nakayama J",Signatures in the gut microbiota of Japanese infants who developed food allergies in early childhood,FEMS microbiology ecology,2017,"16S rRNA gene, Clostridium, fecal microbiota, food allergies, infant",Experiment 1,Japan,Homo sapiens,Feces,UBERON:0001988,Food allergy,EFO:1001890,non-allergy,infant with food allergy,infant with food allergy,27,14,NA,16S,12,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:231/1/NA,Study 231,laboratory experiment,28538678,10.3390/nu9060533,NA,"Koutsos A, Lima M, Conterno L, Gasperotti M, Bianchi M, Fava F, Vrhovsek U, Lovegrove JA , Tuohy KM",Effects of Commercial Apple Varieties on Human Gut Microbiota Composition and Metabolic Output Using an In Vitro Colonic Model,Nutrients,2017,"Fluorescence in situ hybridization (FISH), Illumina 16S rRNA gene sequencing, apples, fiber, gut microbiota, in vitro batch culture fermentation, microbial metabolites, pectin, polyphenols, proanthocyanidins",Experiment 1,United Kingdom,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,Poorly fermentable fiber (cellulose),Renatta canada apple - at 10 hr,Healthy donors administered with Renetta Canada apple,3,3,3 months,16S,34,Illumina,ANOVA,0.05,TRUE,NA,NA,NA,NA,decreased,decreased,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:231/2/NA,Study 231,laboratory experiment,28538678,10.3390/nu9060533,NA,"Koutsos A, Lima M, Conterno L, Gasperotti M, Bianchi M, Fava F, Vrhovsek U, Lovegrove JA , Tuohy KM",Effects of Commercial Apple Varieties on Human Gut Microbiota Composition and Metabolic Output Using an In Vitro Colonic Model,Nutrients,2017,"Fluorescence in situ hybridization (FISH), Illumina 16S rRNA gene sequencing, apples, fiber, gut microbiota, in vitro batch culture fermentation, microbial metabolites, pectin, polyphenols, proanthocyanidins",Experiment 2,United Kingdom,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,Poorly fermentable fiber (cellulose),Golden delicious apple - at 10 hr,Healthy donors administered with Golden delicious apple at 10 hr,3,3,3 months,16S,34,Illumina,ANOVA,0.05,TRUE,NA,NA,NA,NA,decreased,decreased,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:231/3/NA,Study 231,laboratory experiment,28538678,10.3390/nu9060533,NA,"Koutsos A, Lima M, Conterno L, Gasperotti M, Bianchi M, Fava F, Vrhovsek U, Lovegrove JA , Tuohy KM",Effects of Commercial Apple Varieties on Human Gut Microbiota Composition and Metabolic Output Using an In Vitro Colonic Model,Nutrients,2017,"Fluorescence in situ hybridization (FISH), Illumina 16S rRNA gene sequencing, apples, fiber, gut microbiota, in vitro batch culture fermentation, microbial metabolites, pectin, polyphenols, proanthocyanidins",Experiment 3,United Kingdom,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,Poorly fermentable fiber (cellulose),Pink lady apple - at 10 hr,Healthy donors administered with Pink lady apple at 10 hr,3,3,3 months,16S,34,Illumina,ANOVA,0.05,TRUE,NA,NA,NA,NA,decreased,decreased,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:231/4/NA,Study 231,laboratory experiment,28538678,10.3390/nu9060533,NA,"Koutsos A, Lima M, Conterno L, Gasperotti M, Bianchi M, Fava F, Vrhovsek U, Lovegrove JA , Tuohy KM",Effects of Commercial Apple Varieties on Human Gut Microbiota Composition and Metabolic Output Using an In Vitro Colonic Model,Nutrients,2017,"Fluorescence in situ hybridization (FISH), Illumina 16S rRNA gene sequencing, apples, fiber, gut microbiota, in vitro batch culture fermentation, microbial metabolites, pectin, polyphenols, proanthocyanidins",Experiment 4,United Kingdom,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,Poorly fermentable fiber (cellulose),Renetta Canada apple- at 24 hr,Healthy donors administered with Renetta Canada apple at 24 hr,3,3,3 months,16S,34,Illumina,ANOVA,0.05,TRUE,NA,NA,NA,NA,decreased,decreased,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:231/5/NA,Study 231,laboratory experiment,28538678,10.3390/nu9060533,NA,"Koutsos A, Lima M, Conterno L, Gasperotti M, Bianchi M, Fava F, Vrhovsek U, Lovegrove JA , Tuohy KM",Effects of Commercial Apple Varieties on Human Gut Microbiota Composition and Metabolic Output Using an In Vitro Colonic Model,Nutrients,2017,"Fluorescence in situ hybridization (FISH), Illumina 16S rRNA gene sequencing, apples, fiber, gut microbiota, in vitro batch culture fermentation, microbial metabolites, pectin, polyphenols, proanthocyanidins",Experiment 5,United Kingdom,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,Poorly fermentable fiber (cellulose),Golden delicious apple- at 24 hr,Healthy donors administered with Golden delicious apple at 24 hr,3,3,3 months,16S,34,Illumina,ANOVA,0.05,TRUE,NA,NA,NA,NA,decreased,decreased,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:231/6/NA,Study 231,laboratory experiment,28538678,10.3390/nu9060533,NA,"Koutsos A, Lima M, Conterno L, Gasperotti M, Bianchi M, Fava F, Vrhovsek U, Lovegrove JA , Tuohy KM",Effects of Commercial Apple Varieties on Human Gut Microbiota Composition and Metabolic Output Using an In Vitro Colonic Model,Nutrients,2017,"Fluorescence in situ hybridization (FISH), Illumina 16S rRNA gene sequencing, apples, fiber, gut microbiota, in vitro batch culture fermentation, microbial metabolites, pectin, polyphenols, proanthocyanidins",Experiment 6,United Kingdom,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,Poorly fermentable fiber (cellulose),Pink lady apple- at 24 hr,Healthy donors administered with Pink lady apple at 24 hr,3,3,3 months,16S,34,Illumina,ANOVA,0.05,TRUE,NA,NA,NA,NA,decreased,decreased,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:231/7/NA,Study 231,laboratory experiment,28538678,10.3390/nu9060533,NA,"Koutsos A, Lima M, Conterno L, Gasperotti M, Bianchi M, Fava F, Vrhovsek U, Lovegrove JA , Tuohy KM",Effects of Commercial Apple Varieties on Human Gut Microbiota Composition and Metabolic Output Using an In Vitro Colonic Model,Nutrients,2017,"Fluorescence in situ hybridization (FISH), Illumina 16S rRNA gene sequencing, apples, fiber, gut microbiota, in vitro batch culture fermentation, microbial metabolites, pectin, polyphenols, proanthocyanidins",Experiment 7,United Kingdom,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,Inulin,Renatta canada apple - at 10 hr,Healthy donors administered with Renatta canada apple - at 10 hr,3,3,3 months,16S,34,Illumina,ANOVA,0.05,TRUE,NA,NA,NA,NA,decreased,decreased,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:231/8/NA,Study 231,laboratory experiment,28538678,10.3390/nu9060533,NA,"Koutsos A, Lima M, Conterno L, Gasperotti M, Bianchi M, Fava F, Vrhovsek U, Lovegrove JA , Tuohy KM",Effects of Commercial Apple Varieties on Human Gut Microbiota Composition and Metabolic Output Using an In Vitro Colonic Model,Nutrients,2017,"Fluorescence in situ hybridization (FISH), Illumina 16S rRNA gene sequencing, apples, fiber, gut microbiota, in vitro batch culture fermentation, microbial metabolites, pectin, polyphenols, proanthocyanidins",Experiment 8,United Kingdom,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,Inulin,Golden delicious apple - at 10 hr,Healthy donors administered with Golden delicious apple - at 10 hr,3,3,3 months,16S,34,Illumina,ANOVA,0.05,TRUE,NA,NA,NA,NA,decreased,decreased,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:231/9/NA,Study 231,laboratory experiment,28538678,10.3390/nu9060533,NA,"Koutsos A, Lima M, Conterno L, Gasperotti M, Bianchi M, Fava F, Vrhovsek U, Lovegrove JA , Tuohy KM",Effects of Commercial Apple Varieties on Human Gut Microbiota Composition and Metabolic Output Using an In Vitro Colonic Model,Nutrients,2017,"Fluorescence in situ hybridization (FISH), Illumina 16S rRNA gene sequencing, apples, fiber, gut microbiota, in vitro batch culture fermentation, microbial metabolites, pectin, polyphenols, proanthocyanidins",Experiment 9,United Kingdom,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,Inulin,Golden delicious apple - at 24 hr,Healthy donors administered with Golden delicious apple - at 24 hr,3,3,3 months,16S,34,Illumina,ANOVA,0.05,TRUE,NA,NA,NA,NA,increased,decreased,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:231/10/NA,Study 231,laboratory experiment,28538678,10.3390/nu9060533,NA,"Koutsos A, Lima M, Conterno L, Gasperotti M, Bianchi M, Fava F, Vrhovsek U, Lovegrove JA , Tuohy KM",Effects of Commercial Apple Varieties on Human Gut Microbiota Composition and Metabolic Output Using an In Vitro Colonic Model,Nutrients,2017,"Fluorescence in situ hybridization (FISH), Illumina 16S rRNA gene sequencing, apples, fiber, gut microbiota, in vitro batch culture fermentation, microbial metabolites, pectin, polyphenols, proanthocyanidins",Experiment 10,United Kingdom,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,Inulin,Pink Lady apple - at 10 hr,Healthy donors administered with Pink Lady apple at 10 hr,3,3,3 months,16S,34,Illumina,ANOVA,0.05,TRUE,NA,NA,NA,NA,decreased,decreased,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:231/11/NA,Study 231,laboratory experiment,28538678,10.3390/nu9060533,NA,"Koutsos A, Lima M, Conterno L, Gasperotti M, Bianchi M, Fava F, Vrhovsek U, Lovegrove JA , Tuohy KM",Effects of Commercial Apple Varieties on Human Gut Microbiota Composition and Metabolic Output Using an In Vitro Colonic Model,Nutrients,2017,"Fluorescence in situ hybridization (FISH), Illumina 16S rRNA gene sequencing, apples, fiber, gut microbiota, in vitro batch culture fermentation, microbial metabolites, pectin, polyphenols, proanthocyanidins",Experiment 11,United Kingdom,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,Inulin,Pink Lady apple - at 24 hr,Healthy donors administered with Pink Lady apple at 24 hr,3,3,3 months,16S,34,Illumina,ANOVA,0.05,TRUE,NA,NA,NA,NA,increased,decreased,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:231/12/NA,Study 231,laboratory experiment,28538678,10.3390/nu9060533,NA,"Koutsos A, Lima M, Conterno L, Gasperotti M, Bianchi M, Fava F, Vrhovsek U, Lovegrove JA , Tuohy KM",Effects of Commercial Apple Varieties on Human Gut Microbiota Composition and Metabolic Output Using an In Vitro Colonic Model,Nutrients,2017,"Fluorescence in situ hybridization (FISH), Illumina 16S rRNA gene sequencing, apples, fiber, gut microbiota, in vitro batch culture fermentation, microbial metabolites, pectin, polyphenols, proanthocyanidins",Experiment 12,United Kingdom,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,Inulin,Cellulose - at 10hr,Donors administered with cellulose at 10hr,3,3,3 months,16S,34,Illumina,ANOVA,0.05,TRUE,NA,NA,NA,NA,increased,increased,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:231/13/NA,Study 231,laboratory experiment,28538678,10.3390/nu9060533,NA,"Koutsos A, Lima M, Conterno L, Gasperotti M, Bianchi M, Fava F, Vrhovsek U, Lovegrove JA , Tuohy KM",Effects of Commercial Apple Varieties on Human Gut Microbiota Composition and Metabolic Output Using an In Vitro Colonic Model,Nutrients,2017,"Fluorescence in situ hybridization (FISH), Illumina 16S rRNA gene sequencing, apples, fiber, gut microbiota, in vitro batch culture fermentation, microbial metabolites, pectin, polyphenols, proanthocyanidins",Experiment 13,United Kingdom,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,Inulin,Cellulose - at 24hr,Donors administered with cellulose at 24hr,3,3,3 months,16S,34,Illumina,ANOVA,0.05,TRUE,NA,NA,NA,NA,increased,increased,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:232/1/NA,Study 232,"cross-sectional observational, not case-control",24451087,10.1186/2049-2618-1-26,NA,"McHardy IH, Li X, Tong M, Ruegger P, Jacobs J, Borneman J, Anton P , Braun J",HIV Infection is associated with compositional and functional shifts in the rectal mucosal microbiota,Microbiome,2013,NA,Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,HIV infection,EFO:0000764,Healthy controls,HIV infected cART negative,HIV infected patients not on combined anti-retroviral therapy,20,20,NA,16S,4,Illumina,Kruskall-Wallis,0.15,TRUE,NA,NA,NA,NA,unchanged,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:233/1/NA,Study 233,"cross-sectional observational, not case-control",24399150,10.1038/mi.2013.116,NA,"Dillon SM, Lee EJ, Kotter CV, Austin GL, Dong Z, Hecht DK, Gianella S, Siewe B, Smith DM, Landay AL, Robertson CE, Frank DN , Wilson CC",An altered intestinal mucosal microbiome in HIV-1 infection is associated with mucosal and systemic immune activation and endotoxemia,Mucosal immunology,2014,NA,Experiment 1,United States of America,Homo sapiens,Colonic mucosa,UBERON:0000317,HIV infection,EFO:0000764,uninfected controls,HIV-infected subjects,Subjects with untreated chronic HIV-1 infection,14,18,3 months,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,"age,sex",NA,NA,unchanged,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:234/1/NA,Study 234,case-control,31619666,10.1038/s41467-019-12253-y,NA,"Fyhrquist N, Muirhead G, Prast-Nielsen S, Jeanmougin M, Olah P, Skoog T, Jules-Clement G, Feld M, Barrientos-Somarribas M, Sinkko H, van den Bogaard EH, Zeeuwen PLJM, Rikken G, Schalkwijk J, Niehues H, Däubener W, Eller SK, Alexander H, Pennino D, Suomela S, Tessas I, Lybeck E, Baran AM, Darban H, Gangwar RS, Gerstel U, Jahn K, Karisola P, Yan L, Hansmann B, Katayama S, Meller S, Bylesjö M, Hupé P, Levi-Schaffer F, Greco D, Ranki A, Schröder JM, Barker J, Kere J, Tsoka S, Lauerma A, Soumelis V, Nestle FO, Homey B, Andersson B , Alenius H",Microbe-host interplay in atopic dermatitis and psoriasis,Nature communications,2019,NA,Experiment 1,"Finland,Germany,United Kingdom",Homo sapiens,Skin of body,UBERON:0002097,Atopic eczema,EFO:0000274,healthy control,adult with atopic dermatitis,adult with moderate-to-severe chronic atopic dermatitis,115,82,2 weeks,16S,NA,Roche454,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:234/2/NA,Study 234,case-control,31619666,10.1038/s41467-019-12253-y,NA,"Fyhrquist N, Muirhead G, Prast-Nielsen S, Jeanmougin M, Olah P, Skoog T, Jules-Clement G, Feld M, Barrientos-Somarribas M, Sinkko H, van den Bogaard EH, Zeeuwen PLJM, Rikken G, Schalkwijk J, Niehues H, Däubener W, Eller SK, Alexander H, Pennino D, Suomela S, Tessas I, Lybeck E, Baran AM, Darban H, Gangwar RS, Gerstel U, Jahn K, Karisola P, Yan L, Hansmann B, Katayama S, Meller S, Bylesjö M, Hupé P, Levi-Schaffer F, Greco D, Ranki A, Schröder JM, Barker J, Kere J, Tsoka S, Lauerma A, Soumelis V, Nestle FO, Homey B, Andersson B , Alenius H",Microbe-host interplay in atopic dermatitis and psoriasis,Nature communications,2019,NA,Experiment 2,"Finland,Germany,United Kingdom",Homo sapiens,Skin of body,UBERON:0002097,Psoriasis,EFO:0000676,healthy control,adult with psoriasis,adult with psoriasis,115,119,2 weeks,16S,NA,Roche454,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:234/3/NA,Study 234,case-control,31619666,10.1038/s41467-019-12253-y,NA,"Fyhrquist N, Muirhead G, Prast-Nielsen S, Jeanmougin M, Olah P, Skoog T, Jules-Clement G, Feld M, Barrientos-Somarribas M, Sinkko H, van den Bogaard EH, Zeeuwen PLJM, Rikken G, Schalkwijk J, Niehues H, Däubener W, Eller SK, Alexander H, Pennino D, Suomela S, Tessas I, Lybeck E, Baran AM, Darban H, Gangwar RS, Gerstel U, Jahn K, Karisola P, Yan L, Hansmann B, Katayama S, Meller S, Bylesjö M, Hupé P, Levi-Schaffer F, Greco D, Ranki A, Schröder JM, Barker J, Kere J, Tsoka S, Lauerma A, Soumelis V, Nestle FO, Homey B, Andersson B , Alenius H",Microbe-host interplay in atopic dermatitis and psoriasis,Nature communications,2019,NA,Experiment 3,"Finland,Germany,United Kingdom",Homo sapiens,Skin of body,UBERON:0002097,Atopic eczema,EFO:0000274,healthy control,adult with atopic dermatitis,adult with moderate-to-severe chronic atopic dermatitis,115,82,2 weeks,16S,NA,Roche454,"Mann-Whitney (Wilcoxon),Kruskall-Wallis,Spearman Correlation",0.01,TRUE,NA,NA,"age,sex",NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:234/4/NA,Study 234,case-control,31619666,10.1038/s41467-019-12253-y,NA,"Fyhrquist N, Muirhead G, Prast-Nielsen S, Jeanmougin M, Olah P, Skoog T, Jules-Clement G, Feld M, Barrientos-Somarribas M, Sinkko H, van den Bogaard EH, Zeeuwen PLJM, Rikken G, Schalkwijk J, Niehues H, Däubener W, Eller SK, Alexander H, Pennino D, Suomela S, Tessas I, Lybeck E, Baran AM, Darban H, Gangwar RS, Gerstel U, Jahn K, Karisola P, Yan L, Hansmann B, Katayama S, Meller S, Bylesjö M, Hupé P, Levi-Schaffer F, Greco D, Ranki A, Schröder JM, Barker J, Kere J, Tsoka S, Lauerma A, Soumelis V, Nestle FO, Homey B, Andersson B , Alenius H",Microbe-host interplay in atopic dermatitis and psoriasis,Nature communications,2019,NA,Experiment 4,"Finland,Germany,United Kingdom",Homo sapiens,Skin of body,UBERON:0002097,Atopic eczema,EFO:0000274,healthy control,adults with psoriasis,adult with moderate-to-severe chronic plaque-type psoriasis,115,119,2 weeks,16S,NA,Roche454,"Kruskall-Wallis,Mann-Whitney (Wilcoxon),Spearman Correlation",0.01,TRUE,NA,NA,"age,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:235/1/NA,Study 235,case-control,29624747,10.1111/pai.12904,NA,"Kourosh A, Luna RA, Balderas M, Nance C, Anagnostou A, Devaraj S , Davis CM",Fecal microbiome signatures are different in food-allergic children compared to siblings and healthy children,Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology,2018,"T regulatory cells, environment, food allergy, genetics, microbiome",Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Food allergy,EFO:1001890,healthy control,child with food allergy,child with food allergy,21,22,NA,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,"age,sex",NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:235/2/NA,Study 235,case-control,29624747,10.1111/pai.12904,NA,"Kourosh A, Luna RA, Balderas M, Nance C, Anagnostou A, Devaraj S , Davis CM",Fecal microbiome signatures are different in food-allergic children compared to siblings and healthy children,Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology,2018,"T regulatory cells, environment, food allergy, genetics, microbiome",Experiment 2,United States of America,Homo sapiens,Feces,UBERON:0001988,Food allergy,EFO:1001890,healthy sibling,child with food allergy,child with food allergy,25,22,NA,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:235/3/NA,Study 235,case-control,29624747,10.1111/pai.12904,NA,"Kourosh A, Luna RA, Balderas M, Nance C, Anagnostou A, Devaraj S , Davis CM",Fecal microbiome signatures are different in food-allergic children compared to siblings and healthy children,Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology,2018,"T regulatory cells, environment, food allergy, genetics, microbiome",Experiment 3,United States of America,Homo sapiens,Feces,UBERON:0001988,Food allergy,EFO:1001890,healthy control,healthy sibling,sibling with no food allergy,21,25,NA,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,"age,sex",NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:235/4/NA,Study 235,case-control,29624747,10.1111/pai.12904,NA,"Kourosh A, Luna RA, Balderas M, Nance C, Anagnostou A, Devaraj S , Davis CM",Fecal microbiome signatures are different in food-allergic children compared to siblings and healthy children,Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology,2018,"T regulatory cells, environment, food allergy, genetics, microbiome",Experiment 4,United States of America,Homo sapiens,Feces,UBERON:0001988,Age,EFO:0000246,<7 years,7-18 years,child age 7-18,26,42,NA,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:236/1/NA,Study 236,randomized controlled trial,29470389,10.3390/nu10020244,NA,"Bamberger C, Rossmeier A, Lechner K, Wu L, Waldmann E, Fischer S, Stark RG, Altenhofer J, Henze K , Parhofer KG","A Walnut-Enriched Diet Affects Gut Microbiome in Healthy Caucasian Subjects: A Randomized, Controlled Trial",Nutrients,2018,"butyric acid, cholesterol, diet, gut microbiome, lipids, nuts, prebiotic, probiotic, walnuts",Experiment 1,Germany,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,after walnut diet,before walnut diet,before walnut consumption,135,135,"excluded those on ""antibiotic therapy""",16S,34,Illumina,Kruskall-Wallis,0.05,FALSE,NA,NA,NA,NA,unchanged,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:236/2/NA,Study 236,randomized controlled trial,29470389,10.3390/nu10020244,NA,"Bamberger C, Rossmeier A, Lechner K, Wu L, Waldmann E, Fischer S, Stark RG, Altenhofer J, Henze K , Parhofer KG","A Walnut-Enriched Diet Affects Gut Microbiome in Healthy Caucasian Subjects: A Randomized, Controlled Trial",Nutrients,2018,"butyric acid, cholesterol, diet, gut microbiome, lipids, nuts, prebiotic, probiotic, walnuts",Experiment 2,Germany,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,replace both,carbohydrate replacement (with walnuts),before walnut consumption,135,135,"excluded those on ""antibiotic therapy""",16S,34,Illumina,Kruskall-Wallis,0.05,FALSE,NA,NA,"age,body mass index,smoking behavior,triglycerides",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:236/3/NA,Study 236,randomized controlled trial,29470389,10.3390/nu10020244,NA,"Bamberger C, Rossmeier A, Lechner K, Wu L, Waldmann E, Fischer S, Stark RG, Altenhofer J, Henze K , Parhofer KG","A Walnut-Enriched Diet Affects Gut Microbiome in Healthy Caucasian Subjects: A Randomized, Controlled Trial",Nutrients,2018,"butyric acid, cholesterol, diet, gut microbiome, lipids, nuts, prebiotic, probiotic, walnuts",Experiment 3,Germany,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,fat replacement (with walnuts),replace both,before walnut consumption,135,135,"excluded those on ""antibiotic therapy""",16S,34,Illumina,Kruskall-Wallis,0.05,FALSE,NA,NA,"age,body mass index,smoking behavior,triglycerides",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:237/1/NA,Study 237,"cross-sectional observational, not case-control",28561276,10.1111/liv.13485,NA,"Heidrich B, Vital M, Plumeier I, Döscher N, Kahl S, Kirschner J, Ziegert S, Solbach P, Lenzen H, Potthoff A, Manns MP, Wedemeyer H , Pieper DH",Intestinal microbiota in patients with chronic hepatitis C with and without cirrhosis compared with healthy controls,Liver international : official journal of the International Association for the Study of the Liver,2018,"alpha diversity, cirrhosis, gut microbiome, liver elastography, microbial diversity",Experiment 1,Germany,Homo sapiens,Feces,UBERON:0001988,Chronic hepatitis C virus infection,EFO:0004220,healthy controls,cirrhosis patients,hepatitis C patients with cirrhosis,50,38,3 months,16S,12,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,decreased,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:237/2/NA,Study 237,"cross-sectional observational, not case-control",28561276,10.1111/liv.13485,NA,"Heidrich B, Vital M, Plumeier I, Döscher N, Kahl S, Kirschner J, Ziegert S, Solbach P, Lenzen H, Potthoff A, Manns MP, Wedemeyer H , Pieper DH",Intestinal microbiota in patients with chronic hepatitis C with and without cirrhosis compared with healthy controls,Liver international : official journal of the International Association for the Study of the Liver,2018,"alpha diversity, cirrhosis, gut microbiome, liver elastography, microbial diversity",Experiment 2,Germany,Homo sapiens,Feces,UBERON:0001988,Chronic hepatitis C virus infection,EFO:0004220,no cirrhosis,cirrhosis patients,heatitis C patients with cirrhosis,57,38,3 months,16S,12,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,decreased,decreased,NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:237/3/NA,Study 237,"cross-sectional observational, not case-control",28561276,10.1111/liv.13485,NA,"Heidrich B, Vital M, Plumeier I, Döscher N, Kahl S, Kirschner J, Ziegert S, Solbach P, Lenzen H, Potthoff A, Manns MP, Wedemeyer H , Pieper DH",Intestinal microbiota in patients with chronic hepatitis C with and without cirrhosis compared with healthy controls,Liver international : official journal of the International Association for the Study of the Liver,2018,"alpha diversity, cirrhosis, gut microbiome, liver elastography, microbial diversity",Experiment 3,Germany,Homo sapiens,Feces,UBERON:0001988,Chronic hepatitis C virus infection,EFO:0004220,healthy controls,No cirrhosis,Hepatitis C patients with no cirrhosis,50,57,3 months,16S,12,Illumina,DESeq2,0.05,FALSE,NA,NA,NA,unchanged,unchanged,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:238/1/NA,Study 238,case-control,31500892,10.1016/j.ygyno.2019.09.002,NA,"Sims TT, Colbert LE, Zheng J, Delgado Medrano AY, Hoffman KL, Ramondetta L, Jazaeri A, Jhingran A, Schmeler KM, Daniel CR , Klopp A",Gut microbial diversity and genus-level differences identified in cervical cancer patients versus healthy controls,Gynecologic oncology,2019,"Cervical cancer, Gut microbiota, Gynecologic cancer, Microbiome",Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Cervical cancer,MONDO:0002974,healthy controls,cervical cancer patient,patients with biopsy-proven carcinoma of the cervix,46,42,1 month- controls only,16S,4,Illumina,LEfSe,0.05,FALSE,3,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:238/2/NA,Study 238,case-control,31500892,10.1016/j.ygyno.2019.09.002,NA,"Sims TT, Colbert LE, Zheng J, Delgado Medrano AY, Hoffman KL, Ramondetta L, Jazaeri A, Jhingran A, Schmeler KM, Daniel CR , Klopp A",Gut microbial diversity and genus-level differences identified in cervical cancer patients versus healthy controls,Gynecologic oncology,2019,"Cervical cancer, Gut microbiota, Gynecologic cancer, Microbiome",Experiment 2,United States of America,Homo sapiens,Feces,UBERON:0001988,Cervical cancer,MONDO:0002974,healthy controls,cervical cancer patient,patients with biopsy-proven carcinoma of the cervix,46,42,1 month- controls only,16S,4,Illumina,LEfSe,0.05,FALSE,3,NA,age,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:238/3/NA,Study 238,case-control,31500892,10.1016/j.ygyno.2019.09.002,NA,"Sims TT, Colbert LE, Zheng J, Delgado Medrano AY, Hoffman KL, Ramondetta L, Jazaeri A, Jhingran A, Schmeler KM, Daniel CR , Klopp A",Gut microbial diversity and genus-level differences identified in cervical cancer patients versus healthy controls,Gynecologic oncology,2019,"Cervical cancer, Gut microbiota, Gynecologic cancer, Microbiome",Experiment 3,United States of America,Homo sapiens,Feces,UBERON:0001988,Cervical cancer,MONDO:0002974,healthy controls,cervical cancer patient,patients with biopsy-proven carcinoma of the cervix,46,42,1 month- controls only,16S,4,Illumina,LEfSe,0.05,FALSE,3,NA,race,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:239/1/NA,Study 239,case-control,29318631,10.1111/all.13389,NA,"Fazlollahi M, Chun Y, Grishin A, Wood RA, Burks AW, Dawson P, Jones SM, Leung DYM, Sampson HA, Sicherer SH , Bunyavanich S",Early-life gut microbiome and egg allergy,Allergy,2018,"egg allergy, egg sensitization, food allergy, microbiome, purine",Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Egg allergy,EFO:0007248,healthy control,children with egg allergy,children with egg allergy (ages ranging from 3 to 16 months),75,66,NA,16S,4,Illumina,"LEfSe,Logistic Regression",0.05,FALSE,2,NA,"age,antibiotic,atopic eczema,breast feeding",NA,increased,increased,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:239/2/NA,Study 239,case-control,29318631,10.1111/all.13389,NA,"Fazlollahi M, Chun Y, Grishin A, Wood RA, Burks AW, Dawson P, Jones SM, Leung DYM, Sampson HA, Sicherer SH , Bunyavanich S",Early-life gut microbiome and egg allergy,Allergy,2018,"egg allergy, egg sensitization, food allergy, microbiome, purine",Experiment 2,United States of America,Homo sapiens,Feces,UBERON:0001988,Egg allergy,EFO:0007248,healthy control,children with egg sensitization,children with egg sensitization,40,101,NA,16S,4,Illumina,"LEfSe,Logistic Regression",0.05,FALSE,2,NA,"age,race",NA,increased,increased,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:240/1/NA,Study 240,case-control,25599982,10.1111/cea.12487,NA,"Azad MB, Konya T, Guttman DS, Field CJ, Sears MR, HayGlass KT, Mandhane PJ, Turvey SE, Subbarao P, Becker AB, Scott JA , Kozyrskyj AL",Infant gut microbiota and food sensitization: associations in the first year of life,Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology,2015,NA,Experiment 1,Canada,Homo sapiens,Feces,UBERON:0001988,Food allergy,EFO:1001890,non-sensitized group,sensitized group,3 months infants with food sensitization at 1 year,154,12,NA,16S,4,Illumina,Kruskall-Wallis,0.05,TRUE,NA,NA,NA,NA,unchanged,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:240/2/NA,Study 240,case-control,25599982,10.1111/cea.12487,NA,"Azad MB, Konya T, Guttman DS, Field CJ, Sears MR, HayGlass KT, Mandhane PJ, Turvey SE, Subbarao P, Becker AB, Scott JA , Kozyrskyj AL",Infant gut microbiota and food sensitization: associations in the first year of life,Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology,2015,NA,Experiment 2,Canada,Homo sapiens,Feces,UBERON:0001988,Food allergy,EFO:1001890,non-sensitized group,sensitized group,1 year infants with food sensitization at 1 year,154,12,NA,16S,4,Illumina,Kruskall-Wallis,0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:241/1/NA,Study 241,case-control,30418043,10.1556/030.65.2018.045,NA,"Muleviciene A, D'Amico F, Turroni S, Candela M , Jankauskiene A",Iron deficiency anemia-related gut microbiota dysbiosis in infants and young children: A pilot study,Acta microbiologica et immunologica Hungarica,2018,"children, dysbiosis, gut microbiota, infants, iron deficiency anemia",Experiment 1,Lithuania,Homo sapiens,Feces,UBERON:0001988,Iron deficiency anemia,HP:0001891,healthy control,iron deficiency anemia,infants and young children with iron deficiency anemia,10,10,None.,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:242/1/NA,Study 242,"cross-sectional observational, not case-control",31752810,10.1186/s12903-019-0947-6,NA,"Xi R, Wang R, Wang Y, Xiang Z, Su Z, Cao Z, Xu X, Zheng X , Li J",Comparative analysis of the oral microbiota between iron-deficiency anaemia (IDA) patients and healthy individuals by high-throughput sequencing,BMC oral health,2019,"High-throughput sequencing, Infective endocarditis, Iron-deficiency anaemia, Oral microbiota",Experiment 1,China,Homo sapiens,Dental plaque,UBERON:0016482,Iron deficiency anemia,HP:0001891,healthy control,iron deficiency anemia,patients with iron deficiency anemia,24,24,2 weeks,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,"age,sex",NA,NA,decreased,unchanged,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:242/2/NA,Study 242,"cross-sectional observational, not case-control",31752810,10.1186/s12903-019-0947-6,NA,"Xi R, Wang R, Wang Y, Xiang Z, Su Z, Cao Z, Xu X, Zheng X , Li J",Comparative analysis of the oral microbiota between iron-deficiency anaemia (IDA) patients and healthy individuals by high-throughput sequencing,BMC oral health,2019,"High-throughput sequencing, Infective endocarditis, Iron-deficiency anaemia, Oral microbiota",Experiment 2,China,Homo sapiens,Dental plaque,UBERON:0016482,Iron deficiency anemia,HP:0001891,healthy control,iron deficiency anemia,patients with iron deficiency anemia,24,24,2 weeks,16S,34,Illumina,LEfSe,0.05,TRUE,3.5,"age,sex",NA,NA,decreased,unchanged,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:242/3/NA,Study 242,"cross-sectional observational, not case-control",31752810,10.1186/s12903-019-0947-6,NA,"Xi R, Wang R, Wang Y, Xiang Z, Su Z, Cao Z, Xu X, Zheng X , Li J",Comparative analysis of the oral microbiota between iron-deficiency anaemia (IDA) patients and healthy individuals by high-throughput sequencing,BMC oral health,2019,"High-throughput sequencing, Infective endocarditis, Iron-deficiency anaemia, Oral microbiota",Experiment 3,China,Homo sapiens,Dental plaque,UBERON:0016482,Iron deficiency anemia,HP:0001891,iron deficiency anemia moderate,iron deficiency anemia severe,iron defiency anemia,16,8,2 weeks,16S,34,Illumina,LEfSe,0.05,TRUE,3.5,"age,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:243/1/NA,Study 243,"cross-sectional observational, not case-control",29971220,10.3389/fcimb.2018.00202,NA,"Gao JJ, Zhang Y, Gerhard M, Mejias-Luque R, Zhang L, Vieth M, Ma JL, Bajbouj M, Suchanek S, Liu WD, Ulm K, Quante M, Li ZX, Zhou T, Schmid R, Classen M, Li WQ, You WC , Pan KF",Association Between Gut Microbiota and <i>Helicobacter pylori</i>-Related Gastric Lesions in a High-Risk Population of Gastric Cancer,Frontiers in cellular and infection microbiology,2018,"16S ribosomal RNA gene sequencing, Helicobacter pylori, gastric lesions, gut microbiota, microbial diversity",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Gastric cancer,MONDO:0001056,non-current H.pylori infection,current H.pylori infection,patients with H.pylori infection (bacteria were histologically detected in any one of the biopsies or it was positively indicated by C-UBT),23,24,NA,16S,4,Illumina,Welch's T-Test,0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:243/2/NA,Study 243,"cross-sectional observational, not case-control",29971220,10.3389/fcimb.2018.00202,NA,"Gao JJ, Zhang Y, Gerhard M, Mejias-Luque R, Zhang L, Vieth M, Ma JL, Bajbouj M, Suchanek S, Liu WD, Ulm K, Quante M, Li ZX, Zhou T, Schmid R, Classen M, Li WQ, You WC , Pan KF",Association Between Gut Microbiota and <i>Helicobacter pylori</i>-Related Gastric Lesions in a High-Risk Population of Gastric Cancer,Frontiers in cellular and infection microbiology,2018,"16S ribosomal RNA gene sequencing, Helicobacter pylori, gastric lesions, gut microbiota, microbial diversity",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Gastric cancer,MONDO:0001056,past H.pylori infection,current H.pylori infection patients,patients with H.pylori infection (bacteria were histologically detected in any one of the biopsies or it was positively indicated by C-UBT),8,24,NA,16S,4,Illumina,Welch's T-Test,0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:243/3/NA,Study 243,"cross-sectional observational, not case-control",29971220,10.3389/fcimb.2018.00202,NA,"Gao JJ, Zhang Y, Gerhard M, Mejias-Luque R, Zhang L, Vieth M, Ma JL, Bajbouj M, Suchanek S, Liu WD, Ulm K, Quante M, Li ZX, Zhou T, Schmid R, Classen M, Li WQ, You WC , Pan KF",Association Between Gut Microbiota and <i>Helicobacter pylori</i>-Related Gastric Lesions in a High-Risk Population of Gastric Cancer,Frontiers in cellular and infection microbiology,2018,"16S ribosomal RNA gene sequencing, Helicobacter pylori, gastric lesions, gut microbiota, microbial diversity",Experiment 3,China,Homo sapiens,Feces,UBERON:0001988,Gastric cancer,MONDO:0001056,H.pylori negative,past H.pylori infection,subjects with evidence of past H.pylori infection but no current infection,15,8,NA,16S,4,Illumina,Welch's T-Test,0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:243/4/NA,Study 243,"cross-sectional observational, not case-control",29971220,10.3389/fcimb.2018.00202,NA,"Gao JJ, Zhang Y, Gerhard M, Mejias-Luque R, Zhang L, Vieth M, Ma JL, Bajbouj M, Suchanek S, Liu WD, Ulm K, Quante M, Li ZX, Zhou T, Schmid R, Classen M, Li WQ, You WC , Pan KF",Association Between Gut Microbiota and <i>Helicobacter pylori</i>-Related Gastric Lesions in a High-Risk Population of Gastric Cancer,Frontiers in cellular and infection microbiology,2018,"16S ribosomal RNA gene sequencing, Helicobacter pylori, gastric lesions, gut microbiota, microbial diversity",Experiment 4,China,Homo sapiens,Feces,UBERON:0001988,Gastric cancer,MONDO:0001056,normal,gastritis cases,subjects with gastric lesions (gastritis),7,18,NA,16S,4,Illumina,Welch's T-Test,0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:243/5/NA,Study 243,"cross-sectional observational, not case-control",29971220,10.3389/fcimb.2018.00202,NA,"Gao JJ, Zhang Y, Gerhard M, Mejias-Luque R, Zhang L, Vieth M, Ma JL, Bajbouj M, Suchanek S, Liu WD, Ulm K, Quante M, Li ZX, Zhou T, Schmid R, Classen M, Li WQ, You WC , Pan KF",Association Between Gut Microbiota and <i>Helicobacter pylori</i>-Related Gastric Lesions in a High-Risk Population of Gastric Cancer,Frontiers in cellular and infection microbiology,2018,"16S ribosomal RNA gene sequencing, Helicobacter pylori, gastric lesions, gut microbiota, microbial diversity",Experiment 5,China,Homo sapiens,Feces,UBERON:0001988,Gastric cancer,MONDO:0001056,normal,subjects with metaplasia,subjects with metaplasia,7,22,NA,16S,4,Illumina,Welch's T-Test,0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:243/6/NA,Study 243,"cross-sectional observational, not case-control",29971220,10.3389/fcimb.2018.00202,NA,"Gao JJ, Zhang Y, Gerhard M, Mejias-Luque R, Zhang L, Vieth M, Ma JL, Bajbouj M, Suchanek S, Liu WD, Ulm K, Quante M, Li ZX, Zhou T, Schmid R, Classen M, Li WQ, You WC , Pan KF",Association Between Gut Microbiota and <i>Helicobacter pylori</i>-Related Gastric Lesions in a High-Risk Population of Gastric Cancer,Frontiers in cellular and infection microbiology,2018,"16S ribosomal RNA gene sequencing, Helicobacter pylori, gastric lesions, gut microbiota, microbial diversity",Experiment 6,China,Homo sapiens,Feces,UBERON:0001988,Gastric cancer,MONDO:0001056,subjects with gastritis,subjects with metaplasia,subjects with metaplasia,18,22,NA,16S,4,Illumina,Welch's T-Test,0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:244/1/NA,Study 244,case-control,27474122,10.1016/j.jaci.2016.04.053,NA,"Shi B, Bangayan NJ, Curd E, Taylor PA, Gallo RL, Leung DYM , Li H",The skin microbiome is different in pediatric versus adult atopic dermatitis,The Journal of allergy and clinical immunology,2016,NA,Experiment 1,United States of America,Homo sapiens,Skin of body,UBERON:0002097,Age,EFO:0000246,2-12 years,18-62 years,adult age 18-62,13,45,1 week (oral antibiotics),16S,123,Illumina,T-Test,0.05,TRUE,NA,age,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:244/2/NA,Study 244,case-control,27474122,10.1016/j.jaci.2016.04.053,NA,"Shi B, Bangayan NJ, Curd E, Taylor PA, Gallo RL, Leung DYM , Li H",The skin microbiome is different in pediatric versus adult atopic dermatitis,The Journal of allergy and clinical immunology,2016,NA,Experiment 2,United States of America,Homo sapiens,Skin of body,UBERON:0002097,Atopic eczema,EFO:0000274,non-lesional skin,lesional skin,atopic dermatitis lesional skin,59,59,1 week (oral antibiotics),16S,123,Illumina,T-Test,0.05,TRUE,NA,age,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:244/3/NA,Study 244,case-control,27474122,10.1016/j.jaci.2016.04.053,NA,"Shi B, Bangayan NJ, Curd E, Taylor PA, Gallo RL, Leung DYM , Li H",The skin microbiome is different in pediatric versus adult atopic dermatitis,The Journal of allergy and clinical immunology,2016,NA,Experiment 3,United States of America,Homo sapiens,Skin of body,UBERON:0002097,Age,EFO:0000246,2-12 years,13-62 years,teenager/adult age 13-62,59,69,1 week (oral antibiotics),16S,123,Illumina,T-Test,0.05,TRUE,NA,age,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:244/4/NA,Study 244,case-control,27474122,10.1016/j.jaci.2016.04.053,NA,"Shi B, Bangayan NJ, Curd E, Taylor PA, Gallo RL, Leung DYM , Li H",The skin microbiome is different in pediatric versus adult atopic dermatitis,The Journal of allergy and clinical immunology,2016,NA,Experiment 4,United States of America,Homo sapiens,Skin of body,UBERON:0002097,Age,EFO:0000246,2-12 years,18-62 years,adult age 18-62,13,45,1 week (oral antibiotics),16S,123,Illumina,T-Test,0.05,TRUE,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:244/5/NA,Study 244,case-control,27474122,10.1016/j.jaci.2016.04.053,NA,"Shi B, Bangayan NJ, Curd E, Taylor PA, Gallo RL, Leung DYM , Li H",The skin microbiome is different in pediatric versus adult atopic dermatitis,The Journal of allergy and clinical immunology,2016,NA,Experiment 5,United States of America,Homo sapiens,Skin of body,UBERON:0002097,Atopic eczema,EFO:0000274,non-lesional skin in young children,lesional skin in young children,atopic dermatitis lesional skin,69,69,1 week (oral antibiotics),16S,123,Illumina,T-Test,0.05,TRUE,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:244/6/NA,Study 244,case-control,27474122,10.1016/j.jaci.2016.04.053,NA,"Shi B, Bangayan NJ, Curd E, Taylor PA, Gallo RL, Leung DYM , Li H",The skin microbiome is different in pediatric versus adult atopic dermatitis,The Journal of allergy and clinical immunology,2016,NA,Experiment 6,United States of America,Homo sapiens,Skin of body,UBERON:0002097,Atopic eczema,EFO:0000274,non-lesional skin,lesional skin,atopic dermatitis lesional skin,59,59,1 week (oral antibiotics),16S,123,Illumina,T-Test,0.05,TRUE,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:244/7/NA,Study 244,case-control,27474122,10.1016/j.jaci.2016.04.053,NA,"Shi B, Bangayan NJ, Curd E, Taylor PA, Gallo RL, Leung DYM , Li H",The skin microbiome is different in pediatric versus adult atopic dermatitis,The Journal of allergy and clinical immunology,2016,NA,Experiment 7,United States of America,Homo sapiens,Skin of body,UBERON:0002097,Age,EFO:0000246,2-12 years,18-62 years,teenager/adult age 13-62,59,69,1 week (oral antibiotics),16S,123,Illumina,T-Test,0.05,TRUE,NA,age,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:245/1/NA,Study 245,case-control,29353409,10.1007/s00240-018-1037-y,NA,"Tang R, Jiang Y, Tan A, Ye J, Xian X, Xie Y, Wang Q, Yao Z , Mo Z",16S rRNA gene sequencing reveals altered composition of gut microbiota in individuals with kidney stones,Urolithiasis,2018,"16S rRNA, Biomarker, Gut microbiota, Nephrolithiasis",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,"Urolithiasis,Nephrolithiasis","EFO:0004253,MONDO:0024647",healthy control,kidney stone group,patients with kidney stones,13,13,3 months,16S,4,Illumina,LEfSe,3,FALSE,3,"age,race",NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:245/2/NA,Study 245,case-control,29353409,10.1007/s00240-018-1037-y,NA,"Tang R, Jiang Y, Tan A, Ye J, Xian X, Xie Y, Wang Q, Yao Z , Mo Z",16S rRNA gene sequencing reveals altered composition of gut microbiota in individuals with kidney stones,Urolithiasis,2018,"16S rRNA, Biomarker, Gut microbiota, Nephrolithiasis",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,"Urolithiasis,Nephrolithiasis","EFO:0004253,MONDO:0024647",healthy control,kidney stone group,patients with kidney stones,13,13,3 months,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,"age,race",NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:246/1/NA,Study 246,prospective cohort,29167295,10.1183/13993003.00280-2017,NA,"Koleva PT, Tun HM, Konya T, Guttman DS, Becker AB, Mandhane PJ, Turvey SE, Subbarao P, Sears MR, Scott JA , Kozyrskyj AL",Sex-specific impact of asthma during pregnancy on infant gut microbiota,The European respiratory journal,2017,NA,Experiment 1,Canada,Homo sapiens,Feces,UBERON:0001988,Asthma,MONDO:0004979,no asthma,maternal asthma/male caucasian infants,male caucasian infants born to mothers who had prenatal asthma,504,41,NA,16S,NA,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:246/2/NA,Study 246,prospective cohort,29167295,10.1183/13993003.00280-2017,NA,"Koleva PT, Tun HM, Konya T, Guttman DS, Becker AB, Mandhane PJ, Turvey SE, Subbarao P, Sears MR, Scott JA , Kozyrskyj AL",Sex-specific impact of asthma during pregnancy on infant gut microbiota,The European respiratory journal,2017,NA,Experiment 2,Canada,Homo sapiens,Feces,UBERON:0001988,Asthma,MONDO:0004979,no asthma,maternal asthma,female caucasian infants born to mothers who had prenatal asthma,430,46,NA,16S,NA,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:246/4/NA,Study 246,prospective cohort,29167295,10.1183/13993003.00280-2017,NA,"Koleva PT, Tun HM, Konya T, Guttman DS, Becker AB, Mandhane PJ, Turvey SE, Subbarao P, Sears MR, Scott JA , Kozyrskyj AL",Sex-specific impact of asthma during pregnancy on infant gut microbiota,The European respiratory journal,2017,NA,Experiment 4,Canada,Homo sapiens,Feces,UBERON:0001988,Asthma,MONDO:0004979,no asthma,maternal asthma/caucasian infants,mothers of caucasian infants who had prenatal asthma,721,74,NA,16S,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:246/5/NA,Study 246,prospective cohort,29167295,10.1183/13993003.00280-2017,NA,"Koleva PT, Tun HM, Konya T, Guttman DS, Becker AB, Mandhane PJ, Turvey SE, Subbarao P, Sears MR, Scott JA , Kozyrskyj AL",Sex-specific impact of asthma during pregnancy on infant gut microbiota,The European respiratory journal,2017,NA,Experiment 5,Canada,Homo sapiens,Feces,UBERON:0001988,Asthma,MONDO:0004979,no asthma,maternal asthma/female infants,"prenatal asthma mothers of female infants who were vaginally delivered, breastfed, not exposed to maternal antibiotics",186,21,NA,16S,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:246/6/NA,Study 246,prospective cohort,29167295,10.1183/13993003.00280-2017,NA,"Koleva PT, Tun HM, Konya T, Guttman DS, Becker AB, Mandhane PJ, Turvey SE, Subbarao P, Sears MR, Scott JA , Kozyrskyj AL",Sex-specific impact of asthma during pregnancy on infant gut microbiota,The European respiratory journal,2017,NA,Experiment 6,Canada,Homo sapiens,Feces,UBERON:0001988,Asthma,MONDO:0004979,no asthma,maternal asthma/caucasian infants/allergies,"prenatal asthma mothers of caucasian infants, who had allergies during pregnancy",429,64,NA,16S,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:246/7/NA,Study 246,prospective cohort,29167295,10.1183/13993003.00280-2017,NA,"Koleva PT, Tun HM, Konya T, Guttman DS, Becker AB, Mandhane PJ, Turvey SE, Subbarao P, Sears MR, Scott JA , Kozyrskyj AL",Sex-specific impact of asthma during pregnancy on infant gut microbiota,The European respiratory journal,2017,NA,Experiment 7,Canada,Homo sapiens,Feces,UBERON:0001988,Asthma,MONDO:0004979,no asthma,maternal asthma/caucasian infants/no allergies,"prenatal asthma mothers of caucasian infants, who had no allergies during pregnancy",278,10,NA,16S,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:246/8/NA,Study 246,prospective cohort,29167295,10.1183/13993003.00280-2017,NA,"Koleva PT, Tun HM, Konya T, Guttman DS, Becker AB, Mandhane PJ, Turvey SE, Subbarao P, Sears MR, Scott JA , Kozyrskyj AL",Sex-specific impact of asthma during pregnancy on infant gut microbiota,The European respiratory journal,2017,NA,Experiment 8,Canada,Homo sapiens,Feces,UBERON:0001988,Asthma,MONDO:0004979,no asthma,overweight prenatal asthma caucasian mothers,"prenatal asthma mothers of caucasian infants, who were overweight/obese before pregnancy",291,33,NA,16S,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:247/1/NA,Study 247,randomized controlled trial,29307330,10.1017/S0007114517003440,NA,"Healey G, Murphy R, Butts C, Brough L, Whelan K , Coad J","Habitual dietary fibre intake influences gut microbiota response to an inulin-type fructan prebiotic: a randomised, double-blind, placebo-controlled, cross-over, human intervention study",The British journal of nutrition,2018,"HDF high dietary fibre; LDF low dietary fibre, 16S rRNA gene sequencing, Gut microbiota, Habitual dietary fibres, Inulin-type fructan prebiotics, Responsiveness",Experiment 1,New Zealand,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,Prebiotic,Placebo,placebo (control for prebiotic intake - representing lower fiber group),34,33,6 months,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,"age,body mass index,sex",NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:247/2/NA,Study 247,randomized controlled trial,29307330,10.1017/S0007114517003440,NA,"Healey G, Murphy R, Butts C, Brough L, Whelan K , Coad J","Habitual dietary fibre intake influences gut microbiota response to an inulin-type fructan prebiotic: a randomised, double-blind, placebo-controlled, cross-over, human intervention study",The British journal of nutrition,2018,"HDF high dietary fibre; LDF low dietary fibre, 16S rRNA gene sequencing, Gut microbiota, Habitual dietary fibres, Inulin-type fructan prebiotics, Responsiveness",Experiment 2,New Zealand,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,prebiotic (inulin-type fructan) - in participants with low dietary fiber,placebo,placebo (control for prebiotic intake - representing lower fiber group),34,33,6 months,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,"age,body mass index,sex",NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:247/3/NA,Study 247,randomized controlled trial,29307330,10.1017/S0007114517003440,NA,"Healey G, Murphy R, Butts C, Brough L, Whelan K , Coad J","Habitual dietary fibre intake influences gut microbiota response to an inulin-type fructan prebiotic: a randomised, double-blind, placebo-controlled, cross-over, human intervention study",The British journal of nutrition,2018,"HDF high dietary fibre; LDF low dietary fibre, 16S rRNA gene sequencing, Gut microbiota, Habitual dietary fibres, Inulin-type fructan prebiotics, Responsiveness",Experiment 3,New Zealand,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,prebiotic (inulin-type fructan) - in participants with high dietary fiber,placebo,placebo (control for prebiotic intake - representing lower fiber group),34,33,6 months,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,"age,body mass index,sex",NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:247/4/NA,Study 247,randomized controlled trial,29307330,10.1017/S0007114517003440,NA,"Healey G, Murphy R, Butts C, Brough L, Whelan K , Coad J","Habitual dietary fibre intake influences gut microbiota response to an inulin-type fructan prebiotic: a randomised, double-blind, placebo-controlled, cross-over, human intervention study",The British journal of nutrition,2018,"HDF high dietary fibre; LDF low dietary fibre, 16S rRNA gene sequencing, Gut microbiota, Habitual dietary fibres, Inulin-type fructan prebiotics, Responsiveness",Experiment 4,New Zealand,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,Low dietary fiber,High dietary fiber,Placebo (control for prebiotic intake - representing lower fiber group),14,20,6 months,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,"age,body mass index,sex",NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:248/1/NA,Study 248,"cross-sectional observational, not case-control",30986570,10.1016/j.pvr.2019.04.006,NA,"Onywera H, Williamson AL, Mbulawa ZZA, Coetzee D , Meiring TL",The cervical microbiota in reproductive-age South African women with and without human papillomavirus infection,"Papillomavirus research (Amsterdam, Netherlands)",2019,"African, Cervical microbiota, High-risk HPV (HR-HPV), Potential biomarkers, Reproductive-age",Experiment 1,South Africa,Homo sapiens,Uterine cervix,UBERON:0000002,Human papilloma virus infection,EFO:0001668,low risk hpv,high risk hpv,High risk HPV infection confirmed through HPV genotyping test,57,30,NA,16S,34,Illumina,LEfSe,0.2,TRUE,2,NA,NA,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:248/2/NA,Study 248,"cross-sectional observational, not case-control",30986570,10.1016/j.pvr.2019.04.006,NA,"Onywera H, Williamson AL, Mbulawa ZZA, Coetzee D , Meiring TL",The cervical microbiota in reproductive-age South African women with and without human papillomavirus infection,"Papillomavirus research (Amsterdam, Netherlands)",2019,"African, Cervical microbiota, High-risk HPV (HR-HPV), Potential biomarkers, Reproductive-age",Experiment 2,South Africa,Homo sapiens,Uterine cervix,UBERON:0000002,Human papilloma virus infection,EFO:0001668,no HPV,HPV,HPV infection confirmed through HPV genotyping test,50,37,NA,16S,34,Illumina,LEfSe,0.2,TRUE,2,NA,NA,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:249/1/NA,Study 249,case-control,29083504,https://doi.org/10.1002/hep.29623,https://pubmed.ncbi.nlm.nih.gov/29083504/,"Puri P, Liangpunsakul S, Christensen JE, Shah VH, Kamath PS, Gores GJ, Walker S, Comerford M, Katz B, Borst A, Yu Q, Kumar DP, Mirshahi F, Radaeva S, Chalasani NP, Crabb DW , Sanyal AJ",The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis,"Hepatology (Baltimore, Md.)",2018,NA,Experiment 1,United States of America,Homo sapiens,Blood,UBERON:0000178,"Hepatitis, Alcoholic",EFO:1001345,NAC,alcoholics,alcoholic hepatitis,20,56,NA,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:249/2/NA,Study 249,case-control,29083504,https://doi.org/10.1002/hep.29623,https://pubmed.ncbi.nlm.nih.gov/29083504/,"Puri P, Liangpunsakul S, Christensen JE, Shah VH, Kamath PS, Gores GJ, Walker S, Comerford M, Katz B, Borst A, Yu Q, Kumar DP, Mirshahi F, Radaeva S, Chalasani NP, Crabb DW , Sanyal AJ",The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis,"Hepatology (Baltimore, Md.)",2018,NA,Experiment 2,United States of America,Homo sapiens,Blood,UBERON:0000178,"Hepatitis, Alcoholic",EFO:1001345,NAC,HDC,alcoholic hepatitis,20,19,NA,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:249/3/NA,Study 249,case-control,29083504,https://doi.org/10.1002/hep.29623,https://pubmed.ncbi.nlm.nih.gov/29083504/,"Puri P, Liangpunsakul S, Christensen JE, Shah VH, Kamath PS, Gores GJ, Walker S, Comerford M, Katz B, Borst A, Yu Q, Kumar DP, Mirshahi F, Radaeva S, Chalasani NP, Crabb DW , Sanyal AJ",The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis,"Hepatology (Baltimore, Md.)",2018,NA,Experiment 3,United States of America,Homo sapiens,Blood,UBERON:0000178,"Hepatitis, Alcoholic",EFO:1001345,NAC,MAH,alcoholic hepatitis,20,18,NA,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:249/4/NA,Study 249,case-control,29083504,https://doi.org/10.1002/hep.29623,https://pubmed.ncbi.nlm.nih.gov/29083504/,"Puri P, Liangpunsakul S, Christensen JE, Shah VH, Kamath PS, Gores GJ, Walker S, Comerford M, Katz B, Borst A, Yu Q, Kumar DP, Mirshahi F, Radaeva S, Chalasani NP, Crabb DW , Sanyal AJ",The circulating microbiome signature and inferred functional metagenomics in alcoholic hepatitis,"Hepatology (Baltimore, Md.)",2018,NA,Experiment 4,United States of America,Homo sapiens,Blood,UBERON:0000178,"Hepatitis, Alcoholic",EFO:1001345,NAC,SAH,alcoholic hepatitis,20,19,NA,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:250/1/NA,Study 250,time series / longitudinal observational,30919073,10.1007/s00277-019-03599-w,NA,"Ames NJ, Barb JJ, Ranucci A, Kim H, Mudra SE, Cashion AK, Townsley DM, Childs R, Paster BJ, Faller LL , Wallen GR",The oral microbiome of patients undergoing treatment for severe aplastic anemia: a pilot study,Annals of hematology,2019,"Immunosuppression and hematopoietic stem cell transplant, Oral microbiome, Tongue brushings",Experiment 1,United States of America,Homo sapiens,Tongue,UBERON:0001723,Severe aplastic anemia,EFO:0006927,baseline,hematopoietic stem cell transplantation engraftment,"In HSCT patients, The first sample was obtained before transplant conditioning treatment. The second specimen was collected at engraftment, defined as two absolute neutrophil counts of greater than 500 per microliter for at least 2 days. The final specimen collection occurred at the participant’s scheduled clinic visit approximately 100 days following transplant.",4,4,NA,16S,2345678,Ion Torrent,LEfSe,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:250/2/NA,Study 250,time series / longitudinal observational,30919073,10.1007/s00277-019-03599-w,NA,"Ames NJ, Barb JJ, Ranucci A, Kim H, Mudra SE, Cashion AK, Townsley DM, Childs R, Paster BJ, Faller LL , Wallen GR",The oral microbiome of patients undergoing treatment for severe aplastic anemia: a pilot study,Annals of hematology,2019,"Immunosuppression and hematopoietic stem cell transplant, Oral microbiome, Tongue brushings",Experiment 2,United States of America,Homo sapiens,Tongue,UBERON:0001723,Severe aplastic anemia,EFO:0006927,baseline,hematopoietic stem cell transplantation engraftment,"In HSCT patients, The first sample was obtained before transplant conditioning treatment. The second specimen was collected at engraftment, defined as two absolute neutrophil counts of greater than 500 per microliter for at least 2 days. The final specimen collection occurred at the participant’s scheduled clinic visit approximately 100 days following transplant.",4,4,NA,16S,3456789,Ion Torrent,LEfSe,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:250/3/NA,Study 250,time series / longitudinal observational,30919073,10.1007/s00277-019-03599-w,NA,"Ames NJ, Barb JJ, Ranucci A, Kim H, Mudra SE, Cashion AK, Townsley DM, Childs R, Paster BJ, Faller LL , Wallen GR",The oral microbiome of patients undergoing treatment for severe aplastic anemia: a pilot study,Annals of hematology,2019,"Immunosuppression and hematopoietic stem cell transplant, Oral microbiome, Tongue brushings",Experiment 3,United States of America,Homo sapiens,Tongue,UBERON:0001723,Severe aplastic anemia,EFO:0006927,engraftment,hematopoietic stem cell transplantation 100 days after the transplant,"In HSCT patients, The first sample was obtained before transplant conditioning treatment. The second specimen was collected at engraftment, defined as two absolute neutrophil counts of greater than 500 per microliter for at least 2 days. The final specimen collection occurred at the participant’s scheduled clinic visit approximately 100 days following transplant.",4,4,NA,16S,2345678,Ion Torrent,LEfSe,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:250/4/NA,Study 250,time series / longitudinal observational,30919073,10.1007/s00277-019-03599-w,NA,"Ames NJ, Barb JJ, Ranucci A, Kim H, Mudra SE, Cashion AK, Townsley DM, Childs R, Paster BJ, Faller LL , Wallen GR",The oral microbiome of patients undergoing treatment for severe aplastic anemia: a pilot study,Annals of hematology,2019,"Immunosuppression and hematopoietic stem cell transplant, Oral microbiome, Tongue brushings",Experiment 4,United States of America,Homo sapiens,Tongue,UBERON:0001723,Severe aplastic anemia,EFO:0006927,engraftment,hematopoietic stem cell transplantation 100 days after the transplant,"In HSCT patients, The first sample was obtained before transplant conditioning treatment. The second specimen was collected at engraftment, defined as two absolute neutrophil counts of greater than 500 per microliter for at least 2 days. The final specimen collection occurred at the participant’s scheduled clinic visit approximately 100 days following transplant.",4,4,NA,16S,3456789,Ion Torrent,LEfSe,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:251/1/NA,Study 251,laboratory experiment,30643289,10.1038/s41591-018-0324-z,NA,"Feehley T, Plunkett CH, Bao R, Choi Hong SM, Culleen E, Belda-Ferre P, Campbell E, Aitoro R, Nocerino R, Paparo L, Andrade J, Antonopoulos DA, Berni Canani R , Nagler CR",Healthy infants harbor intestinal bacteria that protect against food allergy,Nature medicine,2019,NA,Experiment 1,United States of America,Mus musculus,Feces,UBERON:0001988,Milk allergic reaction,EFO:0007369,healthy Infants-colonised mice,cow’s milk allergic (CMA) infants-colonized mice,Germ-free mice colonised with human feces from cow’s milk allergic (CMA) infant donors,8,9,NA,16S,4,Illumina,LEfSe,0.05,FALSE,2,"age,mode of birth,sex",NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:252/1/NA,Study 252,case-control,31211854,10.1111/sji.12799,NA,"Huang S, Mao J, Zhou L, Xiong X , Deng Y",The imbalance of gut microbiota and its correlation with plasma inflammatory cytokines in pemphigus vulgaris patients,Scandinavian journal of immunology,2019,"cytokines, gut microbiota, pemphigus vulgaris",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Pemphigus vulgaris,EFO:0004719,healthy control,Pemphigus vulgaris (PV)  Patients,Patients with pemphigus vulgaris,14,18,6 months,16S,34,Illumina,LEfSe,0.05,FALSE,2,"age,sex",NA,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:253/1/NA,Study 253,case-control,29052232,10.1111/all.13331,NA,"Kim BS, Lee E, Lee MJ, Kang MJ, Yoon J, Cho HJ, Park J, Won S, Lee SY , Hong SJ",Different functional genes of upper airway microbiome associated with natural course of childhood asthma,Allergy,2018,"airway, childhood asthma, function, microbiome",Experiment 1,South Korea,Homo sapiens,Nasopharynx,UBERON:0001728,Asthma,MONDO:0004979,healthy control,asthma,asthma,31,31,3 months,16S,123,Roche454,Dunn's test,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:253/2/NA,Study 253,case-control,29052232,10.1111/all.13331,NA,"Kim BS, Lee E, Lee MJ, Kang MJ, Yoon J, Cho HJ, Park J, Won S, Lee SY , Hong SJ",Different functional genes of upper airway microbiome associated with natural course of childhood asthma,Allergy,2018,"airway, childhood asthma, function, microbiome",Experiment 2,South Korea,Homo sapiens,Nasopharynx,UBERON:0001728,Asthma,MONDO:0004979,healthy control,asthma remission,asthma remission,31,30,3 months,16S,123,Roche454,Dunn's test,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:254/1/NA,Study 254,"cross-sectional observational, not case-control",27115405,10.1007/s00240-016-0882-9,NA,"Stern JM, Moazami S, Qiu Y, Kurland I, Chen Z, Agalliu I, Burk R , Davies KP",Evidence for a distinct gut microbiome in kidney stone formers compared to non-stone formers,Urolithiasis,2016,"Gut microbiome, Kidney stones, Nephrolithiasis, Urolithiasis",Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,"Nephrolithiasis,Urolithiasis","EFO:0004253,MONDO:0024647",healthy control,kidney stone patient,patients with kidney stones,6,23,2 weeks,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:255/1/NA,Study 255,case-control,30782659,10.1128/mBio.02785-18,NA,"Klein C, Gonzalez D, Samwel K, Kahesa C, Mwaiselage J, Aluthge N, Fernando S, West JT, Wood C , Angeletti PC","Relationship between the Cervical Microbiome, HIV Status, and Precancerous Lesions",mBio,2019,"16S RNA, cervical cancer, deep sequencing, human immunodeficiency virus, human papillomavirus, microbiome",Experiment 1,United Republic of Tanzania,Homo sapiens,Uterine cervix,UBERON:0000002,Human papilloma virus infection,EFO:0001668,negative for intraepithelial lesion or malignancy,high-grade squamous intraepithelial lesions,high-grade squamous intraepithelial lesions (HSIL) comfirmed by Pap smear,23,45,NA,16S,4,Illumina,LEfSe,0.1,TRUE,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:255/2/NA,Study 255,case-control,30782659,10.1128/mBio.02785-18,NA,"Klein C, Gonzalez D, Samwel K, Kahesa C, Mwaiselage J, Aluthge N, Fernando S, West JT, Wood C , Angeletti PC","Relationship between the Cervical Microbiome, HIV Status, and Precancerous Lesions",mBio,2019,"16S RNA, cervical cancer, deep sequencing, human immunodeficiency virus, human papillomavirus, microbiome",Experiment 2,United Republic of Tanzania,Homo sapiens,Uterine cervix,UBERON:0000002,Human papilloma virus infection,EFO:0001668,negative for intraepithelial lesion or malignancy,high-grade squamous intraepithelial lesions,high-grade squamous intraepithelial lesions (HSIL) comfirmed by Pap smear,4,4,NA,16S,4,Illumina,LEfSe,0.1,TRUE,NA,age,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:255/3/NA,Study 255,case-control,30782659,10.1128/mBio.02785-18,NA,"Klein C, Gonzalez D, Samwel K, Kahesa C, Mwaiselage J, Aluthge N, Fernando S, West JT, Wood C , Angeletti PC","Relationship between the Cervical Microbiome, HIV Status, and Precancerous Lesions",mBio,2019,"16S RNA, cervical cancer, deep sequencing, human immunodeficiency virus, human papillomavirus, microbiome",Experiment 3,United Republic of Tanzania,Homo sapiens,Uterine cervix,UBERON:0000002,HIV infection,EFO:0000764,HIV-,HIV+,HIV+ comfirmed by Standard Diagnostics HIV-1/2 3.0 detection kit,95,39,NA,16S,4,Illumina,LEfSe,0.1,TRUE,NA,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:256/1/NA,Study 256,"cross-sectional observational, not case-control",30584008,10.1016/j.ebiom.2018.12.034,NA,"Liu X, Shao L, Liu X, Ji F, Mei Y, Cheng Y, Liu F, Yan C, Li L , Ling Z",Alterations of gastric mucosal microbiota across different stomach microhabitats in a cohort of 276 patients with gastric cancer,EBioMedicine,2019,"Gastric cancer, Gastric microbiota, Helicobacter pylori, Stomach microhabitat, Tumor microenvironment",Experiment 1,China,Homo sapiens,Stomach,UBERON:0000945,Gastric cancer,MONDO:0001056,normal tissues,peritumoral tissues,gastric cancer,230,247,1 month,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,"age,sex",NA,decreased,decreased,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:256/2/NA,Study 256,"cross-sectional observational, not case-control",30584008,10.1016/j.ebiom.2018.12.034,NA,"Liu X, Shao L, Liu X, Ji F, Mei Y, Cheng Y, Liu F, Yan C, Li L , Ling Z",Alterations of gastric mucosal microbiota across different stomach microhabitats in a cohort of 276 patients with gastric cancer,EBioMedicine,2019,"Gastric cancer, Gastric microbiota, Helicobacter pylori, Stomach microhabitat, Tumor microenvironment",Experiment 2,China,Homo sapiens,Stomach,UBERON:0000945,Gastric cancer,MONDO:0001056,peritumoral tissues,tumoral tissues,gastric cancer,247,229,1 month,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,"age,sex",NA,increased,decreased,increased,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:256/3/NA,Study 256,"cross-sectional observational, not case-control",30584008,10.1016/j.ebiom.2018.12.034,NA,"Liu X, Shao L, Liu X, Ji F, Mei Y, Cheng Y, Liu F, Yan C, Li L , Ling Z",Alterations of gastric mucosal microbiota across different stomach microhabitats in a cohort of 276 patients with gastric cancer,EBioMedicine,2019,"Gastric cancer, Gastric microbiota, Helicobacter pylori, Stomach microhabitat, Tumor microenvironment",Experiment 3,China,Homo sapiens,Stomach,UBERON:0000945,Gastric cancer,MONDO:0001056,normal tissues,tumoral tissues,gastric cancer,230,229,1 month,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,"age,sex",NA,decreased,decreased,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:256/4/NA,Study 256,"cross-sectional observational, not case-control",30584008,10.1016/j.ebiom.2018.12.034,NA,"Liu X, Shao L, Liu X, Ji F, Mei Y, Cheng Y, Liu F, Yan C, Li L , Ling Z",Alterations of gastric mucosal microbiota across different stomach microhabitats in a cohort of 276 patients with gastric cancer,EBioMedicine,2019,"Gastric cancer, Gastric microbiota, Helicobacter pylori, Stomach microhabitat, Tumor microenvironment",Experiment 4,China,Homo sapiens,Stomach,UBERON:0000945,Gastric cancer,MONDO:0001056,early stage normal,early stage tumor,gastric cancer,112,116,1 month,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,"age,sex",NA,unchanged,decreased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:256/5/NA,Study 256,"cross-sectional observational, not case-control",30584008,10.1016/j.ebiom.2018.12.034,NA,"Liu X, Shao L, Liu X, Ji F, Mei Y, Cheng Y, Liu F, Yan C, Li L , Ling Z",Alterations of gastric mucosal microbiota across different stomach microhabitats in a cohort of 276 patients with gastric cancer,EBioMedicine,2019,"Gastric cancer, Gastric microbiota, Helicobacter pylori, Stomach microhabitat, Tumor microenvironment",Experiment 5,China,Homo sapiens,Stomach,UBERON:0000945,Gastric cancer,MONDO:0001056,early stage normal,early stage peritumor,gastric cancer,112,118,1 month,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,"age,sex",NA,decreased,decreased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:256/6/NA,Study 256,"cross-sectional observational, not case-control",30584008,10.1016/j.ebiom.2018.12.034,NA,"Liu X, Shao L, Liu X, Ji F, Mei Y, Cheng Y, Liu F, Yan C, Li L , Ling Z",Alterations of gastric mucosal microbiota across different stomach microhabitats in a cohort of 276 patients with gastric cancer,EBioMedicine,2019,"Gastric cancer, Gastric microbiota, Helicobacter pylori, Stomach microhabitat, Tumor microenvironment",Experiment 6,China,Homo sapiens,Stomach,UBERON:0000945,Gastric cancer,MONDO:0001056,late stage normal,late stage tumor,gastric cancer,118,113,1 month,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,"age,sex",NA,decreased,decreased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:256/8/NA,Study 256,"cross-sectional observational, not case-control",30584008,10.1016/j.ebiom.2018.12.034,NA,"Liu X, Shao L, Liu X, Ji F, Mei Y, Cheng Y, Liu F, Yan C, Li L , Ling Z",Alterations of gastric mucosal microbiota across different stomach microhabitats in a cohort of 276 patients with gastric cancer,EBioMedicine,2019,"Gastric cancer, Gastric microbiota, Helicobacter pylori, Stomach microhabitat, Tumor microenvironment",Experiment 8,China,Homo sapiens,Stomach,UBERON:0000945,Gastric cancer,MONDO:0001056,late stage normal,late stage peritumor,gastric cancer,118,129,1 month,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,"age,sex",NA,decreased,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:256/9/NA,Study 256,"cross-sectional observational, not case-control",30584008,10.1016/j.ebiom.2018.12.034,NA,"Liu X, Shao L, Liu X, Ji F, Mei Y, Cheng Y, Liu F, Yan C, Li L , Ling Z",Alterations of gastric mucosal microbiota across different stomach microhabitats in a cohort of 276 patients with gastric cancer,EBioMedicine,2019,"Gastric cancer, Gastric microbiota, Helicobacter pylori, Stomach microhabitat, Tumor microenvironment",Experiment 9,China,Homo sapiens,Stomach,UBERON:0000945,Gastric cancer,MONDO:0001056,normal HP-,normal HP+,normal samples that are H. Pylori positive,64,166,1 month,16S,34,Illumina,LEfSe,0.05,TRUE,2,NA,"age,sex",NA,decreased,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:256/10/NA,Study 256,"cross-sectional observational, not case-control",30584008,10.1016/j.ebiom.2018.12.034,NA,"Liu X, Shao L, Liu X, Ji F, Mei Y, Cheng Y, Liu F, Yan C, Li L , Ling Z",Alterations of gastric mucosal microbiota across different stomach microhabitats in a cohort of 276 patients with gastric cancer,EBioMedicine,2019,"Gastric cancer, Gastric microbiota, Helicobacter pylori, Stomach microhabitat, Tumor microenvironment",Experiment 10,China,Homo sapiens,Stomach,UBERON:0000945,Gastric cancer,MONDO:0001056,peritumor HP-,peritumor HP+,peritumor samples that are H. Pylori positive,65,182,1 month,16S,34,Illumina,LEfSe,0.05,TRUE,2,NA,"age,sex",NA,decreased,unchanged,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:256/11/NA,Study 256,"cross-sectional observational, not case-control",30584008,10.1016/j.ebiom.2018.12.034,NA,"Liu X, Shao L, Liu X, Ji F, Mei Y, Cheng Y, Liu F, Yan C, Li L , Ling Z",Alterations of gastric mucosal microbiota across different stomach microhabitats in a cohort of 276 patients with gastric cancer,EBioMedicine,2019,"Gastric cancer, Gastric microbiota, Helicobacter pylori, Stomach microhabitat, Tumor microenvironment",Experiment 11,China,Homo sapiens,Stomach,UBERON:0000945,Gastric cancer,MONDO:0001056,tumor HP-,tumor HP+,tumor samples that are H. Pylori positive,77,152,1 month,16S,34,Illumina,LEfSe,0.05,TRUE,2,NA,"age,sex",NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:257/1/NA,Study 257,case-control,29687353,10.1007/s00430-018-0542-5,NA,"Allali I, Boukhatem N, Bouguenouch L, Hardi H, Boudouaya HA, Cadenas MB, Ouldim K, Amzazi S, Azcarate-Peril MA , Ghazal H",Gut microbiome of Moroccan colorectal cancer patients,Medical microbiology and immunology,2018,"16S rRNA sequencing, Bacterial community, Colorectal cancer, Gut microbiome composition, Moroccan population",Experiment 1,Morocco,Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,healthy control,colorectal cancer,untreated colorectal cancer patients,12,11,3 months,16S,12,Illumina,Kruskall-Wallis,0.05,TRUE,NA,"age,diet,region","body mass index,family history of cancer,sex",NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:258/1/NA,Study 258,case-control,25104642,10.1158/1940-6207.CAPR-14-0129,NA,"Zackular JP, Rogers MA, Ruffin MT , Schloss PD",The human gut microbiome as a screening tool for colorectal cancer,"Cancer prevention research (Philadelphia, Pa.)",2014,NA,Experiment 1,"United States of America,Canada",Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,Healthy Controls,carcinoma,Patients with colonic adenocarcinoma,30,30,NA,16S,4,Illumina,LEfSe,0.05,FALSE,2.5,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:258/2/NA,Study 258,case-control,25104642,10.1158/1940-6207.CAPR-14-0129,NA,"Zackular JP, Rogers MA, Ruffin MT , Schloss PD",The human gut microbiome as a screening tool for colorectal cancer,"Cancer prevention research (Philadelphia, Pa.)",2014,NA,Experiment 2,"Canada,United States of America",Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,Healthy Controls,Adenoma,Patients with colonic adenoma,30,30,NA,16S,4,Illumina,LEfSe,0.05,FALSE,2.5,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:258/3/NA,Study 258,case-control,25104642,10.1158/1940-6207.CAPR-14-0129,NA,"Zackular JP, Rogers MA, Ruffin MT , Schloss PD",The human gut microbiome as a screening tool for colorectal cancer,"Cancer prevention research (Philadelphia, Pa.)",2014,NA,Experiment 3,"Canada,United States of America",Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,Healthy Controls,Colonic lesions,Combination of the clinical and microbiome data from adenoma and carcinoma subjects to create a combined colonic lesion group.,30,60,NA,16S,4,Illumina,LEfSe,0.05,FALSE,2.5,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:258/4/NA,Study 258,case-control,25104642,10.1158/1940-6207.CAPR-14-0129,NA,"Zackular JP, Rogers MA, Ruffin MT , Schloss PD",The human gut microbiome as a screening tool for colorectal cancer,"Cancer prevention research (Philadelphia, Pa.)",2014,NA,Experiment 4,"Canada,United States of America",Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,Adenoma,Carcinoma,Patients with colonic adenocarcinoma,30,30,NA,16S,4,Illumina,LEfSe,0.05,FALSE,2.5,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:259/1/NA,Study 259,randomized controlled trial,29489859,10.1371/journal.pone.0192443,NA,"Glatz M, Jo JH, Kennedy EA, Polley EC, Segre JA, Simpson EL , Kong HH",Emollient use alters skin barrier and microbes in infants at risk for developing atopic dermatitis,PloS one,2018,NA,Experiment 1,United States of America,Homo sapiens,Skin of cheek,UBERON:0008803,Atopic eczema,EFO:0000274,no emollient use,emollient use,infant randomized to emollient therapy,9,10,during study,16S,123,Roche454,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,increased,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:259/2/NA,Study 259,randomized controlled trial,29489859,10.1371/journal.pone.0192443,NA,"Glatz M, Jo JH, Kennedy EA, Polley EC, Segre JA, Simpson EL , Kong HH",Emollient use alters skin barrier and microbes in infants at risk for developing atopic dermatitis,PloS one,2018,NA,Experiment 2,United States of America,Homo sapiens,Skin of forearm,UBERON:0003403,Atopic eczema,EFO:0000274,no emollient use,emollient use,infant randomized to emollient therapy,9,10,during study,16S,123,Roche454,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,increased,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:260/1/NA,Study 260,prospective cohort,10202341,10.1046/j.1365-2222.1999.00560.x,NA,"Björkstén B, Naaber P, Sepp E , Mikelsaar M",The intestinal microflora in allergic Estonian and Swedish 2-year-old children,Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology,1999,NA,Experiment 1,"Estonia,Sweden",Homo sapiens,Feces,UBERON:0001988,Food allergy,EFO:1001890,Nonallergic  Estonian children.,Allergic Estonian children.,2-year-old children with confirmed diagnosis of allergy,16,13,NIL,NA,NA,NA,T-Test,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:260/2/NA,Study 260,prospective cohort,10202341,10.1046/j.1365-2222.1999.00560.x,NA,"Björkstén B, Naaber P, Sepp E , Mikelsaar M",The intestinal microflora in allergic Estonian and Swedish 2-year-old children,Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology,1999,NA,Experiment 2,"Estonia,Sweden",Homo sapiens,Feces,UBERON:0001988,Food allergy,EFO:1001890,Non-allergic Swedish children.,Allergic Swedish children,2-year-old children with confirmed diagnosis of allergy,19,14,NIL,NA,NA,NA,T-Test,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:261/1/NA,Study 261,"cross-sectional observational, not case-control",29434076,10.1620/tjem.244.113,NA,"Hamada S, Masamune A, Nabeshima T , Shimosegawa T",Differences in Gut Microbiota Profiles between Autoimmune Pancreatitis and Chronic Pancreatitis,The Tohoku journal of experimental medicine,2018,"16S sequence, microbiome, next generation sequencing, pancreatic cancer, pancreatitis",Experiment 1,Japan,Homo sapiens,Feces,UBERON:0001988,Chronic pancreatitis,EFO:0000342,chronic pancreatitis,autoimmune pancreatitis type 1,autoimmune pancreatitis type 1,8,12,NA,16S,45,Illumina,Fisher's Exact Test,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:262/1/NA,Study 262,case-control,29885665,10.1186/s40168-018-0487-3,NA,"Durack J, Huang YJ, Nariya S, Christian LS, Ansel KM, Beigelman A, Castro M, Dyer AM, Israel E, Kraft M, Martin RJ, Mauger DT, Rosenberg SR, King TS, White SR, Denlinger LC, Holguin F, Lazarus SC, Lugogo N, Peters SP, Smith LJ, Wechsler ME, Lynch SV , Boushey HA",Bacterial biogeography of adult airways in atopic asthma,Microbiome,2018,"Adult asthma, Atopy, Bronchial microbiota, Corynebacterium, Eosinophilic inflammation, Induced sputum microbiota, Lower airways, Moraxella, Nasal microbiota, Oral microbiota, Upper airways",Experiment 1,United States of America,Homo sapiens,"Bronchus,Nose","UBERON:0000004,UBERON:0002185",Atopic asthma,EFO:0010638,bronchial brush specimens,nasal brush speciments,nasal brush specimen type,27,27,3 months,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,decreased,decreased,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:262/2/NA,Study 262,case-control,29885665,10.1186/s40168-018-0487-3,NA,"Durack J, Huang YJ, Nariya S, Christian LS, Ansel KM, Beigelman A, Castro M, Dyer AM, Israel E, Kraft M, Martin RJ, Mauger DT, Rosenberg SR, King TS, White SR, Denlinger LC, Holguin F, Lazarus SC, Lugogo N, Peters SP, Smith LJ, Wechsler ME, Lynch SV , Boushey HA",Bacterial biogeography of adult airways in atopic asthma,Microbiome,2018,"Adult asthma, Atopy, Bronchial microbiota, Corynebacterium, Eosinophilic inflammation, Induced sputum microbiota, Lower airways, Moraxella, Nasal microbiota, Oral microbiota, Upper airways",Experiment 2,United States of America,Homo sapiens,"Bronchus,Mouth","UBERON:0000165,UBERON:0002185",Atopic asthma,EFO:0010638,bronchial brush specimens,oral wash specimens,oral wash specimen type,27,27,3 months,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,unchanged,increased,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:262/3/NA,Study 262,case-control,29885665,10.1186/s40168-018-0487-3,NA,"Durack J, Huang YJ, Nariya S, Christian LS, Ansel KM, Beigelman A, Castro M, Dyer AM, Israel E, Kraft M, Martin RJ, Mauger DT, Rosenberg SR, King TS, White SR, Denlinger LC, Holguin F, Lazarus SC, Lugogo N, Peters SP, Smith LJ, Wechsler ME, Lynch SV , Boushey HA",Bacterial biogeography of adult airways in atopic asthma,Microbiome,2018,"Adult asthma, Atopy, Bronchial microbiota, Corynebacterium, Eosinophilic inflammation, Induced sputum microbiota, Lower airways, Moraxella, Nasal microbiota, Oral microbiota, Upper airways",Experiment 3,United States of America,Homo sapiens,"Nose,Sputum","UBERON:0000004,UBERON:0007311",Atopic asthma,EFO:0010638,nasal brush specimens,induced sputum specimens,induced sputum specimen type,27,27,3 months,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,increased,increased,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:262/4/NA,Study 262,case-control,29885665,10.1186/s40168-018-0487-3,NA,"Durack J, Huang YJ, Nariya S, Christian LS, Ansel KM, Beigelman A, Castro M, Dyer AM, Israel E, Kraft M, Martin RJ, Mauger DT, Rosenberg SR, King TS, White SR, Denlinger LC, Holguin F, Lazarus SC, Lugogo N, Peters SP, Smith LJ, Wechsler ME, Lynch SV , Boushey HA",Bacterial biogeography of adult airways in atopic asthma,Microbiome,2018,"Adult asthma, Atopy, Bronchial microbiota, Corynebacterium, Eosinophilic inflammation, Induced sputum microbiota, Lower airways, Moraxella, Nasal microbiota, Oral microbiota, Upper airways",Experiment 4,United States of America,Homo sapiens,"Nose,Mouth","UBERON:0000004,UBERON:0000165",Atopic asthma,EFO:0010638,nasal brush specimens,oral wash specimens,oral wash specimen type,27,27,3 months,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,increased,increased,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:262/5/NA,Study 262,case-control,29885665,10.1186/s40168-018-0487-3,NA,"Durack J, Huang YJ, Nariya S, Christian LS, Ansel KM, Beigelman A, Castro M, Dyer AM, Israel E, Kraft M, Martin RJ, Mauger DT, Rosenberg SR, King TS, White SR, Denlinger LC, Holguin F, Lazarus SC, Lugogo N, Peters SP, Smith LJ, Wechsler ME, Lynch SV , Boushey HA",Bacterial biogeography of adult airways in atopic asthma,Microbiome,2018,"Adult asthma, Atopy, Bronchial microbiota, Corynebacterium, Eosinophilic inflammation, Induced sputum microbiota, Lower airways, Moraxella, Nasal microbiota, Oral microbiota, Upper airways",Experiment 5,United States of America,Homo sapiens,"Sputum,Mouth","UBERON:0000165,UBERON:0007311",Atopic asthma,EFO:0010638,induced sputum specimens,oral wash specimens,oral wash specimen type,27,27,3 months,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,unchanged,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:262/6/NA,Study 262,case-control,29885665,10.1186/s40168-018-0487-3,NA,"Durack J, Huang YJ, Nariya S, Christian LS, Ansel KM, Beigelman A, Castro M, Dyer AM, Israel E, Kraft M, Martin RJ, Mauger DT, Rosenberg SR, King TS, White SR, Denlinger LC, Holguin F, Lazarus SC, Lugogo N, Peters SP, Smith LJ, Wechsler ME, Lynch SV , Boushey HA",Bacterial biogeography of adult airways in atopic asthma,Microbiome,2018,"Adult asthma, Atopy, Bronchial microbiota, Corynebacterium, Eosinophilic inflammation, Induced sputum microbiota, Lower airways, Moraxella, Nasal microbiota, Oral microbiota, Upper airways",Experiment 6,United States of America,Homo sapiens,"Bronchus,Sputum","UBERON:0002185,UBERON:0007311",Atopic asthma,EFO:0010638,bronchial brush specimens,induced sputum specimens,induced sputum specimen type,27,27,3 months,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,unchanged,increased,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:262/7/NA,Study 262,case-control,29885665,10.1186/s40168-018-0487-3,NA,"Durack J, Huang YJ, Nariya S, Christian LS, Ansel KM, Beigelman A, Castro M, Dyer AM, Israel E, Kraft M, Martin RJ, Mauger DT, Rosenberg SR, King TS, White SR, Denlinger LC, Holguin F, Lazarus SC, Lugogo N, Peters SP, Smith LJ, Wechsler ME, Lynch SV , Boushey HA",Bacterial biogeography of adult airways in atopic asthma,Microbiome,2018,"Adult asthma, Atopy, Bronchial microbiota, Corynebacterium, Eosinophilic inflammation, Induced sputum microbiota, Lower airways, Moraxella, Nasal microbiota, Oral microbiota, Upper airways",Experiment 7,United States of America,Homo sapiens,Nose,UBERON:0000004,Atopic asthma,EFO:0010638,healthy controls,atopic asthma subjects,subjects with atopic asthma,11,22,3 months,16S,4,Illumina,Zero-Inflated Negative Binomial Regression,0.1,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:263/1/NA,Study 263,case-control,30545401,10.1186/s40168-018-0603-4,NA,"Forbes JD, Chen CY, Knox NC, Marrie RA, El-Gabalawy H, de Kievit T, Alfa M, Bernstein CN , Van Domselaar G",A comparative study of the gut microbiota in immune-mediated inflammatory diseases-does a common dysbiosis exist?,Microbiome,2018,"16S rRNA gene amplicon sequencing, Bacteria, Gut microbiota, Immune-mediated inflammatory disease, Inflammatory bowel disease, Machine learning classifiers, Multiple sclerosis, Rheumatoid arthritis, Taxonomic biomarkers",Experiment 1,Canada,Homo sapiens,Feces,UBERON:0001988,Crohn's disease,EFO:0000384,healthy controls,crohn's disease,patients with immune-mediated inflammatory disease (IMID),23,20,8 weeks,16S,4,Illumina,Kruskall-Wallis,0.05,TRUE,NA,NA,NA,NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:263/2/NA,Study 263,case-control,30545401,10.1186/s40168-018-0603-4,NA,"Forbes JD, Chen CY, Knox NC, Marrie RA, El-Gabalawy H, de Kievit T, Alfa M, Bernstein CN , Van Domselaar G",A comparative study of the gut microbiota in immune-mediated inflammatory diseases-does a common dysbiosis exist?,Microbiome,2018,"16S rRNA gene amplicon sequencing, Bacteria, Gut microbiota, Immune-mediated inflammatory disease, Inflammatory bowel disease, Machine learning classifiers, Multiple sclerosis, Rheumatoid arthritis, Taxonomic biomarkers",Experiment 2,Canada,Homo sapiens,Feces,UBERON:0001988,Ulcerative colitis,EFO:0000729,healthy controls,ulcerative colitis,patients with immune-mediated inflammatory disease (IMID),23,19,8 weeks,16S,4,Illumina,Kruskall-Wallis,0.05,TRUE,NA,NA,NA,NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:263/3/NA,Study 263,case-control,30545401,10.1186/s40168-018-0603-4,NA,"Forbes JD, Chen CY, Knox NC, Marrie RA, El-Gabalawy H, de Kievit T, Alfa M, Bernstein CN , Van Domselaar G",A comparative study of the gut microbiota in immune-mediated inflammatory diseases-does a common dysbiosis exist?,Microbiome,2018,"16S rRNA gene amplicon sequencing, Bacteria, Gut microbiota, Immune-mediated inflammatory disease, Inflammatory bowel disease, Machine learning classifiers, Multiple sclerosis, Rheumatoid arthritis, Taxonomic biomarkers",Experiment 3,Canada,Homo sapiens,Feces,UBERON:0001988,Multiple sclerosis,MONDO:0005301,healthy controls,multiple sceloris,patients with immune-mediated inflammatory disease (IMID),23,19,8 weeks,16S,4,Illumina,Kruskall-Wallis,0.05,TRUE,NA,NA,NA,NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:263/4/NA,Study 263,case-control,30545401,10.1186/s40168-018-0603-4,NA,"Forbes JD, Chen CY, Knox NC, Marrie RA, El-Gabalawy H, de Kievit T, Alfa M, Bernstein CN , Van Domselaar G",A comparative study of the gut microbiota in immune-mediated inflammatory diseases-does a common dysbiosis exist?,Microbiome,2018,"16S rRNA gene amplicon sequencing, Bacteria, Gut microbiota, Immune-mediated inflammatory disease, Inflammatory bowel disease, Machine learning classifiers, Multiple sclerosis, Rheumatoid arthritis, Taxonomic biomarkers",Experiment 4,Canada,Homo sapiens,Feces,UBERON:0001988,Rheumatoid arthritis,EFO:0000685,healthy controls,arthiritis,patients with immune-mediated inflammatory disease (IMID),23,21,8 weeks,16S,4,Illumina,Kruskall-Wallis,0.05,TRUE,NA,NA,NA,NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:264/1/NA,Study 264,"cross-sectional observational, not case-control",26062721,10.1017/S0950268815000965,NA,"Dareng EO, Ma B, Famooto AO, Adebamowo SN, Offiong RA, Olaniyan O, Dakum PS, Wheeler CM, Fadrosh D, Yang H, Gajer P, Brotman RM, Ravel J , Adebamowo CA",Prevalent high-risk HPV infection and vaginal microbiota in Nigerian women,Epidemiology and infection,2016,"HIV/AIDS, human papilloma virus (HPV), public health",Experiment 1,Nigeria,Homo sapiens,Vagina,UBERON:0000996,Human papilloma virus infection,EFO:0001668,HPV-/HIV-,HPV+/HIV-,HR-HPV+ confirmed by medical records and HPV genotyping test,99,12,NA,16S,4,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:265/1/NA,Study 265,time series / longitudinal observational,30395655,10.1371/journal.pone.0207016,NA,"Tuominen H, Rautava S, Collado MC, Syrjänen S , Rautava J",HPV infection and bacterial microbiota in breast milk and infant oral mucosa,PloS one,2018,NA,Experiment 1,Finland,Homo sapiens,Mouth,UBERON:0000165,"Human papilloma virus infection,Age","EFO:0001668,EFO:0000246",at birth,two months,infants with HPV infection at 2 months of age,13,22,NA,16S,34,Illumina,LEfSe,0.05,FALSE,3,NA,NA,NA,unchanged,increased,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:265/2/NA,Study 265,time series / longitudinal observational,30395655,10.1371/journal.pone.0207016,NA,"Tuominen H, Rautava S, Collado MC, Syrjänen S , Rautava J",HPV infection and bacterial microbiota in breast milk and infant oral mucosa,PloS one,2018,NA,Experiment 2,Finland,Homo sapiens,Mouth,UBERON:0000165,Human papilloma virus infection,EFO:0001668,HPV-,HPV+,infants that were positive for HPV infection,21,14,NA,16S,34,Illumina,LEfSe,0.05,FALSE,4,NA,NA,NA,unchanged,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:265/3/NA,Study 265,time series / longitudinal observational,30395655,10.1371/journal.pone.0207016,NA,"Tuominen H, Rautava S, Collado MC, Syrjänen S , Rautava J",HPV infection and bacterial microbiota in breast milk and infant oral mucosa,PloS one,2018,NA,Experiment 3,Finland,Homo sapiens,Mouth,UBERON:0000165,Human papilloma virus infection,EFO:0001668,HPV- at two months,HPV+ at two months,HPV+ infants at two months,17,5,NA,16S,34,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,unchanged,unchanged,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:266/1/NA,Study 266,case-control,27381339,10.4014/jmb.1603.03057,NA,"Ruengsomwong S, La-Ongkham O, Jiang J, Wannissorn B, Nakayama J , Nitisinprasert S","Microbial Community of Healthy Thai Vegetarians and Non-Vegetarians, Their Core Gut Microbiota, and Pathogen Risk",Journal of microbiology and biotechnology,2016,"Enterobacteriaceae, Fecal microbiota, Prevotella, core gut microbiota, pathogen risk, pyrosequencing",Experiment 1,Thailand,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,Healthy non-vegetarian,Healthy vegetarian,"The vegetarian volunteers consisted of ovo-lacto vegetarians, lacto-vegetarians, an ovo-vegetarian, and vegans. They had all been vegetarians for at least 3 years before participating in this study.",36,36,1 month,16S,678,Roche454,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:267/1/NA,Study 267,"cross-sectional observational, not case-control",27838347,10.1016/j.jaci.2016.08.055,NA,"Durack J, Lynch SV, Nariya S, Bhakta NR, Beigelman A, Castro M, Dyer AM, Israel E, Kraft M, Martin RJ, Mauger DT, Rosenberg SR, Sharp-King T, White SR, Woodruff PG, Avila PC, Denlinger LC, Holguin F, Lazarus SC, Lugogo N, Moore WC, Peters SP, Que L, Smith LJ, Sorkness CA, Wechsler ME, Wenzel SE, Boushey HA , Huang YJ","Features of the bronchial bacterial microbiome associated with atopy, asthma, and responsiveness to inhaled corticosteroid treatment",The Journal of allergy and clinical immunology,2017,"16S ribosomal RNA, Asthma, T(H)2 inflammation, atopy, bacteria, corticosteroids, metabolic pathways, microbiome, short-chain fatty acids, three-gene mean",Experiment 1,United States of America,Homo sapiens,Bronchus,UBERON:0002185,Atopic asthma,EFO:0010638,healthy control,atopic asthma,Patients who have atopic asthma,21,42,3 months,16S,4,Illumina,Negative Binomial Regression,0.1,TRUE,NA,NA,NA,unchanged,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:267/2/NA,Study 267,"cross-sectional observational, not case-control",27838347,10.1016/j.jaci.2016.08.055,NA,"Durack J, Lynch SV, Nariya S, Bhakta NR, Beigelman A, Castro M, Dyer AM, Israel E, Kraft M, Martin RJ, Mauger DT, Rosenberg SR, Sharp-King T, White SR, Woodruff PG, Avila PC, Denlinger LC, Holguin F, Lazarus SC, Lugogo N, Moore WC, Peters SP, Que L, Smith LJ, Sorkness CA, Wechsler ME, Wenzel SE, Boushey HA , Huang YJ","Features of the bronchial bacterial microbiome associated with atopy, asthma, and responsiveness to inhaled corticosteroid treatment",The Journal of allergy and clinical immunology,2017,"16S ribosomal RNA, Asthma, T(H)2 inflammation, atopy, bacteria, corticosteroids, metabolic pathways, microbiome, short-chain fatty acids, three-gene mean",Experiment 2,United States of America,Homo sapiens,Bronchus,UBERON:0002185,Atopic asthma,EFO:0010638,healthy control,atopic no asthma,atopic nonasthmatic subjects,21,21,3 months,16S,4,Illumina,Negative Binomial Regression,0.1,TRUE,NA,NA,NA,unchanged,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:267/3/NA,Study 267,"cross-sectional observational, not case-control",27838347,10.1016/j.jaci.2016.08.055,NA,"Durack J, Lynch SV, Nariya S, Bhakta NR, Beigelman A, Castro M, Dyer AM, Israel E, Kraft M, Martin RJ, Mauger DT, Rosenberg SR, Sharp-King T, White SR, Woodruff PG, Avila PC, Denlinger LC, Holguin F, Lazarus SC, Lugogo N, Moore WC, Peters SP, Que L, Smith LJ, Sorkness CA, Wechsler ME, Wenzel SE, Boushey HA , Huang YJ","Features of the bronchial bacterial microbiome associated with atopy, asthma, and responsiveness to inhaled corticosteroid treatment",The Journal of allergy and clinical immunology,2017,"16S ribosomal RNA, Asthma, T(H)2 inflammation, atopy, bacteria, corticosteroids, metabolic pathways, microbiome, short-chain fatty acids, three-gene mean",Experiment 3,United States of America,Homo sapiens,Bronchus,UBERON:0002185,Atopic asthma,EFO:0010638,atopic no asthma,atopic asthma,atopic asthma subjects,21,42,3 months,16S,4,Illumina,Negative Binomial Regression,0.1,TRUE,NA,NA,NA,unchanged,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:267/4/NA,Study 267,"cross-sectional observational, not case-control",27838347,10.1016/j.jaci.2016.08.055,NA,"Durack J, Lynch SV, Nariya S, Bhakta NR, Beigelman A, Castro M, Dyer AM, Israel E, Kraft M, Martin RJ, Mauger DT, Rosenberg SR, Sharp-King T, White SR, Woodruff PG, Avila PC, Denlinger LC, Holguin F, Lazarus SC, Lugogo N, Moore WC, Peters SP, Que L, Smith LJ, Sorkness CA, Wechsler ME, Wenzel SE, Boushey HA , Huang YJ","Features of the bronchial bacterial microbiome associated with atopy, asthma, and responsiveness to inhaled corticosteroid treatment",The Journal of allergy and clinical immunology,2017,"16S ribosomal RNA, Asthma, T(H)2 inflammation, atopy, bacteria, corticosteroids, metabolic pathways, microbiome, short-chain fatty acids, three-gene mean",Experiment 4,United States of America,Homo sapiens,Bronchus,UBERON:0002185,Atopic asthma,EFO:0010638,nonresponder,inhaled corticosteroid responder,inhaled corticosteroid (ICS) responder,10,15,3 months,16S,4,Illumina,Negative Binomial Regression,0.1,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:267/5/NA,Study 267,"cross-sectional observational, not case-control",27838347,10.1016/j.jaci.2016.08.055,NA,"Durack J, Lynch SV, Nariya S, Bhakta NR, Beigelman A, Castro M, Dyer AM, Israel E, Kraft M, Martin RJ, Mauger DT, Rosenberg SR, Sharp-King T, White SR, Woodruff PG, Avila PC, Denlinger LC, Holguin F, Lazarus SC, Lugogo N, Moore WC, Peters SP, Que L, Smith LJ, Sorkness CA, Wechsler ME, Wenzel SE, Boushey HA , Huang YJ","Features of the bronchial bacterial microbiome associated with atopy, asthma, and responsiveness to inhaled corticosteroid treatment",The Journal of allergy and clinical immunology,2017,"16S ribosomal RNA, Asthma, T(H)2 inflammation, atopy, bacteria, corticosteroids, metabolic pathways, microbiome, short-chain fatty acids, three-gene mean",Experiment 5,United States of America,Homo sapiens,Bronchus,UBERON:0002185,Atopic asthma,EFO:0010638,baseline (corticosteroid treatment group),post inhaled corticosteroid treatment,asthma patients after inhaled corticosteroid treatment,8,8,3 months,16S,4,Illumina,Negative Binomial Regression,0.1,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:267/6/NA,Study 267,"cross-sectional observational, not case-control",27838347,10.1016/j.jaci.2016.08.055,NA,"Durack J, Lynch SV, Nariya S, Bhakta NR, Beigelman A, Castro M, Dyer AM, Israel E, Kraft M, Martin RJ, Mauger DT, Rosenberg SR, Sharp-King T, White SR, Woodruff PG, Avila PC, Denlinger LC, Holguin F, Lazarus SC, Lugogo N, Moore WC, Peters SP, Que L, Smith LJ, Sorkness CA, Wechsler ME, Wenzel SE, Boushey HA , Huang YJ","Features of the bronchial bacterial microbiome associated with atopy, asthma, and responsiveness to inhaled corticosteroid treatment",The Journal of allergy and clinical immunology,2017,"16S ribosomal RNA, Asthma, T(H)2 inflammation, atopy, bacteria, corticosteroids, metabolic pathways, microbiome, short-chain fatty acids, three-gene mean",Experiment 6,United States of America,Homo sapiens,Bronchus,UBERON:0002185,Atopic asthma,EFO:0010638,baseline (placebo group),post placebo treatment,placebo treatment,8,8,3 months,16S,4,Illumina,Negative Binomial Regression,0.1,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:267/7/NA,Study 267,"cross-sectional observational, not case-control",27838347,10.1016/j.jaci.2016.08.055,NA,"Durack J, Lynch SV, Nariya S, Bhakta NR, Beigelman A, Castro M, Dyer AM, Israel E, Kraft M, Martin RJ, Mauger DT, Rosenberg SR, Sharp-King T, White SR, Woodruff PG, Avila PC, Denlinger LC, Holguin F, Lazarus SC, Lugogo N, Moore WC, Peters SP, Que L, Smith LJ, Sorkness CA, Wechsler ME, Wenzel SE, Boushey HA , Huang YJ","Features of the bronchial bacterial microbiome associated with atopy, asthma, and responsiveness to inhaled corticosteroid treatment",The Journal of allergy and clinical immunology,2017,"16S ribosomal RNA, Asthma, T(H)2 inflammation, atopy, bacteria, corticosteroids, metabolic pathways, microbiome, short-chain fatty acids, three-gene mean",Experiment 7,United States of America,Homo sapiens,Bronchus,UBERON:0002185,Atopic asthma,EFO:0010638,healthy control,atopic asthma,atopic asthma subjects,21,42,3 months,16S,4,Illumina,Negative Binomial Regression,0.1,TRUE,NA,NA,NA,unchanged,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:267/8/NA,Study 267,"cross-sectional observational, not case-control",27838347,10.1016/j.jaci.2016.08.055,NA,"Durack J, Lynch SV, Nariya S, Bhakta NR, Beigelman A, Castro M, Dyer AM, Israel E, Kraft M, Martin RJ, Mauger DT, Rosenberg SR, Sharp-King T, White SR, Woodruff PG, Avila PC, Denlinger LC, Holguin F, Lazarus SC, Lugogo N, Moore WC, Peters SP, Que L, Smith LJ, Sorkness CA, Wechsler ME, Wenzel SE, Boushey HA , Huang YJ","Features of the bronchial bacterial microbiome associated with atopy, asthma, and responsiveness to inhaled corticosteroid treatment",The Journal of allergy and clinical immunology,2017,"16S ribosomal RNA, Asthma, T(H)2 inflammation, atopy, bacteria, corticosteroids, metabolic pathways, microbiome, short-chain fatty acids, three-gene mean",Experiment 8,United States of America,Homo sapiens,Bronchus,UBERON:0002185,Atopic asthma,EFO:0010638,healthy control,atopic no asthma,atopic no asthma,21,21,3 months,16S,4,Illumina,Negative Binomial Regression,0.1,TRUE,NA,NA,NA,unchanged,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:267/9/NA,Study 267,"cross-sectional observational, not case-control",27838347,10.1016/j.jaci.2016.08.055,NA,"Durack J, Lynch SV, Nariya S, Bhakta NR, Beigelman A, Castro M, Dyer AM, Israel E, Kraft M, Martin RJ, Mauger DT, Rosenberg SR, Sharp-King T, White SR, Woodruff PG, Avila PC, Denlinger LC, Holguin F, Lazarus SC, Lugogo N, Moore WC, Peters SP, Que L, Smith LJ, Sorkness CA, Wechsler ME, Wenzel SE, Boushey HA , Huang YJ","Features of the bronchial bacterial microbiome associated with atopy, asthma, and responsiveness to inhaled corticosteroid treatment",The Journal of allergy and clinical immunology,2017,"16S ribosomal RNA, Asthma, T(H)2 inflammation, atopy, bacteria, corticosteroids, metabolic pathways, microbiome, short-chain fatty acids, three-gene mean",Experiment 9,United States of America,Homo sapiens,Bronchus,UBERON:0002185,Atopic asthma,EFO:0010638,atopic no asthma,atopic asthma,atopic asthma subjects,21,42,3 months,16S,4,Illumina,Negative Binomial Regression,0.1,TRUE,NA,NA,NA,unchanged,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:268/1/NA,Study 268,time series / longitudinal observational,29563617,10.1038/s41598-018-23389-0,NA,"Zhang H, Lu J, Lu Y, Cai Q, Liu H , Xu C",Cervical microbiome is altered in cervical intraepithelial neoplasia after loop electrosurgical excision procedure in china,Scientific reports,2018,NA,Experiment 1,China,Homo sapiens,Uterine cervix,UBERON:0000002,Cervical glandular intraepithelial neoplasia,EFO:1000165,after loop electrosurgical excision procedure,before,Cervical intraepithelial neoplasia 2/3 patients who underwent Loop electrosurgical excision procedure(LEEP),26,26,6 months,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,NA,NA,unchanged,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:269/1/NA,Study 269,time series / longitudinal observational,32093640,10.1186/s12885-020-6654-5,NA,"Chua LL, Rajasuriar R, Lim YAL, Woo YL, Loke P , Ariffin H","Temporal changes in gut microbiota profile in children with acute lymphoblastic leukemia prior to commencement-, during-, and post-cessation of chemotherapy",BMC cancer,2020,"Bacteroides, Bacteroidetes, Chemotherapy, Childhood acute lymphoblastic leukemia, Microbiome, Microbiota dysbiosis",Experiment 1,Malaysia,Homo sapiens,Feces,UBERON:0001988,Leukemia,EFO:0000565,healthy control,Acute Lymphoblastic Leukemia diagnosis and Pre- Chemotherapy treatment,children (ages 2-6 years old) diagnosed with and treated for Acute Lymphoblastic Leukemia,7,7,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,"age,ethnic group",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:270/1/NA,Study 270,prospective cohort,28860468,10.1038/s41598-017-09842-6,NA,"Di Paola M, Sani C, Clemente AM, Iossa A, Perissi E, Castronovo G, Tanturli M, Rivero D, Cozzolino F, Cavalieri D, Carozzi F, De Filippo C , Torcia MG",Characterization of cervico-vaginal microbiota in women developing persistent high-risk Human Papillomavirus infection,Scientific reports,2017,NA,Experiment 1,Italy,Homo sapiens,Vaginal fluid,UBERON:0036243,Human papilloma virus infection,EFO:0001668,HPV-,HPV+,HPV+  determined through HR-HC2 assay,17,55,3 days,16S,345,Roche454,LEfSe,0.05,FALSE,2,age,NA,NA,unchanged,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:270/2/NA,Study 270,prospective cohort,28860468,10.1038/s41598-017-09842-6,NA,"Di Paola M, Sani C, Clemente AM, Iossa A, Perissi E, Castronovo G, Tanturli M, Rivero D, Cozzolino F, Cavalieri D, Carozzi F, De Filippo C , Torcia MG",Characterization of cervico-vaginal microbiota in women developing persistent high-risk Human Papillomavirus infection,Scientific reports,2017,NA,Experiment 2,Italy,Homo sapiens,Vaginal fluid,UBERON:0036243,Human papilloma virus infection,EFO:0001668,HPV+ (clearance),HPV+ (persistance),HR-HPV+ persistence confirmed by HPV genotyping after 1 year,27,28,3 days,16S,345,Roche454,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:271/1/NA,Study 271,case-control,31289031,10.1182/bloodadvances.2019032276,NA,"Pianko MJ, Devlin SM, Littmann ER, Chansakul A, Mastey D, Salcedo M, Fontana E, Ling L, Tavitian E, Slingerland JB, Slingerland AE, Clurman A, Gomes ALC, Taur Y, Pamer EG, Peled JU, van den Brink MRM, Landgren O , Lesokhin AM",Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition,Blood advances,2019,NA,Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Acute lymphoblastic leukemia,EFO:0000220,Minimal Residual Disease+ (positivity) with Allogenic Stem Cell Transplant,Minimal Residual Disease- (negativity) with Allogenic Stem Cell Transplant,Patients with multiple myeloma (MM) who achieve minimal residual disease (MRD) negativity (MRD-) after upfront treatment,18,16,NA,16S,45,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:271/2/NA,Study 271,case-control,31289031,10.1182/bloodadvances.2019032276,NA,"Pianko MJ, Devlin SM, Littmann ER, Chansakul A, Mastey D, Salcedo M, Fontana E, Ling L, Tavitian E, Slingerland JB, Slingerland AE, Clurman A, Gomes ALC, Taur Y, Pamer EG, Peled JU, van den Brink MRM, Landgren O , Lesokhin AM",Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition,Blood advances,2019,NA,Experiment 2,United States of America,Homo sapiens,Feces,UBERON:0001988,Acute lymphoblastic leukemia,EFO:0000220,Minimal Residual Disease+ (positivity) with Allogenic Stem Cell Transplant,Minimal Residual Disease- (negativity) with Allogenic Stem Cell Transplant,Patients with multiple myeloma (MM) who achieve minimal residual disease (MRD) negativity (MRD-) after upfront treatment,18,16,NA,16S,45,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:271/3/NA,Study 271,case-control,31289031,10.1182/bloodadvances.2019032276,NA,"Pianko MJ, Devlin SM, Littmann ER, Chansakul A, Mastey D, Salcedo M, Fontana E, Ling L, Tavitian E, Slingerland JB, Slingerland AE, Clurman A, Gomes ALC, Taur Y, Pamer EG, Peled JU, van den Brink MRM, Landgren O , Lesokhin AM",Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition,Blood advances,2019,NA,Experiment 3,United States of America,Homo sapiens,Feces,UBERON:0001988,Acute lymphoblastic leukemia,EFO:0000220,Minimal Residual Disease+ (positivity) with Allogenic Stem Cell Transplant,Minimal Residual Disease- (negativity) with Allogenic Stem Cell Transplant,Patients with multiple myeloma (MM) who achieve minimal residual disease (MRD) negativity (MRD-) after upfront treatment,18,16,NA,16S,45,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,2,NA,NA,NA,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:271/4/NA,Study 271,case-control,31289031,10.1182/bloodadvances.2019032276,NA,"Pianko MJ, Devlin SM, Littmann ER, Chansakul A, Mastey D, Salcedo M, Fontana E, Ling L, Tavitian E, Slingerland JB, Slingerland AE, Clurman A, Gomes ALC, Taur Y, Pamer EG, Peled JU, van den Brink MRM, Landgren O , Lesokhin AM",Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition,Blood advances,2019,NA,Experiment 4,United States of America,Homo sapiens,Feces,UBERON:0001988,Acute lymphoblastic leukemia,EFO:0000220,female,males,Patients with multiple myeloma (MM) who achieve minimal residual disease (MRD) negativity (MRD-) after upfront treatment,18,16,NA,16S,45,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,2,NA,NA,NA,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:271/5/NA,Study 271,case-control,31289031,10.1182/bloodadvances.2019032276,NA,"Pianko MJ, Devlin SM, Littmann ER, Chansakul A, Mastey D, Salcedo M, Fontana E, Ling L, Tavitian E, Slingerland JB, Slingerland AE, Clurman A, Gomes ALC, Taur Y, Pamer EG, Peled JU, van den Brink MRM, Landgren O , Lesokhin AM",Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition,Blood advances,2019,NA,Experiment 5,United States of America,Homo sapiens,Feces,UBERON:0001988,Acute lymphoblastic leukemia,EFO:0000220,Minimal Residual Disease+ (positivity) with Allogenic Stem Cell Transplant,Minimal Residual Disease- (negativity) with Allogenic Stem Cell Transplant,Patients with multiple myeloma (MM) who achieve minimal residual disease (MRD) negativity (MRD-) after upfront treatment,18,16,NA,16S,45,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,2,NA,NA,NA,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:271/6/NA,Study 271,case-control,31289031,10.1182/bloodadvances.2019032276,NA,"Pianko MJ, Devlin SM, Littmann ER, Chansakul A, Mastey D, Salcedo M, Fontana E, Ling L, Tavitian E, Slingerland JB, Slingerland AE, Clurman A, Gomes ALC, Taur Y, Pamer EG, Peled JU, van den Brink MRM, Landgren O , Lesokhin AM",Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition,Blood advances,2019,NA,Experiment 6,United States of America,Homo sapiens,Feces,UBERON:0001988,Acute lymphoblastic leukemia,EFO:0000220,Age greater than 65 years old,Age less than 65 years old,Patients with multiple myeloma (MM) who achieve minimal residual disease (MRD) negativity (MRD-) after upfront treatment,18,16,NA,16S,45,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,2,NA,NA,NA,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:272/1/NA,Study 272,case-control,30153231,10.1097/INF.0000000000002174,NA,"Kelly MS, Surette MG, Smieja M, Rossi L, Luinstra K, Steenhoff AP, Goldfarb DM, Pernica JM, Arscott-Mills T, Boiditswe S, Mazhani T, Rawls JF, Cunningham CK, Shah SS, Feemster KA , Seed PC",Pneumococcal Colonization and the Nasopharyngeal Microbiota of Children in Botswana,The Pediatric infectious disease journal,2018,NA,Experiment 1,Botswana,Homo sapiens,Nasopharynx,UBERON:0001728,Pneumonia,EFO:0003106,negative,S.pneumoniae positive,clinical pneumonnia,74,96,NA,16S,3,Illumina,Logistic Regression,0.05,FALSE,NA,"date,primary care clinic",age,NA,unchanged,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:273/1/NA,Study 273,prospective cohort,30838178,10.3389/fcimb.2019.00028,NA,"Nearing JT, Connors J, Whitehouse S, Van Limbergen J, Macdonald T, Kulkarni K , Langille MGI",Infectious Complications Are Associated With Alterations in the Gut Microbiome in Pediatric Patients With Acute Lymphoblastic Leukemia,Frontiers in cellular and infection microbiology,2019,"cancer, clinical, genomics, infection, leukemia, metagenomics, microbiome",Experiment 1,Canada,Homo sapiens,Feces,UBERON:0001988,Acute lymphoblastic leukemia,EFO:0000220,non-infectious complications (NIC),Infectious complications (IC),Infectious complications (IC) in the past 6 months of Acute Lymphoblastic Leukemia treatment,7,9,"Prophylactic Septra which was prescribed ubiquitously to patients throughout the study, as per standard of care.",WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:274/1/NA,Study 274,"cross-sectional observational, not case-control",29765068,10.1038/s41598-018-25879-7,NA,"Łaniewski P, Barnes D, Goulder A, Cui H, Roe DJ, Chase DM , Herbst-Kralovetz MM","Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women",Scientific reports,2018,NA,Experiment 1,United States of America,Homo sapiens,Vagina,UBERON:0000996,Human papilloma virus infection,EFO:0001668,HPV-,HPV+,HPV+ determined by the Linear Array HPV Genotyping Tests,20,31,3 months,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:274/2/NA,Study 274,"cross-sectional observational, not case-control",29765068,10.1038/s41598-018-25879-7,NA,"Łaniewski P, Barnes D, Goulder A, Cui H, Roe DJ, Chase DM , Herbst-Kralovetz MM","Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women",Scientific reports,2018,NA,Experiment 2,United States of America,Homo sapiens,Vagina,UBERON:0000996,Cervical glandular intraepithelial neoplasia,EFO:1000165,HPV-,low grade dysplasia,low grade dysplasia confirmed by histology of colonoscopy-directed biopsy,20,12,3 months,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:274/3/NA,Study 274,"cross-sectional observational, not case-control",29765068,10.1038/s41598-018-25879-7,NA,"Łaniewski P, Barnes D, Goulder A, Cui H, Roe DJ, Chase DM , Herbst-Kralovetz MM","Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women",Scientific reports,2018,NA,Experiment 3,United States of America,Homo sapiens,Vagina,UBERON:0000996,Cervical glandular intraepithelial neoplasia,EFO:1000165,HPV-,high grade dysplasia,high grade dysplasia confirmed by histology of colonoscopy-directed biopsy,20,27,3 months,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:274/4/NA,Study 274,"cross-sectional observational, not case-control",29765068,10.1038/s41598-018-25879-7,NA,"Łaniewski P, Barnes D, Goulder A, Cui H, Roe DJ, Chase DM , Herbst-Kralovetz MM","Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women",Scientific reports,2018,NA,Experiment 4,United States of America,Homo sapiens,Vagina,UBERON:0000996,Cervical cancer,MONDO:0002974,HPV-,invasive cervical carcinoma,invasive cervical carcinoma confirmed by histology of colonoscopy-directed biopsy,20,10,3 months,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:274/5/NA,Study 274,"cross-sectional observational, not case-control",29765068,10.1038/s41598-018-25879-7,NA,"Łaniewski P, Barnes D, Goulder A, Cui H, Roe DJ, Chase DM , Herbst-Kralovetz MM","Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women",Scientific reports,2018,NA,Experiment 5,United States of America,Homo sapiens,Vagina,UBERON:0000996,Human papilloma virus infection,EFO:0001668,HPV-,HPV+,HPV+ determined by the Linear Array HPV Genotyping Tests,20,31,3 months,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,"age,body mass index,ethnic group",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:274/6/NA,Study 274,"cross-sectional observational, not case-control",29765068,10.1038/s41598-018-25879-7,NA,"Łaniewski P, Barnes D, Goulder A, Cui H, Roe DJ, Chase DM , Herbst-Kralovetz MM","Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women",Scientific reports,2018,NA,Experiment 6,United States of America,Homo sapiens,Vagina,UBERON:0000996,Cervical glandular intraepithelial neoplasia,EFO:1000165,HPV-,low grade dysplasia,low grade dysplasia confirmed by histology of colonoscopy-directed biopsy,20,12,3 months,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,"age,body mass index,ethnic group",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:274/7/NA,Study 274,"cross-sectional observational, not case-control",29765068,10.1038/s41598-018-25879-7,NA,"Łaniewski P, Barnes D, Goulder A, Cui H, Roe DJ, Chase DM , Herbst-Kralovetz MM","Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women",Scientific reports,2018,NA,Experiment 7,United States of America,Homo sapiens,Vagina,UBERON:0000996,Cervical glandular intraepithelial neoplasia,EFO:1000165,HPV-,high grade dysplasia,high grade dysplasia confirmed by histology of colonoscopy-directed biopsy,20,27,3 months,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,"age,body mass index,ethnic group",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:274/8/NA,Study 274,"cross-sectional observational, not case-control",29765068,10.1038/s41598-018-25879-7,NA,"Łaniewski P, Barnes D, Goulder A, Cui H, Roe DJ, Chase DM , Herbst-Kralovetz MM","Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women",Scientific reports,2018,NA,Experiment 8,United States of America,Homo sapiens,Vagina,UBERON:0000996,Cervical cancer,MONDO:0002974,HPV-,invasive cervical carcinoma,invasive cervical carcinoma confirmed by histology of colonoscopy-directed biopsy,20,10,3 months,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,"age,body mass index,ethnic group",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:274/9/NA,Study 274,"cross-sectional observational, not case-control",29765068,10.1038/s41598-018-25879-7,NA,"Łaniewski P, Barnes D, Goulder A, Cui H, Roe DJ, Chase DM , Herbst-Kralovetz MM","Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women",Scientific reports,2018,NA,Experiment 9,United States of America,Homo sapiens,Vagina,UBERON:0000996,"Human papilloma virus infection,Cervical cancer","EFO:0001668,MONDO:0002974",abnormal pH,normal pH,"HPV+ determined by the Linear Array HPV Genotyping Tests, low grade dysplasia,high grade dysplasia, invasive cervical carcinoma confirmed by histology of colonoscopy-directed biopsy,",20,74,3 months,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:274/10/NA,Study 274,"cross-sectional observational, not case-control",29765068,10.1038/s41598-018-25879-7,NA,"Łaniewski P, Barnes D, Goulder A, Cui H, Roe DJ, Chase DM , Herbst-Kralovetz MM","Linking cervicovaginal immune signatures, HPV and microbiota composition in cervical carcinogenesis in non-Hispanic and Hispanic women",Scientific reports,2018,NA,Experiment 10,United States of America,Homo sapiens,Vagina,UBERON:0000996,Human papilloma virus infection,EFO:0001668,non-Hispanic,Hispanic,"HPV+ determined by the Linear Array HPV Genotyping Tests, low grade dysplasia,high grade dysplasia, invasive cervical carcinoma confirmed by histology of colonoscopy-directed biopsy,",53,47,3 months,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:275/1/NA,Study 275,case-control,27527070,10.1186/s12864-016-2965-y,NA,"Rajagopala SV, Yooseph S, Harkins DM, Moncera KJ, Zabokrtsky KB, Torralba MG, Tovchigrechko A, Highlander SK, Pieper R, Sender L , Nelson KE",Gastrointestinal microbial populations can distinguish pediatric and adolescent Acute Lymphoblastic Leukemia (ALL) at the time of disease diagnosis,BMC genomics,2016,"16S rRNA gene sequencing, Gastrointestinal microbiota, Pediatric leukemia, Ribosomal RNA, rRNA",Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Acute lymphoblastic leukemia,EFO:0000220,healthy sibling control,adolescent ALL patient,Patients with pediatric and adolescent Acute Lymphoblastic Leukemia at time of disease diagnosis,23,28,NA,16S,123,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:276/1/NA,Study 276,case-control,31678982,10.12659/MSM.919988,NA,"Zhang B, Gu J, Liu J, Huang B , Li J",Fecal Microbiota Taxonomic Shifts in Chinese Multiple Myeloma Patients Analyzed by Quantitative Polimerase Chain Reaction (QPCR) and 16S rRNA High-Throughput Sequencing,Medical science monitor : international medical journal of experimental and clinical research,2019,NA,Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Multiple myeloma,EFO:0001378,healthy control,Multiple Myeloma patient,"patient diagnosis with multiple myeloma and no other disease validated to affect intestinal microbial including digestive disease like liver cirrhosis, liver cancer, inflammatory bowel disease, and irritable bowel syndrome; systemic disease like diabetes and hypertension and thyroid disease; no treatment including antibiotics, chemotherapy, plasma exchange or bone marrow transplant; no cold, fever or other infections within 3 months before sampling with administrated antibacterial drugs, gastrointestinal motility drugs or micro-ecological conditioning agents like eating and living habit change 1 week before sampling",17,40,3 months,16S,34,Illumina,T-Test,0.05,FALSE,NA,NA,NA,NA,decreased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:276/2/NA,Study 276,case-control,31678982,10.12659/MSM.919988,NA,"Zhang B, Gu J, Liu J, Huang B , Li J",Fecal Microbiota Taxonomic Shifts in Chinese Multiple Myeloma Patients Analyzed by Quantitative Polimerase Chain Reaction (QPCR) and 16S rRNA High-Throughput Sequencing,Medical science monitor : international medical journal of experimental and clinical research,2019,NA,Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Multiple myeloma,EFO:0001378,healthy control,Multiple Myeloma patient,"patient diagnosis with multiple myeloma and no other disease validated to affect intestinal microbial including digestive disease like liver cirrhosis, liver cancer, inflammatory bowel disease, and irritable bowel syndrome; systemic disease like diabetes and hypertension and thyroid disease; no treatment including antibiotics, chemotherapy, plasma exchange or bone marrow transplant; no cold, fever or other infections within 3 months before sampling with administrated antibacterial drugs, gastrointestinal motility drugs or micro-ecological conditioning agents like eating and living habit change 1 week before sampling",17,40,3 months,16S,34,Illumina,LEfSe,2,FALSE,2,NA,NA,NA,decreased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:276/3/NA,Study 276,case-control,31678982,10.12659/MSM.919988,NA,"Zhang B, Gu J, Liu J, Huang B , Li J",Fecal Microbiota Taxonomic Shifts in Chinese Multiple Myeloma Patients Analyzed by Quantitative Polimerase Chain Reaction (QPCR) and 16S rRNA High-Throughput Sequencing,Medical science monitor : international medical journal of experimental and clinical research,2019,NA,Experiment 3,China,Homo sapiens,Feces,UBERON:0001988,Multiple myeloma,EFO:0001378,healthy control,Multiple Myeloma patient,"patient diagnosis with multiple myeloma and no other disease validated to affect intestinal microbial including digestive disease like liver cirrhosis, liver cancer, inflammatory bowel disease, and irritable bowel syndrome; systemic disease like diabetes and hypertension and thyroid disease; no treatment including antibiotics, chemotherapy, plasma exchange or bone marrow transplant; no cold, fever or other infections within 3 months before sampling with administrated antibacterial drugs, gastrointestinal motility drugs or micro-ecological conditioning agents like eating and living habit change 1 week before sampling",17,40,3 months,16S,34,Illumina,Metastats,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:276/4/NA,Study 276,case-control,31678982,10.12659/MSM.919988,NA,"Zhang B, Gu J, Liu J, Huang B , Li J",Fecal Microbiota Taxonomic Shifts in Chinese Multiple Myeloma Patients Analyzed by Quantitative Polimerase Chain Reaction (QPCR) and 16S rRNA High-Throughput Sequencing,Medical science monitor : international medical journal of experimental and clinical research,2019,NA,Experiment 4,China,Homo sapiens,Feces,UBERON:0001988,Multiple myeloma,EFO:0001378,healthy relatives control,Multiple Myeloma patient,"patient diagnosis with multiple myeloma and no other disease validated to affect intestinal microbial including digestive disease like liver cirrhosis, liver cancer, inflammatory bowel disease, and irritable bowel syndrome; systemic disease like diabetes and hypertension and thyroid disease; no treatment including antibiotics, chemotherapy, plasma exchange or bone marrow transplant; no cold, fever or other infections within 3 months before sampling with administrated antibacterial drugs, gastrointestinal motility drugs or micro-ecological conditioning agents like eating and living habit change 1 week before sampling",21,21,3 months,16S,34,RT-qPCR,Metastats,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:277/1/NA,Study 277,case-control,30581271,10.3748/wjg.v24.i46.5223,NA,"Rojas-Feria M, Romero-García T, Fernández Caballero-Rico JÁ, Pastor Ramírez H, Avilés-Recio M, Castro-Fernandez M, Chueca Porcuna N, Romero-Gόmez M, García F, Grande L , Del Campo JA",Modulation of faecal metagenome in Crohn's disease: Role of microRNAs as biomarkers,World journal of gastroenterology,2018,"Bacteroidetes, Crohn’s disease, Dysbiosis, Firmicutes, microRNAs",Experiment 1,Spain,Homo sapiens,Feces,UBERON:0001988,Crohn's disease,EFO:0000384,healthy control,crohn's disease,new-onset adult crohn's disease (CD) patients,16,13,10 weeks,16S,123,Illumina,Chi-Square,0.05,FALSE,NA,"age,sex",NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:278/1/NA,Study 278,"cross-sectional observational, not case-control",29362454,10.1038/s41598-018-19753-9,NA,"Da Silva HE, Teterina A, Comelli EM, Taibi A, Arendt BM, Fischer SE, Lou W , Allard JP",Nonalcoholic fatty liver disease is associated with dysbiosis independent of body mass index and insulin resistance,Scientific reports,2018,NA,Experiment 1,Canada,Homo sapiens,Feces,UBERON:0001988,Non-alcoholic fatty liver disease,EFO:0003095,Healthy control,NAFLD- [non alcoholic fatty liver disease],Adults with biopsy-proven steatosis and non-alcoholic fatty liver disease,28,39,6 Months,PCR,NA,Illumina,Metastats,0.05,TRUE,NA,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:279/1/NA,Study 279,time series / longitudinal observational,32295867,10.1128/mSphere.00048-20,NA,"Robinson S, Peterson CB, Sahasrabhojane P, Ajami NJ, Shelburne SA, Kontoyiannis DP , Galloway-Peña JR",Observational Cohort Study of Oral Mycobiome and Interkingdom Interactions over the Course of Induction Therapy for Leukemia,mSphere,2020,"Malassezia, induction chemotherapy, interkingdom interactions, leukemia, mycobiome",Experiment 1,United States of America,Homo sapiens,Mouth,UBERON:0000165,Acute myeloid leukemia,EFO:0000222,Low Intensity Chemotherapy,High Intensity Chemotherapy,Acute Myeloid Leukemia patients receiving low-intensity remission induction chemotherapy at a later timepoint T6,11,28,None,ITS / ITS2,NA,Illumina,ANOVA,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:279/2/NA,Study 279,time series / longitudinal observational,32295867,10.1128/mSphere.00048-20,NA,"Robinson S, Peterson CB, Sahasrabhojane P, Ajami NJ, Shelburne SA, Kontoyiannis DP , Galloway-Peña JR",Observational Cohort Study of Oral Mycobiome and Interkingdom Interactions over the Course of Induction Therapy for Leukemia,mSphere,2020,"Malassezia, induction chemotherapy, interkingdom interactions, leukemia, mycobiome",Experiment 2,United States of America,Homo sapiens,Mouth,UBERON:0000165,Acute myeloid leukemia,EFO:0000222,Patients without bacterial infections at T3,Patients with bacterial infections at T3,Acute Myeloid Leukemia patients that experienced microbiologically defined bacterial infections during remission induction chemotherapy at midpoint timepoint T3,30,9,None,ITS / ITS2,NA,Illumina,LEfSe,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:279/3/NA,Study 279,time series / longitudinal observational,32295867,10.1128/mSphere.00048-20,NA,"Robinson S, Peterson CB, Sahasrabhojane P, Ajami NJ, Shelburne SA, Kontoyiannis DP , Galloway-Peña JR",Observational Cohort Study of Oral Mycobiome and Interkingdom Interactions over the Course of Induction Therapy for Leukemia,mSphere,2020,"Malassezia, induction chemotherapy, interkingdom interactions, leukemia, mycobiome",Experiment 3,United States of America,Homo sapiens,Mouth,UBERON:0000165,Acute myeloid leukemia,EFO:0000222,Patients with no bacterial infections at T6,Patients with bacterial infections at T6,Acute Myeloid Leukemia patients that experience microbiologically defined bacterial infections during remission induction chemotherapy at endpoint timepoint T6,30,9,None,ITS / ITS2,NA,Illumina,LEfSe,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:279/4/NA,Study 279,time series / longitudinal observational,32295867,10.1128/mSphere.00048-20,NA,"Robinson S, Peterson CB, Sahasrabhojane P, Ajami NJ, Shelburne SA, Kontoyiannis DP , Galloway-Peña JR",Observational Cohort Study of Oral Mycobiome and Interkingdom Interactions over the Course of Induction Therapy for Leukemia,mSphere,2020,"Malassezia, induction chemotherapy, interkingdom interactions, leukemia, mycobiome",Experiment 4,United States of America,Homo sapiens,Mouth,UBERON:0000165,Antimicrobial agent,CHEBI:33281,Patients who did not receive Amphotericin B,Patients who received Amphotericin B,Acute Myeloid Leukemia patients who received amphotericin B.,66,6,None,ITS / ITS2,NA,Illumina,ANOVA,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:280/1/NA,Study 280,"cross-sectional observational, not case-control",26574055,10.1038/srep16865,NA,"Mitra A, MacIntyre DA, Lee YS, Smith A, Marchesi JR, Lehne B, Bhatia R, Lyons D, Paraskevaidis E, Li JV, Holmes E, Nicholson JK, Bennett PR , Kyrgiou M",Cervical intraepithelial neoplasia disease progression is associated with increased vaginal microbiome diversity,Scientific reports,2015,NA,Experiment 1,United Kingdom,Homo sapiens,Posterior fornix of vagina,UBERON:0016486,Cervical glandular intraepithelial neoplasia,EFO:1000165,low grade squamus intraepithelial lesion,high grade squamus intraepithelial lesion,high grade squamus intraepithelial lesion confirmed by histology or cytology,52,92,14 days,16S,12,Illumina,LEfSe,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:281/1/NA,Study 281,laboratory experiment,31884727,10.1002/mbo3.982,NA,"Song Y , Gyarmati P",Microbiota changes in a pediatric acute lymphocytic leukemia mouse model,MicrobiologyOpen,2020,"high-throughput sequencing, leukemia, metagenomics, microbiota",Experiment 1,United States of America,Mus musculus,Small intestine,UBERON:0002108,Acute lymphoblastic leukemia,EFO:0000220,Healthy Control,Fecal bacterial composition in small intestines of leukemia mice,Three-week old female mice induced leukemia using lymphomblasts from pediatric acture lymphocytic leukemia patients from ATCC,8,8,NA,16S,4,MGISEQ-2000,T-Test,0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:281/2/NA,Study 281,laboratory experiment,31884727,10.1002/mbo3.982,NA,"Song Y , Gyarmati P",Microbiota changes in a pediatric acute lymphocytic leukemia mouse model,MicrobiologyOpen,2020,"high-throughput sequencing, leukemia, metagenomics, microbiota",Experiment 2,United States of America,Mus musculus,Feces,UBERON:0001988,Acute lymphoblastic leukemia,EFO:0000220,Healthy Control,Fecal bacterial composition of leukemia mice,Three-week old female mice induced leukemia using lymphomblasts from pediatric acture lymphocytic leukemia patients from ATCC,8,8,NA,16S,4,MGISEQ-2000,T-Test,0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:282/1/NA,Study 282,prospective cohort,29740427,10.3389/fimmu.2018.00669,NA,"Han L, Jin H, Zhou L, Zhang X, Fan Z, Dai M, Lin Q, Huang F, Xuan L, Zhang H , Liu Q",Intestinal Microbiota at Engraftment Influence Acute Graft-Versus-Host Disease <i>via</i> the Treg/Th17 Balance in Allo-HSCT Recipients,Frontiers in immunology,2018,"acute graft-versus-host disease, allogeneic hematopoietic stem cell transplantation, histone acetylation, immune homeostasis, intestinal microbiota",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Graft versus host disease,MONDO:0013730,Grades 0-I (non-acute graft-host disease),Grades II-IV (acute graft-host-disease),patients diagnoised with acute graft-versus-host disease (aGVHD),49,32,NA,16S,4,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,decreased,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:282/2/NA,Study 282,prospective cohort,29740427,10.3389/fimmu.2018.00669,NA,"Han L, Jin H, Zhou L, Zhang X, Fan Z, Dai M, Lin Q, Huang F, Xuan L, Zhang H , Liu Q",Intestinal Microbiota at Engraftment Influence Acute Graft-Versus-Host Disease <i>via</i> the Treg/Th17 Balance in Allo-HSCT Recipients,Frontiers in immunology,2018,"acute graft-versus-host disease, allogeneic hematopoietic stem cell transplantation, histone acetylation, immune homeostasis, intestinal microbiota",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Graft versus host disease,MONDO:0013730,standard conditioning,intensified conditioning,patients diagnoised with grade II to IV acute graft-versus-host disease (aGVHD) undergoing intense conditioning,19,13,NA,16S,4,Illumina,NA,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:282/3/NA,Study 282,prospective cohort,29740427,10.3389/fimmu.2018.00669,NA,"Han L, Jin H, Zhou L, Zhang X, Fan Z, Dai M, Lin Q, Huang F, Xuan L, Zhang H , Liu Q",Intestinal Microbiota at Engraftment Influence Acute Graft-Versus-Host Disease <i>via</i> the Treg/Th17 Balance in Allo-HSCT Recipients,Frontiers in immunology,2018,"acute graft-versus-host disease, allogeneic hematopoietic stem cell transplantation, histone acetylation, immune homeostasis, intestinal microbiota",Experiment 3,China,Homo sapiens,Feces,UBERON:0001988,Graft versus host disease,MONDO:0013730,no b-lactum antibiotics,b-lactum antibiotics,"patients diagnoised with grade II to IV acute graft-versus-host disease (aGVHD) undergoing intense conditioning treated with b-lactum (include carbapenem, cephalosporin, and b-lactam-b-lactamase combinations.)",48,31,NA,16S,4,Illumina,NA,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:282/4/NA,Study 282,prospective cohort,29740427,10.3389/fimmu.2018.00669,NA,"Han L, Jin H, Zhou L, Zhang X, Fan Z, Dai M, Lin Q, Huang F, Xuan L, Zhang H , Liu Q",Intestinal Microbiota at Engraftment Influence Acute Graft-Versus-Host Disease <i>via</i> the Treg/Th17 Balance in Allo-HSCT Recipients,Frontiers in immunology,2018,"acute graft-versus-host disease, allogeneic hematopoietic stem cell transplantation, histone acetylation, immune homeostasis, intestinal microbiota",Experiment 4,China,Homo sapiens,Feces,UBERON:0001988,Graft versus host disease,MONDO:0013730,no vancomycin antibiotics,vancomycin antibiotics,patients diagnoised with grade II to IV acute graft-versus-host disease (aGVHD) undergoing intense conditioning treated with vancomycin,59,20,NA,16S,4,Illumina,NA,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:283/1/NA,Study 283,"cross-sectional observational, not case-control",31749298,10.1111/1471-0528.15981,NA,"Borgogna JC, Shardell MD, Santori EK, Nelson TM, Rath JM, Glover ED, Ravel J, Gravitt PE, Yeoman CJ , Brotman RM",The vaginal metabolome and microbiota of cervical HPV-positive and HPV-negative women: a cross-sectional analysis,BJOG : an international journal of obstetrics and gynaecology,2020,"16S rRNA gene amplicon sequencing, human papillomavirus, vaginal metabolome, vaginal microbiota",Experiment 1,United States of America,Homo sapiens,Vagina,UBERON:0000996,Human papilloma virus infection,EFO:0001668,HPV-,HPV+,HPV+ confirmed using Roche Linear Array HPV Genotyping Test,13,26,30 days,16S,123,Roche454,LEfSe,0.05,TRUE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:284/1/NA,Study 284,case-control,30300382,10.1371/journal.pone.0204674,NA,"Yue Q, Yin FT, Zhang Q, Yuan C, Ye MY, Wang XL, Li JJ , Gan YH",Carious status and supragingival plaque microbiota in hemodialysis patients,PloS one,2018,NA,Experiment 1,China,Homo sapiens,Gingiva,UBERON:0001828,Chronic kidney disease,EFO:0003884,healthy controls,Chronic kidney disease,chronic kidney disease patients undergoing hemodialysis,30,30,30 days,16S,34,Illumina,Metastats,0.05,FALSE,NA,"age,sex,smoking behavior",NA,NA,decreased,decreased,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:284/2/NA,Study 284,case-control,30300382,10.1371/journal.pone.0204674,NA,"Yue Q, Yin FT, Zhang Q, Yuan C, Ye MY, Wang XL, Li JJ , Gan YH",Carious status and supragingival plaque microbiota in hemodialysis patients,PloS one,2018,NA,Experiment 2,China,Homo sapiens,Gingiva,UBERON:0001828,Chronic kidney disease,EFO:0003884,healthy controls,Chronic kidney disease,chronic kidney disease patients undergoing hemodialysis,30,30,30 days,16S,345,Illumina,LEfSe,0.05,FALSE,2,"age,sex,smoking behavior",NA,NA,decreased,decreased,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:284/4/NA,Study 284,case-control,30300382,10.1371/journal.pone.0204674,NA,"Yue Q, Yin FT, Zhang Q, Yuan C, Ye MY, Wang XL, Li JJ , Gan YH",Carious status and supragingival plaque microbiota in hemodialysis patients,PloS one,2018,NA,Experiment 4,China,Homo sapiens,Gingiva,UBERON:0001828,Chronic kidney disease,EFO:0003884,healthy controls,Chronic kidney disease,chronic kidney disease patients undergoing hemodialysis,30,30,30 days,16S,3456,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,"age,sex,smoking behavior",NA,NA,decreased,decreased,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:285/1/NA,Study 285,case-control,27176462,10.1111/ene.13026,NA,"Tremlett H, Fadrosh DW, Faruqi AA, Zhu F, Hart J, Roalstad S, Graves J, Lynch S , Waubant E",Gut microbiota in early pediatric multiple sclerosis: a case-control study,European journal of neurology,2016,"16S rRNA, case−control study, gut microbiome, gut microbiota, immunomodulatory drugs, pediatric multiple sclerosis, risk factors",Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Multiple sclerosis,MONDO:0005301,healthy controls,pediatric multiple sclerosis,early pediatric multiple sclerosis,17,18,2 months,16S,4,Illumina,Negative Binomial Regression,0.05,TRUE,NA,"age,sex","age,breast feeding,ethnic group,sex",NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:285/2/NA,Study 285,case-control,27176462,10.1111/ene.13026,NA,"Tremlett H, Fadrosh DW, Faruqi AA, Zhu F, Hart J, Roalstad S, Graves J, Lynch S , Waubant E",Gut microbiota in early pediatric multiple sclerosis: a case-control study,European journal of neurology,2016,"16S rRNA, case−control study, gut microbiome, gut microbiota, immunomodulatory drugs, pediatric multiple sclerosis, risk factors",Experiment 2,United States of America,Homo sapiens,Feces,UBERON:0001988,Multiple sclerosis,MONDO:0005301,IMD naive cases,IMD exposure multiple sclerosis cases,Sclerosis cases influenced by the immunomodulatory drug [IMD] exposure status.,9,9,2 months,16S,4,Illumina,Negative Binomial Regression,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:285/3/NA,Study 285,case-control,27176462,10.1111/ene.13026,NA,"Tremlett H, Fadrosh DW, Faruqi AA, Zhu F, Hart J, Roalstad S, Graves J, Lynch S , Waubant E",Gut microbiota in early pediatric multiple sclerosis: a case-control study,European journal of neurology,2016,"16S rRNA, case−control study, gut microbiome, gut microbiota, immunomodulatory drugs, pediatric multiple sclerosis, risk factors",Experiment 3,United States of America,Homo sapiens,Feces,UBERON:0001988,Multiple sclerosis,MONDO:0005301,healthy controls,IMD naive cases multiple sclerosis,NA,16,9,2 months,16S,4,Illumina,Negative Binomial Regression,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:286/1/NA,Study 286,"cross-sectional observational, not case-control",30674011,10.1007/s40618-019-1010-9,NA,"Shi TT, Xin Z, Hua L, Zhao RX, Yang YL, Wang H, Zhang S, Liu W , Xie RR",Alterations in the intestinal microbiota of patients with severe and active Graves' orbitopathy: a cross-sectional study,Journal of endocrinological investigation,2019,"16S rRNA gene, Graves’ orbitopathy (GO), Gut microbiota, Thyrotropin receptor antibody (TRAb)",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Graves ophthalmopathy,EFO:1001466,Healthy controls,graves orbitopathy,"The diagnosis of GO was established according to the EUGOGO Guidelines. The active GO was defined by a clinical activity score (CAS)≥3/7, and the severe GO was defined by NOSPECS score≥IV. CT or MRI was used to exclude any orbital space-occupying disease such as tumor or extraocular myositis.",32,33,4 weeks,16S,4,Ion Torrent,Metastats,0.05,FALSE,NA,"age,sex",NA,NA,decreased,unchanged,decreased,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:286/2/NA,Study 286,"cross-sectional observational, not case-control",30674011,10.1007/s40618-019-1010-9,NA,"Shi TT, Xin Z, Hua L, Zhao RX, Yang YL, Wang H, Zhang S, Liu W , Xie RR",Alterations in the intestinal microbiota of patients with severe and active Graves' orbitopathy: a cross-sectional study,Journal of endocrinological investigation,2019,"16S rRNA gene, Graves’ orbitopathy (GO), Gut microbiota, Thyrotropin receptor antibody (TRAb)",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Graves ophthalmopathy,EFO:1001466,healthy controls,graves orbitopathy,severe and active graves' orbitopathy,32,33,4 weeks,16S,4,Ion Torrent,LEfSe,0.05,FALSE,3,"age,sex",NA,NA,decreased,unchanged,decreased,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:287/1/NA,Study 287,time series / longitudinal observational,32214382,10.1371/journal.ppat.1008376,NA,"Usyk M, Zolnik CP, Castle PE, Porras C, Herrero R, Gradissimo A, Gonzalez P, Safaeian M, Schiffman M , Burk RD",Cervicovaginal microbiome and natural history of HPV in a longitudinal study,PLoS pathogens,2020,NA,Experiment 1,Costa Rica,Homo sapiens,Uterine cervix,UBERON:0000002,Human papilloma virus infection,EFO:0001668,HPV (clearance),Visit 1 HPV (progression),HPV progression to CIN2+ lesion diagnosis,70,33,NA,16S,4,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:287/2/NA,Study 287,time series / longitudinal observational,32214382,10.1371/journal.ppat.1008376,NA,"Usyk M, Zolnik CP, Castle PE, Porras C, Herrero R, Gradissimo A, Gonzalez P, Safaeian M, Schiffman M , Burk RD",Cervicovaginal microbiome and natural history of HPV in a longitudinal study,PLoS pathogens,2020,NA,Experiment 2,Costa Rica,Homo sapiens,Uterine cervix,UBERON:0000002,Human papilloma virus infection,EFO:0001668,HPV (clearance),Visit 2 HPV (progression),HPV progression to CIN2+ lesion diagnosis,69,33,NA,16S,4,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:288/1/NA,Study 288,case-control,29502926,10.1016/j.numecd.2018.01.004,NA,"Verduci E, Moretti F, Bassanini G, Banderali G, Rovelli V, Casiraghi MC, Morace G, Borgo F , Borghi E",Phenylketonuric diet negatively impacts on butyrate production,"Nutrition, metabolism, and cardiovascular diseases : NMCD",2018,"Butyrate, Faecalibacterium prausnitzii, Phenylketonuria, Short chain fatty acids",Experiment 1,Italy,Homo sapiens,Feces,UBERON:0001988,Phenylketonuria,MONDO:0009861,mild hyperphenylalaninemic with unrestricted diet,phenylketonuric with Phe-restricted diet,phenylketonuric patients with restricted (phenylalanine-free) diets,21,21,3 months,16S,23,RT-qPCR,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,"age,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:289/1/NA,Study 289,case-control,31808612,10.1111/jcmm.14880,NA,"Sun Q, Xu X, Zhang J, Sun M, Tian Q, Li Q, Cao W, Zhang X, Wang H, Liu J, Zhang J, Meng X, Wu L, Song M, Liu H, Wang W , Wang Y",Association of suboptimal health status with intestinal microbiota in Chinese youths,Journal of cellular and molecular medicine,2020,"16S rRNA, LEfSe analysis, intestinal microbiota, random forest tree, suboptimal health status",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Health trait,EFO:0007652,healthy controls,suboptimal health status,subjects with SHSQ-25 (SHS score >= 35),50,50,2 months,16S,4,Illumina,LEfSe,0.05,FALSE,2,"age,body mass index,sex",NA,NA,increased,unchanged,increased,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:290/1/NA,Study 290,time series / longitudinal observational,31729407,10.1038/s41598-019-53073-w,NA,"Laheij AMGA, Raber-Durlacher JE, Koppelmans RGA, Huysmans MDNJM, Potting C, van Leeuwen SJM, Hazenberg MD, Brennan MT, von Bültzingslöwen I, Johansson JE, de Soet JJ, Haverman TM, Buijs MJ, Brandt BW, Rozema FR, Blijlevens NMA , Zaura E",Microbial changes in relation to oral mucositis in autologous hematopoietic stem cell transplantation recipients,Scientific reports,2019,NA,Experiment 1,Netherlands,Homo sapiens,Mouth,UBERON:0000165,Oral mucositis,EFO:1001904,no ulcerative oral mucositis,ulcerative oral mucositis,patient developed uclerative oral mucositis,31,20,NA,16S,4,RT-qPCR,LEfSe,0.05,FALSE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:290/2/NA,Study 290,time series / longitudinal observational,31729407,10.1038/s41598-019-53073-w,NA,"Laheij AMGA, Raber-Durlacher JE, Koppelmans RGA, Huysmans MDNJM, Potting C, van Leeuwen SJM, Hazenberg MD, Brennan MT, von Bültzingslöwen I, Johansson JE, de Soet JJ, Haverman TM, Buijs MJ, Brandt BW, Rozema FR, Blijlevens NMA , Zaura E",Microbial changes in relation to oral mucositis in autologous hematopoietic stem cell transplantation recipients,Scientific reports,2019,NA,Experiment 2,Netherlands,Homo sapiens,Mouth,UBERON:0000165,Oral mucositis,EFO:1001904,one and two weeks after stem cell transplant,pre- and three month after auto stem cell transplant,patient developed uclerative oral mucositis,31,20,NA,16S,4,RT-qPCR,PERMANOVA,0.05,FALSE,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:290/3/NA,Study 290,time series / longitudinal observational,31729407,10.1038/s41598-019-53073-w,NA,"Laheij AMGA, Raber-Durlacher JE, Koppelmans RGA, Huysmans MDNJM, Potting C, van Leeuwen SJM, Hazenberg MD, Brennan MT, von Bültzingslöwen I, Johansson JE, de Soet JJ, Haverman TM, Buijs MJ, Brandt BW, Rozema FR, Blijlevens NMA , Zaura E",Microbial changes in relation to oral mucositis in autologous hematopoietic stem cell transplantation recipients,Scientific reports,2019,NA,Experiment 3,Netherlands,Homo sapiens,Mouth,UBERON:0000165,Oral mucositis,EFO:1001904,one and two weeks after stem cell transplant,pre- and three month after auto stem cell transplant,patient developed uclerative oral mucositis,31,20,NA,16S,4,RT-qPCR,PERMANOVA,0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:290/4/NA,Study 290,time series / longitudinal observational,31729407,10.1038/s41598-019-53073-w,NA,"Laheij AMGA, Raber-Durlacher JE, Koppelmans RGA, Huysmans MDNJM, Potting C, van Leeuwen SJM, Hazenberg MD, Brennan MT, von Bültzingslöwen I, Johansson JE, de Soet JJ, Haverman TM, Buijs MJ, Brandt BW, Rozema FR, Blijlevens NMA , Zaura E",Microbial changes in relation to oral mucositis in autologous hematopoietic stem cell transplantation recipients,Scientific reports,2019,NA,Experiment 4,Netherlands,Homo sapiens,Mouth,UBERON:0000165,Oral mucositis,EFO:1001904,low or no fungi load,0.1% or higher fungi load,patient developed uclerative oral mucositis,31,20,NA,16S,4,RT-qPCR,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:291/1/NA,Study 291,case-control,30263008,10.7150/ijbs.24151,NA,"Ishaq HM, Mohammad IS, Shahzad M, Ma C, Raza MA, Wu X, Guo H, Shi P , Xu J",Molecular Alteration Analysis of Human Gut Microbial Composition in Graves' disease Patients,International journal of biological sciences,2018,"DGGE, GD, Gut microbiota, High-throughput sequencing, Hyperthyroidism, Ophthalmopathy",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Graves disease,EFO:0004237,healthy controls,graves disease,graves' disease patients,11,27,2 months,16S,34,Illumina,T-Test,0.05,FALSE,NA,age,NA,NA,unchanged,decreased,unchanged,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:292/1/NA,Study 292,case-control,32150591,10.1371/journal.ppat.1008348,NA,"Oku S, Takeshita T, Futatsuki T, Kageyama S, Asakawa M, Mori Y, Miyamoto T, Hata J, Ninomiya T, Kashiwazaki H , Yamashita Y",Disrupted tongue microbiota and detection of nonindigenous bacteria on the day of allogeneic hematopoietic stem cell transplantation,PLoS pathogens,2020,NA,Experiment 1,Japan,Homo sapiens,Tongue,UBERON:0001723,Response to allogeneic hematopoietic stem cell transplant,EFO:0007044,community-dwelling controls,allogeneic-hematopoietic stem cell transplant,patient ages 36-69 years old undergoing allogeneic- hematopoietic stem cell transplantation,164,45,NA,16S,12,Ion Torrent,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,age,NA,NA,decreased,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:293/1/NA,Study 293,time series / longitudinal observational,30463989,10.1158/1940-6207.CAPR-18-0233,NA,"Ritu W, Enqi W, Zheng S, Wang J, Ling Y , Wang Y","Evaluation of the Associations Between Cervical Microbiota and HPV Infection, Clearance, and Persistence in Cytologically Normal Women","Cancer prevention research (Philadelphia, Pa.)",2019,NA,Experiment 1,China,Homo sapiens,Uterine cervix,UBERON:0000002,Human papilloma virus infection,EFO:0001668,Baseline HPV-,Baseline HPV+,HPV+ confirmed by HPV assay and genotyping,43,90,2 weeks,16S,4,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,decreased,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:293/2/NA,Study 293,time series / longitudinal observational,30463989,10.1158/1940-6207.CAPR-18-0233,NA,"Ritu W, Enqi W, Zheng S, Wang J, Ling Y , Wang Y","Evaluation of the Associations Between Cervical Microbiota and HPV Infection, Clearance, and Persistence in Cytologically Normal Women","Cancer prevention research (Philadelphia, Pa.)",2019,NA,Experiment 2,China,Homo sapiens,Uterine cervix,UBERON:0000002,Human papilloma virus infection,EFO:0001668,no new acquisition of HPV within a year,new acquisition of HPV within a year,New HPV-type acquisition confirmed by HPV assay and genotyping,109,24,2 weeks,16S,4,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:293/3/NA,Study 293,time series / longitudinal observational,30463989,10.1158/1940-6207.CAPR-18-0233,NA,"Ritu W, Enqi W, Zheng S, Wang J, Ling Y , Wang Y","Evaluation of the Associations Between Cervical Microbiota and HPV Infection, Clearance, and Persistence in Cytologically Normal Women","Cancer prevention research (Philadelphia, Pa.)",2019,NA,Experiment 3,China,Homo sapiens,Uterine cervix,UBERON:0000002,Human papilloma virus infection,EFO:0001668,with at least one HPV type cleared in a year,without any HPV type cleared,No HPV-type cleared confirmed by HPV assay and genotyping,75,15,2 weeks,16S,4,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:293/4/NA,Study 293,time series / longitudinal observational,30463989,10.1158/1940-6207.CAPR-18-0233,NA,"Ritu W, Enqi W, Zheng S, Wang J, Ling Y , Wang Y","Evaluation of the Associations Between Cervical Microbiota and HPV Infection, Clearance, and Persistence in Cytologically Normal Women","Cancer prevention research (Philadelphia, Pa.)",2019,NA,Experiment 4,China,Homo sapiens,Uterine cervix,UBERON:0000002,Human papilloma virus infection,EFO:0001668,HPV-,HPV+,HPV+ confirmed by HPV assay and genotyping,43,90,2 weeks,16S,4,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:293/5/NA,Study 293,time series / longitudinal observational,30463989,10.1158/1940-6207.CAPR-18-0233,NA,"Ritu W, Enqi W, Zheng S, Wang J, Ling Y , Wang Y","Evaluation of the Associations Between Cervical Microbiota and HPV Infection, Clearance, and Persistence in Cytologically Normal Women","Cancer prevention research (Philadelphia, Pa.)",2019,NA,Experiment 5,China,Homo sapiens,Uterine cervix,UBERON:0000002,Human papilloma virus infection,EFO:0001668,no new acquisition of HPV within a year,new acquisition of HPV within a year,New HPV-type acquisition confirmed by HPV assay and genotyping,109,24,2 weeks,16S,4,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:293/6/NA,Study 293,time series / longitudinal observational,30463989,10.1158/1940-6207.CAPR-18-0233,NA,"Ritu W, Enqi W, Zheng S, Wang J, Ling Y , Wang Y","Evaluation of the Associations Between Cervical Microbiota and HPV Infection, Clearance, and Persistence in Cytologically Normal Women","Cancer prevention research (Philadelphia, Pa.)",2019,NA,Experiment 6,China,Homo sapiens,Uterine cervix,UBERON:0000002,Human papilloma virus infection,EFO:0001668,with any HPV type cleared in a year,without any HPV type cleared,No HPV-type cleared confirmed by HPV assay and genotyping,75,15,2 weeks,16S,4,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:293/7/NA,Study 293,time series / longitudinal observational,30463989,10.1158/1940-6207.CAPR-18-0233,NA,"Ritu W, Enqi W, Zheng S, Wang J, Ling Y , Wang Y","Evaluation of the Associations Between Cervical Microbiota and HPV Infection, Clearance, and Persistence in Cytologically Normal Women","Cancer prevention research (Philadelphia, Pa.)",2019,NA,Experiment 7,China,Homo sapiens,Uterine cervix,UBERON:0000002,Human papilloma virus infection,EFO:0001668,no HPV type persisted,at least one HPV type persisted,Any HPV-type persisted confirmed by HPV assay and genotyping,64,29,2 weeks,16S,4,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:294/1/NA,Study 294,time series / longitudinal observational,29518185,10.1093/cid/ciy153,NA,"Hakim H, Dallas R, Wolf J, Tang L, Schultz-Cherry S, Darling V, Johnson C, Karlsson EA, Chang TC, Jeha S, Pui CH, Sun Y, Pounds S, Hayden RT, Tuomanen E , Rosch JW",Gut Microbiome Composition Predicts Infection Risk During Chemotherapy in Children With Acute Lymphoblastic Leukemia,Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,2018,NA,Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Acute lymphoblastic leukemia,EFO:0000220,baseline,post-induction therapy,6 weeks of remission induction therapy,112,87,NA,16S,123,Illumina,Negative Binomial Regression,0.05,TRUE,NA,NA,"antibiotic exposure,demographics",NA,decreased,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:294/2/NA,Study 294,time series / longitudinal observational,29518185,10.1093/cid/ciy153,NA,"Hakim H, Dallas R, Wolf J, Tang L, Schultz-Cherry S, Darling V, Johnson C, Karlsson EA, Chang TC, Jeha S, Pui CH, Sun Y, Pounds S, Hayden RT, Tuomanen E , Rosch JW",Gut Microbiome Composition Predicts Infection Risk During Chemotherapy in Children With Acute Lymphoblastic Leukemia,Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,2018,NA,Experiment 2,United States of America,Homo sapiens,Feces,UBERON:0001988,Acute lymphoblastic leukemia,EFO:0000220,baseline,post-consolidation therapy,8 weeks of consolidation,112,107,NA,16S,123,Illumina,Negative Binomial Regression,0.05,TRUE,NA,NA,"acute lymphoblastic leukemia,chemotherapy",NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:294/3/NA,Study 294,time series / longitudinal observational,29518185,10.1093/cid/ciy153,NA,"Hakim H, Dallas R, Wolf J, Tang L, Schultz-Cherry S, Darling V, Johnson C, Karlsson EA, Chang TC, Jeha S, Pui CH, Sun Y, Pounds S, Hayden RT, Tuomanen E , Rosch JW",Gut Microbiome Composition Predicts Infection Risk During Chemotherapy in Children With Acute Lymphoblastic Leukemia,Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,2018,NA,Experiment 3,United States of America,Homo sapiens,Feces,UBERON:0001988,Acute lymphoblastic leukemia,EFO:0000220,baseline,post re-induction therapy,120 weeks of continuation phase with the last 17-20 weeks of reinduction II therapy,112,90,NA,16S,123,Illumina,Negative Binomial Regression,0.05,TRUE,NA,NA,"acute lymphoblastic leukemia,chemotherapy",NA,decreased,unchanged,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:294/4/NA,Study 294,time series / longitudinal observational,29518185,10.1093/cid/ciy153,NA,"Hakim H, Dallas R, Wolf J, Tang L, Schultz-Cherry S, Darling V, Johnson C, Karlsson EA, Chang TC, Jeha S, Pui CH, Sun Y, Pounds S, Hayden RT, Tuomanen E , Rosch JW",Gut Microbiome Composition Predicts Infection Risk During Chemotherapy in Children With Acute Lymphoblastic Leukemia,Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,2018,NA,Experiment 4,United States of America,Homo sapiens,Feces,UBERON:0001988,Acute lymphoblastic leukemia,EFO:0000220,non-febrile neutropenia,febrile neutropenia,fever as an oral temperature more than 38.0°C persisting for more than 1 hour; neutropenia as an absolute neutrophil count less than or equal to 500 cells per microliter after baseline first sampled,47,65,NA,16S,123,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,"acute lymphoblastic leukemia,chemotherapy",NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:295/1/NA,Study 295,"cross-sectional observational, not case-control",31555603,10.3389/fcimb.2019.00294,NA,"Zhou Y, Wang L, Pei F, Ji M, Zhang F, Sun Y, Zhao Q, Hong Y, Wang X, Tian J , Wang Y",Patients With LR-HPV Infection Have a Distinct Vaginal Microbiota in Comparison With Healthy Controls,Frontiers in cellular and infection microbiology,2019,"16S RNA sequencing, condyloma acuminatum, low-risk HPV, sexually transmitted infections, vaginal microbiome",Experiment 1,China,Homo sapiens,Vagina,UBERON:0000996,Human papilloma virus infection,EFO:0001668,negative control,low risk HPV,LR-HPV+ according to results of screening,20,42,NA,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,increased,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:296/1/NA,Study 296,case-control,32466801,10.1186/s40168-020-00854-5,NA,"Jian X, Zhu Y, Ouyang J, Wang Y, Lei Q, Xia J, Guan Y, Zhang J, Guo J, He Y, Wang J, Li J, Lin J, Su M, Li G, Wu M, Qiu L, Xiang J, Xie L, Jia W , Zhou W",Alterations of gut microbiome accelerate multiple myeloma progression by increasing the relative abundances of nitrogen-recycling bacteria,Microbiome,2020,"Fecal microbiota transplantation, Gut microbiome, Multiple myeloma, Nitrogen-recycling bacteria",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Multiple myeloma,EFO:0001378,healthy control,multiple myeloma patients,newly diagnosed multiple myeloma patients,18,19,NA,16S,12,RT-qPCR,DESeq2,0.05,TRUE,NA,"age,sex",NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:296/2/NA,Study 296,case-control,32466801,10.1186/s40168-020-00854-5,NA,"Jian X, Zhu Y, Ouyang J, Wang Y, Lei Q, Xia J, Guan Y, Zhang J, Guo J, He Y, Wang J, Li J, Lin J, Su M, Li G, Wu M, Qiu L, Xiang J, Xie L, Jia W , Zhou W",Alterations of gut microbiome accelerate multiple myeloma progression by increasing the relative abundances of nitrogen-recycling bacteria,Microbiome,2020,"Fecal microbiota transplantation, Gut microbiome, Multiple myeloma, Nitrogen-recycling bacteria",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Multiple myeloma,EFO:0001378,healthy controls,multiple myeloma patients,newly diagnosed multiple myeloma patients,18,19,NA,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.01,TRUE,NA,"age,sex",NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:297/1/NA,Study 297,prospective cohort,31370796,10.1186/s12879-019-4279-6,NA,"Chen Y, Hong Z, Wang W, Gu L, Gao H, Qiu L , Di W",Association between the vaginal microbiome and high-risk human papillomavirus infection in pregnant Chinese women,BMC infectious diseases,2019,"High-risk human papillomavirus, Pregnancy, Vaginal microbiome",Experiment 1,China,Homo sapiens,Posterior fornix of vagina,UBERON:0016486,Human papilloma virus infection,EFO:0001668,non pregnant no HPV,non pregnant high risk HPV,non pregnant high risk HPV confirmed using HPV genotyping kit,30,19,2 weeks,16S,34,Illumina,LEfSe,0.05,FALSE,3.5,NA,NA,NA,increased,increased,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:297/2/NA,Study 297,prospective cohort,31370796,10.1186/s12879-019-4279-6,NA,"Chen Y, Hong Z, Wang W, Gu L, Gao H, Qiu L , Di W",Association between the vaginal microbiome and high-risk human papillomavirus infection in pregnant Chinese women,BMC infectious diseases,2019,"High-risk human papillomavirus, Pregnancy, Vaginal microbiome",Experiment 2,China,Homo sapiens,Posterior fornix of vagina,UBERON:0016486,Human papilloma virus infection,EFO:0001668,pregnant no HPV,pregnant high risk HPV,pregnant high risk HPV confirmed using HPV genotyping kit,48,38,2 weeks,16S,34,Illumina,LEfSe,0.05,FALSE,3.5,NA,NA,NA,unchanged,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:298/2/NA,Study 298,time series / longitudinal observational,28245856,10.1186/s13073-017-0409-1,NA,"Galloway-Peña JR, Smith DP, Sahasrabhojane P, Wadsworth WD, Fellman BM, Ajami NJ, Shpall EJ, Daver N, Guindani M, Petrosino JF, Kontoyiannis DP , Shelburne SA",Characterization of oral and gut microbiome temporal variability in hospitalized cancer patients,Genome medicine,2017,"Antibiotics, Chemotherapy, Leukemia, Microbiome, Temporal variability",Experiment 2,United States of America,Homo sapiens,Buccal mucosa,UBERON:0006956,Acute myeloid leukemia,EFO:0000222,no infection,infection,acute myeloid leukemia patients that were microbiologically documented with infection during induction chemotherapy before neutrophil recovery,30,15,NA,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:298/3/NA,Study 298,time series / longitudinal observational,28245856,10.1186/s13073-017-0409-1,NA,"Galloway-Peña JR, Smith DP, Sahasrabhojane P, Wadsworth WD, Fellman BM, Ajami NJ, Shpall EJ, Daver N, Guindani M, Petrosino JF, Kontoyiannis DP , Shelburne SA",Characterization of oral and gut microbiome temporal variability in hospitalized cancer patients,Genome medicine,2017,"Antibiotics, Chemotherapy, Leukemia, Microbiome, Temporal variability",Experiment 3,United States of America,Homo sapiens,Feces,UBERON:0001988,Acute myeloid leukemia,EFO:0000222,no infection,infection,acute myeloid leukemia patients that were microbiologically documented with infection during induction chemotherapy before neutrophil recovery,30,15,NA,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:299/1/NA,Study 299,time series / longitudinal observational,32115690,10.1002/ijc.32942,NA,"De Pietri S, Ingham AC, Frandsen TL, Rathe M, Krych L, Castro-Mejía JL, Nielsen DS, Nersting J, Wehner PS, Schmiegelow K, Hasle H, Pamp SJ , Müller K",Gastrointestinal toxicity during induction treatment for childhood acute lymphoblastic leukemia: The impact of the gut microbiota,International journal of cancer,2020,"C-reactive protein, acute lymphoblastic leukemia, citrulline, gastrointestinal toxicity, microbiota, mucositis",Experiment 1,Denmark,Homo sapiens,Feces,UBERON:0001988,Acute lymphoblastic leukemia,EFO:0000220,baseline,induction chemotherapy,children (ages 1-18 years old) newly diagnosed with Acute Lymphoblastic Leukemia and undergoing induction chemotherapy according to the Nordic Society of Paediatric Haematology and Oncology (NOPHO) post initiation of induction chemotherapy,32,51,NA,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:300/1/NA,Study 300,laboratory experiment,28714953,10.1038/nn.4606,NA,"Shen S, Lim G, You Z, Ding W, Huang P, Ran C, Doheny J, Caravan P, Tate S, Hu K, Kim H, McCabe M, Huang B, Xie Z, Kwon D, Chen L , Mao J",Gut microbiota is critical for the induction of chemotherapy-induced pain,Nature neuroscience,2017,NA,Experiment 1,United States of America,Mus musculus,Feces,UBERON:0001988,Response to antibiotic,GO:0046677,H2O mice,Exposed abx mice,Mice fed with antibiotic water,10,10,None,16S,NA,RT-qPCR,ANOVA,0.05,FALSE,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:301/1/NA,Study 301,"cross-sectional observational, not case-control",23717441,10.1371/journal.pone.0063514,NA,"Lee JE, Lee S, Lee H, Song YM, Lee K, Han MJ, Sung J , Ko G",Association of the vaginal microbiota with human papillomavirus infection in a Korean twin cohort,PloS one,2013,NA,Experiment 1,South Korea,Homo sapiens,Uterine cervix,UBERON:0000002,Human papilloma virus infection,EFO:0001668,HPV-,HPV+,HPV infection through PCR confirmation,9,9,6 months,16S,23,Roche454,LEfSe,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:301/2/NA,Study 301,"cross-sectional observational, not case-control",23717441,10.1371/journal.pone.0063514,NA,"Lee JE, Lee S, Lee H, Song YM, Lee K, Han MJ, Sung J , Ko G",Association of the vaginal microbiota with human papillomavirus infection in a Korean twin cohort,PloS one,2013,NA,Experiment 2,South Korea,Homo sapiens,Uterine cervix,UBERON:0000002,Human papilloma virus infection,EFO:0001668,HPV-,HPV+,HPV+ through PCR confirmation,26,19,6 months,16S,23,Roche454,LEfSe,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:301/3/NA,Study 301,"cross-sectional observational, not case-control",23717441,10.1371/journal.pone.0063514,NA,"Lee JE, Lee S, Lee H, Song YM, Lee K, Han MJ, Sung J , Ko G",Association of the vaginal microbiota with human papillomavirus infection in a Korean twin cohort,PloS one,2013,NA,Experiment 3,South Korea,Homo sapiens,Uterine cervix,UBERON:0000002,Human papilloma virus infection,EFO:0001668,HPV-,HR-HPV+,"HR-HPV+ through PCR confirmation, HPV genotype 16, 18, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 66",26,13,6 months,16S,23,Roche454,LEfSe,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:302/1/NA,Study 302,case-control,29518419,10.1016/j.jaci.2018.02.020,NA,"Fazlollahi M, Lee TD, Andrade J, Oguntuyo K, Chun Y, Grishina G, Grishin A , Bunyavanich S",The nasal microbiome in asthma,The Journal of allergy and clinical immunology,2018,"16S rRNA sequencing, Nasal, asthma, microbiome, upper airway, upper respiratory tract",Experiment 1,United States of America,Homo sapiens,Nasal cavity,UBERON:0001707,Asthma,MONDO:0004979,healthy control,exacerbated asthma,physician-diagnosed current asthma presenting with an encounter diagnosis of asthma exacerbation,21,20,NA,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:302/2/NA,Study 302,case-control,29518419,10.1016/j.jaci.2018.02.020,NA,"Fazlollahi M, Lee TD, Andrade J, Oguntuyo K, Chun Y, Grishina G, Grishin A , Bunyavanich S",The nasal microbiome in asthma,The Journal of allergy and clinical immunology,2018,"16S rRNA sequencing, Nasal, asthma, microbiome, upper airway, upper respiratory tract",Experiment 2,United States of America,Homo sapiens,Nasal cavity,UBERON:0001707,Asthma,MONDO:0004979,healthy control,non-exacerbated asthma,"physician-diagnosed current asthma presenting for routine, non-urgent, asthma followup care.",21,31,NA,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:302/3/NA,Study 302,case-control,29518419,10.1016/j.jaci.2018.02.020,NA,"Fazlollahi M, Lee TD, Andrade J, Oguntuyo K, Chun Y, Grishina G, Grishin A , Bunyavanich S",The nasal microbiome in asthma,The Journal of allergy and clinical immunology,2018,"16S rRNA sequencing, Nasal, asthma, microbiome, upper airway, upper respiratory tract",Experiment 3,United States of America,Homo sapiens,Nasal cavity,UBERON:0001707,Asthma,MONDO:0004979,non-exacerbated asthma,exacerbated asthma,physician-diagnosed current asthma presenting with an encounter diagnosis of asthma exacerbation,31,20,NA,16S,34,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:302/4/NA,Study 302,case-control,29518419,10.1016/j.jaci.2018.02.020,NA,"Fazlollahi M, Lee TD, Andrade J, Oguntuyo K, Chun Y, Grishina G, Grishin A , Bunyavanich S",The nasal microbiome in asthma,The Journal of allergy and clinical immunology,2018,"16S rRNA sequencing, Nasal, asthma, microbiome, upper airway, upper respiratory tract",Experiment 4,United States of America,Homo sapiens,Nasal cavity,UBERON:0001707,Asthma,MONDO:0004979,healthy control,asthma,"physician-diagnosed current asthma presenting for routine, non-urgent, asthma followup care or with an encounter diagnosis of asthma exacerbation",21,51,NA,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:302/5/NA,Study 302,case-control,29518419,10.1016/j.jaci.2018.02.020,NA,"Fazlollahi M, Lee TD, Andrade J, Oguntuyo K, Chun Y, Grishina G, Grishin A , Bunyavanich S",The nasal microbiome in asthma,The Journal of allergy and clinical immunology,2018,"16S rRNA sequencing, Nasal, asthma, microbiome, upper airway, upper respiratory tract",Experiment 5,United States of America,Homo sapiens,Nasal cavity,UBERON:0001707,Asthma,MONDO:0004979,healthy control,asthma,"physician-diagnosed current asthma presenting for routine, non-urgent, asthma followup care or with an encounter diagnosis of asthma exacerbation",21,51,NA,16S,34,RT-qPCR,T-Test,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:303/1/NA,Study 303,prospective cohort,26147207,10.1111/apt.13302,NA,"Montassier E, Gastinne T, Vangay P, Al-Ghalith GA, Bruley des Varannes S, Massart S, Moreau P, Potel G, de La Cochetière MF, Batard E , Knights D",Chemotherapy-driven dysbiosis in the intestinal microbiome,Alimentary pharmacology & therapeutics,2015,NA,Experiment 1,France,Homo sapiens,Feces,UBERON:0001988,Non-Hodgkins lymphoma,EFO:0005952,pre-chemotherapy,post-chemotherapy,"non-Hodgkin's lymphoma patients post myeloablative conditiong regimen (chemotherapy) fecal sampling for 5 consecutive days of high-dose Carmustine, Etoposide, Aracytine and Melphalan and with no antibiotics treatment after starting regimen",28,15,1 month,16S,56,Roche454,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:304/1/NA,Study 304,randomized controlled trial,27411009,10.1016/j.cmet.2016.06.016,NA,"Reijnders D, Goossens GH, Hermes GD, Neis EP, van der Beek CM, Most J, Holst JJ, Lenaerts K, Kootte RS, Nieuwdorp M, Groen AK, Olde Damink SW, Boekschoten MV, Smidt H, Zoetendal EG, Dejong CH , Blaak EE",Effects of Gut Microbiota Manipulation by Antibiotics on Host Metabolism in Obese Humans: A Randomized Double-Blind Placebo-Controlled Trial,Cell metabolism,2016,NA,Experiment 1,Netherlands,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,or placebo (microcrystalline cellulose),oral intake of vancomycin (directed against Gram-positive bacteria),"low-active (<3 hr organized sports activities per week), weight-stable (<2 kg body weight change 3 months prior to inclusion) overweight/obese (BMI 25–35 kg/m2) Caucasian men, between 35 and 70 years with impaired glucose metabolism (either fasting glucose >5.6 mmol/l, and/or 2 hr glucose between 7.8–11 mmol/l) and insulin resistant (homeostasis model assessment for insulin resistance; HOMA-IR > 2.2).",37,38,3 months,16S,NA,Human Intestinal Tract Chip,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:305/1/NA,Study 305,case-control,32237205,10.1002/cam4.3027,NA,"Tsementzi D, Pena-Gonzalez A, Bai J, Hu YJ, Patel P, Shelton J, Dolan M, Arluck J, Khanna N, Conrad L, Scott I, Eng TY, Konstantinidis KT , Bruner DW",Comparison of vaginal microbiota in gynecologic cancer patients pre- and post-radiation therapy and healthy women,Cancer medicine,2020,"16S rRNA gene, gynecologic cancer, postmenopausal women, radiation therapy, vaginal microbiota",Experiment 1,United States of America,Homo sapiens,Vagina,UBERON:0000996,"Genital neoplasm, female",EFO:1001331,healthy controls,women with gynecological cancer,postmenopausal women (naturally or due to hysterectomy) with endometrial or cervical cancer treated with radiotherapy with or without surgery and/or chemotherapy,69,65,course of the study,16S,4,Illumina,LEfSe,0.05,TRUE,3,NA,NA,unchanged,increased,increased,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:306/1/NA,Study 306,prospective cohort,31951695,10.21101/cejph.a5393,NA,"Parco S, Benericetti G, Vascotto F , Palmisciano G",Microbiome and diversity indices during blood stem cells transplantation - new perspectives?,Central European journal of public health,2019,"blood stem cells transplantation, graft versus host disease, oral and gut microbiome",Experiment 1,Italy,Homo sapiens,Feces,UBERON:0001988,Response to allogeneic hematopoietic stem cell transplant,EFO:0007044,pre- allogeneic hematopoietic stem cell transplant,post- allogeneic hematopoietic stem cell transplant,children between 3 and 10 years of age that have undergone allogeneic hematopoeitic stem cell transplantation and hospitalized at Institute for Maternal and Child Health of Trieste,5,5,None,16S,123,Ion Torrent,T-Test,0.05,FALSE,NA,NA,NA,NA,decreased,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:307/1/NA,Study 307,randomized controlled trial,29186529,10.1093/infdis/jix604,NA,"de Gunzburg J, Ghozlane A, Ducher A, Le Chatelier E, Duval X, Ruppé E, Armand-Lefevre L, Sablier-Gallis F, Burdet C, Alavoine L, Chachaty E, Augustin V, Varastet M, Levenez F, Kennedy S, Pons N, Mentré F , Andremont A",Protection of the Human Gut Microbiome From Antibiotics,The Journal of infectious diseases,2018,"Clostridium difficile, antibiotics, fluoroquinolones, microbiome",Experiment 1,France,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,Negative control group (CLT),moxifloxacin treated group (MXF),healthy male and female volunteers aged >18 years,8,14,3 months,WMS,NA,Mass spectrometry,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:307/2/NA,Study 307,randomized controlled trial,29186529,10.1093/infdis/jix604,NA,"de Gunzburg J, Ghozlane A, Ducher A, Le Chatelier E, Duval X, Ruppé E, Armand-Lefevre L, Sablier-Gallis F, Burdet C, Alavoine L, Chachaty E, Augustin V, Varastet M, Levenez F, Kennedy S, Pons N, Mentré F , Andremont A",Protection of the Human Gut Microbiome From Antibiotics,The Journal of infectious diseases,2018,"Clostridium difficile, antibiotics, fluoroquinolones, microbiome",Experiment 2,France,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,moxifloxacin treated group (MXF),DAV132+moxifloxacin treated group (MXF+DAV132),healthy male and female volunteers aged >18 years,14,14,3 months,WMS,NA,Mass spectrometry,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:307/3/NA,Study 307,randomized controlled trial,29186529,10.1093/infdis/jix604,NA,"de Gunzburg J, Ghozlane A, Ducher A, Le Chatelier E, Duval X, Ruppé E, Armand-Lefevre L, Sablier-Gallis F, Burdet C, Alavoine L, Chachaty E, Augustin V, Varastet M, Levenez F, Kennedy S, Pons N, Mentré F , Andremont A",Protection of the Human Gut Microbiome From Antibiotics,The Journal of infectious diseases,2018,"Clostridium difficile, antibiotics, fluoroquinolones, microbiome",Experiment 3,France,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,Negative control group (CLT),DAV132+moxifloxacin treated group (MXF+DAV132),healthy male and female volunteers aged >18 years,8,14,3 months,WMS,NA,Mass spectrometry,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:308/1/NA,Study 308,laboratory experiment,29783199,10.1016/j.envpol.2018.04.130,NA,"Mutlu EA, Comba IY, Cho T, Engen PA, Yazıcı C, Soberanes S, Hamanaka RB, Niğdelioğlu R, Meliton AY, Ghio AJ, Budinger GRS , Mutlu GM",Inhalational exposure to particulate matter air pollution alters the composition of the gut microbiome,"Environmental pollution (Barking, Essex : 1987)",2018,"Air pollution, Feces, Gastrointestinal, Intestine, Microbiota",Experiment 1,United States of America,Mus musculus,Small intestine,UBERON:0002108,Air pollution,ENVO:02500037,Filtered air group,PM 2.5 air exposed group,Mice exposed to PM2.5 concentrated from ambient air in Chicago 8 hours per day for 5 days a week for three consecutive weeks in a chamber connected to Versatile Aerosol Concentration Enrichment System (VACES),10,10,NA,16S,NA,Roche454,LEfSe,0.05,FALSE,5,NA,NA,NA,increased,increased,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:308/2/NA,Study 308,laboratory experiment,29783199,10.1016/j.envpol.2018.04.130,NA,"Mutlu EA, Comba IY, Cho T, Engen PA, Yazıcı C, Soberanes S, Hamanaka RB, Niğdelioğlu R, Meliton AY, Ghio AJ, Budinger GRS , Mutlu GM",Inhalational exposure to particulate matter air pollution alters the composition of the gut microbiome,"Environmental pollution (Barking, Essex : 1987)",2018,"Air pollution, Feces, Gastrointestinal, Intestine, Microbiota",Experiment 2,United States of America,Mus musculus,Feces,UBERON:0001988,Air pollution,ENVO:02500037,Filtered air group,PM 2.5 air exposed group,Mice exposed to PM2.5 concentrated from ambient air in Chicago 8 hours per day for 5 days a week for three consecutive weeks in a chamber connected to Versatile Aerosol Concentration Enrichment System (VACES),10,10,NA,16S,NA,Roche454,LEfSe,0.05,FALSE,5,NA,NA,NA,increased,increased,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:308/3/NA,Study 308,laboratory experiment,29783199,10.1016/j.envpol.2018.04.130,NA,"Mutlu EA, Comba IY, Cho T, Engen PA, Yazıcı C, Soberanes S, Hamanaka RB, Niğdelioğlu R, Meliton AY, Ghio AJ, Budinger GRS , Mutlu GM",Inhalational exposure to particulate matter air pollution alters the composition of the gut microbiome,"Environmental pollution (Barking, Essex : 1987)",2018,"Air pollution, Feces, Gastrointestinal, Intestine, Microbiota",Experiment 3,United States of America,Mus musculus,Caecum,UBERON:0001153,Air pollution,ENVO:02500037,Filtered air group,PM 2.5 air exposed group,Mice exposed to PM2.5 concentrated from ambient air in Chicago 8 hours per day for 5 days a week for three consecutive weeks in a chamber connected to Versatile Aerosol Concentration Enrichment System (VACES),10,10,NA,16S,NA,Roche454,LEfSe,0.05,FALSE,5,NA,NA,NA,unchanged,unchanged,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:308/4/NA,Study 308,laboratory experiment,29783199,10.1016/j.envpol.2018.04.130,NA,"Mutlu EA, Comba IY, Cho T, Engen PA, Yazıcı C, Soberanes S, Hamanaka RB, Niğdelioğlu R, Meliton AY, Ghio AJ, Budinger GRS , Mutlu GM",Inhalational exposure to particulate matter air pollution alters the composition of the gut microbiome,"Environmental pollution (Barking, Essex : 1987)",2018,"Air pollution, Feces, Gastrointestinal, Intestine, Microbiota",Experiment 4,United States of America,Mus musculus,Stomach,UBERON:0000945,Air pollution,ENVO:02500037,Filtered air group,PM 2.5 air exposed group,Mice exposed to PM2.5 concentrated from ambient air in Chicago 8 hours per day for 5 days a week for three consecutive weeks in a chamber connected to Versatile Aerosol Concentration Enrichment System (VACES),10,10,NA,16S,NA,Roche454,LEfSe,0.05,FALSE,5,NA,NA,NA,unchanged,unchanged,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:308/5/NA,Study 308,laboratory experiment,29783199,10.1016/j.envpol.2018.04.130,NA,"Mutlu EA, Comba IY, Cho T, Engen PA, Yazıcı C, Soberanes S, Hamanaka RB, Niğdelioğlu R, Meliton AY, Ghio AJ, Budinger GRS , Mutlu GM",Inhalational exposure to particulate matter air pollution alters the composition of the gut microbiome,"Environmental pollution (Barking, Essex : 1987)",2018,"Air pollution, Feces, Gastrointestinal, Intestine, Microbiota",Experiment 5,United States of America,Mus musculus,Colon,UBERON:0001155,Air pollution,ENVO:02500037,Filtered air group,PM 2.5 air exposed group,Mice exposed to PM2.5 concentrated from ambient air in Chicago 8 hours per day for 5 days a week for three consecutive weeks in a chamber connected to Versatile Aerosol Concentration Enrichment System (VACES),10,10,NA,16S,NA,Roche454,LEfSe,0.05,FALSE,5,NA,NA,NA,increased,unchanged,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:308/6/NA,Study 308,laboratory experiment,29783199,10.1016/j.envpol.2018.04.130,NA,"Mutlu EA, Comba IY, Cho T, Engen PA, Yazıcı C, Soberanes S, Hamanaka RB, Niğdelioğlu R, Meliton AY, Ghio AJ, Budinger GRS , Mutlu GM",Inhalational exposure to particulate matter air pollution alters the composition of the gut microbiome,"Environmental pollution (Barking, Essex : 1987)",2018,"Air pollution, Feces, Gastrointestinal, Intestine, Microbiota",Experiment 6,United States of America,Mus musculus,"Feces,Stomach,Caecum,Small intestine,Colon","UBERON:0001988,UBERON:0001153,UBERON:0001155,UBERON:0000945,UBERON:0002108",Air pollution,ENVO:02500037,Filtered air group,PM 2.5 air exposed group,Mice exposed to PM2.5 concentrated from ambient air in Chicago 8 hours per day for 5 days a week for three consecutive weeks in a chamber connected to Versatile Aerosol Concentration Enrichment System (VACES),10,10,NA,16S,NA,Roche454,LEfSe,0.05,FALSE,5,NA,NA,NA,increased,increased,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:309/1/NA,Study 309,"cross-sectional observational, not case-control",26935422,10.1158/1940-6207.CAPR-15-0350,NA,"Piyathilake CJ, Ollberding NJ, Kumar R, Macaluso M, Alvarez RD , Morrow CD",Cervical Microbiota Associated with Higher Grade Cervical Intraepithelial Neoplasia in Women Infected with High-Risk Human Papillomaviruses,"Cancer prevention research (Philadelphia, Pa.)",2016,NA,Experiment 1,United States of America,Homo sapiens,Uterine cervix,UBERON:0000002,Cervical glandular intraepithelial neoplasia,EFO:1000165,CIN1,CIN2+,patients with CIN2+ confirmed by colposcopy,90,340,NA,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:309/2/NA,Study 309,"cross-sectional observational, not case-control",26935422,10.1158/1940-6207.CAPR-15-0350,NA,"Piyathilake CJ, Ollberding NJ, Kumar R, Macaluso M, Alvarez RD , Morrow CD",Cervical Microbiota Associated with Higher Grade Cervical Intraepithelial Neoplasia in Women Infected with High-Risk Human Papillomaviruses,"Cancer prevention research (Philadelphia, Pa.)",2016,NA,Experiment 2,United States of America,Homo sapiens,Uterine cervix,UBERON:0000002,Cervical glandular intraepithelial neoplasia,EFO:1000165,<=38.8% 8-OHdG-positive cervical cells,>38.8% 8-OHdG-positive cervical cells,patients with >38.8% of 8-OHdG-positive cervical cells,NA,NA,NA,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:309/3/NA,Study 309,"cross-sectional observational, not case-control",26935422,10.1158/1940-6207.CAPR-15-0350,NA,"Piyathilake CJ, Ollberding NJ, Kumar R, Macaluso M, Alvarez RD , Morrow CD",Cervical Microbiota Associated with Higher Grade Cervical Intraepithelial Neoplasia in Women Infected with High-Risk Human Papillomaviruses,"Cancer prevention research (Philadelphia, Pa.)",2016,NA,Experiment 3,United States of America,Homo sapiens,Uterine cervix,UBERON:0000002,Cervical glandular intraepithelial neoplasia,EFO:1000165,CIN1,CIN2+,patients with CIN2+ confirmed by colposcopy,90,340,NA,16S,4,Illumina,Negative Binomial Regression,0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:310/1/NA,Study 310,prospective cohort,24402367,10.1007/s00248-013-0355-4,NA,"Montassier E, Batard E, Massart S, Gastinne T, Carton T, Caillon J, Le Fresne S, Caroff N, Hardouin JB, Moreau P, Potel G, Le Vacon F , de La Cochetière MF",16S rRNA gene pyrosequencing reveals shift in patient faecal microbiota during high-dose chemotherapy as conditioning regimen for bone marrow transplantation,Microbial ecology,2014,NA,Experiment 1,France,Homo sapiens,Feces,UBERON:0001988,Non-Hodgkins lymphoma,EFO:0005952,pre-chemotherapy,post-chemotherapy,"patients ages 40 to 60 years old diagnosis with non-Hodgkin's lymphoma undergoing post-chemotherapy high-dose carmustine, etoposide, aracytin and melphalan",8,8,all antibiotics after starting chemotherapy,16S,56,Roche454,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:311/1/NA,Study 311,time series / longitudinal observational,25893458,10.1038/bmt.2015.16,NA,"Biagi E, Zama D, Nastasi C, Consolandi C, Fiori J, Rampelli S, Turroni S, Centanni M, Severgnini M, Peano C, de Bellis G, Basaglia G, Gotti R, Masetti R, Pession A, Brigidi P , Candela M",Gut microbiota trajectory in pediatric patients undergoing hematopoietic SCT,Bone marrow transplantation,2015,NA,Experiment 1,Italy,Homo sapiens,Feces,UBERON:0001988,Graft versus host disease,MONDO:0013730,non-GvHD (Graft-versus-host disease),aGvHD (acute Graft-versus-host disease),pre-HSCT (hematopoietic stem cell transplant) samples of subjects who underwent HSCT who developed acute graft-versus-host disease,5,5,None.,16S,4,Roche454,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:312/1/NA,Study 312,prospective cohort,26971496,10.1007/s00253-016-7410-2,NA,"Aloisio I, Quagliariello A, De Fanti S, Luiselli D, De Filippo C, Albanese D, Corvaglia LT, Faldella G , Di Gioia D",Evaluation of the effects of intrapartum antibiotic prophylaxis on newborn intestinal microbiota using a sequencing approach targeted to multi hypervariable 16S rDNA regions,Applied microbiology and biotechnology,2016,"16S rDNA hypervariable regions, Gut microbiota, Intrapartum antibiotic prophylaxis, Newborns, Next generation sequencing technology",Experiment 1,Italy,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,infants born by mothers negative to GBS,Infants born by mothers positive to GBS and received IAP,Infants of Mothers positive to Streptococcus (GBS) and received intrapartum antibiotic prophylaxis (IAP),10,10,perinatal antibiotics,16S,23456789,Ion Torrent,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,decreased,decreased,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:312/2/NA,Study 312,prospective cohort,26971496,10.1007/s00253-016-7410-2,NA,"Aloisio I, Quagliariello A, De Fanti S, Luiselli D, De Filippo C, Albanese D, Corvaglia LT, Faldella G , Di Gioia D",Evaluation of the effects of intrapartum antibiotic prophylaxis on newborn intestinal microbiota using a sequencing approach targeted to multi hypervariable 16S rDNA regions,Applied microbiology and biotechnology,2016,"16S rDNA hypervariable regions, Gut microbiota, Intrapartum antibiotic prophylaxis, Newborns, Next generation sequencing technology",Experiment 2,Italy,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,infants born by mothers negative to GBS,Infants born by mothers positive to GBS and received IAP,Infants of Mothers positive to Streptococcus (GBS) and received intrapartum antibiotic prophylaxis (IAP),10,10,perinatal antibiotics,16S,23456789,Ion Torrent,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,decreased,decreased,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:313/1/NA,Study 313,prospective cohort,27121964,10.1186/s13073-016-0301-4,NA,"Montassier E, Al-Ghalith GA, Ward T, Corvec S, Gastinne T, Potel G, Moreau P, de la Cochetiere MF, Batard E , Knights D",Pretreatment gut microbiome predicts chemotherapy-related bloodstream infection,Genome medicine,2016,"Bloodstream infection, Chemotherapy, Intestinal microbiome, Prediction",Experiment 1,France,Homo sapiens,Feces,UBERON:0001988,Non-Hodgkins lymphoma,EFO:0005952,non-bloodstream infection,bloodstream infection,"participants had blood stream infection, diagnosis with non-Hodgkins lymphoma (NHL), undergone hematopoeitic stem cell transplant and chemotherapy that did not had a history of inflammatory bowel disease, no exposure to probiotics, prebiotics or broad-soectrium antibiotics, no administered nasal-tube feeding or parenteral nutrition in a month prior to initiation of the study",17,11,NA,16S,56,Roche454,Mann-Whitney (Wilcoxon),0.15,TRUE,NA,NA,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:314/1/NA,Study 314,time series / longitudinal observational,32332850,10.1038/s41467-020-15856-y,NA,"Mitra A, MacIntyre DA, Ntritsos G, Smith A, Tsilidis KK, Marchesi JR, Bennett PR, Moscicki AB , Kyrgiou M",The vaginal microbiota associates with the regression of untreated cervical intraepithelial neoplasia 2 lesions,Nature communications,2020,NA,Experiment 1,United States of America,Homo sapiens,Uterine cervix,UBERON:0000002,Cervical glandular intraepithelial neoplasia,EFO:1000165,CIN regression,CIN non-regression,"histology proven CIN2, no regression after 12 months",42,45,NA,16S,12,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:314/2/NA,Study 314,time series / longitudinal observational,32332850,10.1038/s41467-020-15856-y,NA,"Mitra A, MacIntyre DA, Ntritsos G, Smith A, Tsilidis KK, Marchesi JR, Bennett PR, Moscicki AB , Kyrgiou M",The vaginal microbiota associates with the regression of untreated cervical intraepithelial neoplasia 2 lesions,Nature communications,2020,NA,Experiment 2,United States of America,Homo sapiens,Uterine cervix,UBERON:0000002,Cervical glandular intraepithelial neoplasia,EFO:1000165,CIN regression,CIN non-regression,"histology proven CIN2, no regression after 12 months",42,45,NA,16S,12,Illumina,Welch's T-Test,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,unchanged,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:314/3/NA,Study 314,time series / longitudinal observational,32332850,10.1038/s41467-020-15856-y,NA,"Mitra A, MacIntyre DA, Ntritsos G, Smith A, Tsilidis KK, Marchesi JR, Bennett PR, Moscicki AB , Kyrgiou M",The vaginal microbiota associates with the regression of untreated cervical intraepithelial neoplasia 2 lesions,Nature communications,2020,NA,Experiment 3,United States of America,Homo sapiens,Uterine cervix,UBERON:0000002,Cervical glandular intraepithelial neoplasia,EFO:1000165,CIN regression,CIN non-regression,"histology proven CIN2, no regression after 24 months",63,24,NA,16S,12,Illumina,Welch's T-Test,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,unchanged,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:314/4/NA,Study 314,time series / longitudinal observational,32332850,10.1038/s41467-020-15856-y,NA,"Mitra A, MacIntyre DA, Ntritsos G, Smith A, Tsilidis KK, Marchesi JR, Bennett PR, Moscicki AB , Kyrgiou M",The vaginal microbiota associates with the regression of untreated cervical intraepithelial neoplasia 2 lesions,Nature communications,2020,NA,Experiment 4,United States of America,Homo sapiens,Uterine cervix,UBERON:0000002,Cervical glandular intraepithelial neoplasia,EFO:1000165,CIN regression,CIN non-regression,"histology proven CIN2, no regression after 24 months among women with no regression after 12 months",21,14,NA,16S,12,Illumina,Welch's T-Test,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:315/1/NA,Study 315,prospective cohort,28789705,10.1186/s40168-017-0313-3,NA,"Nogacka A, Salazar N, Suárez M, Milani C, Arboleya S, Solís G, Fernández N, Alaez L, Hernández-Barranco AM, de Los Reyes-Gavilán CG, Ventura M , Gueimonde M",Impact of intrapartum antimicrobial prophylaxis upon the intestinal microbiota and the prevalence of antibiotic resistance genes in vaginally delivered full-term neonates,Microbiome,2017,"Antibiotics, Intestinal microbiota, Intrapartum antimicrobial prophylaxis, Microbiome, Neonate",Experiment 1,Spain,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,Infants to mothers didn't receive IAP,Infants to mothers received IAP,Full-term (gestational ages >37 weeks) vaginally delivered infants born after an uncomplicated pregnancy,22,18,During pregnancy or postnatal period (Mothers); during the study period (infants),16S,34,Illumina,Kruskall-Wallis,0.05,FALSE,NA,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:315/2/NA,Study 315,prospective cohort,28789705,10.1186/s40168-017-0313-3,NA,"Nogacka A, Salazar N, Suárez M, Milani C, Arboleya S, Solís G, Fernández N, Alaez L, Hernández-Barranco AM, de Los Reyes-Gavilán CG, Ventura M , Gueimonde M",Impact of intrapartum antimicrobial prophylaxis upon the intestinal microbiota and the prevalence of antibiotic resistance genes in vaginally delivered full-term neonates,Microbiome,2017,"Antibiotics, Intestinal microbiota, Intrapartum antimicrobial prophylaxis, Microbiome, Neonate",Experiment 2,Spain,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,breast-fed Infants to mothers didn't receive IAP,Breast-fed Infants to mothers received IAP,Full-term (gestational ages >37 weeks) vaginally delivered infants born after an uncomplicated pregnancy,18,11,During pregnancy or postnatal period (Mothers); during the study period (infants),16S,34,Illumina,Kruskall-Wallis,0.05,FALSE,NA,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:315/3/NA,Study 315,prospective cohort,28789705,10.1186/s40168-017-0313-3,NA,"Nogacka A, Salazar N, Suárez M, Milani C, Arboleya S, Solís G, Fernández N, Alaez L, Hernández-Barranco AM, de Los Reyes-Gavilán CG, Ventura M , Gueimonde M",Impact of intrapartum antimicrobial prophylaxis upon the intestinal microbiota and the prevalence of antibiotic resistance genes in vaginally delivered full-term neonates,Microbiome,2017,"Antibiotics, Intestinal microbiota, Intrapartum antimicrobial prophylaxis, Microbiome, Neonate",Experiment 3,Spain,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,Formula-fed Infants to mothers didn't receive IAP,Formula-fed Infants to mothers received IAP,Full-term (gestational ages >37 weeks) vaginally delivered infants born after an uncomplicated pregnancy,4,7,During pregnancy or postnatal period (Mothers); during the study period (infants),16S,34,Illumina,Kruskall-Wallis,0.05,FALSE,NA,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:316/1/NA,Study 316,time series / longitudinal observational,25444008,10.1016/j.jpeds.2014.09.041,NA,"Arboleya S, Sánchez B, Milani C, Duranti S, Solís G, Fernández N, de los Reyes-Gavilán CG, Ventura M, Margolles A , Gueimonde M",Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics,The Journal of pediatrics,2015,NA,Experiment 1,Spain,Homo sapiens,Feces,UBERON:0001988,Premature birth,EFO:0003917,2-day old Full-term infants(born after uncomplicated pregnancy),2-day old Pre-term infants,infants born at gestational ages between 24 and 32 weeks,13,27,NA,16S,34,Ion Torrent,ANOVA,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:316/2/NA,Study 316,time series / longitudinal observational,25444008,10.1016/j.jpeds.2014.09.041,NA,"Arboleya S, Sánchez B, Milani C, Duranti S, Solís G, Fernández N, de los Reyes-Gavilán CG, Ventura M, Margolles A , Gueimonde M",Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics,The Journal of pediatrics,2015,NA,Experiment 2,Spain,Homo sapiens,Feces,UBERON:0001988,Premature birth,EFO:0003917,10-day old Full-term infants(born after uncomplicated pregnancy),10-day old Pre-term,born at gestational ages between 24 and 32 weeks,13,27,NA,16S,34,Ion Torrent,ANOVA,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:316/3/NA,Study 316,time series / longitudinal observational,25444008,10.1016/j.jpeds.2014.09.041,NA,"Arboleya S, Sánchez B, Milani C, Duranti S, Solís G, Fernández N, de los Reyes-Gavilán CG, Ventura M, Margolles A , Gueimonde M",Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics,The Journal of pediatrics,2015,NA,Experiment 3,Spain,Homo sapiens,Feces,UBERON:0001988,Premature birth,EFO:0003917,30 and 90-day old Full-term infants,30 and 90-day old Pre-term infants,infants born at gestational ages between 24 and 32 weeks,13,27,NA,16S,34,Ion Torrent,ANOVA,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:316/4/NA,Study 316,time series / longitudinal observational,25444008,10.1016/j.jpeds.2014.09.041,NA,"Arboleya S, Sánchez B, Milani C, Duranti S, Solís G, Fernández N, de los Reyes-Gavilán CG, Ventura M, Margolles A , Gueimonde M",Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics,The Journal of pediatrics,2015,NA,Experiment 4,Spain,Homo sapiens,Feces,UBERON:0001988,Delivery method,EFO:0000395,10-day old cesarean-delivered pre-term neontes,10-day old vaginally-delivered pre-term neonates,10-day old pre-term infants who were delivered vaginally.,20,7,NA,PCR,NA,Ion Torrent,ANOVA,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:316/5/NA,Study 316,time series / longitudinal observational,25444008,10.1016/j.jpeds.2014.09.041,NA,"Arboleya S, Sánchez B, Milani C, Duranti S, Solís G, Fernández N, de los Reyes-Gavilán CG, Ventura M, Margolles A , Gueimonde M",Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics,The Journal of pediatrics,2015,NA,Experiment 5,Spain,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,2-day old full-term neonates not exposed to antibiotics (IAP/postnatal),2-day old pre-tem neonates exposed to antibiotics (IAP),antenatal/postnatal antibiotic exposure,14,10,NA,16S,34,Ion Torrent,ANOVA,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:316/6/NA,Study 316,time series / longitudinal observational,25444008,10.1016/j.jpeds.2014.09.041,NA,"Arboleya S, Sánchez B, Milani C, Duranti S, Solís G, Fernández N, de los Reyes-Gavilán CG, Ventura M, Margolles A , Gueimonde M",Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics,The Journal of pediatrics,2015,NA,Experiment 6,Spain,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,10-day old full-term neonates not exposed to antibiotics (IAP/postnatal),10-day old pre-tem neonates exposed to antibiotics (IAP),antenatal/postnatal antibiotic exposure,14,10,NA,16S,34,Ion Torrent,ANOVA,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:316/7/NA,Study 316,time series / longitudinal observational,25444008,10.1016/j.jpeds.2014.09.041,NA,"Arboleya S, Sánchez B, Milani C, Duranti S, Solís G, Fernández N, de los Reyes-Gavilán CG, Ventura M, Margolles A , Gueimonde M",Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics,The Journal of pediatrics,2015,NA,Experiment 7,Spain,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,30-day old full-term neonates not exposed to antibiotics (IAP/postnatal),30-day old pre-tem neonates exposed to antibiotics (IAP),antenatal/postnatal antibiotic exposure,14,10,NA,16S,34,Ion Torrent,ANOVA,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:316/8/NA,Study 316,time series / longitudinal observational,25444008,10.1016/j.jpeds.2014.09.041,NA,"Arboleya S, Sánchez B, Milani C, Duranti S, Solís G, Fernández N, de los Reyes-Gavilán CG, Ventura M, Margolles A , Gueimonde M",Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics,The Journal of pediatrics,2015,NA,Experiment 8,Spain,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,90-day old full-term neonates not exposed to antibiotics (IAP/postnatal),90-day old pre-term neonates with mothers exposed to antibiotics (IAP),90-day old pre-term neonates whose mothers received antibiotics (IAP) independently on whether or not the infant received antibiotics.,14,10,NA,16S,34,Ion Torrent,ANOVA,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:316/9/NA,Study 316,time series / longitudinal observational,25444008,10.1016/j.jpeds.2014.09.041,NA,"Arboleya S, Sánchez B, Milani C, Duranti S, Solís G, Fernández N, de los Reyes-Gavilán CG, Ventura M, Margolles A , Gueimonde M",Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics,The Journal of pediatrics,2015,NA,Experiment 9,Spain,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,30-day old full-term neonates not exposed to antibiotics (IAP/postnatal),30-day old pre-tem neonates with mothers exposed to antibiotics (IAP),30-day old pre-term neonates whose mothers received antibiotics (IAP) independently on whether or not the infant received antibiotics.,5,14,NA,16S,34,Ion Torrent,ANOVA,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:316/10/NA,Study 316,time series / longitudinal observational,25444008,10.1016/j.jpeds.2014.09.041,NA,"Arboleya S, Sánchez B, Milani C, Duranti S, Solís G, Fernández N, de los Reyes-Gavilán CG, Ventura M, Margolles A , Gueimonde M",Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics,The Journal of pediatrics,2015,NA,Experiment 10,Spain,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,30-day old pre-term neonates not exposed to antibiotics (IAP/postnatal),30-day old pre-tem neonates exposed to antibiotics (IAP/postnatal),pre-term infants and mothers exposed to antibiotics,5,9,NA,PCR,NA,Ion Torrent,ANOVA,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:316/11/NA,Study 316,time series / longitudinal observational,25444008,10.1016/j.jpeds.2014.09.041,NA,"Arboleya S, Sánchez B, Milani C, Duranti S, Solís G, Fernández N, de los Reyes-Gavilán CG, Ventura M, Margolles A , Gueimonde M",Intestinal microbiota development in preterm neonates and effect of perinatal antibiotics,The Journal of pediatrics,2015,NA,Experiment 11,Spain,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,90-day old pre-term neonates not exposed to antibiotics (IAP/postnatal),90-day old pre-tem neonates exposed to antibiotics (IAP/postnatal),pre-term infants and mothers exposed to antibiotics,5,9,NA,PCR,NA,Ion Torrent,ANOVA,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:317/1/NA,Study 317,case-control,35087123,10.1038/s41598-022-05480-9,https://pubmed.ncbi.nlm.nih.gov/35087123/,"Domènech L, Willis J, Alemany-Navarro M, Morell M, Real E, Escaramís G, Bertolín S, Sánchez Chinchilla D, Balcells S, Segalàs C, Estivill X, Menchón JM, Gabaldón T, Alonso P , Rabionet R",Changes in the stool and oropharyngeal microbiome in obsessive-compulsive disorder,Scientific reports,2022,NA,Experiment 1,Spain,Homo sapiens,Feces,UBERON:0001988,Obsessive-compulsive disorder,EFO:0004242,Control (healthy group),OCD T0 (Baseline),"Patients with Obsessive-compulsive disorder (OCD), which is a neuropsychiatric condition characterized by intrusive and unwanted thoughts (termed obsessions) and repetitive behaviors or mental acts (termed compulsions), which are carried out to at least partially alleviate the anxiety or distress brought on by the obsessions. Timepoint 0 was the baseline timepoint prior to three months of pharmacological treatment and cognitive behavioral therapy (referred to as T0).",33,32,NA,16S,34,Illumina,LEfSe,0.05,TRUE,2,"age,sex",NA,NA,unchanged,decreased,unchanged,unchanged,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:317/2/NA,Study 317,case-control,35087123,10.1038/s41598-022-05480-9,https://pubmed.ncbi.nlm.nih.gov/35087123/,"Domènech L, Willis J, Alemany-Navarro M, Morell M, Real E, Escaramís G, Bertolín S, Sánchez Chinchilla D, Balcells S, Segalàs C, Estivill X, Menchón JM, Gabaldón T, Alonso P , Rabionet R",Changes in the stool and oropharyngeal microbiome in obsessive-compulsive disorder,Scientific reports,2022,NA,Experiment 2,Spain,Homo sapiens,Oropharynx,UBERON:0001729,Obsessive-compulsive disorder,EFO:0004242,Control (healthy group),OCD T0,"Patients with Obsessive-compulsive disorder (OCD), which is a neuropsychiatric condition characterized by intrusive and unwanted thoughts (termed obsessions) and repetitive behaviors or mental acts (termed compulsions), which are carried out to at least partially alleviate the anxiety or distress brought on by the obsessions. Timepoint 0 was the baseline timepoint prior to three months of pharmacological treatment and cognitive behavioral therapy (referred to as T0).",32,32,NA,16S,34,Illumina,LEfSe,0.05,TRUE,2,"age,sex",NA,NA,unchanged,unchanged,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:317/3/NA,Study 317,case-control,35087123,10.1038/s41598-022-05480-9,https://pubmed.ncbi.nlm.nih.gov/35087123/,"Domènech L, Willis J, Alemany-Navarro M, Morell M, Real E, Escaramís G, Bertolín S, Sánchez Chinchilla D, Balcells S, Segalàs C, Estivill X, Menchón JM, Gabaldón T, Alonso P , Rabionet R",Changes in the stool and oropharyngeal microbiome in obsessive-compulsive disorder,Scientific reports,2022,NA,Experiment 3,Spain,Homo sapiens,Feces,UBERON:0001988,Obsessive-compulsive disorder,EFO:0004242,Control (healthy group),OCD T3,"Patients with obsessive-compulsive disorder (OCD) which is a neuropsychiatric condition characterized by intrusive and unwanted thoughts (termed obsessions) and repetitive behaviors or mental acts (termed compulsions), which are carried out to at least partially alleviate the anxiety or distress brought on by the obsessions. Timepoint 3 is following three months of pharmacological treatment and cognitive behavioral therapy (referred to as T3).",33,31,NA,16S,34,Illumina,LEfSe,0.05,TRUE,2,"age,sex",NA,NA,unchanged,unchanged,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:317/4/NA,Study 317,case-control,35087123,10.1038/s41598-022-05480-9,https://pubmed.ncbi.nlm.nih.gov/35087123/,"Domènech L, Willis J, Alemany-Navarro M, Morell M, Real E, Escaramís G, Bertolín S, Sánchez Chinchilla D, Balcells S, Segalàs C, Estivill X, Menchón JM, Gabaldón T, Alonso P , Rabionet R",Changes in the stool and oropharyngeal microbiome in obsessive-compulsive disorder,Scientific reports,2022,NA,Experiment 4,Spain,Homo sapiens,Oropharynx,UBERON:0001729,Obsessive-compulsive disorder,EFO:0004242,Control (healthy group),OCD T3,"Patients with obsessive-compulsive disorder (OCD) which is a neuropsychiatric condition characterized by intrusive and unwanted thoughts (termed obsessions) and repetitive behaviors or mental acts (termed compulsions), which are carried out to at least partially alleviate the anxiety or distress brought on by the obsessions. Timepoint 3 is following three months of pharmacological treatment and cognitive behavioral therapy (referred to as T3).",32,31,NA,16S,34,Illumina,LEfSe,0.05,TRUE,2,"age,sex",NA,NA,unchanged,unchanged,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:318/1/NA,Study 318,prospective cohort,28733895,10.1007/s00277-017-3069-8,NA,"Doki N, Suyama M, Sasajima S, Ota J, Igarashi A, Mimura I, Morita H, Fujioka Y, Sugiyama D, Nishikawa H, Shimazu Y, Suda W, Takeshita K, Atarashi K, Hattori M, Sato E, Watakabe-Inamoto K, Yoshioka K, Najima Y, Kobayashi T, Kakihana K, Takahashi N, Sakamaki H, Honda K , Ohashi K",Clinical impact of pre-transplant gut microbial diversity on outcomes of allogeneic hematopoietic stem cell transplantation,Annals of hematology,2017,"Acute gastrointestinal graft-versus-host disease (GVHD), Allogeneic hematopoietic stem cell transplantation (allo-HSCT), Intestinal microbiota, Microbial diversity",Experiment 1,Japan,Homo sapiens,Feces,UBERON:0001988,Graft versus host disease,MONDO:0013730,non-acute graft-versus-host disease,acute graft-versus-host disease,"participants that developed acute graft-versus-host disease after allogeneic hematopoeitic transplant and graded accordinly to pattern of organ involvement and clinical performance status using a system introduced by Glucksberg et al. (Severity Index), which includes late-onset of acute graft-versus-host disease (more than 100 days after transplantation)",NA,107,NA,16S,12,Roche454,T-Test,0.01,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:318/2/NA,Study 318,prospective cohort,28733895,10.1007/s00277-017-3069-8,NA,"Doki N, Suyama M, Sasajima S, Ota J, Igarashi A, Mimura I, Morita H, Fujioka Y, Sugiyama D, Nishikawa H, Shimazu Y, Suda W, Takeshita K, Atarashi K, Hattori M, Sato E, Watakabe-Inamoto K, Yoshioka K, Najima Y, Kobayashi T, Kakihana K, Takahashi N, Sakamaki H, Honda K , Ohashi K",Clinical impact of pre-transplant gut microbial diversity on outcomes of allogeneic hematopoietic stem cell transplantation,Annals of hematology,2017,"Acute gastrointestinal graft-versus-host disease (GVHD), Allogeneic hematopoietic stem cell transplantation (allo-HSCT), Intestinal microbiota, Microbial diversity",Experiment 2,Japan,Homo sapiens,Feces,UBERON:0001988,Graft versus host disease,MONDO:0013730,non-acute graft-versus-host disease,acute graft-versus-host disease,"participants that developed acute graft-versus-host disease after allogeneic hematopoeitic transplant and graded accordinly to pattern of organ involvement and clinical performance status using a system introduced by Glucksberg et al. (Severity Index), which includes late-onset of acute graft-versus-host disease (more than 100 days after transplantation)",NA,107,NA,16S,12,Roche454,T-Test,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:319/1/NA,Study 319,laboratory experiment,29665823,10.1186/s12989-018-0252-6,NA,"Wang W, Zhou J, Chen M, Huang X, Xie X, Li W, Cao Q, Kan H, Xu Y , Ying Z",Exposure to concentrated ambient PM<sub>2.5</sub> alters the composition of gut microbiota in a murine model,Particle and fibre toxicology,2018,"Diabetes, Glucose homeostatic, Gut microbiota, PM2.5",Experiment 1,China,Mus musculus,Feces,UBERON:0001988,Air pollution,ENVO:02500037,mice exposed to PM 2.5 (CAP),mice exposed to filtered air (FA),male C57Bl/6 J mice exposed to PM2.5 (CAP),10,10,NA,16S,4,Illumina,ANOVA,0.05,TRUE,NA,NA,NA,NA,increased,increased,increased,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:320/1/NA,Study 320,prospective cohort,31006170,10.1111/1471-0528.15799,NA,"Coker MO, Hoen AG, Dade E, Lundgren S, Li Z, Wong AD, Zens MS, Palys TJ, Morrison HG, Sogin ML, Baker ER, Karagas MR , Madan JC",Specific class of intrapartum antibiotics relates to maturation of the infant gut microbiota: a prospective cohort study,BJOG : an international journal of obstetrics and gynaecology,2020,"Gut, infant, intestinal microbiota, intrapartum antibiotics, neonate",Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,infants (6-weeks) to mothers unexposed to  intrapartum antibiotic,infants(6-weeks) to mothers exposed to intrapartum antibiotic,vaginally delivered at full-term (>37 weeks of gestation),179,87,NA,16S,45,Illumina,PERMANOVA,0.05,FALSE,NA,NA,NA,NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:320/2/NA,Study 320,prospective cohort,31006170,10.1111/1471-0528.15799,NA,"Coker MO, Hoen AG, Dade E, Lundgren S, Li Z, Wong AD, Zens MS, Palys TJ, Morrison HG, Sogin ML, Baker ER, Karagas MR , Madan JC",Specific class of intrapartum antibiotics relates to maturation of the infant gut microbiota: a prospective cohort study,BJOG : an international journal of obstetrics and gynaecology,2020,"Gut, infant, intestinal microbiota, intrapartum antibiotics, neonate",Experiment 2,United States of America,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,infants (1-year) to mothers unexposed to  intrapartum antibiotic,infants(1-year) to mothers exposed to intrapartum antibiotic,vaginally delivered at full-term (>37 weeks of gestation),179,87,NA,16S,45,Illumina,PERMANOVA,0.05,FALSE,NA,NA,NA,NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:320/3/NA,Study 320,prospective cohort,31006170,10.1111/1471-0528.15799,NA,"Coker MO, Hoen AG, Dade E, Lundgren S, Li Z, Wong AD, Zens MS, Palys TJ, Morrison HG, Sogin ML, Baker ER, Karagas MR , Madan JC",Specific class of intrapartum antibiotics relates to maturation of the infant gut microbiota: a prospective cohort study,BJOG : an international journal of obstetrics and gynaecology,2020,"Gut, infant, intestinal microbiota, intrapartum antibiotics, neonate",Experiment 3,United States of America,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,infants (6-weeks) to mothers unexposed to  antibiotic,infants(6-weeks) to mothers exposed to  antibiotic penicillin,vaginally delivered at full-term (>37 weeks of gestation),179,55,NA,16S,45,Illumina,PERMANOVA,0.05,FALSE,NA,NA,NA,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:320/4/NA,Study 320,prospective cohort,31006170,10.1111/1471-0528.15799,NA,"Coker MO, Hoen AG, Dade E, Lundgren S, Li Z, Wong AD, Zens MS, Palys TJ, Morrison HG, Sogin ML, Baker ER, Karagas MR , Madan JC",Specific class of intrapartum antibiotics relates to maturation of the infant gut microbiota: a prospective cohort study,BJOG : an international journal of obstetrics and gynaecology,2020,"Gut, infant, intestinal microbiota, intrapartum antibiotics, neonate",Experiment 4,United States of America,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,infants (1-year) to mothers unexposed to  antibiotic,infants(1-year) to mothers exposed to the penicillin group,vaginally delivered at full-term (>37 weeks of gestation),179,55,NA,16S,45,Illumina,PERMANOVA,0.05,FALSE,NA,NA,NA,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:320/5/NA,Study 320,prospective cohort,31006170,10.1111/1471-0528.15799,NA,"Coker MO, Hoen AG, Dade E, Lundgren S, Li Z, Wong AD, Zens MS, Palys TJ, Morrison HG, Sogin ML, Baker ER, Karagas MR , Madan JC",Specific class of intrapartum antibiotics relates to maturation of the infant gut microbiota: a prospective cohort study,BJOG : an international journal of obstetrics and gynaecology,2020,"Gut, infant, intestinal microbiota, intrapartum antibiotics, neonate",Experiment 5,United States of America,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,infants (6-weeks) to mothers unexposed to  antibiotic,infants(6-weeks) to mothers exposed to multi-class antibiotics,vaginally delivered at full-term (>37 weeks of gestation),179,12,NA,16S,45,Illumina,PERMANOVA,0.05,FALSE,NA,NA,NA,NA,increased,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:320/6/NA,Study 320,prospective cohort,31006170,10.1111/1471-0528.15799,NA,"Coker MO, Hoen AG, Dade E, Lundgren S, Li Z, Wong AD, Zens MS, Palys TJ, Morrison HG, Sogin ML, Baker ER, Karagas MR , Madan JC",Specific class of intrapartum antibiotics relates to maturation of the infant gut microbiota: a prospective cohort study,BJOG : an international journal of obstetrics and gynaecology,2020,"Gut, infant, intestinal microbiota, intrapartum antibiotics, neonate",Experiment 6,United States of America,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,infants to mothers unexposed to intrapartum antibiotic,infants to mothers exposed to cephalosporins,NA,179,14,NA,16S,45,Illumina,PERMANOVA,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:321/1/NA,Study 321,time series / longitudinal observational,24819377,10.1038/pr.2014.69,NA,"Dardas M, Gill SR, Grier A, Pryhuber GS, Gill AL, Lee YH , Guillet R",The impact of postnatal antibiotics on the preterm intestinal microbiome,Pediatric research,2014,NA,Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,10 d old 2 day treatment infants,10 d old 7-10 day treatment infants,Infants who received antibiotics for 7-10 days,15,12,None.,16S,123,Roche454,Kruskall-Wallis,0.05,TRUE,NA,NA,delivery procedure,NA,decreased,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:321/2/NA,Study 321,time series / longitudinal observational,24819377,10.1038/pr.2014.69,NA,"Dardas M, Gill SR, Grier A, Pryhuber GS, Gill AL, Lee YH , Guillet R",The impact of postnatal antibiotics on the preterm intestinal microbiome,Pediatric research,2014,NA,Experiment 2,United States of America,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,30 d old minimal antibiotics exposure (2 day treatment infants),30 d old prolonged antibiotics exposure (>=7 day treatment infants),prolonged antibiotics exposure (greater than or equal to 7 day treatment infants),8,11,None.,16S,123,Roche454,Kruskall-Wallis,0.05,TRUE,NA,NA,delivery procedure,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:322/1/NA,Study 322,time series / longitudinal observational,23829394,10.1111/1469-0691.12287,NA,"Ye Y, Carlsson G, Agholme MB, Wilson JA, Roos A, Henriques-Normark B, Engstrand L, Modéer T , Pütsep K",Oral bacterial community dynamics in paediatric patients with malignancies in relation to chemotherapy-related oral mucositis: a prospective study,Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,2013,"16S rRNA gene, 454 pyrosequencing, cancer, oral microflora, stomatitis",Experiment 1,Sweden,Homo sapiens,"Buccal mucosa,Lower lip","UBERON:0006956,UBERON:0001835",Oral mucositis,EFO:1001904,reference,patients with newly diagnosed malignancies,patients that are newly diagnosed with malignancies (before chemotherapy treatment) that are between ages 4 and 18 years old that are treated with cytostatic drug and has a national population registration number (Sweden),38,37,NA,16S,NA,Roche454,T-Test,0.05,TRUE,NA,"age,sex",NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:322/2/NA,Study 322,time series / longitudinal observational,23829394,10.1111/1469-0691.12287,NA,"Ye Y, Carlsson G, Agholme MB, Wilson JA, Roos A, Henriques-Normark B, Engstrand L, Modéer T , Pütsep K",Oral bacterial community dynamics in paediatric patients with malignancies in relation to chemotherapy-related oral mucositis: a prospective study,Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,2013,"16S rRNA gene, 454 pyrosequencing, cancer, oral microflora, stomatitis",Experiment 2,Sweden,Homo sapiens,"Buccal mucosa,Lower lip","UBERON:0006956,UBERON:0001835",Oral mucositis,EFO:1001904,no oral mucositis,oral mucositis,patients that are newly diagnosed with malignancies (before chemotherapy treatment) that are between ages 4 and 18 years old that are treated with cytostatic drug and has a national population registration number (Sweden) that has later developed oral mucositis (graded by the World Health Organization),12,25,NA,16S,NA,Roche454,T-Test,0.05,TRUE,NA,"age,sex",NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:322/3/NA,Study 322,time series / longitudinal observational,23829394,10.1111/1469-0691.12287,NA,"Ye Y, Carlsson G, Agholme MB, Wilson JA, Roos A, Henriques-Normark B, Engstrand L, Modéer T , Pütsep K",Oral bacterial community dynamics in paediatric patients with malignancies in relation to chemotherapy-related oral mucositis: a prospective study,Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,2013,"16S rRNA gene, 454 pyrosequencing, cancer, oral microflora, stomatitis",Experiment 3,Sweden,Homo sapiens,"Buccal mucosa,Lower lip","UBERON:0006956,UBERON:0001835",Oral mucositis,EFO:1001904,at malignancy diagnosis,during chemotherapy,patients that are newly diagnosed with malignancies that are between ages 4 and 18 years old that are treated with cytostatic drug and has a national population registration number (Sweden) that has later developed oral mucositis (graded by the World Health Organization) during chemotherapy treatment,12,12,NA,16S,NA,Roche454,T-Test,0.05,TRUE,NA,"age,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:322/4/NA,Study 322,time series / longitudinal observational,23829394,10.1111/1469-0691.12287,NA,"Ye Y, Carlsson G, Agholme MB, Wilson JA, Roos A, Henriques-Normark B, Engstrand L, Modéer T , Pütsep K",Oral bacterial community dynamics in paediatric patients with malignancies in relation to chemotherapy-related oral mucositis: a prospective study,Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,2013,"16S rRNA gene, 454 pyrosequencing, cancer, oral microflora, stomatitis",Experiment 4,Sweden,Homo sapiens,"Buccal mucosa,Lower lip","UBERON:0006956,UBERON:0001835",Oral mucositis,EFO:1001904,at malignancy diagnosis,during chemotherapy,patients that are newly diagnosed with malignancies that are between ages 4 and 18 years old that are treated with cytostatic drug and has a national population registration number (Sweden) that did not develop oral mucositis (graded by the World Health Organization) during chemotherapy treatment,10,10,NA,16S,NA,Roche454,T-Test,0.05,TRUE,NA,"age,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:322/5/NA,Study 322,time series / longitudinal observational,23829394,10.1111/1469-0691.12287,NA,"Ye Y, Carlsson G, Agholme MB, Wilson JA, Roos A, Henriques-Normark B, Engstrand L, Modéer T , Pütsep K",Oral bacterial community dynamics in paediatric patients with malignancies in relation to chemotherapy-related oral mucositis: a prospective study,Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,2013,"16S rRNA gene, 454 pyrosequencing, cancer, oral microflora, stomatitis",Experiment 5,Sweden,Homo sapiens,"Buccal mucosa,Lower lip","UBERON:0006956,UBERON:0001835",Oral mucositis,EFO:1001904,all samples,mucositis lesions,samples from mucositis lesions,97,27,NA,16S,NA,Roche454,T-Test,0.05,TRUE,NA,"age,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:323/1/NA,Study 323,"cross-sectional observational, not case-control",30365522,10.1371/journal.pone.0206366,NA,"Romano-Keeler J, Shilts MH, Tovchigrechko A, Wang C, Brucker RM, Moore DJ, Fonnesbeck C, Meng S, Correa H, Lovvorn HN, Tang YW, Hooper L, Bordenstein SR, Das SR , Weitkamp JH",Distinct mucosal microbial communities in infants with surgical necrotizing enterocolitis correlate with age and antibiotic exposure,PloS one,2018,NA,Experiment 1,United States of America,Homo sapiens,Mucosa of small intestine,UBERON:0001204,Necrotizing enterocolitis,EFO:0003928,non-NEC,NEC,infants who underwent intestinal resection at <180 days of age with NEC,14,10,NA,16S,123,Roche454,DESeq2,0.1,TRUE,NA,NA,NA,NA,unchanged,decreased,unchanged,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:323/3/NA,Study 323,"cross-sectional observational, not case-control",30365522,10.1371/journal.pone.0206366,NA,"Romano-Keeler J, Shilts MH, Tovchigrechko A, Wang C, Brucker RM, Moore DJ, Fonnesbeck C, Meng S, Correa H, Lovvorn HN, Tang YW, Hooper L, Bordenstein SR, Das SR , Weitkamp JH",Distinct mucosal microbial communities in infants with surgical necrotizing enterocolitis correlate with age and antibiotic exposure,PloS one,2018,NA,Experiment 3,United States of America,Homo sapiens,Feces,UBERON:0001988,Necrotizing enterocolitis,EFO:0003928,non-NEC,NEC,infants who underwent intestinal resection at <180 days of age with NEC,14,10,NA,16S,1234,Roche454,DESeq2,0.1,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:324/1/NA,Study 324,case-control,30565661,10.1002/ijc.32007,NA,"Feng J, Zhao F, Sun J, Lin B, Zhao L, Liu Y, Jin Y, Li S, Li A , Wei Y",Alterations in the gut microbiota and metabolite profiles of thyroid carcinoma patients,International journal of cancer,2019,"clinical parameter, gut microbiota, metabolite, predictive model, thyroid carcinoma",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Thyroid carcinoma,EFO:0002892,healthy controls,patients with thyroid carcinoma,at least one solid lesion identified by thyroid ultrasonagraphy,35,30,NA,16S,34,Illumina,LEfSe,0.05,TRUE,3,"age,body mass index,sex",NA,NA,increased,increased,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:325/1/NA,Study 325,case-control,31141234,10.1111/1346-8138.14933,NA,"Shapiro J, Cohen NA, Shalev V, Uzan A, Koren O , Maharshak N",Psoriatic patients have a distinct structural and functional fecal microbiota compared with controls,The Journal of dermatology,2019,"bacteria, inflammation, metabolome, microbiota, psoriasis",Experiment 1,Israel,Homo sapiens,Feces,UBERON:0001988,Psoriasis,EFO:0000676,healthy controls,psoriasis,patients with active psoriatic disease diagnosed by a senior dermatologist,22,24,3 months,16S,4,Illumina,LEfSe,0.05,TRUE,NA,"age,comorbidity,sex",NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:326/1/NA,Study 326,time series / longitudinal observational,29097494,10.1126/science.aan3706,NA,"Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondragón L, Jacquelot N, Qu B, Ferrere G, Clémenson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel B, Minard-Colin V, Gonin P, Soria JC, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G , Zitvogel L",Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors,"Science (New York, N.Y.)",2018,NA,Experiment 1,France,Homo sapiens,Feces,UBERON:0001988,"Non-small cell lung carcinoma,Renal cell carcinoma,Disease progression measurement","EFO:0003060,EFO:0000681,EFO:0008336",Non-Responders (progression or death),Responders (partial response or stable disease),"non-small cell lung carcinoma or renal carcinoma patients (all samples regardless of ampicillin, colistin, and streptomycin (ATB) anitbiotic treatment) that have been treated with PD-1 blockage with partial response or stable disease",36,42,NA,WMS,NA,Mass spectrometry,LEfSe,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:326/2/NA,Study 326,time series / longitudinal observational,29097494,10.1126/science.aan3706,NA,"Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondragón L, Jacquelot N, Qu B, Ferrere G, Clémenson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel B, Minard-Colin V, Gonin P, Soria JC, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G , Zitvogel L",Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors,"Science (New York, N.Y.)",2018,NA,Experiment 2,France,Homo sapiens,Feces,UBERON:0001988,"Non-small cell lung carcinoma,Renal cell carcinoma,Disease progression measurement","EFO:0003060,EFO:0000681,EFO:0008336",Progressive- Free- Survival more less than 30 days,Progressive -Free- Survival more than 30 days,"non-small cell lung carcinoma or renal carcinoma patients (excluding ampicillin, colistin, and streptomycin (ATB) anitbiotic treatment) that have been treated with PD-1 blockage with partial response or stable disease that are Progressive- Free- Survival greater than 3 months",100,100,none,WMS,NA,Mass spectrometry,LEfSe,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:326/3/NA,Study 326,time series / longitudinal observational,29097494,10.1126/science.aan3706,NA,"Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondragón L, Jacquelot N, Qu B, Ferrere G, Clémenson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel B, Minard-Colin V, Gonin P, Soria JC, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G , Zitvogel L",Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors,"Science (New York, N.Y.)",2018,NA,Experiment 3,France,Homo sapiens,Feces,UBERON:0001988,"Non-small cell lung carcinoma,Renal cell carcinoma,Disease progression measurement","EFO:0003060,EFO:0000681,EFO:0008336",Non-Responders,Responders,"non-small cell lung carcinoma or renal carcinoma patients (all samples regardless of ampicillin, colistin, and streptomycin (ATB) anitbiotic treatment) that have been treated with PD-1 blockage with partial response or stable disease",16,16,none,WMS,NA,Mass spectrometry,LEfSe,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:327/1/NA,Study 327,time series / longitudinal observational,32380969,10.1186/s12887-020-02067-z,NA,"Zwittink RD, van Zoeren-Grobben D, Renes IB, van Lingen RA, Norbruis OF, Martin R, Groot Jebbink LJ, Knol J , Belzer C",Dynamics of the bacterial gut microbiota in preterm and term infants after intravenous amoxicillin/ceftazidime treatment,BMC pediatrics,2020,"Antibiotics, Gut microbiota, Infant, Next generation sequencing, Preterm",Experiment 1,Netherlands,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,control (no treatment) - week 1,infants who received short-term or long-term antibiotic treatment - week 1,infants born between 32-42 weeks of gestation and admitted to the hospital (level III neonatal intensive care or level II neonatal ward) who received short-term antibiotics (<3 days) or longterm antibiotics (>5 days),28,35,NA,16S,34,Illumina,Kruskall-Wallis,0.05,FALSE,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:327/2/NA,Study 327,time series / longitudinal observational,32380969,10.1186/s12887-020-02067-z,NA,"Zwittink RD, van Zoeren-Grobben D, Renes IB, van Lingen RA, Norbruis OF, Martin R, Groot Jebbink LJ, Knol J , Belzer C",Dynamics of the bacterial gut microbiota in preterm and term infants after intravenous amoxicillin/ceftazidime treatment,BMC pediatrics,2020,"Antibiotics, Gut microbiota, Infant, Next generation sequencing, Preterm",Experiment 2,Netherlands,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,control(no treatment) - week 2,infants received long-term(>5days) antibiotic treatment - week 2,"infants born between 32-42 weeks of gestation and admitted to the hospital (level III neonatal intensive care or level II neonatal ward) who received >5 days antibiotics, week 2 timepoint",28,13,NA,16S,34,Illumina,Kruskall-Wallis,0.05,FALSE,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:327/3/NA,Study 327,time series / longitudinal observational,32380969,10.1186/s12887-020-02067-z,NA,"Zwittink RD, van Zoeren-Grobben D, Renes IB, van Lingen RA, Norbruis OF, Martin R, Groot Jebbink LJ, Knol J , Belzer C",Dynamics of the bacterial gut microbiota in preterm and term infants after intravenous amoxicillin/ceftazidime treatment,BMC pediatrics,2020,"Antibiotics, Gut microbiota, Infant, Next generation sequencing, Preterm",Experiment 3,Netherlands,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,infants received short-term (<3days) antibiotic treatment - week 1,infants received long-term (>5days) antibiotic treatment - week 1,"infants born between 32-42 weeks of gestation and admitted to the hospital (level III neonatal intensive care or level II neonatal ward) who received longterm (>5 days) antibiotics, first post-natal week timepoint",22,13,NA,16S,34,Illumina,Kruskall-Wallis,0.05,FALSE,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:328/1/NA,Study 328,"cross-sectional observational, not case-control",25319745,10.1002/art.38892,NA,"Scher JU, Ubeda C, Artacho A, Attur M, Isaac S, Reddy SM, Marmon S, Neimann A, Brusca S, Patel T, Manasson J, Pamer EG, Littman DR , Abramson SB","Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease","Arthritis & rheumatology (Hoboken, N.J.)",2015,NA,Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Psoriatic arthritis,EFO:0003778,healthy controls,psoriatic arthiritis,patients fulfilling the criteria of the Classification of Psoriatic arthritis (CASPAR),17,16,3 months,16S,12,Roche454,LEfSe,0.2,TRUE,2,"age,ethnic group,sex",NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:328/2/NA,Study 328,"cross-sectional observational, not case-control",25319745,10.1002/art.38892,NA,"Scher JU, Ubeda C, Artacho A, Attur M, Isaac S, Reddy SM, Marmon S, Neimann A, Brusca S, Patel T, Manasson J, Pamer EG, Littman DR , Abramson SB","Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease","Arthritis & rheumatology (Hoboken, N.J.)",2015,NA,Experiment 2,United States of America,Homo sapiens,Feces,UBERON:0001988,Psoriatic arthritis,EFO:0003778,healthy controls,skin psoriasis,patients fulfilling the skin psoriasis criteria of the Classification of Psoriatic arthritis (CASPAR),17,15,3 months,16S,12,Roche454,LEfSe,0.2,TRUE,2,"age,ethnic group,sex",NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:328/3/NA,Study 328,"cross-sectional observational, not case-control",25319745,10.1002/art.38892,NA,"Scher JU, Ubeda C, Artacho A, Attur M, Isaac S, Reddy SM, Marmon S, Neimann A, Brusca S, Patel T, Manasson J, Pamer EG, Littman DR , Abramson SB","Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease","Arthritis & rheumatology (Hoboken, N.J.)",2015,NA,Experiment 3,United States of America,Homo sapiens,Feces,UBERON:0001988,Psoriatic arthritis,EFO:0003778,skin psoriasis,psoriatic arthiritis,patients fulfilling the psoriatic arthritis criteria of the Classification of Psoriatic arthritis (CASPAR),15,16,3 months,16S,12,Roche454,LEfSe,0.2,TRUE,2,"age,ethnic group,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:329/1/NA,Study 329,prospective cohort,31337807,10.1038/s41598-019-46964-5,NA,"Tapiainen T, Koivusaari P, Brinkac L, Lorenzi HA, Salo J, Renko M, Pruikkonen H, Pokka T, Li W, Nelson K, Pirttilä AM , Tejesvi MV",Impact of intrapartum and postnatal antibiotics on the gut microbiome and emergence of antimicrobial resistance in infants,Scientific reports,2019,NA,Experiment 1,Finland,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,control group,Postnatal antibiotic group (2-day old infant),"Term, vaginally delivered infants",47,29,NA,16S,45,Ion Torrent,Kruskall-Wallis,0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:329/2/NA,Study 329,prospective cohort,31337807,10.1038/s41598-019-46964-5,NA,"Tapiainen T, Koivusaari P, Brinkac L, Lorenzi HA, Salo J, Renko M, Pruikkonen H, Pokka T, Li W, Nelson K, Pirttilä AM , Tejesvi MV",Impact of intrapartum and postnatal antibiotics on the gut microbiome and emergence of antimicrobial resistance in infants,Scientific reports,2019,NA,Experiment 2,Finland,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,control group,IAP group (4-day old infant),"Term, vaginally delivered infants",47,44,NA,16S,45,Ion Torrent,Kruskall-Wallis,0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:329/3/NA,Study 329,prospective cohort,31337807,10.1038/s41598-019-46964-5,NA,"Tapiainen T, Koivusaari P, Brinkac L, Lorenzi HA, Salo J, Renko M, Pruikkonen H, Pokka T, Li W, Nelson K, Pirttilä AM , Tejesvi MV",Impact of intrapartum and postnatal antibiotics on the gut microbiome and emergence of antimicrobial resistance in infants,Scientific reports,2019,NA,Experiment 3,Finland,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,control group,IAP group (6-month old infant),"Term, vaginally delivered infants",47,44,NA,16S,45,Ion Torrent,Kruskall-Wallis,0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:329/4/NA,Study 329,prospective cohort,31337807,10.1038/s41598-019-46964-5,NA,"Tapiainen T, Koivusaari P, Brinkac L, Lorenzi HA, Salo J, Renko M, Pruikkonen H, Pokka T, Li W, Nelson K, Pirttilä AM , Tejesvi MV",Impact of intrapartum and postnatal antibiotics on the gut microbiome and emergence of antimicrobial resistance in infants,Scientific reports,2019,NA,Experiment 4,Finland,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,control group,IAP+postnatal antibiotic group (2-day old infant),"Term, vaginally delivered infants",47,29,NA,16S,45,Ion Torrent,Kruskall-Wallis,0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:329/5/NA,Study 329,prospective cohort,31337807,10.1038/s41598-019-46964-5,NA,"Tapiainen T, Koivusaari P, Brinkac L, Lorenzi HA, Salo J, Renko M, Pruikkonen H, Pokka T, Li W, Nelson K, Pirttilä AM , Tejesvi MV",Impact of intrapartum and postnatal antibiotics on the gut microbiome and emergence of antimicrobial resistance in infants,Scientific reports,2019,NA,Experiment 5,Finland,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,control group,IAP+postnatal antibiotic group (4-day old infant),"Term, vaginally delivered infants",47,29,NA,16S,45,Ion Torrent,Kruskall-Wallis,0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:329/6/NA,Study 329,prospective cohort,31337807,10.1038/s41598-019-46964-5,NA,"Tapiainen T, Koivusaari P, Brinkac L, Lorenzi HA, Salo J, Renko M, Pruikkonen H, Pokka T, Li W, Nelson K, Pirttilä AM , Tejesvi MV",Impact of intrapartum and postnatal antibiotics on the gut microbiome and emergence of antimicrobial resistance in infants,Scientific reports,2019,NA,Experiment 6,Finland,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,control group,IAP+postnatal antibiotic group (6-month old infant),"Term, vaginally delivered infants",47,29,NA,16S,45,Ion Torrent,Kruskall-Wallis,0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:330/1/NA,Study 330,"cross-sectional observational, not case-control",29955075,10.1038/s41598-018-27980-3,NA,"Tuominen H, Rautava S, Syrjänen S, Collado MC , Rautava J","HPV infection and bacterial microbiota in the placenta, uterine cervix and oral mucosa",Scientific reports,2018,NA,Experiment 1,Finland,Homo sapiens,Placenta,UBERON:0001987,Human papilloma virus infection,EFO:0001668,HPV-,HPV+,HPV+ placenta sample determined by PCR and genotyped with Multimetrix,26,13,NA,16S,34,Illumina,LEfSe,0.05,FALSE,3,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:330/2/NA,Study 330,"cross-sectional observational, not case-control",29955075,10.1038/s41598-018-27980-3,NA,"Tuominen H, Rautava S, Syrjänen S, Collado MC , Rautava J","HPV infection and bacterial microbiota in the placenta, uterine cervix and oral mucosa",Scientific reports,2018,NA,Experiment 2,Finland,Homo sapiens,Uterine cervix,UBERON:0000002,Human papilloma virus infection,EFO:0001668,HPV-,HPV+,HPV+ cervical sample determined by PCR and genotyped with Multimetrix,30,9,NA,16S,34,Illumina,LEfSe,0.05,FALSE,3,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:330/3/NA,Study 330,"cross-sectional observational, not case-control",29955075,10.1038/s41598-018-27980-3,NA,"Tuominen H, Rautava S, Syrjänen S, Collado MC , Rautava J","HPV infection and bacterial microbiota in the placenta, uterine cervix and oral mucosa",Scientific reports,2018,NA,Experiment 3,Finland,Homo sapiens,Mouth,UBERON:0000165,Human papilloma virus infection,EFO:0001668,HPV-,HPV+,HPV+ oral sample determined by PCR and genotyped with Multimetrix,26,13,NA,16S,34,Illumina,LEfSe,0.05,FALSE,3,NA,NA,NA,unchanged,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:331/1/NA,Study 331,case-control,29320965,10.1089/thy.2017.0395,NA,"Zhao F, Feng J, Li J, Zhao L, Liu Y, Chen H, Jin Y, Zhu B , Wei Y",Alterations of the Gut Microbiota in Hashimoto's Thyroiditis Patients,Thyroid : official journal of the American Thyroid Association,2018,"Hashimoto's thyroiditis, biomarker, clinical parameters, dysbiosis, gut microbiota",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Hashimoto's thyroiditis,EFO:0003779,healthy controls,hashimoto's thyroiditis patients,"presence of euthyroidism, free thyroxine, and thyrotropin without hormonal therapy",27,50,3 months,16S,34,Illumina,LEfSe,0.05,TRUE,3,"age,body mass index,sex",NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:332/1/NA,Study 332,case-control,28903182,10.1016/j.biopha.2017.08.101,NA,"Ishaq HM, Mohammad IS, Guo H, Shahzad M, Hou YJ, Ma C, Naseem Z, Wu X, Shi P , Xu J",Molecular estimation of alteration in intestinal microbial composition in Hashimoto's thyroiditis patients,Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,2017,"DGGE, Gut microbiota, Hashimoto’s thyroiditis, Hyporthyroidism, Pyrosequencing",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Hashimoto's thyroiditis,EFO:0003779,healthy controls,hashimoto's thyroiditis patients,"The Thyroid stimulating hormone(TSH) was higher than 5 μIU/ml, T4 was lower than 4.2 μg/dl, T3 was lower than 0.78 ng/ml, anti-thyroid peroxidase antibodies level was higher than 15 IU/ml, and anti-thyroglobulin antibodies was more than 30%",12,29,60 days,16S,34,Illumina,T-Test,0.05,FALSE,NA,NA,NA,NA,unchanged,increased,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:333/1/NA,Study 333,"cross-sectional observational, not case-control",30042470,https://doi.org/10.1038/s41372-018-0172-1,NA,"Imoto N, Morita H, Amanuma F, Maruyama H, Watanabe S , Hashiguchi N",Maternal antimicrobial use at delivery has a stronger impact than mode of delivery on bifidobacterial colonization in infants: a pilot study,Journal of perinatology : official journal of the California Perinatal Association,2018,NA,Experiment 1,Japan,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,without (non-Abx) use of maternal antimicrobial agents at delivery,infants with (Abx),Healthy infants,14,19,NA,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,increased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:333/2/NA,Study 333,"cross-sectional observational, not case-control",30042470,https://doi.org/10.1038/s41372-018-0172-1,NA,"Imoto N, Morita H, Amanuma F, Maruyama H, Watanabe S , Hashiguchi N",Maternal antimicrobial use at delivery has a stronger impact than mode of delivery on bifidobacterial colonization in infants: a pilot study,Journal of perinatology : official journal of the California Perinatal Association,2018,NA,Experiment 2,Japan,Homo sapiens,Feces,UBERON:0001988,NA,NA,Healthy infant not exposed to maternal antimicrobial,Healthy infant  exposed to maternal antimicrobial,"An infant or baby is the very young offspring of human beings. A newborn is, in colloquial use, an infant who is only hours, days, or up to one month old.",14,19,NA,16S,234,Illumina,"T-Test,ANOSIM,Spearman Correlation,Mann-Whitney (Wilcoxon)",0.05,FALSE,NA,NA,NA,NA,increased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:334/1/NA,Study 334,time series / longitudinal observational,29554907,10.1186/s12941-018-0264-y,NA,"Zou ZH, Liu D, Li HD, Zhu DP, He Y, Hou T , Yu JL",Prenatal and postnatal antibiotic exposure influences the gut microbiota of preterm infants in neonatal intensive care units,Annals of clinical microbiology and antimicrobials,2018,"Anti-bacterial agents, Gastrointestinal microbiome, High-throughput nucleotide sequencing, Infant, premature, Intensive care unit, neonatal",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,prenatal antibiotic free group (PAF group),infants(14-d old) exposed to prenatal antibiotic therapy (PAT group),Pre-term infants,12,12,NA,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:334/2/NA,Study 334,time series / longitudinal observational,29554907,10.1186/s12941-018-0264-y,NA,"Zou ZH, Liu D, Li HD, Zhu DP, He Y, Hou T , Yu JL",Prenatal and postnatal antibiotic exposure influences the gut microbiota of preterm infants in neonatal intensive care units,Annals of clinical microbiology and antimicrobials,2018,"Anti-bacterial agents, Gastrointestinal microbiome, High-throughput nucleotide sequencing, Infant, premature, Intensive care unit, neonatal",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,infants exposed to antibiotic <=7day (L group),infants exposed to antibiotic >7day (H group),Pre-term infants,11,11,NA,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:335/1/NA,Study 335,laboratory experiment,23638009,10.1371/journal.pone.0062220,NA,"Kish L, Hotte N, Kaplan GG, Vincent R, Tso R, Gänzle M, Rioux KP, Thiesen A, Barkema HW, Wine E , Madsen KL",Environmental particulate matter induces murine intestinal inflammatory responses and alters the gut microbiome,PloS one,2013,NA,Experiment 1,Canada,Mus musculus,Feces,UBERON:0001988,Air pollution,ENVO:02500037,healthy mice,Chronic treatment group,6-week old female wild-type 129/SvEv mice in chronic treatment group were fed mouse chow ± PM10 (0.09 gm/kg) for 35 days,7,8,NA,16S,NA,Non-quantitative PCR,PLS-DA (Partial least square discriminant analysis),0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:335/2/NA,Study 335,laboratory experiment,23638009,10.1371/journal.pone.0062220,NA,"Kish L, Hotte N, Kaplan GG, Vincent R, Tso R, Gänzle M, Rioux KP, Thiesen A, Barkema HW, Wine E , Madsen KL",Environmental particulate matter induces murine intestinal inflammatory responses and alters the gut microbiome,PloS one,2013,NA,Experiment 2,Canada,Mus musculus,Feces,UBERON:0001988,Air pollution,ENVO:02500037,healthy mice,IL-10−/−  mice fed mouse chow with PM10,IL-10−/−  mice in chronic treatment group were  fed mouse chow ± PM10 (0.09 gm/kg) for 35 days,9,7,NA,16S,NA,Non-quantitative PCR,PLS-DA (Partial least square discriminant analysis),0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:336/1/NA,Study 336,prospective cohort,28808302,10.1038/s41598-017-08530-9,NA,"Zhu D, Xiao S, Yu J, Ai Q, He Y, Cheng C, Zhang Y , Pan Y",Effects of One-Week Empirical Antibiotic Therapy on the Early Development of Gut Microbiota and Metabolites in Preterm Infants,Scientific reports,2017,NA,Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,Antibiotic free group (postnatal day 3),combination of penicillin and moxalactam group (postnatal day 3),"pre-term neonates given a treatment regimen of penicillin (10U kg-1, twice a day) combined with moxalactam (40 mg kg-1, twice a day)",12,12,NA,16S,34,Illumina,"ANOVA,T-Test",0.05,FALSE,NA,"birth weight,delivery procedure,gestational age,sex",NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:336/2/NA,Study 336,prospective cohort,28808302,10.1038/s41598-017-08530-9,NA,"Zhu D, Xiao S, Yu J, Ai Q, He Y, Cheng C, Zhang Y , Pan Y",Effects of One-Week Empirical Antibiotic Therapy on the Early Development of Gut Microbiota and Metabolites in Preterm Infants,Scientific reports,2017,NA,Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,Antibiotic free group (postnatal day 3),piperacillin-tazobactam group (postnatal day 3),"pre-term neonates receiving piperacillin-tazobactam (75 mg kg-1, twice a day)",12,12,NA,16S,34,Illumina,"ANOVA,T-Test",0.05,FALSE,NA,"birth weight,delivery procedure,gestational age,sex",NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:336/3/NA,Study 336,prospective cohort,28808302,10.1038/s41598-017-08530-9,NA,"Zhu D, Xiao S, Yu J, Ai Q, He Y, Cheng C, Zhang Y , Pan Y",Effects of One-Week Empirical Antibiotic Therapy on the Early Development of Gut Microbiota and Metabolites in Preterm Infants,Scientific reports,2017,NA,Experiment 3,China,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,Antibiotic free group (postnatal day 7),combination of penicillin and moxalactam group (postnatal day 7),"pre-term neonates given a treatment regimen of penicillin (10U kg-1, twice a day) combined with moxalactam (40 mg kg-1, twice a day)",12,12,NA,16S,34,Illumina,"ANOVA,T-Test",0.05,FALSE,NA,"birth weight,delivery procedure,gestational age,sex",NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:336/4/NA,Study 336,prospective cohort,28808302,10.1038/s41598-017-08530-9,NA,"Zhu D, Xiao S, Yu J, Ai Q, He Y, Cheng C, Zhang Y , Pan Y",Effects of One-Week Empirical Antibiotic Therapy on the Early Development of Gut Microbiota and Metabolites in Preterm Infants,Scientific reports,2017,NA,Experiment 4,China,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,Antibiotic free group (postnatal day 7),piperacillin-tazobactam group (postnatal day 7),"pre-term neonates receiving piperacillin-tazobactam (75 mg kg-1, twice a day)",12,12,NA,16S,34,Illumina,"ANOVA,T-Test",0.05,FALSE,NA,"birth weight,delivery procedure,gestational age,sex",NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:336/5/NA,Study 336,prospective cohort,28808302,10.1038/s41598-017-08530-9,NA,"Zhu D, Xiao S, Yu J, Ai Q, He Y, Cheng C, Zhang Y , Pan Y",Effects of One-Week Empirical Antibiotic Therapy on the Early Development of Gut Microbiota and Metabolites in Preterm Infants,Scientific reports,2017,NA,Experiment 5,China,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,piperacillin-tazobactam group (postnatal day 3),combination of penicillin and moxalactam group (postnatal day 3),"pre-term neonates given a treatment regimen of penicillin (10U kg-1, twice a day) combined with moxalactam (40 mg kg-1, twice a day)",12,12,NA,16S,34,Illumina,"ANOVA,T-Test",0.05,FALSE,NA,"birth weight,delivery procedure,gestational age,sex",NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:336/6/NA,Study 336,prospective cohort,28808302,10.1038/s41598-017-08530-9,NA,"Zhu D, Xiao S, Yu J, Ai Q, He Y, Cheng C, Zhang Y , Pan Y",Effects of One-Week Empirical Antibiotic Therapy on the Early Development of Gut Microbiota and Metabolites in Preterm Infants,Scientific reports,2017,NA,Experiment 6,China,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,piperacillin-tazobactam group (postnatal day 7),combination of penicillin and moxalactam group (postnatal day 7),"pre-term neonates given a treatment regimen of penicillin (10U kg-1, twice a day) combined with moxalactam (40 mg kg-1, twice a day)",12,12,NA,16S,34,Illumina,"ANOVA,T-Test",0.05,FALSE,NA,"birth weight,delivery procedure,gestational age,sex",NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:337/1/NA,Study 337,prospective cohort,31226994,10.1186/s12941-019-0318-9,NA,"Zhang M, Differding MK, Benjamin-Neelon SE, Østbye T, Hoyo C , Mueller NT",Association of prenatal antibiotics with measures of infant adiposity and the gut microbiome,Annals of clinical microbiology and antimicrobials,2019,"Antibiotic, Child health, Gut microbiome, Pediatric obesity, Pregnancy, Prenatal exposure",Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,3-month old infants not exposed to antibiotics during the second trimester,3-month-old infants exposed to antibiotics in the second trimester,infants born after 28 weeks gestation with no congenital abnormalities who were exposed to antibiotics during the second trimester,56,12,NA,16S,4,Illumina,Beta Binomial Regression,0.05,TRUE,NA,NA,"body mass index,education level,household income,marital status,maternal age,race,smoking behavior",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:337/3/NA,Study 337,prospective cohort,31226994,10.1186/s12941-019-0318-9,NA,"Zhang M, Differding MK, Benjamin-Neelon SE, Østbye T, Hoyo C , Mueller NT",Association of prenatal antibiotics with measures of infant adiposity and the gut microbiome,Annals of clinical microbiology and antimicrobials,2019,"Antibiotic, Child health, Gut microbiome, Pediatric obesity, Pregnancy, Prenatal exposure",Experiment 3,United States of America,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,12-month-old infants not exposed to antibiotics during the second trimester,12-month-old infants exposed to antibiotics during the second trimester,infants born after 28 weeks gestation with no congenital abnormalities who were exposed to antibiotics during the second trimester,40,10,NA,16S,4,Illumina,Beta Binomial Regression,0.05,TRUE,NA,NA,"body mass index,education level,household income,marital status,maternal age,race,smoking behavior",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:338/1/NA,Study 338,case-control,31976177,10.7717/peerj.8317,NA,"Chen X, Sun H, Jiang F, Shen Y, Li X, Hu X, Shen X , Wei P",Alteration of the gut microbiota associated with childhood obesity by 16S rRNA gene sequencing,PeerJ,2020,"16S rRNA gene sequencing, Alpha diversity, Bacterial compositions, Beta Diversity, Childhood obesity, Gut microbiota",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,normal weight children,obese children,volunteers between the ages of 6-11 years old who were determined to be obese by BMI,23,28,4 weeks,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,decreased,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:338/2/NA,Study 338,case-control,31976177,10.7717/peerj.8317,NA,"Chen X, Sun H, Jiang F, Shen Y, Li X, Hu X, Shen X , Wei P",Alteration of the gut microbiota associated with childhood obesity by 16S rRNA gene sequencing,PeerJ,2020,"16S rRNA gene sequencing, Alpha diversity, Bacterial compositions, Beta Diversity, Childhood obesity, Gut microbiota",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,normal weight children,obese children,volunteers between the ages of 6-11 years old who were determined to be obese by BMI,23,28,4 weeks,16S,4,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,NA,decreased,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:339/1/NA,Study 339,laboratory experiment,28211537,10.1038/srep42906,NA,"Li R, Yang J, Saffari A, Jacobs J, Baek KI, Hough G, Larauche MH, Ma J, Jen N, Moussaoui N, Zhou B, Kang H, Reddy S, Henning SM, Campen MJ, Pisegna J, Li Z, Fogelman AM, Sioutas C, Navab M , Hsiai TK",Ambient Ultrafine Particle Ingestion Alters Gut Microbiota in Association with Increased Atherogenic Lipid Metabolites,Scientific reports,2017,NA,Experiment 1,United States of America,Mus musculus,Caecum,UBERON:0001153,Air pollution,ENVO:02500037,vehicle control,mice exposed to UFP,C57BL/6 mice exposed to UFP (Ultrafine particles),11,12,NA,16S,4,Illumina,ANOVA,0.05,FALSE,NA,NA,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:340/1/NA,Study 340,prospective cohort,33653942,https://doi.org/10.1128/mSystems.00984-20,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546988,NA,Dysbiosis in Metabolic Genes of the Gut Microbiomes of Patients with an Ileo-anal Pouch Resembles That Observed in Crohn's Disease,NA,NA,"pouchitis, UC, CD, mucin, butyrate, bile acids, oxidative stress, classifier, Crohn's disease, microbiome, ulcerative colitis",Experiment 1,Israel,Homo sapiens,Feces,UBERON:0001988,Inflammatory bowel disease,EFO:0003767,Normal pouch,Pouchitis,Patients with a pouch that developed inflammation,35,34,1 month (recent use) or 6 months off antibiotics,WMS,NA,Illumina,Linear Regression,0.05,TRUE,NA,NA,age,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:341/1/NA,Study 341,prospective cohort,30157953,10.1186/s40168-018-0531-3,NA,"Shanahan ER, Shah A, Koloski N, Walker MM, Talley NJ, Morrison M , Holtmann GJ",Influence of cigarette smoking on the human duodenal mucosa-associated microbiota,Microbiome,2018,"Cigarettes, Duodenum, Microbiome, Mucosa, Small intestine, Smoking",Experiment 1,Australia,Homo sapiens,Small intestine,UBERON:0002108,Smoking behavior,EFO:0004318,never smoked,"patients with FD, ID,or CD who currently smoked","patient with FD,ID or CD with who previously or currently smokes",41,61,2 months,16S,678,Illumina,Kruskall-Wallis,0.05,TRUE,NA,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:341/2/NA,Study 341,prospective cohort,30157953,10.1186/s40168-018-0531-3,NA,"Shanahan ER, Shah A, Koloski N, Walker MM, Talley NJ, Morrison M , Holtmann GJ",Influence of cigarette smoking on the human duodenal mucosa-associated microbiota,Microbiome,2018,"Cigarettes, Duodenum, Microbiome, Mucosa, Small intestine, Smoking",Experiment 2,Australia,Homo sapiens,Small intestine,UBERON:0002108,Smoking behavior,EFO:0004318,never smoked,"patients with FD, ID,or CD who currently smokes","patient with FD,ID or CD with who previously or currently smokes",41,61,2 months,16S,678,Illumina,Kruskall-Wallis,0.05,TRUE,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:342/1/NA,Study 342,"cross-sectional observational, not case-control",31201890,10.1016/j.jaci.2019.05.035,NA,"McCauley K, Durack J, Valladares R, Fadrosh DW, Lin DL, Calatroni A, LeBeau PK, Tran HT, Fujimura KE, LaMere B, Merana G, Lynch K, Cohen RT, Pongracic J, Khurana Hershey GK, Kercsmar CM, Gill M, Liu AH, Kim H, Kattan M, Teach SJ, Togias A, Boushey HA, Gern JE, Jackson DJ , Lynch SV",Distinct nasal airway bacterial microbiotas differentially relate to exacerbation in pediatric patients with asthma,The Journal of allergy and clinical immunology,2019,"16S rRNA, Microbiota, Moraxella species, Staphylococcus species, airway, asthma, exacerbation, rhinovirus",Experiment 1,United States of America,Homo sapiens,Nasal cavity,UBERON:0001707,Asthma,MONDO:0004979,children who did not experience asthma exacerbation,Children who experienced exacerbation,"children who experienced exacerbation of their asthma (physician-prescribed use of systemic corticosteroids for asthma symptoms, hospitalization for asthma, or both)",346,67,None.,16S,4,Illumina,Zero-Inflated Beta Regression,0.15,TRUE,NA,NA,age,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:342/2/NA,Study 342,"cross-sectional observational, not case-control",31201890,10.1016/j.jaci.2019.05.035,NA,"McCauley K, Durack J, Valladares R, Fadrosh DW, Lin DL, Calatroni A, LeBeau PK, Tran HT, Fujimura KE, LaMere B, Merana G, Lynch K, Cohen RT, Pongracic J, Khurana Hershey GK, Kercsmar CM, Gill M, Liu AH, Kim H, Kattan M, Teach SJ, Togias A, Boushey HA, Gern JE, Jackson DJ , Lynch SV",Distinct nasal airway bacterial microbiotas differentially relate to exacerbation in pediatric patients with asthma,The Journal of allergy and clinical immunology,2019,"16S rRNA, Microbiota, Moraxella species, Staphylococcus species, airway, asthma, exacerbation, rhinovirus",Experiment 2,United States of America,Homo sapiens,Nasal cavity,UBERON:0001707,Asthma,MONDO:0004979,Samples with no rhinovirus infection,Samples with any rhinovirus infection,Samples with rhinovirus infection assessed by using quantitative PCR and partial sequencing to identify viral strain type,1883,1239,None.,16S,4,Illumina,Zero-Inflated Beta Regression,0.15,TRUE,NA,NA,age,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:342/3/NA,Study 342,"cross-sectional observational, not case-control",31201890,10.1016/j.jaci.2019.05.035,NA,"McCauley K, Durack J, Valladares R, Fadrosh DW, Lin DL, Calatroni A, LeBeau PK, Tran HT, Fujimura KE, LaMere B, Merana G, Lynch K, Cohen RT, Pongracic J, Khurana Hershey GK, Kercsmar CM, Gill M, Liu AH, Kim H, Kattan M, Teach SJ, Togias A, Boushey HA, Gern JE, Jackson DJ , Lynch SV",Distinct nasal airway bacterial microbiotas differentially relate to exacerbation in pediatric patients with asthma,The Journal of allergy and clinical immunology,2019,"16S rRNA, Microbiota, Moraxella species, Staphylococcus species, airway, asthma, exacerbation, rhinovirus",Experiment 3,United States of America,Homo sapiens,Nasal cavity,UBERON:0001707,Asthma,MONDO:0004979,Samples that were RV-A negative-,Samples with rhinovirus-A (RV-A),Samples with rhinovirus-A,1883,386,None.,16S,4,Illumina,Zero-Inflated Beta Regression,0.15,TRUE,NA,NA,age,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:342/5/NA,Study 342,"cross-sectional observational, not case-control",31201890,10.1016/j.jaci.2019.05.035,NA,"McCauley K, Durack J, Valladares R, Fadrosh DW, Lin DL, Calatroni A, LeBeau PK, Tran HT, Fujimura KE, LaMere B, Merana G, Lynch K, Cohen RT, Pongracic J, Khurana Hershey GK, Kercsmar CM, Gill M, Liu AH, Kim H, Kattan M, Teach SJ, Togias A, Boushey HA, Gern JE, Jackson DJ , Lynch SV",Distinct nasal airway bacterial microbiotas differentially relate to exacerbation in pediatric patients with asthma,The Journal of allergy and clinical immunology,2019,"16S rRNA, Microbiota, Moraxella species, Staphylococcus species, airway, asthma, exacerbation, rhinovirus",Experiment 5,United States of America,Homo sapiens,Nasal cavity,UBERON:0001707,Asthma,MONDO:0004979,children who did not experience exacerbation,Children who experienced exacerbation,"children who experienced exacerbation of their asthma (physician-prescribed use of systemic corticosteroids for asthma symptoms, hospitalization for asthma, or both)",346,67,None.,16S,4,Illumina,Zero-Inflated Beta Regression,0.15,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:342/7/NA,Study 342,"cross-sectional observational, not case-control",31201890,10.1016/j.jaci.2019.05.035,NA,"McCauley K, Durack J, Valladares R, Fadrosh DW, Lin DL, Calatroni A, LeBeau PK, Tran HT, Fujimura KE, LaMere B, Merana G, Lynch K, Cohen RT, Pongracic J, Khurana Hershey GK, Kercsmar CM, Gill M, Liu AH, Kim H, Kattan M, Teach SJ, Togias A, Boushey HA, Gern JE, Jackson DJ , Lynch SV",Distinct nasal airway bacterial microbiotas differentially relate to exacerbation in pediatric patients with asthma,The Journal of allergy and clinical immunology,2019,"16S rRNA, Microbiota, Moraxella species, Staphylococcus species, airway, asthma, exacerbation, rhinovirus",Experiment 7,United States of America,Homo sapiens,Nasal cavity,UBERON:0001707,Asthma,MONDO:0004979,samples with no rhinovirus infection,samples with any rhinovirus infection,samples with rhinovirus infection,1883,1239,None.,16S,4,Illumina,Zero-Inflated Beta Regression,0.15,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:342/8/NA,Study 342,"cross-sectional observational, not case-control",31201890,10.1016/j.jaci.2019.05.035,NA,"McCauley K, Durack J, Valladares R, Fadrosh DW, Lin DL, Calatroni A, LeBeau PK, Tran HT, Fujimura KE, LaMere B, Merana G, Lynch K, Cohen RT, Pongracic J, Khurana Hershey GK, Kercsmar CM, Gill M, Liu AH, Kim H, Kattan M, Teach SJ, Togias A, Boushey HA, Gern JE, Jackson DJ , Lynch SV",Distinct nasal airway bacterial microbiotas differentially relate to exacerbation in pediatric patients with asthma,The Journal of allergy and clinical immunology,2019,"16S rRNA, Microbiota, Moraxella species, Staphylococcus species, airway, asthma, exacerbation, rhinovirus",Experiment 8,United States of America,Homo sapiens,Nasal cavity,UBERON:0001707,Asthma,MONDO:0004979,Rhinovirus-negative samples,Samples with rhinovirus A,Samples with rhinovirus A present,1883,386,None.,16S,4,Illumina,Zero-Inflated Beta Regression,0.15,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:343/1/NA,Study 343,time series / longitudinal observational,31873965,10.1002/cncr.32641,NA,"Rashidi A, Kaiser T, Graiziger C, Holtan SG, Rehman TU, Weisdorf DJ, Dunny GM, Khoruts A , Staley C",Gut dysbiosis during antileukemia chemotherapy versus allogeneic hematopoietic cell transplantation,Cancer,2020,"dysbiosis, leukemia, microbiota, transplantation",Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Leukemia,EFO:0000565,Allogeneic Hematopoetic Stem Cell Transplant,Acute anti-leukemia treatment,Patients with leukemia who underwent intensive chemotherapy (any regimen involving 4 weeks or more of hospitalization) that did not have allo-HCT,20,20,NA,16S,4,Illumina,LEfSe,0.01,TRUE,4,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:344/1/NA,Study 344,laboratory experiment,31935575,10.1016/j.chemosphere.2020.125879,NA,"Liu W, Zhou Y, Yong Li Y, Qin L, Yu R, Li Y, Chen Y , Xu",Effects of PM<sub>2.5</sub> exposure during gestation on maternal gut microbiota and pregnancy outcomes,Chemosphere,2020,"Gut microbiota, PM(2.5), Pregnancy outcomes, Short chain fatty acids",Experiment 1,China,Mus musculus,Colon,UBERON:0001155,Air pollution,ENVO:02500037,mice exposed suspension from extracts of “blank” filter,mice exposed to Pm 2.5 suspension,exposed to PM2.5 suspension,12,12,NA,16S,34,Illumina,LEfSe,2,FALSE,2,NA,NA,NA,increased,unchanged,increased,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:345/1/NA,Study 345,laboratory experiment,36318010,https://doi.org/10.1128/spectrum.00157-22,https://journals.asm.org/doi/10.1128/spectrum.00157-22,"Zhao J, Lu W, Huang S, Le Maho Y, Habold C , Zhang Z","Impacts of Dietary Protein and Niacin Deficiency on Reproduction Performance, Body Growth, and Gut Microbiota of Female Hamsters (Tscherskia triton) and Their Offspring",Microbiology spectrum,2022,"cropland monoculture, greater long-tailed hamster, gut microbiota, low-protein diet, niacin deficiency",Experiment 1,China,Tscherskia triton,Feces,UBERON:0001988,Response to diet,EFO:0010757,Female hamsters Normal-protein diet (NPD) group,Female hamsters Low-protein diet (LPD) group,Female hamsters under low-protein diet LPD,NA,NA,NA,16S,34,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:345/3/NA,Study 345,laboratory experiment,36318010,https://doi.org/10.1128/spectrum.00157-22,https://journals.asm.org/doi/10.1128/spectrum.00157-22,"Zhao J, Lu W, Huang S, Le Maho Y, Habold C , Zhang Z","Impacts of Dietary Protein and Niacin Deficiency on Reproduction Performance, Body Growth, and Gut Microbiota of Female Hamsters (Tscherskia triton) and Their Offspring",Microbiology spectrum,2022,"cropland monoculture, greater long-tailed hamster, gut microbiota, low-protein diet, niacin deficiency",Experiment 3,China,Tscherskia triton,Feces,UBERON:0001988,Response to diet,EFO:0010757,Offspring hamsters Normal-protein diet (NPD) group,Offspring hamsters Low-protein diet (LPD) group,Offspring hamsters under low-protein diet LPD,NA,NA,NA,16S,34,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,decreased,decreased,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:345/4/NA,Study 345,laboratory experiment,36318010,https://doi.org/10.1128/spectrum.00157-22,https://journals.asm.org/doi/10.1128/spectrum.00157-22,"Zhao J, Lu W, Huang S, Le Maho Y, Habold C , Zhang Z","Impacts of Dietary Protein and Niacin Deficiency on Reproduction Performance, Body Growth, and Gut Microbiota of Female Hamsters (Tscherskia triton) and Their Offspring",Microbiology spectrum,2022,"cropland monoculture, greater long-tailed hamster, gut microbiota, low-protein diet, niacin deficiency",Experiment 4,China,Tscherskia triton,Feces,UBERON:0001988,Response to diet,EFO:0010757,Offspring hamsters naicin+ group,Offspring hamsters niacin- group,Offspring hamsters under niacin-deficient (niacin-) diet.,NA,NA,NA,16S,34,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,increased,increased,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:346/1/NA,Study 346,prospective cohort,32056780,10.1016/j.jad.2019.12.020,NA,"Madan A, Thompson D, Fowler JC, Ajami NJ, Salas R, Frueh BC, Bradshaw MR, Weinstein BL, Oldham JM , Petrosino JF",The gut microbiota is associated with psychiatric symptom severity and treatment outcome among individuals with serious mental illness,Journal of affective disorders,2020,"Anxiety, Depression, Microbiome, Microbiota, Outcomes, Serious mental illness",Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Unipolar depression,EFO:0003761,mild depression,severe depression,"Patients in this group were diagnosed with severe depression
(The primary patient-reported outcome measures used in this study were the Patient Health Questionnaire – 9 (PHQ-9) and the Patient Health Questionnaire – Generalized Anxiety Disorder screener (GAD-7); they were used to quantify depression severity).",NA,NA,None,16S,4,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:346/2/NA,Study 346,prospective cohort,32056780,10.1016/j.jad.2019.12.020,NA,"Madan A, Thompson D, Fowler JC, Ajami NJ, Salas R, Frueh BC, Bradshaw MR, Weinstein BL, Oldham JM , Petrosino JF",The gut microbiota is associated with psychiatric symptom severity and treatment outcome among individuals with serious mental illness,Journal of affective disorders,2020,"Anxiety, Depression, Microbiome, Microbiota, Outcomes, Serious mental illness",Experiment 2,United States of America,Homo sapiens,Feces,UBERON:0001988,Unipolar depression,EFO:0003761,mild depression,moderate depression,Patients in this group were diagnosed with moderate depression (The primary patient-reported outcome measures used in this study were the Patient Health Questionnaire – 9 (PHQ-9) and the Patient Health Questionnaire – Generalized Anxiety Disorder screener (GAD-7); they were used to quantify depression severity).,NA,NA,None,16S,4,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:346/3/NA,Study 346,prospective cohort,32056780,10.1016/j.jad.2019.12.020,NA,"Madan A, Thompson D, Fowler JC, Ajami NJ, Salas R, Frueh BC, Bradshaw MR, Weinstein BL, Oldham JM , Petrosino JF",The gut microbiota is associated with psychiatric symptom severity and treatment outcome among individuals with serious mental illness,Journal of affective disorders,2020,"Anxiety, Depression, Microbiome, Microbiota, Outcomes, Serious mental illness",Experiment 3,United States of America,Homo sapiens,Feces,UBERON:0001988,Anxiety disorder,EFO:0006788,mild anxiety,severe anxiety,Patients in this group were diagnosed with severe anxiety (The primary patient-reported outcome measures used in this study were the Patient Health Questionnaire – 9 (PHQ-9) and the Patient Health Questionnaire – Generalized Anxiety Disorder screener (GAD-7); they were used to quantify anxiety severity).,NA,NA,None,16S,4,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:346/4/NA,Study 346,prospective cohort,32056780,10.1016/j.jad.2019.12.020,NA,"Madan A, Thompson D, Fowler JC, Ajami NJ, Salas R, Frueh BC, Bradshaw MR, Weinstein BL, Oldham JM , Petrosino JF",The gut microbiota is associated with psychiatric symptom severity and treatment outcome among individuals with serious mental illness,Journal of affective disorders,2020,"Anxiety, Depression, Microbiome, Microbiota, Outcomes, Serious mental illness",Experiment 4,United States of America,Homo sapiens,Feces,UBERON:0001988,Anxiety disorder,EFO:0006788,mild anxiety,moderate anxiety,Patients in this group were diagnosed with moderate anxiety (The primary patient-reported outcome measures used in this study were the Patient Health Questionnaire – 9 (PHQ-9) and the Patient Health Questionnaire – Generalized Anxiety Disorder screener (GAD-7); they were used to quantify anxiety severity).,NA,NA,None,16S,4,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:346/5/NA,Study 346,prospective cohort,32056780,10.1016/j.jad.2019.12.020,NA,"Madan A, Thompson D, Fowler JC, Ajami NJ, Salas R, Frueh BC, Bradshaw MR, Weinstein BL, Oldham JM , Petrosino JF",The gut microbiota is associated with psychiatric symptom severity and treatment outcome among individuals with serious mental illness,Journal of affective disorders,2020,"Anxiety, Depression, Microbiome, Microbiota, Outcomes, Serious mental illness",Experiment 5,United States of America,Homo sapiens,Feces,UBERON:0001988,Remission,EFO:0009785,No,Yes,Participants who achieved remission from depression at discharge,NA,NA,None,16S,4,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:346/6/NA,Study 346,prospective cohort,32056780,10.1016/j.jad.2019.12.020,NA,"Madan A, Thompson D, Fowler JC, Ajami NJ, Salas R, Frueh BC, Bradshaw MR, Weinstein BL, Oldham JM , Petrosino JF",The gut microbiota is associated with psychiatric symptom severity and treatment outcome among individuals with serious mental illness,Journal of affective disorders,2020,"Anxiety, Depression, Microbiome, Microbiota, Outcomes, Serious mental illness",Experiment 6,United States of America,Homo sapiens,Feces,UBERON:0001988,Remission,EFO:0009785,No,Yes,Participants who achieved remission from anxiety at discharge,NA,NA,None,16S,4,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:347/1/NA,Study 347,case-control,30267022,10.1038/s41598-018-32730-6,NA,"Gao X, Jia R, Xie L, Kuang L, Feng L , Wan C",A study of the correlation between obesity and intestinal flora in school-age children,Scientific reports,2018,NA,Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,controls,obese children,School children meeting WHO diagnostic criteria for obesity,38,39,4 weeks,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,decreased,decreased,increased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:348/1/NA,Study 348,"cross-sectional observational, not case-control",26551842,10.1016/j.cmi.2015.10.031,NA,"Ignacio A, Fernandes MR, Rodrigues VA, Groppo FC, Cardoso AL, Avila-Campos MJ , Nakano V",Correlation between body mass index and faecal microbiota from children,Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,2016,"Anaerobic bacteria, Escherichia coli, body mass index, childhood obesity, faecal microbiota, quantitative PCR",Experiment 1,Brazil,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,lean children,obese children,Healthy children with obesity based on z-score of >+2,30,30,3 months,16S,NA,RT-qPCR,Kruskall-Wallis,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:348/2/NA,Study 348,"cross-sectional observational, not case-control",26551842,10.1016/j.cmi.2015.10.031,NA,"Ignacio A, Fernandes MR, Rodrigues VA, Groppo FC, Cardoso AL, Avila-Campos MJ , Nakano V",Correlation between body mass index and faecal microbiota from children,Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,2016,"Anaerobic bacteria, Escherichia coli, body mass index, childhood obesity, faecal microbiota, quantitative PCR",Experiment 2,Brazil,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,lean children,overweight children,Healthy children who are considered overweight based on z-score of ≥ +1 and < +2,30,24,3 months,16S,NA,RT-qPCR,Kruskall-Wallis,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:348/3/NA,Study 348,"cross-sectional observational, not case-control",26551842,10.1016/j.cmi.2015.10.031,NA,"Ignacio A, Fernandes MR, Rodrigues VA, Groppo FC, Cardoso AL, Avila-Campos MJ , Nakano V",Correlation between body mass index and faecal microbiota from children,Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,2016,"Anaerobic bacteria, Escherichia coli, body mass index, childhood obesity, faecal microbiota, quantitative PCR",Experiment 3,Brazil,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,lean children,obese children,Healthy children with obesity based on z-score of >+2,30,30,3 months,16S,NA,RT-qPCR,Logistic Regression,0.05,FALSE,NA,NA,age,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:348/4/NA,Study 348,"cross-sectional observational, not case-control",26551842,10.1016/j.cmi.2015.10.031,NA,"Ignacio A, Fernandes MR, Rodrigues VA, Groppo FC, Cardoso AL, Avila-Campos MJ , Nakano V",Correlation between body mass index and faecal microbiota from children,Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,2016,"Anaerobic bacteria, Escherichia coli, body mass index, childhood obesity, faecal microbiota, quantitative PCR",Experiment 4,Brazil,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,lean children,overweight children,Healthy children who are considered overweight based on z-score of ≥ +1 and < +2,30,24,3 months,16S,NA,RT-qPCR,Logistic Regression,0.05,FALSE,NA,NA,age,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:349/1/NA,Study 349,time series / longitudinal observational,30728029,10.1186/s12905-019-0727-0,NA,"Wiik J, Sengpiel V, Kyrgiou M, Nilsson S, Mitra A, Tanbo T, Monceyron Jonassen C, Møller Tannæs T , Sjøborg K","Cervical microbiota in women with cervical intra-epithelial neoplasia, prior to and after local excisional treatment, a Norwegian cohort study",BMC women's health,2019,"CIN, Cervical Intraepithelial Neoplasia, HPV, Human papillomavirus, LEEP, Lactobacillus, Vaginal microbiota",Experiment 1,Norway,Homo sapiens,Endocervix,UBERON:0000458,Cervical glandular intraepithelial neoplasia,EFO:1000165,normal,LEEP group before procedure,women with suspected high grade cervical dysplasia planning for their first Loop Electrosurgical Excision Procedure,100,89,long-term antibiotic use,16S,NA,RT-qPCR,Fisher's Exact Test,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:349/2/NA,Study 349,time series / longitudinal observational,30728029,10.1186/s12905-019-0727-0,NA,"Wiik J, Sengpiel V, Kyrgiou M, Nilsson S, Mitra A, Tanbo T, Monceyron Jonassen C, Møller Tannæs T , Sjøborg K","Cervical microbiota in women with cervical intra-epithelial neoplasia, prior to and after local excisional treatment, a Norwegian cohort study",BMC women's health,2019,"CIN, Cervical Intraepithelial Neoplasia, HPV, Human papillomavirus, LEEP, Lactobacillus, Vaginal microbiota",Experiment 2,Norway,Homo sapiens,Endocervix,UBERON:0000458,Cervical glandular intraepithelial neoplasia,EFO:1000165,normal,LEEP group before procedure,women with suspected high grade cervical dysplasia planning for their first Loop Electrosurgical Excision Procedure,99,89,long-term antibiotic use,16S,NA,RT-qPCR,Logistic Regression,0.05,FALSE,NA,NA,"age,contraception,marital status,smoking behavior",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:349/3/NA,Study 349,time series / longitudinal observational,30728029,10.1186/s12905-019-0727-0,NA,"Wiik J, Sengpiel V, Kyrgiou M, Nilsson S, Mitra A, Tanbo T, Monceyron Jonassen C, Møller Tannæs T , Sjøborg K","Cervical microbiota in women with cervical intra-epithelial neoplasia, prior to and after local excisional treatment, a Norwegian cohort study",BMC women's health,2019,"CIN, Cervical Intraepithelial Neoplasia, HPV, Human papillomavirus, LEEP, Lactobacillus, Vaginal microbiota",Experiment 3,Norway,Homo sapiens,Endocervix,UBERON:0000458,Cervical glandular intraepithelial neoplasia,EFO:1000165,normal,LEEP group before procedure (age <46),women <46 years old with suspected high grade cervical dysplasia planning for their first Loop Electrosurgical Excision Procedure,48,75,long-term antibiotic use,16S,NA,RT-qPCR,Fisher's Exact Test,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:349/4/NA,Study 349,time series / longitudinal observational,30728029,10.1186/s12905-019-0727-0,NA,"Wiik J, Sengpiel V, Kyrgiou M, Nilsson S, Mitra A, Tanbo T, Monceyron Jonassen C, Møller Tannæs T , Sjøborg K","Cervical microbiota in women with cervical intra-epithelial neoplasia, prior to and after local excisional treatment, a Norwegian cohort study",BMC women's health,2019,"CIN, Cervical Intraepithelial Neoplasia, HPV, Human papillomavirus, LEEP, Lactobacillus, Vaginal microbiota",Experiment 4,Norway,Homo sapiens,Endocervix,UBERON:0000458,Cervical glandular intraepithelial neoplasia,EFO:1000165,normal,LEEP group before procedure,women <46 years old with suspected high grade cervical dysplasia planning for their first Loop Electrosurgical Excision Procedure,48,75,long-term antibiotic use,16S,NA,RT-qPCR,Logistic Regression,0.05,FALSE,NA,NA,"age,contraception,marital status,smoking behavior",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:349/5/NA,Study 349,time series / longitudinal observational,30728029,10.1186/s12905-019-0727-0,NA,"Wiik J, Sengpiel V, Kyrgiou M, Nilsson S, Mitra A, Tanbo T, Monceyron Jonassen C, Møller Tannæs T , Sjøborg K","Cervical microbiota in women with cervical intra-epithelial neoplasia, prior to and after local excisional treatment, a Norwegian cohort study",BMC women's health,2019,"CIN, Cervical Intraepithelial Neoplasia, HPV, Human papillomavirus, LEEP, Lactobacillus, Vaginal microbiota",Experiment 5,Norway,Homo sapiens,Endocervix,UBERON:0000458,Cervical glandular intraepithelial neoplasia,EFO:1000165,normal,LEEP group 6 months post-procedure,women 6 months after Loop Electrosurgical Excision Procedure,100,77,long-term antibiotic use,16S,NA,RT-qPCR,Fisher's Exact Test,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:349/6/NA,Study 349,time series / longitudinal observational,30728029,10.1186/s12905-019-0727-0,NA,"Wiik J, Sengpiel V, Kyrgiou M, Nilsson S, Mitra A, Tanbo T, Monceyron Jonassen C, Møller Tannæs T , Sjøborg K","Cervical microbiota in women with cervical intra-epithelial neoplasia, prior to and after local excisional treatment, a Norwegian cohort study",BMC women's health,2019,"CIN, Cervical Intraepithelial Neoplasia, HPV, Human papillomavirus, LEEP, Lactobacillus, Vaginal microbiota",Experiment 6,Norway,Homo sapiens,Endocervix,UBERON:0000458,Cervical glandular intraepithelial neoplasia,EFO:1000165,normal,LEEP group 12 months post-procedure,women 12 months after Loop Electrosurgical Excision Procedure,100,72,long-term antibiotic use,16S,NA,RT-qPCR,Fisher's Exact Test,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:350/1/NA,Study 350,case-control,32143621,10.1186/s12934-020-01319-y,NA,"Gallardo-Becerra L, Cornejo-Granados F, García-López R, Valdez-Lara A, Bikel S, Canizales-Quinteros S, López-Contreras BE, Mendoza-Vargas A, Nielsen H , Ochoa-Leyva A","Metatranscriptomic analysis to define the Secrebiome, and 16S rRNA profiling of the gut microbiome in obesity and metabolic syndrome of Mexican children",Microbial cell factories,2020,"AAR, CAZY, Metabolic syndrome, Metatranscriptome, Metatranscriptomics, Microbiome, Microbiota, Obesity, Secrebiome, Secretome",Experiment 1,Mexico,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,Normal weight (NW),Obese children (O),Obesity was defined by body mass index (BMI) ≥ 95th percentile. Children in the O group were selected so that they did not have more than one trait matching the metabolic syndrome traits.,10,10,3 months,16S,4,Illumina,LEfSe,0.05,FALSE,1,NA,NA,NA,unchanged,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:350/2/NA,Study 350,case-control,32143621,10.1186/s12934-020-01319-y,NA,"Gallardo-Becerra L, Cornejo-Granados F, García-López R, Valdez-Lara A, Bikel S, Canizales-Quinteros S, López-Contreras BE, Mendoza-Vargas A, Nielsen H , Ochoa-Leyva A","Metatranscriptomic analysis to define the Secrebiome, and 16S rRNA profiling of the gut microbiome in obesity and metabolic syndrome of Mexican children",Microbial cell factories,2020,"AAR, CAZY, Metabolic syndrome, Metatranscriptome, Metatranscriptomics, Microbiome, Microbiota, Obesity, Secrebiome, Secretome",Experiment 2,Mexico,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,Normal weight (NW),Obesity with metabolic syndrome (OMS),"OMS were defined by the presence of waist circumference > 75th by age and gender, and at least two of the following metabolic traits: (1) triglycerides > 1.1 mmol/L (100 mg/dL); (2) HDL cholesterol < 1.3 mmol/L (50 mg/dL), (3) glucose > 6.1 mmol/L (110 mg/dL) and (4) systolic blood pressure > 90th percentile for gender, age, and height.",10,7,3 months,16S,4,Illumina,LEfSe,0.05,FALSE,1,NA,NA,NA,unchanged,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:351/1/NA,Study 351,"cross-sectional observational, not case-control",31934770,10.1089/chi.2019.0280,NA,"Da Silva CC, Monteil MA , Davis EM",Overweight and Obesity in Children Are Associated with an Abundance of Firmicutes and Reduction of Bifidobacterium in Their Gastrointestinal Microbiota,Childhood obesity (Print),2020,"bifidobacterium, children, firmicutes, gut, microbiome, obesity",Experiment 1,Trinidad and Tobago,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,normal,overweight/obesity,school aged children (6-14 years),30,21,3 months,16S,NA,Illumina,ANOVA,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:352/1/NA,Study 352,"cross-sectional observational, not case-control",30405584,10.3389/fmicb.2018.02533,NA,"Godoy-Vitorino F, Romaguera J, Zhao C, Vargas-Robles D, Ortiz-Morales G, Vázquez-Sánchez F, Sanchez-Vázquez M, de la Garza-Casillas M, Martinez-Ferrer M, White JR, Bittinger K, Dominguez-Bello MG , Blaser MJ",Cervicovaginal Fungi and Bacteria Associated With Cervical Intraepithelial Neoplasia and High-Risk Human Papillomavirus Infections in a Hispanic Population,Frontiers in microbiology,2018,"16S rRNA, ITS2, cervical cancer, cervicovaginal microbiota, fungi",Experiment 1,United States of America,Homo sapiens,Vagina,UBERON:0000996,"Human papilloma virus infection,Cervical glandular intraepithelial neoplasia","EFO:1000165,EFO:0001668",Atypical Squamous Cells of Undetermined Significance,Low Grade Squamous Intraepithelial Lesion,low grade squamous intraepithelial lesion,6,18,2 months,16S,12,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,decreased,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:352/2/NA,Study 352,"cross-sectional observational, not case-control",30405584,10.3389/fmicb.2018.02533,NA,"Godoy-Vitorino F, Romaguera J, Zhao C, Vargas-Robles D, Ortiz-Morales G, Vázquez-Sánchez F, Sanchez-Vázquez M, de la Garza-Casillas M, Martinez-Ferrer M, White JR, Bittinger K, Dominguez-Bello MG , Blaser MJ",Cervicovaginal Fungi and Bacteria Associated With Cervical Intraepithelial Neoplasia and High-Risk Human Papillomavirus Infections in a Hispanic Population,Frontiers in microbiology,2018,"16S rRNA, ITS2, cervical cancer, cervicovaginal microbiota, fungi",Experiment 2,United States of America,Homo sapiens,Vagina,UBERON:0000996,"Human papilloma virus infection,Cervical glandular intraepithelial neoplasia","EFO:1000165,EFO:0001668",Low risk-HPV,High risk-HPV,High risk-HPV,3,27,2 months,16S,12,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,increased,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:352/3/NA,Study 352,"cross-sectional observational, not case-control",30405584,10.3389/fmicb.2018.02533,NA,"Godoy-Vitorino F, Romaguera J, Zhao C, Vargas-Robles D, Ortiz-Morales G, Vázquez-Sánchez F, Sanchez-Vázquez M, de la Garza-Casillas M, Martinez-Ferrer M, White JR, Bittinger K, Dominguez-Bello MG , Blaser MJ",Cervicovaginal Fungi and Bacteria Associated With Cervical Intraepithelial Neoplasia and High-Risk Human Papillomavirus Infections in a Hispanic Population,Frontiers in microbiology,2018,"16S rRNA, ITS2, cervical cancer, cervicovaginal microbiota, fungi",Experiment 3,United States of America,Homo sapiens,Uterine cervix,UBERON:0000002,"Cervical glandular intraepithelial neoplasia,Human papilloma virus infection","EFO:1000165,EFO:0001668",Atypical Squamous Cells of Undetermined Significance,Low Grade Squamous Intraepithelial Lesion,low grade squamus intraepithelial lesion,6,18,2 months,16S,12,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:352/4/NA,Study 352,"cross-sectional observational, not case-control",30405584,10.3389/fmicb.2018.02533,NA,"Godoy-Vitorino F, Romaguera J, Zhao C, Vargas-Robles D, Ortiz-Morales G, Vázquez-Sánchez F, Sanchez-Vázquez M, de la Garza-Casillas M, Martinez-Ferrer M, White JR, Bittinger K, Dominguez-Bello MG , Blaser MJ",Cervicovaginal Fungi and Bacteria Associated With Cervical Intraepithelial Neoplasia and High-Risk Human Papillomavirus Infections in a Hispanic Population,Frontiers in microbiology,2018,"16S rRNA, ITS2, cervical cancer, cervicovaginal microbiota, fungi",Experiment 4,United States of America,Homo sapiens,Uterine cervix,UBERON:0000002,"Human papilloma virus infection,Cervical glandular intraepithelial neoplasia","EFO:1000165,EFO:0001668",Low risk-HPV,High risk-HPV,High risk-HPV,3,27,2 months,16S,12,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:353/1/NA,Study 353,case-control,19849869,10.1017/S0007114509992182,NA,"Balamurugan R, George G, Kabeerdoss J, Hepsiba J, Chandragunasekaran AM , Ramakrishna BS",Quantitative differences in intestinal Faecalibacterium prausnitzii in obese Indian children,The British journal of nutrition,2010,NA,Experiment 1,India,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,non-obese,obese,(Private) School Children,13,15,1 month,16S,NA,RT-qPCR,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,class/grade level,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:354/1/NA,Study 354,case-control,22546742,10.1038/oby.2012.110,NA,"Karlsson CL, Onnerfält J, Xu J, Molin G, Ahrné S , Thorngren-Jerneck K",The microbiota of the gut in preschool children with normal and excessive body weight,"Obesity (Silver Spring, Md.)",2012,NA,Experiment 1,Sweden,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,control (BMI at normal range),overweight/obese,Overweight/ obese children with BMI ranging 17.6-25.8 kg/m2,20,20,None,16S,NA,RT-qPCR,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:355/1/NA,Study 355,"cross-sectional observational, not case-control",23631345,10.1186/1757-4749-5-10,NA,"Bervoets L, Van Hoorenbeeck K, Kortleven I, Van Noten C, Hens N, Vael C, Goossens H, Desager KN , Vankerckhoven V",Differences in gut microbiota composition between obese and lean children: a cross-sectional study,Gut pathogens,2013,NA,Experiment 1,Belgium,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,control (lean/normal weight),obese (obese/overweight/morbidly obese),Children who are obese by BMI (classified based on the international BMI cut-off values of the Extended International Obesity Task Force (IOTF) for children aged 2 to 18),27,26,1 month,16S,NA,RT-qPCR,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:356/1/NA,Study 356,laboratory experiment,32544691,10.1016/j.scitotenv.2020.139982,NA,"Liu W, Zhou Y, Qin Y, Li Y, Yu L, Li R, Chen Y , Xu Y",Sex-specific effects of PM<sub>2.5</sub> maternal exposure on offspring's serum lipoproteins and gut microbiota,The Science of the total environment,2020,"Gut microbiota, Lipoproteins, Offspring, PM(2.5), Sex-specific",Experiment 1,China,Mus musculus,Colon,UBERON:0001155,Air pollution,ENVO:02500037,mice dams exposed to filtered blanks PND 3,ICR male mice exposed to PM 2.5,ICR mice exposed to PM 2.5 air,8,8,NA,16S,34,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,NA,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:356/2/NA,Study 356,laboratory experiment,32544691,10.1016/j.scitotenv.2020.139982,NA,"Liu W, Zhou Y, Qin Y, Li Y, Yu L, Li R, Chen Y , Xu Y",Sex-specific effects of PM<sub>2.5</sub> maternal exposure on offspring's serum lipoproteins and gut microbiota,The Science of the total environment,2020,"Gut microbiota, Lipoproteins, Offspring, PM(2.5), Sex-specific",Experiment 2,China,Mus musculus,Colon,UBERON:0001155,Air pollution,ENVO:02500037,mice dams exposed to filtered blanks PND 10,ICR male mice exposed to PM 2.5,ICR mice exposed to PM 2.5,8,8,NA,16S,34,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,NA,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:356/3/NA,Study 356,laboratory experiment,32544691,10.1016/j.scitotenv.2020.139982,NA,"Liu W, Zhou Y, Qin Y, Li Y, Yu L, Li R, Chen Y , Xu Y",Sex-specific effects of PM<sub>2.5</sub> maternal exposure on offspring's serum lipoproteins and gut microbiota,The Science of the total environment,2020,"Gut microbiota, Lipoproteins, Offspring, PM(2.5), Sex-specific",Experiment 3,China,Mus musculus,Colon,UBERON:0001155,Air pollution,ENVO:02500037,mice dams exposed to filtered blanks PND 21,ICR male mice exposed to PM 2.5,ICR mice exposed to PM 2.5,8,8,NA,16S,34,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:356/4/NA,Study 356,laboratory experiment,32544691,10.1016/j.scitotenv.2020.139982,NA,"Liu W, Zhou Y, Qin Y, Li Y, Yu L, Li R, Chen Y , Xu Y",Sex-specific effects of PM<sub>2.5</sub> maternal exposure on offspring's serum lipoproteins and gut microbiota,The Science of the total environment,2020,"Gut microbiota, Lipoproteins, Offspring, PM(2.5), Sex-specific",Experiment 4,China,Mus musculus,Colon,UBERON:0001155,Air pollution,ENVO:02500037,mice dams exposed to filtered blanks PND 35,ICR male mice exposed to PM 2.5,ICR mice exposed to PM 2.5,8,8,NA,16S,34,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,NA,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:356/5/NA,Study 356,laboratory experiment,32544691,10.1016/j.scitotenv.2020.139982,NA,"Liu W, Zhou Y, Qin Y, Li Y, Yu L, Li R, Chen Y , Xu Y",Sex-specific effects of PM<sub>2.5</sub> maternal exposure on offspring's serum lipoproteins and gut microbiota,The Science of the total environment,2020,"Gut microbiota, Lipoproteins, Offspring, PM(2.5), Sex-specific",Experiment 5,China,Mus musculus,Colon,UBERON:0001155,Air pollution,ENVO:02500037,mice dams exposed to filtered blanks PND 10,ICR female mice exposed to PM 2.5,ICR mice exposed to PM 2.5,8,8,NA,16S,34,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:356/6/NA,Study 356,laboratory experiment,32544691,10.1016/j.scitotenv.2020.139982,NA,"Liu W, Zhou Y, Qin Y, Li Y, Yu L, Li R, Chen Y , Xu Y",Sex-specific effects of PM<sub>2.5</sub> maternal exposure on offspring's serum lipoproteins and gut microbiota,The Science of the total environment,2020,"Gut microbiota, Lipoproteins, Offspring, PM(2.5), Sex-specific",Experiment 6,China,Mus musculus,Colon,UBERON:0001155,Air pollution,ENVO:02500037,mice dams exposed to filtered blanks PND 21,ICR female mice exposed to PM 2.5,ICR mice exposed to PM 2.5,8,8,NA,16S,34,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,NA,unchanged,unchanged,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:356/7/NA,Study 356,laboratory experiment,32544691,10.1016/j.scitotenv.2020.139982,NA,"Liu W, Zhou Y, Qin Y, Li Y, Yu L, Li R, Chen Y , Xu Y",Sex-specific effects of PM<sub>2.5</sub> maternal exposure on offspring's serum lipoproteins and gut microbiota,The Science of the total environment,2020,"Gut microbiota, Lipoproteins, Offspring, PM(2.5), Sex-specific",Experiment 7,China,Mus musculus,Colon,UBERON:0001155,Air pollution,ENVO:02500037,mice dams exposed to filtered blanks PND 35,ICR female mice exposed to PM 2.5,ICR mice exposed to PM 2.5,8,8,NA,16S,34,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:357/1/NA,Study 357,time series / longitudinal observational,30804895,10.3389/fmicb.2019.00054,NA,"Qin T, Zhang F, Zhou H, Ren H, Du Y, Liang S, Wang F, Cheng L, Xie X, Jin A, Wu Y, Zhao J , Xu J",High-Level PM2.5/PM10 Exposure Is Associated With Alterations in the Human Pharyngeal Microbiota Composition,Frontiers in microbiology,2019,"PM2.5/PM10, microbiome composition, pharynx, respiratory pathogen, smoking",Experiment 1,China,Homo sapiens,Cavity of pharynx,UBERON:0001731,Air pollution,ENVO:02500037,pre-smog swabs,post-smog swabs,Vendors in an open-air farer's market who worked in the same place and were exposed to smog over the same business hours,83,83,NA,16S,34,Illumina,LEfSe,0.001,TRUE,4,NA,NA,NA,unchanged,increased,unchanged,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:358/1/NA,Study 358,"cross-sectional observational, not case-control",32546712,10.1038/s41598-020-66607-4,NA,"Tango CN, Seo SS, Kwon M, Lee DO, Chang HK , Kim MK",Taxonomic and Functional Differences in Cervical Microbiome Associated with Cervical Cancer Development,Scientific reports,2020,NA,Experiment 1,South Korea,Homo sapiens,Uterine cervix,UBERON:0000002,"Cervical glandular intraepithelial neoplasia,Cervical cancer","EFO:1000165,MONDO:0002974",Healthy controls,CIN2/3-CC,patients diagnosed with CIN2/3 or cervical cancer during screening of the cervical tract,50,42,antibiotic therapy within 3 months,16S,NA,Roche454,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,increased,unchanged,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:359/1/NA,Study 359,case-control,27015003,10.1038/ismej.2016.37,NA,"Wu J, Peters BA, Dominianni C, Zhang Y, Pei Z, Yang L, Ma Y, Purdue MP, Jacobs EJ, Gapstur SM, Li H, Alekseyenko AV, Hayes RB , Ahn J",Cigarette smoking and the oral microbiome in a large study of American adults,The ISME journal,2016,NA,Experiment 1,United States of America,Homo sapiens,Mouth,UBERON:0000165,Smoking behavior,EFO:0004318,former smoker,current smoker,participants who developed head and neck or pancreatic cancer at any point after collection of the oral wash samples,521,112,NA,16S,34,Roche454,Kruskall-Wallis,0.05,TRUE,NA,"age,sex",NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:360/1/NA,Study 360,laboratory experiment,31753468,10.1016/j.envres.2019.108913,NA,"Fitch MN, Phillippi D, Zhang Y, Lucero J, Pandey RS, Liu J, Brower J, Allen MS, Campen MJ, McDonald JD , Lund AK","Effects of inhaled air pollution on markers of integrity, inflammation, and microbiota profiles of the intestines in Apolipoprotein E knockout mice",Environmental research,2020,"Air pollution, Inflammation, Intestine epithelial barrier, Microbiome",Experiment 1,United States of America,Mus musculus,Small intestine,UBERON:0002108,Air pollution,ENVO:02500037,mice exposed to Filtered Air,mice exposed to MVE,male ApoE−/- mice exposed to  mixed diesel and gasoline engine emissions (MVE) or Wood Smoke (WS),20,20,NA,16S,4,Illumina,Kruskall-Wallis,0.05,TRUE,NA,NA,NA,NA,decreased,decreased,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:360/2/NA,Study 360,laboratory experiment,31753468,10.1016/j.envres.2019.108913,NA,"Fitch MN, Phillippi D, Zhang Y, Lucero J, Pandey RS, Liu J, Brower J, Allen MS, Campen MJ, McDonald JD , Lund AK","Effects of inhaled air pollution on markers of integrity, inflammation, and microbiota profiles of the intestines in Apolipoprotein E knockout mice",Environmental research,2020,"Air pollution, Inflammation, Intestine epithelial barrier, Microbiome",Experiment 2,United States of America,Mus musculus,Small intestine,UBERON:0002108,Air pollution,ENVO:02500037,mice exposed to Filtered Air,mice exposed to WS,male ApoE−/- mice exposed to  mixed diesel and gasoline engine emissions (MVE) or Wood Smoke (WS),20,20,NA,16S,4,Illumina,Kruskall-Wallis,0.05,TRUE,NA,NA,NA,NA,decreased,decreased,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:361/1/NA,Study 361,laboratory experiment,32251484,10.1371/journal.pone.0230932,NA,"Tam A, Filho FSL, Ra SW, Yang J, Leung JM, Churg A, Wright JL , Sin DD",Effects of sex and chronic cigarette smoke exposure on the mouse cecal microbiome,PloS one,2020,NA,Experiment 1,Canada,Mus musculus,Caecum,UBERON:0001153,Air pollution,ENVO:02500037,all other mice,male mice exposed to cigarette smoke,male mice exposed to smoke,50,8,NA,16S,4,Illumina,LEfSe,0.05,TRUE,3.5,NA,NA,decreased,decreased,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:361/2/NA,Study 361,laboratory experiment,32251484,10.1371/journal.pone.0230932,NA,"Tam A, Filho FSL, Ra SW, Yang J, Leung JM, Churg A, Wright JL , Sin DD",Effects of sex and chronic cigarette smoke exposure on the mouse cecal microbiome,PloS one,2020,NA,Experiment 2,Canada,Mus musculus,Caecum,UBERON:0001153,Air pollution,ENVO:02500037,all other mice,female mice exposed to cigarette smoke,female mice exposed to cigarette smoke,48,10,NA,16S,4,Illumina,LEfSe,0.05,TRUE,3.5,NA,NA,decreased,increased,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:361/3/NA,Study 361,laboratory experiment,32251484,10.1371/journal.pone.0230932,NA,"Tam A, Filho FSL, Ra SW, Yang J, Leung JM, Churg A, Wright JL , Sin DD",Effects of sex and chronic cigarette smoke exposure on the mouse cecal microbiome,PloS one,2020,NA,Experiment 3,Canada,Mus musculus,Caecum,UBERON:0001153,Air pollution,ENVO:02500037,all other mice,ovariectomized female mice exposed to cigarette smoke,ovariectomized female mice exposed to smoke,48,10,NA,16S,4,Illumina,LEfSe,0.05,TRUE,3.5,NA,NA,decreased,decreased,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:361/4/NA,Study 361,laboratory experiment,32251484,10.1371/journal.pone.0230932,NA,"Tam A, Filho FSL, Ra SW, Yang J, Leung JM, Churg A, Wright JL , Sin DD",Effects of sex and chronic cigarette smoke exposure on the mouse cecal microbiome,PloS one,2020,NA,Experiment 4,Canada,Mus musculus,Caecum,UBERON:0001153,Air pollution,ENVO:02500037,control,mice exposed to smoke,"male, female or ovariectomized females mice exposed to smoke",30,28,NA,16S,4,Illumina,LEfSe,0.05,TRUE,3.5,NA,NA,decreased,decreased,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:362/1/NA,Study 362,"cross-sectional observational, not case-control",32429742,10.1089/chi.2019.0312,NA,"Aguilar T, Nava GM, Olvera-Ramírez AM, Ronquillo D, Camacho M, Zavala GA, Caamaño MC, Acevedo-Whitehouse K, Rosado JL , García OP",Gut Bacterial Families Are Associated with Body Composition and Metabolic Risk Markers in School-Aged Children in Rural Mexico,Childhood obesity (Print),2020,"bacterial families, children, metabolic markers, microbiota, obesity",Experiment 1,Mexico,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,normal weight children,obese,School-aged children,56,16,4 months,16S,NA,RT-qPCR,ANOVA,0.05,TRUE,NA,NA,age,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:363/1/NA,Study 363,"cross-sectional observational, not case-control",32341759,10.1080/20002297.2020.1742527,NA,"Sato N, Kakuta M, Uchino E, Hasegawa T, Kojima R, Kobayashi W, Sawada K, Tamura Y, Tokuda I, Imoto S, Nakaji S, Murashita K, Yanagita M , Okuno Y",The relationship between cigarette smoking and the tongue microbiome in an East Asian population,Journal of oral microbiology,2020,"East Asia, Oral cavity, cigarette smoking, microbiome, tongue",Experiment 1,Japan,Homo sapiens,Tongue,UBERON:0001723,Smoking behavior,EFO:0004318,never smokers,current smokers,participants who underwent tongue-coating analysis in 2016 and 2017,384,144,NA,16S,34,Illumina,DESeq2,0.05,TRUE,NA,NA,"age,alcohol drinking,body mass index,dental caries,number of teeth measurement,peridontal microbiome,sex",NA,decreased,NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:364/1/NA,Study 364,case-control,31199220,10.1099/jmm.0.001003,NA,"Karabudak S, Ari O, Durmaz B, Dal T, Basyigit T, Kalcioglu MT , Durmaz R",Analysis of the effect of smoking on the buccal microbiome using next-generation sequencing technology,Journal of medical microbiology,2019,"buccal microbiome, metagenomic analysis, next-generation sequencing, smoking",Experiment 1,Turkey,Homo sapiens,Buccal mucosa,UBERON:0006956,Smoking behavior,EFO:0004318,non-smokers,smokers,"Participants who smoke cigarettes that fulfilled the inclusion criteria for good health: no use of antibiotics in the past 3 months, no respiratory infections, no oral aphthous lesions on buccal mucosa, and absence of dental problems",20,20,3 months,16S,23456789,Ion Torrent,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:365/1/NA,Study 365,laboratory experiment,30562947,10.3390/ijms19124079,NA,"Ishii C, Nakanishi Y, Murakami S, Nozu R, Ueno M, Hioki K, Aw W, Hirayama A, Soga T, Ito M, Tomita M , Fukuda S",A Metabologenomic Approach Reveals Changes in the Intestinal Environment of Mice Fed on American Diet,International journal of molecular sciences,2018,"American diet, CE-TOFMS, intestinal microbiota, metabologenomics, metabolome, microbiome, multi-omics, next-generation sequencing",Experiment 1,United States of America,Mus musculus,Feces,UBERON:0001988,Methionine measurement,EFO:0009771,mice fed control rodent diet.,mice fed American Diet,"C57BL/6J mice fed an American diet (AD), which contained higher amounts of fat and fiber",6,5,NA,16S,12,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,2,NA,NA,NA,unchanged,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:366/1/NA,Study 366,case-control,23454028,10.1016/j.cgh.2013.02.015,NA,"Raman M, Ahmed I, Gillevet PM, Probert CS, Ratcliffe NM, Smith S, Greenwood R, Sikaroodi M, Lam V, Crotty P, Bailey J, Myers RP , Rioux KP",Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease,Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association,2013,NA,Experiment 1,Canada,Homo sapiens,Feces,UBERON:0001988,Non-alcoholic fatty liver disease,EFO:0003095,healthy controls,nonalcoholic fatty liver disease,Obese patients with a body mass index (BMI) greater than 30 kg/m2 and clinically suspected non-alcoholic fatty liver disease,30,30,3 months,16S,NA,Roche454,Metastats,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:367/1/NA,Study 367,"cross-sectional observational, not case-control",25761741,10.1007/s10096-015-2355-4,NA,"Murugesan S, Ulloa-Martínez M, Martínez-Rojano H, Galván-Rodríguez FM, Miranda-Brito C, Romano MC, Piña-Escobedo A, Pizano-Zárate ML, Hoyo-Vadillo C , García-Mena J",Study of the diversity and short-chain fatty acids production by the bacterial community in overweight and obese Mexican children,European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,2015,NA,Experiment 1,Mexico,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,normal weight,obese,"Unrelated children, 9–11 years old",81,80,3 months,16S,3,Ion Torrent,ANOVA,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:368/1/NA,Study 368,"cross-sectional observational, not case-control",32640977,10.1186/s12866-020-01883-8,NA,"Halboub E, Al-Ak'hali MS, Alamir AH, Homeida HE, Baraniya D, Chen T , Al-Hebshi NN",Tongue microbiome of smokeless tobacco users,BMC microbiology,2020,"Microbiota, Mouth neoplasms, Rothia mucilaginosa, high-throughput nucleotide sequencing, Tobacco, Tongue",Experiment 1,Saudi Arabia,Homo sapiens,Tongue,UBERON:0001723,Smoking behavior,EFO:0004318,non-shammah users,shammah users,participants who used shammah daily for at least one year without a period of cessation and those who had no history of shammah use,23,29,3 months,16S,123,Illumina,LEfSe,0.015,TRUE,NA,sex,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:369/1/NA,Study 369,time series / longitudinal observational,30534614,10.1038/s42003-018-0221-5,NA,"Rampelli S, Guenther K, Turroni S, Wolters M, Veidebaum T, Kourides Y, Molnár D, Lissner L, Benitez-Paez A, Sanz Y, Fraterman A, Michels N, Brigidi P, Candela M , Ahrens W",Pre-obese children's dysbiotic gut microbiome and unhealthy diets may predict the development of obesity,Communications biology,2018,NA,Experiment 1,"Cyprus,Estonia,Germany,Hungary,Sweden",Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,normal weight,obese,children aged 2-9 years,34,36,14 days,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,decreased,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:369/2/NA,Study 369,time series / longitudinal observational,30534614,10.1038/s42003-018-0221-5,NA,"Rampelli S, Guenther K, Turroni S, Wolters M, Veidebaum T, Kourides Y, Molnár D, Lissner L, Benitez-Paez A, Sanz Y, Fraterman A, Michels N, Brigidi P, Candela M , Ahrens W",Pre-obese children's dysbiotic gut microbiome and unhealthy diets may predict the development of obesity,Communications biology,2018,NA,Experiment 2,"Cyprus,Estonia,Germany,Hungary,Sweden",Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,before onset of obesity,after onset of obesity,children aged 2-9 years,36,36,14 days,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,decreased,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:370/1/NA,Study 370,time series / longitudinal observational,27836847,10.1128/AEM.02149-16,NA,"Stanaway IB, Wallace JC, Shojaie A, Griffith WC, Hong S, Wilder CS, Green FH, Tsai J, Knight M, Workman T, Vigoren EM, McLean JS, Thompson B , Faustman EM",Human Oral Buccal Microbiomes Are Associated with Farmworker Status and Azinphos-Methyl Agricultural Pesticide Exposure,Applied and environmental microbiology,2017,"16S rRNA, azinphos-methyl, bacteria, buccal mucosa, farmworkers, microbiome, oral, sequencing",Experiment 1,United States of America,Homo sapiens,Buccal mucosa,UBERON:0006956,Air pollution,ENVO:02500037,Winter individuals,Spring/Summer individuals,Individuals for whom sequencing was performed had previous spring/summer blood azinphos-methyl detection by mass spectrometry as evidence of pesticide exposure.,82,101,NA,16S,56,Ion Torrent,Mann-Whitney (Wilcoxon),0.01,TRUE,NA,NA,NA,NA,NA,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:371/1/NA,Study 371,"cross-sectional observational, not case-control",23459324,10.1038/ijo.2013.20,NA,"Million M, Angelakis E, Maraninchi M, Henry M, Giorgi R, Valero R, Vialettes B , Raoult D","Correlation between body mass index and gut concentrations of Lactobacillus reuteri, Bifidobacterium animalis, Methanobrevibacter smithii and Escherichia coli",International journal of obesity (2005),2013,NA,Experiment 1,France,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,"anorexic, lean, and overweight subjects",obese subjects,patients who were obese by BMI (BMI>30 kg m−2),128,134,6 months,WMS,NA,RT-qPCR,Chi-Square,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:371/2/NA,Study 371,"cross-sectional observational, not case-control",23459324,10.1038/ijo.2013.20,NA,"Million M, Angelakis E, Maraninchi M, Henry M, Giorgi R, Valero R, Vialettes B , Raoult D","Correlation between body mass index and gut concentrations of Lactobacillus reuteri, Bifidobacterium animalis, Methanobrevibacter smithii and Escherichia coli",International journal of obesity (2005),2013,NA,Experiment 2,France,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,lean and anorexic subjects,obese and overweight subjects,patients who were overweight or obese by BMI,91,171,6 months,WMS,NA,RT-qPCR,Chi-Square,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:371/3/NA,Study 371,"cross-sectional observational, not case-control",23459324,10.1038/ijo.2013.20,NA,"Million M, Angelakis E, Maraninchi M, Henry M, Giorgi R, Valero R, Vialettes B , Raoult D","Correlation between body mass index and gut concentrations of Lactobacillus reuteri, Bifidobacterium animalis, Methanobrevibacter smithii and Escherichia coli",International journal of obesity (2005),2013,NA,Experiment 3,France,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,lean subjects,obese subjects,obese patients defined by BMI  (BMI>30 kg m−2),64,108,6 months,WMS,NA,RT-qPCR,Chi-Square,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:371/4/NA,Study 371,"cross-sectional observational, not case-control",23459324,10.1038/ijo.2013.20,NA,"Million M, Angelakis E, Maraninchi M, Henry M, Giorgi R, Valero R, Vialettes B , Raoult D","Correlation between body mass index and gut concentrations of Lactobacillus reuteri, Bifidobacterium animalis, Methanobrevibacter smithii and Escherichia coli",International journal of obesity (2005),2013,NA,Experiment 4,France,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,lean subjects,overweight subjects,patients who were overweight by BMI  (BMI>25 and <30 kg m−2),64,32,6 months,WMS,NA,RT-qPCR,Chi-Square,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:371/5/NA,Study 371,"cross-sectional observational, not case-control",23459324,10.1038/ijo.2013.20,NA,"Million M, Angelakis E, Maraninchi M, Henry M, Giorgi R, Valero R, Vialettes B , Raoult D","Correlation between body mass index and gut concentrations of Lactobacillus reuteri, Bifidobacterium animalis, Methanobrevibacter smithii and Escherichia coli",International journal of obesity (2005),2013,NA,Experiment 5,France,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,"anorexic, lean, and overweight subjects (species level)",obese subjects (species level),patients who were obese by BMI (BMI>30 kg m−2),111,108,6 months,WMS,NA,RT-qPCR,Chi-Square,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:371/6/NA,Study 371,"cross-sectional observational, not case-control",23459324,10.1038/ijo.2013.20,NA,"Million M, Angelakis E, Maraninchi M, Henry M, Giorgi R, Valero R, Vialettes B , Raoult D","Correlation between body mass index and gut concentrations of Lactobacillus reuteri, Bifidobacterium animalis, Methanobrevibacter smithii and Escherichia coli",International journal of obesity (2005),2013,NA,Experiment 6,France,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,lean and anorexic subjects,obese and overweight subjects,patients who were overweight or obese by BMI,79,140,6 months,WMS,NA,RT-qPCR,Chi-Square,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:372/1/NA,Study 372,laboratory experiment,31559135,10.1002/advs.201900972,NA,"Li X, Sun H, Li B, Zhang X, Cui J, Yun J, Yang Y, Zhang L, Meng Q, Wu S, Duan J, Yang H, Wu J, Sun Z, Zou Y , Chen R",Probiotics Ameliorate Colon Epithelial Injury Induced by Ambient Ultrafine Particles Exposure,"Advanced science (Weinheim, Baden-Wurttemberg, Germany)",2019,"Lactobacillus, air pollution, colonic epithelium, gut microbiota, ultrafine particles",Experiment 1,China,Mus musculus,Colon,UBERON:0001155,Air pollution,ENVO:02500037,mice exposed to FRA,Diesel exhaust particle (DEP) exposed mice,mice exposed to Diesel exhaust particles (DEP),30,37,NA,16S,34,Illumina,LEfSe,0.05,TRUE,4,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:373/1/NA,Study 373,case-control,29935270,10.1016/j.anaerobe.2018.06.009,NA,"Adamberg K, Adamberg S, Ernits K, Larionova A, Voor T, Jaagura M, Visnapuu T , Alamäe T","Composition and metabolism of fecal microbiota from normal and overweight children are differentially affected by melibiose, raffinose and raffinose-derived fructans",Anaerobe,2018,"Bacteroides, Candidate prebiotic, Dietary fiber, Fructooligosaccharides, Levan, Levansucrase, Short-chain fatty acids",Experiment 1,Estonia,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,normal weight children,overweight children,"overweight, but otherwise healthy children (7-12 years)",9,9,NA,16S,34,Illumina,T-Test,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:373/2/NA,Study 373,case-control,29935270,10.1016/j.anaerobe.2018.06.009,NA,"Adamberg K, Adamberg S, Ernits K, Larionova A, Voor T, Jaagura M, Visnapuu T , Alamäe T","Composition and metabolism of fecal microbiota from normal and overweight children are differentially affected by melibiose, raffinose and raffinose-derived fructans",Anaerobe,2018,"Bacteroides, Candidate prebiotic, Dietary fiber, Fructooligosaccharides, Levan, Levansucrase, Short-chain fatty acids",Experiment 2,Estonia,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,Adults,Overweight children,"overweight, but otherwise healthy children (7-12 years)",9,7,NA,16S,34,Illumina,T-Test,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:373/3/NA,Study 373,case-control,29935270,10.1016/j.anaerobe.2018.06.009,NA,"Adamberg K, Adamberg S, Ernits K, Larionova A, Voor T, Jaagura M, Visnapuu T , Alamäe T","Composition and metabolism of fecal microbiota from normal and overweight children are differentially affected by melibiose, raffinose and raffinose-derived fructans",Anaerobe,2018,"Bacteroides, Candidate prebiotic, Dietary fiber, Fructooligosaccharides, Levan, Levansucrase, Short-chain fatty acids",Experiment 3,Estonia,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,Adults,normal weight children,healthy children with normal weight (7-12 years),7,9,NA,16S,34,Illumina,T-Test,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:374/1/NA,Study 374,case-control,30841606,10.3390/cancers11030309,NA,"Kwon M, Seo SS, Kim MK, Lee DO , Lim MC",Compositional and Functional Differences between Microbiota and Cervical Carcinogenesis as Identified by Shotgun Metagenomic Sequencing,Cancers,2019,"cervical cancer, cervical intraepithelial neoplasia, microbiome, shotgun metagenomic sequencing",Experiment 1,South Korea,Homo sapiens,Uterine cervix,UBERON:0000002,Cervical glandular intraepithelial neoplasia,EFO:1000165,normal controls,cervical intraepithelial neoplasia cases,women with histology proven CIN2/3,18,17,NA,WMS,NA,Illumina,LEfSe,0.05,TRUE,2.5,NA,NA,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:374/2/NA,Study 374,case-control,30841606,10.3390/cancers11030309,NA,"Kwon M, Seo SS, Kim MK, Lee DO , Lim MC",Compositional and Functional Differences between Microbiota and Cervical Carcinogenesis as Identified by Shotgun Metagenomic Sequencing,Cancers,2019,"cervical cancer, cervical intraepithelial neoplasia, microbiome, shotgun metagenomic sequencing",Experiment 2,South Korea,Homo sapiens,Uterine cervix,UBERON:0000002,Cervical cancer,MONDO:0002974,normal control,cervical cancer,histology proven cervical cancer,18,12,NA,WMS,NA,Illumina,LEfSe,0.05,TRUE,2.5,NA,NA,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:375/1/NA,Study 375,"cross-sectional observational, not case-control",26745497,10.1159/000442479,NA,"Radilla-Vázquez RB, Parra-Rojas I, Martínez-Hernández NE, Márquez-Sandoval YF, Illades-Aguiar B , Castro-Alarcón N",Gut Microbiota and Metabolic Endotoxemia in Young Obese Mexican Subjects,Obesity facts,2016,NA,Experiment 1,Mexico,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,normal weight,obese,obese individuals (BMI >=30) both sexes aged between 18 to 25 years,32,32,4 weeks,WMS,NA,RT-qPCR,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:376/1/NA,Study 376,time series / longitudinal observational,24748167,10.1371/journal.pone.0095476,NA,"Panda S, El khader I, Casellas F, López Vivancos J, García Cors M, Santiago A, Cuenca S, Guarner F , Manichanh C",Short-term effect of antibiotics on human gut microbiota,PloS one,2014,NA,Experiment 1,Spain,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,before antibiotic exposure,patients that took amoxiclav,took amoxiclav for 7 days,7,7,2 months,16S,4,"RT-qPCR,Roche454",ANOVA,0.05,TRUE,NA,NA,NA,NA,NA,decreased,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:376/2/NA,Study 376,time series / longitudinal observational,24748167,10.1371/journal.pone.0095476,NA,"Panda S, El khader I, Casellas F, López Vivancos J, García Cors M, Santiago A, Cuenca S, Guarner F , Manichanh C",Short-term effect of antibiotics on human gut microbiota,PloS one,2014,NA,Experiment 2,Spain,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,before antibiotic exposure,patients that took levofloxacin,took levofloxacin for 7 days,8,8,2 months,16S,4,"RT-qPCR,Roche454",ANOVA,0.05,TRUE,NA,NA,NA,NA,NA,decreased,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:377/1/NA,Study 377,"cross-sectional observational, not case-control",32105635,10.1016/j.isci.2020.100884,NA,"Pushalkar S, Paul B, Li Q, Yang J, Vasconcelos R, Makwana S, González JM, Shah S, Xie C, Janal MN, Queiroz E, Bederoff M, Leinwand J, Solarewicz J, Xu F, Aboseria E, Guo Y, Aguallo D, Gomez C, Kamer A, Shelley D, Aphinyanaphongs Y, Barber C, Gordon T, Corby P, Li X , Saxena D",Electronic Cigarette Aerosol Modulates the Oral Microbiome and Increases Risk of Infection,iScience,2020,"In Vitro Toxicology, Microbiome, Oral Microbiology",Experiment 1,United States of America,Homo sapiens,Saliva,UBERON:0001836,Smoking behavior,EFO:0004318,non-smokers,e-cigarette smokers,"participants who were 21 years or older, healthy, diagnosed with periodontal disease, and current e-cigarette smokers",39,40,1 month,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:377/2/NA,Study 377,"cross-sectional observational, not case-control",32105635,10.1016/j.isci.2020.100884,NA,"Pushalkar S, Paul B, Li Q, Yang J, Vasconcelos R, Makwana S, González JM, Shah S, Xie C, Janal MN, Queiroz E, Bederoff M, Leinwand J, Solarewicz J, Xu F, Aboseria E, Guo Y, Aguallo D, Gomez C, Kamer A, Shelley D, Aphinyanaphongs Y, Barber C, Gordon T, Corby P, Li X , Saxena D",Electronic Cigarette Aerosol Modulates the Oral Microbiome and Increases Risk of Infection,iScience,2020,"In Vitro Toxicology, Microbiome, Oral Microbiology",Experiment 2,United States of America,Homo sapiens,Saliva,UBERON:0001836,Smoking behavior,EFO:0004318,never smokers,cigarette smokers,"participants who were 21 years or older, healthy, diagnosed with periodontal disease, and current smokers",39,40,1 month,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:377/3/NA,Study 377,"cross-sectional observational, not case-control",32105635,10.1016/j.isci.2020.100884,NA,"Pushalkar S, Paul B, Li Q, Yang J, Vasconcelos R, Makwana S, González JM, Shah S, Xie C, Janal MN, Queiroz E, Bederoff M, Leinwand J, Solarewicz J, Xu F, Aboseria E, Guo Y, Aguallo D, Gomez C, Kamer A, Shelley D, Aphinyanaphongs Y, Barber C, Gordon T, Corby P, Li X , Saxena D",Electronic Cigarette Aerosol Modulates the Oral Microbiome and Increases Risk of Infection,iScience,2020,"In Vitro Toxicology, Microbiome, Oral Microbiology",Experiment 3,United States of America,Homo sapiens,Saliva,UBERON:0001836,Smoking behavior,EFO:0004318,cigarette smoker,E-cigarette smoker,"participants who were 21 years or older, healthy, diagnosed with periodontal disease, and current e-cigarette users",40,40,1 month,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:378/1/NA,Study 378,case-control,32353108,10.1182/bloodadvances.2020001531,NA,"Payen M, Nicolis I, Robin M, Michonneau D, Delannoye J, Mayeur C, Kapel N, Berçot B, Butel MJ, Le Goff J, Socié G , Rousseau C",Functional and phylogenetic alterations in gut microbiome are linked to graft-versus-host disease severity,Blood advances,2020,NA,Experiment 1,France,Homo sapiens,Feces,UBERON:0001988,Graft versus host disease,MONDO:0013730,controls,Severe acute graft-versus-host-disease,patients who are diagnosed with severe gut acute graft- versus-host disease (between standard stage greater or equal to 2 and less than or equal to 4),35,35,NA,16S,34,Illumina,LEfSe,0.05,TRUE,4,NA,NA,NA,NA,decreased,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:378/2/NA,Study 378,case-control,32353108,10.1182/bloodadvances.2020001531,NA,"Payen M, Nicolis I, Robin M, Michonneau D, Delannoye J, Mayeur C, Kapel N, Berçot B, Butel MJ, Le Goff J, Socié G , Rousseau C",Functional and phylogenetic alterations in gut microbiome are linked to graft-versus-host disease severity,Blood advances,2020,NA,Experiment 2,France,Homo sapiens,Feces,UBERON:0001988,Graft versus host disease,MONDO:0013730,controls,Severe acute graft-versus-host-disease,patients who are diagnosed with severe gut acute graft- versus-host disease (between standard stage greater or equal to 2 and less than or equal to 3),35,35,NA,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,decreased,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:379/1/NA,Study 379,prospective cohort,31489128,10.1080/20002297.2019.1650597,NA,"Yang Y, Cai Q, Zheng W, Steinwandel M, Blot WJ, Shu XO , Long J",Oral microbiome and obesity in a large study of low-income and African-American populations,Journal of oral microbiology,2019,"16S rRNA gene sequencing; Southern Community Cohort Study; Probiotic taxa, Oral microbiome, obesity",Experiment 1,United States of America,Homo sapiens,Mouth,UBERON:0000165,Obesity,EFO:0001073,obese,non-obese,"participants who were selected for four nested case-control studies to investigate the oral microbiome and those diagnosed after mouth rinse sample colection with type 2 diabetes, lung cancer, upper aero-digestive tract cancer, and colorectal cancer",647,969,1 year,16S,4,Illumina,Logistic Regression,0.05,TRUE,NA,"age,race,sex,smoking status","age,alcohol drinking,number of teeth measurement,race,sex,smoking behavior",NA,unchanged,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:379/2/NA,Study 379,prospective cohort,31489128,10.1080/20002297.2019.1650597,NA,"Yang Y, Cai Q, Zheng W, Steinwandel M, Blot WJ, Shu XO , Long J",Oral microbiome and obesity in a large study of low-income and African-American populations,Journal of oral microbiology,2019,"16S rRNA gene sequencing; Southern Community Cohort Study; Probiotic taxa, Oral microbiome, obesity",Experiment 2,United States of America,Homo sapiens,Mouth,UBERON:0000165,Obesity,EFO:0001073,non-obese,obese,"participants who were selected for four nested case-control studies to investigate the oral microbiome and those diagnosed after mouth rinse sample colection with type 2 diabetes, lung cancer, upper aero-digestive tract cancer, and colorectal cancer",969,647,1 year,16S,4,Illumina,Logistic Regression,0.05,TRUE,NA,"age,race,sex,smoking behavior","age,alcohol drinking,number of teeth measurement,race,sex,smoking behavior",NA,unchanged,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:380/1/NA,Study 380,time series / longitudinal observational,29592876,10.1182/bloodadvances.2018017731,NA,"DeFilipp Z, Peled JU, Li S, Mahabamunuge J, Dagher Z, Slingerland AE, Del Rio C, Valles B, Kempner ME, Smith M, Brown J, Dey BR, El-Jawahri A, McAfee SL, Spitzer TR, Ballen KK, Sung AD, Dalton TE, Messina JA, Dettmer K, Liebisch G, Oefner P, Taur Y, Pamer EG, Holler E, Mansour MK, van den Brink MRM, Hohmann E, Jenq RR , Chen YB",Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity,Blood advances,2018,NA,Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Response to allogeneic hematopoietic stem cell transplant,EFO:0007044,patients post allogenic hematopoietic cell transplant/pre Fecal Microbiota Transplant,patients preallogenic hematopoietic cell transplant,patients who received Fecal Microbiome Transplant,5,13,48 hours,16S,45,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,age,"HLA match,acute graft vs. host disease,age,history of GI,transplant conditioning",NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:380/2/NA,Study 380,time series / longitudinal observational,29592876,10.1182/bloodadvances.2018017731,NA,"DeFilipp Z, Peled JU, Li S, Mahabamunuge J, Dagher Z, Slingerland AE, Del Rio C, Valles B, Kempner ME, Smith M, Brown J, Dey BR, El-Jawahri A, McAfee SL, Spitzer TR, Ballen KK, Sung AD, Dalton TE, Messina JA, Dettmer K, Liebisch G, Oefner P, Taur Y, Pamer EG, Holler E, Mansour MK, van den Brink MRM, Hohmann E, Jenq RR , Chen YB",Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity,Blood advances,2018,NA,Experiment 2,United States of America,Homo sapiens,Feces,UBERON:0001988,Response to allogeneic hematopoietic stem cell transplant,EFO:0007044,post fecal mircobiota day 180,post allogenic hematopoietic cell transplant/ pre Fecal microbiota transplant,patients who received Fecal Microbiome Transplant,5,13,48 hours,16S,45,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,age,"HLA match,acute graft vs. host disease,age,history of GI,transplant conditioning",NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:380/3/NA,Study 380,time series / longitudinal observational,29592876,10.1182/bloodadvances.2018017731,NA,"DeFilipp Z, Peled JU, Li S, Mahabamunuge J, Dagher Z, Slingerland AE, Del Rio C, Valles B, Kempner ME, Smith M, Brown J, Dey BR, El-Jawahri A, McAfee SL, Spitzer TR, Ballen KK, Sung AD, Dalton TE, Messina JA, Dettmer K, Liebisch G, Oefner P, Taur Y, Pamer EG, Holler E, Mansour MK, van den Brink MRM, Hohmann E, Jenq RR , Chen YB",Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity,Blood advances,2018,NA,Experiment 3,United States of America,Homo sapiens,Feces,UBERON:0001988,Response to allogeneic hematopoietic stem cell transplant,EFO:0007044,post fecal mircobiota day 7,post allogenic hematopoietic cell transplant/ pre Fecal microbiota transplant,patients who received Fecal Microbiome Transplant,5,13,48 hours,16S,45,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,age,"HLA match,acute graft vs. host disease,age,history of GI,transplant conditioning",NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:380/4/NA,Study 380,time series / longitudinal observational,29592876,10.1182/bloodadvances.2018017731,NA,"DeFilipp Z, Peled JU, Li S, Mahabamunuge J, Dagher Z, Slingerland AE, Del Rio C, Valles B, Kempner ME, Smith M, Brown J, Dey BR, El-Jawahri A, McAfee SL, Spitzer TR, Ballen KK, Sung AD, Dalton TE, Messina JA, Dettmer K, Liebisch G, Oefner P, Taur Y, Pamer EG, Holler E, Mansour MK, van den Brink MRM, Hohmann E, Jenq RR , Chen YB",Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity,Blood advances,2018,NA,Experiment 4,United States of America,Homo sapiens,Feces,UBERON:0001988,Response to allogeneic hematopoietic stem cell transplant,EFO:0007044,post fecal mircobiota day 30,post allogenic hematopoietic cell transplant/ pre Fecal microbiota transplant,patients who received Fecal Microbiome Transplant,5,13,48 hours,16S,45,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,age,"HLA match,acute graft vs. host disease,age,history of GI,transplant conditioning",NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:381/1/NA,Study 381,time series / longitudinal observational,31065565,10.1093/ofid/ofz173,NA,"Galloway-Peña JR, Peterson CB, Malik F, Sahasrabhojane PV, Shah DP, Brumlow CE, Carlin LG, Chemaly RF, Im JS, Rondon G, Felix E, Veillon L, Lorenzi PL, Alousi AM, Jenq RR, Kontoyiannis DP, Shpall EJ, Shelburne SA , Okhuysen PC","Fecal Microbiome, Metabolites, and Stem Cell Transplant Outcomes: A Single-Center Pilot Study",Open forum infectious diseases,2019,"butyrate, graft-vs-host disease (GVHD), hematopoietic stem cell transplant (HSCT), indole, microbiome",Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Response to allogeneic hematopoietic stem cell transplant,EFO:0007044,healthy volunteers,hematopoietic stem cell transplant recipients,patients undergoing T cell repleted allogeneic hematopoietic stem cell transplantation,18,50,NA,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,decreased,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:381/2/NA,Study 381,time series / longitudinal observational,31065565,10.1093/ofid/ofz173,NA,"Galloway-Peña JR, Peterson CB, Malik F, Sahasrabhojane PV, Shah DP, Brumlow CE, Carlin LG, Chemaly RF, Im JS, Rondon G, Felix E, Veillon L, Lorenzi PL, Alousi AM, Jenq RR, Kontoyiannis DP, Shpall EJ, Shelburne SA , Okhuysen PC","Fecal Microbiome, Metabolites, and Stem Cell Transplant Outcomes: A Single-Center Pilot Study",Open forum infectious diseases,2019,"butyrate, graft-vs-host disease (GVHD), hematopoietic stem cell transplant (HSCT), indole, microbiome",Experiment 2,United States of America,Homo sapiens,Feces,UBERON:0001988,Response to allogeneic hematopoietic stem cell transplant,EFO:0007044,low fecal butyrate levels,high fecal butyrate levels,patients undergoing T cell repleted allogeneic hematopoietic stem cell transplantation,50,50,NA,16S,4,Illumina,LEfSe,0.05,FALSE,4,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:382/1/NA,Study 382,"cross-sectional observational, not case-control",29313867,NA,NA,"Di Pietro M, Filardo S, Porpora MG, Recine N, Latino MA , Sessa R",HPV/Chlamydia trachomatis co-infection: metagenomic analysis of cervical microbiota in asymptomatic women,The new microbiologica,2018,"Cervical microbiota, Chlamydia trachomatis, Coinfection, HPV, Metagenomic analysis",Experiment 1,Italy,Homo sapiens,Endocervix,UBERON:0000458,Chlamydia trachomatis infectious disease,EFO:0007205,healthy control,patient with chlamydia infection,patient with Chlamydia infection,7,7,Current,16S,34,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:382/2/NA,Study 382,"cross-sectional observational, not case-control",29313867,NA,NA,"Di Pietro M, Filardo S, Porpora MG, Recine N, Latino MA , Sessa R",HPV/Chlamydia trachomatis co-infection: metagenomic analysis of cervical microbiota in asymptomatic women,The new microbiologica,2018,"Cervical microbiota, Chlamydia trachomatis, Coinfection, HPV, Metagenomic analysis",Experiment 2,Italy,Homo sapiens,Endocervix,UBERON:0000458,"Chlamydophila infectious disease,Human papilloma virus infection","EFO:0001668,EFO:1000863",HPV positive women,patient with chlamydia infection,patient with Chlamydia infection,7,8,Current,16S,34,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:383/1/NA,Study 383,prospective cohort,28632934,10.1111/all.13232,NA,"Savage JH, Lee-Sarwar KA, Sordillo J, Bunyavanich S, Zhou Y, O'Connor G, Sandel M, Bacharier LB, Zeiger R, Sodergren E, Weinstock GM, Gold DR, Weiss ST , Litonjua AA",A prospective microbiome-wide association study of food sensitization and food allergy in early childhood,Allergy,2018,"Dorea, food allergy, food sensitization, microbiome",Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Food allergy,EFO:1001890,no food sensitization,child with food sensitization,"child with serum-specific IgE to milk, egg, peanut, soy, wheat, and walnut greater than 0.35 kU/L at age 3",131,85,1 week,16S,345,Roche454,Negative Binomial Regression,0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:383/2/NA,Study 383,prospective cohort,28632934,10.1111/all.13232,NA,"Savage JH, Lee-Sarwar KA, Sordillo J, Bunyavanich S, Zhou Y, O'Connor G, Sandel M, Bacharier LB, Zeiger R, Sodergren E, Weinstock GM, Gold DR, Weiss ST , Litonjua AA",A prospective microbiome-wide association study of food sensitization and food allergy in early childhood,Allergy,2018,"Dorea, food allergy, food sensitization, microbiome",Experiment 2,United States of America,Homo sapiens,Feces,UBERON:0001988,Food allergy,EFO:1001890,no food allergy,child with food allergy,"child with healthcare provider-diagnosed allergy to milk, egg, peanut, wheat, soy, or other nut allergy prior to age 3 years with evidence of IgE sensitization to that food (>0.1 kU/L) at age 3 years",202,14,1 week,16S,345,Roche454,Negative Binomial Regression,0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:384/1/NA,Study 384,case-control,32065949,10.1016/j.jpsychires.2020.02.005,NA,"Ma X, Asif H, Dai L, He Y, Zheng W, Wang D, Ren H, Tang J, Li C, Jin K, Li Z , Chen X",Alteration of the gut microbiome in first-episode drug-naïve and chronic medicated schizophrenia correlate with regional brain volumes,Journal of psychiatric research,2020,"Brain, Gut microbiome, Schizophrenia, Structural MRI",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Schizophrenia,MONDO:0005090,healthy controls,FSCZ,first-episode drug naive schizophrenia (FSCZ) diagnosed according to the DSM IV criteria and PANSS having illness duration <=12 months and no treatment with antipsychotic medications before,69,40,1 month,16S,4,Illumina,DESeq2,0.05,TRUE,NA,demographics,NA,NA,unchanged,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:384/2/NA,Study 384,case-control,32065949,10.1016/j.jpsychires.2020.02.005,NA,"Ma X, Asif H, Dai L, He Y, Zheng W, Wang D, Ren H, Tang J, Li C, Jin K, Li Z , Chen X",Alteration of the gut microbiome in first-episode drug-naïve and chronic medicated schizophrenia correlate with regional brain volumes,Journal of psychiatric research,2020,"Brain, Gut microbiome, Schizophrenia, Structural MRI",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Schizophrenia,MONDO:0005090,healthy controls,TSCZ,"first-episode drug naive schizophrenia(FSCZ) diagnosed according to the DSM IV criteria and PANSS having illness duration <=12 months and no treatment with antipsycotic medications before, anti-psycotic treated schizophrenia (TSCZ) having illness duration >12 months and received antipsychotic treatment for at least past 3 months",69,85,1 month,16S,4,Illumina,DESeq2,0.05,TRUE,NA,demographics,NA,NA,decreased,decreased,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:384/3/NA,Study 384,case-control,32065949,10.1016/j.jpsychires.2020.02.005,NA,"Ma X, Asif H, Dai L, He Y, Zheng W, Wang D, Ren H, Tang J, Li C, Jin K, Li Z , Chen X",Alteration of the gut microbiome in first-episode drug-naïve and chronic medicated schizophrenia correlate with regional brain volumes,Journal of psychiatric research,2020,"Brain, Gut microbiome, Schizophrenia, Structural MRI",Experiment 3,China,Homo sapiens,Feces,UBERON:0001988,Schizophrenia,MONDO:0005090,FSCZ,TSCZ,"first-episode drug naive schizophrenia(FSCZ) diagnosed according to the DSM IV criteria and PANSS having illness duration <=12 months and no treatment with antipsycotic medications before, anti-psycotic treated schizophrenia (TSCZ) having illness duration >12 months and received antipsychotic treatment for at least past 3 months",40,85,1 month,16S,4,Illumina,DESeq2,0.05,TRUE,NA,demographics,NA,NA,decreased,decreased,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:385/1/NA,Study 385,case-control,30619779,10.3389/fcimb.2018.00433,NA,"Hu YL, Pang W, Huang Y, Zhang Y , Zhang CJ",The Gastric Microbiome Is Perturbed in Advanced Gastric Adenocarcinoma Identified Through Shotgun Metagenomics,Frontiers in cellular and infection microbiology,2018,"gastric adenocarcinoma, human, inflammation, microbiome, shotgun metagenomics",Experiment 1,China,Homo sapiens,Stomach,UBERON:0000945,Gastric adenocarcinoma,EFO:0000503,Superficial gastritis (SG),Gastric adenocarcinoma (GC),SG patients with mild to moderate epigastric discomfort. The disgnosis of malignancy was based on patological analysis of tissue biopsies,5,6,Use of antibiotics within 6 months,WMS,NA,Illumina,LEfSe,0.05,TRUE,2,"age,body mass index,sex",NA,NA,unchanged,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:386/1/NA,Study 386,case-control,31001490,10.3389/fcimb.2019.00090,NA,"Hu Y, Feng Y, Wu J, Liu F, Zhang Z, Hao Y, Liang S, Li B, Li J, Lv N, Xu Y, Zhu B , Sun Z",The Gut Microbiome Signatures Discriminate Healthy From Pulmonary Tuberculosis Patients,Frontiers in cellular and infection microbiology,2019,"human gut microbiota, metabolic potential, metagenomic sequencing, microbial diversity, tuberculosis",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Pulmonary tuberculosis,EFO:1000049,healthy controls,Tuberculosis (TB) patients,"patients diagnosed with TB by assessing symptoms, including the results of acid-fast bacilli (AFB) smear microscopy, culture, the T-SPOT.TB test and a chest radiograph.",31,30,NA,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,decreased,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:387/1/NA,Study 387,randomized controlled trial,25922405,10.1093/cid/civ137,NA,"Rashid MU, Zaura E, Buijs MJ, Keijser BJ, Crielaard W, Nord CE , Weintraub A",Determining the Long-term Effect of Antibiotic Administration on the Human Normal Intestinal Microbiota Using Culture and Pyrosequencing Methods,Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,2015,"antibiotics, culture, intestinal microbiota, pyrosequencing",Experiment 1,Sweden,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,before ciprofloxacin exposure,after ciprofloxacin exposure,"""healthy"" adults between the ages of 18-45 years old with normal medical histories and physical examinations who were given ciprofloxacin",9,9,3 months,16S,567,Roche454,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:387/2/NA,Study 387,randomized controlled trial,25922405,10.1093/cid/civ137,NA,"Rashid MU, Zaura E, Buijs MJ, Keijser BJ, Crielaard W, Nord CE , Weintraub A",Determining the Long-term Effect of Antibiotic Administration on the Human Normal Intestinal Microbiota Using Culture and Pyrosequencing Methods,Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,2015,"antibiotics, culture, intestinal microbiota, pyrosequencing",Experiment 2,Sweden,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,Before clindamycin exposure,after clindamycin exposure,"""healthy"" adults between the ages of 18-45 years old with normal medical histories and physical examinations who were exporsed to clindamycin",9,9,3 months,16S,567,Roche454,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:388/1/NA,Study 388,"cross-sectional observational, not case-control",32753953,10.2147/CMAR.S251021,NA,"Zhou J, Wang L, Yuan R, Yu X, Chen Z, Yang F, Sun G , Dong Q",Signatures of Mucosal Microbiome in Oral Squamous Cell Carcinoma Identified Using a Random Forest Model,Cancer management and research,2020,"microbiome, oral squamous cell carcinoma, predicted functions, random forest machine learning",Experiment 1,China,Homo sapiens,Mucosa of oral region,UBERON:0003343,Oral squamous cell carcinoma,EFO:0000199,paracancerous tissues,cancerous  lesions,patients at different stages of OSCC were enrolled in the study,24,24,2 weeks,16S,34,Illumina,LEfSe,0.05,TRUE,3,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:389/1/NA,Study 389,"cross-sectional observational, not case-control",32334937,10.1016/j.schres.2020.03.010,NA,"Yolken R, Prandovszky E, Severance EG, Hatfield G , Dickerson F",The oropharyngeal microbiome is altered in individuals with schizophrenia and mania,Schizophrenia research,2020,"Depression, Immunity, Mania, Microbiome, Schizophrenia",Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Schizophrenia,MONDO:0005090,healthy controls,schizophrenia,"patients met DSM-IV criteria for schizophrenia, mania participants with symptoms of mania or hypermania could have diagnosis of Bipolar I disorder, single manic episode, most recent episode, mixed Bipolar II episode, most recent episode mixed,or Schizoaffective disorder., bipolar type (manic, hypomanic or mixed state)",85,121,NA,16S,34,Illumina,Wald Test,0.05,TRUE,NA,NA,"age,body mass index,race,sex,smoking behavior",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:389/2/NA,Study 389,"cross-sectional observational, not case-control",32334937,10.1016/j.schres.2020.03.010,NA,"Yolken R, Prandovszky E, Severance EG, Hatfield G , Dickerson F",The oropharyngeal microbiome is altered in individuals with schizophrenia and mania,Schizophrenia research,2020,"Depression, Immunity, Mania, Microbiome, Schizophrenia",Experiment 2,United States of America,Homo sapiens,Feces,UBERON:0001988,Schizophrenia,MONDO:0005090,healthy controls,mania,"patients met DSM-IV criteria for schizophrenia, mania participants with symptoms of mania or hypermania could have diagnosis of Bipolar I disorder, single manic episode, most recent episode, mixed Bipolar II episode, most recent episode mixed,or Schizoaffective disorder., bipolar type (manic, hypomanic or mixed state)",85,62,NA,16S,34,Illumina,Wald Test,0.05,TRUE,NA,NA,"age,body mass index,race,sex,smoking behavior",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:390/1/NA,Study 390,case-control,32763534,10.1016/j.psychres.2020.113260,NA,"Pan R, Zhang X, Gao J, Yi W, Wei Q , Su H",Analysis of the diversity of intestinal microbiome and its potential value as a biomarker in patients with schizophrenia: A cohort study,Psychiatry research,2020,"16S function prediction, 16S rRNA sequencing, Gut microbiome, Random forest, Schizophrenia",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Schizophrenia,MONDO:0005090,healthy controls,acute schizphrenia,"patients who complied with diagnostic criteria for SCZ in the Diagnostic and Statistical Manual of Mental DIsorders Fourth Edition, Positive and negative syndrome scale, PANSS<60; No change in antipsychotic regimen (within two weeks)",29,29,2 weeks,16S,34,Illumina,LEfSe,0.05,FALSE,2,"age,body mass index,sex",NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:390/2/NA,Study 390,case-control,32763534,10.1016/j.psychres.2020.113260,NA,"Pan R, Zhang X, Gao J, Yi W, Wei Q , Su H",Analysis of the diversity of intestinal microbiome and its potential value as a biomarker in patients with schizophrenia: A cohort study,Psychiatry research,2020,"16S function prediction, 16S rRNA sequencing, Gut microbiome, Random forest, Schizophrenia",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Schizophrenia,MONDO:0005090,healthy controls,scizophrenia during remission,"patients who complied with diagnostic criteria for SCZ in the Diagnostic and Statistical Manual of Mental DIsorders Fourth Edition, Positive and negative syndrome scale, PANSS<60; No change in antipsychotic regimen (within two weeks)",29,29,2 weeks,16S,34,Illumina,LEfSe,0.05,FALSE,2,"age,body mass index,sex",NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:390/3/NA,Study 390,case-control,32763534,10.1016/j.psychres.2020.113260,NA,"Pan R, Zhang X, Gao J, Yi W, Wei Q , Su H",Analysis of the diversity of intestinal microbiome and its potential value as a biomarker in patients with schizophrenia: A cohort study,Psychiatry research,2020,"16S function prediction, 16S rRNA sequencing, Gut microbiome, Random forest, Schizophrenia",Experiment 3,China,Homo sapiens,Feces,UBERON:0001988,Schizophrenia,MONDO:0005090,symptomatic remission,acute schizphrenia,"patients who complied with diagnostic criteria for SCZ in the Diagnostic and Statistical Manual of Mental DIsorders Fourth Edition, Positive and negative syndrome scale, PANSS<60; No change in antipsychotic regimen (within two weeks)",29,29,4 weeks,16S,34,Illumina,LEfSe,0.05,FALSE,2,"age,body mass index,sex",NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:391/1/NA,Study 391,"cross-sectional observational, not case-control",31841737,10.1016/j.jneuroim.2019.577126,NA,"Shi Z, Qiu Y, Wang J, Fang Y, Zhang Y, Chen H, Du Q, Zhao Z, Yan C, Yang M , Zhou H",Dysbiosis of gut microbiota in patients with neuromyelitis optica spectrum disorders: A cross sectional study,Journal of neuroimmunology,2020,NA,Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Neuromyelitis optica,EFO:0004256,healthy controls,neuromyelitis optica spectrum disorder,Each patient met the 2015 international diagnostic criteria for NMOSD and tested positive for serum AQP4-IgG using cell-based assays,20,20,currently taking antibiotics,16S,34,Illumina,LEfSe,0.05,TRUE,3,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:392/1/NA,Study 392,"cross-sectional observational, not case-control",30131575,10.1038/s41598-018-30428-3,NA,"Berni Canani R, De Filippis F, Nocerino R, Paparo L, Di Scala C, Cosenza L, Della Gatta G, Calignano A, De Caro C, Laiola M, Gilbert JA , Ercolini D",Gut microbiota composition and butyrate production in children affected by non-IgE-mediated cow's milk allergy,Scientific reports,2018,NA,Experiment 1,Italy,Homo sapiens,Feces,UBERON:0001988,Milk allergic reaction,EFO:0007369,healthy controls,non-IgE mediated cow's milk allergy,"children aged 1-26 months with a diagnosis of non-IgE mediated cow's milk allergy based on clinical history, negative result of skin prick test, and/or negative level of IgE serum-specific anti-cow's milk proteins",23,23,4 weeks,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:392/2/NA,Study 392,"cross-sectional observational, not case-control",30131575,10.1038/s41598-018-30428-3,NA,"Berni Canani R, De Filippis F, Nocerino R, Paparo L, Di Scala C, Cosenza L, Della Gatta G, Calignano A, De Caro C, Laiola M, Gilbert JA , Ercolini D",Gut microbiota composition and butyrate production in children affected by non-IgE-mediated cow's milk allergy,Scientific reports,2018,NA,Experiment 2,Italy,Homo sapiens,Feces,UBERON:0001988,Milk allergic reaction,EFO:0007369,infant with non-IgE-mediated cow's milk allergy at diagnosis,infant with non-IgE-mediated cow's milk allergy treated with EHCF,infant with non-IgE mediated cow's milk allergy treated with EHCF,23,9,4 weeks,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:392/3/NA,Study 392,"cross-sectional observational, not case-control",30131575,10.1038/s41598-018-30428-3,NA,"Berni Canani R, De Filippis F, Nocerino R, Paparo L, Di Scala C, Cosenza L, Della Gatta G, Calignano A, De Caro C, Laiola M, Gilbert JA , Ercolini D",Gut microbiota composition and butyrate production in children affected by non-IgE-mediated cow's milk allergy,Scientific reports,2018,NA,Experiment 3,Italy,Homo sapiens,Feces,UBERON:0001988,Milk allergic reaction,EFO:0007369,infant with non-IgE-mediated cow's milk allergy at diagnosis,infant with non-IgE-mediated cow's milk allergy treated with EHCF+LGG,infant with non-IgE mediated cow's milk allergy treated with EHCF+LGG,23,14,4 weeks,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:392/4/NA,Study 392,"cross-sectional observational, not case-control",30131575,10.1038/s41598-018-30428-3,NA,"Berni Canani R, De Filippis F, Nocerino R, Paparo L, Di Scala C, Cosenza L, Della Gatta G, Calignano A, De Caro C, Laiola M, Gilbert JA , Ercolini D",Gut microbiota composition and butyrate production in children affected by non-IgE-mediated cow's milk allergy,Scientific reports,2018,NA,Experiment 4,Italy,Homo sapiens,Feces,UBERON:0001988,Milk allergic reaction,EFO:0007369,infant with non-IgE-mediated cow's milk allergy treated with EHCF,infant with non-IgE-mediated cow's milk allergy treated with EHCF+LGG,infant with non-IgE mediated cow's milk allergy treated with EHCF+LGG,9,14,4 weeks,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:393/1/NA,Study 393,prospective cohort,30314304,10.3390/nu10101481,NA,"Díaz M, Guadamuro L, Espinosa-Martos I, Mancabelli L, Jiménez S, Molinos-Norniella C, Pérez-Solis D, Milani C, Rodríguez JM, Ventura M, Bousoño C, Gueimonde M, Margolles A, Díaz JJ , Delgado S",Microbiota and Derived Parameters in Fecal Samples of Infants with Non-IgE Cow's Milk Protein Allergy under a Restricted Diet,Nutrients,2018,"cow’s milk protein, fecal microbiota, non-IgE mediated allergy, protein hydrolyzed formulas, tolerance acquisition",Experiment 1,Spain,Homo sapiens,Feces,UBERON:0001988,Milk allergic reaction,EFO:0007369,infant with non-IgE-mediated cow's milk allergy non-tolerant to cow's milk protein,infant with non-IgE-mediated cow's milk allergy tolerant to cow's milk protein,infant with non-IgE mediated cow's milk allergy tolerant to cow's milk after a period of six months dairy-free diet,3,14,4 weeks,16S,34,Illumina,Metastats,0.05,TRUE,NA,age,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:393/2/NA,Study 393,prospective cohort,30314304,10.3390/nu10101481,NA,"Díaz M, Guadamuro L, Espinosa-Martos I, Mancabelli L, Jiménez S, Molinos-Norniella C, Pérez-Solis D, Milani C, Rodríguez JM, Ventura M, Bousoño C, Gueimonde M, Margolles A, Díaz JJ , Delgado S",Microbiota and Derived Parameters in Fecal Samples of Infants with Non-IgE Cow's Milk Protein Allergy under a Restricted Diet,Nutrients,2018,"cow’s milk protein, fecal microbiota, non-IgE mediated allergy, protein hydrolyzed formulas, tolerance acquisition",Experiment 2,Spain,Homo sapiens,Feces,UBERON:0001988,Milk allergic reaction,EFO:0007369,healthy control,infant with non-IgE-mediated cow's milk allergy,"infant with cow's milk protein allergy confirmed by a negative skin prick test, values lower than 0.35 kU/L cow’s milk-specific IgE determined in their blood, and a clear positive standardized oral challenge (SOC), performed under medical supervision",10,17,4 weeks,16S,34,Illumina,Metastats,0.05,TRUE,NA,age,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:394/1/NA,Study 394,prospective cohort,31676759,10.1038/s41467-019-12989-7,NA,"Thorsen J, Rasmussen MA, Waage J, Mortensen M, Brejnrod A, Bønnelykke K, Chawes BL, Brix S, Sørensen SJ, Stokholm J , Bisgaard H",Infant airway microbiota and topical immune perturbations in the origins of childhood asthma,Nature communications,2019,NA,Experiment 1,Denmark,Homo sapiens,Hypopharynx,UBERON:0001051,Asthma,MONDO:0004979,healthy control,child with asthma at age 6,"asthma at age 6 years diagnosed using a pre-defined validated quantitative symptom algorithm based on parental registration of troublesome lung symptoms on structured daily diary cards from birth, verified by study pediatricians at each clinic visit",438,135,NA,16S,4,Illumina,Cox Proportional-Hazards Regression,0.05,TRUE,NA,NA,NA,NA,increased,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:395/1/NA,Study 395,"cross-sectional observational, not case-control",27640125,10.1186/s40168-016-0195-9,NA,"Crespo-Salgado J, Vehaskari VM, Stewart T, Ferris M, Zhang Q, Wang G, Blanchard EE, Taylor CM, Kallash M, Greenbaum LA , Aviles DH",Intestinal microbiota in pediatric patients with end stage renal disease: a Midwest Pediatric Nephrology Consortium study,Microbiome,2016,"Children, End-stage renal disease, Inflammation, Intestinal microbiota, Pyrosequencing, Uremic toxins",Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,"Chronic kidney disease,Stage 5 chronic kidney disease","EFO:0003884,EFO:0009909",healthy controls,peritoneal dialysis,"4 groups of pediatric patients (age 2-18), hemodialysis, peritoneal dialysis, kidney transplant, healthy controls",13,8,1 month,16S,34,Illumina,Kruskall-Wallis,0.05,TRUE,NA,age,NA,NA,NA,decreased,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:395/2/NA,Study 395,"cross-sectional observational, not case-control",27640125,10.1186/s40168-016-0195-9,NA,"Crespo-Salgado J, Vehaskari VM, Stewart T, Ferris M, Zhang Q, Wang G, Blanchard EE, Taylor CM, Kallash M, Greenbaum LA , Aviles DH",Intestinal microbiota in pediatric patients with end stage renal disease: a Midwest Pediatric Nephrology Consortium study,Microbiome,2016,"Children, End-stage renal disease, Inflammation, Intestinal microbiota, Pyrosequencing, Uremic toxins",Experiment 2,United States of America,Homo sapiens,Feces,UBERON:0001988,"Chronic kidney disease,Stage 5 chronic kidney disease","EFO:0003884,EFO:0009909",healthy controls,hemodialysis,"4 groups of pediatric patients (age 2-18), hemodialysis, peritoneal dialysis, kidney transplant, healthy controls",13,8,1 month,16S,34,Illumina,Kruskall-Wallis,0.05,TRUE,NA,age,NA,NA,NA,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:395/3/NA,Study 395,"cross-sectional observational, not case-control",27640125,10.1186/s40168-016-0195-9,NA,"Crespo-Salgado J, Vehaskari VM, Stewart T, Ferris M, Zhang Q, Wang G, Blanchard EE, Taylor CM, Kallash M, Greenbaum LA , Aviles DH",Intestinal microbiota in pediatric patients with end stage renal disease: a Midwest Pediatric Nephrology Consortium study,Microbiome,2016,"Children, End-stage renal disease, Inflammation, Intestinal microbiota, Pyrosequencing, Uremic toxins",Experiment 3,United States of America,Homo sapiens,Feces,UBERON:0001988,"Chronic kidney disease,Stage 5 chronic kidney disease","EFO:0003884,EFO:0009909",peritoneal dialysis,hemodialysis,"4 groups of pediatric patients (age 2-18), hemodialysis, peritoneal dialysis, kidney transplant, healthy controls",8,8,1 month,16S,34,Illumina,Kruskall-Wallis,0.05,TRUE,NA,age,NA,NA,NA,increased,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:396/1/NA,Study 396,randomized controlled trial,27543211,10.1016/j.jaad.2016.04.066,NA,"Gonzalez ME, Schaffer JV, Orlow SJ, Gao Z, Li H, Alekseyenko AV , Blaser MJ",Cutaneous microbiome effects of fluticasone propionate cream and adjunctive bleach baths in childhood atopic dermatitis,Journal of the American Academy of Dermatology,2016,"16S sequencing, Staphylococcus aureus, atopic dermatitis, bleach baths, cutaneous microbiome, quantitative polymerase chain reaction, topical corticosteroids",Experiment 1,United States of America,Homo sapiens,Skin of body,UBERON:0002097,Atopic eczema,EFO:0000274,healthy control,atopic dermatitis,child between the age of 3 months-5 years with moderate to severe atopic dermatitis defined as an investigator’s global assessment (IGA) score of 3 or 4 (0–4 scale),11,21,2 weeks,16S,4,Illumina,Kruskall-Wallis,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:396/2/NA,Study 396,randomized controlled trial,27543211,10.1016/j.jaad.2016.04.066,NA,"Gonzalez ME, Schaffer JV, Orlow SJ, Gao Z, Li H, Alekseyenko AV , Blaser MJ",Cutaneous microbiome effects of fluticasone propionate cream and adjunctive bleach baths in childhood atopic dermatitis,Journal of the American Academy of Dermatology,2016,"16S sequencing, Staphylococcus aureus, atopic dermatitis, bleach baths, cutaneous microbiome, quantitative polymerase chain reaction, topical corticosteroids",Experiment 2,United States of America,Homo sapiens,Skin of body,UBERON:0002097,Atopic eczema,EFO:0000274,baseline,atopic dermatitis after treatment with TCS + Bleach,child with moderate to severe atopic dermatitis after treatment with TCS + bleach,9,9,2 weeks,16S,4,Illumina,Kruskall-Wallis,0.05,TRUE,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:396/3/NA,Study 396,randomized controlled trial,27543211,10.1016/j.jaad.2016.04.066,NA,"Gonzalez ME, Schaffer JV, Orlow SJ, Gao Z, Li H, Alekseyenko AV , Blaser MJ",Cutaneous microbiome effects of fluticasone propionate cream and adjunctive bleach baths in childhood atopic dermatitis,Journal of the American Academy of Dermatology,2016,"16S sequencing, Staphylococcus aureus, atopic dermatitis, bleach baths, cutaneous microbiome, quantitative polymerase chain reaction, topical corticosteroids",Experiment 3,United States of America,Homo sapiens,Skin of body,UBERON:0002097,Atopic eczema,EFO:0000274,baseline,atopic dermatitis after treatment with TCS only,child with moderate to severe atopic dermatitis after treatment with TCS only,9,9,2 weeks,16S,4,Illumina,Kruskall-Wallis,0.05,TRUE,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:397/1/NA,Study 397,case-control,31152265,10.1007/s10096-019-03598-9,NA,"Zheng Y, Wang Q, Ma L, Chen Y, Gao Y, Zhang G, Cui S, Liang H, He C , Song L",Alterations in the skin microbiome are associated with disease severity and treatment in the perioral zone of the skin of infants with atopic dermatitis,European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,2019,"Atopic dermatitis, Bacterial diversity, Perioral skin, Prevotella melaninogenica",Experiment 1,China,Homo sapiens,Skin of body,UBERON:0002097,Atopic eczema,EFO:0000274,healthy control,severe atopic dermatitis,child with severe atopic dermatitis based on eczema area and severity index (EASI) local rating method,20,20,1 month,16S,12,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,decreased,increased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:398/1/NA,Study 398,prospective cohort,27609659,10.1016/j.jaci.2016.07.029,NA,"Kennedy EA, Connolly J, Hourihane JO, Fallon PG, McLean WHI, Murray D, Jo JH, Segre JA, Kong HH , Irvine AD",Skin microbiome before development of atopic dermatitis: Early colonization with commensal staphylococci at 2 months is associated with a lower risk of atopic dermatitis at 1 year,The Journal of allergy and clinical immunology,2017,"16S sequencing, Staphylococcus aureus, atopic dermatitis, longitudinal birth cohort, microbiome, skin",Experiment 1,Ireland,Homo sapiens,Skin of forearm,UBERON:0003403,Atopic eczema,EFO:0000274,healthy control,atopic dermatitis,child with atopic dermatis at month 12 diagnosed by experienced health care personnel using the UK Working Party Diagnostic Criteria,10,10,NA,16S,123,Roche454,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:399/1/NA,Study 399,prospective cohort,31620923,10.1007/s11357-019-00098-8,NA,"Singh H, Torralba MG, Moncera KJ, DiLello L, Petrini J, Nelson KE , Pieper R",Gastro-intestinal and oral microbiome signatures associated with healthy aging,GeroScience,2019,"16S rRNA, Akkermansia, Chronic disease, Gut microbiome, Healthy aging, Longevity, Metagenomic analysis, Oral microbiome, Streptococcus",Experiment 1,United States of America,Homo sapiens,Saliva,UBERON:0001836,Age,EFO:0000246,healthy aging (HA),non-healthy aging (NHA),"participants aged 70–82 who had a medical history linked to one or more of the following major disease categories: cancer, acute or chronic cardiovascular disease, acute or chronic pulmonary disease, chronic liver disease, diabetes and diabetic complications, and stroke or neurodegenerative disorder.",33,32,6 weeks,16S,123,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:399/2/NA,Study 399,prospective cohort,31620923,10.1007/s11357-019-00098-8,NA,"Singh H, Torralba MG, Moncera KJ, DiLello L, Petrini J, Nelson KE , Pieper R",Gastro-intestinal and oral microbiome signatures associated with healthy aging,GeroScience,2019,"16S rRNA, Akkermansia, Chronic disease, Gut microbiome, Healthy aging, Longevity, Metagenomic analysis, Oral microbiome, Streptococcus",Experiment 2,United States of America,Homo sapiens,Feces,UBERON:0001988,Age,EFO:0000246,healthy aging (HA),non-healthy aging (NHA),"participants aged 70–82 who had a medical history linked to one or more of the following major disease categories: cancer, acute or chronic cardiovascular disease, acute or chronic pulmonary disease, chronic liver disease, diabetes and diabetic complications, and stroke or neurodegenerative disorder.",33,32,6 weeks,16S,123,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:400/1/NA,Study 400,case-control,31206804,10.1111/pai.13096,NA,"Chiu CY, Cheng ML, Chiang MH, Kuo YL, Tsai MH, Chiu CC , Lin G",Gut microbial-derived butyrate is inversely associated with IgE responses to allergens in childhood asthma,Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology,2019,"Clostridium spp., asthma, butyrate, histidine, mite-specific IgE, β-alanine",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Asthma,MONDO:0004979,healthy control,asthma,child age 4-7 years with physician diagnosed asthma,24,34,4 weeks,16S,34,Illumina,Kruskall-Wallis,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:400/2/NA,Study 400,case-control,31206804,10.1111/pai.13096,NA,"Chiu CY, Cheng ML, Chiang MH, Kuo YL, Tsai MH, Chiu CC , Lin G",Gut microbial-derived butyrate is inversely associated with IgE responses to allergens in childhood asthma,Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology,2019,"Clostridium spp., asthma, butyrate, histidine, mite-specific IgE, β-alanine",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Allergic rhinitis,EFO:0005854,healthy control,allergic rhinitis,child age 4-7 years with physician diagnosed allergic rhinitis,24,27,4 weeks,16S,34,Illumina,Kruskall-Wallis,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:401/1/NA,Study 401,case-control,28500319,10.1038/s41598-017-02067-7,NA,"Chiu CY, Chan YL, Tsai YS, Chen SA, Wang CJ, Chen KF , Chung IF",Airway Microbial Diversity is Inversely Associated with Mite-Sensitized Rhinitis and Asthma in Early Childhood,Scientific reports,2017,NA,Experiment 1,China,Homo sapiens,Throat,UBERON:0000341,Asthma,MONDO:0004979,healthy control,asthma,"child age 3-5 diagnosed as ever having asthma with the occurrence of recurrent wheeze in the last 12 months, or current use of asthma medication",32,32,4 weeks,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:401/2/NA,Study 401,case-control,28500319,10.1038/s41598-017-02067-7,NA,"Chiu CY, Chan YL, Tsai YS, Chen SA, Wang CJ, Chen KF , Chung IF",Airway Microbial Diversity is Inversely Associated with Mite-Sensitized Rhinitis and Asthma in Early Childhood,Scientific reports,2017,NA,Experiment 2,China,Homo sapiens,Throat,UBERON:0000341,Allergic rhinitis,EFO:0005854,healthy control,allergic rhinitis,"child age 3-5 diagnosed as having symptoms such as sneezing, nasal congestion, itching, and rhinorrhea in the last 12 months",32,23,4 weeks,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:402/1/NA,Study 402,case-control,25944283,10.1111/cea.12566,NA,"West CE, Rydén P, Lundin D, Engstrand L, Tulic MK , Prescott SL",Gut microbiome and innate immune response patterns in IgE-associated eczema,Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology,2015,"16SrRNA, TLR-ligands, diversity, eczema, hygiene hypothesis, innate immunity, intestinal colonization, microbiota, molecular microbiology",Experiment 1,Australia,Homo sapiens,Feces,UBERON:0001988,Atopic eczema,EFO:0000274,healthy control,IgE associated eczema,1 week old Infants with typical skin lesions responsive to topical steroids diagnosed with eczema and with severity determined using the SCORAD index,8,6,NA,16S,34,Roche454,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,"delivery procedure,medical procedure",NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:402/2/NA,Study 402,case-control,25944283,10.1111/cea.12566,NA,"West CE, Rydén P, Lundin D, Engstrand L, Tulic MK , Prescott SL",Gut microbiome and innate immune response patterns in IgE-associated eczema,Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology,2015,"16SrRNA, TLR-ligands, diversity, eczema, hygiene hypothesis, innate immunity, intestinal colonization, microbiota, molecular microbiology",Experiment 2,Australia,Homo sapiens,Feces,UBERON:0001988,Atopic eczema,EFO:0000274,mothers whose infants remained non-allergic,Mothers whose infants developed IgE associated eczema,Mothers whose infants developed typical skin lesions responsive to topical steroids diagnosed with eczema and with severity determined using the SCORAD index,10,9,NA,16S,34,Roche454,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,"delivery procedure,medical procedure",NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:402/3/NA,Study 402,case-control,25944283,10.1111/cea.12566,NA,"West CE, Rydén P, Lundin D, Engstrand L, Tulic MK , Prescott SL",Gut microbiome and innate immune response patterns in IgE-associated eczema,Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology,2015,"16SrRNA, TLR-ligands, diversity, eczema, hygiene hypothesis, innate immunity, intestinal colonization, microbiota, molecular microbiology",Experiment 3,Australia,Homo sapiens,Feces,UBERON:0001988,Delivery method,EFO:0000395,vaginally delivered infant,caesarean delivered infant,infant born by caesarean section,7,7,NA,16S,34,Roche454,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:403/1/NA,Study 403,case-control,30860574,10.1093/femsle/fnz020,NA,"Zhang Y, Jin S, Wang J, Zhang L, Mu Y, Huang K, Zhao B, Zhang K, Cui Y , Li S",Variations in early gut microbiome are associated with childhood eczema,FEMS microbiology letters,2019,"Bifidobacterium, 16S rRNA gene sequencing, childhood eczema, diversity, gut microbiome, qPCR",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Eczema,HP:0000964,healthy control,child with eczema,"children age 0-3 with eczema diagnosed by pediatrician based on clinical criteria such as dry, desquamation skin, increased temperature on the local skin, and oozing or crusting",123,49,NA,16S,34,Illumina,T-Test,0.05,FALSE,NA,age,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:403/2/NA,Study 403,case-control,30860574,10.1093/femsle/fnz020,NA,"Zhang Y, Jin S, Wang J, Zhang L, Mu Y, Huang K, Zhao B, Zhang K, Cui Y , Li S",Variations in early gut microbiome are associated with childhood eczema,FEMS microbiology letters,2019,"Bifidobacterium, 16S rRNA gene sequencing, childhood eczema, diversity, gut microbiome, qPCR",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Eczema,HP:0000964,healthy control,child with eczema,"children age 0-3 with eczema diagnosed by pediatrician based on clinical criteria such as dry, desquamation skin, increased temperature on the local skin, and oozing or crusting",123,49,NA,16S,34,Illumina,LEfSe,0.05,FALSE,4,age,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:403/3/NA,Study 403,case-control,30860574,10.1093/femsle/fnz020,NA,"Zhang Y, Jin S, Wang J, Zhang L, Mu Y, Huang K, Zhao B, Zhang K, Cui Y , Li S",Variations in early gut microbiome are associated with childhood eczema,FEMS microbiology letters,2019,"Bifidobacterium, 16S rRNA gene sequencing, childhood eczema, diversity, gut microbiome, qPCR",Experiment 3,China,Homo sapiens,Feces,UBERON:0001988,Eczema,HP:0000964,healthy control,child with eczema,"children age 0-0.5 with eczema diagnosed by pediatrician based on clinical criteria such as dry, desquamation skin, increased temperature on the local skin, and oozing or crusting",123,49,NA,16S,34,Illumina,T-Test,0.05,FALSE,NA,age,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:403/4/NA,Study 403,case-control,30860574,10.1093/femsle/fnz020,NA,"Zhang Y, Jin S, Wang J, Zhang L, Mu Y, Huang K, Zhao B, Zhang K, Cui Y , Li S",Variations in early gut microbiome are associated with childhood eczema,FEMS microbiology letters,2019,"Bifidobacterium, 16S rRNA gene sequencing, childhood eczema, diversity, gut microbiome, qPCR",Experiment 4,China,Homo sapiens,Feces,UBERON:0001988,Eczema,HP:0000964,healthy control,child with eczema,"children age 0-0.5 with eczema diagnosed by pediatrician based on clinical criteria such as dry, desquamation skin, increased temperature on the local skin, and oozing or crusting",123,49,NA,16S,34,Illumina,LEfSe,0.05,FALSE,4,age,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:403/5/NA,Study 403,case-control,30860574,10.1093/femsle/fnz020,NA,"Zhang Y, Jin S, Wang J, Zhang L, Mu Y, Huang K, Zhao B, Zhang K, Cui Y , Li S",Variations in early gut microbiome are associated with childhood eczema,FEMS microbiology letters,2019,"Bifidobacterium, 16S rRNA gene sequencing, childhood eczema, diversity, gut microbiome, qPCR",Experiment 5,China,Homo sapiens,Feces,UBERON:0001988,Eczema,HP:0000964,healthy control,child with eczema,"children age 0.5-1 with eczema diagnosed by pediatrician based on clinical criteria such as dry, desquamation skin, increased temperature on the local skin, and oozing or crusting",123,49,NA,16S,34,Illumina,T-Test,0.05,FALSE,NA,age,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:403/6/NA,Study 403,case-control,30860574,10.1093/femsle/fnz020,NA,"Zhang Y, Jin S, Wang J, Zhang L, Mu Y, Huang K, Zhao B, Zhang K, Cui Y , Li S",Variations in early gut microbiome are associated with childhood eczema,FEMS microbiology letters,2019,"Bifidobacterium, 16S rRNA gene sequencing, childhood eczema, diversity, gut microbiome, qPCR",Experiment 6,China,Homo sapiens,Feces,UBERON:0001988,Eczema,HP:0000964,healthy control,child with eczema,"children age 0.5-1 with eczema diagnosed by pediatrician based on clinical criteria such as dry, desquamation skin, increased temperature on the local skin, and oozing or crusting",123,49,NA,16S,34,Illumina,LEfSe,0.05,FALSE,4,age,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:403/7/NA,Study 403,case-control,30860574,10.1093/femsle/fnz020,NA,"Zhang Y, Jin S, Wang J, Zhang L, Mu Y, Huang K, Zhao B, Zhang K, Cui Y , Li S",Variations in early gut microbiome are associated with childhood eczema,FEMS microbiology letters,2019,"Bifidobacterium, 16S rRNA gene sequencing, childhood eczema, diversity, gut microbiome, qPCR",Experiment 7,China,Homo sapiens,Feces,UBERON:0001988,Eczema,HP:0000964,healthy control,child with eczema,"children age 1-2 with eczema diagnosed by pediatrician based on clinical criteria such as dry, desquamation skin, increased temperature on the local skin, and oozing or crusting",123,49,NA,16S,34,Illumina,T-Test,0.05,FALSE,NA,age,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:403/8/NA,Study 403,case-control,30860574,10.1093/femsle/fnz020,NA,"Zhang Y, Jin S, Wang J, Zhang L, Mu Y, Huang K, Zhao B, Zhang K, Cui Y , Li S",Variations in early gut microbiome are associated with childhood eczema,FEMS microbiology letters,2019,"Bifidobacterium, 16S rRNA gene sequencing, childhood eczema, diversity, gut microbiome, qPCR",Experiment 8,China,Homo sapiens,Feces,UBERON:0001988,Eczema,HP:0000964,healthy control,child with eczema,"children age 1-2 with eczema diagnosed by pediatrician based on clinical criteria such as dry, desquamation skin, increased temperature on the local skin, and oozing or crusting",123,49,NA,16S,34,Illumina,LEfSe,0.05,FALSE,4,age,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:403/9/NA,Study 403,case-control,30860574,10.1093/femsle/fnz020,NA,"Zhang Y, Jin S, Wang J, Zhang L, Mu Y, Huang K, Zhao B, Zhang K, Cui Y , Li S",Variations in early gut microbiome are associated with childhood eczema,FEMS microbiology letters,2019,"Bifidobacterium, 16S rRNA gene sequencing, childhood eczema, diversity, gut microbiome, qPCR",Experiment 9,China,Homo sapiens,Feces,UBERON:0001988,Eczema,HP:0000964,healthy control,child with eczema,"children age 2-3 with eczema diagnosed by pediatrician based on clinical criteria such as dry, desquamation skin, increased temperature on the local skin, and oozing or crusting",123,49,NA,16S,34,Illumina,T-Test,0.05,FALSE,NA,age,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:403/10/NA,Study 403,case-control,30860574,10.1093/femsle/fnz020,NA,"Zhang Y, Jin S, Wang J, Zhang L, Mu Y, Huang K, Zhao B, Zhang K, Cui Y , Li S",Variations in early gut microbiome are associated with childhood eczema,FEMS microbiology letters,2019,"Bifidobacterium, 16S rRNA gene sequencing, childhood eczema, diversity, gut microbiome, qPCR",Experiment 10,China,Homo sapiens,Feces,UBERON:0001988,Eczema,HP:0000964,healthy control,child with eczema,"children age 2-3 with eczema diagnosed by pediatrician based on clinical criteria such as dry, desquamation skin, increased temperature on the local skin, and oozing or crusting",123,49,NA,16S,34,Illumina,LEfSe,0.05,FALSE,4,age,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:404/1/NA,Study 404,"cross-sectional observational, not case-control",26431583,10.1016/j.jaci.2015.08.021,NA,"Song H, Yoo Y, Hwang J, Na YC , Kim HS",Faecalibacterium prausnitzii subspecies-level dysbiosis in the human gut microbiome underlying atopic dermatitis,The Journal of allergy and clinical immunology,2016,"Atopic dermatitis, Faecalibacterium prausnitzii, dysbiosis, gut microbiota, microbiome",Experiment 1,South Korea,Homo sapiens,Feces,UBERON:0001988,Atopic eczema,EFO:0000274,healthy control,patient with atopic dermatitis,infants (<1 year old) diagnosed with atopic dermatitis based on the SCORAD scoring system,5,15,6 months,16S,12,Roche454,Random Forest Analysis,0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:404/2/NA,Study 404,"cross-sectional observational, not case-control",26431583,10.1016/j.jaci.2015.08.021,NA,"Song H, Yoo Y, Hwang J, Na YC , Kim HS",Faecalibacterium prausnitzii subspecies-level dysbiosis in the human gut microbiome underlying atopic dermatitis,The Journal of allergy and clinical immunology,2016,"Atopic dermatitis, Faecalibacterium prausnitzii, dysbiosis, gut microbiota, microbiome",Experiment 2,South Korea,Homo sapiens,Feces,UBERON:0001988,Atopic eczema,EFO:0000274,healthy control,patient with atopic dermatitis,patient age 1-6 years diagnosed with atopic dermatitis based on the SCORAD scoring system,15,58,6 months,16S,12,Roche454,Random Forest Analysis,0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:404/3/NA,Study 404,"cross-sectional observational, not case-control",26431583,10.1016/j.jaci.2015.08.021,NA,"Song H, Yoo Y, Hwang J, Na YC , Kim HS",Faecalibacterium prausnitzii subspecies-level dysbiosis in the human gut microbiome underlying atopic dermatitis,The Journal of allergy and clinical immunology,2016,"Atopic dermatitis, Faecalibacterium prausnitzii, dysbiosis, gut microbiota, microbiome",Experiment 3,South Korea,Homo sapiens,Feces,UBERON:0001988,Atopic eczema,EFO:0000274,healthy control,patient with atopic dermatitis,patient age >6 years diagnosed with atopic dermatitis based on the SCORAD scoring system,22,17,6 months,16S,12,Roche454,Random Forest Analysis,0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:405/1/NA,Study 405,prospective cohort,29321519,10.1038/s41467-017-02573-2,NA,"Stokholm J, Blaser MJ, Thorsen J, Rasmussen MA, Waage J, Vinding RK, Schoos AM, Kunøe A, Fink NR, Chawes BL, Bønnelykke K, Brejnrod AD, Mortensen MS, Al-Soud WA, Sørensen SJ , Bisgaard H",Maturation of the gut microbiome and risk of asthma in childhood,Nature communications,2018,NA,Experiment 1,Denmark,Homo sapiens,Feces,UBERON:0001988,Asthma,MONDO:0004979,no asthma at 5 years old,child with asthma at 5 years old,"child with physician diagnosed asthma based on verified diary recordings of five episodes of troublesome lung symptoms within 6 months, exercise-induced symptoms, prolonged nocturnal cough, and/or persistent cough outside of common colds, need for intermittent rescue use of inhaled β2-agonist, response to a 3-month course of inhaled corticosteroids andrelapse upon ending treatment",531,58,NA,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,unchanged,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:405/2/NA,Study 405,prospective cohort,29321519,10.1038/s41467-017-02573-2,NA,"Stokholm J, Blaser MJ, Thorsen J, Rasmussen MA, Waage J, Vinding RK, Schoos AM, Kunøe A, Fink NR, Chawes BL, Bønnelykke K, Brejnrod AD, Mortensen MS, Al-Soud WA, Sørensen SJ , Bisgaard H",Maturation of the gut microbiome and risk of asthma in childhood,Nature communications,2018,NA,Experiment 2,Denmark,Homo sapiens,Feces,UBERON:0001988,Asthma,MONDO:0004979,no asthma at 5 years old,child with asthma at 5 years old among mothers with asthma,"child with physician diagnosed asthma based on verified diary recordings of five episodes of troublesome lung symptoms within 6 months, exercise-induced symptoms, prolonged nocturnal cough, and/or persistent cough outside of common colds, need for intermittent rescue use of inhaled β2-agonist, response to a 3-month course of inhaled corticosteroids andrelapse upon ending treatment and mother with asthma",122,25,NA,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,unchanged,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:405/3/NA,Study 405,prospective cohort,29321519,10.1038/s41467-017-02573-2,NA,"Stokholm J, Blaser MJ, Thorsen J, Rasmussen MA, Waage J, Vinding RK, Schoos AM, Kunøe A, Fink NR, Chawes BL, Bønnelykke K, Brejnrod AD, Mortensen MS, Al-Soud WA, Sørensen SJ , Bisgaard H",Maturation of the gut microbiome and risk of asthma in childhood,Nature communications,2018,NA,Experiment 3,Denmark,Homo sapiens,Feces,UBERON:0001988,Asthma,MONDO:0004979,no asthma at 5 years old,child with asthma at 5 years old among mothers without asthma,child with asthma at 5 years old among mothers without asthma,409,33,NA,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,unchanged,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:406/1/NA,Study 406,case-control,30524957,10.3389/fonc.2018.00520,NA,"Yang J, Mu X, Wang Y, Zhu D, Zhang J, Liang C, Chen B, Wang J, Zhao C, Zuo Z, Heng X, Zhang C , Zhang L",Dysbiosis of the Salivary Microbiome Is Associated With Non-smoking Female Lung Cancer and Correlated With Immunocytochemistry Markers,Frontiers in oncology,2018,"biomarker, dysbiosis, lung cancer, non-smoking female patient, salivary microbiome",Experiment 1,China,Homo sapiens,Saliva,UBERON:0001836,Lung cancer,MONDO:0008903,healthy controls,non-smoking female lung cancer patients,female and have confirmed diagnosis of non-small-cell lung cancer,172,75,NA,16S,12,Illumina,LEfSe,0.05,FALSE,3,"age,sex,smoking status",NA,NA,decreased,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:407/1/NA,Study 407,prospective cohort,32733243,10.3389/fphar.2020.01000,NA,"Wang B, Zhang Y, Zhao Q, Yan Y, Yang T, Xia Y , Chen H",Patients With Reflux Esophagitis Possess a Possible Different Oral Microbiota Compared With Healthy Controls,Frontiers in pharmacology,2020,"biomarker, dysbiosis, high-throughput sequencing, oral microbiota, reflux esophagitis",Experiment 1,China,Homo sapiens,Saliva,UBERON:0001836,Peptic esophagitis,EFO:1001095,healthy controls,reflux esophagus patients,symptoms such as heartburn and regurgitation were in accordance with the endoscopic criteria of Los Angeles Grade and taken no drugs as treatment,51,55,6 months,16S,34,Illumina,LEfSe,0.05,TRUE,2,"age,sex",NA,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:408/1/NA,Study 408,case-control,27634868,10.1042/CS20160349,NA,"Stiemsma LT, Arrieta MC, Dimitriu PA, Cheng J, Thorson L, Lefebvre DL, Azad MB, Subbarao P, Mandhane P, Becker A, Sears MR, Kollmann TR, Mohn WW, Finlay BB , Turvey SE",Shifts in Lachnospira and Clostridium sp. in the 3-month stool microbiome are associated with preschool age asthma,"Clinical science (London, England : 1979)",2016,"atopic disease, dysbiosis, gut microbiota, hygiene hypothesis, microflora hypothesis",Experiment 1,Canada,Homo sapiens,Feces,UBERON:0001988,Asthma,MONDO:0004979,healthy controls,asthma at 3 months,physician diagnosis of asthma by 4 years of age or was prescribed inhaled asthma medications (inhaled corticosteroids or bronchodilators) from 3 to 4 years of age,37,39,NA,16S,3,Illumina,DESeq2,0.05,TRUE,NA,"antibiotic exposure,cesarean section,feeding practices,sex",NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:408/2/NA,Study 408,case-control,27634868,10.1042/CS20160349,NA,"Stiemsma LT, Arrieta MC, Dimitriu PA, Cheng J, Thorson L, Lefebvre DL, Azad MB, Subbarao P, Mandhane P, Becker A, Sears MR, Kollmann TR, Mohn WW, Finlay BB , Turvey SE",Shifts in Lachnospira and Clostridium sp. in the 3-month stool microbiome are associated with preschool age asthma,"Clinical science (London, England : 1979)",2016,"atopic disease, dysbiosis, gut microbiota, hygiene hypothesis, microflora hypothesis",Experiment 2,Canada,Homo sapiens,Feces,UBERON:0001988,Asthma,MONDO:0004979,healthy controls,asthma at 1 year,physician diagnosis of asthma by 4 years of age or was prescribed inhaled asthma medications (inhaled corticosteroids or bronchodilators) from 3 to 4 years of age,37,39,NA,16S,3,Illumina,DESeq2,0.05,TRUE,NA,"antibiotic exposure,delivery procedure,feeding practices,sex",NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:409/1/NA,Study 409,randomized controlled trial,26394008,10.1038/ismej.2015.151,NA,"Berni Canani R, Sangwan N, Stefka AT, Nocerino R, Paparo L, Aitoro R, Calignano A, Khan AA, Gilbert JA , Nagler CR",Lactobacillus rhamnosus GG-supplemented formula expands butyrate-producing bacterial strains in food allergic infants,The ISME journal,2016,NA,Experiment 1,Italy,Homo sapiens,Feces,UBERON:0001988,Milk allergic reaction,EFO:0007369,healthy controls,IgE mediated cow's milk allergy,diagnosis of IgE mediated cow's milk allergy based on clinical history and level of IgE serum-specific anti-cow's milk proteins,20,19,4 weeks,16S,4,Illumina,Welch's T-Test,0.05,TRUE,NA,"age,body weight,sex",NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:409/2/NA,Study 409,randomized controlled trial,26394008,10.1038/ismej.2015.151,NA,"Berni Canani R, Sangwan N, Stefka AT, Nocerino R, Paparo L, Aitoro R, Calignano A, Khan AA, Gilbert JA , Nagler CR",Lactobacillus rhamnosus GG-supplemented formula expands butyrate-producing bacterial strains in food allergic infants,The ISME journal,2016,NA,Experiment 2,Italy,Homo sapiens,Feces,UBERON:0001988,Milk allergic reaction,EFO:0007369,pre EHCF with LGG,post EHCF with LGG,cow milk allergic infants post treatment with EHCF with LGG,12,12,4 weeks,16S,4,Illumina,Welch's T-Test,0.05,TRUE,NA,"age,body weight,sex",NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:409/3/NA,Study 409,randomized controlled trial,26394008,10.1038/ismej.2015.151,NA,"Berni Canani R, Sangwan N, Stefka AT, Nocerino R, Paparo L, Aitoro R, Calignano A, Khan AA, Gilbert JA , Nagler CR",Lactobacillus rhamnosus GG-supplemented formula expands butyrate-producing bacterial strains in food allergic infants,The ISME journal,2016,NA,Experiment 3,Italy,Homo sapiens,Feces,UBERON:0001988,Lactobacillus rhamnosus GG,NCBITAXON:568703,Post EHCF treatment,Post EHCF with LGG,cow milk allergic infants post treatment with EHCF with LGG,7,12,4 weeks,16S,4,Illumina,Welch's T-Test,0.05,TRUE,NA,"age,body weight,sex",NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:410/1/NA,Study 410,"cross-sectional observational, not case-control",28118207,10.1097/QAD.0000000000001409,NA,"Nowak RG, Bentzen SM, Ravel J, Crowell TA, Dauda W, Ma B, Liu H, Blattner WA, Baral SD , Charurat ME","Rectal microbiota among HIV-uninfected, untreated HIV, and treated HIV-infected in Nigeria","AIDS (London, England)",2017,NA,Experiment 1,Nigeria,Homo sapiens,Rectum,UBERON:0001052,HIV infection,EFO:0000764,HIV-uninfected MSM,ART-treated HIV infected MSM,Men who have sex with men (MSM) with HIV that has been treated with antiretroviral therapy (ART),55,34,NA,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:411/1/NA,Study 411,"cross-sectional observational, not case-control",32258202,10.1093/ofid/ofz463,NA,"Fulcher JA, Li F, Cook RR, Zabih S, Louie A, Okochi H, Tobin NH, Gandhi M, Shoptaw S, Gorbach PM , Aldrovandi GM",Rectal Microbiome Alterations Associated With Oral Human Immunodeficiency Virus Pre-Exposure Prophylaxis,Open forum infectious diseases,2019,"men who have sex with men (MSM), pre-exposure prophylaxis (PrEP), rectal microbiome",Experiment 1,United States of America,Homo sapiens,Rectum,UBERON:0001052,HIV/AIDS pre-exposure prophylaxis,GSSO:001787,HIV-negative MSM not on PrEP,HIV-negative MSM on PrEP,HIV-negative Men who have sex with men (MSM) on HIV pre-exposure prophylaxis (PrEP),37,37,NA,16S,4,Illumina,Linear Regression,0.1,TRUE,NA,"age,alcohol drinking,anal intercourse,drug dependence,ethnic group,marijuana,nicotine dependence,obesity,race",NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:411/2/NA,Study 411,"cross-sectional observational, not case-control",32258202,10.1093/ofid/ofz463,NA,"Fulcher JA, Li F, Cook RR, Zabih S, Louie A, Okochi H, Tobin NH, Gandhi M, Shoptaw S, Gorbach PM , Aldrovandi GM",Rectal Microbiome Alterations Associated With Oral Human Immunodeficiency Virus Pre-Exposure Prophylaxis,Open forum infectious diseases,2019,"men who have sex with men (MSM), pre-exposure prophylaxis (PrEP), rectal microbiome",Experiment 2,United States of America,Homo sapiens,Rectum,UBERON:0001052,HIV/AIDS pre-exposure prophylaxis,GSSO:001787,HIV-negative MSM not on PrEP,HIV-negative MSM on PrEP,HIV-negative Men who have sex with men (MSM) on HIV pre-exposure prophylaxis (PrEP),37,37,NA,16S,4,Illumina,NA,0.05,TRUE,NA,"age,alcohol drinking,anal intercourse,drug dependence,ethnic group,marijuana,nicotine dependence,obesity,race",NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:412/1/NA,Study 412,"cross-sectional observational, not case-control",31619731,10.1038/s41598-019-51142-8,NA,"Cook RR, Fulcher JA, Tobin NH, Li F, Lee DJ, Woodward C, Javanbakht M, Brookmeyer R, Shoptaw S, Bolan R, Aldrovandi GM , Gorbach PM",Alterations to the Gastrointestinal Microbiome Associated with Methamphetamine Use among Young Men who have Sex with Men,Scientific reports,2019,NA,Experiment 1,United States of America,Homo sapiens,Rectum,UBERON:0001052,"HIV infection,Methamphetamine dependence","EFO:0000764,EFO:0004701",HIV-positive non-MA users,HIV-positive MA users,HIV-positive Men who have sex with men (MSM) who self-reported methamphetamine (MA) use in the past six months,81,101,NA,16S,4,Illumina,Negative Binomial Regression,0.1,TRUE,NA,NA,"HIV/AIDS pre-exposure prophylaxis,age,alcohol drinking,antibiotic,antiretroviral therapy,cannabis use,ethnic group,homelessness,number of sex partners,receptive anal intercourse frequency,sexually transmitted infection,smoking behavior,substance use",NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:412/2/NA,Study 412,"cross-sectional observational, not case-control",31619731,10.1038/s41598-019-51142-8,NA,"Cook RR, Fulcher JA, Tobin NH, Li F, Lee DJ, Woodward C, Javanbakht M, Brookmeyer R, Shoptaw S, Bolan R, Aldrovandi GM , Gorbach PM",Alterations to the Gastrointestinal Microbiome Associated with Methamphetamine Use among Young Men who have Sex with Men,Scientific reports,2019,NA,Experiment 2,United States of America,Homo sapiens,Rectum,UBERON:0001052,Methamphetamine dependence,EFO:0004701,non-users,Methamphetamine users,MSM who self-reported methamphetamine (MA) use in the past six months,225,156,NA,16S,4,Illumina,Negative Binomial Regression,0.1,TRUE,NA,NA,"HIV/AIDS pre-exposure prophylaxis,age,alcohol drinking,antibiotic,antiretroviral therapy,cannabis use,ethnic group,homelessness,number of sex partners,receptive anal intercourse frequency,sexually transmitted infection,smoking behavior,substance use",NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:412/3/NA,Study 412,"cross-sectional observational, not case-control",31619731,10.1038/s41598-019-51142-8,NA,"Cook RR, Fulcher JA, Tobin NH, Li F, Lee DJ, Woodward C, Javanbakht M, Brookmeyer R, Shoptaw S, Bolan R, Aldrovandi GM , Gorbach PM",Alterations to the Gastrointestinal Microbiome Associated with Methamphetamine Use among Young Men who have Sex with Men,Scientific reports,2019,NA,Experiment 3,United States of America,Homo sapiens,Rectum,UBERON:0001052,Methamphetamine dependence,EFO:0004701,MSM who did not test positive on MA urine drug screening,MSM who tested positive on MA urine drug screening,MSM who tested positive for methamphetamine (MA) use in a urine drug screening,329,52,NA,16S,4,Illumina,Negative Binomial Regression,0.1,TRUE,NA,NA,"HIV/AIDS pre-exposure prophylaxis,age,alcohol drinking,antibiotic,antiretroviral therapy,cannabis use,ethnic group,homelessness,number of sex partners,receptive anal intercourse frequency,sexually transmitted infection,smoking behavior,substance use",NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:412/4/NA,Study 412,"cross-sectional observational, not case-control",31619731,10.1038/s41598-019-51142-8,NA,"Cook RR, Fulcher JA, Tobin NH, Li F, Lee DJ, Woodward C, Javanbakht M, Brookmeyer R, Shoptaw S, Bolan R, Aldrovandi GM , Gorbach PM",Alterations to the Gastrointestinal Microbiome Associated with Methamphetamine Use among Young Men who have Sex with Men,Scientific reports,2019,NA,Experiment 4,United States of America,Homo sapiens,Rectum,UBERON:0001052,Methamphetamine dependence,EFO:0004701,HIV-positive men who have sex with men who did not test positive in a methamphetamine drug screening,HIV-positive men who have sex with men who tested positive in a methamphetamine drug screening,HIV-positive Men who have sex with men (MSM) who tested positive in a methamphetamine (MA) drug screening,81,21,NA,16S,4,Illumina,Negative Binomial Regression,0.1,TRUE,NA,NA,"HIV/AIDS pre-exposure prophylaxis,age,alcohol drinking,antibiotic,antiretroviral therapy,cannabis use,ethnic group,homelessness,number of sex partners,receptive anal intercourse frequency,sexually transmitted infection,smoking behavior,substance use",NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:412/5/NA,Study 412,"cross-sectional observational, not case-control",31619731,10.1038/s41598-019-51142-8,NA,"Cook RR, Fulcher JA, Tobin NH, Li F, Lee DJ, Woodward C, Javanbakht M, Brookmeyer R, Shoptaw S, Bolan R, Aldrovandi GM , Gorbach PM",Alterations to the Gastrointestinal Microbiome Associated with Methamphetamine Use among Young Men who have Sex with Men,Scientific reports,2019,NA,Experiment 5,United States of America,Homo sapiens,Rectum,UBERON:0001052,Methamphetamine dependence,EFO:0004701,HIV-negative MSM who did not test positive in a MA drug screening,HIV-negative MSM who tested positive in a MA drug screening,HIV-negative Men who have sex with men (MSM) who tested positive in a methamphetamine (MA) drug screening,248,31,NA,16S,4,Illumina,Negative Binomial Regression,0.1,TRUE,NA,NA,"HIV/AIDS pre-exposure prophylaxis,age,alcohol drinking,antibiotic,antiretroviral therapy,cannabis use,ethnic group,homelessness,number of sex partners,receptive anal intercourse frequency,sexually transmitted infection,smoking behavior,substance use",NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:413/1/NA,Study 413,"cross-sectional observational, not case-control",32307692,10.1111/acps.13175,NA,"Turna J, Grosman Kaplan K, Anglin R, Patterson B, Soreni N, Bercik P, Surette MG , Van Ameringen M",The gut microbiome and inflammation in obsessive-compulsive disorder patients compared to age- and sex-matched controls: a pilot study,Acta psychiatrica Scandinavica,2020,"OCD, anxiety, cytokine, gut microbiota, gut-brain axis, inflammation",Experiment 1,Canada,Homo sapiens,Feces,UBERON:0001988,Obsessive-compulsive disorder,EFO:0004242,healthy controls,OCD,non-depressed medication free individuals or individuals with mild depressive symptoms (MADRS score<16) with a primary DSM-5 diagnosis of OCD as per the MINI or at least moderate OCD (Y-BOCS score >= 20),22,21,8 weeks,16S,3,Illumina,ANCOM,0.05,TRUE,NA,"age,sex",NA,NA,unchanged,unchanged,NA,decreased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:414/1/NA,Study 414,time series / longitudinal observational,30701077,10.1038/s41522-018-0073-2,NA,"Lindefeldt M, Eng A, Darban H, Bjerkner A, Zetterström CK, Allander T, Andersson B, Borenstein E, Dahlin M , Prast-Nielsen S",The ketogenic diet influences taxonomic and functional composition of the gut microbiota in children with severe epilepsy,NPJ biofilms and microbiomes,2019,NA,Experiment 1,Sweden,Homo sapiens,Feces,UBERON:0001988,Epilepsy,EFO:0000474,after keto diet,before keto diet,children with therapy resistent inoperabe epilepsy or a diagnosis of a neorometablic disorder in which KD is recommended,12,12,3 months,WMS,NA,Illumina,LEfSe,0.05,TRUE,4,NA,NA,NA,unchanged,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:415/1/NA,Study 415,"cross-sectional observational, not case-control",29808701,10.1089/AID.2017.0200,NA,"Lewy T, Hong BY, Weiser B, Burger H, Tremain A, Weinstock G, Anastos K , George MD","Oral Microbiome in HIV-Infected Women: Shifts in the Abundance of Pathogenic and Beneficial Bacteria Are Associated with Aging, HIV Load, CD4 Count, and Antiretroviral Therapy",AIDS research and human retroviruses,2019,"HIV, aging, disease progression, opportunistic infection, oral microbiome, saliva",Experiment 1,United States of America,Homo sapiens,Saliva,UBERON:0001836,HIV infection,EFO:0000764,Age-matched HIV-uninfected women,HIV-positive women who have been taking ART for more than 1 year,HIV-positive women who have been taking antiretroviral therapy (ART) for more than 1 year,3,3,NA,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,age,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:415/2/NA,Study 415,"cross-sectional observational, not case-control",29808701,10.1089/AID.2017.0200,NA,"Lewy T, Hong BY, Weiser B, Burger H, Tremain A, Weinstock G, Anastos K , George MD","Oral Microbiome in HIV-Infected Women: Shifts in the Abundance of Pathogenic and Beneficial Bacteria Are Associated with Aging, HIV Load, CD4 Count, and Antiretroviral Therapy",AIDS research and human retroviruses,2019,"HIV, aging, disease progression, opportunistic infection, oral microbiome, saliva",Experiment 2,United States of America,Homo sapiens,Saliva,UBERON:0001836,"HIV infection,Oral candidiasis","EFO:0000764,EFO:0007406",Age-matched HIV-uninfected womenn,HIV-positive women with oral candidiasis,HIV-positive women with oral candidiasis,3,3,NA,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,age,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:415/3/NA,Study 415,"cross-sectional observational, not case-control",29808701,10.1089/AID.2017.0200,NA,"Lewy T, Hong BY, Weiser B, Burger H, Tremain A, Weinstock G, Anastos K , George MD","Oral Microbiome in HIV-Infected Women: Shifts in the Abundance of Pathogenic and Beneficial Bacteria Are Associated with Aging, HIV Load, CD4 Count, and Antiretroviral Therapy",AIDS research and human retroviruses,2019,"HIV, aging, disease progression, opportunistic infection, oral microbiome, saliva",Experiment 3,United States of America,Homo sapiens,Saliva,UBERON:0001836,Age,EFO:0000246,HIV uninfected women who are less than 35 years of age,HIV uninfected women who are 50 years of age or older,HIV-negative women who are 50 years of age or older,4,4,NA,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:415/4/NA,Study 415,"cross-sectional observational, not case-control",29808701,10.1089/AID.2017.0200,NA,"Lewy T, Hong BY, Weiser B, Burger H, Tremain A, Weinstock G, Anastos K , George MD","Oral Microbiome in HIV-Infected Women: Shifts in the Abundance of Pathogenic and Beneficial Bacteria Are Associated with Aging, HIV Load, CD4 Count, and Antiretroviral Therapy",AIDS research and human retroviruses,2019,"HIV, aging, disease progression, opportunistic infection, oral microbiome, saliva",Experiment 4,United States of America,Homo sapiens,Saliva,UBERON:0001836,"Coinfection,Age","EFO:0010716,EFO:0000246",young HIV-infected group without coinfection,aging HIV-infected women with coinfections,"aging HIV-infected women with coinfections; Hairy leukoplakia, oral candida, kaposi's sarcoma, HPV",4,4,NA,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:416/1/NA,Study 416,randomized controlled trial,30944164,10.1126/scitranslmed.aav0537,NA,"Bourke CD, Gough EK, Pimundu G, Shonhai A, Berejena C, Terry L, Baumard L, Choudhry N, Karmali Y, Bwakura-Dangarembizi M, Musiime V, Lutaakome J, Kekitiinwa A, Mutasa K, Szubert AJ, Spyer MJ, Deayton JR, Glass M, Geum HM, Pardieu C, Gibb DM, Klein N, Edens TJ, Walker AS, Manges AR , Prendergast AJ",Cotrimoxazole reduces systemic inflammation in HIV infection by altering the gut microbiome and immune activation,Science translational medicine,2019,NA,Experiment 1,Zimbabwe,Homo sapiens,Feces,UBERON:0001988,"HIV infection,Antimicrobial agent","EFO:0000764,CHEBI:33281",stop cotrimoxazole prophylaxis,continue cotrimoxazole prophylaxis,HIV-positive and antiretroviral therapy (ART) treated children who were randomized to continue taking cotrimoxazole prophylaxis,36,36,NA,WMS,NA,Illumina,Zero-Inflated Beta Regression,0.05,TRUE,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:417/1/NA,Study 417,"cross-sectional observational, not case-control",30366816,10.1016/j.ebiom.2018.10.037,NA,"Moon JY, Zolnik CP, Wang Z, Qiu Y, Usyk M, Wang T, Kizer JR, Landay AL, Kurland IJ, Anastos K, Kaplan RC, Burk RD , Qi Q","Gut microbiota and plasma metabolites associated with diabetes in women with, or at high risk for, HIV infection",EBioMedicine,2018,"Diabetes, Gut microbiota, HIV, Metabolite",Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,"HIV infection,Diabetes mellitus","EFO:0000764,EFO:0000400",Women without diabetes,Women with diabetes,Women with or at high risk for HIV infection who have diabetes,26,22,NA,16S,4,Illumina,Linear Regression,0.1,TRUE,NA,NA,"HIV infection,age",NA,unchanged,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:418/1/NA,Study 418,randomized controlled trial,28388647,10.1371/journal.pone.0173802,NA,"Villar-García J, Güerri-Fernández R, Moya A, González A, Hernández JJ, Lerma E, Guelar A, Sorli L, Horcajada JP, Artacho A, D Auria G , Knobel H","Impact of probiotic Saccharomyces boulardii on the gut microbiome composition in HIV-treated patients: A double-blind, randomised, placebo-controlled trial",PloS one,2017,NA,Experiment 1,Spain,Homo sapiens,Feces,UBERON:0001988,HIV infection,EFO:0000764,baseline,immunological non-responders assigned to treatment for 12 weeks,HIV-infected immunological non-responders (INR) who received S. boulardii probiotic,22,22,2 months,16S,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:418/2/NA,Study 418,randomized controlled trial,28388647,10.1371/journal.pone.0173802,NA,"Villar-García J, Güerri-Fernández R, Moya A, González A, Hernández JJ, Lerma E, Guelar A, Sorli L, Horcajada JP, Artacho A, D Auria G , Knobel H","Impact of probiotic Saccharomyces boulardii on the gut microbiome composition in HIV-treated patients: A double-blind, randomised, placebo-controlled trial",PloS one,2017,NA,Experiment 2,Spain,Homo sapiens,Feces,UBERON:0001988,HIV infection,EFO:0000764,baseline,immunological responders assigned to treatment for 12 weeks,HIV-infected immunological responders (IR) who received S. boulardii probiotic,22,22,2 months,16S,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:419/1/NA,Study 419,prospective cohort,29874201,10.1097/QAI.0000000000001693,NA,"Arnbjerg CJ, Vestad B, Hov JR, Pedersen KK, Jespersen S, Johannesen HH, Holm K, Halvorsen B, Fallentin E, Hansen AE, Lange T, Kjær A, Trøseid M, Fischer BM , Nielsen SD",Effect of Lactobacillus rhamnosus GG Supplementation on Intestinal Inflammation Assessed by PET/MRI Scans and Gut Microbiota Composition in HIV-Infected Individuals,Journal of acquired immune deficiency syndromes (1999),2018,NA,Experiment 1,Denmark,Homo sapiens,Feces,UBERON:0001988,HIV infection,EFO:0000764,baseline,combination antiretroviral therapy treated individuals after taking LGG probiotic for 8 weeks,Persons with HIV,27,27,2 months,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:419/3/NA,Study 419,prospective cohort,29874201,10.1097/QAI.0000000000001693,NA,"Arnbjerg CJ, Vestad B, Hov JR, Pedersen KK, Jespersen S, Johannesen HH, Holm K, Halvorsen B, Fallentin E, Hansen AE, Lange T, Kjær A, Trøseid M, Fischer BM , Nielsen SD",Effect of Lactobacillus rhamnosus GG Supplementation on Intestinal Inflammation Assessed by PET/MRI Scans and Gut Microbiota Composition in HIV-Infected Individuals,Journal of acquired immune deficiency syndromes (1999),2018,NA,Experiment 3,Denmark,Homo sapiens,Feces,UBERON:0001988,HIV infection,EFO:0000764,individuals with no change in uptake,individuals with decreased F-2-fluoro-2-deoxy-D-glucose (F-FDG) uptake on positron emission tomography (PET)/magnetic resonance imaging (MRI),Persons with HIV,7,5,2 months,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:420/1/NA,Study 420,randomized controlled trial,26258571,10.1097/QAI.0000000000000784,NA,"Stiksrud B, Nowak P, Nwosu FC, Kvale D, Thalme A, Sonnerborg A, Ueland PM, Holm K, Birkeland SE, Dahm AE, Sandset PM, Rudi K, Hov JR, Dyrhol-Riise AM , Trøseid M",Reduced Levels of D-dimer and Changes in Gut Microbiota Composition After Probiotic Intervention in HIV-Infected Individuals on Stable ART,Journal of acquired immune deficiency syndromes (1999),2015,NA,Experiment 1,"Norway,Sweden",Homo sapiens,Feces,UBERON:0001988,HIV infection,EFO:0000764,baseline probiotic group,Probiotic group after 8 weeks of intervention,HIV-infected on antiretroviral therapy allocated to probiotic group after 8 weeks of intervention,11,11,2 months,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:420/2/NA,Study 420,randomized controlled trial,26258571,10.1097/QAI.0000000000000784,NA,"Stiksrud B, Nowak P, Nwosu FC, Kvale D, Thalme A, Sonnerborg A, Ueland PM, Holm K, Birkeland SE, Dahm AE, Sandset PM, Rudi K, Hov JR, Dyrhol-Riise AM , Trøseid M",Reduced Levels of D-dimer and Changes in Gut Microbiota Composition After Probiotic Intervention in HIV-Infected Individuals on Stable ART,Journal of acquired immune deficiency syndromes (1999),2015,NA,Experiment 2,"Norway,Sweden",Homo sapiens,Feces,UBERON:0001988,HIV infection,EFO:0000764,Non-probiotic intervention group (after 8 weeks),Probiotic intervention group (after 8 weeks),Probiotic intervention group (after 8 weeks),13,11,2 months,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:421/1/NA,Study 421,randomized controlled trial,32708743,10.3390/nu12072112,NA,"Sainz T, Gosalbes MJ, Talavera-Rodríguez A, Jimenez-Hernandez N, Prieto L, Escosa L, Guillén S, Ramos JT, Muñoz-Fernández MÁ, Moya A, Navarro ML, Mellado MJ , Serrano-Villar S",Effect of a Nutritional Intervention on the Intestinal Microbiota of Vertically HIV-Infected Children: The Pediabiota Study,Nutrients,2020,"HIV, children and adolescents, microbiota, vertical transmission",Experiment 1,Spain,Homo sapiens,Feces,UBERON:0001988,HIV infection,EFO:0000764,HIV-uninfected siblings or children born to HIV-infected mothers,Vertically HIV-infected children,Vertically HIV-infected children,10,23,3 months,16S,34,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,unchanged,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:422/1/NA,Study 422,case-control,30518941,10.1038/s41598-018-35877-4,NA,"Kaur US, Shet A, Rajnala N, Gopalan BP, Moar P, D H, Singh BP, Chaturvedi R , Tandon R",High Abundance of genus Prevotella in the gut of perinatally HIV-infected children is associated with IP-10 levels despite therapy,Scientific reports,2018,NA,Experiment 1,India,Homo sapiens,Feces,UBERON:0001988,HIV infection,EFO:0000764,uninfected age-matched controls,Perinatally HIV-infected children,Perinatally HIV-infected children,14,29,1 month,16S,34,Illumina,LEfSe,0.05,FALSE,2.5,age,NA,NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:423/1/NA,Study 423,case-control,32747678,10.1038/s41598-020-69845-8,https://pubmed.ncbi.nlm.nih.gov/32747678/,"Zeng Q, Shen J, Chen K, Zhou J, Liao Q, Lu K, Yuan J , Bi F",The alteration of gut microbiome and metabolism in amyotrophic lateral sclerosis patients,Scientific reports,2020,NA,Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Amyotrophic lateral sclerosis,MONDO:0004976,Healthy controls,Amyotrophic lateral sclerosis - ALS patients,Patients clinically diagnosed with probably or definite ALS according to the revised El Escorial criteria in the neurology department.,20,20,NA,16S,4,Illumina,LEfSe,0.05,TRUE,4,age,NA,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:424/1/NA,Study 424,"cross-sectional observational, not case-control",31727922,10.1038/s41598-019-53041-4,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6856127/,"Half E, Keren N, Reshef L, Dorfman T, Lachter I, Kluger Y, Reshef N, Knobler H, Maor Y, Stein A, Konikoff FM , Gophna U",Fecal microbiome signatures of pancreatic cancer patients,Scientific reports,2019,NA,Experiment 1,Israel,Homo sapiens,Feces,UBERON:0001988,Pancreatic carcinoma,EFO:0002618,Healthy control,Pancreatic cancer patients,Patients presenting with pancreatic cancer. The diagnosis was verified by histological samples obtained by EUS or by postoperative pathological assessment.,13,30,8 weeks,16S,NA,Illumina,LEfSe,0.05,FALSE,3,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:424/3/NA,Study 424,"cross-sectional observational, not case-control",31727922,10.1038/s41598-019-53041-4,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6856127/,"Half E, Keren N, Reshef L, Dorfman T, Lachter I, Kluger Y, Reshef N, Knobler H, Maor Y, Stein A, Konikoff FM , Gophna U",Fecal microbiome signatures of pancreatic cancer patients,Scientific reports,2019,NA,Experiment 3,Israel,Homo sapiens,Feces,UBERON:0001988,Pancreatic carcinoma,EFO:0002618,NBO PC,BO PC,Bile duct-obstructed pancreatic cancer patients.,16,11,Individuals who were exposed to antibiotics up to 8 weeks before sampling were excluded from the analysis.,16S,NA,Illumina,LEfSe,0.05,FALSE,3,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:424/4/NA,Study 424,"cross-sectional observational, not case-control",31727922,10.1038/s41598-019-53041-4,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6856127/,"Half E, Keren N, Reshef L, Dorfman T, Lachter I, Kluger Y, Reshef N, Knobler H, Maor Y, Stein A, Konikoff FM , Gophna U",Fecal microbiome signatures of pancreatic cancer patients,Scientific reports,2019,NA,Experiment 4,Israel,Homo sapiens,Feces,UBERON:0001988,Pancreatic carcinoma,EFO:0002618,Healthy control,NBO PC,Non-Bile duct-obstructed pancreatic cancer patients.,13,16,Individuals who were exposed to antibiotics up to 8 weeks before sampling were excluded from the analysis.,16S,NA,Illumina,LEfSe,0.05,FALSE,3,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:425/1/NA,Study 425,case-control,33294219,10.1155/2020/1957843,NA,"Zhu LL, Ma ZJ, Ren M, Wei YM, Liao YH, Shen YL, Fan SM, Li L, Wu QX, Gao ZS, Song JF , Ma YL",Distinct Features of Gut Microbiota in High-Altitude Tibetan and Middle-Altitude Han Hypertensive Patients,Cardiology research and practice,2020,NA,Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Hypertension,EFO:0000537,Han Hypertensive at Low Altitude (LHH),Tibetan Hypertensive at High Altitude (HTH),Tibetan participants with hypertension living at high altitudes.,34,38,3 months,16S,34,Illumina,T-Test,0.05,FALSE,NA,"age,sex",NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:425/2/NA,Study 425,case-control,33294219,10.1155/2020/1957843,NA,"Zhu LL, Ma ZJ, Ren M, Wei YM, Liao YH, Shen YL, Fan SM, Li L, Wu QX, Gao ZS, Song JF , Ma YL",Distinct Features of Gut Microbiota in High-Altitude Tibetan and Middle-Altitude Han Hypertensive Patients,Cardiology research and practice,2020,NA,Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Hypertension,EFO:0000537,Han Hypertensive at Middle Altitude (MHH),Tibetan Hypertensive at High Altitude (HTH),Tibetan participants with hypertension living at high altitudes.,49,38,3 months,16S,34,Illumina,T-Test,0.05,NA,NA,"age,sex",NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:425/3/NA,Study 425,case-control,33294219,10.1155/2020/1957843,NA,"Zhu LL, Ma ZJ, Ren M, Wei YM, Liao YH, Shen YL, Fan SM, Li L, Wu QX, Gao ZS, Song JF , Ma YL",Distinct Features of Gut Microbiota in High-Altitude Tibetan and Middle-Altitude Han Hypertensive Patients,Cardiology research and practice,2020,NA,Experiment 3,China,Homo sapiens,Feces,UBERON:0001988,Hypertension,EFO:0000537,Han Healthy at Low Altitude (LHN),Tibetan Healthy at High Altitude (HTN),Tibetan healthy participants living at high altitudes.,35,34,3 months,16S,34,Illumina,T-Test,0.05,NA,NA,"age,sex",NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:425/4/NA,Study 425,case-control,33294219,10.1155/2020/1957843,NA,"Zhu LL, Ma ZJ, Ren M, Wei YM, Liao YH, Shen YL, Fan SM, Li L, Wu QX, Gao ZS, Song JF , Ma YL",Distinct Features of Gut Microbiota in High-Altitude Tibetan and Middle-Altitude Han Hypertensive Patients,Cardiology research and practice,2020,NA,Experiment 4,China,Homo sapiens,Feces,UBERON:0001988,Hypertension,EFO:0000537,Han Healthy at Middle Altitude (MHN),Tibetan Healthy at High Altitude (HTN),Tibetan healthy participants living at high altitudes.,35,34,3 months,16S,34,Illumina,T-Test,0.05,FALSE,NA,"age,sex",NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:425/5/NA,Study 425,case-control,33294219,10.1155/2020/1957843,NA,"Zhu LL, Ma ZJ, Ren M, Wei YM, Liao YH, Shen YL, Fan SM, Li L, Wu QX, Gao ZS, Song JF , Ma YL",Distinct Features of Gut Microbiota in High-Altitude Tibetan and Middle-Altitude Han Hypertensive Patients,Cardiology research and practice,2020,NA,Experiment 5,China,Homo sapiens,Feces,UBERON:0001988,Hypertension,EFO:0000537,Han Hypertensive at Low Altitude (LHH),Han Hypertensive at Middle Altitude (MHH),Han hypertensive participants living at middle altitude.,34,49,3 months,16S,34,Illumina,T-Test,0.05,NA,NA,"age,sex",NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:425/6/NA,Study 425,case-control,33294219,10.1155/2020/1957843,NA,"Zhu LL, Ma ZJ, Ren M, Wei YM, Liao YH, Shen YL, Fan SM, Li L, Wu QX, Gao ZS, Song JF , Ma YL",Distinct Features of Gut Microbiota in High-Altitude Tibetan and Middle-Altitude Han Hypertensive Patients,Cardiology research and practice,2020,NA,Experiment 6,China,Homo sapiens,Feces,UBERON:0001988,Hypertension,EFO:0000537,Han Healthy at Low Altitude (LHN),Han Healthy at Middle Altitude (MHN),Han healthy participants living at middle altitude.,35,35,3 months,16S,34,Illumina,T-Test,0.05,NA,NA,"age,sex",NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:426/1/NA,Study 426,"cross-sectional observational, not case-control",31201284,10.1136/gutjnl-2018-317836,NA,"Wei Y, Li Y, Yan L, Sun C, Miao Q, Wang Q, Xiao X, Lian M, Li B, Chen Y, Zhang J, Li Y, Huang B, Li Y, Cao Q, Fan Z, Chen X, Fang JY, Gershwin ME, Tang R , Ma X",Alterations of gut microbiome in autoimmune hepatitis,Gut,2020,"autoimmune hepatitis, intestinal microbiology",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Autoimmune Hepatitis,EFO:0005676,healthy controls,autoimmune hepatits cases,The diagnosis of AIH was made if patients conformed with (1) 1999 revised International Autoimmune Hepatitis Group (IAIHG) score ≥10 and/or (2) 2008 IAIHG simplified AIH score ≥6 and/or (3) histological features indicative of AIH.,98,91,4 weeks,16S,34,Illumina,LEfSe,0.05,FALSE,2,"age,body mass index,sex","age,antibiotic exposure,body mass index,sex",NA,decreased,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:426/2/NA,Study 426,"cross-sectional observational, not case-control",31201284,10.1136/gutjnl-2018-317836,NA,"Wei Y, Li Y, Yan L, Sun C, Miao Q, Wang Q, Xiao X, Lian M, Li B, Chen Y, Zhang J, Li Y, Huang B, Li Y, Cao Q, Fan Z, Chen X, Fang JY, Gershwin ME, Tang R , Ma X",Alterations of gut microbiome in autoimmune hepatitis,Gut,2020,"autoimmune hepatitis, intestinal microbiology",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Autoimmune Hepatitis,EFO:0005676,healthy controls,autoimmune hepatits cases,The diagnosis of AIH was made if patients conformed with (1) 1999 revised International Autoimmune Hepatitis Group (IAIHG) score ≥10 and/or (2) 2008 IAIHG simplified AIH score ≥6 and/or (3) histological features indicative of AIH.,98,91,NA,16S,34,Illumina,Logistic Regression,0.05,FALSE,NA,"age,body mass index,sex","age,body mass index,sex",NA,decreased,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:427/1/NA,Study 427,prospective cohort,26416813,10.1136/gutjnl-2015-309957,NA,"De Filippis F, Pellegrini N, Vannini L, Jeffery IB, La Storia A, Laghi L, Serrazanetti DI, Di Cagno R, Ferrocino I, Lazzi C, Turroni S, Cocolin L, Brigidi P, Neviani E, Gobbetti M, O'Toole PW , Ercolini D",High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome,Gut,2016,"DIET, DIETARY FIBRE, ENTERIC BACTERIAL MICROFLORA, INTESTINAL BACTERIA, SHORT CHAIN FATTY ACIDS",Experiment 1,Italy,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,vegetarians,omnivores,"individuals who eat animal products in addition to other foods (plants, grains, etc)",51,51,3 months,16S,123,Roche454,DESeq2,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:427/2/NA,Study 427,prospective cohort,26416813,10.1136/gutjnl-2015-309957,NA,"De Filippis F, Pellegrini N, Vannini L, Jeffery IB, La Storia A, Laghi L, Serrazanetti DI, Di Cagno R, Ferrocino I, Lazzi C, Turroni S, Cocolin L, Brigidi P, Neviani E, Gobbetti M, O'Toole PW , Ercolini D",High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome,Gut,2016,"DIET, DIETARY FIBRE, ENTERIC BACTERIAL MICROFLORA, INTESTINAL BACTERIA, SHORT CHAIN FATTY ACIDS",Experiment 2,Italy,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,vegans,omnivores,"individuals who eat animal products in addition to other foods (plants, grains, etc)",51,51,3 months,16S,123,Roche454,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:427/3/NA,Study 427,prospective cohort,26416813,10.1136/gutjnl-2015-309957,NA,"De Filippis F, Pellegrini N, Vannini L, Jeffery IB, La Storia A, Laghi L, Serrazanetti DI, Di Cagno R, Ferrocino I, Lazzi C, Turroni S, Cocolin L, Brigidi P, Neviani E, Gobbetti M, O'Toole PW , Ercolini D",High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome,Gut,2016,"DIET, DIETARY FIBRE, ENTERIC BACTERIAL MICROFLORA, INTESTINAL BACTERIA, SHORT CHAIN FATTY ACIDS",Experiment 3,Italy,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,vegans,vegetarians,individuals who do not eat meat but do eat other animal products,51,51,3 months,16S,123,Roche454,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:428/1/NA,Study 428,case-control,33431578,10.1136/gutjnl-2020-323020,NA,"Yeoh YK, Zuo T, Lui GC, Zhang F, Liu Q, Li AY, Chung AC, Cheung CP, Tso EY, Fung KS, Chan V, Ling L, Joynt G, Hui DS, Chow KM, Ng SSS, Li TC, Ng RW, Yip TC, Wong GL, Chan FK, Wong CK, Chan PK , Ng SC",Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19,Gut,2021,"colonic bacteria, colonic microflora, inflammation",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,COVID-19,MONDO:0100096,Healthy controls,COVID-19 cases,Laboratory-confirmed SARS-CoV-2 positive by quantitative reverse transcription PCR performed on nasopharyngeal swabs,78,87,NA,WMS,NA,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:428/2/NA,Study 428,case-control,33431578,10.1136/gutjnl-2020-323020,NA,"Yeoh YK, Zuo T, Lui GC, Zhang F, Liu Q, Li AY, Chung AC, Cheung CP, Tso EY, Fung KS, Chan V, Ling L, Joynt G, Hui DS, Chow KM, Ng SSS, Li TC, Ng RW, Yip TC, Wong GL, Chan FK, Wong CK, Chan PK , Ng SC",Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19,Gut,2021,"colonic bacteria, colonic microflora, inflammation",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,COVID-19,MONDO:0100096,Healthy controls,Recovered COVID-19 cases,Recovered following negative quantitative reverse transcription PCR (RT-qPCR) tests for SARS-CoV-2 RNA in nasopharyngeal swabs,78,13,Patients whose COVID-19 treatment included antibiotics were excluded,WMS,NA,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:428/3/NA,Study 428,case-control,33431578,10.1136/gutjnl-2020-323020,NA,"Yeoh YK, Zuo T, Lui GC, Zhang F, Liu Q, Li AY, Chung AC, Cheung CP, Tso EY, Fung KS, Chan V, Ling L, Joynt G, Hui DS, Chow KM, Ng SSS, Li TC, Ng RW, Yip TC, Wong GL, Chan FK, Wong CK, Chan PK , Ng SC",Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19,Gut,2021,"colonic bacteria, colonic microflora, inflammation",Experiment 3,China,Homo sapiens,Feces,UBERON:0001988,COVID-19,MONDO:0100096,Healthy controls,Recovered COVID-19 cases,"Recovered following negative quantitative reverse transcription PCR (RT-qPCR) tests for SARS-CoV-2 RNA in nasopharyngeal swabs, treated with antibiotics during course of COVID-19",78,14,NA,WMS,NA,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:428/4/NA,Study 428,case-control,33431578,10.1136/gutjnl-2020-323020,NA,"Yeoh YK, Zuo T, Lui GC, Zhang F, Liu Q, Li AY, Chung AC, Cheung CP, Tso EY, Fung KS, Chan V, Ling L, Joynt G, Hui DS, Chow KM, Ng SSS, Li TC, Ng RW, Yip TC, Wong GL, Chan FK, Wong CK, Chan PK , Ng SC",Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19,Gut,2021,"colonic bacteria, colonic microflora, inflammation",Experiment 4,China,Homo sapiens,Feces,UBERON:0001988,COVID-19,MONDO:0100096,Healthy controls,COVID-19 patients treated with antibiotics,"Laboratory-confirmed SARS-CoV-2 positive by quantitative reverse transcription PCR performed on nasopharyngeal swabs, treated with antibiotics",78,34,NA,WMS,NA,Illumina,Linear Regression,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:429/1/NA,Study 429,case-control,32937864,https://doi.org/10.3390/cancers12092619,NA,"Gunathilake M, Lee J, Choi IJ, Kim YI, Yoon J, Sul WJ, Kim JF , Kim J",Alterations in Gastric Microbial Communities Are Associated with Risk of Gastric Cancer in a Korean Population: A Case-Control Study,Cancers,2020,"case-control, gastric cancer, gastric microbiome, microbial dysbiosis index, pathways",Experiment 1,South Korea,Homo sapiens,Feces,UBERON:0001988,Gastric cancer,MONDO:0001056,healthy controls,gastric cancer patients,"patients with histologically confirmed early gastric cancer (invasive carcinoma confined to the mucosa, regardless of lymph node metastasis status) within the preceding 3 months",288,268,NA,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,decreased,decreased,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:430/1/NA,Study 430,prospective cohort,32690600,10.1136/gutjnl-2020-322294,NA,"Zuo T, Liu Q, Zhang F, Lui GC, Tso EY, Yeoh YK, Chen Z, Boon SS, Chan FK, Chan PK , Ng SC",Depicting SARS-CoV-2 faecal viral activity in association with gut microbiota composition in patients with COVID-19,Gut,2021,"diagnostic virology, gut inflammation, infectious disease",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,COVID-19,MONDO:0100096,Patients with low-to-none SARS CoV-2 infectivity,Patients with high SARS CoV-2 infectivity,"SARS CoV-2 infection confirmed by two consecutive RT-OCR tests. High SARS-CoV2 infectivity defined as higher 3' vs 5', end coverage of SARS CoV-2 genome in fecal viral RNA metagenome.",15,15,NA,WMS,NA,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:431/1/NA,Study 431,"cross-sectional observational, not case-control",33241010,10.21037/atm-20-5832,NA,"Liu J, Luo M, Zhang Y, Cao G , Wang S",Association of high-risk human papillomavirus infection duration and cervical lesions with vaginal microbiota composition,Annals of translational medicine,2020,"Cervical cancer, human papillomavirus infection (HPV infection), cervical intraepithelial neoplasia pathological classification, cervical microbiota",Experiment 1,China,Homo sapiens,Vagina,UBERON:0000996,Cervical glandular intraepithelial neoplasia,EFO:1000165,persistent HPV+ with LSIL,persistent HPV+ with HSIL,persistent HPV+ infection ( same HPV subtype has infected for >12 months) with high grade squamus intraepithelial lesion,NA,NA,NA,16S,NA,Illumina,ANOVA,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:431/2/NA,Study 431,"cross-sectional observational, not case-control",33241010,10.21037/atm-20-5832,NA,"Liu J, Luo M, Zhang Y, Cao G , Wang S",Association of high-risk human papillomavirus infection duration and cervical lesions with vaginal microbiota composition,Annals of translational medicine,2020,"Cervical cancer, human papillomavirus infection (HPV infection), cervical intraepithelial neoplasia pathological classification, cervical microbiota",Experiment 2,China,Homo sapiens,Vagina,UBERON:0000996,Cervical glandular intraepithelial neoplasia,EFO:1000165,transient HPV+ with LSIL,transient HPV+ with HSIL,high-risk HPV transient infection (HPV has regressed within 1 year) with high grade squamus intraepithelial lesion,NA,NA,NA,16S,NA,Illumina,ANOVA,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:431/3/NA,Study 431,"cross-sectional observational, not case-control",33241010,10.21037/atm-20-5832,NA,"Liu J, Luo M, Zhang Y, Cao G , Wang S",Association of high-risk human papillomavirus infection duration and cervical lesions with vaginal microbiota composition,Annals of translational medicine,2020,"Cervical cancer, human papillomavirus infection (HPV infection), cervical intraepithelial neoplasia pathological classification, cervical microbiota",Experiment 3,China,Homo sapiens,Vagina,UBERON:0000996,Cervical glandular intraepithelial neoplasia,EFO:1000165,HPV-,transient HPV+ with LSIL,high-risk HPV transient infection (HPV has regressed within 1 year) with low grade squamus intraepithelial lesion,31,NA,NA,16S,NA,Illumina,ANOVA,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:431/4/NA,Study 431,"cross-sectional observational, not case-control",33241010,10.21037/atm-20-5832,NA,"Liu J, Luo M, Zhang Y, Cao G , Wang S",Association of high-risk human papillomavirus infection duration and cervical lesions with vaginal microbiota composition,Annals of translational medicine,2020,"Cervical cancer, human papillomavirus infection (HPV infection), cervical intraepithelial neoplasia pathological classification, cervical microbiota",Experiment 4,China,Homo sapiens,Vagina,UBERON:0000996,Cervical glandular intraepithelial neoplasia,EFO:1000165,HPV-,persistent HPV+ with HSIL,high-risk HPV persistent infection with high grade squamus intraepithelial lesion,31,NA,NA,16S,NA,Illumina,ANOVA,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:431/5/NA,Study 431,"cross-sectional observational, not case-control",33241010,10.21037/atm-20-5832,NA,"Liu J, Luo M, Zhang Y, Cao G , Wang S",Association of high-risk human papillomavirus infection duration and cervical lesions with vaginal microbiota composition,Annals of translational medicine,2020,"Cervical cancer, human papillomavirus infection (HPV infection), cervical intraepithelial neoplasia pathological classification, cervical microbiota",Experiment 5,China,Homo sapiens,Vagina,UBERON:0000996,Cervical glandular intraepithelial neoplasia,EFO:1000165,persistent HPV+ with LSIL,persistent HPV+ with HSIL,persistent HPV+ infection ( same HPV subtype has infected for >12 months) with high grade squamus intraepithelial lesion,NA,NA,NA,16S,NA,Illumina,LEfSe,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:431/6/NA,Study 431,"cross-sectional observational, not case-control",33241010,10.21037/atm-20-5832,NA,"Liu J, Luo M, Zhang Y, Cao G , Wang S",Association of high-risk human papillomavirus infection duration and cervical lesions with vaginal microbiota composition,Annals of translational medicine,2020,"Cervical cancer, human papillomavirus infection (HPV infection), cervical intraepithelial neoplasia pathological classification, cervical microbiota",Experiment 6,China,Homo sapiens,Vagina,UBERON:0000996,Cervical glandular intraepithelial neoplasia,EFO:1000165,transient HPV+ with HSIL,persistent HPV+ with LSIL,high-risk HPV persistent infection with low grade squamus intraepithelial lesion,NA,NA,NA,16S,NA,Illumina,LEfSe,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:431/7/NA,Study 431,"cross-sectional observational, not case-control",33241010,10.21037/atm-20-5832,NA,"Liu J, Luo M, Zhang Y, Cao G , Wang S",Association of high-risk human papillomavirus infection duration and cervical lesions with vaginal microbiota composition,Annals of translational medicine,2020,"Cervical cancer, human papillomavirus infection (HPV infection), cervical intraepithelial neoplasia pathological classification, cervical microbiota",Experiment 7,China,Homo sapiens,Vagina,UBERON:0000996,Cervical glandular intraepithelial neoplasia,EFO:1000165,transient HPV+ with LSIL,transient HPV+ with HSIL,high-risk HPV transient infection with high grade squamus intraepithelial lesion,NA,NA,NA,16S,NA,Illumina,LEfSe,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:431/8/NA,Study 431,"cross-sectional observational, not case-control",33241010,10.21037/atm-20-5832,NA,"Liu J, Luo M, Zhang Y, Cao G , Wang S",Association of high-risk human papillomavirus infection duration and cervical lesions with vaginal microbiota composition,Annals of translational medicine,2020,"Cervical cancer, human papillomavirus infection (HPV infection), cervical intraepithelial neoplasia pathological classification, cervical microbiota",Experiment 8,China,Homo sapiens,Vagina,UBERON:0000996,Cervical glandular intraepithelial neoplasia,EFO:1000165,HPV-,transient HPV+ with LSIL,high-risk HPV transient infection with low grade squamus intraepithelial lesion,NA,NA,NA,16S,NA,Illumina,LEfSe,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:431/9/NA,Study 431,"cross-sectional observational, not case-control",33241010,10.21037/atm-20-5832,NA,"Liu J, Luo M, Zhang Y, Cao G , Wang S",Association of high-risk human papillomavirus infection duration and cervical lesions with vaginal microbiota composition,Annals of translational medicine,2020,"Cervical cancer, human papillomavirus infection (HPV infection), cervical intraepithelial neoplasia pathological classification, cervical microbiota",Experiment 9,China,Homo sapiens,Vagina,UBERON:0000996,Cervical glandular intraepithelial neoplasia,EFO:1000165,HPV-,persistent HPV+ with HSIL,high-risk HPV persistent infection with low grade squamus intraepithelial lesion,NA,NA,NA,16S,NA,Illumina,LEfSe,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:432/1/NA,Study 432,"cross-sectional observational, not case-control",33490017,10.3389/fpubh.2020.587298,NA,"Wei ZT, Chen HL, Wang CF, Yang GL, Han SM , Zhang SL",Depiction of Vaginal Microbiota in Women With High-Risk Human Papillomavirus Infection,Frontiers in public health,2020,"16s rRNA, bacterial vaginosis, human papillomavirus, persistent infection, vaginal microbiota",Experiment 1,China,Homo sapiens,Vagina,UBERON:0000996,Human papilloma virus infection,EFO:0001668,HPV-,HPV+,HPV+ confirmed by Hybrid Capture II assay,30,30,2 weeks,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:433/1/NA,Study 433,"cross-sectional observational, not case-control",33572693,10.3390/microorganisms9020294,NA,"Kang GU, Jung DR, Lee YH, Jeon SY, Han HS, Chong GO , Shin JH",Potential Association between Vaginal Microbiota and Cervical Carcinogenesis in Korean Women: A Cohort Study,Microorganisms,2021,"CIN prediction, CIN severity, vaginal microbiome, vaginosis",Experiment 1,South Korea,Homo sapiens,Vagina,UBERON:0000996,Cervical glandular intraepithelial neoplasia,EFO:1000165,healthy controls,CIN 2+,Patients with cervical intraepithelial neoplasia 2 or higher,7,8,NA,16S,3,Ion Torrent,LEfSe,0.05,FALSE,7,NA,NA,NA,increased,NA,increased,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:433/2/NA,Study 433,"cross-sectional observational, not case-control",33572693,10.3390/microorganisms9020294,NA,"Kang GU, Jung DR, Lee YH, Jeon SY, Han HS, Chong GO , Shin JH",Potential Association between Vaginal Microbiota and Cervical Carcinogenesis in Korean Women: A Cohort Study,Microorganisms,2021,"CIN prediction, CIN severity, vaginal microbiome, vaginosis",Experiment 2,South Korea,Homo sapiens,Vagina,UBERON:0000996,Cervical cancer,MONDO:0002974,healthy controls,cervical cancer,Patients with cervical cancer,7,8,NA,16S,3,Ion Torrent,LEfSe,0.05,FALSE,7,NA,NA,NA,unchanged,NA,unchanged,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:434/1/NA,Study 434,"cross-sectional observational, not case-control",32842982,0.1186/s12879-020-05324-9,NA,"Chen Y, Qiu X, Wang W, Li D, Wu A, Hong Z, Di W , Qiu L",Human papillomavirus infection and cervical intraepithelial neoplasia progression are associated with increased vaginal microbiome diversity in a Chinese cohort,BMC infectious diseases,2020,"Cervical cancer, Cervical intraepithelial neoplasia, Human papillomavirus, Vaginal microbiome",Experiment 1,China,Homo sapiens,Posterior fornix of vagina,UBERON:0016486,Human papilloma virus infection,EFO:0001668,healthy control,HPV +,HPV-infected women without CIN confirmed by HPV genotyping test and examination,68,78,14 days,16S,34,Illumina,LEfSe,0.05,TRUE,4,NA,NA,NA,increased,increased,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:434/2/NA,Study 434,"cross-sectional observational, not case-control",32842982,0.1186/s12879-020-05324-9,NA,"Chen Y, Qiu X, Wang W, Li D, Wu A, Hong Z, Di W , Qiu L",Human papillomavirus infection and cervical intraepithelial neoplasia progression are associated with increased vaginal microbiome diversity in a Chinese cohort,BMC infectious diseases,2020,"Cervical cancer, Cervical intraepithelial neoplasia, Human papillomavirus, Vaginal microbiome",Experiment 2,China,Homo sapiens,Posterior fornix of vagina,UBERON:0016486,Cervical glandular intraepithelial neoplasia,EFO:1000165,healthy control,LSIL,women with low-grade squamous intraepithelial lesions confirmed by biopsy,78,51,14 days,16S,34,Illumina,LEfSe,0.05,TRUE,4,NA,NA,NA,unchanged,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:434/3/NA,Study 434,"cross-sectional observational, not case-control",32842982,0.1186/s12879-020-05324-9,NA,"Chen Y, Qiu X, Wang W, Li D, Wu A, Hong Z, Di W , Qiu L",Human papillomavirus infection and cervical intraepithelial neoplasia progression are associated with increased vaginal microbiome diversity in a Chinese cohort,BMC infectious diseases,2020,"Cervical cancer, Cervical intraepithelial neoplasia, Human papillomavirus, Vaginal microbiome",Experiment 3,China,Homo sapiens,Posterior fornix of vagina,UBERON:0016486,Cervical glandular intraepithelial neoplasia,EFO:1000165,healthy control,HSIL,women with high-grade squamous intraepithelial lesions confirmed by biopsy,68,23,14 days,16S,34,Illumina,LEfSe,0.05,TRUE,4,NA,NA,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:434/4/NA,Study 434,"cross-sectional observational, not case-control",32842982,0.1186/s12879-020-05324-9,NA,"Chen Y, Qiu X, Wang W, Li D, Wu A, Hong Z, Di W , Qiu L",Human papillomavirus infection and cervical intraepithelial neoplasia progression are associated with increased vaginal microbiome diversity in a Chinese cohort,BMC infectious diseases,2020,"Cervical cancer, Cervical intraepithelial neoplasia, Human papillomavirus, Vaginal microbiome",Experiment 4,China,Homo sapiens,Posterior fornix of vagina,UBERON:0016486,Cervical cancer,MONDO:0002974,healthy control,cervical cancer,women with cervical cancer confirmed by biopsy,68,9,14 days,16S,34,Illumina,LEfSe,0.05,TRUE,4,NA,NA,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:434/5/NA,Study 434,"cross-sectional observational, not case-control",32842982,0.1186/s12879-020-05324-9,NA,"Chen Y, Qiu X, Wang W, Li D, Wu A, Hong Z, Di W , Qiu L",Human papillomavirus infection and cervical intraepithelial neoplasia progression are associated with increased vaginal microbiome diversity in a Chinese cohort,BMC infectious diseases,2020,"Cervical cancer, Cervical intraepithelial neoplasia, Human papillomavirus, Vaginal microbiome",Experiment 5,China,Homo sapiens,Posterior fornix of vagina,UBERON:0016486,Human papilloma virus infection,EFO:0001668,Healthy control,HPV+,HPV-infected women without CIN confirmed by HPV genotyping test and examination,68,78,14 days,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,NA,NA,NA,NA,NA,increased,increased,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:435/1/NA,Study 435,"cross-sectional observational, not case-control",33207260,10.1016/j.micpath.2020.104617,NA,"Qingqing B, Jie Z, Songben Q, Juan C, Lei Z , Mu X",Cervicovaginal microbiota dysbiosis correlates with HPV persistent infection,Microbial pathogenesis,2021,"16S rDNA sequencing, Cervicovaginal microbiota, HPV persistent Infection, Host immunosuppression",Experiment 1,China,Homo sapiens,Uterine cervix,UBERON:0000002,Human papilloma virus infection,EFO:0001668,HPV- controls and HPV+ transient patients,HPV+ persistence,HPV infection of the same type that lasts for more than 12 months,9,6,1 month,16S,4,Ion Torrent,LEfSe,0.05,TRUE,4,NA,NA,NA,increased,increased,increased,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:435/2/NA,Study 435,"cross-sectional observational, not case-control",33207260,10.1016/j.micpath.2020.104617,NA,"Qingqing B, Jie Z, Songben Q, Juan C, Lei Z , Mu X",Cervicovaginal microbiota dysbiosis correlates with HPV persistent infection,Microbial pathogenesis,2021,"16S rDNA sequencing, Cervicovaginal microbiota, HPV persistent Infection, Host immunosuppression",Experiment 2,China,Homo sapiens,Uterine cervix,UBERON:0000002,Human papilloma virus infection,EFO:0001668,HPV- controls and HPV+ persistent patients,HPV+ transient,HPV infection cleared within 12 months,11,4,1 month,16S,4,Ion Torrent,LEfSe,0.05,TRUE,4,NA,NA,NA,decreased,decreased,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:435/3/NA,Study 435,"cross-sectional observational, not case-control",33207260,10.1016/j.micpath.2020.104617,NA,"Qingqing B, Jie Z, Songben Q, Juan C, Lei Z , Mu X",Cervicovaginal microbiota dysbiosis correlates with HPV persistent infection,Microbial pathogenesis,2021,"16S rDNA sequencing, Cervicovaginal microbiota, HPV persistent Infection, Host immunosuppression",Experiment 3,China,Homo sapiens,Uterine cervix,UBERON:0000002,Human papilloma virus infection,EFO:0001668,HPV+ transient,HPV+ persistent,patients whose HPV infection persisted for 12 months,6,4,1 month,16S,4,Ion Torrent,LEfSe,0.05,TRUE,4,NA,NA,NA,increased,increased,increased,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:435/4/NA,Study 435,"cross-sectional observational, not case-control",33207260,10.1016/j.micpath.2020.104617,NA,"Qingqing B, Jie Z, Songben Q, Juan C, Lei Z , Mu X",Cervicovaginal microbiota dysbiosis correlates with HPV persistent infection,Microbial pathogenesis,2021,"16S rDNA sequencing, Cervicovaginal microbiota, HPV persistent Infection, Host immunosuppression",Experiment 4,China,Homo sapiens,Uterine cervix,UBERON:0000002,Human papilloma virus infection,EFO:0001668,HPV- controls,HPV+ persistence,HPV infection of the same type that lasts for more than 12 months,5,6,1 month,16S,4,Ion Torrent,LEfSe,0.05,TRUE,4,NA,NA,NA,increased,increased,increased,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:436/1/NA,Study 436,"cross-sectional observational, not case-control",32941440,10.1371/journal.pone.0238705,NA,"So KA, Yang EJ, Kim NR, Hong SR, Lee JH, Hwang CS, Shim SH, Lee SJ , Kim TJ",Changes of vaginal microbiota during cervical carcinogenesis in women with human papillomavirus infection,PloS one,2020,NA,Experiment 1,South Korea,Homo sapiens,Vaginal fluid,UBERON:0036243,Cervical glandular intraepithelial neoplasia,EFO:1000165,healthy controls,CIN2+/cervical cancer,patients with cervical intraepithelial neoplasia 2+ or cervical cancer confirmed by biopsy,10,20,NA,16S,34,Illumina,Chi-Square,0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:437/1/NA,Study 437,"cross-sectional observational, not case-control",32656096,10.3389/fcimb.2020.00286,NA,"Yang Q, Wang Y, Wei X, Zhu J, Wang X, Xie X , Lu W",The Alterations of Vaginal Microbiome in HPV16 Infection as Identified by Shotgun Metagenomic Sequencing,Frontiers in cellular and infection microbiology,2020,"HPV infection, cervical cancer, metabolism, shotgun metagenomic sequencing, vaginal microbiome",Experiment 1,China,Homo sapiens,Vaginal fluid,UBERON:0036243,Human papilloma virus infection,EFO:0001668,Healthy control,HPV-16+,Patients with HPV-16 positive without lesion confirmed by HPV genotyping assay,25,27,1 month,WMS,NA,Illumina,LEfSe,0.05,TRUE,2,age,NA,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:438/1/NA,Study 438,prospective cohort,22948872,10.1128/AAC.00789-12,NA,"Fouhy F, Guinane CM, Hussey S, Wall R, Ryan CA, Dempsey EM, Murphy B, Ross RP, Fitzgerald GF, Stanton C , Cotter PD","High-throughput sequencing reveals the incomplete, short-term recovery of infant gut microbiota following parenteral antibiotic treatment with ampicillin and gentamicin",Antimicrobial agents and chemotherapy,2012,NA,Experiment 1,Ireland,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,Untreated controls (week 4),Antibiotic treated (week 4),Had received parenteral antibiotic treatment with a combination of ampicillin and gentamicin within 48 hours of birth,9,9,excluded if they required oral antibiotics (no time frame given),16S,4,Roche454,Mann-Whitney (Wilcoxon),0.05,NA,NA,NA,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:438/2/NA,Study 438,prospective cohort,22948872,10.1128/AAC.00789-12,NA,"Fouhy F, Guinane CM, Hussey S, Wall R, Ryan CA, Dempsey EM, Murphy B, Ross RP, Fitzgerald GF, Stanton C , Cotter PD","High-throughput sequencing reveals the incomplete, short-term recovery of infant gut microbiota following parenteral antibiotic treatment with ampicillin and gentamicin",Antimicrobial agents and chemotherapy,2012,NA,Experiment 2,Ireland,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,Untreated controls (week 8),Antibiotic treated (week 8),Received parenteral antibiotic treatment with a combination of ampicillin and gentamicin within 48 hours of birth,9,9,excluded if they required oral antibiotics (no time frame given),16S,4,Roche454,Mann-Whitney (Wilcoxon),0.05,NA,NA,NA,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:438/3/NA,Study 438,prospective cohort,22948872,10.1128/AAC.00789-12,NA,"Fouhy F, Guinane CM, Hussey S, Wall R, Ryan CA, Dempsey EM, Murphy B, Ross RP, Fitzgerald GF, Stanton C , Cotter PD","High-throughput sequencing reveals the incomplete, short-term recovery of infant gut microbiota following parenteral antibiotic treatment with ampicillin and gentamicin",Antimicrobial agents and chemotherapy,2012,NA,Experiment 3,Ireland,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,Week 4 (treated),Week 8 (treated),Had received parenteral antibiotic treatment with a combination of ampicillin and gentamicin within 48 hours of birth,9,9,excluded if they required oral antibiotics (no time frame given),16S,4,Roche454,Mann-Whitney (Wilcoxon),0.05,NA,NA,NA,NA,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:439/1/NA,Study 439,case-control,32158702,10.3389/fcimb.2020.00063,https://pubmed.ncbi.nlm.nih.gov/32158702/,"Doumatey AP, Adeyemo A, Zhou J, Lei L, Adebamowo SN, Adebamowo C , Rotimi CN",Gut Microbiome Profiles Are Associated With Type 2 Diabetes in Urban Africans,Frontiers in cellular and infection microbiology,2020,"16S V4 rRNA sequencing, gut microbiome, microbial composition, type 2 diabetes, urban Africans",Experiment 1,Nigeria,Homo sapiens,Feces,UBERON:0001988,Type II diabetes mellitus,MONDO:0005148,Healthy controls,Individuals diagnosed with Type 2 Diabetes Mellitus,"Individuals diagnosed with Type 2 Diabetes Mellitus; The definition of T2D was based on the American Diabetes Association (ADA) criteria: a fasting plasma glucose concentration (FPG) ≥ 126 mg/dl (7.0 mmol/l) or a 2-h post-load value in the oral glucose tolerance test ≥ 200 mg/dl (11.1 mmol/l) on more than one occasion. Alternatively, a diagnosis of T2D was accepted if an individual was on pharmacological treatment for T2D, and a review of clinical records indicated adequate justification for that therapy.",193,98,NA,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,increased,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:440/1/NA,Study 440,case-control,31502207,10.1007/s40257-019-00471-5,https://pubmed.ncbi.nlm.nih.gov/31502207/,"Rainer BM, Thompson KG, Antonescu C, Florea L, Mongodin EF, Bui J, Fischer AH, Pasieka HB, Garza LA, Kang S , Chien AL",Characterization and Analysis of the Skin Microbiota in Rosacea: A Case-Control Study,American journal of clinical dermatology,2020,NA,Experiment 1,United States of America,Homo sapiens,"Nose,Skin of cheek","UBERON:0000004,UBERON:0008803",Rosacea,EFO:1000760,Healthy controls,Participants with papulopustular rosacea (PPR),Participants with rosacea included individuals with diagnosed papulopustular rosacea (PPR): severity of rosacea assessed using the National Rosacea Society clinical grading system ranged from mild to moderate,19,19,"4 weeks for topical antibiotics, corticosteroids, and other anti-inflammatory medications, within 8 weeks for systemic antibiotics, corticosteroids, and other immunosuppressive agents",16S,34,Illumina,Metastats,0.05,TRUE,NA,"age,race,sex",NA,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:440/2/NA,Study 440,case-control,31502207,10.1007/s40257-019-00471-5,https://pubmed.ncbi.nlm.nih.gov/31502207/,"Rainer BM, Thompson KG, Antonescu C, Florea L, Mongodin EF, Bui J, Fischer AH, Pasieka HB, Garza LA, Kang S , Chien AL",Characterization and Analysis of the Skin Microbiota in Rosacea: A Case-Control Study,American journal of clinical dermatology,2020,NA,Experiment 2,United States of America,Homo sapiens,"Nose,Skin of cheek","UBERON:0000004,UBERON:0008803",Rosacea,EFO:1000760,Healthy controls,Participants with erythematotelangiectatic rosacea,Participants with rosacea included individuals with diagnosed erythematotelangiectatic rosacea (ETR): severity of rosacea assessed using the National Rosacea Society clinical grading system ranged from mild to moderate,19,19,"4 weeks for topical antibiotics, corticosteroids, and other anti-inflammatory medications, within 8 weeks for systemic antibiotics, corticosteroids, and other immunosuppressive agents",16S,34,Illumina,Metastats,0.05,TRUE,NA,"age,race,sex",NA,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:441/1/NA,Study 441,"cross-sectional observational, not case-control",32497191,https://doi.org/10.1093/cid/ciaa709,NA,"Gu S, Chen Y, Wu Z, Chen Y, Gao H, Lv L, Guo F, Zhang X, Luo R, Huang C, Lu H, Zheng B, Zhang J, Yan R, Zhang H, Jiang H, Xu Q, Guo J, Gong Y, Tang L , Li L",Alterations of the Gut Microbiota in Patients With Coronavirus Disease 2019 or H1N1 Influenza,Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,2020,"COVID-19, H1N1, biomarker, dysbiosis, intestinal microbiota",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,COVID-19,MONDO:0100096,Healthy controls,COVID-19 cases,viral COVID-19 infections confirmed by real-time reverse-transcription polymerase chain reaction,30,30,4 weeks,16S,34,Illumina,LEfSe,0.05,TRUE,3.5,"age,body mass index,sex",NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:441/2/NA,Study 441,"cross-sectional observational, not case-control",32497191,https://doi.org/10.1093/cid/ciaa709,NA,"Gu S, Chen Y, Wu Z, Chen Y, Gao H, Lv L, Guo F, Zhang X, Luo R, Huang C, Lu H, Zheng B, Zhang J, Yan R, Zhang H, Jiang H, Xu Q, Guo J, Gong Y, Tang L , Li L",Alterations of the Gut Microbiota in Patients With Coronavirus Disease 2019 or H1N1 Influenza,Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,2020,"COVID-19, H1N1, biomarker, dysbiosis, intestinal microbiota",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Influenza A (H1N1),EFO:1001488,Healthy controls,H1N1 cases,H1N1 patients with viral infection confirmed by real-time reverse-transcription polymerase chain reaction hospitalized between January 2018 and March 2019 with severe disease at time of admission,30,24,4 weeks,16S,34,Illumina,LEfSe,0.05,TRUE,3.5,"age,body mass index,sex",NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:441/3/NA,Study 441,"cross-sectional observational, not case-control",32497191,https://doi.org/10.1093/cid/ciaa709,NA,"Gu S, Chen Y, Wu Z, Chen Y, Gao H, Lv L, Guo F, Zhang X, Luo R, Huang C, Lu H, Zheng B, Zhang J, Yan R, Zhang H, Jiang H, Xu Q, Guo J, Gong Y, Tang L , Li L",Alterations of the Gut Microbiota in Patients With Coronavirus Disease 2019 or H1N1 Influenza,Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,2020,"COVID-19, H1N1, biomarker, dysbiosis, intestinal microbiota",Experiment 3,China,Homo sapiens,Feces,UBERON:0001988,COVID-19,MONDO:0100096,H1N1 patients,COVID-19 patients,viral COVID-19 infections confirmed by real-time reverse-transcription polymerase chain reaction,24,30,subjects who received antibiotics and/or probiotics within 4 weeks of enrollment were excluded,16S,34,Illumina,LEfSe,0.05,TRUE,3.5,NA,NA,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:441/4/NA,Study 441,"cross-sectional observational, not case-control",32497191,https://doi.org/10.1093/cid/ciaa709,NA,"Gu S, Chen Y, Wu Z, Chen Y, Gao H, Lv L, Guo F, Zhang X, Luo R, Huang C, Lu H, Zheng B, Zhang J, Yan R, Zhang H, Jiang H, Xu Q, Guo J, Gong Y, Tang L , Li L",Alterations of the Gut Microbiota in Patients With Coronavirus Disease 2019 or H1N1 Influenza,Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,2020,"COVID-19, H1N1, biomarker, dysbiosis, intestinal microbiota",Experiment 4,China,Homo sapiens,Feces,UBERON:0001988,COVID-19,MONDO:0100096,Healthy controls,COVID-19 cases,viral COVID-19 infections confirmed by real-time reverse-transcription polymerase chain reaction,30,30,4 weeks,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,"age,body mass index,sex",NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:442/1/NA,Study 442,"cross-sectional observational, not case-control",31834952,10.1111/myc.13046,https://pubmed.ncbi.nlm.nih.gov/31834952/,"Han SH, Lee JS, Song KH, Choe YB, Ahn KJ , Lee YW",Differences in foot skin microbiomes between patients with type 2 diabetes and healthy individuals,Mycoses,2020,"Trichophyton rubrum, biodiversity, diabetes mellitus, microbiome",Experiment 1,South Korea,Homo sapiens,"Skin of sole of pes,Interdigital space","UBERON:0013778,UBERON:0036252",Type II diabetes mellitus,MONDO:0005148,Healthy controls,Individuals diagnosed with Type 2 Diabetes Mellitus,"Type 2 Diabetes Mellitus patients diagnosed by an endocrinologist at Konkuk University Medical Center, Seoul, Korea",18,17,concomitant systemic (within four weeks of enrolment) or topical (within two weeks of enrolment) treatments,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,decreased,NA,unchanged,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:442/2/NA,Study 442,"cross-sectional observational, not case-control",31834952,10.1111/myc.13046,https://pubmed.ncbi.nlm.nih.gov/31834952/,"Han SH, Lee JS, Song KH, Choe YB, Ahn KJ , Lee YW",Differences in foot skin microbiomes between patients with type 2 diabetes and healthy individuals,Mycoses,2020,"Trichophyton rubrum, biodiversity, diabetes mellitus, microbiome",Experiment 2,South Korea,Homo sapiens,"Skin of sole of pes,Interdigital space","UBERON:0013778,UBERON:0036252",Type II diabetes mellitus,MONDO:0005148,Healthy controls,Individuals diagnosed with Type 2 Diabetes Mellitus,"Type 2 Diabetes Mellitus patients diagnosed by an endocrinologist at Konkuk University Medical Center, Seoul, Korea",18,17,concomitant systemic (within four weeks of enrolment) or topical (within two weeks of enrolment) treatments,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,unchanged,NA,unchanged,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:443/1/NA,Study 443,case-control,25784074,10.1007/s10620-015-3607-y,NA,"Shukla R, Ghoshal U, Dhole TN , Ghoshal UC",Fecal Microbiota in Patients with Irritable Bowel Syndrome Compared with Healthy Controls Using Real-Time Polymerase Chain Reaction: An Evidence of Dysbiosis,Digestive diseases and sciences,2015,"Dysbiosis, Functional gastrointestinal disorder, Gastrointestinal microbiota, Quantitative real-time polymerase chain reaction",Experiment 1,India,Homo sapiens,Feces,UBERON:0001988,Irritable bowel syndrome,EFO:0000555,Healthy Control,IBS,"Patients with IBS diagnosed using Rome III. Patients were classified into three sub-types
using Rome III criteria: constipation predominant IBS (IBS-C), diarrhea predominant (IBS-D), and un-subtyped (IBS-U). All participants.",30,47,4 weeks,16S,NA,RT-qPCR,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,"age,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:443/2/NA,Study 443,case-control,25784074,10.1007/s10620-015-3607-y,NA,"Shukla R, Ghoshal U, Dhole TN , Ghoshal UC",Fecal Microbiota in Patients with Irritable Bowel Syndrome Compared with Healthy Controls Using Real-Time Polymerase Chain Reaction: An Evidence of Dysbiosis,Digestive diseases and sciences,2015,"Dysbiosis, Functional gastrointestinal disorder, Gastrointestinal microbiota, Quantitative real-time polymerase chain reaction",Experiment 2,India,Homo sapiens,Feces,UBERON:0001988,Irritable bowel syndrome,EFO:0000555,Health Control,IBS-C,"Patients with IBS diagnosed using Rome III. Patients were classified into three sub-types
using Rome III criteria: constipation predominant IBS (IBS-C).",30,20,"Patients who had prior history of gastrointestinal surgery, inflammatory bowel disease, and celiac disease were excluded. Patients with IBS who used antibiotics, probiotics, or prokinetics within last 4 weeks of inclusion into the study were also excluded.",16S,NA,RT-qPCR,Kruskall-Wallis,0.05,TRUE,NA,"age,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:443/3/NA,Study 443,case-control,25784074,10.1007/s10620-015-3607-y,NA,"Shukla R, Ghoshal U, Dhole TN , Ghoshal UC",Fecal Microbiota in Patients with Irritable Bowel Syndrome Compared with Healthy Controls Using Real-Time Polymerase Chain Reaction: An Evidence of Dysbiosis,Digestive diseases and sciences,2015,"Dysbiosis, Functional gastrointestinal disorder, Gastrointestinal microbiota, Quantitative real-time polymerase chain reaction",Experiment 3,India,Homo sapiens,Feces,UBERON:0001988,Irritable bowel syndrome,EFO:0000555,Health Control,IBS-D,"Patients with IBS diagnosed using Rome III. Patients were classified into three sub-types
using Rome III criteria: diarrhea predominant IBS (IBS-D).",30,20,"Patients who had prior history of gastrointestinal surgery, inflammatory bowel disease, and celiac disease were excluded. Patients with IBS who used antibiotics, probiotics, or prokinetics within last 4 weeks of inclusion into the study were also excluded.",16S,NA,RT-qPCR,Kruskall-Wallis,0.05,TRUE,NA,"age,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:443/4/NA,Study 443,case-control,25784074,10.1007/s10620-015-3607-y,NA,"Shukla R, Ghoshal U, Dhole TN , Ghoshal UC",Fecal Microbiota in Patients with Irritable Bowel Syndrome Compared with Healthy Controls Using Real-Time Polymerase Chain Reaction: An Evidence of Dysbiosis,Digestive diseases and sciences,2015,"Dysbiosis, Functional gastrointestinal disorder, Gastrointestinal microbiota, Quantitative real-time polymerase chain reaction",Experiment 4,India,Homo sapiens,Feces,UBERON:0001988,Irritable bowel syndrome,EFO:0000555,Health Control,IBS-U,Patients with IBS diagnosed using Rome III. Patients were classified into sub-types: un-subtyped (IBS-U).,30,7,"Patients who had prior history of gastrointestinal surgery, inflammatory bowel disease, and celiac disease were excluded. Patients with IBS who used antibiotics, probiotics, or prokinetics within last 4 weeks of inclusion into the study were also excluded.",16S,NA,RT-qPCR,Kruskall-Wallis,0.05,TRUE,NA,"age,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:443/5/NA,Study 443,case-control,25784074,10.1007/s10620-015-3607-y,NA,"Shukla R, Ghoshal U, Dhole TN , Ghoshal UC",Fecal Microbiota in Patients with Irritable Bowel Syndrome Compared with Healthy Controls Using Real-Time Polymerase Chain Reaction: An Evidence of Dysbiosis,Digestive diseases and sciences,2015,"Dysbiosis, Functional gastrointestinal disorder, Gastrointestinal microbiota, Quantitative real-time polymerase chain reaction",Experiment 5,India,Homo sapiens,Feces,UBERON:0001988,Irritable bowel syndrome,EFO:0000555,"Irritable Bowel Syndrome, diarrhea predominant (IBS-D)","Irritable Bowel Syndrome, constipation predominant (IBS-C)",Patients were classified into three sub-types using Rome III criteria: diarrhea predominant IBS (IBS-D).,20,20,4 weeks,16S,NA,RT-qPCR,Kruskall-Wallis,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:443/6/NA,Study 443,case-control,25784074,10.1007/s10620-015-3607-y,NA,"Shukla R, Ghoshal U, Dhole TN , Ghoshal UC",Fecal Microbiota in Patients with Irritable Bowel Syndrome Compared with Healthy Controls Using Real-Time Polymerase Chain Reaction: An Evidence of Dysbiosis,Digestive diseases and sciences,2015,"Dysbiosis, Functional gastrointestinal disorder, Gastrointestinal microbiota, Quantitative real-time polymerase chain reaction",Experiment 6,India,Homo sapiens,Feces,UBERON:0001988,Irritable bowel syndrome,EFO:0000555,No Visible abdominal distension,Visible abdominal distension,Patients with IBS showing Visible abdominal distension as symptoms,13,34,4 weeks,16S,NA,RT-qPCR,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:443/7/NA,Study 443,case-control,25784074,10.1007/s10620-015-3607-y,NA,"Shukla R, Ghoshal U, Dhole TN , Ghoshal UC",Fecal Microbiota in Patients with Irritable Bowel Syndrome Compared with Healthy Controls Using Real-Time Polymerase Chain Reaction: An Evidence of Dysbiosis,Digestive diseases and sciences,2015,"Dysbiosis, Functional gastrointestinal disorder, Gastrointestinal microbiota, Quantitative real-time polymerase chain reaction",Experiment 7,India,Homo sapiens,Feces,UBERON:0001988,Irritable bowel syndrome,EFO:0000555,No Abdominal Bloating,Abdominal Bloating,Patients with IBS showing Abdominal Bloating/Abdominal discomfort as symptoms,25,22,4 Weeks,16S,NA,RT-qPCR,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:444/1/NA,Study 444,prospective cohort,36381318,NA,NA,"Himbert C, Stephens WZ, Gigic B, Hardikar S, Holowatyj AN, Lin T, Ose J, Swanson E, Ashworth A, Warby CA, Peoples AR, Nix D, Jedrzkiewicz J, Bronner M, Pickron B, Scaife C, Cohan JN, Schrotz-King P, Habermann N, Boehm J, Hullar M, Figueiredo JC, Toriola AT, Siegel EM, Li CI, Ulrich AB, Shibata D, Boucher K, Huang LC, Schneider M, Round JL , Ulrich CM",Differences in the gut microbiome by physical activity and BMI among colorectal cancer patients,American journal of cancer research,2022,"Colorectal cancer, energy balance, microbiome, obesity, physical activity",Experiment 1,"United States of America,Germany",Homo sapiens,Feces,UBERON:0001988,Physical activity,EFO:0003940,Active patients,Inactive patients,Patients that are not engaged in any regular physical activity or exercise.,72,107,4 weeks,16S,34,Illumina,Wald Test,0.05,TRUE,NA,NA,sex,NA,decreased,NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:444/2/NA,Study 444,prospective cohort,36381318,NA,NA,"Himbert C, Stephens WZ, Gigic B, Hardikar S, Holowatyj AN, Lin T, Ose J, Swanson E, Ashworth A, Warby CA, Peoples AR, Nix D, Jedrzkiewicz J, Bronner M, Pickron B, Scaife C, Cohan JN, Schrotz-King P, Habermann N, Boehm J, Hullar M, Figueiredo JC, Toriola AT, Siegel EM, Li CI, Ulrich AB, Shibata D, Boucher K, Huang LC, Schneider M, Round JL , Ulrich CM",Differences in the gut microbiome by physical activity and BMI among colorectal cancer patients,American journal of cancer research,2022,"Colorectal cancer, energy balance, microbiome, obesity, physical activity",Experiment 2,"United States of America,Germany",Homo sapiens,Feces,UBERON:0001988,Body mass index,EFO:0004340,Normal weight patients,Overweight patients,Patient with a BMI greater than or equal to 25 kg/m2 but not greater than 30 kg/m2.,59,76,4 weeks,16S,34,Illumina,Wald Test,0.05,TRUE,NA,NA,sex,NA,decreased,NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:444/3/NA,Study 444,prospective cohort,36381318,NA,NA,"Himbert C, Stephens WZ, Gigic B, Hardikar S, Holowatyj AN, Lin T, Ose J, Swanson E, Ashworth A, Warby CA, Peoples AR, Nix D, Jedrzkiewicz J, Bronner M, Pickron B, Scaife C, Cohan JN, Schrotz-King P, Habermann N, Boehm J, Hullar M, Figueiredo JC, Toriola AT, Siegel EM, Li CI, Ulrich AB, Shibata D, Boucher K, Huang LC, Schneider M, Round JL , Ulrich CM",Differences in the gut microbiome by physical activity and BMI among colorectal cancer patients,American journal of cancer research,2022,"Colorectal cancer, energy balance, microbiome, obesity, physical activity",Experiment 3,"United States of America,Germany",Homo sapiens,Feces,UBERON:0001988,Body mass index,EFO:0004340,Normal weight patients,Obese patients,Patients with a BMI greater than 30 kg/m2,59,44,4 weeks,16S,34,Illumina,Wald Test,0.05,TRUE,NA,NA,sex,NA,decreased,NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:444/4/NA,Study 444,prospective cohort,36381318,NA,NA,"Himbert C, Stephens WZ, Gigic B, Hardikar S, Holowatyj AN, Lin T, Ose J, Swanson E, Ashworth A, Warby CA, Peoples AR, Nix D, Jedrzkiewicz J, Bronner M, Pickron B, Scaife C, Cohan JN, Schrotz-King P, Habermann N, Boehm J, Hullar M, Figueiredo JC, Toriola AT, Siegel EM, Li CI, Ulrich AB, Shibata D, Boucher K, Huang LC, Schneider M, Round JL , Ulrich CM",Differences in the gut microbiome by physical activity and BMI among colorectal cancer patients,American journal of cancer research,2022,"Colorectal cancer, energy balance, microbiome, obesity, physical activity",Experiment 4,"United States of America,Germany",Homo sapiens,Feces,UBERON:0001988,"Body mass index,Physical activity","EFO:0004340,EFO:0003940",Normal weight/active patients,Normal weight/inactive patients,Patient that has a BMI greater than 18.5 kg/m2 but less than 25 kg/m2 and engaged in little to no physical activity on a regular basis.,26,33,4 weeks,16S,34,Illumina,Wald Test,0.05,TRUE,NA,NA,sex,NA,decreased,NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:444/5/NA,Study 444,prospective cohort,36381318,NA,NA,"Himbert C, Stephens WZ, Gigic B, Hardikar S, Holowatyj AN, Lin T, Ose J, Swanson E, Ashworth A, Warby CA, Peoples AR, Nix D, Jedrzkiewicz J, Bronner M, Pickron B, Scaife C, Cohan JN, Schrotz-King P, Habermann N, Boehm J, Hullar M, Figueiredo JC, Toriola AT, Siegel EM, Li CI, Ulrich AB, Shibata D, Boucher K, Huang LC, Schneider M, Round JL , Ulrich CM",Differences in the gut microbiome by physical activity and BMI among colorectal cancer patients,American journal of cancer research,2022,"Colorectal cancer, energy balance, microbiome, obesity, physical activity",Experiment 5,"United States of America,Germany",Homo sapiens,Feces,UBERON:0001988,"Body mass index,Physical activity","EFO:0004340,EFO:0003940",Normal weight/active patients,Overweight/Obese/active patients,Patient with a BMI greater than or equal to 25 kg/m2 but is also physically active.,26,46,4 weeks,16S,34,Illumina,Wald Test,0.05,TRUE,NA,NA,sex,NA,decreased,NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:444/6/NA,Study 444,prospective cohort,36381318,NA,NA,"Himbert C, Stephens WZ, Gigic B, Hardikar S, Holowatyj AN, Lin T, Ose J, Swanson E, Ashworth A, Warby CA, Peoples AR, Nix D, Jedrzkiewicz J, Bronner M, Pickron B, Scaife C, Cohan JN, Schrotz-King P, Habermann N, Boehm J, Hullar M, Figueiredo JC, Toriola AT, Siegel EM, Li CI, Ulrich AB, Shibata D, Boucher K, Huang LC, Schneider M, Round JL , Ulrich CM",Differences in the gut microbiome by physical activity and BMI among colorectal cancer patients,American journal of cancer research,2022,"Colorectal cancer, energy balance, microbiome, obesity, physical activity",Experiment 6,"United States of America,Germany",Homo sapiens,Feces,UBERON:0001988,"Body mass index,Physical activity","EFO:0004340,EFO:0003940",Normal weight/active patients,Overweight/Obese/inactive patients,Patient with a BMI equal to or greater than 25 kg/m2 and is physically inactive.,26,74,4 weeks,16S,34,Illumina,Wald Test,0.05,TRUE,NA,NA,sex,NA,decreased,NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:444/7/NA,Study 444,prospective cohort,36381318,NA,NA,"Himbert C, Stephens WZ, Gigic B, Hardikar S, Holowatyj AN, Lin T, Ose J, Swanson E, Ashworth A, Warby CA, Peoples AR, Nix D, Jedrzkiewicz J, Bronner M, Pickron B, Scaife C, Cohan JN, Schrotz-King P, Habermann N, Boehm J, Hullar M, Figueiredo JC, Toriola AT, Siegel EM, Li CI, Ulrich AB, Shibata D, Boucher K, Huang LC, Schneider M, Round JL , Ulrich CM",Differences in the gut microbiome by physical activity and BMI among colorectal cancer patients,American journal of cancer research,2022,"Colorectal cancer, energy balance, microbiome, obesity, physical activity",Experiment 7,"United States of America,Germany",Homo sapiens,Feces,UBERON:0001988,"Body mass index,Physical activity","EFO:0004340,EFO:0003940",Overweight/Obese/active patients,Overweight/Obese/inactive patients,Patients with BMI greater than or equal to 25 kg/m2 and are not physically active.,46,74,4 weeks,16S,34,Illumina,Wald Test,0.05,TRUE,NA,NA,sex,NA,decreased,NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:445/1/NA,Study 445,"cross-sectional observational, not case-control",32728349,10.1186/s12575-020-00131-7,https://doi.org/10.1186/s12575-020-00131-7,"De Maio F, Posteraro B, Ponziani FR, Cattani P, Gasbarrini A , Sanguinetti M",Nasopharyngeal Microbiota Profiling of SARS-CoV-2 Infected Patients,Biological procedures online,2020,"16S rRNA sequencing, Bacterial community, Nasopharynx, SARS-CoV-2 infection",Experiment 1,Italy,Homo sapiens,Nasopharynx,UBERON:0001728,COVID-19,MONDO:0100096,COVID-19 negative patients,COVID-19 cases,Diagnosis with COVID-19 based on SARS-CoV-2 RNA detection using real-time reverse transcriptase-polymerase chain reaction (RT-PCR) assay,22,18,NA,16S,56,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:446/1/NA,Study 446,"cross-sectional observational, not case-control",33219095,10.1128/mBio.01969-20,NA,"Mostafa HH, Fissel JA, Fanelli B, Bergman Y, Gniazdowski V, Dadlani M, Carroll KC, Colwell RR , Simner PJ",Metagenomic Next-Generation Sequencing of Nasopharyngeal Specimens Collected from Confirmed and Suspect COVID-19 Patients,mBio,2020,"COVID-19, SARS-CoV-2, metagenomic next-generation sequencing, metagenomics, nasopharyngeal",Experiment 1,United States of America,Homo sapiens,Nasopharynx,UBERON:0001728,COVID-19,MONDO:0100096,COVID-19 negative controls,COVID-19 cases,Positive for SaRS-CoV-2 by diagnostic RT-PCR,10,40,NA,WMS,NA,Nanopore,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,decreased,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:447/1/NA,Study 447,case-control,31891538,10.1152/ajpendo.00266.2019,https://pubmed.ncbi.nlm.nih.gov/31891538/,"Xu Y, Zhang M, Zhang J, Sun Z, Ran L, Ban Y, Wang B, Hou X, Zhai S, Ren L, Wang M , Hu J",Differential intestinal and oral microbiota features associated with gestational diabetes and maternal inflammation,American journal of physiology. Endocrinology and metabolism,2020,"16S rRNA, gestational diabetes mellitus, intestinal microbiota, oral microbiota",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Gestational diabetes,EFO:0004593,Healthy controls,Individuals with gestational diabetes,Individuals with gestational diabetes at third trimester during pregnancy,31,30,2 weeks,16S,34,Illumina,"LEfSe,Mann-Whitney (Wilcoxon)",0.05,TRUE,2,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:447/2/NA,Study 447,case-control,31891538,10.1152/ajpendo.00266.2019,https://pubmed.ncbi.nlm.nih.gov/31891538/,"Xu Y, Zhang M, Zhang J, Sun Z, Ran L, Ban Y, Wang B, Hou X, Zhai S, Ren L, Wang M , Hu J",Differential intestinal and oral microbiota features associated with gestational diabetes and maternal inflammation,American journal of physiology. Endocrinology and metabolism,2020,"16S rRNA, gestational diabetes mellitus, intestinal microbiota, oral microbiota",Experiment 2,China,Homo sapiens,Saliva,UBERON:0001836,Gestational diabetes,EFO:0004593,Healthy controls,Individuals with gestational diabetes,Individuals with gestational diabetes at third trimester during pregnancy,31,30,2 weeks,16S,34,Illumina,"LEfSe,Mann-Whitney (Wilcoxon)",0.05,TRUE,2,NA,NA,NA,unchanged,decreased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:448/1/NA,Study 448,case-control,23167452,https://doi.org/10.1111/1469-0691.12054,NA,"Leung RK, Zhou JW, Guan W, Li SK, Yang ZF , Tsui SK",Modulation of potential respiratory pathogens by pH1N1 viral infection,Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,2013,"Cell motility, chemotaxis, microbiota, pH1N1, pneumonia",Experiment 1,China,Homo sapiens,Throat,UBERON:0000341,Influenza A (H1N1),EFO:1001488,Pneumonia patients without any influenza A infection,Pneumonia patients with pH1N1 infection,"Positive lab test (real-time PCR or cell culture) and criteria for pneumonia simultaneously met, with pH1N1 infection",11,11,NA,WMS,NA,Illumina,DESeq2,0.05,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:449/1/NA,Study 449,"cross-sectional observational, not case-control",35411293,10.34172/bi.2021.23378,NA,"Han Y, Jia Z, Shi J, Wang W , He K",The active lung microbiota landscape of COVID-19 patients through the metatranscriptome data analysis,BioImpacts : BI,2022,"COVID-19, Faecalibacterium prausnitzii, Lactic acid bacteria, Microbiota, SARS-CoV-2",Experiment 1,China,Homo sapiens,Lung,UBERON:0002048,COVID-19,MONDO:0100096,Healthy controls,COVID-19 cases,COVID-19 infected patients,23,19,NIL,WMS,NA,NA,DESeq2,0.05,TRUE,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:450/1/NA,Study 450,laboratory experiment,29483910,10.3389/fimmu.2018.00182,NA,"Groves HT, Cuthbertson L, James P, Moffatt MF, Cox MJ , Tregoning JS",Respiratory Disease following Viral Lung Infection Alters the Murine Gut Microbiota,Frontiers in immunology,2018,"Bacteroidetes, Firmicutes, Mucin 5ac, gut microbiota, influenza, respiratory syncytial virus infections",Experiment 1,United Kingdom,Mus musculus,Feces,UBERON:0001988,Sampling time,EFO:0000689,Day 0,Day 7,Mice assessed 7 days after infection with respiratory syncytial virus (RSV),NA,NA,NA,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:450/2/NA,Study 450,laboratory experiment,29483910,10.3389/fimmu.2018.00182,NA,"Groves HT, Cuthbertson L, James P, Moffatt MF, Cox MJ , Tregoning JS",Respiratory Disease following Viral Lung Infection Alters the Murine Gut Microbiota,Frontiers in immunology,2018,"Bacteroidetes, Firmicutes, Mucin 5ac, gut microbiota, influenza, respiratory syncytial virus infections",Experiment 2,United Kingdom,Mus musculus,Feces,UBERON:0001988,Sampling time,EFO:0000689,Day 0,Day 7,Day 7 of infection for mice infected with influenza virus (H1N1),NA,NA,NA,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:450/3/NA,Study 450,laboratory experiment,29483910,10.3389/fimmu.2018.00182,NA,"Groves HT, Cuthbertson L, James P, Moffatt MF, Cox MJ , Tregoning JS",Respiratory Disease following Viral Lung Infection Alters the Murine Gut Microbiota,Frontiers in immunology,2018,"Bacteroidetes, Firmicutes, Mucin 5ac, gut microbiota, influenza, respiratory syncytial virus infections",Experiment 3,United Kingdom,Mus musculus,Feces,UBERON:0001988,Sampling time,EFO:0000689,Day 0,Day 7,Day 7 of infection for mice infected with phosphate-buffered saline (PBS).,NA,NA,NA,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:451/1/NA,Study 451,case-control,33613481,10.3389/fmicb.2021.610370,https://pubmed.ncbi.nlm.nih.gov/33613481/,"Almeida-Santos A, Martins-Mendes D, Gayà-Vidal M, Pérez-Pardal L , Beja-Pereira A",Characterization of the Oral Microbiome of Medicated Type-2 Diabetes Patients,Frontiers in microbiology,2021,"16S rRNA gene sequencing, Portugal, microbiota, next-generation sequencing, oral hygiene, type 2 diabetes mellitus",Experiment 1,Portugal,Homo sapiens,Saliva,UBERON:0001836,Type II diabetes mellitus,MONDO:0005148,Healthy controls,Medicated Type II Diabetes individuals,Medicated Type II Diabetes individuals,24,22,2 months,16S,34,Illumina,"Mann-Whitney (Wilcoxon),ANCOM",0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:452/1/NA,Study 452,"cross-sectional observational, not case-control",33193081,10.3389/fendo.2020.550319,https://pubmed.ncbi.nlm.nih.gov/33193081/,"Tang N, Luo ZC, Zhang L, Zheng T, Fan P, Tao Y , Ouyang F",The Association Between Gestational Diabetes and Microbiota in Placenta and Cord Blood,Frontiers in endocrinology,2020,"China, cord blood, gestational diabetes mellitus (GDM), microbiota, placenta",Experiment 1,China,Homo sapiens,Placenta,UBERON:0001987,Gestational diabetes,EFO:0004593,euglycemic (control) singleton pregnant women,Pregnant women with Gestational Diabetes Mellitus,"Pregnant women with Gestational Diabetes Mellitus (GDM) who had prenatal care at Xinhua Hospital, a tertiary hospital in Shanghai, and were admitted to the hospital for cesarean deliveries",7,8,Women who were treated with any antibiotics during pregnancy,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,increased,increased,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:453/1/NA,Study 453,case-control,34100340,10.1080/19490976.2021.1926840,NA,"Newsome RC, Gauthier J, Hernandez MC, Abraham GE, Robinson TO, Williams HB, Sloan M, Owings A, Laird H, Christian T, Pride Y, Wilson KJ, Hasan M, Parker A, Senitko M, Glover SC, Gharaibeh RZ , Jobin C",The gut microbiome of COVID-19 recovered patients returns to uninfected status in a minority-dominated United States cohort,Gut microbes,2021,"16S rRNA sequencing, COVID-19, Human gut microbiota, SARS-CoV-2, clinical study, microbiome, microbiota",Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,COVID-19,MONDO:0100096,Non-infected patients with unrelated respiratory medical conditions,SARS-CoV-2 infected patients,">age 18, positive nasopharyngeal swab for SARS-CoV-2 by PCR, COVID-19 related symptoms present, weight > 110 pounds",34,50,NA,16S,123,Illumina,edgeR,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:453/2/NA,Study 453,case-control,34100340,10.1080/19490976.2021.1926840,NA,"Newsome RC, Gauthier J, Hernandez MC, Abraham GE, Robinson TO, Williams HB, Sloan M, Owings A, Laird H, Christian T, Pride Y, Wilson KJ, Hasan M, Parker A, Senitko M, Glover SC, Gharaibeh RZ , Jobin C",The gut microbiome of COVID-19 recovered patients returns to uninfected status in a minority-dominated United States cohort,Gut microbes,2021,"16S rRNA sequencing, COVID-19, Human gut microbiota, SARS-CoV-2, clinical study, microbiome, microbiota",Experiment 2,United States of America,Homo sapiens,Feces,UBERON:0001988,COVID-19,MONDO:0100096,SARS-CoV-2 infected patients,SARS-CoV-2 recovered individuals,">age 18, more than 2 weeks post-COVID-19 infection that was confirmed by positive PCR for SARS-CoV-2",50,9,NA,16S,123,Illumina,edgeR,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:453/3/NA,Study 453,case-control,34100340,10.1080/19490976.2021.1926840,NA,"Newsome RC, Gauthier J, Hernandez MC, Abraham GE, Robinson TO, Williams HB, Sloan M, Owings A, Laird H, Christian T, Pride Y, Wilson KJ, Hasan M, Parker A, Senitko M, Glover SC, Gharaibeh RZ , Jobin C",The gut microbiome of COVID-19 recovered patients returns to uninfected status in a minority-dominated United States cohort,Gut microbes,2021,"16S rRNA sequencing, COVID-19, Human gut microbiota, SARS-CoV-2, clinical study, microbiome, microbiota",Experiment 3,United States of America,Homo sapiens,Feces,UBERON:0001988,COVID-19,MONDO:0100096,Non-infected patients with unrelated respiratory medical conditions,Recovered COVID-19 patients,">age 18, more than 2 weeks post-COVID-19 infection that was confirmed by positive PCR for SARS-CoV-2",38,9,NA,16S,123,Illumina,edgeR,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:453/4/NA,Study 453,case-control,34100340,10.1080/19490976.2021.1926840,NA,"Newsome RC, Gauthier J, Hernandez MC, Abraham GE, Robinson TO, Williams HB, Sloan M, Owings A, Laird H, Christian T, Pride Y, Wilson KJ, Hasan M, Parker A, Senitko M, Glover SC, Gharaibeh RZ , Jobin C",The gut microbiome of COVID-19 recovered patients returns to uninfected status in a minority-dominated United States cohort,Gut microbes,2021,"16S rRNA sequencing, COVID-19, Human gut microbiota, SARS-CoV-2, clinical study, microbiome, microbiota",Experiment 4,United States of America,Homo sapiens,Feces,UBERON:0001988,COVID-19,MONDO:0100096,Negative for COVID-19 viral RNA in feces,Positive for COVID-19 viral RNA in feces,COVID-19 viral RNA present in feces sample,26,24,NA,16S,123,Illumina,PERMANOVA,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:454/1/NA,Study 454,"cross-sectional observational, not case-control",26992426,10.1136/gutjnl-2015-309595,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5529966/,"Flemer B, Lynch DB, Brown JM, Jeffery IB, Ryan FJ, Claesson MJ, O'Riordain M, Shanahan F , O'Toole PW",Tumour-associated and non-tumour-associated microbiota in colorectal cancer,Gut,2017,"COLORECTAL CANCER, GENE EXPRESSION, INTESTINAL MICROBIOLOGY",Experiment 1,Ireland,Homo sapiens,Intestinal mucosa,UBERON:0001242,Colorectal cancer,EFO:0005842,healthy controls,colorectal cancer (CRC),The patients undergoing surgery for CRC have confirmed CRC.,56,59,1 month,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,age,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:454/3/NA,Study 454,"cross-sectional observational, not case-control",26992426,10.1136/gutjnl-2015-309595,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5529966/,"Flemer B, Lynch DB, Brown JM, Jeffery IB, Ryan FJ, Claesson MJ, O'Riordain M, Shanahan F , O'Toole PW",Tumour-associated and non-tumour-associated microbiota in colorectal cancer,Gut,2017,"COLORECTAL CANCER, GENE EXPRESSION, INTESTINAL MICROBIOLOGY",Experiment 3,Ireland,Homo sapiens,Intestinal mucosa,UBERON:0001242,Colorectal cancer,EFO:0005842,Distal (and rectal) cancer,Proximal cancer,Patients with proximal cancer,39,20,1 month,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,age,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:455/1/NA,Study 455,"cross-sectional observational, not case-control",32777190,10.1177/2380084420948779,NA,"Balan P, Brandt BW, Chong YS, Crielaard W, Wong ML, Lopez V, He HG , Seneviratne CJ",Subgingival Microbiota during Healthy Pregnancy and Pregnancy Gingivitis,JDR clinical and translational research,2021,"Singapore, illumina sequencing, oral health, oral microbiota, pregnant women, prenatal care",Experiment 1,Singapore,Homo sapiens,Subgingival dental plaque,UBERON:0016484,Pregnancy,EFO:0002950,non pregnant women without gingivitis,pregnant women without gingivitis,Pregnant women sampled between 21 to 24 wk of gestation without gingivitis,10,10,6 months,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,increased,increased,NA,decreased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:455/2/NA,Study 455,"cross-sectional observational, not case-control",32777190,10.1177/2380084420948779,NA,"Balan P, Brandt BW, Chong YS, Crielaard W, Wong ML, Lopez V, He HG , Seneviratne CJ",Subgingival Microbiota during Healthy Pregnancy and Pregnancy Gingivitis,JDR clinical and translational research,2021,"Singapore, illumina sequencing, oral health, oral microbiota, pregnant women, prenatal care",Experiment 2,Singapore,Homo sapiens,Subgingival dental plaque,UBERON:0016484,Gingivitis,MONDO:0002508,pregnant women without gingivitis,pregnant women with gingivitis,NA,10,10,6 months,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:455/3/NA,Study 455,"cross-sectional observational, not case-control",32777190,10.1177/2380084420948779,NA,"Balan P, Brandt BW, Chong YS, Crielaard W, Wong ML, Lopez V, He HG , Seneviratne CJ",Subgingival Microbiota during Healthy Pregnancy and Pregnancy Gingivitis,JDR clinical and translational research,2021,"Singapore, illumina sequencing, oral health, oral microbiota, pregnant women, prenatal care",Experiment 3,Singapore,Homo sapiens,Subgingival dental plaque,UBERON:0016484,Gingivitis,MONDO:0002508,pregnant women without gingivitis,pregnant women with gingivitis,NA,10,10,6 months,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,unchanged,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:455/4/NA,Study 455,"cross-sectional observational, not case-control",32777190,10.1177/2380084420948779,NA,"Balan P, Brandt BW, Chong YS, Crielaard W, Wong ML, Lopez V, He HG , Seneviratne CJ",Subgingival Microbiota during Healthy Pregnancy and Pregnancy Gingivitis,JDR clinical and translational research,2021,"Singapore, illumina sequencing, oral health, oral microbiota, pregnant women, prenatal care",Experiment 4,Singapore,Homo sapiens,Subgingival dental plaque,UBERON:0016484,Pregnancy,EFO:0002950,non pregnant women,pregnant women,pregnant women,10,10,6 months,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,increased,increased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:456/1/NA,Study 456,"cross-sectional observational, not case-control",33224990,10.1155/2020/8842651,https://pubmed.ncbi.nlm.nih.gov/33224990/,"Zhao X, Zhang Y, Guo R, Yu W, Zhang F, Wu F , Shang J",The Alteration in Composition and Function of Gut Microbiome in Patients with Type 2 Diabetes,Journal of diabetes research,2020,NA,Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Diabetes mellitus,EFO:0000400,Healthy controls,Individuals diagnosed with Type 2 Diabetes Mellitus,"Patients with Type 2 Diabetes who were admitted to the First Affiliated Hospital of Zhengzhou University from October 2018 to October 2019;  The diagnostic criteria of diabetes mellitus were as follows: (1) twice fasting plasma glucose ðFPGÞ ≥ 7:0 mmol/L, (2) twice oral glucose tolerance test (OGTT ≥ 11:1 mmol/L), and (3) diabetic symptoms (polyuria, thirst, drinking more water, and unexplained weight loss) accompanied with twice random blood glucose ≥ 11:1 mmol/L.",179,137,long-term antibiotic application,16S,34,Illumina,"Mann-Whitney (Wilcoxon),LEfSe",0.05,NA,2,"age,sex",NA,NA,decreased,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:457/1/NA,Study 457,"cross-sectional observational, not case-control",32958790,10.1038/s41598-020-72035-1,https://pubmed.ncbi.nlm.nih.gov/32958790/,"Sun X, Li M, Xia L, Fang Z, Yu S, Gao J, Feng Q , Yang P",Alteration of salivary microbiome in periodontitis with or without type-2 diabetes mellitus and metformin treatment,Scientific reports,2020,NA,Experiment 1,China,Homo sapiens,Saliva,UBERON:0001836,Periodontitis,EFO:0000649,Healthy controls group,Individuals diagnosed with Periodontitis group,"Individuals with Peridontitis; Periodontal disease was assessed by determining the PD, CAL, BI, GI, and PLI, which were then measured at six sites (i.e., mesiobuccal, buccal, distobuccal, distolingual, lingual, and mesiolingual) according to the Community Periodontal Index by an experienced dentist. Periodontitis patients had a PD of ≥ 5 mm and CAL of ≥ 3 mm.",27,31,patients treated with antibiotics within 3 months or those that received periodontal treatment within 6 months.,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,increased,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:457/2/NA,Study 457,"cross-sectional observational, not case-control",32958790,10.1038/s41598-020-72035-1,https://pubmed.ncbi.nlm.nih.gov/32958790/,"Sun X, Li M, Xia L, Fang Z, Yu S, Gao J, Feng Q , Yang P",Alteration of salivary microbiome in periodontitis with or without type-2 diabetes mellitus and metformin treatment,Scientific reports,2020,NA,Experiment 2,China,Homo sapiens,Saliva,UBERON:0001836,Periodontitis,EFO:0000649,Healthy controls,Individuals diagnosed with Periodontitis and Type 2 Diabetes Mellitus (DAP),Individuals diagnosed with Periodontitis and Type 2 Diabetes Mellitus (DAP); Patients were classified into the DAP group when both periodontitis and T2DM were present.,27,46,patients treated with antibiotics within 3 months or those that received periodontal treatment within 6 months,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,increased,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:457/3/NA,Study 457,"cross-sectional observational, not case-control",32958790,10.1038/s41598-020-72035-1,https://pubmed.ncbi.nlm.nih.gov/32958790/,"Sun X, Li M, Xia L, Fang Z, Yu S, Gao J, Feng Q , Yang P",Alteration of salivary microbiome in periodontitis with or without type-2 diabetes mellitus and metformin treatment,Scientific reports,2020,NA,Experiment 3,China,Homo sapiens,Saliva,UBERON:0001836,Type II diabetes mellitus,MONDO:0005148,Healthy controls,Individuals diagnosed with Type 2 Diabetes Mellitus,"Individuals with Type 2 Diabetes; Type 2 Diabetes determined by a fasting blood sugar of > 7.0 mmol/L and an HbA1c concentration of > 7%, as stated by the American Diabetes Association in 201834",27,9,3 months,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:457/4/NA,Study 457,"cross-sectional observational, not case-control",32958790,10.1038/s41598-020-72035-1,https://pubmed.ncbi.nlm.nih.gov/32958790/,"Sun X, Li M, Xia L, Fang Z, Yu S, Gao J, Feng Q , Yang P",Alteration of salivary microbiome in periodontitis with or without type-2 diabetes mellitus and metformin treatment,Scientific reports,2020,NA,Experiment 4,China,Homo sapiens,Saliva,UBERON:0001836,Periodontitis,EFO:0000649,Healthy controls,Individuals diagnosed with both Periodontitis and Type 2 Diabetes and treated with metformin (Met group),"Patients with both Periodontitis and Type 2 Diabetes who received metformin for at least 6 months and achieved glycemic control (HbA1c < 6.5%, without any companion diseases), were classified into the Met group",27,20,patients treated with antibiotics within 3 months or those that received periodontal treatment within 6 months,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:457/5/NA,Study 457,"cross-sectional observational, not case-control",32958790,10.1038/s41598-020-72035-1,https://pubmed.ncbi.nlm.nih.gov/32958790/,"Sun X, Li M, Xia L, Fang Z, Yu S, Gao J, Feng Q , Yang P",Alteration of salivary microbiome in periodontitis with or without type-2 diabetes mellitus and metformin treatment,Scientific reports,2020,NA,Experiment 5,China,Homo sapiens,Saliva,UBERON:0001836,Periodontitis,EFO:0000649,Individuals diagnosed with Periodontitis and Type 2 Diabetes Mellitus (DAP),Individuals diagnosed with both Periodontitis and Type 2 Diabetes and treated with metformin (Met group),"Patients with both Periodontitis and Type 2 Diabetes who received metformin for at least 6 months and achieved glycemic control (HbA1c < 6.5%, without any companion diseases), were classified into the Met group",46,20,patients treated with antibiotics within 3 months or those that received periodontal treatment within 6 months,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:458/1/NA,Study 458,"cross-sectional observational, not case-control",34103263,10.1016/j.jmii.2021.03.015,NA,"Miao Q, Ma Y, Ling Y, Jin W, Su Y, Wang Q, Pan J, Zhang Y, Chen H, Yuan J, Wu H , Hu B","Evaluation of superinfection, antimicrobial usage, and airway microbiome with metagenomic sequencing in COVID-19 patients: A cohort study in Shanghai","Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi",2021,"Antimicrobials, COVID-19, Escalation, Metagenomic sequencing, Superinfection",Experiment 1,China,Homo sapiens,Oropharynx,UBERON:0001729,COVID-19,MONDO:0100096,Non-intubated patients with non-incubation viral pneumonia or non-incubation non-infectious diseases,COVID-19 patients,Intubated patients with critically severe COVID-19 infection,54,50,NA,WMS,NA,BGISEQ-500 Sequencing,PERMANOVA,0.05,FALSE,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:458/2/NA,Study 458,"cross-sectional observational, not case-control",34103263,10.1016/j.jmii.2021.03.015,NA,"Miao Q, Ma Y, Ling Y, Jin W, Su Y, Wang Q, Pan J, Zhang Y, Chen H, Yuan J, Wu H , Hu B","Evaluation of superinfection, antimicrobial usage, and airway microbiome with metagenomic sequencing in COVID-19 patients: A cohort study in Shanghai","Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi",2021,"Antimicrobials, COVID-19, Escalation, Metagenomic sequencing, Superinfection",Experiment 2,China,Homo sapiens,Oropharynx,UBERON:0001729,COVID-19,MONDO:0100096,Inbutation non-covid,critically severe covid,Intubated patients with critically severe COVID-19 infection,20,50,NA,WMS,NA,BGISEQ-500 Sequencing,PERMANOVA,0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:459/1/NA,Study 459,"cross-sectional observational, not case-control",34058978,10.1186/s12575-021-00148-6,NA,"Engen PA, Naqib A, Jennings C, Green SJ, Landay A, Keshavarzian A , Voigt RM",Nasopharyngeal Microbiota in SARS-CoV-2 Positive and Negative Patients,Biological procedures online,2021,"COVID-19, Dysbiosis, Microbiota, Nasopharyngeal, SARS-CoV-2",Experiment 1,United States of America,Homo sapiens,Nasopharynx,UBERON:0001728,COVID-19,MONDO:0100096,COVID-19 negative controls,COVID-19 positive patients,Patients who are COVID-19 positive by RT-PCR,10,9,NA,16S,4,Illumina,DESeq2,0.05,FALSE,NA,NA,NA,unchanged,unchanged,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:460/1/NA,Study 460,"cross-sectional observational, not case-control",33903709,10.1038/s41598-021-88536-6,NA,"Braun T, Halevi S, Hadar R, Efroni G, Glick Saar E, Keller N, Amir A, Amit S , Haberman Y",SARS-CoV-2 does not have a strong effect on the nasopharyngeal microbial composition,Scientific reports,2021,NA,Experiment 1,Israel,Homo sapiens,Nasopharynx,UBERON:0001728,COVID-19,MONDO:0100096,COVID-19 negative patients,COVID-19 positive patients,SARS-CoV-2 presence by RT-PCR,29,26,NA,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:461/1/NA,Study 461,"cross-sectional observational, not case-control",25012901,https://doi.org/10.1038/ismej.2014.114,https://pubmed.ncbi.nlm.nih.gov/25012901/,"Mason MR, Preshaw PM, Nagaraja HN, Dabdoub SM, Rahman A , Kumar PS",The subgingival microbiome of clinically healthy current and never smokers,The ISME journal,2015,NA,Experiment 1,United States of America,Homo sapiens,Subgingival dental plaque,UBERON:0016484,Smoking behavior,EFO:0004318,Never smokers,Healthy Current Smokers,people who are current smokers,100,100,3 months,16S,123456789,Roche454,T-Test,0.05,FALSE,NA,"age,education level,race,sex,socioeconomic status",NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:462/1/NA,Study 462,"cross-sectional observational, not case-control",33806027,10.3390/nu13041066,https://pubmed.ncbi.nlm.nih.gov/33806027/,"Salamon D, Sroka-Oleksiak A, Gurgul A, Arent Z, Szopa M, Bulanda M, Małecki MT , Gosiewski T",Analysis of the Gut Mycobiome in Adult Patients with Type 1 and Type 2 Diabetes Using Next-Generation Sequencing (NGS) with Increased Sensitivity-Pilot Study,Nutrients,2021,"diabetes, gut mycobiome, next-generation sequencing (NGS)",Experiment 1,Poland,Homo sapiens,Feces,UBERON:0001988,Type I diabetes mellitus,MONDO:0005147,Healthy controls,Individuals diagnosed with Type 1 Diabetes Mellitus,"Individuals diagnosed with Type 1 Diabetes Mellitus in 2012–2015 at the Department of Metabolic Diseases, University Hospital, Krakow, Poland",26,24,30 days,16S,NA,Illumina,PERMANOVA,0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:462/2/NA,Study 462,"cross-sectional observational, not case-control",33806027,10.3390/nu13041066,https://pubmed.ncbi.nlm.nih.gov/33806027/,"Salamon D, Sroka-Oleksiak A, Gurgul A, Arent Z, Szopa M, Bulanda M, Małecki MT , Gosiewski T",Analysis of the Gut Mycobiome in Adult Patients with Type 1 and Type 2 Diabetes Using Next-Generation Sequencing (NGS) with Increased Sensitivity-Pilot Study,Nutrients,2021,"diabetes, gut mycobiome, next-generation sequencing (NGS)",Experiment 2,Poland,Homo sapiens,Feces,UBERON:0001988,Type II diabetes mellitus,MONDO:0005148,Healthy controls,Individuals diagnosed with Type 2 Diabetes Mellitus,"Individuals diagnosed with Type 1 Diabetes Mellitus in 2012–2015 at the Department of Metabolic Diseases, University Hospital, Krakow, Poland",26,26,30 days,16S,NA,Illumina,PERMANOVA,0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:462/3/NA,Study 462,"cross-sectional observational, not case-control",33806027,10.3390/nu13041066,https://pubmed.ncbi.nlm.nih.gov/33806027/,"Salamon D, Sroka-Oleksiak A, Gurgul A, Arent Z, Szopa M, Bulanda M, Małecki MT , Gosiewski T",Analysis of the Gut Mycobiome in Adult Patients with Type 1 and Type 2 Diabetes Using Next-Generation Sequencing (NGS) with Increased Sensitivity-Pilot Study,Nutrients,2021,"diabetes, gut mycobiome, next-generation sequencing (NGS)",Experiment 3,Poland,Homo sapiens,Feces,UBERON:0001988,Diabetes mellitus,EFO:0000400,Individuals diagnosed with Type 1 Diabetes Mellitus,Individuals diagnosed with Type 2 Diabetes Mellitus,"Individuals diagnosed with Type 2 Diabetes Mellitus in 2012–2015 at the Department of Metabolic Diseases, University Hospital, Krakow, Poland",26,24,30 days,16S,NA,Illumina,PERMANOVA,0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:463/1/NA,Study 463,time series / longitudinal observational,33833065,10.1136/gutjnl-2021-324090,NA,"Chen Y, Gu S, Chen Y, Lu H, Shi D, Guo J, Wu WR, Yang Y, Li Y, Xu KJ, Ding C, Luo R, Huang C, Yu L, Xu M, Yi P, Liu J, Tao JJ, Zhang H, Lv L, Wang B, Sheng J , Li L",Six-month follow-up of gut microbiota richness in patients with COVID-19,Gut,2021,"COVID-19, intestinal microbiology",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,COVID-19,MONDO:0100096,Healthy controls,COVID-19 patients,Patients 6 months post-COVID-19 infection,30,30,Any antibiotic or prebiotic use in previous months,16S,34,Illumina,Kruskall-Wallis,0.05,FALSE,NA,"age,body mass index,sex",NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:463/2/NA,Study 463,time series / longitudinal observational,33833065,10.1136/gutjnl-2021-324090,NA,"Chen Y, Gu S, Chen Y, Lu H, Shi D, Guo J, Wu WR, Yang Y, Li Y, Xu KJ, Ding C, Luo R, Huang C, Yu L, Xu M, Yi P, Liu J, Tao JJ, Zhang H, Lv L, Wang B, Sheng J , Li L",Six-month follow-up of gut microbiota richness in patients with COVID-19,Gut,2021,"COVID-19, intestinal microbiology",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,COVID-19,MONDO:0100096,Healthy controls,COVID-19 patients in convalescence,Sample from COVID-19 convalescence period (from viral clearance to 2 weeks after hospital discharge),30,30,Any antibiotic or prebiotic use in previous months,16S,34,Illumina,Kruskall-Wallis,0.05,FALSE,NA,"age,body mass index,sex",NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:464/1/NA,Study 464,"cross-sectional observational, not case-control",33789966,10.1136/gutjnl-2020-323826,NA,"Ren Z, Wang H, Cui G, Lu H, Wang L, Luo H, Chen X, Ren H, Sun R, Liu W, Liu X, Liu C, Li A, Wang X, Rao B, Yuan C, Zhang H, Sun J, Chen X, Li B, Hu C, Wu Z, Yu Z, Kan Q , Li L",Alterations in the human oral and gut microbiomes and lipidomics in COVID-19,Gut,2021,"COVID-19, intestinal microbiology, lipid metabolism",Experiment 1,China,Homo sapiens,Tongue,UBERON:0001723,COVID-19,MONDO:0100096,Healthy controls,Confirmed COVID-19 patients,"Suspected COVID-19 cases with one of the following etiological or serological evidence:
(1) Fluorescence RT-PCR detects the positive of the COVID-19 virus nucleic acid.
(2) Viral gene sequencing finds highly homologous to COVID-19 virus",100,48,Receipt of antibiotics and/or probiotics within 8 weeks prior to enrollment,16S,345,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:464/2/NA,Study 464,"cross-sectional observational, not case-control",33789966,10.1136/gutjnl-2020-323826,NA,"Ren Z, Wang H, Cui G, Lu H, Wang L, Luo H, Chen X, Ren H, Sun R, Liu W, Liu X, Liu C, Li A, Wang X, Rao B, Yuan C, Zhang H, Sun J, Chen X, Li B, Hu C, Wu Z, Yu Z, Kan Q , Li L",Alterations in the human oral and gut microbiomes and lipidomics in COVID-19,Gut,2021,"COVID-19, intestinal microbiology, lipid metabolism",Experiment 2,China,Homo sapiens,Tongue,UBERON:0001723,COVID-19,MONDO:0100096,Healthy controls,Recovered COVID-19 patients,Confirmed COVID-19 patients who recovered,150,22,Receipt of antibiotics and/or probiotics within 8 weeks prior to enrollment,16S,345,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,2,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:464/3/NA,Study 464,"cross-sectional observational, not case-control",33789966,10.1136/gutjnl-2020-323826,NA,"Ren Z, Wang H, Cui G, Lu H, Wang L, Luo H, Chen X, Ren H, Sun R, Liu W, Liu X, Liu C, Li A, Wang X, Rao B, Yuan C, Zhang H, Sun J, Chen X, Li B, Hu C, Wu Z, Yu Z, Kan Q , Li L",Alterations in the human oral and gut microbiomes and lipidomics in COVID-19,Gut,2021,"COVID-19, intestinal microbiology, lipid metabolism",Experiment 3,China,Homo sapiens,Feces,UBERON:0001988,COVID-19,MONDO:0100096,Healthy controls,COVID-19 patients,"Suspected COVID-19 cases with one of the following etiological or serological evidence:
(1) Fluorescence RT-PCR detects the positive of the COVID-19 virus nucleic acid.
(2) Viral gene sequencing finds highly homologous to COVID-19 virus",48,24,Receipt of antibiotics and/or probiotics within 8 weeks prior to enrollment,16S,345,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,decreased,NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:465/1/NA,Study 465,case-control,32938282,10.1177/0300060520936806,https://pubmed.ncbi.nlm.nih.gov/32938282/,"Wang Y, Ye X, Ding D , Lu Y",Characteristics of the intestinal flora in patients with peripheral neuropathy associated with type 2 diabetes,The Journal of international medical research,2020,"Diabetic peripheral neuropathy, bile acids, blood chemistry, gastrointestinal microbiota, insulin resistance, microbial diversity, richness, type 2 diabetes",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Diabetic neuropathy,EFO:1000783,Healthy controls,Individuals diagnosed with peripheral neuropathy associated with type 2 diabetes,"Individuals diagnosed with peripheral neuropathy associated with type 2 diabetes; The criteria for DPN were as follows: spontaneous limb pain, symmetrical or unilateral limb numbness, sensation of dullness and body tension, muscle weakness, weakened or absent tendon reflexes, and significant decreases in sensory and motor nerve conduction velocities as revealed via electromyography indicating the positive involvement of two or more nerves and normal arterial pulses in the foot and back.",14,45,3 months,16S,34,NA,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:465/2/NA,Study 465,case-control,32938282,10.1177/0300060520936806,https://pubmed.ncbi.nlm.nih.gov/32938282/,"Wang Y, Ye X, Ding D , Lu Y",Characteristics of the intestinal flora in patients with peripheral neuropathy associated with type 2 diabetes,The Journal of international medical research,2020,"Diabetic peripheral neuropathy, bile acids, blood chemistry, gastrointestinal microbiota, insulin resistance, microbial diversity, richness, type 2 diabetes",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Diabetic neuropathy,EFO:1000783,Individuals diagnosed with type 2 diabetes Mellitus,Individuals diagnosed with peripheral neuropathy associated with type 2 diabetes,"Patients with peripheral neuropathy associated with type 2 diabetes; the criteria for DPN were as follows: spontaneous limb pain, symmetrical or unilateral limb numbness, sensation of dullness and body tension, muscle weakness, weakened or absent tendon reflexes, and significant decreases in sensory and motor nerve conduction velocities as revealed via electromyography indicating the positive involvement of two or more nerves and normal arterial pulses in the foot and back.",21,45,3 months,16S,34,NA,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,increased,increased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:465/3/NA,Study 465,case-control,32938282,10.1177/0300060520936806,https://pubmed.ncbi.nlm.nih.gov/32938282/,"Wang Y, Ye X, Ding D , Lu Y",Characteristics of the intestinal flora in patients with peripheral neuropathy associated with type 2 diabetes,The Journal of international medical research,2020,"Diabetic peripheral neuropathy, bile acids, blood chemistry, gastrointestinal microbiota, insulin resistance, microbial diversity, richness, type 2 diabetes",Experiment 3,China,Homo sapiens,Feces,UBERON:0001988,Type II diabetes mellitus,MONDO:0005148,Healthy controls,Individuals diagnosed with Type 2 Diabetes Mellitus,Individuals diagnosed with Type 2 Diabetes Mellitus; The diagnoses of type 2 diabetes mellitus were established according to the diagnostic criteria of the American Diabetes Association,14,21,3 months,16S,34,NA,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,unchanged,decreased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:466/1/NA,Study 466,case-control,34436669,10.1007/s00784-021-04137-7,NA,"Gopinath D, Wie CC, Banerjee M, Thangavelu L, Kumar R P, Nallaswamy D, Botelho MG , Johnson NW",Compositional profile of mucosal bacteriome of smokers and smokeless tobacco users,Clinical oral investigations,2022,"Microbiome, Microbiota, Oral microbiome, Smokeless tobacco, Smoking, Tobacco",Experiment 1,India,Homo sapiens,Buccal mucosa,UBERON:0006956,Chewing tobacco behavior,EFO:0004774,age-matched controls,smokeless tobacco users,Smokeless tobacco users with or without areca nut.,13,14,NA,16S,34,Illumina,DESeq2,0.01,NA,NA,"age,sex",NA,increased,increased,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:466/2/NA,Study 466,case-control,34436669,10.1007/s00784-021-04137-7,NA,"Gopinath D, Wie CC, Banerjee M, Thangavelu L, Kumar R P, Nallaswamy D, Botelho MG , Johnson NW",Compositional profile of mucosal bacteriome of smokers and smokeless tobacco users,Clinical oral investigations,2022,"Microbiome, Microbiota, Oral microbiome, Smokeless tobacco, Smoking, Tobacco",Experiment 2,India,Homo sapiens,Buccal mucosa,UBERON:0006956,Smoking behavior,EFO:0004318,age-matched controls,Smokers who were using either bidis or cigarettes,"Smokers who were using either bidis (thin, hand-rolled cigarettes composed of tobacco wrapped in a “tendu” or “temburni” leaf) or cigarettes",13,17,NA,16S,34,Illumina,DESeq2,0.01,NA,NA,"age,sex",NA,increased,increased,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:466/3/NA,Study 466,case-control,34436669,10.1007/s00784-021-04137-7,NA,"Gopinath D, Wie CC, Banerjee M, Thangavelu L, Kumar R P, Nallaswamy D, Botelho MG , Johnson NW",Compositional profile of mucosal bacteriome of smokers and smokeless tobacco users,Clinical oral investigations,2022,"Microbiome, Microbiota, Oral microbiome, Smokeless tobacco, Smoking, Tobacco",Experiment 3,India,Homo sapiens,Buccal mucosa,UBERON:0006956,Smoking behavior,EFO:0004318,Smokeless tobacco users,Smokers,Smokers who were using either bidis or cigarettes,14,17,NA,16S,34,Illumina,DESeq2,0.01,NA,NA,"age,sex",NA,increased,increased,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:467/1/NA,Study 467,"cross-sectional observational, not case-control",32468338,10.1007/s10549-020-05702-6,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297869/,"Wu AH, Tseng C, Vigen C, Yu Y, Cozen W, Garcia AA , Spicer D",Gut microbiome associations with breast cancer risk factors and tumor characteristics: a pilot study,Breast cancer research and treatment,2020,"Age at menarche, HER2 status, Microbiome, Tumor characteristics",Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,HER2 Positive Breast Carcinoma,EFO:1000294,Her2 negative tumor,Her2 positive tumor,Breast cancer patients with Her2 positive tumors (human epidermal growth factor receptive 2 positive),25,12,Antibiotic use one week or more during the month prior to fecal sample collection.,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.001,FALSE,NA,NA,"age,ethnic group,race",NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:467/2/NA,Study 467,"cross-sectional observational, not case-control",32468338,10.1007/s10549-020-05702-6,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297869/,"Wu AH, Tseng C, Vigen C, Yu Y, Cozen W, Garcia AA , Spicer D",Gut microbiome associations with breast cancer risk factors and tumor characteristics: a pilot study,Breast cancer research and treatment,2020,"Age at menarche, HER2 status, Microbiome, Tumor characteristics",Experiment 2,United States of America,Homo sapiens,Feces,UBERON:0001988,Age at menarche,EFO:0004703,early age at menarche (≤11),later age at menarche (≥12),breast cancer patients with age at menarche being over 12 years old,11,26,Antibiotic use one week or more during the month prior to fecal sample collection.,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.001,FALSE,NA,NA,"age,ethnic group,race",NA,unchanged,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:467/3/NA,Study 467,"cross-sectional observational, not case-control",32468338,10.1007/s10549-020-05702-6,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297869/,"Wu AH, Tseng C, Vigen C, Yu Y, Cozen W, Garcia AA , Spicer D",Gut microbiome associations with breast cancer risk factors and tumor characteristics: a pilot study,Breast cancer research and treatment,2020,"Age at menarche, HER2 status, Microbiome, Tumor characteristics",Experiment 3,United States of America,Homo sapiens,Feces,UBERON:0001988,Estrogen receptor status,EFO:0005512,ER+,ER-,breast cancer patients with negative Estrogen Receptor status,9,28,Antibiotic use one week or more during the month prior to fecal sample collection.,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.001,FALSE,NA,NA,"age,ethnic group,race",NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:467/5/NA,Study 467,"cross-sectional observational, not case-control",32468338,10.1007/s10549-020-05702-6,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297869/,"Wu AH, Tseng C, Vigen C, Yu Y, Cozen W, Garcia AA , Spicer D",Gut microbiome associations with breast cancer risk factors and tumor characteristics: a pilot study,Breast cancer research and treatment,2020,"Age at menarche, HER2 status, Microbiome, Tumor characteristics",Experiment 5,United States of America,Homo sapiens,Feces,UBERON:0001988,Breast cancer,MONDO:0007254,Grade Low (I/II),Grade High (III),breast cancer patients with grade high level tumors (Grade III),14,23,Antibiotic use one week or more during the month prior to fecal sample collection.,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.001,FALSE,NA,NA,"age,ethnic group,race",NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:467/6/NA,Study 467,"cross-sectional observational, not case-control",32468338,10.1007/s10549-020-05702-6,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297869/,"Wu AH, Tseng C, Vigen C, Yu Y, Cozen W, Garcia AA , Spicer D",Gut microbiome associations with breast cancer risk factors and tumor characteristics: a pilot study,Breast cancer research and treatment,2020,"Age at menarche, HER2 status, Microbiome, Tumor characteristics",Experiment 6,United States of America,Homo sapiens,Feces,UBERON:0001988,Breast cancer stage,EFO:0005607,Stage Low (I/II),Stage High (III),Breast cancer patients with high stage progression of breast cancer (Stage III).,22,15,Antibiotic use one week or more during the month prior to fecal sample collection.,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.001,FALSE,NA,NA,"age,ethnic group,race",NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:467/7/NA,Study 467,"cross-sectional observational, not case-control",32468338,10.1007/s10549-020-05702-6,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297869/,"Wu AH, Tseng C, Vigen C, Yu Y, Cozen W, Garcia AA , Spicer D",Gut microbiome associations with breast cancer risk factors and tumor characteristics: a pilot study,Breast cancer research and treatment,2020,"Age at menarche, HER2 status, Microbiome, Tumor characteristics",Experiment 7,United States of America,Homo sapiens,Feces,UBERON:0001988,Age,EFO:0000246,Age 50+,Age ≤50,Breast cancer patients whose age is ≤50 years old.,17,20,Antibiotic use one week or more during the month prior to fecal sample collection.,16S,34,Illumina,Kruskall-Wallis,0.001,FALSE,NA,NA,"ethnic group,race",NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:467/8/NA,Study 467,"cross-sectional observational, not case-control",32468338,10.1007/s10549-020-05702-6,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297869/,"Wu AH, Tseng C, Vigen C, Yu Y, Cozen W, Garcia AA , Spicer D",Gut microbiome associations with breast cancer risk factors and tumor characteristics: a pilot study,Breast cancer research and treatment,2020,"Age at menarche, HER2 status, Microbiome, Tumor characteristics",Experiment 8,United States of America,Homo sapiens,Feces,UBERON:0001988,Parous,EFO:0002947,Parous,Nulliparous,Breast cancer patients who are nulliparous (have had no live births.),29,8,Antibiotic use one week or more during the month prior to fecal sample collection.,16S,34,Illumina,Kruskall-Wallis,0.001,FALSE,NA,NA,"age,ethnic group,race",NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:467/9/NA,Study 467,"cross-sectional observational, not case-control",32468338,10.1007/s10549-020-05702-6,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297869/,"Wu AH, Tseng C, Vigen C, Yu Y, Cozen W, Garcia AA , Spicer D",Gut microbiome associations with breast cancer risk factors and tumor characteristics: a pilot study,Breast cancer research and treatment,2020,"Age at menarche, HER2 status, Microbiome, Tumor characteristics",Experiment 9,United States of America,Homo sapiens,Feces,UBERON:0001988,Body mass index,EFO:0004340,BMI<25,BMI≥25,Breast cancer patients with a high body mass index (BMI≥25),9,28,Antibiotic use one week or more during the month prior to fecal sample collection.,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.001,FALSE,NA,NA,"age,ethnic group,race",NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:467/10/NA,Study 467,"cross-sectional observational, not case-control",32468338,10.1007/s10549-020-05702-6,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297869/,"Wu AH, Tseng C, Vigen C, Yu Y, Cozen W, Garcia AA , Spicer D",Gut microbiome associations with breast cancer risk factors and tumor characteristics: a pilot study,Breast cancer research and treatment,2020,"Age at menarche, HER2 status, Microbiome, Tumor characteristics",Experiment 10,United States of America,Homo sapiens,Feces,UBERON:0001988,Body fat percentage,EFO:0007800,TBF≤46%,TBF>46%,Breast cancer patients with a total body fat percentage ≥46%.,25,12,NA,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.001,FALSE,NA,NA,NA,NA,unchanged,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:467/11/NA,Study 467,"cross-sectional observational, not case-control",32468338,10.1007/s10549-020-05702-6,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297869/,"Wu AH, Tseng C, Vigen C, Yu Y, Cozen W, Garcia AA , Spicer D",Gut microbiome associations with breast cancer risk factors and tumor characteristics: a pilot study,Breast cancer research and treatment,2020,"Age at menarche, HER2 status, Microbiome, Tumor characteristics",Experiment 11,United States of America,Homo sapiens,Feces,UBERON:0001988,Physical activity,EFO:0003940,Yes Physical Activity,No Physical Activity,Breast cancer patients who do not have regular physical activity.,24,13,Antibiotic use one week or more during the month prior to fecal sample collection.,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.001,FALSE,NA,NA,"age,ethnic group,race",NA,unchanged,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:468/1/NA,Study 468,prospective cohort,30778155,10.1038/s41598-019-39700-6,https://pubmed.ncbi.nlm.nih.gov/30778155/,"Ata B, Yildiz S, Turkgeldi E, Brocal VP, Dinleyici EC, Moya A , Urman B","The Endobiota Study: Comparison of Vaginal, Cervical and Gut Microbiota Between Women with Stage 3/4 Endometriosis and Healthy Controls",Scientific reports,2019,NA,Experiment 1,Turkey,Homo sapiens,"Vaginal fluid,Feces,Endocervix","UBERON:0036243,UBERON:0001988,UBERON:0000458",Endometriosis,EFO:0001065,Healthy controls,Stage 3/4 endometriosis patients,Women with histology-proven stage 3/4 endometriosis,14,14,Participants were excluded if they had taken antibiotics within the past 8 weeks,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:469/1/NA,Study 469,"cross-sectional observational, not case-control",34151035,10.1016/j.synbio.2021.06.002,NA,"Liu J, Liu S, Zhang Z, Lee X, Wu W, Huang Z, Lei Z, Xu W, Chen D, Wu X, Guo Y, Peng L, Lin B, Chong Y, Mou X, Shi M, Lan P, Chen T, Zhao W , Gao Z",Association between the nasopharyngeal microbiome and metabolome in patients with COVID-19,Synthetic and systems biotechnology,2021,"COVID-19, Metabolome, Nasopharyngeal microbiome, SARS-CoV-2, Susceptibility",Experiment 1,China,Homo sapiens,Nasopharynx,UBERON:0001728,COVID-19,MONDO:0100096,Non-COVID-19 controls,COVID-19 patients,Positive for infection with SARS-CoV-2 by nucleic acid testing,3,6,NA,WMS,NA,Illumina,LEfSe,0.05,FALSE,3,"age,sex",NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:470/1/NA,Study 470,"case-control,meta-analysis",30936547,10.1038/s41591-019-0406-6,NA,"Wirbel J, Pyl PT, Kartal E, Zych K, Kashani A, Milanese A, Fleck JS, Voigt AY, Palleja A, Ponnudurai R, Sunagawa S, Coelho LP, Schrotz-King P, Vogtmann E, Habermann N, Niméus E, Thomas AM, Manghi P, Gandini S, Serrano D, Mizutani S, Shiroma H, Shiba S, Shibata T, Yachida S, Yamada T, Waldron L, Naccarati A, Segata N, Sinha R, Ulrich CM, Brenner H, Arumugam M, Bork P , Zeller G",Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer,Nature medicine,2019,NA,Experiment 1,"France,Austria,China,United States of America,Germany,Italy,Japan",Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,controls,colorectal cancer,Colorectal cancer cases from eight independent studies,392,386,NA,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:471/1/NA,Study 471,"case-control,meta-analysis",30936548,10.1038/s41591-019-0405-7,NA,"Thomas AM, Manghi P, Asnicar F, Pasolli E, Armanini F, Zolfo M, Beghini F, Manara S, Karcher N, Pozzi C, Gandini S, Serrano D, Tarallo S, Francavilla A, Gallo G, Trompetto M, Ferrero G, Mizutani S, Shiroma H, Shiba S, Shibata T, Yachida S, Yamada T, Wirbel J, Schrotz-King P, Ulrich CM, Brenner H, Arumugam M, Bork P, Zeller G, Cordero F, Dias-Neto E, Setubal JC, Tett A, Pardini B, Rescigno M, Waldron L, Naccarati A , Segata N",Metagenomic analysis of colorectal cancer datasets identifies cross-cohort microbial diagnostic signatures and a link with choline degradation,Nature medicine,2019,NA,Experiment 1,"France,China,Austria,United States of America,Canada,Italy",Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,controls,colorectal cancer cases,colorectal cancer cases,308,313,NA,WMS,NA,Illumina,Linear Regression,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:472/1/NA,Study 472,case-control,34302684,10.1007/s40618-021-01595-4,https://pubmed.ncbi.nlm.nih.gov/34302684/,"Wei J, Qing Y, Zhou H, Liu J, Qi C , Gao J",16S rRNA gene amplicon sequencing of gut microbiota in gestational diabetes mellitus and their correlation with disease risk factors,Journal of endocrinological investigation,2021,"16S rRNA gene amplicon sequencing, Gestational diabetes mellitus, Gut microbiota, qPCR",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Gestational diabetes,EFO:0004593,Pregnant individuals who are normal glucose tolerance (NGT)],Pregnant individuals with gestational diabetes,Pregnant individuals with gestational diabetes,18,15,1 month,16S,4,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:473/1/NA,Study 473,"cross-sectional observational, not case-control",33659220,10.3389/fcimb.2021.625581,NA,"Nardelli C, Gentile I, Setaro M, Di Domenico C, Pinchera B, Buonomo AR, Zappulo E, Scotto R, Scaglione GL, Castaldo G , Capoluongo E",Nasopharyngeal Microbiome Signature in COVID-19 Positive Patients: Can We Definitively Get a Role to <i>Fusobacterium periodonticum</i>?,Frontiers in cellular and infection microbiology,2021,"Fusobacterium periodonticum, SARS-CoV-2, microbiota, nasopharyngeal swab, next generation sequencing",Experiment 1,Italy,Homo sapiens,Nasopharynx,UBERON:0001728,COVID-19,MONDO:0100096,COVID-19 negative controls,COVID-19 positive patients,Symptomatic COVID-19 positive patients,12,18,NA,16S,123,Illumina,Kruskall-Wallis,0.05,FALSE,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:474/1/NA,Study 474,case-control,33977168,10.1016/j.genrep.2021.101200,NA,"Hoque MN, Rahman MS, Ahmed R, Hossain MS, Islam MS, Islam T, Hossain MA , Siddiki AZ",Diversity and genomic determinants of the microbiomes associated with COVID-19 and non-COVID respiratory diseases,Gene reports,2021,"COPD, COVID-19, Diversity, Microbiome, Non-COVID, SARS-CoV-2, URTI",Experiment 1,"Bangladesh,China,United Kingdom,United States of America",Homo sapiens,Nasopharynx,UBERON:0001728,COVID-19,MONDO:0100096,Non-COVID patients with URTI or COPD,COVID-19 patients,Confirmed COVID-19 diagnosis by RT-qPCR,10,11,NA,WMS,NA,Illumina,Kruskall-Wallis,0.05,FALSE,NA,NA,NA,NA,increased,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:475/1/NA,Study 475,time series / longitudinal observational,33603076,10.1038/s42003-021-01796-w,NA,"Xu R, Lu R, Zhang T, Wu Q, Cai W, Han X, Wan Z, Jin X, Zhang Z , Zhang C",Temporal association between human upper respiratory and gut bacterial microbiomes during the course of COVID-19 in adults,Communications biology,2021,NA,Experiment 1,China,Homo sapiens,Oropharynx,UBERON:0001729,COVID-19,MONDO:0100096,Healthy controls (Group H),Non-COVID-19 patients (Group NP),"6 COVID-19 patients, 10 non-COVID-19 patients, 2 healthy controls",13,18,NA,16S,4,Illumina,ANOSIM,0.05,TRUE,NA,NA,NA,unchanged,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:475/2/NA,Study 475,time series / longitudinal observational,33603076,10.1038/s42003-021-01796-w,NA,"Xu R, Lu R, Zhang T, Wu Q, Cai W, Han X, Wan Z, Jin X, Zhang Z , Zhang C",Temporal association between human upper respiratory and gut bacterial microbiomes during the course of COVID-19 in adults,Communications biology,2021,NA,Experiment 2,China,Homo sapiens,Oropharynx,UBERON:0001729,COVID-19,MONDO:0100096,Healthy controls (Group H),Community Type I Patients,"16 COVID-19 patients, 2 healthy controls",13,18,NA,16S,4,Illumina,ANOSIM,0.05,TRUE,NA,NA,NA,increased,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:475/3/NA,Study 475,time series / longitudinal observational,33603076,10.1038/s42003-021-01796-w,NA,"Xu R, Lu R, Zhang T, Wu Q, Cai W, Han X, Wan Z, Jin X, Zhang Z , Zhang C",Temporal association between human upper respiratory and gut bacterial microbiomes during the course of COVID-19 in adults,Communications biology,2021,NA,Experiment 3,China,Homo sapiens,Oropharynx,UBERON:0001729,COVID-19,MONDO:0100096,Healthy controls (Group H),Community Type II patients,"47 COVID-19 patients, 1 healthy control",13,48,NA,16S,4,Illumina,ANOSIM,0.05,TRUE,NA,NA,NA,increased,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:475/4/NA,Study 475,time series / longitudinal observational,33603076,10.1038/s42003-021-01796-w,NA,"Xu R, Lu R, Zhang T, Wu Q, Cai W, Han X, Wan Z, Jin X, Zhang Z , Zhang C",Temporal association between human upper respiratory and gut bacterial microbiomes during the course of COVID-19 in adults,Communications biology,2021,NA,Experiment 4,China,Homo sapiens,Oropharynx,UBERON:0001729,COVID-19,MONDO:0100096,Healthy controls (Group H),Community Type III patients,"10 COVID-19 patients, 1 healthy control",13,11,NA,16S,4,Illumina,ANOSIM,0.05,TRUE,NA,NA,NA,decreased,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:475/5/NA,Study 475,time series / longitudinal observational,33603076,10.1038/s42003-021-01796-w,NA,"Xu R, Lu R, Zhang T, Wu Q, Cai W, Han X, Wan Z, Jin X, Zhang Z , Zhang C",Temporal association between human upper respiratory and gut bacterial microbiomes during the course of COVID-19 in adults,Communications biology,2021,NA,Experiment 5,China,Homo sapiens,Oropharynx,UBERON:0001729,COVID-19,MONDO:0100096,Healthy controls (Group H),Community Type IV patients,4 COVID-19 patients,13,4,NA,16S,4,Illumina,ANOSIM,0.05,TRUE,NA,NA,NA,decreased,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:475/6/NA,Study 475,time series / longitudinal observational,33603076,10.1038/s42003-021-01796-w,NA,"Xu R, Lu R, Zhang T, Wu Q, Cai W, Han X, Wan Z, Jin X, Zhang Z , Zhang C",Temporal association between human upper respiratory and gut bacterial microbiomes during the course of COVID-19 in adults,Communications biology,2021,NA,Experiment 6,China,Homo sapiens,Rectum,UBERON:0001052,COVID-19,MONDO:0100096,Group I - High Diversity COVID-19 patients,Group II - Medium Diversity COVID-19 patients,Patients with medium microbial diversity in rectal samples,15,24,NA,16S,4,Illumina,ANOSIM,0.05,TRUE,NA,NA,NA,unchanged,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:475/7/NA,Study 475,time series / longitudinal observational,33603076,10.1038/s42003-021-01796-w,NA,"Xu R, Lu R, Zhang T, Wu Q, Cai W, Han X, Wan Z, Jin X, Zhang Z , Zhang C",Temporal association between human upper respiratory and gut bacterial microbiomes during the course of COVID-19 in adults,Communications biology,2021,NA,Experiment 7,China,Homo sapiens,Rectum,UBERON:0001052,COVID-19,MONDO:0100096,Group I - High Diversity COVID-19 patients,Group III - Low Diversity COVID-19 patients,Patients with low microbial diversity in rectal swab samples,15,24,NA,16S,4,Illumina,ANOSIM,0.05,TRUE,NA,NA,NA,decreased,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:476/1/NA,Study 476,case-control,34055851,10.3389/fnut.2021.638825,NA,"Tian Y, Sun KY, Meng TQ, Ye Z, Guo SM, Li ZM, Xiong CL, Yin Y, Li HG , Zhou LQ",Gut Microbiota May Not Be Fully Restored in Recovered COVID-19 Patients After 3-Month Recovery,Frontiers in nutrition,2021,"16S sequence, SARS-CoV-2, gut microbiota, recovered COVID-19 patient, short chain fatty acids",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,COVID-19,MONDO:0100096,Healthy controls,Recovered COVID-19 patients,"Patients between 25-45 years of age with documented recovery from COVID-19, detailed medical records during hospitalization and discharge certificate",7,7,Participants instructed to avoid any drugs affecting gastrointestinal function before sampling,16S,34,Illumina,LEfSe,0.05,FALSE,3.5,NA,NA,NA,unchanged,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:477/1/NA,Study 477,"cross-sectional observational, not case-control",33815323,10.3389/fmicb.2021.637430,NA,"Ventero MP, Cuadrat RRC, Vidal I, Andrade BGN, Molina-Pardines C, Haro-Moreno JM, Coutinho FH, Merino E, Regitano LCA, Silveira CB, Afli H, López-Pérez M , Rodríguez JC",Nasopharyngeal Microbial Communities of Patients Infected With SARS-CoV-2 That Developed COVID-19,Frontiers in microbiology,2021,"COVID-19, NGS – next generation sequencing, Prevotella, SARS-CoV-2, coronavirus, microbiome",Experiment 1,Spain,Homo sapiens,Nasopharynx,UBERON:0001728,COVID-19,MONDO:0100096,COVID-19 negative controls,Severe COVID-19 patients,Patients with confirmed COVID-19 infection and severe symptoms; required hospital admission,18,18,NA,16S,34,Illumina,Linear Regression,0.25,TRUE,NA,NA,"age,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:477/2/NA,Study 477,"cross-sectional observational, not case-control",33815323,10.3389/fmicb.2021.637430,NA,"Ventero MP, Cuadrat RRC, Vidal I, Andrade BGN, Molina-Pardines C, Haro-Moreno JM, Coutinho FH, Merino E, Regitano LCA, Silveira CB, Afli H, López-Pérez M , Rodríguez JC",Nasopharyngeal Microbial Communities of Patients Infected With SARS-CoV-2 That Developed COVID-19,Frontiers in microbiology,2021,"COVID-19, NGS – next generation sequencing, Prevotella, SARS-CoV-2, coronavirus, microbiome",Experiment 2,Spain,Homo sapiens,Nasopharynx,UBERON:0001728,COVID-19,MONDO:0100096,COVID-19 negative controls,Severe COVID-19 patients requiring ICU,Patients with confirmed COVID-19 infection and severe symptoms who were admitted into the intensive care unit,18,19,NA,16S,34,Illumina,Linear Regression,0.25,TRUE,NA,NA,"age,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:477/3/NA,Study 477,"cross-sectional observational, not case-control",33815323,10.3389/fmicb.2021.637430,NA,"Ventero MP, Cuadrat RRC, Vidal I, Andrade BGN, Molina-Pardines C, Haro-Moreno JM, Coutinho FH, Merino E, Regitano LCA, Silveira CB, Afli H, López-Pérez M , Rodríguez JC",Nasopharyngeal Microbial Communities of Patients Infected With SARS-CoV-2 That Developed COVID-19,Frontiers in microbiology,2021,"COVID-19, NGS – next generation sequencing, Prevotella, SARS-CoV-2, coronavirus, microbiome",Experiment 3,Spain,Homo sapiens,Nasopharynx,UBERON:0001728,COVID-19,MONDO:0100096,Mild COVID-19 patients,Severe COVID-19 patients,Patients with confirmed COVID-19 infection and severe symptoms who were hospitalized,19,18,NA,16S,34,Illumina,Linear Regression,0.25,TRUE,NA,NA,"age,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:478/1/NA,Study 478,"cross-sectional observational, not case-control",33986253,10.1038/s41392-021-00614-3,NA,"Ma S, Zhang F, Zhou F, Li H, Ge W, Gan R, Nie H, Li B, Wang Y, Wu M, Li D, Wang D, Wang Z, You Y , Huang Z",Metagenomic analysis reveals oropharyngeal microbiota alterations in patients with COVID-19,Signal transduction and targeted therapy,2021,NA,Experiment 1,China,Homo sapiens,Oropharynx,UBERON:0001729,COVID-19,MONDO:0100096,Healthy controls,COVID-19 patients,Confirmed COVID-19 cases,28,31,NA,WMS,NA,MGISEQ-2000,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:478/2/NA,Study 478,"cross-sectional observational, not case-control",33986253,10.1038/s41392-021-00614-3,NA,"Ma S, Zhang F, Zhou F, Li H, Ge W, Gan R, Nie H, Li B, Wang Y, Wu M, Li D, Wang D, Wang Z, You Y , Huang Z",Metagenomic analysis reveals oropharyngeal microbiota alterations in patients with COVID-19,Signal transduction and targeted therapy,2021,NA,Experiment 2,China,Homo sapiens,Oropharynx,UBERON:0001729,COVID-19,MONDO:0100096,Flu patients,COVID-19 patients,Confirmed COVID-19 cases,29,31,NA,WMS,NA,MGISEQ-2000,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:478/3/NA,Study 478,"cross-sectional observational, not case-control",33986253,10.1038/s41392-021-00614-3,NA,"Ma S, Zhang F, Zhou F, Li H, Ge W, Gan R, Nie H, Li B, Wang Y, Wu M, Li D, Wang D, Wang Z, You Y , Huang Z",Metagenomic analysis reveals oropharyngeal microbiota alterations in patients with COVID-19,Signal transduction and targeted therapy,2021,NA,Experiment 3,China,Homo sapiens,Oropharynx,UBERON:0001729,COVID-19,MONDO:0100096,Healthy controls,Flu patients,Patients with influenza B,29,31,NA,WMS,NA,MGISEQ-2000,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:478/4/NA,Study 478,"cross-sectional observational, not case-control",33986253,10.1038/s41392-021-00614-3,NA,"Ma S, Zhang F, Zhou F, Li H, Ge W, Gan R, Nie H, Li B, Wang Y, Wu M, Li D, Wang D, Wang Z, You Y , Huang Z",Metagenomic analysis reveals oropharyngeal microbiota alterations in patients with COVID-19,Signal transduction and targeted therapy,2021,NA,Experiment 4,China,Homo sapiens,Oropharynx,UBERON:0001729,COVID-19,MONDO:0100096,Healthy controls,COVID-19 patients,Confirmed COVID-19 cases,28,31,NA,WMS,NA,MGISEQ-2000,LEfSe,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:478/5/NA,Study 478,"cross-sectional observational, not case-control",33986253,10.1038/s41392-021-00614-3,NA,"Ma S, Zhang F, Zhou F, Li H, Ge W, Gan R, Nie H, Li B, Wang Y, Wu M, Li D, Wang D, Wang Z, You Y , Huang Z",Metagenomic analysis reveals oropharyngeal microbiota alterations in patients with COVID-19,Signal transduction and targeted therapy,2021,NA,Experiment 5,China,Homo sapiens,Oropharynx,UBERON:0001729,COVID-19,MONDO:0100096,Healthy controls,Flu patients,Patients with influenza B,28,29,NA,WMS,NA,MGISEQ-2000,LEfSe,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:479/1/NA,Study 479,case-control,33672177,10.3390/ijerph18042174,NA,"Rueca M, Fontana A, Bartolini B, Piselli P, Mazzarelli A, Copetti M, Binda E, Perri F, Gruber CEM, Nicastri E, Marchioni L, Ippolito G, Capobianchi MR, Di Caro A , Pazienza V",Investigation of Nasal/Oropharyngeal Microbial Community of COVID-19 Patients by 16S rDNA Sequencing,International journal of environmental research and public health,2021,"Nasal/Oropharyngeal, SARS-CoV2, microbiota",Experiment 1,Italy,Homo sapiens,"Nasopharynx,Oropharynx","UBERON:0001729,UBERON:0001728",COVID-19,MONDO:0100096,Healthy controls,ICU COVID-19 patients,COVID-19 patients admitted to intensive care unit,10,10,NA,16S,23456789,Ion Torrent,Kruskall-Wallis,0.05,TRUE,NA,NA,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:479/2/NA,Study 479,case-control,33672177,10.3390/ijerph18042174,NA,"Rueca M, Fontana A, Bartolini B, Piselli P, Mazzarelli A, Copetti M, Binda E, Perri F, Gruber CEM, Nicastri E, Marchioni L, Ippolito G, Capobianchi MR, Di Caro A , Pazienza V",Investigation of Nasal/Oropharyngeal Microbial Community of COVID-19 Patients by 16S rDNA Sequencing,International journal of environmental research and public health,2021,"Nasal/Oropharyngeal, SARS-CoV2, microbiota",Experiment 2,Italy,Homo sapiens,"Nasopharynx,Oropharynx","UBERON:0001729,UBERON:0001728",COVID-19,MONDO:0100096,Healthy controls,Mild-moderate COVID-19 patients,COVID-19 patients with mild to moderate symptoms that were not admitted to an intensive care unit,10,11,NA,16S,23456789,Ion Torrent,Kruskall-Wallis,0.05,TRUE,NA,NA,NA,NA,unchanged,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:479/3/NA,Study 479,case-control,33672177,10.3390/ijerph18042174,NA,"Rueca M, Fontana A, Bartolini B, Piselli P, Mazzarelli A, Copetti M, Binda E, Perri F, Gruber CEM, Nicastri E, Marchioni L, Ippolito G, Capobianchi MR, Di Caro A , Pazienza V",Investigation of Nasal/Oropharyngeal Microbial Community of COVID-19 Patients by 16S rDNA Sequencing,International journal of environmental research and public health,2021,"Nasal/Oropharyngeal, SARS-CoV2, microbiota",Experiment 3,Italy,Homo sapiens,"Nasopharynx,Oropharynx","UBERON:0001729,UBERON:0001728",COVID-19,MONDO:0100096,Mild-Moderate COVID-19 patients,ICU COVID-19 patients,COVID-19 patients admitted to intensive care unit,11,10,NA,16S,23456789,Ion Torrent,Kruskall-Wallis,0.05,TRUE,NA,NA,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:479/4/NA,Study 479,case-control,33672177,10.3390/ijerph18042174,NA,"Rueca M, Fontana A, Bartolini B, Piselli P, Mazzarelli A, Copetti M, Binda E, Perri F, Gruber CEM, Nicastri E, Marchioni L, Ippolito G, Capobianchi MR, Di Caro A , Pazienza V",Investigation of Nasal/Oropharyngeal Microbial Community of COVID-19 Patients by 16S rDNA Sequencing,International journal of environmental research and public health,2021,"Nasal/Oropharyngeal, SARS-CoV2, microbiota",Experiment 4,Italy,Homo sapiens,"Nasopharynx,Oropharynx","UBERON:0001729,UBERON:0001728",COVID-19,MONDO:0100096,Patients infected with other human coronaviruses,ICU COVID-19 patients,COVID-19 patients admitted to intensive care unit,8,10,NA,16S,23456789,Ion Torrent,Kruskall-Wallis,0.05,TRUE,NA,NA,NA,NA,unchanged,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:480/1/NA,Study 480,case-control,32192080,10.3390/diagnostics10030163,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151170/,"Hernandes C, Silveira P, Rodrigues Sereia AF, Christoff AP, Mendes H, Valter de Oliveira LF , Podgaec S","Microbiome Profile of Deep Endometriosis Patients: Comparison of Vaginal Fluid, Endometrium and Lesion","Diagnostics (Basel, Switzerland)",2020,"16S rRNA, endometriosis, microbiome, next generation sequencing (NGS), pathogenesis, vaginal fluid",Experiment 1,Brazil,Homo sapiens,Vagina,UBERON:0000996,Endometriosis,EFO:0001065,Control group,Vaginal Fluid,"Vaginal samples were collected and processed for the evaluation of
their bacterial profile:",11,21,within 30 days prior to sample collection,16S,34,Illumina,DESeq2,0,TRUE,NA,NA,NA,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:480/2/NA,Study 480,case-control,32192080,10.3390/diagnostics10030163,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151170/,"Hernandes C, Silveira P, Rodrigues Sereia AF, Christoff AP, Mendes H, Valter de Oliveira LF , Podgaec S","Microbiome Profile of Deep Endometriosis Patients: Comparison of Vaginal Fluid, Endometrium and Lesion","Diagnostics (Basel, Switzerland)",2020,"16S rRNA, endometriosis, microbiome, next generation sequencing (NGS), pathogenesis, vaginal fluid",Experiment 2,Brazil,Homo sapiens,Uterus,UBERON:0000995,Endometriosis,EFO:0001065,Control group,Eutopic Endometrium Samples,"Eutopic Endometrium samples were collected and processed for the evaluation of
their bacterial profile:",11,18,within 30 days prior to sample collection,16S,34,Illumina,DESeq2,0,TRUE,NA,NA,NA,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:480/3/NA,Study 480,case-control,32192080,10.3390/diagnostics10030163,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7151170/,"Hernandes C, Silveira P, Rodrigues Sereia AF, Christoff AP, Mendes H, Valter de Oliveira LF , Podgaec S","Microbiome Profile of Deep Endometriosis Patients: Comparison of Vaginal Fluid, Endometrium and Lesion","Diagnostics (Basel, Switzerland)",2020,"16S rRNA, endometriosis, microbiome, next generation sequencing (NGS), pathogenesis, vaginal fluid",Experiment 3,Brazil,Homo sapiens,Uterus,UBERON:0000995,Endometriosis,EFO:0001065,Controls group,endometriotic lesion samples,"endometriotic lesion samples  collected and processed for the evaluation of
their bacterial profile:",11,8,within 30 days prior to sample collection,16S,34,Illumina,DESeq2,0,TRUE,NA,NA,NA,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:481/1/NA,Study 481,case-control,33678150,10.1080/19490976.2021.1887722,NA,"Cao J, Wang C, Zhang Y, Lei G, Xu K, Zhao N, Lu J, Meng F, Yu L, Yan J, Bai C, Zhang S, Zhang N, Gong Y, Bi Y, Shi Y, Chen Z, Dai L, Wang J , Yang P",Integrated gut virome and bacteriome dynamics in COVID-19 patients,Gut microbes,2021,"COVID-19, bacteriome, dysbiosis, genetic mutation, virome",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,COVID-19,MONDO:0100096,Healthy controls,COVID-19 patients,Patients with COVID-19,5,13,NA,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:481/2/NA,Study 481,case-control,33678150,10.1080/19490976.2021.1887722,NA,"Cao J, Wang C, Zhang Y, Lei G, Xu K, Zhao N, Lu J, Meng F, Yu L, Yan J, Bai C, Zhang S, Zhang N, Gong Y, Bi Y, Shi Y, Chen Z, Dai L, Wang J , Yang P",Integrated gut virome and bacteriome dynamics in COVID-19 patients,Gut microbes,2021,"COVID-19, bacteriome, dysbiosis, genetic mutation, virome",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,COVID-19,MONDO:0100096,Antibiotic-naive COVID-19 patients,Antibiotic-treated COVID-19 patients,Patients with COVID-19 treated with antibiotics,8,5,NA,WMS,NA,Illumina,Linear Regression,0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:481/3/NA,Study 481,case-control,33678150,10.1080/19490976.2021.1887722,NA,"Cao J, Wang C, Zhang Y, Lei G, Xu K, Zhao N, Lu J, Meng F, Yu L, Yan J, Bai C, Zhang S, Zhang N, Gong Y, Bi Y, Shi Y, Chen Z, Dai L, Wang J , Yang P",Integrated gut virome and bacteriome dynamics in COVID-19 patients,Gut microbes,2021,"COVID-19, bacteriome, dysbiosis, genetic mutation, virome",Experiment 3,China,Homo sapiens,Feces,UBERON:0001988,COVID-19,MONDO:0100096,Mild COVID-19 patients,Severe COVID-19 patients,Patients with severe COVID-19,3,3,NA,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:482/1/NA,Study 482,"cross-sectional observational, not case-control",33850111,10.1038/s41421-021-00257-2,NA,"Zhong H, Wang Y, Shi Z, Zhang L, Ren H, He W, Zhang Z, Zhu A, Zhao J, Xiao F, Yang F, Liang T, Ye F, Zhong B, Ruan S, Gan M, Zhu J, Li F, Li F, Wang D, Li J, Ren P, Zhu S, Yang H, Wang J, Kristiansen K, Tun HM, Chen W, Zhong N, Xu X, Li YM, Li J , Zhao J",Characterization of respiratory microbial dysbiosis in hospitalized COVID-19 patients,Cell discovery,2021,NA,Experiment 1,China,Homo sapiens,Nasopharynx,UBERON:0001728,COVID-19,MONDO:0100096,Mild COVID-19 patients,Severe COVID-19 patients,COVID-19 infected patients admitted to the ICU and requiring mechanical ventilation,8,15,NA,WMS,NA,DNBSEQ-T7,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:482/2/NA,Study 482,"cross-sectional observational, not case-control",33850111,10.1038/s41421-021-00257-2,NA,"Zhong H, Wang Y, Shi Z, Zhang L, Ren H, He W, Zhang Z, Zhu A, Zhao J, Xiao F, Yang F, Liang T, Ye F, Zhong B, Ruan S, Gan M, Zhu J, Li F, Li F, Wang D, Li J, Ren P, Zhu S, Yang H, Wang J, Kristiansen K, Tun HM, Chen W, Zhong N, Xu X, Li YM, Li J , Zhao J",Characterization of respiratory microbial dysbiosis in hospitalized COVID-19 patients,Cell discovery,2021,NA,Experiment 2,China,Homo sapiens,Rectum,UBERON:0001052,COVID-19,MONDO:0100096,Mild COVID-19 patients,Severe COVID-19 patients,COVID-19 infected patients admitted to the ICU and requiring mechanical ventilation,7,15,NA,WMS,NA,DNBSEQ-T7,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:483/1/NA,Study 483,case-control,32442562,10.1053/j.gastro.2020.05.048,NA,"Zuo T, Zhang F, Lui GCY, Yeoh YK, Li AYL, Zhan H, Wan Y, Chung ACK, Cheung CP, Chen N, Lai CKC, Chen Z, Tso EYK, Fung KSC, Chan V, Ling L, Joynt G, Hui DSC, Chan FKL, Chan PKS , Ng SC",Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization,Gastroenterology,2020,"Bacteria, Coronavirus, Fecal Nucleic Acid, Gut Microbiome",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,COVID-19,MONDO:0100096,"Uninfected controls, pneumonia patients, antibiotics treated COVID-19 patients",Antibiotic-naive COVID-19 patients,"COVID-19 patients hospitalized with SARS-CoV-2 infection confirmed by 2 consecutive RT-PCR tests, not treated with antibiotics",29,7,NA,WMS,NA,Illumina,Linear Regression,0.05,TRUE,NA,NA,"age,antibiotic exposure,comorbidity,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:483/2/NA,Study 483,case-control,32442562,10.1053/j.gastro.2020.05.048,NA,"Zuo T, Zhang F, Lui GCY, Yeoh YK, Li AYL, Zhan H, Wan Y, Chung ACK, Cheung CP, Chen N, Lai CKC, Chen Z, Tso EYK, Fung KSC, Chan V, Ling L, Joynt G, Hui DSC, Chan FKL, Chan PKS , Ng SC",Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization,Gastroenterology,2020,"Bacteria, Coronavirus, Fecal Nucleic Acid, Gut Microbiome",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,COVID-19,MONDO:0100096,"Antibiotic-naive COVID-19 patients, pneumonia patients, uninfected controls",Antibiotic-treated COVID-19 patients,"COVID-19 patients hospitalized with SARS-CoV-2 infection confirmed by 2 consecutive RT-PCR tests, treated with antibiotics",28,8,NA,WMS,NA,Illumina,Linear Regression,0.05,TRUE,NA,NA,"age,antibiotic exposure,comorbidity,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:483/3/NA,Study 483,case-control,32442562,10.1053/j.gastro.2020.05.048,NA,"Zuo T, Zhang F, Lui GCY, Yeoh YK, Li AYL, Zhan H, Wan Y, Chung ACK, Cheung CP, Chen N, Lai CKC, Chen Z, Tso EYK, Fung KSC, Chan V, Ling L, Joynt G, Hui DSC, Chan FKL, Chan PKS , Ng SC",Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization,Gastroenterology,2020,"Bacteria, Coronavirus, Fecal Nucleic Acid, Gut Microbiome",Experiment 3,China,Homo sapiens,Feces,UBERON:0001988,COVID-19,MONDO:0100096,"Uninfected controls, COVID-19 patients",Pneumonia controls,Patients hospitalized with community-acquired pneumonia,30,6,NA,WMS,NA,Illumina,Linear Regression,0.05,TRUE,NA,NA,"age,antibiotic exposure,comorbidity,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:484/1/NA,Study 484,case-control,33978940,10.1007/s12250-021-00391-x,NA,"Xiong D, Muema C, Zhang X, Pan X, Xiong J, Yang H, Yu J , Wei H",Enriched Opportunistic Pathogens Revealed by Metagenomic Sequencing Hint Potential Linkages between Pharyngeal Microbiota and COVID-19,Virologica Sinica,2021,"ACE2, COVID-19, Campylobacter, Metagenome sequencing, Prevotella, Streptococcus",Experiment 1,China,Homo sapiens,Nasopharynx,UBERON:0001728,COVID-19,MONDO:0100096,COVID-19 negative patients with fever and cough,COVID-19 positive patients,COVID-19 positive patients with fever and cough symptoms,11,11,NA,WMS,NA,MGISEQ-2000,ANOVA,0.05,FALSE,NA,NA,NA,decreased,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:484/2/NA,Study 484,case-control,33978940,10.1007/s12250-021-00391-x,NA,"Xiong D, Muema C, Zhang X, Pan X, Xiong J, Yang H, Yu J , Wei H",Enriched Opportunistic Pathogens Revealed by Metagenomic Sequencing Hint Potential Linkages between Pharyngeal Microbiota and COVID-19,Virologica Sinica,2021,"ACE2, COVID-19, Campylobacter, Metagenome sequencing, Prevotella, Streptococcus",Experiment 2,China,Homo sapiens,Nasopharynx,UBERON:0001728,COVID-19,MONDO:0100096,Healthy controls,COVID-19 positive patients,COVID-19 positive patients with fever and cough symptoms,7,11,NA,WMS,NA,MGISEQ-2000,ANOVA,0.05,FALSE,NA,NA,NA,decreased,decreased,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:484/3/NA,Study 484,case-control,33978940,10.1007/s12250-021-00391-x,NA,"Xiong D, Muema C, Zhang X, Pan X, Xiong J, Yang H, Yu J , Wei H",Enriched Opportunistic Pathogens Revealed by Metagenomic Sequencing Hint Potential Linkages between Pharyngeal Microbiota and COVID-19,Virologica Sinica,2021,"ACE2, COVID-19, Campylobacter, Metagenome sequencing, Prevotella, Streptococcus",Experiment 3,China,Homo sapiens,Nasopharynx,UBERON:0001728,COVID-19,MONDO:0100096,Healthy controls,COVID-19 negative patients with fever and cough,COVID-19 negative patients with fever and cough,7,11,NA,WMS,NA,MGISEQ-2000,ANOVA,0.05,FALSE,NA,NA,NA,decreased,decreased,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:484/4/NA,Study 484,case-control,33978940,10.1007/s12250-021-00391-x,NA,"Xiong D, Muema C, Zhang X, Pan X, Xiong J, Yang H, Yu J , Wei H",Enriched Opportunistic Pathogens Revealed by Metagenomic Sequencing Hint Potential Linkages between Pharyngeal Microbiota and COVID-19,Virologica Sinica,2021,"ACE2, COVID-19, Campylobacter, Metagenome sequencing, Prevotella, Streptococcus",Experiment 4,China,Homo sapiens,Nasopharynx,UBERON:0001728,COVID-19,MONDO:0100096,COVID-19 negative patients with fever and cough,COVID-19 positive patients,COVID-19 positive patients with fever and cough symptoms,11,11,NA,WMS,NA,MGISEQ-2000,LEfSe,0.05,FALSE,NA,NA,NA,decreased,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:485/1/NA,Study 485,"cross-sectional observational, not case-control",34168484,10.2147/JIR.S311518,NA,"Zhou Y, Shi X, Fu W, Xiang F, He X, Yang B, Wang X , Ma WL",Gut Microbiota Dysbiosis Correlates with Abnormal Immune Response in Moderate COVID-19 Patients with Fever,Journal of inflammation research,2021,"epitopes, fever, gut microbiota, moderate COVID-19, shotgun metagenomic sequencing",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,COVID-19,MONDO:0100096,COVID-19 patients without fever,COVID-19 patients with fever,Symptomatic patients with confirmed COVID-19 (positive for COVID-19 nucleic acid by real-time RT-PCR from throat swab specimens) and fever (axillary temperature > 37.3 degrees Celsius),11,20,NA,WMS,NA,MGISEQ-2000,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:485/2/NA,Study 485,"cross-sectional observational, not case-control",34168484,10.2147/JIR.S311518,NA,"Zhou Y, Shi X, Fu W, Xiang F, He X, Yang B, Wang X , Ma WL",Gut Microbiota Dysbiosis Correlates with Abnormal Immune Response in Moderate COVID-19 Patients with Fever,Journal of inflammation research,2021,"epitopes, fever, gut microbiota, moderate COVID-19, shotgun metagenomic sequencing",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,COVID-19,MONDO:0100096,COVID-19 patients without fever,COVID-19 patients with fever,Symptomatic patients with confirmed COVID-19 (positive for COVID-19 nucleic acid by real-time RT-PCR from throat swab specimens) and fever (axillary temperature > 37.3 degrees Celsius),11,20,NA,WMS,NA,MGISEQ-2000,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:486/1/NA,Study 486,"cross-sectional observational, not case-control",34199203,10.3390/microorganisms9061292,NA,"Khan M, Mathew BJ, Gupta P, Garg G, Khadanga S, Vyas AK , Singh AK",Gut Dysbiosis and IL-21 Response in Patients with Severe COVID-19,Microorganisms,2021,"COVID-19, IL-21, brain–gut interaction, dietary fibre, gut microbiome, mucosal immunity",Experiment 1,India,Homo sapiens,Feces,UBERON:0001988,COVID-19,MONDO:0100096,Healthy controls,Asymptomatic COVID-19 patients,Asymptomatic COVID-19 patients (positive for SARS-CoV-2 in an RT-PCR diagnostic assay) with no symptoms,10,10,NA,16S,34,NA,LEfSe,0.05,FALSE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:486/2/NA,Study 486,"cross-sectional observational, not case-control",34199203,10.3390/microorganisms9061292,NA,"Khan M, Mathew BJ, Gupta P, Garg G, Khadanga S, Vyas AK , Singh AK",Gut Dysbiosis and IL-21 Response in Patients with Severe COVID-19,Microorganisms,2021,"COVID-19, IL-21, brain–gut interaction, dietary fibre, gut microbiome, mucosal immunity",Experiment 2,India,Homo sapiens,Feces,UBERON:0001988,COVID-19,MONDO:0100096,Healthy controls,Asymptomatic COVID-19 patients,COVID-19 patients (positive for SARS-CoV-2 in an RT-PCR diagnostic assay) with mild symptoms and no requirement of oxygen support/ventilator,10,10,NA,16S,34,NA,LEfSe,0.05,FALSE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:486/3/NA,Study 486,"cross-sectional observational, not case-control",34199203,10.3390/microorganisms9061292,NA,"Khan M, Mathew BJ, Gupta P, Garg G, Khadanga S, Vyas AK , Singh AK",Gut Dysbiosis and IL-21 Response in Patients with Severe COVID-19,Microorganisms,2021,"COVID-19, IL-21, brain–gut interaction, dietary fibre, gut microbiome, mucosal immunity",Experiment 3,India,Homo sapiens,Feces,UBERON:0001988,COVID-19,MONDO:0100096,Healthy controls,Severe COVID-19 patients,COVID-19 patients (positive for SARS-CoV-2 in an RT-PCR diagnostic assay) with severe disease and requiring oxygen support/ventilator,10,10,NA,16S,34,NA,LEfSe,0.05,FALSE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:487/1/NA,Study 487,time series / longitudinal observational,34200249,10.3390/microorganisms9061237,NA,"Kim HN, Joo EJ, Lee CW, Ahn KS, Kim HL, Park DI , Park SK",Reversion of Gut Microbiota during the Recovery Phase in Patients with Asymptomatic or Mild COVID-19: Longitudinal Study,Microorganisms,2021,"COVID-19, FB ratio, SARS-CoV2, asymptomatic, gut microbiota, microbiome, mild",Experiment 1,South Korea,Homo sapiens,Feces,UBERON:0001988,COVID-19,MONDO:0100096,Infected COVID-19 samples (respiratory positive),Recovered COVID-19 samples (respiratory negative),Samples from symptomatic/mild COVID-19 patients collected on or after negative conversion for SARS-CoV-2 RNA from the respiratory tract,12,12,No history of antibiotics or probiotics,16S,34,Illumina,Linear Regression,0.05,TRUE,NA,NA,NA,increased,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:487/2/NA,Study 487,time series / longitudinal observational,34200249,10.3390/microorganisms9061237,NA,"Kim HN, Joo EJ, Lee CW, Ahn KS, Kim HL, Park DI , Park SK",Reversion of Gut Microbiota during the Recovery Phase in Patients with Asymptomatic or Mild COVID-19: Longitudinal Study,Microorganisms,2021,"COVID-19, FB ratio, SARS-CoV2, asymptomatic, gut microbiota, microbiome, mild",Experiment 2,South Korea,Homo sapiens,Feces,UBERON:0001988,COVID-19,MONDO:0100096,Healthy controls,Recovered COVID-19 samples (respiratory negative),Samples from symptomatic/mild COVID-19 patients collected on or after negative conversion for SARS-CoV-2 RNA from the respiratory tract,36,12,No history of antibiotics or probiotics,16S,34,Illumina,Linear Regression,0.05,TRUE,NA,NA,NA,decreased,unchanged,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:487/3/NA,Study 487,time series / longitudinal observational,34200249,10.3390/microorganisms9061237,NA,"Kim HN, Joo EJ, Lee CW, Ahn KS, Kim HL, Park DI , Park SK",Reversion of Gut Microbiota during the Recovery Phase in Patients with Asymptomatic or Mild COVID-19: Longitudinal Study,Microorganisms,2021,"COVID-19, FB ratio, SARS-CoV2, asymptomatic, gut microbiota, microbiome, mild",Experiment 3,South Korea,Homo sapiens,Feces,UBERON:0001988,COVID-19,MONDO:0100096,Healthy controls,Infected COVID-19 samples (respiratory positive),Samples from symptomatic/mild COVID-19 patients collected on or before positive detection of SARS-CoV-2 RNA from the respiratory tract,36,12,No history of antibiotics or probiotics,16S,34,Illumina,Linear Regression,0.05,TRUE,NA,NA,NA,decreased,decreased,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:488/1/NA,Study 488,case-control,33663411,10.1186/s12876-021-01693-w,NA,"Mei L, Zhou J, Su Y, Mao K, Wu J, Zhu C, He L , Cui Y",Gut microbiota composition and functional prediction in diarrhea-predominant irritable bowel syndrome,BMC gastroenterology,2021,"Diarrhea-predominant irritable bowel syndrome, Functional prediction, Gut microbiota",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Irritable bowel syndrome,EFO:0000555,Healthy Control,IBS-D,Individuals aged from 20 to 64 meeting the Rome IV diagnostic criteria [19] for IBS-D,30,30,4 weeks,16S,4,Illumina,LEfSe,0.05,FALSE,4,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:489/1/NA,Study 489,"cross-sectional observational, not case-control",33596245,10.1371/journal.pone.0247041,NA,"Mazzarelli A, Giancola ML, Farina A, Marchioni L, Rueca M, Gruber CEM, Bartolini B, Ascoli Bartoli T, Maffongelli G, Capobianchi MR, Ippolito G, Di Caro A, Nicastri E , Pazienza V",16S rRNA gene sequencing of rectal swab in patients affected by COVID-19,PloS one,2021,NA,Experiment 1,Italy,Homo sapiens,Rectum,UBERON:0001052,COVID-19,MONDO:0100096,Pneumonia control patients (COVID-negative),COVID-positive patients admitted to ICU (i-COVID-19),"COVID-19 patients with nasopharyngeal swab positive for SARS-CoV-2, > 18 years of age admitted in ICU",8,6,NA,16S,23456789,Ion Torrent,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:489/2/NA,Study 489,"cross-sectional observational, not case-control",33596245,10.1371/journal.pone.0247041,NA,"Mazzarelli A, Giancola ML, Farina A, Marchioni L, Rueca M, Gruber CEM, Bartolini B, Ascoli Bartoli T, Maffongelli G, Capobianchi MR, Ippolito G, Di Caro A, Nicastri E , Pazienza V",16S rRNA gene sequencing of rectal swab in patients affected by COVID-19,PloS one,2021,NA,Experiment 2,Italy,Homo sapiens,Rectum,UBERON:0001052,COVID-19,MONDO:0100096,COVID-positive patients admitted to infectious disease ward (w-COVID-19),COVID-positive patients admitted to ICU (i-COVID-19),"COVID-19 patients with nasopharyngeal swab positive for SARS-CoV-2, > 18 years of age admitted in ICU",9,6,NA,16S,23456789,Ion Torrent,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:489/3/NA,Study 489,"cross-sectional observational, not case-control",33596245,10.1371/journal.pone.0247041,NA,"Mazzarelli A, Giancola ML, Farina A, Marchioni L, Rueca M, Gruber CEM, Bartolini B, Ascoli Bartoli T, Maffongelli G, Capobianchi MR, Ippolito G, Di Caro A, Nicastri E , Pazienza V",16S rRNA gene sequencing of rectal swab in patients affected by COVID-19,PloS one,2021,NA,Experiment 3,Italy,Homo sapiens,Rectum,UBERON:0001052,COVID-19,MONDO:0100096,Pneumonia controls (COVID-negative),COVID-positive patients admitted to infectious disease ward (w-COVID-19),"COVID-19 patients with nasopharyngeal swab positive for SARS-CoV-2, > 18 years of age admitted in infectious disease ward",8,9,NA,16S,23456789,Ion Torrent,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:490/1/NA,Study 490,case-control,19903265,10.1111/j.1365-2982.2009.01427.x,NA,"Tana C, Umesaki Y, Imaoka A, Handa T, Kanazawa M , Fukudo S",Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome,Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society,2010,NA,Experiment 1,Japan,Homo sapiens,Feces,UBERON:0001988,Irritable bowel syndrome,EFO:0000555,Healthy Control,IBS,"All patients were diagnosed with IBS after conducting a medical interview based on Rome II criteria and positive judgment by a Rome II modular questionnaire retrospectively and positively fulfilling Rome III criteria. According to Rome II criteria related to bowel habits, 11 subjects had constipation-predominant IBS (IBS-C), eight had diarrhoea-predominant IBS (IBS-D) and seven had mixed IBS (IBS-M).",26,26,"In the previous study, agents containing probiotics were administered to humans and stopped thereafter. On day 10 after stopping the administration of probiotics, levels of these bacteria returned to the levels before administration of probiotics. No subject received antibiotics during the abstention period.",WMS,NA,RT-qPCR,Spearman Correlation,0.05,FALSE,NA,"age,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:491/1/NA,Study 491,case-control,21741921,10.1053/j.gastro.2011.06.072,NA,"Saulnier DM, Riehle K, Mistretta TA, Diaz MA, Mandal D, Raza S, Weidler EM, Qin X, Coarfa C, Milosavljevic A, Petrosino JF, Highlander S, Gibbs R, Lynch SV, Shulman RJ , Versalovic J",Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome,Gastroenterology,2011,NA,Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Irritable bowel syndrome,EFO:0000555,Healthy Control,IBS,Children ages 7-12 who met the Pediatric Rome III criteria for IBS (Table 1). Subtyping of IBS was based on previous recommendations for IBS in adults because no Pediatric Rome subtype criteria exist for children.,27,28,6 months,16S,123,PhyloChip,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:492/1/NA,Study 492,case-control,33531650,10.1038/s41598-021-82538-0,https://pubmed.ncbi.nlm.nih.gov/33531650/,"Das T, Jayasudha R, Chakravarthy S, Prashanthi GS, Bhargava A, Tyagi M, Rani PK, Pappuru RR, Sharma S , Shivaji S",Alterations in the gut bacterial microbiome in people with type 2 diabetes mellitus and diabetic retinopathy,Scientific reports,2021,NA,Experiment 1,India,Homo sapiens,Feces,UBERON:0001988,Type II diabetes mellitus,MONDO:0005148,Healthy controls,Individuals having Type 2 Diabetes Mellitus without Diabetic Retinopathy,"Individuals having Type 2 Diabetes Mellitus without Diabetic Retinopathy (T2D group); the T2DM cohort included subjects (a) positive for at least one of the three biochemical tests (HbA1c > 7%, fasting blood sugar > 120 mg% and post-prandial blood sugar > 200 mg%); (b) had history of taking anti-diabetic medications (Metformin or combinations of Metformin and / or Insulin) and (c) had no clinical signs of DR",30,24,3 months,16S,34,Illumina,Kruskall-Wallis,0.05,TRUE,NA,"age,diet,region,sex",NA,NA,increased,increased,unchanged,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:492/2/NA,Study 492,case-control,33531650,10.1038/s41598-021-82538-0,https://pubmed.ncbi.nlm.nih.gov/33531650/,"Das T, Jayasudha R, Chakravarthy S, Prashanthi GS, Bhargava A, Tyagi M, Rani PK, Pappuru RR, Sharma S , Shivaji S",Alterations in the gut bacterial microbiome in people with type 2 diabetes mellitus and diabetic retinopathy,Scientific reports,2021,NA,Experiment 2,India,Homo sapiens,Feces,UBERON:0001988,Diabetic retinopathy,EFO:0003770,Healthy controls,Individuals diagnosed with Type 2 Diabetes and clinically manifest Diabetic Retinopathy (DR),Individuals diagnosed with Type 2 Diabetes and clinically manifest Diabetic Retinopathy (DR); Subjects confirmed to having DR based on the fundus examination/photograph followed by fundus fluorescein angiography (FFA) and optical coherence tomography (OCT).,30,28,3 months,16S,34,Illumina,Kruskall-Wallis,0.05,TRUE,NA,"age,diet,region,sex",NA,NA,increased,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:492/3/NA,Study 492,case-control,33531650,10.1038/s41598-021-82538-0,https://pubmed.ncbi.nlm.nih.gov/33531650/,"Das T, Jayasudha R, Chakravarthy S, Prashanthi GS, Bhargava A, Tyagi M, Rani PK, Pappuru RR, Sharma S , Shivaji S",Alterations in the gut bacterial microbiome in people with type 2 diabetes mellitus and diabetic retinopathy,Scientific reports,2021,NA,Experiment 3,India,Homo sapiens,Feces,UBERON:0001988,Diabetic retinopathy,EFO:0003770,Individuals diagnosed with type 2 diabetes Mellitus,Individuals diagnosed with Type 2 Diabetes and clinically manifest Diabetic Retinopathy (DR),Individuals diagnosed with Type 2 Diabetes and clinically manifest Diabetic Retinopathy (DR); Subjects confirmed to having DR based on the fundus examination/photograph followed by fundus fluorescein angiography (FFA) and optical coherence tomography (OCT).,24,28,3 months,16S,34,Illumina,Kruskall-Wallis,0.05,TRUE,NA,"age,diet,region,sex",NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:493/1/NA,Study 493,case-control,31917273,10.1016/j.micpath.2019.103943,https://pubmed.ncbi.nlm.nih.gov/31917273/,"Yuan X, Wang L, Meng D, Wu L, Wang X, Zhang D, Luo Z, Pang Y , Liu G",The impact of NBUVB on microbial community profiling in the lesional skin of vitiligo subjects,Microbial pathogenesis,2020,"16S rRNA, Bacterial diversity, Cutaneous microbiome, Vitiligo",Experiment 1,China,Homo sapiens,Skin of body,UBERON:0002097,Vitiligo,EFO:0004208,Vitiligo patients before narrowband UV (NBUVB) light irradiation in normal skin (NF group),Vitiligo patients after NBUVB irradiation on normal skin (NB group),"Vitiligo patients after NBUVB irradiation on normal skin (NB group); Vitiligo patients recruited from Weifang Medical University Hospital, Shandong, China, from February 2018 to January 2019.",15,15,6 months,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,increased,unchanged,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:493/2/NA,Study 493,case-control,31917273,10.1016/j.micpath.2019.103943,https://pubmed.ncbi.nlm.nih.gov/31917273/,"Yuan X, Wang L, Meng D, Wu L, Wang X, Zhang D, Luo Z, Pang Y , Liu G",The impact of NBUVB on microbial community profiling in the lesional skin of vitiligo subjects,Microbial pathogenesis,2020,"16S rRNA, Bacterial diversity, Cutaneous microbiome, Vitiligo",Experiment 2,China,Homo sapiens,Skin of body,UBERON:0002097,Vitiligo,EFO:0004208,Normal skin of Vitiligo patients before narrowband UV (NBUVB) light irradiation (NF group),Lesional skin of Vitiligo patients after NBUVB irradiation (DB group),"Lesional skin of Vitiligo patients after NBUVB irradiation (DB group); Vitiligo patients recruited from Weifang Medical University Hospital, Shandong, China, from February 2018 to January 2019.",15,15,6 months,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:493/3/NA,Study 493,case-control,31917273,10.1016/j.micpath.2019.103943,https://pubmed.ncbi.nlm.nih.gov/31917273/,"Yuan X, Wang L, Meng D, Wu L, Wang X, Zhang D, Luo Z, Pang Y , Liu G",The impact of NBUVB on microbial community profiling in the lesional skin of vitiligo subjects,Microbial pathogenesis,2020,"16S rRNA, Bacterial diversity, Cutaneous microbiome, Vitiligo",Experiment 3,China,Homo sapiens,Skin of body,UBERON:0002097,Vitiligo,EFO:0004208,Lesional skin of Vitiligo patients before irradiation (DF group),Lesional skin of Vitiligo patients after NBUVB irradiation (DB group),"Lesional skin of Vitiligo patients after NBUVB irradiation (DB group); Vitiligo patients recruited from Weifang Medical University Hospital, Shandong, China, from February 2018 to January 2019.",15,15,6 months,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:494/1/NA,Study 494,case-control,32214153,10.1038/s41598-020-62224-3,https://pubmed.ncbi.nlm.nih.gov/32214153/,"Li Q, Chang Y, Zhang K, Chen H, Tao S , Zhang Z",Implication of the gut microbiome composition of type 2 diabetic patients from northern China,Scientific reports,2020,NA,Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Type II diabetes mellitus,MONDO:0005148,Healthy controls,Individuals diagnosed with Type 2 Diabetes Mellitus,Individuals diagnosed with Type 2 Diabetes Mellitus; T2D subjects were required to meet the following inclusion criteria: (i) fasting blood glucose test (FBG) 7 mmol/L or greater and/or 2-h fasting oral glucose tolerance test (OGTT) 11.1 mmol/L or greater35; (ii) no previously received pharmacologic treatment; and (iii) body mass index (BMI) > 18.0 kg/m2.,40,20,2 months,16S,45,Illumina,T-Test,0.05,TRUE,NA,NA,NA,NA,unchanged,decreased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:495/1/NA,Study 495,case-control,33828910,10.7717/peerj.10952,https://pubmed.ncbi.nlm.nih.gov/33828910/,"Zhang Z, Tian T, Chen Z, Liu L, Luo T , Dai J",Characteristics of the gut microbiome in patients with prediabetes and type 2 diabetes,PeerJ,2021,"Gut microbiome, Prediabetes, Type 2 diabetes mellitus",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Type II diabetes mellitus,MONDO:0005148,Healthy controls,Individuals diagnosed with Type 2 Diabetes Mellitus,Individuals diagnosed with Type 2 Diabetes Mellitus; Participants with T2DM were required to meet the following inclusion criteria: (i) fasting blood glucose test (FBG) ≥7 mmol/L and/or 2-h fasting oral glucose tolerance test (OGTT) ≥11.1 mmol/L; and (ii) all cases of T2DM were newly diagnosed.,60,60,2 months,16S,45,Illumina,Kruskall-Wallis,0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:495/2/NA,Study 495,case-control,33828910,10.7717/peerj.10952,https://pubmed.ncbi.nlm.nih.gov/33828910/,"Zhang Z, Tian T, Chen Z, Liu L, Luo T , Dai J",Characteristics of the gut microbiome in patients with prediabetes and type 2 diabetes,PeerJ,2021,"Gut microbiome, Prediabetes, Type 2 diabetes mellitus",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Prediabetes syndrome,EFO:1001121,Healthy controls,Individuals with Prediabetes (PreDM),Individuals with Prediabetes (PreDM); PreDM was defined as FBG of 6.1–7.0 mmol/L or HbA1c levels of 6.0%–6.5%.,60,60,2 months,16S,45,Illumina,Kruskall-Wallis,0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:496/1/NA,Study 496,prospective cohort,34173452,10.1016/j.medmic.2020.100023,NA,"Tao W, Zhang G, Wang X, Guo M, Zeng W, Xu Z, Cao D, Pan A, Wang Y, Zhang K, Ma X, Chen Z, Jin T, Liu L, Weng J , Zhu S",Analysis of the intestinal microbiota in COVID-19 patients and its correlation with the inflammatory factor IL-18,Medicine in microecology,2020,"COVID19, Gut microbiota, IL18, SARS2",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,COVID-19,MONDO:0100096,Healthy controls,COVID-19 patients,Patients with COVID-19,40,62,NA,16S,4,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:496/2/NA,Study 496,prospective cohort,34173452,10.1016/j.medmic.2020.100023,NA,"Tao W, Zhang G, Wang X, Guo M, Zeng W, Xu Z, Cao D, Pan A, Wang Y, Zhang K, Ma X, Chen Z, Jin T, Liu L, Weng J , Zhu S",Analysis of the intestinal microbiota in COVID-19 patients and its correlation with the inflammatory factor IL-18,Medicine in microecology,2020,"COVID19, Gut microbiota, IL18, SARS2",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,COVID-19,MONDO:0100096,Seasonal flu patients,COVID-19 patients,Patients with COVID-19,33,62,NA,16S,4,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:497/1/NA,Study 497,time series / longitudinal observational,33112882,https://doi.org/10.1371/journal.pone.0236460,https://pubmed.ncbi.nlm.nih.gov/33112882/,"Rattanathammethee T, Tuitemwong P, Thiennimitr P, Sarichai P, Na Pombejra S, Piriyakhuntorn P, Hantrakool S, Chai-Adisaksopha C, Rattarittamrong E, Tantiworawit A , Norasetthada L",Gut microbiota profiles of treatment-naïve adult acute myeloid leukemia patients with neutropenic fever during intensive chemotherapy,PloS one,2020,NA,Experiment 1,Thailand,Homo sapiens,Feces,UBERON:0001988,Acute myeloid leukemia,EFO:0000222,Pretreatment,Febrile neutropenia,patients with neutropenic fever during intensive chemotherapy,10,10,3 months.,16S,34,Illumina,ANOVA,0.05,TRUE,NA,NA,NA,NA,decreased,NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:497/2/NA,Study 497,time series / longitudinal observational,33112882,https://doi.org/10.1371/journal.pone.0236460,https://pubmed.ncbi.nlm.nih.gov/33112882/,"Rattanathammethee T, Tuitemwong P, Thiennimitr P, Sarichai P, Na Pombejra S, Piriyakhuntorn P, Hantrakool S, Chai-Adisaksopha C, Rattarittamrong E, Tantiworawit A , Norasetthada L",Gut microbiota profiles of treatment-naïve adult acute myeloid leukemia patients with neutropenic fever during intensive chemotherapy,PloS one,2020,NA,Experiment 2,Thailand,Homo sapiens,Feces,UBERON:0001988,Acute myeloid leukemia,EFO:0000222,febrile neutropenia,Bone marrow recovery,After initiation of induction chemotherapy,10,10,3 months.,16S,34,Illumina,ANOVA,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:497/3/NA,Study 497,time series / longitudinal observational,33112882,https://doi.org/10.1371/journal.pone.0236460,https://pubmed.ncbi.nlm.nih.gov/33112882/,"Rattanathammethee T, Tuitemwong P, Thiennimitr P, Sarichai P, Na Pombejra S, Piriyakhuntorn P, Hantrakool S, Chai-Adisaksopha C, Rattarittamrong E, Tantiworawit A , Norasetthada L",Gut microbiota profiles of treatment-naïve adult acute myeloid leukemia patients with neutropenic fever during intensive chemotherapy,PloS one,2020,NA,Experiment 3,Thailand,Homo sapiens,Feces,UBERON:0001988,Acute myeloid leukemia,EFO:0000222,Pre-treatment,Bone marrow recovery,After initiation of  induction chemotherapy treatment,10,10,3 months.,16S,345,Illumina,ANOVA,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:498/1/NA,Study 498,case-control,33577896,10.1016/j.jaci.2021.02.001,NA,"Rosas-Salazar C, Kimura KS, Shilts MH, Strickland BA, Freeman MH, Wessinger BC, Gupta V, Brown HM, Rajagopala SV, Turner JH , Das SR",SARS-CoV-2 infection and viral load are associated with the upper respiratory tract microbiome,The Journal of allergy and clinical immunology,2021,"16S rRNA sequencing, COVID-19, SARS-CoV-2, coronavirus, microbiome, nasal, nasopharynx, respiratory",Experiment 1,United States of America,Homo sapiens,Nasopharynx,UBERON:0001728,COVID-19,MONDO:0100096,Asymptomatic uninfected controls,"Symptomatic, mild to moderate COVID-19 patients","Confirmed symptomatic mild to moderate COVID-19 patients > age 18, nonhospitalized",21,38,2 weeks,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,"age,sex",NA,increased,NA,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:498/2/NA,Study 498,case-control,33577896,10.1016/j.jaci.2021.02.001,NA,"Rosas-Salazar C, Kimura KS, Shilts MH, Strickland BA, Freeman MH, Wessinger BC, Gupta V, Brown HM, Rajagopala SV, Turner JH , Das SR",SARS-CoV-2 infection and viral load are associated with the upper respiratory tract microbiome,The Journal of allergy and clinical immunology,2021,"16S rRNA sequencing, COVID-19, SARS-CoV-2, coronavirus, microbiome, nasal, nasopharynx, respiratory",Experiment 2,United States of America,Homo sapiens,Nasopharynx,UBERON:0001728,COVID-19,MONDO:0100096,COVID-19 patients with low viral load,COVID-19 patients with high viral load,"Confirmed symptomatic mild to moderate COVID-19 patients > age 18, nonhospitalized,  with high viral load (quantitative reverse transcription PCR cycle threshold value
below the median for the detection of SARS-CoV-2 nucleocapside gene region 1)",21,38,2 weeks,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,"age,sex",NA,increased,NA,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:499/1/NA,Study 499,"case-control,prospective cohort",21820992,10.1053/j.gastro.2011.07.043,NA,"Rajilić-Stojanović M, Biagi E, Heilig HG, Kajander K, Kekkonen RA, Tims S , de Vos WM",Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome,Gastroenterology,2011,NA,Experiment 1,Finland,Homo sapiens,Feces,UBERON:0001988,Irritable bowel syndrome,EFO:0000555,Healthy Control,IBS-A,IBS patients fulfilled the Rome II criteria. Alternating IBS (IBS-A),46,19,NA,16S,NA,Human Intestinal Tract Chip,T-Test,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:499/2/NA,Study 499,"case-control,prospective cohort",21820992,10.1053/j.gastro.2011.07.043,NA,"Rajilić-Stojanović M, Biagi E, Heilig HG, Kajander K, Kekkonen RA, Tims S , de Vos WM",Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome,Gastroenterology,2011,NA,Experiment 2,Finland,Homo sapiens,Feces,UBERON:0001988,Irritable bowel syndrome,EFO:0000555,Healthy Control,IBS-C,IBS patients fulfilled the Rome II criteria. Constipation-predominant IBS (IBS-C),46,18,NA,16S,NA,Human Intestinal Tract Chip,T-Test,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:499/3/NA,Study 499,"case-control,prospective cohort",21820992,10.1053/j.gastro.2011.07.043,NA,"Rajilić-Stojanović M, Biagi E, Heilig HG, Kajander K, Kekkonen RA, Tims S , de Vos WM",Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome,Gastroenterology,2011,NA,Experiment 3,Finland,Homo sapiens,Feces,UBERON:0001988,Irritable bowel syndrome,EFO:0000555,Healthy Control,IBS-D,IBS patients fulfilled the Rome II criteria. Diarrhea-predominant IBS (IBS-D),46,25,NA,16S,NA,Human Intestinal Tract Chip,T-Test,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:499/4/NA,Study 499,"case-control,prospective cohort",21820992,10.1053/j.gastro.2011.07.043,NA,"Rajilić-Stojanović M, Biagi E, Heilig HG, Kajander K, Kekkonen RA, Tims S , de Vos WM",Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome,Gastroenterology,2011,NA,Experiment 4,Finland,Homo sapiens,Feces,UBERON:0001988,Irritable bowel syndrome,EFO:0000555,Healthy Control,IBS (All patients),IBS patients fulfilled the Rome II criteria. All IBS patients.,46,62,NA,16S,NA,Human Intestinal Tract Chip,T-Test,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:500/1/NA,Study 500,case-control,33980943,10.1038/s41598-021-89516-6,NA,"Gaibani P, Viciani E, Bartoletti M, Lewis RE, Tonetti T, Lombardo D, Castagnetti A, Bovo F, Horna CS, Ranieri M, Viale P, Re MC , Ambretti S",The lower respiratory tract microbiome of critically ill patients with COVID-19,Scientific reports,2021,NA,Experiment 1,Italy,Homo sapiens,Lung,UBERON:0002048,COVID-19,MONDO:0100096,COVID-19 negative patients with pneumonia,COVID-19 patients,COVID-19 Critically Ill Subjects,24,24,NA,16S,34,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,unchanged,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:501/1/NA,Study 501,"cross-sectional observational, not case-control",NA,https://doi.org/10.21767/2476-1974.100036,https://reproductive-immunology.imedpub.com/reproductive-microbiomes-using-the-microbiome-as-a-novel-diagnostic-tool-for-endometriosis.php?aid=20437,NA,NA,NA,NA,NA,Experiment 1,United States of America,Homo sapiens,Uterine cervix,UBERON:0000002,Endometriosis,EFO:0001065,Women scheduled for laparoscopic surgery for benign uterine/ ovarian conditions as well as women with Stage I or Stage II endometriosis,One (1) Stage III Endometriosis patient,One (1) Stage III Endometriosis patient was diagnosed via laparoscopic surgery and categorized according to the revised American Society for Reproductive Medicine scoring system (r-ASRM).,17,1,None,16S,345,Illumina,PERMANOVA,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:502/1/NA,Study 502,randomized controlled trial,22713265,https://doi.org/10.4161/gmic.21009,https://www.tandfonline.com/doi/full/10.4161/gmic.21009,"Maccaferri S, Candela M, Turroni S, Centanni M, Severgnini M, Consolandi C, Cavina P , Brigidi P",IBS-associated phylogenetic unbalances of the intestinal microbiota are not reverted by probiotic supplementation,Gut microbes,2012,NA,Experiment 1,Italy,Homo sapiens,Feces,UBERON:0001988,Irritable bowel syndrome,EFO:0000555,Healthy Control,IBS,Fulfilled the Rome III criteria for the diagnosis of IBS.,24,19,2 months,16S,23,HTF-Microbi.Array,Kruskall-Wallis,0.05,TRUE,NA,"age,sex",NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:502/2/NA,Study 502,randomized controlled trial,22713265,https://doi.org/10.4161/gmic.21009,https://www.tandfonline.com/doi/full/10.4161/gmic.21009,"Maccaferri S, Candela M, Turroni S, Centanni M, Severgnini M, Consolandi C, Cavina P , Brigidi P",IBS-associated phylogenetic unbalances of the intestinal microbiota are not reverted by probiotic supplementation,Gut microbes,2012,NA,Experiment 2,Italy,Homo sapiens,Feces,UBERON:0001988,Irritable bowel syndrome,EFO:0000555,Healthy Control,IBS-C,Fulfilled the Rome III criteria for the diagnosis of IBS. Constipation IBS (IBS-C),24,4,2 months,16S,23,HTF-Microbi.Array,Kruskall-Wallis,0.05,TRUE,NA,"age,sex",NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:502/3/NA,Study 502,randomized controlled trial,22713265,https://doi.org/10.4161/gmic.21009,https://www.tandfonline.com/doi/full/10.4161/gmic.21009,"Maccaferri S, Candela M, Turroni S, Centanni M, Severgnini M, Consolandi C, Cavina P , Brigidi P",IBS-associated phylogenetic unbalances of the intestinal microbiota are not reverted by probiotic supplementation,Gut microbes,2012,NA,Experiment 3,Italy,Homo sapiens,Feces,UBERON:0001988,Irritable bowel syndrome,EFO:0000555,Healthy Control,IBS-D,Fulfilled the Rome III criteria for the diagnosis of IBS. Diarrhea IBS (IBS-D).,24,10,2 months,16S,23,HTF-Microbi.Array,Kruskall-Wallis,0.05,TRUE,NA,"age,sex",NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:502/4/NA,Study 502,randomized controlled trial,22713265,https://doi.org/10.4161/gmic.21009,https://www.tandfonline.com/doi/full/10.4161/gmic.21009,"Maccaferri S, Candela M, Turroni S, Centanni M, Severgnini M, Consolandi C, Cavina P , Brigidi P",IBS-associated phylogenetic unbalances of the intestinal microbiota are not reverted by probiotic supplementation,Gut microbes,2012,NA,Experiment 4,Italy,Homo sapiens,Feces,UBERON:0001988,Irritable bowel syndrome,EFO:0000555,Healthy Control,IBS-M,Fulfilled the Rome III criteria for the diagnosis of IBS. Mixed IBS (IBS-M).,24,5,2 months,16S,23,HTF-Microbi.Array,Kruskall-Wallis,0.05,TRUE,NA,"age,sex",NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:503/1/NA,Study 503,prospective cohort,23565884,10.1111/1469-0691.12213,NA,"Lazarevic V, Manzano S, Gaïa N, Girard M, Whiteson K, Hibbs J, François P, Gervaix A , Schrenzel J",Effects of amoxicillin treatment on the salivary microbiota in children with acute otitis media,Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,2013,"Antibiotics, metagenomics, microbiota, otitis media, saliva",Experiment 1,Switzerland,Homo sapiens,Saliva,UBERON:0001836,Amoxicillin,CHEBI:2676,Control(Unexposed to Amoxicillin),Amoxicillin-exposed,This is the group of children who were exposed to amoxicillin treatment for acute otitis media (AOM). They received amoxicillin as part of their treatment.,15,18,6 months.,16S,123,Roche454,Mann-Whitney (Wilcoxon),0.05,NA,NA,NA,"age,sex",NA,increased,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:503/2/NA,Study 503,prospective cohort,23565884,10.1111/1469-0691.12213,NA,"Lazarevic V, Manzano S, Gaïa N, Girard M, Whiteson K, Hibbs J, François P, Gervaix A , Schrenzel J",Effects of amoxicillin treatment on the salivary microbiota in children with acute otitis media,Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,2013,"Antibiotics, metagenomics, microbiota, otitis media, saliva",Experiment 2,Switzerland,Homo sapiens,Saliva,UBERON:0001836,Amoxicillin,CHEBI:2676,Control(Unexposed to Amoxicillin),Amoxicillin-exposed,This is the group of children who were exposed to amoxicillin treatment for acute otitis media (AOM). They received amoxicillin as part of their treatment.,15,18,6 months.,16S,123,Roche454,Mann-Whitney (Wilcoxon),0.05,NA,NA,NA,"age,sex",NA,increased,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:504/1/NA,Study 504,case-control,32839514,10.1038/s41598-020-71102-x,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7445256/,"Thyagarajan S, Zhang Y, Thapa S, Allen MS, Phillips N, Chaudhary P, Kashyap MV , Vishwanatha JK",Comparative analysis of racial differences in breast tumor microbiome,Scientific reports,2020,NA,Experiment 1,United States of America,Homo sapiens,Breast,UBERON:0000310,Neoplasm,EFO:0000616,BNH with TNBC normal tissue,BNH with TNBC tumor tissue,Tumor tissue from black non-hispanic patients with triple negative breast cancer,7,7,"Biorepository information revealed that no patients were treated with antibiotics prior to tissue sample collection, however duration window of non-exposure was unidentified.",16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:504/2/NA,Study 504,case-control,32839514,10.1038/s41598-020-71102-x,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7445256/,"Thyagarajan S, Zhang Y, Thapa S, Allen MS, Phillips N, Chaudhary P, Kashyap MV , Vishwanatha JK",Comparative analysis of racial differences in breast tumor microbiome,Scientific reports,2020,NA,Experiment 2,United States of America,Homo sapiens,Breast,UBERON:0000310,Neoplasm,EFO:0000616,WNH with TNBC normal tissue,WNH with TNBC normal tissue,Tumor tissue from white non-hispanic patients with triple negative breast cancer,6,6,"Biorepository information revealed that no patients were treated with antibiotics prior to tissue sample collection, however duration window of non-exposure was unidentified.",16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:504/3/NA,Study 504,case-control,32839514,10.1038/s41598-020-71102-x,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7445256/,"Thyagarajan S, Zhang Y, Thapa S, Allen MS, Phillips N, Chaudhary P, Kashyap MV , Vishwanatha JK",Comparative analysis of racial differences in breast tumor microbiome,Scientific reports,2020,NA,Experiment 3,United States of America,Homo sapiens,Breast,UBERON:0000310,Neoplasm,EFO:0000616,WNH with TNBC normal tissue (second set),WNH with TNBC normal tissue (second set),Tumor tissue from white non-hispanic patients with triple negative breast cancer,10,10,"Biorepository information revealed that no patients were treated with antibiotics prior to tissue sample collection, however duration window of non-exposure was unidentified.",16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,increased,increased,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:504/4/NA,Study 504,case-control,32839514,10.1038/s41598-020-71102-x,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7445256/,"Thyagarajan S, Zhang Y, Thapa S, Allen MS, Phillips N, Chaudhary P, Kashyap MV , Vishwanatha JK",Comparative analysis of racial differences in breast tumor microbiome,Scientific reports,2020,NA,Experiment 4,United States of America,Homo sapiens,Breast,UBERON:0000310,Neoplasm,EFO:0000616,TPBC normal tissue,TPBC tumor tissue,Tumor tissue from patients with triple positive breast cancer,10,10,"Biorepository information revealed that no patients were treated with antibiotics prior to tissue sample collection, however duration window of non-exposure was unidentified.",16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:504/5/NA,Study 504,case-control,32839514,10.1038/s41598-020-71102-x,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7445256/,"Thyagarajan S, Zhang Y, Thapa S, Allen MS, Phillips N, Chaudhary P, Kashyap MV , Vishwanatha JK",Comparative analysis of racial differences in breast tumor microbiome,Scientific reports,2020,NA,Experiment 5,United States of America,Homo sapiens,Breast,UBERON:0000310,Ethnic group,EFO:0001799,WNH,BNH,Normal tissue from black non-hispanic patients with breast cancer,6,7,"Biorepository information revealed that no patients were treated with antibiotics prior to tissue sample collection, however duration window of non-exposure was unidentified.",16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,increased,unchanged,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:504/6/NA,Study 504,case-control,32839514,10.1038/s41598-020-71102-x,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7445256/,"Thyagarajan S, Zhang Y, Thapa S, Allen MS, Phillips N, Chaudhary P, Kashyap MV , Vishwanatha JK",Comparative analysis of racial differences in breast tumor microbiome,Scientific reports,2020,NA,Experiment 6,United States of America,Homo sapiens,Breast,UBERON:0000310,Ethnic group,EFO:0001799,WNH,BNH,Tumor tissue from black non-hispanic patients with breast cancer,6,7,"Biorepository information revealed that no patients were treated with antibiotics prior to tissue sample collection, however duration window of non-exposure was unidentified.",16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,decreased,decreased,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:505/1/NA,Study 505,case-control,19533811,10.3748/wjg.15.2887,NA,"Kerckhoffs AP, Samsom M, van der Rest ME, de Vogel J, Knol J, Ben-Amor K , Akkermans LM",Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients,World journal of gastroenterology,2009,NA,Experiment 1,Netherlands,Homo sapiens,"Feces,Mucosa of small intestine","UBERON:0001988,UBERON:0001204",Irritable bowel syndrome,EFO:0000555,Healthy Control,IBS,"Twelve male and 29 female IBS patients included in this study fulfilled the Rome II criteria for IBS and were categorized as diarrhea predominant (IBS-D), constipation predominant (IBS-C) or alternating IBS subgroup (IBS-A)",26,41,"Subjects taking medication known to influence bacterial composition and gastrointestinal motility, especially antimicrobial medications and/or probiotics were excluded from the study.",NA,NA,RT-qPCR,T-Test,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:505/2/NA,Study 505,case-control,19533811,10.3748/wjg.15.2887,NA,"Kerckhoffs AP, Samsom M, van der Rest ME, de Vogel J, Knol J, Ben-Amor K , Akkermans LM",Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients,World journal of gastroenterology,2009,NA,Experiment 2,Netherlands,Homo sapiens,"Feces,Mucosa of small intestine","UBERON:0001988,UBERON:0001204",Irritable bowel syndrome,EFO:0000555,Healthy Control,IBS-D,IBS patients included in this study fulfilled the Rome II criteria for IBS and were categorized as diarrhea predominant (IBS-D),26,14,"Subjects taking medication known to influence bacterial composition and gastrointestinal motility, especially antimicrobial medications and/or probiotics were excluded from the study.",NA,NA,RT-qPCR,T-Test,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:505/3/NA,Study 505,case-control,19533811,10.3748/wjg.15.2887,NA,"Kerckhoffs AP, Samsom M, van der Rest ME, de Vogel J, Knol J, Ben-Amor K , Akkermans LM",Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients,World journal of gastroenterology,2009,NA,Experiment 3,Netherlands,Homo sapiens,"Feces,Mucosa of small intestine","UBERON:0001988,UBERON:0001204",Irritable bowel syndrome,EFO:0000555,Healthy Control,IBS-A,IBS patients included in this study fulfilled the Rome II criteria for IBS and were categorized as  alternating IBS subgroup (IBS-A),26,16,"Subjects taking medication known to influence bacterial composition and gastrointestinal motility, especially antimicrobial medications and/or probiotics were excluded from the study.",NA,NA,RT-qPCR,T-Test,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:505/4/NA,Study 505,case-control,19533811,10.3748/wjg.15.2887,NA,"Kerckhoffs AP, Samsom M, van der Rest ME, de Vogel J, Knol J, Ben-Amor K , Akkermans LM",Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients,World journal of gastroenterology,2009,NA,Experiment 4,Netherlands,Homo sapiens,"Feces,Mucosa of small intestine","UBERON:0001988,UBERON:0001204",Irritable bowel syndrome,EFO:0000555,Healthy Control,IBS-C,IBS patients included in this study fulfilled the Rome II criteria for IBS and were categorized as  constipation predominant (IBS-C),26,11,"Subjects taking medication known to influence bacterial composition and gastrointestinal motility, especially antimicrobial medications and/or probiotics were excluded from the study.",NA,NA,RT-qPCR,T-Test,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:506/1/NA,Study 506,case-control,22356587,10.1111/j.1365-2982.2012.01893.x,NA,"Duboc H, Rainteau D, Rajca S, Humbert L, Farabos D, Maubert M, Grondin V, Jouet P, Bouhassira D, Seksik P, Sokol H, Coffin B , Sabaté JM",Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome,Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society,2012,NA,Experiment 1,France,Homo sapiens,Feces,UBERON:0001988,Irritable bowel syndrome,EFO:0000555,Healthy Control,IBS-D,The diagnosis of IBS-D was defined by the Rome 3 criteria,18,14,3 months,16S,NA,RT-qPCR,"Mann-Whitney (Wilcoxon),T-Test",0.05,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:507/1/NA,Study 507,time series / longitudinal observational,27027301,10.1159/000443361,NA,"Ponziani FR, Scaldaferri F, Petito V, Paroni Sterbini F, Pecere S, Lopetuso LR, Palladini A, Gerardi V, Masucci L, Pompili M, Cammarota G, Sanguinetti M , Gasbarrini A",The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin,"Digestive diseases (Basel, Switzerland)",2016,NA,Experiment 1,Italy,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,Patients before Rifaximin treatment,Patients after Rifaximin treatment,"Patients affected by ulcerative colitis, Chron's disease, Irritable Bowel Syndrome, diverticular disease, and liver cirrhosis with hepatic encephalopathy consecutively treated with 1,200 mg of Rifaximin daily for 10 days.",20,20,1 month,16S,123,Roche454,metagenomeSeq,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:507/2/NA,Study 507,time series / longitudinal observational,27027301,10.1159/000443361,NA,"Ponziani FR, Scaldaferri F, Petito V, Paroni Sterbini F, Pecere S, Lopetuso LR, Palladini A, Gerardi V, Masucci L, Pompili M, Cammarota G, Sanguinetti M , Gasbarrini A",The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin,"Digestive diseases (Basel, Switzerland)",2016,NA,Experiment 2,Italy,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,Patients before Rifaximin treatment,Patients 1 month after Rifaximin treatment,"Patients 1 month after Rifaximin treatment affected by ulcerative colitis, Chron's disease, Irritable Bowel Syndrome, diverticular disease, and liver cirrhosis with hepatic encephalopathy consecutively.",20,20,1 month prior to Rifaximin treatment.,16S,123,Roche454,metagenomeSeq,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:508/1/NA,Study 508,case-control,33099131,10.1016/j.parkreldis.2020.10.034,https://pubmed.ncbi.nlm.nih.gov/33099131/,"Zhang F, Yue L, Fang X, Wang G, Li C, Sun X, Jia X, Yang J, Song J, Zhang Y, Guo C, Ma G, Sang M, Chen F , Wang P",Altered gut microbiota in Parkinson's disease patients/healthy spouses and its association with clinical features,Parkinsonism & related disorders,2020,"Clinical features/classifications, Gut microbiota dysbiosis, Metagenomics, Neurodegenerative disease, Parkinson's disease (PD)",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Healthy Controls,Parkinson's Disease Patients,"The patients were diagnosed with primary Parkinson's disease according to the Movement Disorder Society Clinical Diagnostic Criteria for Parkinson’s disease (MDS-PD Criteria, 2015) of Xiangyang NO.1 People’s Hospital.",137,63,90 days.,16S,4,Illumina,LEfSe,0.05,FALSE,2,age,NA,NA,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:509/1/NA,Study 509,laboratory experiment,30547792,10.1186/s12931-018-0959-9,https://pubmed.ncbi.nlm.nih.gov/30547792/,"Zhang R, Chen L, Cao L, Li KJ, Huang Y, Luan XQ , Li G",Effects of smoking on the lower respiratory tract microbiome in mice,Respiratory research,2018,"Inflammation, Lower respiratory tract, Mice, Microbiome, Smoking",Experiment 1,China,Mus musculus,Lung,UBERON:0002048,Smoking behavior,EFO:0004318,Non-smoking,Smoking,Male Kunming mice exposed to smoking for 2h per day for 90 days.,20,20,NA,16S,45,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:509/2/NA,Study 509,laboratory experiment,30547792,10.1186/s12931-018-0959-9,https://pubmed.ncbi.nlm.nih.gov/30547792/,"Zhang R, Chen L, Cao L, Li KJ, Huang Y, Luan XQ , Li G",Effects of smoking on the lower respiratory tract microbiome in mice,Respiratory research,2018,"Inflammation, Lower respiratory tract, Mice, Microbiome, Smoking",Experiment 2,China,Mus musculus,Lung,UBERON:0002048,Smoking behavior,EFO:0004318,Non-smoking,Smoking,Male Kunming mice exposed to smoking for 2h per day for 90 days.,20,20,NA,16S,45,Illumina,Mann-Whitney (Wilcoxon),NA,NA,2,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:510/1/NA,Study 510,"cross-sectional observational, not case-control",31182740,10.1038/s41598-019-44674-6,NA,"Corrêa JD, Fernandes GR, Calderaro DC, Mendonça SMS, Silva JM, Albiero ML, Cunha FQ, Xiao E, Ferreira GA, Teixeira AL, Mukherjee C, Leys EJ, Silva TA , Graves DT",Oral microbial dysbiosis linked to worsened periodontal condition in rheumatoid arthritis patients,Scientific reports,2019,NA,Experiment 1,Brazil,Homo sapiens,Subgingival dental plaque,UBERON:0016484,Periodontitis,EFO:0000649,patients with no rheumatoid arthritis,patients with rheumatoid arthritis,patients with rheumatoid arthritis,20,21,3 months,16S,4,Illumina,LEfSe,0.05,TRUE,NA,"age,sex",NA,NA,increased,NA,increased,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:510/2/NA,Study 510,"cross-sectional observational, not case-control",31182740,10.1038/s41598-019-44674-6,NA,"Corrêa JD, Fernandes GR, Calderaro DC, Mendonça SMS, Silva JM, Albiero ML, Cunha FQ, Xiao E, Ferreira GA, Teixeira AL, Mukherjee C, Leys EJ, Silva TA , Graves DT",Oral microbial dysbiosis linked to worsened periodontal condition in rheumatoid arthritis patients,Scientific reports,2019,NA,Experiment 2,Brazil,Homo sapiens,Subgingival dental plaque,UBERON:0016484,Rheumatoid arthritis,EFO:0000685,patients with no rheumatoid arthritis,patients with rheumatoid arthritis,patients with rheumatoid arthritis,27,21,3 months,16S,4,Illumina,LEfSe,0.05,TRUE,NA,"age,sex",NA,NA,increased,NA,increased,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:511/1/NA,Study 511,"cross-sectional observational, not case-control",34294722,10.1038/s41522-021-00232-5,NA,"Wu Y, Cheng X, Jiang G, Tang H, Ming S, Tang L, Lu J, Guo C, Shan H , Huang X",Altered oral and gut microbiota and its association with SARS-CoV-2 viral load in COVID-19 patients during hospitalization,NPJ biofilms and microbiomes,2021,NA,Experiment 1,China,Homo sapiens,Oropharynx,UBERON:0001729,COVID-19,MONDO:0100096,Healthy controls,COVID-19 patients,Patients with confirmed COVID-19 infection per 2 sequential positive RT-PCR tests,44,140,No antibiotics or probiotics within 8 weeks prior to COVID-19 infection (also true for controls),16S,34,Illumina,"LEfSe,Linear Regression",0.05,TRUE,2,"age,sex",NA,NA,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:511/2/NA,Study 511,"cross-sectional observational, not case-control",34294722,10.1038/s41522-021-00232-5,NA,"Wu Y, Cheng X, Jiang G, Tang H, Ming S, Tang L, Lu J, Guo C, Shan H , Huang X",Altered oral and gut microbiota and its association with SARS-CoV-2 viral load in COVID-19 patients during hospitalization,NPJ biofilms and microbiomes,2021,NA,Experiment 2,China,Homo sapiens,Oropharynx,UBERON:0001729,COVID-19,MONDO:0100096,COVID-19 patients (mild/moderate),COVID-19 patients (severe/critical),Patients with confirmed COVID-19 infection per 2 sequential positive RT-PCR tests deemed to have severe/critical disease,30,22,No antibiotics or probiotics within 8 weeks prior to COVID-19 infection (also true for controls),16S,34,Illumina,"LEfSe,Linear Regression",0.05,TRUE,2,"age,sex",NA,NA,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:511/3/NA,Study 511,"cross-sectional observational, not case-control",34294722,10.1038/s41522-021-00232-5,NA,"Wu Y, Cheng X, Jiang G, Tang H, Ming S, Tang L, Lu J, Guo C, Shan H , Huang X",Altered oral and gut microbiota and its association with SARS-CoV-2 viral load in COVID-19 patients during hospitalization,NPJ biofilms and microbiomes,2021,NA,Experiment 3,China,Homo sapiens,Oropharynx,UBERON:0001729,COVID-19,MONDO:0100096,Healthy controls,COVID-19 patients not treated with antibiotics,Patients with confirmed COVID-19 infection per 2 sequential positive RT-PCR tests who were not treated with antibiotics,44,17,No antibiotics or probiotics within 8 weeks prior to or during COVID-19 infection (also true for controls),16S,34,Illumina,"LEfSe,Linear Regression",0.05,TRUE,2,"age,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:511/4/NA,Study 511,"cross-sectional observational, not case-control",34294722,10.1038/s41522-021-00232-5,NA,"Wu Y, Cheng X, Jiang G, Tang H, Ming S, Tang L, Lu J, Guo C, Shan H , Huang X",Altered oral and gut microbiota and its association with SARS-CoV-2 viral load in COVID-19 patients during hospitalization,NPJ biofilms and microbiomes,2021,NA,Experiment 4,China,Homo sapiens,Feces,UBERON:0001988,COVID-19,MONDO:0100096,Healthy controls,COVID-19 patients,Patients with confirmed COVID-19 infection per 2 sequential positive RT-PCR tests,32,81,No antibiotics or probiotics within 8 weeks prior to COVID-19 infection (also true for controls),16S,34,Illumina,"LEfSe,Linear Regression",0.05,TRUE,2,"age,sex",NA,NA,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:511/5/NA,Study 511,"cross-sectional observational, not case-control",34294722,10.1038/s41522-021-00232-5,NA,"Wu Y, Cheng X, Jiang G, Tang H, Ming S, Tang L, Lu J, Guo C, Shan H , Huang X",Altered oral and gut microbiota and its association with SARS-CoV-2 viral load in COVID-19 patients during hospitalization,NPJ biofilms and microbiomes,2021,NA,Experiment 5,China,Homo sapiens,Feces,UBERON:0001988,COVID-19,MONDO:0100096,Healthy controls,COVID-19 patients not treated with antibiotics,Patients with confirmed COVID-19 infection per 2 sequential positive RT-PCR tests who were not treated with antibiotics,32,13,No antibiotics or probiotics within 8 weeks prior to or during COVID-19 infection (also true for controls),16S,34,Illumina,"LEfSe,Linear Regression",0.05,TRUE,2,"age,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:512/1/NA,Study 512,case-control,34031657,https://doi.org/10.1101/2021.05.20.445008,NA,"Rhoades NS, Pinski A, Monsibais AN, Jankeel A, Doratt BM, Cinco IR, Ibraim I , Messaoudi I",Acute SARS-CoV-2 infection is associated with an expansion of bacteria pathogens in the nose including <i>Pseudomonas Aeruginosa</i>,bioRxiv : the preprint server for biology,2021,NA,Experiment 1,United States of America,Homo sapiens,Nasopharynx,UBERON:0001728,COVID-19,MONDO:0100096,COVID-19 negative controls and healthcare workers,COVID-19 positive patients,Patients positive for SARS-CoV-2,66,68,NA,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:512/2/NA,Study 512,case-control,34031657,https://doi.org/10.1101/2021.05.20.445008,NA,"Rhoades NS, Pinski A, Monsibais AN, Jankeel A, Doratt BM, Cinco IR, Ibraim I , Messaoudi I",Acute SARS-CoV-2 infection is associated with an expansion of bacteria pathogens in the nose including <i>Pseudomonas Aeruginosa</i>,bioRxiv : the preprint server for biology,2021,NA,Experiment 2,United States of America,Homo sapiens,Nasopharynx,UBERON:0001728,COVID-19,MONDO:0100096,COVID-19 negative controls,COVID-19 positive patients,Patients positive for SARS-CoV-2,21,68,NA,16S,4,Illumina,Kruskall-Wallis,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:512/3/NA,Study 512,case-control,34031657,https://doi.org/10.1101/2021.05.20.445008,NA,"Rhoades NS, Pinski A, Monsibais AN, Jankeel A, Doratt BM, Cinco IR, Ibraim I , Messaoudi I",Acute SARS-CoV-2 infection is associated with an expansion of bacteria pathogens in the nose including <i>Pseudomonas Aeruginosa</i>,bioRxiv : the preprint server for biology,2021,NA,Experiment 3,United States of America,Homo sapiens,Nasopharynx,UBERON:0001728,COVID-19,MONDO:0100096,COVID-19 negative healthcare workers (controls),COVID-19 positive patients,Patients positive for SARS-CoV-2,45,68,NA,16S,4,Illumina,Kruskall-Wallis,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:512/4/NA,Study 512,case-control,34031657,https://doi.org/10.1101/2021.05.20.445008,NA,"Rhoades NS, Pinski A, Monsibais AN, Jankeel A, Doratt BM, Cinco IR, Ibraim I , Messaoudi I",Acute SARS-CoV-2 infection is associated with an expansion of bacteria pathogens in the nose including <i>Pseudomonas Aeruginosa</i>,bioRxiv : the preprint server for biology,2021,NA,Experiment 4,United States of America,Homo sapiens,Nasopharynx,UBERON:0001728,Viral load,EFO:0010125,high Ct CoV+ patients,low Ct CoV+ patients,SARS-CoV-2 positive patients with low cycle threshold value (>23.5),23,22,NA,16S,4,Illumina,Kruskall-Wallis,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:512/5/NA,Study 512,case-control,34031657,https://doi.org/10.1101/2021.05.20.445008,NA,"Rhoades NS, Pinski A, Monsibais AN, Jankeel A, Doratt BM, Cinco IR, Ibraim I , Messaoudi I",Acute SARS-CoV-2 infection is associated with an expansion of bacteria pathogens in the nose including <i>Pseudomonas Aeruginosa</i>,bioRxiv : the preprint server for biology,2021,NA,Experiment 5,United States of America,Homo sapiens,Nasopharynx,UBERON:0001728,Viral load,EFO:0010125,high Ct CoV+ patients,mid Ct CoV+ patients,SARS-CoV-2 positive patients with mid cycle threshold value (32.9-25.0),23,23,NA,16S,4,Illumina,Kruskall-Wallis,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:512/6/NA,Study 512,case-control,34031657,https://doi.org/10.1101/2021.05.20.445008,NA,"Rhoades NS, Pinski A, Monsibais AN, Jankeel A, Doratt BM, Cinco IR, Ibraim I , Messaoudi I",Acute SARS-CoV-2 infection is associated with an expansion of bacteria pathogens in the nose including <i>Pseudomonas Aeruginosa</i>,bioRxiv : the preprint server for biology,2021,NA,Experiment 6,United States of America,Homo sapiens,Nasopharynx,UBERON:0001728,Viral load,EFO:0010125,mid Ct CoV+ patients,low Ct CoV+ patients,SARS-CoV-2 positive patients with low cycle threshold value (>23.5),23,22,NA,16S,4,Illumina,Kruskall-Wallis,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:512/7/NA,Study 512,case-control,34031657,https://doi.org/10.1101/2021.05.20.445008,NA,"Rhoades NS, Pinski A, Monsibais AN, Jankeel A, Doratt BM, Cinco IR, Ibraim I , Messaoudi I",Acute SARS-CoV-2 infection is associated with an expansion of bacteria pathogens in the nose including <i>Pseudomonas Aeruginosa</i>,bioRxiv : the preprint server for biology,2021,NA,Experiment 7,United States of America,Homo sapiens,Nasopharynx,UBERON:0001728,Viral load,EFO:0010125,low and mid Ct CoV+ patients,high Ct CoV+ patients,SARS-CoV-2 positive patients with high cycle threshold value (>34.6),45,23,NA,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:513/1/NA,Study 513,"cross-sectional observational, not case-control",NA,https://doi.org/10.3390/applmicrobiol1020014,https://www.mdpi.com/2673-8007/1/2/14,"Feehan, A.K., Rose, R., Nolan, D.J., Spitz, A.M., Graubics, K., Colwell, R.R., Garcia-Diaz, J. and Lamers, S.L.",Nasopharyngeal Microbiome Community Composition and Structure Is Associated with Severity of COVID-19 Disease and Breathing Treatment,Applied Microbiology,2021,"SARS-CoV-2, Serratia, hospital, metagenomic sequencing",Experiment 1,United States of America,Homo sapiens,Nasopharynx,UBERON:0001728,COVID-19,MONDO:0100096,COVID-19 negative controls,COVID-19 positive patients,Patients who were confirmed PCR positive for SARS-CoV-2,20,79,NA,WMS,NA,Illumina,Fisher's Exact Test,0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:513/2/NA,Study 513,"cross-sectional observational, not case-control",NA,https://doi.org/10.3390/applmicrobiol1020014,https://www.mdpi.com/2673-8007/1/2/14,"Feehan, A.K., Rose, R., Nolan, D.J., Spitz, A.M., Graubics, K., Colwell, R.R., Garcia-Diaz, J. and Lamers, S.L.",Nasopharyngeal Microbiome Community Composition and Structure Is Associated with Severity of COVID-19 Disease and Breathing Treatment,Applied Microbiology,2021,"SARS-CoV-2, Serratia, hospital, metagenomic sequencing",Experiment 2,United States of America,Homo sapiens,Nasopharynx,UBERON:0001728,COVID-19,MONDO:0100096,COVID-19 positive patients without breathing assistance,COVID-19 positive patients with breathing assistance,"Patients who were confirmed PCR positive for SARS-CoV-2 and had treatment with oxygen mask, non-rebreather mask, nasal cannula, BiPAP, CPAP, or ventilator",67,12,NA,WMS,NA,Illumina,Fisher's Exact Test,0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:513/3/NA,Study 513,"cross-sectional observational, not case-control",NA,https://doi.org/10.3390/applmicrobiol1020014,https://www.mdpi.com/2673-8007/1/2/14,"Feehan, A.K., Rose, R., Nolan, D.J., Spitz, A.M., Graubics, K., Colwell, R.R., Garcia-Diaz, J. and Lamers, S.L.",Nasopharyngeal Microbiome Community Composition and Structure Is Associated with Severity of COVID-19 Disease and Breathing Treatment,Applied Microbiology,2021,"SARS-CoV-2, Serratia, hospital, metagenomic sequencing",Experiment 3,United States of America,Homo sapiens,Nasopharynx,UBERON:0001728,COVID-19,MONDO:0100096,COVID-19 positive patients without antibiotic use,COVID-19 positive patients with antibiotic use,COVID-19 positive patients with antibiotic use,81,27,NA,WMS,NA,Illumina,Fisher's Exact Test,0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:514/1/NA,Study 514,"cross-sectional observational, not case-control",31087436,10.1111/aji.13147,NA,"Akiyama K, Nishioka K, Khan KN, Tanaka Y, Mori T, Nakaya T , Kitawaki J",Molecular detection of microbial colonization in cervical mucus of women with and without endometriosis,"American journal of reproductive immunology (New York, N.Y. : 1989)",2019,"cervical mucus, endometriosis, metagenomic analysis, microbiota",Experiment 1,Japan,Homo sapiens,Uterine cervix,UBERON:0000002,Endometriosis,EFO:0001065,Women scheduled for laparoscopic surgery for benign uterine/ ovarian conditions,Stage 3/4 endometriosis patients,Women were diagnosed with endometriosis via laparoscopic surgery and stages were categorized according to the revised American Society for Reproductive Medicine scoring system (r-ASRM).,39,30,No antibiotics were taken 6 months prior to sample collection,16S,56,Ion Torrent,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,increased,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:515/1/NA,Study 515,"cross-sectional observational, not case-control",29771400,10.26355/eurrev_201805_14899,NA,"Wang XM, Ma ZY , Song N","Inflammatory cytokines IL-6, IL-10, IL-13, TNF-α and peritoneal fluid flora were associated with infertility in patients with endometriosis",European review for medical and pharmacological sciences,2018,NA,Experiment 1,China,Homo sapiens,Uterovesical pouch,UBERON:0011049,Endometriosis,EFO:0001065,Non-endometriosis patients with infertility,Endometriosis patients with infertility,Patients were diagnosed with endometriosis via laparoscopic surgery and stages were categorized according to the revised American Society for Reproductive Medicine scoring system (r-ASRM).,30,55,None,16S,45,Ion Torrent,T-Test,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:516/1/NA,Study 516,laboratory experiment,29462324,10.1093/humrep/dex372,NA,"Yuan M, Li D, Zhang Z, Sun H, An M , Wang G",Endometriosis induces gut microbiota alterations in mice,"Human reproduction (Oxford, England)",2018,NA,Experiment 1,China,Mus musculus,Feces,UBERON:0001988,Endometriosis,EFO:0001065,Healthy mice,Mice who were injected with endometrial tissues,Researchers induced endometriosis models by intraperitoneal injection of endometrial tissues to mimic endometriosis formation in humans.,4,4,N/A,16S,4,Illumina,T-Test,0.05,NA,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:516/2/NA,Study 516,laboratory experiment,29462324,10.1093/humrep/dex372,NA,"Yuan M, Li D, Zhang Z, Sun H, An M , Wang G",Endometriosis induces gut microbiota alterations in mice,"Human reproduction (Oxford, England)",2018,NA,Experiment 2,China,Mus musculus,Feces,UBERON:0001988,Endometriosis,EFO:0001065,Healthy mice,Mice who were injected with endometrial tissues,Researchers induced endometriosis models by intraperitoneal injection of endometrial tissues to mimic endometriosis formation in humans.,4,4,N/A,16S,4,Illumina,LEfSe,0.05,NA,4,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:517/1/NA,Study 517,case-control,26901400,10.1016/j.ejogrb.2016.01.040,NA,"Khan KN, Fujishita A, Masumoto H, Muto H, Kitajima M, Masuzaki H , Kitawaki J",Molecular detection of intrauterine microbial colonization in women with endometriosis,"European journal of obstetrics, gynecology, and reproductive biology",2016,"16S rDNA metagenome assay, Cystic fluid, Endometriosis, Infection",Experiment 1,Japan,Homo sapiens,Endometrium,UBERON:0001295,Endometriosis,EFO:0001065,Untreated control women,Endometriosis patients,Patients were diagnosed with endometriosis via laparoscopic surgery and stages were categorized according to the revised American Society for Reproductive Medicine scoring system (r-ASRM). 16 of the control patients and 16 of the endometriosis patients received GnRHa (gonadotropin releasing hormone agonist) treatment for 4-6 months.,32,32,None,16S,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:517/2/NA,Study 517,case-control,26901400,10.1016/j.ejogrb.2016.01.040,NA,"Khan KN, Fujishita A, Masumoto H, Muto H, Kitajima M, Masuzaki H , Kitawaki J",Molecular detection of intrauterine microbial colonization in women with endometriosis,"European journal of obstetrics, gynecology, and reproductive biology",2016,"16S rDNA metagenome assay, Cystic fluid, Endometriosis, Infection",Experiment 2,Japan,Homo sapiens,Endometrium,UBERON:0001295,Endometriosis,EFO:0001065,Endometriosis patients not treated with GnRHa,Endometriosis patients treated with GnRHa,Patients were diagnosed with endometriosis via laparoscopic surgery and stages were categorized according to the revised American Society for Reproductive Medicine scoring system (r-ASRM). 16 of the 32 endometriosis patients received GnRHa (gonadotropin releasing hormone agonist) treatment for 4-6 months.,16,16,None,16S,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:517/3/NA,Study 517,case-control,26901400,10.1016/j.ejogrb.2016.01.040,NA,"Khan KN, Fujishita A, Masumoto H, Muto H, Kitajima M, Masuzaki H , Kitawaki J",Molecular detection of intrauterine microbial colonization in women with endometriosis,"European journal of obstetrics, gynecology, and reproductive biology",2016,"16S rDNA metagenome assay, Cystic fluid, Endometriosis, Infection",Experiment 3,Japan,Homo sapiens,Ovary,UBERON:0000992,Endometriosis,EFO:0001065,Patients with non-endometrioma cysts,Patients with ovarian endometrioma cysts,Patients with ovarian endometrioma had endometrial cysts in their ovaries. Researchers took samples of the fluid inside these cysts. Ovarian endometrioma is one of the many ways endometriosis manifests in the female reproductive system.,8,8,None,16S,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:518/1/NA,Study 518,case-control,33839907,10.1007/s00404-021-06057-z,NA,"Shan J, Ni Z, Cheng W, Zhou L, Zhai D, Sun S , Yu C",Gut microbiota imbalance and its correlations with hormone and inflammatory factors in patients with stage 3/4 endometriosis,Archives of gynecology and obstetrics,2021,"Dysbiosis, Endometriosis, Estradiol, Gut microbiota, Inflammatory factors",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Endometriosis,EFO:0001065,Healthy controls,Stage 3/4 endometriosis patients,Women were diagnosed with endometriosis via laparoscopic surgery and stages were categorized according to the revised American Society for Reproductive Medicine scoring system (r-ASRM).,12,12,3 months,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:519/1/NA,Study 519,laboratory experiment,31037294,10.1093/humrep/dez041,NA,"Chadchan SB, Cheng M, Parnell LA, Yin Y, Schriefer A, Mysorekar IU , Kommagani R",Antibiotic therapy with metronidazole reduces endometriosis disease progression in mice: a potential role for gut microbiota,"Human reproduction (Oxford, England)",2019,"endometriosis, gut bacteria, inflammation, metronidazole, microbiome",Experiment 1,United States of America,Mus musculus,Feces,UBERON:0001988,Endometriosis,EFO:0001065,Non-endo mice,Endo mice,Uterine tissue was transplanted onto the peritoneal wall in order to induce endometriosis in these mice.,5,5,Mice had never been given antibiotics prior to the start of the experiment,16S,NA,Illumina,T-Test,0.05,FALSE,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:520/2/NA,Study 520,"cross-sectional observational, not case-control",32046455,10.1007/s43032-019-00113-5,NA,"Perrotta AR, Borrelli GM, Martins CO, Kallas EG, Sanabani SS, Griffith LG, Alm EJ , Abrao MS",The Vaginal Microbiome as a Tool to Predict rASRM Stage of Disease in Endometriosis: a Pilot Study,"Reproductive sciences (Thousand Oaks, Calif.)",2020,"Diagnosis, Endometriosis, Microbiome, Pathogenesis, Vaginal microbiome",Experiment 2,Brazil,Homo sapiens,Vagina,UBERON:0000996,Endometriosis,EFO:0001065,patients with rASRM stages 1 - 2,patients with rASRM stages 3 - 4,Patients with vaginal and rectal microbiome profiles and their association to severity of endometriosis (rASRM) stages 3 - 4,12,8,Participants were excluded if they had taken antibiotics within the past 3 months,16S,4,Illumina,T-Test,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:521/1/NA,Study 521,case-control,33925708,10.3390/ijms22094608,NA,"Lee SR, Lee JC, Kim SH, Oh YS, Chae HD, Seo H, Kang CS , Shin TS",Altered Composition of Microbiota in Women with Ovarian Endometrioma: Microbiome Analyses of Extracellular Vesicles in the Peritoneal Fluid,International journal of molecular sciences,2021,"16S rDNA, endometriosis, extracellular vesicles, microbiome",Experiment 1,South Korea,Homo sapiens,Uterovesical pouch,UBERON:0011049,Endometriosis,EFO:0001065,Surgical controls,Stage 3/4 endometriosis patients,Stage 3/4 endometriosis patients that were diagnosed with endometriosis via laparoscopic surgery; stages were categorized according to the revised American Society for Reproductive Medicine scoring system (r-ASRM).,45,45,Patients were excluded if they had taken antibiotics 12 weeks prior to sample collection,16S,34,Illumina,PERMANOVA,0.05,FALSE,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:522/1/NA,Study 522,"cross-sectional observational, not case-control",32299442,10.1186/s12941-020-00356-0,NA,"Wei W, Zhang X, Tang H, Zeng L , Wu R",Microbiota composition and distribution along the female reproductive tract of women with endometriosis,Annals of clinical microbiology and antimicrobials,2020,"16S rRNA gene amplicon sequencing, Endometriosis, Microbial community composition, Microbial distribution",Experiment 1,China,Homo sapiens,"Lower part of vagina,Upper part of vagina,Cervical mucus","UBERON:0015243,UBERON:0003974,UBERON:0000316",Endometriosis,EFO:0001065,Controls Subject undergoing laparoscopic surgery for benign tumors,Endometriosis patients,Women with endometriosis,14,36,6 Months,16S,45,Ion Torrent,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:523/1/NA,Study 523,laboratory experiment,32681566,10.1111/aji.13307,NA,"Ni Z, Sun S, Bi Y, Ding J, Cheng W, Yu J, Zhou L, Li M , Yu C",Correlation of fecal metabolomics and gut microbiota in mice with endometriosis,"American journal of reproductive immunology (New York, N.Y. : 1989)",2020,"endometriosis, intestines, metabolomics, microbiota",Experiment 1,China,Mus musculus,Feces,UBERON:0001988,Endometriosis,EFO:0001065,Non-endo mice,Endo mice,Endometriosis was induced in female mice via transplantation of endometrial fragments.,6,6,N/A,16S,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:524/1/NA,Study 524,prospective cohort,31696774,10.1080/19490976.2019.1681861,https://pubmed.ncbi.nlm.nih.gov/31696774/,"Astbury S, Atallah E, Vijay A, Aithal GP, Grove JI , Valdes AM",Lower gut microbiome diversity and higher abundance of proinflammatory genus <i>Collinsella</i> are associated with biopsy-proven nonalcoholic steatohepatitis,Gut microbes,2020,"Collinsella, Fatty liver, cirrhosis, microbiome, nonalcoholic steatohepatitis",Experiment 1,United Kingdom,Homo sapiens,Feces,UBERON:0001988,Non-alcoholic steatohepatitis,EFO:1001249,Healthy controls,Individuals diagnosed with  Nonalcoholic steatohepatitis (without cirrhosis),"Individuals diagnosed with  Nonalcoholic steatohepatitis (without cirrhosis); The Fatty Liver Inhibition of Progression (FLIP) Consortium algorithm was used as a diagnostic indicator where the histological diagnosis of NASH requires the presence of steatosis, ballooning, and lobular inflammation",76,40,NA,16S,4,Illumina,Kruskall-Wallis,0.05,TRUE,NA,"age,body mass index,sex",NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:524/2/NA,Study 524,prospective cohort,31696774,10.1080/19490976.2019.1681861,https://pubmed.ncbi.nlm.nih.gov/31696774/,"Astbury S, Atallah E, Vijay A, Aithal GP, Grove JI , Valdes AM",Lower gut microbiome diversity and higher abundance of proinflammatory genus <i>Collinsella</i> are associated with biopsy-proven nonalcoholic steatohepatitis,Gut microbes,2020,"Collinsella, Fatty liver, cirrhosis, microbiome, nonalcoholic steatohepatitis",Experiment 2,United Kingdom,Homo sapiens,Feces,UBERON:0001988,Non-alcoholic steatohepatitis,EFO:1001249,Healthy controls,Individuals diagnosed with Nonalcoholic steatohepatitis (NASH) with cirrhosis,"Individuals diagnosed with Nonalcoholic steatohepatitis (NASH) with cirrhosis; The Fatty Liver Inhibition of Progression (FLIP) Consortium algorithm was used as a diagnostic indicator where the histological diagnosis of NASH requires the presence of steatosis, ballooning, and lobular inflammation; Fibrosis was scored following the CRN grading system54 by a single pathologist.",76,25,NA,16S,4,Illumina,Kruskall-Wallis,0.05,TRUE,NA,"age,body mass index,sex",NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:525/1/NA,Study 525,case-control,34268384,10.21037/atm-20-4586,NA,"Chao X, Liu Y, Fan Q, Shi H, Wang S , Lang J",The role of the vaginal microbiome in distinguishing female chronic pelvic pain caused by endometriosis/adenomyosis,Annals of translational medicine,2021,"16S rRNA, Chronic pelvic pain (CPP), endometriosis/adenomyosis (EM/AM), function prediction, vaginal microbiome",Experiment 1,China,Homo sapiens,Posterior fornix of vagina,UBERON:0016486,Endometriosis,EFO:0001065,Women without CPPS presenting for routine examinations,Women with EM-associated CPPS,Thirty-seven women with endometriosis-associated chronic pelvic pain syndrome (CPPS) confirmed  by exploratory laparoscopy or surgical pathology,66,37,Patients were excluded if they had taken antibiotics within 14 days prior to sampling,16S,4,Illumina,T-Test,0.05,FALSE,NA,age,NA,NA,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:525/2/NA,Study 525,case-control,34268384,10.21037/atm-20-4586,NA,"Chao X, Liu Y, Fan Q, Shi H, Wang S , Lang J",The role of the vaginal microbiome in distinguishing female chronic pelvic pain caused by endometriosis/adenomyosis,Annals of translational medicine,2021,"16S rRNA, Chronic pelvic pain (CPP), endometriosis/adenomyosis (EM/AM), function prediction, vaginal microbiome",Experiment 2,China,Homo sapiens,Posterior fornix of vagina,UBERON:0016486,Endometriosis,EFO:0001065,Women without CPPS presenting for routine examinations,Women with EM-associated CPPS,Thirty-seven women with endometriosis-associated chronic pelvic pain syndrome (CPPS) confirmed  by exploratory laparoscopy or surgical pathology,66,37,Patients were excluded if they had taken antibiotics within 14 days prior to sampling,16S,4,Illumina,LEfSe,0.05,FALSE,4,age,NA,NA,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:525/3/NA,Study 525,case-control,34268384,10.21037/atm-20-4586,NA,"Chao X, Liu Y, Fan Q, Shi H, Wang S , Lang J",The role of the vaginal microbiome in distinguishing female chronic pelvic pain caused by endometriosis/adenomyosis,Annals of translational medicine,2021,"16S rRNA, Chronic pelvic pain (CPP), endometriosis/adenomyosis (EM/AM), function prediction, vaginal microbiome",Experiment 3,China,Homo sapiens,Posterior fornix of vagina,UBERON:0016486,Endometriosis,EFO:0001065,Women without CPPS presenting for routine examinations,Women with EM-associated CPPS,Thirty-seven women with endometriosis-associated chronic pelvic pain syndrome (CPPS) confirmed by exploratory laparoscopy or surgical pathology,66,37,Patients were excluded if they had taken antibiotics within 14 days prior to sampling,16S,4,Illumina,Metastats,NA,TRUE,NA,age,NA,NA,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:526/1/NA,Study 526,case-control,33313185,10.21037/atm-20-1309,NA,"Chen S, Gu Z, Zhang W, Jia S, Wu Y, Zheng P, Dai Y , Leng J",Microbiome of the lower genital tract in Chinese women with endometriosis by 16s-rRNA sequencing technique: a pilot study,Annals of translational medicine,2020,"16s-rRNA sequencing, Endometriosis, bioinformatic analysis, microbiome",Experiment 1,China,Homo sapiens,Cervical cavity,UBERON:0013761,"Adenomyosis,Endometriosis","EFO:0001065,EFO:1001757",Endometriosis patients (EM) and Patients without endometriosis(Control-CT),Endometriosis/ adenomyosis patients (AMEM),All participants were diagnosed with adenomyosis accompanied with endometriosis (a condition where endometrial tissue grows into the uterine wall) through laparoscopic surgery,92,14,No antibiotic use within 30 days,16S,34,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:526/2/NA,Study 526,case-control,33313185,10.21037/atm-20-1309,NA,"Chen S, Gu Z, Zhang W, Jia S, Wu Y, Zheng P, Dai Y , Leng J",Microbiome of the lower genital tract in Chinese women with endometriosis by 16s-rRNA sequencing technique: a pilot study,Annals of translational medicine,2020,"16s-rRNA sequencing, Endometriosis, bioinformatic analysis, microbiome",Experiment 2,China,Homo sapiens,Cervical cavity,UBERON:0013761,"Adenomyosis,Endometriosis","EFO:0001065,EFO:1001757","Patients without endometriosis (CT), patients with only endometriosis(EM)) and patients with only adenomysis(AM)",Endometriosis/ adenomyosis patients (AMEM),All participants were diagnosed with adenomyosis accompanied with endometriosis (a condition where endometrial tissue grows into the uterine wall) through laparoscopic surgery,120,14,No antibiotic use within 30 days,16S,34,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:526/3/NA,Study 526,case-control,33313185,10.21037/atm-20-1309,NA,"Chen S, Gu Z, Zhang W, Jia S, Wu Y, Zheng P, Dai Y , Leng J",Microbiome of the lower genital tract in Chinese women with endometriosis by 16s-rRNA sequencing technique: a pilot study,Annals of translational medicine,2020,"16s-rRNA sequencing, Endometriosis, bioinformatic analysis, microbiome",Experiment 3,China,Homo sapiens,Cervical cavity,UBERON:0013761,"Adenomyosis,Endometriosis","EFO:0001065,EFO:1001757",Adenomysis patients,Endometriosis/ adenomyosis patients (AMEM),All participants were diagnosed with endometriosis and/or adenomyosis (a condition where endometrial tissue grows into the uterine wall) through laparoscopic surgery,28,14,No antibiotic use within 30 days,16S,34,Illumina,NA,0.05,FALSE,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:527/1/NA,Study 527,case-control,33660232,10.1007/s43032-021-00506-5,NA,"Svensson A, Brunkwall L, Roth B, Orho-Melander M , Ohlsson B",Associations Between Endometriosis and Gut Microbiota,"Reproductive sciences (Thousand Oaks, Calif.)",2021,"Endometriosis, Gastrointestinal symptoms, Gut microbiota, Pathophysiology",Experiment 1,Sweden,Homo sapiens,Feces,UBERON:0001988,Endometriosis,EFO:0001065,Healthy controls taken from a larger cohort study,Endometriosis patients,"Patients with a diagnosis of endometriosis, confirmed by laparoscopy or laparotomy.",198,66,NA,16S,123,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,"age,body mass index,sex,smoking status",NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:527/2/NA,Study 527,case-control,33660232,10.1007/s43032-021-00506-5,NA,"Svensson A, Brunkwall L, Roth B, Orho-Melander M , Ohlsson B",Associations Between Endometriosis and Gut Microbiota,"Reproductive sciences (Thousand Oaks, Calif.)",2021,"Endometriosis, Gastrointestinal symptoms, Gut microbiota, Pathophysiology",Experiment 2,Sweden,Homo sapiens,Feces,UBERON:0001988,Endometriosis,EFO:0001065,Healthy controls taken from a larger cohort study,Endometriosis patients,"Patients with a diagnosis of endometriosis, confirmed by laparoscopy or laparotomy.",198,66,6 months,16S,123,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,"age,body mass index,sex,smoking status",NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:528/1/NA,Study 528,laboratory experiment,31887116,10.1371/journal.pone.0226835,NA,"Hantschel J, Weis S, Schäfer KH, Menger MD, Kohl M, Egert M , Laschke MW",Effect of endometriosis on the fecal bacteriota composition of mice during the acute phase of lesion formation,PloS one,2019,NA,Experiment 1,United States of America,Mus musculus,Feces,UBERON:0001988,Endometriosis,EFO:0001065,Sham(Healthy controls),Endometriosis mice,Mice for whom endometrial tissue was transplanted into the peritoneal cavity to simulate endometriosis. The sample was taken 3 days before the transplantation of uterine tissue fragments,6,8,None were given prior to the start of the experiment,16S,45,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:528/2/NA,Study 528,laboratory experiment,31887116,10.1371/journal.pone.0226835,NA,"Hantschel J, Weis S, Schäfer KH, Menger MD, Kohl M, Egert M , Laschke MW",Effect of endometriosis on the fecal bacteriota composition of mice during the acute phase of lesion formation,PloS one,2019,NA,Experiment 2,United States of America,Mus musculus,Feces,UBERON:0001988,Endometriosis,EFO:0001065,Sham(Healthy controls),Endometriosis mice,Mice for whom endometrial tissue was transplanted into the peritoneal cavity to simulate endometriosis. The sample was taken 7 days after the induction of endometriosis (after EI).,8,8,None were given prior to the start of the experiment,16S,45,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:528/3/NA,Study 528,laboratory experiment,31887116,10.1371/journal.pone.0226835,NA,"Hantschel J, Weis S, Schäfer KH, Menger MD, Kohl M, Egert M , Laschke MW",Effect of endometriosis on the fecal bacteriota composition of mice during the acute phase of lesion formation,PloS one,2019,NA,Experiment 3,United States of America,Mus musculus,Feces,UBERON:0001988,Endometriosis,EFO:0001065,Sham(Healthy controls),Endometriosis mice,Mice for whom endometrial tissue was transplanted into the peritoneal cavity to simulate endometriosis. The sample was taken 21 days after the induction of endometriosis (after EI).,7,5,None were given prior to the start of the experiment,16S,45,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:529/1/NA,Study 529,case-control,30459400,10.1038/s41598-018-35473-6,NA,"Chen B, Zhao Y, Li S, Yang L, Wang H, Wang T, Bin Shi Z, Gai X, Heng C, Zhang J, Yang L , Zhang",Variations in oral microbiome profiles in rheumatoid arthritis and osteoarthritis with potential biomarkers for arthritis screening,Scientific reports,2018,NA,Experiment 1,China,Homo sapiens,Saliva,UBERON:0001836,"Rheumatoid arthritis,Osteoarthritis","EFO:0000685,MONDO:0005178",healthy controls,arthritis patient,arthritis,155,177,NA,16S,NA,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,increased,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:529/2/NA,Study 529,case-control,30459400,10.1038/s41598-018-35473-6,NA,"Chen B, Zhao Y, Li S, Yang L, Wang H, Wang T, Bin Shi Z, Gai X, Heng C, Zhang J, Yang L , Zhang",Variations in oral microbiome profiles in rheumatoid arthritis and osteoarthritis with potential biomarkers for arthritis screening,Scientific reports,2018,NA,Experiment 2,China,Homo sapiens,Saliva,UBERON:0001836,"Rheumatoid arthritis,Osteoarthritis","EFO:0000685,MONDO:0005178",Osteoarthritis,rheumatoid arthritis,patient with rheumatoid arthritis,67,110,NA,16S,NA,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:530/1/NA,Study 530,case-control,31563898,10.1136/jech-2019-212474,NA,"Yang Y, Zheng W, Cai QY, Shrubsole MJ, Pei Z, Brucker R, Steinwandel MD, Bordenstein SR, Li Z, Blot WJ, Shu XO , Long J",Cigarette smoking and oral microbiota in low-income and African-American populations,Journal of epidemiology and community health,2019,"African-American, European-American, cigarette smoking, oral microbiota",Experiment 1,United States of America,Homo sapiens,Mouth,UBERON:0000165,Smoking status measurement,EFO:0006527,Never-Smokers,Current-Smokers,"Participants with a smoking history were chosen based on four nested-control cases for incident cases of upper-aerodigestive tract cancer, type 2 diabetes, lung cancer, and colorectal cancer.",547,592,Participants who took antibiotics within a year before sample collection.,16S,4,Illumina,Logistic Regression,0.05,FALSE,NA,"age,alcohol drinking,body mass index,oral hygiene,race,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:530/2/NA,Study 530,case-control,31563898,10.1136/jech-2019-212474,NA,"Yang Y, Zheng W, Cai QY, Shrubsole MJ, Pei Z, Brucker R, Steinwandel MD, Bordenstein SR, Li Z, Blot WJ, Shu XO , Long J",Cigarette smoking and oral microbiota in low-income and African-American populations,Journal of epidemiology and community health,2019,"African-American, European-American, cigarette smoking, oral microbiota",Experiment 2,United States of America,Homo sapiens,Mouth,UBERON:0000165,Smoking status measurement,EFO:0006527,Never-Smokers,Former-Smokers,"Participants with a smoking history were chosen based on four nested-control cases for incident cases of upper-aerodigestive tract cancer, type 2 diabetes, lung cancer, and colorectal cancer.",547,477,Participants who took antibiotics within a year before sample collection.,16S,4,Illumina,Logistic Regression,0.05,FALSE,NA,"age,alcohol drinking,body mass index,oral hygiene,race,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:530/3/NA,Study 530,case-control,31563898,10.1136/jech-2019-212474,NA,"Yang Y, Zheng W, Cai QY, Shrubsole MJ, Pei Z, Brucker R, Steinwandel MD, Bordenstein SR, Li Z, Blot WJ, Shu XO , Long J",Cigarette smoking and oral microbiota in low-income and African-American populations,Journal of epidemiology and community health,2019,"African-American, European-American, cigarette smoking, oral microbiota",Experiment 3,United States of America,Homo sapiens,Mouth,UBERON:0000165,Smoking status measurement,EFO:0006527,Former-Smokers,Current-Smokers,"Participants with a smoking history were chosen based on four nested-control cases for incident cases of upper-aerodigestive tract cancer, type 2 diabetes, lung cancer, and colorectal cancer.",477,592,Participants who took antibiotics within a year before sample collection.,16S,4,Illumina,Logistic Regression,0.05,FALSE,NA,"age,alcohol drinking,body mass index,oral hygiene,race,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:531/1/NA,Study 531,case-control,32039051,10.3389/fcimb.2019.00475,NA,"Tong Y, Zheng L, Qing P, Zhao H, Li Y, Su L, Zhang Q, Zhao Y, Luo Y , Liu Y",Oral Microbiota Perturbations Are Linked to High Risk for Rheumatoid Arthritis,Frontiers in cellular and infection microbiology,2019,"anti-citrullinated protein autoantibodies, dysbiosis, high risk, oral microbiome, rheumatoid arthritis",Experiment 1,China,Homo sapiens,Saliva,UBERON:0001836,Rheumatoid arthritis,EFO:0000685,Healthy controls,Pre - High risk Patients,"Pre, “pre-clinical” at risk for RA individuals; RF, rheumatoid factor; ACPA,
anti-citrullinated protein antibodies;",23,29,Individuals having a history of antibiotics treatment or surgery in the last 3 months were excluded,16S,34,Illumina,LEfSe,0.05,TRUE,3,"age,ethnic group,sex",NA,NA,decreased,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:531/2/NA,Study 531,case-control,32039051,10.3389/fcimb.2019.00475,NA,"Tong Y, Zheng L, Qing P, Zhao H, Li Y, Su L, Zhang Q, Zhao Y, Luo Y , Liu Y",Oral Microbiota Perturbations Are Linked to High Risk for Rheumatoid Arthritis,Frontiers in cellular and infection microbiology,2019,"anti-citrullinated protein autoantibodies, dysbiosis, high risk, oral microbiome, rheumatoid arthritis",Experiment 2,China,Homo sapiens,Saliva,UBERON:0001836,Rheumatoid arthritis,EFO:0000685,Healthy controls,Rheumatoid Arthritis,Patients with Rheumatoid Arthritis,23,27,Individuals having a history of antibiotics treatment or surgery in the last 3 months were excluded,16S,34,Illumina,LEfSe,0.05,TRUE,3,"age,ethnic group,sex",NA,NA,increased,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:531/3/NA,Study 531,case-control,32039051,10.3389/fcimb.2019.00475,NA,"Tong Y, Zheng L, Qing P, Zhao H, Li Y, Su L, Zhang Q, Zhao Y, Luo Y , Liu Y",Oral Microbiota Perturbations Are Linked to High Risk for Rheumatoid Arthritis,Frontiers in cellular and infection microbiology,2019,"anti-citrullinated protein autoantibodies, dysbiosis, high risk, oral microbiome, rheumatoid arthritis",Experiment 3,China,Homo sapiens,Saliva,UBERON:0001836,Rheumatoid arthritis,EFO:0000685,Rheumatoid Arthritis,Pre - High risk Patients,"Pre, “pre-clinical” at risk for RA individuals; RF, rheumatoid factor; ACPA, anti-citrullinated protein antibodies;",27,29,Individuals having a history of antibiotics treatment or surgery in the last 3 months were excluded,16S,34,Illumina,LEfSe,0.05,TRUE,3,"age,ethnic group,sex",NA,NA,decreased,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:532/1/NA,Study 532,case-control,27102666,10.1186/s13073-016-0299-7,NA,"Chen J, Wright K, Davis JM, Jeraldo P, Marietta EV, Murray J, Nelson H, Matteson EL , Taneja V",An expansion of rare lineage intestinal microbes characterizes rheumatoid arthritis,Genome medicine,2016,NA,Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Rheumatoid arthritis,EFO:0000685,healthy controls,rheumatoid arthritis patients,rheumatoid arthritis patients,32,40,"Any patient or control on antibiotics, consuming probiotics, or having a known history of inflammatory bowel disease or other autoimmune diseases like diabetes and multiple sclerosis were excluded.",16S,345,Illumina,LEfSe,0.05,TRUE,2,"age,sex",NA,NA,decreased,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:533/1/NA,Study 533,case-control,32934117,10.1128/mSystems.00561-20,https://pubmed.ncbi.nlm.nih.gov/32934117,"Vascellari S, Palmas V, Melis M, Pisanu S, Cusano R, Uva P, Perra D, Madau V, Sarchioto M, Oppo V, Simola N, Morelli M, Santoru ML, Atzori L, Melis M, Cossu G , Manzin A",Gut Microbiota and Metabolome Alterations Associated with Parkinson's Disease,mSystems,2020,"16S RNA, PD, gut microbiota, metabolome",Experiment 1,Italy,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Healthy control,Patients with Parkinson's disease,Patients who have Parkinson's disease,51,64,3 months,16S,34,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:533/2/NA,Study 533,case-control,32934117,10.1128/mSystems.00561-20,https://pubmed.ncbi.nlm.nih.gov/32934117,"Vascellari S, Palmas V, Melis M, Pisanu S, Cusano R, Uva P, Perra D, Madau V, Sarchioto M, Oppo V, Simola N, Morelli M, Santoru ML, Atzori L, Melis M, Cossu G , Manzin A",Gut Microbiota and Metabolome Alterations Associated with Parkinson's Disease,mSystems,2020,"16S RNA, PD, gut microbiota, metabolome",Experiment 2,Italy,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Healthy control,Patients with Parkinson's disease,Patients who have Parkinson's disease,51,64,3 months,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:534/1/NA,Study 534,time series / longitudinal observational,29166320,10.1249/MSS.0000000000001495,NA,"Allen JM, Mailing LJ, Niemiro GM, Moore R, Cook MD, White BA, Holscher HD , Woods JA",Exercise Alters Gut Microbiota Composition and Function in Lean and Obese Humans,Medicine and science in sports and exercise,2018,NA,Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Exercise,EFO:0000483,lean subjects,obese subjects,sedentary participants between 20 and 45 years of age with BMI > 30 (classified as obese),18,14,3 months,16S,4,Illumina,PERMANOVA,0.05,FALSE,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:534/2/NA,Study 534,time series / longitudinal observational,29166320,10.1249/MSS.0000000000001495,NA,"Allen JM, Mailing LJ, Niemiro GM, Moore R, Cook MD, White BA, Holscher HD , Woods JA",Exercise Alters Gut Microbiota Composition and Function in Lean and Obese Humans,Medicine and science in sports and exercise,2018,NA,Experiment 2,United States of America,Homo sapiens,Feces,UBERON:0001988,Exercise,EFO:0000483,lean subjects,obese subjects,sedentary participants between 20 and 45 years of age with BMI >30 (classified as obese),18,14,3 months,16S,NA,Illumina,PERMANOVA,0.05,FALSE,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:535/1/NA,Study 535,"cross-sectional observational, not case-control",22949626,10.1093/jac/dks348,NA,"O'Sullivan O, Coakley M, Lakshminarayanan B, Conde S, Claesson MJ, Cusack S, Fitzgerald AP, O'Toole PW, Stanton C , Ross RP",Alterations in intestinal microbiota of elderly Irish subjects post-antibiotic therapy,The Journal of antimicrobial chemotherapy,2013,NA,Experiment 1,Ireland,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,Antibiotic untreated,Antibiotic treated,subjects receiving antibiotics within 1 month prior to visiting an ELDERMET Clinic,143,42,NA,16S,4,Roche454,"Mann-Whitney (Wilcoxon),Kruskall-Wallis",0.05,TRUE,NA,age,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:535/2/NA,Study 535,"cross-sectional observational, not case-control",22949626,10.1093/jac/dks348,NA,"O'Sullivan O, Coakley M, Lakshminarayanan B, Conde S, Claesson MJ, Cusack S, Fitzgerald AP, O'Toole PW, Stanton C , Ross RP",Alterations in intestinal microbiota of elderly Irish subjects post-antibiotic therapy,The Journal of antimicrobial chemotherapy,2013,NA,Experiment 2,Ireland,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,Antibiotic untreated subjects in day hospital,Antibiotic treated subjects in day hospital,subjects who were antibiotic-treated in a day hospital,33,7,NA,16S,4,Roche454,"Kruskall-Wallis,Mann-Whitney (Wilcoxon),Chi-Square",0.05,TRUE,NA,age,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:535/3/NA,Study 535,"cross-sectional observational, not case-control",22949626,10.1093/jac/dks348,NA,"O'Sullivan O, Coakley M, Lakshminarayanan B, Conde S, Claesson MJ, Cusack S, Fitzgerald AP, O'Toole PW, Stanton C , Ross RP",Alterations in intestinal microbiota of elderly Irish subjects post-antibiotic therapy,The Journal of antimicrobial chemotherapy,2013,NA,Experiment 3,Ireland,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,Antibiotic untreated community dwelling subjects,Antibiotic treated community dwelling subjects,community-dwelling subjects treated with antibiotics within 1 month of study,64,9,NA,16S,4,Roche454,"Kruskall-Wallis,Mann-Whitney (Wilcoxon),Chi-Square",0.05,TRUE,NA,age,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:535/4/NA,Study 535,"cross-sectional observational, not case-control",22949626,10.1093/jac/dks348,NA,"O'Sullivan O, Coakley M, Lakshminarayanan B, Conde S, Claesson MJ, Cusack S, Fitzgerald AP, O'Toole PW, Stanton C , Ross RP",Alterations in intestinal microbiota of elderly Irish subjects post-antibiotic therapy,The Journal of antimicrobial chemotherapy,2013,NA,Experiment 4,Ireland,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,Antibiotic untreated subjects in long stay facility,Antibiotic treated subjects in long stay facility,subjects in long stay facility who have had antibiotic treatment in the past month,32,16,NA,16S,4,Roche454,"Kruskall-Wallis,Mann-Whitney (Wilcoxon),Chi-Square",0.05,TRUE,NA,age,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:536/1/NA,Study 536,randomized controlled trial,30478001,10.1016/j.ebiom.2018.11.035,NA,"Wei S, Mortensen MS, Stokholm J, Brejnrod AD, Thorsen J, Rasmussen MA, Trivedi U, Bisgaard H , Sørensen SJ","Short- and long-term impacts of azithromycin treatment on the gut microbiota in children: A double-blind, randomized, placebo-controlled trial",EBioMedicine,2018,"Antibiotics, Asthma, Azithromycin, Children, Gut microbiota, RCT",Experiment 1,Denmark,Homo sapiens,Feces,UBERON:0001988,Azithromycin,CHEBI:2955,The group given a placebo,The group given an azithromycin oral solution,"1-3-year-olds diagnosed with recurrent asthma-like symptoms from the COPSAC2010 cohort. Exclusion criteria included macrolide allergy, heart, liver, neurological, kidney disease, and or one or more clinical signs of pneumonia. Participants were prescribed a 3-day course of oral azithromycin solution of 10mg/kg per day.",33,39,none mentioned,16S,4,Illumina,Linear Regression,0.05,FALSE,NA,NA,NA,NA,decreased,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:537/1/NA,Study 537,case-control,30576008,10.1002/mds.27581,NA,"Barichella M, Severgnini M, Cilia R, Cassani E, Bolliri C, Caronni S, Ferri V, Cancello R, Ceccarani C, Faierman S, Pinelli G, De Bellis G, Zecca L, Cereda E, Consolandi C , Pezzoli G",Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism,Movement disorders : official journal of the Movement Disorder Society,2019,"MSA, PD, PSP, Parkinson-s disease, clinical features, gut-brain axis, multiple system atrophy, progressive supranuclear palsy",Experiment 1,Italy,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,healthy controls without any form of Parkinson's Disease,patients with idiopathic parkinson's disease,Patients with idiopathic parkinson's disease with stage diagnosed according to UK Brain Bank Criteria(1996),113,193,1 month,16S,34,Illumina,Negative Binomial Regression,0.05,NA,NA,"age,body mass index,geographic area","age,alcohol drinking,breast feeding,constipation,sex,smoking status",NA,NA,increased,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:537/2/NA,Study 537,case-control,30576008,10.1002/mds.27581,NA,"Barichella M, Severgnini M, Cilia R, Cassani E, Bolliri C, Caronni S, Ferri V, Cancello R, Ceccarani C, Faierman S, Pinelli G, De Bellis G, Zecca L, Cereda E, Consolandi C , Pezzoli G",Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism,Movement disorders : official journal of the Movement Disorder Society,2019,"MSA, PD, PSP, Parkinson-s disease, clinical features, gut-brain axis, multiple system atrophy, progressive supranuclear palsy",Experiment 2,Italy,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,healthy controls without any form of Parkinson's Disease,the trend over Parkinson's disease progression,Patients with idiopathic Parkinson's disease with stage diagnosed according to UK Brain Bank Criteria(1996),113,193,NA,16S,34,Illumina,Negative Binomial Regression,0.05,NA,NA,"age,body mass index,geographic area","age,breast feeding,constipation,smoking status",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:537/3/NA,Study 537,case-control,30576008,10.1002/mds.27581,NA,"Barichella M, Severgnini M, Cilia R, Cassani E, Bolliri C, Caronni S, Ferri V, Cancello R, Ceccarani C, Faierman S, Pinelli G, De Bellis G, Zecca L, Cereda E, Consolandi C , Pezzoli G",Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism,Movement disorders : official journal of the Movement Disorder Society,2019,"MSA, PD, PSP, Parkinson-s disease, clinical features, gut-brain axis, multiple system atrophy, progressive supranuclear palsy",Experiment 3,Italy,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,healthy controls without any form of Parkinson's Disease,patients with MSA(multiple system atrophy) disease,Patients diagnosed with synucleinopathy multiple system atrophy (MSA),113,22,NA,16S,34,Illumina,Negative Binomial Regression,0.05,NA,NA,"age,body mass index,geographic area","age,alcohol drinking,breast feeding,constipation,sex,smoking status",NA,NA,increased,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:537/4/NA,Study 537,case-control,30576008,10.1002/mds.27581,NA,"Barichella M, Severgnini M, Cilia R, Cassani E, Bolliri C, Caronni S, Ferri V, Cancello R, Ceccarani C, Faierman S, Pinelli G, De Bellis G, Zecca L, Cereda E, Consolandi C , Pezzoli G",Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism,Movement disorders : official journal of the Movement Disorder Society,2019,"MSA, PD, PSP, Parkinson-s disease, clinical features, gut-brain axis, multiple system atrophy, progressive supranuclear palsy",Experiment 4,Italy,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,healthy controls without any form of Parkinson's Disease,patients with PSP(progressive supranuclear palsy) disease,Patients diagnosed with tauopathy progressive supranuclear palsy (PSP),113,22,NA,16S,34,Illumina,Negative Binomial Regression,0.05,NA,NA,"age,body mass index,geographic area","age,alcohol drinking,breast feeding,constipation,sex,smoking status",NA,NA,increased,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:537/5/NA,Study 537,case-control,30576008,10.1002/mds.27581,NA,"Barichella M, Severgnini M, Cilia R, Cassani E, Bolliri C, Caronni S, Ferri V, Cancello R, Ceccarani C, Faierman S, Pinelli G, De Bellis G, Zecca L, Cereda E, Consolandi C , Pezzoli G",Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism,Movement disorders : official journal of the Movement Disorder Society,2019,"MSA, PD, PSP, Parkinson-s disease, clinical features, gut-brain axis, multiple system atrophy, progressive supranuclear palsy",Experiment 5,Italy,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,healthy controls without any form of Parkinson's Disease,patients with De-novo Parkinson's disease,Patients with de novo Parkinson's disease with stage diagnosed according to UK Brain Bank Criteria(1996),113,39,NA,16S,34,Illumina,Negative Binomial Regression,0.05,NA,NA,"age,body mass index,geographic area","age,alcohol drinking,breast feeding,constipation,sex,smoking status",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:537/6/NA,Study 537,case-control,30576008,10.1002/mds.27581,NA,"Barichella M, Severgnini M, Cilia R, Cassani E, Bolliri C, Caronni S, Ferri V, Cancello R, Ceccarani C, Faierman S, Pinelli G, De Bellis G, Zecca L, Cereda E, Consolandi C , Pezzoli G",Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism,Movement disorders : official journal of the Movement Disorder Society,2019,"MSA, PD, PSP, Parkinson-s disease, clinical features, gut-brain axis, multiple system atrophy, progressive supranuclear palsy",Experiment 6,Italy,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,healthy controls without any form of Parkinson's disease,patients with early Parkinson's disease,Patients with early Parkinson's disease with stage diagnosed according to UK Brain Bank Criteria(1996),113,57,NA,16S,34,Illumina,Negative Binomial Regression,0.05,NA,NA,"age,body mass index,geographic area","age,alcohol drinking,breast feeding,constipation,sex,smoking status",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:537/7/NA,Study 537,case-control,30576008,10.1002/mds.27581,NA,"Barichella M, Severgnini M, Cilia R, Cassani E, Bolliri C, Caronni S, Ferri V, Cancello R, Ceccarani C, Faierman S, Pinelli G, De Bellis G, Zecca L, Cereda E, Consolandi C , Pezzoli G",Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism,Movement disorders : official journal of the Movement Disorder Society,2019,"MSA, PD, PSP, Parkinson-s disease, clinical features, gut-brain axis, multiple system atrophy, progressive supranuclear palsy",Experiment 7,Italy,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,healthy controls without any form of Parkinson's Disease,patients with mid stage Parkinson's,Patients with mid stage Parkinson's disease with stage diagnosed according to UK Brain Bank Criteria(1996),113,53,NA,16S,34,Illumina,Negative Binomial Regression,0.05,NA,NA,"age,body mass index,geographic area","age,alcohol drinking,breast feeding,constipation,sex,smoking status",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:537/8/NA,Study 537,case-control,30576008,10.1002/mds.27581,NA,"Barichella M, Severgnini M, Cilia R, Cassani E, Bolliri C, Caronni S, Ferri V, Cancello R, Ceccarani C, Faierman S, Pinelli G, De Bellis G, Zecca L, Cereda E, Consolandi C , Pezzoli G",Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism,Movement disorders : official journal of the Movement Disorder Society,2019,"MSA, PD, PSP, Parkinson-s disease, clinical features, gut-brain axis, multiple system atrophy, progressive supranuclear palsy",Experiment 8,Italy,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,healthy controls without any form of Parkinson's Disease,patients with advanced stage Parkinson's,Patients with advanced stage Parkinson&#039;s disease with stage diagnosed according to UK Brain Bank Criteria(1996),113,44,NA,16S,34,Illumina,Negative Binomial Regression,0.05,NA,NA,"age,body mass index,geographic area","age,alcohol drinking,breast feeding,constipation,sex,smoking status",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:538/1/NA,Study 538,prospective cohort,25658522,10.1016/j.cmi.2014.11.016,NA,"Stewardson AJ, Gaïa N, François P, Malhotra-Kumar S, Delémont C, Martinez de Tejada B, Schrenzel J, Harbarth S , Lazarevic V",Collateral damage from oral ciprofloxacin versus nitrofurantoin in outpatients with urinary tract infections: a culture-free analysis of gut microbiota,Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,2015,"Antibiotics, ecologic damage, microbiomics, microbiota, urinary tract infection",Experiment 1,Switzerland,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,baseline of the ciprofloxacin treated,ciprofloxacin treated,UTI patients treated with ciprofloxacin 500mg twice daily,10,10,2 months,16S,34,Roche454,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:538/2/NA,Study 538,prospective cohort,25658522,10.1016/j.cmi.2014.11.016,NA,"Stewardson AJ, Gaïa N, François P, Malhotra-Kumar S, Delémont C, Martinez de Tejada B, Schrenzel J, Harbarth S , Lazarevic V",Collateral damage from oral ciprofloxacin versus nitrofurantoin in outpatients with urinary tract infections: a culture-free analysis of gut microbiota,Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,2015,"Antibiotics, ecologic damage, microbiomics, microbiota, urinary tract infection",Experiment 2,Switzerland,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,Baseline of the Nitrofurantoin treated,Nitrofurantoin treated,UTI patients treated with nitrofurantoin macrocrystals 100mg twice daily,10,10,2 months,16S,34,Roche454,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:538/6/NA,Study 538,prospective cohort,25658522,10.1016/j.cmi.2014.11.016,NA,"Stewardson AJ, Gaïa N, François P, Malhotra-Kumar S, Delémont C, Martinez de Tejada B, Schrenzel J, Harbarth S , Lazarevic V",Collateral damage from oral ciprofloxacin versus nitrofurantoin in outpatients with urinary tract infections: a culture-free analysis of gut microbiota,Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,2015,"Antibiotics, ecologic damage, microbiomics, microbiota, urinary tract infection",Experiment 6,Switzerland,Homo sapiens,Feces,UBERON:0001988,"Antimicrobial agent,Urinary tract infection","EFO:0003103,CHEBI:33281",control group (timepoint 2),Ciprofloxacin treated group (timepoint 2),ciprofloxacin group at end of antibiotic treatment,10,10,2 months,16S,34,Roche454,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:538/7/NA,Study 538,prospective cohort,25658522,10.1016/j.cmi.2014.11.016,NA,"Stewardson AJ, Gaïa N, François P, Malhotra-Kumar S, Delémont C, Martinez de Tejada B, Schrenzel J, Harbarth S , Lazarevic V",Collateral damage from oral ciprofloxacin versus nitrofurantoin in outpatients with urinary tract infections: a culture-free analysis of gut microbiota,Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,2015,"Antibiotics, ecologic damage, microbiomics, microbiota, urinary tract infection",Experiment 7,Switzerland,Homo sapiens,Feces,UBERON:0001988,"Antimicrobial agent,Urinary tract infection","CHEBI:33281,EFO:0003103",controls (timepoint 2),nitrofurantoin treated group (timepoint 2),nitrofurantoin-treated group at end of treatment,10,10,2 months,16S,34,Roche454,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:539/1/NA,Study 539,case-control,32381601,10.1681/ASN.2019101131,https://jasn.asnjournals.org/content/31/6/1358.abstract,"Denburg MR, Koepsell K, Lee JJ, Gerber J, Bittinger K , Tasian GE",Perturbations of the Gut Microbiome and Metabolome in Children with Calcium Oxalate Kidney Stone Disease,Journal of the American Society of Nephrology : JASN,2020,"intestine, kidney stones, metabolism, pediatric nephrology",Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Nephrolithiasis,EFO:0004253,Healthy Controls,Patients with kidney stones,The patients suffering from Kidney Stones (nephrolithiasis) are individuals with incident and recurrent kidney stones consisting of 100% calcium (of which at least 50% was calcium oxalate) that spontaneously passed or were removed surgically within the prior 3 years.,44,44,3 months,WMS,NA,Illumina,T-Test,0.05,TRUE,NA,"age,race,sex",NA,NA,decreased,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:540/1/NA,Study 540,"cross-sectional observational, not case-control",31905907,10.3390/ijerph17010256,https://pubmed.ncbi.nlm.nih.gov/31905907/,"Al-Zyoud W, Hajjo R, Abu-Siniyeh A , Hajjaj S",Salivary Microbiome and Cigarette Smoking: A First of Its Kind Investigation in Jordan,International journal of environmental research and public health,2019,"16S rRNA, Jordan, bioinformatics, microbiome, microbiota, next-generation sequencing, operational taxonomic unit (OTU), saliva, smoking",Experiment 1,Jordan,Homo sapiens,Saliva,UBERON:0001836,Smoking behavior,EFO:0004318,Non-smokers,Smokers,Smoking subjects who smoked at least one cigarette per day.,51,49,3 months,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,3,NA,NA,NA,decreased,decreased,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:540/2/NA,Study 540,"cross-sectional observational, not case-control",31905907,10.3390/ijerph17010256,https://pubmed.ncbi.nlm.nih.gov/31905907/,"Al-Zyoud W, Hajjo R, Abu-Siniyeh A , Hajjaj S",Salivary Microbiome and Cigarette Smoking: A First of Its Kind Investigation in Jordan,International journal of environmental research and public health,2019,"16S rRNA, Jordan, bioinformatics, microbiome, microbiota, next-generation sequencing, operational taxonomic unit (OTU), saliva, smoking",Experiment 2,Jordan,Homo sapiens,Saliva,UBERON:0001836,Smoking behavior,EFO:0004318,Non-smokers,Smokers,Smoker subjects smoked at least one cigarette per day.,51,49,3 months,16S,34,Illumina,LEfSe,0.05,TRUE,3,NA,NA,NA,decreased,decreased,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:541/1/NA,Study 541,case-control,32235826,10.1038/s41467-020-15457-9,https://www.nature.com/articles/s41467-020-15457-9,"Zhu F, Ju Y, Wang W, Wang Q, Guo R, Ma Q, Sun Q, Fan Y, Xie Y, Yang Z, Jie Z, Zhao B, Xiao L, Yang L, Zhang T, Feng J, Guo L, He X, Chen Y, Chen C, Gao C, Xu X, Yang H, Wang J, Dang Y, Madsen L, Brix S, Kristiansen K, Jia H , Ma X",Metagenome-wide association of gut microbiome features for schizophrenia,Nature communications,2020,NA,Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Schizophrenia,MONDO:0005090,Healthy controls,"Schizophrenic patients (ARSCZ, FESCZ)","Only acutely relapsed schizophrenic (ARSCZ) and first-episode schizophrenic (FESCZ) patients were recruited in this study. The current episode of ARSCZ patients was required to happen in the last three months. ARSCZ patients were free of treatment for at least six months. The current episode of FESCZ patients was required to happen in the last year. FESCZ patients did not take any antipsychotics, or their accumulative dosages of antipsychotics intake were much less than the effective dosage (generally less than 100 mg chlorpromazine equivalents in the last two weeks based on the transformation method).",81,90,30 days,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,"alcohol drinking,demographics,diet,smoking status,socioeconomic status",NA,NA,increased,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:541/2/NA,Study 541,case-control,32235826,10.1038/s41467-020-15457-9,https://www.nature.com/articles/s41467-020-15457-9,"Zhu F, Ju Y, Wang W, Wang Q, Guo R, Ma Q, Sun Q, Fan Y, Xie Y, Yang Z, Jie Z, Zhao B, Xiao L, Yang L, Zhang T, Feng J, Guo L, He X, Chen Y, Chen C, Gao C, Xu X, Yang H, Wang J, Dang Y, Madsen L, Brix S, Kristiansen K, Jia H , Ma X",Metagenome-wide association of gut microbiome features for schizophrenia,Nature communications,2020,NA,Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Schizophrenia,MONDO:0005090,Healthy controls at baseline,Schizophrenic patients (38 participant subsample) at baseline,"38 participants with schizophrenia selected for followup. Only acutely relapsed schizophrenic (ARSCZ) and first-episode schizophrenic (FESCZ) patients were recruited in this study. The current episode of ARSCZ patients was required to happen in the last three months. ARSCZ patients were free of treatment for at least six months. The current episode of FESCZ patients was required to happen in the last year. FESCZ patients did not take any antipsychotics, or their accumulative dosages of antipsychotics intake were much less than the effective dosage (generally less than 100 mg chlorpromazine equivalents in the last two weeks based on the transformation method).",81,38,30 days,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,"alcohol drinking,demographics,diet,smoking status,socioeconomic status",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:541/3/NA,Study 541,case-control,32235826,10.1038/s41467-020-15457-9,https://www.nature.com/articles/s41467-020-15457-9,"Zhu F, Ju Y, Wang W, Wang Q, Guo R, Ma Q, Sun Q, Fan Y, Xie Y, Yang Z, Jie Z, Zhao B, Xiao L, Yang L, Zhang T, Feng J, Guo L, He X, Chen Y, Chen C, Gao C, Xu X, Yang H, Wang J, Dang Y, Madsen L, Brix S, Kristiansen K, Jia H , Ma X",Metagenome-wide association of gut microbiome features for schizophrenia,Nature communications,2020,NA,Experiment 3,China,Homo sapiens,Feces,UBERON:0001988,Schizophrenia,MONDO:0005090,Baseline Healthy controls,3 Month Follow-up Schizophrenic patients (38 participant subsample),"38 participants with schizophrenia selected for followup at 3 months. Only acutely relapsed schizophrenic (ARSCZ) and first-episode schizophrenic (FESCZ) patients were recruited in this study. The current episode of ARSCZ patients was required to happen in the last three months. ARSCZ patients were free of treatment for at least six months. The current episode of FESCZ patients was required to happen in the last year. FESCZ patients did not take any antipsychotics, or their accumulative dosages of antipsychotics intake were much less than the effective dosage (generally less than 100 mg chlorpromazine equivalents in the last two weeks based on the transformation method).",81,38,30 days,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,"alcohol drinking,demographics,diet,smoking status,socioeconomic status",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:541/4/NA,Study 541,case-control,32235826,10.1038/s41467-020-15457-9,https://www.nature.com/articles/s41467-020-15457-9,"Zhu F, Ju Y, Wang W, Wang Q, Guo R, Ma Q, Sun Q, Fan Y, Xie Y, Yang Z, Jie Z, Zhao B, Xiao L, Yang L, Zhang T, Feng J, Guo L, He X, Chen Y, Chen C, Gao C, Xu X, Yang H, Wang J, Dang Y, Madsen L, Brix S, Kristiansen K, Jia H , Ma X",Metagenome-wide association of gut microbiome features for schizophrenia,Nature communications,2020,NA,Experiment 4,China,Homo sapiens,Feces,UBERON:0001988,Antipsychotic drug,CHEBI:35476,Baseline Schizophrenic patients (38 participant subsample),3 Month Follow-up Schizophrenic patients (38 participant subsample),Alterations in abundance of mOTUs in the gut of SCZ patients after 3-month antipsychotics treatment,38,38,30 days,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,"alcohol drinking,demographics,diet,smoking status,socioeconomic status",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:542/1/NA,Study 542,case-control,28538949,10.1001/jamadermatol.2017.0904,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5710430/,"Ring HC, Thorsen J, Saunte DM, Lilje B, Bay L, Riis PT, Larsen N, Andersen LO, Nielsen HV, Miller IM, Bjarnsholt T, Fuursted K , Jemec GB",The Follicular Skin Microbiome in Patients With Hidradenitis Suppurativa and Healthy Controls,JAMA dermatology,2017,NA,Experiment 1,Denmark,Homo sapiens,Axilla skin,UBERON:0015474,Hidradenitis suppurativa,EFO:1000710,Healthy controls,Hidradenitis suppurativa patients,Lesional skin of biopsy confirmed hidradenitis suppurativa,24,30,1 month,16S,34,Illumina,Linear Regression,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:542/2/NA,Study 542,case-control,28538949,10.1001/jamadermatol.2017.0904,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5710430/,"Ring HC, Thorsen J, Saunte DM, Lilje B, Bay L, Riis PT, Larsen N, Andersen LO, Nielsen HV, Miller IM, Bjarnsholt T, Fuursted K , Jemec GB",The Follicular Skin Microbiome in Patients With Hidradenitis Suppurativa and Healthy Controls,JAMA dermatology,2017,NA,Experiment 2,Denmark,Homo sapiens,Axilla skin,UBERON:0015474,Hidradenitis suppurativa,EFO:1000710,Non lesional skin of Hidradenitis suppurativa patients,Lesional skin of Hidradenitis suppurativa patients,Lesional skin of biopsy confirmed hidradenitis suppurativa,29,30,1 month,16S,34,Illumina,Linear Regression,0.05,TRUE,NA,NA,NA,NA,decreased,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:543/1/NA,Study 543,case-control,32415070,10.1038/s41467-020-16222-8,NA,"Vujkovic-Cvijin I, Sortino O, Verheij E, Sklar J, Wit FW, Kootstra NA, Sellers B, Brenchley JM, Ananworanich J, Loeff MSV, Belkaid Y, Reiss P , Sereti I",HIV-associated gut dysbiosis is independent of sexual practice and correlates with noncommunicable diseases,Nature communications,2020,NA,Experiment 1,Netherlands,Homo sapiens,Feces,UBERON:0001988,HIV infection,EFO:0000764,HIV-seronegative controls,Persons with HIV (PWH),chronically HIV-infected people with suppressed viremia on antiretroviral therapy (ART),80,80,NA,16S,4,Illumina,NA,0.05,TRUE,NA,"age,birth country,body mass index,sex,sexual preference",NA,NA,decreased,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:544/1/NA,Study 544,case-control,30157754,10.1186/s12866-018-1232-6,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6114884/,"Zhang Y, Yu X, Yu E, Wang N, Cai Q, Shuai Q, Yan F, Jiang L, Wang H, Liu J, Chen Y, Li Z , Jiang Q",Changes in gut microbiota and plasma inflammatory factors across the stages of colorectal tumorigenesis: a case-control study,BMC microbiology,2018,"Colorectal cancer (CRC), Correlation analysis, Gut microbiota, Plasma inflammatory factors",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,healthy controls,CRC patients,patients diagnosed with colorectal cancer,130,130,6 months,16S,34,Illumina,Zero-Inflated Beta Regression,0.05,TRUE,NA,"age,sex","age,alcohol drinking,body mass index,sex,smoking status",NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:545/1/NA,Study 545,laboratory experiment,33804656,10.3390/microorganisms9030647,NA,"Laubitz D, Typpo K, Midura-Kiela M, Brown C, Barberán A, Ghishan FK , Kiela PR",Dynamics of Gut Microbiota Recovery after Antibiotic Exposure in Young and Old Mice (A Pilot Study),Microorganisms,2021,"16S, aging, antibiotics, bacteria, ciprofloxacin, metronidazole",Experiment 1,United States of America,Mus musculus,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,7 week old (young) mice before antibiotic treatment,7 week old (young) mice 10 days after antibiotic treatments,7-week old mice (young mice) administered treated with broad-spectrum antibiotics metronidazole (500 mg/L) and ciprofloxacin (200 mg/L) for 10 days.,5,5,Mice were not previously given antibiotics before the study,16S,4,Illumina,LEfSe,0.05,TRUE,NA,NA,sex,NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:545/2/NA,Study 545,laboratory experiment,33804656,10.3390/microorganisms9030647,NA,"Laubitz D, Typpo K, Midura-Kiela M, Brown C, Barberán A, Ghishan FK , Kiela PR",Dynamics of Gut Microbiota Recovery after Antibiotic Exposure in Young and Old Mice (A Pilot Study),Microorganisms,2021,"16S, aging, antibiotics, bacteria, ciprofloxacin, metronidazole",Experiment 2,United States of America,Mus musculus,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,7 week old (young) mice before antibiotic treatment,7 week old (young) mice 6 months after antibiotic treatments,7-week old mice (young mice) administered treated with broad-spectrum antibiotics metronidazole (500 mg/L) and ciprofloxacin (200 mg/L) for 10 days.,5,5,Mice were not previously given antibiotics before the study,16S,4,Illumina,LEfSe,0.05,TRUE,NA,NA,sex,NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:545/3/NA,Study 545,laboratory experiment,33804656,10.3390/microorganisms9030647,NA,"Laubitz D, Typpo K, Midura-Kiela M, Brown C, Barberán A, Ghishan FK , Kiela PR",Dynamics of Gut Microbiota Recovery after Antibiotic Exposure in Young and Old Mice (A Pilot Study),Microorganisms,2021,"16S, aging, antibiotics, bacteria, ciprofloxacin, metronidazole",Experiment 3,United States of America,Mus musculus,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,40 week old (old) mice before antibiotic treatment,40 week old (old) mice 10 days after antibiotic treatments,40-week old mice (old) administered treated with broad-spectrum antibiotics metronidazole (500 mg/L) and ciprofloxacin (200 mg/L) for 10 days.,5,5,Mice were not previously given antibiotics before the study,16S,4,Illumina,LEfSe,0.05,TRUE,NA,NA,sex,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:545/4/NA,Study 545,laboratory experiment,33804656,10.3390/microorganisms9030647,NA,"Laubitz D, Typpo K, Midura-Kiela M, Brown C, Barberán A, Ghishan FK , Kiela PR",Dynamics of Gut Microbiota Recovery after Antibiotic Exposure in Young and Old Mice (A Pilot Study),Microorganisms,2021,"16S, aging, antibiotics, bacteria, ciprofloxacin, metronidazole",Experiment 4,United States of America,Mus musculus,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,40 week old (old) mice before antibiotic treatment,40 week old (old) mice 6 months after antibiotic treatments,40-week old mice (old) administered treated with broad-spectrum antibiotics metronidazole (500 mg/L) and ciprofloxacin (200 mg/L) for 10 days.,5,5,Mice were not previously given antibiotics before the study,16S,4,Illumina,LEfSe,0.05,TRUE,NA,NA,sex,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:546/1/NA,Study 546,"cross-sectional observational, not case-control",34425246,10.1016/j.micinf.2021.104880,NA,"Gupta A, Karyakarte R, Joshi S, Das R, Jani K, Shouche Y , Sharma A",Nasopharyngeal microbiome reveals the prevalence of opportunistic pathogens in SARS-CoV-2 infected individuals and their association with host types,Microbes and infection,2021,"SARS-CoV-2, asymptomatic, host types, nasopharyngeal microbiome, symptomatic",Experiment 1,India,Homo sapiens,Nasopharynx,UBERON:0001728,COVID-19,MONDO:0100096,Non-infected controls,COVID-19 cases,COVID-19 infected individuals,26,63,NA,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,unchanged,decreased,unchanged,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:547/1/NA,Study 547,case-control,34382150,10.1007/s12275-021-1206-5,NA,"Zhou Y, Zhang J, Zhang D, Ma WL , Wang X",Linking the gut microbiota to persistent symptoms in survivors of COVID-19 after discharge,"Journal of microbiology (Seoul, Korea)",2021,"COVID-19, gut microbiota, recovered healthcare workers, symptoms after discharge",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,COVID-19,MONDO:0100096,Healthy controls,Recovered COVID-19 patients,Health-care workers who recovered from COVID-19 and were discharged from the hospital between May and July 2020,14,15,3 months,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,decreased,decreased,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:548/1/NA,Study 548,prospective cohort,34423593,10.1002/advs.202102785,NA,"Gao M, Wang H, Luo H, Sun Y, Wang L, Ding S, Ren H, Gang J, Rao B, Liu S, Wang X, Gao X, Li M, Zou Y, Liu C, Yuan C, Sun J, Cui G , Ren Z",Characterization of the Human Oropharyngeal Microbiomes in SARS-CoV-2 Infection and Recovery Patients,"Advanced science (Weinheim, Baden-Wurttemberg, Germany)",2021,"COVID-19, SARS-CoV-2, noninvasive biomarkers, oropharyngeal microbiome",Experiment 1,China,Homo sapiens,Oropharynx,UBERON:0001729,COVID-19,MONDO:0100096,Healthy controls,COVID-19 cases,Confirmed COVID-19 cases by RT-PCR,48,94,NA,16S,34,Illumina,LEfSe,0.05,FALSE,2.5,"age,body mass index,sex",NA,NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:549/1/NA,Study 549,case-control,33935458,10.5021/ad.2021.33.2.163,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082000/,"Hur MS, Lee JS, Jang M, Shin HJ , Lee YW",Analysis of the Conjunctival Microbiome in Patients with Atopic Keratoconjunctivitis and Healthy Individuals,Annals of dermatology,2021,"Atopic keratoconjunctivitis, Atopy, Dysbiosis, Microbiota",Experiment 1,South Korea,Homo sapiens,Ocular surface region,UBERON:0010409,Keratoconjunctivitis,MONDO:0004768,Healthy controls,Atopic keratoconjunctivitis (AKC),"Patients diagnosed with Atopic keratoconjunctivitis (AKC) by an ophthalmologist, and with no systemic immune-associated diseases.",10,20,4 weeks for systemic treatment; 2 weeks for topical treatment,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:550/1/NA,Study 550,"cross-sectional observational, not case-control",33251163,10.3389/fcimb.2020.602239,NA,"Frid P, Baraniya D, Halbig J, Rypdal V, Songstad NT, Rosèn A, Berstad JR, Flatø B, Alakwaa F, Gil EG, Cetrelli L, Chen T, Al-Hebshi NN, Nordal E , Al-Haroni M",Salivary Oral Microbiome of Children With Juvenile Idiopathic Arthritis: A Norwegian Cross-Sectional Study,Frontiers in cellular and infection microbiology,2020,"16S rRNA, juvenile idiopathic arthritis, next generation sequencing (NGS), oral health, salivary microbiome",Experiment 1,Norway,Homo sapiens,Saliva,UBERON:0001836,Juvenile idiopathic arthritis,EFO:0002609,healthy controls,JIA patients,children with juvenile idiopathic arthritis,34,59,Patients on antibiotics prior to sampling were excluded.,16S,123,Illumina,LEfSe,0.1,TRUE,2.5,"age,sex",NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:550/2/NA,Study 550,"cross-sectional observational, not case-control",33251163,10.3389/fcimb.2020.602239,NA,"Frid P, Baraniya D, Halbig J, Rypdal V, Songstad NT, Rosèn A, Berstad JR, Flatø B, Alakwaa F, Gil EG, Cetrelli L, Chen T, Al-Hebshi NN, Nordal E , Al-Haroni M",Salivary Oral Microbiome of Children With Juvenile Idiopathic Arthritis: A Norwegian Cross-Sectional Study,Frontiers in cellular and infection microbiology,2020,"16S rRNA, juvenile idiopathic arthritis, next generation sequencing (NGS), oral health, salivary microbiome",Experiment 2,Norway,Homo sapiens,Saliva,UBERON:0001836,Temporomandibular joint disorder,EFO:0005279,JIA patients without TMJ,JIA patients with TMJ,children with juvenile idiopathic arthritis,15,44,"Patients on antibiotics on the day of sampling were excluded, but previous antibiotic use were not recorded.",16S,123,Illumina,LEfSe,0.1,TRUE,2.5,"age,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:551/1/NA,Study 551,laboratory experiment,29276170,https://doi.org/10.1016/j.chom.2017.11.003,https://pubmed.ncbi.nlm.nih.gov/29276170/,"Zou J, Chassaing B, Singh V, Pellizzon M, Ricci M, Fythe MD, Kumar MV , Gewirtz AT",Fiber-Mediated Nourishment of Gut Microbiota Protects against Diet-Induced Obesity by Restoring IL-22-Mediated Colonic Health,Cell host & microbe,2018,"germ-free mice, intestinal inflammation, metabolic syndrome, microbiota encroachment, short-chain fatty acids",Experiment 1,United States of America,Mus musculus,Feces,UBERON:0001988,High fat diet,EFO:0002757,High fat diet (HFD: 50 cell),High fat diet (HFD:200 Inul ),"High fat diet - [HFD] enriched with inulin increased gut epithelial proliferation, prevented colon atrophy",6,6,None,16S,4,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:551/2/NA,Study 551,laboratory experiment,29276170,https://doi.org/10.1016/j.chom.2017.11.003,https://pubmed.ncbi.nlm.nih.gov/29276170/,"Zou J, Chassaing B, Singh V, Pellizzon M, Ricci M, Fythe MD, Kumar MV , Gewirtz AT",Fiber-Mediated Nourishment of Gut Microbiota Protects against Diet-Induced Obesity by Restoring IL-22-Mediated Colonic Health,Cell host & microbe,2018,"germ-free mice, intestinal inflammation, metabolic syndrome, microbiota encroachment, short-chain fatty acids",Experiment 2,United States of America,Mus musculus,Feces,UBERON:0001988,High fat diet,EFO:0002757,Chow,High fat diet (HFD:200 Inul ),"High-fat diet - (HFD) enriched with inulin increased guy epithelial proliferation, prevented colon atrophy",6,6,None,16S,4,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:552/1/NA,Study 552,prospective cohort,32488167,10.1038/s41396-020-0686-3,https://pubmed.ncbi.nlm.nih.gov/32488167/,"Rasmussen MA, Thorsen J, Dominguez-Bello MG, Blaser MJ, Mortensen MS, Brejnrod AD, Shah SA, Hjelmsø MH, Lehtimäki J, Trivedi U, Bisgaard H, Sørensen SJ , Stokholm J",Ecological succession in the vaginal microbiota during pregnancy and birth,The ISME journal,2020,NA,Experiment 1,United States of America,Homo sapiens,Vagina,UBERON:0000996,Gestational age,EFO:0005112,Week 24,Week 36,gestational age of 36 weeks,56,57,NA,16S,4,Illumina,Kruskall-Wallis,0.05,TRUE,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:552/2/NA,Study 552,prospective cohort,32488167,10.1038/s41396-020-0686-3,https://pubmed.ncbi.nlm.nih.gov/32488167/,"Rasmussen MA, Thorsen J, Dominguez-Bello MG, Blaser MJ, Mortensen MS, Brejnrod AD, Shah SA, Hjelmsø MH, Lehtimäki J, Trivedi U, Bisgaard H, Sørensen SJ , Stokholm J",Ecological succession in the vaginal microbiota during pregnancy and birth,The ISME journal,2020,NA,Experiment 2,United States of America,Homo sapiens,Vagina,UBERON:0000996,Gestational age,EFO:0005112,36,Birth,birth timepoint,57,57,NA,16S,4,Illumina,Kruskall-Wallis,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:553/1/NA,Study 553,case-control,31573753,10.1111/1471-0528.15972,NA,"Al-Memar M, Bobdiwala S, Fourie H, Mannino R, Lee YS, Smith A, Marchesi JR, Timmerman D, Bourne T, Bennett PR , MacIntyre DA",The association between vaginal bacterial composition and miscarriage: a nested case-control study,BJOG : an international journal of obstetrics and gynaecology,2020,"First trimester miscarriage, second trimester miscarriage, vaginal bacteria, vaginal microbiome",Experiment 1,United Kingdom,Homo sapiens,Posterior fornix of vagina,UBERON:0016486,Spontaneous abortion,EFO:1001255,Viable control pregnancy,First or second-trimester miscarriage,NA,81,77,NA,16S,12,Illumina,Chi-Square,0.05,NA,NA,"age,body mass index,gestational age",NA,NA,NA,NA,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:553/2/NA,Study 553,case-control,31573753,10.1111/1471-0528.15972,NA,"Al-Memar M, Bobdiwala S, Fourie H, Mannino R, Lee YS, Smith A, Marchesi JR, Timmerman D, Bourne T, Bennett PR , MacIntyre DA",The association between vaginal bacterial composition and miscarriage: a nested case-control study,BJOG : an international journal of obstetrics and gynaecology,2020,"First trimester miscarriage, second trimester miscarriage, vaginal bacteria, vaginal microbiome",Experiment 2,United Kingdom,Homo sapiens,Posterior fornix of vagina,UBERON:0016486,Spontaneous abortion,EFO:1001255,Viable control pregnancy,First trimester miscarriage,NA,81,64,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:553/3/NA,Study 553,case-control,31573753,10.1111/1471-0528.15972,NA,"Al-Memar M, Bobdiwala S, Fourie H, Mannino R, Lee YS, Smith A, Marchesi JR, Timmerman D, Bourne T, Bennett PR , MacIntyre DA",The association between vaginal bacterial composition and miscarriage: a nested case-control study,BJOG : an international journal of obstetrics and gynaecology,2020,"First trimester miscarriage, second trimester miscarriage, vaginal bacteria, vaginal microbiome",Experiment 3,United Kingdom,Homo sapiens,Posterior fornix of vagina,UBERON:0016486,Spontaneous abortion,EFO:1001255,missed miscarriage,complete/incomplete miscarriage,"A missed miscarriage is when a baby has died in the womb, but the mother hasn't had any symptoms, such as bleeding or pain.
A complete miscarriage has taken place when all the pregnancy tissue has left your uterus.",61,13,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:554/1/NA,Study 554,case-control,31354427,10.3389/fnmol.2019.00171,https://www.frontiersin.org/articles/10.3389/fnmol.2019.00171/full,"Li C, Cui L, Yang Y, Miao J, Zhao X, Zhang J, Cui G , Zhang Y",Gut Microbiota Differs Between Parkinson's Disease Patients and Healthy Controls in Northeast China,Frontiers in molecular neuroscience,2019,"Akkermansia, Lactobacillus, Parkinson’s disease, dysbiosis, gut microbiota",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Healthy Controls(HC),patients with parkinson's disease,The patients who have been diagnosed with Parkinson's Disease(PD). Parkinson’s disease (PD) is a common neurodegenerative disorder characterized by motor and non-motor symptoms.,48,51,3 months,16S,4,Illumina,LEfSe,0.05,TRUE,4,"age,body mass index",NA,NA,increased,decreased,increased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:554/2/NA,Study 554,case-control,31354427,10.3389/fnmol.2019.00171,https://www.frontiersin.org/articles/10.3389/fnmol.2019.00171/full,"Li C, Cui L, Yang Y, Miao J, Zhao X, Zhang J, Cui G , Zhang Y",Gut Microbiota Differs Between Parkinson's Disease Patients and Healthy Controls in Northeast China,Frontiers in molecular neuroscience,2019,"Akkermansia, Lactobacillus, Parkinson’s disease, dysbiosis, gut microbiota",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Healthy Controls,Parkinson's Disease subjects,"Patients who had been diagnosed with PD according to the diagnostic criteria proposed by the International Parkinson Disease and Movement Disorder Society in 2015 (Postuma et al., 2015) in the First Hospital of Jilin University.",48,51,"Subjects with a history of using medications that have been shown to affect gut microbiota, including COMT inhibitors, anticholinergics, anti-secretory drugs, or cardiological drugs within the 3 months before the start of the study were excluded.",16S,4,Illumina,T-Test,0.05,NA,NA,"age,body mass index",NA,NA,increased,decreased,increased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:555/1/NA,Study 555,case-control,33681234,10.3389/fmed.2020.00538,NA,"Liu Z, Wu Y, Luo Y, Wei S, Lu C, Zhou Y, Wang J, Miao T, Lin H, Zhao Y, Liu Q , Liu Y",Self-Balance of Intestinal Flora in Spouses of Patients With Rheumatoid Arthritis,Frontiers in medicine,2020,"16S rRNA sequencing, environment/gene interaction, gut microbiota, rheumatoid arthritis, spouses",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Rheumatoid arthritis,EFO:0000685,Healthy controls,Rheumatoid arthritis patient,Rheumatoid arthritis patient,20,30,6 Months,16S,34,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:556/1/NA,Study 556,case-control,32694705,10.1038/s41598-020-68952-w,NA,"Willis KA, Postnikoff CK, Freeman A, Rezonzew G, Nichols K, Gaggar A , Lal CV",The closed eye harbours a unique microbiome in dry eye disease,Scientific reports,2020,NA,Experiment 1,United States of America,Homo sapiens,Tear film,UBERON:0022287,Dry eye syndrome,EFO:1000906,Normal Control (NC),Dry Eye,Participants with moderate or severe dry eye disease,36,36,Within 1 month was exclusionary,16S,4,Illumina,LEfSe,0.05,TRUE,NA,NA,NA,unchanged,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:557/1/NA,Study 557,randomized controlled trial,NA,https://doi.org/10.1186/s12866-021-02245-8,https://bmcmicrobiol.biomedcentral.com/articles/10.1186/s12866-021-02245-8#Abs1,"Nuzzo A, Van Horn S, Traini C, Perry CR, Dumont EF, Scangarella-Oman NE, Gardiner DF, Brown JR, Brown JR",Microbiome recovery in adult females with uncomplicated urinary tract infections in a randomised phase 2A trial of the novel antibiotic gepotidacin (GSK2140944),BMC microbiology,2021,"Gepotidacin, microbiome, microbiome, antibiotic, clinical trial, urinary tract infection",Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Urinary tract infection,EFO:0003103,Day 1 (pre-dose),Day 5 (end of dosing or post-dose),This represented the condition at the end of the 5-day regimen of gepotidacin treatment in the GIT microbiome,22,22,NA,16S,4,Illumina,DESeq2,0.01,TRUE,NA,NA,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:557/2/NA,Study 557,randomized controlled trial,NA,https://doi.org/10.1186/s12866-021-02245-8,https://bmcmicrobiol.biomedcentral.com/articles/10.1186/s12866-021-02245-8#Abs1,"Nuzzo A, Van Horn S, Traini C, Perry CR, Dumont EF, Scangarella-Oman NE, Gardiner DF, Brown JR, Brown JR",Microbiome recovery in adult females with uncomplicated urinary tract infections in a randomised phase 2A trial of the novel antibiotic gepotidacin (GSK2140944),BMC microbiology,2021,"Gepotidacin, microbiome, microbiome, antibiotic, clinical trial, urinary tract infection",Experiment 2,United States of America,Homo sapiens,Feces,UBERON:0001988,Urinary tract infection,EFO:0003103,Day 1 (pre-dose),Follow-up (visit around Day 28 ± 3 days).,"This represented the condition approximately one month post-treatment, after the cessation of gepotidacin in the GIT microbiome",22,22,NA,16S,4,Illumina,DESeq2,0.01,TRUE,NA,NA,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:557/3/NA,Study 557,randomized controlled trial,NA,https://doi.org/10.1186/s12866-021-02245-8,https://bmcmicrobiol.biomedcentral.com/articles/10.1186/s12866-021-02245-8#Abs1,"Nuzzo A, Van Horn S, Traini C, Perry CR, Dumont EF, Scangarella-Oman NE, Gardiner DF, Brown JR, Brown JR",Microbiome recovery in adult females with uncomplicated urinary tract infections in a randomised phase 2A trial of the novel antibiotic gepotidacin (GSK2140944),BMC microbiology,2021,"Gepotidacin, microbiome, microbiome, antibiotic, clinical trial, urinary tract infection",Experiment 3,United States of America,Homo sapiens,Saliva,UBERON:0001836,Urinary tract infection,EFO:0003103,Day 1 (pre-dose),Day 5 (end of dosing or post-dose),This represented the condition at the end of the 5-day regimen of gepotidacin treatment in the pharyngeal cavity microbiome.,22,22,NA,16S,4,Illumina,DESeq2,0.01,TRUE,NA,NA,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:557/4/NA,Study 557,randomized controlled trial,NA,https://doi.org/10.1186/s12866-021-02245-8,https://bmcmicrobiol.biomedcentral.com/articles/10.1186/s12866-021-02245-8#Abs1,"Nuzzo A, Van Horn S, Traini C, Perry CR, Dumont EF, Scangarella-Oman NE, Gardiner DF, Brown JR, Brown JR",Microbiome recovery in adult females with uncomplicated urinary tract infections in a randomised phase 2A trial of the novel antibiotic gepotidacin (GSK2140944),BMC microbiology,2021,"Gepotidacin, microbiome, microbiome, antibiotic, clinical trial, urinary tract infection",Experiment 4,United States of America,Homo sapiens,Saliva,UBERON:0001836,Urinary tract infection,EFO:0003103,Day 1 (pre-dose),Follow-up (visit around Day 28 ± 3 days).,"This represented the condition approximately one month post-treatment, after the cessation of gepotidacin in the pharyngeal cavity microbiome.",22,22,NA,16S,4,Illumina,DESeq2,0.01,TRUE,NA,NA,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:557/5/NA,Study 557,randomized controlled trial,NA,https://doi.org/10.1186/s12866-021-02245-8,https://bmcmicrobiol.biomedcentral.com/articles/10.1186/s12866-021-02245-8#Abs1,"Nuzzo A, Van Horn S, Traini C, Perry CR, Dumont EF, Scangarella-Oman NE, Gardiner DF, Brown JR, Brown JR",Microbiome recovery in adult females with uncomplicated urinary tract infections in a randomised phase 2A trial of the novel antibiotic gepotidacin (GSK2140944),BMC microbiology,2021,"Gepotidacin, microbiome, microbiome, antibiotic, clinical trial, urinary tract infection",Experiment 5,United States of America,Homo sapiens,Vagina,UBERON:0000996,Urinary tract infection,EFO:0003103,Day 1 (pre-dose),Day 5 (end of dosing or post-dose),This represented the condition at the end of the 5-day regimen of gepotidacin treatment in vaginal microbiome.,22,22,NA,16S,4,Illumina,DESeq2,0.01,TRUE,NA,NA,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:557/6/NA,Study 557,randomized controlled trial,NA,https://doi.org/10.1186/s12866-021-02245-8,https://bmcmicrobiol.biomedcentral.com/articles/10.1186/s12866-021-02245-8#Abs1,"Nuzzo A, Van Horn S, Traini C, Perry CR, Dumont EF, Scangarella-Oman NE, Gardiner DF, Brown JR, Brown JR",Microbiome recovery in adult females with uncomplicated urinary tract infections in a randomised phase 2A trial of the novel antibiotic gepotidacin (GSK2140944),BMC microbiology,2021,"Gepotidacin, microbiome, microbiome, antibiotic, clinical trial, urinary tract infection",Experiment 6,United States of America,Homo sapiens,Vagina,UBERON:0000996,Urinary tract infection,EFO:0003103,Day 1 (pre-dose),Follow-up (visit around Day 28 ± 3 days).,"this represented the condition approximately one month post-treatment, after the cessation of gepotidacin in vaginal microbiome",22,22,NA,16S,4,Illumina,DESeq2,0.01,TRUE,NA,NA,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:558/1/NA,Study 558,randomized controlled trial,25487798,10.1128/AAC.04506-14,NA,"Arat S, Spivak A, Van Horn S, Thomas E, Traini C, Sathe G, Livi GP, Ingraham K, Jones L, Aubart K, Holmes DJ, Naderer O , Brown JR","Microbiome changes in healthy volunteers treated with GSK1322322, a novel antibiotic targeting bacterial peptide deformylase",Antimicrobial agents and chemotherapy,2015,NA,Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,received oral-i.v.-administered GSK1322322 (prestudy),received oral-i.v.-administered GSK1322322 (end-of-study),received oral-i.v.-administered GSK1322322,38,38,NA,16S,4,Illumina,ANOVA,0.05,TRUE,NA,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:558/2/NA,Study 558,randomized controlled trial,25487798,10.1128/AAC.04506-14,NA,"Arat S, Spivak A, Van Horn S, Thomas E, Traini C, Sathe G, Livi GP, Ingraham K, Jones L, Aubart K, Holmes DJ, Naderer O , Brown JR","Microbiome changes in healthy volunteers treated with GSK1322322, a novel antibiotic targeting bacterial peptide deformylase",Antimicrobial agents and chemotherapy,2015,NA,Experiment 2,United States of America,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,received oral-i.v.-administered GSK1322322 (prestudy),received oral-i.v.-administered GSK1322322 (end-of-study),received oral-i.v.-administered GSK1322322,38,38,NA,16S,4,Illumina,NA,0.05,NA,NA,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:559/1/NA,Study 559,randomized controlled trial,33440171,10.1016/j.chom.2020.12.012,NA,"Tanes C, Bittinger K, Gao Y, Friedman ES, Nessel L, Paladhi UR, Chau L, Panfen E, Fischbach MA, Braun J, Xavier RJ, Clish CB, Li H, Bushman FD, Lewis JD , Wu GD",Role of dietary fiber in the recovery of the human gut microbiome and its metabolome,Cell host & microbe,2021,"dietary fiber, vegan, omnivore, amino acid, enteral nutrition, metabolome, microbiome",Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,regular fiber omnivore diet,no fiber liquid omnivore diet,omnivores randomized to an enteral liquid nutrition diet devoid of any fiber (but similar in profile to regular food omnivore group),10,10,6 months,16S,NA,Illumina,Linear Regression,0.05,TRUE,NA,NA,"age,body mass index",NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:560/1/NA,Study 560,case-control,28449715,10.1186/s13073-017-0428-y,NA,"Bedarf JR, Hildebrand F, Coelho LP, Sunagawa S, Bahram M, Goeser F, Bork P , Wüllner U",Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naïve Parkinson's disease patients,Genome medicine,2017,"Archaea, Bacteria, Enteric nervous system, Gut-brain axis, Microbiome, Parkinson, Viruses",Experiment 1,Germany,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Healthy men without Parkinsons's Disease.,Men with Parkinson's Disease.,Only early stage PD men who were naïve to L-DOPA therapy as diagnosed according to the UK Brain Bank criteria.,28,31,"The use of antibiotics in the past three months in principle was an exclusion criterion. However, we included three PD patients and three controls despite the intake of antibiotics for one to three days in a period of 28–34 days prior to feces sampling as the omission of those cases from the analyses did not change any result",16S,NA,Illumina,Kruskall-Wallis,0.1,TRUE,NA,"age,sex",NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:561/1/NA,Study 561,case-control,31247001,10.1371/journal.pone.0218252,NA,"Mihaila D, Donegan J, Barns S, LaRocca D, Du Q, Zheng D, Vidal M, Neville C, Uhlig R , Middleton FA",The oral microbiome of early stage Parkinson's disease and its relationship with functional measures of motor and non-motor function,PloS one,2019,NA,Experiment 1,United States of America,Homo sapiens,Saliva,UBERON:0001836,Parkinson's disease,MONDO:0005180,Healthy age-sex matched controls without Parkinson's disease.,Participants with early stage Parkinson's Disease.,Subjects included in the Parkinson’s disease (PD) group had been previously diagnosed by a neurologist and met the general diagnostic criteria for early PD.,36,48,None of the participants underwent antibiotic use in the past month prior to sample collection.,16S,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,NA,NA,"age,sex",NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:562/1/NA,Study 562,meta-analysis,NA,10.5281/zenodo.7544549,https://doi.org/10.5281/zenodo.7544549,NA,Body site-typical microbiome signatures for adults,NA,NA,NA,Experiment 1,"United States of America,Italy,Luxembourg",Homo sapiens,Vagina,UBERON:0000996,Health study participation,EFO:0010130,NA,healthy adult vagina 50% up,NA,NA,96,No,WMS,NA,Illumina,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:562/2/NA,Study 562,meta-analysis,NA,10.5281/zenodo.7544549,https://doi.org/10.5281/zenodo.7544549,NA,Body site-typical microbiome signatures for adults,NA,NA,NA,Experiment 2,"China,India,Italy,Malaysia,Singapore,United States of America",Homo sapiens,Skin of body,UBERON:0002097,Health study participation,EFO:0010130,none,healthy adult skin 50% up,NA,NA,362,All records NA,WMS,NA,Illumina,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:562/3/NA,Study 562,meta-analysis,NA,10.5281/zenodo.7544549,https://doi.org/10.5281/zenodo.7544549,NA,Body site-typical microbiome signatures for adults,NA,NA,NA,Experiment 3,"China,Denmark,Israel,Netherlands,United Kingdom,United States of America,Australia,Canada,Finland,France,Germany,India,Spain,Ireland,Italy,Japan,Luxembourg,South Korea,Switzerland,United Republic of Tanzania",Homo sapiens,Feces,UBERON:0001988,Health study participation,EFO:0010130,none - 50% prevalence threshold,feces from healthy adult,non-disease adult participants from curatedMetagenomicData,0,9623,"no (n=5572), yes (n=276)",WMS,NA,Illumina,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:562/4/NA,Study 562,meta-analysis,NA,10.5281/zenodo.7544549,https://doi.org/10.5281/zenodo.7544549,NA,Body site-typical microbiome signatures for adults,NA,NA,NA,Experiment 4,United States of America,Homo sapiens,Nasal cavity,UBERON:0001707,Health study participation,EFO:0010130,none - 50% prevalence threshold,nasal cavity from healthy adult,non-disease adult participants from curatedMetagenomicData,0,92,Unknown,WMS,NA,Illumina,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:562/5/NA,Study 562,meta-analysis,NA,10.5281/zenodo.7544549,https://doi.org/10.5281/zenodo.7544549,NA,Body site-typical microbiome signatures for adults,NA,NA,NA,Experiment 5,"Italy,Philippines,United States of America",Homo sapiens,Nasal cavity,UBERON:0001707,Health study participation,EFO:0010130,none - 50% prevalence threshold,oral cavity from healthy adult,non-disease adult participants from curatedMetagenomicData,0,659,No (n=16),WMS,NA,Illumina,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:562/6/NA,Study 562,meta-analysis,NA,10.5281/zenodo.7544549,https://doi.org/10.5281/zenodo.7544549,NA,Body site-typical microbiome signatures for adults,NA,NA,NA,Experiment 6,Italy,Homo sapiens,Milk,UBERON:0001913,Health study participation,EFO:0010130,none - 50% prevalence threshold,milk from healthy adult,non-disease adult participants from curatedMetagenomicData,0,8,Unknown,WMS,NA,Illumina,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:562/7/NA,Study 562,meta-analysis,NA,10.5281/zenodo.7544549,https://doi.org/10.5281/zenodo.7544549,NA,Body site-typical microbiome signatures for adults,NA,NA,NA,Experiment 7,"Italy,Luxembourg,United States of America",Homo sapiens,Vagina,UBERON:0000996,Health study participation,EFO:0010130,NA,healthy adult vagina 70% up,NA,NA,96,No,WMS,NA,Illumina,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:562/8/NA,Study 562,meta-analysis,NA,10.5281/zenodo.7544549,https://doi.org/10.5281/zenodo.7544549,NA,Body site-typical microbiome signatures for adults,NA,NA,NA,Experiment 8,"China,India,Italy,Malaysia,Singapore,United States of America",Homo sapiens,Skin of body,UBERON:0002097,Health study participation,EFO:0010130,none,healthy adult skin 70% up,NA,NA,362,All records NA,WMS,NA,Illumina,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:562/9/NA,Study 562,meta-analysis,NA,10.5281/zenodo.7544549,https://doi.org/10.5281/zenodo.7544549,NA,Body site-typical microbiome signatures for adults,NA,NA,NA,Experiment 9,"Australia,Canada,China,Denmark,Finland,France,Germany,India,Ireland,Israel,Italy,Japan,Luxembourg,Netherlands,South Korea,Spain,Switzerland,United Kingdom,United Republic of Tanzania,United States of America",Homo sapiens,Feces,UBERON:0001988,Health study participation,EFO:0010130,none - 70% prevalence threshold,feces from healthy adult,non-disease adult participants from curatedMetagenomicData,0,9623,"no (n=5572), yes (n=276)",WMS,NA,Illumina,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:562/10/NA,Study 562,meta-analysis,NA,10.5281/zenodo.7544549,https://doi.org/10.5281/zenodo.7544549,NA,Body site-typical microbiome signatures for adults,NA,NA,NA,Experiment 10,"Australia,Canada,China,Denmark,Finland,France,Germany,India,Ireland,Israel,Italy,Japan,Luxembourg,Netherlands,South Korea,Spain,Switzerland,United Kingdom,United Republic of Tanzania,United States of America",Homo sapiens,Feces,UBERON:0001988,Health study participation,EFO:0010130,none - 0% prevalence threshold,feces from healthy adult,non-disease adult participants from curatedMetagenomicData,0,9623,"no (n=5572), yes (n=276)",WMS,NA,Illumina,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:562/11/NA,Study 562,meta-analysis,NA,10.5281/zenodo.7544549,https://doi.org/10.5281/zenodo.7544549,NA,Body site-typical microbiome signatures for adults,NA,NA,NA,Experiment 11,"Australia,Canada,China,Denmark,Finland,France,Germany,India,Ireland,Israel,Italy,Japan,Luxembourg,Netherlands,South Korea,Spain,Switzerland,United Kingdom,United Republic of Tanzania,United States of America",Homo sapiens,Feces,UBERON:0001988,Health study participation,EFO:0010130,none - 30% prevalence threshold,feces from healthy adult,non-disease adult participants from curatedMetagenomicData,0,9623,"no (n=5572), yes (n=276)",WMS,NA,Illumina,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:563/1/NA,Study 563,case-control,25484919,10.1186/s13073-014-0099-x,https://genomemedicine.biomedcentral.com/articles/10.1186/s13073-014-0099-x,"Zhou Y, Holland MJ, Makalo P, Joof H, Roberts CH, Mabey DC, Bailey RL, Burton MJ, Weinstock GM , Burr SE",The conjunctival microbiome in health and trachomatous disease: a case control study,Genome medicine,2014,NA,Experiment 1,Gambia,Homo sapiens,Conjunctiva,UBERON:0001811,Chlamydia trachomatis,NCBITAXON:813,Controls aged < = 0 years,Controls aged > 10 years,Control individuals with normal conjunctiva (F0P0C0 - 1981 WHO trachoma grading system) and age > 10 years old.,50,170,not mentioned,16S,123,Roche454,Metastats,0.05,TRUE,NA,"age,ethnic group,geographic area,sex",NA,NA,decreased,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:563/2/NA,Study 563,case-control,25484919,10.1186/s13073-014-0099-x,https://genomemedicine.biomedcentral.com/articles/10.1186/s13073-014-0099-x,"Zhou Y, Holland MJ, Makalo P, Joof H, Roberts CH, Mabey DC, Bailey RL, Burton MJ, Weinstock GM , Burr SE",The conjunctival microbiome in health and trachomatous disease: a case control study,Genome medicine,2014,NA,Experiment 2,Gambia,Homo sapiens,Conjunctiva,UBERON:0001811,Chlamydia trachomatis,NCBITAXON:813,Controls aged > 10 years with samples collected in the dry season,Controls aged > 10 years with samples collected in the wet season,"Control individuals with normal conjunctiva (F0P0C0 - 1981 WHO trachoma grading system) and age > 10 years old with samples collected during the dry season. Of note, all samples from participants <= 10 years old were collected during the wet season, therefore, were not included in the analysis of the seasonal effect on the conjunctival microbiome.",126,94,not mentioned,16S,123,Roche454,Metastats,0.05,TRUE,NA,"age,ethnic group,geographic area,sex",NA,NA,increased,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:563/3/NA,Study 563,case-control,25484919,10.1186/s13073-014-0099-x,https://genomemedicine.biomedcentral.com/articles/10.1186/s13073-014-0099-x,"Zhou Y, Holland MJ, Makalo P, Joof H, Roberts CH, Mabey DC, Bailey RL, Burton MJ, Weinstock GM , Burr SE",The conjunctival microbiome in health and trachomatous disease: a case control study,Genome medicine,2014,NA,Experiment 3,Gambia,Homo sapiens,Conjunctiva,UBERON:0001811,Chlamydia trachomatis,NCBITAXON:813,"Cases with conjunctival scarring (C > 0) alone, with samples collected in the dry season","Cases with conjunctival scarring (C = 0) alone, with samples collected in the dry season",Participants aged = 10 years with clinical signs of conjunctival scarring (Cicatricae = 0)  sampled in the dry season. Bacterial community structure was different between the two groups during the dry season but not during the wet season.,63,63,not mentioned,16S,123,Roche454,Metastats,0.05,TRUE,NA,"age,ethnic group,geographic area,sex",NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:563/4/NA,Study 563,case-control,25484919,10.1186/s13073-014-0099-x,https://genomemedicine.biomedcentral.com/articles/10.1186/s13073-014-0099-x,"Zhou Y, Holland MJ, Makalo P, Joof H, Roberts CH, Mabey DC, Bailey RL, Burton MJ, Weinstock GM , Burr SE",The conjunctival microbiome in health and trachomatous disease: a case control study,Genome medicine,2014,NA,Experiment 4,Gambia,Homo sapiens,Conjunctiva,UBERON:0001811,Chlamydia trachomatis,NCBITAXON:813,Cases aged > 10 years with clinical signs of conjunctival scarring sampled during the dry season,Cases aged = 10 years with clinical signs of conjunctival scarring sampled during the dry season,Participants aged 10 years with clinical signs of conjunctival scarring in dry season,63,63,Not mentioned,16S,123,Roche454,Metastats,0.05,TRUE,NA,"age,ethnic group,geographic area,sex",NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:563/6/NA,Study 563,case-control,25484919,10.1186/s13073-014-0099-x,https://genomemedicine.biomedcentral.com/articles/10.1186/s13073-014-0099-x,"Zhou Y, Holland MJ, Makalo P, Joof H, Roberts CH, Mabey DC, Bailey RL, Burton MJ, Weinstock GM , Burr SE",The conjunctival microbiome in health and trachomatous disease: a case control study,Genome medicine,2014,NA,Experiment 6,Gambia,Homo sapiens,Conjunctiva,UBERON:0001811,Chlamydia trachomatis,NCBITAXON:813,"Cases with conjunctival scarring (C>0) alone, with samples collected in the dry season","Cases with conjunctival scarring (C>0) and trachomatous trichiasis (TT),with samples collected in the dry season",Participants aged >10 years with clinical signs of conjunctival scarring (Cicatricae > 0) and with  trachomatous trichiasis (TT)) sampled in the dry season. Bacterial community structure was different between the two groups during the dry season but not during the wet season.,63,63,Not mentioned,16S,123,Roche454,Metastats,0.05,TRUE,NA,"age,ethnic group,geographic area,sex",NA,NA,decreased,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:564/1/NA,Study 564,case-control,26237371,10.1097/MPG.0000000000000928,https://journals.lww.com/jpgn/Fulltext/2016/02000/Influence_of_Intrapartum_Antibiotic_Prophylaxis.20.aspx,"Corvaglia L, Tonti G, Martini S, Aceti A, Mazzola G, Aloisio I, Di Gioia D , Faldella G",Influence of Intrapartum Antibiotic Prophylaxis for Group B Streptococcus on Gut Microbiota in the First Month of Life,Journal of pediatric gastroenterology and nutrition,2016,NA,Experiment 1,Italy,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,Control group (@7 days),IAP group (@7 days),"infants born to GBS-positive mothers who had received IAP. According to the institutional treatment protocol for GBS prophylaxis (derived from the Centers for Disease Control and Prevention guidelines (13)), intravenous ampicillin was given every 4 hours until delivery (first dose 2 g, following doses 1 g each).",49,35,"The mother had received any antibiotic other than IAP in the 4 weeks before delivery, maternal IAP was performed with antibiotics other than ampicillin, such as erythromycin.",PCR,NA,NA,Mann-Whitney (Wilcoxon),0.05,NA,NA,"delivery procedure,feeding practices,gestational age",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:565/1/NA,Study 565,case-control,32674496,10.3390/vetsci7030092,NA,"Cintio M, Scarsella E, Sgorlon S, Sandri M , Stefanon B",Gut Microbiome of Healthy and Arthritic Dogs,Veterinary sciences,2020,"arthritis, dogs, gut microbiome, hematological parameters",Experiment 1,Italy,Canis lupus familiaris,Feces,UBERON:0001988,Arthritis,EFO:0005856,healthy dogs,dogs with hip or elbow arthritis,"dogs with evidence of hip/elbow arthritis as follows: clinical anamnesis for limping forelimbs and/or associated with posterior limping; rapid fatigue after effort; decrease in motor activity; radiographic evidence of osteoarthritis (AD) in one or two joints (elbow, hips)",13,14,1 month,16S,NA,Illumina,LEfSe,0.05,TRUE,2,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:566/1/NA,Study 566,case-control,27833598,https://doi.org/10.3389/fmicb.2016.01703,NA,"Di Paola M, Cavalieri D, Albanese D, Sordo M, Pindo M, Donati C, Pagnini I, Giani T, Simonini G, Paladini A, Lionetti P, De Filippo C , Cimaz R",Alteration of Fecal Microbiota Profiles in Juvenile Idiopathic Arthritis. Associations with HLA-B27 Allele and Disease Status,Frontiers in microbiology,2016,"HLA-B27 allele, enthesitis-related arthritis, gut microbiota, juvenile idiopathic arthritis, metagenomics",Experiment 1,Italy,Homo sapiens,Feces,UBERON:0001988,Juvenile idiopathic arthritis,EFO:0002609,HLAB27-,HLAB27+,enthesitis-related arthritis (JIA-ERA) patients with HLA-B27 allele,10,9,3 months,16S,56,Roche454,LEfSe,0.05,TRUE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:566/2/NA,Study 566,case-control,27833598,https://doi.org/10.3389/fmicb.2016.01703,NA,"Di Paola M, Cavalieri D, Albanese D, Sordo M, Pindo M, Donati C, Pagnini I, Giani T, Simonini G, Paladini A, Lionetti P, De Filippo C , Cimaz R",Alteration of Fecal Microbiota Profiles in Juvenile Idiopathic Arthritis. Associations with HLA-B27 Allele and Disease Status,Frontiers in microbiology,2016,"HLA-B27 allele, enthesitis-related arthritis, gut microbiota, juvenile idiopathic arthritis, metagenomics",Experiment 2,Italy,Homo sapiens,Feces,UBERON:0001988,Juvenile idiopathic arthritis,EFO:0002609,JIA patients with active disease,JIA patients in remission,JIA patients with enthesitis-related arthritis who are in remission,8,21,3 months,16S,56,Roche454,LEfSe,0.05,TRUE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:566/3/NA,Study 566,case-control,27833598,https://doi.org/10.3389/fmicb.2016.01703,NA,"Di Paola M, Cavalieri D, Albanese D, Sordo M, Pindo M, Donati C, Pagnini I, Giani T, Simonini G, Paladini A, Lionetti P, De Filippo C , Cimaz R",Alteration of Fecal Microbiota Profiles in Juvenile Idiopathic Arthritis. Associations with HLA-B27 Allele and Disease Status,Frontiers in microbiology,2016,"HLA-B27 allele, enthesitis-related arthritis, gut microbiota, juvenile idiopathic arthritis, metagenomics",Experiment 3,Italy,Homo sapiens,Feces,UBERON:0001988,Juvenile idiopathic arthritis,EFO:0002609,Healthy subjects,JIA-ERA patients,enthesitis-related arthritis (JIA-ERA) patients,29,19,3 months,16S,56,Roche454,Mann-Whitney (Wilcoxon),0.05,TRUE,2,NA,NA,NA,unchanged,decreased,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:566/4/NA,Study 566,case-control,27833598,https://doi.org/10.3389/fmicb.2016.01703,NA,"Di Paola M, Cavalieri D, Albanese D, Sordo M, Pindo M, Donati C, Pagnini I, Giani T, Simonini G, Paladini A, Lionetti P, De Filippo C , Cimaz R",Alteration of Fecal Microbiota Profiles in Juvenile Idiopathic Arthritis. Associations with HLA-B27 Allele and Disease Status,Frontiers in microbiology,2016,"HLA-B27 allele, enthesitis-related arthritis, gut microbiota, juvenile idiopathic arthritis, metagenomics",Experiment 4,Italy,Homo sapiens,Feces,UBERON:0001988,Juvenile idiopathic arthritis,EFO:0002609,Healthy subjects,JIA-nERA patients,polyarticular arthritis (JIA-ERA) patients,29,10,3 months,16S,56,Roche454,Mann-Whitney (Wilcoxon),0.05,TRUE,2,NA,NA,NA,unchanged,decreased,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:567/1/NA,Study 567,case-control,23553152,10.3945/ajcn.112.046607,https://www.sciencedirect.com/science/article/pii/S0002916523055120?via=ihub,"Chen HM, Fang DC, Fang JY, Kong X, Lin YW, Liu F, Liu ZJ, Wang JL, Wu JX, Yang CQ, Yang L, Yu YN, Yuan YZ, Zhong L, Zou W",Decreased dietary fiber intake and structural alteration of gut microbiota in patients with advanced colorectal adenoma,The American journal of clinical nutrition,2013,"colorectal adenoma, colorectal cancer, dietary fiber, short-chain fatty acids",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Colorectal adenoma,EFO:0005406,Healthy control group (HC),Advanced colorectal adenoma group (A-CRA),Patients with a diagnosis of A-CRA by pathological examination were enrolled in the A-CRA group.,47,47,"6 months

None of the patients had received systemic or oral topical corticosteroids, antibiotics,
aspirin, other nonsteroidal antiinflammatory drugs (16), or health products that regulate intestinal microbiota within 6 mo before enrollment",16S,123,Roche454,Mann-Whitney (Wilcoxon),0.05,NA,NA,"age,sex",NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:568/1/NA,Study 568,case-control,31824239,10.3389/fnins.2019.01184,NA,"Jin M, Li J, Liu F, Lyu N, Wang K, Wang L, Liang S, Tao H, Zhu B , Alkasir R",Analysis of the Gut Microflora in Patients With Parkinson's Disease,Frontiers in neuroscience,2019,"16S rRNA gene, Illumina MiSeq, Parkinson's disease, Prevotella, Turicibacter, gut microflora",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,healthy controls without any form of Parkinson's Disease,NPD group: patients suffering with suffering with with PD for less than 1 year and before treatment.,New Parkinson's disease patients: patients suffering with with PD for less than 1 year and before treatment.,68,13,The use of any antibiotics or probiotics within 90 days before collection of the samples.,16S,NA,Illumina,Metastats,0.05,FALSE,NA,"age,life style",NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:568/2/NA,Study 568,case-control,31824239,10.3389/fnins.2019.01184,NA,"Jin M, Li J, Liu F, Lyu N, Wang K, Wang L, Liang S, Tao H, Zhu B , Alkasir R",Analysis of the Gut Microflora in Patients With Parkinson's Disease,Frontiers in neuroscience,2019,"16S rRNA gene, Illumina MiSeq, Parkinson's disease, Prevotella, Turicibacter, gut microflora",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,healthy controls without any form of Parkinson's Disease,NPD group: patients suffering with PD for less than 1 year and 5 days after treatment.,New Parkinson's disease patients: patients suffering with PD for less than 1 year and samples taken 5 days after treatment.,68,13,The use of any antibiotics or probiotics within 90 days before collection of the samples.,16S,NA,Illumina,Metastats,0.01,NA,NA,"age,life style",NA,NA,increased,unchanged,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:568/3/NA,Study 568,case-control,31824239,10.3389/fnins.2019.01184,NA,"Jin M, Li J, Liu F, Lyu N, Wang K, Wang L, Liang S, Tao H, Zhu B , Alkasir R",Analysis of the Gut Microflora in Patients With Parkinson's Disease,Frontiers in neuroscience,2019,"16S rRNA gene, Illumina MiSeq, Parkinson's disease, Prevotella, Turicibacter, gut microflora",Experiment 3,China,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,healthy controls without any form of Parkinson's Disease,NPD group: patients suffering with PD for less than 1 year and 14 days after treatment.,New Parkinson's disease patients: patients suffering with PD for less than 1 year and samples taken 14 days after treatment.,68,13,The use of any antibiotics or probiotics within 90 days before collection of the samples.,16S,NA,Illumina,Metastats,0.05,NA,NA,"age,life style",NA,NA,increased,unchanged,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:569/1/NA,Study 569,case-control,32280686,10.1155/2020/2948282,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7114766/,"Liu X, Cheng Y, Shao L , Ling Z",Alterations of the Predominant Fecal Microbiota and Disruption of the Gut Mucosal Barrier in Patients with Early-Stage Colorectal Cancer,BioMed research international,2020,NA,Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,healthy controls,colorectal cancer patients,diagnosed with primary early-stage CRC (aged 46-75 years old) between January 2011 and March 2012,45,53,1 month,16S,NA,RT-qPCR,T-Test,0.05,NA,NA,"age,body mass index,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:570/1/NA,Study 570,case-control,31100891,10.3390/jcm8050693,NA,"Jeong Y, Kim JW, You HJ, Park SJ, Lee J, Ju JH, Park MS, Jin H, Cho ML, Kwon B, Park SH , Ji GE",Gut Microbial Composition and Function Are Altered in Patients with Early Rheumatoid Arthritis,Journal of clinical medicine,2019,"Collinsella, autoimmune disease, dysbiosis, gut microbiome, microbial diversity, rheumatoid arthritis",Experiment 1,South Korea,Homo sapiens,Feces,UBERON:0001988,Rheumatoid arthritis,EFO:0000685,female healthy control,female with early RA,female early rheumatoid arthritis patients,25,29,"People using antibiotics, probiotics, or prebiotics at the time of sample collection were excluded
from subject selection.",16S,NA,Illumina,LEfSe,0.1,TRUE,3,NA,NA,NA,increased,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:571/1/NA,Study 571,"cross-sectional observational, not case-control",33924396,10.3390/nu13041272,NA,"Ramasamy B, Magne F, Tripathy SK, Venugopal G, Mukherjee D , Balamurugan R",Association of Gut Microbiome and Vitamin D Deficiency in Knee Osteoarthritis Patients: A Pilot Study,Nutrients,2021,"gut microbiome, knee osteoarthritis, vitamin D",Experiment 1,India,Homo sapiens,Feces,UBERON:0001988,"Osteoarthritis, knee",EFO:0004616,Normal Vitamin D status,Knee osteroarthritis,Knee osteoarthritis,6,4,excluded if antibiotics for last 12 weeks,16S,34,Illumina,LEfSe,0.05,NA,2,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:571/2/NA,Study 571,"cross-sectional observational, not case-control",33924396,10.3390/nu13041272,NA,"Ramasamy B, Magne F, Tripathy SK, Venugopal G, Mukherjee D , Balamurugan R",Association of Gut Microbiome and Vitamin D Deficiency in Knee Osteoarthritis Patients: A Pilot Study,Nutrients,2021,"gut microbiome, knee osteoarthritis, vitamin D",Experiment 2,India,Homo sapiens,Feces,UBERON:0001988,"Osteoarthritis, knee",EFO:0004616,Vitamin D deficiency,Knee osteroarthritis with vit D deficiency,Knee osteoarthritis,7,7,excluded if antibiotics for last 12 weeks,16S,34,Illumina,LEfSe,0.05,NA,2,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:572/1/NA,Study 572,case-control,24192039,https://doi.org/10.7554/eLife.01202.003,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3816614/,"Scher JU, Sczesnak A, Longman RS, Segata N, Ubeda C, Bielski C, Rostron T, Cerundolo V, Pamer EG, Abramson SB, Huttenhower C , Littman DR",Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis,eLife,2013,"arthritis, autoimmunity, inflammation, metagenomics, microbiome, rheumatoid",Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Arthritis,EFO:0005856,Healthy controls,New-onset rheumatoid arthritis - NORA,Patients with new-onset rheumatoid arthritis - NORA,28,44,3 Months,16S,12,Roche454,LEfSe,0.05,TRUE,2,"age,ethnic group,sex",NA,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:573/1/NA,Study 573,"cross-sectional observational, not case-control",32083132,10.1155/2020/7828392,https://pubmed.ncbi.nlm.nih.gov/32083132/,"Liu W, Zhang R, Shu R, Yu J, Li H, Long H, Jin S, Li S, Hu Q, Yao F, Zhou C, Huang Q, Hu X, Chen M, Hu W, Wang Q, Fang S , Wu Q",Study of the Relationship between Microbiome and Colorectal Cancer Susceptibility Using 16SrRNA Sequencing,BioMed research international,2020,NA,Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,Healthy Controls (HC),Colorectal Cancer (CC),Patients who visited the department of gastroenterology of Tianyou hospital of Wuhan from January 2017 to December 2017 and received colonoscopy and histopathological examination were recruited to the study. Patients with colorectal adenocarcinoma were recorded as the colorectal cancer (CC) group.,42,51,2 months,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,decreased,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:574/1/NA,Study 574,randomized controlled trial,31583533,10.1007/s12519-019-00315-6,NA,"Nikolaou E, Kamilari E, Savkov D, Sergeev A, Zakharova I, Vogazianos P, Tomazou M, Antoniades A , Shammas C",Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose,World journal of pediatrics : WJP,2020,"Antibiotics, Azithromycin, Lactulose, Microbiome, Prebiotics",Experiment 1,Russian Federation,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,azithromycin-lactulose treated (day 0),azithromycin-lactulose treated (day 18),"administered a single daily dosage of 10 mg/kg body weight azithromycin in addition with 20 mg/kg body weight lactulose per day, as powder for oral suspension.",42,42,NA,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:574/2/NA,Study 574,randomized controlled trial,31583533,10.1007/s12519-019-00315-6,NA,"Nikolaou E, Kamilari E, Savkov D, Sergeev A, Zakharova I, Vogazianos P, Tomazou M, Antoniades A , Shammas C",Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose,World journal of pediatrics : WJP,2020,"Antibiotics, Azithromycin, Lactulose, Microbiome, Prebiotics",Experiment 2,Russian Federation,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,azithromycin treated (day 0),azithromycin treated (day 18),"administered 10 mg/kg body weight per day of azithromycin, as powder for oral suspension.",42,42,NA,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:574/3/NA,Study 574,randomized controlled trial,31583533,10.1007/s12519-019-00315-6,NA,"Nikolaou E, Kamilari E, Savkov D, Sergeev A, Zakharova I, Vogazianos P, Tomazou M, Antoniades A , Shammas C",Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose,World journal of pediatrics : WJP,2020,"Antibiotics, Azithromycin, Lactulose, Microbiome, Prebiotics",Experiment 3,Russian Federation,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,azithromycin treated (day 0),azithromycin treated (day 60),"administered 10 mg/kg body weight per day of azithromycin, as powder for oral suspension.",42,42,NA,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:574/4/NA,Study 574,randomized controlled trial,31583533,10.1007/s12519-019-00315-6,NA,"Nikolaou E, Kamilari E, Savkov D, Sergeev A, Zakharova I, Vogazianos P, Tomazou M, Antoniades A , Shammas C",Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose,World journal of pediatrics : WJP,2020,"Antibiotics, Azithromycin, Lactulose, Microbiome, Prebiotics",Experiment 4,Russian Federation,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,azithromycin treated (0-18),azithromycin-lactulose treated (0-18),"administered a single daily dosage of 10 mg/kg body weight azithromycin in addition with 20 mg/kg body weight lactulose per day, as powder for oral suspension.",42,42,NA,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,NA,NA,NA,NA,NA,increased,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:574/5/NA,Study 574,randomized controlled trial,31583533,10.1007/s12519-019-00315-6,NA,"Nikolaou E, Kamilari E, Savkov D, Sergeev A, Zakharova I, Vogazianos P, Tomazou M, Antoniades A , Shammas C",Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose,World journal of pediatrics : WJP,2020,"Antibiotics, Azithromycin, Lactulose, Microbiome, Prebiotics",Experiment 5,Russian Federation,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,azithromycin treated (0-60),azithromycin-lactulose treated (0-60),"patients administered a single daily dosage of 10 mg/kg body weight azithromycin in addition with 20 mg/kg body weight lactulose per day, as powder for oral suspension.",42,42,NA,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,NA,NA,NA,NA,NA,increased,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:574/6/NA,Study 574,randomized controlled trial,31583533,10.1007/s12519-019-00315-6,NA,"Nikolaou E, Kamilari E, Savkov D, Sergeev A, Zakharova I, Vogazianos P, Tomazou M, Antoniades A , Shammas C",Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose,World journal of pediatrics : WJP,2020,"Antibiotics, Azithromycin, Lactulose, Microbiome, Prebiotics",Experiment 6,Russian Federation,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,azithromycin treated at day 18,azithromycin-lactulose at day 18,"patients administered a single daily dosage of 10 mg/kg body weight azithromycin in addition with 20 mg/kg body weight lactulose per day, as powder for oral suspension.",42,42,NA,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,NA,NA,NA,NA,NA,increased,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:574/7/NA,Study 574,randomized controlled trial,31583533,10.1007/s12519-019-00315-6,NA,"Nikolaou E, Kamilari E, Savkov D, Sergeev A, Zakharova I, Vogazianos P, Tomazou M, Antoniades A , Shammas C",Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose,World journal of pediatrics : WJP,2020,"Antibiotics, Azithromycin, Lactulose, Microbiome, Prebiotics",Experiment 7,Russian Federation,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,azithromycin treated at day 60,azithromycin-lactulose at day 60,"patients administered a single daily dosage of 10 mg/kg body weight azithromycin in addition with 20 mg/kg body weight lactulose per day, as powder for oral suspension.",42,42,NA,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,NA,NA,NA,NA,NA,increased,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:574/8/NA,Study 574,randomized controlled trial,31583533,10.1007/s12519-019-00315-6,NA,"Nikolaou E, Kamilari E, Savkov D, Sergeev A, Zakharova I, Vogazianos P, Tomazou M, Antoniades A , Shammas C",Intestinal microbiome analysis demonstrates azithromycin post-treatment effects improve when combined with lactulose,World journal of pediatrics : WJP,2020,"Antibiotics, Azithromycin, Lactulose, Microbiome, Prebiotics",Experiment 8,Russian Federation,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,azithromycin-lactulose treated (day 0),azithromycin-lactulose treated (day 60),"administered a single daily dosage of 10 mg/kg body weight azithromycin in addition with 20 mg/kg body weight lactulose per day, as powder for oral suspension.",42,42,NA,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:575/1/NA,Study 575,prospective cohort,33824448,10.1038/s41390-021-01494-7,NA,"Ainonen S, Tejesvi MV, Mahmud MR, Paalanne N, Pokka T, Li W, Nelson KE, Salo J, Renko M, Vänni P, Pirttilä AM , Tapiainen T",Antibiotics at birth and later antibiotic courses: effects on gut microbiota,Pediatric research,2021,NA,Experiment 1,Finland,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,Control group,perinatal antibiotics,Participants who received any perinatal antibiotics (all three perinatal groups combined),27,73,NA,16S,NA,Ion Torrent,ANOVA,0.05,TRUE,NA,NA,NA,unchanged,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:575/2/NA,Study 575,prospective cohort,33824448,10.1038/s41390-021-01494-7,NA,"Ainonen S, Tejesvi MV, Mahmud MR, Paalanne N, Pokka T, Li W, Nelson KE, Salo J, Renko M, Vänni P, Pirttilä AM , Tapiainen T",Antibiotics at birth and later antibiotic courses: effects on gut microbiota,Pediatric research,2021,NA,Experiment 2,Finland,Homo sapiens,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,control group,Antibiotic courses,All perinatal groups that received any antibiotic courses,71,28,NA,16S,NA,Ion Torrent,ANOVA,0.05,NA,NA,NA,NA,unchanged,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:576/1/NA,Study 576,case-control,24316595,10.1093/jnci/djt300,https://pubmed.ncbi.nlm.nih.gov/24316595/,"Ahn J, Sinha R, Pei Z, Dominianni C, Wu J, Shi J, Goedert JJ, Hayes RB , Yang L",Human gut microbiome and risk for colorectal cancer,Journal of the National Cancer Institute,2013,NA,Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,controls with no cancer,patients with adenocarcinoma,"patients with newly diagnosed, histologically confirmed adenocarcinoma of the colon or rectum",94,47,1 year,16S,34,Roche454,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,"body mass index,sex","age,body mass index,race,sex,smoking behavior",unchanged,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:577/1/NA,Study 577,case-control,32931909,10.1016/j.anai.2020.09.007,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8043253/,"Chen R, Wang L, Koch T, Curtis V, Yin-DeClue H, Handley SA, Shan L, Holtzman MJ, Castro M , Wang L",Sex effects in the association between airway microbiome and asthma,"Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology",2020,NA,Experiment 1,United States of America,Homo sapiens,Sputum,UBERON:0007311,Asthma,MONDO:0004979,Female,Male,Male participants,32,15,1 month,16S,12,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:577/2/NA,Study 577,case-control,32931909,10.1016/j.anai.2020.09.007,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8043253/,"Chen R, Wang L, Koch T, Curtis V, Yin-DeClue H, Handley SA, Shan L, Holtzman MJ, Castro M , Wang L",Sex effects in the association between airway microbiome and asthma,"Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology",2020,NA,Experiment 2,United States of America,Homo sapiens,Sputum,UBERON:0007311,Asthma,MONDO:0004979,Female normal controls,Female participants with asthma,Females participants with asthma,17,15,1 month,16S,12,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:578/1/NA,Study 578,prospective cohort,25766736,10.1093/jac/dkv062,NA,"Vervoort J, Xavier BB, Stewardson A, Coenen S, Godycki-Cwirko M, Adriaenssens N, Kowalczyk A, Lammens C, Harbarth S, Goossens H , Malhotra-Kumar S",Metagenomic analysis of the impact of nitrofurantoin treatment on the human faecal microbiota,The Journal of antimicrobial chemotherapy,2015,"16S rDNA, 16S rRNA, antibiotic resistance, compositional changes, culture independent, faecal flora, gastrointestinal flora, stool, urinary tract infections",Experiment 1,"Belgium,Poland",Homo sapiens,Feces,UBERON:0001988,Urinary tract infection,EFO:0003103,Control group,Antibiotic treated - T2,Receiving nitrofurantoin treatment (100 mg three times daily for 3–15 days),5,8,2 months,16S,345,Roche454,Linear Regression,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:578/2/NA,Study 578,prospective cohort,25766736,10.1093/jac/dkv062,NA,"Vervoort J, Xavier BB, Stewardson A, Coenen S, Godycki-Cwirko M, Adriaenssens N, Kowalczyk A, Lammens C, Harbarth S, Goossens H , Malhotra-Kumar S",Metagenomic analysis of the impact of nitrofurantoin treatment on the human faecal microbiota,The Journal of antimicrobial chemotherapy,2015,"16S rDNA, 16S rRNA, antibiotic resistance, compositional changes, culture independent, faecal flora, gastrointestinal flora, stool, urinary tract infections",Experiment 2,"Belgium,Poland",Homo sapiens,Feces,UBERON:0001988,Urinary tract infection,EFO:0003103,Antibiotic treated (day 1),Antibiotic treated (day 5-15),Receiving nitrofurantoin treatment (100 mg three times daily for 3–15 days),8,8,2 months,16S,345,Roche454,Linear Regression,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:578/3/NA,Study 578,prospective cohort,25766736,10.1093/jac/dkv062,NA,"Vervoort J, Xavier BB, Stewardson A, Coenen S, Godycki-Cwirko M, Adriaenssens N, Kowalczyk A, Lammens C, Harbarth S, Goossens H , Malhotra-Kumar S",Metagenomic analysis of the impact of nitrofurantoin treatment on the human faecal microbiota,The Journal of antimicrobial chemotherapy,2015,"16S rDNA, 16S rRNA, antibiotic resistance, compositional changes, culture independent, faecal flora, gastrointestinal flora, stool, urinary tract infections",Experiment 3,"Belgium,Poland",Homo sapiens,Feces,UBERON:0001988,Urinary tract infection,EFO:0003103,Control (day 1),Control (day 5-15),Did not receive nitrofurantoin treatment,5,5,2 months,16S,345,Roche454,Linear Regression,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:579/1/NA,Study 579,"cross-sectional observational, not case-control",32040443,10.18632/aging.102775,https://pubmed.ncbi.nlm.nih.gov/32040443/,"Chen JJ, He S, Fang L, Wang B, Bai SJ, Xie J, Zhou CJ, Wang W , Xie P",Age-specific differential changes on gut microbiota composition in patients with major depressive disorder,Aging,2020,"Actinobacteria, Bacteroidetes, Firmicutes, gut microbiota, major depressive disorder",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Major depressive disorder,MONDO:0002009,Young Healthy Controls(aged 18-29 years),Middle-aged HC (aged 30-59 years),Subjects without major depressive disorder between the ages of 30 to 59 years.,27,44,NOT SPECIFIED,16S,345,Roche454,LEfSe,0.05,FALSE,2,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:579/2/NA,Study 579,"cross-sectional observational, not case-control",32040443,10.18632/aging.102775,https://pubmed.ncbi.nlm.nih.gov/32040443/,"Chen JJ, He S, Fang L, Wang B, Bai SJ, Xie J, Zhou CJ, Wang W , Xie P",Age-specific differential changes on gut microbiota composition in patients with major depressive disorder,Aging,2020,"Actinobacteria, Bacteroidetes, Firmicutes, gut microbiota, major depressive disorder",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Major depressive disorder,MONDO:0002009,Young MDD (aged 18-29 years),Middle-aged MDD (aged 30-59 years),Individuals who have been diagnosed with Major Depressive Disorder(MDD) between the ages of 30-59 years.,25,45,Not specified,16S,345,Roche454,LEfSe,0.05,FALSE,2,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:579/3/NA,Study 579,"cross-sectional observational, not case-control",32040443,10.18632/aging.102775,https://pubmed.ncbi.nlm.nih.gov/32040443/,"Chen JJ, He S, Fang L, Wang B, Bai SJ, Xie J, Zhou CJ, Wang W , Xie P",Age-specific differential changes on gut microbiota composition in patients with major depressive disorder,Aging,2020,"Actinobacteria, Bacteroidetes, Firmicutes, gut microbiota, major depressive disorder",Experiment 3,China,Homo sapiens,Feces,UBERON:0001988,Major depressive disorder,MONDO:0002009,Middle-aged HC (aged 30-59 years),Middle-aged MDD (aged 30-59 years),Individuals who have been diagnosed with Major Depressive Disorder(MDD) between the ages of 30-59 years.,44,45,Not specified,16S,345,Roche454,LEfSe,0.05,FALSE,2,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:579/4/NA,Study 579,"cross-sectional observational, not case-control",32040443,10.18632/aging.102775,https://pubmed.ncbi.nlm.nih.gov/32040443/,"Chen JJ, He S, Fang L, Wang B, Bai SJ, Xie J, Zhou CJ, Wang W , Xie P",Age-specific differential changes on gut microbiota composition in patients with major depressive disorder,Aging,2020,"Actinobacteria, Bacteroidetes, Firmicutes, gut microbiota, major depressive disorder",Experiment 4,China,Homo sapiens,Feces,UBERON:0001988,Major depressive disorder,MONDO:0002009,Young HC (aged 18-29 years),Young MDD (aged 18-29 years),Individuals who have been diagnosed with Major Depressive Disorder(MDD) between the ages of 18-29 years.,27,25,Not specified,16S,345,Roche454,LEfSe,0.05,FALSE,2,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:580/1/NA,Study 580,"cross-sectional observational, not case-control",31682463,10.1164/rccm.201905-1016OC,https://pubmed.ncbi.nlm.nih.gov/31682463/,"Yang L, Dunlap DG, Qin S, Fitch A, Li K, Koch CD, Nouraie M, DeSensi R, Ho KS, Martinson JJ, Methé B , Morris A",Alterations in Oral Microbiota in HIV Are Related to Decreased Pulmonary Function,American journal of respiratory and critical care medicine,2020,"HIV, lung function, microbiome, saliva, stool",Experiment 1,United States of America,Homo sapiens,Saliva,UBERON:0001836,HIV infection,EFO:0000764,HIV-uninfected individuals,HIV+ individuals,People with HIV,93,75,5 days,16S,4,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:580/2/NA,Study 580,"cross-sectional observational, not case-control",31682463,10.1164/rccm.201905-1016OC,https://pubmed.ncbi.nlm.nih.gov/31682463/,"Yang L, Dunlap DG, Qin S, Fitch A, Li K, Koch CD, Nouraie M, DeSensi R, Ho KS, Martinson JJ, Methé B , Morris A",Alterations in Oral Microbiota in HIV Are Related to Decreased Pulmonary Function,American journal of respiratory and critical care medicine,2020,"HIV, lung function, microbiome, saliva, stool",Experiment 2,United States of America,Homo sapiens,Saliva,UBERON:0001836,"Smoking behavior,Nicotine dependence","EFO:0003768,EFO:0004318",HIV+ non-smokers,HIV+ smokers,People with HIV who currently smoke cigarettes,26,23,5 days,16S,4,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:580/3/NA,Study 580,"cross-sectional observational, not case-control",31682463,10.1164/rccm.201905-1016OC,https://pubmed.ncbi.nlm.nih.gov/31682463/,"Yang L, Dunlap DG, Qin S, Fitch A, Li K, Koch CD, Nouraie M, DeSensi R, Ho KS, Martinson JJ, Methé B , Morris A",Alterations in Oral Microbiota in HIV Are Related to Decreased Pulmonary Function,American journal of respiratory and critical care medicine,2020,"HIV, lung function, microbiome, saliva, stool",Experiment 3,United States of America,Homo sapiens,Saliva,UBERON:0001836,Abnormality on pulmonary function testing,HP:0030878,HIV+ patients with normal DLCO,HIV+ patients with reduced DLCO,HIV+ patients with DLCO% predicted <80%,38,37,5 days,16S,4,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:581/1/NA,Study 581,"cross-sectional observational, not case-control",30291996,10.1016/j.eplepsyres.2018.09.013,NA,"Peng A, Qiu X, Lai W, Li W, Zhang L, Zhu X, He S, Duan J , Chen L",Altered composition of the gut microbiome in patients with drug-resistant epilepsy,Epilepsy research,2018,"Drug-resistant epilepsy, Epilepsy, Microbiome, Microbiota, Ruminococcus",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Epilepsy,EFO:0000474,Drug sensitive epilepsy,Drug resistant epilepsy,Drug resistant epilepsy patients were defined according to the 2015 International League Against Epilepsy (ILAE),49,42,3 months,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,increased,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:581/2/NA,Study 581,"cross-sectional observational, not case-control",30291996,10.1016/j.eplepsyres.2018.09.013,NA,"Peng A, Qiu X, Lai W, Li W, Zhang L, Zhu X, He S, Duan J , Chen L",Altered composition of the gut microbiome in patients with drug-resistant epilepsy,Epilepsy research,2018,"Drug-resistant epilepsy, Epilepsy, Microbiome, Microbiota, Ruminococcus",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Epilepsy,EFO:0000474,Healthy controls,Drug resistant epilepsy,Drug sensitive epilepsy patients were defined according to the 2015 International League Against Epilepsy (ILAE),65,49,3 months,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:582/1/NA,Study 582,case-control,32370168,10.3390/cancers12051142,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281174/,"Clos-Garcia M, Garcia K, Alonso C, Iruarrizaga-Lejarreta M, D'Amato M, Crespo A, Iglesias A, Cubiella J, Bujanda L , Falcón-Pérez JM",Integrative Analysis of Fecal Metagenomics and Metabolomics in Colorectal Cancer,Cancers,2020,"integration, metabolomics, microbiome, multiomics, omics, omics integration",Experiment 1,Spain,Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,healthy controls,CRC patients,patients with gastrointestinal symptoms referred for colonoscopy,77,89,none,16S,12,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:582/2/NA,Study 582,case-control,32370168,10.3390/cancers12051142,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281174/,"Clos-Garcia M, Garcia K, Alonso C, Iruarrizaga-Lejarreta M, D'Amato M, Crespo A, Iglesias A, Cubiella J, Bujanda L , Falcón-Pérez JM",Integrative Analysis of Fecal Metagenomics and Metabolomics in Colorectal Cancer,Cancers,2020,"integration, metabolomics, microbiome, multiomics, omics, omics integration",Experiment 2,Spain,Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,adenoma patients,CRC patients,patients with gastrointestinal symptoms referred for colonoscopy,65,89,none,16S,12,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:583/1/NA,Study 583,"cross-sectional observational, not case-control",32024712,10.1128/mSphere.00798-19,https://pubmed.ncbi.nlm.nih.gov/32024712/,"Annavajhala MK, Khan SD, Sullivan SB, Shah J, Pass L, Kister K, Kunen H, Chiang V, Monnot GC, Ricupero CL, Mazur RA, Gordon P, de Jong A, Wadhwa S, Yin MT, Demmer RT , Uhlemann AC",Oral and Gut Microbial Diversity and Immune Regulation in Patients with HIV on Antiretroviral Therapy,mSphere,2020,"HIV, antiretroviral agents, antiretroviral therapy, immune dysfunction, immune system activation, mycobiome, oral microbiome",Experiment 1,United States of America,Homo sapiens,"Oral cavity,Feces","UBERON:0000167,UBERON:0001988",HIV infection,EFO:0000764,PLWH >50 years old with no/mild periodontitis,PLWH >50 years old with severe periodontitis,Patients with severe periodontal disease,4,22,3 Months,16S,34,Illumina,DESeq2,0.05,TRUE,NA,NA,"age,race,sex",NA,unchanged,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:584/1/NA,Study 584,"cross-sectional observational, not case-control",26288821,10.1016/j.ebiom.2015.04.010,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4535156/,"Goedert JJ, Gong Y, Hua X, Zhong H, He Y, Peng P, Yu G, Wang W, Ravel J, Shi J , Zheng Y",Fecal Microbiota Characteristics of Patients with Colorectal Adenoma Detected by Screening: A Population-based Study,EBioMedicine,2015,"Cancer screening, China, Colorectal adenoma, Colorectal cancer, Feces, Microbiota",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Colorectal adenoma,EFO:0005406,normal participants,cra patients,patients with precancerous colorectal adenoma,24,20,none,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,unchanged,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:585/1/NA,Study 585,meta-analysis,30412600,10.1371/journal.pone.0207002,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6226189/,"Shah MS, DeSantis T, Yamal JM, Weir T, Ryan EP, Cope JL , Hollister EB",Re-purposing 16S rRNA gene sequence data from within case paired tumor biopsy and tumor-adjacent biopsy or fecal samples to identify microbial markers for colorectal cancer,PloS one,2018,NA,Experiment 1,United States of America,Homo sapiens,"Colorectal mucosa,Feces","UBERON:0013067,UBERON:0001988",Colorectal cancer,EFO:0005842,Healthy tumor-adjacent biopsy,CRC tumor biopsy,Colorectal tumor tissues,294,294,Cases with previous chemotherapy and antibiotic use were excluded as well as patients with antibiotic use within 1 - 3 months prior to sample collection.,16S,NA,"Illumina,Roche454",DESeq2,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:585/2/NA,Study 585,meta-analysis,30412600,10.1371/journal.pone.0207002,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6226189/,"Shah MS, DeSantis T, Yamal JM, Weir T, Ryan EP, Cope JL , Hollister EB",Re-purposing 16S rRNA gene sequence data from within case paired tumor biopsy and tumor-adjacent biopsy or fecal samples to identify microbial markers for colorectal cancer,PloS one,2018,NA,Experiment 2,United States of America,Homo sapiens,"Feces,Colorectal mucosa","UBERON:0001988,UBERON:0013067",Colorectal cancer,EFO:0005842,Tumor biopsy,Fecal samples,Fecal samples from the same colorectal case,42,42,Cases with previous chemotherapy and antibiotic use were excluded as well as patients with antibiotic use within 1 - 3 months prior to sample collection.,16S,NA,"Illumina,Roche454",DESeq2,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:586/1/NA,Study 586,case-control,29375539,10.3389/fmicb.2017.02699,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5770402/,"Russo E, Bacci G, Chiellini C, Fagorzi C, Niccolai E, Taddei A, Ricci F, Ringressi MN, Borrelli R, Melli F, Miloeva M, Bechi P, Mengoni A, Fani R , Amedei A",Preliminary Comparison of Oral and Intestinal Human Microbiota in Patients with Colorectal Cancer: A Pilot Study,Frontiers in microbiology,2017,"Fusobacterium nucleatum, colorectal cancer, gut microbiota, oral microbiota, quantitative polymerase chain reaction, taxonomic analysis",Experiment 1,Italy,Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,Healthy Controls,Colorectal Cancer Patients,Italian patients aged 71-95 with colorectal adenocarcinoma confirmed by histological analysis undergoing surgical resections,10,10,3 months,16S,34,Illumina,LEfSe,0.05,TRUE,NA,NA,NA,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:586/2/NA,Study 586,case-control,29375539,10.3389/fmicb.2017.02699,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5770402/,"Russo E, Bacci G, Chiellini C, Fagorzi C, Niccolai E, Taddei A, Ricci F, Ringressi MN, Borrelli R, Melli F, Miloeva M, Bechi P, Mengoni A, Fani R , Amedei A",Preliminary Comparison of Oral and Intestinal Human Microbiota in Patients with Colorectal Cancer: A Pilot Study,Frontiers in microbiology,2017,"Fusobacterium nucleatum, colorectal cancer, gut microbiota, oral microbiota, quantitative polymerase chain reaction, taxonomic analysis",Experiment 2,Italy,Homo sapiens,Saliva,UBERON:0001836,Colorectal cancer,EFO:0005842,Healthy Controls,Colorectal cancer Patients,Italian patients aged 71-95 with colorectal adenocarcinoma confirmed by histological analysis undergoing surgical resections.,10,10,3 months,16S,34,Illumina,LEfSe,0.05,NA,NA,NA,NA,NA,increased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:586/3/NA,Study 586,case-control,29375539,10.3389/fmicb.2017.02699,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5770402/,"Russo E, Bacci G, Chiellini C, Fagorzi C, Niccolai E, Taddei A, Ricci F, Ringressi MN, Borrelli R, Melli F, Miloeva M, Bechi P, Mengoni A, Fani R , Amedei A",Preliminary Comparison of Oral and Intestinal Human Microbiota in Patients with Colorectal Cancer: A Pilot Study,Frontiers in microbiology,2017,"Fusobacterium nucleatum, colorectal cancer, gut microbiota, oral microbiota, quantitative polymerase chain reaction, taxonomic analysis",Experiment 3,Italy,Homo sapiens,Colorectum,UBERON:0012652,Colorectal cancer,EFO:0005842,Healthy Controls,Biopsy samples of colorectal cancer patients,Italian patients aged 71-95 with colorectal adenocarcinoma confirmed by histological analysis undergoing surgical resections.,10,10,3 months,16S,34,Illumina,LEfSe,0.05,NA,NA,NA,NA,NA,increased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:587/1/NA,Study 587,"cross-sectional observational, not case-control",31794002,10.1093/ntr/ntz220,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7364824/pdf/ntz220.pdf,"Nolan-Kenney R, Wu F, Hu J, Yang L, Kelly D, Li H, Jasmine F, Kibriya MG, Parvez F, Shaheen I, Sarwar G, Ahmed A, Eunus M, Islam T, Pei Z, Ahsan H , Chen Y",The Association Between Smoking and Gut Microbiome in Bangladesh,Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco,2020,NA,Experiment 1,Bangladesh,Homo sapiens,Feces,UBERON:0001988,"Nicotine dependence,Smoking behavior","EFO:0003768,EFO:0004318",Never smokers,Current Smokers,Current smokers of cigarettes and bidis were categorized as current smokers,151,62,1 month.,16S,34,Illumina,"Beta Binomial Regression,Logistic Regression",0.05,TRUE,NA,NA,"age,body mass index,education level,sex",NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:587/2/NA,Study 587,"cross-sectional observational, not case-control",31794002,10.1093/ntr/ntz220,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7364824/pdf/ntz220.pdf,"Nolan-Kenney R, Wu F, Hu J, Yang L, Kelly D, Li H, Jasmine F, Kibriya MG, Parvez F, Shaheen I, Sarwar G, Ahmed A, Eunus M, Islam T, Pei Z, Ahsan H , Chen Y",The Association Between Smoking and Gut Microbiome in Bangladesh,Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco,2020,NA,Experiment 2,Bangladesh,Homo sapiens,Feces,UBERON:0001988,"Nicotine dependence,Smoking behavior","EFO:0003768,EFO:0004318",Never smokers,Current Smokers,"Current smokers of cigarettes and bidis were categorized as current smokers, further assessed their association with packs of cigarettes smoked",151,62,1 month.,16S,34,Illumina,"Beta Binomial Regression,Logistic Regression",0.05,TRUE,NA,NA,"age,body mass index,education level,sex",NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:588/1/NA,Study 588,case-control,34442626,10.3390/microorganisms9081548,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8401100/,"Fang CY, Chen JS, Hsu BM, Hussain B, Rathod J , Lee KH",Colorectal Cancer Stage-Specific Fecal Bacterial Community Fingerprinting of the Taiwanese Population and Underpinning of Potential Taxonomic Biomarkers,Microorganisms,2021,"biomarker, colorectal cancer, functional predictions, gut microbial dysbiosis, gut microbiota, metagenomics, prognosis",Experiment 1,Taiwan,Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,healthy subjects,colorectal cancer patients,persons aged 25–95 years old with cancerous large intestine tumor symptoms,17,21,1 month,16S,34,Illumina,Metastats,0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:588/2/NA,Study 588,case-control,34442626,10.3390/microorganisms9081548,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8401100/,"Fang CY, Chen JS, Hsu BM, Hussain B, Rathod J , Lee KH",Colorectal Cancer Stage-Specific Fecal Bacterial Community Fingerprinting of the Taiwanese Population and Underpinning of Potential Taxonomic Biomarkers,Microorganisms,2021,"biomarker, colorectal cancer, functional predictions, gut microbial dysbiosis, gut microbiota, metagenomics, prognosis",Experiment 2,Taiwan,Homo sapiens,Feces,UBERON:0001988,Intestinal polyp,EFO:0003855,healthy subjects,polyps patients,persons aged 25–95 years old with polyps,17,21,1 month,16S,NA,Illumina,Metastats,0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:588/3/NA,Study 588,case-control,34442626,10.3390/microorganisms9081548,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8401100/,"Fang CY, Chen JS, Hsu BM, Hussain B, Rathod J , Lee KH",Colorectal Cancer Stage-Specific Fecal Bacterial Community Fingerprinting of the Taiwanese Population and Underpinning of Potential Taxonomic Biomarkers,Microorganisms,2021,"biomarker, colorectal cancer, functional predictions, gut microbial dysbiosis, gut microbiota, metagenomics, prognosis",Experiment 3,Taiwan,Homo sapiens,Feces,UBERON:0001988,Intestinal polyp,EFO:0003855,polyps patients,cancer patients,persons aged 25–95 years old with cancerous large intestine tumor symptoms,21,21,1 month,16S,NA,Illumina,Metastats,0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:589/1/NA,Study 589,case-control,23940645,10.1371/journal.pone.0070803,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3735522/,"Weir TL, Manter DK, Sheflin AM, Barnett BA, Heuberger AL , Ryan EP",Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults,PloS one,2013,NA,Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,healthy control,CRC patients,recently diagnosed colon cancer patients prior to surgery for colonic resection,11,10,2 months,16S,4,Roche454,"ANOVA,T-Test",0.01,FALSE,NA,NA,NA,NA,unchanged,decreased,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:590/1/NA,Study 590,time series / longitudinal observational,31078141,10.1186/s40168-019-0687-5,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6511141/pdf/40168_2019_Article_687.pdf,"Rocafort M, Noguera-Julian M, Rivera J, Pastor L, Guillén Y, Langhorst J, Parera M, Mandomando I, Carrillo J, Urrea V, Rodríguez C, Casadellà M, Calle ML, Clotet B, Blanco J, Naniche D , Paredes R",Evolution of the gut microbiome following acute HIV-1 infection,Microbiome,2019,"AIDS, HIV-1, HIV-1 pathogenesis, Microbiome, acute HIV-1 infection",Experiment 1,Mozambique,Homo sapiens,Feces,UBERON:0001988,HIV infection,EFO:0000764,HIV-1-negative individuals,Recently HIV-1 infected individuals,"Individuals with recent HIV infection (RHI), defined as a negative or indeterminate rapid test serology (first test negative or first test positive and second test negative) and positive HIV-1 viremia",54,49,NA,16S,34,Illumina,Kruskall-Wallis,0.05,TRUE,NA,"age,body mass index",NA,NA,unchanged,unchanged,unchanged,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:591/1/NA,Study 591,"cross-sectional observational, not case-control",33102244,10.3389/fcimb.2020.00434,https://pubmed.ncbi.nlm.nih.gov/33102244/,"Zhou J, Zhang Y, Cui P, Luo L, Chen H, Liang B, Jiang J, Ning C, Tian L, Zhong X, Ye L, Liang H , Huang J",Gut Microbiome Changes Associated With HIV Infection and Sexual Orientation,Frontiers in cellular and infection microbiology,2020,"16S rRNA gene amplicon sequencing, AIDS, HIV, gut microbiome, sexual orientation",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,HIV infection,EFO:0000764,HIV– individuals,HIV+ individuals,HIV positive patients,544,744,NA,16S,NA,Illumina,LEfSe,0.05,TRUE,2,NA,"age,body mass index,sex,sexual preference",NA,decreased,decreased,unchanged,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:591/2/NA,Study 591,"cross-sectional observational, not case-control",33102244,10.3389/fcimb.2020.00434,https://pubmed.ncbi.nlm.nih.gov/33102244/,"Zhou J, Zhang Y, Cui P, Luo L, Chen H, Liang B, Jiang J, Ning C, Tian L, Zhong X, Ye L, Liang H , Huang J",Gut Microbiome Changes Associated With HIV Infection and Sexual Orientation,Frontiers in cellular and infection microbiology,2020,"16S rRNA gene amplicon sequencing, AIDS, HIV, gut microbiome, sexual orientation",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,HIV infection,EFO:0000764,non-MSM,MSM (men who have sex with men),Men who have sex with men,304,328,NA,16S,NA,Illumina,LEfSe,0.05,TRUE,2,NA,"age,body mass index,sex,sexual preference",NA,unchanged,decreased,decreased,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:592/1/NA,Study 592,"cross-sectional observational, not case-control",34378948,10.1128/Spectrum.00708-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8552706/pdf/spectrum.00708-21.pdf,"Ishizaka A, Koga M, Mizutani T, Parbie PK, Prawisuda D, Yusa N, Sedohara A, Kikuchi T, Ikeuchi K, Adachi E, Koibuchi T, Furukawa Y, Tojo A, Imoto S, Suzuki Y, Tsutsumi T, Kiyono H, Matano T , Yotsuyanagi H",Unique Gut Microbiome in HIV Patients on Antiretroviral Therapy (ART) Suggests Association with Chronic Inflammation,Microbiology spectrum,2021,"HIV, dysbiosis, human immunodeficiency virus, inflammation, microbiome, microbiota",Experiment 1,Japan,Homo sapiens,Feces,UBERON:0001988,HIV infection,EFO:0000764,Healthy controls,HIV Patients,Patients with HIV infection,61,71,NA,16S,34,Illumina,LEfSe,0.05,FALSE,3,"age,body mass index,sex",NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:593/1/NA,Study 593,case-control,33013704,10.3389/fendo.2020.00628,NA,"Zhou L, Ni Z, Yu J, Cheng W, Cai Z , Yu C",Correlation Between Fecal Metabolomics and Gut Microbiota in Obesity and Polycystic Ovary Syndrome,Frontiers in endocrinology,2020,"biomarkers, gut microbiota, obesity, polycystic ovary syndrome, untargeted metabolomics",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Polycystic ovary syndrome,EFO:0000660,Obese women without PCOS,Obese women with PCOS,Obese women with PCOS,15,18,3 months.,16S,NA,Illumina,Linear Regression,0.05,TRUE,NA,"age,body mass index",NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:594/1/NA,Study 594,"cross-sectional observational, not case-control",28328799,10.1097/MD.0000000000005821,https://pubmed.ncbi.nlm.nih.gov/28328799/,"Noguera-Julian M, Guillén Y, Peterson J, Reznik D, Harris EV, Joseph SJ, Rivera J, Kannanganat S, Amara R, Nguyen ML, Mutembo S, Paredes R, Read TD , Marconi VC",Oral microbiome in HIV-associated periodontitis,Medicine,2017,NA,Experiment 1,United States of America,Homo sapiens,"Dental plaque,Internal cheek pouch,Saliva","UBERON:0016482,UBERON:0013640,UBERON:0001836",Periodontitis,EFO:0000649,HIV–,HIV+,"Participants who were positive for HIV-1 infection, as verified by ELISA and confirmed by Western blot.",10,40,NA,16S,4,Illumina,Wald Test,0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:595/1/NA,Study 595,"cross-sectional observational, not case-control",25432777,10.15252/msb.20145645,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4299606/,"Zeller G, Tap J, Voigt AY, Sunagawa S, Kultima JR, Costea PI, Amiot A, Böhm J, Brunetti F, Habermann N, Hercog R, Koch M, Luciani A, Mende DR, Schneider MA, Schrotz-King P, Tournigand C, Tran Van Nhieu J, Yamada T, Zimmermann J, Benes V, Kloor M, Ulrich CM, von Knebel Doeberitz M, Sobhani I , Bork P",Potential of fecal microbiota for early-stage detection of colorectal cancer,Molecular systems biology,2014,"cancer screening, colorectal cancer, fecal biomarkers, human gut microbiome, metagenomics",Experiment 1,France,Homo sapiens,Feces,UBERON:0001988,Colorectal carcinoma,EFO:1001951,Neoplasia-free,CRC patients,patients referred for colonoscopy that had cancerous tumors,61,53,none,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.1,TRUE,NA,NA,"age,body mass index,sex",NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:595/2/NA,Study 595,"cross-sectional observational, not case-control",25432777,10.15252/msb.20145645,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4299606/,"Zeller G, Tap J, Voigt AY, Sunagawa S, Kultima JR, Costea PI, Amiot A, Böhm J, Brunetti F, Habermann N, Hercog R, Koch M, Luciani A, Mende DR, Schneider MA, Schrotz-King P, Tournigand C, Tran Van Nhieu J, Yamada T, Zimmermann J, Benes V, Kloor M, Ulrich CM, von Knebel Doeberitz M, Sobhani I , Bork P",Potential of fecal microbiota for early-stage detection of colorectal cancer,Molecular systems biology,2014,"cancer screening, colorectal cancer, fecal biomarkers, human gut microbiome, metagenomics",Experiment 2,France,Homo sapiens,Feces,UBERON:0001988,Colorectal carcinoma,EFO:1001951,Adenoma patients,CRC patients,patients referred for colonoscopy that had cancerous tumors,42,53,none,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.1,TRUE,NA,NA,"age,body mass index,sex",NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:595/3/NA,Study 595,"cross-sectional observational, not case-control",25432777,10.15252/msb.20145645,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4299606/,"Zeller G, Tap J, Voigt AY, Sunagawa S, Kultima JR, Costea PI, Amiot A, Böhm J, Brunetti F, Habermann N, Hercog R, Koch M, Luciani A, Mende DR, Schneider MA, Schrotz-King P, Tournigand C, Tran Van Nhieu J, Yamada T, Zimmermann J, Benes V, Kloor M, Ulrich CM, von Knebel Doeberitz M, Sobhani I , Bork P",Potential of fecal microbiota for early-stage detection of colorectal cancer,Molecular systems biology,2014,"cancer screening, colorectal cancer, fecal biomarkers, human gut microbiome, metagenomics",Experiment 3,France,Homo sapiens,Feces,UBERON:0001988,Colorectal carcinoma,EFO:1001951,Neoplasia free,Adenoma patients,patients referred for colonoscopy that had cancerous tumors,61,42,none,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.1,TRUE,NA,NA,"age,body mass index,sex",NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:595/4/NA,Study 595,"cross-sectional observational, not case-control",25432777,10.15252/msb.20145645,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4299606/,"Zeller G, Tap J, Voigt AY, Sunagawa S, Kultima JR, Costea PI, Amiot A, Böhm J, Brunetti F, Habermann N, Hercog R, Koch M, Luciani A, Mende DR, Schneider MA, Schrotz-King P, Tournigand C, Tran Van Nhieu J, Yamada T, Zimmermann J, Benes V, Kloor M, Ulrich CM, von Knebel Doeberitz M, Sobhani I , Bork P",Potential of fecal microbiota for early-stage detection of colorectal cancer,Molecular systems biology,2014,"cancer screening, colorectal cancer, fecal biomarkers, human gut microbiome, metagenomics",Experiment 4,France,Homo sapiens,Feces,UBERON:0001988,Colorectal carcinoma,EFO:1001951,Neoplasia free control,CRC,patients referred for colonoscopy that had cancerous tumors,88,53,none,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.1,TRUE,NA,NA,"age,body mass index,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:596/1/NA,Study 596,time series / longitudinal observational,25058515,10.1371/journal.ppat.1004262,https://pubmed.ncbi.nlm.nih.gov/25058515/,"Liu CM, Osborne BJ, Hungate BA, Shahabi K, Huibner S, Lester R, Dwan MG, Kovacs C, Contente-Cuomo TL, Benko E, Aziz M, Price LB , Kaul R",The semen microbiome and its relationship with local immunology and viral load in HIV infection,PLoS pathogens,2014,NA,Experiment 1,Canada,Homo sapiens,Semen,UBERON:0001968,HIV infection,EFO:0000764,HIV-uninfected men,HIV-infected men,MSM with HIV infection,22,27,6 months.,16S,3456,Roche454,ANOVA,0.05,FALSE,NA,age,NA,NA,decreased,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:597/1/NA,Study 597,"cross-sectional observational, not case-control",31869338,10.1371/journal.pone.0225622,https://pubmed.ncbi.nlm.nih.gov/31869338/,"Cram JA, Fiore-Gartland AJ, Srinivasan S, Karuna S, Pantaleo G, Tomaras GD, Fredricks DN , Kublin JG",Human gut microbiota is associated with HIV-reactive immunoglobulin at baseline and following HIV vaccination,PloS one,2019,NA,Experiment 1,United States of America,Homo sapiens,Mucosa of rectum,UBERON:0003346,Response to vaccine,EFO:0004645,healthy controls,Vaccinated participants,Participants who were vaccinated,16,20,NA,16S,34,Roche454,Logistic Regression,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:598/1/NA,Study 598,case-control,28743816,10.1128/mBio.00996-17,https://pubmed.ncbi.nlm.nih.gov/28743816/,"Liu CM, Prodger JL, Tobian AAR, Abraham AG, Kigozi G, Hungate BA, Aziz M, Nalugoda F, Sariya S, Serwadda D, Kaul R, Gray RH , Price LB",Penile Anaerobic Dysbiosis as a Risk Factor for HIV Infection,mBio,2017,"anaerobes, cytokines, foreskin inflammation, human immunodeficiency virus, penile microbiome, susceptibility",Experiment 1,Uganda,Homo sapiens,Skin of penis,UBERON:0001331,HIV infection,EFO:0000764,HIV seronegative,HIV seroconverted,HIV-infected trial participants who were randomized to the delayed circumcision arm of the trial and remained uncircumcised who seroconverted during the trial,136,46,24 months.,16S,34,Illumina,PERMANOVA,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:600/1/NA,Study 600,case-control,29501802,10.1016/j.bbi.2018.02.016,NA,"Qian Y, Yang X, Xu S, Wu C, Song Y, Qin N, Chen SD , Xiao Q",Alteration of the fecal microbiota in Chinese patients with Parkinson's disease,"Brain, behavior, and immunity",2018,"16S rRNA gene, Gut microbiota, Neurodegenerative disorder",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Healthy controls,Participants with Parkinson's Disease,All PD patients eligible for this study were diagnosed with PD according to the UK Brain Bank criteria. Patients with IBS were excluded.,45,45,Participants taking antibiotics or probiotic supplements within the three months prior to sample collection.,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,"age,body mass index,constipation,sex",NA,increased,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:601/2/NA,Study 601,case-control,32844199,10.1093/brain/awaa201,NA,"Qian Y, Yang X, Xu S, Huang P, Li B, Du J, He Y, Su B, Xu LM, Wang L, Huang R, Chen S , Xiao Q",Gut metagenomics-derived genes as potential biomarkers of Parkinson's disease,Brain : a journal of neurology,2020,"Parkinson’s disease, biomarker, gut microbiota, metagenome, shotgun",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Healthy controls without any form of Parkinson's Disease,Participants with idiopathic Parkinson's Disease,All Parkinson’s disease patients eligible for this study were diagnosed with idiopathic Parkinson’s disease according to the UK Brain Bank criteria.,75,78,Antibiotic use within 3 months prior to sample collection.,16S,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,"age,body mass index,life style,sex",NA,NA,increased,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:602/1/NA,Study 602,case-control,21737778,https://doi.org/10.1152%2Fajpgi.00154.2011,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3220325/,"Carroll IM, Ringel-Kulka T, Keku TO, Chang YH, Packey CD, Sartor RB , Ringel Y",Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome,American journal of physiology. Gastrointestinal and liver physiology,2011,NA,Experiment 1,United States of America,Homo sapiens,"Feces,Colonic mucosa","UBERON:0001988,UBERON:0000317",Irritable bowel syndrome,EFO:0000555,Healthy Control,IBS-D,Individual who have been diagnosed with diarrhea-predominant Irritable bowel syndrome(IBS-D),21,16,2 Months prior to the study.,PCR,NA,Non-quantitative PCR,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:603/1/NA,Study 603,"case-control,meta-analysis",33947803,10.1128/mSystems.00112-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8269207/,"Jiang P, Wu S, Luo Q, Zhao XM , Chen WH",Metagenomic Analysis of Common Intestinal Diseases Reveals Relationships among Microbial Signatures and Powers Multidisease Diagnostic Models,mSystems,2021,"gut dysbiosis, human microbiome, intestinal disease, machine learning-based disease classification, noninvasive disease diagnosis",Experiment 1,NA,Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,Non disease controls,CRC patients,Patients diagnosed with colorectal cancer,632,354,NA,16S,NA,NA,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,"age,body mass index,sex",NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:604/1/NA,Study 604,case-control,32566740,10.1038/s41531-020-0112-6,NA,"Wallen ZD, Appah M, Dean MN, Sesler CL, Factor SA, Molho E, Zabetian CP, Standaert DG , Payami H",Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens,NPJ Parkinson's disease,2020,"Genomics, Parkinson's disease",Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Healthy controls free of neurological disease,Participants with Parkinson's Disease,"Dataset 1. Participants with Parkinson's Disease, diagnosed by a movement disorder specialist using UK Brain Bank criteria.",136,212,NA,16S,4,Illumina,Kruskall-Wallis,0.05,TRUE,NA,NA,"age,alcohol drinking,body mass index,constipation,geographic area,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:604/2/NA,Study 604,case-control,32566740,10.1038/s41531-020-0112-6,NA,"Wallen ZD, Appah M, Dean MN, Sesler CL, Factor SA, Molho E, Zabetian CP, Standaert DG , Payami H",Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens,NPJ Parkinson's disease,2020,"Genomics, Parkinson's disease",Experiment 2,United States of America,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Healthy control free of neurological disease.,Participants with Parkinson's Disease,Dataset 2. PD was diagnosed by a movement disorder specialist using UK Brain Bank criteria,184,323,NA,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,"age,alcohol drinking,body mass index,constipation,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:605/1/NA,Study 605,case-control,31248424,10.1186/s12974-019-1528-y,NA,"Lin CH, Chen CC, Chiang HL, Liou JM, Chang CM, Lu TP, Chuang EY, Tai YC, Cheng C, Lin HY , Wu MS",Altered gut microbiota and inflammatory cytokine responses in patients with Parkinson's disease,Journal of neuroinflammation,2019,"Cytokines, Dysbiosis, Gut microbiome, Neuroinflammation, Parkinson’s disease",Experiment 1,Japan,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Healthy controls without Parkinson's disease,Participants with Parkinson's Disease,PD was diagnosed according to the United Kingdom PD Society Brain Bank clinical diagnostic criteria.,77,80,Individuals currently taking antibiotics or probiotic supplements within 3 months of sample collection,16S,34,Illumina,LEfSe,0.05,NA,2,"age,sex","age,diet,sex",NA,increased,unchanged,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:605/2/NA,Study 605,case-control,31248424,10.1186/s12974-019-1528-y,NA,"Lin CH, Chen CC, Chiang HL, Liou JM, Chang CM, Lu TP, Chuang EY, Tai YC, Cheng C, Lin HY , Wu MS",Altered gut microbiota and inflammatory cytokine responses in patients with Parkinson's disease,Journal of neuroinflammation,2019,"Cytokines, Dysbiosis, Gut microbiome, Neuroinflammation, Parkinson’s disease",Experiment 2,Japan,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Participants with Parkinson's Disease with non-tremor subtypes,Participants with Parkinson's Disease with tremor subtypes,Participants with Parkinson's Disease with tremor subtypes.,33,47,Individuals currently taking antibiotics or probiotic supplements within 3 months of sample collection,16S,34,Illumina,LEfSe,0.05,NA,2,"age,sex","age,diet,sex",NA,increased,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:606/1/NA,Study 606,case-control,31440136,10.3389/fnins.2019.00839,NA,"Gorecki AM, Preskey L, Bakeberg MC, Kenna JE, Gildenhuys C, MacDougall G, Dunlop SA, Mastaglia FL, Akkari PA, Koengten F , Anderton RS",Altered Gut Microbiome in Parkinson's Disease and the Influence of Lipopolysaccharide in a Human α-Synuclein Over-Expressing Mouse Model,Frontiers in neuroscience,2019,"Gammaproteobacteria, Parkinson’s disease, Thy1-αSyn, gastrointestinal, lipopolysaccharide, microbiome",Experiment 1,Australia,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Healthy controls,Participants with idiopathic Parkinson's Disease and mild symptoms.,"All patients were confirmed to have idiopathic Parkinson’s disease by a movement disorders neurologist, in accordance with the United Kingdom Brain Bank criteria and mild symptoms.",7,7,No history of antibiotic or non-steroidal anti-inflammatory drug use in the previous 3 months.,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:606/2/NA,Study 606,case-control,31440136,10.3389/fnins.2019.00839,NA,"Gorecki AM, Preskey L, Bakeberg MC, Kenna JE, Gildenhuys C, MacDougall G, Dunlop SA, Mastaglia FL, Akkari PA, Koengten F , Anderton RS",Altered Gut Microbiome in Parkinson's Disease and the Influence of Lipopolysaccharide in a Human α-Synuclein Over-Expressing Mouse Model,Frontiers in neuroscience,2019,"Gammaproteobacteria, Parkinson’s disease, Thy1-αSyn, gastrointestinal, lipopolysaccharide, microbiome",Experiment 2,Australia,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Participants with mild PD,Participants with severe PD,"All patients were confirmed to have idiopathic Parkinson’s disease by a movement disorders neurologist, in accordance with the United Kingdom Brain Bank criteria and severe symptoms.",7,7,No history of antibiotic or non-steroidal anti-inflammatory drug use in the previous 3 months.,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:607/1/NA,Study 607,case-control,32517799,10.1186/s12915-020-00775-7,NA,"Baldini F, Hertel J, Sandt E, Thinnes CC, Neuberger-Castillo L, Pavelka L, Betsou F, Krüger R , Thiele I",Parkinson's disease-associated alterations of the gut microbiome predict disease-relevant changes in metabolic functions,BMC biology,2020,"Computational modelling, Gut microbiome, Metabolic modelling, Parkinson’s disease, Transsulfuration pathway",Experiment 1,Luxembourg,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Healthy controls,Participants with typical PD,"PD patients were defined as typical PD, according to the inclusion criteria by the United Kingdom Parkinson’s Disease Society Brain Bank Clinical Diagnostic Criteria.",162,147,6 Months,16S,34,Illumina,Linear Regression,0.05,TRUE,NA,"age,sex","age,body mass index,constipation,sex",NA,unchanged,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:608/1/NA,Study 608,meta-analysis,NA,10.5281/zenodo.7544549,https://doi.org/10.5281/zenodo.7544549,NA,Body site-typical microbiome signatures for children,NA,NA,NA,Experiment 1,"Italy,United States of America",Homo sapiens,Oral cavity,UBERON:0000167,Health study participation,EFO:0010130,none,healthy child oral 50% up,NA,NA,81,NA,16S,NA,Illumina,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:608/2/NA,Study 608,meta-analysis,NA,10.5281/zenodo.7544549,https://doi.org/10.5281/zenodo.7544549,NA,Body site-typical microbiome signatures for children,NA,NA,NA,Experiment 2,"Bangladesh,China,Estonia,Finland,Germany,India,Ireland,Italy,Luxembourg,Netherlands,Russian Federation,Spain,Sweden,United Kingdom,United Republic of Tanzania,United States of America",Homo sapiens,Feces,UBERON:0001988,Health study participation,EFO:0010130,none,healthy child stool 50% up,NA,NA,3375,NA,16S,NA,Illumina,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:609/1/NA,Study 609,case-control,33362375,10.3748/wjg.v26.i45.7173,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7723673/,"Sun XZ, Zhao DY, Zhou YC, Wang QQ, Qin G , Yao SK",Alteration of fecal tryptophan metabolism correlates with shifted microbiota and may be involved in pathogenesis of colorectal cancer,World journal of gastroenterology,2020,"Colorectal adenoma, Colorectal cancer, Indoles, Kynurenine, Microbiota, Tryptophan metabolism",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,Healthy Controls (HC),CRC,Patients with colorectal neoplastic lesions where tumors were removed and pathologically diagnosed with adenomatous polyp or colorectal adenocarcinoma; ages of participants ranged from 18-80.,38,79,4 weeks,16S,34,Illumina,LEfSe,0.05,FALSE,2,"age,body mass index,sex",NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:610/1/NA,Study 610,case-control,22315951,10.1111/j.1365-2036.2012.05007.x,NA,"Chassard C, Dapoigny M, Scott KP, Crouzet L, Del'homme C, Marquet P, Martin JC, Pickering G, Ardid D, Eschalier A, Dubray C, Flint HJ , Bernalier-Donadille A",Functional dysbiosis within the gut microbiota of patients with constipated-irritable bowel syndrome,Alimentary pharmacology & therapeutics,2012,NA,Experiment 1,France,Homo sapiens,Feces,UBERON:0001988,Irritable bowel syndrome,EFO:0000555,Healthy Control,constipated-IBS,"The 14 women IBS patients (age range: 36–59, mean age: 48) included in this study fulfilled the Rome II criteria for IBS. They were classified as IBS with constipation (C-IBS) by a questionnaire following the Rome II subgrouping criteria which have been recognized as valid also in the Rome III criteria.",12,14,"Exclusion criteria included organic intestinal disease, other systemic disease, previous abdominal surgery, lactation, pregnancy, dementia or inadequate cooperative capability and antibiotic therapy during the previous 2 months.",16S,NA,NA,T-Test,0.05,FALSE,NA,sex,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:611/1/NA,Study 611,case-control,31281534,10.7150/thno.35186,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6592169/,"Yang Y, Misra BB, Liang L, Bi D, Weng W, Wu W, Cai S, Qin H, Goel A, Li X , Ma Y",Integrated microbiome and metabolome analysis reveals a novel interplay between commensal bacteria and metabolites in colorectal cancer,Theranostics,2019,"biomarkers, colorectal cancer, gut, metabolomics, microbiome",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,healthy controls,Colorectal Cancer patients,patients diagnosed with colorectal cancer,50,50,2 months,16S,34,Illumina,LEfSe,0.05,TRUE,4,NA,NA,NA,increased,increased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:612/1/NA,Study 612,"case-control,meta-analysis",27171425,10.1371/journal.pone.0155362,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4865240/,"Vogtmann E, Hua X, Zeller G, Sunagawa S, Voigt AY, Hercog R, Goedert JJ, Shi J, Bork P , Sinha R",Colorectal Cancer and the Human Gut Microbiome: Reproducibility with Whole-Genome Shotgun Sequencing,PloS one,2016,NA,Experiment 1,"United States of America,France",Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,control subjects,CRC cases,pre treatment colorectal cancer cases,94,47,NA,16S,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,"body mass index,sex","age,body mass index,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:613/1/NA,Study 613,case-control,30065719,10.3389/fmicb.2018.01607,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6057110/,"Deng X, Li Z, Li G, Li B, Jin X , Lyu G",Comparison of Microbiota in Patients Treated by Surgery or Chemotherapy by 16S rRNA Sequencing Reveals Potential Biomarkers for Colorectal Cancer Therapy,Frontiers in microbiology,2018,"16S rRNA sequencing, bacterial diversity, chemotherapy, colorectal cancer, surgery",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,healthy individuals,CRC patients,patients diagnosed with colorectal cancer,33,31,NA,16S,45,Illumina,PERMANOVA,0.001,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:614/1/NA,Study 614,case-control,31611994,10.3892/ol.2019.10841,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6781660/,"Sheng Q, Du H, Cheng X, Cheng X, Tang Y, Pan L, Wang Q , Lin J",Characteristics of fecal gut microbiota in patients with colorectal cancer at different stages and different sites,Oncology letters,2019,"16S rRNA sequencing, bioinformatics analysis, colorectal cancer, gut microbiota",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,Healthy Controls,CRC,"The CRC patients were selected according to the criteria of no other health complications, no family history of CRC or recurrence of CRC, and no radiotherapy and chemotherapy prior to surgical resection. Patients were then classified according to postoperative clinical data using the tumor-node-metastasis (TNM) staging system for malignant tumors.",30,67,3 months,16S,34,Illumina,"Kruskall-Wallis,Mann-Whitney (Wilcoxon)",0.05,FALSE,NA,"age,sex",NA,NA,increased,unchanged,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:615/1/NA,Study 615,"cross-sectional observational, not case-control",31699813,10.1136/annrheumdis-2019-215743,NA,"Kishikawa T, Maeda Y, Nii T, Motooka D, Matsumoto Y, Matsushita M, Matsuoka H, Yoshimura M, Kawada S, Teshigawara S, Oguro E, Okita Y, Kawamoto K, Higa S, Hirano T, Narazaki M, Ogata A, Saeki Y, Nakamura S, Inohara H, Kumanogoh A, Takeda K , Okada Y",Metagenome-wide association study of gut microbiome revealed novel aetiology of rheumatoid arthritis in the Japanese population,Annals of the rheumatic diseases,2020,"autoimmune diseases, gene polymorphism, rheumatoid arthritis",Experiment 1,Japan,Homo sapiens,Feces,UBERON:0001988,Rheumatoid arthritis,EFO:0000685,healthy controls,rheumatoid arthritis,Patients with RA,42,82,12 weeks,WMS,NA,Illumina,PERMANOVA,0.05,TRUE,NA,"age,sex",NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:616/1/NA,Study 616,randomized controlled trial,32692788,10.4193/Rhin20.055,NA,"Cherian LM, Bassiouni A, Cooksley CM, Vreugde S, Wormald PJ , Psaltis AJ","The clinical outcomes of medical therapies in chronic rhinosinusitis are independent of microbiomic outcomes: a double-blinded, randomised placebo-controlled trial",Rhinology,2020,NA,Experiment 1,Finland,Homo sapiens,Middle nasal meatus,UBERON:0015219,Chronic rhinosinusitis,EFO:1000024,Healthy controls-without polyps,Patients with chronic rhinosinusitis,"CRS patients diagnosed as per the criteria outlined in the Euro-
pean Position Paper on Rhinosinusitis and Nasal Polyps (EPOS)
2012",50,50,"Patients who were on any oral steroid, topical steroid or oral antibiotic in a 
6-weeks period prior to enrollment, below the age of 18, had a history of  
sinus surgery, documented doxycycline or steroid allergy, 
using CYP450 inhibitors, immunosuppression, uncontrolled 
diabetes, were all excluded.",16S,34,Illumina,ANOVA,0.05,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:617/1/NA,Study 617,prospective cohort,28112736,10.1038/nm.4272,https://www.nature.com/articles/nm.4272,"Chu DM, Ma J, Prince AL, Antony KM, Seferovic MD , Aagaard KM",Maturation of the infant microbiome community structure and function across multiple body sites and in relation to mode of delivery,Nature medicine,2017,NA,Experiment 1,United States of America,Homo sapiens,"Feces,Saliva,Anterior naris,Posterior fornix of vagina,Epithelium of elbow","UBERON:0001988,UBERON:0001836,UBERON:2001427,UBERON:0016486,UBERON:0003229",Microbiome,EFO:0004982,Maternal samples taken at delivery.,Neonatal samples taken at delivery,Neonatal samples taken at delivery,82,82,NA,16S,345,Roche454,LEfSe,0.05,FALSE,4,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:617/2/NA,Study 617,prospective cohort,28112736,10.1038/nm.4272,https://www.nature.com/articles/nm.4272,"Chu DM, Ma J, Prince AL, Antony KM, Seferovic MD , Aagaard KM",Maturation of the infant microbiome community structure and function across multiple body sites and in relation to mode of delivery,Nature medicine,2017,NA,Experiment 2,United States of America,Homo sapiens,"Feces,Saliva,Anterior naris,Posterior fornix of vagina,Epithelium of elbow","UBERON:0001988,UBERON:0001836,UBERON:2001427,UBERON:0016486,UBERON:0003229",Microbiome,EFO:0004982,Maternal samples taken at 6  weeks postpartum,Infant samples taken at 6 weeks postpartum,Infant samples taken at 6 weeks postpartum,60,60,NA,16S,345,Roche454,LEfSe,0.05,FALSE,4,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:618/1/NA,Study 618,case-control,32690030,10.1186/s12877-020-01644-2,NA,"Stadlbauer V, Engertsberger L, Komarova I, Feldbacher N, Leber B, Pichler G, Fink N, Scarpatetti M, Schippinger W, Schmidt R , Horvath A","Dysbiosis, gut barrier dysfunction and inflammation in dementia: a pilot study",BMC geriatrics,2020,"Butyrate producer, Cognitive function, Diversity, Gut barrier, Inflammation, Microbiome",Experiment 1,Austria,Homo sapiens,Feces,UBERON:0001988,Dementia,MONDO:0001627,"Control, mild, and moderate dementia",Severe dementia,MMSE 0-9: The Mini-Mental State Examination [19] and the clock drawing test [20] were used to quantify cognitive function. We classified cognitive dysfunction according to the German S3-guideline on Dementia 2016 as MMSE 0–9: severe; MMSE 10–19: moderate; MMSE 20–26: mild; MMSE 27–30: no dementia [21].,NA,NA,4 weeks,16S,12,Illumina,LEfSe,0.05,FALSE,NA,"age,sex",NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:618/2/NA,Study 618,case-control,32690030,10.1186/s12877-020-01644-2,NA,"Stadlbauer V, Engertsberger L, Komarova I, Feldbacher N, Leber B, Pichler G, Fink N, Scarpatetti M, Schippinger W, Schmidt R , Horvath A","Dysbiosis, gut barrier dysfunction and inflammation in dementia: a pilot study",BMC geriatrics,2020,"Butyrate producer, Cognitive function, Diversity, Gut barrier, Inflammation, Microbiome",Experiment 2,Austria,Homo sapiens,Feces,UBERON:0001988,Dementia,MONDO:0001627,Controls without cognitive impairments,Patients with dementia,"Participants with any level of dementia (mild, moderate, severe).",18,23,4 weeks,16S,12,Illumina,LEfSe,0.05,FALSE,NA,"age,sex",NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:618/3/NA,Study 618,case-control,32690030,10.1186/s12877-020-01644-2,NA,"Stadlbauer V, Engertsberger L, Komarova I, Feldbacher N, Leber B, Pichler G, Fink N, Scarpatetti M, Schippinger W, Schmidt R , Horvath A","Dysbiosis, gut barrier dysfunction and inflammation in dementia: a pilot study",BMC geriatrics,2020,"Butyrate producer, Cognitive function, Diversity, Gut barrier, Inflammation, Microbiome",Experiment 3,Austria,Homo sapiens,Feces,UBERON:0001988,Dementia,MONDO:0001627,"control, mild, and severe dementia",moderate dementia,MMSE 10-19: The Mini-Mental State Examination [19] and the clock drawing test [20] were used to quantify cognitive function. We classified cognitive dysfunction according to the German S3-guideline on Dementia 2016 as MMSE 0–9: severe; MMSE 10–19: moderate; MMSE 20–26: mild; MMSE 27–30: no dementia [21].,NA,NA,4 weeks,16S,12,Illumina,LEfSe,0.05,FALSE,NA,"age,sex",NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:618/4/NA,Study 618,case-control,32690030,10.1186/s12877-020-01644-2,NA,"Stadlbauer V, Engertsberger L, Komarova I, Feldbacher N, Leber B, Pichler G, Fink N, Scarpatetti M, Schippinger W, Schmidt R , Horvath A","Dysbiosis, gut barrier dysfunction and inflammation in dementia: a pilot study",BMC geriatrics,2020,"Butyrate producer, Cognitive function, Diversity, Gut barrier, Inflammation, Microbiome",Experiment 4,Austria,Homo sapiens,Feces,UBERON:0001988,Dementia,MONDO:0001627,"control, moderate, and severe dementia",mild dementia,MMSE 20-26: The Mini-Mental State Examination [19] and the clock drawing test [20] were used to quantify cognitive function. We classified cognitive dysfunction according to the German S3-guideline on Dementia 2016 as MMSE 0–9: severe; MMSE 10–19: moderate; MMSE 20–26: mild; MMSE 27–30: no dementia [21].,NA,NA,4 weeks,16S,12,Illumina,LEfSe,0.05,FALSE,NA,"age,sex",NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:619/1/NA,Study 619,"cross-sectional observational, not case-control",20566857,10.1073/pnas.1002601107,NA,"Dominguez-Bello MG, Costello EK, Contreras M, Magris M, Hidalgo G, Fierer N , Knight R",Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns,Proceedings of the National Academy of Sciences of the United States of America,2010,NA,Experiment 1,Venezuela,Homo sapiens,"Mucosa of oral region,Vagina,Skin of forehead,Skin of forearm","UBERON:0003343,UBERON:0000996,UBERON:0016475,UBERON:0003403",Cesarean section,EFO:0009636,vaginal delivery (Va),C-section (Cesarean section),NA,4,5,NA,16S,2,Roche454,ANOSIM,0.001,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:620/1/NA,Study 620,prospective cohort,31609493,doi:10.1111/jgh.14868,NA,"Burt AD, Fujishiro M, Hattori S, Hirooka Y, Honda T, Nakamura M, Singh R, Yamamoto K, Yamamura T, Zorron Cheng Tao Pu L",Microbiota profile is different for early and invasive colorectal cancer and is consistent throughout the colon,Journal of Gastroenterology and Hepatology,2020,"colonoscopy, colorectal neoplasms, fusobacterium nucleatum, gastrointestinal microbiome, microbiota",Experiment 1,Japan,Homo sapiens,Colon,UBERON:0001155,Colorectal cancer,EFO:0005842,Early cancer group,Invasive cancer group,Patients undergoing ESD procedure for colorectal cancer,11,14,NA,16S,34,Illumina,Welch's T-Test,0.05,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:621/1/NA,Study 621,randomized controlled trial,32770859,10.1111/apt.16013,NA,"Church TR, Demmer RT, Knights D, Meyer KA, Onyeaghala GC, Prizment AE, Sadowsky MJ, Shaukat A, Staley C, Straka RJ, Thyagarajan B, Vivek S",Randomised clinical study: oral aspirin 325 mg daily vs placebo alters gut microbial composition and bacterial taxa associated with colorectal cancer risk,Ailmentary Pharmacology and Theraputics,2020,"colorectal cancer, aspirin",Experiment 1,United States of America,Homo sapiens,Colon,UBERON:0001155,Colorectal cancer,EFO:0005842,Placebo,Aspirin,"Experimental group took 325 mg daily aspirin over six weeks, with additional six weeks of washout",20,30,3 months,16S,4,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:621/2/NA,Study 621,randomized controlled trial,32770859,10.1111/apt.16013,NA,"Church TR, Demmer RT, Knights D, Meyer KA, Onyeaghala GC, Prizment AE, Sadowsky MJ, Shaukat A, Staley C, Straka RJ, Thyagarajan B, Vivek S",Randomised clinical study: oral aspirin 325 mg daily vs placebo alters gut microbial composition and bacterial taxa associated with colorectal cancer risk,Ailmentary Pharmacology and Theraputics,2020,"colorectal cancer, aspirin",Experiment 2,United States of America,Homo sapiens,Colon,UBERON:0001155,Colorectal cancer,EFO:0005842,Placebo,Aspirin,"Experimental group took 325 mg daily aspirin over six weeks, with additional six weeks of washout",20,30,3 months,16S,4,Illumina,Mixed-Effects Regression,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:622/1/NA,Study 622,"cross-sectional observational, not case-control",26397137,10.18632/oncotarget.5166,NA,"Yu YN, Yu TC, Zhao HJ, Sun TT, Chen HM, Chen HY, An HF, Weng YR, Yu J, Li M, Qin WX, Ma X, Shen N, Hong J , Fang JY",Berberine may rescue Fusobacterium nucleatum-induced colorectal tumorigenesis by modulating the tumor microenvironment,Oncotarget,2015,"Fusobacterium nucleatum, berberine, colorectal tumorigenesis, intestinal microbiota, tumor-immune cytokine",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,Negative control group,CRA and CRC groups,Patients with CRA (colorectal adenoma) or CRC (colorectal carcinoma) confirmed by colonoscopy and pathological examination,52,89,6 months,16S,123,Roche454,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:622/2/NA,Study 622,"cross-sectional observational, not case-control",26397137,10.18632/oncotarget.5166,NA,"Yu YN, Yu TC, Zhao HJ, Sun TT, Chen HM, Chen HY, An HF, Weng YR, Yu J, Li M, Qin WX, Ma X, Shen N, Hong J , Fang JY",Berberine may rescue Fusobacterium nucleatum-induced colorectal tumorigenesis by modulating the tumor microenvironment,Oncotarget,2015,"Fusobacterium nucleatum, berberine, colorectal tumorigenesis, intestinal microbiota, tumor-immune cytokine",Experiment 2,China,Mus musculus,Intestine,UBERON:0000160,Colorectal cancer,EFO:0005842,Control (male C57BL/6-APCMin/+ and male wild-type C57BL/6),Fn Mice,Mice administered with F. nucleatum (Fn),10,10,None,16S,123,Roche454,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:622/3/NA,Study 622,"cross-sectional observational, not case-control",26397137,10.18632/oncotarget.5166,NA,"Yu YN, Yu TC, Zhao HJ, Sun TT, Chen HM, Chen HY, An HF, Weng YR, Yu J, Li M, Qin WX, Ma X, Shen N, Hong J , Fang JY",Berberine may rescue Fusobacterium nucleatum-induced colorectal tumorigenesis by modulating the tumor microenvironment,Oncotarget,2015,"Fusobacterium nucleatum, berberine, colorectal tumorigenesis, intestinal microbiota, tumor-immune cytokine",Experiment 3,China,Mus musculus,Intestine,UBERON:0000160,Colorectal cancer,EFO:0005842,DMH Treated Mice,Fn+DMH Treated Mice,Mice treated with Fn and DMH,10,10,None,16S,123,Roche454,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:622/4/NA,Study 622,"cross-sectional observational, not case-control",26397137,10.18632/oncotarget.5166,NA,"Yu YN, Yu TC, Zhao HJ, Sun TT, Chen HM, Chen HY, An HF, Weng YR, Yu J, Li M, Qin WX, Ma X, Shen N, Hong J , Fang JY",Berberine may rescue Fusobacterium nucleatum-induced colorectal tumorigenesis by modulating the tumor microenvironment,Oncotarget,2015,"Fusobacterium nucleatum, berberine, colorectal tumorigenesis, intestinal microbiota, tumor-immune cytokine",Experiment 4,China,Mus musculus,Intestine,UBERON:0000160,Colorectal cancer,EFO:0005842,Fn+DMH Treated Mice,BBR+Fn+DMH Treated Mice,"Mice treated with BBR, Fn and DMH",10,10,None,16S,123,Roche454,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:623/1/NA,Study 623,case-control,28753429,10.1016/j.cell.2017.07.008,NA,"Yu T, Guo F, Yu Y, Sun T, Ma D, Han J, Qian Y, Kryczek I, Sun D, Nagarsheth N, Chen Y, Chen H, Hong J, Zou W , Fang JY",Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy,Cell,2017,"Colorectal cancer, F.nucleatum, Toll-like receptor, autophagy, chemoresistance, miRNA, recurrence",Experiment 1,China,Homo sapiens,Intestine,UBERON:0000160,Colorectal cancer,EFO:0005842,Patients without CRC recurrence,Patients with CRC recurrence,Patient tissues with colorectal cancer recurrence,16,15,6 months,16S,123,Roche454,LEfSe,NA,NA,3.5,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:624/2/NA,Study 624,case-control,34584098,10.1038/s41467-021-25965-x,NA,"Okumura S, Konishi Y, Narukawa M, Sugiura Y, Yoshimoto S, Arai Y, Sato S, Yoshida Y, Tsuji S, Uemura K, Wakita M, Matsudaira T, Matsumoto T, Kawamoto S, Takahashi A, Itatani Y, Miki H, Takamatsu M, Obama K, Takeuchi K, Suematsu M, Ohtani N, Fukunaga Y, Ueno M, Sakai Y, Nagayama S , Hara E",Gut bacteria identified in colorectal cancer patients promote tumourigenesis via butyrate secretion,Nature communications,2021,NA,Experiment 2,Japan,Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,Healthy Individuals,Patients with early CRC,Patients with early colorectal cancer,129,136,1 Month,16S,12,Illumina,"Kruskall-Wallis,Mann-Whitney (Wilcoxon)",0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:624/3/NA,Study 624,case-control,34584098,10.1038/s41467-021-25965-x,NA,"Okumura S, Konishi Y, Narukawa M, Sugiura Y, Yoshimoto S, Arai Y, Sato S, Yoshida Y, Tsuji S, Uemura K, Wakita M, Matsudaira T, Matsumoto T, Kawamoto S, Takahashi A, Itatani Y, Miki H, Takamatsu M, Obama K, Takeuchi K, Suematsu M, Ohtani N, Fukunaga Y, Ueno M, Sakai Y, Nagayama S , Hara E",Gut bacteria identified in colorectal cancer patients promote tumourigenesis via butyrate secretion,Nature communications,2021,NA,Experiment 3,Japan,Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,Healthy Individuals,Patients with advanced CRC,Patients with early colorectal cancer,129,153,1 Month,16S,12,Illumina,"Mann-Whitney (Wilcoxon),Kruskall-Wallis",0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:624/4/NA,Study 624,case-control,34584098,10.1038/s41467-021-25965-x,NA,"Okumura S, Konishi Y, Narukawa M, Sugiura Y, Yoshimoto S, Arai Y, Sato S, Yoshida Y, Tsuji S, Uemura K, Wakita M, Matsudaira T, Matsumoto T, Kawamoto S, Takahashi A, Itatani Y, Miki H, Takamatsu M, Obama K, Takeuchi K, Suematsu M, Ohtani N, Fukunaga Y, Ueno M, Sakai Y, Nagayama S , Hara E",Gut bacteria identified in colorectal cancer patients promote tumourigenesis via butyrate secretion,Nature communications,2021,NA,Experiment 4,Japan,Homo sapiens,Feces,UBERON:0001988,Surgical resection,EFO:0009744,Before resection,After resection,Patients post surgical resection of Cohort-1 CRC specimens,380,380,1 Month,16S,12,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:625/1/NA,Study 625,"cross-sectional observational, not case-control",34442687,10.3390/microorganisms9081608,https://pubmed.ncbi.nlm.nih.gov/34442687/,"Lewis CR, Bonham KS, McCann SH, Volpe AR, D'Sa V, Naymik M, De Both MD, Huentelman MJ, Lemery-Chalfant K, Highlander SK, Deoni SCL , Klepac-Ceraj V",Family SES Is Associated with the Gut Microbiome in Infants and Children,Microorganisms,2021,"childhood, infant, microbiome, socioeconomic status, stress",Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Socioeconomic status,EXO:0000114,lower socioeconomic status,Increasing socioeconomic status,588 Metagenomics from infants and children of high and low socioeconomic families as continuous variables.,NA,NA,2 weeks,WMS,NA,Illumina,NA,0.05,NA,NA,NA,"age,delivery procedure,race,sex",NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:626/1/NA,Study 626,"cross-sectional observational, not case-control",34617511,10.7554/eLife.70349,https://pubmed.ncbi.nlm.nih.gov/34617511,"Ang QY, Alba DL, Upadhyay V, Bisanz JE, Cai J, Lee HL, Barajas E, Wei G, Noecker C, Patterson AD, Koliwad SK , Turnbaugh PJ",The East Asian gut microbiome is distinct from colocalized White subjects and connected to metabolic health,eLife,2021,"biogeography, ethnicity, human, human gut microbiome, infectious disease, metabolic syndrome, microbiology, mouse, multi-omics, obesity",Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Ethnic group,EFO:0001799,White (W),East Asian (EA),A balanced distribution of both lean and obese adults who identified as East Asians residing within the Bay area of San Fransisco.,24,22,Unspecified,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,decreased,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:627/1/NA,Study 627,"cross-sectional observational, not case-control",30641975,10.3390/microorganisms7010017,https://pubmed.ncbi.nlm.nih.gov/30641975/,"Bowyer RCE, Jackson MA, Le Roy CI, Ni Lochlainn M, Spector TD, Dowd JB , Steves CJ",Socioeconomic Status and the Gut Microbiome: A TwinsUK Cohort Study,Microorganisms,2019,"SES, microbiome, microbiota, sociobiome, socioeconomic status",Experiment 1,United Kingdom,Homo sapiens,Feces,UBERON:0001988,Socioeconomic status,EXO:0000114,"Higher SES (income= > £25,000)","lower SES (income<£25,000)","Lower socioeconomic status(SES) with higher deprivation by income <£25,000",457,342,Unspecified,16S,4,Illumina,edgeR,0.05,TRUE,NA,NA,"age,body mass index,diet",NA,decreased,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:628/1/NA,Study 628,"cross-sectional observational, not case-control",26859894,10.1371/journal.pone.0148952,https://pubmed.ncbi.nlm.nih.gov/26859894/,"Miller GE, Engen PA, Gillevet PM, Shaikh M, Sikaroodi M, Forsyth CB, Mutlu E , Keshavarzian A",Lower Neighborhood Socioeconomic Status Associated with Reduced Diversity of the Colonic Microbiota in Healthy Adults,PloS one,2016,NA,Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Socioeconomic status,EXO:0000114,High SES,Low SES,"44 healthy participants from low-income neighborhoods with a median annual income of $20,100 and a 35% unemployment rate and neighborhoods at the high end, with a median income of $129,570 and an unemployment rate under 5%).
(Income level as a continuous variable.)",44,NA,3 months,16S,NA,Roche454,"Linear Regression,Spearman Correlation",0.05,NA,NA,NA,"age,alcohol drinking,body mass index,race,sex,smoking status",NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:629/1/NA,Study 629,"cross-sectional observational, not case-control",26181352,10.1001/jamaoncol.2015.1377,NA,"Mima K, Sukawa Y, Nishihara R, Qian ZR, Yamauchi M, Inamura K, Kim SA, Masuda A, Nowak JA, Nosho K, Kostic AD, Giannakis M, Watanabe H, Bullman S, Milner DA, Harris CC, Giovannucci E, Garraway LA, Freeman GJ, Dranoff G, Chan AT, Garrett WS, Huttenhower C, Fuchs CS , Ogino S",Fusobacterium nucleatum and T Cells in Colorectal Carcinoma,JAMA oncology,2015,NA,Experiment 1,United States of America,Homo sapiens,Intestine,UBERON:0000160,Colorectal cancer,EFO:0005842,Tumor Tissue of Colorectal Cancer Cases,Adjacent Non-Tumor Tissue of Colorectal Cancer Cases,Both colon and rectal carcinomas were included on the basis of the colorectal continuum model. Patients were followed up until death or the end of follow-up.,558,558,None,16S,NA,RT-qPCR,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,"age,family history of cancer,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:630/1/NA,Study 630,case-control,31171880,10.1038/s41591-019-0458-7,NA,"Yachida S, Mizutani S, Shiroma H, Shiba S, Nakajima T, Sakamoto T, Watanabe H, Masuda K, Nishimoto Y, Kubo M, Hosoda F, Rokutan H, Matsumoto M, Takamaru H, Yamada M, Matsuda T, Iwasaki M, Yamaji T, Yachida T, Soga T, Kurokawa K, Toyoda A, Ogura Y, Hayashi T, Hatakeyama M, Nakagama H, Saito Y, Fukuda S, Shibata T , Yamada T",Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer,Nature medicine,2019,NA,Experiment 1,Japan,Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,healthy control (normal and a few polyps),stage I/II (SI/II),stage I and II CRCs,251,111,None specified,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.005,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:630/2/NA,Study 630,case-control,31171880,10.1038/s41591-019-0458-7,NA,"Yachida S, Mizutani S, Shiroma H, Shiba S, Nakajima T, Sakamoto T, Watanabe H, Masuda K, Nishimoto Y, Kubo M, Hosoda F, Rokutan H, Matsumoto M, Takamaru H, Yamada M, Matsuda T, Iwasaki M, Yamaji T, Yachida T, Soga T, Kurokawa K, Toyoda A, Ogura Y, Hayashi T, Hatakeyama M, Nakagama H, Saito Y, Fukuda S, Shibata T , Yamada T",Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer,Nature medicine,2019,NA,Experiment 2,Japan,Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,healthy control (normal and a few polyps),stage III/IV (SIII/IV),stage III and IV CRCs,251,74,None specified,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.005,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:630/3/NA,Study 630,case-control,31171880,10.1038/s41591-019-0458-7,NA,"Yachida S, Mizutani S, Shiroma H, Shiba S, Nakajima T, Sakamoto T, Watanabe H, Masuda K, Nishimoto Y, Kubo M, Hosoda F, Rokutan H, Matsumoto M, Takamaru H, Yamada M, Matsuda T, Iwasaki M, Yamaji T, Yachida T, Soga T, Kurokawa K, Toyoda A, Ogura Y, Hayashi T, Hatakeyama M, Nakagama H, Saito Y, Fukuda S, Shibata T , Yamada T",Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer,Nature medicine,2019,NA,Experiment 3,Japan,Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,healthy control (normal and a few polyps),S0,stage 0/pTis CRC (S0),251,73,None specified,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.005,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:630/4/NA,Study 630,case-control,31171880,10.1038/s41591-019-0458-7,NA,"Yachida S, Mizutani S, Shiroma H, Shiba S, Nakajima T, Sakamoto T, Watanabe H, Masuda K, Nishimoto Y, Kubo M, Hosoda F, Rokutan H, Matsumoto M, Takamaru H, Yamada M, Matsuda T, Iwasaki M, Yamaji T, Yachida T, Soga T, Kurokawa K, Toyoda A, Ogura Y, Hayashi T, Hatakeyama M, Nakagama H, Saito Y, Fukuda S, Shibata T , Yamada T",Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer,Nature medicine,2019,NA,Experiment 4,Japan,Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,healthy control (normal and a few polyps),MP,"multiple polypoid adenomas with low- grade dysplasia (MP, more than three adenomas, mostly more than five adenomas)",251,67,None specified,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.005,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:631/1/NA,Study 631,"cross-sectional observational, not case-control",25758642,10.1038/ncomms7528,NA,"Feng Q, Liang S, Jia H, Stadlmayr A, Tang L, Lan Z, Zhang D, Xia H, Xu X, Jie Z, Su L, Li X, Li X, Li J, Xiao L, Huber-Schönauer U, Niederseer D, Xu X, Al-Aama JY, Yang H, Wang J, Kristiansen K, Arumugam M, Tilg H, Datz C , Wang J",Gut microbiome development along the colorectal adenoma-carcinoma sequence,Nature communications,2015,NA,Experiment 1,Austria,Homo sapiens,Feces,UBERON:0001988,Colorectal adenoma,EFO:0005406,Healthy Controls,Advanced Colorectal Adenoma,"colorectal adenoma patients

The study was conducted both in participants of a health screening programme according to national screening recommendations for CRC49 as well as in patients with suspected CRC undergoing colonoscopy as part of the clinical workup at the Department of Internal Medicine,
Oberndorf Hospital.",55,42,3 months,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:631/2/NA,Study 631,"cross-sectional observational, not case-control",25758642,10.1038/ncomms7528,NA,"Feng Q, Liang S, Jia H, Stadlmayr A, Tang L, Lan Z, Zhang D, Xia H, Xu X, Jie Z, Su L, Li X, Li X, Li J, Xiao L, Huber-Schönauer U, Niederseer D, Xu X, Al-Aama JY, Yang H, Wang J, Kristiansen K, Arumugam M, Tilg H, Datz C , Wang J",Gut microbiome development along the colorectal adenoma-carcinoma sequence,Nature communications,2015,NA,Experiment 2,Austria,Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,Healthy Controls,Colorectal Cancer,"colorectal cancer patients

The study was conducted both in participants of a health screening programme according to national screening recommendations for CRC49 as well as in patients with suspected CRC undergoing colonoscopy as part of the clinical workup at the Department of Internal Medicine,
Oberndorf Hospital.",55,41,3 months,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:631/3/NA,Study 631,"cross-sectional observational, not case-control",25758642,10.1038/ncomms7528,NA,"Feng Q, Liang S, Jia H, Stadlmayr A, Tang L, Lan Z, Zhang D, Xia H, Xu X, Jie Z, Su L, Li X, Li X, Li J, Xiao L, Huber-Schönauer U, Niederseer D, Xu X, Al-Aama JY, Yang H, Wang J, Kristiansen K, Arumugam M, Tilg H, Datz C , Wang J",Gut microbiome development along the colorectal adenoma-carcinoma sequence,Nature communications,2015,NA,Experiment 3,Austria,Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,Advanced Colorectal Adenoma,Colorectal Cancer,"colorectal adenoma patients

The study was conducted both in participants of a health screening programme according to national screening recommendations for CRC49 as well as in patients with suspected CRC undergoing colonoscopy as part of the clinical workup at the Department of Internal Medicine,
Oberndorf Hospital.",42,41,3 months,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:632/1/NA,Study 632,prospective cohort,27558272,10.1038/srep31775,https://pubmed.ncbi.nlm.nih.gov/27558272/,"Levin AM, Sitarik AR, Havstad SL, Fujimura KE, Wegienka G, Cassidy-Bushrow AE, Kim H, Zoratti EM, Lukacs NW, Boushey HA, Ownby DR, Lynch SV , Johnson CC","Joint effects of pregnancy, sociocultural, and environmental factors on early life gut microbiome structure and diversity",Scientific reports,2016,NA,Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Gut microbiome measurement,EFO:0007874,Neonates (median age = 1.2 months),Infants (median age = 6.6 months),Infants (median age: 6.6 months) children from a Detroit-based birth cohort,130,168,NIL,16S,4,Illumina,Zero-Inflated Negative Binomial Regression,0.05,TRUE,NA,NA,"age,breast feeding,delivery procedure,education level,household income,marital status,smoking status",increased,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:633/1/NA,Study 633,case-control,25699023,10.3389/fmicb.2015.00020,https://www.frontiersin.org/articles/10.3389/fmicb.2015.00020/full,"Gao Z, Guo B, Gao R, Zhu Q , Qin H",Microbiota disbiosis is associated with colorectal cancer,Frontiers in microbiology,2015,"colorectal cancer, distal colon, gut dysbiosis, mucosa-associated microbiota, proximal colon",Experiment 1,China,Homo sapiens,Colorectal mucosa,UBERON:0013067,Colorectal cancer,EFO:0005842,Healthy controls,Colorectal Cancer Patients,"Individuals that have been diagnosed with cancer that originates in the colon, part of the digestive system.",30,31,2 months,16S,3,Roche454,"T-Test,Chi-Square,Fisher's Exact Test,LEfSe",0.05,FALSE,3,"age,body mass index,sex",NA,NA,decreased,unchanged,increased,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:633/2/NA,Study 633,case-control,25699023,10.3389/fmicb.2015.00020,https://www.frontiersin.org/articles/10.3389/fmicb.2015.00020/full,"Gao Z, Guo B, Gao R, Zhu Q , Qin H",Microbiota disbiosis is associated with colorectal cancer,Frontiers in microbiology,2015,"colorectal cancer, distal colon, gut dysbiosis, mucosa-associated microbiota, proximal colon",Experiment 2,China,Homo sapiens,Colorectal mucosa,UBERON:0013067,Colorectal cancer,EFO:0005842,adjacent non-cancerous tissues,cancerous tissues,"Individuals that have been diagnosed with cancer that originates in the colon, part of the digestive system.",20,31,2 months,16S,3,Roche454,"T-Test,Chi-Square,Fisher's Exact Test",0.05,FALSE,NA,NA,NA,NA,decreased,unchanged,increased,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:633/3/NA,Study 633,case-control,25699023,10.3389/fmicb.2015.00020,https://www.frontiersin.org/articles/10.3389/fmicb.2015.00020/full,"Gao Z, Guo B, Gao R, Zhu Q , Qin H",Microbiota disbiosis is associated with colorectal cancer,Frontiers in microbiology,2015,"colorectal cancer, distal colon, gut dysbiosis, mucosa-associated microbiota, proximal colon",Experiment 3,China,Homo sapiens,Colorectal mucosa,UBERON:0013067,Sigmoid neoplasm,EFO:1001181,Proximal Colon Cancer,Distal Colorectal Cancer,"Distal colon cancer tissue samples obtained from patients diagnosed with colorectal cancer (CRC), located in the sigmoid colon (25–35 cm from anus)",15,16,2 months,16S,3,Roche454,"T-Test,Chi-Square,Fisher's Exact Test",0.05,FALSE,NA,NA,NA,NA,decreased,unchanged,increased,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:634/1/NA,Study 634,prospective cohort,28844190,10.1902/jop.2017.160808,NA,"Duan X, Wu T, Xu X, Chen D, Mo A, Lei Y, Cheng L, Man Y, Zhou X, Wang Y , Yuan Q",Smoking May Lead to Marginal Bone Loss Around Non-Submerged Implants During Bone Healing by Altering Salivary Microbiome: A Prospective Study,Journal of periodontology,2017,"Alveolar bone loss, dental implants, microbiota, smoking",Experiment 1,China,Homo sapiens,Saliva,UBERON:0001836,Smoking behavior,EFO:0004318,non-smokers,smokers,patients who have smoked >10 cigarettes a day for at least 5 years.,10,10,3 months,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,NA,NA,NA,NA,NA,unchanged,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:635/1/NA,Study 635,"cross-sectional observational, not case-control",31151886,https://doi.org/10.1016/j.annepidem.2019.03.006,https://pubmed.ncbi.nlm.nih.gov/31151886/,"Renson A, Jones HE, Beghini F, Segata N, Zolnik CP, Usyk M, Moody TU, Thorpe L, Burk R, Waldron L , Dowd JB",Sociodemographic variation in the oral microbiome,Annals of epidemiology,2019,"Demographics, Health disparities, Oral microbiome, Social epidemiology",Experiment 1,United States of America,Homo sapiens,Saliva,UBERON:0001836,Smoking behavior,EFO:0004318,College graduate or more,Less than High school diploma,Less than High school diploma,87,65,NA,16S,4,Illumina,edgeR,0.01,TRUE,NA,NA,education level,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:635/2/NA,Study 635,"cross-sectional observational, not case-control",31151886,https://doi.org/10.1016/j.annepidem.2019.03.006,https://pubmed.ncbi.nlm.nih.gov/31151886/,"Renson A, Jones HE, Beghini F, Segata N, Zolnik CP, Usyk M, Moody TU, Thorpe L, Burk R, Waldron L , Dowd JB",Sociodemographic variation in the oral microbiome,Annals of epidemiology,2019,"Demographics, Health disparities, Oral microbiome, Social epidemiology",Experiment 2,United States of America,Homo sapiens,Saliva,UBERON:0001836,Smoking behavior,EFO:0004318,College graduate or more,Some college or associate's degree,Some college or associate's degree,87,67,NA,16S,4,Illumina,edgeR,0.01,TRUE,NA,NA,education level,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:635/3/NA,Study 635,"cross-sectional observational, not case-control",31151886,https://doi.org/10.1016/j.annepidem.2019.03.006,https://pubmed.ncbi.nlm.nih.gov/31151886/,"Renson A, Jones HE, Beghini F, Segata N, Zolnik CP, Usyk M, Moody TU, Thorpe L, Burk R, Waldron L , Dowd JB",Sociodemographic variation in the oral microbiome,Annals of epidemiology,2019,"Demographics, Health disparities, Oral microbiome, Social epidemiology",Experiment 3,United States of America,Homo sapiens,Saliva,UBERON:0001836,Smoking behavior,EFO:0004318,Cigarette smokers,Alternative smokers,Alternative smokers,86,72,NA,16S,4,Illumina,edgeR,0.01,TRUE,NA,NA,smoking status,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:635/4/NA,Study 635,"cross-sectional observational, not case-control",31151886,https://doi.org/10.1016/j.annepidem.2019.03.006,https://pubmed.ncbi.nlm.nih.gov/31151886/,"Renson A, Jones HE, Beghini F, Segata N, Zolnik CP, Usyk M, Moody TU, Thorpe L, Burk R, Waldron L , Dowd JB",Sociodemographic variation in the oral microbiome,Annals of epidemiology,2019,"Demographics, Health disparities, Oral microbiome, Social epidemiology",Experiment 4,United States of America,Homo sapiens,Saliva,UBERON:0001836,Smoking behavior,EFO:0004318,Cigarette smokers,Former smokers,Former smokers,86,43,NA,16S,4,Illumina,edgeR,0.01,TRUE,NA,NA,smoking status,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:635/5/NA,Study 635,"cross-sectional observational, not case-control",31151886,https://doi.org/10.1016/j.annepidem.2019.03.006,https://pubmed.ncbi.nlm.nih.gov/31151886/,"Renson A, Jones HE, Beghini F, Segata N, Zolnik CP, Usyk M, Moody TU, Thorpe L, Burk R, Waldron L , Dowd JB",Sociodemographic variation in the oral microbiome,Annals of epidemiology,2019,"Demographics, Health disparities, Oral microbiome, Social epidemiology",Experiment 5,United States of America,Homo sapiens,Saliva,UBERON:0001836,Smoking behavior,EFO:0004318,Cigarette smokers,Never smokers,Never smokers,86,43,NA,16S,4,Illumina,edgeR,0.01,TRUE,NA,NA,smoking status,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:635/6/NA,Study 635,"cross-sectional observational, not case-control",31151886,https://doi.org/10.1016/j.annepidem.2019.03.006,https://pubmed.ncbi.nlm.nih.gov/31151886/,"Renson A, Jones HE, Beghini F, Segata N, Zolnik CP, Usyk M, Moody TU, Thorpe L, Burk R, Waldron L , Dowd JB",Sociodemographic variation in the oral microbiome,Annals of epidemiology,2019,"Demographics, Health disparities, Oral microbiome, Social epidemiology",Experiment 6,United States of America,Homo sapiens,Saliva,UBERON:0001836,Smoking behavior,EFO:0004318,Cigarette smokers,Secondhand smokers,Secondhand smokers,86,38,NA,16S,4,Illumina,edgeR,0.01,TRUE,NA,NA,smoking status,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:635/7/NA,Study 635,"cross-sectional observational, not case-control",31151886,https://doi.org/10.1016/j.annepidem.2019.03.006,https://pubmed.ncbi.nlm.nih.gov/31151886/,"Renson A, Jones HE, Beghini F, Segata N, Zolnik CP, Usyk M, Moody TU, Thorpe L, Burk R, Waldron L , Dowd JB",Sociodemographic variation in the oral microbiome,Annals of epidemiology,2019,"Demographics, Health disparities, Oral microbiome, Social epidemiology",Experiment 7,United States of America,Homo sapiens,Saliva,UBERON:0001836,Smoking behavior,EFO:0004318,Non-Hispanic white,Asian,Asian,97,22,NA,16S,4,Illumina,edgeR,0.01,TRUE,NA,NA,race,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:635/8/NA,Study 635,"cross-sectional observational, not case-control",31151886,https://doi.org/10.1016/j.annepidem.2019.03.006,https://pubmed.ncbi.nlm.nih.gov/31151886/,"Renson A, Jones HE, Beghini F, Segata N, Zolnik CP, Usyk M, Moody TU, Thorpe L, Burk R, Waldron L , Dowd JB",Sociodemographic variation in the oral microbiome,Annals of epidemiology,2019,"Demographics, Health disparities, Oral microbiome, Social epidemiology",Experiment 8,United States of America,Homo sapiens,Saliva,UBERON:0001836,Smoking behavior,EFO:0004318,Non-Hispanic white,Hispanic,Hispanics,97,71,NA,16S,4,Illumina,edgeR,0.01,TRUE,NA,NA,race,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:635/9/NA,Study 635,"cross-sectional observational, not case-control",31151886,https://doi.org/10.1016/j.annepidem.2019.03.006,https://pubmed.ncbi.nlm.nih.gov/31151886/,"Renson A, Jones HE, Beghini F, Segata N, Zolnik CP, Usyk M, Moody TU, Thorpe L, Burk R, Waldron L , Dowd JB",Sociodemographic variation in the oral microbiome,Annals of epidemiology,2019,"Demographics, Health disparities, Oral microbiome, Social epidemiology",Experiment 9,United States of America,Homo sapiens,Saliva,UBERON:0001836,Smoking behavior,EFO:0004318,Non-Hispanic white,Non-Hispanic black,Non-Hispanic black,97,75,NA,16S,4,Illumina,edgeR,0.01,TRUE,NA,NA,race,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:635/10/NA,Study 635,"cross-sectional observational, not case-control",31151886,https://doi.org/10.1016/j.annepidem.2019.03.006,https://pubmed.ncbi.nlm.nih.gov/31151886/,"Renson A, Jones HE, Beghini F, Segata N, Zolnik CP, Usyk M, Moody TU, Thorpe L, Burk R, Waldron L , Dowd JB",Sociodemographic variation in the oral microbiome,Annals of epidemiology,2019,"Demographics, Health disparities, Oral microbiome, Social epidemiology",Experiment 10,United States of America,Homo sapiens,Saliva,UBERON:0001836,Smoking behavior,EFO:0004318,Males,Females,Females,132,150,NA,16S,4,Illumina,edgeR,0.01,TRUE,NA,NA,sex,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:635/11/NA,Study 635,"cross-sectional observational, not case-control",31151886,https://doi.org/10.1016/j.annepidem.2019.03.006,https://pubmed.ncbi.nlm.nih.gov/31151886/,"Renson A, Jones HE, Beghini F, Segata N, Zolnik CP, Usyk M, Moody TU, Thorpe L, Burk R, Waldron L , Dowd JB",Sociodemographic variation in the oral microbiome,Annals of epidemiology,2019,"Demographics, Health disparities, Oral microbiome, Social epidemiology",Experiment 11,United States of America,Homo sapiens,Saliva,UBERON:0001836,Smoking behavior,EFO:0004318,age group 20-29,age group 35-64,age group 35-64,70,NA,NA,16S,4,Illumina,edgeR,0.01,TRUE,NA,NA,age,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:635/12/NA,Study 635,"cross-sectional observational, not case-control",31151886,https://doi.org/10.1016/j.annepidem.2019.03.006,https://pubmed.ncbi.nlm.nih.gov/31151886/,"Renson A, Jones HE, Beghini F, Segata N, Zolnik CP, Usyk M, Moody TU, Thorpe L, Burk R, Waldron L , Dowd JB",Sociodemographic variation in the oral microbiome,Annals of epidemiology,2019,"Demographics, Health disparities, Oral microbiome, Social epidemiology",Experiment 12,United States of America,Homo sapiens,Saliva,UBERON:0001836,Smoking behavior,EFO:0004318,age group 20-29,age group 65 and over,age group 65 and over,70,NA,NA,16S,4,Illumina,edgeR,0.01,TRUE,NA,NA,age,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:636/1/NA,Study 636,"cross-sectional observational, not case-control",35229279,https://doi.org/10.1007%2Fs42770-022-00721-5,NA,"Wang X, Mi Q, Yang J, Guan Y, Zeng W, Xiang H, Liu X, Yang W, Yang G, Li X, Cui Y , Gao Q",Effect of electronic cigarette and tobacco smoking on the human saliva microbial community,Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology],2022,"Community profiles, E-cigarettes, Oral microbial flora, Smoking",Experiment 1,China,Homo sapiens,Saliva,UBERON:0001836,Smoking behavior,EFO:0004318,Non Smokers,Tobacco smokers,The volunteers who smoked tobacco,6,14,6 months,16S,45,Ion Torrent,ANOVA,0.05,FALSE,NA,NA,NA,NA,increased,increased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:636/2/NA,Study 636,"cross-sectional observational, not case-control",35229279,https://doi.org/10.1007%2Fs42770-022-00721-5,NA,"Wang X, Mi Q, Yang J, Guan Y, Zeng W, Xiang H, Liu X, Yang W, Yang G, Li X, Cui Y , Gao Q",Effect of electronic cigarette and tobacco smoking on the human saliva microbial community,Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology],2022,"Community profiles, E-cigarettes, Oral microbial flora, Smoking",Experiment 2,China,Homo sapiens,Saliva,UBERON:0001836,Smoking behavior,EFO:0004318,Non Smokers,E-cigarette smokers,The volunteers who smoked electronic cigarettes.,6,5,6 months,16S,45,Ion Torrent,ANOVA,0.05,FALSE,NA,NA,NA,NA,unchanged,increased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:636/3/NA,Study 636,"cross-sectional observational, not case-control",35229279,https://doi.org/10.1007%2Fs42770-022-00721-5,NA,"Wang X, Mi Q, Yang J, Guan Y, Zeng W, Xiang H, Liu X, Yang W, Yang G, Li X, Cui Y , Gao Q",Effect of electronic cigarette and tobacco smoking on the human saliva microbial community,Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology],2022,"Community profiles, E-cigarettes, Oral microbial flora, Smoking",Experiment 3,China,Homo sapiens,Saliva,UBERON:0001836,Smoking behavior,EFO:0004318,Tobacco smokers,E-cigarette smokers,The volunteers who smoked electronic cigarettes.,14,5,6 months,16S,45,Ion Torrent,ANOVA,0.05,FALSE,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:636/5/NA,Study 636,"cross-sectional observational, not case-control",35229279,https://doi.org/10.1007%2Fs42770-022-00721-5,NA,"Wang X, Mi Q, Yang J, Guan Y, Zeng W, Xiang H, Liu X, Yang W, Yang G, Li X, Cui Y , Gao Q",Effect of electronic cigarette and tobacco smoking on the human saliva microbial community,Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology],2022,"Community profiles, E-cigarettes, Oral microbial flora, Smoking",Experiment 5,China,Homo sapiens,Saliva,UBERON:0001836,Smoking behavior,EFO:0004318,Quitting smokers,Tobacco smokers,Volunteers who are tobacco smokers,8,14,6 months.,16S,45,Ion Torrent,ANOVA,0.05,FALSE,NA,NA,NA,NA,unchanged,increased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:636/6/NA,Study 636,"cross-sectional observational, not case-control",35229279,https://doi.org/10.1007%2Fs42770-022-00721-5,NA,"Wang X, Mi Q, Yang J, Guan Y, Zeng W, Xiang H, Liu X, Yang W, Yang G, Li X, Cui Y , Gao Q",Effect of electronic cigarette and tobacco smoking on the human saliva microbial community,Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology],2022,"Community profiles, E-cigarettes, Oral microbial flora, Smoking",Experiment 6,China,Homo sapiens,Saliva,UBERON:0001836,Smoking behavior,EFO:0004318,Quitting smokers,E-cigarette smokers,Volunteers who smoke E-cigarettes,8,5,6 months.,16S,45,Ion Torrent,ANOVA,0.05,FALSE,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:637/1/NA,Study 637,"cross-sectional observational, not case-control",33052235,10.7150/thno.49515,NA,"Zhang S, Kong C, Yang Y, Cai S, Li X, Cai G , Ma Y",Human oral microbiome dysbiosis as a novel non-invasive biomarker in detection of colorectal cancer,Theranostics,2020,"16S rRNA, colorectal adenomas, colorectal cancers, oral microbiome",Experiment 1,China,Homo sapiens,Oral cavity,UBERON:0000167,Colorectal cancer,EFO:0005842,Healthy Individuals,CRC,Patients with colorectal cancer,58,161,NA,16S,34,Illumina,Welch's T-Test,0.05,TRUE,NA,NA,"age,alcohol drinking,body mass index,sex,smoking status",NA,increased,unchanged,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:637/2/NA,Study 637,"cross-sectional observational, not case-control",33052235,10.7150/thno.49515,NA,"Zhang S, Kong C, Yang Y, Cai S, Li X, Cai G , Ma Y",Human oral microbiome dysbiosis as a novel non-invasive biomarker in detection of colorectal cancer,Theranostics,2020,"16S rRNA, colorectal adenomas, colorectal cancers, oral microbiome",Experiment 2,China,Homo sapiens,Oral cavity,UBERON:0000167,Colorectal adenoma,EFO:0005406,Healthy Individuals,CRA,Patients with colorectal adenoma,58,34,NA,16S,34,Illumina,Welch's T-Test,0.05,TRUE,NA,NA,"age,alcohol drinking,body mass index,sex,smoking status",NA,increased,unchanged,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:637/3/NA,Study 637,"cross-sectional observational, not case-control",33052235,10.7150/thno.49515,NA,"Zhang S, Kong C, Yang Y, Cai S, Li X, Cai G , Ma Y",Human oral microbiome dysbiosis as a novel non-invasive biomarker in detection of colorectal cancer,Theranostics,2020,"16S rRNA, colorectal adenomas, colorectal cancers, oral microbiome",Experiment 3,China,Homo sapiens,Oral cavity,UBERON:0000167,Colorectal cancer,EFO:0005842,CRA,CRC,Patients with colorectal cancer,34,161,NA,16S,34,Illumina,Welch's T-Test,0.05,TRUE,NA,NA,"age,alcohol drinking,body mass index,sex,smoking status",NA,increased,unchanged,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:638/1/NA,Study 638,case-control,28750650,10.1186/s13059-017-1271-6,https://pubmed.ncbi.nlm.nih.gov/28750650/,"Wen C, Zheng Z, Shao T, Liu L, Xie Z, Le Chatelier E, He Z, Zhong W, Fan Y, Zhang L, Li H, Wu C, Hu C, Xu Q, Zhou J, Cai S, Wang D, Huang Y, Breban M, Qin N , Ehrlich SD",Quantitative metagenomics reveals unique gut microbiome biomarkers in ankylosing spondylitis,Genome biology,2017,"Ankylosing spondylitis, Biomarkers, Human gut microbiome, Pathogenesis",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Ankylosing spondylitis,EFO:0003898,Healthy controls,Ankylosing spondylitis patients,Ankylosing spondylitis confirmed by calculating the Bath Ankylosing Spondylitis Functional Index (BASFI) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI),114,97,4 weeks,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.001,NA,NA,NA,NA,NA,decreased,NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:639/1/NA,Study 639,"cross-sectional observational, not case-control",30249275,10.1186/s40168-018-0557-6.,https://pubmed.ncbi.nlm.nih.gov/30249275/,"He Y, Wu W, Wu S, Zheng HM, Li P, Sheng HF, Chen MX, Chen ZH, Ji GY, Zheng ZD, Mujagond P, Chen XJ, Rong ZH, Chen P, Lyu LY, Wang X, Xu JB, Wu CB, Yu N, Xu YJ, Yin J, Raes J, Ma WJ , Zhou HW","Linking gut microbiota, metabolic syndrome and economic status based on a population-level analysis",Microbiome,2018,"16S rRNA gene sequencing, Economic status, Epidemiology, Faecal microbiome, Guangdong Gut Microbiome Project, Metabolic syndrome, Population level survey",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Socioeconomic status,EXO:0000114,NA,underdeveloped cities vs developed cities,"7009 Individuals' fecal samples from underdeveloped cities with GDP/capita of 22.1K to 25.3K CNY, and those from developed cities with GDP/capita of 149.5K to 136.1K CNY. (continuous variables)",NA,7009,Unspecified.,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,"age,geographic area,sex",NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:640/1/NA,Study 640,case-control,34698096,10.3390/cimb43030103,https://www.mdpi.com/1467-3045/43/3/103,"de Jesus VC, Singh M, Schroth RJ, Chelikani P , Hitchon CA","Association of Bitter Taste Receptor T2R38 Polymorphisms, Oral Microbiota, and Rheumatoid Arthritis",Current issues in molecular biology,2021,"G protein-coupled receptor, autoimmune disease, oral microbiome, oral–systemic disease, rheumatoid arthritis, taste genetics",Experiment 1,Canada,Homo sapiens,Internal cheek pouch,UBERON:0013640,Rheumatoid arthritis,EFO:0000685,Non Rheumatoid Arthritis,Rheumatoid Arthritis,Individual who have been diagnosed with Rheumatoid Arthritis(RA).,64,35,N/A,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:640/2/NA,Study 640,case-control,34698096,10.3390/cimb43030103,https://www.mdpi.com/1467-3045/43/3/103,"de Jesus VC, Singh M, Schroth RJ, Chelikani P , Hitchon CA","Association of Bitter Taste Receptor T2R38 Polymorphisms, Oral Microbiota, and Rheumatoid Arthritis",Current issues in molecular biology,2021,"G protein-coupled receptor, autoimmune disease, oral microbiome, oral–systemic disease, rheumatoid arthritis, taste genetics",Experiment 2,Canada,Homo sapiens,Internal cheek pouch,UBERON:0013640,Sensory perception of bitter taste,GO:0050913,rheumatoid arthritis patients carrying the AVI/AVI genotype (“non-tasters”),rheumatoid arthritis patients with the homozygous PAV/PAV (“supertasters”),rheumatoid arthritis patients with the homozygous PAV/PAV (“supertasters”),16,35,N/A,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:640/3/NA,Study 640,case-control,34698096,10.3390/cimb43030103,https://www.mdpi.com/1467-3045/43/3/103,"de Jesus VC, Singh M, Schroth RJ, Chelikani P , Hitchon CA","Association of Bitter Taste Receptor T2R38 Polymorphisms, Oral Microbiota, and Rheumatoid Arthritis",Current issues in molecular biology,2021,"G protein-coupled receptor, autoimmune disease, oral microbiome, oral–systemic disease, rheumatoid arthritis, taste genetics",Experiment 3,Canada,Homo sapiens,Internal cheek pouch,UBERON:0013640,Sensory perception of bitter taste,GO:0050913,Non-rheumatoid arthritis patients carrying the AVI/AVI genotype (“non-tasters”),Non-rheumatoid arthritis patients with the homozygous PAV/PAV (“supertasters”),Non-rheumatoid arthritis patients with the homozygous PAV/PAV (“supertasters”),64,64,N/A,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:640/4/NA,Study 640,case-control,34698096,10.3390/cimb43030103,https://www.mdpi.com/1467-3045/43/3/103,"de Jesus VC, Singh M, Schroth RJ, Chelikani P , Hitchon CA","Association of Bitter Taste Receptor T2R38 Polymorphisms, Oral Microbiota, and Rheumatoid Arthritis",Current issues in molecular biology,2021,"G protein-coupled receptor, autoimmune disease, oral microbiome, oral–systemic disease, rheumatoid arthritis, taste genetics",Experiment 4,Canada,Homo sapiens,Internal cheek pouch,UBERON:0013640,Sensory perception of bitter taste,GO:0050913,All participants carrying the AVI/AVI genotype (“non-tasters”),All participants with the homozygous PAV/PAV (“supertasters”),All participants with the homozygous PAV/PAV (“supertasters”),99,99,N/A,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:641/1/NA,Study 641,"cross-sectional observational, not case-control",33949151,10.1002/art.41780,NA,"Kroese JM, Brandt BW, Buijs MJ, Crielaard W, Lobbezoo F, Loos BG, van Boheemen L, van Schaardenburg D, Zaura E , Volgenant CMC",Differences in the Oral Microbiome in Patients With Early Rheumatoid Arthritis and Individuals at Risk of Rheumatoid Arthritis Compared to Healthy Individuals,"Arthritis & rheumatology (Hoboken, N.J.)",2021,NA,Experiment 1,Netherlands,Homo sapiens,Saliva,UBERON:0001836,Arthritis,EFO:0005856,healthy control,Early Rheumatoid Arthritis,Early Rheumatoid Arthritis patients (diagnosed within the previous year),50,50,3 months,16S,NA,Illumina,LEfSe,0.05,TRUE,3,"age,sex",NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:642/1/NA,Study 642,"cross-sectional observational, not case-control",26290472,10.1038/srep13338,https://pubmed.ncbi.nlm.nih.gov/26290472/,"Chong CW, Ahmad AF, Lim YA, Teh CS, Yap IK, Lee SC, Chin YT, Loke P , Chua KH",Effect of ethnicity and socioeconomic variation to the gut microbiota composition among pre-adolescent in Malaysia,Scientific reports,2015,NA,Experiment 1,Malaysia,Homo sapiens,Feces,UBERON:0001988,Socioeconomic status,EXO:0000114,"Chinese Children (High SES, household income>RM500)",Malays Children (Moderate SES. house income=<RM500),"Gut microbiota from fecal samples of 24 Malays children whose household income =<RM500.

Note: Poverty line = RM 764($254).",17,24,unspecified,16S,345,NA,PERMANOVA,0.05,TRUE,NA,NA,NA,unchanged,increased,NA,NA,unchanged,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:642/2/NA,Study 642,"cross-sectional observational, not case-control",26290472,10.1038/srep13338,https://pubmed.ncbi.nlm.nih.gov/26290472/,"Chong CW, Ahmad AF, Lim YA, Teh CS, Yap IK, Lee SC, Chin YT, Loke P , Chua KH",Effect of ethnicity and socioeconomic variation to the gut microbiota composition among pre-adolescent in Malaysia,Scientific reports,2015,NA,Experiment 2,Malaysia,Homo sapiens,Feces,UBERON:0001988,Socioeconomic status,EXO:0000114,"Chinese Children (High SES, household income >RM500)","Orang Asli Children (low SES, household income<RM500)",Gut microbiota from fecal samples of 20 Orang Asli children whose household income <RM500.,17,20,unspecified,16S,345,NA,PERMANOVA,0.05,TRUE,NA,NA,NA,increased,increased,NA,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:642/3/NA,Study 642,"cross-sectional observational, not case-control",26290472,10.1038/srep13338,https://pubmed.ncbi.nlm.nih.gov/26290472/,"Chong CW, Ahmad AF, Lim YA, Teh CS, Yap IK, Lee SC, Chin YT, Loke P , Chua KH",Effect of ethnicity and socioeconomic variation to the gut microbiota composition among pre-adolescent in Malaysia,Scientific reports,2015,NA,Experiment 3,Malaysia,Homo sapiens,Feces,UBERON:0001988,Socioeconomic status,EXO:0000114,"Malays children (Moderate SES, household income =>RM500)","Orang Asli children (low SES, household income <RM500)","Gut microbiota from fecal samples of 20 Orang Asli children whose household income<RM500.

45% of the households earn < RM500

Note: Poverty line = RM 764($254).",24,20,unspecified,16S,345,NA,PERMANOVA,0.05,TRUE,NA,NA,NA,increased,increased,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:643/1/NA,Study 643,"cross-sectional observational, not case-control",34799562,10.1038/s41467-021-27112-y,NA,"Yang Y, Du L, Shi D, Kong C, Liu J, Liu G, Li X , Ma Y",Dysbiosis of human gut microbiome in young-onset colorectal cancer,Nature communications,2021,NA,Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,yControl,yCRC,young-onset CRC patients (<50 years old),148,144,1 month,16S,34,Illumina,LEfSe,0.05,FALSE,2,age,"age,sex",NA,unchanged,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:643/2/NA,Study 643,"cross-sectional observational, not case-control",34799562,10.1038/s41467-021-27112-y,NA,"Yang Y, Du L, Shi D, Kong C, Liu J, Liu G, Li X , Ma Y",Dysbiosis of human gut microbiome in young-onset colorectal cancer,Nature communications,2021,NA,Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,oControls,oCRC,old-onset CRC patients (50 years old or older),203,233,1 month,16S,34,Illumina,LEfSe,0.05,FALSE,2,age,"age,sex",NA,decreased,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:644/1/NA,Study 644,"cross-sectional observational, not case-control",26515465,10.1038/ncomms9727,NA,"Nakatsu G, Li X, Zhou H, Sheng J, Wong SH, Wu WK, Ng SC, Tsoi H, Dong Y, Zhang N, He Y, Kang Q, Cao L, Wang K, Zhang J, Liang Q, Yu J , Sung JJ",Gut mucosal microbiome across stages of colorectal carcinogenesis,Nature communications,2015,NA,Experiment 1,China,Homo sapiens,Intestine,UBERON:0000160,Colorectal adenoma,EFO:0005406,healthy controls,colorectal adenoma,histology-proven adenoma,61,47,NA,16S,1234,Roche454,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:644/2/NA,Study 644,"cross-sectional observational, not case-control",26515465,10.1038/ncomms9727,NA,"Nakatsu G, Li X, Zhou H, Sheng J, Wong SH, Wu WK, Ng SC, Tsoi H, Dong Y, Zhang N, He Y, Kang Q, Cao L, Wang K, Zhang J, Liang Q, Yu J , Sung JJ",Gut mucosal microbiome across stages of colorectal carcinogenesis,Nature communications,2015,NA,Experiment 2,China,Homo sapiens,Intestine,UBERON:0000160,Colorectal cancer,EFO:0005842,healthy controls,colorectal cancer (adenocarcinoma),subjects with invasive adenocarcinoma,61,52,NA,16S,1234,Roche454,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:644/3/NA,Study 644,"cross-sectional observational, not case-control",26515465,10.1038/ncomms9727,NA,"Nakatsu G, Li X, Zhou H, Sheng J, Wong SH, Wu WK, Ng SC, Tsoi H, Dong Y, Zhang N, He Y, Kang Q, Cao L, Wang K, Zhang J, Liang Q, Yu J , Sung JJ",Gut mucosal microbiome across stages of colorectal carcinogenesis,Nature communications,2015,NA,Experiment 3,China,Homo sapiens,Intestine,UBERON:0000160,Colorectal cancer,EFO:0005842,colorectal adenoma,colorectal cancer,subjects with invasive adenocarcinoma,47,52,NA,16S,1234,Roche454,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:644/4/NA,Study 644,"cross-sectional observational, not case-control",26515465,10.1038/ncomms9727,NA,"Nakatsu G, Li X, Zhou H, Sheng J, Wong SH, Wu WK, Ng SC, Tsoi H, Dong Y, Zhang N, He Y, Kang Q, Cao L, Wang K, Zhang J, Liang Q, Yu J , Sung JJ",Gut mucosal microbiome across stages of colorectal carcinogenesis,Nature communications,2015,NA,Experiment 4,China,Homo sapiens,Intestine,UBERON:0000160,Colorectal cancer,EFO:0005842,carcinoma-adjacent mucosae,carcinoma mucosae,specimens collected from adenocarcinoma tissue,52,52,NA,16S,1234,Roche454,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:644/5/NA,Study 644,"cross-sectional observational, not case-control",26515465,10.1038/ncomms9727,NA,"Nakatsu G, Li X, Zhou H, Sheng J, Wong SH, Wu WK, Ng SC, Tsoi H, Dong Y, Zhang N, He Y, Kang Q, Cao L, Wang K, Zhang J, Liang Q, Yu J , Sung JJ",Gut mucosal microbiome across stages of colorectal carcinogenesis,Nature communications,2015,NA,Experiment 5,China,Homo sapiens,Intestine,UBERON:0000160,Colorectal cancer,EFO:0005842,adenoma-adjacent,adenocarcinoma mucosae,specimens collected from adenocarcinoma tissue,47,52,NA,16S,1234,Roche454,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:644/7/NA,Study 644,"cross-sectional observational, not case-control",26515465,10.1038/ncomms9727,NA,"Nakatsu G, Li X, Zhou H, Sheng J, Wong SH, Wu WK, Ng SC, Tsoi H, Dong Y, Zhang N, He Y, Kang Q, Cao L, Wang K, Zhang J, Liang Q, Yu J , Sung JJ",Gut mucosal microbiome across stages of colorectal carcinogenesis,Nature communications,2015,NA,Experiment 7,China,Homo sapiens,Intestine,UBERON:0000160,Colorectal adenoma,EFO:0005406,healthy controls,adenoma-adjacent,specimen collected adjacent to histology-proven adenoma,61,47,NA,16S,1234,Roche454,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:644/8/NA,Study 644,"cross-sectional observational, not case-control",26515465,10.1038/ncomms9727,NA,"Nakatsu G, Li X, Zhou H, Sheng J, Wong SH, Wu WK, Ng SC, Tsoi H, Dong Y, Zhang N, He Y, Kang Q, Cao L, Wang K, Zhang J, Liang Q, Yu J , Sung JJ",Gut mucosal microbiome across stages of colorectal carcinogenesis,Nature communications,2015,NA,Experiment 8,China,Homo sapiens,Intestine,UBERON:0000160,Colorectal cancer,EFO:0005842,healthy controls,carcinoma-adjacent,specimen collected from tissue adjacent to adenocarcinoma site,61,52,NA,16S,1234,Roche454,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:644/9/NA,Study 644,"cross-sectional observational, not case-control",26515465,10.1038/ncomms9727,NA,"Nakatsu G, Li X, Zhou H, Sheng J, Wong SH, Wu WK, Ng SC, Tsoi H, Dong Y, Zhang N, He Y, Kang Q, Cao L, Wang K, Zhang J, Liang Q, Yu J , Sung JJ",Gut mucosal microbiome across stages of colorectal carcinogenesis,Nature communications,2015,NA,Experiment 9,China,Homo sapiens,Intestine,UBERON:0000160,Colorectal cancer,EFO:0005842,colorectal adenoma tissue,carcinoma-adjacent tissue,specimens collected from tissue adjacent to adenocarcinoma,47,52,Not specified,16S,1234,Roche454,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:645/1/NA,Study 645,prospective cohort,30982856,10.1093/ajcn/nqz006,https://pubmed.ncbi.nlm.nih.gov/30982856/,"Ford SL, Lohmann P, Preidis GA, Gordon PS, O'Donnell A, Hagan J, Venkatachalam A, Balderas M, Luna RA , Hair AB",Improved feeding tolerance and growth are linked to increased gut microbial community diversity in very-low-birth-weight infants fed mother's own milk compared with donor breast milk,The American journal of clinical nutrition,2019,"breast milk, donor milk, feeding intolerance, growth, microbiota, neonate, premature infant, very low birth weight",Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Maternal milk,XCO:0000415,DM (Donor's Milk),MOM (Mother's own milk),Mother's own milk group consists of infants who drank at least >50% of mother's own milk. Any less and they were placed in the other cohort.,43,74,No antibiotic exclusions were listed as infants were at a vulnerable stage in their lives.,16S,4,Illumina,Logistic Regression,0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:646/1/NA,Study 646,case-control,27672054,10.1158/1055-9965.EPI-16-0337,NA,"Hale VL, Chen J, Johnson S, Harrington SC, Yab TC, Smyrk TC, Nelson H, Boardman LA, Druliner BR, Levin TR, Rex DK, Ahnen DJ, Lance P, Ahlquist DA , Chia N",Shifts in the Fecal Microbiota Associated with Adenomatous Polyps,"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology",2017,NA,Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Colorectal adenoma,EFO:0005406,Non-Adenoma,Adenoma,"Patients with colorectal adenoma as identified during a screening colonoscopy. Fecal
samples from patients in which at least one adenoma > 1 cm was identified were included in the “adenoma” group.",547,233,None specified,16S,345,Illumina,Linear Regression,0.2,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:647/1/NA,Study 647,"cross-sectional observational, not case-control",29901485,10.1097/PSY.0000000000000614.,https://pubmed.ncbi.nlm.nih.gov/29901485/,"Carson TL, Wang F, Cui X, Jackson BE, Van Der Pol WJ, Lefkowitz EJ, Morrow C , Baskin ML","Associations Between Race, Perceived Psychological Stress, and the Gut Microbiota in a Sample of Generally Healthy Black and White Women: A Pilot Study on the Role of Race and Perceived Psychological Stress",Psychosomatic medicine,2018,NA,Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Ethnic group,EFO:0001799,White Women,Black Women,Healthy non-Hispanic black females (age ≥19 years),33,47,90 days,16S,4,Illumina,PERMANOVA,0.05,TRUE,NA,NA,"age,body mass index,diet,waist circumference",NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:648/1/NA,Study 648,"cross-sectional observational, not case-control",33596768,10.1080/19490976.2021.1882926,https://pubmed.ncbi.nlm.nih.gov/33596768/,"Balakrishnan B, Selvaraju V, Chen J, Ayine P, Yang L, Babu JR, Geetha T , Taneja V",Ethnic variability associating gut and oral microbiome with obesity in children,Gut microbes,2021,"Microbiome, disparity, minorities, obesity, socioeconomic factors",Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,"Ethnic group,Gut microbiome measurement","EFO:0001799,EFO:0007874",Gut microbiome of European American children (EA),Gut microbiome of African American children (AA),"Gut microbiome of 30 African American children (18 female, 12 male; age 6 - 10 years)",30,30,unspecified,16S,345,Illumina,PERMANOVA,0.05,TRUE,NA,NA,"age,body mass index,education level,household income,sex",NA,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:648/2/NA,Study 648,"cross-sectional observational, not case-control",33596768,10.1080/19490976.2021.1882926,https://pubmed.ncbi.nlm.nih.gov/33596768/,"Balakrishnan B, Selvaraju V, Chen J, Ayine P, Yang L, Babu JR, Geetha T , Taneja V",Ethnic variability associating gut and oral microbiome with obesity in children,Gut microbes,2021,"Microbiome, disparity, minorities, obesity, socioeconomic factors",Experiment 2,United States of America,Homo sapiens,Oral opening,UBERON:0000166,Ethnic group,EFO:0001799,Oral microbiota of European American children (EA),Oral microbiota of African American children (AA),"Oral microbiota of 30 African American children (18 female, 12 male; age 6 - 10 years)",30,30,unspecified,16S,345,Illumina,PERMANOVA,0.05,TRUE,NA,NA,"age,body mass index,education level,household income,sex",NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:648/3/NA,Study 648,"cross-sectional observational, not case-control",33596768,10.1080/19490976.2021.1882926,https://pubmed.ncbi.nlm.nih.gov/33596768/,"Balakrishnan B, Selvaraju V, Chen J, Ayine P, Yang L, Babu JR, Geetha T , Taneja V",Ethnic variability associating gut and oral microbiome with obesity in children,Gut microbes,2021,"Microbiome, disparity, minorities, obesity, socioeconomic factors",Experiment 3,United States of America,Homo sapiens,Feces,UBERON:0001988,Socioeconomic status,EXO:0000114,"Household income (EA & AA) =>$50,000.","Household income (EA & AA) < $50,000.","Gut microbiota of children from low-income households (EA & AA) < $50,000.",30,30,unspecified,16S,345,Illumina,PERMANOVA,0.05,TRUE,NA,NA,"age,body mass index,education level,ethnic group,sex",NA,unchanged,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:648/4/NA,Study 648,"cross-sectional observational, not case-control",33596768,10.1080/19490976.2021.1882926,https://pubmed.ncbi.nlm.nih.gov/33596768/,"Balakrishnan B, Selvaraju V, Chen J, Ayine P, Yang L, Babu JR, Geetha T , Taneja V",Ethnic variability associating gut and oral microbiome with obesity in children,Gut microbes,2021,"Microbiome, disparity, minorities, obesity, socioeconomic factors",Experiment 4,United States of America,Homo sapiens,Oral opening,UBERON:0000166,Socioeconomic status,EXO:0000114,"High income in European American households =>$50,000.","Low  income in European American households  < $50,000.","Oral microbiota of children from low-income EA households < $50,000.",30,30,unspecified,16S,345,Illumina,PERMANOVA,0.05,TRUE,NA,NA,"age,body mass index,education level,ethnic group,sex",NA,unchanged,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:648/5/NA,Study 648,"cross-sectional observational, not case-control",33596768,10.1080/19490976.2021.1882926,https://pubmed.ncbi.nlm.nih.gov/33596768/,"Balakrishnan B, Selvaraju V, Chen J, Ayine P, Yang L, Babu JR, Geetha T , Taneja V",Ethnic variability associating gut and oral microbiome with obesity in children,Gut microbes,2021,"Microbiome, disparity, minorities, obesity, socioeconomic factors",Experiment 5,United States of America,Homo sapiens,Oral opening,UBERON:0000166,Obesity,EFO:0001073,Non-obese EA children,Obese EA children,Obese children in the European American group,22,8,unspecified,16S,345,Illumina,PERMANOVA,0.1,TRUE,NA,NA,"age,body mass index,education level,ethnic group,sex",NA,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:648/6/NA,Study 648,"cross-sectional observational, not case-control",33596768,10.1080/19490976.2021.1882926,https://pubmed.ncbi.nlm.nih.gov/33596768/,"Balakrishnan B, Selvaraju V, Chen J, Ayine P, Yang L, Babu JR, Geetha T , Taneja V",Ethnic variability associating gut and oral microbiome with obesity in children,Gut microbes,2021,"Microbiome, disparity, minorities, obesity, socioeconomic factors",Experiment 6,United States of America,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,Non-obese African American children,Obese African American  children,NA,21,9,unspecified,16S,345,Illumina,PERMANOVA,0.1,TRUE,NA,NA,"age,body mass index,education level,ethnic group,sex",NA,unchanged,NA,NA,unchanged,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:649/1/NA,Study 649,randomized controlled trial,33106549,10.1038/s41598-020-75229-9,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7589489/,"Stan TL, Soylu-Kucharz R, Burleigh S, Prykhodko O, Cao L, Franke N, Sjögren M, Haikal C, Hållenius F , Björkqvist M",Increased intestinal permeability and gut dysbiosis in the R6/2 mouse model of Huntington's disease,Scientific reports,2020,NA,Experiment 1,Sweden,Mus musculus,Feces,UBERON:0001988,Huntington disease,MONDO:0007739,Wild type,R6/2,"The CAG-repeat lengths of the R6/2 mice used in this study ranged between 242 and 257, resulting in a disease progression slower than that of the R6/2 mouse with 150 CAG repeats as described previously.",10,10,NA,16S,4,Illumina,LEfSe,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:650/1/NA,Study 650,"cross-sectional observational, not case-control",32604882,10.3390/microorganisms8060961,https://pubmed.ncbi.nlm.nih.gov/32604882/,"Amaruddin AI, Hamid F, Koopman JPR, Muhammad M, Brienen EA, van Lieshout L, Geelen AR, Wahyuni S, Kuijper EJ, Sartono E, Yazdanbakhsh M , Zwittink RD","The Bacterial Gut Microbiota of Schoolchildren from High and Low Socioeconomic Status: A Study in an Urban Area of Makassar, Indonesia",Microorganisms,2020,"gut microbiota, intestinal parasites, nutritional status, schoolchildren, socioeconomic status",Experiment 1,Indonesia,Homo sapiens,Feces,UBERON:0001988,Gut microbiome measurement,EFO:0007874,Children of low SES,Children of high SES,"High SES school is located in the city centre and is considered of high status, with a majority of the parents working as high-skilled workers or professionals with higher education.",66,74,NA,16S,34,Illumina,PERMANOVA,0.05,TRUE,NA,NA,NA,NA,decreased,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:651/1/NA,Study 651,"cross-sectional observational, not case-control",22761885,10.1371/journal.pone.0039743,NA,"Chen W, Liu F, Ling Z, Tong X , Xiang C",Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer,PloS one,2012,NA,Experiment 1,China,Homo sapiens,Intestine,UBERON:0000160,Colorectal cancer,EFO:0005842,Healthy volunteers (swc),CRC patients (swp),"37-88 years of age, diagnosed with colorectal cancer (swp = gut swab)",34,32,1 month,16S,123,Sanger,Mann-Whitney (Wilcoxon),0.05,NA,NA,"age,sex",NA,NA,unchanged,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:651/2/NA,Study 651,"cross-sectional observational, not case-control",22761885,10.1371/journal.pone.0039743,NA,"Chen W, Liu F, Ling Z, Tong X , Xiang C",Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer,PloS one,2012,NA,Experiment 2,China,Homo sapiens,Intestine,UBERON:0000160,Colorectal cancer,EFO:0005842,paracancerous tissue (pa10t),cancerous tissue (cat),"37-88 years of age, colorectal cancer tissue

Note: group 0 = paracancerous tissue 10-20 cm from cancerous tissue",27,27,1 month,16S,123,Sanger,Mann-Whitney (Wilcoxon),0.05,NA,NA,NA,NA,NA,decreased,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:651/3/NA,Study 651,"cross-sectional observational, not case-control",22761885,10.1371/journal.pone.0039743,NA,"Chen W, Liu F, Ling Z, Tong X , Xiang C",Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer,PloS one,2012,NA,Experiment 3,China,Homo sapiens,Intestine,UBERON:0000160,Colorectal cancer,EFO:0005842,paracancerous tissue (pa2t),cancerous tissue (cat),"37-88 years of age, cancerous tissue.

Note: Group 0 = paracancerous tissue 2-5 cm from cancerous tissue",27,27,1 month,16S,123,Sanger,Mann-Whitney (Wilcoxon),0.05,NA,NA,NA,NA,NA,unchanged,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:651/4/NA,Study 651,"cross-sectional observational, not case-control",22761885,10.1371/journal.pone.0039743,NA,"Chen W, Liu F, Ling Z, Tong X , Xiang C",Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer,PloS one,2012,NA,Experiment 4,China,Homo sapiens,Intestine,UBERON:0000160,Colorectal cancer,EFO:0005842,Healthy volunteers (stc),CRC patients (stp),"37-88 years of age, diagnosed with colorectal cancer (stp = stool sample)",22,21,1 month,16S,123,Sanger,Mann-Whitney (Wilcoxon),0.05,NA,NA,"age,sex",NA,NA,unchanged,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:652/1/NA,Study 652,"cross-sectional observational, not case-control",30794590,10.1371/journal.pone.0212406,NA,"Saito K, Koido S, Odamaki T, Kajihara M, Kato K, Horiuchi S, Adachi S, Arakawa H, Yoshida S, Akasu T, Ito Z, Uchiyama K, Saruta M, Xiao JZ, Sato N , Ohkusa T",Metagenomic analyses of the gut microbiota associated with colorectal adenoma,PloS one,2019,NA,Experiment 1,Japan,Homo sapiens,Intestine,UBERON:0000160,Colorectal cancer,EFO:0005842,Healthy,Intramucosal CRC,Intramucosal CRC is in its earliest stage (stage 0) and is also known as carcinoma in situ or intramucosal carcinoma. Intramucosal CRC has not yet grown beyond the inner mucosal layer of the colorectum,10,24,None Specified,16S,34,Illumina,LEfSe,0.05,NA,3,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:652/2/NA,Study 652,"cross-sectional observational, not case-control",30794590,10.1371/journal.pone.0212406,NA,"Saito K, Koido S, Odamaki T, Kajihara M, Kato K, Horiuchi S, Adachi S, Arakawa H, Yoshida S, Akasu T, Ito Z, Uchiyama K, Saruta M, Xiao JZ, Sato N , Ohkusa T",Metagenomic analyses of the gut microbiota associated with colorectal adenoma,PloS one,2019,NA,Experiment 2,Japan,Homo sapiens,Intestine,UBERON:0000160,Colorectal cancer,EFO:0005842,CRA (colorectal adenoma),Intramucosal CRC,Intramucosal CRC is in its earliest stage (stage 0) and is also known as carcinoma in situ or intramucosal carcinoma. Intramucosal CRC has not yet grown beyond the inner mucosal layer of the colorectum,47,24,None Specified,16S,34,Illumina,LEfSe,0.05,NA,3,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:652/3/NA,Study 652,"cross-sectional observational, not case-control",30794590,10.1371/journal.pone.0212406,NA,"Saito K, Koido S, Odamaki T, Kajihara M, Kato K, Horiuchi S, Adachi S, Arakawa H, Yoshida S, Akasu T, Ito Z, Uchiyama K, Saruta M, Xiao JZ, Sato N , Ohkusa T",Metagenomic analyses of the gut microbiota associated with colorectal adenoma,PloS one,2019,NA,Experiment 3,Japan,Homo sapiens,Intestine,UBERON:0000160,Colorectal adenoma,EFO:0005406,Healthy,CRA (colorectal adenoma),"Colorectal adenoma, as diagnosed after a complete colonoscopic exampination",10,47,None Specified,16S,34,Illumina,LEfSe,0.05,NA,3,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:653/1/NA,Study 653,case-control,28988196,10.1136/gutjnl-2017-314814,https://pubmed.ncbi.nlm.nih.gov/28988196/,"Flemer B, Warren RD, Barrett MP, Cisek K, Das A, Jeffery IB, Hurley E, O'Riordain M, Shanahan F , O'Toole PW",The oral microbiota in colorectal cancer is distinctive and predictive,Gut,2018,"colonic bacteria, colorectal cancer, colorectal cancer screening, diet, tumour markers",Experiment 1,Ireland,Homo sapiens,Oral cavity,UBERON:0000167,Colorectal cancer,EFO:0005842,Healthy Controls,Individuals with CRC,Individuals diagnosed with CRC,103,99,1 month,16S,34,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:653/2/NA,Study 653,case-control,28988196,10.1136/gutjnl-2017-314814,https://pubmed.ncbi.nlm.nih.gov/28988196/,"Flemer B, Warren RD, Barrett MP, Cisek K, Das A, Jeffery IB, Hurley E, O'Riordain M, Shanahan F , O'Toole PW",The oral microbiota in colorectal cancer is distinctive and predictive,Gut,2018,"colonic bacteria, colorectal cancer, colorectal cancer screening, diet, tumour markers",Experiment 2,Ireland,Homo sapiens,Oral cavity,UBERON:0000167,Colorectal cancer,EFO:0005842,Healthy Controls,Individuals with CRC,Individuals diagnosed with CRC,103,99,1 month,16S,34,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:653/3/NA,Study 653,case-control,28988196,10.1136/gutjnl-2017-314814,https://pubmed.ncbi.nlm.nih.gov/28988196/,"Flemer B, Warren RD, Barrett MP, Cisek K, Das A, Jeffery IB, Hurley E, O'Riordain M, Shanahan F , O'Toole PW",The oral microbiota in colorectal cancer is distinctive and predictive,Gut,2018,"colonic bacteria, colorectal cancer, colorectal cancer screening, diet, tumour markers",Experiment 3,Ireland,Homo sapiens,Oral cavity,UBERON:0000167,Colorectal cancer,EFO:0005842,Healthy Controls,Individuals with polyps,Individuals diagnosed with polyps,103,32,1 month,16S,34,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:654/1/NA,Study 654,"cross-sectional observational, not case-control",30513082,10.1371/journal.pbio.2006842,https://pubmed.ncbi.nlm.nih.gov/30513082/,"Brooks AW, Priya S, Blekhman R , Bordenstein SR",Gut microbiota diversity across ethnicities in the United States,PLoS biology,2018,NA,Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Ethnic group,EFO:0001799,Caucasians,Asian Pacific,Asian Pacific sampled from the American Gut Project (AGP) data set,1237,88,NA,16S,345,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,"age,body mass index,sex",NA,decreased,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:654/2/NA,Study 654,"cross-sectional observational, not case-control",30513082,10.1371/journal.pbio.2006842,https://pubmed.ncbi.nlm.nih.gov/30513082/,"Brooks AW, Priya S, Blekhman R , Bordenstein SR",Gut microbiota diversity across ethnicities in the United States,PLoS biology,2018,NA,Experiment 2,United States of America,Homo sapiens,Feces,UBERON:0001988,Ethnic group,EFO:0001799,Caucasians,Hispanic,Hispanics sampled from the American Gut Project (AGP) data set,1237,37,NA,16S,345,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,"age,body mass index,sex",NA,increased,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:654/3/NA,Study 654,"cross-sectional observational, not case-control",30513082,10.1371/journal.pbio.2006842,https://pubmed.ncbi.nlm.nih.gov/30513082/,"Brooks AW, Priya S, Blekhman R , Bordenstein SR",Gut microbiota diversity across ethnicities in the United States,PLoS biology,2018,NA,Experiment 3,United States of America,Homo sapiens,Feces,UBERON:0001988,Ethnic group,EFO:0001799,Caucasians,African Americans,African Americans sampled from the American Gut Project (AGP) data set,1237,13,NA,16S,345,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,"age,body mass index,sex",NA,decreased,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:654/4/NA,Study 654,"cross-sectional observational, not case-control",30513082,10.1371/journal.pbio.2006842,https://pubmed.ncbi.nlm.nih.gov/30513082/,"Brooks AW, Priya S, Blekhman R , Bordenstein SR",Gut microbiota diversity across ethnicities in the United States,PLoS biology,2018,NA,Experiment 4,United States of America,Homo sapiens,Feces,UBERON:0001988,Ethnic group,EFO:0001799,Caucasians,Asian Pacific,Asian Pacific sampled from Human Microbiome Project (HMP) data set,211,34,NA,16S,345,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,"age,body mass index,sex",NA,decreased,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:654/5/NA,Study 654,"cross-sectional observational, not case-control",30513082,10.1371/journal.pbio.2006842,https://pubmed.ncbi.nlm.nih.gov/30513082/,"Brooks AW, Priya S, Blekhman R , Bordenstein SR",Gut microbiota diversity across ethnicities in the United States,PLoS biology,2018,NA,Experiment 5,United States of America,Homo sapiens,Feces,UBERON:0001988,Ethnic group,EFO:0001799,Caucasians,Hispanics,Hispanics sampled from Human Microbiome Project (HMP) data set,211,43,NA,16S,345,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,"age,body mass index,sex",NA,increased,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:654/6/NA,Study 654,"cross-sectional observational, not case-control",30513082,10.1371/journal.pbio.2006842,https://pubmed.ncbi.nlm.nih.gov/30513082/,"Brooks AW, Priya S, Blekhman R , Bordenstein SR",Gut microbiota diversity across ethnicities in the United States,PLoS biology,2018,NA,Experiment 6,United States of America,Homo sapiens,Feces,UBERON:0001988,Ethnic group,EFO:0001799,Caucasians,African Americans,African Americans sampled from Human Microbiome Project (HMP) data set,211,10,NA,16S,345,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,"age,body mass index,sex",NA,decreased,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:655/1/NA,Study 655,prospective cohort,31771977,10.1128/mSystems.00639-19,https://pubmed.ncbi.nlm.nih.gov/31771977/,"Yang Y, Zheng W, Cai Q, Shrubsole MJ, Pei Z, Brucker R, Steinwandel M, Bordenstein SR, Li Z, Blot WJ, Shu XO , Long J",Racial Differences in the Oral Microbiome: Data from Low-Income Populations of African Ancestry and European Ancestry,mSystems,2019,"oral microbiome, racial difference",Experiment 1,United States of America,Homo sapiens,Oral opening,UBERON:0000166,Ethnic group,EFO:0001799,European Americans (EA),African Americans (AA),"Mouth rinse samples of 1,058 African Americans, with about 57% population with low SES of annual household income < $15,000.",558,1058,12 Months,16S,1234,Illumina,Logistic Regression,0.05,TRUE,NA,NA,"age,alcohol drinking,body mass index,household income,sex,smoking status",NA,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:656/1/NA,Study 656,"cross-sectional observational, not case-control",26982745,10.1097/MPG.0000000000001186,https://pubmed.ncbi.nlm.nih.gov/26982745/,"Mello CS, Carmo-Rodrigues MS, Filho HB, Melli LC, Tahan S, Pignatari AC , de Morais MB",Gut Microbiota Differences in Children From Distinct Socioeconomic Levels Living in the Same Urban Area in Brazil,Journal of pediatric gastroenterology and nutrition,2016,NA,Experiment 1,Brazil,Homo sapiens,Feces,UBERON:0001988,Socioeconomic status,EXO:0000114,Private school children (High SES),Children living in slum (Low SES),"Children between 5 and 11 years old living in slums in Sao Paulo State, Brazil.",30,100,1 month,16S,NA,RT-qPCR,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:657/1/NA,Study 657,case-control,37542310,10.1186/s40168-023-01613-y,https://microbiomejournal.biomedcentral.com/articles/10.1186/s40168-023-01613-y,"Mäkinen AI, Pappalardo VY, Buijs MJ, Brandt BW, Mäkitie AA, Meurman JH , Zaura E",Salivary microbiome profiles of oral cancer patients analyzed before and after treatment,Microbiome,2023,"Cancer treatment, Oral cancer, Oral microbiome",Experiment 1,Finland,Homo sapiens,Oral cavity,UBERON:0000167,Oral squamous cell carcinoma,EFO:0000199,Healthy controls,pre-treatment oral squamous cell carcinoma patients,"Patients diagnosed with Oral Squamous Cell Carcinoma (OSCC), prior to receiving cancer treatment",101,99,Not mentioned,16S,4,Illumina,LEfSe,0.05,TRUE,NA,"age,sex",NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:657/2/NA,Study 657,case-control,37542310,10.1186/s40168-023-01613-y,https://microbiomejournal.biomedcentral.com/articles/10.1186/s40168-023-01613-y,"Mäkinen AI, Pappalardo VY, Buijs MJ, Brandt BW, Mäkitie AA, Meurman JH , Zaura E",Salivary microbiome profiles of oral cancer patients analyzed before and after treatment,Microbiome,2023,"Cancer treatment, Oral cancer, Oral microbiome",Experiment 2,Finland,Homo sapiens,Oral cavity,UBERON:0000167,Oral squamous cell carcinoma,EFO:0000199,"Nonsmoking, nondrinking, and dentate healthy controls","Nonsmoking, nondrinking, and dentate pre-treatment OSCC patients","OSCC patients who have not received any cancer treatment yet and who do not smoke tobacco or drink alcohol, and have at least one remaining tooth in their mouth.",34,24,Not mentioned,16S,4,Illumina,LEfSe,0.05,TRUE,NA,"age,sex",NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:657/3/NA,Study 657,case-control,37542310,10.1186/s40168-023-01613-y,https://microbiomejournal.biomedcentral.com/articles/10.1186/s40168-023-01613-y,"Mäkinen AI, Pappalardo VY, Buijs MJ, Brandt BW, Mäkitie AA, Meurman JH , Zaura E",Salivary microbiome profiles of oral cancer patients analyzed before and after treatment,Microbiome,2023,"Cancer treatment, Oral cancer, Oral microbiome",Experiment 3,Finland,Homo sapiens,Oral cavity,UBERON:0000167,Oral squamous cell carcinoma,EFO:0000199,pre-treatment OSCC patients,post-treatment OSCC patients,"OSCC patients who received cancer treatment, and seen after a mean follow-up of 47.8 months.",28,28,Not mentioned,16S,4,Illumina,LEfSe,0.05,TRUE,NA,"age,sex",NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:658/1/NA,Study 658,randomized controlled trial,34622226,https://doi.org/10.1016/j.xcrm.2021.100383,https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(21)00237-8,"Wang F, He MM, Yao YC, Zhao X, Wang ZQ, Jin Y, Luo HY, Li JB, Wang FH, Qiu MZ, Lv ZD, Wang DS, Li YH, Zhang DS , Xu RH",Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib/II clinical trial and gut microbiome analysis,Cell reports. Medicine,2021,"colorectal cancer, immunotherapy, microbiome, programmed cell death protein 1, regorafenib, toripalimab",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,Non-responders (Progressive Disease),Responders (Partial Response or Stable Disease),"Patients with histologically confirmed metastatic or unresectable MSS/MSI-L/pMMR colorectal cancer treated with 80 mg, or 120 mg regorafenib, plus toripalimab resulting in stable disease or partial response.",21,11,Any condition requiring ongoing systemic antibiotic therapy,16S,34,Illumina,LEfSe,0.05,NA,3,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:659/1/NA,Study 659,case-control,33435800,10.1080/19490976.2020.1869504,NA,"Harry Cheuk Hay Lau, Joseph Jao-Yiu Sung",Gut microbiota: impacts on gastrointestinal cancer immunotherapy,Gut microbes,2021,"CpG- oligodeoxynucleotide therapy, Gut microbiota, adoptive cell transfer, blockade-induced adverse events, gastrointestinal cancer, immune checkpoint blockade, probiotics",Experiment 1,United States of America,Mus musculus,Wall of small intestine,UBERON:0001168,Gastric cancer,MONDO:0001056,Mice quarantined to a different breeding environment,Mice kept in original breeding environment,Mature mice from a distinct strain,6,6,4 weeks,16S,NA,RT-qPCR,Kruskall-Wallis,NA,NA,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:660/1/NA,Study 660,case-control,34123872,https://doi.org/10.3389/fcimb.2021.658203,https://pubmed.ncbi.nlm.nih.gov/34123872/,"Jia YJ, Liao Y, He YQ, Zheng MQ, Tong XT, Xue WQ, Zhang JB, Yuan LL, Zhang WL , Jia WH",Association Between Oral Microbiota and Cigarette Smoking in the Chinese Population,Frontiers in cellular and infection microbiology,2021,"16S rRNA gene sequencing, China, cigarette smoking, oral microbiota, saliva",Experiment 1,China,Homo sapiens,Saliva,UBERON:0001836,Smoking behavior,EFO:0004318,Never smokers,Smokers,"Subjects who smoked at least one cigarette every one to three days in the past year, or who smoked at least one cigarette every one to three days but had quit smoking for at least a year (ever smokers + current smokers groups combined)",150,166,NA,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:661/1/NA,Study 661,"cross-sectional observational, not case-control",36350161,https://doi.org/10.1128/spectrum.01926-22,NA,"Li S, Guo J, Liu R, Zhang F, Wen S, Liu Y, Ren W, Zhang X, Shang Y, Gao M, Lu J , Pang Y",Predominance of Escherichia-Shigella in Gut Microbiome and Its Potential Correlation with Elevated Level of Plasma Tumor Necrosis Factor Alpha in Patients with Tuberculous Meningitis,Microbiology spectrum,2022,"Escherichia-Shigella, TNF-α, claudin-5, gut microbiota, tuberculous meningitis",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Meningeal tuberculosis,EFO:1000039,Healthy Control (HC),Tuberculosis Meningitis (TBM),The patients who have been diagnosed from Tuberculosis Meningitis (TBM).,9,9,"proof of extensive antibiotic therapy for 1+ week in previous 6 months. 
also, prior treatment of systemic antituberculous therapy for more than 1 week.",16S,34,Illumina,Welch's T-Test,0.05,FALSE,NA,NA,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:661/2/NA,Study 661,"cross-sectional observational, not case-control",36350161,https://doi.org/10.1128/spectrum.01926-22,NA,"Li S, Guo J, Liu R, Zhang F, Wen S, Liu Y, Ren W, Zhang X, Shang Y, Gao M, Lu J , Pang Y",Predominance of Escherichia-Shigella in Gut Microbiome and Its Potential Correlation with Elevated Level of Plasma Tumor Necrosis Factor Alpha in Patients with Tuberculous Meningitis,Microbiology spectrum,2022,"Escherichia-Shigella, TNF-α, claudin-5, gut microbiota, tuberculous meningitis",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Meningeal tuberculosis,EFO:1000039,Healthy Control (HC),Pulmonary tuberculosis (PTB),The  patients who have been diagnosed from Pulmonary tuberculosis (PTB).,9,13,"therapy for 1+ week in previous 6 months.
also, prior treatment of systemic antituberculous therapy for more than 1 week.",16S,34,Illumina,Welch's T-Test,0.05,FALSE,NA,NA,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:661/3/NA,Study 661,"cross-sectional observational, not case-control",36350161,https://doi.org/10.1128/spectrum.01926-22,NA,"Li S, Guo J, Liu R, Zhang F, Wen S, Liu Y, Ren W, Zhang X, Shang Y, Gao M, Lu J , Pang Y",Predominance of Escherichia-Shigella in Gut Microbiome and Its Potential Correlation with Elevated Level of Plasma Tumor Necrosis Factor Alpha in Patients with Tuberculous Meningitis,Microbiology spectrum,2022,"Escherichia-Shigella, TNF-α, claudin-5, gut microbiota, tuberculous meningitis",Experiment 3,China,Homo sapiens,Feces,UBERON:0001988,Meningeal tuberculosis,EFO:1000039,Pulmonary tuberculosis (PTB),Tuberculosis Meningitis (TBM),The patients who have been diagnosed from Tuberculosis Meningitis (TBM),13,9,"proof of extensive antibiotic therapy for 1+ week in previous 6 months.
also, prior treatment of systemic antituberculous therapy for more than 1 week.",16S,34,Illumina,Welch's T-Test,0.05,FALSE,NA,NA,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:662/1/NA,Study 662,"cross-sectional observational, not case-control",25658868,10.1371/journal.pone.0117427,https://pubmed.ncbi.nlm.nih.gov/25658868/,"Greenhill AR, Tsuji H, Ogata K, Natsuhara K, Morita A, Soli K, Larkins JA, Tadokoro K, Odani S, Baba J, Naito Y, Tomitsuka E, Nomoto K, Siba PM, Horwood PF , Umezaki M",Characterization of the gut microbiota of Papua New Guineans using reverse transcription quantitative PCR,PloS one,2015,NA,Experiment 1,Papua New Guinea,Homo sapiens,Feces,UBERON:0001988,Socioeconomic status,EXO:0000114,High SES (low land region),Low SES (high land region),Participants living a subsistence lifestyle in the high-land rural areas of Papua New Guinea,29,86,NA,16S,NA,RT-qPCR,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,"age,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:663/1/NA,Study 663,"cross-sectional observational, not case-control",33514807,10.1038/s41598-021-82311-3,https://pubmed.ncbi.nlm.nih.gov/33514807/,"Dwiyanto J, Hussain MH, Reidpath D, Ong KS, Qasim A, Lee SWH, Lee SM, Foo SC, Chong CW , Rahman S",Ethnicity influences the gut microbiota of individuals sharing a geographical location: a cross-sectional study from a middle-income country,Scientific reports,2021,NA,Experiment 1,Malaysia,Homo sapiens,Feces,UBERON:0001988,Ethnic group,EFO:0001799,Chinese,Malay,Malay ethnic group living in the  Segamat Malaysian community.,65,46,NA,16S,34,Illumina,Linear Regression,0.05,TRUE,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:663/2/NA,Study 663,"cross-sectional observational, not case-control",33514807,10.1038/s41598-021-82311-3,https://pubmed.ncbi.nlm.nih.gov/33514807/,"Dwiyanto J, Hussain MH, Reidpath D, Ong KS, Qasim A, Lee SWH, Lee SM, Foo SC, Chong CW , Rahman S",Ethnicity influences the gut microbiota of individuals sharing a geographical location: a cross-sectional study from a middle-income country,Scientific reports,2021,NA,Experiment 2,Malaysia,Homo sapiens,Feces,UBERON:0001988,Ethnic group,EFO:0001799,Chinese,India,India ethnic group living in the  Segamat Malaysian community.,65,49,NA,16S,34,Illumina,Linear Regression,0.05,TRUE,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:663/3/NA,Study 663,"cross-sectional observational, not case-control",33514807,10.1038/s41598-021-82311-3,https://pubmed.ncbi.nlm.nih.gov/33514807/,"Dwiyanto J, Hussain MH, Reidpath D, Ong KS, Qasim A, Lee SWH, Lee SM, Foo SC, Chong CW , Rahman S",Ethnicity influences the gut microbiota of individuals sharing a geographical location: a cross-sectional study from a middle-income country,Scientific reports,2021,NA,Experiment 3,Malaysia,Homo sapiens,Feces,UBERON:0001988,Ethnic group,EFO:0001799,Chinese,Jakun,Jakun ethnic group living in the  Segamat Malaysian community.,65,54,Unspecified,16S,34,Illumina,Linear Regression,0.05,TRUE,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:663/4/NA,Study 663,"cross-sectional observational, not case-control",33514807,10.1038/s41598-021-82311-3,https://pubmed.ncbi.nlm.nih.gov/33514807/,"Dwiyanto J, Hussain MH, Reidpath D, Ong KS, Qasim A, Lee SWH, Lee SM, Foo SC, Chong CW , Rahman S",Ethnicity influences the gut microbiota of individuals sharing a geographical location: a cross-sectional study from a middle-income country,Scientific reports,2021,NA,Experiment 4,Malaysia,Homo sapiens,Feces,UBERON:0001988,Ethnic group,EFO:0001799,India,Malay,Malay ethnic group living in the  Segamat Malaysian community.,49,46,NA,16S,34,Illumina,Linear Regression,0.05,TRUE,NA,NA,"demographics,diet,health,hygiene",unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:663/5/NA,Study 663,"cross-sectional observational, not case-control",33514807,10.1038/s41598-021-82311-3,https://pubmed.ncbi.nlm.nih.gov/33514807/,"Dwiyanto J, Hussain MH, Reidpath D, Ong KS, Qasim A, Lee SWH, Lee SM, Foo SC, Chong CW , Rahman S",Ethnicity influences the gut microbiota of individuals sharing a geographical location: a cross-sectional study from a middle-income country,Scientific reports,2021,NA,Experiment 5,Malaysia,Homo sapiens,Feces,UBERON:0001988,Ethnic group,EFO:0001799,Jakun,India,India ethnic group living in the  Segamat Malaysian community.,54,49,NA,16S,34,Illumina,Linear Regression,0.05,TRUE,NA,NA,"demographics,diet,health,hygiene",unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:664/1/NA,Study 664,case-control,28506555,10.1016/j.brainres.2017.04.019,NA,"Hopfner F, Künstner A, Müller SH, Künzel S, Zeuner KE, Margraf NG, Deuschl G, Baines JF , Kuhlenbäumer G",Gut microbiota in Parkinson disease in a northern German cohort,Brain research,2017,"Gut microbiota, Parkinson disease, Stool",Experiment 1,Germany,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Healthy controls.,Participants with Parkinson's Disease.,Participants diagnosed with Parkinson's Disease by a movement disorder specialist in the clinic according to the UK Parkinson’s Disease Society Brain Bank Clinical Diagnostic Criteria.,29,29,Antibiotic use within the last three months and COMT inhibitors.,16S,12,Illumina,Mann-Whitney (Wilcoxon),0.05,NA,NA,age,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:665/1/NA,Study 665,prospective cohort,28368458,10.1093/annonc/mdx108,https://pubmed.ncbi.nlm.nih.gov/28368458/,"Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, Boselli L, Routier E, Cassard L, Collins M, Vaysse T, Marthey L, Eggermont A, Asvatourian V, Lanoy E, Mateus C, Robert C , Carbonnel F",Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab,Annals of oncology : official journal of the European Society for Medical Oncology,2017,"colitis, ipilimumab, melanoma, microbiota",Experiment 1,France,Homo sapiens,Feces,UBERON:0001988,Response to immunochemotherapy,EFO:0007754,"Resistance, Non responders, No colitis","Responders, Colitis",MM patients that developed an immune-mediated colitis following ipilimumab treatment,19,7,NA,16S,34,Illumina,LEfSe,0.05,NA,3.5,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:666/1/NA,Study 666,"cross-sectional observational, not case-control",22228076,10.1097/MPG.0b013e318249039c.,https://pubmed.ncbi.nlm.nih.gov/22228076/,"Grześkowiak Ł, Collado MC, Mangani C, Maleta K, Laitinen K, Ashorn P, Isolauri E , Salminen S",Distinct gut microbiota in southeastern African and northern European infants,Journal of pediatric gastroenterology and nutrition,2012,NA,Experiment 1,"Finland,Malawi",Homo sapiens,Feces,UBERON:0001988,Socioeconomic status,EXO:0000114,High-Income country (Finland),Low-income country (Malawi),44 healthy 6-month-old rural infants from Malawi,31,44,6 months,WMS,NA,RT-qPCR,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:667/1/NA,Study 667,prospective cohort,32925716,10.1097/MD.0000000000021788,https://pubmed.ncbi.nlm.nih.gov/32925716/,"Li L , Ye J",Characterization of gut microbiota in patients with primary hepatocellular carcinoma received immune checkpoint inhibitors: A Chinese population-based study,Medicine,2020,NA,Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Response to immunochemotherapy,EFO:0007754,Non-responders,Responders,"Patients in the clinical response group treated by immune checkpoint inhibitors therapy (defined by radiographic evidence of complete response, partial response or stable disease per RECIST 1.1 criteria for at least 6 months)",NA,NA,NA,16S,4,Illumina,LEfSe,0.05,NA,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:667/2/NA,Study 667,prospective cohort,32925716,10.1097/MD.0000000000021788,https://pubmed.ncbi.nlm.nih.gov/32925716/,"Li L , Ye J",Characterization of gut microbiota in patients with primary hepatocellular carcinoma received immune checkpoint inhibitors: A Chinese population-based study,Medicine,2020,NA,Experiment 2,China,Homo sapiens,Buccal mucosa,UBERON:0006956,Response to immunochemotherapy,EFO:0007754,Non-responders,Responders,"Patients in the clinical response group treated by immune checkpoint inhibitors therapy (defined by radiographic evidence of complete response, partial response or stable disease per RECIST 1.1 criteria for at least 6 months)",NA,NA,NA,16S,4,Illumina,LEfSe,0.05,NA,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:668/1/NA,Study 668,"cross-sectional observational, not case-control",32236123,10.1371/journal.pone.0228574,NA,"Stennett CA, Dyer TV, He X, Robinson CK, Ravel J, Ghanem KG , Brotman RM",A cross-sectional pilot study of birth mode and vaginal microbiota in reproductive-age women,PloS one,2020,NA,Experiment 1,United States of America,Homo sapiens,Vaginal fluid,UBERON:0036243,Bacterial vaginosis,EFO:0003932,vaginal delivery,cesarean section,women reported birth by C-section,117,27,women reported birth by vaginal delivery,PCR,NA,Illumina,LEfSe,NA,FALSE,4,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:669/1/NA,Study 669,"cross-sectional observational, not case-control",20679230,10.1073/pnas.1005963107,https://pubmed.ncbi.nlm.nih.gov/20679230/,"De Filippo C, Cavalieri D, Di Paola M, Ramazzotti M, Poullet JB, Massart S, Collini S, Pieraccini G , Lionetti P",Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa,Proceedings of the National Academy of Sciences of the United States of America,2010,NA,Experiment 1,"Italy,Burkina Faso",Homo sapiens,Feces,UBERON:0001988,"Ethnic group,Place of residence measurement","EFO:0001799,EFO:0009583",European Children in Italy,Rural African Children in Burkina Faso,"14 healthy children (nine male and six female) living in the rural village of Boulpon district of Nanoro, Boulkiemde province, Burkina Faso.",15,14,6 months,16S,56,Roche454,Kruskall-Wallis,0.05,FALSE,NA,NA,NA,NA,increased,increased,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:669/2/NA,Study 669,"cross-sectional observational, not case-control",20679230,10.1073/pnas.1005963107,https://pubmed.ncbi.nlm.nih.gov/20679230/,"De Filippo C, Cavalieri D, Di Paola M, Ramazzotti M, Poullet JB, Massart S, Collini S, Pieraccini G , Lionetti P",Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa,Proceedings of the National Academy of Sciences of the United States of America,2010,NA,Experiment 2,"Burkina Faso,Italy",Homo sapiens,Feces,UBERON:0001988,"Ethnic group,Place of residence measurement","EFO:0001799,EFO:0009583",European Children in Italy,Rural African Children in Burkina Faso,"14 healthy children (nine male and six female) living in the rural village of Boulpon district of Nanoro, Boulkiemde province, Burkina Faso.",15,14,6 months,16S,56,Roche454,T-Test,0.05,TRUE,NA,NA,NA,NA,increased,increased,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:669/3/NA,Study 669,"cross-sectional observational, not case-control",20679230,10.1073/pnas.1005963107,https://pubmed.ncbi.nlm.nih.gov/20679230/,"De Filippo C, Cavalieri D, Di Paola M, Ramazzotti M, Poullet JB, Massart S, Collini S, Pieraccini G , Lionetti P",Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa,Proceedings of the National Academy of Sciences of the United States of America,2010,NA,Experiment 3,"Burkina Faso,Italy",Homo sapiens,Feces,UBERON:0001988,"Ethnic group,Place of residence measurement","EFO:0001799,EFO:0009583",European Children in Italy,Rural African Children in Burkina Faso,"14 healthy children (nine male and six female) living in the rural village of Boulpon district of Nanoro, Boulkiemde province, Burkina Faso.",15,14,6 months,16S,56,Roche454,ANOVA,0.05,FALSE,NA,NA,NA,NA,increased,increased,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:670/1/NA,Study 670,"cross-sectional observational, not case-control",23349750,10.1371/journal.pone.0053838,https://pubmed.ncbi.nlm.nih.gov/23349750/,"Lin A, Bik EM, Costello EK, Dethlefsen L, Haque R, Relman DA , Singh U",Distinct distal gut microbiome diversity and composition in healthy children from Bangladesh and the United States,PloS one,2013,NA,Experiment 1,"United States of America,Bangladesh",Homo sapiens,Feces,UBERON:0001988,"Ethnic group,Socioeconomic status","EFO:0001799,EXO:0000114",US children,Bangladesh Children (Household income < $61),"Fecal specimens from 6 Bangladeshi children (ages 8–13), in low socioeconomic conditions with an average monthly income per family of,5,000 takas (the U.S. $61).",4,6,3 months,16S,123,Roche454,ANOSIM,0.1,TRUE,NA,NA,"age,sex",NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:671/1/NA,Study 671,prospective cohort,32011017,10.1111/ppe.12623,https://pubmed.ncbi.nlm.nih.gov/32011017/,"Kortekangas E, Kamng'ona AW, Fan YM, Cheung YB, Ashorn U, Matchado A, Poelman B, Maleta K, Dewey KG , Ashorn P",Environmental exposures and child and maternal gut microbiota in rural Malawi,Paediatric and perinatal epidemiology,2020,"child health, environment, gut microbiota, seasons, socio-economic factors",Experiment 1,Malawi,Homo sapiens,Feces,UBERON:0001988,Seasonal gut microbiome measurement,EFO:0007753,samples taken in dry/hot or rainy season,samples taken in dry/cold season,samples taken in the dry/cold season,NA,NA,NA,16S,4,Illumina,Zero-Inflated Beta Regression,0.05,TRUE,NA,NA,"antibiotic exposure,delivery procedure,education level,marital status,maternal age,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:672/1/NA,Study 672,time series / longitudinal observational,33732655,10.3389/fcimb.2021.595323,https://pubmed.ncbi.nlm.nih.gov/33732655/,"Chong CYL, Vatanen T, Alexander T, Bloomfield FH , O'Sullivan JM",Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial,Frontiers in cellular and infection microbiology,2021,"early life nutrition, ethnicity, gut microbiome, moderate–late preterm infant, socioeconomic status",Experiment 1,New Zealand,Homo sapiens,Feces,UBERON:0001988,Spontaneous preterm birth,EFO:0006917,Day-10 (D10) (chronological age),4-months corrected age (4M),Faecal samples collected from moderate–late preterm (MLPT) babies enrolled in a randomized controlled trial of nutritional management at 4-months corrected age (4M).,207,118,None,16S,34,Illumina,MaAsLin2,0.05,TRUE,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:672/2/NA,Study 672,time series / longitudinal observational,33732655,10.3389/fcimb.2021.595323,https://pubmed.ncbi.nlm.nih.gov/33732655/,"Chong CYL, Vatanen T, Alexander T, Bloomfield FH , O'Sullivan JM",Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial,Frontiers in cellular and infection microbiology,2021,"early life nutrition, ethnicity, gut microbiome, moderate–late preterm infant, socioeconomic status",Experiment 2,New Zealand,Homo sapiens,Feces,UBERON:0001988,Spontaneous preterm birth,EFO:0006917,Higher SES (D10),Lower SES (D10),Moderate–late preterm (MLPT) babies at Day-10 (D10) whose families lived in the lower SES (socioeconomic status) areas,59,80,None,16S,34,Illumina,MaAsLin2,0.05,TRUE,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:672/3/NA,Study 672,time series / longitudinal observational,33732655,10.3389/fcimb.2021.595323,https://pubmed.ncbi.nlm.nih.gov/33732655/,"Chong CYL, Vatanen T, Alexander T, Bloomfield FH , O'Sullivan JM",Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial,Frontiers in cellular and infection microbiology,2021,"early life nutrition, ethnicity, gut microbiome, moderate–late preterm infant, socioeconomic status",Experiment 3,New Zealand,Homo sapiens,Feces,UBERON:0001988,Spontaneous preterm birth,EFO:0006917,Higher SES (4M),Lower SES (4M),Moderate–Late Preterm (MLPT) babies at 4-months corrected-age (4M) whose families lived in the lower SES (socioeconomic status) areas,59,80,None,16S,34,Illumina,MaAsLin2,0.05,TRUE,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:672/4/NA,Study 672,time series / longitudinal observational,33732655,10.3389/fcimb.2021.595323,https://pubmed.ncbi.nlm.nih.gov/33732655/,"Chong CYL, Vatanen T, Alexander T, Bloomfield FH , O'Sullivan JM",Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial,Frontiers in cellular and infection microbiology,2021,"early life nutrition, ethnicity, gut microbiome, moderate–late preterm infant, socioeconomic status",Experiment 4,New Zealand,Homo sapiens,Feces,UBERON:0001988,Spontaneous preterm birth,EFO:0006917,European (D10),Maori (D10),Moderate–Late Preterm (MLPT) Babies at D10 born to mothers self-reporting as Maori,77,24,None,16S,34,Illumina,MaAsLin2,0.05,TRUE,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:672/5/NA,Study 672,time series / longitudinal observational,33732655,10.3389/fcimb.2021.595323,https://pubmed.ncbi.nlm.nih.gov/33732655/,"Chong CYL, Vatanen T, Alexander T, Bloomfield FH , O'Sullivan JM",Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial,Frontiers in cellular and infection microbiology,2021,"early life nutrition, ethnicity, gut microbiome, moderate–late preterm infant, socioeconomic status",Experiment 5,New Zealand,Homo sapiens,Feces,UBERON:0001988,Spontaneous preterm birth,EFO:0006917,Asian (4M),Maori (4M),Moderate–Late Preterm (MLPT) babies at 4M born to mothers self-reporting as Maori,72,24,None,16S,34,Illumina,MaAsLin2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:672/6/NA,Study 672,time series / longitudinal observational,33732655,10.3389/fcimb.2021.595323,https://pubmed.ncbi.nlm.nih.gov/33732655/,"Chong CYL, Vatanen T, Alexander T, Bloomfield FH , O'Sullivan JM",Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial,Frontiers in cellular and infection microbiology,2021,"early life nutrition, ethnicity, gut microbiome, moderate–late preterm infant, socioeconomic status",Experiment 6,New Zealand,Homo sapiens,Feces,UBERON:0001988,Spontaneous preterm birth,EFO:0006917,Asian (4M),Pacifica (4M),Moderate–Late Preterm (MLPT) babies at 4-months born to mothers self-reporting as Pacifica,72,36,None,16S,34,Illumina,MaAsLin2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:672/7/NA,Study 672,time series / longitudinal observational,33732655,10.3389/fcimb.2021.595323,https://pubmed.ncbi.nlm.nih.gov/33732655/,"Chong CYL, Vatanen T, Alexander T, Bloomfield FH , O'Sullivan JM",Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial,Frontiers in cellular and infection microbiology,2021,"early life nutrition, ethnicity, gut microbiome, moderate–late preterm infant, socioeconomic status",Experiment 7,New Zealand,Homo sapiens,Feces,UBERON:0001988,Spontaneous preterm birth,EFO:0006917,No University (4M),University (4M),Moderate–late preterm (MLPT) babies at 4-months whose mothers have a university degree,108,105,None,16S,34,Illumina,MaAsLin2,0.05,TRUE,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:672/8/NA,Study 672,time series / longitudinal observational,33732655,10.3389/fcimb.2021.595323,https://pubmed.ncbi.nlm.nih.gov/33732655/,"Chong CYL, Vatanen T, Alexander T, Bloomfield FH , O'Sullivan JM",Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial,Frontiers in cellular and infection microbiology,2021,"early life nutrition, ethnicity, gut microbiome, moderate–late preterm infant, socioeconomic status",Experiment 8,New Zealand,Homo sapiens,Feces,UBERON:0001988,Spontaneous preterm birth,EFO:0006917,Mix feeding (4M),Breastmilk feeding (4M),Moderate–late preterm (MLPT) babies at 4-months corrected age who were breastmilk fed,95,36,None,16S,34,Illumina,MaAsLin2,0.05,TRUE,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:672/9/NA,Study 672,time series / longitudinal observational,33732655,10.3389/fcimb.2021.595323,https://pubmed.ncbi.nlm.nih.gov/33732655/,"Chong CYL, Vatanen T, Alexander T, Bloomfield FH , O'Sullivan JM",Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial,Frontiers in cellular and infection microbiology,2021,"early life nutrition, ethnicity, gut microbiome, moderate–late preterm infant, socioeconomic status",Experiment 9,New Zealand,Homo sapiens,Feces,UBERON:0001988,Spontaneous preterm birth,EFO:0006917,Only formula (4M),Breastmilk feeding (4M),Moderate–late preterm (MLPT) babies at 4-months corrected age who were breastmilk fed,42,36,None,16S,34,Illumina,MaAsLin2,0.05,TRUE,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:672/10/NA,Study 672,time series / longitudinal observational,33732655,10.3389/fcimb.2021.595323,https://pubmed.ncbi.nlm.nih.gov/33732655/,"Chong CYL, Vatanen T, Alexander T, Bloomfield FH , O'Sullivan JM",Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial,Frontiers in cellular and infection microbiology,2021,"early life nutrition, ethnicity, gut microbiome, moderate–late preterm infant, socioeconomic status",Experiment 10,New Zealand,Homo sapiens,Feces,UBERON:0001988,Spontaneous preterm birth,EFO:0006917,Only formula (4M),Mixed feeding (4M),Moderate–late preterm (MLPT) babies at 4-months corrected age who were mix fed,42,95,None,16S,34,Illumina,MaAsLin2,0.05,TRUE,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:672/11/NA,Study 672,time series / longitudinal observational,33732655,10.3389/fcimb.2021.595323,https://pubmed.ncbi.nlm.nih.gov/33732655/,"Chong CYL, Vatanen T, Alexander T, Bloomfield FH , O'Sullivan JM",Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial,Frontiers in cellular and infection microbiology,2021,"early life nutrition, ethnicity, gut microbiome, moderate–late preterm infant, socioeconomic status",Experiment 11,New Zealand,Homo sapiens,Feces,UBERON:0001988,Spontaneous preterm birth,EFO:0006917,No maternal antibiotics,Yes maternal antibiotics,Maternal use of antibiotics within the four-week period before the D10 fecal sample collection,69,130,None,16S,34,Illumina,MaAsLin2,0.05,TRUE,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:672/12/NA,Study 672,time series / longitudinal observational,33732655,10.3389/fcimb.2021.595323,https://pubmed.ncbi.nlm.nih.gov/33732655/,"Chong CYL, Vatanen T, Alexander T, Bloomfield FH , O'Sullivan JM",Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial,Frontiers in cellular and infection microbiology,2021,"early life nutrition, ethnicity, gut microbiome, moderate–late preterm infant, socioeconomic status",Experiment 12,New Zealand,Homo sapiens,Feces,UBERON:0001988,Spontaneous preterm birth,EFO:0006917,No maternal probiotics,Yes maternal probiotics,Maternal use of probiotics within the four-week period before the D10 fecal sample collection,147,19,None,16S,34,Illumina,MaAsLin2,0.05,TRUE,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:672/13/NA,Study 672,time series / longitudinal observational,33732655,10.3389/fcimb.2021.595323,https://pubmed.ncbi.nlm.nih.gov/33732655/,"Chong CYL, Vatanen T, Alexander T, Bloomfield FH , O'Sullivan JM",Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial,Frontiers in cellular and infection microbiology,2021,"early life nutrition, ethnicity, gut microbiome, moderate–late preterm infant, socioeconomic status",Experiment 13,New Zealand,Homo sapiens,Feces,UBERON:0001988,Spontaneous preterm birth,EFO:0006917,No infant probiotics,Yes infant probiotics,D10 fecal samples of infants who themselves received probiotics during their admission,159,40,None,16S,34,Illumina,MaAsLin2,0.05,TRUE,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:672/14/NA,Study 672,time series / longitudinal observational,33732655,10.3389/fcimb.2021.595323,https://pubmed.ncbi.nlm.nih.gov/33732655/,"Chong CYL, Vatanen T, Alexander T, Bloomfield FH , O'Sullivan JM",Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial,Frontiers in cellular and infection microbiology,2021,"early life nutrition, ethnicity, gut microbiome, moderate–late preterm infant, socioeconomic status",Experiment 14,New Zealand,Homo sapiens,Feces,UBERON:0001988,Spontaneous preterm birth,EFO:0006917,No Antibiotics,Yes Antibiotics,Infant who received antibiotic within the month immediately preceding the 4-month follow-up appointment,5,108,N/A,16S,34,Illumina,MaAsLin2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:672/15/NA,Study 672,time series / longitudinal observational,33732655,10.3389/fcimb.2021.595323,https://pubmed.ncbi.nlm.nih.gov/33732655/,"Chong CYL, Vatanen T, Alexander T, Bloomfield FH , O'Sullivan JM",Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial,Frontiers in cellular and infection microbiology,2021,"early life nutrition, ethnicity, gut microbiome, moderate–late preterm infant, socioeconomic status",Experiment 15,New Zealand,Homo sapiens,Feces,UBERON:0001988,Spontaneous preterm birth,EFO:0006917,Only Formula (4M),Breast Milk (4M),Moderate–late preterm (MLPT) babies at 4-months corrected age who were breastmilk fed,42,36,N/A,WMS,NA,Illumina,MaAsLin2,0.05,TRUE,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:672/16/NA,Study 672,time series / longitudinal observational,33732655,10.3389/fcimb.2021.595323,https://pubmed.ncbi.nlm.nih.gov/33732655/,"Chong CYL, Vatanen T, Alexander T, Bloomfield FH , O'Sullivan JM",Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial,Frontiers in cellular and infection microbiology,2021,"early life nutrition, ethnicity, gut microbiome, moderate–late preterm infant, socioeconomic status",Experiment 16,New Zealand,Homo sapiens,Feces,UBERON:0001988,Spontaneous preterm birth,EFO:0006917,Only Formula (D10),Breast Milk (D10),Moderate–late preterm (MLPT) babies at Day 10 who were breastmilk fed,42,36,N/A,16S,34,Illumina,MaAsLin2,0.05,TRUE,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:672/17/NA,Study 672,time series / longitudinal observational,33732655,10.3389/fcimb.2021.595323,https://pubmed.ncbi.nlm.nih.gov/33732655/,"Chong CYL, Vatanen T, Alexander T, Bloomfield FH , O'Sullivan JM",Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial,Frontiers in cellular and infection microbiology,2021,"early life nutrition, ethnicity, gut microbiome, moderate–late preterm infant, socioeconomic status",Experiment 17,New Zealand,Homo sapiens,Feces,UBERON:0001988,Spontaneous preterm birth,EFO:0006917,Mixed Feeding (4M),Breast Milk (4M),Moderate–late preterm (MLPT) babies at 4-months corrected age who were breastmilk fed,95,36,N/A,WMS,NA,Illumina,MaAsLin2,0.05,TRUE,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:672/18/NA,Study 672,time series / longitudinal observational,33732655,10.3389/fcimb.2021.595323,https://pubmed.ncbi.nlm.nih.gov/33732655/,"Chong CYL, Vatanen T, Alexander T, Bloomfield FH , O'Sullivan JM",Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial,Frontiers in cellular and infection microbiology,2021,"early life nutrition, ethnicity, gut microbiome, moderate–late preterm infant, socioeconomic status",Experiment 18,New Zealand,Homo sapiens,Feces,UBERON:0001988,Spontaneous preterm birth,EFO:0006917,Mixed Feeding (D10),Only Formula (D10),Moderate–late preterm (MLPT) babies at Day 10 who were fed with only formula,95,42,N/A,16S,34,Illumina,MaAsLin2,0.05,TRUE,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:672/19/NA,Study 672,time series / longitudinal observational,33732655,10.3389/fcimb.2021.595323,https://pubmed.ncbi.nlm.nih.gov/33732655/,"Chong CYL, Vatanen T, Alexander T, Bloomfield FH , O'Sullivan JM",Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial,Frontiers in cellular and infection microbiology,2021,"early life nutrition, ethnicity, gut microbiome, moderate–late preterm infant, socioeconomic status",Experiment 19,New Zealand,Homo sapiens,Feces,UBERON:0001988,Spontaneous preterm birth,EFO:0006917,No Antibiotics (4M),Yes Antibiotics (4M),Maternal use of antibiotics within the one month preceding the four-month follow-up period,69,130,N/A,16S,34,Illumina,MaAsLin2,0.05,TRUE,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:672/20/NA,Study 672,time series / longitudinal observational,33732655,10.3389/fcimb.2021.595323,https://pubmed.ncbi.nlm.nih.gov/33732655/,"Chong CYL, Vatanen T, Alexander T, Bloomfield FH , O'Sullivan JM",Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial,Frontiers in cellular and infection microbiology,2021,"early life nutrition, ethnicity, gut microbiome, moderate–late preterm infant, socioeconomic status",Experiment 20,New Zealand,Homo sapiens,Feces,UBERON:0001988,Spontaneous preterm birth,EFO:0006917,No Infant Antibiotics (4M),Yes Infant Antibiotics (4M),Infant use of antibiotics within the one month preceding the 4-month follow-up appointment,89,4,N/A,WMS,NA,Illumina,MaAsLin2,0.05,TRUE,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:672/21/NA,Study 672,time series / longitudinal observational,33732655,10.3389/fcimb.2021.595323,https://pubmed.ncbi.nlm.nih.gov/33732655/,"Chong CYL, Vatanen T, Alexander T, Bloomfield FH , O'Sullivan JM",Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial,Frontiers in cellular and infection microbiology,2021,"early life nutrition, ethnicity, gut microbiome, moderate–late preterm infant, socioeconomic status",Experiment 21,New Zealand,Homo sapiens,Feces,UBERON:0001988,Spontaneous preterm birth,EFO:0006917,No Infant Antibiotics (D10),Yes Infant Antibiotics (D10),Infants who themselves use antibiotic during neonatal admission at D10,97,102,N/A,16S,34,Illumina,MaAsLin2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:672/22/NA,Study 672,time series / longitudinal observational,33732655,10.3389/fcimb.2021.595323,https://pubmed.ncbi.nlm.nih.gov/33732655/,"Chong CYL, Vatanen T, Alexander T, Bloomfield FH , O'Sullivan JM",Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial,Frontiers in cellular and infection microbiology,2021,"early life nutrition, ethnicity, gut microbiome, moderate–late preterm infant, socioeconomic status",Experiment 22,New Zealand,Homo sapiens,Feces,UBERON:0001988,Spontaneous preterm birth,EFO:0006917,Caesarean section (D10),Vaginal delivery (D10),D10 fecal samples of MLPT babies born vaginally,136,77,N/A,16S,34,Illumina,MaAsLin2,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:672/23/NA,Study 672,time series / longitudinal observational,33732655,10.3389/fcimb.2021.595323,https://pubmed.ncbi.nlm.nih.gov/33732655/,"Chong CYL, Vatanen T, Alexander T, Bloomfield FH , O'Sullivan JM",Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial,Frontiers in cellular and infection microbiology,2021,"early life nutrition, ethnicity, gut microbiome, moderate–late preterm infant, socioeconomic status",Experiment 23,New Zealand,Homo sapiens,Feces,UBERON:0001988,Spontaneous preterm birth,EFO:0006917,Singletons (4M),Twins (4M),Fecal samples of MLPT babies born as twins at 4-month corrected age,63,31,N/A,16S,34,Illumina,MaAsLin2,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:672/24/NA,Study 672,time series / longitudinal observational,33732655,10.3389/fcimb.2021.595323,https://pubmed.ncbi.nlm.nih.gov/33732655/,"Chong CYL, Vatanen T, Alexander T, Bloomfield FH , O'Sullivan JM",Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial,Frontiers in cellular and infection microbiology,2021,"early life nutrition, ethnicity, gut microbiome, moderate–late preterm infant, socioeconomic status",Experiment 24,New Zealand,Homo sapiens,Feces,UBERON:0001988,Spontaneous preterm birth,EFO:0006917,Singletons (4M),Twins (4M),Fecal samples of MLPT babies born as twins at 4-month corrected age,63,31,N/A,WMS,NA,Illumina,MaAsLin2,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:672/25/NA,Study 672,time series / longitudinal observational,33732655,10.3389/fcimb.2021.595323,https://pubmed.ncbi.nlm.nih.gov/33732655/,"Chong CYL, Vatanen T, Alexander T, Bloomfield FH , O'Sullivan JM",Factors Associated With the Microbiome in Moderate-Late Preterm Babies: A Cohort Study From the DIAMOND Randomized Controlled Trial,Frontiers in cellular and infection microbiology,2021,"early life nutrition, ethnicity, gut microbiome, moderate–late preterm infant, socioeconomic status",Experiment 25,New Zealand,Homo sapiens,Feces,UBERON:0001988,Spontaneous preterm birth,EFO:0006917,Auckland city hospital (4M),Middlemore Hospital (4M),MLPT babies born at Middlemore Hospital at 4-month corrected age,83,80,N/A,WMS,NA,Illumina,MaAsLin2,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:673/1/NA,Study 673,"cross-sectional observational, not case-control",25495462,10.1186/s12866-014-0311-6,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4275940/,"Escobar JS, Klotz B, Valdes BE , Agudelo GM","The gut microbiota of Colombians differs from that of Americans, Europeans and Asians",BMC microbiology,2014,NA,Experiment 1,"United States of America,Colombia,South Korea,Japan,Spain,France,Denmark",Homo sapiens,Feces,UBERON:0001988,Ethnic group,EFO:0001799,USA data,Colombia data,"30 healthy Colombia adults of both genders from the general population living in Medellin, Colombia South America.",13,30,4 Months,16S,123,Roche454,PERMANOVA,0.05,TRUE,NA,NA,"age,sex,waist circumference",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:673/2/NA,Study 673,"cross-sectional observational, not case-control",25495462,10.1186/s12866-014-0311-6,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4275940/,"Escobar JS, Klotz B, Valdes BE , Agudelo GM","The gut microbiota of Colombians differs from that of Americans, Europeans and Asians",BMC microbiology,2014,NA,Experiment 2,"Colombia,Denmark,France,Spain,United States of America,South Korea,Japan",Homo sapiens,Feces,UBERON:0001988,Ethnic group,EFO:0001799,USA data,Europe data,"The European dataset consisted of the subset of 13 healthy volunteers (three women and 10 men) among Spanish, French, and Danish inhabitants whose microbiomes were published by the MetaHIT Consortium",13,13,4 Months,16S,123,Roche454,PERMANOVA,0.05,TRUE,NA,NA,"age,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:673/3/NA,Study 673,"cross-sectional observational, not case-control",25495462,10.1186/s12866-014-0311-6,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4275940/,"Escobar JS, Klotz B, Valdes BE , Agudelo GM","The gut microbiota of Colombians differs from that of Americans, Europeans and Asians",BMC microbiology,2014,NA,Experiment 3,"Colombia,Denmark,France,Spain,United States of America,South Korea,Japan",Homo sapiens,Feces,UBERON:0001988,Ethnic group,EFO:0001799,USA data,South Korea data,The Korean dataset consisted of 14 lean and four overweight individuals (six women and 12 men),54,14,4 months,16S,123,Roche454,PERMANOVA,0.05,TRUE,NA,NA,"age,sex,waist circumference",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:673/4/NA,Study 673,"cross-sectional observational, not case-control",25495462,10.1186/s12866-014-0311-6,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4275940/,"Escobar JS, Klotz B, Valdes BE , Agudelo GM","The gut microbiota of Colombians differs from that of Americans, Europeans and Asians",BMC microbiology,2014,NA,Experiment 4,"Colombia,Denmark,France,South Korea,Spain,United States of America,Japan",Homo sapiens,Feces,UBERON:0001988,Ethnic group,EFO:0001799,USA data,Japan data,The Japanese dataset consisted of 454-generated V1 and V2 16S rDNA sequences of 10 lean and one overweight adult (six females and five males) that participated in an intervention with probiotics,54,11,4 months,16S,12,Roche454,PERMANOVA,0.05,TRUE,NA,NA,"age,sex,waist circumference",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:674/1/NA,Study 674,"cross-sectional observational, not case-control",34444813,10.3390/nu13082645,https://pubmed.ncbi.nlm.nih.gov/34444813/,"Lapidot Y, Reshef L, Goldsmith R, Na'amnih W, Kassem E, Ornoy A, Gophna U , Muhsen K",The Associations between Diet and Socioeconomic Disparities and the Intestinal Microbiome in Preadolescence,Nutrients,2021,"dietary intake, microbiome, obesity, school age, socioeconomic status",Experiment 1,Israel,Homo sapiens,Feces,UBERON:0001988,Socioeconomic status,EXO:0000114,Low SES,High SES,"Children from the higher SES village (A)
SES scores below the median score of 6.4 based on (a) residential SES rank; (b) the number of paternal schooling years; and (c) household crowding index.",69,70,NA,16S,4,Illumina,Linear Regression,0.05,TRUE,NA,NA,"age,body mass index,diet,sex",NA,unchanged,NA,unchanged,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:675/1/NA,Study 675,"cross-sectional observational, not case-control",31973685,10.1080/19490976.2020.1712985,https://pubmed.ncbi.nlm.nih.gov/31973685/,"Moran-Ramos S, Lopez-Contreras BE, Villarruel-Vazquez R, Ocampo-Medina E, Macias-Kauffer L, Martinez-Medina JN, Villamil-Ramirez H, León-Mimila P, Del Rio-Navarro BE, Ibarra-Gonzalez I, Vela-Amieva M, Gomez-Perez FJ, Velazquez-Cruz R, Salmeron J, Reyes-Castillo Z, Aguilar-Salinas C , Canizales-Quinteros S",Environmental and intrinsic factors shaping gut microbiota composition and diversity and its relation to metabolic health in children and early adolescents: A population-based study,Gut microbes,2020,"adolescents, children, co-abundance groups, diversity, enterotypes, gut microbiota, obesity",Experiment 1,Mexico,Homo sapiens,Feces,UBERON:0001988,Socioeconomic status,EXO:0000114,lower monthly household income,higher monthly household income,higher monthly household income,NA,NA,6 months,16S,4,Illumina,PERMANOVA,0.05,TRUE,NA,NA,"age,antibiotic exposure,household income,sex",NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:676/1/NA,Study 676,prospective cohort,31026576,10.1016/j.jtho.2019.04.007,"https://pubmed.ncbi.nlm.nih.gov/31026576/#:~:text=Patients_With_NSCLC-,The_Diversity_of_Gut_Microbiome_is_Associated_With_Favorable_Responses,(8):1378-1389.","Jin Y, Dong H, Xia L, Yang Y, Zhu Y, Shen Y, Zheng H, Yao C, Wang Y , Lu S",The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti-Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC,Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer,2019,"Advanced NSCLC, Clinical benefit, Gut microbiota, Nivolumab, Systemic immune signatures",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Response to immunochemotherapy,EFO:0007754,Non-responders,Responders,Patients in this study were defined as responder (R) (with partial response or stable disease),14,23,NA,16S,34,Illumina,Kruskall-Wallis,0.05,NA,NA,NA,NA,NA,increased,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:677/1/NA,Study 677,prospective cohort,33619320,10.1038/s42003-021-01741-x,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7900251/pdf/42003_2021_Article_1741.pdf,"Sims TT, El Alam MB, Karpinets TV, Dorta-Estremera S, Hegde VL, Nookala S, Yoshida-Court K, Wu X, Biegert GWG, Delgado Medrano AY, Solley T, Ahmed-Kaddar M, Chapman BV, Sastry KJ, Mezzari MP, Petrosino JF, Lin LL, Ramondetta L, Jhingran A, Schmeler KM, Ajami NJ, Wargo J, Colbert LE , Klopp AH",Gut microbiome diversity is an independent predictor of survival in cervical cancer patients receiving chemoradiation,Communications biology,2021,NA,Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Survival time,EFO:0000714,Long-term survivors,Short-term surviviors,Cervical Cancer patients that had a follow-up of one year or less because of death,48,7,None,16S,4,Illumina,LEfSe,0.05,FALSE,3.5,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:678/1/NA,Study 678,case-control,30054546,https://doi.org/10.1038/s41598-018-29730-x,NA,"Vallès Y, Inman CK, Peters BA, Ali R, Wareth LA, Abdulle A, Alsafar H, Anouti FA, Dhaheri AA, Galani D, Haji M, Hamiz AA, Hosani AA, Houqani MA, Junaibi AA, Kazim M, Kirchhoff T, Mahmeed WA, Maskari FA, Alnaeemi A, Oumeziane N, Ramasamy R, Schmidt AM, Weitzman M, Zaabi EA, Sherman S, Hayes RB , Ahn J",Types of tobacco consumption and the oral microbiome in the United Arab Emirates Healthy Future (UAEHFS) Pilot Study,Scientific reports,2018,NA,Experiment 1,United Arab Emirates,Homo sapiens,Saliva,UBERON:0001836,Smoking behavior,EFO:0004318,Nonsmokers,Cigarette Smokers,People consuming tobacco in the form of cigarettes (CS),225,33,None,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,increased,increased,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:678/2/NA,Study 678,case-control,30054546,https://doi.org/10.1038/s41598-018-29730-x,NA,"Vallès Y, Inman CK, Peters BA, Ali R, Wareth LA, Abdulle A, Alsafar H, Anouti FA, Dhaheri AA, Galani D, Haji M, Hamiz AA, Hosani AA, Houqani MA, Junaibi AA, Kazim M, Kirchhoff T, Mahmeed WA, Maskari FA, Alnaeemi A, Oumeziane N, Ramasamy R, Schmidt AM, Weitzman M, Zaabi EA, Sherman S, Hayes RB , Ahn J",Types of tobacco consumption and the oral microbiome in the United Arab Emirates Healthy Future (UAEHFS) Pilot Study,Scientific reports,2018,NA,Experiment 2,United Arab Emirates,Homo sapiens,Saliva,UBERON:0001836,Smoking behavior,EFO:0004318,Nonsmokers,Dokha Smokers,People consuming tobacco in the form of dokha (DS),225,16,None,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:678/3/NA,Study 678,case-control,30054546,https://doi.org/10.1038/s41598-018-29730-x,NA,"Vallès Y, Inman CK, Peters BA, Ali R, Wareth LA, Abdulle A, Alsafar H, Anouti FA, Dhaheri AA, Galani D, Haji M, Hamiz AA, Hosani AA, Houqani MA, Junaibi AA, Kazim M, Kirchhoff T, Mahmeed WA, Maskari FA, Alnaeemi A, Oumeziane N, Ramasamy R, Schmidt AM, Weitzman M, Zaabi EA, Sherman S, Hayes RB , Ahn J",Types of tobacco consumption and the oral microbiome in the United Arab Emirates Healthy Future (UAEHFS) Pilot Study,Scientific reports,2018,NA,Experiment 3,United Arab Emirates,Homo sapiens,Saliva,UBERON:0001836,Smoking behavior,EFO:0004318,Nonsmokers,Shisha Smokers,People consuming tobacco in the form of shisha (SS),225,15,None,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:678/4/NA,Study 678,case-control,30054546,https://doi.org/10.1038/s41598-018-29730-x,NA,"Vallès Y, Inman CK, Peters BA, Ali R, Wareth LA, Abdulle A, Alsafar H, Anouti FA, Dhaheri AA, Galani D, Haji M, Hamiz AA, Hosani AA, Houqani MA, Junaibi AA, Kazim M, Kirchhoff T, Mahmeed WA, Maskari FA, Alnaeemi A, Oumeziane N, Ramasamy R, Schmidt AM, Weitzman M, Zaabi EA, Sherman S, Hayes RB , Ahn J",Types of tobacco consumption and the oral microbiome in the United Arab Emirates Healthy Future (UAEHFS) Pilot Study,Scientific reports,2018,NA,Experiment 4,United Arab Emirates,Homo sapiens,Saliva,UBERON:0001836,Smoking behavior,EFO:0004318,Nonsmokers,Mutiple Smokers,"People consuming tobacco in multiple forms out of cigarettes (CS), dokha (DS) and shisha (SS)",225,41,None,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:678/5/NA,Study 678,case-control,30054546,https://doi.org/10.1038/s41598-018-29730-x,NA,"Vallès Y, Inman CK, Peters BA, Ali R, Wareth LA, Abdulle A, Alsafar H, Anouti FA, Dhaheri AA, Galani D, Haji M, Hamiz AA, Hosani AA, Houqani MA, Junaibi AA, Kazim M, Kirchhoff T, Mahmeed WA, Maskari FA, Alnaeemi A, Oumeziane N, Ramasamy R, Schmidt AM, Weitzman M, Zaabi EA, Sherman S, Hayes RB , Ahn J",Types of tobacco consumption and the oral microbiome in the United Arab Emirates Healthy Future (UAEHFS) Pilot Study,Scientific reports,2018,NA,Experiment 5,United Arab Emirates,Homo sapiens,Saliva,UBERON:0001836,Cotinine measurement,EFO:0007813,Cotinine negative,Cotinine positive,Subjects with positive cotinine result,225,22,None,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:678/6/NA,Study 678,case-control,30054546,https://doi.org/10.1038/s41598-018-29730-x,NA,"Vallès Y, Inman CK, Peters BA, Ali R, Wareth LA, Abdulle A, Alsafar H, Anouti FA, Dhaheri AA, Galani D, Haji M, Hamiz AA, Hosani AA, Houqani MA, Junaibi AA, Kazim M, Kirchhoff T, Mahmeed WA, Maskari FA, Alnaeemi A, Oumeziane N, Ramasamy R, Schmidt AM, Weitzman M, Zaabi EA, Sherman S, Hayes RB , Ahn J",Types of tobacco consumption and the oral microbiome in the United Arab Emirates Healthy Future (UAEHFS) Pilot Study,Scientific reports,2018,NA,Experiment 6,United Arab Emirates,Homo sapiens,Saliva,UBERON:0001836,Smoking behavior,EFO:0004318,Non-smokers,Smokers,"People consuming tobacco (in any form; cigarettes, dokha, shisha)",225,105,None,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,increased,increased,increased,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:678/7/NA,Study 678,case-control,30054546,https://doi.org/10.1038/s41598-018-29730-x,NA,"Vallès Y, Inman CK, Peters BA, Ali R, Wareth LA, Abdulle A, Alsafar H, Anouti FA, Dhaheri AA, Galani D, Haji M, Hamiz AA, Hosani AA, Houqani MA, Junaibi AA, Kazim M, Kirchhoff T, Mahmeed WA, Maskari FA, Alnaeemi A, Oumeziane N, Ramasamy R, Schmidt AM, Weitzman M, Zaabi EA, Sherman S, Hayes RB , Ahn J",Types of tobacco consumption and the oral microbiome in the United Arab Emirates Healthy Future (UAEHFS) Pilot Study,Scientific reports,2018,NA,Experiment 7,United Arab Emirates,Homo sapiens,Saliva,UBERON:0001836,Smoking behavior,EFO:0004318,Dokha,CIigarettes,People consuming tobacco in the form of cigarettes (CS),16,33,None,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:678/8/NA,Study 678,case-control,30054546,https://doi.org/10.1038/s41598-018-29730-x,NA,"Vallès Y, Inman CK, Peters BA, Ali R, Wareth LA, Abdulle A, Alsafar H, Anouti FA, Dhaheri AA, Galani D, Haji M, Hamiz AA, Hosani AA, Houqani MA, Junaibi AA, Kazim M, Kirchhoff T, Mahmeed WA, Maskari FA, Alnaeemi A, Oumeziane N, Ramasamy R, Schmidt AM, Weitzman M, Zaabi EA, Sherman S, Hayes RB , Ahn J",Types of tobacco consumption and the oral microbiome in the United Arab Emirates Healthy Future (UAEHFS) Pilot Study,Scientific reports,2018,NA,Experiment 8,United Arab Emirates,Homo sapiens,Saliva,UBERON:0001836,Smoking behavior,EFO:0004318,Shisha,CIigarettes,People consuming tobacco in the form of cigarettes (CS),15,33,None,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:678/9/NA,Study 678,case-control,30054546,https://doi.org/10.1038/s41598-018-29730-x,NA,"Vallès Y, Inman CK, Peters BA, Ali R, Wareth LA, Abdulle A, Alsafar H, Anouti FA, Dhaheri AA, Galani D, Haji M, Hamiz AA, Hosani AA, Houqani MA, Junaibi AA, Kazim M, Kirchhoff T, Mahmeed WA, Maskari FA, Alnaeemi A, Oumeziane N, Ramasamy R, Schmidt AM, Weitzman M, Zaabi EA, Sherman S, Hayes RB , Ahn J",Types of tobacco consumption and the oral microbiome in the United Arab Emirates Healthy Future (UAEHFS) Pilot Study,Scientific reports,2018,NA,Experiment 9,United Arab Emirates,Homo sapiens,Saliva,UBERON:0001836,Smoking behavior,EFO:0004318,Shisha,Dokha,People consuming tobacco in the form of Dokha,15,16,None,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:679/1/NA,Study 679,time series / longitudinal observational,29302014,10.1126/science.aao3290,https://pubmed.ncbi.nlm.nih.gov/29302014/,"Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre ML, Luke JJ , Gajewski TF",The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients,"Science (New York, N.Y.)",2018,NA,Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Response to immunochemotherapy,EFO:0007754,Non-responders,Responders,NA,26,16,NA,16S,4,Illumina,T-Test,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:679/2/NA,Study 679,time series / longitudinal observational,29302014,10.1126/science.aao3290,https://pubmed.ncbi.nlm.nih.gov/29302014/,"Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre ML, Luke JJ , Gajewski TF",The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients,"Science (New York, N.Y.)",2018,NA,Experiment 2,United States of America,Homo sapiens,Feces,UBERON:0001988,Response to immunochemotherapy,EFO:0007754,Non-responders,Responders,NA,26,16,NA,16S,4,RT-qPCR,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:679/3/NA,Study 679,time series / longitudinal observational,29302014,10.1126/science.aao3290,https://pubmed.ncbi.nlm.nih.gov/29302014/,"Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre ML, Luke JJ , Gajewski TF",The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients,"Science (New York, N.Y.)",2018,NA,Experiment 3,United States of America,Mus musculus,Feces,UBERON:0001988,Response to immunochemotherapy,EFO:0007754,"Non-responders, group B","Responders, group A",Mouse with 16.SIY melanoma tumor growth,3,3,NA,16S,NA,RT-qPCR,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:680/1/NA,Study 680,prospective cohort,32733788,10.3389/fonc.2020.00902,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7358584/,"Guan X, Ma F, Sun X, Li C, Li L, Liang F, Li S, Yi Z, Liu B , Xu B",Gut Microbiota Profiling in Patients With HER2-Negative Metastatic Breast Cancer Receiving Metronomic Chemotherapy of Capecitabine Compared to Those Under Conventional Dosage,Frontiers in oncology,2020,"breast cancer, capecitabine, gut microbiota, maintenance chemotherapy, metronomic chemotherapy",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Response to immunochemotherapy,EFO:0007754,non-responders (patients treated with conventional dose),responders (patients treated with metronomic dose of capecitabine),Patients with HER2-negative metastatic breast cancer who receive metronomic capecitabine as maintenance treatment.,16,15,NA,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,NA,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:681/1/NA,Study 681,case-control,28111632,10.5430/jer.v2n2p92,NA,"Kato I, Vasquez AA, Moyerbrailean G, Land S, Sun J, Lin HS , Ram JL",Oral microbiome and history of smoking and colorectal cancer,Journal of epidemiological research,2016,"Cigarette smoking, Colorectal cancer, Oral microbiome",Experiment 1,United States of America,Homo sapiens,Saliva,UBERON:0001836,Colorectal cancer,EFO:0005842,Healthy Controls(HC),Colorectal cancer,colorectal cancer; 24% of the colorectal cancer cases were current smokers. 16% habitual alcohol drinkers,122,68,None specified,16S,34,Illumina,"Zero-Inflated Beta Regression,Negative Binomial Regression",0.05,NA,NA,"race,region of residence,sex","age,smoking status",NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:681/3/NA,Study 681,case-control,28111632,10.5430/jer.v2n2p92,NA,"Kato I, Vasquez AA, Moyerbrailean G, Land S, Sun J, Lin HS , Ram JL",Oral microbiome and history of smoking and colorectal cancer,Journal of epidemiological research,2016,"Cigarette smoking, Colorectal cancer, Oral microbiome",Experiment 3,United States of America,Homo sapiens,Saliva,UBERON:0001836,Colorectal cancer,EFO:0005842,Young,Old (≥ 65 yrs),“Advanced age” was defined as 65 years or older.,103,87,None specified,16S,34,Illumina,"Negative Binomial Regression,Zero-Inflated Beta Regression",0.05,NA,NA,"race,region of residence,sex","age,smoking status",NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:681/4/NA,Study 681,case-control,28111632,10.5430/jer.v2n2p92,NA,"Kato I, Vasquez AA, Moyerbrailean G, Land S, Sun J, Lin HS , Ram JL",Oral microbiome and history of smoking and colorectal cancer,Journal of epidemiological research,2016,"Cigarette smoking, Colorectal cancer, Oral microbiome",Experiment 4,United States of America,Homo sapiens,Saliva,UBERON:0001836,Colorectal cancer,EFO:0005842,Non Smokers,Current Smokers,"Current smokers, where defined as ever smokers who smoked at least one cigarette per day for six months or longer and were smoking within 2 year prior to interview.",138,52,None specified,16S,34,Illumina,"Negative Binomial Regression,Zero-Inflated Beta Regression",0.05,NA,NA,"race,region of residence,sex","age,smoking status",NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:682/1/NA,Study 682,case-control,31674052,10.1111/jgh.14910,NA,"Yang M, Zhang L, Hong G, Li Y, Li G, Qian W, Xiong H, Bai T, Song J , Hou X",Duodenal and rectal mucosal microbiota related to small intestinal bacterial overgrowth in diarrhea-predominant irritable bowel syndrome,Journal of gastroenterology and hepatology,2020,"glucose hydrogen breath test, irritable bowel syndrome, microbial dysbiosis index, mucosal-associated microbiota, small intestinal bacterial overgrowth",Experiment 1,China,Homo sapiens,Duodenal mucosa,UBERON:0000320,Small intestine enteropathy,EFO:0009705,IBS.sibo-,IBS.sibo+,duodenal mucosa samples of patients with typical clinical symptoms and normal colonoscopy presentation fulfilling the Rome III diagnostic criteria with SIBO,43,34,3 months; also includes probiotics and proton-pump inhibitors,16S,123,Roche454,LEfSe,0.05,NA,2,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:682/3/NA,Study 682,case-control,31674052,10.1111/jgh.14910,NA,"Yang M, Zhang L, Hong G, Li Y, Li G, Qian W, Xiong H, Bai T, Song J , Hou X",Duodenal and rectal mucosal microbiota related to small intestinal bacterial overgrowth in diarrhea-predominant irritable bowel syndrome,Journal of gastroenterology and hepatology,2020,"glucose hydrogen breath test, irritable bowel syndrome, microbial dysbiosis index, mucosal-associated microbiota, small intestinal bacterial overgrowth",Experiment 3,China,Homo sapiens,Mucosa of rectum,UBERON:0003346,Small intestine enteropathy,EFO:0009705,IBS.sibo-,IBS.sibo+,rectal mucosa samples of patients with typical clinical symptoms and normal colonoscopy presentation fulfilling the Rome III diagnostic criteria; with SIBO,43,34,3 months; also includes probiotics and proton-pump inhibitors,16S,123,Roche454,LEfSe,0.05,NA,2,NA,"age,body mass index,sex",NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:682/4/NA,Study 682,case-control,31674052,10.1111/jgh.14910,NA,"Yang M, Zhang L, Hong G, Li Y, Li G, Qian W, Xiong H, Bai T, Song J , Hou X",Duodenal and rectal mucosal microbiota related to small intestinal bacterial overgrowth in diarrhea-predominant irritable bowel syndrome,Journal of gastroenterology and hepatology,2020,"glucose hydrogen breath test, irritable bowel syndrome, microbial dysbiosis index, mucosal-associated microbiota, small intestinal bacterial overgrowth",Experiment 4,China,Homo sapiens,Duodenum,UBERON:0002114,Small intestine enteropathy,EFO:0009705,HC.sibo-,HC.sibo+,duodenal fluid samples of healthy controls (with no IBS) with SIBO,12,7,3 months; also includes probiotics and proton-pump inhibitors,16S,123,Roche454,Chi-Square,0.05,NA,NA,NA,"age,body mass index,sex",NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:682/5/NA,Study 682,case-control,31674052,10.1111/jgh.14910,NA,"Yang M, Zhang L, Hong G, Li Y, Li G, Qian W, Xiong H, Bai T, Song J , Hou X",Duodenal and rectal mucosal microbiota related to small intestinal bacterial overgrowth in diarrhea-predominant irritable bowel syndrome,Journal of gastroenterology and hepatology,2020,"glucose hydrogen breath test, irritable bowel syndrome, microbial dysbiosis index, mucosal-associated microbiota, small intestinal bacterial overgrowth",Experiment 5,China,Homo sapiens,Feces,UBERON:0001988,Small intestine enteropathy,EFO:0009705,IBS.sibo-,IBS.sibo+,Feces samples of patients with typical clinical symptoms and normal colonoscopy presentation fulfilling the Rome III diagnostic criteria; with SIBO,43,34,3 months; also includes probiotics and proton-pump inhibitors,16S,123,Roche454,Chi-Square,0.05,NA,NA,NA,"age,body mass index,sex",NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:683/1/NA,Study 683,case-control,35188868,10.1080/19490976.2022.2038863,NA,"Bosch S, Acharjee A, Quraishi MN, Rojas P, Bakkali A, Jansen EE, Brizzio Brentar M, Kuijvenhoven J, Stokkers P, Struys E, Beggs AD, Gkoutos GV, de Meij TG , de Boer NK",The potential of fecal microbiota and amino acids to detect and monitor patients with adenoma,Gut microbes,2022,"Omics, adenoma, biomarker, colorectal cancer, surveillance",Experiment 1,Netherlands,Homo sapiens,Intestine,UBERON:0000160,Colorectal adenoma,EFO:0005406,non-adenoma group,adenoma group,"Patients with a successful polypectomy. A total of 9 patients had advanced adenomas and 10 patients had non-advanced adenoma (NA), with a median size of the largest adenoma being 0.7 cm [IQR 0.5–0.8].
PRIOR to polypectomy.",32,32,3 months prior to study inclusion and 3 months prior to second sample,16S,4,Illumina,LEfSe,2,NA,2,"age,body mass index,smoking behavior",NA,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:683/2/NA,Study 683,case-control,35188868,10.1080/19490976.2022.2038863,NA,"Bosch S, Acharjee A, Quraishi MN, Rojas P, Bakkali A, Jansen EE, Brizzio Brentar M, Kuijvenhoven J, Stokkers P, Struys E, Beggs AD, Gkoutos GV, de Meij TG , de Boer NK",The potential of fecal microbiota and amino acids to detect and monitor patients with adenoma,Gut microbes,2022,"Omics, adenoma, biomarker, colorectal cancer, surveillance",Experiment 2,Netherlands,Homo sapiens,Intestine,UBERON:0000160,Colorectal adenoma,EFO:0005406,non-adenoma group,adenoma group,"Patients with a successful polypectomy. A total of 9 patients had advanced adenomas and 10 patients had non-advanced adenoma (NA), with a median size of the largest adenoma being 0.7 cm [IQR 0.5–0.8].",19,19,3 months prior to study inclusion and 3 months prior to second sample,16S,4,Illumina,LEfSe,0.05,NA,2,"age,body mass index,smoking status",NA,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:683/3/NA,Study 683,case-control,35188868,10.1080/19490976.2022.2038863,NA,"Bosch S, Acharjee A, Quraishi MN, Rojas P, Bakkali A, Jansen EE, Brizzio Brentar M, Kuijvenhoven J, Stokkers P, Struys E, Beggs AD, Gkoutos GV, de Meij TG , de Boer NK",The potential of fecal microbiota and amino acids to detect and monitor patients with adenoma,Gut microbes,2022,"Omics, adenoma, biomarker, colorectal cancer, surveillance",Experiment 3,Netherlands,Homo sapiens,Intestine,UBERON:0000160,Colorectal adenoma,EFO:0005406,non-adenoma group,adenoma group,"Patients with a successful polypectomy. A total of 9 patients had advanced adenomas and 10 patients had non-advanced adenoma (NA), with a median size of the largest adenoma being 0.7 cm [IQR 0.5–0.8].
POST polypectomy.",32,32,3 months prior to study inclusion and 3 months prior to second sample,16S,4,Illumina,LEfSe,0.05,NA,2,NA,NA,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:683/4/NA,Study 683,case-control,35188868,10.1080/19490976.2022.2038863,NA,"Bosch S, Acharjee A, Quraishi MN, Rojas P, Bakkali A, Jansen EE, Brizzio Brentar M, Kuijvenhoven J, Stokkers P, Struys E, Beggs AD, Gkoutos GV, de Meij TG , de Boer NK",The potential of fecal microbiota and amino acids to detect and monitor patients with adenoma,Gut microbes,2022,"Omics, adenoma, biomarker, colorectal cancer, surveillance",Experiment 4,Netherlands,Homo sapiens,Intestine,UBERON:0000160,Colorectal adenoma,EFO:0005406,adenoma group pre-polypectomy,adenoma group post-polypectomy,"Patients with a successful polypectomy. A total of 9 patients had advanced adenomas and 10 patients had non-advanced adenoma (NA), with a median size of the largest adenoma being 0.7 cm [IQR 0.5–0.8].",32,32,3 months prior to study inclusion and 3 months prior to second sample,16S,4,Illumina,LEfSe,0.05,NA,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:683/5/NA,Study 683,case-control,35188868,10.1080/19490976.2022.2038863,NA,"Bosch S, Acharjee A, Quraishi MN, Rojas P, Bakkali A, Jansen EE, Brizzio Brentar M, Kuijvenhoven J, Stokkers P, Struys E, Beggs AD, Gkoutos GV, de Meij TG , de Boer NK",The potential of fecal microbiota and amino acids to detect and monitor patients with adenoma,Gut microbes,2022,"Omics, adenoma, biomarker, colorectal cancer, surveillance",Experiment 5,Netherlands,Homo sapiens,Intestine,UBERON:0000160,Colorectal adenoma,EFO:0005406,control group pre-endoscopy,control group post-endoscopy,Patients with a successful endoscopy.,32,32,3 months prior to study inclusion and 3 months prior to second sample,16S,4,Illumina,LEfSe,0.05,NA,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:684/1/NA,Study 684,"cross-sectional observational, not case-control",31719139,https://doi.org/10.1128/msystems.00438-19,https://pubmed.ncbi.nlm.nih.gov/31719139/,"Gupta A, Dhakan DB, Maji A, Saxena R, P K VP, Mahajan S, Pulikkan J, Kurian J, Gomez AM, Scaria J, Amato KR, Sharma AK , Sharma VK","Association of Flavonifractor plautii, a Flavonoid-Degrading Bacterium, with the Gut Microbiome of Colorectal Cancer Patients in India",mSystems,2019,"Flavonifractor plautii, biomarkers, colorectal cancer, gut microbiome",Experiment 1,India,Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,Healthy control,Colorectal cancer patients,Indians who are colorectial cancer patients,30,30,Recent use of antibiotics.,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:685/1/NA,Study 685,case-control,33050883,10.1186/s12866-020-01938-w,NA,"Zhang Q, Zhao H, Wu D, Cao D , Ma W",A comprehensive analysis of the microbiota composition and gene expression in colorectal cancer,BMC microbiology,2020,"Colorectal cancer, Gene expression, Gut microflora, Pathways enrichment, Survival analysis",Experiment 1,China,Homo sapiens,Intestine,UBERON:0000160,Colorectal cancer,EFO:0005842,Control,CRC,Tumor specimens taken from patients with colorectal cancer,19,19,None specified,16S,34,Illumina,T-Test,0.05,FALSE,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:686/1/NA,Study 686,"cross-sectional observational, not case-control",31530647,10.1128/mSystems.00289-19,NA,"Tarallo S, Ferrero G, Gallo G, Francavilla A, Clerico G, Realis Luc A, Manghi P, Thomas AM, Vineis P, Segata N, Pardini B, Naccarati A , Cordero F",Altered Fecal Small RNA Profiles in Colorectal Cancer Reflect Gut Microbiome Composition in Stool Samples,mSystems,2019,"gut microbiome, human stool samples, microRNAs, small RNAs",Experiment 1,Italy,Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,Healthy controls,Colorectal cancer (CRC),Patients diagnosed with colorectal carcinoma,24,29,NA,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:686/2/NA,Study 686,"cross-sectional observational, not case-control",31530647,10.1128/mSystems.00289-19,NA,"Tarallo S, Ferrero G, Gallo G, Francavilla A, Clerico G, Realis Luc A, Manghi P, Thomas AM, Vineis P, Segata N, Pardini B, Naccarati A , Cordero F",Altered Fecal Small RNA Profiles in Colorectal Cancer Reflect Gut Microbiome Composition in Stool Samples,mSystems,2019,"gut microbiome, human stool samples, microRNAs, small RNAs",Experiment 2,Italy,Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,Healthy controls,Adenomas,Patients diagnosed with colorectal adenomas,24,27,None specified,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:686/3/NA,Study 686,"cross-sectional observational, not case-control",31530647,10.1128/mSystems.00289-19,NA,"Tarallo S, Ferrero G, Gallo G, Francavilla A, Clerico G, Realis Luc A, Manghi P, Thomas AM, Vineis P, Segata N, Pardini B, Naccarati A , Cordero F",Altered Fecal Small RNA Profiles in Colorectal Cancer Reflect Gut Microbiome Composition in Stool Samples,mSystems,2019,"gut microbiome, human stool samples, microRNAs, small RNAs",Experiment 3,Italy,Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,Adenoma,Carcinoma (CRC),Patients diagnosed with colorectal carcinoma,27,29,None specified,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:687/1/NA,Study 687,case-control,35727391,10.1007/s10637-022-01263-1,NA,"Yuan D, Tao Y, Wang H, Wang J, Cao Y, Cao W, Pan S , Yu Z",A comprehensive analysis of the microbiota composition and host driver gene mutations in colorectal cancer,Investigational new drugs,2022,"16S, Colorectal cancer, Driver gene mutation, Microbiota, Target therapy",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Colorectal adenocarcinoma,EFO:0000365,healthy controls,colorectal cancer patients,diagnosed of colorectal cancer by colonoscopy and histopathology,20,44,1 month,16S,34,Illumina,LEfSe,0.05,FALSE,4,NA,NA,NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:687/2/NA,Study 687,case-control,35727391,10.1007/s10637-022-01263-1,NA,"Yuan D, Tao Y, Wang H, Wang J, Cao Y, Cao W, Pan S , Yu Z",A comprehensive analysis of the microbiota composition and host driver gene mutations in colorectal cancer,Investigational new drugs,2022,"16S, Colorectal cancer, Driver gene mutation, Microbiota, Target therapy",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Colorectal adenocarcinoma,EFO:0000365,colorectal cancer patients without KRAS mutation,colorectal cancer patients with KRAS mutation,diagnosed of colorectal cancer by colonoscopy and histopathology,21,18,No antibiotics for one month prior to surgery (fecal sample was taken the night before surgery),16S,34,Illumina,LEfSe,0.05,FALSE,4,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:687/3/NA,Study 687,case-control,35727391,10.1007/s10637-022-01263-1,NA,"Yuan D, Tao Y, Wang H, Wang J, Cao Y, Cao W, Pan S , Yu Z",A comprehensive analysis of the microbiota composition and host driver gene mutations in colorectal cancer,Investigational new drugs,2022,"16S, Colorectal cancer, Driver gene mutation, Microbiota, Target therapy",Experiment 3,China,Homo sapiens,Feces,UBERON:0001988,Colorectal adenocarcinoma,EFO:0000365,colorectal cancer patients without TP53 mutation,colorectal cancer patients with TP53 mutation,diagnosed of colorectal cancer by colonoscopy and histopathology,11,28,No antibiotics for one month prior to surgery (fecal sample was taken the night before surgery),16S,34,Illumina,LEfSe,0.05,FALSE,4,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:687/4/NA,Study 687,case-control,35727391,10.1007/s10637-022-01263-1,NA,"Yuan D, Tao Y, Wang H, Wang J, Cao Y, Cao W, Pan S , Yu Z",A comprehensive analysis of the microbiota composition and host driver gene mutations in colorectal cancer,Investigational new drugs,2022,"16S, Colorectal cancer, Driver gene mutation, Microbiota, Target therapy",Experiment 4,China,Homo sapiens,Feces,UBERON:0001988,Colorectal adenocarcinoma,EFO:0000365,colorectal cancer patients without APC mutation,colorectal cancer patients with APC mutation,diagnosed with colorectal cancer by colonoscopy and histopathology,9,30,No antibiotics for one month prior to surgery (fecal sample was taken the night before surgery),16S,34,Illumina,LEfSe,0.05,FALSE,4,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:687/5/NA,Study 687,case-control,35727391,10.1007/s10637-022-01263-1,NA,"Yuan D, Tao Y, Wang H, Wang J, Cao Y, Cao W, Pan S , Yu Z",A comprehensive analysis of the microbiota composition and host driver gene mutations in colorectal cancer,Investigational new drugs,2022,"16S, Colorectal cancer, Driver gene mutation, Microbiota, Target therapy",Experiment 5,China,Homo sapiens,Feces,UBERON:0001988,Colorectal adenocarcinoma,EFO:0000365,colorectal cancer patients without PIK3CA mutation,colorectal cancer patients with PIK3CA mutation,diagnosed with colorectal cancer by colonoscopy and histopathology,33,6,No antibiotics for one month prior to surgery (fecal sample was taken the night before surgery),16S,34,Illumina,LEfSe,0.05,FALSE,4,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:688/2/NA,Study 688,prospective cohort,29097493,10.1126/science.aan4236,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5827966/,"Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy SM, Szczepaniak Sloane R, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousi AM, Chemaly RF, Shelburne S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, McAllister F, Marcelo Riquelme Sanchez E, Zhang Y, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman JL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Glitza IC, Hwu WJ, Patel SP, Woodman SE, Amaria RN, Davies MA, Gershenwald JE, Hwu P, Lee JE, Zhang J, Coussens LM, Cooper ZA, Futreal PA, Daniel CR, Ajami NJ, Petrosino JF, Tetzlaff MT, Sharma P, Allison JP, Jenq RR , Wargo JA",Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients,"Science (New York, N.Y.)",2018,NA,Experiment 2,United States of America,Homo sapiens,Feces,UBERON:0001988,Response to immunochemotherapy,EFO:0007754,Non-responders,Responders,Patients were classified as R if they achieved an objective response (complete or partial response or stable disease lasting at least 6 months),35,54,NA,16S,NA,Illumina,LEfSe,0.05,NA,3,NA,NA,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:689/1/NA,Study 689,prospective cohort,28923537,10.1016/j.neo.2017.08.004,https://pubmed.ncbi.nlm.nih.gov/28923537/,"Frankel AE, Coughlin LA, Kim J, Froehlich TW, Xie Y, Frenkel EP , Koh AY",Metagenomic Shotgun Sequencing and Unbiased Metabolomic Profiling Identify Specific Human Gut Microbiota and Metabolites Associated with Immune Checkpoint Therapy Efficacy in Melanoma Patients,"Neoplasia (New York, N.Y.)",2017,NA,Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Response to immunochemotherapy,EFO:0007754,Non responders (Progressive disease),Responders,"Twenty-four patients showed RECIST response (19, 49%) or stable (5, 13%) disease to ICT, what we classify as responders in this study",16,23,NA,WMS,NA,Illumina,LEfSe,0.05,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:690/1/NA,Study 690,prospective cohort,32010563,10.21037/tlcr.2019.10.23,NA,"Katayama Y, Yamada T, Shimamoto T, Iwasaku M, Kaneko Y, Uchino J , Takayama K",The role of the gut microbiome on the efficacy of immune checkpoint inhibitors in Japanese responder patients with advanced non-small cell lung cancer,Translational lung cancer research,2019,"Immunotherapy, gut microbiome, non-small cell lung cancer (NSCLC), retrospective analysis",Experiment 1,Japan,Homo sapiens,Feces,UBERON:0001988,Response to immunochemotherapy,EFO:0007754,Non-responders,Responders,We defined responder (R) (partial response to ICI treatment) or non-responder (NR) (stable or progressive disease after ICI treatment at the time of first clinical evaluation) according to the RECIST 1.1 evaluation.,11,6,NA,16S,12,Illumina,LEfSe,0.05,NA,3,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:691/1/NA,Study 691,prospective cohort,31990790,10.1097/CMR.0000000000000656,https://journals.lww.com/melanomaresearch/Fulltext/2020/06000/Gut_microbial_species_and_metabolic_pathways.2.aspx,"Wind TT, Gacesa R, Vich Vila A, de Haan JJ, Jalving M, Weersma RK , Hospers GAP",Gut microbial species and metabolic pathways associated with response to treatment with immune checkpoint inhibitors in metastatic melanoma,Melanoma research,2020,NA,Experiment 1,Netherlands,Homo sapiens,Feces,UBERON:0001988,Response to immunochemotherapy,EFO:0007754,Non-responders,Responders,"Melanoma patients with a confirmed response, defined as a complete response, partial response (PR) or stable disease (SD) according to RECIST 12 weeks after start of therapy that was ongoing at the next radiological evaluation, were labelled ‘responder’. In order to include late responders in our analysis, patients with progressive disease (PD) on the first radiological evaluation but a response at the second radiological evaluation compared to baseline were also labelled ‘responder’.",13,12,NA,WMS,NA,Illumina,Fisher's Exact Test,0.05,TRUE,NA,NA,"age,antibiotic exposure,body mass index,sex",NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:692/1/NA,Study 692,randomized controlled trial,30711862,10.1016/j.nut.2018.10.038,NA,"Xie X, He Y, Li H, Yu D, Na L, Sun T, Zhang D, Shi X, Xia Y, Jiang T, Rong S, Yang S, Ma X , Xu G",Effects of prebiotics on immunologic indicators and intestinal microbiota structure in perioperative colorectal cancer patients,"Nutrition (Burbank, Los Angeles County, Calif.)",2019,"Colorectal cancer, Immune system, Intestinal microbiota, Operation, Prebiotics",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,"Nutraceutical,Colorectal cancer","CHEBI:50733,EFO:0005842",colorectal cancer patients who didn't take prebiotics (preoperative fecal sample),colorectal cancer patients who took prebiotics (preoperative fecal sample),"Patients with radiologic and pathologic diagnosis of CRC (preoperatively). Patients in the intervention group (prebiotic group) received a daily oral dose of 30 g prebiotic supplement (Hangzhou Niuqu Biotech Co., Hainengbo, China) containing fructooligosaccharide (25%), xylooligosaccharide (25%), polydextrose (25%), and resistant dextrin (25%) for 7 d from hospitalization to the day before the operation.",20,18,no treatment with antibiotics within 6 mo before surgery,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:692/2/NA,Study 692,randomized controlled trial,30711862,10.1016/j.nut.2018.10.038,NA,"Xie X, He Y, Li H, Yu D, Na L, Sun T, Zhang D, Shi X, Xia Y, Jiang T, Rong S, Yang S, Ma X , Xu G",Effects of prebiotics on immunologic indicators and intestinal microbiota structure in perioperative colorectal cancer patients,"Nutrition (Burbank, Los Angeles County, Calif.)",2019,"Colorectal cancer, Immune system, Intestinal microbiota, Operation, Prebiotics",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,"Nutraceutical,Colorectal cancer","CHEBI:50733,EFO:0005842",colorectal cancer patients non-prebiotic (preoperative),colorectal cancer patients non-prebiotic (postoperative),Patients with radiologic and pathologic diagnosis of CRC who underwent radical resection (post-operative samples) and did not take prebiotics pre-surgery.,20,20,no treatment with antibiotics within 6 mo before surgery,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:692/3/NA,Study 692,randomized controlled trial,30711862,10.1016/j.nut.2018.10.038,NA,"Xie X, He Y, Li H, Yu D, Na L, Sun T, Zhang D, Shi X, Xia Y, Jiang T, Rong S, Yang S, Ma X , Xu G",Effects of prebiotics on immunologic indicators and intestinal microbiota structure in perioperative colorectal cancer patients,"Nutrition (Burbank, Los Angeles County, Calif.)",2019,"Colorectal cancer, Immune system, Intestinal microbiota, Operation, Prebiotics",Experiment 3,China,Homo sapiens,Feces,UBERON:0001988,"Nutraceutical,Colorectal cancer","CHEBI:50733,EFO:0005842",colorectal cancer patients who took prebiotics (preoperative fecal sample),colorectal cancer patients who took prebiotics (postoperative fecal sample),Patients with radiologic and pathologic diagnosis of CRC who underwent radical resection (post-operative samples) and took prebiotics pre-surgery.,18,18,no treatment with antibiotics within 6 mo before surgery,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:693/1/NA,Study 693,prospective cohort,31337439,10.1186/s40425-019-0650-9,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6651993/,"Zheng Y, Wang T, Tu X, Huang Y, Zhang H, Tan D, Jiang W, Cai S, Zhao P, Song R, Li P, Qin N , Fang W",Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma,Journal for immunotherapy of cancer,2019,"Anti-PD-1 immunotherapy, Gut microbiome, Hepatocellular carcinoma",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Response to immunochemotherapy,EFO:0007754,Non-responders,Responders,"Responders (R, n = 3) were defined by radiographic evidence as complete or partial response, or stable disease lasting for at least six months.",5,3,NA,WMS,NA,BGISEQ-500 Sequencing,LEfSe,0.05,NA,2,NA,NA,NA,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:694/1/NA,Study 694,laboratory experiment,31138779,10.1038/s41419-019-1638-6,NA,"Lv J, Jia Y, Li J, Kuai W, Li Y, Guo F, Xu X, Zhao Z, Lv J , Li Z",Gegen Qinlian decoction enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by remodelling the gut microbiota and the tumour microenvironment,Cell death & disease,2019,NA,Experiment 1,China,Mus musculus,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,non-GQD,low-dose GQD (300 mg/kg),"BALB/c mice (male, ~20 g, aged 5 weeks) were fed adaptively for 1 week under specific pathogen-free conditions with food and water provided ad libitum.  Then the mice were
orally gavaged with 300 mg/kg Gegen Qinlian decoction (GQD), a classical
traditional Chinese medicine (TCM) formula, once a day for 10 days.  The mouse colorectal carcinoma cell line CT26  (~2.5 × 106 cells/mouse) were transplanted subcutaneously
into the left axillary region of each mouse and allowed ~1 week to establish tumours.",20,23,NA,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:694/2/NA,Study 694,laboratory experiment,31138779,10.1038/s41419-019-1638-6,NA,"Lv J, Jia Y, Li J, Kuai W, Li Y, Guo F, Xu X, Zhao Z, Lv J , Li Z",Gegen Qinlian decoction enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by remodelling the gut microbiota and the tumour microenvironment,Cell death & disease,2019,NA,Experiment 2,China,Mus musculus,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,non-GQD,low-dose GQD (300 mg/kg),"BALB/c mice (male, ~20 g, aged 5 weeks) were fed adaptively for 1 week under specific pathogen-free conditions with food and water provided ad libitum.  Then the mice were orally lavaged with 300 mg/kg Gegen Qinlian decoction (GQD), a classical
traditional Chinese medicine (TCM) formula, once a day for 10 days.  The mouse colorectal carcinoma cell line CT26  (~2.5 × 106 cells/mouse) were transplanted subcutaneously into the left axillary region of each mouse and allowed ~1 week to establish tumours.",20,23,NA,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:694/3/NA,Study 694,laboratory experiment,31138779,10.1038/s41419-019-1638-6,NA,"Lv J, Jia Y, Li J, Kuai W, Li Y, Guo F, Xu X, Zhao Z, Lv J , Li Z",Gegen Qinlian decoction enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by remodelling the gut microbiota and the tumour microenvironment,Cell death & disease,2019,NA,Experiment 3,China,Mus musculus,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,control,low-dose GQD (300 mg/kg) + PD-1,"BALB/c mice (male, ~20 g, aged 5 weeks) were fed adaptively for 1 week under specific pathogen-free conditions with food and water provided ad libitum.  Then the mice were orally gavaged with 300 mg/kg Gegen Qinlian decoction (GQD), a classical traditional Chinese medicine (TCM) formula, once a day for 10 days.  The mouse colorectal carcinoma cell line CT26  (~2.5 × 106 cells/mouse) were transplanted subcutaneously into the left axillary region of each mouse and allowed ~1 week to establish tumours.  When the tumours reached a size of 50mm3, the mice were intraperitoneally (i.p.) injected with 250 μg of anti-mouse PD-1 mAb.  The mice in the control group were administered the same volume of PBS. All mice were injected five times at 3-day intervals with antimouse PD-1 mAb or PBS",11,12,NA,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:694/4/NA,Study 694,laboratory experiment,31138779,10.1038/s41419-019-1638-6,NA,"Lv J, Jia Y, Li J, Kuai W, Li Y, Guo F, Xu X, Zhao Z, Lv J , Li Z",Gegen Qinlian decoction enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by remodelling the gut microbiota and the tumour microenvironment,Cell death & disease,2019,NA,Experiment 4,China,Mus musculus,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,control,low-dose GQD (300 mg/kg),"BALB/c mice (male, ~20 g, aged 5 weeks) were fed adaptively for 1 week under specific pathogen-free conditions with food and water provided ad libitum.  Then the mice were orally gavaged with 300 mg/kg Gegen Qinlian decoction (GQD), a classical traditional Chinese medicine (TCM) formula, once a day for 10 days.  The mouse colorectal carcinoma cell line CT26  (~2.5 × 106 cells/mouse) were transplanted subcutaneously into the left axillary region of each mouse and allowed ~1 week to establish tumours.  When the tumours reached a size of 50mm3, the mice were intraperitoneally (i.p.) injected with 250 μg of anti-mouse PD-1 mAb.  The mice in the control group were administered the same volume of PBS. All mice were injected five times at 3-day intervals with antimouse PD-1 mAb or PBS",11,12,NA,16S,4,Illumina,LEfSe,0.05,TRUE,NA,NA,NA,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:694/5/NA,Study 694,laboratory experiment,31138779,10.1038/s41419-019-1638-6,NA,"Lv J, Jia Y, Li J, Kuai W, Li Y, Guo F, Xu X, Zhao Z, Lv J , Li Z",Gegen Qinlian decoction enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by remodelling the gut microbiota and the tumour microenvironment,Cell death & disease,2019,NA,Experiment 5,China,Mus musculus,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,control,PD-1 group,"BALB/c mice (male, ~20 g, aged 5 weeks) were fed adaptively for 1 week under specific pathogen-free conditions with food and water provided ad libitum.  Then the mice were orally gavaged with 300 mg/kg Gegen Qinlian decoction (GQD), a classical traditional Chinese medicine (TCM) formula, once a day for 10 days.  The mouse colorectal carcinoma cell line CT26  (~2.5 × 106 cells/mouse) were transplanted subcutaneously into the left axillary region of each mouse and allowed ~1 week to establish tumours.  When the tumours reached a size of 50mm3, the mice were intraperitoneally (i.p.) injected with 250 μg of anti-mouse PD-1 mAb.  The mice in the control group were administered the same volume of PBS. All mice were injected five times at 3-day intervals with antimouse PD-1 mAb or PBS",11,9,NA,16S,4,Illumina,LEfSe,0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:694/6/NA,Study 694,laboratory experiment,31138779,10.1038/s41419-019-1638-6,NA,"Lv J, Jia Y, Li J, Kuai W, Li Y, Guo F, Xu X, Zhao Z, Lv J , Li Z",Gegen Qinlian decoction enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by remodelling the gut microbiota and the tumour microenvironment,Cell death & disease,2019,NA,Experiment 6,China,Mus musculus,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,control,low dose 300 mg/kg GQD + PD-1 group,"BALB/c mice (male, ~20 g, aged 5 weeks) were fed adaptively for 1 week under specific pathogen-free conditions with food and water provided ad libitum.  Then the mice were orally gavaged with 300 mg/kg Gegen Qinlian decoction (GQD), a classical traditional Chinese medicine (TCM) formula, once a day for 10 days.  The mouse colorectal carcinoma cell line CT26  (~2.5 × 106 cells/mouse) were transplanted subcutaneously into the left axillary region of each mouse and allowed ~1 week to establish tumours.  When the tumours reached a size of 50mm3, the mice were intraperitoneally (i.p.) injected with 250 μg of anti-mouse PD-1 mAb.  The mice in the control group were administered the same volume of PBS. All mice were injected five times at 3-day intervals with antimouse PD-1 mAb or PBS",11,12,NA,16S,4,Illumina,LEfSe,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:695/1/NA,Study 695,laboratory experiment,32425919,10.3389/fmicb.2020.00814,NA,"Xu X, Lv J, Guo F, Li J, Jia Y, Jiang D, Wang N, Zhang C, Kong L, Liu Y, Zhang Y, Lv J , Li Z",Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway,Frontiers in microbiology,2020,"MSS-type CRC, PD-1 antibody, gut microbiota, immunotherapy, metabolic pathway",Experiment 1,China,Mus musculus,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,control,Coli,Group 1 mice were treated with colistin (2 mg/ml) in sterile drinking water (Coli group).  Mice (in all groups) were then subcutaneously injected into the right axillary with 0.25 live CT26 tumor cells.,13,14,NA,16S,4,Illumina,ANOVA,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:695/2/NA,Study 695,laboratory experiment,32425919,10.3389/fmicb.2020.00814,NA,"Xu X, Lv J, Guo F, Li J, Jia Y, Jiang D, Wang N, Zhang C, Kong L, Liu Y, Zhang Y, Lv J , Li Z",Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway,Frontiers in microbiology,2020,"MSS-type CRC, PD-1 antibody, gut microbiota, immunotherapy, metabolic pathway",Experiment 2,China,Mus musculus,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,control,Vanc,"Group 1 mice were treated with vancomycin alone (0.25 mg/ml) in sterile drinking
water (Vanc group).  Mice (in all groups) were then subcutaneously injected into the right axillary with 0.25 live CT26 tumor cells.",13,14,NA,16S,4,Illumina,ANOVA,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:695/3/NA,Study 695,laboratory experiment,32425919,10.3389/fmicb.2020.00814,NA,"Xu X, Lv J, Guo F, Li J, Jia Y, Jiang D, Wang N, Zhang C, Kong L, Liu Y, Zhang Y, Lv J , Li Z",Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway,Frontiers in microbiology,2020,"MSS-type CRC, PD-1 antibody, gut microbiota, immunotherapy, metabolic pathway",Experiment 3,China,Mus musculus,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,Coli,Vanc,"Group 1 mice were treated with vancomycin alone (0.25 mg/ml) in sterile drinking
water (Vanc group).  Mice (in all groups) were then subcutaneously injected into the right axillary with 0.25 live CT26 tumor cells.",14,14,NA,16S,4,Illumina,ANOVA,0.05,NA,NA,NA,NA,NA,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:695/4/NA,Study 695,laboratory experiment,32425919,10.3389/fmicb.2020.00814,NA,"Xu X, Lv J, Guo F, Li J, Jia Y, Jiang D, Wang N, Zhang C, Kong L, Liu Y, Zhang Y, Lv J , Li Z",Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway,Frontiers in microbiology,2020,"MSS-type CRC, PD-1 antibody, gut microbiota, immunotherapy, metabolic pathway",Experiment 4,China,Mus musculus,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,control,Coli,Group 1 mice were treated with colistin (2 mg/ml) in sterile drinking water (Coli group).  Mice (in all groups) were then subcutaneously injected into the right axillary with 0.25 live CT26 tumor cells.,6,7,NA,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:695/5/NA,Study 695,laboratory experiment,32425919,10.3389/fmicb.2020.00814,NA,"Xu X, Lv J, Guo F, Li J, Jia Y, Jiang D, Wang N, Zhang C, Kong L, Liu Y, Zhang Y, Lv J , Li Z",Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway,Frontiers in microbiology,2020,"MSS-type CRC, PD-1 antibody, gut microbiota, immunotherapy, metabolic pathway",Experiment 5,China,Mus musculus,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,control,Vanc,Group 1 mice were treated with  vancomycin alone (0.25 mg/ml) in sterile drinking water (Vanc group)  Mice (in all groups) were then subcutaneously injected into the right axillary with 0.25 live CT26 tumor cells.,6,7,NA,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:695/6/NA,Study 695,laboratory experiment,32425919,10.3389/fmicb.2020.00814,NA,"Xu X, Lv J, Guo F, Li J, Jia Y, Jiang D, Wang N, Zhang C, Kong L, Liu Y, Zhang Y, Lv J , Li Z",Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway,Frontiers in microbiology,2020,"MSS-type CRC, PD-1 antibody, gut microbiota, immunotherapy, metabolic pathway",Experiment 6,China,Mus musculus,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,coli,Vanc,Group 1 mice were treated with  vancomycin alone (0.25 mg/ml) in sterile drinking water (Vanc group)  Mice (in all groups) were then subcutaneously injected into the right axillary with 0.25 live CT26 tumor cells.,7,7,NA,WMS,NA,Illumina,ANOVA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:696/1/NA,Study 696,randomized controlled trial,26238090,10.3892/mmr.2015.4124,NA,"Gao Z, Guo B, Gao R, Zhu Q, Wu W , Qin H",Probiotics modify human intestinal mucosa-associated microbiota in patients with colorectal cancer,Molecular medicine reports,2015,NA,Experiment 1,China,Homo sapiens,Intestinal mucosa,UBERON:0001242,Nutraceutical,CHEBI:50733,CGT group - colorectal cancer patients perioperative placebo,PGT group - colorectal cancer patients perioperative probiotics,"Patients in the PGT group received an encapsulated probiotics preparation (Shanghai Xinyi Pharmaceutical Co., Ltd., Shanghai, China) containing live combined Bifidobacterium longum, Lactobacillus acidophilus and Enterococcus faecalis (1:1:1) with no less than 1.0x107 CFU/g viable cells, three times/day, with a total daily dose of 6.0x107 CFU for five days",11,11,Received antibiotics for the past 3 months prior to surgery,16S,3,Roche454,LEfSe,0.05,FALSE,2,NA,NA,NA,decreased,unchanged,decreased,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:696/2/NA,Study 696,randomized controlled trial,26238090,10.3892/mmr.2015.4124,NA,"Gao Z, Guo B, Gao R, Zhu Q, Wu W , Qin H",Probiotics modify human intestinal mucosa-associated microbiota in patients with colorectal cancer,Molecular medicine reports,2015,NA,Experiment 2,China,Homo sapiens,Intestinal mucosa,UBERON:0001242,Nutraceutical,CHEBI:50733,HGT Group - Healthy controls,PGT group - colorectal cancer patients perioperative probiotics,PGT group - colorectal cancer patients that received perioperative probiotics,11,11,Received antibiotics for the past 3 months prior to surgery,16S,3,Roche454,LEfSe,0.05,FALSE,2,NA,NA,NA,increased,increased,decreased,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:696/3/NA,Study 696,randomized controlled trial,26238090,10.3892/mmr.2015.4124,NA,"Gao Z, Guo B, Gao R, Zhu Q, Wu W , Qin H",Probiotics modify human intestinal mucosa-associated microbiota in patients with colorectal cancer,Molecular medicine reports,2015,NA,Experiment 3,China,Homo sapiens,Intestinal mucosa,UBERON:0001242,Nutraceutical,CHEBI:50733,HGT- Healthy controls,CGT- colorectal cancer patients that received perioperative placebo,Patients that received perioperative placebos,11,11,Received antibiotics for the past 3 months prior to surgery,16S,3,Roche454,LEfSe,0.05,FALSE,2,NA,NA,NA,decreased,unchanged,decreased,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:697/1/NA,Study 697,time series / longitudinal observational,34336726,10.2147/JHC.S315696,NA,"Shen YC, Lee PC, Kuo YL, Wu WK, Chen CC, Lei CH, Yeh CP, Hsu C, Hsu CH, Lin ZZ, Shao YY, Lu LC, Liu TH, Chen CH, Wu MS, Huang YH , Cheng AL",An Exploratory Study for the Association of Gut Microbiome with Efficacy of Immune Checkpoint Inhibitor in Patients with Hepatocellular Carcinoma,Journal of hepatocellular carcinoma,2021,"biomarkers, gut microbiome, hepatocellular carcinoma, immune checkpoint inhibitor",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Hepatocellular carcinoma,EFO:0000182,Non-responders to Immune checkpoint inhibitors,Responders to Immune checkpoint inhibitors,"Patients who responded to ICI therapy, defined as complete or partial response per Response
Evaluation Criteria in Solid Tumors (RECIST) v.1.1.",26,10,NA,16S,34,Illumina,LEfSe,0.05,FALSE,3,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:697/2/NA,Study 697,time series / longitudinal observational,34336726,10.2147/JHC.S315696,NA,"Shen YC, Lee PC, Kuo YL, Wu WK, Chen CC, Lei CH, Yeh CP, Hsu C, Hsu CH, Lin ZZ, Shao YY, Lu LC, Liu TH, Chen CH, Wu MS, Huang YH , Cheng AL",An Exploratory Study for the Association of Gut Microbiome with Efficacy of Immune Checkpoint Inhibitor in Patients with Hepatocellular Carcinoma,Journal of hepatocellular carcinoma,2021,"biomarkers, gut microbiome, hepatocellular carcinoma, immune checkpoint inhibitor",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Hepatocellular carcinoma,EFO:0000182,Non-Disease control with Immune checkpoint inhibitors,Disease control with Immune checkpoint inhibitors,“disease control” was defined as objective response or stable disease lasting =16 weeks.” Objective response was defined as complete or partial response per Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1.,17,19,NA,16S,34,Illumina,LEfSe,0.05,FALSE,3,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:697/3/NA,Study 697,time series / longitudinal observational,34336726,10.2147/JHC.S315696,NA,"Shen YC, Lee PC, Kuo YL, Wu WK, Chen CC, Lei CH, Yeh CP, Hsu C, Hsu CH, Lin ZZ, Shao YY, Lu LC, Liu TH, Chen CH, Wu MS, Huang YH , Cheng AL",An Exploratory Study for the Association of Gut Microbiome with Efficacy of Immune Checkpoint Inhibitor in Patients with Hepatocellular Carcinoma,Journal of hepatocellular carcinoma,2021,"biomarkers, gut microbiome, hepatocellular carcinoma, immune checkpoint inhibitor",Experiment 3,China,Homo sapiens,Feces,UBERON:0001988,Hepatocellular carcinoma,EFO:0000182,Non-responders to Immune checkpoint inhibitors,Responders to Immune checkpoint inhibitors,"“Objective response” was defined as complete or partial response per Response
Evaluation Criteria in Solid Tumors (RECIST) v.1.1.",12,6,NA,WMS,NA,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:698/1/NA,Study 698,case-control,29632427,10.3748/wjg.v24.i13.1464,NA,"Ma HQ, Yu TT, Zhao XJ, Zhang Y , Zhang HJ",Fecal microbial dysbiosis in Chinese patients with inflammatory bowel disease,World journal of gastroenterology,2018,"16S ribosomal DNA, Chinese, Crohn’s disease, Microbial dysbiosis, Ulcerative colitis",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Crohn's disease,EFO:0000384,Healthy controls,Patients with Crohn's disease,"Patients with Crohn's disease (11 with as active disease defined by CDAI > 150, 4 with inactive disease)",29,15,3 months,16S,4,Illumina,Kruskall-Wallis,0.05,TRUE,NA,"age,sex",NA,NA,unchanged,decreased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:698/2/NA,Study 698,case-control,29632427,10.3748/wjg.v24.i13.1464,NA,"Ma HQ, Yu TT, Zhao XJ, Zhang Y , Zhang HJ",Fecal microbial dysbiosis in Chinese patients with inflammatory bowel disease,World journal of gastroenterology,2018,"16S ribosomal DNA, Chinese, Crohn’s disease, Microbial dysbiosis, Ulcerative colitis",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Ulcerative colitis,EFO:0000729,Healthy controls,Patients with ulcerative colitis,Patients with ulcerative colitis,29,14,3 months,16S,4,Illumina,Kruskall-Wallis,0.05,TRUE,NA,"age,sex",NA,NA,unchanged,decreased,unchanged,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:698/3/NA,Study 698,case-control,29632427,10.3748/wjg.v24.i13.1464,NA,"Ma HQ, Yu TT, Zhao XJ, Zhang Y , Zhang HJ",Fecal microbial dysbiosis in Chinese patients with inflammatory bowel disease,World journal of gastroenterology,2018,"16S ribosomal DNA, Chinese, Crohn’s disease, Microbial dysbiosis, Ulcerative colitis",Experiment 3,China,Homo sapiens,Feces,UBERON:0001988,Crohn's disease,EFO:0000384,Patients with ulcerative colitis,Patients with Crohn's disease,Patients with Crohn's disease,14,15,3 months,16S,4,Illumina,Kruskall-Wallis,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:699/1/NA,Study 699,case-control,35440670,https://doi.org/10.1038/s41598-022-07995-7,NA,"Zuo W, Wang B, Bai X, Luan Y, Fan Y, Michail S , Sun F",16S rRNA and metagenomic shotgun sequencing data revealed consistent patterns of gut microbiome signature in pediatric ulcerative colitis,Scientific reports,2022,NA,Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Ulcerative colitis,EFO:0000729,Healthy controls,Patients with ulcerative colitis,Children aged 7-21 with mild to moderate ulcerative colitis,23,19,NA,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:700/1/NA,Study 700,case-control,22170749,10.1002/ibd.22860,NA,"Michail S, Durbin M, Turner D, Griffiths AM, Mack DR, Hyams J, Leleiko N, Kenche H, Stolfi A , Wine E",Alterations in the gut microbiome of children with severe ulcerative colitis,Inflammatory bowel diseases,2012,NA,Experiment 1,Canada,Homo sapiens,Feces,UBERON:0001988,Ulcerative colitis,EFO:0000729,healthy controls,children with ulcerative colitis,Children hospitalized for intravenous corticosteroid therapy for acute UC,26,27,1 month,16S,NA,RT-qPCR,T-Test,0.05,TRUE,NA,age,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:701/1/NA,Study 701,case-control,28852861,10.1007/s00535-017-1384-4,https://doi.org/10.1007/s00535-017-1384-4,"Nishino K, Nishida A, Inoue R, Kawada Y, Ohno M, Sakai S, Inatomi O, Bamba S, Sugimoto M, Kawahara M, Naito Y , Andoh A",Analysis of endoscopic brush samples identified mucosa-associated dysbiosis in inflammatory bowel disease,Journal of gastroenterology,2018,"16S rRNA, IBD, Mucosa-associated microbiome",Experiment 1,Japan,Homo sapiens,Feces,UBERON:0001988,Crohn's disease,EFO:0000384,Non-IBD,CD,Patients with Crohn's disease activity index <150,14,26,Current,16S,34,Illumina,T-Test,0.05,TRUE,NA,NA,NA,NA,decreased,decreased,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:701/2/NA,Study 701,case-control,28852861,10.1007/s00535-017-1384-4,https://doi.org/10.1007/s00535-017-1384-4,"Nishino K, Nishida A, Inoue R, Kawada Y, Ohno M, Sakai S, Inatomi O, Bamba S, Sugimoto M, Kawahara M, Naito Y , Andoh A",Analysis of endoscopic brush samples identified mucosa-associated dysbiosis in inflammatory bowel disease,Journal of gastroenterology,2018,"16S rRNA, IBD, Mucosa-associated microbiome",Experiment 2,Japan,Homo sapiens,Feces,UBERON:0001988,Ulcerative colitis,EFO:0000729,NON-IBD controls,UC,The patient who is diagnosed from ulcerative colitis(UC).,14,43,Current,16S,34,Illumina,Welch's T-Test,0.05,TRUE,NA,NA,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:701/3/NA,Study 701,case-control,28852861,10.1007/s00535-017-1384-4,https://doi.org/10.1007/s00535-017-1384-4,"Nishino K, Nishida A, Inoue R, Kawada Y, Ohno M, Sakai S, Inatomi O, Bamba S, Sugimoto M, Kawahara M, Naito Y , Andoh A",Analysis of endoscopic brush samples identified mucosa-associated dysbiosis in inflammatory bowel disease,Journal of gastroenterology,2018,"16S rRNA, IBD, Mucosa-associated microbiome",Experiment 3,Japan,Homo sapiens,Feces,UBERON:0001988,Crohn's disease,EFO:0000384,UC,CD,The patient who is diagnosed from Crohn's disease(CD).,43,26,Current,16S,34,Illumina,Welch's T-Test,0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:702/1/NA,Study 702,"cross-sectional observational, not case-control",30231060,10.1371/journal.pone.0202278,NA,"Beyer K, Zaura E, Brandt BW, Buijs MJ, Brun JG, Crielaard W , Bolstad AI",Subgingival microbiome of rheumatoid arthritis patients in relation to their disease status and periodontal health,PloS one,2018,NA,Experiment 1,Norway,Homo sapiens,Subgingival dental plaque,UBERON:0016484,Rheumatoid arthritis,EFO:0000685,Rheumatoid Arthritis (RA) Remission,Active (RA) Rheumatoid Arthritis,Individuals with active rheumatoid arthritis (RA),28,60,3 months,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:702/2/NA,Study 702,"cross-sectional observational, not case-control",30231060,10.1371/journal.pone.0202278,NA,"Beyer K, Zaura E, Brandt BW, Buijs MJ, Brun JG, Crielaard W , Bolstad AI",Subgingival microbiome of rheumatoid arthritis patients in relation to their disease status and periodontal health,PloS one,2018,NA,Experiment 2,Norway,Homo sapiens,Saliva,UBERON:0001836,Rheumatoid arthritis,EFO:0000685,No prednisolone,Prednisolone,Individuals who received prednisolone,57,21,3 months,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:702/3/NA,Study 702,"cross-sectional observational, not case-control",30231060,10.1371/journal.pone.0202278,NA,"Beyer K, Zaura E, Brandt BW, Buijs MJ, Brun JG, Crielaard W , Bolstad AI",Subgingival microbiome of rheumatoid arthritis patients in relation to their disease status and periodontal health,PloS one,2018,NA,Experiment 3,Norway,Homo sapiens,Saliva,UBERON:0001836,Rheumatoid arthritis,EFO:0000685,Never Smokers,Former Smokers,Former Smokers,29,35,3 months,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:702/4/NA,Study 702,"cross-sectional observational, not case-control",30231060,10.1371/journal.pone.0202278,NA,"Beyer K, Zaura E, Brandt BW, Buijs MJ, Brun JG, Crielaard W , Bolstad AI",Subgingival microbiome of rheumatoid arthritis patients in relation to their disease status and periodontal health,PloS one,2018,NA,Experiment 4,Norway,Homo sapiens,Saliva,UBERON:0001836,Rheumatoid arthritis,EFO:0000685,Never Smokers,Current Smokers,Current Smokers,29,14,3 Months,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:702/5/NA,Study 702,"cross-sectional observational, not case-control",30231060,10.1371/journal.pone.0202278,NA,"Beyer K, Zaura E, Brandt BW, Buijs MJ, Brun JG, Crielaard W , Bolstad AI",Subgingival microbiome of rheumatoid arthritis patients in relation to their disease status and periodontal health,PloS one,2018,NA,Experiment 5,Norway,Homo sapiens,Saliva,UBERON:0001836,Rheumatoid arthritis,EFO:0000685,Former Smokers,Current Smokers,Current Smokers,35,14,3 Months,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:703/1/NA,Study 703,case-control,36077282,10.3390/ijms23179883,NA,"Chen YJ, Hung WC, Chou YH, Lai CH, Peng P, Jhou PS, Tsai MR, Sheu JJ , Yen JH",Subgingival Microbiome in Rheumatoid Arthritis Patients with Periodontitis,International journal of molecular sciences,2022,"anti-citrullinated protein antibody (ACPA), microbial dysbiosis, periodontitis, rheumatoid arthritis, subgingival microbiome",Experiment 1,Taiwan,Homo sapiens,Subgingival dental plaque,UBERON:0016484,Rheumatoid arthritis,EFO:0000685,Healthy Controls,All Matched (AM) Rheumatoid Arthritis,All Matched (AM) Rheumatoid Arthritis Patients,21,21,3 months,16S,34,Illumina,LEfSe,0.05,FALSE,4,"age,diabetes mellitus,sex",NA,NA,unchanged,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:703/2/NA,Study 703,case-control,36077282,10.3390/ijms23179883,NA,"Chen YJ, Hung WC, Chou YH, Lai CH, Peng P, Jhou PS, Tsai MR, Sheu JJ , Yen JH",Subgingival Microbiome in Rheumatoid Arthritis Patients with Periodontitis,International journal of molecular sciences,2022,"anti-citrullinated protein antibody (ACPA), microbial dysbiosis, periodontitis, rheumatoid arthritis, subgingival microbiome",Experiment 2,Taiwan,Homo sapiens,Subgingival dental plaque,UBERON:0016484,Rheumatoid arthritis,EFO:0000685,Healthy Controls,Periodontally diseased (PD) Rheumatoid Arthritis,"Patients with periodontally
diseased) Rheumatoid Arthritis",12,12,3 months,16S,34,Illumina,LEfSe,0.05,FALSE,4,"age,diabetes mellitus,sex",NA,NA,unchanged,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:704/1/NA,Study 704,case-control,33964928,10.1186/s12903-021-01597-x,NA,"Lehenaff R, Tamashiro R, Nascimento MM, Lee K, Jenkins R, Whitlock J, Li EC, Sidhu G, Anderson S, Progulske-Fox A, Bubb MR, Chan EKL , Wang GP",Subgingival microbiome of deep and shallow periodontal sites in patients with rheumatoid arthritis: a pilot study,BMC oral health,2021,"16S rRNA sequencing, Microbial dysbiosis, Periodontal disease, Rheumatoid arthritis, Subgingival microbiome",Experiment 1,United States of America,Homo sapiens,Subgingival dental plaque,UBERON:0016484,Arthritis,EFO:0005856,Healthy Non-RA Controls,Rheumatoid Arthritis,Biologic Naive Rheumatoid Arthritis patient,10,8,3 months,16S,123,Illumina,LEfSe,NA,FALSE,2,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:705/1/NA,Study 705,case-control,29562298,10.1093/rheumatology/key052,NA,"Mikuls TR, Walker C, Qiu F, Yu F, Thiele GM, Alfant B, Li EC, Zhao LY, Wang GP, Datta S , Payne JB",The subgingival microbiome in patients with established rheumatoid arthritis,"Rheumatology (Oxford, England)",2018,"osteoarthritis, periodontitis, rheumatoid arthritis, subgingival microbiome",Experiment 1,NA,Homo sapiens,Subgingival dental plaque,UBERON:0016484,Arthritis,EFO:0005856,Osteoarthritis (OA),Rheumatoid Arthritis (RA),Patients with Rheumatoid Arthritis,296,260,NA,16S,123,Illumina,Linear Regression,0.05,TRUE,NA,NA,"comorbidity,marital status,race,smoking status",NA,unchanged,increased,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:706/1/NA,Study 706,"cross-sectional observational, not case-control",24273047,10.1093/rheumatology/ket362,NA,"Wolff B, Berger T, Frese C, Max R, Blank N, Lorenz HM , Wolff D","Oral status in patients with early rheumatoid arthritis: a prospective, case-control study","Rheumatology (Oxford, England)",2014,"case–control studies, oral hygiene, periodontal attachment loss, periodontal index, plaque index, rheumatoid arthritis",Experiment 1,Germany,Homo sapiens,Subgingival dental plaque,UBERON:0016484,Rheumatoid arthritis,EFO:0000685,Healthy Controls,Early Rheumatoid Arthritis,Patients with Early Rheumatoid Arthritis,22,22,Intake of antibiotics during the past 6 months,PCR,NA,RT-qPCR,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:707/1/NA,Study 707,case-control,22576262,10.1002/art.34539,NA,"Scher JU, Ubeda C, Equinda M, Khanin R, Buischi Y, Viale A, Lipuma L, Attur M, Pillinger MH, Weissmann G, Littman DR, Pamer EG, Bretz WA , Abramson SB",Periodontal disease and the oral microbiota in new-onset rheumatoid arthritis,Arthritis and rheumatism,2012,NA,Experiment 1,United States of America,Homo sapiens,Subgingival dental plaque,UBERON:0016484,Rheumatoid arthritis,EFO:0000685,Healthy controls,NORA - [New-Onset Rheumatoid Arthritis] Patient,Patients with NORA - [New-Onset Rheumatoid Arthritis],18,31,3 months,16S,12,Roche454,T-Test,0.05,TRUE,NA,"age,ethnic group,sex",NA,NA,unchanged,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:707/2/NA,Study 707,case-control,22576262,10.1002/art.34539,NA,"Scher JU, Ubeda C, Equinda M, Khanin R, Buischi Y, Viale A, Lipuma L, Attur M, Pillinger MH, Weissmann G, Littman DR, Pamer EG, Bretz WA , Abramson SB",Periodontal disease and the oral microbiota in new-onset rheumatoid arthritis,Arthritis and rheumatism,2012,NA,Experiment 2,United States of America,Homo sapiens,Subgingival dental plaque,UBERON:0016484,Rheumatoid arthritis,EFO:0000685,CRA - [Chronic Established  Rheumatoid Arthritis],NORA - [New-Onset Rheumatoid Arthritis] Patient,Patients with NORA - [New-Onset Rheumatoid Arthritis],34,31,3 months,16S,12,Roche454,T-Test,0.05,TRUE,NA,"age,ethnic group,sex",NA,NA,unchanged,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:707/3/NA,Study 707,case-control,22576262,10.1002/art.34539,NA,"Scher JU, Ubeda C, Equinda M, Khanin R, Buischi Y, Viale A, Lipuma L, Attur M, Pillinger MH, Weissmann G, Littman DR, Pamer EG, Bretz WA , Abramson SB",Periodontal disease and the oral microbiota in new-onset rheumatoid arthritis,Arthritis and rheumatism,2012,NA,Experiment 3,United States of America,Homo sapiens,Subgingival dental plaque,UBERON:0016484,Rheumatoid arthritis,EFO:0000685,Healthy Controls,All [RA] - Rheumatoid Arthritis Patients,"All [RA] - Rheumatoid Arthritis Patients, which includes NORA [new-onset RA] and CRA [Chronic-established RA]",18,65,3 months,16S,12,Roche454,T-Test,0.05,TRUE,NA,"age,ethnic group,sex",NA,NA,unchanged,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:708/1/NA,Study 708,case-control,32565704,10.1016/j.sjbs.2020.04.040,NA,"Liu X, Tian K, Ma X, Wang S, Luo C , Du Q",Analysis of subgingival microbiome of periodontal disease and rheumatoid arthritis in Chinese: A case-control study,Saudi journal of biological sciences,2020,"Microbial diversity, Microbiome, Periodontitis, Rheumatoid arthritis, Spirochaetes",Experiment 1,China,Homo sapiens,Supragingival dental plaque,UBERON:0016485,Rheumatoid arthritis,EFO:0000685,healthy controls,rheumatoid arthritis patients,rheumatoid arthritis patients RA,44,54,Three months,16S,4,Illumina,NA,0.05,NA,NA,NA,NA,NA,increased,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:708/2/NA,Study 708,case-control,32565704,10.1016/j.sjbs.2020.04.040,NA,"Liu X, Tian K, Ma X, Wang S, Luo C , Du Q",Analysis of subgingival microbiome of periodontal disease and rheumatoid arthritis in Chinese: A case-control study,Saudi journal of biological sciences,2020,"Microbial diversity, Microbiome, Periodontitis, Rheumatoid arthritis, Spirochaetes",Experiment 2,China,Homo sapiens,Subgingival dental plaque,UBERON:0016484,Periodontitis,EFO:0000649,rheumatoid arthritis patients,periodontal disease patients,periodontal disease patients PA,54,45,Three months,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,NA,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:709/1/NA,Study 709,case-control,34442739,10.3390/microorganisms9081657,NA,"Esberg A, Johansson L, Johansson I , Dahlqvist SR",Oral Microbiota Identifies Patients in Early Onset Rheumatoid Arthritis,Microorganisms,2021,"16S rDNA sequencing, oral microbiota, periodontitis, rheumatoid arthritis",Experiment 1,United States of America,Homo sapiens,Saliva,UBERON:0001836,Rheumatoid arthritis,EFO:0000685,Healthy Controls,Early Rheumatoid Arthritis,Patients with Early Rheumatoid Arthritis,59,61,3 months,16S,34,Illumina,LEfSe,0.05,TRUE,2,"age,sex",NA,NA,increased,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:710/1/NA,Study 710,case-control,31916654,10.1111/odi.13277,NA,"Belstrøm D, Eiberg JM, Enevold C, Grande MA, Jensen CAJ, Skov L , Hansen PR",Salivary microbiota and inflammation-related proteins in patients with psoriasis,Oral diseases,2020,"inflammation, microbiota, periodontitis, psoriasis, saliva",Experiment 1,Denmark,Homo sapiens,Saliva,UBERON:0001836,Psoriasis,EFO:0000676,orally healthy individuals,Psoriasis patient,NA,52,27,3 months,16S,123,Illumina,LEfSe,1e-4,TRUE,2,NA,NA,unchanged,NA,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:710/2/NA,Study 710,case-control,31916654,10.1111/odi.13277,NA,"Belstrøm D, Eiberg JM, Enevold C, Grande MA, Jensen CAJ, Skov L , Hansen PR",Salivary microbiota and inflammation-related proteins in patients with psoriasis,Oral diseases,2020,"inflammation, microbiota, periodontitis, psoriasis, saliva",Experiment 2,Denmark,Homo sapiens,Saliva,UBERON:0001836,Psoriasis,EFO:0000676,periodntitis,Psoriasis,Individuals who have been diagnosed with Psoriasis.,27,58,3 months,16S,123,Illumina,LEfSe,0.001,TRUE,2,NA,NA,unchanged,NA,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:710/3/NA,Study 710,case-control,31916654,10.1111/odi.13277,NA,"Belstrøm D, Eiberg JM, Enevold C, Grande MA, Jensen CAJ, Skov L , Hansen PR",Salivary microbiota and inflammation-related proteins in patients with psoriasis,Oral diseases,2020,"inflammation, microbiota, periodontitis, psoriasis, saliva",Experiment 3,Denmark,Homo sapiens,Saliva,UBERON:0001836,Periodontitis,EFO:0000649,orally healthy individuals,Periodontitis patients,Patients who have been diagnosed with periodontitis,52,27,3 months,16S,123,Illumina,LEfSe,0.001,TRUE,2,NA,NA,unchanged,NA,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:711/1/NA,Study 711,"cross-sectional observational, not case-control",34341764,https://doi.org/10.1155%2F2021%2F5579608,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325587/,"Wen M, Liu T, Zhao M, Dang X, Feng S, Ding X, Xu Z, Huang X, Lin Q, Xiang W, Li X, He X , He Q",Correlation Analysis between Gut Microbiota and Metabolites in Children with Systemic Lupus Erythematosus,Journal of immunology research,2021,NA,Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Systemic lupus erythematosus,MONDO:0007915,HC,SLE,Individuals who have been diagnosed with systemic lupus erythematosus (SLE). Systemic lupus erythematosus (SLE) is an autoimmune-mediated diffuse connective tissue disease characterized by immune inflammation with an unclear aetiology and pathogenesis.,28,33,3 months,16S,45,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:712/1/NA,Study 712,"cross-sectional observational, not case-control",29513935,10.1002/art.40485,NA,"Lopez-Oliva I, Paropkari AD, Saraswat S, Serban S, Yonel Z, Sharma P, de Pablo P, Raza K, Filer A, Chapple I, Dietrich T, Grant MM , Kumar PS",Dysbiotic Subgingival Microbial Communities in Periodontally Healthy Patients With Rheumatoid Arthritis,"Arthritis & rheumatology (Hoboken, N.J.)",2018,NA,Experiment 1,United Kingdom,Homo sapiens,Subgingival dental plaque,UBERON:0016484,Rheumatoid arthritis,EFO:0000685,healthy controls,Rheumatoid Arthritis,periodontally healthy patients with Rheumatoid Arthritis,19,22,12 weeks,16S,123456789,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:713/1/NA,Study 713,case-control,31842923,10.1186/s12969-019-0387-5,NA,"Grevich S, Lee P, Leroux B, Ringold S, Darveau R, Henstorf G, Berg J, Kim A, Velan E, Kelly J, Baltuck C, Reeves A, Leahey H, Hager K, Brittnacher M, Hayden H, Miller S, McLean J , Stevens A",Oral health and plaque microbial profile in juvenile idiopathic arthritis,Pediatric rheumatology online journal,2019,"Gingivitis, Juvenile idiopathic arthritis, Microbiota, Oral health",Experiment 1,United States of America,Homo sapiens,Subgingival dental plaque,UBERON:0016484,Arthritis,EFO:0005856,healthy controls,Juvenile Idiopathic Arthritis,Juvenile Idiopathic Arthritis,11,85,3 months,16S,4,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:714/1/NA,Study 714,"laboratory experiment,time series / longitudinal observational",32437658,https://doi.org/10.1016/j.cell.2020.04.027,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293577/,"Ang QY, Alexander M, Newman JC, Tian Y, Cai J, Upadhyay V, Turnbaugh JA, Verdin E, Hall KD, Leibel RL, Ravussin E, Rosenbaum M, Patterson AD , Turnbaugh PJ",Ketogenic Diets Alter the Gut Microbiome Resulting in Decreased Intestinal Th17 Cells,Cell,2020,"Th17 cells, adipose tissue, bifidobacteria, intestinal immunity, ketogenic diet, ketone bodies, ketone ester, microbiome, β-hydroxybutyrate",Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Response to ketogenic diet,EFO:0009372,Overweight/Obese Men on Baseline Diet (BD),Overweight/Obese Men on Ketogenic Diet (KD),Overweight or class I Obese non-diabetic men who consumed an isocaloric ketogenic diet for 4weeks,17,17,No,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:714/2/NA,Study 714,"laboratory experiment,time series / longitudinal observational",32437658,https://doi.org/10.1016/j.cell.2020.04.027,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293577/,"Ang QY, Alexander M, Newman JC, Tian Y, Cai J, Upadhyay V, Turnbaugh JA, Verdin E, Hall KD, Leibel RL, Ravussin E, Rosenbaum M, Patterson AD , Turnbaugh PJ",Ketogenic Diets Alter the Gut Microbiome Resulting in Decreased Intestinal Th17 Cells,Cell,2020,"Th17 cells, adipose tissue, bifidobacteria, intestinal immunity, ketogenic diet, ketone bodies, ketone ester, microbiome, β-hydroxybutyrate",Experiment 2,United States of America,Mus musculus,Feces,UBERON:0001988,Response to ketogenic diet,EFO:0009372,Mice fed on High-fat Diet (HFD),Mice fed on Ketogenic Diet (KD),"Wild-type C57BL/6J mice of both sexes, between age 5 - 10 weeks, fed on ketogenic diet for 3 weeks.",6,6,No,16S,4,Illumina,DESeq2,0.1,TRUE,NA,diet,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:714/3/NA,Study 714,"laboratory experiment,time series / longitudinal observational",32437658,https://doi.org/10.1016/j.cell.2020.04.027,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293577/,"Ang QY, Alexander M, Newman JC, Tian Y, Cai J, Upadhyay V, Turnbaugh JA, Verdin E, Hall KD, Leibel RL, Ravussin E, Rosenbaum M, Patterson AD , Turnbaugh PJ",Ketogenic Diets Alter the Gut Microbiome Resulting in Decreased Intestinal Th17 Cells,Cell,2020,"Th17 cells, adipose tissue, bifidobacteria, intestinal immunity, ketogenic diet, ketone bodies, ketone ester, microbiome, β-hydroxybutyrate",Experiment 3,United States of America,Mus musculus,Feces,UBERON:0001988,Response to ketogenic diet,EFO:0009372,Mice fed on High-fat Diet (HFD-control),Mice fed High-fat Diet + Ketone Ester (HFD-KE),"C57BL/6J mice fed on High-fat diet that was supplemented with a synthetic Ketone ester(KE), beta-hydroxybutyrate(bHB).",NA,NA,No,16S,4,Illumina,DESeq2,0.05,TRUE,NA,diet,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:715/1/NA,Study 715,prospective cohort,32717152,10.1164/rccm.201912-2441OC,https://pubmed.ncbi.nlm.nih.gov/32717152/,"Kitsios GD, Yang H, Yang L, Qin S, Fitch A, Wang XH, Fair K, Evankovich J, Bain W, Shah F, Li K, Methé B, Benos PV, Morris A , McVerry BJ",Respiratory Tract Dysbiosis Is Associated with Worse Outcomes in Mechanically Ventilated Patients,American journal of respiratory and critical care medicine,2020,"acute respiratory distress syndrome, bacterial infections, endotypes, inflammation, microbiota",Experiment 1,United States of America,Homo sapiens,Posterior wall of oropharynx,UBERON:0035240,Acute respiratory distress syndrome,EFO:1000637,Hyper-inflammatory subphenotype and ventilation-free days(VFDs),Mortality,"patients stratified on the basis of 30-day mortality [survivors vs. non-survivors], for whom respiratory specimen cultures were reported as negative (no growth or only normal respiratory flora detected, n=152) as well as those for whom no cultures were obtained (n=76)",228,228,none,16S,34,Illumina,Logistic Regression,0.05,TRUE,NA,NA,"age,antibiotic exposure,chronic obstructive pulmonary disease",NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:715/2/NA,Study 715,prospective cohort,32717152,10.1164/rccm.201912-2441OC,https://pubmed.ncbi.nlm.nih.gov/32717152/,"Kitsios GD, Yang H, Yang L, Qin S, Fitch A, Wang XH, Fair K, Evankovich J, Bain W, Shah F, Li K, Methé B, Benos PV, Morris A , McVerry BJ",Respiratory Tract Dysbiosis Is Associated with Worse Outcomes in Mechanically Ventilated Patients,American journal of respiratory and critical care medicine,2020,"acute respiratory distress syndrome, bacterial infections, endotypes, inflammation, microbiota",Experiment 2,United States of America,Homo sapiens,Epithelium of oropharynx,UBERON:0001952,Acute respiratory failure,MONDO:0001208,Hyper-inflammatory subphenotype and mortality,VFD (Ventilator free days),"Clinical outcome stratification by numbers of ventilator-free days (VFDs) at 30 days in patients for whom respiratory specimen cultures were reported as negative (no growth or only normal respiratory flora detected, n=152) as well as those for whom no cultures were obtained (n=76)",228,228,none,16S,34,Illumina,Logistic Regression,0.05,TRUE,NA,NA,"age,antibiotic exposure,chronic obstructive pulmonary disease",NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:715/3/NA,Study 715,prospective cohort,32717152,10.1164/rccm.201912-2441OC,https://pubmed.ncbi.nlm.nih.gov/32717152/,"Kitsios GD, Yang H, Yang L, Qin S, Fitch A, Wang XH, Fair K, Evankovich J, Bain W, Shah F, Li K, Methé B, Benos PV, Morris A , McVerry BJ",Respiratory Tract Dysbiosis Is Associated with Worse Outcomes in Mechanically Ventilated Patients,American journal of respiratory and critical care medicine,2020,"acute respiratory distress syndrome, bacterial infections, endotypes, inflammation, microbiota",Experiment 3,United States of America,Homo sapiens,Endothelium of trachea,UBERON:0003279,Acute respiratory failure,MONDO:0001208,VFD (Ventilator free days) and mortality,Hyper-inflammatory subphenotype,participants  were classified into a hyperinflammatory subphenotype of host responses associated with worse outcomes in the pathogen-enriched cluster,112,51,none,16S,34,Illumina,Logistic Regression,0.05,TRUE,NA,NA,"age,antibiotic exposure,chronic obstructive pulmonary disease",NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:715/4/NA,Study 715,prospective cohort,32717152,10.1164/rccm.201912-2441OC,https://pubmed.ncbi.nlm.nih.gov/32717152/,"Kitsios GD, Yang H, Yang L, Qin S, Fitch A, Wang XH, Fair K, Evankovich J, Bain W, Shah F, Li K, Methé B, Benos PV, Morris A , McVerry BJ",Respiratory Tract Dysbiosis Is Associated with Worse Outcomes in Mechanically Ventilated Patients,American journal of respiratory and critical care medicine,2020,"acute respiratory distress syndrome, bacterial infections, endotypes, inflammation, microbiota",Experiment 4,United States of America,Homo sapiens,Posterior wall of oropharynx,UBERON:0035240,Acute respiratory failure,MONDO:0001208,VFD (Ventilator free days) and mortality,Hyper-inflammatory subphenotype,participants  were classified into a hyperinflammatory subphenotype of host responses associated with worse outcomes in the pathogen-enriched cluster,96,51,none,16S,34,Illumina,Logistic Regression,0.05,TRUE,NA,NA,"age,antibiotic exposure,chronic obstructive pulmonary disease",NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:715/5/NA,Study 715,prospective cohort,32717152,10.1164/rccm.201912-2441OC,https://pubmed.ncbi.nlm.nih.gov/32717152/,"Kitsios GD, Yang H, Yang L, Qin S, Fitch A, Wang XH, Fair K, Evankovich J, Bain W, Shah F, Li K, Methé B, Benos PV, Morris A , McVerry BJ",Respiratory Tract Dysbiosis Is Associated with Worse Outcomes in Mechanically Ventilated Patients,American journal of respiratory and critical care medicine,2020,"acute respiratory distress syndrome, bacterial infections, endotypes, inflammation, microbiota",Experiment 5,United States of America,Homo sapiens,Posterior wall of oropharynx,UBERON:0035240,Acute respiratory failure,MONDO:0001208,Hyper-inflammatory subphenotype and ventilation-free days(VFDs),Mortality,patients stratified on the basis of 30-day mortality [survivors vs. non-survivors],92,55,none,16S,34,Illumina,Logistic Regression,0.05,TRUE,NA,NA,"age,antibiotic exposure,chronic obstructive pulmonary disease",NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:715/6/NA,Study 715,prospective cohort,32717152,10.1164/rccm.201912-2441OC,https://pubmed.ncbi.nlm.nih.gov/32717152/,"Kitsios GD, Yang H, Yang L, Qin S, Fitch A, Wang XH, Fair K, Evankovich J, Bain W, Shah F, Li K, Methé B, Benos PV, Morris A , McVerry BJ",Respiratory Tract Dysbiosis Is Associated with Worse Outcomes in Mechanically Ventilated Patients,American journal of respiratory and critical care medicine,2020,"acute respiratory distress syndrome, bacterial infections, endotypes, inflammation, microbiota",Experiment 6,United States of America,Homo sapiens,Endothelium of trachea,UBERON:0003279,Acute respiratory failure,MONDO:0001208,Hyper-inflammatory subphenotype and ventilation-free days(VFDs),Mortality,patients stratified on the basis of 30-day mortality [survivors vs. non-survivors],111,52,none,16S,34,Illumina,Logistic Regression,0.05,TRUE,NA,NA,"age,antibiotic exposure,chronic obstructive pulmonary disease",NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:715/7/NA,Study 715,prospective cohort,32717152,10.1164/rccm.201912-2441OC,https://pubmed.ncbi.nlm.nih.gov/32717152/,"Kitsios GD, Yang H, Yang L, Qin S, Fitch A, Wang XH, Fair K, Evankovich J, Bain W, Shah F, Li K, Methé B, Benos PV, Morris A , McVerry BJ",Respiratory Tract Dysbiosis Is Associated with Worse Outcomes in Mechanically Ventilated Patients,American journal of respiratory and critical care medicine,2020,"acute respiratory distress syndrome, bacterial infections, endotypes, inflammation, microbiota",Experiment 7,United States of America,Homo sapiens,Endothelium of trachea,UBERON:0003279,Acute respiratory failure,MONDO:0001208,Hyper-inflammatory subphenotype and mortality,VFD (Ventilator free days),clinical outcome stratifications by the number of days patients were ventilator-free,103,60,none,16S,34,Illumina,Logistic Regression,0.05,TRUE,NA,NA,"age,antibiotic exposure,chronic obstructive pulmonary disease",NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:715/8/NA,Study 715,prospective cohort,32717152,10.1164/rccm.201912-2441OC,https://pubmed.ncbi.nlm.nih.gov/32717152/,"Kitsios GD, Yang H, Yang L, Qin S, Fitch A, Wang XH, Fair K, Evankovich J, Bain W, Shah F, Li K, Methé B, Benos PV, Morris A , McVerry BJ",Respiratory Tract Dysbiosis Is Associated with Worse Outcomes in Mechanically Ventilated Patients,American journal of respiratory and critical care medicine,2020,"acute respiratory distress syndrome, bacterial infections, endotypes, inflammation, microbiota",Experiment 8,United States of America,Homo sapiens,Posterior wall of oropharynx,UBERON:0035240,Acute respiratory failure,MONDO:0001208,Hyper-inflammatory subphenotype and mortality,VFD (Ventilator free days),clinical outcome stratifications by the number of days patients were ventilator-free,106,41,none,16S,34,Illumina,Logistic Regression,0.05,TRUE,NA,NA,"age,antibiotic exposure,chronic obstructive pulmonary disease",NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:715/9/NA,Study 715,prospective cohort,32717152,10.1164/rccm.201912-2441OC,https://pubmed.ncbi.nlm.nih.gov/32717152/,"Kitsios GD, Yang H, Yang L, Qin S, Fitch A, Wang XH, Fair K, Evankovich J, Bain W, Shah F, Li K, Methé B, Benos PV, Morris A , McVerry BJ",Respiratory Tract Dysbiosis Is Associated with Worse Outcomes in Mechanically Ventilated Patients,American journal of respiratory and critical care medicine,2020,"acute respiratory distress syndrome, bacterial infections, endotypes, inflammation, microbiota",Experiment 9,United States of America,Homo sapiens,Endothelium of trachea,UBERON:0003279,Acute respiratory failure,MONDO:0001208,Hyper-inflammatory subphenotype and ventilation-free days(VFDs),Mortality,"patients stratified on the basis of 30-day mortality [survivors vs. non-survivors] , for whom respiratory specimen cultures were reported as negative (no growth or only normal respiratory flora detected, n=152) as well as those for whom no cultures were obtained (n=76)",228,228,30 days,16S,34,Illumina,Logistic Regression,0.05,TRUE,NA,NA,"age,antibiotic exposure,chronic obstructive pulmonary disease",NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:715/10/NA,Study 715,prospective cohort,32717152,10.1164/rccm.201912-2441OC,https://pubmed.ncbi.nlm.nih.gov/32717152/,"Kitsios GD, Yang H, Yang L, Qin S, Fitch A, Wang XH, Fair K, Evankovich J, Bain W, Shah F, Li K, Methé B, Benos PV, Morris A , McVerry BJ",Respiratory Tract Dysbiosis Is Associated with Worse Outcomes in Mechanically Ventilated Patients,American journal of respiratory and critical care medicine,2020,"acute respiratory distress syndrome, bacterial infections, endotypes, inflammation, microbiota",Experiment 10,United States of America,Homo sapiens,Endothelium of trachea,UBERON:0003279,Acute respiratory failure,MONDO:0001208,Hyper-inflammatory subphenotype and mortality,VFD (Ventilator free days),"clinical outcome stratifications by the number of days patients were ventilator-free for whom respiratory specimen cultures were reported as negative (no growth or only normal respiratory flora detected, n=152) as well as those for whom no cultures were obtained (n=76)",228,228,none,16S,34,Illumina,Logistic Regression,0.05,TRUE,NA,NA,"age,antibiotic exposure,chronic obstructive pulmonary disease",NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:715/11/NA,Study 715,prospective cohort,32717152,10.1164/rccm.201912-2441OC,https://pubmed.ncbi.nlm.nih.gov/32717152/,"Kitsios GD, Yang H, Yang L, Qin S, Fitch A, Wang XH, Fair K, Evankovich J, Bain W, Shah F, Li K, Methé B, Benos PV, Morris A , McVerry BJ",Respiratory Tract Dysbiosis Is Associated with Worse Outcomes in Mechanically Ventilated Patients,American journal of respiratory and critical care medicine,2020,"acute respiratory distress syndrome, bacterial infections, endotypes, inflammation, microbiota",Experiment 11,United States of America,Homo sapiens,Endothelium of trachea,UBERON:0003279,Acute respiratory failure,MONDO:0001208,VFD (Ventilator free days) and mortality,Hyper-inflammatory subphenotype,"participants who were classified into a hyperinflammatory subphenotype of host responses, for whom respiratory specimen cultures were reported as negative (no growth or only normal respiratory flora detected, n=152) as well as those for whom no cultures were obtained (n=76)",228,228,none,16S,34,Illumina,Logistic Regression,0.05,TRUE,NA,NA,"age,antibiotic exposure,chronic obstructive pulmonary disease",NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:715/12/NA,Study 715,prospective cohort,32717152,10.1164/rccm.201912-2441OC,https://pubmed.ncbi.nlm.nih.gov/32717152/,"Kitsios GD, Yang H, Yang L, Qin S, Fitch A, Wang XH, Fair K, Evankovich J, Bain W, Shah F, Li K, Methé B, Benos PV, Morris A , McVerry BJ",Respiratory Tract Dysbiosis Is Associated with Worse Outcomes in Mechanically Ventilated Patients,American journal of respiratory and critical care medicine,2020,"acute respiratory distress syndrome, bacterial infections, endotypes, inflammation, microbiota",Experiment 12,United States of America,Homo sapiens,Epithelium of oropharynx,UBERON:0001952,Acute respiratory failure,MONDO:0001208,VFD (Ventilator free days) and mortality,Hyper-inflammatory subphenotype,"participants who were classified into a hyperinflammatory subphenotype of host responses, for whom respiratory specimen cultures were reported as negative (no growth or only normal respiratory flora detected, n=152) as well as those for whom no cultures were obtained (n=76)",228,228,none,16S,34,Illumina,Logistic Regression,0.05,TRUE,NA,NA,"age,antibiotic exposure,chronic obstructive pulmonary disease",NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:716/1/NA,Study 716,case-control,29776865,10.1016/j.parkreldis.2018.05.007,https://pubmed.ncbi.nlm.nih.gov/29776865/,"Lin A, Zheng W, He Y, Tang W, Wei X, He R, Huang W, Su Y, Huang Y, Zhou H , Xie H",Gut microbiota in patients with Parkinson's disease in southern China,Parkinsonism & related disorders,2018,"16S rRNA next-generation-sequencing, Clinical motor phenotype, Gut microbiota, Parkinson's disease",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Controls,Parkinson's disease,"Patient diagnosed by a movement disorder specialist according to the 2015 Clinical Diagnostic Criteria for Parkinson's disease, from the International Parkinson and Movement Disorder Society, and were receiving the medications to treat PD at the time of this study.",45,75,3 months,16S,4,Illumina,LEfSe,0.05,TRUE,2,age,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:716/2/NA,Study 716,case-control,29776865,10.1016/j.parkreldis.2018.05.007,https://pubmed.ncbi.nlm.nih.gov/29776865/,"Lin A, Zheng W, He Y, Tang W, Wei X, He R, Huang W, Su Y, Huang Y, Zhou H , Xie H",Gut microbiota in patients with Parkinson's disease in southern China,Parkinsonism & related disorders,2018,"16S rRNA next-generation-sequencing, Clinical motor phenotype, Gut microbiota, Parkinson's disease",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,PD duration less than 5 years,PD duration more than 5 years,"Patients with PD were classified into two groups according to disease duration: at least five years and less than five years.. Patients with PD were diagnosed by a movement disorder specialist according to the 2015 Clinical Diagnostic Criteria for Parkinson's disease, from the International Parkinson and Movement Disorder Society, and were receiving the medications to treat PD at the time of this study.",44,30,3 months,16S,4,Illumina,LEfSe,0.05,TRUE,2,age,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:716/3/NA,Study 716,case-control,29776865,10.1016/j.parkreldis.2018.05.007,https://pubmed.ncbi.nlm.nih.gov/29776865/,"Lin A, Zheng W, He Y, Tang W, Wei X, He R, Huang W, Su Y, Huang Y, Zhou H , Xie H",Gut microbiota in patients with Parkinson's disease in southern China,Parkinsonism & related disorders,2018,"16S rRNA next-generation-sequencing, Clinical motor phenotype, Gut microbiota, Parkinson's disease",Experiment 3,China,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Late-onset PD,Early-onset PD,Parkinson's disease patient with age of onset less than 50.,51,23,3 months,16S,4,Illumina,LEfSe,0.05,TRUE,2,age,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:716/4/NA,Study 716,case-control,29776865,10.1016/j.parkreldis.2018.05.007,https://pubmed.ncbi.nlm.nih.gov/29776865/,"Lin A, Zheng W, He Y, Tang W, Wei X, He R, Huang W, Su Y, Huang Y, Zhou H , Xie H",Gut microbiota in patients with Parkinson's disease in southern China,Parkinsonism & related disorders,2018,"16S rRNA next-generation-sequencing, Clinical motor phenotype, Gut microbiota, Parkinson's disease",Experiment 4,China,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Non-tremor dominant PD,Tremor dominant PD,Parkinson's disease patient with tremor dominant motor symptoms.,56,18,3 months,16S,4,Illumina,LEfSe,0.05,TRUE,2,age,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:717/1/NA,Study 717,case-control,31221587,10.1016/j.ebiom.2019.05.064,NA,"Aho VTE, Pereira PAB, Voutilainen S, Paulin L, Pekkonen E, Auvinen P , Scheperjans F",Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,EBioMedicine,2019,"Disease progression, Gut microbiota, Gut-brain-axis, Parkinson's disease",Experiment 1,Finland,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Healthy controls at baseline,Participants with Parkinson's Disease at baseline,Patients with Parkinson's disease at baseline.,64,64,None.,16S,34,Illumina,"ANCOM,DESeq2",0.05,TRUE,NA,"age,sex","body mass index,irritable bowel syndrome",NA,unchanged,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:717/2/NA,Study 717,case-control,31221587,10.1016/j.ebiom.2019.05.064,NA,"Aho VTE, Pereira PAB, Voutilainen S, Paulin L, Pekkonen E, Auvinen P , Scheperjans F",Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,EBioMedicine,2019,"Disease progression, Gut microbiota, Gut-brain-axis, Parkinson's disease",Experiment 2,Finland,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Stable PD patients at follow up,Progressed PD patients at follow up,"Patients with progressed Parkinson's disease, defined based
on between-timepoint change in Unified Parkinson's Disease Rating
Scale (UPDRS) I-III sum and total medication load calculated using the
Levodopa Equivalent Dose (LED).",41,15,None,16S,34,Illumina,"ANCOM,DESeq2",0.05,TRUE,NA,"age,sex",NA,NA,unchanged,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:717/3/NA,Study 717,case-control,31221587,10.1016/j.ebiom.2019.05.064,NA,"Aho VTE, Pereira PAB, Voutilainen S, Paulin L, Pekkonen E, Auvinen P , Scheperjans F",Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,EBioMedicine,2019,"Disease progression, Gut microbiota, Gut-brain-axis, Parkinson's disease",Experiment 3,Finland,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Healthy controls at time of follow-up,Participants with Parkinson's Disease at time of follow-up,Participants with Parkinson's Disease at time of follow-up,64,64,None.,16S,34,Illumina,"ANCOM,DESeq2",0.05,TRUE,NA,"age,sex","body mass index,irritable bowel syndrome",NA,unchanged,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:717/4/NA,Study 717,case-control,31221587,10.1016/j.ebiom.2019.05.064,NA,"Aho VTE, Pereira PAB, Voutilainen S, Paulin L, Pekkonen E, Auvinen P , Scheperjans F",Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,EBioMedicine,2019,"Disease progression, Gut microbiota, Gut-brain-axis, Parkinson's disease",Experiment 4,Finland,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Tremor-dominant phenotype (TD) at baseline,Postural instability and gait difficulty (PIGD) phenotype at baseline,Parkinson's disease patients with PIGD phenotype at baseline.,21,28,none,16S,34,Illumina,"ANCOM,DESeq2",0.05,TRUE,NA,"age,sex",NA,NA,unchanged,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:717/5/NA,Study 717,case-control,31221587,10.1016/j.ebiom.2019.05.064,NA,"Aho VTE, Pereira PAB, Voutilainen S, Paulin L, Pekkonen E, Auvinen P , Scheperjans F",Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,EBioMedicine,2019,"Disease progression, Gut microbiota, Gut-brain-axis, Parkinson's disease",Experiment 5,Finland,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Tremor-dominant phenotype (TD) at follow-up,Postural instability and gait difficulty (PIGD) phenotype at follow-up,Parkinson's disease patients with PIGD phenotype at follow-up,20,35,none,16S,34,Illumina,"ANCOM,DESeq2",0.05,TRUE,NA,"age,sex",NA,NA,unchanged,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:717/6/NA,Study 717,case-control,31221587,10.1016/j.ebiom.2019.05.064,NA,"Aho VTE, Pereira PAB, Voutilainen S, Paulin L, Pekkonen E, Auvinen P , Scheperjans F",Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression,EBioMedicine,2019,"Disease progression, Gut microbiota, Gut-brain-axis, Parkinson's disease",Experiment 6,Finland,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Stable PD patients at baseline,Progressed PD patients at baseline,"Patients with progressed Parkinson's disease, defined based
on between-timepoint change in Unified Parkinson's Disease Rating
Scale (UPDRS) I-III sum and total medication load calculated using the
Levodopa Equivalent Dose (LED).",41,15,None,16S,34,Illumina,DESeq2,0.05,FALSE,NA,"age,sex",NA,NA,unchanged,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:718/1/NA,Study 718,"laboratory experiment,time series / longitudinal observational",26731268,https://doi.org/10.1371/journal.pone.0146509,https://pubmed.ncbi.nlm.nih.gov/26731268/,"Kelley ST, Skarra DV, Rivera AJ , Thackray VG",The Gut Microbiome Is Altered in a Letrozole-Induced Mouse Model of Polycystic Ovary Syndrome,PloS one,2016,NA,Experiment 1,United States of America,Mus musculus,Feces,UBERON:0001988,Polycystic ovary syndrome,EFO:0000660,Placebo-treated,Letrozole-treated,"At 4 weeks of age, the mice were implanted subcutaneously with a 3 mg letrozole pellet (Innovative Research of America, Sarasota, FL) that provided a constant, slow release of letrozole (50 μg/day) (n = 10/group).",10,10,N/A,16S,4,Illumina,Kruskall-Wallis,0.05,TRUE,NA,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:719/1/NA,Study 719,case-control,28843021,10.1002/mds.27105,https://pubmed.ncbi.nlm.nih.gov/28843021/,"Heintz-Buschart A, Pandey U, Wicke T, Sixel-Döring F, Janzen A, Sittig-Wiegand E, Trenkwalder C, Oertel WH, Mollenhauer B , Wilmes P",The nasal and gut microbiome in Parkinson's disease and idiopathic rapid eye movement sleep behavior disorder,Movement disorders : official journal of the Movement Disorder Society,2018,"16S rRNA gene amplicon sequencing, PD, RBD, genome reconstructions, nonmotor phenotype",Experiment 1,Germany,Homo sapiens,Nasal cavity,UBERON:0001707,Parkinson's disease,MONDO:0005180,Healthy Controls,Parkinson's Disease Patients,"PD patients underwent deep clinical characterization, including the International Parkinson and Movement Disorder Society (MDS) Unified Parkinson's Disease rating Scale (MDS‐UPDRS I–III), assessment of autonomic dysfunction in Parkinson's disease (Scopa‐AUT) gastrointestinal part (Questions 1‐7), depression by Geriatric Depression Scale and Montgomery‐Åsberg Depression Scale (MADRS), cognition by Mini–Mental State Examination (MMSE) as well as Montréal Cognitive Assessment (MoCA), and sleepiness by Epworth Sleepiness Scale (ESS).",78,76,NA,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:719/2/NA,Study 719,case-control,28843021,10.1002/mds.27105,https://pubmed.ncbi.nlm.nih.gov/28843021/,"Heintz-Buschart A, Pandey U, Wicke T, Sixel-Döring F, Janzen A, Sittig-Wiegand E, Trenkwalder C, Oertel WH, Mollenhauer B , Wilmes P",The nasal and gut microbiome in Parkinson's disease and idiopathic rapid eye movement sleep behavior disorder,Movement disorders : official journal of the Movement Disorder Society,2018,"16S rRNA gene amplicon sequencing, PD, RBD, genome reconstructions, nonmotor phenotype",Experiment 2,Germany,Homo sapiens,Nasal cavity,UBERON:0001707,REM sleep behavior disorder,EFO:0007462,Healthy Controls,idiopathic rapid eye movement sleep behavior disorder,Subjects with iRBD diagnosed according to the consensus criteria of the International RBD Study group and no signs for neurodegenerative disorder (by clinical examination and neuropsychological testing).,78,21,NA,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:719/3/NA,Study 719,case-control,28843021,10.1002/mds.27105,https://pubmed.ncbi.nlm.nih.gov/28843021/,"Heintz-Buschart A, Pandey U, Wicke T, Sixel-Döring F, Janzen A, Sittig-Wiegand E, Trenkwalder C, Oertel WH, Mollenhauer B , Wilmes P",The nasal and gut microbiome in Parkinson's disease and idiopathic rapid eye movement sleep behavior disorder,Movement disorders : official journal of the Movement Disorder Society,2018,"16S rRNA gene amplicon sequencing, PD, RBD, genome reconstructions, nonmotor phenotype",Experiment 3,Germany,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Healthy Controls,Parkinson's Disease Patients,"PD patients underwent deep clinical characterization, including the International Parkinson and Movement Disorder Society (MDS) Unified Parkinson's Disease rating Scale (MDS‐UPDRS I–III), assessment of autonomic dysfunction in Parkinson's disease (Scopa‐AUT) gastrointestinal part (Questions 1‐7), depression by Geriatric Depression Scale and Montgomery‐Åsberg Depression Scale (MADRS), cognition by Mini–Mental State Examination (MMSE) as well as Montréal Cognitive Assessment (MoCA), and sleepiness by Epworth Sleepiness Scale (ESS).",78,76,NA,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,intake of diabetes medication,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:719/4/NA,Study 719,case-control,28843021,10.1002/mds.27105,https://pubmed.ncbi.nlm.nih.gov/28843021/,"Heintz-Buschart A, Pandey U, Wicke T, Sixel-Döring F, Janzen A, Sittig-Wiegand E, Trenkwalder C, Oertel WH, Mollenhauer B , Wilmes P",The nasal and gut microbiome in Parkinson's disease and idiopathic rapid eye movement sleep behavior disorder,Movement disorders : official journal of the Movement Disorder Society,2018,"16S rRNA gene amplicon sequencing, PD, RBD, genome reconstructions, nonmotor phenotype",Experiment 4,Germany,Homo sapiens,Feces,UBERON:0001988,REM sleep behavior disorder,EFO:0007462,Healthy Controls,idiopathic rapid eye movement sleep behavior disorder,Subjects with iRBD diagnosed according to the consensus criteria of the International RBD Study group and no signs for neurodegenerative disorder (by clinical examination and neuropsychological testing).,78,21,NA,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,intake of diabetes medication,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:720/1/NA,Study 720,"cross-sectional observational, not case-control",31575935,10.1038/s41598-019-50410-x,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6773718/,"Ceccarani C, Foschi C, Parolin C, D'Antuono A, Gaspari V, Consolandi C, Laghi L, Camboni T, Vitali B, Severgnini M , Marangoni A",Diversity of vaginal microbiome and metabolome during genital infections,Scientific reports,2019,NA,Experiment 1,Italy,Homo sapiens,Vagina,UBERON:0000996,Chlamydia trachomatis infectious disease,EFO:0007205,Healthy Controls,Chlamydia trachomatis,‘Chlamydia’ (CT) (detection of C. trachomatis DNA by Versant CT/GC DNA 1.0 Assay),21,20,n/a,16S,34,Illumina,Kruskall-Wallis,0.05,FALSE,NA,NA,NA,NA,unchanged,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:720/2/NA,Study 720,"cross-sectional observational, not case-control",31575935,10.1038/s41598-019-50410-x,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6773718/,"Ceccarani C, Foschi C, Parolin C, D'Antuono A, Gaspari V, Consolandi C, Laghi L, Camboni T, Vitali B, Severgnini M , Marangoni A",Diversity of vaginal microbiome and metabolome during genital infections,Scientific reports,2019,NA,Experiment 2,Italy,Homo sapiens,Vagina,UBERON:0000996,Vulvovaginal candidiasis,EFO:0007543,Healthy Controls,Vulvovaginal candidiasis,vulvovaginal candidiasis (VVC),21,18,n/a,16S,34,Illumina,Kruskall-Wallis,0.05,FALSE,NA,NA,NA,NA,unchanged,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:720/3/NA,Study 720,"cross-sectional observational, not case-control",31575935,10.1038/s41598-019-50410-x,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6773718/,"Ceccarani C, Foschi C, Parolin C, D'Antuono A, Gaspari V, Consolandi C, Laghi L, Camboni T, Vitali B, Severgnini M , Marangoni A",Diversity of vaginal microbiome and metabolome during genital infections,Scientific reports,2019,NA,Experiment 3,Italy,Homo sapiens,Vagina,UBERON:0000996,Bacterial vaginosis,EFO:0003932,Healthy Controls,bacterial vaginosis,bacterial vaginosis (BV),21,20,n/a,16S,34,Illumina,Kruskall-Wallis,0.05,FALSE,NA,NA,NA,NA,increased,increased,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:721/1/NA,Study 721,prospective cohort,36073815,10.1128/mbio.01229-22,NA,"Jackson CL, Frank DN, Robertson CE, Ir D, Kofonow JM, Montlha MP, Mutsaerts EAML, Nunes MC, Madhi SA, Ghosh D , Weinberg A",Evolution of the Gut Microbiome in HIV-Exposed Uninfected and Unexposed Infants during the First Year of Life,mBio,2022,"HIV, HIV-exposed uninfected infants, breast milk microbiome, gut microbiome, human immunodeficiency virus, pregnant women with HIV",Experiment 1,South Africa,Homo sapiens,Feces,UBERON:0001988,HIV mother to child transmission,EFO:0004595,HIV-unexposed infants (HUU) at 6 weeks,HIV-exposed uninfected infants (HEU) at 6 weeks,In utero-HIV exposed uninfected infants (HEU) at 6 weeks,78,76,"Infants that did not pass the sequence quality control, those on antibiotics, and HEU infants on Bactrim after 6 weeks of birth.",16S,34,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:721/2/NA,Study 721,prospective cohort,36073815,10.1128/mbio.01229-22,NA,"Jackson CL, Frank DN, Robertson CE, Ir D, Kofonow JM, Montlha MP, Mutsaerts EAML, Nunes MC, Madhi SA, Ghosh D , Weinberg A",Evolution of the Gut Microbiome in HIV-Exposed Uninfected and Unexposed Infants during the First Year of Life,mBio,2022,"HIV, HIV-exposed uninfected infants, breast milk microbiome, gut microbiome, human immunodeficiency virus, pregnant women with HIV",Experiment 2,South Africa,Homo sapiens,Feces,UBERON:0001988,HIV mother to child transmission,EFO:0004595,HIV-unexposed infants (HUU) at 28 weeks,HIV-exposed uninfected infants (HEU) at 28 weeks,In utero-HIV exposed uninfected infants (HEU),74,71,Unexposed Infants who had been on antibiotics and HIV-exposed uninfected infants that had not been on Bactrim after 28 weeks of birth were excluded,16S,34,Illumina,DESeq2,0.05,TRUE,NA,NA,antibiotic exposure,NA,unchanged,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:721/3/NA,Study 721,prospective cohort,36073815,10.1128/mbio.01229-22,NA,"Jackson CL, Frank DN, Robertson CE, Ir D, Kofonow JM, Montlha MP, Mutsaerts EAML, Nunes MC, Madhi SA, Ghosh D , Weinberg A",Evolution of the Gut Microbiome in HIV-Exposed Uninfected and Unexposed Infants during the First Year of Life,mBio,2022,"HIV, HIV-exposed uninfected infants, breast milk microbiome, gut microbiome, human immunodeficiency virus, pregnant women with HIV",Experiment 3,South Africa,Homo sapiens,Feces,UBERON:0001988,HIV mother to child transmission,EFO:0004595,HIV-unexposed infants (HUU) at 62 weeks,HIV-exposed uninfected infants (HEU) at 62 weeks,In utero-HIV exposed uninfected infants (HEU) at 62 weeks,70,61,Infants who had been on antibiotics and HIV-exposed uninfected infants that had not been on Bactrim after 62 weeks of birth were excluded,16S,34,Illumina,DESeq2,0.05,TRUE,NA,NA,antibiotic exposure,NA,unchanged,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:721/4/NA,Study 721,prospective cohort,36073815,10.1128/mbio.01229-22,NA,"Jackson CL, Frank DN, Robertson CE, Ir D, Kofonow JM, Montlha MP, Mutsaerts EAML, Nunes MC, Madhi SA, Ghosh D , Weinberg A",Evolution of the Gut Microbiome in HIV-Exposed Uninfected and Unexposed Infants during the First Year of Life,mBio,2022,"HIV, HIV-exposed uninfected infants, breast milk microbiome, gut microbiome, human immunodeficiency virus, pregnant women with HIV",Experiment 4,South Africa,Homo sapiens,Feces,UBERON:0001988,HIV mother to child transmission,EFO:0004595,Healthy controls at delivery,HIV-infected mothers at delivery,Mothers infected with HIV at delivery time point,110,119,Mothers on antibiotics as at the time of delivery,16S,34,Illumina,DESeq2,0.05,TRUE,NA,sex,NA,NA,unchanged,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:721/5/NA,Study 721,prospective cohort,36073815,10.1128/mbio.01229-22,NA,"Jackson CL, Frank DN, Robertson CE, Ir D, Kofonow JM, Montlha MP, Mutsaerts EAML, Nunes MC, Madhi SA, Ghosh D , Weinberg A",Evolution of the Gut Microbiome in HIV-Exposed Uninfected and Unexposed Infants during the First Year of Life,mBio,2022,"HIV, HIV-exposed uninfected infants, breast milk microbiome, gut microbiome, human immunodeficiency virus, pregnant women with HIV",Experiment 5,South Africa,Homo sapiens,Feces,UBERON:0001988,HIV mother to child transmission,EFO:0004595,Healthy controls at 62 weeks,HIV-infected  mothers at 62 weeks,Mothers infected with HIV at 62 weeks time point,65,71,NA,16S,34,Illumina,DESeq2,0.05,TRUE,NA,sex,NA,NA,unchanged,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:721/6/NA,Study 721,prospective cohort,36073815,10.1128/mbio.01229-22,NA,"Jackson CL, Frank DN, Robertson CE, Ir D, Kofonow JM, Montlha MP, Mutsaerts EAML, Nunes MC, Madhi SA, Ghosh D , Weinberg A",Evolution of the Gut Microbiome in HIV-Exposed Uninfected and Unexposed Infants during the First Year of Life,mBio,2022,"HIV, HIV-exposed uninfected infants, breast milk microbiome, gut microbiome, human immunodeficiency virus, pregnant women with HIV",Experiment 6,South Africa,Homo sapiens,Milk,UBERON:0001913,HIV mother to child transmission,EFO:0004595,Healthy controls,HIV-infected mothers,Mothers infected with HIV,76,88,NA,16S,34,Illumina,DESeq2,0.05,TRUE,NA,sex,NA,NA,unchanged,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:721/7/NA,Study 721,prospective cohort,36073815,10.1128/mbio.01229-22,NA,"Jackson CL, Frank DN, Robertson CE, Ir D, Kofonow JM, Montlha MP, Mutsaerts EAML, Nunes MC, Madhi SA, Ghosh D , Weinberg A",Evolution of the Gut Microbiome in HIV-Exposed Uninfected and Unexposed Infants during the First Year of Life,mBio,2022,"HIV, HIV-exposed uninfected infants, breast milk microbiome, gut microbiome, human immunodeficiency virus, pregnant women with HIV",Experiment 7,South Africa,Homo sapiens,Feces,UBERON:0001988,HIV mother to child transmission,EFO:0004595,Exclusively breastfed HIV-unexposed infants (HUU) at 28 weeks,Exclusively breastfed HIV-exposed uninfected infants (HEU) at 28 weeks,Exclusively breastfed In utero-HIV exposed uninfected infants (HEU) at 28 weeks,40,52,Unexposed Infants who had been on antibiotics and HIV-exposed uninfected infants that had not been on Bactrim after 28 weeks of birth were excluded,16S,34,Illumina,DESeq2,0.05,TRUE,NA,NA,antibiotic exposure,NA,unchanged,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:721/8/NA,Study 721,prospective cohort,36073815,10.1128/mbio.01229-22,NA,"Jackson CL, Frank DN, Robertson CE, Ir D, Kofonow JM, Montlha MP, Mutsaerts EAML, Nunes MC, Madhi SA, Ghosh D , Weinberg A",Evolution of the Gut Microbiome in HIV-Exposed Uninfected and Unexposed Infants during the First Year of Life,mBio,2022,"HIV, HIV-exposed uninfected infants, breast milk microbiome, gut microbiome, human immunodeficiency virus, pregnant women with HIV",Experiment 8,South Africa,Homo sapiens,Feces,UBERON:0001988,HIV mother to child transmission,EFO:0004595,Not exclusively breastfed HIV-unexposed infants (HUU) at 28 weeks,Not exclusively breastfed HIV-exposed uninfected infants (HEU) at 28 weeks,Not exclusively breastfed (formula feeding) In utero-HIV exposed uninfected infants (HEU) at 28 weeks,9,19,Unexposed Infants who had been on antibiotics and HIV-exposed uninfected infants that had not been on Bactrim after 28 weeks of birth were excluded,16S,34,Illumina,DESeq2,0.05,TRUE,NA,NA,antibiotic exposure,NA,unchanged,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:722/1/NA,Study 722,case-control,31200089,10.1016/j.neulet.2019.134297,https://pubmed.ncbi.nlm.nih.gov/31200089/,"Li F, Wang P, Chen Z, Sui X, Xie X , Zhang J",Alteration of the fecal microbiota in North-Eastern Han Chinese population with sporadic Parkinson's disease,Neuroscience letters,2019,"16S rRNA gene, Gut microbiome, Microbiota–gut–brain axis, Parkinson’s disease, Pathogenesis",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Healthy Controls,Parkinson's Disease Patients,Patients with sporadic PD and over 65 age.,10,10,One month.,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:723/1/NA,Study 723,case-control,33085540,10.2217/fmb-2019-0336,https://pubmed.ncbi.nlm.nih.gov/33085540/,"Del Chierico F, Grassini P, Quagliariello A, Torti M, Russo A, Reddel S , Stocchi F",The impact of intestinal microbiota on weight loss in Parkinson's disease patients: a pilot study,Future microbiology,2020,"Parkinson's disease, inflammation, metabolism, microbiota, weight loss",Experiment 1,United Kingdom,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Healthy Controls,Idiopathic Parkinson's Disease Patients,"Patients diagnosed with idiopathic PD according to the UK Brain Bank criteria that either referred an unintended weight loss of at least 7% of the usual weight, in the period from the diagnosis to the time of assessment (WL group) or reported stability of body weight from the diagnosis to the time of evaluation (NWL group).",8,20,2 months.,16S,34,Illumina,LEfSe,0.05,FALSE,2,"age,sex",NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:723/2/NA,Study 723,case-control,33085540,10.2217/fmb-2019-0336,https://pubmed.ncbi.nlm.nih.gov/33085540/,"Del Chierico F, Grassini P, Quagliariello A, Torti M, Russo A, Reddel S , Stocchi F",The impact of intestinal microbiota on weight loss in Parkinson's disease patients: a pilot study,Future microbiology,2020,"Parkinson's disease, inflammation, metabolism, microbiota, weight loss",Experiment 2,United Kingdom,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Healthy Controls and Idiopathic Parkinson's Disease Patients with Weight Loss,Idiopathic Parkinson's Disease Patients without Weight Loss,Patients diagnosed with idiopathic PD according to the UK Brain Bank criteria that reported stability of body weight from the diagnosis to the time of evaluation (NWL group).,18,10,2 months.,16S,34,Illumina,LEfSe,0.05,FALSE,2,"age,sex",NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:723/3/NA,Study 723,case-control,33085540,10.2217/fmb-2019-0336,https://pubmed.ncbi.nlm.nih.gov/33085540/,"Del Chierico F, Grassini P, Quagliariello A, Torti M, Russo A, Reddel S , Stocchi F",The impact of intestinal microbiota on weight loss in Parkinson's disease patients: a pilot study,Future microbiology,2020,"Parkinson's disease, inflammation, metabolism, microbiota, weight loss",Experiment 3,United Kingdom,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Healthy Controls,Idiopathic Parkinson's Disease Patients with Weight Loss,"Patients diagnosed with idiopathic PD according to the UK Brain Bank criteria that referred an unintended weight loss of at least 7% of the usual weight, in the period from the diagnosis to the time of assessment (WL group).",8,10,2 months.,16S,34,Illumina,LEfSe,0.05,FALSE,2,"age,sex",NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:723/4/NA,Study 723,case-control,33085540,10.2217/fmb-2019-0336,https://pubmed.ncbi.nlm.nih.gov/33085540/,"Del Chierico F, Grassini P, Quagliariello A, Torti M, Russo A, Reddel S , Stocchi F",The impact of intestinal microbiota on weight loss in Parkinson's disease patients: a pilot study,Future microbiology,2020,"Parkinson's disease, inflammation, metabolism, microbiota, weight loss",Experiment 4,United Kingdom,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Healthy Controls,Idiopathic Parkinson's Disease Patients without Weight Loss,Patients diagnosed with idiopathic PD according to the UK Brain Bank criteria that reported stability of body weight from the diagnosis to the time of evaluation (NWL group).,8,10,2 months.,16S,34,Illumina,LEfSe,0.05,FALSE,2,"age,sex",NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:723/5/NA,Study 723,case-control,33085540,10.2217/fmb-2019-0336,https://pubmed.ncbi.nlm.nih.gov/33085540/,"Del Chierico F, Grassini P, Quagliariello A, Torti M, Russo A, Reddel S , Stocchi F",The impact of intestinal microbiota on weight loss in Parkinson's disease patients: a pilot study,Future microbiology,2020,"Parkinson's disease, inflammation, metabolism, microbiota, weight loss",Experiment 5,United Kingdom,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Idiopathic Parkinson's Disease Patients without Weight Loss,Idiopathic Parkinson's Disease Patients with Weight Loss,"Patients diagnosed with idiopathic PD according to the UK Brain Bank criteria that referred an unintended weight loss of at least 7% of the usual weight, in the period from the diagnosis to the time of assessment (WL group).",10,10,2 months.,16S,34,Illumina,LEfSe,0.05,FALSE,2,"age,sex,time from diagnosis",NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:724/1/NA,Study 724,case-control,32161568,10.3389/fneur.2020.00137,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052381/,"Ren T, Gao Y, Qiu Y, Jiang S, Zhang Q, Zhang J, Wang L, Zhang Y, Wang L , Nie K",Gut Microbiota Altered in Mild Cognitive Impairment Compared With Normal Cognition in Sporadic Parkinson's Disease,Frontiers in neurology,2020,"Parkinson's disease, cognition impairment, gut micro biome, high throughput sequencing, short fatty acids",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Healthy spouses and Parkinson's disease patients with mild cognitive impairment,Parkinson's disease patients with normal cognition,"All patients eligible for this study were diagnosed for PD according to the UK Brain Bank criteria. Cognition abilities were estimated using the Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA), and the scores were obtained from two other neuropsychological tests in each of the five cognitive domains.",26,14,NA,16S,34,Illumina,LEfSe,0.05,FALSE,2,age,"age,body mass index,constipation,education level,sex",NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:724/2/NA,Study 724,case-control,32161568,10.3389/fneur.2020.00137,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052381/,"Ren T, Gao Y, Qiu Y, Jiang S, Zhang Q, Zhang J, Wang L, Zhang Y, Wang L , Nie K",Gut Microbiota Altered in Mild Cognitive Impairment Compared With Normal Cognition in Sporadic Parkinson's Disease,Frontiers in neurology,2020,"Parkinson's disease, cognition impairment, gut micro biome, high throughput sequencing, short fatty acids",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Healthy spouses and Parkinson's disease patients with normal cognition,Parkinson's disease patients with mild cognitive impairment,"All patients eligible for this study were diagnosed for PD according to the UK Brain Bank criteria. Cognition abilities were estimated using the Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA), and the scores were obtained from two other neuropsychological tests in each of the five cognitive domains.",27,13,NA,16S,34,Illumina,LEfSe,0.05,FALSE,2,age,"age,body mass index,constipation,education level,sex",NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:724/3/NA,Study 724,case-control,32161568,10.3389/fneur.2020.00137,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052381/,"Ren T, Gao Y, Qiu Y, Jiang S, Zhang Q, Zhang J, Wang L, Zhang Y, Wang L , Nie K",Gut Microbiota Altered in Mild Cognitive Impairment Compared With Normal Cognition in Sporadic Parkinson's Disease,Frontiers in neurology,2020,"Parkinson's disease, cognition impairment, gut micro biome, high throughput sequencing, short fatty acids",Experiment 3,China,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Healthy spouses,Parkinson's disease patients with mild cognitive impairment and Parkinson's disease patients with normal cognition,"All patients eligible for this study were diagnosed for PD according to the UK Brain Bank criteria. Cognition abilities were estimated using the Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA), and the scores were obtained from two other neuropsychological tests in each of the five cognitive domains.",13,27,NA,16S,34,Illumina,LEfSe,0.05,FALSE,2,age,"age,body mass index,constipation,education level,sex",NA,increased,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:725/1/NA,Study 725,case-control,27562258,10.1038/nmicrobiol.2016.106,https://www.nature.com/articles/nmicrobiol2016106,"Chng KR, Tay AS, Li C, Ng AH, Wang J, Suri BK, Matta SA, McGovern N, Janela B, Wong XF, Sio YY, Au BV, Wilm A, De Sessions PF, Lim TC, Tang MB, Ginhoux F, Connolly JE, Lane EB, Chew FT, Common JE , Nagarajan N",Whole metagenome profiling reveals skin microbiome-dependent susceptibility to atopic dermatitis flare,Nature microbiology,2016,NA,Experiment 1,Singapore,Homo sapiens,Skin epithelium,UBERON:0019204,Eczema,HP:0000964,Healthy controls,Atopic dermatitis case group,Atopic dermatitis case group with volunteers reporting past atopic dermatitis episodes,15,19,NA,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,"age,sex",NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:725/2/NA,Study 725,case-control,27562258,10.1038/nmicrobiol.2016.106,https://www.nature.com/articles/nmicrobiol2016106,"Chng KR, Tay AS, Li C, Ng AH, Wang J, Suri BK, Matta SA, McGovern N, Janela B, Wong XF, Sio YY, Au BV, Wilm A, De Sessions PF, Lim TC, Tang MB, Ginhoux F, Connolly JE, Lane EB, Chew FT, Common JE , Nagarajan N",Whole metagenome profiling reveals skin microbiome-dependent susceptibility to atopic dermatitis flare,Nature microbiology,2016,NA,Experiment 2,Singapore,Homo sapiens,Skin epithelium,UBERON:0019204,Eczema,HP:0000964,Females (controls),Females (cases),Atopic dermatitis (AD) case females,7,11,NA,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,"age,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:725/3/NA,Study 725,case-control,27562258,10.1038/nmicrobiol.2016.106,https://www.nature.com/articles/nmicrobiol2016106,"Chng KR, Tay AS, Li C, Ng AH, Wang J, Suri BK, Matta SA, McGovern N, Janela B, Wong XF, Sio YY, Au BV, Wilm A, De Sessions PF, Lim TC, Tang MB, Ginhoux F, Connolly JE, Lane EB, Chew FT, Common JE , Nagarajan N",Whole metagenome profiling reveals skin microbiome-dependent susceptibility to atopic dermatitis flare,Nature microbiology,2016,NA,Experiment 3,Singapore,Homo sapiens,Skin epithelium,UBERON:0019204,Eczema,HP:0000964,Males (control),Males (case),Atopic dermatitis (AD) case males,8,8,NA,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:725/4/NA,Study 725,case-control,27562258,10.1038/nmicrobiol.2016.106,https://www.nature.com/articles/nmicrobiol2016106,"Chng KR, Tay AS, Li C, Ng AH, Wang J, Suri BK, Matta SA, McGovern N, Janela B, Wong XF, Sio YY, Au BV, Wilm A, De Sessions PF, Lim TC, Tang MB, Ginhoux F, Connolly JE, Lane EB, Chew FT, Common JE , Nagarajan N",Whole metagenome profiling reveals skin microbiome-dependent susceptibility to atopic dermatitis flare,Nature microbiology,2016,NA,Experiment 4,Singapore,Homo sapiens,Skin epithelium,UBERON:0019204,Eczema,HP:0000964,Normal control,AD cases with no reported cream usage,AD cases with no reported cream usage (no emollient creams or topical corticosteroids),15,11,NA,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:726/1/NA,Study 726,prospective cohort,34592155,10.1016/j.celrep.2021.109765,https://pubmed.ncbi.nlm.nih.gov/34592155/,"Leite G, Pimentel M, Barlow GM, Chang C, Hosseini A, Wang J, Parodi G, Sedighi R, Rezaie A , Mathur R",Age and the aging process significantly alter the small bowel microbiome,Cell reports,2021,"Escherichia, Lactobacillus, Proteobacteria, age, aging, coliforms, concomitant diseases, duodenal microbiome, medication use, small intestinal microbiome",Experiment 1,Switzerland,Homo sapiens,Duodenum,UBERON:0002114,Aging,GO:0007568,Group 1 (18–35 years old),Group 2,36-50 years old,32,41,NA,16S,34,Illumina,Linear Regression,0.05,TRUE,NA,NA,NA,NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:726/2/NA,Study 726,prospective cohort,34592155,10.1016/j.celrep.2021.109765,https://pubmed.ncbi.nlm.nih.gov/34592155/,"Leite G, Pimentel M, Barlow GM, Chang C, Hosseini A, Wang J, Parodi G, Sedighi R, Rezaie A , Mathur R",Age and the aging process significantly alter the small bowel microbiome,Cell reports,2021,"Escherichia, Lactobacillus, Proteobacteria, age, aging, coliforms, concomitant diseases, duodenal microbiome, medication use, small intestinal microbiome",Experiment 2,Switzerland,Homo sapiens,Duodenum,UBERON:0002114,Aging,GO:0007568,Group 1 (18–35 years old),Group 3,participants aged 51 to 65 years old,32,96,NA,16S,34,Illumina,Linear Regression,0.05,TRUE,NA,NA,NA,NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:726/3/NA,Study 726,prospective cohort,34592155,10.1016/j.celrep.2021.109765,https://pubmed.ncbi.nlm.nih.gov/34592155/,"Leite G, Pimentel M, Barlow GM, Chang C, Hosseini A, Wang J, Parodi G, Sedighi R, Rezaie A , Mathur R",Age and the aging process significantly alter the small bowel microbiome,Cell reports,2021,"Escherichia, Lactobacillus, Proteobacteria, age, aging, coliforms, concomitant diseases, duodenal microbiome, medication use, small intestinal microbiome",Experiment 3,Switzerland,Homo sapiens,Duodenum,UBERON:0002114,Aging,GO:0007568,Group 1 (18–35 years old),Group 4,66 to 80 years old,32,82,NA,16S,34,Illumina,Linear Regression,0.05,TRUE,NA,NA,NA,NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:727/1/NA,Study 727,case-control,31076212,https://doi.org/10.1016/j.annepidem.2019.03.005,NA,"Beghini F, Renson A, Zolnik CP, Geistlinger L, Usyk M, Moody TU, Thorpe L, Dowd JB, Burk R, Segata N, Jones HE , Waldron L",Tobacco exposure associated with oral microbiota oxygen utilization in the New York City Health and Nutrition Examination Study,Annals of epidemiology,2019,"16S, Human microbiome, Microbiota, Oral health, RNA, Ribosomal, Smoking, Tobacco",Experiment 1,United States of America,Homo sapiens,Saliva,UBERON:0001836,Tobacco smoke exposure measurement,EFO:0009115,Never smokers,Current cigarette smokers,"Participants who reported smoking more than 100 cigarettes in their lifetime, smoking a cigarette in the last 5 days, and not using any alternative tobacco product in the last 5 days (the 90 with highest measured serum cotinine were selected)",43,86,NA,16S,4,Illumina,edgeR,0.05,TRUE,NA,NA,"age,diabetes mellitus,education level,physical activity,race,sex",NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:727/2/NA,Study 727,case-control,31076212,https://doi.org/10.1016/j.annepidem.2019.03.005,NA,"Beghini F, Renson A, Zolnik CP, Geistlinger L, Usyk M, Moody TU, Thorpe L, Dowd JB, Burk R, Segata N, Jones HE , Waldron L",Tobacco exposure associated with oral microbiota oxygen utilization in the New York City Health and Nutrition Examination Study,Annals of epidemiology,2019,"16S, Human microbiome, Microbiota, Oral health, RNA, Ribosomal, Smoking, Tobacco",Experiment 2,United States of America,Homo sapiens,Saliva,UBERON:0001836,Tobacco smoke exposure measurement,EFO:0009115,Never Smokers,Alternative Tobacco Smokers,"Participants who used e-cigarettes, hookah, and/or 
cigar or cigarillo but not cigarettes",43,49,NA,16S,4,Illumina,edgeR,0.05,TRUE,NA,NA,"age,diabetes mellitus,education level,physical activity,race,sex",NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:727/3/NA,Study 727,case-control,31076212,https://doi.org/10.1016/j.annepidem.2019.03.005,NA,"Beghini F, Renson A, Zolnik CP, Geistlinger L, Usyk M, Moody TU, Thorpe L, Dowd JB, Burk R, Segata N, Jones HE , Waldron L",Tobacco exposure associated with oral microbiota oxygen utilization in the New York City Health and Nutrition Examination Study,Annals of epidemiology,2019,"16S, Human microbiome, Microbiota, Oral health, RNA, Ribosomal, Smoking, Tobacco",Experiment 3,United States of America,Homo sapiens,Saliva,UBERON:0001836,Tobacco smoke exposure measurement,EFO:0009115,Never Smokers,participants who only smoked hookah,participants who only smoked hookah,43,28,NA,16S,4,Illumina,edgeR,0.05,TRUE,NA,NA,"age,diabetes mellitus,education level,physical activity,race,sex",NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:728/1/NA,Study 728,prospective cohort,29920927,10.1111/ajt.14974,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6301138/,"Lee JR, Magruder M, Zhang L, Westblade LF, Satlin MJ, Robertson A, Edusei E, Crawford C, Ling L, Taur Y, Schluter J, Lubetzky M, Dadhania D, Pamer E , Suthanthiran M",Gut microbiota dysbiosis and diarrhea in kidney transplant recipients,American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,2019,"complication: medical/metabolic, diarrhea, gut microbiota, kidney disease, kidney transplantation/nephrology, microbiomics, translational research/science",Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Diarrhea,HP:0002014,Controls (No Diarrhea Group),Diarrhea Group,Kidney transplant recipients that developed post-transplant diarrhea within the first 3 months after transplantation,46,18,"Applicable, but exact duration not specified",16S,45,Illumina,Mann-Whitney (Wilcoxon),NA,NA,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:728/2/NA,Study 728,prospective cohort,29920927,10.1111/ajt.14974,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6301138/,"Lee JR, Magruder M, Zhang L, Westblade LF, Satlin MJ, Robertson A, Edusei E, Crawford C, Ling L, Taur Y, Schluter J, Lubetzky M, Dadhania D, Pamer E , Suthanthiran M",Gut microbiota dysbiosis and diarrhea in kidney transplant recipients,American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,2019,"complication: medical/metabolic, diarrhea, gut microbiota, kidney disease, kidney transplantation/nephrology, microbiomics, translational research/science",Experiment 2,United States of America,Homo sapiens,Feces,UBERON:0001988,Diarrhea,HP:0002014,Antibiotic-excluded Controls (No Diarrhea Group),Antibiotic-excluded Diarrhea Group,Antibiotic-excluded diarrheal group; Kidney transplant recipients that developed post-transplant diarrhea within the first 3 months after transplantation,46,13,Applicable; but exact duration not specified,16S,45,Illumina,Mann-Whitney (Wilcoxon),0.15,TRUE,NA,antibiotic exposure,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:728/3/NA,Study 728,prospective cohort,29920927,10.1111/ajt.14974,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6301138/,"Lee JR, Magruder M, Zhang L, Westblade LF, Satlin MJ, Robertson A, Edusei E, Crawford C, Ling L, Taur Y, Schluter J, Lubetzky M, Dadhania D, Pamer E , Suthanthiran M",Gut microbiota dysbiosis and diarrhea in kidney transplant recipients,American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,2019,"complication: medical/metabolic, diarrhea, gut microbiota, kidney disease, kidney transplantation/nephrology, microbiomics, translational research/science",Experiment 3,United States of America,Homo sapiens,Feces,UBERON:0001988,Diarrhea,HP:0002014,1000 mg/day MMF Dosage No Diarrhea Group,2000 mg/day MMF Dosage No Diarrhea Group,2000 mg/day MMF Dosage administered to the No Diarrhea Group,21,25,NA,16S,45,Illumina,Mann-Whitney (Wilcoxon),0.15,TRUE,NA,intake of diabetes medication,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:728/4/NA,Study 728,prospective cohort,29920927,10.1111/ajt.14974,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6301138/,"Lee JR, Magruder M, Zhang L, Westblade LF, Satlin MJ, Robertson A, Edusei E, Crawford C, Ling L, Taur Y, Schluter J, Lubetzky M, Dadhania D, Pamer E , Suthanthiran M",Gut microbiota dysbiosis and diarrhea in kidney transplant recipients,American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,2019,"complication: medical/metabolic, diarrhea, gut microbiota, kidney disease, kidney transplantation/nephrology, microbiomics, translational research/science",Experiment 4,United States of America,Homo sapiens,Feces,UBERON:0001988,Diarrhea,HP:0002014,1000 mg/day MMF Dosage No Diarrhea Group,1000 mg/day MMF Dosage Diarrhea Group,1000 mg/day MMF Dosage administered to the Diarrhea Group,21,4,NA,16S,45,Illumina,Mann-Whitney (Wilcoxon),0.15,TRUE,NA,intake of diabetes medication,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:728/5/NA,Study 728,prospective cohort,29920927,10.1111/ajt.14974,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6301138/,"Lee JR, Magruder M, Zhang L, Westblade LF, Satlin MJ, Robertson A, Edusei E, Crawford C, Ling L, Taur Y, Schluter J, Lubetzky M, Dadhania D, Pamer E , Suthanthiran M",Gut microbiota dysbiosis and diarrhea in kidney transplant recipients,American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,2019,"complication: medical/metabolic, diarrhea, gut microbiota, kidney disease, kidney transplantation/nephrology, microbiomics, translational research/science",Experiment 5,United States of America,Homo sapiens,Feces,UBERON:0001988,Diarrhea,HP:0002014,2000 mg/day MMF Dosage No Diarrhea Group,2000 mg/day MMF Dosage Diarrhea Group,2000 mg/day MMF Dosage administered to the Diarrhea Group,25,13,NA,16S,45,Illumina,Mann-Whitney (Wilcoxon),0.15,TRUE,NA,intake of diabetes medication,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:728/6/NA,Study 728,prospective cohort,29920927,10.1111/ajt.14974,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6301138/,"Lee JR, Magruder M, Zhang L, Westblade LF, Satlin MJ, Robertson A, Edusei E, Crawford C, Ling L, Taur Y, Schluter J, Lubetzky M, Dadhania D, Pamer E , Suthanthiran M",Gut microbiota dysbiosis and diarrhea in kidney transplant recipients,American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,2019,"complication: medical/metabolic, diarrhea, gut microbiota, kidney disease, kidney transplantation/nephrology, microbiomics, translational research/science",Experiment 6,United States of America,Homo sapiens,Feces,UBERON:0001988,Diarrhea,HP:0002014,Pre-Diarrheal specimens,Diarrheal specimens,Diarrheal specimens,14,14,NA,16S,45,Illumina,Mann-Whitney (Wilcoxon),0.15,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:728/7/NA,Study 728,prospective cohort,29920927,10.1111/ajt.14974,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6301138/,"Lee JR, Magruder M, Zhang L, Westblade LF, Satlin MJ, Robertson A, Edusei E, Crawford C, Ling L, Taur Y, Schluter J, Lubetzky M, Dadhania D, Pamer E , Suthanthiran M",Gut microbiota dysbiosis and diarrhea in kidney transplant recipients,American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,2019,"complication: medical/metabolic, diarrhea, gut microbiota, kidney disease, kidney transplantation/nephrology, microbiomics, translational research/science",Experiment 7,United States of America,Homo sapiens,Feces,UBERON:0001988,Diarrhea,HP:0002014,First Diarrheal Specimens Time-Matched Fecal Specimens from the No Diarrhea Group,First Diarrheal Specimens in the Diarrhea group,First Diarrheal Specimens in the Diarrhea group,46,18,NA,16S,45,Illumina,Mann-Whitney (Wilcoxon),0.15,NA,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:729/1/NA,Study 729,case-control,35719348,https://doi.org/10.3389/fcimb.2022.886872,https://www.frontiersin.org/articles/10.3389/fcimb.2022.886872/full,"Ling Z, Jin G, Yan X, Cheng Y, Shao L, Song Q, Liu X , Zhao L",Fecal Dysbiosis and Immune Dysfunction in Chinese Elderly Patients With Schizophrenia: An Observational Study,Frontiers in cellular and infection microbiology,2022,"Faecalibacterium, LEfSe, Schizophrenia, dysbiosis, non-invasive diagnosis",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Schizophrenia,MONDO:0005090,healthy control,Elderly Schizophrenia Patients,Elderly Schizophrenia Patients,71,90,1 month,16S,34,Illumina,LEfSe,0.05,TRUE,3,"age,sex",NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:729/2/NA,Study 729,case-control,35719348,https://doi.org/10.3389/fcimb.2022.886872,https://www.frontiersin.org/articles/10.3389/fcimb.2022.886872/full,"Ling Z, Jin G, Yan X, Cheng Y, Shao L, Song Q, Liu X , Zhao L",Fecal Dysbiosis and Immune Dysfunction in Chinese Elderly Patients With Schizophrenia: An Observational Study,Frontiers in cellular and infection microbiology,2022,"Faecalibacterium, LEfSe, Schizophrenia, dysbiosis, non-invasive diagnosis",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Schizophrenia,MONDO:0005090,healthy control,Schizophrenia,Elderly Schizophrenia Patients,71,90,1 month,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,3,"age,sex",NA,NA,decreased,increased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:730/1/NA,Study 730,case-control,36803646,10.1186/s13041-023-01014-0,https://pubmed.ncbi.nlm.nih.gov/36803646/,"Kong G, Zhang W, Zhang S, Chen J, He K, Zhang C, Yuan X , Xie B",The gut microbiota and metabolite profiles are altered in patients with spinal cord injury,Molecular brain,2023,"16S rRNA gene sequencing, Gut microbiota, Spinal cord injury, Untargeted metabolomics",Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Spinal cord injury,EFO:1001919,healthy control (without SCI),SCI (spinal cord injury),"Spinal cord injury (SCI), which is typically caused by severe trauma such as falls and traffic accidents, is one of the most severe forms of central nervous system injury (CNS).",10,11,Patients taking antibiotics or probiotics one month prior to the study were excluded from the SCI group for this experiment.,16S,34,Illumina,LEfSe,0.05,TRUE,3,"age,geographic area,sex",NA,NA,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:730/2/NA,Study 730,case-control,36803646,10.1186/s13041-023-01014-0,https://pubmed.ncbi.nlm.nih.gov/36803646/,"Kong G, Zhang W, Zhang S, Chen J, He K, Zhang C, Yuan X , Xie B",The gut microbiota and metabolite profiles are altered in patients with spinal cord injury,Molecular brain,2023,"16S rRNA gene sequencing, Gut microbiota, Spinal cord injury, Untargeted metabolomics",Experiment 2,United States of America,Homo sapiens,Venous blood,UBERON:0013756,Spinal cord injury,EFO:1001919,healthy control (without SCI),SCI (spinal cord injury),"Spinal cord injury (SCI), which is typically caused by severe trauma such as falls and traffic accidents, is one of the most severe forms of central nervous system injury (CNS).",10,10,Patients taking antibiotics or probiotics one month prior to the study were excluded from the SCI group for this experiment.,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,"age,geographic area,sex",NA,NA,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:731/1/NA,Study 731,case-control,36216843,10.1038/s41531-022-00395-8,NA,"Boertien JM, Murtomäki K, Pereira PAB, van der Zee S, Mertsalmi TH, Levo R, Nojonen T, Mäkinen E, Jaakkola E, Laine P, Paulin L, Pekkonen E, Kaasinen V, Auvinen P, Scheperjans F , van Laar T",Fecal microbiome alterations in treatment-naive de novo Parkinson's disease,NPJ Parkinson's disease,2022,NA,Experiment 1,Netherlands,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Healthy controls,Parkinson's Disease subjects,"Dutch(NL) Cohort: Parkinson's disease diagnosis by a movement disorder specialist according to the Movement Disorders Society (MDS) clinical diagnostic criteria1, confirmed by a dopaminergic deficit quantified by FDOPA-PET or one-year follow-up if no FDOPA-PET was performed.",85,136,1 month,16S,4,Illumina,ANCOM,0.1,NA,NA,NA,"age,body mass index",NA,NA,increased,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:731/2/NA,Study 731,case-control,36216843,10.1038/s41531-022-00395-8,NA,"Boertien JM, Murtomäki K, Pereira PAB, van der Zee S, Mertsalmi TH, Levo R, Nojonen T, Mäkinen E, Jaakkola E, Laine P, Paulin L, Pekkonen E, Kaasinen V, Auvinen P, Scheperjans F , van Laar T",Fecal microbiome alterations in treatment-naive de novo Parkinson's disease,NPJ Parkinson's disease,2022,NA,Experiment 2,Finland,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Healthy controls,Parkinson's Disease subjects,"Finnish(FIN) Cohort: Parkinson's disease diagnosis by a movement disorder specialist according to the MDS clinical diagnostic criteria1, confirmed by a dopaminergic deficit quantified by [I-123]FP-CIT SPECT. [I-123]FP-CIT SPECT were analyzed with BRASS software (Hermes Medical Solutions AB, Stockholm, Sweden), in which a dopaminergic deficit was defined as more than two standard deviations below the reference mean in any of the six analyzed regions.",87,56,Recent antibiotics usage in the previous month.,16S,4,Illumina,ANCOM,0.1,NA,NA,NA,NA,NA,decreased,decreased,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:731/3/NA,Study 731,case-control,36216843,10.1038/s41531-022-00395-8,NA,"Boertien JM, Murtomäki K, Pereira PAB, van der Zee S, Mertsalmi TH, Levo R, Nojonen T, Mäkinen E, Jaakkola E, Laine P, Paulin L, Pekkonen E, Kaasinen V, Auvinen P, Scheperjans F , van Laar T",Fecal microbiome alterations in treatment-naive de novo Parkinson's disease,NPJ Parkinson's disease,2022,NA,Experiment 3,Netherlands,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Healthy controls,Parkinson's Disease subjects,"Dutch(NL) Cohort: Parkinson's disease diagnosis by a movement disorder specialist according to the Movement Disorders Society (MDS) clinical diagnostic criteria1, confirmed by a dopaminergic deficit quantified by FDOPA-PET or one-year follow-up if no FDOPA-PET was performed.",85,136,Recent antibiotics usage in the previous month.,16S,4,Illumina,DESeq2,0.1,NA,NA,NA,"age,body mass index",NA,NA,increased,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:731/4/NA,Study 731,case-control,36216843,10.1038/s41531-022-00395-8,NA,"Boertien JM, Murtomäki K, Pereira PAB, van der Zee S, Mertsalmi TH, Levo R, Nojonen T, Mäkinen E, Jaakkola E, Laine P, Paulin L, Pekkonen E, Kaasinen V, Auvinen P, Scheperjans F , van Laar T",Fecal microbiome alterations in treatment-naive de novo Parkinson's disease,NPJ Parkinson's disease,2022,NA,Experiment 4,Finland,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Healthy controls,Parkinson's Disease subjects,"Finnish(FIN) Cohort: Parkinson's disease diagnosis by a movement disorder specialist according to the MDS clinical diagnostic criteria1, confirmed by a dopaminergic deficit quantified by [I-123]FP-CIT SPECT. [I-123]FP-CIT SPECT were analyzed with BRASS software (Hermes Medical Solutions AB, Stockholm, Sweden), in which a dopaminergic deficit was defined as more than two standard deviations below the reference mean in any of the six analyzed regions.",87,56,Recent antibiotics usage in the previous month.,16S,4,Illumina,DESeq2,0.1,NA,NA,NA,NA,NA,decreased,decreased,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:732/1/NA,Study 732,"cross-sectional observational, not case-control",31672155,10.1186/s13059-019-1831-z,https://pubmed.ncbi.nlm.nih.gov/31672155/,"Kaplan RC, Wang Z, Usyk M, Sotres-Alvarez D, Daviglus ML, Schneiderman N, Talavera GA, Gellman MD, Thyagarajan B, Moon JY, Vázquez-Baeza Y, McDonald D, Williams-Nguyen JS, Wu MC, North KE, Shaffer J, Sollecito CC, Qi Q, Isasi CR, Wang T, Knight R , Burk RD","Gut microbiome composition in the Hispanic Community Health Study/Study of Latinos is shaped by geographic relocation, environmental factors, and obesity",Genome biology,2019,"Epidemiology, Hispanic population, Microbiome, Mycobiome, Obesity",Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,Individuals with a healthy body mass index,Obese individuals,Individuals who had a class II or class III obesity,293,294,6 months,16S,4,Illumina,Linear Regression,0.05,TRUE,NA,NA,"age,sex",NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:732/2/NA,Study 732,"cross-sectional observational, not case-control",31672155,10.1186/s13059-019-1831-z,https://pubmed.ncbi.nlm.nih.gov/31672155/,"Kaplan RC, Wang Z, Usyk M, Sotres-Alvarez D, Daviglus ML, Schneiderman N, Talavera GA, Gellman MD, Thyagarajan B, Moon JY, Vázquez-Baeza Y, McDonald D, Williams-Nguyen JS, Wu MC, North KE, Shaffer J, Sollecito CC, Qi Q, Isasi CR, Wang T, Knight R , Burk RD","Gut microbiome composition in the Hispanic Community Health Study/Study of Latinos is shaped by geographic relocation, environmental factors, and obesity",Genome biology,2019,"Epidemiology, Hispanic population, Microbiome, Mycobiome, Obesity",Experiment 2,United States of America,Homo sapiens,Feces,UBERON:0001988,Age,EFO:0000246,Early age,Later age,NA,1674,1674,6 months,16S,4,Illumina,Linear Regression,0.05,TRUE,NA,NA,"age,race,sex",NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:732/4/NA,Study 732,"cross-sectional observational, not case-control",31672155,10.1186/s13059-019-1831-z,https://pubmed.ncbi.nlm.nih.gov/31672155/,"Kaplan RC, Wang Z, Usyk M, Sotres-Alvarez D, Daviglus ML, Schneiderman N, Talavera GA, Gellman MD, Thyagarajan B, Moon JY, Vázquez-Baeza Y, McDonald D, Williams-Nguyen JS, Wu MC, North KE, Shaffer J, Sollecito CC, Qi Q, Isasi CR, Wang T, Knight R , Burk RD","Gut microbiome composition in the Hispanic Community Health Study/Study of Latinos is shaped by geographic relocation, environmental factors, and obesity",Genome biology,2019,"Epidemiology, Hispanic population, Microbiome, Mycobiome, Obesity",Experiment 4,United States of America,Homo sapiens,Feces,UBERON:0001988,Ethnic group,EFO:0001799,USB (US born),LAB,Latin American Born,225,1532,6 months,16S,4,Illumina,Linear Regression,0.05,NA,NA,NA,age,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:732/5/NA,Study 732,"cross-sectional observational, not case-control",31672155,10.1186/s13059-019-1831-z,https://pubmed.ncbi.nlm.nih.gov/31672155/,"Kaplan RC, Wang Z, Usyk M, Sotres-Alvarez D, Daviglus ML, Schneiderman N, Talavera GA, Gellman MD, Thyagarajan B, Moon JY, Vázquez-Baeza Y, McDonald D, Williams-Nguyen JS, Wu MC, North KE, Shaffer J, Sollecito CC, Qi Q, Isasi CR, Wang T, Knight R , Burk RD","Gut microbiome composition in the Hispanic Community Health Study/Study of Latinos is shaped by geographic relocation, environmental factors, and obesity",Genome biology,2019,"Epidemiology, Hispanic population, Microbiome, Mycobiome, Obesity",Experiment 5,United States of America,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,Individuals with a healthy body mass index,Individuals who were obese,Individuals with class II or class III obesity,293,294,6 months,16S,4,Illumina,Linear Regression,NA,TRUE,NA,NA,"age,sex",NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:732/6/NA,Study 732,"cross-sectional observational, not case-control",31672155,10.1186/s13059-019-1831-z,https://pubmed.ncbi.nlm.nih.gov/31672155/,"Kaplan RC, Wang Z, Usyk M, Sotres-Alvarez D, Daviglus ML, Schneiderman N, Talavera GA, Gellman MD, Thyagarajan B, Moon JY, Vázquez-Baeza Y, McDonald D, Williams-Nguyen JS, Wu MC, North KE, Shaffer J, Sollecito CC, Qi Q, Isasi CR, Wang T, Knight R , Burk RD","Gut microbiome composition in the Hispanic Community Health Study/Study of Latinos is shaped by geographic relocation, environmental factors, and obesity",Genome biology,2019,"Epidemiology, Hispanic population, Microbiome, Mycobiome, Obesity",Experiment 6,United States of America,Homo sapiens,Feces,UBERON:0001988,Age,EFO:0000246,Early age,Later age,Individuals who had relocated to the USA at a younger age( 18 and below),1674,1674,6 months,16S,4,Illumina,Linear Regression,NA,TRUE,NA,NA,"age,sex",NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:733/1/NA,Study 733,"cross-sectional observational, not case-control",33996618,https://doi.org/10.3389/fcimb.2021.625589,NA,"Han J, Wu S, Fan Y, Tian Y , Kong J",Biliary Microbiota in Choledocholithiasis and Correlation With Duodenal Microbiota,Frontiers in cellular and infection microbiology,2021,"antimicrobial resistance, biliary microbiota, choledocholithiasis, duodenal microbiota, duodenal–biliary reflux",Experiment 1,China,Homo sapiens,"Duodenum,Bile duct","UBERON:0002114,UBERON:0002394",Sampling site,EFO:0000688,biliary microbiota,duodenal microbiota,duodenal juice samples from patients with choledocholithiasis,10,10,4 weeks,16S,34,Illumina,LEfSe,0.05,NA,4,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:734/1/NA,Study 734,case-control,36894986,https://doi.org/10.1186/s40168-023-01472-7,NA,"de Nies L, Galata V, Martin-Gallausiaux C, Despotovic M, Busi SB, Snoeck CJ, Delacour L, Budagavi DP, Laczny CC, Habier J, Lupu PC, Halder R, Fritz JV, Marques T, Sandt E, O'Sullivan MP, Ghosh S, Satagopam V, Krüger R, Fagherazzi G, Ollert M, Hefeng FQ, May P , Wilmes P",Altered infective competence of the human gut microbiome in COVID-19,Microbiome,2023,"COVID-19, Gut microbiome, Metagenomics, Metatranscriptomics, SARS-CoV-2",Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,COVID-19,MONDO:0100096,Control group,COVID-19 infection cases.,"These individuals had confirmed SARS-CoV-2 infection by a positive RT-PCR test result and presented with COVID-19 symptoms such as fever, cough, and difficulty breathing.",57,61,3 months,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),NA,TRUE,2,age,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:735/1/NA,Study 735,case-control,24629344,https:/doi.org/10.1016/j.chom.2014.02.005,https://pubmed.ncbi.nlm.nih.gov/24629344/,"Gevers D, Kugathasan S, Denson LA, Vázquez-Baeza Y, Van Treuren W, Ren B, Schwager E, Knights D, Song SJ, Yassour M, Morgan XC, Kostic AD, Luo C, González A, McDonald D, Haberman Y, Walters T, Baker S, Rosh J, Stephens M, Heyman M, Markowitz J, Baldassano R, Griffiths A, Sylvester F, Mack D, Kim S, Crandall W, Hyams J, Huttenhower C, Knight R , Xavier RJ",The treatment-naive microbiome in new-onset Crohn's disease,Cell host & microbe,2014,NA,Experiment 1,China,Homo sapiens,"Ileum,Rectum","UBERON:0002116,UBERON:0001052",Crohn's disease,EFO:0000384,Healthy control,Crohn's disease,Treatment-naive pediatric patients (ages 3-17) with new-onset Crohn's disease,221,447,NA,16S,4,Illumina,Linear Regression,NA,NA,NA,NA,"age,antibiotic exposure,race,sex",NA,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:735/2/NA,Study 735,case-control,24629344,https:/doi.org/10.1016/j.chom.2014.02.005,https://pubmed.ncbi.nlm.nih.gov/24629344/,"Gevers D, Kugathasan S, Denson LA, Vázquez-Baeza Y, Van Treuren W, Ren B, Schwager E, Knights D, Song SJ, Yassour M, Morgan XC, Kostic AD, Luo C, González A, McDonald D, Haberman Y, Walters T, Baker S, Rosh J, Stephens M, Heyman M, Markowitz J, Baldassano R, Griffiths A, Sylvester F, Mack D, Kim S, Crandall W, Hyams J, Huttenhower C, Knight R , Xavier RJ",The treatment-naive microbiome in new-onset Crohn's disease,Cell host & microbe,2014,NA,Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Crohn's disease,EFO:0000384,Healthy control,Crohn's disease,Treatment-naive pediatric patients (ages 3-17) with new-onset Crohn's disease,221,447,NA,16S,4,Illumina,Linear Regression,NA,NA,NA,NA,"age,antibiotic exposure,race,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:735/3/NA,Study 735,case-control,24629344,https:/doi.org/10.1016/j.chom.2014.02.005,https://pubmed.ncbi.nlm.nih.gov/24629344/,"Gevers D, Kugathasan S, Denson LA, Vázquez-Baeza Y, Van Treuren W, Ren B, Schwager E, Knights D, Song SJ, Yassour M, Morgan XC, Kostic AD, Luo C, González A, McDonald D, Haberman Y, Walters T, Baker S, Rosh J, Stephens M, Heyman M, Markowitz J, Baldassano R, Griffiths A, Sylvester F, Mack D, Kim S, Crandall W, Hyams J, Huttenhower C, Knight R , Xavier RJ",The treatment-naive microbiome in new-onset Crohn's disease,Cell host & microbe,2014,NA,Experiment 3,China,Homo sapiens,"Ileum,Rectum,Feces","UBERON:0002116,UBERON:0001052,UBERON:0001988",Crohn's disease,EFO:0000384,Healthy control,Crohn's disease,Treatment-naive pediatric patients (ages 3-17) with new-onset Crohn's disease,221,447,NA,16S,4,Illumina,Linear Regression,NA,NA,NA,NA,"age,antibiotic exposure,race,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:736/1/NA,Study 736,case-control,33614635,https://doi.org/10.3389/fcell.2020.634069,https://www.frontiersin.org/articles/10.3389/fcell.2020.634069,"Ling Z, Zhu M, Yan X, Cheng Y, Shao L, Liu X, Jiang R , Wu S",Structural and Functional Dysbiosis of Fecal Microbiota in Chinese Patients With Alzheimer's Disease,Frontiers in cell and developmental biology,2020,"Alzheimer's disease, Bifidobacterium, Faecalibacterium, gut-brain axis, sequencing",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Alzheimer's disease,MONDO:0004975,healthy controls,Alzheimer’s disease patients,patients with Alzheimer’s disease,71,100,"1 month including prebiotic, probiotic or synbiotic use.",16S,34,Illumina,LEfSe,0.05,FALSE,3,"age,sex",NA,NA,decreased,decreased,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:737/1/NA,Study 737,prospective cohort,23491408,https://doi.org/10.1164/rccm.201210-1913oc,https://pubmed.ncbi.nlm.nih.gov/23491408/,"Morris A, Beck JM, Schloss PD, Campbell TB, Crothers K, Curtis JL, Flores SC, Fontenot AP, Ghedin E, Huang L, Jablonski K, Kleerup E, Lynch SV, Sodergren E, Twigg H, Young VB, Bassis CM, Venkataraman A, Schmidt TM , Weinstock GM",Comparison of the respiratory microbiome in healthy nonsmokers and smokers,American journal of respiratory and critical care medicine,2013,NA,Experiment 1,United States of America,Homo sapiens,Mouth,UBERON:0000165,Smoking behavior,EFO:0004318,Healthy non-smokers,Healthy current smokers,Subjects who currently smoke.,45,19,No use of antibiotics in the past 3 months.,16S,123,Roche454,Mann-Whitney (Wilcoxon),NA,NA,NA,NA,"body mass index,sex,smoking status",NA,increased,NA,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:737/2/NA,Study 737,prospective cohort,23491408,https://doi.org/10.1164/rccm.201210-1913oc,https://pubmed.ncbi.nlm.nih.gov/23491408/,"Morris A, Beck JM, Schloss PD, Campbell TB, Crothers K, Curtis JL, Flores SC, Fontenot AP, Ghedin E, Huang L, Jablonski K, Kleerup E, Lynch SV, Sodergren E, Twigg H, Young VB, Bassis CM, Venkataraman A, Schmidt TM , Weinstock GM",Comparison of the respiratory microbiome in healthy nonsmokers and smokers,American journal of respiratory and critical care medicine,2013,NA,Experiment 2,United States of America,Homo sapiens,Middle lobe of lung,UBERON:0008955,Smoking behavior,EFO:0004318,Healthy non-smokers,Healthy current smokers,Subjects who currently smoke.,45,19,No use of antibiotics in the past 3 months.,16S,123,Roche454,Mann-Whitney (Wilcoxon),NA,NA,NA,NA,"body mass index,sex,smoking status",NA,decreased,NA,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:737/3/NA,Study 737,prospective cohort,23491408,https://doi.org/10.1164/rccm.201210-1913oc,https://pubmed.ncbi.nlm.nih.gov/23491408/,"Morris A, Beck JM, Schloss PD, Campbell TB, Crothers K, Curtis JL, Flores SC, Fontenot AP, Ghedin E, Huang L, Jablonski K, Kleerup E, Lynch SV, Sodergren E, Twigg H, Young VB, Bassis CM, Venkataraman A, Schmidt TM , Weinstock GM",Comparison of the respiratory microbiome in healthy nonsmokers and smokers,American journal of respiratory and critical care medicine,2013,NA,Experiment 3,United States of America,Homo sapiens,Saliva,UBERON:0001836,Smoking behavior,EFO:0004318,Healthy non-smokers,Healthy current smokers,Subjects who currently smoke.,45,19,No use of antibiotics in the past 3 months.,16S,345,Roche454,Mann-Whitney (Wilcoxon),NA,NA,NA,NA,"body mass index,sex,smoking status",NA,increased,NA,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:737/4/NA,Study 737,prospective cohort,23491408,https://doi.org/10.1164/rccm.201210-1913oc,https://pubmed.ncbi.nlm.nih.gov/23491408/,"Morris A, Beck JM, Schloss PD, Campbell TB, Crothers K, Curtis JL, Flores SC, Fontenot AP, Ghedin E, Huang L, Jablonski K, Kleerup E, Lynch SV, Sodergren E, Twigg H, Young VB, Bassis CM, Venkataraman A, Schmidt TM , Weinstock GM",Comparison of the respiratory microbiome in healthy nonsmokers and smokers,American journal of respiratory and critical care medicine,2013,NA,Experiment 4,United States of America,Homo sapiens,Middle lobe of lung,UBERON:0008955,Smoking behavior,EFO:0004318,Healthy non-smokers,Healthy current smokers,Subjects who currently smoke.,45,19,No use of antibiotics in the past 3 months.,16S,345,Roche454,Mann-Whitney (Wilcoxon),NA,NA,NA,NA,"body mass index,sex,smoking status",NA,decreased,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:738/1/NA,Study 738,case-control,32807798,https://doi.org/10.1038/s41467-020-17916-9,https://www.nature.com/articles/s41467-020-17916-9,"Zhang X, Ning Z, Mayne J, Yang Y, Deeke SA, Walker K, Farnsworth CL, Stokes MP, Couture JF, Mack D, Stintzi A , Figeys D",Widespread protein lysine acetylation in gut microbiome and its alterations in patients with Crohn's disease,Nature communications,2020,NA,Experiment 1,Canada,Homo sapiens,"Feces,Mucosa of descending colon","UBERON:0001988,UBERON:0004992",Crohn's disease,EFO:0000384,healthy adults,pediatric crohn's disease,"children (<18 years old) diagnosed with crohn’s disease. 
The exclusion criteria implemented to further refine the cohort in this study include: presence of diabetes mellitus, presence of infectious gastroenteritis within the past 2 months, and irritable bowel syndrome.",8,10,4 weeks including probiotics use,NA,NA,Mass spectrometry,LEfSe,0.05,NA,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:738/2/NA,Study 738,case-control,32807798,https://doi.org/10.1038/s41467-020-17916-9,https://www.nature.com/articles/s41467-020-17916-9,"Zhang X, Ning Z, Mayne J, Yang Y, Deeke SA, Walker K, Farnsworth CL, Stokes MP, Couture JF, Mack D, Stintzi A , Figeys D",Widespread protein lysine acetylation in gut microbiome and its alterations in patients with Crohn's disease,Nature communications,2020,NA,Experiment 2,Canada,Homo sapiens,"Feces,Mucosa of descending colon","UBERON:0001988,UBERON:0004992",Crohn's disease,EFO:0000384,healthy adults,pediatric crohn's disease,"children (<18 years old) diagnosed with crohn’s disease. 
The exclusion criteria implemented to further refine the cohort in this study include: presence of diabetes mellitus, presence of infectious gastroenteritis within the past 2 months, and irritable bowel syndrome.",8,10,4 weeks including probiotics use,NA,NA,Mass spectrometry,LEfSe,0.05,NA,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:738/3/NA,Study 738,case-control,32807798,https://doi.org/10.1038/s41467-020-17916-9,https://www.nature.com/articles/s41467-020-17916-9,"Zhang X, Ning Z, Mayne J, Yang Y, Deeke SA, Walker K, Farnsworth CL, Stokes MP, Couture JF, Mack D, Stintzi A , Figeys D",Widespread protein lysine acetylation in gut microbiome and its alterations in patients with Crohn's disease,Nature communications,2020,NA,Experiment 3,Canada,Homo sapiens,"Feces,Mucosa of descending colon","UBERON:0001988,UBERON:0004992",Crohn's disease,EFO:0000384,healthy adults,pediatric crohn's disease,"children (<18 years old) diagnosed with crohn’s disease. 
The exclusion criteria implemented to further refine the cohort in this study include: presence of diabetes mellitus, presence of infectious gastroenteritis within the past 2 months, and irritable bowel syndrome.",8,10,4 weeks including probiotics use,NA,NA,Mass spectrometry,LEfSe,0.05,NA,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:738/4/NA,Study 738,case-control,32807798,https://doi.org/10.1038/s41467-020-17916-9,https://www.nature.com/articles/s41467-020-17916-9,"Zhang X, Ning Z, Mayne J, Yang Y, Deeke SA, Walker K, Farnsworth CL, Stokes MP, Couture JF, Mack D, Stintzi A , Figeys D",Widespread protein lysine acetylation in gut microbiome and its alterations in patients with Crohn's disease,Nature communications,2020,NA,Experiment 4,Canada,Homo sapiens,Feces,UBERON:0001988,Gut microbiome measurement,EFO:0007874,Metaproteome aliquot of human gut,Lysine acetylome aliquot of human gut,relative abundance of kac levels (for each taxon listed in supplementary data 3) in human fecal microbiome samples lysine acetylome aliquot,209,209,4 weeks including probiotics use,NA,NA,Mass spectrometry,Mann-Whitney (Wilcoxon),0.05,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:739/1/NA,Study 739,randomized controlled trial,36198385,10.1016/j.anaerobe.2022.102652,NA,"Bamola VD, Dubey D, Samanta P, Kedia S, Ahuja V, Madempudi RS, Neelamraju J , Chaudhry R",Role of a probiotic strain in the modulation of gut microbiota and cytokines in inflammatory bowel disease,Anaerobe,2022,"Bacillus clausii UBBC-07, Cytokines, Gut microbiome, IBD, Probiotic",Experiment 1,India,Homo sapiens,Feces,UBERON:0001988,Treatment,EFO:0000727,Placebo group before intervention/treatment,Bacillus clausii UBBC-07 group after intervention/treatment,"Patients who were treated with Bacillus clausii UBBC-07 and evaluated after treatment/intervention for the effect of the probiotic on gut microbiota. Patients were of either sex, clinically diagnosed with Ulcerative Colitis or Crohn's Disease, and between 18 and 60 years.",54,54,NA,16S,34,Illumina,Kruskall-Wallis,0.01,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:740/1/NA,Study 740,"cross-sectional observational, not case-control",31063846,https://doi.org/10.1016/j.bbi.2019.05.008,https://www.sciencedirect.com/science/article/pii/S0889159118307190,"Liu P, Wu L, Peng G, Han Y, Tang R, Ge J, Zhang L, Jia L, Yue S, Zhou K, Li L, Luo B , Wang B",Altered microbiomes distinguish Alzheimer's disease from amnestic mild cognitive impairment and health in a Chinese cohort,"Brain, behavior, and immunity",2019,"Alzheimer’s disease, Amnestic mild cognitive impairment, Microbiome marker",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Alzheimer's disease,MONDO:0004975,healthy controls,Alzheimer’s disease,Patients with dementia stage of alzheimer's disease.,32,33,Two months,16S,34,Illumina,LEfSe,0.05,FALSE,2,"age,sex",NA,NA,decreased,unchanged,decreased,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:740/2/NA,Study 740,"cross-sectional observational, not case-control",31063846,https://doi.org/10.1016/j.bbi.2019.05.008,https://www.sciencedirect.com/science/article/pii/S0889159118307190,"Liu P, Wu L, Peng G, Han Y, Tang R, Ge J, Zhang L, Jia L, Yue S, Zhou K, Li L, Luo B , Wang B",Altered microbiomes distinguish Alzheimer's disease from amnestic mild cognitive impairment and health in a Chinese cohort,"Brain, behavior, and immunity",2019,"Alzheimer’s disease, Amnestic mild cognitive impairment, Microbiome marker",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Alzheimer's disease,MONDO:0004975,healthy controls,aMCI patients,Patients with amnestic mild cognitive impairment of alzheimer's disease.,32,32,Two months,16S,34,Illumina,LEfSe,0.05,FALSE,2,"age,sex",NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:740/3/NA,Study 740,"cross-sectional observational, not case-control",31063846,https://doi.org/10.1016/j.bbi.2019.05.008,https://www.sciencedirect.com/science/article/pii/S0889159118307190,"Liu P, Wu L, Peng G, Han Y, Tang R, Ge J, Zhang L, Jia L, Yue S, Zhou K, Li L, Luo B , Wang B",Altered microbiomes distinguish Alzheimer's disease from amnestic mild cognitive impairment and health in a Chinese cohort,"Brain, behavior, and immunity",2019,"Alzheimer’s disease, Amnestic mild cognitive impairment, Microbiome marker",Experiment 3,China,Homo sapiens,Feces,UBERON:0001988,Alzheimer's disease,MONDO:0004975,Alzheimers patients in dementia stage,aMCI patients,Patients with amnestic mild cognitive impairment of alzheimer's disease.,33,32,Two months,16S,34,Illumina,LEfSe,0.05,FALSE,2,"age,sex",NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:741/1/NA,Study 741,case-control,35035709,NA,https://pubmed.ncbi.nlm.nih.gov/35035709/,"Chen W, Bi Z, Zhu Q, Gao H, Fan Y, Zhang C, Liu X , Ye M",An analysis of the characteristics of the intestinal flora in patients with Parkinson's disease complicated with constipation,American journal of translational research,2021,"16S rRNA sequencing, Parkinson’s disease (PD), constipation, gut microbiota",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Healthy Controls and Parkinson's Disease patients with constipation,Parkinson's Disease patients without constipation,The PD patients were all screened from the outpatients and inpatients in the Department of Neurology and their Wexner scores (evaluation of constipation severity) were collected. Patients diagnosed with idiopathic PD by a neurologist according to the revised PD diagnostic criteria published by the International Movement Disorders Association in 2015.,30,14,3 months.,16S,45,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:741/2/NA,Study 741,case-control,35035709,NA,https://pubmed.ncbi.nlm.nih.gov/35035709/,"Chen W, Bi Z, Zhu Q, Gao H, Fan Y, Zhang C, Liu X , Ye M",An analysis of the characteristics of the intestinal flora in patients with Parkinson's disease complicated with constipation,American journal of translational research,2021,"16S rRNA sequencing, Parkinson’s disease (PD), constipation, gut microbiota",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Healthy Controls,Parkinson's Disease patients without constipation and Parkinson's Disease patients with constipation,The PD patients were all screened from the outpatients and inpatients in the Department of Neurology and their Wexner scores (evaluation of constipation severity) were collected. Patients diagnosed with idiopathic PD by a neurologist according to the revised PD diagnostic criteria published by the International Movement Disorders Association in 2015.,15,29,3 months.,16S,45,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:741/3/NA,Study 741,case-control,35035709,NA,https://pubmed.ncbi.nlm.nih.gov/35035709/,"Chen W, Bi Z, Zhu Q, Gao H, Fan Y, Zhang C, Liu X , Ye M",An analysis of the characteristics of the intestinal flora in patients with Parkinson's disease complicated with constipation,American journal of translational research,2021,"16S rRNA sequencing, Parkinson’s disease (PD), constipation, gut microbiota",Experiment 3,China,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Healthy Controls and Parkinson's Disease patients without constipation,Parkinson's Disease patients with constipation,The PD patients were all screened from the outpatients and inpatients in the Department of Neurology and their Wexner scores (evaluation of constipation severity) were collected. Patients diagnosed with idiopathic PD by a neurologist according to the revised PD diagnostic criteria published by the International Movement Disorders Association in 2015.,29,15,3 months.,16S,45,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:741/4/NA,Study 741,case-control,35035709,NA,https://pubmed.ncbi.nlm.nih.gov/35035709/,"Chen W, Bi Z, Zhu Q, Gao H, Fan Y, Zhang C, Liu X , Ye M",An analysis of the characteristics of the intestinal flora in patients with Parkinson's disease complicated with constipation,American journal of translational research,2021,"16S rRNA sequencing, Parkinson’s disease (PD), constipation, gut microbiota",Experiment 4,China,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Parkinson's Disease patients without constipation,Parkinson's Disease patients with constipation,The PD patients were all screened from the outpatients and inpatients in the Department of Neurology and their Wexner scores (evaluation of constipation severity) were collected. Patients diagnosed with idiopathic PD by a neurologist according to the revised PD diagnostic criteria published by the International Movement Disorders Association in 2015.,14,15,3 months.,16S,45,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:742/1/NA,Study 742,"cross-sectional observational, not case-control",34650532,10.3389/fmicb.2021.728479,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506127/,"Mao L, Zhang Y, Tian J, Sang M, Zhang G, Zhou Y , Wang P",Cross-Sectional Study on the Gut Microbiome of Parkinson's Disease Patients in Central China,Frontiers in microbiology,2021,"Parkinson’s disease, gastrointestinal dysbiosis, gut-brain-axis, short-chain fatty acids, shotgun metagenomic sequencing",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Healthy spouses,Parkinson's Disease Patients,Partcipants with Parkinson's Disease,39,39,3 months.,WMS,NA,BGISEQ-500 Sequencing,LEfSe,0.05,FALSE,2,NA,NA,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:743/1/NA,Study 743,case-control,26179554,10.1002/mds.26307,NA,"Keshavarzian A, Green SJ, Engen PA, Voigt RM, Naqib A, Forsyth CB, Mutlu E , Shannon KM",Colonic bacterial composition in Parkinson's disease,Movement disorders : official journal of the Movement Disorder Society,2015,"a-synuclein, colonic mucosa and feces, dysbiosis, microbiota, putative butyrate producing short-chain fatty acids",Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Healthy control volunteers,Parkinson's Disease subjects,Parkinson's disease was diagnosed according to the UK Brain Bank Criteria.,34,38,The use of probiotics or antibiotics within three months prior to sample collection.,16S,4,NA,Kruskall-Wallis,0.05,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:743/2/NA,Study 743,case-control,26179554,10.1002/mds.26307,NA,"Keshavarzian A, Green SJ, Engen PA, Voigt RM, Naqib A, Forsyth CB, Mutlu E , Shannon KM",Colonic bacterial composition in Parkinson's disease,Movement disorders : official journal of the Movement Disorder Society,2015,"a-synuclein, colonic mucosa and feces, dysbiosis, microbiota, putative butyrate producing short-chain fatty acids",Experiment 2,United States of America,Homo sapiens,Colonic mucosa,UBERON:0000317,Parkinson's disease,MONDO:0005180,Healthy control volunteers,Parkinson's Disease subjects,Parkinson's disease was diagnosed according to the UK Brain Bank Criteria.,34,38,The use of probiotics or antibiotics within three months prior to sample collection.,16S,4,NA,Kruskall-Wallis,0.05,NA,NA,NA,NA,NA,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:744/1/NA,Study 744,case-control,36442206,10.3233/JPD-223500,NA,"Zhang K, Paul KC, Jacobs JP, Chou HL, Duarte Folle A, Del Rosario I, Yu Y, Bronstein JM, Keener AM , Ritz B",Parkinson's Disease and the Gut Microbiome in Rural California,Journal of Parkinson's disease,2022,"Parkinson’s disease, Unified Parkinson’s Disease Rating Scale, brain-gut axis, gut microbiome",Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Healthy controls.,Parkinson's Disease Patients,Participants newly diagnosed with Parkinson's Disease (within 3–5 years).,74,96,Participants were required to not have taken antibiotics within the past 3 months.,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,"age,race,sex",NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:745/1/NA,Study 745,time series / longitudinal observational,32073296,https://doi.org/10.3920/BM2019.0039,NA,"Ozkul C, Yalinay M , Karakan T",Structural changes in gut microbiome after Ramadan fasting: a pilot study,Beneficial microbes,2020,"Ramadan fasting, gut microbiota, intermittent fasting, microbiome",Experiment 1,Turkey,Homo sapiens,Feces,UBERON:0001988,Fasting,EFO:0002756,Adults before fasting,Adults after fasting,healthy adults who were on Ramadan fast with a fasting period of approximately 17H per day for 29 days.,9,9,8 weeks,16S,4,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:746/1/NA,Study 746,case-control,36376318,10.1038/s41467-022-34667-x,NA,"Wallen ZD, Demirkan A, Twa G, Cohen G, Dean MN, Standaert DG, Sampson TR , Payami H",Metagenomics of Parkinson's disease implicates the gut microbiome in multiple disease mechanisms,Nature communications,2022,NA,Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Healthy controls.,Parkinson's Disease subjects.,Potential PD cases for enrollment were identified via systematic pre-screening of electronic medical records (EMR) of patients with an upcoming appointment in the Movement Disorder Clinic at UAB. Subjects were invited to enroll in the study after their clinic visit if the attending specialist confirmed PD diagnosis and the patient was willing to hear about the study.,234,490,3 Months,WMS,NA,Illumina,"ANCOM,MaAsLin2",0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:747/1/NA,Study 747,"cross-sectional observational, not case-control",35615912,10.1002/acr2.11436,https://onlinelibrary.wiley.com/doi/pdf/10.1002/acr2.11436,"Bae SS, Dong TS, Wang J, Lagishetty V, Katzka W, Jacobs JP , Charles-Schoeman C",Altered Gut Microbiome in Patients With Dermatomyositis,ACR open rheumatology,2022,NA,Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Dermatomyositis,EFO:0000398,healthy controls,dermatomyositis - ILD-MSA,Patients with dermatomyositis - ILD-associated myositis antibodies subgroup,26,12,3 months,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:747/2/NA,Study 747,"cross-sectional observational, not case-control",35615912,10.1002/acr2.11436,https://onlinelibrary.wiley.com/doi/pdf/10.1002/acr2.11436,"Bae SS, Dong TS, Wang J, Lagishetty V, Katzka W, Jacobs JP , Charles-Schoeman C",Altered Gut Microbiome in Patients With Dermatomyositis,ACR open rheumatology,2022,NA,Experiment 2,United States of America,Homo sapiens,Feces,UBERON:0001988,Dermatomyositis,EFO:0000398,healthy controls,dermatomyositis - Cancer-MSA,Patients with dermatomyositis - cancer-associated myositis antibodies subgroup,26,13,3 months,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:747/3/NA,Study 747,"cross-sectional observational, not case-control",35615912,10.1002/acr2.11436,https://onlinelibrary.wiley.com/doi/pdf/10.1002/acr2.11436,"Bae SS, Dong TS, Wang J, Lagishetty V, Katzka W, Jacobs JP , Charles-Schoeman C",Altered Gut Microbiome in Patients With Dermatomyositis,ACR open rheumatology,2022,NA,Experiment 3,United States of America,Homo sapiens,Feces,UBERON:0001988,Dermatomyositis,EFO:0000398,dermatomyositis - Cancer-MSA,dermatomyositis - ILD-MSA,Patients with dermatomyositis - ILD associated myositis antibodies,13,12,3 months,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:748/1/NA,Study 748,"cross-sectional observational, not case-control",26408641,https://doi.org/10.1136/gutjnl-2015-309800,https://gut.bmj.com/content/66/1/70,"Yu J, Feng Q, Wong SH, Zhang D, Liang QY, Qin Y, Tang L, Zhao H, Stenvang J, Li Y, Wang X, Xu X, Chen N, Wu WK, Al-Aama J, Nielsen HJ, Kiilerich P, Jensen BA, Yau TO, Lan Z, Jia H, Li J, Xiao L, Lam TY, Ng SC, Cheng AS, Wong VW, Chan FK, Xu X, Yang H, Madsen L, Datz C, Tilg H, Wang J, Brünner N, Kristiansen K, Arumugam M, Sung JJ , Wang J",Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer,Gut,2017,"BACTERIAL INTERACTIONS, COLONIC MICROFLORA, COLORECTAL CANCER",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,control,Colorectal cancer patients,Patients with colorectal cancer.,54,74,NA,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,decreased,NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:749/1/NA,Study 749,case-control,36203175,10.1186/s12903-022-02480-z,https://bmcoralhealth.biomedcentral.com/articles/10.1186/s12903-022-02480-z,"Morishima S, Takeda K, Greenan S , Maki Y",Salivary microbiome in children with Down syndrome: a case-control study,BMC oral health,2022,"Children, Down syndrome, Microbiota, Saliva",Experiment 1,Japan,Homo sapiens,Oral cavity,UBERON:0000167,Down syndrome,EFO:0001064,Controls children with primary dentition (PD),Down Syndrome children with primary dentition (PD),Children with Down Syndrome and in the primary dentition stage (from 0.5 years to around 6 years old),12,12,7 days,16S,12,Illumina,Mann-Whitney (Wilcoxon),0.05,NA,NA,age,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:749/2/NA,Study 749,case-control,36203175,10.1186/s12903-022-02480-z,https://bmcoralhealth.biomedcentral.com/articles/10.1186/s12903-022-02480-z,"Morishima S, Takeda K, Greenan S , Maki Y",Salivary microbiome in children with Down syndrome: a case-control study,BMC oral health,2022,"Children, Down syndrome, Microbiota, Saliva",Experiment 2,Japan,Homo sapiens,Oral cavity,UBERON:0000167,Down syndrome,EFO:0001064,Controls children with mixed dentition (PD),Down Syndrome children with mixed dentition (PD),Children with Down Syndrome and in the mixed dentition stage (from 6 years to around 12 years old),15,15,7 days,16S,12,Illumina,Mann-Whitney (Wilcoxon),0.05,NA,NA,age,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:750/1/NA,Study 750,"cross-sectional observational, not case-control",32169076,10.1186/s12967-020-02291-2,NA,"Murugesan S, Al Ahmad SF, Singh P, Saadaoui M, Kumar M , Al Khodor S",Profiling the Salivary microbiome of the Qatari population,Journal of translational medicine,2020,"16S rRNA gene sequencing, Dysbiosis, Oral health, Qatar Biobank, Qatari, Saliva",Experiment 1,Qatar,Homo sapiens,Saliva,UBERON:0001836,Sex design,EFO:0001752,Males,Females,NA,555,442,NA,16S,123,Illumina,LEfSe,2,NA,2,NA,"age,sex,smoking status",NA,unchanged,unchanged,unchanged,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:750/2/NA,Study 750,"cross-sectional observational, not case-control",32169076,10.1186/s12967-020-02291-2,NA,"Murugesan S, Al Ahmad SF, Singh P, Saadaoui M, Kumar M , Al Khodor S",Profiling the Salivary microbiome of the Qatari population,Journal of translational medicine,2020,"16S rRNA gene sequencing, Dysbiosis, Oral health, Qatar Biobank, Qatari, Saliva",Experiment 2,Qatar,Homo sapiens,Saliva,UBERON:0001836,Aging,GO:0007568,Adults,Elderly,People older than 65years of age,979,18,NA,16S,123,Illumina,LEfSe,0.007,NA,2,NA,"age,sex",NA,decreased,decreased,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:750/3/NA,Study 750,"cross-sectional observational, not case-control",32169076,10.1186/s12967-020-02291-2,NA,"Murugesan S, Al Ahmad SF, Singh P, Saadaoui M, Kumar M , Al Khodor S",Profiling the Salivary microbiome of the Qatari population,Journal of translational medicine,2020,"16S rRNA gene sequencing, Dysbiosis, Oral health, Qatar Biobank, Qatari, Saliva",Experiment 3,Qatar,Homo sapiens,Saliva,UBERON:0001836,Gingival bleeding,HP:0000225,Participants without gingivitis bleeding,Participants with gingival bleeding,Participants reported suffering from a bleeding gum,913,84,NA,16S,123,Illumina,LEfSe,2,NA,2,"age,sex",NA,NA,decreased,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:750/4/NA,Study 750,"cross-sectional observational, not case-control",32169076,10.1186/s12967-020-02291-2,NA,"Murugesan S, Al Ahmad SF, Singh P, Saadaoui M, Kumar M , Al Khodor S",Profiling the Salivary microbiome of the Qatari population,Journal of translational medicine,2020,"16S rRNA gene sequencing, Dysbiosis, Oral health, Qatar Biobank, Qatari, Saliva",Experiment 4,Qatar,Homo sapiens,Saliva,UBERON:0001836,Oral ulcer,HP:0000155,Participants without oral ulcers,Participants with oral ulcers,Participants who reported suffering from oral ulcers,960,37,NA,16S,123,Illumina,LEfSe,2,NA,2,"age,sex",NA,NA,decreased,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:750/5/NA,Study 750,"cross-sectional observational, not case-control",32169076,10.1186/s12967-020-02291-2,NA,"Murugesan S, Al Ahmad SF, Singh P, Saadaoui M, Kumar M , Al Khodor S",Profiling the Salivary microbiome of the Qatari population,Journal of translational medicine,2020,"16S rRNA gene sequencing, Dysbiosis, Oral health, Qatar Biobank, Qatari, Saliva",Experiment 5,Qatar,Homo sapiens,Saliva,UBERON:0001836,Dentures,EFO:0010078,Participants without dentures,Participants with dentures,Participants who reported using dentures,861,136,NA,16S,123,Illumina,LEfSe,2,NA,2,"age,sex",NA,NA,decreased,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:750/6/NA,Study 750,"cross-sectional observational, not case-control",32169076,10.1186/s12967-020-02291-2,NA,"Murugesan S, Al Ahmad SF, Singh P, Saadaoui M, Kumar M , Al Khodor S",Profiling the Salivary microbiome of the Qatari population,Journal of translational medicine,2020,"16S rRNA gene sequencing, Dysbiosis, Oral health, Qatar Biobank, Qatari, Saliva",Experiment 6,Qatar,Homo sapiens,Saliva,UBERON:0001836,Smoking behavior,EFO:0004318,Non-smokers,Smokers,Participants classified as smokers,733,264,NA,16S,123,Illumina,LEfSe,2,NA,2,NA,NA,NA,decreased,unchanged,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:750/7/NA,Study 750,"cross-sectional observational, not case-control",32169076,10.1186/s12967-020-02291-2,NA,"Murugesan S, Al Ahmad SF, Singh P, Saadaoui M, Kumar M , Al Khodor S",Profiling the Salivary microbiome of the Qatari population,Journal of translational medicine,2020,"16S rRNA gene sequencing, Dysbiosis, Oral health, Qatar Biobank, Qatari, Saliva",Experiment 7,Qatar,Homo sapiens,Saliva,UBERON:0001836,Coffee consumption,EFO:0004330,Non-coffee drinkers,Coffee drinkers,Participants considered coffee drinkers,887,110,NA,16S,123,Illumina,LEfSe,2,NA,2,NA,"age,sex",NA,increased,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:750/8/NA,Study 750,"cross-sectional observational, not case-control",32169076,10.1186/s12967-020-02291-2,NA,"Murugesan S, Al Ahmad SF, Singh P, Saadaoui M, Kumar M , Al Khodor S",Profiling the Salivary microbiome of the Qatari population,Journal of translational medicine,2020,"16S rRNA gene sequencing, Dysbiosis, Oral health, Qatar Biobank, Qatari, Saliva",Experiment 8,Qatar,Homo sapiens,Saliva,UBERON:0001836,Tea consumption measurement,EFO:0010091,Non tea drinkers,Tea drinkers,Participants considered tea drinkers,229,768,NA,16S,123,Illumina,LEfSe,2,NA,2,NA,NA,NA,increased,increased,increased,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:751/1/NA,Study 751,"cross-sectional observational, not case-control",29685174,10.1186/s40168-018-0448-x,NA,"Fan X, Peters BA, Jacobs EJ, Gapstur SM, Purdue MP, Freedman ND, Alekseyenko AV, Wu J, Yang L, Pei Z, Hayes RB , Ahn J",Drinking alcohol is associated with variation in the human oral microbiome in a large study of American adults,Microbiome,2018,"16s rRNA genes, Alcohol consumption, Large population-based study, Oral microbiome",Experiment 1,United States of America,Homo sapiens,Mouth,UBERON:0000165,Alcohol drinking,EFO:0004329,Non-drinkers,Moderate drinkers,"> 0 but ≤ 1 drinks per day, on average, for women, and > 0 but ≤ 2 drinks per day, on average, for men",270,614,NA,16S,34,Roche454,DESeq2,NA,TRUE,NA,NA,"age,body mass index,education level,race,sex,smoking status",NA,NA,NA,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:751/2/NA,Study 751,"cross-sectional observational, not case-control",29685174,10.1186/s40168-018-0448-x,NA,"Fan X, Peters BA, Jacobs EJ, Gapstur SM, Purdue MP, Freedman ND, Alekseyenko AV, Wu J, Yang L, Pei Z, Hayes RB , Ahn J",Drinking alcohol is associated with variation in the human oral microbiome in a large study of American adults,Microbiome,2018,"16s rRNA genes, Alcohol consumption, Large population-based study, Oral microbiome",Experiment 2,United States of America,Homo sapiens,Mouth,UBERON:0000165,Alcohol drinking,EFO:0004329,Non-drinkers,Heavy drinkers,Women and men who had greater than one or two drinks per day respectively,270,160,NA,16S,34,Roche454,DESeq2,0.05,TRUE,NA,NA,"age,body mass index,education level,race,sex,smoking status",NA,NA,NA,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:751/3/NA,Study 751,"cross-sectional observational, not case-control",29685174,10.1186/s40168-018-0448-x,NA,"Fan X, Peters BA, Jacobs EJ, Gapstur SM, Purdue MP, Freedman ND, Alekseyenko AV, Wu J, Yang L, Pei Z, Hayes RB , Ahn J",Drinking alcohol is associated with variation in the human oral microbiome in a large study of American adults,Microbiome,2018,"16s rRNA genes, Alcohol consumption, Large population-based study, Oral microbiome",Experiment 3,United States of America,Homo sapiens,Mouth,UBERON:0000165,Alcohol drinking,EFO:0004329,Non-drinkers,Wine drinkers,Alcohol drinkers who drank exclusively wine,270,101,NA,16S,34,Roche454,DESeq2,0.1,TRUE,NA,NA,"age,alcohol drinking,body mass index,education level,race,sex,smoking status",NA,increased,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:751/4/NA,Study 751,"cross-sectional observational, not case-control",29685174,10.1186/s40168-018-0448-x,NA,"Fan X, Peters BA, Jacobs EJ, Gapstur SM, Purdue MP, Freedman ND, Alekseyenko AV, Wu J, Yang L, Pei Z, Hayes RB , Ahn J",Drinking alcohol is associated with variation in the human oral microbiome in a large study of American adults,Microbiome,2018,"16s rRNA genes, Alcohol consumption, Large population-based study, Oral microbiome",Experiment 4,United States of America,Homo sapiens,Mouth,UBERON:0000165,Alcohol drinking,EFO:0004329,Non-drinkers,Beer drinkers,Alcohol drinkers who drink beer exclusively,270,39,NA,16S,34,Roche454,DESeq2,0.1,TRUE,NA,NA,"age,alcohol drinking,body mass index,education level,race,sex,smoking status",NA,increased,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:751/5/NA,Study 751,"cross-sectional observational, not case-control",29685174,10.1186/s40168-018-0448-x,NA,"Fan X, Peters BA, Jacobs EJ, Gapstur SM, Purdue MP, Freedman ND, Alekseyenko AV, Wu J, Yang L, Pei Z, Hayes RB , Ahn J",Drinking alcohol is associated with variation in the human oral microbiome in a large study of American adults,Microbiome,2018,"16s rRNA genes, Alcohol consumption, Large population-based study, Oral microbiome",Experiment 5,United States of America,Homo sapiens,Mouth,UBERON:0000165,Alcohol drinking,EFO:0004329,Non-drinkers,Liquor drinkers,Alcohol drinkers who exclusively drank liquor,270,26,NA,16S,34,Roche454,DESeq2,0.1,TRUE,NA,NA,"age,alcohol drinking,body mass index,education level,race,sex,smoking status",NA,increased,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:752/1/NA,Study 752,case-control,30405010,https://doi.org/10.3390/ijerph15112479,https://www.mdpi.com/1660-4601/15/11/2479,"Rodríguez-Rabassa M, López P, Rodríguez-Santiago RE, Cases A, Felici M, Sánchez R, Yamamura Y , Rivera-Amill V",Cigarette Smoking Modulation of Saliva Microbial Composition and Cytokine Levels,International journal of environmental research and public health,2018,"cytokines, microbiome, saliva, smoking, tobacco",Experiment 1,United States of America,Homo sapiens,Saliva,UBERON:0001836,Smoking behavior,EFO:0004318,Non-smokers,Smokers,Current smokers.,16,18,None of the participants were taking antibiotics.,16S,34,Illumina,LEfSe,0.05,FALSE,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:753/1/NA,Study 753,"cross-sectional observational, not case-control",34505401,https://doi.org/10.1002/cre2.489,https://pubmed.ncbi.nlm.nih.gov/34505401/,"Masahiro Yoneda, Nao Suzuki, Takao Hirofuji, Takashi Hanioka, Yoshio Nakano",The effects of cigarette smoking on the salivary and tongue microbiome,Clinical and experimental dental research,2022,"saliva, 16S rRNA gene sequencing, cigarette smoking, oral microbiome, tongue",Experiment 1,Japan,Homo sapiens,Saliva,UBERON:0001836,Smoking behavior,EFO:0004318,Nonsmokers,Smokers,Smokers who have smoked 100 or more cigarettes since they started smoking.,32,18,The both groups did not take any antibiotics 3 months prior to the study.,16S,34,Roche454,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:753/2/NA,Study 753,"cross-sectional observational, not case-control",34505401,https://doi.org/10.1002/cre2.489,https://pubmed.ncbi.nlm.nih.gov/34505401/,"Masahiro Yoneda, Nao Suzuki, Takao Hirofuji, Takashi Hanioka, Yoshio Nakano",The effects of cigarette smoking on the salivary and tongue microbiome,Clinical and experimental dental research,2022,"saliva, 16S rRNA gene sequencing, cigarette smoking, oral microbiome, tongue",Experiment 2,Japan,Homo sapiens,Tongue,UBERON:0001723,Smoking behavior,EFO:0004318,Nonsmokers,Smokers,Smokers who have smoked 100 or more cigarettes since they started smoking.,32,18,The both groups did not take any antibiotics 3 months prior to the study.,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:754/1/NA,Study 754,case-control,25283067,https://doi.org/10.1111/omi.12086,https://pubmed.ncbi.nlm.nih.gov/25283067/,"Moon JH, Lee JH , Lee JY",Subgingival microbiome in smokers and non-smokers in Korean chronic periodontitis patients,Molecular oral microbiology,2015,"Korean, periodontitis, pyrosequencing, smoking, subgingival microflora",Experiment 1,Republic of Korea,Homo sapiens,Subgingival dental plaque,UBERON:0016484,Smoking behavior,EFO:0004318,Non-smokers,Smokers,A patient was defined as a smoker if he was currently smoking and had been smoking five or more cigarettes a day for at least 10 years.,36,57,Patients were excluded if they had received antibiotic therapy within the past 3 months.,16S,123,Roche454,NA,NA,NA,NA,"age,sex",NA,NA,increased,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:755/1/NA,Study 755,case-control,33557896,https://doi.org/10.1186/s13024-021-00427-6,https://pubmed.ncbi.nlm.nih.gov/33557896/,"Aho VTE, Houser MC, Pereira PAB, Chang J, Rudi K, Paulin L, Hertzberg V, Auvinen P, Tansey MG , Scheperjans F","Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson's disease",Molecular neurodegeneration,2021,"Inflammation, Intestine, Microbiota, Parkinson’s disease, Short-chain fatty acids",Experiment 1,Norway,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Healthy control,Parkinson's disease patients,Patients who have Parkinson's disease,56,55,NA,16S,34,Illumina,DESeq2,NA,TRUE,NA,"age,body mass index,sex",sex,NA,decreased,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:756/1/NA,Study 756,case-control,25278091,https://doi.org/10.1186/s12866-014-0250-2,https://pubmed.ncbi.nlm.nih.gov/25278091/,"Thomas AM, Gleber-Netto FO, Fernandes GR, Amorim M, Barbosa LF, Francisco AL, de Andrade AG, Setubal JC, Kowalski LP, Nunes DN , Dias-Neto E",Alcohol and tobacco consumption affects bacterial richness in oral cavity mucosa biofilms,BMC microbiology,2014,NA,Experiment 1,Brazil,Homo sapiens,Mouth mucosa,UBERON:0003729,Smoking behavior,EFO:0004318,Controls (C),Smokers (S),All individuals in this group reported the use of at least 20 cigarettes/day with a regular smoking history of at least 10 years.,9,6,last 3 months,16S,1,Ion Torrent,Kruskall-Wallis,NA,TRUE,NA,NA,NA,NA,decreased,decreased,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:756/2/NA,Study 756,case-control,25278091,https://doi.org/10.1186/s12866-014-0250-2,https://pubmed.ncbi.nlm.nih.gov/25278091/,"Thomas AM, Gleber-Netto FO, Fernandes GR, Amorim M, Barbosa LF, Francisco AL, de Andrade AG, Setubal JC, Kowalski LP, Nunes DN , Dias-Neto E",Alcohol and tobacco consumption affects bacterial richness in oral cavity mucosa biofilms,BMC microbiology,2014,NA,Experiment 2,Brazil,Homo sapiens,Mouth mucosa,UBERON:0003729,"Smoking behavior,Alcohol drinking","EFO:0004329,EFO:0004318",Controls (C),Smokers/Drinkers (SD),"All individuals in this group reported the use of at least 20 cigarettes/day with a regular smoking history of at least 10 years. These individuals also reported daily drinking habits (>1×/day, >3 drinks/occasion) and a regular drinking history of at least 10 years.",9,7,last 3 months,16S,1,Ion Torrent,Kruskall-Wallis,0.05,TRUE,NA,NA,NA,NA,decreased,decreased,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:757/1/NA,Study 757,prospective cohort,37586456,10.1016/j.exer.2023.109615,NA,"Ozkan J, Majzoub ME, Coroneo M, Thomas T , Willcox M",Ocular microbiome changes in dry eye disease and meibomian gland dysfunction,Experimental eye research,2023,"16S rRNA gene sequencing, Dry eye disease, Meibomian gland dysfunction, Microbiome, Ocular microbiology",Experiment 1,Australia,Homo sapiens,Margin of eyelid,UBERON:0034772,Microbiome,EFO:0004982,Meibomian Gland Dysfunction,Meibomian Gland Dysfunction + Lacrimal Dysfunction,Participants with MGD + LD corresponding to both evaporative dry eye disease and aqueous deficient dry eye disease (severe DED).,15,17,No use of antibiotics in the prior 3 months.,16S,34,Illumina,Linear Regression,0.05,NA,NA,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:757/2/NA,Study 757,prospective cohort,37586456,10.1016/j.exer.2023.109615,NA,"Ozkan J, Majzoub ME, Coroneo M, Thomas T , Willcox M",Ocular microbiome changes in dry eye disease and meibomian gland dysfunction,Experimental eye research,2023,"16S rRNA gene sequencing, Dry eye disease, Meibomian gland dysfunction, Microbiome, Ocular microbiology",Experiment 2,Australia,Homo sapiens,Margin of eyelid,UBERON:0034772,Microbiome,EFO:0004982,Healthy Control,Meibomian Gland Dysfunction + Lacrimal Dysfunction,Participants with MGD + LD corresponding to both evaporative dry eye disease and aqueous deficient dry eye disease (severe DED).,15,17,No use of antibiotics in the prior 3 months.,16S,34,Illumina,Linear Regression,0.05,NA,NA,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:757/3/NA,Study 757,prospective cohort,37586456,10.1016/j.exer.2023.109615,NA,"Ozkan J, Majzoub ME, Coroneo M, Thomas T , Willcox M",Ocular microbiome changes in dry eye disease and meibomian gland dysfunction,Experimental eye research,2023,"16S rRNA gene sequencing, Dry eye disease, Meibomian gland dysfunction, Microbiome, Ocular microbiology",Experiment 3,Australia,Homo sapiens,Margin of eyelid,UBERON:0034772,Microbiome,EFO:0004982,Control,Meibomian Gland Dysfunction,Participants with MGD corresponding to  evaporative dry eye disease (moderate).,15,15,No use of antibiotics in the prior 3 months.,16S,34,Illumina,Linear Regression,0.05,NA,NA,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:757/4/NA,Study 757,prospective cohort,37586456,10.1016/j.exer.2023.109615,NA,"Ozkan J, Majzoub ME, Coroneo M, Thomas T , Willcox M",Ocular microbiome changes in dry eye disease and meibomian gland dysfunction,Experimental eye research,2023,"16S rRNA gene sequencing, Dry eye disease, Meibomian gland dysfunction, Microbiome, Ocular microbiology",Experiment 4,Australia,Homo sapiens,Conjunctiva,UBERON:0001811,Microbiome,EFO:0004982,Meibomian Gland Dysfunction,Meibomian Gland Dysfunction + Lacrimal Dysfunction,Participants with MGD + LD corresponding to both evaporative dry eye disease and aqueous deficient dry eye disease (severe DED).,15,17,No use of antibiotics in the prior 3 months.,16S,34,Illumina,Linear Regression,0.05,NA,NA,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:757/5/NA,Study 757,prospective cohort,37586456,10.1016/j.exer.2023.109615,NA,"Ozkan J, Majzoub ME, Coroneo M, Thomas T , Willcox M",Ocular microbiome changes in dry eye disease and meibomian gland dysfunction,Experimental eye research,2023,"16S rRNA gene sequencing, Dry eye disease, Meibomian gland dysfunction, Microbiome, Ocular microbiology",Experiment 5,Australia,Homo sapiens,Conjunctiva,UBERON:0001811,Microbiome,EFO:0004982,control,Meibomian Gland Dysfunction + Lacrimal Dysfunction,Participants with MGD + LD corresponding to both evaporative dry eye disease and aqueous deficient dry eye disease (severe DED).,15,17,No use of antibiotics in the prior 3 months.,16S,34,Illumina,Linear Regression,0.05,NA,NA,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:757/6/NA,Study 757,prospective cohort,37586456,10.1016/j.exer.2023.109615,NA,"Ozkan J, Majzoub ME, Coroneo M, Thomas T , Willcox M",Ocular microbiome changes in dry eye disease and meibomian gland dysfunction,Experimental eye research,2023,"16S rRNA gene sequencing, Dry eye disease, Meibomian gland dysfunction, Microbiome, Ocular microbiology",Experiment 6,Australia,Homo sapiens,Conjunctiva,UBERON:0001811,Microbiome,EFO:0004982,control,Meibomian Gland Dysfunction,Participants with MGD  to  evaporative dry eye disease (moderate DED).,15,15,No use of antibiotics in the prior 3 months.,16S,34,Illumina,Linear Regression,0.05,NA,NA,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:758/1/NA,Study 758,"case-control,time series / longitudinal observational",24370189,https://doi.org/10.1016/j.archoralbio.2013.10.011,https://www.sciencedirect.com/science/article/abs/pii/S0003996913003282?via=ihub,"Xu Y, Teng F, Huang S, Lin Z, Yuan X, Zeng X , Yang F",Changes of saliva microbiota in nasopharyngeal carcinoma patients under chemoradiation therapy,Archives of oral biology,2014,"Nasopharyngeal carcinoma, Oral microbiota, Pyrosequencing, Radiation therapy, Saliva",Experiment 1,China,Homo sapiens,Saliva,UBERON:0001836,Nasopharyngeal squamous cell carcinoma,EFO:1000058,Healthy controls at Baseline,Nasopharyngeal carcinoma patients at baseline,Patients who have not received treatment yet,3,3,30 days,16S,123,Roche454,Metastats,0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:758/2/NA,Study 758,"case-control,time series / longitudinal observational",24370189,https://doi.org/10.1016/j.archoralbio.2013.10.011,https://www.sciencedirect.com/science/article/abs/pii/S0003996913003282?via=ihub,"Xu Y, Teng F, Huang S, Lin Z, Yuan X, Zeng X , Yang F",Changes of saliva microbiota in nasopharyngeal carcinoma patients under chemoradiation therapy,Archives of oral biology,2014,"Nasopharyngeal carcinoma, Oral microbiota, Pyrosequencing, Radiation therapy, Saliva",Experiment 2,China,Homo sapiens,Saliva,UBERON:0001836,Nasopharyngeal squamous cell carcinoma,EFO:1000058,Nasopharyngeal carcinoma patients at baseline,Nasopharyngeal carcinoma patients after treatment,Patients who have received treatment after 7 or 12 months,3,3,30 days,16S,123,Roche454,Metastats,0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:759/1/NA,Study 759,case-control,32931939,10.1016/j.jtos.2020.09.003,NA,"Andersson J, Vogt JK, Dalgaard MD, Pedersen O, Holmgaard K , Heegaard S",Ocular surface microbiota in patients with aqueous tear-deficient dry eye,The ocular surface,2021,"16S rRNA gene amplicon sequencing, ADDE, Bacilli class, Bacterial biomarker, Dry eye, Ocular surface microbiota",Experiment 1,Denmark,Homo sapiens,Conjunctival fornix,UBERON:0010307,Dry eye syndrome,EFO:1000906,control,Dry Eye,Patients with Aqueous Deficient Dry Eye without Ocular Graft vs Host Disease,28,21,For controls- those with hx of recent (within 3 mos) use of antibiotics (local or systemic) were excluded.  ADDE patients were allowed and 7/21 had received local or systemic antibiotics within the previous 3 mos.,16S,34,Illumina,DESeq2,0.05,NA,NA,NA,NA,NA,decreased,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:759/2/NA,Study 759,case-control,32931939,10.1016/j.jtos.2020.09.003,NA,"Andersson J, Vogt JK, Dalgaard MD, Pedersen O, Holmgaard K , Heegaard S",Ocular surface microbiota in patients with aqueous tear-deficient dry eye,The ocular surface,2021,"16S rRNA gene amplicon sequencing, ADDE, Bacilli class, Bacterial biomarker, Dry eye, Ocular surface microbiota",Experiment 2,Denmark,Homo sapiens,Conjunctival fornix,UBERON:0010307,Dry eye syndrome,EFO:1000906,control,OGVHD,"Patients with Aqueous Deficient Dry Eye and Ocular Graft vs Host Disease as diagnosed using the criteria described by the International Chronic Ocular Graft-vs-Host-Disease (GVHD) Consensus.
Group and the patients included were classified as either probable or definite chronic GVHD",28,18,For controls- those with hx of recent (within 3 mos) use of antibiotics (local or systemic) were excluded.  ADDE patients were allowed and 7/21 had received local or systemic antibiotics within the previous 3 mos.,16S,34,Illumina,DESeq2,0.05,NA,NA,NA,NA,NA,decreased,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:759/3/NA,Study 759,case-control,32931939,10.1016/j.jtos.2020.09.003,NA,"Andersson J, Vogt JK, Dalgaard MD, Pedersen O, Holmgaard K , Heegaard S",Ocular surface microbiota in patients with aqueous tear-deficient dry eye,The ocular surface,2021,"16S rRNA gene amplicon sequencing, ADDE, Bacilli class, Bacterial biomarker, Dry eye, Ocular surface microbiota",Experiment 3,Denmark,Homo sapiens,Conjunctival fornix,UBERON:0010307,Dry eye syndrome,EFO:1000906,control,ADDE,"Patients with Aqueous Deficient Dry Eye including those with and without Ocular Graft vs Host Disease as diagnosed using the criteria described by the International Chronic Ocular Graft-vs-Host-Disease (GVHD) Consensus.
Group and the patients included were classified as either probable or definite chronic GVHD",28,39,For controls- those with hx of recent (within 3 mos) use of antibiotics (local or systemic) were excluded.  ADDE patients were allowed and 7/21 had received local or systemic antibiotics within the previous 3 mos.,16S,34,Illumina,LEfSe,0.05,NA,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:760/1/NA,Study 760,randomized controlled trial,36678227,10.3390/nu15020356,NA,"Huang F, Li S, Chen W, Han Y, Yao Y, Yang L, Li Q, Xiao Q, Wei J, Liu Z, Chen T , Deng X",Postoperative Probiotics Administration Attenuates Gastrointestinal Complications and Gut Microbiota Dysbiosis Caused by Chemotherapy in Colorectal Cancer Patients,Nutrients,2023,"CRC, chemotherapy, gastrointestinal complications, gut microbiota, probiotics",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,Placebo control group,Probio group,Patients in the Probio group were instructed to take probiotic tablets orally,50,50,2 Weeks,16S,4,Illumina,LEfSe,0.05,FALSE,2,NA,NA,increased,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:760/2/NA,Study 760,randomized controlled trial,36678227,10.3390/nu15020356,NA,"Huang F, Li S, Chen W, Han Y, Yao Y, Yang L, Li Q, Xiao Q, Wei J, Liu Z, Chen T , Deng X",Postoperative Probiotics Administration Attenuates Gastrointestinal Complications and Gut Microbiota Dysbiosis Caused by Chemotherapy in Colorectal Cancer Patients,Nutrients,2023,"CRC, chemotherapy, gastrointestinal complications, gut microbiota, probiotics",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,CRC [colorectal cancer]  Patients Pre-treatment group,Probio group,Patients in the Probio group were instructed to take probiotic tablets orally,50,50,2 Weeks,16S,4,Illumina,LEfSe,0.05,FALSE,2,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:760/3/NA,Study 760,randomized controlled trial,36678227,10.3390/nu15020356,NA,"Huang F, Li S, Chen W, Han Y, Yao Y, Yang L, Li Q, Xiao Q, Wei J, Liu Z, Chen T , Deng X",Postoperative Probiotics Administration Attenuates Gastrointestinal Complications and Gut Microbiota Dysbiosis Caused by Chemotherapy in Colorectal Cancer Patients,Nutrients,2023,"CRC, chemotherapy, gastrointestinal complications, gut microbiota, probiotics",Experiment 3,China,Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,CRC [colorectal cancer] Patients Pre-treatment group,Placebo group,"Patients in the Placebo group routinely treated with placebo tablets instead of
probiotics",50,50,2 Weeks,16S,4,Illumina,LEfSe,0.05,FALSE,2,NA,NA,decreased,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:761/1/NA,Study 761,case-control,35657343,10.1002/ijc.34145,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9420782/,"Wu Z, Byrd DA, Wan Y, Ansong D, Clegg-Lamptey JN, Wiafe-Addai B, Edusei L, Adjei E, Titiloye N, Dedey F, Aitpillah F, Oppong J, Vanderpuye V, Osei-Bonsu E, Dagnall CL, Jones K, Hutchinson A, Hicks BD, Ahearn TU, Shi J, Knight R, Biritwum R, Yarney J, Wiafe S, Awuah B, Nyarko K, Figueroa JD, Sinha R, Garcia-Closas M, Brinton LA , Vogtmann E","The oral microbiome and breast cancer and nonmalignant breast disease, and its relationship with the fecal microbiome in the Ghana Breast Health Study",International journal of cancer,2022,"Ghana, breast cancer, fecal microbiome, nonmalignant breast diseases, oral microbiome",Experiment 1,Ghana,Homo sapiens,Saliva,UBERON:0001836,Breast cancer,MONDO:0007254,Control,Breast Health Condition,Women with breast cancer cases,419,369,1 month,16S,4,Illumina,Logistic Regression,0.05,TRUE,NA,"age,geographic area","age,alcohol drinking,antibiotic exposure,body mass index,contraception,education level,family history of cancer,geographic area,smoking status",NA,increased,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:761/2/NA,Study 761,case-control,35657343,10.1002/ijc.34145,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9420782/,"Wu Z, Byrd DA, Wan Y, Ansong D, Clegg-Lamptey JN, Wiafe-Addai B, Edusei L, Adjei E, Titiloye N, Dedey F, Aitpillah F, Oppong J, Vanderpuye V, Osei-Bonsu E, Dagnall CL, Jones K, Hutchinson A, Hicks BD, Ahearn TU, Shi J, Knight R, Biritwum R, Yarney J, Wiafe S, Awuah B, Nyarko K, Figueroa JD, Sinha R, Garcia-Closas M, Brinton LA , Vogtmann E","The oral microbiome and breast cancer and nonmalignant breast disease, and its relationship with the fecal microbiome in the Ghana Breast Health Study",International journal of cancer,2022,"Ghana, breast cancer, fecal microbiome, nonmalignant breast diseases, oral microbiome",Experiment 2,Ghana,Homo sapiens,Saliva,UBERON:0001836,Breast cancer,MONDO:0007254,Control,Breast Health Condition,Women with non malignant cases,419,93,1 month,16S,4,Illumina,Logistic Regression,0.05,TRUE,NA,"age,geographic area","age,alcohol drinking,antibiotic exposure,body mass index,contraception,education level,family history of cancer,geographic area,smoking status",NA,increased,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:761/3/NA,Study 761,case-control,35657343,10.1002/ijc.34145,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9420782/,"Wu Z, Byrd DA, Wan Y, Ansong D, Clegg-Lamptey JN, Wiafe-Addai B, Edusei L, Adjei E, Titiloye N, Dedey F, Aitpillah F, Oppong J, Vanderpuye V, Osei-Bonsu E, Dagnall CL, Jones K, Hutchinson A, Hicks BD, Ahearn TU, Shi J, Knight R, Biritwum R, Yarney J, Wiafe S, Awuah B, Nyarko K, Figueroa JD, Sinha R, Garcia-Closas M, Brinton LA , Vogtmann E","The oral microbiome and breast cancer and nonmalignant breast disease, and its relationship with the fecal microbiome in the Ghana Breast Health Study",International journal of cancer,2022,"Ghana, breast cancer, fecal microbiome, nonmalignant breast diseases, oral microbiome",Experiment 3,Ghana,Homo sapiens,Saliva,UBERON:0001836,Breast cancer,MONDO:0007254,Non malignant,Breast cancer,Women with breast cancer cases,93,369,1 month,16S,4,Illumina,Logistic Regression,0.05,TRUE,NA,"age,geographic area","age,alcohol drinking,antibiotic exposure,body mass index,contraception,education level,family history of cancer,geographic area,smoking status",NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:762/1/NA,Study 762,case-control,31463790,10.1007/s12275-019-9127-2,NA,"Li Z, Gong Y, Chen S, Li S, Zhang Y, Zhong H, Wang Z, Chen Y, Deng Q, Jiang Y, Li L, Fu M , Yi G",Comparative portrayal of ocular surface microbe with and without dry eye,"Journal of microbiology (Seoul, Korea)",2019,"16S rRNA gene sequencing, dry eye, meibomian gland dysfunction, ocular surface bacteria",Experiment 1,China,Homo sapiens,Conjunctiva,UBERON:0001811,Dry eye syndrome,EFO:1000906,healthy controls,Dry Eye,"Patients with Dry Eye  (with or without Meibomian Gland Disease).  
Subjects were considered to have DE if a positive
dry eye survey OSDI ≥ 13 was recorded in addition
to a positive score in one or more tests (tear break-up time
≤ 10; osmolarity ≥ 308 mOsm/L or interocular difference > 8
mOsm/L; ocular surface staining > 5 corneal spots, > 9 conjunctival
spots, or lid margin ≥ 2 mm length, and 25% width).",54,35,No antibiotics for 6 months prior to study entry,16S,34,Illumina,LEfSe,0.05,NA,4,NA,NA,NA,decreased,unchanged,decreased,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:762/2/NA,Study 762,case-control,31463790,10.1007/s12275-019-9127-2,NA,"Li Z, Gong Y, Chen S, Li S, Zhang Y, Zhong H, Wang Z, Chen Y, Deng Q, Jiang Y, Li L, Fu M , Yi G",Comparative portrayal of ocular surface microbe with and without dry eye,"Journal of microbiology (Seoul, Korea)",2019,"16S rRNA gene sequencing, dry eye, meibomian gland dysfunction, ocular surface bacteria",Experiment 2,China,Homo sapiens,Conjunctiva,UBERON:0001811,Dry eye syndrome,EFO:1000906,Non-MGD,MGD,Patients with Dry Eye with Meibomian Gland Disease,10,25,No antibiotics for 6 months prior to study entry,16S,34,Illumina,LEfSe,0.05,NA,4,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:763/1/NA,Study 763,case-control,29196767,10.1167/iovs.17-22957,NA,"Wen X, Miao L, Deng Y, Bible PW, Hu X, Zou Y, Liu Y, Guo S, Liang J, Chen T, Peng GH, Chen W, Liang L , Wei L",The Influence of Age and Sex on Ocular Surface Microbiota in Healthy Adults,Investigative ophthalmology & visual science,2017,NA,Experiment 1,China,Homo sapiens,Bulbar conjunctiva,UBERON:0010306,Age at assessment,EFO:0008007,Young,Old,Aged 47-84 years old,48,42,No history of antibiotics in the past 6 months,WMS,NA,Illumina,LEfSe,0.05,FALSE,3,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:763/2/NA,Study 763,case-control,29196767,10.1167/iovs.17-22957,NA,"Wen X, Miao L, Deng Y, Bible PW, Hu X, Zou Y, Liu Y, Guo S, Liang J, Chen T, Peng GH, Chen W, Liang L , Wei L",The Influence of Age and Sex on Ocular Surface Microbiota in Healthy Adults,Investigative ophthalmology & visual science,2017,NA,Experiment 2,China,Homo sapiens,Bulbar conjunctiva,UBERON:0010306,Biological sex,PATO:0000047,Male,Female,Biological sex=female,42,48,No history of antibiotics in the past 6 months,WMS,NA,Illumina,LEfSe,0.05,FALSE,3,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:764/1/NA,Study 764,case-control,29172724,10.1080/02713683.2017.1406528,NA,"Ham B, Hwang HB, Jung SH, Chang S, Kang KD , Kwon MJ",Distribution and Diversity of Ocular Microbial Communities in Diabetic Patients Compared with Healthy Subjects,Current eye research,2018,"Bacterial diversity, Bradyrhizobiaceae, Burkholderia, LFR analysis, Staphylococcus",Experiment 1,Republic of Korea,Homo sapiens,Bulbar conjunctiva,UBERON:0010306,Type II diabetes mellitus,MONDO:0005148,healthy controls,diabetic,Type 2 diabetic patients undergoing vitrectomy,16,9,No antibiotics in the 6 months prior to enrollment,16S,4,Illumina,LEfSe,0.05,NA,2.6,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:765/1/NA,Study 765,case-control,35171931,10.1371/journal.pone.0263283,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0263283,"Kunaseth J, Waiyaput W, Chanchaem P, Sawaswong V, Permpech R, Payungporn S , Sophonsritsuk A",Vaginal microbiome of women with adenomyosis: A case-control study,PloS one,2022,NA,Experiment 1,Thailand,Homo sapiens,Upper part of vagina,UBERON:0003974,Adenomyosis,EFO:1001757,Healthy controls,adenomyosis patients,"Patients with adenomoysis diagnosed using at least three diagnostic ultrasound-based criteria: globular shape uterus, asymmetric myometrial wall, thickening of the endometrial myometrial junction, hyperechoic striae along the sub-endometrial region, and presence of sub-endometrial microcyst",38,40,Not mentioned,16S,34,Illumina,LEfSe,0.05,NA,2,age,NA,NA,unchanged,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:766/1/NA,Study 766,case-control,32152391,https://doi.org/10.1038/s41598-020-60794-w,NA,"Kittipibul T, Puangsricharern V , Chatsuwan T",Comparison of the ocular microbiome between chronic Stevens-Johnson syndrome patients and healthy subjects,Scientific reports,2020,NA,Experiment 1,Thailand,Homo sapiens,Conjunctival sac,UBERON:0005908,Stevens-Johnson syndrome,EFO:0004276,healthy controls,Stevens-Johnson Syndrome,Stevens-Johnson Syndrome patients,20,20,Topical antibiotics within the 4 weeks prior to study entry were excluded,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,NA,NA,"age,sex",NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:767/1/NA,Study 767,case-control,35133187,10.1128/msystems.00004-22,NA,"Yıldırım S, Nalbantoğlu ÖU, Bayraktar A, Ercan FB, Gündoğdu A, Velioğlu HA, Göl MF, Soylu AE, Koç F, Gülpınar EA, Kadak KS, Arıkan M, Mardinoğlu A, Koçak M, Köseoğlu E , Hanoğlu L",Stratification of the Gut Microbiota Composition Landscape across the Alzheimer's Disease Continuum in a Turkish Cohort,mSystems,2022,"16S rRNA, Alzheimer’s disease, brain-gut axis, gut microbiome, gut microbiota, precision medicine, precision nutrition, stratification",Experiment 1,Turkey,Homo sapiens,Feces,UBERON:0001988,Alzheimer's disease,MONDO:0004975,Non-demented Controls,Alzheimer's disease patients,"Patients with Alzheimer's disease, mostly exhibiting mild to very mild dementia",51,47,1 month,16S,34,Illumina,Kruskall-Wallis,0.05,TRUE,NA,diet,"age,sex",NA,increased,increased,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:767/2/NA,Study 767,case-control,35133187,10.1128/msystems.00004-22,NA,"Yıldırım S, Nalbantoğlu ÖU, Bayraktar A, Ercan FB, Gündoğdu A, Velioğlu HA, Göl MF, Soylu AE, Koç F, Gülpınar EA, Kadak KS, Arıkan M, Mardinoğlu A, Koçak M, Köseoğlu E , Hanoğlu L",Stratification of the Gut Microbiota Composition Landscape across the Alzheimer's Disease Continuum in a Turkish Cohort,mSystems,2022,"16S rRNA, Alzheimer’s disease, brain-gut axis, gut microbiome, gut microbiota, precision medicine, precision nutrition, stratification",Experiment 2,Turkey,Homo sapiens,Feces,UBERON:0001988,Alzheimer's disease,MONDO:0004975,Non-demented Controls,Mild Cognitive Impairment group,Amnestic patients with mild cognitive impairment (MCI),51,27,1 month,16S,34,Illumina,Kruskall-Wallis,0.05,TRUE,NA,NA,"age,sex",NA,increased,decreased,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:768/1/NA,Study 768,case-control,37597851,10.1136/jitc-2023-007420,NA,"Li J, Guo Y, Liu J, Guo F, Du L, Yang Y, Li X , Ma Y",Depicting the landscape of gut microbial-metabolic interaction and microbial-host immune heterogeneity in deficient and proficient DNA mismatch repair colorectal cancers,Journal for immunotherapy of cancer,2023,gastrointestinal neoplasms,Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Mismatch repair cancer syndrome,MONDO:0031219,proficient DNA mismatch repair (pMMR) CRC,deficient DNA mismatch repair (dMMR) CRC,dMMR in colorectal cancer (CRC) characterized by robust immune environment,207,21,NA,WMS,NA,Illumina,Linear Regression,0.05,FALSE,NA,NA,"age,body mass index,sex",NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:768/2/NA,Study 768,case-control,37597851,10.1136/jitc-2023-007420,NA,"Li J, Guo Y, Liu J, Guo F, Du L, Yang Y, Li X , Ma Y",Depicting the landscape of gut microbial-metabolic interaction and microbial-host immune heterogeneity in deficient and proficient DNA mismatch repair colorectal cancers,Journal for immunotherapy of cancer,2023,gastrointestinal neoplasms,Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,Healthy controls (CTRL),deficient DNA mismatch repair (dMMR) CRC,dMMR in colorectal cancer (CRC) characterized by robust immune environment,227,21,NA,WMS,NA,Illumina,Linear Regression,0.05,FALSE,NA,NA,"age,body mass index,sex",NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:768/3/NA,Study 768,case-control,37597851,10.1136/jitc-2023-007420,NA,"Li J, Guo Y, Liu J, Guo F, Du L, Yang Y, Li X , Ma Y",Depicting the landscape of gut microbial-metabolic interaction and microbial-host immune heterogeneity in deficient and proficient DNA mismatch repair colorectal cancers,Journal for immunotherapy of cancer,2023,gastrointestinal neoplasms,Experiment 3,China,Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,Healthy controls (CTRL),proficient DNA mismatch repair (pMMR) CRC,pMMR in colorectal cancer (CRC) characterized by immunosuppressive tumor microenvironment,227,207,NA,WMS,NA,Illumina,Linear Regression,0.05,FALSE,NA,NA,"age,body mass index,sex",NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:769/1/NA,Study 769,time series / longitudinal observational,36894532,10.1038/s41467-023-36781-w,https://pubmed.ncbi.nlm.nih.gov/36894532/,"Sukumar S, Wang F, Simpson CA, Willet CE, Chew T, Hughes TE, Bockmann MR, Sadsad R, Martin FE, Lydecker HW, Browne GV, Davis KM, Bui M, Martinez E , Adler CJ",Development of the oral resistome during the first decade of life,Nature communications,2023,NA,Experiment 1,Australia,Homo sapiens,Mouth,UBERON:0000165,Dental caries,EFO:0003819,T1 - Timepoint 1 - (T1. edentulous (no teeth)),T2 - Timepoint 2,Samples (1.6 ± 0.4 years) at T2 (primary/deciduous/baby teeth only),139,180,3 Months,WMS,NA,Illumina,MaAsLin2,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:769/2/NA,Study 769,time series / longitudinal observational,36894532,10.1038/s41467-023-36781-w,https://pubmed.ncbi.nlm.nih.gov/36894532/,"Sukumar S, Wang F, Simpson CA, Willet CE, Chew T, Hughes TE, Bockmann MR, Sadsad R, Martin FE, Lydecker HW, Browne GV, Davis KM, Bui M, Martinez E , Adler CJ",Development of the oral resistome during the first decade of life,Nature communications,2023,NA,Experiment 2,Australia,Homo sapiens,Mouth,UBERON:0000165,Dental caries,EFO:0003819,T1 - Timepoint 1 - (T1. edentulous (no teeth)),T3 - Timepoint 3,"Samples at T3 (mixed dentition, 8.5 ± 1.2 years old)",139,211,3 Months,WMS,NA,Illumina,MaAsLin2,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:769/3/NA,Study 769,time series / longitudinal observational,36894532,10.1038/s41467-023-36781-w,https://pubmed.ncbi.nlm.nih.gov/36894532/,"Sukumar S, Wang F, Simpson CA, Willet CE, Chew T, Hughes TE, Bockmann MR, Sadsad R, Martin FE, Lydecker HW, Browne GV, Davis KM, Bui M, Martinez E , Adler CJ",Development of the oral resistome during the first decade of life,Nature communications,2023,NA,Experiment 3,Australia,Homo sapiens,Mouth,UBERON:0000165,Dental caries,EFO:0003819,T2 - Timepoint 2,T3 - Timepoint 3,"Samples at T3 (mixed dentition, 8.5 ± 1.2 years old)",180,211,3 Months,WMS,NA,Illumina,MaAsLin2,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:770/1/NA,Study 770,case-control,37762390,10.3390/ijms241814091,NA,"Schlegel I, De Goüyon Matignon de Pontourade CMF, Lincke JB, Keller I, Zinkernagel MS , Zysset-Burri DC",The Human Ocular Surface Microbiome and Its Associations with the Tear Proteome in Dry Eye Disease,International journal of molecular sciences,2023,"chromatography–tandem mass spectrometry, dry eye disease, ocular surface microbiome, tear proteome, whole-metagenome shotgun sequencing",Experiment 1,Switzerland,Homo sapiens,Eyelid,UBERON:0001711,Dry eye syndrome,EFO:1000906,healthy controls,Dry Eye,Dry Eye Disease diagnosis,10,10,Antibiotics within the past 3 months,WMS,NA,Illumina,Welch's T-Test,0.05,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:770/2/NA,Study 770,case-control,37762390,10.3390/ijms241814091,NA,"Schlegel I, De Goüyon Matignon de Pontourade CMF, Lincke JB, Keller I, Zinkernagel MS , Zysset-Burri DC",The Human Ocular Surface Microbiome and Its Associations with the Tear Proteome in Dry Eye Disease,International journal of molecular sciences,2023,"chromatography–tandem mass spectrometry, dry eye disease, ocular surface microbiome, tear proteome, whole-metagenome shotgun sequencing",Experiment 2,Switzerland,Homo sapiens,Palpebral conjunctiva,UBERON:0001812,Dry eye syndrome,EFO:1000906,healthy controls,Dry Eye,Dry Eye Disease diagnosis,10,10,Antibiotics within the past 3 months,WMS,NA,Illumina,Welch's T-Test,0.05,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:771/1/NA,Study 771,case-control,32106294,10.1167/iovs.61.2.47,NA,"Deng Y, Wen X, Hu X, Zou Y, Zhao C, Chen X, Miao L, Li X, Deng X, Bible PW, Ke H, Situ J, Guo S, Liang J, Chen T, Zou B, Liu Y, Chen W, Wu K, Zhang M, Jin ZB, Liang L , Wei L","Geographic Difference Shaped Human Ocular Surface Metagenome of Young Han Chinese From Beijing, Wenzhou, and Guangzhou Cities",Investigative ophthalmology & visual science,2020,NA,Experiment 1,China,Homo sapiens,Bulbar conjunctiva,UBERON:0010306,Health study participation,EFO:0010130,Guangzhou healthy volunteers,Bejing healthy volunteers,Healthy nonsmokers from Bejing,48,20,6 months prior to enrollment,WMS,NA,Illumina,LEfSe,NA,NA,3,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:772/1/NA,Study 772,laboratory experiment,33178173,10.3389/fmicb.2020.591462,NA,"Li Q , Pan Y",Differential Responses to Dietary Protein and Carbohydrate Ratio on Gut Microbiome in Obese vs. Lean Cats,Frontiers in microbiology,2020,"carbohydrate, cat, diet, feline, microbiome, obesity, protein",Experiment 1,United States of America,Felis catus,Feces,UBERON:0001988,Obesity,EFO:0001073,LN cats at T1,OW cats at T1,Overweight domestic felines that have an excess accumulation of body fat at the end of T1 (baseline feeding),19,20,NA,16S,34,Illumina,"Dunn's test,Kruskall-Wallis",0.05,TRUE,NA,"age,sex",NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:772/2/NA,Study 772,laboratory experiment,33178173,10.3389/fmicb.2020.591462,NA,"Li Q , Pan Y",Differential Responses to Dietary Protein and Carbohydrate Ratio on Gut Microbiome in Obese vs. Lean Cats,Frontiers in microbiology,2020,"carbohydrate, cat, diet, feline, microbiome, obesity, protein",Experiment 2,United States of America,Felis catus,Feces,UBERON:0001988,Diet,EFO:0002755,CON-fed OW cats at T1(end of baseline feeding),CON-fed OW cats at T2 (end of intervention),Overweight domestic felines placed on the control diet at T2 (end of intervention),20,10,NA,16S,34,Illumina,"Kruskall-Wallis,Dunn's test",0.05,TRUE,NA,"age,sex",NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:772/3/NA,Study 772,laboratory experiment,33178173,10.3389/fmicb.2020.591462,NA,"Li Q , Pan Y",Differential Responses to Dietary Protein and Carbohydrate Ratio on Gut Microbiome in Obese vs. Lean Cats,Frontiers in microbiology,2020,"carbohydrate, cat, diet, feline, microbiome, obesity, protein",Experiment 3,United States of America,Felis catus,Feces,UBERON:0001988,Diet,EFO:0002755,CON-fed OW cats at T1(end of baseline feeding),HPLC-fed OW cats at T2 (end of intervention),Overweight domestic felines placed on the HPLC diet at T2 (end of intervention),20,10,NA,16S,34,Illumina,"Kruskall-Wallis,Dunn's test",0.05,TRUE,NA,"age,sex",NA,NA,increased,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:772/4/NA,Study 772,laboratory experiment,33178173,10.3389/fmicb.2020.591462,NA,"Li Q , Pan Y",Differential Responses to Dietary Protein and Carbohydrate Ratio on Gut Microbiome in Obese vs. Lean Cats,Frontiers in microbiology,2020,"carbohydrate, cat, diet, feline, microbiome, obesity, protein",Experiment 4,United States of America,Felis catus,Feces,UBERON:0001988,Diet,EFO:0002755,CON-fed OW cats at T2 (end of intervention),HPLC-fed OW cats at T2 (end of intervention),HPLC-fed overweight domestic felines at T2 (end of intervention),10,10,NA,16S,34,Illumina,"Kruskall-Wallis,Dunn's test",0.05,TRUE,NA,"age,sex",NA,NA,decreased,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:773/1/NA,Study 773,time series / longitudinal observational,21957459,10.1371/journal.pone.0024767,NA,"Wang Y, Gilbreath TM, Kukutla P, Yan G , Xu J",Dynamic gut microbiome across life history of the malaria mosquito Anopheles gambiae in Kenya,PloS one,2011,NA,Experiment 1,Kenya,Anopheles gambiae,"Instar larval stage,Pupa","UBERON:0004730,UBERON:0003143",Gut microbiome measurement,EFO:0007874,Pupal (Triplicates),Newly emerged adult guts,"1-day-old adult, no feeding (triplicates)",9,6,NIL,16S,123,Roche454,Metastats,0.05,FALSE,NA,NA,NA,NA,NA,decreased,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:773/2/NA,Study 773,time series / longitudinal observational,21957459,10.1371/journal.pone.0024767,NA,"Wang Y, Gilbreath TM, Kukutla P, Yan G , Xu J",Dynamic gut microbiome across life history of the malaria mosquito Anopheles gambiae in Kenya,PloS one,2011,NA,Experiment 2,Kenya,Anopheles gambiae,"Instar larval stage,Pupa","UBERON:0004730,UBERON:0003143",Gut microbiome measurement,EFO:0007874,"Sugar fed mosquito - 3-day-old,sugar (triplicates)",Blood fed mosquito - 2 days post blood meal (triplicates),Blood-fed mosquito at different time points,6,6,NIL,16S,123,Roche454,Metastats,0.05,FALSE,NA,NA,NA,NA,NA,increased,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:774/1/NA,Study 774,case-control,36573834,10.1080/19490976.2022.2157697,NA,"Su Q, Tun HM, Liu Q, Yeoh YK, Mak JWY, Chan FK , Ng SC",Gut microbiome signatures reflect different subtypes of irritable bowel syndrome,Gut microbes,2023,"Irritable bowel syndrome, depression, diet, gut microbiome, subtype",Experiment 1,"United States of America,United Kingdom,Canada",Homo sapiens,Feces,UBERON:0001988,Irritable bowel syndrome,EFO:0000555,Non-IBS1 (Non-irritable bowel syndrome 1),IBS-C (IBS-Constipation),"Patients diagnosed with IBS-C, a subtype of IBS characterized by constipation (difficulty passing stool)",180,180,6 months,16S,4,Illumina,LEfSe,0.05,FALSE,2,"age,alcohol drinking,body mass index,diet,geographic area,sex","age,alcohol drinking,diet,sex",NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:774/2/NA,Study 774,case-control,36573834,10.1080/19490976.2022.2157697,NA,"Su Q, Tun HM, Liu Q, Yeoh YK, Mak JWY, Chan FK , Ng SC",Gut microbiome signatures reflect different subtypes of irritable bowel syndrome,Gut microbes,2023,"Irritable bowel syndrome, depression, diet, gut microbiome, subtype",Experiment 2,"United Kingdom,United States of America,Canada",Homo sapiens,Feces,UBERON:0001988,Irritable bowel syndrome,EFO:0000555,Non-IBS2 (Non-irritable bowel syndrome 2),IBS-D (IBS-Diarrhea),"Patients diagnosed with IBS-D, a subtype of IBS characterized by diarrhea (watery stool)",302,302,6 months,16S,4,Illumina,LEfSe,0.05,FALSE,2,"age,alcohol drinking,body mass index,diet,geographic area,sex","age,alcohol drinking,diet,sex",NA,decreased,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:774/3/NA,Study 774,case-control,36573834,10.1080/19490976.2022.2157697,NA,"Su Q, Tun HM, Liu Q, Yeoh YK, Mak JWY, Chan FK , Ng SC",Gut microbiome signatures reflect different subtypes of irritable bowel syndrome,Gut microbes,2023,"Irritable bowel syndrome, depression, diet, gut microbiome, subtype",Experiment 3,"United Kingdom,United States of America,Canada",Homo sapiens,Feces,UBERON:0001988,Irritable bowel syndrome,EFO:0000555,Non-IBS3 (Non-irritable bowel syndrome 3),IBS-U (IBS-Unclassified),"Patients diagnosed with IBS-U, a distinct category characterized by normal formed stool",460,460,6 months,16S,4,Illumina,LEfSe,0.05,FALSE,2,"age,alcohol drinking,body mass index,diet,geographic area,sex","age,alcohol drinking,diet,sex",NA,decreased,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:774/4/NA,Study 774,case-control,36573834,10.1080/19490976.2022.2157697,NA,"Su Q, Tun HM, Liu Q, Yeoh YK, Mak JWY, Chan FK , Ng SC",Gut microbiome signatures reflect different subtypes of irritable bowel syndrome,Gut microbes,2023,"Irritable bowel syndrome, depression, diet, gut microbiome, subtype",Experiment 4,"United Kingdom,United States of America,Canada",Homo sapiens,Feces,UBERON:0001988,Depressive disorder,MONDO:0002050,IBS patients without depression,"IBS patients with depression in all three subtypes (IBS-D, IBS-C and IBS-U)","IBS patients with depression in all three subtypes (IBS-D, IBS-C and IBS-U)",134,134,6 months,16S,4,Illumina,MaAsLin2,0.05,FALSE,NA,"age,alcohol drinking,body mass index,diet,geographic area,sex","age,alcohol drinking,diet,sex",NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:774/5/NA,Study 774,case-control,36573834,10.1080/19490976.2022.2157697,NA,"Su Q, Tun HM, Liu Q, Yeoh YK, Mak JWY, Chan FK , Ng SC",Gut microbiome signatures reflect different subtypes of irritable bowel syndrome,Gut microbes,2023,"Irritable bowel syndrome, depression, diet, gut microbiome, subtype",Experiment 5,"United Kingdom,United States of America,Canada",Homo sapiens,Feces,UBERON:0001988,Irritable bowel syndrome,EFO:0000555,Non-IBS (Non-irritable bowel syndrome),IBS-C (IBS-Constipation) Validation Cohort,"Patients diagnosed with IBS-C, a subtype of IBS characterized by constipation (difficulty passing stool) in the Validation Cohort",44,44,6 months,16S,4,Illumina,LEfSe,0.05,FALSE,2,"age,alcohol drinking,body mass index,diet,geographic area,sex","age,alcohol drinking,diet,sex",NA,decreased,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:774/6/NA,Study 774,case-control,36573834,10.1080/19490976.2022.2157697,NA,"Su Q, Tun HM, Liu Q, Yeoh YK, Mak JWY, Chan FK , Ng SC",Gut microbiome signatures reflect different subtypes of irritable bowel syndrome,Gut microbes,2023,"Irritable bowel syndrome, depression, diet, gut microbiome, subtype",Experiment 6,"United Kingdom,United States of America,Canada",Homo sapiens,Feces,UBERON:0001988,Irritable bowel syndrome,EFO:0000555,Non-IBS (Non-irritable bowel syndrome),IBS-D (IBS-Diarrhea) Validation Cohort,"Patients diagnosed with IBS-D, a subtype of IBS characterized by diarrhea (watery stool) in the Validation Cohort",48,48,6 months,16S,4,Illumina,LEfSe,0.05,FALSE,2,"age,alcohol drinking,body mass index,diet,geographic area,sex","age,alcohol drinking,diet,sex",NA,decreased,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:774/7/NA,Study 774,case-control,36573834,10.1080/19490976.2022.2157697,NA,"Su Q, Tun HM, Liu Q, Yeoh YK, Mak JWY, Chan FK , Ng SC",Gut microbiome signatures reflect different subtypes of irritable bowel syndrome,Gut microbes,2023,"Irritable bowel syndrome, depression, diet, gut microbiome, subtype",Experiment 7,"United Kingdom,United States of America,Canada",Homo sapiens,Feces,UBERON:0001988,Irritable bowel syndrome,EFO:0000555,Non-IBS (Non-irritable bowel syndrome),IBS-U (IBS-Unclassified) Validation Cohort,"Patients diagnosed with IBS-U, a distinct category characterized by normal formed stool in the Validation Cohort",61,61,6 months,16S,4,Illumina,LEfSe,0.05,FALSE,2,"age,alcohol drinking,body mass index,diet,geographic area,sex","age,alcohol drinking,diet,sex",NA,decreased,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:775/1/NA,Study 775,case-control,36631533,10.1038/s41598-023-27436-3,NA,"Shrode RL, Knobbe JE, Cady N, Yadav M, Hoang J, Cherwin C, Curry M, Garje R, Vikas P, Sugg S, Phadke S, Filardo E , Mangalam AK",Breast cancer patients from the Midwest region of the United States have reduced levels of short-chain fatty acid-producing gut bacteria,Scientific reports,2023,NA,Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Breast cancer,MONDO:0007254,Healthy controls (HC),Breast cancer (BC),"All BC patients eligible for this study were diagnosed with invasive BC of any stage, and recruited from the Breast Molecular Epidemiology Resource (BMER) of the Holden Comprehensive Cancer Center (HCCC)",19,22,Antibiotic use within four weeks of sample collection,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,"body mass index,race,sex",NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:776/1/NA,Study 776,case-control,29230385,10.3389/fcimb.2017.00488,https://www.frontiersin.org/articles/10.3389/fcimb.2017.00488/full,"Wu P, Chen Y, Zhao J, Zhang G, Chen J, Wang J , Zhang H",Urinary Microbiome and Psychological Factors in Women with Overactive Bladder,Frontiers in cellular and infection microbiology,2017,"bacteria, depression, overactive bladder, psychology, urinary microbiome",Experiment 1,China,Homo sapiens,Female urethra,UBERON:0001334,Overactive bladder,EFO:1000781,Asymptomatic controls,Overactive Bladder (OAB) patients,"Adult patients aged 18 or above, diagnosed with OAB",25,30,NA,16S,4,Illumina,LEfSe,0.05,FALSE,2.5,NA,NA,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:776/2/NA,Study 776,case-control,29230385,10.3389/fcimb.2017.00488,https://www.frontiersin.org/articles/10.3389/fcimb.2017.00488/full,"Wu P, Chen Y, Zhao J, Zhang G, Chen J, Wang J , Zhang H",Urinary Microbiome and Psychological Factors in Women with Overactive Bladder,Frontiers in cellular and infection microbiology,2017,"bacteria, depression, overactive bladder, psychology, urinary microbiome",Experiment 2,China,Homo sapiens,Female urethra,UBERON:0001334,Anxiety,EFO:0005230,Overactive Bladder (OAB) without anxiety,Overactive Bladder (OAB) with anxiety,"Adult patients aged 18 or above, diagnosed with OAB and have anxiety",18,12,NA,16S,4,Illumina,LEfSe,0.05,FALSE,2.5,NA,NA,increased,increased,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:776/3/NA,Study 776,case-control,29230385,10.3389/fcimb.2017.00488,https://www.frontiersin.org/articles/10.3389/fcimb.2017.00488/full,"Wu P, Chen Y, Zhao J, Zhang G, Chen J, Wang J , Zhang H",Urinary Microbiome and Psychological Factors in Women with Overactive Bladder,Frontiers in cellular and infection microbiology,2017,"bacteria, depression, overactive bladder, psychology, urinary microbiome",Experiment 3,China,Homo sapiens,Female urethra,UBERON:0001334,Depressive disorder,MONDO:0002050,Overactive Bladder (OAB) without depression,Overactive Bladder (OAB) with depression,"Adult patients aged 18 or above, diagnosed with OAB and have anxiety",16,14,NA,16S,4,Illumina,LEfSe,0.05,FALSE,2.5,NA,NA,increased,decreased,decreased,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:777/1/NA,Study 777,case-control,37507685,10.1186/s12876-023-02904-2,NA,"Alsulaiman RM, Al-Quorain AA, Al-Muhanna FA, Piotrowski S, Kurdi EA, Vatte C, Alquorain AA, Alfaraj NH, Alrezuk AM, Robinson F, Dowdell AK, Alamri TA, Hamilton L, Lad H, Gao H, Gandla D, Keating BJ, Meng R, Piening B , Al-Ali AK",Gut microbiota analyses of inflammatory bowel diseases from a representative Saudi population,BMC gastroenterology,2023,"Crohn’s disease, IBD, Inflammation, Microbiota, Saudi, Ulcerative colitis",Experiment 1,Saudi Arabia,Homo sapiens,Feces,UBERON:0001988,Ulcerative colitis,EFO:0000729,healthy controls,ulcerative colitis (UC),"Patients diagnosed with inflammatory bowel disease (IBD) through colonoscopy examinations, for ulcerative colitis (UC)",124,84,2 months,16S,123456789,Illumina,DESeq2,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:777/2/NA,Study 777,case-control,37507685,10.1186/s12876-023-02904-2,NA,"Alsulaiman RM, Al-Quorain AA, Al-Muhanna FA, Piotrowski S, Kurdi EA, Vatte C, Alquorain AA, Alfaraj NH, Alrezuk AM, Robinson F, Dowdell AK, Alamri TA, Hamilton L, Lad H, Gao H, Gandla D, Keating BJ, Meng R, Piening B , Al-Ali AK",Gut microbiota analyses of inflammatory bowel diseases from a representative Saudi population,BMC gastroenterology,2023,"Crohn’s disease, IBD, Inflammation, Microbiota, Saudi, Ulcerative colitis",Experiment 2,Saudi Arabia,Homo sapiens,Feces,UBERON:0001988,Crohn's disease,EFO:0000384,healthy controls,Crohn's disease (CD),"Patients diagnosed with inflammatory bowel disease (IBD) through endoscopy examinations, for Crohn's disease (CD)",124,135,2 months,16S,123456789,Illumina,DESeq2,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:777/3/NA,Study 777,case-control,37507685,10.1186/s12876-023-02904-2,NA,"Alsulaiman RM, Al-Quorain AA, Al-Muhanna FA, Piotrowski S, Kurdi EA, Vatte C, Alquorain AA, Alfaraj NH, Alrezuk AM, Robinson F, Dowdell AK, Alamri TA, Hamilton L, Lad H, Gao H, Gandla D, Keating BJ, Meng R, Piening B , Al-Ali AK",Gut microbiota analyses of inflammatory bowel diseases from a representative Saudi population,BMC gastroenterology,2023,"Crohn’s disease, IBD, Inflammation, Microbiota, Saudi, Ulcerative colitis",Experiment 3,Saudi Arabia,Homo sapiens,Feces,UBERON:0001988,Crohn's disease,EFO:0000384,ulcerative colitis (UC),Crohn's disease (CD),"Patients diagnosed with inflammatory bowel disease (IBD) through endoscopy examinations, for Crohn's disease (CD)",84,135,2 months,16S,123456789,Illumina,DESeq2,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:778/1/NA,Study 778,case-control,32591968,http://dx.doi.org/10.1007/s10620-020-06415-y,NA,"Wu ZF, Zou K, Wu GN, Jin ZJ, Xiang CJ, Xu S, Wang YH, Wu XY, Chen C, Xu Z, Li WS, Yao XQ, Zhang JF , Liu FK",A Comparison of Tumor-Associated and Non-Tumor-Associated Gastric Microbiota in Gastric Cancer Patients,Digestive diseases and sciences,2021,"Carcinogenesis, Gastric cancer, Microbiota, Stomach",Experiment 1,China,Homo sapiens,Gastric pit,UBERON:0000424,Gastric cancer,MONDO:0001056,Superficial gastritis,Gastric cancer (GC),Gastric microbiome in paired tumor and paracancerous tissue samples from GC patients undergoing surgical treatment,64,96,1 month,16S,345,Illumina,LEfSe,0.05,FALSE,3,NA,NA,NA,decreased,decreased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:778/2/NA,Study 778,case-control,32591968,http://dx.doi.org/10.1007/s10620-020-06415-y,NA,"Wu ZF, Zou K, Wu GN, Jin ZJ, Xiang CJ, Xu S, Wang YH, Wu XY, Chen C, Xu Z, Li WS, Yao XQ, Zhang JF , Liu FK",A Comparison of Tumor-Associated and Non-Tumor-Associated Gastric Microbiota in Gastric Cancer Patients,Digestive diseases and sciences,2021,"Carcinogenesis, Gastric cancer, Microbiota, Stomach",Experiment 2,China,Homo sapiens,Gastric pit,UBERON:0000424,Gastric cancer,MONDO:0001056,non-tumor tissues of gastric cancer patients,tumor tissues of gastric cancer patients,Gastric microbiome in tumor tissue samples from GC patients undergoing surgical treatment,78,18,1 month,16S,345,Illumina,LEfSe,0.05,FALSE,3,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:779/1/NA,Study 779,"cross-sectional observational, not case-control",37468867,10.1186/s12916-023-02972-x,NA,"Zhang D, Weng S, Xia C, Ren Y, Liu Z, Xu Y, Yang X, Wu R, Peng L, Sun L, Zhu J, Liang X, Jia Y, Wang H, Chen Q, Liu D, Chen Y, Guo H, Han X, Jin Z, Chen C, Yang X, Li Z , Huang H",Gastrointestinal symptoms of long COVID-19 related to the ectopic colonization of specific bacteria that move between the upper and lower alimentary tract and alterations in serum metabolites,BMC medicine,2023,"Coronavirus, Gut microbiome, Microbial functions, Serum metabolomics",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Post-COVID-19 disorder,MONDO:0100320,healthy controls and mild COVID-19 patients,long COVID-19,patients with gastrointestinal symptoms associated with long COVID-19 at 3 months follow-up,70,45,3 months before enrollment,WMS,NA,Illumina,T-Test,0.05,TRUE,NA,"age,sex",NA,NA,decreased,decreased,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:779/2/NA,Study 779,"cross-sectional observational, not case-control",37468867,10.1186/s12916-023-02972-x,NA,"Zhang D, Weng S, Xia C, Ren Y, Liu Z, Xu Y, Yang X, Wu R, Peng L, Sun L, Zhu J, Liang X, Jia Y, Wang H, Chen Q, Liu D, Chen Y, Guo H, Han X, Jin Z, Chen C, Yang X, Li Z , Huang H",Gastrointestinal symptoms of long COVID-19 related to the ectopic colonization of specific bacteria that move between the upper and lower alimentary tract and alterations in serum metabolites,BMC medicine,2023,"Coronavirus, Gut microbiome, Microbial functions, Serum metabolomics",Experiment 2,China,Homo sapiens,Saliva,UBERON:0001836,Post-COVID-19 disorder,MONDO:0100320,healthy controls and mild COVID-19 patients,long COVID-19,patients with gastrointestinal symptoms associated with long COVID-19 at 3 months follow-up,70,45,3 months before enrollment,WMS,NA,Illumina,T-Test,0.05,TRUE,NA,"age,sex",NA,NA,decreased,decreased,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:780/1/NA,Study 780,"cross-sectional observational, not case-control",36760344,10.1136/gpsych-2022-100893,NA,"Sun Y, Ju P, Xue T, Ali U, Cui D , Chen J",Alteration of faecal microbiota balance related to long-term deep meditation,General psychiatry,2023,"Healthy Lifestyle, Mental Health, Psychosomatic Medicine",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Exercise,EFO:0000483,Control group,Meditation group,Tibetan Buddhist monks that performed meditation practices of Samatha and Vipassana for at least 2 hours a day for 3 to 30 years.,19,37,3 months,16S,34,Illumina,LEfSe,0.05,FALSE,3.6,"age,alcohol drinking,diet,sex,smoking status",NA,NA,decreased,decreased,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:782/1/NA,Study 782,case-control,36869345,https://doi.org/10.1186/s40168-022-01447-0,https://microbiomejournal.biomedcentral.com/articles/10.1186/s40168-022-01447-0,"Li J, Jing Q, Li J, Hua M, Di L, Song C, Huang Y, Wang J, Chen C , Wu AR",Assessment of microbiota in the gut and upper respiratory tract associated with SARS-CoV-2 infection,Microbiome,2023,"COVID-19, Gut, Human microbiota, SARS-CoV-2, Upper respiratory tract",Experiment 1,China,Homo sapiens,Nasopharynx,UBERON:0001728,COVID-19,MONDO:0100096,samples from Healthy patients,Pharyngeal samples from COVID-19 patients,"The samples were collected from a cohort of patients diagnosed with COVID-19, classified into three severity degrees: mild, moderate, and severe illness, based on specific criteria.",39,174,NA,PCR,NA,Illumina,LEfSe,0.05,TRUE,NA,NA,NA,NA,decreased,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:782/2/NA,Study 782,case-control,36869345,https://doi.org/10.1186/s40168-022-01447-0,https://microbiomejournal.biomedcentral.com/articles/10.1186/s40168-022-01447-0,"Li J, Jing Q, Li J, Hua M, Di L, Song C, Huang Y, Wang J, Chen C , Wu AR",Assessment of microbiota in the gut and upper respiratory tract associated with SARS-CoV-2 infection,Microbiome,2023,"COVID-19, Gut, Human microbiota, SARS-CoV-2, Upper respiratory tract",Experiment 2,China,Homo sapiens,Sputum,UBERON:0007311,COVID-19,MONDO:0100096,samples from Healthy patients,Sputum samples from COVID-19 patients,"The samples were collected from a cohort of patients diagnosed with COVID-19, classified into three severity degrees: mild, moderate, and severe illness, based on specific criteria",15,235,Not Specified,PCR,NA,Illumina,LEfSe,0.05,TRUE,NA,NA,NA,NA,decreased,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:782/3/NA,Study 782,case-control,36869345,https://doi.org/10.1186/s40168-022-01447-0,https://microbiomejournal.biomedcentral.com/articles/10.1186/s40168-022-01447-0,"Li J, Jing Q, Li J, Hua M, Di L, Song C, Huang Y, Wang J, Chen C , Wu AR",Assessment of microbiota in the gut and upper respiratory tract associated with SARS-CoV-2 infection,Microbiome,2023,"COVID-19, Gut, Human microbiota, SARS-CoV-2, Upper respiratory tract",Experiment 3,China,Homo sapiens,Feces,UBERON:0001988,COVID-19,MONDO:0100096,samples from Healthy patients,Feces samples from COVID-19 patients,"The samples were collected from a cohort of patients diagnosed with COVID-19, classified into three severity degrees: mild, moderate, and severe illness, based on specific criteria.",40,112,N/A,PCR,NA,Illumina,LEfSe,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:784/1/NA,Study 784,time series / longitudinal observational,37438797,10.1186/s13073-023-01202-6,NA,"Nguyen LH, Okin D, Drew DA, Battista VM, Jesudasen SJ, Kuntz TM, Bhosle A, Thompson KN, Reinicke T, Lo CH, Woo JE, Caraballo A, Berra L, Vieira J, Huang CY, Das Adhikari U, Kim M, Sui HY, Magicheva-Gupta M, McIver L, Goldberg MB, Kwon DS, Huttenhower C, Chan AT , Lai PS",Metagenomic assessment of gut microbial communities and risk of severe COVID-19,Genome medicine,2023,"Machine learning, Microbiome, SARS-CoV-2",Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Gut microbiome measurement,EFO:0007874,Moderate COVID-19,Severe COVID-19,Hospitalized patients with severe Covid-19,48,79,NIL,PCR,NA,Illumina,Random Forest Analysis,0.05,TRUE,NA,NA,"age,antibiotic exposure,body mass index,comorbidity,ethnic group,race,sequence read depth",NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:785/1/NA,Study 785,"cross-sectional observational, not case-control",35692191,10.5217/ir.2021.00168,NA,"Shin SY, Kim Y, Kim WS, Moon JM, Lee KM, Jung SA, Park H, Huh EY, Kim BC, Lee SC , Choi CH",Compositional changes in fecal microbiota associated with clinical phenotypes and prognosis in Korean patients with inflammatory bowel disease,Intestinal research,2023,"Biomarkers, Inflammatory bowel disease, Microbiota, Phenotype, Prognosis",Experiment 1,South Korea,Homo sapiens,Feces,UBERON:0001988,Ulcerative colitis,EFO:0000729,Healthy control individual,Ulcerative colitis patient,Patients diagnosed with ulcerative colitis from 3 different academic hospitals in Korea.,100,70,"Patients who used drugs can affect intestinal microbial community, such as probiotics and antibiotics, within a month were excluded.",16S,4,Illumina,LEfSe,NA,FALSE,3,NA,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:785/2/NA,Study 785,"cross-sectional observational, not case-control",35692191,10.5217/ir.2021.00168,NA,"Shin SY, Kim Y, Kim WS, Moon JM, Lee KM, Jung SA, Park H, Huh EY, Kim BC, Lee SC , Choi CH",Compositional changes in fecal microbiota associated with clinical phenotypes and prognosis in Korean patients with inflammatory bowel disease,Intestinal research,2023,"Biomarkers, Inflammatory bowel disease, Microbiota, Phenotype, Prognosis",Experiment 2,South Korea,Homo sapiens,Feces,UBERON:0001988,Crohn's disease,EFO:0000384,Healthy control individual,Crohn's disease patient,Patients diagnosed with Crohn's disease from 3 different academic hospitals in Korea.,100,39,"Patients who used drugs can affect intestinal microbial community, such as probiotics and antibiotics, within a month were excluded.",16S,4,Illumina,LEfSe,NA,FALSE,3,NA,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:785/3/NA,Study 785,"cross-sectional observational, not case-control",35692191,10.5217/ir.2021.00168,NA,"Shin SY, Kim Y, Kim WS, Moon JM, Lee KM, Jung SA, Park H, Huh EY, Kim BC, Lee SC , Choi CH",Compositional changes in fecal microbiota associated with clinical phenotypes and prognosis in Korean patients with inflammatory bowel disease,Intestinal research,2023,"Biomarkers, Inflammatory bowel disease, Microbiota, Phenotype, Prognosis",Experiment 3,South Korea,Homo sapiens,Feces,UBERON:0001988,Ulcerative colitis,EFO:0000729,Patients with mild ulcerative colitis,Patients with moderate to severe ulcerative colitis,"patients diagnosed with ulcerative colitis (UC) from 3 different academic hospitals in Korea categorized as moderate to severe forms of UC. The severity of disease was assessed by the Mayo score for UC. Severity was estimated at the time of fecal sampling, and the average follow-up period was 8.0 ± 1.3 years.",37,18,"Patients who used drugs can affect intestinal microbial community, such as probiotics and antibiotics, within a month were excluded.",16S,4,Illumina,LEfSe,NA,FALSE,3,NA,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:785/4/NA,Study 785,"cross-sectional observational, not case-control",35692191,10.5217/ir.2021.00168,NA,"Shin SY, Kim Y, Kim WS, Moon JM, Lee KM, Jung SA, Park H, Huh EY, Kim BC, Lee SC , Choi CH",Compositional changes in fecal microbiota associated with clinical phenotypes and prognosis in Korean patients with inflammatory bowel disease,Intestinal research,2023,"Biomarkers, Inflammatory bowel disease, Microbiota, Phenotype, Prognosis",Experiment 4,South Korea,Homo sapiens,Feces,UBERON:0001988,Ulcerative colitis,EFO:0000729,Patients with remission ulcerative colitis (symptoms of UC are reduced or inapparent),Patients with moderate to severe ulcerative colitis,"Patients diagnosed with ulcerative colitis (UC) from 3 different academic hospitals in Korea categorized as moderate to severe forms of UC. The severity of disease was assessed by the Mayo score for UC. Severity was estimated at the time of fecal sampling, and the average follow-up period was 8.0 ± 1.3 years.",15,18,"Patients who used drugs can affect intestinal microbial community, such as probiotics and antibiotics, within a month were excluded.",16S,4,Illumina,LEfSe,NA,FALSE,3,NA,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:785/5/NA,Study 785,"cross-sectional observational, not case-control",35692191,10.5217/ir.2021.00168,NA,"Shin SY, Kim Y, Kim WS, Moon JM, Lee KM, Jung SA, Park H, Huh EY, Kim BC, Lee SC , Choi CH",Compositional changes in fecal microbiota associated with clinical phenotypes and prognosis in Korean patients with inflammatory bowel disease,Intestinal research,2023,"Biomarkers, Inflammatory bowel disease, Microbiota, Phenotype, Prognosis",Experiment 5,South Korea,Homo sapiens,Feces,UBERON:0001988,"Pancolitis,Distal colitis","EFO:0005623,EFO:0005626",patients with proctitis ulcerative colitis,patients with left sided or extensive ulcerative colitis,patients diagnosed with ulcerative colitis (UC) from 3 different academic hospitals in Korea defined as left sided (distal colitis) or extensive (pancolitis).,21,28,"Patients who used drugs can affect intestinal microbial community, such as probiotics and antibiotics, within a month were excluded.",16S,4,Illumina,LEfSe,NA,FALSE,3,NA,NA,NA,decreased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:785/6/NA,Study 785,"cross-sectional observational, not case-control",35692191,10.5217/ir.2021.00168,NA,"Shin SY, Kim Y, Kim WS, Moon JM, Lee KM, Jung SA, Park H, Huh EY, Kim BC, Lee SC , Choi CH",Compositional changes in fecal microbiota associated with clinical phenotypes and prognosis in Korean patients with inflammatory bowel disease,Intestinal research,2023,"Biomarkers, Inflammatory bowel disease, Microbiota, Phenotype, Prognosis",Experiment 6,South Korea,Homo sapiens,Feces,UBERON:0001988,Crohn's disease,EFO:0000384,patients with remission Crohn's disease,patients with active Crohn's disease,"Patients diagnosed with Crohn's disease (CD) from 3 different academic hospitals in Korea. The severity of disease was assessed by the Crohn’s Disease Activity Index CD. Active status including mild, moderate, severe forms of CD. Severity was estimated at the time of fecal sampling, and the average follow-up period was 8.0 ± 1.3 years.",24,15,"Patients who used drugs can affect intestinal microbial community, such as probiotics and antibiotics, within a month were excluded.",16S,4,Illumina,LEfSe,NA,FALSE,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:785/7/NA,Study 785,"cross-sectional observational, not case-control",35692191,10.5217/ir.2021.00168,NA,"Shin SY, Kim Y, Kim WS, Moon JM, Lee KM, Jung SA, Park H, Huh EY, Kim BC, Lee SC , Choi CH",Compositional changes in fecal microbiota associated with clinical phenotypes and prognosis in Korean patients with inflammatory bowel disease,Intestinal research,2023,"Biomarkers, Inflammatory bowel disease, Microbiota, Phenotype, Prognosis",Experiment 7,South Korea,Homo sapiens,Feces,UBERON:0001988,Ileocolitis,EFO:0005624,patients with small bowel Crohn's disease,patients with ileocolonic Crohn's disease,Patients diagnosed with ileocolonic Crohn's disease (CD) from 3 different academic hospitals in Korea.,17,17,"Patients who used drugs can affect intestinal microbial community, such as probiotics and antibiotics, within a month were excluded.",16S,4,Illumina,LEfSe,NA,FALSE,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:786/1/NA,Study 786,"cross-sectional observational, not case-control",37605183,https://doi.org/10.1186/s12902-023-01432-0,NA,"Gravdal K, Kirste KH, Grzelak K, Kirubakaran GT, Leissner P, Saliou A , Casèn C",Exploring the gut microbiota in patients with pre-diabetes and treatment naïve diabetes type 2 - a pilot study,BMC endocrine disorders,2023,"16S rRNA bacterial gene, Bacterial profiling, Microbiota signatures, Prediabetes, Type 2 diabetes",Experiment 1,Norway,Homo sapiens,Feces,UBERON:0001988,Type II diabetes mellitus,MONDO:0005148,Healthy controls - based on GA- map,Pre-Type 2 Diabetes,"Pre-Type 2 Diabetes patients are Individuals that have blood glucose levels higher than normal but below the threshold for T2D, are often overweight, and have an elevated risk of T2D and cardiovascular disease.",38,22,4 weeks,16S,3456789,Illumina,Mann-Whitney (Wilcoxon),0.01,TRUE,NA,NA,"age,body mass index,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:786/2/NA,Study 786,"cross-sectional observational, not case-control",37605183,https://doi.org/10.1186/s12902-023-01432-0,NA,"Gravdal K, Kirste KH, Grzelak K, Kirubakaran GT, Leissner P, Saliou A , Casèn C",Exploring the gut microbiota in patients with pre-diabetes and treatment naïve diabetes type 2 - a pilot study,BMC endocrine disorders,2023,"16S rRNA bacterial gene, Bacterial profiling, Microbiota signatures, Prediabetes, Type 2 diabetes",Experiment 2,Norway,Homo sapiens,Feces,UBERON:0001988,Type II diabetes mellitus,MONDO:0005148,Healthy Controls - based on LUMI -Seq data,Pre-Type 2 Diabetes,"Pre-Type 2 Diabetes patients are Individuals that have blood glucose levels higher than normal but below the threshold for T2D, are often overweight, and have an elevated risk of T2D and cardiovascular disease.",48,22,4 weeks,16S,123456789,Illumina,DESeq2,0.05,TRUE,NA,NA,"age,body mass index,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:786/3/NA,Study 786,"cross-sectional observational, not case-control",37605183,https://doi.org/10.1186/s12902-023-01432-0,NA,"Gravdal K, Kirste KH, Grzelak K, Kirubakaran GT, Leissner P, Saliou A , Casèn C",Exploring the gut microbiota in patients with pre-diabetes and treatment naïve diabetes type 2 - a pilot study,BMC endocrine disorders,2023,"16S rRNA bacterial gene, Bacterial profiling, Microbiota signatures, Prediabetes, Type 2 diabetes",Experiment 3,Norway,Homo sapiens,Feces,UBERON:0001988,Type II diabetes mellitus,MONDO:0005148,Healthy Controls - based on LUMI -Seq data,Type 2 Diabetes - T2D,Patients with  Type 2 diabetes (T2D),48,16,4 weeks,16S,123456789,Illumina,DESeq2,0.05,TRUE,NA,NA,"age,body mass index,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:786/4/NA,Study 786,"cross-sectional observational, not case-control",37605183,https://doi.org/10.1186/s12902-023-01432-0,NA,"Gravdal K, Kirste KH, Grzelak K, Kirubakaran GT, Leissner P, Saliou A , Casèn C",Exploring the gut microbiota in patients with pre-diabetes and treatment naïve diabetes type 2 - a pilot study,BMC endocrine disorders,2023,"16S rRNA bacterial gene, Bacterial profiling, Microbiota signatures, Prediabetes, Type 2 diabetes",Experiment 4,Norway,Homo sapiens,Feces,UBERON:0001988,Type II diabetes mellitus,MONDO:0005148,Pre- Type 2 Diabetes individuals,Type 2 Diabetes - T2D Patients,Patients with Type 2 Diabetes,22,16,4 weeks,16S,123456789,Illumina,DESeq2,0.05,TRUE,NA,NA,"age,body mass index,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:787/1/NA,Study 787,"cross-sectional observational, not case-control",35305613,10.1186/s12894-022-00990-0,NA,"Li K, Chen C, Zeng J, Wen Y, Chen W, Zhao J , Wu P",Interplay between bladder microbiota and overactive bladder symptom severity: a cross-sectional study,BMC urology,2022,"Bladder microbiota, Overactive bladder, Severity of OAB symptom, Urinary microbiome",Experiment 1,China,Homo sapiens,Urinary bladder,UBERON:0001255,Overactive bladder,EFO:1000781,Mild Overactive Bladder,Moderate/Severe Overactive Bladder,Adult patients with Overactive Bladder Symptom Score greater than five (OABSS > 5).,17,53,4 weeks,16S,34,Illumina,LEfSe,0.05,NA,2,"age,body mass index,hypertension,race",NA,unchanged,increased,increased,increased,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:788/1/NA,Study 788,time series / longitudinal observational,32630754,https://doi.org/10.3390/ani10071127,NA,"Kim DH, Kim MH, Kim SB, Son JK, Lee JH, Joo SS, Gu BH, Park T, Park BY , Kim ET",Differential Dynamics of the Ruminal Microbiome of Jersey Cows in a Heat Stress Environment,Animals : an open access journal from MDPI,2020,"Holstein, Jersey, KEGG pathways, heat stress, ruminal microbiome",Experiment 1,Republic of Korea,Bos taurus,Rumen,UBERON:0007365,Response to heat,GO:0009408,Holstein cows under normal condition,Holstein cows under heat stress condition,"Holstein cows under heat stress condition. The measurement of the respiration rate and rectal temperature in May was considered as the normal condition, while  measurement of the respiration rate and rectal temperature in August was considered the heat stress condition.",8,8,none,16S,34,Illumina,LEfSe,0.05,FALSE,3,NA,NA,NA,increased,NA,increased,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:788/2/NA,Study 788,time series / longitudinal observational,32630754,https://doi.org/10.3390/ani10071127,NA,"Kim DH, Kim MH, Kim SB, Son JK, Lee JH, Joo SS, Gu BH, Park T, Park BY , Kim ET",Differential Dynamics of the Ruminal Microbiome of Jersey Cows in a Heat Stress Environment,Animals : an open access journal from MDPI,2020,"Holstein, Jersey, KEGG pathways, heat stress, ruminal microbiome",Experiment 2,Republic of Korea,Bos taurus,Rumen,UBERON:0007365,Ruminative stress response,EFO:0009857,Jersey cows under normal condition,Jersey cows under heat stress condition,"Jersey cows under heat stress condition. The measurement of the respiration rate and rectal temperature in May was considered as the normal condition, while  measurement of the respiration rate and rectal temperature in August was considered the heat stress condition.",8,8,none,16S,34,Illumina,LEfSe,0.05,FALSE,3,NA,NA,NA,increased,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:789/1/NA,Study 789,"cross-sectional observational, not case-control",35642922,10.1128/msystems.01489-21,NA,"Hoskinson C, Zheng K, Gabel J, Kump A, German R, Podicheti R, Marino N , Stiemsma LT",Composition and Functional Potential of the Human Mammary Microbiota Prior to and Following Breast Tumor Diagnosis,mSystems,2022,"16S, breast cancer, breast tissue, functional metagenome, microbiome, transcriptome",Experiment 1,United States of America,Homo sapiens,Breast,UBERON:0000310,Breast cancer,MONDO:0007254,Healthy (H),Prediagnostic (PD),Samples donated prior to breast cancer diagnosis,49,15,NA,16S,34,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:789/2/NA,Study 789,"cross-sectional observational, not case-control",35642922,10.1128/msystems.01489-21,NA,"Hoskinson C, Zheng K, Gabel J, Kump A, German R, Podicheti R, Marino N , Stiemsma LT",Composition and Functional Potential of the Human Mammary Microbiota Prior to and Following Breast Tumor Diagnosis,mSystems,2022,"16S, breast cancer, breast tissue, functional metagenome, microbiome, transcriptome",Experiment 2,United States of America,Homo sapiens,Breast,UBERON:0000310,Breast cancer,MONDO:0007254,Healthy (H),Adjacent normal (AN),samples donated after breast cancer diagnosis (AN),49,49,NA,16S,34,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:789/3/NA,Study 789,"cross-sectional observational, not case-control",35642922,10.1128/msystems.01489-21,NA,"Hoskinson C, Zheng K, Gabel J, Kump A, German R, Podicheti R, Marino N , Stiemsma LT",Composition and Functional Potential of the Human Mammary Microbiota Prior to and Following Breast Tumor Diagnosis,mSystems,2022,"16S, breast cancer, breast tissue, functional metagenome, microbiome, transcriptome",Experiment 3,United States of America,Homo sapiens,Breast,UBERON:0000310,Breast cancer,MONDO:0007254,Healthy (H),Tumor (T),Samples donated after breast cancer diagnosis (tumor),49,46,NA,16S,34,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:789/4/NA,Study 789,"cross-sectional observational, not case-control",35642922,10.1128/msystems.01489-21,NA,"Hoskinson C, Zheng K, Gabel J, Kump A, German R, Podicheti R, Marino N , Stiemsma LT",Composition and Functional Potential of the Human Mammary Microbiota Prior to and Following Breast Tumor Diagnosis,mSystems,2022,"16S, breast cancer, breast tissue, functional metagenome, microbiome, transcriptome",Experiment 4,United States of America,Homo sapiens,Breast,UBERON:0000310,Breast cancer,MONDO:0007254,Prediagnostic (PD),Tumor (T),Samples donated after breast cancer diagnosis (tumor),15,46,NA,16S,34,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,decreased,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:789/5/NA,Study 789,"cross-sectional observational, not case-control",35642922,10.1128/msystems.01489-21,NA,"Hoskinson C, Zheng K, Gabel J, Kump A, German R, Podicheti R, Marino N , Stiemsma LT",Composition and Functional Potential of the Human Mammary Microbiota Prior to and Following Breast Tumor Diagnosis,mSystems,2022,"16S, breast cancer, breast tissue, functional metagenome, microbiome, transcriptome",Experiment 5,United States of America,Homo sapiens,Breast,UBERON:0000310,Breast cancer,MONDO:0007254,Adjacent Normal (AN),Tumor (T),Samples donated after breast cancer diagnosis (tumor),49,46,NA,16S,34,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,decreased,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:790/1/NA,Study 790,case-control,35888992,10.3390/microorganisms10071273,NA,"Olbjørn C, Småstuen MC , Moen AEF","Targeted Analysis of the Gut Microbiome for Diagnosis, Prognosis and Treatment Individualization in Pediatric Inflammatory Bowel Disease",Microorganisms,2022,"IBD, biologic therapy, biomarker, microbiota, pediatric, prognosis",Experiment 1,Norway,Homo sapiens,Feces,UBERON:0001988,Inflammatory bowel disease,EFO:0003767,Healthy controls,Inflammatory bowel disease patients,Patients under 18 years old diagnosed with inflammatory bowel disease (Crohn's Disease or ulcerative colitis) from the catchment areas of two university hospitals in three population-based prospective epidemiological studies of treatment-naïve pediatric IBD in South-Eastern Norway between 2005-2015.,75,107,Six Months,PCR,NA,RT-qPCR,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:790/2/NA,Study 790,case-control,35888992,10.3390/microorganisms10071273,NA,"Olbjørn C, Småstuen MC , Moen AEF","Targeted Analysis of the Gut Microbiome for Diagnosis, Prognosis and Treatment Individualization in Pediatric Inflammatory Bowel Disease",Microorganisms,2022,"IBD, biologic therapy, biomarker, microbiota, pediatric, prognosis",Experiment 2,Norway,Homo sapiens,Feces,UBERON:0001988,Inflammatory bowel disease,EFO:0003767,Healthy children,Non-inflammatory bowel disease symptomatic controls,patients under 18 years presented with symptoms of inflammatory bowel disease (Crohn's Disease or ulcerative colitis) but did not meet the criteria for IBD and who had a  macroscopically and histologically normal mucosa and normal MRI examination from the catchment areas of two university hospitals in three population-based prospective epidemiological studies of treatment-naïve pediatric IBD in South-Eastern Norway between 2005-2015.,75,50,antibiotics use within the last six months of study for healthy controls (group 0),PCR,NA,RT-qPCR,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:790/3/NA,Study 790,case-control,35888992,10.3390/microorganisms10071273,NA,"Olbjørn C, Småstuen MC , Moen AEF","Targeted Analysis of the Gut Microbiome for Diagnosis, Prognosis and Treatment Individualization in Pediatric Inflammatory Bowel Disease",Microorganisms,2022,"IBD, biologic therapy, biomarker, microbiota, pediatric, prognosis",Experiment 3,Norway,Homo sapiens,Feces,UBERON:0001988,Inflammatory bowel disease,EFO:0003767,non-inflammatory bowel disease symptomatic controls,inflammatory bowel disease patients,patients under 18 diagnosed with inflammatory bowel disease (Crohn's Disease or ulcerative colitis) from the catchment areas of two university hospitals in three population-based prospective epidemiological studies of treatment-naïve pediatric IBD in South-Eastern Norway between 2005-2015.,50,110,antibiotics use within the last six months of study for healthy controls (group 0),PCR,NA,RT-qPCR,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:790/4/NA,Study 790,case-control,35888992,10.3390/microorganisms10071273,NA,"Olbjørn C, Småstuen MC , Moen AEF","Targeted Analysis of the Gut Microbiome for Diagnosis, Prognosis and Treatment Individualization in Pediatric Inflammatory Bowel Disease",Microorganisms,2022,"IBD, biologic therapy, biomarker, microbiota, pediatric, prognosis",Experiment 4,Norway,Homo sapiens,Feces,UBERON:0001988,Phenotype,EFO:0000651,Crohn's Disease patients with inflammatory phenotypes,Crohn's Disease patients with stricturing and/or penetrating phenotypes,patients under 18 diagnosed with Crohn's Disease with stricturing and/or penetrating phenotypes,53,27,NA,PCR,NA,RT-qPCR,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:790/5/NA,Study 790,case-control,35888992,10.3390/microorganisms10071273,NA,"Olbjørn C, Småstuen MC , Moen AEF","Targeted Analysis of the Gut Microbiome for Diagnosis, Prognosis and Treatment Individualization in Pediatric Inflammatory Bowel Disease",Microorganisms,2022,"IBD, biologic therapy, biomarker, microbiota, pediatric, prognosis",Experiment 5,Norway,Homo sapiens,Feces,UBERON:0001988,Treatment,EFO:0000727,Inflammatory bowel disease patients treated with conventional therapy,Inflammatory bowel disease patients treated with biological therapy,58% of inflammatory bowel disease patients were later treated with biologic therapy due to failure to induce remission with conventional treatments or relapse after primary induction.,46,64,NA,PCR,NA,RT-qPCR,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:790/6/NA,Study 790,case-control,35888992,10.3390/microorganisms10071273,NA,"Olbjørn C, Småstuen MC , Moen AEF","Targeted Analysis of the Gut Microbiome for Diagnosis, Prognosis and Treatment Individualization in Pediatric Inflammatory Bowel Disease",Microorganisms,2022,"IBD, biologic therapy, biomarker, microbiota, pediatric, prognosis",Experiment 6,Norway,Homo sapiens,Feces,UBERON:0001988,Increased inflammatory response,HP:0012649,Inflammatory bowel disease patients with fecal calprotectin levels < 1000 mg/kg,Inflammatory bowel disease patients with fecal calprotectin levels > 1000 mg/kg,Inflammatory bowel disease patients with higher fecal protectin levels (31 with CD and 12 with UC had above 1000 mg/kg).,67,43,NA,PCR,NA,RT-qPCR,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:790/7/NA,Study 790,case-control,35888992,10.3390/microorganisms10071273,NA,"Olbjørn C, Småstuen MC , Moen AEF","Targeted Analysis of the Gut Microbiome for Diagnosis, Prognosis and Treatment Individualization in Pediatric Inflammatory Bowel Disease",Microorganisms,2022,"IBD, biologic therapy, biomarker, microbiota, pediatric, prognosis",Experiment 7,Norway,Homo sapiens,Feces,UBERON:0001988,Increased inflammatory response,HP:0012649,Inflammatory bowel disease patients receiving one biologic or conventional therapy,Inflammatory bowel disease patients receiving second class of biologic drug,A subset of the IBD patients receiving biologic therapy needed further treatment escalation to a second class of biologics.,88,22,antibiotics use within the last six months of study for healthy controls (group 0),PCR,NA,RT-qPCR,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:791/1/NA,Study 791,prospective cohort,33184260,10.1038/s41522-020-00162-8,NA,"Feehily C, Crosby D, Walsh CJ, Lawton EM, Higgins S, McAuliffe FM , Cotter PD",Shotgun sequencing of the vaginal microbiome reveals both a species and functional potential signature of preterm birth,NPJ biofilms and microbiomes,2020,NA,Experiment 1,Ireland,Homo sapiens,"Posterior fornix of vagina,External cervical os","UBERON:0016486,UBERON:0013760",Spontaneous preterm birth,EFO:0006917,Full-term Birth,Preterm Birth,Pregnant women who delivered before 37 weeks’ gestation.,41,8,Women currently on antibiotic treatment.,WMS,NA,Illumina,"T-Test,Linear Regression",0.25,TRUE,NA,NA,NA,NA,unchanged,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:791/2/NA,Study 791,prospective cohort,33184260,10.1038/s41522-020-00162-8,NA,"Feehily C, Crosby D, Walsh CJ, Lawton EM, Higgins S, McAuliffe FM , Cotter PD",Shotgun sequencing of the vaginal microbiome reveals both a species and functional potential signature of preterm birth,NPJ biofilms and microbiomes,2020,NA,Experiment 2,Ireland,Homo sapiens,"Posterior fornix of vagina,External cervical os","UBERON:0016486,UBERON:0013760",Spontaneous preterm birth,EFO:0006917,Low-risk controls,Risk Group,Pregnant women with either a history of previous spontaneous preterm birth (risk_PTB) or women with risk factors for preterm birth but who delivered full term (risk_FTB),14,35,Women currently on antibiotic treatment.,WMS,NA,Illumina,Linear Regression,0.25,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:791/3/NA,Study 791,prospective cohort,33184260,10.1038/s41522-020-00162-8,NA,"Feehily C, Crosby D, Walsh CJ, Lawton EM, Higgins S, McAuliffe FM , Cotter PD",Shotgun sequencing of the vaginal microbiome reveals both a species and functional potential signature of preterm birth,NPJ biofilms and microbiomes,2020,NA,Experiment 3,Ireland,Homo sapiens,"Posterior fornix of vagina,External cervical os","UBERON:0016486,UBERON:0013760",Spontaneous preterm birth,EFO:0006917,No Previous Preterm birth,Previous Preterm birth,Pregnant women with a history of previous spontaneous preterm birth (PTB),20,29,Women currently on antibiotic treatment.,WMS,NA,Illumina,Linear Regression,0.25,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:792/1/NA,Study 792,"cross-sectional observational, not case-control",30631088,http://dx.doi.org/10.1038/s41598-018-37208-z,NA,"Jana Mittelstrass, Joy Bergelson, Mathew W. Horton",Characterizing both bacteria and fungi improves understanding of the Arabidopsis root microbiome,Scientific reports,2019,"Arabidopsis thaliana, bacteria, fungi, microbiome, roots, leaves, field experiment",Experiment 1,United States of America,Arabidopsis thaliana,Accessory nerve root,UBERON:0014615,Root,PO:0009005,Control group (Leaves),Test group (Roots),"The leaf microbiome, representing the microbial communities associated with the leaves of the Arabidopsis plants.",4,4,NIL,16S,567,Roche454,Linear Regression,0.1,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:793/1/NA,Study 793,"cross-sectional observational, not case-control",37604954,https://doi.org/10.1038/s41598-023-40872-5,NA,"Fongang B, Satizabal C, Kautz TF, Wadop YN, Muhammad JAS, Vasquez E, Mathews J, Gireud-Goss M, Saklad AR, Himali J, Beiser A, Cavazos JE, Mahaney MC, Maestre G, DeCarli C, Shipp EL, Vasan RS , Seshadri S",Cerebral small vessel disease burden is associated with decreased abundance of gut Barnesiella intestinihominis bacterium in the Framingham Heart Study,Scientific reports,2023,NA,Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Cerebral small vessel disease,EFO:0008493,Lower burden (Healthy),High burden (Unhealthy),Participants with Cerebral small vessel disease that were tested using the PSMD marker,674,108,unspecified,16S,4,Illumina,MaAsLin2,0.05,TRUE,NA,"age,body mass index,education level,sex,time",NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:793/2/NA,Study 793,"cross-sectional observational, not case-control",37604954,https://doi.org/10.1038/s41598-023-40872-5,NA,"Fongang B, Satizabal C, Kautz TF, Wadop YN, Muhammad JAS, Vasquez E, Mathews J, Gireud-Goss M, Saklad AR, Himali J, Beiser A, Cavazos JE, Mahaney MC, Maestre G, DeCarli C, Shipp EL, Vasan RS , Seshadri S",Cerebral small vessel disease burden is associated with decreased abundance of gut Barnesiella intestinihominis bacterium in the Framingham Heart Study,Scientific reports,2023,NA,Experiment 2,United States of America,Homo sapiens,Feces,UBERON:0001988,Cerebral small vessel disease,EFO:0008493,Lower burden (Healthy),High burden (Unhealthy),Participants with Cerebral small vessel disease that were tested using the WMH marker,832,136,unspecified,16S,4,Illumina,MaAsLin2,0.05,TRUE,NA,"age,body mass index,education level,sex,time",NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:793/3/NA,Study 793,"cross-sectional observational, not case-control",37604954,https://doi.org/10.1038/s41598-023-40872-5,NA,"Fongang B, Satizabal C, Kautz TF, Wadop YN, Muhammad JAS, Vasquez E, Mathews J, Gireud-Goss M, Saklad AR, Himali J, Beiser A, Cavazos JE, Mahaney MC, Maestre G, DeCarli C, Shipp EL, Vasan RS , Seshadri S",Cerebral small vessel disease burden is associated with decreased abundance of gut Barnesiella intestinihominis bacterium in the Framingham Heart Study,Scientific reports,2023,NA,Experiment 3,United States of America,Homo sapiens,Feces,UBERON:0001988,Cerebral small vessel disease,EFO:0008493,Lower burden (Healthy),High burden (Unhealthy),Participants with Cerebral small vessel disease that were tested using the EF marker,822,121,unspecified,16S,4,Illumina,MaAsLin2,0.05,TRUE,NA,"age,body mass index,education level,sex,time",NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:794/1/NA,Study 794,case-control,36389150,10.3389/fcimb.2022.1036946,NA,"Xiong H, Wang J, Chang Z, Hu H, Yuan Z, Zhu Y, Hu Z, Wang C, Liu Y, Wang Y, Wang G , Tang Q",Gut microbiota display alternative profiles in patients with early-onset colorectal cancer,Frontiers in cellular and infection microbiology,2022,"16S rRNA, colorectal cancer, early onset, functional annotation, gut microbiota",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,Healthy controls,EOCRC (Early-onset Colorectal cancer) patients,Colorectal cancer diagnosed before the age of 50 years.,31,24,"3 months, including probiotics and corticosteroids use.",16S,34,Illumina,"LEfSe,Kruskall-Wallis",0.05,NA,3.5,"age,alcohol drinking,body mass index,sex",NA,NA,decreased,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:794/3/NA,Study 794,case-control,36389150,10.3389/fcimb.2022.1036946,NA,"Xiong H, Wang J, Chang Z, Hu H, Yuan Z, Zhu Y, Hu Z, Wang C, Liu Y, Wang Y, Wang G , Tang Q",Gut microbiota display alternative profiles in patients with early-onset colorectal cancer,Frontiers in cellular and infection microbiology,2022,"16S rRNA, colorectal cancer, early onset, functional annotation, gut microbiota",Experiment 3,China,Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,Healthy controls,LOCRC (Late onset colorectal cancer),Late onset colorectal cancer (diagnosed >=50 years of age),31,43,"3 months, including probiotics and corticosteroids use.",16S,34,Illumina,"LEfSe,Kruskall-Wallis",0.05,NA,3.5,"age,alcohol drinking,body mass index,sex",NA,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:795/1/NA,Study 795,case-control,37658443,https://doi.org/10.1186/s40168-023-01640-9,NA,"Paulo AC, Lança J, Almeida ST, Hilty M , Sá-Leão R","The upper respiratory tract microbiota of healthy adults is affected by Streptococcus pneumoniae carriage, smoking habits, and contact with children",Microbiome,2023,"Healthy adults, Microbiota, Nasopharynx, Oropharynx, Streptococcus pneumoniae",Experiment 1,Portugal,Homo sapiens,"Nasopharyngeal gland,Saliva","UBERON:0008310,UBERON:0001836",Streptococcus pneumoniae,NCBITAXON:1313,Pneumococcal non-carriers.,Pneumococcal carriers,Individuals who carry pneumococci in the nasopharynx,47,12,1 month,16S,4,MGISEQ-2000,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,decreased,NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:795/2/NA,Study 795,case-control,37658443,https://doi.org/10.1186/s40168-023-01640-9,NA,"Paulo AC, Lança J, Almeida ST, Hilty M , Sá-Leão R","The upper respiratory tract microbiota of healthy adults is affected by Streptococcus pneumoniae carriage, smoking habits, and contact with children",Microbiome,2023,"Healthy adults, Microbiota, Nasopharynx, Oropharynx, Streptococcus pneumoniae",Experiment 2,Portugal,Homo sapiens,"Nasopharyngeal gland,Saliva","UBERON:0008310,UBERON:0001836",Streptococcus pneumoniae,NCBITAXON:1313,non- smokers,Smokers,The nasopharyngeal area of smokers,20,5,1 month,16S,4,MGISEQ-2000,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:795/3/NA,Study 795,case-control,37658443,https://doi.org/10.1186/s40168-023-01640-9,NA,"Paulo AC, Lança J, Almeida ST, Hilty M , Sá-Leão R","The upper respiratory tract microbiota of healthy adults is affected by Streptococcus pneumoniae carriage, smoking habits, and contact with children",Microbiome,2023,"Healthy adults, Microbiota, Nasopharynx, Oropharynx, Streptococcus pneumoniae",Experiment 3,Portugal,Homo sapiens,"Nasopharyngeal gland,Saliva","UBERON:0008310,UBERON:0001836",Streptococcus pneumoniae,NCBITAXON:1313,No contact with children,Contact with children,The nasopharyngeal microbiota of individuals that  regular contact with children.,22,10,1 month,16S,4,MGISEQ-2000,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:795/4/NA,Study 795,case-control,37658443,https://doi.org/10.1186/s40168-023-01640-9,NA,"Paulo AC, Lança J, Almeida ST, Hilty M , Sá-Leão R","The upper respiratory tract microbiota of healthy adults is affected by Streptococcus pneumoniae carriage, smoking habits, and contact with children",Microbiome,2023,"Healthy adults, Microbiota, Nasopharynx, Oropharynx, Streptococcus pneumoniae",Experiment 4,Portugal,Homo sapiens,"Oropharyngeal gland,Saliva","UBERON:0003410,UBERON:0001836",Streptococcus pneumoniae,NCBITAXON:1313,Pneumococcal non-carriers.,Pneumococcal carriers,Oropharyngeal microbiota of pneumococcal carriers,47,12,1 month,16S,4,MGISEQ-2000,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,decreased,NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:795/5/NA,Study 795,case-control,37658443,https://doi.org/10.1186/s40168-023-01640-9,NA,"Paulo AC, Lança J, Almeida ST, Hilty M , Sá-Leão R","The upper respiratory tract microbiota of healthy adults is affected by Streptococcus pneumoniae carriage, smoking habits, and contact with children",Microbiome,2023,"Healthy adults, Microbiota, Nasopharynx, Oropharynx, Streptococcus pneumoniae",Experiment 5,Portugal,Homo sapiens,"Oropharyngeal gland,Saliva","UBERON:0003410,UBERON:0001836",Streptococcus pneumoniae,NCBITAXON:1313,Non- smokers,Smokers,Oropharyngeal microbiota of smokers,20,5,1 month,16S,4,MGISEQ-2000,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:795/6/NA,Study 795,case-control,37658443,https://doi.org/10.1186/s40168-023-01640-9,NA,"Paulo AC, Lança J, Almeida ST, Hilty M , Sá-Leão R","The upper respiratory tract microbiota of healthy adults is affected by Streptococcus pneumoniae carriage, smoking habits, and contact with children",Microbiome,2023,"Healthy adults, Microbiota, Nasopharynx, Oropharynx, Streptococcus pneumoniae",Experiment 6,Portugal,Homo sapiens,"Oropharyngeal gland,Saliva","UBERON:0003410,UBERON:0001836",Streptococcus pneumoniae,NCBITAXON:1313,No Contact with Children,Contact with children,Oropharyngeal microbiota of individuals that have regular contact with children.,22,10,1 month,16S,4,MGISEQ-2000,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:796/1/NA,Study 796,"cross-sectional observational, not case-control",35083314,10.1016/j.celrep.2021.109765,https://www.sciencedirect.com/science/article/pii/S2211124721012195,"Leite G, Pimentel M, Barlow GM , Mathur R",The small bowel microbiome changes significantly with age and aspects of the ageing process,"Microbial cell (Graz, Austria)",2022,"age, aging, coliforms, concomitant diseases, medication use, proteobacteria, small intestinal microbiome",Experiment 1,United States of America,Homo sapiens,Small intestine,UBERON:0002108,Aging,GO:0007568,Group 1- youngest age group (18 to 35 years old),Group 4- oldest age group (66 to 80 years old. elderly people),This is the oldest age advanced group from the study,32,82,None.,16S,34,Illumina,PLS-DA (Partial least square discriminant analysis),1e-4,TRUE,NA,NA,NA,NA,decreased,NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:796/2/NA,Study 796,"cross-sectional observational, not case-control",35083314,10.1016/j.celrep.2021.109765,https://www.sciencedirect.com/science/article/pii/S2211124721012195,"Leite G, Pimentel M, Barlow GM , Mathur R",The small bowel microbiome changes significantly with age and aspects of the ageing process,"Microbial cell (Graz, Austria)",2022,"age, aging, coliforms, concomitant diseases, medication use, proteobacteria, small intestinal microbiome",Experiment 2,United States of America,Homo sapiens,Small intestine,UBERON:0002108,Aging,GO:0007568,Group 1- youngest age group (18 to 35 years old),"Group 2, 3 and 4 - older age groups (36 to 50 years old; 51 to 65 years old and 66 to 80 years old.)","These are the remaining 3 groups of subjects grouped according to advancing chronological age (N= 41, 36 to 50 years old; N= 96, 51 to 65 years old and N= 82, 66 to 80 years old).",32,219,None.,16S,34,Illumina,Linear Regression,0.05,FALSE,NA,NA,NA,NA,decreased,NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:797/1/NA,Study 797,prospective cohort,37091735,10.1099/acmi.0.000497.v3,NA,"Campos M, Cickovski T, Fernandez M, Jaric M, Wanner A, Holt G, Donna E, Mendes E, Silva-Herzog E, Schneper L, Segal J, Amador DM, Riveros JD, Aguiar-Pulido V, Banerjee S, Salathe M, Mathee K , Narasimhan G",Lower respiratory tract microbiome composition and community interactions in smokers,Access microbiology,2023,"clustering, co-occurrence networks, lower respiratory tract (LRT), microbiome, smoking",Experiment 1,United States of America,Homo sapiens,Lung,UBERON:0002048,Smoking status measurement,EFO:0006527,Never smokers,Active smokers,Participants who have smoked at least one cigarette within 3days of enrolment,9,22,use of antibiotics within 12weeks prior to study,16S,678,Roche454,DESeq2,0.05,TRUE,NA,NA,NA,NA,NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:797/2/NA,Study 797,prospective cohort,37091735,10.1099/acmi.0.000497.v3,NA,"Campos M, Cickovski T, Fernandez M, Jaric M, Wanner A, Holt G, Donna E, Mendes E, Silva-Herzog E, Schneper L, Segal J, Amador DM, Riveros JD, Aguiar-Pulido V, Banerjee S, Salathe M, Mathee K , Narasimhan G",Lower respiratory tract microbiome composition and community interactions in smokers,Access microbiology,2023,"clustering, co-occurrence networks, lower respiratory tract (LRT), microbiome, smoking",Experiment 2,United States of America,Homo sapiens,Lung,UBERON:0002048,Smoking status measurement,EFO:0006527,Never smokers,former smokers,subjects that are abstinent of tobacco use for at least 12months,9,24,use of antibiotics within 12weeks prior to study,16S,678,Roche454,DESeq2,0.05,TRUE,NA,NA,NA,NA,NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:797/3/NA,Study 797,prospective cohort,37091735,10.1099/acmi.0.000497.v3,NA,"Campos M, Cickovski T, Fernandez M, Jaric M, Wanner A, Holt G, Donna E, Mendes E, Silva-Herzog E, Schneper L, Segal J, Amador DM, Riveros JD, Aguiar-Pulido V, Banerjee S, Salathe M, Mathee K , Narasimhan G",Lower respiratory tract microbiome composition and community interactions in smokers,Access microbiology,2023,"clustering, co-occurrence networks, lower respiratory tract (LRT), microbiome, smoking",Experiment 3,United States of America,Homo sapiens,Lung,UBERON:0002048,Smoking status measurement,EFO:0006527,former smokers,active smokers,Participants who have smoked at least one cigarette within 3days of enrolment,24,22,use of antibiotics within 12weeks prior to study,16S,678,Roche454,DESeq2,0.05,TRUE,NA,NA,NA,NA,NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:797/4/NA,Study 797,prospective cohort,37091735,10.1099/acmi.0.000497.v3,NA,"Campos M, Cickovski T, Fernandez M, Jaric M, Wanner A, Holt G, Donna E, Mendes E, Silva-Herzog E, Schneper L, Segal J, Amador DM, Riveros JD, Aguiar-Pulido V, Banerjee S, Salathe M, Mathee K , Narasimhan G",Lower respiratory tract microbiome composition and community interactions in smokers,Access microbiology,2023,"clustering, co-occurrence networks, lower respiratory tract (LRT), microbiome, smoking",Experiment 4,United States of America,Homo sapiens,Lung,UBERON:0002048,Smoking status measurement,EFO:0006527,Active smokers & former smokers,Never smokers,Participants who have never smoked,46,9,use of antibiotics within 12weeks prior to study,16S,678,Roche454,LEfSe,0.05,TRUE,2.5,NA,NA,NA,NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:797/5/NA,Study 797,prospective cohort,37091735,10.1099/acmi.0.000497.v3,NA,"Campos M, Cickovski T, Fernandez M, Jaric M, Wanner A, Holt G, Donna E, Mendes E, Silva-Herzog E, Schneper L, Segal J, Amador DM, Riveros JD, Aguiar-Pulido V, Banerjee S, Salathe M, Mathee K , Narasimhan G",Lower respiratory tract microbiome composition and community interactions in smokers,Access microbiology,2023,"clustering, co-occurrence networks, lower respiratory tract (LRT), microbiome, smoking",Experiment 5,United States of America,Homo sapiens,Lung,UBERON:0002048,Smoking status measurement,EFO:0006527,never smokers & former smokers,Active smokers,Participants who have smoked at least one cigarette within 3days of enrolment,33,22,use of antibiotics within 12weeks prior to study,16S,678,Roche454,DESeq2,0.05,TRUE,NA,NA,NA,NA,NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:797/6/NA,Study 797,prospective cohort,37091735,10.1099/acmi.0.000497.v3,NA,"Campos M, Cickovski T, Fernandez M, Jaric M, Wanner A, Holt G, Donna E, Mendes E, Silva-Herzog E, Schneper L, Segal J, Amador DM, Riveros JD, Aguiar-Pulido V, Banerjee S, Salathe M, Mathee K , Narasimhan G",Lower respiratory tract microbiome composition and community interactions in smokers,Access microbiology,2023,"clustering, co-occurrence networks, lower respiratory tract (LRT), microbiome, smoking",Experiment 6,United States of America,Homo sapiens,Lung,UBERON:0002048,Smoking status measurement,EFO:0006527,Active smokers & former smokers,Never smokers,Participants who have smoked at least one cigarette within 3days of enrolment,46,9,use of antibiotics within 12weeks prior to study,16S,678,Roche454,DESeq2,0.05,TRUE,NA,NA,NA,NA,NA,increased,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:797/7/NA,Study 797,prospective cohort,37091735,10.1099/acmi.0.000497.v3,NA,"Campos M, Cickovski T, Fernandez M, Jaric M, Wanner A, Holt G, Donna E, Mendes E, Silva-Herzog E, Schneper L, Segal J, Amador DM, Riveros JD, Aguiar-Pulido V, Banerjee S, Salathe M, Mathee K , Narasimhan G",Lower respiratory tract microbiome composition and community interactions in smokers,Access microbiology,2023,"clustering, co-occurrence networks, lower respiratory tract (LRT), microbiome, smoking",Experiment 7,United States of America,Homo sapiens,Lung,UBERON:0002048,Smoking status measurement,EFO:0006527,Active smokers & former smokers,never smokers,Participants who have never smoked,46,9,use of antibiotics within 12weeks prior to study,16S,678,Roche454,DESeq2,0.05,TRUE,NA,NA,NA,NA,NA,increased,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:798/1/NA,Study 798,case-control,35722326,10.3389/fmicb.2022.888681,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9200618/,"Huang L, Li X, Zheng B, Li P, Wei D, Huang C, Sun L , Li H",Differential Urinary Microbiota Composition Between Women With and Without Recurrent Urinary Tract Infection,Frontiers in microbiology,2022,"16S rRNA, next generation sequencing (NGS), recurrent urinary tract infection (RUTI), standard urine culture, urinary microbiota",Experiment 1,China,Homo sapiens,Urine,UBERON:0001088,Urinary tract infection,EFO:0003103,Asymptomatic controls,Recurrent Urinary Tract Infection (RUTI) patients,Women with clinically diagnosed RUTI with negative Standard Urine Cultures (SUCs),44,67,Patients with antibiotic treatment in the previous 48 hours (2 days) and their symptoms relieved.,16S,34,Illumina,LEfSe,0.05,FALSE,3,age,NA,NA,unchanged,decreased,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:799/1/NA,Study 799,"cross-sectional observational, not case-control",36790203,10.1128/spectrum.02139-21,NA,"Kayongo A, Bartolomaeus TUP, Birkner T, Markó L, Löber U, Kigozi E, Atugonza C, Munana R, Mawanda D, Sekibira R, Uwimaana E, Alupo P, Kalyesubula R, Knauf F, Siddharthan T, Bagaya BS, Kateete DP, Joloba ML, Sewankambo NK, Jjingo D, Kirenga B, Checkley W , Forslund SK",Sputum Microbiome and Chronic Obstructive Pulmonary Disease in a Rural Ugandan Cohort of Well-Controlled HIV Infection,Microbiology spectrum,2023,"AIDS, COPD, HIV, HIV-associated COPD, airway, airway microbiome, human immunodeficiency virus, microbiome, sputum",Experiment 1,Uganda,Homo sapiens,Sputum,UBERON:0007311,Chronic obstructive pulmonary disease,EFO:0000341,HIV-negative individuals with COPD,HIV-positive individuals diagnosed with COPD,The exposed group (Group 1) consists of individuals with both HIV infection and COPD.,50,50,Antibiotic use within 2 weeks,16S,34,Illumina,Linear Regression,0.05,NA,NA,"age,sex,smoking status",NA,increased,increased,decreased,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:799/2/NA,Study 799,"cross-sectional observational, not case-control",36790203,10.1128/spectrum.02139-21,NA,"Kayongo A, Bartolomaeus TUP, Birkner T, Markó L, Löber U, Kigozi E, Atugonza C, Munana R, Mawanda D, Sekibira R, Uwimaana E, Alupo P, Kalyesubula R, Knauf F, Siddharthan T, Bagaya BS, Kateete DP, Joloba ML, Sewankambo NK, Jjingo D, Kirenga B, Checkley W , Forslund SK",Sputum Microbiome and Chronic Obstructive Pulmonary Disease in a Rural Ugandan Cohort of Well-Controlled HIV Infection,Microbiology spectrum,2023,"AIDS, COPD, HIV, HIV-associated COPD, airway, airway microbiome, human immunodeficiency virus, microbiome, sputum",Experiment 2,Uganda,Homo sapiens,Sputum,UBERON:0007311,Chronic obstructive pulmonary disease,EFO:0000341,HIV-negative individuals (without COPD),HIV-positive individuals (without COPD),The exposed group (Group 1) consists of individuals with HIV infection but without COPD.,50,50,Antibiotic use within 2 weeks,16S,34,Illumina,Linear Regression,0.05,NA,NA,"age,sex,smoking status",NA,increased,increased,decreased,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:800/1/NA,Study 800,time series / longitudinal observational,37587195,10.1038/s41598-023-40102-y,NA,"Querdasi FR, Vogel SC, Thomason ME, Callaghan BL , Brito NH",A comparison of the infant gut microbiome before versus after the start of the covid-19 pandemic,Scientific reports,2023,NA,Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Health study participation,EFO:0010130,pre-pandemic group with covariates controlled for,pandemic group with covariates controlled for,"healthy 12-month old infants who provided stool samples during the first 9 months of the pandemic with covariates ( diet(average fat intake), child sex, still breastfeeding at sample collection, and birth mode) controlled for.",34,20,no antibiotic within a month preceding stool collection.,16S,NA,Illumina,MaAsLin2,0.25,TRUE,NA,NA,"breast feeding,delivery procedure,diet,sex",NA,unchanged,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:800/2/NA,Study 800,time series / longitudinal observational,37587195,10.1038/s41598-023-40102-y,NA,"Querdasi FR, Vogel SC, Thomason ME, Callaghan BL , Brito NH",A comparison of the infant gut microbiome before versus after the start of the covid-19 pandemic,Scientific reports,2023,NA,Experiment 2,United States of America,Homo sapiens,Feces,UBERON:0001988,Health study participation,EFO:0010130,pre-pandemic group without covariates controlled for,pandemic group without covariates controlled for,healthy 12-month old infants who provided stool samples during the first 9 months of the pandemic without controlling for covariates.,34,20,no antibiotic within a month preceding stool collection.,16S,NA,Illumina,MaAsLin2,0.25,TRUE,NA,NA,"age,breast feeding,delivery procedure,diet",NA,unchanged,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:800/3/NA,Study 800,time series / longitudinal observational,37587195,10.1038/s41598-023-40102-y,NA,"Querdasi FR, Vogel SC, Thomason ME, Callaghan BL , Brito NH",A comparison of the infant gut microbiome before versus after the start of the covid-19 pandemic,Scientific reports,2023,NA,Experiment 3,United States of America,Homo sapiens,Feces,UBERON:0001988,Health study participation,EFO:0010130,pandemic group (without covariates),pandemic group according to the number of days,"Healthy 12-month old infants who provided stool samples during the first 9 months of the pandemic according to the number of days since the pandemic began. Due to the small sample size of the during pandemic group (N = 20), analyses restricted to this group did not include any covariates.",34,20,no antibiotic within a month preceding stool collection.,16S,NA,Illumina,MaAsLin2,0.25,TRUE,NA,NA,"breast feeding,delivery procedure,diet,sex",NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:801/1/NA,Study 801,prospective cohort,32320621,10.1164/rccm.201911-2202OC,NA,"Mac Aogáin M, Lau KJX, Cai Z, Kumar Narayana J, Purbojati RW, Drautz-Moses DI, Gaultier NE, Jaggi TK, Tiew PY, Ong TH, Siyue Koh M, Lim Yick Hou A, Abisheganaden JA, Tsaneva-Atanasova K, Schuster SC , Chotirmall SH",Metagenomics Reveals a Core Macrolide Resistome Related to Microbiota in Chronic Respiratory Disease,American journal of respiratory and critical care medicine,2020,"antimicrobial resistance, macrolides, metagenomics, resistome, respiratory disease",Experiment 1,Singapore,Homo sapiens,Sputum,UBERON:0007311,Respiratory system disease,EFO:0000684,Non-diseased/ healthy individuals (ND),Diseased individuals (D),"Patients with a range of chronic respiratory disease states (severe asthma, chronic obstructive pulmonary disease- COPD, and bronchiectasis)",13,41,None,WMS,NA,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,increased,decreased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:802/1/NA,Study 802,laboratory experiment,37220908,10.5483/BMBRep.2023-0068,NA,"Jeong SM, Jin EJ, Wei S, Bae JH, Ji Y, Jo Y, Jeong JH, Im SJ , Ryu D",The impact of cancer cachexia on gut microbiota composition and short-chain fatty acid metabolism in a murine model,BMB reports,2023,NA,Experiment 1,Republic of Korea,Mus musculus,Feces,UBERON:0001988,Cachexia,HP:0004326,Healthy controls,cachexia-induced mice,All mice that were induced with cancer cachexia (Lewis lung cancer cells).,3,4,NA,16S,34,Illumina,DESeq2,0.05,FALSE,NA,NA,NA,NA,decreased,decreased,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:803/1/NA,Study 803,"cross-sectional observational, not case-control",37483698,10.1016/j.heliyon.2023.e18035,https://www.sciencedirect.com/science/article/pii/S240584402305243X,"Elkholy A, Avuthu N, Abdalla M, Behring M, Bajpai P, Kim HG, Header D, Abo Elwafa RA, Saed H, Embaby A, El-Nikhely N, Obuya S, Mohamed M, Badawy AA, Nawar A, Afaq F, Rogers LQ, Bae S, Shikany JM, Bateman LB, Fouad M, Saleh M, Samuel T, Varambally S, Guda C, Arafat W , Manne U","Microbiome diversity in African American, European American, and Egyptian colorectal cancer patients",Heliyon,2023,"African American, Colorectal cancer, Egyptian, European American, Microbiome",Experiment 1,Egypt,Homo sapiens,Colorectal mucosa,UBERON:0013067,Colorectal cancer,EFO:0005842,Normal samples free from Colorectal Cancer,Egyptian Samples with Colorectal Cancer,Egyptian Patients with colocrectal cancer,17,17,NA,16S,4,Illumina,LEfSe,0.05,FALSE,2,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:803/2/NA,Study 803,"cross-sectional observational, not case-control",37483698,10.1016/j.heliyon.2023.e18035,https://www.sciencedirect.com/science/article/pii/S240584402305243X,"Elkholy A, Avuthu N, Abdalla M, Behring M, Bajpai P, Kim HG, Header D, Abo Elwafa RA, Saed H, Embaby A, El-Nikhely N, Obuya S, Mohamed M, Badawy AA, Nawar A, Afaq F, Rogers LQ, Bae S, Shikany JM, Bateman LB, Fouad M, Saleh M, Samuel T, Varambally S, Guda C, Arafat W , Manne U","Microbiome diversity in African American, European American, and Egyptian colorectal cancer patients",Heliyon,2023,"African American, Colorectal cancer, Egyptian, European American, Microbiome",Experiment 2,United States of America,Homo sapiens,Colorectal mucosa,UBERON:0013067,Colorectal cancer,EFO:0005842,Normal samples free from Colorectal Cancer,African American Samples with Colorectal Cancer,African American Patients with Colorectal cancer.,18,18,NA,16S,4,Illumina,LEfSe,0.05,FALSE,2,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:803/3/NA,Study 803,"cross-sectional observational, not case-control",37483698,10.1016/j.heliyon.2023.e18035,https://www.sciencedirect.com/science/article/pii/S240584402305243X,"Elkholy A, Avuthu N, Abdalla M, Behring M, Bajpai P, Kim HG, Header D, Abo Elwafa RA, Saed H, Embaby A, El-Nikhely N, Obuya S, Mohamed M, Badawy AA, Nawar A, Afaq F, Rogers LQ, Bae S, Shikany JM, Bateman LB, Fouad M, Saleh M, Samuel T, Varambally S, Guda C, Arafat W , Manne U","Microbiome diversity in African American, European American, and Egyptian colorectal cancer patients",Heliyon,2023,"African American, Colorectal cancer, Egyptian, European American, Microbiome",Experiment 3,United States of America,Homo sapiens,Colorectal mucosa,UBERON:0013067,Colorectal cancer,EFO:0005842,Normal samples free from Colorectal Cancer,European American Samples with Colorectal Cancer,European American Patients with colorectal cancer,19,19,NA,16S,4,Illumina,LEfSe,0.05,FALSE,2,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:803/4/NA,Study 803,"cross-sectional observational, not case-control",37483698,10.1016/j.heliyon.2023.e18035,https://www.sciencedirect.com/science/article/pii/S240584402305243X,"Elkholy A, Avuthu N, Abdalla M, Behring M, Bajpai P, Kim HG, Header D, Abo Elwafa RA, Saed H, Embaby A, El-Nikhely N, Obuya S, Mohamed M, Badawy AA, Nawar A, Afaq F, Rogers LQ, Bae S, Shikany JM, Bateman LB, Fouad M, Saleh M, Samuel T, Varambally S, Guda C, Arafat W , Manne U","Microbiome diversity in African American, European American, and Egyptian colorectal cancer patients",Heliyon,2023,"African American, Colorectal cancer, Egyptian, European American, Microbiome",Experiment 4,United States of America,Homo sapiens,Colorectal mucosa,UBERON:0013067,Population,IDOMAL:0001254,"KeNyaN, African American and Egyptians patients",Tumor samples of European American,sample of European Americans patients,53,19,NA,16S,4,Illumina,LEfSe,0.05,FALSE,2,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:803/5/NA,Study 803,"cross-sectional observational, not case-control",37483698,10.1016/j.heliyon.2023.e18035,https://www.sciencedirect.com/science/article/pii/S240584402305243X,"Elkholy A, Avuthu N, Abdalla M, Behring M, Bajpai P, Kim HG, Header D, Abo Elwafa RA, Saed H, Embaby A, El-Nikhely N, Obuya S, Mohamed M, Badawy AA, Nawar A, Afaq F, Rogers LQ, Bae S, Shikany JM, Bateman LB, Fouad M, Saleh M, Samuel T, Varambally S, Guda C, Arafat W , Manne U","Microbiome diversity in African American, European American, and Egyptian colorectal cancer patients",Heliyon,2023,"African American, Colorectal cancer, Egyptian, European American, Microbiome",Experiment 5,Kenya,Homo sapiens,Colorectal mucosa,UBERON:0013067,Population,IDOMAL:0001254,"Egyptian, African American and European American Patients",Tumor samples of kenyans,Tumor samples of kenyan patients,54,18,NA,16S,4,Illumina,LEfSe,0.05,FALSE,2,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:803/6/NA,Study 803,"cross-sectional observational, not case-control",37483698,10.1016/j.heliyon.2023.e18035,https://www.sciencedirect.com/science/article/pii/S240584402305243X,"Elkholy A, Avuthu N, Abdalla M, Behring M, Bajpai P, Kim HG, Header D, Abo Elwafa RA, Saed H, Embaby A, El-Nikhely N, Obuya S, Mohamed M, Badawy AA, Nawar A, Afaq F, Rogers LQ, Bae S, Shikany JM, Bateman LB, Fouad M, Saleh M, Samuel T, Varambally S, Guda C, Arafat W , Manne U","Microbiome diversity in African American, European American, and Egyptian colorectal cancer patients",Heliyon,2023,"African American, Colorectal cancer, Egyptian, European American, Microbiome",Experiment 6,United States of America,Homo sapiens,Colorectal mucosa,UBERON:0013067,Population,IDOMAL:0001254,"Egyptian, Kenyan and European American patients",Tumor samples of African Americans,Sample of African American patients,54,18,NA,16S,4,Illumina,LEfSe,0.05,FALSE,2,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:803/7/NA,Study 803,"cross-sectional observational, not case-control",37483698,10.1016/j.heliyon.2023.e18035,https://www.sciencedirect.com/science/article/pii/S240584402305243X,"Elkholy A, Avuthu N, Abdalla M, Behring M, Bajpai P, Kim HG, Header D, Abo Elwafa RA, Saed H, Embaby A, El-Nikhely N, Obuya S, Mohamed M, Badawy AA, Nawar A, Afaq F, Rogers LQ, Bae S, Shikany JM, Bateman LB, Fouad M, Saleh M, Samuel T, Varambally S, Guda C, Arafat W , Manne U","Microbiome diversity in African American, European American, and Egyptian colorectal cancer patients",Heliyon,2023,"African American, Colorectal cancer, Egyptian, European American, Microbiome",Experiment 7,Egypt,Homo sapiens,Colorectal mucosa,UBERON:0013067,Population,IDOMAL:0001254,"African American, Kenya and European American patients",Tumor samples of Egyptians,sample of Egyptian patients,55,17,NA,16S,4,Illumina,LEfSe,0.05,FALSE,2,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:804/1/NA,Study 804,laboratory experiment,36721179,https://doi.org/10.1186/s40168-022-01452-3,NA,"Wang X, Wang Z, Cao J, Dong Y , Chen Y",Gut microbiota-derived metabolites mediate the neuroprotective effect of melatonin in cognitive impairment induced by sleep deprivation,Microbiome,2023,"Cognitive impairment, Hippocampus, Melatonin, Microbial–gut–brain axis, Sleep deprivation",Experiment 1,China,Mus musculus,Feces,UBERON:0001988,Response to transplant,EFO:0007043,SD-FMT AND SD+MEL-FMT,CON-FMT: receiving control microbiota FMT mice,FMT administered mice without sleep deprivation.,7,7,There were no antibiotic exclusions,16S,123456789,PacBio RS,LEfSe,0.05,FALSE,3,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:804/2/NA,Study 804,laboratory experiment,36721179,https://doi.org/10.1186/s40168-022-01452-3,NA,"Wang X, Wang Z, Cao J, Dong Y , Chen Y",Gut microbiota-derived metabolites mediate the neuroprotective effect of melatonin in cognitive impairment induced by sleep deprivation,Microbiome,2023,"Cognitive impairment, Hippocampus, Melatonin, Microbial–gut–brain axis, Sleep deprivation",Experiment 2,China,Mus musculus,Feces,UBERON:0001988,Response to transplant,EFO:0007043,CON-FMT:( receiving control microbiota FMT mice) and SD+Mel-FMT:( receiving SD+Mel (20 mg/kg) microbiota  FMT mice),SD-FMT: receiving Sleep deprivation  FMT mice,This are sleep deprived mice that are also subjected to FMT .,7,7,There were no antibiotic,16S,123456789,PacBio RS,LEfSe,0.05,FALSE,3,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:804/3/NA,Study 804,laboratory experiment,36721179,https://doi.org/10.1186/s40168-022-01452-3,NA,"Wang X, Wang Z, Cao J, Dong Y , Chen Y",Gut microbiota-derived metabolites mediate the neuroprotective effect of melatonin in cognitive impairment induced by sleep deprivation,Microbiome,2023,"Cognitive impairment, Hippocampus, Melatonin, Microbial–gut–brain axis, Sleep deprivation",Experiment 3,China,Mus musculus,Feces,UBERON:0001988,Response to transplant,EFO:0007043,CON-FMT and SD-FMT,SD+Mel-FMT:( receiving SD+Mel (20 mg/kg) microbiota FMT mice),Sleep deprived mice receiving Mel and FMT,7,7,There were no antibiotics exclusions from this study,16S,123456789,PacBio RS,LEfSe,0.05,FALSE,3,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:805/1/NA,Study 805,"cross-sectional observational, not case-control",36651663,10.1080/19490976.2022.2162306,NA,"Malan-Müller S, Valles-Colomer M, Palomo T , Leza JC","The gut-microbiota-brain axis in a Spanish population in the aftermath of the COVID-19 pandemic: microbiota composition linked to anxiety, trauma, and depression profiles",Gut microbes,2023,"COVID-19, Microbiome, anxiety, depression, gut-microbiota-brain axis, mental health, posttraumatic stress disorder, trauma",Experiment 1,Spain,Homo sapiens,Feces,UBERON:0001988,Psychiatric disorder,MONDO:0002025,Individuals without the comorbid state,Individuals with comorbid PTSD + depression + state + trait anxiety symptoms (Comorbidity with Psychiatric Symptoms),"This group included individuals with comorbid PTSD, depression, state and trait anxiety symptoms",190,8,6 months.,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,"age,body mass index,inflammatory bowel disease,irritable bowel syndrome,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:805/2/NA,Study 805,"cross-sectional observational, not case-control",36651663,10.1080/19490976.2022.2162306,NA,"Malan-Müller S, Valles-Colomer M, Palomo T , Leza JC","The gut-microbiota-brain axis in a Spanish population in the aftermath of the COVID-19 pandemic: microbiota composition linked to anxiety, trauma, and depression profiles",Gut microbes,2023,"COVID-19, Microbiome, anxiety, depression, gut-microbiota-brain axis, mental health, posttraumatic stress disorder, trauma",Experiment 2,Spain,Homo sapiens,Feces,UBERON:0001988,Psychiatric disorder,MONDO:0002025,Healthy controls (good mental health),PTSD + depression + state + trait anxiety symptoms (Comorbidity with Psychiatric Symptoms),"This group included individuals with comorbid PTSD, depression, state and trait anxiety symptoms",106,8,6 months.,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:805/3/NA,Study 805,"cross-sectional observational, not case-control",36651663,10.1080/19490976.2022.2162306,NA,"Malan-Müller S, Valles-Colomer M, Palomo T , Leza JC","The gut-microbiota-brain axis in a Spanish population in the aftermath of the COVID-19 pandemic: microbiota composition linked to anxiety, trauma, and depression profiles",Gut microbes,2023,"COVID-19, Microbiome, anxiety, depression, gut-microbiota-brain axis, mental health, posttraumatic stress disorder, trauma",Experiment 3,Spain,Homo sapiens,Feces,UBERON:0001988,Depressive disorder,MONDO:0002050,Individuals without depressive symptoms,Individuals with depressive symptoms,This group included individuals with depressive symptoms,166,32,6 months.,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:805/4/NA,Study 805,"cross-sectional observational, not case-control",36651663,10.1080/19490976.2022.2162306,NA,"Malan-Müller S, Valles-Colomer M, Palomo T , Leza JC","The gut-microbiota-brain axis in a Spanish population in the aftermath of the COVID-19 pandemic: microbiota composition linked to anxiety, trauma, and depression profiles",Gut microbes,2023,"COVID-19, Microbiome, anxiety, depression, gut-microbiota-brain axis, mental health, posttraumatic stress disorder, trauma",Experiment 4,Spain,Homo sapiens,Feces,UBERON:0001988,Childhood trauma measurement,EFO:0007979,Individuals who did not experience life-threatening childhood trauma,Individuals who experienced life-threatening childhood trauma,This group included individuals who experienced life-threatening childhood trauma,162,36,6 months.,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:806/1/NA,Study 806,case-control,32274300,10.1002/advs.201902862,NA,"Zheng P, Yang J, Li Y, Wu J, Liang W, Yin B, Tan X, Huang Y, Chai T, Zhang H, Duan J, Zhou J, Sun Z, Chen X, Marwari S, Lai J, Huang T, Du Y, Zhang P, Perry SW, Wong ML, Licinio J, Hu S, Xie P , Wang G",Gut Microbial Signatures Can Discriminate Unipolar from Bipolar Depression,"Advanced science (Weinheim, Baden-Wurttemberg, Germany)",2020,"bipolar disorder, gut microbiome, major depressive disorder, microbiota–gut–brain axis, unipolar depression",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Mood disorder,EFO:0004247,healthy controls (HCs),bipolar disorder (BD),Participants who suffer from depressive episodes of bipolar disorder (BD),217,217,1 month,16S,34,Illumina,LEfSe,0.05,NA,2.5,"age,body mass index,sex",NA,NA,unchanged,decreased,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:806/2/NA,Study 806,case-control,32274300,10.1002/advs.201902862,NA,"Zheng P, Yang J, Li Y, Wu J, Liang W, Yin B, Tan X, Huang Y, Chai T, Zhang H, Duan J, Zhou J, Sun Z, Chen X, Marwari S, Lai J, Huang T, Du Y, Zhang P, Perry SW, Wong ML, Licinio J, Hu S, Xie P , Wang G",Gut Microbial Signatures Can Discriminate Unipolar from Bipolar Depression,"Advanced science (Weinheim, Baden-Wurttemberg, Germany)",2020,"bipolar disorder, gut microbiome, major depressive disorder, microbiota–gut–brain axis, unipolar depression",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Mood disorder,EFO:0004247,healthy controls (HCs),Major depressive disorder (MDD),Participants who suffer from depressive episodes from major depressive disorder (MDD),217,165,1 month,16S,34,Illumina,LEfSe,0.05,NA,2.5,"age,body mass index,sex",NA,NA,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:806/3/NA,Study 806,case-control,32274300,10.1002/advs.201902862,NA,"Zheng P, Yang J, Li Y, Wu J, Liang W, Yin B, Tan X, Huang Y, Chai T, Zhang H, Duan J, Zhou J, Sun Z, Chen X, Marwari S, Lai J, Huang T, Du Y, Zhang P, Perry SW, Wong ML, Licinio J, Hu S, Xie P , Wang G",Gut Microbial Signatures Can Discriminate Unipolar from Bipolar Depression,"Advanced science (Weinheim, Baden-Wurttemberg, Germany)",2020,"bipolar disorder, gut microbiome, major depressive disorder, microbiota–gut–brain axis, unipolar depression",Experiment 3,China,Homo sapiens,Feces,UBERON:0001988,Mood disorder,EFO:0004247,bipolar disorder (BD),Major depressive disorder (MDD),Participants who suffer from depressive episodes from major depressive disorder (MDD),217,165,1 month,16S,34,Illumina,LEfSe,0.05,NA,2.5,"age,body mass index",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:807/1/NA,Study 807,time series / longitudinal observational,37525095,10.1186/s12866-023-02951-5,https://bmcmicrobiol.biomedcentral.com/articles/10.1186/s12866-023-02951-5,"Konecna E, Videnska P, Buresova L, Urik M, Smetanova S, Smatana S, Prokes R, Lanickova B, Budinska E, Klanova J , Borilova Linhartova P",Enrichment of human nasopharyngeal bacteriome with bacteria from dust after short-term exposure to indoor environment: a pilot study,BMC microbiology,2023,"16S rRNA, Bacteriome, Dust, Exposure, Hospital, Household, Indoor environment, Nasopharynx, Sequencing",Experiment 1,Czechia,Homo sapiens,Nasopharyngeal gland,UBERON:0008310,Microbiome measurement,EFO:0007882,Indoor dust samples,Nasopharyngeal swab samples from workplaces,"The workplaces in the study were commercially used buildings characterized by higher levels of human occupancy and usage of HVAC (heating, ventilation, air conditioning) systems, both contributing to the higher abundance of microorganisms and their spread in the building . The participants working at NEO, ENT, or RCX workplaces were included in the study",44,43,None.,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:807/2/NA,Study 807,time series / longitudinal observational,37525095,10.1186/s12866-023-02951-5,https://bmcmicrobiol.biomedcentral.com/articles/10.1186/s12866-023-02951-5,"Konecna E, Videnska P, Buresova L, Urik M, Smetanova S, Smatana S, Prokes R, Lanickova B, Budinska E, Klanova J , Borilova Linhartova P",Enrichment of human nasopharyngeal bacteriome with bacteria from dust after short-term exposure to indoor environment: a pilot study,BMC microbiology,2023,"16S rRNA, Bacteriome, Dust, Exposure, Hospital, Household, Indoor environment, Nasopharynx, Sequencing",Experiment 2,Czechia,Homo sapiens,Nasopharyngeal gland,UBERON:0008310,Microbiome measurement,EFO:0007882,"Nasopharyngeal swab samples collected in the Morning from workplaces (NEO, ENT, RCX)","Nasopharyngeal swab samples collected in the afternoon from workplaces (NEO, ENT, RCX)","Nasopharyngeal swabs collected in the afternoon (after an 8 h exposure to the workplace environment). The participants were working at NEO, ENT, or RCX workplaces.",22,21,None.,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,2,NA,NA,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:808/1/NA,Study 808,laboratory experiment,37784178,10.1186/s40168-023-01588-w,https://pubmed.ncbi.nlm.nih.gov/37784178/,"Salvador AC, Huda MN, Arends D, Elsaadi AM, Gacasan CA, Brockmann GA, Valdar W, Bennett BJ , Threadgill DW","Analysis of strain, sex, and diet-dependent modulation of gut microbiota reveals candidate keystone organisms driving microbial diversity in response to American and ketogenic diets",Microbiome,2023,"diet, ketogenic, keystone species, microbiome, mouse",Experiment 1,United States of America,Mus musculus,Feces,UBERON:0001988,Response to diet,EFO:0010757,mice on American diet,mice on ketogenic diet,male and female mice placed on American diet during feeding trial,224,245,NA,16S,4,Illumina,ANOVA,0.001,TRUE,NA,NA,"diet,sex",NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:809/1/NA,Study 809,case-control,33816351,10.3389/fcimb.2021.646348,NA,"Huang Y, Wang Z, Ma H, Ji S, Chen Z, Cui Z, Chen J , Tang S",Dysbiosis and Implication of the Gut Microbiota in Diabetic Retinopathy,Frontiers in cellular and infection microbiology,2021,"16S rRNA gene sequence, diabetes mellitus, diabetic retinopathy, gut microbiota, human",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Retinopathy,EFO:0003839,healthy controls (HC),diabetes mellitus (DM),Participants who identify as diabetic patients without retinopathy (DM),25,25,1 month,16S,34,Illumina,LEfSe,0.05,NA,2.5,"age,body mass index,sex",NA,NA,decreased,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:809/2/NA,Study 809,case-control,33816351,10.3389/fcimb.2021.646348,NA,"Huang Y, Wang Z, Ma H, Ji S, Chen Z, Cui Z, Chen J , Tang S",Dysbiosis and Implication of the Gut Microbiota in Diabetic Retinopathy,Frontiers in cellular and infection microbiology,2021,"16S rRNA gene sequence, diabetes mellitus, diabetic retinopathy, gut microbiota, human",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Retinopathy,EFO:0003839,diabetes mellitus (DM),diabetes retinopathy (DR),Participants who identify as diabetic patients with retinopathy (DR),25,25,1 month,16S,34,Illumina,Kruskall-Wallis,0.05,NA,2.5,"age,body mass index,sex",NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:809/3/NA,Study 809,case-control,33816351,10.3389/fcimb.2021.646348,NA,"Huang Y, Wang Z, Ma H, Ji S, Chen Z, Cui Z, Chen J , Tang S",Dysbiosis and Implication of the Gut Microbiota in Diabetic Retinopathy,Frontiers in cellular and infection microbiology,2021,"16S rRNA gene sequence, diabetes mellitus, diabetic retinopathy, gut microbiota, human",Experiment 3,China,Homo sapiens,Feces,UBERON:0001988,Retinopathy,EFO:0003839,healthy controls (HC),diabetes retinopathy (DR),Participants who identify as diabetic patients with retinopathy (DR),25,25,1 month,16S,34,Illumina,LEfSe,0.05,NA,2.5,"age,body mass index,sex",NA,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:810/1/NA,Study 810,case-control,36004326,10.3389/fcimb.2022.858732,NA,"Yan C, Hong F, Xin G, Duan S, Deng X , Xu Y",Alterations in the vaginal microbiota of patients with preterm premature rupture of membranes,Frontiers in cellular and infection microbiology,2022,"PPROM, PROM, PTB, preterm birth, vaginal microbiota",Experiment 1,China,Homo sapiens,"Uterine cervix,Anterior fornix of vagina,Lateral fornix of vagina","UBERON:0000002,UBERON:0016487,UBERON:0034963",Preterm premature rupture of the membranes,MONDO:0012511,Control(term delivery),Preterm premature rupture of membranes (PPROM),PPROM is characterized by vaginal microbial dysbiosis.,54,48,2 months,16S,34,Illumina,LEfSe,0.05,NA,3.5,"age,gestational age",NA,increased,increased,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:811/1/NA,Study 811,case-control,34897759,10.1111/lam.13630,https://academic.oup.com/lambio/article-abstract/74/4/498/6989204?redirectedFrom=fulltext&login=false,"Schade L, Mesa D, Faria AR, Santamaria JR, Xavier CA, Ribeiro D, Hajar FN , Azevedo VF",The gut microbiota profile in psoriasis: a Brazilian case-control study,Letters in applied microbiology,2022,"Akkermansia muciniphila, dysbiosis, gut microbiome, inflammatory bowel disease, psoriasis, psoriatic arthritis, skin disease",Experiment 1,Brazil,Homo sapiens,Feces,UBERON:0001988,Psoriasis,EFO:0000676,Healthy controls,Psoriasis patients,Psoriasis has been diagnosed by a dermatologist,24,21,3 months,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,NA,NA,"age,body mass index,comorbidity,sex,smoking status",NA,NA,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:812/1/NA,Study 812,"cross-sectional observational, not case-control",36182683,10.1016/j.xcrm.2022.100753,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588997/,"Neugent ML, Kumar A, Hulyalkar NV, Lutz KC, Nguyen VH, Fuentes JL, Zhang C, Nguyen A, Sharon BM, Kuprasertkul A, Arute AP, Ebrahimzadeh T, Natesan N, Xing C, Shulaev V, Li Q, Zimmern PE, Palmer KL , De Nisco NJ",Recurrent urinary tract infection and estrogen shape the taxonomic ecology and function of the postmenopausal urogenital microbiome,Cell reports. Medicine,2022,"Escherichia coli, Lactobacillus crispatus, antibiotic resistance, bladder, dysbiosis, estrogen, metagenomics, postmenopausal women, urinary tract infection, urogenital microbiome",Experiment 1,United States of America,Homo sapiens,Urine,UBERON:0001088,Urinary tract infection,EFO:0003103,No UTI History,"rUTI History, UTI (-)","Consists of post menopausal (PM) women with a recent history of recurring urinary tract infection ( rUTI) but no active UTI at the time of urine donation (rUTI History, UTI(−))",25,25,4 weeks,WMS,NA,Sanger,Negative Binomial Regression,0.05,FALSE,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:812/2/NA,Study 812,"cross-sectional observational, not case-control",36182683,10.1016/j.xcrm.2022.100753,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588997/,"Neugent ML, Kumar A, Hulyalkar NV, Lutz KC, Nguyen VH, Fuentes JL, Zhang C, Nguyen A, Sharon BM, Kuprasertkul A, Arute AP, Ebrahimzadeh T, Natesan N, Xing C, Shulaev V, Li Q, Zimmern PE, Palmer KL , De Nisco NJ",Recurrent urinary tract infection and estrogen shape the taxonomic ecology and function of the postmenopausal urogenital microbiome,Cell reports. Medicine,2022,"Escherichia coli, Lactobacillus crispatus, antibiotic resistance, bladder, dysbiosis, estrogen, metagenomics, postmenopausal women, urinary tract infection, urogenital microbiome",Experiment 2,United States of America,Homo sapiens,Urine,UBERON:0001088,Hormone replacement therapy,EFO:0003961,EHT- Group (Premenopausal women in the 'No UTI History and rUTI History( UTI(−) cohorts' who did not use estrogen hormone therapy (EHT)),EHT+ Group (Premenopausal women in the 'No UTI History and rUTI History( UTI(−) cohorts' who used estrogen hormone therapy (EHT)),Premenopausal women in the 'No UTI History and rUTI History( UTI(−) cohorts' with systemic and vaginal estrogen hormone therapy (EHT) who did not have UTI at the time of urine donation.,21,29,4 weeks,WMS,NA,Sanger,LEfSe,0.05,TRUE,4.5,NA,NA,NA,decreased,NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:812/3/NA,Study 812,"cross-sectional observational, not case-control",36182683,10.1016/j.xcrm.2022.100753,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588997/,"Neugent ML, Kumar A, Hulyalkar NV, Lutz KC, Nguyen VH, Fuentes JL, Zhang C, Nguyen A, Sharon BM, Kuprasertkul A, Arute AP, Ebrahimzadeh T, Natesan N, Xing C, Shulaev V, Li Q, Zimmern PE, Palmer KL , De Nisco NJ",Recurrent urinary tract infection and estrogen shape the taxonomic ecology and function of the postmenopausal urogenital microbiome,Cell reports. Medicine,2022,"Escherichia coli, Lactobacillus crispatus, antibiotic resistance, bladder, dysbiosis, estrogen, metagenomics, postmenopausal women, urinary tract infection, urogenital microbiome",Experiment 3,United States of America,Homo sapiens,Urine,UBERON:0001088,Urinary tract infection,EFO:0003103,No UTI History,"rUTI History, UTI (+)","Consists of post menopausal (PM) women with a recent history of recurring urinary tract infection ( rUTI) and an active, symptomatic UTI at the time of urine donation",25,25,4 weeks,WMS,NA,Sanger,Negative Binomial Regression,0.05,FALSE,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:813/1/NA,Study 813,laboratory experiment,33046129,10.1186/s13073-020-00784-9,NA,"Binyamin D, Werbner N, Nuriel-Ohayon M, Uzan A, Mor H, Abbas A, Ziv O, Teperino R, Gutman R , Koren O",The aging mouse microbiome has obesogenic characteristics,Genome medicine,2020,"Aging, Fecal microbiota transplantation, Metabolism, Microbiome",Experiment 1,Israel,Mus musculus,"Feces,Blood vessel","UBERON:0001988,UBERON:0001981",Body weight,EFO:0004338,Adult,Aging,Aging Mice,42,32,NIL,16S,4,Illumina,PERMANOVA,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:813/2/NA,Study 813,laboratory experiment,33046129,10.1186/s13073-020-00784-9,NA,"Binyamin D, Werbner N, Nuriel-Ohayon M, Uzan A, Mor H, Abbas A, Ziv O, Teperino R, Gutman R , Koren O",The aging mouse microbiome has obesogenic characteristics,Genome medicine,2020,"Aging, Fecal microbiota transplantation, Metabolism, Microbiome",Experiment 2,Israel,Mus musculus,"Feces,Blood vessel","UBERON:0001988,UBERON:0001981",Body fat percentage,EFO:0007800,low body fat percentage,high body fat percentage,High body fat adult and aged mice,32,13,NIL,16S,4,Illumina,PERMANOVA,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:813/3/NA,Study 813,laboratory experiment,33046129,10.1186/s13073-020-00784-9,NA,"Binyamin D, Werbner N, Nuriel-Ohayon M, Uzan A, Mor H, Abbas A, Ziv O, Teperino R, Gutman R , Koren O",The aging mouse microbiome has obesogenic characteristics,Genome medicine,2020,"Aging, Fecal microbiota transplantation, Metabolism, Microbiome",Experiment 3,Israel,Mus musculus,"Feces,Blood vessel","UBERON:0001988,UBERON:0001981",Body weight,EFO:0004338,Less weight,Higher weight,Mice with Higher Body Weight,13,32,NIL,16S,4,Illumina,PERMANOVA,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:814/1/NA,Study 814,"cross-sectional observational, not case-control",36870237,https://doi.org/10.1016/j.semarthrit.2023.152185,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10148899/,"Nguyen AD, Andréasson K, McMahan ZH, Bukiri H, Howlett N, Lagishetty V, Lee SM, Jacobs JP , Volkmann ER",Gastrointestinal tract involvement in systemic sclerosis: The roles of diet and the microbiome,Seminars in arthritis and rheumatism,2023,"FODMAP diet, Gastrointestinal microbiome, Systemic sclerosis, nutrition",Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Diet measurement,EFO:0008111,"Adult Systemic Sclerosis patients on a low fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP) diet.","Adult Systemic Sclerosis patients on a non-low fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP) diet.","Adult patients with Systemic Sclerosis of any duration, as diagnosed according to the 2013 American College of Rheumatology/European League Against Rheumatism Classification Criteria for  Systemic Sclerosis, on a non-low fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP) diet.",19,16,three weeks,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:814/2/NA,Study 814,"cross-sectional observational, not case-control",36870237,https://doi.org/10.1016/j.semarthrit.2023.152185,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10148899/,"Nguyen AD, Andréasson K, McMahan ZH, Bukiri H, Howlett N, Lagishetty V, Lee SM, Jacobs JP , Volkmann ER",Gastrointestinal tract involvement in systemic sclerosis: The roles of diet and the microbiome,Seminars in arthritis and rheumatism,2023,"FODMAP diet, Gastrointestinal microbiome, Systemic sclerosis, nutrition",Experiment 2,United States of America,Homo sapiens,Feces,UBERON:0001988,Systemic scleroderma,EFO:0000717,Not Applicable,Systemic Sclerosis patients with increased GIT 2.0 score,"Adult patients with Systemic Sclerosis of any duration, as diagnosed according to the 2013 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Systemic Sclerosis, reporting more severe Gastrointestinal Tract symptoms",NA,66,"Four weeks, no antibiotics use more than 2 times in the preceding 12 months prior to the stool collection.",16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:814/3/NA,Study 814,"cross-sectional observational, not case-control",36870237,https://doi.org/10.1016/j.semarthrit.2023.152185,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10148899/,"Nguyen AD, Andréasson K, McMahan ZH, Bukiri H, Howlett N, Lagishetty V, Lee SM, Jacobs JP , Volkmann ER",Gastrointestinal tract involvement in systemic sclerosis: The roles of diet and the microbiome,Seminars in arthritis and rheumatism,2023,"FODMAP diet, Gastrointestinal microbiome, Systemic sclerosis, nutrition",Experiment 3,United States of America,Homo sapiens,Feces,UBERON:0001988,Systemic scleroderma,EFO:0000717,NA,Systemic Sclerosis patients with more severe diarrhoea,"Adult patients with Systemic Sclerosis of any duration, as diagnosed according to the 2013 American College of Rheumatology/European League Against Rheumatism Classification Criteria for  Systemic Sclerosis, reporting more severe diarrhea based on the diarrhea score.",NA,66,"Four weeks, no antibiotics use more than 2 times in the preceding 12 months prior to the stool collection.",16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:814/4/NA,Study 814,"cross-sectional observational, not case-control",36870237,https://doi.org/10.1016/j.semarthrit.2023.152185,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10148899/,"Nguyen AD, Andréasson K, McMahan ZH, Bukiri H, Howlett N, Lagishetty V, Lee SM, Jacobs JP , Volkmann ER",Gastrointestinal tract involvement in systemic sclerosis: The roles of diet and the microbiome,Seminars in arthritis and rheumatism,2023,"FODMAP diet, Gastrointestinal microbiome, Systemic sclerosis, nutrition",Experiment 4,United States of America,Homo sapiens,Feces,UBERON:0001988,Systemic scleroderma,EFO:0000717,NA,Systemic Sclerosis patients with  worsened social functioning,"Adult patients with Systemic Sclerosis of any duration, as diagnosed according to the 2013 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Systemic Sclerosis, reporting worsened social functioning",NA,66,four weeks,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:815/1/NA,Study 815,time series / longitudinal observational,36138438,https://doi.org/10.1186/s40168-022-01322-y,https://pubmed.ncbi.nlm.nih.gov/36138438/,"Martin VM, Virkud YV, Dahan E, Seay HL, Itzkovits D, Vlamakis H, Xavier R, Shreffler WG, Yuan Q , Yassour M",Longitudinal disease-associated gut microbiome differences in infants with food protein-induced allergic proctocolitis,Microbiome,2022,NA,Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Ulcerative proctosigmoiditis,EFO:1001223,Infants diagnosed without food protein-induced allergic proctocolitis (FPIAP),Infants diagnosed with food protein-induced allergic proctocolitis (FPIAP),Infants diagnosed with food protein-induced allergic proctocolitis (FPIAP) who had a minimum of 4 longitudinal stool samples in the first year.  FPIAP was diagnosed by the treating physician and confirmed by comprehensive study staff chart review.,81,79,NIL,16S,4,Illumina,MaAsLin2,0.2,TRUE,NA,age,"age,diet,mode of birth",NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:816/1/NA,Study 816,"cross-sectional observational, not case-control",33584071,10.3748/wjg.v27.i5.391,https://www.wjgnet.com/1007-9327/full/v27/i5/391.htm,"Li YD, Liu BN, Zhao SH, Zhou YL, Bai L , Liu EQ",Changes in gut microbiota composition and diversity associated with post-cholecystectomy diarrhea,World journal of gastroenterology,2021,"16S rRNA, Bifidobacterium, Cholecystectomy, Diarrhea, Microbiota, Post-cholecystectomy",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Postcholecystectomy syndrome,EFO:1001117,healthy control (HC),post-cholecystectomy (PC),Participants who have post-cholecystectomy (PC) syndrome are difficult to treat.,20,31,3 months,16S,34,Illumina,LEfSe,0.05,NA,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:816/2/NA,Study 816,"cross-sectional observational, not case-control",33584071,10.3748/wjg.v27.i5.391,https://www.wjgnet.com/1007-9327/full/v27/i5/391.htm,"Li YD, Liu BN, Zhao SH, Zhou YL, Bai L , Liu EQ",Changes in gut microbiota composition and diversity associated with post-cholecystectomy diarrhea,World journal of gastroenterology,2021,"16S rRNA, Bifidobacterium, Cholecystectomy, Diarrhea, Microbiota, Post-cholecystectomy",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Diarrhea,HP:0002014,post-cholecystectomy non-diarrhea (PCND),post-cholecystectomy diarrhea (PCD),This group included patients who experienced post-cholecystectomy diarrhea (PCD). These individuals had diarrhea as a clinical symptom following gallbladder removal.,15,16,3 months,16S,34,Illumina,LEfSe,0.05,NA,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:817/1/NA,Study 817,case-control,NA,NA,https://www.sciencedirect.com/science/article/abs/pii/S0044848623000224,"Christina Pavloudi, Efthimia Antonopoulou, Maria Ioanna Tsertou","Investigation of systemic granulomatosis in cultured meagre, Argyrosomus  regius, using clinical metagenomics",Aquaculture,2023,"16S, rRNA, amplicon, sequencing, Metagenomics,  Granuloma,  Meagre,  Microbiome,  Lesion",Experiment 1,Greece,Argyrosomus regius,Kidney,UBERON:0002113,Granulomatosis with Polyangiitis,EFO:0005297,Healthy/Healthy with no visible granuloma,Kidneys with calcification,Meagre fishes with tissue calcification in their kidneys,7,10,None,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:817/2/NA,Study 817,case-control,NA,NA,https://www.sciencedirect.com/science/article/abs/pii/S0044848623000224,"Christina Pavloudi, Efthimia Antonopoulou, Maria Ioanna Tsertou","Investigation of systemic granulomatosis in cultured meagre, Argyrosomus  regius, using clinical metagenomics",Aquaculture,2023,"16S, rRNA, amplicon, sequencing, Metagenomics,  Granuloma,  Meagre,  Microbiome,  Lesion",Experiment 2,Greece,Argyrosomus regius,Kidney,UBERON:0002113,Granulomatosis with Polyangiitis,EFO:0005297,Systemic Granulomatosis (SG)-affected,Sick with Kidney calcification,Meagre fishes with tissue calcifications in their kidneys,10,10,None,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:817/3/NA,Study 817,case-control,NA,NA,https://www.sciencedirect.com/science/article/abs/pii/S0044848623000224,"Christina Pavloudi, Efthimia Antonopoulou, Maria Ioanna Tsertou","Investigation of systemic granulomatosis in cultured meagre, Argyrosomus  regius, using clinical metagenomics",Aquaculture,2023,"16S, rRNA, amplicon, sequencing, Metagenomics,  Granuloma,  Meagre,  Microbiome,  Lesion",Experiment 3,Greece,Argyrosomus regius,Kidney,UBERON:0002113,Granulomatosis with Polyangiitis,EFO:0005297,Healthy/Healthy with no visible granuloma,Sick,Meagre fishes with SG-affected kidneys and tissue calcification in their kidneys,7,20,None,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:818/1/NA,Study 818,"prospective cohort,time series / longitudinal observational",37644001,10.1038/s41467-023-40336-4,NA,"Hoskinson C, Dai DLY, Del Bel KL, Becker AB, Moraes TJ, Mandhane PJ, Finlay BB, Simons E, Kozyrskyj AL, Azad MB, Subbarao P, Petersen C , Turvey SE",Delayed gut microbiota maturation in the first year of life is a hallmark of pediatric allergic disease,Nature communications,2023,NA,Experiment 1,Canada,Homo sapiens,Feces,UBERON:0001988,"Asthma,Allergic rhinitis,Dermatitis,Food allergy","MONDO:0002406,MONDO:0004979,EFO:1001890,EFO:0005854",Healthy controls,Allergic Children,Children diagnosed by an expert physician at the 5-year scheduled visit with one or more allergic disorders.,523,592,No Antibiotics exclusion was mentioned,WMS,NA,Illumina,Random Forest Analysis,0.05,FALSE,NA,age,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:819/1/NA,Study 819,time series / longitudinal observational,29851662,10.1097/QAD.0000000000001811,NA,"Presti RM, Handley SA, Droit L, Ghannoum M, Jacobson M, Shiboski CH, Webster-Cyriaque J, Brown T, Yin MT , Overton ET",Alterations in the oral microbiome in HIV-infected participants after antiretroviral therapy administration are influenced by immune status,"AIDS (London, England)",2018,NA,Experiment 1,United States of America,Homo sapiens,Saliva,UBERON:0001836,Viral load,EFO:0010125,High viral load at baseline,Low viral load at baseline,Participants with viral load less than 100 000 copies/ml at baseline,9,26,N/A,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:819/2/NA,Study 819,time series / longitudinal observational,29851662,10.1097/QAD.0000000000001811,NA,"Presti RM, Handley SA, Droit L, Ghannoum M, Jacobson M, Shiboski CH, Webster-Cyriaque J, Brown T, Yin MT , Overton ET",Alterations in the oral microbiome in HIV-infected participants after antiretroviral therapy administration are influenced by immune status,"AIDS (London, England)",2018,NA,Experiment 2,United States of America,Homo sapiens,Saliva,UBERON:0001836,Response to antiviral drug,EFO:0010123,Baseline samples,Week 24 samples,Saliva samples after 24 weeks of antiretroviral therapy,35,35,N/A,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:819/3/NA,Study 819,time series / longitudinal observational,29851662,10.1097/QAD.0000000000001811,NA,"Presti RM, Handley SA, Droit L, Ghannoum M, Jacobson M, Shiboski CH, Webster-Cyriaque J, Brown T, Yin MT , Overton ET",Alterations in the oral microbiome in HIV-infected participants after antiretroviral therapy administration are influenced by immune status,"AIDS (London, England)",2018,NA,Experiment 3,United States of America,Homo sapiens,Saliva,UBERON:0001836,CD4-positive T-lymphocyte count,EFO:0010105,Baseline CD4+ low samples,Baseline CD4+ high samples,Baseline CD4+ high samples before administering Anti Retroviral Therapy,35,35,N/A,16S,4,Illumina,Kruskall-Wallis,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:819/4/NA,Study 819,time series / longitudinal observational,29851662,10.1097/QAD.0000000000001811,NA,"Presti RM, Handley SA, Droit L, Ghannoum M, Jacobson M, Shiboski CH, Webster-Cyriaque J, Brown T, Yin MT , Overton ET",Alterations in the oral microbiome in HIV-infected participants after antiretroviral therapy administration are influenced by immune status,"AIDS (London, England)",2018,NA,Experiment 4,United States of America,Homo sapiens,Saliva,UBERON:0001836,CD4-positive T-lymphocyte count,EFO:0010105,week 24 CD4+ low samples,week 24 CD4+ high samples,samples with high CD4+ at Week 24 following Anti Retroviral Therapy,35,35,N/A,16S,4,Illumina,Kruskall-Wallis,0.05,TRUE,NA,NA,NA,NA,decreased,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:820/1/NA,Study 820,time series / longitudinal observational,37032359,10.1186/s40168-023-01516-y,NA,"Spatz M, Da Costa G, Ventin-Holmberg R, Planchais J, Michaudel C, Wang Y, Danne C, Lapiere A, Michel ML, Kolho KL, Langella P, Sokol H , Richard ML",Antibiotic treatment using amoxicillin-clavulanic acid impairs gut mycobiota development through modification of the bacterial ecosystem,Microbiome,2023,"Antibiotics, Enterobacteriaceae, Microbiota, Mycobiota",Experiment 1,France,Mus musculus,Feces,UBERON:0001988,"Antimicrobial agent,Amoxicillin","CHEBI:33281,CHEBI:2676",mouse before antibiotic treatment,mouse  after antibiotic treatment,Mouse sample fungal results post-antibiotic treatment using Amoxicillin/clavulanate acid,7,12,NA,ITS / ITS2,NA,NA,DESeq2,0.05,FALSE,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:820/2/NA,Study 820,time series / longitudinal observational,37032359,10.1186/s40168-023-01516-y,NA,"Spatz M, Da Costa G, Ventin-Holmberg R, Planchais J, Michaudel C, Wang Y, Danne C, Lapiere A, Michel ML, Kolho KL, Langella P, Sokol H , Richard ML",Antibiotic treatment using amoxicillin-clavulanic acid impairs gut mycobiota development through modification of the bacterial ecosystem,Microbiome,2023,"Antibiotics, Enterobacteriaceae, Microbiota, Mycobiota",Experiment 2,France,Mus musculus,Feces,UBERON:0001988,"Antimicrobial agent,Amoxicillin","CHEBI:33281,CHEBI:2676",Mouse before antibiotic  treatment,Mouse after antibiotic treatment,Mouse sample bacterial results post-antibiotic treatment using amoxicillin-acid clavulanic,7,12,NA,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:821/1/NA,Study 821,laboratory experiment,31686318,10.1007/s11427-019-9540-y,NA,"Li J, Rui J, Li Y, Tang N, Zhan S, Jiang J , Li X",Ambient temperature alters body size and gut microbiota of Xenopus tropicalis,Science China. Life sciences,2020,"Xenopus tropicalis, body size, gut microbiota, temperature, thermal adaptation",Experiment 1,China,Xenopus tropicalis,Midgut,UBERON:0001045,Temperature,EFO:0001702,Cool Gut,Warm Gut,Xenopus tropicalis gut microbiota response to warm environmental conditions,23,28,None,16S,45,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:822/1/NA,Study 822,randomized controlled trial,36803868,10.1186/s40168-023-01460-x,NA,"Abotsi RE, Dube FS, Rehman AM, Claassen-Weitz S, Xia Y, Simms V, Mwaikono KS, Gardner-Lubbe S, McHugh G, Ngwira LG, Kwambana-Adams B, Heyderman RS, Odland JØ, Ferrand RA , Nicol MP",Sputum bacterial load and bacterial composition correlate with lung function and are altered by long-term azithromycin treatment in children with HIV-associated chronic lung disease,Microbiome,2023,"Adolescents, Africa, Bacteriome, FEV1z, HIV, Haemophilus, Microbiome, Moraxella, Obliterative bronchiolitis",Experiment 1,"Zimbabwe,Malawi",Homo sapiens,Sputum,UBERON:0007311,Azithromycin,CHEBI:2955,Placebo at 48 Weeks,Azithromycin(AZM) at 48 weeks,Participants with HIV-associated Chronic Lung Disease (HCLD) who received  azithromycin (AZM),150,154,NIL,16S,4,Illumina,ANCOM,0.05,TRUE,NA,NA,"age,sex",NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:822/2/NA,Study 822,randomized controlled trial,36803868,10.1186/s40168-023-01460-x,NA,"Abotsi RE, Dube FS, Rehman AM, Claassen-Weitz S, Xia Y, Simms V, Mwaikono KS, Gardner-Lubbe S, McHugh G, Ngwira LG, Kwambana-Adams B, Heyderman RS, Odland JØ, Ferrand RA , Nicol MP",Sputum bacterial load and bacterial composition correlate with lung function and are altered by long-term azithromycin treatment in children with HIV-associated chronic lung disease,Microbiome,2023,"Adolescents, Africa, Bacteriome, FEV1z, HIV, Haemophilus, Microbiome, Moraxella, Obliterative bronchiolitis",Experiment 2,"Malawi,Zimbabwe",Homo sapiens,Sputum,UBERON:0007311,Azithromycin,CHEBI:2955,Placebo at 72 weeks,AZM at 72 weeks,Participants with HIV-associated Chronic Lung Disease (HCLD) who received  azithromycin (AZM),117,123,NIL,16S,4,Illumina,"DESeq2,ANCOM",0.05,TRUE,NA,NA,"age,sex",NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:822/3/NA,Study 822,randomized controlled trial,36803868,10.1186/s40168-023-01460-x,NA,"Abotsi RE, Dube FS, Rehman AM, Claassen-Weitz S, Xia Y, Simms V, Mwaikono KS, Gardner-Lubbe S, McHugh G, Ngwira LG, Kwambana-Adams B, Heyderman RS, Odland JØ, Ferrand RA , Nicol MP",Sputum bacterial load and bacterial composition correlate with lung function and are altered by long-term azithromycin treatment in children with HIV-associated chronic lung disease,Microbiome,2023,"Adolescents, Africa, Bacteriome, FEV1z, HIV, Haemophilus, Microbiome, Moraxella, Obliterative bronchiolitis",Experiment 3,"Malawi,Zimbabwe",Homo sapiens,Sputum,UBERON:0007311,Azithromycin,CHEBI:2955,AZM at baseline - Azithromycin arm only,AZM at 48 weeks - Azithromycin arm only,Participants with HIV-associated Chronic Lung Disease (HCLD) who received  azithromycin (AZM) at 48weeks,173,154,NIL,16S,4,Illumina,ANCOM,0.05,TRUE,NA,NA,"age,sex",NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:822/4/NA,Study 822,randomized controlled trial,36803868,10.1186/s40168-023-01460-x,NA,"Abotsi RE, Dube FS, Rehman AM, Claassen-Weitz S, Xia Y, Simms V, Mwaikono KS, Gardner-Lubbe S, McHugh G, Ngwira LG, Kwambana-Adams B, Heyderman RS, Odland JØ, Ferrand RA , Nicol MP",Sputum bacterial load and bacterial composition correlate with lung function and are altered by long-term azithromycin treatment in children with HIV-associated chronic lung disease,Microbiome,2023,"Adolescents, Africa, Bacteriome, FEV1z, HIV, Haemophilus, Microbiome, Moraxella, Obliterative bronchiolitis",Experiment 4,"Malawi,Zimbabwe",Homo sapiens,Sputum,UBERON:0007311,Azithromycin,CHEBI:2955,Placebo at 48 Weeks - Arm Only,Placebo at 72 Weeks - Arm Only,Placebo treatment at 72 Weeks (arm only),174,174,NIL,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,"age,sex",NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:822/5/NA,Study 822,randomized controlled trial,36803868,10.1186/s40168-023-01460-x,NA,"Abotsi RE, Dube FS, Rehman AM, Claassen-Weitz S, Xia Y, Simms V, Mwaikono KS, Gardner-Lubbe S, McHugh G, Ngwira LG, Kwambana-Adams B, Heyderman RS, Odland JØ, Ferrand RA , Nicol MP",Sputum bacterial load and bacterial composition correlate with lung function and are altered by long-term azithromycin treatment in children with HIV-associated chronic lung disease,Microbiome,2023,"Adolescents, Africa, Bacteriome, FEV1z, HIV, Haemophilus, Microbiome, Moraxella, Obliterative bronchiolitis",Experiment 5,"Malawi,Zimbabwe",Homo sapiens,Sputum,UBERON:0007311,Azithromycin,CHEBI:2955,Placebo at baseline,Placebo at 72 weeks,Placebo at 72 weeks,174,117,NIL,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,"age,sex",NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:823/1/NA,Study 823,case-control,31738825,10.1167/iovs.19-27719,NA,"Dong X, Wang Y, Wang W, Lin P , Huang Y",Composition and Diversity of Bacterial Community on the Ocular Surface of Patients With Meibomian Gland Dysfunction,Investigative ophthalmology & visual science,2019,NA,Experiment 1,China,Homo sapiens,"Margin of eyelid,Conjunctival sac","UBERON:0034772,UBERON:0005908",Dry eye syndrome,EFO:1000906,Healthy controls,Meibomian Gland Dysfunction (MGD) Groups,Patients with diagnosis of  Meibomian Gland Dysfunction MGD,42,47,No participant used oral antibiotics within 2 weeks,16S,34,Illumina,LEfSe,0.05,NA,4,"age,sex",NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:824/1/NA,Study 824,prospective cohort,37740058,10.1038/s41598-023-43108-8,https://pubmed.ncbi.nlm.nih.gov/37740058/,"Komori E, Kato-Kogoe N, Imai Y, Sakaguchi S, Taniguchi K, Omori M, Ohmichi M, Nakamura S, Nakano T, Lee SW , Ueno T",Changes in salivary microbiota due to gastric cancer resection and its relation to gastric fluid microbiota,Scientific reports,2023,NA,Experiment 1,Japan,Homo sapiens,Saliva,UBERON:0001836,Gastric cancer,MONDO:0001056,Gastric cancer patients (Pre-gastrectomy),Gastric cancer patients (Post-gastrectomy),Patients diagnosed with primary gastric cancer who underwent distal gastrectomy and B1 or RY reconstruction,63,63,Patients who were on antibiotics three months preceding the sample collection were excluded from the study,16S,12,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:824/2/NA,Study 824,prospective cohort,37740058,10.1038/s41598-023-43108-8,https://pubmed.ncbi.nlm.nih.gov/37740058/,"Komori E, Kato-Kogoe N, Imai Y, Sakaguchi S, Taniguchi K, Omori M, Ohmichi M, Nakamura S, Nakano T, Lee SW , Ueno T",Changes in salivary microbiota due to gastric cancer resection and its relation to gastric fluid microbiota,Scientific reports,2023,NA,Experiment 2,Japan,Homo sapiens,Gastric juice,UBERON:0001971,Gastric cancer,MONDO:0001056,Gastric cancer patients (Pre-gastrectomy),Gastric cancer patients (Post-gastrectomy),Patients diagnosed with primary gastric cancer who underwent distal gastrectomy and B1 or RY reconstruction,63,63,Patients who were on antibiotics three months preceding the sample collection were excluded from the study,16S,12,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,decreased,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:825/1/NA,Study 825,meta-analysis,37602324,https://doi.org/10.3389/fmolb.2023.1210225,NA,"Suryavanshi M, Agudelo J , Miller A","Rare phylotypes in stone, stool, and urine microbiomes are associated with urinary stone disease",Frontiers in molecular biosciences,2023,"human microbiome, kidney stones, rare phylotype, reference database, urinary stone disease, urobiome, urology",Experiment 1,NA,Homo sapiens,Feces,UBERON:0001988,Urolithiasis,MONDO:0024647,healthy controls,urinary stone disease patients,patients with urinary stone disease,136,201,NA,NA,NA,NA,DESeq2,0.05,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:825/2/NA,Study 825,meta-analysis,37602324,https://doi.org/10.3389/fmolb.2023.1210225,NA,"Suryavanshi M, Agudelo J , Miller A","Rare phylotypes in stone, stool, and urine microbiomes are associated with urinary stone disease",Frontiers in molecular biosciences,2023,"human microbiome, kidney stones, rare phylotype, reference database, urinary stone disease, urobiome, urology",Experiment 2,NA,Homo sapiens,Urine,UBERON:0001088,Urolithiasis,MONDO:0024647,healthy controls,urinary stone disease patients,patients with urinary stone disease,136,201,TEST,NA,NA,NA,DESeq2,0.05,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:826/1/NA,Study 826,"case-control,time series / longitudinal observational",37182146,10.3389/fonc.2023.1183039,NA,"Bucher-Johannessen C, Birkeland EE, Vinberg E, Bemanian V, Hoff G, Berstad P , Rounge TB",Long-term follow-up of colorectal cancer screening attendees identifies differences in <i>Phascolarctobacterium</i> spp. using 16S rRNA and metagenome sequencing,Frontiers in oncology,2023,"16S rRNA, archived fecal samples, colorectal cancer screening, long term follow-up, metagenome, microbiome, sequencing",Experiment 1,Norway,Homo sapiens,Feces,UBERON:0001988,Colorectal adenoma,EFO:0005406,Healthy controls,HRA (high-risk adenoma),"Individuals selected from available archive of fresh-frozen stool samples with high-risk adenomas were defined as those presenting with one or more adenomas of ≥10 mm, with high-grade dysplasia or villous components regardless of polyp size, or those with three or more adenomas regardless of size, dysplasia, and villosity.",53,63,NA,16S,34,Illumina,Negative Binomial Regression,0.05,TRUE,NA,"age,sex,time","geographic area,sex",NA,unchanged,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:826/2/NA,Study 826,"case-control,time series / longitudinal observational",37182146,10.3389/fonc.2023.1183039,NA,"Bucher-Johannessen C, Birkeland EE, Vinberg E, Bemanian V, Hoff G, Berstad P , Rounge TB",Long-term follow-up of colorectal cancer screening attendees identifies differences in <i>Phascolarctobacterium</i> spp. using 16S rRNA and metagenome sequencing,Frontiers in oncology,2023,"16S rRNA, archived fecal samples, colorectal cancer screening, long term follow-up, metagenome, microbiome, sequencing",Experiment 2,Norway,Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,Healthy controls,CRC (participants diagnosed with colorectal cancer),participants who were diagnosed with colorectal cancer at screening during the Norwegian Colorectal Prevention trial or by registry follow-up selected from available archive of fresh-frozen stool samples.,53,28,NA,16S,34,Illumina,Negative Binomial Regression,0.05,TRUE,NA,"age,sex,time","geographic area,sex",NA,unchanged,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:826/3/NA,Study 826,"case-control,time series / longitudinal observational",37182146,10.3389/fonc.2023.1183039,NA,"Bucher-Johannessen C, Birkeland EE, Vinberg E, Bemanian V, Hoff G, Berstad P , Rounge TB",Long-term follow-up of colorectal cancer screening attendees identifies differences in <i>Phascolarctobacterium</i> spp. using 16S rRNA and metagenome sequencing,Frontiers in oncology,2023,"16S rRNA, archived fecal samples, colorectal cancer screening, long term follow-up, metagenome, microbiome, sequencing",Experiment 3,Norway,Homo sapiens,Feces,UBERON:0001988,"Colorectal adenoma,Colorectal cancer","EFO:0005406,EFO:0005842",Healthy controls,HRA (high-risk adenoma) group combined with CRC (colorectal cancer) group,"Individuals selected from available archive of fresh-frozen stool samples with high-risk adenomas were defined as those presenting with one or more adenomas of ≥10 mm, with high-grade dysplasia or villous components regardless of polyp size, or those with three or more adenomas regardless of size, dysplasia, and villosity. Combined with individuals selected from available archive of fresh-frozen stool samples diagnosed with colorectal cancer at screening or by registry follow-up.",53,91,NA,16S,34,Illumina,Negative Binomial Regression,0.05,TRUE,NA,"age,sex,time","geographic area,sex",NA,unchanged,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:826/4/NA,Study 826,"case-control,time series / longitudinal observational",37182146,10.3389/fonc.2023.1183039,NA,"Bucher-Johannessen C, Birkeland EE, Vinberg E, Bemanian V, Hoff G, Berstad P , Rounge TB",Long-term follow-up of colorectal cancer screening attendees identifies differences in <i>Phascolarctobacterium</i> spp. using 16S rRNA and metagenome sequencing,Frontiers in oncology,2023,"16S rRNA, archived fecal samples, colorectal cancer screening, long term follow-up, metagenome, microbiome, sequencing",Experiment 4,Norway,Homo sapiens,Feces,UBERON:0001988,Colorectal adenoma,EFO:0005406,Healthy controls,HRA (high-risk adenoma),"Individuals selected from available archive of fresh-frozen stool samples with high-risk adenomas were defined as those presenting with one or more adenomas of ≥10 mm, with high-grade dysplasia or villous components regardless of polyp size, or those with three or more adenomas regardless of size, dysplasia, and villosity.",53,63,NA,WMS,NA,Illumina,Negative Binomial Regression,0.05,TRUE,NA,"age,sex,time","geographic area,sex",NA,unchanged,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:826/5/NA,Study 826,"case-control,time series / longitudinal observational",37182146,10.3389/fonc.2023.1183039,NA,"Bucher-Johannessen C, Birkeland EE, Vinberg E, Bemanian V, Hoff G, Berstad P , Rounge TB",Long-term follow-up of colorectal cancer screening attendees identifies differences in <i>Phascolarctobacterium</i> spp. using 16S rRNA and metagenome sequencing,Frontiers in oncology,2023,"16S rRNA, archived fecal samples, colorectal cancer screening, long term follow-up, metagenome, microbiome, sequencing",Experiment 5,Norway,Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,Healthy controls,CRC (participants diagnosed with colorectal cancer),participants who were diagnosed with colorectal cancer at screening during the Norwegian Colorectal Prevention trial or by registry follow-up selected from available archive of fresh-frozen stool samples.,22,7,NA,WMS,NA,Illumina,Negative Binomial Regression,0.05,TRUE,NA,"age,sex,time","geographic area,sex",NA,unchanged,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:826/6/NA,Study 826,"case-control,time series / longitudinal observational",37182146,10.3389/fonc.2023.1183039,NA,"Bucher-Johannessen C, Birkeland EE, Vinberg E, Bemanian V, Hoff G, Berstad P , Rounge TB",Long-term follow-up of colorectal cancer screening attendees identifies differences in <i>Phascolarctobacterium</i> spp. using 16S rRNA and metagenome sequencing,Frontiers in oncology,2023,"16S rRNA, archived fecal samples, colorectal cancer screening, long term follow-up, metagenome, microbiome, sequencing",Experiment 6,Norway,Homo sapiens,Feces,UBERON:0001988,"Colorectal adenoma,Colorectal cancer","EFO:0005406,EFO:0005842",Healthy controls,HRA (high-risk adenoma) group combined with CRC (colorectal cancer) group,"Individuals selected from available archive of fresh-frozen stool samples with high-risk adenomas were defined as those presenting with one or more adenomas of ≥10 mm, with high-grade dysplasia or villous components regardless of polyp size, or those with three or more adenomas regardless of size, dysplasia, and villosity. Combined with individuals selected from available archive of fresh-frozen stool samples diagnosed with colorectal cancer at screening or by registry follow-up.",22,25,NA,WMS,NA,Illumina,Negative Binomial Regression,0.05,TRUE,NA,"age,sex,time","geographic area,sex",NA,unchanged,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:826/7/NA,Study 826,"case-control,time series / longitudinal observational",37182146,10.3389/fonc.2023.1183039,NA,"Bucher-Johannessen C, Birkeland EE, Vinberg E, Bemanian V, Hoff G, Berstad P , Rounge TB",Long-term follow-up of colorectal cancer screening attendees identifies differences in <i>Phascolarctobacterium</i> spp. using 16S rRNA and metagenome sequencing,Frontiers in oncology,2023,"16S rRNA, archived fecal samples, colorectal cancer screening, long term follow-up, metagenome, microbiome, sequencing",Experiment 7,Norway,Homo sapiens,Feces,UBERON:0001988,Time,EFO:0000721,Colorectal cancer diagnosed at time of screening,Colorectal cancer diagnosed during 17-year follow-up/post screening,Diagnosed with colorectal cancer at screening in the beginning of the Norwegian Colorectal Cancer Prevention Trial,5,23,NA,16S,34,Illumina,Negative Binomial Regression,0.05,TRUE,NA,NA,"geographic area,sex",NA,unchanged,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:827/1/NA,Study 827,"cross-sectional observational, not case-control",35624429,10.1186/s12866-022-02557-3,NA,"Kirishima M, Yokoyama S, Matsuo K, Hamada T, Shimokawa M, Akahane T, Sugimoto T, Tsurumaru H, Ishibashi M, Mataki Y, Ootsuka T, Nomoto M, Hayashi C, Horiguchi A, Higashi M , Tanimoto A",Gallbladder microbiota composition is associated with pancreaticobiliary and gallbladder cancer prognosis,BMC microbiology,2022,"Alpha diversity, Beta diversity, Bile, Biomarker, Cancer, Gallbladder, Microbiota, Overall survival, Pancreaticobiliary tract, Prognosis",Experiment 1,Japan,Homo sapiens,Bile,UBERON:0001970,Disease progression measurement,EFO:0008336,Early cholangiocarcinoma,Advanced cholangiocarcinoma,"Patients with lymph node metastasis in cholangiocarcinoma, where lymph node metastasis denotes advanced stage and the absence of lymph node metastasis denotes early stage.",NA,NA,none,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:827/2/NA,Study 827,"cross-sectional observational, not case-control",35624429,10.1186/s12866-022-02557-3,NA,"Kirishima M, Yokoyama S, Matsuo K, Hamada T, Shimokawa M, Akahane T, Sugimoto T, Tsurumaru H, Ishibashi M, Mataki Y, Ootsuka T, Nomoto M, Hayashi C, Horiguchi A, Higashi M , Tanimoto A",Gallbladder microbiota composition is associated with pancreaticobiliary and gallbladder cancer prognosis,BMC microbiology,2022,"Alpha diversity, Beta diversity, Bile, Biomarker, Cancer, Gallbladder, Microbiota, Overall survival, Pancreaticobiliary tract, Prognosis",Experiment 2,Japan,Homo sapiens,Bile,UBERON:0001970,Disease progression measurement,EFO:0008336,Early pancreatic ductal adenocarcinoma,Advanced pancreatic ductal adenocarcinoma,"Patients with lymph node metastasis in pancreatic ductal adenocarcinoma (PDAC), where lymph node metastasis denotes advanced stage and the absence of lymph node metastasis denotes early stage.",NA,NA,none,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:827/3/NA,Study 827,"cross-sectional observational, not case-control",35624429,10.1186/s12866-022-02557-3,NA,"Kirishima M, Yokoyama S, Matsuo K, Hamada T, Shimokawa M, Akahane T, Sugimoto T, Tsurumaru H, Ishibashi M, Mataki Y, Ootsuka T, Nomoto M, Hayashi C, Horiguchi A, Higashi M , Tanimoto A",Gallbladder microbiota composition is associated with pancreaticobiliary and gallbladder cancer prognosis,BMC microbiology,2022,"Alpha diversity, Beta diversity, Bile, Biomarker, Cancer, Gallbladder, Microbiota, Overall survival, Pancreaticobiliary tract, Prognosis",Experiment 3,Japan,Homo sapiens,Bile,UBERON:0001970,Disease progression measurement,EFO:0008336,intraductal papillary mucinous neoplasm (IPMN),Intraductal papillary mucinous carcinoma (IPMC),Patients with Intraductal papillary mucinous carcinoma (IPMC) in pancreas cystic lesions.,20,10,none,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:827/4/NA,Study 827,"cross-sectional observational, not case-control",35624429,10.1186/s12866-022-02557-3,NA,"Kirishima M, Yokoyama S, Matsuo K, Hamada T, Shimokawa M, Akahane T, Sugimoto T, Tsurumaru H, Ishibashi M, Mataki Y, Ootsuka T, Nomoto M, Hayashi C, Horiguchi A, Higashi M , Tanimoto A",Gallbladder microbiota composition is associated with pancreaticobiliary and gallbladder cancer prognosis,BMC microbiology,2022,"Alpha diversity, Beta diversity, Bile, Biomarker, Cancer, Gallbladder, Microbiota, Overall survival, Pancreaticobiliary tract, Prognosis",Experiment 4,Japan,Homo sapiens,Bile,UBERON:0001970,Disease prognosis measurement,EFO:0007936,Poor prognosis in bile duct lesion cases,Good prognosis in bile duct lesion cases,"The group with good prognostic factors after adjustment for clinicopathologic variables ( sex, age, ASA score, stages, and the administration of preoperative chemotherapy) in bile duct lesion cases. These clinical conditions were found to be non-confounding.",101,101,none,16S,34,Illumina,Cox Proportional-Hazards Regression,0.05,NA,NA,NA,NA,unchanged,increased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:827/5/NA,Study 827,"cross-sectional observational, not case-control",35624429,10.1186/s12866-022-02557-3,NA,"Kirishima M, Yokoyama S, Matsuo K, Hamada T, Shimokawa M, Akahane T, Sugimoto T, Tsurumaru H, Ishibashi M, Mataki Y, Ootsuka T, Nomoto M, Hayashi C, Horiguchi A, Higashi M , Tanimoto A",Gallbladder microbiota composition is associated with pancreaticobiliary and gallbladder cancer prognosis,BMC microbiology,2022,"Alpha diversity, Beta diversity, Bile, Biomarker, Cancer, Gallbladder, Microbiota, Overall survival, Pancreaticobiliary tract, Prognosis",Experiment 5,Japan,Homo sapiens,Bile,UBERON:0001970,Disease prognosis measurement,EFO:0007936,Poor prognosis in pancreatic lesion cases,Good prognosis in pancreatic lesion cases,"The group with good prognostic factors after adjustment for clinicopathologic variables ( sex, age, ASA score, stages, and the administration of preoperative chemotherapy) in pancreatic lesion cases. These clinicopathologic variables were found to be non-confounding.",112,112,none,16S,34,Illumina,Cox Proportional-Hazards Regression,0.05,NA,NA,NA,NA,unchanged,increased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:828/1/NA,Study 828,"cross-sectional observational, not case-control",37803040,10.1038/s41598-023-43040-x,NA,"Bellato M, Cappellato M, Longhin F, Del Vecchio C, Brancaccio G, Cattelan AM, Brun P, Salaris C, Castagliuolo I , Di Camillo B",Uncover a microbiota signature of upper respiratory tract in patients with SARS-CoV-2 + ,Scientific reports,2023,NA,Experiment 1,Italy,Homo sapiens,Nasal cavity,UBERON:0001707,COVID-19,MONDO:0100096,Asymptomatic patients,Symptomatic patients,Symptomatic patients with signs of COVID-19,36,156,Patients were excluded from the study if they had received antibiotics within 4 weeks of enrollment.,16S,34,Illumina,MaAsLin2,0.05,TRUE,NA,NA,NA,unchanged,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:828/2/NA,Study 828,"cross-sectional observational, not case-control",37803040,10.1038/s41598-023-43040-x,NA,"Bellato M, Cappellato M, Longhin F, Del Vecchio C, Brancaccio G, Cattelan AM, Brun P, Salaris C, Castagliuolo I , Di Camillo B",Uncover a microbiota signature of upper respiratory tract in patients with SARS-CoV-2 + ,Scientific reports,2023,NA,Experiment 2,Italy,Homo sapiens,Nasal cavity,UBERON:0001707,"COVID-19,Pneumonia","EFO:0003106,MONDO:0100096",COVID-19 patients with mild pneumonia,COVID-19 patients with severe pneumonia,"COVID-19 patients with severe pneumonia. Severe pneumonia is a type of pneumonia that is characterized by inflammation of the lungs, difficulty breathing, and low oxygen levels in the blood. It can be a life-threatening condition. 

This was the most exposed group in the study",17,89,4 weeks,16S,34,Illumina,MaAsLin2,0.05,TRUE,NA,NA,NA,unchanged,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:828/3/NA,Study 828,"cross-sectional observational, not case-control",37803040,10.1038/s41598-023-43040-x,NA,"Bellato M, Cappellato M, Longhin F, Del Vecchio C, Brancaccio G, Cattelan AM, Brun P, Salaris C, Castagliuolo I , Di Camillo B",Uncover a microbiota signature of upper respiratory tract in patients with SARS-CoV-2 + ,Scientific reports,2023,NA,Experiment 3,Italy,Homo sapiens,Nasal cavity,UBERON:0001707,"COVID-19,Respiratory failure requiring assisted ventilation","MONDO:0100096,HP:0004887",Non-intubated,Intubated,Patients unable to provide enough oxygen to their body.,0,18,4 weeks,16S,34,Illumina,MaAsLin2,0.05,TRUE,NA,NA,NA,unchanged,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:828/4/NA,Study 828,"cross-sectional observational, not case-control",37803040,10.1038/s41598-023-43040-x,NA,"Bellato M, Cappellato M, Longhin F, Del Vecchio C, Brancaccio G, Cattelan AM, Brun P, Salaris C, Castagliuolo I , Di Camillo B",Uncover a microbiota signature of upper respiratory tract in patients with SARS-CoV-2 + ,Scientific reports,2023,NA,Experiment 4,Italy,Homo sapiens,Nasal cavity,UBERON:0001707,Response to supplemental oxygen,EFO:0009796,No Supplemental O2,Supplemental O2 (High/Low),Patients in need of supply of oxygen to help them breathe better and keep their blood oxygen levels up.,0,72,4 weeks,16S,34,Illumina,MaAsLin2,0.05,TRUE,NA,NA,NA,unchanged,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:829/1/NA,Study 829,"cross-sectional observational, not case-control",37556398,10.1371/journal.pone.0287839,NA,"Holdsworth EA, Williams JE, Pace RM, Lane AA, Gartstein M, McGuire MA, McGuire MK , Meehan CL","Breastfeeding patterns are associated with human milk microbiome composition: The Mother-Infant Microbiomes, Behavior, and Ecology Study (MIMBES)",PloS one,2023,NA,Experiment 1,United States of America,Homo sapiens,Milk,UBERON:0001913,Breastfeeding duration,EFO:0006864,Medium Total Time Breastfeeding,Low Total Time Breastfeeding,Breastfeeding pattern,28,10,Any antibiotics consumed by or administered to the mother or infant in the past 30 days,16S,123,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:829/2/NA,Study 829,"cross-sectional observational, not case-control",37556398,10.1371/journal.pone.0287839,NA,"Holdsworth EA, Williams JE, Pace RM, Lane AA, Gartstein M, McGuire MA, McGuire MK , Meehan CL","Breastfeeding patterns are associated with human milk microbiome composition: The Mother-Infant Microbiomes, Behavior, and Ecology Study (MIMBES)",PloS one,2023,NA,Experiment 2,United States of America,Homo sapiens,Milk,UBERON:0001913,Breastfeeding duration,EFO:0006864,Medium Total Time Breastfeeding,High Total Time Breastfeeding,Breastfeeding pattern,28,8,Any antibiotics consumed by or administered to the mother or infant in the past 30 days,16S,123,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:829/3/NA,Study 829,"cross-sectional observational, not case-control",37556398,10.1371/journal.pone.0287839,NA,"Holdsworth EA, Williams JE, Pace RM, Lane AA, Gartstein M, McGuire MA, McGuire MK , Meehan CL","Breastfeeding patterns are associated with human milk microbiome composition: The Mother-Infant Microbiomes, Behavior, and Ecology Study (MIMBES)",PloS one,2023,NA,Experiment 3,United States of America,Homo sapiens,Milk,UBERON:0001913,Breastfeeding duration,EFO:0006864,Medium Breastfeeding Bouts,Low Breastfeeding Bouts,Breastfeeding pattern,30,10,Any antibiotics consumed by or administered to the mother or infant in the past 30 days,16S,123,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:829/4/NA,Study 829,"cross-sectional observational, not case-control",37556398,10.1371/journal.pone.0287839,NA,"Holdsworth EA, Williams JE, Pace RM, Lane AA, Gartstein M, McGuire MA, McGuire MK , Meehan CL","Breastfeeding patterns are associated with human milk microbiome composition: The Mother-Infant Microbiomes, Behavior, and Ecology Study (MIMBES)",PloS one,2023,NA,Experiment 4,United States of America,Homo sapiens,Milk,UBERON:0001913,Breastfeeding duration,EFO:0006864,Medium Breastfeeding Bouts,High Breastfeeding Bouts,Breastfeeding pattern,30,6,Any antibiotics consumed by or administered to the mother or infant in the past 30 days,16S,123,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:830/1/NA,Study 830,case-control,34900990,10.3389/fcell.2021.731867,NA,"Liang Q, Li J, Zou Y, Hu X, Deng X, Zou B, Liu Y, Wei L, Liang L , Wen X",Metagenomic Analysis Reveals the Heterogeneity of Conjunctival Microbiota Dysbiosis in Dry Eye Disease,Frontiers in cell and developmental biology,2021,"aqueous tear deficiency, conjunctival microbiota, dry eye disease, meibomian gland dysfunction, metagenomic shotgun sequencing",Experiment 1,China,Homo sapiens,Bulbar conjunctiva,UBERON:0010306,Biological sex,PATO:0000047,female patients with dry eye disease,male patients with dry eye disease,male patients with dry eye disease,22,25,90 days prior to enrollment,WMS,NA,Illumina,Linear Regression,0.05,NA,NA,NA,age,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:830/2/NA,Study 830,case-control,34900990,10.3389/fcell.2021.731867,NA,"Liang Q, Li J, Zou Y, Hu X, Deng X, Zou B, Liu Y, Wei L, Liang L , Wen X",Metagenomic Analysis Reveals the Heterogeneity of Conjunctival Microbiota Dysbiosis in Dry Eye Disease,Frontiers in cell and developmental biology,2021,"aqueous tear deficiency, conjunctival microbiota, dry eye disease, meibomian gland dysfunction, metagenomic shotgun sequencing",Experiment 2,China,Homo sapiens,Bulbar conjunctiva,UBERON:0010306,Biological sex,PATO:0000047,Healthy female,Healthy male,Healthy male without dry eye disease,22,25,90 days prior to enrollment,WMS,NA,Illumina,Linear Regression,0.05,NA,NA,NA,age,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:830/3/NA,Study 830,case-control,34900990,10.3389/fcell.2021.731867,NA,"Liang Q, Li J, Zou Y, Hu X, Deng X, Zou B, Liu Y, Wei L, Liang L , Wen X",Metagenomic Analysis Reveals the Heterogeneity of Conjunctival Microbiota Dysbiosis in Dry Eye Disease,Frontiers in cell and developmental biology,2021,"aqueous tear deficiency, conjunctival microbiota, dry eye disease, meibomian gland dysfunction, metagenomic shotgun sequencing",Experiment 3,China,Homo sapiens,Bulbar conjunctiva,UBERON:0010306,Dry eye syndrome,EFO:1000906,Aqueous tear deficient (ATD) DED,Meibomian Gland Dysfunction (MGD) DED,Patients with MGD DED,14,19,90 days prior to study enrollment,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.15,NA,NA,NA,"age,sex",NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:830/4/NA,Study 830,case-control,34900990,10.3389/fcell.2021.731867,NA,"Liang Q, Li J, Zou Y, Hu X, Deng X, Zou B, Liu Y, Wei L, Liang L , Wen X",Metagenomic Analysis Reveals the Heterogeneity of Conjunctival Microbiota Dysbiosis in Dry Eye Disease,Frontiers in cell and developmental biology,2021,"aqueous tear deficiency, conjunctival microbiota, dry eye disease, meibomian gland dysfunction, metagenomic shotgun sequencing",Experiment 4,China,Homo sapiens,Bulbar conjunctiva,UBERON:0010306,Dry eye syndrome,EFO:1000906,Aqueous tear deficient (ATD) DED,Mixed DED,Patients with mixed type diagnosis of DED (more closely related to MGD than ATD),14,35,90 days prior to study enrollment,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.15,NA,NA,NA,"age,sex",NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:830/5/NA,Study 830,case-control,34900990,10.3389/fcell.2021.731867,NA,"Liang Q, Li J, Zou Y, Hu X, Deng X, Zou B, Liu Y, Wei L, Liang L , Wen X",Metagenomic Analysis Reveals the Heterogeneity of Conjunctival Microbiota Dysbiosis in Dry Eye Disease,Frontiers in cell and developmental biology,2021,"aqueous tear deficiency, conjunctival microbiota, dry eye disease, meibomian gland dysfunction, metagenomic shotgun sequencing",Experiment 5,China,Homo sapiens,Bulbar conjunctiva,UBERON:0010306,Dry eye syndrome,EFO:1000906,Meibomian Gland Dysfunction (MGD) DED,Mixed DED,Patients with mixed type diagnosis of DED (more closely related to MGD than ATD),19,35,90 days prior to study enrollment,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.15,NA,NA,NA,"age,sex",NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:830/6/NA,Study 830,case-control,34900990,10.3389/fcell.2021.731867,NA,"Liang Q, Li J, Zou Y, Hu X, Deng X, Zou B, Liu Y, Wei L, Liang L , Wen X",Metagenomic Analysis Reveals the Heterogeneity of Conjunctival Microbiota Dysbiosis in Dry Eye Disease,Frontiers in cell and developmental biology,2021,"aqueous tear deficiency, conjunctival microbiota, dry eye disease, meibomian gland dysfunction, metagenomic shotgun sequencing",Experiment 6,China,Homo sapiens,Bulbar conjunctiva,UBERON:0010306,Dry eye syndrome,EFO:1000906,healthy controls,Dry Eye,Patients with Dry eye disease,48,47,90 days prior to study enrollment,WMS,NA,Illumina,MaAsLin2,0.05,NA,NA,NA,"age,sex",NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:830/7/NA,Study 830,case-control,34900990,10.3389/fcell.2021.731867,NA,"Liang Q, Li J, Zou Y, Hu X, Deng X, Zou B, Liu Y, Wei L, Liang L , Wen X",Metagenomic Analysis Reveals the Heterogeneity of Conjunctival Microbiota Dysbiosis in Dry Eye Disease,Frontiers in cell and developmental biology,2021,"aqueous tear deficiency, conjunctival microbiota, dry eye disease, meibomian gland dysfunction, metagenomic shotgun sequencing",Experiment 7,China,Homo sapiens,Bulbar conjunctiva,UBERON:0010306,Dry eye syndrome,EFO:1000906,Dry Eye -nonATD,Dry Eye- ATD,Patients with Dry eye disease characterized as aqueous tear deficient,54,14,90 days prior to study enrollment,WMS,NA,Illumina,MaAsLin2,0.1,NA,NA,NA,"age,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:830/8/NA,Study 830,case-control,34900990,10.3389/fcell.2021.731867,NA,"Liang Q, Li J, Zou Y, Hu X, Deng X, Zou B, Liu Y, Wei L, Liang L , Wen X",Metagenomic Analysis Reveals the Heterogeneity of Conjunctival Microbiota Dysbiosis in Dry Eye Disease,Frontiers in cell and developmental biology,2021,"aqueous tear deficiency, conjunctival microbiota, dry eye disease, meibomian gland dysfunction, metagenomic shotgun sequencing",Experiment 8,China,Homo sapiens,Bulbar conjunctiva,UBERON:0010306,Dry eye syndrome,EFO:1000906,Dry Eye -nonMGD,Dry Eye- MGD,Patients with Dry eye disease characterized as meibomian gland disorder,49,19,90 days prior to study enrollment,WMS,NA,Illumina,MaAsLin2,0.1,NA,NA,NA,"age,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:831/1/NA,Study 831,time series / longitudinal observational,37596518,https://doi.org/10.1186/s12879-023-08511-6,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10436399/,"Galperine T, Choi Y, Pagani JL, Kritikos A, Papadimitriou-Olivgeris M, Méan M, Scherz V, Opota O, Greub G, Guery B , Bertelli C",Temporal changes in fecal microbiota of patients infected with COVID-19: a longitudinal cohort,BMC infectious diseases,2023,"COVID-19, Gut microbiota, Gut-lung axis, Microbiota profiling, SARS-CoV-2",Experiment 1,Switzerland,Homo sapiens,Feces,UBERON:0001988,COVID-19,MONDO:0100096,Non-Covid 19 Patients - pneumonia patients,COVID-19 Patients,Patients admitted for COVID-19,19,57,3 Months,16S,34,Illumina,LEfSe,0.05,TRUE,2.5,NA,NA,NA,decreased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:831/2/NA,Study 831,time series / longitudinal observational,37596518,https://doi.org/10.1186/s12879-023-08511-6,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10436399/,"Galperine T, Choi Y, Pagani JL, Kritikos A, Papadimitriou-Olivgeris M, Méan M, Scherz V, Opota O, Greub G, Guery B , Bertelli C",Temporal changes in fecal microbiota of patients infected with COVID-19: a longitudinal cohort,BMC infectious diseases,2023,"COVID-19, Gut microbiota, Gut-lung axis, Microbiota profiling, SARS-CoV-2",Experiment 2,Switzerland,Homo sapiens,Feces,UBERON:0001988,COVID-19,MONDO:0100096,COVID-19 patients - Non-Ventilated,COVID-19 patients - Ventilated,COVID-19 patients in Intensive Care Unit [ICU] - Ventilated,43,14,3 Months,16S,34,Illumina,LEfSe,0.05,TRUE,2.5,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:832/1/NA,Study 832,"cross-sectional observational, not case-control,prospective cohort",37119735,10.1016/j.ebiom.2023.104583,NA,"Palmu J, Börschel CS, Ortega-Alonso A, Markó L, Inouye M, Jousilahti P, Salido RA, Sanders K, Brennan C, Humphrey GC, Sanders JG, Gutmann F, Linz D, Salomaa V, Havulinna AS, Forslund SK, Knight R, Lahti L, Niiranen T , Schnabel RB",Gut microbiome and atrial fibrillation-results from a large population-based study,EBioMedicine,2023,"Atrial fibrillation, Epidemiology, Gut microbiome, Metagenomics",Experiment 1,Finland,Homo sapiens,Feces,UBERON:0001988,Atrial fibrillation,EFO:0000275,Individuals without Prevalent Atrial Fibrillation (AF),Individuals with Prevalent Atrial Fibrillation (AF),Participants with prevalent atrial fibrillation. Atrial fibrillation (AF) is an important heart rhythm disorder in aging populations,6647,116,None.,WMS,NA,Illumina,DESeq2,0.05,TRUE,NA,NA,"age,alcohol consumption measurement,blood pressure,body mass index,diabetes mellitus,physical activity,sex,smoking status,total cholesterol measurement",NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:832/2/NA,Study 832,"cross-sectional observational, not case-control,prospective cohort",37119735,10.1016/j.ebiom.2023.104583,NA,"Palmu J, Börschel CS, Ortega-Alonso A, Markó L, Inouye M, Jousilahti P, Salido RA, Sanders K, Brennan C, Humphrey GC, Sanders JG, Gutmann F, Linz D, Salomaa V, Havulinna AS, Forslund SK, Knight R, Lahti L, Niiranen T , Schnabel RB",Gut microbiome and atrial fibrillation-results from a large population-based study,EBioMedicine,2023,"Atrial fibrillation, Epidemiology, Gut microbiome, Metagenomics",Experiment 2,Finland,Homo sapiens,Feces,UBERON:0001988,Atrial fibrillation,EFO:0000275,Individuals without Incident Atrial Fibrillation (AF),Individuals with Incident Atrial Fibrillation (AF),"Incident AF refers to new cases of atrial fibrillation that occurred during the follow-up period of the study, among individuals who did not have a history of atrial fibrillation at baseline.",6647,539,None.,WMS,NA,Illumina,DESeq2,0.05,TRUE,NA,NA,"age,alcohol consumption measurement,blood pressure,body mass index,diabetes mellitus,sex,smoking status,total cholesterol measurement",NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:832/3/NA,Study 832,"cross-sectional observational, not case-control,prospective cohort",37119735,10.1016/j.ebiom.2023.104583,NA,"Palmu J, Börschel CS, Ortega-Alonso A, Markó L, Inouye M, Jousilahti P, Salido RA, Sanders K, Brennan C, Humphrey GC, Sanders JG, Gutmann F, Linz D, Salomaa V, Havulinna AS, Forslund SK, Knight R, Lahti L, Niiranen T , Schnabel RB",Gut microbiome and atrial fibrillation-results from a large population-based study,EBioMedicine,2023,"Atrial fibrillation, Epidemiology, Gut microbiome, Metagenomics",Experiment 3,Finland,Homo sapiens,Feces,UBERON:0001988,Atrial fibrillation,EFO:0000275,NA,Individuals with Incident Atrial Fibrillation (AF),"Incident AF refers to new cases of atrial fibrillation that occurred during the follow-up period of the study, among individuals who did not have a history of atrial fibrillation at baseline.",NA,6923,NA,WMS,NA,Illumina,Cox Proportional-Hazards Regression,0.05,TRUE,NA,"age,body mass index,sex","age,body mass index,diabetes mellitus,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:833/1/NA,Study 833,case-control,36624530,10.1186/s40168-022-01450-5,NA,"Jacobs JP, Lagishetty V, Hauer MC, Labus JS, Dong TS, Toma R, Vuyisich M, Naliboff BD, Lackner JM, Gupta A, Tillisch K , Mayer EA",Multi-omics profiles of the intestinal microbiome in irritable bowel syndrome and its bowel habit subtypes,Microbiome,2023,"Biomarkers, Bowel habit subtypes, Irritable bowel syndrome, Metabolomics, Metatranscriptomics, Microbiome, Multi-omics",Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Irritable bowel syndrome,EFO:0000555,Healthy controls,Irritable Bowel Syndrome,Patients diagnosed with Irritable Bowel Syndrome via Rome III criteria,177,318,12 weeks,16S,4,Illumina,Random Forest Analysis,0.05,TRUE,NA,NA,"age,anxiety disorder,body mass index,diet,race,sex",NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:834/1/NA,Study 834,case-control,37737154,10.1186/s12866-023-03020-7,NA,"Luan M, Niu M, Yang P, Han D, Zhang Y, Li W, He Q, Zhao Y, Mao B, Chen J, Mou K , Li P",Metagenomic sequencing reveals altered gut microbial compositions and gene functions in patients with non-segmental vitiligo,BMC microbiology,2023,"Gut microbiota, Metagenomic sequencing, Vitiligo",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Vitiligo,EFO:0004208,Healthy controls,Non-segmental Vitiligo patients,"Individuals characterized by the progressive loss of skin pigmentation in various areas of the body, resulting in depigmented white patches that is mostly widespread in distribution.",25,25,3 months,WMS,NA,BGISEQ-500 Sequencing,"Mann-Whitney (Wilcoxon),LEfSe",0.05,TRUE,2,"age,body mass index,sex",NA,NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:835/1/NA,Study 835,time series / longitudinal observational,37798293,10.1038/s41541-023-00745-4,NA,"Zhao S, Lok KYW, Sin ZY, Peng Y, Fan HSL, Nagesh N, Choi MSL, Kwok JYY, Choi EPH, Zhang X, Wai HK, Tsang LCH, Cheng SSM, Wong MKL, Zhu J, Mok CKP, Ng SC, Chan FKL, Peiris M, Poon LLM , Tun HM",COVID-19 mRNA vaccine-mediated antibodies in human breast milk and their association with breast milk microbiota composition,NPJ vaccines,2023,NA,Experiment 1,China,Homo sapiens,"Breast,Milk","UBERON:0000310,UBERON:0001913","Response to vaccine,Timepoint","EFO:0004645,EFO:0000724",Mothers at pre-vaccination timepoint,Mothers at post vaccination timepoints,"Breastfeeding mothers at post vaccination timepoints; one week post-first dose, one week post second-dose, one month post-second dose.",44,44,None,16S,34,Illumina,LEfSe,0.05,FALSE,1.5,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:835/2/NA,Study 835,time series / longitudinal observational,37798293,10.1038/s41541-023-00745-4,NA,"Zhao S, Lok KYW, Sin ZY, Peng Y, Fan HSL, Nagesh N, Choi MSL, Kwok JYY, Choi EPH, Zhang X, Wai HK, Tsang LCH, Cheng SSM, Wong MKL, Zhu J, Mok CKP, Ng SC, Chan FKL, Peiris M, Poon LLM , Tun HM",COVID-19 mRNA vaccine-mediated antibodies in human breast milk and their association with breast milk microbiota composition,NPJ vaccines,2023,NA,Experiment 2,China,Homo sapiens,"Breast,Milk","UBERON:0000310,UBERON:0001913",Response to vaccine,EFO:0004645,Low IgA mothers at Baseline,High IgA mothers at Baseline,Breastfeeding mothers with high IgA at baseline,25,18,None,16S,34,Illumina,LEfSe,0.004,FALSE,2,NA,NA,NA,increased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:835/3/NA,Study 835,time series / longitudinal observational,37798293,10.1038/s41541-023-00745-4,NA,"Zhao S, Lok KYW, Sin ZY, Peng Y, Fan HSL, Nagesh N, Choi MSL, Kwok JYY, Choi EPH, Zhang X, Wai HK, Tsang LCH, Cheng SSM, Wong MKL, Zhu J, Mok CKP, Ng SC, Chan FKL, Peiris M, Poon LLM , Tun HM",COVID-19 mRNA vaccine-mediated antibodies in human breast milk and their association with breast milk microbiota composition,NPJ vaccines,2023,NA,Experiment 3,China,Homo sapiens,"Breast,Milk","UBERON:0000310,UBERON:0001913",Response to vaccine,EFO:0004645,Low IgA mothers at one week post-second dose,High IgA mothers at one week post-second dose,Breastfeeding mothers with high IgA at one week after receiving the second dose of the SARS-CoV-2 mRNA vaccine (BNT162b2).,25,18,None,16S,34,Illumina,LEfSe,0.004,FALSE,2,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:835/4/NA,Study 835,time series / longitudinal observational,37798293,10.1038/s41541-023-00745-4,NA,"Zhao S, Lok KYW, Sin ZY, Peng Y, Fan HSL, Nagesh N, Choi MSL, Kwok JYY, Choi EPH, Zhang X, Wai HK, Tsang LCH, Cheng SSM, Wong MKL, Zhu J, Mok CKP, Ng SC, Chan FKL, Peiris M, Poon LLM , Tun HM",COVID-19 mRNA vaccine-mediated antibodies in human breast milk and their association with breast milk microbiota composition,NPJ vaccines,2023,NA,Experiment 4,China,Homo sapiens,"Breast,Milk","UBERON:0000310,UBERON:0001913",Response to vaccine,EFO:0004645,Mothers at pre-vaccination timepoint (baseline),Mothers at one week post-first dose,Breastfeeding mothers at one week after receiving the first dose of BNT162b2 vaccine.,44,44,None,16S,34,Illumina,LEfSe,0.05,FALSE,1.5,NA,NA,NA,unchanged,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:835/5/NA,Study 835,time series / longitudinal observational,37798293,10.1038/s41541-023-00745-4,NA,"Zhao S, Lok KYW, Sin ZY, Peng Y, Fan HSL, Nagesh N, Choi MSL, Kwok JYY, Choi EPH, Zhang X, Wai HK, Tsang LCH, Cheng SSM, Wong MKL, Zhu J, Mok CKP, Ng SC, Chan FKL, Peiris M, Poon LLM , Tun HM",COVID-19 mRNA vaccine-mediated antibodies in human breast milk and their association with breast milk microbiota composition,NPJ vaccines,2023,NA,Experiment 5,China,Homo sapiens,"Breast,Milk","UBERON:0000310,UBERON:0001913",Response to vaccine,EFO:0004645,Mothers at pre-vaccination timepoint (baseline),Mothers at one week post-second dose,Breastfeeding mothers at one week post-second dose of BNT162b2 vaccine.,44,43,None,16S,34,Illumina,LEfSe,0.05,FALSE,1.5,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:835/6/NA,Study 835,time series / longitudinal observational,37798293,10.1038/s41541-023-00745-4,NA,"Zhao S, Lok KYW, Sin ZY, Peng Y, Fan HSL, Nagesh N, Choi MSL, Kwok JYY, Choi EPH, Zhang X, Wai HK, Tsang LCH, Cheng SSM, Wong MKL, Zhu J, Mok CKP, Ng SC, Chan FKL, Peiris M, Poon LLM , Tun HM",COVID-19 mRNA vaccine-mediated antibodies in human breast milk and their association with breast milk microbiota composition,NPJ vaccines,2023,NA,Experiment 6,China,Homo sapiens,"Breast,Milk","UBERON:0000310,UBERON:0001913",Response to vaccine,EFO:0004645,Mothers at pre-vaccination timepoint (baseline),Mothers at one month post second-dose,Breastfeeding mothers at one month post second-dose of BNT162b2 vaccine.,44,44,None,16S,34,Illumina,LEfSe,0.05,FALSE,1.5,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:836/1/NA,Study 836,case-control,NA,10.3389/fcimb.2021.770913,https://www.frontiersin.org/articles/10.3389/fcimb.2021.770913/full,"Shuo Wang, Yuan Wei, Luyan Liu, Zailing Li",Association Between Breastmilk Microbiota and Food Allergy in Infants,NA,2022,"breast milk microbiome, breastfeeding, food allergies, butyrate, infant",Experiment 1,China,Homo sapiens,Milk,UBERON:0001913,Food allergy,EFO:1001890,non-allergy (NA) group,food allergy (FA) group,Group with food allergy.,22,11,"use of antibiotics or probiotics for 2 weeks
before or after delivery, resulted in being excluded from the study",16S,34,Illumina,LEfSe,0.05,NA,2,"gestational age,maternal age,race",NA,NA,unchanged,decreased,unchanged,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:837/1/NA,Study 837,case-control,38243297,10.1186/s13293-024-00582-7,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10797902/,"Garcia-Fernandez H, Arenas-de Larriva AP, Lopez-Moreno J, Gutierrez-Mariscal FM, Romero-Cabrera JL, Molina-Abril H, Torres-Peña JD, Rodriguez-Cano D, Malagon MM, Ordovas JM, Delgado-Lista J, Perez-Martinez P, Lopez-Miranda J , Camargo A",Sex-specific differences in intestinal microbiota associated with cardiovascular diseases,Biology of sex differences,2024,"CORDIOPREV, Cardiovascular diseases, Dysbiosis, Gut microbiota, Sexual dimorphism",Experiment 1,Spain,Homo sapiens,Feces,UBERON:0001988,Cardiovascular disease,EFO:0000319,Men with coronary heart disease (CHD),Women with coronary heart disease (CHD),"Women with coronary heart disease, and enrolled in the CORDIOPREV study.",567,112,1 month,16S,NA,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:837/2/NA,Study 837,case-control,38243297,10.1186/s13293-024-00582-7,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10797902/,"Garcia-Fernandez H, Arenas-de Larriva AP, Lopez-Moreno J, Gutierrez-Mariscal FM, Romero-Cabrera JL, Molina-Abril H, Torres-Peña JD, Rodriguez-Cano D, Malagon MM, Ordovas JM, Delgado-Lista J, Perez-Martinez P, Lopez-Miranda J , Camargo A",Sex-specific differences in intestinal microbiota associated with cardiovascular diseases,Biology of sex differences,2024,"CORDIOPREV, Cardiovascular diseases, Dysbiosis, Gut microbiota, Sexual dimorphism",Experiment 2,Spain,Homo sapiens,Feces,UBERON:0001988,Cardiovascular disease,EFO:0000319,Men without cardiovascular disease,Women without cardiovascular disease,"Women without cardiovascular disease, and enrolled in the ONCOVER study",242,87,1 month,16S,NA,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:837/3/NA,Study 837,case-control,38243297,10.1186/s13293-024-00582-7,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10797902/,"Garcia-Fernandez H, Arenas-de Larriva AP, Lopez-Moreno J, Gutierrez-Mariscal FM, Romero-Cabrera JL, Molina-Abril H, Torres-Peña JD, Rodriguez-Cano D, Malagon MM, Ordovas JM, Delgado-Lista J, Perez-Martinez P, Lopez-Miranda J , Camargo A",Sex-specific differences in intestinal microbiota associated with cardiovascular diseases,Biology of sex differences,2024,"CORDIOPREV, Cardiovascular diseases, Dysbiosis, Gut microbiota, Sexual dimorphism",Experiment 3,Spain,Homo sapiens,Feces,UBERON:0001988,Cardiovascular disease,EFO:0000319,Men without cardiovascular disease,Men with coronary heart disease (CHD),"Men with coronary heart disease, and enrolled in the CORDIOPREV study.",242,567,1 month,16S,NA,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,decreased,NA,decreased,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:837/4/NA,Study 837,case-control,38243297,10.1186/s13293-024-00582-7,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10797902/,"Garcia-Fernandez H, Arenas-de Larriva AP, Lopez-Moreno J, Gutierrez-Mariscal FM, Romero-Cabrera JL, Molina-Abril H, Torres-Peña JD, Rodriguez-Cano D, Malagon MM, Ordovas JM, Delgado-Lista J, Perez-Martinez P, Lopez-Miranda J , Camargo A",Sex-specific differences in intestinal microbiota associated with cardiovascular diseases,Biology of sex differences,2024,"CORDIOPREV, Cardiovascular diseases, Dysbiosis, Gut microbiota, Sexual dimorphism",Experiment 4,Spain,Homo sapiens,Feces,UBERON:0001988,Cardiovascular disease,EFO:0000319,Women without cardiovascular disease,Women with coronary heart disease (CHD),"Women with coronary heart disease, and enrolled in the CORDIOPREV study",87,112,1 month,16S,NA,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,decreased,NA,decreased,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:838/1/NA,Study 838,case-control,26277095,10.1186/s12920-015-0121-1,NA,"Castro-Nallar E, Shen Y, Freishtat RJ, Pérez-Losada M, Manimaran S, Liu G, Johnson WE , Crandall KA",Integrating microbial and host transcriptomics to characterize asthma-associated microbial communities,BMC medical genomics,2015,NA,Experiment 1,United States of America,Homo sapiens,Nasal cavity,UBERON:0001707,Asthma,MONDO:0004979,Healthy controls,Asthma Samples,"Participants ranged between the ages of 6 and 20 years, with physician-diagnosed asthma for at least one year prior to the time of recruitment.",6,8,N/A,WMS,NA,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,decreased,increased,decreased,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:839/1/NA,Study 839,time series / longitudinal observational,36405958,10.3389/fcimb.2022.965471,NA,"Zhou C, Gong S, Xiang S, Liang L, Hu X, Huang R, Liao Z, Ma Y, Xiao Z , Qiu J",Changes and significance of gut microbiota in children with focal epilepsy before and after treatment,Frontiers in cellular and infection microbiology,2022,"16S rDNA gene sequencing, children, epilepsy, focal onset, gut microbiota",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Epilepsy,EFO:0000474,healthy control (HC),pre-treatment (focal epilepsy),These are individuals with newly diagnosed focal epilepsy before they started receiving treatment.,14,10,2 weeks,16S,45,Illumina,LEfSe,0.05,TRUE,NA,NA,NA,NA,increased,increased,decreased,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:839/2/NA,Study 839,time series / longitudinal observational,36405958,10.3389/fcimb.2022.965471,NA,"Zhou C, Gong S, Xiang S, Liang L, Hu X, Huang R, Liao Z, Ma Y, Xiao Z , Qiu J",Changes and significance of gut microbiota in children with focal epilepsy before and after treatment,Frontiers in cellular and infection microbiology,2022,"16S rDNA gene sequencing, children, epilepsy, focal onset, gut microbiota",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Epilepsy,EFO:0000474,healthy control (HC),post-treatment (focal epilepsy),"This subgroup comprises individuals from the case group who have undergone a specific treatment, in this case, three months of treatment with oxcarbazepine (OXC).",14,10,2 weeks,16S,45,Illumina,LEfSe,0.05,TRUE,NA,NA,NA,NA,increased,increased,unchanged,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:839/3/NA,Study 839,time series / longitudinal observational,36405958,10.3389/fcimb.2022.965471,NA,"Zhou C, Gong S, Xiang S, Liang L, Hu X, Huang R, Liao Z, Ma Y, Xiao Z , Qiu J",Changes and significance of gut microbiota in children with focal epilepsy before and after treatment,Frontiers in cellular and infection microbiology,2022,"16S rDNA gene sequencing, children, epilepsy, focal onset, gut microbiota",Experiment 3,China,Homo sapiens,Feces,UBERON:0001988,Response to oxcarbazepine,EFO:0009893,pre-treatment (focal epilepsy),post-treatment (focal epilepsy),"This subgroup comprises individuals from the case group who have undergone a specific treatment, in this case, three months of treatment with oxcarbazepine (OXC).",14,10,2 weeks,16S,45,Illumina,LEfSe,0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:839/4/NA,Study 839,time series / longitudinal observational,36405958,10.3389/fcimb.2022.965471,NA,"Zhou C, Gong S, Xiang S, Liang L, Hu X, Huang R, Liao Z, Ma Y, Xiao Z , Qiu J",Changes and significance of gut microbiota in children with focal epilepsy before and after treatment,Frontiers in cellular and infection microbiology,2022,"16S rDNA gene sequencing, children, epilepsy, focal onset, gut microbiota",Experiment 4,China,Homo sapiens,Feces,UBERON:0001988,Epilepsy,EFO:0000474,healthy control (HC),pre-treatment (focal epilepsy),These are individuals with newly diagnosed focal epilepsy before they started receiving treatment.,14,10,2 weeks,16S,45,Illumina,Metastats,0.05,TRUE,NA,NA,NA,NA,increased,increased,decreased,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:839/5/NA,Study 839,time series / longitudinal observational,36405958,10.3389/fcimb.2022.965471,NA,"Zhou C, Gong S, Xiang S, Liang L, Hu X, Huang R, Liao Z, Ma Y, Xiao Z , Qiu J",Changes and significance of gut microbiota in children with focal epilepsy before and after treatment,Frontiers in cellular and infection microbiology,2022,"16S rDNA gene sequencing, children, epilepsy, focal onset, gut microbiota",Experiment 5,China,Homo sapiens,Feces,UBERON:0001988,Epilepsy,EFO:0000474,healthy control (HC),post-treatment (focal epilepsy),"This subgroup comprises individuals from the case group who have undergone a specific treatment, in this case, three months of treatment with oxcarbazepine (OXC).",14,10,2 weeks,16S,45,Illumina,Metastats,0.05,TRUE,NA,NA,NA,NA,increased,increased,unchanged,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:839/6/NA,Study 839,time series / longitudinal observational,36405958,10.3389/fcimb.2022.965471,NA,"Zhou C, Gong S, Xiang S, Liang L, Hu X, Huang R, Liao Z, Ma Y, Xiao Z , Qiu J",Changes and significance of gut microbiota in children with focal epilepsy before and after treatment,Frontiers in cellular and infection microbiology,2022,"16S rDNA gene sequencing, children, epilepsy, focal onset, gut microbiota",Experiment 6,China,Homo sapiens,Feces,UBERON:0001988,Response to oxcarbazepine,EFO:0009893,pre-treatment (focal epilepsy),post-treatment (focal epilepsy),"This subgroup comprises individuals from the case group who have undergone a specific treatment, in this case, three months of treatment with oxcarbazepine (OXC).",14,10,2 weeks,16S,45,Illumina,Metastats,0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:840/1/NA,Study 840,time series / longitudinal observational,37750731,https://doi.org/10.1128/spectrum.02974-23,https://journals.asm.org/doi/10.1128/spectrum.02974-23,"Roche CE, Montague MJ, Wang J, Dickey AN, Ruiz-Lambides A, Brent LJN, Platt ML , Horvath JE",Yearly variation coupled with social interactions shape the skin microbiome in free-ranging rhesus macaques,Microbiology spectrum,2023,"16S rRNA, Cayo Santiago, microbial diversity, primates, rhesus macaques, skin microbiome, social behavior, year-to-year environment",Experiment 1,United States of America,Macaca mulatta,Axilla skin,UBERON:0015474,Microbiome measurement,EFO:0007882,2013 sampling period,2015 sampling period,The 2015 sampling period occurred from October 2015 through December 2015,42,33,NA,16S,4,Illumina,"Mann-Whitney (Wilcoxon),Welch's T-Test",0.05,TRUE,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:840/2/NA,Study 840,time series / longitudinal observational,37750731,https://doi.org/10.1128/spectrum.02974-23,https://journals.asm.org/doi/10.1128/spectrum.02974-23,"Roche CE, Montague MJ, Wang J, Dickey AN, Ruiz-Lambides A, Brent LJN, Platt ML , Horvath JE",Yearly variation coupled with social interactions shape the skin microbiome in free-ranging rhesus macaques,Microbiology spectrum,2023,"16S rRNA, Cayo Santiago, microbial diversity, primates, rhesus macaques, skin microbiome, social behavior, year-to-year environment",Experiment 2,United States of America,Macaca mulatta,Axilla skin,UBERON:0015474,Microbiome measurement,EFO:0007882,Non-Core microbiome social group (R),Non-Core microbiome social group (F),"The core features 1.0 list (e.g., features present in 100% of samples) was used to filter the complete microbiome table and output a “core” microbiome feature table, via q2-filter-features. The same core features were then removed from the complete microbiome table to output a “non-core” microbiome feature table. Core and non-core feature tables were then exported to biom format",NA,NA,NA,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:840/3/NA,Study 840,time series / longitudinal observational,37750731,https://doi.org/10.1128/spectrum.02974-23,https://journals.asm.org/doi/10.1128/spectrum.02974-23,"Roche CE, Montague MJ, Wang J, Dickey AN, Ruiz-Lambides A, Brent LJN, Platt ML , Horvath JE",Yearly variation coupled with social interactions shape the skin microbiome in free-ranging rhesus macaques,Microbiology spectrum,2023,"16S rRNA, Cayo Santiago, microbial diversity, primates, rhesus macaques, skin microbiome, social behavior, year-to-year environment",Experiment 3,United States of America,Macaca mulatta,Axilla skin,UBERON:0015474,Microbiome measurement,EFO:0007882,Core microbiome social groups (V),Core microbiome social groups (F),"The core features 1.0 list (e.g., features present in 100% of samples) was used to filter the complete microbiome table and output a “core” microbiome feature table, via q2-filter-features.",NA,NA,NA,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:840/4/NA,Study 840,time series / longitudinal observational,37750731,https://doi.org/10.1128/spectrum.02974-23,https://journals.asm.org/doi/10.1128/spectrum.02974-23,"Roche CE, Montague MJ, Wang J, Dickey AN, Ruiz-Lambides A, Brent LJN, Platt ML , Horvath JE",Yearly variation coupled with social interactions shape the skin microbiome in free-ranging rhesus macaques,Microbiology spectrum,2023,"16S rRNA, Cayo Santiago, microbial diversity, primates, rhesus macaques, skin microbiome, social behavior, year-to-year environment",Experiment 4,United States of America,Macaca mulatta,Axilla skin,UBERON:0015474,Microbiome measurement,EFO:0007882,Non-Core microbiome 2013 sampling period,Non-Core microbiome 2015 sampling period,"The core features 1.0 list (e.g., features present in 100% of samples) was used to filter the complete microbiome table and output a “core” microbiome feature table, via q2-filter-features. The same core features were then removed from the complete microbiome table to output a “non-core” microbiome feature table. Core and non-core feature tables were then exported to biom format",NA,NA,NA,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:840/5/NA,Study 840,time series / longitudinal observational,37750731,https://doi.org/10.1128/spectrum.02974-23,https://journals.asm.org/doi/10.1128/spectrum.02974-23,"Roche CE, Montague MJ, Wang J, Dickey AN, Ruiz-Lambides A, Brent LJN, Platt ML , Horvath JE",Yearly variation coupled with social interactions shape the skin microbiome in free-ranging rhesus macaques,Microbiology spectrum,2023,"16S rRNA, Cayo Santiago, microbial diversity, primates, rhesus macaques, skin microbiome, social behavior, year-to-year environment",Experiment 5,United States of America,Macaca mulatta,Axilla skin,UBERON:0015474,Microbiome measurement,EFO:0007882,Core microbiome 2013 sampling period,Core microbiome 2015 sampling period,"The core features 1.0 list (e.g., features present in 100% of samples) was used to filter the complete microbiome table and output a “core” microbiome feature table, via q2-filter-features.",NA,NA,NA,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:840/6/NA,Study 840,time series / longitudinal observational,37750731,https://doi.org/10.1128/spectrum.02974-23,https://journals.asm.org/doi/10.1128/spectrum.02974-23,"Roche CE, Montague MJ, Wang J, Dickey AN, Ruiz-Lambides A, Brent LJN, Platt ML , Horvath JE",Yearly variation coupled with social interactions shape the skin microbiome in free-ranging rhesus macaques,Microbiology spectrum,2023,"16S rRNA, Cayo Santiago, microbial diversity, primates, rhesus macaques, skin microbiome, social behavior, year-to-year environment",Experiment 6,United States of America,Macaca mulatta,Axilla skin,UBERON:0015474,Microbiome measurement,EFO:0007882,Complete microbiome social group R,Complete microbiome social group F,"Colony members self-organize into social groups, demonstrate various forms of social behaviors, most notably grooming",11,43,NA,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:840/7/NA,Study 840,time series / longitudinal observational,37750731,https://doi.org/10.1128/spectrum.02974-23,https://journals.asm.org/doi/10.1128/spectrum.02974-23,"Roche CE, Montague MJ, Wang J, Dickey AN, Ruiz-Lambides A, Brent LJN, Platt ML , Horvath JE",Yearly variation coupled with social interactions shape the skin microbiome in free-ranging rhesus macaques,Microbiology spectrum,2023,"16S rRNA, Cayo Santiago, microbial diversity, primates, rhesus macaques, skin microbiome, social behavior, year-to-year environment",Experiment 7,United States of America,Macaca mulatta,Axilla skin,UBERON:0015474,Microbiome measurement,EFO:0007882,Complete microbiome social group R,Complete microbiome social group V,"Colony members self-organize into social groups, demonstrate various forms of social behaviors, most notably grooming",11,12,NA,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:840/8/NA,Study 840,time series / longitudinal observational,37750731,https://doi.org/10.1128/spectrum.02974-23,https://journals.asm.org/doi/10.1128/spectrum.02974-23,"Roche CE, Montague MJ, Wang J, Dickey AN, Ruiz-Lambides A, Brent LJN, Platt ML , Horvath JE",Yearly variation coupled with social interactions shape the skin microbiome in free-ranging rhesus macaques,Microbiology spectrum,2023,"16S rRNA, Cayo Santiago, microbial diversity, primates, rhesus macaques, skin microbiome, social behavior, year-to-year environment",Experiment 8,United States of America,Macaca mulatta,Axilla skin,UBERON:0015474,Microbiome measurement,EFO:0007882,Complete microbiome social group F,Complete microbiome social group KK,"Colony members self-organize into social groups, demonstrate various forms of social behaviors, most notably grooming",43,8,NA,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:840/9/NA,Study 840,time series / longitudinal observational,37750731,https://doi.org/10.1128/spectrum.02974-23,https://journals.asm.org/doi/10.1128/spectrum.02974-23,"Roche CE, Montague MJ, Wang J, Dickey AN, Ruiz-Lambides A, Brent LJN, Platt ML , Horvath JE",Yearly variation coupled with social interactions shape the skin microbiome in free-ranging rhesus macaques,Microbiology spectrum,2023,"16S rRNA, Cayo Santiago, microbial diversity, primates, rhesus macaques, skin microbiome, social behavior, year-to-year environment",Experiment 9,United States of America,Macaca mulatta,Axilla skin,UBERON:0015474,Microbiome measurement,EFO:0007882,Complete microbiome social group F,Complete microbiome social group V,"Colony members self-organize into social groups, demonstrate various forms of social behaviors, most notably grooming",43,12,NA,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:840/10/NA,Study 840,time series / longitudinal observational,37750731,https://doi.org/10.1128/spectrum.02974-23,https://journals.asm.org/doi/10.1128/spectrum.02974-23,"Roche CE, Montague MJ, Wang J, Dickey AN, Ruiz-Lambides A, Brent LJN, Platt ML , Horvath JE",Yearly variation coupled with social interactions shape the skin microbiome in free-ranging rhesus macaques,Microbiology spectrum,2023,"16S rRNA, Cayo Santiago, microbial diversity, primates, rhesus macaques, skin microbiome, social behavior, year-to-year environment",Experiment 10,United States of America,Macaca mulatta,Axilla skin,UBERON:0015474,Microbiome measurement,EFO:0007882,Complete microbiome social group HH,Complete microbiome social group KK,"Colony members self-organize into social groups, demonstrate various forms of social behaviors, most notably grooming",4,8,NA,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:840/11/NA,Study 840,time series / longitudinal observational,37750731,https://doi.org/10.1128/spectrum.02974-23,https://journals.asm.org/doi/10.1128/spectrum.02974-23,"Roche CE, Montague MJ, Wang J, Dickey AN, Ruiz-Lambides A, Brent LJN, Platt ML , Horvath JE",Yearly variation coupled with social interactions shape the skin microbiome in free-ranging rhesus macaques,Microbiology spectrum,2023,"16S rRNA, Cayo Santiago, microbial diversity, primates, rhesus macaques, skin microbiome, social behavior, year-to-year environment",Experiment 11,United States of America,Macaca mulatta,Axilla skin,UBERON:0015474,Microbiome measurement,EFO:0007882,Complete microbiome social group V,Complete microbiome social group KK,"Colony members self-organize into social groups, demonstrate various forms of social behaviors, most notably grooming",12,8,NA,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:840/12/NA,Study 840,time series / longitudinal observational,37750731,https://doi.org/10.1128/spectrum.02974-23,https://journals.asm.org/doi/10.1128/spectrum.02974-23,"Roche CE, Montague MJ, Wang J, Dickey AN, Ruiz-Lambides A, Brent LJN, Platt ML , Horvath JE",Yearly variation coupled with social interactions shape the skin microbiome in free-ranging rhesus macaques,Microbiology spectrum,2023,"16S rRNA, Cayo Santiago, microbial diversity, primates, rhesus macaques, skin microbiome, social behavior, year-to-year environment",Experiment 12,United States of America,Macaca mulatta,Axilla skin,UBERON:0015474,Microbiome measurement,EFO:0007882,2013 sampling period (Complete microbiome),2015 sampling period (Complete microbiome),The 2015 sampling period occurred from October 2015 through December 2015,42,33,NA,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:841/1/NA,Study 841,laboratory experiment,35386429,10.7717/peerj.12826,NA,"Li M, Wang Z, Wang L, Xue B, Hu R, Zou H, Liu S, Shah AM , Peng Q",Comparison of changes in fecal microbiota of calves with and without dam,PeerJ,2022,"Calf, Cultivation method, Dynamics, Microbial community",Experiment 1,China,Bos grunniens,Feces,UBERON:0001988,Breastfeeding duration,EFO:0006864,Calves with dam on day 35,Calves without dam on day 35,Calves without dam on day 35 of the whole 95 days formal experimental period.,8,8,none,16S,4,Illumina,LEfSe,0.05,NA,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:841/2/NA,Study 841,laboratory experiment,35386429,10.7717/peerj.12826,NA,"Li M, Wang Z, Wang L, Xue B, Hu R, Zou H, Liu S, Shah AM , Peng Q",Comparison of changes in fecal microbiota of calves with and without dam,PeerJ,2022,"Calf, Cultivation method, Dynamics, Microbial community",Experiment 2,China,Bos grunniens,Feces,UBERON:0001988,Breastfeeding duration,EFO:0006864,Calves with dam on day 65,Calves without dam on day 65,Calves without dam on day 65 of the whole 95 days formal experimental period.,8,8,none,16S,4,Illumina,LEfSe,0.05,NA,NA,NA,NA,NA,decreased,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:841/3/NA,Study 841,laboratory experiment,35386429,10.7717/peerj.12826,NA,"Li M, Wang Z, Wang L, Xue B, Hu R, Zou H, Liu S, Shah AM , Peng Q",Comparison of changes in fecal microbiota of calves with and without dam,PeerJ,2022,"Calf, Cultivation method, Dynamics, Microbial community",Experiment 3,China,Bos grunniens,Feces,UBERON:0001988,Breastfeeding duration,EFO:0006864,Calves with dam on day 95,Calves without dam on day 95,Calves without dam on day 95 of the whole 95 days formal experimental period.,8,8,none,16S,4,Illumina,LEfSe,0.05,NA,NA,NA,NA,NA,decreased,decreased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:842/1/NA,Study 842,case-control,34063398,10.3390/nu13051682,NA,"Łoś-Rycharska E, Gołębiewski M, Sikora M, Grzybowski T, Gorzkiewicz M, Popielarz M, Gawryjołek J , Krogulska A",A Combined Analysis of Gut and Skin Microbiota in Infants with Food Allergy and Atopic Dermatitis: A Pilot Study,Nutrients,2021,"16S rRNA sequencing, atopic dermatitis, dysbiosis, food allergy, gut, infants, microbiota, skin",Experiment 1,Poland,Homo sapiens,Feces,UBERON:0001988,Food allergy,EFO:1001890,Control group,Food Allergy,Infants with food allergy,28,16,1 month,16S,34,Illumina,Kruskall-Wallis,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:842/2/NA,Study 842,case-control,34063398,10.3390/nu13051682,NA,"Łoś-Rycharska E, Gołębiewski M, Sikora M, Grzybowski T, Gorzkiewicz M, Popielarz M, Gawryjołek J , Krogulska A",A Combined Analysis of Gut and Skin Microbiota in Infants with Food Allergy and Atopic Dermatitis: A Pilot Study,Nutrients,2021,"16S rRNA sequencing, atopic dermatitis, dysbiosis, food allergy, gut, infants, microbiota, skin",Experiment 2,Poland,Homo sapiens,Skin of body,UBERON:0002097,Dermatitis,MONDO:0002406,Control group,Atopic dermatitis,Infants with atopic dermatitis,28,5,1 month,16S,34,Illumina,Kruskall-Wallis,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:842/3/NA,Study 842,case-control,34063398,10.3390/nu13051682,NA,"Łoś-Rycharska E, Gołębiewski M, Sikora M, Grzybowski T, Gorzkiewicz M, Popielarz M, Gawryjołek J , Krogulska A",A Combined Analysis of Gut and Skin Microbiota in Infants with Food Allergy and Atopic Dermatitis: A Pilot Study,Nutrients,2021,"16S rRNA sequencing, atopic dermatitis, dysbiosis, food allergy, gut, infants, microbiota, skin",Experiment 3,Poland,Homo sapiens,Feces,UBERON:0001988,"Food allergy,Dermatitis","EFO:1001890,MONDO:0002406",Control group,Atopic dermatitis and Food Allergy (ADFA),Infants with both Atopic dermatitis and Food Allergy,28,38,1 month,16S,34,Illumina,Kruskall-Wallis,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:842/4/NA,Study 842,case-control,34063398,10.3390/nu13051682,NA,"Łoś-Rycharska E, Gołębiewski M, Sikora M, Grzybowski T, Gorzkiewicz M, Popielarz M, Gawryjołek J , Krogulska A",A Combined Analysis of Gut and Skin Microbiota in Infants with Food Allergy and Atopic Dermatitis: A Pilot Study,Nutrients,2021,"16S rRNA sequencing, atopic dermatitis, dysbiosis, food allergy, gut, infants, microbiota, skin",Experiment 4,Poland,Homo sapiens,Feces,UBERON:0001988,"Food allergy,Dermatitis","EFO:1001890,MONDO:0002406",Control group,Infants with Allergy Symptoms,"All infants with Allergy symptoms including Food Allergy, Atopic dermatitis, and both Atopic dermatitis and Food Allergy",28,59,1 month,16S,34,Illumina,Spearman Correlation,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:843/1/NA,Study 843,case-control,36975801,10.1128/msystems.01003-22,NA,"Carter KA, Fodor AA, Balkus JE, Zhang A, Serrano MG, Buck GA, Engel SM, Wu MC , Sun S",Vaginal Microbiome Metagenome Inference Accuracy: Differential Measurement Error according to Community Composition,mSystems,2023,"Lactobacillus crispatus, Lactobacillus iners, measurement error, metagenome inference, vaginal microbiome",Experiment 1,United States of America,Homo sapiens,Vagina,UBERON:0000996,Premature birth,EFO:0003917,term birth(control),preterm birth (PTB),Cases were participants who experienced early preterm birth at <32 weeks of gestation.,37,35,None.,16S,123,Illumina,Mann-Whitney (Wilcoxon),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:844/1/NA,Study 844,case-control,33658058,10.1186/s13073-021-00856-4,NA,"Alvarez-Silva C, Kashani A, Hansen TH, Pinna NK, Anjana RM, Dutta A, Saxena S, Støy J, Kampmann U, Nielsen T, Jørgensen T, Gnanaprakash V, Gnanavadivel R, Sukumaran A, Rani CSS, Færch K, Radha V, Balasubramanyam M, Nair GB, Das B, Vestergaard H, Hansen T, Mande SS, Mohan V, Arumugam M , Pedersen O",Trans-ethnic gut microbiota signatures of type 2 diabetes in Denmark and India,Genome medicine,2021,"Danes, Gut microbiota, Indians, Metformin, Populations, Trans-ethnic, Type 2 diabetes",Experiment 1,India,Homo sapiens,Feces,UBERON:0001988,Response to metformin,GO:1901558,metformin-naive type 2 diabetes (T2D) patients,metformin-treated T2D patients,"T2D patients treated with the anti-hyperglycemic drug, metformin",71,86,None,16S,12345,Roche454,DESeq2,0.05,TRUE,NA,NA,"age,body mass index,proton-pump inhibitor,sex",NA,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:844/2/NA,Study 844,case-control,33658058,10.1186/s13073-021-00856-4,NA,"Alvarez-Silva C, Kashani A, Hansen TH, Pinna NK, Anjana RM, Dutta A, Saxena S, Støy J, Kampmann U, Nielsen T, Jørgensen T, Gnanaprakash V, Gnanavadivel R, Sukumaran A, Rani CSS, Færch K, Radha V, Balasubramanyam M, Nair GB, Das B, Vestergaard H, Hansen T, Mande SS, Mohan V, Arumugam M , Pedersen O",Trans-ethnic gut microbiota signatures of type 2 diabetes in Denmark and India,Genome medicine,2021,"Danes, Gut microbiota, Indians, Metformin, Populations, Trans-ethnic, Type 2 diabetes",Experiment 2,Denmark,Homo sapiens,Feces,UBERON:0001988,Response to metformin,GO:1901558,metformin-naive type 2 diabetes (T2D) patients,metformin-treated T2D patients,"T2D patients treated with the anti-hyperglycemic drug, metformin",61,80,4 months,16S,12345,Roche454,DESeq2,0.05,TRUE,NA,NA,"age,body mass index,proton-pump inhibitor,sex",NA,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:844/3/NA,Study 844,case-control,33658058,10.1186/s13073-021-00856-4,NA,"Alvarez-Silva C, Kashani A, Hansen TH, Pinna NK, Anjana RM, Dutta A, Saxena S, Støy J, Kampmann U, Nielsen T, Jørgensen T, Gnanaprakash V, Gnanavadivel R, Sukumaran A, Rani CSS, Færch K, Radha V, Balasubramanyam M, Nair GB, Das B, Vestergaard H, Hansen T, Mande SS, Mohan V, Arumugam M , Pedersen O",Trans-ethnic gut microbiota signatures of type 2 diabetes in Denmark and India,Genome medicine,2021,"Danes, Gut microbiota, Indians, Metformin, Populations, Trans-ethnic, Type 2 diabetes",Experiment 3,"Denmark,India",Homo sapiens,Feces,UBERON:0001988,Population,IDOMAL:0001254,Indians (normoglycaemic controls and T2D patients),Denmark (normoglycaemic controls and T2D patients),Gut microbiota in Denmark participants,294,279,4 months (Denmark participants),16S,12345,Roche454,DESeq2,0.05,TRUE,NA,NA,"age,body mass index,proton-pump inhibitor,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:844/4/NA,Study 844,case-control,33658058,10.1186/s13073-021-00856-4,NA,"Alvarez-Silva C, Kashani A, Hansen TH, Pinna NK, Anjana RM, Dutta A, Saxena S, Støy J, Kampmann U, Nielsen T, Jørgensen T, Gnanaprakash V, Gnanavadivel R, Sukumaran A, Rani CSS, Færch K, Radha V, Balasubramanyam M, Nair GB, Das B, Vestergaard H, Hansen T, Mande SS, Mohan V, Arumugam M , Pedersen O",Trans-ethnic gut microbiota signatures of type 2 diabetes in Denmark and India,Genome medicine,2021,"Danes, Gut microbiota, Indians, Metformin, Populations, Trans-ethnic, Type 2 diabetes",Experiment 4,"Denmark,India",Homo sapiens,Feces,UBERON:0001988,Metformin,CHEBI:6801,metformin-naive type 2 diabetes (T2D) patients,metformin-treated T2D patients,"T2D patients treated with the anti-hyperglycemic drug, metformin",132,166,4 months (Denmark participants),16S,12345,Roche454,DESeq2,0.05,TRUE,NA,NA,"age,body mass index,geographic area,proton-pump inhibitor,sex",NA,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:844/5/NA,Study 844,case-control,33658058,10.1186/s13073-021-00856-4,NA,"Alvarez-Silva C, Kashani A, Hansen TH, Pinna NK, Anjana RM, Dutta A, Saxena S, Støy J, Kampmann U, Nielsen T, Jørgensen T, Gnanaprakash V, Gnanavadivel R, Sukumaran A, Rani CSS, Færch K, Radha V, Balasubramanyam M, Nair GB, Das B, Vestergaard H, Hansen T, Mande SS, Mohan V, Arumugam M , Pedersen O",Trans-ethnic gut microbiota signatures of type 2 diabetes in Denmark and India,Genome medicine,2021,"Danes, Gut microbiota, Indians, Metformin, Populations, Trans-ethnic, Type 2 diabetes",Experiment 5,"Denmark,India",Homo sapiens,Feces,UBERON:0001988,Type II diabetes mellitus,MONDO:0005148,Normoglycemic (NG) controls,Type 2 diabetes (T2D) patients,Individuals diagnosed with T2D,275,298,4 months (Denmark participants),16S,12345,Roche454,DESeq2,0.05,TRUE,NA,NA,geographic area,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:844/6/NA,Study 844,case-control,33658058,10.1186/s13073-021-00856-4,NA,"Alvarez-Silva C, Kashani A, Hansen TH, Pinna NK, Anjana RM, Dutta A, Saxena S, Støy J, Kampmann U, Nielsen T, Jørgensen T, Gnanaprakash V, Gnanavadivel R, Sukumaran A, Rani CSS, Færch K, Radha V, Balasubramanyam M, Nair GB, Das B, Vestergaard H, Hansen T, Mande SS, Mohan V, Arumugam M , Pedersen O",Trans-ethnic gut microbiota signatures of type 2 diabetes in Denmark and India,Genome medicine,2021,"Danes, Gut microbiota, Indians, Metformin, Populations, Trans-ethnic, Type 2 diabetes",Experiment 6,"Denmark,India",Homo sapiens,Feces,UBERON:0001988,Type II diabetes mellitus,MONDO:0005148,Normoglycemic (NG) controls,Type 2 diabetes (T2D) patients,Individuals diagnosed with T2D,275,298,4 months (Denmark participants),16S,12345,Roche454,DESeq2,0.05,TRUE,NA,NA,"age,body mass index,geographic area,proton-pump inhibitor,sex",NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:844/7/NA,Study 844,case-control,33658058,10.1186/s13073-021-00856-4,NA,"Alvarez-Silva C, Kashani A, Hansen TH, Pinna NK, Anjana RM, Dutta A, Saxena S, Støy J, Kampmann U, Nielsen T, Jørgensen T, Gnanaprakash V, Gnanavadivel R, Sukumaran A, Rani CSS, Færch K, Radha V, Balasubramanyam M, Nair GB, Das B, Vestergaard H, Hansen T, Mande SS, Mohan V, Arumugam M , Pedersen O",Trans-ethnic gut microbiota signatures of type 2 diabetes in Denmark and India,Genome medicine,2021,"Danes, Gut microbiota, Indians, Metformin, Populations, Trans-ethnic, Type 2 diabetes",Experiment 7,Denmark,Homo sapiens,Feces,UBERON:0001988,Type II diabetes mellitus,MONDO:0005148,Normoglycemic (NG) controls,Type 2 diabetes (T2D) patients,Individuals diagnosed with T2D,275,298,4 months,16S,12345,Roche454,DESeq2,0.05,TRUE,NA,NA,"age,body mass index,proton-pump inhibitor,sex",NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:845/1/NA,Study 845,"cross-sectional observational, not case-control",37919319,10.1038/s41598-023-42474-7,NA,"Antonello G, Blostein F, Bhaumik D, Davis E, Gögele M, Melotti R, Pramstaller P, Pattaro C, Segata N, Foxman B , Fuchsberger C",Smoking and salivary microbiota: a cross-sectional analysis of an Italian alpine population,Scientific reports,2023,NA,Experiment 1,Italy,Homo sapiens,Mouth,UBERON:0000165,Smoking status measurement,EFO:0006527,Never smokers,Current smokers,Individuals who reported being smokers at the day of examination with daily smoking intensity at least 1 month prior to the visit.,880,326,12 weeks,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,"age,number of teeth measurement,sex",NA,unchanged,unchanged,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:845/2/NA,Study 845,"cross-sectional observational, not case-control",37919319,10.1038/s41598-023-42474-7,NA,"Antonello G, Blostein F, Bhaumik D, Davis E, Gögele M, Melotti R, Pramstaller P, Pattaro C, Segata N, Foxman B , Fuchsberger C",Smoking and salivary microbiota: a cross-sectional analysis of an Italian alpine population,Scientific reports,2023,NA,Experiment 2,Italy,Homo sapiens,Mouth,UBERON:0000165,Smoking status measurement,EFO:0006527,Never smokers,Former smokers,Individuals who quit smoking 17.96 years on average,880,395,12 weeks,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,"age,number of teeth measurement,sex",NA,unchanged,unchanged,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:846/1/NA,Study 846,case-control,32804973,https://doi.org/10.1371/journal.pone.0237874,https://pubmed.ncbi.nlm.nih.gov/32804973/,"Scarsella E, Stefanon B, Cintio M, Licastro D, Sgorlon S, Dal Monego S , Sandri M",Learning machine approach reveals microbial signatures of diet and sex in dog,PloS one,2020,NA,Experiment 1,Italy,Canis lupus familiaris,Feces,UBERON:0001988,Diet,EFO:0002755,Home Made Diet - H,Base Diet - B,"A raw meat diet with the addition of a complementary food, from here on called Base",30,56,NIL,16S,34,Illumina,Kruskall-Wallis,0.05,TRUE,NA,"diet,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:846/2/NA,Study 846,case-control,32804973,https://doi.org/10.1371/journal.pone.0237874,https://pubmed.ncbi.nlm.nih.gov/32804973/,"Scarsella E, Stefanon B, Cintio M, Licastro D, Sgorlon S, Dal Monego S , Sandri M",Learning machine approach reveals microbial signatures of diet and sex in dog,PloS one,2020,NA,Experiment 2,Italy,Canis lupus familiaris,Feces,UBERON:0001988,Diet,EFO:0002755,Commercial moist complete diet - W,Complete diet - K,Commercial extruded complete diet (K),83,171,NIL,16S,34,Illumina,Kruskall-Wallis,0.05,TRUE,NA,"diet,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:846/3/NA,Study 846,case-control,32804973,https://doi.org/10.1371/journal.pone.0237874,https://pubmed.ncbi.nlm.nih.gov/32804973/,"Scarsella E, Stefanon B, Cintio M, Licastro D, Sgorlon S, Dal Monego S , Sandri M",Learning machine approach reveals microbial signatures of diet and sex in dog,PloS one,2020,NA,Experiment 3,Italy,Canis lupus familiaris,Feces,UBERON:0001988,Diet,EFO:0002755,Spayed Female - FC,Whole Female - F,Whole Female,28,145,NIL,16S,34,Illumina,Kruskall-Wallis,0.05,TRUE,NA,"age,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:846/4/NA,Study 846,case-control,32804973,https://doi.org/10.1371/journal.pone.0237874,https://pubmed.ncbi.nlm.nih.gov/32804973/,"Scarsella E, Stefanon B, Cintio M, Licastro D, Sgorlon S, Dal Monego S , Sandri M",Learning machine approach reveals microbial signatures of diet and sex in dog,PloS one,2020,NA,Experiment 4,Italy,Canis lupus familiaris,Feces,UBERON:0001988,Diet,EFO:0002755,Castrated Male - MC,Whole Male - M,Whole Male,89,78,NIL,16S,34,Illumina,Kruskall-Wallis,0.05,TRUE,NA,"age,diet",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:847/1/NA,Study 847,case-control,34222034,10.3389/fcimb.2021.598093,https://pubmed.ncbi.nlm.nih.gov/34222034/,"Martínez-Cuesta MC, Del Campo R, Garriga-García M, Peláez C , Requena T",Taxonomic Characterization and Short-Chain Fatty Acids Production of the Obese Microbiota,Frontiers in cellular and infection microbiology,2021,"diversity, in vitro incubations, metabolic activity, microbiota, obesity, short-chain fatty acids",Experiment 1,Spain,Homo sapiens,Feces,UBERON:0001988,Obesity,EFO:0001073,Normal weight volunteers (N),Obese Volunteers (O),Obese adult volunteers with body mass index (BMI) > 30 kg/m^2,13,13,Volunteers who were on antibiotics six (6) months preceding the sample collection were excluded from the study,16S,34,Illumina,LEfSe,0.05,FALSE,3,NA,NA,NA,unchanged,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:848/1/NA,Study 848,"cross-sectional observational, not case-control",37925571,10.1038/s41598-023-46566-2,NA,"He J, Gong X, Hu B, Lin L, Lin X, Gong W, Zhang B, Cao M, Xu Y, Xia R, Zheng G, Wu S , Zhang Y",Altered Gut Microbiota and Short-chain Fatty Acids in Chinese Children with Constipated Autism Spectrum Disorder,Scientific reports,2023,NA,Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Autism spectrum disorder,EFO:0003756,Typically developing (TD) group,Constipated autism spectrum disorder (C-ASD) group,Children with autism spectrum disorder (ASD) while also experiencing constipation as an important gastrointestinal (GI) comorbidity.,40,40,"3 months, including probiotics, acid suppressors, or other drugs affecting the gut microbiota",16S,34,Illumina,LEfSe,0.05,FALSE,3,"age,body mass index,sex",NA,NA,unchanged,decreased,unchanged,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:849/1/NA,Study 849,"cross-sectional observational, not case-control",36687728,10.3389/fnut.2022.1059163,NA,"Moser B, Moore D, Khadka B, Lyons C, Foxall T, Andam CP, Parker CJ, Ochin C, Garelnabi M, Sevigny J, Thomas WK, Bigornia S , Dao MC","Association between inflammation, lipopolysaccharide binding protein, and gut microbiota composition in a New Hampshire Bhutanese refugee population with a high burden of type 2 diabetes",Frontiers in nutrition,2022,"Bhutanese refugee adults, gastrointestinal microbiome, inflammation, metabolic endotoxemia, type 2 diabetes",Experiment 1,United States of America,Homo sapiens,"Blood,Feces","UBERON:0000178,UBERON:0001988",Age,EFO:0000246,Non-T2D(prediabetes),type 2 diabetes (T2D),"Participants with chronic metabolic condition characterized by high levels of blood sugar (glucose), insulin resistance, and relative insulin deficiency.",29,21,6 months,WMS,NA,Illumina,Spearman Correlation,0.05,TRUE,NA,NA,"age,sex",NA,decreased,NA,unchanged,unchanged,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:849/2/NA,Study 849,"cross-sectional observational, not case-control",36687728,10.3389/fnut.2022.1059163,NA,"Moser B, Moore D, Khadka B, Lyons C, Foxall T, Andam CP, Parker CJ, Ochin C, Garelnabi M, Sevigny J, Thomas WK, Bigornia S , Dao MC","Association between inflammation, lipopolysaccharide binding protein, and gut microbiota composition in a New Hampshire Bhutanese refugee population with a high burden of type 2 diabetes",Frontiers in nutrition,2022,"Bhutanese refugee adults, gastrointestinal microbiome, inflammation, metabolic endotoxemia, type 2 diabetes",Experiment 2,United States of America,Homo sapiens,"Feces,Blood","UBERON:0001988,UBERON:0000178",Cytokine,EFO:0003786,Non-Type 2 Diabetes (Prediabetes),Type 2 Diabetes,"Participants with chronic metabolic condition characterized by high levels of blood sugar (glucose), insulin resistance, and relative insulin deficiency, after adjusting for age (used as a covariate).",29,21,6 Months,WMS,NA,Illumina,Spearman Correlation,0.05,TRUE,NA,NA,"age,sex",NA,decreased,NA,unchanged,unchanged,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:849/3/NA,Study 849,"cross-sectional observational, not case-control",36687728,10.3389/fnut.2022.1059163,NA,"Moser B, Moore D, Khadka B, Lyons C, Foxall T, Andam CP, Parker CJ, Ochin C, Garelnabi M, Sevigny J, Thomas WK, Bigornia S , Dao MC","Association between inflammation, lipopolysaccharide binding protein, and gut microbiota composition in a New Hampshire Bhutanese refugee population with a high burden of type 2 diabetes",Frontiers in nutrition,2022,"Bhutanese refugee adults, gastrointestinal microbiome, inflammation, metabolic endotoxemia, type 2 diabetes",Experiment 3,United States of America,Homo sapiens,"Feces,Blood","UBERON:0001988,UBERON:0000178",Diet,EFO:0002755,Non-Type 2 Diabetes (Prediabetes),Type 2 Diabetes,"Participants with chronic metabolic condition characterized by high levels of blood sugar (glucose), insulin resistance, and relative insulin deficiency, after adjusting for age (used as a covariate).",29,21,6 Months,WMS,NA,Illumina,Spearman Correlation,0.05,TRUE,NA,NA,"age,sex",NA,decreased,NA,unchanged,unchanged,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:849/4/NA,Study 849,"cross-sectional observational, not case-control",36687728,10.3389/fnut.2022.1059163,NA,"Moser B, Moore D, Khadka B, Lyons C, Foxall T, Andam CP, Parker CJ, Ochin C, Garelnabi M, Sevigny J, Thomas WK, Bigornia S , Dao MC","Association between inflammation, lipopolysaccharide binding protein, and gut microbiota composition in a New Hampshire Bhutanese refugee population with a high burden of type 2 diabetes",Frontiers in nutrition,2022,"Bhutanese refugee adults, gastrointestinal microbiome, inflammation, metabolic endotoxemia, type 2 diabetes",Experiment 4,United States of America,Homo sapiens,"Feces,Blood","UBERON:0001988,UBERON:0000178",HbA1c measurement,EFO:0004541,Non-Type 2 Diabetes (Prediabetes),Type 2 Diabetes,"Participants with chronic metabolic condition characterized by high levels of blood sugar (glucose), insulin resistance, and relative insulin deficiency, after adjusting for age (used as a covariate).",29,21,6 Months,WMS,NA,Illumina,Spearman Correlation,0.05,TRUE,NA,NA,"age,sex",NA,decreased,NA,unchanged,unchanged,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:850/1/NA,Study 850,meta-analysis,36171758,10.3389/fcimb.2022.961644,NA,"Chai J, Liu X, Usdrowski H, Deng F, Li Y , Zhao J","Geography, niches, and transportation influence bovine respiratory microbiome and health",Frontiers in cellular and infection microbiology,2022,"bovine, bovine respiratory disease, geography, lung, metagenomics, nasopharynx, respiratory microbiota, transportation",Experiment 1,"Canada,China",Bos taurus,"Nasopharynx,Lung","UBERON:0001728,UBERON:0002048",Population,IDOMAL:0001254,Nasopharyngeal swabs from Canada and bronchoalveolar lavage from Canada,Nasopharyngeal swabs from China,Nasopharyngeal swabs from two cities (Qiqihaer and Guangan) in China from the study of Cui et al (2021).,127,18,none,WMS,NA,Illumina,LEfSe,0.05,NA,2,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:850/2/NA,Study 850,meta-analysis,36171758,10.3389/fcimb.2022.961644,NA,"Chai J, Liu X, Usdrowski H, Deng F, Li Y , Zhao J","Geography, niches, and transportation influence bovine respiratory microbiome and health",Frontiers in cellular and infection microbiology,2022,"bovine, bovine respiratory disease, geography, lung, metagenomics, nasopharynx, respiratory microbiota, transportation",Experiment 2,"Canada,China",Bos taurus,"Nasopharynx,Lung","UBERON:0001728,UBERON:0002048",Population,IDOMAL:0001254,Nasopharyngeal swabs from China and bronchoalveolar lavage from Canada,"Nasopharyngeal swabs from Saskatoon, Canada.",Nasopharyngeal swabs from Saskatoon in Canada from the study of Malmuthuge et al. (2021).,33,112,none,WMS,NA,Illumina,LEfSe,0.05,NA,2,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:850/3/NA,Study 850,meta-analysis,36171758,10.3389/fcimb.2022.961644,NA,"Chai J, Liu X, Usdrowski H, Deng F, Li Y , Zhao J","Geography, niches, and transportation influence bovine respiratory microbiome and health",Frontiers in cellular and infection microbiology,2022,"bovine, bovine respiratory disease, geography, lung, metagenomics, nasopharynx, respiratory microbiota, transportation",Experiment 3,"Canada,China",Bos taurus,"Nasopharynx,Lung","UBERON:0001728,UBERON:0002048",Sampling site,EFO:0000688,Nasopharyngeal swabs from Canada and Nasopharyngeal swabs from China,"Bronchoalveolar lavage from Alberta, Canada","Bronchoalveolar lavage collected from feedlot calves which died from bovine respiratory disease in Alberta, Canada from the study of Klima et al. (2019).",130,15,none,WMS,NA,Illumina,LEfSe,0.05,NA,2,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:850/4/NA,Study 850,meta-analysis,36171758,10.3389/fcimb.2022.961644,NA,"Chai J, Liu X, Usdrowski H, Deng F, Li Y , Zhao J","Geography, niches, and transportation influence bovine respiratory microbiome and health",Frontiers in cellular and infection microbiology,2022,"bovine, bovine respiratory disease, geography, lung, metagenomics, nasopharynx, respiratory microbiota, transportation",Experiment 4,"Canada,China",Bos taurus,Nasopharynx,UBERON:0001728,Transport,GO:0006810,Non-transportation (control),Before loading for short distance transportation,"calves before loading to truck for transportation at short distance. LefSe was used to identify the longitudinal changes of microbiota from the studies of Cui et al. (2021) and Malmuthuge et al. (2021), following transportation",10,10,none,WMS,NA,Illumina,LEfSe,0.05,NA,2,NA,NA,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:850/5/NA,Study 850,meta-analysis,36171758,10.3389/fcimb.2022.961644,NA,"Chai J, Liu X, Usdrowski H, Deng F, Li Y , Zhao J","Geography, niches, and transportation influence bovine respiratory microbiome and health",Frontiers in cellular and infection microbiology,2022,"bovine, bovine respiratory disease, geography, lung, metagenomics, nasopharynx, respiratory microbiota, transportation",Experiment 5,"Canada,China",Bos taurus,Nasopharynx,UBERON:0001728,Transport,GO:0006810,Non-transportation (control),unloading after short distance transportation,"calves at the time of unloading from truck after transportation at short distance. LefSe was used to identify the longitudinal changes of microbiota from the studies of Cui et al. (2021) and Malmuthuge et al. (2021), following transportation",10,10,none,WMS,NA,Illumina,LEfSe,0.05,NA,2,NA,NA,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:850/6/NA,Study 850,meta-analysis,36171758,10.3389/fcimb.2022.961644,NA,"Chai J, Liu X, Usdrowski H, Deng F, Li Y , Zhao J","Geography, niches, and transportation influence bovine respiratory microbiome and health",Frontiers in cellular and infection microbiology,2022,"bovine, bovine respiratory disease, geography, lung, metagenomics, nasopharynx, respiratory microbiota, transportation",Experiment 6,"Canada,China",Bos taurus,Nasopharynx,UBERON:0001728,Transport,GO:0006810,Non-transportation (control),7 days after placement and adaptive feeding (short distance),"calves 7 days after placement and adaptive feeding following transportation at short distance. LefSe was used to identify the longitudinal changes of microbiota from the studies of Cui et al. (2021) and Malmuthuge et al. (2021), following transportation.",10,10,none,WMS,NA,Illumina,LEfSe,0.05,NA,2,NA,NA,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:850/7/NA,Study 850,meta-analysis,36171758,10.3389/fcimb.2022.961644,NA,"Chai J, Liu X, Usdrowski H, Deng F, Li Y , Zhao J","Geography, niches, and transportation influence bovine respiratory microbiome and health",Frontiers in cellular and infection microbiology,2022,"bovine, bovine respiratory disease, geography, lung, metagenomics, nasopharynx, respiratory microbiota, transportation",Experiment 7,"Canada,China",Bos taurus,Nasopharynx,UBERON:0001728,Transport,GO:0006810,Non-transportation (control),before loading for long distance transportation,"calves before loading into truck for long distance transportation. LefSe was used to identify the longitudinal changes of microbiota from the studies of Cui et al. (2021) and Malmuthuge et al. (2021), following transportation.",10,18,none,WMS,NA,Illumina,LEfSe,0.05,NA,2,NA,NA,NA,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:850/8/NA,Study 850,meta-analysis,36171758,10.3389/fcimb.2022.961644,NA,"Chai J, Liu X, Usdrowski H, Deng F, Li Y , Zhao J","Geography, niches, and transportation influence bovine respiratory microbiome and health",Frontiers in cellular and infection microbiology,2022,"bovine, bovine respiratory disease, geography, lung, metagenomics, nasopharynx, respiratory microbiota, transportation",Experiment 8,"Canada,China",Bos taurus,Nasopharynx,UBERON:0001728,Transport,GO:0006810,Non-transportation (control),unloading from long distance transportation,"calves at the time of unloading from truck after long distance transportation. LefSe was used to identify the longitudinal changes of microbiota from the studies of Cui et al. (2021) and Malmuthuge et al. (2021), following transportation.",10,18,none,WMS,NA,Illumina,LEfSe,0.05,NA,2,NA,NA,NA,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:850/9/NA,Study 850,meta-analysis,36171758,10.3389/fcimb.2022.961644,NA,"Chai J, Liu X, Usdrowski H, Deng F, Li Y , Zhao J","Geography, niches, and transportation influence bovine respiratory microbiome and health",Frontiers in cellular and infection microbiology,2022,"bovine, bovine respiratory disease, geography, lung, metagenomics, nasopharynx, respiratory microbiota, transportation",Experiment 9,"Canada,China",Bos taurus,Nasopharynx,UBERON:0001728,Transport,GO:0006810,Non-transportation (control),7 days after placement and adaptive feeding(long distance),"calves at  7 days after placement and adaptive feeding after long distance transportation. LefSe was used to identify the longitudinal changes of microbiota from the studies of Cui et al. (2021) and Malmuthuge et al. (2021), following transportation.",10,18,none,WMS,NA,Illumina,LEfSe,0.05,NA,2,NA,NA,NA,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:850/10/NA,Study 850,meta-analysis,36171758,10.3389/fcimb.2022.961644,NA,"Chai J, Liu X, Usdrowski H, Deng F, Li Y , Zhao J","Geography, niches, and transportation influence bovine respiratory microbiome and health",Frontiers in cellular and infection microbiology,2022,"bovine, bovine respiratory disease, geography, lung, metagenomics, nasopharynx, respiratory microbiota, transportation",Experiment 10,Canada,Bos taurus,Nasopharynx,UBERON:0001728,"Breastfeeding duration,Transport","EFO:0006864,GO:0006810",suckling calves (control),weaning+short transportation,"These were the calves in the treatment group that got weaned and transported at short distance. Metagenomics of the bovine respiratory microbiome in treatment groups on days 0 (prior to weaning and short-distance transportation), 2, 4, 8, 14, and 28 was used to compare with the control group that stayed with their dams (suckling).",10,10,none,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:851/1/NA,Study 851,"cross-sectional observational, not case-control",26937623,10.1097/MIB.0000000000000684,NA,"Forbes JD, Van Domselaar G , Bernstein CN",Microbiome Survey of the Inflamed and Noninflamed Gut at Different Compartments Within the Gastrointestinal Tract of Inflammatory Bowel Disease Patients,Inflammatory bowel diseases,2016,NA,Experiment 1,Canada,Homo sapiens,"Cecum mucosa,Colonic mucosa,Mucosa of rectum,Ileal mucosa","UBERON:0000314,UBERON:0000317,UBERON:0003346,UBERON:0000331",Crohn's disease,EFO:0000384,non-inflammatory bowel disease who were undergoing colonoscopy either for screening or for other gastrointestinal complaints unrelated to IBD,non-inflamed crohn's disease,biopsies collected from patients with crohn's disease at colonoscopy that were deemed as non-inflamed as per the clinical pathologist.,7,15,N/A,16S,6,Illumina,Kruskall-Wallis,0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:851/2/NA,Study 851,"cross-sectional observational, not case-control",26937623,10.1097/MIB.0000000000000684,NA,"Forbes JD, Van Domselaar G , Bernstein CN",Microbiome Survey of the Inflamed and Noninflamed Gut at Different Compartments Within the Gastrointestinal Tract of Inflammatory Bowel Disease Patients,Inflammatory bowel diseases,2016,NA,Experiment 2,Canada,Homo sapiens,"Cecum mucosa,Colonic mucosa,Mucosa of rectum,Ileal mucosa","UBERON:0000314,UBERON:0000317,UBERON:0003346,UBERON:0000331",Ulcerative colitis,EFO:0000729,non-inflammatory bowel disease patients who were undergoing colonoscopy either for screening or for other gastrointestinal complaints unrelated to IBD,non-inflamed ulcerative colitis,biopsies collected from patients with ulcerative colitis at colonoscopy that were deemed as non-inflamed as per the clinical pathologist.,7,21,N/A,16S,6,Illumina,Kruskall-Wallis,0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:851/3/NA,Study 851,"cross-sectional observational, not case-control",26937623,10.1097/MIB.0000000000000684,NA,"Forbes JD, Van Domselaar G , Bernstein CN",Microbiome Survey of the Inflamed and Noninflamed Gut at Different Compartments Within the Gastrointestinal Tract of Inflammatory Bowel Disease Patients,Inflammatory bowel diseases,2016,NA,Experiment 3,Canada,Homo sapiens,"Cecum mucosa,Colonic mucosa,Mucosa of rectum,Ileal mucosa","UBERON:0000314,UBERON:0000317,UBERON:0003346,UBERON:0000331",Ulcerative colitis,EFO:0000729,non-inflammatory bowel disease patients who were undergoing colonoscopy either for screening or for other gastrointestinal complaints unrelated to IBD,inflamed ulcerative colitis,biopsies collected from patients with ulcerative colitis at colonoscopy that were deemed as inflamed as per the clinical pathologist.,27,26,N/A,16S,6,Illumina,Kruskall-Wallis,0.05,TRUE,NA,NA,NA,NA,unchanged,decreased,increased,increased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:852/1/NA,Study 852,case-control,33565055,10.1007/s12275-021-0647-1,NA,"Kim J, Park T, Kim HJ, An S , Sul WJ",Inferences in microbial structural signatures of acne microbiome and mycobiome,"Journal of microbiology (Seoul, Korea)",2021,"16S rRNA gene sequencing, ITS1 region sequencing, Staphylococcus, acne, microbiome, mycobiome, skin",Experiment 1,South Korea,Homo sapiens,"Cheek,Forehead","UBERON:0001567,UBERON:0008200",Acne,EFO:0003894,Healthy group,Acne group,"Korean women aged 19-28 years with acne, a common skin condition that affects the hair follicles and sebaceous (oil) glands in the skin.",16,17,NA,16S,45,Illumina,LEfSe,0.05,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:852/2/NA,Study 852,case-control,33565055,10.1007/s12275-021-0647-1,NA,"Kim J, Park T, Kim HJ, An S , Sul WJ",Inferences in microbial structural signatures of acne microbiome and mycobiome,"Journal of microbiology (Seoul, Korea)",2021,"16S rRNA gene sequencing, ITS1 region sequencing, Staphylococcus, acne, microbiome, mycobiome, skin",Experiment 2,South Korea,Homo sapiens,"Cheek,Forehead","UBERON:0001567,UBERON:0008200",Acne,EFO:0003894,Healthy group,Acne group,"Korean women aged 19-28 years with acne, a common skin condition that affects the hair follicles and sebaceous (oil) glands in the skin.",16,17,NA,16S,45,Illumina,LEfSe,0.05,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:852/3/NA,Study 852,case-control,33565055,10.1007/s12275-021-0647-1,NA,"Kim J, Park T, Kim HJ, An S , Sul WJ",Inferences in microbial structural signatures of acne microbiome and mycobiome,"Journal of microbiology (Seoul, Korea)",2021,"16S rRNA gene sequencing, ITS1 region sequencing, Staphylococcus, acne, microbiome, mycobiome, skin",Experiment 3,South Korea,Homo sapiens,"Cheek,Forehead","UBERON:0001567,UBERON:0008200",Acne,EFO:0003894,Healthy group,Acne group,"Korean women aged 19-28 years with acne, a common skin condition that affects the hair follicles and sebaceous (oil) glands in the skin.",16,17,NA,16S,45,Illumina,LEfSe,0.05,NA,NA,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:852/4/NA,Study 852,case-control,33565055,10.1007/s12275-021-0647-1,NA,"Kim J, Park T, Kim HJ, An S , Sul WJ",Inferences in microbial structural signatures of acne microbiome and mycobiome,"Journal of microbiology (Seoul, Korea)",2021,"16S rRNA gene sequencing, ITS1 region sequencing, Staphylococcus, acne, microbiome, mycobiome, skin",Experiment 4,South Korea,Homo sapiens,"Cheek,Forehead","UBERON:0001567,UBERON:0008200",Acne,EFO:0003894,Healthy group,Acne group,"Korean women aged 19-28 years with acne, a common skin condition that affects the hair follicles and sebaceous (oil) glands in the skin.",16,17,NA,16S,45,Illumina,LEfSe,0.05,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:853/1/NA,Study 853,meta-analysis,36220843,10.1038/s41598-022-21327-9,NA,"West KA, Yin X, Rutherford EM, Wee B, Choi J, Chrisman BS, Dunlap KL, Hannibal RL, Hartono W, Lin M, Raack E, Sabino K, Wu Y, Wall DP, David MM, Dabbagh K, DeSantis TZ , Iwai S",Multi-angle meta-analysis of the gut microbiome in Autism Spectrum Disorder: a step toward understanding patient subgroups,Scientific reports,2022,NA,Experiment 1,"Canada,China,India,Italy,United States of America",Homo sapiens,Feces,UBERON:0001988,Autism spectrum disorder,EFO:0003756,neurotypical (NT),Autism Spectrum Disorder (ASD),The study focuses on the composition of the human gut microbiome in children with ASD compared to neurotypical children.,NA,NA,NA,16S,4,Illumina,DESeq2,NA,NA,NA,age,"age,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:853/2/NA,Study 853,meta-analysis,36220843,10.1038/s41598-022-21327-9,NA,"West KA, Yin X, Rutherford EM, Wee B, Choi J, Chrisman BS, Dunlap KL, Hannibal RL, Hartono W, Lin M, Raack E, Sabino K, Wu Y, Wall DP, David MM, Dabbagh K, DeSantis TZ , Iwai S",Multi-angle meta-analysis of the gut microbiome in Autism Spectrum Disorder: a step toward understanding patient subgroups,Scientific reports,2022,NA,Experiment 2,"Canada,China,India,Italy,United States of America",Homo sapiens,Feces,UBERON:0001988,Autism spectrum disorder,EFO:0003756,neurotypical (NT),Autism Spectrum Disorder (ASD),The study focuses on the composition of the human gut microbiome in children with ASD compared to neurotypical children.,NA,NA,NA,WMS,NA,Illumina,NA,NA,NA,NA,age,"age,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:853/3/NA,Study 853,meta-analysis,36220843,10.1038/s41598-022-21327-9,NA,"West KA, Yin X, Rutherford EM, Wee B, Choi J, Chrisman BS, Dunlap KL, Hannibal RL, Hartono W, Lin M, Raack E, Sabino K, Wu Y, Wall DP, David MM, Dabbagh K, DeSantis TZ , Iwai S",Multi-angle meta-analysis of the gut microbiome in Autism Spectrum Disorder: a step toward understanding patient subgroups,Scientific reports,2022,NA,Experiment 3,"Canada,China,India,Italy,United States of America",Homo sapiens,Feces,UBERON:0001988,Autism spectrum disorder,EFO:0003756,neurotypical (NT),Autism Spectrum Disorder (ASD),The study focuses on the composition of the human gut microbiome in children with ASD compared to neurotypical children.,20,20,NA,16S,23,NA,DESeq2,0.05,NA,NA,age,"age,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:854/1/NA,Study 854,case-control,35350577,10.3389/fmed.2022.841112,NA,"Song H, Xiao K, Chen Z , Long Q",Analysis of Conjunctival Sac Microbiome in Dry Eye Patients With and Without Sjögren's Syndrome,Frontiers in medicine,2022,"Sjögren's syndrome, dry eyes, microbial composition, microbial diversity, ocular surface",Experiment 1,China,Homo sapiens,Conjunctival sac,UBERON:0005908,Dry eye syndrome,EFO:1000906,Normal Control (NC),Sjogrens Syndrome Dry Eye (SSDE),Patients with Sjogrens Syndrome Dry Eye,39,23,"Application of antibiotic or immunomodulatory eyedrops in the
previous 4 weeks,",16S,34,Illumina,ANOVA,0.05,NA,NA,NA,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:854/2/NA,Study 854,case-control,35350577,10.3389/fmed.2022.841112,NA,"Song H, Xiao K, Chen Z , Long Q",Analysis of Conjunctival Sac Microbiome in Dry Eye Patients With and Without Sjögren's Syndrome,Frontiers in medicine,2022,"Sjögren's syndrome, dry eyes, microbial composition, microbial diversity, ocular surface",Experiment 2,China,Homo sapiens,Conjunctival sac,UBERON:0005908,Dry eye syndrome,EFO:1000906,Normal Control (NC),Non Sjogrens Syndrome Dry Eye (NSSDE),Patients with Non-Sjogrens Syndrome Dry Eye,39,36,"Application of antibiotic or immunomodulatory eyedrops in the
previous 4 weeks,",16S,34,Illumina,ANOVA,0.05,NA,NA,NA,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:854/3/NA,Study 854,case-control,35350577,10.3389/fmed.2022.841112,NA,"Song H, Xiao K, Chen Z , Long Q",Analysis of Conjunctival Sac Microbiome in Dry Eye Patients With and Without Sjögren's Syndrome,Frontiers in medicine,2022,"Sjögren's syndrome, dry eyes, microbial composition, microbial diversity, ocular surface",Experiment 3,China,Homo sapiens,Conjunctival sac,UBERON:0005908,Dry eye syndrome,EFO:1000906,Non Sjogrens Syndrome Dry Eye (NSSDE),Sjogrens Syndrome Dry Eye (SSDE),Patients with Sjogrens Syndrome Dry Eye,36,23,"Application of antibiotic or immunomodulatory eyedrops in the
previous 4 weeks,",16S,34,Illumina,ANOVA,0.05,NA,NA,NA,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:855/1/NA,Study 855,case-control,37026303,10.4103/IJO.IJO_2821_22,NA,"Pal S, Vani G, Donthineni PR, Basu S , Arunasri K",Tear film microbiome in Sjogren's and non-Sjogren's aqueous deficiency dry eye,Indian journal of ophthalmology,2023,"Dry eye disease, Prevotella, Sjogren's syndrome, non-Sjogren's syndrome, tear film microbiome",Experiment 1,India,Homo sapiens,Tear film,UBERON:0022287,Dry eye syndrome,EFO:1000906,Healthy Controls,Dry Eye Disease patients,Both Sjogren's and non-Sjogren's patients with Dry Eye Disease,18,24,No medications in the past month,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,NA,NA,NA,NA,NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:855/2/NA,Study 855,case-control,37026303,10.4103/IJO.IJO_2821_22,NA,"Pal S, Vani G, Donthineni PR, Basu S , Arunasri K",Tear film microbiome in Sjogren's and non-Sjogren's aqueous deficiency dry eye,Indian journal of ophthalmology,2023,"Dry eye disease, Prevotella, Sjogren's syndrome, non-Sjogren's syndrome, tear film microbiome",Experiment 2,India,Homo sapiens,Tear film,UBERON:0022287,Dry eye syndrome,EFO:1000906,Healthy Controls,Sjogren's patients with Dry Eye Disease,Sjogren's patients with Dry Eye Disease,18,9,No medications in the past month,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,NA,NA,NA,NA,NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:855/3/NA,Study 855,case-control,37026303,10.4103/IJO.IJO_2821_22,NA,"Pal S, Vani G, Donthineni PR, Basu S , Arunasri K",Tear film microbiome in Sjogren's and non-Sjogren's aqueous deficiency dry eye,Indian journal of ophthalmology,2023,"Dry eye disease, Prevotella, Sjogren's syndrome, non-Sjogren's syndrome, tear film microbiome",Experiment 3,India,Homo sapiens,Tear film,UBERON:0022287,Dry eye syndrome,EFO:1000906,Healthy Controls,Non-Sjogren's Syndrome patients with Dry Eye Disease,Non-Sjogren's patients with Dry Eye Disease,18,15,No medications in the past month,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,NA,NA,NA,NA,NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:856/1/NA,Study 856,case-control,37803284,10.1186/s12866-023-03013-6,NA,"Chen Z, Xiao Y, Jia Y, Lin Q, Qian Y, Cui L, Xiang Z, Li M, Yang C , Zou H",Metagenomic analysis of microbiological changes on the ocular surface of diabetic children and adolescents with a dry eye,BMC microbiology,2023,"Children and adolescents, Diabetes mellitus, Dry eye, Metagenome, Microecology, Ocular surface",Experiment 1,China,Homo sapiens,Conjunctival sac,UBERON:0005908,Dry eye syndrome,EFO:1000906,Normal healthy (NDM) children,Diabetic children with Dry Eye Disease (DM-DE),Children aged 8-16 with Diabetes and Dry Eye Disease,10,10,NA,WMS,NA,Illumina,LEfSe,0.05,NA,NA,"age,body mass index,sex",NA,NA,NA,decreased,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:856/2/NA,Study 856,case-control,37803284,10.1186/s12866-023-03013-6,NA,"Chen Z, Xiao Y, Jia Y, Lin Q, Qian Y, Cui L, Xiang Z, Li M, Yang C , Zou H",Metagenomic analysis of microbiological changes on the ocular surface of diabetic children and adolescents with a dry eye,BMC microbiology,2023,"Children and adolescents, Diabetes mellitus, Dry eye, Metagenome, Microecology, Ocular surface",Experiment 2,China,Homo sapiens,Conjunctival sac,UBERON:0005908,Dry eye syndrome,EFO:1000906,Normal healthy (NDM) children,Diabetic children with Dry Eye Disease (DM-DE),Children aged 8-16 with Diabetes and Dry Eye Disease,10,10,NA,WMS,NA,Illumina,ANOSIM,0.05,NA,NA,"age,body mass index,sex",NA,NA,NA,decreased,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:857/1/NA,Study 857,case-control,28536926,10.1007/s11427-016-9001-4,NA,"Li W, Wu X, Hu X, Wang T, Liang S, Duan Y, Jin F , Qin B",Structural changes of gut microbiota in Parkinson's disease and its correlation with clinical features,Science China. Life sciences,2017,"16S rRNA sequencing, gastrointestinal dysfunction, gut-brain-axis, microbiome, short chain fatty acids, α-synuclein",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Healthy controls,Parkinson's disease,Patients with Parkinson's disease,14,24,3 months,16S,345,Illumina,Metastats,0.05,FALSE,NA,"age,sex",NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:858/1/NA,Study 858,case-control,36941248,10.1038/s41398-023-02325-5,NA,"Butler MI, Bastiaanssen TFS, Long-Smith C, Morkl S, Berding K, Ritz NL, Strain C, Patangia D, Patel S, Stanton C, O'Mahony SM, Cryan JF, Clarke G , Dinan TG",The gut microbiome in social anxiety disorder: evidence of altered composition and function,Translational psychiatry,2023,NA,Experiment 1,Ireland,Homo sapiens,Feces,UBERON:0001988,Social anxiety disorder,EFO:1001917,Healthy controls,Patients with Social Anxiety Disorder (SAD),Patients with Social Anxiety Disorder (SAD),31,18,4 weeks,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,"age,sex","age,body mass index,sex",NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:859/1/NA,Study 859,time series / longitudinal observational,37184522,10.1097/HC9.0000000000000151,NA,"Waldner B, Aldrian D, Zöggeler T, Oberacher H, Oberhuber R, Schneeberger S, Messner F, Schneider AM, Kohlmaier B, Lanzersdorfer R, Huber WD, Entenmann A, Müller T , Vogel GF",The influence of liver transplantation on the interplay between gut microbiome and bile acid homeostasis in children with biliary atresia,Hepatology communications,2023,NA,Experiment 1,Austria,Homo sapiens,Feces,UBERON:0001988,Biliary atresia,MONDO:0008867,Children with BA before - [pre],Post24 + m,The impact of LT and reestablishment of bile flow on gut microbiome–bile acid homeostasis in children with BA for more than 24 months (post24 + m) after liver transplantation (LT),10,12,NA,16S,34,Illumina,LEfSe,0.05,TRUE,NA,age,NA,NA,increased,increased,increased,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:859/2/NA,Study 859,time series / longitudinal observational,37184522,10.1097/HC9.0000000000000151,NA,"Waldner B, Aldrian D, Zöggeler T, Oberacher H, Oberhuber R, Schneeberger S, Messner F, Schneider AM, Kohlmaier B, Lanzersdorfer R, Huber WD, Entenmann A, Müller T , Vogel GF",The influence of liver transplantation on the interplay between gut microbiome and bile acid homeostasis in children with biliary atresia,Hepatology communications,2023,NA,Experiment 2,Austria,Homo sapiens,Feces,UBERON:0001988,Biliary atresia,MONDO:0008867,post 24 + m Control,Post24 + m,The impact of LT and reestablishment of bile flow on gut microbiome–bile acid homeostasis in children with BA for more than 24 months (post24 + m) after liver transplantation (LT),19,12,NA,16S,34,Illumina,LEfSe,0.05,TRUE,NA,age,NA,NA,decreased,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:860/1/NA,Study 860,time series / longitudinal observational,34766210,10.1007/s00248-021-01914-5,NA,"Sanseverino I, Pretto P, António DC, Lahm A, Facca C, Loos R, Skejo H, Beghi A, Pandolfi F, Genoni P , Lettieri T",Metagenomics Analysis to Investigate the Microbial Communities and Their Functional Profile During Cyanobacterial Blooms in Lake Varese,Microbial ecology,2022,"Algal bloom, Freshwater, Lyngbya, Metagenomics, Microbial populations, Water quality",Experiment 1,Italy,Not specified,NA,NA,NA,NA,No healthy samples,2017 samples,"2017 samples are samples obtained from the three river depths(Meso, Secchi, and surface depth) during the cyanobacterial bloom in 2017.",NA,3,non,16S,34,Illumina,NA,0.05,NA,NA,NA,NA,decreased,decreased,unchanged,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:861/1/NA,Study 861,time series / longitudinal observational,34711536,10.1183/13993003.01932-2021,https://erj.ersjournals.com/content/59/1/2101932.long,"Cuthbertson L, James P, Habibi MS, Thwaites RS, Paras A, Chiu C, Openshaw PJM, Cookson WOC , Moffatt MF",Resilience of the respiratory microbiome in controlled adult RSV challenge study,The European respiratory journal,2022,NA,Experiment 1,United Kingdom,Homo sapiens,"Nasal cavity,Throat","UBERON:0001707,UBERON:0000341",Respiratory Syncytial Virus Infection,EFO:1001413,NA,Healthy non-smoking adults,Healthy non-smoking adults between 18 and 50 years of age.,NA,37,NA,16S,4,Illumina,"DESeq2,Mann-Whitney (Wilcoxon),PERMANOVA,ANOVA",0.05,TRUE,NA,NA,NA,NA,unchanged,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:862/1/NA,Study 862,prospective cohort,33961805,10.1016/S2213-2600(20)30557-9,https://linkinghub.elsevier.com/retrieve/pii/S2213-2600(20)30557-9,"Dicker AJ, Lonergan M, Keir HR, Smith AH, Pollock J, Finch S, Cassidy AJ, Huang JTJ , Chalmers JD",The sputum microbiome and clinical outcomes in patients with bronchiectasis: a prospective observational study,The Lancet. Respiratory medicine,2021,NA,Experiment 1,United Kingdom,Homo sapiens,Sputum,UBERON:0007311,Bronchiectasis,MONDO:0004822,Less severe bronchiectasis,Severe bronchiectasis,Stable sputum samples with more severe bronchiectasis severity index (BSI) score [BSI ≥ 9],281,281,None,16S,34,Illumina,"PERMANOVA,Random Forest Analysis",0.05,FALSE,NA,NA,"age,smoking status",NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:862/2/NA,Study 862,prospective cohort,33961805,10.1016/S2213-2600(20)30557-9,https://linkinghub.elsevier.com/retrieve/pii/S2213-2600(20)30557-9,"Dicker AJ, Lonergan M, Keir HR, Smith AH, Pollock J, Finch S, Cassidy AJ, Huang JTJ , Chalmers JD",The sputum microbiome and clinical outcomes in patients with bronchiectasis: a prospective observational study,The Lancet. Respiratory medicine,2021,NA,Experiment 2,United Kingdom,Homo sapiens,Sputum,UBERON:0007311,Bronchiectasis,MONDO:0004822,Non-frequent exacerbating stable patients,Frequent exacerbating stable patients,Frequent exacerbating stable patients (≥ 3 exacerbation),281,281,None,16S,34,Illumina,"PERMANOVA,Random Forest Analysis",0.05,FALSE,NA,NA,"age,smoking status",NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:862/3/NA,Study 862,prospective cohort,33961805,10.1016/S2213-2600(20)30557-9,https://linkinghub.elsevier.com/retrieve/pii/S2213-2600(20)30557-9,"Dicker AJ, Lonergan M, Keir HR, Smith AH, Pollock J, Finch S, Cassidy AJ, Huang JTJ , Chalmers JD",The sputum microbiome and clinical outcomes in patients with bronchiectasis: a prospective observational study,The Lancet. Respiratory medicine,2021,NA,Experiment 3,United Kingdom,Homo sapiens,Sputum,UBERON:0007311,Bronchiectasis,MONDO:0004822,Stable samples,Exacerbation samples,Sputum samples at onset of exacerbation,64,64,None,16S,34,Illumina,"PERMANOVA,Random Forest Analysis",0.05,FALSE,NA,NA,"age,smoking status",NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:863/1/NA,Study 863,"cross-sectional observational, not case-control",33655988,10.1097/MD.0000000000025091,NA,"Su YJ, Luo SD, Hsu CY , Kuo HC","Differences in gut microbiota between allergic rhinitis, atopic dermatitis, and skin urticaria: A pilot study",Medicine,2021,NA,Experiment 1,Taiwan,Homo sapiens,Feces,UBERON:0001988,"Eczema,Urticaria","HP:0000964,EFO:0005531",Chronic urticaria (hives),Atopic dermatitis (eczema),Patients with atopic dermatitis (eczema),9,19,Those with a history of antibiotics,16S,34,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,increased,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:863/2/NA,Study 863,"cross-sectional observational, not case-control",33655988,10.1097/MD.0000000000025091,NA,"Su YJ, Luo SD, Hsu CY , Kuo HC","Differences in gut microbiota between allergic rhinitis, atopic dermatitis, and skin urticaria: A pilot study",Medicine,2021,NA,Experiment 2,Taiwan,Homo sapiens,Feces,UBERON:0001988,"Eczema,Allergic rhinitis","HP:0000964,EFO:0005854",Allergic rhinitis,Atopic dermatitis (eczema),Patients with atopic dermatitis (eczema),9,19,Those with a history of antibiotics,16S,34,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,increased,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:864/1/NA,Study 864,time series / longitudinal observational,30446559,https://doi.org/10.1128/AEM.02479-18,NA,"Parris DJ, Morgan MM , Stewart FJ",Feeding Rapidly Alters Microbiome Composition and Gene Transcription in the Clownfish Gut,Applied and environmental microbiology,2019,"digestion, diurnal, feeding, food-associated microbes, gut microbiome dynamics",Experiment 1,Georgia,Premnas biaculeatus,Digestive tract,UBERON:0001555,Diet,EFO:0002755,Pre-fed group at 1100 h,Post-fed group at 1230 h,The post-fed group consists of fish fed at 1230 hours. (1.5 hours postfeeding),17,18,NA,16S,34,Illumina,ANCOM,0.05,FALSE,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:864/2/NA,Study 864,time series / longitudinal observational,30446559,https://doi.org/10.1128/AEM.02479-18,NA,"Parris DJ, Morgan MM , Stewart FJ",Feeding Rapidly Alters Microbiome Composition and Gene Transcription in the Clownfish Gut,Applied and environmental microbiology,2019,"digestion, diurnal, feeding, food-associated microbes, gut microbiome dynamics",Experiment 2,Georgia,Premnas biaculeatus,Digestive tract,UBERON:0001555,Diet,EFO:0002755,Pre-fed group at 1100 h,Post-fed group at 1400 h,The post-fed group consists of fish fed at 1400 hours. (3 hours post-feeding),17,18,NA,16S,34,Illumina,ANCOM,0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:864/3/NA,Study 864,time series / longitudinal observational,30446559,https://doi.org/10.1128/AEM.02479-18,NA,"Parris DJ, Morgan MM , Stewart FJ",Feeding Rapidly Alters Microbiome Composition and Gene Transcription in the Clownfish Gut,Applied and environmental microbiology,2019,"digestion, diurnal, feeding, food-associated microbes, gut microbiome dynamics",Experiment 3,Georgia,Premnas biaculeatus,Digestive tract,UBERON:0001555,Diet,EFO:0002755,Pre-fed group at 1100 h,Post-fed group at 1600 h,The post-fed group consists of fish fed at 1600 hours. (5 hours postfeeding),17,18,NA,16S,34,Illumina,ANCOM,0.05,FALSE,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:864/4/NA,Study 864,time series / longitudinal observational,30446559,https://doi.org/10.1128/AEM.02479-18,NA,"Parris DJ, Morgan MM , Stewart FJ",Feeding Rapidly Alters Microbiome Composition and Gene Transcription in the Clownfish Gut,Applied and environmental microbiology,2019,"digestion, diurnal, feeding, food-associated microbes, gut microbiome dynamics",Experiment 4,Georgia,Premnas biaculeatus,Digestive tract,UBERON:0001555,Diet,EFO:0002755,Pre-fed group at 1100 h,Post-fed group at 2000 h,The post-fed group consists of fish fed at 2000 hours. (9 hours post-feeding),17,17,NA,16S,34,Illumina,ANCOM,0.05,FALSE,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:865/1/NA,Study 865,randomized controlled trial,33708251,10.1155/2021/6645970,NA,"Liu L, Yang M, Dong W, Liu T, Song X, Gu Y, Wang S, Liu Y, Abla Z, Qiao X, Liu W, Jiang K, Wang B, Zhang J , Cao H",Gut Dysbiosis and Abnormal Bile Acid Metabolism in Colitis-Associated Cancer,Gastroenterology research and practice,2021,NA,Experiment 1,China,Mus musculus,Feces,UBERON:0001988,Colorectal cancer cell line,BTO:0001616,control group at week 10 (C10 group),azoxymethane/dextran sodiumsulfate (AOM/DSS) group at week 10 (AD10 group),"C57BL/6mice aged 7 weeks were obtained from Beijing Huafukang Bioscience Co. Inc. and acclimatized 1 week before the experiment. Intraperitoneal injection of 10mg/kg azoxymethane(AOM) was applied to the AOM/DSS group. After seven days, the AOM/DSS group was given1.5% dextran sodium sulfate (DSS) in drinking water on days 8–13, 27–32, and 46–51, and each cycle of DSS treatment was followed by 14-day drinking water. This was to create the colitis-induced colorectal cancer (CAC) model in the mice. Group 1 is the mice that developed CAC and had their fecal sample collected before being euthanized on day 70 (week 10).",5,5,none,16S,34,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,decreased,decreased,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:866/1/NA,Study 866,case-control,37894412,10.3390/cancers15205045,NA,"Welham Z, Li J, Engel AF , Molloy MP",Mucosal Microbiome in Patients with Early Bowel Polyps: Inferences from Short-Read and Long-Read 16S rRNA Sequencing,Cancers,2023,"16S rRNA sequencing, PacBio long-read sequencing, bowel polyps, gut microbiome",Experiment 1,Australia,Homo sapiens,Colonic mucosa,UBERON:0000317,Intestinal polyp,EFO:0003855,Polyp-free control patients,Patients with low-grade colorectal polyps cohort,"Colorectal polyps were removed as standard clinical care during the colonoscopy procedure. For each polyp removed, two further 2 mm mucosal biopsies 20 mm and 50 mm adjacent to the polyp were collected.",27,27,Patients who had taken antibiotics up to four weeks before the colonoscopy.,16S,34,Illumina,LEfSe,0.05,FALSE,NA,"age,body mass index,sex",NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:866/2/NA,Study 866,case-control,37894412,10.3390/cancers15205045,NA,"Welham Z, Li J, Engel AF , Molloy MP",Mucosal Microbiome in Patients with Early Bowel Polyps: Inferences from Short-Read and Long-Read 16S rRNA Sequencing,Cancers,2023,"16S rRNA sequencing, PacBio long-read sequencing, bowel polyps, gut microbiome",Experiment 2,Australia,Homo sapiens,Colonic mucosa,UBERON:0000317,Intestinal polyp,EFO:0003855,Polyp-free control patients,Patients with low-grade colorectal polyps cohort,"Colorectal polyps were removed as standard clinical care during the colonoscopy procedure. For each polyp removed, two further 2 mm mucosal biopsies 20 mm and 50 mm adjacent to the polyp were collected.",27,27,Patients who had taken antibiotics up to four weeks before the colonoscopy.,16S,123456789,PacBio RS,LEfSe,0.05,FALSE,NA,"age,body mass index,sex",NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:867/1/NA,Study 867,case-control,37960281,10.3390/nu15214628,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10649662/,"Altinok Dindar D, Chun B, Palma A, Cheney J, Krieger M, Kasschau K, Stagaman K, Mitri ZI, Goodyear SM, Shannon J, Karstens L, Sharpton T , Zhang Z",Association between Gut Microbiota and Breast Cancer: Diet as a Potential Modulating Factor,Nutrients,2023,"Acidaminococus, Hungatella, Tyzzerella, breast cancer, gut microbiome",Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Breast cancer,MONDO:0007254,Healthy controls,Breast cancer patients,"Biopsy-confirmed diagnosis of breast cancer prior to initiating any treatment, including surgery, chemotherapy, or radiation therapy.",44,42,Not mentioned,16S,4,Illumina,LEfSe,0.05,FALSE,2,age,body mass index,decreased,decreased,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:868/1/NA,Study 868,case-control,33748490,10.1016/j.heliyon.2021.e06432,NA,"Gryaznova MV, Solodskikh SA, Panevina AV, Syromyatnikov MY, Dvoretskaya YD, Sviridova TN, Popov ES , Popov VN",Study of microbiome changes in patients with ulcerative colitis in the Central European part of Russia,Heliyon,2021,"Inflammatory bowel disease, Intestinal microbiota, Russian population, Sequencing, Ulcerative colitis",Experiment 1,Russian Federation,Homo sapiens,Feces,UBERON:0001988,Ulcerative colitis,EFO:0000729,Healthy controls,Ulcerative colitis,Patients with ulcerative colitis,10,10,NIL,PCR,NA,Ion Torrent,DESeq2,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:869/1/NA,Study 869,case-control,35630486,10.3390/microorganisms10051044,NA,"Kitae H, Takagi T, Naito Y, Inoue R, Azuma Y, Torii T, Mizushima K, Doi T, Inoue K, Dohi O, Yoshida N, Kamada K, Uchiyama K, Ishikawa T, Konishi H , Itoh Y",Gut Microbiota Associated with Clinical Relapse in Patients with Quiescent Ulcerative Colitis,Microorganisms,2022,"LEfSe, fecal microbiota, quiescent ulcerative colitis, ulcerative colitis relapse",Experiment 1,Japan,Homo sapiens,Feces,UBERON:0001988,Ulcerative colitis,EFO:0000729,healthy controls,quiescent ulcerative colitis patients,consecutive recruitment of patients with quiescent UC in our outpatient clinic from November 2016 to September 2017. Clinical remission was defined as a Lichtiger index score of ≤4.,59,59,no history of antibiotic use within three months,16S,34,Illumina,LEfSe,0.05,NA,4,"age,sex",NA,NA,decreased,decreased,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:869/2/NA,Study 869,case-control,35630486,10.3390/microorganisms10051044,NA,"Kitae H, Takagi T, Naito Y, Inoue R, Azuma Y, Torii T, Mizushima K, Doi T, Inoue K, Dohi O, Yoshida N, Kamada K, Uchiyama K, Ishikawa T, Konishi H , Itoh Y",Gut Microbiota Associated with Clinical Relapse in Patients with Quiescent Ulcerative Colitis,Microorganisms,2022,"LEfSe, fecal microbiota, quiescent ulcerative colitis, ulcerative colitis relapse",Experiment 2,Japan,Homo sapiens,Feces,UBERON:0001988,Disease progression measurement,EFO:0008336,sustained remission of ulcerative colitis group,relapsed ulcerative colitis group,Patients who had clinically relapsed during the 3.5 year-long follow-up period. Clinical relapse was defined as clinical or endoscopic deterioration requiring therapeutic modification.,40,19,NA,16S,34,Illumina,LEfSe,0.05,NA,4,NA,NA,NA,unchanged,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:870/1/NA,Study 870,case-control,37077242,10.3389/fmicb.2023.1113174,https://pubmed.ncbi.nlm.nih.gov/37077242/,"Huang D, Wang J, Zeng Y, Li Q , Wang Y",Identifying microbial signatures for patients with postmenopausal osteoporosis using gut microbiota analyses and feature selection approaches,Frontiers in microbiology,2023,"bone mineral density, feature selection, gut microbiota, microbial biomarker, postmenopausal osteoporosis",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Postmenopausal osteoporosis,EFO:0003854,Healthy controls,Postmenopausal osteoporosis (PMOP) patients,Patients with Postmenopausal osteoporosis (PMOP),37,21,Subjects who were on antibiotics one (1) month preceding the sample collection were excluded from the study,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.1,NA,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:871/1/NA,Study 871,prospective cohort,38006691,10.1016/j.oraloncology.2023.106623,https://www.sciencedirect.com/science/article/abs/pii/S1368837523003196?via=ihub,"Hes C, Desilets A, Tonneau M, El Ouarzadi O, De Figueiredo Sousa M, Bahig H, Filion É, Nguyen-Tan PF, Christopoulos A, Benlaïfaoui M, Derosa L, Alves Costa Silva C, Ponce M, Malo J, Belkad W, Charpentier D, Aubin F, Hamilou Z, Jamal R, Messaoudene M, Soulières D , Routy B",Gut microbiome predicts gastrointestinal toxicity outcomes from chemoradiation therapy in patients with head and neck squamous cell carcinoma,Oral oncology,2023,"Chemoradiation therapy, Head and neck squamous cell cancer, Microbiome, Mucositis",Experiment 1,Canada,Homo sapiens,Feces,UBERON:0001988,Head and neck squamous cell carcinoma,EFO:0000181,Oral mucositis CTCAE grade 1-2 (mild),Oral mucositis CTCAE grade 3 (severe),Patients with severe mucositis following chemoradiation therapy,30,22,NA,WMS,NA,Illumina,LEfSe,0.05,NA,2,NA,NA,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:871/2/NA,Study 871,prospective cohort,38006691,10.1016/j.oraloncology.2023.106623,https://www.sciencedirect.com/science/article/abs/pii/S1368837523003196?via=ihub,"Hes C, Desilets A, Tonneau M, El Ouarzadi O, De Figueiredo Sousa M, Bahig H, Filion É, Nguyen-Tan PF, Christopoulos A, Benlaïfaoui M, Derosa L, Alves Costa Silva C, Ponce M, Malo J, Belkad W, Charpentier D, Aubin F, Hamilou Z, Jamal R, Messaoudene M, Soulières D , Routy B",Gut microbiome predicts gastrointestinal toxicity outcomes from chemoradiation therapy in patients with head and neck squamous cell carcinoma,Oral oncology,2023,"Chemoradiation therapy, Head and neck squamous cell cancer, Microbiome, Mucositis",Experiment 2,Canada,Homo sapiens,Feces,UBERON:0001988,Head and neck squamous cell carcinoma,EFO:0000181,No enteral feeding plus mild mucositis,Enteral feeding plus mucositis of any grade,Head and neck squamous cell carcinoma with severe mucositis and enteral feeding need,27,13,NA,WMS,NA,Illumina,LEfSe,0.05,NA,2,NA,NA,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:871/3/NA,Study 871,prospective cohort,38006691,10.1016/j.oraloncology.2023.106623,https://www.sciencedirect.com/science/article/abs/pii/S1368837523003196?via=ihub,"Hes C, Desilets A, Tonneau M, El Ouarzadi O, De Figueiredo Sousa M, Bahig H, Filion É, Nguyen-Tan PF, Christopoulos A, Benlaïfaoui M, Derosa L, Alves Costa Silva C, Ponce M, Malo J, Belkad W, Charpentier D, Aubin F, Hamilou Z, Jamal R, Messaoudene M, Soulières D , Routy B",Gut microbiome predicts gastrointestinal toxicity outcomes from chemoradiation therapy in patients with head and neck squamous cell carcinoma,Oral oncology,2023,"Chemoradiation therapy, Head and neck squamous cell cancer, Microbiome, Mucositis",Experiment 3,Canada,Homo sapiens,Feces,UBERON:0001988,Head and neck squamous cell carcinoma,EFO:0000181,No Enteral feeding tube placement,Enteral feeding tube placement,Patients needing enteral feeding,27,13,NA,WMS,NA,Illumina,LEfSe,0.05,NA,2,NA,NA,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:872/1/NA,Study 872,case-control,NA,https://doi.org/10.1186/s13041-023-01014-0,NA,"Wenwu Zhang, Siyun Zhang, Jiewen Chen, kejun He, Changming Zhang",The gut microbiota and metabolite profiles are altered in patients with spinal cord injury,Molecular brain,2023,"Spinal cord injury, Gut microbiota, 16S rRNA gene sequencing, Untargeted metabolomics",Experiment 1,China,Homo sapiens,NA,NA,NA,NA,typically healthy control group,spinal cord injury patient,"Spinal cord injury (SCI) is an insult to the spinal cord resulting in a change, either temporary or permanent, in the cord's normal motor, sensory, or autonomic function",10,11,NA,16S,34,DNA-DNA Hybridization,"LEfSe,T-Test,ANOSIM",0.05,FALSE,3,NA,age,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:873/1/NA,Study 873,case-control,38381714,10.1371/journal.pone.0297858,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0297858,"Humińska-Lisowska K, Zielińska K, Mieszkowski J, Michałowska-Sawczyn M, Cięszczyk P, Łabaj PP, Wasąg B, Frączek B, Grzywacz A, Kochanowicz A , Kosciolek T",Microbiome features associated with performance measures in athletic and non-athletic individuals: A case-control study,PloS one,2024,NA,Experiment 1,Poland,Homo sapiens,Feces,UBERON:0001988,Health study participation,EFO:0010130,Non-athletes,Strength athletes,Athletes engaged in strength athletics at timepoint B0 (in the morning before the Bruce Treadmill Test),19,15,Individuals who were on antibiotics six (6) months before the start of the study.,PCR,NA,Illumina,LEfSe,0.05,TRUE,2,NA,diet,NA,unchanged,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:873/2/NA,Study 873,case-control,38381714,10.1371/journal.pone.0297858,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0297858,"Humińska-Lisowska K, Zielińska K, Mieszkowski J, Michałowska-Sawczyn M, Cięszczyk P, Łabaj PP, Wasąg B, Frączek B, Grzywacz A, Kochanowicz A , Kosciolek T",Microbiome features associated with performance measures in athletic and non-athletic individuals: A case-control study,PloS one,2024,NA,Experiment 2,Poland,Homo sapiens,Feces,UBERON:0001988,Health study participation,EFO:0010130,Non-athletes,Endurance athletes,Athletes engaged in endurance athletics (in the morning before the Bruce Treadmill Test),19,13,Individuals who were on antibiotics six (6) months before the start of the study.,PCR,NA,Illumina,LEfSe,0.05,TRUE,2,NA,diet,NA,unchanged,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:873/3/NA,Study 873,case-control,38381714,10.1371/journal.pone.0297858,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0297858,"Humińska-Lisowska K, Zielińska K, Mieszkowski J, Michałowska-Sawczyn M, Cięszczyk P, Łabaj PP, Wasąg B, Frączek B, Grzywacz A, Kochanowicz A , Kosciolek T",Microbiome features associated with performance measures in athletic and non-athletic individuals: A case-control study,PloS one,2024,NA,Experiment 3,Poland,Homo sapiens,Feces,UBERON:0001988,Health study participation,EFO:0010130,Non-athletes,Strength athletes,Athletes engaged in strength athletics at timepoint W1 (the same day after the repeated lower body 30s-all-out wingate's test),19,15,Individuals who were on antibiotics six (6) months before the start of the study.,PCR,NA,Illumina,LEfSe,0.05,TRUE,2,NA,diet,NA,unchanged,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:873/4/NA,Study 873,case-control,38381714,10.1371/journal.pone.0297858,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0297858,"Humińska-Lisowska K, Zielińska K, Mieszkowski J, Michałowska-Sawczyn M, Cięszczyk P, Łabaj PP, Wasąg B, Frączek B, Grzywacz A, Kochanowicz A , Kosciolek T",Microbiome features associated with performance measures in athletic and non-athletic individuals: A case-control study,PloS one,2024,NA,Experiment 4,Poland,Homo sapiens,Feces,UBERON:0001988,Health study participation,EFO:0010130,Non-athletes,Endurance athletes,Athletes engaged in endurance athletics at time point W1 (the same day after the repeated lower body 30s-all-out wingate's test),19,13,Individuals who were on antibiotics six (6) months before the start of the study.,PCR,NA,Illumina,LEfSe,0.05,TRUE,2,NA,diet,NA,unchanged,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:873/5/NA,Study 873,case-control,38381714,10.1371/journal.pone.0297858,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0297858,"Humińska-Lisowska K, Zielińska K, Mieszkowski J, Michałowska-Sawczyn M, Cięszczyk P, Łabaj PP, Wasąg B, Frączek B, Grzywacz A, Kochanowicz A , Kosciolek T",Microbiome features associated with performance measures in athletic and non-athletic individuals: A case-control study,PloS one,2024,NA,Experiment 5,Poland,Homo sapiens,Feces,UBERON:0001988,Health study participation,EFO:0010130,Non-athletes,Strength athletes,Athletes engaged in strength athletics at timepoint W2 (morning fasting after the WT on an empty stomach),19,15,Individuals who were on antibiotics six (6) months before the start of the study.,PCR,NA,Illumina,LEfSe,0.05,TRUE,2,NA,diet,NA,unchanged,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:873/6/NA,Study 873,case-control,38381714,10.1371/journal.pone.0297858,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0297858,"Humińska-Lisowska K, Zielińska K, Mieszkowski J, Michałowska-Sawczyn M, Cięszczyk P, Łabaj PP, Wasąg B, Frączek B, Grzywacz A, Kochanowicz A , Kosciolek T",Microbiome features associated with performance measures in athletic and non-athletic individuals: A case-control study,PloS one,2024,NA,Experiment 6,Poland,Homo sapiens,Feces,UBERON:0001988,Health study participation,EFO:0010130,Non-athletes,Endurance athletes,Athletes engaged in endurance athletics at timepoint W2 (morning fasting after the WT on an empty stomach),19,13,Individuals who were on antibiotics six (6) months before the start of the study.,PCR,NA,Illumina,LEfSe,0.05,TRUE,2,NA,diet,NA,unchanged,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:873/7/NA,Study 873,case-control,38381714,10.1371/journal.pone.0297858,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0297858,"Humińska-Lisowska K, Zielińska K, Mieszkowski J, Michałowska-Sawczyn M, Cięszczyk P, Łabaj PP, Wasąg B, Frączek B, Grzywacz A, Kochanowicz A , Kosciolek T",Microbiome features associated with performance measures in athletic and non-athletic individuals: A case-control study,PloS one,2024,NA,Experiment 7,Poland,Homo sapiens,Feces,UBERON:0001988,Health study participation,EFO:0010130,Non-athletes,Strength athletes,Athletes engaged in strength athletics at timepoint B1 (the same day after the Bruce Treadmill Test),19,15,Individuals who were on antibiotics six (6) months before the start of the study.,PCR,NA,Illumina,LEfSe,0.05,TRUE,2,NA,diet,NA,unchanged,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:873/8/NA,Study 873,case-control,38381714,10.1371/journal.pone.0297858,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0297858,"Humińska-Lisowska K, Zielińska K, Mieszkowski J, Michałowska-Sawczyn M, Cięszczyk P, Łabaj PP, Wasąg B, Frączek B, Grzywacz A, Kochanowicz A , Kosciolek T",Microbiome features associated with performance measures in athletic and non-athletic individuals: A case-control study,PloS one,2024,NA,Experiment 8,Poland,Homo sapiens,Feces,UBERON:0001988,Health study participation,EFO:0010130,Non-athletes,Endurance athletes,Athletes engaged in endurance athletics  at timepoint B1 (the same day after the Bruce Treadmill Test),19,13,Individuals who were on antibiotics six (6) months before the start of the study.,PCR,NA,Illumina,LEfSe,0.05,TRUE,2,NA,diet,NA,unchanged,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:873/9/NA,Study 873,case-control,38381714,10.1371/journal.pone.0297858,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0297858,"Humińska-Lisowska K, Zielińska K, Mieszkowski J, Michałowska-Sawczyn M, Cięszczyk P, Łabaj PP, Wasąg B, Frączek B, Grzywacz A, Kochanowicz A , Kosciolek T",Microbiome features associated with performance measures in athletic and non-athletic individuals: A case-control study,PloS one,2024,NA,Experiment 9,Poland,Homo sapiens,Feces,UBERON:0001988,Health study participation,EFO:0010130,Non-athletes,Strength athletes,Athletes engaged in strength athletics  at timepoint B2 (morning after the Bruce Treadmill Test on an empty stomach),19,15,Individuals who were on antibiotics six (6) months before the start of the study.,PCR,NA,Illumina,LEfSe,0.05,TRUE,2,NA,diet,NA,unchanged,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:873/10/NA,Study 873,case-control,38381714,10.1371/journal.pone.0297858,https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0297858,"Humińska-Lisowska K, Zielińska K, Mieszkowski J, Michałowska-Sawczyn M, Cięszczyk P, Łabaj PP, Wasąg B, Frączek B, Grzywacz A, Kochanowicz A , Kosciolek T",Microbiome features associated with performance measures in athletic and non-athletic individuals: A case-control study,PloS one,2024,NA,Experiment 10,Poland,Homo sapiens,Feces,UBERON:0001988,Health study participation,EFO:0010130,Non-athletes,Endurance athletes,Athletes engaged in endurance athletics  at timepoint B2 (morning after the Bruce Treadmill Test on an empty stomach),19,13,Individuals who were on antibiotics six (6) months before the start of the study.,PCR,NA,Illumina,LEfSe,0.05,TRUE,2,NA,diet,NA,unchanged,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:874/1/NA,Study 874,case-control,25023578,https://doi.org/10.1097/MPG.0000000000000495,NA,"Walia R, Garg S, Song Y, Girotra M, Cuffari C, Fricke WF , Dutta SK",Efficacy of fecal microbiota transplantation in 2 children with recurrent Clostridium difficile infection and its impact on their growth and gut microbiome,Journal of pediatric gastroenterology and nutrition,2014,NA,Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Clostridium difficile infection,EFO:0009130,NA,Children with recurrent Clostridium difficile Infection,Efficacy of Fecal Microbiota Transplantation on Children with Recurrent Clostridium difficile Infection.,NA,2,NA,16S,NA,Illumina,NA,NA,NA,NA,NA,"age,antibiotic exposure,cesarean section,premature birth",NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:876/1/NA,Study 876,case-control,38366600,https://doi.org/10.1016/j.xcrm.2024.101426,https://pubmed.ncbi.nlm.nih.gov/38366600/,"Huang KD, Amend L, Gálvez EJC, Lesker TR, de Oliveira R, Bielecka A, Blanco-Míguez A, Valles-Colomer M, Ruf I, Pasolli E, Buer J, Segata N, Esser S, Strowig T , Kehrmann J",Establishment of a non-Westernized gut microbiota in men who have sex with men is associated with sexual practices,Cell reports. Medicine,2024,"MSM, Prevotella, RAI, Segatella, gut microbiome, non-Westernized microbiota, oral sex, sex partner, sexual orientation",Experiment 1,"Germany,China",Homo sapiens,Feces,UBERON:0001988,Male homosexuality,EFO:0008486,Men with 0-3 sexual partners,Men with >3 sexual partners,Men in the risk increasing category with more than 3 sexual partners (in the last 12 months).,38,29,6 months,WMS,NA,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:876/2/NA,Study 876,case-control,38366600,https://doi.org/10.1016/j.xcrm.2024.101426,https://pubmed.ncbi.nlm.nih.gov/38366600/,"Huang KD, Amend L, Gálvez EJC, Lesker TR, de Oliveira R, Bielecka A, Blanco-Míguez A, Valles-Colomer M, Ruf I, Pasolli E, Buer J, Segata N, Esser S, Strowig T , Kehrmann J",Establishment of a non-Westernized gut microbiota in men who have sex with men is associated with sexual practices,Cell reports. Medicine,2024,"MSM, Prevotella, RAI, Segatella, gut microbiome, non-Westernized microbiota, oral sex, sex partner, sexual orientation",Experiment 2,"Germany,China",Homo sapiens,Feces,UBERON:0001988,Male homosexuality,EFO:0008486,Condom use (Always during RAI),No Condom use (during RAI),Men in the risk increasing category who never use Condom during Receptive Anal intercourse.,12,37,6 Months,WMS,NA,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,increased,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:876/3/NA,Study 876,case-control,38366600,https://doi.org/10.1016/j.xcrm.2024.101426,https://pubmed.ncbi.nlm.nih.gov/38366600/,"Huang KD, Amend L, Gálvez EJC, Lesker TR, de Oliveira R, Bielecka A, Blanco-Míguez A, Valles-Colomer M, Ruf I, Pasolli E, Buer J, Segata N, Esser S, Strowig T , Kehrmann J",Establishment of a non-Westernized gut microbiota in men who have sex with men is associated with sexual practices,Cell reports. Medicine,2024,"MSM, Prevotella, RAI, Segatella, gut microbiome, non-Westernized microbiota, oral sex, sex partner, sexual orientation",Experiment 3,"Germany,China",Homo sapiens,Feces,UBERON:0001988,Male homosexuality,EFO:0008486,No Oral Sex,Yes Oral Sex,Men in the risk increasing category who practice Oral sex.,21,42,6 Months,WMS,NA,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:876/4/NA,Study 876,case-control,38366600,https://doi.org/10.1016/j.xcrm.2024.101426,https://pubmed.ncbi.nlm.nih.gov/38366600/,"Huang KD, Amend L, Gálvez EJC, Lesker TR, de Oliveira R, Bielecka A, Blanco-Míguez A, Valles-Colomer M, Ruf I, Pasolli E, Buer J, Segata N, Esser S, Strowig T , Kehrmann J",Establishment of a non-Westernized gut microbiota in men who have sex with men is associated with sexual practices,Cell reports. Medicine,2024,"MSM, Prevotella, RAI, Segatella, gut microbiome, non-Westernized microbiota, oral sex, sex partner, sexual orientation",Experiment 4,"Germany,China",Homo sapiens,Feces,UBERON:0001988,Male homosexuality,EFO:0008486,Condom use (Sometimes during RAI),No Condom use (during RAI),Men in the risk increasing category who never use Condom during Receptive Anal intercourse.,15,37,6 Months,WMS,NA,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,increased,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:876/5/NA,Study 876,case-control,38366600,https://doi.org/10.1016/j.xcrm.2024.101426,https://pubmed.ncbi.nlm.nih.gov/38366600/,"Huang KD, Amend L, Gálvez EJC, Lesker TR, de Oliveira R, Bielecka A, Blanco-Míguez A, Valles-Colomer M, Ruf I, Pasolli E, Buer J, Segata N, Esser S, Strowig T , Kehrmann J",Establishment of a non-Westernized gut microbiota in men who have sex with men is associated with sexual practices,Cell reports. Medicine,2024,"MSM, Prevotella, RAI, Segatella, gut microbiome, non-Westernized microbiota, oral sex, sex partner, sexual orientation",Experiment 5,"Germany,China",Homo sapiens,Feces,UBERON:0001988,Male homosexuality,EFO:0008486,Condom use (Always during RAI),Condom use (Sometimes during RAI),Men in the risk increasing category who sometimes use Condom during Receptive Anal intercourse.,12,15,6 Months,WMS,NA,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:876/6/NA,Study 876,case-control,38366600,https://doi.org/10.1016/j.xcrm.2024.101426,https://pubmed.ncbi.nlm.nih.gov/38366600/,"Huang KD, Amend L, Gálvez EJC, Lesker TR, de Oliveira R, Bielecka A, Blanco-Míguez A, Valles-Colomer M, Ruf I, Pasolli E, Buer J, Segata N, Esser S, Strowig T , Kehrmann J",Establishment of a non-Westernized gut microbiota in men who have sex with men is associated with sexual practices,Cell reports. Medicine,2024,"MSM, Prevotella, RAI, Segatella, gut microbiome, non-Westernized microbiota, oral sex, sex partner, sexual orientation",Experiment 6,"China,Germany",Homo sapiens,Feces,UBERON:0001988,Male homosexuality,EFO:0008486,STI Negative,STI Positive,Men in the risk increasing category who were positive to sexually transmitted infection.,44,23,6 Months,WMS,NA,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:876/7/NA,Study 876,case-control,38366600,https://doi.org/10.1016/j.xcrm.2024.101426,https://pubmed.ncbi.nlm.nih.gov/38366600/,"Huang KD, Amend L, Gálvez EJC, Lesker TR, de Oliveira R, Bielecka A, Blanco-Míguez A, Valles-Colomer M, Ruf I, Pasolli E, Buer J, Segata N, Esser S, Strowig T , Kehrmann J",Establishment of a non-Westernized gut microbiota in men who have sex with men is associated with sexual practices,Cell reports. Medicine,2024,"MSM, Prevotella, RAI, Segatella, gut microbiome, non-Westernized microbiota, oral sex, sex partner, sexual orientation",Experiment 7,"China,Germany",Homo sapiens,Feces,UBERON:0001988,Male homosexuality,EFO:0008486,No RAI,Yes RAI,Men in the risk increasing category who practice Receptive Anal intercourse.,21,46,6 Months,WMS,NA,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:876/8/NA,Study 876,case-control,38366600,https://doi.org/10.1016/j.xcrm.2024.101426,https://pubmed.ncbi.nlm.nih.gov/38366600/,"Huang KD, Amend L, Gálvez EJC, Lesker TR, de Oliveira R, Bielecka A, Blanco-Míguez A, Valles-Colomer M, Ruf I, Pasolli E, Buer J, Segata N, Esser S, Strowig T , Kehrmann J",Establishment of a non-Westernized gut microbiota in men who have sex with men is associated with sexual practices,Cell reports. Medicine,2024,"MSM, Prevotella, RAI, Segatella, gut microbiome, non-Westernized microbiota, oral sex, sex partner, sexual orientation",Experiment 8,"China,Germany",Homo sapiens,Feces,UBERON:0001988,Male homosexuality,EFO:0008486,MSM,Westernized,"Westernization describes a population with incremental urbanization, profound lifestyle changes, including but not limited to, transition from autarchic means of producing food to controlled food production chain, increased hygiene and accessibility to modern medicals, introduction of food sterilization, increased exposure to pollutants, and switch from high-fiber simple diets to high-fat high-protein processes that has been undergoing for centuries.",93,93,6 Months,WMS,NA,Illumina,Fisher's Exact Test,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:876/9/NA,Study 876,case-control,38366600,https://doi.org/10.1016/j.xcrm.2024.101426,https://pubmed.ncbi.nlm.nih.gov/38366600/,"Huang KD, Amend L, Gálvez EJC, Lesker TR, de Oliveira R, Bielecka A, Blanco-Míguez A, Valles-Colomer M, Ruf I, Pasolli E, Buer J, Segata N, Esser S, Strowig T , Kehrmann J",Establishment of a non-Westernized gut microbiota in men who have sex with men is associated with sexual practices,Cell reports. Medicine,2024,"MSM, Prevotella, RAI, Segatella, gut microbiome, non-Westernized microbiota, oral sex, sex partner, sexual orientation",Experiment 9,"China,Germany",Homo sapiens,Feces,UBERON:0001988,Male homosexuality,EFO:0008486,Non MSM,MSM,Men who have sex with Men (Prevotella Family comparison),24,84,6 Months,WMS,NA,Illumina,Fisher's Exact Test,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:876/10/NA,Study 876,case-control,38366600,https://doi.org/10.1016/j.xcrm.2024.101426,https://pubmed.ncbi.nlm.nih.gov/38366600/,"Huang KD, Amend L, Gálvez EJC, Lesker TR, de Oliveira R, Bielecka A, Blanco-Míguez A, Valles-Colomer M, Ruf I, Pasolli E, Buer J, Segata N, Esser S, Strowig T , Kehrmann J",Establishment of a non-Westernized gut microbiota in men who have sex with men is associated with sexual practices,Cell reports. Medicine,2024,"MSM, Prevotella, RAI, Segatella, gut microbiome, non-Westernized microbiota, oral sex, sex partner, sexual orientation",Experiment 10,"China,Germany",Homo sapiens,Feces,UBERON:0001988,Male homosexuality,EFO:0008486,Non MSM,MSM,Men who have sex with Men,31,93,6 Months,WMS,NA,Illumina,Fisher's Exact Test,0.05,TRUE,NA,NA,NA,NA,increased,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:876/11/NA,Study 876,case-control,38366600,https://doi.org/10.1016/j.xcrm.2024.101426,https://pubmed.ncbi.nlm.nih.gov/38366600/,"Huang KD, Amend L, Gálvez EJC, Lesker TR, de Oliveira R, Bielecka A, Blanco-Míguez A, Valles-Colomer M, Ruf I, Pasolli E, Buer J, Segata N, Esser S, Strowig T , Kehrmann J",Establishment of a non-Westernized gut microbiota in men who have sex with men is associated with sexual practices,Cell reports. Medicine,2024,"MSM, Prevotella, RAI, Segatella, gut microbiome, non-Westernized microbiota, oral sex, sex partner, sexual orientation",Experiment 11,"China,Germany",Homo sapiens,Feces,UBERON:0001988,Male homosexuality,EFO:0008486,MSM,Non Westernized,"Non-Westernized describes a population practicing a traditional lifestyle relating to factors such as diet, hygiene, and with limited access to modern medical healthcare and pharmaceuticals (e.g., antibiotics).",93,481,6 Months,WMS,NA,Illumina,Fisher's Exact Test,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:876/12/NA,Study 876,case-control,38366600,https://doi.org/10.1016/j.xcrm.2024.101426,https://pubmed.ncbi.nlm.nih.gov/38366600/,"Huang KD, Amend L, Gálvez EJC, Lesker TR, de Oliveira R, Bielecka A, Blanco-Míguez A, Valles-Colomer M, Ruf I, Pasolli E, Buer J, Segata N, Esser S, Strowig T , Kehrmann J",Establishment of a non-Westernized gut microbiota in men who have sex with men is associated with sexual practices,Cell reports. Medicine,2024,"MSM, Prevotella, RAI, Segatella, gut microbiome, non-Westernized microbiota, oral sex, sex partner, sexual orientation",Experiment 12,"China,Germany",Homo sapiens,Feces,UBERON:0001988,Male homosexuality,EFO:0008486,MSM,Westernized,"Westernization describes a population with incremental urbanization, profound lifestyle changes, including but not limited to, transition from autarchic means of producing food to controlled food production chain, increased hygiene and accessibility to modern medicals, introduction of food sterilization, increased exposure to pollutants, and switch from high-fiber simple diets to high-fat high-protein processes that has been undergoing for centuries.",93,481,6 Months,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:876/13/NA,Study 876,case-control,38366600,https://doi.org/10.1016/j.xcrm.2024.101426,https://pubmed.ncbi.nlm.nih.gov/38366600/,"Huang KD, Amend L, Gálvez EJC, Lesker TR, de Oliveira R, Bielecka A, Blanco-Míguez A, Valles-Colomer M, Ruf I, Pasolli E, Buer J, Segata N, Esser S, Strowig T , Kehrmann J",Establishment of a non-Westernized gut microbiota in men who have sex with men is associated with sexual practices,Cell reports. Medicine,2024,"MSM, Prevotella, RAI, Segatella, gut microbiome, non-Westernized microbiota, oral sex, sex partner, sexual orientation",Experiment 13,"China,Germany",Homo sapiens,Feces,UBERON:0001988,Male homosexuality,EFO:0008486,MSM,Non Westernized,"Non-Westernized describes a population practicing a traditional lifestyle relating to factors such as diet, hygiene, and with limited access to modern medical healthcare and pharmaceuticals (e.g., antibiotics).",93,389,6 Months,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:876/14/NA,Study 876,case-control,38366600,https://doi.org/10.1016/j.xcrm.2024.101426,https://pubmed.ncbi.nlm.nih.gov/38366600/,"Huang KD, Amend L, Gálvez EJC, Lesker TR, de Oliveira R, Bielecka A, Blanco-Míguez A, Valles-Colomer M, Ruf I, Pasolli E, Buer J, Segata N, Esser S, Strowig T , Kehrmann J",Establishment of a non-Westernized gut microbiota in men who have sex with men is associated with sexual practices,Cell reports. Medicine,2024,"MSM, Prevotella, RAI, Segatella, gut microbiome, non-Westernized microbiota, oral sex, sex partner, sexual orientation",Experiment 14,"China,Germany",Homo sapiens,Feces,UBERON:0001988,Male homosexuality,EFO:0008486,MSM,China (Urban),Two Chinese cities - GuangDong and TangShan - which are located in Southern China and have been experiencing rapid urbanization in the last decade. They were used to represent populations from non-Western but relatively urbanized communities.,93,66,6 Months,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:877/1/NA,Study 877,time series / longitudinal observational,38374114,https://doi.org/10.1038/s41522-024-00482-z,NA,"Bazzani D, Heidrich V, Manghi P, Blanco-Miguez A, Asnicar F, Armanini F, Cavaliere S, Bertelle A, Dell'Acqua F, Dellasega E, Waldner R, Vicentini D, Bolzan M, Tomasi C, Segata N, Pasolli E , Ghensi P",Favorable subgingival plaque microbiome shifts are associated with clinical treatment for peri-implant diseases,NPJ biofilms and microbiomes,2024,NA,Experiment 1,Italy,Homo sapiens,Subgingival dental plaque,UBERON:0016484,Peri-Implantitis,EFO:1001390,Healthy group (case samples),Mucositis group (case samples),Healthy species/ biomarkers enriched or significant in mucositis patients compared with healthy group patients who underwent surgical (n=9) or non-surgical treatment (n=22) as decided by clinical practitioners,32,28,intake of systemic antibiotics  within the past 6 months,WMS,NA,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:877/2/NA,Study 877,time series / longitudinal observational,38374114,https://doi.org/10.1038/s41522-024-00482-z,NA,"Bazzani D, Heidrich V, Manghi P, Blanco-Miguez A, Asnicar F, Armanini F, Cavaliere S, Bertelle A, Dell'Acqua F, Dellasega E, Waldner R, Vicentini D, Bolzan M, Tomasi C, Segata N, Pasolli E , Ghensi P",Favorable subgingival plaque microbiome shifts are associated with clinical treatment for peri-implant diseases,NPJ biofilms and microbiomes,2024,NA,Experiment 2,Italy,Homo sapiens,Subgingival dental plaque,UBERON:0016484,Peri-Implantitis,EFO:1001390,Healthy group (case samples),Peri-implantitis group (case samples),Healthy species/ biomarkers enriched or significant in peri-implantitis patients compared with healthy group patients who underwent surgical (n=9) or non-surgical treatment (n=22) as decided by clinical practitioners,32,31,intake of systemic antibiotics  within the past 6 months,WMS,NA,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:877/3/NA,Study 877,time series / longitudinal observational,38374114,https://doi.org/10.1038/s41522-024-00482-z,NA,"Bazzani D, Heidrich V, Manghi P, Blanco-Miguez A, Asnicar F, Armanini F, Cavaliere S, Bertelle A, Dell'Acqua F, Dellasega E, Waldner R, Vicentini D, Bolzan M, Tomasi C, Segata N, Pasolli E , Ghensi P",Favorable subgingival plaque microbiome shifts are associated with clinical treatment for peri-implant diseases,NPJ biofilms and microbiomes,2024,NA,Experiment 3,Italy,Homo sapiens,Subgingival dental plaque,UBERON:0016484,Peri-Implantitis,EFO:1001390,Healthy group (case samples),Peri-implantitis group (case samples),Peri-implantitis species/ biomarkers enriched or significant in peri-implantitis patients compared with healthy group patients who underwent surgical (n=9) or non-surgical treatment (n=22) as decided by clinical practitioners,32,31,intake of systemic antibiotics  within the past 6 months,WMS,NA,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:877/4/NA,Study 877,time series / longitudinal observational,38374114,https://doi.org/10.1038/s41522-024-00482-z,NA,"Bazzani D, Heidrich V, Manghi P, Blanco-Miguez A, Asnicar F, Armanini F, Cavaliere S, Bertelle A, Dell'Acqua F, Dellasega E, Waldner R, Vicentini D, Bolzan M, Tomasi C, Segata N, Pasolli E , Ghensi P",Favorable subgingival plaque microbiome shifts are associated with clinical treatment for peri-implant diseases,NPJ biofilms and microbiomes,2024,NA,Experiment 4,Italy,Homo sapiens,Subgingival dental plaque,UBERON:0016484,Peri-Implantitis,EFO:1001390,Healthy group (contralateral site samples),Mucositis group (contralateral site samples),Healthy species/ biomarkers enriched or significant in mucositis patients compared with healthy group patients who underwent surgical (n=9) or non-surgical treatment (n=22) as decided by clinical practitioners,32,28,intake of systemic antibiotics  within the past 6 months,WMS,NA,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:877/5/NA,Study 877,time series / longitudinal observational,38374114,https://doi.org/10.1038/s41522-024-00482-z,NA,"Bazzani D, Heidrich V, Manghi P, Blanco-Miguez A, Asnicar F, Armanini F, Cavaliere S, Bertelle A, Dell'Acqua F, Dellasega E, Waldner R, Vicentini D, Bolzan M, Tomasi C, Segata N, Pasolli E , Ghensi P",Favorable subgingival plaque microbiome shifts are associated with clinical treatment for peri-implant diseases,NPJ biofilms and microbiomes,2024,NA,Experiment 5,Italy,Homo sapiens,Subgingival dental plaque,UBERON:0016484,Peri-Implantitis,EFO:1001390,Healthy group (contralateral site samples),Peri-implantitis group (contralateral site samples),Healthy species/ biomarkers enriched or significant in Peri-implantitis patients compared with healthy group patients who underwent surgical (n=9) or non-surgical treatment (n=22) as decided by clinical practitioners,32,31,intake of systemic antibiotics  within the past 6 months,WMS,NA,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:877/6/NA,Study 877,time series / longitudinal observational,38374114,https://doi.org/10.1038/s41522-024-00482-z,NA,"Bazzani D, Heidrich V, Manghi P, Blanco-Miguez A, Asnicar F, Armanini F, Cavaliere S, Bertelle A, Dell'Acqua F, Dellasega E, Waldner R, Vicentini D, Bolzan M, Tomasi C, Segata N, Pasolli E , Ghensi P",Favorable subgingival plaque microbiome shifts are associated with clinical treatment for peri-implant diseases,NPJ biofilms and microbiomes,2024,NA,Experiment 6,Italy,Homo sapiens,Subgingival dental plaque,UBERON:0016484,Peri-Implantitis,EFO:1001390,Healthy group  (contralteral samples),Peri-implantitis and mucositis groups (contralteral samples),Peri-implantitis species/ biomarkers enriched or significant in peri-implantitis and mucositis patients compared with healthy group patients who underwent surgical (n=9) or non-surgical treatment (n=22) as decided by clinical practitioners,32,59,intake of systemic antibiotics  within the past 6 months,WMS,NA,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:878/1/NA,Study 878,"cross-sectional observational, not case-control",22009990,10.1101/gr.126573.111,NA,"Kostic AD, Gevers D, Pedamallu CS, Michaud M, Duke F, Earl AM, Ojesina AI, Jung J, Bass AJ, Tabernero J, Baselga J, Liu C, Shivdasani RA, Ogino S, Birren BW, Huttenhower C, Garrett WS , Meyerson M",Genomic analysis identifies association of Fusobacterium with colorectal carcinoma,Genome research,2012,NA,Experiment 1,Spain,Homo sapiens,Colon,UBERON:0001155,Colorectal carcinoma,EFO:1001951,Adjacent normal colonic tissue,Colon Tumor,Tumor tissues with colorectal carcinoma,9,9,N/A,WMS,NA,Illumina,LEfSe,0.05,FALSE,1.8,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:878/2/NA,Study 878,"cross-sectional observational, not case-control",22009990,10.1101/gr.126573.111,NA,"Kostic AD, Gevers D, Pedamallu CS, Michaud M, Duke F, Earl AM, Ojesina AI, Jung J, Bass AJ, Tabernero J, Baselga J, Liu C, Shivdasani RA, Ogino S, Birren BW, Huttenhower C, Garrett WS , Meyerson M",Genomic analysis identifies association of Fusobacterium with colorectal carcinoma,Genome research,2012,NA,Experiment 2,Spain,Homo sapiens,Colon,UBERON:0001155,Colorectal carcinoma,EFO:1001951,Adjacent normal colonic tissue,Colon Tumor,Tumor tissues with colorectal carcinoma,95,95,N/A,16S,345,Roche454,LEfSe,0.05,FALSE,4.2,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:879/1/NA,Study 879,prospective cohort,NA,10.22541/au.169511765.50376146/v1,https://www.authorea.com/users/666162/articles/667143-oral-lesion-and-microbiome-diversity-in-covid-19-hospitalized-patients,"Alessandra Lunis, Bernal Stewart, Cesar Augusto Migliorati, Ester Cerdeira Sabino, Joyce Vanessa Da Silva Fonseca, Nazareno Scaccia, Pablo Andres Munoz Torres, Paulo Henrique Braz Da Silva, Roberta Pilleggii, Rodrigo Melim Zerbinati, Silvia Figueiredo Costa, Sumatra Melo Da Costa Pereira Jales",Oral lesion and microbiome diversity in COVID-19 hospitalized patients,Authorea Inc.,2023,"Brazil, Oral lesion, covid-19, hospitalized patients, sars coronavirus",Experiment 1,Brazil,Homo sapiens,Oral cavity,UBERON:0000167,Oral ulcer,HP:0000155,Covid-19 patients without oral lesions,Covid-19 with oral lesions,COVID-19 patients with the presence of oral lesions,101,14,NA,16S,4,Ion Torrent,DESeq2,0.05,TRUE,NA,NA,"age,sex",NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:879/2/NA,Study 879,prospective cohort,NA,10.22541/au.169511765.50376146/v1,https://www.authorea.com/users/666162/articles/667143-oral-lesion-and-microbiome-diversity-in-covid-19-hospitalized-patients,"Alessandra Lunis, Bernal Stewart, Cesar Augusto Migliorati, Ester Cerdeira Sabino, Joyce Vanessa Da Silva Fonseca, Nazareno Scaccia, Pablo Andres Munoz Torres, Paulo Henrique Braz Da Silva, Roberta Pilleggii, Rodrigo Melim Zerbinati, Silvia Figueiredo Costa, Sumatra Melo Da Costa Pereira Jales",Oral lesion and microbiome diversity in COVID-19 hospitalized patients,Authorea Inc.,2023,"Brazil, Oral lesion, covid-19, hospitalized patients, sars coronavirus",Experiment 2,Brazil,Homo sapiens,Oral cavity,UBERON:0000167,Illness severity status,EFO:0007863,Non severe COVID patients,Severe COVID patients,COVID-19 patients with severe symptoms,NA,NA,NA,16S,4,Ion Torrent,DESeq2,0.05,TRUE,NA,NA,"age,sex",NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:879/3/NA,Study 879,prospective cohort,NA,10.22541/au.169511765.50376146/v1,https://www.authorea.com/users/666162/articles/667143-oral-lesion-and-microbiome-diversity-in-covid-19-hospitalized-patients,"Alessandra Lunis, Bernal Stewart, Cesar Augusto Migliorati, Ester Cerdeira Sabino, Joyce Vanessa Da Silva Fonseca, Nazareno Scaccia, Pablo Andres Munoz Torres, Paulo Henrique Braz Da Silva, Roberta Pilleggii, Rodrigo Melim Zerbinati, Silvia Figueiredo Costa, Sumatra Melo Da Costa Pereira Jales",Oral lesion and microbiome diversity in COVID-19 hospitalized patients,Authorea Inc.,2023,"Brazil, Oral lesion, covid-19, hospitalized patients, sars coronavirus",Experiment 3,Brazil,Homo sapiens,Oral cavity,UBERON:0000167,Antimicrobial agent,CHEBI:33281,No antibiotics use,Antibiotics use,COVID-19 patients who had antibiotic therapy in the previous 3 months.,NA,NA,NA,16S,4,Ion Torrent,DESeq2,0.05,TRUE,NA,NA,"age,sex",NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:879/4/NA,Study 879,prospective cohort,NA,10.22541/au.169511765.50376146/v1,https://www.authorea.com/users/666162/articles/667143-oral-lesion-and-microbiome-diversity-in-covid-19-hospitalized-patients,"Alessandra Lunis, Bernal Stewart, Cesar Augusto Migliorati, Ester Cerdeira Sabino, Joyce Vanessa Da Silva Fonseca, Nazareno Scaccia, Pablo Andres Munoz Torres, Paulo Henrique Braz Da Silva, Roberta Pilleggii, Rodrigo Melim Zerbinati, Silvia Figueiredo Costa, Sumatra Melo Da Costa Pereira Jales",Oral lesion and microbiome diversity in COVID-19 hospitalized patients,Authorea Inc.,2023,"Brazil, Oral lesion, covid-19, hospitalized patients, sars coronavirus",Experiment 4,Brazil,Homo sapiens,Oral cavity,UBERON:0000167,Oxygen,CHEBI:15379,No oxygen therapy,Oxygen therapy,COVID-19 patients who had oxygen therapy.,NA,NA,NA,16S,4,Ion Torrent,DESeq2,0.05,TRUE,NA,NA,"age,sex",NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:879/5/NA,Study 879,prospective cohort,NA,10.22541/au.169511765.50376146/v1,https://www.authorea.com/users/666162/articles/667143-oral-lesion-and-microbiome-diversity-in-covid-19-hospitalized-patients,"Alessandra Lunis, Bernal Stewart, Cesar Augusto Migliorati, Ester Cerdeira Sabino, Joyce Vanessa Da Silva Fonseca, Nazareno Scaccia, Pablo Andres Munoz Torres, Paulo Henrique Braz Da Silva, Roberta Pilleggii, Rodrigo Melim Zerbinati, Silvia Figueiredo Costa, Sumatra Melo Da Costa Pereira Jales",Oral lesion and microbiome diversity in COVID-19 hospitalized patients,Authorea Inc.,2023,"Brazil, Oral lesion, covid-19, hospitalized patients, sars coronavirus",Experiment 5,Brazil,Homo sapiens,Oral cavity,UBERON:0000167,Illness severity status,EFO:0007863,Non ICU patients,ICU patients,COVID-19 patients who were in intensive care units.,NA,NA,NA,16S,4,Ion Torrent,DESeq2,0.05,TRUE,NA,NA,"age,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:879/6/NA,Study 879,prospective cohort,NA,10.22541/au.169511765.50376146/v1,https://www.authorea.com/users/666162/articles/667143-oral-lesion-and-microbiome-diversity-in-covid-19-hospitalized-patients,"Alessandra Lunis, Bernal Stewart, Cesar Augusto Migliorati, Ester Cerdeira Sabino, Joyce Vanessa Da Silva Fonseca, Nazareno Scaccia, Pablo Andres Munoz Torres, Paulo Henrique Braz Da Silva, Roberta Pilleggii, Rodrigo Melim Zerbinati, Silvia Figueiredo Costa, Sumatra Melo Da Costa Pereira Jales",Oral lesion and microbiome diversity in COVID-19 hospitalized patients,Authorea Inc.,2023,"Brazil, Oral lesion, covid-19, hospitalized patients, sars coronavirus",Experiment 6,Brazil,Homo sapiens,Oral cavity,UBERON:0000167,Diet,EFO:0002755,Non enteral diet,Covid-19 patients on enteral diet,COVID-19 patients who were on the enteral diet.,NA,NA,NA,16S,4,Ion Torrent,DESeq2,0.05,TRUE,NA,NA,"age,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:880/1/NA,Study 880,"cross-sectional observational, not case-control",35039079,10.1186/s40168-021-01204-9,NA,"Adu-Oppong B, Thänert R, Wallace MA, Burnham CD , Dantas G",Substantial overlap between symptomatic and asymptomatic genitourinary microbiota states,Microbiome,2022,"Clinical diagnostics, Dysbiosis, Genitourinary microbiome, Urinary tract infections",Experiment 1,United States of America,Homo sapiens,Urine,UBERON:0001088,Urinary tract infection,EFO:0003103,No Growth,Culture Positive,Patients with urine specimen with significant growth of 1–2 uropathogenic species at ≥10^5 colony forming units (CFU)/mL,51,48,2 Weeks,WMS,NA,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:880/2/NA,Study 880,"cross-sectional observational, not case-control",35039079,10.1186/s40168-021-01204-9,NA,"Adu-Oppong B, Thänert R, Wallace MA, Burnham CD , Dantas G",Substantial overlap between symptomatic and asymptomatic genitourinary microbiota states,Microbiome,2022,"Clinical diagnostics, Dysbiosis, Genitourinary microbiome, Urinary tract infections",Experiment 2,United States of America,Homo sapiens,Urine,UBERON:0001088,Urinary tract infection,EFO:0003103,Insignificant Samples,Culture Positive Samples,Patients with urine specimen with significant growth of 1–2 uropathogenic species at ≥10^5 colony forming units (CFU)/mL,17,48,2 Weeks,WMS,NA,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:880/3/NA,Study 880,"cross-sectional observational, not case-control",35039079,10.1186/s40168-021-01204-9,NA,"Adu-Oppong B, Thänert R, Wallace MA, Burnham CD , Dantas G",Substantial overlap between symptomatic and asymptomatic genitourinary microbiota states,Microbiome,2022,"Clinical diagnostics, Dysbiosis, Genitourinary microbiome, Urinary tract infections",Experiment 3,United States of America,Homo sapiens,Urine,UBERON:0001088,Urinary tract infection,EFO:0003103,Asymptomatic,Insignificant Samples,Patients with specimen with bacterial growth <10^5 CFU/mL present during culturing but below the threshold for significance,10,17,2 Weeks,WMS,NA,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:880/4/NA,Study 880,"cross-sectional observational, not case-control",35039079,10.1186/s40168-021-01204-9,NA,"Adu-Oppong B, Thänert R, Wallace MA, Burnham CD , Dantas G",Substantial overlap between symptomatic and asymptomatic genitourinary microbiota states,Microbiome,2022,"Clinical diagnostics, Dysbiosis, Genitourinary microbiome, Urinary tract infections",Experiment 4,United States of America,Homo sapiens,Urine,UBERON:0001088,Urinary tract infection,EFO:0003103,Asymptomatic,No Growth,Patients with urine samples with no visible Microorganism growth (Bacterial/Fungal),10,51,2 Weeks,WMS,NA,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:881/1/NA,Study 881,case-control,34923209,10.1016/j.euroneuro.2021.11.009,NA,"Malan-Muller S, Valles-Colomer M, Foxx CL, Vieira-Silva S, van den Heuvel LL, Raes J, Seedat S, Lowry CA , Hemmings SMJ",Exploring the relationship between the gut microbiome and mental health outcomes in a posttraumatic stress disorder cohort relative to trauma-exposed controls,European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology,2022,"Depression, Gut microbiome, Microbiome-gut-brain axis, Oral microbiome, Posttraumatic stress disorder, Psychotropics",Experiment 1,South Africa,Homo sapiens,Feces,UBERON:0001988,Post-traumatic stress disorder,EFO:0001358,Trauma exposed controls (TECs),Post Traumatic Stress Disorder (PTSD),"Individuals with Post Traumatic Stress Disorder (PTSD). 
Post traumatic stress disorder (PTSD) cases met the DSM-5 criteria of PTSD, in accordance with diagnostic evaluation using the Clinician Administered Post Traumatic Stress Disorder Scale for DSM–5 (CAPS-5) and had a CAPS 5 severity score greater than 23.",58,79,Antibiotic use within 4 weeks before stool sampling.,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.1,TRUE,NA,NA,"age,body mass index,sex",NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:881/2/NA,Study 881,case-control,34923209,10.1016/j.euroneuro.2021.11.009,NA,"Malan-Muller S, Valles-Colomer M, Foxx CL, Vieira-Silva S, van den Heuvel LL, Raes J, Seedat S, Lowry CA , Hemmings SMJ",Exploring the relationship between the gut microbiome and mental health outcomes in a posttraumatic stress disorder cohort relative to trauma-exposed controls,European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology,2022,"Depression, Gut microbiome, Microbiome-gut-brain axis, Oral microbiome, Posttraumatic stress disorder, Psychotropics",Experiment 2,South Africa,Homo sapiens,Feces,UBERON:0001988,Clinical treatment,EFO:0007056,Individuals not using psychotropic medication,Individuals using psychotropic medication,Individuals using psychotropic medication that may associate with the gut microbiome of the sample.,6,21,Antibiotic use within 4 weeks before stool sampling.,16S,4,Illumina,Linear Regression,0.1,TRUE,NA,NA,"age,body mass index,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:881/3/NA,Study 881,case-control,34923209,10.1016/j.euroneuro.2021.11.009,NA,"Malan-Muller S, Valles-Colomer M, Foxx CL, Vieira-Silva S, van den Heuvel LL, Raes J, Seedat S, Lowry CA , Hemmings SMJ",Exploring the relationship between the gut microbiome and mental health outcomes in a posttraumatic stress disorder cohort relative to trauma-exposed controls,European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology,2022,"Depression, Gut microbiome, Microbiome-gut-brain axis, Oral microbiome, Posttraumatic stress disorder, Psychotropics",Experiment 3,South Africa,Homo sapiens,Feces,UBERON:0001988,Major depressive disorder,MONDO:0002009,Individuals without MDD diagnoses,Individuals with MDD diagnoses,Individuals diagnosed with Major Depressive Disorder (MDD). The MINI was used to diagnose MDD.,2,20,Antibiotic use within 4 weeks before stool sampling.,16S,4,Illumina,Linear Regression,0.1,TRUE,NA,NA,"age,body mass index,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:882/1/NA,Study 882,"cross-sectional observational, not case-control,laboratory experiment",36627678,10.1186/s13578-023-00956-1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9832664,"Fu J, Shan J, Cui Y, Yan C, Wang Q, Han J , Cao G",Metabolic disorder and intestinal microflora dysbiosis in chronic inflammatory demyelinating polyradiculoneuropathy,Cell & bioscience,2023,"Arachidonic acid, Bile acids, Chronic inflammatory demyelinating polyradiculoneuropathy, Gut microbial dysbiosis, Metabolic disorder",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Chronic inflammatory demyelinating polyradiculoneuropathy,EFO:1000868,Healthy controls (non-CIDP),Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP),"Patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), a rare acquired immune-mediated neuropathy",33,31,None,WMS,NA,DNBSEQ-T7,T-Test,0.05,FALSE,NA,"age,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:883/1/NA,Study 883,case-control,37905804,10.1128/spectrum.02368-23,NA,"Nath S, Sarkar M, Maddheshiya A, De D, Paul S, Dey S, Pal K, Roy SK, Ghosh A, Sengupta S, Paine SK, Biswas NK, Basu A , Mukherjee S",Upper respiratory tract microbiome profiles in SARS-CoV-2 Delta and Omicron infected patients exhibit variant specific patterns and robust prediction of disease groups,Microbiology spectrum,2023,"COVID-19, Delta, Omicron, URT, microbiome, next generation sequencing",Experiment 1,India,Homo sapiens,Upper respiratory tract,UBERON:0001557,SARS-CoV-2-related disease,MONDO:0100318,Healthy Controls,COVID-19 patients,Patients infected with COVID-19 virus (Delta and Omicron),19,43,1 month,16S,34,Illumina,LEfSe,0.05,TRUE,3,NA,NA,NA,decreased,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:883/2/NA,Study 883,case-control,37905804,10.1128/spectrum.02368-23,NA,"Nath S, Sarkar M, Maddheshiya A, De D, Paul S, Dey S, Pal K, Roy SK, Ghosh A, Sengupta S, Paine SK, Biswas NK, Basu A , Mukherjee S",Upper respiratory tract microbiome profiles in SARS-CoV-2 Delta and Omicron infected patients exhibit variant specific patterns and robust prediction of disease groups,Microbiology spectrum,2023,"COVID-19, Delta, Omicron, URT, microbiome, next generation sequencing",Experiment 2,India,Homo sapiens,Upper respiratory tract,UBERON:0001557,SARS-CoV-2-related disease,MONDO:0100318,Healthy Controls,Delta and Omicron-infected patients,Patients infected with the Delta and Omicron variants of  SARS-CoV-2,19,43,1 month,16S,34,Illumina,ANOVA,0.05,TRUE,NA,NA,NA,NA,decreased,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:883/3/NA,Study 883,case-control,37905804,10.1128/spectrum.02368-23,NA,"Nath S, Sarkar M, Maddheshiya A, De D, Paul S, Dey S, Pal K, Roy SK, Ghosh A, Sengupta S, Paine SK, Biswas NK, Basu A , Mukherjee S",Upper respiratory tract microbiome profiles in SARS-CoV-2 Delta and Omicron infected patients exhibit variant specific patterns and robust prediction of disease groups,Microbiology spectrum,2023,"COVID-19, Delta, Omicron, URT, microbiome, next generation sequencing",Experiment 3,India,Homo sapiens,Upper respiratory tract,UBERON:0001557,SARS-CoV-2-related disease,MONDO:0100318,Omicron-infected patients,Delta-infected patients,Patients infected with Delta virus,19,24,1 month,16S,34,Illumina,LEfSe,0.05,FALSE,3,NA,NA,NA,decreased,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:884/1/NA,Study 884,case-control,35863004,10.1128/spectrum.00324-22,NA,"Zhang L, Wang Z, Zhang X, Zhao L, Chu J, Li H, Sun W, Yang C, Wang H, Dai W, Yan S, Chen X , Xu D",Alterations of the Gut Microbiota in Patients with Diabetic Nephropathy,Microbiology spectrum,2022,"composition, diabetic nephropathy, function, gut microbiota, metagenomics",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Diabetic nephropathy,EFO:0000401,healthy controls (CON),Diabetic nephropathy (DN),"Patients with diabetic nephropathy (DN). DN is a chronic kidney disease (CKD), which is one of the most common complications of diabetic microangiopathy and the primary cause of end-stage renal disease (ESRD).",14,12,Past 1 month,WMS,NA,Illumina,LEfSe,0.05,NA,2,"age,body mass index,sex",NA,NA,unchanged,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:884/2/NA,Study 884,case-control,35863004,10.1128/spectrum.00324-22,NA,"Zhang L, Wang Z, Zhang X, Zhao L, Chu J, Li H, Sun W, Yang C, Wang H, Dai W, Yan S, Chen X , Xu D",Alterations of the Gut Microbiota in Patients with Diabetic Nephropathy,Microbiology spectrum,2022,"composition, diabetic nephropathy, function, gut microbiota, metagenomics",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Diabetes mellitus,EFO:0000400,healthy controls (CON),type 2 diabetes mellitus (T2DM),Patients with type 2 diabetes mellitus (T2DM) without DN,14,12,Past 1 month,WMS,NA,Illumina,LEfSe,0.05,NA,2,"age,body mass index,sex",NA,NA,unchanged,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:884/3/NA,Study 884,case-control,35863004,10.1128/spectrum.00324-22,NA,"Zhang L, Wang Z, Zhang X, Zhao L, Chu J, Li H, Sun W, Yang C, Wang H, Dai W, Yan S, Chen X , Xu D",Alterations of the Gut Microbiota in Patients with Diabetic Nephropathy,Microbiology spectrum,2022,"composition, diabetic nephropathy, function, gut microbiota, metagenomics",Experiment 3,China,Homo sapiens,Feces,UBERON:0001988,Gut microbiome measurement,EFO:0007874,type 2 diabetes mellitus (T2DM),Diabetic nephropathy (DN),Patients with diabetic nephropathy (DN).,12,12,Past 1 month,WMS,NA,Illumina,LEfSe,0.05,NA,2,"age,body mass index,sex",NA,NA,unchanged,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:885/1/NA,Study 885,"cross-sectional observational, not case-control",36744910,https://doi.org/10.1128/mbio.03519-22,https://journals.asm.org/doi/10.1128/mbio.03519-22,"Guo M, Wu G, Tan Y, Li Y, Jin X, Qi W, Guo X, Zhang C, Zhu Z , Zhao L",Guild-Level Microbiome Signature Associated with COVID-19 Severity and Prognosis,mBio,2023,"COVID-19, guild, gut microbiome",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,COVID-19,MONDO:0100096,Mild severity,Moderate severity,COVID-19 Patients with moderate severity symptoms.,88,196,NA,WMS,NA,Illumina,"Dunn's test,Kruskall-Wallis",0.05,TRUE,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:885/2/NA,Study 885,"cross-sectional observational, not case-control",36744910,https://doi.org/10.1128/mbio.03519-22,https://journals.asm.org/doi/10.1128/mbio.03519-22,"Guo M, Wu G, Tan Y, Li Y, Jin X, Qi W, Guo X, Zhang C, Zhu Z , Zhao L",Guild-Level Microbiome Signature Associated with COVID-19 Severity and Prognosis,mBio,2023,"COVID-19, guild, gut microbiome",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,COVID-19,MONDO:0100096,Mild severity,Severe/Critical severity,COVID-19 Patients with severe/critical severity symptoms.,88,12,NA,WMS,NA,Illumina,"Dunn's test,Kruskall-Wallis",0.05,TRUE,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:885/3/NA,Study 885,"cross-sectional observational, not case-control",36744910,https://doi.org/10.1128/mbio.03519-22,https://journals.asm.org/doi/10.1128/mbio.03519-22,"Guo M, Wu G, Tan Y, Li Y, Jin X, Qi W, Guo X, Zhang C, Zhu Z , Zhao L",Guild-Level Microbiome Signature Associated with COVID-19 Severity and Prognosis,mBio,2023,"COVID-19, guild, gut microbiome",Experiment 3,China,Homo sapiens,Feces,UBERON:0001988,COVID-19,MONDO:0100096,Moderate severity,Severe/Critical severity,COVID-19 Patients with severe/critical severity symptoms.,196,12,NA,WMS,NA,Illumina,"Dunn's test,Kruskall-Wallis",0.05,TRUE,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:886/1/NA,Study 886,laboratory experiment,30738924,https://doi.org/10.1016/j.ijpara.2018.10.007,NA,"Wang Y, Liu F, Urban JF, Paerewijck O, Geldhof P , Li RW",Ascaris suum infection was associated with a worm-independent reduction in microbial diversity and altered metabolic potential in the porcine gut microbiome,International journal for parasitology,2019,"16S rRNA gene, Ascaris suum, Infection, Microbiome, Network, Swine",Experiment 1,Belgium,Sus scrofa domesticus,Colon,UBERON:0001155,Ascariasis,EFO:0007154,Uninfected piglets,Ascaris suum infected piglets,Colon samples from ascariasis infected piglets,4,10,None,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,decreased,decreased,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:886/2/NA,Study 886,laboratory experiment,30738924,https://doi.org/10.1016/j.ijpara.2018.10.007,NA,"Wang Y, Liu F, Urban JF, Paerewijck O, Geldhof P , Li RW",Ascaris suum infection was associated with a worm-independent reduction in microbial diversity and altered metabolic potential in the porcine gut microbiome,International journal for parasitology,2019,"16S rRNA gene, Ascaris suum, Infection, Microbiome, Network, Swine",Experiment 2,Belgium,Sus scrofa domesticus,Feces,UBERON:0001988,Ascariasis,EFO:0007154,Uninfected piglets,Ascaris suum infected piglets,Feces samples from ascariasis infected piglets,4,10,None,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,decreased,decreased,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:886/3/NA,Study 886,laboratory experiment,30738924,https://doi.org/10.1016/j.ijpara.2018.10.007,NA,"Wang Y, Liu F, Urban JF, Paerewijck O, Geldhof P , Li RW",Ascaris suum infection was associated with a worm-independent reduction in microbial diversity and altered metabolic potential in the porcine gut microbiome,International journal for parasitology,2019,"16S rRNA gene, Ascaris suum, Infection, Microbiome, Network, Swine",Experiment 3,Belgium,Sus scrofa domesticus,Colon,UBERON:0001155,Ascariasis,EFO:0007154,Uninfected piglets,Low worm burden ascaris suum infected piglets,Colon samples from low worm burden ascariasis infected piglets,4,5,None,16S,34,Illumina,"LEfSe,Kruskall-Wallis",0.05,FALSE,2,NA,NA,decreased,decreased,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:886/4/NA,Study 886,laboratory experiment,30738924,https://doi.org/10.1016/j.ijpara.2018.10.007,NA,"Wang Y, Liu F, Urban JF, Paerewijck O, Geldhof P , Li RW",Ascaris suum infection was associated with a worm-independent reduction in microbial diversity and altered metabolic potential in the porcine gut microbiome,International journal for parasitology,2019,"16S rRNA gene, Ascaris suum, Infection, Microbiome, Network, Swine",Experiment 4,Belgium,Sus scrofa domesticus,Colon,UBERON:0001155,Ascariasis,EFO:0007154,Uninfected piglets,High worm burden ascaris suum infected piglets,Colon samples from high worm burden ascariasis infected piglets,4,5,None,16S,34,Illumina,"Kruskall-Wallis,LEfSe",0.05,FALSE,2,NA,NA,decreased,decreased,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/1/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 1,Denmark,Homo sapiens,Feces,UBERON:0001988,Microbiome measurement,EFO:0007882,InnuPURE,MagNAPure,"DNA isolation from human fecal samples using MagNA Pure LC DNA isolation Kit III, Roche (MagNAPure).",3,3,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/2/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 2,Denmark,Homo sapiens,Feces,UBERON:0001988,Microbiome measurement,EFO:0007882,InnuPURE,Easy-DNA,"DNA isolation from human fecal samples using Easy-DNATM gDNA Purification Kit, Invitrogen (Easy-DNA).",3,3,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/3/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 3,Denmark,Homo sapiens,Feces,UBERON:0001988,Microbiome measurement,EFO:0007882,InnuPURE,FastDNA,"DNA isolation from human fecal samples using MP FastDNATM Spin Kit, MP Biomedicals (FastDNA).",3,3,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/4/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 4,Denmark,Homo sapiens,Feces,UBERON:0001988,Microbiome measurement,EFO:0007882,InnuPURE,PowerSoil.HMP,"DNA isolation from human fecal samples using PowerSoil® DNA Isolation kit, MoBio Laboratories Inc. (PowerSoil.HMP).",3,3,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,unchanged,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/5/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 5,Denmark,Homo sapiens,Feces,UBERON:0001988,Microbiome measurement,EFO:0007882,InnuPURE,QIAStool,"DNA isolation from human fecal samples using QIAamp® DNA Stool Mini Kit, Qiagen (QIAStool).",3,3,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/6/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 6,Denmark,Homo sapiens,Feces,UBERON:0001988,Microbiome measurement,EFO:0007882,InnuPURE,QIAStool+BB,"DNA isolation from human fecal samples using QIAamp® DNA Stool Mini Kit, Qiagen +Bead Beating (QIAStool+BB).",3,3,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,unchanged,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/7/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 7,Denmark,Homo sapiens,Feces,UBERON:0001988,Microbiome measurement,EFO:0007882,MagNAPure,Easy-DNA,"DNA isolation from human fecal samples using Easy-DNATM gDNA Purification Kit, Invitrogen (Easy-DNA).",3,3,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,unchanged,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/8/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 8,Denmark,Homo sapiens,Feces,UBERON:0001988,Microbiome measurement,EFO:0007882,MagNAPure,FastDNA,"DNA isolation from human fecal samples using MP FastDNATM Spin Kit, MP Biomedicals (FastDNA).",3,3,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/9/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 9,Denmark,Homo sapiens,Feces,UBERON:0001988,Microbiome measurement,EFO:0007882,MagNAPure,PowerSoil.HMP,"DNA isolation from human fecal samples using PowerSoil® DNA Isolation kit, MoBio Laboratories Inc. (PowerSoil.HMP).",3,3,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/10/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 10,Denmark,Homo sapiens,Feces,UBERON:0001988,Microbiome measurement,EFO:0007882,MagNAPure,QIAStool,"DNA isolation from human fecal samples using QIAamp® DNA Stool Mini Kit, Qiagen (QIAStool).",3,3,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/11/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 11,Denmark,Homo sapiens,Feces,UBERON:0001988,Microbiome measurement,EFO:0007882,MagNAPure,QIAStool+BB,"DNA isolation from human fecal samples using QIAamp® DNA Stool Mini Kit, Qiagen +Bead Beating (QIAStool+BB).",3,3,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/12/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 12,Denmark,Homo sapiens,Feces,UBERON:0001988,Microbiome measurement,EFO:0007882,Easy-DNA,FastDNA,"DNA isolation from human fecal samples using MP FastDNATM Spin Kit, MP Biomedicals (FastDNA).",3,3,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/13/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 13,Denmark,Homo sapiens,Feces,UBERON:0001988,Microbiome measurement,EFO:0007882,Easy-DNA,PowerSoil.HMP,"DNA isolation from human fecal samples using PowerSoil® DNA Isolation kit, MoBio Laboratories Inc. (PowerSoil.HMP).",3,3,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/14/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 14,Denmark,Homo sapiens,Feces,UBERON:0001988,Microbiome measurement,EFO:0007882,Easy-DNA,QIAStool,"DNA isolation from human fecal samples using QIAamp® DNA Stool Mini Kit, Qiagen (QIAStool).",3,3,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,decreased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/15/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 15,Denmark,Homo sapiens,Feces,UBERON:0001988,Microbiome measurement,EFO:0007882,Easy-DNA,QIAStool+BB,"DNA isolation from human fecal samples using QIAamp® DNA Stool Mini Kit, Qiagen +Bead Beating (QIAStool+BB).",3,3,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/16/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 16,Denmark,Homo sapiens,Feces,UBERON:0001988,Microbiome measurement,EFO:0007882,FastDNA,PowerSoil.HMP,"DNA isolation from human fecal samples using PowerSoil® DNA Isolation kit, MoBio Laboratories Inc. (PowerSoil.HMP).",3,3,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,decreased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/17/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 17,Denmark,Homo sapiens,Feces,UBERON:0001988,Microbiome measurement,EFO:0007882,FastDNA,QIAStool,"DNA isolation from human fecal samples using QIAamp® DNA Stool Mini Kit, Qiagen (QIAStool).",3,3,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/18/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 18,Denmark,Homo sapiens,Feces,UBERON:0001988,Microbiome measurement,EFO:0007882,FastDNA,QIAStool+BB,"DNA isolation from human fecal samples using QIAamp® DNA Stool Mini Kit, Qiagen +Bead Beating (QIAStool+BB).",3,3,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,decreased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/19/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 19,Denmark,Homo sapiens,Feces,UBERON:0001988,Microbiome measurement,EFO:0007882,PowerSoil.HMP,QIAStool,"DNA isolation from human fecal samples using QIAamp® DNA Stool Mini Kit, Qiagen (QIAStool).",3,3,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/20/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 20,Denmark,Homo sapiens,Feces,UBERON:0001988,Microbiome measurement,EFO:0007882,PowerSoil.HMP,QIAStool+BB,"DNA isolation from human fecal samples using QIAamp® DNA Stool Mini Kit, Qiagen +Bead Beating (QIAStool+BB).",3,3,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/21/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 21,Denmark,Homo sapiens,Feces,UBERON:0001988,Microbiome measurement,EFO:0007882,QIAStool,QIAStool+BB,"DNA isolation from human fecal samples using QIAamp® DNA Stool Mini Kit, Qiagen +Bead Beating (QIAStool+BB).",3,3,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/22/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 22,Denmark,Homo sapiens,Feces,UBERON:0001988,Microbiome measurement,EFO:0007882,MagNAPure,Easy-DNA,"DNA isolation from human fecal samples using Easy-DNATM gDNA Purification Kit, Invitrogen (Easy-DNA).",3,3,NA,WMS,NA,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/23/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 23,Denmark,Homo sapiens,Feces,UBERON:0001988,Microbiome measurement,EFO:0007882,MagNAPure,QIAStool,"DNA isolation from human fecal samples using QIAamp® DNA Stool Mini Kit, Qiagen (QIAStool).",3,3,NA,WMS,NA,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,decreased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/24/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 24,Denmark,Homo sapiens,Feces,UBERON:0001988,Microbiome measurement,EFO:0007882,Easy-DNA,QIAStool,"DNA isolation from human fecal samples using QIAamp® DNA Stool Mini Kit, Qiagen (QIAStool).",3,3,NA,WMS,NA,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/25/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 25,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome measurement,EFO:0007882,InnuPURE,MagNAPure,"DNA isolation from pig fecal samples using MagNA Pure LC DNA isolation Kit III, Roche (MagNAPure).",3,3,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/26/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 26,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome measurement,EFO:0007882,InnuPURE,Easy-DNA,"DNA isolation from pig fecal samples using Easy-DNATM gDNA Purification Kit, Invitrogen (Easy-DNA).",3,3,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,unchanged,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/27/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 27,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome measurement,EFO:0007882,InnuPURE,FastDNA,"DNA isolation from pig fecal samples using MP FastDNATM Spin Kit, MP Biomedicals (FastDNA).",3,3,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/28/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 28,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome measurement,EFO:0007882,InnuPURE,PowerSoil.HMP,"DNA isolation from pig fecal samples using PowerSoil® DNA Isolation kit, MoBio Laboratories Inc. (PowerSoil.HMP).",3,3,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/29/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 29,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome measurement,EFO:0007882,InnuPURE,QIAStool,"DNA isolation from pig fecal samples using QIAamp® DNA Stool Mini Kit, Qiagen (QIAStool).",3,3,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/30/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 30,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome measurement,EFO:0007882,InnuPURE,QIAStool+BB,"DNA isolation from pig fecal samples using QIAamp® DNA Stool Mini Kit, Qiagen +Bead Beating (QIAStool+BB).",3,3,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/31/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 31,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome measurement,EFO:0007882,MagNAPure,Easy-DNA,"DNA isolation from pig fecal samples using Easy-DNATM gDNA Purification Kit, Invitrogen (Easy-DNA).",3,3,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/32/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 32,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome measurement,EFO:0007882,MagNAPure,FastDNA,"DNA isolation from pig fecal samples using MP FastDNATM Spin Kit, MP Biomedicals (FastDNA).",3,3,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/33/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 33,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome measurement,EFO:0007882,MagNAPure,PowerSoil.HMP,"DNA isolation from pig fecal samples using PowerSoil® DNA Isolation kit, MoBio Laboratories Inc. (PowerSoil.HMP)",3,3,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/34/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 34,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome measurement,EFO:0007882,MagNAPure,QIAStool,"DNA isolation from pig fecal samples using QIAamp® DNA Stool Mini Kit, Qiagen (QIAStool).",3,3,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,unchanged,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/35/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 35,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome measurement,EFO:0007882,MagNAPure,QIAStool+BB,"DNA isolation from pig fecal samples using QIAamp® DNA Stool Mini Kit, Qiagen +Bead Beating (QIAStool+BB).",3,3,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/36/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 36,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome measurement,EFO:0007882,Easy-DNA,FastDNA,"DNA isolation from pig fecal samples using MP FastDNATM Spin Kit, MP Biomedicals (FastDNA).",3,3,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/37/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 37,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome measurement,EFO:0007882,Easy-DNA,PowerSoil.HMP,"DNA isolation from pig fecal samples using PowerSoil® DNA Isolation kit, MoBio Laboratories Inc. (PowerSoil.HMP).",3,3,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/38/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 38,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome measurement,EFO:0007882,Easy-DNA,QIAStool,"DNA isolation from pig fecal samples using QIAamp® DNA Stool Mini Kit, Qiagen (QIAStool).",3,3,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/39/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 39,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome measurement,EFO:0007882,Easy-DNA,QIAStool+BB,"DNA isolation from pig fecal samples using QIAamp® DNA Stool Mini Kit, Qiagen +Bead Beating (QIAStool+BB).",3,3,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/40/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 40,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome measurement,EFO:0007882,FastDNA,PowerSoil.HMP,"DNA isolation from pig fecal samples using PowerSoil® DNA Isolation kit, MoBio Laboratories Inc. (PowerSoil.HMP).",3,3,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/41/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 41,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome measurement,EFO:0007882,FastDNA,QIAStool,"DNA isolation from pig fecal samples using QIAamp® DNA Stool Mini Kit, Qiagen (QIAStool).",3,3,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/42/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 42,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome measurement,EFO:0007882,FastDNA,QIAStool+BB,"DNA isolation from pig fecal samples using QIAamp® DNA Stool Mini Kit, Qiagen +Bead Beating (QIAStool+BB).",3,3,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/43/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 43,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome measurement,EFO:0007882,PowerSoil.HMP,QIAStool,"DNA isolation from pig fecal samples using QIAamp® DNA Stool Mini Kit, Qiagen (QIAStool).",3,3,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/44/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 44,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome measurement,EFO:0007882,PowerSoil.HMP,QIAStool+BB,"DNA isolation from pig fecal samples using QIAamp® DNA Stool Mini Kit, Qiagen +Bead Beating (QIAStool+BB).",3,3,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/45/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 45,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome measurement,EFO:0007882,QIAStool,QIAStool+BB,"DNA isolation from pig fecal samples using QIAamp® DNA Stool Mini Kit, Qiagen +Bead Beating (QIAStool+BB).",3,3,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,unchanged,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/46/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 46,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome measurement,EFO:0007882,MagNAPure,Easy-DNA,"DNA isolation from pig fecal samples using Easy-DNATM gDNA Purification Kit, Invitrogen (Easy-DNA).",3,3,NA,WMS,NA,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/47/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 47,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome measurement,EFO:0007882,MagNAPure,QIAStool,"DNA isolation from pig fecal samples using QIAamp® DNA Stool Mini Kit, Qiagen (QIAStool).",3,3,NA,WMS,NA,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/48/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 48,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome measurement,EFO:0007882,Easy-DNA,QIAStool,"DNA isolation from pig fecal samples using QIAamp® DNA Stool Mini Kit, Qiagen (QIAStool).",3,3,NA,WMS,NA,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/49/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 49,Denmark,Not specified,NA,NA,Microbiome measurement,EFO:0007882,InnuPURE,MagNAPure,"DNA isolation from sewage samples using MagNA Pure LC DNA isolation Kit III, Roche (MagNAPure).",24,24,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/50/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 50,Denmark,Not specified,NA,NA,Microbiome measurement,EFO:0007882,InnuPURE,Easy-DNA,"DNA isolation from sewage samples using Easy-DNATM gDNA Purification Kit, Invitrogen (Easy-DNA).",24,24,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/51/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 51,Denmark,Not specified,NA,NA,Microbiome measurement,EFO:0007882,InnuPURE,FastDNA,"DNA isolation from sewage samples using MP FastDNATM Spin Kit, MP Biomedicals (FastDNA).",24,24,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,unchanged,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/52/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 52,Denmark,Not specified,NA,NA,Microbiome measurement,EFO:0007882,InnuPURE,PowerSoil.HMP,"DNA isolation from sewage samples using PowerSoil® DNA Isolation kit, MoBio Laboratories Inc. (PowerSoil.HMP).",24,24,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/53/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 53,Denmark,Not specified,NA,NA,Microbiome measurement,EFO:0007882,InnuPURE,QIAStool,"DNA isolation from sewage samples using QIAamp® DNA Stool Mini Kit, Qiagen (QIAStool).",24,24,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/54/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 54,Denmark,Not specified,NA,NA,Microbiome measurement,EFO:0007882,InnuPURE,QIAStool+BB,"DNA isolation from sewage samples using QIAamp® DNA Stool Mini Kit, Qiagen +Bead Beating (QIAStool+BB).",24,24,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,unchanged,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/55/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 55,Denmark,Not specified,NA,NA,Microbiome measurement,EFO:0007882,MagNA Pure,Easy-DNA,"DNA isolation from sewage samples using Easy-DNATM gDNA Purification Kit, Invitrogen (Easy-DNA).",24,24,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,unchanged,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/56/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 56,Denmark,Not specified,NA,NA,Microbiome measurement,EFO:0007882,MagNA Pure,FastDNA,"DNA isolation from sewage samples using MP FastDNATM Spin Kit, MP Biomedicals (FastDNA).",24,24,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,unchanged,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/57/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 57,Denmark,Not specified,NA,NA,Microbiome measurement,EFO:0007882,MagNA Pure,PowerSoil.HMP,"DNA isolation from sewage samples using PowerSoil® DNA Isolation kit, MoBio Laboratories Inc. (PowerSoil.HMP).",24,24,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,unchanged,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/58/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 58,Denmark,Not specified,NA,NA,Microbiome measurement,EFO:0007882,MagNA Pure,QIAStool,"DNA isolation from sewage samples using QIAamp® DNA Stool Mini Kit, Qiagen (QIAStool).",24,24,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,unchanged,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/59/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 59,Denmark,Not specified,NA,NA,Microbiome measurement,EFO:0007882,MagNA Pure,QIAStool+BB,"DNA isolation from sewage samples using QIAamp® DNA Stool Mini Kit, Qiagen +Bead Beating (QIAStool+BB).",24,24,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,unchanged,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/60/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 60,Denmark,Not specified,NA,NA,Microbiome measurement,EFO:0007882,Easy-DNA,FastDNA,"DNA isolation from sewage samples using MP FastDNATM Spin Kit, MP Biomedicals (FastDNA).",24,24,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/61/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 61,Denmark,Not specified,NA,NA,Microbiome measurement,EFO:0007882,Easy-DNA,PowerSoil.HMP,"DNA isolation from sewage samples using PowerSoil® DNA Isolation kit, MoBio Laboratories Inc. (PowerSoil.HMP).",24,24,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/62/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 62,Denmark,Not specified,NA,NA,Microbiome measurement,EFO:0007882,Easy-DNA,QIAStool,"DNA isolation from sewage samples using QIAamp® DNA Stool Mini Kit, Qiagen (QIAStool).",24,24,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/63/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 63,Denmark,Not specified,NA,NA,Microbiome measurement,EFO:0007882,Easy-DNA,QIAStool+BB,"DNA isolation from sewage samples using QIAamp® DNA Stool Mini Kit, Qiagen +Bead Beating (QIAStool+BB).",24,24,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/64/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 64,Denmark,Not specified,NA,NA,Microbiome measurement,EFO:0007882,FastDNA,PowerSoil.HMP,"DNA isolation from sewage samples using PowerSoil® DNA Isolation kit, MoBio Laboratories Inc. (PowerSoil.HMP).",24,24,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,decreased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/65/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 65,Denmark,Not specified,NA,NA,Microbiome measurement,EFO:0007882,FastDNA,QIAStool,"DNA isolation from sewage samples using QIAamp® DNA Stool Mini Kit, Qiagen (QIAStool).",24,24,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,decreased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/66/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 66,Denmark,Not specified,NA,NA,Microbiome measurement,EFO:0007882,FastDNA,QIAStool+BB,"DNA isolation from sewage samples using QIAamp® DNA Stool Mini Kit, Qiagen +Bead Beating (QIAStool+BB).",24,24,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/67/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 67,Denmark,Not specified,NA,NA,Microbiome measurement,EFO:0007882,PowerSoil.HMP,QIAStool,"DNA isolation from sewage samples using QIAamp® DNA Stool Mini Kit, Qiagen (QIAStool).",24,24,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,unchanged,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/68/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 68,Denmark,Not specified,NA,NA,Microbiome measurement,EFO:0007882,PowerSoil.HMP,QIAStool+BB,"DNA isolation from sewage samples using QIAamp® DNA Stool Mini Kit, Qiagen +Bead Beating (QIAStool+BB).",24,24,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,increased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:888/69/NA,Study 888,laboratory experiment,27822556,10.1128/mSystems.00095-16,https://journals.asm.org/doi/full/10.1128/msystems.00095-16,"Knudsen BE, Bergmark L, Munk P, Lukjancenko O, Priemé A, Aarestrup FM , Pamp SJ",Impact of Sample Type and DNA Isolation Procedure on Genomic Inference of Microbiome Composition,mSystems,2016,"16S rRNA gene profiling, DNA isolation, metagenomics, microbial ecology, microbiome, next-generation sequencing",Experiment 69,Denmark,Not specified,NA,NA,Microbiome measurement,EFO:0007882,QIAStool,QIAStool+BB,"DNA isolation from sewage samples using QIAamp® DNA Stool Mini Kit, Qiagen +Bead Beating (QIAStool+BB).",24,24,NA,16S,4,Illumina,DESeq2,0.1,TRUE,NA,NA,NA,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:889/1/NA,Study 889,case-control,37432374,10.3390/nu15092173,NA,"Silvano A, Meriggi N, Renzi S, Seravalli V, Torcia MG, Cavalieri D , Di Tommaso M",Vaginal Microbiome in Pregnant Women with and without Short Cervix,Nutrients,2023,"Gardenerella vaginalis, Lactobacillus, aerobic vaginitis, microbiome, risk in pregnancy, shortened cervix",Experiment 1,Italy,Homo sapiens,Vagina,UBERON:0000996,Cervix erosion,EFO:1000862,Control,Short Cervix Length,Pregnant women of predominantly Caucasian ethnicity with singleton gestation and a cervical length ≤ 25 mm in their second or early third trimester (23–32 weeks’ gestation),29,68,At the time of recruitment,16S,34,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,unchanged,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:890/1/NA,Study 890,case-control,37608830,10.3389/fmed.2023.1177990,NA,"Vidmar Šimic M, Maver A, Zimani AN, Hočevar K, Peterlin B, Kovanda A , Premru-Sršen T",Oral microbiome and preterm birth,Frontiers in medicine,2023,"16S rDNA, 16S rRNA gene, microbiome, oral microbiome, pregnancy, preterm delivery",Experiment 1,Slovenia,Homo sapiens,Oral cavity,UBERON:0000167,Premature birth,EFO:0003917,Term birth (TB),Preterm birth (PTB),"Spontaneous onset of preterm labor (≤36 6/7 weeks) due to various causes, including spontaneous contractions, preterm premature rupture of membranes (PPROM), intrauterine infection, cervical insufficiency, and others",91,61,Week before inclusion,16S,34,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:891/1/NA,Study 891,"cross-sectional observational, not case-control",35579429,10.1128/spectrum.02311-21,NA,"Devi P, Maurya R, Mehta P, Shamim U, Yadav A, Chattopadhyay P, Kanakan A, Khare K, Vasudevan JS, Sahni S, Mishra P, Tyagi A, Jha S, Budhiraja S, Tarai B , Pandey R",Increased Abundance of Achromobacter xylosoxidans and Bacillus cereus in Upper Airway Transcriptionally Active Microbiome of COVID-19 Mortality Patients Indicates Role of Co-Infections in Disease Severity and Outcome,Microbiology spectrum,2022,"COVID-19, Holo-Seq, co-infection, disease outcome, disease sub-phenotype, host-pathogen interactions, metabolic pathways, nasopharyngeal RNA, pathogen genomics, respiratory virus oligo panel (RVOP), transcriptionally active microbial isolates",Experiment 1,India,Homo sapiens,Nasopharynx,UBERON:0001728,COVID-19 symptoms measurement,EFO:0600019,mild,moderate,patients showing breathing difficulty with SpO2 levels ranging between 91% and 93%.,24,36,NA,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:891/2/NA,Study 891,"cross-sectional observational, not case-control",35579429,10.1128/spectrum.02311-21,NA,"Devi P, Maurya R, Mehta P, Shamim U, Yadav A, Chattopadhyay P, Kanakan A, Khare K, Vasudevan JS, Sahni S, Mishra P, Tyagi A, Jha S, Budhiraja S, Tarai B , Pandey R",Increased Abundance of Achromobacter xylosoxidans and Bacillus cereus in Upper Airway Transcriptionally Active Microbiome of COVID-19 Mortality Patients Indicates Role of Co-Infections in Disease Severity and Outcome,Microbiology spectrum,2022,"COVID-19, Holo-Seq, co-infection, disease outcome, disease sub-phenotype, host-pathogen interactions, metabolic pathways, nasopharyngeal RNA, pathogen genomics, respiratory virus oligo panel (RVOP), transcriptionally active microbial isolates",Experiment 2,India,Homo sapiens,Nasopharynx,UBERON:0001728,COVID-19 symptoms measurement,EFO:0600019,mild,mortality,patients who succumbed to COVID-19 during hospital stay,24,12,NA,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:891/3/NA,Study 891,"cross-sectional observational, not case-control",35579429,10.1128/spectrum.02311-21,NA,"Devi P, Maurya R, Mehta P, Shamim U, Yadav A, Chattopadhyay P, Kanakan A, Khare K, Vasudevan JS, Sahni S, Mishra P, Tyagi A, Jha S, Budhiraja S, Tarai B , Pandey R",Increased Abundance of Achromobacter xylosoxidans and Bacillus cereus in Upper Airway Transcriptionally Active Microbiome of COVID-19 Mortality Patients Indicates Role of Co-Infections in Disease Severity and Outcome,Microbiology spectrum,2022,"COVID-19, Holo-Seq, co-infection, disease outcome, disease sub-phenotype, host-pathogen interactions, metabolic pathways, nasopharyngeal RNA, pathogen genomics, respiratory virus oligo panel (RVOP), transcriptionally active microbial isolates",Experiment 3,India,Homo sapiens,Nasopharynx,UBERON:0001728,COVID-19 symptoms measurement,EFO:0600019,moderate,severe,patients showing respiratory distress with respiratory support requirement and SpO2 levels < 90%,36,14,NA,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:891/4/NA,Study 891,"cross-sectional observational, not case-control",35579429,10.1128/spectrum.02311-21,NA,"Devi P, Maurya R, Mehta P, Shamim U, Yadav A, Chattopadhyay P, Kanakan A, Khare K, Vasudevan JS, Sahni S, Mishra P, Tyagi A, Jha S, Budhiraja S, Tarai B , Pandey R",Increased Abundance of Achromobacter xylosoxidans and Bacillus cereus in Upper Airway Transcriptionally Active Microbiome of COVID-19 Mortality Patients Indicates Role of Co-Infections in Disease Severity and Outcome,Microbiology spectrum,2022,"COVID-19, Holo-Seq, co-infection, disease outcome, disease sub-phenotype, host-pathogen interactions, metabolic pathways, nasopharyngeal RNA, pathogen genomics, respiratory virus oligo panel (RVOP), transcriptionally active microbial isolates",Experiment 4,India,Homo sapiens,Nasopharynx,UBERON:0001728,COVID-19 symptoms measurement,EFO:0600019,moderate,mortality,patients who succumbed to COVID-19 during hospital stay,36,12,NA,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:891/5/NA,Study 891,"cross-sectional observational, not case-control",35579429,10.1128/spectrum.02311-21,NA,"Devi P, Maurya R, Mehta P, Shamim U, Yadav A, Chattopadhyay P, Kanakan A, Khare K, Vasudevan JS, Sahni S, Mishra P, Tyagi A, Jha S, Budhiraja S, Tarai B , Pandey R",Increased Abundance of Achromobacter xylosoxidans and Bacillus cereus in Upper Airway Transcriptionally Active Microbiome of COVID-19 Mortality Patients Indicates Role of Co-Infections in Disease Severity and Outcome,Microbiology spectrum,2022,"COVID-19, Holo-Seq, co-infection, disease outcome, disease sub-phenotype, host-pathogen interactions, metabolic pathways, nasopharyngeal RNA, pathogen genomics, respiratory virus oligo panel (RVOP), transcriptionally active microbial isolates",Experiment 5,India,Homo sapiens,Nasopharynx,UBERON:0001728,COVID-19 symptoms measurement,EFO:0600019,severe,mortality,patients who succumbed to COVID-19 during hospital stay,14,12,NA,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:892/1/NA,Study 892,case-control,37805557,https://doi.org/10.1186/s40168-023-01657-0,NA,"Huang G, Shi W, Wang L, Qu Q, Zuo Z, Wang J, Zhao F , Wei F","PandaGUT provides new insights into bacterial diversity, function, and resistome landscapes with implications for conservation",Microbiome,2023,"Adaptive evolution, Conservation, Diversity, Giant panda, Gut microbiome, Wild mammal",Experiment 1,China,Ailuropoda melanoleuca,Feces,UBERON:0001988,Diet,EFO:0002755,Pandas in shoot-eating season,Pandas in leaf-eating season,Pandas in leaf-eating season from the Qinling cohort of wild pandas,24,33,NA,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:892/2/NA,Study 892,case-control,37805557,https://doi.org/10.1186/s40168-023-01657-0,NA,"Huang G, Shi W, Wang L, Qu Q, Zuo Z, Wang J, Zhao F , Wei F","PandaGUT provides new insights into bacterial diversity, function, and resistome landscapes with implications for conservation",Microbiome,2023,"Adaptive evolution, Conservation, Diversity, Giant panda, Gut microbiome, Wild mammal",Experiment 2,China,Ailuropoda melanoleuca,Feces,UBERON:0001988,Diet,EFO:0002755,MIN wild pandas,QXL wild pandas,"Only 1864 wild giant pandas are extant and are distributed in six mountain ranges including the Qinling (QIN), Minshan (MIN), Qionglai (QIO), Daxiangling (DXL), Xiaoxiangling (XXL), and Liangshan (LSH) mountains that can be classified into three genetic populations including the QIN, MIN, and QIO-DXL-XXL-LSH (QXL) populations",7,7,NA,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,increased,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:892/3/NA,Study 892,case-control,37805557,https://doi.org/10.1186/s40168-023-01657-0,NA,"Huang G, Shi W, Wang L, Qu Q, Zuo Z, Wang J, Zhao F , Wei F","PandaGUT provides new insights into bacterial diversity, function, and resistome landscapes with implications for conservation",Microbiome,2023,"Adaptive evolution, Conservation, Diversity, Giant panda, Gut microbiome, Wild mammal",Experiment 3,China,Ailuropoda melanoleuca,Feces,UBERON:0001988,Diet,EFO:0002755,QIN wild pandas,QXL wild pandas,"Only 1864 wild giant pandas are extant and are distributed in six mountain ranges including the Qinling (QIN), Minshan (MIN), Qionglai (QIO), Daxiangling (DXL), Xiaoxiangling (XXL), and Liangshan (LSH) mountains that can be classified into three genetic populations including the QIN, MIN, and QIO-DXL-XXL-LSH (QXL) populations",31,7,NA,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,increased,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:893/1/NA,Study 893,"cross-sectional observational, not case-control",35865814,10.3389/fcimb.2022.894777,NA,"Sarkar P, Malik S, Banerjee A, Datta C, Pal DK, Ghosh A , Saha A",Differential Microbial Signature Associated With Benign Prostatic Hyperplasia and Prostate Cancer,Frontiers in cellular and infection microbiology,2022,"EBV, HPV, benign prostate hyperplasia, microbiome, prostate cancer",Experiment 1,India,Homo sapiens,Prostate gland,UBERON:0002367,Prostate carcinoma,EFO:0001663,"Benign prostatic hyperplasia (BPH),  Cohort-1 (Discovery Cohort)","Prostate Cancer (PCa),  Cohort-1 (Discovery Cohort)",Patients who are diagnosed with Prostate Cancer (PCa),13,33,None,16S,23456789,Ion Torrent,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,decreased,unchanged,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:894/1/NA,Study 894,time series / longitudinal observational,36197290,10.1128/spectrum.01899-22,NA,"Jiang CH, Fang X, Huang W, Guo JY, Chen JY, Wu HY, Li ZS, Zou WB , Liao Z",Alterations in the Gut Microbiota and Metabolomics of Seafarers after a Six-Month Sea Voyage,Microbiology spectrum,2022,"16S rRNA gene sequencing, gut microbiota, metabolic pathways, sea voyage, seafarers’ health care, untargeted metabolomics",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Seasonal gut microbiome measurement,EFO:0007753,Day 0,Day 180,Seafarers at the end (day 180) of the 6-month voyage,30,30,None,16S,34,Illumina,"LEfSe,Mann-Whitney (Wilcoxon)",0.05,TRUE,2,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:895/1/NA,Study 895,laboratory experiment,38421192,https://doi.org/10.1128/spectrum.01437-23,NA,"Zhang N, Gao X, Li D, Xu L, Zhou G, Xu M, Peng L, Sun G, Pan F, Li Y, Ren R, Huang R, Yang Y , Wang Z",Sleep deprivation-induced anxiety-like behaviors are associated with alterations in the gut microbiota and metabolites,Microbiology spectrum,2024,"anxiety, gut microbiota, metabolomics, probiotics, sleep deprivation",Experiment 1,China,Rattus norvegicus,Feces,UBERON:0001988,Anxiety disorder,EFO:0006788,Baseline samples (BSL),Post sleep deprivation samples (7d-SD),Samples collected from rats after being subjected to 7 days of sleep deprivation (7d-SD).,30,29,NA,WMS,NA,Illumina,LEfSe,0.05,TRUE,3,NA,NA,NA,unchanged,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:895/2/NA,Study 895,laboratory experiment,38421192,https://doi.org/10.1128/spectrum.01437-23,NA,"Zhang N, Gao X, Li D, Xu L, Zhou G, Xu M, Peng L, Sun G, Pan F, Li Y, Ren R, Huang R, Yang Y , Wang Z",Sleep deprivation-induced anxiety-like behaviors are associated with alterations in the gut microbiota and metabolites,Microbiology spectrum,2024,"anxiety, gut microbiota, metabolomics, probiotics, sleep deprivation",Experiment 2,China,Rattus norvegicus,Feces,UBERON:0001988,Anxiety disorder,EFO:0006788,Baseline samples (BSL),Saline supplementation - SA (21d-SA),Samples collected from rats after 14 days of saline supplementation (21d-SA).,30,15,NA,WMS,NA,Illumina,LEfSe,0.05,TRUE,3,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:895/3/NA,Study 895,laboratory experiment,38421192,https://doi.org/10.1128/spectrum.01437-23,NA,"Zhang N, Gao X, Li D, Xu L, Zhou G, Xu M, Peng L, Sun G, Pan F, Li Y, Ren R, Huang R, Yang Y , Wang Z",Sleep deprivation-induced anxiety-like behaviors are associated with alterations in the gut microbiota and metabolites,Microbiology spectrum,2024,"anxiety, gut microbiota, metabolomics, probiotics, sleep deprivation",Experiment 3,China,Rattus norvegicus,Feces,UBERON:0001988,Anxiety disorder,EFO:0006788,Baseline samples (BSL),Multi-probiotic supplementation - MP (21d-MP),Samples collected from rats after 14 days of multi-probiotic supplementation (21d-MP).,30,14,NA,WMS,NA,Illumina,LEfSe,0.05,TRUE,3,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:895/4/NA,Study 895,laboratory experiment,38421192,https://doi.org/10.1128/spectrum.01437-23,NA,"Zhang N, Gao X, Li D, Xu L, Zhou G, Xu M, Peng L, Sun G, Pan F, Li Y, Ren R, Huang R, Yang Y , Wang Z",Sleep deprivation-induced anxiety-like behaviors are associated with alterations in the gut microbiota and metabolites,Microbiology spectrum,2024,"anxiety, gut microbiota, metabolomics, probiotics, sleep deprivation",Experiment 4,China,Rattus norvegicus,Feces,UBERON:0001988,Anxiety disorder,EFO:0006788,Post sleep deprivation samples (7d-SD),Saline supplementation - SA (21d-SA),Samples collected from rats after 14 days of saline supplementation (21d-SA).,29,15,NA,WMS,NA,Illumina,LEfSe,0.05,TRUE,3,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:895/5/NA,Study 895,laboratory experiment,38421192,https://doi.org/10.1128/spectrum.01437-23,NA,"Zhang N, Gao X, Li D, Xu L, Zhou G, Xu M, Peng L, Sun G, Pan F, Li Y, Ren R, Huang R, Yang Y , Wang Z",Sleep deprivation-induced anxiety-like behaviors are associated with alterations in the gut microbiota and metabolites,Microbiology spectrum,2024,"anxiety, gut microbiota, metabolomics, probiotics, sleep deprivation",Experiment 5,China,Rattus norvegicus,Feces,UBERON:0001988,Anxiety disorder,EFO:0006788,Post sleep deprivation samples (7d-SD),Multi-probiotic supplementation - MP (21d-MP),Samples collected from rats after 14 days of multi-probiotic supplementation (21d-MP).,29,14,NA,WMS,NA,Illumina,LEfSe,0.05,TRUE,3,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:895/6/NA,Study 895,laboratory experiment,38421192,https://doi.org/10.1128/spectrum.01437-23,NA,"Zhang N, Gao X, Li D, Xu L, Zhou G, Xu M, Peng L, Sun G, Pan F, Li Y, Ren R, Huang R, Yang Y , Wang Z",Sleep deprivation-induced anxiety-like behaviors are associated with alterations in the gut microbiota and metabolites,Microbiology spectrum,2024,"anxiety, gut microbiota, metabolomics, probiotics, sleep deprivation",Experiment 6,China,Rattus norvegicus,Feces,UBERON:0001988,Anxiety disorder,EFO:0006788,Saline supplementation - SA (21d-SA),Multi-probiotic supplementation - MP (21d-MP),Samples collected from rats after 14 days of multi-probiotic supplementation (21d-MP).,15,14,NA,WMS,NA,Illumina,LEfSe,0.05,TRUE,3,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:896/1/NA,Study 896,time series / longitudinal observational,30488079,10.11622/smedj.2018152,https://pubmed.ncbi.nlm.nih.gov/30488079/,"Koo SH, Deng J, Ang DSW, Hsiang JC, Lee LS, Aazmi S, Mohamed EHM, Yang H, Yap SY, Teh LK, Salleh MZ, Lee EJD , Ang TL",Effects of proton pump inhibitor on the human gut microbiome profile in multi-ethnic groups in Singapore,Singapore medical journal,2019,"gastroesophageal reflux disease, gastrointestinal microbiome, omeprazole",Experiment 1,Singapore,Homo sapiens,Feces,UBERON:0001988,Health study participation,EFO:0010130,Day 1 participants,Day 7 participants,The day participants stopped the course of Omeprazole at therapeutic dose (20mg daily),34,34,1 month,16S,34,Illumina,"LEfSe,Kruskall-Wallis",0.05,FALSE,2,NA,NA,NA,unchanged,NA,unchanged,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:896/3/NA,Study 896,time series / longitudinal observational,30488079,10.11622/smedj.2018152,https://pubmed.ncbi.nlm.nih.gov/30488079/,"Koo SH, Deng J, Ang DSW, Hsiang JC, Lee LS, Aazmi S, Mohamed EHM, Yang H, Yap SY, Teh LK, Salleh MZ, Lee EJD , Ang TL",Effects of proton pump inhibitor on the human gut microbiome profile in multi-ethnic groups in Singapore,Singapore medical journal,2019,"gastroesophageal reflux disease, gastrointestinal microbiome, omeprazole",Experiment 3,Singapore,Homo sapiens,Feces,UBERON:0001988,Health study participation,EFO:0010130,Day 7,Day 14,The day that marked the 7th day after participants stopped the course of Omeprazole at therapeutic dose (20mg daily),34,34,1 month,16S,34,Illumina,"LEfSe,Kruskall-Wallis",0.05,FALSE,2,NA,NA,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:896/4/NA,Study 896,time series / longitudinal observational,30488079,10.11622/smedj.2018152,https://pubmed.ncbi.nlm.nih.gov/30488079/,"Koo SH, Deng J, Ang DSW, Hsiang JC, Lee LS, Aazmi S, Mohamed EHM, Yang H, Yap SY, Teh LK, Salleh MZ, Lee EJD , Ang TL",Effects of proton pump inhibitor on the human gut microbiome profile in multi-ethnic groups in Singapore,Singapore medical journal,2019,"gastroesophageal reflux disease, gastrointestinal microbiome, omeprazole",Experiment 4,Singapore,Homo sapiens,Feces,UBERON:0001988,Health study participation,EFO:0010130,Chinese participants,Indian participants,Participants who belong to the Indian ethnic group,12,10,1 month,16S,34,Illumina,"Kruskall-Wallis,LEfSe",0.05,FALSE,2,NA,NA,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:896/6/NA,Study 896,time series / longitudinal observational,30488079,10.11622/smedj.2018152,https://pubmed.ncbi.nlm.nih.gov/30488079/,"Koo SH, Deng J, Ang DSW, Hsiang JC, Lee LS, Aazmi S, Mohamed EHM, Yang H, Yap SY, Teh LK, Salleh MZ, Lee EJD , Ang TL",Effects of proton pump inhibitor on the human gut microbiome profile in multi-ethnic groups in Singapore,Singapore medical journal,2019,"gastroesophageal reflux disease, gastrointestinal microbiome, omeprazole",Experiment 6,Singapore,Homo sapiens,Feces,UBERON:0001988,Health study participation,EFO:0010130,Indian participants,Malay participants,Participants who belong to the Malay ethnic group,10,12,1 month,16S,34,Illumina,"LEfSe,Kruskall-Wallis",0.05,FALSE,2,NA,NA,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:896/7/NA,Study 896,time series / longitudinal observational,30488079,10.11622/smedj.2018152,https://pubmed.ncbi.nlm.nih.gov/30488079/,"Koo SH, Deng J, Ang DSW, Hsiang JC, Lee LS, Aazmi S, Mohamed EHM, Yang H, Yap SY, Teh LK, Salleh MZ, Lee EJD , Ang TL",Effects of proton pump inhibitor on the human gut microbiome profile in multi-ethnic groups in Singapore,Singapore medical journal,2019,"gastroesophageal reflux disease, gastrointestinal microbiome, omeprazole",Experiment 7,Singapore,Homo sapiens,Feces,UBERON:0001988,Health study participation,EFO:0010130,Male participants,Female participants,Participants who identify with the female gender,16,18,1 month,16S,34,Illumina,"LEfSe,Kruskall-Wallis",0.05,FALSE,2,NA,NA,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:897/1/NA,Study 897,laboratory experiment,37060097,https://doi.org/10.1186/s40168-023-01527-9,NA,"Maidment TI, Bryan ER, Pyne M, Barnes M, Eccleston S, Cunningham S, Whitlock E, Redman K, Nicolson V, Beagley KW , Pelzer E",Characterisation of the koala (Phascolarctos cinereus) pouch microbiota in a captive population reveals a dysbiotic compositional profile associated with neonatal mortality,Microbiome,2023,"Dysbiosis, Endangered species, Enterobacteriaceae, Klebsiella pneumoniae, Koala, Marsupial, Muribaculaceae, Phascolarctos cinereus, Pluralibacter gergoviae, Pouch, Reproduction",Experiment 1,Australia,Phascolarctos cinereus,Marsupium,UBERON:0009118,Neonatal death,HP:0003811,Successful breeders,Unsuccessful breeders,Captive Koalas who lost their pouch young during lactation.,10,7,NA,16S,34,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:898/1/NA,Study 898,case-control,29904624,10.3389/fcimb.2018.00167,NA,"Wu P, Zhang G, Zhao J, Chen J, Chen Y, Huang W, Zhong J , Zeng J",Profiling the Urinary Microbiota in Male Patients With Bladder Cancer in China,Frontiers in cellular and infection microbiology,2018,"extracellular matrix, inflammation, microbiota, urinary bladder neoplasms, urinary tract",Experiment 1,China,Homo sapiens,Urine,UBERON:0001088,Bladder carcinoma,MONDO:0004986,Non-neoplastic (controls),Bladder cancer,Male patients with bladder cancer,18,31,1 month,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,increased,unchanged,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:898/2/NA,Study 898,case-control,29904624,10.3389/fcimb.2018.00167,NA,"Wu P, Zhang G, Zhao J, Chen J, Chen Y, Huang W, Zhong J , Zeng J",Profiling the Urinary Microbiota in Male Patients With Bladder Cancer in China,Frontiers in cellular and infection microbiology,2018,"extracellular matrix, inflammation, microbiota, urinary bladder neoplasms, urinary tract",Experiment 2,China,Homo sapiens,Urine,UBERON:0001088,Disease recurrence,EFO:0004952,Lower risk of recurrence (LER),Higher risk of recurrence (HER),"Male bladder cancer patients stratified into the higher risk of recurrence group (HER, recurrence score of EORTC ≥ 5) based on European Organization for Research and Treatment of Cancer (EORTC) scoring system",16,10,1 month,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,increased,unchanged,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:898/3/NA,Study 898,case-control,29904624,10.3389/fcimb.2018.00167,NA,"Wu P, Zhang G, Zhao J, Chen J, Chen Y, Huang W, Zhong J , Zeng J",Profiling the Urinary Microbiota in Male Patients With Bladder Cancer in China,Frontiers in cellular and infection microbiology,2018,"extracellular matrix, inflammation, microbiota, urinary bladder neoplasms, urinary tract",Experiment 3,China,Homo sapiens,Urine,UBERON:0001088,Disease progression measurement,EFO:0008336,Lower risk of progression (LEP),Higher risk of progression (HEP),"Male bladder cancer patients stratified into the higher risk of progression group (HEP, progression score of EORTC ≥ 7) based on European Organization for Research and Treatment of Cancer (EORTC) scoring system",15,11,1 month,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,increased,unchanged,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:899/1/NA,Study 899,"cross-sectional observational, not case-control",34264502,https://doi.org/10.1007/s42770-021-00539-7,NA,"de Oliveira Scoaris D, Hughes FM, Silveira MA, Evans JD, Pettis JS, Bastos EMAF , Rosa CA",Microbial communities associated with honey bees in Brazil and in the United States,Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology],2021,"Apis mellifera, Bacteria, Diversity, Environment, Microorganisms, Yeasts",Experiment 1,"Brazil,United States of America",Not specified,Intestinal mucosa,UBERON:0001242,Restricted to specific location,MONDO:0045042,Brazilian hive microenvironment,North American hive microenvironments,North American samples were collected from four hives of honey bees,5,4,2 weeks,ITS / ITS2,NA,RT-qPCR,NA,NA,NA,NA,NA,physical activity,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:900/3/NA,Study 900,laboratory experiment,32987006,https://doi.org/10.1016/j.envres.2020.110245,NA,"Gust KA, Indest KJ, Lotufo G, Everman SJ, Jung CM, Ballentine ML, Hoke AV, Sowe B, Gautam A, Hammamieh R, Ji Q , Barker ND",Genomic investigations of acute munitions exposures on the health and skin microbiome composition of leopard frog (Rana pipiens) tadpoles,Environmental research,2021,"Amphibian health, Amphibian skin microbiome, Aquatic ecotoxicology, Munitions constituents, Transcript expression",Experiment 3,United States of America,Rana pipiens,Tadpole,UBERON:0002547,Environmental exposure measurement,EFO:0008360,Control group,Tadpoles exposed to 3560 mg/L Nitroguanidine (NQ),Tadpoles were exposed to the concentration of 3560 mg/L of Nitroguanidine (NQ) for 96 hours.,4,4,None,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:901/1/NA,Study 901,case-control,37700874,10.2147/JAA.S422537,NA,"Wan J, Song J, Lv Q, Zhang H, Xiang Q, Dai H, Zheng H, Lin X , Zhang W",Alterations in the Gut Microbiome of Young Children with Airway Allergic Disease Revealed by Next-Generation Sequencing,Journal of asthma and allergy,2023,"allergic asthma, allergic rhinitis, childhood, gut microbiome, metagenomic sequencing",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Allergic asthma,MONDO:0004784,Healthy control,Allergic asthma,Children with allergic asthma,19,23,2 months,WMS,NA,Illumina,LEfSe,0.05,FALSE,3,"age,body mass index,sex",NA,NA,increased,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:901/2/NA,Study 901,case-control,37700874,10.2147/JAA.S422537,NA,"Wan J, Song J, Lv Q, Zhang H, Xiang Q, Dai H, Zheng H, Lin X , Zhang W",Alterations in the Gut Microbiome of Young Children with Airway Allergic Disease Revealed by Next-Generation Sequencing,Journal of asthma and allergy,2023,"allergic asthma, allergic rhinitis, childhood, gut microbiome, metagenomic sequencing",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Allergic rhinitis,EFO:0005854,Healthy control,Allergic rhinitis,Children with allergic rhinitis,19,18,2 months,WMS,NA,Illumina,LEfSe,0.05,FALSE,3,"age,body mass index,sex",NA,NA,increased,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:902/1/NA,Study 902,case-control,NA,https://doi.org/10.1186/s12866-021-02221-2,NA,"Chen Li, Hesong Wang, Jianhua Zhen, Li Wang, Lu Zhao, Pengfei Zhao, Yini Li",Abundance alteration of nondominant species in fecal-associated microbiome of patients with SAPHO syndrome,BMC microbiology,2021,Fecal-associated microbiome SAPHO syndrome Biomarkers,Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,SAPHO syndrome,EFO:1001164,Healthy control group,SAPHO syndrome Patients,"SAPHO (synovitis, acne, pustulosis, hyperostosis and osteosis) syndrome, The main features of SAPHO syndrome consist of cutaneous and osteoarticular manifestations, the latter more often affects the anterior chest wall and has a typical radiologic finding called the “bull’s head sign”",14,17,3months,16S,34,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:903/1/NA,Study 903,case-control,36523636,https://doi.org/10.3389/fcimb.2022.943609,https://www.frontiersin.org/articles/10.3389/fcimb.2022.943609/full,"Morales C, Rojas G, Rebolledo C, Rojas-Herrera M, Arias-Carrasco R, Cuadros-Orellana S, Maracaja-Coutinho V, Saavedra K, Leal P, Lanas F, Salazar LA , Saavedra N",Characterization of microbial communities from gut microbiota of hypercholesterolemic and control subjects,Frontiers in cellular and infection microbiology,2022,"16S rRNA sequencing, LDL cholesterol, LEfSe analysis, gut microbiota, microbial signature",Experiment 1,Chile,Homo sapiens,Feces,UBERON:0001988,Hypercholesterolemia,HP:0003124,normocholesterolemic individuals (controls),hypercholesterolemic (cases),Patients with hypercholesterolemia (concentration of LDL-C greater than 4.16mmol/L),30,27,6 Months,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:904/1/NA,Study 904,time series / longitudinal observational,34220852,10.3389/fimmu.2021.692225,NA,"Heidrich V, Bruno JS, Knebel FH, de Molla VC, Miranda-Silva W, Asprino PF, Tucunduva L, Rocha V, Novis Y, Arrais-Rodrigues C, Fregnani ER , Camargo AA",Dental Biofilm Microbiota Dysbiosis Is Associated With the Risk of Acute Graft-<i>Versus</i>-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation,Frontiers in immunology,2021,"acute GVHD, allogeneic HSCT, bone marrow transplant, microbiome dysbiosis, oral microbiota, supragingival plaque",Experiment 1,Brazil,Homo sapiens,Supragingival dental plaque,UBERON:0016485,Response to allogeneic hematopoietic stem cell transplant,EFO:0007044,Preconditioning (Patients Before Allogeneic Hematopoietic Stem Cell Transplantation),Engraftment (Patients After Allogeneic Hematopoietic Stem Cell Transplantation),"Patients at the final phase of Allogeneic Hematopoietic Stem Cell transplant, when the new transplanted stem cells start to grow and produce new blood cells.",30,27,No,16S,34,Illumina,ANCOM,0.7,FALSE,NA,NA,NA,NA,decreased,NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:904/2/NA,Study 904,time series / longitudinal observational,34220852,10.3389/fimmu.2021.692225,NA,"Heidrich V, Bruno JS, Knebel FH, de Molla VC, Miranda-Silva W, Asprino PF, Tucunduva L, Rocha V, Novis Y, Arrais-Rodrigues C, Fregnani ER , Camargo AA",Dental Biofilm Microbiota Dysbiosis Is Associated With the Risk of Acute Graft-<i>Versus</i>-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation,Frontiers in immunology,2021,"acute GVHD, allogeneic HSCT, bone marrow transplant, microbiome dysbiosis, oral microbiota, supragingival plaque",Experiment 2,Brazil,Homo sapiens,Supragingival dental plaque,UBERON:0016485,Response to allogeneic hematopoietic stem cell transplant,EFO:0007044,Preconditioning (Patients Before Allogeneic Hematopoietic Stem Cell Transplantation),Aplasia group,"Patients after the conditioning regimen, when the patient's bone marrow is intentionally depleted of cells, necessary for the success of the transplant",30,30,No,16S,34,Illumina,ANCOM,0.7,FALSE,NA,NA,NA,NA,decreased,NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:904/3/NA,Study 904,time series / longitudinal observational,34220852,10.3389/fimmu.2021.692225,NA,"Heidrich V, Bruno JS, Knebel FH, de Molla VC, Miranda-Silva W, Asprino PF, Tucunduva L, Rocha V, Novis Y, Arrais-Rodrigues C, Fregnani ER , Camargo AA",Dental Biofilm Microbiota Dysbiosis Is Associated With the Risk of Acute Graft-<i>Versus</i>-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation,Frontiers in immunology,2021,"acute GVHD, allogeneic HSCT, bone marrow transplant, microbiome dysbiosis, oral microbiota, supragingival plaque",Experiment 3,Brazil,Homo sapiens,Supragingival dental plaque,UBERON:0016485,Response to allogeneic hematopoietic stem cell transplant,EFO:0007044,Aplasia group,Engraftment group,"Patients at the final phase of Allogeneic Hematopoietic Stem Cell transplant, when the new transplanted stem cells start to grow and produce new blood cells.",30,27,No,16S,34,Illumina,ANCOM,0.7,FALSE,NA,NA,NA,NA,decreased,NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:905/1/NA,Study 905,case-control,28195358,10.1002/mds.26942,https://pubmed.ncbi.nlm.nih.gov/28195358/,"Hill-Burns EM, Debelius JW, Morton JT, Wissemann WT, Lewis MR, Wallen ZD, Peddada SD, Factor SA, Molho E, Zabetian CP, Knight R , Payami H",Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,Movement disorders : official journal of the Movement Disorder Society,2017,"Parkinson's disease, confounding, functional pathways, gut microbiome, medications",Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Controls,Parkinson's Disease Patients,Participants diagnosed with Parkinson's disease by a movement disorder specialist according to the modified UK Brain Bank criteria.,130,197,NA,16S,NA,Illumina,"ANCOM,Kruskall-Wallis",0.05,TRUE,NA,NA,"age,diet,geographic area,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:905/2/NA,Study 905,case-control,28195358,10.1002/mds.26942,https://pubmed.ncbi.nlm.nih.gov/28195358/,"Hill-Burns EM, Debelius JW, Morton JT, Wissemann WT, Lewis MR, Wallen ZD, Peddada SD, Factor SA, Molho E, Zabetian CP, Knight R , Payami H",Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome,Movement disorders : official journal of the Movement Disorder Society,2017,"Parkinson's disease, confounding, functional pathways, gut microbiome, medications",Experiment 2,United States of America,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Controls,Parkinson's Disease Patients,Participants diagnosed with Parkinson's disease who were not on catechol-o-methyl-transferase (COMT) inhibitors or anticholinergic drugs (AC).,130,141,NA,16S,NA,Illumina,"ANCOM,Kruskall-Wallis",0.05,TRUE,NA,NA,"age,diet,geographic area,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:906/1/NA,Study 906,laboratory experiment,NA,10.1038/s41598-019-43280-w,https://doi.org/10.1038/s41598-019-43280-w,"Choi In-Soo, La Tae-Min, Lee Hong-Jae, Lee Joong-Bok, Lee Sangwon, Park Seung-Yong, Song Chang-Seon",Characterization of microbial communities in the chicken oviduct and the origin of chicken embryo gut microbiota,Scientific reports,2019,"Metagenomics, Metagenomics",Experiment 1,South Korea,Gallus gallus,Oviduct,UBERON:0000993,Developmental stage,EFO:0000399,Immature hen magnum sample (23 weeks-old),Mature hen magnum sample,Magnum samples of 34 weeks-old laying SPF hens,8,16,NA,16S,23456789,Ion Torrent,ANCOM,0.05,NA,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:907/1/NA,Study 907,case-control,36453905,https://doi.org/10.1128/spectrum.01593-22,https://journals.asm.org/doi/10.1128/spectrum.01593-22,"Han S, Zhuang J, Pan Y, Wu W , Ding K",Different Characteristics in Gut Microbiome between Advanced Adenoma Patients and Colorectal Cancer Patients by Metagenomic Analysis,Microbiology spectrum,2022,"SNP, artificial intelligence, colorectal cancer, gut microbiome, metagenomic sequencing",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,Advanced Adenoma Patients,Colorectal Cancer Patients,Patients with fully  developed Colorectal cancer,26,26,2 Months,WMS,NA,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:908/1/NA,Study 908,case-control,34650681,NA,NA,"Wu R, Ruan XL, Ruan DD, Zhang JH, Wang HL, Zeng QZ, Lu T, Gan YM, Luo JW , Wu JB",Differences in gut microbiota structure in patients with stages 4-5 chronic kidney disease,American journal of translational research,2021,"16S rDNA sequencing, Chronic kidney disease stages 4-5, gut microbiota",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Chronic kidney disease,EFO:0003884,Healthy Controls,Chronic kidney disease,Diagnosed with stage 4-5 Chronic Kidney Disease (CKD) based on established medical criteria and diagnostic assessments conducted by nephrology experts.,40,39,4 weeks,16S,34,MGISEQ-2000,LEfSe,0.05,FALSE,2,NA,NA,NA,decreased,decreased,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:909/1/NA,Study 909,case-control,34884399,https://doi.org/10.3390/jcm10235698,NA,"Zapała B, Stefura T, Wójcik-Pędziwiatr M, Kabut R, Bałajewicz-Nowak M, Milewicz T, Dudek A, Stój A , Rudzińska-Bar M",Differences in the Composition of Gut Microbiota between Patients with Parkinson's Disease and Healthy Controls: A Cohort Study,Journal of clinical medicine,2021,"Parkinson’s disease, gut microbiome, microbiota",Experiment 1,Poland,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Healthy Controls,Parkinson's Disease Patients,Hospitalized Patients diagnosed with Parkinson's disease with well-controlled symptoms.,44,27,3 weeks,16S,34,"Illumina,MGISEQ-2000",LEfSe,0.05,FALSE,2,age,NA,NA,increased,increased,increased,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:910/1/NA,Study 910,laboratory experiment,27912057,https://doi.org/10.1016%2Fj.cell.2016.11.018,NA,"Sampson TR, Debelius JW, Thron T, Janssen S, Shastri GG, Ilhan ZE, Challis C, Schretter CE, Rocha S, Gradinaru V, Chesselet MF, Keshavarzian A, Shannon KM, Krajmalnik-Brown R, Wittung-Stafshede P, Knight R , Mazmanian SK",Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson's Disease,Cell,2016,"Parkinson’s disease, gut-brain axis, microbiome, microglia, mouse model, short chain fatty acids, synuclein",Experiment 1,United States of America,Mus musculus,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Wild-type (WT) mice with fecal microbes from healthy controls (HC),Wild-type (WT) mice with fecal microbes from Parkinson’s disease patients (PD),Germ-free wild-type (WT) mice colonized with fecal microbes from Parkinson’s disease patients (PD),6,6,NA,16S,4,Illumina,ANCOM,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:910/2/NA,Study 910,laboratory experiment,27912057,https://doi.org/10.1016%2Fj.cell.2016.11.018,NA,"Sampson TR, Debelius JW, Thron T, Janssen S, Shastri GG, Ilhan ZE, Challis C, Schretter CE, Rocha S, Gradinaru V, Chesselet MF, Keshavarzian A, Shannon KM, Krajmalnik-Brown R, Wittung-Stafshede P, Knight R , Mazmanian SK",Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson's Disease,Cell,2016,"Parkinson’s disease, gut-brain axis, microbiome, microglia, mouse model, short chain fatty acids, synuclein",Experiment 2,United States of America,Mus musculus,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,ASO mice with fecal microbes from healthy controls (HC),ASO mice with fecal microbes from Parkinson’s disease patients (PD),"Germ-free mice, Thy1-α-synuclein genotype (ASO) colonized with fecal microbes from Parkinson’s disease patients (PD)",6,6,NA,16S,4,Illumina,ANCOM,NA,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:911/1/NA,Study 911,"cross-sectional observational, not case-control",37501202,https://doi.org/10.25625/SFHRIT,NA,"Anzà S, Schneider D, Daniel R, Heistermann M, Sangmaneedet S, Ostner J , Schülke O",The long-term gut bacterial signature of a wild primate is associated with a timing effect of pre- and postnatal maternal glucocorticoid levels,Microbiome,2023,"16S rRNA gene, Bacteria, Development, Dysbiosis, Health, Long-term, Macaques, Prenatal stress, Primates, Programming",Experiment 1,Thailand,Macaca assamensis,Feces,UBERON:0001988,Response to glucocorticoid,GO:0051384,Early pregnancy glucocorticoid(Early-preGC) exposure in 4.7years (mean age),Early pregnancy glucocorticoid (Early-preGC) exposure in 2.3years (mean age -1SD),"Assamese macaques aged 2.3 years (roughly equivalent to infants age class), who were exposed to prenatal, maternal glucocorticoid in early pregnancy/gestation (Early-preGC) during the Rich season(periods of abundant food availability)",16,16,NA,16S,34,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,unchanged,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:911/2/NA,Study 911,"cross-sectional observational, not case-control",37501202,https://doi.org/10.25625/SFHRIT,NA,"Anzà S, Schneider D, Daniel R, Heistermann M, Sangmaneedet S, Ostner J , Schülke O",The long-term gut bacterial signature of a wild primate is associated with a timing effect of pre- and postnatal maternal glucocorticoid levels,Microbiome,2023,"16S rRNA gene, Bacteria, Development, Dysbiosis, Health, Long-term, Macaques, Prenatal stress, Primates, Programming",Experiment 2,Thailand,Macaca assamensis,Feces,UBERON:0001988,Response to glucocorticoid,GO:0051384,Early pregnancy glucocorticoid(Early-preGC)  exposure in 4.7years old(mean age),Early pregnancy glucocorticoid (Early-preGC) exposure in 7.1years old(mean age +1SD),"Assamese macaques aged 7.1years (equivalent to Adult age class), who were exposed to prenatal, maternal glucocorticoid in early pregnancy/gestation (Early-preGC) during the Rich season (periods of abundant food availability).",16,16,NA,16S,34,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,unchanged,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:911/3/NA,Study 911,"cross-sectional observational, not case-control",37501202,https://doi.org/10.25625/SFHRIT,NA,"Anzà S, Schneider D, Daniel R, Heistermann M, Sangmaneedet S, Ostner J , Schülke O",The long-term gut bacterial signature of a wild primate is associated with a timing effect of pre- and postnatal maternal glucocorticoid levels,Microbiome,2023,"16S rRNA gene, Bacteria, Development, Dysbiosis, Health, Long-term, Macaques, Prenatal stress, Primates, Programming",Experiment 3,Thailand,Macaca assamensis,Feces,UBERON:0001988,Response to glucocorticoid,GO:0051384,Late pregnancy glucocorticoid (Late-preGC) exposure in 4.7years old (mean age),Late pregnancy glucocorticoid (Late-preGC) exposure in 2.3years old (mean age -1SD),"Assamese macaques aged 2.3 years (equivalent to infant age class), who were exposed to prenatal, maternal glucocorticoid in late pregnancy/gestation (Late-preGC) during the Rich season (periods of abundant food availability).",16,16,NA,16S,34,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:911/4/NA,Study 911,"cross-sectional observational, not case-control",37501202,https://doi.org/10.25625/SFHRIT,NA,"Anzà S, Schneider D, Daniel R, Heistermann M, Sangmaneedet S, Ostner J , Schülke O",The long-term gut bacterial signature of a wild primate is associated with a timing effect of pre- and postnatal maternal glucocorticoid levels,Microbiome,2023,"16S rRNA gene, Bacteria, Development, Dysbiosis, Health, Long-term, Macaques, Prenatal stress, Primates, Programming",Experiment 4,Thailand,Macaca assamensis,Feces,UBERON:0001988,Response to glucocorticoid,GO:0051384,Late pregnancy glucocorticoid(Late-preGC) exposure in 4.7years old(mean age),Late pregnancy glucocorticoid (Late-preGC) exposure in 7.1years old(mean age +1SD),"Assamese macaques aged 7.1 years (equivalent to Adult age class), who were exposed to prenatal, maternal glucocorticoid in late pregnancy/gestation (Late-preGC) during the Rich season (periods of abundant food availability).",16,16,NA,16S,34,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:911/5/NA,Study 911,"cross-sectional observational, not case-control",37501202,https://doi.org/10.25625/SFHRIT,NA,"Anzà S, Schneider D, Daniel R, Heistermann M, Sangmaneedet S, Ostner J , Schülke O",The long-term gut bacterial signature of a wild primate is associated with a timing effect of pre- and postnatal maternal glucocorticoid levels,Microbiome,2023,"16S rRNA gene, Bacteria, Development, Dysbiosis, Health, Long-term, Macaques, Prenatal stress, Primates, Programming",Experiment 5,Thailand,Macaca assamensis,Feces,UBERON:0001988,Response to glucocorticoid,GO:0051384,Post-pregnancy glucocorticoid(PostGC) exposure in 4.7years old(mean age),Post-pregnancy glucocorticoid (PostGC) exposure in 2.3years old(mean age -1SD),"Assamese macaques aged 2.3 years (equivalent to infant age class), who were exposed to postnatal, maternal glucocorticoid in post pregnancy/lactation (PostGC) for the first 6 months of life during the Rich season (periods of abundant food availability)",16,16,NA,16S,34,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:911/6/NA,Study 911,"cross-sectional observational, not case-control",37501202,https://doi.org/10.25625/SFHRIT,NA,"Anzà S, Schneider D, Daniel R, Heistermann M, Sangmaneedet S, Ostner J , Schülke O",The long-term gut bacterial signature of a wild primate is associated with a timing effect of pre- and postnatal maternal glucocorticoid levels,Microbiome,2023,"16S rRNA gene, Bacteria, Development, Dysbiosis, Health, Long-term, Macaques, Prenatal stress, Primates, Programming",Experiment 6,Thailand,Macaca assamensis,Feces,UBERON:0001988,Response to glucocorticoid,GO:0051384,Post-pregnancy glucocorticoid(PostGC) exposure in 4.7years old(mean age),Post-pregnancy glucocorticoid (PostGC) exposure in 7.1years old(mean age +1SD),"Assamese macaques aged 7.1 years (equivalent toAdult age class), who were exposed to postnatal, maternal glucocorticoid in post pregnancy/lactation (PostGC) for the first 6 months of life during the Rich season (periods of abundant food availability)",16,16,NA,16S,34,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:911/7/NA,Study 911,"cross-sectional observational, not case-control",37501202,https://doi.org/10.25625/SFHRIT,NA,"Anzà S, Schneider D, Daniel R, Heistermann M, Sangmaneedet S, Ostner J , Schülke O",The long-term gut bacterial signature of a wild primate is associated with a timing effect of pre- and postnatal maternal glucocorticoid levels,Microbiome,2023,"16S rRNA gene, Bacteria, Development, Dysbiosis, Health, Long-term, Macaques, Prenatal stress, Primates, Programming",Experiment 7,Thailand,Macaca assamensis,Feces,UBERON:0001988,Response to glucocorticoid,GO:0051384,Offspring glucocorticoid (OffspringGC) in 4.7 years old (mean age),Offspring glucocorticoid (OffspringGC) in 2.3 years old (mean age -1SD),"Assamese macaques aged 2.3 years (equivalent to infant age class), who were affected by increased Offspring Glucocorticoid level (OffspringGC) during the Rich season (periods of abundant food availability)",16,16,NA,16S,34,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:911/8/NA,Study 911,"cross-sectional observational, not case-control",37501202,https://doi.org/10.25625/SFHRIT,NA,"Anzà S, Schneider D, Daniel R, Heistermann M, Sangmaneedet S, Ostner J , Schülke O",The long-term gut bacterial signature of a wild primate is associated with a timing effect of pre- and postnatal maternal glucocorticoid levels,Microbiome,2023,"16S rRNA gene, Bacteria, Development, Dysbiosis, Health, Long-term, Macaques, Prenatal stress, Primates, Programming",Experiment 8,Thailand,Macaca assamensis,Feces,UBERON:0001988,Response to glucocorticoid,GO:0051384,Offspring glucocorticoid (OffspringGC) in 4.7 years old (mean age),Offspring glucocorticoid (OffspringGC) in 7.1 years old (mean age +1SD),"Assamese macaques aged 7.1 years (equivalent to Adult age class), who were affected by increased Offspring Glucocorticoid level (OffspringGC) during the Rich season (periods of abundant food availability).",16,16,NA,16S,34,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:911/9/NA,Study 911,"cross-sectional observational, not case-control",37501202,https://doi.org/10.25625/SFHRIT,NA,"Anzà S, Schneider D, Daniel R, Heistermann M, Sangmaneedet S, Ostner J , Schülke O",The long-term gut bacterial signature of a wild primate is associated with a timing effect of pre- and postnatal maternal glucocorticoid levels,Microbiome,2023,"16S rRNA gene, Bacteria, Development, Dysbiosis, Health, Long-term, Macaques, Prenatal stress, Primates, Programming",Experiment 9,Thailand,Macaca assamensis,Feces,UBERON:0001988,Gut microbiome measurement,EFO:0007874,Infant macaques,Adult macaques,Assamese macaques aged 6–10 years,16,7,NA,16S,34,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,unchanged,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:911/10/NA,Study 911,"cross-sectional observational, not case-control",37501202,https://doi.org/10.25625/SFHRIT,NA,"Anzà S, Schneider D, Daniel R, Heistermann M, Sangmaneedet S, Ostner J , Schülke O",The long-term gut bacterial signature of a wild primate is associated with a timing effect of pre- and postnatal maternal glucocorticoid levels,Microbiome,2023,"16S rRNA gene, Bacteria, Development, Dysbiosis, Health, Long-term, Macaques, Prenatal stress, Primates, Programming",Experiment 10,Thailand,Macaca assamensis,Feces,UBERON:0001988,Gut microbiome measurement,EFO:0007874,Infant macaques,Juvenile macaques,Assamese macaques aged 4–5 years,16,7,NA,16S,34,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,unchanged,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:911/11/NA,Study 911,"cross-sectional observational, not case-control",37501202,https://doi.org/10.25625/SFHRIT,NA,"Anzà S, Schneider D, Daniel R, Heistermann M, Sangmaneedet S, Ostner J , Schülke O",The long-term gut bacterial signature of a wild primate is associated with a timing effect of pre- and postnatal maternal glucocorticoid levels,Microbiome,2023,"16S rRNA gene, Bacteria, Development, Dysbiosis, Health, Long-term, Macaques, Prenatal stress, Primates, Programming",Experiment 11,Thailand,Macaca assamensis,Feces,UBERON:0001988,Gut microbiome measurement,EFO:0007874,Lean season,Rich season,"The hot and rainy season in the Assamese macaques' habitat, usually occurring between March to October and marked by abundant food availability",30,16,NA,16S,34,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,decreased,NA,NA,unchanged,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:911/12/NA,Study 911,"cross-sectional observational, not case-control",37501202,https://doi.org/10.25625/SFHRIT,NA,"Anzà S, Schneider D, Daniel R, Heistermann M, Sangmaneedet S, Ostner J , Schülke O",The long-term gut bacterial signature of a wild primate is associated with a timing effect of pre- and postnatal maternal glucocorticoid levels,Microbiome,2023,"16S rRNA gene, Bacteria, Development, Dysbiosis, Health, Long-term, Macaques, Prenatal stress, Primates, Programming",Experiment 12,Thailand,Macaca assamensis,Feces,UBERON:0001988,Gut microbiome measurement,EFO:0007874,MOT,MST,Second grouping of Assamese macaques by research team.,NA,NA,NA,16S,34,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,decreased,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:911/13/NA,Study 911,"cross-sectional observational, not case-control",37501202,https://doi.org/10.25625/SFHRIT,NA,"Anzà S, Schneider D, Daniel R, Heistermann M, Sangmaneedet S, Ostner J , Schülke O",The long-term gut bacterial signature of a wild primate is associated with a timing effect of pre- and postnatal maternal glucocorticoid levels,Microbiome,2023,"16S rRNA gene, Bacteria, Development, Dysbiosis, Health, Long-term, Macaques, Prenatal stress, Primates, Programming",Experiment 13,Thailand,Macaca assamensis,Feces,UBERON:0001988,Gut microbiome measurement,EFO:0007874,MOT,SST,Third grouping of Assamese macaques by the research team,NA,NA,NA,16S,34,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,decreased,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:913/1/NA,Study 913,prospective cohort,NA,https://doi.org/10.1186/s12866-023-03042-1,NA,"Ju Zhang, Xiuhai Lu, Zhiwei Cheng, Dulei Zou",Alterations of conjunctival microbiota associated with orthokeratology lens wearing in myopic children,BMC microbiology,2023,"Orthokeratology lenses, Conjunctiva sac, Microbiome, Microbiome, Brevundimonas, Acinetobacter, Proteus, genomics, 16s rdna gene sequencing",Experiment 1,China,Homo sapiens,Conjunctival sac,UBERON:0005908,Myopia,HP:0000545,N group -  Non-wearer group,L group -  Ok Lens group,Myopic patients who had been wearing OK lenses for 12–13 months,22,28,6 months,16S,34,Illumina,LEfSe,0.05,TRUE,3,"age,sex",NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:914/1/NA,Study 914,case-control,30800106,https://doi.org/10.3389/fmicb.2019.00164,NA,"Bodkhe R, Shetty SA, Dhotre DP, Verma AK, Bhatia K, Mishra A, Kaur G, Pande P, Bangarusamy DK, Santosh BP, Perumal RC, Ahuja V, Shouche YS , Makharia GK",Comparison of Small Gut and Whole Gut Microbiota of First-Degree Relatives With Adult Celiac Disease Patients and Controls,Frontiers in microbiology,2019,"H. pylori, butyrate, celiac, duodenal microbiota, gluten, gut microbiota",Experiment 1,India,Homo sapiens,Duodenum,UBERON:0002114,Celiac disease,EFO:0001060,Disease Control (DC),First-degree relatives (FDRs) of celiac disease (CeD) patients,First-degree relatives (FDRs) of celiac disease (CeD) patients genetically susceptible to celiac disease (CeD),14,13,None,16S,4,Illumina,DESeq2,0.01,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:914/2/NA,Study 914,case-control,30800106,https://doi.org/10.3389/fmicb.2019.00164,NA,"Bodkhe R, Shetty SA, Dhotre DP, Verma AK, Bhatia K, Mishra A, Kaur G, Pande P, Bangarusamy DK, Santosh BP, Perumal RC, Ahuja V, Shouche YS , Makharia GK",Comparison of Small Gut and Whole Gut Microbiota of First-Degree Relatives With Adult Celiac Disease Patients and Controls,Frontiers in microbiology,2019,"H. pylori, butyrate, celiac, duodenal microbiota, gluten, gut microbiota",Experiment 2,India,Homo sapiens,Duodenum,UBERON:0002114,Celiac disease,EFO:0001060,First-degree relatives (FDRs) of celiac disease (CeD) patients,Celiac disease (CeD),Patients with celiac disease (CeD),13,16,None,16S,4,Illumina,DESeq2,0.01,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:914/3/NA,Study 914,case-control,30800106,https://doi.org/10.3389/fmicb.2019.00164,NA,"Bodkhe R, Shetty SA, Dhotre DP, Verma AK, Bhatia K, Mishra A, Kaur G, Pande P, Bangarusamy DK, Santosh BP, Perumal RC, Ahuja V, Shouche YS , Makharia GK",Comparison of Small Gut and Whole Gut Microbiota of First-Degree Relatives With Adult Celiac Disease Patients and Controls,Frontiers in microbiology,2019,"H. pylori, butyrate, celiac, duodenal microbiota, gluten, gut microbiota",Experiment 3,India,Homo sapiens,Duodenum,UBERON:0002114,Celiac disease,EFO:0001060,Disease Control (DC),Celiac disease (CeD),Patients with celiac disease (CeD),14,16,None,16S,4,Illumina,DESeq2,0.01,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:914/4/NA,Study 914,case-control,30800106,https://doi.org/10.3389/fmicb.2019.00164,NA,"Bodkhe R, Shetty SA, Dhotre DP, Verma AK, Bhatia K, Mishra A, Kaur G, Pande P, Bangarusamy DK, Santosh BP, Perumal RC, Ahuja V, Shouche YS , Makharia GK",Comparison of Small Gut and Whole Gut Microbiota of First-Degree Relatives With Adult Celiac Disease Patients and Controls,Frontiers in microbiology,2019,"H. pylori, butyrate, celiac, duodenal microbiota, gluten, gut microbiota",Experiment 4,India,Homo sapiens,Feces,UBERON:0001988,Celiac disease,EFO:0001060,Disease Control (DC),First-degree relatives (FDRs) of celiac disease (CeD) patients,Fecal samples of first-degree relatives (FDRs) of celiac disease (CeD) patients genetically susceptible to celiac disease (CeD),23,15,None,16S,4,Illumina,DESeq2,0.01,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:914/5/NA,Study 914,case-control,30800106,https://doi.org/10.3389/fmicb.2019.00164,NA,"Bodkhe R, Shetty SA, Dhotre DP, Verma AK, Bhatia K, Mishra A, Kaur G, Pande P, Bangarusamy DK, Santosh BP, Perumal RC, Ahuja V, Shouche YS , Makharia GK",Comparison of Small Gut and Whole Gut Microbiota of First-Degree Relatives With Adult Celiac Disease Patients and Controls,Frontiers in microbiology,2019,"H. pylori, butyrate, celiac, duodenal microbiota, gluten, gut microbiota",Experiment 5,India,Homo sapiens,Feces,UBERON:0001988,Celiac disease,EFO:0001060,Disease Control (DC),First-degree relatives (FDRs) of celiac disease (CeD) patients,First-degree relatives (FDRs) of celiac disease (CeD) patients genetically susceptible to celiac disease (CeD),23,15,None,16S,4,Illumina,DESeq2,0.01,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:914/6/NA,Study 914,case-control,30800106,https://doi.org/10.3389/fmicb.2019.00164,NA,"Bodkhe R, Shetty SA, Dhotre DP, Verma AK, Bhatia K, Mishra A, Kaur G, Pande P, Bangarusamy DK, Santosh BP, Perumal RC, Ahuja V, Shouche YS , Makharia GK",Comparison of Small Gut and Whole Gut Microbiota of First-Degree Relatives With Adult Celiac Disease Patients and Controls,Frontiers in microbiology,2019,"H. pylori, butyrate, celiac, duodenal microbiota, gluten, gut microbiota",Experiment 6,India,Homo sapiens,Feces,UBERON:0001988,Celiac disease,EFO:0001060,First-degree relatives (FDRs) of celiac disease (CeD) patients,Celiac disease (CeD),Patients with celiac disease (CeD),15,21,None,16S,4,Illumina,DESeq2,0.01,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:915/1/NA,Study 915,case-control,34707191,10.1038/s12276-021-00686-9,NA,"Hou MF, Ou-Yang F, Li CL, Chen FM, Chuang CH, Kan JY, Wu CC, Shih SL, Shiau JP, Kao LC, Kao CN, Lee YC, Moi SH, Yeh YT, Cheng CJ , Chiang CP",Comprehensive profiles and diagnostic value of menopausal-specific gut microbiota in premenopausal breast cancer,Experimental & molecular medicine,2021,NA,Experiment 1,Taiwan,Homo sapiens,Feces,UBERON:0001988,Breast carcinoma,EFO:0000305,Premenopausal female controls (Pre-C),premenopausal breast cancer patients (Pre-BC),Premenopausal breast cancer patients diagnosed with stage I–II disease by pathological examination.,50,100,4 weeks,16S,34,Illumina,LEfSe,0.05,FALSE,2,age,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:915/2/NA,Study 915,case-control,34707191,10.1038/s12276-021-00686-9,NA,"Hou MF, Ou-Yang F, Li CL, Chen FM, Chuang CH, Kan JY, Wu CC, Shih SL, Shiau JP, Kao LC, Kao CN, Lee YC, Moi SH, Yeh YT, Cheng CJ , Chiang CP",Comprehensive profiles and diagnostic value of menopausal-specific gut microbiota in premenopausal breast cancer,Experimental & molecular medicine,2021,NA,Experiment 2,Taiwan,Homo sapiens,Feces,UBERON:0001988,Breast carcinoma,EFO:0000305,Postmenopausal female controls (Post-C),Postmenopausal breast cancer patients (Post-BC),Postmenopausal breast cancer patients diagnosed with stage I–II disease by pathological examination.,17,100,4 weeks,16S,34,Illumina,LEfSe,0.05,FALSE,2,age,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:915/3/NA,Study 915,case-control,34707191,10.1038/s12276-021-00686-9,NA,"Hou MF, Ou-Yang F, Li CL, Chen FM, Chuang CH, Kan JY, Wu CC, Shih SL, Shiau JP, Kao LC, Kao CN, Lee YC, Moi SH, Yeh YT, Cheng CJ , Chiang CP",Comprehensive profiles and diagnostic value of menopausal-specific gut microbiota in premenopausal breast cancer,Experimental & molecular medicine,2021,NA,Experiment 3,Taiwan,Homo sapiens,Feces,UBERON:0001988,Menopause,EFO:0003922,Premenopausal female controls (Pre-C),Postmenopausal female controls (Post-C),Postmenopausal female controls (Post-C) participants,50,17,4 weeks,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:915/4/NA,Study 915,case-control,34707191,10.1038/s12276-021-00686-9,NA,"Hou MF, Ou-Yang F, Li CL, Chen FM, Chuang CH, Kan JY, Wu CC, Shih SL, Shiau JP, Kao LC, Kao CN, Lee YC, Moi SH, Yeh YT, Cheng CJ , Chiang CP",Comprehensive profiles and diagnostic value of menopausal-specific gut microbiota in premenopausal breast cancer,Experimental & molecular medicine,2021,NA,Experiment 4,Taiwan,Homo sapiens,Feces,UBERON:0001988,Menopause,EFO:0003922,Premenopausal breast cancer patients (Pre-BC),Postmenopausal breast cancer patients (Post-BC),Postmenopausal breast cancer patients diagnosed with stage I–II disease by pathological examination.,100,100,4 weeks,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:916/1/NA,Study 916,case-control,35250962,10.3389/fmicb.2022.851670,NA,"Kim MJ, Lee S, Kwon MY , Kim M",Clinical Significance of Composition and Functional Diversity of the Vaginal Microbiome in Recurrent Vaginitis,Frontiers in microbiology,2022,"Lactobacillus spp., microbiome, recurrent vaginitis, taxonomy, vagina",Experiment 1,South Korea,Homo sapiens,Posterior fornix of vagina,UBERON:0016486,Vaginitis,MONDO:0002234,Healthy women (control),Recurrent vaginitis (RV),Women of reproductive age diagnosed with Recurrent vaginitis (RV).,100,40,3 months,16S,34,Illumina,Kruskall-Wallis,0.05,FALSE,NA,NA,NA,NA,increased,decreased,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:916/2/NA,Study 916,case-control,35250962,10.3389/fmicb.2022.851670,NA,"Kim MJ, Lee S, Kwon MY , Kim M",Clinical Significance of Composition and Functional Diversity of the Vaginal Microbiome in Recurrent Vaginitis,Frontiers in microbiology,2022,"Lactobacillus spp., microbiome, recurrent vaginitis, taxonomy, vagina",Experiment 2,South Korea,Homo sapiens,Posterior fornix of vagina,UBERON:0016486,Vaginal microbiome measurement,EFO:0011013,Community state type (CST) I,Community state type (CST) III and IV,Women of reproductive age diagnosed with Recurrent vaginitis (RV) categorized as community state type (CST) III and IV,5,29,3 months,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:916/3/NA,Study 916,case-control,35250962,10.3389/fmicb.2022.851670,NA,"Kim MJ, Lee S, Kwon MY , Kim M",Clinical Significance of Composition and Functional Diversity of the Vaginal Microbiome in Recurrent Vaginitis,Frontiers in microbiology,2022,"Lactobacillus spp., microbiome, recurrent vaginitis, taxonomy, vagina",Experiment 3,South Korea,Homo sapiens,Posterior fornix of vagina,UBERON:0016486,Vaginal microbiome measurement,EFO:0011013,Community state type (CST) I and IV,Community state type (CST) III,Women of reproductive age diagnosed with Recurrent vaginitis (RV) categorized as community state type (CST) III,26,8,3 months,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:916/4/NA,Study 916,case-control,35250962,10.3389/fmicb.2022.851670,NA,"Kim MJ, Lee S, Kwon MY , Kim M",Clinical Significance of Composition and Functional Diversity of the Vaginal Microbiome in Recurrent Vaginitis,Frontiers in microbiology,2022,"Lactobacillus spp., microbiome, recurrent vaginitis, taxonomy, vagina",Experiment 4,South Korea,Homo sapiens,Posterior fornix of vagina,UBERON:0016486,Vaginal microbiome measurement,EFO:0011013,Community state type (CST) I and III,Community state type (CST) IV,Women of reproductive age diagnosed with Recurrent vaginitis (RV) categorized as community state type (CST) III and IV,13,21,3 months,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:917/1/NA,Study 917,time series / longitudinal observational,38310301,10.1186/s40168-023-01718-4,NA,"Burkhart Colorado AS, Lazzaro A, Neff CP, Nusbacher N, Boyd K, Fiorillo S, Martin C, Siebert JC, Campbell TB, Borok M, Palmer BE , Lozupone C",Differential effects of antiretroviral treatment on immunity and gut microbiome composition in people living with HIV in rural versus urban Zimbabwe,Microbiome,2024,"ART response, HIV, Immune activation and exhaustion, Inflammation, Intestinal microbiome, Rural, Urban",Experiment 1,Zimbabwe,Homo sapiens,Feces,UBERON:0001988,Gut microbiome measurement,EFO:0007874,Healthy controls (HC),Antiretroviral therapy (ART) Naïve at baseline,PLWH (people living with HIV) who were not on ART at the first timepoint but who subsequently commenced first-line ART with efavirenz/lamivudine/tenofovir disoproxil fumarate (EFV/3TC/TDF) and the prophylactic antibiotic cotrimoxazole (ART Naïve) - Baseline,42,67,Use of antibiotics (apart from co-trimoxazole) within 2 months,16S,4,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:917/2/NA,Study 917,time series / longitudinal observational,38310301,10.1186/s40168-023-01718-4,NA,"Burkhart Colorado AS, Lazzaro A, Neff CP, Nusbacher N, Boyd K, Fiorillo S, Martin C, Siebert JC, Campbell TB, Borok M, Palmer BE , Lozupone C",Differential effects of antiretroviral treatment on immunity and gut microbiome composition in people living with HIV in rural versus urban Zimbabwe,Microbiome,2024,"ART response, HIV, Immune activation and exhaustion, Inflammation, Intestinal microbiome, Rural, Urban",Experiment 2,Zimbabwe,Homo sapiens,Feces,UBERON:0001988,Clinical treatment,EFO:0007056,Healthy controls (HC),Antiretroviral therapy (ART) naïve at baseline and after 24 weeks of first-line ART,PLWH (people living with HIV) who were not on antiretroviral therapy (ART) at the first timepoint but who subsequently commenced first-line ART with efavirenz/lamivudine/tenofovir disoproxil fumarate (EFV/3TC/TDF) and the prophylactic antibiotic cotrimoxazole (ART Naïve) - two time points.,42,52,Use of antibiotics (apart from co-trimoxazole) within 2 months,16S,4,Illumina,ANCOM,0.05,TRUE,NA,NA,time,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:917/3/NA,Study 917,time series / longitudinal observational,38310301,10.1186/s40168-023-01718-4,NA,"Burkhart Colorado AS, Lazzaro A, Neff CP, Nusbacher N, Boyd K, Fiorillo S, Martin C, Siebert JC, Campbell TB, Borok M, Palmer BE , Lozupone C",Differential effects of antiretroviral treatment on immunity and gut microbiome composition in people living with HIV in rural versus urban Zimbabwe,Microbiome,2024,"ART response, HIV, Immune activation and exhaustion, Inflammation, Intestinal microbiome, Rural, Urban",Experiment 3,Zimbabwe,Homo sapiens,Feces,UBERON:0001988,Clinical treatment,EFO:0007056,Healthy controls (HC),Antiretroviral therapy (ART) experienced at baseline,PLWH (people living with HIV) who were on  ART regimen and cotrimoxazole at baseline,42,33,Use of antibiotics (apart from co-trimoxazole) within 2 months,16S,4,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:917/4/NA,Study 917,time series / longitudinal observational,38310301,10.1186/s40168-023-01718-4,NA,"Burkhart Colorado AS, Lazzaro A, Neff CP, Nusbacher N, Boyd K, Fiorillo S, Martin C, Siebert JC, Campbell TB, Borok M, Palmer BE , Lozupone C",Differential effects of antiretroviral treatment on immunity and gut microbiome composition in people living with HIV in rural versus urban Zimbabwe,Microbiome,2024,"ART response, HIV, Immune activation and exhaustion, Inflammation, Intestinal microbiome, Rural, Urban",Experiment 4,Zimbabwe,Homo sapiens,Feces,UBERON:0001988,Clinical treatment,EFO:0007056,Healthy controls (HC),Antiretroviral therapy (ART) experienced at baseline and after 24 weeks,PLWH (people living with HIV) who were on ART regimen and cotrimoxazole at both time points,42,NA,Use of antibiotics (apart from co-trimoxazole) within 2 months,16S,4,Illumina,ANCOM,0.05,TRUE,NA,NA,time,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:918/1/NA,Study 918,"case-control,time series / longitudinal observational",33985520,10.1186/s12934-021-01589-0,NA,"Kuai XY, Yao XH, Xu LJ, Zhou YQ, Zhang LP, Liu Y, Pei SF , Zhou CL",Evaluation of fecal microbiota transplantation in Parkinson's disease patients with constipation,Microbial cell factories,2021,"16s rDNA sequencing, Constipation, FMT, Gut microbiota, Parkinson’s disease",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,"Constipation,Parkinson's disease","HP:0002019,MONDO:0005180",Healthy Control group,Parkinson's disease patients (PD) before Fecal microbiota transplant (FMT),Parkinson's disease patients with constipation before FMT,13,11,None,16S,NA,NA,LEfSe,0.05,NA,2,NA,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:918/2/NA,Study 918,"case-control,time series / longitudinal observational",33985520,10.1186/s12934-021-01589-0,NA,"Kuai XY, Yao XH, Xu LJ, Zhou YQ, Zhang LP, Liu Y, Pei SF , Zhou CL",Evaluation of fecal microbiota transplantation in Parkinson's disease patients with constipation,Microbial cell factories,2021,"16s rDNA sequencing, Constipation, FMT, Gut microbiota, Parkinson’s disease",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Response to transplant,EFO:0007043,Parkinson's disease patients before fecal microbiota transplant (FMT),Parkinson's disease patients after fecal microbiota transplant (FMT),Parkinson's disease patients 12 weeks after FMT,11,11,None,16S,NA,NA,LEfSe,0.05,NA,2,NA,NA,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:918/3/NA,Study 918,"case-control,time series / longitudinal observational",33985520,10.1186/s12934-021-01589-0,NA,"Kuai XY, Yao XH, Xu LJ, Zhou YQ, Zhang LP, Liu Y, Pei SF , Zhou CL",Evaluation of fecal microbiota transplantation in Parkinson's disease patients with constipation,Microbial cell factories,2021,"16s rDNA sequencing, Constipation, FMT, Gut microbiota, Parkinson’s disease",Experiment 3,China,Homo sapiens,Feces,UBERON:0001988,Response to transplant,EFO:0007043,Parkinson's disease patients before fecal microbiota transplant (FMT),Parkinson's disease patients after fecal microbiota transplant (FMT),Parkinson's disease patients 12 weeks after FMT,11,11,None,16S,NA,NA,T-Test,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:918/4/NA,Study 918,"case-control,time series / longitudinal observational",33985520,10.1186/s12934-021-01589-0,NA,"Kuai XY, Yao XH, Xu LJ, Zhou YQ, Zhang LP, Liu Y, Pei SF , Zhou CL",Evaluation of fecal microbiota transplantation in Parkinson's disease patients with constipation,Microbial cell factories,2021,"16s rDNA sequencing, Constipation, FMT, Gut microbiota, Parkinson’s disease",Experiment 4,China,Homo sapiens,Feces,UBERON:0001988,Response to transplant,EFO:0007043,Parkinson's disease patients before fecal microbiota transplant (FMT),Parkinson's disease patients after fecal microbiota transplant (FMT),Parkinson's disease patients 8 weeks after FMT,11,11,None,16S,NA,NA,T-Test,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:918/5/NA,Study 918,"case-control,time series / longitudinal observational",33985520,10.1186/s12934-021-01589-0,NA,"Kuai XY, Yao XH, Xu LJ, Zhou YQ, Zhang LP, Liu Y, Pei SF , Zhou CL",Evaluation of fecal microbiota transplantation in Parkinson's disease patients with constipation,Microbial cell factories,2021,"16s rDNA sequencing, Constipation, FMT, Gut microbiota, Parkinson’s disease",Experiment 5,China,Homo sapiens,Feces,UBERON:0001988,Response to transplant,EFO:0007043,Parkinson's disease patients before fecal microbiota transplant (FMT),Parkinson's disease patients after fecal microbiota transplant (FMT),Parkinson's disease patients 4 weeks after FMT,11,11,None,16S,NA,NA,T-Test,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:920/1/NA,Study 920,randomized controlled trial,38291301,10.1038/s41591-023-02761-2,https://pubmed.ncbi.nlm.nih.gov/38291301/,"Link VM, Subramanian P, Cheung F, Han KL, Stacy A, Chi L, Sellers BA, Koroleva G, Courville AB, Mistry S, Burns A, Apps R, Hall KD , Belkaid Y",Differential peripheral immune signatures elicited by vegan versus ketogenic diets in humans,Nature medicine,2024,NA,Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,Participants on vegan diet,Participants on ketogenic diet,"To determine the impact of dietary intervention on human immunity and microbiota, this group of participants were placed on a ketogenic diet, and would later be switched to a vegan diet.",10,10,NA,WMS,NA,Illumina,MaAsLin2,0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:921/1/NA,Study 921,meta-analysis,37686135,10.3390/ijms241713329,NA,"Park S, Li C, Wu X , Zhang T",Gut Microbiota Alterations and Their Functional Differences in Depression According to Enterotypes in Asian Individuals,International journal of molecular sciences,2023,"enterotype, glucose metabolism, gut microbiota, gut–brain axis, network analysis",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Depressive disorder,MONDO:0002050,Healthy group,Depressive group,patients with depressive disorder in the high bacteroidaceae enterotype (ET-B). Enterotypes were identified through PCA using gut microbiota from the collected fecal FASTA/Q files.,45,84,None,16S,NA,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:921/2/NA,Study 921,meta-analysis,37686135,10.3390/ijms241713329,NA,"Park S, Li C, Wu X , Zhang T",Gut Microbiota Alterations and Their Functional Differences in Depression According to Enterotypes in Asian Individuals,International journal of molecular sciences,2023,"enterotype, glucose metabolism, gut microbiota, gut–brain axis, network analysis",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Depressive disorder,MONDO:0002050,Healthy group,Depressive group,patients with depression in the high lachnospiraceae enterotype (ET-L). Enterotypes were identified through PCA using gut microbiota from the collected fecal FASTA/Q files.,47,127,None,16S,NA,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:921/3/NA,Study 921,meta-analysis,37686135,10.3390/ijms241713329,NA,"Park S, Li C, Wu X , Zhang T",Gut Microbiota Alterations and Their Functional Differences in Depression According to Enterotypes in Asian Individuals,International journal of molecular sciences,2023,"enterotype, glucose metabolism, gut microbiota, gut–brain axis, network analysis",Experiment 3,China,Homo sapiens,Feces,UBERON:0001988,Depressive disorder,MONDO:0002050,Healthy group,Depressive group,patients with depressive disorder in the high prevotellaceae enterotype (ET-P). Enterotypes were identified through PCA using gut microbiota from the collected fecal FASTA/Q files.,15,15,None,16S,34,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:922/1/NA,Study 922,case-control,31561385,https://doi.org/10.3233%2FJPD-191693,NA,"Vidal-Martinez G, Chin B, Camarillo C, Herrera GV, Yang B, Sarosiek I , Perez RG","A Pilot Microbiota Study in Parkinson's Disease Patients versus Control Subjects, and Effects of FTY720 and FTY720-Mitoxy Therapies in Parkinsonian and Multiple System Atrophy Mouse Models",Journal of Parkinson's disease,2020,"FTY720, FTY720-Mitoxy, Microbiota, Parkinson’s disease, multiple system atrophy, transgenic mouse models",Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Healthy controls,Parkinson’s disease,Patients diagnosed with Parkinson’s disease (confirmed by a neurologist) between 35 and 95 years of age.,13,9,Participants who used antibiotics within 2 weeks prior to the initiation of the study.,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:922/2/NA,Study 922,case-control,31561385,https://doi.org/10.3233%2FJPD-191693,NA,"Vidal-Martinez G, Chin B, Camarillo C, Herrera GV, Yang B, Sarosiek I , Perez RG","A Pilot Microbiota Study in Parkinson's Disease Patients versus Control Subjects, and Effects of FTY720 and FTY720-Mitoxy Therapies in Parkinsonian and Multiple System Atrophy Mouse Models",Journal of Parkinson's disease,2020,"FTY720, FTY720-Mitoxy, Microbiota, Parkinson’s disease, multiple system atrophy, transgenic mouse models",Experiment 2,United States of America,Mus musculus,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Wild Type mice,Parkinsonian mice,10-month old transgenic (Tg) parkinsonian mice that expresses A53T mutant human alpha-synuclein (a-Syn) in neurons,2,5,None,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,age,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:923/1/NA,Study 923,laboratory experiment,37529095,10.55730/1300-0152.2617,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10388120/,"Fan T, Li X, Zhang X, Zhang J, Sun L, Chen J , Fu C",Influence of aerobic exercise training on mice gut microbiota in Parkinson's disease,Turkish journal of biology = Turk biyoloji dergisi,2022,"16S rRNA gene sequencing, Parkinson’s disease, aerobic exercise training, gut microbiota",Experiment 1,China,Mus musculus,Feces,UBERON:0001988,Response to exercise,EFO:0007768,Sham group and parkison's disease (PD) group,Aerobic exercise training group (AET),"Mice group that received grasping, rotating, walking and balance training exercises once a day, 6 days a week, 30 min each time, a total of 4 weeks.",10,5,NA,16S,34,Illumina,LEfSe,0.05,FALSE,4,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:923/2/NA,Study 923,laboratory experiment,37529095,10.55730/1300-0152.2617,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10388120/,"Fan T, Li X, Zhang X, Zhang J, Sun L, Chen J , Fu C",Influence of aerobic exercise training on mice gut microbiota in Parkinson's disease,Turkish journal of biology = Turk biyoloji dergisi,2022,"16S rRNA gene sequencing, Parkinson’s disease, aerobic exercise training, gut microbiota",Experiment 2,China,Mus musculus,Feces,UBERON:0001988,Response to exercise,EFO:0007768,Sham group and Aerobic exercise training group (AET) group,parkison's disease (PD) group,"Mice group that were administered intraperitoneally with 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) at 30 mg/kg for 7 days to construct PD mouse models.",10,5,NA,16S,34,Illumina,LEfSe,0.05,FALSE,4,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:923/3/NA,Study 923,laboratory experiment,37529095,10.55730/1300-0152.2617,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10388120/,"Fan T, Li X, Zhang X, Zhang J, Sun L, Chen J , Fu C",Influence of aerobic exercise training on mice gut microbiota in Parkinson's disease,Turkish journal of biology = Turk biyoloji dergisi,2022,"16S rRNA gene sequencing, Parkinson’s disease, aerobic exercise training, gut microbiota",Experiment 3,China,Mus musculus,Feces,UBERON:0001988,Response to exercise,EFO:0007768,Aerobic exercise training group (AET) and parkison's disease (PD) group,Sham group,group of mice that were injected intraperitoneally with equivalent volumes of normal saline for 7 days and did not receive any training,10,5,NA,16S,34,Illumina,LEfSe,0.05,FALSE,4,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:924/1/NA,Study 924,case-control,31174953,10.1016/j.parkreldis.2019.06.003,NA,"Pietrucci D, Cerroni R, Unida V, Farcomeni A, Pierantozzi M, Mercuri NB, Biocca S, Stefani A , Desideri A",Dysbiosis of gut microbiota in a selected population of Parkinson's patients,Parkinsonism & related disorders,2019,"16S rRNA, Dysbiosis, Functional pathways, Gut microbiota, Parkinson's disease, Predictors",Experiment 1,Italy,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Healthy controls (HC),Parkinson's disease (PD),"Patients with severe and active Parkinson disease.
Recruited patients had a diagnosis of idiopathic PD according to the UK Parkinson's Disease Society Brain Bank criteria with a disease duration (measured as the time following the first diagnosis) longer than 6 months",72,80,4 weeks,16S,34,Illumina,"Linear Regression,Mann-Whitney (Wilcoxon)",0.05,TRUE,NA,NA,"age,sex",NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:924/2/NA,Study 924,case-control,31174953,10.1016/j.parkreldis.2019.06.003,NA,"Pietrucci D, Cerroni R, Unida V, Farcomeni A, Pierantozzi M, Mercuri NB, Biocca S, Stefani A , Desideri A",Dysbiosis of gut microbiota in a selected population of Parkinson's patients,Parkinsonism & related disorders,2019,"16S rRNA, Dysbiosis, Functional pathways, Gut microbiota, Parkinson's disease, Predictors",Experiment 2,Italy,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Healthy controls (HC),Parkinson's disease (excluding iCOMT users),Patients with Parkinson's disease (PD) excluding eight patients taking catechol-O-methyl transferase (COMT) inhibitors,72,72,4 weeks,16S,34,Illumina,"Linear Regression,Mann-Whitney (Wilcoxon)",0.05,TRUE,NA,NA,"age,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:925/1/NA,Study 925,laboratory experiment,35076270,https://doi.org/10.1128/msystems.01191-21,NA,"van Kessel SP, Bullock A, van Dijk G , El Aidy S",Parkinson's Disease Medication Alters Small Intestinal Motility and Microbiota Composition in Healthy Rats,mSystems,2022,"Parkinson’s disease treatment, dopamine, drug side effects, gut motility, levodopa, microbiota, pramipexole, ropinirole, small intestinal bacterial overgrowth",Experiment 1,Netherlands,Rattus norvegicus,Jejunum,UBERON:0002115,Treatment,EFO:0000727,Vehicle group (VH),Dopamine treatment group (D),Jejunal samples from rats treated for 14 sequential days with dopamine (D),6,10,None,16S,34,Illumina,LEfSe,0.01,TRUE,2,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:925/2/NA,Study 925,laboratory experiment,35076270,https://doi.org/10.1128/msystems.01191-21,NA,"van Kessel SP, Bullock A, van Dijk G , El Aidy S",Parkinson's Disease Medication Alters Small Intestinal Motility and Microbiota Composition in Healthy Rats,mSystems,2022,"Parkinson’s disease treatment, dopamine, drug side effects, gut motility, levodopa, microbiota, pramipexole, ropinirole, small intestinal bacterial overgrowth",Experiment 2,Netherlands,Rattus norvegicus,Jejunum,UBERON:0002115,Treatment,EFO:0000727,Vehicle group (VH),Pramipexole treatment group (P),"Jejunal samples from rats treated for 14 sequential days with pramipexole (P, in combination with levodopa-carbidopa)",6,10,None,16S,34,Illumina,LEfSe,0.01,TRUE,2,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:925/3/NA,Study 925,laboratory experiment,35076270,https://doi.org/10.1128/msystems.01191-21,NA,"van Kessel SP, Bullock A, van Dijk G , El Aidy S",Parkinson's Disease Medication Alters Small Intestinal Motility and Microbiota Composition in Healthy Rats,mSystems,2022,"Parkinson’s disease treatment, dopamine, drug side effects, gut motility, levodopa, microbiota, pramipexole, ropinirole, small intestinal bacterial overgrowth",Experiment 3,Netherlands,Rattus norvegicus,Jejunum,UBERON:0002115,Treatment,EFO:0000727,Vehicle group (VH),Ropinirole treatment group (R),"Jejunal samples from rats treated for 14 sequential days with ropinirole (R, in combination with levodopa-carbidopa)",6,10,None,16S,34,Illumina,LEfSe,0.01,TRUE,2,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:925/4/NA,Study 925,laboratory experiment,35076270,https://doi.org/10.1128/msystems.01191-21,NA,"van Kessel SP, Bullock A, van Dijk G , El Aidy S",Parkinson's Disease Medication Alters Small Intestinal Motility and Microbiota Composition in Healthy Rats,mSystems,2022,"Parkinson’s disease treatment, dopamine, drug side effects, gut motility, levodopa, microbiota, pramipexole, ropinirole, small intestinal bacterial overgrowth",Experiment 4,Netherlands,Rattus norvegicus,Ileum,UBERON:0002116,Treatment,EFO:0000727,Vehicle group (VH),Dopamine treatment group (D),Ileal samples from rats treated for 14 sequential days with dopamine (D),6,10,None,16S,34,Illumina,LEfSe,0.01,TRUE,2,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:925/5/NA,Study 925,laboratory experiment,35076270,https://doi.org/10.1128/msystems.01191-21,NA,"van Kessel SP, Bullock A, van Dijk G , El Aidy S",Parkinson's Disease Medication Alters Small Intestinal Motility and Microbiota Composition in Healthy Rats,mSystems,2022,"Parkinson’s disease treatment, dopamine, drug side effects, gut motility, levodopa, microbiota, pramipexole, ropinirole, small intestinal bacterial overgrowth",Experiment 5,Netherlands,Rattus norvegicus,Ileum,UBERON:0002116,Treatment,EFO:0000727,Vehicle group (VH),Pramipexole treatment group (P),"Ileal samples from rats treated for 14 sequential days with pramipexole (P, in combination with levodopa-carbidopa)",6,10,None,16S,34,Illumina,LEfSe,0.01,TRUE,2,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:925/6/NA,Study 925,laboratory experiment,35076270,https://doi.org/10.1128/msystems.01191-21,NA,"van Kessel SP, Bullock A, van Dijk G , El Aidy S",Parkinson's Disease Medication Alters Small Intestinal Motility and Microbiota Composition in Healthy Rats,mSystems,2022,"Parkinson’s disease treatment, dopamine, drug side effects, gut motility, levodopa, microbiota, pramipexole, ropinirole, small intestinal bacterial overgrowth",Experiment 6,Netherlands,Rattus norvegicus,Ileum,UBERON:0002116,Treatment,EFO:0000727,Vehicle group (VH),Ropinirole treatment group (R),"Ileal samples from rats treated for 14 sequential days with ropinirole (R, in combination with levodopa-carbidopa)",6,10,None,16S,34,Illumina,LEfSe,0.01,TRUE,2,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:926/1/NA,Study 926,case-control,37951857,10.1186/s12866-023-03084-5,NA,"Kang DY, Park JL, Yeo MK, Kang SB, Kim JM, Kim JS , Kim SY",Diagnosis of Crohn's disease and ulcerative colitis using the microbiome,BMC microbiology,2023,"Crohn’s disease, Gut microbiome, Inflammatory bowel disease, Machine learning, Ulcerative colitis, Whole metagenome shotgun (WMS) sequencing",Experiment 1,South Korea,Homo sapiens,Feces,UBERON:0001988,Crohn's disease,EFO:0000384,Healthy controls (HC),Crohn’s disease (CD) patients,Patients with Crohn's disease,50,69,None.,WMS,NA,MGISEQ-2000,Linear Regression,1e-4,TRUE,NA,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:926/2/NA,Study 926,case-control,37951857,10.1186/s12866-023-03084-5,NA,"Kang DY, Park JL, Yeo MK, Kang SB, Kim JM, Kim JS , Kim SY",Diagnosis of Crohn's disease and ulcerative colitis using the microbiome,BMC microbiology,2023,"Crohn’s disease, Gut microbiome, Inflammatory bowel disease, Machine learning, Ulcerative colitis, Whole metagenome shotgun (WMS) sequencing",Experiment 2,South Korea,Homo sapiens,Feces,UBERON:0001988,Ulcerative colitis,EFO:0000729,Healthy controls (HC),Ulcerative colitis (UC) patients,Patients with ulcerative colitis,50,198,None.,WMS,NA,MGISEQ-2000,Linear Regression,1e-4,TRUE,NA,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:926/3/NA,Study 926,case-control,37951857,10.1186/s12866-023-03084-5,NA,"Kang DY, Park JL, Yeo MK, Kang SB, Kim JM, Kim JS , Kim SY",Diagnosis of Crohn's disease and ulcerative colitis using the microbiome,BMC microbiology,2023,"Crohn’s disease, Gut microbiome, Inflammatory bowel disease, Machine learning, Ulcerative colitis, Whole metagenome shotgun (WMS) sequencing",Experiment 3,South Korea,Homo sapiens,Feces,UBERON:0001988,Gut microbiome measurement,EFO:0007874,Ulcerative colitis (UC) patients,Crohn's disease (CD) patients,Patients with Crohn's disease,198,69,None.,WMS,NA,MGISEQ-2000,Linear Regression,1e-4,TRUE,NA,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:926/4/NA,Study 926,case-control,37951857,10.1186/s12866-023-03084-5,NA,"Kang DY, Park JL, Yeo MK, Kang SB, Kim JM, Kim JS , Kim SY",Diagnosis of Crohn's disease and ulcerative colitis using the microbiome,BMC microbiology,2023,"Crohn’s disease, Gut microbiome, Inflammatory bowel disease, Machine learning, Ulcerative colitis, Whole metagenome shotgun (WMS) sequencing",Experiment 4,South Korea,Homo sapiens,Feces,UBERON:0001988,Crohn's disease,EFO:0000384,Health controls (HC),Crohn's disease patients- Mild group,Patients with Crohn's disease in the mild group according to disease activity,50,49,None.,WMS,NA,MGISEQ-2000,"Mann-Whitney (Wilcoxon),T-Test",0.05,TRUE,NA,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:926/5/NA,Study 926,case-control,37951857,10.1186/s12866-023-03084-5,NA,"Kang DY, Park JL, Yeo MK, Kang SB, Kim JM, Kim JS , Kim SY",Diagnosis of Crohn's disease and ulcerative colitis using the microbiome,BMC microbiology,2023,"Crohn’s disease, Gut microbiome, Inflammatory bowel disease, Machine learning, Ulcerative colitis, Whole metagenome shotgun (WMS) sequencing",Experiment 5,South Korea,Homo sapiens,Feces,UBERON:0001988,Crohn's disease,EFO:0000384,Health controls (HC),Crohn's disease patients- Moderate group,Patients with Crohn's disease in the moderate group according to disease activity,50,19,None.,WMS,NA,MGISEQ-2000,"Mann-Whitney (Wilcoxon),T-Test",0.05,TRUE,NA,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:926/6/NA,Study 926,case-control,37951857,10.1186/s12866-023-03084-5,NA,"Kang DY, Park JL, Yeo MK, Kang SB, Kim JM, Kim JS , Kim SY",Diagnosis of Crohn's disease and ulcerative colitis using the microbiome,BMC microbiology,2023,"Crohn’s disease, Gut microbiome, Inflammatory bowel disease, Machine learning, Ulcerative colitis, Whole metagenome shotgun (WMS) sequencing",Experiment 6,South Korea,Homo sapiens,Feces,UBERON:0001988,Ulcerative colitis,EFO:0000729,Health controls (HC),"Ulcerative colitis disease patients- Mild, moderate and severe groups","Patients with Ulcerative colitis disease in the mild, moderate and severe groups according to disease activity",50,NA,None.,WMS,NA,MGISEQ-2000,"Mann-Whitney (Wilcoxon),T-Test",0.05,TRUE,NA,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:926/7/NA,Study 926,case-control,37951857,10.1186/s12866-023-03084-5,NA,"Kang DY, Park JL, Yeo MK, Kang SB, Kim JM, Kim JS , Kim SY",Diagnosis of Crohn's disease and ulcerative colitis using the microbiome,BMC microbiology,2023,"Crohn’s disease, Gut microbiome, Inflammatory bowel disease, Machine learning, Ulcerative colitis, Whole metagenome shotgun (WMS) sequencing",Experiment 7,South Korea,Homo sapiens,Feces,UBERON:0001988,Gut microbiome measurement,EFO:0007874,Ulcerative colitis disease patients- Mild group,Ulcerative colitis disease patients- Severe group,Patients with Ulcerative colitis disease in the severe group according to disease activity,162,11,None.,WMS,NA,MGISEQ-2000,"Mann-Whitney (Wilcoxon),T-Test",0.05,TRUE,NA,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:926/8/NA,Study 926,case-control,37951857,10.1186/s12866-023-03084-5,NA,"Kang DY, Park JL, Yeo MK, Kang SB, Kim JM, Kim JS , Kim SY",Diagnosis of Crohn's disease and ulcerative colitis using the microbiome,BMC microbiology,2023,"Crohn’s disease, Gut microbiome, Inflammatory bowel disease, Machine learning, Ulcerative colitis, Whole metagenome shotgun (WMS) sequencing",Experiment 8,South Korea,Homo sapiens,Feces,UBERON:0001988,Gut microbiome measurement,EFO:0007874,Ulcerative colitis disease patients- Moderate group,Ulcerative colitis disease patients- Severe group,Patients with Ulcerative colitis disease in the severe group according to disease activity,25,11,None.,WMS,NA,MGISEQ-2000,"Mann-Whitney (Wilcoxon),T-Test",0.05,TRUE,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:926/9/NA,Study 926,case-control,37951857,10.1186/s12866-023-03084-5,NA,"Kang DY, Park JL, Yeo MK, Kang SB, Kim JM, Kim JS , Kim SY",Diagnosis of Crohn's disease and ulcerative colitis using the microbiome,BMC microbiology,2023,"Crohn’s disease, Gut microbiome, Inflammatory bowel disease, Machine learning, Ulcerative colitis, Whole metagenome shotgun (WMS) sequencing",Experiment 9,South Korea,Homo sapiens,Feces,UBERON:0001988,Gut microbiome measurement,EFO:0007874,Ulcerative colitis disease patients- Mild group,Ulcerative colitis disease patients- Severe group,Patients with Ulcerative colitis disease in the severe group according to disease activity,162,11,None.,WMS,NA,MGISEQ-2000,Linear Regression,0.01,TRUE,NA,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:927/1/NA,Study 927,"case-control,laboratory experiment",30077182,https://doi.org/10.1186/s40168-018-0520-6,https://microbiomejournal.biomedcentral.com/articles/10.1186/s40168-018-0520-6,"Ye Z, Zhang N, Wu C, Zhang X, Wang Q, Huang X, Du L, Cao Q, Tang J, Zhou C, Hou S, He Y, Xu Q, Xiong X, Kijlstra A, Qin N , Yang P",A metagenomic study of the gut microbiome in Behcet's disease,Microbiome,2018,"Behcet’s disease, Fecal microbiota transplant, Gut microbiome, Metagenomic analysis",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Behcet's syndrome,EFO:0003780,Healthy Control,Untreated active Behcet's disease (BD) patients,"Active BD was defined according to  presence of active intraocular inflammation 
(case-control)",52,24,1 month,WMS,NA,Illumina,LEfSe,0.05,TRUE,2,"age,body mass index,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:927/2/NA,Study 927,"case-control,laboratory experiment",30077182,https://doi.org/10.1186/s40168-018-0520-6,https://microbiomejournal.biomedcentral.com/articles/10.1186/s40168-018-0520-6,"Ye Z, Zhang N, Wu C, Zhang X, Wang Q, Huang X, Du L, Cao Q, Tang J, Zhou C, Hou S, He Y, Xu Q, Xiong X, Kijlstra A, Qin N , Yang P",A metagenomic study of the gut microbiome in Behcet's disease,Microbiome,2018,"Behcet’s disease, Fecal microbiota transplant, Gut microbiome, Metagenomic analysis",Experiment 2,China,Homo sapiens,Saliva,UBERON:0001836,Behcet's syndrome,EFO:0003780,Healthy Control,Untreated active Behcet's disease (BD) patients,Patients with Behcet's disease (case-control),43,15,1 month,16S,34,Illumina,LEfSe,0.05,TRUE,2,"age,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:927/3/NA,Study 927,"case-control,laboratory experiment",30077182,https://doi.org/10.1186/s40168-018-0520-6,https://microbiomejournal.biomedcentral.com/articles/10.1186/s40168-018-0520-6,"Ye Z, Zhang N, Wu C, Zhang X, Wang Q, Huang X, Du L, Cao Q, Tang J, Zhou C, Hou S, He Y, Xu Q, Xiong X, Kijlstra A, Qin N , Yang P",A metagenomic study of the gut microbiome in Behcet's disease,Microbiome,2018,"Behcet’s disease, Fecal microbiota transplant, Gut microbiome, Metagenomic analysis",Experiment 3,China,Homo sapiens,Feces,UBERON:0001988,Response to transplant,EFO:0007043,Healthy Control feces treated group,Behcet's disease (BD) feces treated group,B10RIII mice (mice undergoing autoimmune uveitis) colonized with untreated BD patients stool samples (experimental),4,4,None,NA,NA,NA,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:927/4/NA,Study 927,"case-control,laboratory experiment",30077182,https://doi.org/10.1186/s40168-018-0520-6,https://microbiomejournal.biomedcentral.com/articles/10.1186/s40168-018-0520-6,"Ye Z, Zhang N, Wu C, Zhang X, Wang Q, Huang X, Du L, Cao Q, Tang J, Zhou C, Hou S, He Y, Xu Q, Xiong X, Kijlstra A, Qin N , Yang P",A metagenomic study of the gut microbiome in Behcet's disease,Microbiome,2018,"Behcet’s disease, Fecal microbiota transplant, Gut microbiome, Metagenomic analysis",Experiment 4,China,Homo sapiens,Feces,UBERON:0001988,Behcet's syndrome,EFO:0003780,Healthy Control,Untreated active Behcet's disease (BD) patients,"Active BD was defined according to  presence of active intraocular inflammation 
(case-control)",52,24,1 month,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,"age,body mass index,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:928/1/NA,Study 928,"cross-sectional observational, not case-control",37659505,https://doi.org/10.1016/j.jaci.2023.07.022,NA,"Chandrasekaran P, Han Y, Zerbe CS, Heller T, DeRavin SS, Kreuzberg SA, Marciano BE, Siu Y, Jones DR, Abraham RS, Stephens MC, Tsou AM, Snapper S, Conlan S, Subramanian P, Quinones M, Grou C, Calderon V, Deming C, Leiding JW, Arnold DE, Logan BR, Griffith LM, Petrovic A, Mousallem TI, Kapoor N, Heimall JR, Barnum JL, Kapadia M, Wright N, Rayes A, Chandra S, Broglie LA, Chellapandian D, Deal CL, Grunebaum E, Lim SS, Mallhi K, Marsh RA, Murguia-Favela L, Parikh S, Touzot F, Cowan MJ, Dvorak CC, Haddad E, Kohn DB, Notarangelo LD, Pai SY, Puck JM, Pulsipher MA, Torgerson TR, Kang EM, Malech HL, Segre JA, Bryant CE, Holland SM , Falcone EL",Intestinal microbiome and metabolome signatures in patients with chronic granulomatous disease,The Journal of allergy and clinical immunology,2023,"CGD, Chronic granulomatous disease, IBD, NADPH oxidase, dysbiosis, inborn errors of immunity, inflammatory bowel disease, intestinal inflammation, metabolome, microbiome, primary immune deficiency",Experiment 1,"Canada,United States of America",Homo sapiens,Feces,UBERON:0001988,Chronic granulomatous disease,MONDO:0018305,Healthy controls,Chronic granulomatous disease,Patients with Chronic granulomatous disease and only receiving prophylactic antimicrobials and without a history of inflammatory bowel disease at the time of stool collection,16,17,Recent treatment with nonprophylactic antibiotics (acute antibiotics),16S,4,Illumina,LEfSe,0.05,FALSE,2.5,NA,"antibiotic,antimicrobial agent,inflammatory bowel disease",NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:928/2/NA,Study 928,"cross-sectional observational, not case-control",37659505,https://doi.org/10.1016/j.jaci.2023.07.022,NA,"Chandrasekaran P, Han Y, Zerbe CS, Heller T, DeRavin SS, Kreuzberg SA, Marciano BE, Siu Y, Jones DR, Abraham RS, Stephens MC, Tsou AM, Snapper S, Conlan S, Subramanian P, Quinones M, Grou C, Calderon V, Deming C, Leiding JW, Arnold DE, Logan BR, Griffith LM, Petrovic A, Mousallem TI, Kapoor N, Heimall JR, Barnum JL, Kapadia M, Wright N, Rayes A, Chandra S, Broglie LA, Chellapandian D, Deal CL, Grunebaum E, Lim SS, Mallhi K, Marsh RA, Murguia-Favela L, Parikh S, Touzot F, Cowan MJ, Dvorak CC, Haddad E, Kohn DB, Notarangelo LD, Pai SY, Puck JM, Pulsipher MA, Torgerson TR, Kang EM, Malech HL, Segre JA, Bryant CE, Holland SM , Falcone EL",Intestinal microbiome and metabolome signatures in patients with chronic granulomatous disease,The Journal of allergy and clinical immunology,2023,"CGD, Chronic granulomatous disease, IBD, NADPH oxidase, dysbiosis, inborn errors of immunity, inflammatory bowel disease, intestinal inflammation, metabolome, microbiome, primary immune deficiency",Experiment 2,"Canada,United States of America",Homo sapiens,Feces,UBERON:0001988,Chronic granulomatous disease,MONDO:0018305,Healthy individuals,Chronic granulomatous disease (CGD) patients,CGD patients without a history of IBD and only receiving prophylactic antimicrobials,17,16,N/A,16S,4,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:928/4/NA,Study 928,"cross-sectional observational, not case-control",37659505,https://doi.org/10.1016/j.jaci.2023.07.022,NA,"Chandrasekaran P, Han Y, Zerbe CS, Heller T, DeRavin SS, Kreuzberg SA, Marciano BE, Siu Y, Jones DR, Abraham RS, Stephens MC, Tsou AM, Snapper S, Conlan S, Subramanian P, Quinones M, Grou C, Calderon V, Deming C, Leiding JW, Arnold DE, Logan BR, Griffith LM, Petrovic A, Mousallem TI, Kapoor N, Heimall JR, Barnum JL, Kapadia M, Wright N, Rayes A, Chandra S, Broglie LA, Chellapandian D, Deal CL, Grunebaum E, Lim SS, Mallhi K, Marsh RA, Murguia-Favela L, Parikh S, Touzot F, Cowan MJ, Dvorak CC, Haddad E, Kohn DB, Notarangelo LD, Pai SY, Puck JM, Pulsipher MA, Torgerson TR, Kang EM, Malech HL, Segre JA, Bryant CE, Holland SM , Falcone EL",Intestinal microbiome and metabolome signatures in patients with chronic granulomatous disease,The Journal of allergy and clinical immunology,2023,"CGD, Chronic granulomatous disease, IBD, NADPH oxidase, dysbiosis, inborn errors of immunity, inflammatory bowel disease, intestinal inflammation, metabolome, microbiome, primary immune deficiency",Experiment 4,"United States of America,Canada",Homo sapiens,Feces,UBERON:0001988,Cohort,EFO:0004445,PIDTC Cohort (CGD without IBD),NIHCC Cohort (CGD without IBD),Patients with Chronic granulomatous disease (CGD) without a history of Inflammatory bowel disease (IBD) and not receiving any medications other than prophylactic antimicrobials.,23,16,Recent treatment with nonprophylactic antibiotics (acute antibiotics),16S,4,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:928/5/NA,Study 928,"cross-sectional observational, not case-control",37659505,https://doi.org/10.1016/j.jaci.2023.07.022,NA,"Chandrasekaran P, Han Y, Zerbe CS, Heller T, DeRavin SS, Kreuzberg SA, Marciano BE, Siu Y, Jones DR, Abraham RS, Stephens MC, Tsou AM, Snapper S, Conlan S, Subramanian P, Quinones M, Grou C, Calderon V, Deming C, Leiding JW, Arnold DE, Logan BR, Griffith LM, Petrovic A, Mousallem TI, Kapoor N, Heimall JR, Barnum JL, Kapadia M, Wright N, Rayes A, Chandra S, Broglie LA, Chellapandian D, Deal CL, Grunebaum E, Lim SS, Mallhi K, Marsh RA, Murguia-Favela L, Parikh S, Touzot F, Cowan MJ, Dvorak CC, Haddad E, Kohn DB, Notarangelo LD, Pai SY, Puck JM, Pulsipher MA, Torgerson TR, Kang EM, Malech HL, Segre JA, Bryant CE, Holland SM , Falcone EL",Intestinal microbiome and metabolome signatures in patients with chronic granulomatous disease,The Journal of allergy and clinical immunology,2023,"CGD, Chronic granulomatous disease, IBD, NADPH oxidase, dysbiosis, inborn errors of immunity, inflammatory bowel disease, intestinal inflammation, metabolome, microbiome, primary immune deficiency",Experiment 5,"United States of America,Canada",Homo sapiens,Feces,UBERON:0001988,Cohort,EFO:0004445,PIDTC Cohort (CGD Patients),NIHCC Cohort (CGD Patients),Patients with Chronic granulomatous disease (CGD) regardless of IBD status or antimicrobial use,36,79,Recent treatment with non prophylactic antibiotics (acute antibiotics),16S,4,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:928/6/NA,Study 928,"cross-sectional observational, not case-control",37659505,https://doi.org/10.1016/j.jaci.2023.07.022,NA,"Chandrasekaran P, Han Y, Zerbe CS, Heller T, DeRavin SS, Kreuzberg SA, Marciano BE, Siu Y, Jones DR, Abraham RS, Stephens MC, Tsou AM, Snapper S, Conlan S, Subramanian P, Quinones M, Grou C, Calderon V, Deming C, Leiding JW, Arnold DE, Logan BR, Griffith LM, Petrovic A, Mousallem TI, Kapoor N, Heimall JR, Barnum JL, Kapadia M, Wright N, Rayes A, Chandra S, Broglie LA, Chellapandian D, Deal CL, Grunebaum E, Lim SS, Mallhi K, Marsh RA, Murguia-Favela L, Parikh S, Touzot F, Cowan MJ, Dvorak CC, Haddad E, Kohn DB, Notarangelo LD, Pai SY, Puck JM, Pulsipher MA, Torgerson TR, Kang EM, Malech HL, Segre JA, Bryant CE, Holland SM , Falcone EL",Intestinal microbiome and metabolome signatures in patients with chronic granulomatous disease,The Journal of allergy and clinical immunology,2023,"CGD, Chronic granulomatous disease, IBD, NADPH oxidase, dysbiosis, inborn errors of immunity, inflammatory bowel disease, intestinal inflammation, metabolome, microbiome, primary immune deficiency",Experiment 6,"United States of America,Canada",Homo sapiens,Feces,UBERON:0001988,Age,EFO:0000246,CGD patients less than or equal to 12 years,CGD patients above 12 years,CGD patients above 12 years old with no active IBD or history of IBD,26,12,Recent treatment with non prophylactic antibiotics (acute antibiotics),16S,4,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:929/1/NA,Study 929,"laboratory experiment,time series / longitudinal observational",35017199,10.1136/gutjnl-2021-326269,NA,"Chen C, Liao J, Xia Y, Liu X, Jones R, Haran J, McCormick B, Sampson TR, Alam A , Ye K",Gut microbiota regulate Alzheimer's disease pathologies and cognitive disorders via PUFA-associated neuroinflammation,Gut,2022,brain/gut interaction,Experiment 1,United States of America,Mus musculus,Feces,UBERON:0001988,Alzheimer's disease,MONDO:0004975,Healthy control FMT mice,Alzheimer's disease FMT mice,ex germ-free mice inoculated with fecal samples from human Alzheimer's disease donors,3,3,human donors had no antimicrobial exposure within the preceding 4 weeks,16S,4,Illumina,ANOVA,0.05,TRUE,NA,age,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:930/1/NA,Study 930,laboratory experiment,30154758,https://doi.org/10.3389/fmicb.2018.01665,NA,"Wang H, Ji Y, Yin C, Deng M, Tang T, Deng B, Ren W, Deng J, Yin Y , Tan C",Differential Analysis of Gut Microbiota Correlated With Oxidative Stress in Sows With High or Low Litter Performance During Lactation,Frontiers in microbiology,2018,"gut microbiota, lactation, litter performance, oxidative stress, sows",Experiment 1,China,Sus scrofa domesticus,Feces,UBERON:0001988,Gut microbiome measurement,EFO:0007874,High litter performance sows at G109,Low litter performance sows at G109,Low litter performance sows group at day 109 of gestation,10,10,None,16S,34,Illumina,LEfSe,0.05,NA,3,NA,NA,NA,increased,increased,decreased,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:930/2/NA,Study 930,laboratory experiment,30154758,https://doi.org/10.3389/fmicb.2018.01665,NA,"Wang H, Ji Y, Yin C, Deng M, Tang T, Deng B, Ren W, Deng J, Yin Y , Tan C",Differential Analysis of Gut Microbiota Correlated With Oxidative Stress in Sows With High or Low Litter Performance During Lactation,Frontiers in microbiology,2018,"gut microbiota, lactation, litter performance, oxidative stress, sows",Experiment 2,China,Sus scrofa domesticus,Feces,UBERON:0001988,Gut microbiome measurement,EFO:0007874,High litter performance sows at L21,Low litter performance sows at L21,Low litter performance sows group at day 21 of lactation (L21),10,10,None,16S,34,Illumina,LEfSe,0.05,NA,3,NA,NA,NA,increased,increased,decreased,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:930/3/NA,Study 930,laboratory experiment,30154758,https://doi.org/10.3389/fmicb.2018.01665,NA,"Wang H, Ji Y, Yin C, Deng M, Tang T, Deng B, Ren W, Deng J, Yin Y , Tan C",Differential Analysis of Gut Microbiota Correlated With Oxidative Stress in Sows With High or Low Litter Performance During Lactation,Frontiers in microbiology,2018,"gut microbiota, lactation, litter performance, oxidative stress, sows",Experiment 3,China,Sus scrofa domesticus,Feces,UBERON:0001988,Gut microbiome measurement,EFO:0007874,Day 109 of gestation (G109) of H group,Day 21 of lactation (L21) of H group,Day 21 of lactation (L21) of high litter performance sows group,10,10,None,16S,34,Illumina,LEfSe,0.05,NA,3,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:930/4/NA,Study 930,laboratory experiment,30154758,https://doi.org/10.3389/fmicb.2018.01665,NA,"Wang H, Ji Y, Yin C, Deng M, Tang T, Deng B, Ren W, Deng J, Yin Y , Tan C",Differential Analysis of Gut Microbiota Correlated With Oxidative Stress in Sows With High or Low Litter Performance During Lactation,Frontiers in microbiology,2018,"gut microbiota, lactation, litter performance, oxidative stress, sows",Experiment 4,China,Sus scrofa domesticus,Feces,UBERON:0001988,Gut microbiome measurement,EFO:0007874,Day 109 of gestation (G109) of L group,Day 21 of lactation (L21) of L group,Day 21 of lactation (L21) of low litter performance sows group,10,10,None,16S,34,Illumina,LEfSe,0.05,NA,3,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:931/1/NA,Study 931,"cross-sectional observational, not case-control",37460569,https://doi.org/10.1038/s41531-023-00554-5,NA,"Huang P, Zhang P, Du J, Gao C, Liu J, Tan Y , Chen S",Association of fecal short-chain fatty acids with clinical severity and gut microbiota in essential tremor and its difference from Parkinson's disease,NPJ Parkinson's disease,2023,NA,Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Essential tremor,EFO:0003108,Healthy Control,Essential Tremor,"Participants face an action tremor of the upper limbs, possibly with the involvement of other parts of the body, such as the head, vocal cords, and lower limbs. Not only motor symptoms but also some nonmotor features, including gastrointestinal disorders, were experienced by them.",35,37,One month,16S,34,NA,LEfSe,0.05,FALSE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:931/2/NA,Study 931,"cross-sectional observational, not case-control",37460569,https://doi.org/10.1038/s41531-023-00554-5,NA,"Huang P, Zhang P, Du J, Gao C, Liu J, Tan Y , Chen S",Association of fecal short-chain fatty acids with clinical severity and gut microbiota in essential tremor and its difference from Parkinson's disease,NPJ Parkinson's disease,2023,NA,Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Essential tremor,EFO:0003108,Parkinson's Disease,Essential Tremor,"Participants face an action tremor of the upper limbs, possibly with the involvement of other parts of the body, such as the head, vocal cords, and lower limbs. Not only motor symptoms but also some nonmotor features, including gastrointestinal disorders, were experienced by them.",37,37,One month,16S,34,NA,LEfSe,0.05,FALSE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:932/1/NA,Study 932,time series / longitudinal observational,35547149,10.3389/fmicb.2022.780568,NA,"Hanachi M, Maghrebi O, Bichiou H, Trabelsi F, Bouyahia NM, Zhioua F, Belghith M, Harigua-Souiai E, Baouendi M, Guizani-Tabbane L, Benkahla A , Souiai O",Longitudinal and Comparative Analysis of Gut Microbiota of Tunisian Newborns According to Delivery Mode,Frontiers in microbiology,2022,"ESKAPE bacteria, Tunisia, elective cesarean deliveries, microbiome, newborns, shotgun metagenome sequencing",Experiment 1,Tunisia,Homo sapiens,Feces,UBERON:0001988,Delivery method,EFO:0000395,Vaginally Delivered(VD),Elective Cesarean Section (ECS),Participants whose delivery mode (DM) was through elective cesarean section (ECS),5,5,Last trimester of pregnancy.,WMS,NA,NA,LEfSe,0.05,TRUE,3,NA,NA,NA,unchanged,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:932/2/NA,Study 932,time series / longitudinal observational,35547149,10.3389/fmicb.2022.780568,NA,"Hanachi M, Maghrebi O, Bichiou H, Trabelsi F, Bouyahia NM, Zhioua F, Belghith M, Harigua-Souiai E, Baouendi M, Guizani-Tabbane L, Benkahla A , Souiai O",Longitudinal and Comparative Analysis of Gut Microbiota of Tunisian Newborns According to Delivery Mode,Frontiers in microbiology,2022,"ESKAPE bacteria, Tunisia, elective cesarean deliveries, microbiome, newborns, shotgun metagenome sequencing",Experiment 2,Tunisia,Homo sapiens,Feces,UBERON:0001988,Delivery method,EFO:0000395,Vaginally Delivered(VD) at Day 0,Elective Cesarean Section (ECS) at Day 0,Participants whose delivery mode (DM) was through elective cesarean section (ECS),5,5,Last trimester of pregnancy.,WMS,NA,NA,LEfSe,0.05,TRUE,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:932/3/NA,Study 932,time series / longitudinal observational,35547149,10.3389/fmicb.2022.780568,NA,"Hanachi M, Maghrebi O, Bichiou H, Trabelsi F, Bouyahia NM, Zhioua F, Belghith M, Harigua-Souiai E, Baouendi M, Guizani-Tabbane L, Benkahla A , Souiai O",Longitudinal and Comparative Analysis of Gut Microbiota of Tunisian Newborns According to Delivery Mode,Frontiers in microbiology,2022,"ESKAPE bacteria, Tunisia, elective cesarean deliveries, microbiome, newborns, shotgun metagenome sequencing",Experiment 3,Tunisia,Homo sapiens,Feces,UBERON:0001988,Delivery method,EFO:0000395,Vaginally Delivered(VD) at Day 15,Elective Cesarean Section (ECS) at Day 15,Participants whose delivery mode (DM) was through elective cesarean section (ECS),5,5,Last trimester of pregnancy.,WMS,NA,NA,LEfSe,0.05,TRUE,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:932/4/NA,Study 932,time series / longitudinal observational,35547149,10.3389/fmicb.2022.780568,NA,"Hanachi M, Maghrebi O, Bichiou H, Trabelsi F, Bouyahia NM, Zhioua F, Belghith M, Harigua-Souiai E, Baouendi M, Guizani-Tabbane L, Benkahla A , Souiai O",Longitudinal and Comparative Analysis of Gut Microbiota of Tunisian Newborns According to Delivery Mode,Frontiers in microbiology,2022,"ESKAPE bacteria, Tunisia, elective cesarean deliveries, microbiome, newborns, shotgun metagenome sequencing",Experiment 4,Tunisia,Homo sapiens,Feces,UBERON:0001988,Delivery method,EFO:0000395,Vaginally Delivered(VD) at Day 30,Elective Cesarean Section (ECS) at Day 30,Participants whose delivery mode (DM) was through elective cesarean section (ECS),5,5,Last trimester of pregnancy.,WMS,NA,NA,LEfSe,0.05,TRUE,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:932/5/NA,Study 932,time series / longitudinal observational,35547149,10.3389/fmicb.2022.780568,NA,"Hanachi M, Maghrebi O, Bichiou H, Trabelsi F, Bouyahia NM, Zhioua F, Belghith M, Harigua-Souiai E, Baouendi M, Guizani-Tabbane L, Benkahla A , Souiai O",Longitudinal and Comparative Analysis of Gut Microbiota of Tunisian Newborns According to Delivery Mode,Frontiers in microbiology,2022,"ESKAPE bacteria, Tunisia, elective cesarean deliveries, microbiome, newborns, shotgun metagenome sequencing",Experiment 5,Tunisia,Homo sapiens,Feces,UBERON:0001988,Delivery method,EFO:0000395,NA,An experiment for group 1 (day 0) vs. group 0 (days 15 and 30),Tunisian newborns' at day 0 sampling time points.,5,5,Last trimester of pregnancy.,WMS,NA,NA,LEfSe,0.05,TRUE,3,NA,NA,NA,decreased,NA,decreased,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:932/6/NA,Study 932,time series / longitudinal observational,35547149,10.3389/fmicb.2022.780568,NA,"Hanachi M, Maghrebi O, Bichiou H, Trabelsi F, Bouyahia NM, Zhioua F, Belghith M, Harigua-Souiai E, Baouendi M, Guizani-Tabbane L, Benkahla A , Souiai O",Longitudinal and Comparative Analysis of Gut Microbiota of Tunisian Newborns According to Delivery Mode,Frontiers in microbiology,2022,"ESKAPE bacteria, Tunisia, elective cesarean deliveries, microbiome, newborns, shotgun metagenome sequencing",Experiment 6,Tunisia,Homo sapiens,Feces,UBERON:0001988,Delivery method,EFO:0000395,NA,An experiment for group 1 (day 15) vs. group 0 (days 0 and 30),Tunisian newborns' at day 15 sampling time points.,5,5,Last trimester of pregnancy.,WMS,NA,NA,LEfSe,0.05,TRUE,3,NA,NA,NA,decreased,NA,decreased,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:932/7/NA,Study 932,time series / longitudinal observational,35547149,10.3389/fmicb.2022.780568,NA,"Hanachi M, Maghrebi O, Bichiou H, Trabelsi F, Bouyahia NM, Zhioua F, Belghith M, Harigua-Souiai E, Baouendi M, Guizani-Tabbane L, Benkahla A , Souiai O",Longitudinal and Comparative Analysis of Gut Microbiota of Tunisian Newborns According to Delivery Mode,Frontiers in microbiology,2022,"ESKAPE bacteria, Tunisia, elective cesarean deliveries, microbiome, newborns, shotgun metagenome sequencing",Experiment 7,Tunisia,Homo sapiens,Feces,UBERON:0001988,Delivery method,EFO:0000395,NA,An experiment for group 1 (day 30) vs. group 0 (days 0 and 15),Tunisian newborns' at day 30 sampling time points.,5,5,Last trimester of pregnancy.,WMS,NA,NA,LEfSe,0.05,TRUE,3,NA,NA,NA,decreased,NA,decreased,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:933/1/NA,Study 933,case-control,37980506,0.1186/s12866-023-03115-1,https://doi.org/10.1186/s12866-023-03115-1,"Huijuan Ning, Jing Yuan, Jinghua Cui, Kunyu Yao, Meijuan Wang, Meng Jin, Wenwen Liu, Xuemei Zhong",Alterations in gut microbiota and metabolite profiles in patients with infantile cholestasis,BMC microbiology,2023,"Infantile cholestasis (IC), Gut microbiota, Microbiota-derived metabolites, Ruminococcus, Butyrivibrio,  Veillonella",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Cholestasis,MONDO:0001751,Healthy Control (CON),Infantile  cholestasis (IC),Infants aged less than 1 year with all diagnostic criteria for cholestasis met upon admission.,20,20,No antibiotics were administered over the preceding 2 weeks.,16S,34,Illumina,LEfSe,0.05,FALSE,NA,age,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:934/1/NA,Study 934,case-control,25476529,https://doi.org/10.1002/mds.26069,NA,"Scheperjans F, Aho V, Pereira PA, Koskinen K, Paulin L, Pekkonen E, Haapaniemi E, Kaakkola S, Eerola-Rautio J, Pohja M, Kinnunen E, Murros K , Auvinen P",Gut microbiota are related to Parkinson's disease and clinical phenotype,Movement disorders : official journal of the Movement Disorder Society,2015,"biomarker, gastrointestinal dysfunction, gut-brain-axis, microbiome, non-motor symptoms",Experiment 1,Finland,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,healthy controls,Parkinson's disease,Patients diagnosed with Parkinson's disease,72,72,Within the last month,16S,123,Roche454,Metastats,0.05,TRUE,NA,"age,sex",NA,NA,unchanged,unchanged,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:935/1/NA,Study 935,case-control,33657381,https://doi.org/10.1016/j.celrep.2021.108807,NA,"Rosario D, Bidkhori G, Lee S, Bedarf J, Hildebrand F, Le Chatelier E, Uhlen M, Ehrlich SD, Proctor G, Wüllner U, Mardinoglu A , Shoaie S",Systematic analysis of gut microbiome reveals the role of bacterial folate and homocysteine metabolism in Parkinson's disease,Cell reports,2021,"Parkinson’s disease, gut microbiota, gut-brain axis, metabolic modeling, metagenomics",Experiment 1,Germany,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Healthy controls,Patients with Parkinson's Disease,Patient with Early-stage L-DOPA-Naive Parkinson's Disease,11,26,N/A,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,age,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:935/2/NA,Study 935,case-control,33657381,https://doi.org/10.1016/j.celrep.2021.108807,NA,"Rosario D, Bidkhori G, Lee S, Bedarf J, Hildebrand F, Le Chatelier E, Uhlen M, Ehrlich SD, Proctor G, Wüllner U, Mardinoglu A , Shoaie S",Systematic analysis of gut microbiome reveals the role of bacterial folate and homocysteine metabolism in Parkinson's disease,Cell reports,2021,"Parkinson’s disease, gut microbiota, gut-brain axis, metabolic modeling, metagenomics",Experiment 2,Germany,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Diseased Controls,Patients with Parkinson's Disease,Patients with Early-stage L-DOPA-Naive Parkinson's Disease,14,26,N/A,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,age,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:936/1/NA,Study 936,case-control,38548910,10.1038/s41598-024-58118-3,NA,"Prasanchit P, Pongchaikul P, Lertsittichai P, Tantitham C , Manonai J",Vaginal microbiomes of breast cancer survivors treated with aromatase inhibitors with and without vulvovaginal symptoms,Scientific reports,2024,NA,Experiment 1,Thailand,Homo sapiens,Vaginal fluid,UBERON:0036243,Vulvovaginitis,EFO:1001240,Non-vulvovaginal symptoms (control),Vulvovaginal symptoms,Breast cancer survivors treated with aromatase inhibitors with vulvovaginal symptoms,20,20,Within 7 days,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:937/1/NA,Study 937,case-control,34631595,10.3389/fcimb.2021.654202,NA,"Hao X, Li P, Wu S , Tan J",Association of the Cervical Microbiota With Pregnancy Outcome in a Subfertile Population Undergoing <i>In Vitro</i> Fertilization: A Case-Control Study,Frontiers in cellular and infection microbiology,2021,"16S r RNA, IVF (in vitro fertilization), cervical microbiota, infertility, pregnancy",Experiment 1,China,Homo sapiens,Cervical mucus,UBERON:0000316,Pregnancy,EFO:0002950,Non-pregnant (FN),Clinical pregnancy (FP),Female IVF patients undergoing fresh embryo transfer (ET) who achieved clinical pregnancy,26,25,None,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,increased,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:938/1/NA,Study 938,laboratory experiment,37936065,10.1186/s12866-023-03079-2,NA,"Li Z, Cui R, Wang YB, Luo YB, Xue PX, Tang QG , Fang MY",Specific gastrointestinal microbiota profiles in Chinese Tan sheep are associated with lauric acid content in muscle,BMC microbiology,2023,"16S rDNA, Gut microbiota, Metagenomics, Tan sheep",Experiment 1,China,Ovis aries,Rumen,UBERON:0007365,Gut microbiome measurement,EFO:0007874,Rumen of Dorper sheep (D_R),Rumen of Tan Sheep (T_R),"Rumen of Tan sheep bred in Ningxia, China",4,4,No antibiotics during the experiment period,WMS,NA,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:938/2/NA,Study 938,laboratory experiment,37936065,10.1186/s12866-023-03079-2,NA,"Li Z, Cui R, Wang YB, Luo YB, Xue PX, Tang QG , Fang MY",Specific gastrointestinal microbiota profiles in Chinese Tan sheep are associated with lauric acid content in muscle,BMC microbiology,2023,"16S rDNA, Gut microbiota, Metagenomics, Tan sheep",Experiment 2,China,Ovis aries,Duodenum,UBERON:0002114,Gut microbiome measurement,EFO:0007874,Duodenum of Dorper sheep (D_Du),Duodenum of Tan Sheep (T_Du),"Duodenum of Tan sheep bred in Ningxia, China",3,3,No antibiotics during the experiment period,WMS,NA,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:938/3/NA,Study 938,laboratory experiment,37936065,10.1186/s12866-023-03079-2,NA,"Li Z, Cui R, Wang YB, Luo YB, Xue PX, Tang QG , Fang MY",Specific gastrointestinal microbiota profiles in Chinese Tan sheep are associated with lauric acid content in muscle,BMC microbiology,2023,"16S rDNA, Gut microbiota, Metagenomics, Tan sheep",Experiment 3,China,Ovis aries,Colon,UBERON:0001155,Gut microbiome measurement,EFO:0007874,Colon of Dorper sheep (D_Co),Colon of Tan Sheep (T_Co),"Colon of Tan sheep bred in Ningxia, China",4,4,No antibiotics during the experiment period,WMS,NA,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:938/4/NA,Study 938,laboratory experiment,37936065,10.1186/s12866-023-03079-2,NA,"Li Z, Cui R, Wang YB, Luo YB, Xue PX, Tang QG , Fang MY",Specific gastrointestinal microbiota profiles in Chinese Tan sheep are associated with lauric acid content in muscle,BMC microbiology,2023,"16S rDNA, Gut microbiota, Metagenomics, Tan sheep",Experiment 4,China,Ovis aries,Rumen,UBERON:0007365,Gut microbiome measurement,EFO:0007874,Rumen of Dorper sheep (D_R),Rumen of Tan Sheep (T_R),"Rumen of Tan sheep bred in Ningxia, China",6,6,No antibiotics during the experiment period,16S,34,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:938/5/NA,Study 938,laboratory experiment,37936065,10.1186/s12866-023-03079-2,NA,"Li Z, Cui R, Wang YB, Luo YB, Xue PX, Tang QG , Fang MY",Specific gastrointestinal microbiota profiles in Chinese Tan sheep are associated with lauric acid content in muscle,BMC microbiology,2023,"16S rDNA, Gut microbiota, Metagenomics, Tan sheep",Experiment 5,China,Ovis aries,Duodenum,UBERON:0002114,Gut microbiome measurement,EFO:0007874,Duodenum of Dorper sheep (D_Du),Duodenum of Tan Sheep (T_Du),"Duodenum of Tan sheep bred in Ningxia, China",6,6,No antibiotics during the experiment period,16S,34,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:938/6/NA,Study 938,laboratory experiment,37936065,10.1186/s12866-023-03079-2,NA,"Li Z, Cui R, Wang YB, Luo YB, Xue PX, Tang QG , Fang MY",Specific gastrointestinal microbiota profiles in Chinese Tan sheep are associated with lauric acid content in muscle,BMC microbiology,2023,"16S rDNA, Gut microbiota, Metagenomics, Tan sheep",Experiment 6,China,Ovis aries,Jejunum,UBERON:0002115,Gut microbiome measurement,EFO:0007874,Jejunum of Dorper sheep (D_J),Jejunum of Tan Sheep (T_J),"Jejunum of Tan sheep bred in Ningxia, China",6,6,No antibiotics during the experiment period,16S,34,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:938/7/NA,Study 938,laboratory experiment,37936065,10.1186/s12866-023-03079-2,NA,"Li Z, Cui R, Wang YB, Luo YB, Xue PX, Tang QG , Fang MY",Specific gastrointestinal microbiota profiles in Chinese Tan sheep are associated with lauric acid content in muscle,BMC microbiology,2023,"16S rDNA, Gut microbiota, Metagenomics, Tan sheep",Experiment 7,China,Ovis aries,Colon,UBERON:0001155,Gut microbiome measurement,EFO:0007874,Colon of Dorper sheep (D_Co),Colon of Tan Sheep (T_Co),"Colon of Tan sheep bred in Ningxia, China",6,6,No antibiotics during the experiment period,16S,34,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:938/8/NA,Study 938,laboratory experiment,37936065,10.1186/s12866-023-03079-2,NA,"Li Z, Cui R, Wang YB, Luo YB, Xue PX, Tang QG , Fang MY",Specific gastrointestinal microbiota profiles in Chinese Tan sheep are associated with lauric acid content in muscle,BMC microbiology,2023,"16S rDNA, Gut microbiota, Metagenomics, Tan sheep",Experiment 8,China,Ovis aries,Caecum,UBERON:0001153,Gut microbiome measurement,EFO:0007874,Cecum of Dorper sheep (D_C),Cecum of Tan Sheep (T_C),"Cecum of Tan sheep bred in Ningxia, China",6,6,No antibiotics during the experiment period,16S,34,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:939/1/NA,Study 939,case-control,28891262,10.1111/ene.13398,https://pubmed.ncbi.nlm.nih.gov/28891262/,"Mertsalmi TH, Aho VTE, Pereira PAB, Paulin L, Pekkonen E, Auvinen P , Scheperjans F",More than constipation - bowel symptoms in Parkinson's disease and their connection to gut microbiota,European journal of neurology,2017,"Parkinson's disease, constipation, irritable bowel syndrome, microbiota, non-motor symptoms",Experiment 1,Finland,Homo sapiens,Feces,UBERON:0001988,Irritable bowel syndrome,EFO:0000555,Irritable Bowel Syndrome negative (IBS-),Irritable Bowel Syndrome positive (IBS+),Parkinson’s Disease patients with Irritable Bowel Syndrome (IBS)-like symptoms.,56,18,Within the last month.,16S,123,Roche454,DESeq2,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:940/1/NA,Study 940,prospective cohort,37119437,10.1002/advs.202205058,NA,"Hu X, Wang H, Yu B, Yu J, Lu H, Sun J, Sun Y, Zou Y, Luo H, Zeng Z, Liu S, Jiang Y, Wu Z , Ren Z",Oral Fungal Alterations in Patients with COVID-19 and Recovered Patients,"Advanced science (Weinheim, Baden-Wurttemberg, Germany)",2023,"coronavirus disease 2019, mycobiome, non-invasive biomarkers, oral fungi, severe acute respiratory syndrome coronavirus 2",Experiment 1,China,Homo sapiens,Surface of tongue,UBERON:0007367,COVID-19,MONDO:0100096,Control group,Covid-19 group,This group consists of 71 patients with Covid-19.,132,71,8 weeks,ITS / ITS2,NA,Illumina,LEfSe,0.05,FALSE,3,"age,sex",NA,NA,unchanged,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:940/2/NA,Study 940,prospective cohort,37119437,10.1002/advs.202205058,NA,"Hu X, Wang H, Yu B, Yu J, Lu H, Sun J, Sun Y, Zou Y, Luo H, Zeng Z, Liu S, Jiang Y, Wu Z , Ren Z",Oral Fungal Alterations in Patients with COVID-19 and Recovered Patients,"Advanced science (Weinheim, Baden-Wurttemberg, Germany)",2023,"coronavirus disease 2019, mycobiome, non-invasive biomarkers, oral fungi, severe acute respiratory syndrome coronavirus 2",Experiment 2,China,Homo sapiens,Surface of tongue,UBERON:0007367,COVID-19,MONDO:0100096,Covid-19 group,Post-Covid-19 group,This group consists of patients who have recovered from Covid-19.,71,22,8 weeks,ITS / ITS2,NA,Illumina,LEfSe,0.05,FALSE,3,"age,sex",NA,NA,decreased,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:940/3/NA,Study 940,prospective cohort,37119437,10.1002/advs.202205058,NA,"Hu X, Wang H, Yu B, Yu J, Lu H, Sun J, Sun Y, Zou Y, Luo H, Zeng Z, Liu S, Jiang Y, Wu Z , Ren Z",Oral Fungal Alterations in Patients with COVID-19 and Recovered Patients,"Advanced science (Weinheim, Baden-Wurttemberg, Germany)",2023,"coronavirus disease 2019, mycobiome, non-invasive biomarkers, oral fungi, severe acute respiratory syndrome coronavirus 2",Experiment 3,China,Homo sapiens,Surface of tongue,UBERON:0007367,COVID-19,MONDO:0100096,Control group,Post-Covid-19 group,This group consists of 22 patients who have recovered from Covid-19.,132,22,8 weeks,ITS / ITS2,NA,Illumina,LEfSe,0.05,FALSE,3,"age,sex",NA,NA,decreased,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:940/4/NA,Study 940,prospective cohort,37119437,10.1002/advs.202205058,NA,"Hu X, Wang H, Yu B, Yu J, Lu H, Sun J, Sun Y, Zou Y, Luo H, Zeng Z, Liu S, Jiang Y, Wu Z , Ren Z",Oral Fungal Alterations in Patients with COVID-19 and Recovered Patients,"Advanced science (Weinheim, Baden-Wurttemberg, Germany)",2023,"coronavirus disease 2019, mycobiome, non-invasive biomarkers, oral fungi, severe acute respiratory syndrome coronavirus 2",Experiment 4,China,Homo sapiens,Surface of tongue,UBERON:0007367,COVID-19,MONDO:0100096,Control group,Covid-19-N group,This group consists of 56 Covid-19 patients without comorbidities.,132,56,8 weeks,ITS / ITS2,NA,Illumina,LEfSe,0.05,FALSE,3,"age,sex",NA,NA,unchanged,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:940/5/NA,Study 940,prospective cohort,37119437,10.1002/advs.202205058,NA,"Hu X, Wang H, Yu B, Yu J, Lu H, Sun J, Sun Y, Zou Y, Luo H, Zeng Z, Liu S, Jiang Y, Wu Z , Ren Z",Oral Fungal Alterations in Patients with COVID-19 and Recovered Patients,"Advanced science (Weinheim, Baden-Wurttemberg, Germany)",2023,"coronavirus disease 2019, mycobiome, non-invasive biomarkers, oral fungi, severe acute respiratory syndrome coronavirus 2",Experiment 5,China,Homo sapiens,Surface of tongue,UBERON:0007367,COVID-19,MONDO:0100096,Control group,Covid-19-C group,This group consists of 15 Covid-19 patients with comorbidities.,132,15,8 weeks,ITS / ITS2,NA,Illumina,LEfSe,0.05,FALSE,3,"age,sex",NA,NA,increased,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:940/6/NA,Study 940,prospective cohort,37119437,10.1002/advs.202205058,NA,"Hu X, Wang H, Yu B, Yu J, Lu H, Sun J, Sun Y, Zou Y, Luo H, Zeng Z, Liu S, Jiang Y, Wu Z , Ren Z",Oral Fungal Alterations in Patients with COVID-19 and Recovered Patients,"Advanced science (Weinheim, Baden-Wurttemberg, Germany)",2023,"coronavirus disease 2019, mycobiome, non-invasive biomarkers, oral fungi, severe acute respiratory syndrome coronavirus 2",Experiment 6,China,Homo sapiens,Surface of tongue,UBERON:0007367,COVID-19,MONDO:0100096,Covid-19-N group,Covid-19-C group,This group consists of 15 Covid-19 patients with comorbidities.,56,15,8 weeks,ITS / ITS2,NA,Illumina,LEfSe,0.05,FALSE,3,"age,sex",NA,NA,increased,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:941/1/NA,Study 941,case-control,38225541,https://doi.org/10.1186/s12866-023-03173-5,NA,"Li Liu, Shangren Wang, Xiaoqiang Liu, Yang Pan",Characteristics of gut microbiota in patients with asthenozoospermia: a Chinese pilot study,BMC microbiology,2024,"16s rrna, Asthenozoospermia, Semen quality, dysbiosis, gut microbiota",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Abnormal sperm morphology,HP:0012864,Healthy Control,Asthenozoospermia,Patients with reduced sperm mortility,60,48,6 months,16S,34,Illumina,LEfSe,0.05,FALSE,3,NA,NA,NA,unchanged,decreased,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:942/1/NA,Study 942,case-control,36209079,doi: 10.1186/s12967-022-03669-0.,https://pubmed.ncbi.nlm.nih.gov/36209079/,"Zhao L, Wang C, Peng S, Zhu X, Zhang Z, Zhao Y, Zhang J, Zhao G, Zhang T, Heng X , Zhang L",Pivotal interplays between fecal metabolome and gut microbiome reveal functional signatures in cerebral ischemic stroke,Journal of translational medicine,2022,"Gut microbiota, Integrative analysis, Ischemic stroke, Metabolomics, Microbiome",Experiment 1,China,Homo sapiens,"Feces,Urine,Blood plasma","UBERON:0001988,UBERON:0001088,UBERON:0001969",Stroke,EFO:0000712,Healthy individuals,Cerebral ischemic stroke patients,Patients diagnosed with ischemic stroke by skull computed tomography examination who have not experienced any pre-existing metabolic or gut diseases.,30,60,1 month,WMS,NA,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,increased,increased,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:943/1/NA,Study 943,"case-control,laboratory experiment",38589368,10.1038/s41467-024-47273-w,NA,"Liu P, Liu Z, Wang J, Wang J, Gao M, Zhang Y, Yang C, Zhang A, Li G, Li X, Liu S, Liu L, Sun N , Zhang K",Immunoregulatory role of the gut microbiota in inflammatory depression,Nature communications,2024,NA,Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Major depressive disorder,MONDO:0002009,Healthy controls (HC),Major depressive disorder (MDD),"First-episode, drug-naïve patients with major depressive disorder (MDD) ages of 18–55.",85,85,3 months,16S,34,Illumina,LEfSe,0.05,TRUE,2,NA,NA,unchanged,unchanged,increased,unchanged,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:943/2/NA,Study 943,"case-control,laboratory experiment",38589368,10.1038/s41467-024-47273-w,NA,"Liu P, Liu Z, Wang J, Wang J, Gao M, Zhang Y, Yang C, Zhang A, Li G, Li X, Liu S, Liu L, Sun N , Zhang K",Immunoregulatory role of the gut microbiota in inflammatory depression,Nature communications,2024,NA,Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Gut microbiome measurement,EFO:0007874,Healthy controls (HC) and inflammatory depression group,Non-inflammatory depression,Patients with major depressive disorder (MDD) who had non-inflammatory depression,127,43,3 months,16S,34,Illumina,LEfSe,0.05,TRUE,2.72,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:943/3/NA,Study 943,"case-control,laboratory experiment",38589368,10.1038/s41467-024-47273-w,NA,"Liu P, Liu Z, Wang J, Wang J, Gao M, Zhang Y, Yang C, Zhang A, Li G, Li X, Liu S, Liu L, Sun N , Zhang K",Immunoregulatory role of the gut microbiota in inflammatory depression,Nature communications,2024,NA,Experiment 3,China,Homo sapiens,Feces,UBERON:0001988,Gut microbiome measurement,EFO:0007874,Healthy controls (HC) and non-inflammatory depression group,Inflammatory depression,Patients with major depressive disorder (MDD) who had inflammatory depression,128,42,3 months,16S,34,Illumina,LEfSe,0.05,TRUE,2.72,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:943/4/NA,Study 943,"case-control,laboratory experiment",38589368,10.1038/s41467-024-47273-w,NA,"Liu P, Liu Z, Wang J, Wang J, Gao M, Zhang Y, Yang C, Zhang A, Li G, Li X, Liu S, Liu L, Sun N , Zhang K",Immunoregulatory role of the gut microbiota in inflammatory depression,Nature communications,2024,NA,Experiment 4,China,Homo sapiens,Feces,UBERON:0001988,Gut microbiome measurement,EFO:0007874,Non-inflammatory depression,Inflammatory depression,Patients with major depressive disorder (MDD) who had inflammatory depression,43,42,3 months,16S,34,Illumina,LEfSe,0.05,TRUE,2.45,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:943/5/NA,Study 943,"case-control,laboratory experiment",38589368,10.1038/s41467-024-47273-w,NA,"Liu P, Liu Z, Wang J, Wang J, Gao M, Zhang Y, Yang C, Zhang A, Li G, Li X, Liu S, Liu L, Sun N , Zhang K",Immunoregulatory role of the gut microbiota in inflammatory depression,Nature communications,2024,NA,Experiment 5,China,Homo sapiens,Feces,UBERON:0001988,Major depressive disorder,MONDO:0002009,Healthy controls (HC),Inflammatory depression,Patients with major depressive disorder (MDD) who had inflammatory depression,20,20,3 months,WMS,NA,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:943/6/NA,Study 943,"case-control,laboratory experiment",38589368,10.1038/s41467-024-47273-w,NA,"Liu P, Liu Z, Wang J, Wang J, Gao M, Zhang Y, Yang C, Zhang A, Li G, Li X, Liu S, Liu L, Sun N , Zhang K",Immunoregulatory role of the gut microbiota in inflammatory depression,Nature communications,2024,NA,Experiment 6,China,Homo sapiens,Feces,UBERON:0001988,Major depressive disorder,MONDO:0002009,Healthy control (HC),Inflammatory and non-inflammatory depression,Patients with major depressive disorder (MDD) grouped into inflammatory and non-inflammatory depression groups,85,85,3 months,16S,34,Illumina,LEfSe,0.05,TRUE,2.72,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:943/7/NA,Study 943,"case-control,laboratory experiment",38589368,10.1038/s41467-024-47273-w,NA,"Liu P, Liu Z, Wang J, Wang J, Gao M, Zhang Y, Yang C, Zhang A, Li G, Li X, Liu S, Liu L, Sun N , Zhang K",Immunoregulatory role of the gut microbiota in inflammatory depression,Nature communications,2024,NA,Experiment 7,China,Mus musculus,Feces,UBERON:0001988,Gut microbiome measurement,EFO:0007874,"Low-inflammatory, healthy control and blank groups",High-inflammatory group,Mice classified into the high-inflammatory group,24,20,None,16S,34,Illumina,LEfSe,0.05,NA,4.31,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:943/8/NA,Study 943,"case-control,laboratory experiment",38589368,10.1038/s41467-024-47273-w,NA,"Liu P, Liu Z, Wang J, Wang J, Gao M, Zhang Y, Yang C, Zhang A, Li G, Li X, Liu S, Liu L, Sun N , Zhang K",Immunoregulatory role of the gut microbiota in inflammatory depression,Nature communications,2024,NA,Experiment 8,China,Mus musculus,Feces,UBERON:0001988,Gut microbiome measurement,EFO:0007874,"High-inflammatory, healthy control and blank groups",Low-inflammatory group,Mice classified into the low-inflammatory group,36,8,None,16S,34,Illumina,LEfSe,0.05,NA,4.31,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:943/9/NA,Study 943,"case-control,laboratory experiment",38589368,10.1038/s41467-024-47273-w,NA,"Liu P, Liu Z, Wang J, Wang J, Gao M, Zhang Y, Yang C, Zhang A, Li G, Li X, Liu S, Liu L, Sun N , Zhang K",Immunoregulatory role of the gut microbiota in inflammatory depression,Nature communications,2024,NA,Experiment 9,China,Mus musculus,Feces,UBERON:0001988,Gut microbiome measurement,EFO:0007874,Healthy control (HC) group,"High-inflammatory, low-inflammatory and blank groups","Mice classified into the high-inflammatory, low-inflammatory and blank groups",7,37,None,16S,34,Illumina,LEfSe,0.05,NA,4.31,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:943/10/NA,Study 943,"case-control,laboratory experiment",38589368,10.1038/s41467-024-47273-w,NA,"Liu P, Liu Z, Wang J, Wang J, Gao M, Zhang Y, Yang C, Zhang A, Li G, Li X, Liu S, Liu L, Sun N , Zhang K",Immunoregulatory role of the gut microbiota in inflammatory depression,Nature communications,2024,NA,Experiment 10,China,Mus musculus,Feces,UBERON:0001988,Gut microbiome measurement,EFO:0007874,"High-inflammatory, low-inflammatory and healthy control groups",Blank group,Mice administered normal saline and classified into the blank group,35,9,None,16S,34,Illumina,LEfSe,0.05,NA,4.31,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:943/11/NA,Study 943,"case-control,laboratory experiment",38589368,10.1038/s41467-024-47273-w,NA,"Liu P, Liu Z, Wang J, Wang J, Gao M, Zhang Y, Yang C, Zhang A, Li G, Li X, Liu S, Liu L, Sun N , Zhang K",Immunoregulatory role of the gut microbiota in inflammatory depression,Nature communications,2024,NA,Experiment 11,China,Mus musculus,Feces,UBERON:0001988,Gut microbiome measurement,EFO:0007874,Clostridium butyricum (CB) and normal saline (NS) groups,High-inflammatory group,Mice classified into the high-inflammatory group,13,7,None,16S,34,Illumina,LEfSe,0.05,NA,4.22,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:943/12/NA,Study 943,"case-control,laboratory experiment",38589368,10.1038/s41467-024-47273-w,NA,"Liu P, Liu Z, Wang J, Wang J, Gao M, Zhang Y, Yang C, Zhang A, Li G, Li X, Liu S, Liu L, Sun N , Zhang K",Immunoregulatory role of the gut microbiota in inflammatory depression,Nature communications,2024,NA,Experiment 12,China,Mus musculus,Feces,UBERON:0001988,Gut microbiome measurement,EFO:0007874,High-inflammatory and normal saline (NS) groups,Clostridium butyricum (CB),Mice administered probiotics (Clostridium butyricum),13,7,None,16S,34,Illumina,LEfSe,0.05,NA,4.22,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:943/13/NA,Study 943,"case-control,laboratory experiment",38589368,10.1038/s41467-024-47273-w,NA,"Liu P, Liu Z, Wang J, Wang J, Gao M, Zhang Y, Yang C, Zhang A, Li G, Li X, Liu S, Liu L, Sun N , Zhang K",Immunoregulatory role of the gut microbiota in inflammatory depression,Nature communications,2024,NA,Experiment 13,China,Mus musculus,Feces,UBERON:0001988,Gut microbiome measurement,EFO:0007874,Normal saline (NS),High-inflammatory and Clostridium butyricum (CB) groups,Mice administered normal saline (NS),6,14,None,16S,34,Illumina,LEfSe,0.05,NA,4.22,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:944/1/NA,Study 944,case-control,27591074,10.1016/j.parkreldis.2016.08.019,NA,"Unger MM, Spiegel J, Dillmann KU, Grundmann D, Philippeit H, Bürmann J, Faßbender K, Schwiertz A , Schäfer KH",Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls,Parkinsonism & related disorders,2016,"Butyrate, Enteric nervous system, Gut microbiota, Parkinson's disease, Short chain fatty acids",Experiment 1,Germany,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Healthy control (control matched- CM),Parkinson's disease group,Patients with Parkinson's disease,34,34,Three months,PCR,NA,RT-qPCR,Kruskall-Wallis,0.01,TRUE,NA,age,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:944/2/NA,Study 944,case-control,27591074,10.1016/j.parkreldis.2016.08.019,NA,"Unger MM, Spiegel J, Dillmann KU, Grundmann D, Philippeit H, Bürmann J, Faßbender K, Schwiertz A , Schäfer KH",Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls,Parkinsonism & related disorders,2016,"Butyrate, Enteric nervous system, Gut microbiota, Parkinson's disease, Short chain fatty acids",Experiment 2,Germany,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Healthy control group (control young-CY),Parkinson's disease group,Patients with Parkinson's disease,10,34,Three months,PCR,NA,RT-qPCR,Kruskall-Wallis,0.01,TRUE,NA,age,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:945/1/NA,Study 945,randomized controlled trial,31477562,10.1016/j.ebiom.2019.08.032,NA,"Nagpal R, Neth BJ, Wang S, Craft S , Yadav H",Modified Mediterranean-ketogenic diet modulates gut microbiome and short-chain fatty acids in association with Alzheimer's disease markers in subjects with mild cognitive impairment,EBioMedicine,2019,"Alzheimer, Dementia, Diet, High fat, Ketogenic, Microbiota, Nutrition, Short-chain fatty acids",Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Cognitive impairment,HP:0100543,Cognitive Normal,Mild Cognitive Impairment,Participants diagnosed with early Mild Cognitive Impairment (diagnosed using ADNI-2 criteria) randomly assigned to either a modified Mediterranean-ketogenic diet (MMKD) or an American heart association diet (AHAD) group,6,11,None,16S,4,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:945/2/NA,Study 945,randomized controlled trial,31477562,10.1016/j.ebiom.2019.08.032,NA,"Nagpal R, Neth BJ, Wang S, Craft S , Yadav H",Modified Mediterranean-ketogenic diet modulates gut microbiome and short-chain fatty acids in association with Alzheimer's disease markers in subjects with mild cognitive impairment,EBioMedicine,2019,"Alzheimer, Dementia, Diet, High fat, Ketogenic, Microbiota, Nutrition, Short-chain fatty acids",Experiment 2,United States of America,Homo sapiens,Feces,UBERON:0001988,Cognitive impairment,HP:0100543,Post American heart association diet (AHAD) in MCI,Post modified Mediterranean-ketogenic diet (MMKD) in MCI,Participants diagnosed with early mild cognitive impairment (MCI) at endpoint of the modified Mediterranean-ketogenic diet (MMKD) intervention,11,11,None,16S,4,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:945/3/NA,Study 945,randomized controlled trial,31477562,10.1016/j.ebiom.2019.08.032,NA,"Nagpal R, Neth BJ, Wang S, Craft S , Yadav H",Modified Mediterranean-ketogenic diet modulates gut microbiome and short-chain fatty acids in association with Alzheimer's disease markers in subjects with mild cognitive impairment,EBioMedicine,2019,"Alzheimer, Dementia, Diet, High fat, Ketogenic, Microbiota, Nutrition, Short-chain fatty acids",Experiment 3,United States of America,Homo sapiens,Feces,UBERON:0001988,Cognitive impairment,HP:0100543,Post American heart association diet (AHAD) in CN and MCI,Post modified Mediterranean-ketogenic diet (MMKD) in CN and MCI,All Participants including cognitively normal (CN) and those diagnosed with early mild cognitive impairment (MCI) at endpoint of the modified Mediterranean-ketogenic diet (MMKD) intervention,17,17,None,16S,4,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:945/4/NA,Study 945,randomized controlled trial,31477562,10.1016/j.ebiom.2019.08.032,NA,"Nagpal R, Neth BJ, Wang S, Craft S , Yadav H",Modified Mediterranean-ketogenic diet modulates gut microbiome and short-chain fatty acids in association with Alzheimer's disease markers in subjects with mild cognitive impairment,EBioMedicine,2019,"Alzheimer, Dementia, Diet, High fat, Ketogenic, Microbiota, Nutrition, Short-chain fatty acids",Experiment 4,United States of America,Homo sapiens,Feces,UBERON:0001988,Cognitive impairment,HP:0100543,Pre modified Mediterranean-ketogenic diet (MMKD) in CN and MCI,Post modified Mediterranean-ketogenic diet (MMKD) in CN and MCI,All Participants including cognitively normal (CN) and those diagnosed with early mild cognitive impairment (MCI) at endpoint of the modified Mediterranean-ketogenic diet (MMKD) intervention,17,17,None,16S,4,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:946/1/NA,Study 946,meta-analysis,36691982,10.1002/mds.29300,NA,"Boktor JC, Sharon G, Verhagen Metman LA, Hall DA, Engen PA, Zreloff Z, Hakim DJ, Bostick JW, Ousey J, Lange D, Humphrey G, Ackermann G, Carlin M, Knight R, Keshavarzian A , Mazmanian SK",Integrated Multi-Cohort Analysis of the Parkinson's Disease Gut Metagenome,Movement disorders : official journal of the Movement Disorder Society,2023,"Parkinson's disease, dysbiosis, gut microbiome, microbial metabolism, shotgun metagenomics",Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,HC: household controls,PD: individuals with Parkinson's disease,"cohort 1: movement disorder specialists examined and confirmed the diagnosis of all PD participants at a baseline screening. Parkinsonian symptoms were assessed using the Unified Parkinson's Disease Rating Scale (UPDRS) and Hoehn and Yahr (H&Y) staging scale.
cohort 2: PD participants were self-identified, verifying that they had received a PD diagnosis from a qualified physician.",56,88,12 weeks,WMS,NA,Illumina,MaAsLin2,0.1,TRUE,NA,NA,NA,NA,unchanged,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:946/2/NA,Study 946,meta-analysis,36691982,10.1002/mds.29300,NA,"Boktor JC, Sharon G, Verhagen Metman LA, Hall DA, Engen PA, Zreloff Z, Hakim DJ, Bostick JW, Ousey J, Lange D, Humphrey G, Ackermann G, Carlin M, Knight R, Keshavarzian A , Mazmanian SK",Integrated Multi-Cohort Analysis of the Parkinson's Disease Gut Metagenome,Movement disorders : official journal of the Movement Disorder Society,2023,"Parkinson's disease, dysbiosis, gut microbiome, microbial metabolism, shotgun metagenomics",Experiment 2,United States of America,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,PC: healthy population controls without Parkinson's Disease,PD: Individuals with Parkinson's disease,"cohort 1: movement disorder specialists examined and confirmed the diagnosis of all PD participants at a baseline screening. Parkinsonian symptoms were assessed using the Unified Parkinson's Disease Rating Scale (UPDRS) and Hoehn and Yahr (H&Y) staging scale. 
cohort 2: PD participants were self-identified, verifying that they had received a PD diagnosis from a qualified physician.",83,88,12 weeks,WMS,NA,Illumina,MaAsLin2,0.1,TRUE,NA,"age,body mass index,race,sex",NA,NA,unchanged,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:947/1/NA,Study 947,laboratory experiment,38479554,https://doi.org/10.1016/j.neulet.2024.137714,NA,"Wang Y, Ullah H, Deng T, Ren X, Zhao Z, Xin Y , Qiu J",Social isolation induces intestinal barrier disorder and imbalances gut microbiota in mice,Neuroscience letters,2024,"Gut microbiota, Intestinal barrier, Social isolation",Experiment 1,China,Mus musculus,Feces,UBERON:0001988,Social deprivation,EFO:0009696,Normal Control NCd (8-week normal control group),Socially Isolated SId (8-week socially isolated group),Individually housed mice without any sensory communication with other mice for 8 weeks,10,10,None,16S,4,Illumina,LEfSe,0.05,NA,NA,NA,NA,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:947/2/NA,Study 947,laboratory experiment,38479554,https://doi.org/10.1016/j.neulet.2024.137714,NA,"Wang Y, Ullah H, Deng T, Ren X, Zhao Z, Xin Y , Qiu J",Social isolation induces intestinal barrier disorder and imbalances gut microbiota in mice,Neuroscience letters,2024,"Gut microbiota, Intestinal barrier, Social isolation",Experiment 2,China,Mus musculus,Feces,UBERON:0001988,Social deprivation,EFO:0009696,Normal Control NCc (15-week normal control group),Socially Isolated SIc (15-week socially isolated group),Individually housed mice without any sensory communication with other mice for 15 weeks,10,10,None,16S,4,Illumina,LEfSe,0.05,NA,NA,NA,NA,NA,increased,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:948/1/NA,Study 948,prospective cohort,29091972,10.1371/journal.pone.0187307,NA,"Minato T, Maeda T, Fujisawa Y, Tsuji H, Nomoto K, Ohno K , Hirayama M",Progression of Parkinson's disease is associated with gut dysbiosis: Two-year follow-up study,PloS one,2017,NA,Experiment 1,Japan,Homo sapiens,Feces,UBERON:0001988,Disease staging,EFO:0000410,Stable Group at year 0,Deteriorated Group at year 0,The Deteriorated Group is the group of patients with significantly higher UPDRS(United Parkinson's Disease Rating Scale) score at year 0,18,18,NA,PCR,NA,RT-qPCR,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:948/2/NA,Study 948,prospective cohort,29091972,10.1371/journal.pone.0187307,NA,"Minato T, Maeda T, Fujisawa Y, Tsuji H, Nomoto K, Ohno K , Hirayama M",Progression of Parkinson's disease is associated with gut dysbiosis: Two-year follow-up study,PloS one,2017,NA,Experiment 2,Japan,Homo sapiens,Feces,UBERON:0001988,Timepoint,EFO:0000724,Parkinson's disease patients at year 0,Parkinson's disease patients at year 2,Patients with Parkinson's disease followed up after year 2,36,28,NA,PCR,NA,RT-qPCR,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:948/3/NA,Study 948,prospective cohort,29091972,10.1371/journal.pone.0187307,NA,"Minato T, Maeda T, Fujisawa Y, Tsuji H, Nomoto K, Ohno K , Hirayama M",Progression of Parkinson's disease is associated with gut dysbiosis: Two-year follow-up study,PloS one,2017,NA,Experiment 3,Japan,Homo sapiens,Feces,UBERON:0001988,Timepoint,EFO:0000724,Deteriorated Group at year 0,Deteriorated Group at year 2,The Deteriorated Group is the group of patients with significantly higher UPDRS(United Parkinson's Disease Rating Scale) score at year 2,18,11,NA,PCR,NA,RT-qPCR,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:948/4/NA,Study 948,prospective cohort,29091972,10.1371/journal.pone.0187307,NA,"Minato T, Maeda T, Fujisawa Y, Tsuji H, Nomoto K, Ohno K , Hirayama M",Progression of Parkinson's disease is associated with gut dysbiosis: Two-year follow-up study,PloS one,2017,NA,Experiment 4,Japan,Homo sapiens,Feces,UBERON:0001988,Timepoint,EFO:0000724,Stable group at year 0,Stable group at year 2,The Stable Group is the group of patients with significantly lower UPDRS(United Parkinson's Disease Rating Scale) score at year 2,18,17,NA,PCR,NA,RT-qPCR,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:949/8/NA,Study 949,laboratory experiment,36527132,https://doi.org/10.1186/s40168-022-01399-5,NA,"Midha A, Jarquín-Díaz VH, Ebner F, Löber U, Hayani R, Kundik A, Cardilli A, Heitlinger E, Forslund SK , Hartmann S",Guts within guts: the microbiome of the intestinal helminth parasite Ascaris suum is derived but distinct from its host,Microbiome,2022,NA,Experiment 8,Germany,Sus scrofa domesticus,Jejunum,UBERON:0002115,Gut microbiome measurement,EFO:0007874,Ascaris summ (Males),Ascaris suum (Females),Microbiome of intestines harvested from female adult Ascaris worms that were harvested from host's (pig) gut,NA,NA,NA,16S,34,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:949/9/NA,Study 949,laboratory experiment,36527132,https://doi.org/10.1186/s40168-022-01399-5,NA,"Midha A, Jarquín-Díaz VH, Ebner F, Löber U, Hayani R, Kundik A, Cardilli A, Heitlinger E, Forslund SK , Hartmann S",Guts within guts: the microbiome of the intestinal helminth parasite Ascaris suum is derived but distinct from its host,Microbiome,2022,NA,Experiment 9,Germany,Sus scrofa domesticus,Jejunum,UBERON:0002115,Gut microbiome measurement,EFO:0007874,Host (Ascaris suum infected Pigs) Microbiome,Parasite (Ascaris suum) Microbiome,Microbiome of intestines harvested from female adult Ascaris worms that were harvested from host's (pig) gut,10,NA,NA,16S,34,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:950/1/NA,Study 950,case-control,37428087,https://doi.org/10.1128/spectrum.00590-23,https://journals.asm.org/doi/10.1128/spectrum.00590-23,"Bai H, Liu T, Wang S, Gong W, Shen L, Zhang S , Wang Z",Identification of Gut Microbiome and Metabolites Associated with Acute Diarrhea in Cats,Microbiology spectrum,2023,"QIIME2, acute diarrhea, domestic cat, gut microbiota, metabolome, microbiome",Experiment 1,China,Felis catus,Feces,UBERON:0001988,Diarrhea,HP:0002014,Healthy American Shorthair (MH),Acutely diarrheic American Shorthair cats (MD),American Shorthair cats with acute diarrhea,12,12,1 month,16S,4,Illumina,LEfSe,0.05,FALSE,4,NA,NA,unchanged,unchanged,increased,unchanged,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:950/2/NA,Study 950,case-control,37428087,https://doi.org/10.1128/spectrum.00590-23,https://journals.asm.org/doi/10.1128/spectrum.00590-23,"Bai H, Liu T, Wang S, Gong W, Shen L, Zhang S , Wang Z",Identification of Gut Microbiome and Metabolites Associated with Acute Diarrhea in Cats,Microbiology spectrum,2023,"QIIME2, acute diarrhea, domestic cat, gut microbiota, metabolome, microbiome",Experiment 2,China,Felis catus,Feces,UBERON:0001988,Diarrhea,HP:0002014,Healthy British Shorthair (BH),Acutely diarrheic British Shorthair cats (BD),British Shorthair cats with acute diarrhea,12,12,1 month,16S,4,Illumina,LEfSe,0.05,FALSE,4,NA,NA,unchanged,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:950/3/NA,Study 950,case-control,37428087,https://doi.org/10.1128/spectrum.00590-23,https://journals.asm.org/doi/10.1128/spectrum.00590-23,"Bai H, Liu T, Wang S, Gong W, Shen L, Zhang S , Wang Z",Identification of Gut Microbiome and Metabolites Associated with Acute Diarrhea in Cats,Microbiology spectrum,2023,"QIIME2, acute diarrhea, domestic cat, gut microbiota, metabolome, microbiome",Experiment 3,China,Felis catus,Feces,UBERON:0001988,Diarrhea,HP:0002014,Healthy British Shorthair (BH),Acutely diarrheic British Shorthair cats (BD),British Shorthair cats with acute diarrhea,12,12,1 month,WMS,NA,Illumina,LEfSe,0.05,FALSE,4,NA,NA,unchanged,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:950/4/NA,Study 950,case-control,37428087,https://doi.org/10.1128/spectrum.00590-23,https://journals.asm.org/doi/10.1128/spectrum.00590-23,"Bai H, Liu T, Wang S, Gong W, Shen L, Zhang S , Wang Z",Identification of Gut Microbiome and Metabolites Associated with Acute Diarrhea in Cats,Microbiology spectrum,2023,"QIIME2, acute diarrhea, domestic cat, gut microbiota, metabolome, microbiome",Experiment 4,China,Felis catus,Feces,UBERON:0001988,Breed,EFO:0005238,Healthy British Shorthair (BH),Healthy American Shorthair (MH),Healthy American Shorthair (MH) cats,12,12,1 month,16S,4,Illumina,LEfSe,0.05,FALSE,4,NA,NA,unchanged,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:950/5/NA,Study 950,case-control,37428087,https://doi.org/10.1128/spectrum.00590-23,https://journals.asm.org/doi/10.1128/spectrum.00590-23,"Bai H, Liu T, Wang S, Gong W, Shen L, Zhang S , Wang Z",Identification of Gut Microbiome and Metabolites Associated with Acute Diarrhea in Cats,Microbiology spectrum,2023,"QIIME2, acute diarrhea, domestic cat, gut microbiota, metabolome, microbiome",Experiment 5,China,Felis catus,Feces,UBERON:0001988,Breed,EFO:0005238,Healthy British Shorthair (BH),Healthy American Shorthair (MH),Healthy American Shorthair (MH) cats,12,12,1 month,16S,4,Illumina,Metastats,0.05,FALSE,NA,NA,NA,unchanged,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:950/6/NA,Study 950,case-control,37428087,https://doi.org/10.1128/spectrum.00590-23,https://journals.asm.org/doi/10.1128/spectrum.00590-23,"Bai H, Liu T, Wang S, Gong W, Shen L, Zhang S , Wang Z",Identification of Gut Microbiome and Metabolites Associated with Acute Diarrhea in Cats,Microbiology spectrum,2023,"QIIME2, acute diarrhea, domestic cat, gut microbiota, metabolome, microbiome",Experiment 6,China,Felis catus,Feces,UBERON:0001988,Diarrhea,HP:0002014,Healthy American Shorthair (MH),Acutely diarrheic American Shorthair cats (MD),American Shorthair cats with acute diarrhea,12,12,1 month,16S,4,Illumina,Metastats,0.05,FALSE,NA,NA,NA,unchanged,unchanged,increased,unchanged,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:950/7/NA,Study 950,case-control,37428087,https://doi.org/10.1128/spectrum.00590-23,https://journals.asm.org/doi/10.1128/spectrum.00590-23,"Bai H, Liu T, Wang S, Gong W, Shen L, Zhang S , Wang Z",Identification of Gut Microbiome and Metabolites Associated with Acute Diarrhea in Cats,Microbiology spectrum,2023,"QIIME2, acute diarrhea, domestic cat, gut microbiota, metabolome, microbiome",Experiment 7,China,Felis catus,Feces,UBERON:0001988,Diarrhea,HP:0002014,Healthy British Shorthair (BH),Acutely diarrheic British Shorthair cats (BD),British Shorthair cats with acute diarrhea,12,12,1 month,16S,4,Illumina,Metastats,0.05,FALSE,NA,NA,NA,unchanged,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:951/1/NA,Study 951,case-control,36625596,10.1128/spectrum.03796-22,NA,"Li Y, Qian F, Cheng X, Wang D, Wang Y, Pan Y, Chen L, Wang W , Tian Y",Dysbiosis of Oral Microbiota and Metabolite Profiles Associated with Type 2 Diabetes Mellitus,Microbiology spectrum,2023,"metabolomic, metagenomic, oral diseases, oral microbiome, type 2 diabetes mellitus",Experiment 1,China,Homo sapiens,Saliva,UBERON:0001836,Type II diabetes mellitus,MONDO:0005148,Healthy Control,Type 2 Diabetes Mellitus Patients,"Saliva samples of patients with Type 2 Diabetes Mellitus ( fasting plasma glucose (FPG)≥7.0 mmol/L, HbA1C ≥6.5%, and 2-h postprandial blood glucose (2-hPBG)≥11.1 mmol/L)",10,10,"Participants were excluded if they used antibiotics in the past 6 months, or if they used local antibiotics in the past 7 days",WMS,NA,MGISEQ-2000,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:951/2/NA,Study 951,case-control,36625596,10.1128/spectrum.03796-22,NA,"Li Y, Qian F, Cheng X, Wang D, Wang Y, Pan Y, Chen L, Wang W , Tian Y",Dysbiosis of Oral Microbiota and Metabolite Profiles Associated with Type 2 Diabetes Mellitus,Microbiology spectrum,2023,"metabolomic, metagenomic, oral diseases, oral microbiome, type 2 diabetes mellitus",Experiment 2,China,Homo sapiens,Supragingival dental plaque,UBERON:0016485,Type II diabetes mellitus,MONDO:0005148,Healthy Control,Type 2 Diabetes Mellitus Patients,"Supragingival dental plaque samples of patients with Type 2 Diabetes Mellitus ( fasting plasma glucose (FPG)≥7.0 mmol/L, HbA1C ≥6.5%, and 2-h postprandial blood glucose (2-hPBG)≥11.1 mmol/L)",10,10,"Participants were excluded if they used antibiotics in the past 6 months, or if they used local antibiotics in the past 7 days",WMS,NA,MGISEQ-2000,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:952/1/NA,Study 952,"cross-sectional observational, not case-control",35463646,10.3389/fcimb.2022.837019,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9022099/,"Fu SC, Lee CH, Hsieh YC, Wu PH, Lin SH , Wang H","A Pilot Study Exploring the Association of Entacapone, Gut Microbiota, and the Subsequent Side Effects in Patients With Parkinson's Disease",Frontiers in cellular and infection microbiology,2022,"Parkinson’s disease, constipation, drowsiness, entacapone, levodopa, microbiome",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Clinical treatment,EFO:0007056,Parkinson's disease (PD) patients treated with levodopa only (PD_L),Parkinson's disease (PD) patients treated with both levodopa and Entacapone (PD_LE),"Parkinson's disease (PD) patients treated with both levodopa and Entacapone, a peripherally acting catechol-O-methyltransferase (COMT) inhibitor that is used in addition to levodopa to control symptoms.",13,11,None,16S,45,Ion Torrent,T-Test,0.05,TRUE,NA,"age,sex",NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:953/1/NA,Study 953,"cross-sectional observational, not case-control",35467373,10.1128/spectrum.00645-21,https://journals.asm.org/doi/10.1128/spectrum.00645-21#tab1,"Li M, Shao D, Zhou J, Gu J, Qin J, Li X, Hao C , Wei W","Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China",Microbiology spectrum,2022,"Helicobacter pylori, gastric cardia, gastric juice, gastric pH, gastrointestinal tract, microbiota",Experiment 1,China,Homo sapiens,Saliva,UBERON:0001836,Upper digestive tract disease,MONDO:0044991,Esophagus samples,Saliva samples,Saliva samples from 40 participants undergoing upper gastrointestinal endoscopy.,40,40,One month before sample collection.,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,increased,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:953/2/NA,Study 953,"cross-sectional observational, not case-control",35467373,10.1128/spectrum.00645-21,https://journals.asm.org/doi/10.1128/spectrum.00645-21#tab1,"Li M, Shao D, Zhou J, Gu J, Qin J, Li X, Hao C , Wei W","Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China",Microbiology spectrum,2022,"Helicobacter pylori, gastric cardia, gastric juice, gastric pH, gastrointestinal tract, microbiota",Experiment 2,China,Homo sapiens,Saliva,UBERON:0001836,Upper digestive tract disease,MONDO:0044991,Cardia biopsy samples,Saliva samples,Saliva samples from 40 participants undergoing upper gastrointestinal endoscopy.,40,40,One month before sample collection.,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,increased,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:953/3/NA,Study 953,"cross-sectional observational, not case-control",35467373,10.1128/spectrum.00645-21,https://journals.asm.org/doi/10.1128/spectrum.00645-21#tab1,"Li M, Shao D, Zhou J, Gu J, Qin J, Li X, Hao C , Wei W","Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China",Microbiology spectrum,2022,"Helicobacter pylori, gastric cardia, gastric juice, gastric pH, gastrointestinal tract, microbiota",Experiment 3,China,Homo sapiens,Saliva,UBERON:0001836,Upper digestive tract disease,MONDO:0044991,Non-cardia biopsy samples,Saliva samples,Saliva samples from 40 participants undergoing upper gastrointestinal endoscopy.,40,40,One month before sample collection.,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,increased,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:953/4/NA,Study 953,"cross-sectional observational, not case-control",35467373,10.1128/spectrum.00645-21,https://journals.asm.org/doi/10.1128/spectrum.00645-21#tab1,"Li M, Shao D, Zhou J, Gu J, Qin J, Li X, Hao C , Wei W","Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China",Microbiology spectrum,2022,"Helicobacter pylori, gastric cardia, gastric juice, gastric pH, gastrointestinal tract, microbiota",Experiment 4,China,Homo sapiens,Saliva,UBERON:0001836,Upper digestive tract disease,MONDO:0044991,Gastric juice sample,Saliva samples,Saliva samples from 40 participants undergoing upper gastrointestinal endoscopy.,40,40,One month before sample collection.,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,increased,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:953/5/NA,Study 953,"cross-sectional observational, not case-control",35467373,10.1128/spectrum.00645-21,https://journals.asm.org/doi/10.1128/spectrum.00645-21#tab1,"Li M, Shao D, Zhou J, Gu J, Qin J, Li X, Hao C , Wei W","Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China",Microbiology spectrum,2022,"Helicobacter pylori, gastric cardia, gastric juice, gastric pH, gastrointestinal tract, microbiota",Experiment 5,China,Homo sapiens,Saliva,UBERON:0001836,Upper digestive tract disease,MONDO:0044991,Fecal samples,Saliva samples,Saliva samples from 40 participants undergoing upper gastrointestinal endoscopy.,40,40,One month before sample collection.,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,increased,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:953/6/NA,Study 953,"cross-sectional observational, not case-control",35467373,10.1128/spectrum.00645-21,https://journals.asm.org/doi/10.1128/spectrum.00645-21#tab1,"Li M, Shao D, Zhou J, Gu J, Qin J, Li X, Hao C , Wei W","Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China",Microbiology spectrum,2022,"Helicobacter pylori, gastric cardia, gastric juice, gastric pH, gastrointestinal tract, microbiota",Experiment 6,China,Homo sapiens,Esophagus,UBERON:0001043,Upper digestive tract disease,MONDO:0044991,Cardia biopsy samples,Esophageal swab samples,Esophageal swab samples from 40 participants undergoing upper gastrointestinal endoscopy.,40,40,One month before sample collection.,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:953/7/NA,Study 953,"cross-sectional observational, not case-control",35467373,10.1128/spectrum.00645-21,https://journals.asm.org/doi/10.1128/spectrum.00645-21#tab1,"Li M, Shao D, Zhou J, Gu J, Qin J, Li X, Hao C , Wei W","Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China",Microbiology spectrum,2022,"Helicobacter pylori, gastric cardia, gastric juice, gastric pH, gastrointestinal tract, microbiota",Experiment 7,China,Homo sapiens,Esophagus,UBERON:0001043,Upper digestive tract disease,MONDO:0044991,Non-cardia biopsy samples,Esophageal swab samples,Esophageal swab samples from 40 participants undergoing upper gastrointestinal endoscopy.,40,40,One month before sample collection.,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:953/8/NA,Study 953,"cross-sectional observational, not case-control",35467373,10.1128/spectrum.00645-21,https://journals.asm.org/doi/10.1128/spectrum.00645-21#tab1,"Li M, Shao D, Zhou J, Gu J, Qin J, Li X, Hao C , Wei W","Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China",Microbiology spectrum,2022,"Helicobacter pylori, gastric cardia, gastric juice, gastric pH, gastrointestinal tract, microbiota",Experiment 8,China,Homo sapiens,Esophagus,UBERON:0001043,Upper digestive tract disease,MONDO:0044991,Gastric juice samples,Esophageal swab samples,Esophageal swab samples from 40 participants undergoing upper gastrointestinal endoscopy.,40,40,One month before sample collection.,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:953/9/NA,Study 953,"cross-sectional observational, not case-control",35467373,10.1128/spectrum.00645-21,https://journals.asm.org/doi/10.1128/spectrum.00645-21#tab1,"Li M, Shao D, Zhou J, Gu J, Qin J, Li X, Hao C , Wei W","Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China",Microbiology spectrum,2022,"Helicobacter pylori, gastric cardia, gastric juice, gastric pH, gastrointestinal tract, microbiota",Experiment 9,China,Homo sapiens,Esophagus,UBERON:0001043,Upper digestive tract disease,MONDO:0044991,Fecal samples,Esophageal swab samples,Esophageal swab samples from 40 participants undergoing upper gastrointestinal endoscopy.,40,40,One month before sample collection.,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:953/10/NA,Study 953,"cross-sectional observational, not case-control",35467373,10.1128/spectrum.00645-21,https://journals.asm.org/doi/10.1128/spectrum.00645-21#tab1,"Li M, Shao D, Zhou J, Gu J, Qin J, Li X, Hao C , Wei W","Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China",Microbiology spectrum,2022,"Helicobacter pylori, gastric cardia, gastric juice, gastric pH, gastrointestinal tract, microbiota",Experiment 10,China,Homo sapiens,Cardia of stomach,UBERON:0001162,Upper digestive tract disease,MONDO:0044991,Non-cardia biopsy samples,Cardia biopsy samples,Cardia biopsy samples from 40 participants undergoing upper gastrointestinal endoscopy.,40,40,One month before sample collection.,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:953/11/NA,Study 953,"cross-sectional observational, not case-control",35467373,10.1128/spectrum.00645-21,https://journals.asm.org/doi/10.1128/spectrum.00645-21#tab1,"Li M, Shao D, Zhou J, Gu J, Qin J, Li X, Hao C , Wei W","Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China",Microbiology spectrum,2022,"Helicobacter pylori, gastric cardia, gastric juice, gastric pH, gastrointestinal tract, microbiota",Experiment 11,China,Homo sapiens,Cardia of stomach,UBERON:0001162,Upper digestive tract disease,MONDO:0044991,Gastric juice samples,Cardia biopsy samples,Cardia biopsy samples from 40 participants undergoing upper gastrointestinal endoscopy.,40,40,One month before sample collection.,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:953/12/NA,Study 953,"cross-sectional observational, not case-control",35467373,10.1128/spectrum.00645-21,https://journals.asm.org/doi/10.1128/spectrum.00645-21#tab1,"Li M, Shao D, Zhou J, Gu J, Qin J, Li X, Hao C , Wei W","Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China",Microbiology spectrum,2022,"Helicobacter pylori, gastric cardia, gastric juice, gastric pH, gastrointestinal tract, microbiota",Experiment 12,China,Homo sapiens,Cardia of stomach,UBERON:0001162,Upper digestive tract disease,MONDO:0044991,Fecal samples,Cardia biopsy samples,Cardia biopsy samples from 40 participants undergoing upper gastrointestinal endoscopy.,40,40,One month before sample collection.,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:953/13/NA,Study 953,"cross-sectional observational, not case-control",35467373,10.1128/spectrum.00645-21,https://journals.asm.org/doi/10.1128/spectrum.00645-21#tab1,"Li M, Shao D, Zhou J, Gu J, Qin J, Li X, Hao C , Wei W","Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China",Microbiology spectrum,2022,"Helicobacter pylori, gastric cardia, gastric juice, gastric pH, gastrointestinal tract, microbiota",Experiment 13,China,Homo sapiens,Body of stomach,UBERON:0001161,Upper digestive tract disease,MONDO:0044991,Gastric juice samples,Non-cardia biopsy samples,Non-cardia biopsy samples from 40 participants undergoing upper gastrointestinal endoscopy.,40,40,One month before sample collection.,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:953/14/NA,Study 953,"cross-sectional observational, not case-control",35467373,10.1128/spectrum.00645-21,https://journals.asm.org/doi/10.1128/spectrum.00645-21#tab1,"Li M, Shao D, Zhou J, Gu J, Qin J, Li X, Hao C , Wei W","Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China",Microbiology spectrum,2022,"Helicobacter pylori, gastric cardia, gastric juice, gastric pH, gastrointestinal tract, microbiota",Experiment 14,China,Homo sapiens,Body of stomach,UBERON:0001161,Upper digestive tract disease,MONDO:0044991,Fecal samples,Non-cardia biopsy samples,Non-cardia biopsy samples from 40 participants undergoing upper gastrointestinal endoscopy.,40,40,One month before sample collection.,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,decreased,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:953/15/NA,Study 953,"cross-sectional observational, not case-control",35467373,10.1128/spectrum.00645-21,https://journals.asm.org/doi/10.1128/spectrum.00645-21#tab1,"Li M, Shao D, Zhou J, Gu J, Qin J, Li X, Hao C , Wei W","Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China",Microbiology spectrum,2022,"Helicobacter pylori, gastric cardia, gastric juice, gastric pH, gastrointestinal tract, microbiota",Experiment 15,China,Homo sapiens,Gastric juice,UBERON:0001971,Upper digestive tract disease,MONDO:0044991,Fecal samples,Gastric juice samples,Gastric juice samples from 40 participants undergoing upper gastrointestinal endoscopy.,40,40,One month before sample collection.,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:953/16/NA,Study 953,"cross-sectional observational, not case-control",35467373,10.1128/spectrum.00645-21,https://journals.asm.org/doi/10.1128/spectrum.00645-21#tab1,"Li M, Shao D, Zhou J, Gu J, Qin J, Li X, Hao C , Wei W","Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China",Microbiology spectrum,2022,"Helicobacter pylori, gastric cardia, gastric juice, gastric pH, gastrointestinal tract, microbiota",Experiment 16,China,Homo sapiens,Cardia of stomach,UBERON:0001162,Upper digestive tract disease,MONDO:0044991,H. pylori negative group,H. pylori positive group,Participants who tested positive for H. pylori infection (cardia samples),20,20,One month before sample collection.,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,decreased,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:953/17/NA,Study 953,"cross-sectional observational, not case-control",35467373,10.1128/spectrum.00645-21,https://journals.asm.org/doi/10.1128/spectrum.00645-21#tab1,"Li M, Shao D, Zhou J, Gu J, Qin J, Li X, Hao C , Wei W","Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China",Microbiology spectrum,2022,"Helicobacter pylori, gastric cardia, gastric juice, gastric pH, gastrointestinal tract, microbiota",Experiment 17,China,Homo sapiens,Body of stomach,UBERON:0001161,Upper digestive tract disease,MONDO:0044991,H. pylori negative group,H. pylori positive group,Participants who tested positive for H. pylori infection (non-cardia samples),20,20,One month before sample collection.,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,decreased,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:953/18/NA,Study 953,"cross-sectional observational, not case-control",35467373,10.1128/spectrum.00645-21,https://journals.asm.org/doi/10.1128/spectrum.00645-21#tab1,"Li M, Shao D, Zhou J, Gu J, Qin J, Li X, Hao C , Wei W","Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China",Microbiology spectrum,2022,"Helicobacter pylori, gastric cardia, gastric juice, gastric pH, gastrointestinal tract, microbiota",Experiment 18,China,Homo sapiens,Gastric juice,UBERON:0001971,Upper digestive tract disease,MONDO:0044991,H (higher pH) group,HP (higher pH and H. pylori positive) group,Participants with higher pH and H. pylori positive.,12,NA,One month before sample collection.,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:953/19/NA,Study 953,"cross-sectional observational, not case-control",35467373,10.1128/spectrum.00645-21,https://journals.asm.org/doi/10.1128/spectrum.00645-21#tab1,"Li M, Shao D, Zhou J, Gu J, Qin J, Li X, Hao C , Wei W","Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China",Microbiology spectrum,2022,"Helicobacter pylori, gastric cardia, gastric juice, gastric pH, gastrointestinal tract, microbiota",Experiment 19,China,Homo sapiens,Gastric juice,UBERON:0001971,Upper digestive tract disease,MONDO:0044991,HN (higher pH and H. pylori negative) group,HP (higher pH and H. pylori positive) group,Participants with higher pH and H. pylori positive.,NA,NA,One month before sample collection.,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:953/20/NA,Study 953,"cross-sectional observational, not case-control",35467373,10.1128/spectrum.00645-21,https://journals.asm.org/doi/10.1128/spectrum.00645-21#tab1,"Li M, Shao D, Zhou J, Gu J, Qin J, Li X, Hao C , Wei W","Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China",Microbiology spectrum,2022,"Helicobacter pylori, gastric cardia, gastric juice, gastric pH, gastrointestinal tract, microbiota",Experiment 20,China,Homo sapiens,Gastric juice,UBERON:0001971,Upper digestive tract disease,MONDO:0044991,P (H. pylori positive) group,HP (higher pH and H. pylori positive) group,Participants with higher pH and H. pylori positive.,20,NA,One month before sample collection.,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:953/21/NA,Study 953,"cross-sectional observational, not case-control",35467373,10.1128/spectrum.00645-21,https://journals.asm.org/doi/10.1128/spectrum.00645-21#tab1,"Li M, Shao D, Zhou J, Gu J, Qin J, Li X, Hao C , Wei W","Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China",Microbiology spectrum,2022,"Helicobacter pylori, gastric cardia, gastric juice, gastric pH, gastrointestinal tract, microbiota",Experiment 21,China,Homo sapiens,Gastric juice,UBERON:0001971,Upper digestive tract disease,MONDO:0044991,LP (Lower pH and H. pylori positive) group,HP (higher pH and H. pylori positive) group,Participants with higher pH and H. pylori positive.,NA,NA,One month before sample collection.,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:953/22/NA,Study 953,"cross-sectional observational, not case-control",35467373,10.1128/spectrum.00645-21,https://journals.asm.org/doi/10.1128/spectrum.00645-21#tab1,"Li M, Shao D, Zhou J, Gu J, Qin J, Li X, Hao C , Wei W","Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China",Microbiology spectrum,2022,"Helicobacter pylori, gastric cardia, gastric juice, gastric pH, gastrointestinal tract, microbiota",Experiment 22,China,Homo sapiens,Gastric juice,UBERON:0001971,Upper digestive tract disease,MONDO:0044991,L (Lower pH ) group,HP (higher pH and H. pylori positive) group,Participants with higher pH and H. pylori positive.,28,NA,One month before sample collection.,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,increased,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:953/23/NA,Study 953,"cross-sectional observational, not case-control",35467373,10.1128/spectrum.00645-21,https://journals.asm.org/doi/10.1128/spectrum.00645-21#tab1,"Li M, Shao D, Zhou J, Gu J, Qin J, Li X, Hao C , Wei W","Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China",Microbiology spectrum,2022,"Helicobacter pylori, gastric cardia, gastric juice, gastric pH, gastrointestinal tract, microbiota",Experiment 23,China,Homo sapiens,Gastric juice,UBERON:0001971,Upper digestive tract disease,MONDO:0044991,N (H. pylori negative) group,HP (higher pH and H. pylori positive) group,Participants with higher pH and H. pylori positive.,20,NA,One month before sample collection.,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,increased,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:953/24/NA,Study 953,"cross-sectional observational, not case-control",35467373,10.1128/spectrum.00645-21,https://journals.asm.org/doi/10.1128/spectrum.00645-21#tab1,"Li M, Shao D, Zhou J, Gu J, Qin J, Li X, Hao C , Wei W","Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China",Microbiology spectrum,2022,"Helicobacter pylori, gastric cardia, gastric juice, gastric pH, gastrointestinal tract, microbiota",Experiment 24,China,Homo sapiens,Gastric juice,UBERON:0001971,Upper digestive tract disease,MONDO:0044991,LN (Lower pH and H. pylori negative) group,HP (higher pH and H. pylori positive) group,Participants with higher pH and H. pylori positive.,NA,NA,One month before sample collection.,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,increased,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:953/25/NA,Study 953,"cross-sectional observational, not case-control",35467373,10.1128/spectrum.00645-21,https://journals.asm.org/doi/10.1128/spectrum.00645-21#tab1,"Li M, Shao D, Zhou J, Gu J, Qin J, Li X, Hao C , Wei W","Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China",Microbiology spectrum,2022,"Helicobacter pylori, gastric cardia, gastric juice, gastric pH, gastrointestinal tract, microbiota",Experiment 25,China,Homo sapiens,Gastric juice,UBERON:0001971,Upper digestive tract disease,MONDO:0044991,HN (higher pH and H. pylori negative) group,H (higher pH ) group,Participants with higher pH (pH of gastric juice of >2).,NA,12,One month before sample collection.,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:953/26/NA,Study 953,"cross-sectional observational, not case-control",35467373,10.1128/spectrum.00645-21,https://journals.asm.org/doi/10.1128/spectrum.00645-21#tab1,"Li M, Shao D, Zhou J, Gu J, Qin J, Li X, Hao C , Wei W","Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China",Microbiology spectrum,2022,"Helicobacter pylori, gastric cardia, gastric juice, gastric pH, gastrointestinal tract, microbiota",Experiment 26,China,Homo sapiens,Gastric juice,UBERON:0001971,Upper digestive tract disease,MONDO:0044991,P (H. pylori positive) group,H (higher pH ) group,Participants with higher pH (pH of gastric juice of >2).,20,12,One month before sample collection.,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:953/27/NA,Study 953,"cross-sectional observational, not case-control",35467373,10.1128/spectrum.00645-21,https://journals.asm.org/doi/10.1128/spectrum.00645-21#tab1,"Li M, Shao D, Zhou J, Gu J, Qin J, Li X, Hao C , Wei W","Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China",Microbiology spectrum,2022,"Helicobacter pylori, gastric cardia, gastric juice, gastric pH, gastrointestinal tract, microbiota",Experiment 27,China,Homo sapiens,Gastric juice,UBERON:0001971,Upper digestive tract disease,MONDO:0044991,LP (Lower pH and H. pylori positive) group,H (higher pH ) group,Participants with higher pH (pH of gastric juice of >2).,NA,12,One month before sample collection.,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:953/28/NA,Study 953,"cross-sectional observational, not case-control",35467373,10.1128/spectrum.00645-21,https://journals.asm.org/doi/10.1128/spectrum.00645-21#tab1,"Li M, Shao D, Zhou J, Gu J, Qin J, Li X, Hao C , Wei W","Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China",Microbiology spectrum,2022,"Helicobacter pylori, gastric cardia, gastric juice, gastric pH, gastrointestinal tract, microbiota",Experiment 28,China,Homo sapiens,Gastric juice,UBERON:0001971,Upper digestive tract disease,MONDO:0044991,L (Lower pH ) group,H (higher pH ) group,Participants with higher pH (pH of gastric juice of >2).,28,12,One month before sample collection.,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,increased,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:953/29/NA,Study 953,"cross-sectional observational, not case-control",35467373,10.1128/spectrum.00645-21,https://journals.asm.org/doi/10.1128/spectrum.00645-21#tab1,"Li M, Shao D, Zhou J, Gu J, Qin J, Li X, Hao C , Wei W","Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China",Microbiology spectrum,2022,"Helicobacter pylori, gastric cardia, gastric juice, gastric pH, gastrointestinal tract, microbiota",Experiment 29,China,Homo sapiens,Gastric juice,UBERON:0001971,Upper digestive tract disease,MONDO:0044991,N (H. pylori negative) group,H (higher pH ) group,Participants with higher pH (pH of gastric juice of >2).,20,12,One month before sample collection.,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,increased,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:953/30/NA,Study 953,"cross-sectional observational, not case-control",35467373,10.1128/spectrum.00645-21,https://journals.asm.org/doi/10.1128/spectrum.00645-21#tab1,"Li M, Shao D, Zhou J, Gu J, Qin J, Li X, Hao C , Wei W","Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China",Microbiology spectrum,2022,"Helicobacter pylori, gastric cardia, gastric juice, gastric pH, gastrointestinal tract, microbiota",Experiment 30,China,Homo sapiens,Gastric juice,UBERON:0001971,Upper digestive tract disease,MONDO:0044991,LN (Lower pH and H. pylori negative) group,H (higher pH ) group,Participants with higher pH (pH of gastric juice of >2).,NA,12,One month before sample collection.,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,increased,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:953/31/NA,Study 953,"cross-sectional observational, not case-control",35467373,10.1128/spectrum.00645-21,https://journals.asm.org/doi/10.1128/spectrum.00645-21#tab1,"Li M, Shao D, Zhou J, Gu J, Qin J, Li X, Hao C , Wei W","Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China",Microbiology spectrum,2022,"Helicobacter pylori, gastric cardia, gastric juice, gastric pH, gastrointestinal tract, microbiota",Experiment 31,China,Homo sapiens,Gastric juice,UBERON:0001971,Upper digestive tract disease,MONDO:0044991,P (H. pylori positive) group,HN (Higher pH and H. pylori negative ) group,Participants with Higher pH and are H. pylori negative.,20,NA,One month before sample collection.,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:953/32/NA,Study 953,"cross-sectional observational, not case-control",35467373,10.1128/spectrum.00645-21,https://journals.asm.org/doi/10.1128/spectrum.00645-21#tab1,"Li M, Shao D, Zhou J, Gu J, Qin J, Li X, Hao C , Wei W","Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China",Microbiology spectrum,2022,"Helicobacter pylori, gastric cardia, gastric juice, gastric pH, gastrointestinal tract, microbiota",Experiment 32,China,Homo sapiens,Gastric juice,UBERON:0001971,Upper digestive tract disease,MONDO:0044991,LP (Lower pH and H. pylori positive) group,HN (Higher pH and H. pylori negative ) group,Participants with Higher pH and are H. pylori negative.,NA,NA,One month before sample collection.,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:953/33/NA,Study 953,"cross-sectional observational, not case-control",35467373,10.1128/spectrum.00645-21,https://journals.asm.org/doi/10.1128/spectrum.00645-21#tab1,"Li M, Shao D, Zhou J, Gu J, Qin J, Li X, Hao C , Wei W","Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China",Microbiology spectrum,2022,"Helicobacter pylori, gastric cardia, gastric juice, gastric pH, gastrointestinal tract, microbiota",Experiment 33,China,Homo sapiens,Gastric juice,UBERON:0001971,Upper digestive tract disease,MONDO:0044991,L (Lower pH) group,HN (Higher pH and H. pylori negative ) group,Participants with Higher pH and are H. pylori negative.,28,NA,One month before sample collection.,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:953/34/NA,Study 953,"cross-sectional observational, not case-control",35467373,10.1128/spectrum.00645-21,https://journals.asm.org/doi/10.1128/spectrum.00645-21#tab1,"Li M, Shao D, Zhou J, Gu J, Qin J, Li X, Hao C , Wei W","Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China",Microbiology spectrum,2022,"Helicobacter pylori, gastric cardia, gastric juice, gastric pH, gastrointestinal tract, microbiota",Experiment 34,China,Homo sapiens,Gastric juice,UBERON:0001971,Upper digestive tract disease,MONDO:0044991,N (H. pylori negative) group,HN (Higher pH and H. pylori negative ) group,Participants with Higher pH and are H. pylori negative.,20,NA,One month before sample collection.,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:953/35/NA,Study 953,"cross-sectional observational, not case-control",35467373,10.1128/spectrum.00645-21,https://journals.asm.org/doi/10.1128/spectrum.00645-21#tab1,"Li M, Shao D, Zhou J, Gu J, Qin J, Li X, Hao C , Wei W","Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China",Microbiology spectrum,2022,"Helicobacter pylori, gastric cardia, gastric juice, gastric pH, gastrointestinal tract, microbiota",Experiment 35,China,Homo sapiens,Gastric juice,UBERON:0001971,Upper digestive tract disease,MONDO:0044991,LN (Lower pH and H. pylori negative) group,HN (Higher pH and H. pylori negative ) group,Participants with Higher pH and are H. pylori negative.,NA,NA,One month before sample collection.,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:953/36/NA,Study 953,"cross-sectional observational, not case-control",35467373,10.1128/spectrum.00645-21,https://journals.asm.org/doi/10.1128/spectrum.00645-21#tab1,"Li M, Shao D, Zhou J, Gu J, Qin J, Li X, Hao C , Wei W","Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China",Microbiology spectrum,2022,"Helicobacter pylori, gastric cardia, gastric juice, gastric pH, gastrointestinal tract, microbiota",Experiment 36,China,Homo sapiens,Gastric juice,UBERON:0001971,Upper digestive tract disease,MONDO:0044991,LP (Lower pH and H. pylori positive) group,P (H. pylori positive) group,Participants that tested positive for the H. pylori infection.,NA,20,One month before sample collection.,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:953/37/NA,Study 953,"cross-sectional observational, not case-control",35467373,10.1128/spectrum.00645-21,https://journals.asm.org/doi/10.1128/spectrum.00645-21#tab1,"Li M, Shao D, Zhou J, Gu J, Qin J, Li X, Hao C , Wei W","Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China",Microbiology spectrum,2022,"Helicobacter pylori, gastric cardia, gastric juice, gastric pH, gastrointestinal tract, microbiota",Experiment 37,China,Homo sapiens,Gastric juice,UBERON:0001971,Upper digestive tract disease,MONDO:0044991,L (Lower pH) group,P (H. pylori positive) group,Participants that tested positive for the H. pylori infection.,28,20,One month before sample collection.,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:953/38/NA,Study 953,"cross-sectional observational, not case-control",35467373,10.1128/spectrum.00645-21,https://journals.asm.org/doi/10.1128/spectrum.00645-21#tab1,"Li M, Shao D, Zhou J, Gu J, Qin J, Li X, Hao C , Wei W","Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China",Microbiology spectrum,2022,"Helicobacter pylori, gastric cardia, gastric juice, gastric pH, gastrointestinal tract, microbiota",Experiment 38,China,Homo sapiens,Gastric juice,UBERON:0001971,Upper digestive tract disease,MONDO:0044991,N (H. pylori negative) group,P (H. pylori positive) group,Participants that tested positive for the H. pylori infection.,20,20,One month before sample collection.,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:953/39/NA,Study 953,"cross-sectional observational, not case-control",35467373,10.1128/spectrum.00645-21,https://journals.asm.org/doi/10.1128/spectrum.00645-21#tab1,"Li M, Shao D, Zhou J, Gu J, Qin J, Li X, Hao C , Wei W","Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China",Microbiology spectrum,2022,"Helicobacter pylori, gastric cardia, gastric juice, gastric pH, gastrointestinal tract, microbiota",Experiment 39,China,Homo sapiens,Gastric juice,UBERON:0001971,Upper digestive tract disease,MONDO:0044991,LN (Lower pH and H. pylori negative) group,P (H. pylori positive) group,Participants that tested positive for the H. pylori infection.,NA,20,One month before sample collection.,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:953/40/NA,Study 953,"cross-sectional observational, not case-control",35467373,10.1128/spectrum.00645-21,https://journals.asm.org/doi/10.1128/spectrum.00645-21#tab1,"Li M, Shao D, Zhou J, Gu J, Qin J, Li X, Hao C , Wei W","Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China",Microbiology spectrum,2022,"Helicobacter pylori, gastric cardia, gastric juice, gastric pH, gastrointestinal tract, microbiota",Experiment 40,China,Homo sapiens,Gastric juice,UBERON:0001971,Upper digestive tract disease,MONDO:0044991,L (Lower pH) group,LP (Lower pH and H. pylori positive) group,Participants with lower pH and tested positive for the H. pylori infection.,28,NA,One month before sample collection.,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:953/41/NA,Study 953,"cross-sectional observational, not case-control",35467373,10.1128/spectrum.00645-21,https://journals.asm.org/doi/10.1128/spectrum.00645-21#tab1,"Li M, Shao D, Zhou J, Gu J, Qin J, Li X, Hao C , Wei W","Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China",Microbiology spectrum,2022,"Helicobacter pylori, gastric cardia, gastric juice, gastric pH, gastrointestinal tract, microbiota",Experiment 41,China,Homo sapiens,Gastric juice,UBERON:0001971,Upper digestive tract disease,MONDO:0044991,N (H. pylori negative) group,LP (Lower pH and H. pylori positive) group,Participants with lower pH and tested positive for the H. pylori infection.,20,NA,One month before sample collection.,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:953/42/NA,Study 953,"cross-sectional observational, not case-control",35467373,10.1128/spectrum.00645-21,https://journals.asm.org/doi/10.1128/spectrum.00645-21#tab1,"Li M, Shao D, Zhou J, Gu J, Qin J, Li X, Hao C , Wei W","Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China",Microbiology spectrum,2022,"Helicobacter pylori, gastric cardia, gastric juice, gastric pH, gastrointestinal tract, microbiota",Experiment 42,China,Homo sapiens,Gastric juice,UBERON:0001971,Upper digestive tract disease,MONDO:0044991,LN (Lower pH and H. pylori negative) group,LP (Lower pH and H. pylori positive) group,Participants with lower pH and tested positive for the H. pylori infection.,NA,NA,One month before sample collection.,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:953/43/NA,Study 953,"cross-sectional observational, not case-control",35467373,10.1128/spectrum.00645-21,https://journals.asm.org/doi/10.1128/spectrum.00645-21#tab1,"Li M, Shao D, Zhou J, Gu J, Qin J, Li X, Hao C , Wei W","Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China",Microbiology spectrum,2022,"Helicobacter pylori, gastric cardia, gastric juice, gastric pH, gastrointestinal tract, microbiota",Experiment 43,China,Homo sapiens,Gastric juice,UBERON:0001971,Upper digestive tract disease,MONDO:0044991,N (H. pylori negative) group,L (Lower pH) group,Participants with lower pH (pH of gastric juice of <2).,20,28,One month before sample collection.,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:953/44/NA,Study 953,"cross-sectional observational, not case-control",35467373,10.1128/spectrum.00645-21,https://journals.asm.org/doi/10.1128/spectrum.00645-21#tab1,"Li M, Shao D, Zhou J, Gu J, Qin J, Li X, Hao C , Wei W","Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China",Microbiology spectrum,2022,"Helicobacter pylori, gastric cardia, gastric juice, gastric pH, gastrointestinal tract, microbiota",Experiment 44,China,Homo sapiens,Gastric juice,UBERON:0001971,Upper digestive tract disease,MONDO:0044991,LN (Lower pH and H. pylori negative) group,L (Lower pH) group,Participants with lower pH (pH of gastric juice of <2).,NA,28,One month before sample collection.,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:953/45/NA,Study 953,"cross-sectional observational, not case-control",35467373,10.1128/spectrum.00645-21,https://journals.asm.org/doi/10.1128/spectrum.00645-21#tab1,"Li M, Shao D, Zhou J, Gu J, Qin J, Li X, Hao C , Wei W","Microbial Diversity and Composition in Six Different Gastrointestinal Sites among Participants Undergoing Upper Gastrointestinal Endoscopy in Henan, China",Microbiology spectrum,2022,"Helicobacter pylori, gastric cardia, gastric juice, gastric pH, gastrointestinal tract, microbiota",Experiment 45,China,Homo sapiens,Gastric juice,UBERON:0001971,Upper digestive tract disease,MONDO:0044991,LN (Lower pH and H. pylori negative) group,N (H. pylori negative) group,Participants that tested negative for the H. pylori infection.,NA,20,One month before sample collection.,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:954/1/NA,Study 954,laboratory experiment,37819112,10.1128/msphere.00431-23,NA,"Cui C, Song H, Han Y, Yu H, Li H, Yang Y , Zhang B",Gut microbiota-associated taurine metabolism dysregulation in a mouse model of Parkinson's disease,mSphere,2023,"Lactobacillus, Parkinson's disease, metabolism, microbiota, taurine",Experiment 1,China,Mus musculus,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Control mice,MPTP-treated mice,"Mice were injected with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), to induce Parkinson's disease.",10,9,NA,16S,34,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,decreased,decreased,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:955/1/NA,Study 955,case-control,36795141,10.1007/s00253-023-12410-w,NA,"Shi J, Wang Y, Chen D, Xu X, Li W, Li K, He J, Su W , Luo Q",The alteration of intestinal mucosal α-synuclein expression and mucosal microbiota in Parkinson's disease,Applied microbiology and biotechnology,2023,"Diagnosis, Intestinal mucosa, Mucosal microbiota, Parkinson’s disease, α-Synuclein",Experiment 1,China,Homo sapiens,Duodenal mucosa,UBERON:0000320,Parkinson's disease,MONDO:0005180,Healthy controls,Parkinson's Disease (PD) Patients,Parkinson's disease (PD) patients diagnosed by an experienced neurologist (the stage of Hoehn and Yahr Scale < 5),22,19,None,16S,4,Illumina,LEfSe,0.05,FALSE,4,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:955/2/NA,Study 955,case-control,36795141,10.1007/s00253-023-12410-w,NA,"Shi J, Wang Y, Chen D, Xu X, Li W, Li K, He J, Su W , Luo Q",The alteration of intestinal mucosal α-synuclein expression and mucosal microbiota in Parkinson's disease,Applied microbiology and biotechnology,2023,"Diagnosis, Intestinal mucosa, Mucosal microbiota, Parkinson’s disease, α-Synuclein",Experiment 2,China,Homo sapiens,Mucosa of sigmoid colon,UBERON:0004993,Parkinson's disease,MONDO:0005180,Healthy controls,Parkinson's Disease Patients,Parkinson's disease (PD) patients diagnosed by an experienced neurologist (the stage of Hoehn and Yahr Scale < 5),21,19,None,16S,4,Illumina,LEfSe,0.05,FALSE,4,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:955/3/NA,Study 955,case-control,36795141,10.1007/s00253-023-12410-w,NA,"Shi J, Wang Y, Chen D, Xu X, Li W, Li K, He J, Su W , Luo Q",The alteration of intestinal mucosal α-synuclein expression and mucosal microbiota in Parkinson's disease,Applied microbiology and biotechnology,2023,"Diagnosis, Intestinal mucosa, Mucosal microbiota, Parkinson’s disease, α-Synuclein",Experiment 3,China,Homo sapiens,Mucosa of sigmoid colon,UBERON:0004993,Parkinson's disease,MONDO:0005180,Duodenal mucosa,Sigmoid mucosa,Samples from the sigmoid mucosa of Parkinson's disease (PD) patients,19,19,None,16S,4,Illumina,Kruskall-Wallis,0.05,FALSE,4,NA,NA,NA,increased,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:956/1/NA,Study 956,case-control,38841824,https://doi.org/10.1002/brb3.3579,NA,"Chen YH, Yu H, Xue F, Bai J, Guo L , Peng ZW",16S rRNA gene sequencing reveals altered gut microbiota in young adults with schizophrenia and prominent negative symptoms,Brain and behavior,2024,"gut microbiota, negative symptoms, schizophrenia, young adults",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Schizophrenia,MONDO:0005090,Healthy controls,Schizophrenia patients with prominent negative symptoms (SCH-N),Patients with schizophrenia with prominent negative symptoms (SCH-N) who met the diagnostic criteria of schizophrenia with a total positive and negative syndrome scale (PANSS) score ≥60 according to the Statistical Clinical Interview for DSM-5 by two psychiatrists.,36,30,1 month,16S,34,Illumina,LEfSe,0.05,FALSE,3,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:956/2/NA,Study 956,case-control,38841824,https://doi.org/10.1002/brb3.3579,NA,"Chen YH, Yu H, Xue F, Bai J, Guo L , Peng ZW",16S rRNA gene sequencing reveals altered gut microbiota in young adults with schizophrenia and prominent negative symptoms,Brain and behavior,2024,"gut microbiota, negative symptoms, schizophrenia, young adults",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Schizophrenia,MONDO:0005090,Schizophrenia patients with prominent negative symptoms (SCH-N),Schizophrenia patients with prominent positive symptoms (SCH-P),"Patients with schizophrenia with prominent positive symptoms (SCH-P) who met the diagnostic criteria of schizophrenia with a total positive and negative syndrome scale (PANSS) score ≥60; at least three out of seven items of PANSS positive subscale score ≥4, or at least two items score ≥5, and a total PANSS positive subscale score ≥20, and at least 3 points more than the total PANSS negative subscale score.",30,32,1 month,16S,34,Illumina,LEfSe,0.05,FALSE,1.5,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:957/1/NA,Study 957,case-control,35798742,https://doi.org/10.1038/s41531-022-00351-6,NA,"Jo S, Kang W, Hwang YS, Lee SH, Park KW, Kim MS, Lee H, Yoon HJ, Park YK, Chalita M, Lee JH, Sung H, Lee JY, Bae JW , Chung SJ",Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,NPJ Parkinson's disease,2022,NA,Experiment 1,South Korea,Homo sapiens,Buccal mucosa,UBERON:0006956,Parkinson's disease,MONDO:0005180,Healthy controls (HC),Patients with Parkinson's Disease (PD),Patients with Parkinson's disease enrolled using the UK PD Society brain bank clinical diagnostic criteria.,69,74,participants using antibiotics,16S,34,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:957/2/NA,Study 957,case-control,35798742,https://doi.org/10.1038/s41531-022-00351-6,NA,"Jo S, Kang W, Hwang YS, Lee SH, Park KW, Kim MS, Lee H, Yoon HJ, Park YK, Chalita M, Lee JH, Sung H, Lee JY, Bae JW , Chung SJ",Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,NPJ Parkinson's disease,2022,NA,Experiment 2,South Korea,Homo sapiens,Buccal mucosa,UBERON:0006956,Parkinson's disease symptom measurement,EFO:0600011,Patients with mild Parkinson's disease  (mild PD),Patients with severe Parkinson's disease (severe PD),Patients with Parkinson's disease whose H&Y stage was 3 or greater,NA,NA,participants using antibiotics,16S,34,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:957/3/NA,Study 957,case-control,35798742,https://doi.org/10.1038/s41531-022-00351-6,NA,"Jo S, Kang W, Hwang YS, Lee SH, Park KW, Kim MS, Lee H, Yoon HJ, Park YK, Chalita M, Lee JH, Sung H, Lee JY, Bae JW , Chung SJ",Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,NPJ Parkinson's disease,2022,NA,Experiment 3,South Korea,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease symptom measurement,EFO:0600011,Patients with mild Parkinson's disease  (mild PD),Patients with severe Parkinson's disease (severe PD),Parkinson's disease patients whose H&Y scale stage was 3 or greater.,NA,NA,participants using antibiotics.,16S,34,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:957/4/NA,Study 957,case-control,35798742,https://doi.org/10.1038/s41531-022-00351-6,NA,"Jo S, Kang W, Hwang YS, Lee SH, Park KW, Kim MS, Lee H, Yoon HJ, Park YK, Chalita M, Lee JH, Sung H, Lee JY, Bae JW , Chung SJ",Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,NPJ Parkinson's disease,2022,NA,Experiment 4,South Korea,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Healthy controls (HC),Patients with Parkinson's Disease (PD),Patients with Parkinson's disease enrolled using the UK PD Society brain bank clinical diagnostic criteria.,84,88,participants using antibiotics,16S,34,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,increased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:957/5/NA,Study 957,case-control,35798742,https://doi.org/10.1038/s41531-022-00351-6,NA,"Jo S, Kang W, Hwang YS, Lee SH, Park KW, Kim MS, Lee H, Yoon HJ, Park YK, Chalita M, Lee JH, Sung H, Lee JY, Bae JW , Chung SJ",Oral and gut dysbiosis leads to functional alterations in Parkinson's disease,NPJ Parkinson's disease,2022,NA,Experiment 5,South Korea,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Healthy controls (HC),Patients with Parkinson's Disease (PD),Patients with Parkinson's disease enrolled using the UK PD Society brain bank clinical diagnostic criteria.,84,88,participants using antibiotics,WMS,NA,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:958/1/NA,Study 958,time series / longitudinal observational,38385646,https://doi.org/10.1128/spectrum.03142-23,https://journals.asm.org/doi/pdf/10.1128/spectrum.03142-23,"Bo Wu, Peng Wang, Tangjuan Zhang, Ting Qian, Xiangnan Li, Xue Pan, Zheng Ding, Zhichao Hou",Analysis on the change of gut microbiota and metabolome in lung transplant patients,American Society for Microbiology,2024,"gut microbiota, metabolome, lung transplantation, transplant rejection",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Lung transplantation,EFO:0010721,No lung transplant group (NT),Lung transplant event-free group (EF),cases without any symptoms and with negative pathology were considered event-free patients after transplantation.,20,15,1 month,16S,4,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:958/2/NA,Study 958,time series / longitudinal observational,38385646,https://doi.org/10.1128/spectrum.03142-23,https://journals.asm.org/doi/pdf/10.1128/spectrum.03142-23,"Bo Wu, Peng Wang, Tangjuan Zhang, Ting Qian, Xiangnan Li, Xue Pan, Zheng Ding, Zhichao Hou",Analysis on the change of gut microbiota and metabolome in lung transplant patients,American Society for Microbiology,2024,"gut microbiota, metabolome, lung transplantation, transplant rejection",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Lung transplantation,EFO:0010721,No lung transplant group (NT),Lung transplant chronic rejection group (CR),The lung transplant rejection participants were patients who survived more than 6 months after transplant and were all cases of chronic rejection.,20,17,1 month,16S,4,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:958/3/NA,Study 958,time series / longitudinal observational,38385646,https://doi.org/10.1128/spectrum.03142-23,https://journals.asm.org/doi/pdf/10.1128/spectrum.03142-23,"Bo Wu, Peng Wang, Tangjuan Zhang, Ting Qian, Xiangnan Li, Xue Pan, Zheng Ding, Zhichao Hou",Analysis on the change of gut microbiota and metabolome in lung transplant patients,American Society for Microbiology,2024,"gut microbiota, metabolome, lung transplantation, transplant rejection",Experiment 3,China,Homo sapiens,Feces,UBERON:0001988,Lung transplantation,EFO:0010721,Lung transplant event-free group (EF),Lung transplant chronic rejection group (CR),The lung transplant rejection participants were patients who survived more than 6 months after transplant and were all cases of chronic rejection.,15,17,1 month,16S,4,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:959/1/NA,Study 959,case-control,37695126,10.1128/spectrum.00662-23,NA,"Eickhardt-Dalbøge CS, Ingham AC, Nielsen HV, Fuursted K, Stensvold CR, Andersen LO, Larsen MK, Kjær L, Christensen SF, Knudsen TA, Skov V, Ellervik C, Olsen LR, Hasselbalch HC, Elmer Christensen JJ , Nielsen XC",Pronounced gut microbiota signatures in patients with <i>JAK2V617F-</i>positive essential thrombocythemia,Microbiology spectrum,2023,"ET, JAK2V617F, essential thrombocythemia, gut microbiome, gut microbiota, inflammation, myelofibrosis, myeloproliferative neoplasms, polycythemia vera",Experiment 1,Denmark,Homo sapiens,Feces,UBERON:0001988,Essential thrombocythemia,EFO:0000479,Healthy Controls,Essential thrombocythemia (ET),"Patients with essential thrombocythemia (ET), a cancer characterized by thrombocyte overproduction",42,54,2 months,16S,34,Illumina,LEfSe,0.05,TRUE,0.005,sex,NA,NA,NA,NA,NA,unchanged,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:959/2/NA,Study 959,case-control,37695126,10.1128/spectrum.00662-23,NA,"Eickhardt-Dalbøge CS, Ingham AC, Nielsen HV, Fuursted K, Stensvold CR, Andersen LO, Larsen MK, Kjær L, Christensen SF, Knudsen TA, Skov V, Ellervik C, Olsen LR, Hasselbalch HC, Elmer Christensen JJ , Nielsen XC",Pronounced gut microbiota signatures in patients with <i>JAK2V617F-</i>positive essential thrombocythemia,Microbiology spectrum,2023,"ET, JAK2V617F, essential thrombocythemia, gut microbiome, gut microbiota, inflammation, myelofibrosis, myeloproliferative neoplasms, polycythemia vera",Experiment 2,Denmark,Homo sapiens,Feces,UBERON:0001988,Essential thrombocythemia,EFO:0000479,Healthy Controls,Janus-kinase 2 (JAK2V617F)-positive,Essential thrombocythemia patients positive for the Janus-kinase 2 (JAK2V617F) mutation,42,36,2 months,16S,34,Illumina,LEfSe,0.05,TRUE,0.005,sex,NA,NA,NA,NA,NA,unchanged,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:959/3/NA,Study 959,case-control,37695126,10.1128/spectrum.00662-23,NA,"Eickhardt-Dalbøge CS, Ingham AC, Nielsen HV, Fuursted K, Stensvold CR, Andersen LO, Larsen MK, Kjær L, Christensen SF, Knudsen TA, Skov V, Ellervik C, Olsen LR, Hasselbalch HC, Elmer Christensen JJ , Nielsen XC",Pronounced gut microbiota signatures in patients with <i>JAK2V617F-</i>positive essential thrombocythemia,Microbiology spectrum,2023,"ET, JAK2V617F, essential thrombocythemia, gut microbiome, gut microbiota, inflammation, myelofibrosis, myeloproliferative neoplasms, polycythemia vera",Experiment 3,Denmark,Homo sapiens,Feces,UBERON:0001988,Essential thrombocythemia,EFO:0000479,Healthy Controls,Janus-kinase 2 (JAK2V617F)-negative,Essential thrombocythemia patients negative for the Janus-kinase 2 (JAK2V617F) mutation,42,16,2 months,16S,34,Illumina,LEfSe,0.05,TRUE,0.005,sex,NA,NA,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:959/4/NA,Study 959,case-control,37695126,10.1128/spectrum.00662-23,NA,"Eickhardt-Dalbøge CS, Ingham AC, Nielsen HV, Fuursted K, Stensvold CR, Andersen LO, Larsen MK, Kjær L, Christensen SF, Knudsen TA, Skov V, Ellervik C, Olsen LR, Hasselbalch HC, Elmer Christensen JJ , Nielsen XC",Pronounced gut microbiota signatures in patients with <i>JAK2V617F-</i>positive essential thrombocythemia,Microbiology spectrum,2023,"ET, JAK2V617F, essential thrombocythemia, gut microbiome, gut microbiota, inflammation, myelofibrosis, myeloproliferative neoplasms, polycythemia vera",Experiment 4,Denmark,Homo sapiens,Feces,UBERON:0001988,Essential thrombocythemia,EFO:0000479,Janus-kinase 2 (JAK2V617F)-negative,Janus-kinase 2 (JAK2V617F)-positive,Essential thrombocythemia patients positive for the Janus-kinase 2 (JAK2V617F) mutation,16,36,2 months,16S,34,Illumina,LEfSe,0.05,TRUE,0.005,sex,NA,NA,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:960/1/NA,Study 960,laboratory experiment,36467550,10.1155/2022/9110560,NA,"Zhu H, Zhang H, Hou B, Xu B, Ji L , Wu Y",Curcumin Regulates Gut Microbiota and Exerts a Neuroprotective Effect in the MPTP Model of Parkinson's Disease,Evidence-based complementary and alternative medicine : eCAM,2022,NA,Experiment 1,China,Mus musculus,Feces,UBERON:0001988,Curcumin,CHEBI:3962,MPTP,CUR-L,"Curcumin low-dose (CUR-L) group received a combination of both treatments in
which curcumin (40 mg/kg)",12,12,NA,16S,NA,Illumina,LEfSe,0.05,FALSE,3,NA,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:960/2/NA,Study 960,laboratory experiment,36467550,10.1155/2022/9110560,NA,"Zhu H, Zhang H, Hou B, Xu B, Ji L , Wu Y",Curcumin Regulates Gut Microbiota and Exerts a Neuroprotective Effect in the MPTP Model of Parkinson's Disease,Evidence-based complementary and alternative medicine : eCAM,2022,NA,Experiment 2,China,Mus musculus,Feces,UBERON:0001988,Curcumin,CHEBI:3962,MPTP,CUR-M,Curcumin Medium-dose (CUR-M) group received a combination of both treatments in which curcumin (80 mg/kg),12,12,NA,16S,NA,Illumina,LEfSe,0.05,FALSE,3,NA,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:960/3/NA,Study 960,laboratory experiment,36467550,10.1155/2022/9110560,NA,"Zhu H, Zhang H, Hou B, Xu B, Ji L , Wu Y",Curcumin Regulates Gut Microbiota and Exerts a Neuroprotective Effect in the MPTP Model of Parkinson's Disease,Evidence-based complementary and alternative medicine : eCAM,2022,NA,Experiment 3,China,Mus musculus,Feces,UBERON:0001988,Curcumin,CHEBI:3962,MPTP,CUR-H,Curcumin High-dose (CUR-H) group received a combination of both treatments in which curcumin (160 mg/kg),12,12,NA,16S,NA,Illumina,LEfSe,0.05,FALSE,3,NA,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:961/1/NA,Study 961,laboratory experiment,37334756,https://doi.org/10.1111/cns.14302,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651963/,"Yang C, Wang W, Deng P, Wang X, Zhu L, Zhao L, Li C , Gao H",Fibroblast growth factor 21 ameliorates behavior deficits in Parkinson's disease mouse model via modulating gut microbiota and metabolic homeostasis,CNS neuroscience & therapeutics,2023,"FGF21, Parkinson's disease, metabolism, microbiota-gut-brain metabolic axis, neurotransmitter",Experiment 1,China,Mus musculus,Colon,UBERON:0001155,Parkinson's disease,MONDO:0005180,Control (CON groups),MPTP (untreated PD mice),"1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) induced Parkinson's disease (PD) mice model.",10,10,None,16S,4,Ion Torrent,LEfSe,0.05,FALSE,4,NA,NA,NA,unchanged,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:961/2/NA,Study 961,laboratory experiment,37334756,https://doi.org/10.1111/cns.14302,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651963/,"Yang C, Wang W, Deng P, Wang X, Zhu L, Zhao L, Li C , Gao H",Fibroblast growth factor 21 ameliorates behavior deficits in Parkinson's disease mouse model via modulating gut microbiota and metabolic homeostasis,CNS neuroscience & therapeutics,2023,"FGF21, Parkinson's disease, metabolism, microbiota-gut-brain metabolic axis, neurotransmitter",Experiment 2,China,Mus musculus,Colon,UBERON:0001155,Clinical treatment,EFO:0007056,FGF21 + MPTP mice (mice treated with Fibroblast growth factor 21 (FGF21)),MPTP (untreated PD mice),"1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) induced Parkinson's disease (PD) mice model.",10,10,None,16S,4,Ion Torrent,LEfSe,0.05,FALSE,4,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:962/1/NA,Study 962,laboratory experiment,38627869,10.1186/s42523-024-00306-7,https://animalmicrobiome.biomedcentral.com/articles/10.1186/s42523-024-00306-7,"Ortiz Sanjuán JM, Argüello H, Cabrera-Rubio R, Crispie F, Cotter PD, Garrido JJ, Ekhlas D, Burgess CM , Manzanilla EG",Effects of removing in-feed antibiotics and zinc oxide on the taxonomy and functionality of the microbiota in post weaning pigs,Animal microbiome,2024,"Antimicrobial use, Diarrhea, Piglet, Shotgun sequencing, Swine",Experiment 1,Ireland,Sus scrofa domesticus,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,Non-medicated control (CT) global data set,Antibiotic (Ab) global data set,"Piglets treated with antibiotics
Global data set involves both consistency and Day post weaning (dpw) factors",NA,NA,NA,WMS,NA,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:962/2/NA,Study 962,laboratory experiment,38627869,10.1186/s42523-024-00306-7,https://animalmicrobiome.biomedcentral.com/articles/10.1186/s42523-024-00306-7,"Ortiz Sanjuán JM, Argüello H, Cabrera-Rubio R, Crispie F, Cotter PD, Garrido JJ, Ekhlas D, Burgess CM , Manzanilla EG",Effects of removing in-feed antibiotics and zinc oxide on the taxonomy and functionality of the microbiota in post weaning pigs,Animal microbiome,2024,"Antimicrobial use, Diarrhea, Piglet, Shotgun sequencing, Swine",Experiment 2,Ireland,Sus scrofa domesticus,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,Non-medicated control (CT) global data set,Therapeutic Zinc oxide (Zn) global data set,"Piglets treated with Therapeutic Zinc oxide
Global data set involves both consistency and Day post weaning (dpw) factors",NA,NA,NA,WMS,NA,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:962/3/NA,Study 962,laboratory experiment,38627869,10.1186/s42523-024-00306-7,https://animalmicrobiome.biomedcentral.com/articles/10.1186/s42523-024-00306-7,"Ortiz Sanjuán JM, Argüello H, Cabrera-Rubio R, Crispie F, Cotter PD, Garrido JJ, Ekhlas D, Burgess CM , Manzanilla EG",Effects of removing in-feed antibiotics and zinc oxide on the taxonomy and functionality of the microbiota in post weaning pigs,Animal microbiome,2024,"Antimicrobial use, Diarrhea, Piglet, Shotgun sequencing, Swine",Experiment 3,Ireland,Sus scrofa domesticus,Feces,UBERON:0001988,Antimicrobial agent,CHEBI:33281,Antibiotics (AB) global data set,Therapeutic Zinc oxide (Zn) global data set,"Piglets treated with Therapeutic Zinc oxide
Global data set involves both consistency and Day post weaning (dpw) factors",NA,NA,NA,WMS,NA,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:962/4/NA,Study 962,laboratory experiment,38627869,10.1186/s42523-024-00306-7,https://animalmicrobiome.biomedcentral.com/articles/10.1186/s42523-024-00306-7,"Ortiz Sanjuán JM, Argüello H, Cabrera-Rubio R, Crispie F, Cotter PD, Garrido JJ, Ekhlas D, Burgess CM , Manzanilla EG",Effects of removing in-feed antibiotics and zinc oxide on the taxonomy and functionality of the microbiota in post weaning pigs,Animal microbiome,2024,"Antimicrobial use, Diarrhea, Piglet, Shotgun sequencing, Swine",Experiment 4,Ireland,Sus scrofa domesticus,Feces,UBERON:0001988,Sampling time,EFO:0000689,Day 0 post weaning (0dpw),Day 7 post weaning (7dpw),"The dietary treatments were administered in the first two weeks post weaning and samplings were scheduled at days 0, 7 and 14 post weaning (0dpw, 7dpw, and 14dpw. respectively).",NA,NA,NA,WMS,NA,Illumina,LEfSe,0.05,TRUE,2,NA,NA,decreased,decreased,decreased,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:962/5/NA,Study 962,laboratory experiment,38627869,10.1186/s42523-024-00306-7,https://animalmicrobiome.biomedcentral.com/articles/10.1186/s42523-024-00306-7,"Ortiz Sanjuán JM, Argüello H, Cabrera-Rubio R, Crispie F, Cotter PD, Garrido JJ, Ekhlas D, Burgess CM , Manzanilla EG",Effects of removing in-feed antibiotics and zinc oxide on the taxonomy and functionality of the microbiota in post weaning pigs,Animal microbiome,2024,"Antimicrobial use, Diarrhea, Piglet, Shotgun sequencing, Swine",Experiment 5,Ireland,Sus scrofa domesticus,Feces,UBERON:0001988,Sampling time,EFO:0000689,Day 0 post weaning (0dpw),Day 14 post weaning (14dpw),"The dietary treatments were administered in the first two weeks post weaning and samplings were scheduled at days 0, 7 and 14 post weaning (0dpw, 7dpw, and 14dpw. respectively).",NA,NA,NA,WMS,NA,Illumina,LEfSe,0.05,TRUE,2,NA,NA,decreased,decreased,decreased,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:962/6/NA,Study 962,laboratory experiment,38627869,10.1186/s42523-024-00306-7,https://animalmicrobiome.biomedcentral.com/articles/10.1186/s42523-024-00306-7,"Ortiz Sanjuán JM, Argüello H, Cabrera-Rubio R, Crispie F, Cotter PD, Garrido JJ, Ekhlas D, Burgess CM , Manzanilla EG",Effects of removing in-feed antibiotics and zinc oxide on the taxonomy and functionality of the microbiota in post weaning pigs,Animal microbiome,2024,"Antimicrobial use, Diarrhea, Piglet, Shotgun sequencing, Swine",Experiment 6,Ireland,Sus scrofa domesticus,Feces,UBERON:0001988,Sampling time,EFO:0000689,Day 7 post weaning (7dpw),Day 14 post weaning (14dpw),"The dietary treatments were administered in the first two weeks post weaning and samplings were scheduled at days 0, 7 and 14 post weaning (0dpw, 7dpw, and 14dpw. respectively).",NA,NA,NA,WMS,NA,Illumina,LEfSe,0.05,TRUE,2,NA,NA,decreased,decreased,decreased,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:962/7/NA,Study 962,laboratory experiment,38627869,10.1186/s42523-024-00306-7,https://animalmicrobiome.biomedcentral.com/articles/10.1186/s42523-024-00306-7,"Ortiz Sanjuán JM, Argüello H, Cabrera-Rubio R, Crispie F, Cotter PD, Garrido JJ, Ekhlas D, Burgess CM , Manzanilla EG",Effects of removing in-feed antibiotics and zinc oxide on the taxonomy and functionality of the microbiota in post weaning pigs,Animal microbiome,2024,"Antimicrobial use, Diarrhea, Piglet, Shotgun sequencing, Swine",Experiment 7,Ireland,Sus scrofa domesticus,Feces,UBERON:0001988,Abnormal sample,EFO:0009655,Faecal_7dpw CT(no-medication) group,Diarrhoea_7dpw CT(no-medication) group,Diarrhoea samples collected at day 7 post weaning from piglets not treated with medication,NA,NA,NA,WMS,NA,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:962/8/NA,Study 962,laboratory experiment,38627869,10.1186/s42523-024-00306-7,https://animalmicrobiome.biomedcentral.com/articles/10.1186/s42523-024-00306-7,"Ortiz Sanjuán JM, Argüello H, Cabrera-Rubio R, Crispie F, Cotter PD, Garrido JJ, Ekhlas D, Burgess CM , Manzanilla EG",Effects of removing in-feed antibiotics and zinc oxide on the taxonomy and functionality of the microbiota in post weaning pigs,Animal microbiome,2024,"Antimicrobial use, Diarrhea, Piglet, Shotgun sequencing, Swine",Experiment 8,Ireland,Sus scrofa domesticus,Feces,UBERON:0001988,Abnormal sample,EFO:0009655,Faecal_7dpw AB(antibiotics) group,Diarrhoea_7dpw AB(antibiotics) group,Diarrhoea samples collected at day 7 post weaning from piglets treated with antibiotics,NA,NA,NA,WMS,NA,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:962/9/NA,Study 962,laboratory experiment,38627869,10.1186/s42523-024-00306-7,https://animalmicrobiome.biomedcentral.com/articles/10.1186/s42523-024-00306-7,"Ortiz Sanjuán JM, Argüello H, Cabrera-Rubio R, Crispie F, Cotter PD, Garrido JJ, Ekhlas D, Burgess CM , Manzanilla EG",Effects of removing in-feed antibiotics and zinc oxide on the taxonomy and functionality of the microbiota in post weaning pigs,Animal microbiome,2024,"Antimicrobial use, Diarrhea, Piglet, Shotgun sequencing, Swine",Experiment 9,Ireland,Sus scrofa domesticus,Feces,UBERON:0001988,Abnormal sample,EFO:0009655,Faecal_7dpw Zn(Zinc Oxide) group,Diarrhoea_7dpw Zn(Zinc Oxide) group,Diarrhoea samples collected at day 7 post weaning from piglets treated with Zinc Oxide,NA,NA,NA,WMS,NA,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:962/10/NA,Study 962,laboratory experiment,38627869,10.1186/s42523-024-00306-7,https://animalmicrobiome.biomedcentral.com/articles/10.1186/s42523-024-00306-7,"Ortiz Sanjuán JM, Argüello H, Cabrera-Rubio R, Crispie F, Cotter PD, Garrido JJ, Ekhlas D, Burgess CM , Manzanilla EG",Effects of removing in-feed antibiotics and zinc oxide on the taxonomy and functionality of the microbiota in post weaning pigs,Animal microbiome,2024,"Antimicrobial use, Diarrhea, Piglet, Shotgun sequencing, Swine",Experiment 10,Ireland,Sus scrofa domesticus,Feces,UBERON:0001988,Abnormal sample,EFO:0009655,Faecal_0dpw AB(antibiotics) group,Diarrhoea_0dpw AB(antibiotics) group,Diarrhoea samples collected at day 0 post weaning from piglets treated with antibiotics,NA,NA,NA,WMS,NA,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:962/11/NA,Study 962,laboratory experiment,38627869,10.1186/s42523-024-00306-7,https://animalmicrobiome.biomedcentral.com/articles/10.1186/s42523-024-00306-7,"Ortiz Sanjuán JM, Argüello H, Cabrera-Rubio R, Crispie F, Cotter PD, Garrido JJ, Ekhlas D, Burgess CM , Manzanilla EG",Effects of removing in-feed antibiotics and zinc oxide on the taxonomy and functionality of the microbiota in post weaning pigs,Animal microbiome,2024,"Antimicrobial use, Diarrhea, Piglet, Shotgun sequencing, Swine",Experiment 11,Ireland,Sus scrofa domesticus,Feces,UBERON:0001988,Abnormal sample,EFO:0009655,Faecal_14dpw CT(no medication) group,Diarrhoea_14pw CT(no medication) group,Diarrhoea samples collected at day 14 post weaning from piglets not treated with medication,NA,NA,NA,WMS,NA,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:962/12/NA,Study 962,laboratory experiment,38627869,10.1186/s42523-024-00306-7,https://animalmicrobiome.biomedcentral.com/articles/10.1186/s42523-024-00306-7,"Ortiz Sanjuán JM, Argüello H, Cabrera-Rubio R, Crispie F, Cotter PD, Garrido JJ, Ekhlas D, Burgess CM , Manzanilla EG",Effects of removing in-feed antibiotics and zinc oxide on the taxonomy and functionality of the microbiota in post weaning pigs,Animal microbiome,2024,"Antimicrobial use, Diarrhea, Piglet, Shotgun sequencing, Swine",Experiment 12,Ireland,Sus scrofa domesticus,Feces,UBERON:0001988,Abnormal sample,EFO:0009655,Faecal_14dpw AB(antibiotics) group,Diarrhoea_14dpw AB(antibiotics) group,Diarrhoea samples collected at day 14 post weaning from piglets treated with antibiotics,NA,NA,NA,WMS,NA,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:962/13/NA,Study 962,laboratory experiment,38627869,10.1186/s42523-024-00306-7,https://animalmicrobiome.biomedcentral.com/articles/10.1186/s42523-024-00306-7,"Ortiz Sanjuán JM, Argüello H, Cabrera-Rubio R, Crispie F, Cotter PD, Garrido JJ, Ekhlas D, Burgess CM , Manzanilla EG",Effects of removing in-feed antibiotics and zinc oxide on the taxonomy and functionality of the microbiota in post weaning pigs,Animal microbiome,2024,"Antimicrobial use, Diarrhea, Piglet, Shotgun sequencing, Swine",Experiment 13,Ireland,Sus scrofa domesticus,Feces,UBERON:0001988,Abnormal sample,EFO:0009655,Faecal_14dpw Zn(Zinc Oxide) group,Diarrhoea_14dpw Zn(Zinc Oxide) group,Diarrhoea samples collected at day 14 post weaning from piglets treated with Zinc Oxide,NA,NA,NA,WMS,NA,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:963/1/NA,Study 963,"laboratory experiment,time series / longitudinal observational",33963313,10.1038/s41418-021-00784-1,NA,"Terrisse S, Derosa L, Iebba V, Ghiringhelli F, Vaz-Luis I, Kroemer G, Fidelle M, Christodoulidis S, Segata N, Thomas AM, Martin AL, Sirven A, Everhard S, Aprahamian F, Nirmalathasan N, Aarnoutse R, Smidt M, Ziemons J, Caldas C, Loibl S, Denkert C, Durand S, Iglesias C, Pietrantonio F, Routy B, André F, Pasolli E, Delaloge S , Zitvogel L",Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment,Cell death and differentiation,2021,NA,Experiment 1,France,Homo sapiens,Feces,UBERON:0001988,Tumor stage,EFO:0004925,Pre-CT Stage I,Pre-CT Stage II/III,Breast cancer patients before chemotherapy with TNM Stage II/III,21,35,None,WMS,NA,Ion Torrent,PLS-DA (Partial least square discriminant analysis),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:963/2/NA,Study 963,"laboratory experiment,time series / longitudinal observational",33963313,10.1038/s41418-021-00784-1,NA,"Terrisse S, Derosa L, Iebba V, Ghiringhelli F, Vaz-Luis I, Kroemer G, Fidelle M, Christodoulidis S, Segata N, Thomas AM, Martin AL, Sirven A, Everhard S, Aprahamian F, Nirmalathasan N, Aarnoutse R, Smidt M, Ziemons J, Caldas C, Loibl S, Denkert C, Durand S, Iglesias C, Pietrantonio F, Routy B, André F, Pasolli E, Delaloge S , Zitvogel L",Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment,Cell death and differentiation,2021,NA,Experiment 2,France,Homo sapiens,Feces,UBERON:0001988,Tumor stage,EFO:0004925,Post-CT Stage I,Post-CT Stage II/III,Breast cancer patients after chemotherapy with TNM Stage II/III,14,20,None,WMS,NA,Ion Torrent,PLS-DA (Partial least square discriminant analysis),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:963/3/NA,Study 963,"laboratory experiment,time series / longitudinal observational",33963313,10.1038/s41418-021-00784-1,NA,"Terrisse S, Derosa L, Iebba V, Ghiringhelli F, Vaz-Luis I, Kroemer G, Fidelle M, Christodoulidis S, Segata N, Thomas AM, Martin AL, Sirven A, Everhard S, Aprahamian F, Nirmalathasan N, Aarnoutse R, Smidt M, Ziemons J, Caldas C, Loibl S, Denkert C, Durand S, Iglesias C, Pietrantonio F, Routy B, André F, Pasolli E, Delaloge S , Zitvogel L",Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment,Cell death and differentiation,2021,NA,Experiment 3,France,Homo sapiens,Feces,UBERON:0001988,Tumor size,EFO:0004134,Pre-Chemo tumor size <pT1,Pre-Chemo tumor size >pT1,Breast cancer patients before chemotherapy with pathological tumor size greater than pT1,24,32,None,WMS,NA,Ion Torrent,PLS-DA (Partial least square discriminant analysis),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:963/4/NA,Study 963,"laboratory experiment,time series / longitudinal observational",33963313,10.1038/s41418-021-00784-1,NA,"Terrisse S, Derosa L, Iebba V, Ghiringhelli F, Vaz-Luis I, Kroemer G, Fidelle M, Christodoulidis S, Segata N, Thomas AM, Martin AL, Sirven A, Everhard S, Aprahamian F, Nirmalathasan N, Aarnoutse R, Smidt M, Ziemons J, Caldas C, Loibl S, Denkert C, Durand S, Iglesias C, Pietrantonio F, Routy B, André F, Pasolli E, Delaloge S , Zitvogel L",Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment,Cell death and differentiation,2021,NA,Experiment 4,France,Homo sapiens,Feces,UBERON:0001988,Tumor size,EFO:0004134,Post-Chemo tumor size <pT1,Post-Chemo tumor size >pT1,Breast cancer patients after chemotherapy with pathological tumor size greater than pT1,13,21,None,WMS,NA,Ion Torrent,PLS-DA (Partial least square discriminant analysis),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:963/5/NA,Study 963,"laboratory experiment,time series / longitudinal observational",33963313,10.1038/s41418-021-00784-1,NA,"Terrisse S, Derosa L, Iebba V, Ghiringhelli F, Vaz-Luis I, Kroemer G, Fidelle M, Christodoulidis S, Segata N, Thomas AM, Martin AL, Sirven A, Everhard S, Aprahamian F, Nirmalathasan N, Aarnoutse R, Smidt M, Ziemons J, Caldas C, Loibl S, Denkert C, Durand S, Iglesias C, Pietrantonio F, Routy B, André F, Pasolli E, Delaloge S , Zitvogel L",Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment,Cell death and differentiation,2021,NA,Experiment 5,France,Homo sapiens,Feces,UBERON:0001988,Tumor grading,OBI:0600002,SBR Gr1/2 Post-Chemo,SBR Gr3 Post-Chemo,Breast cancer patients after chemotherapy with Scarff Bloom & Richardson (SBR) grade Gr3,20,24,None,WMS,NA,Ion Torrent,PLS-DA (Partial least square discriminant analysis),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:963/6/NA,Study 963,"laboratory experiment,time series / longitudinal observational",33963313,10.1038/s41418-021-00784-1,NA,"Terrisse S, Derosa L, Iebba V, Ghiringhelli F, Vaz-Luis I, Kroemer G, Fidelle M, Christodoulidis S, Segata N, Thomas AM, Martin AL, Sirven A, Everhard S, Aprahamian F, Nirmalathasan N, Aarnoutse R, Smidt M, Ziemons J, Caldas C, Loibl S, Denkert C, Durand S, Iglesias C, Pietrantonio F, Routy B, André F, Pasolli E, Delaloge S , Zitvogel L",Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment,Cell death and differentiation,2021,NA,Experiment 6,France,Homo sapiens,Feces,UBERON:0001988,Tumor stage,EFO:0004925,pN- pre-Chemo,pN+ pre-Chemo,Breast cancer patients before chemotherapy with positive axillary lymph node involvement,30,26,None,WMS,NA,Ion Torrent,PLS-DA (Partial least square discriminant analysis),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:963/7/NA,Study 963,"laboratory experiment,time series / longitudinal observational",33963313,10.1038/s41418-021-00784-1,NA,"Terrisse S, Derosa L, Iebba V, Ghiringhelli F, Vaz-Luis I, Kroemer G, Fidelle M, Christodoulidis S, Segata N, Thomas AM, Martin AL, Sirven A, Everhard S, Aprahamian F, Nirmalathasan N, Aarnoutse R, Smidt M, Ziemons J, Caldas C, Loibl S, Denkert C, Durand S, Iglesias C, Pietrantonio F, Routy B, André F, Pasolli E, Delaloge S , Zitvogel L",Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment,Cell death and differentiation,2021,NA,Experiment 7,France,Homo sapiens,Feces,UBERON:0001988,Tumor stage,EFO:0004925,pN- post-Chemo,pN+ post-Chemo,Breast cancer patients after chemotherapy with positive axillary lymph node involvement,19,15,None,WMS,NA,Ion Torrent,PLS-DA (Partial least square discriminant analysis),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:963/8/NA,Study 963,"laboratory experiment,time series / longitudinal observational",33963313,10.1038/s41418-021-00784-1,NA,"Terrisse S, Derosa L, Iebba V, Ghiringhelli F, Vaz-Luis I, Kroemer G, Fidelle M, Christodoulidis S, Segata N, Thomas AM, Martin AL, Sirven A, Everhard S, Aprahamian F, Nirmalathasan N, Aarnoutse R, Smidt M, Ziemons J, Caldas C, Loibl S, Denkert C, Durand S, Iglesias C, Pietrantonio F, Routy B, André F, Pasolli E, Delaloge S , Zitvogel L",Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment,Cell death and differentiation,2021,NA,Experiment 8,"France,Italy",Homo sapiens,Feces,UBERON:0001988,Breast cancer,MONDO:0007254,Healthy volunteers,Breast cancer patients,Breast cancer patients enrolled in the CANTO study,336,76,None,WMS,NA,Ion Torrent,LEfSe,0.05,TRUE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:963/9/NA,Study 963,"laboratory experiment,time series / longitudinal observational",33963313,10.1038/s41418-021-00784-1,NA,"Terrisse S, Derosa L, Iebba V, Ghiringhelli F, Vaz-Luis I, Kroemer G, Fidelle M, Christodoulidis S, Segata N, Thomas AM, Martin AL, Sirven A, Everhard S, Aprahamian F, Nirmalathasan N, Aarnoutse R, Smidt M, Ziemons J, Caldas C, Loibl S, Denkert C, Durand S, Iglesias C, Pietrantonio F, Routy B, André F, Pasolli E, Delaloge S , Zitvogel L",Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment,Cell death and differentiation,2021,NA,Experiment 9,France,Homo sapiens,Feces,UBERON:0001988,Tumor stage,EFO:0004925,Neoadjuvant_pN-,Neoadjuvant_pN+,Breast cancer patients after neoadjuvant chemotherapy treatment with pathological lymph node involvement,8,2,None,WMS,NA,Ion Torrent,PLS-DA (Partial least square discriminant analysis),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:963/10/NA,Study 963,"laboratory experiment,time series / longitudinal observational",33963313,10.1038/s41418-021-00784-1,NA,"Terrisse S, Derosa L, Iebba V, Ghiringhelli F, Vaz-Luis I, Kroemer G, Fidelle M, Christodoulidis S, Segata N, Thomas AM, Martin AL, Sirven A, Everhard S, Aprahamian F, Nirmalathasan N, Aarnoutse R, Smidt M, Ziemons J, Caldas C, Loibl S, Denkert C, Durand S, Iglesias C, Pietrantonio F, Routy B, André F, Pasolli E, Delaloge S , Zitvogel L",Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment,Cell death and differentiation,2021,NA,Experiment 10,France,Homo sapiens,Feces,UBERON:0001988,Tumor stage,EFO:0004925,Neoadjuvant stage post-Chemo (Stage 0),Neoadjuvant stage post-Chemo (Stage I/II),Breast cancer patients after neoadjuvant chemotherapy treatment who are pathological non-complete responders (stage I–II),5,5,None,WMS,NA,Ion Torrent,PLS-DA (Partial least square discriminant analysis),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:963/11/NA,Study 963,"laboratory experiment,time series / longitudinal observational",33963313,10.1038/s41418-021-00784-1,NA,"Terrisse S, Derosa L, Iebba V, Ghiringhelli F, Vaz-Luis I, Kroemer G, Fidelle M, Christodoulidis S, Segata N, Thomas AM, Martin AL, Sirven A, Everhard S, Aprahamian F, Nirmalathasan N, Aarnoutse R, Smidt M, Ziemons J, Caldas C, Loibl S, Denkert C, Durand S, Iglesias C, Pietrantonio F, Routy B, André F, Pasolli E, Delaloge S , Zitvogel L",Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment,Cell death and differentiation,2021,NA,Experiment 11,France,Homo sapiens,Feces,UBERON:0001988,Response to combination chemotherapy,EFO:0007965,Pre-Chemotherapy,Post-Chemotherapy,Breast cancer patients after Chemotherapy,45,45,None,WMS,NA,Ion Torrent,PLS-DA (Partial least square discriminant analysis),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:963/12/NA,Study 963,"laboratory experiment,time series / longitudinal observational",33963313,10.1038/s41418-021-00784-1,NA,"Terrisse S, Derosa L, Iebba V, Ghiringhelli F, Vaz-Luis I, Kroemer G, Fidelle M, Christodoulidis S, Segata N, Thomas AM, Martin AL, Sirven A, Everhard S, Aprahamian F, Nirmalathasan N, Aarnoutse R, Smidt M, Ziemons J, Caldas C, Loibl S, Denkert C, Durand S, Iglesias C, Pietrantonio F, Routy B, André F, Pasolli E, Delaloge S , Zitvogel L",Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment,Cell death and differentiation,2021,NA,Experiment 12,France,Homo sapiens,Feces,UBERON:0001988,Adverse effect,EFO:0009658,No - increased BMI (Pre-Chemo),Yes - increased BMI (Pre-Chemo),Breast cancer patients before Chemotherapy with increased Body Mass Index (BMI),30,34,None,WMS,NA,Ion Torrent,PLS-DA (Partial least square discriminant analysis),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:963/13/NA,Study 963,"laboratory experiment,time series / longitudinal observational",33963313,10.1038/s41418-021-00784-1,NA,"Terrisse S, Derosa L, Iebba V, Ghiringhelli F, Vaz-Luis I, Kroemer G, Fidelle M, Christodoulidis S, Segata N, Thomas AM, Martin AL, Sirven A, Everhard S, Aprahamian F, Nirmalathasan N, Aarnoutse R, Smidt M, Ziemons J, Caldas C, Loibl S, Denkert C, Durand S, Iglesias C, Pietrantonio F, Routy B, André F, Pasolli E, Delaloge S , Zitvogel L",Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment,Cell death and differentiation,2021,NA,Experiment 13,France,Homo sapiens,Feces,UBERON:0001988,Adverse effect,EFO:0009658,No - increased BMI (Post-Chemo),Yes - increased BMI (Post-Chemo),Breast cancer patients 12 months after Chemotherapy with increased Body Mass Index (BMI),15,24,None,WMS,NA,Ion Torrent,PLS-DA (Partial least square discriminant analysis),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:963/14/NA,Study 963,"laboratory experiment,time series / longitudinal observational",33963313,10.1038/s41418-021-00784-1,NA,"Terrisse S, Derosa L, Iebba V, Ghiringhelli F, Vaz-Luis I, Kroemer G, Fidelle M, Christodoulidis S, Segata N, Thomas AM, Martin AL, Sirven A, Everhard S, Aprahamian F, Nirmalathasan N, Aarnoutse R, Smidt M, Ziemons J, Caldas C, Loibl S, Denkert C, Durand S, Iglesias C, Pietrantonio F, Routy B, André F, Pasolli E, Delaloge S , Zitvogel L",Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment,Cell death and differentiation,2021,NA,Experiment 14,France,Homo sapiens,Feces,UBERON:0001988,Adverse effect,EFO:0009658,No - constipation (Post-Chemo),Yes - constipation (Post-Chemo),Breast cancer patients 12 months after Chemotherapy with constipation,27,15,None,WMS,NA,Ion Torrent,NA,0.05,TRUE,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:963/15/NA,Study 963,"laboratory experiment,time series / longitudinal observational",33963313,10.1038/s41418-021-00784-1,NA,"Terrisse S, Derosa L, Iebba V, Ghiringhelli F, Vaz-Luis I, Kroemer G, Fidelle M, Christodoulidis S, Segata N, Thomas AM, Martin AL, Sirven A, Everhard S, Aprahamian F, Nirmalathasan N, Aarnoutse R, Smidt M, Ziemons J, Caldas C, Loibl S, Denkert C, Durand S, Iglesias C, Pietrantonio F, Routy B, André F, Pasolli E, Delaloge S , Zitvogel L",Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment,Cell death and differentiation,2021,NA,Experiment 15,France,Homo sapiens,Feces,UBERON:0001988,Adverse effect,EFO:0009658,No - diarrhea (Post-Chemo),Yes - diarrhea (Post-Chemo),Breast cancer patients 12 months after Chemotherapy with diarrhea,33,9,None,WMS,NA,Ion Torrent,NA,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:963/16/NA,Study 963,"laboratory experiment,time series / longitudinal observational",33963313,10.1038/s41418-021-00784-1,NA,"Terrisse S, Derosa L, Iebba V, Ghiringhelli F, Vaz-Luis I, Kroemer G, Fidelle M, Christodoulidis S, Segata N, Thomas AM, Martin AL, Sirven A, Everhard S, Aprahamian F, Nirmalathasan N, Aarnoutse R, Smidt M, Ziemons J, Caldas C, Loibl S, Denkert C, Durand S, Iglesias C, Pietrantonio F, Routy B, André F, Pasolli E, Delaloge S , Zitvogel L",Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment,Cell death and differentiation,2021,NA,Experiment 16,France,Homo sapiens,Feces,UBERON:0001988,Adverse effect,EFO:0009658,No - hot flashes (Post-Chemo),Yes - hot flashes (Post-Chemo),Breast cancer patients 12 months after Chemotherapy with hot flashes,21,21,None,WMS,NA,Ion Torrent,NA,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:963/17/NA,Study 963,"laboratory experiment,time series / longitudinal observational",33963313,10.1038/s41418-021-00784-1,NA,"Terrisse S, Derosa L, Iebba V, Ghiringhelli F, Vaz-Luis I, Kroemer G, Fidelle M, Christodoulidis S, Segata N, Thomas AM, Martin AL, Sirven A, Everhard S, Aprahamian F, Nirmalathasan N, Aarnoutse R, Smidt M, Ziemons J, Caldas C, Loibl S, Denkert C, Durand S, Iglesias C, Pietrantonio F, Routy B, André F, Pasolli E, Delaloge S , Zitvogel L",Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment,Cell death and differentiation,2021,NA,Experiment 17,France,Homo sapiens,Feces,UBERON:0001988,Adverse effect,EFO:0009658,Without neurotoxicity (Post-Chemo),With neurotoxicity (Post-Chemo),Breast cancer patients with neurotoxicity evaluated 12 months after Chemotherapy,12,30,None,WMS,NA,Ion Torrent,PLS-DA (Partial least square discriminant analysis),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:963/18/NA,Study 963,"laboratory experiment,time series / longitudinal observational",33963313,10.1038/s41418-021-00784-1,NA,"Terrisse S, Derosa L, Iebba V, Ghiringhelli F, Vaz-Luis I, Kroemer G, Fidelle M, Christodoulidis S, Segata N, Thomas AM, Martin AL, Sirven A, Everhard S, Aprahamian F, Nirmalathasan N, Aarnoutse R, Smidt M, Ziemons J, Caldas C, Loibl S, Denkert C, Durand S, Iglesias C, Pietrantonio F, Routy B, André F, Pasolli E, Delaloge S , Zitvogel L",Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment,Cell death and differentiation,2021,NA,Experiment 18,France,Mus musculus,Feces,UBERON:0001988,Breast cancer,MONDO:0007254,Heathy mice,Breast cancer mice,Mice “humanized” by fecal microbial transplantation (FMT) from breast cancer patients,7,5,None,WMS,NA,Ion Torrent,LEfSe,0.05,TRUE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:964/1/NA,Study 964,case-control,33665172,https://doi.org/10.3389%2Ffcimb.2020.624504,NA,"Li N, Li Y, Qian C, Liu Q, Cao W, Ma M, He R, Chen R, Geng R , Liu Y",Dysbiosis of the Saliva Microbiome in Patients With Polycystic Ovary Syndrome,Frontiers in cellular and infection microbiology,2020,"16S rRNA, diurnal rhythm, fecal microbiota, polycystic ovary syndrome, salivary microbiome",Experiment 1,China,Homo sapiens,Saliva,UBERON:0001836,Polycystic ovary syndrome,EFO:0000660,Healthy control at Zeitgeber (ZT) 0,PCOS patients at Zeitgeber (ZT) 0,"Samples collected from patients with Polycystic Ovary Syndrome who were diagnosed according to the Rotterdam Criteria, who met two out of three of the following criteria: clinical/biochemical hyperandrogenism, oligo-/anovulation, and polycystic ovaries at Zeitgeber (ZT) 0",10,10,use of antibiotics within 3 months,16S,34,Illumina,LEfSe,0.05,FALSE,4,"age,body mass index,metabolic syndrome",NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:964/2/NA,Study 964,case-control,33665172,https://doi.org/10.3389%2Ffcimb.2020.624504,NA,"Li N, Li Y, Qian C, Liu Q, Cao W, Ma M, He R, Chen R, Geng R , Liu Y",Dysbiosis of the Saliva Microbiome in Patients With Polycystic Ovary Syndrome,Frontiers in cellular and infection microbiology,2020,"16S rRNA, diurnal rhythm, fecal microbiota, polycystic ovary syndrome, salivary microbiome",Experiment 2,China,Homo sapiens,Saliva,UBERON:0001836,Polycystic ovary syndrome,EFO:0000660,Healthy control at Zeitgeber (ZT) 6,PCOS patients at Zeitgeber (ZT) 6,"Samples collected from patients with Polycystic Ovary Syndrome who were diagnosed according to the Rotterdam Criteria, who met two out of three of the following criteria: clinical/biochemical hyperandrogenism, oligo-/anovulation, and polycystic ovaries at Zeitgeber (ZT) 6",10,10,use of antibiotics within 3 months,16S,34,Illumina,LEfSe,0.05,FALSE,4,"age,body mass index,metabolic syndrome",NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:964/3/NA,Study 964,case-control,33665172,https://doi.org/10.3389%2Ffcimb.2020.624504,NA,"Li N, Li Y, Qian C, Liu Q, Cao W, Ma M, He R, Chen R, Geng R , Liu Y",Dysbiosis of the Saliva Microbiome in Patients With Polycystic Ovary Syndrome,Frontiers in cellular and infection microbiology,2020,"16S rRNA, diurnal rhythm, fecal microbiota, polycystic ovary syndrome, salivary microbiome",Experiment 3,China,Homo sapiens,Saliva,UBERON:0001836,Polycystic ovary syndrome,EFO:0000660,Healthy control at Zeitgeber (ZT) 12,PCOS patients at Zeitgeber (ZT) 12,"Samples collected from patients with Polycystic Ovary Syndrome who were diagnosed according to the Rotterdam Criteria, who met two out of three of the following criteria: clinical/biochemical hyperandrogenism, oligo-/anovulation, and polycystic ovaries at Zeitgeber (ZT) 12",10,10,use of antibiotics within 3 months,16S,34,Illumina,LEfSe,0.05,FALSE,4,"age,body mass index,metabolic syndrome",NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:964/4/NA,Study 964,case-control,33665172,https://doi.org/10.3389%2Ffcimb.2020.624504,NA,"Li N, Li Y, Qian C, Liu Q, Cao W, Ma M, He R, Chen R, Geng R , Liu Y",Dysbiosis of the Saliva Microbiome in Patients With Polycystic Ovary Syndrome,Frontiers in cellular and infection microbiology,2020,"16S rRNA, diurnal rhythm, fecal microbiota, polycystic ovary syndrome, salivary microbiome",Experiment 4,China,Homo sapiens,Saliva,UBERON:0001836,Polycystic ovary syndrome,EFO:0000660,Healthy control at Zeitgeber (ZT) 18,PCOS patients at Zeitgeber (ZT) 18,"Samples collected from patients with Polycystic Ovary Syndrome who were diagnosed according to the Rotterdam Criteria, who met two out of three of the following criteria: clinical/biochemical hyperandrogenism, oligo-/anovulation, and polycystic ovaries at Zeitgeber (ZT) 18",10,10,use of antibiotics within 3 months,16S,34,Illumina,LEfSe,0.05,FALSE,4,"age,body mass index,metabolic syndrome",NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:964/5/NA,Study 964,case-control,33665172,https://doi.org/10.3389%2Ffcimb.2020.624504,NA,"Li N, Li Y, Qian C, Liu Q, Cao W, Ma M, He R, Chen R, Geng R , Liu Y",Dysbiosis of the Saliva Microbiome in Patients With Polycystic Ovary Syndrome,Frontiers in cellular and infection microbiology,2020,"16S rRNA, diurnal rhythm, fecal microbiota, polycystic ovary syndrome, salivary microbiome",Experiment 5,China,Homo sapiens,Feces,UBERON:0001988,Polycystic ovary syndrome,EFO:0000660,Healthy controls,PCOS Patients,"PCOS patients who were diagnosed according to the Rotterdam Criteria, who met two out of three of the following criteria: clinical/biochemical hyperandrogenism, oligo-/anovulation, and polycystic ovaries",10,10,use of antibiotics within 3 months,16S,34,Illumina,LEfSe,0.05,FALSE,4,"age,body mass index,metabolic syndrome",NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:965/1/NA,Study 965,prospective cohort,NA,https://doi.org/10.1128/spectrum.03009-23,https://journals.asm.org/doi/10.1128/spectrum.03009-23,"Romani L, Del Chierico F, Pane S, Ristori MV, Pirona I, Guarrasi V, Cotugno N, Bernardi S, Lancella L, Perno CF, Rossi P, Villani A, Campana A, Palma P",Exploring nasopharyngeal microbiota profile in children affected by SARS-CoV-2 infection,Microbiology spectrum,NA,NA,Experiment 1,United States of America,Homo sapiens,Nasopharynx,UBERON:0001728,COVID-19,MONDO:0100096,healthy controls,COVID-19 patients,"Children whose Nasopharyngeal swab were positive for SARS-CoV-2 infection, as assayed by a molecular test.",59,71,none,16S,34,Illumina,LEfSe,0.05,TRUE,2,age,NA,NA,decreased,decreased,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:965/2/NA,Study 965,prospective cohort,NA,https://doi.org/10.1128/spectrum.03009-23,https://journals.asm.org/doi/10.1128/spectrum.03009-23,"Romani L, Del Chierico F, Pane S, Ristori MV, Pirona I, Guarrasi V, Cotugno N, Bernardi S, Lancella L, Perno CF, Rossi P, Villani A, Campana A, Palma P",Exploring nasopharyngeal microbiota profile in children affected by SARS-CoV-2 infection,Microbiology spectrum,NA,NA,Experiment 2,United States of America,Homo sapiens,Nasopharynx,UBERON:0001728,COVID-19,MONDO:0100096,NO COVID-19 (Patients with diagnosis different from COVID-19),COVID-19 patients,"Children whose Nasopharyngeal swab were positive for SARS-CoV-2 infection, as assayed by a molecular test.",7,71,none,16S,34,Illumina,LEfSe,0.05,TRUE,2,age,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:966/1/NA,Study 966,time series / longitudinal observational,35656540,10.3389/fnagi.2022.875261,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9152137/,"Lubomski M, Xu X, Holmes AJ, Muller S, Yang JYH, Davis RL , Sue CM",The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies,Frontiers in aging neuroscience,2022,"Parkinson’s disease, deep brain stimulation, device-assisted therapies, gastrointestinal microbiome, gut microbiota, levodopa-carbidopa intestinal gel, longitudinal, progression",Experiment 1,Australia,Homo sapiens,"Blood,Feces","UBERON:0000178,UBERON:0001988",Parkinson's disease,MONDO:0005180,Household Control,Parkinson's diease (PD) patients,PD patients on standard therapies,74,74,1 month,16S,34,Illumina,"ANOVA,T-Test",0.05,TRUE,NA,NA,"age,constipation,diet,sex",NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:966/2/NA,Study 966,time series / longitudinal observational,35656540,10.3389/fnagi.2022.875261,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9152137/,"Lubomski M, Xu X, Holmes AJ, Muller S, Yang JYH, Davis RL , Sue CM",The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies,Frontiers in aging neuroscience,2022,"Parkinson’s disease, deep brain stimulation, device-assisted therapies, gastrointestinal microbiome, gut microbiota, levodopa-carbidopa intestinal gel, longitudinal, progression",Experiment 2,Australia,Homo sapiens,"Blood,Feces","UBERON:0000178,UBERON:0001988",Parkinson's disease,MONDO:0005180,Patients with Slow progressing Parkinson's disease,Patients with Faster progressing Parkinson's disease,Patients with faster progressing parkinson's disease over a 12 month period,40,34,All participants had not received antibiotics supplements for at least 1 month prior sample collection,16S,34,Illumina,"ANOVA,T-Test",0.05,TRUE,NA,NA,"age,sex",NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:966/3/NA,Study 966,time series / longitudinal observational,35656540,10.3389/fnagi.2022.875261,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9152137/,"Lubomski M, Xu X, Holmes AJ, Muller S, Yang JYH, Davis RL , Sue CM",The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies,Frontiers in aging neuroscience,2022,"Parkinson’s disease, deep brain stimulation, device-assisted therapies, gastrointestinal microbiome, gut microbiota, levodopa-carbidopa intestinal gel, longitudinal, progression",Experiment 3,Australia,Homo sapiens,"Blood,Feces","UBERON:0000178,UBERON:0001988",Parkinson's disease,MONDO:0005180,Pre DAT(device assisted therapy),DBS(deep brain stimulation),initiation of DBS therapy on parkinson's disease patients at 0 month,74,9,1 month,16S,34,Illumina,ANOVA,0.01,TRUE,NA,NA,"age,constipation,diet,sex",NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:966/4/NA,Study 966,time series / longitudinal observational,35656540,10.3389/fnagi.2022.875261,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9152137/,"Lubomski M, Xu X, Holmes AJ, Muller S, Yang JYH, Davis RL , Sue CM",The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies,Frontiers in aging neuroscience,2022,"Parkinson’s disease, deep brain stimulation, device-assisted therapies, gastrointestinal microbiome, gut microbiota, levodopa-carbidopa intestinal gel, longitudinal, progression",Experiment 4,Australia,Homo sapiens,"Blood,Feces","UBERON:0000178,UBERON:0001988",Parkinson's disease,MONDO:0005180,Pre DAT(device assisted therapy) PD patients,LCIG(Levodopa-Carbidopa Intestinal Gel),initiation of LCIG therapy on parkinson's disease patients at 0 month,74,10,1 month,16S,34,Illumina,ANOVA,0.01,TRUE,NA,NA,"age,constipation,diet,sex",NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:966/5/NA,Study 966,time series / longitudinal observational,35656540,10.3389/fnagi.2022.875261,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9152137/,"Lubomski M, Xu X, Holmes AJ, Muller S, Yang JYH, Davis RL , Sue CM",The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies,Frontiers in aging neuroscience,2022,"Parkinson’s disease, deep brain stimulation, device-assisted therapies, gastrointestinal microbiome, gut microbiota, levodopa-carbidopa intestinal gel, longitudinal, progression",Experiment 5,Australia,Homo sapiens,"Blood,Feces","UBERON:0000178,UBERON:0001988",Parkinson's disease,MONDO:0005180,Household Control,Parkinson's diease patients at 6 months,PD patients on standard therapies at 6months,74,74,1 month,16S,34,Illumina,ANOVA,0.05,TRUE,NA,NA,"age,body mass index,sex",NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:966/6/NA,Study 966,time series / longitudinal observational,35656540,10.3389/fnagi.2022.875261,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9152137/,"Lubomski M, Xu X, Holmes AJ, Muller S, Yang JYH, Davis RL , Sue CM",The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies,Frontiers in aging neuroscience,2022,"Parkinson’s disease, deep brain stimulation, device-assisted therapies, gastrointestinal microbiome, gut microbiota, levodopa-carbidopa intestinal gel, longitudinal, progression",Experiment 6,Australia,Homo sapiens,"Blood,Feces","UBERON:0000178,UBERON:0001988",Parkinson's disease,MONDO:0005180,Household Control,Parkinson's diease patients at 12 months,Parkinson's disease patients samples collected at 12months,74,74,1 month,16S,34,Illumina,ANOVA,0.05,TRUE,NA,NA,"age,constipation,diet,sex",NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:966/7/NA,Study 966,time series / longitudinal observational,35656540,10.3389/fnagi.2022.875261,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9152137/,"Lubomski M, Xu X, Holmes AJ, Muller S, Yang JYH, Davis RL , Sue CM",The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies,Frontiers in aging neuroscience,2022,"Parkinson’s disease, deep brain stimulation, device-assisted therapies, gastrointestinal microbiome, gut microbiota, levodopa-carbidopa intestinal gel, longitudinal, progression",Experiment 7,Australia,Homo sapiens,"Blood,Feces","UBERON:0000178,UBERON:0001988",Parkinson's disease,MONDO:0005180,Pre DAT(device assisted therapy),DBS(deep brain stimulation),initiation of DBS therapy on parkinson's disease patients at 6 month,74,9,1 month,16S,34,Illumina,ANOVA,0.01,TRUE,NA,NA,"age,constipation,diet,sex",NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:966/8/NA,Study 966,time series / longitudinal observational,35656540,10.3389/fnagi.2022.875261,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9152137/,"Lubomski M, Xu X, Holmes AJ, Muller S, Yang JYH, Davis RL , Sue CM",The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies,Frontiers in aging neuroscience,2022,"Parkinson’s disease, deep brain stimulation, device-assisted therapies, gastrointestinal microbiome, gut microbiota, levodopa-carbidopa intestinal gel, longitudinal, progression",Experiment 8,Australia,Homo sapiens,"Blood,Feces","UBERON:0000178,UBERON:0001988",Parkinson's disease,MONDO:0005180,Pre DAT(device assisted therapy),DBS(deep brain stimulation),initiation of DBS therapy on parkinson's disease patients at 12 month,74,9,1 month,16S,34,Illumina,ANOVA,0.01,TRUE,NA,NA,"age,constipation,diet,sex",NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:966/9/NA,Study 966,time series / longitudinal observational,35656540,10.3389/fnagi.2022.875261,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9152137/,"Lubomski M, Xu X, Holmes AJ, Muller S, Yang JYH, Davis RL , Sue CM",The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies,Frontiers in aging neuroscience,2022,"Parkinson’s disease, deep brain stimulation, device-assisted therapies, gastrointestinal microbiome, gut microbiota, levodopa-carbidopa intestinal gel, longitudinal, progression",Experiment 9,Australia,Homo sapiens,"Blood,Feces","UBERON:0000178,UBERON:0001988",Parkinson's disease,MONDO:0005180,Pre DAT(device assisted therapy) PD patients,LCIG(Levodopa-Carbidopa Intestinal Gel),initiation of LCIG therapy on parkinson's disease patients at 6 month,74,10,1 month,16S,34,Illumina,ANOVA,0.01,TRUE,NA,NA,"age,constipation,diet,sex",NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:966/10/NA,Study 966,time series / longitudinal observational,35656540,10.3389/fnagi.2022.875261,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9152137/,"Lubomski M, Xu X, Holmes AJ, Muller S, Yang JYH, Davis RL , Sue CM",The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies,Frontiers in aging neuroscience,2022,"Parkinson’s disease, deep brain stimulation, device-assisted therapies, gastrointestinal microbiome, gut microbiota, levodopa-carbidopa intestinal gel, longitudinal, progression",Experiment 10,Australia,Homo sapiens,"Blood,Feces","UBERON:0000178,UBERON:0001988",Parkinson's disease,MONDO:0005180,Pre DAT(device assisted therapy) PD patients,LCIG(Levodopa-Carbidopa Intestinal Gel),initiation of LCIG therapy on parkinson's disease patients at 12 month,74,10,1 month,16S,34,Illumina,ANOVA,0.01,TRUE,NA,NA,"age,constipation,diet,sex",NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:967/1/NA,Study 967,case-control,37208728,10.1186/s12974-023-02782-1,NA,"Yu J, Meng J, Qin Z, Yu Y, Liang Y, Wang Y , Min D",Dysbiosis of gut microbiota inhibits NMNAT2 to promote neurobehavioral deficits and oxidative stress response in the 6-OHDA-lesioned rat model of Parkinson's disease,Journal of neuroinflammation,2023,"Dysbiosis of gut microbiota, Fecal microbiota transplantation, NMNAT2, Neurobehavioral symptoms, Oxidative stress response, Parkinson’s disease",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Healthy,Parkinson's Disease (PD)-patients,Individuals with early-stage Parkinson's disease,28,31,NA,WMS,NA,Illumina,LEfSe,0.05,FALSE,2,age,NA,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:968/1/NA,Study 968,case-control,36068280,10.1038/s41598-022-19393-0,NA,"Kaiyrlykyzy A, Kozhakhmetov S, Babenko D, Zholdasbekova G, Alzhanova D, Olzhayev F, Baibulatova A, Kushugulova AR , Askarova S",Study of gut microbiota alterations in Alzheimer's dementia patients from Kazakhstan,Scientific reports,2022,NA,Experiment 1,Kazakhstan,Homo sapiens,Feces,UBERON:0001988,Alzheimer's disease,MONDO:0004975,Healthy senior group,Alzheimer's group,Patients with Alzheimer's disease,43,41,None,16S,NA,Illumina,MaAsLin2,0.05,FALSE,NA,NA,NA,NA,unchanged,unchanged,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:968/2/NA,Study 968,case-control,36068280,10.1038/s41598-022-19393-0,NA,"Kaiyrlykyzy A, Kozhakhmetov S, Babenko D, Zholdasbekova G, Alzhanova D, Olzhayev F, Baibulatova A, Kushugulova AR , Askarova S",Study of gut microbiota alterations in Alzheimer's dementia patients from Kazakhstan,Scientific reports,2022,NA,Experiment 2,Kazakhstan,Homo sapiens,Feces,UBERON:0001988,Alzheimer's disease,MONDO:0004975,Healthy senior group,Alzheimer's disease group,Patients with Alzheimer's disease,43,41,None,16S,NA,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,unchanged,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:969/1/NA,Study 969,case-control,34880258,10.1038/s41531-021-00254-y,NA,"Pal G, Ramirez V, Engen PA, Naqib A, Forsyth CB, Green SJ, Mahdavinia M, Batra PS, Tajudeen BA , Keshavarzian A",Deep nasal sinus cavity microbiota dysbiosis in Parkinson's disease,NPJ Parkinson's disease,2021,NA,Experiment 1,United States of America,Homo sapiens,Nasal cavity,UBERON:0001707,Parkinson's disease,MONDO:0005180,rHC (Random non-household healthy controls),PD (Parkinson's Disease),This group consists of 30 Parkinson's disease subjects.,17,30,12 weeks,16S,4,Illumina,DESeq2,0.05,TRUE,NA,"age,race,sex",NA,NA,unchanged,NA,unchanged,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:969/2/NA,Study 969,case-control,34880258,10.1038/s41531-021-00254-y,NA,"Pal G, Ramirez V, Engen PA, Naqib A, Forsyth CB, Green SJ, Mahdavinia M, Batra PS, Tajudeen BA , Keshavarzian A",Deep nasal sinus cavity microbiota dysbiosis in Parkinson's disease,NPJ Parkinson's disease,2021,NA,Experiment 2,United States of America,Homo sapiens,Nasal cavity,UBERON:0001707,Parkinson's disease,MONDO:0005180,rHC (Random non-household healthy controls),PD (Parkinson's Disease),This group consists of 30 Parkinson's disease subjects.,17,30,12 weeks,16S,4,Illumina,ANCOM,0.05,TRUE,NA,"age,race,sex",NA,NA,unchanged,NA,unchanged,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:969/3/NA,Study 969,case-control,34880258,10.1038/s41531-021-00254-y,NA,"Pal G, Ramirez V, Engen PA, Naqib A, Forsyth CB, Green SJ, Mahdavinia M, Batra PS, Tajudeen BA , Keshavarzian A",Deep nasal sinus cavity microbiota dysbiosis in Parkinson's disease,NPJ Parkinson's disease,2021,NA,Experiment 3,United States of America,Homo sapiens,Nasal cavity,UBERON:0001707,Parkinson's disease,MONDO:0005180,rHC (Random non-household healthy controls),SpHC (Spousal household healthy controls),This group consists of 11 spousal healthy controls of Parkinson's disease subjects.,17,11,12 weeks,16S,4,Illumina,DESeq2,0.05,TRUE,NA,"age,race,sex",NA,NA,unchanged,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:969/4/NA,Study 969,case-control,34880258,10.1038/s41531-021-00254-y,NA,"Pal G, Ramirez V, Engen PA, Naqib A, Forsyth CB, Green SJ, Mahdavinia M, Batra PS, Tajudeen BA , Keshavarzian A",Deep nasal sinus cavity microbiota dysbiosis in Parkinson's disease,NPJ Parkinson's disease,2021,NA,Experiment 4,United States of America,Homo sapiens,Nasal cavity,UBERON:0001707,Parkinson's disease,MONDO:0005180,rHC (Random non-household healthy controls),SpHC (Spousal household healthy controls),This group consists of 11 spousal healthy controls of Parkinson's disease subjects.,17,11,12 weeks,16S,4,Illumina,ANCOM,0.05,TRUE,NA,"age,race,sex",NA,NA,unchanged,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:969/5/NA,Study 969,case-control,34880258,10.1038/s41531-021-00254-y,NA,"Pal G, Ramirez V, Engen PA, Naqib A, Forsyth CB, Green SJ, Mahdavinia M, Batra PS, Tajudeen BA , Keshavarzian A",Deep nasal sinus cavity microbiota dysbiosis in Parkinson's disease,NPJ Parkinson's disease,2021,NA,Experiment 5,United States of America,Homo sapiens,Nasal cavity,UBERON:0001707,Parkinson's disease,MONDO:0005180,SpHC (Spousal household Healthy Control),SpPD (Spousal household Parkinson's Disease),This group consists of Parkinson's Disease subjects living in the same household as their healthy control spouses.,11,11,12 weeks,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,"age,race,sex",NA,NA,unchanged,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:970/1/NA,Study 970,laboratory experiment,35619714,10.3389/fimmu.2022.900132,NA,"Zhang B, Chen T, Cao M, Yuan C, Reiter RJ, Zhao Z, Zhao Y, Chen L, Fan W, Wang X, Zhou X , Li C",Gut Microbiota Dysbiosis Induced by Decreasing Endogenous Melatonin Mediates the Pathogenesis of Alzheimer's Disease and Obesity,Frontiers in immunology,2022,"alzheimer's disease, fecal microbiota transplantation, gut- brain axis, melatonin, microbiota dysbiosis, obesity, systemic inflammation",Experiment 1,China,Mus musculus,Feces,UBERON:0001988,Alzheimer's disease biomarker measurement,EFO:0006514,Wild type (WT) mice,Endogenous melatonin reduction (EMR) mice,"Mice that exhibited a pan-metabolic disorder, with significant transcriptome changes in 11 organs, serum metabolome alterations as well as microbiota dysbiosis.",NA,NA,NA,16S,34,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:971/1/NA,Study 971,case-control,31815177,10.1038/s41531-019-0100-x,NA,"Weis S, Schwiertz A, Unger MM, Becker A, Faßbender K, Ratering S, Kohl M, Schnell S, Schäfer KH , Egert M",Effect of Parkinson's disease and related medications on the composition of the fecal bacterial microbiota,NPJ Parkinson's disease,2019,"Constipation, Parkinson's disease",Experiment 1,Germany,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Healthy Controls,Parkinson's Disease Patients,Patients with Parkinson's Disease.,25,34,Not Applicable.,16S,45,Ion Torrent,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,age,NA,NA,unchanged,decreased,unchanged,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:971/2/NA,Study 971,case-control,31815177,10.1038/s41531-019-0100-x,NA,"Weis S, Schwiertz A, Unger MM, Becker A, Faßbender K, Ratering S, Kohl M, Schnell S, Schäfer KH , Egert M",Effect of Parkinson's disease and related medications on the composition of the fecal bacterial microbiota,NPJ Parkinson's disease,2019,"Constipation, Parkinson's disease",Experiment 2,Germany,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Male Parkinson's disease Patients,Female Parkinson's disease Patients,Female Patients with Parkinson's disease,23,11,Not Applicable,16S,45,Ion Torrent,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,age,NA,NA,unchanged,decreased,unchanged,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:971/3/NA,Study 971,case-control,31815177,10.1038/s41531-019-0100-x,NA,"Weis S, Schwiertz A, Unger MM, Becker A, Faßbender K, Ratering S, Kohl M, Schnell S, Schäfer KH , Egert M",Effect of Parkinson's disease and related medications on the composition of the fecal bacterial microbiota,NPJ Parkinson's disease,2019,"Constipation, Parkinson's disease",Experiment 3,Germany,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Calprotectin Negative Controls,Parkinson's Disease Patients with elevated Calprotectin levels,Parkinson's Disease Patients with elevated levels of Fecal Calprotectin,22,14,Not Applicable.,16S,45,Ion Torrent,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,age,NA,NA,unchanged,decreased,unchanged,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:971/4/NA,Study 971,case-control,31815177,10.1038/s41531-019-0100-x,NA,"Weis S, Schwiertz A, Unger MM, Becker A, Faßbender K, Ratering S, Kohl M, Schnell S, Schäfer KH , Egert M",Effect of Parkinson's disease and related medications on the composition of the fecal bacterial microbiota,NPJ Parkinson's disease,2019,"Constipation, Parkinson's disease",Experiment 4,Germany,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Calprotectin positive Parkinson's Disease Patients,Parkinson's Disease Patients with normal Calprotectin levels,Patients with Parkinson's disease that had normal Calprotectin levels..,14,NA,Not Applicable.,16S,45,Ion Torrent,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,age,NA,NA,unchanged,decreased,unchanged,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:971/5/NA,Study 971,case-control,31815177,10.1038/s41531-019-0100-x,NA,"Weis S, Schwiertz A, Unger MM, Becker A, Faßbender K, Ratering S, Kohl M, Schnell S, Schäfer KH , Egert M",Effect of Parkinson's disease and related medications on the composition of the fecal bacterial microbiota,NPJ Parkinson's disease,2019,"Constipation, Parkinson's disease",Experiment 5,Germany,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Male Healthy Controls,Female Healthy Controls,Healthy Control persons who were of the female gender,11,14,Not Aplicable,16S,45,Ion Torrent,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,age,NA,NA,unchanged,decreased,unchanged,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:971/6/NA,Study 971,case-control,31815177,10.1038/s41531-019-0100-x,NA,"Weis S, Schwiertz A, Unger MM, Becker A, Faßbender K, Ratering S, Kohl M, Schnell S, Schäfer KH , Egert M",Effect of Parkinson's disease and related medications on the composition of the fecal bacterial microbiota,NPJ Parkinson's disease,2019,"Constipation, Parkinson's disease",Experiment 6,Germany,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Female Parkinson's Disease Patients,Male Parkinson's Disease Patients,Parkinson's Disease Patients of the Male Gender,11,23,Not Applicable,16S,45,Ion Torrent,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,age,NA,NA,unchanged,decreased,unchanged,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:971/7/NA,Study 971,case-control,31815177,10.1038/s41531-019-0100-x,NA,"Weis S, Schwiertz A, Unger MM, Becker A, Faßbender K, Ratering S, Kohl M, Schnell S, Schäfer KH , Egert M",Effect of Parkinson's disease and related medications on the composition of the fecal bacterial microbiota,NPJ Parkinson's disease,2019,"Constipation, Parkinson's disease",Experiment 7,Germany,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Healthy Controls,Normal Calprotectin levels Parkinson's Disease Patients,Parkinson's disease Patients with Normal Calprotectin levels.,25,14,Not Applicable,16S,45,Ion Torrent,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,age,NA,NA,unchanged,decreased,unchanged,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:971/8/NA,Study 971,case-control,31815177,10.1038/s41531-019-0100-x,NA,"Weis S, Schwiertz A, Unger MM, Becker A, Faßbender K, Ratering S, Kohl M, Schnell S, Schäfer KH , Egert M",Effect of Parkinson's disease and related medications on the composition of the fecal bacterial microbiota,NPJ Parkinson's disease,2019,"Constipation, Parkinson's disease",Experiment 8,Germany,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Healthy Controls,Parkinson's Disease Patients treated with L-dopa,Parkinson's disease Patients who were treated with L-dopa.,25,24,Not Applicable,16S,45,Ion Torrent,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,age,NA,NA,unchanged,decreased,unchanged,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:971/9/NA,Study 971,case-control,31815177,10.1038/s41531-019-0100-x,NA,"Weis S, Schwiertz A, Unger MM, Becker A, Faßbender K, Ratering S, Kohl M, Schnell S, Schäfer KH , Egert M",Effect of Parkinson's disease and related medications on the composition of the fecal bacterial microbiota,NPJ Parkinson's disease,2019,"Constipation, Parkinson's disease",Experiment 9,Germany,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Healthy Controls,Parkinson's Disease Patients not treated with L-dopa,Parkinson's disease Patients who were not treated with L-dopa.,25,10,Not Applicable,16S,45,Ion Torrent,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,age,NA,NA,unchanged,decreased,unchanged,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:971/10/NA,Study 971,case-control,31815177,10.1038/s41531-019-0100-x,NA,"Weis S, Schwiertz A, Unger MM, Becker A, Faßbender K, Ratering S, Kohl M, Schnell S, Schäfer KH , Egert M",Effect of Parkinson's disease and related medications on the composition of the fecal bacterial microbiota,NPJ Parkinson's disease,2019,"Constipation, Parkinson's disease",Experiment 10,Germany,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Parkinson's disease Patients treated with L-dopa,Parkinson's Disease Patients not treated with L-dopa,Parkinson's disease Patients who were not treated with L-dopa.,24,10,Not Applicable,16S,45,Ion Torrent,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,age,NA,NA,unchanged,decreased,unchanged,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:971/11/NA,Study 971,case-control,31815177,10.1038/s41531-019-0100-x,NA,"Weis S, Schwiertz A, Unger MM, Becker A, Faßbender K, Ratering S, Kohl M, Schnell S, Schäfer KH , Egert M",Effect of Parkinson's disease and related medications on the composition of the fecal bacterial microbiota,NPJ Parkinson's disease,2019,"Constipation, Parkinson's disease",Experiment 11,Germany,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Healthy Controls,Parkinson's disease Patients treated with entacapone,Parkinson's disease patients who were treated with entacapone.,25,11,Not Applicable,16S,45,Ion Torrent,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,age,NA,NA,unchanged,decreased,unchanged,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:971/12/NA,Study 971,case-control,31815177,10.1038/s41531-019-0100-x,NA,"Weis S, Schwiertz A, Unger MM, Becker A, Faßbender K, Ratering S, Kohl M, Schnell S, Schäfer KH , Egert M",Effect of Parkinson's disease and related medications on the composition of the fecal bacterial microbiota,NPJ Parkinson's disease,2019,"Constipation, Parkinson's disease",Experiment 12,Germany,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Healthy Controls,Parkinson's disease Patients with HR Phenotype,Parkinson's disease Patients with a Hypokinetic-rigid phenotype.,25,15,Not Applicable,16S,45,Ion Torrent,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,age,NA,NA,unchanged,decreased,unchanged,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:971/13/NA,Study 971,case-control,31815177,10.1038/s41531-019-0100-x,NA,"Weis S, Schwiertz A, Unger MM, Becker A, Faßbender K, Ratering S, Kohl M, Schnell S, Schäfer KH , Egert M",Effect of Parkinson's disease and related medications on the composition of the fecal bacterial microbiota,NPJ Parkinson's disease,2019,"Constipation, Parkinson's disease",Experiment 13,Germany,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Healthy Controls,Parkinson's disease Patients with Tremor dominant Phenotype,Parkinson's disease Patients with Tremor dominant [T] phenotype.,25,6,Not Applicable,16S,45,Ion Torrent,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,age,NA,NA,unchanged,decreased,unchanged,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:971/14/NA,Study 971,case-control,31815177,10.1038/s41531-019-0100-x,NA,"Weis S, Schwiertz A, Unger MM, Becker A, Faßbender K, Ratering S, Kohl M, Schnell S, Schäfer KH , Egert M",Effect of Parkinson's disease and related medications on the composition of the fecal bacterial microbiota,NPJ Parkinson's disease,2019,"Constipation, Parkinson's disease",Experiment 14,Germany,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Healthy Controls,Parkinson's disease Patients with HY Stage of 1 to 2.5,Parkinson's disease Patients with Hoehn-Yahr [HY] Stage of 1 to 2.5.,25,18,Not Applicable,16S,45,Ion Torrent,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,age,NA,NA,unchanged,decreased,unchanged,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:971/15/NA,Study 971,case-control,31815177,10.1038/s41531-019-0100-x,NA,"Weis S, Schwiertz A, Unger MM, Becker A, Faßbender K, Ratering S, Kohl M, Schnell S, Schäfer KH , Egert M",Effect of Parkinson's disease and related medications on the composition of the fecal bacterial microbiota,NPJ Parkinson's disease,2019,"Constipation, Parkinson's disease",Experiment 15,Germany,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Healthy Controls,Parkinson's disease Patients with HY Stage of 3 to 4,Parkinson's disease Patients with Hoehn-Yahr [HY] Stage of 3 to 4.,25,16,Not Applicable.,16S,45,Ion Torrent,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,age,NA,NA,unchanged,decreased,unchanged,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:971/16/NA,Study 971,case-control,31815177,10.1038/s41531-019-0100-x,NA,"Weis S, Schwiertz A, Unger MM, Becker A, Faßbender K, Ratering S, Kohl M, Schnell S, Schäfer KH , Egert M",Effect of Parkinson's disease and related medications on the composition of the fecal bacterial microbiota,NPJ Parkinson's disease,2019,"Constipation, Parkinson's disease",Experiment 16,Germany,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Parkinson's disease Patients with HY Stage of 1 to 2.5,Parkinson's disease Patients with HY Stage of 3 to 4,Parkinson's disease Patients with Hoehn-Yahr [HY] Stage of 3 to 4.,18,16,Not Applicable.,16S,45,Ion Torrent,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,age,NA,NA,unchanged,decreased,unchanged,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:972/3/NA,Study 972,laboratory experiment,36171620,10.1186/s12974-022-02599-4,NA,"Qian XH, Liu XL, Chen G, Chen SD , Tang HD",Injection of amyloid-β to lateral ventricle induces gut microbiota dysbiosis in association with inhibition of cholinergic anti-inflammatory pathways in Alzheimer's disease,Journal of neuroinflammation,2022,"Alzheimer’s disease, Aβ, Cholinergic anti-inflammatory pathway, Gut microbiota",Experiment 3,China,Mus musculus,Feces,UBERON:0001988,Alzheimer's disease,MONDO:0004975,Sham-operated group,Alzheimer’s disease (4 weeks after surgery),Alzheimer's disease (AD) model mice injected in the lateral ventricle with Aβ1–42 intracerebroventricular injection 4 weeks after surgery,10,10,NA,16S,34,Illumina,ANOVA,0.05,FALSE,NA,NA,NA,NA,NA,unchanged,unchanged,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:972/6/NA,Study 972,laboratory experiment,36171620,10.1186/s12974-022-02599-4,NA,"Qian XH, Liu XL, Chen G, Chen SD , Tang HD",Injection of amyloid-β to lateral ventricle induces gut microbiota dysbiosis in association with inhibition of cholinergic anti-inflammatory pathways in Alzheimer's disease,Journal of neuroinflammation,2022,"Alzheimer’s disease, Aβ, Cholinergic anti-inflammatory pathway, Gut microbiota",Experiment 6,China,Mus musculus,Feces,UBERON:0001988,Alzheimer's disease,MONDO:0004975,Control group,Alzheimer’s disease (4 weeks after surgery),Alzheimer's disease (AD) model mice injected in the lateral ventricle with Aβ1–42 intracerebroventricular injection 4 weeks after surgery,10,10,NA,16S,34,Illumina,ANOVA,0.05,FALSE,NA,NA,NA,NA,NA,unchanged,unchanged,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:973/1/NA,Study 973,case-control,34776854,10.3389/fnins.2021.756951,NA,"Kenna JE, Chua EG, Bakeberg M, Tay A, McGregor S, Gorecki A, Horne M, Marshall B, Mastaglia FL , Anderton RS",Changes in the Gut Microbiome and Predicted Functional Metabolic Effects in an Australian Parkinson's Disease Cohort,Frontiers in neuroscience,2021,"16S, KEGG, Parkinson’s disease, gut bacteria, gut microbiome",Experiment 1,Australia,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Healthy Controls,People with Parkinson's Disease (PWP),People with Parkinson's Disease from multiple Movement Disorders Clinics,47,87,3 Months,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,decreased,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:974/1/NA,Study 974,"cross-sectional observational, not case-control",36975828,10.1128/spectrum.03549-22,NA,"Sheng D, Yue K, Li H, Zhao L, Zhao G, Jin C , Zhang L",The Interaction between Intratumoral Microbiome and Immunity Is Related to the Prognosis of Ovarian Cancer,Microbiology spectrum,2023,"gynecological, microbiome, ovarian cancer, prognostic biomarkers, tumor microenvironment",Experiment 1,China,Homo sapiens,Ovary,UBERON:0000992,Ovarian cancer,MONDO:0008170,Immune-enriched subtype (clust2),Immune-deficient subtype (clust1),Patients with the ovarian cancer subtype which is characterized by the lack of immune infiltration and high tumor purity,191,182,None,PCR,NA,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:975/1/NA,Study 975,case-control,38229613,10.4103/aian.aian_460_23,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10789430/,"Pavan S, Gorthi SP, Prabhu AN, Das B, Mutreja A, Vasudevan K, Shetty V, Ramamurthy T , Ballal M",Dysbiosis of the Beneficial Gut Bacteria in Patients with Parkinson's Disease from India,Annals of Indian Academy of Neurology,2023,"16S rRNA gene sequencing, Parkinson's disease, dysbiosis, gut microbiota, neurodegenerative disease, stool",Experiment 1,India,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Healthy controls,Parkinson's disease,Patients with Parkinson's disease from India,13,23,4 weeks,16S,NA,Nanopore,LEfSe,0.01,TRUE,2,NA,NA,NA,increased,unchanged,increased,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:976/1/NA,Study 976,case-control,36511710,https://doi.org/10.1128/spectrum.02472-22,NA,"Meng J, Tao J, Abu Y, Sussman DA, Girotra M, Franceschi D , Roy S",HIV-Positive Patients on Antiretroviral Therapy Have an Altered Mucosal Intestinal but Not Oral Microbiome,Microbiology spectrum,2023,"16S RNA, HIV, antiretroviral therapy, human microbiome, intestinal microbiome, oral microbiome",Experiment 1,United States of America,Homo sapiens,"Ileum,Colon","UBERON:0002116,UBERON:0001155",Response to antiviral drug,EFO:0010123,Intestinal samples of Healthy Control,Intestinal samples of HIV Positive Patients,"All intestinal samples (colon brush, colon wash, terminal ileum brush, and terminal ileum wash) of HIV-positive individuals on antiretroviral therapy",12,5,30 days,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:976/2/NA,Study 976,case-control,36511710,https://doi.org/10.1128/spectrum.02472-22,NA,"Meng J, Tao J, Abu Y, Sussman DA, Girotra M, Franceschi D , Roy S",HIV-Positive Patients on Antiretroviral Therapy Have an Altered Mucosal Intestinal but Not Oral Microbiome,Microbiology spectrum,2023,"16S RNA, HIV, antiretroviral therapy, human microbiome, intestinal microbiome, oral microbiome",Experiment 2,United States of America,Homo sapiens,Colon,UBERON:0001155,Response to antiviral drug,EFO:0010123,Colon wash samples of Healthy Control,Colon wash samples of HIV Positive Patients,Colon wash samples of HIV-positive individuals on antiretroviral therapy,12,5,30 days,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:976/3/NA,Study 976,case-control,36511710,https://doi.org/10.1128/spectrum.02472-22,NA,"Meng J, Tao J, Abu Y, Sussman DA, Girotra M, Franceschi D , Roy S",HIV-Positive Patients on Antiretroviral Therapy Have an Altered Mucosal Intestinal but Not Oral Microbiome,Microbiology spectrum,2023,"16S RNA, HIV, antiretroviral therapy, human microbiome, intestinal microbiome, oral microbiome",Experiment 3,United States of America,Homo sapiens,Colon,UBERON:0001155,Response to antiviral drug,EFO:0010123,Colon brush samples of Healthy Control,Colon brush samples of HIV Positive Patients,Colon brush samples of HIV-positive individuals on antiretroviral therapy,12,5,30 days,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:976/4/NA,Study 976,case-control,36511710,https://doi.org/10.1128/spectrum.02472-22,NA,"Meng J, Tao J, Abu Y, Sussman DA, Girotra M, Franceschi D , Roy S",HIV-Positive Patients on Antiretroviral Therapy Have an Altered Mucosal Intestinal but Not Oral Microbiome,Microbiology spectrum,2023,"16S RNA, HIV, antiretroviral therapy, human microbiome, intestinal microbiome, oral microbiome",Experiment 4,United States of America,Homo sapiens,Ileum,UBERON:0002116,Response to antiviral drug,EFO:0010123,Terminal ileum wash samples of Healthy Control,Terminal ileum wash samples of HIV Positive Patients,Terminal ileum (TI) wash samples of HIV-positive individuals on antiretroviral therapy,12,5,30 days,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:977/1/NA,Study 977,case-control,36350127,10.1128/spectrum.02196-22,https://journals.asm.org/doi/10.1128/spectrum.02196-22#fig1,"Lai CKC, Cheung MK, Lui GCY, Ling L, Chan JYK, Ng RWY, Chan HC, Yeung ACM, Ho WCS, Boon SS, Chan PKS , Chen Z",Limited Impact of SARS-CoV-2 on the Human Naso-Oropharyngeal Microbiota in Hospitalized Patients,Microbiology spectrum,2022,"16S rRNA, COVID-19, SARS-CoV-2, hospitalized, naso-oropharyngeal microbiome",Experiment 1,China,Homo sapiens,"Nasopharynx,Throat","UBERON:0001728,UBERON:0000341",COVID-19,MONDO:0100096,local controls,COVID-19 patients,Hospitalized COVID-19 patients,76,76,2 weeks,16S,34,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:977/2/NA,Study 977,case-control,36350127,10.1128/spectrum.02196-22,https://journals.asm.org/doi/10.1128/spectrum.02196-22#fig1,"Lai CKC, Cheung MK, Lui GCY, Ling L, Chan JYK, Ng RWY, Chan HC, Yeung ACM, Ho WCS, Boon SS, Chan PKS , Chen Z",Limited Impact of SARS-CoV-2 on the Human Naso-Oropharyngeal Microbiota in Hospitalized Patients,Microbiology spectrum,2022,"16S rRNA, COVID-19, SARS-CoV-2, hospitalized, naso-oropharyngeal microbiome",Experiment 2,China,Homo sapiens,"Nasopharynx,Throat","UBERON:0001728,UBERON:0000341",Abnormality of the respiratory system,HP:0002086,local controls,Non-Covid-19 Patients,Hospitalized non-COVID-19 patients with respiratory symptoms or related illnesses.,76,69,2 weeks,16S,34,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,decreased,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:977/3/NA,Study 977,case-control,36350127,10.1128/spectrum.02196-22,https://journals.asm.org/doi/10.1128/spectrum.02196-22#fig1,"Lai CKC, Cheung MK, Lui GCY, Ling L, Chan JYK, Ng RWY, Chan HC, Yeung ACM, Ho WCS, Boon SS, Chan PKS , Chen Z",Limited Impact of SARS-CoV-2 on the Human Naso-Oropharyngeal Microbiota in Hospitalized Patients,Microbiology spectrum,2022,"16S rRNA, COVID-19, SARS-CoV-2, hospitalized, naso-oropharyngeal microbiome",Experiment 3,China,Homo sapiens,"Nasopharynx,Throat","UBERON:0001728,UBERON:0000341",COVID-19,MONDO:0100096,non-Covid-19 patients,Covid-19 patients,Hospitalised Covid-19 patients.,69,76,2 weeks,16S,34,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:977/4/NA,Study 977,case-control,36350127,10.1128/spectrum.02196-22,https://journals.asm.org/doi/10.1128/spectrum.02196-22#fig1,"Lai CKC, Cheung MK, Lui GCY, Ling L, Chan JYK, Ng RWY, Chan HC, Yeung ACM, Ho WCS, Boon SS, Chan PKS , Chen Z",Limited Impact of SARS-CoV-2 on the Human Naso-Oropharyngeal Microbiota in Hospitalized Patients,Microbiology spectrum,2022,"16S rRNA, COVID-19, SARS-CoV-2, hospitalized, naso-oropharyngeal microbiome",Experiment 4,China,Homo sapiens,"Nasopharynx,Throat","UBERON:0001728,UBERON:0000341",Pneumonia,EFO:0003106,Covid-19 with no Pneumonia,Covid-19 with Pneumonia,Hospitalized COVID-19 patients with Pneumonia,38,38,2 weeks,16S,34,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:977/5/NA,Study 977,case-control,36350127,10.1128/spectrum.02196-22,https://journals.asm.org/doi/10.1128/spectrum.02196-22#fig1,"Lai CKC, Cheung MK, Lui GCY, Ling L, Chan JYK, Ng RWY, Chan HC, Yeung ACM, Ho WCS, Boon SS, Chan PKS , Chen Z",Limited Impact of SARS-CoV-2 on the Human Naso-Oropharyngeal Microbiota in Hospitalized Patients,Microbiology spectrum,2022,"16S rRNA, COVID-19, SARS-CoV-2, hospitalized, naso-oropharyngeal microbiome",Experiment 5,China,Homo sapiens,"Nasopharynx,Throat","UBERON:0001728,UBERON:0000341",Viral load,EFO:0010125,viral load (≤7.5),viral load (>7.5),COVID-19 patients with viral load greater than 7.5,33,35,2 weeks,16S,34,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:977/6/NA,Study 977,case-control,36350127,10.1128/spectrum.02196-22,https://journals.asm.org/doi/10.1128/spectrum.02196-22#fig1,"Lai CKC, Cheung MK, Lui GCY, Ling L, Chan JYK, Ng RWY, Chan HC, Yeung ACM, Ho WCS, Boon SS, Chan PKS , Chen Z",Limited Impact of SARS-CoV-2 on the Human Naso-Oropharyngeal Microbiota in Hospitalized Patients,Microbiology spectrum,2022,"16S rRNA, COVID-19, SARS-CoV-2, hospitalized, naso-oropharyngeal microbiome",Experiment 6,China,Homo sapiens,"Nasopharynx,Throat","UBERON:0001728,UBERON:0000341",COVID-19,MONDO:0100096,local controls,Hospitalized patients,"Hospitalized COVID and non-COVID patients,",76,145,2 weeks,16S,34,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:978/1/NA,Study 978,"cross-sectional observational, not case-control",32855157,https://doi.org/10.1158/2326-6066.CIR-19-1014,NA,"Peng Z, Cheng S, Kou Y, Wang Z, Jin R, Hu H, Zhang X, Gong JF, Li J, Lu M, Wang X, Zhou J, Lu Z, Zhang Q, Tzeng DTW, Bi D, Tan Y , Shen L",The Gut Microbiome Is Associated with Clinical Response to Anti-PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer,Cancer immunology research,2020,NA,Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Digestive System Carcinoma,EFO:1000218,Non-responders to anti–PD-1/PD-L1 immunotherapy,Responders to anti–PD-1/PD-L1 immunotherapy,Patients with stage 3 or stage 4 gastrointestinal cancer who achieved an objective response (Partial Responders/Stable Disease) lasting at least 3 months upon treatment start with anti–PD-1/PD-L1 immunotherapy.,29,45,None,16S,34,Illumina,Zero-Inflated Negative Binomial Regression,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:978/2/NA,Study 978,"cross-sectional observational, not case-control",32855157,https://doi.org/10.1158/2326-6066.CIR-19-1014,NA,"Peng Z, Cheng S, Kou Y, Wang Z, Jin R, Hu H, Zhang X, Gong JF, Li J, Lu M, Wang X, Zhou J, Lu Z, Zhang Q, Tzeng DTW, Bi D, Tan Y , Shen L",The Gut Microbiome Is Associated with Clinical Response to Anti-PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer,Cancer immunology research,2020,NA,Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,Non-responders (colorectal cancer - CRC),Responders (colorectal cancer - CRC),Patients with colorectal cancer (CRC) who achieved an objective response (Partial Responders/Stable Disease) lasting at least 3 months upon treatment start with anti–PD-1/PD-L1 immunotherapy.,7,12,None,16S,34,Illumina,Zero-Inflated Negative Binomial Regression,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:978/3/NA,Study 978,"cross-sectional observational, not case-control",32855157,https://doi.org/10.1158/2326-6066.CIR-19-1014,NA,"Peng Z, Cheng S, Kou Y, Wang Z, Jin R, Hu H, Zhang X, Gong JF, Li J, Lu M, Wang X, Zhou J, Lu Z, Zhang Q, Tzeng DTW, Bi D, Tan Y , Shen L",The Gut Microbiome Is Associated with Clinical Response to Anti-PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer,Cancer immunology research,2020,NA,Experiment 3,China,Homo sapiens,Feces,UBERON:0001988,Esophageal carcinoma,EFO:0002916,Non-responders (esophageal carcinoma),Responders (esophageal carcinoma),Patients with esophageal carcinoma who achieved an objective response (Partial Responders/Stable Disease) lasting at least 3 months upon treatment start with anti–PD-1/PD-L1 immunotherapy.,6,8,None,16S,34,Illumina,Zero-Inflated Negative Binomial Regression,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:978/4/NA,Study 978,"cross-sectional observational, not case-control",32855157,https://doi.org/10.1158/2326-6066.CIR-19-1014,NA,"Peng Z, Cheng S, Kou Y, Wang Z, Jin R, Hu H, Zhang X, Gong JF, Li J, Lu M, Wang X, Zhou J, Lu Z, Zhang Q, Tzeng DTW, Bi D, Tan Y , Shen L",The Gut Microbiome Is Associated with Clinical Response to Anti-PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer,Cancer immunology research,2020,NA,Experiment 4,China,Homo sapiens,Feces,UBERON:0001988,Gastric cancer,MONDO:0001056,Non-responders (gastric cancer),Responders (gastric cancer),Patients with gastric cancer who achieved an objective response (Partial Responders/Stable Disease) lasting at least 3 months upon treatment start with anti–PD-1/PD-L1 immunotherapy.,8,15,None,16S,34,Illumina,Zero-Inflated Negative Binomial Regression,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:978/5/NA,Study 978,"cross-sectional observational, not case-control",32855157,https://doi.org/10.1158/2326-6066.CIR-19-1014,NA,"Peng Z, Cheng S, Kou Y, Wang Z, Jin R, Hu H, Zhang X, Gong JF, Li J, Lu M, Wang X, Zhou J, Lu Z, Zhang Q, Tzeng DTW, Bi D, Tan Y , Shen L",The Gut Microbiome Is Associated with Clinical Response to Anti-PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer,Cancer immunology research,2020,NA,Experiment 5,China,Homo sapiens,Feces,UBERON:0001988,Digestive System Carcinoma,EFO:1000218,Responders to anti–PD-1/PD-L1 immunotherapy,Non-responders to anti–PD-1/PD-L1 immunotherapy,Patients with stage 3 or stage 4 gastrointestinal cancer who did not achieved an objective response (Partial Responders/Stable Disease) lasting at least 3 months upon treatment start with anti–PD-1/PD-L1 immunotherapy.,25,15,None,WMS,NA,Illumina,Zero-Inflated Negative Binomial Regression,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:979/1/NA,Study 979,"cross-sectional observational, not case-control",37502423,10.3389/fnagi.2023.1148546,NA,"Zhang M, Zhai Z, Yang B, He L, Wang J, Dai W, Xue L, Yang X, Feng Y , Wang H",Exploring the alteration of gut microbiota and brain function in gender-specific Parkinson's disease based on metagenomic sequencing,Frontiers in aging neuroscience,2023,"Parkinson’s disease, fMRI, gender, gut microbiota, metagenomic sequencing",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Female Parkinson’s disease (PD_F) patients,Male Parkinson’s disease (PD_M) patients,Male patients with Parkinson’s disease (PD) diagnosed according to the primary Parkinson’s disease diagnostic criteria.,11,13,History of antibiotic use in the last month,WMS,NA,Illumina,LEfSe,0.05,FALSE,3,"age,body weight",NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:980/1/NA,Study 980,case-control,38189294,https://doi.org/10.1128/spectrum.01006-23,NA,"Zhang J, Shi M, Zhao C, Liang G, Li C, Ge X, Pei C, Kong Y, Li D, Yang W, Cao B, Fu L, Yan Y, Wu J, Zhou J, Fang Y, Meng X, Li Y , Wang L",Role of intestinal flora in the development of nonalcoholic fatty liver disease in children,Microbiology spectrum,2024,"BMI, NAFLD, NASH, children, gut microbiota, metabolism",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Non-alcoholic fatty liver disease,EFO:0003095,Healthy controls,Non-alcoholic fatty liver disease (NAFLD),Pediatric patients with non-alcoholic fatty liver disease (NAFLD) whose body mass index (BMI) was higher than the 95th percentile and defined through a clinical evaluation and liver ultrasonography,35,79,2 months,16S,34,Illumina,LEfSe,0.05,TRUE,2,NA,NA,unchanged,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:980/2/NA,Study 980,case-control,38189294,https://doi.org/10.1128/spectrum.01006-23,NA,"Zhang J, Shi M, Zhao C, Liang G, Li C, Ge X, Pei C, Kong Y, Li D, Yang W, Cao B, Fu L, Yan Y, Wu J, Zhou J, Fang Y, Meng X, Li Y , Wang L",Role of intestinal flora in the development of nonalcoholic fatty liver disease in children,Microbiology spectrum,2024,"BMI, NAFLD, NASH, children, gut microbiota, metabolism",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Non-alcoholic steatohepatitis,EFO:1001249,NAFL (Non-alcoholic fatty liver) patients,NASH (Non-alcoholic steatohepatitis) patients,Non-alcoholic fatty liver disease (NAFLD) patients with the presence of hepatic steatosis with necroinflammation and hepatocellular injury with or without fibrosis,5,8,2 months,WMS,NA,Illumina,LEfSe,0.05,TRUE,2,NA,NA,increased,increased,NA,increased,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:981/1/NA,Study 981,case-control,35645785,10.3389/fnagi.2022.881872,NA,"Lubomski M, Xu X, Holmes AJ, Muller S, Yang JYH, Davis RL , Sue CM",Nutritional Intake and Gut Microbiome Composition Predict Parkinson's Disease,Frontiers in aging neuroscience,2022,"Parkinson’s disease, biomarker, dysbiosis, gastrointestinal microbiome, gut microbiota, medication, prediction model",Experiment 1,Australia,Homo sapiens,"Feces,Blood","UBERON:0001988,UBERON:0000178",Parkinson's disease,MONDO:0005180,Healthy controls,Participants with Parkinson's Disease,Patients with a clinical diagnosis of idiopathic PD according to the UK Parkinson’s Disease Society Brain Bank Diagnostic Criteria,81,103,All participants did not receive antibiotics or probiotic supplements for at least 1-month prior to sample collection.,16S,34,Illumina,ANOVA,0.05,FALSE,NA,NA,"age,body mass index,sex",NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:982/1/NA,Study 982,laboratory experiment,31837420,https://doi.org/10.1016/j.nbd.2019.104704,NA,"Yang D, Zhao D, Shah SZA, Wu W, Lai M, Zhang X, Li J, Guan Z, Zhao H, Li W, Gao H, Zhou X , Yang L",Implications of gut microbiota dysbiosis and metabolic changes in prion disease,Neurobiology of disease,2020,"Metabolomics, Microbiome, Multi-omics analysis, Prion infection, Short chain fatty acids",Experiment 1,China,Mus musculus,Feces,UBERON:0001988,Prion disease,EFO:0004720,Healthy Control (C),Prion-infected mice (R),Prion-infected mice,25,12,NA,16S,34,Illumina,LEfSe,0.05,FALSE,3,NA,NA,NA,decreased,decreased,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:983/1/NA,Study 983,case-control,23335968,10.1371/journal.pone.0053653,https://pubmed.ncbi.nlm.nih.gov/23335968/,"McCoy AN, Araújo-Pérez F, Azcárate-Peril A, Yeh JJ, Sandler RS , Keku TO",Fusobacterium is associated with colorectal adenomas,PloS one,2013,NA,Experiment 1,United States of America,Homo sapiens,Colorectal mucosa,UBERON:0013067,Colorectal adenoma,EFO:0005406,Non-adenoma,Adenoma,Patients with colorectal adenoma,67,48,None,16S,123,Roche454,T-Test,0.01,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:984/1/NA,Study 984,case-control,31815177,10.1038/s41531-019-0100-x,NA,"Weis S, Schwiertz A, Unger MM, Becker A, Faßbender K, Ratering S, Kohl M, Schnell S, Schäfer KH , Egert M",Effect of Parkinson's disease and related medications on the composition of the fecal bacterial microbiota,NPJ Parkinson's disease,2019,"Constipation, Parkinson's disease",Experiment 1,Germany,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Healthy Controls,Parkinson's Disease,Patients with Parkinson's Disease.,25,34,Not Reported,16S,45,Ion Torrent,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,age,NA,NA,unchanged,decreased,unchanged,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:985/1/NA,Study 985,case-control,36475922,10.1128/spectrum.02805-22,NA,"Chen TH, Cheng CY, Huang CK, Ho YH , Lin JC",Exploring the Relevance between Gut Microbiota-Metabolites Profile and Chronic Kidney Disease with Distinct Pathogenic Factor,Microbiology spectrum,2023,"chronic kidney disease, diabetes mellitus, fecal metabolite, gut microbiota, hypertension",Experiment 1,Taiwan,Homo sapiens,Feces,UBERON:0001988,Chronic kidney disease,EFO:0003884,Healthy Controls,Chronic Kidney Disease,Chronic kidney disease patients,60,105,NA,16S,NA,Nanopore,LEfSe,0.05,FALSE,3,NA,NA,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:985/2/NA,Study 985,case-control,36475922,10.1128/spectrum.02805-22,NA,"Chen TH, Cheng CY, Huang CK, Ho YH , Lin JC",Exploring the Relevance between Gut Microbiota-Metabolites Profile and Chronic Kidney Disease with Distinct Pathogenic Factor,Microbiology spectrum,2023,"chronic kidney disease, diabetes mellitus, fecal metabolite, gut microbiota, hypertension",Experiment 2,Taiwan,Homo sapiens,Feces,UBERON:0001988,Chronic kidney disease,EFO:0003884,Healthy Controls,NC-CKD,Chronic kidney disease patients without comorbidities,60,40,NA,16S,NA,Nanopore,LEfSe,0.05,FALSE,3,NA,NA,NA,increased,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:985/3/NA,Study 985,case-control,36475922,10.1128/spectrum.02805-22,NA,"Chen TH, Cheng CY, Huang CK, Ho YH , Lin JC",Exploring the Relevance between Gut Microbiota-Metabolites Profile and Chronic Kidney Disease with Distinct Pathogenic Factor,Microbiology spectrum,2023,"chronic kidney disease, diabetes mellitus, fecal metabolite, gut microbiota, hypertension",Experiment 3,Taiwan,Homo sapiens,Feces,UBERON:0001988,Chronic kidney disease,EFO:0003884,Healthy Controls,H-CKD,Hypertensive chronic kidney disease patients,60,26,NA,16S,NA,Nanopore,LEfSe,0.05,FALSE,3,NA,NA,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:985/4/NA,Study 985,case-control,36475922,10.1128/spectrum.02805-22,NA,"Chen TH, Cheng CY, Huang CK, Ho YH , Lin JC",Exploring the Relevance between Gut Microbiota-Metabolites Profile and Chronic Kidney Disease with Distinct Pathogenic Factor,Microbiology spectrum,2023,"chronic kidney disease, diabetes mellitus, fecal metabolite, gut microbiota, hypertension",Experiment 4,Taiwan,Homo sapiens,Feces,UBERON:0001988,Chronic kidney disease,EFO:0003884,Healthy Controls,D-CKD,Diabetic chronic kidney disease patients,60,39,NA,16S,NA,Nanopore,LEfSe,0.05,FALSE,3,NA,NA,NA,increased,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:987/1/NA,Study 987,case-control,35900092,https://doi.org/10.1128/spectrum.01676-22,NA,"Yang X, Pan X, Li M, Zeng Z, Guo Y, Chen P, Liang X, Chen P , Liu G",Interaction between Cervical Microbiota and Host Gene Regulation in Caesarean Section Scar Diverticulum,Microbiology spectrum,2022,"cesarean section scar diverticulum, gene regulation, host-microbiota interaction, microbiome",Experiment 1,China,Homo sapiens,"Endometrium,Uterine cervix","UBERON:0001295,UBERON:0000002",Cesarean section,EFO:0009636,Control,Cesarean section scar diverticulum (CSD),"Women with cesarean section scar diverticulum (CSD), a complication that can occur following a cesarean section (C-section) delivery.",24,28,1 Month,16S,NA,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:988/1/NA,Study 988,case-control,35196800,https://doi.org/10.1128/spectrum.01901-21,NA,"Guohui Xiao, Guoliang Zhang, Juanjuan Zhang, Lei Liu, Liang Yang yangl@sustech.edu.cn, Lili Ren, Min Ou, Minfei Yu, Peikun Guan, Qinglong Guo, Taosheng Ye, Xiangdong Fu, Yimin Tang, Zhao Cai, Zhaoqin Wang",Insights into the Unique Lung Microbiota Profile of Pulmonary Tuberculosis Patients Using Metagenomic Next-Generation Sequencing,Insights into the Unique Lung Microbiota Profile of Pulmonary Tuberculosis Patients Using Metagenomic Next-Generation Sequencing,2022,"tuberculosis, Mycobacterium tuberculosis, anti-TB treatment, antibiotic resistance genes, lung microbiota, metagenomics",Experiment 1,China,Homo sapiens,Throat,UBERON:0000341,"Mycobacterium tuberculosis,Lung cancer","NCBITAXON:1773,MONDO:0008903",Healthy Control Group (HCG),Untreated TB Group (UTG) and lung cancer patient group (LCG),"This group consists of patients who have untreated pulmonary tuberculosis group (UTG; 5 males, 7 females) and lung cancer patient group (LCG; 5 males, 2 females)",8,19,NA,WMS,NA,Illumina,LEfSe,0.05,FALSE,4,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:988/2/NA,Study 988,case-control,35196800,https://doi.org/10.1128/spectrum.01901-21,NA,"Guohui Xiao, Guoliang Zhang, Juanjuan Zhang, Lei Liu, Liang Yang yangl@sustech.edu.cn, Lili Ren, Min Ou, Minfei Yu, Peikun Guan, Qinglong Guo, Taosheng Ye, Xiangdong Fu, Yimin Tang, Zhao Cai, Zhaoqin Wang",Insights into the Unique Lung Microbiota Profile of Pulmonary Tuberculosis Patients Using Metagenomic Next-Generation Sequencing,Insights into the Unique Lung Microbiota Profile of Pulmonary Tuberculosis Patients Using Metagenomic Next-Generation Sequencing,2022,"tuberculosis, Mycobacterium tuberculosis, anti-TB treatment, antibiotic resistance genes, lung microbiota, metagenomics",Experiment 2,China,Homo sapiens,Throat,UBERON:0000341,Mycobacterium tuberculosis,NCBITAXON:1773,Healthy Control Group (HCG) and Lung Cancer Group (LCG),Untreated TB Group (UTG),This group consists of patients who have Untreated Pulmonary Tuberculosis and are not taking any antibiotics.,15,12,NA,WMS,NA,Illumina,LEfSe,0.05,FALSE,4,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:988/3/NA,Study 988,case-control,35196800,https://doi.org/10.1128/spectrum.01901-21,NA,"Guohui Xiao, Guoliang Zhang, Juanjuan Zhang, Lei Liu, Liang Yang yangl@sustech.edu.cn, Lili Ren, Min Ou, Minfei Yu, Peikun Guan, Qinglong Guo, Taosheng Ye, Xiangdong Fu, Yimin Tang, Zhao Cai, Zhaoqin Wang",Insights into the Unique Lung Microbiota Profile of Pulmonary Tuberculosis Patients Using Metagenomic Next-Generation Sequencing,Insights into the Unique Lung Microbiota Profile of Pulmonary Tuberculosis Patients Using Metagenomic Next-Generation Sequencing,2022,"tuberculosis, Mycobacterium tuberculosis, anti-TB treatment, antibiotic resistance genes, lung microbiota, metagenomics",Experiment 3,China,Homo sapiens,Throat,UBERON:0000341,Lung cancer,MONDO:0008903,Healthy Control Group (HCG) and Untreated TB Group (UTG),Lung cancer patient group (LCG),Patients with lung cancer,20,7,NA,WMS,NA,Illumina,LEfSe,0.05,FALSE,4,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:988/4/NA,Study 988,case-control,35196800,https://doi.org/10.1128/spectrum.01901-21,NA,"Guohui Xiao, Guoliang Zhang, Juanjuan Zhang, Lei Liu, Liang Yang yangl@sustech.edu.cn, Lili Ren, Min Ou, Minfei Yu, Peikun Guan, Qinglong Guo, Taosheng Ye, Xiangdong Fu, Yimin Tang, Zhao Cai, Zhaoqin Wang",Insights into the Unique Lung Microbiota Profile of Pulmonary Tuberculosis Patients Using Metagenomic Next-Generation Sequencing,Insights into the Unique Lung Microbiota Profile of Pulmonary Tuberculosis Patients Using Metagenomic Next-Generation Sequencing,2022,"tuberculosis, Mycobacterium tuberculosis, anti-TB treatment, antibiotic resistance genes, lung microbiota, metagenomics",Experiment 4,China,Homo sapiens,Throat,UBERON:0000341,Mycobacterium tuberculosis,NCBITAXON:1773,Treated pulmonary TB group (TTG) and cured pulmonary TB group (CTG),Untreated pulmonary TB group (UTG),This group consists of patients who have Untreated Pulmonary Tuberculosis and are not taking any antibiotics.,26,12,NA,WMS,NA,Illumina,LEfSe,0.05,FALSE,4,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:989/1/NA,Study 989,laboratory experiment,36943054,https://doi.org/10.1128/spectrum.03330-22,NA,"Zhou C, Wang Y, Li C, Xie Z , Dai L",Amelioration of Colitis by a Gut Bacterial Consortium Producing Anti-Inflammatory Secondary Bile Acids,Microbiology spectrum,2023,"bacterial consortium, colitis, gut microbiome, metabolomics, secondary bile acids, targeted metabolomics",Experiment 1,China,Mus musculus,Feces,UBERON:0001988,Colitis,EFO:0003872,DSS Group (Day 7),DSS + BAC Group (Day 7),Mice were given dextran sulfate sodium (DSS) to induce Colitis and then treated with Bile Acid Consortium (BAC).,7,7,NA,WMS,NA,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:990/1/NA,Study 990,laboratory experiment,37655887,https://doi.org/10.1128/spectrum.00189-23,NA,"Xu F, Li Q, Wang S, Dong M, Xiao G, Bai J, Wang J , Sun X",The efficacy of prevention for colon cancer based on the microbiota therapy and the antitumor mechanisms with intervention of dietary <i>Lactobacillus</i>,Microbiology spectrum,2023,"Lactobacillus, colon cancer, gut microbiota, serine, sphingosine 1-phosphate signaling",Experiment 1,China,Mus musculus,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,Tumor control group (CK),Living bacteria group (LB),"BALB/c mice (male, 6 wk) purchased from Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences. These mice were given oral administration of living Lactobacillus bacteria.",30,30,none,16S,34,Illumina,LEfSe,0.05,FALSE,2,"age,sex",NA,NA,unchanged,increased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:990/2/NA,Study 990,laboratory experiment,37655887,https://doi.org/10.1128/spectrum.00189-23,NA,"Xu F, Li Q, Wang S, Dong M, Xiao G, Bai J, Wang J , Sun X",The efficacy of prevention for colon cancer based on the microbiota therapy and the antitumor mechanisms with intervention of dietary <i>Lactobacillus</i>,Microbiology spectrum,2023,"Lactobacillus, colon cancer, gut microbiota, serine, sphingosine 1-phosphate signaling",Experiment 2,China,Mus musculus,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,Tumor control group (CK),Inactivated bacteria group (IB),"BALB/c mice (male, 6 wk) purchased from Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences. These mice were given oral administration of inactivated Lactobacillus bacteria.",30,30,none,16S,34,Illumina,LEfSe,0.05,FALSE,2,"age,sex",NA,NA,unchanged,increased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:990/3/NA,Study 990,laboratory experiment,37655887,https://doi.org/10.1128/spectrum.00189-23,NA,"Xu F, Li Q, Wang S, Dong M, Xiao G, Bai J, Wang J , Sun X",The efficacy of prevention for colon cancer based on the microbiota therapy and the antitumor mechanisms with intervention of dietary <i>Lactobacillus</i>,Microbiology spectrum,2023,"Lactobacillus, colon cancer, gut microbiota, serine, sphingosine 1-phosphate signaling",Experiment 3,China,Mus musculus,Feces,UBERON:0001988,Colorectal cancer,EFO:0005842,Inactivated bacteria group,Living bacteria group,"BALB/c mice (male, 6 wk) purchased from Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences. These mice were given oral administration of living Lactobacillus bacteria.",30,30,none,16S,34,Illumina,LEfSe,0.05,FALSE,2,"age,sex",NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:991/1/NA,Study 991,laboratory experiment,35216552,https://doi.org/10.1186/s12866-022-02458-5,https://bmcmicrobiol.biomedcentral.com/articles/10.1186/s12866-022-02458-5,"Mekadim C, Skalnikova HK, Cizkova J, Cizkova V, Palanova A, Horak V , Mrazek J",Dysbiosis of skin microbiome and gut microbiome in melanoma progression,BMC microbiology,2022,"Dysbiosis, Gut microbiome, Gut-skin axis, MeLiM, Melanoma, Metagenomic analysis, NGS, Pig, Skin cancer, Skin microbiome, Tumour microenvironment",Experiment 1,Czechia,Sus scrofa domesticus,Skin of body,UBERON:0002097,Disease staging,EFO:0000410,Melanoma surface of pigs with with melanoma regression,Melanoma surface of pigs with Melanoma progression,Melanoma surface samples collected from piglets with melanoma progression,14,10,NA,16S,45,Ion Torrent,LEfSe,0.05,FALSE,3,NA,NA,NA,unchanged,unchanged,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:991/2/NA,Study 991,laboratory experiment,35216552,https://doi.org/10.1186/s12866-022-02458-5,https://bmcmicrobiol.biomedcentral.com/articles/10.1186/s12866-022-02458-5,"Mekadim C, Skalnikova HK, Cizkova J, Cizkova V, Palanova A, Horak V , Mrazek J",Dysbiosis of skin microbiome and gut microbiome in melanoma progression,BMC microbiology,2022,"Dysbiosis, Gut microbiome, Gut-skin axis, MeLiM, Melanoma, Metagenomic analysis, NGS, Pig, Skin cancer, Skin microbiome, Tumour microenvironment",Experiment 2,Czechia,Sus scrofa domesticus,Skin of body,UBERON:0002097,Disease staging,EFO:0000410,Melanoma tissue of pigs with with melanoma regression,Melanoma tissue of pigs with Melanoma progression,Melanoma tissue samples collected from piglets with melanoma progression,14,10,NA,16S,45,Ion Torrent,LEfSe,0.05,FALSE,3,NA,NA,NA,unchanged,unchanged,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:991/3/NA,Study 991,laboratory experiment,35216552,https://doi.org/10.1186/s12866-022-02458-5,https://bmcmicrobiol.biomedcentral.com/articles/10.1186/s12866-022-02458-5,"Mekadim C, Skalnikova HK, Cizkova J, Cizkova V, Palanova A, Horak V , Mrazek J",Dysbiosis of skin microbiome and gut microbiome in melanoma progression,BMC microbiology,2022,"Dysbiosis, Gut microbiome, Gut-skin axis, MeLiM, Melanoma, Metagenomic analysis, NGS, Pig, Skin cancer, Skin microbiome, Tumour microenvironment",Experiment 3,Czechia,Sus scrofa domesticus,Skin of body,UBERON:0002097,Cutaneous melanoma,EFO:0000389,healthy skin,melanoma surface from black pigs,cutaneous melanoma surface samples collected from the skin of black pigs,10,24,NA,16S,45,Ion Torrent,LEfSe,0.05,FALSE,3,NA,NA,NA,decreased,decreased,decreased,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:991/4/NA,Study 991,laboratory experiment,35216552,https://doi.org/10.1186/s12866-022-02458-5,https://bmcmicrobiol.biomedcentral.com/articles/10.1186/s12866-022-02458-5,"Mekadim C, Skalnikova HK, Cizkova J, Cizkova V, Palanova A, Horak V , Mrazek J",Dysbiosis of skin microbiome and gut microbiome in melanoma progression,BMC microbiology,2022,"Dysbiosis, Gut microbiome, Gut-skin axis, MeLiM, Melanoma, Metagenomic analysis, NGS, Pig, Skin cancer, Skin microbiome, Tumour microenvironment",Experiment 4,Czechia,Sus scrofa domesticus,Skin of body,UBERON:0002097,Cutaneous melanoma,EFO:0000389,healthy skin,melanoma tissue from black pigs,cutaneous melanoma tissue samples collected from the skin of black pigs,10,24,NA,16S,45,Ion Torrent,LEfSe,0.05,FALSE,3,NA,NA,NA,decreased,decreased,decreased,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:991/5/NA,Study 991,laboratory experiment,35216552,https://doi.org/10.1186/s12866-022-02458-5,https://bmcmicrobiol.biomedcentral.com/articles/10.1186/s12866-022-02458-5,"Mekadim C, Skalnikova HK, Cizkova J, Cizkova V, Palanova A, Horak V , Mrazek J",Dysbiosis of skin microbiome and gut microbiome in melanoma progression,BMC microbiology,2022,"Dysbiosis, Gut microbiome, Gut-skin axis, MeLiM, Melanoma, Metagenomic analysis, NGS, Pig, Skin cancer, Skin microbiome, Tumour microenvironment",Experiment 5,Czechia,Sus scrofa domesticus,Feces,UBERON:0001988,Cutaneous melanoma,EFO:0000389,controls without melanoma and melanoma regression,Melanoma progression,samples collected from piglets undergoing melanoma progression.,24,10,NA,16S,45,Ion Torrent,LEfSe,0.05,FALSE,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:991/6/NA,Study 991,laboratory experiment,35216552,https://doi.org/10.1186/s12866-022-02458-5,https://bmcmicrobiol.biomedcentral.com/articles/10.1186/s12866-022-02458-5,"Mekadim C, Skalnikova HK, Cizkova J, Cizkova V, Palanova A, Horak V , Mrazek J",Dysbiosis of skin microbiome and gut microbiome in melanoma progression,BMC microbiology,2022,"Dysbiosis, Gut microbiome, Gut-skin axis, MeLiM, Melanoma, Metagenomic analysis, NGS, Pig, Skin cancer, Skin microbiome, Tumour microenvironment",Experiment 6,Czechia,Sus scrofa domesticus,Feces,UBERON:0001988,Cutaneous melanoma,EFO:0000389,controls without melanoma and melanoma progression,melanoma regression,samples collected from piglets undergoing melanoma regression,20,14,NA,16S,45,Ion Torrent,LEfSe,0.05,FALSE,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:991/7/NA,Study 991,laboratory experiment,35216552,https://doi.org/10.1186/s12866-022-02458-5,https://bmcmicrobiol.biomedcentral.com/articles/10.1186/s12866-022-02458-5,"Mekadim C, Skalnikova HK, Cizkova J, Cizkova V, Palanova A, Horak V , Mrazek J",Dysbiosis of skin microbiome and gut microbiome in melanoma progression,BMC microbiology,2022,"Dysbiosis, Gut microbiome, Gut-skin axis, MeLiM, Melanoma, Metagenomic analysis, NGS, Pig, Skin cancer, Skin microbiome, Tumour microenvironment",Experiment 7,Czechia,Sus scrofa domesticus,Feces,UBERON:0001988,Cutaneous melanoma,EFO:0000389,Controls without melanoma,Melanoma progression and regression,samples collected from piglets undergoing melanoma regression and progression,10,24,NA,16S,45,Ion Torrent,LEfSe,0.05,FALSE,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:991/8/NA,Study 991,laboratory experiment,35216552,https://doi.org/10.1186/s12866-022-02458-5,https://bmcmicrobiol.biomedcentral.com/articles/10.1186/s12866-022-02458-5,"Mekadim C, Skalnikova HK, Cizkova J, Cizkova V, Palanova A, Horak V , Mrazek J",Dysbiosis of skin microbiome and gut microbiome in melanoma progression,BMC microbiology,2022,"Dysbiosis, Gut microbiome, Gut-skin axis, MeLiM, Melanoma, Metagenomic analysis, NGS, Pig, Skin cancer, Skin microbiome, Tumour microenvironment",Experiment 8,Czechia,Sus scrofa domesticus,Feces,UBERON:0001988,Breed,EFO:0005238,Crossbreed between MeLiM and white piglets,Homogenous breed MeLiM piglets,MeLiM piglets whose parents are both MeLiM black pigs,14,20,NA,16S,45,Ion Torrent,LEfSe,0.05,FALSE,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:991/9/NA,Study 991,laboratory experiment,35216552,https://doi.org/10.1186/s12866-022-02458-5,https://bmcmicrobiol.biomedcentral.com/articles/10.1186/s12866-022-02458-5,"Mekadim C, Skalnikova HK, Cizkova J, Cizkova V, Palanova A, Horak V , Mrazek J",Dysbiosis of skin microbiome and gut microbiome in melanoma progression,BMC microbiology,2022,"Dysbiosis, Gut microbiome, Gut-skin axis, MeLiM, Melanoma, Metagenomic analysis, NGS, Pig, Skin cancer, Skin microbiome, Tumour microenvironment",Experiment 9,Czechia,Sus scrofa domesticus,Skin of body,UBERON:0002097,Sample splitting,EFO:0030016,melanoma surface,melanoma tissue,melanoma inner tissue samples collected from piglets with melanoma,24,24,NA,16S,45,Ion Torrent,NA,NA,NA,NA,NA,NA,NA,decreased,decreased,decreased,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:991/10/NA,Study 991,laboratory experiment,35216552,https://doi.org/10.1186/s12866-022-02458-5,https://bmcmicrobiol.biomedcentral.com/articles/10.1186/s12866-022-02458-5,"Mekadim C, Skalnikova HK, Cizkova J, Cizkova V, Palanova A, Horak V , Mrazek J",Dysbiosis of skin microbiome and gut microbiome in melanoma progression,BMC microbiology,2022,"Dysbiosis, Gut microbiome, Gut-skin axis, MeLiM, Melanoma, Metagenomic analysis, NGS, Pig, Skin cancer, Skin microbiome, Tumour microenvironment",Experiment 10,Czechia,Sus scrofa domesticus,Skin of body,UBERON:0002097,Cutaneous melanoma,EFO:0000389,skin samples from white piglets,skin samples from crossbred piglets,skin samples from Black crossbred piglets.,10,4,NA,16S,45,Ion Torrent,NA,NA,NA,NA,NA,NA,NA,decreased,decreased,unchanged,unchanged,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:991/11/NA,Study 991,laboratory experiment,35216552,https://doi.org/10.1186/s12866-022-02458-5,https://bmcmicrobiol.biomedcentral.com/articles/10.1186/s12866-022-02458-5,"Mekadim C, Skalnikova HK, Cizkova J, Cizkova V, Palanova A, Horak V , Mrazek J",Dysbiosis of skin microbiome and gut microbiome in melanoma progression,BMC microbiology,2022,"Dysbiosis, Gut microbiome, Gut-skin axis, MeLiM, Melanoma, Metagenomic analysis, NGS, Pig, Skin cancer, Skin microbiome, Tumour microenvironment",Experiment 11,Czechia,Sus scrofa domesticus,Skin of body,UBERON:0002097,Cutaneous melanoma,EFO:0000389,samples from white piglets,samples from MeLiM piglets,samples from piglets gotten through Homogenous breeding of two Black MeLiM pigs.,10,20,NA,16S,45,Ion Torrent,NA,NA,NA,NA,NA,NA,NA,decreased,decreased,decreased,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:991/12/NA,Study 991,laboratory experiment,35216552,https://doi.org/10.1186/s12866-022-02458-5,https://bmcmicrobiol.biomedcentral.com/articles/10.1186/s12866-022-02458-5,"Mekadim C, Skalnikova HK, Cizkova J, Cizkova V, Palanova A, Horak V , Mrazek J",Dysbiosis of skin microbiome and gut microbiome in melanoma progression,BMC microbiology,2022,"Dysbiosis, Gut microbiome, Gut-skin axis, MeLiM, Melanoma, Metagenomic analysis, NGS, Pig, Skin cancer, Skin microbiome, Tumour microenvironment",Experiment 12,Czechia,Sus scrofa domesticus,Skin of body,UBERON:0002097,Breed,EFO:0005238,Black crossbred between white and MeLiM piglets,Homogenous breed Black MeLiM piglets,samples from piglets gotten through Homogenous breeding of two Black MeLiM pigs.,4,20,NA,16S,45,Ion Torrent,NA,NA,NA,NA,NA,NA,NA,decreased,decreased,decreased,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:991/13/NA,Study 991,laboratory experiment,35216552,https://doi.org/10.1186/s12866-022-02458-5,https://bmcmicrobiol.biomedcentral.com/articles/10.1186/s12866-022-02458-5,"Mekadim C, Skalnikova HK, Cizkova J, Cizkova V, Palanova A, Horak V , Mrazek J",Dysbiosis of skin microbiome and gut microbiome in melanoma progression,BMC microbiology,2022,"Dysbiosis, Gut microbiome, Gut-skin axis, MeLiM, Melanoma, Metagenomic analysis, NGS, Pig, Skin cancer, Skin microbiome, Tumour microenvironment",Experiment 13,Czechia,Sus scrofa domesticus,Skin of body,UBERON:0002097,Age at assessment,EFO:0008007,melanoma regression at age 8 weeks,melanoma regression at age 12 weeks,samples gotten from piglets undergoing melanoma regression at age 12 weeks,14,14,NA,16S,45,Ion Torrent,NA,NA,NA,NA,NA,NA,NA,increased,increased,unchanged,unchanged,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:991/14/NA,Study 991,laboratory experiment,35216552,https://doi.org/10.1186/s12866-022-02458-5,https://bmcmicrobiol.biomedcentral.com/articles/10.1186/s12866-022-02458-5,"Mekadim C, Skalnikova HK, Cizkova J, Cizkova V, Palanova A, Horak V , Mrazek J",Dysbiosis of skin microbiome and gut microbiome in melanoma progression,BMC microbiology,2022,"Dysbiosis, Gut microbiome, Gut-skin axis, MeLiM, Melanoma, Metagenomic analysis, NGS, Pig, Skin cancer, Skin microbiome, Tumour microenvironment",Experiment 14,Czechia,Sus scrofa domesticus,Skin of body,UBERON:0002097,Age at assessment,EFO:0008007,melanoma regression at age 10 weeks,melanoma regression at age 12 weeks,samples gotten from piglets undergoing melanoma regression at age 12 weeks,14,14,NA,16S,45,Ion Torrent,NA,NA,NA,NA,NA,NA,NA,decreased,decreased,decreased,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:991/15/NA,Study 991,laboratory experiment,35216552,https://doi.org/10.1186/s12866-022-02458-5,https://bmcmicrobiol.biomedcentral.com/articles/10.1186/s12866-022-02458-5,"Mekadim C, Skalnikova HK, Cizkova J, Cizkova V, Palanova A, Horak V , Mrazek J",Dysbiosis of skin microbiome and gut microbiome in melanoma progression,BMC microbiology,2022,"Dysbiosis, Gut microbiome, Gut-skin axis, MeLiM, Melanoma, Metagenomic analysis, NGS, Pig, Skin cancer, Skin microbiome, Tumour microenvironment",Experiment 15,Czechia,Sus scrofa domesticus,Skin of body,UBERON:0002097,Age at assessment,EFO:0008007,melanoma regression at age 8 weeks,melanoma regression at age 10 weeks,samples gotten from piglets undergoing melanoma regression at age 10 weeks,14,14,NA,16S,45,Ion Torrent,NA,NA,NA,NA,NA,NA,NA,increased,increased,increased,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:991/16/NA,Study 991,laboratory experiment,35216552,https://doi.org/10.1186/s12866-022-02458-5,https://bmcmicrobiol.biomedcentral.com/articles/10.1186/s12866-022-02458-5,"Mekadim C, Skalnikova HK, Cizkova J, Cizkova V, Palanova A, Horak V , Mrazek J",Dysbiosis of skin microbiome and gut microbiome in melanoma progression,BMC microbiology,2022,"Dysbiosis, Gut microbiome, Gut-skin axis, MeLiM, Melanoma, Metagenomic analysis, NGS, Pig, Skin cancer, Skin microbiome, Tumour microenvironment",Experiment 16,Czechia,Sus scrofa domesticus,Feces,UBERON:0001988,Age at assessment,EFO:0008007,melanoma regression at age 8 weeks,melanoma regression at age 10 weeks,samples gotten from piglets undergoing melanoma regression at age 10 weeks,14,14,NA,16S,45,Ion Torrent,NA,NA,NA,NA,NA,NA,NA,increased,increased,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:991/17/NA,Study 991,laboratory experiment,35216552,https://doi.org/10.1186/s12866-022-02458-5,https://bmcmicrobiol.biomedcentral.com/articles/10.1186/s12866-022-02458-5,"Mekadim C, Skalnikova HK, Cizkova J, Cizkova V, Palanova A, Horak V , Mrazek J",Dysbiosis of skin microbiome and gut microbiome in melanoma progression,BMC microbiology,2022,"Dysbiosis, Gut microbiome, Gut-skin axis, MeLiM, Melanoma, Metagenomic analysis, NGS, Pig, Skin cancer, Skin microbiome, Tumour microenvironment",Experiment 17,Czechia,Sus scrofa domesticus,Feces,UBERON:0001988,Breed,EFO:0005238,crossbred piglets undergoing regression,MeLiM piglets undergoing regression,samples gotten from Black MeLiM piglets undergoing regression,4,10,NA,16S,45,Ion Torrent,NA,NA,NA,NA,NA,NA,NA,decreased,decreased,decreased,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:992/1/NA,Study 992,case-control,34795317,10.1038/s41531-021-00244-0,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602383/,"Weis S, Meisner A, Schwiertz A, Unger MM, Becker A, Faßbender K, Schnell S, Schäfer KH , Egert M",Association between Parkinson's disease and the faecal eukaryotic microbiota,NPJ Parkinson's disease,2021,NA,Experiment 1,Germany,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Healthy controls (HC),Parkinson's disease patients (PD),Patients suffering from Parkinson's disease,25,34,3 months.,18S,NA,Illumina,ANCOM,0.05,TRUE,NA,age,NA,NA,decreased,NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:993/1/NA,Study 993,"prospective cohort,time series / longitudinal observational",38326891,https://doi.org/10.1186/s40168-023-01735-3,NA,"Mercer EM, Ramay HR, Moossavi S, Laforest-Lapointe I, Reyna ME, Becker AB, Simons E, Mandhane PJ, Turvey SE, Moraes TJ, Sears MR, Subbarao P, Azad MB , Arrieta MC",Divergent maturational patterns of the infant bacterial and fungal gut microbiome in the first year of life are associated with inter-kingdom community dynamics and infant nutrition,Microbiome,2024,"Alpha diversity, Colonization patterns, Early life, Gut fungi, Gut microbiome, Gut mycobiome, Inter-kingdom dynamics, Microbial succession, Microbiome maturation",Experiment 1,Canada,Homo sapiens,Feces,UBERON:0001988,Gut microbiome measurement,EFO:0007874,3 months,12 months,infants when they are 12 months of age,99,99,exposure prior to 3 months,16S,4,Illumina,DESeq2,0.001,TRUE,NA,NA,NA,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:993/2/NA,Study 993,"prospective cohort,time series / longitudinal observational",38326891,https://doi.org/10.1186/s40168-023-01735-3,NA,"Mercer EM, Ramay HR, Moossavi S, Laforest-Lapointe I, Reyna ME, Becker AB, Simons E, Mandhane PJ, Turvey SE, Moraes TJ, Sears MR, Subbarao P, Azad MB , Arrieta MC",Divergent maturational patterns of the infant bacterial and fungal gut microbiome in the first year of life are associated with inter-kingdom community dynamics and infant nutrition,Microbiome,2024,"Alpha diversity, Colonization patterns, Early life, Gut fungi, Gut microbiome, Gut mycobiome, Inter-kingdom dynamics, Microbial succession, Microbiome maturation",Experiment 2,Canada,Homo sapiens,Feces,UBERON:0001988,Gut microbiome measurement,EFO:0007874,3 months,12 months,infants when they are 12 months of age,95,95,before 3 months,ITS / ITS2,NA,Illumina,DESeq2,0.001,TRUE,NA,NA,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:994/1/NA,Study 994,case-control,22622349,10.1038/ismej.2012.43,https://pubmed.ncbi.nlm.nih.gov/22622349/,"Sanapareddy N, Legge RM, Jovov B, McCoy A, Burcal L, Araujo-Perez F, Randall TA, Galanko J, Benson A, Sandler RS, Rawls JF, Abdo Z, Fodor AA , Keku TO",Increased rectal microbial richness is associated with the presence of colorectal adenomas in humans,The ISME journal,2012,NA,Experiment 1,United States of America,Homo sapiens,Colorectal mucosa,UBERON:0013067,Colorectal adenoma,EFO:0005406,Adenoma-free (controls),Adenoma patients (cases),Patients who have colorectal adenoma,38,33,"Subjects were asked if they used antibiotics in the last 3 months before colonoscopy. In all, 33 subjects (11 controls and 22 cases) answered the question. Among these subjects, one case subject (4.55%) and one control subject (9.09%) reported antibiotics use.",16S,12,NA,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:995/1/NA,Study 995,laboratory experiment,32827699,10.1016/j.bbi.2020.08.015,https://pubmed.ncbi.nlm.nih.gov/32827699/,"Jang JH, Yeom MJ, Ahn S, Oh JY, Ji S, Kim TH , Park HJ",Acupuncture inhibits neuroinflammation and gut microbial dysbiosis in a mouse model of Parkinson's disease,"Brain, behavior, and immunity",2020,"Acupuncture, Gut microbial dysbiosis, Microbiome-gut-brain axis, Neuroinflammation, Parkinson’s disease",Experiment 1,South Korea,Mus musculus,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Control Group,MPTP Group,"Mice were treated with MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine).",6,10,NA,16S,34,Illumina,LEfSe,0.05,FALSE,2.5,NA,NA,NA,unchanged,decreased,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:995/3/NA,Study 995,laboratory experiment,32827699,10.1016/j.bbi.2020.08.015,https://pubmed.ncbi.nlm.nih.gov/32827699/,"Jang JH, Yeom MJ, Ahn S, Oh JY, Ji S, Kim TH , Park HJ",Acupuncture inhibits neuroinflammation and gut microbial dysbiosis in a mouse model of Parkinson's disease,"Brain, behavior, and immunity",2020,"Acupuncture, Gut microbial dysbiosis, Microbiome-gut-brain axis, Neuroinflammation, Parkinson’s disease",Experiment 3,South Korea,Mus musculus,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Control Group,MPTP + Acu Group,Mice treated with MPTP received acupuncture.,6,9,NA,16S,34,Illumina,LEfSe,0.05,FALSE,2.5,NA,NA,NA,unchanged,increased,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:995/4/NA,Study 995,laboratory experiment,32827699,10.1016/j.bbi.2020.08.015,https://pubmed.ncbi.nlm.nih.gov/32827699/,"Jang JH, Yeom MJ, Ahn S, Oh JY, Ji S, Kim TH , Park HJ",Acupuncture inhibits neuroinflammation and gut microbial dysbiosis in a mouse model of Parkinson's disease,"Brain, behavior, and immunity",2020,"Acupuncture, Gut microbial dysbiosis, Microbiome-gut-brain axis, Neuroinflammation, Parkinson’s disease",Experiment 4,South Korea,Mus musculus,Feces,UBERON:0001988,Treatment,EFO:0000727,MPTP + Acu Group,MPTP + Non Acu Group,Mice treated with MPTP did not receive acupuncture,9,5,NA,16S,34,Illumina,LEfSe,0.05,FALSE,2.5,NA,NA,NA,unchanged,decreased,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:995/5/NA,Study 995,laboratory experiment,32827699,10.1016/j.bbi.2020.08.015,https://pubmed.ncbi.nlm.nih.gov/32827699/,"Jang JH, Yeom MJ, Ahn S, Oh JY, Ji S, Kim TH , Park HJ",Acupuncture inhibits neuroinflammation and gut microbial dysbiosis in a mouse model of Parkinson's disease,"Brain, behavior, and immunity",2020,"Acupuncture, Gut microbial dysbiosis, Microbiome-gut-brain axis, Neuroinflammation, Parkinson’s disease",Experiment 5,South Korea,Mus musculus,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Control group,MPTP group,"Mice that were treated with MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine).",6,10,N/A,16S,34,Illumina,Kruskall-Wallis,0.05,TRUE,NA,NA,NA,NA,unchanged,decreased,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:995/6/NA,Study 995,laboratory experiment,32827699,10.1016/j.bbi.2020.08.015,https://pubmed.ncbi.nlm.nih.gov/32827699/,"Jang JH, Yeom MJ, Ahn S, Oh JY, Ji S, Kim TH , Park HJ",Acupuncture inhibits neuroinflammation and gut microbial dysbiosis in a mouse model of Parkinson's disease,"Brain, behavior, and immunity",2020,"Acupuncture, Gut microbial dysbiosis, Microbiome-gut-brain axis, Neuroinflammation, Parkinson’s disease",Experiment 6,South Korea,Mus musculus,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Control group,MPTP+Acu group,"Mice treated with MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) that received Acupuncture",6,9,N/A,16S,34,Illumina,Kruskall-Wallis,0.05,TRUE,NA,NA,NA,NA,unchanged,increased,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:995/7/NA,Study 995,laboratory experiment,32827699,10.1016/j.bbi.2020.08.015,https://pubmed.ncbi.nlm.nih.gov/32827699/,"Jang JH, Yeom MJ, Ahn S, Oh JY, Ji S, Kim TH , Park HJ",Acupuncture inhibits neuroinflammation and gut microbial dysbiosis in a mouse model of Parkinson's disease,"Brain, behavior, and immunity",2020,"Acupuncture, Gut microbial dysbiosis, Microbiome-gut-brain axis, Neuroinflammation, Parkinson’s disease",Experiment 7,South Korea,Mus musculus,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,MPTP group,MPTP+Acu group,"Mice treated with MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) that received Acupuncture",10,9,N/A,16S,34,Illumina,Kruskall-Wallis,0.05,TRUE,NA,NA,NA,NA,unchanged,increased,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:996/1/NA,Study 996,case-control,34937163,10.1128/Spectrum.01255-21,https://journals.asm.org/doi/10.1128/spectrum.01255-21,"Zhu X, Hong G, Li Y, Yang P, Cheng M, Zhang L, Li Y, Ji L, Li G, Chen C, Zhong C, Jin Y, Yang M, Xiong H, Qian W, Ding Z, Ning K , Hou X",Understanding of the Site-Specific Microbial Patterns towards Accurate Identification for Patients with Diarrhea-Predominant Irritable Bowel Syndrome,Microbiology spectrum,2021,"IBS-D, microbial biomarkers, multiple intestinal sites, site-specific microbial patterns",Experiment 1,China,Homo sapiens,Duodenal mucosa,UBERON:0000320,Irritable bowel syndrome,EFO:0000555,Healthy controls (Duodenal mucosa samples),IBS-D patients (Duodenal mucosa samples),Patients with diarrhea-dominant irritable bowel syndrome (IBS-D),20,37,Within one month before the start of this study,16S,123,Roche454,LEfSe,0.05,TRUE,2.5,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:996/2/NA,Study 996,case-control,34937163,10.1128/Spectrum.01255-21,https://journals.asm.org/doi/10.1128/spectrum.01255-21,"Zhu X, Hong G, Li Y, Yang P, Cheng M, Zhang L, Li Y, Ji L, Li G, Chen C, Zhong C, Jin Y, Yang M, Xiong H, Qian W, Ding Z, Ning K , Hou X",Understanding of the Site-Specific Microbial Patterns towards Accurate Identification for Patients with Diarrhea-Predominant Irritable Bowel Syndrome,Microbiology spectrum,2021,"IBS-D, microbial biomarkers, multiple intestinal sites, site-specific microbial patterns",Experiment 2,China,Homo sapiens,Lumen of duodenum,UBERON:0016512,Irritable bowel syndrome,EFO:0000555,Healthy controls (Duodenal lumen samples),IBS-D patients (Duodenal lumen samples),Patients with diarrhea-dominant irritable bowel syndrome (IBS-D),19,43,Within one month before the start of this study,16S,123,Roche454,LEfSe,0.05,TRUE,2.5,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:996/3/NA,Study 996,case-control,34937163,10.1128/Spectrum.01255-21,https://journals.asm.org/doi/10.1128/spectrum.01255-21,"Zhu X, Hong G, Li Y, Yang P, Cheng M, Zhang L, Li Y, Ji L, Li G, Chen C, Zhong C, Jin Y, Yang M, Xiong H, Qian W, Ding Z, Ning K , Hou X",Understanding of the Site-Specific Microbial Patterns towards Accurate Identification for Patients with Diarrhea-Predominant Irritable Bowel Syndrome,Microbiology spectrum,2021,"IBS-D, microbial biomarkers, multiple intestinal sites, site-specific microbial patterns",Experiment 3,China,Homo sapiens,Mucosa of rectum,UBERON:0003346,Irritable bowel syndrome,EFO:0000555,Healthy controls (Rectal mucosa samples),IBS-D patients (Rectal mucosa samples),Patients with diarrhea-dominant irritable bowel syndrome (IBS-D),20,53,Within one month before the start of this study,16S,123,Roche454,LEfSe,0.05,TRUE,2.5,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:996/4/NA,Study 996,case-control,34937163,10.1128/Spectrum.01255-21,https://journals.asm.org/doi/10.1128/spectrum.01255-21,"Zhu X, Hong G, Li Y, Yang P, Cheng M, Zhang L, Li Y, Ji L, Li G, Chen C, Zhong C, Jin Y, Yang M, Xiong H, Qian W, Ding Z, Ning K , Hou X",Understanding of the Site-Specific Microbial Patterns towards Accurate Identification for Patients with Diarrhea-Predominant Irritable Bowel Syndrome,Microbiology spectrum,2021,"IBS-D, microbial biomarkers, multiple intestinal sites, site-specific microbial patterns",Experiment 4,China,Homo sapiens,Rectal lumen,UBERON:0009670,Irritable bowel syndrome,EFO:0000555,Healthy controls (Rectal lumen samples),IBS-D patients (Rectal lumen samples),Patients with diarrhea-dominant irritable bowel syndrome (IBS-D),17,74,Within one month before the start of this study,16S,123,Roche454,LEfSe,0.05,TRUE,2.5,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:997/1/NA,Study 997,"laboratory experiment,meta-analysis",36362360,10.3390/ijms232113574,NA,"Park S , Wu X",Modulation of the Gut Microbiota in Memory Impairment and Alzheimer's Disease via the Inhibition of the Parasympathetic Nervous System,International journal of molecular sciences,2022,"Alzheimer’s disease, gut dysbiosis, mild memory impairment, parasympathetic nervous system, scopolamine",Experiment 1,"China,Singapore,Turkey",Homo sapiens,Feces,UBERON:0001988,Gut microbiome measurement,EFO:0007874,Healthy group,Mild cognitive impairment (MCI) and Alzheimer’s disease (AD),Patients with mild cognitive impairment (MCI) and Alzheimer’s disease (AD),125,244,None,16S,NA,Illumina,LEfSe,0.05,FALSE,3,NA,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:997/2/NA,Study 997,"laboratory experiment,meta-analysis",36362360,10.3390/ijms232113574,NA,"Park S , Wu X",Modulation of the Gut Microbiota in Memory Impairment and Alzheimer's Disease via the Inhibition of the Parasympathetic Nervous System,International journal of molecular sciences,2022,"Alzheimer’s disease, gut dysbiosis, mild memory impairment, parasympathetic nervous system, scopolamine",Experiment 2,"China,Singapore,Turkey",Homo sapiens,Feces,UBERON:0001988,Alzheimer's disease,MONDO:0004975,Healthy group and mild cognitive impairment (MCI),Alzheimer’s disease (AD),Patients with Alzheimer’s disease (AD),266,103,None,16S,NA,Illumina,LEfSe,0.05,FALSE,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:997/3/NA,Study 997,"laboratory experiment,meta-analysis",36362360,10.3390/ijms232113574,NA,"Park S , Wu X",Modulation of the Gut Microbiota in Memory Impairment and Alzheimer's Disease via the Inhibition of the Parasympathetic Nervous System,International journal of molecular sciences,2022,"Alzheimer’s disease, gut dysbiosis, mild memory impairment, parasympathetic nervous system, scopolamine",Experiment 3,"China,Singapore,Turkey",Homo sapiens,Feces,UBERON:0001988,Cognitive impairment,HP:0100543,Healthy group and Alzheimer's Disease (AD),Mild Cognitive Impairment (MCI),Patients with mild cognitive impairment (MCI),228,141,None,16S,NA,Illumina,LEfSe,0.05,FALSE,3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:997/4/NA,Study 997,"laboratory experiment,meta-analysis",36362360,10.3390/ijms232113574,NA,"Park S , Wu X",Modulation of the Gut Microbiota in Memory Impairment and Alzheimer's Disease via the Inhibition of the Parasympathetic Nervous System,International journal of molecular sciences,2022,"Alzheimer’s disease, gut dysbiosis, mild memory impairment, parasympathetic nervous system, scopolamine",Experiment 4,South Korea,Rattus norvegicus,Feces,UBERON:0001988,Memory impairment,EFO:0001072,Normal health group,Positive and memory deficit (MD) group,Rats divided into the positive group (n = 10) given intraperitoneal scopolamine plus donepezil injection and those belonging to the memory deficit (MD) group (n = 10) given intraperitoneal scopolamine injection,10,20,None,16S,34,"Illumina,Roche454",LEfSe,0.05,FALSE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:997/5/NA,Study 997,"laboratory experiment,meta-analysis",36362360,10.3390/ijms232113574,NA,"Park S , Wu X",Modulation of the Gut Microbiota in Memory Impairment and Alzheimer's Disease via the Inhibition of the Parasympathetic Nervous System,International journal of molecular sciences,2022,"Alzheimer’s disease, gut dysbiosis, mild memory impairment, parasympathetic nervous system, scopolamine",Experiment 5,South Korea,Rattus norvegicus,Feces,UBERON:0001988,Memory impairment,EFO:0001072,Normal health group and memory deficit (MD) group,Positive group,Rats in the positive group (n = 10) given intraperitoneal scopolamine plus donepezil injection,20,10,None,16S,34,"Illumina,Roche454",LEfSe,0.05,FALSE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:997/6/NA,Study 997,"laboratory experiment,meta-analysis",36362360,10.3390/ijms232113574,NA,"Park S , Wu X",Modulation of the Gut Microbiota in Memory Impairment and Alzheimer's Disease via the Inhibition of the Parasympathetic Nervous System,International journal of molecular sciences,2022,"Alzheimer’s disease, gut dysbiosis, mild memory impairment, parasympathetic nervous system, scopolamine",Experiment 6,South Korea,Rattus norvegicus,Feces,UBERON:0001988,Memory impairment,EFO:0001072,Normal health group and positive group,Memory deficit (MD) group,Rats in the memory deficit (MD) group (n = 10) given intraperitoneal scopolamine injection,20,10,None,16S,34,"Illumina,Roche454",LEfSe,0.05,FALSE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:998/1/NA,Study 998,meta-analysis,35722294,https://doi.org/10.3389%2Ffmicb.2022.875101,NA,"Guo X, Tang P, Hou C, Chong L, Zhang X, Liu P, Chen L, Liu Y, Zhang L , Li R","Integrated Microbiome and Host Transcriptome Profiles Link Parkinson's Disease to <i>Blautia</i> Genus: Evidence From Feces, Blood, and Brain",Frontiers in microbiology,2022,"16S, Blautia, Parkinson’s disease, feces, microbiome",Experiment 1,"Japan,United States of America,Denmark,Finland,Germany,China,Italy",Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Controls,PD patients,Patients with Parkinson's disease,1028,1441,NA,16S,NA,"Illumina,Roche454",DESeq2,0.05,FALSE,NA,NA,NA,NA,increased,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:998/2/NA,Study 998,meta-analysis,35722294,https://doi.org/10.3389%2Ffmicb.2022.875101,NA,"Guo X, Tang P, Hou C, Chong L, Zhang X, Liu P, Chen L, Liu Y, Zhang L , Li R","Integrated Microbiome and Host Transcriptome Profiles Link Parkinson's Disease to <i>Blautia</i> Genus: Evidence From Feces, Blood, and Brain",Frontiers in microbiology,2022,"16S, Blautia, Parkinson’s disease, feces, microbiome",Experiment 2,China,Homo sapiens,Blood,UBERON:0000178,Parkinson's disease,MONDO:0005180,Controls,PD patients,Patients with Parkinson's disease,90,90,NA,16S,34,Illumina,DESeq2,0.05,FALSE,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:998/3/NA,Study 998,meta-analysis,35722294,https://doi.org/10.3389%2Ffmicb.2022.875101,NA,"Guo X, Tang P, Hou C, Chong L, Zhang X, Liu P, Chen L, Liu Y, Zhang L , Li R","Integrated Microbiome and Host Transcriptome Profiles Link Parkinson's Disease to <i>Blautia</i> Genus: Evidence From Feces, Blood, and Brain",Frontiers in microbiology,2022,"16S, Blautia, Parkinson’s disease, feces, microbiome",Experiment 3,"United States of America,Israel,Netherlands",Homo sapiens,Brain,UBERON:0000955,Parkinson's disease,MONDO:0005180,Controls,PD patients,Patients with Parkinson's disease,119,150,NA,NA,NA,Illumina,DESeq2,0.05,FALSE,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:999/1/NA,Study 999,laboratory experiment,35276770,10.3390/nu14030412,NA,"McMillen S, Thomas S, Liang E, Nonnecke EB, Slupsky C , Lönnerdal B",Gut Microbiome Alterations following Postnatal Iron Supplementation Depend on Iron Form and Persist into Adulthood,Nutrients,2022,"ferrous bis-glycinate chelate, ferrous sulfate, gut microbiome, infant nutrition, iron supplement, metabolomics, rat model",Experiment 1,United States of America,Rattus norvegicus,Cecum mucosa,UBERON:0000314,Iron biomarker measurement,EFO:0004461,Vehicle control-supplemented (CON) pups,Ferrous sulfate (FS) treated pups (PD 15),Pre-weaning Sprague-Dawley rat pups given oral supplements of ferrous sulfate (FS) on postnatal day (PD) 2–14 and samples collected from 4–6 hours fasted animals on postnatal day (PD) 15.,28,27,None,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:999/2/NA,Study 999,laboratory experiment,35276770,10.3390/nu14030412,NA,"McMillen S, Thomas S, Liang E, Nonnecke EB, Slupsky C , Lönnerdal B",Gut Microbiome Alterations following Postnatal Iron Supplementation Depend on Iron Form and Persist into Adulthood,Nutrients,2022,"ferrous bis-glycinate chelate, ferrous sulfate, gut microbiome, infant nutrition, iron supplement, metabolomics, rat model",Experiment 2,United States of America,Rattus norvegicus,Cecum mucosa,UBERON:0000314,Iron biomarker measurement,EFO:0004461,Vehicle control-supplemented (CON) pups,Ferrous bis-glycinate chelate (FC) treated pups (PD 15),"Pre-weaning Sprague-Dawley rat pups given oral supplements of ferrous bis-glycinate chelate (Ferrochel, FC) on postnatal day (PD) and samples collected from 4–6 hours fasted animals on postnatal day (PD) 15.",28,29,None,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,decreased,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:999/3/NA,Study 999,laboratory experiment,35276770,10.3390/nu14030412,NA,"McMillen S, Thomas S, Liang E, Nonnecke EB, Slupsky C , Lönnerdal B",Gut Microbiome Alterations following Postnatal Iron Supplementation Depend on Iron Form and Persist into Adulthood,Nutrients,2022,"ferrous bis-glycinate chelate, ferrous sulfate, gut microbiome, infant nutrition, iron supplement, metabolomics, rat model",Experiment 3,United States of America,Rattus norvegicus,Cecum mucosa,UBERON:0000314,Iron biomarker measurement,EFO:0004461,Ferrous sulfate (FS) treated pups (PD 15),Ferrous bis-glycinate chelate (FC) treated pups (PD 15),"Pre-weaning Sprague-Dawley rat pups given oral supplements of ferrous bis-glycinate chelate (Ferrochel, FC) on postnatal day (PD) 2-14 and samples collected from 4–6 hours-fasted animals on postnatal day (PD) 15",27,29,None,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,decreased,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:999/4/NA,Study 999,laboratory experiment,35276770,10.3390/nu14030412,NA,"McMillen S, Thomas S, Liang E, Nonnecke EB, Slupsky C , Lönnerdal B",Gut Microbiome Alterations following Postnatal Iron Supplementation Depend on Iron Form and Persist into Adulthood,Nutrients,2022,"ferrous bis-glycinate chelate, ferrous sulfate, gut microbiome, infant nutrition, iron supplement, metabolomics, rat model",Experiment 4,United States of America,Rattus norvegicus,Cecum mucosa,UBERON:0000314,Iron biomarker measurement,EFO:0004461,Vehicle control-supplemented (CON) young Adult (YA) rats,Ferrous sulfate (FS) treated young Adult  (YA) rats (PD 58 +/- 4),"Young Adult (YA) Sprague-Dawley rats given oral supplements of ferrous sulfate (FS) on postnatal day (PD) 2-20, weaned on postnatal day (PD) 21 and samples collected from 4–6 hours fasted animals on postnatal day (PD) 58 +/- 4.",23,23,None,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,increased,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:999/5/NA,Study 999,laboratory experiment,35276770,10.3390/nu14030412,NA,"McMillen S, Thomas S, Liang E, Nonnecke EB, Slupsky C , Lönnerdal B",Gut Microbiome Alterations following Postnatal Iron Supplementation Depend on Iron Form and Persist into Adulthood,Nutrients,2022,"ferrous bis-glycinate chelate, ferrous sulfate, gut microbiome, infant nutrition, iron supplement, metabolomics, rat model",Experiment 5,United States of America,Rattus norvegicus,Cecum mucosa,UBERON:0000314,Iron biomarker measurement,EFO:0004461,Vehicle control-supplemented (CON) young Adult rats,Ferrous bis-glycinate chelate (FC) treated young Adult  (YA) rats (PD 58 +/- 4),"Young Adult (YA) Sprague-Dawley rats given oral supplements of ferrous bis-glycinate chelate (FC) on postnatal day (PD) 2-20, weaned on postnatal day (PD) 21 and samples collected from 4–6 h-fasted animals on postnatal day (PD) 58 +/- 4.",23,19,None,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,decreased,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:999/6/NA,Study 999,laboratory experiment,35276770,10.3390/nu14030412,NA,"McMillen S, Thomas S, Liang E, Nonnecke EB, Slupsky C , Lönnerdal B",Gut Microbiome Alterations following Postnatal Iron Supplementation Depend on Iron Form and Persist into Adulthood,Nutrients,2022,"ferrous bis-glycinate chelate, ferrous sulfate, gut microbiome, infant nutrition, iron supplement, metabolomics, rat model",Experiment 6,United States of America,Rattus norvegicus,Cecum mucosa,UBERON:0000314,Iron biomarker measurement,EFO:0004461,Ferrous sulfate (FS) treated young Adult  (YA) rats (PD 58 +/- 4),Ferrous bis-glycinate chelate (FC) treated young Adult  (YA) rats (PD 58 +/- 4),"Young Adult (YA) Sprague-Dawley rats given oral supplements of ferrous bis-glycinate chelate (FC) on postnatal day (PD) 2-20, weaned on postnatal day (PD) 21 and samples collected from 4–6 h-fasted animals on postnatal day (PD) 58 +/- 4.",23,19,None,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1000/1/NA,Study 1000,case-control,33293403,10.1128/mSystems.00797-20,NA,"Nishiwaki H, Hamaguchi T, Ito M, Ishida T, Maeda T, Kashihara K, Tsuboi Y, Ueyama J, Shimamura T, Mori H, Kurokawa K, Katsuno M, Hirayama M , Ohno K",Short-Chain Fatty Acid-Producing Gut Microbiota Is Decreased in Parkinson's Disease but Not in Rapid-Eye-Movement Sleep Behavior Disorder,mSystems,2020,"Parkinson’s disease, gut microbiota, meta-analysis, rapid-eye-movement behavior disorder, topic model",Experiment 1,"Germany,Japan",Homo sapiens,Intestine,UBERON:0000160,Parkinson's disease,MONDO:0005180,Controls,Rapid-eye-movement sleep behavior disorder (iRBD) patients,Patients with idiopathic rapid-eye-movement sleep behavior disorder (iRBD) diagnosed according to the International Classification of Sleep Disorders Criteria-Third Edition,137,26,1 month,16S,34,Illumina,"ANCOM,PERMANOVA,T-Test",0.05,TRUE,NA,NA,"age,body mass index,constipation,proton-pump inhibitor,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1001/1/NA,Study 1001,case-control,33499229,10.3390/biom11020144,NA,"Vascellari S, Melis M, Palmas V, Pisanu S, Serra A, Perra D, Santoru ML, Oppo V, Cusano R, Uva P, Atzori L, Morelli M, Cossu G , Manzin A",Clinical Phenotypes of Parkinson's Disease Associate with Distinct Gut Microbiota and Metabolome Enterotypes,Biomolecules,2021,"clinical phenotype, gut microbiota, metabolome, parkinson’s disease",Experiment 1,Italy,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Parkinson's disease patients with Tremor Dominant  - TD,Parkinson's disease patients with Akinetic Rigid - AR,A phenotype category based on motor signs,19,23,3 months prior to enrollment,16S,NA,Illumina,LEfSe,0.05,TRUE,2,NA,"age,body mass index,sex,smoking status",NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1001/2/NA,Study 1001,case-control,33499229,10.3390/biom11020144,NA,"Vascellari S, Melis M, Palmas V, Pisanu S, Serra A, Perra D, Santoru ML, Oppo V, Cusano R, Uva P, Atzori L, Morelli M, Cossu G , Manzin A",Clinical Phenotypes of Parkinson's Disease Associate with Distinct Gut Microbiota and Metabolome Enterotypes,Biomolecules,2021,"clinical phenotype, gut microbiota, metabolome, parkinson’s disease",Experiment 2,Italy,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Parkinson's disease patients with Tremor Dominant - TD,Parkinson's disease patients with Diskinetic - D,A phenotype category based on motor signs,19,14,3 months prior to enrollment,16S,NA,Illumina,LEfSe,0.05,TRUE,2,NA,"age,body mass index,sex,smoking status",NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1001/3/NA,Study 1001,case-control,33499229,10.3390/biom11020144,NA,"Vascellari S, Melis M, Palmas V, Pisanu S, Serra A, Perra D, Santoru ML, Oppo V, Cusano R, Uva P, Atzori L, Morelli M, Cossu G , Manzin A",Clinical Phenotypes of Parkinson's Disease Associate with Distinct Gut Microbiota and Metabolome Enterotypes,Biomolecules,2021,"clinical phenotype, gut microbiota, metabolome, parkinson’s disease",Experiment 3,Italy,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,Parkinson's disease patients with Diskinetic - D,Parkinson's disease patients with Akinetic Rigid - AR,A phenotype category based on motor signs,14,23,3 months prior to enrollment,16S,NA,Illumina,LEfSe,0.05,TRUE,2,NA,"age,body mass index,sex,smoking status",NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1002/1/NA,Study 1002,"laboratory experiment,meta-analysis",26170900,10.1186/s13073-015-0177-8,NA,"Burns MB, Lynch J, Starr TK, Knights D , Blekhman R",Virulence genes are a signature of the microbiome in the colorectal tumor microenvironment,Genome medicine,2015,NA,Experiment 1,United States of America,Homo sapiens,Colon,UBERON:0001155,Colorectal cancer,EFO:0005842,Patient-Matched Normal Colon Tissue Samples,Colorectal Tumor Samples,This group consists of primary tumor tissue samples obtained from patients diagnosed with colorectal cancer. They were collected from the site of tumor microenvironment.,44,44,NA,16S,56,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,decreased,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1003/1/NA,Study 1003,randomized controlled trial,35019769,10.1128/spectrum.01757-21,https://pubmed.ncbi.nlm.nih.gov/35019769/,"Plummer EL, Maddaford K, Murray GL, Fairley CK, Pasricha S, Mu A, Bradshaw CS, Williamson DA , Chow EPF",The Impact of Mouthwash on the Oropharyngeal Microbiota of Men Who Have Sex with Men: a Substudy of the OMEGA Trial,Microbiology spectrum,2022,"Neisseria gonorrhoeae, men who have sex with men, mouthwash, oral microbiome, oropharyngeal gonorrhea",Experiment 1,Australia,Homo sapiens,Tonsillar fossa,UBERON:0035228,Gonorrhea,DOID:7551,men who have sex with men using Listerine,men who have sex with men using Biotène,men who have sex with men using Biotène for 12 weeks affect the microbial composition of the oropharynx.,78,75,NA,16S,4,Illumina,"ANOVA,ANCOM",0.05,FALSE,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1003/2/NA,Study 1003,randomized controlled trial,35019769,10.1128/spectrum.01757-21,https://pubmed.ncbi.nlm.nih.gov/35019769/,"Plummer EL, Maddaford K, Murray GL, Fairley CK, Pasricha S, Mu A, Bradshaw CS, Williamson DA , Chow EPF",The Impact of Mouthwash on the Oropharyngeal Microbiota of Men Who Have Sex with Men: a Substudy of the OMEGA Trial,Microbiology spectrum,2022,"Neisseria gonorrhoeae, men who have sex with men, mouthwash, oral microbiome, oropharyngeal gonorrhea",Experiment 2,Australia,Homo sapiens,Tonsillar fossa,UBERON:0035228,Gonorrhea,DOID:7551,did not have gonorrhea detected,gonorrhea detected by NAAT at baseline,the oropharyngeal microbial communities at week-0 in men with and without oropharyngeal N. gonorrhoeae detected by NAAT,99,54,NA,16S,4,Illumina,"ANOVA,PERMANOVA",0.05,FALSE,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1003/3/NA,Study 1003,randomized controlled trial,35019769,10.1128/spectrum.01757-21,https://pubmed.ncbi.nlm.nih.gov/35019769/,"Plummer EL, Maddaford K, Murray GL, Fairley CK, Pasricha S, Mu A, Bradshaw CS, Williamson DA , Chow EPF",The Impact of Mouthwash on the Oropharyngeal Microbiota of Men Who Have Sex with Men: a Substudy of the OMEGA Trial,Microbiology spectrum,2022,"Neisseria gonorrhoeae, men who have sex with men, mouthwash, oral microbiome, oropharyngeal gonorrhea",Experiment 3,Australia,Homo sapiens,Tonsillar fossa,UBERON:0035228,Gonorrhea,DOID:7551,men sex with men who are non-smokers,men sex with men who are smokers,The oropharyngeal microbiota of smokers at week-0,123,22,NA,16S,4,Illumina,PERMANOVA,0.05,FALSE,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1003/4/NA,Study 1003,randomized controlled trial,35019769,10.1128/spectrum.01757-21,https://pubmed.ncbi.nlm.nih.gov/35019769/,"Plummer EL, Maddaford K, Murray GL, Fairley CK, Pasricha S, Mu A, Bradshaw CS, Williamson DA , Chow EPF",The Impact of Mouthwash on the Oropharyngeal Microbiota of Men Who Have Sex with Men: a Substudy of the OMEGA Trial,Microbiology spectrum,2022,"Neisseria gonorrhoeae, men who have sex with men, mouthwash, oral microbiome, oropharyngeal gonorrhea",Experiment 4,Australia,Homo sapiens,Tonsillar fossa,UBERON:0035228,Gonorrhea,DOID:7551,men who have sex with men using Biotène,men who have sex with men using listerine,men who have sex with men using Listerine for 12 weeks affect the microbial composition of the oropharynx.,153,153,NA,16S,4,Illumina,ANOVA,0.05,FALSE,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1004/1/NA,Study 1004,time series / longitudinal observational,38230936,10.1128/spectrum.03190-23,https://journals.asm.org/doi/10.1128/spectrum.03190-23,"Iwase SC, Osawe S, Happel A-U, Gray CM, Holmes SP, Blackburn JM, Abimiku A , Jaspan HB",Longitudinal gut microbiota composition of South African and Nigerian infants in relation to tetanus vaccine responses,Microbiology spectrum,2024,"HIV-exposed uninfected infants, Nigeria, South Africa, gut microbiota, tetanus toxoid, vaccine response",Experiment 1,South Africa,Homo sapiens,Feces,UBERON:0001988,Gut microbiome measurement,EFO:0007874,Infants who are HIV unexposed and uninfected (iHUU) at week 1,Infants who are HIV exposed but uninfected (iHEU) at week 1,Infants at 1 week of age born to mothers from South Africa who have HIV but are not themselves infected with HIV,21,61,None,16S,34,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1004/2/NA,Study 1004,time series / longitudinal observational,38230936,10.1128/spectrum.03190-23,https://journals.asm.org/doi/10.1128/spectrum.03190-23,"Iwase SC, Osawe S, Happel A-U, Gray CM, Holmes SP, Blackburn JM, Abimiku A , Jaspan HB",Longitudinal gut microbiota composition of South African and Nigerian infants in relation to tetanus vaccine responses,Microbiology spectrum,2024,"HIV-exposed uninfected infants, Nigeria, South Africa, gut microbiota, tetanus toxoid, vaccine response",Experiment 2,South Africa,Homo sapiens,Feces,UBERON:0001988,Gut microbiome measurement,EFO:0007874,Infants who are HIV unexposed and uninfected (iHUU) at week 15,Infants who are HIV exposed but uninfected (iHEU) at week 15,Infants at 15 weeks of age born to mothers from South Africa who have HIV but are not themselves infected with HIV adjusted by mode of feeding,21,61,None,16S,34,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1004/3/NA,Study 1004,time series / longitudinal observational,38230936,10.1128/spectrum.03190-23,https://journals.asm.org/doi/10.1128/spectrum.03190-23,"Iwase SC, Osawe S, Happel A-U, Gray CM, Holmes SP, Blackburn JM, Abimiku A , Jaspan HB",Longitudinal gut microbiota composition of South African and Nigerian infants in relation to tetanus vaccine responses,Microbiology spectrum,2024,"HIV-exposed uninfected infants, Nigeria, South Africa, gut microbiota, tetanus toxoid, vaccine response",Experiment 3,South Africa,Homo sapiens,Feces,UBERON:0001988,Gut microbiome measurement,EFO:0007874,Infants who are HIV unexposed and uninfected (iHUU) at week 15,Infants who are HIV exposed but uninfected (iHEU) at week 15,Infants at 15 weeks of age born to mothers from South Africa who have HIV but are not themselves infected with HIV when adjusted for reported antibiotic (co-trimoxazole) prophylaxis history adjusted by mode of feeding and reported antibiotics history,21,61,None,16S,34,Illumina,ANCOM,0.05,TRUE,NA,NA,antibiotic exposure,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1005/1/NA,Study 1005,laboratory experiment,38171017,https://doi.org/10.1128/spectrum.02037-23,NA,"Matějková T, Dodoková A, Kreisinger J, Stopka P , Stopková R","Microbial, proteomic, and metabolomic profiling of the estrous cycle in wild house mice",Microbiology spectrum,2024,"16S RNA sequencing, Mus musculus, Pasteurellaceae, estrous cycle, estrus, microbiome, oral, proteome, saliva, vaginal",Experiment 1,Czechia,Mus musculus,"Vagina,Saliva","UBERON:0000996,UBERON:0001836",Microbiome measurement,EFO:0007882,Oral (saliva),Vagina,Vaginal samples of lived-trapped females of Mus musculus musculus mice,18,18,None,16S,34,Illumina,ANCOM,0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1005/2/NA,Study 1005,laboratory experiment,38171017,https://doi.org/10.1128/spectrum.02037-23,NA,"Matějková T, Dodoková A, Kreisinger J, Stopka P , Stopková R","Microbial, proteomic, and metabolomic profiling of the estrous cycle in wild house mice",Microbiology spectrum,2024,"16S RNA sequencing, Mus musculus, Pasteurellaceae, estrous cycle, estrus, microbiome, oral, proteome, saliva, vaginal",Experiment 2,Czechia,Mus musculus,Vagina,UBERON:0000996,Vaginal microbiome measurement,EFO:0011013,Vaginal estrus samples,Vaginal metestrus samples,Vaginal samples collected during the metestrus phase,18,18,None,16S,34,Illumina,ANCOM,0.05,FALSE,NA,NA,NA,NA,increased,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1006/1/NA,Study 1006,"cross-sectional observational, not case-control",34954497,10.1016/j.parkreldis.2021.12.012,https://doi.org/10.1016/j.parkreldis.2021.12.012,"Takahashi K, Nishiwaki H, Ito M, Iwaoka K, Takahashi K, Suzuki Y, Taguchi K, Yamahara K, Tsuboi Y, Kashihara K, Hirayama M, Ohno K , Maeda T",Altered gut microbiota in Parkinson's disease patients with motor complications,Parkinsonism & related disorders,2022,"Dyskinesia, Gut microbiota, Motor complications, Parkinson's disease, Wearing-off",Experiment 1,Japan,Homo sapiens,Feces,UBERON:0001988,Parkinson's disease,MONDO:0005180,PD patients with dyskinesia,PD patients with  wearing-off,Parkinson's disease patients with wearing-off,106,49,Within a month before the start of this study,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1007/1/NA,Study 1007,"cross-sectional observational, not case-control",35532243,https://doi.org/10.1128/spectrum.00616-22,NA,"Pisani A, Rausch P, Bang C, Ellul S, Tabone T, Marantidis Cordina C, Zahra G, Franke A , Ellul P",Dysbiosis in the Gut Microbiota in Patients with Inflammatory Bowel Disease during Remission,Microbiology spectrum,2022,"Enterobacteriaceae, dysbiosis, flavonoid-degrading bacteria, inflammatory bowel disease, microbiota, remission",Experiment 1,Malta,Homo sapiens,Feces,UBERON:0001988,Ulcerative colitis,EFO:0000729,Healthy controls (HC),Ulcerative colitis (UC),Patients with Ulcerative colitis (UC) in a state of remission,97,66,3 months,16S,12,Illumina,DESeq2,0.05,TRUE,NA,NA,"age,body mass index,sex",NA,NA,decreased,increased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1007/2/NA,Study 1007,"cross-sectional observational, not case-control",35532243,https://doi.org/10.1128/spectrum.00616-22,NA,"Pisani A, Rausch P, Bang C, Ellul S, Tabone T, Marantidis Cordina C, Zahra G, Franke A , Ellul P",Dysbiosis in the Gut Microbiota in Patients with Inflammatory Bowel Disease during Remission,Microbiology spectrum,2022,"Enterobacteriaceae, dysbiosis, flavonoid-degrading bacteria, inflammatory bowel disease, microbiota, remission",Experiment 2,Malta,Homo sapiens,Feces,UBERON:0001988,Ulcerative colitis,EFO:0000729,Healthy controls (HC),Crohn’s disease (CD),Patients with Crohn’s disease (CD) in a state of remission,97,32,3 months,16S,12,Illumina,DESeq2,0.05,TRUE,NA,NA,"age,body mass index,sex",NA,NA,decreased,unchanged,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1007/3/NA,Study 1007,"cross-sectional observational, not case-control",35532243,https://doi.org/10.1128/spectrum.00616-22,NA,"Pisani A, Rausch P, Bang C, Ellul S, Tabone T, Marantidis Cordina C, Zahra G, Franke A , Ellul P",Dysbiosis in the Gut Microbiota in Patients with Inflammatory Bowel Disease during Remission,Microbiology spectrum,2022,"Enterobacteriaceae, dysbiosis, flavonoid-degrading bacteria, inflammatory bowel disease, microbiota, remission",Experiment 3,Malta,Homo sapiens,Feces,UBERON:0001988,Gut microbiome measurement,EFO:0007874,Crohn's disease (CD),Ulcerative colitis (UC),Patients with Ulcerative colitis (UC) in a state of remission,32,66,3 months,16S,12,Illumina,DESeq2,0.05,TRUE,NA,NA,"age,body mass index,sex",NA,NA,decreased,increased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1007/4/NA,Study 1007,"cross-sectional observational, not case-control",35532243,https://doi.org/10.1128/spectrum.00616-22,NA,"Pisani A, Rausch P, Bang C, Ellul S, Tabone T, Marantidis Cordina C, Zahra G, Franke A , Ellul P",Dysbiosis in the Gut Microbiota in Patients with Inflammatory Bowel Disease during Remission,Microbiology spectrum,2022,"Enterobacteriaceae, dysbiosis, flavonoid-degrading bacteria, inflammatory bowel disease, microbiota, remission",Experiment 4,Malta,Homo sapiens,Feces,UBERON:0001988,Smoking behavior,EFO:0004318,No,Yes,Patients with Inflammatory Bowel Disease (IBD) who are smokers,63,10,3 months,16S,12,Illumina,DESeq2,0.05,TRUE,NA,NA,"age,body mass index,sex",NA,NA,decreased,increased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1007/5/NA,Study 1007,"cross-sectional observational, not case-control",35532243,https://doi.org/10.1128/spectrum.00616-22,NA,"Pisani A, Rausch P, Bang C, Ellul S, Tabone T, Marantidis Cordina C, Zahra G, Franke A , Ellul P",Dysbiosis in the Gut Microbiota in Patients with Inflammatory Bowel Disease during Remission,Microbiology spectrum,2022,"Enterobacteriaceae, dysbiosis, flavonoid-degrading bacteria, inflammatory bowel disease, microbiota, remission",Experiment 5,Malta,Homo sapiens,Feces,UBERON:0001988,Smoking behavior,EFO:0004318,No,Ex,"Patients with Inflammatory Bowel Disease (IBD) who were ex-smokers (had
stopped smoking for at least 6 months).",63,15,3 months,16S,12,Illumina,DESeq2,0.05,TRUE,NA,NA,"age,body mass index,sex",NA,NA,decreased,increased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1007/6/NA,Study 1007,"cross-sectional observational, not case-control",35532243,https://doi.org/10.1128/spectrum.00616-22,NA,"Pisani A, Rausch P, Bang C, Ellul S, Tabone T, Marantidis Cordina C, Zahra G, Franke A , Ellul P",Dysbiosis in the Gut Microbiota in Patients with Inflammatory Bowel Disease during Remission,Microbiology spectrum,2022,"Enterobacteriaceae, dysbiosis, flavonoid-degrading bacteria, inflammatory bowel disease, microbiota, remission",Experiment 6,Malta,Homo sapiens,Feces,UBERON:0001988,Smoking behavior,EFO:0004318,Ex,Yes,Patients with Inflammatory Bowel Disease (IBD) who are smokers,25,10,3 months,16S,12,Illumina,DESeq2,0.05,TRUE,NA,NA,"age,body mass index,sex",NA,NA,decreased,increased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1008/1/NA,Study 1008,laboratory experiment,35476894,10.15252/embr.202052316,https://www.embopress.org/doi/full/10.15252/embr.202052316,"Lee CC, Liang F, Lee IC, Lu TH, Shan YY, Jeng CF, Zou YF, Yu HT , Chen Alen SK",External light-dark cycle shapes gut microbiota through intrinsically photosensitive retinal ganglion cells,EMBO reports,2022,"dim light at night, gut microbiota, ipRGC, melanopsin",Experiment 1,Taiwan,Mus musculus,Feces,UBERON:0001988,Light,EFO:0000568,Normal light‐dark cycle (LD) - Control group,Dim light at night (dLAN) - Control group,Exposure to aberrant light conditions such as dim light at night (dLAN) in the control group,NA,NA,NA,16S,45,Illumina,LEfSe,0.05,TRUE,2,age,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1008/2/NA,Study 1008,laboratory experiment,35476894,10.15252/embr.202052316,https://www.embopress.org/doi/full/10.15252/embr.202052316,"Lee CC, Liang F, Lee IC, Lu TH, Shan YY, Jeng CF, Zou YF, Yu HT , Chen Alen SK",External light-dark cycle shapes gut microbiota through intrinsically photosensitive retinal ganglion cells,EMBO reports,2022,"dim light at night, gut microbiota, ipRGC, melanopsin",Experiment 2,Taiwan,Mus musculus,Feces,UBERON:0001988,Light,EFO:0000568,Normal light‐dark cycle (LD) - MKO group,Dim light at night (dLAN) - MKO group,Exposure to aberrant light conditions such as dim light at night (dLAN) in the group with knockout of the photopigment melanopsin (MKO).,NA,NA,NA,16S,45,Illumina,LEfSe,0.05,TRUE,2,age,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1008/3/NA,Study 1008,laboratory experiment,35476894,10.15252/embr.202052316,https://www.embopress.org/doi/full/10.15252/embr.202052316,"Lee CC, Liang F, Lee IC, Lu TH, Shan YY, Jeng CF, Zou YF, Yu HT , Chen Alen SK",External light-dark cycle shapes gut microbiota through intrinsically photosensitive retinal ganglion cells,EMBO reports,2022,"dim light at night, gut microbiota, ipRGC, melanopsin",Experiment 3,Taiwan,Mus musculus,Feces,UBERON:0001988,Light,EFO:0000568,Normal light‐dark cycle (LD) - DTA group,Dim light at night (dLAN) - DTA group,Exposure to aberrant light conditions such as dim light at night (dLAN) in the group that underwent the genetic elimination of ipRGCs using the Opn4‐DTA or Opn4‐Cre (DTA).,NA,NA,NA,16S,45,Illumina,LEfSe,0.05,TRUE,2,age,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1008/4/NA,Study 1008,laboratory experiment,35476894,10.15252/embr.202052316,https://www.embopress.org/doi/full/10.15252/embr.202052316,"Lee CC, Liang F, Lee IC, Lu TH, Shan YY, Jeng CF, Zou YF, Yu HT , Chen Alen SK",External light-dark cycle shapes gut microbiota through intrinsically photosensitive retinal ganglion cells,EMBO reports,2022,"dim light at night, gut microbiota, ipRGC, melanopsin",Experiment 4,Taiwan,Mus musculus,Feces,UBERON:0001988,Light,EFO:0000568,Normal light‐dark cycle (LD) - Control group,Normal light‐dark cycle (LD) - MKO group,Exposure to normal daily light‐dark cycle (LD) in the group with knockout of the photopigment melanopsin (MKO).,NA,NA,NA,16S,45,Illumina,LEfSe,0.05,TRUE,2,age,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1008/5/NA,Study 1008,laboratory experiment,35476894,10.15252/embr.202052316,https://www.embopress.org/doi/full/10.15252/embr.202052316,"Lee CC, Liang F, Lee IC, Lu TH, Shan YY, Jeng CF, Zou YF, Yu HT , Chen Alen SK",External light-dark cycle shapes gut microbiota through intrinsically photosensitive retinal ganglion cells,EMBO reports,2022,"dim light at night, gut microbiota, ipRGC, melanopsin",Experiment 5,Taiwan,Mus musculus,Feces,UBERON:0001988,Light,EFO:0000568,Normal light‐dark cycle (LD) - Control group,Normal light‐dark cycle (LD) - DTA group,Exposure to normal daily light‐dark cycle (LD) in the group that underwent the genetic elimination of ipRGCs using the Opn4‐DTA or Opn4‐Cre (DTA).,NA,NA,NA,16S,45,Illumina,LEfSe,0.05,TRUE,2,age,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1008/6/NA,Study 1008,laboratory experiment,35476894,10.15252/embr.202052316,https://www.embopress.org/doi/full/10.15252/embr.202052316,"Lee CC, Liang F, Lee IC, Lu TH, Shan YY, Jeng CF, Zou YF, Yu HT , Chen Alen SK",External light-dark cycle shapes gut microbiota through intrinsically photosensitive retinal ganglion cells,EMBO reports,2022,"dim light at night, gut microbiota, ipRGC, melanopsin",Experiment 6,Taiwan,Mus musculus,Feces,UBERON:0001988,Light,EFO:0000568,Dim light at night (dLAN) - Control group,Dim light at night (dLAN) - MKO group,Exposure to aberrant light conditions such as dim light at night (dLAN) in the group with knockout of the photopigment melanopsin (MKO).,NA,NA,NA,16S,45,Illumina,LEfSe,0.05,TRUE,2,age,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1008/7/NA,Study 1008,laboratory experiment,35476894,10.15252/embr.202052316,https://www.embopress.org/doi/full/10.15252/embr.202052316,"Lee CC, Liang F, Lee IC, Lu TH, Shan YY, Jeng CF, Zou YF, Yu HT , Chen Alen SK",External light-dark cycle shapes gut microbiota through intrinsically photosensitive retinal ganglion cells,EMBO reports,2022,"dim light at night, gut microbiota, ipRGC, melanopsin",Experiment 7,Taiwan,Mus musculus,Feces,UBERON:0001988,Light,EFO:0000568,Dim light at night (dLAN) - Control group,Dim light at night (dLAN) - DTA group,Exposure to aberrant light conditions such as dim light at night (dLAN) in the group that underwent the genetic elimination of ipRGCs using the Opn4‐DTA or Opn4‐Cre (DTA).,NA,NA,NA,16S,45,Illumina,LEfSe,0.05,TRUE,2,age,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1008/8/NA,Study 1008,laboratory experiment,35476894,10.15252/embr.202052316,https://www.embopress.org/doi/full/10.15252/embr.202052316,"Lee CC, Liang F, Lee IC, Lu TH, Shan YY, Jeng CF, Zou YF, Yu HT , Chen Alen SK",External light-dark cycle shapes gut microbiota through intrinsically photosensitive retinal ganglion cells,EMBO reports,2022,"dim light at night, gut microbiota, ipRGC, melanopsin",Experiment 8,Taiwan,Mus musculus,Feces,UBERON:0001988,Light,EFO:0000568,Normal light‐dark cycle (LD) - MKO group,Normal light‐dark cycle (LD) - DTA group,Exposure to normal daily light‐dark cycle (LD) in the group that underwent the genetic elimination of ipRGCs using the Opn4‐DTA or Opn4‐Cre (DTA).,NA,NA,NA,16S,45,Illumina,LEfSe,0.05,TRUE,2,age,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1008/9/NA,Study 1008,laboratory experiment,35476894,10.15252/embr.202052316,https://www.embopress.org/doi/full/10.15252/embr.202052316,"Lee CC, Liang F, Lee IC, Lu TH, Shan YY, Jeng CF, Zou YF, Yu HT , Chen Alen SK",External light-dark cycle shapes gut microbiota through intrinsically photosensitive retinal ganglion cells,EMBO reports,2022,"dim light at night, gut microbiota, ipRGC, melanopsin",Experiment 9,Taiwan,Mus musculus,Feces,UBERON:0001988,Light,EFO:0000568,Dim light at night (dLAN) - MKO group,Dim light at night (dLAN) - DTA group,Exposure to aberrant light conditions such as dim light at night (dLAN) in the group that underwent the genetic elimination of ipRGCs using the Opn4‐DTA or Opn4‐Cre (DTA).,NA,NA,NA,16S,45,Illumina,LEfSe,0.05,TRUE,2,age,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1009/1/NA,Study 1009,case-control,36719190,10.1128/spectrum.02819-22,NA,"Wang Z, Liang L, Liu L, Wang Z, Wang Y, Yu Z, Wu B , Chen Y",Changes in the Gut Microbiome Associated with Intussusception in Patients with Peutz-Jeghers Syndrome,Microbiology spectrum,2023,"Peutz-Jeghers syndrome, biomarkers, functional analysis, gut microbiota, intussusception",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Peutz-Jeghers Polyp,EFO:1000470,healthy control (family members),Peutz-Jeghers syndrome (PJS),Patients who has Peutz-Jeghers syndrome (PJS),68,168,within 3 months,16S,34,Illumina,LEfSe,0.05,TRUE,3,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1009/2/NA,Study 1009,case-control,36719190,10.1128/spectrum.02819-22,NA,"Wang Z, Liang L, Liu L, Wang Z, Wang Y, Yu Z, Wu B , Chen Y",Changes in the Gut Microbiome Associated with Intussusception in Patients with Peutz-Jeghers Syndrome,Microbiology spectrum,2023,"Peutz-Jeghers syndrome, biomarkers, functional analysis, gut microbiota, intussusception",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Peutz-Jeghers Polyp,EFO:1000470,Without Intussusception (NI-PJS),With Intussusception (I-PJS),Patients who had undergone at least one intussusception (I-PJS),57,106,within 3 months,16S,34,Illumina,LEfSe,0.05,TRUE,3,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1009/3/NA,Study 1009,case-control,36719190,10.1128/spectrum.02819-22,NA,"Wang Z, Liang L, Liu L, Wang Z, Wang Y, Yu Z, Wu B , Chen Y",Changes in the Gut Microbiome Associated with Intussusception in Patients with Peutz-Jeghers Syndrome,Microbiology spectrum,2023,"Peutz-Jeghers syndrome, biomarkers, functional analysis, gut microbiota, intussusception",Experiment 3,China,Homo sapiens,Feces,UBERON:0001988,Peutz-Jeghers Polyp,EFO:1000470,healthy control (family members),Peutz-Jeghers syndrome (PJS),Patients who has Peutz-Jeghers syndrome (PJS),27,61,within 3 months,WMS,NA,Illumina,"Mann-Whitney (Wilcoxon),LEfSe",0.05,TRUE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1009/4/NA,Study 1009,case-control,36719190,10.1128/spectrum.02819-22,NA,"Wang Z, Liang L, Liu L, Wang Z, Wang Y, Yu Z, Wu B , Chen Y",Changes in the Gut Microbiome Associated with Intussusception in Patients with Peutz-Jeghers Syndrome,Microbiology spectrum,2023,"Peutz-Jeghers syndrome, biomarkers, functional analysis, gut microbiota, intussusception",Experiment 4,China,Homo sapiens,Feces,UBERON:0001988,Peutz-Jeghers Polyp,EFO:1000470,Without Intussusception (NI-PJS),With Intussusception (I-PJS),Patients who had undergone at least one intussusception (I-PJS),26,35,within 3 months,WMS,NA,Illumina,"LEfSe,Mann-Whitney (Wilcoxon)",0.05,TRUE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1010/1/NA,Study 1010,randomized controlled trial,37199608,https://doi.org/10.1128/spectrum.05273-22,NA,"Finlayson-Trick E, Nearing J, Fischer JA, Ma Y, Wang S, Krouen H, Goldfarb DM , Karakochuk CD","The Effect of Oral Iron Supplementation on Gut Microbial Composition: a Secondary Analysis of a Double-Blind, Randomized Controlled Trial among Cambodian Women of Reproductive Age",Microbiology spectrum,2023,"enteropathogen, gut microbiome, iron supplementation",Experiment 1,Cambodia,Homo sapiens,Feces,UBERON:0001988,Environmental exposure measurement,EFO:0008360,Placebo group,Ferrous bisglycinate group,"Healthy, non pregnant women of reproductive age who received oral supplementation of ferrous bisglycinate capsule containing 18 mg of elemental iron.",47,46,Women who were taking antibiotics in the previous 12 weeks were excluded.,16S,678,Illumina,Beta Binomial Regression,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1010/2/NA,Study 1010,randomized controlled trial,37199608,https://doi.org/10.1128/spectrum.05273-22,NA,"Finlayson-Trick E, Nearing J, Fischer JA, Ma Y, Wang S, Krouen H, Goldfarb DM , Karakochuk CD","The Effect of Oral Iron Supplementation on Gut Microbial Composition: a Secondary Analysis of a Double-Blind, Randomized Controlled Trial among Cambodian Women of Reproductive Age",Microbiology spectrum,2023,"enteropathogen, gut microbiome, iron supplementation",Experiment 2,Cambodia,Homo sapiens,Feces,UBERON:0001988,Environmental exposure measurement,EFO:0008360,Placebo Group,Ferrous sulfate group,"Healthy, non pregnant women of reproductive age who received oral supplementation of ferrous sulfate capsule containing 60 mg of elemental iron.",47,40,Women who were taking antibiotics in the previous 12 weeks were excluded.,16S,678,Illumina,Beta Binomial Regression,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1011/1/NA,Study 1011,"cross-sectional observational, not case-control",38596264,10.3892/ol.2024.14368,https://www.spandidos-publications.com/10.3892/ol.2024.14368,"Jin M, Fan Q, Shang F, Zhang T, Ogino S , Liu H",Fusobacteria alterations are associated with colorectal cancer liver metastasis and a poor prognosis,Oncology letters,2024,"colorectal cancer, fusobacteria, gut microbiota, liver metastasis",Experiment 1,China,Homo sapiens,Colorectum,UBERON:0012652,Metastatic colorectal cancer,EFO:1001480,No liver metastasis (NLM),Liver metastasis (LM),Colorectal patients with liver metastasis (LM) in the supplementary discovery cohort (cohort 1),10,8,Within 3 months prior to specimen collection.,16S,34,Illumina,LEfSe,0.05,NA,4,NA,NA,NA,increased,unchanged,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1011/2/NA,Study 1011,"cross-sectional observational, not case-control",38596264,10.3892/ol.2024.14368,https://www.spandidos-publications.com/10.3892/ol.2024.14368,"Jin M, Fan Q, Shang F, Zhang T, Ogino S , Liu H",Fusobacteria alterations are associated with colorectal cancer liver metastasis and a poor prognosis,Oncology letters,2024,"colorectal cancer, fusobacteria, gut microbiota, liver metastasis",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Metastatic colorectal cancer,EFO:1001480,No liver metastasis (NLM),Liver metastasis (LM),Colorectal patients with liver metastasis (LM) in the discovery cohort (cohort 2),36,18,Within 3 months prior to specimen collection.,16S,34,Illumina,LEfSe,0.05,NA,4,NA,NA,NA,unchanged,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1011/3/NA,Study 1011,"cross-sectional observational, not case-control",38596264,10.3892/ol.2024.14368,https://www.spandidos-publications.com/10.3892/ol.2024.14368,"Jin M, Fan Q, Shang F, Zhang T, Ogino S , Liu H",Fusobacteria alterations are associated with colorectal cancer liver metastasis and a poor prognosis,Oncology letters,2024,"colorectal cancer, fusobacteria, gut microbiota, liver metastasis",Experiment 3,China,Homo sapiens,Feces,UBERON:0001988,Metastatic colorectal cancer,EFO:1001480,No liver metastasis (NLM),Liver metastasis (LM),Colorectal patients with liver metastasis (LM) in the validation cohort (cohort 3),41,13,Within 3 months prior to specimen collection.,16S,34,Illumina,LEfSe,0.05,NA,4,NA,NA,NA,unchanged,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1013/1/NA,Study 1013,"cross-sectional observational, not case-control",34248903,10.3389/fmicb.2021.683685,NA,"de Jesus VC, Khan MW, Mittermuller BA, Duan K, Hu P, Schroth RJ , Chelikani P",Characterization of Supragingival Plaque and Oral Swab Microbiomes in Children With Severe Early Childhood Caries,Frontiers in microbiology,2021,"artificial intelligence, bacteria, case-control, dental plaque, fungi, machine learning, microbiota, oral swab",Experiment 1,Canada,Homo sapiens,"Saliva,Supragingival dental plaque","UBERON:0001836,UBERON:0016485",Microbiome measurement,EFO:0007882,Oral swab from severe early childhood caries (S-ECC),Supragingival plaque from severe early childhood caries (S-ECC),Supragingival plaque samples of children < 72 months of age with severe early childhood caries (S-ECC),40,40,Use of antibiotics,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1013/2/NA,Study 1013,"cross-sectional observational, not case-control",34248903,10.3389/fmicb.2021.683685,NA,"de Jesus VC, Khan MW, Mittermuller BA, Duan K, Hu P, Schroth RJ , Chelikani P",Characterization of Supragingival Plaque and Oral Swab Microbiomes in Children With Severe Early Childhood Caries,Frontiers in microbiology,2021,"artificial intelligence, bacteria, case-control, dental plaque, fungi, machine learning, microbiota, oral swab",Experiment 2,Canada,Homo sapiens,"Saliva,Supragingival dental plaque","UBERON:0001836,UBERON:0016485",Microbiome measurement,EFO:0007882,Oral swab from caries-free,Supragingival plaque from caries-free,"Supragingival plaque samples of children < 72 months of age who are caries-free, confirmed by a dental examination",40,40,Use of antibiotics,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1013/3/NA,Study 1013,"cross-sectional observational, not case-control",34248903,10.3389/fmicb.2021.683685,NA,"de Jesus VC, Khan MW, Mittermuller BA, Duan K, Hu P, Schroth RJ , Chelikani P",Characterization of Supragingival Plaque and Oral Swab Microbiomes in Children With Severe Early Childhood Caries,Frontiers in microbiology,2021,"artificial intelligence, bacteria, case-control, dental plaque, fungi, machine learning, microbiota, oral swab",Experiment 3,Canada,Homo sapiens,"Supragingival dental plaque,Saliva","UBERON:0016485,UBERON:0001836",Microbiome measurement,EFO:0007882,Oral swab from severe early childhood caries (S-ECC),Supragingival plaque from severe early childhood caries (S-ECC),Supragingival plaque samples of children < 72 months of age with severe early childhood caries (S-ECC),40,40,Use of antibiotics,ITS / ITS2,NA,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1013/4/NA,Study 1013,"cross-sectional observational, not case-control",34248903,10.3389/fmicb.2021.683685,NA,"de Jesus VC, Khan MW, Mittermuller BA, Duan K, Hu P, Schroth RJ , Chelikani P",Characterization of Supragingival Plaque and Oral Swab Microbiomes in Children With Severe Early Childhood Caries,Frontiers in microbiology,2021,"artificial intelligence, bacteria, case-control, dental plaque, fungi, machine learning, microbiota, oral swab",Experiment 4,Canada,Homo sapiens,"Saliva,Supragingival dental plaque","UBERON:0001836,UBERON:0016485",Microbiome measurement,EFO:0007882,Oral swab from caries-free,Supragingival plaque from caries-free,"Supragingival plaque samples of children < 72 months of age who are caries-free, confirmed by a dental examination",40,40,Use of antibiotics,ITS / ITS2,NA,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1013/5/NA,Study 1013,"cross-sectional observational, not case-control",34248903,10.3389/fmicb.2021.683685,NA,"de Jesus VC, Khan MW, Mittermuller BA, Duan K, Hu P, Schroth RJ , Chelikani P",Characterization of Supragingival Plaque and Oral Swab Microbiomes in Children With Severe Early Childhood Caries,Frontiers in microbiology,2021,"artificial intelligence, bacteria, case-control, dental plaque, fungi, machine learning, microbiota, oral swab",Experiment 5,Canada,Homo sapiens,Saliva,UBERON:0001836,Microbiome measurement,EFO:0007882,Oral swab from caries-free,Oral swab from severe early childhood caries (S-ECC),"Oral swap samples of children < 72 months of age who are caries-free, confirmed by a dental examination",40,40,Use of antibiotics,ITS / ITS2,NA,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1014/1/NA,Study 1014,laboratory experiment,37439681,10.1128/spectrum.02376-23,NA,"Costa SK, Antosca K, Beekman CN, Peterson RL, Penumutchu S , Belenky P",Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis,Microbiology spectrum,2023,"antibiotic-induced dysbiosis, dysbiosis, gut microbiome, microbiome",Experiment 1,United States of America,Mus musculus,Feces,UBERON:0001988,Response to diet,EFO:0010757,Always Dextrose Day 5 Abx,Prophylactic oats Day 5 Abx,Fecal pellets collected on day 5 from mice that were fed diet supplemented with oats as a preventive measure during amoxicillin treatment,10,3,None,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1014/2/NA,Study 1014,laboratory experiment,37439681,10.1128/spectrum.02376-23,NA,"Costa SK, Antosca K, Beekman CN, Peterson RL, Penumutchu S , Belenky P",Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis,Microbiology spectrum,2023,"antibiotic-induced dysbiosis, dysbiosis, gut microbiome, microbiome",Experiment 2,United States of America,Mus musculus,Feces,UBERON:0001988,Response to diet,EFO:0010757,Always Dextrose Day 0 Abx,Always Dextrose Day 5 Abx,Always Dextrose plus amoxicillin fecal pellets that were collected on day 5,9,10,None,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1014/3/NA,Study 1014,laboratory experiment,37439681,10.1128/spectrum.02376-23,NA,"Costa SK, Antosca K, Beekman CN, Peterson RL, Penumutchu S , Belenky P",Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis,Microbiology spectrum,2023,"antibiotic-induced dysbiosis, dysbiosis, gut microbiome, microbiome",Experiment 3,United States of America,Mus musculus,Feces,UBERON:0001988,Response to diet,EFO:0010757,Always Dextrose Day 0 Abx,Always Dextrose Day 9 Post Abx,Always Dextrose without amoxicillin fecal pellets that were collected on day 9,9,3,None,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1014/4/NA,Study 1014,laboratory experiment,37439681,10.1128/spectrum.02376-23,NA,"Costa SK, Antosca K, Beekman CN, Peterson RL, Penumutchu S , Belenky P",Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis,Microbiology spectrum,2023,"antibiotic-induced dysbiosis, dysbiosis, gut microbiome, microbiome",Experiment 4,United States of America,Mus musculus,Feces,UBERON:0001988,Response to diet,EFO:0010757,Always Dextrose Day 0 Abx,Always Dextrose Day 14 Post Abx,Always Dextrose without amoxicillin fecal pellets that were collected on day 14,9,7,None,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1014/5/NA,Study 1014,laboratory experiment,37439681,10.1128/spectrum.02376-23,NA,"Costa SK, Antosca K, Beekman CN, Peterson RL, Penumutchu S , Belenky P",Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis,Microbiology spectrum,2023,"antibiotic-induced dysbiosis, dysbiosis, gut microbiome, microbiome",Experiment 5,United States of America,Mus musculus,Feces,UBERON:0001988,Response to diet,EFO:0010757,Always Dextrose Day 5 Abx,Always Dextrose Day 9 Post A Pbx,Always Dextrose without amoxicillin fecal pellets that were collected on day 9,10,3,None,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1014/6/NA,Study 1014,laboratory experiment,37439681,10.1128/spectrum.02376-23,NA,"Costa SK, Antosca K, Beekman CN, Peterson RL, Penumutchu S , Belenky P",Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis,Microbiology spectrum,2023,"antibiotic-induced dysbiosis, dysbiosis, gut microbiome, microbiome",Experiment 6,United States of America,Mus musculus,Feces,UBERON:0001988,Response to diet,EFO:0010757,Always Dextrose Day 5 Abx,Always Dextrose Day 14 Post Abx,Always Dextrose without amoxicillin fecal pellets that were collected on day 14,10,7,None,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1014/7/NA,Study 1014,laboratory experiment,37439681,10.1128/spectrum.02376-23,NA,"Costa SK, Antosca K, Beekman CN, Peterson RL, Penumutchu S , Belenky P",Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis,Microbiology spectrum,2023,"antibiotic-induced dysbiosis, dysbiosis, gut microbiome, microbiome",Experiment 7,United States of America,Mus musculus,Feces,UBERON:0001988,Response to diet,EFO:0010757,Always Dextrose Day 9 Post Abx,Always Dextrose Day 14 Post Abx,Always Dextrose without amoxicillin fecal pellets that were collected on day 14,3,7,None,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1014/8/NA,Study 1014,laboratory experiment,37439681,10.1128/spectrum.02376-23,NA,"Costa SK, Antosca K, Beekman CN, Peterson RL, Penumutchu S , Belenky P",Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis,Microbiology spectrum,2023,"antibiotic-induced dysbiosis, dysbiosis, gut microbiome, microbiome",Experiment 8,United States of America,Mus musculus,Feces,UBERON:0001988,Response to diet,EFO:0010757,Always Oats Day 0 Abx,Always oats Day 5 Abx,Always Oats with amoxicillin fecal pellets that were collected on day 5,12,6,None,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1014/9/NA,Study 1014,laboratory experiment,37439681,10.1128/spectrum.02376-23,NA,"Costa SK, Antosca K, Beekman CN, Peterson RL, Penumutchu S , Belenky P",Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis,Microbiology spectrum,2023,"antibiotic-induced dysbiosis, dysbiosis, gut microbiome, microbiome",Experiment 9,United States of America,Mus musculus,Feces,UBERON:0001988,Response to diet,EFO:0010757,Always Oats Day 0 Abx,Always oats Day 11 Post Abx,Always oats without amoxicillin fecal pellets that were collected on day 11,12,3,None,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1014/10/NA,Study 1014,laboratory experiment,37439681,10.1128/spectrum.02376-23,NA,"Costa SK, Antosca K, Beekman CN, Peterson RL, Penumutchu S , Belenky P",Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis,Microbiology spectrum,2023,"antibiotic-induced dysbiosis, dysbiosis, gut microbiome, microbiome",Experiment 10,United States of America,Mus musculus,Feces,UBERON:0001988,Response to diet,EFO:0010757,Always Oats Day 0 Abx,Always oats Day 14 Post Abx,Always oats without amoxicillin fecal pellets that were collected on day 14,12,4,None,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1014/11/NA,Study 1014,laboratory experiment,37439681,10.1128/spectrum.02376-23,NA,"Costa SK, Antosca K, Beekman CN, Peterson RL, Penumutchu S , Belenky P",Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis,Microbiology spectrum,2023,"antibiotic-induced dysbiosis, dysbiosis, gut microbiome, microbiome",Experiment 11,United States of America,Mus musculus,Feces,UBERON:0001988,Response to diet,EFO:0010757,Always Oats Day 5 Abx,Always Oats Day 11 Post Abx,Always oats without amoxicillin fecal pellets that were collected on day 11,6,3,None,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1014/12/NA,Study 1014,laboratory experiment,37439681,10.1128/spectrum.02376-23,NA,"Costa SK, Antosca K, Beekman CN, Peterson RL, Penumutchu S , Belenky P",Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis,Microbiology spectrum,2023,"antibiotic-induced dysbiosis, dysbiosis, gut microbiome, microbiome",Experiment 12,United States of America,Mus musculus,Feces,UBERON:0001988,Response to diet,EFO:0010757,Always oats Day 5 Abx,Always oats Day 14 Post Abx,Always oats without amoxicillin fecal pellets that were collected on day 14,6,4,None,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1014/13/NA,Study 1014,laboratory experiment,37439681,10.1128/spectrum.02376-23,NA,"Costa SK, Antosca K, Beekman CN, Peterson RL, Penumutchu S , Belenky P",Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis,Microbiology spectrum,2023,"antibiotic-induced dysbiosis, dysbiosis, gut microbiome, microbiome",Experiment 13,United States of America,Mus musculus,Feces,UBERON:0001988,Response to diet,EFO:0010757,Always oats Day 11 Post Abx,Always oats Day 14 Post Abx,Always oats without amoxicillin fecal pellets that were collected on day 14,3,4,None,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1014/14/NA,Study 1014,laboratory experiment,37439681,10.1128/spectrum.02376-23,NA,"Costa SK, Antosca K, Beekman CN, Peterson RL, Penumutchu S , Belenky P",Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis,Microbiology spectrum,2023,"antibiotic-induced dysbiosis, dysbiosis, gut microbiome, microbiome",Experiment 14,United States of America,Mus musculus,Feces,UBERON:0001988,Response to diet,EFO:0010757,Prophylactic oats Day 0 Abx,Prophylactic oats Day 6 Post Abx,Prophylactic oats without amoxicillin fecal pellets that were collected on day 6,9,3,None,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1014/15/NA,Study 1014,laboratory experiment,37439681,10.1128/spectrum.02376-23,NA,"Costa SK, Antosca K, Beekman CN, Peterson RL, Penumutchu S , Belenky P",Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis,Microbiology spectrum,2023,"antibiotic-induced dysbiosis, dysbiosis, gut microbiome, microbiome",Experiment 15,United States of America,Mus musculus,Feces,UBERON:0001988,Response to diet,EFO:0010757,Prophylactic oats Day 0 Abx,Prophylactic oats Day 14 Post Abx,Prophylactic oats without amoxicillin fecal pellets that were collected on day 14,9,3,None,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1014/16/NA,Study 1014,laboratory experiment,37439681,10.1128/spectrum.02376-23,NA,"Costa SK, Antosca K, Beekman CN, Peterson RL, Penumutchu S , Belenky P",Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis,Microbiology spectrum,2023,"antibiotic-induced dysbiosis, dysbiosis, gut microbiome, microbiome",Experiment 16,United States of America,Mus musculus,Feces,UBERON:0001988,Response to diet,EFO:0010757,Prophylactic oats Day 6 Post Abx,Prophylactic oats Day 14 Post Abx,Prophylactic oats without amoxicillin fecal pellets that were collected on day 14,3,3,None,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1014/17/NA,Study 1014,laboratory experiment,37439681,10.1128/spectrum.02376-23,NA,"Costa SK, Antosca K, Beekman CN, Peterson RL, Penumutchu S , Belenky P",Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis,Microbiology spectrum,2023,"antibiotic-induced dysbiosis, dysbiosis, gut microbiome, microbiome",Experiment 17,United States of America,Mus musculus,Feces,UBERON:0001988,Response to diet,EFO:0010757,Recovery oats Day 0 Abx,Recovery oats Day 5 Abx,Recovery oats with amoxicillin fecal pellets that were collected on day 5,6,10,None,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1014/18/NA,Study 1014,laboratory experiment,37439681,10.1128/spectrum.02376-23,NA,"Costa SK, Antosca K, Beekman CN, Peterson RL, Penumutchu S , Belenky P",Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis,Microbiology spectrum,2023,"antibiotic-induced dysbiosis, dysbiosis, gut microbiome, microbiome",Experiment 18,United States of America,Mus musculus,Feces,UBERON:0001988,Response to diet,EFO:0010757,Recovery oats Day 0 Abx,Recovery oats Day 7 Post Abx,Recovery oats without amoxicillin fecal pellets that were collected on day 7,6,4,None,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1014/19/NA,Study 1014,laboratory experiment,37439681,10.1128/spectrum.02376-23,NA,"Costa SK, Antosca K, Beekman CN, Peterson RL, Penumutchu S , Belenky P",Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis,Microbiology spectrum,2023,"antibiotic-induced dysbiosis, dysbiosis, gut microbiome, microbiome",Experiment 19,United States of America,Mus musculus,Feces,UBERON:0001988,Response to diet,EFO:0010757,Recovery oats Day 0 Abx,Recovery oats Day 14 Post Abx,Recovery oats without amoxicillin fecal pellets that were collected on day 14,6,4,None,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1014/20/NA,Study 1014,laboratory experiment,37439681,10.1128/spectrum.02376-23,NA,"Costa SK, Antosca K, Beekman CN, Peterson RL, Penumutchu S , Belenky P",Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis,Microbiology spectrum,2023,"antibiotic-induced dysbiosis, dysbiosis, gut microbiome, microbiome",Experiment 20,United States of America,Mus musculus,Feces,UBERON:0001988,Response to diet,EFO:0010757,Recovery oats Day 5 Abx,Recovery oats Day 7 Post Abx,Recovery oats without amoxicillin fecal pellets that were collected on day 7,10,4,None,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1014/21/NA,Study 1014,laboratory experiment,37439681,10.1128/spectrum.02376-23,NA,"Costa SK, Antosca K, Beekman CN, Peterson RL, Penumutchu S , Belenky P",Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis,Microbiology spectrum,2023,"antibiotic-induced dysbiosis, dysbiosis, gut microbiome, microbiome",Experiment 21,United States of America,Mus musculus,Feces,UBERON:0001988,Response to diet,EFO:0010757,Recovery oats Day 5 Abx,Recovery oats Day 14 Post Abx,Recovery oats without amoxicillin fecal pellets that were collected on day 14,10,4,None,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1014/22/NA,Study 1014,laboratory experiment,37439681,10.1128/spectrum.02376-23,NA,"Costa SK, Antosca K, Beekman CN, Peterson RL, Penumutchu S , Belenky P",Short-Term Dietary Intervention with Whole Oats Protects from Antibiotic-Induced Dysbiosis,Microbiology spectrum,2023,"antibiotic-induced dysbiosis, dysbiosis, gut microbiome, microbiome",Experiment 22,United States of America,Mus musculus,Feces,UBERON:0001988,Response to diet,EFO:0010757,Recovery oats Day 7 Post Abx,Recovery oats Day 14 Post Abx,Recovery oats without amoxicillin fecal pellets that were collected on day 14,4,4,None,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1015/1/NA,Study 1015,case-control,37800955,10.1128/spectrum.00234-23,NA,"Ji X, Li P, Guo Q, Guan L, Gao P, Wu B, Cheng H, Xiao J , Ye L",Salivary microbiome profiles for different clinical phenotypes of pituitary adenomas by single-molecular long-read sequencing,Microbiology spectrum,2023,"clinical phenotype, diagnostics, pituitary adenomas, saliva microbiome",Experiment 1,China,Homo sapiens,Saliva,UBERON:0001836,Pituitary Gland Adenoma,EFO:1000478,Healthy controls,Patients with pituitary adenomas (PA),"Patients with pituitary adenomas (PA) which included four clinical phenotypes: adrenocorticotropic hormone-secreting PA (n = 6), growth hormone-secreting PA (n = 9), prolactin-secreting PA (n = 18), and nonfunctioning PA (n = 9)",20,42,6 months,16S,NA,PacBio RS,NA,0.05,FALSE,NA,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1016/1/NA,Study 1016,time series / longitudinal observational,38037123,10.1186/s40168-023-01677-w,NA,"Medeiros MC, The S, Bellile E, Russo N, Schmitd L, Danella E, Singh P, Banerjee R, Bassis C, Murphy GR, Sartor MA, Lombaert I, Schmidt TM, Eisbruch A, Murdoch-Kinch CA, Rozek L, Wolf GT, Li G, Chen GY , D'Silva NJ",Salivary microbiome changes distinguish response to chemoradiotherapy in patients with oral cancer,Microbiome,2023,NA,Experiment 1,United States of America,Homo sapiens,Saliva,UBERON:0001836,Treatment,EFO:0000727,Pre-treatment (baseline),Post-treatment (6 months later),Saliva samples collected from patients with oral squamous cell carcinoma (SCC) at 6 months after treatment,106,72,None,16S,4,Illumina,LEfSe,0.05,FALSE,3,NA,NA,NA,NA,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1016/2/NA,Study 1016,time series / longitudinal observational,38037123,10.1186/s40168-023-01677-w,NA,"Medeiros MC, The S, Bellile E, Russo N, Schmitd L, Danella E, Singh P, Banerjee R, Bassis C, Murphy GR, Sartor MA, Lombaert I, Schmidt TM, Eisbruch A, Murdoch-Kinch CA, Rozek L, Wolf GT, Li G, Chen GY , D'Silva NJ",Salivary microbiome changes distinguish response to chemoradiotherapy in patients with oral cancer,Microbiome,2023,NA,Experiment 2,United States of America,Homo sapiens,Saliva,UBERON:0001836,Response to surgery,EFO:0009951,Pre-surgery,Post-surgery,Saliva samples collected from patients with oral squamous cell carcinoma (SCC) at 6 months after treatment with surgery alone,15,15,None,16S,4,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,NA,NA,NA,unchanged,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1016/3/NA,Study 1016,time series / longitudinal observational,38037123,10.1186/s40168-023-01677-w,NA,"Medeiros MC, The S, Bellile E, Russo N, Schmitd L, Danella E, Singh P, Banerjee R, Bassis C, Murphy GR, Sartor MA, Lombaert I, Schmidt TM, Eisbruch A, Murdoch-Kinch CA, Rozek L, Wolf GT, Li G, Chen GY , D'Silva NJ",Salivary microbiome changes distinguish response to chemoradiotherapy in patients with oral cancer,Microbiome,2023,NA,Experiment 3,United States of America,Homo sapiens,Saliva,UBERON:0001836,Microbiome measurement,EFO:0007882,Pre-chemoradiotherapy,Post-chemoradiotherapy,Saliva samples collected from patients with oral squamous cell carcinoma (SCC) at 6 months who had undergone chemoradiotherapy,33,33,None,16S,4,Illumina,LEfSe,0.05,FALSE,3,NA,NA,NA,NA,NA,NA,unchanged,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1016/4/NA,Study 1016,time series / longitudinal observational,38037123,10.1186/s40168-023-01677-w,NA,"Medeiros MC, The S, Bellile E, Russo N, Schmitd L, Danella E, Singh P, Banerjee R, Bassis C, Murphy GR, Sartor MA, Lombaert I, Schmidt TM, Eisbruch A, Murdoch-Kinch CA, Rozek L, Wolf GT, Li G, Chen GY , D'Silva NJ",Salivary microbiome changes distinguish response to chemoradiotherapy in patients with oral cancer,Microbiome,2023,NA,Experiment 4,United States of America,Homo sapiens,Saliva,UBERON:0001836,Response to combination chemotherapy,EFO:0007965,Responders at baseline,Non-Responders at baseline,Patients with oral squamous cell carcinoma (SCC) at baseline deemed non-responders if any recurrence (local or metastatic) occurred within the follow-up period,39,11,None,16S,4,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1016/5/NA,Study 1016,time series / longitudinal observational,38037123,10.1186/s40168-023-01677-w,NA,"Medeiros MC, The S, Bellile E, Russo N, Schmitd L, Danella E, Singh P, Banerjee R, Bassis C, Murphy GR, Sartor MA, Lombaert I, Schmidt TM, Eisbruch A, Murdoch-Kinch CA, Rozek L, Wolf GT, Li G, Chen GY , D'Silva NJ",Salivary microbiome changes distinguish response to chemoradiotherapy in patients with oral cancer,Microbiome,2023,NA,Experiment 5,United States of America,Homo sapiens,Saliva,UBERON:0001836,Response to combination chemotherapy,EFO:0007965,Responders at 6 months,Non-Responders at 6 months,Patients with oral squamous cell carcinoma (SCC) at 6 months deemed non-responders if any recurrence (local or metastatic) occurred within the follow-up period,25,8,None,16S,4,Illumina,LEfSe,0.05,FALSE,3.5,NA,NA,NA,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1017/1/NA,Study 1017,"cross-sectional observational, not case-control",36973353,https://doi.org/10.1038/s41559-023-02013-z,https://pubmed.ncbi.nlm.nih.gov/36973353/,"Fackelmann G, Pham CK, Rodríguez Y, Mallory ML, Provencher JF, Baak JE , Sommer S",Current levels of microplastic pollution impact wild seabird gut microbiomes,Nature ecology & evolution,2023,NA,Experiment 1,Portugal,Calonectris borealis,"Proventriculus,Cloaca","UBERON:0007357,UBERON:0000162",Exposure,EFO:0000487,Proventricular microbiome in Cory's sheawater individuals,Cloacal microbiome in Cory's sheawater individuals,effect of microplastic count in the Cloacal microbiome in Cory's sheawater individuals,85,84,NA,16S,4,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,increased,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1017/2/NA,Study 1017,"cross-sectional observational, not case-control",36973353,https://doi.org/10.1038/s41559-023-02013-z,https://pubmed.ncbi.nlm.nih.gov/36973353/,"Fackelmann G, Pham CK, Rodríguez Y, Mallory ML, Provencher JF, Baak JE , Sommer S",Current levels of microplastic pollution impact wild seabird gut microbiomes,Nature ecology & evolution,2023,NA,Experiment 2,Portugal,Calonectris borealis,"Proventriculus,Cloaca","UBERON:0007357,UBERON:0000162",Exposure,EFO:0000487,abundance of microplastic mass in proventriculus,abundance of microplastic mass in cloaca,effect of in microplastic mass in c. borealis,85,84,NA,16S,4,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,decreased,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1017/3/NA,Study 1017,"cross-sectional observational, not case-control",36973353,https://doi.org/10.1038/s41559-023-02013-z,https://pubmed.ncbi.nlm.nih.gov/36973353/,"Fackelmann G, Pham CK, Rodríguez Y, Mallory ML, Provencher JF, Baak JE , Sommer S",Current levels of microplastic pollution impact wild seabird gut microbiomes,Nature ecology & evolution,2023,NA,Experiment 3,"Portugal,Canada",Calonectris borealis,"Proventriculus,Cloaca","UBERON:0007357,UBERON:0000162",Exposure,EFO:0000487,abundance of microplastic count and mass in cory's shearwaters,abundance of microplastic count and mass in nothern fulmars,effect of microplastic count and mass in  proventriculus and cloaca in seabirds,58,27,NA,16S,4,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1017/4/NA,Study 1017,"cross-sectional observational, not case-control",36973353,https://doi.org/10.1038/s41559-023-02013-z,https://pubmed.ncbi.nlm.nih.gov/36973353/,"Fackelmann G, Pham CK, Rodríguez Y, Mallory ML, Provencher JF, Baak JE , Sommer S",Current levels of microplastic pollution impact wild seabird gut microbiomes,Nature ecology & evolution,2023,NA,Experiment 4,Canada,Fulmarus glacialis,"Proventriculus,Cloaca","UBERON:0007357,UBERON:0000162",Exposure,EFO:0000487,Proventricular microbiome in nothern fulmars individuals,Cloacal microbiome in nothern fulmars individuals,effect of microplastic count in the Cloacal microbiome in nothern fulmars individuals,85,84,NA,16S,4,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,increased,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1017/5/NA,Study 1017,"cross-sectional observational, not case-control",36973353,https://doi.org/10.1038/s41559-023-02013-z,https://pubmed.ncbi.nlm.nih.gov/36973353/,"Fackelmann G, Pham CK, Rodríguez Y, Mallory ML, Provencher JF, Baak JE , Sommer S",Current levels of microplastic pollution impact wild seabird gut microbiomes,Nature ecology & evolution,2023,NA,Experiment 5,Canada,Fulmarus glacialis,"Proventriculus,Cloaca","UBERON:0007357,UBERON:0000162",Exposure,EFO:0000487,abundance of microplastic mass in proventriculus,abundance of microplastic mass in cloaca,effect of microplastic mass in f. glacialis,85,84,NA,16S,4,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,decreased,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1018/1/NA,Study 1018,laboratory experiment,38172649,https://doi.org/10.1186/s12866-023-03161-9,NA,"Shaw CG, Pavloudi C, Crow RS, Saw JH , Smith LC","Spotting disease disrupts the microbiome of infected purple sea urchins, Strongylocentrotus purpuratus",BMC microbiology,2024,"16S rRNA, Disease, Infection, Lesion, Microbiome, Pathogenic",Experiment 1,United States of America,Strongylocentrotus purpuratus,Body external integument structure,UBERON:3000977,Strongylocentrotus purpuratus,NCBITAXON:7668,Healthy sea urchins,Diseased sea urchins,Sea urchins with spotting disease,4,4,NA,16S,34,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,NA,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1018/2/NA,Study 1018,laboratory experiment,38172649,https://doi.org/10.1186/s12866-023-03161-9,NA,"Shaw CG, Pavloudi C, Crow RS, Saw JH , Smith LC","Spotting disease disrupts the microbiome of infected purple sea urchins, Strongylocentrotus purpuratus",BMC microbiology,2024,"16S rRNA, Disease, Infection, Lesion, Microbiome, Pathogenic",Experiment 2,United States of America,Strongylocentrotus purpuratus,Body external integument structure,UBERON:3000977,Microbiome measurement,EFO:0007882,Lesion surface samples (LS),Lesion body wall samples (LBW),Lesion body wall samples from sea urchins with spotting disease,5,7,NA,16S,34,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,NA,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1018/3/NA,Study 1018,laboratory experiment,38172649,https://doi.org/10.1186/s12866-023-03161-9,NA,"Shaw CG, Pavloudi C, Crow RS, Saw JH , Smith LC","Spotting disease disrupts the microbiome of infected purple sea urchins, Strongylocentrotus purpuratus",BMC microbiology,2024,"16S rRNA, Disease, Infection, Lesion, Microbiome, Pathogenic",Experiment 3,United States of America,Strongylocentrotus purpuratus,"Coelomic fluid,Body wall","UBERON:0036217,UBERON:0000309",Microbiome measurement,EFO:0007882,Healthy coelomic fluid (HCF),Diseased coelomic fluid (DCF) and lesion body wall (LBW),Diseased coelomic fluid (DCF) and lesion body wall (LBW) samples from sea urchins with spotting disease,3,10,NA,16S,34,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1018/4/NA,Study 1018,laboratory experiment,38172649,https://doi.org/10.1186/s12866-023-03161-9,NA,"Shaw CG, Pavloudi C, Crow RS, Saw JH , Smith LC","Spotting disease disrupts the microbiome of infected purple sea urchins, Strongylocentrotus purpuratus",BMC microbiology,2024,"16S rRNA, Disease, Infection, Lesion, Microbiome, Pathogenic",Experiment 4,United States of America,Strongylocentrotus purpuratus,"Coelomic fluid,Body wall","UBERON:0036217,UBERON:0000309",Microbiome measurement,EFO:0007882,Healthy coelomic fluid (HCF) and diseased coelomic fluid (DCF),Lesion body wall (LBW),Lesion body wall (LBW) samples from sea urchins with spotting disease,6,7,NA,16S,34,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1018/5/NA,Study 1018,laboratory experiment,38172649,https://doi.org/10.1186/s12866-023-03161-9,NA,"Shaw CG, Pavloudi C, Crow RS, Saw JH , Smith LC","Spotting disease disrupts the microbiome of infected purple sea urchins, Strongylocentrotus purpuratus",BMC microbiology,2024,"16S rRNA, Disease, Infection, Lesion, Microbiome, Pathogenic",Experiment 5,United States of America,Strongylocentrotus purpuratus,"Coelomic fluid,Body wall","UBERON:0036217,UBERON:0000309",Microbiome measurement,EFO:0007882,Healthy coelomic fluid (HCF) and lesion body wall (LBW),Diseased coelomic fluid (DCF),Diseased coelomic fluid (DCF) samples from sea urchins with spotting disease,10,3,NA,16S,34,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1019/1/NA,Study 1019,"cross-sectional observational, not case-control",38262927,https://doi.org/10.1186/s12866-023-03150-y,NA,"Liu S, Imad S, Hussain S, Xiao S, Yu X , Cao H","Sex, health status and habitat alter the community composition and assembly processes of symbiotic bacteria in captive frogs",BMC microbiology,2024,"Assembly, Frog, Habitat, Health status, Network structure, Sex",Experiment 1,China,Pelophylax nigromaculatus,Intestine,UBERON:0000160,Sex design,EFO:0001752,male,female,female black spotted frog,8,8,NA,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1019/2/NA,Study 1019,"cross-sectional observational, not case-control",38262927,https://doi.org/10.1186/s12866-023-03150-y,NA,"Liu S, Imad S, Hussain S, Xiao S, Yu X , Cao H","Sex, health status and habitat alter the community composition and assembly processes of symbiotic bacteria in captive frogs",BMC microbiology,2024,"Assembly, Frog, Habitat, Health status, Network structure, Sex",Experiment 2,China,Pelophylax nigromaculatus,Intestine,UBERON:0000160,Infectious meningitis,EFO:0000584,H: uninfected individuals,NH: infected individuals,frogs found to be infected with Meningitis-like infectious diseases.,8,8,NA,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1020/1/NA,Study 1020,case-control,38491387,10.1186/s12866-024-03233-4,NA,"Chen H, Jiang X, Zhu F, Yang R, Yu X, Zhou X , Tang N",Characteristics of the oral and gastric microbiome in patients with early-stage intramucosal esophageal squamous cell carcinoma,BMC microbiology,2024,"Amplicon sequencing analysis, Early esophageal cancer, Gastric microbiome, Intramucosal esophageal squamous carcinoma, Oral microbiome",Experiment 1,China,Homo sapiens,Saliva,UBERON:0001836,Esophageal squamous cell carcinoma,EFO:0005922,NC_oral - No carcinoma.,EIESC_oral - Early-stage intramucosal esophageal squamous carcinoma.,Patients diagnosed with Early-stage Intramucosal Esophageal Squamous Carcinoma (EIESC) who provided Oral samples (saliva).,21,31,4 weeks,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1020/2/NA,Study 1020,case-control,38491387,10.1186/s12866-024-03233-4,NA,"Chen H, Jiang X, Zhu F, Yang R, Yu X, Zhou X , Tang N",Characteristics of the oral and gastric microbiome in patients with early-stage intramucosal esophageal squamous cell carcinoma,BMC microbiology,2024,"Amplicon sequencing analysis, Early esophageal cancer, Gastric microbiome, Intramucosal esophageal squamous carcinoma, Oral microbiome",Experiment 2,China,Homo sapiens,Mucosa of body of stomach,UBERON:0004995,Esophageal squamous cell carcinoma,EFO:0005922,No Carcinoma (NC)_gastric,Early-stage Intramucosal Esophageal Squamous Carcinoma  (EIESC)_gastric,Patients diagnosed with Early-stage Intramucosal Esophageal Squamous Carcinoma (EIESC) who provided Gastric biopsy samples.,21,31,4 weeks,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1021/1/NA,Study 1021,time series / longitudinal observational,38436093,https://doi.org/10.1080/19490976.2024.2323234,NA,"Peng Y, Tun HM, Ng SC, Wai HK, Zhang X, Parks J, Field CJ, Mandhane P, Moraes TJ, Simons E, Turvey SE, Subbarao P, Brook JR, Takaro TK, Scott JA, Chan FK , Kozyrskyj AL",Maternal smoking during pregnancy increases the risk of gut microbiome-associated childhood overweight and obesity,Gut microbes,2024,"Maternal smoking, butyrate production, childhood obesity, gut microbiota",Experiment 1,Canada,Homo sapiens,Feces,UBERON:0001988,Smoking behaviour measurement,EFO:0005671,Early infants (3 months) with maternal history of  'NO' 'smoking,Early infants (3 months) with maternal history of  'YES' 'smoking,"Infants (3 months old) whose mothers quit smoking during pregnancy, reduced the number of cigarettes, or had the same number of cigarettes (as before conception) during pregnancy.",1458,134,NA,16S,4,NA,LEfSe,0.05,TRUE,2,NA,NA,NA,increased,increased,increased,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1021/2/NA,Study 1021,time series / longitudinal observational,38436093,https://doi.org/10.1080/19490976.2024.2323234,NA,"Peng Y, Tun HM, Ng SC, Wai HK, Zhang X, Parks J, Field CJ, Mandhane P, Moraes TJ, Simons E, Turvey SE, Subbarao P, Brook JR, Takaro TK, Scott JA, Chan FK , Kozyrskyj AL",Maternal smoking during pregnancy increases the risk of gut microbiome-associated childhood overweight and obesity,Gut microbes,2024,"Maternal smoking, butyrate production, childhood obesity, gut microbiota",Experiment 2,Canada,Homo sapiens,Feces,UBERON:0001988,Smoking behaviour measurement,EFO:0005671,Late infants (12months) with maternal history of  'NO' 'smoking,Late infants (12months) with maternal history of  'YES' 'smoking,"Infants (12 months old) whose mothers quit smoking during pregnancy, reduced the number of cigarettes, or had the same number of cigarettes (as before conception) during pregnancy.",1458,134,NA,16S,4,NA,LEfSe,0.05,TRUE,2,NA,NA,NA,increased,increased,increased,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1022/1/NA,Study 1022,laboratory experiment,37888992,10.1128/spectrum.02715-23,NA,"Ange-Stark M, Parise KL, Cheng TL, Hoyt JR, Langwig KE, Frick WF, Kilpatrick AM, Gillece J, MacManes MD , Foster JT",White-nose syndrome restructures bat skin microbiomes,Microbiology spectrum,2023,"Eptesicus fuscus, Myotis lucifugus, Perimyotis subflavus, Pseudogymnoascus destructans, bat populations, disease ecology, microbiome, white-nose syndrome",Experiment 1,United States of America,Myotis lucifugus,Skin epidermis,UBERON:0001003,Fungal infectious disease,MONDO:0002041,Pseudogymnoascus Destructans (PD) Negative,Pseudogymnoascus Destructans (PD) positive,Myotis lucifugus Bats species infected with Pseudogymnoascus destructans (Pd).,29,81,NA,16S,4,Illumina,LEfSe,0.05,FALSE,2,NA,NA,decreased,decreased,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1022/2/NA,Study 1022,laboratory experiment,37888992,10.1128/spectrum.02715-23,NA,"Ange-Stark M, Parise KL, Cheng TL, Hoyt JR, Langwig KE, Frick WF, Kilpatrick AM, Gillece J, MacManes MD , Foster JT",White-nose syndrome restructures bat skin microbiomes,Microbiology spectrum,2023,"Eptesicus fuscus, Myotis lucifugus, Perimyotis subflavus, Pseudogymnoascus destructans, bat populations, disease ecology, microbiome, white-nose syndrome",Experiment 2,United States of America,Perimyotis subflavus,Skin epidermis,UBERON:0001003,Fungal infectious disease,MONDO:0002041,Pseudogymnoascus Destructans (PD) Negative,Pseudogymnoascus Destructans (PD) positive,Perimyotis subflavus Bats species infected with Pseudogymnoascus destructans (Pd).,43,95,NA,ITS / ITS2,NA,Illumina,LEfSe,0.05,FALSE,2,NA,NA,increased,increased,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1022/3/NA,Study 1022,laboratory experiment,37888992,10.1128/spectrum.02715-23,NA,"Ange-Stark M, Parise KL, Cheng TL, Hoyt JR, Langwig KE, Frick WF, Kilpatrick AM, Gillece J, MacManes MD , Foster JT",White-nose syndrome restructures bat skin microbiomes,Microbiology spectrum,2023,"Eptesicus fuscus, Myotis lucifugus, Perimyotis subflavus, Pseudogymnoascus destructans, bat populations, disease ecology, microbiome, white-nose syndrome",Experiment 3,United States of America,Myotis lucifugus,Skin epidermis,UBERON:0001003,Fungal infectious disease,MONDO:0002041,Batsskin swaps,Substrate (Environmental swaps),Substrate swab samples simultaneously collected from the ceiling or walls of each hibernaculum at least 10 cm from the bat species.,154,70,NA,16S,4,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1023/1/NA,Study 1023,time series / longitudinal observational,38479397,https://doi.org/10.1016/j.chom.2024.02.012,NA,"Zhou X, Shen X, Johnson JS, Spakowicz DJ, Agnello M, Zhou W, Avina M, Honkala A, Chleilat F, Chen SJ, Cha K, Leopold S, Zhu C, Chen L, Lyu L, Hornburg D, Wu S, Zhang X, Jiang C, Jiang L, Jiang L, Jian R, Brooks AW, Wang M, Contrepois K, Gao P, Rose SMS, Tran TDB, Nguyen H, Celli A, Hong BY, Bautista EJ, Dorsett Y, Kavathas PB, Zhou Y, Sodergren E, Weinstock GM , Snyder MP",Longitudinal profiling of the microbiome at four body sites reveals core stability and individualized dynamics during health and disease,Cell host & microbe,2024,"insulin resistance, longitudinal profiling, microbiome host interaction, microbiome stability, nasal microbiome, oral microbiome, precision medicine, prediabetes, skin microbiome, stool microbiome",Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Insulin sensitivity measurement,EFO:0004471,Insulin Sensitive (IS) Individuals,Insulin Resistant (IR) Individuals,"Individuals who are at risk for type 2 diabetes or  voluntarily interested in diabetes-related research, whose steady-state plasma glucose (SSPG) was greater than or equal to 150 mg/dl after undergoing Glucose control assessments, comprising an annual oral glucose tolerance test and a gold-standard steady-state plasma glucose (SSPG) measurement.",28,30,No,16S,123,Illumina,LEfSe,0.05,TRUE,2,date,NA,unchanged,decreased,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1023/2/NA,Study 1023,time series / longitudinal observational,38479397,https://doi.org/10.1016/j.chom.2024.02.012,NA,"Zhou X, Shen X, Johnson JS, Spakowicz DJ, Agnello M, Zhou W, Avina M, Honkala A, Chleilat F, Chen SJ, Cha K, Leopold S, Zhu C, Chen L, Lyu L, Hornburg D, Wu S, Zhang X, Jiang C, Jiang L, Jiang L, Jian R, Brooks AW, Wang M, Contrepois K, Gao P, Rose SMS, Tran TDB, Nguyen H, Celli A, Hong BY, Bautista EJ, Dorsett Y, Kavathas PB, Zhou Y, Sodergren E, Weinstock GM , Snyder MP",Longitudinal profiling of the microbiome at four body sites reveals core stability and individualized dynamics during health and disease,Cell host & microbe,2024,"insulin resistance, longitudinal profiling, microbiome host interaction, microbiome stability, nasal microbiome, oral microbiome, precision medicine, prediabetes, skin microbiome, stool microbiome",Experiment 2,United States of America,Homo sapiens,Skin of body,UBERON:0002097,Insulin sensitivity measurement,EFO:0004471,Insulin Sensitive (IS) Individuals,Insulin Resistant (IR) Individuals,"Individuals who are at risk for type 2 diabetes or  voluntarily interested in diabetes-related research, whose steady-state plasma glucose (SSPG) was greater than or equal to 150 mg/dl after undergoing Glucose control assessments, comprising an annual oral glucose tolerance test and a gold-standard steady-state plasma glucose (SSPG) measurement.",28,30,No,16S,4,Illumina,LEfSe,0.05,TRUE,2,date,NA,increased,increased,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1023/3/NA,Study 1023,time series / longitudinal observational,38479397,https://doi.org/10.1016/j.chom.2024.02.012,NA,"Zhou X, Shen X, Johnson JS, Spakowicz DJ, Agnello M, Zhou W, Avina M, Honkala A, Chleilat F, Chen SJ, Cha K, Leopold S, Zhu C, Chen L, Lyu L, Hornburg D, Wu S, Zhang X, Jiang C, Jiang L, Jiang L, Jian R, Brooks AW, Wang M, Contrepois K, Gao P, Rose SMS, Tran TDB, Nguyen H, Celli A, Hong BY, Bautista EJ, Dorsett Y, Kavathas PB, Zhou Y, Sodergren E, Weinstock GM , Snyder MP",Longitudinal profiling of the microbiome at four body sites reveals core stability and individualized dynamics during health and disease,Cell host & microbe,2024,"insulin resistance, longitudinal profiling, microbiome host interaction, microbiome stability, nasal microbiome, oral microbiome, precision medicine, prediabetes, skin microbiome, stool microbiome",Experiment 3,United States of America,Homo sapiens,Anterior naris,UBERON:2001427,Insulin sensitivity measurement,EFO:0004471,Insulin Sensitive (IS) Individuals,Insulin Resistant (IR) Individuals,"Individuals who are at risk for type 2 diabetes or  voluntarily interested in diabetes-related research, whose steady-state plasma glucose (SSPG) was greater than or equal to 150 mg/dl after undergoing Glucose control assessments, comprising an annual oral glucose tolerance test and a gold-standard steady-state plasma glucose (SSPG) measurement.",28,30,No,16S,123,Illumina,LEfSe,0.05,TRUE,2,date,NA,unchanged,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1023/4/NA,Study 1023,time series / longitudinal observational,38479397,https://doi.org/10.1016/j.chom.2024.02.012,NA,"Zhou X, Shen X, Johnson JS, Spakowicz DJ, Agnello M, Zhou W, Avina M, Honkala A, Chleilat F, Chen SJ, Cha K, Leopold S, Zhu C, Chen L, Lyu L, Hornburg D, Wu S, Zhang X, Jiang C, Jiang L, Jiang L, Jian R, Brooks AW, Wang M, Contrepois K, Gao P, Rose SMS, Tran TDB, Nguyen H, Celli A, Hong BY, Bautista EJ, Dorsett Y, Kavathas PB, Zhou Y, Sodergren E, Weinstock GM , Snyder MP",Longitudinal profiling of the microbiome at four body sites reveals core stability and individualized dynamics during health and disease,Cell host & microbe,2024,"insulin resistance, longitudinal profiling, microbiome host interaction, microbiome stability, nasal microbiome, oral microbiome, precision medicine, prediabetes, skin microbiome, stool microbiome",Experiment 4,United States of America,Homo sapiens,Posterior wall of oropharynx,UBERON:0035240,Insulin sensitivity measurement,EFO:0004471,Insulin Sensitive (IS) Individuals,Insulin Resistant (IR) Individuals,"Individuals who are at risk for type 2 diabetes or  voluntarily interested in diabetes-related research, whose steady-state plasma glucose (SSPG) was greater than or equal to 150 mg/dl after undergoing Glucose control assessments, comprising an annual oral glucose tolerance test and a gold-standard steady-state plasma glucose (SSPG) measurement.",28,30,No,16S,4,Illumina,LEfSe,0.05,TRUE,2,date,NA,unchanged,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1024/1/NA,Study 1024,case-control,29758946,http://dx.doi. 438 org/10.3233/JAD-180176,NA,"Zhuang ZQ, Shen LL, Li WW, Fu X, Zeng F, Gui L, Lü Y, Cai M, Zhu C, Tan YL, Zheng P, Li HY, Zhu J, Zhou HD, Bu XL , Wang YJ",Gut Microbiota is Altered in Patients with Alzheimer's Disease,Journal of Alzheimer's disease : JAD,2018,"16S ribosomal RNA sequencing, Alzheimer’s disease, amyloid-β peptide, gut microbiota",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Alzheimer's disease,MONDO:0004975,Healthy controls,Alzheimer's disease,Patients with active Alzheimer's disease,43,43,6 Months,16S,34,Illumina,LEfSe,0.01,FALSE,NA,"age,sex",NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1025/1/NA,Study 1025,"cross-sectional observational, not case-control",38387693,10.1016/j.alcohol.2024.02.003,NA,"Qiao NN, Fang Q, Zhang XH, Ke SS, Wang ZW, Tang G, Leng RX , Fan YG",Effects of alcohol on the composition and metabolism of the intestinal microbiota among people with HIV: a cross-sectional study,"Alcohol (Fayetteville, N.Y.)",2024,"Alcohol, Cross-sectional study, HIV/AIDS, Intestinal microbiota, Metabolism",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Alcohol consumption measurement,EFO:0007878,Non Drinking,Low to Moderate drinking,HIV infected persons who consume alcohol ≥1 time/month or ≥12 times/year in the last year. Individuals in the low to moderate drinking group consumed <210 g of alcohol per week.,72,21,3 months,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1026/1/NA,Study 1026,case-control,38172680,https://doi.org/10.1186/s12866-023-03157-5,https://bmcmicrobiol.biomedcentral.com/articles/10.1186/s12866-023-03157-5,"Aya Ishizaka, Eisuke Adachi, Hiroshi Yotsuyanagi, Kiyoko Iwatsuki-Horimoto, Michiko Koga, Seiya Yamayoshi, Taketoshi Mizutani, Yoshihiro Kawaoka, Yutaka Suzuki",Association of gut microbiota with the pathogenesis of SARS-CoV-2 Infection in people living with HIV,BMC microbiology,2024,"SARS-CoV-2, COVID-19, HIV, Microbiota, Post-acute COVID-19 syndrome",Experiment 1,Japan,Homo sapiens,Feces,UBERON:0001988,SARS coronavirus,NCBITAXON:694009,SARS-CoV-2-uninfected PLWH (< 8 days),SARS-CoV-2-infected PLWH (< 8 days),Hospitalized severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected PLWH  (People living with HIV) within 7 days of COVID-19 onset (< 8 days),10,10,None,16S,34,Illumina,"LEfSe,MaAsLin2",0.05,FALSE,3,NA,body mass index,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1026/2/NA,Study 1026,case-control,38172680,https://doi.org/10.1186/s12866-023-03157-5,https://bmcmicrobiol.biomedcentral.com/articles/10.1186/s12866-023-03157-5,"Aya Ishizaka, Eisuke Adachi, Hiroshi Yotsuyanagi, Kiyoko Iwatsuki-Horimoto, Michiko Koga, Seiya Yamayoshi, Taketoshi Mizutani, Yoshihiro Kawaoka, Yutaka Suzuki",Association of gut microbiota with the pathogenesis of SARS-CoV-2 Infection in people living with HIV,BMC microbiology,2024,"SARS-CoV-2, COVID-19, HIV, Microbiota, Post-acute COVID-19 syndrome",Experiment 2,Japan,Homo sapiens,Feces,UBERON:0001988,SARS coronavirus,NCBITAXON:694009,SARS-CoV-2-uninfected PLWH (8–14 days),SARS-CoV-2-infected PLWH (8–14 days),Hospitalized severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected PLWH (People living with HIV) 8 − 14 days after COVID-19 onset,9,9,None,16S,34,Illumina,"LEfSe,MaAsLin2",0.05,FALSE,3,NA,body mass index,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1026/3/NA,Study 1026,case-control,38172680,https://doi.org/10.1186/s12866-023-03157-5,https://bmcmicrobiol.biomedcentral.com/articles/10.1186/s12866-023-03157-5,"Aya Ishizaka, Eisuke Adachi, Hiroshi Yotsuyanagi, Kiyoko Iwatsuki-Horimoto, Michiko Koga, Seiya Yamayoshi, Taketoshi Mizutani, Yoshihiro Kawaoka, Yutaka Suzuki",Association of gut microbiota with the pathogenesis of SARS-CoV-2 Infection in people living with HIV,BMC microbiology,2024,"SARS-CoV-2, COVID-19, HIV, Microbiota, Post-acute COVID-19 syndrome",Experiment 3,Japan,Homo sapiens,Feces,UBERON:0001988,SARS coronavirus,NCBITAXON:694009,SARS-CoV-2-uninfected PLWH (>1 M),SARS-CoV-2-infected PLWH (>1 M),Hospitalized severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected PLWH (People living with HIV) over 1 month after COVID-19 onset,7,7,None,16S,34,Illumina,"LEfSe,MaAsLin2",0.05,FALSE,3,NA,body mass index,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1026/4/NA,Study 1026,case-control,38172680,https://doi.org/10.1186/s12866-023-03157-5,https://bmcmicrobiol.biomedcentral.com/articles/10.1186/s12866-023-03157-5,"Aya Ishizaka, Eisuke Adachi, Hiroshi Yotsuyanagi, Kiyoko Iwatsuki-Horimoto, Michiko Koga, Seiya Yamayoshi, Taketoshi Mizutani, Yoshihiro Kawaoka, Yutaka Suzuki",Association of gut microbiota with the pathogenesis of SARS-CoV-2 Infection in people living with HIV,BMC microbiology,2024,"SARS-CoV-2, COVID-19, HIV, Microbiota, Post-acute COVID-19 syndrome",Experiment 4,Japan,Homo sapiens,Feces,UBERON:0001988,Illness severity status,EFO:0007863,Mildly ill SARS-CoV-2-infected PLWH (8–14 days),Moderately/severely ill SARS-CoV-2-infected PLWH (8–14 days),Moderately (n = 4) and severely (n = 1) ill hospitalized severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected PLWH  (People living with HIV) within 7 days of COVID-19 onset (8–14 days),6,5,None,16S,34,Illumina,LEfSe,0.05,FALSE,3,NA,body mass index,NA,decreased,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1027/1/NA,Study 1027,case-control,37978347,10.1186/s12866-023-03067-6,NA,"Xiaofeng N, Jian C, Jingjing W, Zhanbo Q, Yifei S, Jing Z , Shuwen H",Correlation of gut microbiota with leukopenia after chemotherapy in patients with colorectal cancer,BMC microbiology,2023,"Chemotherapy, Colorectal cancer, Gut microbiota, Leukopenia, Myelosuppression",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Colorectal carcinoma,EFO:1001951,Healthy,Colorectal cancer (CRC),Patients who has colorectal cancer (CRC),56,55,None,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1027/2/NA,Study 1027,case-control,37978347,10.1186/s12866-023-03067-6,NA,"Xiaofeng N, Jian C, Jingjing W, Zhanbo Q, Yifei S, Jing Z , Shuwen H",Correlation of gut microbiota with leukopenia after chemotherapy in patients with colorectal cancer,BMC microbiology,2023,"Chemotherapy, Colorectal cancer, Gut microbiota, Leukopenia, Myelosuppression",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Leukopenia,EFO:0004233,Normal leukocytes,Hypoleukocytes,Colorectal cancer patients with lower-than-normal levels of leukocytes (below 3.5 × 10^9/L) after chemotherapy,42,13,None,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1028/1/NA,Study 1028,"cross-sectional observational, not case-control",38245675,10.1186/s12866-023-03149-5,NA,"Bayardo-González RA, Peña-Rodríguez M, Pereira-Suárez AL, Rubio-Sánchez AX, García-Chagollán M, Valenzuela-Orozco DN, Lizarazo-Taborda MDR, Mora-Mora J , Vega-Magaña N",Insights into estrogen impact in oral health & microbiome in COVID-19,BMC microbiology,2024,"COVID-19, Cytokines, Inflammation, Microbiome, Women-s health",Experiment 1,Mexico,Homo sapiens,Saliva,UBERON:0001836,Menopause,EFO:0003922,Premenopausal women group,Postmenopausal women group,Postmenopausal women with COVID-19,20,18,30 days,16S,34,Illumina,DESeq2,0.05,FALSE,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1028/2/NA,Study 1028,"cross-sectional observational, not case-control",38245675,10.1186/s12866-023-03149-5,NA,"Bayardo-González RA, Peña-Rodríguez M, Pereira-Suárez AL, Rubio-Sánchez AX, García-Chagollán M, Valenzuela-Orozco DN, Lizarazo-Taborda MDR, Mora-Mora J , Vega-Magaña N",Insights into estrogen impact in oral health & microbiome in COVID-19,BMC microbiology,2024,"COVID-19, Cytokines, Inflammation, Microbiome, Women-s health",Experiment 2,Mexico,Homo sapiens,Saliva,UBERON:0001836,Microbiome measurement,EFO:0007882,Adequate oral health group,Poor oral health group,"COVID-19 patients with poor oral health status. Patients were classified as having poor oral health when there were more than two caries, hygiene index higher than 2.5, gingival inflammation between 2–3 and bleeding when toothbrushing.",NA,NA,30 days,16S,34,Illumina,DESeq2,0.05,FALSE,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1028/3/NA,Study 1028,"cross-sectional observational, not case-control",38245675,10.1186/s12866-023-03149-5,NA,"Bayardo-González RA, Peña-Rodríguez M, Pereira-Suárez AL, Rubio-Sánchez AX, García-Chagollán M, Valenzuela-Orozco DN, Lizarazo-Taborda MDR, Mora-Mora J , Vega-Magaña N",Insights into estrogen impact in oral health & microbiome in COVID-19,BMC microbiology,2024,"COVID-19, Cytokines, Inflammation, Microbiome, Women-s health",Experiment 3,Mexico,Homo sapiens,Saliva,UBERON:0001836,Viral load,EFO:0010125,Moderate SARS-CoV-2 viral load group,High SARS-CoV-2 viral load group,COVID-19 patients with high SARS-CoV-2 viral load,11,41,30 days,16S,34,Illumina,DESeq2,0.05,FALSE,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1029/1/NA,Study 1029,"cross-sectional observational, not case-control",35459771,10.1038/s41598-022-10532-1,NA,"Xu X, Zhang Y, Yu L, Shi X, Min M, Xiong L, Pan J, Liu P, Wu G , Gao G","A cross-sectional analysis about bacterial vaginosis, high-risk human papillomavirus infection, and cervical intraepithelial neoplasia in Chinese women",Scientific reports,2022,NA,Experiment 1,China,Homo sapiens,"Uterine cervix,Vaginal fluid","UBERON:0000002,UBERON:0036243",Vaginal microbiome measurement,EFO:0011013,Normal Healthy Women & High‑risk human papillomavirus(HR-HPV) Infected Women (HPV),Bacterial Vaginosis (BV) Infected Women,"Women attending the Aviation General hospital, located in Beijing, China, who were diagnosed with Bacterial Vaginosis (BV) Infection.",136,52,30 days,16S,34,Illumina,LEfSe,0.05,NA,4,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1029/2/NA,Study 1029,"cross-sectional observational, not case-control",35459771,10.1038/s41598-022-10532-1,NA,"Xu X, Zhang Y, Yu L, Shi X, Min M, Xiong L, Pan J, Liu P, Wu G , Gao G","A cross-sectional analysis about bacterial vaginosis, high-risk human papillomavirus infection, and cervical intraepithelial neoplasia in Chinese women",Scientific reports,2022,NA,Experiment 2,China,Homo sapiens,"Uterine cervix,Vaginal fluid","UBERON:0000002,UBERON:0036243",Vaginal microbiome measurement,EFO:0011013,Normal Healthy Women & Bacterial Vaginosis (BV) Infected Women,High‑risk human papillomavirus(HR-HPV) Infected Women (HPV),"Women attending the Aviation General hospital, located in Beijing, China, who were diagnosed with High‑risk human papillomavirus (HR-HPV) infection.",117,71,30 days,16S,34,Illumina,LEfSe,0.05,NA,4,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1029/3/NA,Study 1029,"cross-sectional observational, not case-control",35459771,10.1038/s41598-022-10532-1,NA,"Xu X, Zhang Y, Yu L, Shi X, Min M, Xiong L, Pan J, Liu P, Wu G , Gao G","A cross-sectional analysis about bacterial vaginosis, high-risk human papillomavirus infection, and cervical intraepithelial neoplasia in Chinese women",Scientific reports,2022,NA,Experiment 3,China,Homo sapiens,"Uterine cervix,Vaginal fluid","UBERON:0000002,UBERON:0036243",Vaginal microbiome measurement,EFO:0011013,Normal Healthy Women,Bacterial vaginosis (BV) infected women & High‑risk human papillomavirus (HR-HPV) (HPV) infected Women,"Women attending the Aviation General hospital, located in Beijing, China, who were diagnosed with Bacterial vaginosis (BV) infection and those diagnosed with High‑risk human papillomavirus (HR-HPV) infection.",65,123,30 days,16S,34,Illumina,LEfSe,0.05,NA,4,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1029/4/NA,Study 1029,"cross-sectional observational, not case-control",35459771,10.1038/s41598-022-10532-1,NA,"Xu X, Zhang Y, Yu L, Shi X, Min M, Xiong L, Pan J, Liu P, Wu G , Gao G","A cross-sectional analysis about bacterial vaginosis, high-risk human papillomavirus infection, and cervical intraepithelial neoplasia in Chinese women",Scientific reports,2022,NA,Experiment 4,China,Homo sapiens,"Uterine cervix,Vaginal fluid","UBERON:0000002,UBERON:0036243",Vaginal microbiome measurement,EFO:0011013,Normal Healthy Women,High‑risk human papillomavirus(HR-HPV) & Cervical Intraepithelial Neoplasia(CIN) co-infected women (HC),"Women attending the Aviation General hospital, located in Beijing, China, who were diagnosed with infection of High‑risk human papillomavirus (HR-HPV) combined with Cervical Intraepithelial Neoplasia (CIN).",65,48,30 days,16S,34,Illumina,LEfSe,0.05,NA,4,NA,NA,NA,increased,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1029/5/NA,Study 1029,"cross-sectional observational, not case-control",35459771,10.1038/s41598-022-10532-1,NA,"Xu X, Zhang Y, Yu L, Shi X, Min M, Xiong L, Pan J, Liu P, Wu G , Gao G","A cross-sectional analysis about bacterial vaginosis, high-risk human papillomavirus infection, and cervical intraepithelial neoplasia in Chinese women",Scientific reports,2022,NA,Experiment 5,China,Homo sapiens,"Uterine cervix,Vaginal fluid","UBERON:0000002,UBERON:0036243",Vaginal microbiome measurement,EFO:0011013,Normal Healthy Women,Bacteial Vaginosis (BV) & High‑risk human papillomavirus(HR-HPV) with Cervical Intraepithelial Neoplasia(CIN) co-infected women (BHC),"Women attending the Aviation General hospital, located in Beijing, China, who were diagnosed with co-infection of Bacteial Vaginosis (BV) & High‑risk human papillomavirus (HR-HPV) in combination with Cervical Intraepithelial Neoplasia (CIN).",65,46,30 days,16S,34,Illumina,LEfSe,0.05,NA,4,NA,NA,NA,increased,increased,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1029/6/NA,Study 1029,"cross-sectional observational, not case-control",35459771,10.1038/s41598-022-10532-1,NA,"Xu X, Zhang Y, Yu L, Shi X, Min M, Xiong L, Pan J, Liu P, Wu G , Gao G","A cross-sectional analysis about bacterial vaginosis, high-risk human papillomavirus infection, and cervical intraepithelial neoplasia in Chinese women",Scientific reports,2022,NA,Experiment 6,China,Homo sapiens,"Uterine cervix,Vaginal fluid","UBERON:0000002,UBERON:0036243",Vaginal microbiome measurement,EFO:0011013,Bacterial Vaginosis (BV) Infected Women,High‑risk human papillomavirus(HR-HPV) & Cervical Intraepithelial Neoplasia(CIN) co-infected women (HC),"Women attending the Aviation General hospital, located in Beijing, China, who were diagnosed with infection of High‑risk human papillomavirus (HR-HPV) combined with Cervical Intraepithelial Neoplasia (CIN).",52,48,30 days,16S,34,Illumina,LEfSe,0.05,NA,4,NA,NA,NA,decreased,decreased,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1029/7/NA,Study 1029,"cross-sectional observational, not case-control",35459771,10.1038/s41598-022-10532-1,NA,"Xu X, Zhang Y, Yu L, Shi X, Min M, Xiong L, Pan J, Liu P, Wu G , Gao G","A cross-sectional analysis about bacterial vaginosis, high-risk human papillomavirus infection, and cervical intraepithelial neoplasia in Chinese women",Scientific reports,2022,NA,Experiment 7,China,Homo sapiens,"Uterine cervix,Vaginal fluid","UBERON:0000002,UBERON:0036243",Vaginal microbiome measurement,EFO:0011013,High‑risk human papillomavirus (HR-HPV) Infected Women (HPV),High‑risk human papillomavirus(HR-HPV) & Cervical Intraepithelial Neoplasia(CIN) co-infected women (HC),"Women attending the Aviation General hospital, located in Beijing, China, who were diagnosed with infection of High‑risk human papillomavirus (HR-HPV) combined with Cervical Intraepithelial Neoplasia (CIN).",71,48,30 days,16S,34,Illumina,LEfSe,0.05,NA,4,NA,NA,NA,increased,decreased,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1029/8/NA,Study 1029,"cross-sectional observational, not case-control",35459771,10.1038/s41598-022-10532-1,NA,"Xu X, Zhang Y, Yu L, Shi X, Min M, Xiong L, Pan J, Liu P, Wu G , Gao G","A cross-sectional analysis about bacterial vaginosis, high-risk human papillomavirus infection, and cervical intraepithelial neoplasia in Chinese women",Scientific reports,2022,NA,Experiment 8,China,Homo sapiens,"Uterine cervix,Vaginal fluid","UBERON:0000002,UBERON:0036243",Vaginal microbiome measurement,EFO:0011013,Bacterial vaginosis (BV) and High‑risk human papillomavirus (HR-HPV) (HPV) co-infected Women (BH),High‑risk human papillomavirus(HR-HPV) & Cervical Intraepithelial Neoplasia(CIN) co-infected women (HC),"Women attending the Aviation General hospital, located in Beijing, China, who were diagnosed with infection of High‑risk human papillomavirus (HR-HPV) combined with Cervical Intraepithelial Neoplasia (CIN).",60,48,30 days,16S,34,Illumina,LEfSe,0.05,NA,4,NA,NA,NA,increased,increased,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1029/9/NA,Study 1029,"cross-sectional observational, not case-control",35459771,10.1038/s41598-022-10532-1,NA,"Xu X, Zhang Y, Yu L, Shi X, Min M, Xiong L, Pan J, Liu P, Wu G , Gao G","A cross-sectional analysis about bacterial vaginosis, high-risk human papillomavirus infection, and cervical intraepithelial neoplasia in Chinese women",Scientific reports,2022,NA,Experiment 9,China,Homo sapiens,"Uterine cervix,Vaginal fluid","UBERON:0000002,UBERON:0036243",Vaginal microbiome measurement,EFO:0011013,High‑risk human papillomavirus(HR-HPV) Infected Women (HPV),Bacteial Vaginosis (BV) & High‑risk human papillomavirus(HR-HPV) with Cervical Intraepithelial Neoplasia(CIN) co-infected women (BHC),"Women attending the Aviation General hospital, located in Beijing, China, who were diagnosed with with co-infection of Bacteial Vaginosis (BV) & High‑risk human papillomavirus (HR-HPV) in combination with Cervical Intraepithelial Neoplasia (CIN).",71,46,30 days,16S,34,Illumina,LEfSe,0.05,NA,4,NA,NA,NA,increased,increased,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1029/10/NA,Study 1029,"cross-sectional observational, not case-control",35459771,10.1038/s41598-022-10532-1,NA,"Xu X, Zhang Y, Yu L, Shi X, Min M, Xiong L, Pan J, Liu P, Wu G , Gao G","A cross-sectional analysis about bacterial vaginosis, high-risk human papillomavirus infection, and cervical intraepithelial neoplasia in Chinese women",Scientific reports,2022,NA,Experiment 10,China,Homo sapiens,"Uterine cervix,Vaginal fluid","UBERON:0000002,UBERON:0036243",Vaginal microbiome measurement,EFO:0011013,High‑risk human papillomavirus(HR-HPV) & Cervical Intraepithelial Neoplasia(CIN) co-infected women (HC),Bacteial Vaginosis (BV) & High‑risk human papillomavirus(HR-HPV) with Cervical Intraepithelial Neoplasia(CIN) co-infected women (BHC),"Women attending the Aviation General hospital, located in Beijing, China, who were diagnosed with with co-infection of Bacteial Vaginosis (BV) & High‑risk human papillomavirus (HR-HPV) in combination with Cervical Intraepithelial Neoplasia (CIN).",48,46,30 days,16S,34,Illumina,LEfSe,0.05,NA,4,NA,NA,NA,increased,increased,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1029/11/NA,Study 1029,"cross-sectional observational, not case-control",35459771,10.1038/s41598-022-10532-1,NA,"Xu X, Zhang Y, Yu L, Shi X, Min M, Xiong L, Pan J, Liu P, Wu G , Gao G","A cross-sectional analysis about bacterial vaginosis, high-risk human papillomavirus infection, and cervical intraepithelial neoplasia in Chinese women",Scientific reports,2022,NA,Experiment 11,China,Homo sapiens,"Uterine cervix,Vaginal fluid","UBERON:0000002,UBERON:0036243",Vaginal microbiome measurement,EFO:0011013,Normal Healthy Women,Bacterial Vaginosis (BV) Infected Women,"Women attending the Aviation General hospital, located in Beijing, China, who were diagnosed with Bacterial Vaginosis (BV) Infection.",65,52,30 days,16S,34,Illumina,LEfSe,0.05,NA,4,NA,NA,NA,increased,increased,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1029/12/NA,Study 1029,"cross-sectional observational, not case-control",35459771,10.1038/s41598-022-10532-1,NA,"Xu X, Zhang Y, Yu L, Shi X, Min M, Xiong L, Pan J, Liu P, Wu G , Gao G","A cross-sectional analysis about bacterial vaginosis, high-risk human papillomavirus infection, and cervical intraepithelial neoplasia in Chinese women",Scientific reports,2022,NA,Experiment 12,China,Homo sapiens,"Uterine cervix,Vaginal fluid","UBERON:0000002,UBERON:0036243",Vaginal microbiome measurement,EFO:0011013,Normal Healthy Women,High‑risk human papillomavirus(HR-HPV) Infected Women (HPV),"Women attending the Aviation General hospital, located in Beijing, China, who were diagnosed with High‑risk human papillomavirus (HR-HPV) infection.",65,71,30 days,16S,34,Illumina,LEfSe,0.05,NA,4,NA,NA,NA,increased,increased,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1029/13/NA,Study 1029,"cross-sectional observational, not case-control",35459771,10.1038/s41598-022-10532-1,NA,"Xu X, Zhang Y, Yu L, Shi X, Min M, Xiong L, Pan J, Liu P, Wu G , Gao G","A cross-sectional analysis about bacterial vaginosis, high-risk human papillomavirus infection, and cervical intraepithelial neoplasia in Chinese women",Scientific reports,2022,NA,Experiment 13,China,Homo sapiens,"Uterine cervix,Vaginal fluid","UBERON:0000002,UBERON:0036243",Vaginal microbiome measurement,EFO:0011013,Normal Healthy Women,Bacterial vaginosis (BV) and High‑risk human papillomavirus (HR-HPV) (HPV) co-infected Women (BH),"Women attending the Aviation General hospital, located in Beijing, China, who were diagnosed with co-infection of Bacterial vaginosis (BV) and High‑risk human papillomavirus (HR-HPV).",65,71,30 days,16S,34,Illumina,LEfSe,0.05,NA,4,NA,NA,NA,increased,increased,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1031/1/NA,Study 1031,case-control,34643448,10.1128/Spectrum.00055-21,NA,"Miller EH, Annavajhala MK, Chong AM, Park H, Nobel YR, Soroush A, Blackett JW, Krigel A, Phipps MM, Freedberg DE, Zucker J, Sano ED, Uhlemann AC , Abrams JA",Oral Microbiome Alterations and SARS-CoV-2 Saliva Viral Load in Patients with COVID-19,Microbiology spectrum,2021,"COVID-19, SARS-CoV-2, saliva microbiome, viral load",Experiment 1,United States of America,Homo sapiens,Saliva,UBERON:0001836,SARS coronavirus,NCBITAXON:694009,Controls,Covid-19,Patients who tested positive for SARS-CoV-2 based on nasopharyngeal swabs and who did not require intensive care at admission.,54,46,None,16S,12,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1031/2/NA,Study 1031,case-control,34643448,10.1128/Spectrum.00055-21,NA,"Miller EH, Annavajhala MK, Chong AM, Park H, Nobel YR, Soroush A, Blackett JW, Krigel A, Phipps MM, Freedberg DE, Zucker J, Sano ED, Uhlemann AC , Abrams JA",Oral Microbiome Alterations and SARS-CoV-2 Saliva Viral Load in Patients with COVID-19,Microbiology spectrum,2021,"COVID-19, SARS-CoV-2, saliva microbiome, viral load",Experiment 2,United States of America,Homo sapiens,Saliva,UBERON:0001836,SARS coronavirus,NCBITAXON:694009,SARS Cov-2 Saliva Negative,SARS Cov-2 Saliva Positive,COVID-19 patients with positive SARS-CoV-2 viral load in saliva,15,28,None,16S,12,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1031/3/NA,Study 1031,case-control,34643448,10.1128/Spectrum.00055-21,NA,"Miller EH, Annavajhala MK, Chong AM, Park H, Nobel YR, Soroush A, Blackett JW, Krigel A, Phipps MM, Freedberg DE, Zucker J, Sano ED, Uhlemann AC , Abrams JA",Oral Microbiome Alterations and SARS-CoV-2 Saliva Viral Load in Patients with COVID-19,Microbiology spectrum,2021,"COVID-19, SARS-CoV-2, saliva microbiome, viral load",Experiment 3,United States of America,Homo sapiens,Saliva,UBERON:0001836,SARS coronavirus,NCBITAXON:694009,SARS Cov-2 Negative,SARS Cov-2 Low Viral Load,Patients who tested positive to SARS Cov-2 with low viral load (CT>30) in saliva,15,14,None,16S,12,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1031/4/NA,Study 1031,case-control,34643448,10.1128/Spectrum.00055-21,NA,"Miller EH, Annavajhala MK, Chong AM, Park H, Nobel YR, Soroush A, Blackett JW, Krigel A, Phipps MM, Freedberg DE, Zucker J, Sano ED, Uhlemann AC , Abrams JA",Oral Microbiome Alterations and SARS-CoV-2 Saliva Viral Load in Patients with COVID-19,Microbiology spectrum,2021,"COVID-19, SARS-CoV-2, saliva microbiome, viral load",Experiment 4,United States of America,Homo sapiens,Saliva,UBERON:0001836,SARS coronavirus,NCBITAXON:694009,SARS-CoV-2 Negative,SARS-CoV-2 High Viral load,Patients who tested positive to SARS-CoV-2 with high (CT<30) viral load in saliva,15,14,None,16S,12,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1032/1/NA,Study 1032,case-control,38183473,10.1007/s00253-023-12845-1,NA,"Jinato T, Anuntakarun S, Satthawiwat N, Chuaypen N , Tangkijvanich P",Distinct alterations of gut microbiota between viral- and non-viral-related hepatocellular carcinoma,Applied microbiology and biotechnology,2024,"16 s rRNA, Biomarker, Gut dysbiosis, HCC, NAFLD, Viral hepatitis",Experiment 1,Thailand,Homo sapiens,Feces,UBERON:0001988,Hepatocellular carcinoma,EFO:0000182,Healthy controls,Patients with Hepatocellular carcinoma (HCC),"patients with viral related hepatocellular carcinoma or non-hepatitis B-, non-hepatitis C-related hepatocellular carcinoma whose diagnosis of HCC was documented by dynamic computed tomography (CT) and/or magnetic resonance imaging (MRI) regarding the clinical guideline of the American Association for the Study of Liver Diseases (AASLD)",16,51,within 2 weeks of fecal sample collection,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1032/2/NA,Study 1032,case-control,38183473,10.1007/s00253-023-12845-1,NA,"Jinato T, Anuntakarun S, Satthawiwat N, Chuaypen N , Tangkijvanich P",Distinct alterations of gut microbiota between viral- and non-viral-related hepatocellular carcinoma,Applied microbiology and biotechnology,2024,"16 s rRNA, Biomarker, Gut dysbiosis, HCC, NAFLD, Viral hepatitis",Experiment 2,Thailand,Homo sapiens,Feces,UBERON:0001988,Hepatitis virus-related hepatocellular carcinoma,EFO:0008505,viral-related Hepatocellular carcinoma,"non-hepatitis B-, non-hepatitis C-related Hepatocellular carcinoma","Patients with non-hepatitis B-, non-hepatitis C-related Hepatocellular carcinoma whose  diagnosis of HCC was documented by dynamic computed tomography (CT) and/or magnetic resonance imaging (MRI) regarding the clinical guideline of the American Association for the Study of Liver Diseases (AASLD)",33,18,within 2 weeks of fecal sample collection,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,decreased,unchanged,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1032/3/NA,Study 1032,case-control,38183473,10.1007/s00253-023-12845-1,NA,"Jinato T, Anuntakarun S, Satthawiwat N, Chuaypen N , Tangkijvanich P",Distinct alterations of gut microbiota between viral- and non-viral-related hepatocellular carcinoma,Applied microbiology and biotechnology,2024,"16 s rRNA, Biomarker, Gut dysbiosis, HCC, NAFLD, Viral hepatitis",Experiment 3,Thailand,Homo sapiens,Feces,UBERON:0001988,Hepatitis virus-related hepatocellular carcinoma,EFO:0008505,viral-related Hepatocellular carcinoma,"non-hepatitis B-, non-hepatitis C-related Hepatocellular carcinoma","Patients with non-hepatitis B-, non-hepatitis C-related Hepatocellular carcinoma whose  diagnosis of HCC was documented by dynamic computed tomography (CT) and/or magnetic resonance imaging (MRI) regarding the clinical guideline of the American Association for the Study of Liver Diseases (AASLD)",33,18,within 2 weeks of fecal sample collection,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,decreased,unchanged,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1032/4/NA,Study 1032,case-control,38183473,10.1007/s00253-023-12845-1,NA,"Jinato T, Anuntakarun S, Satthawiwat N, Chuaypen N , Tangkijvanich P",Distinct alterations of gut microbiota between viral- and non-viral-related hepatocellular carcinoma,Applied microbiology and biotechnology,2024,"16 s rRNA, Biomarker, Gut dysbiosis, HCC, NAFLD, Viral hepatitis",Experiment 4,Thailand,Homo sapiens,Feces,UBERON:0001988,Hepatocellular carcinoma,EFO:0000182,Healthy controls,"non-hepatitis B-, non-hepatitis C-related Hepatocellular carcinoma","Patients with non-hepatitis B-, non-hepatitis C-related Hepatocellular carcinoma whose diagnosis of HCC was documented by dynamic computed tomography (CT) and/or magnetic resonance imaging (MRI) regarding the clinical guideline of the American Association for the Study of Liver Diseases (AASLD)",16,18,within 2 weeks of fecal sample collection,16S,34,Illumina,NA,0.05,NA,NA,NA,NA,NA,decreased,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1032/5/NA,Study 1032,case-control,38183473,10.1007/s00253-023-12845-1,NA,"Jinato T, Anuntakarun S, Satthawiwat N, Chuaypen N , Tangkijvanich P",Distinct alterations of gut microbiota between viral- and non-viral-related hepatocellular carcinoma,Applied microbiology and biotechnology,2024,"16 s rRNA, Biomarker, Gut dysbiosis, HCC, NAFLD, Viral hepatitis",Experiment 5,Thailand,Homo sapiens,Feces,UBERON:0001988,Hepatitis virus-related hepatocellular carcinoma,EFO:0008505,Hepatitis-B virus related Hepatocellular carcinoma,"non-hepatitis B-, non-hepatitis C-related Hepatocellular carcinoma","Patients with non-hepatitis B-, non-hepatitis C-related Hepatocellular carcinoma whose diagnosis of HCC was documented by dynamic computed tomography (CT) and/or magnetic resonance imaging (MRI) regarding the clinical guideline of the American Association for the Study of Liver Diseases (AASLD)",17,18,within 2 weeks of fecal sample collection,16S,34,Illumina,NA,0.05,NA,NA,NA,NA,NA,decreased,unchanged,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1033/1/NA,Study 1033,prospective cohort,36002642,10.1038/s42003-022-03814-x,https://www.nature.com/articles/s42003-022-03814-x,"Yuan L, Yang P, Wei G, Hu X, Chen S, Lu J, Yang L, He X , Bao G",Tumor microbiome diversity influences papillary thyroid cancer invasion,Communications biology,2022,NA,Experiment 1,China,Homo sapiens,Thyroid gland,UBERON:0002046,Papillary thyroid carcinoma,EFO:0000641,PTC patients with mild lesions (T1_2),PTC patients with advanced lesions (T3_4),Papillary thyroid cancer (PTC) patients with advanced lesions.,64,16,NA,16S,34,Illumina,LEfSe,0.05,TRUE,3.2,NA,NA,NA,increased,NA,decreased,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1033/2/NA,Study 1033,prospective cohort,36002642,10.1038/s42003-022-03814-x,https://www.nature.com/articles/s42003-022-03814-x,"Yuan L, Yang P, Wei G, Hu X, Chen S, Lu J, Yang L, He X , Bao G",Tumor microbiome diversity influences papillary thyroid cancer invasion,Communications biology,2022,NA,Experiment 2,China,Homo sapiens,Thyroid gland,UBERON:0002046,Papillary thyroid carcinoma,EFO:0000641,Patients with PTC at clinical stage T1,Patients with PTC at clinical stage T2,Patients with Papillary thyroid cancer (PTC) at clinical stage T2.,35,29,NA,16S,34,Illumina,Welch's T-Test,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1033/3/NA,Study 1033,prospective cohort,36002642,10.1038/s42003-022-03814-x,https://www.nature.com/articles/s42003-022-03814-x,"Yuan L, Yang P, Wei G, Hu X, Chen S, Lu J, Yang L, He X , Bao G",Tumor microbiome diversity influences papillary thyroid cancer invasion,Communications biology,2022,NA,Experiment 3,China,Homo sapiens,Thyroid gland,UBERON:0002046,Papillary thyroid carcinoma,EFO:0000641,Patients with PTC at clinical stage T1,Patients with PTC at clinical stage T3,Patients with Papillary thyroid cancer (PTC) at clinical stage T3.,35,10,NA,16S,34,Illumina,Welch's T-Test,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,decreased,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1033/4/NA,Study 1033,prospective cohort,36002642,10.1038/s42003-022-03814-x,https://www.nature.com/articles/s42003-022-03814-x,"Yuan L, Yang P, Wei G, Hu X, Chen S, Lu J, Yang L, He X , Bao G",Tumor microbiome diversity influences papillary thyroid cancer invasion,Communications biology,2022,NA,Experiment 4,China,Homo sapiens,Thyroid gland,UBERON:0002046,Papillary thyroid carcinoma,EFO:0000641,Patients with PTC at clinical stage T1,Patients with PTC at clinical stage T4,Patients with Papillary thyroid cancer (PTC) at clinical stage T4.,35,6,NA,16S,34,Illumina,Welch's T-Test,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1033/5/NA,Study 1033,prospective cohort,36002642,10.1038/s42003-022-03814-x,https://www.nature.com/articles/s42003-022-03814-x,"Yuan L, Yang P, Wei G, Hu X, Chen S, Lu J, Yang L, He X , Bao G",Tumor microbiome diversity influences papillary thyroid cancer invasion,Communications biology,2022,NA,Experiment 5,China,Homo sapiens,Thyroid gland,UBERON:0002046,Papillary thyroid carcinoma,EFO:0000641,Patients with PTC at clinical stage T2,Patients with PTC at clinical stage T3,Patients with Papillary thyroid cancer (PTC) at clinical stage T3.,29,10,NA,16S,34,Illumina,Welch's T-Test,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,decreased,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1033/6/NA,Study 1033,prospective cohort,36002642,10.1038/s42003-022-03814-x,https://www.nature.com/articles/s42003-022-03814-x,"Yuan L, Yang P, Wei G, Hu X, Chen S, Lu J, Yang L, He X , Bao G",Tumor microbiome diversity influences papillary thyroid cancer invasion,Communications biology,2022,NA,Experiment 6,China,Homo sapiens,Thyroid gland,UBERON:0002046,Papillary thyroid carcinoma,EFO:0000641,Patients with PTC at clinical stage T2,Patients with PTC at clinical stage T4,Patients with Papillary thyroid cancer (PTC) at clinical stage T4.,29,6,NA,16S,34,Illumina,Welch's T-Test,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1033/7/NA,Study 1033,prospective cohort,36002642,10.1038/s42003-022-03814-x,https://www.nature.com/articles/s42003-022-03814-x,"Yuan L, Yang P, Wei G, Hu X, Chen S, Lu J, Yang L, He X , Bao G",Tumor microbiome diversity influences papillary thyroid cancer invasion,Communications biology,2022,NA,Experiment 7,China,Homo sapiens,Thyroid gland,UBERON:0002046,Papillary thyroid carcinoma,EFO:0000641,Patients with PTC at clinical stage T3,Patients with PTC at clinical stage T4,Patients with Papillary thyroid cancer (PTC) at clinical stage T4.,10,6,NA,16S,34,Illumina,Welch's T-Test,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1033/8/NA,Study 1033,prospective cohort,36002642,10.1038/s42003-022-03814-x,https://www.nature.com/articles/s42003-022-03814-x,"Yuan L, Yang P, Wei G, Hu X, Chen S, Lu J, Yang L, He X , Bao G",Tumor microbiome diversity influences papillary thyroid cancer invasion,Communications biology,2022,NA,Experiment 8,China,Homo sapiens,Thyroid gland,UBERON:0002046,Papillary thyroid carcinoma,EFO:0000641,Male Patients with PTC (G1),Female Patients with PTC (G2),Female Patients with Papillary thyroid cancer (PTC),19,61,NA,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,increased,NA,decreased,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1033/9/NA,Study 1033,prospective cohort,36002642,10.1038/s42003-022-03814-x,https://www.nature.com/articles/s42003-022-03814-x,"Yuan L, Yang P, Wei G, Hu X, Chen S, Lu J, Yang L, He X , Bao G",Tumor microbiome diversity influences papillary thyroid cancer invasion,Communications biology,2022,NA,Experiment 9,China,Homo sapiens,Thyroid gland,UBERON:0002046,Hormone,CHEBI:24621,NA,Thyroid-Stimulating Hormone (TSH),The association between Thyroid-Stimulating Hormone (TSH) and different microbial genera in Papillary Thyroid Cancer (PTC) patients.,NA,NA,NA,16S,34,Illumina,Spearman Correlation,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1033/10/NA,Study 1033,prospective cohort,36002642,10.1038/s42003-022-03814-x,https://www.nature.com/articles/s42003-022-03814-x,"Yuan L, Yang P, Wei G, Hu X, Chen S, Lu J, Yang L, He X , Bao G",Tumor microbiome diversity influences papillary thyroid cancer invasion,Communications biology,2022,NA,Experiment 10,China,Homo sapiens,Thyroid gland,UBERON:0002046,Hormone,CHEBI:24621,NA,Triiodothyronine (T3),The association between Triiodothyronine (T3) and different microbial genera in Papillary Thyroid Cancer (PTC) patients.,NA,NA,NA,16S,34,Illumina,Spearman Correlation,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1033/11/NA,Study 1033,prospective cohort,36002642,10.1038/s42003-022-03814-x,https://www.nature.com/articles/s42003-022-03814-x,"Yuan L, Yang P, Wei G, Hu X, Chen S, Lu J, Yang L, He X , Bao G",Tumor microbiome diversity influences papillary thyroid cancer invasion,Communications biology,2022,NA,Experiment 11,China,Homo sapiens,Thyroid gland,UBERON:0002046,Hormone,CHEBI:24621,NA,Thyroxine (T4),The association between Thyroxine (T4) and different microbial genera in Papillary Thyroid Cancer (PTC) patients.,NA,NA,NA,16S,34,Illumina,Spearman Correlation,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1033/12/NA,Study 1033,prospective cohort,36002642,10.1038/s42003-022-03814-x,https://www.nature.com/articles/s42003-022-03814-x,"Yuan L, Yang P, Wei G, Hu X, Chen S, Lu J, Yang L, He X , Bao G",Tumor microbiome diversity influences papillary thyroid cancer invasion,Communications biology,2022,NA,Experiment 12,China,Homo sapiens,Thyroid gland,UBERON:0002046,Hormone,CHEBI:24621,NA,Free Triiodothyronine (FT3),The association between Free Triiodothyronine (FT3) and different microbial genera in Papillary Thyroid Cancer (PTC) patients.,NA,NA,NA,16S,34,Illumina,Spearman Correlation,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1033/13/NA,Study 1033,prospective cohort,36002642,10.1038/s42003-022-03814-x,https://www.nature.com/articles/s42003-022-03814-x,"Yuan L, Yang P, Wei G, Hu X, Chen S, Lu J, Yang L, He X , Bao G",Tumor microbiome diversity influences papillary thyroid cancer invasion,Communications biology,2022,NA,Experiment 13,China,Homo sapiens,Thyroid gland,UBERON:0002046,Hormone,CHEBI:24621,NA,Free Thyroxine (FT4),The association between Free Thyroxine (FT4) and different microbial genera in Papillary Thyroid Cancer (PTC) patients.,NA,NA,NA,16S,34,Illumina,Spearman Correlation,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1033/14/NA,Study 1033,prospective cohort,36002642,10.1038/s42003-022-03814-x,https://www.nature.com/articles/s42003-022-03814-x,"Yuan L, Yang P, Wei G, Hu X, Chen S, Lu J, Yang L, He X , Bao G",Tumor microbiome diversity influences papillary thyroid cancer invasion,Communications biology,2022,NA,Experiment 14,China,Homo sapiens,Thyroid gland,UBERON:0002046,Antibody,EFO:0000264,NA,Anti-thyroid-stimulating receptors (Anti-TSHR),The association between Anti-thyroid-stimulating receptors (Anti-TSHR) and microbial abundance in Papillary Thyroid Cancer (PTC) patients.,NA,NA,NA,16S,34,Illumina,Spearman Correlation,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1033/15/NA,Study 1033,prospective cohort,36002642,10.1038/s42003-022-03814-x,https://www.nature.com/articles/s42003-022-03814-x,"Yuan L, Yang P, Wei G, Hu X, Chen S, Lu J, Yang L, He X , Bao G",Tumor microbiome diversity influences papillary thyroid cancer invasion,Communications biology,2022,NA,Experiment 15,China,Homo sapiens,Thyroid gland,UBERON:0002046,Antibody,EFO:0000264,NA,Anti-thyroid peroxidase (Anti-TPO),The association between Anti-thyroid peroxidase (Anti-TPO) and microbial abundance in Papillary Thyroid Cancer (PTC) patients.,NA,NA,NA,16S,34,Illumina,Spearman Correlation,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1033/16/NA,Study 1033,prospective cohort,36002642,10.1038/s42003-022-03814-x,https://www.nature.com/articles/s42003-022-03814-x,"Yuan L, Yang P, Wei G, Hu X, Chen S, Lu J, Yang L, He X , Bao G",Tumor microbiome diversity influences papillary thyroid cancer invasion,Communications biology,2022,NA,Experiment 16,China,Homo sapiens,Thyroid gland,UBERON:0002046,Antibody,EFO:0000264,NA,Anti-thyroglobulin (Anti-TG),The association between Anti-thyroglobulin (Anti-TG) and microbial abundance in Papillary Thyroid Cancer (PTC) patients.,NA,NA,NA,16S,34,Illumina,Spearman Correlation,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1033/17/NA,Study 1033,prospective cohort,36002642,10.1038/s42003-022-03814-x,https://www.nature.com/articles/s42003-022-03814-x,"Yuan L, Yang P, Wei G, Hu X, Chen S, Lu J, Yang L, He X , Bao G",Tumor microbiome diversity influences papillary thyroid cancer invasion,Communications biology,2022,NA,Experiment 17,China,Homo sapiens,Thyroid gland,UBERON:0002046,Hormone,CHEBI:24621,NA,Triiodothyronine (T3),The association between Triiodothyronine (T3) and different microbial genera in Papillary Thyroid Cancer (PTC) patients in the validation set.,NA,NA,NA,16S,34,Illumina,Spearman Correlation,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1033/18/NA,Study 1033,prospective cohort,36002642,10.1038/s42003-022-03814-x,https://www.nature.com/articles/s42003-022-03814-x,"Yuan L, Yang P, Wei G, Hu X, Chen S, Lu J, Yang L, He X , Bao G",Tumor microbiome diversity influences papillary thyroid cancer invasion,Communications biology,2022,NA,Experiment 18,China,Homo sapiens,Thyroid gland,UBERON:0002046,Hormone,CHEBI:24621,NA,Free Triiodothyronine (FT3),The association between Free Triiodothyronine (FT3) and different microbial genera in Papillary Thyroid Cancer (PTC) patients in the validation set.,NA,NA,NA,16S,34,Illumina,Spearman Correlation,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1033/19/NA,Study 1033,prospective cohort,36002642,10.1038/s42003-022-03814-x,https://www.nature.com/articles/s42003-022-03814-x,"Yuan L, Yang P, Wei G, Hu X, Chen S, Lu J, Yang L, He X , Bao G",Tumor microbiome diversity influences papillary thyroid cancer invasion,Communications biology,2022,NA,Experiment 19,China,Homo sapiens,Thyroid gland,UBERON:0002046,Hormone,CHEBI:24621,NA,Free Thyroxine (FT4),The association between Free Thyroxine (FT4) and different microbial genera in Papillary Thyroid Cancer (PTC) patients in the validation set.,NA,NA,NA,16S,34,Illumina,Spearman Correlation,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1033/20/NA,Study 1033,prospective cohort,36002642,10.1038/s42003-022-03814-x,https://www.nature.com/articles/s42003-022-03814-x,"Yuan L, Yang P, Wei G, Hu X, Chen S, Lu J, Yang L, He X , Bao G",Tumor microbiome diversity influences papillary thyroid cancer invasion,Communications biology,2022,NA,Experiment 20,China,Homo sapiens,Thyroid gland,UBERON:0002046,Antibody,EFO:0000264,NA,Anti-thyroid-stimulating receptors (Anti-TSHR),The association between Anti-thyroid-stimulating receptors (Anti-TSHR) and microbial abundance in Papillary Thyroid Cancer (PTC) patients in the validation set.,NA,NA,NA,16S,34,Illumina,Spearman Correlation,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1033/21/NA,Study 1033,prospective cohort,36002642,10.1038/s42003-022-03814-x,https://www.nature.com/articles/s42003-022-03814-x,"Yuan L, Yang P, Wei G, Hu X, Chen S, Lu J, Yang L, He X , Bao G",Tumor microbiome diversity influences papillary thyroid cancer invasion,Communications biology,2022,NA,Experiment 21,China,Homo sapiens,Thyroid gland,UBERON:0002046,Antibody,EFO:0000264,NA,Anti-thyroid peroxidase (Anti-TPO),The association between Anti-thyroid peroxidase (Anti-TPO) and microbial abundance in Papillary Thyroid Cancer (PTC) patients in the validation set.,NA,NA,NA,16S,34,Illumina,Spearman Correlation,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1034/1/NA,Study 1034,"cross-sectional observational, not case-control",34930922,10.1038/s41522-021-00261-0,NA,"Ng S, Chen M, Kundu S, Wang X, Zhou Z, Zheng Z, Qing W, Sheng H, Wang Y, He Y, Bennett PR, MacIntyre DA , Zhou H",Large-scale characterisation of the pregnancy vaginal microbiome and sialidase activity in a low-risk Chinese population,NPJ biofilms and microbiomes,2021,NA,Experiment 1,China,Homo sapiens,Posterior fornix of vagina,UBERON:0016486,Birth measurement,EFO:0006921,Low vaginal sialidase activity,High vaginal sialidase activity,"Women with high vaginal sialidase activity, which is often associated with bacterial vaginosis (BV)",783,36,Within 30 days,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,increased,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1034/2/NA,Study 1034,"cross-sectional observational, not case-control",34930922,10.1038/s41522-021-00261-0,NA,"Ng S, Chen M, Kundu S, Wang X, Zhou Z, Zheng Z, Qing W, Sheng H, Wang Y, He Y, Bennett PR, MacIntyre DA , Zhou H",Large-scale characterisation of the pregnancy vaginal microbiome and sialidase activity in a low-risk Chinese population,NPJ biofilms and microbiomes,2021,NA,Experiment 2,China,Homo sapiens,Posterior fornix of vagina,UBERON:0016486,Birth measurement,EFO:0006921,Leukocyte low (grades I-II),Leukocyte high (grades III-IV),Vaginal microbiota of women  with Leukocyte high (grades III-IV),783,36,Within 30 days,16S,4,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1035/1/NA,Study 1035,case-control,28793309,https://doi.org/10.1371/journal.pntd.0005826,NA,"Adebayo AS, Suryavanshi MV, Bhute S, Agunloye AM, Isokpehi RD, Anumudu CI , Shouche YS",The microbiome in urogenital schistosomiasis and induced bladder pathologies,PLoS neglected tropical diseases,2017,NA,Experiment 1,Nigeria,Homo sapiens,Urine,UBERON:0001088,Urinary schistosomiasis,EFO:0007530,Healthy Control,Infection-Only,Urine samples infected with urogenital schistosomiasis,13,25,Recent use of Antibiotics,16S,3,Ion Torrent,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1035/2/NA,Study 1035,case-control,28793309,https://doi.org/10.1371/journal.pntd.0005826,NA,"Adebayo AS, Suryavanshi MV, Bhute S, Agunloye AM, Isokpehi RD, Anumudu CI , Shouche YS",The microbiome in urogenital schistosomiasis and induced bladder pathologies,PLoS neglected tropical diseases,2017,NA,Experiment 2,Nigeria,Homo sapiens,Urine,UBERON:0001088,Urinary schistosomiasis,EFO:0007530,Healthy Control,Advanced,Urine samples infected with urogenital schistosomiasis induced bladder pathology.,13,22,Recent use of Antibiotics,16S,3,Ion Torrent,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1035/3/NA,Study 1035,case-control,28793309,https://doi.org/10.1371/journal.pntd.0005826,NA,"Adebayo AS, Suryavanshi MV, Bhute S, Agunloye AM, Isokpehi RD, Anumudu CI , Shouche YS",The microbiome in urogenital schistosomiasis and induced bladder pathologies,PLoS neglected tropical diseases,2017,NA,Experiment 3,Nigeria,Homo sapiens,Urine,UBERON:0001088,Urinary schistosomiasis,EFO:0007530,Non-Infected,Infected,Infected with urogenital schistosomiasis,24,46,Recent use of Antibiotics,16S,3,Ion Torrent,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1035/4/NA,Study 1035,case-control,28793309,https://doi.org/10.1371/journal.pntd.0005826,NA,"Adebayo AS, Suryavanshi MV, Bhute S, Agunloye AM, Isokpehi RD, Anumudu CI , Shouche YS",The microbiome in urogenital schistosomiasis and induced bladder pathologies,PLoS neglected tropical diseases,2017,NA,Experiment 4,Nigeria,Homo sapiens,Urine,UBERON:0001088,Urinary schistosomiasis,EFO:0007530,Pathology only,Advanced,Urogenital schistosomiasis induced bladder pathology.,10,22,Recent use of Antibiotics,16S,3,Ion Torrent,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1035/5/NA,Study 1035,case-control,28793309,https://doi.org/10.1371/journal.pntd.0005826,NA,"Adebayo AS, Suryavanshi MV, Bhute S, Agunloye AM, Isokpehi RD, Anumudu CI , Shouche YS",The microbiome in urogenital schistosomiasis and induced bladder pathologies,PLoS neglected tropical diseases,2017,NA,Experiment 5,Nigeria,Homo sapiens,Urine,UBERON:0001088,Urinary schistosomiasis,EFO:0007530,Infection Only,Advanced,urogenital schistosomiasis induced bladder pathology.,25,22,Recent use of Antibiotics,16S,3,Ion Torrent,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1035/6/NA,Study 1035,case-control,28793309,https://doi.org/10.1371/journal.pntd.0005826,NA,"Adebayo AS, Suryavanshi MV, Bhute S, Agunloye AM, Isokpehi RD, Anumudu CI , Shouche YS",The microbiome in urogenital schistosomiasis and induced bladder pathologies,PLoS neglected tropical diseases,2017,NA,Experiment 6,Nigeria,Homo sapiens,Urine,UBERON:0001088,Urinary schistosomiasis,EFO:0007530,Pathology Only,Infection Only,Urogenital schistosomiasis infection,10,25,Recent use of Antibiotics,16S,3,Ion Torrent,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1035/7/NA,Study 1035,case-control,28793309,https://doi.org/10.1371/journal.pntd.0005826,NA,"Adebayo AS, Suryavanshi MV, Bhute S, Agunloye AM, Isokpehi RD, Anumudu CI , Shouche YS",The microbiome in urogenital schistosomiasis and induced bladder pathologies,PLoS neglected tropical diseases,2017,NA,Experiment 7,Nigeria,Homo sapiens,Urine,UBERON:0001088,Urinary schistosomiasis,EFO:0007530,Non-Infected,Infected,Not infected with urogenital schistosomiasis.,24,46,Recent use of Antibiotics,16S,3,Ion Torrent,LEfSe,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1036/1/NA,Study 1036,laboratory experiment,34568329,10.3389/fcell.2021.716760,NA,"Wang Q, Yi S, Su G, Du Z, Pan S, Huang X, Cao Q, Yuan G, Kijlstra A , Yang P",Changes in the Gut Microbiome Contribute to the Development of Behcet's Disease <i>via</i> Adjuvant Effects,Frontiers in cell and developmental biology,2021,"Behcet’s disease, T cells, autoimmune disease, fecal transplantation, gut microbiome, neutrophils",Experiment 1,China,Mus musculus,Feces,UBERON:0001988,Behcet's syndrome,EFO:0003780,Healthy controls-recipient mice,Behcet's disease-recipient mice,Mice colonized by fecal microbial transplantation (FMT) from Behcet's disease patients,5,5,1 month,16S,34,Illumina,LEfSe,0.05,TRUE,2,"age,sex",NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1037/1/NA,Study 1037,case-control,33552996,10.3389/fcimb.2020.557515,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7859112/,"Li H, Chen J, Ren X, Yang C, Liu S, Bai X, Shan S , Dong X",Gut Microbiota Composition Changes in Constipated Women of Reproductive Age,Frontiers in cellular and infection microbiology,2020,"16S rRNA gene sequencing, chronic constipation, gut microbiota, influence factors, women of reproductive age",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Chronic constipation,HP:0012450,Healthy women,Constipated women,Female constipated patients of reproductive age.,30,29,One month preceding sample collection.,16S,34,Illumina,LEfSe,0.05,TRUE,4,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1038/1/NA,Study 1038,time series / longitudinal observational,36249017,10.3389/fonc.2022.1005537,NA,"Zeber-Lubecka N, Kulecka M, Lindner B, Krynicki R, Paziewska A, Nowakowski A, Bidzinski M , Ostrowski J",Increased diversity of a cervical microbiome associates with cervical cancer,Frontiers in oncology,2022,"16S rRNA gene sequencing, cervical microbiome, chemoradiation therapy, lactobacillus, postmenopause",Experiment 1,Poland,Homo sapiens,Uterine cervix,UBERON:0000002,Response to radiation,GO:0009314,Premenopausal healthy controls (HPV Negative women),Premenopausal Pre-treatment group,"Women, aged 25–54 years, with squamous cell carcinoma of the cervix who were indicated for primary Radiation therapy(RT), and their samples collected a day before starting external beam radiation therapy (EBRT).",15,6,2 months,16S,23456789,Ion Torrent,ANCOM,0.05,TRUE,NA,NA,NA,NA,increased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1038/2/NA,Study 1038,time series / longitudinal observational,36249017,10.3389/fonc.2022.1005537,NA,"Zeber-Lubecka N, Kulecka M, Lindner B, Krynicki R, Paziewska A, Nowakowski A, Bidzinski M , Ostrowski J",Increased diversity of a cervical microbiome associates with cervical cancer,Frontiers in oncology,2022,"16S rRNA gene sequencing, cervical microbiome, chemoradiation therapy, lactobacillus, postmenopause",Experiment 2,Poland,Homo sapiens,Uterine cervix,UBERON:0000002,Response to radiation,GO:0009314,Postmenopausal healthy controls (HPV Negative women),Postmenopausal Pre-treatment group,"Women, aged 54–62 years, with squamous cell carcinoma of the cervix who were indicated for primary Radiation therapy(RT), and their samples collected a day before starting external beam radiation therapy (EBRT).",15,10,2 months,16S,23456789,Ion Torrent,ANCOM,0.05,TRUE,NA,NA,NA,NA,increased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1038/3/NA,Study 1038,time series / longitudinal observational,36249017,10.3389/fonc.2022.1005537,NA,"Zeber-Lubecka N, Kulecka M, Lindner B, Krynicki R, Paziewska A, Nowakowski A, Bidzinski M , Ostrowski J",Increased diversity of a cervical microbiome associates with cervical cancer,Frontiers in oncology,2022,"16S rRNA gene sequencing, cervical microbiome, chemoradiation therapy, lactobacillus, postmenopause",Experiment 3,Poland,Homo sapiens,Uterine cervix,UBERON:0000002,Response to radiation,GO:0009314,Premenopausal healthy controls (HPV Negative women),Premenopausal Post-treatment group,"Women, aged 25–54 years, with squamous cell carcinoma of the cervix who were indicated for primary Radiation therapy(RT), and their samples collected immediately after the last fraction of brachytherapy (ICBT) was given.",15,6,2 months,16S,23456789,Ion Torrent,ANCOM,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1038/4/NA,Study 1038,time series / longitudinal observational,36249017,10.3389/fonc.2022.1005537,NA,"Zeber-Lubecka N, Kulecka M, Lindner B, Krynicki R, Paziewska A, Nowakowski A, Bidzinski M , Ostrowski J",Increased diversity of a cervical microbiome associates with cervical cancer,Frontiers in oncology,2022,"16S rRNA gene sequencing, cervical microbiome, chemoradiation therapy, lactobacillus, postmenopause",Experiment 4,Poland,Homo sapiens,Uterine cervix,UBERON:0000002,Response to radiation,GO:0009314,Postmenopausal healthy controls (HPV Negative women),Postmenopausal Post-treatment group,"Women, aged 54–62 years, with squamous cell carcinoma of the cervix who were indicated for primary Radiation therapy(RT), and their samples collected immediately after the last fraction of brachytherapy (ICBT) was given.",15,10,2 months,16S,23456789,Ion Torrent,ANCOM,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1038/5/NA,Study 1038,time series / longitudinal observational,36249017,10.3389/fonc.2022.1005537,NA,"Zeber-Lubecka N, Kulecka M, Lindner B, Krynicki R, Paziewska A, Nowakowski A, Bidzinski M , Ostrowski J",Increased diversity of a cervical microbiome associates with cervical cancer,Frontiers in oncology,2022,"16S rRNA gene sequencing, cervical microbiome, chemoradiation therapy, lactobacillus, postmenopause",Experiment 5,Poland,Homo sapiens,Uterine cervix,UBERON:0000002,Response to radiation,GO:0009314,Pre-treatment group,Post-treatment group,"Women with squamous cell carcinoma of the cervix who were indicated for primary Radiation therapy(RT), and their samples collected immediately after the last fraction of brachytherapy (ICBT) was given.",15,15,2 months,16S,23456789,Ion Torrent,ANCOM,0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1038/6/NA,Study 1038,time series / longitudinal observational,36249017,10.3389/fonc.2022.1005537,NA,"Zeber-Lubecka N, Kulecka M, Lindner B, Krynicki R, Paziewska A, Nowakowski A, Bidzinski M , Ostrowski J",Increased diversity of a cervical microbiome associates with cervical cancer,Frontiers in oncology,2022,"16S rRNA gene sequencing, cervical microbiome, chemoradiation therapy, lactobacillus, postmenopause",Experiment 6,Poland,Homo sapiens,Uterine cervix,UBERON:0000002,Response to radiation,GO:0009314,Pre-treatment group,3-months post treatment group (follow-up samples),"Women with squamous cell carcinoma of the cervix who were indicated for primary Radiation therapy(RT), 3 months after the last fraction of brachytherapy (ICBT) was given.",15,9,2 months,16S,23456789,Ion Torrent,ANCOM,0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1039/1/NA,Study 1039,"cross-sectional observational, not case-control",38643180,10.1038/s41467-024-46265-0,NA,"Ramaboli MC, Ocvirk S, Khan Mirzaei M, Eberhart BL, Valdivia-Garcia M, Metwaly A, Neuhaus K, Barker G, Ru J, Nesengani LT, Mahdi-Joest D, Wilson AS, Joni SK, Layman DC, Zheng J, Mandal R, Chen Q, Perez MR, Fortuin S, Gaunt B, Wishart D, Methé B, Haller D, Li JV, Deng L, Swart R , O'Keefe SJD",Diet changes due to urbanization in South Africa are linked to microbiome and metabolome signatures of Westernization and colorectal cancer,Nature communications,2024,NA,Experiment 1,South Africa,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,Rural Xhosa Cohort,Urban Xhosa Cohort,People from Urban Xhosa of South Africa transitioning from traditional high-fiber to Western diets,21,20,6 weeks,16S,NA,Illumina,LEfSe,0.05,TRUE,3,NA,NA,NA,decreased,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1039/3/NA,Study 1039,"cross-sectional observational, not case-control",38643180,10.1038/s41467-024-46265-0,NA,"Ramaboli MC, Ocvirk S, Khan Mirzaei M, Eberhart BL, Valdivia-Garcia M, Metwaly A, Neuhaus K, Barker G, Ru J, Nesengani LT, Mahdi-Joest D, Wilson AS, Joni SK, Layman DC, Zheng J, Mandal R, Chen Q, Perez MR, Fortuin S, Gaunt B, Wishart D, Methé B, Haller D, Li JV, Deng L, Swart R , O'Keefe SJD",Diet changes due to urbanization in South Africa are linked to microbiome and metabolome signatures of Westernization and colorectal cancer,Nature communications,2024,NA,Experiment 3,South Africa,Homo sapiens,Ingested food,UBERON:0012112,Diet,EFO:0002755,Frozen food samples from rural Xhosa households,Frozen food samples from urban Xhosa households,Frozen food samples collected from representative households of urban Xhosa of South Africa,7,6,6 weeks,16S,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1039/4/NA,Study 1039,"cross-sectional observational, not case-control",38643180,10.1038/s41467-024-46265-0,NA,"Ramaboli MC, Ocvirk S, Khan Mirzaei M, Eberhart BL, Valdivia-Garcia M, Metwaly A, Neuhaus K, Barker G, Ru J, Nesengani LT, Mahdi-Joest D, Wilson AS, Joni SK, Layman DC, Zheng J, Mandal R, Chen Q, Perez MR, Fortuin S, Gaunt B, Wishart D, Methé B, Haller D, Li JV, Deng L, Swart R , O'Keefe SJD",Diet changes due to urbanization in South Africa are linked to microbiome and metabolome signatures of Westernization and colorectal cancer,Nature communications,2024,NA,Experiment 4,South Africa,Homo sapiens,Manual digit skin,UBERON:0003533,Diet,EFO:0002755,Rural Xhosa Cohort,Urban Xhosa Cohort,Hand skin swabs from urban Xhosa cohort of South Africa,7,6,Oral or I.V antibiotic therapy within the last 6 weeks,16S,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1040/1/NA,Study 1040,case-control,37158877,10.1186/s12866-023-02872-3,NA,"Wei N, Zhu G, Zhao T, Wang Y, Lou H, Li H, Yang Z, Zhang Z, Wang Q, Han M, Lin Z , Li S",Characterization of oral bacterial and fungal microbiome in recovered COVID-19 patients,BMC microbiology,2023,"COVID-19, Oral bacteria, Oral fungi, Recovered patients, Virus clearance",Experiment 1,China,Homo sapiens,Throat,UBERON:0000341,COVID-19,MONDO:0100096,HCs (Healthy Controls),RPs (Recovered Patients),This group consists of patients who have recovered from COVID-19.,29,23,6 months,16S,34,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1041/1/NA,Study 1041,"cross-sectional observational, not case-control",37409975,10.1128/spectrum.04596-22,NA,"Pratap Singh R, Kumari N, Gupta S, Jaiswal R, Mehrotra D, Singh S, Mukherjee S , Kumar R",Intratumoral Microbiota Changes with Tumor Stage and Influences the Immune Signature of Oral Squamous Cell Carcinoma,Microbiology spectrum,2023,"OSCC, biomarker, inflammation, microbiome, tumor microenvironment",Experiment 1,India,Homo sapiens,Mouth,UBERON:0000165,Oral cavity carcinoma,MONDO:0044925,Adjacent normal tissue (AT),Tumor tissue (TT) samples,Tumor tissue (TT) specimens were obtained from the inner part of the tumor,20,NA,N/A,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1041/2/NA,Study 1041,"cross-sectional observational, not case-control",37409975,10.1128/spectrum.04596-22,NA,"Pratap Singh R, Kumari N, Gupta S, Jaiswal R, Mehrotra D, Singh S, Mukherjee S , Kumar R",Intratumoral Microbiota Changes with Tumor Stage and Influences the Immune Signature of Oral Squamous Cell Carcinoma,Microbiology spectrum,2023,"OSCC, biomarker, inflammation, microbiome, tumor microenvironment",Experiment 2,India,Homo sapiens,Mouth,UBERON:0000165,Oral cavity carcinoma,MONDO:0044925,Adjacent normal tissue (AT),Precancer,"Precancerous lesion samples were collected from patients with leukoplakia, fibrosis, and
erythroplakia.",20,15,N/A,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1041/3/NA,Study 1041,"cross-sectional observational, not case-control",37409975,10.1128/spectrum.04596-22,NA,"Pratap Singh R, Kumari N, Gupta S, Jaiswal R, Mehrotra D, Singh S, Mukherjee S , Kumar R",Intratumoral Microbiota Changes with Tumor Stage and Influences the Immune Signature of Oral Squamous Cell Carcinoma,Microbiology spectrum,2023,"OSCC, biomarker, inflammation, microbiome, tumor microenvironment",Experiment 3,India,Homo sapiens,Mouth,UBERON:0000165,Oral cavity carcinoma,MONDO:0044925,Precancer,Early Stage Cancer,Cancer Samples subdivided into T1 and T2,20,30,N/A,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1041/4/NA,Study 1041,"cross-sectional observational, not case-control",37409975,10.1128/spectrum.04596-22,NA,"Pratap Singh R, Kumari N, Gupta S, Jaiswal R, Mehrotra D, Singh S, Mukherjee S , Kumar R",Intratumoral Microbiota Changes with Tumor Stage and Influences the Immune Signature of Oral Squamous Cell Carcinoma,Microbiology spectrum,2023,"OSCC, biomarker, inflammation, microbiome, tumor microenvironment",Experiment 4,India,Homo sapiens,Mouth,UBERON:0000165,Oral cavity carcinoma,MONDO:0044925,Precancer,Late Stage Cancer,Cancer Samples subdivided into T3 and T4,20,30,N/A,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1041/5/NA,Study 1041,"cross-sectional observational, not case-control",37409975,10.1128/spectrum.04596-22,NA,"Pratap Singh R, Kumari N, Gupta S, Jaiswal R, Mehrotra D, Singh S, Mukherjee S , Kumar R",Intratumoral Microbiota Changes with Tumor Stage and Influences the Immune Signature of Oral Squamous Cell Carcinoma,Microbiology spectrum,2023,"OSCC, biomarker, inflammation, microbiome, tumor microenvironment",Experiment 5,India,Homo sapiens,Mouth,UBERON:0000165,Oral cavity carcinoma,MONDO:0044925,Precancer,Cancer,Participants at different stages of disease pathogenesis (T1 to T4).,15,60,N/A,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1041/6/NA,Study 1041,"cross-sectional observational, not case-control",37409975,10.1128/spectrum.04596-22,NA,"Pratap Singh R, Kumari N, Gupta S, Jaiswal R, Mehrotra D, Singh S, Mukherjee S , Kumar R",Intratumoral Microbiota Changes with Tumor Stage and Influences the Immune Signature of Oral Squamous Cell Carcinoma,Microbiology spectrum,2023,"OSCC, biomarker, inflammation, microbiome, tumor microenvironment",Experiment 6,India,Homo sapiens,Mouth,UBERON:0000165,Oral cavity carcinoma,MONDO:0044925,Early Stage Cancer,Late Stage Cancer,Cancer Samples subdivided into T3 and T4,30,30,N/A,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1041/7/NA,Study 1041,"cross-sectional observational, not case-control",37409975,10.1128/spectrum.04596-22,NA,"Pratap Singh R, Kumari N, Gupta S, Jaiswal R, Mehrotra D, Singh S, Mukherjee S , Kumar R",Intratumoral Microbiota Changes with Tumor Stage and Influences the Immune Signature of Oral Squamous Cell Carcinoma,Microbiology spectrum,2023,"OSCC, biomarker, inflammation, microbiome, tumor microenvironment",Experiment 7,India,Homo sapiens,Mouth,UBERON:0000165,Oral cavity carcinoma,MONDO:0044925,Precancer,T1,Early Stage Cancer Patients grouped as T1,15,15,N/A,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1041/8/NA,Study 1041,"cross-sectional observational, not case-control",37409975,10.1128/spectrum.04596-22,NA,"Pratap Singh R, Kumari N, Gupta S, Jaiswal R, Mehrotra D, Singh S, Mukherjee S , Kumar R",Intratumoral Microbiota Changes with Tumor Stage and Influences the Immune Signature of Oral Squamous Cell Carcinoma,Microbiology spectrum,2023,"OSCC, biomarker, inflammation, microbiome, tumor microenvironment",Experiment 8,India,Homo sapiens,Mouth,UBERON:0000165,Oral cavity carcinoma,MONDO:0044925,Precancer,T2,Early Stage Cancer Patients grouped as T2,15,15,N/A,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1041/9/NA,Study 1041,"cross-sectional observational, not case-control",37409975,10.1128/spectrum.04596-22,NA,"Pratap Singh R, Kumari N, Gupta S, Jaiswal R, Mehrotra D, Singh S, Mukherjee S , Kumar R",Intratumoral Microbiota Changes with Tumor Stage and Influences the Immune Signature of Oral Squamous Cell Carcinoma,Microbiology spectrum,2023,"OSCC, biomarker, inflammation, microbiome, tumor microenvironment",Experiment 9,India,Homo sapiens,Mouth,UBERON:0000165,Oral cavity carcinoma,MONDO:0044925,Precancer,T3,Late Stage Cancer Patients grouped as T3,15,15,N/A,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1041/10/NA,Study 1041,"cross-sectional observational, not case-control",37409975,10.1128/spectrum.04596-22,NA,"Pratap Singh R, Kumari N, Gupta S, Jaiswal R, Mehrotra D, Singh S, Mukherjee S , Kumar R",Intratumoral Microbiota Changes with Tumor Stage and Influences the Immune Signature of Oral Squamous Cell Carcinoma,Microbiology spectrum,2023,"OSCC, biomarker, inflammation, microbiome, tumor microenvironment",Experiment 10,India,Homo sapiens,Mouth,UBERON:0000165,Oral cavity carcinoma,MONDO:0044925,Precancer,T4,Late Stage Cancer Patients grouped as T4,15,15,N/A,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1041/11/NA,Study 1041,"cross-sectional observational, not case-control",37409975,10.1128/spectrum.04596-22,NA,"Pratap Singh R, Kumari N, Gupta S, Jaiswal R, Mehrotra D, Singh S, Mukherjee S , Kumar R",Intratumoral Microbiota Changes with Tumor Stage and Influences the Immune Signature of Oral Squamous Cell Carcinoma,Microbiology spectrum,2023,"OSCC, biomarker, inflammation, microbiome, tumor microenvironment",Experiment 11,India,Homo sapiens,Mouth,UBERON:0000165,Oral cavity carcinoma,MONDO:0044925,T1,T3,Late Stage Cancer Patients grouped as T3,15,15,N/A,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1041/12/NA,Study 1041,"cross-sectional observational, not case-control",37409975,10.1128/spectrum.04596-22,NA,"Pratap Singh R, Kumari N, Gupta S, Jaiswal R, Mehrotra D, Singh S, Mukherjee S , Kumar R",Intratumoral Microbiota Changes with Tumor Stage and Influences the Immune Signature of Oral Squamous Cell Carcinoma,Microbiology spectrum,2023,"OSCC, biomarker, inflammation, microbiome, tumor microenvironment",Experiment 12,India,Homo sapiens,Mouth,UBERON:0000165,Oral cavity carcinoma,MONDO:0044925,T2,T4,Late Stage Cancer Patients grouped as T4,15,15,N/A,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1041/13/NA,Study 1041,"cross-sectional observational, not case-control",37409975,10.1128/spectrum.04596-22,NA,"Pratap Singh R, Kumari N, Gupta S, Jaiswal R, Mehrotra D, Singh S, Mukherjee S , Kumar R",Intratumoral Microbiota Changes with Tumor Stage and Influences the Immune Signature of Oral Squamous Cell Carcinoma,Microbiology spectrum,2023,"OSCC, biomarker, inflammation, microbiome, tumor microenvironment",Experiment 13,India,Homo sapiens,Mouth,UBERON:0000165,Oral cavity carcinoma,MONDO:0044925,T3,T4,Late Stage Cancer Patients grouped as T4,15,15,N/A,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1042/1/NA,Study 1042,laboratory experiment,33557825,10.1186/s12936-021-03606-4,NA,"Omoke D, Kipsum M, Otieno S, Esalimba E, Sheth M, Lenhart A, Njeru EM, Ochomo E , Dada N",Western Kenyan Anopheles gambiae showing intense permethrin resistance harbour distinct microbiota,Malaria journal,2021,"16S rRNA gene amplicon sequencing, Anopheles gambiae s.s., Insecticide resistance, Metabarcoding, Mosquito microbiome, Mosquito microbiota, pyrethroid resistance",Experiment 1,Kenya,Anopheles gambiae,Body proper,UBERON:0013702,Insecticide,CHEBI:24852,permethrin susceptible mosquito,permethrin resistant mosquito,Mosquitoes that were alive after the bioassay with permethrin insecticide were categorized as resistant,36,39,NA,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1043/1/NA,Study 1043,time series / longitudinal observational,34336719,10.3389/fcimb.2021.695515,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317457/,"Li S, Zhu J, Su B, Wei H, Chen F, Liu H, Wei J, Yang X, Zhang Q, Xia W, Wu H, He Q , Zhang T",Alteration in Oral Microbiome Among Men Who Have Sex With Men With Acute and Chronic HIV Infection on Antiretroviral Therapy,Frontiers in cellular and infection microbiology,2021,"16S rRNA sequencing, antiretroviral therapy, human immunodeficiency virus, men who have sex with men, oral microbiome",Experiment 1,China,Homo sapiens,Throat,UBERON:0000341,Human immunodeficiency virus,NCBITAXON:12721,HIV-uninfected MSM -  controls (D),Acute HIV-infected participants at baseline (A0),Men who have sex with men (MSM) with acute HIV infection at baseline (A0).,15,15,Participants who had used antibiotics within the previous 4 weeks were excluded,16S,45,Illumina,T-Test,0.05,NA,NA,NA,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1043/2/NA,Study 1043,time series / longitudinal observational,34336719,10.3389/fcimb.2021.695515,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317457/,"Li S, Zhu J, Su B, Wei H, Chen F, Liu H, Wei J, Yang X, Zhang Q, Xia W, Wu H, He Q , Zhang T",Alteration in Oral Microbiome Among Men Who Have Sex With Men With Acute and Chronic HIV Infection on Antiretroviral Therapy,Frontiers in cellular and infection microbiology,2021,"16S rRNA sequencing, antiretroviral therapy, human immunodeficiency virus, men who have sex with men, oral microbiome",Experiment 2,China,Homo sapiens,Throat,UBERON:0000341,Human immunodeficiency virus,NCBITAXON:12721,HIV-uninfected MSM -  controls (D),Chronic HIV-infected participants at baseline (B0),Men who have sex with men (MSM) with Chronic HIV infection at baseline (B0).,15,15,Participants who had used antibiotics within the previous 4 weeks were excluded,16S,45,Illumina,T-Test,0.05,NA,NA,NA,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1043/3/NA,Study 1043,time series / longitudinal observational,34336719,10.3389/fcimb.2021.695515,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317457/,"Li S, Zhu J, Su B, Wei H, Chen F, Liu H, Wei J, Yang X, Zhang Q, Xia W, Wu H, He Q , Zhang T",Alteration in Oral Microbiome Among Men Who Have Sex With Men With Acute and Chronic HIV Infection on Antiretroviral Therapy,Frontiers in cellular and infection microbiology,2021,"16S rRNA sequencing, antiretroviral therapy, human immunodeficiency virus, men who have sex with men, oral microbiome",Experiment 3,China,Homo sapiens,Throat,UBERON:0000341,Human immunodeficiency virus,NCBITAXON:12721,HIV-uninfected MSM -  controls (D),Acute HIV-infected participants (A12),Men who have sex with men (MSM) with Acute HIV infection after 12 weeks of Antiretroviral Therapy (ART).,15,15,Participants who had used antibiotics within the previous 4 weeks were excluded,16S,45,Illumina,LEfSe,0.05,NA,2,NA,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1043/4/NA,Study 1043,time series / longitudinal observational,34336719,10.3389/fcimb.2021.695515,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317457/,"Li S, Zhu J, Su B, Wei H, Chen F, Liu H, Wei J, Yang X, Zhang Q, Xia W, Wu H, He Q , Zhang T",Alteration in Oral Microbiome Among Men Who Have Sex With Men With Acute and Chronic HIV Infection on Antiretroviral Therapy,Frontiers in cellular and infection microbiology,2021,"16S rRNA sequencing, antiretroviral therapy, human immunodeficiency virus, men who have sex with men, oral microbiome",Experiment 4,China,Homo sapiens,Throat,UBERON:0000341,Human immunodeficiency virus,NCBITAXON:12721,HIV-uninfected MSM -  controls (D),Chronic HIV-infected participants (B12),Men who have sex with men (MSM) with Chronic HIV infection after 12 weeks of Antiretroviral Therapy (ART).,15,15,Participants who had used antibiotics within the previous 4 weeks were excluded,16S,45,Illumina,LEfSe,0.05,NA,2,NA,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1043/5/NA,Study 1043,time series / longitudinal observational,34336719,10.3389/fcimb.2021.695515,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317457/,"Li S, Zhu J, Su B, Wei H, Chen F, Liu H, Wei J, Yang X, Zhang Q, Xia W, Wu H, He Q , Zhang T",Alteration in Oral Microbiome Among Men Who Have Sex With Men With Acute and Chronic HIV Infection on Antiretroviral Therapy,Frontiers in cellular and infection microbiology,2021,"16S rRNA sequencing, antiretroviral therapy, human immunodeficiency virus, men who have sex with men, oral microbiome",Experiment 5,China,Homo sapiens,Throat,UBERON:0000341,Human immunodeficiency virus,NCBITAXON:12721,Acute HIV-infected participants at baseline (A0),Acute HIV-infected participants on Antiretroviral Therapy (A12),Men who have sex with men (MSM) with Acute HIV infection after 12 weeks of Antiretroviral Therapy (ART).,15,15,Participants who had used antibiotics within the previous 4 weeks were excluded,16S,45,Illumina,LEfSe,0.05,NA,2,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1043/6/NA,Study 1043,time series / longitudinal observational,34336719,10.3389/fcimb.2021.695515,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317457/,"Li S, Zhu J, Su B, Wei H, Chen F, Liu H, Wei J, Yang X, Zhang Q, Xia W, Wu H, He Q , Zhang T",Alteration in Oral Microbiome Among Men Who Have Sex With Men With Acute and Chronic HIV Infection on Antiretroviral Therapy,Frontiers in cellular and infection microbiology,2021,"16S rRNA sequencing, antiretroviral therapy, human immunodeficiency virus, men who have sex with men, oral microbiome",Experiment 6,China,Homo sapiens,Throat,UBERON:0000341,Human immunodeficiency virus,NCBITAXON:12721,Chronic HIV-infected participants at baseline (B0),Chronic HIV-infected participants on Antiretroviral Therapy(B12),Men who have sex with men (MSM) with Chronic HIV infection after 12 weeks of Antiretroviral Therapy (ART).,15,15,Participants who had used antibiotics within the previous 4 weeks were excluded,16S,45,Illumina,LEfSe,0.05,NA,2,NA,NA,NA,unchanged,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1043/7/NA,Study 1043,time series / longitudinal observational,34336719,10.3389/fcimb.2021.695515,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317457/,"Li S, Zhu J, Su B, Wei H, Chen F, Liu H, Wei J, Yang X, Zhang Q, Xia W, Wu H, He Q , Zhang T",Alteration in Oral Microbiome Among Men Who Have Sex With Men With Acute and Chronic HIV Infection on Antiretroviral Therapy,Frontiers in cellular and infection microbiology,2021,"16S rRNA sequencing, antiretroviral therapy, human immunodeficiency virus, men who have sex with men, oral microbiome",Experiment 7,China,Homo sapiens,Throat,UBERON:0000341,Human immunodeficiency virus,NCBITAXON:12721,Acute HIV-infected participants at baseline (A0),Chronic HIV-infected participants at baseline (B0),Men who have sex with men (MSM) with Chronic HIV infection.,15,15,Participants who had used antibiotics within the previous 4 weeks were excluded,16S,45,Illumina,T-Test,0.05,NA,NA,NA,NA,NA,unchanged,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1043/8/NA,Study 1043,time series / longitudinal observational,34336719,10.3389/fcimb.2021.695515,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317457/,"Li S, Zhu J, Su B, Wei H, Chen F, Liu H, Wei J, Yang X, Zhang Q, Xia W, Wu H, He Q , Zhang T",Alteration in Oral Microbiome Among Men Who Have Sex With Men With Acute and Chronic HIV Infection on Antiretroviral Therapy,Frontiers in cellular and infection microbiology,2021,"16S rRNA sequencing, antiretroviral therapy, human immunodeficiency virus, men who have sex with men, oral microbiome",Experiment 8,China,Homo sapiens,Throat,UBERON:0000341,Human immunodeficiency virus,NCBITAXON:12721,Acute HIV-infected participants on Antiretroviral Therapy(A12),Chronic HIV-infected participants on Antiretroviral Therapy(B12),Men who have sex with men (MSM) with Chronic HIV infection after 12 weeks of Antiretroviral Therapy (ART).,15,15,Participants who had used antibiotics within the previous 4 weeks were excluded,16S,45,Illumina,T-Test,0.05,NA,NA,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1043/9/NA,Study 1043,time series / longitudinal observational,34336719,10.3389/fcimb.2021.695515,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317457/,"Li S, Zhu J, Su B, Wei H, Chen F, Liu H, Wei J, Yang X, Zhang Q, Xia W, Wu H, He Q , Zhang T",Alteration in Oral Microbiome Among Men Who Have Sex With Men With Acute and Chronic HIV Infection on Antiretroviral Therapy,Frontiers in cellular and infection microbiology,2021,"16S rRNA sequencing, antiretroviral therapy, human immunodeficiency virus, men who have sex with men, oral microbiome",Experiment 9,China,Homo sapiens,Throat,UBERON:0000341,Human immunodeficiency virus,NCBITAXON:12721,Uninfected Controls,CD4+ T cells < 200 cells/mm3,Subjects whose CD4+ T cells were defined as < 200 cells/mm3.,15,NA,Participants who had used antibiotics within the previous 4 weeks were excluded,16S,45,Illumina,T-Test,0.05,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1043/10/NA,Study 1043,time series / longitudinal observational,34336719,10.3389/fcimb.2021.695515,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317457/,"Li S, Zhu J, Su B, Wei H, Chen F, Liu H, Wei J, Yang X, Zhang Q, Xia W, Wu H, He Q , Zhang T",Alteration in Oral Microbiome Among Men Who Have Sex With Men With Acute and Chronic HIV Infection on Antiretroviral Therapy,Frontiers in cellular and infection microbiology,2021,"16S rRNA sequencing, antiretroviral therapy, human immunodeficiency virus, men who have sex with men, oral microbiome",Experiment 10,China,Homo sapiens,Throat,UBERON:0000341,Human immunodeficiency virus,NCBITAXON:12721,Uninfected Controls,CD4+ T cells > 200 cells/mm3,Subjects whose CD4+ T cells were defined as > 200 cells/mm3.,15,NA,Participants who had used antibiotics within the previous 4 weeks were excluded,16S,45,Illumina,T-Test,0.05,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1043/11/NA,Study 1043,time series / longitudinal observational,34336719,10.3389/fcimb.2021.695515,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317457/,"Li S, Zhu J, Su B, Wei H, Chen F, Liu H, Wei J, Yang X, Zhang Q, Xia W, Wu H, He Q , Zhang T",Alteration in Oral Microbiome Among Men Who Have Sex With Men With Acute and Chronic HIV Infection on Antiretroviral Therapy,Frontiers in cellular and infection microbiology,2021,"16S rRNA sequencing, antiretroviral therapy, human immunodeficiency virus, men who have sex with men, oral microbiome",Experiment 11,China,Homo sapiens,Throat,UBERON:0000341,Human immunodeficiency virus,NCBITAXON:12721,CD4+ T cells < 200 cells/mm3,CD4+ T cells > 200 cells/mm3,Subjects whose CD4+ T cells were defined as > 200 cells/mm3.,NA,NA,Participants who had used antibiotics within the previous 4 weeks were excluded,16S,45,Illumina,T-Test,0.05,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1044/1/NA,Study 1044,"cross-sectional observational, not case-control",35416686,https://doi.org/10.1128/spectrum.00344-21,NA,"Su J, Li CX, Liu HY, Lian QY, Chen A, You ZX, Li K, Cai YH, Lin YX, Pan JB, Zhang GX, Ju CR, You CX , He JX",The Airway Microbiota Signatures of Infection and Rejection in Lung Transplant Recipients,Microbiology spectrum,2022,"16S rRNA, airway microbiota, infection, lung transplant, rejection",Experiment 1,China,Homo sapiens,Sputum,UBERON:0007311,Lung transplantation,EFO:0010721,Clinically stable (or event-free) recipients,Recipients with infection,Lung transplant recipients (LTRs) with infection,47,103,None,16S,34,Illumina,LEfSe,0.05,TRUE,4,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1044/2/NA,Study 1044,"cross-sectional observational, not case-control",35416686,https://doi.org/10.1128/spectrum.00344-21,NA,"Su J, Li CX, Liu HY, Lian QY, Chen A, You ZX, Li K, Cai YH, Lin YX, Pan JB, Zhang GX, Ju CR, You CX , He JX",The Airway Microbiota Signatures of Infection and Rejection in Lung Transplant Recipients,Microbiology spectrum,2022,"16S rRNA, airway microbiota, infection, lung transplant, rejection",Experiment 2,China,Homo sapiens,Sputum,UBERON:0007311,Lung transplantation,EFO:0010721,Clinically stable (or event-free) recipients,Recipients with rejection,Lung transplant recipients (LTRs) with rejection,47,31,None,16S,34,Illumina,LEfSe,0.05,TRUE,4,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1044/3/NA,Study 1044,"cross-sectional observational, not case-control",35416686,https://doi.org/10.1128/spectrum.00344-21,NA,"Su J, Li CX, Liu HY, Lian QY, Chen A, You ZX, Li K, Cai YH, Lin YX, Pan JB, Zhang GX, Ju CR, You CX , He JX",The Airway Microbiota Signatures of Infection and Rejection in Lung Transplant Recipients,Microbiology spectrum,2022,"16S rRNA, airway microbiota, infection, lung transplant, rejection",Experiment 3,China,Homo sapiens,Sputum,UBERON:0007311,Lung transplantation,EFO:0010721,Recipients with infection,Recipients with rejection,Lung transplant recipients (LTRs) with rejection,103,31,None,16S,34,Illumina,LEfSe,0.05,TRUE,4,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1045/1/NA,Study 1045,prospective cohort,33407119,https://doi.org/10.1186/s12866-020-02056-3,NA,"Lu ZH, Liu YW, Ji ZH, Fu T, Yan M, Shao ZJ , Long Y",Alterations in the intestinal microbiome and mental health status of workers in an underground tunnel environment,BMC microbiology,2021,"16S rRNA, Brain-gut-microbiota axis, Gut microbiome, Mental distress, Underground tunnel environment",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Gut microbiome measurement,EFO:0007874,Workers before entry into an underground tunnel (Baseline status (BS)),Workers after entry into an underground tunnel (Exposed status (ES)),Tunnel workers who spent 3 (three) weeks working in the underground tunnel.,48,48,NA,16S,45,Illumina,LEfSe,0.05,FALSE,3.5,NA,NA,NA,decreased,unchanged,decreased,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1046/1/NA,Study 1046,case-control,38383483,doi: 10.1186/s40168-024-01758-4.,https://microbiomejournal.biomedcentral.com/articles/10.1186/s40168-024-01758-4,"Singh S, Giron LB, Shaikh MW, Shankaran S, Engen PA, Bogin ZR, Bambi SA, Goldman AR, Azevedo JLLC, Orgaz L, de Pedro N, González P, Giera M, Verhoeven A, Sánchez-López E, Pandrea I, Kannan T, Tanes CE, Bittinger K, Landay AL, Corley MJ, Keshavarzian A , Abdel-Mohsen M",Distinct intestinal microbial signatures linked to accelerated systemic and intestinal biological aging,Microbiome,2024,"Aging clocks, Biological aging, Gut, HIV, Intestines, Metabolome, Microbiome",Experiment 1,United States of America,Homo sapiens,Colon,UBERON:0001155,Aging,GO:0007568,PLWOH,PLWH on ART,People living with HIV(PLWH) on Anti-Retroviral Therapy(ART),23,25,Not stated,16S,12,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,"age,body mass index,ethnic group,sex",NA,NA,decreased,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1046/2/NA,Study 1046,case-control,38383483,doi: 10.1186/s40168-024-01758-4.,https://microbiomejournal.biomedcentral.com/articles/10.1186/s40168-024-01758-4,"Singh S, Giron LB, Shaikh MW, Shankaran S, Engen PA, Bogin ZR, Bambi SA, Goldman AR, Azevedo JLLC, Orgaz L, de Pedro N, González P, Giera M, Verhoeven A, Sánchez-López E, Pandrea I, Kannan T, Tanes CE, Bittinger K, Landay AL, Corley MJ, Keshavarzian A , Abdel-Mohsen M",Distinct intestinal microbial signatures linked to accelerated systemic and intestinal biological aging,Microbiome,2024,"Aging clocks, Biological aging, Gut, HIV, Intestines, Metabolome, Microbiome",Experiment 2,United States of America,Homo sapiens,Ileum,UBERON:0002116,Aging,GO:0007568,PLWOH,PLWH on ART,People living with HIV(PLWH) on Anti-Retroviral Therapy(ART),23,25,Not stated,16S,12,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,"age,body mass index,ethnic group,sex",NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1046/3/NA,Study 1046,case-control,38383483,doi: 10.1186/s40168-024-01758-4.,https://microbiomejournal.biomedcentral.com/articles/10.1186/s40168-024-01758-4,"Singh S, Giron LB, Shaikh MW, Shankaran S, Engen PA, Bogin ZR, Bambi SA, Goldman AR, Azevedo JLLC, Orgaz L, de Pedro N, González P, Giera M, Verhoeven A, Sánchez-López E, Pandrea I, Kannan T, Tanes CE, Bittinger K, Landay AL, Corley MJ, Keshavarzian A , Abdel-Mohsen M",Distinct intestinal microbial signatures linked to accelerated systemic and intestinal biological aging,Microbiome,2024,"Aging clocks, Biological aging, Gut, HIV, Intestines, Metabolome, Microbiome",Experiment 3,United States of America,Homo sapiens,Feces,UBERON:0001988,Aging,GO:0007568,PLWOH,PLWH on ART,People living with HIV(PLWH) on Anti-Retroviral Therapy (ART),23,25,Not stated,16S,12,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,"age,body mass index,ethnic group,sex",NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1046/4/NA,Study 1046,case-control,38383483,doi: 10.1186/s40168-024-01758-4.,https://microbiomejournal.biomedcentral.com/articles/10.1186/s40168-024-01758-4,"Singh S, Giron LB, Shaikh MW, Shankaran S, Engen PA, Bogin ZR, Bambi SA, Goldman AR, Azevedo JLLC, Orgaz L, de Pedro N, González P, Giera M, Verhoeven A, Sánchez-López E, Pandrea I, Kannan T, Tanes CE, Bittinger K, Landay AL, Corley MJ, Keshavarzian A , Abdel-Mohsen M",Distinct intestinal microbial signatures linked to accelerated systemic and intestinal biological aging,Microbiome,2024,"Aging clocks, Biological aging, Gut, HIV, Intestines, Metabolome, Microbiome",Experiment 4,United States of America,Homo sapiens,"Colon,Feces","UBERON:0001155,UBERON:0001988",Aging,GO:0007568,Samples of PLWOH,Samples PLWH on ART,Colon vs fecal samples of People living with HIV on ART,23,25,Not stated,16S,12,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,"age,body mass index,ethnic group,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1046/5/NA,Study 1046,case-control,38383483,doi: 10.1186/s40168-024-01758-4.,https://microbiomejournal.biomedcentral.com/articles/10.1186/s40168-024-01758-4,"Singh S, Giron LB, Shaikh MW, Shankaran S, Engen PA, Bogin ZR, Bambi SA, Goldman AR, Azevedo JLLC, Orgaz L, de Pedro N, González P, Giera M, Verhoeven A, Sánchez-López E, Pandrea I, Kannan T, Tanes CE, Bittinger K, Landay AL, Corley MJ, Keshavarzian A , Abdel-Mohsen M",Distinct intestinal microbial signatures linked to accelerated systemic and intestinal biological aging,Microbiome,2024,"Aging clocks, Biological aging, Gut, HIV, Intestines, Metabolome, Microbiome",Experiment 5,United States of America,Homo sapiens,"Ileum,Feces","UBERON:0002116,UBERON:0001988",Aging,GO:0007568,Samples of PLWOH,Samples of PLWH on ART,Ileum vs Feces of people living with HIV on ART,23,25,Not stated,16S,12,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,"age,body mass index,ethnic group,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1047/1/NA,Study 1047,laboratory experiment,38378622,10.1186/s40168-024-01756-6,https://pubmed.ncbi.nlm.nih.gov/38378622/,"Hao W, Ma Q, Wang L, Yuan N, Gan H, He L, Li X, Huang J , Chen J",Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3,Microbiome,2024,"Complement C3, Depression, Fecal microbiota transplantation, Gut microbiota, Microglia, Synaptic pruning",Experiment 1,China,Mus musculus,Feces,UBERON:0001988,Major depressive disorder,MONDO:0002009,Control group,CUMS group,Mice group induced with chronic unpredictable mild stress (CUMS) for 8 weeks.,6,6,NA,16S,34,NA,LEfSe,0.05,NA,4,NA,NA,NA,decreased,decreased,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1047/2/NA,Study 1047,laboratory experiment,38378622,10.1186/s40168-024-01756-6,https://pubmed.ncbi.nlm.nih.gov/38378622/,"Hao W, Ma Q, Wang L, Yuan N, Gan H, He L, Li X, Huang J , Chen J",Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3,Microbiome,2024,"Complement C3, Depression, Fecal microbiota transplantation, Gut microbiota, Microglia, Synaptic pruning",Experiment 2,China,Mus musculus,Feces,UBERON:0001988,Major depressive disorder,MONDO:0002009,Control group,CUMS + XYS group,"Mice group induced with chronic unpredictable mild stress (CUMS) for 8 weeks, followed by daily oral administration of XYS.",6,6,NA,16S,34,NA,LEfSe,0.05,NA,4,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1047/3/NA,Study 1047,laboratory experiment,38378622,10.1186/s40168-024-01756-6,https://pubmed.ncbi.nlm.nih.gov/38378622/,"Hao W, Ma Q, Wang L, Yuan N, Gan H, He L, Li X, Huang J , Chen J",Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3,Microbiome,2024,"Complement C3, Depression, Fecal microbiota transplantation, Gut microbiota, Microglia, Synaptic pruning",Experiment 3,China,Mus musculus,Feces,UBERON:0001988,Major depressive disorder,MONDO:0002009,Control group,CUMS + FLX group,"Mice group induced with chronic unpredictable mild stress (CUMS) for 8 weeks, followed by daily oral administration of FLX.",6,6,NA,16S,34,NA,LEfSe,0.05,NA,4,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1047/4/NA,Study 1047,laboratory experiment,38378622,10.1186/s40168-024-01756-6,https://pubmed.ncbi.nlm.nih.gov/38378622/,"Hao W, Ma Q, Wang L, Yuan N, Gan H, He L, Li X, Huang J , Chen J",Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3,Microbiome,2024,"Complement C3, Depression, Fecal microbiota transplantation, Gut microbiota, Microglia, Synaptic pruning",Experiment 4,China,Mus musculus,Feces,UBERON:0001988,Major depressive disorder,MONDO:0002009,CUMS group,CUMS + XYS group,"Mice group induced with chronic unpredictable mild stress (CUMS) for 8 weeks, followed by daily oral administration of XYS.",6,6,NA,16S,34,NA,LEfSe,0.05,NA,4,NA,NA,NA,increased,increased,increased,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1047/5/NA,Study 1047,laboratory experiment,38378622,10.1186/s40168-024-01756-6,https://pubmed.ncbi.nlm.nih.gov/38378622/,"Hao W, Ma Q, Wang L, Yuan N, Gan H, He L, Li X, Huang J , Chen J",Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3,Microbiome,2024,"Complement C3, Depression, Fecal microbiota transplantation, Gut microbiota, Microglia, Synaptic pruning",Experiment 5,China,Mus musculus,Feces,UBERON:0001988,Major depressive disorder,MONDO:0002009,CUMS group,CUMS + FLX group,"Mice group induced with chronic unpredictable mild stress (CUMS) for 8 weeks, followed by daily oral administration of FLX.",6,6,NA,16S,34,NA,LEfSe,0.05,NA,4,NA,NA,NA,increased,increased,increased,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1047/6/NA,Study 1047,laboratory experiment,38378622,10.1186/s40168-024-01756-6,https://pubmed.ncbi.nlm.nih.gov/38378622/,"Hao W, Ma Q, Wang L, Yuan N, Gan H, He L, Li X, Huang J , Chen J",Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3,Microbiome,2024,"Complement C3, Depression, Fecal microbiota transplantation, Gut microbiota, Microglia, Synaptic pruning",Experiment 6,China,Mus musculus,Feces,UBERON:0001988,Major depressive disorder,MONDO:0002009,CUMS + XYS group,CUMS + FLX group,"Mice group induced with chronic unpredictable mild stress (CUMS) for 8 weeks, followed by daily oral administration of FLX.",6,6,NA,16S,34,NA,LEfSe,0.05,NA,4,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1047/7/NA,Study 1047,laboratory experiment,38378622,10.1186/s40168-024-01756-6,https://pubmed.ncbi.nlm.nih.gov/38378622/,"Hao W, Ma Q, Wang L, Yuan N, Gan H, He L, Li X, Huang J , Chen J",Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3,Microbiome,2024,"Complement C3, Depression, Fecal microbiota transplantation, Gut microbiota, Microglia, Synaptic pruning",Experiment 7,China,Mus musculus,Feces,UBERON:0001988,Major depressive disorder,MONDO:0002009,Control group,CUMS,Mice group induced with chronic unpredictable mild stress (CUMS) for 8 weeks.,6,6,NA,16S,34,NA,LEfSe,0.05,NA,4,NA,NA,NA,decreased,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1047/8/NA,Study 1047,laboratory experiment,38378622,10.1186/s40168-024-01756-6,https://pubmed.ncbi.nlm.nih.gov/38378622/,"Hao W, Ma Q, Wang L, Yuan N, Gan H, He L, Li X, Huang J , Chen J",Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3,Microbiome,2024,"Complement C3, Depression, Fecal microbiota transplantation, Gut microbiota, Microglia, Synaptic pruning",Experiment 8,China,Mus musculus,Feces,UBERON:0001988,Major depressive disorder,MONDO:0002009,Control group,Control + FMT(CUMS) group,"Mice group with no stress stimulation for 8 weeks, followed by daily FMT (feces from CUMS group in the first experiment.",6,6,NA,16S,34,NA,LEfSe,0.05,NA,4,NA,NA,NA,decreased,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1047/9/NA,Study 1047,laboratory experiment,38378622,10.1186/s40168-024-01756-6,https://pubmed.ncbi.nlm.nih.gov/38378622/,"Hao W, Ma Q, Wang L, Yuan N, Gan H, He L, Li X, Huang J , Chen J",Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3,Microbiome,2024,"Complement C3, Depression, Fecal microbiota transplantation, Gut microbiota, Microglia, Synaptic pruning",Experiment 9,China,Mus musculus,Feces,UBERON:0001988,Major depressive disorder,MONDO:0002009,Control group,CUMS + FMT(XYS) group,"Mice group induced with chronic unpredictable mild stress (CUMS) for 8 weeks, followed by daily FMT (feces from CUMS + XYS group in the first experiment) for 4 weeks.",6,6,NA,16S,34,NA,LEfSe,0.05,NA,4,NA,NA,NA,decreased,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1047/10/NA,Study 1047,laboratory experiment,38378622,10.1186/s40168-024-01756-6,https://pubmed.ncbi.nlm.nih.gov/38378622/,"Hao W, Ma Q, Wang L, Yuan N, Gan H, He L, Li X, Huang J , Chen J",Gut dysbiosis induces the development of depression-like behavior through abnormal synapse pruning in microglia-mediated by complement C3,Microbiome,2024,"Complement C3, Depression, Fecal microbiota transplantation, Gut microbiota, Microglia, Synaptic pruning",Experiment 10,China,Mus musculus,Feces,UBERON:0001988,Major depressive disorder,MONDO:0002009,CUMS group,CUMS + FMT(XYS) group,"Mice group induced with chronic unpredictable mild stress (CUMS) for 8 weeks, followed by daily FMT (feces from CUMS + XYS group in the first experiment) for 4 weeks.",6,6,NA,16S,34,NA,LEfSe,0.05,NA,4,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/1/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 1,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P1) at 0 hour,Spiked pig feces(P1) at 64 hours (-80°C),P1 sample spiked with a mock community and stored at a temperature of -80°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,decreased,NA,decreased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/2/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 2,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P1) at 0 hour,Spiked pig feces(P1) at 64 hours (22°C),P1 sample spiked with a mock community and stored at a temperature of 22°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,increased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/3/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 3,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P1) at 0 hour,Spiked pig feces(P1) at 64 hours (5°C),P1 sample spiked with a mock community and stored at a temperature of 5°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,decreased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/4/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 4,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P1) at 0 hour,Spiked pig feces(P1) at 64 hours (-20°C),P1 sample spiked with a mock community and stored at a temperature of -20°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,decreased,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/5/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 5,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P1) at 0 hour,Spiked pig feces(P1) at 16 hours (-80°C),P1 sample spiked with a mock community and stored at a temperature of -80°C for 16 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,increased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/6/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 6,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P1) at 0 hour,Spiked pig feces(P1) at 16 hours (5°C),P1 samplespiked with a mock community and stored at a temperature of 5°C for 16 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,unchanged,NA,decreased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/7/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 7,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P1) at 0 hour,Spiked pig feces(P1) at 16 hours (22°C),P1 sample spiked with a mock community and stored at a temperature of 22°C for 16 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/8/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 8,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P1) at 0 hour,Spiked pig feces(P1) at 16 hours (-20°C),P1 sample spiked with a mock community and stored at a temperature of -20°C for 16 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,decreased,NA,increased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/9/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 9,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P1) at 16 hours (-80°C),Spiked pig feces(P1) at 64 hours (22°C),P1 sample spiked with a mock community and stored at a temperature of 64 hours (22°C),1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,decreased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/10/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 10,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P1) at 16 hours (-80°C),Spiked pig feces(P1) at 64 hours (-80°C),P1 sample spiked with a mock community and stored at a temperature of 64 hours (-80°C),1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,decreased,NA,increased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/11/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 11,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P1) at 16 hours (-80°C),Spiked pig feces(P1) at 64 hours (-20°C),P1 samplespiked with a mock community and  stored at a temperature of 64 hours (-20°C),1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,unchanged,NA,increased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/12/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 12,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P1) at 16 hours (-80°C),Spiked pig feces(P1) at 16 hours (-20°C),P1 sample spiked with a mock community and stored at a temperature of 16 hours (-20°C),1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,unchanged,NA,increased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/13/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 13,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P1) at 16 hours (-80°C),Spiked pig feces(P1) at 64 hours (5°C),P1 sample spiked with a mock community and stored at a temperature of 64 hours (5°C),1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,decreased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/14/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 14,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P1) at 16 hours (-80°C),Spiked pig feces(P1) at 16 hours (22°C),P1 sample spiked with a mock community and stored at a temperature of 16 hours (22°C),1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/15/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 15,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P1) at 16 hours (-80°C),Spiked pig feces(P1) at 16 hours (5°C),P1 sample spiked with a mock community and stored at a temperature of 16 hours (5°C),1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,unchanged,NA,decreased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/16/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 16,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P1) at 64 hours (-80°C),Spiked pig feces(P1) at 16 hours (5°C),P1 sample spiked with a mock community and stored at a temperature of 16 hours (5°C),1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,unchanged,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/17/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 17,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P1) at 64 hours (-80°C),Spiked pig feces(P1) at 16 hours (22°C),P1 sample spiked with a mock community and stored at a temperature of 16 hours (22°C),1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/18/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 18,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P1) at 64 hours (-80°C),Spiked pig feces(P1) at 64 hours (22°C),P1 sample spiked with a mock community and stored at a temperature of 64 hours (22°C),1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,decreased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/19/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 19,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P1) at 16 hours (5°C),Spiked pig feces(P1) at 64 hours (22°C),P1 sample spiked with a mock community and  stored at a temperature of 64 hours (22°C),1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,decreased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/20/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 20,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P1) at 16 hours (-20°C),Spiked pig feces(P1) at 64 hours (22°C),P1 sample spiked with a mock community and  stored at a temperature of 64 hours (22°C),1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/21/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 21,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P1) at 64 hours (22°C),Spiked pig feces(P1) at 64 hours (5°C),P1 sample spiked with a mock community and stored at a temperature of 64 hours (5°C),1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,unchanged,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/22/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 22,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P1) at 64 hours (-20°C),Spiked pig feces(P1) at 64 hours (22°C),P1 sample spiked with a mock community and  stored at a temperature of 64 hours (22°C),1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,decreased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/23/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 23,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P1) at 16 hours (22°C),Spiked pig feces(P1) at 64 hours (-20°C),P1 sample spiked with a mock community and stored at a temperature of 64 hours (-20°C),1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/24/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 24,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P1) at 16 hours (-80°C),Spiked pig feces(P1) at 16 hours (22°C),P1 sample spiked with a mock community and stored at a temperature of 16 hours (22°C),1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/25/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 25,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P1) at 16 hours (-20°C),Spiked pig feces(P1) at 16 hours (22°C),P1 sample spiked with a mock community and  stored at a temperature of 16 hours (22°C),1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,decreased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/26/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 26,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P1) at 64 hours (-20°C),Spiked pig feces(P1) at 64 hours (5°C),P1 sample spiked with a mock community and stored at a temperature of 64 hours (5°C),1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,decreased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/27/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 27,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P1) at 64 hours (-80°C),Spiked pig feces(P1) at 64 hours (5°C),P1 sample spiked with a mock community and  stored at a temperature of 64 hours (5°C),1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,decreased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/28/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 28,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P1) at 16 hours (-20°C),Spiked pig feces(P1) at 64 hours (5°C),P1 sample spiked with a mock community and stored at a temperature of 64 hours (5°C),1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,decreased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/29/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 29,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P1) at 16 hours (5°C),Spiked pig feces(P1) at 64 hours (-20°C),P1 sample spiked with a mock community and stored at a temperature of 64 hours (-20°C),1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/30/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 30,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P1) at 64 hours (-80°C),Spiked pig feces(P1) at 16 hours (-20°C),P1 sample spiked with a mock community and stored at a temperature of 16 hours (-20°C),1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/31/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 31,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P1) at 64 hours (-80°C),Spiked pig feces(P1) at 64 hours (-20°C),P1 sample spiked with a mock community and stored at a temperature of 64 hours (-20°C),1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,unchanged,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/32/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 32,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P1) at 16 hours (-20°C),Spiked pig feces(P1) at 64 hours (-20°C),P1 sample spiked with a mock community and stored at a temperature of 64 hours (-20°C),1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,decreased,NA,increased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/33/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 33,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P1) at 0 hour,Unspiked pig feces(P1) at 16 hours (-80°C),Unspiked P1 sample stored at a temperature of -80°C for 16 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,decreased,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/34/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 34,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P1) at 0 hour,Unspiked pig feces(P1) at 64 hours (-80°C),Unspiked P1 sample stored at a temperature of -80°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,decreased,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/35/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 35,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P1) at 0 hour,Unspiked pig feces(P1) at 16 hours (-20°C),Unspiked P1 sample stored at a temperature of -20°C for 16 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,decreased,NA,increased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/36/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 36,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P1) at 0 hour,Unspiked pig feces(P1) at 64 hours (-20°C),Unspiked P1 sample stored at a temperature of -20°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,decreased,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/37/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 37,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P1) at 0 hour,Unspiked pig feces(P1) at 16 hours (5°C),Unspiked P1 sample stored at a temperature of 5°C for 16 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,unchanged,NA,increased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/38/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 38,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P1) at 0 hour,Unspiked pig feces(P1) at 64 hours (5°C),Unspiked P1 sample stored at a temperature of 5°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,unchanged,NA,unchanged,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/39/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 39,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P1) at 0 hour,Unspiked pig feces(P1) at 16 hours (22°C),Unspiked P1 sample stored at a temperature of 22°C for 16 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,unchanged,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/40/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 40,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P1) at 0 hour,Unspiked pig feces(P1) at 64 hours (22°C),Unspiked P1 sample stored at a temperature of 22°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/41/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 41,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P1) at 16 hours (-80°C),Unspiked pig feces(P1) at 64 hours (-80°C),Unspiked P1 sample stored at a temperature of -80°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,unchanged,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/42/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 42,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P1) at 16 hours (-80°C),Unspiked pig feces(P1) at 16 hours (-20°C),Unspiked P1 sample stored at a temperature of -20°C for 16 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,unchanged,NA,increased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/43/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 43,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P1) at 16 hours (-80°C),Unspiked pig feces(P1) at 64 hours (-20°C),Unspiked P1 sample stored at a temperature of -20°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,unchanged,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/44/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 44,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P1) at 16 hours (-80°C),Unspiked pig feces(P1) at 16 hours (5°C),Unspiked P1 sample stored at a temperature of 5°C for 16 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/45/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 45,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P1) at 16 hours (-80°C),Unspiked pig feces(P1) at 64 hours (5°C),Unspiked P1 sample stored at a temperature of 5°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/46/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 46,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P1) at 16 hours (-80°C),Unspiked pig feces(P1) at 16 hours (22°C),Unspiked P1 sample stored at a temperature of 22°C for 16 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/47/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 47,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P1) at 16 hours (-80°C),Unspiked pig feces(P1) at 64 hours (22°C),Unspiked P1 sample stored at a temperature of 22°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/48/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 48,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P1) at 64 hours (-80°C),Unspiked pig feces(P1) at 16 hours (-20°C),Unspiked P1 sample stored at a temperature of -20°C for 16 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,unchanged,NA,increased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/49/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 49,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P1) at 64 hours (-80°C),Unspiked pig feces(P1) at 64 hours (-20°C),Unspiked P1 sample stored at a temperature of -20°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,unchanged,NA,increased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/50/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 50,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P1) at 64 hours (-80°C),Unspiked pig feces(P1) at 16 hours (5°C),Unspiked P1 sample stored at a temperature of 5°C for 16 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/51/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 51,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P1) at 64 hours (-80°C),Unspiked pig feces(P1) at 64 hours (5°C),Unspiked P1 sample stored at a temperature of 5°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/52/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 52,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P1) at 64 hours (-80°C),Unspiked pig feces(P1) at 16 hours (22°C),Unspiked P1 sample stored at a temperature of 22°C for 16 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/53/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 53,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P1) at 64 hours (-80°C),Unspiked pig feces(P1) at 64 hours (22°C),Unspiked P1 sample stored at a temperature of 22°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/54/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 54,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P1) at 16 hours (-20°C),Unspiked pig feces(P1) at 64 hours (-20°C),Unspiked P1 sample stored at a temperature of -20°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,unchanged,NA,decreased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/55/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 55,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P1) at 16 hours (-20°C),Unspiked pig feces(P1) at 16 hours (5°C),Unspiked P1 sample stored at a temperature of 5°C for 16 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/56/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 56,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P1) at 16 hours (-20°C),Unspiked pig feces(P1) at 64 hours (5°C),Unspiked P1 sample stored at a temperature of 5°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,decreased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/57/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 57,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P1) at 16 hours (-20°C),Unspiked pig feces(P1) at 16 hours (22°C),Unspiked P1 sample stored at a temperature of 22°C for 16 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,decreased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/58/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 58,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P1) at 16 hours (-20°C),Unspiked pig feces(P1) at 64 hours (22°C),Unspiked P1 sample stored at a temperature of 22°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,decreased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/59/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 59,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P1) at 16 hours (5°C),Spiked pig feces(P1) at 64 hours (5°C),P1 samplespiked with a mock community and stored at a temperature of 64 hours (5°C),1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,unchanged,NA,decreased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/60/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 60,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P1) at 16 hours (5°C),Spiked pig feces(P1) at 16 hours (22°C),P1 sample spiked with a mock community and stored at a temperature of 16 hours (22°C),1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,unchanged,NA,decreased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/61/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 61,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P1) at 64 hours (5°C),Spiked pig feces(P1) at 16 hours (22°C),P1 sample spiked with a mock community and stored at a temperature of 16 hours (22°C),1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,unchanged,NA,decreased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/62/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 62,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P1) at 64 hours (-20°C),Unspiked pig feces(P1) at 16 hours (5°C),Unspiked P1 sample stored at a temperature of 5°C for 16 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/63/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 63,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P1) at 16 hours (22°C),Spiked pig feces(P1) at 64 hours (22°C),P1 sample spiked with a mock community and stored at a temperature of 64 hours (22°C),1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,decreased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/64/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 64,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P1) at 64 hours (-20°C),Unspiked pig feces(P1) at 64 hours (5°C),Unspiked P1 sample stored at a temperature of 5°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,unchanged,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/65/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 65,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P1) at 64 hours (-20°C),Unspiked pig feces(P1) at 16 hours (22°C),Unspiked P1 sample stored at a temperature of 22°C for 16 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,unchanged,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/66/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 66,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P1) at 64 hours (-20°C),Unspiked pig feces(P1) at 64 hours (22°C),Unspiked P1 sample stored at a temperature of 22°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/67/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 67,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P1) at 16 hours (5°C),Unspiked pig feces(P1) at 64 hours (5°C),Unspiked P1 sample stored at a temperature of 5°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,decreased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/68/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 68,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P1) at 16 hours (5°C),Unspiked pig feces(P1) at 16 hours (22°C),Unspiked P1 sample stored at a temperature of 22°C for 16 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,decreased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/69/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 69,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P1) at 16 hours (5°C),Unspiked pig feces(P1) at 64 hours (22°C),Unspiked P1 sample stored at a temperature of 22°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,unchanged,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/70/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 70,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P1) at 64 hours (5°C),Unspiked pig feces(P1) at 16 hours (22°C),Unspiked P1 sample stored at a temperature of 22°C for 16 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,unchanged,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/71/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 71,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P1) at 64 hours (5°C),Unspiked pig feces(P1) at 64 hours (22°C),Unspiked P1 sample stored at a temperature of 22°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/72/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 72,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P1) at 16 hours (22°C),Unspiked pig feces(P1) at 64 hours (22°C),Unspiked P1 sample stored at a temperature of 22°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/73/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 73,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P2) at 0 hour,Spiked pig feces(P2) at 64 hours (-80°C),P2 sample spiked with a mock community and stored at a temperature of -80°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,decreased,NA,increased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/74/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 74,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P2) at 0 hour,Spiked pig feces(P2) at 64 hours (22°C),P2 sample spiked with a mock community and stored at a temperature of 22°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,decreased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/75/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 75,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P2) at 0 hour,Spiked pig feces(P2) at 64 hours (5°C),P2 sample spiked with a mock community and stored at a temperature of 5°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,decreased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/76/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 76,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P2) at 0 hour,Spiked pig feces(P2) at 64 hours (-20°C),P2 sample spiked with a mock community and stored at a temperature of -20°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,decreased,NA,increased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/77/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 77,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P2) at 0 hour,Spiked pig feces(P2) at 16 hours (-80°C),P2 sample spiked with a mock community and stored at a temperature of -80°C for 16 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,decreased,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/78/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 78,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P2) at 0 hour,Spiked pig feces(P2) at 16 hours (5°C),P2 sample spiked with a mock community and stored at a temperature of 5°C for 16 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,unchanged,NA,decreased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/79/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 79,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P2) at 0 hour,Spiked pig feces(P2) at 16 hours (22°C),P2 sample spiked with a mock community and stored at a temperature of 22°C for 16 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,decreased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/80/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 80,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P2) at 0 hour,Spiked pig feces(P2) at 16 hours (-20°C),P2 sample spiked with a mock community and stored at a temperature of -20°C for 16 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,decreased,NA,increased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/81/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 81,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P2) at 16 hours (-80°C),Spiked pig feces(P2) at 64 hours (22°C),P2 sample spiked with a mock community and stored at a temperature of 64 hours (22°C),1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/82/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 82,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P2) at 16 hours (-80°C),Spiked pig feces(P2) at 64 hours (-80°C),P2 sample spiked with a mock community and stored at a temperature of 64 hours (-80°C),1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,decreased,NA,increased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/83/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 83,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P2) at 16 hours (-80°C),Spiked pig feces(P2) at 64 hours (-20°C),P2 sample spiked with a mock community and  stored at a temperature of 64 hours (-20°C),1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,decreased,NA,increased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/84/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 84,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P2) at 16 hours (-80°C),Spiked pig feces(P2) at 16 hours (-20°C),P2 sample spiked with a mock community and stored at a temperature of 16 hours (-20°C),1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,unchanged,NA,increased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/85/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 85,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P2) at 16 hours (-80°C),Spiked pig feces(P2) at 64 hours (5°C),P2 sample spiked with a mock community and stored at a temperature of 64 hours (5°C),1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,decreased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/86/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 86,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P2) at 16 hours (-80°C),Spiked pig feces(P2) at 16 hours (22°C),P2 sample spiked with a mock community and stored at a temperature of 16 hours (22°C),1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,decreased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/87/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 87,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P2) at 16 hours (-80°C),Spiked pig feces(P2) at 16 hours (5°C),P2 sample spiked with a mock community and stored at a temperature of 16 hours (5°C),1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/88/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 88,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P2) at 64 hours (-80°C),Spiked pig feces(P2) at 16 hours (5°C),P2 sample spiked with a mock community and stored at a temperature of 16 hours (5°C),1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,decreased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/89/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 89,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P2) at 64 hours (-80°C),Spiked pig feces(P2) at 16 hours (22°C),P2 sample spiked with a mock community and stored at a temperature of 16 hours (22°C),1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,decreased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/90/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 90,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P2) at 64 hours (-80°C),Spiked pig feces(P2) at 64 hours (22°C),P2 sample spiked with a mock community and stored at a temperature of 64 hours (22°C),1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,decreased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/91/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 91,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P2) at 16 hours (5°C),Spiked pig feces(P2) at 64 hours (22°C),P2 sample spiked with a mock community and  stored at a temperature of 64 hours (22°C),1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/92/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 92,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P2) at 16 hours (-20°C),Spiked pig feces(P2) at 64 hours (22°C),P2 sample spiked with a mock community and  stored at a temperature of 64 hours (22°C),1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/93/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 93,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P2) at 64 hours (22°C),Spiked pig feces(P2) at 64 hours (5°C),P2 sample spiked with a mock community and stored at a temperature of 64 hours (5°C),1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/94/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 94,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P2) at 64 hours (-20°C),Spiked pig feces(P2) at 64 hours (22°C),P2 sample spiked with a mock community and  stored at a temperature of 64 hours (22°C),1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/95/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 95,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P2) at 16 hours (22°C),Spiked pig feces(P2) at 64 hours (-20°C),P2 sample spiked with a mock community and stored at a temperature of 64 hours (-20°C),1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,decreased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/96/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 96,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P2) at 16 hours (-80°C),Spiked pig feces(P2) at 16 hours (22°C),P2 sample spiked with a mock community and stored at a temperature of 16 hours (22°C),1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,decreased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/97/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 97,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P2) at 16 hours (-20°C),Spiked pig feces(P2) at 16 hours (22°C),P2 sample spiked with a mock community and  stored at a temperature of 16 hours (22°C),1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,decreased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/98/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 98,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P2) at 64 hours (-20°C),Spiked pig feces(P2) at 64 hours (5°C),P2 sample spiked with a mock community and stored at a temperature of 64 hours (5°C),1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,decreased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/99/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 99,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P2) at 64 hours (-80°C),Spiked pig feces(P2) at 64 hours (5°C),P2 sample spiked with a mock community and  stored at a temperature of 64 hours (5°C),1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,decreased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/100/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 100,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P2) at 16 hours (-20°C),Spiked pig feces(P2) at 64 hours (5°C),P2 sample spiked with a mock community and stored at a temperature of 64 hours (5°C),1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,decreased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/101/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 101,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P2) at 16 hours (5°C),Spiked pig feces(P2) at 64 hours (-20°C),P2 sample spiked with a mock community and stored at a temperature of 64 hours (-20°C),1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,decreased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/102/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 102,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P2) at 64 hours (-80°C),Spiked pig feces(P2) at 16 hours (-20°C),P2 sample spiked with a mock community and stored at a temperature of 16 hours (-20°C),1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,unchanged,NA,decreased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/103/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 103,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P2) at 64 hours (-80°C),Spiked pig feces(P2) at 64 hours (-20°C),P2 sample spiked with a mock community and stored at a temperature of 64 hours (-20°C),1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,decreased,NA,decreased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/104/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 104,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P2) at 16 hours (-20°C),Spiked pig feces(P2) at 64 hours (-20°C),P2 sample spiked with a mock community and stored at a temperature of 64 hours (-20°C),1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,decreased,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/105/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 105,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P2) at 16 hours (5°C),Spiked pig feces(P2) at 64 hours (5°C),P2 sample spiked with a mock community and stored at a temperature of 64 hours (5°C),1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,decreased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/106/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 106,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P2) at 16 hours (5°C),Spiked pig feces(P2) at 16 hours (22°C),P2 sample spiked with a mock community and stored at a temperature of 16 hours (22°C),1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/107/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 107,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,NA,NA,Spiked pig feces(P2) at 64 hours (5°C),Spiked pig feces(P2) at 16 hours (22°C),P2 sample spiked with a mock community and stored at a temperature of 16 hours (22°C),1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,decreased,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/108/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 108,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Spiked pig feces(P2) at 16 hours (22°C),Spiked pig feces(P2) at 64 hours (22°C),P2 sample spiked with a mock community and stored at a temperature of 64 hours (22°C),1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,decreased,NA,increased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/109/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 109,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P2) at 0 hour,Unspiked pig feces(P2) at 16 hours (-80°C),Unspiked P2 sample stored at a temperature of -80°C for 16 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,decreased,NA,increased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/110/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 110,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P2) at 0 hour,Unspiked pig feces(P2) at 64 hours (-80°C),Unspiked P2 sample stored at a temperature of -80°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,decreased,NA,unchanged,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/111/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 111,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P2) at 0 hour,Unspiked pig feces(P2) at 16 hours (-20°C),Unspiked P2 sample stored at a temperature of -20°C for 16 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,decreased,NA,unchanged,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/112/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 112,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P2) at 0 hour,Unspiked pig feces(P2) at 64 hours (-20°C),Unspiked P2 sample stored at a temperature of -20°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,decreased,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/113/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 113,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P2) at 0 hour,Unspiked pig feces(P2) at 16 hours (5°C),Unspiked P2 sample stored at a temperature of 5°C for 16 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,decreased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/114/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 114,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P2) at 0 hour,Unspiked pig feces(P2) at 64 hours (5°C),Unspiked P2 sample stored at a temperature of 5°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,decreased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/115/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 115,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P2) at 0 hour,Unspiked pig feces(P2) at 16 hours (22°C),Unspiked P2 sample stored at a temperature of 22°C for 16 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,unchanged,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/116/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 116,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P2) at 0 hour,Unspiked pig feces(P2) at 64 hours (22°C),Unspiked P2 sample stored at a temperature of 22°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,decreased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/117/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 117,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P2) at 16 hours (-80°C),Unspiked pig feces(P2) at 64 hours (80°C),Unspiked P2 sample stored at a temperature of -80°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,decreased,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/118/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 118,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P2) at 16 hours (-80°C),Unspiked pig feces(P2) at 16 hours (-20°C),Unspiked P2 sample stored at a temperature of -20°C for 16 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,decreased,NA,increased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/119/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 119,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P2) at 16 hours (-80°C),Unspiked pig feces(P2) at 64 hours (-20°C),Unspiked P2 sample stored at a temperature of -20°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,decreased,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/120/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 120,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P2) at 16 hours (-80°C),Unspiked pig feces(P2) at 16 hours (5°C),Unspiked P2 sample stored at a temperature of 5°C for 16 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,decreased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/121/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 121,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P2) at 16 hours (-80°C),Unspiked pig feces(P2) at 64 hours (5°C),Unspiked P2 sample stored at a temperature of 5°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,decreased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/122/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 122,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P2) at 16 hours (-80°C),Unspiked pig feces(P2) at 16 hours (22°C),Unspiked P2 sample stored at a temperature of 22°C for 16 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,decreased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/123/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 123,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P2) at 16 hours (-80°C),Unspiked pig feces(P2) at 64 hours (22°C),Unspiked P2 sample stored at a temperature of 22°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,decreased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/124/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 124,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P2) at 64 hours (-80°C),Unspiked pig feces(P2) at 16 hours (-20°C),Unspiked P2 sample stored at a temperature of -20°C for 16 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,unchanged,NA,increased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/125/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 125,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P2) at 64 hours (-80°C),Unspiked pig feces(P2) at 64 hours (-20°C),Unspiked P2 sample stored at a temperature of -20°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,unchanged,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/126/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 126,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P2) at 64 hours (-80°C),Unspiked pig feces(P2) at 16 hours (5°C),Unspiked P2 sample stored at a temperature of 5°C for 16 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,decreased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/127/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 127,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P2) at 64 hours (-80°C),Unspiked pig feces(P2) at 64 hours (5°C),Unspiked P2 sample stored at a temperature of 5°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,decreased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/128/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 128,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P2) at 64 hours (-80°C),Unspiked pig feces(P2) at 16 hours (22°C),Unspiked P2 sample stored at a temperature of 22°C for 16 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/129/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 129,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P2) at 64 hours (-80°C),Unspiked pig feces(P2) at 64 hours (22°C),Unspiked P2 sample stored at a temperature of 22°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,decreased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/130/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 130,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P2) at 16 hours (-20°C),Unspiked pig feces(P2) at 64 hours (-20°C),Unspiked P2 sample stored at a temperature of -20°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/131/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 131,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P2) at 16 hours (-20°C),Unspiked pig feces(P2) at 16 hours (5°C),Unspiked P2 sample stored at a temperature of 5°C for 16 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,decreased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/132/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 132,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P2) at 16 hours (-20°C),Unspiked pig feces(P2) at 64 hours (5°C),Unspiked P2 sample stored at a temperature of 5°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,decreased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/133/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 133,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P2) at 16 hours (-20°C),Unspiked pig feces(P2) at 16 hours (22°C),Unspiked P2 sample stored at a temperature of 22°C for 16 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,decreased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/134/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 134,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P2) at 16 hours (-20°C),Unspiked pig feces(P2) at 64 hours (22°C),Unspiked P2 sample stored at a temperature of 22°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,decreased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/135/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 135,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P2) at 64 hours (-20°C),Unspiked pig feces(P2) at 16 hours (5°C),Unspiked P2 sample stored at a temperature of 5°C for 16 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/136/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 136,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P2) at 64 hours (-20°C),Unspiked pig feces(P2) at 64 hours (5°C),Unspiked P2 sample stored at a temperature of 5°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/137/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 137,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P2) at 64 hours (-20°C),Unspiked pig feces(P2) at 16 hours (22°C),Unspiked P2 sample stored at a temperature of 22°C for 16 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/138/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 138,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P2) at 64 hours (-20°C),Unspiked pig feces(P2) at 64 hours (22°C),Unspiked P2 sample stored at a temperature of 22°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/139/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 139,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P2) at 16 hours (5°C),Unspiked pig feces(P2) at 64 hours (5°C),Unspiked P2 sample stored at a temperature of 5°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,decreased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/140/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 140,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P2) at 16 hours (5°C),Unspiked pig feces(P2) at 16 hours (22°C),Unspiked P2 sample stored at a temperature of 22°C for 16 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/141/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 141,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P2) at 16 hours (5°C),Unspiked pig feces(P2) at 64 hours (22°C),Unspiked P2 sample stored at a temperature of 22°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/142/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 142,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P2) at 64 hours (5°C),Unspiked pig feces(P2) at 16 hours (22°C),Unspiked P2 sample stored at a temperature of 22°C for 16 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,decreased,NA,increased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/143/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 143,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P2) at 64 hours (5°C),Unspiked pig feces(P2) at 64 hours (22°C),Unspiked P2 sample stored at a temperature of 22°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,unchanged,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/144/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 144,Denmark,Sus scrofa domesticus,Feces,UBERON:0001988,Microbiome,EFO:0004982,Unspiked pig feces(P2) at 16 hours (22°C),Unspiked pig feces(P2) at 64 hours (22°C),Unspiked P2 sample stored at a temperature of 22°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,decreased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/145/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 145,Denmark,Not specified,NA,NA,Microbiome,EFO:0004982,Unspiked sewage samples (S1) at 0 hours,Unspiked sewage samples (S1) at 16 hours (-80°C),Unspiked S1 sample stored at a temperature of -80°C for 16 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,decreased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/146/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 146,Denmark,Not specified,NA,NA,Microbiome,EFO:0004982,Unspiked sewage samples (S1) at 0 hours,Unspiked sewage samples (S1) at 64 hours (-80°C),Unspiked S1 sample stored at a temperature of -80°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/147/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 147,Denmark,Not specified,NA,NA,Microbiome,EFO:0004982,Unspiked sewage samples (S1) at 0 hours,Unspiked sewage samples (S1) at 16 hours (-20°C),Unspiked S1 sample stored at a temperature of -20°C for 16 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,unchanged,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/148/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 148,Denmark,Not specified,NA,NA,Microbiome,EFO:0004982,Unspiked sewage samples (S1) at 0 hours,Unspiked sewage samples (S1) at 64 hours (-20°C),Unspiked S1 sample stored at a temperature of -20°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,unchanged,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/149/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 149,Denmark,Not specified,NA,NA,Microbiome,EFO:0004982,Unspiked sewage samples (S1) at 0 hours,Unspiked sewage samples (S1) at 16 hours (5°C),Unspiked S1 sample stored at a temperature of 5°C for 16 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,unchanged,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/150/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 150,Denmark,Not specified,NA,NA,Microbiome,EFO:0004982,Unspiked sewage samples (S1) at 0 hours,Unspiked sewage samples (S1) at 64 hours (5°C),Unspiked S1 sample stored at a temperature of 5°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,unchanged,NA,increased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/151/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 151,Denmark,Not specified,NA,NA,Microbiome,EFO:0004982,Unspiked sewage samples (S1) at 0 hours,Unspiked sewage samples (S1) at 16 hours (22°C),Unspiked S1 sample stored at a temperature of 22°C for 16 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,unchanged,NA,decreased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/152/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 152,Denmark,Not specified,NA,NA,Microbiome,EFO:0004982,Unspiked sewage samples (S1) at 0 hours,Unspiked sewage samples (S1) at 64 hours (22°C),Unspiked S1 sample stored at a temperature of 22°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,unchanged,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/153/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 153,Denmark,Not specified,NA,NA,Microbiome,EFO:0004982,Unspiked sewage samples (S1) at 16 hours (-80°C),Unspiked sewage samples (S1) at 64 hours (-80°C),Unspiked S1 sample stored at a temperature of -80°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,decreased,NA,increased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/154/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 154,Denmark,Not specified,NA,NA,Microbiome,EFO:0004982,Unspiked sewage samples (S1) at 16 hours (-80°C),Unspiked sewage samples (S1) at 16 hours (-20°C),Unspiked S1 sample stored at a temperature of -20°C for 16 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,decreased,NA,increased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/155/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 155,Denmark,Not specified,NA,NA,Microbiome,EFO:0004982,Unspiked sewage samples (S1) at 16 hours (-80°C),Unspiked sewage samples (S1) at 64 hours (-20°C),Unspiked S1 sample stored at a temperature of -20°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,decreased,NA,increased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/156/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 156,Denmark,Not specified,NA,NA,Microbiome,EFO:0004982,Unspiked sewage samples (S1) at 16 hours (-80°C),Unspiked sewage samples (S1) at 16 hours (5°C),Unspiked S1 sample stored at a temperature of 5°C for 16 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,decreased,NA,increased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/157/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 157,Denmark,Not specified,NA,NA,Microbiome,EFO:0004982,Unspiked sewage samples (S1) at 16 hours (-80°C),Unspiked sewage samples (S1) at 64 hours (5°C),Unspiked S1 sample stored at a temperature of 5°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,decreased,NA,increased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/158/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 158,Denmark,Not specified,NA,NA,Microbiome,EFO:0004982,Unspiked sewage samples (S1) at 16 hours (-80°C),Unspiked sewage samples (S1) at 16 hours (22°C),Unspiked S1 sample stored at a temperature of 22°C for 16 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,decreased,NA,increased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/159/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 159,Denmark,Not specified,NA,NA,Microbiome,EFO:0004982,Unspiked sewage samples (S1) at 16 hours (-80°C),Unspiked sewage samples (S1) at 64 hours (22°C),Unspiked S1 sample stored at a temperature of 22°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/160/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 160,Denmark,Not specified,NA,NA,Microbiome,EFO:0004982,Unspiked sewage samples (S1) at 64 hours (-80°C),Unspiked sewage samples (S1) at 16 hours (-20°C),Unspiked S1 sample stored at a temperature of -20°C for 16 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,decreased,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/161/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 161,Denmark,Not specified,NA,NA,Microbiome,EFO:0004982,Unspiked sewage samples (S1) at 64 hours (-80°C),Unspiked sewage samples (S1) at 64 hours (-20°C),Unspiked S1 sample stored at a temperature of -20°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,decreased,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/162/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 162,Denmark,Not specified,NA,NA,Microbiome,EFO:0004982,Unspiked sewage samples (S1) at 64 hours (-80°C),Unspiked sewage samples (S1) at 16 hours (5°C),Unspiked S1 sample stored at a temperature of 5°C for 16 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,decreased,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/163/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 163,Denmark,Not specified,NA,NA,Microbiome,EFO:0004982,Unspiked sewage samples (S1) at 64 hours (-80°C),Unspiked sewage samples (S1) at 64 hours (5°C),Unspiked S1 sample stored at a temperature of 5°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,decreased,NA,unchanged,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/164/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 164,Denmark,Not specified,NA,NA,Microbiome,EFO:0004982,Unspiked sewage samples (S1) at 64 hours (-80°C),Unspiked sewage samples (S1) at 16 hours (22°C),Unspiked S1 sample stored at a temperature of 22°C for 16 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,decreased,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/165/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 165,Denmark,Not specified,NA,NA,Microbiome,EFO:0004982,Unspiked sewage samples (S1) at 64 hours (-80°C),Unspiked sewage samples (S1) at 64 hours (22°C),Unspiked S1 sample stored at a temperature of 22°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,decreased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/166/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 166,Denmark,Not specified,NA,NA,Microbiome,EFO:0004982,Unspiked sewage samples (S1) at 16 hours (-20°C),Unspiked sewage samples (S1) at 64 hours (-20°C),Unspiked S1 sample stored at a temperature of -20°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,unchanged,NA,increased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/167/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 167,Denmark,Not specified,NA,NA,Microbiome,EFO:0004982,Unspiked sewage samples (S1) at 16 hours (-20°C),Unspiked sewage samples (S1) at 16 hours (5°C),Unspiked S1 sample stored at a temperature of 5°C for 16 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,unchanged,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/168/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 168,Denmark,Not specified,NA,NA,Microbiome,EFO:0004982,Unspiked sewage samples (S1) at 16 hours (-20°C),Unspiked sewage samples (S1) at 64 hours (5°C),Unspiked S1 sample stored at a temperature of 5°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,unchanged,NA,increased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/169/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 169,Denmark,Not specified,NA,NA,Microbiome,EFO:0004982,Unspiked sewage samples (S1) at 16 hours (-20°C),Unspiked sewage samples (S1) at 16 hours (22°C),Unspiked S1 sample stored at a temperature of 22°C for 16 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,unchanged,NA,decreased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/170/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 170,Denmark,Not specified,NA,NA,Microbiome,EFO:0004982,Unspiked sewage samples (S1) at 16 hours (-20°C),Unspiked sewage samples (S1) at 64 hours (22°C),Unspiked S1 sample stored at a temperature of 22°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,unchanged,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/171/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 171,Denmark,Not specified,NA,NA,Microbiome,EFO:0004982,Unspiked sewage samples (S1) at 64 hours (-20°C),Unspiked sewage samples (S1) at 16 hours (5°C),Unspiked S1 sample stored at a temperature of 5°C for 16 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,unchanged,NA,decreased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/172/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 172,Denmark,Not specified,NA,NA,Microbiome,EFO:0004982,Unspiked sewage samples (S1) at 64 hours (-20°C),Unspiked sewage samples (S1) at 64 hours (5°C),Unspiked S1 sample stored at a temperature of 5°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,unchanged,NA,increased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/173/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 173,Denmark,Not specified,NA,NA,Microbiome,EFO:0004982,Unspiked sewage samples (S1) at 64 hours (-20°C),Unspiked sewage samples (S1) at 16 hours (22°C),Unspiked S1 sample stored at a temperature of 22°C for 16 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,unchanged,NA,decreased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/174/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 174,Denmark,Not specified,NA,NA,Microbiome,EFO:0004982,Unspiked sewage samples (S1) at 64 hours (-20°C),Unspiked sewage samples (S1) at 64 hours (22°C),Unspiked S1 sample stored at a temperature of 22°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,unchanged,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/175/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 175,Denmark,Not specified,NA,NA,Microbiome,EFO:0004982,Unspiked sewage samples (S1) at 16 hours (5°C),Unspiked sewage samples (S1) at 64 hours (5°C),Unspiked S1 sample stored at a temperature of 5°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,unchanged,NA,increased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/176/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 176,Denmark,Not specified,NA,NA,Microbiome,EFO:0004982,Unspiked sewage samples (S1) at 16 hours (5°C),Unspiked sewage samples (S1) at 16 hours (22°C),Unspiked S1 sample stored at a temperature of 22°C for 16 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,unchanged,NA,decreased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/177/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 177,Denmark,Not specified,NA,NA,Microbiome,EFO:0004982,Unspiked sewage samples (S1) at 16 hours (5°C),Unspiked sewage samples (S1) at 64 hours (22°C),Unspiked S1 sample stored at a temperature of 22°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,unchanged,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/178/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 178,Denmark,Not specified,NA,NA,Microbiome,EFO:0004982,Unspiked sewage samples (S1) at 64 hours (5°C),Unspiked sewage samples (S1) at 16 hours (22°C),Unspiked S1 sample stored at a temperature of 22°C for 16 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,decreased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/179/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 179,Denmark,Not specified,NA,NA,Microbiome,EFO:0004982,Unspiked sewage samples (S1) at 64 hours (5°C),Unspiked sewage samples (S1) at 64 hours (22°C),Unspiked S1 sample stored at a temperature of 22°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/180/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 180,Denmark,Not specified,NA,NA,Microbiome,EFO:0004982,Unspiked sewage samples (S1) at 16 hours (22°C),Unspiked sewage samples (S1) at 64 hours (22°C),Unspiked S1 sample stored at a temperature of 22°C for 64 hours,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/181/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 181,Denmark,Not specified,NA,NA,Microbiome,EFO:0004982,Unspiked sewage samples (S2) at 0 hour,Unspiked sewage samples (S2) at 16 hours (-80°C),Unspiked S2 sample stored at a temperature of -80°C for 16 hours.,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,unchanged,NA,unchanged,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/182/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 182,Denmark,Not specified,NA,NA,Microbiome,EFO:0004982,Unspiked sewage samples (S2) at 0 hour,Unspiked sewage samples (S2) at 64 hours (-80°C),Unspiked S2 sample stored at a temperature of -80°C for 64 hours.,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,unchanged,NA,decreased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/183/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 183,Denmark,Not specified,NA,NA,Microbiome,EFO:0004982,Unspiked sewage samples (S2) at 0 hour,Unspiked sewage samples (S2) at 16 hours (-20°C),Unspiked S2 sample stored at a temperature of -20°C for 16 hours.,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,unchanged,NA,unchanged,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/184/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 184,Denmark,Not specified,NA,NA,Microbiome,EFO:0004982,Unspiked sewage samples (S2) at 0 hour,Unspiked sewage samples (S2) at 64 hours (-20°C),Unspiked S2 sample stored at a temperature of -20°C for 64 hours.,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,unchanged,NA,decreased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/185/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 185,Denmark,Not specified,NA,NA,Microbiome,EFO:0004982,Unspiked sewage samples (S2) at 0 hour,Unspiked sewage samples (S2) at 16 hours (5°C),Unspiked S2 sample stored at a temperature of 5°C for 16 hours.,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,decreased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/186/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 186,Denmark,Not specified,NA,NA,Microbiome,EFO:0004982,Unspiked sewage samples (S2) at 0 hour,Unspiked sewage samples (S2) at 64 hours (5°C),Unspiked S2 sample stored at a temperature of 5°C for 64 hours.,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,decreased,NA,increased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/187/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 187,Denmark,Not specified,NA,NA,Microbiome,EFO:0004982,Unspiked sewage samples (S2) at 0 hour,Unspiked sewage samples (S2) at 16 hours (22°C),Unspiked S2 sample stored at a temperature of 22°C for 16 hours.,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,unchanged,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/188/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 188,Denmark,Not specified,NA,NA,Microbiome,EFO:0004982,Unspiked sewage samples (S2) at 0 hour,Unspiked sewage samples (S2) at 64 hours (22°C),Unspiked S2 sample stored at a temperature of 22°C for 64 hours.,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,unchanged,NA,unchanged,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/189/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 189,Denmark,Not specified,NA,NA,Microbiome,EFO:0004982,Unspiked sewage samples (S2) at 16 hours (-80°C),Unspiked sewage samples (S2) at 64 hours (-80°C),Unspiked S2 sample stored at a temperature of -80°C for 64 hours.,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,decreased,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/190/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 190,Denmark,Not specified,NA,NA,Microbiome,EFO:0004982,Unspiked sewage samples (S2) at 16 hours (-80°C),Unspiked sewage samples (S2) at 16 hours (-20°C),Unspiked S2 sample stored at a temperature of -20°C for 16 hours.,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,unchanged,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/191/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 191,Denmark,Not specified,NA,NA,Microbiome,EFO:0004982,Unspiked sewage samples (S2) at 16 hours (-80°C),Unspiked sewage samples (S2) at 64 hours (-20°C),Unspiked S2 sample stored at a temperature of -20°C for 64 hours.,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,unchanged,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/192/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 192,Denmark,Not specified,NA,NA,Microbiome,EFO:0004982,Unspiked sewage samples (S2) at 16 hours (-80°C),Unspiked sewage samples (S2) at 16 hours (5°C),Unspiked S2 sample stored at a temperature of 5°C for 16 hours.,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,decreased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/193/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 193,Denmark,Not specified,NA,NA,Microbiome,EFO:0004982,Unspiked sewage samples (S2) at 16 hours (-80°C),Unspiked sewage samples (S2) at 64 hours (5°C),Unspiked S2 sample stored at a temperature of 5°C for 64 hours.,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,decreased,NA,increased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/194/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 194,Denmark,Not specified,NA,NA,Microbiome,EFO:0004982,Unspiked sewage samples (S2) at 16 hours (-80°C),Unspiked sewage samples (S2) at 16 hours (22°C),Unspiked S2 sample stored at a temperature of 22°C for 16 hours.,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,decreased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/195/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 195,Denmark,Not specified,NA,NA,Microbiome,EFO:0004982,Unspiked sewage samples (S2) at 16 hours (-80°C),Unspiked sewage samples (S2) at 64 hours (22°C),Unspiked S2 sample stored at a temperature of 22°C for 64 hours.,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,unchanged,NA,unchanged,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/196/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 196,Denmark,Not specified,NA,NA,Microbiome,EFO:0004982,Unspiked sewage samples (S2) at 64 hours (-80°C),Unspiked sewage samples (S2) at 16 hours (-20°C),Unspiked S2 sample stored at a temperature of -20°C for 16 hours.,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/197/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 197,Denmark,Not specified,NA,NA,Microbiome,EFO:0004982,Unspiked sewage samples (S2) at 64 hours (-80°C),Unspiked sewage samples (S2) at 64 hours (-20°C),Unspiked S2 sample stored at a temperature of -20°C for 64 hours.,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,unchanged,NA,decreased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/198/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 198,Denmark,Not specified,NA,NA,Microbiome,EFO:0004982,Unspiked sewage samples (S2) at 64 hours (-80°C),Unspiked sewage samples (S2) at 16 hours (5°C),Unspiked S2 sample stored at a temperature of 5°C for 16 hours.,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/199/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 199,Denmark,Not specified,NA,NA,Microbiome,EFO:0004982,Unspiked sewage samples (S2) at 64 hours (-80°C),Unspiked sewage samples (S2) at 64 hours (5°C),Unspiked S2 sample stored at a temperature of 5°C for 64 hours.,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,decreased,NA,increased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/200/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 200,Denmark,Not specified,NA,NA,Microbiome,EFO:0004982,Unspiked sewage samples (S2) at 64 hours (-80°C),Unspiked sewage samples (S2) at 16 hours (22°C),Unspiked S2 sample stored at a temperature of 22°C for 16 hours.,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/201/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 201,Denmark,Not specified,NA,NA,Microbiome,EFO:0004982,Unspiked sewage samples (S2) at 64 hours (-80°C),Unspiked sewage samples (S2) at 64 hours (22°C),Unspiked S2 sample stored at a temperature of 22°C for 64 hours.,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,unchanged,NA,increased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/202/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 202,Denmark,Not specified,NA,NA,Microbiome,EFO:0004982,Unspiked sewage samples (S2) at 16 hours (-20°C),Unspiked sewage samples (S2) at 64 hours (-20°C),Unspiked S2 sample stored at a temperature of -20°C for 64 hours.,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,unchanged,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/203/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 203,Denmark,Not specified,NA,NA,Microbiome,EFO:0004982,Unspiked sewage samples (S2) at 16 hours (-20°C),Unspiked sewage samples (S2) at 16 hours (5°C),Unspiked S2 sample stored at a temperature of 5°C for 16 hours.,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,unchanged,NA,decreased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/204/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 204,Denmark,Not specified,NA,NA,Microbiome,EFO:0004982,Unspiked sewage samples (S2) at 16 hours (-20°C),Unspiked sewage samples (S2) at 64 hours (5°C),Unspiked S2 sample stored at a temperature of 5°C for 64 hours.,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,decreased,NA,increased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1048/205/NA,Study 1048,laboratory experiment,34612701,10.1128%2FSpectrum.01387-21,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8510183/,"Poulsen CS, Kaas RS, Aarestrup FM , Pamp SJ",Standard Sample Storage Conditions Have an Impact on Inferred Microbiome Composition and Antimicrobial Resistance Patterns,Microbiology spectrum,2021,"antimicrobial resistance, bacteria, complex samples, freezing, metagenomics, microbial community composition, microbiome, mock community, parasite, sample storage, spiking, synthetic mock community",Experiment 205,Denmark,Not specified,NA,NA,Microbiome,EFO:0004982,Unspiked sewage samples (S2) at 16 hours (-20°C),Unspiked sewage samples (S2) at 16 hours (22°C),Unspiked S2 sample stored at a temperature of 22°C for 16 hours.,1,1,NA,WMS,NA,Illumina,DESeq2,0.01,FALSE,NA,NA,NA,increased,NA,unchanged,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1049/1/NA,Study 1049,time series / longitudinal observational,37864204,10.1186/s40168-023-01671-2,NA,"Thomsen M, Künstner A, Wohlers I, Olbrich M, Lenfers T, Osumi T, Shimazaki Y, Nishifuji K, Ibrahim SM, Watson A, Busch H , Hirose M",A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs,Microbiome,2023,"16S rRNA, Canine atopic dermatitis, Fusobacterium, JAK inhibitor, Megamonas, Mitochondrial DNA, Mitochondrial haplogroup, Shiba Inu dogs, Skin and gut microbiota, Staphylococcus",Experiment 1,Japan,Canis lupus familiaris,Skin of abdomen,UBERON:0001416,Atopic eczema,EFO:0000274,Healthy dogs,cADtreat dogs,Dogs that were already diagnosed with cAD (canine atopic dermatitis) before the study cohort recruitment and had been on oclacitinib treatment,20,10,Not applicable.,16S,12,Illumina,Beta Binomial Regression,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1049/2/NA,Study 1049,time series / longitudinal observational,37864204,10.1186/s40168-023-01671-2,NA,"Thomsen M, Künstner A, Wohlers I, Olbrich M, Lenfers T, Osumi T, Shimazaki Y, Nishifuji K, Ibrahim SM, Watson A, Busch H , Hirose M",A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs,Microbiome,2023,"16S rRNA, Canine atopic dermatitis, Fusobacterium, JAK inhibitor, Megamonas, Mitochondrial DNA, Mitochondrial haplogroup, Shiba Inu dogs, Skin and gut microbiota, Staphylococcus",Experiment 2,Japan,Canis lupus familiaris,Skin of abdomen,UBERON:0001416,Atopic eczema,EFO:0000274,cADpre dogs,cADpost dogs,cADpre dogs that were consequently placed under oclacitinib treatment for two weeks after the diagnosis,10,10,Not applicable,16S,12,Illumina,Beta Binomial Regression,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1049/3/NA,Study 1049,time series / longitudinal observational,37864204,10.1186/s40168-023-01671-2,NA,"Thomsen M, Künstner A, Wohlers I, Olbrich M, Lenfers T, Osumi T, Shimazaki Y, Nishifuji K, Ibrahim SM, Watson A, Busch H , Hirose M",A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs,Microbiome,2023,"16S rRNA, Canine atopic dermatitis, Fusobacterium, JAK inhibitor, Megamonas, Mitochondrial DNA, Mitochondrial haplogroup, Shiba Inu dogs, Skin and gut microbiota, Staphylococcus",Experiment 3,Japan,Canis lupus familiaris,Forelimb skin,UBERON:0003531,Atopic eczema,EFO:0000274,Healthy dogs,cADPre dogs,Dogs that were newly diagnosed with cAD (canine atopic dermatitis) without any previous medical treatments,20,10,Not applicable,16S,12,Illumina,Beta Binomial Regression,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1049/4/NA,Study 1049,time series / longitudinal observational,37864204,10.1186/s40168-023-01671-2,NA,"Thomsen M, Künstner A, Wohlers I, Olbrich M, Lenfers T, Osumi T, Shimazaki Y, Nishifuji K, Ibrahim SM, Watson A, Busch H , Hirose M",A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs,Microbiome,2023,"16S rRNA, Canine atopic dermatitis, Fusobacterium, JAK inhibitor, Megamonas, Mitochondrial DNA, Mitochondrial haplogroup, Shiba Inu dogs, Skin and gut microbiota, Staphylococcus",Experiment 4,Japan,Canis lupus familiaris,Forelimb skin,UBERON:0003531,Atopic eczema,EFO:0000274,Healthy dogs,cADtreat dogs,Dogs that were already diagnosed with cAD (canine atopic dermatitis) before the study cohort recruitment and had been on oclacitinib treatment,20,10,Not applicable,16S,12,Illumina,Beta Binomial Regression,0.05,TRUE,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1049/5/NA,Study 1049,time series / longitudinal observational,37864204,10.1186/s40168-023-01671-2,NA,"Thomsen M, Künstner A, Wohlers I, Olbrich M, Lenfers T, Osumi T, Shimazaki Y, Nishifuji K, Ibrahim SM, Watson A, Busch H , Hirose M",A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs,Microbiome,2023,"16S rRNA, Canine atopic dermatitis, Fusobacterium, JAK inhibitor, Megamonas, Mitochondrial DNA, Mitochondrial haplogroup, Shiba Inu dogs, Skin and gut microbiota, Staphylococcus",Experiment 5,Japan,Canis lupus familiaris,Forelimb skin,UBERON:0003531,Atopic eczema,EFO:0000274,cADpre dogs,cADpost dogs,cADpre dogs that were consequently placed under oclacitinib treatment for two weeks after the diagnosis,10,10,Not applicable,16S,12,Illumina,Beta Binomial Regression,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1049/6/NA,Study 1049,time series / longitudinal observational,37864204,10.1186/s40168-023-01671-2,NA,"Thomsen M, Künstner A, Wohlers I, Olbrich M, Lenfers T, Osumi T, Shimazaki Y, Nishifuji K, Ibrahim SM, Watson A, Busch H , Hirose M",A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs,Microbiome,2023,"16S rRNA, Canine atopic dermatitis, Fusobacterium, JAK inhibitor, Megamonas, Mitochondrial DNA, Mitochondrial haplogroup, Shiba Inu dogs, Skin and gut microbiota, Staphylococcus",Experiment 6,Japan,Canis lupus familiaris,Mouth,UBERON:0000165,Atopic eczema,EFO:0000274,Healthy dogs,cADPre dogs,Dogs that were newly diagnosed with cAD (canine atopic dermatitis) without any previous medical treatments,20,10,Not applicable,16S,12,Illumina,Beta Binomial Regression,0.05,TRUE,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1049/7/NA,Study 1049,time series / longitudinal observational,37864204,10.1186/s40168-023-01671-2,NA,"Thomsen M, Künstner A, Wohlers I, Olbrich M, Lenfers T, Osumi T, Shimazaki Y, Nishifuji K, Ibrahim SM, Watson A, Busch H , Hirose M",A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs,Microbiome,2023,"16S rRNA, Canine atopic dermatitis, Fusobacterium, JAK inhibitor, Megamonas, Mitochondrial DNA, Mitochondrial haplogroup, Shiba Inu dogs, Skin and gut microbiota, Staphylococcus",Experiment 7,Japan,Canis lupus familiaris,Mouth,UBERON:0000165,Atopic eczema,EFO:0000274,Healthy dogs,cADtreat dogs,Dogs that were already diagnosed with cAD (canine atopic dermatitis) before the study cohort recruitment and had been on oclacitinib treatment,20,10,Not applicable,16S,12,Illumina,Beta Binomial Regression,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1049/8/NA,Study 1049,time series / longitudinal observational,37864204,10.1186/s40168-023-01671-2,NA,"Thomsen M, Künstner A, Wohlers I, Olbrich M, Lenfers T, Osumi T, Shimazaki Y, Nishifuji K, Ibrahim SM, Watson A, Busch H , Hirose M",A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs,Microbiome,2023,"16S rRNA, Canine atopic dermatitis, Fusobacterium, JAK inhibitor, Megamonas, Mitochondrial DNA, Mitochondrial haplogroup, Shiba Inu dogs, Skin and gut microbiota, Staphylococcus",Experiment 8,Japan,Canis lupus familiaris,Mouth,UBERON:0000165,Atopic eczema,EFO:0000274,cADpre dogs,cADpost dogs,cADpre dogs that were consequently placed under oclacitinib treatment for two weeks after the diagnosis,10,10,Not applicable,16S,12,Illumina,Beta Binomial Regression,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1049/9/NA,Study 1049,time series / longitudinal observational,37864204,10.1186/s40168-023-01671-2,NA,"Thomsen M, Künstner A, Wohlers I, Olbrich M, Lenfers T, Osumi T, Shimazaki Y, Nishifuji K, Ibrahim SM, Watson A, Busch H , Hirose M",A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs,Microbiome,2023,"16S rRNA, Canine atopic dermatitis, Fusobacterium, JAK inhibitor, Megamonas, Mitochondrial DNA, Mitochondrial haplogroup, Shiba Inu dogs, Skin and gut microbiota, Staphylococcus",Experiment 9,Japan,Canis lupus familiaris,Ventral side of post-anal tail,UBERON:0018691,Atopic eczema,EFO:0000274,Healthy dogs,cADpre dogs,Dogs that were newly diagnosed with cAD (canine atopic dermatitis) without any previous medical treatments,20,10,Not applicable,16S,12,Illumina,Beta Binomial Regression,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1049/10/NA,Study 1049,time series / longitudinal observational,37864204,10.1186/s40168-023-01671-2,NA,"Thomsen M, Künstner A, Wohlers I, Olbrich M, Lenfers T, Osumi T, Shimazaki Y, Nishifuji K, Ibrahim SM, Watson A, Busch H , Hirose M",A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs,Microbiome,2023,"16S rRNA, Canine atopic dermatitis, Fusobacterium, JAK inhibitor, Megamonas, Mitochondrial DNA, Mitochondrial haplogroup, Shiba Inu dogs, Skin and gut microbiota, Staphylococcus",Experiment 10,Japan,Canis lupus familiaris,Ventral side of post-anal tail,UBERON:0018691,Atopic eczema,EFO:0000274,Healthy dogs,cADtreat dogs,Dogs that were already diagnosed with cAD (canine atopic dermatitis) before the study cohort recruitment and had been on oclacitinib treatment,20,10,Not applicable,16S,12,Illumina,Beta Binomial Regression,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1049/11/NA,Study 1049,time series / longitudinal observational,37864204,10.1186/s40168-023-01671-2,NA,"Thomsen M, Künstner A, Wohlers I, Olbrich M, Lenfers T, Osumi T, Shimazaki Y, Nishifuji K, Ibrahim SM, Watson A, Busch H , Hirose M",A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs,Microbiome,2023,"16S rRNA, Canine atopic dermatitis, Fusobacterium, JAK inhibitor, Megamonas, Mitochondrial DNA, Mitochondrial haplogroup, Shiba Inu dogs, Skin and gut microbiota, Staphylococcus",Experiment 11,Japan,Canis lupus familiaris,Ventral side of post-anal tail,UBERON:0018691,Atopic eczema,EFO:0000274,cADpre dogs,cADpost dogs,cADpre dogs that were consequently placed under oclacitinib treatment for two weeks after the diagnosis,10,10,Not applicable,16S,12,Illumina,Beta Binomial Regression,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1049/12/NA,Study 1049,time series / longitudinal observational,37864204,10.1186/s40168-023-01671-2,NA,"Thomsen M, Künstner A, Wohlers I, Olbrich M, Lenfers T, Osumi T, Shimazaki Y, Nishifuji K, Ibrahim SM, Watson A, Busch H , Hirose M",A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs,Microbiome,2023,"16S rRNA, Canine atopic dermatitis, Fusobacterium, JAK inhibitor, Megamonas, Mitochondrial DNA, Mitochondrial haplogroup, Shiba Inu dogs, Skin and gut microbiota, Staphylococcus",Experiment 12,Japan,Canis lupus familiaris,Feces,UBERON:0001988,Atopic eczema,EFO:0000274,Healthy,cADpre dogs,Dogs that were newly diagnosed with cAD (canine atopic dermatitis) without any previous medical treatments,20,10,Not applicable.,16S,34,Illumina,Beta Binomial Regression,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1049/13/NA,Study 1049,time series / longitudinal observational,37864204,10.1186/s40168-023-01671-2,NA,"Thomsen M, Künstner A, Wohlers I, Olbrich M, Lenfers T, Osumi T, Shimazaki Y, Nishifuji K, Ibrahim SM, Watson A, Busch H , Hirose M",A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs,Microbiome,2023,"16S rRNA, Canine atopic dermatitis, Fusobacterium, JAK inhibitor, Megamonas, Mitochondrial DNA, Mitochondrial haplogroup, Shiba Inu dogs, Skin and gut microbiota, Staphylococcus",Experiment 13,Japan,Canis lupus familiaris,Feces,UBERON:0001988,Atopic eczema,EFO:0000274,cADpre,cADpost dogs,cADpre dogs that were consequently placed under oclacitinib treatment for two weeks after the diagnosis,10,10,Not applicable.,16S,34,Illumina,Beta Binomial Regression,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1049/14/NA,Study 1049,time series / longitudinal observational,37864204,10.1186/s40168-023-01671-2,NA,"Thomsen M, Künstner A, Wohlers I, Olbrich M, Lenfers T, Osumi T, Shimazaki Y, Nishifuji K, Ibrahim SM, Watson A, Busch H , Hirose M",A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs,Microbiome,2023,"16S rRNA, Canine atopic dermatitis, Fusobacterium, JAK inhibitor, Megamonas, Mitochondrial DNA, Mitochondrial haplogroup, Shiba Inu dogs, Skin and gut microbiota, Staphylococcus",Experiment 14,Japan,Canis lupus familiaris,Feces,UBERON:0001988,Atopic eczema,EFO:0000274,Healthy dogs,cADtreat dogs,Dogs that were already diagnosed with cAD (canine atopic dermatitis) before the study cohort recruitment and had been on oclacitinib treatment,20,10,Not applicable.,16S,34,Illumina,Beta Binomial Regression,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1049/15/NA,Study 1049,time series / longitudinal observational,37864204,10.1186/s40168-023-01671-2,NA,"Thomsen M, Künstner A, Wohlers I, Olbrich M, Lenfers T, Osumi T, Shimazaki Y, Nishifuji K, Ibrahim SM, Watson A, Busch H , Hirose M",A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs,Microbiome,2023,"16S rRNA, Canine atopic dermatitis, Fusobacterium, JAK inhibitor, Megamonas, Mitochondrial DNA, Mitochondrial haplogroup, Shiba Inu dogs, Skin and gut microbiota, Staphylococcus",Experiment 15,Japan,Canis lupus familiaris,Skin of abdomen,UBERON:0001416,Atopic eczema,EFO:0000274,Healthy controls,cAD Pre,Dogs that were newly diagnosed with cAD (canine atopic dermatitis) without any previous medical treatments,20,10,Not applicable,16S,12,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1049/16/NA,Study 1049,time series / longitudinal observational,37864204,10.1186/s40168-023-01671-2,NA,"Thomsen M, Künstner A, Wohlers I, Olbrich M, Lenfers T, Osumi T, Shimazaki Y, Nishifuji K, Ibrahim SM, Watson A, Busch H , Hirose M",A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs,Microbiome,2023,"16S rRNA, Canine atopic dermatitis, Fusobacterium, JAK inhibitor, Megamonas, Mitochondrial DNA, Mitochondrial haplogroup, Shiba Inu dogs, Skin and gut microbiota, Staphylococcus",Experiment 16,Japan,Canis lupus familiaris,Skin of abdomen,UBERON:0001416,Atopic eczema,EFO:0000274,cAD Pre,cAD post,cADpre dogs that were consequently placed under oclacitinib treatment for two weeks after the diagnosis,10,10,N/A,16S,12,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1049/17/NA,Study 1049,time series / longitudinal observational,37864204,10.1186/s40168-023-01671-2,NA,"Thomsen M, Künstner A, Wohlers I, Olbrich M, Lenfers T, Osumi T, Shimazaki Y, Nishifuji K, Ibrahim SM, Watson A, Busch H , Hirose M",A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs,Microbiome,2023,"16S rRNA, Canine atopic dermatitis, Fusobacterium, JAK inhibitor, Megamonas, Mitochondrial DNA, Mitochondrial haplogroup, Shiba Inu dogs, Skin and gut microbiota, Staphylococcus",Experiment 17,Japan,Canis lupus familiaris,Skin of abdomen,UBERON:0001416,Atopic eczema,EFO:0000274,Healthy,cAD Treat,Dogs that were already diagnosed with cAD (canine atopic dermatitis) before the study cohort recruitment and had been on oclacitinib treatment,20,10,N/A,16S,12,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1049/18/NA,Study 1049,time series / longitudinal observational,37864204,10.1186/s40168-023-01671-2,NA,"Thomsen M, Künstner A, Wohlers I, Olbrich M, Lenfers T, Osumi T, Shimazaki Y, Nishifuji K, Ibrahim SM, Watson A, Busch H , Hirose M",A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs,Microbiome,2023,"16S rRNA, Canine atopic dermatitis, Fusobacterium, JAK inhibitor, Megamonas, Mitochondrial DNA, Mitochondrial haplogroup, Shiba Inu dogs, Skin and gut microbiota, Staphylococcus",Experiment 18,Japan,Canis lupus familiaris,Axilla skin,UBERON:0015474,Atopic eczema,EFO:0000274,Healthy,cAD Pre,Dogs that were newly diagnosed with cAD (canine atopic dermatitis) without any previous medical treatments,20,10,N/A,16S,12,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1049/19/NA,Study 1049,time series / longitudinal observational,37864204,10.1186/s40168-023-01671-2,NA,"Thomsen M, Künstner A, Wohlers I, Olbrich M, Lenfers T, Osumi T, Shimazaki Y, Nishifuji K, Ibrahim SM, Watson A, Busch H , Hirose M",A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs,Microbiome,2023,"16S rRNA, Canine atopic dermatitis, Fusobacterium, JAK inhibitor, Megamonas, Mitochondrial DNA, Mitochondrial haplogroup, Shiba Inu dogs, Skin and gut microbiota, Staphylococcus",Experiment 19,Japan,Canis lupus familiaris,Axilla skin,UBERON:0015474,Atopic eczema,EFO:0000274,cAD Pre,cAD post,cADpre dogs that were consequently placed under oclacitinib treatment for two weeks after the diagnosis,10,10,N/A,16S,12,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1049/20/NA,Study 1049,time series / longitudinal observational,37864204,10.1186/s40168-023-01671-2,NA,"Thomsen M, Künstner A, Wohlers I, Olbrich M, Lenfers T, Osumi T, Shimazaki Y, Nishifuji K, Ibrahim SM, Watson A, Busch H , Hirose M",A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs,Microbiome,2023,"16S rRNA, Canine atopic dermatitis, Fusobacterium, JAK inhibitor, Megamonas, Mitochondrial DNA, Mitochondrial haplogroup, Shiba Inu dogs, Skin and gut microbiota, Staphylococcus",Experiment 20,Japan,Canis lupus familiaris,Axilla skin,UBERON:0015474,Atopic eczema,EFO:0000274,Healthy dogs,cADtreat dogs,Dogs that were already diagnosed with cAD (canine atopic dermatitis) before the study cohort recruitment and had been on oclacitinib treatment,20,10,Not applicable,16S,12,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1049/21/NA,Study 1049,time series / longitudinal observational,37864204,10.1186/s40168-023-01671-2,NA,"Thomsen M, Künstner A, Wohlers I, Olbrich M, Lenfers T, Osumi T, Shimazaki Y, Nishifuji K, Ibrahim SM, Watson A, Busch H , Hirose M",A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs,Microbiome,2023,"16S rRNA, Canine atopic dermatitis, Fusobacterium, JAK inhibitor, Megamonas, Mitochondrial DNA, Mitochondrial haplogroup, Shiba Inu dogs, Skin and gut microbiota, Staphylococcus",Experiment 21,Japan,Canis lupus familiaris,Brachialis muscle,UBERON:0001506,Atopic eczema,EFO:0000274,Healthy dogs,cADPre dogs,Dogs that were newly diagnosed with cAD (canine atopic dermatitis) without any previous medical treatments,20,10,Not applicable,16S,12,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1049/22/NA,Study 1049,time series / longitudinal observational,37864204,10.1186/s40168-023-01671-2,NA,"Thomsen M, Künstner A, Wohlers I, Olbrich M, Lenfers T, Osumi T, Shimazaki Y, Nishifuji K, Ibrahim SM, Watson A, Busch H , Hirose M",A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs,Microbiome,2023,"16S rRNA, Canine atopic dermatitis, Fusobacterium, JAK inhibitor, Megamonas, Mitochondrial DNA, Mitochondrial haplogroup, Shiba Inu dogs, Skin and gut microbiota, Staphylococcus",Experiment 22,Japan,Canis lupus familiaris,Brachialis muscle,UBERON:0001506,Atopic eczema,EFO:0000274,Healthy dogs,cADtreat dogs,Dogs that were already diagnosed with cAD (canine atopic dermatitis) before the study cohort recruitment and had been on oclacitinib treatment,20,10,Not applicable,16S,12,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1049/23/NA,Study 1049,time series / longitudinal observational,37864204,10.1186/s40168-023-01671-2,NA,"Thomsen M, Künstner A, Wohlers I, Olbrich M, Lenfers T, Osumi T, Shimazaki Y, Nishifuji K, Ibrahim SM, Watson A, Busch H , Hirose M",A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs,Microbiome,2023,"16S rRNA, Canine atopic dermatitis, Fusobacterium, JAK inhibitor, Megamonas, Mitochondrial DNA, Mitochondrial haplogroup, Shiba Inu dogs, Skin and gut microbiota, Staphylococcus",Experiment 23,Japan,Canis lupus familiaris,Lateral lumbar region of abdomen,UBERON:0000180,Atopic eczema,EFO:0000274,Healthy controls,cAD Pre,Dogs that were newly diagnosed with cAD (canine atopic dermatitis) without any previous medical treatments,20,10,Not Applicable,16S,12,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1049/24/NA,Study 1049,time series / longitudinal observational,37864204,10.1186/s40168-023-01671-2,NA,"Thomsen M, Künstner A, Wohlers I, Olbrich M, Lenfers T, Osumi T, Shimazaki Y, Nishifuji K, Ibrahim SM, Watson A, Busch H , Hirose M",A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs,Microbiome,2023,"16S rRNA, Canine atopic dermatitis, Fusobacterium, JAK inhibitor, Megamonas, Mitochondrial DNA, Mitochondrial haplogroup, Shiba Inu dogs, Skin and gut microbiota, Staphylococcus",Experiment 24,Japan,Canis lupus familiaris,Lateral lumbar region of abdomen,UBERON:0000180,Atopic eczema,EFO:0000274,Healthy controls,cAD Treat,Dogs that were already diagnosed with cAD (canine atopic dermatitis) before the study cohort recruitment and had been on oclacitinib treatment,20,10,Not Applicable,16S,12,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1049/25/NA,Study 1049,time series / longitudinal observational,37864204,10.1186/s40168-023-01671-2,NA,"Thomsen M, Künstner A, Wohlers I, Olbrich M, Lenfers T, Osumi T, Shimazaki Y, Nishifuji K, Ibrahim SM, Watson A, Busch H , Hirose M",A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs,Microbiome,2023,"16S rRNA, Canine atopic dermatitis, Fusobacterium, JAK inhibitor, Megamonas, Mitochondrial DNA, Mitochondrial haplogroup, Shiba Inu dogs, Skin and gut microbiota, Staphylococcus",Experiment 25,Japan,Canis lupus familiaris,Lateral lumbar region of abdomen,UBERON:0000180,Atopic eczema,EFO:0000274,cADpre,cAD Post,cADpre dogs that were consequently placed under oclacitinib treatment for two weeks after the diagnosis,20,10,Not Applicable,16S,12,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1049/26/NA,Study 1049,time series / longitudinal observational,37864204,10.1186/s40168-023-01671-2,NA,"Thomsen M, Künstner A, Wohlers I, Olbrich M, Lenfers T, Osumi T, Shimazaki Y, Nishifuji K, Ibrahim SM, Watson A, Busch H , Hirose M",A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs,Microbiome,2023,"16S rRNA, Canine atopic dermatitis, Fusobacterium, JAK inhibitor, Megamonas, Mitochondrial DNA, Mitochondrial haplogroup, Shiba Inu dogs, Skin and gut microbiota, Staphylococcus",Experiment 26,Japan,Canis lupus familiaris,Forelimb skin,UBERON:0003531,Atopic eczema,EFO:0000274,Healthy controls,cAD Pre,Dogs that were newly diagnosed with cAD (canine atopic dermatitis) without any previous medical treatments,20,10,Not Applicable,16S,12,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1049/27/NA,Study 1049,time series / longitudinal observational,37864204,10.1186/s40168-023-01671-2,NA,"Thomsen M, Künstner A, Wohlers I, Olbrich M, Lenfers T, Osumi T, Shimazaki Y, Nishifuji K, Ibrahim SM, Watson A, Busch H , Hirose M",A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs,Microbiome,2023,"16S rRNA, Canine atopic dermatitis, Fusobacterium, JAK inhibitor, Megamonas, Mitochondrial DNA, Mitochondrial haplogroup, Shiba Inu dogs, Skin and gut microbiota, Staphylococcus",Experiment 27,Japan,Canis lupus familiaris,Forelimb skin,UBERON:0003531,Atopic eczema,EFO:0000274,Healthy controls,cAD Treat,Dogs that were already diagnosed with cAD (canine atopic dermatitis) before the study cohort recruitment and had been on oclacitinib treatment,20,10,Not Applicable,16S,12,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1049/28/NA,Study 1049,time series / longitudinal observational,37864204,10.1186/s40168-023-01671-2,NA,"Thomsen M, Künstner A, Wohlers I, Olbrich M, Lenfers T, Osumi T, Shimazaki Y, Nishifuji K, Ibrahim SM, Watson A, Busch H , Hirose M",A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs,Microbiome,2023,"16S rRNA, Canine atopic dermatitis, Fusobacterium, JAK inhibitor, Megamonas, Mitochondrial DNA, Mitochondrial haplogroup, Shiba Inu dogs, Skin and gut microbiota, Staphylococcus",Experiment 28,Japan,Canis lupus familiaris,Forelimb skin,UBERON:0003531,Atopic eczema,EFO:0000274,cADpre,cAD Post,cADpre dogs that were consequently placed under oclacitinib treatment for two weeks after the diagnosis,20,10,Not Applicable,16S,12,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1049/29/NA,Study 1049,time series / longitudinal observational,37864204,10.1186/s40168-023-01671-2,NA,"Thomsen M, Künstner A, Wohlers I, Olbrich M, Lenfers T, Osumi T, Shimazaki Y, Nishifuji K, Ibrahim SM, Watson A, Busch H , Hirose M",A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs,Microbiome,2023,"16S rRNA, Canine atopic dermatitis, Fusobacterium, JAK inhibitor, Megamonas, Mitochondrial DNA, Mitochondrial haplogroup, Shiba Inu dogs, Skin and gut microbiota, Staphylococcus",Experiment 29,Japan,Canis lupus familiaris,Hindlimb skin,UBERON:0003532,Atopic eczema,EFO:0000274,Healthy controls,cAD Pre,Dogs that were newly diagnosed with cAD (canine atopic dermatitis) without any previous medical treatments,20,10,Not Applicable,16S,12,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1049/30/NA,Study 1049,time series / longitudinal observational,37864204,10.1186/s40168-023-01671-2,NA,"Thomsen M, Künstner A, Wohlers I, Olbrich M, Lenfers T, Osumi T, Shimazaki Y, Nishifuji K, Ibrahim SM, Watson A, Busch H , Hirose M",A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs,Microbiome,2023,"16S rRNA, Canine atopic dermatitis, Fusobacterium, JAK inhibitor, Megamonas, Mitochondrial DNA, Mitochondrial haplogroup, Shiba Inu dogs, Skin and gut microbiota, Staphylococcus",Experiment 30,Japan,Canis lupus familiaris,Hindlimb skin,UBERON:0003532,Atopic eczema,EFO:0000274,Healthy controls,cADtreat dogs,Dogs that were already diagnosed with cAD (canine atopic dermatitis) before the study cohort recruitment and had been on oclacitinib treatment,20,10,Not Applicable,16S,12,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1049/31/NA,Study 1049,time series / longitudinal observational,37864204,10.1186/s40168-023-01671-2,NA,"Thomsen M, Künstner A, Wohlers I, Olbrich M, Lenfers T, Osumi T, Shimazaki Y, Nishifuji K, Ibrahim SM, Watson A, Busch H , Hirose M",A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs,Microbiome,2023,"16S rRNA, Canine atopic dermatitis, Fusobacterium, JAK inhibitor, Megamonas, Mitochondrial DNA, Mitochondrial haplogroup, Shiba Inu dogs, Skin and gut microbiota, Staphylococcus",Experiment 31,Japan,Canis lupus familiaris,Hindlimb skin,UBERON:0003532,Atopic eczema,EFO:0000274,cADpre dogs,cADpost dogs,cADpre dogs that were consequently placed under oclacitinib treatment for two weeks after the diagnosis,20,10,Not Applicable,16S,12,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1049/32/NA,Study 1049,time series / longitudinal observational,37864204,10.1186/s40168-023-01671-2,NA,"Thomsen M, Künstner A, Wohlers I, Olbrich M, Lenfers T, Osumi T, Shimazaki Y, Nishifuji K, Ibrahim SM, Watson A, Busch H , Hirose M",A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs,Microbiome,2023,"16S rRNA, Canine atopic dermatitis, Fusobacterium, JAK inhibitor, Megamonas, Mitochondrial DNA, Mitochondrial haplogroup, Shiba Inu dogs, Skin and gut microbiota, Staphylococcus",Experiment 32,Japan,Canis lupus familiaris,Inguinal part of abdomen,UBERON:0008337,Atopic eczema,EFO:0000274,Healthy dogs,cADpre dogs,Dogs that were newly diagnosed with cAD (canine atopic dermatitis) without any previous medical treatments,20,10,Not Applicable,16S,12,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1049/33/NA,Study 1049,time series / longitudinal observational,37864204,10.1186/s40168-023-01671-2,NA,"Thomsen M, Künstner A, Wohlers I, Olbrich M, Lenfers T, Osumi T, Shimazaki Y, Nishifuji K, Ibrahim SM, Watson A, Busch H , Hirose M",A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs,Microbiome,2023,"16S rRNA, Canine atopic dermatitis, Fusobacterium, JAK inhibitor, Megamonas, Mitochondrial DNA, Mitochondrial haplogroup, Shiba Inu dogs, Skin and gut microbiota, Staphylococcus",Experiment 33,Japan,Canis lupus familiaris,Inguinal part of abdomen,UBERON:0008337,Atopic eczema,EFO:0000274,cADpre dogs,cADpost dogs,cADpre dogs that were consequently placed under oclacitinib treatment for two weeks after the diagnosis,10,10,Not applicable,16S,12,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1049/34/NA,Study 1049,time series / longitudinal observational,37864204,10.1186/s40168-023-01671-2,NA,"Thomsen M, Künstner A, Wohlers I, Olbrich M, Lenfers T, Osumi T, Shimazaki Y, Nishifuji K, Ibrahim SM, Watson A, Busch H , Hirose M",A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs,Microbiome,2023,"16S rRNA, Canine atopic dermatitis, Fusobacterium, JAK inhibitor, Megamonas, Mitochondrial DNA, Mitochondrial haplogroup, Shiba Inu dogs, Skin and gut microbiota, Staphylococcus",Experiment 34,Japan,Canis lupus familiaris,Pinna,UBERON:0001757,Atopic eczema,EFO:0000274,Healthy dogs,cADpre dogs,Dogs that were newly diagnosed with cAD (canine atopic dermatitis) without any previous medical treatments,20,10,Not applicable,16S,12,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1049/35/NA,Study 1049,time series / longitudinal observational,37864204,10.1186/s40168-023-01671-2,NA,"Thomsen M, Künstner A, Wohlers I, Olbrich M, Lenfers T, Osumi T, Shimazaki Y, Nishifuji K, Ibrahim SM, Watson A, Busch H , Hirose M",A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs,Microbiome,2023,"16S rRNA, Canine atopic dermatitis, Fusobacterium, JAK inhibitor, Megamonas, Mitochondrial DNA, Mitochondrial haplogroup, Shiba Inu dogs, Skin and gut microbiota, Staphylococcus",Experiment 35,Japan,Canis lupus familiaris,Pinna,UBERON:0001757,Atopic eczema,EFO:0000274,Healthy dogs,cADtreat dogs,Dogs that were already diagnosed with cAD (canine atopic dermatitis) before the study cohort recruitment and had been on oclacitinib treatment,20,10,Not applicable,16S,12,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1049/36/NA,Study 1049,time series / longitudinal observational,37864204,10.1186/s40168-023-01671-2,NA,"Thomsen M, Künstner A, Wohlers I, Olbrich M, Lenfers T, Osumi T, Shimazaki Y, Nishifuji K, Ibrahim SM, Watson A, Busch H , Hirose M",A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs,Microbiome,2023,"16S rRNA, Canine atopic dermatitis, Fusobacterium, JAK inhibitor, Megamonas, Mitochondrial DNA, Mitochondrial haplogroup, Shiba Inu dogs, Skin and gut microbiota, Staphylococcus",Experiment 36,Japan,Canis lupus familiaris,Pinna,UBERON:0001757,Atopic eczema,EFO:0000274,cADpre dogs,cADpost dogs,cADpre dogs that were consequently placed under oclacitinib treatment for two weeks after the diagnosis,10,10,Not applicable,16S,12,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1049/37/NA,Study 1049,time series / longitudinal observational,37864204,10.1186/s40168-023-01671-2,NA,"Thomsen M, Künstner A, Wohlers I, Olbrich M, Lenfers T, Osumi T, Shimazaki Y, Nishifuji K, Ibrahim SM, Watson A, Busch H , Hirose M",A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs,Microbiome,2023,"16S rRNA, Canine atopic dermatitis, Fusobacterium, JAK inhibitor, Megamonas, Mitochondrial DNA, Mitochondrial haplogroup, Shiba Inu dogs, Skin and gut microbiota, Staphylococcus",Experiment 37,Japan,Canis lupus familiaris,Skin of palmar/plantar part of autopod,UBERON:0013776,Atopic eczema,EFO:0000274,Healthy dogs,cADPre dogs,Dogs that were newly diagnosed with cAD (canine atopic dermatitis) without any previous medical treatments,20,10,Not applicable,16S,12,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1049/38/NA,Study 1049,time series / longitudinal observational,37864204,10.1186/s40168-023-01671-2,NA,"Thomsen M, Künstner A, Wohlers I, Olbrich M, Lenfers T, Osumi T, Shimazaki Y, Nishifuji K, Ibrahim SM, Watson A, Busch H , Hirose M",A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs,Microbiome,2023,"16S rRNA, Canine atopic dermatitis, Fusobacterium, JAK inhibitor, Megamonas, Mitochondrial DNA, Mitochondrial haplogroup, Shiba Inu dogs, Skin and gut microbiota, Staphylococcus",Experiment 38,Japan,Canis lupus familiaris,Skin of palmar/plantar part of autopod,UBERON:0013776,Atopic eczema,EFO:0000274,Healthy dogs,cADtreat dogs,Dogs that were already diagnosed with cAD (canine atopic dermatitis) before the study cohort recruitment and had been on oclacitinib treatment,20,10,Not applicable,16S,12,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1049/39/NA,Study 1049,time series / longitudinal observational,37864204,10.1186/s40168-023-01671-2,NA,"Thomsen M, Künstner A, Wohlers I, Olbrich M, Lenfers T, Osumi T, Shimazaki Y, Nishifuji K, Ibrahim SM, Watson A, Busch H , Hirose M",A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs,Microbiome,2023,"16S rRNA, Canine atopic dermatitis, Fusobacterium, JAK inhibitor, Megamonas, Mitochondrial DNA, Mitochondrial haplogroup, Shiba Inu dogs, Skin and gut microbiota, Staphylococcus",Experiment 39,Japan,Canis lupus familiaris,Skin of palmar/plantar part of autopod,UBERON:0013776,Atopic eczema,EFO:0000274,cADpre dogs,cADpost dogs,cADpre dogs that were consequently placed under oclacitinib treatment for two weeks after the diagnosis,10,10,Not applicable,16S,12,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1049/40/NA,Study 1049,time series / longitudinal observational,37864204,10.1186/s40168-023-01671-2,NA,"Thomsen M, Künstner A, Wohlers I, Olbrich M, Lenfers T, Osumi T, Shimazaki Y, Nishifuji K, Ibrahim SM, Watson A, Busch H , Hirose M",A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs,Microbiome,2023,"16S rRNA, Canine atopic dermatitis, Fusobacterium, JAK inhibitor, Megamonas, Mitochondrial DNA, Mitochondrial haplogroup, Shiba Inu dogs, Skin and gut microbiota, Staphylococcus",Experiment 40,Japan,Canis lupus familiaris,Mouth,UBERON:0000165,Atopic eczema,EFO:0000274,Healthy dogs,cADpre dogs,Dogs that were newly diagnosed with cAD (canine atopic dermatitis) without any previous medical treatments,20,10,Not applicable,16S,12,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1049/41/NA,Study 1049,time series / longitudinal observational,37864204,10.1186/s40168-023-01671-2,NA,"Thomsen M, Künstner A, Wohlers I, Olbrich M, Lenfers T, Osumi T, Shimazaki Y, Nishifuji K, Ibrahim SM, Watson A, Busch H , Hirose M",A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs,Microbiome,2023,"16S rRNA, Canine atopic dermatitis, Fusobacterium, JAK inhibitor, Megamonas, Mitochondrial DNA, Mitochondrial haplogroup, Shiba Inu dogs, Skin and gut microbiota, Staphylococcus",Experiment 41,Japan,Canis lupus familiaris,Mouth,UBERON:0000165,Atopic eczema,EFO:0000274,cADpre dogs,cADpost dogs,cADpre dogs that were consequently placed under oclacitinib treatment for two weeks after the diagnosis,10,10,Not applicable,16S,12,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1049/42/NA,Study 1049,time series / longitudinal observational,37864204,10.1186/s40168-023-01671-2,NA,"Thomsen M, Künstner A, Wohlers I, Olbrich M, Lenfers T, Osumi T, Shimazaki Y, Nishifuji K, Ibrahim SM, Watson A, Busch H , Hirose M",A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs,Microbiome,2023,"16S rRNA, Canine atopic dermatitis, Fusobacterium, JAK inhibitor, Megamonas, Mitochondrial DNA, Mitochondrial haplogroup, Shiba Inu dogs, Skin and gut microbiota, Staphylococcus",Experiment 42,Japan,Canis lupus familiaris,Perineum,UBERON:0002356,Atopic eczema,EFO:0000274,Healthy dogs,cADpre dogs,Dogs that were newly diagnosed with cAD (canine atopic dermatitis) without any previous medical treatments,20,10,Not applicable,16S,12,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1049/43/NA,Study 1049,time series / longitudinal observational,37864204,10.1186/s40168-023-01671-2,NA,"Thomsen M, Künstner A, Wohlers I, Olbrich M, Lenfers T, Osumi T, Shimazaki Y, Nishifuji K, Ibrahim SM, Watson A, Busch H , Hirose M",A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs,Microbiome,2023,"16S rRNA, Canine atopic dermatitis, Fusobacterium, JAK inhibitor, Megamonas, Mitochondrial DNA, Mitochondrial haplogroup, Shiba Inu dogs, Skin and gut microbiota, Staphylococcus",Experiment 43,Japan,Canis lupus familiaris,Ventral side of post-anal tail,UBERON:0018691,Atopic eczema,EFO:0000274,Healthy dogs,cADpre dogs,Dogs that were newly diagnosed with cAD (canine atopic dermatitis) without any previous medical treatments,20,10,Not applicable,16S,12,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1049/44/NA,Study 1049,time series / longitudinal observational,37864204,10.1186/s40168-023-01671-2,NA,"Thomsen M, Künstner A, Wohlers I, Olbrich M, Lenfers T, Osumi T, Shimazaki Y, Nishifuji K, Ibrahim SM, Watson A, Busch H , Hirose M",A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs,Microbiome,2023,"16S rRNA, Canine atopic dermatitis, Fusobacterium, JAK inhibitor, Megamonas, Mitochondrial DNA, Mitochondrial haplogroup, Shiba Inu dogs, Skin and gut microbiota, Staphylococcus",Experiment 44,Japan,Canis lupus familiaris,Ventral side of post-anal tail,UBERON:0018691,Atopic eczema,EFO:0000274,Healthy dogs,cADtreat dogs,Dogs that were already diagnosed with cAD (canine atopic dermatitis) before the study cohort recruitment and had been on oclacitinib treatment,20,10,Not applicable,16S,12,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1049/45/NA,Study 1049,time series / longitudinal observational,37864204,10.1186/s40168-023-01671-2,NA,"Thomsen M, Künstner A, Wohlers I, Olbrich M, Lenfers T, Osumi T, Shimazaki Y, Nishifuji K, Ibrahim SM, Watson A, Busch H , Hirose M",A comprehensive analysis of gut and skin microbiota in canine atopic dermatitis in Shiba Inu dogs,Microbiome,2023,"16S rRNA, Canine atopic dermatitis, Fusobacterium, JAK inhibitor, Megamonas, Mitochondrial DNA, Mitochondrial haplogroup, Shiba Inu dogs, Skin and gut microbiota, Staphylococcus",Experiment 45,Japan,Canis lupus familiaris,Ventral side of post-anal tail,UBERON:0018691,Atopic eczema,EFO:0000274,cADpre dogs,cADpost dogs,cADpre dogs that were consequently placed under oclacitinib treatment for two weeks after the diagnosis,10,10,Not applicable,16S,12,Illumina,ANCOM,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1050/1/NA,Study 1050,"cross-sectional observational, not case-control",30065718,10.3389/fmicb.2018.01603,NA,"Dong L, Yin J, Zhao J, Ma SR, Wang HR, Wang M, Chen W , Wei WQ",Microbial Similarity and Preference for Specific Sites in Healthy Oral Cavity and Esophagus,Frontiers in microbiology,2018,"16S rRNA gene sequencing, esophagus, microbial preference, microbial similarity, oral cavity",Experiment 1,China,Homo sapiens,"Oral cavity,Esophagus","UBERON:0000167,UBERON:0001043",Taxonomic microbiome measurement,EFO:0007883,Oral cavity,Esophagus,"Healthy individual who are esophageal disease-free, confirmed by endoscopic examination and then biopsy-based pathological diagnosis if necessary.",27,27,None,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,decreased,increased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1050/2/NA,Study 1050,"cross-sectional observational, not case-control",30065718,10.3389/fmicb.2018.01603,NA,"Dong L, Yin J, Zhao J, Ma SR, Wang HR, Wang M, Chen W , Wei WQ",Microbial Similarity and Preference for Specific Sites in Healthy Oral Cavity and Esophagus,Frontiers in microbiology,2018,"16S rRNA gene sequencing, esophagus, microbial preference, microbial similarity, oral cavity",Experiment 2,China,Homo sapiens,Oral cavity,UBERON:0000167,Taxonomic microbiome measurement,EFO:0007883,Saliva and tongue dorsum,Supragingival plaque,Supragingival plaque samples of healthy individual confirmed free of periodontal diseases and no incident caries at the time of sampling by a dentist.,27,27,None,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,increased,unchanged,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1050/3/NA,Study 1050,"cross-sectional observational, not case-control",30065718,10.3389/fmicb.2018.01603,NA,"Dong L, Yin J, Zhao J, Ma SR, Wang HR, Wang M, Chen W , Wei WQ",Microbial Similarity and Preference for Specific Sites in Healthy Oral Cavity and Esophagus,Frontiers in microbiology,2018,"16S rRNA gene sequencing, esophagus, microbial preference, microbial similarity, oral cavity",Experiment 3,China,Homo sapiens,Oral cavity,UBERON:0000167,Taxonomic microbiome measurement,EFO:0007883,Tongue dorsum and supragingival plaque,Saliva,Saliva samples of healthy individual confirmed free of periodontal diseases and no incident caries at the time of sampling by a dentist.,27,27,None,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1050/4/NA,Study 1050,"cross-sectional observational, not case-control",30065718,10.3389/fmicb.2018.01603,NA,"Dong L, Yin J, Zhao J, Ma SR, Wang HR, Wang M, Chen W , Wei WQ",Microbial Similarity and Preference for Specific Sites in Healthy Oral Cavity and Esophagus,Frontiers in microbiology,2018,"16S rRNA gene sequencing, esophagus, microbial preference, microbial similarity, oral cavity",Experiment 4,China,Homo sapiens,Oral cavity,UBERON:0000167,Taxonomic microbiome measurement,EFO:0007883,Supragingival plaque and Saliva,Tongue dorsum,Tongue dorsum samples of healthy individual confirmed free of periodontal diseases and no incident caries at the time of sampling by a dentist.,27,27,None,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1051/1/NA,Study 1051,"cross-sectional observational, not case-control",38166904,10.1186/s12890-023-02825-6,NA,"Luan J, Zhang F, Suo L, Zhang W, Li Y, Yu X, Liu B , Cao H",Analyzing lung cancer risks in patients with impaired pulmonary function through characterization of gut microbiome and metabolites,BMC pulmonary medicine,2024,"Biomarkers, Gut microbiota, Lung cancer, Metabolomics, Pulmonary function",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Lung cancer,MONDO:0008903,Benign pulmonary diseases (N group),Lung cancer (L group),"Lung cancer patients graded according to the American Thoracic Society/ European Respiratory Society (ATS/ERS) five level classification method for pulmonary ventilation impairment and divided into 3 groups, including 20 patients with normal lung ventilation, 23 patients with mild pulmonary ventilation dysfunction and 12 patients with moderate or above pulmonary ventilation dysfunction.",28,55,3 months,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1052/1/NA,Study 1052,case-control,34384375,10.1186/s12866-021-02286-z,NA,"Xi J, Ding D, Zhu H, Wang R, Su F, Wu W, Xiao Z, Liang X, Zhao Q, Hong Z, Fu H , Xiao Q",Disturbed microbial ecology in Alzheimer's disease: evidence from the gut microbiota and fecal metabolome,BMC microbiology,2021,"Alzheimer’s disease, Fecal markers, Fecal metabolome, Gut microbiota, Inflammatory cytokines",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Alzheimer's disease,MONDO:0004975,Cognitively normal control (NC),Alzheimer’s Disease (AD),Participants with Alzheimer’s Disease (AD); the most prevalent neurodegenerative disorder.,44,21,1 month,16S,34,Illumina,LEfSe,0.05,FALSE,2.5,NA,NA,NA,unchanged,unchanged,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1053/1/NA,Study 1053,case-control,32111156,10.1186/s12866-020-01734-6,NA,"Xie J, Huang JS, Huang XJ, Peng JM, Yu Z, Yuan YQ, Xiao KF , Guo JN",Profiling the urinary microbiome in men with calcium-based kidney stones,BMC microbiology,2020,"Calcium-based, Kidney stone, Microbiome, Renal pelvis, Urine",Experiment 1,China,Homo sapiens,Urinary bladder,UBERON:0001255,Nephrolithiasis,EFO:0004253,HB group - Bladder urine from healthy controls.,KB group - Bladder urine from kidney stone patients.,Bladder urine collected from nephrolithiasis (Kidney stone) patients.,21,22,30 days.,16S,34,Illumina,LEfSe,0.05,FALSE,2,age,NA,NA,decreased,decreased,increased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1053/2/NA,Study 1053,case-control,32111156,10.1186/s12866-020-01734-6,NA,"Xie J, Huang JS, Huang XJ, Peng JM, Yu Z, Yuan YQ, Xiao KF , Guo JN",Profiling the urinary microbiome in men with calcium-based kidney stones,BMC microbiology,2020,"Calcium-based, Kidney stone, Microbiome, Renal pelvis, Urine",Experiment 2,China,Homo sapiens,Renal pelvis/ureter,UBERON:0036295,Nephrolithiasis,EFO:0004253,KB group - Bladder urine from kidney stone patients.,KP group - Renal pelvis urine from kidney stone patients.,Renal pelvis urine collected from nephrolithiasis (Kidney stone) patients.,22,22,Participants using antibiotics within 30days were excluded.,16S,34,Illumina,LEfSe,0.05,FALSE,2,age,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1054/1/NA,Study 1054,case-control,36544085,10.1186/s12866-022-02730-8,NA,"Shabayek S, Abdellah AM, Salah M, Ramadan M , Fahmy N",Alterations of the vaginal microbiome in healthy pregnant women positive for group B Streptococcus colonization during the third trimester,BMC microbiology,2022,"Group B Streptococcus, Healthy, Microbiome, Pregnant, Streptococcus agalactiae, Third trimester, Vagina",Experiment 1,Egypt,Homo sapiens,Vagina,UBERON:0000996,Streptococcal infection,EFO:1001476,GBS culture-negative pregnant women,GBS culture-positive pregnant women,Pregnant women who tested positive for Group B Streptococcus (GBS) by culture during the third trimester,22,22,6 months,16S,34,Illumina,LEfSe,0.05,TRUE,2,"age,parity",NA,NA,increased,unchanged,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1055/1/NA,Study 1055,"cross-sectional observational, not case-control",37953319,10.1186/s40168-023-01694-9,NA,"Kaisanlahti A, Turunen J, Byts N, Samoylenko A, Bart G, Virtanen N, Tejesvi MV, Zhyvolozhnyi A, Sarfraz S, Kumpula S, Hekkala J, Salmi S, Will O, Korvala J, Paalanne N, Erawijantari PP, Suokas M, Medina TP, Vainio S, Medina OP, Lahti L, Tapiainen T , Reunanen J",Maternal microbiota communicates with the fetus through microbiota-derived extracellular vesicles,Microbiome,2023,"Amniotic fluid, Extracellular vesicles, Fetal environment, Fetal microbiota, Gut microbiota, Intestine",Experiment 1,Finland,Homo sapiens,Amniotic fluid,UBERON:0000173,Pregnancy,EFO:0002950,Amniotic fluid (AM),Amniotic fluid-derived extracellular vesicles (AM EVs),Amniotic fluid EV group,10,24,NA,16S,45,Ion Torrent,"Kruskall-Wallis,ANCOM,Mann-Whitney (Wilcoxon)",0.05,TRUE,NA,NA,NA,NA,increased,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1055/2/NA,Study 1055,"cross-sectional observational, not case-control",37953319,10.1186/s40168-023-01694-9,NA,"Kaisanlahti A, Turunen J, Byts N, Samoylenko A, Bart G, Virtanen N, Tejesvi MV, Zhyvolozhnyi A, Sarfraz S, Kumpula S, Hekkala J, Salmi S, Will O, Korvala J, Paalanne N, Erawijantari PP, Suokas M, Medina TP, Vainio S, Medina OP, Lahti L, Tapiainen T , Reunanen J",Maternal microbiota communicates with the fetus through microbiota-derived extracellular vesicles,Microbiome,2023,"Amniotic fluid, Extracellular vesicles, Fetal environment, Fetal microbiota, Gut microbiota, Intestine",Experiment 2,Finland,Homo sapiens,"Amniotic fluid,Feces","UBERON:0000173,UBERON:0001988",Pregnancy,EFO:0002950,Amniotic fluid (AM),Maternal feces (FE),Contrasts in the AM and FE pair,10,22,NA,16S,45,Ion Torrent,"ANCOM,Kruskall-Wallis,Mann-Whitney (Wilcoxon)",0.05,TRUE,NA,NA,NA,NA,increased,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1055/3/NA,Study 1055,"cross-sectional observational, not case-control",37953319,10.1186/s40168-023-01694-9,NA,"Kaisanlahti A, Turunen J, Byts N, Samoylenko A, Bart G, Virtanen N, Tejesvi MV, Zhyvolozhnyi A, Sarfraz S, Kumpula S, Hekkala J, Salmi S, Will O, Korvala J, Paalanne N, Erawijantari PP, Suokas M, Medina TP, Vainio S, Medina OP, Lahti L, Tapiainen T , Reunanen J",Maternal microbiota communicates with the fetus through microbiota-derived extracellular vesicles,Microbiome,2023,"Amniotic fluid, Extracellular vesicles, Fetal environment, Fetal microbiota, Gut microbiota, Intestine",Experiment 3,Finland,Homo sapiens,"Amniotic fluid,Feces","UBERON:0000173,UBERON:0001988",Pregnancy,EFO:0002950,Amniotic fluid (AM),Feces-derived extracellular vesicles (FE EV),Contrasts between AM and FE_EV pair,10,22,NA,16S,45,Ion Torrent,"ANCOM,Kruskall-Wallis,Mann-Whitney (Wilcoxon)",0.05,TRUE,NA,NA,NA,NA,increased,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1055/4/NA,Study 1055,"cross-sectional observational, not case-control",37953319,10.1186/s40168-023-01694-9,NA,"Kaisanlahti A, Turunen J, Byts N, Samoylenko A, Bart G, Virtanen N, Tejesvi MV, Zhyvolozhnyi A, Sarfraz S, Kumpula S, Hekkala J, Salmi S, Will O, Korvala J, Paalanne N, Erawijantari PP, Suokas M, Medina TP, Vainio S, Medina OP, Lahti L, Tapiainen T , Reunanen J",Maternal microbiota communicates with the fetus through microbiota-derived extracellular vesicles,Microbiome,2023,"Amniotic fluid, Extracellular vesicles, Fetal environment, Fetal microbiota, Gut microbiota, Intestine",Experiment 4,Finland,Homo sapiens,"Amniotic fluid,Feces","UBERON:0000173,UBERON:0001988",Pregnancy,EFO:0002950,Amniotic fluid-derived extracellular vesicles (AM EV),Maternal feces (FE),Differences between AM_EV and FE pair,24,22,NA,16S,45,Ion Torrent,"ANCOM,Kruskall-Wallis,Mann-Whitney (Wilcoxon)",0.05,TRUE,NA,NA,NA,NA,decreased,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1055/5/NA,Study 1055,"cross-sectional observational, not case-control",37953319,10.1186/s40168-023-01694-9,NA,"Kaisanlahti A, Turunen J, Byts N, Samoylenko A, Bart G, Virtanen N, Tejesvi MV, Zhyvolozhnyi A, Sarfraz S, Kumpula S, Hekkala J, Salmi S, Will O, Korvala J, Paalanne N, Erawijantari PP, Suokas M, Medina TP, Vainio S, Medina OP, Lahti L, Tapiainen T , Reunanen J",Maternal microbiota communicates with the fetus through microbiota-derived extracellular vesicles,Microbiome,2023,"Amniotic fluid, Extracellular vesicles, Fetal environment, Fetal microbiota, Gut microbiota, Intestine",Experiment 5,Finland,Homo sapiens,"Amniotic fluid,Feces","UBERON:0000173,UBERON:0001988",Pregnancy,EFO:0002950,Amniotic fluid-derived extracellular vesicles (AM EV),Feces-derived extracellular vesicles (FE EV),Differences in AM_EV and FE_EV pair,24,22,NA,16S,45,Ion Torrent,"ANCOM,Kruskall-Wallis,Mann-Whitney (Wilcoxon)",0.05,TRUE,NA,NA,NA,NA,decreased,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1055/6/NA,Study 1055,"cross-sectional observational, not case-control",37953319,10.1186/s40168-023-01694-9,NA,"Kaisanlahti A, Turunen J, Byts N, Samoylenko A, Bart G, Virtanen N, Tejesvi MV, Zhyvolozhnyi A, Sarfraz S, Kumpula S, Hekkala J, Salmi S, Will O, Korvala J, Paalanne N, Erawijantari PP, Suokas M, Medina TP, Vainio S, Medina OP, Lahti L, Tapiainen T , Reunanen J",Maternal microbiota communicates with the fetus through microbiota-derived extracellular vesicles,Microbiome,2023,"Amniotic fluid, Extracellular vesicles, Fetal environment, Fetal microbiota, Gut microbiota, Intestine",Experiment 6,Finland,Homo sapiens,Feces,UBERON:0001988,Pregnancy,EFO:0002950,Maternal feces (FE),Feces-derived extracellular vesicles (FE EV),Differences in FE and FE_EV,22,22,NA,16S,45,Ion Torrent,"ANCOM,Kruskall-Wallis,Mann-Whitney (Wilcoxon)",0.05,TRUE,NA,NA,NA,NA,increased,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1056/1/NA,Study 1056,prospective cohort,34809575,https://doi.org/10.1186/s12866-021-02387-9,https://bmcmicrobiol.biomedcentral.com/articles/10.1186/s12866-021-02387-9,"Wu Z, Hullings AG, Ghanbari R, Etemadi A, Wan Y, Zhu B, Poustchi H, Fahraji BB, Sakhvidi MJZ, Shi J, Knight R, Malekzadeh R, Sinha R , Vogtmann E",Comparison of fecal and oral collection methods for studies of the human microbiota in two Iranian cohorts,BMC microbiology,2021,"Comparability, Feces, Iran, Microbiome, Saliva, Stability",Experiment 1,Iran,Homo sapiens,Feces,UBERON:0001988,Microbiome measurement,EFO:0007882,RNAlater - Day 0,RNAlater - Day 4,"RNAlater fecal samples after incubation at room temperature for four days (day-4) from Gonbad and Yazd, Iran",69,64,None,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.01,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1056/2/NA,Study 1056,prospective cohort,34809575,https://doi.org/10.1186/s12866-021-02387-9,https://bmcmicrobiol.biomedcentral.com/articles/10.1186/s12866-021-02387-9,"Wu Z, Hullings AG, Ghanbari R, Etemadi A, Wan Y, Zhu B, Poustchi H, Fahraji BB, Sakhvidi MJZ, Shi J, Knight R, Malekzadeh R, Sinha R , Vogtmann E",Comparison of fecal and oral collection methods for studies of the human microbiota in two Iranian cohorts,BMC microbiology,2021,"Comparability, Feces, Iran, Microbiome, Saliva, Stability",Experiment 2,Iran,Homo sapiens,Feces,UBERON:0001988,Microbiome measurement,EFO:0007882,RNAlater - Day 0,Fecal occult blood test [FOBT] cards - Day 0,"Fecal occult blood test [FOBT] cards fecal samples frozen immediately (day-0) from Gonbad and Yazd, Iran",69,70,None,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.01,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1056/3/NA,Study 1056,prospective cohort,34809575,https://doi.org/10.1186/s12866-021-02387-9,https://bmcmicrobiol.biomedcentral.com/articles/10.1186/s12866-021-02387-9,"Wu Z, Hullings AG, Ghanbari R, Etemadi A, Wan Y, Zhu B, Poustchi H, Fahraji BB, Sakhvidi MJZ, Shi J, Knight R, Malekzadeh R, Sinha R , Vogtmann E",Comparison of fecal and oral collection methods for studies of the human microbiota in two Iranian cohorts,BMC microbiology,2021,"Comparability, Feces, Iran, Microbiome, Saliva, Stability",Experiment 3,Iran,Homo sapiens,Saliva,UBERON:0001836,Microbiome measurement,EFO:0007882,Scope mouthwash - Day 0,Scope mouthwash - Day 4,"Scope mouthwash samples after incubation at room temperature for four days (day-4) from Gonbad and Yazd, Iran",70,55,None,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.01,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1056/4/NA,Study 1056,prospective cohort,34809575,https://doi.org/10.1186/s12866-021-02387-9,https://bmcmicrobiol.biomedcentral.com/articles/10.1186/s12866-021-02387-9,"Wu Z, Hullings AG, Ghanbari R, Etemadi A, Wan Y, Zhu B, Poustchi H, Fahraji BB, Sakhvidi MJZ, Shi J, Knight R, Malekzadeh R, Sinha R , Vogtmann E",Comparison of fecal and oral collection methods for studies of the human microbiota in two Iranian cohorts,BMC microbiology,2021,"Comparability, Feces, Iran, Microbiome, Saliva, Stability",Experiment 4,Iran,Homo sapiens,Saliva,UBERON:0001836,Microbiome measurement,EFO:0007882,OMNIgene ORAL kit,Scope mouthwash,"Scope mouthwash oral samples from Gonbad and Yazd, Iran",77,125,None,16S,4,Illumina,Mann-Whitney (Wilcoxon),0.01,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1057/1/NA,Study 1057,"cross-sectional observational, not case-control",33129264,https://doi.org/10.1186/s12866-020-02017-w,NA,"Oduaran OH, Tamburini FB, Sahibdeen V, Brewster R, Gómez-Olivé FX, Kahn K, Norris SA, Tollman SM, Twine R, Wade AN, Wagner RG, Lombard Z, Bhatt AS , Hazelhurst S",Gut microbiome profiling of a rural and urban South African cohort reveals biomarkers of a population in lifestyle transition,BMC microbiology,2020,"16S, African microbiome, Epidemiological transition, Obesity, South African microbiome, Transitional microbiome",Experiment 1,South Africa,Homo sapiens,Feces,UBERON:0001988,Lifestyle measurement,EFO:0010724,Female subjects situated in Bushbuckridge,Female subjects situated in Soweto,Female subjects (both obese and lean) living in Soweto whose microbiota was studied to reflect transitional changes in microbiome on account of the adoption of a more Westernized lifestyle (in terms of diet and activity levels). Soweto represented the urban site of the two; the other (Bushbuckridge) being more relatively rural.,119,51,None,16S,34,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1057/2/NA,Study 1057,"cross-sectional observational, not case-control",33129264,https://doi.org/10.1186/s12866-020-02017-w,NA,"Oduaran OH, Tamburini FB, Sahibdeen V, Brewster R, Gómez-Olivé FX, Kahn K, Norris SA, Tollman SM, Twine R, Wade AN, Wagner RG, Lombard Z, Bhatt AS , Hazelhurst S",Gut microbiome profiling of a rural and urban South African cohort reveals biomarkers of a population in lifestyle transition,BMC microbiology,2020,"16S, African microbiome, Epidemiological transition, Obesity, South African microbiome, Transitional microbiome",Experiment 2,South Africa,Homo sapiens,Feces,UBERON:0001988,Lifestyle measurement,EFO:0010724,Lean female subjects in Bushbuckridge,Lean female subjects in Soweto,Lean females subjects living in Soweto whose microbiota was studied to understand transitional microbiome differences between subjects in Bushbuckridge and those in Soweto.,21,9,None,16S,34,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1057/3/NA,Study 1057,"cross-sectional observational, not case-control",33129264,https://doi.org/10.1186/s12866-020-02017-w,NA,"Oduaran OH, Tamburini FB, Sahibdeen V, Brewster R, Gómez-Olivé FX, Kahn K, Norris SA, Tollman SM, Twine R, Wade AN, Wagner RG, Lombard Z, Bhatt AS , Hazelhurst S",Gut microbiome profiling of a rural and urban South African cohort reveals biomarkers of a population in lifestyle transition,BMC microbiology,2020,"16S, African microbiome, Epidemiological transition, Obesity, South African microbiome, Transitional microbiome",Experiment 3,South Africa,Homo sapiens,Feces,UBERON:0001988,Lifestyle measurement,EFO:0010724,Obese female subjects in Bushbuckridge,Obese female subjects in Soweto,Obese females in Soweto whose microbiota was studied to understand transitional microbiome differences between subjects in Bushbuckridge and those in Soweto.,66,40,None,16S,34,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1057/4/NA,Study 1057,"cross-sectional observational, not case-control",33129264,https://doi.org/10.1186/s12866-020-02017-w,NA,"Oduaran OH, Tamburini FB, Sahibdeen V, Brewster R, Gómez-Olivé FX, Kahn K, Norris SA, Tollman SM, Twine R, Wade AN, Wagner RG, Lombard Z, Bhatt AS , Hazelhurst S",Gut microbiome profiling of a rural and urban South African cohort reveals biomarkers of a population in lifestyle transition,BMC microbiology,2020,"16S, African microbiome, Epidemiological transition, Obesity, South African microbiome, Transitional microbiome",Experiment 4,South Africa,Homo sapiens,Feces,UBERON:0001988,Lifestyle measurement,EFO:0010724,Lean female subjects in both cohorts,Obese female subjects in both cohorts,Obese female subjects in both the Bushbuckridge and Soweto cohorts.,30,106,None,16S,34,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1057/5/NA,Study 1057,"cross-sectional observational, not case-control",33129264,https://doi.org/10.1186/s12866-020-02017-w,NA,"Oduaran OH, Tamburini FB, Sahibdeen V, Brewster R, Gómez-Olivé FX, Kahn K, Norris SA, Tollman SM, Twine R, Wade AN, Wagner RG, Lombard Z, Bhatt AS , Hazelhurst S",Gut microbiome profiling of a rural and urban South African cohort reveals biomarkers of a population in lifestyle transition,BMC microbiology,2020,"16S, African microbiome, Epidemiological transition, Obesity, South African microbiome, Transitional microbiome",Experiment 5,South Africa,Homo sapiens,Feces,UBERON:0001988,Lifestyle measurement,EFO:0010724,Lean female subjects in Bushbuckridge,Obese female subjects in Bushbuckridge,Obese females in Bushbuckridge whose microbiota is studied for transitional differences between lean and obese subjects in both Cohorts (Bushbuckridge and Soweto).,21,66,None,16S,34,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1057/6/NA,Study 1057,"cross-sectional observational, not case-control",33129264,https://doi.org/10.1186/s12866-020-02017-w,NA,"Oduaran OH, Tamburini FB, Sahibdeen V, Brewster R, Gómez-Olivé FX, Kahn K, Norris SA, Tollman SM, Twine R, Wade AN, Wagner RG, Lombard Z, Bhatt AS , Hazelhurst S",Gut microbiome profiling of a rural and urban South African cohort reveals biomarkers of a population in lifestyle transition,BMC microbiology,2020,"16S, African microbiome, Epidemiological transition, Obesity, South African microbiome, Transitional microbiome",Experiment 6,South Africa,Homo sapiens,Feces,UBERON:0001988,Lifestyle measurement,EFO:0010724,Lean female subjects in Soweto,Obese female subjects in Soweto,Obese females in Soweto whose microbiota is studied to observe transitional changes between lean and obese groups in the Soweto cohort.,9,40,None,16S,34,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1058/1/NA,Study 1058,case-control,37924005,10.1186/s12866-023-03071-w,NA,"Chen L, Mou X, Li J, Li M, Ye C, Gao X, Liu X, Ma Y, Xu Y , Zhong Y",Alterations in gut microbiota and host transcriptome of patients with coronary artery disease,BMC microbiology,2023,"Biomarkers, Coronary artery disease, Gut microbe, Risk genes, Transcriptome",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Coronary artery disease,EFO:0001645,Healthy controls,Patient with coronary artery disease,patients with coronary artery disease between the age of 25 - 80 years and show greater than 70% stenosis in at least one major branch of the coronary artery.,21,31,NA,16S,34,Illumina,T-Test,0.05,FALSE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1059/1/NA,Study 1059,time series / longitudinal observational,36997838,10.1186/s12866-023-02822-z,https://bmcmicrobiol.biomedcentral.com/articles/10.1186/s12866-023-02822-z,"Jacky D, Bibi C, Meng LMC, Jason F, Gwendoline T, Jeremy L , Wie CC",Effects of OsomeFood Clean Label plant-based meals on the gut microbiome,BMC microbiology,2023,"Intervention, Metagenomic, Microbiota, Nutrition",Experiment 1,Singapore,Homo sapiens,Feces,UBERON:0001988,Diet,EFO:0002755,Participants before the AWE diet - D0,Participants after the AWE diet - D21,Participants who strictly adhered to OsomeFoods plant-based meal plans for five consecutive days (Monday through to Friday; 'AWE') for 3 weeks.,10,10,3 months,WMS,NA,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1060/1/NA,Study 1060,"cross-sectional observational, not case-control",37596536,10.1186/s12866-023-02970-2,NA,"Araújo V, Fehn AM, Phiri A, Wills J, Rocha J , Gayà-Vidal M",Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe,BMC microbiology,2023,"African populations, Exome sequencing, Metagenomics, Oral microbiome, Oral microbiota, Saliva, Socio-economic status, Subsistence methods",Experiment 1,"Angola,Zimbabwe",Homo sapiens,Saliva,UBERON:0001836,Population,IDOMAL:0001254,Kuvale,Kwepe,"The Kwepe are small stock herders possibly linked to early pastoral migrations from eastern to southern Africa. They dwell in the coastal lowlands of the Angola Namib Desert, which is characterized by an arid and warm climate.",7,7,NA,16S,12,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1060/2/NA,Study 1060,"cross-sectional observational, not case-control",37596536,10.1186/s12866-023-02970-2,NA,"Araújo V, Fehn AM, Phiri A, Wills J, Rocha J , Gayà-Vidal M",Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe,BMC microbiology,2023,"African populations, Exome sequencing, Metagenomics, Oral microbiome, Oral microbiota, Saliva, Socio-economic status, Subsistence methods",Experiment 2,"Angola,Zimbabwe",Homo sapiens,Saliva,UBERON:0001836,Population,IDOMAL:0001254,Kuvale,Himba,The Himba are also Bantu-speaking cattle herders of the Herero tradition. They reside in the same coastal lowlands as the Kuvale and share similar environmental conditions.,7,7,NA,16S,12,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1060/3/NA,Study 1060,"cross-sectional observational, not case-control",37596536,10.1186/s12866-023-02970-2,NA,"Araújo V, Fehn AM, Phiri A, Wills J, Rocha J , Gayà-Vidal M",Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe,BMC microbiology,2023,"African populations, Exome sequencing, Metagenomics, Oral microbiome, Oral microbiota, Saliva, Socio-economic status, Subsistence methods",Experiment 3,"Angola,Zimbabwe",Homo sapiens,Saliva,UBERON:0001836,Population,IDOMAL:0001254,Kuvale,Tjimba,The Tjimba inhabit the same coastal lowlands as the Kuvale and Himba. They may represent a subgroup or offshoot of the Himba community.,7,4,NA,16S,12,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1060/4/NA,Study 1060,"cross-sectional observational, not case-control",37596536,10.1186/s12866-023-02970-2,NA,"Araújo V, Fehn AM, Phiri A, Wills J, Rocha J , Gayà-Vidal M",Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe,BMC microbiology,2023,"African populations, Exome sequencing, Metagenomics, Oral microbiome, Oral microbiota, Saliva, Socio-economic status, Subsistence methods",Experiment 4,"Angola,Zimbabwe",Homo sapiens,Saliva,UBERON:0001836,Population,IDOMAL:0001254,Kuvale,Kwisi,The Kwisi are a marginalized group whose origins have been considered enigmatic. Their livelihoods also deviate from traditional food production or foraging patterns.,7,8,NA,16S,12,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1060/5/NA,Study 1060,"cross-sectional observational, not case-control",37596536,10.1186/s12866-023-02970-2,NA,"Araújo V, Fehn AM, Phiri A, Wills J, Rocha J , Gayà-Vidal M",Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe,BMC microbiology,2023,"African populations, Exome sequencing, Metagenomics, Oral microbiome, Oral microbiota, Saliva, Socio-economic status, Subsistence methods",Experiment 5,"Angola,Zimbabwe",Homo sapiens,Saliva,UBERON:0001836,Population,IDOMAL:0001254,Kuvale,Twa,"The Twa are a marginalized group in the region, describing themselves as the indigenous people of the area. Their livelihoods do not conform to traditional food production or foraging patterns.",7,7,NA,16S,12,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1060/6/NA,Study 1060,"cross-sectional observational, not case-control",37596536,10.1186/s12866-023-02970-2,NA,"Araújo V, Fehn AM, Phiri A, Wills J, Rocha J , Gayà-Vidal M",Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe,BMC microbiology,2023,"African populations, Exome sequencing, Metagenomics, Oral microbiome, Oral microbiota, Saliva, Socio-economic status, Subsistence methods",Experiment 6,"Angola,Zimbabwe",Homo sapiens,Saliva,UBERON:0001836,Population,IDOMAL:0001254,Kuvale,Tshwa,"They traditionally relied on foraging but were forced to leave their hunting grounds in Hwange National Park during the early 20th century, leading to social marginalization.",7,5,NA,16S,12,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1060/7/NA,Study 1060,"cross-sectional observational, not case-control",37596536,10.1186/s12866-023-02970-2,NA,"Araújo V, Fehn AM, Phiri A, Wills J, Rocha J , Gayà-Vidal M",Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe,BMC microbiology,2023,"African populations, Exome sequencing, Metagenomics, Oral microbiome, Oral microbiota, Saliva, Socio-economic status, Subsistence methods",Experiment 7,"Angola,Zimbabwe",Homo sapiens,Saliva,UBERON:0001836,Population,IDOMAL:0001254,Kuvale,!Xun,"The !Xun are Kx’a-speaking foragers residing in neighboring Kunene Province in Angola. They inhabit areas characterized by open savanna woodland, differing from the coastal plains occupied by the other groups.",7,7,NA,16S,12,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1060/8/NA,Study 1060,"cross-sectional observational, not case-control",37596536,10.1186/s12866-023-02970-2,NA,"Araújo V, Fehn AM, Phiri A, Wills J, Rocha J , Gayà-Vidal M",Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe,BMC microbiology,2023,"African populations, Exome sequencing, Metagenomics, Oral microbiome, Oral microbiota, Saliva, Socio-economic status, Subsistence methods",Experiment 8,"Angola,Zimbabwe",Homo sapiens,Saliva,UBERON:0001836,Population,IDOMAL:0001254,Kwepe,Himba,the Himba are also Bantu-speaking cattle herders of the Herero tradition. They reside in the same coastal lowlands as the Kuvale and share similar environmental conditions.,7,7,NA,16S,12,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1060/9/NA,Study 1060,"cross-sectional observational, not case-control",37596536,10.1186/s12866-023-02970-2,NA,"Araújo V, Fehn AM, Phiri A, Wills J, Rocha J , Gayà-Vidal M",Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe,BMC microbiology,2023,"African populations, Exome sequencing, Metagenomics, Oral microbiome, Oral microbiota, Saliva, Socio-economic status, Subsistence methods",Experiment 9,"Angola,Zimbabwe",Homo sapiens,Saliva,UBERON:0001836,Population,IDOMAL:0001254,Kwepe,Tjimba,The Tjimba inhabit the same coastal lowlands as the Kuvale and Himba. They may represent a subgroup or offshoot of the Himba community.,7,4,NA,16S,12,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1060/10/NA,Study 1060,"cross-sectional observational, not case-control",37596536,10.1186/s12866-023-02970-2,NA,"Araújo V, Fehn AM, Phiri A, Wills J, Rocha J , Gayà-Vidal M",Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe,BMC microbiology,2023,"African populations, Exome sequencing, Metagenomics, Oral microbiome, Oral microbiota, Saliva, Socio-economic status, Subsistence methods",Experiment 10,"Angola,Zimbabwe",Homo sapiens,Saliva,UBERON:0001836,Population,IDOMAL:0001254,Kwepe,Kwisi,The Kwisi are a marginalized group whose origins have been considered enigmatic. Their livelihoods also deviate from traditional food production or foraging patterns.,7,8,NA,16S,12,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1060/11/NA,Study 1060,"cross-sectional observational, not case-control",37596536,10.1186/s12866-023-02970-2,NA,"Araújo V, Fehn AM, Phiri A, Wills J, Rocha J , Gayà-Vidal M",Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe,BMC microbiology,2023,"African populations, Exome sequencing, Metagenomics, Oral microbiome, Oral microbiota, Saliva, Socio-economic status, Subsistence methods",Experiment 11,"Angola,Zimbabwe",Homo sapiens,Saliva,UBERON:0001836,Population,IDOMAL:0001254,Kwepe,Twa,"The Twa are a marginalized group in the region, describing themselves as the indigenous people of the area. Their livelihoods do not conform to traditional food production or foraging patterns.",7,7,NA,16S,12,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1060/12/NA,Study 1060,"cross-sectional observational, not case-control",37596536,10.1186/s12866-023-02970-2,NA,"Araújo V, Fehn AM, Phiri A, Wills J, Rocha J , Gayà-Vidal M",Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe,BMC microbiology,2023,"African populations, Exome sequencing, Metagenomics, Oral microbiome, Oral microbiota, Saliva, Socio-economic status, Subsistence methods",Experiment 12,"Angola,Zimbabwe",Homo sapiens,Saliva,UBERON:0001836,Population,IDOMAL:0001254,Kwepe,Tshwa,"Khoe-Kwadi-speaking foragers from the Tsholotsho District of western Zimbabwe. They traditionally relied on foraging but were forced to leave their hunting grounds in Hwange National Park during the early 20th century, leading to social marginalization.",7,5,NA,16S,12,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1060/13/NA,Study 1060,"cross-sectional observational, not case-control",37596536,10.1186/s12866-023-02970-2,NA,"Araújo V, Fehn AM, Phiri A, Wills J, Rocha J , Gayà-Vidal M",Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe,BMC microbiology,2023,"African populations, Exome sequencing, Metagenomics, Oral microbiome, Oral microbiota, Saliva, Socio-economic status, Subsistence methods",Experiment 13,"Angola,Zimbabwe",Homo sapiens,Saliva,UBERON:0001836,Population,IDOMAL:0001254,Kwepe,!Xun,"The !Xun are Kx’a-speaking foragers residing in neighboring Kunene Province in Angola. They inhabit areas characterized by open savanna woodland, differing from the coastal plains occupied by the other groups",7,7,NA,16S,12,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1060/14/NA,Study 1060,"cross-sectional observational, not case-control",37596536,10.1186/s12866-023-02970-2,NA,"Araújo V, Fehn AM, Phiri A, Wills J, Rocha J , Gayà-Vidal M",Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe,BMC microbiology,2023,"African populations, Exome sequencing, Metagenomics, Oral microbiome, Oral microbiota, Saliva, Socio-economic status, Subsistence methods",Experiment 14,"Angola,Zimbabwe",Homo sapiens,Saliva,UBERON:0001836,Population,IDOMAL:0001254,Himba,Tjimba,The Tjimba inhabit the same coastal lowlands as the Kuvale and Himba.,7,4,NA,16S,12,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1060/15/NA,Study 1060,"cross-sectional observational, not case-control",37596536,10.1186/s12866-023-02970-2,NA,"Araújo V, Fehn AM, Phiri A, Wills J, Rocha J , Gayà-Vidal M",Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe,BMC microbiology,2023,"African populations, Exome sequencing, Metagenomics, Oral microbiome, Oral microbiota, Saliva, Socio-economic status, Subsistence methods",Experiment 15,"Angola,Zimbabwe",Homo sapiens,Saliva,UBERON:0001836,Population,IDOMAL:0001254,Himba,Kwisi,The Kwisi are a marginalized group whose origins have been considered enigmatic. Their livelihoods also deviate from traditional food production or foraging patterns.,7,8,NA,16S,12,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1060/16/NA,Study 1060,"cross-sectional observational, not case-control",37596536,10.1186/s12866-023-02970-2,NA,"Araújo V, Fehn AM, Phiri A, Wills J, Rocha J , Gayà-Vidal M",Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe,BMC microbiology,2023,"African populations, Exome sequencing, Metagenomics, Oral microbiome, Oral microbiota, Saliva, Socio-economic status, Subsistence methods",Experiment 16,"Angola,Zimbabwe",Homo sapiens,Saliva,UBERON:0001836,Population,IDOMAL:0001254,Himba,Twa,"The Twa are a marginalized group in the region, describing themselves as the indigenous people of the area. Their livelihoods do not conform to traditional food production or foraging patterns.",7,7,NA,16S,12,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1060/17/NA,Study 1060,"cross-sectional observational, not case-control",37596536,10.1186/s12866-023-02970-2,NA,"Araújo V, Fehn AM, Phiri A, Wills J, Rocha J , Gayà-Vidal M",Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe,BMC microbiology,2023,"African populations, Exome sequencing, Metagenomics, Oral microbiome, Oral microbiota, Saliva, Socio-economic status, Subsistence methods",Experiment 17,"Angola,Zimbabwe",Homo sapiens,Saliva,UBERON:0001836,Population,IDOMAL:0001254,Himba,Tshwa,"They traditionally relied on foraging but were forced to leave their hunting grounds in Hwange National Park during the early 20th century, leading to social marginalization.",7,5,NA,16S,12,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1060/18/NA,Study 1060,"cross-sectional observational, not case-control",37596536,10.1186/s12866-023-02970-2,NA,"Araújo V, Fehn AM, Phiri A, Wills J, Rocha J , Gayà-Vidal M",Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe,BMC microbiology,2023,"African populations, Exome sequencing, Metagenomics, Oral microbiome, Oral microbiota, Saliva, Socio-economic status, Subsistence methods",Experiment 18,"Angola,Zimbabwe",Homo sapiens,Saliva,UBERON:0001836,Population,IDOMAL:0001254,Himba,!Xun,"The !Xun are Kx’a-speaking foragers residing in neighboring Kunene Province in Angola. They inhabit areas characterized by open savanna woodland, differing from the coastal plains occupied by the other groups.",7,7,NA,16S,12,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1060/19/NA,Study 1060,"cross-sectional observational, not case-control",37596536,10.1186/s12866-023-02970-2,NA,"Araújo V, Fehn AM, Phiri A, Wills J, Rocha J , Gayà-Vidal M",Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe,BMC microbiology,2023,"African populations, Exome sequencing, Metagenomics, Oral microbiome, Oral microbiota, Saliva, Socio-economic status, Subsistence methods",Experiment 19,"Angola,Zimbabwe",Homo sapiens,Saliva,UBERON:0001836,Population,IDOMAL:0001254,Twa,Tshwa,"The Twa are a marginalized group in the region, describing themselves as the indigenous people of the area. Their livelihoods do not conform to traditional food production or foraging patterns.",7,5,NA,16S,12,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1060/20/NA,Study 1060,"cross-sectional observational, not case-control",37596536,10.1186/s12866-023-02970-2,NA,"Araújo V, Fehn AM, Phiri A, Wills J, Rocha J , Gayà-Vidal M",Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe,BMC microbiology,2023,"African populations, Exome sequencing, Metagenomics, Oral microbiome, Oral microbiota, Saliva, Socio-economic status, Subsistence methods",Experiment 20,"Angola,Zimbabwe",Homo sapiens,Saliva,UBERON:0001836,Population,IDOMAL:0001254,Twa,!Xun,"The !Xun are Kx’a-speaking foragers residing in neighboring Kunene Province in Angola. They inhabit areas characterized by open savanna woodland, differing from the coastal plains occupied by the other groups.",7,7,NA,16S,12,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1060/21/NA,Study 1060,"cross-sectional observational, not case-control",37596536,10.1186/s12866-023-02970-2,NA,"Araújo V, Fehn AM, Phiri A, Wills J, Rocha J , Gayà-Vidal M",Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe,BMC microbiology,2023,"African populations, Exome sequencing, Metagenomics, Oral microbiome, Oral microbiota, Saliva, Socio-economic status, Subsistence methods",Experiment 21,"Angola,Zimbabwe",Homo sapiens,Saliva,UBERON:0001836,Population,IDOMAL:0001254,Tshwa,!Xun,"The !Xun are Kx’a-speaking foragers residing in neighboring Kunene Province in Angola. They inhabit areas characterized by open savanna woodland, differing from the coastal plains occupied by the other groups.",5,7,NA,16S,12,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1060/22/NA,Study 1060,"cross-sectional observational, not case-control",37596536,10.1186/s12866-023-02970-2,NA,"Araújo V, Fehn AM, Phiri A, Wills J, Rocha J , Gayà-Vidal M",Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe,BMC microbiology,2023,"African populations, Exome sequencing, Metagenomics, Oral microbiome, Oral microbiota, Saliva, Socio-economic status, Subsistence methods",Experiment 22,"Angola,Zimbabwe",Homo sapiens,Saliva,UBERON:0001836,Population,IDOMAL:0001254,Tjimba,Kwisi,The Kwisi are a marginalized group whose origins have been considered enigmatic. Their livelihoods also deviate from traditional food production or foraging patterns.,4,8,NA,16S,12,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1060/23/NA,Study 1060,"cross-sectional observational, not case-control",37596536,10.1186/s12866-023-02970-2,NA,"Araújo V, Fehn AM, Phiri A, Wills J, Rocha J , Gayà-Vidal M",Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe,BMC microbiology,2023,"African populations, Exome sequencing, Metagenomics, Oral microbiome, Oral microbiota, Saliva, Socio-economic status, Subsistence methods",Experiment 23,"Angola,Zimbabwe",Homo sapiens,Saliva,UBERON:0001836,Population,IDOMAL:0001254,Tjimba,Twa,"The Twa are a marginalized group in the region, describing themselves as the indigenous people of the area. Their livelihoods do not conform to traditional food production or foraging patterns.",4,7,NA,16S,12,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1060/24/NA,Study 1060,"cross-sectional observational, not case-control",37596536,10.1186/s12866-023-02970-2,NA,"Araújo V, Fehn AM, Phiri A, Wills J, Rocha J , Gayà-Vidal M",Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe,BMC microbiology,2023,"African populations, Exome sequencing, Metagenomics, Oral microbiome, Oral microbiota, Saliva, Socio-economic status, Subsistence methods",Experiment 24,"Angola,Zimbabwe",Homo sapiens,Saliva,UBERON:0001836,Population,IDOMAL:0001254,Tjimba,Tshwa,"Khoe-Kwadi-speaking foragers from the Tsholotsho District of western Zimbabwe. They traditionally relied on foraging but were forced to leave their hunting grounds in Hwange National Park during the early 20th century, leading to social marginalization.",4,5,NA,16S,12,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1060/25/NA,Study 1060,"cross-sectional observational, not case-control",37596536,10.1186/s12866-023-02970-2,NA,"Araújo V, Fehn AM, Phiri A, Wills J, Rocha J , Gayà-Vidal M",Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe,BMC microbiology,2023,"African populations, Exome sequencing, Metagenomics, Oral microbiome, Oral microbiota, Saliva, Socio-economic status, Subsistence methods",Experiment 25,"Angola,Zimbabwe",Homo sapiens,Saliva,UBERON:0001836,Population,IDOMAL:0001254,Tjimba,!Xun,"The !Xun are Kx’a-speaking foragers residing in neighboring Kunene Province in Angola. They inhabit areas characterized by open savanna woodland, differing from the coastal plains occupied by the other groups",4,7,NA,16S,12,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1060/26/NA,Study 1060,"cross-sectional observational, not case-control",37596536,10.1186/s12866-023-02970-2,NA,"Araújo V, Fehn AM, Phiri A, Wills J, Rocha J , Gayà-Vidal M",Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe,BMC microbiology,2023,"African populations, Exome sequencing, Metagenomics, Oral microbiome, Oral microbiota, Saliva, Socio-economic status, Subsistence methods",Experiment 26,"Angola,Zimbabwe",Homo sapiens,Saliva,UBERON:0001836,Population,IDOMAL:0001254,Kwisi,Twa,"The Twa are a marginalized group in the region, describing themselves as the indigenous people of the area. Their livelihoods do not conform to traditional food production or foraging patterns.",8,7,NA,16S,12,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1060/27/NA,Study 1060,"cross-sectional observational, not case-control",37596536,10.1186/s12866-023-02970-2,NA,"Araújo V, Fehn AM, Phiri A, Wills J, Rocha J , Gayà-Vidal M",Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe,BMC microbiology,2023,"African populations, Exome sequencing, Metagenomics, Oral microbiome, Oral microbiota, Saliva, Socio-economic status, Subsistence methods",Experiment 27,"Angola,Zimbabwe",Homo sapiens,Saliva,UBERON:0001836,Population,IDOMAL:0001254,Kwisi,Tshwa,"Khoe-Kwadi-speaking foragers from the Tsholotsho District of western Zimbabwe. They traditionally relied on foraging but were forced to leave their hunting grounds in Hwange National Park during the early 20th century, leading to social marginalization.",8,5,NA,16S,12,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1060/28/NA,Study 1060,"cross-sectional observational, not case-control",37596536,10.1186/s12866-023-02970-2,NA,"Araújo V, Fehn AM, Phiri A, Wills J, Rocha J , Gayà-Vidal M",Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe,BMC microbiology,2023,"African populations, Exome sequencing, Metagenomics, Oral microbiome, Oral microbiota, Saliva, Socio-economic status, Subsistence methods",Experiment 28,"Angola,Zimbabwe",Homo sapiens,Saliva,UBERON:0001836,Population,IDOMAL:0001254,Kwisi,!Xun,"The !Xun are Kx’a-speaking foragers residing in neighboring Kunene Province in Angola. They inhabit areas characterized by open savanna woodland, differing from the coastal plains occupied by the other groups",8,7,NA,16S,12,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1060/29/NA,Study 1060,"cross-sectional observational, not case-control",37596536,10.1186/s12866-023-02970-2,NA,"Araújo V, Fehn AM, Phiri A, Wills J, Rocha J , Gayà-Vidal M",Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe,BMC microbiology,2023,"African populations, Exome sequencing, Metagenomics, Oral microbiome, Oral microbiota, Saliva, Socio-economic status, Subsistence methods",Experiment 29,"Angola,Zimbabwe",Homo sapiens,Saliva,UBERON:0001836,Socioeconomic status,EXO:0000114,Pastoralists,Foragers,"They are the !Xun group from Kunene Province, Angola, they traditionally rely on hunting and gathering for subsistence in an area characterized by open savanna woodland.",21,7,NA,16S,12,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1060/30/NA,Study 1060,"cross-sectional observational, not case-control",37596536,10.1186/s12866-023-02970-2,NA,"Araújo V, Fehn AM, Phiri A, Wills J, Rocha J , Gayà-Vidal M",Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe,BMC microbiology,2023,"African populations, Exome sequencing, Metagenomics, Oral microbiome, Oral microbiota, Saliva, Socio-economic status, Subsistence methods",Experiment 30,"Angola,Zimbabwe",Homo sapiens,Saliva,UBERON:0001836,Socioeconomic status,EXO:0000114,Pastoralists,Peripatetics,"Includes the Twa, Tjimba, Kwisi, and Kwepe in southwestern Angola, these groups have a mobile lifestyle without a fixed settlement. They inhabit coastal lowlands and may have mixed livelihoods, combining aspects of both pastoralism and foraging.",21,24,NA,16S,12,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1060/31/NA,Study 1060,"cross-sectional observational, not case-control",37596536,10.1186/s12866-023-02970-2,NA,"Araújo V, Fehn AM, Phiri A, Wills J, Rocha J , Gayà-Vidal M",Oral microbiome homogeneity across diverse human groups from southern Africa: first results from southwestern Angola and Zimbabwe,BMC microbiology,2023,"African populations, Exome sequencing, Metagenomics, Oral microbiome, Oral microbiota, Saliva, Socio-economic status, Subsistence methods",Experiment 31,"Angola,Zimbabwe",Homo sapiens,Saliva,UBERON:0001836,Socioeconomic status,EXO:0000114,Peripatetics,Foragers,"They are represented by the !Xun group from Kunene Province, Angola, they traditionally rely on hunting and gathering for subsistence in an area characterized by open savanna woodland.",24,7,NA,16S,12,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1061/1/NA,Study 1061,"cross-sectional observational, not case-control",38373985,https://doi.org/10.1186/s13195-024-01402-1,NA,"Qiu C, Zhou W, Shen H, Wang J, Tang R, Wang T, Xie X, Hong B, Ren R, Wang G , Song Z",Profiles of subgingival microbiomes and gingival crevicular metabolic signatures in patients with amnestic mild cognitive impairment and Alzheimer's disease,Alzheimer's research & therapy,2024,"Alzheimer’s disease, Metabolome, Microbiome, Mild cognitive impairment, Multiomics, Periodontitis",Experiment 1,China,Homo sapiens,Subgingival dental plaque,UBERON:0016484,Alzheimer's disease,MONDO:0004975,Cognitively normal (CN) and amnestic mild cognitive impairment (aMCI),Alzheimer’s Disease (AD),Patients with Alzheimer’s Disease (AD) dementia who were diagnosed following the National Institute on Aging and Alzheimer’s Association guidelines for probable AD dementia with the support of magnetic resonance imaging,64,32,3 months,16S,NA,PacBio RS,LEfSe,0.05,TRUE,2,NA,NA,unchanged,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1061/2/NA,Study 1061,"cross-sectional observational, not case-control",38373985,https://doi.org/10.1186/s13195-024-01402-1,NA,"Qiu C, Zhou W, Shen H, Wang J, Tang R, Wang T, Xie X, Hong B, Ren R, Wang G , Song Z",Profiles of subgingival microbiomes and gingival crevicular metabolic signatures in patients with amnestic mild cognitive impairment and Alzheimer's disease,Alzheimer's research & therapy,2024,"Alzheimer’s disease, Metabolome, Microbiome, Mild cognitive impairment, Multiomics, Periodontitis",Experiment 2,China,Homo sapiens,Subgingival dental plaque,UBERON:0016484,Alzheimer's disease,MONDO:0004975,Cognitively normal (CN) and Alzheimer’s Disease (AD),Amnestic mild cognitive impairment (aMCI),"Patients with aMCI who met the previously published National Institute on Aging and Alzheimer’s Association criteria (2011) for “MCI due to AD,” with memory deficits as the only complaint of cognitive impairment.",64,32,3 months,16S,NA,PacBio RS,LEfSe,0.05,TRUE,2,NA,NA,unchanged,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1061/3/NA,Study 1061,"cross-sectional observational, not case-control",38373985,https://doi.org/10.1186/s13195-024-01402-1,NA,"Qiu C, Zhou W, Shen H, Wang J, Tang R, Wang T, Xie X, Hong B, Ren R, Wang G , Song Z",Profiles of subgingival microbiomes and gingival crevicular metabolic signatures in patients with amnestic mild cognitive impairment and Alzheimer's disease,Alzheimer's research & therapy,2024,"Alzheimer’s disease, Metabolome, Microbiome, Mild cognitive impairment, Multiomics, Periodontitis",Experiment 3,China,Homo sapiens,Subgingival dental plaque,UBERON:0016484,Alzheimer's disease,MONDO:0004975,Cognitively normal (CN),Alzheimer’s Disease (AD) and Amnestic mild cognitive impairment (aMCI),"Patients with AD dementia who were diagnosed following the National Institute on Aging and Alzheimer’s Association guidelines for probable AD dementia with the support of magnetic resonance imaging and all patients with aMCI who met the previously published National Institute on Aging and Alzheimer’s Association criteria (2011) for “MCI due to AD,” with memory deficits as the only complaint of cognitive impairment.",32,64,3 months,16S,NA,PacBio RS,LEfSe,0.05,TRUE,2,NA,NA,unchanged,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1062/1/NA,Study 1062,"cross-sectional observational, not case-control",37715296,10.1186/s40168-023-01636-5,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10503196/,"Mills M, Lee S, Piperata BA, Garabed R, Choi B , Lee J",Household environment and animal fecal contamination are critical modifiers of the gut microbiome and resistome in young children from rural Nicaragua,Microbiome,2023,"Animals, Breastfeeding duration, Dirt floor, E. coli as antibiotic resistance host, Microbial source tracking, Multi-drug resistance, One Health",Experiment 1,Nicaragua,Homo sapiens,Feces,UBERON:0001988,Gut microbiome measurement,EFO:0007874,Infants,Children,Participants between 2.0 – 6.0 years of age,26,31,None,WMS,NA,Nanopore,LEfSe,0.05,TRUE,2,NA,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1062/2/NA,Study 1062,"cross-sectional observational, not case-control",37715296,10.1186/s40168-023-01636-5,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10503196/,"Mills M, Lee S, Piperata BA, Garabed R, Choi B , Lee J",Household environment and animal fecal contamination are critical modifiers of the gut microbiome and resistome in young children from rural Nicaragua,Microbiome,2023,"Animals, Breastfeeding duration, Dirt floor, E. coli as antibiotic resistance host, Microbial source tracking, Multi-drug resistance, One Health",Experiment 2,Nicaragua,Homo sapiens,Feces,UBERON:0001988,Gut microbiome measurement,EFO:0007874,No - antibiotics,Yes - antibiotics,Infants and young children (ages 4 days - 6 years) in rural Nicaragua who had ever received antibiotics,11,11,None,WMS,NA,Nanopore,LEfSe,0.05,TRUE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1063/1/NA,Study 1063,case-control,32245419,https://doi.org/10.1186/s12866-020-01733-7,https://bmcmicrobiol.biomedcentral.com/articles/10.1186/s12866-020-01733-7,"Yu FY, Wang QQ, Li M, Cheng YH, Cheng YL, Zhou Y, Yang X, Zhang F, Ge X, Zhao B , Ren XY",Dysbiosis of saliva microbiome in patients with oral lichen planus,BMC microbiology,2020,"16S rDNA, High-throughput sequencing, Oral lichen planus, Salivary microbiome",Experiment 1,China,Homo sapiens,Saliva,UBERON:0001836,Oral lichen planus,EFO:0008517,Healthy Control,Oral lichen planus (both erosive and non-erosive ),"Oral lichen planus (OLP) is a common oral mucosal disease with or without accompanying lesions in skin, nails, eyes, or urogenital tissue",10,20,NA,16S,4,Illumina,Random Forest Analysis,0.05,FALSE,NA,NA,NA,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1063/2/NA,Study 1063,case-control,32245419,https://doi.org/10.1186/s12866-020-01733-7,https://bmcmicrobiol.biomedcentral.com/articles/10.1186/s12866-020-01733-7,"Yu FY, Wang QQ, Li M, Cheng YH, Cheng YL, Zhou Y, Yang X, Zhang F, Ge X, Zhao B , Ren XY",Dysbiosis of saliva microbiome in patients with oral lichen planus,BMC microbiology,2020,"16S rDNA, High-throughput sequencing, Oral lichen planus, Salivary microbiome",Experiment 2,China,Homo sapiens,Saliva,UBERON:0001836,Oral lichen planus,EFO:0008517,OLP patients without erosive lesions (NE),Patients with oral aphthous ulcer (RAU/U),"Recurrent aphthous ulceration (RAU) is a common oral mucosal disease also characterized by multiple oral ulcers, a feature similar to erosive OLP but different from OLP in the pattern of the clinical lesions and the pathogenesis mechanism",10,10,NA,16S,4,Illumina,NA,0.05,FALSE,NA,NA,NA,NA,increased,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1063/3/NA,Study 1063,case-control,32245419,https://doi.org/10.1186/s12866-020-01733-7,https://bmcmicrobiol.biomedcentral.com/articles/10.1186/s12866-020-01733-7,"Yu FY, Wang QQ, Li M, Cheng YH, Cheng YL, Zhou Y, Yang X, Zhang F, Ge X, Zhao B , Ren XY",Dysbiosis of saliva microbiome in patients with oral lichen planus,BMC microbiology,2020,"16S rDNA, High-throughput sequencing, Oral lichen planus, Salivary microbiome",Experiment 3,China,Homo sapiens,Saliva,UBERON:0001836,Oral lichen planus,EFO:0008517,Healthy control,Patients with oral aphthous ulcer (U/RAU),"Recurrent aphthous ulceration (RAU) is a common oral mucosal disease also characterized by multiple oral ulcers, a feature similar to erosive OLP but different from OLP in the pattern of the clinical lesions and the pathogenesis mechanism",10,10,NA,16S,4,Illumina,NA,0.05,FALSE,NA,NA,NA,NA,increased,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1063/4/NA,Study 1063,case-control,32245419,https://doi.org/10.1186/s12866-020-01733-7,https://bmcmicrobiol.biomedcentral.com/articles/10.1186/s12866-020-01733-7,"Yu FY, Wang QQ, Li M, Cheng YH, Cheng YL, Zhou Y, Yang X, Zhang F, Ge X, Zhao B , Ren XY",Dysbiosis of saliva microbiome in patients with oral lichen planus,BMC microbiology,2020,"16S rDNA, High-throughput sequencing, Oral lichen planus, Salivary microbiome",Experiment 4,China,Homo sapiens,Saliva,UBERON:0001836,Oral lichen planus,EFO:0008517,Healthy control,OLP patients with erosive lesions (E),Erosive OLP is a common oral mucosal disease characterized by multiple oral ulcers in its clinical presentation with chronic and painful ulceration of the skin and mucosal surfaces,10,10,NA,16S,4,Illumina,Random Forest Analysis,0.05,FALSE,NA,NA,NA,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1063/5/NA,Study 1063,case-control,32245419,https://doi.org/10.1186/s12866-020-01733-7,https://bmcmicrobiol.biomedcentral.com/articles/10.1186/s12866-020-01733-7,"Yu FY, Wang QQ, Li M, Cheng YH, Cheng YL, Zhou Y, Yang X, Zhang F, Ge X, Zhao B , Ren XY",Dysbiosis of saliva microbiome in patients with oral lichen planus,BMC microbiology,2020,"16S rDNA, High-throughput sequencing, Oral lichen planus, Salivary microbiome",Experiment 5,China,Homo sapiens,Saliva,UBERON:0001836,Oral lichen planus,EFO:0008517,Healthy control,OLP patients without erosive lesions (NE),"Non-erosive OLP is a common oral mucosal disease without accompanying lesions in skin, nails, eyes, or urogenital tissue",10,10,NA,16S,4,Illumina,Random Forest Analysis,0.05,FALSE,NA,NA,NA,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1063/6/NA,Study 1063,case-control,32245419,https://doi.org/10.1186/s12866-020-01733-7,https://bmcmicrobiol.biomedcentral.com/articles/10.1186/s12866-020-01733-7,"Yu FY, Wang QQ, Li M, Cheng YH, Cheng YL, Zhou Y, Yang X, Zhang F, Ge X, Zhao B , Ren XY",Dysbiosis of saliva microbiome in patients with oral lichen planus,BMC microbiology,2020,"16S rDNA, High-throughput sequencing, Oral lichen planus, Salivary microbiome",Experiment 6,China,Homo sapiens,Saliva,UBERON:0001836,Oral lichen planus,EFO:0008517,Patients with oral aphthous ulcer (U/RAU),OLP patients with erosive lesions (E),Erosive OLP is a common oral mucosal disease characterized by multiple oral ulcers in its clinical presentation with chronic and painful ulceration of the skin and mucosal surfaces,10,10,NA,16S,4,Illumina,NA,0.05,FALSE,NA,NA,NA,NA,increased,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1063/7/NA,Study 1063,case-control,32245419,https://doi.org/10.1186/s12866-020-01733-7,https://bmcmicrobiol.biomedcentral.com/articles/10.1186/s12866-020-01733-7,"Yu FY, Wang QQ, Li M, Cheng YH, Cheng YL, Zhou Y, Yang X, Zhang F, Ge X, Zhao B , Ren XY",Dysbiosis of saliva microbiome in patients with oral lichen planus,BMC microbiology,2020,"16S rDNA, High-throughput sequencing, Oral lichen planus, Salivary microbiome",Experiment 7,China,Homo sapiens,Saliva,UBERON:0001836,Oral lichen planus,EFO:0008517,OLP patients without erosive lesions (NE),OLP patients with erosive lesions (E),Erosive OLP is a common oral mucosal disease characterized by multiple oral ulcers in its clinical presentation with chronic and painful ulceration of the skin and mucosal surfaces,10,10,NA,16S,4,Illumina,Random Forest Analysis,0.05,FALSE,NA,NA,NA,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1064/1/NA,Study 1064,case-control,36864380,10.1186/s12866-023-02791-3,https://pubmed.ncbi.nlm.nih.gov/36864380/,"Mahdy MS, Azmy AF, Dishisha T, Mohamed WR, Ahmed KA, Hassan A, Aidy SE , El-Gendy AO",Irinotecan-gut microbiota interactions and the capability of probiotics to mitigate Irinotecan-associated toxicity,BMC microbiology,2023,"Anticancer, Beta-glucuronidase, Colon, Inflammation, Irinotecan, Probiotics",Experiment 1,Egypt,Homo sapiens,Feces,UBERON:0001988,Response to irinotecan,EFO:0004829,Healthy individuals,Colon cancer and Irinotecan treated patients,"Patients with colorectal cancer and Irinotecan treated patients. Irinotecan is a chemotherapeutic agent used to treat a variety of tumors, including colorectal cancer (CRC).",5,10,3 months,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1064/2/NA,Study 1064,case-control,36864380,10.1186/s12866-023-02791-3,https://pubmed.ncbi.nlm.nih.gov/36864380/,"Mahdy MS, Azmy AF, Dishisha T, Mohamed WR, Ahmed KA, Hassan A, Aidy SE , El-Gendy AO",Irinotecan-gut microbiota interactions and the capability of probiotics to mitigate Irinotecan-associated toxicity,BMC microbiology,2023,"Anticancer, Beta-glucuronidase, Colon, Inflammation, Irinotecan, Probiotics",Experiment 2,Egypt,Homo sapiens,Feces,UBERON:0001988,Response to irinotecan,EFO:0004829,Healthy individuals and colon cancer (CRC) patients,Irinotecan treated patients,"Patients treated with Irinotecan, a chemotherapeutic agent used to treat a variety of tumors, including colorectal cancer (CRC).",10,5,3 months,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1064/3/NA,Study 1064,case-control,36864380,10.1186/s12866-023-02791-3,https://pubmed.ncbi.nlm.nih.gov/36864380/,"Mahdy MS, Azmy AF, Dishisha T, Mohamed WR, Ahmed KA, Hassan A, Aidy SE , El-Gendy AO",Irinotecan-gut microbiota interactions and the capability of probiotics to mitigate Irinotecan-associated toxicity,BMC microbiology,2023,"Anticancer, Beta-glucuronidase, Colon, Inflammation, Irinotecan, Probiotics",Experiment 3,Egypt,Homo sapiens,Feces,UBERON:0001988,Response to irinotecan,EFO:0004829,Healthy individuals and Irinotecan treated patients,Colon cancer patients,Patients with colon cancer,10,5,3 months,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1065/1/NA,Study 1065,case-control,38327745,10.3389/fonc.2024.1279132,NA,"Zeber-Lubecka N, Kulecka M, Jagiełło-Gruszfeld A, Dąbrowska M, Kluska A, Piątkowska M, Bagińska K, Głowienka M, Surynt P, Tenderenda M, Mikula M , Ostrowski J",Breast cancer but not the menopausal status is associated with small changes of the gut microbiota,Frontiers in oncology,2024,"breast cancer, gut dysbiosis, menopausal status, microbiome, shotgun",Experiment 1,Poland,Homo sapiens,Feces,UBERON:0001988,Breast cancer,MONDO:0007254,pre-menopausal controls,pre-menopausal breast cancer (BC) patients,Newly diagnosed pre- or perimenopausal breast cancer patients at the Maria Sklodowska-Curie National Research Institute of Oncology.,51,47,2 months,WMS,NA,Illumina,Linear Regression,0.05,TRUE,NA,NA,NA,NA,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1065/2/NA,Study 1065,case-control,38327745,10.3389/fonc.2024.1279132,NA,"Zeber-Lubecka N, Kulecka M, Jagiełło-Gruszfeld A, Dąbrowska M, Kluska A, Piątkowska M, Bagińska K, Głowienka M, Surynt P, Tenderenda M, Mikula M , Ostrowski J",Breast cancer but not the menopausal status is associated with small changes of the gut microbiota,Frontiers in oncology,2024,"breast cancer, gut dysbiosis, menopausal status, microbiome, shotgun",Experiment 2,Poland,Homo sapiens,Feces,UBERON:0001988,Breast cancer,MONDO:0007254,post-menopausal controls,post-menopausal BC patients,Newly diagnosed postmenopausal breast cancer patients at the Maria Sklodowska-Curie National Research Institute of Oncology.,35,41,2 months,WMS,NA,Illumina,Linear Regression,0.05,TRUE,NA,NA,NA,NA,decreased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1066/1/NA,Study 1066,case-control,37702484,10.1128/spectrum.02360-23,NA,"Chen K, Geng H, Liu J , Ye C",Alteration in gut mycobiota of patients with polycystic ovary syndrome,Microbiology spectrum,2023,"Aspergillus, Lentinula, Saccharomyces, gut mycobiota, polycystic ovary syndrome",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Polycystic ovary syndrome,EFO:0000660,Healthy Controls,Polycystic ovary syndrome (PCOS) patients,Women with PCOS diagnosed according to the 2003 Rotterdam criteria.,17,17,NA,PCR,NA,Illumina,LEfSe,0.05,TRUE,4,age,NA,decreased,decreased,unchanged,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1067/1/NA,Study 1067,case-control,32727366,https://doi.org/10.1186/s12866-020-01918-0,NA,"Wang J, Xu J, Han Q, Chu W, Lu G, Chan WY, Qin Y , Du Y",Changes in the vaginal microbiota associated with primary ovarian failure,BMC microbiology,2020,"16S rRNA, Female reproductive tract, Pathogenesis, Primary ovarian failure, Vaginal microbiota",Experiment 1,China,Homo sapiens,Vaginal fluid,UBERON:0036243,Acquired primary ovarian failure,MONDO:0019851,Healthy controls,Primary ovarian failure (POF),Women of reproductive age with follicular failure,29,22,3 months,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,increased,increased,increased,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1068/1/NA,Study 1068,laboratory experiment,33138790,10.1186/s12866-020-02001-4,NA,"Feye KM, Swaggerty CL, Kogut MH, Ricke SC, Piva A , Grilli E",The biological effects of microencapsulated organic acids and botanicals induces tissue-specific and dose-dependent changes to the Gallus gallus microbiota,BMC microbiology,2020,"Botanicals, Ileum, Jejunum, Microbiota, Microencapsulated, Organic acids",Experiment 1,United States of America,Gallus gallus,Ileum,UBERON:0002116,NA,NA,Chicken with no AviPlus®P. (0 g/MT),Chickens feed with 300 g/MT,Chickens feed with 300 g/MT of AviPlus®P.,5,5,NA,16S,2,Illumina,LEfSe,0.05,NA,2,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1068/2/NA,Study 1068,laboratory experiment,33138790,10.1186/s12866-020-02001-4,NA,"Feye KM, Swaggerty CL, Kogut MH, Ricke SC, Piva A , Grilli E",The biological effects of microencapsulated organic acids and botanicals induces tissue-specific and dose-dependent changes to the Gallus gallus microbiota,BMC microbiology,2020,"Botanicals, Ileum, Jejunum, Microbiota, Microencapsulated, Organic acids",Experiment 2,United States of America,Gallus gallus,Ileum,UBERON:0002116,NA,NA,chicken with no AviPlus®P. (0 g/MT),Chicken feed with 500 g/MT,Chickens feed with 500 g/MT of AviPlus®P.,5,5,NA,16S,2,Illumina,LEfSe,0.05,NA,2,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1068/3/NA,Study 1068,laboratory experiment,33138790,10.1186/s12866-020-02001-4,NA,"Feye KM, Swaggerty CL, Kogut MH, Ricke SC, Piva A , Grilli E",The biological effects of microencapsulated organic acids and botanicals induces tissue-specific and dose-dependent changes to the Gallus gallus microbiota,BMC microbiology,2020,"Botanicals, Ileum, Jejunum, Microbiota, Microencapsulated, Organic acids",Experiment 3,United States of America,Gallus gallus,Ileum,UBERON:0002116,NA,NA,Chickens feed with 300 g/MT,Chickens feed with 500 g/MT,Chickens feed with 500 g/MT of AviPlus®P.,5,5,NA,16S,2,Illumina,LEfSe,0.05,NA,2,NA,NA,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1068/4/NA,Study 1068,laboratory experiment,33138790,10.1186/s12866-020-02001-4,NA,"Feye KM, Swaggerty CL, Kogut MH, Ricke SC, Piva A , Grilli E",The biological effects of microencapsulated organic acids and botanicals induces tissue-specific and dose-dependent changes to the Gallus gallus microbiota,BMC microbiology,2020,"Botanicals, Ileum, Jejunum, Microbiota, Microencapsulated, Organic acids",Experiment 4,United States of America,Gallus gallus,Jejunum,UBERON:0002115,NA,NA,Chicken with no AviPlus®P. (0 g/MT),Chickens feed with 300 g/MT,Chickens that were fed with 300 g/MT of AviPlus®P.,5,5,NA,16S,2,Illumina,LEfSe,0.05,FALSE,2,NA,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1068/5/NA,Study 1068,laboratory experiment,33138790,10.1186/s12866-020-02001-4,NA,"Feye KM, Swaggerty CL, Kogut MH, Ricke SC, Piva A , Grilli E",The biological effects of microencapsulated organic acids and botanicals induces tissue-specific and dose-dependent changes to the Gallus gallus microbiota,BMC microbiology,2020,"Botanicals, Ileum, Jejunum, Microbiota, Microencapsulated, Organic acids",Experiment 5,United States of America,Gallus gallus,Jejunum,UBERON:0002115,NA,NA,Chicken feed with 300g/MT,Chickens feed with 500 g/MT,Chickens that were fed with 500 g/MT of AviPlus®P.,5,5,NA,16S,2,Illumina,LEfSe,0.05,FALSE,2,NA,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1069/1/NA,Study 1069,case-control,35073343,https://doi.org/10.1371/journal.pone.0262806,NA,"Burton M, Krumbeck JA, Wu G, Tang S, Prem A, Gupta AK , Dawson TL",The adult microbiome of healthy and otitis patients: Definition of the core healthy and diseased ear microbiomes,PloS one,2022,NA,Experiment 1,United States of America,Homo sapiens,Ear,UBERON:0001690,"Otitis media,Otitis externa","EFO:0004992,EFO:0009560",Healthy group,Otitis media and otitis externa,Adults patients affected by otitis externa (OE) and otitis media (OM),92,70,Patients receiving any antimicrobial treatment at time of sample collection,16S,123,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1069/2/NA,Study 1069,case-control,35073343,https://doi.org/10.1371/journal.pone.0262806,NA,"Burton M, Krumbeck JA, Wu G, Tang S, Prem A, Gupta AK , Dawson TL",The adult microbiome of healthy and otitis patients: Definition of the core healthy and diseased ear microbiomes,PloS one,2022,NA,Experiment 2,United States of America,Homo sapiens,Ear,UBERON:0001690,"Otitis externa,Otitis media","EFO:0009560,EFO:0004992",Healthy and Otitis media,Otitis externa,Adults patients affected by otitis externa (OE),140,22,Patients receiving any antimicrobial treatment at time of sample collection,16S,123,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1069/3/NA,Study 1069,case-control,35073343,https://doi.org/10.1371/journal.pone.0262806,NA,"Burton M, Krumbeck JA, Wu G, Tang S, Prem A, Gupta AK , Dawson TL",The adult microbiome of healthy and otitis patients: Definition of the core healthy and diseased ear microbiomes,PloS one,2022,NA,Experiment 3,United States of America,Homo sapiens,Ear,UBERON:0001690,"Otitis externa,Otitis media","EFO:0009560,EFO:0004992",Healthy and Otitis externa,Otitis media,Adults patients affected by otitis media (OM),114,48,Patients receiving any antimicrobial treatment at time of sample collection,16S,123,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1069/4/NA,Study 1069,case-control,35073343,https://doi.org/10.1371/journal.pone.0262806,NA,"Burton M, Krumbeck JA, Wu G, Tang S, Prem A, Gupta AK , Dawson TL",The adult microbiome of healthy and otitis patients: Definition of the core healthy and diseased ear microbiomes,PloS one,2022,NA,Experiment 4,United States of America,Homo sapiens,Ear,UBERON:0001690,"Otitis media,Otitis externa","EFO:0004992,EFO:0009560",Healthy group,Otitis media and otitis externa,Adults patients affected by otitis externa (OE) and otitis media (OM),92,70,Patients receiving any antimicrobial treatment at time of sample collection,ITS / ITS2,NA,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,increased,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1069/5/NA,Study 1069,case-control,35073343,https://doi.org/10.1371/journal.pone.0262806,NA,"Burton M, Krumbeck JA, Wu G, Tang S, Prem A, Gupta AK , Dawson TL",The adult microbiome of healthy and otitis patients: Definition of the core healthy and diseased ear microbiomes,PloS one,2022,NA,Experiment 5,United States of America,Homo sapiens,Ear,UBERON:0001690,"Otitis externa,Otitis media","EFO:0009560,EFO:0004992",Healthy and Otitis media,Otitis externa,Adults patients affected by otitis externa (OE),140,22,Patients receiving any antimicrobial treatment at time of sample collection,ITS / ITS2,NA,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1069/6/NA,Study 1069,case-control,35073343,https://doi.org/10.1371/journal.pone.0262806,NA,"Burton M, Krumbeck JA, Wu G, Tang S, Prem A, Gupta AK , Dawson TL",The adult microbiome of healthy and otitis patients: Definition of the core healthy and diseased ear microbiomes,PloS one,2022,NA,Experiment 6,United States of America,Homo sapiens,Ear,UBERON:0001690,"Otitis externa,Otitis media","EFO:0009560,EFO:0004992",Healthy and Otitis externa,Otitis media,Adults patients affected by otitis media (OM),114,48,Patients receiving any antimicrobial treatment at time of sample collection,ITS / ITS2,NA,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,NA,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1070/1/NA,Study 1070,case-control,36475759,10.1128/spectrum.01956-22,NA,"Chen BY, Lin WZ, Li YL, Bi C, Du LJ, Liu Y, Zhou LJ, Liu T, Xu S, Shi CJ, Zhu H, Wang YL, Sun JY, Liu Y, Zhang WC, Zhang Z, Zhang HL, Zhu YQ , Duan SZ",Characteristics and Correlations of the Oral and Gut Fungal Microbiome with Hypertension,Microbiology spectrum,2023,"gut fungal microbiome, hypertension, oral fungal microbiome, oral-gut fungal correlations",Experiment 1,China,Homo sapiens,"Subgingival dental plaque,Saliva","UBERON:0016484,UBERON:0001836",Hypertension,EFO:0000537,Saliva samples,Subgingival plague samples,"Subgingival plague samples from participants with Hypertension (HTN); n = 36
and without Hypertension (No HTN); n = 24",60,60,2 months,WMS,NA,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,increased,increased,unchanged,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1070/2/NA,Study 1070,case-control,36475759,10.1128/spectrum.01956-22,NA,"Chen BY, Lin WZ, Li YL, Bi C, Du LJ, Liu Y, Zhou LJ, Liu T, Xu S, Shi CJ, Zhu H, Wang YL, Sun JY, Liu Y, Zhang WC, Zhang Z, Zhang HL, Zhu YQ , Duan SZ",Characteristics and Correlations of the Oral and Gut Fungal Microbiome with Hypertension,Microbiology spectrum,2023,"gut fungal microbiome, hypertension, oral fungal microbiome, oral-gut fungal correlations",Experiment 2,China,Homo sapiens,"Saliva,Feces","UBERON:0001836,UBERON:0001988",Hypertension,EFO:0000537,Saliva samples,Fecal samples,Fecal samples from participants with Hypertension (HTN); n = 36 and without Hypertension (No HTN); n = 24,60,60,2 months,WMS,NA,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1070/3/NA,Study 1070,case-control,36475759,10.1128/spectrum.01956-22,NA,"Chen BY, Lin WZ, Li YL, Bi C, Du LJ, Liu Y, Zhou LJ, Liu T, Xu S, Shi CJ, Zhu H, Wang YL, Sun JY, Liu Y, Zhang WC, Zhang Z, Zhang HL, Zhu YQ , Duan SZ",Characteristics and Correlations of the Oral and Gut Fungal Microbiome with Hypertension,Microbiology spectrum,2023,"gut fungal microbiome, hypertension, oral fungal microbiome, oral-gut fungal correlations",Experiment 3,China,Homo sapiens,"Subgingival dental plaque,Feces","UBERON:0016484,UBERON:0001988",Hypertension,EFO:0000537,Subgingival plague samples,Fecal samples,Fecal samples from participants with Hypertension (HTN); n = 36 and without Hypertension (No HTN); n = 24,60,60,2 months,WMS,NA,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,decreased,decreased,unchanged,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1070/4/NA,Study 1070,case-control,36475759,10.1128/spectrum.01956-22,NA,"Chen BY, Lin WZ, Li YL, Bi C, Du LJ, Liu Y, Zhou LJ, Liu T, Xu S, Shi CJ, Zhu H, Wang YL, Sun JY, Liu Y, Zhang WC, Zhang Z, Zhang HL, Zhu YQ , Duan SZ",Characteristics and Correlations of the Oral and Gut Fungal Microbiome with Hypertension,Microbiology spectrum,2023,"gut fungal microbiome, hypertension, oral fungal microbiome, oral-gut fungal correlations",Experiment 4,China,Homo sapiens,Saliva,UBERON:0001836,Hypertension,EFO:0000537,no-Hypertension (no-HTN),Hypertension (HTN),Participants with Hypertension (HTN),24,36,2 months,WMS,NA,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1070/5/NA,Study 1070,case-control,36475759,10.1128/spectrum.01956-22,NA,"Chen BY, Lin WZ, Li YL, Bi C, Du LJ, Liu Y, Zhou LJ, Liu T, Xu S, Shi CJ, Zhu H, Wang YL, Sun JY, Liu Y, Zhang WC, Zhang Z, Zhang HL, Zhu YQ , Duan SZ",Characteristics and Correlations of the Oral and Gut Fungal Microbiome with Hypertension,Microbiology spectrum,2023,"gut fungal microbiome, hypertension, oral fungal microbiome, oral-gut fungal correlations",Experiment 5,China,Homo sapiens,Subgingival dental plaque,UBERON:0016484,Hypertension,EFO:0000537,no-Hypertension (no-HTN),Hypertension (HTN),Participants with Hypertension (HTN),24,36,2 months,WMS,NA,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,unchanged,unchanged,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1070/6/NA,Study 1070,case-control,36475759,10.1128/spectrum.01956-22,NA,"Chen BY, Lin WZ, Li YL, Bi C, Du LJ, Liu Y, Zhou LJ, Liu T, Xu S, Shi CJ, Zhu H, Wang YL, Sun JY, Liu Y, Zhang WC, Zhang Z, Zhang HL, Zhu YQ , Duan SZ",Characteristics and Correlations of the Oral and Gut Fungal Microbiome with Hypertension,Microbiology spectrum,2023,"gut fungal microbiome, hypertension, oral fungal microbiome, oral-gut fungal correlations",Experiment 6,China,Homo sapiens,Feces,UBERON:0001988,Hypertension,EFO:0000537,no-Hypertension (no-HTN),Hypertension (HTN),Participants with Hypertension (HTN),24,36,2 months,WMS,NA,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,unchanged,increased,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1070/7/NA,Study 1070,case-control,36475759,10.1128/spectrum.01956-22,NA,"Chen BY, Lin WZ, Li YL, Bi C, Du LJ, Liu Y, Zhou LJ, Liu T, Xu S, Shi CJ, Zhu H, Wang YL, Sun JY, Liu Y, Zhang WC, Zhang Z, Zhang HL, Zhu YQ , Duan SZ",Characteristics and Correlations of the Oral and Gut Fungal Microbiome with Hypertension,Microbiology spectrum,2023,"gut fungal microbiome, hypertension, oral fungal microbiome, oral-gut fungal correlations",Experiment 7,China,Homo sapiens,"Subgingival dental plaque,Saliva","UBERON:0016484,UBERON:0001836",Hypertension,EFO:0000537,Saliva samples (No HTN),Subgingival plague samples (No HTN),Subgingival plague samples from participants without Hypertension (No HTN),24,24,2 months,WMS,NA,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,increased,increased,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1070/8/NA,Study 1070,case-control,36475759,10.1128/spectrum.01956-22,NA,"Chen BY, Lin WZ, Li YL, Bi C, Du LJ, Liu Y, Zhou LJ, Liu T, Xu S, Shi CJ, Zhu H, Wang YL, Sun JY, Liu Y, Zhang WC, Zhang Z, Zhang HL, Zhu YQ , Duan SZ",Characteristics and Correlations of the Oral and Gut Fungal Microbiome with Hypertension,Microbiology spectrum,2023,"gut fungal microbiome, hypertension, oral fungal microbiome, oral-gut fungal correlations",Experiment 8,China,Homo sapiens,"Saliva,Subgingival dental plaque","UBERON:0001836,UBERON:0016484",Hypertension,EFO:0000537,Saliva samples (HTN),Subgingival plague samples (HTN),Subgingival plague samples from participants with Hypertension (HTN),36,36,2 months,WMS,NA,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,increased,increased,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1070/9/NA,Study 1070,case-control,36475759,10.1128/spectrum.01956-22,NA,"Chen BY, Lin WZ, Li YL, Bi C, Du LJ, Liu Y, Zhou LJ, Liu T, Xu S, Shi CJ, Zhu H, Wang YL, Sun JY, Liu Y, Zhang WC, Zhang Z, Zhang HL, Zhu YQ , Duan SZ",Characteristics and Correlations of the Oral and Gut Fungal Microbiome with Hypertension,Microbiology spectrum,2023,"gut fungal microbiome, hypertension, oral fungal microbiome, oral-gut fungal correlations",Experiment 9,China,Homo sapiens,"Subgingival dental plaque,Feces","UBERON:0016484,UBERON:0001988",Hypertension,EFO:0000537,Subgingival plague samples (No HTN),Fecal samples (No HTN),Fecal samples from participants without Hypertension (No HTN),24,24,2 months,WMS,NA,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,decreased,decreased,unchanged,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1070/10/NA,Study 1070,case-control,36475759,10.1128/spectrum.01956-22,NA,"Chen BY, Lin WZ, Li YL, Bi C, Du LJ, Liu Y, Zhou LJ, Liu T, Xu S, Shi CJ, Zhu H, Wang YL, Sun JY, Liu Y, Zhang WC, Zhang Z, Zhang HL, Zhu YQ , Duan SZ",Characteristics and Correlations of the Oral and Gut Fungal Microbiome with Hypertension,Microbiology spectrum,2023,"gut fungal microbiome, hypertension, oral fungal microbiome, oral-gut fungal correlations",Experiment 10,China,Homo sapiens,"Subgingival dental plaque,Feces","UBERON:0016484,UBERON:0001988",Hypertension,EFO:0000537,Subgingival plague samples (HTN),Fecal samples (HTN),Fecal samples from participants with Hypertension (HTN),36,36,2 months,WMS,NA,Illumina,LEfSe,0.05,TRUE,2,NA,NA,NA,decreased,decreased,unchanged,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1071/1/NA,Study 1071,case-control,33685393,10.1186/s12866-021-02125-1,https://rdcu.be/dCvoU,"Zhang X, Shi L, Sun T, Guo K , Geng S",Dysbiosis of gut microbiota and its correlation with dysregulation of cytokines in psoriasis patients,BMC microbiology,2021,"16S, Cytokines, Gut microbiome, Microbiota, Psoriasis",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Psoriasis,EFO:0000676,Healthy Control (HC),Psoriasis,"Patients with a clinical diagnosis of psoriasis who were attending a dermatology outpatient clinic in the Second Affiliated Hospital of Xi ‘an Jiaotong University, among them 24 were diagnosed with psoriasis vulgaris (PV), 6 with pustular psoriasis (PP).",30,30,1 month,16S,34,Illumina,LEfSe,0.05,FALSE,2,"age,sex",NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1071/2/NA,Study 1071,case-control,33685393,10.1186/s12866-021-02125-1,https://rdcu.be/dCvoU,"Zhang X, Shi L, Sun T, Guo K , Geng S",Dysbiosis of gut microbiota and its correlation with dysregulation of cytokines in psoriasis patients,BMC microbiology,2021,"16S, Cytokines, Gut microbiome, Microbiota, Psoriasis",Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Gut microbiome measurement,EFO:0007874,Pustular Psoriasis (PP),Psoriasis Vulgaris (PV),Patients with psoriasis diagnosed with psoriasis vulgaris (PV),6,24,1 month,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1072/1/NA,Study 1072,"cross-sectional observational, not case-control",38162648,10.3389/fimmu.2023.1297378,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10755913/,"Martínez-Sanz J, Talavera-Rodríguez A, Díaz-Álvarez J, Rosas Cancio-Suárez M, Rodríguez JM, Alba C, Montes ML, Martín-Mateos R, Burgos-Santamaría D, Moreno S, Serrano-Villar S , Sánchez-Conde M",A gut microbiome signature for HIV and metabolic dysfunction-associated steatotic liver disease,Frontiers in immunology,2023,"HIV, MASLD, NAFLD, gut microbiome, microbiome",Experiment 1,Spain,Homo sapiens,Feces,UBERON:0001988,Non-alcoholic fatty liver disease,EFO:0003095,HIV- MASLD+,HIV+ MASLD+,Participants living with HIV (PLWH) and Metabolic dysfunction-associated steatotic liver disease (MASLD).,20,30,NA,16S,34,Illumina,LEfSe,0.05,TRUE,4,NA,NA,NA,unchanged,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1072/2/NA,Study 1072,"cross-sectional observational, not case-control",38162648,10.3389/fimmu.2023.1297378,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10755913/,"Martínez-Sanz J, Talavera-Rodríguez A, Díaz-Álvarez J, Rosas Cancio-Suárez M, Rodríguez JM, Alba C, Montes ML, Martín-Mateos R, Burgos-Santamaría D, Moreno S, Serrano-Villar S , Sánchez-Conde M",A gut microbiome signature for HIV and metabolic dysfunction-associated steatotic liver disease,Frontiers in immunology,2023,"HIV, MASLD, NAFLD, gut microbiome, microbiome",Experiment 2,Spain,Homo sapiens,Feces,UBERON:0001988,Non-alcoholic fatty liver disease,EFO:0003095,HIV+ MASLD-,HIV+ MASLD+,Participants living with HIV (PLWH) and Metabolic dysfunction-associated steatotic liver disease (MASLD).,30,30,NA,16S,34,Illumina,LEfSe,0.05,TRUE,4,NA,NA,NA,unchanged,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1072/3/NA,Study 1072,"cross-sectional observational, not case-control",38162648,10.3389/fimmu.2023.1297378,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10755913/,"Martínez-Sanz J, Talavera-Rodríguez A, Díaz-Álvarez J, Rosas Cancio-Suárez M, Rodríguez JM, Alba C, Montes ML, Martín-Mateos R, Burgos-Santamaría D, Moreno S, Serrano-Villar S , Sánchez-Conde M",A gut microbiome signature for HIV and metabolic dysfunction-associated steatotic liver disease,Frontiers in immunology,2023,"HIV, MASLD, NAFLD, gut microbiome, microbiome",Experiment 3,Spain,Homo sapiens,Feces,UBERON:0001988,Non-alcoholic fatty liver disease,EFO:0003095,HIV+ MASLD-,HIV- MASLD+,Participants with Metabolic dysfunction-associated steatotic liver disease (MASLD) without HIV infection.,30,20,NA,16S,34,Illumina,LEfSe,0.05,TRUE,4,NA,NA,NA,unchanged,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1073/1/NA,Study 1073,laboratory experiment,37715299,https://doi.org/10.1093/femspd/ftad025,NA,"Shaw CG, Pavloudi C, Barela Hudgell MA, Crow RS, Saw JH, Pyron RA , Smith LC",Bald sea urchin disease shifts the surface microbiome on purple sea urchins in an aquarium,Pathogens and disease,2023,"16S rRNA high throughput sequencing, Strongylocentrotus purpuratus, bacterial infection, echinoderm, microbiome",Experiment 1,United States of America,Strongylocentrotus purpuratus,Cellular bone tissue,UBERON:4000118,Bacterial disease,EFO:0000771,Healthy sea urchins,Diseased sea urchins,Bald sea urchin disease (BSUD) is a bacterial infection that occurs in a wide range of sea urchin species and causes the loss of surface appendages.,4,4,NA,16S,34,Illumina,LEfSe,0.05,FALSE,3,NA,NA,NA,NA,unchanged,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1073/2/NA,Study 1073,laboratory experiment,37715299,https://doi.org/10.1093/femspd/ftad025,NA,"Shaw CG, Pavloudi C, Barela Hudgell MA, Crow RS, Saw JH, Pyron RA , Smith LC",Bald sea urchin disease shifts the surface microbiome on purple sea urchins in an aquarium,Pathogens and disease,2023,"16S rRNA high throughput sequencing, Strongylocentrotus purpuratus, bacterial infection, echinoderm, microbiome",Experiment 2,United States of America,Strongylocentrotus purpuratus,Cellular bone tissue,UBERON:4000118,Bacterial disease,EFO:0000771,Healthy sea urchins,Recovered sea urchins,"A quality in which complete clearance of the disorder is attained; however, physiological 'memory' may persist.",4,4,NA,16S,34,Illumina,LEfSe,0.05,FALSE,3,NA,NA,NA,NA,decreased,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1073/3/NA,Study 1073,laboratory experiment,37715299,https://doi.org/10.1093/femspd/ftad025,NA,"Shaw CG, Pavloudi C, Barela Hudgell MA, Crow RS, Saw JH, Pyron RA , Smith LC",Bald sea urchin disease shifts the surface microbiome on purple sea urchins in an aquarium,Pathogens and disease,2023,"16S rRNA high throughput sequencing, Strongylocentrotus purpuratus, bacterial infection, echinoderm, microbiome",Experiment 3,United States of America,Strongylocentrotus purpuratus,Cellular bone tissue,UBERON:4000118,Bacterial disease,EFO:0000771,Recovered sea urchins,Diseased sea urchins,Bald sea urchin disease (BSUD) is a bacterial infection that occurs in a wide range of sea urchin species and causes the loss of surface appendages.,4,4,NA,16S,34,Illumina,LEfSe,0.05,FALSE,3,NA,NA,NA,NA,decreased,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1073/4/NA,Study 1073,laboratory experiment,37715299,https://doi.org/10.1093/femspd/ftad025,NA,"Shaw CG, Pavloudi C, Barela Hudgell MA, Crow RS, Saw JH, Pyron RA , Smith LC",Bald sea urchin disease shifts the surface microbiome on purple sea urchins in an aquarium,Pathogens and disease,2023,"16S rRNA high throughput sequencing, Strongylocentrotus purpuratus, bacterial infection, echinoderm, microbiome",Experiment 4,United States of America,Strongylocentrotus purpuratus,Anatomical surface,UBERON:0006984,Bacterial disease,EFO:0000771,Sea water from healthy sea urchins aquarium,Sea water from diseased sea urchins aquarium,Bald sea urchin disease (BSUD) is a bacterial infection that occurs in a wide range of sea urchin species and causes the loss of surface appendages.,2,2,NA,16S,34,"Illumina,Non-quantitative PCR",LEfSe,0.05,FALSE,3,NA,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1073/5/NA,Study 1073,laboratory experiment,37715299,https://doi.org/10.1093/femspd/ftad025,NA,"Shaw CG, Pavloudi C, Barela Hudgell MA, Crow RS, Saw JH, Pyron RA , Smith LC",Bald sea urchin disease shifts the surface microbiome on purple sea urchins in an aquarium,Pathogens and disease,2023,"16S rRNA high throughput sequencing, Strongylocentrotus purpuratus, bacterial infection, echinoderm, microbiome",Experiment 5,United States of America,Strongylocentrotus purpuratus,Anatomical surface,UBERON:0006984,Bacterial disease,EFO:0000771,Sea water from healthy sea urchins aquarium,Sea water from recovered sea urchins aquarium,"A quality in which complete clearance of the disorder is attained; however, physiological 'memory' may persist.",2,2,NA,16S,34,"Illumina,Non-quantitative PCR",LEfSe,0.05,FALSE,3,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1073/6/NA,Study 1073,laboratory experiment,37715299,https://doi.org/10.1093/femspd/ftad025,NA,"Shaw CG, Pavloudi C, Barela Hudgell MA, Crow RS, Saw JH, Pyron RA , Smith LC",Bald sea urchin disease shifts the surface microbiome on purple sea urchins in an aquarium,Pathogens and disease,2023,"16S rRNA high throughput sequencing, Strongylocentrotus purpuratus, bacterial infection, echinoderm, microbiome",Experiment 6,United States of America,Strongylocentrotus purpuratus,Cellular bone tissue,UBERON:4000118,Bacterial disease,EFO:0000771,Recovered sea urchins,Diseased sea urchins,Bald sea urchin disease (BSUD) is a bacterial infection that occurs in a wide range of sea urchin species and causes the loss of surface appendages.,4,4,NA,PCR,NA,RT-qPCR,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1073/7/NA,Study 1073,laboratory experiment,37715299,https://doi.org/10.1093/femspd/ftad025,NA,"Shaw CG, Pavloudi C, Barela Hudgell MA, Crow RS, Saw JH, Pyron RA , Smith LC",Bald sea urchin disease shifts the surface microbiome on purple sea urchins in an aquarium,Pathogens and disease,2023,"16S rRNA high throughput sequencing, Strongylocentrotus purpuratus, bacterial infection, echinoderm, microbiome",Experiment 7,United States of America,Strongylocentrotus purpuratus,Anatomical surface,UBERON:0006984,Bacterial disease,EFO:0000771,Sea water from recovered sea urchins aquarium,Sea water diseased sea urchins aquarium,The sample collected from the water in the aquarium where the sea urchins with Bald sea urchin disease (BSUD) were cultured.,2,2,NA,16S,34,"Illumina,Non-quantitative PCR",LEfSe,0.05,FALSE,3,NA,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1073/8/NA,Study 1073,laboratory experiment,37715299,https://doi.org/10.1093/femspd/ftad025,NA,"Shaw CG, Pavloudi C, Barela Hudgell MA, Crow RS, Saw JH, Pyron RA , Smith LC",Bald sea urchin disease shifts the surface microbiome on purple sea urchins in an aquarium,Pathogens and disease,2023,"16S rRNA high throughput sequencing, Strongylocentrotus purpuratus, bacterial infection, echinoderm, microbiome",Experiment 8,United States of America,Strongylocentrotus purpuratus,Cellular bone tissue,UBERON:4000118,Bacterial disease,EFO:0000771,Healthy sea urchins,Recovered sea urchins,"A quality in which complete clearance of the disorder is attained; however, physiological 'memory' may persist.",4,4,NA,PCR,NA,RT-qPCR,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1074/1/NA,Study 1074,time series / longitudinal observational,37660163,10.1038/s41598-023-41664-7,NA,"Chuaypen N, Jinato T, Avihingsanon A, Nookaew I, Tanaka Y , Tangkijvanich P",Long-term benefit of DAAs on gut dysbiosis and microbial translocation in HCV-infected patients with and without HIV coinfection,Scientific reports,2023,NA,Experiment 1,Thailand,Homo sapiens,Feces,UBERON:0001988,Response to antiviral drug,EFO:0010123,Healthy controls,Patients at baseline - SVR,Patients at baseline with HCV monoinfection and HCV/HIV coinfection  who achieved sustained virological response (SVR),20,NA,Patients were asked to stop antibiotics within 2 weeks before acceptance and during the study period.,16S,34,Illumina,NA,NA,NA,NA,NA,NA,NA,NA,decreased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1074/2/NA,Study 1074,time series / longitudinal observational,37660163,10.1038/s41598-023-41664-7,NA,"Chuaypen N, Jinato T, Avihingsanon A, Nookaew I, Tanaka Y , Tangkijvanich P",Long-term benefit of DAAs on gut dysbiosis and microbial translocation in HCV-infected patients with and without HIV coinfection,Scientific reports,2023,NA,Experiment 2,Thailand,Homo sapiens,Feces,UBERON:0001988,Response to antiviral drug,EFO:0010123,Baseline - SVR,Follow-up at week 72 (FUw72) -SVR,Patients at week 72 after treatment completion who achieved sustained virological response (SVR),NA,NA,Patients were asked to stop antibiotics within 2 weeks before acceptance and during the study period.,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1074/3/NA,Study 1074,time series / longitudinal observational,37660163,10.1038/s41598-023-41664-7,NA,"Chuaypen N, Jinato T, Avihingsanon A, Nookaew I, Tanaka Y , Tangkijvanich P",Long-term benefit of DAAs on gut dysbiosis and microbial translocation in HCV-infected patients with and without HIV coinfection,Scientific reports,2023,NA,Experiment 3,Thailand,Homo sapiens,Feces,UBERON:0001988,Response to antiviral drug,EFO:0010123,Healthy controls,Follow-up at week 72 (FUw72) -SVR,Patients at week 72 after treatment completion who achieved sustained virological response (SVR),20,NA,Patients were asked to stop antibiotics within 2 weeks before acceptance and during the study period.,16S,34,Illumina,NA,NA,NA,NA,NA,NA,NA,NA,unchanged,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1074/4/NA,Study 1074,time series / longitudinal observational,37660163,10.1038/s41598-023-41664-7,NA,"Chuaypen N, Jinato T, Avihingsanon A, Nookaew I, Tanaka Y , Tangkijvanich P",Long-term benefit of DAAs on gut dysbiosis and microbial translocation in HCV-infected patients with and without HIV coinfection,Scientific reports,2023,NA,Experiment 4,Thailand,Homo sapiens,Feces,UBERON:0001988,Response to antiviral drug,EFO:0010123,Patients with mild fibrosis at baseline (F0–F1),Patients with mild fibrosis at FUw72 (F0–F1),Patients with mild fibrosis (F0–F1) at week 72 after treatment completion,NA,NA,Patients were asked to stop antibiotics within 2 weeks before acceptance and during the study period.,16S,34,Illumina,NA,NA,NA,NA,NA,NA,NA,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1074/5/NA,Study 1074,time series / longitudinal observational,37660163,10.1038/s41598-023-41664-7,NA,"Chuaypen N, Jinato T, Avihingsanon A, Nookaew I, Tanaka Y , Tangkijvanich P",Long-term benefit of DAAs on gut dysbiosis and microbial translocation in HCV-infected patients with and without HIV coinfection,Scientific reports,2023,NA,Experiment 5,Thailand,Homo sapiens,Feces,UBERON:0001988,Response to antiviral drug,EFO:0010123,Patients with significant fibrosis to cirrhosis at baseline (F2–F4),Patients with significant fibrosis to cirrhosis at FUw72 (F2–F4),Patients with significant fibrosis to cirrhosis (F2–F4) at week 72 after treatment completion (FUw72),NA,NA,Patients were asked to stop antibiotics within 2 weeks before acceptance and during the study period.,16S,34,Illumina,NA,NA,NA,NA,NA,NA,NA,NA,unchanged,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1074/6/NA,Study 1074,time series / longitudinal observational,37660163,10.1038/s41598-023-41664-7,NA,"Chuaypen N, Jinato T, Avihingsanon A, Nookaew I, Tanaka Y , Tangkijvanich P",Long-term benefit of DAAs on gut dysbiosis and microbial translocation in HCV-infected patients with and without HIV coinfection,Scientific reports,2023,NA,Experiment 6,Thailand,Homo sapiens,Feces,UBERON:0001988,Response to antiviral drug,EFO:0010123,Patients with HCV monoinfection & (F2-F4) fibrosis at baseline,Patients with HCV monoinfection & (F2-F4) fibrosis at FUw72,Patients with HCV monoinfection and significant fibrosis to cirrhosis (F2-F4) at week 72 after treatment completion (FUw72).,NA,NA,Patients were asked to stop antibiotics within 2 weeks before acceptance and during the study period.,16S,34,Illumina,NA,NA,NA,NA,NA,NA,NA,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1074/7/NA,Study 1074,time series / longitudinal observational,37660163,10.1038/s41598-023-41664-7,NA,"Chuaypen N, Jinato T, Avihingsanon A, Nookaew I, Tanaka Y , Tangkijvanich P",Long-term benefit of DAAs on gut dysbiosis and microbial translocation in HCV-infected patients with and without HIV coinfection,Scientific reports,2023,NA,Experiment 7,Thailand,Homo sapiens,Feces,UBERON:0001988,Response to antiviral drug,EFO:0010123,Patients with HCV/HIV coinfection at baseline,Patients with HCV/HIV coinfection at FUw72,Patients with HCV/HIV coinfection at week 72 after treatment completion (FUw72),24,19,Patients were asked to stop antibiotics within 2 weeks before acceptance and during the study period.,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,unchanged,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1074/8/NA,Study 1074,time series / longitudinal observational,37660163,10.1038/s41598-023-41664-7,NA,"Chuaypen N, Jinato T, Avihingsanon A, Nookaew I, Tanaka Y , Tangkijvanich P",Long-term benefit of DAAs on gut dysbiosis and microbial translocation in HCV-infected patients with and without HIV coinfection,Scientific reports,2023,NA,Experiment 8,Thailand,Homo sapiens,Feces,UBERON:0001988,Response to antiviral drug,EFO:0010123,Patients with HCV monoinfection + mild fibrosis at baseline,Patients with HCV monoinfection + mild fibrosis at FUw72,Patients with HCV monoinfection who had F0–F1 fibrosis stage at week 72 after treatment completion (FUw72),NA,NA,Patients were asked to stop antibiotics within 2 weeks before acceptance and during the study period.,16S,34,Illumina,NA,NA,NA,NA,NA,NA,NA,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1074/9/NA,Study 1074,time series / longitudinal observational,37660163,10.1038/s41598-023-41664-7,NA,"Chuaypen N, Jinato T, Avihingsanon A, Nookaew I, Tanaka Y , Tangkijvanich P",Long-term benefit of DAAs on gut dysbiosis and microbial translocation in HCV-infected patients with and without HIV coinfection,Scientific reports,2023,NA,Experiment 9,Thailand,Homo sapiens,Feces,UBERON:0001988,Response to antiviral drug,EFO:0010123,Patients with HCV monoinfection + significant fibrosis at baseline,Patients with HCV monoinfection + significant fibrosis at FUw72,Patients with HCV monoinfection who had F2–F4 fibrosis stage at week 72 after treatment completion (FUw72),NA,NA,Patients were asked to stop antibiotics within 2 weeks before acceptance and during the study period.,16S,34,Illumina,NA,NA,NA,NA,NA,NA,NA,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1074/10/NA,Study 1074,time series / longitudinal observational,37660163,10.1038/s41598-023-41664-7,NA,"Chuaypen N, Jinato T, Avihingsanon A, Nookaew I, Tanaka Y , Tangkijvanich P",Long-term benefit of DAAs on gut dysbiosis and microbial translocation in HCV-infected patients with and without HIV coinfection,Scientific reports,2023,NA,Experiment 10,Thailand,Homo sapiens,Feces,UBERON:0001988,Response to antiviral drug,EFO:0010123,Patients with HCV/HIV coinfection + mild fibrosis at baseline,Patients with HCV/HIV coinfection + mild fibrosis at FUw72,Patients with HCV/HIV coinfection who had F0–F1 fibrosis stage at week 72 after treatment completion (FUw72),NA,NA,Patients were asked to stop antibiotics within 2 weeks before acceptance and during the study period.,16S,34,Illumina,NA,NA,NA,NA,NA,NA,NA,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1074/11/NA,Study 1074,time series / longitudinal observational,37660163,10.1038/s41598-023-41664-7,NA,"Chuaypen N, Jinato T, Avihingsanon A, Nookaew I, Tanaka Y , Tangkijvanich P",Long-term benefit of DAAs on gut dysbiosis and microbial translocation in HCV-infected patients with and without HIV coinfection,Scientific reports,2023,NA,Experiment 11,Thailand,Homo sapiens,Feces,UBERON:0001988,Response to antiviral drug,EFO:0010123,patients with HCV monoinfection at baseline,patients with HCV monoinfection at FUw72,patients with HCV monoinfection at week 72 after treatment completion (FUw72),62,50,Patients were asked to stop antibiotics within 2 weeks before acceptance and during the study period.,16S,34,Illumina,Mann-Whitney (Wilcoxon),0.05,FALSE,NA,NA,NA,NA,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1074/12/NA,Study 1074,time series / longitudinal observational,37660163,10.1038/s41598-023-41664-7,NA,"Chuaypen N, Jinato T, Avihingsanon A, Nookaew I, Tanaka Y , Tangkijvanich P",Long-term benefit of DAAs on gut dysbiosis and microbial translocation in HCV-infected patients with and without HIV coinfection,Scientific reports,2023,NA,Experiment 12,Thailand,Homo sapiens,Feces,UBERON:0001988,Response to antiviral drug,EFO:0010123,healthy control,patients with HCV monoinfection at baseline,patients with HCV monoinfection at baseline,20,50,Patients were asked to stop antibiotics within 2 weeks before acceptance and during the study period.,16S,34,Illumina,T-Test,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1074/13/NA,Study 1074,time series / longitudinal observational,37660163,10.1038/s41598-023-41664-7,NA,"Chuaypen N, Jinato T, Avihingsanon A, Nookaew I, Tanaka Y , Tangkijvanich P",Long-term benefit of DAAs on gut dysbiosis and microbial translocation in HCV-infected patients with and without HIV coinfection,Scientific reports,2023,NA,Experiment 13,Thailand,Homo sapiens,Feces,UBERON:0001988,Response to antiviral drug,EFO:0010123,Healthy controls,patients with HCV/HIV coinfection at baseline,Patients with HIV/HCV coinfection at baseline,20,19,Patients were asked to stop antibiotics within 2 weeks before acceptance and during the study period.,16S,34,Illumina,T-Test,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1074/14/NA,Study 1074,time series / longitudinal observational,37660163,10.1038/s41598-023-41664-7,NA,"Chuaypen N, Jinato T, Avihingsanon A, Nookaew I, Tanaka Y , Tangkijvanich P",Long-term benefit of DAAs on gut dysbiosis and microbial translocation in HCV-infected patients with and without HIV coinfection,Scientific reports,2023,NA,Experiment 14,Thailand,Homo sapiens,Feces,UBERON:0001988,Response to antiviral drug,EFO:0010123,patients with HCV monoinfection at baseline,patients with HCV/HIV coinfection at baseline,patients with HCV/HIV coinfection at baseline,50,19,Patients were asked to stop antibiotics within 2 weeks before acceptance and during the study period.,16S,34,Illumina,T-Test,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1075/1/NA,Study 1075,"cross-sectional observational, not case-control",33143658,https://doi.org/10.1186/s12866-020-02021-0,NA,"Yuan X, Chen R, Zhang Y, Lin X , Yang X",Gut microbiota: effect of pubertal status,BMC microbiology,2020,"16 s rRNA, Adolescent, Children, Gut microbiota, Puberty",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Puberty,EFO:0001382,Non-pubertal,Pubertal,Male children who have undergone puberty.,42,47,None,16S,34,NA,LEfSe,0.05,FALSE,2,NA,NA,unchanged,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1076/1/NA,Study 1076,case-control,35069544,10.3389/fimmu.2021.771136,NA,"Yuan Y, Wang C, Wang G, Guo X, Jiang S, Zuo X, Wang X, Hsu AC, Qi M , Wang F",Airway Microbiome and Serum Metabolomics Analysis Identify Differential Candidate Biomarkers in Allergic Rhinitis,Frontiers in immunology,2021,"allergic rhinitis, biomarkers, metabolomics, microbiome, multiomics",Experiment 1,China,Homo sapiens,Inferior nasal concha,UBERON:0005922,Allergic rhinitis,EFO:0005854,healthy controls (HC),Allergic rhinitis (AR),Patients with allergic rhinitis (AR),15,28,NA,16S,34,Ion Torrent,T-Test,0.05,TRUE,NA,"age,sex",NA,NA,NA,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1077/1/NA,Study 1077,"cross-sectional observational, not case-control",31067473,https://doi.org/10.1016/j.celrep.2019.04.023,https://pubmed.ncbi.nlm.nih.gov/31067473/,"Robertson SJ, Lemire P, Maughan H, Goethel A, Turpin W, Bedrani L, Guttman DS, Croitoru K, Girardin SE , Philpott DJ",Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models,Cell reports,2019,"co-housing, intestinal, littermates, microbiota, microbiota standardization, mouse",Experiment 1,Canada,Mus musculus,Feces,UBERON:0001988,Gut microbiome measurement,EFO:0007874,JAX group,JAX-CH group,Samples taken from co-housed mice from Jackson Laboratory (JAX-CH).,12,16,None,16S,4,Illumina,LEfSe,0.05,TRUE,2,age,NA,NA,unchanged,NA,unchanged,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1077/2/NA,Study 1077,"cross-sectional observational, not case-control",31067473,https://doi.org/10.1016/j.celrep.2019.04.023,https://pubmed.ncbi.nlm.nih.gov/31067473/,"Robertson SJ, Lemire P, Maughan H, Goethel A, Turpin W, Bedrani L, Guttman DS, Croitoru K, Girardin SE , Philpott DJ",Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models,Cell reports,2019,"co-housing, intestinal, littermates, microbiota, microbiota standardization, mouse",Experiment 2,Canada,Mus musculus,Feces,UBERON:0001988,Gut microbiome measurement,EFO:0007874,TAC group,TAC-CH group,Samples taken from co-housed mice from Taconic Farms (TAC-CH).,12,16,None,16S,4,Illumina,LEfSe,0.05,TRUE,2,age,NA,NA,unchanged,NA,unchanged,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1077/3/NA,Study 1077,"cross-sectional observational, not case-control",31067473,https://doi.org/10.1016/j.celrep.2019.04.023,https://pubmed.ncbi.nlm.nih.gov/31067473/,"Robertson SJ, Lemire P, Maughan H, Goethel A, Turpin W, Bedrani L, Guttman DS, Croitoru K, Girardin SE , Philpott DJ",Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models,Cell reports,2019,"co-housing, intestinal, littermates, microbiota, microbiota standardization, mouse",Experiment 3,Canada,Mus musculus,Feces,UBERON:0001988,Gut microbiome measurement,EFO:0007874,TAC-CH group,JAX-CH group,Samples taken from co-housed mice from Jackson Laboratory (JAX-CH).,16,16,None,16S,4,Illumina,LEfSe,0.05,TRUE,2,age,NA,NA,unchanged,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1077/4/NA,Study 1077,"cross-sectional observational, not case-control",31067473,https://doi.org/10.1016/j.celrep.2019.04.023,https://pubmed.ncbi.nlm.nih.gov/31067473/,"Robertson SJ, Lemire P, Maughan H, Goethel A, Turpin W, Bedrani L, Guttman DS, Croitoru K, Girardin SE , Philpott DJ",Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models,Cell reports,2019,"co-housing, intestinal, littermates, microbiota, microbiota standardization, mouse",Experiment 4,Canada,Mus musculus,Colon,UBERON:0001155,Gut microbiome measurement,EFO:0007874,JAX group,JAX-CH group,Samples taken from co-housed mice from Jackson Laboratory (JAX-CH).,12,16,None,16S,4,Illumina,LEfSe,0.05,TRUE,2,age,NA,NA,unchanged,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1077/5/NA,Study 1077,"cross-sectional observational, not case-control",31067473,https://doi.org/10.1016/j.celrep.2019.04.023,https://pubmed.ncbi.nlm.nih.gov/31067473/,"Robertson SJ, Lemire P, Maughan H, Goethel A, Turpin W, Bedrani L, Guttman DS, Croitoru K, Girardin SE , Philpott DJ",Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models,Cell reports,2019,"co-housing, intestinal, littermates, microbiota, microbiota standardization, mouse",Experiment 5,Canada,Mus musculus,Colon,UBERON:0001155,Gut microbiome measurement,EFO:0007874,TAC group,TAC-CH group,Samples taken from co-housed mice from Taconic Farms (TAC-CH).,12,16,None,16S,4,Illumina,LEfSe,0.05,TRUE,2,age,NA,NA,increased,NA,unchanged,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1077/6/NA,Study 1077,"cross-sectional observational, not case-control",31067473,https://doi.org/10.1016/j.celrep.2019.04.023,https://pubmed.ncbi.nlm.nih.gov/31067473/,"Robertson SJ, Lemire P, Maughan H, Goethel A, Turpin W, Bedrani L, Guttman DS, Croitoru K, Girardin SE , Philpott DJ",Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models,Cell reports,2019,"co-housing, intestinal, littermates, microbiota, microbiota standardization, mouse",Experiment 6,Canada,Mus musculus,Colon,UBERON:0001155,Gut microbiome measurement,EFO:0007874,TAC-CH group,JAX-CH group,Samples taken from co-housed mice from Jackson Laboratory (JAX-CH).,16,16,None,16S,4,Illumina,LEfSe,0.05,TRUE,2,age,NA,NA,unchanged,NA,unchanged,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1077/7/NA,Study 1077,"cross-sectional observational, not case-control",31067473,https://doi.org/10.1016/j.celrep.2019.04.023,https://pubmed.ncbi.nlm.nih.gov/31067473/,"Robertson SJ, Lemire P, Maughan H, Goethel A, Turpin W, Bedrani L, Guttman DS, Croitoru K, Girardin SE , Philpott DJ",Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models,Cell reports,2019,"co-housing, intestinal, littermates, microbiota, microbiota standardization, mouse",Experiment 7,Canada,Mus musculus,Ileum,UBERON:0002116,Gut microbiome measurement,EFO:0007874,JAX group,JAX-CH group,Samples taken from co-housed mice from Jackson Laboratory (JAX-CH).,12,16,None,16S,4,Illumina,LEfSe,0.05,TRUE,2,age,NA,NA,unchanged,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1077/8/NA,Study 1077,"cross-sectional observational, not case-control",31067473,https://doi.org/10.1016/j.celrep.2019.04.023,https://pubmed.ncbi.nlm.nih.gov/31067473/,"Robertson SJ, Lemire P, Maughan H, Goethel A, Turpin W, Bedrani L, Guttman DS, Croitoru K, Girardin SE , Philpott DJ",Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models,Cell reports,2019,"co-housing, intestinal, littermates, microbiota, microbiota standardization, mouse",Experiment 8,Canada,Mus musculus,Ileum,UBERON:0002116,Gut microbiome measurement,EFO:0007874,TAC group,TAC-CH group,Samples taken from co-housed mice from Taconic Farms (TAC-CH).,12,16,None,16S,4,Illumina,LEfSe,0.05,TRUE,2,age,NA,NA,unchanged,NA,unchanged,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1077/9/NA,Study 1077,"cross-sectional observational, not case-control",31067473,https://doi.org/10.1016/j.celrep.2019.04.023,https://pubmed.ncbi.nlm.nih.gov/31067473/,"Robertson SJ, Lemire P, Maughan H, Goethel A, Turpin W, Bedrani L, Guttman DS, Croitoru K, Girardin SE , Philpott DJ",Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models,Cell reports,2019,"co-housing, intestinal, littermates, microbiota, microbiota standardization, mouse",Experiment 9,Canada,Mus musculus,Ileum,UBERON:0002116,Gut microbiome measurement,EFO:0007874,TAC-CH group,JAX-CH group,Samples taken from co-housed mice from Jackson Laboratory (JAX-CH).,16,16,None,16S,4,Illumina,LEfSe,0.05,TRUE,2,age,NA,NA,unchanged,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1077/10/NA,Study 1077,"cross-sectional observational, not case-control",31067473,https://doi.org/10.1016/j.celrep.2019.04.023,https://pubmed.ncbi.nlm.nih.gov/31067473/,"Robertson SJ, Lemire P, Maughan H, Goethel A, Turpin W, Bedrani L, Guttman DS, Croitoru K, Girardin SE , Philpott DJ",Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models,Cell reports,2019,"co-housing, intestinal, littermates, microbiota, microbiota standardization, mouse",Experiment 10,Canada,Mus musculus,"Feces,Colon","UBERON:0001988,UBERON:0001155",Gut microbiome measurement,EFO:0007874,JAX-CH colon group,JAX-CH fecal pellets group,Samples taken from the fecal pellets of co-housed mice from Jackson Laboratory (JAX-CH).,16,16,None,16S,4,Illumina,LEfSe,0.05,TRUE,2,age,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1077/11/NA,Study 1077,"cross-sectional observational, not case-control",31067473,https://doi.org/10.1016/j.celrep.2019.04.023,https://pubmed.ncbi.nlm.nih.gov/31067473/,"Robertson SJ, Lemire P, Maughan H, Goethel A, Turpin W, Bedrani L, Guttman DS, Croitoru K, Girardin SE , Philpott DJ",Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models,Cell reports,2019,"co-housing, intestinal, littermates, microbiota, microbiota standardization, mouse",Experiment 11,Canada,Mus musculus,"Feces,Colon","UBERON:0001988,UBERON:0001155",Gut microbiome measurement,EFO:0007874,TAC-CH colon group,TAC-CH fecal pellets group,Samples taken from the fecal pellets of co-housed mice from Taconic Farms (TAC-CH).,16,16,None,16S,4,Illumina,LEfSe,0.05,TRUE,2,age,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1077/12/NA,Study 1077,"cross-sectional observational, not case-control",31067473,https://doi.org/10.1016/j.celrep.2019.04.023,https://pubmed.ncbi.nlm.nih.gov/31067473/,"Robertson SJ, Lemire P, Maughan H, Goethel A, Turpin W, Bedrani L, Guttman DS, Croitoru K, Girardin SE , Philpott DJ",Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models,Cell reports,2019,"co-housing, intestinal, littermates, microbiota, microbiota standardization, mouse",Experiment 12,Canada,Mus musculus,Feces,UBERON:0001988,Gut microbiome measurement,EFO:0007874,P1 TAC group,P1 JAX group,Fecal pellet samples of the parental generation (P1) of Jackson Laboratory (JAX) mice.,4,4,None,16S,4,Illumina,"Kruskall-Wallis,Dunn's test",0.05,TRUE,NA,NA,NA,NA,unchanged,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1077/13/NA,Study 1077,"cross-sectional observational, not case-control",31067473,https://doi.org/10.1016/j.celrep.2019.04.023,https://pubmed.ncbi.nlm.nih.gov/31067473/,"Robertson SJ, Lemire P, Maughan H, Goethel A, Turpin W, Bedrani L, Guttman DS, Croitoru K, Girardin SE , Philpott DJ",Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models,Cell reports,2019,"co-housing, intestinal, littermates, microbiota, microbiota standardization, mouse",Experiment 13,Canada,Mus musculus,Feces,UBERON:0001988,Gut microbiome measurement,EFO:0007874,P1 JAX group,F1 mJAX group,Fecal pellet samples from the maternal F1-generation of Jackson Laboratory (mJAX) mice.,4,15,None,16S,4,Illumina,"Dunn's test,Kruskall-Wallis",0.05,TRUE,NA,NA,NA,NA,increased,NA,increased,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1077/14/NA,Study 1077,"cross-sectional observational, not case-control",31067473,https://doi.org/10.1016/j.celrep.2019.04.023,https://pubmed.ncbi.nlm.nih.gov/31067473/,"Robertson SJ, Lemire P, Maughan H, Goethel A, Turpin W, Bedrani L, Guttman DS, Croitoru K, Girardin SE , Philpott DJ",Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models,Cell reports,2019,"co-housing, intestinal, littermates, microbiota, microbiota standardization, mouse",Experiment 14,Canada,Mus musculus,Feces,UBERON:0001988,Gut microbiome measurement,EFO:0007874,P1 TAC group,F1 mTAC group,Fecal pellet samples from the maternal F1-generation of Taconic farms (mTAC) mice.,4,15,None,16S,4,Illumina,"Dunn's test,Kruskall-Wallis",0.05,TRUE,NA,NA,NA,NA,unchanged,NA,unchanged,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1077/15/NA,Study 1077,"cross-sectional observational, not case-control",31067473,https://doi.org/10.1016/j.celrep.2019.04.023,https://pubmed.ncbi.nlm.nih.gov/31067473/,"Robertson SJ, Lemire P, Maughan H, Goethel A, Turpin W, Bedrani L, Guttman DS, Croitoru K, Girardin SE , Philpott DJ",Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models,Cell reports,2019,"co-housing, intestinal, littermates, microbiota, microbiota standardization, mouse",Experiment 15,Canada,Mus musculus,Feces,UBERON:0001988,Gut microbiome measurement,EFO:0007874,F1 mTAC group,F1 mJAX group,Fecal pellet samples from the maternal F1-generation of Jackson Laboratory (mJAX) mice.,15,15,None,16S,4,Illumina,"Dunn's test,Kruskall-Wallis",0.05,TRUE,NA,NA,NA,NA,unchanged,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1077/16/NA,Study 1077,"cross-sectional observational, not case-control",31067473,https://doi.org/10.1016/j.celrep.2019.04.023,https://pubmed.ncbi.nlm.nih.gov/31067473/,"Robertson SJ, Lemire P, Maughan H, Goethel A, Turpin W, Bedrani L, Guttman DS, Croitoru K, Girardin SE , Philpott DJ",Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models,Cell reports,2019,"co-housing, intestinal, littermates, microbiota, microbiota standardization, mouse",Experiment 16,Canada,Mus musculus,Colon,UBERON:0001155,Gut microbiome measurement,EFO:0007874,P1 TAC group,P1 JAX group,Colon samples of the parental generation (P1) of Jackson Laboratory (JAX) mice.,4,4,None,16S,4,Illumina,"Dunn's test,Kruskall-Wallis",0.05,TRUE,NA,NA,NA,NA,unchanged,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1077/17/NA,Study 1077,"cross-sectional observational, not case-control",31067473,https://doi.org/10.1016/j.celrep.2019.04.023,https://pubmed.ncbi.nlm.nih.gov/31067473/,"Robertson SJ, Lemire P, Maughan H, Goethel A, Turpin W, Bedrani L, Guttman DS, Croitoru K, Girardin SE , Philpott DJ",Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models,Cell reports,2019,"co-housing, intestinal, littermates, microbiota, microbiota standardization, mouse",Experiment 17,Canada,Mus musculus,Colon,UBERON:0001155,Gut microbiome measurement,EFO:0007874,P1 JAX group,F1 mJAX group,Colon samples from the maternal F1-generation of Jackson Laboratory (mJAX) mice.,4,15,None,16S,4,Illumina,"Dunn's test,Kruskall-Wallis",0.05,TRUE,NA,NA,NA,NA,unchanged,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1077/18/NA,Study 1077,"cross-sectional observational, not case-control",31067473,https://doi.org/10.1016/j.celrep.2019.04.023,https://pubmed.ncbi.nlm.nih.gov/31067473/,"Robertson SJ, Lemire P, Maughan H, Goethel A, Turpin W, Bedrani L, Guttman DS, Croitoru K, Girardin SE , Philpott DJ",Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models,Cell reports,2019,"co-housing, intestinal, littermates, microbiota, microbiota standardization, mouse",Experiment 18,Canada,Mus musculus,Colon,UBERON:0001155,Gut microbiome measurement,EFO:0007874,P1 TAC group,F1 mTAC group,Colon samples from the maternal F1-generation of Taconic farms (mTAC) mice.,4,15,None,16S,4,Illumina,"Dunn's test,Kruskall-Wallis",0.05,TRUE,NA,NA,NA,NA,unchanged,NA,increased,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1077/19/NA,Study 1077,"cross-sectional observational, not case-control",31067473,https://doi.org/10.1016/j.celrep.2019.04.023,https://pubmed.ncbi.nlm.nih.gov/31067473/,"Robertson SJ, Lemire P, Maughan H, Goethel A, Turpin W, Bedrani L, Guttman DS, Croitoru K, Girardin SE , Philpott DJ",Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models,Cell reports,2019,"co-housing, intestinal, littermates, microbiota, microbiota standardization, mouse",Experiment 19,Canada,Mus musculus,Colon,UBERON:0001155,Gut microbiome measurement,EFO:0007874,F1 mTAC group,F1 mJAX group,Colon samples from the maternal F1-generation of Jackson Laboratory (mJAX) mice.,15,15,None,16S,4,Illumina,"Dunn's test,Kruskall-Wallis",0.05,TRUE,NA,NA,NA,NA,unchanged,NA,unchanged,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1077/20/NA,Study 1077,"cross-sectional observational, not case-control",31067473,https://doi.org/10.1016/j.celrep.2019.04.023,https://pubmed.ncbi.nlm.nih.gov/31067473/,"Robertson SJ, Lemire P, Maughan H, Goethel A, Turpin W, Bedrani L, Guttman DS, Croitoru K, Girardin SE , Philpott DJ",Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models,Cell reports,2019,"co-housing, intestinal, littermates, microbiota, microbiota standardization, mouse",Experiment 20,Canada,Mus musculus,Ileum,UBERON:0002116,Gut microbiome measurement,EFO:0007874,P1 TAC group,P1 JAX group,Ileum samples of the parental generation (P1) of Jackson Laboratory (JAX) mice.,4,4,None,16S,4,Illumina,"Dunn's test,Kruskall-Wallis",0.05,TRUE,NA,NA,NA,NA,unchanged,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1077/21/NA,Study 1077,"cross-sectional observational, not case-control",31067473,https://doi.org/10.1016/j.celrep.2019.04.023,https://pubmed.ncbi.nlm.nih.gov/31067473/,"Robertson SJ, Lemire P, Maughan H, Goethel A, Turpin W, Bedrani L, Guttman DS, Croitoru K, Girardin SE , Philpott DJ",Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models,Cell reports,2019,"co-housing, intestinal, littermates, microbiota, microbiota standardization, mouse",Experiment 21,Canada,Mus musculus,Ileum,UBERON:0002116,Gut microbiome measurement,EFO:0007874,P1 JAX group,F1 mJAX group,Ileum samples from the maternal F1-generation of Jackson Laboratory (mJAX) mice.,4,15,None,16S,4,Illumina,"Dunn's test,Kruskall-Wallis",0.05,TRUE,NA,NA,NA,NA,unchanged,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1077/22/NA,Study 1077,"cross-sectional observational, not case-control",31067473,https://doi.org/10.1016/j.celrep.2019.04.023,https://pubmed.ncbi.nlm.nih.gov/31067473/,"Robertson SJ, Lemire P, Maughan H, Goethel A, Turpin W, Bedrani L, Guttman DS, Croitoru K, Girardin SE , Philpott DJ",Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models,Cell reports,2019,"co-housing, intestinal, littermates, microbiota, microbiota standardization, mouse",Experiment 22,Canada,Mus musculus,Ileum,UBERON:0002116,Gut microbiome measurement,EFO:0007874,P1 TAC group,F1 mTAC group,Ileum samples from the maternal F1-generation of Taconic farms (mTAC) mice.,4,15,None,16S,4,Illumina,"Dunn's test,Kruskall-Wallis",0.05,TRUE,NA,NA,NA,NA,unchanged,NA,unchanged,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1077/23/NA,Study 1077,"cross-sectional observational, not case-control",31067473,https://doi.org/10.1016/j.celrep.2019.04.023,https://pubmed.ncbi.nlm.nih.gov/31067473/,"Robertson SJ, Lemire P, Maughan H, Goethel A, Turpin W, Bedrani L, Guttman DS, Croitoru K, Girardin SE , Philpott DJ",Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse Models,Cell reports,2019,"co-housing, intestinal, littermates, microbiota, microbiota standardization, mouse",Experiment 23,Canada,Mus musculus,Ileum,UBERON:0002116,Gut microbiome measurement,EFO:0007874,F1 mTAC group,F1 mJAX group,Ileum samples from the maternal F1-generation of Jackson Laboratory (mJAX) mice.,15,15,None,16S,4,Illumina,"Dunn's test,Kruskall-Wallis",0.05,TRUE,NA,NA,NA,NA,unchanged,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1078/1/NA,Study 1078,laboratory experiment,NA,10.1016/j.jff.2024.106106,https://www.sciencedirect.com/science/article/pii/S1756464624001087#s0125,"Haoyu Wang, Kaiwei Chen, Liang Xiao, Ningning He, Shangyong Li, Shengnan Yu, Xiaoqian Lin, Yuanqiang Zou, Zhinan Wu",Stachyose ameliorates obesity-related metabolic syndrome via improving intestinal barrier function and remodeling gut microbiota,Journal of Functional Foods,2024,"Butyrate-producing strains, Stachyose, gut microbiota, intestinal barrier, metabolic syndrome",Experiment 1,China,Mus musculus,Feces,UBERON:0001988,High fat diet,EFO:0002757,High-Fat Diet fed Mice (HFD),Stachyose-treated High-Fat Diet fed Mice (STA),"Male C57BL/6J mice (18–20g, 6 weeks old) which were fed a High-Fat Diet (D12492-HFD diet, #XTHF60-1) with 60% of energy from fat, for 12 weeks and treatment with stachyose in the last 8 weeks (200 mg/ kg/day).",7,7,None,WMS,NA,DNBSEQ-T7,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1079/1/NA,Study 1079,"cross-sectional observational, not case-control",30558669,https://doi.org/10.1186/s40168-018-0611-4,https://microbiomejournal.biomedcentral.com/articles/10.1186/s40168-018-0611-4,"Deshpande NP, Riordan SM, Castaño-Rodríguez N, Wilkins MR , Kaakoush NO","Signatures within the esophageal microbiome are associated with host genetics, age, and disease",Microbiome,2018,"Community types, Esophagus, Metagenomics, Microbiota, Single nucleotide polymorphisms",Experiment 1,Australia,Homo sapiens,Esophagus,UBERON:0001043,Esophageal adenocarcinoma,EFO:0000478,Cluster 1,Cluster 2,"The esophageal microbiome was found to cluster into functionally distinct community types (esotypes) defined by the relative abundances of Streptococcus and Prevotella.

This group consists of esotypes that are dominated by Streptococcus (Streptococcus mitis/oralis/pneumoniae).",NA,NA,2 months,16S,NA,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,decreased,NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1079/2/NA,Study 1079,"cross-sectional observational, not case-control",30558669,https://doi.org/10.1186/s40168-018-0611-4,https://microbiomejournal.biomedcentral.com/articles/10.1186/s40168-018-0611-4,"Deshpande NP, Riordan SM, Castaño-Rodríguez N, Wilkins MR , Kaakoush NO","Signatures within the esophageal microbiome are associated with host genetics, age, and disease",Microbiome,2018,"Community types, Esophagus, Metagenomics, Microbiota, Single nucleotide polymorphisms",Experiment 2,Australia,Homo sapiens,Esophagus,UBERON:0001043,Esophageal adenocarcinoma,EFO:0000478,Cluster 1,Cluster 3,"The esophageal microbiome was found to cluster into functionally distinct community types (esotypes) defined by the relative abundances of Streptococcus and Prevotella.

This group consists of esotypes that are dominated by by Prevotella (Prevotella melaninogenica and Prevotella pallens), and to a lesser extent Veillonella.",NA,NA,2 months,16S,NA,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1079/3/NA,Study 1079,"cross-sectional observational, not case-control",30558669,https://doi.org/10.1186/s40168-018-0611-4,https://microbiomejournal.biomedcentral.com/articles/10.1186/s40168-018-0611-4,"Deshpande NP, Riordan SM, Castaño-Rodríguez N, Wilkins MR , Kaakoush NO","Signatures within the esophageal microbiome are associated with host genetics, age, and disease",Microbiome,2018,"Community types, Esophagus, Metagenomics, Microbiota, Single nucleotide polymorphisms",Experiment 3,Australia,Homo sapiens,Esophagus,UBERON:0001043,Esophageal adenocarcinoma,EFO:0000478,Cluster 2,Cluster 3,"The esophageal microbiome was found to cluster into functionally distinct community types (esotypes) defined by the relative abundances of Streptococcus and Prevotella. This group consists of esotypes that are dominated by by Prevotella (Prevotella melaninogenica and Prevotella pallens), and to a lesser extent Veillonella.",NA,NA,2 months,16S,NA,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1079/4/NA,Study 1079,"cross-sectional observational, not case-control",30558669,https://doi.org/10.1186/s40168-018-0611-4,https://microbiomejournal.biomedcentral.com/articles/10.1186/s40168-018-0611-4,"Deshpande NP, Riordan SM, Castaño-Rodríguez N, Wilkins MR , Kaakoush NO","Signatures within the esophageal microbiome are associated with host genetics, age, and disease",Microbiome,2018,"Community types, Esophagus, Metagenomics, Microbiota, Single nucleotide polymorphisms",Experiment 4,Australia,Homo sapiens,Esophagus,UBERON:0001043,Esophageal adenocarcinoma,EFO:0000478,Cluster 1,Cluster 2,The esophageal microbiome was found to cluster into functionally distinct community types (esotypes) defined by the relative abundances of Streptococcus and Prevotella. This group consists of esotypes that are dominated by Streptococcus (Streptococcus mitis/oralis/pneumoniae).,NA,NA,2 months,WMS,NA,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,decreased,NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1079/5/NA,Study 1079,"cross-sectional observational, not case-control",30558669,https://doi.org/10.1186/s40168-018-0611-4,https://microbiomejournal.biomedcentral.com/articles/10.1186/s40168-018-0611-4,"Deshpande NP, Riordan SM, Castaño-Rodríguez N, Wilkins MR , Kaakoush NO","Signatures within the esophageal microbiome are associated with host genetics, age, and disease",Microbiome,2018,"Community types, Esophagus, Metagenomics, Microbiota, Single nucleotide polymorphisms",Experiment 5,Australia,Homo sapiens,Esophagus,UBERON:0001043,Esophageal adenocarcinoma,EFO:0000478,Cluster 1,Cluster 3,"The esophageal microbiome was found to cluster into functionally distinct community types (esotypes) defined by the relative abundances of Streptococcus and Prevotella. This group consists of esotypes that are dominated by by Prevotella (Prevotella melaninogenica and Prevotella pallens), and to a lesser extent Veillonella.",NA,NA,2 months,WMS,NA,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,unchanged,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1079/6/NA,Study 1079,"cross-sectional observational, not case-control",30558669,https://doi.org/10.1186/s40168-018-0611-4,https://microbiomejournal.biomedcentral.com/articles/10.1186/s40168-018-0611-4,"Deshpande NP, Riordan SM, Castaño-Rodríguez N, Wilkins MR , Kaakoush NO","Signatures within the esophageal microbiome are associated with host genetics, age, and disease",Microbiome,2018,"Community types, Esophagus, Metagenomics, Microbiota, Single nucleotide polymorphisms",Experiment 6,Australia,Homo sapiens,Esophagus,UBERON:0001043,Esophageal adenocarcinoma,EFO:0000478,Cluster 2,Cluster 3,"The esophageal microbiome was found to cluster into functionally distinct community types (esotypes) defined by the relative abundances of Streptococcus and Prevotella. This group consists of esotypes that are dominated by by Prevotella (Prevotella melaninogenica and Prevotella pallens), and to a lesser extent Veillonella.",NA,NA,2 months,WMS,NA,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,unchanged,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1079/7/NA,Study 1079,"cross-sectional observational, not case-control",30558669,https://doi.org/10.1186/s40168-018-0611-4,https://microbiomejournal.biomedcentral.com/articles/10.1186/s40168-018-0611-4,"Deshpande NP, Riordan SM, Castaño-Rodríguez N, Wilkins MR , Kaakoush NO","Signatures within the esophageal microbiome are associated with host genetics, age, and disease",Microbiome,2018,"Community types, Esophagus, Metagenomics, Microbiota, Single nucleotide polymorphisms",Experiment 7,Australia,Homo sapiens,Esophagus,UBERON:0001043,Gastroesophageal reflux disease,EFO:0003948,Normal (Normal esophagus),GERD (Gastroesophageal reflux disease),This group consists of patients with Gastroesophageal reflux disease.,59,29,2 months,16S,NA,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1079/8/NA,Study 1079,"cross-sectional observational, not case-control",30558669,https://doi.org/10.1186/s40168-018-0611-4,https://microbiomejournal.biomedcentral.com/articles/10.1186/s40168-018-0611-4,"Deshpande NP, Riordan SM, Castaño-Rodríguez N, Wilkins MR , Kaakoush NO","Signatures within the esophageal microbiome are associated with host genetics, age, and disease",Microbiome,2018,"Community types, Esophagus, Metagenomics, Microbiota, Single nucleotide polymorphisms",Experiment 8,Australia,Homo sapiens,Esophagus,UBERON:0001043,Gastroesophageal reflux disease,EFO:0003948,Normal,Gastroesophageal reflux disease GERD(within subjects classified as PPI NO),This group consists of patients with Gastroesophageal reflux disease(within subjects classified as PPI NO),59,19,2 months,16S,NA,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1079/9/NA,Study 1079,"cross-sectional observational, not case-control",30558669,https://doi.org/10.1186/s40168-018-0611-4,https://microbiomejournal.biomedcentral.com/articles/10.1186/s40168-018-0611-4,"Deshpande NP, Riordan SM, Castaño-Rodríguez N, Wilkins MR , Kaakoush NO","Signatures within the esophageal microbiome are associated with host genetics, age, and disease",Microbiome,2018,"Community types, Esophagus, Metagenomics, Microbiota, Single nucleotide polymorphisms",Experiment 9,Australia,Homo sapiens,Esophagus,UBERON:0001043,Barrett's esophagus,EFO:0000280,Normal,Barrett’s Esophagus (BE),This group consists of patients with Barrett’s Esophagus,59,12,2 months,16S,NA,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1079/10/NA,Study 1079,"cross-sectional observational, not case-control",30558669,https://doi.org/10.1186/s40168-018-0611-4,https://microbiomejournal.biomedcentral.com/articles/10.1186/s40168-018-0611-4,"Deshpande NP, Riordan SM, Castaño-Rodríguez N, Wilkins MR , Kaakoush NO","Signatures within the esophageal microbiome are associated with host genetics, age, and disease",Microbiome,2018,"Community types, Esophagus, Metagenomics, Microbiota, Single nucleotide polymorphisms",Experiment 10,Australia,Homo sapiens,Esophagus,UBERON:0001043,Barrett's esophagus,EFO:0000280,Gastroesophageal reflux disease (GERD),Barrett’s Esophagus (BE),This group consists of patients with Barrett’s Esophagus,29,12,2 months,16S,NA,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1079/11/NA,Study 1079,"cross-sectional observational, not case-control",30558669,https://doi.org/10.1186/s40168-018-0611-4,https://microbiomejournal.biomedcentral.com/articles/10.1186/s40168-018-0611-4,"Deshpande NP, Riordan SM, Castaño-Rodríguez N, Wilkins MR , Kaakoush NO","Signatures within the esophageal microbiome are associated with host genetics, age, and disease",Microbiome,2018,"Community types, Esophagus, Metagenomics, Microbiota, Single nucleotide polymorphisms",Experiment 11,Australia,Homo sapiens,Esophagus,UBERON:0001043,Esophageal adenocarcinoma,EFO:0000478,Gastroesophageal reflux disease (GERD),Glandular mucosa (GM),This group consists of patients with Glandular mucosa,29,14,2 months,16S,NA,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1079/12/NA,Study 1079,"cross-sectional observational, not case-control",30558669,https://doi.org/10.1186/s40168-018-0611-4,https://microbiomejournal.biomedcentral.com/articles/10.1186/s40168-018-0611-4,"Deshpande NP, Riordan SM, Castaño-Rodríguez N, Wilkins MR , Kaakoush NO","Signatures within the esophageal microbiome are associated with host genetics, age, and disease",Microbiome,2018,"Community types, Esophagus, Metagenomics, Microbiota, Single nucleotide polymorphisms",Experiment 12,Australia,Homo sapiens,Esophagus,UBERON:0001043,Esophageal adenocarcinoma,EFO:0000478,Normal,Glandular mucosa (GM),This group consists of patients with Glandular mucosa,59,14,2 months,16S,NA,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1079/13/NA,Study 1079,"cross-sectional observational, not case-control",30558669,https://doi.org/10.1186/s40168-018-0611-4,https://microbiomejournal.biomedcentral.com/articles/10.1186/s40168-018-0611-4,"Deshpande NP, Riordan SM, Castaño-Rodríguez N, Wilkins MR , Kaakoush NO","Signatures within the esophageal microbiome are associated with host genetics, age, and disease",Microbiome,2018,"Community types, Esophagus, Metagenomics, Microbiota, Single nucleotide polymorphisms",Experiment 13,Australia,Homo sapiens,Esophagus,UBERON:0001043,Gastroesophageal reflux disease,EFO:0003948,Normal (Normal esophagus),GERD (Gastroesophageal reflux disease),This group consists of patients with Gastroesophageal reflux disease.,59,29,2 months,WMS,NA,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1079/14/NA,Study 1079,"cross-sectional observational, not case-control",30558669,https://doi.org/10.1186/s40168-018-0611-4,https://microbiomejournal.biomedcentral.com/articles/10.1186/s40168-018-0611-4,"Deshpande NP, Riordan SM, Castaño-Rodríguez N, Wilkins MR , Kaakoush NO","Signatures within the esophageal microbiome are associated with host genetics, age, and disease",Microbiome,2018,"Community types, Esophagus, Metagenomics, Microbiota, Single nucleotide polymorphisms",Experiment 14,Australia,Homo sapiens,Esophagus,UBERON:0001043,Gastroesophageal reflux disease,EFO:0003948,Normal (Normal esophagus),GERD (Gastroesophageal reflux disease)within subjects classified as PPI NO,This group consists of patients with Gastroesophageal reflux disease(within subjects classified as PPI NO),59,19,2 months,WMS,NA,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1079/15/NA,Study 1079,"cross-sectional observational, not case-control",30558669,https://doi.org/10.1186/s40168-018-0611-4,https://microbiomejournal.biomedcentral.com/articles/10.1186/s40168-018-0611-4,"Deshpande NP, Riordan SM, Castaño-Rodríguez N, Wilkins MR , Kaakoush NO","Signatures within the esophageal microbiome are associated with host genetics, age, and disease",Microbiome,2018,"Community types, Esophagus, Metagenomics, Microbiota, Single nucleotide polymorphisms",Experiment 15,Australia,Homo sapiens,Esophagus,UBERON:0001043,Barrett's esophagus,EFO:0000280,Normal,Barrett’s Esophagus (BE),This group consists of patients with Barrett’s Esophagus,59,12,2 months,WMS,NA,Illumina,LEfSe,0.05,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1080/1/NA,Study 1080,"cross-sectional observational, not case-control",31637220,10.3389/fcimb.2019.00339,NA,"Kolbe AR, Castro-Nallar E, Preciado D , Pérez-Losada M",Altered Middle Ear Microbiome in Children With Chronic Otitis Media With Effusion and Respiratory Illnesses,Frontiers in cellular and infection microbiology,2019,"amplicon sequence variants, asthma, bronchiolitis, middle ear microbiome, otitis media",Experiment 1,United States of America,Homo sapiens,Middle ear,UBERON:0001756,Lower respiratory tract disease,EFO:0009433,Chronic Otitis Media With Effusion (COME) without asthma or bronchiolitis,Chronic Otitis Media With Effusion (COME) with asthma or bronchiolitis,"Children from 3 to 176 months of age, with Chronic Otitis Media With Effusion (COME) with a history of lower airway disease (i.e., asthma or bronchiolitis),  defined by a history of pulmonary physician-diagnosed asthma; documented chronic wheezing being treated with a daily respiratory inhaler; or PCR (+) for rhinovirus bronchiolitis diagnosis.",37,13,2 weeks,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,"age,sex",NA,decreased,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1081/1/NA,Study 1081,"cross-sectional observational, not case-control",35410125,10.1186/s12866-022-02502-4,https://link.springer.com/article/10.1186/s12866-022-02502-4,"Showering A, Martinez J, Benavente ED, Gezan SA, Jones RT, Oke C, Tytheridge S, Pretorius E, Scott D, Allen RL, D'Alessandro U, Lindsay SW, Armour JAL, Pickett J , Logan JG",Skin microbiome alters attractiveness to Anopheles mosquitoes,BMC microbiology,2022,"Anopheles coluzzii, Body odour, Diversity, Human attractiveness, Malaria, Mosquitoes, Repellents, Skin microbiome",Experiment 1,United Kingdom,Homo sapiens,Skin of sole of pes,UBERON:0013778,Taxonomic microbiome measurement,EFO:0007883,Poorly-attractive group,Highly-attractive group,"Post-menopausal females, aged between 50 and 90 years, whose skin/body odour were highly attractive to Anopheles mosquitoes.",28,27,NA,16S,34,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1082/1/NA,Study 1082,laboratory experiment,35787106,10.1080/19490976.2022.2085961,NA,"Rodriguez Paris V, Wong XYD, Solon-Biet SM, Edwards MC, Aflatounian A, Gilchrist RB, Simpson SJ, Handelsman DJ, Kaakoush NO , Walters KA",The interplay between PCOS pathology and diet on gut microbiota in a mouse model,Gut microbes,2022,"Microbiome, PCOS, animal model, diet, hyperandrogenism, polycystic ovary syndrome",Experiment 1,Australia,Mus musculus,Feces,UBERON:0001988,Polycystic ovary syndrome,EFO:0000660,Controls,polycystic ovary syndrome (PCOS)-like mice,"Dihydrotestosterone (DHT)-induced PCOS- like mice exposed to diets that varied in protein (P), carbohydrate (C) and fat (F) content.",NA,NA,None,16S,4,Illumina,DESeq2,0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1083/1/NA,Study 1083,laboratory experiment,33789672,10.1186/s12934-021-01568-5,NA,"Li A, Yang Y, Qin S, Lv S, Jin T, Li K, Han Z , Li Y",Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age,Microbial cell factories,2021,"Age, Gut microbiota, Milk replacer, Weaned, Yimeng black goats",Experiment 1,China,Capra hircus,Jejunum,UBERON:0002115,Age,EFO:0000246,B-Group (B15.2),B-Group (B25.2),This group consists of young black goats in the control group (B-Group) whose intestines (Jejunum) were obtained on the 25th day of the experiment.,3,3,NA,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,increased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1083/2/NA,Study 1083,laboratory experiment,33789672,10.1186/s12934-021-01568-5,NA,"Li A, Yang Y, Qin S, Lv S, Jin T, Li K, Han Z , Li Y",Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age,Microbial cell factories,2021,"Age, Gut microbiota, Milk replacer, Weaned, Yimeng black goats",Experiment 2,China,Capra hircus,Jejunum,UBERON:0002115,Age,EFO:0000246,B-Group (B15.2)),B-Group (B45.2),This group consists of young black goats in the control group (B-Group) whose intestines (Jejunum) were obtained on the 45th day of the experiment.,3,3,NA,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,decreased,decreased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1083/3/NA,Study 1083,laboratory experiment,33789672,10.1186/s12934-021-01568-5,NA,"Li A, Yang Y, Qin S, Lv S, Jin T, Li K, Han Z , Li Y",Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age,Microbial cell factories,2021,"Age, Gut microbiota, Milk replacer, Weaned, Yimeng black goats",Experiment 3,China,Capra hircus,Jejunum,UBERON:0002115,Age,EFO:0000246,B-Group (B15.2),B-Group (B75.2),This group consists of young black goats in the control group (B-Group) whose intestines (Jejunum) were obtained on the 75th day of the experiment.,3,3,NA,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,increased,increased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1083/4/NA,Study 1083,laboratory experiment,33789672,10.1186/s12934-021-01568-5,NA,"Li A, Yang Y, Qin S, Lv S, Jin T, Li K, Han Z , Li Y",Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age,Microbial cell factories,2021,"Age, Gut microbiota, Milk replacer, Weaned, Yimeng black goats",Experiment 4,China,Capra hircus,Caecum,UBERON:0001153,Age,EFO:0000246,B-Group (B15.4),B-Group (B25.4),This group consists of young black goats in the control group (B-Group) whose intestines (Cecum) were obtained on the 25th day of the experiment.,3,3,NA,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,unchanged,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1083/5/NA,Study 1083,laboratory experiment,33789672,10.1186/s12934-021-01568-5,NA,"Li A, Yang Y, Qin S, Lv S, Jin T, Li K, Han Z , Li Y",Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age,Microbial cell factories,2021,"Age, Gut microbiota, Milk replacer, Weaned, Yimeng black goats",Experiment 5,China,Capra hircus,Caecum,UBERON:0001153,Age,EFO:0000246,B-Group (B15.4),B-Group (B45.4),This group consists of young black goats in the control group (B-Group) whose intestines (Cecum) were obtained on the 45th day of the experiment.,3,3,NA,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,increased,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1083/6/NA,Study 1083,laboratory experiment,33789672,10.1186/s12934-021-01568-5,NA,"Li A, Yang Y, Qin S, Lv S, Jin T, Li K, Han Z , Li Y",Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age,Microbial cell factories,2021,"Age, Gut microbiota, Milk replacer, Weaned, Yimeng black goats",Experiment 6,China,Capra hircus,Caecum,UBERON:0001153,Age,EFO:0000246,B-Group (B15.4),B-Group (B75.4),This group consists of young black goats in the control group (B-Group) whose intestines (Cecum) were obtained on the 75th day of the experiment.,3,3,NA,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,increased,increased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1083/7/NA,Study 1083,laboratory experiment,33789672,10.1186/s12934-021-01568-5,NA,"Li A, Yang Y, Qin S, Lv S, Jin T, Li K, Han Z , Li Y",Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age,Microbial cell factories,2021,"Age, Gut microbiota, Milk replacer, Weaned, Yimeng black goats",Experiment 7,China,Capra hircus,Jejunum,UBERON:0002115,Diet,EFO:0002755,B-Group (B15.2),R-Group (R15.2),This group consists of young black goats in the milk replacer group (R Group) whose intestines (Jejunum) were obtained on the 15th day of the experiment. This group was provided with milk replacer after weaning on the 10th day of the experiment.,3,3,NA,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,decreased,increased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1083/8/NA,Study 1083,laboratory experiment,33789672,10.1186/s12934-021-01568-5,NA,"Li A, Yang Y, Qin S, Lv S, Jin T, Li K, Han Z , Li Y",Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age,Microbial cell factories,2021,"Age, Gut microbiota, Milk replacer, Weaned, Yimeng black goats",Experiment 8,China,Capra hircus,Jejunum,UBERON:0002115,Diet,EFO:0002755,B-Group (B25.2),R-Group (R25.2),This group consists of young black goats in the milk replacer group (R Group) whose intestines (Jejunum) were obtained on the 25th day of the experiment. This group was provided with milk replacer after weaning on the 10th day of the experiment.,3,3,NA,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,decreased,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1083/9/NA,Study 1083,laboratory experiment,33789672,10.1186/s12934-021-01568-5,NA,"Li A, Yang Y, Qin S, Lv S, Jin T, Li K, Han Z , Li Y",Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age,Microbial cell factories,2021,"Age, Gut microbiota, Milk replacer, Weaned, Yimeng black goats",Experiment 9,China,Capra hircus,Jejunum,UBERON:0002115,Diet,EFO:0002755,B-Group (B45.2),R-Group (R45.2),This group consists of young black goats in the milk replacer group (R Group) whose intestines (Jejunum) were obtained on the 45th day of the experiment. This group was provided with milk replacer after weaning on the 10th day of the experiment.,3,3,NA,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,increased,increased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1083/10/NA,Study 1083,laboratory experiment,33789672,10.1186/s12934-021-01568-5,NA,"Li A, Yang Y, Qin S, Lv S, Jin T, Li K, Han Z , Li Y",Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age,Microbial cell factories,2021,"Age, Gut microbiota, Milk replacer, Weaned, Yimeng black goats",Experiment 10,China,Capra hircus,Jejunum,UBERON:0002115,Diet,EFO:0002755,B-Group (B75.2),R-Group (R75.2),This group consists of young black goats in the milk replacer group (R Group) whose intestines (Jejunum) were obtained on the 75th day of the experiment. This group was provided with milk replacer after weaning on the 10th day of the experiment.,3,3,NA,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,decreased,decreased,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1083/11/NA,Study 1083,laboratory experiment,33789672,10.1186/s12934-021-01568-5,NA,"Li A, Yang Y, Qin S, Lv S, Jin T, Li K, Han Z , Li Y",Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age,Microbial cell factories,2021,"Age, Gut microbiota, Milk replacer, Weaned, Yimeng black goats",Experiment 11,China,Capra hircus,Caecum,UBERON:0001153,Diet,EFO:0002755,B-Group (B15.4),R-Group (R15.4),This group consists of young black goats in the milk replacer group (R Group) whose intestines (Cecum) were obtained on the 15th day of the experiment. This group was provided with milk replacer after weaning on the 10th day of the experiment.,3,3,NA,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,decreased,decreased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1083/12/NA,Study 1083,laboratory experiment,33789672,10.1186/s12934-021-01568-5,NA,"Li A, Yang Y, Qin S, Lv S, Jin T, Li K, Han Z , Li Y",Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age,Microbial cell factories,2021,"Age, Gut microbiota, Milk replacer, Weaned, Yimeng black goats",Experiment 12,China,Capra hircus,Caecum,UBERON:0001153,Diet,EFO:0002755,B-Group (B25.4),R-Group (R25.4),This group consists of young black goats in the milk replacer group (R Group) whose intestines (Cecum) were obtained on the 25th day of the experiment. This group was provided with milk replacer after weaning on the 10th day of the experiment.,3,3,NA,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,decreased,unchanged,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1083/13/NA,Study 1083,laboratory experiment,33789672,10.1186/s12934-021-01568-5,NA,"Li A, Yang Y, Qin S, Lv S, Jin T, Li K, Han Z , Li Y",Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age,Microbial cell factories,2021,"Age, Gut microbiota, Milk replacer, Weaned, Yimeng black goats",Experiment 13,China,Capra hircus,Caecum,UBERON:0001153,Diet,EFO:0002755,B-Group (B45.4),R-Group (R45.4),This group consists of young black goats in the milk replacer group (R Group) whose intestines (Cecum) were obtained on the 45th day of the experiment. This group was provided with milk replacer after weaning on the 10th day of the experiment.,3,3,NA,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,decreased,unchanged,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1083/14/NA,Study 1083,laboratory experiment,33789672,10.1186/s12934-021-01568-5,NA,"Li A, Yang Y, Qin S, Lv S, Jin T, Li K, Han Z , Li Y",Microbiome analysis reveals gut microbiota alteration of early-weaned Yimeng black goats with the effect of milk replacer and age,Microbial cell factories,2021,"Age, Gut microbiota, Milk replacer, Weaned, Yimeng black goats",Experiment 14,China,Capra hircus,Caecum,UBERON:0001153,Diet,EFO:0002755,B-Group (B75.4),R-Group (R75.4),This group consists of young black goats in the milk replacer group (R Group) whose intestines (Cecum) were obtained on the 75th day of the experiment. This group was provided with milk replacer after weaning on the 10th day of the experiment.,3,3,NA,16S,34,Illumina,LEfSe,0.05,FALSE,2,NA,NA,NA,increased,increased,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1085/1/NA,Study 1085,time series / longitudinal observational,38798019,10.1080/19490976.2024.2357176,https://www.tandfonline.com/doi/full/10.1080/19490976.2024.2357176,"Samarra A, Cabrera-Rubio R, Martínez-Costa C , Collado MC",The role of <i>Bifidobacterium</i> genus in modulating the neonate microbiota: implications for antibiotic resistance acquisition in early life,Gut microbes,2024,"Bifidobacterium, antibiotic, gut, infant, microbiota, resistance",Experiment 1,Spain,Homo sapiens,Feces,UBERON:0001988,Gut microbiome measurement,EFO:0007874,Low-Bifidobacterium group,High-Bifidobacterium group,High-Bifidobacterium group in the seven (7) day-old infants.,57,42,NA,16S,34,Illumina,"LEfSe,Mann-Whitney (Wilcoxon)",0.05,TRUE,3,NA,"antibiotic exposure,feeding practices,mode of birth",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1085/2/NA,Study 1085,time series / longitudinal observational,38798019,10.1080/19490976.2024.2357176,https://www.tandfonline.com/doi/full/10.1080/19490976.2024.2357176,"Samarra A, Cabrera-Rubio R, Martínez-Costa C , Collado MC",The role of <i>Bifidobacterium</i> genus in modulating the neonate microbiota: implications for antibiotic resistance acquisition in early life,Gut microbes,2024,"Bifidobacterium, antibiotic, gut, infant, microbiota, resistance",Experiment 2,Spain,Homo sapiens,Feces,UBERON:0001988,Gut microbiome measurement,EFO:0007874,Low-Bifidobacterium group,High-Bifidobacterium group,High-Bifidobacterium group in the one (1) month-old infants.,58,43,NA,16S,34,Illumina,"LEfSe,Mann-Whitney (Wilcoxon)",0.05,TRUE,3,NA,"antibiotic exposure,feeding practices,mode of birth",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1086/1/NA,Study 1086,case-control,38745393,10.1111/jcpe.13998,NA,"Bingöl M, Cardilli A, Bingöl AC, Löber U, Bang C, Franke A, Bartzela T, Beblo S, Mönch E, Stolz S, Schaefer AS, Forslund SK , Richter GM",Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study,Journal of clinical periodontology,2024,"16s rDNA sequencing, periodontitis, phenylketonuria, saliva, subgingival plaque",Experiment 1,Germany,Homo sapiens,Saliva,UBERON:0001836,Phenylketonuria,MONDO:0009861,Control (CTRL-S),Phenylketonuria (PKU-S),Patients diagnosed with Phenylketonuria (PKU) and who stimulated Saliva samples were gotten from.,114,109,N/A,16S,12,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,increased,decreased,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1086/2/NA,Study 1086,case-control,38745393,10.1111/jcpe.13998,NA,"Bingöl M, Cardilli A, Bingöl AC, Löber U, Bang C, Franke A, Bartzela T, Beblo S, Mönch E, Stolz S, Schaefer AS, Forslund SK , Richter GM",Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study,Journal of clinical periodontology,2024,"16s rDNA sequencing, periodontitis, phenylketonuria, saliva, subgingival plaque",Experiment 2,Germany,Homo sapiens,Subgingival dental plaque,UBERON:0016484,Phenylketonuria,MONDO:0009861,Controls (CTRL-SP),Phenylketonuria (PKU-SP),Patients diagnosed with Phenylketonuria (PKU) and who stimulated Sub gingival plaque samples were gotten from.,113,96,N/A,16S,12,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,decreased,decreased,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1086/3/NA,Study 1086,case-control,38745393,10.1111/jcpe.13998,NA,"Bingöl M, Cardilli A, Bingöl AC, Löber U, Bang C, Franke A, Bartzela T, Beblo S, Mönch E, Stolz S, Schaefer AS, Forslund SK , Richter GM",Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study,Journal of clinical periodontology,2024,"16s rDNA sequencing, periodontitis, phenylketonuria, saliva, subgingival plaque",Experiment 3,Germany,Homo sapiens,Saliva,UBERON:0001836,Phenylketonuria,MONDO:0009861,Control Adults (CTRL-S),Phenylketonuria (PKU-S),Patients diagnosed with Phenylketonuria (PKU) and who stimulated Saliva samples were gotten from.,52,50,N/A,16S,12,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,unchanged,decreased,NA,NA,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1086/4/NA,Study 1086,case-control,38745393,10.1111/jcpe.13998,NA,"Bingöl M, Cardilli A, Bingöl AC, Löber U, Bang C, Franke A, Bartzela T, Beblo S, Mönch E, Stolz S, Schaefer AS, Forslund SK , Richter GM",Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study,Journal of clinical periodontology,2024,"16s rDNA sequencing, periodontitis, phenylketonuria, saliva, subgingival plaque",Experiment 4,Germany,Homo sapiens,Subgingival dental plaque,UBERON:0016484,Phenylketonuria,MONDO:0009861,Control Adults (CTRL-SP),Phenylketonuria (PKU-SP),Patients diagnosed with Phenylketonuria (PKU) and who stimulated Sub gingival plaque samples were gotten from.,52,45,N/A,16S,12,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,unchanged,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1086/5/NA,Study 1086,case-control,38745393,10.1111/jcpe.13998,NA,"Bingöl M, Cardilli A, Bingöl AC, Löber U, Bang C, Franke A, Bartzela T, Beblo S, Mönch E, Stolz S, Schaefer AS, Forslund SK , Richter GM",Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study,Journal of clinical periodontology,2024,"16s rDNA sequencing, periodontitis, phenylketonuria, saliva, subgingival plaque",Experiment 5,Germany,Homo sapiens,Saliva,UBERON:0001836,Phenylketonuria,MONDO:0009861,Control Children (CTRL-S),Phenylketonuria (PKU-S),Patients diagnosed with Phenylketonuria (PKU) and who stimulated Saliva samples were gotten from.,62,59,N/A,16S,12,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,unchanged,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1086/6/NA,Study 1086,case-control,38745393,10.1111/jcpe.13998,NA,"Bingöl M, Cardilli A, Bingöl AC, Löber U, Bang C, Franke A, Bartzela T, Beblo S, Mönch E, Stolz S, Schaefer AS, Forslund SK , Richter GM",Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study,Journal of clinical periodontology,2024,"16s rDNA sequencing, periodontitis, phenylketonuria, saliva, subgingival plaque",Experiment 6,Germany,Homo sapiens,Subgingival dental plaque,UBERON:0016484,Phenylketonuria,MONDO:0009861,Control Children (CTRL-SP),Phenylketonuria (PKU-SP),Patients diagnosed with Phenylketonuria (PKU) and who stimulated Sub gingival plaque samples were gotten from.,61,51,N/A,16S,12,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,unchanged,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1086/7/NA,Study 1086,case-control,38745393,10.1111/jcpe.13998,NA,"Bingöl M, Cardilli A, Bingöl AC, Löber U, Bang C, Franke A, Bartzela T, Beblo S, Mönch E, Stolz S, Schaefer AS, Forslund SK , Richter GM",Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study,Journal of clinical periodontology,2024,"16s rDNA sequencing, periodontitis, phenylketonuria, saliva, subgingival plaque",Experiment 7,Germany,Homo sapiens,Saliva,UBERON:0001836,Phenylketonuria,MONDO:0009861,Ch-CTRL-rel (Healthy siblings of PKU patients),Ch-CTRL-unrel (unrelated control children),Control Children unrelated to Phenylketonuria (PKU) patients who stimulated saliva samples were gotten from.,12,26,N/A,16S,12,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,decreased,unchanged,NA,NA,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1086/8/NA,Study 1086,case-control,38745393,10.1111/jcpe.13998,NA,"Bingöl M, Cardilli A, Bingöl AC, Löber U, Bang C, Franke A, Bartzela T, Beblo S, Mönch E, Stolz S, Schaefer AS, Forslund SK , Richter GM",Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study,Journal of clinical periodontology,2024,"16s rDNA sequencing, periodontitis, phenylketonuria, saliva, subgingival plaque",Experiment 8,Germany,Homo sapiens,Saliva,UBERON:0001836,Phenylketonuria,MONDO:0009861,Ch CTRL rel (Healthy siblings of PKU patients),Ch PKU (PKU children),Children diagnosed with Phenylketonuria (PKU) and who stimulated Saliva samples were gotten from.,12,59,N/A,16S,12,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,unchanged,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1086/9/NA,Study 1086,case-control,38745393,10.1111/jcpe.13998,NA,"Bingöl M, Cardilli A, Bingöl AC, Löber U, Bang C, Franke A, Bartzela T, Beblo S, Mönch E, Stolz S, Schaefer AS, Forslund SK , Richter GM",Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study,Journal of clinical periodontology,2024,"16s rDNA sequencing, periodontitis, phenylketonuria, saliva, subgingival plaque",Experiment 9,Germany,Homo sapiens,Mouth,UBERON:0000165,Phenylketonuria,MONDO:0009861,Control (CTRL-S),Control (CTRL-SP),Healthy Controls who stimulated Subgingival plaque samples were gotten from.,114,113,N/A,16S,12,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1086/10/NA,Study 1086,case-control,38745393,10.1111/jcpe.13998,NA,"Bingöl M, Cardilli A, Bingöl AC, Löber U, Bang C, Franke A, Bartzela T, Beblo S, Mönch E, Stolz S, Schaefer AS, Forslund SK , Richter GM",Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study,Journal of clinical periodontology,2024,"16s rDNA sequencing, periodontitis, phenylketonuria, saliva, subgingival plaque",Experiment 10,Germany,Homo sapiens,Mouth,UBERON:0000165,Phenylketonuria,MONDO:0009861,Control Adults (CTRL-S),Control Adults (CTRL-SP),Healthy Control adults who stimulated Sub gingival plaque samples were gotten from,52,52,N/A,16S,12,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1086/11/NA,Study 1086,case-control,38745393,10.1111/jcpe.13998,NA,"Bingöl M, Cardilli A, Bingöl AC, Löber U, Bang C, Franke A, Bartzela T, Beblo S, Mönch E, Stolz S, Schaefer AS, Forslund SK , Richter GM",Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study,Journal of clinical periodontology,2024,"16s rDNA sequencing, periodontitis, phenylketonuria, saliva, subgingival plaque",Experiment 11,Germany,Homo sapiens,Mouth,UBERON:0000165,Phenylketonuria,MONDO:0009861,Control Children (CTRL Ch-S),Control Children (CTRL Ch-SP),Healthy Control Children without PKU who stimulated Sub gingival plaque samples were gotten from.,62,61,N/A,16S,12,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1086/12/NA,Study 1086,case-control,38745393,10.1111/jcpe.13998,NA,"Bingöl M, Cardilli A, Bingöl AC, Löber U, Bang C, Franke A, Bartzela T, Beblo S, Mönch E, Stolz S, Schaefer AS, Forslund SK , Richter GM",Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study,Journal of clinical periodontology,2024,"16s rDNA sequencing, periodontitis, phenylketonuria, saliva, subgingival plaque",Experiment 12,Germany,Homo sapiens,Mouth,UBERON:0000165,Phenylketonuria,MONDO:0009861,Phenylketonuria (PKU-S),Phenylketonuria (PKU-SP),Patients diagnosed with Phenylketonuria (PKU) and who stimulated Sub gingival plaque samples were gotten from.,109,96,N/A,16S,12,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1086/13/NA,Study 1086,case-control,38745393,10.1111/jcpe.13998,NA,"Bingöl M, Cardilli A, Bingöl AC, Löber U, Bang C, Franke A, Bartzela T, Beblo S, Mönch E, Stolz S, Schaefer AS, Forslund SK , Richter GM",Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study,Journal of clinical periodontology,2024,"16s rDNA sequencing, periodontitis, phenylketonuria, saliva, subgingival plaque",Experiment 13,Germany,Homo sapiens,Mouth,UBERON:0000165,Phenylketonuria,MONDO:0009861,Phenylketonuria Adults (PKU-S),Phenylketonuria Adults (PKU-SP),Adult Patients diagnosed with Phenylketonuria (PKU) and who stimulated Subgingival plaque samples were gotten from.,50,45,N/A,16S,12,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1086/14/NA,Study 1086,case-control,38745393,10.1111/jcpe.13998,NA,"Bingöl M, Cardilli A, Bingöl AC, Löber U, Bang C, Franke A, Bartzela T, Beblo S, Mönch E, Stolz S, Schaefer AS, Forslund SK , Richter GM",Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study,Journal of clinical periodontology,2024,"16s rDNA sequencing, periodontitis, phenylketonuria, saliva, subgingival plaque",Experiment 14,Germany,Homo sapiens,Mouth,UBERON:0000165,Phenylketonuria,MONDO:0009861,Phenylketonuria Ch (PKU-S),Phenylketonuria Ch (PKU-SP),Children diagnosed with Phenylketonuria (PKU) and who stimulated Subgingival plaque samples were gotten from.,59,51,N/A,16S,12,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1086/15/NA,Study 1086,case-control,38745393,10.1111/jcpe.13998,NA,"Bingöl M, Cardilli A, Bingöl AC, Löber U, Bang C, Franke A, Bartzela T, Beblo S, Mönch E, Stolz S, Schaefer AS, Forslund SK , Richter GM",Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study,Journal of clinical periodontology,2024,"16s rDNA sequencing, periodontitis, phenylketonuria, saliva, subgingival plaque",Experiment 15,Germany,Homo sapiens,Mouth,UBERON:0000165,Phenylketonuria,MONDO:0009861,Control No period (CTRL-S),Phenylketonuria No Period (PKU-S),Patients diagnosed with Phenylketonuria (PKU) without suspected Periodontitis and who stimulated Saliva samples were gotten from.,NA,NA,N/A,16S,12,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1086/16/NA,Study 1086,case-control,38745393,10.1111/jcpe.13998,NA,"Bingöl M, Cardilli A, Bingöl AC, Löber U, Bang C, Franke A, Bartzela T, Beblo S, Mönch E, Stolz S, Schaefer AS, Forslund SK , Richter GM",Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study,Journal of clinical periodontology,2024,"16s rDNA sequencing, periodontitis, phenylketonuria, saliva, subgingival plaque",Experiment 16,Germany,Homo sapiens,Mouth,UBERON:0000165,Phenylketonuria,MONDO:0009861,Control Period (CTRL-S),Phenylketonuria Period (PKU-S),Patients diagnosed with Phenylketonuria (PKU) with suspected Periodontitis and who stimulated Saliva samples were gotten from.,NA,NA,N/A,16S,12,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1086/17/NA,Study 1086,case-control,38745393,10.1111/jcpe.13998,NA,"Bingöl M, Cardilli A, Bingöl AC, Löber U, Bang C, Franke A, Bartzela T, Beblo S, Mönch E, Stolz S, Schaefer AS, Forslund SK , Richter GM",Oral microbiota of patients with phenylketonuria: A nation-based cross-sectional study,Journal of clinical periodontology,2024,"16s rDNA sequencing, periodontitis, phenylketonuria, saliva, subgingival plaque",Experiment 17,Germany,Homo sapiens,Mouth,UBERON:0000165,Phenylketonuria,MONDO:0009861,Phenylketonuria No Period (PKU-S),Phenylketonuria Period (PKU-S),Patients diagnosed with Phenylketonuria (PKU) with suspected Periodontitis and who stimulated Saliva samples were gotten from.,NA,NA,N/A,16S,12,Illumina,Mann-Whitney (Wilcoxon),0.05,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1087/1/NA,Study 1087,case-control,38294805,10.1001/jamapsychiatry.2023.5371,NA,"Vasileva SS, Yang Y, Baker A, Siskind D, Gratten J , Eyles D",Associations of the Gut Microbiome With Treatment Resistance in Schizophrenia,JAMA psychiatry,2024,NA,Experiment 1,Australia,Homo sapiens,Feces,UBERON:0001988,Schizophrenia,MONDO:0005090,control individuals without a psychiatric diagnosis (past or present),SCZ: individuals with a psychiatric diagnosis of schizophrenia,"Participants with a schizophrenia diagnosis categorized as follows:
1. AAP: individuals with treatment-responsive schizophrenia taking atypical antipsychotics (not clozapine) with a total Positive and Negative Symptom Scale (PANSS) score of 60 or low.
2. CR: individuals with treatment-resistant schizophrenia who were clozapine responsive total PANSS score ≤60).
3. CNR: individuals with treatment-resistant schizophrenia who were clozapine nonresponsive
(total PANSS score >60).",25,72,2 months,WMS,NA,Illumina,ANCOM,0.05,TRUE,NA,"age,body mass index,sex","age,body mass index,sex",NA,unchanged,NA,unchanged,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1087/2/NA,Study 1087,case-control,38294805,10.1001/jamapsychiatry.2023.5371,NA,"Vasileva SS, Yang Y, Baker A, Siskind D, Gratten J , Eyles D",Associations of the Gut Microbiome With Treatment Resistance in Schizophrenia,JAMA psychiatry,2024,NA,Experiment 2,Australia,Homo sapiens,Feces,UBERON:0001988,Response to antipsychotic drug,GO:0097332,control individuals without a psychiatric diagnosis of schizophrenia,AAP: individuals with treatment-responsive schizophrenia taking atypical antipsychotics (not clozapine),AAP: individuals with treatment-responsive schizophrenia taking atypical antipsychotics (not clozapine) with a total Positive and Negative Symptom Scale (PANSS) score of 60 or low.,25,24,2 months,WMS,NA,Illumina,ANCOM,0.05,TRUE,NA,"age,body mass index,sex","age,body mass index,sex",NA,unchanged,NA,unchanged,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1087/3/NA,Study 1087,case-control,38294805,10.1001/jamapsychiatry.2023.5371,NA,"Vasileva SS, Yang Y, Baker A, Siskind D, Gratten J , Eyles D",Associations of the Gut Microbiome With Treatment Resistance in Schizophrenia,JAMA psychiatry,2024,NA,Experiment 3,Australia,Homo sapiens,Feces,UBERON:0001988,Treatment refractory schizophrenia,EFO:0004609,AAP: individuals with treatment-responsive schizophrenia taking atypical antipsychotics (not clozapine),TRS: individuals with treatment-resistant schizophrenia taking clozapine,"Participants with treatment-resistant schizophrenia categorized as follows: 1. CR: individuals with treatment-resistant schizophrenia who were clozapine responsive total PANSS score ≤60).
2. CNR: individuals with treatment-resistant schizophrenia who were clozapine nonresponsive
(total PANSS score >60).",24,48,2 months,WMS,NA,Illumina,ANCOM,0.05,TRUE,NA,"age,body mass index,sex","age,body mass index,sex",NA,unchanged,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1087/4/NA,Study 1087,case-control,38294805,10.1001/jamapsychiatry.2023.5371,NA,"Vasileva SS, Yang Y, Baker A, Siskind D, Gratten J , Eyles D",Associations of the Gut Microbiome With Treatment Resistance in Schizophrenia,JAMA psychiatry,2024,NA,Experiment 4,Australia,Homo sapiens,Feces,UBERON:0001988,Treatment refractory schizophrenia,EFO:0004609,control individuals without a psychiatric diagnosis of schizophrenia,TRS: individuals with treatment-resistant schizophrenia taking clozapine,Participants with treatment-resistant schizophrenia categorized as follows: 1. CR: individuals with treatment-resistant schizophrenia who were clozapine responsive total PANSS score ≤60). 2. CNR: individuals with treatment-resistant schizophrenia who were clozapine nonresponsive (total PANSS score >60).,25,48,2 months,WMS,NA,Illumina,ANCOM,0.05,TRUE,NA,"age,body mass index,sex","age,body mass index,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1087/5/NA,Study 1087,case-control,38294805,10.1001/jamapsychiatry.2023.5371,NA,"Vasileva SS, Yang Y, Baker A, Siskind D, Gratten J , Eyles D",Associations of the Gut Microbiome With Treatment Resistance in Schizophrenia,JAMA psychiatry,2024,NA,Experiment 5,Australia,Homo sapiens,Feces,UBERON:0001988,Response to clozapine,GO:0097338,control individuals without a psychiatric diagnosis of schizophrenia,CR: individuals with treatment-resistant schizophrenia responsive to clozapine,CR: individuals with treatment-resistant schizophrenia who were clozapine responsive (total PANSS score ≤60).,25,26,2 months,WMS,NA,Illumina,ANCOM,0.05,TRUE,NA,"age,body mass index,sex","age,body mass index,sex",NA,unchanged,NA,unchanged,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1087/6/NA,Study 1087,case-control,38294805,10.1001/jamapsychiatry.2023.5371,NA,"Vasileva SS, Yang Y, Baker A, Siskind D, Gratten J , Eyles D",Associations of the Gut Microbiome With Treatment Resistance in Schizophrenia,JAMA psychiatry,2024,NA,Experiment 6,Australia,Homo sapiens,Feces,UBERON:0001988,Treatment refractory schizophrenia,EFO:0004609,control individuals without a psychiatric diagnosis of schizophrenia,CNR: individuals with treatment-resistant schizophrenia nonresponsive to clozapine,CNR: individuals with treatment-resistant schizophrenia who were clozapine nonresponsive (total PANSS score >60).,25,22,2 months,WMS,NA,Illumina,ANCOM,0.05,TRUE,NA,"age,body mass index,sex","age,body mass index,sex",NA,unchanged,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1088/1/NA,Study 1088,"case-control,laboratory experiment",38589422,https://doi.org/10.1038/s41537-024-00460-6,NA,"Wei N, Ju M, Su X, Zhang Y, Huang Y, Rao X, Cui L, Lin Z , Dong Y",Transplantation of gut microbiota derived from patients with schizophrenia induces schizophrenia-like behaviors and dysregulated brain transcript response in mice,"Schizophrenia (Heidelberg, Germany)",2024,NA,Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Schizophrenia,MONDO:0005090,HCF: healthy controls (no psychiatric diagnosis of schizophrenia),SCZF: patients with schizophrenia,antipsychotic-treated patients with schizophrenia,15,20,1 month,16S,34,Illumina,LEfSe,0.05,NA,NA,NA,NA,decreased,decreased,decreased,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1088/2/NA,Study 1088,"case-control,laboratory experiment",38589422,https://doi.org/10.1038/s41537-024-00460-6,NA,"Wei N, Ju M, Su X, Zhang Y, Huang Y, Rao X, Cui L, Lin Z , Dong Y",Transplantation of gut microbiota derived from patients with schizophrenia induces schizophrenia-like behaviors and dysregulated brain transcript response in mice,"Schizophrenia (Heidelberg, Germany)",2024,NA,Experiment 2,China,Mus musculus,Feces,UBERON:0001988,Schizophrenia,MONDO:0005090,HC: healthy control fecal microbiota-recipient mice,SCZ: schizophrenia fecal microbiota-recipient mice,Male C57BL/6 mice which transplanted fecal microbiota from a human patient with a schizophrenia psychiatric disorder.,5,5,NA,16S,34,Illumina,LEfSe,0.05,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1089/1/NA,Study 1089,time series / longitudinal observational,35783418,https://doi.org/10.3389/fmicb.2022.909729,NA,"Xiang M, Zheng L, Pu D, Lin F, Ma X, Ye H, Pu D, Zhang Y, Wang D, Wang X, Zou K, Chen L, Zhang Y, Sun Z, Zhang T , Wu G",Intestinal Microbes in Patients With Schizophrenia Undergoing Short-Term Treatment: Core Species Identification Based on Co-Occurrence Networks and Regression Analysis,Frontiers in microbiology,2022,"16S rRNA sequencing, fecal microbiota transplantation, gut microbiota, gut-brain axis, schizophrenia",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Treatment,EFO:0000727,Schizophrenia patients before treatment (BT),Schizophrenia patients after treatment (AT),Schizophrenia patients after antipsychotic treatment,25,25,14 days,16S,34,Illumina,LEfSe,0.05,FALSE,4,NA,NA,NA,unchanged,NA,NA,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1090/1/NA,Study 1090,"cross-sectional observational, not case-control",37576972,https://doi.org/10.3389/fendo.2023.1190954,https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2023.1190954/full,"Xing M, Gao H, Yao L, Wang L, Zhang C, Zhu L , Cui D",Profiles and diagnostic value of intestinal microbiota in schizophrenia patients with metabolic syndrome,Frontiers in endocrinology,2023,"16S rRNA, dyslipidemia, intestinal microbiota, metabolic syndrome, schizophrenia, type 2 diabetes",Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Metabolic syndrome,EFO:0000195,Schizophrenia patients with MetS,Schizophrenia patients without MetS,Schizophrenia patients with metabolic syndrome (MetS),58,57,3 Months,16S,34,Illumina,LEfSe,0.05,FALSE,3,NA,NA,NA,increased,NA,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1091/1/NA,Study 1091,case-control,38658841,https://doi.org/10.1186/s12866-024-03219-2,https://bmcmicrobiol.biomedcentral.com/articles/10.1186/s12866-024-03219-2,"Jeong S, Liao YT, Tsai MH, Wang YK, Wu IC, Liu CJ, Wu MS, Chan TS, Chen MY, Hu PJ, Kao WY, Liu HC, Tsai MJ, Liu CY, Chang CC, Wu DC , Hsu YH",Microbiome signatures associated with clinical stages of gastric Cancer: whole metagenome shotgun sequencing study,BMC microbiology,2024,"Bacteroides_caccae, Bifidobacterium_longum, Fusobacteria, GLCMANNANAUT-PWY, Lachnospiraceae_bacterium_5_1_63FAA, Streptococcus_anginosus",Experiment 1,Taiwan,Homo sapiens,Feces,UBERON:0001988,"Chronic gastritis,Gastric cancer","EFO:0000337,MONDO:0001056",Chronic gastritis,Gastric Cancer,"Gastric cancer is one of the major health problems worldwide, ranking fifth in incidence and third in cancer-related mortality, as reported in the latest published global cancer statistics",33,32,6 months,WMS,NA,Illumina,"Mann-Whitney (Wilcoxon),LEfSe",0.041,TRUE,4.27,NA,"age,body mass index,sex",NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1091/2/NA,Study 1091,case-control,38658841,https://doi.org/10.1186/s12866-024-03219-2,https://bmcmicrobiol.biomedcentral.com/articles/10.1186/s12866-024-03219-2,"Jeong S, Liao YT, Tsai MH, Wang YK, Wu IC, Liu CJ, Wu MS, Chan TS, Chen MY, Hu PJ, Kao WY, Liu HC, Tsai MJ, Liu CY, Chang CC, Wu DC , Hsu YH",Microbiome signatures associated with clinical stages of gastric Cancer: whole metagenome shotgun sequencing study,BMC microbiology,2024,"Bacteroides_caccae, Bifidobacterium_longum, Fusobacteria, GLCMANNANAUT-PWY, Lachnospiraceae_bacterium_5_1_63FAA, Streptococcus_anginosus",Experiment 2,NA,Not specified,NA,NA,NA,NA,"LEfSe analysis, for the 2-group comparison",NA,NA,NA,NA,NA,WMS,NA,Illumina,LEfSe,0.014,TRUE,4.27,NA,"age,sex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1092/1/NA,Study 1092,randomized controlled trial,36228569,10.1016/j.clnu.2022.09.012,NA,"Aljumaah MR, Bhatia U, Roach J, Gunstad J , Azcarate Peril MA","The gut microbiome, mild cognitive impairment, and probiotics: A randomized clinical trial in middle-aged and older adults","Clinical nutrition (Edinburgh, Scotland)",2022,"Cogitative aging, Gut microbiome, Lactobacillus rhamnosus GG, Prevotella, Psychobiotics",Experiment 1,United States of America,Homo sapiens,Feces,UBERON:0001988,Cognitive decline measurement,EFO:0007710,Placebo group,Probiotic group,Participants who received L. rhamnosus GG (LGG) supplementation,83,86,90,PCR,NA,Illumina,ANCOM,0.05,TRUE,4,NA,NA,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1093/1/NA,Study 1093,case-control,30775438,10.1126/sciadv.aau8317,NA,"Zheng P, Zeng B, Liu M, Chen J, Pan J, Han Y, Liu Y, Cheng K, Zhou C, Wang H, Zhou X, Gui S, Perry SW, Wong ML, Licinio J, Wei H , Xie P",The gut microbiome from patients with schizophrenia modulates the glutamate-glutamine-GABA cycle and schizophrenia-relevant behaviors in mice,Science advances,2019,NA,Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Schizophrenia,MONDO:0005090,HC: individuals without a psychiatric diagnosis of schizophrenia,SCZ: individuals with a psychiatric diagnosis of schizophrenia,"individuals with schizophrenia diagnosed by Structured Psychiatric Interview using Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV)",69,63,1 month,16S,34,Illumina,LEfSe,0.05,NA,NA,NA,NA,NA,NA,decreased,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1094/1/NA,Study 1094,case-control,38959253,10.1371/journal.pone.0306582,NA,"Wang Y, Bi S, Li X, Zhong Y , Qi D",Perturbations in gut microbiota composition in schizophrenia,PloS one,2024,NA,Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Schizophrenia,MONDO:0005090,NC: normal controls,SZ: patients with schizophrenia,"individuals with schizophrenia diagnosed by a clinician using the systematic structured clinical interview method and detailed background information approach detailed in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition.",30,29,3 months,16S,34,Illumina,LEfSe,0.05,NA,2,age,NA,unchanged,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1094/2/NA,Study 1094,case-control,38959253,10.1371/journal.pone.0306582,NA,"Wang Y, Bi S, Li X, Zhong Y , Qi D",Perturbations in gut microbiota composition in schizophrenia,PloS one,2024,NA,Experiment 2,China,Homo sapiens,Feces,UBERON:0001988,Schizophrenia,MONDO:0005090,NC: normal controls,SZ: patients with schizophrenia,"individuals with schizophrenia diagnosed by a clinician using the systematic structured clinical interview method and detailed background information approach detailed in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition.",6,6,3 months,WMS,NA,Illumina,LEfSe,0.05,NA,2,age,NA,unchanged,unchanged,unchanged,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1095/1/NA,Study 1095,laboratory experiment,36810115,10.1186/s40168-023-01471-8,NA,"Pan W, Zhao J, Wu J, Xu D, Meng X, Jiang P, Shi H, Ge X, Yang X, Hu M, Zhang P, Tang R, Nagaratnam N, Zheng K, Huang XF , Yu Y",Dimethyl itaconate ameliorates cognitive impairment induced by a high-fat diet via the gut-brain axis in mice,Microbiome,2023,"Cognition, Gut microbiome, Gut-brain axis, Itaconate, Microglia, Obesity",Experiment 1,China,Mus musculus,Feces,UBERON:0001988,Metabolite,CHEBI:25212,HF+Veh (High fat and Vehicle treated mice),HF+DI (High fat and Dimethyl Itaconate treated mice),"Mice in this group received a high-fat diet (30% fat by weight) to induce cognitive impairment. Then, they were intraperitoneally injected with Dimethy Itaconate (25mg/kg) twice a week.",12,12,NA,16S,34,Illumina,LEfSe,0.05,FALSE,3,NA,NA,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1095/2/NA,Study 1095,laboratory experiment,36810115,10.1186/s40168-023-01471-8,NA,"Pan W, Zhao J, Wu J, Xu D, Meng X, Jiang P, Shi H, Ge X, Yang X, Hu M, Zhang P, Tang R, Nagaratnam N, Zheng K, Huang XF , Yu Y",Dimethyl itaconate ameliorates cognitive impairment induced by a high-fat diet via the gut-brain axis in mice,Microbiome,2023,"Cognition, Gut microbiome, Gut-brain axis, Itaconate, Microglia, Obesity",Experiment 2,China,Mus musculus,Feces,UBERON:0001988,Metabolite,CHEBI:25212,FMT-HF+Veh (Fecal microbiome transplantation-High fat and Vehicle treated mice),FMT-HF+DI (Fecal microbiome transplantation-High fat and Dimethyl Itaconate treated mice),"Mice in this group received a high-fat diet (30% fat by weight) to induce cognitive impairment. Then, they were intraperitoneally injected with Dimethy Itaconate (25mg/kg) twice a week. Afterward, they received fecal microbiome transplantation.",8,8,NA,16S,34,Illumina,LEfSe,0.05,FALSE,3,NA,NA,NA,increased,increased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1096/1/NA,Study 1096,"cross-sectional observational, not case-control",38589361,10.1038/s41467-024-47182-y,https://www.nature.com/articles/s41467-024-47182-y,"Barker-Tejeda TC, Zubeldia-Varela E, Macías-Camero A, Alonso L, Martín-Antoniano IA, Rey-Stolle MF, Mera-Berriatua L, Bazire R, Cabrera-Freitag P, Shanmuganathan M, Britz-McKibbin P, Ubeda C, Francino MP, Barber D, Ibáñez-Sandín MD, Barbas C, Pérez-Gordo M , Villaseñor A",Comparative characterization of the infant gut microbiome and their maternal lineage by a multi-omics approach,Nature communications,2024,NA,Experiment 1,Spain,Homo sapiens,Feces,UBERON:0001988,Gut microbiome measurement,EFO:0007874,Mothers,Infants,Infants (0 - 12 months old),43,38,3 months prior to study recruitment,16S,34,Illumina,MaAsLin2,0.05,TRUE,NA,NA,NA,NA,NA,NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1096/2/NA,Study 1096,"cross-sectional observational, not case-control",38589361,10.1038/s41467-024-47182-y,https://www.nature.com/articles/s41467-024-47182-y,"Barker-Tejeda TC, Zubeldia-Varela E, Macías-Camero A, Alonso L, Martín-Antoniano IA, Rey-Stolle MF, Mera-Berriatua L, Bazire R, Cabrera-Freitag P, Shanmuganathan M, Britz-McKibbin P, Ubeda C, Francino MP, Barber D, Ibáñez-Sandín MD, Barbas C, Pérez-Gordo M , Villaseñor A",Comparative characterization of the infant gut microbiome and their maternal lineage by a multi-omics approach,Nature communications,2024,NA,Experiment 2,Spain,Homo sapiens,Feces,UBERON:0001988,Gut microbiome measurement,EFO:0007874,Grandmothers,Infants,Infants (0 - 12 months old),40,38,3 months prior to study recruitment,16S,34,Illumina,MaAsLin2,0.05,TRUE,NA,NA,NA,NA,NA,NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1096/3/NA,Study 1096,"cross-sectional observational, not case-control",38589361,10.1038/s41467-024-47182-y,https://www.nature.com/articles/s41467-024-47182-y,"Barker-Tejeda TC, Zubeldia-Varela E, Macías-Camero A, Alonso L, Martín-Antoniano IA, Rey-Stolle MF, Mera-Berriatua L, Bazire R, Cabrera-Freitag P, Shanmuganathan M, Britz-McKibbin P, Ubeda C, Francino MP, Barber D, Ibáñez-Sandín MD, Barbas C, Pérez-Gordo M , Villaseñor A",Comparative characterization of the infant gut microbiome and their maternal lineage by a multi-omics approach,Nature communications,2024,NA,Experiment 3,Spain,Homo sapiens,Feces,UBERON:0001988,Gut microbiome measurement,EFO:0007874,Mothers,Infants,Infants (0 - 12 months old),43,38,3 months prior to study recruitment,WMS,NA,Illumina,MaAsLin2,0.05,TRUE,NA,NA,NA,NA,NA,NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1096/4/NA,Study 1096,"cross-sectional observational, not case-control",38589361,10.1038/s41467-024-47182-y,https://www.nature.com/articles/s41467-024-47182-y,"Barker-Tejeda TC, Zubeldia-Varela E, Macías-Camero A, Alonso L, Martín-Antoniano IA, Rey-Stolle MF, Mera-Berriatua L, Bazire R, Cabrera-Freitag P, Shanmuganathan M, Britz-McKibbin P, Ubeda C, Francino MP, Barber D, Ibáñez-Sandín MD, Barbas C, Pérez-Gordo M , Villaseñor A",Comparative characterization of the infant gut microbiome and their maternal lineage by a multi-omics approach,Nature communications,2024,NA,Experiment 4,Spain,Homo sapiens,Feces,UBERON:0001988,Gut microbiome measurement,EFO:0007874,Grandmothers,Infants,Infants (0 - 12 months old),40,38,3 months prior to study recruitment,WMS,NA,Illumina,MaAsLin2,0.05,TRUE,NA,NA,NA,NA,NA,NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1097/1/NA,Study 1097,randomized controlled trial,34152099,10.1002/brb3.2259,NA,"Bharwani A, Szamosi JC, Taylor VH, Lee Y, Bala A, Mansur R, Subramaniapillai M, Surette M , McIntyre RS",Changes in the gut microbiome associated with infliximab in patients with bipolar disorder,Brain and behavior,2021,"16S rRNA sequencing, bipolar disorder, gut microbiota, inflammation, infliximab",Experiment 1,Canada,Homo sapiens,Feces,UBERON:0001988,Bipolar disorder,MONDO:0004985,Placebo,Infliximab,"Participants who received infliximab, an antibody administered intravenously that is used for treating several chronic inflammatory diseases and works by blocking the effects of TNF-α",8,9,NA,16S,NA,Illumina,"PERMANOVA,ANCOM",0.05,FALSE,NA,bipolar disorder,NA,NA,unchanged,NA,unchanged,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
bsdb:1099/1/NA,Study 1099,time series / longitudinal observational,34376634,10.1038/s41398-021-01531-3,NA,"Yuan X, Wang Y, Li X, Jiang J, Kang Y, Pang L, Zhang P, Li A, Lv L, Andreassen OA, Fan X, Hu S , Song X","Gut microbial biomarkers for the treatment response in first-episode, drug-naïve schizophrenia: a 24-week follow-up study",Translational psychiatry,2021,NA,Experiment 1,China,Homo sapiens,Feces,UBERON:0001988,Schizophrenia,MONDO:0005090,healthy controls,SCH patients,"first-episode, drug-naïve SCH patients",107,107,30,16S,34,Ion Torrent,Random Forest Analysis,0.05,TRUE,3,NA,NA,NA,decreased,NA,decreased,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
